7352670
D009599_D006973 NONE rebound_0\NN\7309781 <e2>hypertensive</e2>_1\NN\10405694 after_2\IN\1740 <e1>sodium_3\NN\14625458 nitroprusside</e1>_4\NN\1740 prevented_5\VBN\1740 by_6\IN\1740 saralasin_7\NN\1740 in_8\IN\13603305 rats_9\NNS\2329401 ._10\.\1740
D009599_D006973 NONE during_0\IN\1740 the_1\DT\1740 <e1>snp</e1>_2\NN\11493266 infusion_3\NN\14589223 the_4\DT\1740 control_5\NN\5190804 animals_6\NNS\4475 demonstrated_7\VBD\2137132 a_8\DT\13649268 progressive_9\JJ\1740 <e2>increase_10\NN\13576355 in_11\IN\13603305 blood_12\NN\5397468 pressure</e2>_13\NN\11419404 to_14\IN\1740 61_15\CD\1740 torr_16\NN\13607985 ,_17\,\1740 whereas_18\IN\1740 the_19\DT\1740 saralasin-treated_20\JJ\1740 animals_21\NNS\4475 showed_22\VBD\2137132 no_23\DT\7204911 change_24\NN\7283608 ._25\.\1740
D012504_D006973 NONE rebound_0\NN\7309781 <e2>hypertensive</e2>_1\NN\10405694 after_2\IN\1740 sodium_3\NN\14625458 nitroprusside_4\NN\1740 prevented_5\VBN\1740 by_6\IN\1740 <e1>saralasin</e1>_7\NN\1740 in_8\IN\13603305 rats_9\NNS\2329401 ._10\.\1740
D012504_D006973 NONE during_0\IN\1740 the_1\DT\1740 snp_2\NN\11493266 infusion_3\NN\14589223 the_4\DT\1740 control_5\NN\5190804 animals_6\NNS\4475 demonstrated_7\VBD\2137132 a_8\DT\13649268 progressive_9\JJ\1740 <e2>increase_10\NN\13576355 in_11\IN\13603305 blood_12\NN\5397468 pressure</e2>_13\NN\11419404 to_14\IN\1740 61_15\CD\1740 torr_16\NN\13607985 ,_17\,\1740 whereas_18\IN\1740 the_19\DT\1740 <e1>saralasin-treated</e1>_20\JJ\1740 animals_21\NNS\4475 showed_22\VBD\2137132 no_23\DT\7204911 change_24\NN\7283608 ._25\.\1740
D000809_D007022 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 the_3\DT\1740 renin_4\NN\14999106 --_5\:\1740 <e1>angiotensin</e1>_6\NN\4522421 system_7\NN\3575240 in_8\IN\13603305 the_9\DT\1740 maintenance_10\NN\266806 of_11\IN\1740 blood_12\NN\5397468 pressure_13\NN\11419404 during_14\IN\1740 halothane_15\NN\3570838 anesthesia_16\NN\14034177 and_17\CC\1740 sodium_18\NN\14625458 nitroprusside_19\NN\1740 (snp)-induced_20\JJ\1740 <e2>hypotension</e2>_21\NN\14057371 was_22\VBD\836236 evaluated_23\VBN\670261 ._24\.\1740
D000809_D007022 NONE this_0\DT\1740 demonstrates_1\VBZ\2137132 the_2\DT\1740 participation_3\NN\1080366 of_4\IN\1740 the_5\DT\1740 renin_6\NN\14999106 --_7\:\1740 <e1>angiotensin</e1>_8\NN\4522421 system_9\NN\3575240 in_10\IN\13603305 antagonizing_11\VBG\1787955 the_12\DT\1740 combined_13\JJ\1740 <e2>hypotensive</e2>_14\JJ\1740 effects_15\NNS\13245626 of_16\IN\1740 halothane_17\NN\3570838 and_18\CC\1740 snp_19\NN\11493266 ._20\.\1740
D006221_D007022 CID the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 the_3\DT\1740 renin_4\NN\14999106 --_5\:\1740 angiotensin_6\NN\4522421 system_7\NN\3575240 in_8\IN\13603305 the_9\DT\1740 maintenance_10\NN\266806 of_11\IN\1740 blood_12\NN\5397468 pressure_13\NN\11419404 during_14\IN\1740 <e1>halothane</e1>_15\NN\3570838 anesthesia_16\NN\14034177 and_17\CC\1740 sodium_18\NN\14625458 nitroprusside_19\NN\1740 (snp)-induced_20\JJ\1740 <e2>hypotension</e2>_21\NN\14057371 was_22\VBD\836236 evaluated_23\VBN\670261 ._24\.\1740
D006221_D007022 CID this_0\DT\1740 demonstrates_1\VBZ\2137132 the_2\DT\1740 participation_3\NN\1080366 of_4\IN\1740 the_5\DT\1740 renin_6\NN\14999106 --_7\:\1740 angiotensin_8\NN\4522421 system_9\NN\3575240 in_10\IN\13603305 antagonizing_11\VBG\1787955 the_12\DT\1740 combined_13\JJ\1740 <e2>hypotensive</e2>_14\JJ\1740 effects_15\NNS\13245626 of_16\IN\1740 <e1>halothane</e1>_17\NN\3570838 and_18\CC\1740 snp_19\NN\11493266 ._20\.\1740
D009599_D007022 CID the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 the_3\DT\1740 renin_4\NN\14999106 --_5\:\1740 angiotensin_6\NN\4522421 system_7\NN\3575240 in_8\IN\13603305 the_9\DT\1740 maintenance_10\NN\266806 of_11\IN\1740 blood_12\NN\5397468 pressure_13\NN\11419404 during_14\IN\1740 halothane_15\NN\3570838 anesthesia_16\NN\14034177 and_17\CC\1740 <e1>sodium_18\NN\14625458 nitroprusside</e1>_19\NN\1740 (snp)-induced_20\JJ\1740 <e2>hypotension</e2>_21\NN\14057371 was_22\VBD\836236 evaluated_23\VBN\670261 ._24\.\1740
D009599_D007022 CID the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 the_3\DT\1740 renin_4\NN\14999106 --_5\:\1740 angiotensin_6\NN\4522421 system_7\NN\3575240 in_8\IN\13603305 the_9\DT\1740 maintenance_10\NN\266806 of_11\IN\1740 blood_12\NN\5397468 pressure_13\NN\11419404 during_14\IN\1740 halothane_15\NN\3570838 anesthesia_16\NN\14034177 and_17\CC\1740 sodium_18\NN\14625458 nitroprusside_19\NN\1740 <e1>(snp)-induced</e1>_20\JJ\1740 <e2>hypotension</e2>_21\NN\14057371 was_22\VBD\836236 evaluated_23\VBN\670261 ._24\.\1740
D009599_D007022 CID this_0\DT\1740 demonstrates_1\VBZ\2137132 the_2\DT\1740 participation_3\NN\1080366 of_4\IN\1740 the_5\DT\1740 renin_6\NN\14999106 --_7\:\1740 angiotensin_8\NN\4522421 system_9\NN\3575240 in_10\IN\13603305 antagonizing_11\VBG\1787955 the_12\DT\1740 combined_13\JJ\1740 <e2>hypotensive</e2>_14\JJ\1740 effects_15\NNS\13245626 of_16\IN\1740 halothane_17\NN\3570838 and_18\CC\1740 <e1>snp</e1>_19\NN\11493266 ._20\.\1740
15145918
D004967_D007022 NONE differential_0\JJ\1740 modulation_1\NN\7044917 by_2\IN\1740 <e1>estrogen</e1>_3\NN\14745635 of_4\IN\1740 alpha2-adrenergic_5\JJ\1740 and_6\CC\1740 i1-imidazoline_7\JJ\1740 receptor-mediated_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 in_10\IN\13603305 female_11\JJ\1740 rats_12\NNS\2329401 ._13\.\1740
D004967_D007022 NONE we_0\PRP\1740 have_1\VBP\2108377 recently_2\RB\1740 shown_3\VBN\2137132 that_4\IN\1740 <e1>estrogen</e1>_5\NN\14745635 negatively_6\RB\1740 modulates_7\VBZ\1724459 the_8\DT\1740 <e2>hypotensive</e2>_9\JJ\1740 effect_10\NN\34213 of_11\IN\1740 clonidine_12\NN\2721160 (_13\-LRB-\1740 mixed_14\JJ\1740 alpha2-/i1-receptor_15\NN\1740 agonist_16\NN\9613191 )_17\-RRB-\1740 in_18\IN\13603305 female_19\JJ\1740 rats_20\NNS\2329401 and_21\CC\1740 implicates_22\VBZ\2677097 the_23\DT\1740 cardiovascular_24\JJ\1740 autonomic_25\JJ\1740 control_26\NN\5190804 in_27\IN\13603305 this_28\DT\1740 interaction_29\NN\37396 ._30\.\1740
D004967_D007022 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>estrogen</e1>_4\NN\14745635 downregulates_5\VBZ\1740 alpha2-_6\NN\1740 but_7\CC\1740 not_8\RB\1740 i1-receptor-mediated_9\VBN\1740 <e2>hypotension</e2>_10\NN\14057371 and_11\CC\1740 highlight_12\VB\514463 a_13\DT\13649268 role_14\NN\719494 for_15\IN\1740 the_16\DT\1740 cardiac_17\JJ\1740 autonomic_18\JJ\1740 control_19\NN\5190804 in_20\IN\13603305 alpha-methyldopa-estrogen_21\NN\1740 interaction_22\NN\37396 ._23\.\1740
D004967_D007022 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 estrogen_4\NN\14745635 downregulates_5\VBZ\1740 alpha2-_6\NN\1740 but_7\CC\1740 not_8\RB\1740 i1-receptor-mediated_9\VBN\1740 <e2>hypotension</e2>_10\NN\14057371 and_11\CC\1740 highlight_12\VB\514463 a_13\DT\13649268 role_14\NN\719494 for_15\IN\1740 the_16\DT\1740 cardiac_17\JJ\1740 autonomic_18\JJ\1740 control_19\NN\5190804 in_20\IN\13603305 <e1>alpha-methyldopa-estrogen</e1>_21\NN\1740 interaction_22\NN\37396 ._23\.\1740
D048288_D007022 NONE differential_0\JJ\1740 modulation_1\NN\7044917 by_2\IN\1740 estrogen_3\NN\14745635 of_4\IN\1740 alpha2-adrenergic_5\JJ\1740 and_6\CC\1740 <e1>i1-imidazoline</e1>_7\JJ\1740 receptor-mediated_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 in_10\IN\13603305 female_11\JJ\1740 rats_12\NNS\2329401 ._13\.\1740
D003000_D007022 NONE we_0\PRP\1740 have_1\VBP\2108377 recently_2\RB\1740 shown_3\VBN\2137132 that_4\IN\1740 estrogen_5\NN\14745635 negatively_6\RB\1740 modulates_7\VBZ\1724459 the_8\DT\1740 <e2>hypotensive</e2>_9\JJ\1740 effect_10\NN\34213 of_11\IN\1740 <e1>clonidine</e1>_12\NN\2721160 (_13\-LRB-\1740 mixed_14\JJ\1740 alpha2-/i1-receptor_15\NN\1740 agonist_16\NN\9613191 )_17\-RRB-\1740 in_18\IN\13603305 female_19\JJ\1740 rats_20\NNS\2329401 and_21\CC\1740 implicates_22\VBZ\2677097 the_23\DT\1740 cardiovascular_24\JJ\1740 autonomic_25\JJ\1740 control_26\NN\5190804 in_27\IN\13603305 this_28\DT\1740 interaction_29\NN\37396 ._30\.\1740
C032302_D007022 CID in_0\IN\13603305 sham-operated_1\JJ\1740 rats_2\NNS\2329401 ,_3\,\1740 <e1>rilmenidine</e1>_4\NN\1740 or_5\CC\3541091 alpha-methyldopa_6\JJ\1740 elicited_7\VBN\1617192 similar_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 that_10\WDT\1740 lasted_11\VBD\2704349 at_12\IN\14622893 least_13\JJS\1740 5_14\CD\13741022 h_15\NN\14622893 and_16\CC\1740 was_17\VBD\836236 associated_18\VBN\628491 with_19\IN\1740 reductions_20\NNS\351485 in_21\IN\13603305 standard_22\JJ\1740 deviation_23\NN\7337390 of_24\IN\1740 mean_25\NN\6021761 arterial_26\JJ\1740 pressure_27\NN\11419404 ._28\.\1740
C032302_D007022 CID ovx_0\NNP\1740 significantly_1\RB\1740 enhanced_2\VBD\227165 the_3\DT\1740 <e2>hypotensive</e2>_4\JJ\1740 response_5\NN\11410625 to_6\TO\1740 alpha-methyldopa_7\JJ\1740 ,_8\,\1740 in_9\IN\13603305 contrast_10\NN\13854649 to_11\TO\1740 no_12\DT\7204911 effect_13\NN\34213 on_14\IN\1740 <e1>rilmenidine</e1>_15\JJ\1740 hypotension_16\NN\14057371 ._17\.\1740
C032302_D007022 CID ovx_0\NNP\1740 significantly_1\RB\1740 enhanced_2\VBD\227165 the_3\DT\1740 hypotensive_4\JJ\1740 response_5\NN\11410625 to_6\TO\1740 alpha-methyldopa_7\JJ\1740 ,_8\,\1740 in_9\IN\13603305 contrast_10\NN\13854649 to_11\TO\1740 no_12\DT\7204911 effect_13\NN\34213 on_14\IN\1740 <e1>rilmenidine</e1>_15\JJ\1740 <e2>hypotension</e2>_16\NN\14057371 ._17\.\1740
D008750_D007022 CID in_0\IN\13603305 sham-operated_1\JJ\1740 rats_2\NNS\2329401 ,_3\,\1740 rilmenidine_4\NN\1740 or_5\CC\3541091 <e1>alpha-methyldopa</e1>_6\JJ\1740 elicited_7\VBN\1617192 similar_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 that_10\WDT\1740 lasted_11\VBD\2704349 at_12\IN\14622893 least_13\JJS\1740 5_14\CD\13741022 h_15\NN\14622893 and_16\CC\1740 was_17\VBD\836236 associated_18\VBN\628491 with_19\IN\1740 reductions_20\NNS\351485 in_21\IN\13603305 standard_22\JJ\1740 deviation_23\NN\7337390 of_24\IN\1740 mean_25\NN\6021761 arterial_26\JJ\1740 pressure_27\NN\11419404 ._28\.\1740
D008750_D007022 CID ovx_0\NNP\1740 significantly_1\RB\1740 enhanced_2\VBD\227165 the_3\DT\1740 <e2>hypotensive</e2>_4\JJ\1740 response_5\NN\11410625 to_6\TO\1740 <e1>alpha-methyldopa</e1>_7\JJ\1740 ,_8\,\1740 in_9\IN\13603305 contrast_10\NN\13854649 to_11\TO\1740 no_12\DT\7204911 effect_13\NN\34213 on_14\IN\1740 rilmenidine_15\JJ\1740 hypotension_16\NN\14057371 ._17\.\1740
D008750_D007022 CID ovx_0\NNP\1740 significantly_1\RB\1740 enhanced_2\VBD\227165 the_3\DT\1740 hypotensive_4\JJ\1740 response_5\NN\11410625 to_6\TO\1740 <e1>alpha-methyldopa</e1>_7\JJ\1740 ,_8\,\1740 in_9\IN\13603305 contrast_10\NN\13854649 to_11\TO\1740 no_12\DT\7204911 effect_13\NN\34213 on_14\IN\1740 rilmenidine_15\JJ\1740 <e2>hypotension</e2>_16\NN\14057371 ._17\.\1740
D008750_D007022 CID the_0\DT\1740 enhanced_1\VBN\227165 <e1>alpha-methyldopa</e1>_2\JJ\1740 <e2>hypotension</e2>_3\NN\14057371 in_4\IN\13603305 ovx_5\JJ\1740 rats_6\NNS\2329401 was_7\VBD\836236 paralleled_8\VBN\2657219 with_9\IN\1740 further_10\JJ\1740 reduction_11\NN\351485 in_12\IN\13603305 sdrr_13\NN\1740 and_14\CC\1740 a_15\DT\13649268 reduced_16\VBN\441445 locomotor_17\NN\1740 activity_18\NN\30358 ._19\.\1740
D008750_D007022 CID these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 estrogen_4\NN\14745635 downregulates_5\VBZ\1740 alpha2-_6\NN\1740 but_7\CC\1740 not_8\RB\1740 i1-receptor-mediated_9\VBN\1740 <e2>hypotension</e2>_10\NN\14057371 and_11\CC\1740 highlight_12\VB\514463 a_13\DT\13649268 role_14\NN\719494 for_15\IN\1740 the_16\DT\1740 cardiac_17\JJ\1740 autonomic_18\JJ\1740 control_19\NN\5190804 in_20\IN\13603305 <e1>alpha-methyldopa-estrogen</e1>_21\NN\1740 interaction_22\NN\37396 ._23\.\1740
D008750_D001523 NONE the_0\DT\1740 enhanced_1\VBN\227165 <e1>alpha-methyldopa</e1>_2\JJ\1740 hypotension_3\NN\14057371 in_4\IN\13603305 ovx_5\JJ\1740 rats_6\NNS\2329401 was_7\VBD\836236 paralleled_8\VBN\2657219 with_9\IN\1740 further_10\JJ\1740 reduction_11\NN\351485 in_12\IN\13603305 sdrr_13\NN\1740 and_14\CC\1740 <e2>a_15\DT\13649268 reduced_16\VBN\441445 locomotor_17\NN\1740 activity</e2>_18\NN\30358 ._19\.\1740
11672959
D012460_D003872 CID a_0\DT\13649268 34-year-old_1\JJ\1740 lady_2\NN\10787470 developed_3\VBD\1753788 a_4\DT\13649268 constellation_5\NN\5728678 of_6\IN\1740 <e2>dermatitis</e2>_7\NN\14226056 ,_8\,\1740 fever_9\NN\14299637 ,_10\,\1740 lymphadenopathy_11\NN\14204950 and_12\CC\1740 hepatitis_13\NN\14127211 ,_14\,\1740 beginning_15\VBG\941990 on_16\IN\1740 the_17\DT\1740 17th_18\JJ\1740 day_19\NN\15154774 of_20\IN\1740 a_21\DT\13649268 course_22\NN\883297 of_23\IN\1740 oral_24\JJ\1740 <e1>sulphasalazine</e1>_25\NN\1740 for_26\IN\1740 sero-negative_27\JJ\1740 rheumatoid_28\JJ\1740 arthritis_29\NN\14171682 ._30\.\1740
D012460_D005334 CID a_0\DT\13649268 34-year-old_1\JJ\1740 lady_2\NN\10787470 developed_3\VBD\1753788 a_4\DT\13649268 constellation_5\NN\5728678 of_6\IN\1740 dermatitis_7\NN\14226056 ,_8\,\1740 <e2>fever</e2>_9\NN\14299637 ,_10\,\1740 lymphadenopathy_11\NN\14204950 and_12\CC\1740 hepatitis_13\NN\14127211 ,_14\,\1740 beginning_15\VBG\941990 on_16\IN\1740 the_17\DT\1740 17th_18\JJ\1740 day_19\NN\15154774 of_20\IN\1740 a_21\DT\13649268 course_22\NN\883297 of_23\IN\1740 oral_24\JJ\1740 <e1>sulphasalazine</e1>_25\NN\1740 for_26\IN\1740 sero-negative_27\JJ\1740 rheumatoid_28\JJ\1740 arthritis_29\NN\14171682 ._30\.\1740
D012460_D008206 CID a_0\DT\13649268 34-year-old_1\JJ\1740 lady_2\NN\10787470 developed_3\VBD\1753788 a_4\DT\13649268 constellation_5\NN\5728678 of_6\IN\1740 dermatitis_7\NN\14226056 ,_8\,\1740 fever_9\NN\14299637 ,_10\,\1740 <e2>lymphadenopathy</e2>_11\NN\14204950 and_12\CC\1740 hepatitis_13\NN\14127211 ,_14\,\1740 beginning_15\VBG\941990 on_16\IN\1740 the_17\DT\1740 17th_18\JJ\1740 day_19\NN\15154774 of_20\IN\1740 a_21\DT\13649268 course_22\NN\883297 of_23\IN\1740 oral_24\JJ\1740 <e1>sulphasalazine</e1>_25\NN\1740 for_26\IN\1740 sero-negative_27\JJ\1740 rheumatoid_28\JJ\1740 arthritis_29\NN\14171682 ._30\.\1740
D012460_D056486 CID a_0\DT\13649268 34-year-old_1\JJ\1740 lady_2\NN\10787470 developed_3\VBD\1753788 a_4\DT\13649268 constellation_5\NN\5728678 of_6\IN\1740 dermatitis_7\NN\14226056 ,_8\,\1740 fever_9\NN\14299637 ,_10\,\1740 lymphadenopathy_11\NN\14204950 and_12\CC\1740 <e2>hepatitis</e2>_13\NN\14127211 ,_14\,\1740 beginning_15\VBG\941990 on_16\IN\1740 the_17\DT\1740 17th_18\JJ\1740 day_19\NN\15154774 of_20\IN\1740 a_21\DT\13649268 course_22\NN\883297 of_23\IN\1740 oral_24\JJ\1740 <e1>sulphasalazine</e1>_25\NN\1740 for_26\IN\1740 sero-negative_27\JJ\1740 rheumatoid_28\JJ\1740 arthritis_29\NN\14171682 ._30\.\1740
D012460_D001172 NONE a_0\DT\13649268 34-year-old_1\JJ\1740 lady_2\NN\10787470 developed_3\VBD\1753788 a_4\DT\13649268 constellation_5\NN\5728678 of_6\IN\1740 dermatitis_7\NN\14226056 ,_8\,\1740 fever_9\NN\14299637 ,_10\,\1740 lymphadenopathy_11\NN\14204950 and_12\CC\1740 hepatitis_13\NN\14127211 ,_14\,\1740 beginning_15\VBG\941990 on_16\IN\1740 the_17\DT\1740 17th_18\JJ\1740 day_19\NN\15154774 of_20\IN\1740 a_21\DT\13649268 course_22\NN\883297 of_23\IN\1740 oral_24\JJ\1740 <e1>sulphasalazine</e1>_25\NN\1740 for_26\IN\1740 sero-negative_27\JJ\1740 <e2>rheumatoid_28\JJ\1740 arthritis</e2>_29\NN\14171682 ._30\.\1740
1664218
D000677_D002289 NONE phase_0\NN\15113229 ii_1\CD\13741022 study_2\NN\635850 of_3\IN\1740 the_4\DT\1740 <e1>amsacrine</e1>_5\NN\1740 analogue_6\NN\4743605 ci-921_7\NN\1740 (_8\-LRB-\1740 nsc_9\NNP\8123696 343499_10\CD\1740 )_11\-RRB-\1740 in_12\IN\13603305 <e2>non-small_13\JJ\1740 cell_14\NN\3080309 lung_15\NN\5528060 cancer</e2>_16\NN\14239425 ._17\.\1740
C042315_D002289 NONE phase_0\NN\15113229 ii_1\CD\13741022 study_2\NN\635850 of_3\IN\1740 the_4\DT\1740 amsacrine_5\NN\1740 analogue_6\NN\4743605 <e1>ci-921</e1>_7\NN\1740 (_8\-LRB-\1740 nsc_9\NNP\8123696 343499_10\CD\1740 )_11\-RRB-\1740 in_12\IN\13603305 <e2>non-small_13\JJ\1740 cell_14\NN\3080309 lung_15\NN\5528060 cancer</e2>_16\NN\14239425 ._17\.\1740
C042315_D002289 NONE phase_0\NN\15113229 ii_1\CD\13741022 study_2\NN\635850 of_3\IN\1740 the_4\DT\1740 amsacrine_5\NN\1740 analogue_6\NN\4743605 ci-921_7\NN\1740 (_8\-LRB-\1740 <e1>nsc_9\NNP\8123696 343499</e1>_10\CD\1740 )_11\-RRB-\1740 in_12\IN\13603305 <e2>non-small_13\JJ\1740 cell_14\NN\3080309 lung_15\NN\5528060 cancer</e2>_16\NN\14239425 ._17\.\1740
6103707
D005445_D010146 CID there_0\EX\27167 was_1\VBD\836236 <e2>pain</e2>_2\NN\14299637 on_3\IN\1740 i.m._4\NN\1740 injection_5\NN\320852 of_6\IN\1740 <e1>flunitrazepam</e1>_7\NN\1740 significantly_8\RB\1740 more_9\RBR\1740 often_10\RB\1740 than_11\IN\1740 with_12\IN\1740 isotonic_13\JJ\1740 saline_14\NN\14849367 ._15\.\1740
16787750
D014635_D001927 CID <e1>valproic_0\JJ\1740 acid</e1>_1\NN\14818238 induced_2\VBD\1627355 <e2>encephalopathy--19</e2>_3\JJ\1740 new_4\JJ\1740 cases_5\NNS\7283608 in_6\IN\13603305 germany_7\NNP\1740 from_8\IN\1740 1994_9\CD\1740 to_10\IN\1740 2003_11\CD\1740 -_12\HYPH\1740 -a_13\NFP\1740 side_14\NN\8630039 effect_15\NN\34213 associated_16\VBN\628491 to_17\TO\1740 vpa-therapy_18\NN\1740 not_19\RB\1740 only_20\RB\1740 in_21\IN\13603305 young_22\JJ\1740 children_23\NNS\9622049 ._24\.\1740
D014635_D001927 CID valproic_0\JJ\1740 acid_1\NN\14818238 induced_2\VBD\1627355 <e2>encephalopathy--19</e2>_3\JJ\1740 new_4\JJ\1740 cases_5\NNS\7283608 in_6\IN\13603305 germany_7\NNP\1740 from_8\IN\1740 1994_9\CD\1740 to_10\IN\1740 2003_11\CD\1740 -_12\HYPH\1740 -a_13\NFP\1740 side_14\NN\8630039 effect_15\NN\34213 associated_16\VBN\628491 to_17\TO\1740 <e1>vpa-therapy</e1>_18\NN\1740 not_19\RB\1740 only_20\RB\1740 in_21\IN\13603305 young_22\JJ\1740 children_23\NNS\9622049 ._24\.\1740
D014635_D001927 CID rare_0\JJ\1740 serious_1\JJ\1740 complications_2\NNS\1073995 may_3\MD\15209706 occur_4\VB\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 including_9\VBG\690614 haemorrhagic_10\JJ\1740 pancreatitis_11\NN\14336539 ,_12\,\1740 bone_13\NN\5286536 marrow_14\NN\5286536 suppression_15\NN\13489037 ,_16\,\1740 <e1>vpa-induced</e1>_17\JJ\1740 hepatotoxicity_18\NN\1740 and_19\CC\1740 vpa-induced_20\JJ\1740 <e2>encephalopathy</e2>_21\JJ\1740 ._22\.\1740
D014635_D001927 CID rare_0\JJ\1740 serious_1\JJ\1740 complications_2\NNS\1073995 may_3\MD\15209706 occur_4\VB\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 including_9\VBG\690614 haemorrhagic_10\JJ\1740 pancreatitis_11\NN\14336539 ,_12\,\1740 bone_13\NN\5286536 marrow_14\NN\5286536 suppression_15\NN\13489037 ,_16\,\1740 vpa-induced_17\JJ\1740 hepatotoxicity_18\NN\1740 and_19\CC\1740 <e1>vpa-induced</e1>_20\JJ\1740 <e2>encephalopathy</e2>_21\JJ\1740 ._22\.\1740
D014635_D001927 CID the_0\DT\1740 typical_1\JJ\1740 signs_2\NNS\6643763 of_3\IN\1740 <e1>vpa-induced</e1>_4\JJ\1740 <e2>encephalopathy</e2>_5\NN\14084880 are_6\VBP\836236 impaired_7\JJ\1740 consciousness_8\NN\5669934 ,_9\,\1740 sometimes_10\RB\1740 marked_11\JJ\1740 eeg_12\NN\7000195 background_13\NN\4921011 slowing_14\NN\7296428 ,_15\,\1740 increased_16\VBD\169651 seizure_17\JJ\1740 frequency_18\NN\15286249 ,_19\,\1740 with_20\IN\1740 or_21\CC\3541091 without_22\IN\1740 hyperammonemia_23\NN\1740 ._24\.\1740
D014635_D001927 CID there_0\EX\27167 is_1\VBZ\836236 still_2\RB\1740 no_3\DT\7204911 proof_4\NN\5823932 of_5\IN\1740 causative_6\JJ\1740 effect_7\NN\34213 of_8\IN\1740 <e1>vpa</e1>_9\NN\1740 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 <e2>encephalopathy</e2>_13\JJ\1740 ,_14\,\1740 but_15\CC\1740 only_16\RB\1740 of_17\IN\1740 an_18\DT\6697703 association_19\NN\8008335 with_20\IN\1740 an_21\DT\6697703 assumed_22\VBN\719734 causal_23\JJ\1740 relation_24\NN\2137 ._25\.\1740
D014635_D001927 CID we_0\PRP\1740 report_1\VBP\831651 19_2\CD\13745420 patients_3\NNS\9898892 with_4\IN\1740 <e1>vpa-associated</e1>_5\JJ\1740 <e2>encephalopathy</e2>_6\JJ\1740 in_7\IN\13603305 germany_8\NNP\1740 from_9\IN\1740 the_10\DT\1740 years_11\NNS\15144371 1994_12\CD\1740 to_13\IN\1740 2003_14\CD\1740 ,_15\,\1740 none_16\NN\15228378 of_17\IN\1740 whom_18\WP\1740 had_19\VBD\2108377 been_20\VBN\836236 published_21\VBN\1621555 previously_22\RB\1740 ._23\.\1740
D014635_D010195 CID rare_0\JJ\1740 serious_1\JJ\1740 complications_2\NNS\1073995 may_3\MD\15209706 occur_4\VB\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 including_9\VBG\690614 haemorrhagic_10\JJ\1740 <e2>pancreatitis</e2>_11\NN\14336539 ,_12\,\1740 bone_13\NN\5286536 marrow_14\NN\5286536 suppression_15\NN\13489037 ,_16\,\1740 <e1>vpa-induced</e1>_17\JJ\1740 hepatotoxicity_18\NN\1740 and_19\CC\1740 vpa-induced_20\JJ\1740 encephalopathy_21\JJ\1740 ._22\.\1740
D014635_D010195 CID rare_0\JJ\1740 serious_1\JJ\1740 complications_2\NNS\1073995 may_3\MD\15209706 occur_4\VB\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 including_9\VBG\690614 haemorrhagic_10\JJ\1740 <e2>pancreatitis</e2>_11\NN\14336539 ,_12\,\1740 bone_13\NN\5286536 marrow_14\NN\5286536 suppression_15\NN\13489037 ,_16\,\1740 vpa-induced_17\JJ\1740 hepatotoxicity_18\NN\1740 and_19\CC\1740 <e1>vpa-induced</e1>_20\JJ\1740 encephalopathy_21\JJ\1740 ._22\.\1740
D014635_D001855 CID rare_0\JJ\1740 serious_1\JJ\1740 complications_2\NNS\1073995 may_3\MD\15209706 occur_4\VB\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 including_9\VBG\690614 haemorrhagic_10\JJ\1740 pancreatitis_11\NN\14336539 ,_12\,\1740 <e2>bone_13\NN\5286536 marrow_14\NN\5286536 suppression</e2>_15\NN\13489037 ,_16\,\1740 <e1>vpa-induced</e1>_17\JJ\1740 hepatotoxicity_18\NN\1740 and_19\CC\1740 vpa-induced_20\JJ\1740 encephalopathy_21\JJ\1740 ._22\.\1740
D014635_D001855 CID rare_0\JJ\1740 serious_1\JJ\1740 complications_2\NNS\1073995 may_3\MD\15209706 occur_4\VB\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 including_9\VBG\690614 haemorrhagic_10\JJ\1740 pancreatitis_11\NN\14336539 ,_12\,\1740 <e2>bone_13\NN\5286536 marrow_14\NN\5286536 suppression</e2>_15\NN\13489037 ,_16\,\1740 vpa-induced_17\JJ\1740 hepatotoxicity_18\NN\1740 and_19\CC\1740 <e1>vpa-induced</e1>_20\JJ\1740 encephalopathy_21\JJ\1740 ._22\.\1740
D014635_D056486 CID rare_0\JJ\1740 serious_1\JJ\1740 complications_2\NNS\1073995 may_3\MD\15209706 occur_4\VB\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 including_9\VBG\690614 haemorrhagic_10\JJ\1740 pancreatitis_11\NN\14336539 ,_12\,\1740 bone_13\NN\5286536 marrow_14\NN\5286536 suppression_15\NN\13489037 ,_16\,\1740 <e1>vpa-induced</e1>_17\JJ\1740 <e2>hepatotoxicity</e2>_18\NN\1740 and_19\CC\1740 vpa-induced_20\JJ\1740 encephalopathy_21\JJ\1740 ._22\.\1740
D014635_D056486 CID rare_0\JJ\1740 serious_1\JJ\1740 complications_2\NNS\1073995 may_3\MD\15209706 occur_4\VB\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 including_9\VBG\690614 haemorrhagic_10\JJ\1740 pancreatitis_11\NN\14336539 ,_12\,\1740 bone_13\NN\5286536 marrow_14\NN\5286536 suppression_15\NN\13489037 ,_16\,\1740 vpa-induced_17\JJ\1740 <e2>hepatotoxicity</e2>_18\NN\1740 and_19\CC\1740 <e1>vpa-induced</e1>_20\JJ\1740 encephalopathy_21\JJ\1740 ._22\.\1740
D014635_D003244 CID the_0\DT\1740 typical_1\JJ\1740 signs_2\NNS\6643763 of_3\IN\1740 <e1>vpa-induced</e1>_4\JJ\1740 encephalopathy_5\NN\14084880 are_6\VBP\836236 <e2>impaired_7\JJ\1740 consciousness</e2>_8\NN\5669934 ,_9\,\1740 sometimes_10\RB\1740 marked_11\JJ\1740 eeg_12\NN\7000195 background_13\NN\4921011 slowing_14\NN\7296428 ,_15\,\1740 increased_16\VBD\169651 seizure_17\JJ\1740 frequency_18\NN\15286249 ,_19\,\1740 with_20\IN\1740 or_21\CC\3541091 without_22\IN\1740 hyperammonemia_23\NN\1740 ._24\.\1740
D014635_D012640 NONE the_0\DT\1740 typical_1\JJ\1740 signs_2\NNS\6643763 of_3\IN\1740 <e1>vpa-induced</e1>_4\JJ\1740 encephalopathy_5\NN\14084880 are_6\VBP\836236 impaired_7\JJ\1740 consciousness_8\NN\5669934 ,_9\,\1740 sometimes_10\RB\1740 marked_11\JJ\1740 eeg_12\NN\7000195 background_13\NN\4921011 slowing_14\NN\7296428 ,_15\,\1740 increased_16\VBD\169651 <e2>seizure</e2>_17\JJ\1740 frequency_18\NN\15286249 ,_19\,\1740 with_20\IN\1740 or_21\CC\3541091 without_22\IN\1740 hyperammonemia_23\NN\1740 ._24\.\1740
D014635_D022124 NONE the_0\DT\1740 typical_1\JJ\1740 signs_2\NNS\6643763 of_3\IN\1740 <e1>vpa-induced</e1>_4\JJ\1740 encephalopathy_5\NN\14084880 are_6\VBP\836236 impaired_7\JJ\1740 consciousness_8\NN\5669934 ,_9\,\1740 sometimes_10\RB\1740 marked_11\JJ\1740 eeg_12\NN\7000195 background_13\NN\4921011 slowing_14\NN\7296428 ,_15\,\1740 increased_16\VBD\169651 seizure_17\JJ\1740 frequency_18\NN\15286249 ,_19\,\1740 with_20\IN\1740 or_21\CC\3541091 without_22\IN\1740 <e2>hyperammonemia</e2>_23\NN\1740 ._24\.\1740
9931093
D016559_D006973 CID mechanisms_0\NNS\13446390 of_1\IN\1740 <e1>fk_2\NN\1740 506-induced</e1>_3\JJ\1740 <e2>hypertension</e2>_4\NN\14057371 in_5\IN\13603305 the_6\DT\1740 rat_7\NN\2329401 ._8\.\1740
D016559_D006973 CID the_0\DT\1740 clinical_1\JJ\1740 utility_2\NN\8186047 of_3\IN\1740 <e1>fk_4\NN\1740 506</e1>_5\CD\1740 is_6\VBZ\836236 complicated_7\VBN\126264 by_8\IN\1740 substantial_9\JJ\1740 <e2>hypertension</e2>_10\NN\14057371 and_11\CC\1740 nephrotoxicity_12\NN\1740 ._13\.\1740
D016559_D006973 CID to_0\TO\1740 clarify_1\VB\939277 the_2\DT\1740 mechanisms_3\NNS\13446390 of_4\IN\1740 <e1>fk_5\NN\1740 506-induced</e1>_6\JJ\1740 <e2>hypertension</e2>_7\NN\14057371 ,_8\,\1740 we_9\PRP\1740 studied_10\VBD\630380 the_11\DT\1740 chronic_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 fk_15\NN\1740 506_16\CD\1740 on_17\IN\1740 the_18\DT\1740 synthesis_19\NN\13446390 of_20\IN\1740 endothelin-1_21\NN\1740 (_22\-LRB-\1740 et-1_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 the_26\DT\1740 expression_27\NN\4679549 of_28\IN\1740 mrna_29\NN\14832193 of_30\IN\1740 et-1_31\NN\1740 and_32\CC\1740 endothelin-converting_33\JJ\1740 enzyme-1_34\NN\1740 (_35\-LRB-\1740 ece-1_36\NN\1740 )_37\-RRB-\1740 ,_38\,\1740 the_39\DT\1740 endothelial_40\JJ\1740 nitric_41\JJ\1740 oxide_42\NN\14818238 synthase_43\NN\1740 (_44\-LRB-\1740 enos_45\NN\1740 )_46\-RRB-\1740 activity_47\NN\30358 ,_48\,\1740 and_49\CC\1740 the_50\DT\1740 expression_51\NN\4679549 of_52\IN\1740 mrna_53\NN\14832193 of_54\IN\1740 enos_55\NN\1740 and_56\CC\1740 c-type_57\JJ\1740 natriuretic_58\JJ\1740 peptide_59\NN\14724264 (_60\-LRB-\1740 cnp_61\NN\1740 )_62\-RRB-\1740 in_63\IN\13603305 rat_64\NN\2329401 blood_65\NN\5397468 vessels_66\NNS\5246511 ._67\.\1740
D016559_D006973 CID to_0\TO\1740 clarify_1\VB\939277 the_2\DT\1740 mechanisms_3\NNS\13446390 of_4\IN\1740 fk_5\NN\1740 506-induced_6\JJ\1740 <e2>hypertension</e2>_7\NN\14057371 ,_8\,\1740 we_9\PRP\1740 studied_10\VBD\630380 the_11\DT\1740 chronic_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 <e1>fk_15\NN\1740 506</e1>_16\CD\1740 on_17\IN\1740 the_18\DT\1740 synthesis_19\NN\13446390 of_20\IN\1740 endothelin-1_21\NN\1740 (_22\-LRB-\1740 et-1_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 the_26\DT\1740 expression_27\NN\4679549 of_28\IN\1740 mrna_29\NN\14832193 of_30\IN\1740 et-1_31\NN\1740 and_32\CC\1740 endothelin-converting_33\JJ\1740 enzyme-1_34\NN\1740 (_35\-LRB-\1740 ece-1_36\NN\1740 )_37\-RRB-\1740 ,_38\,\1740 the_39\DT\1740 endothelial_40\JJ\1740 nitric_41\JJ\1740 oxide_42\NN\14818238 synthase_43\NN\1740 (_44\-LRB-\1740 enos_45\NN\1740 )_46\-RRB-\1740 activity_47\NN\30358 ,_48\,\1740 and_49\CC\1740 the_50\DT\1740 expression_51\NN\4679549 of_52\IN\1740 mrna_53\NN\14832193 of_54\IN\1740 enos_55\NN\1740 and_56\CC\1740 c-type_57\JJ\1740 natriuretic_58\JJ\1740 peptide_59\NN\14724264 (_60\-LRB-\1740 cnp_61\NN\1740 )_62\-RRB-\1740 in_63\IN\13603305 rat_64\NN\2329401 blood_65\NN\5397468 vessels_66\NNS\5246511 ._67\.\1740
D016559_D006973 CID in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 the_6\DT\1740 specific_7\JJ\1740 endothelin_8\NN\1740 type_9\NN\5839024 a_10\NN\13649268 receptor_11\NN\5225602 antagonist_12\NN\7846 fr_13\NN\14625458 139317_14\CD\1740 on_15\IN\1740 <e1>fk_16\NN\1740 506-induced</e1>_17\JJ\1740 <e2>hypertension</e2>_18\NN\14057371 in_19\IN\13603305 rats_20\NNS\2329401 was_21\VBD\836236 studied_22\VBN\630380 ._23\.\1740
D016559_D006973 CID d-1_0\JJ\1740 )_1\-RRB-\1740 prevented_2\VBD\1740 <e1>fk_3\NN\1740 506-induced</e1>_4\JJ\1740 <e2>hypertension</e2>_5\NN\14057371 in_6\IN\13603305 rats_7\NNS\2329401 ._8\.\1740
D016559_D007674 NONE the_0\DT\1740 clinical_1\JJ\1740 utility_2\NN\8186047 of_3\IN\1740 <e1>fk_4\NN\1740 506</e1>_5\CD\1740 is_6\VBZ\836236 complicated_7\VBN\126264 by_8\IN\1740 substantial_9\JJ\1740 hypertension_10\NN\14057371 and_11\CC\1740 <e2>nephrotoxicity</e2>_12\NN\1740 ._13\.\1740
D009569_D006973 NONE to_0\TO\1740 clarify_1\VB\939277 the_2\DT\1740 mechanisms_3\NNS\13446390 of_4\IN\1740 fk_5\NN\1740 506-induced_6\JJ\1740 <e2>hypertension</e2>_7\NN\14057371 ,_8\,\1740 we_9\PRP\1740 studied_10\VBD\630380 the_11\DT\1740 chronic_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 fk_15\NN\1740 506_16\CD\1740 on_17\IN\1740 the_18\DT\1740 synthesis_19\NN\13446390 of_20\IN\1740 endothelin-1_21\NN\1740 (_22\-LRB-\1740 et-1_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 the_26\DT\1740 expression_27\NN\4679549 of_28\IN\1740 mrna_29\NN\14832193 of_30\IN\1740 et-1_31\NN\1740 and_32\CC\1740 endothelin-converting_33\JJ\1740 enzyme-1_34\NN\1740 (_35\-LRB-\1740 ece-1_36\NN\1740 )_37\-RRB-\1740 ,_38\,\1740 the_39\DT\1740 endothelial_40\JJ\1740 <e1>nitric_41\JJ\1740 oxide</e1>_42\NN\14818238 synthase_43\NN\1740 (_44\-LRB-\1740 enos_45\NN\1740 )_46\-RRB-\1740 activity_47\NN\30358 ,_48\,\1740 and_49\CC\1740 the_50\DT\1740 expression_51\NN\4679549 of_52\IN\1740 mrna_53\NN\14832193 of_54\IN\1740 enos_55\NN\1740 and_56\CC\1740 c-type_57\JJ\1740 natriuretic_58\JJ\1740 peptide_59\NN\14724264 (_60\-LRB-\1740 cnp_61\NN\1740 )_62\-RRB-\1740 in_63\IN\13603305 rat_64\NN\2329401 blood_65\NN\5397468 vessels_66\NNS\5246511 ._67\.\1740
C079574_D006973 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 the_6\DT\1740 specific_7\JJ\1740 endothelin_8\NN\1740 type_9\NN\5839024 a_10\NN\13649268 receptor_11\NN\5225602 antagonist_12\NN\7846 <e1>fr_13\NN\14625458 139317</e1>_14\CD\1740 on_15\IN\1740 fk_16\NN\1740 506-induced_17\JJ\1740 <e2>hypertension</e2>_18\NN\14057371 in_19\IN\13603305 rats_20\NNS\2329401 was_21\VBD\836236 studied_22\VBN\630380 ._23\.\1740
230316
D006912_D020258 NONE <e2>neurotoxicity</e2>_0\NN\1740 of_1\IN\1740 <e1>halogenated_2\VBN\1740 hydroxyquinolines</e1>_3\NNS\1740 :_4\:\1740 clinical_5\JJ\1740 analysis_6\NN\633864 of_7\IN\1740 cases_8\NNS\7283608 reported_9\VBN\831651 outside_10\IN\8630039 japan_11\NNP\3631922 ._12\.\1740
D006912_D020258 NONE an_0\DT\6697703 analysis_1\NN\633864 is_2\VBZ\836236 presented_3\VBN\2137132 of_4\IN\1740 220_5\CD\1740 cases_6\NNS\7283608 of_7\IN\1740 possible_8\JJ\1740 <e2>neurotoxic</e2>_9\JJ\1740 reactions_10\NNS\13446390 to_11\TO\1740 <e1>halogenated_12\VBN\1740 hydroxyquinolines</e1>_13\NNS\1740 reported_14\VBN\831651 from_15\IN\1740 outside_16\IN\8630039 japan_17\NNP\3631922 ._18\.\1740
D007464_D009422 NONE in_0\IN\13603305 six_1\CD\13741022 of_2\IN\1740 the_3\DT\1740 probable_4\JJ\1740 cases_5\NNS\7283608 the_6\DT\1740 <e2>neurological_7\JJ\1740 disturbance</e2>_8\NN\407535 consisted_9\VBD\2603699 of_10\IN\1740 an_11\DT\6697703 acute_12\JJ\1740 reversible_13\JJ\1740 encephalopathy_14\RB\1740 usually_15\RB\1740 related_16\JJ\1740 to_17\TO\1740 the_18\DT\1740 ingestion_19\NN\13440063 of_20\IN\1740 a_21\DT\13649268 high_22\JJ\1740 dose_23\NN\3740161 of_24\IN\1740 <e1>clioquinol</e1>_25\NN\2720201 over_26\IN\5867413 a_27\DT\13649268 short_28\JJ\1740 period_29\NN\13575869 ._30\.\1740
D007464_D001927 CID in_0\IN\13603305 six_1\CD\13741022 of_2\IN\1740 the_3\DT\1740 probable_4\JJ\1740 cases_5\NNS\7283608 the_6\DT\1740 neurological_7\JJ\1740 disturbance_8\NN\407535 consisted_9\VBD\2603699 of_10\IN\1740 an_11\DT\6697703 acute_12\JJ\1740 reversible_13\JJ\1740 <e2>encephalopathy</e2>_14\RB\1740 usually_15\RB\1740 related_16\JJ\1740 to_17\TO\1740 the_18\DT\1740 ingestion_19\NN\13440063 of_20\IN\1740 a_21\DT\13649268 high_22\JJ\1740 dose_23\NN\3740161 of_24\IN\1740 <e1>clioquinol</e1>_25\NN\2720201 over_26\IN\5867413 a_27\DT\13649268 short_28\JJ\1740 period_29\NN\13575869 ._30\.\1740
D007464_C538178 NONE this_0\DT\1740 was_1\VBD\836236 most_2\RBS\1740 frequently_3\RB\1740 found_4\VBN\2426171 in_5\IN\13603305 children_6\NNS\9622049 ,_7\,\1740 many_8\DT\1740 of_9\IN\1740 whom_10\WP\1740 had_11\VBD\2108377 received_12\VBN\2210855 <e1>clioquinol</e1>_13\NN\2720201 as_14\IN\14622893 treatment_15\NN\654885 for_16\IN\1740 <e2>acrodermatitis_17\NN\1740 enteropathica</e2>_18\NN\1740 ._19\.\1740
9727773
D001067_D006976 CID high_0\JJ\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>primary_3\JJ\1740 pulmonary_4\JJ\1740 hypertension</e2>_5\NN\14057371 associated_6\VBN\628491 with_7\IN\1740 <e1>appetite_8\JJ\1740 suppressants</e1>_9\NNS\3247620 in_10\IN\13603305 belgium_11\NNP\1740 ._12\.\1740
D001067_D006976 CID <e2>primary_0\JJ\1740 pulmonary_1\JJ\1740 hypertension</e2>_2\NN\14057371 is_3\VBZ\836236 a_4\DT\13649268 rare_5\JJ\1740 ,_6\,\1740 progressive_7\JJ\1740 and_8\CC\1740 incurable_9\JJ\1740 disease_10\NN\14061805 ,_11\,\1740 which_12\WDT\1740 has_13\VBZ\2108377 been_14\VBN\836236 associated_15\VBN\628491 with_16\IN\1740 the_17\DT\1740 intake_18\NN\13440063 of_19\IN\1740 <e1>appetite_20\JJ\1740 suppressant</e1>_21\JJ\1740 drugs_22\NNS\14778436 ._23\.\1740
D001067_D006976 CID in_0\IN\13603305 8_1\CD\13741022 patients_2\NNS\9898892 the_3\DT\1740 diagnosis_4\NN\152018 of_5\IN\1740 <e2>primary_6\JJ\1740 pulmonary_7\JJ\1740 hypertension</e2>_8\NN\14057371 was_9\VBD\836236 uncertain_10\JJ\1740 ,_11\,\1740 5_12\CD\13741022 of_13\IN\1740 them_14\PRP\1740 had_15\VBD\2108377 taken_16\VBN\2367363 <e1>appetite_17\JJ\1740 suppressants</e1>_18\NNS\3247620 ._19\.\1740
D001067_D006976 CID a_0\DT\13649268 policy_1\NN\5902545 of_2\IN\1740 unrestricted_3\JJ\1740 prescription_4\NN\6786629 of_5\IN\1740 <e1>appetite_6\JJ\1740 suppressants</e1>_7\NNS\3247620 may_8\MD\15209706 lead_9\VB\1752884 to_10\TO\1740 a_11\DT\13649268 high_12\JJ\1740 incidence_13\NN\13821570 of_14\IN\1740 associated_15\VBN\628491 <e2>primary_16\JJ\1740 pulmonary_17\JJ\1740 hypertension</e2>_18\NN\14057371 ._19\.\1740
8302922
D000527_D007022 CID epidural_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 during_3\IN\1740 <e1>prostaglandin_4\NN\5414534 e1</e1>_5\NN\1740 or_6\CC\3541091 trimethaphan_7\NN\1740 induced_8\VBD\1627355 <e2>hypotension</e2>_9\NN\14057371 ._10\.\1740
D000527_D007022 CID to_0\TO\1740 evaluate_1\VB\670261 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 <e1>prostaglandin_5\NN\5414534 e1</e1>_6\NN\1740 (_7\-LRB-\1740 pge1_8\NN\1740 )_9\-RRB-\1740 or_10\CC\3541091 trimethaphan_11\NN\1740 (_12\-LRB-\1740 tmp_13\NN\1740 )_14\-RRB-\1740 induced_15\VBD\1627355 <e2>hypotension</e2>_16\NN\14057371 on_17\IN\1740 epidural_18\JJ\1740 blood_19\NN\5397468 flow_20\NN\7311115 (_21\-LRB-\1740 ebf_22\NN\1740 )_23\-RRB-\1740 during_24\IN\1740 spinal_25\JJ\1740 surgery_26\NN\6045562 ,_27\,\1740 ebf_28\NN\1740 was_29\VBD\836236 measured_30\VBN\697589 using_31\VBG\1156834 the_32\DT\1740 heat_33\NN\11452218 clearance_34\NN\5089947 method_35\NN\5616786 in_36\IN\13603305 30_37\CD\13745420 patients_38\NNS\9898892 who_39\WP\8299493 underwent_40\VBD\109660 postero-lateral_41\JJ\1740 interbody_42\NN\1740 fusion_43\NN\7373277 under_44\IN\1740 isoflurane_45\NN\3570838 anaesthesia_46\NN\14034177 ._47\.\1740
D000527_D007022 CID to_0\TO\1740 evaluate_1\VB\670261 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 prostaglandin_5\NN\5414534 e1_6\NN\1740 (_7\-LRB-\1740 <e1>pge1</e1>_8\NN\1740 )_9\-RRB-\1740 or_10\CC\3541091 trimethaphan_11\NN\1740 (_12\-LRB-\1740 tmp_13\NN\1740 )_14\-RRB-\1740 induced_15\VBD\1627355 <e2>hypotension</e2>_16\NN\14057371 on_17\IN\1740 epidural_18\JJ\1740 blood_19\NN\5397468 flow_20\NN\7311115 (_21\-LRB-\1740 ebf_22\NN\1740 )_23\-RRB-\1740 during_24\IN\1740 spinal_25\JJ\1740 surgery_26\NN\6045562 ,_27\,\1740 ebf_28\NN\1740 was_29\VBD\836236 measured_30\VBN\697589 using_31\VBG\1156834 the_32\DT\1740 heat_33\NN\11452218 clearance_34\NN\5089947 method_35\NN\5616786 in_36\IN\13603305 30_37\CD\13745420 patients_38\NNS\9898892 who_39\WP\8299493 underwent_40\VBD\109660 postero-lateral_41\JJ\1740 interbody_42\NN\1740 fusion_43\NN\7373277 under_44\IN\1740 isoflurane_45\NN\3570838 anaesthesia_46\NN\14034177 ._47\.\1740
D000527_D007022 CID after_0\IN\1740 starting_1\VBG\2009433 <e1>pge1</e1>_2\NN\1740 or_3\CC\3541091 tmp_4\NN\1740 ,_5\,\1740 map_6\NN\4076846 and_7\CC\1740 rate_8\NN\13815152 pressure_9\NN\11419404 product_10\NN\3076708 (_11\-LRB-\1740 rpp_12\NN\1740 )_13\-RRB-\1740 decreased_14\VBD\169651 significantly_15\RB\1740 compared_16\VBN\644583 with_17\IN\1740 preinfusion_18\NN\1740 values_19\NNS\5941423 (_20\-LRB-\1740 p_21\NN\14622893 <_22\XX\1740 0.01_23\CD\1740 )_24\-RRB-\1740 ,_25\,\1740 and_26\CC\1740 the_27\DT\1740 degree_28\NN\4916342 of_29\IN\1740 <e2>hypotension</e2>_30\NN\14057371 due_31\IN\5174653 to_32\TO\1740 pge1_33\NN\1740 remained_34\VBD\2604760 constant_35\JJ\1740 until_36\IN\1740 60_37\CD\13745420 min_38\NN\15154774 after_39\IN\1740 its_40\PRP$\6125041 discontinuation_41\NN\209943 ._42\.\1740
D000527_D007022 CID after_0\IN\1740 starting_1\VBG\2009433 pge1_2\NN\1740 or_3\CC\3541091 tmp_4\NN\1740 ,_5\,\1740 map_6\NN\4076846 and_7\CC\1740 rate_8\NN\13815152 pressure_9\NN\11419404 product_10\NN\3076708 (_11\-LRB-\1740 rpp_12\NN\1740 )_13\-RRB-\1740 decreased_14\VBD\169651 significantly_15\RB\1740 compared_16\VBN\644583 with_17\IN\1740 preinfusion_18\NN\1740 values_19\NNS\5941423 (_20\-LRB-\1740 p_21\NN\14622893 <_22\XX\1740 0.01_23\CD\1740 )_24\-RRB-\1740 ,_25\,\1740 and_26\CC\1740 the_27\DT\1740 degree_28\NN\4916342 of_29\IN\1740 <e2>hypotension</e2>_30\NN\14057371 due_31\IN\5174653 to_32\TO\1740 <e1>pge1</e1>_33\NN\1740 remained_34\VBD\2604760 constant_35\JJ\1740 until_36\IN\1740 60_37\CD\13745420 min_38\NN\15154774 after_39\IN\1740 its_40\PRP$\6125041 discontinuation_41\NN\209943 ._42\.\1740
D000527_D007022 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e1>pge1</e1>_4\NN\1740 may_5\MD\15209706 be_6\VB\836236 preferable_7\JJ\1740 to_8\IN\1740 tmp_9\NNP\1740 for_10\IN\1740 <e2>hypotensive</e2>_11\JJ\1740 anaesthesia_12\NN\14034177 in_13\IN\13603305 spinal_14\JJ\1740 surgery_15\NN\6045562 because_16\IN\1740 tmp_17\NN\1740 decreased_18\VBD\169651 ebf_19\NN\1740 ._20\.\1740
D014294_D007022 CID epidural_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 during_3\IN\1740 prostaglandin_4\NN\5414534 e1_5\NN\1740 or_6\CC\3541091 <e1>trimethaphan</e1>_7\NN\1740 induced_8\VBD\1627355 <e2>hypotension</e2>_9\NN\14057371 ._10\.\1740
D014294_D007022 CID to_0\TO\1740 evaluate_1\VB\670261 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 prostaglandin_5\NN\5414534 e1_6\NN\1740 (_7\-LRB-\1740 pge1_8\NN\1740 )_9\-RRB-\1740 or_10\CC\3541091 <e1>trimethaphan</e1>_11\NN\1740 (_12\-LRB-\1740 tmp_13\NN\1740 )_14\-RRB-\1740 induced_15\VBD\1627355 <e2>hypotension</e2>_16\NN\14057371 on_17\IN\1740 epidural_18\JJ\1740 blood_19\NN\5397468 flow_20\NN\7311115 (_21\-LRB-\1740 ebf_22\NN\1740 )_23\-RRB-\1740 during_24\IN\1740 spinal_25\JJ\1740 surgery_26\NN\6045562 ,_27\,\1740 ebf_28\NN\1740 was_29\VBD\836236 measured_30\VBN\697589 using_31\VBG\1156834 the_32\DT\1740 heat_33\NN\11452218 clearance_34\NN\5089947 method_35\NN\5616786 in_36\IN\13603305 30_37\CD\13745420 patients_38\NNS\9898892 who_39\WP\8299493 underwent_40\VBD\109660 postero-lateral_41\JJ\1740 interbody_42\NN\1740 fusion_43\NN\7373277 under_44\IN\1740 isoflurane_45\NN\3570838 anaesthesia_46\NN\14034177 ._47\.\1740
D014294_D007022 CID to_0\TO\1740 evaluate_1\VB\670261 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 prostaglandin_5\NN\5414534 e1_6\NN\1740 (_7\-LRB-\1740 pge1_8\NN\1740 )_9\-RRB-\1740 or_10\CC\3541091 trimethaphan_11\NN\1740 (_12\-LRB-\1740 <e1>tmp</e1>_13\NN\1740 )_14\-RRB-\1740 induced_15\VBD\1627355 <e2>hypotension</e2>_16\NN\14057371 on_17\IN\1740 epidural_18\JJ\1740 blood_19\NN\5397468 flow_20\NN\7311115 (_21\-LRB-\1740 ebf_22\NN\1740 )_23\-RRB-\1740 during_24\IN\1740 spinal_25\JJ\1740 surgery_26\NN\6045562 ,_27\,\1740 ebf_28\NN\1740 was_29\VBD\836236 measured_30\VBN\697589 using_31\VBG\1156834 the_32\DT\1740 heat_33\NN\11452218 clearance_34\NN\5089947 method_35\NN\5616786 in_36\IN\13603305 30_37\CD\13745420 patients_38\NNS\9898892 who_39\WP\8299493 underwent_40\VBD\109660 postero-lateral_41\JJ\1740 interbody_42\NN\1740 fusion_43\NN\7373277 under_44\IN\1740 isoflurane_45\NN\3570838 anaesthesia_46\NN\14034177 ._47\.\1740
D014294_D007022 CID after_0\IN\1740 starting_1\VBG\2009433 pge1_2\NN\1740 or_3\CC\3541091 <e1>tmp</e1>_4\NN\1740 ,_5\,\1740 map_6\NN\4076846 and_7\CC\1740 rate_8\NN\13815152 pressure_9\NN\11419404 product_10\NN\3076708 (_11\-LRB-\1740 rpp_12\NN\1740 )_13\-RRB-\1740 decreased_14\VBD\169651 significantly_15\RB\1740 compared_16\VBN\644583 with_17\IN\1740 preinfusion_18\NN\1740 values_19\NNS\5941423 (_20\-LRB-\1740 p_21\NN\14622893 <_22\XX\1740 0.01_23\CD\1740 )_24\-RRB-\1740 ,_25\,\1740 and_26\CC\1740 the_27\DT\1740 degree_28\NN\4916342 of_29\IN\1740 <e2>hypotension</e2>_30\NN\14057371 due_31\IN\5174653 to_32\TO\1740 pge1_33\NN\1740 remained_34\VBD\2604760 constant_35\JJ\1740 until_36\IN\1740 60_37\CD\13745420 min_38\NN\15154774 after_39\IN\1740 its_40\PRP$\6125041 discontinuation_41\NN\209943 ._42\.\1740
D014294_D007022 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 pge1_4\NN\1740 may_5\MD\15209706 be_6\VB\836236 preferable_7\JJ\1740 to_8\IN\1740 <e1>tmp</e1>_9\NNP\1740 for_10\IN\1740 <e2>hypotensive</e2>_11\JJ\1740 anaesthesia_12\NN\14034177 in_13\IN\13603305 spinal_14\JJ\1740 surgery_15\NN\6045562 because_16\IN\1740 tmp_17\NN\1740 decreased_18\VBD\169651 ebf_19\NN\1740 ._20\.\1740
D014294_D007022 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 pge1_4\NN\1740 may_5\MD\15209706 be_6\VB\836236 preferable_7\JJ\1740 to_8\IN\1740 tmp_9\NNP\1740 for_10\IN\1740 <e2>hypotensive</e2>_11\JJ\1740 anaesthesia_12\NN\14034177 in_13\IN\13603305 spinal_14\JJ\1740 surgery_15\NN\6045562 because_16\IN\1740 <e1>tmp</e1>_17\NN\1740 decreased_18\VBD\169651 ebf_19\NN\1740 ._20\.\1740
D007530_D007022 NONE to_0\TO\1740 evaluate_1\VB\670261 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 prostaglandin_5\NN\5414534 e1_6\NN\1740 (_7\-LRB-\1740 pge1_8\NN\1740 )_9\-RRB-\1740 or_10\CC\3541091 trimethaphan_11\NN\1740 (_12\-LRB-\1740 tmp_13\NN\1740 )_14\-RRB-\1740 induced_15\VBD\1627355 <e2>hypotension</e2>_16\NN\14057371 on_17\IN\1740 epidural_18\JJ\1740 blood_19\NN\5397468 flow_20\NN\7311115 (_21\-LRB-\1740 ebf_22\NN\1740 )_23\-RRB-\1740 during_24\IN\1740 spinal_25\JJ\1740 surgery_26\NN\6045562 ,_27\,\1740 ebf_28\NN\1740 was_29\VBD\836236 measured_30\VBN\697589 using_31\VBG\1156834 the_32\DT\1740 heat_33\NN\11452218 clearance_34\NN\5089947 method_35\NN\5616786 in_36\IN\13603305 30_37\CD\13745420 patients_38\NNS\9898892 who_39\WP\8299493 underwent_40\VBD\109660 postero-lateral_41\JJ\1740 interbody_42\NN\1740 fusion_43\NN\7373277 under_44\IN\1740 <e1>isoflurane</e1>_45\NN\3570838 anaesthesia_46\NN\14034177 ._47\.\1740
3437726
D013034_D064420 NONE therefore_0\RB\1740 ,_1\,\1740 patients_2\NNS\9898892 belonging_3\VBG\2604760 to_4\TO\1740 the_5\DT\1740 poor-metabolizer_6\JJ\1740 phenotype_7\NN\4933544 of_8\IN\1740 <e1>sparteine/debrisoquine</e1>_9\NN\1740 polymorphism_10\NN\11418750 in_11\IN\13603305 drug_12\NN\14778436 metabolism_13\NN\13526110 ,_14\,\1740 which_15\WDT\1740 constitutes_16\VBZ\1647229 6.4_17\CD\1740 %_18\NN\1740 of_19\IN\1740 the_20\DT\1740 german_21\JJ\1740 population_22\NN\7942152 ,_23\,\1740 may_24\MD\15209706 experience_25\VB\2108377 <e2>adverse_26\JJ\1740 drug_27\NN\14778436 reactions</e2>_28\NNS\13446390 when_29\WRB\1740 treated_30\VBN\2376958 with_31\IN\1740 standard_32\JJ\1740 doses_33\NNS\3740161 of_34\IN\1740 one_35\CD\13741022 of_36\IN\1740 these_37\DT\1740 drugs_38\NNS\14778436 alone_39\RB\1740 ._40\.\1740
D003647_D064420 NONE therefore_0\RB\1740 ,_1\,\1740 patients_2\NNS\9898892 belonging_3\VBG\2604760 to_4\TO\1740 the_5\DT\1740 poor-metabolizer_6\JJ\1740 phenotype_7\NN\4933544 of_8\IN\1740 <e1>sparteine/debrisoquine</e1>_9\NN\1740 polymorphism_10\NN\11418750 in_11\IN\13603305 drug_12\NN\14778436 metabolism_13\NN\13526110 ,_14\,\1740 which_15\WDT\1740 constitutes_16\VBZ\1647229 6.4_17\CD\1740 %_18\NN\1740 of_19\IN\1740 the_20\DT\1740 german_21\JJ\1740 population_22\NN\7942152 ,_23\,\1740 may_24\MD\15209706 experience_25\VB\2108377 <e2>adverse_26\JJ\1740 drug_27\NN\14778436 reactions</e2>_28\NNS\13446390 when_29\WRB\1740 treated_30\VBN\2376958 with_31\IN\1740 standard_32\JJ\1740 doses_33\NNS\3740161 of_34\IN\1740 one_35\CD\13741022 of_36\IN\1740 these_37\DT\1740 drugs_38\NNS\14778436 alone_39\RB\1740 ._40\.\1740
12789195
D008914_D004194 NONE <e2>pseudoacromegaly</e2>_0\NNP\1740 induced_1\VBN\1627355 by_2\IN\1740 the_3\DT\1740 long-term_4\JJ\1740 use_5\NN\407535 of_6\IN\1740 <e1>minoxidil</e1>_7\NN\4522904 ._8\.\1740
D008914_D004194 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 <e2>pseudoacromegaly</e2>_5\NN\1740 that_6\WDT\1740 resulted_7\VBD\2633881 from_8\IN\1740 the_9\DT\1740 long-term_10\JJ\1740 use_11\NN\407535 of_12\IN\1740 <e1>minoxidil</e1>_13\NN\4522904 at_14\IN\14622893 an_15\DT\6697703 unusually_16\RB\1740 high_17\JJ\1740 dose_18\NN\3740161 ._19\.\1740
D008914_D004194 NONE this_0\DT\1740 is_1\VBZ\836236 the_2\DT\1740 first_3\JJ\1740 case_4\NN\7283608 report_5\NN\6470073 of_6\IN\1740 <e2>pseudoacromegaly</e2>_7\NN\1740 as_8\IN\14622893 a_9\DT\13649268 side_10\JJ\1740 effect_11\NN\34213 of_12\IN\1740 <e1>minoxidil</e1>_13\NN\4522904 use_14\NN\407535 ._15\.\1740
12198388
D000109_D012640 NONE the_0\DT\1740 relationship_1\NN\31921 between_2\IN\1740 hippocampal_3\NN\1740 <e1>acetylcholine</e1>_4\NN\14807558 release_5\NN\3748886 and_6\CC\1740 cholinergic_7\JJ\1740 convulsant_8\NN\1740 sensitivity_9\NN\5651971 in_10\IN\13603305 withdrawal_11\NN\7206096 <e2>seizure-prone</e2>_12\NN\1740 and_13\CC\1740 withdrawal_14\NN\7206096 seizure-resistant_15\JJ\1740 selected_16\VBN\697589 mouse_17\NN\2329401 lines_18\NNS\8426461 ._19\.\1740
D000109_D012640 NONE the_0\DT\1740 relationship_1\NN\31921 between_2\IN\1740 hippocampal_3\NN\1740 <e1>acetylcholine</e1>_4\NN\14807558 release_5\NN\3748886 and_6\CC\1740 cholinergic_7\JJ\1740 convulsant_8\NN\1740 sensitivity_9\NN\5651971 in_10\IN\13603305 withdrawal_11\NN\7206096 seizure-prone_12\NN\1740 and_13\CC\1740 withdrawal_14\NN\7206096 <e2>seizure-resistant</e2>_15\JJ\1740 selected_16\VBN\697589 mouse_17\NN\2329401 lines_18\NNS\8426461 ._19\.\1740
D000109_D012640 NONE hippocampal_0\NN\1740 <e1>ach</e1>_1\NN\1740 also_2\RB\1740 was_3\VBD\836236 measured_4\VBN\697589 during_5\IN\1740 testing_6\VBG\670261 for_7\IN\1740 handling-induced_8\JJ\1740 <e2>convulsions</e2>_9\NNS\14081375 ._10\.\1740
D000109_D012640 NONE when_0\WRB\1740 hippocampal_1\NN\1740 <e1>ach</e1>_2\NN\1740 was_3\VBD\836236 measured_4\VBN\697589 during_5\IN\1740 testing_6\VBG\670261 for_7\IN\1740 handling-induced_8\JJ\1740 <e2>convulsions</e2>_9\NNS\14081375 ,_10\,\1740 extracellular_11\JJ\1740 ach_12\NN\1740 was_13\VBD\836236 significantly_14\RB\1740 elevated_15\JJ\1740 (_16\-LRB-\1740 192_17\CD\1740 %_18\NN\1740 )_19\-RRB-\1740 in_20\IN\13603305 wsp_21\NN\1740 mice_22\NNS\2329401 ,_23\,\1740 but_24\CC\1740 was_25\VBD\836236 nonsignificantly_26\RB\1740 elevated_27\JJ\1740 (_28\-LRB-\1740 59_29\CD\1740 %_30\NN\1740 )_31\-RRB-\1740 in_32\IN\13603305 wsr_33\NN\1740 mice_34\NNS\2329401 ._35\.\1740
D000109_D012640 NONE when_0\WRB\1740 hippocampal_1\NN\1740 ach_2\NN\1740 was_3\VBD\836236 measured_4\VBN\697589 during_5\IN\1740 testing_6\VBG\670261 for_7\IN\1740 handling-induced_8\JJ\1740 <e2>convulsions</e2>_9\NNS\14081375 ,_10\,\1740 extracellular_11\JJ\1740 <e1>ach</e1>_12\NN\1740 was_13\VBD\836236 significantly_14\RB\1740 elevated_15\JJ\1740 (_16\-LRB-\1740 192_17\CD\1740 %_18\NN\1740 )_19\-RRB-\1740 in_20\IN\13603305 wsp_21\NN\1740 mice_22\NNS\2329401 ,_23\,\1740 but_24\CC\1740 was_25\VBD\836236 nonsignificantly_26\RB\1740 elevated_27\JJ\1740 (_28\-LRB-\1740 59_29\CD\1740 %_30\NN\1740 )_31\-RRB-\1740 in_32\IN\13603305 wsr_33\NN\1740 mice_34\NNS\2329401 ._35\.\1740
D000431_D012640 NONE methods_0\NNS\5616786 :_1\:\1740 cholinergic_2\JJ\1740 convulsant_3\JJ\1740 sensitivity_4\NN\5651971 was_5\VBD\836236 examined_6\VBN\789138 in_7\IN\13603305 <e1>alcohol-na</e1>_8\NN\1740 ve_9\NN\1740 withdrawal_10\NNP\7206096 <e2>seizure-prone</e2>_11\NN\1740 (_12\-LRB-\1740 wsp_13\NN\1740 )_14\-RRB-\1740 and-resistant_15\JJ\1740 (_16\-LRB-\1740 wsr_17\NN\1740 )_18\-RRB-\1740 mice_19\NNS\2329401 ._20\.\1740
D000431_D012640 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 differences_6\NNS\4723816 in_7\IN\13603305 cholinergic_8\JJ\1740 activity_9\NN\30358 and_10\CC\1740 postsynaptic_11\JJ\1740 sensitivity_12\NN\5651971 to_13\TO\1740 cholinergic_14\JJ\1740 <e2>convulsants</e2>_15\NNS\1740 may_16\MD\15209706 be_17\VB\836236 associated_18\VBN\628491 with_19\IN\1740 <e1>ethanol</e1>_20\NN\14708720 withdrawal_21\NN\7206096 severity_22\NN\5036394 and_23\CC\1740 implicate_24\VB\2677097 cholinergic_25\NN\1740 mechanisms_26\NNS\13446390 in_27\IN\13603305 alcohol_28\NN\7881800 withdrawal_29\NN\7206096 ._30\.\1740
D000431_D012640 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 differences_6\NNS\4723816 in_7\IN\13603305 cholinergic_8\JJ\1740 activity_9\NN\30358 and_10\CC\1740 postsynaptic_11\JJ\1740 sensitivity_12\NN\5651971 to_13\TO\1740 cholinergic_14\JJ\1740 <e2>convulsants</e2>_15\NNS\1740 may_16\MD\15209706 be_17\VB\836236 associated_18\VBN\628491 with_19\IN\1740 ethanol_20\NN\14708720 withdrawal_21\NN\7206096 severity_22\NN\5036394 and_23\CC\1740 implicate_24\VB\2677097 cholinergic_25\NN\1740 mechanisms_26\NNS\13446390 in_27\IN\13603305 <e1>alcohol</e1>_28\NN\7881800 withdrawal_29\NN\7206096 ._30\.\1740
D009538_D014202 NONE animals_0\NNS\4475 were_1\VBD\836236 administered_2\VBN\2436349 <e1>nicotine</e1>_3\NN\14712692 ,_4\,\1740 carbachol_5\NN\1740 ,_6\,\1740 or_7\CC\3541091 neostigmine_8\NN\2718084 via_9\IN\1740 timed_10\VBN\489837 tail_11\NN\5470189 vein_12\NN\5417975 infusion_13\NN\14589223 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 latencies_17\NNS\15269513 to_18\TO\1740 onset_19\NN\7325190 of_20\IN\1740 <e2>tremor</e2>_21\NN\345926 and_22\CC\1740 clonus_23\NNS\14082595 were_24\VBD\836236 recorded_25\VBN\2225492 and_26\CC\1740 converted_27\VBN\126264 to_28\TO\1740 threshold_29\JJ\1740 dose_30\NN\3740161 ._31\.\1740
D002217_D014202 NONE animals_0\NNS\4475 were_1\VBD\836236 administered_2\VBN\2436349 nicotine_3\NN\14712692 ,_4\,\1740 <e1>carbachol</e1>_5\NN\1740 ,_6\,\1740 or_7\CC\3541091 neostigmine_8\NN\2718084 via_9\IN\1740 timed_10\VBN\489837 tail_11\NN\5470189 vein_12\NN\5417975 infusion_13\NN\14589223 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 latencies_17\NNS\15269513 to_18\TO\1740 onset_19\NN\7325190 of_20\IN\1740 <e2>tremor</e2>_21\NN\345926 and_22\CC\1740 clonus_23\NNS\14082595 were_24\VBD\836236 recorded_25\VBN\2225492 and_26\CC\1740 converted_27\VBN\126264 to_28\TO\1740 threshold_29\JJ\1740 dose_30\NN\3740161 ._31\.\1740
D009388_D014202 NONE animals_0\NNS\4475 were_1\VBD\836236 administered_2\VBN\2436349 nicotine_3\NN\14712692 ,_4\,\1740 carbachol_5\NN\1740 ,_6\,\1740 or_7\CC\3541091 <e1>neostigmine</e1>_8\NN\2718084 via_9\IN\1740 timed_10\VBN\489837 tail_11\NN\5470189 vein_12\NN\5417975 infusion_13\NN\14589223 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 latencies_17\NNS\15269513 to_18\TO\1740 onset_19\NN\7325190 of_20\IN\1740 <e2>tremor</e2>_21\NN\345926 and_22\CC\1740 clonus_23\NNS\14082595 were_24\VBD\836236 recorded_25\VBN\2225492 and_26\CC\1740 converted_27\VBN\126264 to_28\TO\1740 threshold_29\JJ\1740 dose_30\NN\3740161 ._31\.\1740
D009538_D012640 CID results_0\NNS\34213 :_1\:\1740 sensitivity_2\NN\5651971 to_3\TO\1740 several_4\JJ\1740 <e2>convulsion</e2>_5\NN\14081375 endpoints_6\NNS\8566028 induced_7\VBN\1627355 by_8\IN\1740 <e1>nicotine</e1>_9\NN\14712692 ,_10\,\1740 carbachol_11\NN\1740 ,_12\,\1740 and_13\CC\1740 neostigmine_14\NN\2718084 were_15\VBD\836236 significantly_16\RB\1740 greater_17\JJR\1740 in_18\IN\13603305 wsr_19\NN\1740 versus_20\CC\1740 wsp_21\NN\1740 mice_22\NNS\2329401 ._23\.\1740
D002217_D012640 CID results_0\NNS\34213 :_1\:\1740 sensitivity_2\NN\5651971 to_3\TO\1740 several_4\JJ\1740 <e2>convulsion</e2>_5\NN\14081375 endpoints_6\NNS\8566028 induced_7\VBN\1627355 by_8\IN\1740 nicotine_9\NN\14712692 ,_10\,\1740 <e1>carbachol</e1>_11\NN\1740 ,_12\,\1740 and_13\CC\1740 neostigmine_14\NN\2718084 were_15\VBD\836236 significantly_16\RB\1740 greater_17\JJR\1740 in_18\IN\13603305 wsr_19\NN\1740 versus_20\CC\1740 wsp_21\NN\1740 mice_22\NNS\2329401 ._23\.\1740
D009388_D012640 CID results_0\NNS\34213 :_1\:\1740 sensitivity_2\NN\5651971 to_3\TO\1740 several_4\JJ\1740 <e2>convulsion</e2>_5\NN\14081375 endpoints_6\NNS\8566028 induced_7\VBN\1627355 by_8\IN\1740 nicotine_9\NN\14712692 ,_10\,\1740 carbachol_11\NN\1740 ,_12\,\1740 and_13\CC\1740 <e1>neostigmine</e1>_14\NN\2718084 were_15\VBD\836236 significantly_16\RB\1740 greater_17\JJR\1740 in_18\IN\13603305 wsr_19\NN\1740 versus_20\CC\1740 wsp_21\NN\1740 mice_22\NNS\2329401 ._23\.\1740
6518066
D008094_D004437 CID maternal_0\JJ\1740 <e1>lithium</e1>_1\NN\14625458 and_2\CC\1740 neonatal_3\JJ\1740 <e2>ebstein_4\NNP\1740 's_5\POS\1740 anomaly</e2>_6\NN\14501726 :_7\:\1740 evaluation_8\NN\874067 with_9\IN\1740 cross-sectional_10\JJ\1740 echocardiography_11\NN\177127 ._12\.\1740
D008094_D006331 NONE cross-sectional_0\JJ\1740 echocardiographic_1\JJ\1740 screening_2\NN\6887726 of_3\IN\1740 newborns_4\NNS\9827683 exposed_5\VBN\2110927 to_6\TO\1740 <e1>lithium</e1>_7\NN\14625458 during_8\IN\1740 gestation_9\NN\15116532 can_10\MD\3094503 provide_11\VB\2199590 highly_12\RB\1740 accurate_13\JJ\1740 ,_14\,\1740 noninvasive_15\JJ\1740 assessment_16\NN\5732756 of_17\IN\1740 the_18\DT\1740 presence_19\NN\13954253 or_20\CC\3541091 absence_21\NN\14449405 of_22\IN\1740 lithium-induced_23\JJ\1740 <e2>cardiac_24\JJ\1740 malformations</e2>_25\NNS\14213199 ._26\.\1740
D008094_D006331 NONE cross-sectional_0\JJ\1740 echocardiographic_1\JJ\1740 screening_2\NN\6887726 of_3\IN\1740 newborns_4\NNS\9827683 exposed_5\VBN\2110927 to_6\TO\1740 lithium_7\NN\14625458 during_8\IN\1740 gestation_9\NN\15116532 can_10\MD\3094503 provide_11\VB\2199590 highly_12\RB\1740 accurate_13\JJ\1740 ,_14\,\1740 noninvasive_15\JJ\1740 assessment_16\NN\5732756 of_17\IN\1740 the_18\DT\1740 presence_19\NN\13954253 or_20\CC\3541091 absence_21\NN\14449405 of_22\IN\1740 <e1>lithium-induced</e1>_23\JJ\1740 <e2>cardiac_24\JJ\1740 malformations</e2>_25\NNS\14213199 ._26\.\1740
10520387
D004809_D007022 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 safety_3\NN\13920835 and_4\CC\1740 efficacy_5\NN\5199286 of_6\IN\1740 adding_7\VBG\156601 different_8\JJ\1740 doses_9\NNS\3740161 of_10\IN\1740 <e1>ephedrine</e1>_11\NN\14712692 to_12\TO\1740 propofol_13\VB\1740 in_14\IN\13603305 order_15\NN\7168131 to_16\TO\1740 obtund_17\VB\192051 the_18\DT\1740 <e2>hypotensive</e2>_19\JJ\1740 response_20\NN\11410625 ._21\.\1740
D004809_D007022 NONE the_0\DT\1740 addition_1\NN\3081021 of_2\IN\1740 <e1>ephedrine</e1>_3\NN\14712692 to_4\TO\1740 propofol_5\NN\1740 appears_6\VBZ\2604760 to_7\TO\1740 be_8\VB\836236 an_9\DT\6697703 effective_10\JJ\1740 method_11\NN\5616786 of_12\IN\1740 obtunding_13\VBG\192051 the_14\DT\1740 <e2>hypotensive</e2>_15\JJ\1740 response_16\NN\11410625 to_17\TO\1740 propofol_18\NN\1740 at_19\IN\14622893 all_20\DT\1740 doses_21\NNS\3740161 used_22\VBN\1156834 in_23\IN\13603305 this_24\DT\1740 study_25\NN\635850 ._26\.\1740
D015742_D007022 CID we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 safety_3\NN\13920835 and_4\CC\1740 efficacy_5\NN\5199286 of_6\IN\1740 adding_7\VBG\156601 different_8\JJ\1740 doses_9\NNS\3740161 of_10\IN\1740 ephedrine_11\NN\14712692 to_12\TO\1740 <e1>propofol</e1>_13\VB\1740 in_14\IN\13603305 order_15\NN\7168131 to_16\TO\1740 obtund_17\VB\192051 the_18\DT\1740 <e2>hypotensive</e2>_19\JJ\1740 response_20\NN\11410625 ._21\.\1740
D015742_D007022 CID the_0\DT\1740 addition_1\NN\3081021 of_2\IN\1740 ephedrine_3\NN\14712692 to_4\TO\1740 <e1>propofol</e1>_5\NN\1740 appears_6\VBZ\2604760 to_7\TO\1740 be_8\VB\836236 an_9\DT\6697703 effective_10\JJ\1740 method_11\NN\5616786 of_12\IN\1740 obtunding_13\VBG\192051 the_14\DT\1740 <e2>hypotensive</e2>_15\JJ\1740 response_16\NN\11410625 to_17\TO\1740 propofol_18\NN\1740 at_19\IN\14622893 all_20\DT\1740 doses_21\NNS\3740161 used_22\VBN\1156834 in_23\IN\13603305 this_24\DT\1740 study_25\NN\635850 ._26\.\1740
D015742_D007022 CID the_0\DT\1740 addition_1\NN\3081021 of_2\IN\1740 ephedrine_3\NN\14712692 to_4\TO\1740 propofol_5\NN\1740 appears_6\VBZ\2604760 to_7\TO\1740 be_8\VB\836236 an_9\DT\6697703 effective_10\JJ\1740 method_11\NN\5616786 of_12\IN\1740 obtunding_13\VBG\192051 the_14\DT\1740 <e2>hypotensive</e2>_15\JJ\1740 response_16\NN\11410625 to_17\TO\1740 <e1>propofol</e1>_18\NN\1740 at_19\IN\14622893 all_20\DT\1740 doses_21\NNS\3740161 used_22\VBN\1156834 in_23\IN\13603305 this_24\DT\1740 study_25\NN\635850 ._26\.\1740
D004809_D013610 CID however_0\RB\1740 ,_1\,\1740 marked_2\JJ\1740 <e2>tachycardia</e2>_3\NN\14110674 associated_4\VBN\628491 with_5\IN\1740 the_6\DT\1740 use_7\NN\407535 of_8\IN\1740 <e1>ephedrine</e1>_9\NN\14712692 in_10\IN\13603305 combination_11\NN\7951464 with_12\IN\1740 propofol_13\NN\1740 occurred_14\VBD\2623529 in_15\IN\13603305 the_16\DT\1740 majority_17\NN\5121418 of_18\IN\1740 patients_19\NNS\9898892 ,_20\,\1740 occasionally_21\RB\1740 reaching_22\VBG\2005948 high_23\JJ\1740 levels_24\NNS\4916342 in_25\IN\13603305 individual_26\JJ\1740 patients_27\NNS\9898892 ._28\.\1740
D004809_D013610 CID due_0\IN\5174653 to_1\IN\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 this_5\DT\1740 <e2>tachycardia</e2>_6\NN\14110674 inducing_7\VBG\1627355 myocardial_8\JJ\1740 ischemia_9\NN\14195315 ,_10\,\1740 we_11\PRP\1740 would_12\MD\1740 not_13\RB\1740 recommend_14\VB\875394 the_15\DT\1740 use_16\NN\407535 in_17\IN\13603305 elderly_18\JJ\1740 patients_19\NNS\9898892 of_20\IN\1740 any_21\DT\1740 of_22\IN\1740 the_23\DT\1740 <e1>ephedrine/propofol/mixtures</e1>_24\NNS\1740 studied_25\VBN\630380 ._26\.\1740
D015742_D013610 CID however_0\RB\1740 ,_1\,\1740 marked_2\JJ\1740 <e2>tachycardia</e2>_3\NN\14110674 associated_4\VBN\628491 with_5\IN\1740 the_6\DT\1740 use_7\NN\407535 of_8\IN\1740 ephedrine_9\NN\14712692 in_10\IN\13603305 combination_11\NN\7951464 with_12\IN\1740 <e1>propofol</e1>_13\NN\1740 occurred_14\VBD\2623529 in_15\IN\13603305 the_16\DT\1740 majority_17\NN\5121418 of_18\IN\1740 patients_19\NNS\9898892 ,_20\,\1740 occasionally_21\RB\1740 reaching_22\VBG\2005948 high_23\JJ\1740 levels_24\NNS\4916342 in_25\IN\13603305 individual_26\JJ\1740 patients_27\NNS\9898892 ._28\.\1740
D015742_D013610 CID due_0\IN\5174653 to_1\IN\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 this_5\DT\1740 <e2>tachycardia</e2>_6\NN\14110674 inducing_7\VBG\1627355 myocardial_8\JJ\1740 ischemia_9\NN\14195315 ,_10\,\1740 we_11\PRP\1740 would_12\MD\1740 not_13\RB\1740 recommend_14\VB\875394 the_15\DT\1740 use_16\NN\407535 in_17\IN\13603305 elderly_18\JJ\1740 patients_19\NNS\9898892 of_20\IN\1740 any_21\DT\1740 of_22\IN\1740 the_23\DT\1740 <e1>ephedrine/propofol/mixtures</e1>_24\NNS\1740 studied_25\VBN\630380 ._26\.\1740
D004809_D017202 NONE due_0\IN\5174653 to_1\IN\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 this_5\DT\1740 tachycardia_6\NN\14110674 inducing_7\VBG\1627355 <e2>myocardial_8\JJ\1740 ischemia</e2>_9\NN\14195315 ,_10\,\1740 we_11\PRP\1740 would_12\MD\1740 not_13\RB\1740 recommend_14\VB\875394 the_15\DT\1740 use_16\NN\407535 in_17\IN\13603305 elderly_18\JJ\1740 patients_19\NNS\9898892 of_20\IN\1740 any_21\DT\1740 of_22\IN\1740 the_23\DT\1740 <e1>ephedrine/propofol/mixtures</e1>_24\NNS\1740 studied_25\VBN\630380 ._26\.\1740
D015742_D017202 NONE due_0\IN\5174653 to_1\IN\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 this_5\DT\1740 tachycardia_6\NN\14110674 inducing_7\VBG\1627355 <e2>myocardial_8\JJ\1740 ischemia</e2>_9\NN\14195315 ,_10\,\1740 we_11\PRP\1740 would_12\MD\1740 not_13\RB\1740 recommend_14\VB\875394 the_15\DT\1740 use_16\NN\407535 in_17\IN\13603305 elderly_18\JJ\1740 patients_19\NNS\9898892 of_20\IN\1740 any_21\DT\1740 of_22\IN\1740 the_23\DT\1740 <e1>ephedrine/propofol/mixtures</e1>_24\NNS\1740 studied_25\VBN\630380 ._26\.\1740
6888657
D004967_D010911 NONE characterization_0\NN\6724763 of_1\IN\1740 <e1>estrogen-induced</e1>_2\JJ\1740 <e2>adenohypophyseal_3\JJ\1740 tumors</e2>_4\NNS\14234074 in_5\IN\13603305 the_6\DT\1740 fischer_7\NNP\1740 344_8\CD\1740 rat_9\NN\2329401 ._10\.\1740
D004054_D010911 CID <e2>pituitary_0\JJ\1740 tumors</e2>_1\NNS\14234074 were_2\VBD\836236 induced_3\VBN\1627355 in_4\IN\13603305 f344_5\NN\1740 female_6\JJ\1740 rats_7\NNS\2329401 by_8\IN\1740 chronic_9\JJ\1740 treatment_10\NN\654885 with_11\IN\1740 <e1>diethylstilbestrol</e1>_12\NN\14749794 (_13\-LRB-\1740 des_14\NN\14749794 ,_15\,\1740 8_16\CD\13741022 -_17\SYM\1740 10_18\CD\13745420 mg_19\NN\13717155 )_20\-RRB-\1740 implanted_21\VBN\1421622 subcutaneously_22\RB\1740 in_23\IN\13603305 silastic_24\JJ\1740 capsules_25\NNS\3094503 ._26\.\1740
D004054_D010911 CID <e2>pituitary_0\JJ\1740 tumors</e2>_1\NNS\14234074 were_2\VBD\836236 induced_3\VBN\1627355 in_4\IN\13603305 f344_5\NN\1740 female_6\JJ\1740 rats_7\NNS\2329401 by_8\IN\1740 chronic_9\JJ\1740 treatment_10\NN\654885 with_11\IN\1740 diethylstilbestrol_12\NN\14749794 (_13\-LRB-\1740 <e1>des</e1>_14\NN\14749794 ,_15\,\1740 8_16\CD\13741022 -_17\SYM\1740 10_18\CD\13745420 mg_19\NN\13717155 )_20\-RRB-\1740 implanted_21\VBN\1421622 subcutaneously_22\RB\1740 in_23\IN\13603305 silastic_24\JJ\1740 capsules_25\NNS\3094503 ._26\.\1740
D004054_D009369 NONE the_0\DT\1740 data_1\NNS\7951464 extend_2\VBP\153263 the_3\DT\1740 findings_4\NNS\7951464 of_5\IN\1740 other_6\JJ\1740 investigators_7\NNS\10560637 ,_8\,\1740 further_9\RB\1740 establishing_10\VBG\2426171 the_11\DT\1740 <e1>des-induced</e1>_12\JJ\1740 <e2>tumor</e2>_13\NN\14234074 as_14\IN\14622893 a_15\DT\13649268 model_16\NN\5888929 for_17\IN\1740 study_18\NN\635850 of_19\IN\1740 prl_20\NN\1740 cellular_21\JJ\1740 control_22\NN\5190804 mechanisms_23\NNS\13446390 ._24\.\1740
15036754
D010755_D012640 NONE <e1>organophosphate-induced</e1>_0\JJ\1740 <e2>convulsions</e2>_1\NNS\14081375 and_2\CC\1740 prevention_3\NN\1073995 of_4\IN\1740 neuropathological_5\JJ\1740 damages_6\NNS\13282550 ._7\.\1740
D010755_D004194 NONE <e1>organophosphate-induced</e1>_0\JJ\1740 convulsions_1\NNS\14081375 and_2\CC\1740 prevention_3\NN\1073995 of_4\IN\1740 <e2>neuropathological_5\JJ\1740 damages</e2>_6\NNS\13282550 ._7\.\1740
D010755_D064420 NONE the_0\DT\1740 acute_1\JJ\1740 <e2>toxicity</e2>_2\NN\13576101 of_3\IN\1740 <e1>ops</e1>_4\NNS\1740 is_5\VBZ\836236 the_6\DT\1740 result_7\NN\34213 of_8\IN\1740 their_9\PRP$\1740 irreversible_10\JJ\1740 binding_11\NN\4688246 with_12\IN\1740 aches_13\NN\14322699 in_14\IN\13603305 the_15\DT\1740 central_16\JJ\1740 nervous_17\JJ\1740 system_18\NN\3575240 (_19\-LRB-\1740 cns_20\NN\5237227 )_21\-RRB-\1740 ,_22\,\1740 which_23\WDT\1740 elevates_24\VBZ\2391803 acetylcholine_25\NN\14807558 (_26\-LRB-\1740 ach_27\NN\1740 )_28\-RRB-\1740 levels_29\NNS\4916342 ._30\.\1740
D010755_D064420 NONE the_0\DT\1740 rats_1\NNS\2329401 treated_2\VBN\2376958 with_3\IN\1740 dfp-atropine_4\NN\1740 showed_5\VBD\2137132 severe_6\JJ\1740 typical_7\JJ\1740 <e1>op-induced</e1>_8\JJ\1740 <e2>toxicity</e2>_9\NN\13576101 signs_10\NNS\6643763 ._11\.\1740
D000109_D064420 NONE the_0\DT\1740 acute_1\JJ\1740 <e2>toxicity</e2>_2\NN\13576101 of_3\IN\1740 ops_4\NNS\1740 is_5\VBZ\836236 the_6\DT\1740 result_7\NN\34213 of_8\IN\1740 their_9\PRP$\1740 irreversible_10\JJ\1740 binding_11\NN\4688246 with_12\IN\1740 aches_13\NN\14322699 in_14\IN\13603305 the_15\DT\1740 central_16\JJ\1740 nervous_17\JJ\1740 system_18\NN\3575240 (_19\-LRB-\1740 cns_20\NN\5237227 )_21\-RRB-\1740 ,_22\,\1740 which_23\WDT\1740 elevates_24\VBZ\2391803 <e1>acetylcholine</e1>_25\NN\14807558 (_26\-LRB-\1740 ach_27\NN\1740 )_28\-RRB-\1740 levels_29\NNS\4916342 ._30\.\1740
D000109_D064420 NONE the_0\DT\1740 acute_1\JJ\1740 <e2>toxicity</e2>_2\NN\13576101 of_3\IN\1740 ops_4\NNS\1740 is_5\VBZ\836236 the_6\DT\1740 result_7\NN\34213 of_8\IN\1740 their_9\PRP$\1740 irreversible_10\JJ\1740 binding_11\NN\4688246 with_12\IN\1740 aches_13\NN\14322699 in_14\IN\13603305 the_15\DT\1740 central_16\JJ\1740 nervous_17\JJ\1740 system_18\NN\3575240 (_19\-LRB-\1740 cns_20\NN\5237227 )_21\-RRB-\1740 ,_22\,\1740 which_23\WDT\1740 elevates_24\VBZ\2391803 acetylcholine_25\NN\14807558 (_26\-LRB-\1740 <e1>ach</e1>_27\NN\1740 )_28\-RRB-\1740 levels_29\NNS\4916342 ._30\.\1740
D007531_D064420 NONE the_0\DT\1740 rats_1\NNS\2329401 treated_2\VBN\2376958 with_3\IN\1740 <e1>dfp-atropine</e1>_4\NN\1740 showed_5\VBD\2137132 severe_6\JJ\1740 typical_7\JJ\1740 op-induced_8\JJ\1740 <e2>toxicity</e2>_9\NN\13576101 signs_10\NNS\6643763 ._11\.\1740
D007531_D064420 NONE atropine-mk801_0\JJ\1740 did_1\VBD\1640855 not_2\RB\1740 offer_3\VB\2327200 any_4\DT\1740 additional_5\JJ\1740 protection_6\NN\407535 against_7\IN\1740 <e1>dfp</e1>_8\NN\1740 <e2>toxicity</e2>_9\NN\13576101 ._10\.\1740
D007531_D064420 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 cpa_3\NN\9761403 ,_4\,\1740 diazepam_5\NN\2830852 and_6\CC\1740 2pam_7\NN\1740 in_8\IN\13603305 combination_9\NN\7951464 with_10\IN\1740 atropine_11\NN\14712692 prevented_12\VBD\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 serious_16\JJ\1740 signs_17\NNS\6643763 of_18\IN\1740 poisoning_19\NN\14034177 and_20\CC\1740 thus_21\RB\1740 reduced_22\VBD\441445 the_23\DT\1740 <e2>toxicity</e2>_24\NN\13576101 of_25\IN\1740 <e1>dfp</e1>_26\NN\1740 in_27\IN\13603305 rat_28\NN\2329401 ._29\.\1740
D001285_D064420 NONE the_0\DT\1740 rats_1\NNS\2329401 treated_2\VBN\2376958 with_3\IN\1740 <e1>dfp-atropine</e1>_4\NN\1740 showed_5\VBD\2137132 severe_6\JJ\1740 typical_7\JJ\1740 op-induced_8\JJ\1740 <e2>toxicity</e2>_9\NN\13576101 signs_10\NNS\6643763 ._11\.\1740
D001285_D064420 NONE <e1>atropine-mk801</e1>_0\JJ\1740 did_1\VBD\1640855 not_2\RB\1740 offer_3\VB\2327200 any_4\DT\1740 additional_5\JJ\1740 protection_6\NN\407535 against_7\IN\1740 dfp_8\NN\1740 <e2>toxicity</e2>_9\NN\13576101 ._10\.\1740
D001285_D064420 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 cpa_3\NN\9761403 ,_4\,\1740 diazepam_5\NN\2830852 and_6\CC\1740 2pam_7\NN\1740 in_8\IN\13603305 combination_9\NN\7951464 with_10\IN\1740 <e1>atropine</e1>_11\NN\14712692 prevented_12\VBD\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 serious_16\JJ\1740 signs_17\NNS\6643763 of_18\IN\1740 poisoning_19\NN\14034177 and_20\CC\1740 thus_21\RB\1740 reduced_22\VBD\441445 the_23\DT\1740 <e2>toxicity</e2>_24\NN\13576101 of_25\IN\1740 dfp_26\NN\1740 in_27\IN\13603305 rat_28\NN\2329401 ._29\.\1740
C048599_D011041 NONE when_0\WRB\1740 <e1>cpa</e1>_1\NN\9761403 ,_2\,\1740 diazepam_3\NN\2830852 or_4\CC\3541091 2pam_5\NN\1740 was_6\VBD\836236 given_7\VBN\2327200 immediately_8\RB\1740 after_9\IN\1740 dfp-atropine_10\NN\1740 ,_11\,\1740 these_12\DT\1740 treatments_13\NNS\654885 prevented_14\VBD\1740 ,_15\,\1740 delayed_16\VBN\439958 or_17\CC\3541091 shortened_18\VBD\429060 the_19\DT\1740 occurrence_20\NN\29378 of_21\IN\1740 serious_22\JJ\1740 signs_23\NNS\6643763 of_24\IN\1740 <e2>poisoning</e2>_25\NN\14034177 ._26\.\1740
C048599_D011041 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>cpa</e1>_3\NN\9761403 ,_4\,\1740 diazepam_5\NN\2830852 and_6\CC\1740 2pam_7\NN\1740 in_8\IN\13603305 combination_9\NN\7951464 with_10\IN\1740 atropine_11\NN\14712692 prevented_12\VBD\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 serious_16\JJ\1740 signs_17\NNS\6643763 of_18\IN\1740 <e2>poisoning</e2>_19\NN\14034177 and_20\CC\1740 thus_21\RB\1740 reduced_22\VBD\441445 the_23\DT\1740 toxicity_24\NN\13576101 of_25\IN\1740 dfp_26\NN\1740 in_27\IN\13603305 rat_28\NN\2329401 ._29\.\1740
D003975_D011041 NONE when_0\WRB\1740 cpa_1\NN\9761403 ,_2\,\1740 <e1>diazepam</e1>_3\NN\2830852 or_4\CC\3541091 2pam_5\NN\1740 was_6\VBD\836236 given_7\VBN\2327200 immediately_8\RB\1740 after_9\IN\1740 dfp-atropine_10\NN\1740 ,_11\,\1740 these_12\DT\1740 treatments_13\NNS\654885 prevented_14\VBD\1740 ,_15\,\1740 delayed_16\VBN\439958 or_17\CC\3541091 shortened_18\VBD\429060 the_19\DT\1740 occurrence_20\NN\29378 of_21\IN\1740 serious_22\JJ\1740 signs_23\NNS\6643763 of_24\IN\1740 <e2>poisoning</e2>_25\NN\14034177 ._26\.\1740
D003975_D011041 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 cpa_3\NN\9761403 ,_4\,\1740 <e1>diazepam</e1>_5\NN\2830852 and_6\CC\1740 2pam_7\NN\1740 in_8\IN\13603305 combination_9\NN\7951464 with_10\IN\1740 atropine_11\NN\14712692 prevented_12\VBD\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 serious_16\JJ\1740 signs_17\NNS\6643763 of_18\IN\1740 <e2>poisoning</e2>_19\NN\14034177 and_20\CC\1740 thus_21\RB\1740 reduced_22\VBD\441445 the_23\DT\1740 toxicity_24\NN\13576101 of_25\IN\1740 dfp_26\NN\1740 in_27\IN\13603305 rat_28\NN\2329401 ._29\.\1740
D011220_D011041 NONE when_0\WRB\1740 cpa_1\NN\9761403 ,_2\,\1740 diazepam_3\NN\2830852 or_4\CC\3541091 <e1>2pam</e1>_5\NN\1740 was_6\VBD\836236 given_7\VBN\2327200 immediately_8\RB\1740 after_9\IN\1740 dfp-atropine_10\NN\1740 ,_11\,\1740 these_12\DT\1740 treatments_13\NNS\654885 prevented_14\VBD\1740 ,_15\,\1740 delayed_16\VBN\439958 or_17\CC\3541091 shortened_18\VBD\429060 the_19\DT\1740 occurrence_20\NN\29378 of_21\IN\1740 serious_22\JJ\1740 signs_23\NNS\6643763 of_24\IN\1740 <e2>poisoning</e2>_25\NN\14034177 ._26\.\1740
D011220_D011041 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 cpa_3\NN\9761403 ,_4\,\1740 diazepam_5\NN\2830852 and_6\CC\1740 <e1>2pam</e1>_7\NN\1740 in_8\IN\13603305 combination_9\NN\7951464 with_10\IN\1740 atropine_11\NN\14712692 prevented_12\VBD\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 serious_16\JJ\1740 signs_17\NNS\6643763 of_18\IN\1740 <e2>poisoning</e2>_19\NN\14034177 and_20\CC\1740 thus_21\RB\1740 reduced_22\VBD\441445 the_23\DT\1740 toxicity_24\NN\13576101 of_25\IN\1740 dfp_26\NN\1740 in_27\IN\13603305 rat_28\NN\2329401 ._29\.\1740
D007531_D011041 NONE when_0\WRB\1740 cpa_1\NN\9761403 ,_2\,\1740 diazepam_3\NN\2830852 or_4\CC\3541091 2pam_5\NN\1740 was_6\VBD\836236 given_7\VBN\2327200 immediately_8\RB\1740 after_9\IN\1740 <e1>dfp-atropine</e1>_10\NN\1740 ,_11\,\1740 these_12\DT\1740 treatments_13\NNS\654885 prevented_14\VBD\1740 ,_15\,\1740 delayed_16\VBN\439958 or_17\CC\3541091 shortened_18\VBD\429060 the_19\DT\1740 occurrence_20\NN\29378 of_21\IN\1740 serious_22\JJ\1740 signs_23\NNS\6643763 of_24\IN\1740 <e2>poisoning</e2>_25\NN\14034177 ._26\.\1740
D007531_D011041 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 cpa_3\NN\9761403 ,_4\,\1740 diazepam_5\NN\2830852 and_6\CC\1740 2pam_7\NN\1740 in_8\IN\13603305 combination_9\NN\7951464 with_10\IN\1740 atropine_11\NN\14712692 prevented_12\VBD\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 serious_16\JJ\1740 signs_17\NNS\6643763 of_18\IN\1740 <e2>poisoning</e2>_19\NN\14034177 and_20\CC\1740 thus_21\RB\1740 reduced_22\VBD\441445 the_23\DT\1740 toxicity_24\NN\13576101 of_25\IN\1740 <e1>dfp</e1>_26\NN\1740 in_27\IN\13603305 rat_28\NN\2329401 ._29\.\1740
D001285_D011041 NONE when_0\WRB\1740 cpa_1\NN\9761403 ,_2\,\1740 diazepam_3\NN\2830852 or_4\CC\3541091 2pam_5\NN\1740 was_6\VBD\836236 given_7\VBN\2327200 immediately_8\RB\1740 after_9\IN\1740 <e1>dfp-atropine</e1>_10\NN\1740 ,_11\,\1740 these_12\DT\1740 treatments_13\NNS\654885 prevented_14\VBD\1740 ,_15\,\1740 delayed_16\VBN\439958 or_17\CC\3541091 shortened_18\VBD\429060 the_19\DT\1740 occurrence_20\NN\29378 of_21\IN\1740 serious_22\JJ\1740 signs_23\NNS\6643763 of_24\IN\1740 <e2>poisoning</e2>_25\NN\14034177 ._26\.\1740
D001285_D011041 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 cpa_3\NN\9761403 ,_4\,\1740 diazepam_5\NN\2830852 and_6\CC\1740 2pam_7\NN\1740 in_8\IN\13603305 combination_9\NN\7951464 with_10\IN\1740 <e1>atropine</e1>_11\NN\14712692 prevented_12\VBD\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 serious_16\JJ\1740 signs_17\NNS\6643763 of_18\IN\1740 <e2>poisoning</e2>_19\NN\14034177 and_20\CC\1740 thus_21\RB\1740 reduced_22\VBD\441445 the_23\DT\1740 toxicity_24\NN\13576101 of_25\IN\1740 dfp_26\NN\1740 in_27\IN\13603305 rat_28\NN\2329401 ._29\.\1740
D016291_D064420 NONE <e1>atropine-mk801</e1>_0\JJ\1740 did_1\VBD\1640855 not_2\RB\1740 offer_3\VB\2327200 any_4\DT\1740 additional_5\JJ\1740 protection_6\NN\407535 against_7\IN\1740 dfp_8\NN\1740 <e2>toxicity</e2>_9\NN\13576101 ._10\.\1740
C048599_D064420 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>cpa</e1>_3\NN\9761403 ,_4\,\1740 diazepam_5\NN\2830852 and_6\CC\1740 2pam_7\NN\1740 in_8\IN\13603305 combination_9\NN\7951464 with_10\IN\1740 atropine_11\NN\14712692 prevented_12\VBD\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 serious_16\JJ\1740 signs_17\NNS\6643763 of_18\IN\1740 poisoning_19\NN\14034177 and_20\CC\1740 thus_21\RB\1740 reduced_22\VBD\441445 the_23\DT\1740 <e2>toxicity</e2>_24\NN\13576101 of_25\IN\1740 dfp_26\NN\1740 in_27\IN\13603305 rat_28\NN\2329401 ._29\.\1740
D003975_D064420 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 cpa_3\NN\9761403 ,_4\,\1740 <e1>diazepam</e1>_5\NN\2830852 and_6\CC\1740 2pam_7\NN\1740 in_8\IN\13603305 combination_9\NN\7951464 with_10\IN\1740 atropine_11\NN\14712692 prevented_12\VBD\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 serious_16\JJ\1740 signs_17\NNS\6643763 of_18\IN\1740 poisoning_19\NN\14034177 and_20\CC\1740 thus_21\RB\1740 reduced_22\VBD\441445 the_23\DT\1740 <e2>toxicity</e2>_24\NN\13576101 of_25\IN\1740 dfp_26\NN\1740 in_27\IN\13603305 rat_28\NN\2329401 ._29\.\1740
D011220_D064420 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 cpa_3\NN\9761403 ,_4\,\1740 diazepam_5\NN\2830852 and_6\CC\1740 <e1>2pam</e1>_7\NN\1740 in_8\IN\13603305 combination_9\NN\7951464 with_10\IN\1740 atropine_11\NN\14712692 prevented_12\VBD\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 serious_16\JJ\1740 signs_17\NNS\6643763 of_18\IN\1740 poisoning_19\NN\14034177 and_20\CC\1740 thus_21\RB\1740 reduced_22\VBD\441445 the_23\DT\1740 <e2>toxicity</e2>_24\NN\13576101 of_25\IN\1740 dfp_26\NN\1740 in_27\IN\13603305 rat_28\NN\2329401 ._29\.\1740
2887062
D004967_D015175 CID immunohistochemical_0\JJ\1740 ,_1\,\1740 electron_2\NN\9338013 microscopic_3\JJ\1740 and_4\CC\1740 morphometric_5\JJ\1740 studies_6\NNS\635850 of_7\IN\1740 <e1>estrogen-induced</e1>_8\JJ\1740 rat_9\NN\2329401 <e2>prolactinomas</e2>_10\NNS\1740 after_11\IN\1740 bromocriptine_12\NN\1740 treatment_13\NN\654885 ._14\.\1740
D004967_D015175 CID to_0\TO\1740 clarify_1\VB\939277 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 bromocriptine_5\NN\1740 on_6\IN\1740 <e2>prolactinoma</e2>_7\NN\1740 cells_8\NNS\3080309 in_9\FW\13603305 vivo_10\FW\1740 ,_11\,\1740 immunohistochemical_12\JJ\1740 ,_13\,\1740 ultrastructural_14\JJ\1740 and_15\CC\1740 morphometrical_16\JJ\1740 analyses_17\NNS\633864 were_18\VBD\836236 applied_19\VBN\2676054 to_20\TO\1740 <e1>estrogen-induced</e1>_21\JJ\1740 rat_22\NN\2329401 prolactinoma_23\NN\1740 cells_24\NNS\3080309 1_25\CD\13741022 h_26\NN\14622893 and_27\CC\1740 6_28\CD\13741022 h_29\NN\14622893 after_30\IN\1740 injection_31\NN\320852 of_32\IN\1740 bromocriptine_33\NN\1740 (_34\-LRB-\1740 3_35\CD\13741022 mg/kg_36\NN\1740 of_37\IN\1740 body_38\NN\19128 weight_39\NN\5009170 )_40\-RRB-\1740 ._41\.\1740
D004967_D015175 CID to_0\TO\1740 clarify_1\VB\939277 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 bromocriptine_5\NN\1740 on_6\IN\1740 prolactinoma_7\NN\1740 cells_8\NNS\3080309 in_9\FW\13603305 vivo_10\FW\1740 ,_11\,\1740 immunohistochemical_12\JJ\1740 ,_13\,\1740 ultrastructural_14\JJ\1740 and_15\CC\1740 morphometrical_16\JJ\1740 analyses_17\NNS\633864 were_18\VBD\836236 applied_19\VBN\2676054 to_20\TO\1740 <e1>estrogen-induced</e1>_21\JJ\1740 rat_22\NN\2329401 <e2>prolactinoma</e2>_23\NN\1740 cells_24\NNS\3080309 1_25\CD\13741022 h_26\NN\14622893 and_27\CC\1740 6_28\CD\13741022 h_29\NN\14622893 after_30\IN\1740 injection_31\NN\320852 of_32\IN\1740 bromocriptine_33\NN\1740 (_34\-LRB-\1740 3_35\CD\13741022 mg/kg_36\NN\1740 of_37\IN\1740 body_38\NN\19128 weight_39\NN\5009170 )_40\-RRB-\1740 ._41\.\1740
D001971_D015175 NONE immunohistochemical_0\JJ\1740 ,_1\,\1740 electron_2\NN\9338013 microscopic_3\JJ\1740 and_4\CC\1740 morphometric_5\JJ\1740 studies_6\NNS\635850 of_7\IN\1740 estrogen-induced_8\JJ\1740 rat_9\NN\2329401 <e2>prolactinomas</e2>_10\NNS\1740 after_11\IN\1740 <e1>bromocriptine</e1>_12\NN\1740 treatment_13\NN\654885 ._14\.\1740
D001971_D015175 NONE to_0\TO\1740 clarify_1\VB\939277 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>bromocriptine</e1>_5\NN\1740 on_6\IN\1740 <e2>prolactinoma</e2>_7\NN\1740 cells_8\NNS\3080309 in_9\FW\13603305 vivo_10\FW\1740 ,_11\,\1740 immunohistochemical_12\JJ\1740 ,_13\,\1740 ultrastructural_14\JJ\1740 and_15\CC\1740 morphometrical_16\JJ\1740 analyses_17\NNS\633864 were_18\VBD\836236 applied_19\VBN\2676054 to_20\TO\1740 estrogen-induced_21\JJ\1740 rat_22\NN\2329401 prolactinoma_23\NN\1740 cells_24\NNS\3080309 1_25\CD\13741022 h_26\NN\14622893 and_27\CC\1740 6_28\CD\13741022 h_29\NN\14622893 after_30\IN\1740 injection_31\NN\320852 of_32\IN\1740 bromocriptine_33\NN\1740 (_34\-LRB-\1740 3_35\CD\13741022 mg/kg_36\NN\1740 of_37\IN\1740 body_38\NN\19128 weight_39\NN\5009170 )_40\-RRB-\1740 ._41\.\1740
D001971_D015175 NONE to_0\TO\1740 clarify_1\VB\939277 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>bromocriptine</e1>_5\NN\1740 on_6\IN\1740 prolactinoma_7\NN\1740 cells_8\NNS\3080309 in_9\FW\13603305 vivo_10\FW\1740 ,_11\,\1740 immunohistochemical_12\JJ\1740 ,_13\,\1740 ultrastructural_14\JJ\1740 and_15\CC\1740 morphometrical_16\JJ\1740 analyses_17\NNS\633864 were_18\VBD\836236 applied_19\VBN\2676054 to_20\TO\1740 estrogen-induced_21\JJ\1740 rat_22\NN\2329401 <e2>prolactinoma</e2>_23\NN\1740 cells_24\NNS\3080309 1_25\CD\13741022 h_26\NN\14622893 and_27\CC\1740 6_28\CD\13741022 h_29\NN\14622893 after_30\IN\1740 injection_31\NN\320852 of_32\IN\1740 bromocriptine_33\NN\1740 (_34\-LRB-\1740 3_35\CD\13741022 mg/kg_36\NN\1740 of_37\IN\1740 body_38\NN\19128 weight_39\NN\5009170 )_40\-RRB-\1740 ._41\.\1740
D001971_D015175 NONE to_0\TO\1740 clarify_1\VB\939277 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 bromocriptine_5\NN\1740 on_6\IN\1740 <e2>prolactinoma</e2>_7\NN\1740 cells_8\NNS\3080309 in_9\FW\13603305 vivo_10\FW\1740 ,_11\,\1740 immunohistochemical_12\JJ\1740 ,_13\,\1740 ultrastructural_14\JJ\1740 and_15\CC\1740 morphometrical_16\JJ\1740 analyses_17\NNS\633864 were_18\VBD\836236 applied_19\VBN\2676054 to_20\TO\1740 estrogen-induced_21\JJ\1740 rat_22\NN\2329401 prolactinoma_23\NN\1740 cells_24\NNS\3080309 1_25\CD\13741022 h_26\NN\14622893 and_27\CC\1740 6_28\CD\13741022 h_29\NN\14622893 after_30\IN\1740 injection_31\NN\320852 of_32\IN\1740 <e1>bromocriptine</e1>_33\NN\1740 (_34\-LRB-\1740 3_35\CD\13741022 mg/kg_36\NN\1740 of_37\IN\1740 body_38\NN\19128 weight_39\NN\5009170 )_40\-RRB-\1740 ._41\.\1740
D001971_D015175 NONE to_0\TO\1740 clarify_1\VB\939277 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 bromocriptine_5\NN\1740 on_6\IN\1740 prolactinoma_7\NN\1740 cells_8\NNS\3080309 in_9\FW\13603305 vivo_10\FW\1740 ,_11\,\1740 immunohistochemical_12\JJ\1740 ,_13\,\1740 ultrastructural_14\JJ\1740 and_15\CC\1740 morphometrical_16\JJ\1740 analyses_17\NNS\633864 were_18\VBD\836236 applied_19\VBN\2676054 to_20\TO\1740 estrogen-induced_21\JJ\1740 rat_22\NN\2329401 <e2>prolactinoma</e2>_23\NN\1740 cells_24\NNS\3080309 1_25\CD\13741022 h_26\NN\14622893 and_27\CC\1740 6_28\CD\13741022 h_29\NN\14622893 after_30\IN\1740 injection_31\NN\320852 of_32\IN\1740 <e1>bromocriptine</e1>_33\NN\1740 (_34\-LRB-\1740 3_35\CD\13741022 mg/kg_36\NN\1740 of_37\IN\1740 body_38\NN\19128 weight_39\NN\5009170 )_40\-RRB-\1740 ._41\.\1740
D001971_D000236 NONE however_0\RB\1740 ,_1\,\1740 only_2\RB\1740 secretory_3\JJ\1740 granules_4\NNS\9290777 showed_5\VBD\2137132 the_6\DT\1740 positive_7\JJ\1740 reaction_8\NN\13446390 products_9\NNS\3076708 for_10\IN\1740 prolactin_11\NN\5410315 6_12\CD\13741022 h_13\NN\14622893 after_14\IN\1740 <e1>bromocriptine</e1>_15\NN\1740 treatment_16\NN\654885 of_17\IN\1740 the_18\DT\1740 <e2>adenoma</e2>_19\NN\14236226 cells_20\NNS\3080309 ._21\.\1740
10669626
D014859_D061205 CID <e1>warfarin-induced</e1>_0\JJ\1740 <e2>artery_1\NN\5417975 calcification</e2>_2\NN\13446390 is_3\VBZ\836236 accelerated_4\VBN\226566 by_5\IN\1740 growth_6\NN\13526110 and_7\CC\1740 vitamin_8\NN\7570720 d._9\NN\1740
D014859_D061205 CID the_0\DT\1740 present_1\JJ\1740 studies_2\NNS\635850 demonstrate_3\VBP\2137132 that_4\IN\1740 growth_5\NN\13526110 and_6\CC\1740 vitamin_7\NN\7570720 d_8\NN\15089472 treatment_9\NN\654885 enhance_10\VBP\227165 the_11\DT\1740 extent_12\NN\13939892 of_13\IN\1740 <e2>artery_14\NN\5417975 calcification</e2>_15\NN\13446390 in_16\IN\13603305 rats_17\NNS\2329401 given_18\VBN\2327200 sufficient_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 <e1>warfarin</e1>_22\NN\2718259 to_23\TO\1740 inhibit_24\VB\2510337 gamma-carboxylation_25\NN\1740 of_26\IN\1740 matrix_27\NN\7939382 gla_28\NN\1740 protein_29\NN\14944888 ,_30\,\1740 a_31\DT\13649268 calcification_32\NN\13446390 inhibitor_33\NN\20090 known_34\VBN\2110220 to_35\TO\1740 be_36\VB\836236 expressed_37\VBN\928630 by_38\IN\1740 smooth_39\JJ\1740 muscle_40\NN\5289601 cells_41\NNS\3080309 and_42\CC\1740 macrophages_43\NNS\5450888 in_44\IN\13603305 the_45\DT\1740 artery_46\NN\5417975 wall_47\NN\3894379 ._48\.\1740
D014859_D061205 CID the_0\DT\1740 first_1\JJ\1740 series_2\NN\8456993 of_3\IN\1740 experiments_4\NNS\641820 examined_5\VBD\789138 the_6\DT\1740 influence_7\NN\5190804 of_8\IN\1740 age_9\NN\4916342 and_10\CC\1740 growth_11\NN\13526110 status_12\NN\24720 on_13\IN\1740 <e2>artery_14\NN\5417975 calcification</e2>_15\NN\13446390 in_16\IN\13603305 <e1>warfarin-treated</e1>_17\JJ\1740 rats_18\NNS\2329401 ._19\.\1740
D014859_D061205 CID treatment_0\NN\654885 for_1\IN\1740 2_2\CD\13741022 weeks_3\NNS\15113229 with_4\IN\1740 <e1>warfarin</e1>_5\NNP\2718259 caused_6\VBD\1617192 massive_7\JJ\1740 focal_8\JJ\1740 <e2>calcification_9\NN\13446390 of_10\IN\1740 the_11\DT\1740 artery</e2>_12\NN\5417975 media_13\NNS\3575240 in_14\IN\13603305 20-day-old_15\JJ\1740 rats_16\NNS\2329401 and_17\CC\1740 less_18\RBR\1740 extensive_19\JJ\1740 focal_20\JJ\1740 calcification_21\NN\13446390 in_22\IN\13603305 42-day-old_23\JJ\1740 rats_24\NNS\2329401 ._25\.\1740
D014859_D061205 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 no_3\DT\7204911 <e2>artery_4\NN\5417975 calcification</e2>_5\NN\13446390 could_6\MD\1740 be_7\VB\836236 detected_8\VBN\2163746 in_9\IN\13603305 10-month-old_10\JJ\1740 adult_11\JJ\1740 rats_12\NNS\2329401 even_13\RB\1740 after_14\IN\1740 4_15\CD\13741022 weeks_16\NNS\15113229 of_17\IN\1740 <e1>warfarin</e1>_18\NN\2718259 treatment_19\NN\654885 ._20\.\1740
D014859_D061205 CID to_0\TO\1740 directly_1\RB\1740 examine_2\VB\789138 the_3\DT\1740 importance_4\NN\5138488 of_5\IN\1740 growth_6\NN\13526110 to_7\TO\1740 <e1>warfarin-induced</e1>_8\JJ\1740 <e2>artery_9\NN\5417975 calcification</e2>_10\NN\13446390 in_11\IN\13603305 animals_12\NNS\4475 of_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 age_16\NN\4916342 ,_17\,\1740 20-day-old_18\JJ\1740 rats_19\NNS\2329401 were_20\VBD\836236 fed_21\VBN\1182709 for_22\IN\1740 2_23\CD\13741022 weeks_24\NNS\15113229 either_25\CC\1740 an_26\DT\6697703 ad_27\NN\7247071 libitum_28\NN\1740 diet_29\NN\7560652 or_30\CC\3541091 a_31\DT\13649268 6-g/d_32\CD\1740 restricted_33\JJ\1740 diet_34\NN\7560652 that_35\WDT\1740 maintains_36\VBZ\2202928 weight_37\NN\5009170 but_38\CC\1740 prevents_39\VBZ\1740 growth_40\NN\13526110 ._41\.\1740
D014859_D061205 CID concurrent_0\JJ\1740 treatment_1\NN\654885 of_2\IN\1740 both_3\CC\1740 dietary_4\JJ\1740 groups_5\NNS\2137 with_6\IN\1740 <e1>warfarin</e1>_7\NNP\2718259 produced_8\VBD\1617192 massive_9\JJ\1740 focal_10\JJ\1740 <e2>calcification_11\NN\13446390 of_12\IN\1740 the_13\DT\1740 artery</e2>_14\NN\5417975 media_15\NNS\3575240 in_16\IN\13603305 the_17\DT\1740 ad_18\NN\7247071 libitum-fed_19\JJ\1740 rats_20\NNS\2329401 but_21\CC\1740 no_22\DT\7204911 detectable_23\JJ\1740 artery_24\NN\5417975 calcification_25\NN\13446390 in_26\IN\13603305 the_27\DT\1740 restricted-diet_28\JJ\1740 ,_29\,\1740 growth-inhibited_30\JJ\1740 group_31\NN\2137 ._32\.\1740
D014859_D061205 CID concurrent_0\JJ\1740 treatment_1\NN\654885 of_2\IN\1740 both_3\CC\1740 dietary_4\JJ\1740 groups_5\NNS\2137 with_6\IN\1740 <e1>warfarin</e1>_7\NNP\2718259 produced_8\VBD\1617192 massive_9\JJ\1740 focal_10\JJ\1740 calcification_11\NN\13446390 of_12\IN\1740 the_13\DT\1740 artery_14\NN\5417975 media_15\NNS\3575240 in_16\IN\13603305 the_17\DT\1740 ad_18\NN\7247071 libitum-fed_19\JJ\1740 rats_20\NNS\2329401 but_21\CC\1740 no_22\DT\7204911 detectable_23\JJ\1740 <e2>artery_24\NN\5417975 calcification</e2>_25\NN\13446390 in_26\IN\13603305 the_27\DT\1740 restricted-diet_28\JJ\1740 ,_29\,\1740 growth-inhibited_30\JJ\1740 group_31\NN\2137 ._32\.\1740
D014859_D061205 CID although_0\IN\1740 the_1\DT\1740 explanation_2\NN\6722453 for_3\IN\1740 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 <e2>artery_7\NN\5417975 calcification</e2>_8\NN\13446390 and_9\CC\1740 growth_10\NN\13526110 status_11\NN\24720 can_12\MD\3094503 not_13\RB\1740 be_14\VB\836236 determined_15\VBN\1645601 from_16\IN\1740 the_17\DT\1740 present_18\JJ\1740 study_19\NN\635850 ,_20\,\1740 there_21\EX\27167 was_22\VBD\836236 a_23\DT\13649268 relationship_24\NN\31921 between_25\IN\1740 higher_26\JJR\1740 serum_27\NN\5397468 phosphate_28\NN\15010703 and_29\CC\1740 susceptibility_30\NN\13920835 to_31\TO\1740 artery_32\NN\5417975 calcification_33\NN\13446390 ,_34\,\1740 with_35\IN\1740 30_36\CD\13745420 %_37\NN\1740 higher_38\JJR\1740 levels_39\NNS\4916342 of_40\IN\1740 serum_41\NN\5397468 phosphate_42\NN\15010703 in_43\IN\13603305 young_44\JJ\1740 ,_45\,\1740 ad_46\NN\7247071 libitum-fed_47\JJ\1740 rats_48\NNS\2329401 compared_49\VBN\644583 with_50\IN\1740 either_51\DT\1740 of_52\IN\1740 the_53\DT\1740 groups_54\NNS\2137 that_55\WDT\1740 was_56\VBD\836236 resistant_57\JJ\1740 to_58\TO\1740 <e1>warfarin-induced</e1>_59\JJ\1740 artery_60\NN\5417975 calcification_61\NN\13446390 ,_62\,\1740 ie_63\FW\1740 ,_64\,\1740 the_65\DT\1740 10-month-old_66\JJ\1740 rats_67\NNS\2329401 and_68\CC\1740 the_69\DT\1740 restricted-diet_70\JJ\1740 ,_71\,\1740 growth-inhibited_72\JJ\1740 young_73\JJ\1740 rats_74\NNS\2329401 ._75\.\1740
D014859_D061205 CID although_0\IN\1740 the_1\DT\1740 explanation_2\NN\6722453 for_3\IN\1740 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 artery_7\NN\5417975 calcification_8\NN\13446390 and_9\CC\1740 growth_10\NN\13526110 status_11\NN\24720 can_12\MD\3094503 not_13\RB\1740 be_14\VB\836236 determined_15\VBN\1645601 from_16\IN\1740 the_17\DT\1740 present_18\JJ\1740 study_19\NN\635850 ,_20\,\1740 there_21\EX\27167 was_22\VBD\836236 a_23\DT\13649268 relationship_24\NN\31921 between_25\IN\1740 higher_26\JJR\1740 serum_27\NN\5397468 phosphate_28\NN\15010703 and_29\CC\1740 susceptibility_30\NN\13920835 to_31\TO\1740 <e2>artery_32\NN\5417975 calcification</e2>_33\NN\13446390 ,_34\,\1740 with_35\IN\1740 30_36\CD\13745420 %_37\NN\1740 higher_38\JJR\1740 levels_39\NNS\4916342 of_40\IN\1740 serum_41\NN\5397468 phosphate_42\NN\15010703 in_43\IN\13603305 young_44\JJ\1740 ,_45\,\1740 ad_46\NN\7247071 libitum-fed_47\JJ\1740 rats_48\NNS\2329401 compared_49\VBN\644583 with_50\IN\1740 either_51\DT\1740 of_52\IN\1740 the_53\DT\1740 groups_54\NNS\2137 that_55\WDT\1740 was_56\VBD\836236 resistant_57\JJ\1740 to_58\TO\1740 <e1>warfarin-induced</e1>_59\JJ\1740 artery_60\NN\5417975 calcification_61\NN\13446390 ,_62\,\1740 ie_63\FW\1740 ,_64\,\1740 the_65\DT\1740 10-month-old_66\JJ\1740 rats_67\NNS\2329401 and_68\CC\1740 the_69\DT\1740 restricted-diet_70\JJ\1740 ,_71\,\1740 growth-inhibited_72\JJ\1740 young_73\JJ\1740 rats_74\NNS\2329401 ._75\.\1740
D014859_D061205 CID although_0\IN\1740 the_1\DT\1740 explanation_2\NN\6722453 for_3\IN\1740 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 artery_7\NN\5417975 calcification_8\NN\13446390 and_9\CC\1740 growth_10\NN\13526110 status_11\NN\24720 can_12\MD\3094503 not_13\RB\1740 be_14\VB\836236 determined_15\VBN\1645601 from_16\IN\1740 the_17\DT\1740 present_18\JJ\1740 study_19\NN\635850 ,_20\,\1740 there_21\EX\27167 was_22\VBD\836236 a_23\DT\13649268 relationship_24\NN\31921 between_25\IN\1740 higher_26\JJR\1740 serum_27\NN\5397468 phosphate_28\NN\15010703 and_29\CC\1740 susceptibility_30\NN\13920835 to_31\TO\1740 artery_32\NN\5417975 calcification_33\NN\13446390 ,_34\,\1740 with_35\IN\1740 30_36\CD\13745420 %_37\NN\1740 higher_38\JJR\1740 levels_39\NNS\4916342 of_40\IN\1740 serum_41\NN\5397468 phosphate_42\NN\15010703 in_43\IN\13603305 young_44\JJ\1740 ,_45\,\1740 ad_46\NN\7247071 libitum-fed_47\JJ\1740 rats_48\NNS\2329401 compared_49\VBN\644583 with_50\IN\1740 either_51\DT\1740 of_52\IN\1740 the_53\DT\1740 groups_54\NNS\2137 that_55\WDT\1740 was_56\VBD\836236 resistant_57\JJ\1740 to_58\TO\1740 <e1>warfarin-induced</e1>_59\JJ\1740 <e2>artery_60\NN\5417975 calcification</e2>_61\NN\13446390 ,_62\,\1740 ie_63\FW\1740 ,_64\,\1740 the_65\DT\1740 10-month-old_66\JJ\1740 rats_67\NNS\2329401 and_68\CC\1740 the_69\DT\1740 restricted-diet_70\JJ\1740 ,_71\,\1740 growth-inhibited_72\JJ\1740 young_73\JJ\1740 rats_74\NNS\2329401 ._75\.\1740
D014859_D061205 CID this_0\DT\1740 observation_1\NN\996969 suggests_2\VBZ\1010118 that_3\IN\1740 increased_4\VBN\169651 susceptibility_5\NN\13920835 to_6\TO\1740 <e1>warfarin-induced</e1>_7\JJ\1740 <e2>artery_8\NN\5417975 calcification</e2>_9\NN\13446390 could_10\MD\1740 be_11\VB\836236 related_12\JJ\1740 to_13\TO\1740 higher_14\JJR\1740 serum_15\NN\5397468 phosphate_16\NN\15010703 levels_17\NNS\4916342 ._18\.\1740
D014859_D061205 CID the_0\DT\1740 second_1\JJ\1740 set_2\NN\7951464 of_3\IN\1740 experiments_4\NNS\641820 examined_5\VBD\789138 the_6\DT\1740 possible_7\JJ\1740 synergy_8\NN\13518963 between_9\IN\1740 vitamin_10\NN\7570720 d_11\NN\15089472 and_12\CC\1740 <e1>warfarin</e1>_13\NN\2718259 in_14\IN\13603305 <e2>artery_15\NN\5417975 calcification</e2>_16\NN\13446390 ._17\.\1740
D014859_D061205 CID high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 the_3\DT\1740 vitamin_4\NN\7570720 k_5\NN\13608598 antagonist_6\NN\7846 <e1>warfarin</e1>_7\NN\2718259 are_8\VBP\836236 also_9\RB\1740 known_10\VBN\2110220 to_11\TO\1740 cause_12\VB\1617192 <e2>calcification_13\NN\13446390 of_14\IN\1740 the_15\DT\1740 artery</e2>_16\NN\5417975 media_17\NNS\3575240 ,_18\,\1740 but_19\CC\1740 at_20\IN\14622893 treatment_21\NN\654885 times_22\NNS\15113229 of_23\IN\1740 2_24\CD\13741022 weeks_25\NNS\15113229 or_26\CC\3541091 longer_27\RBR\1740 yet_28\CC\1740 not_29\RB\1740 at_30\IN\14622893 1_31\CD\13741022 week_32\NN\15113229 ._33\.\1740
D014859_D061205 CID high_0\JJ\1740 levels_1\NNS\4916342 of_2\IN\1740 matrix_3\NN\7939382 gla_4\NN\1740 protein_5\NN\14944888 are_6\VBP\836236 found_7\VBN\2426171 at_8\IN\14622893 sites_9\NNS\8673395 of_10\IN\1740 <e2>artery_11\NN\5417975 calcification</e2>_12\NN\13446390 in_13\IN\13603305 rats_14\NNS\2329401 treated_15\VBN\2376958 with_16\IN\1740 vitamin_17\NN\7570720 d_18\NN\15089472 plus_19\CC\4723816 <e1>warfarin</e1>_20\NN\2718259 ,_21\,\1740 and_22\CC\1740 chemical_23\NN\14580897 analysis_24\NN\633864 showed_25\VBD\2137132 that_26\IN\1740 the_27\DT\1740 protein_28\NN\14944888 that_29\WDT\1740 accumulated_30\VBN\2281093 was_31\VBD\836236 indeed_32\RB\1740 not_33\RB\1740 gamma-carboxylated_34\JJ\1740 ._35\.\1740
D014807_D061205 NONE warfarin-induced_0\JJ\1740 <e2>artery_1\NN\5417975 calcification</e2>_2\NN\13446390 is_3\VBZ\836236 accelerated_4\VBN\226566 by_5\IN\1740 growth_6\NN\13526110 and_7\CC\1740 <e1>vitamin_8\NN\7570720 d.</e1>_9\NN\1740
D014807_D061205 NONE the_0\DT\1740 present_1\JJ\1740 studies_2\NNS\635850 demonstrate_3\VBP\2137132 that_4\IN\1740 growth_5\NN\13526110 and_6\CC\1740 <e1>vitamin_7\NN\7570720 d</e1>_8\NN\15089472 treatment_9\NN\654885 enhance_10\VBP\227165 the_11\DT\1740 extent_12\NN\13939892 of_13\IN\1740 <e2>artery_14\NN\5417975 calcification</e2>_15\NN\13446390 in_16\IN\13603305 rats_17\NNS\2329401 given_18\VBN\2327200 sufficient_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 warfarin_22\NN\2718259 to_23\TO\1740 inhibit_24\VB\2510337 gamma-carboxylation_25\NN\1740 of_26\IN\1740 matrix_27\NN\7939382 gla_28\NN\1740 protein_29\NN\14944888 ,_30\,\1740 a_31\DT\13649268 calcification_32\NN\13446390 inhibitor_33\NN\20090 known_34\VBN\2110220 to_35\TO\1740 be_36\VB\836236 expressed_37\VBN\928630 by_38\IN\1740 smooth_39\JJ\1740 muscle_40\NN\5289601 cells_41\NNS\3080309 and_42\CC\1740 macrophages_43\NNS\5450888 in_44\IN\13603305 the_45\DT\1740 artery_46\NN\5417975 wall_47\NN\3894379 ._48\.\1740
D014807_D061205 NONE the_0\DT\1740 second_1\JJ\1740 set_2\NN\7951464 of_3\IN\1740 experiments_4\NNS\641820 examined_5\VBD\789138 the_6\DT\1740 possible_7\JJ\1740 synergy_8\NN\13518963 between_9\IN\1740 <e1>vitamin_10\NN\7570720 d</e1>_11\NN\15089472 and_12\CC\1740 warfarin_13\NN\2718259 in_14\IN\13603305 <e2>artery_15\NN\5417975 calcification</e2>_16\NN\13446390 ._17\.\1740
D014807_D061205 NONE high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 <e1>vitamin_3\NN\7570720 d</e1>_4\NN\15089472 are_5\VBP\836236 known_6\VBN\2110220 to_7\TO\1740 cause_8\VB\1617192 <e2>calcification_9\NN\13446390 of_10\IN\1740 the_11\DT\1740 artery</e2>_12\NN\5417975 media_13\NNS\3575240 in_14\IN\13603305 as_15\RB\1740 little_16\JJ\1740 as_17\IN\14622893 3_18\CD\13741022 to_19\TO\1740 4_20\CD\13741022 days_21\NNS\15140892 ._22\.\1740
D014807_D061205 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 close_3\JJ\1740 parallel_4\NN\4743605 between_5\IN\1740 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 <e1>vitamin_9\NN\7570720 d</e1>_10\NN\15089472 dose_11\NN\3740161 on_12\IN\1740 <e2>artery_13\NN\5417975 calcification</e2>_14\NN\13446390 and_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 of_18\IN\1740 vitamin_19\NN\7570720 d_20\NN\15089472 dose_21\NN\3740161 on_22\IN\1740 the_23\DT\1740 elevation_24\NN\7445480 of_25\IN\1740 serum_26\NN\5397468 calcium_27\NN\14625458 ,_28\,\1740 which_29\WDT\1740 suggests_30\VBZ\1010118 that_31\IN\1740 vitamin_32\NN\7570720 d_33\NN\15089472 may_34\MD\15209706 induce_35\VB\1627355 artery_36\NN\5417975 calcification_37\NN\13446390 through_38\IN\1740 its_39\PRP$\6125041 effect_40\NN\34213 on_41\IN\1740 serum_42\NN\5397468 calcium_43\NN\14625458 ._44\.\1740
D014807_D061205 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 close_3\JJ\1740 parallel_4\NN\4743605 between_5\IN\1740 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 <e1>vitamin_9\NN\7570720 d</e1>_10\NN\15089472 dose_11\NN\3740161 on_12\IN\1740 artery_13\NN\5417975 calcification_14\NN\13446390 and_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 of_18\IN\1740 vitamin_19\NN\7570720 d_20\NN\15089472 dose_21\NN\3740161 on_22\IN\1740 the_23\DT\1740 elevation_24\NN\7445480 of_25\IN\1740 serum_26\NN\5397468 calcium_27\NN\14625458 ,_28\,\1740 which_29\WDT\1740 suggests_30\VBZ\1010118 that_31\IN\1740 vitamin_32\NN\7570720 d_33\NN\15089472 may_34\MD\15209706 induce_35\VB\1627355 <e2>artery_36\NN\5417975 calcification</e2>_37\NN\13446390 through_38\IN\1740 its_39\PRP$\6125041 effect_40\NN\34213 on_41\IN\1740 serum_42\NN\5397468 calcium_43\NN\14625458 ._44\.\1740
D014807_D061205 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 close_3\JJ\1740 parallel_4\NN\4743605 between_5\IN\1740 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 vitamin_9\NN\7570720 d_10\NN\15089472 dose_11\NN\3740161 on_12\IN\1740 <e2>artery_13\NN\5417975 calcification</e2>_14\NN\13446390 and_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 of_18\IN\1740 <e1>vitamin_19\NN\7570720 d</e1>_20\NN\15089472 dose_21\NN\3740161 on_22\IN\1740 the_23\DT\1740 elevation_24\NN\7445480 of_25\IN\1740 serum_26\NN\5397468 calcium_27\NN\14625458 ,_28\,\1740 which_29\WDT\1740 suggests_30\VBZ\1010118 that_31\IN\1740 vitamin_32\NN\7570720 d_33\NN\15089472 may_34\MD\15209706 induce_35\VB\1627355 artery_36\NN\5417975 calcification_37\NN\13446390 through_38\IN\1740 its_39\PRP$\6125041 effect_40\NN\34213 on_41\IN\1740 serum_42\NN\5397468 calcium_43\NN\14625458 ._44\.\1740
D014807_D061205 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 close_3\JJ\1740 parallel_4\NN\4743605 between_5\IN\1740 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 vitamin_9\NN\7570720 d_10\NN\15089472 dose_11\NN\3740161 on_12\IN\1740 artery_13\NN\5417975 calcification_14\NN\13446390 and_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 of_18\IN\1740 <e1>vitamin_19\NN\7570720 d</e1>_20\NN\15089472 dose_21\NN\3740161 on_22\IN\1740 the_23\DT\1740 elevation_24\NN\7445480 of_25\IN\1740 serum_26\NN\5397468 calcium_27\NN\14625458 ,_28\,\1740 which_29\WDT\1740 suggests_30\VBZ\1010118 that_31\IN\1740 vitamin_32\NN\7570720 d_33\NN\15089472 may_34\MD\15209706 induce_35\VB\1627355 <e2>artery_36\NN\5417975 calcification</e2>_37\NN\13446390 through_38\IN\1740 its_39\PRP$\6125041 effect_40\NN\34213 on_41\IN\1740 serum_42\NN\5397468 calcium_43\NN\14625458 ._44\.\1740
D014807_D061205 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 close_3\JJ\1740 parallel_4\NN\4743605 between_5\IN\1740 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 vitamin_9\NN\7570720 d_10\NN\15089472 dose_11\NN\3740161 on_12\IN\1740 <e2>artery_13\NN\5417975 calcification</e2>_14\NN\13446390 and_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 of_18\IN\1740 vitamin_19\NN\7570720 d_20\NN\15089472 dose_21\NN\3740161 on_22\IN\1740 the_23\DT\1740 elevation_24\NN\7445480 of_25\IN\1740 serum_26\NN\5397468 calcium_27\NN\14625458 ,_28\,\1740 which_29\WDT\1740 suggests_30\VBZ\1010118 that_31\IN\1740 <e1>vitamin_32\NN\7570720 d</e1>_33\NN\15089472 may_34\MD\15209706 induce_35\VB\1627355 artery_36\NN\5417975 calcification_37\NN\13446390 through_38\IN\1740 its_39\PRP$\6125041 effect_40\NN\34213 on_41\IN\1740 serum_42\NN\5397468 calcium_43\NN\14625458 ._44\.\1740
D014807_D061205 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 close_3\JJ\1740 parallel_4\NN\4743605 between_5\IN\1740 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 vitamin_9\NN\7570720 d_10\NN\15089472 dose_11\NN\3740161 on_12\IN\1740 artery_13\NN\5417975 calcification_14\NN\13446390 and_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 of_18\IN\1740 vitamin_19\NN\7570720 d_20\NN\15089472 dose_21\NN\3740161 on_22\IN\1740 the_23\DT\1740 elevation_24\NN\7445480 of_25\IN\1740 serum_26\NN\5397468 calcium_27\NN\14625458 ,_28\,\1740 which_29\WDT\1740 suggests_30\VBZ\1010118 that_31\IN\1740 <e1>vitamin_32\NN\7570720 d</e1>_33\NN\15089472 may_34\MD\15209706 induce_35\VB\1627355 <e2>artery_36\NN\5417975 calcification</e2>_37\NN\13446390 through_38\IN\1740 its_39\PRP$\6125041 effect_40\NN\34213 on_41\IN\1740 serum_42\NN\5397468 calcium_43\NN\14625458 ._44\.\1740
D014807_D061205 NONE high_0\JJ\1740 levels_1\NNS\4916342 of_2\IN\1740 matrix_3\NN\7939382 gla_4\NN\1740 protein_5\NN\14944888 are_6\VBP\836236 found_7\VBN\2426171 at_8\IN\14622893 sites_9\NNS\8673395 of_10\IN\1740 <e2>artery_11\NN\5417975 calcification</e2>_12\NN\13446390 in_13\IN\13603305 rats_14\NNS\2329401 treated_15\VBN\2376958 with_16\IN\1740 <e1>vitamin_17\NN\7570720 d</e1>_18\NN\15089472 plus_19\CC\4723816 warfarin_20\NN\2718259 ,_21\,\1740 and_22\CC\1740 chemical_23\NN\14580897 analysis_24\NN\633864 showed_25\VBD\2137132 that_26\IN\1740 the_27\DT\1740 protein_28\NN\14944888 that_29\WDT\1740 accumulated_30\VBN\2281093 was_31\VBD\836236 indeed_32\RB\1740 not_33\RB\1740 gamma-carboxylated_34\JJ\1740 ._35\.\1740
D014807_D002114 NONE the_0\DT\1740 present_1\JJ\1740 studies_2\NNS\635850 demonstrate_3\VBP\2137132 that_4\IN\1740 growth_5\NN\13526110 and_6\CC\1740 <e1>vitamin_7\NN\7570720 d</e1>_8\NN\15089472 treatment_9\NN\654885 enhance_10\VBP\227165 the_11\DT\1740 extent_12\NN\13939892 of_13\IN\1740 artery_14\NN\5417975 calcification_15\NN\13446390 in_16\IN\13603305 rats_17\NNS\2329401 given_18\VBN\2327200 sufficient_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 warfarin_22\NN\2718259 to_23\TO\1740 inhibit_24\VB\2510337 gamma-carboxylation_25\NN\1740 of_26\IN\1740 matrix_27\NN\7939382 gla_28\NN\1740 protein_29\NN\14944888 ,_30\,\1740 a_31\DT\13649268 <e2>calcification</e2>_32\NN\13446390 inhibitor_33\NN\20090 known_34\VBN\2110220 to_35\TO\1740 be_36\VB\836236 expressed_37\VBN\928630 by_38\IN\1740 smooth_39\JJ\1740 muscle_40\NN\5289601 cells_41\NNS\3080309 and_42\CC\1740 macrophages_43\NNS\5450888 in_44\IN\13603305 the_45\DT\1740 artery_46\NN\5417975 wall_47\NN\3894379 ._48\.\1740
D014807_D002114 NONE in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 the_7\DT\1740 synergy_8\NN\13518963 between_9\IN\1740 these_10\DT\1740 2_11\CD\13741022 treatments_12\NNS\654885 and_13\CC\1740 found_14\VBD\2426171 that_15\IN\1740 concurrent_16\JJ\1740 warfarin_17\NNP\2718259 administration_18\NN\1133281 dramatically_19\RB\1740 increased_20\VBD\169651 the_21\DT\1740 extent_22\NN\13939892 of_23\IN\1740 <e2>calcification</e2>_24\NN\13446390 in_25\IN\13603305 the_26\DT\1740 media_27\NNS\3575240 of_28\IN\1740 <e1>vitamin_29\NN\7570720 d-treated</e1>_30\JJ\1740 rats_31\NNS\2329401 at_32\IN\14622893 3_33\CD\13741022 and_34\CC\1740 4_35\CD\13741022 days_36\NNS\15140892 ._37\.\1740
D014807_D002114 NONE because_0\IN\1740 warfarin_1\NN\2718259 treatment_2\NN\654885 had_3\VBD\2108377 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 the_7\DT\1740 elevation_8\NN\7445480 in_9\IN\13603305 serum_10\NN\5397468 calcium_11\NN\14625458 produced_12\VBN\1617192 by_13\IN\1740 <e1>vitamin_14\NN\7570720 d</e1>_15\NN\15089472 ,_16\,\1740 the_17\DT\1740 synergy_18\NN\13518963 between_19\IN\1740 warfarin_20\NN\2718259 and_21\CC\1740 vitamin_22\NN\7570720 d_23\NN\15089472 is_24\VBZ\836236 probably_25\RB\1740 best_26\RBS\1740 explained_27\VBN\831651 by_28\IN\1740 the_29\DT\1740 hypothesis_30\NN\7162194 that_31\IN\1740 warfarin_32\NN\2718259 inhibits_33\VBZ\2510337 the_34\DT\1740 activity_35\NN\30358 of_36\IN\1740 matrix_37\NN\7939382 gla_38\NN\1740 protein_39\NN\14944888 as_40\IN\14622893 a_41\DT\13649268 <e2>calcification</e2>_42\NN\13446390 inhibitor_43\NN\20090 ._44\.\1740
D014807_D002114 NONE because_0\IN\1740 warfarin_1\NN\2718259 treatment_2\NN\654885 had_3\VBD\2108377 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 the_7\DT\1740 elevation_8\NN\7445480 in_9\IN\13603305 serum_10\NN\5397468 calcium_11\NN\14625458 produced_12\VBN\1617192 by_13\IN\1740 vitamin_14\NN\7570720 d_15\NN\15089472 ,_16\,\1740 the_17\DT\1740 synergy_18\NN\13518963 between_19\IN\1740 warfarin_20\NN\2718259 and_21\CC\1740 <e1>vitamin_22\NN\7570720 d</e1>_23\NN\15089472 is_24\VBZ\836236 probably_25\RB\1740 best_26\RBS\1740 explained_27\VBN\831651 by_28\IN\1740 the_29\DT\1740 hypothesis_30\NN\7162194 that_31\IN\1740 warfarin_32\NN\2718259 inhibits_33\VBZ\2510337 the_34\DT\1740 activity_35\NN\30358 of_36\IN\1740 matrix_37\NN\7939382 gla_38\NN\1740 protein_39\NN\14944888 as_40\IN\14622893 a_41\DT\13649268 <e2>calcification</e2>_42\NN\13446390 inhibitor_43\NN\20090 ._44\.\1740
D014859_D002114 NONE the_0\DT\1740 present_1\JJ\1740 studies_2\NNS\635850 demonstrate_3\VBP\2137132 that_4\IN\1740 growth_5\NN\13526110 and_6\CC\1740 vitamin_7\NN\7570720 d_8\NN\15089472 treatment_9\NN\654885 enhance_10\VBP\227165 the_11\DT\1740 extent_12\NN\13939892 of_13\IN\1740 artery_14\NN\5417975 calcification_15\NN\13446390 in_16\IN\13603305 rats_17\NNS\2329401 given_18\VBN\2327200 sufficient_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 <e1>warfarin</e1>_22\NN\2718259 to_23\TO\1740 inhibit_24\VB\2510337 gamma-carboxylation_25\NN\1740 of_26\IN\1740 matrix_27\NN\7939382 gla_28\NN\1740 protein_29\NN\14944888 ,_30\,\1740 a_31\DT\13649268 <e2>calcification</e2>_32\NN\13446390 inhibitor_33\NN\20090 known_34\VBN\2110220 to_35\TO\1740 be_36\VB\836236 expressed_37\VBN\928630 by_38\IN\1740 smooth_39\JJ\1740 muscle_40\NN\5289601 cells_41\NNS\3080309 and_42\CC\1740 macrophages_43\NNS\5450888 in_44\IN\13603305 the_45\DT\1740 artery_46\NN\5417975 wall_47\NN\3894379 ._48\.\1740
D014859_D002114 NONE treatment_0\NN\654885 for_1\IN\1740 2_2\CD\13741022 weeks_3\NNS\15113229 with_4\IN\1740 <e1>warfarin</e1>_5\NNP\2718259 caused_6\VBD\1617192 massive_7\JJ\1740 focal_8\JJ\1740 calcification_9\NN\13446390 of_10\IN\1740 the_11\DT\1740 artery_12\NN\5417975 media_13\NNS\3575240 in_14\IN\13603305 20-day-old_15\JJ\1740 rats_16\NNS\2329401 and_17\CC\1740 less_18\RBR\1740 extensive_19\JJ\1740 focal_20\JJ\1740 <e2>calcification</e2>_21\NN\13446390 in_22\IN\13603305 42-day-old_23\JJ\1740 rats_24\NNS\2329401 ._25\.\1740
D014859_D002114 NONE in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 the_7\DT\1740 synergy_8\NN\13518963 between_9\IN\1740 these_10\DT\1740 2_11\CD\13741022 treatments_12\NNS\654885 and_13\CC\1740 found_14\VBD\2426171 that_15\IN\1740 concurrent_16\JJ\1740 <e1>warfarin</e1>_17\NNP\2718259 administration_18\NN\1133281 dramatically_19\RB\1740 increased_20\VBD\169651 the_21\DT\1740 extent_22\NN\13939892 of_23\IN\1740 <e2>calcification</e2>_24\NN\13446390 in_25\IN\13603305 the_26\DT\1740 media_27\NNS\3575240 of_28\IN\1740 vitamin_29\NN\7570720 d-treated_30\JJ\1740 rats_31\NNS\2329401 at_32\IN\14622893 3_33\CD\13741022 and_34\CC\1740 4_35\CD\13741022 days_36\NNS\15140892 ._37\.\1740
D014859_D002114 NONE because_0\IN\1740 <e1>warfarin</e1>_1\NN\2718259 treatment_2\NN\654885 had_3\VBD\2108377 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 the_7\DT\1740 elevation_8\NN\7445480 in_9\IN\13603305 serum_10\NN\5397468 calcium_11\NN\14625458 produced_12\VBN\1617192 by_13\IN\1740 vitamin_14\NN\7570720 d_15\NN\15089472 ,_16\,\1740 the_17\DT\1740 synergy_18\NN\13518963 between_19\IN\1740 warfarin_20\NN\2718259 and_21\CC\1740 vitamin_22\NN\7570720 d_23\NN\15089472 is_24\VBZ\836236 probably_25\RB\1740 best_26\RBS\1740 explained_27\VBN\831651 by_28\IN\1740 the_29\DT\1740 hypothesis_30\NN\7162194 that_31\IN\1740 warfarin_32\NN\2718259 inhibits_33\VBZ\2510337 the_34\DT\1740 activity_35\NN\30358 of_36\IN\1740 matrix_37\NN\7939382 gla_38\NN\1740 protein_39\NN\14944888 as_40\IN\14622893 a_41\DT\13649268 <e2>calcification</e2>_42\NN\13446390 inhibitor_43\NN\20090 ._44\.\1740
D014859_D002114 NONE because_0\IN\1740 warfarin_1\NN\2718259 treatment_2\NN\654885 had_3\VBD\2108377 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 the_7\DT\1740 elevation_8\NN\7445480 in_9\IN\13603305 serum_10\NN\5397468 calcium_11\NN\14625458 produced_12\VBN\1617192 by_13\IN\1740 vitamin_14\NN\7570720 d_15\NN\15089472 ,_16\,\1740 the_17\DT\1740 synergy_18\NN\13518963 between_19\IN\1740 <e1>warfarin</e1>_20\NN\2718259 and_21\CC\1740 vitamin_22\NN\7570720 d_23\NN\15089472 is_24\VBZ\836236 probably_25\RB\1740 best_26\RBS\1740 explained_27\VBN\831651 by_28\IN\1740 the_29\DT\1740 hypothesis_30\NN\7162194 that_31\IN\1740 warfarin_32\NN\2718259 inhibits_33\VBZ\2510337 the_34\DT\1740 activity_35\NN\30358 of_36\IN\1740 matrix_37\NN\7939382 gla_38\NN\1740 protein_39\NN\14944888 as_40\IN\14622893 a_41\DT\13649268 <e2>calcification</e2>_42\NN\13446390 inhibitor_43\NN\20090 ._44\.\1740
D014859_D002114 NONE because_0\IN\1740 warfarin_1\NN\2718259 treatment_2\NN\654885 had_3\VBD\2108377 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 the_7\DT\1740 elevation_8\NN\7445480 in_9\IN\13603305 serum_10\NN\5397468 calcium_11\NN\14625458 produced_12\VBN\1617192 by_13\IN\1740 vitamin_14\NN\7570720 d_15\NN\15089472 ,_16\,\1740 the_17\DT\1740 synergy_18\NN\13518963 between_19\IN\1740 warfarin_20\NN\2718259 and_21\CC\1740 vitamin_22\NN\7570720 d_23\NN\15089472 is_24\VBZ\836236 probably_25\RB\1740 best_26\RBS\1740 explained_27\VBN\831651 by_28\IN\1740 the_29\DT\1740 hypothesis_30\NN\7162194 that_31\IN\1740 <e1>warfarin</e1>_32\NN\2718259 inhibits_33\VBZ\2510337 the_34\DT\1740 activity_35\NN\30358 of_36\IN\1740 matrix_37\NN\7939382 gla_38\NN\1740 protein_39\NN\14944888 as_40\IN\14622893 a_41\DT\13649268 <e2>calcification</e2>_42\NN\13446390 inhibitor_43\NN\20090 ._44\.\1740
D010710_D061205 NONE although_0\IN\1740 the_1\DT\1740 explanation_2\NN\6722453 for_3\IN\1740 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 <e2>artery_7\NN\5417975 calcification</e2>_8\NN\13446390 and_9\CC\1740 growth_10\NN\13526110 status_11\NN\24720 can_12\MD\3094503 not_13\RB\1740 be_14\VB\836236 determined_15\VBN\1645601 from_16\IN\1740 the_17\DT\1740 present_18\JJ\1740 study_19\NN\635850 ,_20\,\1740 there_21\EX\27167 was_22\VBD\836236 a_23\DT\13649268 relationship_24\NN\31921 between_25\IN\1740 higher_26\JJR\1740 serum_27\NN\5397468 <e1>phosphate</e1>_28\NN\15010703 and_29\CC\1740 susceptibility_30\NN\13920835 to_31\TO\1740 artery_32\NN\5417975 calcification_33\NN\13446390 ,_34\,\1740 with_35\IN\1740 30_36\CD\13745420 %_37\NN\1740 higher_38\JJR\1740 levels_39\NNS\4916342 of_40\IN\1740 serum_41\NN\5397468 phosphate_42\NN\15010703 in_43\IN\13603305 young_44\JJ\1740 ,_45\,\1740 ad_46\NN\7247071 libitum-fed_47\JJ\1740 rats_48\NNS\2329401 compared_49\VBN\644583 with_50\IN\1740 either_51\DT\1740 of_52\IN\1740 the_53\DT\1740 groups_54\NNS\2137 that_55\WDT\1740 was_56\VBD\836236 resistant_57\JJ\1740 to_58\TO\1740 warfarin-induced_59\JJ\1740 artery_60\NN\5417975 calcification_61\NN\13446390 ,_62\,\1740 ie_63\FW\1740 ,_64\,\1740 the_65\DT\1740 10-month-old_66\JJ\1740 rats_67\NNS\2329401 and_68\CC\1740 the_69\DT\1740 restricted-diet_70\JJ\1740 ,_71\,\1740 growth-inhibited_72\JJ\1740 young_73\JJ\1740 rats_74\NNS\2329401 ._75\.\1740
D010710_D061205 NONE although_0\IN\1740 the_1\DT\1740 explanation_2\NN\6722453 for_3\IN\1740 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 artery_7\NN\5417975 calcification_8\NN\13446390 and_9\CC\1740 growth_10\NN\13526110 status_11\NN\24720 can_12\MD\3094503 not_13\RB\1740 be_14\VB\836236 determined_15\VBN\1645601 from_16\IN\1740 the_17\DT\1740 present_18\JJ\1740 study_19\NN\635850 ,_20\,\1740 there_21\EX\27167 was_22\VBD\836236 a_23\DT\13649268 relationship_24\NN\31921 between_25\IN\1740 higher_26\JJR\1740 serum_27\NN\5397468 <e1>phosphate</e1>_28\NN\15010703 and_29\CC\1740 susceptibility_30\NN\13920835 to_31\TO\1740 <e2>artery_32\NN\5417975 calcification</e2>_33\NN\13446390 ,_34\,\1740 with_35\IN\1740 30_36\CD\13745420 %_37\NN\1740 higher_38\JJR\1740 levels_39\NNS\4916342 of_40\IN\1740 serum_41\NN\5397468 phosphate_42\NN\15010703 in_43\IN\13603305 young_44\JJ\1740 ,_45\,\1740 ad_46\NN\7247071 libitum-fed_47\JJ\1740 rats_48\NNS\2329401 compared_49\VBN\644583 with_50\IN\1740 either_51\DT\1740 of_52\IN\1740 the_53\DT\1740 groups_54\NNS\2137 that_55\WDT\1740 was_56\VBD\836236 resistant_57\JJ\1740 to_58\TO\1740 warfarin-induced_59\JJ\1740 artery_60\NN\5417975 calcification_61\NN\13446390 ,_62\,\1740 ie_63\FW\1740 ,_64\,\1740 the_65\DT\1740 10-month-old_66\JJ\1740 rats_67\NNS\2329401 and_68\CC\1740 the_69\DT\1740 restricted-diet_70\JJ\1740 ,_71\,\1740 growth-inhibited_72\JJ\1740 young_73\JJ\1740 rats_74\NNS\2329401 ._75\.\1740
D010710_D061205 NONE although_0\IN\1740 the_1\DT\1740 explanation_2\NN\6722453 for_3\IN\1740 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 artery_7\NN\5417975 calcification_8\NN\13446390 and_9\CC\1740 growth_10\NN\13526110 status_11\NN\24720 can_12\MD\3094503 not_13\RB\1740 be_14\VB\836236 determined_15\VBN\1645601 from_16\IN\1740 the_17\DT\1740 present_18\JJ\1740 study_19\NN\635850 ,_20\,\1740 there_21\EX\27167 was_22\VBD\836236 a_23\DT\13649268 relationship_24\NN\31921 between_25\IN\1740 higher_26\JJR\1740 serum_27\NN\5397468 <e1>phosphate</e1>_28\NN\15010703 and_29\CC\1740 susceptibility_30\NN\13920835 to_31\TO\1740 artery_32\NN\5417975 calcification_33\NN\13446390 ,_34\,\1740 with_35\IN\1740 30_36\CD\13745420 %_37\NN\1740 higher_38\JJR\1740 levels_39\NNS\4916342 of_40\IN\1740 serum_41\NN\5397468 phosphate_42\NN\15010703 in_43\IN\13603305 young_44\JJ\1740 ,_45\,\1740 ad_46\NN\7247071 libitum-fed_47\JJ\1740 rats_48\NNS\2329401 compared_49\VBN\644583 with_50\IN\1740 either_51\DT\1740 of_52\IN\1740 the_53\DT\1740 groups_54\NNS\2137 that_55\WDT\1740 was_56\VBD\836236 resistant_57\JJ\1740 to_58\TO\1740 warfarin-induced_59\JJ\1740 <e2>artery_60\NN\5417975 calcification</e2>_61\NN\13446390 ,_62\,\1740 ie_63\FW\1740 ,_64\,\1740 the_65\DT\1740 10-month-old_66\JJ\1740 rats_67\NNS\2329401 and_68\CC\1740 the_69\DT\1740 restricted-diet_70\JJ\1740 ,_71\,\1740 growth-inhibited_72\JJ\1740 young_73\JJ\1740 rats_74\NNS\2329401 ._75\.\1740
D010710_D061205 NONE although_0\IN\1740 the_1\DT\1740 explanation_2\NN\6722453 for_3\IN\1740 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 <e2>artery_7\NN\5417975 calcification</e2>_8\NN\13446390 and_9\CC\1740 growth_10\NN\13526110 status_11\NN\24720 can_12\MD\3094503 not_13\RB\1740 be_14\VB\836236 determined_15\VBN\1645601 from_16\IN\1740 the_17\DT\1740 present_18\JJ\1740 study_19\NN\635850 ,_20\,\1740 there_21\EX\27167 was_22\VBD\836236 a_23\DT\13649268 relationship_24\NN\31921 between_25\IN\1740 higher_26\JJR\1740 serum_27\NN\5397468 phosphate_28\NN\15010703 and_29\CC\1740 susceptibility_30\NN\13920835 to_31\TO\1740 artery_32\NN\5417975 calcification_33\NN\13446390 ,_34\,\1740 with_35\IN\1740 30_36\CD\13745420 %_37\NN\1740 higher_38\JJR\1740 levels_39\NNS\4916342 of_40\IN\1740 serum_41\NN\5397468 <e1>phosphate</e1>_42\NN\15010703 in_43\IN\13603305 young_44\JJ\1740 ,_45\,\1740 ad_46\NN\7247071 libitum-fed_47\JJ\1740 rats_48\NNS\2329401 compared_49\VBN\644583 with_50\IN\1740 either_51\DT\1740 of_52\IN\1740 the_53\DT\1740 groups_54\NNS\2137 that_55\WDT\1740 was_56\VBD\836236 resistant_57\JJ\1740 to_58\TO\1740 warfarin-induced_59\JJ\1740 artery_60\NN\5417975 calcification_61\NN\13446390 ,_62\,\1740 ie_63\FW\1740 ,_64\,\1740 the_65\DT\1740 10-month-old_66\JJ\1740 rats_67\NNS\2329401 and_68\CC\1740 the_69\DT\1740 restricted-diet_70\JJ\1740 ,_71\,\1740 growth-inhibited_72\JJ\1740 young_73\JJ\1740 rats_74\NNS\2329401 ._75\.\1740
D010710_D061205 NONE although_0\IN\1740 the_1\DT\1740 explanation_2\NN\6722453 for_3\IN\1740 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 artery_7\NN\5417975 calcification_8\NN\13446390 and_9\CC\1740 growth_10\NN\13526110 status_11\NN\24720 can_12\MD\3094503 not_13\RB\1740 be_14\VB\836236 determined_15\VBN\1645601 from_16\IN\1740 the_17\DT\1740 present_18\JJ\1740 study_19\NN\635850 ,_20\,\1740 there_21\EX\27167 was_22\VBD\836236 a_23\DT\13649268 relationship_24\NN\31921 between_25\IN\1740 higher_26\JJR\1740 serum_27\NN\5397468 phosphate_28\NN\15010703 and_29\CC\1740 susceptibility_30\NN\13920835 to_31\TO\1740 <e2>artery_32\NN\5417975 calcification</e2>_33\NN\13446390 ,_34\,\1740 with_35\IN\1740 30_36\CD\13745420 %_37\NN\1740 higher_38\JJR\1740 levels_39\NNS\4916342 of_40\IN\1740 serum_41\NN\5397468 <e1>phosphate</e1>_42\NN\15010703 in_43\IN\13603305 young_44\JJ\1740 ,_45\,\1740 ad_46\NN\7247071 libitum-fed_47\JJ\1740 rats_48\NNS\2329401 compared_49\VBN\644583 with_50\IN\1740 either_51\DT\1740 of_52\IN\1740 the_53\DT\1740 groups_54\NNS\2137 that_55\WDT\1740 was_56\VBD\836236 resistant_57\JJ\1740 to_58\TO\1740 warfarin-induced_59\JJ\1740 artery_60\NN\5417975 calcification_61\NN\13446390 ,_62\,\1740 ie_63\FW\1740 ,_64\,\1740 the_65\DT\1740 10-month-old_66\JJ\1740 rats_67\NNS\2329401 and_68\CC\1740 the_69\DT\1740 restricted-diet_70\JJ\1740 ,_71\,\1740 growth-inhibited_72\JJ\1740 young_73\JJ\1740 rats_74\NNS\2329401 ._75\.\1740
D010710_D061205 NONE although_0\IN\1740 the_1\DT\1740 explanation_2\NN\6722453 for_3\IN\1740 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 artery_7\NN\5417975 calcification_8\NN\13446390 and_9\CC\1740 growth_10\NN\13526110 status_11\NN\24720 can_12\MD\3094503 not_13\RB\1740 be_14\VB\836236 determined_15\VBN\1645601 from_16\IN\1740 the_17\DT\1740 present_18\JJ\1740 study_19\NN\635850 ,_20\,\1740 there_21\EX\27167 was_22\VBD\836236 a_23\DT\13649268 relationship_24\NN\31921 between_25\IN\1740 higher_26\JJR\1740 serum_27\NN\5397468 phosphate_28\NN\15010703 and_29\CC\1740 susceptibility_30\NN\13920835 to_31\TO\1740 artery_32\NN\5417975 calcification_33\NN\13446390 ,_34\,\1740 with_35\IN\1740 30_36\CD\13745420 %_37\NN\1740 higher_38\JJR\1740 levels_39\NNS\4916342 of_40\IN\1740 serum_41\NN\5397468 <e1>phosphate</e1>_42\NN\15010703 in_43\IN\13603305 young_44\JJ\1740 ,_45\,\1740 ad_46\NN\7247071 libitum-fed_47\JJ\1740 rats_48\NNS\2329401 compared_49\VBN\644583 with_50\IN\1740 either_51\DT\1740 of_52\IN\1740 the_53\DT\1740 groups_54\NNS\2137 that_55\WDT\1740 was_56\VBD\836236 resistant_57\JJ\1740 to_58\TO\1740 warfarin-induced_59\JJ\1740 <e2>artery_60\NN\5417975 calcification</e2>_61\NN\13446390 ,_62\,\1740 ie_63\FW\1740 ,_64\,\1740 the_65\DT\1740 10-month-old_66\JJ\1740 rats_67\NNS\2329401 and_68\CC\1740 the_69\DT\1740 restricted-diet_70\JJ\1740 ,_71\,\1740 growth-inhibited_72\JJ\1740 young_73\JJ\1740 rats_74\NNS\2329401 ._75\.\1740
D010710_D061205 NONE this_0\DT\1740 observation_1\NN\996969 suggests_2\VBZ\1010118 that_3\IN\1740 increased_4\VBN\169651 susceptibility_5\NN\13920835 to_6\TO\1740 warfarin-induced_7\JJ\1740 <e2>artery_8\NN\5417975 calcification</e2>_9\NN\13446390 could_10\MD\1740 be_11\VB\836236 related_12\JJ\1740 to_13\TO\1740 higher_14\JJR\1740 serum_15\NN\5397468 <e1>phosphate</e1>_16\NN\15010703 levels_17\NNS\4916342 ._18\.\1740
D014812_D061205 NONE high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 the_3\DT\1740 <e1>vitamin_4\NN\7570720 k</e1>_5\NN\13608598 antagonist_6\NN\7846 warfarin_7\NN\2718259 are_8\VBP\836236 also_9\RB\1740 known_10\VBN\2110220 to_11\TO\1740 cause_12\VB\1617192 <e2>calcification_13\NN\13446390 of_14\IN\1740 the_15\DT\1740 artery</e2>_16\NN\5417975 media_17\NNS\3575240 ,_18\,\1740 but_19\CC\1740 at_20\IN\14622893 treatment_21\NN\654885 times_22\NNS\15113229 of_23\IN\1740 2_24\CD\13741022 weeks_25\NNS\15113229 or_26\CC\3541091 longer_27\RBR\1740 yet_28\CC\1740 not_29\RB\1740 at_30\IN\14622893 1_31\CD\13741022 week_32\NN\15113229 ._33\.\1740
D002118_D061205 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 close_3\JJ\1740 parallel_4\NN\4743605 between_5\IN\1740 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 vitamin_9\NN\7570720 d_10\NN\15089472 dose_11\NN\3740161 on_12\IN\1740 <e2>artery_13\NN\5417975 calcification</e2>_14\NN\13446390 and_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 of_18\IN\1740 vitamin_19\NN\7570720 d_20\NN\15089472 dose_21\NN\3740161 on_22\IN\1740 the_23\DT\1740 elevation_24\NN\7445480 of_25\IN\1740 serum_26\NN\5397468 <e1>calcium</e1>_27\NN\14625458 ,_28\,\1740 which_29\WDT\1740 suggests_30\VBZ\1010118 that_31\IN\1740 vitamin_32\NN\7570720 d_33\NN\15089472 may_34\MD\15209706 induce_35\VB\1627355 artery_36\NN\5417975 calcification_37\NN\13446390 through_38\IN\1740 its_39\PRP$\6125041 effect_40\NN\34213 on_41\IN\1740 serum_42\NN\5397468 calcium_43\NN\14625458 ._44\.\1740
D002118_D061205 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 close_3\JJ\1740 parallel_4\NN\4743605 between_5\IN\1740 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 vitamin_9\NN\7570720 d_10\NN\15089472 dose_11\NN\3740161 on_12\IN\1740 artery_13\NN\5417975 calcification_14\NN\13446390 and_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 of_18\IN\1740 vitamin_19\NN\7570720 d_20\NN\15089472 dose_21\NN\3740161 on_22\IN\1740 the_23\DT\1740 elevation_24\NN\7445480 of_25\IN\1740 serum_26\NN\5397468 <e1>calcium</e1>_27\NN\14625458 ,_28\,\1740 which_29\WDT\1740 suggests_30\VBZ\1010118 that_31\IN\1740 vitamin_32\NN\7570720 d_33\NN\15089472 may_34\MD\15209706 induce_35\VB\1627355 <e2>artery_36\NN\5417975 calcification</e2>_37\NN\13446390 through_38\IN\1740 its_39\PRP$\6125041 effect_40\NN\34213 on_41\IN\1740 serum_42\NN\5397468 calcium_43\NN\14625458 ._44\.\1740
D002118_D061205 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 close_3\JJ\1740 parallel_4\NN\4743605 between_5\IN\1740 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 vitamin_9\NN\7570720 d_10\NN\15089472 dose_11\NN\3740161 on_12\IN\1740 <e2>artery_13\NN\5417975 calcification</e2>_14\NN\13446390 and_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 of_18\IN\1740 vitamin_19\NN\7570720 d_20\NN\15089472 dose_21\NN\3740161 on_22\IN\1740 the_23\DT\1740 elevation_24\NN\7445480 of_25\IN\1740 serum_26\NN\5397468 calcium_27\NN\14625458 ,_28\,\1740 which_29\WDT\1740 suggests_30\VBZ\1010118 that_31\IN\1740 vitamin_32\NN\7570720 d_33\NN\15089472 may_34\MD\15209706 induce_35\VB\1627355 artery_36\NN\5417975 calcification_37\NN\13446390 through_38\IN\1740 its_39\PRP$\6125041 effect_40\NN\34213 on_41\IN\1740 serum_42\NN\5397468 <e1>calcium</e1>_43\NN\14625458 ._44\.\1740
D002118_D061205 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 close_3\JJ\1740 parallel_4\NN\4743605 between_5\IN\1740 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 vitamin_9\NN\7570720 d_10\NN\15089472 dose_11\NN\3740161 on_12\IN\1740 artery_13\NN\5417975 calcification_14\NN\13446390 and_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 of_18\IN\1740 vitamin_19\NN\7570720 d_20\NN\15089472 dose_21\NN\3740161 on_22\IN\1740 the_23\DT\1740 elevation_24\NN\7445480 of_25\IN\1740 serum_26\NN\5397468 calcium_27\NN\14625458 ,_28\,\1740 which_29\WDT\1740 suggests_30\VBZ\1010118 that_31\IN\1740 vitamin_32\NN\7570720 d_33\NN\15089472 may_34\MD\15209706 induce_35\VB\1627355 <e2>artery_36\NN\5417975 calcification</e2>_37\NN\13446390 through_38\IN\1740 its_39\PRP$\6125041 effect_40\NN\34213 on_41\IN\1740 serum_42\NN\5397468 <e1>calcium</e1>_43\NN\14625458 ._44\.\1740
D002118_D002114 NONE because_0\IN\1740 warfarin_1\NN\2718259 treatment_2\NN\654885 had_3\VBD\2108377 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 the_7\DT\1740 elevation_8\NN\7445480 in_9\IN\13603305 serum_10\NN\5397468 <e1>calcium</e1>_11\NN\14625458 produced_12\VBN\1617192 by_13\IN\1740 vitamin_14\NN\7570720 d_15\NN\15089472 ,_16\,\1740 the_17\DT\1740 synergy_18\NN\13518963 between_19\IN\1740 warfarin_20\NN\2718259 and_21\CC\1740 vitamin_22\NN\7570720 d_23\NN\15089472 is_24\VBZ\836236 probably_25\RB\1740 best_26\RBS\1740 explained_27\VBN\831651 by_28\IN\1740 the_29\DT\1740 hypothesis_30\NN\7162194 that_31\IN\1740 warfarin_32\NN\2718259 inhibits_33\VBZ\2510337 the_34\DT\1740 activity_35\NN\30358 of_36\IN\1740 matrix_37\NN\7939382 gla_38\NN\1740 protein_39\NN\14944888 as_40\IN\14622893 a_41\DT\13649268 <e2>calcification</e2>_42\NN\13446390 inhibitor_43\NN\20090 ._44\.\1740
D015055_D061205 NONE high_0\JJ\1740 levels_1\NNS\4916342 of_2\IN\1740 matrix_3\NN\7939382 gla_4\NN\1740 protein_5\NN\14944888 are_6\VBP\836236 found_7\VBN\2426171 at_8\IN\14622893 sites_9\NNS\8673395 of_10\IN\1740 <e2>artery_11\NN\5417975 calcification</e2>_12\NN\13446390 in_13\IN\13603305 rats_14\NNS\2329401 treated_15\VBN\2376958 with_16\IN\1740 vitamin_17\NN\7570720 d_18\NN\15089472 plus_19\CC\4723816 warfarin_20\NN\2718259 ,_21\,\1740 and_22\CC\1740 chemical_23\NN\14580897 analysis_24\NN\633864 showed_25\VBD\2137132 that_26\IN\1740 the_27\DT\1740 protein_28\NN\14944888 that_29\WDT\1740 accumulated_30\VBN\2281093 was_31\VBD\836236 indeed_32\RB\1740 not_33\RB\1740 <e1>gamma-carboxylated</e1>_34\JJ\1740 ._35\.\1740
D015055_D002114 NONE these_0\DT\1740 observations_1\NNS\996969 indicate_2\VBP\952524 that_3\IN\1740 although_4\IN\1740 the_5\DT\1740 <e1>gamma-carboxyglutamate</e1>_6\JJ\1740 residues_7\NNS\20827 of_8\IN\1740 matrix_9\NN\7939382 gla_10\NN\1740 protein_11\NN\14944888 are_12\VBP\836236 apparently_13\RB\1740 required_14\VBN\754942 for_15\IN\1740 its_16\PRP$\6125041 function_17\NN\13783581 as_18\IN\14622893 a_19\DT\13649268 <e2>calcification</e2>_20\NN\13446390 inhibitor_21\NN\20090 ,_22\,\1740 they_23\PRP\1740 are_24\VBP\836236 not_25\RB\1740 required_26\VBN\754942 for_27\IN\1740 its_28\PRP$\6125041 accumulation_29\NN\13497135 at_30\IN\14622893 calcification_31\NN\13446390 sites_32\NNS\8673395 ._33\.\1740
D015055_D002114 NONE these_0\DT\1740 observations_1\NNS\996969 indicate_2\VBP\952524 that_3\IN\1740 although_4\IN\1740 the_5\DT\1740 <e1>gamma-carboxyglutamate</e1>_6\JJ\1740 residues_7\NNS\20827 of_8\IN\1740 matrix_9\NN\7939382 gla_10\NN\1740 protein_11\NN\14944888 are_12\VBP\836236 apparently_13\RB\1740 required_14\VBN\754942 for_15\IN\1740 its_16\PRP$\6125041 function_17\NN\13783581 as_18\IN\14622893 a_19\DT\13649268 calcification_20\NN\13446390 inhibitor_21\NN\20090 ,_22\,\1740 they_23\PRP\1740 are_24\VBP\836236 not_25\RB\1740 required_26\VBN\754942 for_27\IN\1740 its_28\PRP$\6125041 accumulation_29\NN\13497135 at_30\IN\14622893 <e2>calcification</e2>_31\NN\13446390 sites_32\NNS\8673395 ._33\.\1740
18004067
D000431_D017114 NONE <e2>acute_0\JJ\1740 liver_1\NN\5298729 failure</e2>_2\NN\66216 in_3\IN\13603305 two_4\CD\13741022 patients_5\NNS\9898892 with_6\IN\1740 regular_7\JJ\1740 <e1>alcohol</e1>_8\NN\7881800 consumption_9\NN\13440063 ingesting_10\VBG\597915 paracetamol_11\NN\1740 at_12\IN\14622893 therapeutic_13\JJ\1740 dosage_14\NN\13576355 ._15\.\1740
D000082_D017114 NONE <e2>acute_0\JJ\1740 liver_1\NN\5298729 failure</e2>_2\NN\66216 in_3\IN\13603305 two_4\CD\13741022 patients_5\NNS\9898892 with_6\IN\1740 regular_7\JJ\1740 alcohol_8\NN\7881800 consumption_9\NN\13440063 ingesting_10\VBG\597915 <e1>paracetamol</e1>_11\NN\1740 at_12\IN\14622893 therapeutic_13\JJ\1740 dosage_14\NN\13576355 ._15\.\1740
D000431_D056486 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 possible_3\JJ\1740 role_4\NN\719494 of_5\IN\1740 <e1>alcohol</e1>_6\NN\7881800 in_7\IN\13603305 the_8\DT\1740 development_9\NN\248977 of_10\IN\1740 <e2>hepatotoxicity</e2>_11\NN\1740 associated_12\VBN\628491 with_13\IN\1740 therapeutic_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 paracetamol_17\NN\1740 (_18\-LRB-\1740 acetaminophen_19\RB\1740 )_20\-RRB-\1740 is_21\VBZ\836236 currently_22\RB\1740 debated_23\VBN\813044 ._24\.\1740
D000082_D056486 CID background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 possible_3\JJ\1740 role_4\NN\719494 of_5\IN\1740 alcohol_6\NN\7881800 in_7\IN\13603305 the_8\DT\1740 development_9\NN\248977 of_10\IN\1740 <e2>hepatotoxicity</e2>_11\NN\1740 associated_12\VBN\628491 with_13\IN\1740 therapeutic_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 <e1>paracetamol</e1>_17\NN\1740 (_18\-LRB-\1740 acetaminophen_19\RB\1740 )_20\-RRB-\1740 is_21\VBZ\836236 currently_22\RB\1740 debated_23\VBN\813044 ._24\.\1740
D000082_D056486 CID background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 possible_3\JJ\1740 role_4\NN\719494 of_5\IN\1740 alcohol_6\NN\7881800 in_7\IN\13603305 the_8\DT\1740 development_9\NN\248977 of_10\IN\1740 <e2>hepatotoxicity</e2>_11\NN\1740 associated_12\VBN\628491 with_13\IN\1740 therapeutic_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 paracetamol_17\NN\1740 (_18\-LRB-\1740 <e1>acetaminophen</e1>_19\RB\1740 )_20\-RRB-\1740 is_21\VBZ\836236 currently_22\RB\1740 debated_23\VBN\813044 ._24\.\1740
D000082_D056486 CID possible_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 for_3\IN\1740 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 <e2>hepatotoxicity</e2>_7\NN\1740 in_8\IN\13603305 patients_9\NNS\9898892 treated_10\VBN\2376958 with_11\IN\1740 therapeutic_12\JJ\1740 doses_13\NNS\3740161 of_14\IN\1740 <e1>paracetamol</e1>_15\NN\1740 are_16\VBP\836236 discussed_17\VBN\1033527 ._18\.\1740
D000431_D017093 NONE case_0\NN\7283608 report_1\NN\6470073 :_2\:\1740 we_3\PRP\1740 describe_4\VBP\1001294 2_5\CD\13741022 patients_6\NNS\9898892 who_7\WP\8299493 were_8\VBD\836236 regular_9\JJ\1740 consumers_10\NNS\10741590 of_11\IN\1740 <e1>alcohol</e1>_12\NN\7881800 and_13\CC\1740 who_14\WP\8299493 developed_15\VBD\1753788 <e2>liver_16\NN\5298729 failure</e2>_17\NN\66216 within_18\IN\1740 3_19\CD\13741022 -_20\SYM\1740 5_21\CD\13741022 days_22\NNS\15140892 after_23\IN\1740 hospitalization_24\NN\15113229 and_25\CC\1740 stopping_26\VBG\2452885 alcohol_27\NN\7881800 consumption_28\NN\13440063 while_29\IN\15122231 being_30\VBG\836236 treated_31\VBN\2376958 with_32\IN\1740 4_33\CD\13741022 g_34\NN\13717155 paracetamol/day_35\NN\1740 ._36\.\1740
D000431_D017093 NONE case_0\NN\7283608 report_1\NN\6470073 :_2\:\1740 we_3\PRP\1740 describe_4\VBP\1001294 2_5\CD\13741022 patients_6\NNS\9898892 who_7\WP\8299493 were_8\VBD\836236 regular_9\JJ\1740 consumers_10\NNS\10741590 of_11\IN\1740 alcohol_12\NN\7881800 and_13\CC\1740 who_14\WP\8299493 developed_15\VBD\1753788 <e2>liver_16\NN\5298729 failure</e2>_17\NN\66216 within_18\IN\1740 3_19\CD\13741022 -_20\SYM\1740 5_21\CD\13741022 days_22\NNS\15140892 after_23\IN\1740 hospitalization_24\NN\15113229 and_25\CC\1740 stopping_26\VBG\2452885 <e1>alcohol</e1>_27\NN\7881800 consumption_28\NN\13440063 while_29\IN\15122231 being_30\VBG\836236 treated_31\VBN\2376958 with_32\IN\1740 4_33\CD\13741022 g_34\NN\13717155 paracetamol/day_35\NN\1740 ._36\.\1740
D000431_D017093 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 risk_5\NN\14541044 factors_6\NNS\7326557 ,_7\,\1740 e.g._8\FW\1740 regular_9\JJ\1740 consumption_10\NN\13440063 of_11\IN\1740 <e1>alcohol</e1>_12\NN\7881800 ,_13\,\1740 <e2>liver_14\NN\5298729 failure</e2>_15\NN\66216 is_16\VBZ\836236 possible_17\JJ\1740 when_18\WRB\1740 therapeutic_19\JJ\1740 doses_20\NNS\3740161 are_21\VBP\836236 ingested_22\VBN\597915 ._23\.\1740
D000082_D017093 CID case_0\NN\7283608 report_1\NN\6470073 :_2\:\1740 we_3\PRP\1740 describe_4\VBP\1001294 2_5\CD\13741022 patients_6\NNS\9898892 who_7\WP\8299493 were_8\VBD\836236 regular_9\JJ\1740 consumers_10\NNS\10741590 of_11\IN\1740 alcohol_12\NN\7881800 and_13\CC\1740 who_14\WP\8299493 developed_15\VBD\1753788 <e2>liver_16\NN\5298729 failure</e2>_17\NN\66216 within_18\IN\1740 3_19\CD\13741022 -_20\SYM\1740 5_21\CD\13741022 days_22\NNS\15140892 after_23\IN\1740 hospitalization_24\NN\15113229 and_25\CC\1740 stopping_26\VBG\2452885 alcohol_27\NN\7881800 consumption_28\NN\13440063 while_29\IN\15122231 being_30\VBG\836236 treated_31\VBN\2376958 with_32\IN\1740 4_33\CD\13741022 g_34\NN\13717155 <e1>paracetamol/day</e1>_35\NN\1740 ._36\.\1740
17439425
D019820_D006973 NONE role_0\NN\719494 of_1\IN\1740 <e1>xanthine</e1>_2\NN\14727670 oxidase_3\NN\14732946 in_4\IN\13603305 dexamethasone-induced_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D019820_D006973 NONE 2_0\LS\13741022 ._1\.\1740 we_2\PRP\1740 studied_3\VBD\630380 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 <e1>xanthine</e1>_7\NN\14727670 oxidase_8\NN\14732946 (_9\-LRB-\1740 xo_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 which_13\WDT\1740 is_14\VBZ\836236 implicated_15\VBN\2677097 in_16\IN\13603305 the_17\DT\1740 production_18\NN\30358 of_19\IN\1740 reactive_20\JJ\1740 oxygen_21\NN\14622893 species_22\NNS\7992450 ,_23\,\1740 in_24\IN\13603305 dexamethasone-induced_25\JJ\1740 <e2>hypertension</e2>_26\NN\14057371 (_27\-LRB-\1740 dex-ht_28\NNS\1740 )_29\-RRB-\1740 ._30\.\1740
D019820_D006973 NONE 2_0\LS\13741022 ._1\.\1740 we_2\PRP\1740 studied_3\VBD\630380 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 <e1>xanthine</e1>_7\NN\14727670 oxidase_8\NN\14732946 (_9\-LRB-\1740 xo_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 which_13\WDT\1740 is_14\VBZ\836236 implicated_15\VBN\2677097 in_16\IN\13603305 the_17\DT\1740 production_18\NN\30358 of_19\IN\1740 reactive_20\JJ\1740 oxygen_21\NN\14622893 species_22\NNS\7992450 ,_23\,\1740 in_24\IN\13603305 dexamethasone-induced_25\JJ\1740 hypertension_26\NN\14057371 (_27\-LRB-\1740 <e2>dex-ht</e2>_28\NNS\1740 )_29\-RRB-\1740 ._30\.\1740
D003907_D006973 CID role_0\NN\719494 of_1\IN\1740 xanthine_2\NN\14727670 oxidase_3\NN\14732946 in_4\IN\13603305 <e1>dexamethasone-induced</e1>_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D003907_D006973 CID 2_0\LS\13741022 ._1\.\1740 we_2\PRP\1740 studied_3\VBD\630380 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 xanthine_7\NN\14727670 oxidase_8\NN\14732946 (_9\-LRB-\1740 xo_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 which_13\WDT\1740 is_14\VBZ\836236 implicated_15\VBN\2677097 in_16\IN\13603305 the_17\DT\1740 production_18\NN\30358 of_19\IN\1740 reactive_20\JJ\1740 oxygen_21\NN\14622893 species_22\NNS\7992450 ,_23\,\1740 in_24\IN\13603305 <e1>dexamethasone-induced</e1>_25\JJ\1740 <e2>hypertension</e2>_26\NN\14057371 (_27\-LRB-\1740 dex-ht_28\NNS\1740 )_29\-RRB-\1740 ._30\.\1740
D003907_D006973 CID 2_0\LS\13741022 ._1\.\1740 we_2\PRP\1740 studied_3\VBD\630380 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 xanthine_7\NN\14727670 oxidase_8\NN\14732946 (_9\-LRB-\1740 xo_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 which_13\WDT\1740 is_14\VBZ\836236 implicated_15\VBN\2677097 in_16\IN\13603305 the_17\DT\1740 production_18\NN\30358 of_19\IN\1740 reactive_20\JJ\1740 oxygen_21\NN\14622893 species_22\NNS\7992450 ,_23\,\1740 in_24\IN\13603305 <e1>dexamethasone-induced</e1>_25\JJ\1740 hypertension_26\NN\14057371 (_27\-LRB-\1740 <e2>dex-ht</e2>_28\NNS\1740 )_29\-RRB-\1740 ._30\.\1740
D003907_D006973 CID 2_0\LS\13741022 ._1\.\1740 we_2\PRP\1740 studied_3\VBD\630380 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 xanthine_7\NN\14727670 oxidase_8\NN\14732946 (_9\-LRB-\1740 xo_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 which_13\WDT\1740 is_14\VBZ\836236 implicated_15\VBN\2677097 in_16\IN\13603305 the_17\DT\1740 production_18\NN\30358 of_19\IN\1740 reactive_20\JJ\1740 oxygen_21\NN\14622893 species_22\NNS\7992450 ,_23\,\1740 in_24\IN\13603305 dexamethasone-induced_25\JJ\1740 <e2>hypertension</e2>_26\NN\14057371 (_27\-LRB-\1740 <e1>dex-ht</e1>_28\NNS\1740 )_29\-RRB-\1740 ._30\.\1740
D003907_D006973 CID 2_0\LS\13741022 ._1\.\1740 we_2\PRP\1740 studied_3\VBD\630380 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 xanthine_7\NN\14727670 oxidase_8\NN\14732946 (_9\-LRB-\1740 xo_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 which_13\WDT\1740 is_14\VBZ\836236 implicated_15\VBN\2677097 in_16\IN\13603305 the_17\DT\1740 production_18\NN\30358 of_19\IN\1740 reactive_20\JJ\1740 oxygen_21\NN\14622893 species_22\NNS\7992450 ,_23\,\1740 in_24\IN\13603305 dexamethasone-induced_25\JJ\1740 hypertension_26\NN\14057371 (_27\-LRB-\1740 <e2><e1>dex-ht</e1></e2>_28\NNS\1740 )_29\-RRB-\1740 ._30\.\1740
D003907_D006973 CID <e1>dex</e1>_0\NN\1740 <e2>increased_1\VBD\169651 sbp</e2>_2\NN\1740 (_3\-LRB-\1740 110_4\CD\1740 +/-_5\CC\1740 2_6\CD\13741022 -_7\SYM\1740 126_8\CD\1740 +/-_9\CC\1740 3_10\CD\13741022 mmhg_11\NN\1740 ;_12\:\1740 p_13\NN\14622893 <_14\XX\1740 0.001_15\CD\1740 )_16\-RRB-\1740 and_17\CC\1740 decreased_18\VBN\169651 thymus_19\NN\11579418 (_20\-LRB-\1740 p_21\NN\14622893 <_22\XX\1740 0.001_23\CD\1740 )_24\-RRB-\1740 and_25\CC\1740 bodyweights_26\NNS\1740 (_27\-LRB-\1740 p_28\NN\14622893 "_29\''\1740 <_30\CD\1740 0.01_31\CD\1740 )_32\-RRB-\1740 ._33\.\1740
D003907_D006973 CID 6_0\CD\13741022 ._1\.\1740 allopurinol_2\NN\3740161 did_3\VBD\1640855 not_4\RB\1740 prevent_5\VB\1740 <e2><e1>dex-ht</e1></e2>_6\JJ\1740 ._7\.\1740
D009569_D006973 NONE 1_0\LS\13741022 ._1\.\1740 glucocorticoid-induced_2\JJ\1740 <e2>hypertension</e2>_3\NN\14057371 (_4\-LRB-\1740 gc-ht_5\NN\1740 )_6\-RRB-\1740 in_7\IN\13603305 the_8\DT\1740 rat_9\NN\2329401 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 <e1>nitric_13\JJ\1740 oxide-redox</e1>_14\NN\1740 imbalance_15\NN\13934274 ._16\.\1740
D009569_D006973 NONE 1_0\LS\13741022 ._1\.\1740 glucocorticoid-induced_2\JJ\1740 hypertension_3\NN\14057371 (_4\-LRB-\1740 <e2>gc-ht</e2>_5\NN\1740 )_6\-RRB-\1740 in_7\IN\13603305 the_8\DT\1740 rat_9\NN\2329401 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 <e1>nitric_13\JJ\1740 oxide-redox</e1>_14\NN\1740 imbalance_15\NN\13934274 ._16\.\1740
D003907_D015431 CID <e1>dex</e1>_0\NN\1740 increased_1\VBD\169651 sbp_2\NN\1740 (_3\-LRB-\1740 110_4\CD\1740 +/-_5\CC\1740 2_6\CD\13741022 -_7\SYM\1740 126_8\CD\1740 +/-_9\CC\1740 3_10\CD\13741022 mmhg_11\NN\1740 ;_12\:\1740 p_13\NN\14622893 <_14\XX\1740 0.001_15\CD\1740 )_16\-RRB-\1740 and_17\CC\1740 <e2>decreased_18\VBN\169651 thymus_19\NN\11579418 (_20\-LRB-\1740 p_21\NN\14622893 <_22\XX\1740 0.001_23\CD\1740 )_24\-RRB-\1740 and_25\CC\1740 bodyweights</e2>_26\NNS\1740 (_27\-LRB-\1740 p_28\NN\14622893 "_29\''\1740 <_30\CD\1740 0.01_31\CD\1740 )_32\-RRB-\1740 ._33\.\1740
D000493_D006973 NONE 6_0\CD\13741022 ._1\.\1740 <e1>allopurinol</e1>_2\NN\3740161 did_3\VBD\1640855 not_4\RB\1740 prevent_5\VB\1740 <e2>dex-ht</e2>_6\JJ\1740 ._7\.\1740
D000493_D006973 NONE this_0\DT\1740 ,_1\,\1740 together_2\RB\1740 with_3\IN\1740 our_4\PRP$\1740 previous_5\JJ\1740 findings_6\NNS\7951464 that_7\IN\1740 <e1>allopurinol</e1>_8\NN\3740161 failed_9\VBD\1798936 to_10\TO\1740 prevent_11\VB\1740 adrenocorticotrophic_12\JJ\1740 hormone_13\NN\5404728 induced_14\JJ\1740 <e2>hypertension</e2>_15\NN\14057371 ,_16\,\1740 suggests_17\VBZ\1010118 that_18\IN\1740 xo_19\NN\1740 activity_20\NN\30358 is_21\VBZ\836236 not_22\RB\1740 a_23\DT\13649268 major_24\JJ\1740 determinant_25\NN\5686481 of_26\IN\1740 gc-ht_27\NN\1740 in_28\IN\13603305 the_29\DT\1740 rat_30\NN\2329401 ._31\.\1740
D000493_D006973 NONE this_0\DT\1740 ,_1\,\1740 together_2\RB\1740 with_3\IN\1740 our_4\PRP$\1740 previous_5\JJ\1740 findings_6\NNS\7951464 that_7\IN\1740 <e1>allopurinol</e1>_8\NN\3740161 failed_9\VBD\1798936 to_10\TO\1740 prevent_11\VB\1740 adrenocorticotrophic_12\JJ\1740 hormone_13\NN\5404728 induced_14\JJ\1740 hypertension_15\NN\14057371 ,_16\,\1740 suggests_17\VBZ\1010118 that_18\IN\1740 xo_19\NN\1740 activity_20\NN\30358 is_21\VBZ\836236 not_22\RB\1740 a_23\DT\13649268 major_24\JJ\1740 determinant_25\NN\5686481 of_26\IN\1740 <e2>gc-ht</e2>_27\NN\1740 in_28\IN\13603305 the_29\DT\1740 rat_30\NN\2329401 ._31\.\1740
18996674
D004837_D011317 NONE intracavernous_0\JJ\1740 <e1>epinephrine</e1>_1\NN\14807929 :_2\:\1740 a_3\DT\13649268 minimally_4\RB\1740 invasive_5\JJ\1740 treatment_6\NN\654885 for_7\IN\1740 <e2>priapism</e2>_8\NN\14204950 in_9\IN\13603305 the_10\DT\1740 emergency_11\NN\7417644 department_12\NN\8220714 ._13\.\1740
D003042_D011317 CID a_0\DT\13649268 45-year-old_1\JJ\1740 man_2\NN\9605289 ,_3\,\1740 an_4\DT\6697703 admitted_5\VBN\822367 frequent_6\JJ\1740 <e1>cocaine</e1>_7\NN\3492717 user_8\NN\7846 ,_9\,\1740 presented_10\VBN\2137132 to_11\IN\1740 the_12\DT\1740 emergency_13\NNP\7417644 department_14\NNP\8220714 (_15\-LRB-\1740 ed_16\NNP\14557898 )_17\-RRB-\1740 on_18\IN\1740 two_19\CD\13741022 separate_20\JJ\1740 occasions_21\NNS\5983801 with_22\IN\1740 a_23\DT\13649268 history_24\NN\15120823 of_25\IN\1740 <e2>priapism</e2>_26\NN\14204950 after_27\IN\1740 cocaine_28\NN\3492717 use_29\NN\407535 ._30\.\1740
D003042_D011317 CID a_0\DT\13649268 45-year-old_1\JJ\1740 man_2\NN\9605289 ,_3\,\1740 an_4\DT\6697703 admitted_5\VBN\822367 frequent_6\JJ\1740 cocaine_7\NN\3492717 user_8\NN\7846 ,_9\,\1740 presented_10\VBN\2137132 to_11\IN\1740 the_12\DT\1740 emergency_13\NNP\7417644 department_14\NNP\8220714 (_15\-LRB-\1740 ed_16\NNP\14557898 )_17\-RRB-\1740 on_18\IN\1740 two_19\CD\13741022 separate_20\JJ\1740 occasions_21\NNS\5983801 with_22\IN\1740 a_23\DT\13649268 history_24\NN\15120823 of_25\IN\1740 <e2>priapism</e2>_26\NN\14204950 after_27\IN\1740 <e1>cocaine</e1>_28\NN\3492717 use_29\NN\407535 ._30\.\1740
9653867
D013974_D013971 CID <e1>thyroxine</e1>_0\JJ\1740 abuse_1\NN\418025 :_2\:\1740 an_3\DT\6697703 unusual_4\JJ\1740 case_5\NN\7283608 of_6\IN\1740 <e2>thyrotoxicosis</e2>_7\NN\14059928 in_8\IN\13603305 pregnancy_9\NN\14034177 ._10\.\1740
D013974_D013971 CID in_0\IN\13603305 particular_1\JJ\1740 it_2\PRP\6125041 illustrates_3\VBZ\955601 the_4\DT\1740 derangements_5\NNS\14395018 of_6\IN\1740 thyroid_7\NN\5329735 function_8\NN\13783581 seen_9\VBN\2106506 in_10\IN\13603305 pregnant_11\JJ\1740 women_12\NNS\9605289 with_13\IN\1740 eating_14\VBG\1156834 disorders_15\NNS\14034177 and_16\CC\1740 reminds_17\VBZ\831651 us_18\PRP\14964590 that_19\IN\1740 when_20\WRB\1740 a_21\DT\13649268 cause_22\NN\7323922 for_23\IN\1740 <e2>thyrotoxicosis</e2>_24\NN\14059928 remains_25\VBZ\2604760 obscure_26\JJ\1740 ,_27\,\1740 <e1>thyroxine</e1>_28\JJ\1740 abuse_29\NN\418025 should_30\MD\1740 be_31\VB\836236 considered_32\VBN\689344 and_33\CC\1740 explored_34\VBN\789138 ._35\.\1740
D013974_D001068 NONE in_0\IN\13603305 particular_1\JJ\1740 it_2\PRP\6125041 illustrates_3\VBZ\955601 the_4\DT\1740 derangements_5\NNS\14395018 of_6\IN\1740 thyroid_7\NN\5329735 function_8\NN\13783581 seen_9\VBN\2106506 in_10\IN\13603305 pregnant_11\JJ\1740 women_12\NNS\9605289 with_13\IN\1740 <e2>eating_14\VBG\1156834 disorders</e2>_15\NNS\14034177 and_16\CC\1740 reminds_17\VBZ\831651 us_18\PRP\14964590 that_19\IN\1740 when_20\WRB\1740 a_21\DT\13649268 cause_22\NN\7323922 for_23\IN\1740 thyrotoxicosis_24\NN\14059928 remains_25\VBZ\2604760 obscure_26\JJ\1740 ,_27\,\1740 <e1>thyroxine</e1>_28\JJ\1740 abuse_29\NN\418025 should_30\MD\1740 be_31\VB\836236 considered_32\VBN\689344 and_33\CC\1740 explored_34\VBN\789138 ._35\.\1740
2348231
D010431_D006940 NONE <e1>pentoxifylline</e1>_0\NN\3247620 (_1\-LRB-\1740 trental_2\JJ\1740 )_3\-RRB-\1740 does_4\VBZ\1640855 not_5\RB\1740 inhibit_6\VB\2510337 dipyridamole-induced_7\JJ\1740 coronary_8\JJ\1740 <e2>hyperemia</e2>_9\NN\14320394 :_10\:\1740 implications_11\NNS\5774614 for_12\IN\1740 dipyridamole-thallium-201_13\JJ\1740 myocardial_14\JJ\1740 imaging_15\NN\5765159 ._16\.\1740
D010431_D006940 NONE pentoxifylline_0\NN\3247620 (_1\-LRB-\1740 <e1>trental</e1>_2\JJ\1740 )_3\-RRB-\1740 does_4\VBZ\1640855 not_5\RB\1740 inhibit_6\VB\2510337 dipyridamole-induced_7\JJ\1740 coronary_8\JJ\1740 <e2>hyperemia</e2>_9\NN\14320394 :_10\:\1740 implications_11\NNS\5774614 for_12\IN\1740 dipyridamole-thallium-201_13\JJ\1740 myocardial_14\JJ\1740 imaging_15\NN\5765159 ._16\.\1740
D010431_D006940 NONE whether_0\IN\1740 <e1>pentoxifylline</e1>_1\NN\3247620 inhibits_2\VBZ\2510337 dipyridamole-induced_3\JJ\1740 coronary_4\JJ\1740 <e2>hyperemia</e2>_5\NN\14320394 like_6\IN\5839024 other_7\JJ\1740 methylxanthines_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 theophylline_11\NN\2905612 and_12\CC\1740 should_13\MD\1740 be_14\VB\836236 stopped_15\VBN\2452885 prior_16\RB\1740 to_17\IN\1740 dipyridamole-thallium-201_18\NN\1740 imaging_19\NN\5765159 is_20\VBZ\836236 unknown_21\JJ\1740 ._22\.\1740
D010431_D006940 NONE neither_0\DT\1740 dose_1\NN\3740161 of_2\IN\1740 <e1>pentoxifylline</e1>_3\NN\3247620 significantly_4\RB\1740 decreased_5\VBD\169651 the_6\DT\1740 dipyridamole-induced_7\JJ\1740 <e2>hyperemia</e2>_8\NN\14320394 ,_9\,\1740 while_10\IN\15122231 peak_11\JJ\1740 coronary_12\JJ\1740 blood_13\NN\5397468 flow_14\NN\7311115 was_15\VBD\836236 significantly_16\RB\1740 lower_17\JJR\1740 after_18\IN\1740 theophylline_19\NN\2905612 (_20\-LRB-\1740 p_21\NN\14622893 less_22\JJR\1740 than_23\IN\1740 0.01_24\CD\1740 )_25\-RRB-\1740 ._26\.\1740
D010431_D006940 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>pentoxyifylline</e1>_3\NN\1740 does_4\VBZ\1640855 not_5\RB\1740 inhibit_6\VB\2510337 dipyridamole-induced_7\JJ\1740 coronary_8\JJ\1740 <e2>hyperemia</e2>_9\NN\14320394 even_10\RB\1740 at_11\IN\14622893 high_12\JJ\1740 doses_13\NNS\3740161 ._14\.\1740
D004176_D006940 CID pentoxifylline_0\NN\3247620 (_1\-LRB-\1740 trental_2\JJ\1740 )_3\-RRB-\1740 does_4\VBZ\1640855 not_5\RB\1740 inhibit_6\VB\2510337 <e1>dipyridamole-induced</e1>_7\JJ\1740 coronary_8\JJ\1740 <e2>hyperemia</e2>_9\NN\14320394 :_10\:\1740 implications_11\NNS\5774614 for_12\IN\1740 dipyridamole-thallium-201_13\JJ\1740 myocardial_14\JJ\1740 imaging_15\NN\5765159 ._16\.\1740
D004176_D006940 CID pentoxifylline_0\NN\3247620 (_1\-LRB-\1740 trental_2\JJ\1740 )_3\-RRB-\1740 does_4\VBZ\1640855 not_5\RB\1740 inhibit_6\VB\2510337 dipyridamole-induced_7\JJ\1740 coronary_8\JJ\1740 <e2>hyperemia</e2>_9\NN\14320394 :_10\:\1740 implications_11\NNS\5774614 for_12\IN\1740 <e1>dipyridamole-thallium-201</e1>_13\JJ\1740 myocardial_14\JJ\1740 imaging_15\NN\5765159 ._16\.\1740
D004176_D006940 CID whether_0\IN\1740 pentoxifylline_1\NN\3247620 inhibits_2\VBZ\2510337 <e1>dipyridamole-induced</e1>_3\JJ\1740 coronary_4\JJ\1740 <e2>hyperemia</e2>_5\NN\14320394 like_6\IN\5839024 other_7\JJ\1740 methylxanthines_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 theophylline_11\NN\2905612 and_12\CC\1740 should_13\MD\1740 be_14\VB\836236 stopped_15\VBN\2452885 prior_16\RB\1740 to_17\IN\1740 dipyridamole-thallium-201_18\NN\1740 imaging_19\NN\5765159 is_20\VBZ\836236 unknown_21\JJ\1740 ._22\.\1740
D004176_D006940 CID whether_0\IN\1740 pentoxifylline_1\NN\3247620 inhibits_2\VBZ\2510337 dipyridamole-induced_3\JJ\1740 coronary_4\JJ\1740 <e2>hyperemia</e2>_5\NN\14320394 like_6\IN\5839024 other_7\JJ\1740 methylxanthines_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 theophylline_11\NN\2905612 and_12\CC\1740 should_13\MD\1740 be_14\VB\836236 stopped_15\VBN\2452885 prior_16\RB\1740 to_17\IN\1740 <e1>dipyridamole-thallium-201</e1>_18\NN\1740 imaging_19\NN\5765159 is_20\VBZ\836236 unknown_21\JJ\1740 ._22\.\1740
D004176_D006940 CID neither_0\DT\1740 dose_1\NN\3740161 of_2\IN\1740 pentoxifylline_3\NN\3247620 significantly_4\RB\1740 decreased_5\VBD\169651 the_6\DT\1740 <e1>dipyridamole-induced</e1>_7\JJ\1740 <e2>hyperemia</e2>_8\NN\14320394 ,_9\,\1740 while_10\IN\15122231 peak_11\JJ\1740 coronary_12\JJ\1740 blood_13\NN\5397468 flow_14\NN\7311115 was_15\VBD\836236 significantly_16\RB\1740 lower_17\JJR\1740 after_18\IN\1740 theophylline_19\NN\2905612 (_20\-LRB-\1740 p_21\NN\14622893 less_22\JJR\1740 than_23\IN\1740 0.01_24\CD\1740 )_25\-RRB-\1740 ._26\.\1740
D004176_D006940 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 pentoxyifylline_3\NN\1740 does_4\VBZ\1640855 not_5\RB\1740 inhibit_6\VB\2510337 <e1>dipyridamole-induced</e1>_7\JJ\1740 coronary_8\JJ\1740 <e2>hyperemia</e2>_9\NN\14320394 even_10\RB\1740 at_11\IN\14622893 high_12\JJ\1740 doses_13\NNS\3740161 ._14\.\1740
D013793_D006940 NONE pentoxifylline_0\NN\3247620 (_1\-LRB-\1740 trental_2\JJ\1740 )_3\-RRB-\1740 does_4\VBZ\1640855 not_5\RB\1740 inhibit_6\VB\2510337 dipyridamole-induced_7\JJ\1740 coronary_8\JJ\1740 <e2>hyperemia</e2>_9\NN\14320394 :_10\:\1740 implications_11\NNS\5774614 for_12\IN\1740 <e1>dipyridamole-thallium-201</e1>_13\JJ\1740 myocardial_14\JJ\1740 imaging_15\NN\5765159 ._16\.\1740
D013793_D006940 NONE whether_0\IN\1740 pentoxifylline_1\NN\3247620 inhibits_2\VBZ\2510337 dipyridamole-induced_3\JJ\1740 coronary_4\JJ\1740 <e2>hyperemia</e2>_5\NN\14320394 like_6\IN\5839024 other_7\JJ\1740 methylxanthines_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 theophylline_11\NN\2905612 and_12\CC\1740 should_13\MD\1740 be_14\VB\836236 stopped_15\VBN\2452885 prior_16\RB\1740 to_17\IN\1740 <e1>dipyridamole-thallium-201</e1>_18\NN\1740 imaging_19\NN\5765159 is_20\VBZ\836236 unknown_21\JJ\1740 ._22\.\1740
D004176_D016491 NONE <e1>dipyridamole-thallium-201</e1>_0\NN\1740 imaging_1\NN\5765159 is_2\VBZ\836236 often_3\RB\1740 performed_4\VBN\2367363 in_5\IN\13603305 patients_6\NNS\9898892 unable_7\JJ\1740 to_8\TO\1740 exercise_9\VB\1158872 because_10\IN\1740 of_11\IN\1740 <e2>peripheral_12\JJ\1740 vascular_13\JJ\1740 disease</e2>_14\NN\14061805 ._15\.\1740
D013793_D016491 NONE <e1>dipyridamole-thallium-201</e1>_0\NN\1740 imaging_1\NN\5765159 is_2\VBZ\836236 often_3\RB\1740 performed_4\VBN\2367363 in_5\IN\13603305 patients_6\NNS\9898892 unable_7\JJ\1740 to_8\TO\1740 exercise_9\VB\1158872 because_10\IN\1740 of_11\IN\1740 <e2>peripheral_12\JJ\1740 vascular_13\JJ\1740 disease</e2>_14\NN\14061805 ._15\.\1740
D010431_D007383 CID many_0\JJ\1740 of_1\IN\1740 these_2\DT\1740 patients_3\NNS\9898892 are_4\VBP\836236 taking_5\VBG\2367363 <e1>pentoxifylline</e1>_6\NN\3247620 (_7\-LRB-\1740 trental_8\NNP\3247620 )_9\-RRB-\1740 ,_10\,\1740 a_11\DT\13649268 methylxanthine_12\NN\1740 derivative_13\NN\5802185 which_14\WDT\1740 may_15\MD\15209706 improve_16\VB\126264 <e2>intermittent_17\NN\1740 claudication</e2>_18\NN\14548913 ._19\.\1740
D010431_D007383 CID many_0\JJ\1740 of_1\IN\1740 these_2\DT\1740 patients_3\NNS\9898892 are_4\VBP\836236 taking_5\VBG\2367363 pentoxifylline_6\NN\3247620 (_7\-LRB-\1740 <e1>trental</e1>_8\NNP\3247620 )_9\-RRB-\1740 ,_10\,\1740 a_11\DT\13649268 methylxanthine_12\NN\1740 derivative_13\NN\5802185 which_14\WDT\1740 may_15\MD\15209706 improve_16\VB\126264 <e2>intermittent_17\NN\1740 claudication</e2>_18\NN\14548913 ._19\.\1740
C008514_D007383 NONE many_0\JJ\1740 of_1\IN\1740 these_2\DT\1740 patients_3\NNS\9898892 are_4\VBP\836236 taking_5\VBG\2367363 pentoxifylline_6\NN\3247620 (_7\-LRB-\1740 trental_8\NNP\3247620 )_9\-RRB-\1740 ,_10\,\1740 a_11\DT\13649268 <e1>methylxanthine</e1>_12\NN\1740 derivative_13\NN\5802185 which_14\WDT\1740 may_15\MD\15209706 improve_16\VB\126264 <e2>intermittent_17\NN\1740 claudication</e2>_18\NN\14548913 ._19\.\1740
C008514_D006940 NONE whether_0\IN\1740 pentoxifylline_1\NN\3247620 inhibits_2\VBZ\2510337 dipyridamole-induced_3\JJ\1740 coronary_4\JJ\1740 <e2>hyperemia</e2>_5\NN\14320394 like_6\IN\5839024 other_7\JJ\1740 <e1>methylxanthines</e1>_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 theophylline_11\NN\2905612 and_12\CC\1740 should_13\MD\1740 be_14\VB\836236 stopped_15\VBN\2452885 prior_16\RB\1740 to_17\IN\1740 dipyridamole-thallium-201_18\NN\1740 imaging_19\NN\5765159 is_20\VBZ\836236 unknown_21\JJ\1740 ._22\.\1740
D013806_D006940 NONE whether_0\IN\1740 pentoxifylline_1\NN\3247620 inhibits_2\VBZ\2510337 dipyridamole-induced_3\JJ\1740 coronary_4\JJ\1740 <e2>hyperemia</e2>_5\NN\14320394 like_6\IN\5839024 other_7\JJ\1740 methylxanthines_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 <e1>theophylline</e1>_11\NN\2905612 and_12\CC\1740 should_13\MD\1740 be_14\VB\836236 stopped_15\VBN\2452885 prior_16\RB\1740 to_17\IN\1740 dipyridamole-thallium-201_18\NN\1740 imaging_19\NN\5765159 is_20\VBZ\836236 unknown_21\JJ\1740 ._22\.\1740
D013806_D006940 NONE neither_0\DT\1740 dose_1\NN\3740161 of_2\IN\1740 pentoxifylline_3\NN\3247620 significantly_4\RB\1740 decreased_5\VBD\169651 the_6\DT\1740 dipyridamole-induced_7\JJ\1740 <e2>hyperemia</e2>_8\NN\14320394 ,_9\,\1740 while_10\IN\15122231 peak_11\JJ\1740 coronary_12\JJ\1740 blood_13\NN\5397468 flow_14\NN\7311115 was_15\VBD\836236 significantly_16\RB\1740 lower_17\JJR\1740 after_18\IN\1740 <e1>theophylline</e1>_19\NN\2905612 (_20\-LRB-\1740 p_21\NN\14622893 less_22\JJR\1740 than_23\IN\1740 0.01_24\CD\1740 )_25\-RRB-\1740 ._26\.\1740
10807237
D003042_D000783 NONE methods_0\NNS\5616786 :_1\:\1740 a_2\DT\13649268 review_3\NN\5733583 of_4\IN\1740 admissions_5\NNS\49003 during_6\IN\1740 a_7\DT\13649268 6-year_8\JJ\1740 period_9\NN\13575869 revealed_10\VBD\2137132 14_11\CD\13745420 patients_12\NNS\9898892 with_13\IN\1740 <e1>cocaine-related</e1>_14\JJ\1740 <e2>aneurysms</e2>_15\NNS\14057371 ._16\.\1740
D003042_D000783 NONE hunt_0\NNP\8227214 and_1\CC\1740 hess_2\NNP\1740 grade_3\NN\7975026 (_4\-LRB-\1740 p_5\NN\14622893 <_6\XX\1740 0.005_7\CD\1740 )_8\-RRB-\1740 and_9\CC\1740 age_10\NN\4916342 (_11\-LRB-\1740 p_12\NN\14622893 <_13\XX\1740 0.007_14\CD\1740 )_15\-RRB-\1740 were_16\VBD\836236 significant_17\JJ\1740 predictors_18\NNS\10756433 of_19\IN\1740 outcome_20\NN\7291312 for_21\IN\1740 the_22\DT\1740 patients_23\NNS\9898892 with_24\IN\1740 <e1>cocaine-related</e1>_25\JJ\1740 <e2>aneurysms</e2>_26\NNS\14057371 ._27\.\1740
D003042_D000783 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>cocaine</e1>_2\NN\3492717 use_3\VBP\1156834 predisposed_4\VBN\680841 aneurysmal_5\JJ\1740 rupture_6\NN\14285662 at_7\IN\14622893 a_8\DT\13649268 significantly_9\RB\1740 earlier_10\JJR\1740 age_11\NN\4916342 and_12\CC\1740 in_13\IN\13603305 much_14\RB\1740 smaller_15\JJR\1740 <e2>aneurysms</e2>_16\NNS\14057371 ._17\.\1740
D003042_D017542 CID conclusion_0\NN\5837957 :_1\:\1740 <e1>cocaine</e1>_2\NN\3492717 use_3\VBP\1156834 predisposed_4\VBN\680841 <e2>aneurysmal_5\JJ\1740 rupture</e2>_6\NN\14285662 at_7\IN\14622893 a_8\DT\13649268 significantly_9\RB\1740 earlier_10\JJR\1740 age_11\NN\4916342 and_12\CC\1740 in_13\IN\13603305 much_14\RB\1740 smaller_15\JJR\1740 aneurysms_16\NNS\14057371 ._17\.\1740
3865016
D005047_D054218 NONE a_0\DT\13649268 synergistic_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 <e1>etoposide</e1>_4\NN\1740 and_5\CC\1740 cyclosporin_6\NN\1740 a_7\NN\13649268 was_8\VBD\836236 observed_9\VBN\2163746 in_10\IN\13603305 a_11\DT\13649268 patient_12\NN\9898892 with_13\IN\1740 <e2>acute_14\JJ\1740 t-lymphocytic_15\JJ\1740 leukemia</e2>_16\NN\14239918 in_17\IN\13603305 relapse_18\NN\66636 ._19\.\1740
D016572_D054218 NONE a_0\DT\13649268 synergistic_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 etoposide_4\NN\1740 and_5\CC\1740 <e1>cyclosporin_6\NN\1740 a</e1>_7\NN\13649268 was_8\VBD\836236 observed_9\VBN\2163746 in_10\IN\13603305 a_11\DT\13649268 patient_12\NN\9898892 with_13\IN\1740 <e2>acute_14\JJ\1740 t-lymphocytic_15\JJ\1740 leukemia</e2>_16\NN\14239918 in_17\IN\13603305 relapse_18\NN\66636 ._19\.\1740
D005047_D017254 NONE the_0\DT\1740 concomitant_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 <e1>etoposide</e1>_4\NN\1740 and_5\CC\1740 cyclosporin_6\NN\1740 a_7\NN\13649268 resulted_8\VBD\2633881 in_9\IN\13603305 eradication_10\NN\7334490 of_11\IN\1740 hitherto_12\RB\1740 refractory_13\JJ\1740 <e2>leukemic_14\JJ\1740 infiltration</e2>_15\NN\975452 of_16\IN\1740 bone_17\NN\5286536 marrow_18\NN\5286536 ._19\.\1740
D016572_D017254 NONE the_0\DT\1740 concomitant_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 etoposide_4\NN\1740 and_5\CC\1740 <e1>cyclosporin_6\NN\1740 a</e1>_7\NN\13649268 resulted_8\VBD\2633881 in_9\IN\13603305 eradication_10\NN\7334490 of_11\IN\1740 hitherto_12\RB\1740 refractory_13\JJ\1740 <e2>leukemic_14\JJ\1740 infiltration</e2>_15\NN\975452 of_16\IN\1740 bone_17\NN\5286536 marrow_18\NN\5286536 ._19\.\1740
3192036
10791295
D001058_D010554 CID development_0\NN\248977 of_1\IN\1740 <e1>apomorphine-induced</e1>_2\JJ\1740 <e2>aggressive_3\JJ\1740 behavior</e2>_4\NN\407535 :_5\:\1740 comparison_6\NN\635850 of_7\IN\1740 adult_8\JJ\1740 male_9\JJ\1740 and_10\CC\1740 female_11\NN\15388 wistar_12\NNP\1740 rats_13\NNS\2329401 ._14\.\1740
D001058_D010554 CID the_0\DT\1740 development_1\NN\248977 of_2\IN\1740 <e1>apomorphine-induced</e1>_3\JJ\1740 (_4\-LRB-\1740 1.0_5\CD\1740 mg/kg_6\NN\1740 s.c._7\NN\1740 once_8\RB\1740 daily_9\RB\1740 )_10\-RRB-\1740 <e2>aggressive_11\JJ\1740 behavior</e2>_12\NN\407535 of_13\IN\1740 adult_14\JJ\1740 male_15\JJ\1740 and_16\CC\1740 female_17\NN\15388 wistar_18\NNP\1740 rats_19\NNS\2329401 obtained_20\VBN\2210855 from_21\IN\1740 the_22\DT\1740 same_23\JJ\1740 breeder_24\NN\10658501 was_25\VBD\836236 studied_26\VBN\630380 in_27\IN\13603305 two_28\CD\13741022 consecutive_29\JJ\1740 sets_30\NNS\7951464 ._31\.\1740
D001058_D010554 CID in_0\IN\13603305 male_1\JJ\1740 animals_2\NNS\4475 ,_3\,\1740 repeated_4\VBN\952524 <e1>apomorphine</e1>_5\NN\3786417 treatment_6\NN\654885 induced_7\VBD\1627355 a_8\DT\13649268 gradual_9\JJ\1740 development_10\NN\248977 of_11\IN\1740 <e2>aggressive_12\JJ\1740 behavior</e2>_13\NN\407535 as_14\IN\14622893 evidenced_15\VBN\1015244 by_16\IN\1740 the_17\DT\1740 increased_18\VBN\169651 intensity_19\NN\5090441 of_20\IN\1740 aggressiveness_21\NN\4835724 and_22\CC\1740 shortened_23\VBD\429060 latency_24\NN\15269513 before_25\IN\1740 the_26\DT\1740 first_27\JJ\1740 attack_28\NN\955060 toward_29\IN\1740 the_30\DT\1740 opponent_31\NN\9613191 ._32\.\1740
D001058_D010554 CID in_0\IN\13603305 male_1\JJ\1740 animals_2\NNS\4475 ,_3\,\1740 repeated_4\VBN\952524 <e1>apomorphine</e1>_5\NN\3786417 treatment_6\NN\654885 induced_7\VBD\1627355 a_8\DT\13649268 gradual_9\JJ\1740 development_10\NN\248977 of_11\IN\1740 aggressive_12\JJ\1740 behavior_13\NN\407535 as_14\IN\14622893 evidenced_15\VBN\1015244 by_16\IN\1740 the_17\DT\1740 increased_18\VBN\169651 intensity_19\NN\5090441 of_20\IN\1740 <e2>aggressiveness</e2>_21\NN\4835724 and_22\CC\1740 shortened_23\VBD\429060 latency_24\NN\15269513 before_25\IN\1740 the_26\DT\1740 first_27\JJ\1740 attack_28\NN\955060 toward_29\IN\1740 the_30\DT\1740 opponent_31\NN\9613191 ._32\.\1740
D001058_D010554 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 demonstrates_6\VBZ\2137132 gender_7\NN\6309383 differences_8\NNS\4723816 in_9\IN\13603305 the_10\DT\1740 development_11\NN\248977 of_12\IN\1740 the_13\DT\1740 <e1>apomorphine-induced</e1>_14\JJ\1740 <e2>aggressive_15\JJ\1740 behavior</e2>_16\NN\407535 and_17\CC\1740 indicates_18\VBZ\952524 that_19\IN\1740 the_20\DT\1740 female_21\JJ\1740 rats_22\NNS\2329401 do_23\VBP\1640855 not_24\RB\1740 fill_25\VB\126264 the_26\DT\1740 validation_27\NN\151497 criteria_28\NNS\13577171 for_29\IN\1740 use_30\NN\407535 in_31\IN\13603305 this_32\DT\1740 method_33\NN\5616786 ._34\.\1740
1992636
D009853_D000743 CID <e2>hemolytic_0\JJ\1740 anemia</e2>_1\NN\14189204 associated_2\VBN\628491 with_3\IN\1740 the_4\DT\1740 use_5\NN\407535 of_6\IN\1740 <e1>omeprazole</e1>_7\NN\14778019 ._8\.\1740
D009853_D000743 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 first_3\JJ\1740 case_4\NN\7283608 of_5\IN\1740 a_6\DT\13649268 serious_7\JJ\1740 short-term_8\JJ\1740 adverse_9\JJ\1740 reaction_10\NN\13446390 with_11\IN\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>omeprazole</e1>_15\NN\14778019 :_16\:\1740 <e2>hemolytic_17\JJ\1740 anemia</e2>_18\NN\14189204 ._19\.\1740
D009853_D000743 CID the_0\DT\1740 mechanism_1\NN\13446390 by_2\IN\1740 which_3\WDT\1740 <e1>omeprazole</e1>_4\NN\14778019 caused_5\VBD\1617192 the_6\DT\1740 patient_7\NN\9898892 's_8\POS\1740 <e2>hemolytic_9\JJ\1740 anemia</e2>_10\NN\14189204 is_11\VBZ\836236 uncertain_12\JJ\1740 ,_13\,\1740 but_14\CC\1740 physicians_15\NNS\10305802 should_16\MD\1740 be_17\VB\836236 alerted_18\VBN\870213 to_19\TO\1740 this_20\DT\1740 possible_21\JJ\1740 adverse_22\JJ\1740 effect_23\NN\34213 ._24\.\1740
D009853_D053609 CID the_0\DT\1740 patient_1\NN\9898892 developed_2\VBD\1753788 weakness_3\NN\14462666 ,_4\,\1740 <e2>lethargy</e2>_5\NN\14014621 ,_6\,\1740 and_7\CC\1740 shortness_8\NN\5129201 of_9\IN\1740 breath_10\NN\13440063 2_11\CD\13741022 days_12\NNS\15140892 after_13\IN\1740 starting_14\VBG\2009433 therapy_15\NN\657604 with_16\IN\1740 <e1>omeprazole</e1>_17\NN\14778019 ._18\.\1740
D009853_D004417 CID the_0\DT\1740 patient_1\NN\9898892 developed_2\VBD\1753788 weakness_3\NN\14462666 ,_4\,\1740 lethargy_5\NN\14014621 ,_6\,\1740 and_7\CC\1740 <e2>shortness_8\NN\5129201 of_9\IN\1740 breath</e2>_10\NN\13440063 2_11\CD\13741022 days_12\NNS\15140892 after_13\IN\1740 starting_14\VBG\2009433 therapy_15\NN\657604 with_16\IN\1740 <e1>omeprazole</e1>_17\NN\14778019 ._18\.\1740
9660111
D014299_D007035 NONE in_0\IN\13603305 the_1\DT\1740 acute_2\JJ\1740 experiment_3\NN\641820 <e1>tri</e1>_4\NNP\1740 (_5\-LRB-\1740 given_6\VBN\2327200 i.p._7\RB\1740 )_8\-RRB-\1740 does_9\VBZ\1640855 not_10\RB\1740 antagonize_11\VB\1787955 the_12\DT\1740 reserpine_13\NN\2721160 <e2>hypothermia</e2>_14\NN\14034177 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 does_18\VBZ\1640855 not_19\RB\1740 potentiate_20\VB\229605 the_21\DT\1740 5-hydroxytryptophan_22\JJ\1740 head_23\NN\5225090 twitches_24\VBZ\10054 in_25\IN\13603305 rats_26\NNS\2329401 ._27\.\1740
D012110_D007035 CID in_0\IN\13603305 the_1\DT\1740 acute_2\JJ\1740 experiment_3\NN\641820 tri_4\NNP\1740 (_5\-LRB-\1740 given_6\VBN\2327200 i.p._7\RB\1740 )_8\-RRB-\1740 does_9\VBZ\1640855 not_10\RB\1740 antagonize_11\VB\1787955 the_12\DT\1740 <e1>reserpine</e1>_13\NN\2721160 <e2>hypothermia</e2>_14\NN\14034177 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 does_18\VBZ\1640855 not_19\RB\1740 potentiate_20\VB\229605 the_21\DT\1740 5-hydroxytryptophan_22\JJ\1740 head_23\NN\5225090 twitches_24\VBZ\10054 in_25\IN\13603305 rats_26\NNS\2329401 ._27\.\1740
D006916_D007035 NONE in_0\IN\13603305 the_1\DT\1740 acute_2\JJ\1740 experiment_3\NN\641820 tri_4\NNP\1740 (_5\-LRB-\1740 given_6\VBN\2327200 i.p._7\RB\1740 )_8\-RRB-\1740 does_9\VBZ\1640855 not_10\RB\1740 antagonize_11\VB\1787955 the_12\DT\1740 reserpine_13\NN\2721160 <e2>hypothermia</e2>_14\NN\14034177 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 does_18\VBZ\1640855 not_19\RB\1740 potentiate_20\VB\229605 the_21\DT\1740 <e1>5-hydroxytryptophan</e1>_22\JJ\1740 head_23\NN\5225090 twitches_24\VBZ\10054 in_25\IN\13603305 rats_26\NNS\2329401 ._27\.\1740
D014299_D006948 CID <e1>tri</e1>_0\NNP\1740 given_1\VBN\2327200 repeatedly_2\RB\1740 to_3\TO\1740 rats_4\NNS\2329401 increases_5\VBZ\169651 the_6\DT\1740 locomotor_7\NN\1740 <e2>hyperactivity</e2>_8\NN\14052403 induced_9\VBN\1627355 by_10\IN\1740 d-amphetamine_11\NN\1740 ,_12\,\1740 quinpirole_13\NN\1740 and_14\CC\1740 (+)-7-hydroxy-dipropyloaminotetralin_15\NN\1740 (_16\-LRB-\1740 dopamine_17\NN\14807737 d2_18\NN\1740 and_19\CC\1740 d3_20\NN\1740 effects_21\NNS\13245626 )_22\-RRB-\1740 ._23\.\1740
D003913_D006948 CID tri_0\NNP\1740 given_1\VBN\2327200 repeatedly_2\RB\1740 to_3\TO\1740 rats_4\NNS\2329401 increases_5\VBZ\169651 the_6\DT\1740 locomotor_7\NN\1740 <e2>hyperactivity</e2>_8\NN\14052403 induced_9\VBN\1627355 by_10\IN\1740 <e1>d-amphetamine</e1>_11\NN\1740 ,_12\,\1740 quinpirole_13\NN\1740 and_14\CC\1740 (+)-7-hydroxy-dipropyloaminotetralin_15\NN\1740 (_16\-LRB-\1740 dopamine_17\NN\14807737 d2_18\NN\1740 and_19\CC\1740 d3_20\NN\1740 effects_21\NNS\13245626 )_22\-RRB-\1740 ._23\.\1740
D019257_D006948 CID tri_0\NNP\1740 given_1\VBN\2327200 repeatedly_2\RB\1740 to_3\TO\1740 rats_4\NNS\2329401 increases_5\VBZ\169651 the_6\DT\1740 locomotor_7\NN\1740 <e2>hyperactivity</e2>_8\NN\14052403 induced_9\VBN\1627355 by_10\IN\1740 d-amphetamine_11\NN\1740 ,_12\,\1740 <e1>quinpirole</e1>_13\NN\1740 and_14\CC\1740 (+)-7-hydroxy-dipropyloaminotetralin_15\NN\1740 (_16\-LRB-\1740 dopamine_17\NN\14807737 d2_18\NN\1740 and_19\CC\1740 d3_20\NN\1740 effects_21\NNS\13245626 )_22\-RRB-\1740 ._23\.\1740
D004298_D006948 NONE tri_0\NNP\1740 given_1\VBN\2327200 repeatedly_2\RB\1740 to_3\TO\1740 rats_4\NNS\2329401 increases_5\VBZ\169651 the_6\DT\1740 locomotor_7\NN\1740 <e2>hyperactivity</e2>_8\NN\14052403 induced_9\VBN\1627355 by_10\IN\1740 d-amphetamine_11\NN\1740 ,_12\,\1740 quinpirole_13\NN\1740 and_14\CC\1740 (+)-7-hydroxy-dipropyloaminotetralin_15\NN\1740 (_16\-LRB-\1740 <e1>dopamine</e1>_17\NN\14807737 d2_18\NN\1740 and_19\CC\1740 d3_20\NN\1740 effects_21\NNS\13245626 )_22\-RRB-\1740 ._23\.\1740
D010656_D010554 NONE it_0\PRP\6125041 increases_1\VBZ\169651 the_2\DT\1740 behaviour_3\NN\14006945 stimulation_4\NN\242808 evoked_5\VBN\1617192 by_6\IN\1740 <e1>phenylephrine</e1>_7\NN\2682038 (_8\-LRB-\1740 given_9\VBN\2327200 intraventricularly_10\NN\1740 )_11\-RRB-\1740 in_12\IN\13603305 rats_13\NNS\2329401 ,_14\,\1740 evaluated_15\VBN\670261 in_16\IN\13603305 the_17\DT\1740 open_18\JJ\1740 field_19\NN\8673395 test_20\NN\5798043 as_21\RB\1740 well_22\RB\1740 as_23\IN\14622893 the_24\DT\1740 <e2>aggressiveness</e2>_25\NN\4835724 evoked_26\VBN\1617192 by_27\IN\1740 clonidine_28\NN\2721160 in_29\IN\13603305 mice_30\NNS\2329401 ,_31\,\1740 both_32\CC\1740 these_33\DT\1740 effects_34\NNS\13245626 being_35\VBG\836236 mediated_36\VBN\761713 by_37\IN\1740 an_38\DT\6697703 alpha1-adrenergic_39\JJ\1740 receptor_40\NN\5225602 ._41\.\1740
D003000_D010554 NONE it_0\PRP\6125041 increases_1\VBZ\169651 the_2\DT\1740 behaviour_3\NN\14006945 stimulation_4\NN\242808 evoked_5\VBN\1617192 by_6\IN\1740 phenylephrine_7\NN\2682038 (_8\-LRB-\1740 given_9\VBN\2327200 intraventricularly_10\NN\1740 )_11\-RRB-\1740 in_12\IN\13603305 rats_13\NNS\2329401 ,_14\,\1740 evaluated_15\VBN\670261 in_16\IN\13603305 the_17\DT\1740 open_18\JJ\1740 field_19\NN\8673395 test_20\NN\5798043 as_21\RB\1740 well_22\RB\1740 as_23\IN\14622893 the_24\DT\1740 <e2>aggressiveness</e2>_25\NN\4835724 evoked_26\VBN\1617192 by_27\IN\1740 <e1>clonidine</e1>_28\NN\2721160 in_29\IN\13603305 mice_30\NNS\2329401 ,_31\,\1740 both_32\CC\1740 these_33\DT\1740 effects_34\NNS\13245626 being_35\VBG\836236 mediated_36\VBN\761713 by_37\IN\1740 an_38\DT\6697703 alpha1-adrenergic_39\JJ\1740 receptor_40\NN\5225602 ._41\.\1740
19211690
D013739_D006973 NONE <e1>testosterone-dependent</e1>_0\JJ\1740 <e2>hypertension</e2>_1\NN\14057371 and_2\CC\1740 upregulation_3\NN\1740 of_4\IN\1740 intrarenal_5\JJ\1740 angiotensinogen_6\NN\1740 in_7\IN\13603305 dahl_8\NN\13112664 salt-sensitive_9\JJ\1740 rats_10\NNS\2329401 ._11\.\1740
D013739_D006973 NONE <e1>testosterone</e1>_0\NN\14747587 contributes_1\VBZ\126264 to_2\TO\1740 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 <e2>hypertension</e2>_6\NN\14057371 and_7\CC\1740 renal_8\JJ\1740 injury_9\NN\14052046 in_10\IN\13603305 male_11\JJ\1740 ds_12\NN\14622893 rats_13\NNS\2329401 on_14\IN\1740 hs_15\NN\14622893 diet_16\NN\7560652 possibly_17\RB\1740 through_18\IN\1740 upregulation_19\NN\1740 of_20\IN\1740 the_21\DT\1740 intrarenal_22\JJ\1740 renin-angiotensin_23\JJ\1740 system_24\NN\3575240 ._25\.\1740
D017673_D006973 NONE testosterone-dependent_0\JJ\1740 <e2>hypertension</e2>_1\NN\14057371 and_2\CC\1740 upregulation_3\NN\1740 of_4\IN\1740 intrarenal_5\JJ\1740 angiotensinogen_6\NN\1740 in_7\IN\13603305 dahl_8\NN\13112664 <e1>salt-sensitive</e1>_9\JJ\1740 rats_10\NNS\2329401 ._11\.\1740
D013739_D007674 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 the_4\DT\1740 hypothesis_5\NN\7162194 was_6\VBD\836236 tested_7\VBN\670261 that_8\IN\1740 there_9\EX\27167 is_10\VBZ\836236 a_11\DT\13649268 sexual_12\JJ\1740 dimorphism_13\NN\11492833 in_14\IN\13603305 hs-induced_15\JJ\1740 upregulation_16\NN\1740 of_17\IN\1740 intrarenal_18\JJ\1740 angiotensinogen_19\NN\1740 mediated_20\VBN\761713 by_21\IN\1740 <e1>testosterone</e1>_22\NN\14747587 that_23\WDT\1740 also_24\RB\1740 causes_25\VBZ\1617192 increases_26\NNS\13576355 in_27\IN\13603305 bp_28\NN\1740 and_29\CC\1740 <e2>renal_30\JJ\1740 injury</e2>_31\NN\14052046 ._32\.\1740
D013739_D007674 NONE <e1>testosterone</e1>_0\NN\14747587 replacement_1\NN\196485 in_2\IN\13603305 castrated_3\VBN\224901 ds_4\NN\14622893 rats_5\NNS\2329401 increased_6\VBD\169651 bp_7\NN\1740 ,_8\,\1740 <e2>renal_9\JJ\1740 injury</e2>_10\NN\14052046 ,_11\,\1740 and_12\CC\1740 upregulation_13\NN\1740 of_14\IN\1740 renal_15\JJ\1740 angiotensinogen_16\NN\1740 associated_17\VBN\628491 with_18\IN\1740 hs_19\NN\14622893 diet_20\NN\7560652 ._21\.\1740
D013739_D007674 NONE <e1>testosterone</e1>_0\NN\14747587 contributes_1\VBZ\126264 to_2\TO\1740 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 hypertension_6\NN\14057371 and_7\CC\1740 <e2>renal_8\JJ\1740 injury</e2>_9\NN\14052046 in_10\IN\13603305 male_11\JJ\1740 ds_12\NN\14622893 rats_13\NNS\2329401 on_14\IN\1740 hs_15\NN\14622893 diet_16\NN\7560652 possibly_17\RB\1740 through_18\IN\1740 upregulation_19\NN\1740 of_20\IN\1740 the_21\DT\1740 intrarenal_22\JJ\1740 renin-angiotensin_23\JJ\1740 system_24\NN\3575240 ._25\.\1740
D000809_D006973 NONE testosterone_0\NN\14747587 contributes_1\VBZ\126264 to_2\TO\1740 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 <e2>hypertension</e2>_6\NN\14057371 and_7\CC\1740 renal_8\JJ\1740 injury_9\NN\14052046 in_10\IN\13603305 male_11\JJ\1740 ds_12\NN\14622893 rats_13\NNS\2329401 on_14\IN\1740 hs_15\NN\14622893 diet_16\NN\7560652 possibly_17\RB\1740 through_18\IN\1740 upregulation_19\NN\1740 of_20\IN\1740 the_21\DT\1740 intrarenal_22\JJ\1740 <e1>renin-angiotensin</e1>_23\JJ\1740 system_24\NN\3575240 ._25\.\1740
D000809_D007674 NONE testosterone_0\NN\14747587 contributes_1\VBZ\126264 to_2\TO\1740 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 hypertension_6\NN\14057371 and_7\CC\1740 <e2>renal_8\JJ\1740 injury</e2>_9\NN\14052046 in_10\IN\13603305 male_11\JJ\1740 ds_12\NN\14622893 rats_13\NNS\2329401 on_14\IN\1740 hs_15\NN\14622893 diet_16\NN\7560652 possibly_17\RB\1740 through_18\IN\1740 upregulation_19\NN\1740 of_20\IN\1740 the_21\DT\1740 intrarenal_22\JJ\1740 <e1>renin-angiotensin</e1>_23\JJ\1740 system_24\NN\3575240 ._25\.\1740
18410508
D008694_D020258 NONE <e1>methamphetamine-induced</e1>_0\JJ\1740 <e2>neurotoxicity</e2>_1\NN\1740 and_2\CC\1740 microglial_3\JJ\1740 activation_4\NN\13561719 are_5\VBP\836236 not_6\RB\1740 mediated_7\VBN\761713 by_8\IN\1740 fractalkine_9\NN\1740 receptor_10\NN\5225602 signaling_11\NN\33020 ._12\.\1740
D008694_D020258 NONE because_0\IN\1740 the_1\DT\1740 cns_2\NN\5237227 damage_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 <e1>meth</e1>_6\NN\2704153 and_7\CC\1740 mptp_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 da_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 <e2>neurotoxicity</e2>_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 meth-induced_32\JJ\1740 neurotoxicity_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
D008694_D020258 NONE because_0\IN\1740 the_1\DT\1740 cns_2\NN\5237227 damage_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 <e1>meth</e1>_6\NN\2704153 and_7\CC\1740 mptp_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 da_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 neurotoxicity_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 meth-induced_32\JJ\1740 <e2>neurotoxicity</e2>_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
D008694_D020258 NONE because_0\IN\1740 the_1\DT\1740 cns_2\NN\5237227 damage_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 meth_6\NN\2704153 and_7\CC\1740 mptp_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 da_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 <e2>neurotoxicity</e2>_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 <e1>meth-induced</e1>_32\JJ\1740 neurotoxicity_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
D008694_D020258 NONE because_0\IN\1740 the_1\DT\1740 cns_2\NN\5237227 damage_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 meth_6\NN\2704153 and_7\CC\1740 mptp_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 da_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 neurotoxicity_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 <e1>meth-induced</e1>_32\JJ\1740 <e2>neurotoxicity</e2>_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
D008694_D020258 NONE mice_0\NNS\2329401 in_1\IN\13603305 which_2\WDT\1740 the_3\DT\1740 cx3cr1_4\NN\1740 gene_5\NN\8459252 has_6\VBZ\2108377 been_7\VBN\836236 deleted_8\VBN\173338 and_9\CC\1740 replaced_10\VBD\1631072 with_11\IN\1740 a_12\DT\13649268 cdna_13\NN\14830364 encoding_14\NN\614489 enhanced_15\VBD\227165 green_16\JJ\1740 fluorescent_17\JJ\1740 protein_18\NN\14944888 (_19\-LRB-\1740 egfp_20\NN\1740 )_21\-RRB-\1740 were_22\VBD\836236 treated_23\VBN\2376958 with_24\IN\1740 <e1>meth</e1>_25\NN\2704153 and_26\CC\1740 examined_27\VBN\789138 for_28\IN\1740 striatal_29\JJ\1740 <e2>neurotoxicity</e2>_30\NN\1740 ._31\.\1740
D008694_D020258 NONE we_0\PRP\1740 conclude_1\VBP\628491 from_2\IN\1740 these_3\DT\1740 studies_4\NNS\635850 that_5\WDT\1740 cx3cr1_6\NN\1740 signaling_7\NN\33020 does_8\VBZ\1640855 not_9\RB\1740 modulate_10\VB\1724459 <e1>meth</e1>_11\NN\2704153 <e2>neurotoxicity</e2>_12\NN\1740 or_13\CC\3541091 microglial_14\JJ\1740 activation_15\NN\13561719 ._16\.\1740
D015632_D009422 CID 9_0\CD\13741022 (_1\-LRB-\1740 2006_2\CD\1740 )_3\-RRB-\1740 ,_4\,\1740 917_5\CD\1740 ]_6\-RRB-\1740 recently_7\RB\1740 identified_8\VBD\699815 the_9\DT\1740 microglial-specific_10\JJ\1740 fractalkine_11\NN\1740 receptor_12\NN\5225602 (_13\-LRB-\1740 cx3cr1_14\NN\1740 )_15\-RRB-\1740 as_16\IN\14622893 an_17\DT\6697703 important_18\JJ\1740 mediator_19\NN\10351874 of_20\IN\1740 <e1>mptp-induced</e1>_21\JJ\1740 <e2>neurodegeneration</e2>_22\NN\1740 of_23\IN\1740 da_24\NN\10484858 neurons_25\NNS\5430628 ._26\.\1740
D015632_D009422 CID because_0\IN\1740 the_1\DT\1740 <e2>cns_2\NN\5237227 damage</e2>_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 meth_6\NN\2704153 and_7\CC\1740 <e1>mptp</e1>_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 da_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 neurotoxicity_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 meth-induced_32\JJ\1740 neurotoxicity_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
D004298_D009422 NONE 9_0\CD\13741022 (_1\-LRB-\1740 2006_2\CD\1740 )_3\-RRB-\1740 ,_4\,\1740 917_5\CD\1740 ]_6\-RRB-\1740 recently_7\RB\1740 identified_8\VBD\699815 the_9\DT\1740 microglial-specific_10\JJ\1740 fractalkine_11\NN\1740 receptor_12\NN\5225602 (_13\-LRB-\1740 cx3cr1_14\NN\1740 )_15\-RRB-\1740 as_16\IN\14622893 an_17\DT\6697703 important_18\JJ\1740 mediator_19\NN\10351874 of_20\IN\1740 mptp-induced_21\JJ\1740 <e2>neurodegeneration</e2>_22\NN\1740 of_23\IN\1740 <e1>da</e1>_24\NN\10484858 neurons_25\NNS\5430628 ._26\.\1740
D004298_D009422 NONE because_0\IN\1740 the_1\DT\1740 <e2>cns_2\NN\5237227 damage</e2>_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 meth_6\NN\2704153 and_7\CC\1740 mptp_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 <e1>da</e1>_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 neurotoxicity_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 meth-induced_32\JJ\1740 neurotoxicity_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
D008694_D009422 CID because_0\IN\1740 the_1\DT\1740 <e2>cns_2\NN\5237227 damage</e2>_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 <e1>meth</e1>_6\NN\2704153 and_7\CC\1740 mptp_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 da_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 neurotoxicity_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 meth-induced_32\JJ\1740 neurotoxicity_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
D008694_D009422 CID because_0\IN\1740 the_1\DT\1740 <e2>cns_2\NN\5237227 damage</e2>_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 meth_6\NN\2704153 and_7\CC\1740 mptp_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 da_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 neurotoxicity_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 <e1>meth-induced</e1>_32\JJ\1740 neurotoxicity_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
D015632_D020258 NONE because_0\IN\1740 the_1\DT\1740 cns_2\NN\5237227 damage_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 meth_6\NN\2704153 and_7\CC\1740 <e1>mptp</e1>_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 da_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 <e2>neurotoxicity</e2>_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 meth-induced_32\JJ\1740 neurotoxicity_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
D015632_D020258 NONE because_0\IN\1740 the_1\DT\1740 cns_2\NN\5237227 damage_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 meth_6\NN\2704153 and_7\CC\1740 <e1>mptp</e1>_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 da_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 neurotoxicity_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 meth-induced_32\JJ\1740 <e2>neurotoxicity</e2>_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
D004298_D020258 NONE because_0\IN\1740 the_1\DT\1740 cns_2\NN\5237227 damage_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 meth_6\NN\2704153 and_7\CC\1740 mptp_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 <e1>da</e1>_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 <e2>neurotoxicity</e2>_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 meth-induced_32\JJ\1740 neurotoxicity_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
D004298_D020258 NONE because_0\IN\1740 the_1\DT\1740 cns_2\NN\5237227 damage_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 meth_6\NN\2704153 and_7\CC\1740 mptp_8\NNP\1740 is_9\VBZ\836236 highly_10\RB\1740 selective_11\JJ\1740 for_12\IN\1740 the_13\DT\1740 <e1>da</e1>_14\NN\10484858 neuronal_15\JJ\1740 system_16\NN\3575240 in_17\IN\13603305 mouse_18\NN\2329401 models_19\NNS\5888929 of_20\IN\1740 neurotoxicity_21\NN\1740 ,_22\,\1740 we_23\PRP\1740 hypothesized_24\VBD\719734 that_25\IN\1740 the_26\DT\1740 cx3cr1_27\NNP\1740 plays_28\VBZ\1072262 a_29\DT\13649268 role_30\NN\719494 in_31\IN\13603305 meth-induced_32\JJ\1740 <e2>neurotoxicity</e2>_33\NN\1740 and_34\CC\1740 microglial_35\JJ\1740 activation_36\NN\13561719 ._37\.\1740
10743446
D007649_D006930 NONE differential_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 systemically_3\RB\1740 administered_4\VBN\2436349 <e1>ketamine</e1>_5\NN\3054098 and_6\CC\1740 lidocaine_7\NN\3681148 on_8\IN\1740 dynamic_9\JJ\1740 and_10\CC\1740 static_11\JJ\1740 <e2>hyperalgesia</e2>_12\NN\1740 induced_13\VBN\1627355 by_14\IN\1740 intradermal_15\JJ\1740 capsaicin_16\NN\15032661 in_17\IN\13603305 humans_18\NNS\31264 ._19\.\1740
D007649_D006930 NONE we_0\PRP\1740 have_1\VBP\2108377 examined_2\VBN\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 systemic_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 <e1>ketamine</e1>_9\NN\3054098 and_10\CC\1740 lidocaine_11\NN\3681148 on_12\IN\1740 brush-evoked_13\JJ\1740 (_14\-LRB-\1740 dynamic_15\JJ\1740 )_16\-RRB-\1740 pain_17\NN\14299637 and_18\CC\1740 punctate-evoked_19\JJ\1740 (_20\-LRB-\1740 static_21\JJ\1740 )_22\-RRB-\1740 <e2>hyperalgesia</e2>_23\NN\1740 induced_24\VBN\1627355 by_25\IN\1740 capsaicin_26\NN\15032661 ._27\.\1740
D007649_D006930 NONE <e1>ketamine</e1>_0\NNP\3054098 reduced_1\VBD\441445 both_2\CC\1740 the_3\DT\1740 area_4\NN\8630985 of_5\IN\1740 brush-evoked_6\JJ\1740 and_7\CC\1740 punctate-evoked_8\JJ\1740 <e2>hyperalgesia</e2>_9\NN\1740 significantly_10\RB\1740 and_11\CC\1740 it_12\PRP\6125041 tended_13\VBD\2604760 to_14\TO\1740 reduce_15\VB\441445 brush-evoked_16\JJ\1740 pain_17\NN\14299637 ._18\.\1740
D007649_D006930 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>ketamine</e1>_4\NN\3054098 and_5\CC\1740 lidocaine_6\NN\3681148 on_7\IN\1740 static_8\JJ\1740 and_9\CC\1740 dynamic_10\JJ\1740 <e2>hyperalgesia</e2>_11\NN\1740 suggest_12\VBP\1010118 that_13\IN\1740 the_14\DT\1740 two_15\CD\13741022 types_16\NNS\5839024 of_17\IN\1740 hyperalgesia_18\NN\1740 are_19\VBP\836236 mediated_20\VBN\761713 by_21\IN\1740 separate_22\JJ\1740 mechanisms_23\NNS\13446390 and_24\CC\1740 have_25\VBP\2108377 a_26\DT\13649268 distinct_27\JJ\1740 pharmacology_28\NN\6043075 ._29\.\1740
D007649_D006930 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>ketamine</e1>_4\NN\3054098 and_5\CC\1740 lidocaine_6\NN\3681148 on_7\IN\1740 static_8\JJ\1740 and_9\CC\1740 dynamic_10\JJ\1740 hyperalgesia_11\NN\1740 suggest_12\VBP\1010118 that_13\IN\1740 the_14\DT\1740 two_15\CD\13741022 types_16\NNS\5839024 of_17\IN\1740 <e2>hyperalgesia</e2>_18\NN\1740 are_19\VBP\836236 mediated_20\VBN\761713 by_21\IN\1740 separate_22\JJ\1740 mechanisms_23\NNS\13446390 and_24\CC\1740 have_25\VBP\2108377 a_26\DT\13649268 distinct_27\JJ\1740 pharmacology_28\NN\6043075 ._29\.\1740
D008012_D006930 NONE differential_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 systemically_3\RB\1740 administered_4\VBN\2436349 ketamine_5\NN\3054098 and_6\CC\1740 <e1>lidocaine</e1>_7\NN\3681148 on_8\IN\1740 dynamic_9\JJ\1740 and_10\CC\1740 static_11\JJ\1740 <e2>hyperalgesia</e2>_12\NN\1740 induced_13\VBN\1627355 by_14\IN\1740 intradermal_15\JJ\1740 capsaicin_16\NN\15032661 in_17\IN\13603305 humans_18\NNS\31264 ._19\.\1740
D008012_D006930 NONE we_0\PRP\1740 have_1\VBP\2108377 examined_2\VBN\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 systemic_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 ketamine_9\NN\3054098 and_10\CC\1740 <e1>lidocaine</e1>_11\NN\3681148 on_12\IN\1740 brush-evoked_13\JJ\1740 (_14\-LRB-\1740 dynamic_15\JJ\1740 )_16\-RRB-\1740 pain_17\NN\14299637 and_18\CC\1740 punctate-evoked_19\JJ\1740 (_20\-LRB-\1740 static_21\JJ\1740 )_22\-RRB-\1740 <e2>hyperalgesia</e2>_23\NN\1740 induced_24\VBN\1627355 by_25\IN\1740 capsaicin_26\NN\15032661 ._27\.\1740
D008012_D006930 NONE <e1>lidocaine</e1>_0\NN\3681148 reduced_1\VBD\441445 the_2\DT\1740 area_3\NN\8630985 of_4\IN\1740 punctate-evoked_5\JJ\1740 <e2>hyperalgesia</e2>_6\NN\1740 significantly_7\RB\1740 ._8\.\1740
D008012_D006930 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 ketamine_4\NN\3054098 and_5\CC\1740 <e1>lidocaine</e1>_6\NN\3681148 on_7\IN\1740 static_8\JJ\1740 and_9\CC\1740 dynamic_10\JJ\1740 <e2>hyperalgesia</e2>_11\NN\1740 suggest_12\VBP\1010118 that_13\IN\1740 the_14\DT\1740 two_15\CD\13741022 types_16\NNS\5839024 of_17\IN\1740 hyperalgesia_18\NN\1740 are_19\VBP\836236 mediated_20\VBN\761713 by_21\IN\1740 separate_22\JJ\1740 mechanisms_23\NNS\13446390 and_24\CC\1740 have_25\VBP\2108377 a_26\DT\13649268 distinct_27\JJ\1740 pharmacology_28\NN\6043075 ._29\.\1740
D008012_D006930 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 ketamine_4\NN\3054098 and_5\CC\1740 <e1>lidocaine</e1>_6\NN\3681148 on_7\IN\1740 static_8\JJ\1740 and_9\CC\1740 dynamic_10\JJ\1740 hyperalgesia_11\NN\1740 suggest_12\VBP\1010118 that_13\IN\1740 the_14\DT\1740 two_15\CD\13741022 types_16\NNS\5839024 of_17\IN\1740 <e2>hyperalgesia</e2>_18\NN\1740 are_19\VBP\836236 mediated_20\VBN\761713 by_21\IN\1740 separate_22\JJ\1740 mechanisms_23\NNS\13446390 and_24\CC\1740 have_25\VBP\2108377 a_26\DT\13649268 distinct_27\JJ\1740 pharmacology_28\NN\6043075 ._29\.\1740
D002211_D006930 CID differential_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 systemically_3\RB\1740 administered_4\VBN\2436349 ketamine_5\NN\3054098 and_6\CC\1740 lidocaine_7\NN\3681148 on_8\IN\1740 dynamic_9\JJ\1740 and_10\CC\1740 static_11\JJ\1740 <e2>hyperalgesia</e2>_12\NN\1740 induced_13\VBN\1627355 by_14\IN\1740 intradermal_15\JJ\1740 <e1>capsaicin</e1>_16\NN\15032661 in_17\IN\13603305 humans_18\NNS\31264 ._19\.\1740
D002211_D006930 CID we_0\PRP\1740 have_1\VBP\2108377 examined_2\VBN\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 systemic_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 ketamine_9\NN\3054098 and_10\CC\1740 lidocaine_11\NN\3681148 on_12\IN\1740 brush-evoked_13\JJ\1740 (_14\-LRB-\1740 dynamic_15\JJ\1740 )_16\-RRB-\1740 pain_17\NN\14299637 and_18\CC\1740 punctate-evoked_19\JJ\1740 (_20\-LRB-\1740 static_21\JJ\1740 )_22\-RRB-\1740 <e2>hyperalgesia</e2>_23\NN\1740 induced_24\VBN\1627355 by_25\IN\1740 <e1>capsaicin</e1>_26\NN\15032661 ._27\.\1740
D007649_D010146 NONE we_0\PRP\1740 have_1\VBP\2108377 examined_2\VBN\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 systemic_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 <e1>ketamine</e1>_9\NN\3054098 and_10\CC\1740 lidocaine_11\NN\3681148 on_12\IN\1740 brush-evoked_13\JJ\1740 (_14\-LRB-\1740 dynamic_15\JJ\1740 )_16\-RRB-\1740 <e2>pain</e2>_17\NN\14299637 and_18\CC\1740 punctate-evoked_19\JJ\1740 (_20\-LRB-\1740 static_21\JJ\1740 )_22\-RRB-\1740 hyperalgesia_23\NN\1740 induced_24\VBN\1627355 by_25\IN\1740 capsaicin_26\NN\15032661 ._27\.\1740
D007649_D010146 NONE <e1>ketamine</e1>_0\NNP\3054098 reduced_1\VBD\441445 both_2\CC\1740 the_3\DT\1740 area_4\NN\8630985 of_5\IN\1740 brush-evoked_6\JJ\1740 and_7\CC\1740 punctate-evoked_8\JJ\1740 hyperalgesia_9\NN\1740 significantly_10\RB\1740 and_11\CC\1740 it_12\PRP\6125041 tended_13\VBD\2604760 to_14\TO\1740 reduce_15\VB\441445 brush-evoked_16\JJ\1740 <e2>pain</e2>_17\NN\14299637 ._18\.\1740
D008012_D010146 NONE we_0\PRP\1740 have_1\VBP\2108377 examined_2\VBN\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 systemic_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 ketamine_9\NN\3054098 and_10\CC\1740 <e1>lidocaine</e1>_11\NN\3681148 on_12\IN\1740 brush-evoked_13\JJ\1740 (_14\-LRB-\1740 dynamic_15\JJ\1740 )_16\-RRB-\1740 <e2>pain</e2>_17\NN\14299637 and_18\CC\1740 punctate-evoked_19\JJ\1740 (_20\-LRB-\1740 static_21\JJ\1740 )_22\-RRB-\1740 hyperalgesia_23\NN\1740 induced_24\VBN\1627355 by_25\IN\1740 capsaicin_26\NN\15032661 ._27\.\1740
D002211_D010146 CID we_0\PRP\1740 have_1\VBP\2108377 examined_2\VBN\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 systemic_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 ketamine_9\NN\3054098 and_10\CC\1740 lidocaine_11\NN\3681148 on_12\IN\1740 brush-evoked_13\JJ\1740 (_14\-LRB-\1740 dynamic_15\JJ\1740 )_16\-RRB-\1740 <e2>pain</e2>_17\NN\14299637 and_18\CC\1740 punctate-evoked_19\JJ\1740 (_20\-LRB-\1740 static_21\JJ\1740 )_22\-RRB-\1740 hyperalgesia_23\NN\1740 induced_24\VBN\1627355 by_25\IN\1740 <e1>capsaicin</e1>_26\NN\15032661 ._27\.\1740
18442015
D014700_D006471 NONE protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>verapamil</e1>_3\NN\2938514 on_4\IN\1740 <e2>gastric_5\JJ\1740 hemorrhagic</e2>_6\JJ\1740 ulcers_7\NNS\14211294 in_8\IN\13603305 severe_9\JJ\1740 atherosclerotic_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
D014700_D006471 NONE this_0\DT\1740 <e2>hemorrhagic</e2>_1\JJ\1740 ulcer_2\NN\14211294 and_3\CC\1740 various_4\JJ\1740 ulcerogenic_5\JJ\1740 parameters_6\NNS\5858936 were_7\VBD\836236 dose-dependently_8\RB\1740 ameliorated_9\VBN\126264 by_10\IN\1740 daily_11\RB\1740 intragastric_12\JJ\1740 <e1>verapamil</e1>_13\RB\1740 ._14\.\1740
D014700_D006471 NONE atherosclerosis_0\NN\14108324 could_1\MD\1740 produce_2\VB\1617192 <e2>gastric_3\JJ\1740 hemorrhagic</e2>_4\JJ\1740 ulcer_5\NN\14211294 via_6\IN\1740 aggravation_7\NN\7518261 of_8\IN\1740 gastric_9\JJ\1740 acid_10\NN\14818238 back-diffusion_11\NN\1740 ,_12\,\1740 lpo_13\NN\1740 generation_14\NN\7942152 ,_15\,\1740 histamine_16\NN\14739004 release_17\NN\3748886 and_18\CC\1740 microvascular_19\JJ\1740 permeability_20\NN\4940146 that_21\WDT\1740 could_22\MD\1740 be_23\VB\836236 ameliorated_24\VBN\126264 by_25\IN\1740 <e1>verapamil</e1>_26\NNS\2938514 in_27\IN\13603305 rats_28\NNS\2329401 ._29\.\1740
D014700_D014456 NONE protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>verapamil</e1>_3\NN\2938514 on_4\IN\1740 gastric_5\JJ\1740 hemorrhagic_6\JJ\1740 <e2>ulcers</e2>_7\NNS\14211294 in_8\IN\13603305 severe_9\JJ\1740 atherosclerotic_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
D014700_D014456 NONE additionally_0\RB\1740 ,_1\,\1740 the_2\DT\1740 protective_3\JJ\1740 effect_4\NN\34213 of_5\IN\1740 <e1>verapamil</e1>_6\NN\2938514 on_7\IN\1740 this_8\DT\1740 <e2>ulcer</e2>_9\NN\14211294 model_10\NN\5888929 was_11\VBD\836236 evaluated_12\VBN\670261 ._13\.\1740
D014700_D014456 NONE this_0\DT\1740 hemorrhagic_1\JJ\1740 <e2>ulcer</e2>_2\NN\14211294 and_3\CC\1740 various_4\JJ\1740 ulcerogenic_5\JJ\1740 parameters_6\NNS\5858936 were_7\VBD\836236 dose-dependently_8\RB\1740 ameliorated_9\VBN\126264 by_10\IN\1740 daily_11\RB\1740 intragastric_12\JJ\1740 <e1>verapamil</e1>_13\RB\1740 ._14\.\1740
D014700_D014456 NONE atherosclerosis_0\NN\14108324 could_1\MD\1740 produce_2\VB\1617192 gastric_3\JJ\1740 hemorrhagic_4\JJ\1740 <e2>ulcer</e2>_5\NN\14211294 via_6\IN\1740 aggravation_7\NN\7518261 of_8\IN\1740 gastric_9\JJ\1740 acid_10\NN\14818238 back-diffusion_11\NN\1740 ,_12\,\1740 lpo_13\NN\1740 generation_14\NN\7942152 ,_15\,\1740 histamine_16\NN\14739004 release_17\NN\3748886 and_18\CC\1740 microvascular_19\JJ\1740 permeability_20\NN\4940146 that_21\WDT\1740 could_22\MD\1740 be_23\VB\836236 ameliorated_24\VBN\126264 by_25\IN\1740 <e1>verapamil</e1>_26\NNS\2938514 in_27\IN\13603305 rats_28\NNS\2329401 ._29\.\1740
D014700_D050197 NONE protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>verapamil</e1>_3\NN\2938514 on_4\IN\1740 gastric_5\JJ\1740 hemorrhagic_6\JJ\1740 ulcers_7\NNS\14211294 in_8\IN\13603305 severe_9\JJ\1740 <e2>atherosclerotic</e2>_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
D014700_D050197 NONE <e2>atherosclerosis</e2>_0\NN\14108324 could_1\MD\1740 produce_2\VB\1617192 gastric_3\JJ\1740 hemorrhagic_4\JJ\1740 ulcer_5\NN\14211294 via_6\IN\1740 aggravation_7\NN\7518261 of_8\IN\1740 gastric_9\JJ\1740 acid_10\NN\14818238 back-diffusion_11\NN\1740 ,_12\,\1740 lpo_13\NN\1740 generation_14\NN\7942152 ,_15\,\1740 histamine_16\NN\14739004 release_17\NN\3748886 and_18\CC\1740 microvascular_19\JJ\1740 permeability_20\NN\4940146 that_21\WDT\1740 could_22\MD\1740 be_23\VB\836236 ameliorated_24\VBN\126264 by_25\IN\1740 <e1>verapamil</e1>_26\NNS\2938514 in_27\IN\13603305 rats_28\NNS\2329401 ._29\.\1740
D006632_D006471 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 is_5\VBZ\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 gastric_11\JJ\1740 acid_12\NN\14818238 back-diffusion_13\NN\1740 ,_14\,\1740 mast_15\NN\4267577 cell_16\NN\3080309 <e1>histamine</e1>_17\NN\14739004 release_18\NN\3748886 ,_19\,\1740 lipid_20\NN\14944888 peroxide_21\NN\14780040 (_22\-LRB-\1740 lpo_23\NN\1740 )_24\-RRB-\1740 generation_25\NN\7942152 and_26\CC\1740 mucosal_27\JJ\1740 microvascular_28\JJ\1740 permeability_29\NN\4940146 in_30\IN\13603305 modulating_31\VBG\1724459 <e2>gastric_32\JJ\1740 hemorrhage</e2>_33\NN\14285662 and_34\CC\1740 ulcer_35\NN\14211294 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 atherosclerosis_39\NN\14108324 induced_40\VBN\1627355 by_41\IN\1740 coadministration_42\NN\1740 of_43\IN\1740 vitamin_44\NN\7570720 d2_45\NN\1740 and_46\CC\1740 cholesterol_47\NN\15058310 ._48\.\1740
D006632_D006471 NONE moreover_0\RB\1740 ,_1\,\1740 a_2\DT\13649268 positive_3\JJ\1740 correlation_4\NN\13841213 of_5\IN\1740 <e1>histamine</e1>_6\NN\14739004 to_7\TO\1740 <e2>gastric_8\JJ\1740 hemorrhage</e2>_9\NN\14285662 and_10\CC\1740 to_11\TO\1740 ulcer_12\NN\14211294 was_13\VBD\836236 found_14\VBN\2426171 in_15\IN\13603305 those_16\DT\1740 atherosclerotic_17\JJ\1740 rats_18\NNS\2329401 ._19\.\1740
D006632_D006471 NONE atherosclerosis_0\NN\14108324 could_1\MD\1740 produce_2\VB\1617192 <e2>gastric_3\JJ\1740 hemorrhagic</e2>_4\JJ\1740 ulcer_5\NN\14211294 via_6\IN\1740 aggravation_7\NN\7518261 of_8\IN\1740 gastric_9\JJ\1740 acid_10\NN\14818238 back-diffusion_11\NN\1740 ,_12\,\1740 lpo_13\NN\1740 generation_14\NN\7942152 ,_15\,\1740 <e1>histamine</e1>_16\NN\14739004 release_17\NN\3748886 and_18\CC\1740 microvascular_19\JJ\1740 permeability_20\NN\4940146 that_21\WDT\1740 could_22\MD\1740 be_23\VB\836236 ameliorated_24\VBN\126264 by_25\IN\1740 verapamil_26\NNS\2938514 in_27\IN\13603305 rats_28\NNS\2329401 ._29\.\1740
D006632_D014456 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 is_5\VBZ\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 gastric_11\JJ\1740 acid_12\NN\14818238 back-diffusion_13\NN\1740 ,_14\,\1740 mast_15\NN\4267577 cell_16\NN\3080309 <e1>histamine</e1>_17\NN\14739004 release_18\NN\3748886 ,_19\,\1740 lipid_20\NN\14944888 peroxide_21\NN\14780040 (_22\-LRB-\1740 lpo_23\NN\1740 )_24\-RRB-\1740 generation_25\NN\7942152 and_26\CC\1740 mucosal_27\JJ\1740 microvascular_28\JJ\1740 permeability_29\NN\4940146 in_30\IN\13603305 modulating_31\VBG\1724459 gastric_32\JJ\1740 hemorrhage_33\NN\14285662 and_34\CC\1740 <e2>ulcer</e2>_35\NN\14211294 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 atherosclerosis_39\NN\14108324 induced_40\VBN\1627355 by_41\IN\1740 coadministration_42\NN\1740 of_43\IN\1740 vitamin_44\NN\7570720 d2_45\NN\1740 and_46\CC\1740 cholesterol_47\NN\15058310 ._48\.\1740
D006632_D014456 NONE gastric_0\JJ\1740 acid_1\NN\14818238 back-diffusion_2\NN\1740 ,_3\,\1740 mucosal_4\JJ\1740 lpo_5\NN\1740 generation_6\NN\7942152 ,_7\,\1740 <e1>histamine</e1>_8\NN\14739004 concentration_9\NN\4916342 ,_10\,\1740 microvascular_11\JJ\1740 permeability_12\NN\4940146 ,_13\,\1740 luminal_14\JJ\1740 hemoglobin_15\NN\14888884 content_16\NN\7951464 and_17\CC\1740 <e2>ulcer</e2>_18\NN\14211294 areas_19\NNS\8630985 were_20\VBD\836236 determined_21\VBN\1645601 ._22\.\1740
D006632_D014456 NONE severe_0\JJ\1740 gastric_1\NN\1740 <e2>ulcers</e2>_2\NNS\14211294 accompanied_3\VBN\1835496 with_4\IN\1740 increased_5\VBN\169651 ulcerogenic_6\JJ\1740 factors_7\NNS\7326557 ,_8\,\1740 including_9\VBG\690614 gastric_10\JJ\1740 acid_11\NN\14818238 back-diffusion_12\NN\1740 ,_13\,\1740 <e1>histamine</e1>_14\NN\14739004 release_15\NN\3748886 ,_16\,\1740 lpo_17\NN\1740 generation_18\NN\7942152 and_19\CC\1740 luminal_20\JJ\1740 hemoglobin_21\NN\14888884 content_22\NN\7951464 were_23\VBD\836236 also_24\RB\1740 observed_25\VBN\2163746 in_26\IN\13603305 these_27\DT\1740 rats_28\NNS\2329401 ._29\.\1740
D006632_D014456 NONE moreover_0\RB\1740 ,_1\,\1740 a_2\DT\13649268 positive_3\JJ\1740 correlation_4\NN\13841213 of_5\IN\1740 <e1>histamine</e1>_6\NN\14739004 to_7\TO\1740 gastric_8\JJ\1740 hemorrhage_9\NN\14285662 and_10\CC\1740 to_11\TO\1740 <e2>ulcer</e2>_12\NN\14211294 was_13\VBD\836236 found_14\VBN\2426171 in_15\IN\13603305 those_16\DT\1740 atherosclerotic_17\JJ\1740 rats_18\NNS\2329401 ._19\.\1740
D006632_D014456 NONE atherosclerosis_0\NN\14108324 could_1\MD\1740 produce_2\VB\1617192 gastric_3\JJ\1740 hemorrhagic_4\JJ\1740 <e2>ulcer</e2>_5\NN\14211294 via_6\IN\1740 aggravation_7\NN\7518261 of_8\IN\1740 gastric_9\JJ\1740 acid_10\NN\14818238 back-diffusion_11\NN\1740 ,_12\,\1740 lpo_13\NN\1740 generation_14\NN\7942152 ,_15\,\1740 <e1>histamine</e1>_16\NN\14739004 release_17\NN\3748886 and_18\CC\1740 microvascular_19\JJ\1740 permeability_20\NN\4940146 that_21\WDT\1740 could_22\MD\1740 be_23\VB\836236 ameliorated_24\VBN\126264 by_25\IN\1740 verapamil_26\NNS\2938514 in_27\IN\13603305 rats_28\NNS\2329401 ._29\.\1740
D006632_D050197 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 is_5\VBZ\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 gastric_11\JJ\1740 acid_12\NN\14818238 back-diffusion_13\NN\1740 ,_14\,\1740 mast_15\NN\4267577 cell_16\NN\3080309 <e1>histamine</e1>_17\NN\14739004 release_18\NN\3748886 ,_19\,\1740 lipid_20\NN\14944888 peroxide_21\NN\14780040 (_22\-LRB-\1740 lpo_23\NN\1740 )_24\-RRB-\1740 generation_25\NN\7942152 and_26\CC\1740 mucosal_27\JJ\1740 microvascular_28\JJ\1740 permeability_29\NN\4940146 in_30\IN\13603305 modulating_31\VBG\1724459 gastric_32\JJ\1740 hemorrhage_33\NN\14285662 and_34\CC\1740 ulcer_35\NN\14211294 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 <e2>atherosclerosis</e2>_39\NN\14108324 induced_40\VBN\1627355 by_41\IN\1740 coadministration_42\NN\1740 of_43\IN\1740 vitamin_44\NN\7570720 d2_45\NN\1740 and_46\CC\1740 cholesterol_47\NN\15058310 ._48\.\1740
D006632_D050197 NONE moreover_0\RB\1740 ,_1\,\1740 a_2\DT\13649268 positive_3\JJ\1740 correlation_4\NN\13841213 of_5\IN\1740 <e1>histamine</e1>_6\NN\14739004 to_7\TO\1740 gastric_8\JJ\1740 hemorrhage_9\NN\14285662 and_10\CC\1740 to_11\TO\1740 ulcer_12\NN\14211294 was_13\VBD\836236 found_14\VBN\2426171 in_15\IN\13603305 those_16\DT\1740 <e2>atherosclerotic</e2>_17\JJ\1740 rats_18\NNS\2329401 ._19\.\1740
D006632_D050197 NONE <e2>atherosclerosis</e2>_0\NN\14108324 could_1\MD\1740 produce_2\VB\1617192 gastric_3\JJ\1740 hemorrhagic_4\JJ\1740 ulcer_5\NN\14211294 via_6\IN\1740 aggravation_7\NN\7518261 of_8\IN\1740 gastric_9\JJ\1740 acid_10\NN\14818238 back-diffusion_11\NN\1740 ,_12\,\1740 lpo_13\NN\1740 generation_14\NN\7942152 ,_15\,\1740 <e1>histamine</e1>_16\NN\14739004 release_17\NN\3748886 and_18\CC\1740 microvascular_19\JJ\1740 permeability_20\NN\4940146 that_21\WDT\1740 could_22\MD\1740 be_23\VB\836236 ameliorated_24\VBN\126264 by_25\IN\1740 verapamil_26\NNS\2938514 in_27\IN\13603305 rats_28\NNS\2329401 ._29\.\1740
D004872_D006471 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 is_5\VBZ\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 gastric_11\JJ\1740 acid_12\NN\14818238 back-diffusion_13\NN\1740 ,_14\,\1740 mast_15\NN\4267577 cell_16\NN\3080309 histamine_17\NN\14739004 release_18\NN\3748886 ,_19\,\1740 lipid_20\NN\14944888 peroxide_21\NN\14780040 (_22\-LRB-\1740 lpo_23\NN\1740 )_24\-RRB-\1740 generation_25\NN\7942152 and_26\CC\1740 mucosal_27\JJ\1740 microvascular_28\JJ\1740 permeability_29\NN\4940146 in_30\IN\13603305 modulating_31\VBG\1724459 <e2>gastric_32\JJ\1740 hemorrhage</e2>_33\NN\14285662 and_34\CC\1740 ulcer_35\NN\14211294 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 atherosclerosis_39\NN\14108324 induced_40\VBN\1627355 by_41\IN\1740 coadministration_42\NN\1740 of_43\IN\1740 <e1>vitamin_44\NN\7570720 d2</e1>_45\NN\1740 and_46\CC\1740 cholesterol_47\NN\15058310 ._48\.\1740
D004872_D014456 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 is_5\VBZ\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 gastric_11\JJ\1740 acid_12\NN\14818238 back-diffusion_13\NN\1740 ,_14\,\1740 mast_15\NN\4267577 cell_16\NN\3080309 histamine_17\NN\14739004 release_18\NN\3748886 ,_19\,\1740 lipid_20\NN\14944888 peroxide_21\NN\14780040 (_22\-LRB-\1740 lpo_23\NN\1740 )_24\-RRB-\1740 generation_25\NN\7942152 and_26\CC\1740 mucosal_27\JJ\1740 microvascular_28\JJ\1740 permeability_29\NN\4940146 in_30\IN\13603305 modulating_31\VBG\1724459 gastric_32\JJ\1740 hemorrhage_33\NN\14285662 and_34\CC\1740 <e2>ulcer</e2>_35\NN\14211294 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 atherosclerosis_39\NN\14108324 induced_40\VBN\1627355 by_41\IN\1740 coadministration_42\NN\1740 of_43\IN\1740 <e1>vitamin_44\NN\7570720 d2</e1>_45\NN\1740 and_46\CC\1740 cholesterol_47\NN\15058310 ._48\.\1740
D004872_D050197 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 is_5\VBZ\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 gastric_11\JJ\1740 acid_12\NN\14818238 back-diffusion_13\NN\1740 ,_14\,\1740 mast_15\NN\4267577 cell_16\NN\3080309 histamine_17\NN\14739004 release_18\NN\3748886 ,_19\,\1740 lipid_20\NN\14944888 peroxide_21\NN\14780040 (_22\-LRB-\1740 lpo_23\NN\1740 )_24\-RRB-\1740 generation_25\NN\7942152 and_26\CC\1740 mucosal_27\JJ\1740 microvascular_28\JJ\1740 permeability_29\NN\4940146 in_30\IN\13603305 modulating_31\VBG\1724459 gastric_32\JJ\1740 hemorrhage_33\NN\14285662 and_34\CC\1740 ulcer_35\NN\14211294 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 <e2>atherosclerosis</e2>_39\NN\14108324 induced_40\VBN\1627355 by_41\IN\1740 coadministration_42\NN\1740 of_43\IN\1740 <e1>vitamin_44\NN\7570720 d2</e1>_45\NN\1740 and_46\CC\1740 cholesterol_47\NN\15058310 ._48\.\1740
D004872_D050197 CID male_0\NNP\15388 wistar_1\NNP\1740 rats_2\NNS\2329401 were_3\VBD\836236 challenged_4\VBN\869596 intragastrically_5\RB\1740 once_6\RB\1740 daily_7\RB\1740 for_8\IN\1740 9_9\CD\13741022 days_10\NNS\15140892 with_11\IN\1740 1.0_12\CD\1740 ml/kg_13\NN\1740 of_14\IN\1740 corn_15\NN\12141495 oil_16\NN\14938907 containing_17\VBG\2632940 <e1>vitamin_18\NN\7570720 d2</e1>_19\NN\1740 and_20\CC\1740 cholesterol_21\NN\15058310 to_22\TO\1740 induce_23\VB\1627355 <e2>atherosclerosis</e2>_24\NN\14108324 ._25\.\1740
D002784_D006471 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 is_5\VBZ\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 gastric_11\JJ\1740 acid_12\NN\14818238 back-diffusion_13\NN\1740 ,_14\,\1740 mast_15\NN\4267577 cell_16\NN\3080309 histamine_17\NN\14739004 release_18\NN\3748886 ,_19\,\1740 lipid_20\NN\14944888 peroxide_21\NN\14780040 (_22\-LRB-\1740 lpo_23\NN\1740 )_24\-RRB-\1740 generation_25\NN\7942152 and_26\CC\1740 mucosal_27\JJ\1740 microvascular_28\JJ\1740 permeability_29\NN\4940146 in_30\IN\13603305 modulating_31\VBG\1724459 <e2>gastric_32\JJ\1740 hemorrhage</e2>_33\NN\14285662 and_34\CC\1740 ulcer_35\NN\14211294 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 atherosclerosis_39\NN\14108324 induced_40\VBN\1627355 by_41\IN\1740 coadministration_42\NN\1740 of_43\IN\1740 vitamin_44\NN\7570720 d2_45\NN\1740 and_46\CC\1740 <e1>cholesterol</e1>_47\NN\15058310 ._48\.\1740
D002784_D014456 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 is_5\VBZ\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 gastric_11\JJ\1740 acid_12\NN\14818238 back-diffusion_13\NN\1740 ,_14\,\1740 mast_15\NN\4267577 cell_16\NN\3080309 histamine_17\NN\14739004 release_18\NN\3748886 ,_19\,\1740 lipid_20\NN\14944888 peroxide_21\NN\14780040 (_22\-LRB-\1740 lpo_23\NN\1740 )_24\-RRB-\1740 generation_25\NN\7942152 and_26\CC\1740 mucosal_27\JJ\1740 microvascular_28\JJ\1740 permeability_29\NN\4940146 in_30\IN\13603305 modulating_31\VBG\1724459 gastric_32\JJ\1740 hemorrhage_33\NN\14285662 and_34\CC\1740 <e2>ulcer</e2>_35\NN\14211294 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 atherosclerosis_39\NN\14108324 induced_40\VBN\1627355 by_41\IN\1740 coadministration_42\NN\1740 of_43\IN\1740 vitamin_44\NN\7570720 d2_45\NN\1740 and_46\CC\1740 <e1>cholesterol</e1>_47\NN\15058310 ._48\.\1740
D002784_D050197 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 is_5\VBZ\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 gastric_11\JJ\1740 acid_12\NN\14818238 back-diffusion_13\NN\1740 ,_14\,\1740 mast_15\NN\4267577 cell_16\NN\3080309 histamine_17\NN\14739004 release_18\NN\3748886 ,_19\,\1740 lipid_20\NN\14944888 peroxide_21\NN\14780040 (_22\-LRB-\1740 lpo_23\NN\1740 )_24\-RRB-\1740 generation_25\NN\7942152 and_26\CC\1740 mucosal_27\JJ\1740 microvascular_28\JJ\1740 permeability_29\NN\4940146 in_30\IN\13603305 modulating_31\VBG\1724459 gastric_32\JJ\1740 hemorrhage_33\NN\14285662 and_34\CC\1740 ulcer_35\NN\14211294 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 <e2>atherosclerosis</e2>_39\NN\14108324 induced_40\VBN\1627355 by_41\IN\1740 coadministration_42\NN\1740 of_43\IN\1740 vitamin_44\NN\7570720 d2_45\NN\1740 and_46\CC\1740 <e1>cholesterol</e1>_47\NN\15058310 ._48\.\1740
D002784_D050197 CID male_0\NNP\15388 wistar_1\NNP\1740 rats_2\NNS\2329401 were_3\VBD\836236 challenged_4\VBN\869596 intragastrically_5\RB\1740 once_6\RB\1740 daily_7\RB\1740 for_8\IN\1740 9_9\CD\13741022 days_10\NNS\15140892 with_11\IN\1740 1.0_12\CD\1740 ml/kg_13\NN\1740 of_14\IN\1740 corn_15\NN\12141495 oil_16\NN\14938907 containing_17\VBG\2632940 vitamin_18\NN\7570720 d2_19\NN\1740 and_20\CC\1740 <e1>cholesterol</e1>_21\NN\15058310 to_22\TO\1740 induce_23\VB\1627355 <e2>atherosclerosis</e2>_24\NN\14108324 ._25\.\1740
D002784_D050197 CID elevated_0\JJ\1740 <e2>atherosclerotic</e2>_1\JJ\1740 parameters_2\NNS\5858936 ,_3\,\1740 such_4\JJ\1740 as_5\IN\14622893 serum_6\NN\5397468 calcium_7\NN\14625458 ,_8\,\1740 total_9\JJ\1740 <e1>cholesterol</e1>_10\NN\15058310 and_11\CC\1740 low-density_12\JJ\1740 lipoprotein_13\NN\14731135 concentration_14\NN\4916342 were_15\VBD\836236 obtained_16\VBN\2210855 in_17\IN\13603305 atherosclerotic_18\JJ\1740 rats_19\NNS\2329401 ._20\.\1740
D002784_D050197 CID elevated_0\JJ\1740 atherosclerotic_1\JJ\1740 parameters_2\NNS\5858936 ,_3\,\1740 such_4\JJ\1740 as_5\IN\14622893 serum_6\NN\5397468 calcium_7\NN\14625458 ,_8\,\1740 total_9\JJ\1740 <e1>cholesterol</e1>_10\NN\15058310 and_11\CC\1740 low-density_12\JJ\1740 lipoprotein_13\NN\14731135 concentration_14\NN\4916342 were_15\VBD\836236 obtained_16\VBN\2210855 in_17\IN\13603305 <e2>atherosclerotic</e2>_18\JJ\1740 rats_19\NNS\2329401 ._20\.\1740
D010634_D014456 NONE gastric_0\JJ\1740 acid_1\NN\14818238 back-diffusion_2\NN\1740 ,_3\,\1740 mucosal_4\JJ\1740 lpo_5\NN\1740 generation_6\NN\7942152 ,_7\,\1740 histamine_8\NN\14739004 concentration_9\NN\4916342 ,_10\,\1740 microvascular_11\JJ\1740 permeability_12\NN\4940146 ,_13\,\1740 <e1>luminal</e1>_14\JJ\1740 hemoglobin_15\NN\14888884 content_16\NN\7951464 and_17\CC\1740 <e2>ulcer</e2>_18\NN\14211294 areas_19\NNS\8630985 were_20\VBD\836236 determined_21\VBN\1645601 ._22\.\1740
D010634_D014456 NONE severe_0\JJ\1740 gastric_1\NN\1740 <e2>ulcers</e2>_2\NNS\14211294 accompanied_3\VBN\1835496 with_4\IN\1740 increased_5\VBN\169651 ulcerogenic_6\JJ\1740 factors_7\NNS\7326557 ,_8\,\1740 including_9\VBG\690614 gastric_10\JJ\1740 acid_11\NN\14818238 back-diffusion_12\NN\1740 ,_13\,\1740 histamine_14\NN\14739004 release_15\NN\3748886 ,_16\,\1740 lpo_17\NN\1740 generation_18\NN\7942152 and_19\CC\1740 <e1>luminal</e1>_20\JJ\1740 hemoglobin_21\NN\14888884 content_22\NN\7951464 were_23\VBD\836236 also_24\RB\1740 observed_25\VBN\2163746 in_26\IN\13603305 these_27\DT\1740 rats_28\NNS\2329401 ._29\.\1740
D002118_D050197 NONE elevated_0\JJ\1740 <e2>atherosclerotic</e2>_1\JJ\1740 parameters_2\NNS\5858936 ,_3\,\1740 such_4\JJ\1740 as_5\IN\14622893 serum_6\NN\5397468 <e1>calcium</e1>_7\NN\14625458 ,_8\,\1740 total_9\JJ\1740 cholesterol_10\NN\15058310 and_11\CC\1740 low-density_12\JJ\1740 lipoprotein_13\NN\14731135 concentration_14\NN\4916342 were_15\VBD\836236 obtained_16\VBN\2210855 in_17\IN\13603305 atherosclerotic_18\JJ\1740 rats_19\NNS\2329401 ._20\.\1740
D002118_D050197 NONE elevated_0\JJ\1740 atherosclerotic_1\JJ\1740 parameters_2\NNS\5858936 ,_3\,\1740 such_4\JJ\1740 as_5\IN\14622893 serum_6\NN\5397468 <e1>calcium</e1>_7\NN\14625458 ,_8\,\1740 total_9\JJ\1740 cholesterol_10\NN\15058310 and_11\CC\1740 low-density_12\JJ\1740 lipoprotein_13\NN\14731135 concentration_14\NN\4916342 were_15\VBD\836236 obtained_16\VBN\2210855 in_17\IN\13603305 <e2>atherosclerotic</e2>_18\JJ\1740 rats_19\NNS\2329401 ._20\.\1740
6286738
D002762_D064420 NONE <e1>vitamin_0\NN\7570720 d3</e1>_1\NN\1740 <e2>toxicity</e2>_2\NN\13576101 in_3\IN\13603305 dairy_4\NN\3322099 cows_5\NNS\2402010 ._6\.\1740
D002762_D064420 NONE signs_0\NNS\6643763 of_1\IN\1740 <e1>vitamin_2\NN\7570720 d3</e1>_3\NN\1740 <e2>toxicity</e2>_4\NN\13576101 were_5\VBD\836236 not_6\RB\1740 observed_7\VBN\2163746 in_8\IN\13603305 nonlactating_9\VBG\1740 nonpregnant_10\JJ\1740 cows_11\NNS\2402010 ;_12\:\1740 however_13\RB\1740 ,_14\,\1740 pregnant_15\JJ\1740 cows_16\NNS\2402010 commonly_17\RB\1740 developed_18\VBD\1753788 severe_19\JJ\1740 signs_20\NNS\6643763 of_21\IN\1740 vitamin_22\NN\7570720 d3_23\NN\1740 toxicity_24\NN\13576101 and_25\CC\1740 10_26\CD\13745420 of_27\IN\1740 17_28\CD\13745420 cows_29\NNS\2402010 died_30\VBD\146138 ._31\.\1740
D002762_D064420 NONE signs_0\NNS\6643763 of_1\IN\1740 <e1>vitamin_2\NN\7570720 d3</e1>_3\NN\1740 toxicity_4\NN\13576101 were_5\VBD\836236 not_6\RB\1740 observed_7\VBN\2163746 in_8\IN\13603305 nonlactating_9\VBG\1740 nonpregnant_10\JJ\1740 cows_11\NNS\2402010 ;_12\:\1740 however_13\RB\1740 ,_14\,\1740 pregnant_15\JJ\1740 cows_16\NNS\2402010 commonly_17\RB\1740 developed_18\VBD\1753788 severe_19\JJ\1740 signs_20\NNS\6643763 of_21\IN\1740 vitamin_22\NN\7570720 d3_23\NN\1740 <e2>toxicity</e2>_24\NN\13576101 and_25\CC\1740 10_26\CD\13745420 of_27\IN\1740 17_28\CD\13745420 cows_29\NNS\2402010 died_30\VBD\146138 ._31\.\1740
D002762_D064420 NONE signs_0\NNS\6643763 of_1\IN\1740 vitamin_2\NN\7570720 d3_3\NN\1740 <e2>toxicity</e2>_4\NN\13576101 were_5\VBD\836236 not_6\RB\1740 observed_7\VBN\2163746 in_8\IN\13603305 nonlactating_9\VBG\1740 nonpregnant_10\JJ\1740 cows_11\NNS\2402010 ;_12\:\1740 however_13\RB\1740 ,_14\,\1740 pregnant_15\JJ\1740 cows_16\NNS\2402010 commonly_17\RB\1740 developed_18\VBD\1753788 severe_19\JJ\1740 signs_20\NNS\6643763 of_21\IN\1740 <e1>vitamin_22\NN\7570720 d3</e1>_23\NN\1740 toxicity_24\NN\13576101 and_25\CC\1740 10_26\CD\13745420 of_27\IN\1740 17_28\CD\13745420 cows_29\NNS\2402010 died_30\VBD\146138 ._31\.\1740
D002762_D064420 NONE signs_0\NNS\6643763 of_1\IN\1740 vitamin_2\NN\7570720 d3_3\NN\1740 toxicity_4\NN\13576101 were_5\VBD\836236 not_6\RB\1740 observed_7\VBN\2163746 in_8\IN\13603305 nonlactating_9\VBG\1740 nonpregnant_10\JJ\1740 cows_11\NNS\2402010 ;_12\:\1740 however_13\RB\1740 ,_14\,\1740 pregnant_15\JJ\1740 cows_16\NNS\2402010 commonly_17\RB\1740 developed_18\VBD\1753788 severe_19\JJ\1740 signs_20\NNS\6643763 of_21\IN\1740 <e1>vitamin_22\NN\7570720 d3</e1>_23\NN\1740 <e2>toxicity</e2>_24\NN\13576101 and_25\CC\1740 10_26\CD\13745420 of_27\IN\1740 17_28\CD\13745420 cows_29\NNS\2402010 died_30\VBD\146138 ._31\.\1740
D002762_D064420 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 of_5\IN\1740 <e1>vitamin_6\NN\7570720 d3</e1>_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 vitamin_21\NN\7570720 d3_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 milk_25\NN\7881800 fever_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 milk_31\NN\7881800 fever_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 vitamin_37\NN\7570720 d3_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 milk_46\NN\7881800 fever_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
D002762_D064420 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 of_5\IN\1740 vitamin_6\NN\7570720 d3_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 <e1>vitamin_21\NN\7570720 d3</e1>_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 milk_25\NN\7881800 fever_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 milk_31\NN\7881800 fever_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 vitamin_37\NN\7570720 d3_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 milk_46\NN\7881800 fever_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
D002762_D064420 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 of_5\IN\1740 vitamin_6\NN\7570720 d3_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 vitamin_21\NN\7570720 d3_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 milk_25\NN\7881800 fever_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 milk_31\NN\7881800 fever_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 <e1>vitamin_37\NN\7570720 d3</e1>_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 milk_46\NN\7881800 fever_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
D002762_D006934 CID large_0\JJ\1740 parenteral_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 <e1>vitamin_4\NN\7570720 d3</e1>_5\NN\1740 (_6\-LRB-\1740 15_7\CD\13745420 to_8\TO\1740 17.5_9\CD\1740 x_10\NN\13745420 10(6_11\NN\1740 )_12\-RRB-\1740 iu_13\NN\1740 vitamin_14\NN\7570720 d3_15\NN\1740 )_16\-RRB-\1740 were_17\VBD\836236 associated_18\VBN\628491 with_19\IN\1740 prolonged_20\JJ\1740 <e2>hypercalcemia</e2>_21\NN\14299637 ,_22\,\1740 hyperphosphatemia_23\NN\1740 ,_24\,\1740 and_25\CC\1740 large_26\JJ\1740 increases_27\NNS\13576355 of_28\IN\1740 vitamin_29\NN\7570720 d3_30\NN\1740 and_31\CC\1740 its_32\PRP$\6125041 metabolites_33\NNS\20090 in_34\IN\13603305 the_35\DT\1740 blood_36\NN\5397468 plasma_37\NN\5398023 of_38\IN\1740 nonlactating_39\VBG\1740 nonpregnant_40\JJ\1740 and_41\CC\1740 pregnant_42\JJ\1740 jersey_43\NNP\8887013 cows_44\VBZ\1779644 ._45\.\1740
D002762_D006934 CID large_0\JJ\1740 parenteral_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 vitamin_4\NN\7570720 d3_5\NN\1740 (_6\-LRB-\1740 15_7\CD\13745420 to_8\TO\1740 17.5_9\CD\1740 x_10\NN\13745420 10(6_11\NN\1740 )_12\-RRB-\1740 iu_13\NN\1740 <e1>vitamin_14\NN\7570720 d3</e1>_15\NN\1740 )_16\-RRB-\1740 were_17\VBD\836236 associated_18\VBN\628491 with_19\IN\1740 prolonged_20\JJ\1740 <e2>hypercalcemia</e2>_21\NN\14299637 ,_22\,\1740 hyperphosphatemia_23\NN\1740 ,_24\,\1740 and_25\CC\1740 large_26\JJ\1740 increases_27\NNS\13576355 of_28\IN\1740 vitamin_29\NN\7570720 d3_30\NN\1740 and_31\CC\1740 its_32\PRP$\6125041 metabolites_33\NNS\20090 in_34\IN\13603305 the_35\DT\1740 blood_36\NN\5397468 plasma_37\NN\5398023 of_38\IN\1740 nonlactating_39\VBG\1740 nonpregnant_40\JJ\1740 and_41\CC\1740 pregnant_42\JJ\1740 jersey_43\NNP\8887013 cows_44\VBZ\1779644 ._45\.\1740
D002762_D006934 CID large_0\JJ\1740 parenteral_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 vitamin_4\NN\7570720 d3_5\NN\1740 (_6\-LRB-\1740 15_7\CD\13745420 to_8\TO\1740 17.5_9\CD\1740 x_10\NN\13745420 10(6_11\NN\1740 )_12\-RRB-\1740 iu_13\NN\1740 vitamin_14\NN\7570720 d3_15\NN\1740 )_16\-RRB-\1740 were_17\VBD\836236 associated_18\VBN\628491 with_19\IN\1740 prolonged_20\JJ\1740 <e2>hypercalcemia</e2>_21\NN\14299637 ,_22\,\1740 hyperphosphatemia_23\NN\1740 ,_24\,\1740 and_25\CC\1740 large_26\JJ\1740 increases_27\NNS\13576355 of_28\IN\1740 <e1>vitamin_29\NN\7570720 d3</e1>_30\NN\1740 and_31\CC\1740 its_32\PRP$\6125041 metabolites_33\NNS\20090 in_34\IN\13603305 the_35\DT\1740 blood_36\NN\5397468 plasma_37\NN\5398023 of_38\IN\1740 nonlactating_39\VBG\1740 nonpregnant_40\JJ\1740 and_41\CC\1740 pregnant_42\JJ\1740 jersey_43\NNP\8887013 cows_44\VBZ\1779644 ._45\.\1740
D002762_D054559 CID large_0\JJ\1740 parenteral_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 <e1>vitamin_4\NN\7570720 d3</e1>_5\NN\1740 (_6\-LRB-\1740 15_7\CD\13745420 to_8\TO\1740 17.5_9\CD\1740 x_10\NN\13745420 10(6_11\NN\1740 )_12\-RRB-\1740 iu_13\NN\1740 vitamin_14\NN\7570720 d3_15\NN\1740 )_16\-RRB-\1740 were_17\VBD\836236 associated_18\VBN\628491 with_19\IN\1740 prolonged_20\JJ\1740 hypercalcemia_21\NN\14299637 ,_22\,\1740 <e2>hyperphosphatemia</e2>_23\NN\1740 ,_24\,\1740 and_25\CC\1740 large_26\JJ\1740 increases_27\NNS\13576355 of_28\IN\1740 vitamin_29\NN\7570720 d3_30\NN\1740 and_31\CC\1740 its_32\PRP$\6125041 metabolites_33\NNS\20090 in_34\IN\13603305 the_35\DT\1740 blood_36\NN\5397468 plasma_37\NN\5398023 of_38\IN\1740 nonlactating_39\VBG\1740 nonpregnant_40\JJ\1740 and_41\CC\1740 pregnant_42\JJ\1740 jersey_43\NNP\8887013 cows_44\VBZ\1779644 ._45\.\1740
D002762_D054559 CID large_0\JJ\1740 parenteral_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 vitamin_4\NN\7570720 d3_5\NN\1740 (_6\-LRB-\1740 15_7\CD\13745420 to_8\TO\1740 17.5_9\CD\1740 x_10\NN\13745420 10(6_11\NN\1740 )_12\-RRB-\1740 iu_13\NN\1740 <e1>vitamin_14\NN\7570720 d3</e1>_15\NN\1740 )_16\-RRB-\1740 were_17\VBD\836236 associated_18\VBN\628491 with_19\IN\1740 prolonged_20\JJ\1740 hypercalcemia_21\NN\14299637 ,_22\,\1740 <e2>hyperphosphatemia</e2>_23\NN\1740 ,_24\,\1740 and_25\CC\1740 large_26\JJ\1740 increases_27\NNS\13576355 of_28\IN\1740 vitamin_29\NN\7570720 d3_30\NN\1740 and_31\CC\1740 its_32\PRP$\6125041 metabolites_33\NNS\20090 in_34\IN\13603305 the_35\DT\1740 blood_36\NN\5397468 plasma_37\NN\5398023 of_38\IN\1740 nonlactating_39\VBG\1740 nonpregnant_40\JJ\1740 and_41\CC\1740 pregnant_42\JJ\1740 jersey_43\NNP\8887013 cows_44\VBZ\1779644 ._45\.\1740
D002762_D054559 CID large_0\JJ\1740 parenteral_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 vitamin_4\NN\7570720 d3_5\NN\1740 (_6\-LRB-\1740 15_7\CD\13745420 to_8\TO\1740 17.5_9\CD\1740 x_10\NN\13745420 10(6_11\NN\1740 )_12\-RRB-\1740 iu_13\NN\1740 vitamin_14\NN\7570720 d3_15\NN\1740 )_16\-RRB-\1740 were_17\VBD\836236 associated_18\VBN\628491 with_19\IN\1740 prolonged_20\JJ\1740 hypercalcemia_21\NN\14299637 ,_22\,\1740 <e2>hyperphosphatemia</e2>_23\NN\1740 ,_24\,\1740 and_25\CC\1740 large_26\JJ\1740 increases_27\NNS\13576355 of_28\IN\1740 <e1>vitamin_29\NN\7570720 d3</e1>_30\NN\1740 and_31\CC\1740 its_32\PRP$\6125041 metabolites_33\NNS\20090 in_34\IN\13603305 the_35\DT\1740 blood_36\NN\5397468 plasma_37\NN\5398023 of_38\IN\1740 nonlactating_39\VBG\1740 nonpregnant_40\JJ\1740 and_41\CC\1740 pregnant_42\JJ\1740 jersey_43\NNP\8887013 cows_44\VBZ\1779644 ._45\.\1740
D002762_D010319 NONE none_0\NN\15228378 of_1\IN\1740 the_2\DT\1740 cows_3\NNS\2402010 treated_4\VBN\2376958 with_5\IN\1740 <e1>vitamin_6\NN\7570720 d3</e1>_7\NN\1740 showed_8\VBD\2137132 signs_9\NNS\6643763 of_10\IN\1740 <e2>milk_11\NN\7881800 fever</e2>_12\NN\14299637 during_13\IN\1740 the_14\DT\1740 peripartal_15\JJ\1740 period_16\NN\13575869 ;_17\:\1740 however_18\RB\1740 ,_19\,\1740 22_20\CD\13745420 %_21\NN\1740 of_22\IN\1740 the_23\DT\1740 control_24\NN\5190804 cows_25\NNS\2402010 developed_26\VBD\1753788 clinical_27\JJ\1740 signs_28\NNS\6643763 of_29\IN\1740 milk_30\NN\7881800 fever_31\NN\14299637 during_32\IN\1740 this_33\DT\1740 period_34\NN\13575869 ._35\.\1740
D002762_D010319 NONE none_0\NN\15228378 of_1\IN\1740 the_2\DT\1740 cows_3\NNS\2402010 treated_4\VBN\2376958 with_5\IN\1740 <e1>vitamin_6\NN\7570720 d3</e1>_7\NN\1740 showed_8\VBD\2137132 signs_9\NNS\6643763 of_10\IN\1740 milk_11\NN\7881800 fever_12\NN\14299637 during_13\IN\1740 the_14\DT\1740 peripartal_15\JJ\1740 period_16\NN\13575869 ;_17\:\1740 however_18\RB\1740 ,_19\,\1740 22_20\CD\13745420 %_21\NN\1740 of_22\IN\1740 the_23\DT\1740 control_24\NN\5190804 cows_25\NNS\2402010 developed_26\VBD\1753788 clinical_27\JJ\1740 signs_28\NNS\6643763 of_29\IN\1740 <e2>milk_30\NN\7881800 fever</e2>_31\NN\14299637 during_32\IN\1740 this_33\DT\1740 period_34\NN\13575869 ._35\.\1740
D002762_D010319 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 toxicity_4\NN\13576101 of_5\IN\1740 <e1>vitamin_6\NN\7570720 d3</e1>_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 vitamin_21\NN\7570720 d3_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 <e2>milk_25\NN\7881800 fever</e2>_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 milk_31\NN\7881800 fever_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 vitamin_37\NN\7570720 d3_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 milk_46\NN\7881800 fever_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
D002762_D010319 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 toxicity_4\NN\13576101 of_5\IN\1740 <e1>vitamin_6\NN\7570720 d3</e1>_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 vitamin_21\NN\7570720 d3_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 milk_25\NN\7881800 fever_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 <e2>milk_31\NN\7881800 fever</e2>_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 vitamin_37\NN\7570720 d3_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 milk_46\NN\7881800 fever_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
D002762_D010319 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 toxicity_4\NN\13576101 of_5\IN\1740 <e1>vitamin_6\NN\7570720 d3</e1>_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 vitamin_21\NN\7570720 d3_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 milk_25\NN\7881800 fever_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 milk_31\NN\7881800 fever_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 vitamin_37\NN\7570720 d3_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 <e2>milk_46\NN\7881800 fever</e2>_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
D002762_D010319 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 toxicity_4\NN\13576101 of_5\IN\1740 vitamin_6\NN\7570720 d3_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 <e1>vitamin_21\NN\7570720 d3</e1>_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 <e2>milk_25\NN\7881800 fever</e2>_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 milk_31\NN\7881800 fever_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 vitamin_37\NN\7570720 d3_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 milk_46\NN\7881800 fever_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
D002762_D010319 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 toxicity_4\NN\13576101 of_5\IN\1740 vitamin_6\NN\7570720 d3_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 <e1>vitamin_21\NN\7570720 d3</e1>_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 milk_25\NN\7881800 fever_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 <e2>milk_31\NN\7881800 fever</e2>_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 vitamin_37\NN\7570720 d3_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 milk_46\NN\7881800 fever_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
D002762_D010319 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 toxicity_4\NN\13576101 of_5\IN\1740 vitamin_6\NN\7570720 d3_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 <e1>vitamin_21\NN\7570720 d3</e1>_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 milk_25\NN\7881800 fever_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 milk_31\NN\7881800 fever_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 vitamin_37\NN\7570720 d3_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 <e2>milk_46\NN\7881800 fever</e2>_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
D002762_D010319 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 toxicity_4\NN\13576101 of_5\IN\1740 vitamin_6\NN\7570720 d3_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 vitamin_21\NN\7570720 d3_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 <e2>milk_25\NN\7881800 fever</e2>_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 milk_31\NN\7881800 fever_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 <e1>vitamin_37\NN\7570720 d3</e1>_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 milk_46\NN\7881800 fever_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
D002762_D010319 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 toxicity_4\NN\13576101 of_5\IN\1740 vitamin_6\NN\7570720 d3_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 vitamin_21\NN\7570720 d3_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 milk_25\NN\7881800 fever_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 <e2>milk_31\NN\7881800 fever</e2>_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 <e1>vitamin_37\NN\7570720 d3</e1>_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 milk_46\NN\7881800 fever_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
D002762_D010319 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 extreme_3\JJ\1740 toxicity_4\NN\13576101 of_5\IN\1740 vitamin_6\NN\7570720 d3_7\NN\1740 in_8\IN\13603305 pregnant_9\JJ\1740 jersey_10\NNP\8887013 cows_11\VBZ\1779644 and_12\CC\1740 the_13\DT\1740 low_14\JJ\1740 margin_15\NN\13903079 of_16\IN\1740 safety_17\NN\13920835 between_18\IN\1740 doses_19\NNS\3740161 of_20\IN\1740 vitamin_21\NN\7570720 d3_22\NN\1740 that_23\WDT\1740 prevent_24\VBP\1740 milk_25\NN\7881800 fever_26\NN\14299637 and_27\CC\1740 doses_28\NNS\3740161 that_29\WDT\1740 induce_30\VBP\1627355 milk_31\NN\7881800 fever_32\NN\14299637 ,_33\,\1740 we_34\PRP\1740 concluded_35\VBD\628491 that_36\IN\1740 <e1>vitamin_37\NN\7570720 d3</e1>_38\NN\1740 can_39\MD\3094503 not_40\RB\1740 be_41\VB\836236 used_42\VBN\1156834 practically_43\RB\1740 to_44\TO\1740 prevent_45\VB\1740 <e2>milk_46\NN\7881800 fever</e2>_47\NN\14299637 when_48\WRB\1740 injected_49\VBN\81072 several_50\JJ\1740 weeks_51\NNS\15113229 prepartum_52\NN\1740 ._53\.\1740
603022
D005702_D062787 NONE <e1>galanthamine_0\NN\1740 hydrobromide</e1>_1\NN\1740 ,_2\,\1740 an_3\DT\6697703 anticholinesterase_4\NN\3740161 drug_5\NN\14778436 capable_6\JJ\1740 of_7\IN\1740 penetrating_8\VBG\2016523 the_9\DT\1740 blood-brain_10\JJ\1740 barrier_11\NN\3839993 ,_12\,\1740 was_13\VBD\836236 used_14\VBN\1156834 in_15\IN\13603305 a_16\DT\13649268 patient_17\NN\9898892 demonstrating_18\VBG\2137132 central_19\JJ\1740 effects_20\NNS\13245626 of_21\IN\1740 scopolamine_22\NN\14712692 (_23\-LRB-\1740 hyoscine_24\NN\14712692 )_25\-RRB-\1740 <e2>overdosage</e2>_26\NN\1740 ._27\.\1740
D012601_D062787 CID galanthamine_0\NN\1740 hydrobromide_1\NN\1740 ,_2\,\1740 an_3\DT\6697703 anticholinesterase_4\NN\3740161 drug_5\NN\14778436 capable_6\JJ\1740 of_7\IN\1740 penetrating_8\VBG\2016523 the_9\DT\1740 blood-brain_10\JJ\1740 barrier_11\NN\3839993 ,_12\,\1740 was_13\VBD\836236 used_14\VBN\1156834 in_15\IN\13603305 a_16\DT\13649268 patient_17\NN\9898892 demonstrating_18\VBG\2137132 central_19\JJ\1740 effects_20\NNS\13245626 of_21\IN\1740 <e1>scopolamine</e1>_22\NN\14712692 (_23\-LRB-\1740 hyoscine_24\NN\14712692 )_25\-RRB-\1740 <e2>overdosage</e2>_26\NN\1740 ._27\.\1740
D012601_D062787 CID galanthamine_0\NN\1740 hydrobromide_1\NN\1740 ,_2\,\1740 an_3\DT\6697703 anticholinesterase_4\NN\3740161 drug_5\NN\14778436 capable_6\JJ\1740 of_7\IN\1740 penetrating_8\VBG\2016523 the_9\DT\1740 blood-brain_10\JJ\1740 barrier_11\NN\3839993 ,_12\,\1740 was_13\VBD\836236 used_14\VBN\1156834 in_15\IN\13603305 a_16\DT\13649268 patient_17\NN\9898892 demonstrating_18\VBG\2137132 central_19\JJ\1740 effects_20\NNS\13245626 of_21\IN\1740 scopolamine_22\NN\14712692 (_23\-LRB-\1740 <e1>hyoscine</e1>_24\NN\14712692 )_25\-RRB-\1740 <e2>overdosage</e2>_26\NN\1740 ._27\.\1740
1601297
D003042_D009202 NONE electrocardiographic_0\JJ\1740 evidence_1\NN\5816287 of_2\IN\1740 <e2>myocardial_3\JJ\1740 injury</e2>_4\NN\14052046 in_5\IN\13603305 psychiatrically_6\RB\1740 hospitalized_7\VBN\2348568 <e1>cocaine</e1>_8\NN\3492717 abusers_9\NNS\9633969 ._10\.\1740
D003042_D009202 NONE eleven_0\CD\13745420 of_1\IN\1740 the_2\DT\1740 <e1>cocaine</e1>_3\NN\3492717 abusers_4\NNS\9633969 and_5\CC\1740 none_6\NN\15228378 of_7\IN\1740 the_8\DT\1740 controls_9\NNS\5190804 had_10\VBD\2108377 ecg_11\NNP\7000195 evidence_12\NN\5816287 of_13\IN\1740 significant_14\JJ\1740 <e2>myocardial_15\JJ\1740 injury</e2>_16\NN\14052046 defined_17\VBN\2604760 as_18\IN\14622893 myocardial_19\JJ\1740 infarction_20\NN\14204950 ,_21\,\1740 ischemia_22\NN\14195315 ,_23\,\1740 and_24\CC\1740 bundle_25\VBP\1482449 branch_26\NN\8220714 block_27\NN\21939 ._28\.\1740
D003042_D012559 NONE the_0\DT\1740 electrocardiograms_1\NNS\7000195 (_2\-LRB-\1740 ecg_3\NN\7000195 )_4\-RRB-\1740 of_5\IN\1740 99_6\CD\1740 <e1>cocaine-abusing</e1>_7\JJ\1740 patients_8\NNS\9898892 were_9\VBD\836236 compared_10\VBN\644583 with_11\IN\1740 the_12\DT\1740 ecgs_13\NNS\7000195 of_14\IN\1740 50_15\CD\13745420 <e2>schizophrenic</e2>_16\JJ\1740 controls_17\NNS\5190804 ._18\.\1740
D003042_D009203 CID eleven_0\CD\13745420 of_1\IN\1740 the_2\DT\1740 <e1>cocaine</e1>_3\NN\3492717 abusers_4\NNS\9633969 and_5\CC\1740 none_6\NN\15228378 of_7\IN\1740 the_8\DT\1740 controls_9\NNS\5190804 had_10\VBD\2108377 ecg_11\NNP\7000195 evidence_12\NN\5816287 of_13\IN\1740 significant_14\JJ\1740 myocardial_15\JJ\1740 injury_16\NN\14052046 defined_17\VBN\2604760 as_18\IN\14622893 <e2>myocardial_19\JJ\1740 infarction</e2>_20\NN\14204950 ,_21\,\1740 ischemia_22\NN\14195315 ,_23\,\1740 and_24\CC\1740 bundle_25\VBP\1482449 branch_26\NN\8220714 block_27\NN\21939 ._28\.\1740
D003042_D007511 NONE eleven_0\CD\13745420 of_1\IN\1740 the_2\DT\1740 <e1>cocaine</e1>_3\NN\3492717 abusers_4\NNS\9633969 and_5\CC\1740 none_6\NN\15228378 of_7\IN\1740 the_8\DT\1740 controls_9\NNS\5190804 had_10\VBD\2108377 ecg_11\NNP\7000195 evidence_12\NN\5816287 of_13\IN\1740 significant_14\JJ\1740 myocardial_15\JJ\1740 injury_16\NN\14052046 defined_17\VBN\2604760 as_18\IN\14622893 myocardial_19\JJ\1740 infarction_20\NN\14204950 ,_21\,\1740 <e2>ischemia</e2>_22\NN\14195315 ,_23\,\1740 and_24\CC\1740 bundle_25\VBP\1482449 branch_26\NN\8220714 block_27\NN\21939 ._28\.\1740
D003042_D002037 CID eleven_0\CD\13745420 of_1\IN\1740 the_2\DT\1740 <e1>cocaine</e1>_3\NN\3492717 abusers_4\NNS\9633969 and_5\CC\1740 none_6\NN\15228378 of_7\IN\1740 the_8\DT\1740 controls_9\NNS\5190804 had_10\VBD\2108377 ecg_11\NNP\7000195 evidence_12\NN\5816287 of_13\IN\1740 significant_14\JJ\1740 myocardial_15\JJ\1740 injury_16\NN\14052046 defined_17\VBN\2604760 as_18\IN\14622893 myocardial_19\JJ\1740 infarction_20\NN\14204950 ,_21\,\1740 ischemia_22\NN\14195315 ,_23\,\1740 and_24\CC\1740 <e2>bundle_25\VBP\1482449 branch_26\NN\8220714 block</e2>_27\NN\21939 ._28\.\1740
8643971
D017239_D006258 NONE a_0\DT\13649268 phase_1\NN\15113229 i/ii_2\NN\1740 study_3\NN\635850 of_4\IN\1740 <e1>paclitaxel</e1>_5\NN\1740 plus_6\CC\4723816 cisplatin_7\NN\1740 as_8\IN\14622893 first-line_9\JJ\1740 therapy_10\NN\657604 for_11\IN\1740 <e2>head_12\NN\5225090 and_13\CC\1740 neck_14\NN\5225090 cancers</e2>_15\NNS\14239425 :_16\:\1740 preliminary_17\JJ\1740 results_18\NNS\34213 ._19\.\1740
D017239_D006258 NONE preliminary_0\JJ\1740 results_1\NNS\34213 of_2\IN\1740 an_3\DT\6697703 eastern_4\JJ\1740 cooperative_5\NNP\8065093 oncology_6\NN\6043075 group_7\NNP\2137 study_8\NN\635850 of_9\IN\1740 single-agent_10\JJ\1740 <e1>paclitaxel</e1>_11\NN\1740 (_12\-LRB-\1740 taxol_13\NN\1740 ;_14\:\1740 bristol-myers_15\NNP\1740 squibb_16\NNP\1740 company_17\NNP\8053576 ,_18\,\1740 princeton_19\NNP\1740 ,_20\,\1740 nj_21\NNP\1740 )_22\-RRB-\1740 reported_23\VBD\831651 a_24\DT\13649268 37_25\CD\1740 %_26\NN\1740 response_27\NN\11410625 rate_28\NN\13815152 in_29\IN\13603305 patients_30\NNS\9898892 with_31\IN\1740 <e2>head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 cancer</e2>_35\NN\14239425 ,_36\,\1740 and_37\CC\1740 the_38\DT\1740 paclitaxel/cisplatin_39\NN\1740 combination_40\NN\7951464 has_41\VBZ\2108377 been_42\VBN\836236 used_43\VBN\1156834 successfully_44\RB\1740 and_45\CC\1740 has_46\VBZ\2108377 significantly_47\RB\1740 improved_48\VBN\126264 median_49\JJ\1740 response_50\NN\11410625 duration_51\NN\15113229 in_52\IN\13603305 ovarian_53\JJ\1740 cancer_54\NN\14239425 patients_55\NNS\9898892 ._56\.\1740
D017239_D006258 NONE preliminary_0\JJ\1740 results_1\NNS\34213 of_2\IN\1740 an_3\DT\6697703 eastern_4\JJ\1740 cooperative_5\NNP\8065093 oncology_6\NN\6043075 group_7\NNP\2137 study_8\NN\635850 of_9\IN\1740 single-agent_10\JJ\1740 paclitaxel_11\NN\1740 (_12\-LRB-\1740 <e1>taxol</e1>_13\NN\1740 ;_14\:\1740 bristol-myers_15\NNP\1740 squibb_16\NNP\1740 company_17\NNP\8053576 ,_18\,\1740 princeton_19\NNP\1740 ,_20\,\1740 nj_21\NNP\1740 )_22\-RRB-\1740 reported_23\VBD\831651 a_24\DT\13649268 37_25\CD\1740 %_26\NN\1740 response_27\NN\11410625 rate_28\NN\13815152 in_29\IN\13603305 patients_30\NNS\9898892 with_31\IN\1740 <e2>head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 cancer</e2>_35\NN\14239425 ,_36\,\1740 and_37\CC\1740 the_38\DT\1740 paclitaxel/cisplatin_39\NN\1740 combination_40\NN\7951464 has_41\VBZ\2108377 been_42\VBN\836236 used_43\VBN\1156834 successfully_44\RB\1740 and_45\CC\1740 has_46\VBZ\2108377 significantly_47\RB\1740 improved_48\VBN\126264 median_49\JJ\1740 response_50\NN\11410625 duration_51\NN\15113229 in_52\IN\13603305 ovarian_53\JJ\1740 cancer_54\NN\14239425 patients_55\NNS\9898892 ._56\.\1740
D017239_D006258 NONE preliminary_0\JJ\1740 results_1\NNS\34213 of_2\IN\1740 an_3\DT\6697703 eastern_4\JJ\1740 cooperative_5\NNP\8065093 oncology_6\NN\6043075 group_7\NNP\2137 study_8\NN\635850 of_9\IN\1740 single-agent_10\JJ\1740 paclitaxel_11\NN\1740 (_12\-LRB-\1740 taxol_13\NN\1740 ;_14\:\1740 bristol-myers_15\NNP\1740 squibb_16\NNP\1740 company_17\NNP\8053576 ,_18\,\1740 princeton_19\NNP\1740 ,_20\,\1740 nj_21\NNP\1740 )_22\-RRB-\1740 reported_23\VBD\831651 a_24\DT\13649268 37_25\CD\1740 %_26\NN\1740 response_27\NN\11410625 rate_28\NN\13815152 in_29\IN\13603305 patients_30\NNS\9898892 with_31\IN\1740 <e2>head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 cancer</e2>_35\NN\14239425 ,_36\,\1740 and_37\CC\1740 the_38\DT\1740 <e1>paclitaxel/cisplatin</e1>_39\NN\1740 combination_40\NN\7951464 has_41\VBZ\2108377 been_42\VBN\836236 used_43\VBN\1156834 successfully_44\RB\1740 and_45\CC\1740 has_46\VBZ\2108377 significantly_47\RB\1740 improved_48\VBN\126264 median_49\JJ\1740 response_50\NN\11410625 duration_51\NN\15113229 in_52\IN\13603305 ovarian_53\JJ\1740 cancer_54\NN\14239425 patients_55\NNS\9898892 ._56\.\1740
D017239_D006258 NONE we_0\PRP\1740 initiated_1\VBD\1617192 a_2\DT\13649268 phase_3\NN\15113229 i/ii_4\NN\1740 trial_5\NN\786195 to_6\TO\1740 determine_7\VB\1645601 the_8\DT\1740 response_9\NN\11410625 and_10\CC\1740 toxicity_11\NN\13576101 of_12\IN\1740 escalating_13\VBG\153263 <e1>paclitaxel</e1>_14\NN\1740 doses_15\NNS\3740161 combined_16\VBN\2630189 with_17\IN\1740 fixed-dose_18\JJ\1740 cisplatin_19\NN\1740 with_20\IN\1740 granulocyte_21\NN\5449959 colony-stimulating_22\JJ\1740 factor_23\NN\7326557 support_24\NN\407535 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 untreated_28\JJ\1740 locally_29\RB\1740 advanced_30\VBN\1835496 inoperable_31\JJ\1740 <e2>head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 carcinoma</e2>_35\NN\14239918 ._36\.\1740
D017239_D006258 NONE <e1>paclitaxel/cisplatin</e1>_0\NN\1740 is_1\VBZ\836236 an_2\DT\6697703 effective_3\JJ\1740 first-line_4\JJ\1740 regimen_5\NN\5898568 for_6\IN\1740 locoregionally_7\RB\1740 advanced_8\JJ\1740 <e2>head_9\NN\5225090 and_10\CC\1740 neck_11\NN\5225090 cancer</e2>_12\NN\14239425 and_13\CC\1740 continued_14\VBN\2367363 study_15\NN\635850 is_16\VBZ\836236 warranted_17\VBN\1012073 ._18\.\1740
D002945_D006258 NONE a_0\DT\13649268 phase_1\NN\15113229 i/ii_2\NN\1740 study_3\NN\635850 of_4\IN\1740 paclitaxel_5\NN\1740 plus_6\CC\4723816 <e1>cisplatin</e1>_7\NN\1740 as_8\IN\14622893 first-line_9\JJ\1740 therapy_10\NN\657604 for_11\IN\1740 <e2>head_12\NN\5225090 and_13\CC\1740 neck_14\NN\5225090 cancers</e2>_15\NNS\14239425 :_16\:\1740 preliminary_17\JJ\1740 results_18\NNS\34213 ._19\.\1740
D002945_D006258 NONE preliminary_0\JJ\1740 results_1\NNS\34213 of_2\IN\1740 an_3\DT\6697703 eastern_4\JJ\1740 cooperative_5\NNP\8065093 oncology_6\NN\6043075 group_7\NNP\2137 study_8\NN\635850 of_9\IN\1740 single-agent_10\JJ\1740 paclitaxel_11\NN\1740 (_12\-LRB-\1740 taxol_13\NN\1740 ;_14\:\1740 bristol-myers_15\NNP\1740 squibb_16\NNP\1740 company_17\NNP\8053576 ,_18\,\1740 princeton_19\NNP\1740 ,_20\,\1740 nj_21\NNP\1740 )_22\-RRB-\1740 reported_23\VBD\831651 a_24\DT\13649268 37_25\CD\1740 %_26\NN\1740 response_27\NN\11410625 rate_28\NN\13815152 in_29\IN\13603305 patients_30\NNS\9898892 with_31\IN\1740 <e2>head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 cancer</e2>_35\NN\14239425 ,_36\,\1740 and_37\CC\1740 the_38\DT\1740 <e1>paclitaxel/cisplatin</e1>_39\NN\1740 combination_40\NN\7951464 has_41\VBZ\2108377 been_42\VBN\836236 used_43\VBN\1156834 successfully_44\RB\1740 and_45\CC\1740 has_46\VBZ\2108377 significantly_47\RB\1740 improved_48\VBN\126264 median_49\JJ\1740 response_50\NN\11410625 duration_51\NN\15113229 in_52\IN\13603305 ovarian_53\JJ\1740 cancer_54\NN\14239425 patients_55\NNS\9898892 ._56\.\1740
D002945_D006258 NONE we_0\PRP\1740 initiated_1\VBD\1617192 a_2\DT\13649268 phase_3\NN\15113229 i/ii_4\NN\1740 trial_5\NN\786195 to_6\TO\1740 determine_7\VB\1645601 the_8\DT\1740 response_9\NN\11410625 and_10\CC\1740 toxicity_11\NN\13576101 of_12\IN\1740 escalating_13\VBG\153263 paclitaxel_14\NN\1740 doses_15\NNS\3740161 combined_16\VBN\2630189 with_17\IN\1740 fixed-dose_18\JJ\1740 <e1>cisplatin</e1>_19\NN\1740 with_20\IN\1740 granulocyte_21\NN\5449959 colony-stimulating_22\JJ\1740 factor_23\NN\7326557 support_24\NN\407535 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 untreated_28\JJ\1740 locally_29\RB\1740 advanced_30\VBN\1835496 inoperable_31\JJ\1740 <e2>head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 carcinoma</e2>_35\NN\14239918 ._36\.\1740
D002945_D006258 NONE <e1>paclitaxel/cisplatin</e1>_0\NN\1740 is_1\VBZ\836236 an_2\DT\6697703 effective_3\JJ\1740 first-line_4\JJ\1740 regimen_5\NN\5898568 for_6\IN\1740 locoregionally_7\RB\1740 advanced_8\JJ\1740 <e2>head_9\NN\5225090 and_10\CC\1740 neck_11\NN\5225090 cancer</e2>_12\NN\14239425 and_13\CC\1740 continued_14\VBN\2367363 study_15\NN\635850 is_16\VBZ\836236 warranted_17\VBN\1012073 ._18\.\1740
D017239_D010051 NONE preliminary_0\JJ\1740 results_1\NNS\34213 of_2\IN\1740 an_3\DT\6697703 eastern_4\JJ\1740 cooperative_5\NNP\8065093 oncology_6\NN\6043075 group_7\NNP\2137 study_8\NN\635850 of_9\IN\1740 single-agent_10\JJ\1740 <e1>paclitaxel</e1>_11\NN\1740 (_12\-LRB-\1740 taxol_13\NN\1740 ;_14\:\1740 bristol-myers_15\NNP\1740 squibb_16\NNP\1740 company_17\NNP\8053576 ,_18\,\1740 princeton_19\NNP\1740 ,_20\,\1740 nj_21\NNP\1740 )_22\-RRB-\1740 reported_23\VBD\831651 a_24\DT\13649268 37_25\CD\1740 %_26\NN\1740 response_27\NN\11410625 rate_28\NN\13815152 in_29\IN\13603305 patients_30\NNS\9898892 with_31\IN\1740 head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 cancer_35\NN\14239425 ,_36\,\1740 and_37\CC\1740 the_38\DT\1740 paclitaxel/cisplatin_39\NN\1740 combination_40\NN\7951464 has_41\VBZ\2108377 been_42\VBN\836236 used_43\VBN\1156834 successfully_44\RB\1740 and_45\CC\1740 has_46\VBZ\2108377 significantly_47\RB\1740 improved_48\VBN\126264 median_49\JJ\1740 response_50\NN\11410625 duration_51\NN\15113229 in_52\IN\13603305 <e2>ovarian_53\JJ\1740 cancer</e2>_54\NN\14239425 patients_55\NNS\9898892 ._56\.\1740
D017239_D010051 NONE preliminary_0\JJ\1740 results_1\NNS\34213 of_2\IN\1740 an_3\DT\6697703 eastern_4\JJ\1740 cooperative_5\NNP\8065093 oncology_6\NN\6043075 group_7\NNP\2137 study_8\NN\635850 of_9\IN\1740 single-agent_10\JJ\1740 paclitaxel_11\NN\1740 (_12\-LRB-\1740 <e1>taxol</e1>_13\NN\1740 ;_14\:\1740 bristol-myers_15\NNP\1740 squibb_16\NNP\1740 company_17\NNP\8053576 ,_18\,\1740 princeton_19\NNP\1740 ,_20\,\1740 nj_21\NNP\1740 )_22\-RRB-\1740 reported_23\VBD\831651 a_24\DT\13649268 37_25\CD\1740 %_26\NN\1740 response_27\NN\11410625 rate_28\NN\13815152 in_29\IN\13603305 patients_30\NNS\9898892 with_31\IN\1740 head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 cancer_35\NN\14239425 ,_36\,\1740 and_37\CC\1740 the_38\DT\1740 paclitaxel/cisplatin_39\NN\1740 combination_40\NN\7951464 has_41\VBZ\2108377 been_42\VBN\836236 used_43\VBN\1156834 successfully_44\RB\1740 and_45\CC\1740 has_46\VBZ\2108377 significantly_47\RB\1740 improved_48\VBN\126264 median_49\JJ\1740 response_50\NN\11410625 duration_51\NN\15113229 in_52\IN\13603305 <e2>ovarian_53\JJ\1740 cancer</e2>_54\NN\14239425 patients_55\NNS\9898892 ._56\.\1740
D017239_D010051 NONE preliminary_0\JJ\1740 results_1\NNS\34213 of_2\IN\1740 an_3\DT\6697703 eastern_4\JJ\1740 cooperative_5\NNP\8065093 oncology_6\NN\6043075 group_7\NNP\2137 study_8\NN\635850 of_9\IN\1740 single-agent_10\JJ\1740 paclitaxel_11\NN\1740 (_12\-LRB-\1740 taxol_13\NN\1740 ;_14\:\1740 bristol-myers_15\NNP\1740 squibb_16\NNP\1740 company_17\NNP\8053576 ,_18\,\1740 princeton_19\NNP\1740 ,_20\,\1740 nj_21\NNP\1740 )_22\-RRB-\1740 reported_23\VBD\831651 a_24\DT\13649268 37_25\CD\1740 %_26\NN\1740 response_27\NN\11410625 rate_28\NN\13815152 in_29\IN\13603305 patients_30\NNS\9898892 with_31\IN\1740 head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 cancer_35\NN\14239425 ,_36\,\1740 and_37\CC\1740 the_38\DT\1740 <e1>paclitaxel/cisplatin</e1>_39\NN\1740 combination_40\NN\7951464 has_41\VBZ\2108377 been_42\VBN\836236 used_43\VBN\1156834 successfully_44\RB\1740 and_45\CC\1740 has_46\VBZ\2108377 significantly_47\RB\1740 improved_48\VBN\126264 median_49\JJ\1740 response_50\NN\11410625 duration_51\NN\15113229 in_52\IN\13603305 <e2>ovarian_53\JJ\1740 cancer</e2>_54\NN\14239425 patients_55\NNS\9898892 ._56\.\1740
D002945_D010051 NONE preliminary_0\JJ\1740 results_1\NNS\34213 of_2\IN\1740 an_3\DT\6697703 eastern_4\JJ\1740 cooperative_5\NNP\8065093 oncology_6\NN\6043075 group_7\NNP\2137 study_8\NN\635850 of_9\IN\1740 single-agent_10\JJ\1740 paclitaxel_11\NN\1740 (_12\-LRB-\1740 taxol_13\NN\1740 ;_14\:\1740 bristol-myers_15\NNP\1740 squibb_16\NNP\1740 company_17\NNP\8053576 ,_18\,\1740 princeton_19\NNP\1740 ,_20\,\1740 nj_21\NNP\1740 )_22\-RRB-\1740 reported_23\VBD\831651 a_24\DT\13649268 37_25\CD\1740 %_26\NN\1740 response_27\NN\11410625 rate_28\NN\13815152 in_29\IN\13603305 patients_30\NNS\9898892 with_31\IN\1740 head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 cancer_35\NN\14239425 ,_36\,\1740 and_37\CC\1740 the_38\DT\1740 <e1>paclitaxel/cisplatin</e1>_39\NN\1740 combination_40\NN\7951464 has_41\VBZ\2108377 been_42\VBN\836236 used_43\VBN\1156834 successfully_44\RB\1740 and_45\CC\1740 has_46\VBZ\2108377 significantly_47\RB\1740 improved_48\VBN\126264 median_49\JJ\1740 response_50\NN\11410625 duration_51\NN\15113229 in_52\IN\13603305 <e2>ovarian_53\JJ\1740 cancer</e2>_54\NN\14239425 patients_55\NNS\9898892 ._56\.\1740
D017239_D064420 NONE we_0\PRP\1740 initiated_1\VBD\1617192 a_2\DT\13649268 phase_3\NN\15113229 i/ii_4\NN\1740 trial_5\NN\786195 to_6\TO\1740 determine_7\VB\1645601 the_8\DT\1740 response_9\NN\11410625 and_10\CC\1740 <e2>toxicity</e2>_11\NN\13576101 of_12\IN\1740 escalating_13\VBG\153263 <e1>paclitaxel</e1>_14\NN\1740 doses_15\NNS\3740161 combined_16\VBN\2630189 with_17\IN\1740 fixed-dose_18\JJ\1740 cisplatin_19\NN\1740 with_20\IN\1740 granulocyte_21\NN\5449959 colony-stimulating_22\JJ\1740 factor_23\NN\7326557 support_24\NN\407535 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 untreated_28\JJ\1740 locally_29\RB\1740 advanced_30\VBN\1835496 inoperable_31\JJ\1740 head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 carcinoma_35\NN\14239918 ._36\.\1740
D017239_D064420 NONE the_0\DT\1740 dose_1\NN\3740161 levels_2\NNS\4916342 incorporate_3\VBP\1461328 escalating_4\VBG\153263 <e1>paclitaxel</e1>_5\NN\1740 doses_6\NNS\3740161 ,_7\,\1740 and_8\CC\1740 intrapatient_9\JJ\1740 escalations_10\NNS\363260 within_11\IN\1740 a_12\DT\13649268 given_13\VBN\2327200 dose_14\NN\3740161 level_15\NN\4916342 are_16\VBP\836236 permitted_17\VBN\797697 if_18\IN\1740 <e2>toxicity</e2>_19\NN\13576101 permits_20\NNS\6479665 ._21\.\1740
D002945_D064420 NONE we_0\PRP\1740 initiated_1\VBD\1617192 a_2\DT\13649268 phase_3\NN\15113229 i/ii_4\NN\1740 trial_5\NN\786195 to_6\TO\1740 determine_7\VB\1645601 the_8\DT\1740 response_9\NN\11410625 and_10\CC\1740 <e2>toxicity</e2>_11\NN\13576101 of_12\IN\1740 escalating_13\VBG\153263 paclitaxel_14\NN\1740 doses_15\NNS\3740161 combined_16\VBN\2630189 with_17\IN\1740 fixed-dose_18\JJ\1740 <e1>cisplatin</e1>_19\NN\1740 with_20\IN\1740 granulocyte_21\NN\5449959 colony-stimulating_22\JJ\1740 factor_23\NN\7326557 support_24\NN\407535 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 untreated_28\JJ\1740 locally_29\RB\1740 advanced_30\VBN\1835496 inoperable_31\JJ\1740 head_32\NN\5225090 and_33\CC\1740 neck_34\NN\5225090 carcinoma_35\NN\14239918 ._36\.\1740
9523805
D011318_D009422 CID <e2>transient_0\JJ\1740 neurologic_1\JJ\1740 symptoms</e2>_2\NNS\5823932 after_3\IN\1740 spinal_4\JJ\1740 anesthesia_5\NN\14034177 :_6\:\1740 a_7\DT\13649268 lower_8\JJR\1740 incidence_9\NN\13821570 with_10\IN\1740 <e1>prilocaine</e1>_11\NN\1740 and_12\CC\1740 bupivacaine_13\NN\1740 than_14\IN\1740 with_15\IN\1740 lidocaine_16\NN\3681148 ._17\.\1740
D011318_D009422 CID accordingly_0\RB\1740 ,_1\,\1740 the_2\DT\1740 present_3\JJ\1740 ,_4\,\1740 prospective_5\JJ\1740 double-blind_6\JJ\1740 study_7\NN\635850 compares_8\VBZ\644583 <e1>prilocaine</e1>_9\NN\1740 with_10\IN\1740 lidocaine_11\NN\3681148 and_12\CC\1740 bupivacaine_13\VB\1740 with_14\IN\1740 respect_15\NN\5817845 to_16\TO\1740 duration_17\NN\15113229 of_18\IN\1740 action_19\NN\30358 and_20\CC\1740 relative_21\JJ\1740 risk_22\NN\14541044 of_23\IN\1740 <e2>tnss</e2>_24\NNS\1740 ._25\.\1740
D011318_D009422 CID results_0\NNS\34213 :_1\:\1740 nine_2\CD\13741022 of_3\IN\1740 30_4\CD\13745420 patients_5\NNS\9898892 receiving_6\VBG\2210855 lidocaine_7\NN\3681148 experienced_8\JJ\1740 <e2>tnss</e2>_9\NNS\1740 ,_10\,\1740 1_11\CD\13741022 of_12\IN\1740 30_13\CD\13745420 patients_14\NNS\9898892 receiving_15\VBG\2210855 <e1>prilocaine</e1>_16\NN\1740 (_17\-LRB-\1740 p_18\NN\14622893 =_19\JJ\1740 0.03_20\CD\1740 )_21\-RRB-\1740 had_22\VBD\2108377 them_23\PRP\1740 ,_24\,\1740 and_25\CC\1740 none_26\NN\15228378 of_27\IN\1740 30_28\CD\13745420 patients_29\NNS\9898892 receiving_30\VBG\2210855 bupivacaine_31\NN\1740 had_32\VBD\2108377 tnss_33\NNS\1740 ._34\.\1740
D011318_D009422 CID results_0\NNS\34213 :_1\:\1740 nine_2\CD\13741022 of_3\IN\1740 30_4\CD\13745420 patients_5\NNS\9898892 receiving_6\VBG\2210855 lidocaine_7\NN\3681148 experienced_8\JJ\1740 tnss_9\NNS\1740 ,_10\,\1740 1_11\CD\13741022 of_12\IN\1740 30_13\CD\13745420 patients_14\NNS\9898892 receiving_15\VBG\2210855 <e1>prilocaine</e1>_16\NN\1740 (_17\-LRB-\1740 p_18\NN\14622893 =_19\JJ\1740 0.03_20\CD\1740 )_21\-RRB-\1740 had_22\VBD\2108377 them_23\PRP\1740 ,_24\,\1740 and_25\CC\1740 none_26\NN\15228378 of_27\IN\1740 30_28\CD\13745420 patients_29\NNS\9898892 receiving_30\VBG\2210855 bupivacaine_31\NN\1740 had_32\VBD\2108377 <e2>tnss</e2>_33\NNS\1740 ._34\.\1740
D011318_D009422 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>prilocaine</e1>_2\NN\1740 may_3\MD\15209706 be_4\VB\836236 preferable_5\JJ\1740 to_6\TO\1740 lidocaine_7\NN\3681148 for_8\IN\1740 short_9\JJ\1740 surgical_10\JJ\1740 procedures_11\NNS\407535 because_12\IN\1740 it_13\PRP\6125041 has_14\VBZ\2108377 a_15\DT\13649268 similar_16\JJ\1740 duration_17\NN\15113229 of_18\IN\1740 action_19\NN\30358 but_20\CC\1740 a_21\DT\13649268 lower_22\JJR\1740 incidence_23\NN\13821570 of_24\IN\1740 <e2>tnss</e2>_25\NNS\1740 ._26\.\1740
D002045_D009422 NONE <e2>transient_0\JJ\1740 neurologic_1\JJ\1740 symptoms</e2>_2\NNS\5823932 after_3\IN\1740 spinal_4\JJ\1740 anesthesia_5\NN\14034177 :_6\:\1740 a_7\DT\13649268 lower_8\JJR\1740 incidence_9\NN\13821570 with_10\IN\1740 prilocaine_11\NN\1740 and_12\CC\1740 <e1>bupivacaine</e1>_13\NN\1740 than_14\IN\1740 with_15\IN\1740 lidocaine_16\NN\3681148 ._17\.\1740
D002045_D009422 NONE background_0\NN\4921011 :_1\:\1740 recent_2\JJ\1740 evidence_3\NN\5816287 suggests_4\VBZ\1010118 that_5\IN\1740 <e2>transient_6\JJ\1740 neurologic_7\JJ\1740 symptoms</e2>_8\NNS\5823932 (_9\-LRB-\1740 tnss_10\NNS\1740 )_11\-RRB-\1740 frequently_12\RB\1740 follow_13\VBP\1835496 lidocaine_14\NN\3681148 spinal_15\JJ\1740 anesthesia_16\NN\14034177 but_17\CC\1740 are_18\VBP\836236 infrequent_19\JJ\1740 with_20\IN\1740 <e1>bupivacaine</e1>_21\NN\1740 ._22\.\1740
D002045_D009422 NONE background_0\NN\4921011 :_1\:\1740 recent_2\JJ\1740 evidence_3\NN\5816287 suggests_4\VBZ\1010118 that_5\IN\1740 transient_6\JJ\1740 neurologic_7\JJ\1740 symptoms_8\NNS\5823932 (_9\-LRB-\1740 <e2>tnss</e2>_10\NNS\1740 )_11\-RRB-\1740 frequently_12\RB\1740 follow_13\VBP\1835496 lidocaine_14\NN\3681148 spinal_15\JJ\1740 anesthesia_16\NN\14034177 but_17\CC\1740 are_18\VBP\836236 infrequent_19\JJ\1740 with_20\IN\1740 <e1>bupivacaine</e1>_21\NN\1740 ._22\.\1740
D002045_D009422 NONE accordingly_0\RB\1740 ,_1\,\1740 the_2\DT\1740 present_3\JJ\1740 ,_4\,\1740 prospective_5\JJ\1740 double-blind_6\JJ\1740 study_7\NN\635850 compares_8\VBZ\644583 prilocaine_9\NN\1740 with_10\IN\1740 lidocaine_11\NN\3681148 and_12\CC\1740 <e1>bupivacaine</e1>_13\VB\1740 with_14\IN\1740 respect_15\NN\5817845 to_16\TO\1740 duration_17\NN\15113229 of_18\IN\1740 action_19\NN\30358 and_20\CC\1740 relative_21\JJ\1740 risk_22\NN\14541044 of_23\IN\1740 <e2>tnss</e2>_24\NNS\1740 ._25\.\1740
D002045_D009422 NONE results_0\NNS\34213 :_1\:\1740 nine_2\CD\13741022 of_3\IN\1740 30_4\CD\13745420 patients_5\NNS\9898892 receiving_6\VBG\2210855 lidocaine_7\NN\3681148 experienced_8\JJ\1740 <e2>tnss</e2>_9\NNS\1740 ,_10\,\1740 1_11\CD\13741022 of_12\IN\1740 30_13\CD\13745420 patients_14\NNS\9898892 receiving_15\VBG\2210855 prilocaine_16\NN\1740 (_17\-LRB-\1740 p_18\NN\14622893 =_19\JJ\1740 0.03_20\CD\1740 )_21\-RRB-\1740 had_22\VBD\2108377 them_23\PRP\1740 ,_24\,\1740 and_25\CC\1740 none_26\NN\15228378 of_27\IN\1740 30_28\CD\13745420 patients_29\NNS\9898892 receiving_30\VBG\2210855 <e1>bupivacaine</e1>_31\NN\1740 had_32\VBD\2108377 tnss_33\NNS\1740 ._34\.\1740
D002045_D009422 NONE results_0\NNS\34213 :_1\:\1740 nine_2\CD\13741022 of_3\IN\1740 30_4\CD\13745420 patients_5\NNS\9898892 receiving_6\VBG\2210855 lidocaine_7\NN\3681148 experienced_8\JJ\1740 tnss_9\NNS\1740 ,_10\,\1740 1_11\CD\13741022 of_12\IN\1740 30_13\CD\13745420 patients_14\NNS\9898892 receiving_15\VBG\2210855 prilocaine_16\NN\1740 (_17\-LRB-\1740 p_18\NN\14622893 =_19\JJ\1740 0.03_20\CD\1740 )_21\-RRB-\1740 had_22\VBD\2108377 them_23\PRP\1740 ,_24\,\1740 and_25\CC\1740 none_26\NN\15228378 of_27\IN\1740 30_28\CD\13745420 patients_29\NNS\9898892 receiving_30\VBG\2210855 <e1>bupivacaine</e1>_31\NN\1740 had_32\VBD\2108377 <e2>tnss</e2>_33\NNS\1740 ._34\.\1740
D008012_D009422 CID <e2>transient_0\JJ\1740 neurologic_1\JJ\1740 symptoms</e2>_2\NNS\5823932 after_3\IN\1740 spinal_4\JJ\1740 anesthesia_5\NN\14034177 :_6\:\1740 a_7\DT\13649268 lower_8\JJR\1740 incidence_9\NN\13821570 with_10\IN\1740 prilocaine_11\NN\1740 and_12\CC\1740 bupivacaine_13\NN\1740 than_14\IN\1740 with_15\IN\1740 <e1>lidocaine</e1>_16\NN\3681148 ._17\.\1740
D008012_D009422 CID background_0\NN\4921011 :_1\:\1740 recent_2\JJ\1740 evidence_3\NN\5816287 suggests_4\VBZ\1010118 that_5\IN\1740 <e2>transient_6\JJ\1740 neurologic_7\JJ\1740 symptoms</e2>_8\NNS\5823932 (_9\-LRB-\1740 tnss_10\NNS\1740 )_11\-RRB-\1740 frequently_12\RB\1740 follow_13\VBP\1835496 <e1>lidocaine</e1>_14\NN\3681148 spinal_15\JJ\1740 anesthesia_16\NN\14034177 but_17\CC\1740 are_18\VBP\836236 infrequent_19\JJ\1740 with_20\IN\1740 bupivacaine_21\NN\1740 ._22\.\1740
D008012_D009422 CID background_0\NN\4921011 :_1\:\1740 recent_2\JJ\1740 evidence_3\NN\5816287 suggests_4\VBZ\1010118 that_5\IN\1740 transient_6\JJ\1740 neurologic_7\JJ\1740 symptoms_8\NNS\5823932 (_9\-LRB-\1740 <e2>tnss</e2>_10\NNS\1740 )_11\-RRB-\1740 frequently_12\RB\1740 follow_13\VBP\1835496 <e1>lidocaine</e1>_14\NN\3681148 spinal_15\JJ\1740 anesthesia_16\NN\14034177 but_17\CC\1740 are_18\VBP\836236 infrequent_19\JJ\1740 with_20\IN\1740 bupivacaine_21\NN\1740 ._22\.\1740
D008012_D009422 CID accordingly_0\RB\1740 ,_1\,\1740 the_2\DT\1740 present_3\JJ\1740 ,_4\,\1740 prospective_5\JJ\1740 double-blind_6\JJ\1740 study_7\NN\635850 compares_8\VBZ\644583 prilocaine_9\NN\1740 with_10\IN\1740 <e1>lidocaine</e1>_11\NN\3681148 and_12\CC\1740 bupivacaine_13\VB\1740 with_14\IN\1740 respect_15\NN\5817845 to_16\TO\1740 duration_17\NN\15113229 of_18\IN\1740 action_19\NN\30358 and_20\CC\1740 relative_21\JJ\1740 risk_22\NN\14541044 of_23\IN\1740 <e2>tnss</e2>_24\NNS\1740 ._25\.\1740
D008012_D009422 CID results_0\NNS\34213 :_1\:\1740 nine_2\CD\13741022 of_3\IN\1740 30_4\CD\13745420 patients_5\NNS\9898892 receiving_6\VBG\2210855 <e1>lidocaine</e1>_7\NN\3681148 experienced_8\JJ\1740 <e2>tnss</e2>_9\NNS\1740 ,_10\,\1740 1_11\CD\13741022 of_12\IN\1740 30_13\CD\13745420 patients_14\NNS\9898892 receiving_15\VBG\2210855 prilocaine_16\NN\1740 (_17\-LRB-\1740 p_18\NN\14622893 =_19\JJ\1740 0.03_20\CD\1740 )_21\-RRB-\1740 had_22\VBD\2108377 them_23\PRP\1740 ,_24\,\1740 and_25\CC\1740 none_26\NN\15228378 of_27\IN\1740 30_28\CD\13745420 patients_29\NNS\9898892 receiving_30\VBG\2210855 bupivacaine_31\NN\1740 had_32\VBD\2108377 tnss_33\NNS\1740 ._34\.\1740
D008012_D009422 CID results_0\NNS\34213 :_1\:\1740 nine_2\CD\13741022 of_3\IN\1740 30_4\CD\13745420 patients_5\NNS\9898892 receiving_6\VBG\2210855 <e1>lidocaine</e1>_7\NN\3681148 experienced_8\JJ\1740 tnss_9\NNS\1740 ,_10\,\1740 1_11\CD\13741022 of_12\IN\1740 30_13\CD\13745420 patients_14\NNS\9898892 receiving_15\VBG\2210855 prilocaine_16\NN\1740 (_17\-LRB-\1740 p_18\NN\14622893 =_19\JJ\1740 0.03_20\CD\1740 )_21\-RRB-\1740 had_22\VBD\2108377 them_23\PRP\1740 ,_24\,\1740 and_25\CC\1740 none_26\NN\15228378 of_27\IN\1740 30_28\CD\13745420 patients_29\NNS\9898892 receiving_30\VBG\2210855 bupivacaine_31\NN\1740 had_32\VBD\2108377 <e2>tnss</e2>_33\NNS\1740 ._34\.\1740
D008012_D009422 CID conclusions_0\NNS\5837957 :_1\:\1740 prilocaine_2\NN\1740 may_3\MD\15209706 be_4\VB\836236 preferable_5\JJ\1740 to_6\TO\1740 <e1>lidocaine</e1>_7\NN\3681148 for_8\IN\1740 short_9\JJ\1740 surgical_10\JJ\1740 procedures_11\NNS\407535 because_12\IN\1740 it_13\PRP\6125041 has_14\VBZ\2108377 a_15\DT\13649268 similar_16\JJ\1740 duration_17\NN\15113229 of_18\IN\1740 action_19\NN\30358 but_20\CC\1740 a_21\DT\13649268 lower_22\JJR\1740 incidence_23\NN\13821570 of_24\IN\1740 <e2>tnss</e2>_25\NNS\1740 ._26\.\1740
16167916
D020849_D054556 CID conclusion_0\NN\5837957 :_1\:\1740 we_2\PRP\1740 suggest_3\VBP\1010118 that_4\IN\1740 the_5\DT\1740 increased_6\VBN\169651 risk_7\NN\14541044 of_8\IN\1740 <e2>venous_9\JJ\1740 thromboembolism</e2>_10\NN\14100769 due_11\JJ\1740 to_12\TO\1740 <e1>raloxifene</e1>_13\NN\1740 treatment_14\NN\654885 may_15\MD\15209706 be_16\VB\836236 related_17\JJ\1740 to_18\TO\1740 increased_19\VBN\169651 tpa_20\NN\1740 levels_21\NNS\4916342 ,_22\,\1740 but_23\CC\1740 not_24\RB\1740 tafi_25\NN\1740 levels_26\NNS\4916342 ._27\.\1740
8092427
D000658_D004342 CID immediate_0\JJ\1740 <e2>allergic_1\JJ\1740 reactions</e2>_2\NNS\13446390 to_3\TO\1740 <e1>amoxicillin</e1>_4\NN\3910033 ._5\.\1740
D000658_D004342 CID a_0\DT\13649268 detailed_1\JJ\1740 clinical_2\JJ\1740 history_3\NN\15120823 ,_4\,\1740 together_5\RB\1740 with_6\IN\1740 skin_7\NN\5237755 tests_8\NNS\5798043 ,_9\,\1740 rast_10\NN\1740 (_11\-LRB-\1740 radioallergosorbent_12\JJ\1740 test_13\NN\5798043 )_14\-RRB-\1740 ,_15\,\1740 and_16\CC\1740 controlled_17\VBN\2422663 challenge_18\NN\13927383 tests_19\NNS\5798043 ,_20\,\1740 was_21\VBD\836236 used_22\VBN\1156834 to_23\TO\1740 establish_24\VB\2426171 whether_25\IN\1740 patients_26\NNS\9898892 <e2>allergic</e2>_27\JJ\1740 to_28\TO\1740 beta-lactam_29\JJ\1740 antibiotics_30\NNS\2716205 had_31\VBD\2108377 selective_32\JJ\1740 immediate_33\JJ\1740 allergic_34\JJ\1740 responses_35\NNS\11410625 to_36\TO\1740 <e1>amoxicillin</e1>_37\NN\3910033 (_38\-LRB-\1740 ax_39\NN\3265032 )_40\-RRB-\1740 or_41\CC\3541091 were_42\VBD\836236 cross-reacting_43\JJ\1740 with_44\IN\1740 other_45\JJ\1740 penicillin_46\NN\2716866 derivatives_47\NNS\5802185 ._48\.\1740
D000658_D004342 CID a_0\DT\13649268 detailed_1\JJ\1740 clinical_2\JJ\1740 history_3\NN\15120823 ,_4\,\1740 together_5\RB\1740 with_6\IN\1740 skin_7\NN\5237755 tests_8\NNS\5798043 ,_9\,\1740 rast_10\NN\1740 (_11\-LRB-\1740 radioallergosorbent_12\JJ\1740 test_13\NN\5798043 )_14\-RRB-\1740 ,_15\,\1740 and_16\CC\1740 controlled_17\VBN\2422663 challenge_18\NN\13927383 tests_19\NNS\5798043 ,_20\,\1740 was_21\VBD\836236 used_22\VBN\1156834 to_23\TO\1740 establish_24\VB\2426171 whether_25\IN\1740 patients_26\NNS\9898892 allergic_27\JJ\1740 to_28\TO\1740 beta-lactam_29\JJ\1740 antibiotics_30\NNS\2716205 had_31\VBD\2108377 selective_32\JJ\1740 immediate_33\JJ\1740 <e2>allergic</e2>_34\JJ\1740 responses_35\NNS\11410625 to_36\TO\1740 <e1>amoxicillin</e1>_37\NN\3910033 (_38\-LRB-\1740 ax_39\NN\3265032 )_40\-RRB-\1740 or_41\CC\3541091 were_42\VBD\836236 cross-reacting_43\JJ\1740 with_44\IN\1740 other_45\JJ\1740 penicillin_46\NN\2716866 derivatives_47\NNS\5802185 ._48\.\1740
D000658_D004342 CID a_0\DT\13649268 detailed_1\JJ\1740 clinical_2\JJ\1740 history_3\NN\15120823 ,_4\,\1740 together_5\RB\1740 with_6\IN\1740 skin_7\NN\5237755 tests_8\NNS\5798043 ,_9\,\1740 rast_10\NN\1740 (_11\-LRB-\1740 radioallergosorbent_12\JJ\1740 test_13\NN\5798043 )_14\-RRB-\1740 ,_15\,\1740 and_16\CC\1740 controlled_17\VBN\2422663 challenge_18\NN\13927383 tests_19\NNS\5798043 ,_20\,\1740 was_21\VBD\836236 used_22\VBN\1156834 to_23\TO\1740 establish_24\VB\2426171 whether_25\IN\1740 patients_26\NNS\9898892 <e2>allergic</e2>_27\JJ\1740 to_28\TO\1740 beta-lactam_29\JJ\1740 antibiotics_30\NNS\2716205 had_31\VBD\2108377 selective_32\JJ\1740 immediate_33\JJ\1740 allergic_34\JJ\1740 responses_35\NNS\11410625 to_36\TO\1740 amoxicillin_37\NN\3910033 (_38\-LRB-\1740 <e1>ax</e1>_39\NN\3265032 )_40\-RRB-\1740 or_41\CC\3541091 were_42\VBD\836236 cross-reacting_43\JJ\1740 with_44\IN\1740 other_45\JJ\1740 penicillin_46\NN\2716866 derivatives_47\NNS\5802185 ._48\.\1740
D000658_D004342 CID a_0\DT\13649268 detailed_1\JJ\1740 clinical_2\JJ\1740 history_3\NN\15120823 ,_4\,\1740 together_5\RB\1740 with_6\IN\1740 skin_7\NN\5237755 tests_8\NNS\5798043 ,_9\,\1740 rast_10\NN\1740 (_11\-LRB-\1740 radioallergosorbent_12\JJ\1740 test_13\NN\5798043 )_14\-RRB-\1740 ,_15\,\1740 and_16\CC\1740 controlled_17\VBN\2422663 challenge_18\NN\13927383 tests_19\NNS\5798043 ,_20\,\1740 was_21\VBD\836236 used_22\VBN\1156834 to_23\TO\1740 establish_24\VB\2426171 whether_25\IN\1740 patients_26\NNS\9898892 allergic_27\JJ\1740 to_28\TO\1740 beta-lactam_29\JJ\1740 antibiotics_30\NNS\2716205 had_31\VBD\2108377 selective_32\JJ\1740 immediate_33\JJ\1740 <e2>allergic</e2>_34\JJ\1740 responses_35\NNS\11410625 to_36\TO\1740 amoxicillin_37\NN\3910033 (_38\-LRB-\1740 <e1>ax</e1>_39\NN\3265032 )_40\-RRB-\1740 or_41\CC\3541091 were_42\VBD\836236 cross-reacting_43\JJ\1740 with_44\IN\1740 other_45\JJ\1740 penicillin_46\NN\2716866 derivatives_47\NNS\5802185 ._48\.\1740
D000658_D004342 CID we_0\PRP\1740 selected_1\VBD\697589 the_2\DT\1740 54_3\CD\1740 (_4\-LRB-\1740 30.5_5\CD\1740 %_6\NN\1740 )_7\-RRB-\1740 cases_8\NNS\7283608 of_9\IN\1740 immediate_10\JJ\1740 <e1>ax</e1>_11\NN\3265032 <e2>allergy</e2>_12\NN\14533203 with_13\IN\1740 good_14\JJ\1740 tolerance_15\NN\5032565 of_16\IN\1740 pg_17\NN\1740 ._18\.\1740
D000658_D004342 CID challenge_0\NN\13927383 tests_1\NNS\5798043 with_2\IN\1740 <e1>ax</e1>_3\NN\3265032 were_4\VBD\836236 performed_5\VBN\2367363 in_6\IN\13603305 23_7\CD\13745420 subjects_8\NNS\6598915 (_9\-LRB-\1740 43_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 to_13\TO\1740 establish_14\VB\2426171 the_15\DT\1740 diagnosis_16\NN\152018 of_17\IN\1740 immediate_18\JJ\1740 <e2>allergic_19\JJ\1740 reaction</e2>_20\NN\13446390 to_21\TO\1740 ax_22\NN\3265032 ,_23\,\1740 and_24\CC\1740 in_25\IN\13603305 15_26\CD\13745420 cases_27\NNS\7283608 (_28\-LRB-\1740 28_29\CD\13745420 %_30\NN\1740 )_31\-RRB-\1740 both_32\CC\1740 skin_33\NN\5237755 test_34\NN\5798043 and_35\CC\1740 rast_36\NN\1740 for_37\IN\1740 ax_38\NN\3265032 were_39\VBD\836236 negative_40\JJ\1740 ._41\.\1740
D000658_D004342 CID challenge_0\NN\13927383 tests_1\NNS\5798043 with_2\IN\1740 ax_3\NN\3265032 were_4\VBD\836236 performed_5\VBN\2367363 in_6\IN\13603305 23_7\CD\13745420 subjects_8\NNS\6598915 (_9\-LRB-\1740 43_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 to_13\TO\1740 establish_14\VB\2426171 the_15\DT\1740 diagnosis_16\NN\152018 of_17\IN\1740 immediate_18\JJ\1740 <e2>allergic_19\JJ\1740 reaction</e2>_20\NN\13446390 to_21\TO\1740 <e1>ax</e1>_22\NN\3265032 ,_23\,\1740 and_24\CC\1740 in_25\IN\13603305 15_26\CD\13745420 cases_27\NNS\7283608 (_28\-LRB-\1740 28_29\CD\13745420 %_30\NN\1740 )_31\-RRB-\1740 both_32\CC\1740 skin_33\NN\5237755 test_34\NN\5798043 and_35\CC\1740 rast_36\NN\1740 for_37\IN\1740 ax_38\NN\3265032 were_39\VBD\836236 negative_40\JJ\1740 ._41\.\1740
D000658_D004342 CID challenge_0\NN\13927383 tests_1\NNS\5798043 with_2\IN\1740 ax_3\NN\3265032 were_4\VBD\836236 performed_5\VBN\2367363 in_6\IN\13603305 23_7\CD\13745420 subjects_8\NNS\6598915 (_9\-LRB-\1740 43_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 to_13\TO\1740 establish_14\VB\2426171 the_15\DT\1740 diagnosis_16\NN\152018 of_17\IN\1740 immediate_18\JJ\1740 <e2>allergic_19\JJ\1740 reaction</e2>_20\NN\13446390 to_21\TO\1740 ax_22\NN\3265032 ,_23\,\1740 and_24\CC\1740 in_25\IN\13603305 15_26\CD\13745420 cases_27\NNS\7283608 (_28\-LRB-\1740 28_29\CD\13745420 %_30\NN\1740 )_31\-RRB-\1740 both_32\CC\1740 skin_33\NN\5237755 test_34\NN\5798043 and_35\CC\1740 rast_36\NN\1740 for_37\IN\1740 <e1>ax</e1>_38\NN\3265032 were_39\VBD\836236 negative_40\JJ\1740 ._41\.\1740
D000658_D004342 CID we_0\PRP\1740 describe_1\VBP\1001294 the_2\DT\1740 largest_3\JJS\1740 group_4\NN\2137 of_5\IN\1740 <e2><e1>ax-allergic</e1></e2>_6\JJ\1740 patients_7\NNS\9898892 who_8\WP\8299493 have_9\VBP\2108377 tolerated_10\VBN\802318 pg_11\NN\1740 reported_12\VBD\831651 so_13\RB\1740 far_14\RB\1740 ._15\.\1740
D047090_D004342 NONE a_0\DT\13649268 large_1\JJ\1740 group_2\NN\2137 of_3\IN\1740 patients_4\NNS\9898892 with_5\IN\1740 suspected_6\VBN\916909 <e2>allergic_7\JJ\1740 reactions</e2>_8\NNS\13446390 to_9\TO\1740 <e1>beta-lactam</e1>_10\NN\1740 antibiotics_11\NNS\2716205 was_12\VBD\836236 evaluated_13\VBN\670261 ._14\.\1740
D047090_D004342 NONE a_0\DT\13649268 detailed_1\JJ\1740 clinical_2\JJ\1740 history_3\NN\15120823 ,_4\,\1740 together_5\RB\1740 with_6\IN\1740 skin_7\NN\5237755 tests_8\NNS\5798043 ,_9\,\1740 rast_10\NN\1740 (_11\-LRB-\1740 radioallergosorbent_12\JJ\1740 test_13\NN\5798043 )_14\-RRB-\1740 ,_15\,\1740 and_16\CC\1740 controlled_17\VBN\2422663 challenge_18\NN\13927383 tests_19\NNS\5798043 ,_20\,\1740 was_21\VBD\836236 used_22\VBN\1156834 to_23\TO\1740 establish_24\VB\2426171 whether_25\IN\1740 patients_26\NNS\9898892 <e2>allergic</e2>_27\JJ\1740 to_28\TO\1740 <e1>beta-lactam</e1>_29\JJ\1740 antibiotics_30\NNS\2716205 had_31\VBD\2108377 selective_32\JJ\1740 immediate_33\JJ\1740 allergic_34\JJ\1740 responses_35\NNS\11410625 to_36\TO\1740 amoxicillin_37\NN\3910033 (_38\-LRB-\1740 ax_39\NN\3265032 )_40\-RRB-\1740 or_41\CC\3541091 were_42\VBD\836236 cross-reacting_43\JJ\1740 with_44\IN\1740 other_45\JJ\1740 penicillin_46\NN\2716866 derivatives_47\NNS\5802185 ._48\.\1740
D047090_D004342 NONE a_0\DT\13649268 detailed_1\JJ\1740 clinical_2\JJ\1740 history_3\NN\15120823 ,_4\,\1740 together_5\RB\1740 with_6\IN\1740 skin_7\NN\5237755 tests_8\NNS\5798043 ,_9\,\1740 rast_10\NN\1740 (_11\-LRB-\1740 radioallergosorbent_12\JJ\1740 test_13\NN\5798043 )_14\-RRB-\1740 ,_15\,\1740 and_16\CC\1740 controlled_17\VBN\2422663 challenge_18\NN\13927383 tests_19\NNS\5798043 ,_20\,\1740 was_21\VBD\836236 used_22\VBN\1156834 to_23\TO\1740 establish_24\VB\2426171 whether_25\IN\1740 patients_26\NNS\9898892 allergic_27\JJ\1740 to_28\TO\1740 <e1>beta-lactam</e1>_29\JJ\1740 antibiotics_30\NNS\2716205 had_31\VBD\2108377 selective_32\JJ\1740 immediate_33\JJ\1740 <e2>allergic</e2>_34\JJ\1740 responses_35\NNS\11410625 to_36\TO\1740 amoxicillin_37\NN\3910033 (_38\-LRB-\1740 ax_39\NN\3265032 )_40\-RRB-\1740 or_41\CC\3541091 were_42\VBD\836236 cross-reacting_43\JJ\1740 with_44\IN\1740 other_45\JJ\1740 penicillin_46\NN\2716866 derivatives_47\NNS\5802185 ._48\.\1740
D047090_D004342 NONE a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 177_3\CD\1740 patients_4\NNS\9898892 were_5\VBD\836236 diagnosed_6\VBN\644583 as_7\IN\14622893 <e2>allergic</e2>_8\JJ\1740 to_9\TO\1740 <e1>beta-lactam</e1>_10\JJ\1740 antibiotics_11\NNS\2716205 ._12\.\1740
D010406_D004342 NONE a_0\DT\13649268 detailed_1\JJ\1740 clinical_2\JJ\1740 history_3\NN\15120823 ,_4\,\1740 together_5\RB\1740 with_6\IN\1740 skin_7\NN\5237755 tests_8\NNS\5798043 ,_9\,\1740 rast_10\NN\1740 (_11\-LRB-\1740 radioallergosorbent_12\JJ\1740 test_13\NN\5798043 )_14\-RRB-\1740 ,_15\,\1740 and_16\CC\1740 controlled_17\VBN\2422663 challenge_18\NN\13927383 tests_19\NNS\5798043 ,_20\,\1740 was_21\VBD\836236 used_22\VBN\1156834 to_23\TO\1740 establish_24\VB\2426171 whether_25\IN\1740 patients_26\NNS\9898892 <e2>allergic</e2>_27\JJ\1740 to_28\TO\1740 beta-lactam_29\JJ\1740 antibiotics_30\NNS\2716205 had_31\VBD\2108377 selective_32\JJ\1740 immediate_33\JJ\1740 allergic_34\JJ\1740 responses_35\NNS\11410625 to_36\TO\1740 amoxicillin_37\NN\3910033 (_38\-LRB-\1740 ax_39\NN\3265032 )_40\-RRB-\1740 or_41\CC\3541091 were_42\VBD\836236 cross-reacting_43\JJ\1740 with_44\IN\1740 other_45\JJ\1740 <e1>penicillin</e1>_46\NN\2716866 derivatives_47\NNS\5802185 ._48\.\1740
D010406_D004342 NONE a_0\DT\13649268 detailed_1\JJ\1740 clinical_2\JJ\1740 history_3\NN\15120823 ,_4\,\1740 together_5\RB\1740 with_6\IN\1740 skin_7\NN\5237755 tests_8\NNS\5798043 ,_9\,\1740 rast_10\NN\1740 (_11\-LRB-\1740 radioallergosorbent_12\JJ\1740 test_13\NN\5798043 )_14\-RRB-\1740 ,_15\,\1740 and_16\CC\1740 controlled_17\VBN\2422663 challenge_18\NN\13927383 tests_19\NNS\5798043 ,_20\,\1740 was_21\VBD\836236 used_22\VBN\1156834 to_23\TO\1740 establish_24\VB\2426171 whether_25\IN\1740 patients_26\NNS\9898892 allergic_27\JJ\1740 to_28\TO\1740 beta-lactam_29\JJ\1740 antibiotics_30\NNS\2716205 had_31\VBD\2108377 selective_32\JJ\1740 immediate_33\JJ\1740 <e2>allergic</e2>_34\JJ\1740 responses_35\NNS\11410625 to_36\TO\1740 amoxicillin_37\NN\3910033 (_38\-LRB-\1740 ax_39\NN\3265032 )_40\-RRB-\1740 or_41\CC\3541091 were_42\VBD\836236 cross-reacting_43\JJ\1740 with_44\IN\1740 other_45\JJ\1740 <e1>penicillin</e1>_46\NN\2716866 derivatives_47\NNS\5802185 ._48\.\1740
D010400_D004342 NONE we_0\PRP\1740 selected_1\VBD\697589 the_2\DT\1740 54_3\CD\1740 (_4\-LRB-\1740 30.5_5\CD\1740 %_6\NN\1740 )_7\-RRB-\1740 cases_8\NNS\7283608 of_9\IN\1740 immediate_10\JJ\1740 ax_11\NN\3265032 <e2>allergy</e2>_12\NN\14533203 with_13\IN\1740 good_14\JJ\1740 tolerance_15\NN\5032565 of_16\IN\1740 <e1>pg</e1>_17\NN\1740 ._18\.\1740
D010400_D004342 NONE we_0\PRP\1740 describe_1\VBP\1001294 the_2\DT\1740 largest_3\JJS\1740 group_4\NN\2137 of_5\IN\1740 <e2>ax-allergic</e2>_6\JJ\1740 patients_7\NNS\9898892 who_8\WP\8299493 have_9\VBP\2108377 tolerated_10\VBN\802318 <e1>pg</e1>_11\NN\1740 reported_12\VBD\831651 so_13\RB\1740 far_14\RB\1740 ._15\.\1740
-1_D007645 NONE all_0\PDT\1740 the_1\DT\1740 patients_2\NNS\9898892 were_3\VBD\836236 skin_4\NN\5237755 test_5\NN\5798043 negative_6\JJ\1740 to_7\TO\1740 <e1>bpo</e1>_8\NN\1740 ;_9\:\1740 49_10\CD\1740 of_11\IN\1740 51_12\CD\1740 (_13\-LRB-\1740 96_14\CD\1740 %_15\NN\1740 )_16\-RRB-\1740 were_17\VBD\836236 also_18\RB\1740 negative_19\JJ\1740 to_20\TO\1740 <e2>mdm</e2>_21\NN\1740 ,_22\,\1740 and_23\CC\1740 44_24\CD\1740 of_25\IN\1740 46_26\CD\1740 (_27\-LRB-\1740 96_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 to_31\TO\1740 pg_32\NN\1740 ._33\.\1740
D010400_D007645 NONE all_0\PDT\1740 the_1\DT\1740 patients_2\NNS\9898892 were_3\VBD\836236 skin_4\NN\5237755 test_5\NN\5798043 negative_6\JJ\1740 to_7\TO\1740 bpo_8\NN\1740 ;_9\:\1740 49_10\CD\1740 of_11\IN\1740 51_12\CD\1740 (_13\-LRB-\1740 96_14\CD\1740 %_15\NN\1740 )_16\-RRB-\1740 were_17\VBD\836236 also_18\RB\1740 negative_19\JJ\1740 to_20\TO\1740 <e2>mdm</e2>_21\NN\1740 ,_22\,\1740 and_23\CC\1740 44_24\CD\1740 of_25\IN\1740 46_26\CD\1740 (_27\-LRB-\1740 96_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 to_31\TO\1740 <e1>pg</e1>_32\NN\1740 ._33\.\1740
11807648
D014148_D004827 NONE <e2>epileptic_0\JJ\1740 seizures</e2>_1\NNS\14081375 following_2\VBG\1835496 cortical_3\JJ\1740 application_4\NN\947128 of_5\IN\1740 fibrin_6\NN\14728724 sealants_7\NNS\14705533 containing_8\VBG\2632940 <e1>tranexamic_9\JJ\1740 acid</e1>_10\NN\14818238 in_11\IN\13603305 rats_12\NNS\2329401 ._13\.\1740
D014148_D004827 NONE however_0\RB\1740 ,_1\,\1740 <e1>tamca</e1>_2\NN\1740 has_3\VBZ\2108377 been_4\VBN\836236 shown_5\VBN\2137132 to_6\TO\1740 cause_7\VB\1617192 <e2>epileptic_8\JJ\1740 seizures</e2>_9\NNS\14081375 ._10\.\1740
D014148_D012640 CID we_0\PRP\1740 wanted_1\VBD\2604760 to_2\TO\1740 study_3\VB\630380 whether_4\IN\1740 <e1>tamca</e1>_5\NN\1740 retains_6\VBZ\2700867 its_7\PRP$\6125041 <e2>convulsive</e2>_8\JJ\1740 action_9\NN\30358 if_10\IN\1740 incorporated_11\VBN\1461328 into_12\IN\1740 a_13\DT\13649268 fs_14\NN\13714184 ._15\.\1740
D014148_D012640 CID findings_0\NNS\7951464 :_1\:\1740 fs_2\NN\13714184 containing_3\VBG\2632940 <e1>tamca</e1>_4\NN\1740 caused_5\VBD\1617192 paroxysmal_6\JJ\1740 brain_7\NN\5462674 activity_8\NN\30358 which_9\WDT\1740 was_10\VBD\836236 associated_11\VBN\628491 with_12\IN\1740 distinct_13\JJ\1740 <e2>convulsive</e2>_14\JJ\1740 behaviours_15\NNS\14006945 ._16\.\1740
D014148_D012640 CID the_0\DT\1740 degree_1\NN\4916342 of_2\IN\1740 these_3\DT\1740 <e2>seizures</e2>_4\NNS\14081375 increased_5\VBD\169651 with_6\IN\1740 increasing_7\VBG\169651 concentration_8\NN\4916342 of_9\IN\1740 <e1>tamca</e1>_10\NN\1740 ._11\.\1740
D014148_D012640 CID thus_0\RB\1740 ,_1\,\1740 fs_2\NN\13714184 containing_3\VBG\2632940 47.5_4\CD\1740 mg/ml_5\NN\1740 <e1>tamca</e1>_6\NN\1740 evoked_7\VBD\1617192 <e2>generalized_8\JJ\1740 seizures</e2>_9\NNS\14081375 in_10\IN\13603305 all_11\DT\1740 tested_12\VBN\670261 rats_13\NNS\2329401 (_14\-LRB-\1740 n=6_15\NN\1740 )_16\-RRB-\1740 while_17\IN\15122231 the_18\DT\1740 lowest_19\JJS\1740 concentration_20\NN\4916342 of_21\IN\1740 tamca_22\NN\1740 (_23\-LRB-\1740 0.5_24\CD\1740 mg/ml_25\NN\1740 )_26\-RRB-\1740 only_27\RB\1740 evoked_28\VBD\1617192 brief_29\JJ\1740 episodes_30\NNS\7283608 of_31\IN\1740 jerk-correlated_32\JJ\1740 convulsive_33\JJ\1740 potentials_34\NNS\14481929 in_35\IN\13603305 1_36\CD\13741022 of_37\IN\1740 6_38\CD\13741022 rats_39\NNS\2329401 ._40\.\1740
D014148_D012640 CID thus_0\RB\1740 ,_1\,\1740 fs_2\NN\13714184 containing_3\VBG\2632940 47.5_4\CD\1740 mg/ml_5\NN\1740 <e1>tamca</e1>_6\NN\1740 evoked_7\VBD\1617192 generalized_8\JJ\1740 seizures_9\NNS\14081375 in_10\IN\13603305 all_11\DT\1740 tested_12\VBN\670261 rats_13\NNS\2329401 (_14\-LRB-\1740 n=6_15\NN\1740 )_16\-RRB-\1740 while_17\IN\15122231 the_18\DT\1740 lowest_19\JJS\1740 concentration_20\NN\4916342 of_21\IN\1740 tamca_22\NN\1740 (_23\-LRB-\1740 0.5_24\CD\1740 mg/ml_25\NN\1740 )_26\-RRB-\1740 only_27\RB\1740 evoked_28\VBD\1617192 brief_29\JJ\1740 episodes_30\NNS\7283608 of_31\IN\1740 jerk-correlated_32\JJ\1740 <e2>convulsive</e2>_33\JJ\1740 potentials_34\NNS\14481929 in_35\IN\13603305 1_36\CD\13741022 of_37\IN\1740 6_38\CD\13741022 rats_39\NNS\2329401 ._40\.\1740
D014148_D012640 CID thus_0\RB\1740 ,_1\,\1740 fs_2\NN\13714184 containing_3\VBG\2632940 47.5_4\CD\1740 mg/ml_5\NN\1740 tamca_6\NN\1740 evoked_7\VBD\1617192 <e2>generalized_8\JJ\1740 seizures</e2>_9\NNS\14081375 in_10\IN\13603305 all_11\DT\1740 tested_12\VBN\670261 rats_13\NNS\2329401 (_14\-LRB-\1740 n=6_15\NN\1740 )_16\-RRB-\1740 while_17\IN\15122231 the_18\DT\1740 lowest_19\JJS\1740 concentration_20\NN\4916342 of_21\IN\1740 <e1>tamca</e1>_22\NN\1740 (_23\-LRB-\1740 0.5_24\CD\1740 mg/ml_25\NN\1740 )_26\-RRB-\1740 only_27\RB\1740 evoked_28\VBD\1617192 brief_29\JJ\1740 episodes_30\NNS\7283608 of_31\IN\1740 jerk-correlated_32\JJ\1740 convulsive_33\JJ\1740 potentials_34\NNS\14481929 in_35\IN\13603305 1_36\CD\13741022 of_37\IN\1740 6_38\CD\13741022 rats_39\NNS\2329401 ._40\.\1740
D014148_D012640 CID thus_0\RB\1740 ,_1\,\1740 fs_2\NN\13714184 containing_3\VBG\2632940 47.5_4\CD\1740 mg/ml_5\NN\1740 tamca_6\NN\1740 evoked_7\VBD\1617192 generalized_8\JJ\1740 seizures_9\NNS\14081375 in_10\IN\13603305 all_11\DT\1740 tested_12\VBN\670261 rats_13\NNS\2329401 (_14\-LRB-\1740 n=6_15\NN\1740 )_16\-RRB-\1740 while_17\IN\15122231 the_18\DT\1740 lowest_19\JJS\1740 concentration_20\NN\4916342 of_21\IN\1740 <e1>tamca</e1>_22\NN\1740 (_23\-LRB-\1740 0.5_24\CD\1740 mg/ml_25\NN\1740 )_26\-RRB-\1740 only_27\RB\1740 evoked_28\VBD\1617192 brief_29\JJ\1740 episodes_30\NNS\7283608 of_31\IN\1740 jerk-correlated_32\JJ\1740 <e2>convulsive</e2>_33\JJ\1740 potentials_34\NNS\14481929 in_35\IN\13603305 1_36\CD\13741022 of_37\IN\1740 6_38\CD\13741022 rats_39\NNS\2329401 ._40\.\1740
D014148_D012640 CID interpretation_0\NN\5926676 :_1\:\1740 <e1>tranexamic_2\JJ\1740 acid</e1>_3\NN\14818238 retains_4\VBZ\2700867 its_5\PRP$\6125041 <e2>convulsive</e2>_6\JJ\1740 action_7\NN\30358 within_8\IN\1740 fs_9\NN\13714184 ._10\.\1740
3101906
D007654_D003643 NONE in_0\IN\13603305 two_1\CD\13741022 of_2\IN\1740 the_3\DT\1740 three_4\CD\13741022 <e2>deaths</e2>_5\NNS\7296428 probably_6\RB\1740 associated_7\VBN\628491 with_8\IN\1740 <e1>ketoconazole</e1>_9\NN\1740 treatment_10\NN\654885 the_11\DT\1740 drug_12\NN\14778436 had_13\VBD\2108377 been_14\VBN\836236 continued_15\VBN\2367363 after_16\IN\1740 the_17\DT\1740 onset_18\NN\7325190 of_19\IN\1740 jaundice_20\NN\14299637 and_21\CC\1740 other_22\JJ\1740 symptoms_23\NNS\5823932 of_24\IN\1740 hepatitis_25\NN\14127211 ._26\.\1740
D007654_D007565 CID in_0\IN\13603305 two_1\CD\13741022 of_2\IN\1740 the_3\DT\1740 three_4\CD\13741022 deaths_5\NNS\7296428 probably_6\RB\1740 associated_7\VBN\628491 with_8\IN\1740 <e1>ketoconazole</e1>_9\NN\1740 treatment_10\NN\654885 the_11\DT\1740 drug_12\NN\14778436 had_13\VBD\2108377 been_14\VBN\836236 continued_15\VBN\2367363 after_16\IN\1740 the_17\DT\1740 onset_18\NN\7325190 of_19\IN\1740 <e2>jaundice</e2>_20\NN\14299637 and_21\CC\1740 other_22\JJ\1740 symptoms_23\NNS\5823932 of_24\IN\1740 hepatitis_25\NN\14127211 ._26\.\1740
D007654_D056486 CID in_0\IN\13603305 two_1\CD\13741022 of_2\IN\1740 the_3\DT\1740 three_4\CD\13741022 deaths_5\NNS\7296428 probably_6\RB\1740 associated_7\VBN\628491 with_8\IN\1740 <e1>ketoconazole</e1>_9\NN\1740 treatment_10\NN\654885 the_11\DT\1740 drug_12\NN\14778436 had_13\VBD\2108377 been_14\VBN\836236 continued_15\VBN\2367363 after_16\IN\1740 the_17\DT\1740 onset_18\NN\7325190 of_19\IN\1740 jaundice_20\NN\14299637 and_21\CC\1740 other_22\JJ\1740 symptoms_23\NNS\5823932 of_24\IN\1740 <e2>hepatitis</e2>_25\NN\14127211 ._26\.\1740
D007654_D056486 CID clinical_0\JJ\1740 and_1\CC\1740 biochemical_2\JJ\1740 monitoring_3\NN\879759 at_4\IN\14622893 regular_5\JJ\1740 intervals_6\NNS\33615 for_7\IN\1740 evidence_8\NN\5816287 of_9\IN\1740 <e2>hepatitis</e2>_10\NN\14127211 is_11\VBZ\836236 advised_12\VBN\813978 during_13\IN\1740 long_14\JJ\1740 term_15\NN\6286395 treatment_16\NN\654885 with_17\IN\1740 <e1>ketoconazole</e1>_18\NN\1740 to_19\TO\1740 prevent_20\VB\1740 possible_21\JJ\1740 serious_22\JJ\1740 hepatic_23\JJ\1740 injury_24\NN\14052046 ._25\.\1740
D007654_D056486 CID clinical_0\JJ\1740 and_1\CC\1740 biochemical_2\JJ\1740 monitoring_3\NN\879759 at_4\IN\14622893 regular_5\JJ\1740 intervals_6\NNS\33615 for_7\IN\1740 evidence_8\NN\5816287 of_9\IN\1740 hepatitis_10\NN\14127211 is_11\VBZ\836236 advised_12\VBN\813978 during_13\IN\1740 long_14\JJ\1740 term_15\NN\6286395 treatment_16\NN\654885 with_17\IN\1740 <e1>ketoconazole</e1>_18\NN\1740 to_19\TO\1740 prevent_20\VB\1740 possible_21\JJ\1740 serious_22\JJ\1740 <e2>hepatic_23\JJ\1740 injury</e2>_24\NN\14052046 ._25\.\1740
17244258
D003520_D003556 CID in_0\FW\13603305 vitro_1\FW\1740 characterization_2\NN\6724763 of_3\IN\1740 parasympathetic_4\JJ\1740 and_5\CC\1740 sympathetic_6\JJ\1740 responses_7\NNS\11410625 in_8\IN\13603305 <e1>cyclophosphamide-induced</e1>_9\JJ\1740 <e2>cystitis</e2>_10\NN\14566129 in_11\IN\13603305 the_12\DT\1740 rat_13\NN\2329401 ._14\.\1740
D003520_D003556 CID in_0\IN\13603305 <e1>cyclophosphamide-induced</e1>_1\JJ\1740 <e2>cystitis</e2>_2\NN\14566129 in_3\IN\13603305 the_4\DT\1740 rat_5\NN\2329401 ,_6\,\1740 detrusor_7\NN\1740 function_8\NN\13783581 is_9\VBZ\836236 impaired_10\JJ\1740 and_11\CC\1740 the_12\DT\1740 expression_13\NN\4679549 and_14\CC\1740 effects_15\NNS\13245626 of_16\IN\1740 muscarinic_17\NN\1740 receptors_18\NNS\5225602 altered_19\VBN\126264 ._20\.\1740
26094
D008750_D003866 CID this_0\DT\1740 was_1\VBD\836236 accounted_2\VBN\2604760 for_3\IN\1740 by_4\IN\1740 a_5\DT\13649268 significant_6\JJ\1740 number_7\NN\5107765 of_8\IN\1740 <e2>depressions</e2>_9\NNS\14373582 occurring_10\VBG\2623529 in_11\IN\13603305 <e1>methyl_12\JJ\1740 dopa</e1>_13\NN\14601829 treated_14\VBN\2376958 patients_15\NNS\9898892 with_16\IN\1740 psychiatric_17\JJ\1740 histories_18\NNS\15120823 ._19\.\1740
D008750_D001523 NONE this_0\DT\1740 was_1\VBD\836236 accounted_2\VBN\2604760 for_3\IN\1740 by_4\IN\1740 a_5\DT\13649268 significant_6\JJ\1740 number_7\NN\5107765 of_8\IN\1740 depressions_9\NNS\14373582 occurring_10\VBG\2623529 in_11\IN\13603305 <e1>methyl_12\JJ\1740 dopa</e1>_13\NN\14601829 treated_14\VBN\2376958 patients_15\NNS\9898892 with_16\IN\1740 <e2>psychiatric</e2>_17\JJ\1740 histories_18\NNS\15120823 ._19\.\1740
1428568
D013999_D005901 NONE eight_0\CD\13741022 <e2>glaucomatous</e2>_1\JJ\1740 patients_2\NNS\9898892 chronically_3\RB\1740 treated_4\VBN\2376958 with_5\IN\1740 <e1>timolol</e1>_6\JJ\1740 0.5%/12h_7\NN\1740 ,_8\,\1740 suffering_9\VBG\2110220 from_10\IN\1740 depression_11\NN\14373582 diagnosed_12\VBN\644583 through_13\IN\1740 dms-iii-r_14\NN\1740 criteria_15\NNS\13577171 ,_16\,\1740 were_17\VBD\836236 included_18\VBN\690614 in_19\IN\13603305 the_20\DT\1740 study_21\NN\635850 ._22\.\1740
D013999_D003866 CID eight_0\CD\13741022 glaucomatous_1\JJ\1740 patients_2\NNS\9898892 chronically_3\RB\1740 treated_4\VBN\2376958 with_5\IN\1740 <e1>timolol</e1>_6\JJ\1740 0.5%/12h_7\NN\1740 ,_8\,\1740 suffering_9\VBG\2110220 from_10\IN\1740 <e2>depression</e2>_11\NN\14373582 diagnosed_12\VBN\644583 through_13\IN\1740 dms-iii-r_14\NN\1740 criteria_15\NNS\13577171 ,_16\,\1740 were_17\VBD\836236 included_18\VBN\690614 in_19\IN\13603305 the_20\DT\1740 study_21\NN\635850 ._22\.\1740
D013999_D003866 CID in_0\IN\13603305 a_1\DT\13649268 double_2\JJ\1740 blind_3\JJ\1740 cross-over_4\JJ\1740 study_5\NN\635850 with_6\IN\1740 control_7\NN\5190804 group_8\NN\2137 ,_9\,\1740 the_10\DT\1740 patients_11\NNS\9898892 under_12\IN\1740 <e1>timolol</e1>_13\JJ\1740 treatment_14\NN\654885 presented_15\VBD\2137132 higher_16\JJR\1740 <e2>depression</e2>_17\NN\14373582 values_18\NNS\5941423 measured_19\VBN\697589 through_20\IN\1740 the_21\DT\1740 beck_22\NNP\6876309 and_23\CC\1740 the_24\DT\1740 zung-conde_25\NNP\1740 scales_26\NNS\7260623 (_27\-LRB-\1740 p_28\NN\14622893 <_29\XX\1740 0.001_30\CD\1740 vs_31\CC\13634784 control_32\NN\5190804 )_33\-RRB-\1740 ._34\.\1740
D013999_D003866 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 betaxolol_4\NN\1740 could_5\MD\1740 be_6\VB\836236 less_7\JJR\1740 of_8\IN\1740 a_9\DT\13649268 <e2>depression-inducer</e2>_10\NN\1740 than_11\IN\1740 <e1>timolol</e1>_12\CD\2832168 in_13\IN\13603305 predisposed_14\JJ\1740 patients_15\NNS\9898892 ._16\.\1740
D015784_D003866 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e1>betaxolol</e1>_4\NN\1740 could_5\MD\1740 be_6\VB\836236 less_7\JJR\1740 of_8\IN\1740 a_9\DT\13649268 <e2>depression-inducer</e2>_10\NN\1740 than_11\IN\1740 timolol_12\CD\2832168 in_13\IN\13603305 predisposed_14\JJ\1740 patients_15\NNS\9898892 ._16\.\1740
20722491
-1_D009369 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 <e1>fluoropyrimidines</e1>_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 5-fluorouracil_9\NN\1740 (_10\-LRB-\1740 5-fu_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 <e2>tumors</e2>_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
-1_D015179 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 <e1>fluoropyrimidines</e1>_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 5-fluorouracil_9\NN\1740 (_10\-LRB-\1740 5-fu_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 tumors_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 <e2>colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers</e2>_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
-1_D001943 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 <e1>fluoropyrimidines</e1>_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 5-fluorouracil_9\NN\1740 (_10\-LRB-\1740 5-fu_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 tumors_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 <e2>colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers</e2>_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
-1_D006258 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 <e1>fluoropyrimidines</e1>_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 5-fluorouracil_9\NN\1740 (_10\-LRB-\1740 5-fu_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 tumors_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 <e2>colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers</e2>_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
D005472_D009369 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 fluoropyrimidines_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 <e1>5-fluorouracil</e1>_9\NN\1740 (_10\-LRB-\1740 5-fu_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 <e2>tumors</e2>_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
D005472_D009369 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 fluoropyrimidines_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 5-fluorouracil_9\NN\1740 (_10\-LRB-\1740 <e1>5-fu</e1>_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 <e2>tumors</e2>_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
D005472_D015179 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 fluoropyrimidines_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 <e1>5-fluorouracil</e1>_9\NN\1740 (_10\-LRB-\1740 5-fu_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 tumors_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 <e2>colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers</e2>_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
D005472_D015179 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 fluoropyrimidines_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 5-fluorouracil_9\NN\1740 (_10\-LRB-\1740 <e1>5-fu</e1>_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 tumors_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 <e2>colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers</e2>_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
D005472_D001943 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 fluoropyrimidines_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 <e1>5-fluorouracil</e1>_9\NN\1740 (_10\-LRB-\1740 5-fu_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 tumors_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 <e2>colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers</e2>_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
D005472_D001943 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 fluoropyrimidines_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 5-fluorouracil_9\NN\1740 (_10\-LRB-\1740 <e1>5-fu</e1>_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 tumors_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 <e2>colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers</e2>_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
D005472_D006258 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 fluoropyrimidines_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 <e1>5-fluorouracil</e1>_9\NN\1740 (_10\-LRB-\1740 5-fu_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 tumors_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 <e2>colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers</e2>_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
D005472_D006258 NONE importance_0\NN\5138488 of_1\IN\1740 the_2\DT\1740 field_3\NN\8673395 :_4\:\1740 fluoropyrimidines_5\NNS\1740 ,_6\,\1740 in_7\IN\13603305 particular_8\JJ\1740 5-fluorouracil_9\NN\1740 (_10\-LRB-\1740 <e1>5-fu</e1>_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 mainstay_17\NN\10677713 of_18\IN\1740 treatment_19\NN\654885 for_20\IN\1740 several_21\JJ\1740 solid_22\JJ\1740 tumors_23\NNS\14234074 ,_24\,\1740 including_25\VBG\690614 <e2>colorectal_26\JJ\1740 ,_27\,\1740 breast_28\NN\5225090 and_29\CC\1740 head_30\NN\5225090 and_31\CC\1740 neck_32\NN\5225090 cancers</e2>_33\NNS\14239425 ,_34\,\1740 for_35\IN\1740 >_36\NNS\1740 40_37\CD\13745420 years_38\NNS\15144371 ._39\.\1740
C110904_D007674 NONE what_0\WP\1740 the_1\DT\1740 reader_2\NN\10557854 will_3\NN\5650329 gain_4\NNP\13576355 :_5\:\1740 the_6\DT\1740 reader_7\NN\10557854 will_8\MD\5650329 gain_9\VB\2238085 better_10\JJR\1740 insight_11\NN\5710020 into_12\IN\1740 the_13\DT\1740 safety_14\NN\13920835 of_15\IN\1740 <e1>capecitabine</e1>_16\NN\1740 in_17\IN\13603305 special_18\JJ\1740 populations_19\NNS\7942152 such_20\JJ\1740 as_21\IN\14622893 patients_22\NNS\9898892 with_23\IN\1740 advanced_24\JJ\1740 age_25\NN\4916342 ,_26\,\1740 <e2>renal_27\JJ\1740 and_28\CC\1740 kidney_29\NN\5333259 disease</e2>_30\NN\14061805 ._31\.\1740
C110904_D007674 NONE <e1>capecitabine</e1>_0\NNP\1740 has_1\VBZ\2108377 a_2\DT\13649268 well-established_3\JJ\1740 safety_4\NN\13920835 profile_5\NN\6999802 and_6\CC\1740 can_7\MD\3094503 be_8\VB\836236 given_9\VBN\2327200 safely_10\RB\1740 to_11\TO\1740 patients_12\NNS\9898892 with_13\IN\1740 advanced_14\JJ\1740 age_15\NN\4916342 ,_16\,\1740 <e2>hepatic_17\JJ\1740 and_18\CC\1740 renal_19\JJ\1740 dysfunctions</e2>_20\NNS\14204950 ._21\.\1740
C110904_D003967 CID the_0\DT\1740 most_1\RBS\1740 commonly_2\RB\1740 reported_3\VBD\831651 toxic_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>capecitabine</e1>_7\NN\1740 are_8\VBP\836236 <e2>diarrhea</e2>_9\NN\14299637 ,_10\,\1740 nausea_11\NN\14299637 ,_12\,\1740 vomiting_13\NN\116687 ,_14\,\1740 stomatitis_15\NN\14336539 and_16\CC\1740 hand-foot_17\JJ\1740 syndrome_18\NN\5870365 ._19\.\1740
C110904_D009325 CID the_0\DT\1740 most_1\RBS\1740 commonly_2\RB\1740 reported_3\VBD\831651 toxic_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>capecitabine</e1>_7\NN\1740 are_8\VBP\836236 diarrhea_9\NN\14299637 ,_10\,\1740 <e2>nausea</e2>_11\NN\14299637 ,_12\,\1740 vomiting_13\NN\116687 ,_14\,\1740 stomatitis_15\NN\14336539 and_16\CC\1740 hand-foot_17\JJ\1740 syndrome_18\NN\5870365 ._19\.\1740
C110904_D014839 CID the_0\DT\1740 most_1\RBS\1740 commonly_2\RB\1740 reported_3\VBD\831651 toxic_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>capecitabine</e1>_7\NN\1740 are_8\VBP\836236 diarrhea_9\NN\14299637 ,_10\,\1740 nausea_11\NN\14299637 ,_12\,\1740 <e2>vomiting</e2>_13\NN\116687 ,_14\,\1740 stomatitis_15\NN\14336539 and_16\CC\1740 hand-foot_17\JJ\1740 syndrome_18\NN\5870365 ._19\.\1740
C110904_D013280 CID the_0\DT\1740 most_1\RBS\1740 commonly_2\RB\1740 reported_3\VBD\831651 toxic_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>capecitabine</e1>_7\NN\1740 are_8\VBP\836236 diarrhea_9\NN\14299637 ,_10\,\1740 nausea_11\NN\14299637 ,_12\,\1740 vomiting_13\NN\116687 ,_14\,\1740 <e2>stomatitis</e2>_15\NN\14336539 and_16\CC\1740 hand-foot_17\JJ\1740 syndrome_18\NN\5870365 ._19\.\1740
C110904_D060831 CID the_0\DT\1740 most_1\RBS\1740 commonly_2\RB\1740 reported_3\VBD\831651 toxic_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>capecitabine</e1>_7\NN\1740 are_8\VBP\836236 diarrhea_9\NN\14299637 ,_10\,\1740 nausea_11\NN\14299637 ,_12\,\1740 vomiting_13\NN\116687 ,_14\,\1740 stomatitis_15\NN\14336539 and_16\CC\1740 <e2>hand-foot_17\JJ\1740 syndrome</e2>_18\NN\5870365 ._19\.\1740
C110904_D008107 NONE <e1>capecitabine</e1>_0\NNP\1740 has_1\VBZ\2108377 a_2\DT\13649268 well-established_3\JJ\1740 safety_4\NN\13920835 profile_5\NN\6999802 and_6\CC\1740 can_7\MD\3094503 be_8\VB\836236 given_9\VBN\2327200 safely_10\RB\1740 to_11\TO\1740 patients_12\NNS\9898892 with_13\IN\1740 advanced_14\JJ\1740 age_15\NN\4916342 ,_16\,\1740 <e2>hepatic_17\JJ\1740 and_18\CC\1740 renal_19\JJ\1740 dysfunctions</e2>_20\NNS\14204950 ._21\.\1740
9855119
D016559_D005922 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 main_3\JJ\1740 pathologic_4\JJ\1740 diagnoses_5\NNS\152018 (_6\-LRB-\1740 some_7\DT\1740 overlap_8\NN\5926676 )_9\-RRB-\1740 were_10\VBD\836236 acute_11\JJ\1740 rejection_12\NN\30358 (_13\-LRB-\1740 ar_14\NN\14622893 ;_15\:\1740 n_16\NN\14622893 =_17\JJ\1740 4_18\CD\13741022 )_19\-RRB-\1740 ,_20\,\1740 chronic_21\JJ\1740 rejection_22\NN\30358 (_23\-LRB-\1740 cr_24\NN\14625458 ;_25\:\1740 n=5_26\JJ\1740 )_27\-RRB-\1740 ,_28\,\1740 ar+cr_29\NN\1740 (_30\-LRB-\1740 n_31\NN\14622893 =_32\JJ\1740 4_33\CD\13741022 )_34\-RRB-\1740 ,_35\,\1740 recurrent_36\JJ\1740 <e2>iga_37\NN\15030481 nephropathy</e2>_38\NN\14573196 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 5_42\CD\13741022 )_43\-RRB-\1740 ,_44\,\1740 normal_45\JJ\1740 findings_46\NNS\7951464 (_47\-LRB-\1740 n_48\NN\14622893 =_49\JJ\1740 2_50\CD\13741022 )_51\-RRB-\1740 ,_52\,\1740 minimal-type_53\JJ\1740 chronic_54\JJ\1740 <e1>fk506</e1>_55\NN\1740 nephropathy_56\NN\14573196 (_57\-LRB-\1740 n_58\NN\14622893 =_59\JJ\1740 9_60\CD\13741022 )_61\-RRB-\1740 ,_62\,\1740 and_63\CC\1740 mild-type_64\JJ\1740 fk506_65\NN\1740 nephropathy_66\NN\14573196 (_67\-LRB-\1740 n_68\NN\14622893 =_69\JJ\1740 11_70\CD\13745420 )_71\-RRB-\1740 ._72\.\1740
D016559_D005922 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 main_3\JJ\1740 pathologic_4\JJ\1740 diagnoses_5\NNS\152018 (_6\-LRB-\1740 some_7\DT\1740 overlap_8\NN\5926676 )_9\-RRB-\1740 were_10\VBD\836236 acute_11\JJ\1740 rejection_12\NN\30358 (_13\-LRB-\1740 ar_14\NN\14622893 ;_15\:\1740 n_16\NN\14622893 =_17\JJ\1740 4_18\CD\13741022 )_19\-RRB-\1740 ,_20\,\1740 chronic_21\JJ\1740 rejection_22\NN\30358 (_23\-LRB-\1740 cr_24\NN\14625458 ;_25\:\1740 n=5_26\JJ\1740 )_27\-RRB-\1740 ,_28\,\1740 ar+cr_29\NN\1740 (_30\-LRB-\1740 n_31\NN\14622893 =_32\JJ\1740 4_33\CD\13741022 )_34\-RRB-\1740 ,_35\,\1740 recurrent_36\JJ\1740 <e2>iga_37\NN\15030481 nephropathy</e2>_38\NN\14573196 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 5_42\CD\13741022 )_43\-RRB-\1740 ,_44\,\1740 normal_45\JJ\1740 findings_46\NNS\7951464 (_47\-LRB-\1740 n_48\NN\14622893 =_49\JJ\1740 2_50\CD\13741022 )_51\-RRB-\1740 ,_52\,\1740 minimal-type_53\JJ\1740 chronic_54\JJ\1740 fk506_55\NN\1740 nephropathy_56\NN\14573196 (_57\-LRB-\1740 n_58\NN\14622893 =_59\JJ\1740 9_60\CD\13741022 )_61\-RRB-\1740 ,_62\,\1740 and_63\CC\1740 mild-type_64\JJ\1740 <e1>fk506</e1>_65\NN\1740 nephropathy_66\NN\14573196 (_67\-LRB-\1740 n_68\NN\14622893 =_69\JJ\1740 11_70\CD\13745420 )_71\-RRB-\1740 ._72\.\1740
D016559_D007674 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 main_3\JJ\1740 pathologic_4\JJ\1740 diagnoses_5\NNS\152018 (_6\-LRB-\1740 some_7\DT\1740 overlap_8\NN\5926676 )_9\-RRB-\1740 were_10\VBD\836236 acute_11\JJ\1740 rejection_12\NN\30358 (_13\-LRB-\1740 ar_14\NN\14622893 ;_15\:\1740 n_16\NN\14622893 =_17\JJ\1740 4_18\CD\13741022 )_19\-RRB-\1740 ,_20\,\1740 chronic_21\JJ\1740 rejection_22\NN\30358 (_23\-LRB-\1740 cr_24\NN\14625458 ;_25\:\1740 n=5_26\JJ\1740 )_27\-RRB-\1740 ,_28\,\1740 ar+cr_29\NN\1740 (_30\-LRB-\1740 n_31\NN\14622893 =_32\JJ\1740 4_33\CD\13741022 )_34\-RRB-\1740 ,_35\,\1740 recurrent_36\JJ\1740 iga_37\NN\15030481 nephropathy_38\NN\14573196 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 5_42\CD\13741022 )_43\-RRB-\1740 ,_44\,\1740 normal_45\JJ\1740 findings_46\NNS\7951464 (_47\-LRB-\1740 n_48\NN\14622893 =_49\JJ\1740 2_50\CD\13741022 )_51\-RRB-\1740 ,_52\,\1740 minimal-type_53\JJ\1740 chronic_54\JJ\1740 <e1>fk506</e1>_55\NN\1740 <e2>nephropathy</e2>_56\NN\14573196 (_57\-LRB-\1740 n_58\NN\14622893 =_59\JJ\1740 9_60\CD\13741022 )_61\-RRB-\1740 ,_62\,\1740 and_63\CC\1740 mild-type_64\JJ\1740 fk506_65\NN\1740 nephropathy_66\NN\14573196 (_67\-LRB-\1740 n_68\NN\14622893 =_69\JJ\1740 11_70\CD\13745420 )_71\-RRB-\1740 ._72\.\1740
D016559_D007674 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 main_3\JJ\1740 pathologic_4\JJ\1740 diagnoses_5\NNS\152018 (_6\-LRB-\1740 some_7\DT\1740 overlap_8\NN\5926676 )_9\-RRB-\1740 were_10\VBD\836236 acute_11\JJ\1740 rejection_12\NN\30358 (_13\-LRB-\1740 ar_14\NN\14622893 ;_15\:\1740 n_16\NN\14622893 =_17\JJ\1740 4_18\CD\13741022 )_19\-RRB-\1740 ,_20\,\1740 chronic_21\JJ\1740 rejection_22\NN\30358 (_23\-LRB-\1740 cr_24\NN\14625458 ;_25\:\1740 n=5_26\JJ\1740 )_27\-RRB-\1740 ,_28\,\1740 ar+cr_29\NN\1740 (_30\-LRB-\1740 n_31\NN\14622893 =_32\JJ\1740 4_33\CD\13741022 )_34\-RRB-\1740 ,_35\,\1740 recurrent_36\JJ\1740 iga_37\NN\15030481 nephropathy_38\NN\14573196 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 5_42\CD\13741022 )_43\-RRB-\1740 ,_44\,\1740 normal_45\JJ\1740 findings_46\NNS\7951464 (_47\-LRB-\1740 n_48\NN\14622893 =_49\JJ\1740 2_50\CD\13741022 )_51\-RRB-\1740 ,_52\,\1740 minimal-type_53\JJ\1740 chronic_54\JJ\1740 <e1>fk506</e1>_55\NN\1740 nephropathy_56\NN\14573196 (_57\-LRB-\1740 n_58\NN\14622893 =_59\JJ\1740 9_60\CD\13741022 )_61\-RRB-\1740 ,_62\,\1740 and_63\CC\1740 mild-type_64\JJ\1740 fk506_65\NN\1740 <e2>nephropathy</e2>_66\NN\14573196 (_67\-LRB-\1740 n_68\NN\14622893 =_69\JJ\1740 11_70\CD\13745420 )_71\-RRB-\1740 ._72\.\1740
D016559_D007674 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 main_3\JJ\1740 pathologic_4\JJ\1740 diagnoses_5\NNS\152018 (_6\-LRB-\1740 some_7\DT\1740 overlap_8\NN\5926676 )_9\-RRB-\1740 were_10\VBD\836236 acute_11\JJ\1740 rejection_12\NN\30358 (_13\-LRB-\1740 ar_14\NN\14622893 ;_15\:\1740 n_16\NN\14622893 =_17\JJ\1740 4_18\CD\13741022 )_19\-RRB-\1740 ,_20\,\1740 chronic_21\JJ\1740 rejection_22\NN\30358 (_23\-LRB-\1740 cr_24\NN\14625458 ;_25\:\1740 n=5_26\JJ\1740 )_27\-RRB-\1740 ,_28\,\1740 ar+cr_29\NN\1740 (_30\-LRB-\1740 n_31\NN\14622893 =_32\JJ\1740 4_33\CD\13741022 )_34\-RRB-\1740 ,_35\,\1740 recurrent_36\JJ\1740 iga_37\NN\15030481 nephropathy_38\NN\14573196 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 5_42\CD\13741022 )_43\-RRB-\1740 ,_44\,\1740 normal_45\JJ\1740 findings_46\NNS\7951464 (_47\-LRB-\1740 n_48\NN\14622893 =_49\JJ\1740 2_50\CD\13741022 )_51\-RRB-\1740 ,_52\,\1740 minimal-type_53\JJ\1740 chronic_54\JJ\1740 fk506_55\NN\1740 <e2>nephropathy</e2>_56\NN\14573196 (_57\-LRB-\1740 n_58\NN\14622893 =_59\JJ\1740 9_60\CD\13741022 )_61\-RRB-\1740 ,_62\,\1740 and_63\CC\1740 mild-type_64\JJ\1740 <e1>fk506</e1>_65\NN\1740 nephropathy_66\NN\14573196 (_67\-LRB-\1740 n_68\NN\14622893 =_69\JJ\1740 11_70\CD\13745420 )_71\-RRB-\1740 ._72\.\1740
D016559_D007674 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 main_3\JJ\1740 pathologic_4\JJ\1740 diagnoses_5\NNS\152018 (_6\-LRB-\1740 some_7\DT\1740 overlap_8\NN\5926676 )_9\-RRB-\1740 were_10\VBD\836236 acute_11\JJ\1740 rejection_12\NN\30358 (_13\-LRB-\1740 ar_14\NN\14622893 ;_15\:\1740 n_16\NN\14622893 =_17\JJ\1740 4_18\CD\13741022 )_19\-RRB-\1740 ,_20\,\1740 chronic_21\JJ\1740 rejection_22\NN\30358 (_23\-LRB-\1740 cr_24\NN\14625458 ;_25\:\1740 n=5_26\JJ\1740 )_27\-RRB-\1740 ,_28\,\1740 ar+cr_29\NN\1740 (_30\-LRB-\1740 n_31\NN\14622893 =_32\JJ\1740 4_33\CD\13741022 )_34\-RRB-\1740 ,_35\,\1740 recurrent_36\JJ\1740 iga_37\NN\15030481 nephropathy_38\NN\14573196 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 5_42\CD\13741022 )_43\-RRB-\1740 ,_44\,\1740 normal_45\JJ\1740 findings_46\NNS\7951464 (_47\-LRB-\1740 n_48\NN\14622893 =_49\JJ\1740 2_50\CD\13741022 )_51\-RRB-\1740 ,_52\,\1740 minimal-type_53\JJ\1740 chronic_54\JJ\1740 fk506_55\NN\1740 nephropathy_56\NN\14573196 (_57\-LRB-\1740 n_58\NN\14622893 =_59\JJ\1740 9_60\CD\13741022 )_61\-RRB-\1740 ,_62\,\1740 and_63\CC\1740 mild-type_64\JJ\1740 <e1>fk506</e1>_65\NN\1740 <e2>nephropathy</e2>_66\NN\14573196 (_67\-LRB-\1740 n_68\NN\14622893 =_69\JJ\1740 11_70\CD\13745420 )_71\-RRB-\1740 ._72\.\1740
D016559_D007674 NONE of_0\IN\1740 the_1\DT\1740 nonepisode_2\NN\1740 biopsies_3\NNS\5739043 ,_4\,\1740 7_5\CD\13741022 and_6\CC\1740 4_7\CD\13741022 biopsies_8\NNS\5739043 showed_9\VBD\2137132 minimal-type_10\JJ\1740 and_11\CC\1740 mild-type_12\JJ\1740 chronic_13\JJ\1740 <e1>fk506</e1>_14\NN\1740 <e2>nephropathy</e2>_15\NN\14573196 ,_16\,\1740 respectively_17\RB\1740 ._18\.\1740
D016559_D007674 NONE chronic_0\JJ\1740 <e1>fk506</e1>_1\NN\1740 <e2>nephropathy</e2>_2\NN\14573196 consisted_3\VBD\2603699 of_4\IN\1740 rough_5\JJ\1740 and_6\CC\1740 foamy_7\NN\1740 tubular_8\JJ\1740 vacuolization_9\NN\13920835 (_10\-LRB-\1740 5_11\CD\13741022 biopsies_12\NNS\5739043 )_13\-RRB-\1740 ,_14\,\1740 arteriolopathy_15\NN\1740 (_16\-LRB-\1740 angiodegeneration_17\NN\1740 of_18\IN\1740 the_19\DT\1740 arteriolar_20\JJ\1740 wall_21\NN\3894379 ;_22\:\1740 20_23\CD\13745420 biopsies_24\NNS\5739043 )_25\-RRB-\1740 ,_26\,\1740 focal_27\JJ\1740 segmental_28\JJ\1740 glomerulosclerosis_29\NN\1740 (_30\-LRB-\1740 4_31\CD\13741022 biopsies_32\NNS\5739043 )_33\-RRB-\1740 and_34\CC\1740 the_35\DT\1740 striped_36\JJ\1740 form_37\NN\6286395 of_38\IN\1740 interstitial_39\JJ\1740 fibrosis_40\NN\14204950 (_41\-LRB-\1740 11_42\CD\13745420 biopsies_43\NNS\5739043 )_44\-RRB-\1740 ._45\.\1740
D016559_D007674 NONE the_0\DT\1740 serum_1\NN\5397468 creatinine_2\NN\1740 levels_3\NNS\4916342 of_4\IN\1740 patients_5\NNS\9898892 in_6\IN\13603305 the_7\DT\1740 mild-type_8\JJ\1740 chronic_9\JJ\1740 <e1>fk506</e1>_10\NN\1740 <e2>nephropathy</e2>_11\NN\14573196 group_12\NN\2137 ,_13\,\1740 which_14\WDT\1740 included_15\VBD\690614 7_16\CD\13741022 episode_17\NN\7283608 biopsies_18\NNS\5739043 ,_19\,\1740 were_20\VBD\836236 statistically_21\RB\1740 higher_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 in_25\IN\13603305 the_26\DT\1740 minimum-type_27\JJ\1740 chronic_28\JJ\1740 fk506-nephropathy_29\JJ\1740 group_30\NN\2137 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 0.001_34\CD\1740 )_35\-RRB-\1740 ._36\.\1740
D016559_D007674 NONE the_0\DT\1740 serum_1\NN\5397468 creatinine_2\NN\1740 levels_3\NNS\4916342 of_4\IN\1740 patients_5\NNS\9898892 in_6\IN\13603305 the_7\DT\1740 mild-type_8\JJ\1740 chronic_9\JJ\1740 <e1>fk506</e1>_10\NN\1740 nephropathy_11\NN\14573196 group_12\NN\2137 ,_13\,\1740 which_14\WDT\1740 included_15\VBD\690614 7_16\CD\13741022 episode_17\NN\7283608 biopsies_18\NNS\5739043 ,_19\,\1740 were_20\VBD\836236 statistically_21\RB\1740 higher_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 in_25\IN\13603305 the_26\DT\1740 minimum-type_27\JJ\1740 chronic_28\JJ\1740 <e2>fk506-nephropathy</e2>_29\JJ\1740 group_30\NN\2137 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 0.001_34\CD\1740 )_35\-RRB-\1740 ._36\.\1740
D016559_D007674 NONE the_0\DT\1740 serum_1\NN\5397468 creatinine_2\NN\1740 levels_3\NNS\4916342 of_4\IN\1740 patients_5\NNS\9898892 in_6\IN\13603305 the_7\DT\1740 mild-type_8\JJ\1740 chronic_9\JJ\1740 fk506_10\NN\1740 <e2>nephropathy</e2>_11\NN\14573196 group_12\NN\2137 ,_13\,\1740 which_14\WDT\1740 included_15\VBD\690614 7_16\CD\13741022 episode_17\NN\7283608 biopsies_18\NNS\5739043 ,_19\,\1740 were_20\VBD\836236 statistically_21\RB\1740 higher_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 in_25\IN\13603305 the_26\DT\1740 minimum-type_27\JJ\1740 chronic_28\JJ\1740 <e1>fk506-nephropathy</e1>_29\JJ\1740 group_30\NN\2137 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 0.001_34\CD\1740 )_35\-RRB-\1740 ._36\.\1740
D016559_D007674 NONE the_0\DT\1740 serum_1\NN\5397468 creatinine_2\NN\1740 levels_3\NNS\4916342 of_4\IN\1740 patients_5\NNS\9898892 in_6\IN\13603305 the_7\DT\1740 mild-type_8\JJ\1740 chronic_9\JJ\1740 fk506_10\NN\1740 nephropathy_11\NN\14573196 group_12\NN\2137 ,_13\,\1740 which_14\WDT\1740 included_15\VBD\690614 7_16\CD\13741022 episode_17\NN\7283608 biopsies_18\NNS\5739043 ,_19\,\1740 were_20\VBD\836236 statistically_21\RB\1740 higher_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 in_25\IN\13603305 the_26\DT\1740 minimum-type_27\JJ\1740 chronic_28\JJ\1740 <e2><e1>fk506-nephropathy</e1></e2>_29\JJ\1740 group_30\NN\2137 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 0.001_34\CD\1740 )_35\-RRB-\1740 ._36\.\1740
D016559_D007674 NONE conclusions_0\NNS\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 demonstrates_4\VBZ\2137132 that_5\IN\1740 chronic_6\JJ\1740 <e1>fk506</e1>_7\NN\1740 <e2>nephropathy</e2>_8\NN\14573196 consists_9\VBZ\2603699 primarily_10\RB\1740 of_11\IN\1740 arteriolopathy_12\JJ\1740 manifesting_13\NN\1740 as_14\IN\14622893 insudative_15\JJ\1740 hyalinosis_16\NN\1740 of_17\IN\1740 the_18\DT\1740 arteriolar_19\JJ\1740 wall_20\NN\3894379 ,_21\,\1740 and_22\CC\1740 suggests_23\VBZ\1010118 that_24\IN\1740 mild-type_25\JJ\1740 chronic_26\JJ\1740 fk506_27\NN\1740 nephropathy_28\NN\14573196 is_29\VBZ\836236 a_30\DT\13649268 condition_31\NN\24720 which_32\WDT\1740 may_33\MD\15209706 lead_34\VB\1752884 to_35\TO\1740 deterioration_36\NN\14560612 of_37\IN\1740 renal_38\JJ\1740 allograft_39\NN\5582859 function_40\NN\13783581 ._41\.\1740
D016559_D007674 NONE conclusions_0\NNS\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 demonstrates_4\VBZ\2137132 that_5\IN\1740 chronic_6\JJ\1740 <e1>fk506</e1>_7\NN\1740 nephropathy_8\NN\14573196 consists_9\VBZ\2603699 primarily_10\RB\1740 of_11\IN\1740 arteriolopathy_12\JJ\1740 manifesting_13\NN\1740 as_14\IN\14622893 insudative_15\JJ\1740 hyalinosis_16\NN\1740 of_17\IN\1740 the_18\DT\1740 arteriolar_19\JJ\1740 wall_20\NN\3894379 ,_21\,\1740 and_22\CC\1740 suggests_23\VBZ\1010118 that_24\IN\1740 mild-type_25\JJ\1740 chronic_26\JJ\1740 fk506_27\NN\1740 <e2>nephropathy</e2>_28\NN\14573196 is_29\VBZ\836236 a_30\DT\13649268 condition_31\NN\24720 which_32\WDT\1740 may_33\MD\15209706 lead_34\VB\1752884 to_35\TO\1740 deterioration_36\NN\14560612 of_37\IN\1740 renal_38\JJ\1740 allograft_39\NN\5582859 function_40\NN\13783581 ._41\.\1740
D016559_D007674 NONE conclusions_0\NNS\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 demonstrates_4\VBZ\2137132 that_5\IN\1740 chronic_6\JJ\1740 fk506_7\NN\1740 <e2>nephropathy</e2>_8\NN\14573196 consists_9\VBZ\2603699 primarily_10\RB\1740 of_11\IN\1740 arteriolopathy_12\JJ\1740 manifesting_13\NN\1740 as_14\IN\14622893 insudative_15\JJ\1740 hyalinosis_16\NN\1740 of_17\IN\1740 the_18\DT\1740 arteriolar_19\JJ\1740 wall_20\NN\3894379 ,_21\,\1740 and_22\CC\1740 suggests_23\VBZ\1010118 that_24\IN\1740 mild-type_25\JJ\1740 chronic_26\JJ\1740 <e1>fk506</e1>_27\NN\1740 nephropathy_28\NN\14573196 is_29\VBZ\836236 a_30\DT\13649268 condition_31\NN\24720 which_32\WDT\1740 may_33\MD\15209706 lead_34\VB\1752884 to_35\TO\1740 deterioration_36\NN\14560612 of_37\IN\1740 renal_38\JJ\1740 allograft_39\NN\5582859 function_40\NN\13783581 ._41\.\1740
D016559_D007674 NONE conclusions_0\NNS\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 demonstrates_4\VBZ\2137132 that_5\IN\1740 chronic_6\JJ\1740 fk506_7\NN\1740 nephropathy_8\NN\14573196 consists_9\VBZ\2603699 primarily_10\RB\1740 of_11\IN\1740 arteriolopathy_12\JJ\1740 manifesting_13\NN\1740 as_14\IN\14622893 insudative_15\JJ\1740 hyalinosis_16\NN\1740 of_17\IN\1740 the_18\DT\1740 arteriolar_19\JJ\1740 wall_20\NN\3894379 ,_21\,\1740 and_22\CC\1740 suggests_23\VBZ\1010118 that_24\IN\1740 mild-type_25\JJ\1740 chronic_26\JJ\1740 <e1>fk506</e1>_27\NN\1740 <e2>nephropathy</e2>_28\NN\14573196 is_29\VBZ\836236 a_30\DT\13649268 condition_31\NN\24720 which_32\WDT\1740 may_33\MD\15209706 lead_34\VB\1752884 to_35\TO\1740 deterioration_36\NN\14560612 of_37\IN\1740 renal_38\JJ\1740 allograft_39\NN\5582859 function_40\NN\13783581 ._41\.\1740
D016559_D005923 CID chronic_0\JJ\1740 <e1>fk506</e1>_1\NN\1740 nephropathy_2\NN\14573196 consisted_3\VBD\2603699 of_4\IN\1740 rough_5\JJ\1740 and_6\CC\1740 foamy_7\NN\1740 tubular_8\JJ\1740 vacuolization_9\NN\13920835 (_10\-LRB-\1740 5_11\CD\13741022 biopsies_12\NNS\5739043 )_13\-RRB-\1740 ,_14\,\1740 arteriolopathy_15\NN\1740 (_16\-LRB-\1740 angiodegeneration_17\NN\1740 of_18\IN\1740 the_19\DT\1740 arteriolar_20\JJ\1740 wall_21\NN\3894379 ;_22\:\1740 20_23\CD\13745420 biopsies_24\NNS\5739043 )_25\-RRB-\1740 ,_26\,\1740 <e2>focal_27\JJ\1740 segmental_28\JJ\1740 glomerulosclerosis</e2>_29\NN\1740 (_30\-LRB-\1740 4_31\CD\13741022 biopsies_32\NNS\5739043 )_33\-RRB-\1740 and_34\CC\1740 the_35\DT\1740 striped_36\JJ\1740 form_37\NN\6286395 of_38\IN\1740 interstitial_39\JJ\1740 fibrosis_40\NN\14204950 (_41\-LRB-\1740 11_42\CD\13745420 biopsies_43\NNS\5739043 )_44\-RRB-\1740 ._45\.\1740
D016559_D005355 NONE chronic_0\JJ\1740 <e1>fk506</e1>_1\NN\1740 nephropathy_2\NN\14573196 consisted_3\VBD\2603699 of_4\IN\1740 rough_5\JJ\1740 and_6\CC\1740 foamy_7\NN\1740 tubular_8\JJ\1740 vacuolization_9\NN\13920835 (_10\-LRB-\1740 5_11\CD\13741022 biopsies_12\NNS\5739043 )_13\-RRB-\1740 ,_14\,\1740 arteriolopathy_15\NN\1740 (_16\-LRB-\1740 angiodegeneration_17\NN\1740 of_18\IN\1740 the_19\DT\1740 arteriolar_20\JJ\1740 wall_21\NN\3894379 ;_22\:\1740 20_23\CD\13745420 biopsies_24\NNS\5739043 )_25\-RRB-\1740 ,_26\,\1740 focal_27\JJ\1740 segmental_28\JJ\1740 glomerulosclerosis_29\NN\1740 (_30\-LRB-\1740 4_31\CD\13741022 biopsies_32\NNS\5739043 )_33\-RRB-\1740 and_34\CC\1740 the_35\DT\1740 striped_36\JJ\1740 form_37\NN\6286395 of_38\IN\1740 <e2>interstitial_39\JJ\1740 fibrosis</e2>_40\NN\14204950 (_41\-LRB-\1740 11_42\CD\13745420 biopsies_43\NNS\5739043 )_44\-RRB-\1740 ._45\.\1740
D003404_D007674 NONE the_0\DT\1740 serum_1\NN\5397468 <e1>creatinine</e1>_2\NN\1740 levels_3\NNS\4916342 of_4\IN\1740 patients_5\NNS\9898892 in_6\IN\13603305 the_7\DT\1740 mild-type_8\JJ\1740 chronic_9\JJ\1740 fk506_10\NN\1740 <e2>nephropathy</e2>_11\NN\14573196 group_12\NN\2137 ,_13\,\1740 which_14\WDT\1740 included_15\VBD\690614 7_16\CD\13741022 episode_17\NN\7283608 biopsies_18\NNS\5739043 ,_19\,\1740 were_20\VBD\836236 statistically_21\RB\1740 higher_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 in_25\IN\13603305 the_26\DT\1740 minimum-type_27\JJ\1740 chronic_28\JJ\1740 fk506-nephropathy_29\JJ\1740 group_30\NN\2137 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 0.001_34\CD\1740 )_35\-RRB-\1740 ._36\.\1740
D003404_D007674 NONE the_0\DT\1740 serum_1\NN\5397468 <e1>creatinine</e1>_2\NN\1740 levels_3\NNS\4916342 of_4\IN\1740 patients_5\NNS\9898892 in_6\IN\13603305 the_7\DT\1740 mild-type_8\JJ\1740 chronic_9\JJ\1740 fk506_10\NN\1740 nephropathy_11\NN\14573196 group_12\NN\2137 ,_13\,\1740 which_14\WDT\1740 included_15\VBD\690614 7_16\CD\13741022 episode_17\NN\7283608 biopsies_18\NNS\5739043 ,_19\,\1740 were_20\VBD\836236 statistically_21\RB\1740 higher_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 in_25\IN\13603305 the_26\DT\1740 minimum-type_27\JJ\1740 chronic_28\JJ\1740 <e2>fk506-nephropathy</e2>_29\JJ\1740 group_30\NN\2137 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 0.001_34\CD\1740 )_35\-RRB-\1740 ._36\.\1740
16755009
D003975_D000647 CID <e1>diazepam-</e1>_0\NN\1740 ,_1\,\1740 scopolamine-_2\NN\1740 and_3\CC\1740 ageing-induced_4\JJ\1740 <e2>amnesia</e2>_5\NN\5669934 served_6\VBD\2669789 as_7\IN\14622893 the_8\DT\1740 interoceptive_9\JJ\1740 behavioral_10\JJ\1740 models_11\NNS\5888929 ._12\.\1740
D003975_D000647 CID furthermore_0\RB\1740 ,_1\,\1740 dce_2\NN\1740 reversed_3\VBD\109660 the_4\DT\1740 <e2>amnesia</e2>_5\NN\5669934 induced_6\VBN\1627355 by_7\IN\1740 scopolamine_8\NN\14712692 (_9\-LRB-\1740 0.4_10\CD\1740 mg/kg_11\NN\1740 ,_12\,\1740 i.p._13\RB\1740 )_14\-RRB-\1740 and_15\CC\1740 <e1>diazepam</e1>_16\NN\2830852 (_17\-LRB-\1740 1_18\CD\13741022 mg/kg_19\NN\1740 ,_20\,\1740 i.p._21\RB\1740 )_22\-RRB-\1740 ._23\.\1740
D012601_D000647 CID diazepam-_0\NN\1740 ,_1\,\1740 <e1>scopolamine-</e1>_2\NN\1740 and_3\CC\1740 ageing-induced_4\JJ\1740 <e2>amnesia</e2>_5\NN\5669934 served_6\VBD\2669789 as_7\IN\14622893 the_8\DT\1740 interoceptive_9\JJ\1740 behavioral_10\JJ\1740 models_11\NNS\5888929 ._12\.\1740
D012601_D000647 CID furthermore_0\RB\1740 ,_1\,\1740 dce_2\NN\1740 reversed_3\VBD\109660 the_4\DT\1740 <e2>amnesia</e2>_5\NN\5669934 induced_6\VBN\1627355 by_7\IN\1740 <e1>scopolamine</e1>_8\NN\14712692 (_9\-LRB-\1740 0.4_10\CD\1740 mg/kg_11\NN\1740 ,_12\,\1740 i.p._13\RB\1740 )_14\-RRB-\1740 and_15\CC\1740 diazepam_16\NN\2830852 (_17\-LRB-\1740 1_18\CD\13741022 mg/kg_19\NN\1740 ,_20\,\1740 i.p._21\RB\1740 )_22\-RRB-\1740 ._23\.\1740
D010936_D000647 NONE furthermore_0\RB\1740 ,_1\,\1740 <e1>dce</e1>_2\NN\1740 reversed_3\VBD\109660 the_4\DT\1740 <e2>amnesia</e2>_5\NN\5669934 induced_6\VBN\1627355 by_7\IN\1740 scopolamine_8\NN\14712692 (_9\-LRB-\1740 0.4_10\CD\1740 mg/kg_11\NN\1740 ,_12\,\1740 i.p._13\RB\1740 )_14\-RRB-\1740 and_15\CC\1740 diazepam_16\NN\2830852 (_17\-LRB-\1740 1_18\CD\13741022 mg/kg_19\NN\1740 ,_20\,\1740 i.p._21\RB\1740 )_22\-RRB-\1740 ._23\.\1740
D010936_D003072 NONE therefore_0\RB\1740 ,_1\,\1740 <e1>dce</e1>_2\NN\1740 may_3\MD\15209706 prove_4\VB\2604760 to_5\TO\1740 be_6\VB\836236 a_7\DT\13649268 useful_8\JJ\1740 remedy_9\NN\258854 for_10\IN\1740 the_11\DT\1740 management_12\NN\1123598 of_13\IN\1740 <e2>cognitive_14\JJ\1740 dysfunctions</e2>_15\NNS\14204950 on_16\IN\1740 account_17\NN\6647206 of_18\IN\1740 its_19\PRP$\6125041 multifarious_20\JJ\1740 beneficial_21\JJ\1740 effects_22\NNS\13245626 such_23\JJ\1740 as_24\IN\14622893 ,_25\,\1740 memory_26\NN\5926676 improving_27\VBG\126264 property_28\NN\32613 ,_29\,\1740 cholesterol_30\NN\15058310 lowering_31\VBG\1850315 property_32\NN\32613 and_33\CC\1740 anticholinesterase_34\NN\3740161 activity_35\NN\30358 ._36\.\1740
D002784_D003072 NONE therefore_0\RB\1740 ,_1\,\1740 dce_2\NN\1740 may_3\MD\15209706 prove_4\VB\2604760 to_5\TO\1740 be_6\VB\836236 a_7\DT\13649268 useful_8\JJ\1740 remedy_9\NN\258854 for_10\IN\1740 the_11\DT\1740 management_12\NN\1123598 of_13\IN\1740 <e2>cognitive_14\JJ\1740 dysfunctions</e2>_15\NNS\14204950 on_16\IN\1740 account_17\NN\6647206 of_18\IN\1740 its_19\PRP$\6125041 multifarious_20\JJ\1740 beneficial_21\JJ\1740 effects_22\NNS\13245626 such_23\JJ\1740 as_24\IN\14622893 ,_25\,\1740 memory_26\NN\5926676 improving_27\VBG\126264 property_28\NN\32613 ,_29\,\1740 <e1>cholesterol</e1>_30\NN\15058310 lowering_31\VBG\1850315 property_32\NN\32613 and_33\CC\1740 anticholinesterase_34\NN\3740161 activity_35\NN\30358 ._36\.\1740
19843802
D004837_D006973 CID however_0\RB\1740 ,_1\,\1740 a_2\DT\13649268 bolus_3\NN\13899404 of_4\IN\1740 <e1>epinephrine</e1>_5\NN\14807929 injected_6\VBN\81072 through_7\IN\1740 an_8\DT\6697703 alternative_9\JJ\1740 catheter_10\NN\4493505 provoked_11\VBD\1617192 a_12\DT\13649268 <e2>hypertensive</e2>_13\JJ\1740 crisis_14\NN\14411243 ._15\.\1740
6534871
D007545_D009203 CID the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 exercise_3\NN\621627 on_4\IN\1740 the_5\DT\1740 severity_6\NN\5036394 of_7\IN\1740 <e1>isoproterenol-induced</e1>_8\JJ\1740 <e2>myocardial_9\JJ\1740 infarction</e2>_10\NN\14204950 were_11\VBD\836236 studied_12\VBN\630380 in_13\IN\13603305 female_14\JJ\1740 albino_15\NN\9606527 rats_16\NNS\2329401 of_17\IN\1740 20,40,60_18\CD\1740 and_19\CC\1740 80_20\CD\13745420 weeks_21\NNS\15113229 of_22\IN\1740 age_23\NN\4916342 ._24\.\1740
7449470
D004317_D066126 NONE late_0\RB\1740 ,_1\,\1740 late_2\JJ\1740 <e1>doxorubicin</e1>_3\NN\2716866 <e2>cardiotoxicity</e2>_4\NN\1740 ._5\.\1740
D004317_D066126 NONE <e2>cardiac_0\JJ\1740 toxicity</e2>_1\NN\13576101 is_2\VBZ\836236 a_3\DT\13649268 major_4\JJ\1740 complication_5\NN\1073995 which_6\WDT\1740 limits_7\VBZ\2510337 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>adriamycin</e1>_11\NN\1740 as_12\IN\14622893 a_13\DT\13649268 chemotherapeutic_14\JJ\1740 agent_15\NN\7347 ._16\.\1740
11419773
D002110_D001145 NONE <e1>caffeine-induced</e1>_0\JJ\1740 <e2>cardiac_1\JJ\1740 arrhythmia</e2>_2\NN\14103288 :_3\:\1740 an_4\DT\6697703 unrecognised_5\JJ\1740 danger_6\NN\13920835 of_7\IN\1740 healthfood_8\NN\1740 products_9\NNS\3076708 ._10\.\1740
D002110_D008945 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 25-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 pre-existing_6\JJ\1740 <e2>mitral_7\JJ\1740 valve_8\NN\5225602 prolapse</e2>_9\NN\14548343 who_10\WP\8299493 developed_11\VBD\1753788 intractable_12\JJ\1740 ventricular_13\JJ\1740 fibrillation_14\NN\14361664 after_15\IN\1740 consuming_16\VBG\1168468 a_17\DT\13649268 "_18\``\1740 natural_19\JJ\1740 energy_20\NN\11419404 "_21\''\1740 guarana_22\VBZ\1740 health_23\NN\14447525 drink_24\VBP\1156834 containing_25\VBG\2632940 a_26\DT\13649268 high_27\JJ\1740 concentration_28\NN\4916342 of_29\IN\1740 <e1>caffeine</e1>_30\NN\14712692 ._31\.\1740
D002110_D014693 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 25-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 pre-existing_6\JJ\1740 mitral_7\JJ\1740 valve_8\NN\5225602 prolapse_9\NN\14548343 who_10\WP\8299493 developed_11\VBD\1753788 intractable_12\JJ\1740 <e2>ventricular_13\JJ\1740 fibrillation</e2>_14\NN\14361664 after_15\IN\1740 consuming_16\VBG\1168468 a_17\DT\13649268 "_18\``\1740 natural_19\JJ\1740 energy_20\NN\11419404 "_21\''\1740 guarana_22\VBZ\1740 health_23\NN\14447525 drink_24\VBP\1156834 containing_25\VBG\2632940 a_26\DT\13649268 high_27\JJ\1740 concentration_28\NN\4916342 of_29\IN\1740 <e1>caffeine</e1>_30\NN\14712692 ._31\.\1740
6287825
D013831_D010523 CID <e2>peripheral_0\JJ\1740 neuropathy</e2>_1\NN\14204950 due_2\JJ\1740 to_3\TO\1740 nutritional_4\JJ\1740 deficiency_5\NN\14449126 of_6\IN\1740 <e1>thiamine</e1>_7\NN\15090742 and_8\CC\1740 riboflavin_9\NN\15090742 was_10\VBD\836236 common_11\JJ\1740 (_12\-LRB-\1740 10.1_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 presented_17\VBN\2137132 mainly_18\RB\1740 as_19\IN\14622893 sensory_20\JJ\1740 and_21\CC\1740 sensori-motor_22\JJ\1740 neuropathy_23\JJ\1740 ._24\.\1740
D013831_D010523 CID peripheral_0\JJ\1740 neuropathy_1\NN\14204950 due_2\JJ\1740 to_3\TO\1740 nutritional_4\JJ\1740 deficiency_5\NN\14449126 of_6\IN\1740 <e1>thiamine</e1>_7\NN\15090742 and_8\CC\1740 riboflavin_9\NN\15090742 was_10\VBD\836236 common_11\JJ\1740 (_12\-LRB-\1740 10.1_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 presented_17\VBN\2137132 mainly_18\RB\1740 as_19\IN\14622893 sensory_20\JJ\1740 and_21\CC\1740 <e2>sensori-motor_22\JJ\1740 neuropathy</e2>_23\JJ\1740 ._24\.\1740
D013831_D044342 NONE peripheral_0\JJ\1740 neuropathy_1\NN\14204950 due_2\JJ\1740 to_3\TO\1740 <e2>nutritional_4\JJ\1740 deficiency</e2>_5\NN\14449126 of_6\IN\1740 <e1>thiamine</e1>_7\NN\15090742 and_8\CC\1740 riboflavin_9\NN\15090742 was_10\VBD\836236 common_11\JJ\1740 (_12\-LRB-\1740 10.1_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 presented_17\VBN\2137132 mainly_18\RB\1740 as_19\IN\14622893 sensory_20\JJ\1740 and_21\CC\1740 sensori-motor_22\JJ\1740 neuropathy_23\JJ\1740 ._24\.\1740
D012256_D010523 CID <e2>peripheral_0\JJ\1740 neuropathy</e2>_1\NN\14204950 due_2\JJ\1740 to_3\TO\1740 nutritional_4\JJ\1740 deficiency_5\NN\14449126 of_6\IN\1740 thiamine_7\NN\15090742 and_8\CC\1740 <e1>riboflavin</e1>_9\NN\15090742 was_10\VBD\836236 common_11\JJ\1740 (_12\-LRB-\1740 10.1_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 presented_17\VBN\2137132 mainly_18\RB\1740 as_19\IN\14622893 sensory_20\JJ\1740 and_21\CC\1740 sensori-motor_22\JJ\1740 neuropathy_23\JJ\1740 ._24\.\1740
D012256_D010523 CID peripheral_0\JJ\1740 neuropathy_1\NN\14204950 due_2\JJ\1740 to_3\TO\1740 nutritional_4\JJ\1740 deficiency_5\NN\14449126 of_6\IN\1740 thiamine_7\NN\15090742 and_8\CC\1740 <e1>riboflavin</e1>_9\NN\15090742 was_10\VBD\836236 common_11\JJ\1740 (_12\-LRB-\1740 10.1_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 presented_17\VBN\2137132 mainly_18\RB\1740 as_19\IN\14622893 sensory_20\JJ\1740 and_21\CC\1740 <e2>sensori-motor_22\JJ\1740 neuropathy</e2>_23\JJ\1740 ._24\.\1740
D012256_D044342 NONE peripheral_0\JJ\1740 neuropathy_1\NN\14204950 due_2\JJ\1740 to_3\TO\1740 <e2>nutritional_4\JJ\1740 deficiency</e2>_5\NN\14449126 of_6\IN\1740 thiamine_7\NN\15090742 and_8\CC\1740 <e1>riboflavin</e1>_9\NN\15090742 was_10\VBD\836236 common_11\JJ\1740 (_12\-LRB-\1740 10.1_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 presented_17\VBN\2137132 mainly_18\RB\1740 as_19\IN\14622893 sensory_20\JJ\1740 and_21\CC\1740 sensori-motor_22\JJ\1740 neuropathy_23\JJ\1740 ._24\.\1740
D007538_D009422 NONE <e1>isoniazid</e1>_0\NNP\2716205 was_1\VBD\836236 the_2\DT\1740 most_3\RBS\1740 frequent_4\JJ\1740 agent_5\NN\7347 in_6\IN\13603305 drug-induced_7\JJ\1740 <e2>neuropathy</e2>_8\JJ\1740 ._9\.\1740
19820426
C558899_D066126 NONE twin_0\JJ\1740 preterm_1\NN\1740 neonates_2\NNS\9827683 with_3\IN\1740 <e2>cardiac_4\JJ\1740 toxicity</e2>_5\NN\13576101 related_6\JJ\1740 to_7\TO\1740 <e1>lopinavir/ritonavir</e1>_8\NN\1740 therapy_9\NN\657604 ._10\.\1740
C558899_D006327 CID one_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 twins_3\NNS\14883206 developed_4\VBD\1753788 complete_5\JJ\1740 <e2>heart_6\NN\5919034 block</e2>_7\NN\21939 and_8\CC\1740 dilated_9\VBN\303465 cardiomyopathy_10\DT\14103288 related_11\JJ\1740 to_12\TO\1740 <e1>lopinavir/ritonavir</e1>_13\NN\1740 therapy_14\NN\657604 ,_15\,\1740 a_16\DT\13649268 boosted_17\JJ\1740 protease-inhibitor_18\JJ\1740 agent_19\NN\7347 ,_20\,\1740 while_21\IN\15122231 the_22\DT\1740 other_23\JJ\1740 twin_24\NN\10595164 developed_25\VBN\1753788 mild_26\JJ\1740 bradycardia_27\NN\14110674 ._28\.\1740
C558899_D002311 CID one_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 twins_3\NNS\14883206 developed_4\VBD\1753788 complete_5\JJ\1740 heart_6\NN\5919034 block_7\NN\21939 and_8\CC\1740 <e2>dilated_9\VBN\303465 cardiomyopathy</e2>_10\DT\14103288 related_11\JJ\1740 to_12\TO\1740 <e1>lopinavir/ritonavir</e1>_13\NN\1740 therapy_14\NN\657604 ,_15\,\1740 a_16\DT\13649268 boosted_17\JJ\1740 protease-inhibitor_18\JJ\1740 agent_19\NN\7347 ,_20\,\1740 while_21\IN\15122231 the_22\DT\1740 other_23\JJ\1740 twin_24\NN\10595164 developed_25\VBN\1753788 mild_26\JJ\1740 bradycardia_27\NN\14110674 ._28\.\1740
C558899_D001919 CID one_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 twins_3\NNS\14883206 developed_4\VBD\1753788 complete_5\JJ\1740 heart_6\NN\5919034 block_7\NN\21939 and_8\CC\1740 dilated_9\VBN\303465 cardiomyopathy_10\DT\14103288 related_11\JJ\1740 to_12\TO\1740 <e1>lopinavir/ritonavir</e1>_13\NN\1740 therapy_14\NN\657604 ,_15\,\1740 a_16\DT\13649268 boosted_17\JJ\1740 protease-inhibitor_18\JJ\1740 agent_19\NN\7347 ,_20\,\1740 while_21\IN\15122231 the_22\DT\1740 other_23\JJ\1740 twin_24\NN\10595164 developed_25\VBN\1753788 mild_26\JJ\1740 <e2>bradycardia</e2>_27\NN\14110674 ._28\.\1740
9766615
D003024_D001480 NONE the_0\DT\1740 newer_1\JJR\1740 atypical_2\JJ\1740 agents_3\NNS\7347 have_4\VBP\2108377 a_5\DT\13649268 lower_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>eps</e2>_9\NN\1740 ,_10\,\1740 but_11\CC\1740 are_12\VBP\836236 associated_13\VBN\628491 in_14\IN\13603305 varying_15\VBG\2666239 degrees_16\NNS\4916342 with_17\IN\1740 sedation_18\NN\14034177 ,_19\,\1740 cardiovascular_20\JJ\1740 effects_21\NNS\13245626 ,_22\,\1740 anticholinergic_23\JJ\1740 effects_24\NNS\13245626 ,_25\,\1740 weight_26\NN\5009170 gain_27\NN\13576355 ,_28\,\1740 sexual_29\JJ\1740 dysfunction_30\NN\14204950 ,_31\,\1740 hepatic_32\JJ\1740 effects_33\NNS\13245626 ,_34\,\1740 lowered_35\VBD\1850315 seizure_36\JJ\1740 threshold_37\NN\15265518 (_38\-LRB-\1740 primarily_39\RB\1740 <e1>clozapine</e1>_40\NN\3713736 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 agranulocytosis_44\NN\14189204 (_45\-LRB-\1740 clozapine_46\NN\3713736 only_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D003024_D001480 NONE the_0\DT\1740 newer_1\JJR\1740 atypical_2\JJ\1740 agents_3\NNS\7347 have_4\VBP\2108377 a_5\DT\13649268 lower_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>eps</e2>_9\NN\1740 ,_10\,\1740 but_11\CC\1740 are_12\VBP\836236 associated_13\VBN\628491 in_14\IN\13603305 varying_15\VBG\2666239 degrees_16\NNS\4916342 with_17\IN\1740 sedation_18\NN\14034177 ,_19\,\1740 cardiovascular_20\JJ\1740 effects_21\NNS\13245626 ,_22\,\1740 anticholinergic_23\JJ\1740 effects_24\NNS\13245626 ,_25\,\1740 weight_26\NN\5009170 gain_27\NN\13576355 ,_28\,\1740 sexual_29\JJ\1740 dysfunction_30\NN\14204950 ,_31\,\1740 hepatic_32\JJ\1740 effects_33\NNS\13245626 ,_34\,\1740 lowered_35\VBD\1850315 seizure_36\JJ\1740 threshold_37\NN\15265518 (_38\-LRB-\1740 primarily_39\RB\1740 clozapine_40\NN\3713736 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 agranulocytosis_44\NN\14189204 (_45\-LRB-\1740 <e1>clozapine</e1>_46\NN\3713736 only_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D003024_D015430 NONE the_0\DT\1740 newer_1\JJR\1740 atypical_2\JJ\1740 agents_3\NNS\7347 have_4\VBP\2108377 a_5\DT\13649268 lower_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 eps_9\NN\1740 ,_10\,\1740 but_11\CC\1740 are_12\VBP\836236 associated_13\VBN\628491 in_14\IN\13603305 varying_15\VBG\2666239 degrees_16\NNS\4916342 with_17\IN\1740 sedation_18\NN\14034177 ,_19\,\1740 cardiovascular_20\JJ\1740 effects_21\NNS\13245626 ,_22\,\1740 anticholinergic_23\JJ\1740 effects_24\NNS\13245626 ,_25\,\1740 <e2>weight_26\NN\5009170 gain</e2>_27\NN\13576355 ,_28\,\1740 sexual_29\JJ\1740 dysfunction_30\NN\14204950 ,_31\,\1740 hepatic_32\JJ\1740 effects_33\NNS\13245626 ,_34\,\1740 lowered_35\VBD\1850315 seizure_36\JJ\1740 threshold_37\NN\15265518 (_38\-LRB-\1740 primarily_39\RB\1740 <e1>clozapine</e1>_40\NN\3713736 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 agranulocytosis_44\NN\14189204 (_45\-LRB-\1740 clozapine_46\NN\3713736 only_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D003024_D015430 NONE the_0\DT\1740 newer_1\JJR\1740 atypical_2\JJ\1740 agents_3\NNS\7347 have_4\VBP\2108377 a_5\DT\13649268 lower_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 eps_9\NN\1740 ,_10\,\1740 but_11\CC\1740 are_12\VBP\836236 associated_13\VBN\628491 in_14\IN\13603305 varying_15\VBG\2666239 degrees_16\NNS\4916342 with_17\IN\1740 sedation_18\NN\14034177 ,_19\,\1740 cardiovascular_20\JJ\1740 effects_21\NNS\13245626 ,_22\,\1740 anticholinergic_23\JJ\1740 effects_24\NNS\13245626 ,_25\,\1740 <e2>weight_26\NN\5009170 gain</e2>_27\NN\13576355 ,_28\,\1740 sexual_29\JJ\1740 dysfunction_30\NN\14204950 ,_31\,\1740 hepatic_32\JJ\1740 effects_33\NNS\13245626 ,_34\,\1740 lowered_35\VBD\1850315 seizure_36\JJ\1740 threshold_37\NN\15265518 (_38\-LRB-\1740 primarily_39\RB\1740 clozapine_40\NN\3713736 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 agranulocytosis_44\NN\14189204 (_45\-LRB-\1740 <e1>clozapine</e1>_46\NN\3713736 only_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D003024_D012735 NONE the_0\DT\1740 newer_1\JJR\1740 atypical_2\JJ\1740 agents_3\NNS\7347 have_4\VBP\2108377 a_5\DT\13649268 lower_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 eps_9\NN\1740 ,_10\,\1740 but_11\CC\1740 are_12\VBP\836236 associated_13\VBN\628491 in_14\IN\13603305 varying_15\VBG\2666239 degrees_16\NNS\4916342 with_17\IN\1740 sedation_18\NN\14034177 ,_19\,\1740 cardiovascular_20\JJ\1740 effects_21\NNS\13245626 ,_22\,\1740 anticholinergic_23\JJ\1740 effects_24\NNS\13245626 ,_25\,\1740 weight_26\NN\5009170 gain_27\NN\13576355 ,_28\,\1740 <e2>sexual_29\JJ\1740 dysfunction</e2>_30\NN\14204950 ,_31\,\1740 hepatic_32\JJ\1740 effects_33\NNS\13245626 ,_34\,\1740 lowered_35\VBD\1850315 seizure_36\JJ\1740 threshold_37\NN\15265518 (_38\-LRB-\1740 primarily_39\RB\1740 <e1>clozapine</e1>_40\NN\3713736 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 agranulocytosis_44\NN\14189204 (_45\-LRB-\1740 clozapine_46\NN\3713736 only_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D003024_D012735 NONE the_0\DT\1740 newer_1\JJR\1740 atypical_2\JJ\1740 agents_3\NNS\7347 have_4\VBP\2108377 a_5\DT\13649268 lower_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 eps_9\NN\1740 ,_10\,\1740 but_11\CC\1740 are_12\VBP\836236 associated_13\VBN\628491 in_14\IN\13603305 varying_15\VBG\2666239 degrees_16\NNS\4916342 with_17\IN\1740 sedation_18\NN\14034177 ,_19\,\1740 cardiovascular_20\JJ\1740 effects_21\NNS\13245626 ,_22\,\1740 anticholinergic_23\JJ\1740 effects_24\NNS\13245626 ,_25\,\1740 weight_26\NN\5009170 gain_27\NN\13576355 ,_28\,\1740 <e2>sexual_29\JJ\1740 dysfunction</e2>_30\NN\14204950 ,_31\,\1740 hepatic_32\JJ\1740 effects_33\NNS\13245626 ,_34\,\1740 lowered_35\VBD\1850315 seizure_36\JJ\1740 threshold_37\NN\15265518 (_38\-LRB-\1740 primarily_39\RB\1740 clozapine_40\NN\3713736 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 agranulocytosis_44\NN\14189204 (_45\-LRB-\1740 <e1>clozapine</e1>_46\NN\3713736 only_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D003024_D012640 NONE the_0\DT\1740 newer_1\JJR\1740 atypical_2\JJ\1740 agents_3\NNS\7347 have_4\VBP\2108377 a_5\DT\13649268 lower_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 eps_9\NN\1740 ,_10\,\1740 but_11\CC\1740 are_12\VBP\836236 associated_13\VBN\628491 in_14\IN\13603305 varying_15\VBG\2666239 degrees_16\NNS\4916342 with_17\IN\1740 sedation_18\NN\14034177 ,_19\,\1740 cardiovascular_20\JJ\1740 effects_21\NNS\13245626 ,_22\,\1740 anticholinergic_23\JJ\1740 effects_24\NNS\13245626 ,_25\,\1740 weight_26\NN\5009170 gain_27\NN\13576355 ,_28\,\1740 sexual_29\JJ\1740 dysfunction_30\NN\14204950 ,_31\,\1740 hepatic_32\JJ\1740 effects_33\NNS\13245626 ,_34\,\1740 lowered_35\VBD\1850315 <e2>seizure</e2>_36\JJ\1740 threshold_37\NN\15265518 (_38\-LRB-\1740 primarily_39\RB\1740 <e1>clozapine</e1>_40\NN\3713736 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 agranulocytosis_44\NN\14189204 (_45\-LRB-\1740 clozapine_46\NN\3713736 only_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D003024_D012640 NONE the_0\DT\1740 newer_1\JJR\1740 atypical_2\JJ\1740 agents_3\NNS\7347 have_4\VBP\2108377 a_5\DT\13649268 lower_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 eps_9\NN\1740 ,_10\,\1740 but_11\CC\1740 are_12\VBP\836236 associated_13\VBN\628491 in_14\IN\13603305 varying_15\VBG\2666239 degrees_16\NNS\4916342 with_17\IN\1740 sedation_18\NN\14034177 ,_19\,\1740 cardiovascular_20\JJ\1740 effects_21\NNS\13245626 ,_22\,\1740 anticholinergic_23\JJ\1740 effects_24\NNS\13245626 ,_25\,\1740 weight_26\NN\5009170 gain_27\NN\13576355 ,_28\,\1740 sexual_29\JJ\1740 dysfunction_30\NN\14204950 ,_31\,\1740 hepatic_32\JJ\1740 effects_33\NNS\13245626 ,_34\,\1740 lowered_35\VBD\1850315 <e2>seizure</e2>_36\JJ\1740 threshold_37\NN\15265518 (_38\-LRB-\1740 primarily_39\RB\1740 clozapine_40\NN\3713736 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 agranulocytosis_44\NN\14189204 (_45\-LRB-\1740 <e1>clozapine</e1>_46\NN\3713736 only_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D003024_D000380 CID the_0\DT\1740 newer_1\JJR\1740 atypical_2\JJ\1740 agents_3\NNS\7347 have_4\VBP\2108377 a_5\DT\13649268 lower_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 eps_9\NN\1740 ,_10\,\1740 but_11\CC\1740 are_12\VBP\836236 associated_13\VBN\628491 in_14\IN\13603305 varying_15\VBG\2666239 degrees_16\NNS\4916342 with_17\IN\1740 sedation_18\NN\14034177 ,_19\,\1740 cardiovascular_20\JJ\1740 effects_21\NNS\13245626 ,_22\,\1740 anticholinergic_23\JJ\1740 effects_24\NNS\13245626 ,_25\,\1740 weight_26\NN\5009170 gain_27\NN\13576355 ,_28\,\1740 sexual_29\JJ\1740 dysfunction_30\NN\14204950 ,_31\,\1740 hepatic_32\JJ\1740 effects_33\NNS\13245626 ,_34\,\1740 lowered_35\VBD\1850315 seizure_36\JJ\1740 threshold_37\NN\15265518 (_38\-LRB-\1740 primarily_39\RB\1740 <e1>clozapine</e1>_40\NN\3713736 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 <e2>agranulocytosis</e2>_44\NN\14189204 (_45\-LRB-\1740 clozapine_46\NN\3713736 only_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D003024_D000380 CID the_0\DT\1740 newer_1\JJR\1740 atypical_2\JJ\1740 agents_3\NNS\7347 have_4\VBP\2108377 a_5\DT\13649268 lower_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 eps_9\NN\1740 ,_10\,\1740 but_11\CC\1740 are_12\VBP\836236 associated_13\VBN\628491 in_14\IN\13603305 varying_15\VBG\2666239 degrees_16\NNS\4916342 with_17\IN\1740 sedation_18\NN\14034177 ,_19\,\1740 cardiovascular_20\JJ\1740 effects_21\NNS\13245626 ,_22\,\1740 anticholinergic_23\JJ\1740 effects_24\NNS\13245626 ,_25\,\1740 weight_26\NN\5009170 gain_27\NN\13576355 ,_28\,\1740 sexual_29\JJ\1740 dysfunction_30\NN\14204950 ,_31\,\1740 hepatic_32\JJ\1740 effects_33\NNS\13245626 ,_34\,\1740 lowered_35\VBD\1850315 seizure_36\JJ\1740 threshold_37\NN\15265518 (_38\-LRB-\1740 primarily_39\RB\1740 clozapine_40\NN\3713736 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 <e2>agranulocytosis</e2>_44\NN\14189204 (_45\-LRB-\1740 <e1>clozapine</e1>_46\NN\3713736 only_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
16330766
C040029_D009437 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 assess_7\VB\670261 the_8\DT\1740 effects_9\NNS\13245626 of_10\IN\1740 <e1>gabapentin</e1>_11\NN\2718469 ,_12\,\1740 a_13\DT\13649268 drug_14\NN\14778436 effective_15\JJ\1740 in_16\IN\13603305 <e2>neuropathic_17\JJ\1740 pain</e2>_18\NN\14299637 patients_19\NNS\9898892 ,_20\,\1740 on_21\IN\1740 brain_22\NN\5462674 processing_23\NN\29677 of_24\IN\1740 nociceptive_25\JJ\1740 information_26\NN\6598915 in_27\IN\13603305 normal_28\JJ\1740 and_29\CC\1740 central_30\JJ\1740 sensitization_31\NN\14531772 states_32\NNS\8491826 ._33\.\1740
C040029_D006930 NONE using_0\VBG\1156834 functional_1\JJ\1740 magnetic_2\JJ\1740 resonance_3\NN\11419404 imaging_4\NN\5765159 (_5\-LRB-\1740 fmri_6\NN\902579 )_7\-RRB-\1740 in_8\IN\13603305 normal_9\JJ\1740 volunteers_10\NNS\10582746 ,_11\,\1740 we_12\PRP\1740 studied_13\VBD\630380 the_14\DT\1740 <e1>gabapentin-induced</e1>_15\JJ\1740 modulation_16\NN\7044917 of_17\IN\1740 brain_18\NN\5462674 activity_19\NN\30358 in_20\IN\13603305 response_21\NN\11410625 to_22\TO\1740 nociceptive_23\JJ\1740 mechanical_24\JJ\1740 stimulation_25\NN\242808 of_26\IN\1740 normal_27\JJ\1740 skin_28\NN\5237755 and_29\CC\1740 capsaicin-induced_30\JJ\1740 <e2>secondary_31\JJ\1740 hyperalgesia</e2>_32\NN\1740 ._33\.\1740
D002211_D006930 CID using_0\VBG\1156834 functional_1\JJ\1740 magnetic_2\JJ\1740 resonance_3\NN\11419404 imaging_4\NN\5765159 (_5\-LRB-\1740 fmri_6\NN\902579 )_7\-RRB-\1740 in_8\IN\13603305 normal_9\JJ\1740 volunteers_10\NNS\10582746 ,_11\,\1740 we_12\PRP\1740 studied_13\VBD\630380 the_14\DT\1740 gabapentin-induced_15\JJ\1740 modulation_16\NN\7044917 of_17\IN\1740 brain_18\NN\5462674 activity_19\NN\30358 in_20\IN\13603305 response_21\NN\11410625 to_22\TO\1740 nociceptive_23\JJ\1740 mechanical_24\JJ\1740 stimulation_25\NN\242808 of_26\IN\1740 normal_27\JJ\1740 skin_28\NN\5237755 and_29\CC\1740 <e1>capsaicin-induced</e1>_30\JJ\1740 <e2>secondary_31\JJ\1740 hyperalgesia</e2>_32\NN\1740 ._33\.\1740
6640832
D004317_D001749 NONE early_0\JJ\1740 adjuvant_1\JJ\1740 <e1>adriamycin</e1>_2\NN\1740 in_3\IN\13603305 superficial_4\JJ\1740 <e2>bladder_5\NN\5515670 carcinoma</e2>_6\NN\14239918 ._7\.\1740
D004317_D001749 NONE <e1>adriamycin</e1>_0\NN\1740 (_1\-LRB-\1740 50_2\CD\13745420 mg/50_3\NN\1740 ml_4\NN\13616054 )_5\-RRB-\1740 was_6\VBD\836236 administered_7\VBN\2436349 intravesically_8\RB\1740 within_9\IN\1740 24_10\CD\13745420 h_11\NN\14622893 after_12\IN\1740 transurethral_13\JJ\1740 resection_14\NN\671351 of_15\IN\1740 ta-t1_16\NN\1740 (_17\-LRB-\1740 o-a_18\JJ\1740 )_19\-RRB-\1740 <e2>bladder_20\NN\5515670 tumors</e2>_21\NNS\14234074 ._22\.\1740
D004317_D002277 NONE early_0\JJ\1740 adjuvant_1\JJ\1740 <e1>adriamycin</e1>_2\NN\1740 in_3\IN\13603305 superficial_4\JJ\1740 <e2>bladder_5\NN\5515670 carcinoma</e2>_6\NN\14239918 ._7\.\1740
8421099
D015282_D042882 CID prospective_0\JJ\1740 study_1\NN\635850 of_2\IN\1740 the_3\DT\1740 long-term_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 somatostatin_7\NN\1740 analog_8\NN\4743605 (_9\-LRB-\1740 <e1>octreotide</e1>_10\NN\1740 )_11\-RRB-\1740 on_12\IN\1740 gallbladder_13\NN\5512139 function_14\NN\13783581 and_15\CC\1740 <e2>gallstone</e2>_16\NN\9230768 formation_17\NN\7938773 in_18\IN\13603305 chinese_19\JJ\1740 acromegalic_20\JJ\1740 patients_21\NNS\9898892 ._22\.\1740
D015282_D042882 CID after_0\IN\1740 withdrawal_1\NN\7206096 of_2\IN\1740 <e1>octreotide</e1>_3\NN\1740 in_4\IN\13603305 10_5\CD\13745420 patients_6\NNS\9898892 without_7\IN\1740 <e2>gallstones</e2>_8\NNS\9230768 ,_9\,\1740 8_10\CD\13741022 patients_11\NNS\9898892 assessed_12\VBN\670261 had_13\VBD\2108377 return_14\NN\6479665 of_15\IN\1740 normal_16\JJ\1740 gallbladder_17\NN\5512139 contractility_18\NN\5200169 within_19\IN\1740 1_20\CD\13741022 month_21\NN\15113229 ._22\.\1740
D015282_D042882 CID our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 suppression_5\NN\13489037 of_6\IN\1740 gallbladder_7\NN\5512139 contractility_8\NN\5200169 is_9\VBZ\836236 the_10\DT\1740 cause_11\NN\7323922 of_12\IN\1740 the_13\DT\1740 successive_14\JJ\1740 formation_15\NN\7938773 of_16\IN\1740 bile_17\NN\5405946 sludge_18\NN\14591635 ,_19\,\1740 <e2>gallstones</e2>_20\NNS\9230768 ,_21\,\1740 and_22\CC\1740 cholecystitis_23\NN\14336539 during_24\IN\1740 <e1>octreotide</e1>_25\NN\1740 therapy_26\NN\657604 in_27\IN\13603305 chinese_28\JJ\1740 acromegalic_29\JJ\1740 patients_30\NNS\9898892 ._31\.\1740
D015282_D000172 NONE prospective_0\JJ\1740 study_1\NN\635850 of_2\IN\1740 the_3\DT\1740 long-term_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 somatostatin_7\NN\1740 analog_8\NN\4743605 (_9\-LRB-\1740 <e1>octreotide</e1>_10\NN\1740 )_11\-RRB-\1740 on_12\IN\1740 gallbladder_13\NN\5512139 function_14\NN\13783581 and_15\CC\1740 gallstone_16\NN\9230768 formation_17\NN\7938773 in_18\IN\13603305 chinese_19\JJ\1740 <e2>acromegalic</e2>_20\JJ\1740 patients_21\NNS\9898892 ._22\.\1740
D015282_D000172 NONE this_0\DT\1740 article_1\NN\6367571 reports_2\VBZ\831651 the_3\DT\1740 changes_4\NNS\7283608 in_5\IN\13603305 gallbladder_6\NN\5512139 function_7\NN\13783581 examined_8\VBN\789138 by_9\IN\1740 ultrasonography_10\NN\901083 in_11\IN\13603305 20_12\CD\13745420 chinese_13\JJ\1740 patients_14\NNS\9898892 with_15\IN\1740 active_16\JJ\1740 <e2>acromegaly</e2>_17\NN\14366759 treated_18\VBN\2376958 with_19\IN\1740 sc_20\NN\14625458 injection_21\NN\320852 of_22\IN\1740 the_23\DT\1740 somatostatin_24\NN\1740 analog_25\NN\4743605 <e1>octreotide</e1>_26\NN\1740 in_27\IN\13603305 dosages_28\NNS\13576355 of_29\IN\1740 300_30\CD\1740 -_31\SYM\1740 1500_32\CD\1740 micrograms/day_33\NN\1740 for_34\IN\1740 a_35\DT\13649268 mean_36\NN\6021761 of_37\IN\1740 24.2_38\CD\1740 +/-_39\CC\1740 13.9_40\CD\1740 months_41\NNS\15113229 ._42\.\1740
D015282_D000172 NONE our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 suppression_5\NN\13489037 of_6\IN\1740 gallbladder_7\NN\5512139 contractility_8\NN\5200169 is_9\VBZ\836236 the_10\DT\1740 cause_11\NN\7323922 of_12\IN\1740 the_13\DT\1740 successive_14\JJ\1740 formation_15\NN\7938773 of_16\IN\1740 bile_17\NN\5405946 sludge_18\NN\14591635 ,_19\,\1740 gallstones_20\NNS\9230768 ,_21\,\1740 and_22\CC\1740 cholecystitis_23\NN\14336539 during_24\IN\1740 <e1>octreotide</e1>_25\NN\1740 therapy_26\NN\657604 in_27\IN\13603305 chinese_28\JJ\1740 <e2>acromegalic</e2>_29\JJ\1740 patients_30\NNS\9898892 ._31\.\1740
D015282_D000172 NONE it_0\PRP\6125041 is_1\VBZ\836236 therefore_2\RB\1740 very_3\RB\1740 important_4\JJ\1740 to_5\TO\1740 follow_6\VB\1835496 the_7\DT\1740 changes_8\NNS\7283608 of_9\IN\1740 gallbladder_10\NN\5512139 function_11\NN\13783581 during_12\IN\1740 long-term_13\JJ\1740 <e1>octreotide</e1>_14\NN\1740 therapy_15\NN\657604 of_16\IN\1740 <e2>acromegalic</e2>_17\JJ\1740 patients_18\NNS\9898892 ._19\.\1740
D015282_D002764 NONE our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 suppression_5\NN\13489037 of_6\IN\1740 gallbladder_7\NN\5512139 contractility_8\NN\5200169 is_9\VBZ\836236 the_10\DT\1740 cause_11\NN\7323922 of_12\IN\1740 the_13\DT\1740 successive_14\JJ\1740 formation_15\NN\7938773 of_16\IN\1740 bile_17\NN\5405946 sludge_18\NN\14591635 ,_19\,\1740 gallstones_20\NNS\9230768 ,_21\,\1740 and_22\CC\1740 <e2>cholecystitis</e2>_23\NN\14336539 during_24\IN\1740 <e1>octreotide</e1>_25\NN\1740 therapy_26\NN\657604 in_27\IN\13603305 chinese_28\JJ\1740 acromegalic_29\JJ\1740 patients_30\NNS\9898892 ._31\.\1740
7453952
D008094_D003919 CID attenuation_0\NN\7427337 of_1\IN\1740 the_2\DT\1740 <e1>lithium-induced</e1>_3\JJ\1740 <e2>diabetes-insipidus-like_4\JJ\1740 syndrome</e2>_5\NN\5870365 by_6\IN\1740 amiloride_7\NN\1740 in_8\IN\13603305 rats_9\NNS\2329401 ._10\.\1740
D008094_D003919 CID in_0\IN\13603305 all_1\PDT\1740 the_2\DT\1740 experiments_3\NNS\641820 ,_4\,\1740 the_5\DT\1740 attenuation_6\NN\7427337 of_7\IN\1740 the_8\DT\1740 <e1>lithium-induced</e1>_9\JJ\1740 <e2>diabetes-insipidus-like_10\JJ\1740 syndrome</e2>_11\NN\5870365 by_12\IN\1740 amiloride_13\NN\1740 was_14\VBD\836236 accompanied_15\VBN\1835496 by_16\IN\1740 a_17\DT\13649268 reduction_18\NN\351485 of_19\IN\1740 the_20\DT\1740 ratio_21\NN\13815152 between_22\IN\1740 the_23\DT\1740 lithium_24\NN\14625458 concentration_25\NN\4916342 in_26\IN\13603305 the_27\DT\1740 renal_28\JJ\1740 medulla_29\NN\14864360 and_30\CC\1740 its_31\PRP$\6125041 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 blood_35\NN\5397468 and_36\CC\1740 an_37\DT\6697703 elevation_38\NN\7445480 in_39\IN\13603305 the_40\DT\1740 plasma_41\NN\5398023 potassium_42\NN\14625458 level_43\NN\4916342 ._44\.\1740
D008094_D003919 CID in_0\IN\13603305 all_1\PDT\1740 the_2\DT\1740 experiments_3\NNS\641820 ,_4\,\1740 the_5\DT\1740 attenuation_6\NN\7427337 of_7\IN\1740 the_8\DT\1740 lithium-induced_9\JJ\1740 <e2>diabetes-insipidus-like_10\JJ\1740 syndrome</e2>_11\NN\5870365 by_12\IN\1740 amiloride_13\NN\1740 was_14\VBD\836236 accompanied_15\VBN\1835496 by_16\IN\1740 a_17\DT\13649268 reduction_18\NN\351485 of_19\IN\1740 the_20\DT\1740 ratio_21\NN\13815152 between_22\IN\1740 the_23\DT\1740 <e1>lithium</e1>_24\NN\14625458 concentration_25\NN\4916342 in_26\IN\13603305 the_27\DT\1740 renal_28\JJ\1740 medulla_29\NN\14864360 and_30\CC\1740 its_31\PRP$\6125041 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 blood_35\NN\5397468 and_36\CC\1740 an_37\DT\6697703 elevation_38\NN\7445480 in_39\IN\13603305 the_40\DT\1740 plasma_41\NN\5398023 potassium_42\NN\14625458 level_43\NN\4916342 ._44\.\1740
D000584_D003919 NONE attenuation_0\NN\7427337 of_1\IN\1740 the_2\DT\1740 lithium-induced_3\JJ\1740 <e2>diabetes-insipidus-like_4\JJ\1740 syndrome</e2>_5\NN\5870365 by_6\IN\1740 <e1>amiloride</e1>_7\NN\1740 in_8\IN\13603305 rats_9\NNS\2329401 ._10\.\1740
D000584_D003919 NONE in_0\IN\13603305 all_1\PDT\1740 the_2\DT\1740 experiments_3\NNS\641820 ,_4\,\1740 the_5\DT\1740 attenuation_6\NN\7427337 of_7\IN\1740 the_8\DT\1740 lithium-induced_9\JJ\1740 <e2>diabetes-insipidus-like_10\JJ\1740 syndrome</e2>_11\NN\5870365 by_12\IN\1740 <e1>amiloride</e1>_13\NN\1740 was_14\VBD\836236 accompanied_15\VBN\1835496 by_16\IN\1740 a_17\DT\13649268 reduction_18\NN\351485 of_19\IN\1740 the_20\DT\1740 ratio_21\NN\13815152 between_22\IN\1740 the_23\DT\1740 lithium_24\NN\14625458 concentration_25\NN\4916342 in_26\IN\13603305 the_27\DT\1740 renal_28\JJ\1740 medulla_29\NN\14864360 and_30\CC\1740 its_31\PRP$\6125041 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 blood_35\NN\5397468 and_36\CC\1740 an_37\DT\6697703 elevation_38\NN\7445480 in_39\IN\13603305 the_40\DT\1740 plasma_41\NN\5398023 potassium_42\NN\14625458 level_43\NN\4916342 ._44\.\1740
D000584_D059606 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>amiloride</e1>_3\NN\1740 on_4\IN\1740 lithium-induced_5\JJ\1740 <e2>polydipsia</e2>_6\NN\14040660 and_7\CC\1740 polyuria_8\NN\14113228 and_9\CC\1740 on_10\IN\1740 the_11\DT\1740 lithium_12\NN\14625458 concentration_13\NN\4916342 in_14\IN\13603305 the_15\DT\1740 plasma_16\NN\5398023 ,_17\,\1740 brain_18\NN\5462674 ,_19\,\1740 kidney_20\NN\5333259 ,_21\,\1740 thyroid_22\NN\5329735 and_23\CC\1740 red_24\JJ\1740 blood_25\NN\5397468 cells_26\NNS\3080309 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ,_31\,\1740 chronically_32\RB\1740 treated_33\VBN\2376958 with_34\IN\1740 licl_35\NN\1740 ._36\.\1740
D000584_D059606 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 acute_4\JJ\1740 <e1>amiloride</e1>_5\NN\1740 administration_6\NN\1133281 to_7\TO\1740 lithium-treated_8\JJ\1740 patients_9\NNS\9898892 suffering_10\VBG\2110220 from_11\IN\1740 <e2>polydipsia</e2>_12\NN\14040660 and_13\CC\1740 polyuria_14\NN\14113228 might_15\MD\5029706 relieve_16\VB\205885 these_17\DT\1740 patients_18\NNS\9898892 but_19\CC\1740 prolonged_20\JJ\1740 amiloride_21\NN\1740 supplementation_22\NN\5108947 would_23\MD\1740 result_24\VB\2633881 in_25\IN\13603305 elevated_26\JJ\1740 lithium_27\NN\14625458 levels_28\NNS\4916342 and_29\CC\1740 might_30\MD\5029706 be_31\VB\836236 hazardous_32\JJ\1740 ._33\.\1740
D000584_D059606 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 acute_4\JJ\1740 amiloride_5\NN\1740 administration_6\NN\1133281 to_7\TO\1740 lithium-treated_8\JJ\1740 patients_9\NNS\9898892 suffering_10\VBG\2110220 from_11\IN\1740 <e2>polydipsia</e2>_12\NN\14040660 and_13\CC\1740 polyuria_14\NN\14113228 might_15\MD\5029706 relieve_16\VB\205885 these_17\DT\1740 patients_18\NNS\9898892 but_19\CC\1740 prolonged_20\JJ\1740 <e1>amiloride</e1>_21\NN\1740 supplementation_22\NN\5108947 would_23\MD\1740 result_24\VB\2633881 in_25\IN\13603305 elevated_26\JJ\1740 lithium_27\NN\14625458 levels_28\NNS\4916342 and_29\CC\1740 might_30\MD\5029706 be_31\VB\836236 hazardous_32\JJ\1740 ._33\.\1740
D000584_D011141 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>amiloride</e1>_3\NN\1740 on_4\IN\1740 lithium-induced_5\JJ\1740 polydipsia_6\NN\14040660 and_7\CC\1740 <e2>polyuria</e2>_8\NN\14113228 and_9\CC\1740 on_10\IN\1740 the_11\DT\1740 lithium_12\NN\14625458 concentration_13\NN\4916342 in_14\IN\13603305 the_15\DT\1740 plasma_16\NN\5398023 ,_17\,\1740 brain_18\NN\5462674 ,_19\,\1740 kidney_20\NN\5333259 ,_21\,\1740 thyroid_22\NN\5329735 and_23\CC\1740 red_24\JJ\1740 blood_25\NN\5397468 cells_26\NNS\3080309 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ,_31\,\1740 chronically_32\RB\1740 treated_33\VBN\2376958 with_34\IN\1740 licl_35\NN\1740 ._36\.\1740
D000584_D011141 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 acute_4\JJ\1740 <e1>amiloride</e1>_5\NN\1740 administration_6\NN\1133281 to_7\TO\1740 lithium-treated_8\JJ\1740 patients_9\NNS\9898892 suffering_10\VBG\2110220 from_11\IN\1740 polydipsia_12\NN\14040660 and_13\CC\1740 <e2>polyuria</e2>_14\NN\14113228 might_15\MD\5029706 relieve_16\VB\205885 these_17\DT\1740 patients_18\NNS\9898892 but_19\CC\1740 prolonged_20\JJ\1740 amiloride_21\NN\1740 supplementation_22\NN\5108947 would_23\MD\1740 result_24\VB\2633881 in_25\IN\13603305 elevated_26\JJ\1740 lithium_27\NN\14625458 levels_28\NNS\4916342 and_29\CC\1740 might_30\MD\5029706 be_31\VB\836236 hazardous_32\JJ\1740 ._33\.\1740
D000584_D011141 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 acute_4\JJ\1740 amiloride_5\NN\1740 administration_6\NN\1133281 to_7\TO\1740 lithium-treated_8\JJ\1740 patients_9\NNS\9898892 suffering_10\VBG\2110220 from_11\IN\1740 polydipsia_12\NN\14040660 and_13\CC\1740 <e2>polyuria</e2>_14\NN\14113228 might_15\MD\5029706 relieve_16\VB\205885 these_17\DT\1740 patients_18\NNS\9898892 but_19\CC\1740 prolonged_20\JJ\1740 <e1>amiloride</e1>_21\NN\1740 supplementation_22\NN\5108947 would_23\MD\1740 result_24\VB\2633881 in_25\IN\13603305 elevated_26\JJ\1740 lithium_27\NN\14625458 levels_28\NNS\4916342 and_29\CC\1740 might_30\MD\5029706 be_31\VB\836236 hazardous_32\JJ\1740 ._33\.\1740
D008094_D059606 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 amiloride_3\NN\1740 on_4\IN\1740 <e1>lithium-induced</e1>_5\JJ\1740 <e2>polydipsia</e2>_6\NN\14040660 and_7\CC\1740 polyuria_8\NN\14113228 and_9\CC\1740 on_10\IN\1740 the_11\DT\1740 lithium_12\NN\14625458 concentration_13\NN\4916342 in_14\IN\13603305 the_15\DT\1740 plasma_16\NN\5398023 ,_17\,\1740 brain_18\NN\5462674 ,_19\,\1740 kidney_20\NN\5333259 ,_21\,\1740 thyroid_22\NN\5329735 and_23\CC\1740 red_24\JJ\1740 blood_25\NN\5397468 cells_26\NNS\3080309 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ,_31\,\1740 chronically_32\RB\1740 treated_33\VBN\2376958 with_34\IN\1740 licl_35\NN\1740 ._36\.\1740
D008094_D059606 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 amiloride_3\NN\1740 on_4\IN\1740 lithium-induced_5\JJ\1740 <e2>polydipsia</e2>_6\NN\14040660 and_7\CC\1740 polyuria_8\NN\14113228 and_9\CC\1740 on_10\IN\1740 the_11\DT\1740 <e1>lithium</e1>_12\NN\14625458 concentration_13\NN\4916342 in_14\IN\13603305 the_15\DT\1740 plasma_16\NN\5398023 ,_17\,\1740 brain_18\NN\5462674 ,_19\,\1740 kidney_20\NN\5333259 ,_21\,\1740 thyroid_22\NN\5329735 and_23\CC\1740 red_24\JJ\1740 blood_25\NN\5397468 cells_26\NNS\3080309 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ,_31\,\1740 chronically_32\RB\1740 treated_33\VBN\2376958 with_34\IN\1740 licl_35\NN\1740 ._36\.\1740
D008094_D059606 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 acute_4\JJ\1740 amiloride_5\NN\1740 administration_6\NN\1133281 to_7\TO\1740 <e1>lithium-treated</e1>_8\JJ\1740 patients_9\NNS\9898892 suffering_10\VBG\2110220 from_11\IN\1740 <e2>polydipsia</e2>_12\NN\14040660 and_13\CC\1740 polyuria_14\NN\14113228 might_15\MD\5029706 relieve_16\VB\205885 these_17\DT\1740 patients_18\NNS\9898892 but_19\CC\1740 prolonged_20\JJ\1740 amiloride_21\NN\1740 supplementation_22\NN\5108947 would_23\MD\1740 result_24\VB\2633881 in_25\IN\13603305 elevated_26\JJ\1740 lithium_27\NN\14625458 levels_28\NNS\4916342 and_29\CC\1740 might_30\MD\5029706 be_31\VB\836236 hazardous_32\JJ\1740 ._33\.\1740
D008094_D059606 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 acute_4\JJ\1740 amiloride_5\NN\1740 administration_6\NN\1133281 to_7\TO\1740 lithium-treated_8\JJ\1740 patients_9\NNS\9898892 suffering_10\VBG\2110220 from_11\IN\1740 <e2>polydipsia</e2>_12\NN\14040660 and_13\CC\1740 polyuria_14\NN\14113228 might_15\MD\5029706 relieve_16\VB\205885 these_17\DT\1740 patients_18\NNS\9898892 but_19\CC\1740 prolonged_20\JJ\1740 amiloride_21\NN\1740 supplementation_22\NN\5108947 would_23\MD\1740 result_24\VB\2633881 in_25\IN\13603305 elevated_26\JJ\1740 <e1>lithium</e1>_27\NN\14625458 levels_28\NNS\4916342 and_29\CC\1740 might_30\MD\5029706 be_31\VB\836236 hazardous_32\JJ\1740 ._33\.\1740
D008094_D011141 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 amiloride_3\NN\1740 on_4\IN\1740 <e1>lithium-induced</e1>_5\JJ\1740 polydipsia_6\NN\14040660 and_7\CC\1740 <e2>polyuria</e2>_8\NN\14113228 and_9\CC\1740 on_10\IN\1740 the_11\DT\1740 lithium_12\NN\14625458 concentration_13\NN\4916342 in_14\IN\13603305 the_15\DT\1740 plasma_16\NN\5398023 ,_17\,\1740 brain_18\NN\5462674 ,_19\,\1740 kidney_20\NN\5333259 ,_21\,\1740 thyroid_22\NN\5329735 and_23\CC\1740 red_24\JJ\1740 blood_25\NN\5397468 cells_26\NNS\3080309 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ,_31\,\1740 chronically_32\RB\1740 treated_33\VBN\2376958 with_34\IN\1740 licl_35\NN\1740 ._36\.\1740
D008094_D011141 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 amiloride_3\NN\1740 on_4\IN\1740 lithium-induced_5\JJ\1740 polydipsia_6\NN\14040660 and_7\CC\1740 <e2>polyuria</e2>_8\NN\14113228 and_9\CC\1740 on_10\IN\1740 the_11\DT\1740 <e1>lithium</e1>_12\NN\14625458 concentration_13\NN\4916342 in_14\IN\13603305 the_15\DT\1740 plasma_16\NN\5398023 ,_17\,\1740 brain_18\NN\5462674 ,_19\,\1740 kidney_20\NN\5333259 ,_21\,\1740 thyroid_22\NN\5329735 and_23\CC\1740 red_24\JJ\1740 blood_25\NN\5397468 cells_26\NNS\3080309 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ,_31\,\1740 chronically_32\RB\1740 treated_33\VBN\2376958 with_34\IN\1740 licl_35\NN\1740 ._36\.\1740
D008094_D011141 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 acute_4\JJ\1740 amiloride_5\NN\1740 administration_6\NN\1133281 to_7\TO\1740 <e1>lithium-treated</e1>_8\JJ\1740 patients_9\NNS\9898892 suffering_10\VBG\2110220 from_11\IN\1740 polydipsia_12\NN\14040660 and_13\CC\1740 <e2>polyuria</e2>_14\NN\14113228 might_15\MD\5029706 relieve_16\VB\205885 these_17\DT\1740 patients_18\NNS\9898892 but_19\CC\1740 prolonged_20\JJ\1740 amiloride_21\NN\1740 supplementation_22\NN\5108947 would_23\MD\1740 result_24\VB\2633881 in_25\IN\13603305 elevated_26\JJ\1740 lithium_27\NN\14625458 levels_28\NNS\4916342 and_29\CC\1740 might_30\MD\5029706 be_31\VB\836236 hazardous_32\JJ\1740 ._33\.\1740
D008094_D011141 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 acute_4\JJ\1740 amiloride_5\NN\1740 administration_6\NN\1133281 to_7\TO\1740 lithium-treated_8\JJ\1740 patients_9\NNS\9898892 suffering_10\VBG\2110220 from_11\IN\1740 polydipsia_12\NN\14040660 and_13\CC\1740 <e2>polyuria</e2>_14\NN\14113228 might_15\MD\5029706 relieve_16\VB\205885 these_17\DT\1740 patients_18\NNS\9898892 but_19\CC\1740 prolonged_20\JJ\1740 amiloride_21\NN\1740 supplementation_22\NN\5108947 would_23\MD\1740 result_24\VB\2633881 in_25\IN\13603305 elevated_26\JJ\1740 <e1>lithium</e1>_27\NN\14625458 levels_28\NNS\4916342 and_29\CC\1740 might_30\MD\5029706 be_31\VB\836236 hazardous_32\JJ\1740 ._33\.\1740
D018021_D059606 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 amiloride_3\NN\1740 on_4\IN\1740 lithium-induced_5\JJ\1740 <e2>polydipsia</e2>_6\NN\14040660 and_7\CC\1740 polyuria_8\NN\14113228 and_9\CC\1740 on_10\IN\1740 the_11\DT\1740 lithium_12\NN\14625458 concentration_13\NN\4916342 in_14\IN\13603305 the_15\DT\1740 plasma_16\NN\5398023 ,_17\,\1740 brain_18\NN\5462674 ,_19\,\1740 kidney_20\NN\5333259 ,_21\,\1740 thyroid_22\NN\5329735 and_23\CC\1740 red_24\JJ\1740 blood_25\NN\5397468 cells_26\NNS\3080309 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ,_31\,\1740 chronically_32\RB\1740 treated_33\VBN\2376958 with_34\IN\1740 <e1>licl</e1>_35\NN\1740 ._36\.\1740
D018021_D011141 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 amiloride_3\NN\1740 on_4\IN\1740 lithium-induced_5\JJ\1740 polydipsia_6\NN\14040660 and_7\CC\1740 <e2>polyuria</e2>_8\NN\14113228 and_9\CC\1740 on_10\IN\1740 the_11\DT\1740 lithium_12\NN\14625458 concentration_13\NN\4916342 in_14\IN\13603305 the_15\DT\1740 plasma_16\NN\5398023 ,_17\,\1740 brain_18\NN\5462674 ,_19\,\1740 kidney_20\NN\5333259 ,_21\,\1740 thyroid_22\NN\5329735 and_23\CC\1740 red_24\JJ\1740 blood_25\NN\5397468 cells_26\NNS\3080309 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ,_31\,\1740 chronically_32\RB\1740 treated_33\VBN\2376958 with_34\IN\1740 <e1>licl</e1>_35\NN\1740 ._36\.\1740
D011188_D003919 NONE in_0\IN\13603305 all_1\PDT\1740 the_2\DT\1740 experiments_3\NNS\641820 ,_4\,\1740 the_5\DT\1740 attenuation_6\NN\7427337 of_7\IN\1740 the_8\DT\1740 lithium-induced_9\JJ\1740 <e2>diabetes-insipidus-like_10\JJ\1740 syndrome</e2>_11\NN\5870365 by_12\IN\1740 amiloride_13\NN\1740 was_14\VBD\836236 accompanied_15\VBN\1835496 by_16\IN\1740 a_17\DT\13649268 reduction_18\NN\351485 of_19\IN\1740 the_20\DT\1740 ratio_21\NN\13815152 between_22\IN\1740 the_23\DT\1740 lithium_24\NN\14625458 concentration_25\NN\4916342 in_26\IN\13603305 the_27\DT\1740 renal_28\JJ\1740 medulla_29\NN\14864360 and_30\CC\1740 its_31\PRP$\6125041 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 blood_35\NN\5397468 and_36\CC\1740 an_37\DT\6697703 elevation_38\NN\7445480 in_39\IN\13603305 the_40\DT\1740 plasma_41\NN\5398023 <e1>potassium</e1>_42\NN\14625458 level_43\NN\4916342 ._44\.\1740
3564823
D008012_D013035 NONE drug-induced_0\JJ\1740 arterial_1\JJ\1740 <e2>spasm</e2>_2\NN\14299637 relieved_3\VBN\205885 by_4\IN\1740 <e1>lidocaine</e1>_5\NN\3681148 ._6\.\1740
D013874_D002545 NONE following_0\VBG\1835496 major_1\JJ\1740 intracranial_2\JJ\1740 surgery_3\NN\6045562 in_4\IN\13603305 a_5\DT\13649268 35-year-old_6\JJ\1740 man_7\NN\9605289 ,_8\,\1740 <e1>sodium_9\NN\14625458 pentothal</e1>_10\NN\2792049 was_11\VBD\836236 intravenously_12\RB\1740 infused_13\JJ\1740 to_14\TO\1740 minimize_15\VB\441445 <e2>cerebral_16\JJ\1740 ischaemia</e2>_17\NN\14195315 ._18\.\1740
D008012_D020301 NONE since_0\IN\1740 the_1\DT\1740 cranial_2\JJ\1740 condition_3\NN\24720 precluded_4\VBD\2629256 use_5\NN\407535 of_6\IN\1740 more_7\JJR\1740 usual_8\JJ\1740 methods_9\NNS\5616786 ,_10\,\1740 <e1>lidocaine</e1>_11\NN\3681148 was_12\VBD\836236 given_13\VBN\2327200 intra-arterially_14\RB\1740 ,_15\,\1740 with_16\IN\1740 careful_17\JJ\1740 cardiovascular_18\JJ\1740 monitoring_19\NN\879759 ,_20\,\1740 to_21\TO\1740 counteract_22\VB\2367363 the_23\DT\1740 <e2>vasospasm</e2>_24\NN\1740 ._25\.\1740
2304736
D011224_D014550 CID <e1>prazosin-induced</e1>_0\JJ\1740 <e2>stress_1\NN\7083732 incontinence</e2>_2\NN\13473097 ._3\.\1740
D011224_D014550 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 genuine_3\JJ\1740 <e2>stress_4\NN\7083732 incontinence</e2>_5\NN\13473097 due_6\JJ\1740 to_7\IN\1740 <e1>prazosin</e1>_8\NN\2698769 ,_9\,\1740 a_10\DT\13649268 common_11\JJ\1740 antihypertensive_12\JJ\1740 drug_13\NN\14778436 ,_14\,\1740 is_15\VBZ\836236 presented_16\VBN\2137132 ._17\.\1740
D011224_D014550 CID patients_0\NNS\9898892 who_1\WP\8299493 present_2\VBP\2137132 with_3\IN\1740 <e2>stress_4\NN\7083732 incontinence</e2>_5\NN\13473097 while_6\IN\15122231 taking_7\VBG\2367363 <e1>prazosin</e1>_8\NN\2698769 should_9\MD\1740 change_10\VB\46534 their_11\PRP$\1740 antihypertensive_12\JJ\1740 medication_13\NN\3247620 before_14\IN\1740 considering_15\VBG\689344 surgery_16\NN\6045562 ,_17\,\1740 because_18\IN\1740 their_19\PRP$\1740 incontinence_20\NN\13473097 may_21\MD\15209706 resolve_22\VB\352826 spontaneously_23\RB\1740 with_24\IN\1740 a_25\DT\13649268 change_26\NN\7283608 in_27\IN\13603305 drug_28\NN\14778436 therapy_29\NN\657604 ._30\.\1740
D011224_D014549 NONE patients_0\NNS\9898892 who_1\WP\8299493 present_2\VBP\2137132 with_3\IN\1740 stress_4\NN\7083732 incontinence_5\NN\13473097 while_6\IN\15122231 taking_7\VBG\2367363 <e1>prazosin</e1>_8\NN\2698769 should_9\MD\1740 change_10\VB\46534 their_11\PRP$\1740 antihypertensive_12\JJ\1740 medication_13\NN\3247620 before_14\IN\1740 considering_15\VBG\689344 surgery_16\NN\6045562 ,_17\,\1740 because_18\IN\1740 their_19\PRP$\1740 <e2>incontinence</e2>_20\NN\13473097 may_21\MD\15209706 resolve_22\VB\352826 spontaneously_23\RB\1740 with_24\IN\1740 a_25\DT\13649268 change_26\NN\7283608 in_27\IN\13603305 drug_28\NN\14778436 therapy_29\NN\657604 ._30\.\1740
4071154
D007213_D051437 NONE <e1>indomethacin-induced</e1>_0\JJ\1740 <e2>renal_1\JJ\1740 insufficiency</e2>_2\NN\14462946 :_3\:\1740 recurrence_4\NN\7342049 on_5\IN\1740 rechallenge_6\NN\1740 ._7\.\1740
D007213_D051437 NONE we_0\PRP\1740 have_1\VBP\2108377 reported_2\VBN\831651 a_3\DT\13649268 case_4\NN\7283608 of_5\IN\1740 acute_6\JJ\1740 oliguric_7\JJ\1740 <e2>renal_8\JJ\1740 failure</e2>_9\NN\66216 with_10\IN\1740 hyperkalemia_11\NN\14299637 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 with_15\IN\1740 cirrhosis_16\NN\14116321 ,_17\,\1740 ascites_18\NNS\14204950 ,_19\,\1740 and_20\CC\1740 cor_21\NN\1740 pulmonale_22\NN\1740 after_23\IN\1740 <e1>indomethacin</e1>_24\NN\3828465 therapy_25\NN\657604 ._26\.\1740
D007213_D006947 CID we_0\PRP\1740 have_1\VBP\2108377 reported_2\VBN\831651 a_3\DT\13649268 case_4\NN\7283608 of_5\IN\1740 acute_6\JJ\1740 oliguric_7\JJ\1740 renal_8\JJ\1740 failure_9\NN\66216 with_10\IN\1740 <e2>hyperkalemia</e2>_11\NN\14299637 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 with_15\IN\1740 cirrhosis_16\NN\14116321 ,_17\,\1740 ascites_18\NNS\14204950 ,_19\,\1740 and_20\CC\1740 cor_21\NN\1740 pulmonale_22\NN\1740 after_23\IN\1740 <e1>indomethacin</e1>_24\NN\3828465 therapy_25\NN\657604 ._26\.\1740
D007213_D005355 CID we_0\PRP\1740 have_1\VBP\2108377 reported_2\VBN\831651 a_3\DT\13649268 case_4\NN\7283608 of_5\IN\1740 acute_6\JJ\1740 oliguric_7\JJ\1740 renal_8\JJ\1740 failure_9\NN\66216 with_10\IN\1740 hyperkalemia_11\NN\14299637 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 with_15\IN\1740 <e2>cirrhosis</e2>_16\NN\14116321 ,_17\,\1740 ascites_18\NNS\14204950 ,_19\,\1740 and_20\CC\1740 cor_21\NN\1740 pulmonale_22\NN\1740 after_23\IN\1740 <e1>indomethacin</e1>_24\NN\3828465 therapy_25\NN\657604 ._26\.\1740
D007213_D001201 CID we_0\PRP\1740 have_1\VBP\2108377 reported_2\VBN\831651 a_3\DT\13649268 case_4\NN\7283608 of_5\IN\1740 acute_6\JJ\1740 oliguric_7\JJ\1740 renal_8\JJ\1740 failure_9\NN\66216 with_10\IN\1740 hyperkalemia_11\NN\14299637 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 with_15\IN\1740 cirrhosis_16\NN\14116321 ,_17\,\1740 <e2>ascites</e2>_18\NNS\14204950 ,_19\,\1740 and_20\CC\1740 cor_21\NN\1740 pulmonale_22\NN\1740 after_23\IN\1740 <e1>indomethacin</e1>_24\NN\3828465 therapy_25\NN\657604 ._26\.\1740
D007213_D011660 CID we_0\PRP\1740 have_1\VBP\2108377 reported_2\VBN\831651 a_3\DT\13649268 case_4\NN\7283608 of_5\IN\1740 acute_6\JJ\1740 oliguric_7\JJ\1740 renal_8\JJ\1740 failure_9\NN\66216 with_10\IN\1740 hyperkalemia_11\NN\14299637 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 with_15\IN\1740 cirrhosis_16\NN\14116321 ,_17\,\1740 ascites_18\NNS\14204950 ,_19\,\1740 and_20\CC\1740 <e2>cor_21\NN\1740 pulmonale</e2>_22\NN\1740 after_23\IN\1740 <e1>indomethacin</e1>_24\NN\3828465 therapy_25\NN\657604 ._26\.\1740
D007213_D009846 CID prompt_0\JJ\1740 restoration_1\NN\266806 of_2\IN\1740 renal_3\JJ\1740 function_4\NN\13783581 followed_5\VBD\1835496 drug_6\NN\14778436 withdrawal_7\NN\7206096 ,_8\,\1740 while_9\IN\15122231 re-exposure_10\VBP\1740 to_11\TO\1740 a_12\DT\13649268 single_13\JJ\1740 dose_14\NN\3740161 of_15\IN\1740 <e1>indomethacin</e1>_16\NN\3828465 caused_17\VBD\1617192 recurrence_18\NN\7342049 of_19\IN\1740 acute_20\JJ\1740 reversible_21\JJ\1740 <e2>oliguria</e2>_22\NN\14299637 ._23\.\1740
3800626
D010423_D009408 CID <e2>compression_0\NNS\7413899 neuropathy_1\JJ\1740 of_2\IN\1740 the_3\DT\1740 radial_4\JJ\1740 nerve</e2>_5\NN\5475681 due_6\JJ\1740 to_7\TO\1740 <e1>pentazocine-induced</e1>_8\JJ\1740 fibrous_9\JJ\1740 myopathy_10\NN\14204950 ._11\.\1740
D010423_D009408 CID however_0\RB\1740 ,_1\,\1740 <e2>compression_2\NN\7413899 neuropathy</e2>_3\JJ\1740 due_4\JJ\1740 to_5\TO\1740 fibrotic_6\JJ\1740 muscle_7\NN\5289601 affected_8\VBN\126264 by_9\IN\1740 <e1>pentazocine-induced</e1>_10\JJ\1740 myopathy_11\NN\14204950 has_12\VBZ\2108377 not_13\RB\1740 previously_14\RB\1740 been_15\VBN\836236 reported_16\VBN\831651 ._17\.\1740
D010423_D020425 CID <e2>compression_0\NNS\7413899 neuropathy_1\JJ\1740 of_2\IN\1740 the_3\DT\1740 radial_4\JJ\1740 nerve</e2>_5\NN\5475681 due_6\JJ\1740 to_7\TO\1740 <e1>pentazocine-induced</e1>_8\JJ\1740 fibrous_9\JJ\1740 myopathy_10\NN\14204950 ._11\.\1740
D010423_D005355 CID compression_0\NNS\7413899 neuropathy_1\JJ\1740 of_2\IN\1740 the_3\DT\1740 radial_4\JJ\1740 nerve_5\NN\5475681 due_6\JJ\1740 to_7\TO\1740 <e1>pentazocine-induced</e1>_8\JJ\1740 <e2>fibrous_9\JJ\1740 myopathy</e2>_10\NN\14204950 ._11\.\1740
D010423_D005355 CID <e2>fibrous_0\JJ\1740 myopathy</e2>_1\NN\14204950 is_2\VBZ\836236 a_3\DT\13649268 common_4\JJ\1740 ,_5\,\1740 well-known_6\JJ\1740 side_7\NN\8630039 effect_8\NN\34213 of_9\IN\1740 repeated_10\VBN\952524 <e1>pentazocine</e1>_11\NN\2707683 injection_12\NN\320852 ._13\.\1740
D010423_D005355 CID in_0\IN\13603305 a_1\DT\13649268 37-year-old_2\JJ\1740 woman_3\NN\9605289 with_4\IN\1740 documented_5\VBN\1000214 <e1>pentazocine-induced</e1>_6\JJ\1740 <e2>fibrous_7\JJ\1740 myopathy</e2>_8\NN\14204950 of_9\IN\1740 triceps_10\NN\5289861 and_11\CC\1740 deltoid_12\JJ\1740 muscles_13\NNS\5289601 bilaterally_14\RB\1740 and_15\CC\1740 a_16\DT\13649268 three-week_17\JJ\1740 history_18\NN\15120823 of_19\IN\1740 right_20\JJ\1740 wrist_21\NN\5578251 drop_22\NN\13899200 ,_23\,\1740 electrodiagnostic_24\JJ\1740 examination_25\NN\633864 showed_26\VBD\2137132 a_27\DT\13649268 severe_28\JJ\1740 but_29\CC\1740 partial_30\JJ\1740 lesion_31\NN\14204950 of_32\IN\1740 the_33\DT\1740 right_34\JJ\1740 radial_35\JJ\1740 nerve_36\NN\5475681 distal_37\JJ\1740 to_38\IN\1740 the_39\DT\1740 branches_40\NNS\8220714 to_41\IN\1740 the_42\DT\1740 triceps_43\NN\5289861 ,_44\,\1740 in_45\IN\13603305 addition_46\NN\3081021 to_47\TO\1740 the_48\DT\1740 fibrous_49\JJ\1740 myopathy_50\NN\14204950 ._51\.\1740
D010423_D005355 CID in_0\IN\13603305 a_1\DT\13649268 37-year-old_2\JJ\1740 woman_3\NN\9605289 with_4\IN\1740 documented_5\VBN\1000214 <e1>pentazocine-induced</e1>_6\JJ\1740 fibrous_7\JJ\1740 myopathy_8\NN\14204950 of_9\IN\1740 triceps_10\NN\5289861 and_11\CC\1740 deltoid_12\JJ\1740 muscles_13\NNS\5289601 bilaterally_14\RB\1740 and_15\CC\1740 a_16\DT\13649268 three-week_17\JJ\1740 history_18\NN\15120823 of_19\IN\1740 right_20\JJ\1740 wrist_21\NN\5578251 drop_22\NN\13899200 ,_23\,\1740 electrodiagnostic_24\JJ\1740 examination_25\NN\633864 showed_26\VBD\2137132 a_27\DT\13649268 severe_28\JJ\1740 but_29\CC\1740 partial_30\JJ\1740 lesion_31\NN\14204950 of_32\IN\1740 the_33\DT\1740 right_34\JJ\1740 radial_35\JJ\1740 nerve_36\NN\5475681 distal_37\JJ\1740 to_38\IN\1740 the_39\DT\1740 branches_40\NNS\8220714 to_41\IN\1740 the_42\DT\1740 triceps_43\NN\5289861 ,_44\,\1740 in_45\IN\13603305 addition_46\NN\3081021 to_47\TO\1740 the_48\DT\1740 <e2>fibrous_49\JJ\1740 myopathy</e2>_50\NN\14204950 ._51\.\1740
D010423_D009135 CID compression_0\NNS\7413899 neuropathy_1\JJ\1740 of_2\IN\1740 the_3\DT\1740 radial_4\JJ\1740 nerve_5\NN\5475681 due_6\JJ\1740 to_7\TO\1740 <e1>pentazocine-induced</e1>_8\JJ\1740 <e2>fibrous_9\JJ\1740 myopathy</e2>_10\NN\14204950 ._11\.\1740
D010423_D009135 CID <e2>fibrous_0\JJ\1740 myopathy</e2>_1\NN\14204950 is_2\VBZ\836236 a_3\DT\13649268 common_4\JJ\1740 ,_5\,\1740 well-known_6\JJ\1740 side_7\NN\8630039 effect_8\NN\34213 of_9\IN\1740 repeated_10\VBN\952524 <e1>pentazocine</e1>_11\NN\2707683 injection_12\NN\320852 ._13\.\1740
D010423_D009135 CID however_0\RB\1740 ,_1\,\1740 compression_2\NN\7413899 neuropathy_3\JJ\1740 due_4\JJ\1740 to_5\TO\1740 fibrotic_6\JJ\1740 muscle_7\NN\5289601 affected_8\VBN\126264 by_9\IN\1740 <e1>pentazocine-induced</e1>_10\JJ\1740 <e2>myopathy</e2>_11\NN\14204950 has_12\VBZ\2108377 not_13\RB\1740 previously_14\RB\1740 been_15\VBN\836236 reported_16\VBN\831651 ._17\.\1740
D010423_D009135 CID in_0\IN\13603305 a_1\DT\13649268 37-year-old_2\JJ\1740 woman_3\NN\9605289 with_4\IN\1740 documented_5\VBN\1000214 <e1>pentazocine-induced</e1>_6\JJ\1740 <e2>fibrous_7\JJ\1740 myopathy</e2>_8\NN\14204950 of_9\IN\1740 triceps_10\NN\5289861 and_11\CC\1740 deltoid_12\JJ\1740 muscles_13\NNS\5289601 bilaterally_14\RB\1740 and_15\CC\1740 a_16\DT\13649268 three-week_17\JJ\1740 history_18\NN\15120823 of_19\IN\1740 right_20\JJ\1740 wrist_21\NN\5578251 drop_22\NN\13899200 ,_23\,\1740 electrodiagnostic_24\JJ\1740 examination_25\NN\633864 showed_26\VBD\2137132 a_27\DT\13649268 severe_28\JJ\1740 but_29\CC\1740 partial_30\JJ\1740 lesion_31\NN\14204950 of_32\IN\1740 the_33\DT\1740 right_34\JJ\1740 radial_35\JJ\1740 nerve_36\NN\5475681 distal_37\JJ\1740 to_38\IN\1740 the_39\DT\1740 branches_40\NNS\8220714 to_41\IN\1740 the_42\DT\1740 triceps_43\NN\5289861 ,_44\,\1740 in_45\IN\13603305 addition_46\NN\3081021 to_47\TO\1740 the_48\DT\1740 fibrous_49\JJ\1740 myopathy_50\NN\14204950 ._51\.\1740
D010423_D009135 CID in_0\IN\13603305 a_1\DT\13649268 37-year-old_2\JJ\1740 woman_3\NN\9605289 with_4\IN\1740 documented_5\VBN\1000214 <e1>pentazocine-induced</e1>_6\JJ\1740 fibrous_7\JJ\1740 myopathy_8\NN\14204950 of_9\IN\1740 triceps_10\NN\5289861 and_11\CC\1740 deltoid_12\JJ\1740 muscles_13\NNS\5289601 bilaterally_14\RB\1740 and_15\CC\1740 a_16\DT\13649268 three-week_17\JJ\1740 history_18\NN\15120823 of_19\IN\1740 right_20\JJ\1740 wrist_21\NN\5578251 drop_22\NN\13899200 ,_23\,\1740 electrodiagnostic_24\JJ\1740 examination_25\NN\633864 showed_26\VBD\2137132 a_27\DT\13649268 severe_28\JJ\1740 but_29\CC\1740 partial_30\JJ\1740 lesion_31\NN\14204950 of_32\IN\1740 the_33\DT\1740 right_34\JJ\1740 radial_35\JJ\1740 nerve_36\NN\5475681 distal_37\JJ\1740 to_38\IN\1740 the_39\DT\1740 branches_40\NNS\8220714 to_41\IN\1740 the_42\DT\1740 triceps_43\NN\5289861 ,_44\,\1740 in_45\IN\13603305 addition_46\NN\3081021 to_47\TO\1740 the_48\DT\1740 <e2>fibrous_49\JJ\1740 myopathy</e2>_50\NN\14204950 ._51\.\1740
15804801
D017239_D003323 CID <e2>coronary_0\JJ\1740 aneurysm</e2>_1\NN\14057371 after_2\IN\1740 implantation_3\NN\13526110 of_4\IN\1740 a_5\DT\13649268 <e1>paclitaxel-eluting</e1>_6\JJ\1740 stent_7\NN\4493505 ._8\.\1740
D017239_D003323 CID we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 43-year-old_3\JJ\1740 man_4\NN\9605289 who_5\WP\8299493 developed_6\VBD\1753788 a_7\DT\13649268 <e2>coronary_8\JJ\1740 aneurysm</e2>_9\NN\14057371 in_10\IN\13603305 the_11\DT\1740 right_12\JJ\1740 coronary_13\JJ\1740 artery_14\NN\5417975 6_15\CD\13741022 months_16\NNS\15113229 after_17\IN\1740 receiving_18\VBG\2210855 a_19\DT\13649268 <e1>paclitaxel-eluting</e1>_20\JJ\1740 stent_21\NN\4493505 ._22\.\1740
11773892
D016572_D007674 CID background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 calcineurin_3\NN\1740 inhibitors_4\NNS\20090 <e1>cyclosporine</e1>_5\NN\1740 and_6\CC\1740 tacrolimus_7\NN\1740 are_8\VBP\836236 both_9\CC\1740 known_10\VBN\2110220 to_11\TO\1740 be_12\VB\836236 <e2>nephrotoxic</e2>_13\JJ\1740 ._14\.\1740
D016559_D007674 CID background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 calcineurin_3\NN\1740 inhibitors_4\NNS\20090 cyclosporine_5\NN\1740 and_6\CC\1740 <e1>tacrolimus</e1>_7\NN\1740 are_8\VBP\836236 both_9\CC\1740 known_10\VBN\2110220 to_11\TO\1740 be_12\VB\836236 <e2>nephrotoxic</e2>_13\JJ\1740 ._14\.\1740
D003404_D007676 NONE patients_0\NNS\9898892 were_1\VBD\836236 divided_2\VBN\140123 into_3\IN\1740 three_4\CD\13741022 groups_5\NNS\2137 :_6\:\1740 controls_7\NNS\5190804 ,_8\,\1740 no_9\DT\7204911 <e2>crf</e2>_10\NN\1740 or_11\CC\3541091 esrd_12\NN\1740 ,_13\,\1740 n=748_14\CC\1740 ;_15\:\1740 crf_16\NN\1740 ,_17\,\1740 sustained_18\JJ\1740 serum_19\NN\5397468 <e1>creatinine</e1>_20\NN\1740 >_21\NN\1740 2.5_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 n=41_25\NN\1740 ;_26\:\1740 and_27\CC\1740 esrd_28\NN\1740 ,_29\,\1740 n=45_30\NN\1740 ._31\.\1740
D003404_D007676 NONE patients_0\NNS\9898892 were_1\VBD\836236 divided_2\VBN\140123 into_3\IN\1740 three_4\CD\13741022 groups_5\NNS\2137 :_6\:\1740 controls_7\NNS\5190804 ,_8\,\1740 no_9\DT\7204911 crf_10\NN\1740 or_11\CC\3541091 <e2>esrd</e2>_12\NN\1740 ,_13\,\1740 n=748_14\CC\1740 ;_15\:\1740 crf_16\NN\1740 ,_17\,\1740 sustained_18\JJ\1740 serum_19\NN\5397468 <e1>creatinine</e1>_20\NN\1740 >_21\NN\1740 2.5_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 n=41_25\NN\1740 ;_26\:\1740 and_27\CC\1740 esrd_28\NN\1740 ,_29\,\1740 n=45_30\NN\1740 ._31\.\1740
D003404_D007676 NONE patients_0\NNS\9898892 were_1\VBD\836236 divided_2\VBN\140123 into_3\IN\1740 three_4\CD\13741022 groups_5\NNS\2137 :_6\:\1740 controls_7\NNS\5190804 ,_8\,\1740 no_9\DT\7204911 crf_10\NN\1740 or_11\CC\3541091 esrd_12\NN\1740 ,_13\,\1740 n=748_14\CC\1740 ;_15\:\1740 <e2>crf</e2>_16\NN\1740 ,_17\,\1740 sustained_18\JJ\1740 serum_19\NN\5397468 <e1>creatinine</e1>_20\NN\1740 >_21\NN\1740 2.5_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 n=41_25\NN\1740 ;_26\:\1740 and_27\CC\1740 esrd_28\NN\1740 ,_29\,\1740 n=45_30\NN\1740 ._31\.\1740
D003404_D007676 NONE patients_0\NNS\9898892 were_1\VBD\836236 divided_2\VBN\140123 into_3\IN\1740 three_4\CD\13741022 groups_5\NNS\2137 :_6\:\1740 controls_7\NNS\5190804 ,_8\,\1740 no_9\DT\7204911 crf_10\NN\1740 or_11\CC\3541091 esrd_12\NN\1740 ,_13\,\1740 n=748_14\CC\1740 ;_15\:\1740 crf_16\NN\1740 ,_17\,\1740 sustained_18\JJ\1740 serum_19\NN\5397468 <e1>creatinine</e1>_20\NN\1740 >_21\NN\1740 2.5_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 n=41_25\NN\1740 ;_26\:\1740 and_27\CC\1740 <e2>esrd</e2>_28\NN\1740 ,_29\,\1740 n=45_30\NN\1740 ._31\.\1740
D003404_D007676 NONE compared_0\VBN\644583 with_1\IN\1740 control_2\NN\5190804 patients_3\NNS\9898892 ,_4\,\1740 <e2>crf</e2>_5\NN\1740 and_6\CC\1740 esrd_7\NN\1740 patients_8\NNS\9898892 had_9\VBD\2108377 higher_10\JJR\1740 preoperative_11\JJ\1740 serum_12\NN\5397468 <e1>creatinine</e1>_13\NN\1740 levels_14\NNS\4916342 ,_15\,\1740 a_16\DT\13649268 greater_17\JJR\1740 percentage_18\NN\13815742 of_19\IN\1740 patients_20\NNS\9898892 with_21\IN\1740 hepatorenal_22\JJ\1740 syndrome_23\NN\5870365 ,_24\,\1740 higher_25\JJR\1740 percentage_26\NN\13815742 requirement_27\NN\1129920 for_28\IN\1740 dialysis_29\NN\646833 in_30\IN\13603305 the_31\DT\1740 first_32\JJ\1740 3_33\CD\13741022 months_34\NNS\15113229 postoperatively_35\RB\1740 ,_36\,\1740 and_37\CC\1740 a_38\DT\13649268 higher_39\JJR\1740 1-year_40\JJ\1740 serum_41\NN\5397468 creatinine_42\NN\1740 ._43\.\1740
D003404_D007676 NONE compared_0\VBN\644583 with_1\IN\1740 control_2\NN\5190804 patients_3\NNS\9898892 ,_4\,\1740 crf_5\NN\1740 and_6\CC\1740 <e2>esrd</e2>_7\NN\1740 patients_8\NNS\9898892 had_9\VBD\2108377 higher_10\JJR\1740 preoperative_11\JJ\1740 serum_12\NN\5397468 <e1>creatinine</e1>_13\NN\1740 levels_14\NNS\4916342 ,_15\,\1740 a_16\DT\13649268 greater_17\JJR\1740 percentage_18\NN\13815742 of_19\IN\1740 patients_20\NNS\9898892 with_21\IN\1740 hepatorenal_22\JJ\1740 syndrome_23\NN\5870365 ,_24\,\1740 higher_25\JJR\1740 percentage_26\NN\13815742 requirement_27\NN\1129920 for_28\IN\1740 dialysis_29\NN\646833 in_30\IN\13603305 the_31\DT\1740 first_32\JJ\1740 3_33\CD\13741022 months_34\NNS\15113229 postoperatively_35\RB\1740 ,_36\,\1740 and_37\CC\1740 a_38\DT\13649268 higher_39\JJR\1740 1-year_40\JJ\1740 serum_41\NN\5397468 creatinine_42\NN\1740 ._43\.\1740
D003404_D007676 NONE compared_0\VBN\644583 with_1\IN\1740 control_2\NN\5190804 patients_3\NNS\9898892 ,_4\,\1740 <e2>crf</e2>_5\NN\1740 and_6\CC\1740 esrd_7\NN\1740 patients_8\NNS\9898892 had_9\VBD\2108377 higher_10\JJR\1740 preoperative_11\JJ\1740 serum_12\NN\5397468 creatinine_13\NN\1740 levels_14\NNS\4916342 ,_15\,\1740 a_16\DT\13649268 greater_17\JJR\1740 percentage_18\NN\13815742 of_19\IN\1740 patients_20\NNS\9898892 with_21\IN\1740 hepatorenal_22\JJ\1740 syndrome_23\NN\5870365 ,_24\,\1740 higher_25\JJR\1740 percentage_26\NN\13815742 requirement_27\NN\1129920 for_28\IN\1740 dialysis_29\NN\646833 in_30\IN\13603305 the_31\DT\1740 first_32\JJ\1740 3_33\CD\13741022 months_34\NNS\15113229 postoperatively_35\RB\1740 ,_36\,\1740 and_37\CC\1740 a_38\DT\13649268 higher_39\JJR\1740 1-year_40\JJ\1740 serum_41\NN\5397468 <e1>creatinine</e1>_42\NN\1740 ._43\.\1740
D003404_D007676 NONE compared_0\VBN\644583 with_1\IN\1740 control_2\NN\5190804 patients_3\NNS\9898892 ,_4\,\1740 crf_5\NN\1740 and_6\CC\1740 <e2>esrd</e2>_7\NN\1740 patients_8\NNS\9898892 had_9\VBD\2108377 higher_10\JJR\1740 preoperative_11\JJ\1740 serum_12\NN\5397468 creatinine_13\NN\1740 levels_14\NNS\4916342 ,_15\,\1740 a_16\DT\13649268 greater_17\JJR\1740 percentage_18\NN\13815742 of_19\IN\1740 patients_20\NNS\9898892 with_21\IN\1740 hepatorenal_22\JJ\1740 syndrome_23\NN\5870365 ,_24\,\1740 higher_25\JJR\1740 percentage_26\NN\13815742 requirement_27\NN\1129920 for_28\IN\1740 dialysis_29\NN\646833 in_30\IN\13603305 the_31\DT\1740 first_32\JJ\1740 3_33\CD\13741022 months_34\NNS\15113229 postoperatively_35\RB\1740 ,_36\,\1740 and_37\CC\1740 a_38\DT\13649268 higher_39\JJR\1740 1-year_40\JJ\1740 serum_41\NN\5397468 <e1>creatinine</e1>_42\NN\1740 ._43\.\1740
D003404_D007676 NONE multivariate_0\JJ\1740 stepwise_1\NN\1740 logistic_2\JJ\1740 regression_3\NN\14501726 analysis_4\NN\633864 using_5\VBG\1156834 preoperative_6\JJ\1740 and_7\CC\1740 postoperative_8\JJ\1740 variables_9\NNS\2452 identified_10\VBD\699815 that_11\IN\1740 an_12\DT\6697703 increase_13\NN\13576355 of_14\IN\1740 serum_15\NN\5397468 <e1>creatinine</e1>_16\NN\1740 compared_17\VBN\644583 with_18\IN\1740 average_19\JJ\1740 at_20\IN\14622893 1_21\CD\13741022 year_22\NN\15113229 ,_23\,\1740 3_24\CD\13741022 months_25\NNS\15113229 ,_26\,\1740 and_27\CC\1740 4_28\CD\13741022 weeks_29\NNS\15113229 postoperatively_30\RB\1740 were_31\VBD\836236 independent_32\JJ\1740 risk_33\NN\14541044 factors_34\NNS\7326557 for_35\IN\1740 the_36\DT\1740 development_37\NN\248977 of_38\IN\1740 <e2>crf</e2>_39\NN\1740 or_40\CC\3541091 esrd_41\NN\1740 with_42\IN\1740 odds_43\NNS\4756635 ratios_44\NNS\13815152 of_45\IN\1740 2.6_46\CD\1740 ,_47\,\1740 2.2_48\CD\1740 ,_49\,\1740 and_50\CC\1740 1.6_51\CD\1740 ,_52\,\1740 respectively_53\RB\1740 ._54\.\1740
D003404_D007676 NONE multivariate_0\JJ\1740 stepwise_1\NN\1740 logistic_2\JJ\1740 regression_3\NN\14501726 analysis_4\NN\633864 using_5\VBG\1156834 preoperative_6\JJ\1740 and_7\CC\1740 postoperative_8\JJ\1740 variables_9\NNS\2452 identified_10\VBD\699815 that_11\IN\1740 an_12\DT\6697703 increase_13\NN\13576355 of_14\IN\1740 serum_15\NN\5397468 <e1>creatinine</e1>_16\NN\1740 compared_17\VBN\644583 with_18\IN\1740 average_19\JJ\1740 at_20\IN\14622893 1_21\CD\13741022 year_22\NN\15113229 ,_23\,\1740 3_24\CD\13741022 months_25\NNS\15113229 ,_26\,\1740 and_27\CC\1740 4_28\CD\13741022 weeks_29\NNS\15113229 postoperatively_30\RB\1740 were_31\VBD\836236 independent_32\JJ\1740 risk_33\NN\14541044 factors_34\NNS\7326557 for_35\IN\1740 the_36\DT\1740 development_37\NN\248977 of_38\IN\1740 crf_39\NN\1740 or_40\CC\3541091 <e2>esrd</e2>_41\NN\1740 with_42\IN\1740 odds_43\NNS\4756635 ratios_44\NNS\13815152 of_45\IN\1740 2.6_46\CD\1740 ,_47\,\1740 2.2_48\CD\1740 ,_49\,\1740 and_50\CC\1740 1.6_51\CD\1740 ,_52\,\1740 respectively_53\RB\1740 ._54\.\1740
D003404_D007676 NONE patients_0\NNS\9898892 who_1\WP\8299493 develop_2\VBP\1753788 <e2>esrd</e2>_3\NN\1740 have_4\VBP\2108377 a_5\DT\13649268 higher_6\JJR\1740 preoperative_7\JJ\1740 and_8\CC\1740 1-year_9\JJ\1740 serum_10\NN\5397468 <e1>creatinine</e1>_11\NN\1740 and_12\CC\1740 are_13\VBP\836236 more_14\RBR\1740 likely_15\JJ\1740 to_16\TO\1740 have_17\VB\2108377 hepatorenal_18\JJ\1740 syndrome_19\NN\5870365 ._20\.\1740
D003404_D007676 NONE however_0\RB\1740 ,_1\,\1740 an_2\DT\6697703 increase_3\NN\13576355 of_4\IN\1740 serum_5\NN\5397468 <e1>creatinine</e1>_6\NN\1740 at_7\IN\14622893 various_8\JJ\1740 times_9\NNS\15113229 postoperatively_10\RB\1740 is_11\VBZ\836236 more_12\RBR\1740 predictive_13\JJ\1740 of_14\IN\1740 the_15\DT\1740 development_16\NN\248977 of_17\IN\1740 <e2>crf</e2>_18\NN\1740 or_19\CC\3541091 esrd_20\NN\1740 ._21\.\1740
D003404_D007676 NONE however_0\RB\1740 ,_1\,\1740 an_2\DT\6697703 increase_3\NN\13576355 of_4\IN\1740 serum_5\NN\5397468 <e1>creatinine</e1>_6\NN\1740 at_7\IN\14622893 various_8\JJ\1740 times_9\NNS\15113229 postoperatively_10\RB\1740 is_11\VBZ\836236 more_12\RBR\1740 predictive_13\JJ\1740 of_14\IN\1740 the_15\DT\1740 development_16\NN\248977 of_17\IN\1740 crf_18\NN\1740 or_19\CC\3541091 <e2>esrd</e2>_20\NN\1740 ._21\.\1740
D003404_D006530 NONE compared_0\VBN\644583 with_1\IN\1740 control_2\NN\5190804 patients_3\NNS\9898892 ,_4\,\1740 crf_5\NN\1740 and_6\CC\1740 esrd_7\NN\1740 patients_8\NNS\9898892 had_9\VBD\2108377 higher_10\JJR\1740 preoperative_11\JJ\1740 serum_12\NN\5397468 <e1>creatinine</e1>_13\NN\1740 levels_14\NNS\4916342 ,_15\,\1740 a_16\DT\13649268 greater_17\JJR\1740 percentage_18\NN\13815742 of_19\IN\1740 patients_20\NNS\9898892 with_21\IN\1740 <e2>hepatorenal_22\JJ\1740 syndrome</e2>_23\NN\5870365 ,_24\,\1740 higher_25\JJR\1740 percentage_26\NN\13815742 requirement_27\NN\1129920 for_28\IN\1740 dialysis_29\NN\646833 in_30\IN\13603305 the_31\DT\1740 first_32\JJ\1740 3_33\CD\13741022 months_34\NNS\15113229 postoperatively_35\RB\1740 ,_36\,\1740 and_37\CC\1740 a_38\DT\13649268 higher_39\JJR\1740 1-year_40\JJ\1740 serum_41\NN\5397468 creatinine_42\NN\1740 ._43\.\1740
D003404_D006530 NONE compared_0\VBN\644583 with_1\IN\1740 control_2\NN\5190804 patients_3\NNS\9898892 ,_4\,\1740 crf_5\NN\1740 and_6\CC\1740 esrd_7\NN\1740 patients_8\NNS\9898892 had_9\VBD\2108377 higher_10\JJR\1740 preoperative_11\JJ\1740 serum_12\NN\5397468 creatinine_13\NN\1740 levels_14\NNS\4916342 ,_15\,\1740 a_16\DT\13649268 greater_17\JJR\1740 percentage_18\NN\13815742 of_19\IN\1740 patients_20\NNS\9898892 with_21\IN\1740 <e2>hepatorenal_22\JJ\1740 syndrome</e2>_23\NN\5870365 ,_24\,\1740 higher_25\JJR\1740 percentage_26\NN\13815742 requirement_27\NN\1129920 for_28\IN\1740 dialysis_29\NN\646833 in_30\IN\13603305 the_31\DT\1740 first_32\JJ\1740 3_33\CD\13741022 months_34\NNS\15113229 postoperatively_35\RB\1740 ,_36\,\1740 and_37\CC\1740 a_38\DT\13649268 higher_39\JJR\1740 1-year_40\JJ\1740 serum_41\NN\5397468 <e1>creatinine</e1>_42\NN\1740 ._43\.\1740
D003404_D006530 NONE patients_0\NNS\9898892 who_1\WP\8299493 develop_2\VBP\1753788 esrd_3\NN\1740 have_4\VBP\2108377 a_5\DT\13649268 higher_6\JJR\1740 preoperative_7\JJ\1740 and_8\CC\1740 1-year_9\JJ\1740 serum_10\NN\5397468 <e1>creatinine</e1>_11\NN\1740 and_12\CC\1740 are_13\VBP\836236 more_14\RBR\1740 likely_15\JJ\1740 to_16\TO\1740 have_17\VB\2108377 <e2>hepatorenal_18\JJ\1740 syndrome</e2>_19\NN\5870365 ._20\.\1740
17466854
D008775_D002386 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 postoperative_7\JJ\1740 emetic_8\JJ\1740 side_9\NN\8630039 effects_10\NNS\13245626 after_11\IN\1740 the_12\DT\1740 administration_13\NN\1133281 of_14\IN\1740 <e1>methylprednisolone</e1>_15\NN\1740 and_16\CC\1740 gentamicin_17\NN\2716866 into_18\IN\1740 the_19\DT\1740 posterior_20\JJ\1740 sub-tenon_21\NNP\1740 's_22\POS\1740 space_23\NN\24264 at_24\IN\14622893 the_25\DT\1740 end_26\NN\8568978 of_27\IN\1740 routine_28\JJ\1740 <e2>cataract</e2>_29\JJ\1740 surgery_30\NN\6045562 ._31\.\1740
D005839_D002386 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 postoperative_7\JJ\1740 emetic_8\JJ\1740 side_9\NN\8630039 effects_10\NNS\13245626 after_11\IN\1740 the_12\DT\1740 administration_13\NN\1133281 of_14\IN\1740 methylprednisolone_15\NN\1740 and_16\CC\1740 <e1>gentamicin</e1>_17\NN\2716866 into_18\IN\1740 the_19\DT\1740 posterior_20\JJ\1740 sub-tenon_21\NNP\1740 's_22\POS\1740 space_23\NN\24264 at_24\IN\14622893 the_25\DT\1740 end_26\NN\8568978 of_27\IN\1740 routine_28\JJ\1740 <e2>cataract</e2>_29\JJ\1740 surgery_30\NN\6045562 ._31\.\1740
D008775_D020250 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 administration_3\NN\1133281 of_4\IN\1740 <e1>methylprednisolone</e1>_5\NN\1740 and_6\CC\1740 gentamicin_7\NN\2716866 in_8\IN\13603305 the_9\DT\1740 posterior_10\JJ\1740 sub-tenon_11\NNP\1740 's_12\POS\1740 space_13\NN\24264 was_14\VBD\836236 related_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 high_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 side_21\NN\8630039 effects_22\NNS\13245626 including_23\VBG\690614 <e2>nausea_24\NN\14299637 ,_25\,\1740 vomiting</e2>_26\NN\116687 ,_27\,\1740 and_28\CC\1740 headache_29\VB\1740 ._30\.\1740
D008775_D006261 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 administration_3\NN\1133281 of_4\IN\1740 <e1>methylprednisolone</e1>_5\NN\1740 and_6\CC\1740 gentamicin_7\NN\2716866 in_8\IN\13603305 the_9\DT\1740 posterior_10\JJ\1740 sub-tenon_11\NNP\1740 's_12\POS\1740 space_13\NN\24264 was_14\VBD\836236 related_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 high_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 side_21\NN\8630039 effects_22\NNS\13245626 including_23\VBG\690614 nausea_24\NN\14299637 ,_25\,\1740 vomiting_26\NN\116687 ,_27\,\1740 and_28\CC\1740 <e2>headache</e2>_29\VB\1740 ._30\.\1740
D005839_D020250 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 administration_3\NN\1133281 of_4\IN\1740 methylprednisolone_5\NN\1740 and_6\CC\1740 <e1>gentamicin</e1>_7\NN\2716866 in_8\IN\13603305 the_9\DT\1740 posterior_10\JJ\1740 sub-tenon_11\NNP\1740 's_12\POS\1740 space_13\NN\24264 was_14\VBD\836236 related_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 high_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 side_21\NN\8630039 effects_22\NNS\13245626 including_23\VBG\690614 <e2>nausea_24\NN\14299637 ,_25\,\1740 vomiting</e2>_26\NN\116687 ,_27\,\1740 and_28\CC\1740 headache_29\VB\1740 ._30\.\1740
D005839_D006261 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 administration_3\NN\1133281 of_4\IN\1740 methylprednisolone_5\NN\1740 and_6\CC\1740 <e1>gentamicin</e1>_7\NN\2716866 in_8\IN\13603305 the_9\DT\1740 posterior_10\JJ\1740 sub-tenon_11\NNP\1740 's_12\POS\1740 space_13\NN\24264 was_14\VBD\836236 related_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 high_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 side_21\NN\8630039 effects_22\NNS\13245626 including_23\VBG\690614 nausea_24\NN\14299637 ,_25\,\1740 vomiting_26\NN\116687 ,_27\,\1740 and_28\CC\1740 <e2>headache</e2>_29\VB\1740 ._30\.\1740
8590259
C016986_D015814 CID the_0\DT\1740 <e2>ocular_1\JJ\1740 hypotensive</e2>_2\JJ\1740 effects_3\NNS\13245626 were_4\VBD\836236 statistically_5\RB\1740 significant_6\JJ\1740 for_7\IN\1740 <e1>apraclonidine-treated</e1>_8\JJ\1740 eyes_9\NNS\5945642 throughout_10\IN\1740 the_11\DT\1740 study_12\NN\635850 and_13\CC\1740 also_14\RB\1740 statistically_15\RB\1740 significant_16\JJ\1740 for_17\IN\1740 contralateral_18\JJ\1740 eyes_19\NNS\5945642 from_20\IN\1740 three_21\CD\13741022 hours_22\NNS\15118228 after_23\IN\1740 topical_24\JJ\1740 administration_25\NN\1133281 of_26\IN\1740 1_27\CD\13741022 %_28\NN\1740 apraclonidine_29\NN\1740 ._30\.\1740
C016986_D015814 CID the_0\DT\1740 <e2>ocular_1\JJ\1740 hypotensive</e2>_2\JJ\1740 effects_3\NNS\13245626 were_4\VBD\836236 statistically_5\RB\1740 significant_6\JJ\1740 for_7\IN\1740 apraclonidine-treated_8\JJ\1740 eyes_9\NNS\5945642 throughout_10\IN\1740 the_11\DT\1740 study_12\NN\635850 and_13\CC\1740 also_14\RB\1740 statistically_15\RB\1740 significant_16\JJ\1740 for_17\IN\1740 contralateral_18\JJ\1740 eyes_19\NNS\5945642 from_20\IN\1740 three_21\CD\13741022 hours_22\NNS\15118228 after_23\IN\1740 topical_24\JJ\1740 administration_25\NN\1133281 of_26\IN\1740 1_27\CD\13741022 %_28\NN\1740 <e1>apraclonidine</e1>_29\NN\1740 ._30\.\1740
14568327
D007980_D004409 CID development_0\NN\248977 of_1\IN\1740 <e1>levodopa-induced</e1>_2\JJ\1740 <e2>dyskinesias</e2>_3\NNS\14084880 in_4\IN\13603305 parkinsonian_5\JJ\1740 monkeys_6\NNS\2469914 may_7\MD\15209706 depend_8\VB\2604760 upon_9\IN\1740 rate_10\NN\13815152 of_11\IN\1740 symptom_12\NN\5823932 onset_13\NN\7325190 and/or_14\CC\1740 duration_15\NN\15113229 of_16\IN\1740 symptoms_17\NNS\5823932 ._18\.\1740
D007980_D004409 CID <e1>levodopa-induced</e1>_0\JJ\1740 <e2>dyskinesias</e2>_1\NNS\14084880 (_2\-LRB-\1740 lids_3\NNS\5313679 )_4\-RRB-\1740 present_5\VBP\2137132 a_6\DT\13649268 major_7\JJ\1740 problem_8\NN\14408086 for_9\IN\1740 the_10\DT\1740 long-term_11\JJ\1740 management_12\NN\1123598 of_13\IN\1740 parkinson_14\NNP\1740 's_15\POS\1740 disease_16\NN\14061805 (_17\-LRB-\1740 pd_18\NN\14625458 )_19\-RRB-\1740 patients_20\NNS\9898892 ._21\.\1740
D007980_D004409 CID <e1>levodopa-induced</e1>_0\JJ\1740 dyskinesias_1\NNS\14084880 (_2\-LRB-\1740 <e2>lids</e2>_3\NNS\5313679 )_4\-RRB-\1740 present_5\VBP\2137132 a_6\DT\13649268 major_7\JJ\1740 problem_8\NN\14408086 for_9\IN\1740 the_10\DT\1740 long-term_11\JJ\1740 management_12\NN\1123598 of_13\IN\1740 parkinson_14\NNP\1740 's_15\POS\1740 disease_16\NN\14061805 (_17\-LRB-\1740 pd_18\NN\14625458 )_19\-RRB-\1740 patients_20\NNS\9898892 ._21\.\1740
D007980_D004409 CID using_0\VBG\1156834 macaque_1\JJ\1740 monkeys_2\NNS\2469914 with_3\IN\1740 different_4\JJ\1740 types_5\NNS\5839024 of_6\IN\1740 mptp-induced_7\JJ\1740 parkinsonism_8\NN\14085708 ,_9\,\1740 the_10\DT\1740 current_11\JJ\1740 study_12\NN\635850 evaluated_13\VBD\670261 the_14\DT\1740 degree_15\NN\4916342 to_16\IN\1740 which_17\WDT\1740 rate_18\NN\13815152 of_19\IN\1740 symptom_20\NN\5823932 progression_21\NN\8457976 ,_22\,\1740 symptom_23\NN\5823932 severity_24\NN\5036394 ,_25\,\1740 and_26\CC\1740 response_27\NN\11410625 to_28\TO\1740 and_29\CC\1740 duration_30\NN\15113229 of_31\IN\1740 <e1>levodopa</e1>_32\NN\14604959 therapy_33\NN\657604 may_34\MD\15209706 be_35\VB\836236 involved_36\VBN\2676054 in_37\IN\13603305 the_38\DT\1740 development_39\NN\248977 of_40\IN\1740 <e2>lids</e2>_41\NNS\5313679 ._42\.\1740
D007980_D004409 CID monkeys_0\NNS\2469914 with_1\IN\1740 acute_2\JJ\1740 (_3\-LRB-\1740 short-term_4\JJ\1740 )_5\-RRB-\1740 mptp_6\NN\1740 exposure_7\NN\5042871 ,_8\,\1740 rapid_9\JJ\1740 symptom_10\NN\5823932 onset_11\NN\7325190 and_12\CC\1740 short_13\JJ\1740 symptom_14\NN\5823932 duration_15\NN\15113229 prior_16\RB\1740 to_17\TO\1740 initiation_18\NN\7450842 of_19\IN\1740 <e1>levodopa</e1>_20\NN\14604959 therapy_21\NN\657604 developed_22\VBD\1753788 <e2>dyskinesia</e2>_23\NN\14084880 between_24\IN\1740 11_25\CD\13745420 and_26\CC\1740 24_27\CD\13745420 days_28\NNS\15140892 of_29\IN\1740 daily_30\RB\1740 levodopa_31\NN\14604959 administration_32\NN\1133281 ._33\.\1740
D007980_D004409 CID monkeys_0\NNS\2469914 with_1\IN\1740 acute_2\JJ\1740 (_3\-LRB-\1740 short-term_4\JJ\1740 )_5\-RRB-\1740 mptp_6\NN\1740 exposure_7\NN\5042871 ,_8\,\1740 rapid_9\JJ\1740 symptom_10\NN\5823932 onset_11\NN\7325190 and_12\CC\1740 short_13\JJ\1740 symptom_14\NN\5823932 duration_15\NN\15113229 prior_16\RB\1740 to_17\TO\1740 initiation_18\NN\7450842 of_19\IN\1740 levodopa_20\NN\14604959 therapy_21\NN\657604 developed_22\VBD\1753788 <e2>dyskinesia</e2>_23\NN\14084880 between_24\IN\1740 11_25\CD\13745420 and_26\CC\1740 24_27\CD\13745420 days_28\NNS\15140892 of_29\IN\1740 daily_30\RB\1740 <e1>levodopa</e1>_31\NN\14604959 administration_32\NN\1133281 ._33\.\1740
D007980_D004409 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 monkeys_3\NNS\2469914 with_4\IN\1740 long-term_5\JJ\1740 mptp_6\NN\1740 exposure_7\NN\5042871 ,_8\,\1740 slow_9\JJ\1740 symptom_10\NN\5823932 progression_11\NN\8457976 and/or_12\CC\1740 long_13\JJ\1740 symptom_14\NN\5823932 duration_15\NN\15113229 prior_16\RB\1740 to_17\TO\1740 initiation_18\NN\7450842 of_19\IN\1740 <e1>levodopa</e1>_20\NN\14604959 therapy_21\NN\657604 were_22\VBD\836236 more_23\RBR\1740 resistant_24\JJ\1740 to_25\TO\1740 developing_26\VBG\1753788 <e2>lids</e2>_27\NNS\5313679 (_28\-LRB-\1740 e.g._29\FW\1740 ,_30\,\1740 dyskinesia_31\NNP\14084880 developed_32\VBD\1753788 no_33\RB\1740 sooner_34\JJR\1740 than_35\IN\1740 146_36\CD\1740 days_37\NNS\15140892 of_38\IN\1740 chronic_39\JJ\1740 levodopa_40\NN\14604959 administration_41\NN\1133281 )_42\-RRB-\1740 ._43\.\1740
D007980_D004409 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 monkeys_3\NNS\2469914 with_4\IN\1740 long-term_5\JJ\1740 mptp_6\NN\1740 exposure_7\NN\5042871 ,_8\,\1740 slow_9\JJ\1740 symptom_10\NN\5823932 progression_11\NN\8457976 and/or_12\CC\1740 long_13\JJ\1740 symptom_14\NN\5823932 duration_15\NN\15113229 prior_16\RB\1740 to_17\TO\1740 initiation_18\NN\7450842 of_19\IN\1740 <e1>levodopa</e1>_20\NN\14604959 therapy_21\NN\657604 were_22\VBD\836236 more_23\RBR\1740 resistant_24\JJ\1740 to_25\TO\1740 developing_26\VBG\1753788 lids_27\NNS\5313679 (_28\-LRB-\1740 e.g._29\FW\1740 ,_30\,\1740 <e2>dyskinesia</e2>_31\NNP\14084880 developed_32\VBD\1753788 no_33\RB\1740 sooner_34\JJR\1740 than_35\IN\1740 146_36\CD\1740 days_37\NNS\15140892 of_38\IN\1740 chronic_39\JJ\1740 levodopa_40\NN\14604959 administration_41\NN\1133281 )_42\-RRB-\1740 ._43\.\1740
D007980_D004409 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 monkeys_3\NNS\2469914 with_4\IN\1740 long-term_5\JJ\1740 mptp_6\NN\1740 exposure_7\NN\5042871 ,_8\,\1740 slow_9\JJ\1740 symptom_10\NN\5823932 progression_11\NN\8457976 and/or_12\CC\1740 long_13\JJ\1740 symptom_14\NN\5823932 duration_15\NN\15113229 prior_16\RB\1740 to_17\TO\1740 initiation_18\NN\7450842 of_19\IN\1740 levodopa_20\NN\14604959 therapy_21\NN\657604 were_22\VBD\836236 more_23\RBR\1740 resistant_24\JJ\1740 to_25\TO\1740 developing_26\VBG\1753788 <e2>lids</e2>_27\NNS\5313679 (_28\-LRB-\1740 e.g._29\FW\1740 ,_30\,\1740 dyskinesia_31\NNP\14084880 developed_32\VBD\1753788 no_33\RB\1740 sooner_34\JJR\1740 than_35\IN\1740 146_36\CD\1740 days_37\NNS\15140892 of_38\IN\1740 chronic_39\JJ\1740 <e1>levodopa</e1>_40\NN\14604959 administration_41\NN\1133281 )_42\-RRB-\1740 ._43\.\1740
D007980_D004409 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 monkeys_3\NNS\2469914 with_4\IN\1740 long-term_5\JJ\1740 mptp_6\NN\1740 exposure_7\NN\5042871 ,_8\,\1740 slow_9\JJ\1740 symptom_10\NN\5823932 progression_11\NN\8457976 and/or_12\CC\1740 long_13\JJ\1740 symptom_14\NN\5823932 duration_15\NN\15113229 prior_16\RB\1740 to_17\TO\1740 initiation_18\NN\7450842 of_19\IN\1740 levodopa_20\NN\14604959 therapy_21\NN\657604 were_22\VBD\836236 more_23\RBR\1740 resistant_24\JJ\1740 to_25\TO\1740 developing_26\VBG\1753788 lids_27\NNS\5313679 (_28\-LRB-\1740 e.g._29\FW\1740 ,_30\,\1740 <e2>dyskinesia</e2>_31\NNP\14084880 developed_32\VBD\1753788 no_33\RB\1740 sooner_34\JJR\1740 than_35\IN\1740 146_36\CD\1740 days_37\NNS\15140892 of_38\IN\1740 chronic_39\JJ\1740 <e1>levodopa</e1>_40\NN\14604959 administration_41\NN\1133281 )_42\-RRB-\1740 ._43\.\1740
D007980_D004409 CID these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 distinct_3\JJ\1740 differences_4\NNS\4723816 in_5\IN\13603305 the_6\DT\1740 propensity_7\NN\7498854 to_8\TO\1740 develop_9\VB\1753788 <e2>lids</e2>_10\NNS\5313679 in_11\IN\13603305 monkeys_12\NNS\2469914 with_13\IN\1740 different_14\JJ\1740 rates_15\NNS\13308999 of_16\IN\1740 symptom_17\NN\5823932 progression_18\NN\8457976 or_19\CC\3541091 symptom_20\NN\5823932 durations_21\NNS\15113229 prior_22\RB\1740 to_23\TO\1740 <e1>levodopa</e1>_24\NN\14604959 and_25\CC\1740 demonstrate_26\VBP\2137132 the_27\DT\1740 value_28\NN\5856066 of_29\IN\1740 these_30\DT\1740 models_31\NNS\5888929 for_32\IN\1740 further_33\RB\1740 studying_34\VBG\630380 the_35\DT\1740 pathophysiology_36\NN\1740 of_37\IN\1740 lids_38\NNS\5313679 ._39\.\1740
D007980_D004409 CID these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 distinct_3\JJ\1740 differences_4\NNS\4723816 in_5\IN\13603305 the_6\DT\1740 propensity_7\NN\7498854 to_8\TO\1740 develop_9\VB\1753788 lids_10\NNS\5313679 in_11\IN\13603305 monkeys_12\NNS\2469914 with_13\IN\1740 different_14\JJ\1740 rates_15\NNS\13308999 of_16\IN\1740 symptom_17\NN\5823932 progression_18\NN\8457976 or_19\CC\3541091 symptom_20\NN\5823932 durations_21\NNS\15113229 prior_22\RB\1740 to_23\TO\1740 <e1>levodopa</e1>_24\NN\14604959 and_25\CC\1740 demonstrate_26\VBP\2137132 the_27\DT\1740 value_28\NN\5856066 of_29\IN\1740 these_30\DT\1740 models_31\NNS\5888929 for_32\IN\1740 further_33\RB\1740 studying_34\VBG\630380 the_35\DT\1740 pathophysiology_36\NN\1740 of_37\IN\1740 <e2>lids</e2>_38\NNS\5313679 ._39\.\1740
D007980_D010300 NONE development_0\NN\248977 of_1\IN\1740 <e1>levodopa-induced</e1>_2\JJ\1740 dyskinesias_3\NNS\14084880 in_4\IN\13603305 <e2>parkinsonian</e2>_5\JJ\1740 monkeys_6\NNS\2469914 may_7\MD\15209706 depend_8\VB\2604760 upon_9\IN\1740 rate_10\NN\13815152 of_11\IN\1740 symptom_12\NN\5823932 onset_13\NN\7325190 and/or_14\CC\1740 duration_15\NN\15113229 of_16\IN\1740 symptoms_17\NNS\5823932 ._18\.\1740
D007980_D010300 NONE <e1>levodopa-induced</e1>_0\JJ\1740 dyskinesias_1\NNS\14084880 (_2\-LRB-\1740 lids_3\NNS\5313679 )_4\-RRB-\1740 present_5\VBP\2137132 a_6\DT\13649268 major_7\JJ\1740 problem_8\NN\14408086 for_9\IN\1740 the_10\DT\1740 long-term_11\JJ\1740 management_12\NN\1123598 of_13\IN\1740 <e2>parkinson_14\NNP\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 (_17\-LRB-\1740 pd_18\NN\14625458 )_19\-RRB-\1740 patients_20\NNS\9898892 ._21\.\1740
D007980_D010300 NONE <e1>levodopa-induced</e1>_0\JJ\1740 dyskinesias_1\NNS\14084880 (_2\-LRB-\1740 lids_3\NNS\5313679 )_4\-RRB-\1740 present_5\VBP\2137132 a_6\DT\13649268 major_7\JJ\1740 problem_8\NN\14408086 for_9\IN\1740 the_10\DT\1740 long-term_11\JJ\1740 management_12\NN\1123598 of_13\IN\1740 parkinson_14\NNP\1740 's_15\POS\1740 disease_16\NN\14061805 (_17\-LRB-\1740 <e2>pd</e2>_18\NN\14625458 )_19\-RRB-\1740 patients_20\NNS\9898892 ._21\.\1740
D015632_D010302 CID using_0\VBG\1156834 macaque_1\JJ\1740 monkeys_2\NNS\2469914 with_3\IN\1740 different_4\JJ\1740 types_5\NNS\5839024 of_6\IN\1740 <e1>mptp-induced</e1>_7\JJ\1740 <e2>parkinsonism</e2>_8\NN\14085708 ,_9\,\1740 the_10\DT\1740 current_11\JJ\1740 study_12\NN\635850 evaluated_13\VBD\670261 the_14\DT\1740 degree_15\NN\4916342 to_16\IN\1740 which_17\WDT\1740 rate_18\NN\13815152 of_19\IN\1740 symptom_20\NN\5823932 progression_21\NN\8457976 ,_22\,\1740 symptom_23\NN\5823932 severity_24\NN\5036394 ,_25\,\1740 and_26\CC\1740 response_27\NN\11410625 to_28\TO\1740 and_29\CC\1740 duration_30\NN\15113229 of_31\IN\1740 levodopa_32\NN\14604959 therapy_33\NN\657604 may_34\MD\15209706 be_35\VB\836236 involved_36\VBN\2676054 in_37\IN\13603305 the_38\DT\1740 development_39\NN\248977 of_40\IN\1740 lids_41\NNS\5313679 ._42\.\1740
D015632_D004409 NONE using_0\VBG\1156834 macaque_1\JJ\1740 monkeys_2\NNS\2469914 with_3\IN\1740 different_4\JJ\1740 types_5\NNS\5839024 of_6\IN\1740 <e1>mptp-induced</e1>_7\JJ\1740 parkinsonism_8\NN\14085708 ,_9\,\1740 the_10\DT\1740 current_11\JJ\1740 study_12\NN\635850 evaluated_13\VBD\670261 the_14\DT\1740 degree_15\NN\4916342 to_16\IN\1740 which_17\WDT\1740 rate_18\NN\13815152 of_19\IN\1740 symptom_20\NN\5823932 progression_21\NN\8457976 ,_22\,\1740 symptom_23\NN\5823932 severity_24\NN\5036394 ,_25\,\1740 and_26\CC\1740 response_27\NN\11410625 to_28\TO\1740 and_29\CC\1740 duration_30\NN\15113229 of_31\IN\1740 levodopa_32\NN\14604959 therapy_33\NN\657604 may_34\MD\15209706 be_35\VB\836236 involved_36\VBN\2676054 in_37\IN\13603305 the_38\DT\1740 development_39\NN\248977 of_40\IN\1740 <e2>lids</e2>_41\NNS\5313679 ._42\.\1740
D015632_D004409 NONE monkeys_0\NNS\2469914 with_1\IN\1740 acute_2\JJ\1740 (_3\-LRB-\1740 short-term_4\JJ\1740 )_5\-RRB-\1740 <e1>mptp</e1>_6\NN\1740 exposure_7\NN\5042871 ,_8\,\1740 rapid_9\JJ\1740 symptom_10\NN\5823932 onset_11\NN\7325190 and_12\CC\1740 short_13\JJ\1740 symptom_14\NN\5823932 duration_15\NN\15113229 prior_16\RB\1740 to_17\TO\1740 initiation_18\NN\7450842 of_19\IN\1740 levodopa_20\NN\14604959 therapy_21\NN\657604 developed_22\VBD\1753788 <e2>dyskinesia</e2>_23\NN\14084880 between_24\IN\1740 11_25\CD\13745420 and_26\CC\1740 24_27\CD\13745420 days_28\NNS\15140892 of_29\IN\1740 daily_30\RB\1740 levodopa_31\NN\14604959 administration_32\NN\1133281 ._33\.\1740
D015632_D004409 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 monkeys_3\NNS\2469914 with_4\IN\1740 long-term_5\JJ\1740 <e1>mptp</e1>_6\NN\1740 exposure_7\NN\5042871 ,_8\,\1740 slow_9\JJ\1740 symptom_10\NN\5823932 progression_11\NN\8457976 and/or_12\CC\1740 long_13\JJ\1740 symptom_14\NN\5823932 duration_15\NN\15113229 prior_16\RB\1740 to_17\TO\1740 initiation_18\NN\7450842 of_19\IN\1740 levodopa_20\NN\14604959 therapy_21\NN\657604 were_22\VBD\836236 more_23\RBR\1740 resistant_24\JJ\1740 to_25\TO\1740 developing_26\VBG\1753788 <e2>lids</e2>_27\NNS\5313679 (_28\-LRB-\1740 e.g._29\FW\1740 ,_30\,\1740 dyskinesia_31\NNP\14084880 developed_32\VBD\1753788 no_33\RB\1740 sooner_34\JJR\1740 than_35\IN\1740 146_36\CD\1740 days_37\NNS\15140892 of_38\IN\1740 chronic_39\JJ\1740 levodopa_40\NN\14604959 administration_41\NN\1133281 )_42\-RRB-\1740 ._43\.\1740
D015632_D004409 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 monkeys_3\NNS\2469914 with_4\IN\1740 long-term_5\JJ\1740 <e1>mptp</e1>_6\NN\1740 exposure_7\NN\5042871 ,_8\,\1740 slow_9\JJ\1740 symptom_10\NN\5823932 progression_11\NN\8457976 and/or_12\CC\1740 long_13\JJ\1740 symptom_14\NN\5823932 duration_15\NN\15113229 prior_16\RB\1740 to_17\TO\1740 initiation_18\NN\7450842 of_19\IN\1740 levodopa_20\NN\14604959 therapy_21\NN\657604 were_22\VBD\836236 more_23\RBR\1740 resistant_24\JJ\1740 to_25\TO\1740 developing_26\VBG\1753788 lids_27\NNS\5313679 (_28\-LRB-\1740 e.g._29\FW\1740 ,_30\,\1740 <e2>dyskinesia</e2>_31\NNP\14084880 developed_32\VBD\1753788 no_33\RB\1740 sooner_34\JJR\1740 than_35\IN\1740 146_36\CD\1740 days_37\NNS\15140892 of_38\IN\1740 chronic_39\JJ\1740 levodopa_40\NN\14604959 administration_41\NN\1133281 )_42\-RRB-\1740 ._43\.\1740
D007980_D010302 NONE using_0\VBG\1156834 macaque_1\JJ\1740 monkeys_2\NNS\2469914 with_3\IN\1740 different_4\JJ\1740 types_5\NNS\5839024 of_6\IN\1740 mptp-induced_7\JJ\1740 <e2>parkinsonism</e2>_8\NN\14085708 ,_9\,\1740 the_10\DT\1740 current_11\JJ\1740 study_12\NN\635850 evaluated_13\VBD\670261 the_14\DT\1740 degree_15\NN\4916342 to_16\IN\1740 which_17\WDT\1740 rate_18\NN\13815152 of_19\IN\1740 symptom_20\NN\5823932 progression_21\NN\8457976 ,_22\,\1740 symptom_23\NN\5823932 severity_24\NN\5036394 ,_25\,\1740 and_26\CC\1740 response_27\NN\11410625 to_28\TO\1740 and_29\CC\1740 duration_30\NN\15113229 of_31\IN\1740 <e1>levodopa</e1>_32\NN\14604959 therapy_33\NN\657604 may_34\MD\15209706 be_35\VB\836236 involved_36\VBN\2676054 in_37\IN\13603305 the_38\DT\1740 development_39\NN\248977 of_40\IN\1740 lids_41\NNS\5313679 ._42\.\1740
9522143
D011318_D034381 CID patients_0\NNS\9898892 given_1\VBN\2327200 <e1>prilocaine</e1>_2\NN\1740 were_3\VBD\836236 more_4\RBR\1740 likely_5\JJ\1740 to_6\TO\1740 develop_7\VB\1753788 <e2>hearing_8\VBG\2106506 loss</e2>_9\NN\13252973 (_10\-LRB-\1740 10_11\CD\13745420 out_12\IN\66636 of_13\IN\1740 22_14\CD\13745420 )_15\-RRB-\1740 than_16\IN\1740 those_17\DT\1740 given_18\VBN\2327200 bupivacaine_19\NN\1740 (_20\-LRB-\1740 4_21\CD\13741022 out_22\IN\66636 of_23\IN\1740 22_24\CD\13745420 )_25\-RRB-\1740 (_26\-LRB-\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D011318_D034381 CID the_0\DT\1740 average_1\JJ\1740 <e2>hearing_2\NN\1184814 loss</e2>_3\NN\13252973 for_4\IN\1740 speech_5\NN\7160883 frequencies_6\NNS\15286249 was_7\VBD\836236 about_8\RB\1740 10_9\CD\13745420 db_10\NN\14622893 after_11\IN\1740 <e1>prilocaine</e1>_12\NN\1740 and_13\CC\1740 15_14\CD\13745420 db_15\NN\14622893 after_16\IN\1740 bupivacaine_17\NN\1740 ._18\.\1740
D002045_D034381 CID patients_0\NNS\9898892 given_1\VBN\2327200 prilocaine_2\NN\1740 were_3\VBD\836236 more_4\RBR\1740 likely_5\JJ\1740 to_6\TO\1740 develop_7\VB\1753788 <e2>hearing_8\VBG\2106506 loss</e2>_9\NN\13252973 (_10\-LRB-\1740 10_11\CD\13745420 out_12\IN\66636 of_13\IN\1740 22_14\CD\13745420 )_15\-RRB-\1740 than_16\IN\1740 those_17\DT\1740 given_18\VBN\2327200 <e1>bupivacaine</e1>_19\NN\1740 (_20\-LRB-\1740 4_21\CD\13741022 out_22\IN\66636 of_23\IN\1740 22_24\CD\13745420 )_25\-RRB-\1740 (_26\-LRB-\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D002045_D034381 CID the_0\DT\1740 average_1\JJ\1740 <e2>hearing_2\NN\1184814 loss</e2>_3\NN\13252973 for_4\IN\1740 speech_5\NN\7160883 frequencies_6\NNS\15286249 was_7\VBD\836236 about_8\RB\1740 10_9\CD\13745420 db_10\NN\14622893 after_11\IN\1740 prilocaine_12\NN\1740 and_13\CC\1740 15_14\CD\13745420 db_15\NN\14622893 after_16\IN\1740 <e1>bupivacaine</e1>_17\NN\1740 ._18\.\1740
15233872
C007145_D009203 NONE cardioprotective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>tincture_3\NN\14984973 of_4\IN\1740 crataegus</e1>_5\NN\11585340 on_6\IN\1740 isoproterenol-induced_7\JJ\1740 <e2>myocardial_8\JJ\1740 infarction</e2>_9\NN\14204950 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
C007145_D009203 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 done_4\VBN\1640855 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 protective_8\JJ\1740 effect_9\NN\34213 of_10\IN\1740 <e1>tcr</e1>_11\NN\1740 on_12\IN\1740 experimentally_13\RB\1740 induced_14\VBN\1627355 <e2>myocardial_15\JJ\1740 infarction</e2>_16\NN\14204950 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
D007545_D009203 CID cardioprotective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 tincture_3\NN\14984973 of_4\IN\1740 crataegus_5\NN\11585340 on_6\IN\1740 <e1>isoproterenol-induced</e1>_7\JJ\1740 <e2>myocardial_8\JJ\1740 infarction</e2>_9\NN\14204950 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
1378968
D008094_D007676 CID effects_0\NNS\13245626 of_1\IN\1740 uninephrectomy_2\NN\1740 and_3\CC\1740 high_4\JJ\1740 protein_5\NN\14944888 feeding_6\NN\838098 on_7\IN\1740 <e1>lithium-induced</e1>_8\JJ\1740 <e2>chronic_9\JJ\1740 renal_10\JJ\1740 failure</e2>_11\NN\66216 in_12\IN\13603305 rats_13\NNS\2329401 ._14\.\1740
D008094_D007674 NONE rats_0\NNS\2329401 with_1\IN\1740 <e1>lithium-induced</e1>_2\JJ\1740 <e2>nephropathy</e2>_3\NN\14573196 were_4\VBD\836236 subjected_5\VBN\137313 to_6\TO\1740 high_7\JJ\1740 protein_8\NN\14944888 (_9\-LRB-\1740 hp_10\NN\13635108 )_11\-RRB-\1740 feeding_12\NN\838098 ,_13\,\1740 uninephrectomy_14\NN\1740 (_15\-LRB-\1740 nx_16\NN\1740 )_17\-RRB-\1740 or_18\CC\3541091 a_19\DT\13649268 combination_20\NN\7951464 of_21\IN\1740 these_22\DT\1740 ,_23\,\1740 in_24\IN\13603305 an_25\DT\6697703 attempt_26\NN\407535 to_27\TO\1740 induce_28\VB\1627355 glomerular_29\JJ\1740 hyperfiltration_30\NN\1740 and_31\CC\1740 further_32\JJ\1740 progression_33\NN\8457976 of_34\IN\1740 renal_35\JJ\1740 failure_36\NN\66216 ._37\.\1740
D008094_D007674 NONE the_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e1>li-induced</e1>_4\JJ\1740 <e2>nephropathy</e2>_5\NN\14573196 ,_6\,\1740 even_7\RB\1740 when_8\WRB\1740 the_9\DT\1740 gfr_10\NN\1740 is_11\VBZ\836236 only_12\RB\1740 modestly_13\RB\1740 reduced_14\VBN\441445 ,_15\,\1740 is_16\VBZ\836236 associated_17\VBN\628491 with_18\IN\1740 proteinuria_19\NN\14299637 and_20\CC\1740 arterial_21\JJ\1740 systolic_22\JJ\1740 hypertension_23\NN\14057371 ._24\.\1740
D008094_D051437 NONE rats_0\NNS\2329401 with_1\IN\1740 <e1>lithium-induced</e1>_2\JJ\1740 nephropathy_3\NN\14573196 were_4\VBD\836236 subjected_5\VBN\137313 to_6\TO\1740 high_7\JJ\1740 protein_8\NN\14944888 (_9\-LRB-\1740 hp_10\NN\13635108 )_11\-RRB-\1740 feeding_12\NN\838098 ,_13\,\1740 uninephrectomy_14\NN\1740 (_15\-LRB-\1740 nx_16\NN\1740 )_17\-RRB-\1740 or_18\CC\3541091 a_19\DT\13649268 combination_20\NN\7951464 of_21\IN\1740 these_22\DT\1740 ,_23\,\1740 in_24\IN\13603305 an_25\DT\6697703 attempt_26\NN\407535 to_27\TO\1740 induce_28\VB\1627355 glomerular_29\JJ\1740 hyperfiltration_30\NN\1740 and_31\CC\1740 further_32\JJ\1740 progression_33\NN\8457976 of_34\IN\1740 <e2>renal_35\JJ\1740 failure</e2>_36\NN\66216 ._37\.\1740
D008094_D051437 NONE hp_0\NN\13635108 failed_1\VBD\1798936 to_2\TO\1740 accentuante_3\VB\1740 progression_4\NN\8457976 of_5\IN\1740 <e2>renal_6\JJ\1740 failure</e2>_7\NN\66216 and_8\CC\1740 in_9\IN\13603305 fact_10\NN\5816287 tended_11\VBD\2604760 to_12\TO\1740 increase_13\VB\169651 gfr_14\NN\1740 and_15\CC\1740 decrease_16\VB\169651 plasma_17\NN\5398023 creatinine_18\NN\1740 levels_19\NNS\4916342 in_20\IN\13603305 <e1>lithium</e1>_21\FW\14625458 pretreated_22\JJ\1740 rats_23\NNS\2329401 ._24\.\1740
D008094_D011507 CID <e1>lithium</e1>_0\NNP\14625458 also_1\RB\1740 caused_2\VBD\1617192 <e2>proteinuria</e2>_3\NN\14299637 and_4\CC\1740 systolic_5\JJ\1740 hypertension_6\NN\14057371 in_7\IN\13603305 absence_8\NN\14449405 of_9\IN\1740 glomerulosclerosis_10\NN\1740 ._11\.\1740
D008094_D011507 CID the_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e1>li-induced</e1>_4\JJ\1740 nephropathy_5\NN\14573196 ,_6\,\1740 even_7\RB\1740 when_8\WRB\1740 the_9\DT\1740 gfr_10\NN\1740 is_11\VBZ\836236 only_12\RB\1740 modestly_13\RB\1740 reduced_14\VBN\441445 ,_15\,\1740 is_16\VBZ\836236 associated_17\VBN\628491 with_18\IN\1740 <e2>proteinuria</e2>_19\NN\14299637 and_20\CC\1740 arterial_21\JJ\1740 systolic_22\JJ\1740 hypertension_23\NN\14057371 ._24\.\1740
D008094_D006973 CID <e1>lithium</e1>_0\NNP\14625458 also_1\RB\1740 caused_2\VBD\1617192 proteinuria_3\NN\14299637 and_4\CC\1740 systolic_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 in_7\IN\13603305 absence_8\NN\14449405 of_9\IN\1740 glomerulosclerosis_10\NN\1740 ._11\.\1740
D008094_D006973 CID the_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e1>li-induced</e1>_4\JJ\1740 nephropathy_5\NN\14573196 ,_6\,\1740 even_7\RB\1740 when_8\WRB\1740 the_9\DT\1740 gfr_10\NN\1740 is_11\VBZ\836236 only_12\RB\1740 modestly_13\RB\1740 reduced_14\VBN\441445 ,_15\,\1740 is_16\VBZ\836236 associated_17\VBN\628491 with_18\IN\1740 proteinuria_19\NN\14299637 and_20\CC\1740 arterial_21\JJ\1740 systolic_22\JJ\1740 <e2>hypertension</e2>_23\NN\14057371 ._24\.\1740
D008094_D005921 NONE <e1>lithium</e1>_0\NNP\14625458 also_1\RB\1740 caused_2\VBD\1617192 proteinuria_3\NN\14299637 and_4\CC\1740 systolic_5\JJ\1740 hypertension_6\NN\14057371 in_7\IN\13603305 absence_8\NN\14449405 of_9\IN\1740 <e2>glomerulosclerosis</e2>_10\NN\1740 ._11\.\1740
D003404_D051437 NONE hp_0\NN\13635108 failed_1\VBD\1798936 to_2\TO\1740 accentuante_3\VB\1740 progression_4\NN\8457976 of_5\IN\1740 <e2>renal_6\JJ\1740 failure</e2>_7\NN\66216 and_8\CC\1740 in_9\IN\13603305 fact_10\NN\5816287 tended_11\VBD\2604760 to_12\TO\1740 increase_13\VB\169651 gfr_14\NN\1740 and_15\CC\1740 decrease_16\VB\169651 plasma_17\NN\5398023 <e1>creatinine</e1>_18\NN\1740 levels_19\NNS\4916342 in_20\IN\13603305 lithium_21\FW\14625458 pretreated_22\JJ\1740 rats_23\NNS\2329401 ._24\.\1740
3503576
D003676_D006311 NONE serial_0\JJ\1740 studies_1\NNS\635850 of_2\IN\1740 <e2>auditory_3\JJ\1740 neurotoxicity</e2>_4\NN\1740 in_5\IN\13603305 patients_6\NNS\9898892 receiving_7\VBG\2210855 <e1>deferoxamine</e1>_8\NN\1740 therapy_9\NN\657604 ._10\.\1740
D003676_D006311 NONE <e2>visual_0\JJ\1740 and_1\CC\1740 auditory_2\JJ\1740 neurotoxicity</e2>_3\NN\1740 was_4\VBD\836236 previously_5\RB\1740 documented_6\VBN\1000214 in_7\IN\13603305 42_8\CD\1740 of_9\IN\1740 89_10\CD\1740 patients_11\NNS\9898892 with_12\IN\1740 transfusion-dependent_13\JJ\1740 anemia_14\NN\14189204 who_15\WP\8299493 were_16\VBD\836236 receiving_17\VBG\2210855 iron_18\NN\14625458 chelation_19\NN\29677 therapy_20\NN\657604 with_21\IN\1740 daily_22\RB\1740 subcutaneous_23\JJ\1740 <e1>deferoxamine</e1>_24\NN\1740 ._25\.\1740
D003676_D006311 NONE since_0\IN\1740 18_1\CD\13745420 of_2\IN\1740 the_3\DT\1740 22_4\CD\13745420 patients_5\NNS\9898892 were_6\VBD\836236 initially_7\RB\1740 receiving_8\VBG\2210855 <e1>deferoxamine</e1>_9\NN\1740 doses_10\NNS\3740161 in_11\IN\13603305 excess_12\NN\5119367 of_13\IN\1740 the_14\DT\1740 commonly_15\RB\1740 recommended_16\VBN\875394 50_17\CD\13745420 mg/kg_18\NN\1740 per_19\IN\1740 dose_20\NN\3740161 ,_21\,\1740 therapy_22\NN\657604 was_23\VBD\836236 restarted_24\VBN\1857717 with_25\IN\1740 lower_26\JJR\1740 doses_27\NNS\3740161 ,_28\,\1740 usually_29\RB\1740 50_30\CD\13745420 mg/kg_31\NN\1740 per_32\IN\1740 dose_33\NN\3740161 or_34\CC\3541091 less_35\RBR\1740 depending_36\VBG\2604760 on_37\IN\1740 the_38\DT\1740 degree_39\NN\4916342 of_40\IN\1740 <e2>auditory_41\JJ\1740 abnormality</e2>_42\NN\14034177 ,_43\,\1740 and_44\CC\1740 with_45\IN\1740 the_46\DT\1740 exception_47\NN\5706954 of_48\IN\1740 two_49\CD\13741022 cases_50\NNS\7283608 no_51\DT\7204911 further_52\JJ\1740 toxicity_53\NN\13576101 was_54\VBD\836236 demonstrated_55\VBN\2137132 ._56\.\1740
D003676_D006311 NONE auditory_0\JJ\1740 deterioration_1\NN\14560612 and_2\CC\1740 improvement_3\NN\7359599 ,_4\,\1740 demonstrated_5\VBN\2137132 serially_6\RB\1740 in_7\IN\13603305 individual_8\JJ\1740 patients_9\NNS\9898892 receiving_10\VBG\2210855 and_11\CC\1740 not_12\RB\1740 receiving_13\VBG\2210855 <e1>deferoxamine</e1>_14\NN\1740 ,_15\,\1740 respectively_16\RB\1740 ,_17\,\1740 provided_18\VBN\2199590 convincing_19\VBG\766418 evidence_20\NN\5816287 for_21\IN\1740 a_22\DT\13649268 cause-and-effect_23\JJ\1740 relation_24\NN\2137 between_25\IN\1740 deferoxamine_26\NN\1740 administration_27\NN\1133281 and_28\CC\1740 <e2>ototoxicity</e2>_29\NN\1740 ._30\.\1740
D003676_D006311 NONE auditory_0\JJ\1740 deterioration_1\NN\14560612 and_2\CC\1740 improvement_3\NN\7359599 ,_4\,\1740 demonstrated_5\VBN\2137132 serially_6\RB\1740 in_7\IN\13603305 individual_8\JJ\1740 patients_9\NNS\9898892 receiving_10\VBG\2210855 and_11\CC\1740 not_12\RB\1740 receiving_13\VBG\2210855 deferoxamine_14\NN\1740 ,_15\,\1740 respectively_16\RB\1740 ,_17\,\1740 provided_18\VBN\2199590 convincing_19\VBG\766418 evidence_20\NN\5816287 for_21\IN\1740 a_22\DT\13649268 cause-and-effect_23\JJ\1740 relation_24\NN\2137 between_25\IN\1740 <e1>deferoxamine</e1>_26\NN\1740 administration_27\NN\1133281 and_28\CC\1740 <e2>ototoxicity</e2>_29\NN\1740 ._30\.\1740
D007501_D014786 NONE <e2>visual_0\JJ\1740 and_1\CC\1740 auditory_2\JJ\1740 neurotoxicity</e2>_3\NN\1740 was_4\VBD\836236 previously_5\RB\1740 documented_6\VBN\1000214 in_7\IN\13603305 42_8\CD\1740 of_9\IN\1740 89_10\CD\1740 patients_11\NNS\9898892 with_12\IN\1740 transfusion-dependent_13\JJ\1740 anemia_14\NN\14189204 who_15\WP\8299493 were_16\VBD\836236 receiving_17\VBG\2210855 <e1>iron</e1>_18\NN\14625458 chelation_19\NN\29677 therapy_20\NN\657604 with_21\IN\1740 daily_22\RB\1740 subcutaneous_23\JJ\1740 deferoxamine_24\NN\1740 ._25\.\1740
D007501_D006311 NONE <e2>visual_0\JJ\1740 and_1\CC\1740 auditory_2\JJ\1740 neurotoxicity</e2>_3\NN\1740 was_4\VBD\836236 previously_5\RB\1740 documented_6\VBN\1000214 in_7\IN\13603305 42_8\CD\1740 of_9\IN\1740 89_10\CD\1740 patients_11\NNS\9898892 with_12\IN\1740 transfusion-dependent_13\JJ\1740 anemia_14\NN\14189204 who_15\WP\8299493 were_16\VBD\836236 receiving_17\VBG\2210855 <e1>iron</e1>_18\NN\14625458 chelation_19\NN\29677 therapy_20\NN\657604 with_21\IN\1740 daily_22\RB\1740 subcutaneous_23\JJ\1740 deferoxamine_24\NN\1740 ._25\.\1740
D007501_D000740 NONE visual_0\JJ\1740 and_1\CC\1740 auditory_2\JJ\1740 neurotoxicity_3\NN\1740 was_4\VBD\836236 previously_5\RB\1740 documented_6\VBN\1000214 in_7\IN\13603305 42_8\CD\1740 of_9\IN\1740 89_10\CD\1740 patients_11\NNS\9898892 with_12\IN\1740 transfusion-dependent_13\JJ\1740 <e2>anemia</e2>_14\NN\14189204 who_15\WP\8299493 were_16\VBD\836236 receiving_17\VBG\2210855 <e1>iron</e1>_18\NN\14625458 chelation_19\NN\29677 therapy_20\NN\657604 with_21\IN\1740 daily_22\RB\1740 subcutaneous_23\JJ\1740 deferoxamine_24\NN\1740 ._25\.\1740
D003676_D014786 NONE <e2>visual_0\JJ\1740 and_1\CC\1740 auditory_2\JJ\1740 neurotoxicity</e2>_3\NN\1740 was_4\VBD\836236 previously_5\RB\1740 documented_6\VBN\1000214 in_7\IN\13603305 42_8\CD\1740 of_9\IN\1740 89_10\CD\1740 patients_11\NNS\9898892 with_12\IN\1740 transfusion-dependent_13\JJ\1740 anemia_14\NN\14189204 who_15\WP\8299493 were_16\VBD\836236 receiving_17\VBG\2210855 iron_18\NN\14625458 chelation_19\NN\29677 therapy_20\NN\657604 with_21\IN\1740 daily_22\RB\1740 subcutaneous_23\JJ\1740 <e1>deferoxamine</e1>_24\NN\1740 ._25\.\1740
D003676_D000740 NONE visual_0\JJ\1740 and_1\CC\1740 auditory_2\JJ\1740 neurotoxicity_3\NN\1740 was_4\VBD\836236 previously_5\RB\1740 documented_6\VBN\1000214 in_7\IN\13603305 42_8\CD\1740 of_9\IN\1740 89_10\CD\1740 patients_11\NNS\9898892 with_12\IN\1740 transfusion-dependent_13\JJ\1740 <e2>anemia</e2>_14\NN\14189204 who_15\WP\8299493 were_16\VBD\836236 receiving_17\VBG\2210855 iron_18\NN\14625458 chelation_19\NN\29677 therapy_20\NN\657604 with_21\IN\1740 daily_22\RB\1740 subcutaneous_23\JJ\1740 <e1>deferoxamine</e1>_24\NN\1740 ._25\.\1740
D003676_D064420 NONE since_0\IN\1740 18_1\CD\13745420 of_2\IN\1740 the_3\DT\1740 22_4\CD\13745420 patients_5\NNS\9898892 were_6\VBD\836236 initially_7\RB\1740 receiving_8\VBG\2210855 <e1>deferoxamine</e1>_9\NN\1740 doses_10\NNS\3740161 in_11\IN\13603305 excess_12\NN\5119367 of_13\IN\1740 the_14\DT\1740 commonly_15\RB\1740 recommended_16\VBN\875394 50_17\CD\13745420 mg/kg_18\NN\1740 per_19\IN\1740 dose_20\NN\3740161 ,_21\,\1740 therapy_22\NN\657604 was_23\VBD\836236 restarted_24\VBN\1857717 with_25\IN\1740 lower_26\JJR\1740 doses_27\NNS\3740161 ,_28\,\1740 usually_29\RB\1740 50_30\CD\13745420 mg/kg_31\NN\1740 per_32\IN\1740 dose_33\NN\3740161 or_34\CC\3541091 less_35\RBR\1740 depending_36\VBG\2604760 on_37\IN\1740 the_38\DT\1740 degree_39\NN\4916342 of_40\IN\1740 auditory_41\JJ\1740 abnormality_42\NN\14034177 ,_43\,\1740 and_44\CC\1740 with_45\IN\1740 the_46\DT\1740 exception_47\NN\5706954 of_48\IN\1740 two_49\CD\13741022 cases_50\NNS\7283608 no_51\DT\7204911 further_52\JJ\1740 <e2>toxicity</e2>_53\NN\13576101 was_54\VBD\836236 demonstrated_55\VBN\2137132 ._56\.\1740
7628595
D014805_D064420 NONE study_0\NN\635850 of_1\IN\1740 the_2\DT\1740 role_3\NN\719494 of_4\IN\1740 <e1>vitamin_5\NN\7570720 b12</e1>_6\NN\1740 and_7\CC\1740 folinic_8\JJ\1740 acid_9\NN\14818238 supplementation_10\NN\5108947 in_11\IN\13603305 preventing_12\VBG\1740 hematologic_13\JJ\1740 <e2>toxicity</e2>_14\NN\13576101 of_15\IN\1740 zidovudine_16\NN\3834836 ._17\.\1740
D002955_D064420 NONE study_0\NN\635850 of_1\IN\1740 the_2\DT\1740 role_3\NN\719494 of_4\IN\1740 vitamin_5\NN\7570720 b12_6\NN\1740 and_7\CC\1740 <e1>folinic_8\JJ\1740 acid</e1>_9\NN\14818238 supplementation_10\NN\5108947 in_11\IN\13603305 preventing_12\VBG\1740 hematologic_13\JJ\1740 <e2>toxicity</e2>_14\NN\13576101 of_15\IN\1740 zidovudine_16\NN\3834836 ._17\.\1740
D015215_D064420 NONE study_0\NN\635850 of_1\IN\1740 the_2\DT\1740 role_3\NN\719494 of_4\IN\1740 vitamin_5\NN\7570720 b12_6\NN\1740 and_7\CC\1740 folinic_8\JJ\1740 acid_9\NN\14818238 supplementation_10\NN\5108947 in_11\IN\13603305 preventing_12\VBG\1740 hematologic_13\JJ\1740 <e2>toxicity</e2>_14\NN\13576101 of_15\IN\1740 <e1>zidovudine</e1>_16\NN\3834836 ._17\.\1740
D014805_D001855 NONE a_0\DT\13649268 prospective_1\JJ\1740 ,_2\,\1740 randomized_3\JJ\1740 study_4\NN\635850 was_5\VBD\836236 conducted_6\VBN\2436349 to_7\TO\1740 evaluate_8\VB\670261 the_9\DT\1740 role_10\NN\719494 of_11\IN\1740 <e1>vitamin_12\NN\7570720 b12</e1>_13\NN\1740 and_14\CC\1740 folinic_15\JJ\1740 acid_16\NN\14818238 supplementation_17\NN\5108947 in_18\IN\13603305 preventing_19\VBG\1740 zidovudine_20\NN\3834836 (zdv)-induced_21\JJ\1740 <e2>bone_22\NN\5286536 marrow_23\NN\5286536 suppression</e2>_24\NN\13489037 ._25\.\1740
D014805_D001855 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 correlation_3\NN\13841213 between_4\IN\1740 <e1>vitamin_5\NN\7570720 b12</e1>_6\NN\1740 or_7\CC\3541091 folate_8\VBP\1740 levels_9\NNS\4916342 and_10\CC\1740 development_11\NN\248977 of_12\IN\1740 <e2>myelosuppression</e2>_13\NN\1740 ._14\.\1740
D014805_D001855 NONE <e1>vitamin_0\NN\7570720 b12</e1>_1\NN\1740 and_2\CC\1740 folinic_3\JJ\1740 acid_4\NN\14818238 supplementation_5\NN\5108947 of_6\IN\1740 zdv_7\NN\3834836 therapy_8\NN\657604 does_9\VBZ\1640855 not_10\RB\1740 seem_11\VB\2604760 useful_12\JJ\1740 in_13\IN\13603305 preventing_14\VBG\1740 or_15\CC\3541091 reducing_16\VBG\441445 zdv-induced_17\JJ\1740 <e2>myelotoxicity</e2>_18\NN\1740 in_19\IN\13603305 the_20\DT\1740 overall_21\JJ\1740 treated_22\VBN\2376958 population_23\NN\7942152 ,_24\,\1740 although_25\IN\1740 a_26\DT\13649268 beneficial_27\JJ\1740 effect_28\NN\34213 in_29\IN\13603305 certain_30\JJ\1740 subgroups_31\NNS\31264 of_32\IN\1740 patients_33\NNS\9898892 can_34\MD\3094503 not_35\RB\1740 be_36\VB\836236 excluded_37\VBN\471711 ._38\.\1740
D002955_D001855 NONE a_0\DT\13649268 prospective_1\JJ\1740 ,_2\,\1740 randomized_3\JJ\1740 study_4\NN\635850 was_5\VBD\836236 conducted_6\VBN\2436349 to_7\TO\1740 evaluate_8\VB\670261 the_9\DT\1740 role_10\NN\719494 of_11\IN\1740 vitamin_12\NN\7570720 b12_13\NN\1740 and_14\CC\1740 <e1>folinic_15\JJ\1740 acid</e1>_16\NN\14818238 supplementation_17\NN\5108947 in_18\IN\13603305 preventing_19\VBG\1740 zidovudine_20\NN\3834836 (zdv)-induced_21\JJ\1740 <e2>bone_22\NN\5286536 marrow_23\NN\5286536 suppression</e2>_24\NN\13489037 ._25\.\1740
D002955_D001855 NONE vitamin_0\NN\7570720 b12_1\NN\1740 and_2\CC\1740 <e1>folinic_3\JJ\1740 acid</e1>_4\NN\14818238 supplementation_5\NN\5108947 of_6\IN\1740 zdv_7\NN\3834836 therapy_8\NN\657604 does_9\VBZ\1640855 not_10\RB\1740 seem_11\VB\2604760 useful_12\JJ\1740 in_13\IN\13603305 preventing_14\VBG\1740 or_15\CC\3541091 reducing_16\VBG\441445 zdv-induced_17\JJ\1740 <e2>myelotoxicity</e2>_18\NN\1740 in_19\IN\13603305 the_20\DT\1740 overall_21\JJ\1740 treated_22\VBN\2376958 population_23\NN\7942152 ,_24\,\1740 although_25\IN\1740 a_26\DT\13649268 beneficial_27\JJ\1740 effect_28\NN\34213 in_29\IN\13603305 certain_30\JJ\1740 subgroups_31\NNS\31264 of_32\IN\1740 patients_33\NNS\9898892 can_34\MD\3094503 not_35\RB\1740 be_36\VB\836236 excluded_37\VBN\471711 ._38\.\1740
D015215_D001855 CID a_0\DT\13649268 prospective_1\JJ\1740 ,_2\,\1740 randomized_3\JJ\1740 study_4\NN\635850 was_5\VBD\836236 conducted_6\VBN\2436349 to_7\TO\1740 evaluate_8\VB\670261 the_9\DT\1740 role_10\NN\719494 of_11\IN\1740 vitamin_12\NN\7570720 b12_13\NN\1740 and_14\CC\1740 folinic_15\JJ\1740 acid_16\NN\14818238 supplementation_17\NN\5108947 in_18\IN\13603305 preventing_19\VBG\1740 <e1>zidovudine</e1>_20\NN\3834836 (zdv)-induced_21\JJ\1740 <e2>bone_22\NN\5286536 marrow_23\NN\5286536 suppression</e2>_24\NN\13489037 ._25\.\1740
D015215_D001855 CID a_0\DT\13649268 prospective_1\JJ\1740 ,_2\,\1740 randomized_3\JJ\1740 study_4\NN\635850 was_5\VBD\836236 conducted_6\VBN\2436349 to_7\TO\1740 evaluate_8\VB\670261 the_9\DT\1740 role_10\NN\719494 of_11\IN\1740 vitamin_12\NN\7570720 b12_13\NN\1740 and_14\CC\1740 folinic_15\JJ\1740 acid_16\NN\14818238 supplementation_17\NN\5108947 in_18\IN\13603305 preventing_19\VBG\1740 zidovudine_20\NN\3834836 <e1>(zdv)-induced</e1>_21\JJ\1740 <e2>bone_22\NN\5286536 marrow_23\NN\5286536 suppression</e2>_24\NN\13489037 ._25\.\1740
D015215_D001855 CID vitamin_0\NN\7570720 b12_1\NN\1740 and_2\CC\1740 folinic_3\JJ\1740 acid_4\NN\14818238 supplementation_5\NN\5108947 of_6\IN\1740 <e1>zdv</e1>_7\NN\3834836 therapy_8\NN\657604 does_9\VBZ\1640855 not_10\RB\1740 seem_11\VB\2604760 useful_12\JJ\1740 in_13\IN\13603305 preventing_14\VBG\1740 or_15\CC\3541091 reducing_16\VBG\441445 zdv-induced_17\JJ\1740 <e2>myelotoxicity</e2>_18\NN\1740 in_19\IN\13603305 the_20\DT\1740 overall_21\JJ\1740 treated_22\VBN\2376958 population_23\NN\7942152 ,_24\,\1740 although_25\IN\1740 a_26\DT\13649268 beneficial_27\JJ\1740 effect_28\NN\34213 in_29\IN\13603305 certain_30\JJ\1740 subgroups_31\NNS\31264 of_32\IN\1740 patients_33\NNS\9898892 can_34\MD\3094503 not_35\RB\1740 be_36\VB\836236 excluded_37\VBN\471711 ._38\.\1740
D015215_D001855 CID vitamin_0\NN\7570720 b12_1\NN\1740 and_2\CC\1740 folinic_3\JJ\1740 acid_4\NN\14818238 supplementation_5\NN\5108947 of_6\IN\1740 zdv_7\NN\3834836 therapy_8\NN\657604 does_9\VBZ\1640855 not_10\RB\1740 seem_11\VB\2604760 useful_12\JJ\1740 in_13\IN\13603305 preventing_14\VBG\1740 or_15\CC\3541091 reducing_16\VBG\441445 <e1>zdv-induced</e1>_17\JJ\1740 <e2>myelotoxicity</e2>_18\NN\1740 in_19\IN\13603305 the_20\DT\1740 overall_21\JJ\1740 treated_22\VBN\2376958 population_23\NN\7942152 ,_24\,\1740 although_25\IN\1740 a_26\DT\13649268 beneficial_27\JJ\1740 effect_28\NN\34213 in_29\IN\13603305 certain_30\JJ\1740 subgroups_31\NNS\31264 of_32\IN\1740 patients_33\NNS\9898892 can_34\MD\3094503 not_35\RB\1740 be_36\VB\836236 excluded_37\VBN\471711 ._38\.\1740
D015215_D015658 NONE seventy-five_0\JJ\1740 <e2>human_1\JJ\1740 immunodeficiency_2\NN\13973990 virus_3\NN\9312843 (hiv)-infected</e2>_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 cd4_7\NN\14888310 +_8\CC\1740 cell_9\NN\3080309 counts_10\NNS\13582013 <_11\NN\1740 500/mm3_12\NN\1740 were_13\VBD\836236 randomized_14\VBN\278117 to_15\TO\1740 receive_16\VB\2210855 either_17\CC\1740 <e1>zdv</e1>_18\NN\3834836 (_19\-LRB-\1740 500_20\CD\13745420 mg_21\NN\13717155 daily_22\RB\1740 )_23\-RRB-\1740 alone_24\RB\1740 (_25\-LRB-\1740 group_26\NN\2137 i_27\NN\14622893 ,_28\,\1740 n_29\NN\14622893 =_30\JJ\1740 38_31\CD\1740 )_32\-RRB-\1740 or_33\CC\3541091 in_34\IN\13603305 combination_35\NN\7951464 with_36\IN\1740 folinic_37\JJ\1740 acid_38\NN\14818238 (_39\-LRB-\1740 15_40\CD\13745420 mg_41\NN\13717155 daily_42\RB\1740 )_43\-RRB-\1740 and_44\CC\1740 intramascular_45\JJ\1740 vitamin_46\NN\7570720 b12_47\NN\1740 (_48\-LRB-\1740 1000_49\CD\13745420 micrograms_50\NNS\13717155 monthly_51\RB\1740 )_52\-RRB-\1740 (_53\-LRB-\1740 group_54\NN\2137 ii_55\CD\13741022 ,_56\,\1740 n_57\NN\14622893 =_58\JJ\1740 37_59\CD\1740 )_60\-RRB-\1740 ._61\.\1740
D002955_D015658 NONE seventy-five_0\JJ\1740 <e2>human_1\JJ\1740 immunodeficiency_2\NN\13973990 virus_3\NN\9312843 (hiv)-infected</e2>_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 cd4_7\NN\14888310 +_8\CC\1740 cell_9\NN\3080309 counts_10\NNS\13582013 <_11\NN\1740 500/mm3_12\NN\1740 were_13\VBD\836236 randomized_14\VBN\278117 to_15\TO\1740 receive_16\VB\2210855 either_17\CC\1740 zdv_18\NN\3834836 (_19\-LRB-\1740 500_20\CD\13745420 mg_21\NN\13717155 daily_22\RB\1740 )_23\-RRB-\1740 alone_24\RB\1740 (_25\-LRB-\1740 group_26\NN\2137 i_27\NN\14622893 ,_28\,\1740 n_29\NN\14622893 =_30\JJ\1740 38_31\CD\1740 )_32\-RRB-\1740 or_33\CC\3541091 in_34\IN\13603305 combination_35\NN\7951464 with_36\IN\1740 <e1>folinic_37\JJ\1740 acid</e1>_38\NN\14818238 (_39\-LRB-\1740 15_40\CD\13745420 mg_41\NN\13717155 daily_42\RB\1740 )_43\-RRB-\1740 and_44\CC\1740 intramascular_45\JJ\1740 vitamin_46\NN\7570720 b12_47\NN\1740 (_48\-LRB-\1740 1000_49\CD\13745420 micrograms_50\NNS\13717155 monthly_51\RB\1740 )_52\-RRB-\1740 (_53\-LRB-\1740 group_54\NN\2137 ii_55\CD\13741022 ,_56\,\1740 n_57\NN\14622893 =_58\JJ\1740 37_59\CD\1740 )_60\-RRB-\1740 ._61\.\1740
D014805_D015658 NONE seventy-five_0\JJ\1740 <e2>human_1\JJ\1740 immunodeficiency_2\NN\13973990 virus_3\NN\9312843 (hiv)-infected</e2>_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 cd4_7\NN\14888310 +_8\CC\1740 cell_9\NN\3080309 counts_10\NNS\13582013 <_11\NN\1740 500/mm3_12\NN\1740 were_13\VBD\836236 randomized_14\VBN\278117 to_15\TO\1740 receive_16\VB\2210855 either_17\CC\1740 zdv_18\NN\3834836 (_19\-LRB-\1740 500_20\CD\13745420 mg_21\NN\13717155 daily_22\RB\1740 )_23\-RRB-\1740 alone_24\RB\1740 (_25\-LRB-\1740 group_26\NN\2137 i_27\NN\14622893 ,_28\,\1740 n_29\NN\14622893 =_30\JJ\1740 38_31\CD\1740 )_32\-RRB-\1740 or_33\CC\3541091 in_34\IN\13603305 combination_35\NN\7951464 with_36\IN\1740 folinic_37\JJ\1740 acid_38\NN\14818238 (_39\-LRB-\1740 15_40\CD\13745420 mg_41\NN\13717155 daily_42\RB\1740 )_43\-RRB-\1740 and_44\CC\1740 intramascular_45\JJ\1740 <e1>vitamin_46\NN\7570720 b12</e1>_47\NN\1740 (_48\-LRB-\1740 1000_49\CD\13745420 micrograms_50\NNS\13717155 monthly_51\RB\1740 )_52\-RRB-\1740 (_53\-LRB-\1740 group_54\NN\2137 ii_55\CD\13741022 ,_56\,\1740 n_57\NN\14622893 =_58\JJ\1740 37_59\CD\1740 )_60\-RRB-\1740 ._61\.\1740
D005492_D001855 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 correlation_3\NN\13841213 between_4\IN\1740 vitamin_5\NN\7570720 b12_6\NN\1740 or_7\CC\3541091 <e1>folate</e1>_8\VBP\1740 levels_9\NNS\4916342 and_10\CC\1740 development_11\NN\248977 of_12\IN\1740 <e2>myelosuppression</e2>_13\NN\1740 ._14\.\1740
16298782
D019331_D006311 NONE <e1>nitro-l-arginine_0\NN\1740 methyl_1\NN\14617189 ester</e1>_2\NN\14727670 :_3\:\1740 a_4\DT\13649268 potential_5\JJ\1740 protector_6\NN\10466918 against_7\IN\1740 gentamicin_8\NN\2716866 <e2>ototoxicity</e2>_9\NN\1740 ._10\.\1740
D005839_D006311 NONE nitro-l-arginine_0\NN\1740 methyl_1\NN\14617189 ester_2\NN\14727670 :_3\:\1740 a_4\DT\13649268 potential_5\JJ\1740 protector_6\NN\10466918 against_7\IN\1740 <e1>gentamicin</e1>_8\NN\2716866 <e2>ototoxicity</e2>_9\NN\1740 ._10\.\1740
D009569_D006316 NONE the_0\DT\1740 <e1>nitric_1\JJ\1740 oxide</e1>_2\NN\14818238 (_3\-LRB-\1740 no_4\NN\7204911 )_5\-RRB-\1740 inhibitor_6\NN\20090 nitro-l-arginine_7\NN\1740 methyl_8\NN\14617189 ester_9\NN\14727670 (_10\-LRB-\1740 l-name_11\NN\1740 )_12\-RRB-\1740 may_13\MD\15209706 act_14\VB\1619354 as_15\IN\14622893 an_16\DT\6697703 otoprotectant_17\NN\1740 against_18\IN\1740 <e2>high-frequency_19\NN\1740 hearing_20\NN\1184814 loss</e2>_21\NN\13252973 caused_22\VBN\1617192 by_23\IN\1740 gentamicin_24\NN\2716866 ,_25\,\1740 but_26\CC\1740 further_27\JJ\1740 studies_28\NNS\635850 are_29\VBP\836236 needed_30\VBN\2604760 to_31\TO\1740 confirm_32\VB\1011725 this_33\DT\1740 ._34\.\1740
D009569_D006316 NONE the_0\DT\1740 nitric_1\JJ\1740 oxide_2\NN\14818238 (_3\-LRB-\1740 <e1>no</e1>_4\NN\7204911 )_5\-RRB-\1740 inhibitor_6\NN\20090 nitro-l-arginine_7\NN\1740 methyl_8\NN\14617189 ester_9\NN\14727670 (_10\-LRB-\1740 l-name_11\NN\1740 )_12\-RRB-\1740 may_13\MD\15209706 act_14\VB\1619354 as_15\IN\14622893 an_16\DT\6697703 otoprotectant_17\NN\1740 against_18\IN\1740 <e2>high-frequency_19\NN\1740 hearing_20\NN\1184814 loss</e2>_21\NN\13252973 caused_22\VBN\1617192 by_23\IN\1740 gentamicin_24\NN\2716866 ,_25\,\1740 but_26\CC\1740 further_27\JJ\1740 studies_28\NNS\635850 are_29\VBP\836236 needed_30\VBN\2604760 to_31\TO\1740 confirm_32\VB\1011725 this_33\DT\1740 ._34\.\1740
D019331_D006316 NONE the_0\DT\1740 nitric_1\JJ\1740 oxide_2\NN\14818238 (_3\-LRB-\1740 no_4\NN\7204911 )_5\-RRB-\1740 inhibitor_6\NN\20090 <e1>nitro-l-arginine_7\NN\1740 methyl_8\NN\14617189 ester</e1>_9\NN\14727670 (_10\-LRB-\1740 l-name_11\NN\1740 )_12\-RRB-\1740 may_13\MD\15209706 act_14\VB\1619354 as_15\IN\14622893 an_16\DT\6697703 otoprotectant_17\NN\1740 against_18\IN\1740 <e2>high-frequency_19\NN\1740 hearing_20\NN\1184814 loss</e2>_21\NN\13252973 caused_22\VBN\1617192 by_23\IN\1740 gentamicin_24\NN\2716866 ,_25\,\1740 but_26\CC\1740 further_27\JJ\1740 studies_28\NNS\635850 are_29\VBP\836236 needed_30\VBN\2604760 to_31\TO\1740 confirm_32\VB\1011725 this_33\DT\1740 ._34\.\1740
D019331_D006316 NONE the_0\DT\1740 nitric_1\JJ\1740 oxide_2\NN\14818238 (_3\-LRB-\1740 no_4\NN\7204911 )_5\-RRB-\1740 inhibitor_6\NN\20090 nitro-l-arginine_7\NN\1740 methyl_8\NN\14617189 ester_9\NN\14727670 (_10\-LRB-\1740 <e1>l-name</e1>_11\NN\1740 )_12\-RRB-\1740 may_13\MD\15209706 act_14\VB\1619354 as_15\IN\14622893 an_16\DT\6697703 otoprotectant_17\NN\1740 against_18\IN\1740 <e2>high-frequency_19\NN\1740 hearing_20\NN\1184814 loss</e2>_21\NN\13252973 caused_22\VBN\1617192 by_23\IN\1740 gentamicin_24\NN\2716866 ,_25\,\1740 but_26\CC\1740 further_27\JJ\1740 studies_28\NNS\635850 are_29\VBP\836236 needed_30\VBN\2604760 to_31\TO\1740 confirm_32\VB\1011725 this_33\DT\1740 ._34\.\1740
D005839_D006316 NONE the_0\DT\1740 nitric_1\JJ\1740 oxide_2\NN\14818238 (_3\-LRB-\1740 no_4\NN\7204911 )_5\-RRB-\1740 inhibitor_6\NN\20090 nitro-l-arginine_7\NN\1740 methyl_8\NN\14617189 ester_9\NN\14727670 (_10\-LRB-\1740 l-name_11\NN\1740 )_12\-RRB-\1740 may_13\MD\15209706 act_14\VB\1619354 as_15\IN\14622893 an_16\DT\6697703 otoprotectant_17\NN\1740 against_18\IN\1740 <e2>high-frequency_19\NN\1740 hearing_20\NN\1184814 loss</e2>_21\NN\13252973 caused_22\VBN\1617192 by_23\IN\1740 <e1>gentamicin</e1>_24\NN\2716866 ,_25\,\1740 but_26\CC\1740 further_27\JJ\1740 studies_28\NNS\635850 are_29\VBP\836236 needed_30\VBN\2604760 to_31\TO\1740 confirm_32\VB\1011725 this_33\DT\1740 ._34\.\1740
D009569_D006311 NONE their_0\PRP$\1740 <e2>ototoxicity</e2>_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 serious_4\JJ\1740 health_5\NN\14447525 problem_6\NN\14408086 and_7\CC\1740 ,_8\,\1740 as_9\IN\14622893 their_10\PRP$\1740 ototoxic_11\JJ\1740 mechanism_12\NN\13446390 involves_13\VBZ\2676054 the_14\DT\1740 production_15\NN\30358 of_16\IN\1740 <e1>no</e1>_17\NN\7204911 ,_18\,\1740 we_19\PRP\1740 need_20\VBP\2604760 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 no_26\DT\7204911 inhibitors_27\NNS\20090 for_28\IN\1740 the_29\DT\1740 prevention_30\NN\1073995 of_31\IN\1740 aminoglycoside-induced_32\JJ\1740 sensorineural_33\JJ\1740 hearing_34\NN\1184814 loss_35\NN\13252973 ._36\.\1740
D009569_D006311 NONE their_0\PRP$\1740 ototoxicity_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 serious_4\JJ\1740 health_5\NN\14447525 problem_6\NN\14408086 and_7\CC\1740 ,_8\,\1740 as_9\IN\14622893 their_10\PRP$\1740 <e2>ototoxic</e2>_11\JJ\1740 mechanism_12\NN\13446390 involves_13\VBZ\2676054 the_14\DT\1740 production_15\NN\30358 of_16\IN\1740 <e1>no</e1>_17\NN\7204911 ,_18\,\1740 we_19\PRP\1740 need_20\VBP\2604760 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 no_26\DT\7204911 inhibitors_27\NNS\20090 for_28\IN\1740 the_29\DT\1740 prevention_30\NN\1073995 of_31\IN\1740 aminoglycoside-induced_32\JJ\1740 sensorineural_33\JJ\1740 hearing_34\NN\1184814 loss_35\NN\13252973 ._36\.\1740
D009569_D006311 NONE their_0\PRP$\1740 <e2>ototoxicity</e2>_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 serious_4\JJ\1740 health_5\NN\14447525 problem_6\NN\14408086 and_7\CC\1740 ,_8\,\1740 as_9\IN\14622893 their_10\PRP$\1740 ototoxic_11\JJ\1740 mechanism_12\NN\13446390 involves_13\VBZ\2676054 the_14\DT\1740 production_15\NN\30358 of_16\IN\1740 no_17\NN\7204911 ,_18\,\1740 we_19\PRP\1740 need_20\VBP\2604760 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 <e1>no</e1>_26\DT\7204911 inhibitors_27\NNS\20090 for_28\IN\1740 the_29\DT\1740 prevention_30\NN\1073995 of_31\IN\1740 aminoglycoside-induced_32\JJ\1740 sensorineural_33\JJ\1740 hearing_34\NN\1184814 loss_35\NN\13252973 ._36\.\1740
D009569_D006311 NONE their_0\PRP$\1740 ototoxicity_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 serious_4\JJ\1740 health_5\NN\14447525 problem_6\NN\14408086 and_7\CC\1740 ,_8\,\1740 as_9\IN\14622893 their_10\PRP$\1740 <e2>ototoxic</e2>_11\JJ\1740 mechanism_12\NN\13446390 involves_13\VBZ\2676054 the_14\DT\1740 production_15\NN\30358 of_16\IN\1740 no_17\NN\7204911 ,_18\,\1740 we_19\PRP\1740 need_20\VBP\2604760 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 <e1>no</e1>_26\DT\7204911 inhibitors_27\NNS\20090 for_28\IN\1740 the_29\DT\1740 prevention_30\NN\1073995 of_31\IN\1740 aminoglycoside-induced_32\JJ\1740 sensorineural_33\JJ\1740 hearing_34\NN\1184814 loss_35\NN\13252973 ._36\.\1740
D009569_D006319 NONE their_0\PRP$\1740 ototoxicity_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 serious_4\JJ\1740 health_5\NN\14447525 problem_6\NN\14408086 and_7\CC\1740 ,_8\,\1740 as_9\IN\14622893 their_10\PRP$\1740 ototoxic_11\JJ\1740 mechanism_12\NN\13446390 involves_13\VBZ\2676054 the_14\DT\1740 production_15\NN\30358 of_16\IN\1740 <e1>no</e1>_17\NN\7204911 ,_18\,\1740 we_19\PRP\1740 need_20\VBP\2604760 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 no_26\DT\7204911 inhibitors_27\NNS\20090 for_28\IN\1740 the_29\DT\1740 prevention_30\NN\1073995 of_31\IN\1740 aminoglycoside-induced_32\JJ\1740 <e2>sensorineural_33\JJ\1740 hearing_34\NN\1184814 loss</e2>_35\NN\13252973 ._36\.\1740
D009569_D006319 NONE their_0\PRP$\1740 ototoxicity_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 serious_4\JJ\1740 health_5\NN\14447525 problem_6\NN\14408086 and_7\CC\1740 ,_8\,\1740 as_9\IN\14622893 their_10\PRP$\1740 ototoxic_11\JJ\1740 mechanism_12\NN\13446390 involves_13\VBZ\2676054 the_14\DT\1740 production_15\NN\30358 of_16\IN\1740 no_17\NN\7204911 ,_18\,\1740 we_19\PRP\1740 need_20\VBP\2604760 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 <e1>no</e1>_26\DT\7204911 inhibitors_27\NNS\20090 for_28\IN\1740 the_29\DT\1740 prevention_30\NN\1073995 of_31\IN\1740 aminoglycoside-induced_32\JJ\1740 <e2>sensorineural_33\JJ\1740 hearing_34\NN\1184814 loss</e2>_35\NN\13252973 ._36\.\1740
D000617_D006311 NONE their_0\PRP$\1740 <e2>ototoxicity</e2>_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 serious_4\JJ\1740 health_5\NN\14447525 problem_6\NN\14408086 and_7\CC\1740 ,_8\,\1740 as_9\IN\14622893 their_10\PRP$\1740 ototoxic_11\JJ\1740 mechanism_12\NN\13446390 involves_13\VBZ\2676054 the_14\DT\1740 production_15\NN\30358 of_16\IN\1740 no_17\NN\7204911 ,_18\,\1740 we_19\PRP\1740 need_20\VBP\2604760 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 no_26\DT\7204911 inhibitors_27\NNS\20090 for_28\IN\1740 the_29\DT\1740 prevention_30\NN\1073995 of_31\IN\1740 <e1>aminoglycoside-induced</e1>_32\JJ\1740 sensorineural_33\JJ\1740 hearing_34\NN\1184814 loss_35\NN\13252973 ._36\.\1740
D000617_D006311 NONE their_0\PRP$\1740 ototoxicity_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 serious_4\JJ\1740 health_5\NN\14447525 problem_6\NN\14408086 and_7\CC\1740 ,_8\,\1740 as_9\IN\14622893 their_10\PRP$\1740 <e2>ototoxic</e2>_11\JJ\1740 mechanism_12\NN\13446390 involves_13\VBZ\2676054 the_14\DT\1740 production_15\NN\30358 of_16\IN\1740 no_17\NN\7204911 ,_18\,\1740 we_19\PRP\1740 need_20\VBP\2604760 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 no_26\DT\7204911 inhibitors_27\NNS\20090 for_28\IN\1740 the_29\DT\1740 prevention_30\NN\1073995 of_31\IN\1740 <e1>aminoglycoside-induced</e1>_32\JJ\1740 sensorineural_33\JJ\1740 hearing_34\NN\1184814 loss_35\NN\13252973 ._36\.\1740
D000617_D006319 NONE their_0\PRP$\1740 ototoxicity_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 serious_4\JJ\1740 health_5\NN\14447525 problem_6\NN\14408086 and_7\CC\1740 ,_8\,\1740 as_9\IN\14622893 their_10\PRP$\1740 ototoxic_11\JJ\1740 mechanism_12\NN\13446390 involves_13\VBZ\2676054 the_14\DT\1740 production_15\NN\30358 of_16\IN\1740 no_17\NN\7204911 ,_18\,\1740 we_19\PRP\1740 need_20\VBP\2604760 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 no_26\DT\7204911 inhibitors_27\NNS\20090 for_28\IN\1740 the_29\DT\1740 prevention_30\NN\1073995 of_31\IN\1740 <e1>aminoglycoside-induced</e1>_32\JJ\1740 <e2>sensorineural_33\JJ\1740 hearing_34\NN\1184814 loss</e2>_35\NN\13252973 ._36\.\1740
D019331_D034381 NONE <e1>l-name</e1>_0\NNP\1740 reduced_1\VBD\441445 gentamicin-induced_2\JJ\1740 <e2>hearing_3\NN\1184814 loss</e2>_4\NN\13252973 in_5\IN\13603305 the_6\DT\1740 high-frequency_7\NN\1740 range_8\NN\5123416 ,_9\,\1740 but_10\CC\1740 gave_11\VBD\2327200 no_12\DT\7204911 protection_13\NN\407535 in_14\IN\13603305 the_15\DT\1740 middle_16\NN\8497294 or_17\CC\3541091 low_18\JJ\1740 frequencies_19\NNS\15286249 ._20\.\1740
D005839_D034381 CID l-name_0\NNP\1740 reduced_1\VBD\441445 <e1>gentamicin-induced</e1>_2\JJ\1740 <e2>hearing_3\NN\1184814 loss</e2>_4\NN\13252973 in_5\IN\13603305 the_6\DT\1740 high-frequency_7\NN\1740 range_8\NN\5123416 ,_9\,\1740 but_10\CC\1740 gave_11\VBD\2327200 no_12\DT\7204911 protection_13\NN\407535 in_14\IN\13603305 the_15\DT\1740 middle_16\NN\8497294 or_17\CC\3541091 low_18\JJ\1740 frequencies_19\NNS\15286249 ._20\.\1740
6538499
D011092_D064420 NONE effect_0\NN\34213 of_1\IN\1740 <e1>polyethylene_2\NN\14902141 glycol_3\NN\14766364 400</e1>_4\CD\1740 on_5\IN\1740 adriamycin_6\NN\1740 <e2>toxicity</e2>_7\NN\13576101 in_8\IN\13603305 mice_9\NNS\2329401 ._10\.\1740
D004317_D064420 NONE effect_0\NN\34213 of_1\IN\1740 polyethylene_2\NN\14902141 glycol_3\NN\14766364 400_4\CD\1740 on_5\IN\1740 <e1>adriamycin</e1>_6\NN\1740 <e2>toxicity</e2>_7\NN\13576101 in_8\IN\13603305 mice_9\NNS\2329401 ._10\.\1740
D004317_D009202 CID light_0\JJ\1740 microscopic_1\JJ\1740 analysis_2\NN\633864 showed_3\VBD\2137132 a_4\DT\13649268 significant_5\JJ\1740 protection_6\NN\407535 against_7\IN\1740 <e1>adr-induced</e1>_8\JJ\1740 <e2>cardiac_9\JJ\1740 morphological_10\JJ\1740 alterations</e2>_11\NNS\7283608 ._12\.\1740
D004317_D007939 NONE such_0\JJ\1740 treatment_1\NN\654885 did_2\VBD\1640855 not_3\RB\1740 diminish_4\VB\169651 the_5\DT\1740 <e1>adr</e1>_6\NN\1740 antitumor_7\NN\1740 activity_8\NN\30358 in_9\IN\13603305 <e2>l1210_10\NN\1740 leukemia</e2>_11\NN\14239918 and_12\CC\1740 in_13\IN\13603305 ehrlich_14\JJ\1740 ascites_15\NNS\14204950 tumor_16\NN\14234074 ._17\.\1740
D004317_D002286 NONE such_0\JJ\1740 treatment_1\NN\654885 did_2\VBD\1640855 not_3\RB\1740 diminish_4\VB\169651 the_5\DT\1740 <e1>adr</e1>_6\NN\1740 antitumor_7\NN\1740 activity_8\NN\30358 in_9\IN\13603305 l1210_10\NN\1740 leukemia_11\NN\14239918 and_12\CC\1740 in_13\IN\13603305 <e2>ehrlich_14\JJ\1740 ascites_15\NNS\14204950 tumor</e2>_16\NN\14234074 ._17\.\1740
12653683
D012964_D009404 NONE epithelial_0\JJ\1740 <e1>sodium</e1>_1\NN\14625458 channel_2\NN\6251781 (_3\-LRB-\1740 enac_4\NN\1740 )_5\-RRB-\1740 subunit_6\NN\13604718 mrna_7\NN\14832193 and_8\CC\1740 protein_9\NN\14944888 expression_10\NN\4679549 in_11\IN\13603305 rats_12\NNS\2329401 with_13\IN\1740 puromycin_14\NN\1740 aminonucleoside-induced_15\JJ\1740 <e2>nephrotic_16\JJ\1740 syndrome</e2>_17\NN\5870365 ._18\.\1740
D012964_D009404 NONE in_0\IN\13603305 experimental_1\JJ\1740 <e2>nephrotic_2\JJ\1740 syndrome</e2>_3\NN\5870365 ,_4\,\1740 urinary_5\JJ\1740 <e1>sodium</e1>_6\NN\14625458 excretion_7\NN\13466586 is_8\VBZ\836236 decreased_9\VBN\169651 during_10\IN\1740 the_11\DT\1740 early_12\JJ\1740 phase_13\NN\15113229 of_14\IN\1740 the_15\DT\1740 disease_16\NN\14061805 ._17\.\1740
D011692_D009404 CID epithelial_0\JJ\1740 sodium_1\NN\14625458 channel_2\NN\6251781 (_3\-LRB-\1740 enac_4\NN\1740 )_5\-RRB-\1740 subunit_6\NN\13604718 mrna_7\NN\14832193 and_8\CC\1740 protein_9\NN\14944888 expression_10\NN\4679549 in_11\IN\13603305 rats_12\NNS\2329401 with_13\IN\1740 <e1>puromycin_14\NN\1740 aminonucleoside-induced</e1>_15\JJ\1740 <e2>nephrotic_16\JJ\1740 syndrome</e2>_17\NN\5870365 ._18\.\1740
D011692_D009404 CID we_0\PRP\1740 examined_1\VBD\789138 the_2\DT\1740 abundance_3\NN\5108740 of_4\IN\1740 enac_5\NN\1740 subunit_6\NN\13604718 mrnas_7\NNS\14832193 and_8\CC\1740 proteins_9\NNS\14944888 in_10\IN\13603305 <e1>puromycin_11\NN\1740 aminonucleoside</e1>_12\NN\1740 (pan)-induced_13\JJ\1740 <e2>nephrotic_14\JJ\1740 syndrome</e2>_15\NN\5870365 ._16\.\1740
D011692_D009404 CID we_0\PRP\1740 examined_1\VBD\789138 the_2\DT\1740 abundance_3\NN\5108740 of_4\IN\1740 enac_5\NN\1740 subunit_6\NN\13604718 mrnas_7\NNS\14832193 and_8\CC\1740 proteins_9\NNS\14944888 in_10\IN\13603305 puromycin_11\NN\1740 aminonucleoside_12\NN\1740 <e1>(pan)-induced</e1>_13\JJ\1740 <e2>nephrotic_14\JJ\1740 syndrome</e2>_15\NN\5870365 ._16\.\1740
D011692_D009404 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 enac_3\NN\1740 mrna_4\NN\14832193 expression_5\NN\4679549 ,_6\,\1740 especially_7\RB\1740 alphaenac_8\NN\1740 ,_9\,\1740 is_10\VBZ\836236 increased_11\VBN\169651 in_12\IN\13603305 the_13\DT\1740 very_14\RB\1740 early_15\JJ\1740 phase_16\NN\15113229 of_17\IN\1740 the_18\DT\1740 experimental_19\JJ\1740 model_20\NN\5888929 of_21\IN\1740 <e1>pan-induced</e1>_22\JJ\1740 <e2>nephrotic_23\JJ\1740 syndrome</e2>_24\NN\5870365 in_25\IN\13603305 rats_26\NNS\2329401 ,_27\,\1740 but_28\CC\1740 appears_29\VBZ\2604760 to_30\TO\1740 escape_31\VB\2075462 from_32\IN\1740 the_33\DT\1740 regulation_34\NN\6652242 by_35\IN\1740 aldosterone_36\NN\14751863 after_37\IN\1740 day_38\NN\15154774 3_39\CD\13741022 ._40\.\1740
D012964_D011507 NONE the_0\DT\1740 time_1\NN\7308889 courses_2\NNS\883297 of_3\IN\1740 urinary_4\JJ\1740 <e1>sodium</e1>_5\NN\14625458 excretion_6\NN\13466586 ,_7\,\1740 plasma_8\NN\5398023 aldosterone_9\NN\14751863 concentration_10\NN\4916342 and_11\CC\1740 <e2>proteinuria</e2>_12\NN\14299637 were_13\VBD\836236 studied_14\VBN\630380 in_15\IN\13603305 male_16\JJ\1740 sprague-dawley_17\NN\1740 rats_18\NNS\2329401 treated_19\VBN\2376958 with_20\IN\1740 a_21\DT\13649268 single_22\JJ\1740 dose_23\NN\3740161 of_24\IN\1740 either_25\CC\1740 pan_26\NN\3101986 or_27\CC\3541091 vehicle_28\NN\3100490 ._29\.\1740
D012964_D011507 NONE the_0\DT\1740 kinetics_1\NNS\6100236 of_2\IN\1740 urinary_3\JJ\1740 <e1>sodium</e1>_4\NN\14625458 excretion_5\NN\13466586 and_6\CC\1740 the_7\DT\1740 appearance_8\NN\4723816 of_9\IN\1740 <e2>proteinuria</e2>_10\NN\14299637 were_11\VBD\836236 comparable_12\JJ\1740 with_13\IN\1740 those_14\DT\1740 reported_15\VBN\831651 previously_16\RB\1740 ._17\.\1740
D000450_D011507 NONE the_0\DT\1740 time_1\NN\7308889 courses_2\NNS\883297 of_3\IN\1740 urinary_4\JJ\1740 sodium_5\NN\14625458 excretion_6\NN\13466586 ,_7\,\1740 plasma_8\NN\5398023 <e1>aldosterone</e1>_9\NN\14751863 concentration_10\NN\4916342 and_11\CC\1740 <e2>proteinuria</e2>_12\NN\14299637 were_13\VBD\836236 studied_14\VBN\630380 in_15\IN\13603305 male_16\JJ\1740 sprague-dawley_17\NN\1740 rats_18\NNS\2329401 treated_19\VBN\2376958 with_20\IN\1740 a_21\DT\13649268 single_22\JJ\1740 dose_23\NN\3740161 of_24\IN\1740 either_25\CC\1740 pan_26\NN\3101986 or_27\CC\3541091 vehicle_28\NN\3100490 ._29\.\1740
D011692_D011507 CID the_0\DT\1740 time_1\NN\7308889 courses_2\NNS\883297 of_3\IN\1740 urinary_4\JJ\1740 sodium_5\NN\14625458 excretion_6\NN\13466586 ,_7\,\1740 plasma_8\NN\5398023 aldosterone_9\NN\14751863 concentration_10\NN\4916342 and_11\CC\1740 <e2>proteinuria</e2>_12\NN\14299637 were_13\VBD\836236 studied_14\VBN\630380 in_15\IN\13603305 male_16\JJ\1740 sprague-dawley_17\NN\1740 rats_18\NNS\2329401 treated_19\VBN\2376958 with_20\IN\1740 a_21\DT\13649268 single_22\JJ\1740 dose_23\NN\3740161 of_24\IN\1740 either_25\CC\1740 <e1>pan</e1>_26\NN\3101986 or_27\CC\3541091 vehicle_28\NN\3100490 ._29\.\1740
D000450_D009404 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 enac_3\NN\1740 mrna_4\NN\14832193 expression_5\NN\4679549 ,_6\,\1740 especially_7\RB\1740 alphaenac_8\NN\1740 ,_9\,\1740 is_10\VBZ\836236 increased_11\VBN\169651 in_12\IN\13603305 the_13\DT\1740 very_14\RB\1740 early_15\JJ\1740 phase_16\NN\15113229 of_17\IN\1740 the_18\DT\1740 experimental_19\JJ\1740 model_20\NN\5888929 of_21\IN\1740 pan-induced_22\JJ\1740 <e2>nephrotic_23\JJ\1740 syndrome</e2>_24\NN\5870365 in_25\IN\13603305 rats_26\NNS\2329401 ,_27\,\1740 but_28\CC\1740 appears_29\VBZ\2604760 to_30\TO\1740 escape_31\VB\2075462 from_32\IN\1740 the_33\DT\1740 regulation_34\NN\6652242 by_35\IN\1740 <e1>aldosterone</e1>_36\NN\14751863 after_37\IN\1740 day_38\NN\15154774 3_39\CD\13741022 ._40\.\1740
3615541
D000661_D006948 CID regional_0\JJ\1740 localization_1\NN\151497 of_2\IN\1740 the_3\DT\1740 antagonism_4\NN\24720 of_5\IN\1740 <e1>amphetamine-induced</e1>_6\JJ\1740 <e2>hyperactivity</e2>_7\NN\14052403 by_8\IN\1740 intracerebral_9\JJ\1740 calcitonin_10\NN\5413241 injections_11\NNS\320852 ._12\.\1740
D002116_D006948 NONE regional_0\JJ\1740 localization_1\NN\151497 of_2\IN\1740 the_3\DT\1740 antagonism_4\NN\24720 of_5\IN\1740 amphetamine-induced_6\JJ\1740 <e2>hyperactivity</e2>_7\NN\14052403 by_8\IN\1740 intracerebral_9\JJ\1740 <e1>calcitonin</e1>_10\NN\5413241 injections_11\NNS\320852 ._12\.\1740
20084309
D008874_D020521 NONE uni-_0\NN\1740 and_1\CC\1740 multivariate_2\NN\1740 analyses_3\NNS\633864 were_4\VBD\836236 used_5\VBN\1156834 to_6\TO\1740 test_7\VB\670261 the_8\DT\1740 influence_9\NN\5190804 of_10\IN\1740 the_11\DT\1740 clinical_12\JJ\1740 variables_13\NNS\2452 :_14\:\1740 age_15\NN\4916342 ,_16\,\1740 sex_17\NN\13440063 ,_18\,\1740 <e2>stroke</e2>_19\NN\556313 ,_20\,\1740 myocardiopathy_21\JJ\1740 (_22\-LRB-\1740 mp_23\NN\10249459 )_24\-RRB-\1740 ,_25\,\1740 duration_26\NN\15113229 of_27\IN\1740 the_28\DT\1740 test_29\NN\5798043 ,_30\,\1740 mitral_31\JJ\1740 regurgitation_32\NN\7406350 (_33\-LRB-\1740 mr_34\NN\6339416 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 <e1>mz</e1>_38\NN\1740 dose_39\NN\3740161 ._40\.\1740
D008874_D009202 NONE uni-_0\NN\1740 and_1\CC\1740 multivariate_2\NN\1740 analyses_3\NNS\633864 were_4\VBD\836236 used_5\VBN\1156834 to_6\TO\1740 test_7\VB\670261 the_8\DT\1740 influence_9\NN\5190804 of_10\IN\1740 the_11\DT\1740 clinical_12\JJ\1740 variables_13\NNS\2452 :_14\:\1740 age_15\NN\4916342 ,_16\,\1740 sex_17\NN\13440063 ,_18\,\1740 stroke_19\NN\556313 ,_20\,\1740 <e2>myocardiopathy</e2>_21\JJ\1740 (_22\-LRB-\1740 mp_23\NN\10249459 )_24\-RRB-\1740 ,_25\,\1740 duration_26\NN\15113229 of_27\IN\1740 the_28\DT\1740 test_29\NN\5798043 ,_30\,\1740 mitral_31\JJ\1740 regurgitation_32\NN\7406350 (_33\-LRB-\1740 mr_34\NN\6339416 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 <e1>mz</e1>_38\NN\1740 dose_39\NN\3740161 ._40\.\1740
D008874_D009202 NONE uni-_0\NN\1740 and_1\CC\1740 multivariate_2\NN\1740 analyses_3\NNS\633864 were_4\VBD\836236 used_5\VBN\1156834 to_6\TO\1740 test_7\VB\670261 the_8\DT\1740 influence_9\NN\5190804 of_10\IN\1740 the_11\DT\1740 clinical_12\JJ\1740 variables_13\NNS\2452 :_14\:\1740 age_15\NN\4916342 ,_16\,\1740 sex_17\NN\13440063 ,_18\,\1740 stroke_19\NN\556313 ,_20\,\1740 myocardiopathy_21\JJ\1740 (_22\-LRB-\1740 <e2>mp</e2>_23\NN\10249459 )_24\-RRB-\1740 ,_25\,\1740 duration_26\NN\15113229 of_27\IN\1740 the_28\DT\1740 test_29\NN\5798043 ,_30\,\1740 mitral_31\JJ\1740 regurgitation_32\NN\7406350 (_33\-LRB-\1740 mr_34\NN\6339416 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 <e1>mz</e1>_38\NN\1740 dose_39\NN\3740161 ._40\.\1740
D008874_D009202 NONE the_0\DT\1740 multivariate_1\NN\1740 analysis_2\NN\633864 showed_3\VBD\2137132 that_4\IN\1740 severe_5\JJ\1740 mr_6\NN\6339416 ,_7\,\1740 <e2>mp</e2>_8\NN\10249459 (_9\-LRB-\1740 ef<45_10\NN\1740 %_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 high_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 <e1>mz</e1>_17\NN\1740 (_18\-LRB-\1740 >_19\NNS\1740 5_20\CD\13741022 mg_21\NN\13717155 )_22\-RRB-\1740 were_23\VBD\836236 associated_24\VBN\628491 with_25\IN\1740 events_26\NNS\23100 (_27\-LRB-\1740 p<0.001_28\NN\1740 )_29\-RRB-\1740 ._30\.\1740
D008874_D008944 NONE uni-_0\NN\1740 and_1\CC\1740 multivariate_2\NN\1740 analyses_3\NNS\633864 were_4\VBD\836236 used_5\VBN\1156834 to_6\TO\1740 test_7\VB\670261 the_8\DT\1740 influence_9\NN\5190804 of_10\IN\1740 the_11\DT\1740 clinical_12\JJ\1740 variables_13\NNS\2452 :_14\:\1740 age_15\NN\4916342 ,_16\,\1740 sex_17\NN\13440063 ,_18\,\1740 stroke_19\NN\556313 ,_20\,\1740 myocardiopathy_21\JJ\1740 (_22\-LRB-\1740 mp_23\NN\10249459 )_24\-RRB-\1740 ,_25\,\1740 duration_26\NN\15113229 of_27\IN\1740 the_28\DT\1740 test_29\NN\5798043 ,_30\,\1740 <e2>mitral_31\JJ\1740 regurgitation</e2>_32\NN\7406350 (_33\-LRB-\1740 mr_34\NN\6339416 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 <e1>mz</e1>_38\NN\1740 dose_39\NN\3740161 ._40\.\1740
D008874_D008944 NONE uni-_0\NN\1740 and_1\CC\1740 multivariate_2\NN\1740 analyses_3\NNS\633864 were_4\VBD\836236 used_5\VBN\1156834 to_6\TO\1740 test_7\VB\670261 the_8\DT\1740 influence_9\NN\5190804 of_10\IN\1740 the_11\DT\1740 clinical_12\JJ\1740 variables_13\NNS\2452 :_14\:\1740 age_15\NN\4916342 ,_16\,\1740 sex_17\NN\13440063 ,_18\,\1740 stroke_19\NN\556313 ,_20\,\1740 myocardiopathy_21\JJ\1740 (_22\-LRB-\1740 mp_23\NN\10249459 )_24\-RRB-\1740 ,_25\,\1740 duration_26\NN\15113229 of_27\IN\1740 the_28\DT\1740 test_29\NN\5798043 ,_30\,\1740 mitral_31\JJ\1740 regurgitation_32\NN\7406350 (_33\-LRB-\1740 <e2>mr</e2>_34\NN\6339416 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 <e1>mz</e1>_38\NN\1740 dose_39\NN\3740161 ._40\.\1740
D008874_D008944 NONE the_0\DT\1740 multivariate_1\NN\1740 analysis_2\NN\633864 showed_3\VBD\2137132 that_4\IN\1740 severe_5\JJ\1740 <e2>mr</e2>_6\NN\6339416 ,_7\,\1740 mp_8\NN\10249459 (_9\-LRB-\1740 ef<45_10\NN\1740 %_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 high_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 <e1>mz</e1>_17\NN\1740 (_18\-LRB-\1740 >_19\NNS\1740 5_20\CD\13741022 mg_21\NN\13717155 )_22\-RRB-\1740 were_23\VBD\836236 associated_24\VBN\628491 with_25\IN\1740 events_26\NNS\23100 (_27\-LRB-\1740 p<0.001_28\NN\1740 )_29\-RRB-\1740 ._30\.\1740
D008874_D000860 CID mild_0\JJ\1740 <e2>hypoxia</e2>_1\NN\14035298 (_2\-LRB-\1740 so2<90_3\NN\1740 %_4\NN\1740 )_5\-RRB-\1740 was_6\VBD\836236 the_7\DT\1740 most_8\RBS\1740 common_9\JJ\1740 event_10\NN\23100 (_11\-LRB-\1740 11_12\CD\13745420 patients_13\NNS\9898892 )_14\-RRB-\1740 ;_15\:\1740 3_16\CD\13741022 patients_17\NNS\9898892 (_18\-LRB-\1740 2_19\CD\13741022 %_20\NN\1740 )_21\-RRB-\1740 presented_22\VBD\2137132 transient_23\JJ\1740 hypoxia_24\NN\14035298 due_25\IN\5174653 to_26\TO\1740 upper_27\JJ\1740 airway_28\NN\3253398 obstruction_29\NN\4341686 by_30\IN\1740 probe_31\NN\5797597 introduction_32\NN\235435 and_33\CC\1740 8_34\CD\13741022 (_35\-LRB-\1740 5.8_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 due_39\JJ\1740 to_40\TO\1740 hypoxia_41\NN\14035298 caused_42\VBN\1617192 by_43\IN\1740 <e1>mz</e1>_44\JJ\1740 use_45\NN\407535 ._46\.\1740
D008874_D000860 CID mild_0\JJ\1740 hypoxia_1\NN\14035298 (_2\-LRB-\1740 so2<90_3\NN\1740 %_4\NN\1740 )_5\-RRB-\1740 was_6\VBD\836236 the_7\DT\1740 most_8\RBS\1740 common_9\JJ\1740 event_10\NN\23100 (_11\-LRB-\1740 11_12\CD\13745420 patients_13\NNS\9898892 )_14\-RRB-\1740 ;_15\:\1740 3_16\CD\13741022 patients_17\NNS\9898892 (_18\-LRB-\1740 2_19\CD\13741022 %_20\NN\1740 )_21\-RRB-\1740 presented_22\VBD\2137132 transient_23\JJ\1740 <e2>hypoxia</e2>_24\NN\14035298 due_25\IN\5174653 to_26\TO\1740 upper_27\JJ\1740 airway_28\NN\3253398 obstruction_29\NN\4341686 by_30\IN\1740 probe_31\NN\5797597 introduction_32\NN\235435 and_33\CC\1740 8_34\CD\13741022 (_35\-LRB-\1740 5.8_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 due_39\JJ\1740 to_40\TO\1740 hypoxia_41\NN\14035298 caused_42\VBN\1617192 by_43\IN\1740 <e1>mz</e1>_44\JJ\1740 use_45\NN\407535 ._46\.\1740
D008874_D000860 CID mild_0\JJ\1740 hypoxia_1\NN\14035298 (_2\-LRB-\1740 so2<90_3\NN\1740 %_4\NN\1740 )_5\-RRB-\1740 was_6\VBD\836236 the_7\DT\1740 most_8\RBS\1740 common_9\JJ\1740 event_10\NN\23100 (_11\-LRB-\1740 11_12\CD\13745420 patients_13\NNS\9898892 )_14\-RRB-\1740 ;_15\:\1740 3_16\CD\13741022 patients_17\NNS\9898892 (_18\-LRB-\1740 2_19\CD\13741022 %_20\NN\1740 )_21\-RRB-\1740 presented_22\VBD\2137132 transient_23\JJ\1740 hypoxia_24\NN\14035298 due_25\IN\5174653 to_26\TO\1740 upper_27\JJ\1740 airway_28\NN\3253398 obstruction_29\NN\4341686 by_30\IN\1740 probe_31\NN\5797597 introduction_32\NN\235435 and_33\CC\1740 8_34\CD\13741022 (_35\-LRB-\1740 5.8_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 due_39\JJ\1740 to_40\TO\1740 <e2>hypoxia</e2>_41\NN\14035298 caused_42\VBN\1617192 by_43\IN\1740 <e1>mz</e1>_44\JJ\1740 use_45\NN\407535 ._46\.\1740
D008874_D000402 NONE mild_0\JJ\1740 hypoxia_1\NN\14035298 (_2\-LRB-\1740 so2<90_3\NN\1740 %_4\NN\1740 )_5\-RRB-\1740 was_6\VBD\836236 the_7\DT\1740 most_8\RBS\1740 common_9\JJ\1740 event_10\NN\23100 (_11\-LRB-\1740 11_12\CD\13745420 patients_13\NNS\9898892 )_14\-RRB-\1740 ;_15\:\1740 3_16\CD\13741022 patients_17\NNS\9898892 (_18\-LRB-\1740 2_19\CD\13741022 %_20\NN\1740 )_21\-RRB-\1740 presented_22\VBD\2137132 transient_23\JJ\1740 hypoxia_24\NN\14035298 due_25\IN\5174653 to_26\TO\1740 upper_27\JJ\1740 <e2>airway_28\NN\3253398 obstruction</e2>_29\NN\4341686 by_30\IN\1740 probe_31\NN\5797597 introduction_32\NN\235435 and_33\CC\1740 8_34\CD\13741022 (_35\-LRB-\1740 5.8_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 due_39\JJ\1740 to_40\TO\1740 hypoxia_41\NN\14035298 caused_42\VBN\1617192 by_43\IN\1740 <e1>mz</e1>_44\JJ\1740 use_45\NN\407535 ._46\.\1740
1786266
D000928_D001480 NONE <e2>rabbit_0\NN\2323902 syndrome</e2>_1\NN\5870365 ,_2\,\1740 <e1>antidepressant</e1>_3\JJ\1740 use_4\NN\407535 ,_5\,\1740 and_6\CC\1740 cerebral_7\JJ\1740 perfusion_8\NN\320852 spect_9\NN\1740 scan_10\JJ\1740 findings_11\NNS\7951464 ._12\.\1740
15325671
D003520_D066126 NONE <e2>cardiac_0\JJ\1740 toxicity</e2>_1\NN\13576101 observed_2\VBN\2163746 in_3\IN\13603305 association_4\NN\8008335 with_5\IN\1740 high-dose_6\JJ\1740 <e1>cyclophosphamide-based</e1>_7\JJ\1740 chemotherapy_8\NN\661091 for_9\IN\1740 metastatic_10\JJ\1740 breast_11\NN\5225090 cancer_12\NN\14239425 ._13\.\1740
D003520_D066126 NONE incidence_0\NN\13821570 of_1\IN\1740 transient_2\JJ\1740 <e1>cyclophosphamide-related</e1>_3\JJ\1740 <e2>cardiac_4\JJ\1740 toxicity</e2>_5\NN\13576101 (_6\-LRB-\1740 10_7\CD\13745420 %_8\NN\1740 )_9\-RRB-\1740 is_10\VBZ\836236 comparable_11\JJ\1740 to_12\TO\1740 previous_13\JJ\1740 recorded_14\JJ\1740 literature_15\NN\6362953 ._16\.\1740
D003520_D001943 NONE cardiac_0\JJ\1740 toxicity_1\NN\13576101 observed_2\VBN\2163746 in_3\IN\13603305 association_4\NN\8008335 with_5\IN\1740 high-dose_6\JJ\1740 <e1>cyclophosphamide-based</e1>_7\JJ\1740 chemotherapy_8\NN\661091 for_9\IN\1740 metastatic_10\JJ\1740 <e2>breast_11\NN\5225090 cancer</e2>_12\NN\14239425 ._13\.\1740
D003520_D001943 NONE study_0\NN\635850 design_1\NN\927261 :_2\:\1740 we_3\PRP\1740 combined_4\VBD\2630189 paclitaxel_5\NN\1740 ,_6\,\1740 melphalan_7\NN\2722458 and_8\CC\1740 high-dose_9\JJ\1740 <e1>cyclophosphamide</e1>_10\NN\1740 ,_11\,\1740 thiotepa_12\NN\2722458 ,_13\,\1740 and_14\CC\1740 carboplatin_15\NN\1740 in_16\IN\13603305 a_17\DT\13649268 triple_18\RB\1740 sequential_19\JJ\1740 high-dose_20\JJ\1740 regimen_21\NN\5898568 for_22\IN\1740 patients_23\NNS\9898892 with_24\IN\1740 metastatic_25\JJ\1740 <e2>breast_26\NN\5225090 cancer</e2>_27\NN\14239425 ._28\.\1740
D003520_D001943 NONE analysis_0\NN\633864 was_1\VBD\836236 performed_2\VBN\2367363 on_3\IN\1740 61_4\CD\1740 women_5\NNS\9605289 with_6\IN\1740 chemotherapy-responsive_7\JJ\1740 metastatic_8\JJ\1740 <e2>breast_9\NN\5225090 cancer</e2>_10\NN\14239425 receiving_11\VBG\2210855 96-h_12\JJ\1740 infusional_13\JJ\1740 <e1>cyclophosphamide</e1>_14\NN\1740 as_15\IN\14622893 part_16\NN\31921 of_17\IN\1740 a_18\DT\13649268 triple_19\RB\1740 sequential_20\JJ\1740 high-dose_21\JJ\1740 regimen_22\NN\5898568 to_23\TO\1740 assess_24\VB\670261 association_25\NN\8008335 between_26\IN\1740 presence_27\NN\13954253 of_28\IN\1740 peritransplant_29\JJ\1740 congestive_30\JJ\1740 heart_31\NN\5919034 failure_32\NN\66216 (_33\-LRB-\1740 chf_34\NN\1740 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 following_38\VBG\1835496 pretreatment_39\NN\1740 characteristics_40\NNS\5849040 :_41\:\1740 presence_42\NN\13954253 of_43\IN\1740 electrocardiogram_44\NN\7000195 (_45\-LRB-\1740 ekg_46\NN\7000195 )_47\-RRB-\1740 abnormalities_48\NNS\14034177 ,_49\,\1740 age_50\NN\4916342 ,_51\,\1740 hypertension_52\NN\14057371 ,_53\,\1740 prior_54\JJ\1740 cardiac_55\JJ\1740 history_56\NN\15120823 ,_57\,\1740 smoking_58\NN\831191 ,_59\,\1740 diabetes_60\NN\14075199 mellitus_61\NN\1740 ,_62\,\1740 prior_63\JJ\1740 use_64\NN\407535 of_65\IN\1740 anthracyclines_66\NNS\1740 ,_67\,\1740 and_68\CC\1740 left-sided_69\JJ\1740 chest_70\NN\5220461 irradiation_71\NN\13920835 ._72\.\1740
D017239_D001943 NONE study_0\NN\635850 design_1\NN\927261 :_2\:\1740 we_3\PRP\1740 combined_4\VBD\2630189 <e1>paclitaxel</e1>_5\NN\1740 ,_6\,\1740 melphalan_7\NN\2722458 and_8\CC\1740 high-dose_9\JJ\1740 cyclophosphamide_10\NN\1740 ,_11\,\1740 thiotepa_12\NN\2722458 ,_13\,\1740 and_14\CC\1740 carboplatin_15\NN\1740 in_16\IN\13603305 a_17\DT\13649268 triple_18\RB\1740 sequential_19\JJ\1740 high-dose_20\JJ\1740 regimen_21\NN\5898568 for_22\IN\1740 patients_23\NNS\9898892 with_24\IN\1740 metastatic_25\JJ\1740 <e2>breast_26\NN\5225090 cancer</e2>_27\NN\14239425 ._28\.\1740
D008558_D001943 NONE study_0\NN\635850 design_1\NN\927261 :_2\:\1740 we_3\PRP\1740 combined_4\VBD\2630189 paclitaxel_5\NN\1740 ,_6\,\1740 <e1>melphalan</e1>_7\NN\2722458 and_8\CC\1740 high-dose_9\JJ\1740 cyclophosphamide_10\NN\1740 ,_11\,\1740 thiotepa_12\NN\2722458 ,_13\,\1740 and_14\CC\1740 carboplatin_15\NN\1740 in_16\IN\13603305 a_17\DT\13649268 triple_18\RB\1740 sequential_19\JJ\1740 high-dose_20\JJ\1740 regimen_21\NN\5898568 for_22\IN\1740 patients_23\NNS\9898892 with_24\IN\1740 metastatic_25\JJ\1740 <e2>breast_26\NN\5225090 cancer</e2>_27\NN\14239425 ._28\.\1740
D013852_D001943 NONE study_0\NN\635850 design_1\NN\927261 :_2\:\1740 we_3\PRP\1740 combined_4\VBD\2630189 paclitaxel_5\NN\1740 ,_6\,\1740 melphalan_7\NN\2722458 and_8\CC\1740 high-dose_9\JJ\1740 cyclophosphamide_10\NN\1740 ,_11\,\1740 <e1>thiotepa</e1>_12\NN\2722458 ,_13\,\1740 and_14\CC\1740 carboplatin_15\NN\1740 in_16\IN\13603305 a_17\DT\13649268 triple_18\RB\1740 sequential_19\JJ\1740 high-dose_20\JJ\1740 regimen_21\NN\5898568 for_22\IN\1740 patients_23\NNS\9898892 with_24\IN\1740 metastatic_25\JJ\1740 <e2>breast_26\NN\5225090 cancer</e2>_27\NN\14239425 ._28\.\1740
D016190_D001943 NONE study_0\NN\635850 design_1\NN\927261 :_2\:\1740 we_3\PRP\1740 combined_4\VBD\2630189 paclitaxel_5\NN\1740 ,_6\,\1740 melphalan_7\NN\2722458 and_8\CC\1740 high-dose_9\JJ\1740 cyclophosphamide_10\NN\1740 ,_11\,\1740 thiotepa_12\NN\2722458 ,_13\,\1740 and_14\CC\1740 <e1>carboplatin</e1>_15\NN\1740 in_16\IN\13603305 a_17\DT\13649268 triple_18\RB\1740 sequential_19\JJ\1740 high-dose_20\JJ\1740 regimen_21\NN\5898568 for_22\IN\1740 patients_23\NNS\9898892 with_24\IN\1740 metastatic_25\JJ\1740 <e2>breast_26\NN\5225090 cancer</e2>_27\NN\14239425 ._28\.\1740
D003520_D006333 CID analysis_0\NN\633864 was_1\VBD\836236 performed_2\VBN\2367363 on_3\IN\1740 61_4\CD\1740 women_5\NNS\9605289 with_6\IN\1740 chemotherapy-responsive_7\JJ\1740 metastatic_8\JJ\1740 breast_9\NN\5225090 cancer_10\NN\14239425 receiving_11\VBG\2210855 96-h_12\JJ\1740 infusional_13\JJ\1740 <e1>cyclophosphamide</e1>_14\NN\1740 as_15\IN\14622893 part_16\NN\31921 of_17\IN\1740 a_18\DT\13649268 triple_19\RB\1740 sequential_20\JJ\1740 high-dose_21\JJ\1740 regimen_22\NN\5898568 to_23\TO\1740 assess_24\VB\670261 association_25\NN\8008335 between_26\IN\1740 presence_27\NN\13954253 of_28\IN\1740 peritransplant_29\JJ\1740 <e2>congestive_30\JJ\1740 heart_31\NN\5919034 failure</e2>_32\NN\66216 (_33\-LRB-\1740 chf_34\NN\1740 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 following_38\VBG\1835496 pretreatment_39\NN\1740 characteristics_40\NNS\5849040 :_41\:\1740 presence_42\NN\13954253 of_43\IN\1740 electrocardiogram_44\NN\7000195 (_45\-LRB-\1740 ekg_46\NN\7000195 )_47\-RRB-\1740 abnormalities_48\NNS\14034177 ,_49\,\1740 age_50\NN\4916342 ,_51\,\1740 hypertension_52\NN\14057371 ,_53\,\1740 prior_54\JJ\1740 cardiac_55\JJ\1740 history_56\NN\15120823 ,_57\,\1740 smoking_58\NN\831191 ,_59\,\1740 diabetes_60\NN\14075199 mellitus_61\NN\1740 ,_62\,\1740 prior_63\JJ\1740 use_64\NN\407535 of_65\IN\1740 anthracyclines_66\NNS\1740 ,_67\,\1740 and_68\CC\1740 left-sided_69\JJ\1740 chest_70\NN\5220461 irradiation_71\NN\13920835 ._72\.\1740
D003520_D006333 CID analysis_0\NN\633864 was_1\VBD\836236 performed_2\VBN\2367363 on_3\IN\1740 61_4\CD\1740 women_5\NNS\9605289 with_6\IN\1740 chemotherapy-responsive_7\JJ\1740 metastatic_8\JJ\1740 breast_9\NN\5225090 cancer_10\NN\14239425 receiving_11\VBG\2210855 96-h_12\JJ\1740 infusional_13\JJ\1740 <e1>cyclophosphamide</e1>_14\NN\1740 as_15\IN\14622893 part_16\NN\31921 of_17\IN\1740 a_18\DT\13649268 triple_19\RB\1740 sequential_20\JJ\1740 high-dose_21\JJ\1740 regimen_22\NN\5898568 to_23\TO\1740 assess_24\VB\670261 association_25\NN\8008335 between_26\IN\1740 presence_27\NN\13954253 of_28\IN\1740 peritransplant_29\JJ\1740 congestive_30\JJ\1740 heart_31\NN\5919034 failure_32\NN\66216 (_33\-LRB-\1740 <e2>chf</e2>_34\NN\1740 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 following_38\VBG\1835496 pretreatment_39\NN\1740 characteristics_40\NNS\5849040 :_41\:\1740 presence_42\NN\13954253 of_43\IN\1740 electrocardiogram_44\NN\7000195 (_45\-LRB-\1740 ekg_46\NN\7000195 )_47\-RRB-\1740 abnormalities_48\NNS\14034177 ,_49\,\1740 age_50\NN\4916342 ,_51\,\1740 hypertension_52\NN\14057371 ,_53\,\1740 prior_54\JJ\1740 cardiac_55\JJ\1740 history_56\NN\15120823 ,_57\,\1740 smoking_58\NN\831191 ,_59\,\1740 diabetes_60\NN\14075199 mellitus_61\NN\1740 ,_62\,\1740 prior_63\JJ\1740 use_64\NN\407535 of_65\IN\1740 anthracyclines_66\NNS\1740 ,_67\,\1740 and_68\CC\1740 left-sided_69\JJ\1740 chest_70\NN\5220461 irradiation_71\NN\13920835 ._72\.\1740
D003520_D006333 CID results_0\NNS\34213 :_1\:\1740 six_2\CD\13741022 of_3\IN\1740 61_4\CD\1740 women_5\NNS\9605289 (_6\-LRB-\1740 10_7\CD\13745420 %_8\NN\1740 )_9\-RRB-\1740 developed_10\VBD\1753788 clinically_11\RB\1740 reversible_12\JJ\1740 grade_13\NN\7975026 3_14\CD\13741022 <e2>chf</e2>_15\NN\1740 following_16\VBG\1835496 infusional_17\JJ\1740 <e1>cyclophosphamide</e1>_18\NN\1740 with_19\IN\1740 a_20\DT\13649268 median_21\JJ\1740 percent_22\NN\13815742 decline_23\NN\13458571 in_24\IN\13603305 ejection_25\NN\45250 fraction_26\NN\14806838 of_27\IN\1740 31_28\CD\1740 %_29\NN\1740 ._30\.\1740
D003520_D006333 CID routine_0\JJ\1740 ekg_1\NN\7000195 monitoring_2\NN\879759 during_3\IN\1740 infusional_4\JJ\1740 <e1>cyclophosphamide</e1>_5\NN\1740 did_6\VBD\1640855 not_7\RB\1740 predict_8\VB\916909 <e2>chf</e2>_9\NN\1740 development_10\NN\248977 ._11\.\1740
D003520_D006973 NONE analysis_0\NN\633864 was_1\VBD\836236 performed_2\VBN\2367363 on_3\IN\1740 61_4\CD\1740 women_5\NNS\9605289 with_6\IN\1740 chemotherapy-responsive_7\JJ\1740 metastatic_8\JJ\1740 breast_9\NN\5225090 cancer_10\NN\14239425 receiving_11\VBG\2210855 96-h_12\JJ\1740 infusional_13\JJ\1740 <e1>cyclophosphamide</e1>_14\NN\1740 as_15\IN\14622893 part_16\NN\31921 of_17\IN\1740 a_18\DT\13649268 triple_19\RB\1740 sequential_20\JJ\1740 high-dose_21\JJ\1740 regimen_22\NN\5898568 to_23\TO\1740 assess_24\VB\670261 association_25\NN\8008335 between_26\IN\1740 presence_27\NN\13954253 of_28\IN\1740 peritransplant_29\JJ\1740 congestive_30\JJ\1740 heart_31\NN\5919034 failure_32\NN\66216 (_33\-LRB-\1740 chf_34\NN\1740 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 following_38\VBG\1835496 pretreatment_39\NN\1740 characteristics_40\NNS\5849040 :_41\:\1740 presence_42\NN\13954253 of_43\IN\1740 electrocardiogram_44\NN\7000195 (_45\-LRB-\1740 ekg_46\NN\7000195 )_47\-RRB-\1740 abnormalities_48\NNS\14034177 ,_49\,\1740 age_50\NN\4916342 ,_51\,\1740 <e2>hypertension</e2>_52\NN\14057371 ,_53\,\1740 prior_54\JJ\1740 cardiac_55\JJ\1740 history_56\NN\15120823 ,_57\,\1740 smoking_58\NN\831191 ,_59\,\1740 diabetes_60\NN\14075199 mellitus_61\NN\1740 ,_62\,\1740 prior_63\JJ\1740 use_64\NN\407535 of_65\IN\1740 anthracyclines_66\NNS\1740 ,_67\,\1740 and_68\CC\1740 left-sided_69\JJ\1740 chest_70\NN\5220461 irradiation_71\NN\13920835 ._72\.\1740
D003520_D003920 NONE analysis_0\NN\633864 was_1\VBD\836236 performed_2\VBN\2367363 on_3\IN\1740 61_4\CD\1740 women_5\NNS\9605289 with_6\IN\1740 chemotherapy-responsive_7\JJ\1740 metastatic_8\JJ\1740 breast_9\NN\5225090 cancer_10\NN\14239425 receiving_11\VBG\2210855 96-h_12\JJ\1740 infusional_13\JJ\1740 <e1>cyclophosphamide</e1>_14\NN\1740 as_15\IN\14622893 part_16\NN\31921 of_17\IN\1740 a_18\DT\13649268 triple_19\RB\1740 sequential_20\JJ\1740 high-dose_21\JJ\1740 regimen_22\NN\5898568 to_23\TO\1740 assess_24\VB\670261 association_25\NN\8008335 between_26\IN\1740 presence_27\NN\13954253 of_28\IN\1740 peritransplant_29\JJ\1740 congestive_30\JJ\1740 heart_31\NN\5919034 failure_32\NN\66216 (_33\-LRB-\1740 chf_34\NN\1740 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 following_38\VBG\1835496 pretreatment_39\NN\1740 characteristics_40\NNS\5849040 :_41\:\1740 presence_42\NN\13954253 of_43\IN\1740 electrocardiogram_44\NN\7000195 (_45\-LRB-\1740 ekg_46\NN\7000195 )_47\-RRB-\1740 abnormalities_48\NNS\14034177 ,_49\,\1740 age_50\NN\4916342 ,_51\,\1740 hypertension_52\NN\14057371 ,_53\,\1740 prior_54\JJ\1740 cardiac_55\JJ\1740 history_56\NN\15120823 ,_57\,\1740 smoking_58\NN\831191 ,_59\,\1740 <e2>diabetes_60\NN\14075199 mellitus</e2>_61\NN\1740 ,_62\,\1740 prior_63\JJ\1740 use_64\NN\407535 of_65\IN\1740 anthracyclines_66\NNS\1740 ,_67\,\1740 and_68\CC\1740 left-sided_69\JJ\1740 chest_70\NN\5220461 irradiation_71\NN\13920835 ._72\.\1740
D018943_D001943 NONE analysis_0\NN\633864 was_1\VBD\836236 performed_2\VBN\2367363 on_3\IN\1740 61_4\CD\1740 women_5\NNS\9605289 with_6\IN\1740 chemotherapy-responsive_7\JJ\1740 metastatic_8\JJ\1740 <e2>breast_9\NN\5225090 cancer</e2>_10\NN\14239425 receiving_11\VBG\2210855 96-h_12\JJ\1740 infusional_13\JJ\1740 cyclophosphamide_14\NN\1740 as_15\IN\14622893 part_16\NN\31921 of_17\IN\1740 a_18\DT\13649268 triple_19\RB\1740 sequential_20\JJ\1740 high-dose_21\JJ\1740 regimen_22\NN\5898568 to_23\TO\1740 assess_24\VB\670261 association_25\NN\8008335 between_26\IN\1740 presence_27\NN\13954253 of_28\IN\1740 peritransplant_29\JJ\1740 congestive_30\JJ\1740 heart_31\NN\5919034 failure_32\NN\66216 (_33\-LRB-\1740 chf_34\NN\1740 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 following_38\VBG\1835496 pretreatment_39\NN\1740 characteristics_40\NNS\5849040 :_41\:\1740 presence_42\NN\13954253 of_43\IN\1740 electrocardiogram_44\NN\7000195 (_45\-LRB-\1740 ekg_46\NN\7000195 )_47\-RRB-\1740 abnormalities_48\NNS\14034177 ,_49\,\1740 age_50\NN\4916342 ,_51\,\1740 hypertension_52\NN\14057371 ,_53\,\1740 prior_54\JJ\1740 cardiac_55\JJ\1740 history_56\NN\15120823 ,_57\,\1740 smoking_58\NN\831191 ,_59\,\1740 diabetes_60\NN\14075199 mellitus_61\NN\1740 ,_62\,\1740 prior_63\JJ\1740 use_64\NN\407535 of_65\IN\1740 <e1>anthracyclines</e1>_66\NNS\1740 ,_67\,\1740 and_68\CC\1740 left-sided_69\JJ\1740 chest_70\NN\5220461 irradiation_71\NN\13920835 ._72\.\1740
D018943_D006333 NONE analysis_0\NN\633864 was_1\VBD\836236 performed_2\VBN\2367363 on_3\IN\1740 61_4\CD\1740 women_5\NNS\9605289 with_6\IN\1740 chemotherapy-responsive_7\JJ\1740 metastatic_8\JJ\1740 breast_9\NN\5225090 cancer_10\NN\14239425 receiving_11\VBG\2210855 96-h_12\JJ\1740 infusional_13\JJ\1740 cyclophosphamide_14\NN\1740 as_15\IN\14622893 part_16\NN\31921 of_17\IN\1740 a_18\DT\13649268 triple_19\RB\1740 sequential_20\JJ\1740 high-dose_21\JJ\1740 regimen_22\NN\5898568 to_23\TO\1740 assess_24\VB\670261 association_25\NN\8008335 between_26\IN\1740 presence_27\NN\13954253 of_28\IN\1740 peritransplant_29\JJ\1740 <e2>congestive_30\JJ\1740 heart_31\NN\5919034 failure</e2>_32\NN\66216 (_33\-LRB-\1740 chf_34\NN\1740 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 following_38\VBG\1835496 pretreatment_39\NN\1740 characteristics_40\NNS\5849040 :_41\:\1740 presence_42\NN\13954253 of_43\IN\1740 electrocardiogram_44\NN\7000195 (_45\-LRB-\1740 ekg_46\NN\7000195 )_47\-RRB-\1740 abnormalities_48\NNS\14034177 ,_49\,\1740 age_50\NN\4916342 ,_51\,\1740 hypertension_52\NN\14057371 ,_53\,\1740 prior_54\JJ\1740 cardiac_55\JJ\1740 history_56\NN\15120823 ,_57\,\1740 smoking_58\NN\831191 ,_59\,\1740 diabetes_60\NN\14075199 mellitus_61\NN\1740 ,_62\,\1740 prior_63\JJ\1740 use_64\NN\407535 of_65\IN\1740 <e1>anthracyclines</e1>_66\NNS\1740 ,_67\,\1740 and_68\CC\1740 left-sided_69\JJ\1740 chest_70\NN\5220461 irradiation_71\NN\13920835 ._72\.\1740
D018943_D006333 NONE analysis_0\NN\633864 was_1\VBD\836236 performed_2\VBN\2367363 on_3\IN\1740 61_4\CD\1740 women_5\NNS\9605289 with_6\IN\1740 chemotherapy-responsive_7\JJ\1740 metastatic_8\JJ\1740 breast_9\NN\5225090 cancer_10\NN\14239425 receiving_11\VBG\2210855 96-h_12\JJ\1740 infusional_13\JJ\1740 cyclophosphamide_14\NN\1740 as_15\IN\14622893 part_16\NN\31921 of_17\IN\1740 a_18\DT\13649268 triple_19\RB\1740 sequential_20\JJ\1740 high-dose_21\JJ\1740 regimen_22\NN\5898568 to_23\TO\1740 assess_24\VB\670261 association_25\NN\8008335 between_26\IN\1740 presence_27\NN\13954253 of_28\IN\1740 peritransplant_29\JJ\1740 congestive_30\JJ\1740 heart_31\NN\5919034 failure_32\NN\66216 (_33\-LRB-\1740 <e2>chf</e2>_34\NN\1740 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 following_38\VBG\1835496 pretreatment_39\NN\1740 characteristics_40\NNS\5849040 :_41\:\1740 presence_42\NN\13954253 of_43\IN\1740 electrocardiogram_44\NN\7000195 (_45\-LRB-\1740 ekg_46\NN\7000195 )_47\-RRB-\1740 abnormalities_48\NNS\14034177 ,_49\,\1740 age_50\NN\4916342 ,_51\,\1740 hypertension_52\NN\14057371 ,_53\,\1740 prior_54\JJ\1740 cardiac_55\JJ\1740 history_56\NN\15120823 ,_57\,\1740 smoking_58\NN\831191 ,_59\,\1740 diabetes_60\NN\14075199 mellitus_61\NN\1740 ,_62\,\1740 prior_63\JJ\1740 use_64\NN\407535 of_65\IN\1740 <e1>anthracyclines</e1>_66\NNS\1740 ,_67\,\1740 and_68\CC\1740 left-sided_69\JJ\1740 chest_70\NN\5220461 irradiation_71\NN\13920835 ._72\.\1740
D018943_D006973 NONE analysis_0\NN\633864 was_1\VBD\836236 performed_2\VBN\2367363 on_3\IN\1740 61_4\CD\1740 women_5\NNS\9605289 with_6\IN\1740 chemotherapy-responsive_7\JJ\1740 metastatic_8\JJ\1740 breast_9\NN\5225090 cancer_10\NN\14239425 receiving_11\VBG\2210855 96-h_12\JJ\1740 infusional_13\JJ\1740 cyclophosphamide_14\NN\1740 as_15\IN\14622893 part_16\NN\31921 of_17\IN\1740 a_18\DT\13649268 triple_19\RB\1740 sequential_20\JJ\1740 high-dose_21\JJ\1740 regimen_22\NN\5898568 to_23\TO\1740 assess_24\VB\670261 association_25\NN\8008335 between_26\IN\1740 presence_27\NN\13954253 of_28\IN\1740 peritransplant_29\JJ\1740 congestive_30\JJ\1740 heart_31\NN\5919034 failure_32\NN\66216 (_33\-LRB-\1740 chf_34\NN\1740 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 following_38\VBG\1835496 pretreatment_39\NN\1740 characteristics_40\NNS\5849040 :_41\:\1740 presence_42\NN\13954253 of_43\IN\1740 electrocardiogram_44\NN\7000195 (_45\-LRB-\1740 ekg_46\NN\7000195 )_47\-RRB-\1740 abnormalities_48\NNS\14034177 ,_49\,\1740 age_50\NN\4916342 ,_51\,\1740 <e2>hypertension</e2>_52\NN\14057371 ,_53\,\1740 prior_54\JJ\1740 cardiac_55\JJ\1740 history_56\NN\15120823 ,_57\,\1740 smoking_58\NN\831191 ,_59\,\1740 diabetes_60\NN\14075199 mellitus_61\NN\1740 ,_62\,\1740 prior_63\JJ\1740 use_64\NN\407535 of_65\IN\1740 <e1>anthracyclines</e1>_66\NNS\1740 ,_67\,\1740 and_68\CC\1740 left-sided_69\JJ\1740 chest_70\NN\5220461 irradiation_71\NN\13920835 ._72\.\1740
D018943_D003920 NONE analysis_0\NN\633864 was_1\VBD\836236 performed_2\VBN\2367363 on_3\IN\1740 61_4\CD\1740 women_5\NNS\9605289 with_6\IN\1740 chemotherapy-responsive_7\JJ\1740 metastatic_8\JJ\1740 breast_9\NN\5225090 cancer_10\NN\14239425 receiving_11\VBG\2210855 96-h_12\JJ\1740 infusional_13\JJ\1740 cyclophosphamide_14\NN\1740 as_15\IN\14622893 part_16\NN\31921 of_17\IN\1740 a_18\DT\13649268 triple_19\RB\1740 sequential_20\JJ\1740 high-dose_21\JJ\1740 regimen_22\NN\5898568 to_23\TO\1740 assess_24\VB\670261 association_25\NN\8008335 between_26\IN\1740 presence_27\NN\13954253 of_28\IN\1740 peritransplant_29\JJ\1740 congestive_30\JJ\1740 heart_31\NN\5919034 failure_32\NN\66216 (_33\-LRB-\1740 chf_34\NN\1740 )_35\-RRB-\1740 and_36\CC\1740 the_37\DT\1740 following_38\VBG\1835496 pretreatment_39\NN\1740 characteristics_40\NNS\5849040 :_41\:\1740 presence_42\NN\13954253 of_43\IN\1740 electrocardiogram_44\NN\7000195 (_45\-LRB-\1740 ekg_46\NN\7000195 )_47\-RRB-\1740 abnormalities_48\NNS\14034177 ,_49\,\1740 age_50\NN\4916342 ,_51\,\1740 hypertension_52\NN\14057371 ,_53\,\1740 prior_54\JJ\1740 cardiac_55\JJ\1740 history_56\NN\15120823 ,_57\,\1740 smoking_58\NN\831191 ,_59\,\1740 <e2>diabetes_60\NN\14075199 mellitus</e2>_61\NN\1740 ,_62\,\1740 prior_63\JJ\1740 use_64\NN\407535 of_65\IN\1740 <e1>anthracyclines</e1>_66\NNS\1740 ,_67\,\1740 and_68\CC\1740 left-sided_69\JJ\1740 chest_70\NN\5220461 irradiation_71\NN\13920835 ._72\.\1740
2802551
D012964_D007674 NONE <e1>sodium</e1>_0\NN\14625458 status_1\NN\24720 influences_2\VBZ\137313 chronic_3\JJ\1740 amphotericin_4\NN\2716866 b_5\NN\1355326 <e2>nephrotoxicity</e2>_6\NN\1740 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D000666_D007674 CID sodium_0\NN\14625458 status_1\NN\24720 influences_2\VBZ\137313 chronic_3\JJ\1740 <e1>amphotericin_4\NN\2716866 b</e1>_5\NN\1355326 <e2>nephrotoxicity</e2>_6\NN\1740 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D000666_D007674 CID the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 potential_2\NN\14481929 of_3\IN\1740 <e1>amphotericin_4\NN\2716866 b</e1>_5\NN\1355326 (_6\-LRB-\1740 5_7\CD\13741022 mg/kg_8\NN\1740 per_9\IN\1740 day_10\NN\15154774 intraperitoneally_11\RB\1740 for_12\IN\1740 3_13\CD\13741022 weeks_14\NNS\15113229 )_15\-RRB-\1740 has_16\VBZ\2108377 been_17\VBN\836236 investigated_18\VBN\644583 in_19\IN\13603305 salt-depleted_20\JJ\1740 ,_21\,\1740 normal-salt_22\JJ\1740 ,_23\,\1740 and_24\CC\1740 salt-loaded_25\JJ\1740 rats_26\NNS\2329401 ._27\.\1740
2505783
C004656_D006470 CID based_0\VBN\2694933 on_1\IN\1740 clinical_2\JJ\1740 data_3\NNS\7951464 ,_4\,\1740 indicating_5\VBG\952524 that_6\IN\1740 <e1>chloroacetaldehyde</e1>_7\NN\1740 (_8\-LRB-\1740 caa_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 an_12\DT\6697703 important_13\JJ\1740 metabolite_14\NN\20090 of_15\IN\1740 oxazaphosphorine_16\NN\1740 cytostatics_17\NNS\1740 ,_18\,\1740 an_19\DT\6697703 experimental_20\JJ\1740 study_21\NN\635850 was_22\VBD\836236 carried_23\VBN\1850315 out_24\RP\1740 in_25\IN\13603305 order_26\NN\7168131 to_27\TO\1740 elucidate_28\VB\939277 the_29\DT\1740 role_30\NN\719494 of_31\IN\1740 caa_32\NN\1740 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 <e2>hemorrhagic_37\JJ\1740 cystitis</e2>_38\NN\14566129 ._39\.\1740
C004656_D006470 CID based_0\VBN\2694933 on_1\IN\1740 clinical_2\JJ\1740 data_3\NNS\7951464 ,_4\,\1740 indicating_5\VBG\952524 that_6\IN\1740 chloroacetaldehyde_7\NN\1740 (_8\-LRB-\1740 <e1>caa</e1>_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 an_12\DT\6697703 important_13\JJ\1740 metabolite_14\NN\20090 of_15\IN\1740 oxazaphosphorine_16\NN\1740 cytostatics_17\NNS\1740 ,_18\,\1740 an_19\DT\6697703 experimental_20\JJ\1740 study_21\NN\635850 was_22\VBD\836236 carried_23\VBN\1850315 out_24\RP\1740 in_25\IN\13603305 order_26\NN\7168131 to_27\TO\1740 elucidate_28\VB\939277 the_29\DT\1740 role_30\NN\719494 of_31\IN\1740 caa_32\NN\1740 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 <e2>hemorrhagic_37\JJ\1740 cystitis</e2>_38\NN\14566129 ._39\.\1740
C004656_D006470 CID based_0\VBN\2694933 on_1\IN\1740 clinical_2\JJ\1740 data_3\NNS\7951464 ,_4\,\1740 indicating_5\VBG\952524 that_6\IN\1740 chloroacetaldehyde_7\NN\1740 (_8\-LRB-\1740 caa_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 an_12\DT\6697703 important_13\JJ\1740 metabolite_14\NN\20090 of_15\IN\1740 oxazaphosphorine_16\NN\1740 cytostatics_17\NNS\1740 ,_18\,\1740 an_19\DT\6697703 experimental_20\JJ\1740 study_21\NN\635850 was_22\VBD\836236 carried_23\VBN\1850315 out_24\RP\1740 in_25\IN\13603305 order_26\NN\7168131 to_27\TO\1740 elucidate_28\VB\939277 the_29\DT\1740 role_30\NN\719494 of_31\IN\1740 <e1>caa</e1>_32\NN\1740 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 <e2>hemorrhagic_37\JJ\1740 cystitis</e2>_38\NN\14566129 ._39\.\1740
C004656_D003556 CID based_0\VBN\2694933 on_1\IN\1740 clinical_2\JJ\1740 data_3\NNS\7951464 ,_4\,\1740 indicating_5\VBG\952524 that_6\IN\1740 <e1>chloroacetaldehyde</e1>_7\NN\1740 (_8\-LRB-\1740 caa_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 an_12\DT\6697703 important_13\JJ\1740 metabolite_14\NN\20090 of_15\IN\1740 oxazaphosphorine_16\NN\1740 cytostatics_17\NNS\1740 ,_18\,\1740 an_19\DT\6697703 experimental_20\JJ\1740 study_21\NN\635850 was_22\VBD\836236 carried_23\VBN\1850315 out_24\RP\1740 in_25\IN\13603305 order_26\NN\7168131 to_27\TO\1740 elucidate_28\VB\939277 the_29\DT\1740 role_30\NN\719494 of_31\IN\1740 caa_32\NN\1740 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 <e2>hemorrhagic_37\JJ\1740 cystitis</e2>_38\NN\14566129 ._39\.\1740
C004656_D003556 CID based_0\VBN\2694933 on_1\IN\1740 clinical_2\JJ\1740 data_3\NNS\7951464 ,_4\,\1740 indicating_5\VBG\952524 that_6\IN\1740 chloroacetaldehyde_7\NN\1740 (_8\-LRB-\1740 <e1>caa</e1>_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 an_12\DT\6697703 important_13\JJ\1740 metabolite_14\NN\20090 of_15\IN\1740 oxazaphosphorine_16\NN\1740 cytostatics_17\NNS\1740 ,_18\,\1740 an_19\DT\6697703 experimental_20\JJ\1740 study_21\NN\635850 was_22\VBD\836236 carried_23\VBN\1850315 out_24\RP\1740 in_25\IN\13603305 order_26\NN\7168131 to_27\TO\1740 elucidate_28\VB\939277 the_29\DT\1740 role_30\NN\719494 of_31\IN\1740 caa_32\NN\1740 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 <e2>hemorrhagic_37\JJ\1740 cystitis</e2>_38\NN\14566129 ._39\.\1740
C004656_D003556 CID based_0\VBN\2694933 on_1\IN\1740 clinical_2\JJ\1740 data_3\NNS\7951464 ,_4\,\1740 indicating_5\VBG\952524 that_6\IN\1740 chloroacetaldehyde_7\NN\1740 (_8\-LRB-\1740 caa_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 an_12\DT\6697703 important_13\JJ\1740 metabolite_14\NN\20090 of_15\IN\1740 oxazaphosphorine_16\NN\1740 cytostatics_17\NNS\1740 ,_18\,\1740 an_19\DT\6697703 experimental_20\JJ\1740 study_21\NN\635850 was_22\VBD\836236 carried_23\VBN\1850315 out_24\RP\1740 in_25\IN\13603305 order_26\NN\7168131 to_27\TO\1740 elucidate_28\VB\939277 the_29\DT\1740 role_30\NN\719494 of_31\IN\1740 <e1>caa</e1>_32\NN\1740 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 <e2>hemorrhagic_37\JJ\1740 cystitis</e2>_38\NN\14566129 ._39\.\1740
C004656_D001745 NONE the_0\DT\1740 data_1\NNS\7951464 demonstrate_2\VBP\2137132 that_3\IN\1740 <e1>caa</e1>_4\NNP\1740 after_5\IN\1740 i.v._6\NN\1740 administration_7\NN\1133281 does_8\VBZ\1640855 not_9\RB\1740 contribute_10\VB\126264 to_11\TO\1740 <e2>bladder_12\NN\5515670 damage</e2>_13\NN\7296428 ._14\.\1740
11532387
D018967_D013375 CID <e2>withdrawal-emergent_0\JJ\1740 rabbit_1\NN\2323902 syndrome</e2>_2\NN\5870365 during_3\IN\1740 dose_4\NN\3740161 reduction_5\NN\351485 of_6\IN\1740 <e1>risperidone</e1>_7\NN\1740 ._8\.\1740
D018967_D013375 CID the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 <e2>withdrawal-emergent_4\JJ\1740 rs</e2>_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 <e1>risperidone</e1>_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 serotonin-dopamine_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 serotonin_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 rs_37\NN\13635336 ._38\.\1740
D018967_D001480 CID <e2>withdrawal-emergent_0\JJ\1740 rabbit_1\NN\2323902 syndrome</e2>_2\NN\5870365 during_3\IN\1740 dose_4\NN\3740161 reduction_5\NN\351485 of_6\IN\1740 <e1>risperidone</e1>_7\NN\1740 ._8\.\1740
D018967_D001480 CID the_0\DT\1740 patient_1\NN\9898892 developed_2\VBD\1753788 <e2>rs</e2>_3\NN\13635336 during_4\IN\1740 dose_5\NN\3740161 reduction_6\NN\351485 of_7\IN\1740 <e1>risperidone</e1>_8\NN\1740 ._9\.\1740
D018967_D001480 CID the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 <e2>withdrawal-emergent_4\JJ\1740 rs</e2>_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 <e1>risperidone</e1>_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 serotonin-dopamine_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 serotonin_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 rs_37\NN\13635336 ._38\.\1740
D018967_D001480 CID the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 withdrawal-emergent_4\JJ\1740 rs_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 <e1>risperidone</e1>_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 serotonin-dopamine_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 serotonin_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 <e2>rs</e2>_37\NN\13635336 ._38\.\1740
D012701_D013375 NONE the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 <e2>withdrawal-emergent_4\JJ\1740 rs</e2>_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 risperidone_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 <e1>serotonin-dopamine</e1>_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 serotonin_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 rs_37\NN\13635336 ._38\.\1740
D012701_D013375 NONE the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 <e2>withdrawal-emergent_4\JJ\1740 rs</e2>_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 risperidone_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 serotonin-dopamine_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 <e1>serotonin</e1>_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 rs_37\NN\13635336 ._38\.\1740
D012701_D001480 NONE the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 <e2>withdrawal-emergent_4\JJ\1740 rs</e2>_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 risperidone_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 <e1>serotonin-dopamine</e1>_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 serotonin_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 rs_37\NN\13635336 ._38\.\1740
D012701_D001480 NONE the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 withdrawal-emergent_4\JJ\1740 rs_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 risperidone_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 <e1>serotonin-dopamine</e1>_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 serotonin_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 <e2>rs</e2>_37\NN\13635336 ._38\.\1740
D012701_D001480 NONE the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 <e2>withdrawal-emergent_4\JJ\1740 rs</e2>_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 risperidone_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 serotonin-dopamine_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 <e1>serotonin</e1>_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 rs_37\NN\13635336 ._38\.\1740
D012701_D001480 NONE the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 withdrawal-emergent_4\JJ\1740 rs_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 risperidone_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 serotonin-dopamine_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 <e1>serotonin</e1>_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 <e2>rs</e2>_37\NN\13635336 ._38\.\1740
D004298_D013375 NONE the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 <e2>withdrawal-emergent_4\JJ\1740 rs</e2>_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 risperidone_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 <e1>serotonin-dopamine</e1>_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 serotonin_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 rs_37\NN\13635336 ._38\.\1740
D004298_D001480 NONE the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 <e2>withdrawal-emergent_4\JJ\1740 rs</e2>_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 risperidone_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 <e1>serotonin-dopamine</e1>_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 serotonin_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 rs_37\NN\13635336 ._38\.\1740
D004298_D001480 NONE the_0\DT\1740 underlying_1\VBG\2604760 mechanism_2\NN\13446390 of_3\IN\1740 withdrawal-emergent_4\JJ\1740 rs_5\NN\13635336 in_6\IN\13603305 the_7\DT\1740 present_8\JJ\1740 case_9\NN\7283608 may_10\MD\15209706 have_11\VB\2108377 been_12\VBN\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 pharmacological_16\JJ\1740 profile_17\NN\6999802 of_18\IN\1740 risperidone_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 <e1>serotonin-dopamine</e1>_22\JJ\1740 antagonist_23\NN\7846 ,_24\,\1740 suggesting_25\VBG\1010118 the_26\DT\1740 pathophysiologic_27\JJ\1740 influence_28\NN\5190804 of_29\IN\1740 the_30\DT\1740 serotonin_31\NN\14807737 system_32\NN\3575240 in_33\IN\13603305 the_34\DT\1740 development_35\NN\248977 of_36\IN\1740 <e2>rs</e2>_37\NN\13635336 ._38\.\1740
7420681
D014031_D007674 NONE clinical_0\JJ\1740 <e2>nephrotoxicity</e2>_1\NN\1740 of_2\IN\1740 <e1>tobramycin</e1>_3\NN\2716866 and_4\CC\1740 gentamicin_5\NN\2716866 ._6\.\1740
D014031_D007674 NONE gentamicin_0\NN\2716866 sulfate_1\NN\15010703 and_2\CC\1740 <e1>tobramycin_3\NN\2716866 sulfate</e1>_4\NN\15010703 continue_5\VBP\2367363 to_6\TO\1740 demonstrate_7\VB\2137132 ototoxicity_8\NN\1740 and_9\CC\1740 <e2>nephrotoxicity</e2>_10\NN\1740 in_11\IN\13603305 both_12\CC\1740 animal_13\NN\4475 and_14\CC\1740 clinical_15\JJ\1740 studies_16\NNS\635850 ._17\.\1740
D005839_D007674 NONE clinical_0\JJ\1740 <e2>nephrotoxicity</e2>_1\NN\1740 of_2\IN\1740 tobramycin_3\NN\2716866 and_4\CC\1740 <e1>gentamicin</e1>_5\NN\2716866 ._6\.\1740
D005839_D007674 NONE <e1>gentamicin_0\NN\2716866 sulfate</e1>_1\NN\15010703 and_2\CC\1740 tobramycin_3\NN\2716866 sulfate_4\NN\15010703 continue_5\VBP\2367363 to_6\TO\1740 demonstrate_7\VB\2137132 ototoxicity_8\NN\1740 and_9\CC\1740 <e2>nephrotoxicity</e2>_10\NN\1740 in_11\IN\13603305 both_12\CC\1740 animal_13\NN\4475 and_14\CC\1740 clinical_15\JJ\1740 studies_16\NNS\635850 ._17\.\1740
D005839_D006311 NONE <e1>gentamicin_0\NN\2716866 sulfate</e1>_1\NN\15010703 and_2\CC\1740 tobramycin_3\NN\2716866 sulfate_4\NN\15010703 continue_5\VBP\2367363 to_6\TO\1740 demonstrate_7\VB\2137132 <e2>ototoxicity</e2>_8\NN\1740 and_9\CC\1740 nephrotoxicity_10\NN\1740 in_11\IN\13603305 both_12\CC\1740 animal_13\NN\4475 and_14\CC\1740 clinical_15\JJ\1740 studies_16\NNS\635850 ._17\.\1740
D014031_D006311 NONE gentamicin_0\NN\2716866 sulfate_1\NN\15010703 and_2\CC\1740 <e1>tobramycin_3\NN\2716866 sulfate</e1>_4\NN\15010703 continue_5\VBP\2367363 to_6\TO\1740 demonstrate_7\VB\2137132 <e2>ototoxicity</e2>_8\NN\1740 and_9\CC\1740 nephrotoxicity_10\NN\1740 in_11\IN\13603305 both_12\CC\1740 animal_13\NN\4475 and_14\CC\1740 clinical_15\JJ\1740 studies_16\NNS\635850 ._17\.\1740
D005839_D051437 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 62_4\CD\1740 patients_5\NNS\9898892 with_6\IN\1740 confirmed_7\VBN\1011725 initial_8\JJ\1740 normal_9\JJ\1740 renal_10\JJ\1740 function_11\NN\13783581 and_12\CC\1740 treated_13\VBN\2376958 with_14\IN\1740 2_15\CD\13741022 to_16\TO\1740 5_17\CD\13741022 mg/kg/day_18\NN\1740 of_19\IN\1740 <e1>gentamicin_20\NN\2716866 sulfate</e1>_21\NN\15010703 or_22\CC\3541091 tobramycin_23\NN\2716866 sulfate_24\NN\15010703 for_25\IN\1740 a_26\DT\13649268 minimum_27\NN\13653902 of_28\IN\1740 seven_29\CD\13741022 days_30\NNS\15140892 were_31\VBD\836236 followed_32\VBN\1835496 up_33\RP\1740 prospectively_34\RB\1740 for_35\IN\1740 the_36\DT\1740 development_37\NN\248977 of_38\IN\1740 aminoglycoside-related_39\JJ\1740 <e2>renal_40\JJ\1740 failure</e2>_41\NN\66216 ,_42\,\1740 defined_43\VBN\2604760 as_44\IN\14622893 at_45\IN\14622893 least_46\JJS\1740 a_47\DT\13649268 one-third_48\JJ\1740 reduction_49\NN\351485 in_50\IN\13603305 renal_51\JJ\1740 function_52\NN\13783581 ._53\.\1740
D005839_D051437 CID five_0\CD\13741022 of_1\IN\1740 33_2\CD\1740 (_3\-LRB-\1740 15_4\CD\13745420 %_5\NN\1740 )_6\-RRB-\1740 of_7\IN\1740 the_8\DT\1740 tobramycin-treated_9\JJ\1740 patients_10\NNS\9898892 and_11\CC\1740 16_12\CD\13745420 of_13\IN\1740 29_14\CD\13745420 (_15\-LRB-\1740 55.2_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 of_19\IN\1740 the_20\DT\1740 <e1>gentamicin-treated</e1>_21\JJ\1740 patients_22\NNS\9898892 had_23\VBD\2108377 <e2>renal_24\JJ\1740 failure</e2>_25\NN\66216 ._26\.\1740
D005839_D051437 CID thus_0\RB\1740 ,_1\,\1740 <e1>gentamicin</e1>_2\NN\2716866 was_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 <e2>renal_6\JJ\1740 failure</e2>_7\NN\66216 more_8\JJR\1740 than_9\IN\1740 three_10\CD\13741022 times_11\NNS\15113229 as_12\RB\1740 often_13\RB\1740 as_14\IN\14622893 was_15\VBD\836236 tobramycin_16\NN\2716866 ._17\.\1740
D014031_D051437 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 62_4\CD\1740 patients_5\NNS\9898892 with_6\IN\1740 confirmed_7\VBN\1011725 initial_8\JJ\1740 normal_9\JJ\1740 renal_10\JJ\1740 function_11\NN\13783581 and_12\CC\1740 treated_13\VBN\2376958 with_14\IN\1740 2_15\CD\13741022 to_16\TO\1740 5_17\CD\13741022 mg/kg/day_18\NN\1740 of_19\IN\1740 gentamicin_20\NN\2716866 sulfate_21\NN\15010703 or_22\CC\3541091 <e1>tobramycin_23\NN\2716866 sulfate</e1>_24\NN\15010703 for_25\IN\1740 a_26\DT\13649268 minimum_27\NN\13653902 of_28\IN\1740 seven_29\CD\13741022 days_30\NNS\15140892 were_31\VBD\836236 followed_32\VBN\1835496 up_33\RP\1740 prospectively_34\RB\1740 for_35\IN\1740 the_36\DT\1740 development_37\NN\248977 of_38\IN\1740 aminoglycoside-related_39\JJ\1740 <e2>renal_40\JJ\1740 failure</e2>_41\NN\66216 ,_42\,\1740 defined_43\VBN\2604760 as_44\IN\14622893 at_45\IN\14622893 least_46\JJS\1740 a_47\DT\13649268 one-third_48\JJ\1740 reduction_49\NN\351485 in_50\IN\13603305 renal_51\JJ\1740 function_52\NN\13783581 ._53\.\1740
D014031_D051437 CID five_0\CD\13741022 of_1\IN\1740 33_2\CD\1740 (_3\-LRB-\1740 15_4\CD\13745420 %_5\NN\1740 )_6\-RRB-\1740 of_7\IN\1740 the_8\DT\1740 <e1>tobramycin-treated</e1>_9\JJ\1740 patients_10\NNS\9898892 and_11\CC\1740 16_12\CD\13745420 of_13\IN\1740 29_14\CD\13745420 (_15\-LRB-\1740 55.2_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 of_19\IN\1740 the_20\DT\1740 gentamicin-treated_21\JJ\1740 patients_22\NNS\9898892 had_23\VBD\2108377 <e2>renal_24\JJ\1740 failure</e2>_25\NN\66216 ._26\.\1740
D014031_D051437 CID thus_0\RB\1740 ,_1\,\1740 gentamicin_2\NN\2716866 was_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 <e2>renal_6\JJ\1740 failure</e2>_7\NN\66216 more_8\JJR\1740 than_9\IN\1740 three_10\CD\13741022 times_11\NNS\15113229 as_12\RB\1740 often_13\RB\1740 as_14\IN\14622893 was_15\VBD\836236 <e1>tobramycin</e1>_16\NN\2716866 ._17\.\1740
D000617_D051437 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 62_4\CD\1740 patients_5\NNS\9898892 with_6\IN\1740 confirmed_7\VBN\1011725 initial_8\JJ\1740 normal_9\JJ\1740 renal_10\JJ\1740 function_11\NN\13783581 and_12\CC\1740 treated_13\VBN\2376958 with_14\IN\1740 2_15\CD\13741022 to_16\TO\1740 5_17\CD\13741022 mg/kg/day_18\NN\1740 of_19\IN\1740 gentamicin_20\NN\2716866 sulfate_21\NN\15010703 or_22\CC\3541091 tobramycin_23\NN\2716866 sulfate_24\NN\15010703 for_25\IN\1740 a_26\DT\13649268 minimum_27\NN\13653902 of_28\IN\1740 seven_29\CD\13741022 days_30\NNS\15140892 were_31\VBD\836236 followed_32\VBN\1835496 up_33\RP\1740 prospectively_34\RB\1740 for_35\IN\1740 the_36\DT\1740 development_37\NN\248977 of_38\IN\1740 <e1>aminoglycoside-related</e1>_39\JJ\1740 <e2>renal_40\JJ\1740 failure</e2>_41\NN\66216 ,_42\,\1740 defined_43\VBN\2604760 as_44\IN\14622893 at_45\IN\14622893 least_46\JJS\1740 a_47\DT\13649268 one-third_48\JJ\1740 reduction_49\NN\351485 in_50\IN\13603305 renal_51\JJ\1740 function_52\NN\13783581 ._53\.\1740
12905102
D003024_D003693 CID <e2>delirium</e2>_0\NN\14391660 during_1\IN\1740 <e1>clozapine</e1>_2\NN\3713736 treatment_3\NN\654885 :_4\:\1740 incidence_5\NN\13821570 and_6\CC\1740 associated_7\VBN\628491 risk_8\NN\14541044 factors_9\NNS\7326557 ._10\.\1740
D003024_D003693 CID background_0\NN\4921011 :_1\:\1740 incidence_2\NN\13821570 and_3\CC\1740 risk_4\NN\14541044 factors_5\NNS\7326557 for_6\IN\1740 <e2>delirium</e2>_7\NN\14391660 during_8\IN\1740 <e1>clozapine</e1>_9\NN\3713736 treatment_10\NN\654885 require_11\VBP\754942 further_12\JJ\1740 clarification_13\NN\7170753 ._14\.\1740
D003024_D003693 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 used_3\VBD\1156834 computerized_4\JJ\1740 pharmacy_5\NN\6043075 records_6\NNS\6643408 to_7\TO\1740 identify_8\VB\699815 all_9\DT\1740 adult_10\JJ\1740 psychiatric_11\JJ\1740 inpatients_12\NNS\10405694 treated_13\VBN\2376958 with_14\IN\1740 <e1>clozapine</e1>_15\NN\3713736 (_16\-LRB-\1740 1995_17\CD\1740 -_18\SYM\1740 96_19\CD\1740 )_20\-RRB-\1740 ,_21\,\1740 reviewed_22\VBD\644583 their_23\PRP$\1740 medical_24\JJ\1740 records_25\NNS\6643408 to_26\TO\1740 score_27\VB\1111028 incidence_28\NN\13821570 and_29\CC\1740 severity_30\NN\5036394 of_31\IN\1740 <e2>delirium</e2>_32\NN\14391660 ,_33\,\1740 and_34\CC\1740 tested_35\VBN\670261 associations_36\NNS\8008335 with_37\IN\1740 potential_38\JJ\1740 risk_39\NN\14541044 factors_40\NNS\7326557 ._41\.\1740
D003024_D003693 CID conclusions_0\NNS\5837957 :_1\:\1740 <e2>delirium</e2>_2\NN\14391660 was_3\VBD\836236 found_4\VBN\2426171 in_5\IN\13603305 10_6\CD\13745420 %_7\NN\1740 of_8\IN\1740 <e1>clozapine-treated</e1>_9\JJ\1740 inpatients_10\NNS\10405694 ,_11\,\1740 particularly_12\RB\1740 in_13\IN\13603305 older_14\JJR\1740 patients_15\NNS\9898892 exposed_16\VBN\2110927 to_17\TO\1740 other_18\JJ\1740 central_19\JJ\1740 anticholinergics_20\NNS\3740161 ._21\.\1740
D003024_D001523 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 used_3\VBD\1156834 computerized_4\JJ\1740 pharmacy_5\NN\6043075 records_6\NNS\6643408 to_7\TO\1740 identify_8\VB\699815 all_9\DT\1740 adult_10\JJ\1740 <e2>psychiatric</e2>_11\JJ\1740 inpatients_12\NNS\10405694 treated_13\VBN\2376958 with_14\IN\1740 <e1>clozapine</e1>_15\NN\3713736 (_16\-LRB-\1740 1995_17\CD\1740 -_18\SYM\1740 96_19\CD\1740 )_20\-RRB-\1740 ,_21\,\1740 reviewed_22\VBD\644583 their_23\PRP$\1740 medical_24\JJ\1740 records_25\NNS\6643408 to_26\TO\1740 score_27\VB\1111028 incidence_28\NN\13821570 and_29\CC\1740 severity_30\NN\5036394 of_31\IN\1740 delirium_32\NN\14391660 ,_33\,\1740 and_34\CC\1740 tested_35\VBN\670261 associations_36\NNS\8008335 with_37\IN\1740 potential_38\JJ\1740 risk_39\NN\14541044 factors_40\NNS\7326557 ._41\.\1740
8864707
D010672_D004827 NONE magnetic_0\JJ\1740 resonance_1\NN\11419404 volumetry_2\NN\1740 of_3\IN\1740 the_4\DT\1740 cerebellum_5\NN\5462674 in_6\IN\13603305 <e2>epileptic</e2>_7\JJ\1740 patients_8\NNS\9898892 after_9\IN\1740 <e1>phenytoin</e1>_10\NN\3550533 overdosages_11\NNS\1740 ._12\.\1740
D010672_D062787 CID magnetic_0\JJ\1740 resonance_1\NN\11419404 volumetry_2\NN\1740 of_3\IN\1740 the_4\DT\1740 cerebellum_5\NN\5462674 in_6\IN\13603305 epileptic_7\JJ\1740 patients_8\NNS\9898892 after_9\IN\1740 <e1>phenytoin</e1>_10\NN\3550533 <e2>overdosages</e2>_11\NNS\1740 ._12\.\1740
D010672_D062787 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>phenytoin</e1>_3\NN\3550533 <e2>overdosage</e2>_4\NN\1740 does_5\VBZ\1640855 not_6\RB\1740 necessarily_7\RB\1740 result_8\VB\2633881 in_9\IN\13603305 cerebellar_10\JJ\1740 atrophy_11\NN\14299637 and_12\CC\1740 it_13\PRP\6125041 is_14\VBZ\836236 unlikely_15\JJ\1740 that_16\IN\1740 phenytoin_17\NN\3550533 medication_18\NN\3247620 was_19\VBD\836236 the_20\DT\1740 only_21\JJ\1740 cause_22\NN\7323922 of_23\IN\1740 cerebellar_24\JJ\1740 atrophy_25\NN\14299637 in_26\IN\13603305 the_27\DT\1740 remaining_28\VBG\2604760 patients_29\NNS\9898892 ._30\.\1740
D010672_D062787 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 phenytoin_3\NN\3550533 <e2>overdosage</e2>_4\NN\1740 does_5\VBZ\1640855 not_6\RB\1740 necessarily_7\RB\1740 result_8\VB\2633881 in_9\IN\13603305 cerebellar_10\JJ\1740 atrophy_11\NN\14299637 and_12\CC\1740 it_13\PRP\6125041 is_14\VBZ\836236 unlikely_15\JJ\1740 that_16\IN\1740 <e1>phenytoin</e1>_17\NN\3550533 medication_18\NN\3247620 was_19\VBD\836236 the_20\DT\1740 only_21\JJ\1740 cause_22\NN\7323922 of_23\IN\1740 cerebellar_24\JJ\1740 atrophy_25\NN\14299637 in_26\IN\13603305 the_27\DT\1740 remaining_28\VBG\2604760 patients_29\NNS\9898892 ._30\.\1740
D010672_D002526 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 evaluate_7\VB\670261 the_8\DT\1740 relationship_9\NN\31921 between_10\IN\1740 <e1>phenytoin</e1>_11\NN\3550533 medication_12\NN\3247620 and_13\CC\1740 <e2>cerebellar_14\JJ\1740 atrophy</e2>_15\NN\14299637 in_16\IN\13603305 patients_17\NNS\9898892 who_18\WP\8299493 had_19\VBD\2108377 experienced_20\VBN\2108377 clinical_21\JJ\1740 intoxication_22\NN\14034177 ._23\.\1740
D010672_D002526 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>phenytoin</e1>_3\NN\3550533 overdosage_4\NN\1740 does_5\VBZ\1640855 not_6\RB\1740 necessarily_7\RB\1740 result_8\VB\2633881 in_9\IN\13603305 <e2>cerebellar_10\JJ\1740 atrophy</e2>_11\NN\14299637 and_12\CC\1740 it_13\PRP\6125041 is_14\VBZ\836236 unlikely_15\JJ\1740 that_16\IN\1740 phenytoin_17\NN\3550533 medication_18\NN\3247620 was_19\VBD\836236 the_20\DT\1740 only_21\JJ\1740 cause_22\NN\7323922 of_23\IN\1740 cerebellar_24\JJ\1740 atrophy_25\NN\14299637 in_26\IN\13603305 the_27\DT\1740 remaining_28\VBG\2604760 patients_29\NNS\9898892 ._30\.\1740
D010672_D002526 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>phenytoin</e1>_3\NN\3550533 overdosage_4\NN\1740 does_5\VBZ\1640855 not_6\RB\1740 necessarily_7\RB\1740 result_8\VB\2633881 in_9\IN\13603305 cerebellar_10\JJ\1740 atrophy_11\NN\14299637 and_12\CC\1740 it_13\PRP\6125041 is_14\VBZ\836236 unlikely_15\JJ\1740 that_16\IN\1740 phenytoin_17\NN\3550533 medication_18\NN\3247620 was_19\VBD\836236 the_20\DT\1740 only_21\JJ\1740 cause_22\NN\7323922 of_23\IN\1740 <e2>cerebellar_24\JJ\1740 atrophy</e2>_25\NN\14299637 in_26\IN\13603305 the_27\DT\1740 remaining_28\VBG\2604760 patients_29\NNS\9898892 ._30\.\1740
D010672_D002526 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 phenytoin_3\NN\3550533 overdosage_4\NN\1740 does_5\VBZ\1640855 not_6\RB\1740 necessarily_7\RB\1740 result_8\VB\2633881 in_9\IN\13603305 <e2>cerebellar_10\JJ\1740 atrophy</e2>_11\NN\14299637 and_12\CC\1740 it_13\PRP\6125041 is_14\VBZ\836236 unlikely_15\JJ\1740 that_16\IN\1740 <e1>phenytoin</e1>_17\NN\3550533 medication_18\NN\3247620 was_19\VBD\836236 the_20\DT\1740 only_21\JJ\1740 cause_22\NN\7323922 of_23\IN\1740 cerebellar_24\JJ\1740 atrophy_25\NN\14299637 in_26\IN\13603305 the_27\DT\1740 remaining_28\VBG\2604760 patients_29\NNS\9898892 ._30\.\1740
D010672_D002526 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 phenytoin_3\NN\3550533 overdosage_4\NN\1740 does_5\VBZ\1640855 not_6\RB\1740 necessarily_7\RB\1740 result_8\VB\2633881 in_9\IN\13603305 cerebellar_10\JJ\1740 atrophy_11\NN\14299637 and_12\CC\1740 it_13\PRP\6125041 is_14\VBZ\836236 unlikely_15\JJ\1740 that_16\IN\1740 <e1>phenytoin</e1>_17\NN\3550533 medication_18\NN\3247620 was_19\VBD\836236 the_20\DT\1740 only_21\JJ\1740 cause_22\NN\7323922 of_23\IN\1740 <e2>cerebellar_24\JJ\1740 atrophy</e2>_25\NN\14299637 in_26\IN\13603305 the_27\DT\1740 remaining_28\VBG\2604760 patients_29\NNS\9898892 ._30\.\1740
D010672_D012640 NONE using_0\VBG\1156834 linear_1\JJ\1740 regression_2\NN\14501726 we_3\PRP\1740 found_4\VBD\2426171 that_5\IN\1740 no_6\DT\7204911 correlation_7\NN\13841213 exists_8\VBZ\1740 between_9\IN\1740 <e2>seizure</e2>_10\JJ\1740 duration_11\NN\15113229 ,_12\,\1740 elevation_13\NN\7445480 of_14\IN\1740 <e1>phenytoin</e1>_15\NN\3550533 serum_16\NN\5397468 levels_17\NNS\4916342 and_18\CC\1740 cerebellar_19\JJ\1740 volume_20\NN\33615 ._21\.\1740
8372922
20003049
C031942_D013921 NONE prolonged_0\JJ\1740 elevation_1\NN\7445480 of_2\IN\1740 plasma_3\NN\5398023 <e1>argatroban</e1>_4\NN\1740 in_5\IN\13603305 a_6\DT\13649268 cardiac_7\JJ\1740 transplant_8\NN\5267548 patient_9\NN\9898892 with_10\IN\1740 a_11\DT\13649268 suspected_12\VBN\916909 history_13\NN\15120823 of_14\IN\1740 heparin-induced_15\JJ\1740 <e2>thrombocytopenia</e2>_16\NN\14189204 with_17\IN\1740 thrombosis_18\NN\14100769 ._19\.\1740
C031942_D013921 NONE in_0\IN\13603305 the_1\DT\1740 following_2\VBG\1835496 report_3\NN\6470073 ,_4\,\1740 a_5\DT\13649268 65-year-old_6\RB\1740 critically_7\RB\1740 ill_8\JJ\1740 patient_9\NN\9898892 with_10\IN\1740 a_11\DT\13649268 suspected_12\VBN\916909 history_13\NN\15120823 of_14\IN\1740 <e2>hitt</e2>_15\NN\1740 was_16\VBD\836236 administered_17\VBN\2436349 <e1>argatroban</e1>_18\NN\1740 for_19\IN\1740 anticoagulation_20\NN\657604 on_21\IN\1740 bypass_22\NN\3519981 during_23\IN\1740 heart_24\NN\5919034 transplantation_25\NN\671351 ._26\.\1740
C031942_D013927 NONE prolonged_0\JJ\1740 elevation_1\NN\7445480 of_2\IN\1740 plasma_3\NN\5398023 <e1>argatroban</e1>_4\NN\1740 in_5\IN\13603305 a_6\DT\13649268 cardiac_7\JJ\1740 transplant_8\NN\5267548 patient_9\NN\9898892 with_10\IN\1740 a_11\DT\13649268 suspected_12\VBN\916909 history_13\NN\15120823 of_14\IN\1740 heparin-induced_15\JJ\1740 thrombocytopenia_16\NN\14189204 with_17\IN\1740 <e2>thrombosis</e2>_18\NN\14100769 ._19\.\1740
C031942_D013927 NONE in_0\IN\13603305 the_1\DT\1740 following_2\VBG\1835496 report_3\NN\6470073 ,_4\,\1740 a_5\DT\13649268 65-year-old_6\RB\1740 critically_7\RB\1740 ill_8\JJ\1740 patient_9\NN\9898892 with_10\IN\1740 a_11\DT\13649268 suspected_12\VBN\916909 history_13\NN\15120823 of_14\IN\1740 <e2>hitt</e2>_15\NN\1740 was_16\VBD\836236 administered_17\VBN\2436349 <e1>argatroban</e1>_18\NN\1740 for_19\IN\1740 anticoagulation_20\NN\657604 on_21\IN\1740 bypass_22\NN\3519981 during_23\IN\1740 heart_24\NN\5919034 transplantation_25\NN\671351 ._26\.\1740
D006493_D013921 NONE prolonged_0\JJ\1740 elevation_1\NN\7445480 of_2\IN\1740 plasma_3\NN\5398023 argatroban_4\NN\1740 in_5\IN\13603305 a_6\DT\13649268 cardiac_7\JJ\1740 transplant_8\NN\5267548 patient_9\NN\9898892 with_10\IN\1740 a_11\DT\13649268 suspected_12\VBN\916909 history_13\NN\15120823 of_14\IN\1740 <e1>heparin-induced</e1>_15\JJ\1740 <e2>thrombocytopenia</e2>_16\NN\14189204 with_17\IN\1740 thrombosis_18\NN\14100769 ._19\.\1740
D006493_D013921 NONE background_0\NN\4921011 :_1\:\1740 direct_2\JJ\1740 thrombin_3\NN\14735953 inhibitors_4\NNS\20090 (_5\-LRB-\1740 dtis_6\NNS\1740 )_7\-RRB-\1740 provide_8\VBP\2199590 an_9\DT\6697703 alternative_10\JJ\1740 method_11\NN\5616786 of_12\IN\1740 anticoagulation_13\NN\657604 for_14\IN\1740 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 history_18\NN\15120823 of_19\IN\1740 <e1>heparin-induced</e1>_20\JJ\1740 <e2>thrombocytopenia</e2>_21\NN\14189204 (_22\-LRB-\1740 hit_23\NN\36762 )_24\-RRB-\1740 or_25\CC\3541091 hit_26\NN\36762 with_27\IN\1740 thrombosis_28\NN\14100769 (_29\-LRB-\1740 hitt_30\NN\1740 )_31\-RRB-\1740 undergoing_32\VBG\109660 cardiopulmonary_33\JJ\1740 bypass_34\NN\3519981 (_35\-LRB-\1740 cpb_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D006493_D013921 NONE background_0\NN\4921011 :_1\:\1740 direct_2\JJ\1740 thrombin_3\NN\14735953 inhibitors_4\NNS\20090 (_5\-LRB-\1740 dtis_6\NNS\1740 )_7\-RRB-\1740 provide_8\VBP\2199590 an_9\DT\6697703 alternative_10\JJ\1740 method_11\NN\5616786 of_12\IN\1740 anticoagulation_13\NN\657604 for_14\IN\1740 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 history_18\NN\15120823 of_19\IN\1740 <e1>heparin-induced</e1>_20\JJ\1740 thrombocytopenia_21\NN\14189204 (_22\-LRB-\1740 <e2>hit</e2>_23\NN\36762 )_24\-RRB-\1740 or_25\CC\3541091 hit_26\NN\36762 with_27\IN\1740 thrombosis_28\NN\14100769 (_29\-LRB-\1740 hitt_30\NN\1740 )_31\-RRB-\1740 undergoing_32\VBG\109660 cardiopulmonary_33\JJ\1740 bypass_34\NN\3519981 (_35\-LRB-\1740 cpb_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D006493_D013921 NONE background_0\NN\4921011 :_1\:\1740 direct_2\JJ\1740 thrombin_3\NN\14735953 inhibitors_4\NNS\20090 (_5\-LRB-\1740 dtis_6\NNS\1740 )_7\-RRB-\1740 provide_8\VBP\2199590 an_9\DT\6697703 alternative_10\JJ\1740 method_11\NN\5616786 of_12\IN\1740 anticoagulation_13\NN\657604 for_14\IN\1740 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 history_18\NN\15120823 of_19\IN\1740 <e1>heparin-induced</e1>_20\JJ\1740 thrombocytopenia_21\NN\14189204 (_22\-LRB-\1740 hit_23\NN\36762 )_24\-RRB-\1740 or_25\CC\3541091 <e2>hit</e2>_26\NN\36762 with_27\IN\1740 thrombosis_28\NN\14100769 (_29\-LRB-\1740 hitt_30\NN\1740 )_31\-RRB-\1740 undergoing_32\VBG\109660 cardiopulmonary_33\JJ\1740 bypass_34\NN\3519981 (_35\-LRB-\1740 cpb_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D006493_D013921 NONE background_0\NN\4921011 :_1\:\1740 direct_2\JJ\1740 thrombin_3\NN\14735953 inhibitors_4\NNS\20090 (_5\-LRB-\1740 dtis_6\NNS\1740 )_7\-RRB-\1740 provide_8\VBP\2199590 an_9\DT\6697703 alternative_10\JJ\1740 method_11\NN\5616786 of_12\IN\1740 anticoagulation_13\NN\657604 for_14\IN\1740 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 history_18\NN\15120823 of_19\IN\1740 <e1>heparin-induced</e1>_20\JJ\1740 thrombocytopenia_21\NN\14189204 (_22\-LRB-\1740 hit_23\NN\36762 )_24\-RRB-\1740 or_25\CC\3541091 hit_26\NN\36762 with_27\IN\1740 thrombosis_28\NN\14100769 (_29\-LRB-\1740 <e2>hitt</e2>_30\NN\1740 )_31\-RRB-\1740 undergoing_32\VBG\109660 cardiopulmonary_33\JJ\1740 bypass_34\NN\3519981 (_35\-LRB-\1740 cpb_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D006493_D013927 NONE prolonged_0\JJ\1740 elevation_1\NN\7445480 of_2\IN\1740 plasma_3\NN\5398023 argatroban_4\NN\1740 in_5\IN\13603305 a_6\DT\13649268 cardiac_7\JJ\1740 transplant_8\NN\5267548 patient_9\NN\9898892 with_10\IN\1740 a_11\DT\13649268 suspected_12\VBN\916909 history_13\NN\15120823 of_14\IN\1740 <e1>heparin-induced</e1>_15\JJ\1740 thrombocytopenia_16\NN\14189204 with_17\IN\1740 <e2>thrombosis</e2>_18\NN\14100769 ._19\.\1740
D006493_D013927 NONE background_0\NN\4921011 :_1\:\1740 direct_2\JJ\1740 thrombin_3\NN\14735953 inhibitors_4\NNS\20090 (_5\-LRB-\1740 dtis_6\NNS\1740 )_7\-RRB-\1740 provide_8\VBP\2199590 an_9\DT\6697703 alternative_10\JJ\1740 method_11\NN\5616786 of_12\IN\1740 anticoagulation_13\NN\657604 for_14\IN\1740 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 history_18\NN\15120823 of_19\IN\1740 <e1>heparin-induced</e1>_20\JJ\1740 thrombocytopenia_21\NN\14189204 (_22\-LRB-\1740 hit_23\NN\36762 )_24\-RRB-\1740 or_25\CC\3541091 hit_26\NN\36762 with_27\IN\1740 <e2>thrombosis</e2>_28\NN\14100769 (_29\-LRB-\1740 hitt_30\NN\1740 )_31\-RRB-\1740 undergoing_32\VBG\109660 cardiopulmonary_33\JJ\1740 bypass_34\NN\3519981 (_35\-LRB-\1740 cpb_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D006493_D013927 NONE background_0\NN\4921011 :_1\:\1740 direct_2\JJ\1740 thrombin_3\NN\14735953 inhibitors_4\NNS\20090 (_5\-LRB-\1740 dtis_6\NNS\1740 )_7\-RRB-\1740 provide_8\VBP\2199590 an_9\DT\6697703 alternative_10\JJ\1740 method_11\NN\5616786 of_12\IN\1740 anticoagulation_13\NN\657604 for_14\IN\1740 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 history_18\NN\15120823 of_19\IN\1740 <e1>heparin-induced</e1>_20\JJ\1740 thrombocytopenia_21\NN\14189204 (_22\-LRB-\1740 hit_23\NN\36762 )_24\-RRB-\1740 or_25\CC\3541091 hit_26\NN\36762 with_27\IN\1740 thrombosis_28\NN\14100769 (_29\-LRB-\1740 <e2>hitt</e2>_30\NN\1740 )_31\-RRB-\1740 undergoing_32\VBG\109660 cardiopulmonary_33\JJ\1740 bypass_34\NN\3519981 (_35\-LRB-\1740 cpb_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
C031942_D016638 NONE in_0\IN\13603305 the_1\DT\1740 following_2\VBG\1835496 report_3\NN\6470073 ,_4\,\1740 a_5\DT\13649268 65-year-old_6\RB\1740 <e2>critically_7\RB\1740 ill</e2>_8\JJ\1740 patient_9\NN\9898892 with_10\IN\1740 a_11\DT\13649268 suspected_12\VBN\916909 history_13\NN\15120823 of_14\IN\1740 hitt_15\NN\1740 was_16\VBD\836236 administered_17\VBN\2436349 <e1>argatroban</e1>_18\NN\1740 for_19\IN\1740 anticoagulation_20\NN\657604 on_21\IN\1740 bypass_22\NN\3519981 during_23\IN\1740 heart_24\NN\5919034 transplantation_25\NN\671351 ._26\.\1740
C031942_D008107 NONE results_0\NNS\34213 :_1\:\1740 unexpectedly_2\RB\1740 high_3\JJ\1740 concentrations_4\NNS\4916342 of_5\IN\1740 <e1>argatroban</e1>_6\NN\1740 were_7\VBD\836236 measured_8\VBN\697589 in_9\IN\13603305 these_10\DT\1740 samples_11\NNS\5820620 (_12\-LRB-\1740 range_13\NN\5123416 ,_14\,\1740 0_15\CD\13741022 -_16\SYM\1740 32_17\CD\1740 microg/ml_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 a_22\DT\13649268 prolonged_23\JJ\1740 plasma_24\NN\5398023 argatroban_25\NN\1740 half_26\NN\13732295 life_27\NN\13954253 (_28\-LRB-\1740 t(1/2_29\NN\1740 )_30\-RRB-\1740 )_31\-RRB-\1740 of_32\IN\1740 514_33\CD\1740 minutes_34\NNS\6502378 was_35\VBD\836236 observed_36\VBN\2163746 (_37\-LRB-\1740 published_38\VBN\1621555 elimination_39\NN\391599 t(1/2_40\NN\1740 )_41\-RRB-\1740 is_42\VBZ\836236 39_43\CD\1740 -_44\SYM\1740 51_45\CD\1740 minutes_46\NNS\6502378 [_47\-LRB-\1740 <_48\XX\1740 or_49\CC\3541091 =_50\JJ\1740 181_51\CD\1740 minutes_52\NNS\6502378 with_53\IN\1740 <e2>hepatic_54\JJ\1740 impairment</e2>_55\NN\7296428 ]_56\-RRB-\1740 )_57\-RRB-\1740 ._58\.\1740
C031942_D008107 NONE results_0\NNS\34213 :_1\:\1740 unexpectedly_2\RB\1740 high_3\JJ\1740 concentrations_4\NNS\4916342 of_5\IN\1740 argatroban_6\NN\1740 were_7\VBD\836236 measured_8\VBN\697589 in_9\IN\13603305 these_10\DT\1740 samples_11\NNS\5820620 (_12\-LRB-\1740 range_13\NN\5123416 ,_14\,\1740 0_15\CD\13741022 -_16\SYM\1740 32_17\CD\1740 microg/ml_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 a_22\DT\13649268 prolonged_23\JJ\1740 plasma_24\NN\5398023 <e1>argatroban</e1>_25\NN\1740 half_26\NN\13732295 life_27\NN\13954253 (_28\-LRB-\1740 t(1/2_29\NN\1740 )_30\-RRB-\1740 )_31\-RRB-\1740 of_32\IN\1740 514_33\CD\1740 minutes_34\NNS\6502378 was_35\VBD\836236 observed_36\VBN\2163746 (_37\-LRB-\1740 published_38\VBN\1621555 elimination_39\NN\391599 t(1/2_40\NN\1740 )_41\-RRB-\1740 is_42\VBZ\836236 39_43\CD\1740 -_44\SYM\1740 51_45\CD\1740 minutes_46\NNS\6502378 [_47\-LRB-\1740 <_48\XX\1740 or_49\CC\3541091 =_50\JJ\1740 181_51\CD\1740 minutes_52\NNS\6502378 with_53\IN\1740 <e2>hepatic_54\JJ\1740 impairment</e2>_55\NN\7296428 ]_56\-RRB-\1740 )_57\-RRB-\1740 ._58\.\1740
C031942_D001778 NONE conclusions_0\NNS\5837957 :_1\:\1740 correlation_2\NN\13841213 of_3\IN\1740 plasma_4\NN\5398023 <e1>argatroban</e1>_5\NN\1740 concentration_6\NN\4916342 versus_7\CC\1740 the_8\DT\1740 patient_9\NN\9898892 's_10\POS\1740 coagulation_11\NN\13518963 variables_12\NNS\2452 and_13\CC\1740 clinical_14\JJ\1740 course_15\NN\883297 suggest_16\VBP\1010118 that_17\IN\1740 prolonged_18\JJ\1740 elevated_19\JJ\1740 levels_20\NNS\4916342 of_21\IN\1740 plasma_22\NN\5398023 argatroban_23\NN\1740 may_24\MD\15209706 have_25\VB\2108377 contributed_26\VBN\126264 to_27\IN\1740 the_28\DT\1740 patient_29\NN\9898892 's_30\POS\1740 extended_31\VBN\153263 <e2>coagulopathy</e2>_32\JJ\1740 ._33\.\1740
C031942_D001778 NONE conclusions_0\NNS\5837957 :_1\:\1740 correlation_2\NN\13841213 of_3\IN\1740 plasma_4\NN\5398023 argatroban_5\NN\1740 concentration_6\NN\4916342 versus_7\CC\1740 the_8\DT\1740 patient_9\NN\9898892 's_10\POS\1740 coagulation_11\NN\13518963 variables_12\NNS\2452 and_13\CC\1740 clinical_14\JJ\1740 course_15\NN\883297 suggest_16\VBP\1010118 that_17\IN\1740 prolonged_18\JJ\1740 elevated_19\JJ\1740 levels_20\NNS\4916342 of_21\IN\1740 plasma_22\NN\5398023 <e1>argatroban</e1>_23\NN\1740 may_24\MD\15209706 have_25\VB\2108377 contributed_26\VBN\126264 to_27\IN\1740 the_28\DT\1740 patient_29\NN\9898892 's_30\POS\1740 extended_31\VBN\153263 <e2>coagulopathy</e2>_32\JJ\1740 ._33\.\1740
C031942_D001778 NONE this_0\DT\1740 is_1\VBZ\836236 the_2\DT\1740 first_3\JJ\1740 report_4\NN\6470073 to_5\TO\1740 measure_6\VB\697589 plasma_7\NN\5398023 <e1>argatroban</e1>_8\NN\1740 concentration_9\NN\4916342 in_10\IN\13603305 the_11\DT\1740 context_12\NN\6284777 of_13\IN\1740 cpb_14\NN\1740 and_15\CC\1740 extended_16\VBD\153263 <e2>coagulopathy</e2>_17\RB\1740 ._18\.\1740
17111419
C102006_D064420 NONE severe_0\JJ\1740 <e1>citrate</e1>_1\NN\14850483 <e2>toxicity</e2>_2\NN\13576101 complicating_3\VBG\126264 volunteer_4\NN\10582746 apheresis_5\NN\13524399 platelet_6\NN\5432736 donation_7\NN\13265011 ._8\.\1740
C102006_D064420 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 severe_5\JJ\1740 <e1>citrate</e1>_6\NN\14850483 <e2>toxicity</e2>_7\NN\13576101 during_8\IN\1740 volunteer_9\NN\10582746 donor_10\NN\9608709 apheresis_11\NN\13524399 platelet_12\NN\5432736 collection_13\NN\31264 ._14\.\1740
C102006_D064420 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 careful_3\JJ\1740 screening_4\NN\6887726 for_5\IN\1740 medications_6\NNS\3247620 and_7\CC\1740 underlying_8\VBG\2604760 conditions_9\NNS\14512817 predisposing_10\VBG\680841 to_11\TO\1740 hypocalcemia_12\NN\14299637 is_13\VBZ\836236 recommended_14\VBN\875394 to_15\TO\1740 help_16\VB\2556126 prevent_17\VB\1740 severe_18\JJ\1740 reactions_19\NNS\13446390 due_20\IN\5174653 to_21\TO\1740 <e1>citrate</e1>_22\NN\14850483 <e2>toxicity</e2>_23\NN\13576101 ._24\.\1740
D002125_C536214 NONE empirical_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 intravenous_3\JJ\1740 <e1>calcium_4\NN\14625458 gluconate</e1>_5\NN\1740 was_6\VBD\836236 initiated_7\VBN\1617192 ,_8\,\1740 and_9\CC\1740 <e2>muscle_10\NN\5289601 contractions</e2>_11\NNS\358931 slowly_12\RB\1740 subsided_13\VBD\223500 over_14\RB\1740 approximately_15\RB\1740 10_16\CD\13745420 to_17\TO\1740 15_18\CD\13745420 minutes_19\NNS\6502378 ._20\.\1740
D002118_D006996 NONE the_0\DT\1740 events_1\NNS\23100 are_2\VBP\836236 consistent_3\JJ\1740 with_4\IN\1740 a_5\DT\13649268 severe_6\JJ\1740 reaction_7\NN\13446390 to_8\TO\1740 <e1>calcium</e1>_9\NN\14625458 chelation_10\NN\29677 by_11\IN\1740 sodium_12\NN\14625458 citrate_13\NN\14850483 anticoagulant_14\NN\3740161 resulting_15\VBG\2633881 in_16\IN\13603305 symptomatic_17\JJ\1740 systemic_18\JJ\1740 <e2>hypocalcemia</e2>_19\NN\14299637 ._20\.\1740
C102006_D006996 CID the_0\DT\1740 events_1\NNS\23100 are_2\VBP\836236 consistent_3\JJ\1740 with_4\IN\1740 a_5\DT\13649268 severe_6\JJ\1740 reaction_7\NN\13446390 to_8\TO\1740 calcium_9\NN\14625458 chelation_10\NN\29677 by_11\IN\1740 <e1>sodium_12\NN\14625458 citrate</e1>_13\NN\14850483 anticoagulant_14\NN\3740161 resulting_15\VBG\2633881 in_16\IN\13603305 symptomatic_17\JJ\1740 systemic_18\JJ\1740 <e2>hypocalcemia</e2>_19\NN\14299637 ._20\.\1740
C102006_D006996 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 careful_3\JJ\1740 screening_4\NN\6887726 for_5\IN\1740 medications_6\NNS\3247620 and_7\CC\1740 underlying_8\VBG\2604760 conditions_9\NNS\14512817 predisposing_10\VBG\680841 to_11\TO\1740 <e2>hypocalcemia</e2>_12\NN\14299637 is_13\VBZ\836236 recommended_14\VBN\875394 to_15\TO\1740 help_16\VB\2556126 prevent_17\VB\1740 severe_18\JJ\1740 reactions_19\NNS\13446390 due_20\IN\5174653 to_21\TO\1740 <e1>citrate</e1>_22\NN\14850483 toxicity_23\NN\13576101 ._24\.\1740
D002034_D006996 NONE upon_0\IN\1740 additional_1\JJ\1740 retrospective_2\JJ\1740 analysis_3\NN\633864 ,_4\,\1740 it_5\PRP\6125041 was_6\VBD\836236 noted_7\VBN\1009240 that_8\IN\1740 <e1>bumetanide</e1>_9\NN\1740 is_10\VBZ\836236 a_11\DT\13649268 loop_12\NN\3323703 diuretic_13\NN\3247620 that_14\WDT\1740 may_15\MD\15209706 cause_16\VB\1617192 significant_17\JJ\1740 <e2>hypocalcemia</e2>_18\NN\14299637 ._19\.\1740
D049994_D006996 NONE upon_0\IN\1740 additional_1\JJ\1740 retrospective_2\JJ\1740 analysis_3\NN\633864 ,_4\,\1740 it_5\PRP\6125041 was_6\VBD\836236 noted_7\VBN\1009240 that_8\IN\1740 bumetanide_9\NN\1740 is_10\VBZ\836236 a_11\DT\13649268 <e1>loop_12\NN\3323703 diuretic</e1>_13\NN\3247620 that_14\WDT\1740 may_15\MD\15209706 cause_16\VB\1617192 significant_17\JJ\1740 <e2>hypocalcemia</e2>_18\NN\14299637 ._19\.\1740
2070391
D008012_D010146 CID reduction_0\NN\351485 in_1\IN\13603305 injection_2\NN\320852 <e2>pain</e2>_3\NN\14299637 using_4\VBG\1156834 buffered_5\VBN\169806 <e1>lidocaine</e1>_6\NN\3681148 as_7\IN\14622893 a_8\DT\13649268 local_9\JJ\1740 anesthetic_10\JJ\1740 before_11\IN\1740 cardiac_12\JJ\1740 catheterization_13\NN\671351 ._14\.\1740
D008012_D010146 CID previous_0\JJ\1740 reports_1\NNS\6470073 have_2\VBP\2108377 suggested_3\VBN\1010118 that_4\IN\1740 <e2>pain</e2>_5\NN\14299637 associated_6\VBN\628491 with_7\IN\1740 the_8\DT\1740 injection_9\NN\320852 of_10\IN\1740 <e1>lidocaine</e1>_11\NN\3681148 is_12\VBZ\836236 related_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 acidic_16\JJ\1740 ph_17\NN\5038959 of_18\IN\1740 the_19\DT\1740 solution_20\NN\14586258 ._21\.\1740
D008012_D010146 CID to_0\TO\1740 determine_1\VB\1645601 if_2\IN\1740 the_3\DT\1740 addition_4\NN\3081021 of_5\IN\1740 a_6\DT\13649268 buffering_7\NN\1740 solution_8\NN\14586258 to_9\TO\1740 adjust_10\VB\126264 the_11\DT\1740 ph_12\NN\5038959 of_13\IN\1740 <e1>lidocaine</e1>_14\NN\3681148 into_15\IN\1740 the_16\DT\1740 physiologic_17\JJ\1740 range_18\NN\5123416 would_19\MD\1740 reduce_20\VB\441445 <e2>pain</e2>_21\NN\14299637 during_22\IN\1740 injection_23\NN\320852 ,_24\,\1740 we_25\PRP\1740 performed_26\VBD\2367363 a_27\DT\13649268 blinded_28\VBN\126264 randomized_29\JJ\1740 study_30\NN\635850 in_31\IN\13603305 patients_32\NNS\9898892 undergoing_33\VBG\109660 cardiac_34\JJ\1740 catheterization_35\NN\671351 ._36\.\1740
D008012_D010146 CID twenty_0\CD\13745420 patients_1\NNS\9898892 were_2\VBD\836236 asked_3\VBN\740577 to_4\TO\1740 quantify_5\VB\947077 the_6\DT\1740 severity_7\NN\5036394 of_8\IN\1740 <e2>pain</e2>_9\NN\14299637 after_10\IN\1740 receiving_11\VBG\2210855 standard_12\JJ\1740 <e1>lidocaine</e1>_13\NN\3681148 in_14\IN\13603305 one_15\CD\13741022 femoral_16\JJ\1740 area_17\NN\8630985 and_18\CC\1740 buffered_19\VBD\169806 lidocaine_20\NN\3681148 in_21\IN\13603305 the_22\DT\1740 opposite_23\JJ\1740 femoral_24\JJ\1740 area_25\NN\8630985 ._26\.\1740
D008012_D010146 CID twenty_0\CD\13745420 patients_1\NNS\9898892 were_2\VBD\836236 asked_3\VBN\740577 to_4\TO\1740 quantify_5\VB\947077 the_6\DT\1740 severity_7\NN\5036394 of_8\IN\1740 <e2>pain</e2>_9\NN\14299637 after_10\IN\1740 receiving_11\VBG\2210855 standard_12\JJ\1740 lidocaine_13\NN\3681148 in_14\IN\13603305 one_15\CD\13741022 femoral_16\JJ\1740 area_17\NN\8630985 and_18\CC\1740 buffered_19\VBD\169806 <e1>lidocaine</e1>_20\NN\3681148 in_21\IN\13603305 the_22\DT\1740 opposite_23\JJ\1740 femoral_24\JJ\1740 area_25\NN\8630985 ._26\.\1740
D008012_D010146 CID the_0\DT\1740 mean_1\NN\6021761 <e2>pain</e2>_2\NN\14299637 score_3\NN\5736149 for_4\IN\1740 buffered_5\VBN\169806 <e1>lidocaine</e1>_6\NN\3681148 was_7\VBD\836236 significantly_8\RB\1740 lower_9\JJR\1740 than_10\IN\1740 the_11\DT\1740 mean_12\NN\6021761 score_13\NN\5736149 for_14\IN\1740 standard_15\JJ\1740 lidocaine_16\NN\3681148 (_17\-LRB-\1740 2.7_18\CD\1740 +/-_19\CC\1740 1.9_20\CD\1740 vs._21\CC\1740 3.8_22\CD\1740 +/-_23\CC\1740 2.2_24\CD\1740 ,_25\,\1740 p_26\NN\14622893 =_27\JJ\1740 0.03_28\CD\1740 )_29\-RRB-\1740 ._30\.\1740
D008012_D010146 CID the_0\DT\1740 mean_1\NN\6021761 <e2>pain</e2>_2\NN\14299637 score_3\NN\5736149 for_4\IN\1740 buffered_5\VBN\169806 lidocaine_6\NN\3681148 was_7\VBD\836236 significantly_8\RB\1740 lower_9\JJR\1740 than_10\IN\1740 the_11\DT\1740 mean_12\NN\6021761 score_13\NN\5736149 for_14\IN\1740 standard_15\JJ\1740 <e1>lidocaine</e1>_16\NN\3681148 (_17\-LRB-\1740 2.7_18\CD\1740 +/-_19\CC\1740 1.9_20\CD\1740 vs._21\CC\1740 3.8_22\CD\1740 +/-_23\CC\1740 2.2_24\CD\1740 ,_25\,\1740 p_26\NN\14622893 =_27\JJ\1740 0.03_28\CD\1740 )_29\-RRB-\1740 ._30\.\1740
D008012_D010146 CID the_0\DT\1740 ph_1\NN\5038959 adjustment_2\NN\7357388 of_3\IN\1740 standard_4\JJ\1740 <e1>lidocaine</e1>_5\NN\3681148 can_6\MD\3094503 be_7\VB\836236 accomplished_8\VBN\484166 easily_9\RB\1740 in_10\IN\13603305 the_11\DT\1740 catheterization_12\NN\671351 laboratory_13\NN\4602044 before_14\IN\1740 injection_15\NN\320852 and_16\CC\1740 results_17\VBZ\2633881 in_18\IN\13603305 a_19\DT\13649268 reduction_20\NN\351485 of_21\IN\1740 the_22\DT\1740 <e2>pain</e2>_23\NN\14299637 occurring_24\VBG\2623529 during_25\IN\1740 the_26\DT\1740 infiltration_27\NN\975452 of_28\IN\1740 tissues_29\NNS\5220461 ._30\.\1740
2611118
D004008_D006521 NONE <e2>chronic_0\JJ\1740 active_1\JJ\1740 hepatitis</e2>_2\NN\14127211 associated_3\VBN\628491 with_4\IN\1740 <e1>diclofenac_5\JJ\1740 sodium</e1>_6\NN\14625458 therapy_7\NN\657604 ._8\.\1740
D004008_D006521 NONE the_0\DT\1740 patient_1\NN\9898892 described_2\VBD\1001294 developed_3\VBD\1753788 <e2>chronic_4\JJ\1740 active_5\JJ\1740 hepatitis</e2>_6\NN\14127211 after_7\IN\1740 six_8\CD\13741022 months_9\NNS\15113229 therapy_10\NN\657604 with_11\IN\1740 <e1>diclofenac_12\JJ\1740 sodium</e1>_13\NN\14625458 which_14\WDT\1740 progressed_15\VBD\252019 despite_16\IN\7501545 the_17\DT\1740 withdrawal_18\NN\7206096 of_19\IN\1740 the_20\DT\1740 drug_21\NN\14778436 ,_22\,\1740 a_23\DT\13649268 finding_24\NN\43195 not_25\RB\1740 previously_26\RB\1740 reported_27\VBN\831651 ._28\.\1740
D004008_D056486 CID although_0\IN\1740 generally_1\RB\1740 well-tolerated_2\JJ\1740 ,_3\,\1740 asymptomatic_4\JJ\1740 <e2>abnormalities_5\NNS\14034177 of_6\IN\1740 liver_7\NN\5298729 function</e2>_8\NN\13783581 have_9\VBP\2108377 been_10\VBN\836236 recorded_11\VBN\2225492 and_12\CC\1740 ,_13\,\1740 less_14\RBR\1740 commonly_15\RB\1740 ,_16\,\1740 severe_17\JJ\1740 hepatitis_18\NN\14127211 induced_19\VBN\1627355 by_20\IN\1740 <e1>diclofenac</e1>_21\VBN\1740 ._22\.\1740
D004008_D056486 CID although_0\IN\1740 generally_1\RB\1740 well-tolerated_2\JJ\1740 ,_3\,\1740 asymptomatic_4\JJ\1740 abnormalities_5\NNS\14034177 of_6\IN\1740 liver_7\NN\5298729 function_8\NN\13783581 have_9\VBP\2108377 been_10\VBN\836236 recorded_11\VBN\2225492 and_12\CC\1740 ,_13\,\1740 less_14\RBR\1740 commonly_15\RB\1740 ,_16\,\1740 severe_17\JJ\1740 <e2>hepatitis</e2>_18\NN\14127211 induced_19\VBN\1627355 by_20\IN\1740 <e1>diclofenac</e1>_21\VBN\1740 ._22\.\1740
2484011
D000547_D003866 NONE the_0\DT\1740 initial_1\JJ\1740 dose_2\NN\3740161 of_3\IN\1740 <e1>amantadine</e1>_4\NN\1740 <e2>depressed</e2>_5\JJ\1740 locomotor_6\NN\1740 activity_7\NN\30358 in_8\IN\13603305 all_9\DT\1740 mouse_10\NN\2329401 strains_11\NNS\7358060 studied_12\VBN\630380 with_13\IN\1740 the_14\DT\1740 balb/c_15\NN\1740 mice_16\NNS\2329401 being_17\VBG\836236 the_18\DT\1740 most_19\RBS\1740 sensitive_20\JJ\1740 ._21\.\1740
D000547_D011596 CID readministration_0\NN\1740 of_1\IN\1740 <e1>amantadine</e1>_2\NN\1740 ,_3\,\1740 after_4\IN\1740 a_5\DT\13649268 drug-free_6\JJ\1740 overnight_7\JJ\1740 period_8\NN\13575869 ,_9\,\1740 increased_10\VBN\169651 motility_11\NN\4773351 from_12\IN\1740 respective_13\JJ\1740 saline_14\NN\14849367 control_15\NN\5190804 in_16\IN\13603305 all_17\DT\1740 strains_18\NNS\7358060 with_19\IN\1740 exception_20\NN\5706954 of_21\IN\1740 the_22\DT\1740 balb/c_23\NN\1740 mice_24\NNS\2329401 where_25\WRB\1740 <e2>suppression_26\NN\13489037 of_27\IN\1740 motility</e2>_28\NN\4773351 occurred_29\VBD\2623529 ._30\.\1740
D000547_D011596 CID the_0\DT\1740 biochemical_1\JJ\1740 results_2\NNS\34213 of_3\IN\1740 brain_4\NN\5462674 biogenic_5\JJ\1740 amines_6\NNS\14951377 of_7\IN\1740 balb/c_8\NN\1740 mouse_9\NN\2329401 strain_10\NN\7358060 suggest_11\VBP\1010118 a_12\DT\13649268 probable_13\JJ\1740 decrease_14\NN\7296428 of_15\IN\1740 catecholamine_16\NN\5407119 turnover_17\NN\13819207 rate_18\NN\13815152 and/or_19\CC\1740 metabolism_20\NN\13526110 by_21\IN\1740 monoamine_22\NN\14739004 oxidase_23\NN\14732946 and_24\CC\1740 a_25\DT\13649268 resulting_26\VBG\2633881 increase_27\NN\13576355 in_28\IN\13603305 o-methylation_29\NN\1740 of_30\IN\1740 norepinephrine_31\NN\14807929 which_32\WDT\1740 may_33\MD\15209706 account_34\VB\2604760 for_35\IN\1740 a_36\DT\13649268 <e2>behavioral_37\JJ\1740 depression</e2>_38\NN\14373582 caused_39\VBN\1617192 by_40\IN\1740 <e1>amantadine</e1>_41\NN\1740 in_42\IN\13603305 the_43\DT\1740 balb/c_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
D000588_D011596 NONE the_0\DT\1740 biochemical_1\JJ\1740 results_2\NNS\34213 of_3\IN\1740 brain_4\NN\5462674 biogenic_5\JJ\1740 <e1>amines</e1>_6\NNS\14951377 of_7\IN\1740 balb/c_8\NN\1740 mouse_9\NN\2329401 strain_10\NN\7358060 suggest_11\VBP\1010118 a_12\DT\13649268 probable_13\JJ\1740 decrease_14\NN\7296428 of_15\IN\1740 catecholamine_16\NN\5407119 turnover_17\NN\13819207 rate_18\NN\13815152 and/or_19\CC\1740 metabolism_20\NN\13526110 by_21\IN\1740 monoamine_22\NN\14739004 oxidase_23\NN\14732946 and_24\CC\1740 a_25\DT\13649268 resulting_26\VBG\2633881 increase_27\NN\13576355 in_28\IN\13603305 o-methylation_29\NN\1740 of_30\IN\1740 norepinephrine_31\NN\14807929 which_32\WDT\1740 may_33\MD\15209706 account_34\VB\2604760 for_35\IN\1740 a_36\DT\13649268 <e2>behavioral_37\JJ\1740 depression</e2>_38\NN\14373582 caused_39\VBN\1617192 by_40\IN\1740 amantadine_41\NN\1740 in_42\IN\13603305 the_43\DT\1740 balb/c_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
D002395_D011596 NONE the_0\DT\1740 biochemical_1\JJ\1740 results_2\NNS\34213 of_3\IN\1740 brain_4\NN\5462674 biogenic_5\JJ\1740 amines_6\NNS\14951377 of_7\IN\1740 balb/c_8\NN\1740 mouse_9\NN\2329401 strain_10\NN\7358060 suggest_11\VBP\1010118 a_12\DT\13649268 probable_13\JJ\1740 decrease_14\NN\7296428 of_15\IN\1740 <e1>catecholamine</e1>_16\NN\5407119 turnover_17\NN\13819207 rate_18\NN\13815152 and/or_19\CC\1740 metabolism_20\NN\13526110 by_21\IN\1740 monoamine_22\NN\14739004 oxidase_23\NN\14732946 and_24\CC\1740 a_25\DT\13649268 resulting_26\VBG\2633881 increase_27\NN\13576355 in_28\IN\13603305 o-methylation_29\NN\1740 of_30\IN\1740 norepinephrine_31\NN\14807929 which_32\WDT\1740 may_33\MD\15209706 account_34\VB\2604760 for_35\IN\1740 a_36\DT\13649268 <e2>behavioral_37\JJ\1740 depression</e2>_38\NN\14373582 caused_39\VBN\1617192 by_40\IN\1740 amantadine_41\NN\1740 in_42\IN\13603305 the_43\DT\1740 balb/c_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
D009638_D011596 NONE the_0\DT\1740 biochemical_1\JJ\1740 results_2\NNS\34213 of_3\IN\1740 brain_4\NN\5462674 biogenic_5\JJ\1740 amines_6\NNS\14951377 of_7\IN\1740 balb/c_8\NN\1740 mouse_9\NN\2329401 strain_10\NN\7358060 suggest_11\VBP\1010118 a_12\DT\13649268 probable_13\JJ\1740 decrease_14\NN\7296428 of_15\IN\1740 catecholamine_16\NN\5407119 turnover_17\NN\13819207 rate_18\NN\13815152 and/or_19\CC\1740 metabolism_20\NN\13526110 by_21\IN\1740 monoamine_22\NN\14739004 oxidase_23\NN\14732946 and_24\CC\1740 a_25\DT\13649268 resulting_26\VBG\2633881 increase_27\NN\13576355 in_28\IN\13603305 o-methylation_29\NN\1740 of_30\IN\1740 <e1>norepinephrine</e1>_31\NN\14807929 which_32\WDT\1740 may_33\MD\15209706 account_34\VB\2604760 for_35\IN\1740 a_36\DT\13649268 <e2>behavioral_37\JJ\1740 depression</e2>_38\NN\14373582 caused_39\VBN\1617192 by_40\IN\1740 amantadine_41\NN\1740 in_42\IN\13603305 the_43\DT\1740 balb/c_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
9754849
D008691_D002819 CID <e2>choreoathetoid_0\NN\1740 movements</e2>_1\NNS\191142 associated_2\VBN\628491 with_3\IN\1740 rapid_4\JJ\1740 adjustment_5\NN\7357388 to_6\IN\1740 <e1>methadone</e1>_7\NN\3808564 ._8\.\1740
D008691_D002819 CID this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 of_5\IN\1740 euphoria_6\NN\7527656 and_7\CC\1740 <e2>choreoathetoid_8\JJ\1740 movements</e2>_9\NNS\191142 both_10\CC\1740 transiently_11\RB\1740 induced_12\VBN\1627355 by_13\IN\1740 rapid_14\JJ\1740 adjustment_15\NN\7357388 to_16\IN\1740 the_17\DT\1740 selective_18\JJ\1740 mu-opioid_19\JJ\1740 receptor_20\NN\5225602 agonist_21\NN\9613191 <e1>methadone</e1>_22\NN\3808564 in_23\IN\13603305 an_24\DT\6697703 inpatient_25\JJ\1740 previously_26\RB\1740 abusing_27\VBG\2514187 heroine_28\NN\5929008 and_29\CC\1740 cocaine_30\NN\3492717 ._31\.\1740
D003042_D002819 CID <e2>choreatiform_0\NN\1740 hyperkinesias</e2>_1\NNS\1740 are_2\VBP\836236 known_3\VBN\2110220 to_4\TO\1740 be_5\VB\836236 occasional_6\JJ\1740 movement_7\NN\191142 abnormalities_8\NNS\14034177 during_9\IN\1740 intoxications_10\NNS\14034177 with_11\IN\1740 <e1>cocaine</e1>_12\NN\3492717 but_13\CC\1740 not_14\RB\1740 opiates_15\NNS\3808564 ._16\.\1740
D003042_D002819 CID this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 of_5\IN\1740 euphoria_6\NN\7527656 and_7\CC\1740 <e2>choreoathetoid_8\JJ\1740 movements</e2>_9\NNS\191142 both_10\CC\1740 transiently_11\RB\1740 induced_12\VBN\1627355 by_13\IN\1740 rapid_14\JJ\1740 adjustment_15\NN\7357388 to_16\IN\1740 the_17\DT\1740 selective_18\JJ\1740 mu-opioid_19\JJ\1740 receptor_20\NN\5225602 agonist_21\NN\9613191 methadone_22\NN\3808564 in_23\IN\13603305 an_24\DT\6697703 inpatient_25\JJ\1740 previously_26\RB\1740 abusing_27\VBG\2514187 heroine_28\NN\5929008 and_29\CC\1740 <e1>cocaine</e1>_30\NN\3492717 ._31\.\1740
D003042_D006948 CID <e2>choreatiform_0\NN\1740 hyperkinesias</e2>_1\NNS\1740 are_2\VBP\836236 known_3\VBN\2110220 to_4\TO\1740 be_5\VB\836236 occasional_6\JJ\1740 movement_7\NN\191142 abnormalities_8\NNS\14034177 during_9\IN\1740 intoxications_10\NNS\14034177 with_11\IN\1740 <e1>cocaine</e1>_12\NN\3492717 but_13\CC\1740 not_14\RB\1740 opiates_15\NNS\3808564 ._16\.\1740
D003042_D020820 NONE choreatiform_0\NN\1740 hyperkinesias_1\NNS\1740 are_2\VBP\836236 known_3\VBN\2110220 to_4\TO\1740 be_5\VB\836236 occasional_6\JJ\1740 <e2>movement_7\NN\191142 abnormalities</e2>_8\NNS\14034177 during_9\IN\1740 intoxications_10\NNS\14034177 with_11\IN\1740 <e1>cocaine</e1>_12\NN\3492717 but_13\CC\1740 not_14\RB\1740 opiates_15\NNS\3808564 ._16\.\1740
D003932_D002819 NONE this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 of_5\IN\1740 euphoria_6\NN\7527656 and_7\CC\1740 <e2>choreoathetoid_8\JJ\1740 movements</e2>_9\NNS\191142 both_10\CC\1740 transiently_11\RB\1740 induced_12\VBN\1627355 by_13\IN\1740 rapid_14\JJ\1740 adjustment_15\NN\7357388 to_16\IN\1740 the_17\DT\1740 selective_18\JJ\1740 mu-opioid_19\JJ\1740 receptor_20\NN\5225602 agonist_21\NN\9613191 methadone_22\NN\3808564 in_23\IN\13603305 an_24\DT\6697703 inpatient_25\JJ\1740 previously_26\RB\1740 abusing_27\VBG\2514187 <e1>heroine</e1>_28\NN\5929008 and_29\CC\1740 cocaine_30\NN\3492717 ._31\.\1740
354896
D008012_D006323 CID <e1>lidocaine-induced</e1>_0\JJ\1740 <e2>cardiac_1\JJ\1740 asystole</e2>_2\NN\14204950 ._3\.\1740
D008012_D003866 NONE intravenous_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a_3\DT\13649268 single_4\JJ\1740 50-mg_5\JJ\1740 bolus_6\NN\13899404 of_7\IN\1740 <e1>lidocaine</e1>_8\NN\3681148 in_9\IN\13603305 a_10\DT\13649268 67-year-old_11\JJ\1740 man_12\NN\9605289 resulted_13\VBD\2633881 in_14\IN\13603305 profound_15\JJ\1740 <e2>depression</e2>_16\NN\14373582 of_17\IN\1740 the_18\DT\1740 activity_19\NN\30358 of_20\IN\1740 the_21\DT\1740 sinoatrial_22\NN\1740 and_23\CC\1740 atrioventricular_24\JJ\1740 nodal_25\NN\1740 pacemakers_26\NNS\5925366 ._27\.\1740
D008012_D001919 NONE the_0\DT\1740 patient_1\NN\9898892 had_2\VBD\2108377 no_3\DT\7204911 apparent_4\JJ\1740 associated_5\VBN\628491 conditions_6\NNS\14512817 which_7\WDT\1740 might_8\MD\5029706 have_9\VB\2108377 predisposed_10\VBN\680841 him_11\PRP\1740 to_12\IN\1740 the_13\DT\1740 development_14\NN\248977 of_15\IN\1740 <e2>bradyarrhythmias</e2>_16\NNS\1740 ;_17\:\1740 and_18\CC\1740 ,_19\,\1740 thus_20\RB\1740 ,_21\,\1740 this_22\DT\1740 probably_23\RB\1740 represented_24\VBD\2664769 a_25\DT\13649268 true_26\JJ\1740 idiosyncrasy_27\JJ\1740 to_28\TO\1740 <e1>lidocaine</e1>_29\VB\1740 ._30\.\1740
20619828
D002997_D001008 CID results_0\NNS\34213 :_1\:\1740 <e1>clomipramine</e1>_2\NN\4482543 exposure_3\NN\5042871 in_4\IN\13603305 immature_5\JJ\1740 rats_6\NNS\2329401 produced_7\VBD\1617192 significant_8\JJ\1740 behavioral_9\JJ\1740 and_10\CC\1740 biochemical_11\JJ\1740 changes_12\NNS\7283608 that_13\WDT\1740 include_14\VBP\690614 enhanced_15\VBN\227165 <e2>anxiety</e2>_16\NN\14373582 (_17\-LRB-\1740 elevated_18\JJ\1740 plus_19\CC\4723816 maze_20\NN\4377057 and_21\CC\1740 marble_22\NN\14696793 burying_23\NN\1048912 )_24\-RRB-\1740 ,_25\,\1740 behavioral_26\JJ\1740 inflexibility_27\NN\5023741 (_28\-LRB-\1740 perseveration_29\NN\6196584 in_30\IN\13603305 the_31\DT\1740 spontaneous_32\JJ\1740 alternation_33\NN\1010458 task_34\NN\575741 and_35\CC\1740 impaired_36\JJ\1740 reversal_37\JJ\1740 learning_38\NN\5701944 )_39\-RRB-\1740 ,_40\,\1740 working_41\VBG\2524171 memory_42\NN\5926676 impairment_43\NN\7296428 (_44\-LRB-\1740 e.g._45\FW\1740 ,_46\,\1740 win-shift_47\JJ\1740 paradigm_48\NN\13803782 )_49\-RRB-\1740 ,_50\,\1740 hoarding_51\VBG\2265979 ,_52\,\1740 and_53\CC\1740 corticostriatal_54\JJ\1740 dysfunction_55\NN\14204950 ._56\.\1740
D002997_-1 NONE results_0\NNS\34213 :_1\:\1740 <e1>clomipramine</e1>_2\NN\4482543 exposure_3\NN\5042871 in_4\IN\13603305 immature_5\JJ\1740 rats_6\NNS\2329401 produced_7\VBD\1617192 significant_8\JJ\1740 behavioral_9\JJ\1740 and_10\CC\1740 biochemical_11\JJ\1740 changes_12\NNS\7283608 that_13\WDT\1740 include_14\VBP\690614 enhanced_15\VBN\227165 anxiety_16\NN\14373582 (_17\-LRB-\1740 elevated_18\JJ\1740 plus_19\CC\4723816 maze_20\NN\4377057 and_21\CC\1740 marble_22\NN\14696793 burying_23\NN\1048912 )_24\-RRB-\1740 ,_25\,\1740 <e2>behavioral_26\JJ\1740 inflexibility</e2>_27\NN\5023741 (_28\-LRB-\1740 perseveration_29\NN\6196584 in_30\IN\13603305 the_31\DT\1740 spontaneous_32\JJ\1740 alternation_33\NN\1010458 task_34\NN\575741 and_35\CC\1740 impaired_36\JJ\1740 reversal_37\JJ\1740 learning_38\NN\5701944 )_39\-RRB-\1740 ,_40\,\1740 working_41\VBG\2524171 memory_42\NN\5926676 impairment_43\NN\7296428 (_44\-LRB-\1740 e.g._45\FW\1740 ,_46\,\1740 win-shift_47\JJ\1740 paradigm_48\NN\13803782 )_49\-RRB-\1740 ,_50\,\1740 hoarding_51\VBG\2265979 ,_52\,\1740 and_53\CC\1740 corticostriatal_54\JJ\1740 dysfunction_55\NN\14204950 ._56\.\1740
D002997_-1 NONE results_0\NNS\34213 :_1\:\1740 <e1>clomipramine</e1>_2\NN\4482543 exposure_3\NN\5042871 in_4\IN\13603305 immature_5\JJ\1740 rats_6\NNS\2329401 produced_7\VBD\1617192 significant_8\JJ\1740 behavioral_9\JJ\1740 and_10\CC\1740 biochemical_11\JJ\1740 changes_12\NNS\7283608 that_13\WDT\1740 include_14\VBP\690614 enhanced_15\VBN\227165 anxiety_16\NN\14373582 (_17\-LRB-\1740 elevated_18\JJ\1740 plus_19\CC\4723816 maze_20\NN\4377057 and_21\CC\1740 marble_22\NN\14696793 burying_23\NN\1048912 )_24\-RRB-\1740 ,_25\,\1740 behavioral_26\JJ\1740 inflexibility_27\NN\5023741 (_28\-LRB-\1740 perseveration_29\NN\6196584 in_30\IN\13603305 the_31\DT\1740 spontaneous_32\JJ\1740 alternation_33\NN\1010458 task_34\NN\575741 and_35\CC\1740 impaired_36\JJ\1740 reversal_37\JJ\1740 learning_38\NN\5701944 )_39\-RRB-\1740 ,_40\,\1740 working_41\VBG\2524171 memory_42\NN\5926676 impairment_43\NN\7296428 (_44\-LRB-\1740 e.g._45\FW\1740 ,_46\,\1740 win-shift_47\JJ\1740 paradigm_48\NN\13803782 )_49\-RRB-\1740 ,_50\,\1740 hoarding_51\VBG\2265979 ,_52\,\1740 and_53\CC\1740 <e2>corticostriatal_54\JJ\1740 dysfunction</e2>_55\NN\14204950 ._56\.\1740
D002997_D008569 CID results_0\NNS\34213 :_1\:\1740 <e1>clomipramine</e1>_2\NN\4482543 exposure_3\NN\5042871 in_4\IN\13603305 immature_5\JJ\1740 rats_6\NNS\2329401 produced_7\VBD\1617192 significant_8\JJ\1740 behavioral_9\JJ\1740 and_10\CC\1740 biochemical_11\JJ\1740 changes_12\NNS\7283608 that_13\WDT\1740 include_14\VBP\690614 enhanced_15\VBN\227165 anxiety_16\NN\14373582 (_17\-LRB-\1740 elevated_18\JJ\1740 plus_19\CC\4723816 maze_20\NN\4377057 and_21\CC\1740 marble_22\NN\14696793 burying_23\NN\1048912 )_24\-RRB-\1740 ,_25\,\1740 behavioral_26\JJ\1740 inflexibility_27\NN\5023741 (_28\-LRB-\1740 perseveration_29\NN\6196584 in_30\IN\13603305 the_31\DT\1740 spontaneous_32\JJ\1740 alternation_33\NN\1010458 task_34\NN\575741 and_35\CC\1740 impaired_36\JJ\1740 reversal_37\JJ\1740 learning_38\NN\5701944 )_39\-RRB-\1740 ,_40\,\1740 working_41\VBG\2524171 <e2>memory_42\NN\5926676 impairment</e2>_43\NN\7296428 (_44\-LRB-\1740 e.g._45\FW\1740 ,_46\,\1740 win-shift_47\JJ\1740 paradigm_48\NN\13803782 )_49\-RRB-\1740 ,_50\,\1740 hoarding_51\VBG\2265979 ,_52\,\1740 and_53\CC\1740 corticostriatal_54\JJ\1740 dysfunction_55\NN\14204950 ._56\.\1740
D002997_D060845 CID results_0\NNS\34213 :_1\:\1740 <e1>clomipramine</e1>_2\NN\4482543 exposure_3\NN\5042871 in_4\IN\13603305 immature_5\JJ\1740 rats_6\NNS\2329401 produced_7\VBD\1617192 significant_8\JJ\1740 behavioral_9\JJ\1740 and_10\CC\1740 biochemical_11\JJ\1740 changes_12\NNS\7283608 that_13\WDT\1740 include_14\VBP\690614 enhanced_15\VBN\227165 anxiety_16\NN\14373582 (_17\-LRB-\1740 elevated_18\JJ\1740 plus_19\CC\4723816 maze_20\NN\4377057 and_21\CC\1740 marble_22\NN\14696793 burying_23\NN\1048912 )_24\-RRB-\1740 ,_25\,\1740 behavioral_26\JJ\1740 inflexibility_27\NN\5023741 (_28\-LRB-\1740 perseveration_29\NN\6196584 in_30\IN\13603305 the_31\DT\1740 spontaneous_32\JJ\1740 alternation_33\NN\1010458 task_34\NN\575741 and_35\CC\1740 impaired_36\JJ\1740 reversal_37\JJ\1740 learning_38\NN\5701944 )_39\-RRB-\1740 ,_40\,\1740 working_41\VBG\2524171 memory_42\NN\5926676 impairment_43\NN\7296428 (_44\-LRB-\1740 e.g._45\FW\1740 ,_46\,\1740 win-shift_47\JJ\1740 paradigm_48\NN\13803782 )_49\-RRB-\1740 ,_50\,\1740 <e2>hoarding</e2>_51\VBG\2265979 ,_52\,\1740 and_53\CC\1740 corticostriatal_54\JJ\1740 dysfunction_55\NN\14204950 ._56\.\1740
18329269
D006220_D002375 CID sar_0\NNP\1740 studies_1\NNS\635850 led_2\VBD\1752884 to_3\TO\1740 compound_4\VB\156601 14_5\CD\13745420 with_6\IN\1740 excellent_7\JJ\1740 potency_8\NN\5196375 (_9\-LRB-\1740 k(i_10\NN\1740 )_11\-RRB-\1740 =_12\JJ\1740 0.4_13\CD\1740 nm_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 selectivity_17\NN\4916342 (_18\-LRB-\1740 a(1)/a(2a_19\NN\1740 )_20\-RRB-\1740 >_21\$\1740 100_22\CD\13745420 )_23\-RRB-\1740 ,_24\,\1740 and_25\CC\1740 efficacy_26\NN\5199286 (_27\-LRB-\1740 med_28\NN\6700447 10_29\CD\13745420 mg/kg_30\NN\1740 p.o._31\NN\10360747 )_32\-RRB-\1740 in_33\IN\13603305 the_34\DT\1740 rat_35\NN\2329401 <e1>haloperidol-induced</e1>_36\JJ\1740 <e2>catalepsy</e2>_37\NN\14023236 model_38\NN\5888929 for_39\IN\1740 parkinson_40\NN\1740 's_41\POS\1740 disease_42\NN\14061805 ._43\.\1740
D006220_D010300 NONE sar_0\NNP\1740 studies_1\NNS\635850 led_2\VBD\1752884 to_3\TO\1740 compound_4\VB\156601 14_5\CD\13745420 with_6\IN\1740 excellent_7\JJ\1740 potency_8\NN\5196375 (_9\-LRB-\1740 k(i_10\NN\1740 )_11\-RRB-\1740 =_12\JJ\1740 0.4_13\CD\1740 nm_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 selectivity_17\NN\4916342 (_18\-LRB-\1740 a(1)/a(2a_19\NN\1740 )_20\-RRB-\1740 >_21\$\1740 100_22\CD\13745420 )_23\-RRB-\1740 ,_24\,\1740 and_25\CC\1740 efficacy_26\NN\5199286 (_27\-LRB-\1740 med_28\NN\6700447 10_29\CD\13745420 mg/kg_30\NN\1740 p.o._31\NN\10360747 )_32\-RRB-\1740 in_33\IN\13603305 the_34\DT\1740 rat_35\NN\2329401 <e1>haloperidol-induced</e1>_36\JJ\1740 catalepsy_37\NN\14023236 model_38\NN\5888929 for_39\IN\1740 <e2>parkinson_40\NN\1740 's_41\POS\1740 disease</e2>_42\NN\14061805 ._43\.\1740
18752389
C492458_D017093 NONE <e1>simvastatin-ezetimibe-induced</e1>_0\JJ\1740 <e2>hepatic_1\JJ\1740 failure</e2>_2\NN\66216 necessitating_3\NN\1740 liver_4\NN\5298729 transplantation_5\NN\671351 ._6\.\1740
C492458_D017093 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 first_7\JJ\1740 case_8\NN\7283608 report_9\NN\6470073 of_10\IN\1740 <e1>simvastatin-ezetimibe-induced</e1>_11\JJ\1740 <e2>liver_12\NN\5298729 failure</e2>_13\NN\66216 that_14\WDT\1740 resulted_15\VBD\2633881 in_16\IN\13603305 liver_17\NN\5298729 transplantation_18\NN\671351 ._19\.\1740
C108606_D056486 NONE however_0\RB\1740 ,_1\,\1740 <e2>hepatotoxic</e2>_2\JJ\1740 events_3\NNS\23100 have_4\VBP\2108377 not_5\RB\1740 been_6\VBN\836236 widely_7\RB\1740 published_8\VBN\1621555 with_9\IN\1740 <e1>ezetimibe</e1>_10\NN\1740 or_11\CC\3541091 the_12\DT\1740 combination_13\NN\7951464 agent_14\NN\7347 simvastatin-ezetimibe_15\JJ\1740 ._16\.\1740
C108606_D056486 NONE <e1>ezetimibe</e1>_0\NN\1740 undergoes_1\VBZ\109660 extensive_2\JJ\1740 glucuronidation_3\NN\1740 by_4\IN\1740 uridine_5\JJ\1740 diphosphate_6\NN\1740 glucoronosyltransferases_7\NNS\1740 (_8\-LRB-\1740 ugt_9\NN\1740 )_10\-RRB-\1740 in_11\IN\13603305 the_12\DT\1740 intestine_13\NN\5298729 and_14\CC\1740 liver_15\NN\5298729 and_16\CC\1740 may_17\MD\15209706 have_18\VB\2108377 inhibited_19\VBN\2510337 the_20\DT\1740 glucuronidation_21\NN\1740 of_22\IN\1740 simvastatin_23\JJ\1740 hydroxy_24\JJ\1740 acid_25\NN\14818238 ,_26\,\1740 resulting_27\VBG\2633881 in_28\IN\13603305 increased_29\VBN\169651 simvastatin_30\NN\3676175 exposure_31\NN\5042871 and_32\CC\1740 subsequent_33\JJ\1740 <e2>hepatotoxicity</e2>_34\NN\1740 ._35\.\1740
C108606_D056486 NONE we_0\PRP\1740 postulate_1\VBP\756338 that_2\IN\1740 the_3\DT\1740 mechanism_4\NN\13446390 of_5\IN\1740 the_6\DT\1740 simvastatinezetimibe-induced_7\JJ\1740 <e2>hepatotoxicity</e2>_8\NN\1740 is_9\VBZ\836236 the_10\DT\1740 increased_11\VBN\169651 simvastatin_12\NN\3676175 exposure_13\NN\5042871 by_14\IN\1740 <e1>ezetimibe</e1>_15\JJ\1740 inhibition_16\NN\1068773 of_17\IN\1740 ugt_18\NN\1740 enzymes_19\NNS\14723628 ._20\.\1740
C492458_D056486 CID however_0\RB\1740 ,_1\,\1740 <e2>hepatotoxic</e2>_2\JJ\1740 events_3\NNS\23100 have_4\VBP\2108377 not_5\RB\1740 been_6\VBN\836236 widely_7\RB\1740 published_8\VBN\1621555 with_9\IN\1740 ezetimibe_10\NN\1740 or_11\CC\3541091 the_12\DT\1740 combination_13\NN\7951464 agent_14\NN\7347 <e1>simvastatin-ezetimibe</e1>_15\JJ\1740 ._16\.\1740
C492458_D056486 CID <e1>simvastatinezetimibe</e1>_0\NN\1740 and_1\CC\1740 escitalopram_2\NN\1740 (_3\-LRB-\1740 which_4\WDT\1740 she_5\PRP\1740 was_6\VBD\836236 taking_7\VBG\2367363 for_8\IN\1740 depression_9\NN\14373582 )_10\-RRB-\1740 were_11\VBD\836236 discontinued_12\VBN\2609764 ,_13\,\1740 and_14\CC\1740 other_15\JJ\1740 potential_16\JJ\1740 causes_17\NNS\7323922 of_18\IN\1740 <e2>hepatotoxicity</e2>_19\NN\1740 were_20\VBD\836236 excluded_21\VBN\471711 ._22\.\1740
C492458_D056486 CID we_0\PRP\1740 postulate_1\VBP\756338 that_2\IN\1740 the_3\DT\1740 mechanism_4\NN\13446390 of_5\IN\1740 the_6\DT\1740 <e1>simvastatinezetimibe-induced</e1>_7\JJ\1740 <e2>hepatotoxicity</e2>_8\NN\1740 is_9\VBZ\836236 the_10\DT\1740 increased_11\VBN\169651 simvastatin_12\NN\3676175 exposure_13\NN\5042871 by_14\IN\1740 ezetimibe_15\JJ\1740 inhibition_16\NN\1068773 of_17\IN\1740 ugt_18\NN\1740 enzymes_19\NNS\14723628 ._20\.\1740
C492458_D056486 CID clinicians_0\NNS\10462860 should_1\MD\1740 be_2\VB\836236 aware_3\JJ\1740 of_4\IN\1740 potential_5\JJ\1740 <e2>hepatotoxicity</e2>_6\NN\1740 with_7\IN\1740 <e1>simvastatin-ezetimibe</e1>_8\NN\1740 especially_9\RB\1740 in_10\IN\13603305 elderly_11\JJ\1740 patients_12\NNS\9898892 and_13\CC\1740 should_14\MD\1740 carefully_15\RB\1740 monitor_16\VB\2169352 serum_17\NN\5397468 aminotransferase_18\NN\15077571 levels_19\NNS\4916342 when_20\WRB\1740 starting_21\VBG\2009433 therapy_22\NN\657604 and_23\CC\1740 titrating_24\VBG\489837 the_25\DT\1740 dosage_26\NN\13576355 ._27\.\1740
D019821_D017114 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 70-year-old_3\JJ\1740 hispanic_4\JJ\1740 woman_5\NN\9605289 who_6\WP\8299493 developed_7\VBD\1753788 <e2>fulminant_8\JJ\1740 hepatic_9\JJ\1740 failure</e2>_10\NN\66216 necessitating_11\NN\1740 liver_12\NN\5298729 transplantation_13\NN\671351 10_14\CD\13745420 weeks_15\NNS\15113229 after_16\IN\1740 conversion_17\NN\7359599 from_18\IN\1740 <e1>simvastatin</e1>_19\NN\3676175 40_20\CD\13745420 mg/day_21\NN\1740 to_22\TO\1740 simvastatin_23\NN\3676175 10_24\CD\13745420 mg-ezetimibe_25\NNS\1740 40_26\CD\13745420 mg/day_27\NN\1740 ._28\.\1740
C492458_D017114 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 70-year-old_3\JJ\1740 hispanic_4\JJ\1740 woman_5\NN\9605289 who_6\WP\8299493 developed_7\VBD\1753788 <e2>fulminant_8\JJ\1740 hepatic_9\JJ\1740 failure</e2>_10\NN\66216 necessitating_11\NN\1740 liver_12\NN\5298729 transplantation_13\NN\671351 10_14\CD\13745420 weeks_15\NNS\15113229 after_16\IN\1740 conversion_17\NN\7359599 from_18\IN\1740 simvastatin_19\NN\3676175 40_20\CD\13745420 mg/day_21\NN\1740 to_22\TO\1740 <e1>simvastatin_23\NN\3676175 10_24\CD\13745420 mg-ezetimibe_25\NNS\1740 40_26\CD\13745420 mg/day</e1>_27\NN\1740 ._28\.\1740
D019821_D056486 NONE the_0\DT\1740 patient_1\NN\9898892 's_2\POS\1740 lipid_3\NN\14944888 panel_4\NN\4188643 had_5\VBD\2108377 been_6\VBN\836236 maintained_7\VBN\2202928 with_8\IN\1740 <e1>simvastatin</e1>_9\NN\3676175 for_10\IN\1740 18_11\CD\13745420 months_12\NNS\15113229 before_13\IN\1740 the_14\DT\1740 conversion_15\NN\7359599 without_16\IN\1740 evidence_17\NN\5816287 of_18\IN\1740 <e2>hepatotoxicity</e2>_19\NN\1740 ._20\.\1740
D019821_D056486 NONE ezetimibe_0\NN\1740 undergoes_1\VBZ\109660 extensive_2\JJ\1740 glucuronidation_3\NN\1740 by_4\IN\1740 uridine_5\JJ\1740 diphosphate_6\NN\1740 glucoronosyltransferases_7\NNS\1740 (_8\-LRB-\1740 ugt_9\NN\1740 )_10\-RRB-\1740 in_11\IN\13603305 the_12\DT\1740 intestine_13\NN\5298729 and_14\CC\1740 liver_15\NN\5298729 and_16\CC\1740 may_17\MD\15209706 have_18\VB\2108377 inhibited_19\VBN\2510337 the_20\DT\1740 glucuronidation_21\NN\1740 of_22\IN\1740 simvastatin_23\JJ\1740 hydroxy_24\JJ\1740 acid_25\NN\14818238 ,_26\,\1740 resulting_27\VBG\2633881 in_28\IN\13603305 increased_29\VBN\169651 <e1>simvastatin</e1>_30\NN\3676175 exposure_31\NN\5042871 and_32\CC\1740 subsequent_33\JJ\1740 <e2>hepatotoxicity</e2>_34\NN\1740 ._35\.\1740
D019821_D056486 NONE we_0\PRP\1740 postulate_1\VBP\756338 that_2\IN\1740 the_3\DT\1740 mechanism_4\NN\13446390 of_5\IN\1740 the_6\DT\1740 simvastatinezetimibe-induced_7\JJ\1740 <e2>hepatotoxicity</e2>_8\NN\1740 is_9\VBZ\836236 the_10\DT\1740 increased_11\VBN\169651 <e1>simvastatin</e1>_12\NN\3676175 exposure_13\NN\5042871 by_14\IN\1740 ezetimibe_15\JJ\1740 inhibition_16\NN\1068773 of_17\IN\1740 ugt_18\NN\1740 enzymes_19\NNS\14723628 ._20\.\1740
C492458_D003866 NONE <e1>simvastatinezetimibe</e1>_0\NN\1740 and_1\CC\1740 escitalopram_2\NN\1740 (_3\-LRB-\1740 which_4\WDT\1740 she_5\PRP\1740 was_6\VBD\836236 taking_7\VBG\2367363 for_8\IN\1740 <e2>depression</e2>_9\NN\14373582 )_10\-RRB-\1740 were_11\VBD\836236 discontinued_12\VBN\2609764 ,_13\,\1740 and_14\CC\1740 other_15\JJ\1740 potential_16\JJ\1740 causes_17\NNS\7323922 of_18\IN\1740 hepatotoxicity_19\NN\1740 were_20\VBD\836236 excluded_21\VBN\471711 ._22\.\1740
D015283_D003866 NONE simvastatinezetimibe_0\NN\1740 and_1\CC\1740 <e1>escitalopram</e1>_2\NN\1740 (_3\-LRB-\1740 which_4\WDT\1740 she_5\PRP\1740 was_6\VBD\836236 taking_7\VBG\2367363 for_8\IN\1740 <e2>depression</e2>_9\NN\14373582 )_10\-RRB-\1740 were_11\VBD\836236 discontinued_12\VBN\2609764 ,_13\,\1740 and_14\CC\1740 other_15\JJ\1740 potential_16\JJ\1740 causes_17\NNS\7323922 of_18\IN\1740 hepatotoxicity_19\NN\1740 were_20\VBD\836236 excluded_21\VBN\471711 ._22\.\1740
D015283_D056486 NONE simvastatinezetimibe_0\NN\1740 and_1\CC\1740 <e1>escitalopram</e1>_2\NN\1740 (_3\-LRB-\1740 which_4\WDT\1740 she_5\PRP\1740 was_6\VBD\836236 taking_7\VBG\2367363 for_8\IN\1740 depression_9\NN\14373582 )_10\-RRB-\1740 were_11\VBD\836236 discontinued_12\VBN\2609764 ,_13\,\1740 and_14\CC\1740 other_15\JJ\1740 potential_16\JJ\1740 causes_17\NNS\7323922 of_18\IN\1740 <e2>hepatotoxicity</e2>_19\NN\1740 were_20\VBD\836236 excluded_21\VBN\471711 ._22\.\1740
D014530_D056486 NONE ezetimibe_0\NN\1740 undergoes_1\VBZ\109660 extensive_2\JJ\1740 glucuronidation_3\NN\1740 by_4\IN\1740 <e1>uridine_5\JJ\1740 diphosphate</e1>_6\NN\1740 glucoronosyltransferases_7\NNS\1740 (_8\-LRB-\1740 ugt_9\NN\1740 )_10\-RRB-\1740 in_11\IN\13603305 the_12\DT\1740 intestine_13\NN\5298729 and_14\CC\1740 liver_15\NN\5298729 and_16\CC\1740 may_17\MD\15209706 have_18\VB\2108377 inhibited_19\VBN\2510337 the_20\DT\1740 glucuronidation_21\NN\1740 of_22\IN\1740 simvastatin_23\JJ\1740 hydroxy_24\JJ\1740 acid_25\NN\14818238 ,_26\,\1740 resulting_27\VBG\2633881 in_28\IN\13603305 increased_29\VBN\169651 simvastatin_30\NN\3676175 exposure_31\NN\5042871 and_32\CC\1740 subsequent_33\JJ\1740 <e2>hepatotoxicity</e2>_34\NN\1740 ._35\.\1740
C532833_D056486 NONE ezetimibe_0\NN\1740 undergoes_1\VBZ\109660 extensive_2\JJ\1740 glucuronidation_3\NN\1740 by_4\IN\1740 uridine_5\JJ\1740 diphosphate_6\NN\1740 glucoronosyltransferases_7\NNS\1740 (_8\-LRB-\1740 ugt_9\NN\1740 )_10\-RRB-\1740 in_11\IN\13603305 the_12\DT\1740 intestine_13\NN\5298729 and_14\CC\1740 liver_15\NN\5298729 and_16\CC\1740 may_17\MD\15209706 have_18\VB\2108377 inhibited_19\VBN\2510337 the_20\DT\1740 glucuronidation_21\NN\1740 of_22\IN\1740 <e1>simvastatin_23\JJ\1740 hydroxy_24\JJ\1740 acid</e1>_25\NN\14818238 ,_26\,\1740 resulting_27\VBG\2633881 in_28\IN\13603305 increased_29\VBN\169651 simvastatin_30\NN\3676175 exposure_31\NN\5042871 and_32\CC\1740 subsequent_33\JJ\1740 <e2>hepatotoxicity</e2>_34\NN\1740 ._35\.\1740
8996652
D000617_D006311 NONE <e2>ototoxicity</e2>_0\NN\1740 appeared_1\VBD\2604760 closely_2\RB\1740 related_3\JJ\1740 to_4\TO\1740 a_5\DT\13649268 prolonged_6\JJ\1740 administration_7\NN\1133281 and_8\CC\1740 higher_9\JJR\1740 total_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 ototoxic_13\JJ\1740 drugs_14\NNS\14778436 ,_15\,\1740 particularly_16\RB\1740 <e1>aminoglycosides</e1>_17\NNS\1740 and_18\CC\1740 furosemide_19\NN\3214670 ._20\.\1740
D000617_D006311 NONE ototoxicity_0\NN\1740 appeared_1\VBD\2604760 closely_2\RB\1740 related_3\JJ\1740 to_4\TO\1740 a_5\DT\13649268 prolonged_6\JJ\1740 administration_7\NN\1133281 and_8\CC\1740 higher_9\JJR\1740 total_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 <e2>ototoxic</e2>_13\JJ\1740 drugs_14\NNS\14778436 ,_15\,\1740 particularly_16\RB\1740 <e1>aminoglycosides</e1>_17\NNS\1740 and_18\CC\1740 furosemide_19\NN\3214670 ._20\.\1740
D005665_D006311 NONE <e2>ototoxicity</e2>_0\NN\1740 appeared_1\VBD\2604760 closely_2\RB\1740 related_3\JJ\1740 to_4\TO\1740 a_5\DT\13649268 prolonged_6\JJ\1740 administration_7\NN\1133281 and_8\CC\1740 higher_9\JJR\1740 total_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 ototoxic_13\JJ\1740 drugs_14\NNS\14778436 ,_15\,\1740 particularly_16\RB\1740 aminoglycosides_17\NNS\1740 and_18\CC\1740 <e1>furosemide</e1>_19\NN\3214670 ._20\.\1740
D005665_D006311 NONE ototoxicity_0\NN\1740 appeared_1\VBD\2604760 closely_2\RB\1740 related_3\JJ\1740 to_4\TO\1740 a_5\DT\13649268 prolonged_6\JJ\1740 administration_7\NN\1133281 and_8\CC\1740 higher_9\JJR\1740 total_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 <e2>ototoxic</e2>_13\JJ\1740 drugs_14\NNS\14778436 ,_15\,\1740 particularly_16\RB\1740 aminoglycosides_17\NNS\1740 and_18\CC\1740 <e1>furosemide</e1>_19\NN\3214670 ._20\.\1740
19759529
D004298_D012559 NONE <e2>schizophrenia</e2>_0\NNP\14398067 has_1\VBZ\2108377 been_2\VBN\836236 initially_3\RB\1740 associated_4\VBN\628491 with_5\IN\1740 dysfunction_6\NN\14204950 in_7\IN\13603305 <e1>dopamine</e1>_8\NN\14807737 neurotransmission_9\NN\1740 ._10\.\1740
D018698_D012559 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 observation_3\NN\996969 that_4\IN\1740 antagonists_5\NNS\7846 of_6\IN\1740 the_7\DT\1740 <e1>glutamate</e1>_8\JJ\1740 n-methyl-d-aspartate_9\NN\1740 (_10\-LRB-\1740 nmda_11\NN\1740 )_12\-RRB-\1740 receptor_13\NN\5225602 produce_14\VBP\1617192 <e2>schizophrenic-like</e2>_15\JJ\1740 symptoms_16\NNS\5823932 in_17\IN\13603305 humans_18\NNS\31264 has_19\VBZ\2108377 led_20\VBN\1752884 to_21\IN\1740 the_22\DT\1740 idea_23\NN\5809192 of_24\IN\1740 a_25\DT\13649268 dysfunctioning_26\NN\1740 of_27\IN\1740 the_28\DT\1740 glutamatergic_29\JJ\1740 system_30\NN\3575240 via_31\IN\1740 its_32\PRP$\6125041 nmda_33\NN\1740 receptor_34\NN\5225602 ._35\.\1740
D016202_D012559 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 observation_3\NN\996969 that_4\IN\1740 antagonists_5\NNS\7846 of_6\IN\1740 the_7\DT\1740 glutamate_8\JJ\1740 <e1>n-methyl-d-aspartate</e1>_9\NN\1740 (_10\-LRB-\1740 nmda_11\NN\1740 )_12\-RRB-\1740 receptor_13\NN\5225602 produce_14\VBP\1617192 <e2>schizophrenic-like</e2>_15\JJ\1740 symptoms_16\NNS\5823932 in_17\IN\13603305 humans_18\NNS\31264 has_19\VBZ\2108377 led_20\VBN\1752884 to_21\IN\1740 the_22\DT\1740 idea_23\NN\5809192 of_24\IN\1740 a_25\DT\13649268 dysfunctioning_26\NN\1740 of_27\IN\1740 the_28\DT\1740 glutamatergic_29\JJ\1740 system_30\NN\3575240 via_31\IN\1740 its_32\PRP$\6125041 nmda_33\NN\1740 receptor_34\NN\5225602 ._35\.\1740
D016202_D012559 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 observation_3\NN\996969 that_4\IN\1740 antagonists_5\NNS\7846 of_6\IN\1740 the_7\DT\1740 glutamate_8\JJ\1740 n-methyl-d-aspartate_9\NN\1740 (_10\-LRB-\1740 <e1>nmda</e1>_11\NN\1740 )_12\-RRB-\1740 receptor_13\NN\5225602 produce_14\VBP\1617192 <e2>schizophrenic-like</e2>_15\JJ\1740 symptoms_16\NNS\5823932 in_17\IN\13603305 humans_18\NNS\31264 has_19\VBZ\2108377 led_20\VBN\1752884 to_21\IN\1740 the_22\DT\1740 idea_23\NN\5809192 of_24\IN\1740 a_25\DT\13649268 dysfunctioning_26\NN\1740 of_27\IN\1740 the_28\DT\1740 glutamatergic_29\JJ\1740 system_30\NN\3575240 via_31\IN\1740 its_32\PRP$\6125041 nmda_33\NN\1740 receptor_34\NN\5225602 ._35\.\1740
D016202_D012559 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 observation_3\NN\996969 that_4\IN\1740 antagonists_5\NNS\7846 of_6\IN\1740 the_7\DT\1740 glutamate_8\JJ\1740 n-methyl-d-aspartate_9\NN\1740 (_10\-LRB-\1740 nmda_11\NN\1740 )_12\-RRB-\1740 receptor_13\NN\5225602 produce_14\VBP\1617192 <e2>schizophrenic-like</e2>_15\JJ\1740 symptoms_16\NNS\5823932 in_17\IN\13603305 humans_18\NNS\31264 has_19\VBZ\2108377 led_20\VBN\1752884 to_21\IN\1740 the_22\DT\1740 idea_23\NN\5809192 of_24\IN\1740 a_25\DT\13649268 dysfunctioning_26\NN\1740 of_27\IN\1740 the_28\DT\1740 glutamatergic_29\JJ\1740 system_30\NN\3575240 via_31\IN\1740 its_32\PRP$\6125041 <e1>nmda</e1>_33\NN\1740 receptor_34\NN\5225602 ._35\.\1740
-1_D006948 NONE this_0\DT\1740 study_1\NN\635850 aimed_2\VBN\1987160 at_3\IN\14622893 investigating_4\VBG\644583 the_5\DT\1740 potential_6\JJ\1740 antipsychotic-like_7\JJ\1740 properties_8\NNS\32613 of_9\IN\1740 <e1>ssr103800</e1>_10\NN\1740 ,_11\,\1740 with_12\IN\1740 a_13\DT\13649268 particular_14\JJ\1740 focus_15\NN\5704266 on_16\IN\1740 models_17\NNS\5888929 of_18\IN\1740 <e2>hyperactivity</e2>_19\NN\14052403 ,_20\,\1740 involving_21\VBG\2676054 either_22\DT\1740 drug_23\NN\14778436 challenge_24\NN\13927383 (_25\-LRB-\1740 ie_26\FW\1740 ,_27\,\1740 amphetamine_28\NN\3248958 and_29\CC\1740 mk-801_30\NN\1740 )_31\-RRB-\1740 or_32\CC\3541091 transgenic_33\JJ\1740 mice_34\NNS\2329401 (_35\-LRB-\1740 ie_36\FW\1740 ,_37\,\1740 nmda_38\NN\1740 nr1(neo-/-_39\NN\1740 )_40\-RRB-\1740 and_41\CC\1740 dat(-/-_42\NN\1740 )_43\-RRB-\1740 )_44\-RRB-\1740 ._45\.\1740
-1_D006948 NONE results_0\NNS\34213 showed_1\VBD\2137132 that_2\IN\1740 <e1>ssr103800</e1>_3\NN\1740 (_4\-LRB-\1740 10_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 mg/kg_8\NN\1740 p.o._9\NN\10360747 )_10\-RRB-\1740 blocked_11\VBD\1476483 <e2>hyperactivity</e2>_12\NN\14052403 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 non-competitive_16\JJ\1740 nmda_17\NN\1740 receptor_18\NN\5225602 antagonist_19\NN\7846 ,_20\,\1740 mk-801_21\NN\1740 and_22\CC\1740 partially_23\RB\1740 reversed_24\VBN\109660 spontaneous_25\JJ\1740 hyperactivity_26\NN\14052403 of_27\IN\1740 nmda_28\NN\1740 nr1(neo-/-_29\NN\1740 )_30\-RRB-\1740 mice_31\NNS\2329401 ._32\.\1740
-1_D006948 NONE results_0\NNS\34213 showed_1\VBD\2137132 that_2\IN\1740 <e1>ssr103800</e1>_3\NN\1740 (_4\-LRB-\1740 10_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 mg/kg_8\NN\1740 p.o._9\NN\10360747 )_10\-RRB-\1740 blocked_11\VBD\1476483 hyperactivity_12\NN\14052403 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 non-competitive_16\JJ\1740 nmda_17\NN\1740 receptor_18\NN\5225602 antagonist_19\NN\7846 ,_20\,\1740 mk-801_21\NN\1740 and_22\CC\1740 partially_23\RB\1740 reversed_24\VBN\109660 spontaneous_25\JJ\1740 <e2>hyperactivity</e2>_26\NN\14052403 of_27\IN\1740 nmda_28\NN\1740 nr1(neo-/-_29\NN\1740 )_30\-RRB-\1740 mice_31\NNS\2329401 ._32\.\1740
-1_D006948 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 <e1>ssr103800</e1>_3\NN\1740 failed_4\VBD\1798936 to_5\TO\1740 affect_6\VB\126264 <e2>hyperactivity</e2>_7\NN\14052403 induced_8\VBN\1627355 by_9\IN\1740 amphetamine_10\NN\3248958 or_11\CC\3541091 naturally_12\RB\1740 observed_13\VBN\2163746 in_14\IN\13603305 dopamine_15\NN\14807737 transporter_16\NN\4490091 (_17\-LRB-\1740 dat(-/-_18\NN\1740 )_19\-RRB-\1740 )_20\-RRB-\1740 knockout_21\JJ\1740 mice_22\NNS\2329401 (_23\-LRB-\1740 10_24\CD\13745420 -_25\SYM\1740 30_26\CD\13745420 mg/kg_27\NN\1740 p.o._28\NN\10360747 )_29\-RRB-\1740 ._30\.\1740
D000661_D006948 CID this_0\DT\1740 study_1\NN\635850 aimed_2\VBN\1987160 at_3\IN\14622893 investigating_4\VBG\644583 the_5\DT\1740 potential_6\JJ\1740 antipsychotic-like_7\JJ\1740 properties_8\NNS\32613 of_9\IN\1740 ssr103800_10\NN\1740 ,_11\,\1740 with_12\IN\1740 a_13\DT\13649268 particular_14\JJ\1740 focus_15\NN\5704266 on_16\IN\1740 models_17\NNS\5888929 of_18\IN\1740 <e2>hyperactivity</e2>_19\NN\14052403 ,_20\,\1740 involving_21\VBG\2676054 either_22\DT\1740 drug_23\NN\14778436 challenge_24\NN\13927383 (_25\-LRB-\1740 ie_26\FW\1740 ,_27\,\1740 <e1>amphetamine</e1>_28\NN\3248958 and_29\CC\1740 mk-801_30\NN\1740 )_31\-RRB-\1740 or_32\CC\3541091 transgenic_33\JJ\1740 mice_34\NNS\2329401 (_35\-LRB-\1740 ie_36\FW\1740 ,_37\,\1740 nmda_38\NN\1740 nr1(neo-/-_39\NN\1740 )_40\-RRB-\1740 and_41\CC\1740 dat(-/-_42\NN\1740 )_43\-RRB-\1740 )_44\-RRB-\1740 ._45\.\1740
D000661_D006948 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 ssr103800_3\NN\1740 failed_4\VBD\1798936 to_5\TO\1740 affect_6\VB\126264 <e2>hyperactivity</e2>_7\NN\14052403 induced_8\VBN\1627355 by_9\IN\1740 <e1>amphetamine</e1>_10\NN\3248958 or_11\CC\3541091 naturally_12\RB\1740 observed_13\VBN\2163746 in_14\IN\13603305 dopamine_15\NN\14807737 transporter_16\NN\4490091 (_17\-LRB-\1740 dat(-/-_18\NN\1740 )_19\-RRB-\1740 )_20\-RRB-\1740 knockout_21\JJ\1740 mice_22\NNS\2329401 (_23\-LRB-\1740 10_24\CD\13745420 -_25\SYM\1740 30_26\CD\13745420 mg/kg_27\NN\1740 p.o._28\NN\10360747 )_29\-RRB-\1740 ._30\.\1740
D016291_D006948 CID this_0\DT\1740 study_1\NN\635850 aimed_2\VBN\1987160 at_3\IN\14622893 investigating_4\VBG\644583 the_5\DT\1740 potential_6\JJ\1740 antipsychotic-like_7\JJ\1740 properties_8\NNS\32613 of_9\IN\1740 ssr103800_10\NN\1740 ,_11\,\1740 with_12\IN\1740 a_13\DT\13649268 particular_14\JJ\1740 focus_15\NN\5704266 on_16\IN\1740 models_17\NNS\5888929 of_18\IN\1740 <e2>hyperactivity</e2>_19\NN\14052403 ,_20\,\1740 involving_21\VBG\2676054 either_22\DT\1740 drug_23\NN\14778436 challenge_24\NN\13927383 (_25\-LRB-\1740 ie_26\FW\1740 ,_27\,\1740 amphetamine_28\NN\3248958 and_29\CC\1740 <e1>mk-801</e1>_30\NN\1740 )_31\-RRB-\1740 or_32\CC\3541091 transgenic_33\JJ\1740 mice_34\NNS\2329401 (_35\-LRB-\1740 ie_36\FW\1740 ,_37\,\1740 nmda_38\NN\1740 nr1(neo-/-_39\NN\1740 )_40\-RRB-\1740 and_41\CC\1740 dat(-/-_42\NN\1740 )_43\-RRB-\1740 )_44\-RRB-\1740 ._45\.\1740
D016291_D006948 CID results_0\NNS\34213 showed_1\VBD\2137132 that_2\IN\1740 ssr103800_3\NN\1740 (_4\-LRB-\1740 10_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 mg/kg_8\NN\1740 p.o._9\NN\10360747 )_10\-RRB-\1740 blocked_11\VBD\1476483 <e2>hyperactivity</e2>_12\NN\14052403 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 non-competitive_16\JJ\1740 nmda_17\NN\1740 receptor_18\NN\5225602 antagonist_19\NN\7846 ,_20\,\1740 <e1>mk-801</e1>_21\NN\1740 and_22\CC\1740 partially_23\RB\1740 reversed_24\VBN\109660 spontaneous_25\JJ\1740 hyperactivity_26\NN\14052403 of_27\IN\1740 nmda_28\NN\1740 nr1(neo-/-_29\NN\1740 )_30\-RRB-\1740 mice_31\NNS\2329401 ._32\.\1740
D016291_D006948 CID results_0\NNS\34213 showed_1\VBD\2137132 that_2\IN\1740 ssr103800_3\NN\1740 (_4\-LRB-\1740 10_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 mg/kg_8\NN\1740 p.o._9\NN\10360747 )_10\-RRB-\1740 blocked_11\VBD\1476483 hyperactivity_12\NN\14052403 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 non-competitive_16\JJ\1740 nmda_17\NN\1740 receptor_18\NN\5225602 antagonist_19\NN\7846 ,_20\,\1740 <e1>mk-801</e1>_21\NN\1740 and_22\CC\1740 partially_23\RB\1740 reversed_24\VBN\109660 spontaneous_25\JJ\1740 <e2>hyperactivity</e2>_26\NN\14052403 of_27\IN\1740 nmda_28\NN\1740 nr1(neo-/-_29\NN\1740 )_30\-RRB-\1740 mice_31\NNS\2329401 ._32\.\1740
D016202_D006948 NONE this_0\DT\1740 study_1\NN\635850 aimed_2\VBN\1987160 at_3\IN\14622893 investigating_4\VBG\644583 the_5\DT\1740 potential_6\JJ\1740 antipsychotic-like_7\JJ\1740 properties_8\NNS\32613 of_9\IN\1740 ssr103800_10\NN\1740 ,_11\,\1740 with_12\IN\1740 a_13\DT\13649268 particular_14\JJ\1740 focus_15\NN\5704266 on_16\IN\1740 models_17\NNS\5888929 of_18\IN\1740 <e2>hyperactivity</e2>_19\NN\14052403 ,_20\,\1740 involving_21\VBG\2676054 either_22\DT\1740 drug_23\NN\14778436 challenge_24\NN\13927383 (_25\-LRB-\1740 ie_26\FW\1740 ,_27\,\1740 amphetamine_28\NN\3248958 and_29\CC\1740 mk-801_30\NN\1740 )_31\-RRB-\1740 or_32\CC\3541091 transgenic_33\JJ\1740 mice_34\NNS\2329401 (_35\-LRB-\1740 ie_36\FW\1740 ,_37\,\1740 <e1>nmda</e1>_38\NN\1740 nr1(neo-/-_39\NN\1740 )_40\-RRB-\1740 and_41\CC\1740 dat(-/-_42\NN\1740 )_43\-RRB-\1740 )_44\-RRB-\1740 ._45\.\1740
D016202_D006948 NONE results_0\NNS\34213 showed_1\VBD\2137132 that_2\IN\1740 ssr103800_3\NN\1740 (_4\-LRB-\1740 10_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 mg/kg_8\NN\1740 p.o._9\NN\10360747 )_10\-RRB-\1740 blocked_11\VBD\1476483 <e2>hyperactivity</e2>_12\NN\14052403 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 non-competitive_16\JJ\1740 <e1>nmda</e1>_17\NN\1740 receptor_18\NN\5225602 antagonist_19\NN\7846 ,_20\,\1740 mk-801_21\NN\1740 and_22\CC\1740 partially_23\RB\1740 reversed_24\VBN\109660 spontaneous_25\JJ\1740 hyperactivity_26\NN\14052403 of_27\IN\1740 nmda_28\NN\1740 nr1(neo-/-_29\NN\1740 )_30\-RRB-\1740 mice_31\NNS\2329401 ._32\.\1740
D016202_D006948 NONE results_0\NNS\34213 showed_1\VBD\2137132 that_2\IN\1740 ssr103800_3\NN\1740 (_4\-LRB-\1740 10_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 mg/kg_8\NN\1740 p.o._9\NN\10360747 )_10\-RRB-\1740 blocked_11\VBD\1476483 hyperactivity_12\NN\14052403 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 non-competitive_16\JJ\1740 <e1>nmda</e1>_17\NN\1740 receptor_18\NN\5225602 antagonist_19\NN\7846 ,_20\,\1740 mk-801_21\NN\1740 and_22\CC\1740 partially_23\RB\1740 reversed_24\VBN\109660 spontaneous_25\JJ\1740 <e2>hyperactivity</e2>_26\NN\14052403 of_27\IN\1740 nmda_28\NN\1740 nr1(neo-/-_29\NN\1740 )_30\-RRB-\1740 mice_31\NNS\2329401 ._32\.\1740
D016202_D006948 NONE results_0\NNS\34213 showed_1\VBD\2137132 that_2\IN\1740 ssr103800_3\NN\1740 (_4\-LRB-\1740 10_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 mg/kg_8\NN\1740 p.o._9\NN\10360747 )_10\-RRB-\1740 blocked_11\VBD\1476483 <e2>hyperactivity</e2>_12\NN\14052403 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 non-competitive_16\JJ\1740 nmda_17\NN\1740 receptor_18\NN\5225602 antagonist_19\NN\7846 ,_20\,\1740 mk-801_21\NN\1740 and_22\CC\1740 partially_23\RB\1740 reversed_24\VBN\109660 spontaneous_25\JJ\1740 hyperactivity_26\NN\14052403 of_27\IN\1740 <e1>nmda</e1>_28\NN\1740 nr1(neo-/-_29\NN\1740 )_30\-RRB-\1740 mice_31\NNS\2329401 ._32\.\1740
D016202_D006948 NONE results_0\NNS\34213 showed_1\VBD\2137132 that_2\IN\1740 ssr103800_3\NN\1740 (_4\-LRB-\1740 10_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 mg/kg_8\NN\1740 p.o._9\NN\10360747 )_10\-RRB-\1740 blocked_11\VBD\1476483 hyperactivity_12\NN\14052403 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 non-competitive_16\JJ\1740 nmda_17\NN\1740 receptor_18\NN\5225602 antagonist_19\NN\7846 ,_20\,\1740 mk-801_21\NN\1740 and_22\CC\1740 partially_23\RB\1740 reversed_24\VBN\109660 spontaneous_25\JJ\1740 <e2>hyperactivity</e2>_26\NN\14052403 of_27\IN\1740 <e1>nmda</e1>_28\NN\1740 nr1(neo-/-_29\NN\1740 )_30\-RRB-\1740 mice_31\NNS\2329401 ._32\.\1740
D004298_D006948 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 ssr103800_3\NN\1740 failed_4\VBD\1798936 to_5\TO\1740 affect_6\VB\126264 <e2>hyperactivity</e2>_7\NN\14052403 induced_8\VBN\1627355 by_9\IN\1740 amphetamine_10\NN\3248958 or_11\CC\3541091 naturally_12\RB\1740 observed_13\VBN\2163746 in_14\IN\13603305 <e1>dopamine</e1>_15\NN\14807737 transporter_16\NN\4490091 (_17\-LRB-\1740 dat(-/-_18\NN\1740 )_19\-RRB-\1740 )_20\-RRB-\1740 knockout_21\JJ\1740 mice_22\NNS\2329401 (_23\-LRB-\1740 10_24\CD\13745420 -_25\SYM\1740 30_26\CD\13745420 mg/kg_27\NN\1740 p.o._28\NN\10360747 )_29\-RRB-\1740 ._30\.\1740
D006220_D006948 NONE importantly_0\RB\1740 ,_1\,\1740 both_2\CC\1740 classical_3\JJ\1740 (_4\-LRB-\1740 <e1>haloperidol</e1>_5\NN\3713736 )_6\-RRB-\1740 and_7\CC\1740 atypical_8\JJ\1740 (_9\-LRB-\1740 olanzapine_10\NN\1740 ,_11\,\1740 clozapine_12\NN\3713736 and_13\CC\1740 aripiprazole_14\NN\1740 )_15\-RRB-\1740 antipsychotics_16\NNS\4470232 were_17\VBD\836236 effective_18\JJ\1740 in_19\IN\13603305 all_20\PDT\1740 these_21\DT\1740 models_22\NNS\5888929 of_23\IN\1740 <e2>hyperactivity</e2>_24\NN\14052403 ._25\.\1740
C076029_D006948 NONE importantly_0\RB\1740 ,_1\,\1740 both_2\CC\1740 classical_3\JJ\1740 (_4\-LRB-\1740 haloperidol_5\NN\3713736 )_6\-RRB-\1740 and_7\CC\1740 atypical_8\JJ\1740 (_9\-LRB-\1740 <e1>olanzapine</e1>_10\NN\1740 ,_11\,\1740 clozapine_12\NN\3713736 and_13\CC\1740 aripiprazole_14\NN\1740 )_15\-RRB-\1740 antipsychotics_16\NNS\4470232 were_17\VBD\836236 effective_18\JJ\1740 in_19\IN\13603305 all_20\PDT\1740 these_21\DT\1740 models_22\NNS\5888929 of_23\IN\1740 <e2>hyperactivity</e2>_24\NN\14052403 ._25\.\1740
D003024_D006948 NONE importantly_0\RB\1740 ,_1\,\1740 both_2\CC\1740 classical_3\JJ\1740 (_4\-LRB-\1740 haloperidol_5\NN\3713736 )_6\-RRB-\1740 and_7\CC\1740 atypical_8\JJ\1740 (_9\-LRB-\1740 olanzapine_10\NN\1740 ,_11\,\1740 <e1>clozapine</e1>_12\NN\3713736 and_13\CC\1740 aripiprazole_14\NN\1740 )_15\-RRB-\1740 antipsychotics_16\NNS\4470232 were_17\VBD\836236 effective_18\JJ\1740 in_19\IN\13603305 all_20\PDT\1740 these_21\DT\1740 models_22\NNS\5888929 of_23\IN\1740 <e2>hyperactivity</e2>_24\NN\14052403 ._25\.\1740
C094645_D006948 NONE importantly_0\RB\1740 ,_1\,\1740 both_2\CC\1740 classical_3\JJ\1740 (_4\-LRB-\1740 haloperidol_5\NN\3713736 )_6\-RRB-\1740 and_7\CC\1740 atypical_8\JJ\1740 (_9\-LRB-\1740 olanzapine_10\NN\1740 ,_11\,\1740 clozapine_12\NN\3713736 and_13\CC\1740 <e1>aripiprazole</e1>_14\NN\1740 )_15\-RRB-\1740 antipsychotics_16\NNS\4470232 were_17\VBD\836236 effective_18\JJ\1740 in_19\IN\13603305 all_20\PDT\1740 these_21\DT\1740 models_22\NNS\5888929 of_23\IN\1740 <e2>hyperactivity</e2>_24\NN\14052403 ._25\.\1740
-1_D002375 NONE however_0\RB\1740 ,_1\,\1740 unlike_2\IN\1740 these_3\DT\1740 latter_4\JJ\1740 ,_5\,\1740 <e1>ssr103800</e1>_6\NN\1740 did_7\VBD\1640855 not_8\RB\1740 produce_9\VB\1617192 <e2>catalepsy</e2>_10\NN\14023236 (_11\-LRB-\1740 retention_12\NN\809465 on_13\IN\1740 the_14\DT\1740 bar_15\NN\4105893 test_16\NN\5798043 )_17\-RRB-\1740 up_18\IN\1740 to_19\TO\1740 30_20\CD\13745420 mg/kg_21\NN\1740 p.o._22\NN\10360747 together_23\RB\1740 these_24\DT\1740 findings_25\NNS\7951464 show_26\VBP\2137132 that_27\IN\1740 the_28\DT\1740 glyt1_29\NN\1740 inhibitor_30\NN\20090 ,_31\,\1740 ssr103800_32\NN\1740 ,_33\,\1740 produces_34\VBZ\1617192 antipsychotic-like_35\JJ\1740 effects_36\NNS\13245626 ,_37\,\1740 which_38\WDT\1740 differ_39\VBP\1740 from_40\IN\1740 those_41\DT\1740 observed_42\VBN\2163746 with_43\IN\1740 compounds_44\NNS\5869584 primarily_45\RB\1740 targeting_46\VBG\1151110 the_47\DT\1740 dopaminergic_48\JJ\1740 system_49\NN\3575240 ,_50\,\1740 and_51\CC\1740 has_52\VBZ\2108377 a_53\DT\13649268 reduced_54\VBN\441445 side-effect_55\JJ\1740 potential_56\NN\14481929 as_57\IN\14622893 compared_58\VBN\644583 with_59\IN\1740 these_60\DT\1740 latter_61\JJ\1740 drugs_62\NNS\14778436 ._63\.\1740
-1_D002375 NONE however_0\RB\1740 ,_1\,\1740 unlike_2\IN\1740 these_3\DT\1740 latter_4\JJ\1740 ,_5\,\1740 ssr103800_6\NN\1740 did_7\VBD\1640855 not_8\RB\1740 produce_9\VB\1617192 <e2>catalepsy</e2>_10\NN\14023236 (_11\-LRB-\1740 retention_12\NN\809465 on_13\IN\1740 the_14\DT\1740 bar_15\NN\4105893 test_16\NN\5798043 )_17\-RRB-\1740 up_18\IN\1740 to_19\TO\1740 30_20\CD\13745420 mg/kg_21\NN\1740 p.o._22\NN\10360747 together_23\RB\1740 these_24\DT\1740 findings_25\NNS\7951464 show_26\VBP\2137132 that_27\IN\1740 the_28\DT\1740 glyt1_29\NN\1740 inhibitor_30\NN\20090 ,_31\,\1740 <e1>ssr103800</e1>_32\NN\1740 ,_33\,\1740 produces_34\VBZ\1617192 antipsychotic-like_35\JJ\1740 effects_36\NNS\13245626 ,_37\,\1740 which_38\WDT\1740 differ_39\VBP\1740 from_40\IN\1740 those_41\DT\1740 observed_42\VBN\2163746 with_43\IN\1740 compounds_44\NNS\5869584 primarily_45\RB\1740 targeting_46\VBG\1151110 the_47\DT\1740 dopaminergic_48\JJ\1740 system_49\NN\3575240 ,_50\,\1740 and_51\CC\1740 has_52\VBZ\2108377 a_53\DT\13649268 reduced_54\VBN\441445 side-effect_55\JJ\1740 potential_56\NN\14481929 as_57\IN\14622893 compared_58\VBN\644583 with_59\IN\1740 these_60\DT\1740 latter_61\JJ\1740 drugs_62\NNS\14778436 ._63\.\1740
8170551
D000086_D053040 NONE <e1>acetazolamide-induced</e1>_0\JJ\1740 <e2>nephrolithiasis</e2>_1\NN\14115914 :_2\:\1740 implications_3\NNS\5774614 for_4\IN\1740 treatment_5\NN\654885 of_6\IN\1740 neuromuscular_7\JJ\1740 disorders_8\NNS\14034177 ._9\.\1740
D000086_D053040 NONE <e2>nephrolithiasis</e2>_0\NN\14115914 is_1\VBZ\836236 a_2\DT\13649268 complication_3\NN\1073995 of_4\IN\1740 <e1>acetazolamide</e1>_5\NN\1740 but_6\CC\1740 does_7\VBZ\1640855 not_8\RB\1740 preclude_9\VB\2629256 its_10\PRP$\6125041 use_11\NN\407535 ._12\.\1740
D000086_D009468 NONE <e1>acetazolamide-induced</e1>_0\JJ\1740 nephrolithiasis_1\NN\14115914 :_2\:\1740 implications_3\NNS\5774614 for_4\IN\1740 treatment_5\NN\654885 of_6\IN\1740 <e2>neuromuscular_7\JJ\1740 disorders</e2>_8\NNS\14034177 ._9\.\1740
D000086_D007669 CID three_0\CD\13741022 patients_1\NNS\9898892 on_2\IN\1740 <e1>acetazolamide</e1>_3\NN\1740 (_4\-LRB-\1740 15_5\CD\13745420 %_6\NN\1740 )_7\-RRB-\1740 developed_8\VBD\1753788 <e2>renal_9\JJ\1740 calculi</e2>_10\NNS\9416076 ._11\.\1740
10342929
D000806_D000799 CID <e2>angioedema</e2>_0\NNP\14316714 due_1\JJ\1740 to_2\TO\1740 <e1>ace_3\NN\13741022 inhibitors</e1>_4\NNS\20090 :_5\:\1740 common_6\JJ\1740 and_7\CC\1740 inadequately_8\RB\1740 diagnosed_9\VBN\644583 ._10\.\1740
D000806_D000799 CID the_0\DT\1740 estimated_1\VBN\637259 incidence_2\NN\13821570 of_3\IN\1740 <e2>angioedema</e2>_4\NN\14316714 during_5\IN\1740 <e1>angiotensin-converting_6\JJ\1740 enzyme_7\NN\14723628 (_8\-LRB-\1740 ace_9\NN\13741022 )_10\-RRB-\1740 inhibitor</e1>_11\NN\20090 treatment_12\NN\654885 is_13\VBZ\836236 between_14\IN\1740 1_15\CD\13741022 and_16\CC\1740 7_17\CD\13741022 per_18\IN\1740 thousand_19\CD\13745420 patients_20\NNS\9898892 ._21\.\1740
15275829
D000109_D012640 NONE the_0\DT\1740 alpha3_1\NN\1740 and_2\CC\1740 beta4_3\NN\1740 nicotinic_4\JJ\1740 <e1>acetylcholine</e1>_5\NN\14807558 receptor_6\NN\5225602 subunits_7\NNS\13604718 are_8\VBP\836236 necessary_9\JJ\1740 for_10\IN\1740 nicotine-induced_11\JJ\1740 <e2>seizures</e2>_12\NNS\14081375 and_13\CC\1740 hypolocomotion_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 ._17\.\1740
D000109_D012640 NONE binding_0\NN\4688246 of_1\IN\1740 nicotine_2\NN\14712692 to_3\TO\1740 nicotinic_4\JJ\1740 <e1>acetylcholine</e1>_5\NN\14807558 receptors_6\NNS\5225602 (_7\-LRB-\1740 nachrs_8\NNS\1740 )_9\-RRB-\1740 elicits_10\VBZ\1617192 a_11\DT\13649268 series_12\NN\8456993 of_13\IN\1740 dose-dependent_14\JJ\1740 behaviors_15\NNS\407535 that_16\WDT\1740 go_17\VBP\2367363 from_18\IN\1740 altered_19\JJ\1740 exploration_20\NN\309647 ,_21\,\1740 sedation_22\NN\14034177 ,_23\,\1740 and_24\CC\1740 tremors_25\NNS\345926 ,_26\,\1740 to_27\IN\1740 <e2>seizures</e2>_28\NNS\14081375 and_29\CC\1740 death_30\NN\7296428 ._31\.\1740
D000109_D006948 NONE the_0\DT\1740 alpha3_1\NN\1740 and_2\CC\1740 beta4_3\NN\1740 nicotinic_4\JJ\1740 <e1>acetylcholine</e1>_5\NN\14807558 receptor_6\NN\5225602 subunits_7\NNS\13604718 are_8\VBP\836236 necessary_9\JJ\1740 for_10\IN\1740 nicotine-induced_11\JJ\1740 seizures_12\NNS\14081375 and_13\CC\1740 <e2>hypolocomotion</e2>_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 ._17\.\1740
D009538_D012640 CID the_0\DT\1740 alpha3_1\NN\1740 and_2\CC\1740 beta4_3\NN\1740 nicotinic_4\JJ\1740 acetylcholine_5\NN\14807558 receptor_6\NN\5225602 subunits_7\NNS\13604718 are_8\VBP\836236 necessary_9\JJ\1740 for_10\IN\1740 <e1>nicotine-induced</e1>_11\JJ\1740 <e2>seizures</e2>_12\NNS\14081375 and_13\CC\1740 hypolocomotion_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 ._17\.\1740
D009538_D012640 CID binding_0\NN\4688246 of_1\IN\1740 <e1>nicotine</e1>_2\NN\14712692 to_3\TO\1740 nicotinic_4\JJ\1740 acetylcholine_5\NN\14807558 receptors_6\NNS\5225602 (_7\-LRB-\1740 nachrs_8\NNS\1740 )_9\-RRB-\1740 elicits_10\VBZ\1617192 a_11\DT\13649268 series_12\NN\8456993 of_13\IN\1740 dose-dependent_14\JJ\1740 behaviors_15\NNS\407535 that_16\WDT\1740 go_17\VBP\2367363 from_18\IN\1740 altered_19\JJ\1740 exploration_20\NN\309647 ,_21\,\1740 sedation_22\NN\14034177 ,_23\,\1740 and_24\CC\1740 tremors_25\NNS\345926 ,_26\,\1740 to_27\IN\1740 <e2>seizures</e2>_28\NNS\14081375 and_29\CC\1740 death_30\NN\7296428 ._31\.\1740
D009538_D012640 CID we_0\PRP\1740 examined_1\VBD\789138 the_2\DT\1740 role_3\NN\719494 of_4\IN\1740 the_5\DT\1740 beta4_6\CD\1740 subunits_7\NNS\13604718 in_8\IN\13603305 <e1>nicotine-induced</e1>_9\JJ\1740 <e2>seizures</e2>_10\NNS\14081375 and_11\CC\1740 hypolocomotion_12\NN\1740 in_13\IN\13603305 beta4_14\CD\1740 homozygous_15\JJ\1740 null_16\NN\13576982 (_17\-LRB-\1740 beta4_18\CD\1740 -/-_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 alpha3_22\NN\1740 heterozygous_23\JJ\1740 (_24\-LRB-\1740 +/-_25\CC\1740 )_26\-RRB-\1740 mice_27\NNS\2329401 ._28\.\1740
D009538_D012640 CID beta4_0\NN\1740 -/-_1\JJ\1740 mice_2\NNS\2329401 were_3\VBD\836236 less_4\RBR\1740 sensitive_5\JJ\1740 to_6\TO\1740 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 <e1>nicotine</e1>_10\NN\14712692 both_11\CC\1740 at_12\IN\14622893 low_13\JJ\1740 doses_14\NNS\3740161 ,_15\,\1740 measured_16\VBN\697589 as_17\IN\14622893 decreased_18\VBN\169651 exploration_19\NN\309647 in_20\IN\13603305 an_21\DT\6697703 open_22\JJ\1740 field_23\NN\8673395 ,_24\,\1740 and_25\CC\1740 at_26\IN\14622893 high_27\JJ\1740 doses_28\NNS\3740161 ,_29\,\1740 measured_30\VBN\697589 as_31\IN\14622893 sensitivity_32\NN\5651971 to_33\TO\1740 nicotine-induced_34\JJ\1740 <e2>seizures</e2>_35\NNS\14081375 ._36\.\1740
D009538_D012640 CID beta4_0\NN\1740 -/-_1\JJ\1740 mice_2\NNS\2329401 were_3\VBD\836236 less_4\RBR\1740 sensitive_5\JJ\1740 to_6\TO\1740 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 nicotine_10\NN\14712692 both_11\CC\1740 at_12\IN\14622893 low_13\JJ\1740 doses_14\NNS\3740161 ,_15\,\1740 measured_16\VBN\697589 as_17\IN\14622893 decreased_18\VBN\169651 exploration_19\NN\309647 in_20\IN\13603305 an_21\DT\6697703 open_22\JJ\1740 field_23\NN\8673395 ,_24\,\1740 and_25\CC\1740 at_26\IN\14622893 high_27\JJ\1740 doses_28\NNS\3740161 ,_29\,\1740 measured_30\VBN\697589 as_31\IN\14622893 sensitivity_32\NN\5651971 to_33\TO\1740 <e1>nicotine-induced</e1>_34\JJ\1740 <e2>seizures</e2>_35\NNS\14081375 ._36\.\1740
D009538_D012640 CID alpha3_0\NN\1740 +/-_1\CC\1740 mice_2\NNS\2329401 were_3\VBD\836236 partially_4\RB\1740 resistant_5\JJ\1740 to_6\TO\1740 <e1>nicotine-induced</e1>_7\JJ\1740 <e2>seizures</e2>_8\NNS\14081375 when_9\WRB\1740 compared_10\VBN\644583 to_11\TO\1740 wild-type_12\JJ\1740 littermates_13\NNS\1740 ._14\.\1740
D009538_D012640 CID together_0\RB\1740 ,_1\,\1740 these_2\DT\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 the_6\DT\1740 beta4_7\NN\1740 and_8\CC\1740 the_9\DT\1740 alpha3_10\NN\1740 subunits_11\NNS\13604718 are_12\VBP\836236 mediators_13\NNS\10351874 of_14\IN\1740 <e1>nicotine-induced</e1>_15\JJ\1740 <e2>seizures</e2>_16\NNS\14081375 and_17\CC\1740 hypolocomotion_18\NN\1740 ._19\.\1740
D009538_D006948 NONE the_0\DT\1740 alpha3_1\NN\1740 and_2\CC\1740 beta4_3\NN\1740 nicotinic_4\JJ\1740 acetylcholine_5\NN\14807558 receptor_6\NN\5225602 subunits_7\NNS\13604718 are_8\VBP\836236 necessary_9\JJ\1740 for_10\IN\1740 <e1>nicotine-induced</e1>_11\JJ\1740 seizures_12\NNS\14081375 and_13\CC\1740 <e2>hypolocomotion</e2>_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 ._17\.\1740
D009538_D006948 NONE we_0\PRP\1740 examined_1\VBD\789138 the_2\DT\1740 role_3\NN\719494 of_4\IN\1740 the_5\DT\1740 beta4_6\CD\1740 subunits_7\NNS\13604718 in_8\IN\13603305 <e1>nicotine-induced</e1>_9\JJ\1740 seizures_10\NNS\14081375 and_11\CC\1740 <e2>hypolocomotion</e2>_12\NN\1740 in_13\IN\13603305 beta4_14\CD\1740 homozygous_15\JJ\1740 null_16\NN\13576982 (_17\-LRB-\1740 beta4_18\CD\1740 -/-_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 alpha3_22\NN\1740 heterozygous_23\JJ\1740 (_24\-LRB-\1740 +/-_25\CC\1740 )_26\-RRB-\1740 mice_27\NNS\2329401 ._28\.\1740
D009538_D006948 NONE together_0\RB\1740 ,_1\,\1740 these_2\DT\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 the_6\DT\1740 beta4_7\NN\1740 and_8\CC\1740 the_9\DT\1740 alpha3_10\NN\1740 subunits_11\NNS\13604718 are_12\VBP\836236 mediators_13\NNS\10351874 of_14\IN\1740 <e1>nicotine-induced</e1>_15\JJ\1740 seizures_16\NNS\14081375 and_17\CC\1740 <e2>hypolocomotion</e2>_18\NN\1740 ._19\.\1740
D009538_D014202 NONE binding_0\NN\4688246 of_1\IN\1740 <e1>nicotine</e1>_2\NN\14712692 to_3\TO\1740 nicotinic_4\JJ\1740 acetylcholine_5\NN\14807558 receptors_6\NNS\5225602 (_7\-LRB-\1740 nachrs_8\NNS\1740 )_9\-RRB-\1740 elicits_10\VBZ\1617192 a_11\DT\13649268 series_12\NN\8456993 of_13\IN\1740 dose-dependent_14\JJ\1740 behaviors_15\NNS\407535 that_16\WDT\1740 go_17\VBP\2367363 from_18\IN\1740 altered_19\JJ\1740 exploration_20\NN\309647 ,_21\,\1740 sedation_22\NN\14034177 ,_23\,\1740 and_24\CC\1740 <e2>tremors</e2>_25\NNS\345926 ,_26\,\1740 to_27\IN\1740 seizures_28\NNS\14081375 and_29\CC\1740 death_30\NN\7296428 ._31\.\1740
D009538_D003643 NONE binding_0\NN\4688246 of_1\IN\1740 <e1>nicotine</e1>_2\NN\14712692 to_3\TO\1740 nicotinic_4\JJ\1740 acetylcholine_5\NN\14807558 receptors_6\NNS\5225602 (_7\-LRB-\1740 nachrs_8\NNS\1740 )_9\-RRB-\1740 elicits_10\VBZ\1617192 a_11\DT\13649268 series_12\NN\8456993 of_13\IN\1740 dose-dependent_14\JJ\1740 behaviors_15\NNS\407535 that_16\WDT\1740 go_17\VBP\2367363 from_18\IN\1740 altered_19\JJ\1740 exploration_20\NN\309647 ,_21\,\1740 sedation_22\NN\14034177 ,_23\,\1740 and_24\CC\1740 tremors_25\NNS\345926 ,_26\,\1740 to_27\IN\1740 seizures_28\NNS\14081375 and_29\CC\1740 <e2>death</e2>_30\NN\7296428 ._31\.\1740
D000109_D014202 NONE binding_0\NN\4688246 of_1\IN\1740 nicotine_2\NN\14712692 to_3\TO\1740 nicotinic_4\JJ\1740 <e1>acetylcholine</e1>_5\NN\14807558 receptors_6\NNS\5225602 (_7\-LRB-\1740 nachrs_8\NNS\1740 )_9\-RRB-\1740 elicits_10\VBZ\1617192 a_11\DT\13649268 series_12\NN\8456993 of_13\IN\1740 dose-dependent_14\JJ\1740 behaviors_15\NNS\407535 that_16\WDT\1740 go_17\VBP\2367363 from_18\IN\1740 altered_19\JJ\1740 exploration_20\NN\309647 ,_21\,\1740 sedation_22\NN\14034177 ,_23\,\1740 and_24\CC\1740 <e2>tremors</e2>_25\NNS\345926 ,_26\,\1740 to_27\IN\1740 seizures_28\NNS\14081375 and_29\CC\1740 death_30\NN\7296428 ._31\.\1740
D000109_D003643 NONE binding_0\NN\4688246 of_1\IN\1740 nicotine_2\NN\14712692 to_3\TO\1740 nicotinic_4\JJ\1740 <e1>acetylcholine</e1>_5\NN\14807558 receptors_6\NNS\5225602 (_7\-LRB-\1740 nachrs_8\NNS\1740 )_9\-RRB-\1740 elicits_10\VBZ\1617192 a_11\DT\13649268 series_12\NN\8456993 of_13\IN\1740 dose-dependent_14\JJ\1740 behaviors_15\NNS\407535 that_16\WDT\1740 go_17\VBP\2367363 from_18\IN\1740 altered_19\JJ\1740 exploration_20\NN\309647 ,_21\,\1740 sedation_22\NN\14034177 ,_23\,\1740 and_24\CC\1740 tremors_25\NNS\345926 ,_26\,\1740 to_27\IN\1740 seizures_28\NNS\14081375 and_29\CC\1740 <e2>death</e2>_30\NN\7296428 ._31\.\1740
9812111
D006220_D011618 NONE a_0\DT\13649268 randomized_1\JJ\1740 ,_2\,\1740 placebo-controlled_3\JJ\1740 dose-comparison_4\JJ\1740 trial_5\NN\786195 of_6\IN\1740 <e1>haloperidol</e1>_7\NN\3713736 for_8\IN\1740 <e2>psychosis</e2>_9\NN\14380140 and_10\CC\1740 disruptive_11\JJ\1740 behaviors_12\NNS\407535 in_13\IN\13603305 alzheimer_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 ._17\.\1740
D006220_D011618 NONE objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 goal_3\NN\5809192 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 compare_9\VB\644583 the_10\DT\1740 efficacy_11\NN\5199286 and_12\CC\1740 side_13\JJ\1740 effects_14\NNS\13245626 of_15\IN\1740 two_16\CD\13741022 doses_17\NNS\3740161 of_18\IN\1740 <e1>haloperidol</e1>_19\NN\3713736 and_20\CC\1740 placebo_21\VB\1740 in_22\IN\13603305 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 <e2>psychosis</e2>_26\NN\14380140 and_27\CC\1740 disruptive_28\JJ\1740 behaviors_29\NNS\407535 in_30\IN\13603305 patients_31\NNS\9898892 with_32\IN\1740 alzheimer_33\NN\1740 's_34\POS\1740 disease_35\NN\14061805 ._36\.\1740
D006220_D011618 NONE results_0\NNS\34213 :_1\:\1740 for_2\IN\1740 the_3\DT\1740 60_4\CD\13745420 patients_5\NNS\9898892 who_6\WP\8299493 completed_7\VBD\352826 phase_8\NN\15113229 a_9\NN\13649268 ,_10\,\1740 standard-dose_11\JJ\1740 <e1>haloperidol</e1>_12\NN\3713736 was_13\VBD\836236 efficacious_14\JJ\1740 and_15\CC\1740 superior_16\JJ\1740 to_17\TO\1740 both_18\CC\1740 low-dose_19\JJ\1740 haloperidol_20\NN\3713736 and_21\CC\1740 placebo_22\NN\3740161 for_23\IN\1740 scores_24\NNS\13757724 on_25\IN\1740 the_26\DT\1740 brief_27\NNP\6479665 psychiatric_28\NNP\1740 rating_29\NNP\5733583 scale_30\NN\7260623 <e2>psychosis</e2>_31\NN\14380140 factor_32\NN\7326557 and_33\CC\1740 on_34\IN\1740 psychomotor_35\NN\1740 agitation_36\NN\14373582 ._37\.\1740
D006220_D011618 NONE results_0\NNS\34213 :_1\:\1740 for_2\IN\1740 the_3\DT\1740 60_4\CD\13745420 patients_5\NNS\9898892 who_6\WP\8299493 completed_7\VBD\352826 phase_8\NN\15113229 a_9\NN\13649268 ,_10\,\1740 standard-dose_11\JJ\1740 haloperidol_12\NN\3713736 was_13\VBD\836236 efficacious_14\JJ\1740 and_15\CC\1740 superior_16\JJ\1740 to_17\TO\1740 both_18\CC\1740 low-dose_19\JJ\1740 <e1>haloperidol</e1>_20\NN\3713736 and_21\CC\1740 placebo_22\NN\3740161 for_23\IN\1740 scores_24\NNS\13757724 on_25\IN\1740 the_26\DT\1740 brief_27\NNP\6479665 psychiatric_28\NNP\1740 rating_29\NNP\5733583 scale_30\NN\7260623 <e2>psychosis</e2>_31\NN\14380140 factor_32\NN\7326557 and_33\CC\1740 on_34\IN\1740 psychomotor_35\NN\1740 agitation_36\NN\14373582 ._37\.\1740
D006220_D011618 NONE the_0\DT\1740 narrow_1\JJ\1740 therapeutic_2\JJ\1740 window_3\NN\3391770 observed_4\VBN\2163746 with_5\IN\1740 <e1>haloperidol</e1>_6\NN\3713736 may_7\MD\15209706 also_8\RB\1740 apply_9\VB\2676054 to_10\IN\1740 other_11\JJ\1740 neuroleptics_12\NNS\4470232 used_13\VBN\1156834 in_14\IN\13603305 alzheimer_15\NN\1740 's_16\POS\1740 disease_17\NN\14061805 patients_18\NNS\9898892 with_19\IN\1740 <e2>psychosis</e2>_20\NN\14380140 and_21\CC\1740 disruptive_22\JJ\1740 behaviors_23\NNS\407535 ._24\.\1740
D006220_D019958 NONE a_0\DT\13649268 randomized_1\JJ\1740 ,_2\,\1740 placebo-controlled_3\JJ\1740 dose-comparison_4\JJ\1740 trial_5\NN\786195 of_6\IN\1740 <e1>haloperidol</e1>_7\NN\3713736 for_8\IN\1740 psychosis_9\NN\14380140 and_10\CC\1740 <e2>disruptive_11\JJ\1740 behaviors</e2>_12\NNS\407535 in_13\IN\13603305 alzheimer_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 ._17\.\1740
D006220_D019958 NONE objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 goal_3\NN\5809192 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 compare_9\VB\644583 the_10\DT\1740 efficacy_11\NN\5199286 and_12\CC\1740 side_13\JJ\1740 effects_14\NNS\13245626 of_15\IN\1740 two_16\CD\13741022 doses_17\NNS\3740161 of_18\IN\1740 <e1>haloperidol</e1>_19\NN\3713736 and_20\CC\1740 placebo_21\VB\1740 in_22\IN\13603305 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 psychosis_26\NN\14380140 and_27\CC\1740 <e2>disruptive_28\JJ\1740 behaviors</e2>_29\NNS\407535 in_30\IN\13603305 patients_31\NNS\9898892 with_32\IN\1740 alzheimer_33\NN\1740 's_34\POS\1740 disease_35\NN\14061805 ._36\.\1740
D006220_D019958 NONE the_0\DT\1740 narrow_1\JJ\1740 therapeutic_2\JJ\1740 window_3\NN\3391770 observed_4\VBN\2163746 with_5\IN\1740 <e1>haloperidol</e1>_6\NN\3713736 may_7\MD\15209706 also_8\RB\1740 apply_9\VB\2676054 to_10\IN\1740 other_11\JJ\1740 neuroleptics_12\NNS\4470232 used_13\VBN\1156834 in_14\IN\13603305 alzheimer_15\NN\1740 's_16\POS\1740 disease_17\NN\14061805 patients_18\NNS\9898892 with_19\IN\1740 psychosis_20\NN\14380140 and_21\CC\1740 <e2>disruptive_22\JJ\1740 behaviors</e2>_23\NNS\407535 ._24\.\1740
D006220_D000544 NONE a_0\DT\13649268 randomized_1\JJ\1740 ,_2\,\1740 placebo-controlled_3\JJ\1740 dose-comparison_4\JJ\1740 trial_5\NN\786195 of_6\IN\1740 <e1>haloperidol</e1>_7\NN\3713736 for_8\IN\1740 psychosis_9\NN\14380140 and_10\CC\1740 disruptive_11\JJ\1740 behaviors_12\NNS\407535 in_13\IN\13603305 <e2>alzheimer_14\NN\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 ._17\.\1740
D006220_D000544 NONE objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 goal_3\NN\5809192 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 compare_9\VB\644583 the_10\DT\1740 efficacy_11\NN\5199286 and_12\CC\1740 side_13\JJ\1740 effects_14\NNS\13245626 of_15\IN\1740 two_16\CD\13741022 doses_17\NNS\3740161 of_18\IN\1740 <e1>haloperidol</e1>_19\NN\3713736 and_20\CC\1740 placebo_21\VB\1740 in_22\IN\13603305 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 psychosis_26\NN\14380140 and_27\CC\1740 disruptive_28\JJ\1740 behaviors_29\NNS\407535 in_30\IN\13603305 patients_31\NNS\9898892 with_32\IN\1740 <e2>alzheimer_33\NN\1740 's_34\POS\1740 disease</e2>_35\NN\14061805 ._36\.\1740
D006220_D000544 NONE method_0\NNP\5616786 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 6-week_4\JJ\1740 random-assignment_5\JJ\1740 ,_6\,\1740 double-blind_7\JJ\1740 ,_8\,\1740 placebo-controlled_9\JJ\1740 trial_10\NN\786195 (_11\-LRB-\1740 phase_12\NN\15113229 a_13\NN\13649268 )_14\-RRB-\1740 ,_15\,\1740 <e1>haloperidol</e1>_16\NN\3713736 ,_17\,\1740 2_18\CD\13741022 -_19\SYM\1740 3_20\CD\13741022 mg/day_21\NN\1740 (_22\-LRB-\1740 standard_23\JJ\1740 dose_24\NN\3740161 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 haloperidol_28\VB\1740 ,_29\,\1740 0.50_30\CD\1740 -_31\HYPH\1740 0.75_32\CD\1740 mg/day_33\NN\1740 (_34\-LRB-\1740 low_35\JJ\1740 dose_36\NN\3740161 )_37\-RRB-\1740 ,_38\,\1740 were_39\VBD\836236 compared_40\VBN\644583 in_41\IN\13603305 71_42\CD\1740 outpatients_43\NNS\10405694 with_44\IN\1740 <e2>alzheimer_45\NN\1740 's_46\POS\1740 disease</e2>_47\NN\14061805 ._48\.\1740
D006220_D000544 NONE method_0\NNP\5616786 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 6-week_4\JJ\1740 random-assignment_5\JJ\1740 ,_6\,\1740 double-blind_7\JJ\1740 ,_8\,\1740 placebo-controlled_9\JJ\1740 trial_10\NN\786195 (_11\-LRB-\1740 phase_12\NN\15113229 a_13\NN\13649268 )_14\-RRB-\1740 ,_15\,\1740 haloperidol_16\NN\3713736 ,_17\,\1740 2_18\CD\13741022 -_19\SYM\1740 3_20\CD\13741022 mg/day_21\NN\1740 (_22\-LRB-\1740 standard_23\JJ\1740 dose_24\NN\3740161 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 <e1>haloperidol</e1>_28\VB\1740 ,_29\,\1740 0.50_30\CD\1740 -_31\HYPH\1740 0.75_32\CD\1740 mg/day_33\NN\1740 (_34\-LRB-\1740 low_35\JJ\1740 dose_36\NN\3740161 )_37\-RRB-\1740 ,_38\,\1740 were_39\VBD\836236 compared_40\VBN\644583 in_41\IN\13603305 71_42\CD\1740 outpatients_43\NNS\10405694 with_44\IN\1740 <e2>alzheimer_45\NN\1740 's_46\POS\1740 disease</e2>_47\NN\14061805 ._48\.\1740
D006220_D000544 NONE the_0\DT\1740 narrow_1\JJ\1740 therapeutic_2\JJ\1740 window_3\NN\3391770 observed_4\VBN\2163746 with_5\IN\1740 <e1>haloperidol</e1>_6\NN\3713736 may_7\MD\15209706 also_8\RB\1740 apply_9\VB\2676054 to_10\IN\1740 other_11\JJ\1740 neuroleptics_12\NNS\4470232 used_13\VBN\1156834 in_14\IN\13603305 <e2>alzheimer_15\NN\1740 's_16\POS\1740 disease</e2>_17\NN\14061805 patients_18\NNS\9898892 with_19\IN\1740 psychosis_20\NN\14380140 and_21\CC\1740 disruptive_22\JJ\1740 behaviors_23\NNS\407535 ._24\.\1740
D006220_D011595 NONE results_0\NNS\34213 :_1\:\1740 for_2\IN\1740 the_3\DT\1740 60_4\CD\13745420 patients_5\NNS\9898892 who_6\WP\8299493 completed_7\VBD\352826 phase_8\NN\15113229 a_9\NN\13649268 ,_10\,\1740 standard-dose_11\JJ\1740 <e1>haloperidol</e1>_12\NN\3713736 was_13\VBD\836236 efficacious_14\JJ\1740 and_15\CC\1740 superior_16\JJ\1740 to_17\TO\1740 both_18\CC\1740 low-dose_19\JJ\1740 haloperidol_20\NN\3713736 and_21\CC\1740 placebo_22\NN\3740161 for_23\IN\1740 scores_24\NNS\13757724 on_25\IN\1740 the_26\DT\1740 brief_27\NNP\6479665 psychiatric_28\NNP\1740 rating_29\NNP\5733583 scale_30\NN\7260623 psychosis_31\NN\14380140 factor_32\NN\7326557 and_33\CC\1740 on_34\IN\1740 <e2>psychomotor_35\NN\1740 agitation</e2>_36\NN\14373582 ._37\.\1740
D006220_D011595 NONE results_0\NNS\34213 :_1\:\1740 for_2\IN\1740 the_3\DT\1740 60_4\CD\13745420 patients_5\NNS\9898892 who_6\WP\8299493 completed_7\VBD\352826 phase_8\NN\15113229 a_9\NN\13649268 ,_10\,\1740 standard-dose_11\JJ\1740 haloperidol_12\NN\3713736 was_13\VBD\836236 efficacious_14\JJ\1740 and_15\CC\1740 superior_16\JJ\1740 to_17\TO\1740 both_18\CC\1740 low-dose_19\JJ\1740 <e1>haloperidol</e1>_20\NN\3713736 and_21\CC\1740 placebo_22\NN\3740161 for_23\IN\1740 scores_24\NNS\13757724 on_25\IN\1740 the_26\DT\1740 brief_27\NNP\6479665 psychiatric_28\NNP\1740 rating_29\NNP\5733583 scale_30\NN\7260623 psychosis_31\NN\14380140 factor_32\NN\7326557 and_33\CC\1740 on_34\IN\1740 <e2>psychomotor_35\NN\1740 agitation</e2>_36\NN\14373582 ._37\.\1740
D006220_D001480 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 indicated_4\VBD\952524 a_5\DT\13649268 favorable_6\JJ\1740 therapeutic_7\JJ\1740 profile_8\NN\6999802 for_9\IN\1740 <e1>haloperidol</e1>_10\NN\3713736 in_11\IN\13603305 doses_12\NNS\3740161 of_13\IN\1740 2_14\CD\13741022 -_15\SYM\1740 3_16\CD\13741022 mg/day_17\NN\1740 ,_18\,\1740 although_19\IN\1740 a_20\DT\13649268 subgroup_21\NN\31264 developed_22\VBD\1753788 moderate_23\JJ\1740 to_24\TO\1740 severe_25\JJ\1740 <e2>extrapyramidal_26\JJ\1740 signs</e2>_27\NNS\6643763 ._28\.\1740
9351491
D018967_D011618 NONE previous_0\JJ\1740 clinical_1\JJ\1740 studies_2\NNS\635850 have_3\VBP\2108377 proposed_4\VBN\1010118 that_5\IN\1740 <e1>risperidone</e1>_6\NN\1740 's_7\POS\1740 pharmacologic_8\JJ\1740 profile_9\NN\6999802 may_10\MD\15209706 produce_11\VB\1617192 improved_12\VBN\126264 efficacy_13\NN\5199286 for_14\IN\1740 negative_15\JJ\1740 <e2>psychotic_16\JJ\1740 symptoms</e2>_17\NNS\5823932 and_18\CC\1740 decreased_19\VBD\169651 propensity_20\NN\7498854 for_21\IN\1740 extrapyramidal_22\JJ\1740 side_23\NN\8630039 effects_24\NNS\13245626 ;_25\:\1740 features_26\NNS\5849040 shared_27\VBN\2660631 by_28\IN\1740 so-called_29\JJ\1740 '_30\``\1740 atypical_31\JJ\1740 '_32\''\1740 neuroleptics_33\NNS\4470232 ._34\.\1740
D018967_D010302 CID <e2>drug-induced_0\JJ\1740 parkinsonism</e2>_1\NN\14085708 was_2\VBD\836236 observed_3\VBN\2163746 in_4\IN\13603305 subjects_5\NNS\6598915 treated_6\VBN\2376958 with_7\IN\1740 <e1>risperidone</e1>_8\NN\1740 (_9\-LRB-\1740 42_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 haloperidol_14\NN\3713736 (_15\-LRB-\1740 29_16\CD\13745420 %_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 was_20\VBD\836236 observed_21\VBN\2163746 at_22\IN\14622893 occupancy_23\NN\1053920 levels_24\NNS\4916342 above_25\IN\6392001 60_26\CD\13745420 %_27\NN\1740 ._28\.\1740
D006220_D010302 CID <e2>drug-induced_0\JJ\1740 parkinsonism</e2>_1\NN\14085708 was_2\VBD\836236 observed_3\VBN\2163746 in_4\IN\13603305 subjects_5\NNS\6598915 treated_6\VBN\2376958 with_7\IN\1740 risperidone_8\NN\1740 (_9\-LRB-\1740 42_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 <e1>haloperidol</e1>_14\NN\3713736 (_15\-LRB-\1740 29_16\CD\13745420 %_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 was_20\VBD\836236 observed_21\VBN\2163746 at_22\IN\14622893 occupancy_23\NN\1053920 levels_24\NNS\4916342 above_25\IN\6392001 60_26\CD\13745420 %_27\NN\1740 ._28\.\1740
8829025
D016559_D006973 CID two_0\CD\13741022 groups_1\NNS\2137 of_2\IN\1740 patients_3\NNS\9898892 receiving_4\VBG\2210855 <e1>tacrolimus</e1>_5\NN\1740 were_6\VBD\836236 compared_7\VBN\644583 over_8\IN\5867413 a_9\DT\13649268 period_10\NN\13575869 of_11\IN\1740 1_12\CD\13741022 year_13\NN\15113229 ,_14\,\1740 one_15\CD\13741022 group_16\NN\2137 comprising_17\VBG\2604760 <e2>hypertensive</e2>_18\JJ\1740 patients_19\NNS\9898892 who_20\WP\8299493 were_21\VBD\836236 receiving_22\VBG\2210855 nifedipine_23\NN\2938514 ,_24\,\1740 and_25\CC\1740 the_26\DT\1740 other_27\JJ\1740 comprising_28\VBG\2604760 nonhypertensive_29\JJ\1740 patients_30\NNS\9898892 not_31\RB\1740 receiving_32\VBG\2210855 nifedipine_33\NN\2938514 ._34\.\1740
D016559_D006973 CID the_0\DT\1740 observed_1\VBN\2163746 positive_2\JJ\1740 impact_3\NN\7339329 of_4\IN\1740 nifedipine_5\NN\2938514 on_6\IN\1740 reducing_7\VBG\441445 the_8\DT\1740 nephrotoxicity_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 <e1>tacrolimus</e1>_12\NN\1740 in_13\IN\13603305 liver_14\NN\5298729 transplant_15\NN\5267548 recipients_16\NNS\9764201 should_17\MD\1740 be_18\VB\836236 an_19\DT\6697703 important_20\JJ\1740 factor_21\NN\7326557 in_22\IN\13603305 selecting_23\VBG\697589 an_24\DT\6697703 agent_25\NN\7347 to_26\TO\1740 treat_27\VB\2376958 <e2>hypertension</e2>_28\NN\14057371 in_29\IN\13603305 this_30\DT\1740 population_31\NN\7942152 ._32\.\1740
D009543_D006973 NONE two_0\CD\13741022 groups_1\NNS\2137 of_2\IN\1740 patients_3\NNS\9898892 receiving_4\VBG\2210855 tacrolimus_5\NN\1740 were_6\VBD\836236 compared_7\VBN\644583 over_8\IN\5867413 a_9\DT\13649268 period_10\NN\13575869 of_11\IN\1740 1_12\CD\13741022 year_13\NN\15113229 ,_14\,\1740 one_15\CD\13741022 group_16\NN\2137 comprising_17\VBG\2604760 <e2>hypertensive</e2>_18\JJ\1740 patients_19\NNS\9898892 who_20\WP\8299493 were_21\VBD\836236 receiving_22\VBG\2210855 <e1>nifedipine</e1>_23\NN\2938514 ,_24\,\1740 and_25\CC\1740 the_26\DT\1740 other_27\JJ\1740 comprising_28\VBG\2604760 nonhypertensive_29\JJ\1740 patients_30\NNS\9898892 not_31\RB\1740 receiving_32\VBG\2210855 nifedipine_33\NN\2938514 ._34\.\1740
D009543_D006973 NONE two_0\CD\13741022 groups_1\NNS\2137 of_2\IN\1740 patients_3\NNS\9898892 receiving_4\VBG\2210855 tacrolimus_5\NN\1740 were_6\VBD\836236 compared_7\VBN\644583 over_8\IN\5867413 a_9\DT\13649268 period_10\NN\13575869 of_11\IN\1740 1_12\CD\13741022 year_13\NN\15113229 ,_14\,\1740 one_15\CD\13741022 group_16\NN\2137 comprising_17\VBG\2604760 <e2>hypertensive</e2>_18\JJ\1740 patients_19\NNS\9898892 who_20\WP\8299493 were_21\VBD\836236 receiving_22\VBG\2210855 nifedipine_23\NN\2938514 ,_24\,\1740 and_25\CC\1740 the_26\DT\1740 other_27\JJ\1740 comprising_28\VBG\2604760 nonhypertensive_29\JJ\1740 patients_30\NNS\9898892 not_31\RB\1740 receiving_32\VBG\2210855 <e1>nifedipine</e1>_33\NN\2938514 ._34\.\1740
D009543_D006973 NONE the_0\DT\1740 observed_1\VBN\2163746 positive_2\JJ\1740 impact_3\NN\7339329 of_4\IN\1740 <e1>nifedipine</e1>_5\NN\2938514 on_6\IN\1740 reducing_7\VBG\441445 the_8\DT\1740 nephrotoxicity_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 tacrolimus_12\NN\1740 in_13\IN\13603305 liver_14\NN\5298729 transplant_15\NN\5267548 recipients_16\NNS\9764201 should_17\MD\1740 be_18\VB\836236 an_19\DT\6697703 important_20\JJ\1740 factor_21\NN\7326557 in_22\IN\13603305 selecting_23\VBG\697589 an_24\DT\6697703 agent_25\NN\7347 to_26\TO\1740 treat_27\VB\2376958 <e2>hypertension</e2>_28\NN\14057371 in_29\IN\13603305 this_30\DT\1740 population_31\NN\7942152 ._32\.\1740
D009543_D007674 NONE the_0\DT\1740 observed_1\VBN\2163746 positive_2\JJ\1740 impact_3\NN\7339329 of_4\IN\1740 <e1>nifedipine</e1>_5\NN\2938514 on_6\IN\1740 reducing_7\VBG\441445 the_8\DT\1740 <e2>nephrotoxicity</e2>_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 tacrolimus_12\NN\1740 in_13\IN\13603305 liver_14\NN\5298729 transplant_15\NN\5267548 recipients_16\NNS\9764201 should_17\MD\1740 be_18\VB\836236 an_19\DT\6697703 important_20\JJ\1740 factor_21\NN\7326557 in_22\IN\13603305 selecting_23\VBG\697589 an_24\DT\6697703 agent_25\NN\7347 to_26\TO\1740 treat_27\VB\2376958 hypertension_28\NN\14057371 in_29\IN\13603305 this_30\DT\1740 population_31\NN\7942152 ._32\.\1740
D016559_D007674 NONE the_0\DT\1740 observed_1\VBN\2163746 positive_2\JJ\1740 impact_3\NN\7339329 of_4\IN\1740 nifedipine_5\NN\2938514 on_6\IN\1740 reducing_7\VBG\441445 the_8\DT\1740 <e2>nephrotoxicity</e2>_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 <e1>tacrolimus</e1>_12\NN\1740 in_13\IN\13603305 liver_14\NN\5298729 transplant_15\NN\5267548 recipients_16\NNS\9764201 should_17\MD\1740 be_18\VB\836236 an_19\DT\6697703 important_20\JJ\1740 factor_21\NN\7326557 in_22\IN\13603305 selecting_23\VBG\697589 an_24\DT\6697703 agent_25\NN\7347 to_26\TO\1740 treat_27\VB\2376958 hypertension_28\NN\14057371 in_29\IN\13603305 this_30\DT\1740 population_31\NN\7942152 ._32\.\1740
2670794
D000809_D011665 NONE effects_0\NNS\13245626 of_1\IN\1740 an_2\DT\6697703 inhibitor_3\NN\20090 of_4\IN\1740 <e1>angiotensin</e1>_5\NN\4522421 converting_6\NN\1740 enzyme_7\NN\14723628 (_8\-LRB-\1740 captopril_9\NNP\2673637 )_10\-RRB-\1740 on_11\IN\1740 <e2>pulmonary_12\JJ\1740 and_13\CC\1740 renal_14\JJ\1740 insufficiency</e2>_15\NN\14462946 due_16\IN\5174653 to_17\TO\1740 intravascular_18\JJ\1740 coagulation_19\NN\13518963 in_20\IN\13603305 the_21\DT\1740 rat_22\NN\2329401 ._23\.\1740
D000809_D011665 NONE injection_0\NN\320852 of_1\IN\1740 captopril_2\NNP\2673637 (_3\-LRB-\1740 1_4\CD\13741022 mg/kg_5\NN\1740 )_6\-RRB-\1740 ,_7\,\1740 an_8\DT\6697703 inhibitor_9\NN\20090 of_10\IN\1740 <e1>angiotensin</e1>_11\NN\4522421 converting_12\NN\1740 enzyme_13\NN\14723628 (_14\-LRB-\1740 ace_15\NN\13741022 )_16\-RRB-\1740 ,_17\,\1740 reduced_18\VBD\441445 both_19\CC\1740 <e2>pulmonary_20\JJ\1740 and_21\CC\1740 renal_22\JJ\1740 insufficiency</e2>_23\NN\14462946 in_24\IN\13603305 this_25\DT\1740 rat_26\NN\2329401 model_27\NN\5888929 ._28\.\1740
D000809_D051437 NONE effects_0\NNS\13245626 of_1\IN\1740 an_2\DT\6697703 inhibitor_3\NN\20090 of_4\IN\1740 <e1>angiotensin</e1>_5\NN\4522421 converting_6\NN\1740 enzyme_7\NN\14723628 (_8\-LRB-\1740 captopril_9\NNP\2673637 )_10\-RRB-\1740 on_11\IN\1740 <e2>pulmonary_12\JJ\1740 and_13\CC\1740 renal_14\JJ\1740 insufficiency</e2>_15\NN\14462946 due_16\IN\5174653 to_17\TO\1740 intravascular_18\JJ\1740 coagulation_19\NN\13518963 in_20\IN\13603305 the_21\DT\1740 rat_22\NN\2329401 ._23\.\1740
D000809_D051437 NONE injection_0\NN\320852 of_1\IN\1740 captopril_2\NNP\2673637 (_3\-LRB-\1740 1_4\CD\13741022 mg/kg_5\NN\1740 )_6\-RRB-\1740 ,_7\,\1740 an_8\DT\6697703 inhibitor_9\NN\20090 of_10\IN\1740 <e1>angiotensin</e1>_11\NN\4522421 converting_12\NN\1740 enzyme_13\NN\14723628 (_14\-LRB-\1740 ace_15\NN\13741022 )_16\-RRB-\1740 ,_17\,\1740 reduced_18\VBD\441445 both_19\CC\1740 <e2>pulmonary_20\JJ\1740 and_21\CC\1740 renal_22\JJ\1740 insufficiency</e2>_23\NN\14462946 in_24\IN\13603305 this_25\DT\1740 rat_26\NN\2329401 model_27\NN\5888929 ._28\.\1740
D000809_D004211 NONE effects_0\NNS\13245626 of_1\IN\1740 an_2\DT\6697703 inhibitor_3\NN\20090 of_4\IN\1740 <e1>angiotensin</e1>_5\NN\4522421 converting_6\NN\1740 enzyme_7\NN\14723628 (_8\-LRB-\1740 captopril_9\NNP\2673637 )_10\-RRB-\1740 on_11\IN\1740 pulmonary_12\JJ\1740 and_13\CC\1740 renal_14\JJ\1740 insufficiency_15\NN\14462946 due_16\IN\5174653 to_17\TO\1740 <e2>intravascular_18\JJ\1740 coagulation</e2>_19\NN\13518963 in_20\IN\13603305 the_21\DT\1740 rat_22\NN\2329401 ._23\.\1740
D002216_D011665 NONE effects_0\NNS\13245626 of_1\IN\1740 an_2\DT\6697703 inhibitor_3\NN\20090 of_4\IN\1740 angiotensin_5\NN\4522421 converting_6\NN\1740 enzyme_7\NN\14723628 (_8\-LRB-\1740 <e1>captopril</e1>_9\NNP\2673637 )_10\-RRB-\1740 on_11\IN\1740 <e2>pulmonary_12\JJ\1740 and_13\CC\1740 renal_14\JJ\1740 insufficiency</e2>_15\NN\14462946 due_16\IN\5174653 to_17\TO\1740 intravascular_18\JJ\1740 coagulation_19\NN\13518963 in_20\IN\13603305 the_21\DT\1740 rat_22\NN\2329401 ._23\.\1740
D002216_D011665 NONE injection_0\NN\320852 of_1\IN\1740 <e1>captopril</e1>_2\NNP\2673637 (_3\-LRB-\1740 1_4\CD\13741022 mg/kg_5\NN\1740 )_6\-RRB-\1740 ,_7\,\1740 an_8\DT\6697703 inhibitor_9\NN\20090 of_10\IN\1740 angiotensin_11\NN\4522421 converting_12\NN\1740 enzyme_13\NN\14723628 (_14\-LRB-\1740 ace_15\NN\13741022 )_16\-RRB-\1740 ,_17\,\1740 reduced_18\VBD\441445 both_19\CC\1740 <e2>pulmonary_20\JJ\1740 and_21\CC\1740 renal_22\JJ\1740 insufficiency</e2>_23\NN\14462946 in_24\IN\13603305 this_25\DT\1740 rat_26\NN\2329401 model_27\NN\5888929 ._28\.\1740
D002216_D051437 NONE effects_0\NNS\13245626 of_1\IN\1740 an_2\DT\6697703 inhibitor_3\NN\20090 of_4\IN\1740 angiotensin_5\NN\4522421 converting_6\NN\1740 enzyme_7\NN\14723628 (_8\-LRB-\1740 <e1>captopril</e1>_9\NNP\2673637 )_10\-RRB-\1740 on_11\IN\1740 <e2>pulmonary_12\JJ\1740 and_13\CC\1740 renal_14\JJ\1740 insufficiency</e2>_15\NN\14462946 due_16\IN\5174653 to_17\TO\1740 intravascular_18\JJ\1740 coagulation_19\NN\13518963 in_20\IN\13603305 the_21\DT\1740 rat_22\NN\2329401 ._23\.\1740
D002216_D051437 NONE injection_0\NN\320852 of_1\IN\1740 <e1>captopril</e1>_2\NNP\2673637 (_3\-LRB-\1740 1_4\CD\13741022 mg/kg_5\NN\1740 )_6\-RRB-\1740 ,_7\,\1740 an_8\DT\6697703 inhibitor_9\NN\20090 of_10\IN\1740 angiotensin_11\NN\4522421 converting_12\NN\1740 enzyme_13\NN\14723628 (_14\-LRB-\1740 ace_15\NN\13741022 )_16\-RRB-\1740 ,_17\,\1740 reduced_18\VBD\441445 both_19\CC\1740 <e2>pulmonary_20\JJ\1740 and_21\CC\1740 renal_22\JJ\1740 insufficiency</e2>_23\NN\14462946 in_24\IN\13603305 this_25\DT\1740 rat_26\NN\2329401 model_27\NN\5888929 ._28\.\1740
D002216_D004211 NONE effects_0\NNS\13245626 of_1\IN\1740 an_2\DT\6697703 inhibitor_3\NN\20090 of_4\IN\1740 angiotensin_5\NN\4522421 converting_6\NN\1740 enzyme_7\NN\14723628 (_8\-LRB-\1740 <e1>captopril</e1>_9\NNP\2673637 )_10\-RRB-\1740 on_11\IN\1740 pulmonary_12\JJ\1740 and_13\CC\1740 renal_14\JJ\1740 insufficiency_15\NN\14462946 due_16\IN\5174653 to_17\TO\1740 <e2>intravascular_18\JJ\1740 coagulation</e2>_19\NN\13518963 in_20\IN\13603305 the_21\DT\1740 rat_22\NN\2329401 ._23\.\1740
D014148_D004211 CID induction_0\NN\7450842 of_1\IN\1740 <e2>intravascular_2\JJ\1740 coagulation</e2>_3\NN\13518963 and_4\CC\1740 inhibition_5\NN\1068773 of_6\IN\1740 fibrinolysis_7\NN\13467916 by_8\IN\1740 injection_9\NN\320852 of_10\IN\1740 thrombin_11\NN\14735953 and_12\CC\1740 <e1>tranexamic_13\JJ\1740 acid</e1>_14\NN\14818238 (_15\-LRB-\1740 amca_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 the_19\DT\1740 rat_20\NN\2329401 gives_21\VBZ\2327200 rise_22\NN\7324673 to_23\TO\1740 pulmonary_24\JJ\1740 and_25\CC\1740 renal_26\JJ\1740 insufficiency_27\NN\14462946 resembling_28\VBG\2657219 that_29\DT\1740 occurring_30\VBG\2623529 after_31\IN\1740 trauma_32\NN\14052046 or_33\CC\3541091 sepsis_34\NN\14174549 in_35\IN\13603305 man_36\NN\9605289 ._37\.\1740
D014148_D004211 CID induction_0\NN\7450842 of_1\IN\1740 <e2>intravascular_2\JJ\1740 coagulation</e2>_3\NN\13518963 and_4\CC\1740 inhibition_5\NN\1068773 of_6\IN\1740 fibrinolysis_7\NN\13467916 by_8\IN\1740 injection_9\NN\320852 of_10\IN\1740 thrombin_11\NN\14735953 and_12\CC\1740 tranexamic_13\JJ\1740 acid_14\NN\14818238 (_15\-LRB-\1740 <e1>amca</e1>_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 the_19\DT\1740 rat_20\NN\2329401 gives_21\VBZ\2327200 rise_22\NN\7324673 to_23\TO\1740 pulmonary_24\JJ\1740 and_25\CC\1740 renal_26\JJ\1740 insufficiency_27\NN\14462946 resembling_28\VBG\2657219 that_29\DT\1740 occurring_30\VBG\2623529 after_31\IN\1740 trauma_32\NN\14052046 or_33\CC\3541091 sepsis_34\NN\14174549 in_35\IN\13603305 man_36\NN\9605289 ._37\.\1740
D014148_D011665 NONE induction_0\NN\7450842 of_1\IN\1740 intravascular_2\JJ\1740 coagulation_3\NN\13518963 and_4\CC\1740 inhibition_5\NN\1068773 of_6\IN\1740 fibrinolysis_7\NN\13467916 by_8\IN\1740 injection_9\NN\320852 of_10\IN\1740 thrombin_11\NN\14735953 and_12\CC\1740 <e1>tranexamic_13\JJ\1740 acid</e1>_14\NN\14818238 (_15\-LRB-\1740 amca_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 the_19\DT\1740 rat_20\NN\2329401 gives_21\VBZ\2327200 rise_22\NN\7324673 to_23\TO\1740 <e2>pulmonary_24\JJ\1740 and_25\CC\1740 renal_26\JJ\1740 insufficiency</e2>_27\NN\14462946 resembling_28\VBG\2657219 that_29\DT\1740 occurring_30\VBG\2623529 after_31\IN\1740 trauma_32\NN\14052046 or_33\CC\3541091 sepsis_34\NN\14174549 in_35\IN\13603305 man_36\NN\9605289 ._37\.\1740
D014148_D011665 NONE induction_0\NN\7450842 of_1\IN\1740 intravascular_2\JJ\1740 coagulation_3\NN\13518963 and_4\CC\1740 inhibition_5\NN\1068773 of_6\IN\1740 fibrinolysis_7\NN\13467916 by_8\IN\1740 injection_9\NN\320852 of_10\IN\1740 thrombin_11\NN\14735953 and_12\CC\1740 tranexamic_13\JJ\1740 acid_14\NN\14818238 (_15\-LRB-\1740 <e1>amca</e1>_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 the_19\DT\1740 rat_20\NN\2329401 gives_21\VBZ\2327200 rise_22\NN\7324673 to_23\TO\1740 <e2>pulmonary_24\JJ\1740 and_25\CC\1740 renal_26\JJ\1740 insufficiency</e2>_27\NN\14462946 resembling_28\VBG\2657219 that_29\DT\1740 occurring_30\VBG\2623529 after_31\IN\1740 trauma_32\NN\14052046 or_33\CC\3541091 sepsis_34\NN\14174549 in_35\IN\13603305 man_36\NN\9605289 ._37\.\1740
D014148_D051437 NONE induction_0\NN\7450842 of_1\IN\1740 intravascular_2\JJ\1740 coagulation_3\NN\13518963 and_4\CC\1740 inhibition_5\NN\1068773 of_6\IN\1740 fibrinolysis_7\NN\13467916 by_8\IN\1740 injection_9\NN\320852 of_10\IN\1740 thrombin_11\NN\14735953 and_12\CC\1740 <e1>tranexamic_13\JJ\1740 acid</e1>_14\NN\14818238 (_15\-LRB-\1740 amca_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 the_19\DT\1740 rat_20\NN\2329401 gives_21\VBZ\2327200 rise_22\NN\7324673 to_23\TO\1740 <e2>pulmonary_24\JJ\1740 and_25\CC\1740 renal_26\JJ\1740 insufficiency</e2>_27\NN\14462946 resembling_28\VBG\2657219 that_29\DT\1740 occurring_30\VBG\2623529 after_31\IN\1740 trauma_32\NN\14052046 or_33\CC\3541091 sepsis_34\NN\14174549 in_35\IN\13603305 man_36\NN\9605289 ._37\.\1740
D014148_D051437 NONE induction_0\NN\7450842 of_1\IN\1740 intravascular_2\JJ\1740 coagulation_3\NN\13518963 and_4\CC\1740 inhibition_5\NN\1068773 of_6\IN\1740 fibrinolysis_7\NN\13467916 by_8\IN\1740 injection_9\NN\320852 of_10\IN\1740 thrombin_11\NN\14735953 and_12\CC\1740 tranexamic_13\JJ\1740 acid_14\NN\14818238 (_15\-LRB-\1740 <e1>amca</e1>_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 the_19\DT\1740 rat_20\NN\2329401 gives_21\VBZ\2327200 rise_22\NN\7324673 to_23\TO\1740 <e2>pulmonary_24\JJ\1740 and_25\CC\1740 renal_26\JJ\1740 insufficiency</e2>_27\NN\14462946 resembling_28\VBG\2657219 that_29\DT\1740 occurring_30\VBG\2623529 after_31\IN\1740 trauma_32\NN\14052046 or_33\CC\3541091 sepsis_34\NN\14174549 in_35\IN\13603305 man_36\NN\9605289 ._37\.\1740
D014148_D014947 NONE induction_0\NN\7450842 of_1\IN\1740 intravascular_2\JJ\1740 coagulation_3\NN\13518963 and_4\CC\1740 inhibition_5\NN\1068773 of_6\IN\1740 fibrinolysis_7\NN\13467916 by_8\IN\1740 injection_9\NN\320852 of_10\IN\1740 thrombin_11\NN\14735953 and_12\CC\1740 <e1>tranexamic_13\JJ\1740 acid</e1>_14\NN\14818238 (_15\-LRB-\1740 amca_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 the_19\DT\1740 rat_20\NN\2329401 gives_21\VBZ\2327200 rise_22\NN\7324673 to_23\TO\1740 pulmonary_24\JJ\1740 and_25\CC\1740 renal_26\JJ\1740 insufficiency_27\NN\14462946 resembling_28\VBG\2657219 that_29\DT\1740 occurring_30\VBG\2623529 after_31\IN\1740 <e2>trauma</e2>_32\NN\14052046 or_33\CC\3541091 sepsis_34\NN\14174549 in_35\IN\13603305 man_36\NN\9605289 ._37\.\1740
D014148_D014947 NONE induction_0\NN\7450842 of_1\IN\1740 intravascular_2\JJ\1740 coagulation_3\NN\13518963 and_4\CC\1740 inhibition_5\NN\1068773 of_6\IN\1740 fibrinolysis_7\NN\13467916 by_8\IN\1740 injection_9\NN\320852 of_10\IN\1740 thrombin_11\NN\14735953 and_12\CC\1740 tranexamic_13\JJ\1740 acid_14\NN\14818238 (_15\-LRB-\1740 <e1>amca</e1>_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 the_19\DT\1740 rat_20\NN\2329401 gives_21\VBZ\2327200 rise_22\NN\7324673 to_23\TO\1740 pulmonary_24\JJ\1740 and_25\CC\1740 renal_26\JJ\1740 insufficiency_27\NN\14462946 resembling_28\VBG\2657219 that_29\DT\1740 occurring_30\VBG\2623529 after_31\IN\1740 <e2>trauma</e2>_32\NN\14052046 or_33\CC\3541091 sepsis_34\NN\14174549 in_35\IN\13603305 man_36\NN\9605289 ._37\.\1740
D014148_D018805 NONE induction_0\NN\7450842 of_1\IN\1740 intravascular_2\JJ\1740 coagulation_3\NN\13518963 and_4\CC\1740 inhibition_5\NN\1068773 of_6\IN\1740 fibrinolysis_7\NN\13467916 by_8\IN\1740 injection_9\NN\320852 of_10\IN\1740 thrombin_11\NN\14735953 and_12\CC\1740 <e1>tranexamic_13\JJ\1740 acid</e1>_14\NN\14818238 (_15\-LRB-\1740 amca_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 the_19\DT\1740 rat_20\NN\2329401 gives_21\VBZ\2327200 rise_22\NN\7324673 to_23\TO\1740 pulmonary_24\JJ\1740 and_25\CC\1740 renal_26\JJ\1740 insufficiency_27\NN\14462946 resembling_28\VBG\2657219 that_29\DT\1740 occurring_30\VBG\2623529 after_31\IN\1740 trauma_32\NN\14052046 or_33\CC\3541091 <e2>sepsis</e2>_34\NN\14174549 in_35\IN\13603305 man_36\NN\9605289 ._37\.\1740
D014148_D018805 NONE induction_0\NN\7450842 of_1\IN\1740 intravascular_2\JJ\1740 coagulation_3\NN\13518963 and_4\CC\1740 inhibition_5\NN\1068773 of_6\IN\1740 fibrinolysis_7\NN\13467916 by_8\IN\1740 injection_9\NN\320852 of_10\IN\1740 thrombin_11\NN\14735953 and_12\CC\1740 tranexamic_13\JJ\1740 acid_14\NN\14818238 (_15\-LRB-\1740 <e1>amca</e1>_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 the_19\DT\1740 rat_20\NN\2329401 gives_21\VBZ\2327200 rise_22\NN\7324673 to_23\TO\1740 pulmonary_24\JJ\1740 and_25\CC\1740 renal_26\JJ\1740 insufficiency_27\NN\14462946 resembling_28\VBG\2657219 that_29\DT\1740 occurring_30\VBG\2623529 after_31\IN\1740 trauma_32\NN\14052046 or_33\CC\3541091 <e2>sepsis</e2>_34\NN\14174549 in_35\IN\13603305 man_36\NN\9605289 ._37\.\1740
D014508_D007674 NONE <e2>renal_0\JJ\1740 damage</e2>_1\NN\7296428 as_2\IN\14622893 reflected_3\VBN\923793 by_4\IN\1740 an_5\DT\6697703 increase_6\NN\13576355 in_7\IN\13603305 serum_8\NN\5397468 <e1>urea</e1>_9\NN\14727670 and_10\CC\1740 in_11\IN\13603305 kidney_12\NN\5333259 weight_13\NN\5009170 was_14\VBD\836236 prevented_15\VBN\1740 by_16\IN\1740 captopril_17\NNP\2673637 ._18\.\1740
D002216_D007674 NONE <e2>renal_0\JJ\1740 damage</e2>_1\NN\7296428 as_2\IN\14622893 reflected_3\VBN\923793 by_4\IN\1740 an_5\DT\6697703 increase_6\NN\13576355 in_7\IN\13603305 serum_8\NN\5397468 urea_9\NN\14727670 and_10\CC\1740 in_11\IN\13603305 kidney_12\NN\5333259 weight_13\NN\5009170 was_14\VBD\836236 prevented_15\VBN\1740 by_16\IN\1740 <e1>captopril</e1>_17\NNP\2673637 ._18\.\1740
D002216_D007674 NONE <e1>captopril</e1>_0\NNP\2673637 may_1\MD\15209706 ,_2\,\1740 by_3\IN\1740 the_4\DT\1740 same_5\JJ\1740 mechanism_6\NN\13446390 ,_7\,\1740 reduce_8\VB\441445 the_9\DT\1740 increase_10\NN\13576355 in_11\IN\13603305 glomerular_12\JJ\1740 filtration_13\NN\13518963 that_14\WDT\1740 is_15\VBZ\836236 known_16\VBN\2110220 to_17\TO\1740 occur_18\VB\2623529 after_19\IN\1740 an_20\DT\6697703 injection_21\NN\320852 of_22\IN\1740 thrombin_23\NN\14735953 ,_24\,\1740 thereby_25\RB\1740 diminishing_26\VBG\169651 the_27\DT\1740 aggregation_28\NN\31264 of_29\IN\1740 fibrin_30\NN\14728724 monomers_31\NNS\14818238 in_32\IN\13603305 the_33\DT\1740 glomeruli_34\NNS\5425910 ,_35\,\1740 with_36\IN\1740 the_37\DT\1740 result_38\NN\34213 that_39\IN\1740 less_40\JJR\1740 fibrin_41\NN\14728724 will_42\MD\5650329 be_43\VB\836236 deposited_44\VBN\1340439 and_45\CC\1740 thus_46\RB\1740 less_47\JJR\1740 <e2>kidney_48\NN\5333259 damage</e2>_49\NN\7296428 will_50\MD\5650329 be_51\VB\836236 produced_52\VBN\1617192 ._53\.\1740
1728522
D019980_D006099 CID <e2>granulomatous_0\JJ\1740 hepatitis</e2>_1\NN\14127211 due_2\IN\5174653 to_3\TO\1740 <e1>combination_4\NN\7951464 of_5\IN\1740 amoxicillin_6\NN\3910033 and_7\CC\1740 clavulanic_8\JJ\1740 acid</e1>_9\NN\14818238 ._10\.\1740
D019980_D006099 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 <e1>amoxicillin-clavulanic_8\JJ\1740 acid-induced</e1>_9\JJ\1740 hepatitis_10\NN\14127211 with_11\IN\1740 histologic_12\JJ\1740 multiple_13\JJ\1740 <e2>granulomas</e2>_14\NNS\14235200 ._15\.\1740
D019980_D056486 CID <e2>granulomatous_0\JJ\1740 hepatitis</e2>_1\NN\14127211 due_2\IN\5174653 to_3\TO\1740 <e1>combination_4\NN\7951464 of_5\IN\1740 amoxicillin_6\NN\3910033 and_7\CC\1740 clavulanic_8\JJ\1740 acid</e1>_9\NN\14818238 ._10\.\1740
D019980_D056486 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 <e1>amoxicillin-clavulanic_8\JJ\1740 acid-induced</e1>_9\JJ\1740 <e2>hepatitis</e2>_10\NN\14127211 with_11\IN\1740 histologic_12\JJ\1740 multiple_13\JJ\1740 granulomas_14\NNS\14235200 ._15\.\1740
7890216
D015282_D042882 CID composition_0\NN\5075602 of_1\IN\1740 <e2>gall_2\NN\14253124 bladder_3\NN\5515670 stones</e2>_4\NNS\19128 associated_5\VBN\628491 with_6\IN\1740 <e1>octreotide</e1>_7\NN\1740 :_8\:\1740 response_9\NN\11410625 to_10\TO\1740 oral_11\JJ\1740 ursodeoxycholic_12\JJ\1740 acid_13\NN\14818238 ._14\.\1740
D015282_D042882 CID <e1>octreotide</e1>_0\NNP\1740 ,_1\,\1740 an_2\DT\6697703 effective_3\JJ\1740 treatment_4\NN\654885 for_5\IN\1740 acromegaly_6\NN\14366759 ,_7\,\1740 induces_8\VBZ\1627355 <e2>gall_9\NN\14253124 bladder_10\NN\5515670 stones</e2>_11\NNS\19128 in_12\IN\13603305 13_13\CD\13745420 -_14\SYM\1740 60_15\CD\13745420 %_16\NN\1740 of_17\IN\1740 patients_18\NNS\9898892 ._19\.\1740
D015282_D042882 CID because_0\IN\1740 knowledge_1\NN\23100 of_2\IN\1740 stone_3\NN\19128 composition_4\NN\5075602 is_5\VBZ\836236 essential_6\JJ\1740 for_7\IN\1740 studies_8\NNS\635850 of_9\IN\1740 their_10\PRP$\1740 pathogenesis_11\NN\13533470 ,_12\,\1740 treatment_13\NN\654885 ,_14\,\1740 and_15\CC\1740 prevention_16\NN\1073995 ,_17\,\1740 this_18\DT\1740 was_19\VBD\836236 investigated_20\VBN\644583 by_21\IN\1740 direct_22\JJ\1740 and_23\CC\1740 indirect_24\JJ\1740 methods_25\NNS\5616786 in_26\IN\13603305 14_27\CD\13745420 <e1>octreotide</e1>_28\NN\1740 treated_29\VBN\2376958 acromegalic_30\JJ\1740 patients_31\NNS\9898892 with_32\IN\1740 <e2>gall_33\NN\14253124 stones</e2>_34\NNS\19128 ._35\.\1740
D015282_D042882 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>octreotide</e1>_3\NN\1740 induced_4\VBD\1627355 <e2>gall_5\NN\14253124 stones</e2>_6\NNS\19128 are_7\VBP\836236 generally_8\RB\1740 small_9\JJ\1740 ,_10\,\1740 multiple_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 cholesterol_14\NN\15058310 rich_15\JJ\1740 although_16\IN\1740 ,_17\,\1740 in_18\IN\13603305 common_19\JJ\1740 with_20\IN\1740 spontaneous_21\JJ\1740 gall_22\NN\14253124 stone_23\NN\19128 disease_24\NN\14061805 ,_25\,\1740 at_26\IN\14622893 presentation_27\NN\1027379 some_28\DT\1740 patients_29\NNS\9898892 will_30\MD\5650329 have_31\VB\2108377 a_32\DT\13649268 blocked_33\VBN\1476483 cystic_34\JJ\1740 duct_35\NN\5248181 and_36\CC\1740 some_37\DT\1740 gall_38\NN\14253124 stones_39\NNS\19128 containing_40\VBG\2632940 calcium_41\NN\14625458 ._42\.\1740
D015282_D042882 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>octreotide</e1>_3\NN\1740 induced_4\VBD\1627355 gall_5\NN\14253124 stones_6\NNS\19128 are_7\VBP\836236 generally_8\RB\1740 small_9\JJ\1740 ,_10\,\1740 multiple_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 cholesterol_14\NN\15058310 rich_15\JJ\1740 although_16\IN\1740 ,_17\,\1740 in_18\IN\13603305 common_19\JJ\1740 with_20\IN\1740 spontaneous_21\JJ\1740 <e2>gall_22\NN\14253124 stone_23\NN\19128 disease</e2>_24\NN\14061805 ,_25\,\1740 at_26\IN\14622893 presentation_27\NN\1027379 some_28\DT\1740 patients_29\NNS\9898892 will_30\MD\5650329 have_31\VB\2108377 a_32\DT\13649268 blocked_33\VBN\1476483 cystic_34\JJ\1740 duct_35\NN\5248181 and_36\CC\1740 some_37\DT\1740 gall_38\NN\14253124 stones_39\NNS\19128 containing_40\VBG\2632940 calcium_41\NN\14625458 ._42\.\1740
D015282_D042882 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>octreotide</e1>_3\NN\1740 induced_4\VBD\1627355 gall_5\NN\14253124 stones_6\NNS\19128 are_7\VBP\836236 generally_8\RB\1740 small_9\JJ\1740 ,_10\,\1740 multiple_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 cholesterol_14\NN\15058310 rich_15\JJ\1740 although_16\IN\1740 ,_17\,\1740 in_18\IN\13603305 common_19\JJ\1740 with_20\IN\1740 spontaneous_21\JJ\1740 gall_22\NN\14253124 stone_23\NN\19128 disease_24\NN\14061805 ,_25\,\1740 at_26\IN\14622893 presentation_27\NN\1027379 some_28\DT\1740 patients_29\NNS\9898892 will_30\MD\5650329 have_31\VB\2108377 a_32\DT\13649268 blocked_33\VBN\1476483 cystic_34\JJ\1740 duct_35\NN\5248181 and_36\CC\1740 some_37\DT\1740 <e2>gall_38\NN\14253124 stones</e2>_39\NNS\19128 containing_40\VBG\2632940 calcium_41\NN\14625458 ._42\.\1740
D014580_D042882 NONE composition_0\NN\5075602 of_1\IN\1740 <e2>gall_2\NN\14253124 bladder_3\NN\5515670 stones</e2>_4\NNS\19128 associated_5\VBN\628491 with_6\IN\1740 octreotide_7\NN\1740 :_8\:\1740 response_9\NN\11410625 to_10\TO\1740 oral_11\JJ\1740 <e1>ursodeoxycholic_12\JJ\1740 acid</e1>_13\NN\14818238 ._14\.\1740
D015282_D000172 NONE <e1>octreotide</e1>_0\NNP\1740 ,_1\,\1740 an_2\DT\6697703 effective_3\JJ\1740 treatment_4\NN\654885 for_5\IN\1740 <e2>acromegaly</e2>_6\NN\14366759 ,_7\,\1740 induces_8\VBZ\1627355 gall_9\NN\14253124 bladder_10\NN\5515670 stones_11\NNS\19128 in_12\IN\13603305 13_13\CD\13745420 -_14\SYM\1740 60_15\CD\13745420 %_16\NN\1740 of_17\IN\1740 patients_18\NNS\9898892 ._19\.\1740
D015282_D000172 NONE because_0\IN\1740 knowledge_1\NN\23100 of_2\IN\1740 stone_3\NN\19128 composition_4\NN\5075602 is_5\VBZ\836236 essential_6\JJ\1740 for_7\IN\1740 studies_8\NNS\635850 of_9\IN\1740 their_10\PRP$\1740 pathogenesis_11\NN\13533470 ,_12\,\1740 treatment_13\NN\654885 ,_14\,\1740 and_15\CC\1740 prevention_16\NN\1073995 ,_17\,\1740 this_18\DT\1740 was_19\VBD\836236 investigated_20\VBN\644583 by_21\IN\1740 direct_22\JJ\1740 and_23\CC\1740 indirect_24\JJ\1740 methods_25\NNS\5616786 in_26\IN\13603305 14_27\CD\13745420 <e1>octreotide</e1>_28\NN\1740 treated_29\VBN\2376958 <e2>acromegalic</e2>_30\JJ\1740 patients_31\NNS\9898892 with_32\IN\1740 gall_33\NN\14253124 stones_34\NNS\19128 ._35\.\1740
D002784_D042882 NONE chemical_0\JJ\1740 analysis_1\NN\633864 of_2\IN\1740 <e2>gall_3\NN\14253124 stones</e2>_4\NNS\19128 retrieved_5\VBN\2210855 at_6\IN\14622893 cholecystectomy_7\NN\393369 from_8\IN\1740 two_9\CD\13741022 patients_10\NNS\9898892 ,_11\,\1740 showed_12\VBD\2137132 that_13\IN\1740 they_14\PRP\1740 contained_15\VBD\2632940 71_16\CD\1740 %_17\NN\1740 and_18\CC\1740 87_19\CD\1740 %_20\NN\1740 <e1>cholesterol</e1>_21\NN\15058310 by_22\IN\1740 weight_23\NN\5009170 ._24\.\1740
D002784_D042882 NONE after_0\IN\1740 one_1\CD\13741022 year_2\NN\15113229 of_3\IN\1740 treatment_4\NN\654885 ,_5\,\1740 five_6\CD\13741022 of_7\IN\1740 the_8\DT\1740 remaining_9\VBG\2604760 nine_10\CD\13741022 patients_11\NNS\9898892 showed_12\VBD\2137132 either_13\CC\1740 partial_14\JJ\1740 (_15\-LRB-\1740 n_16\NN\14622893 =_17\JJ\1740 3_18\CD\13741022 )_19\-RRB-\1740 or_20\CC\3541091 complete_21\JJ\1740 (_22\-LRB-\1740 n_23\NN\14622893 =_24\JJ\1740 2_25\CD\13741022 )_26\-RRB-\1740 <e2>gall_27\VBP\63291 stone</e2>_28\NN\19128 dissolution_29\NN\13518963 ,_30\,\1740 suggesting_31\VBG\1010118 that_32\IN\1740 their_33\PRP$\1740 stones_34\NNS\19128 were_35\VBD\836236 <e1>cholesterol</e1>_36\NN\15058310 rich_37\JJ\1740 ._38\.\1740
D002784_D042882 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 octreotide_3\NN\1740 induced_4\VBD\1627355 <e2>gall_5\NN\14253124 stones</e2>_6\NNS\19128 are_7\VBP\836236 generally_8\RB\1740 small_9\JJ\1740 ,_10\,\1740 multiple_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 <e1>cholesterol</e1>_14\NN\15058310 rich_15\JJ\1740 although_16\IN\1740 ,_17\,\1740 in_18\IN\13603305 common_19\JJ\1740 with_20\IN\1740 spontaneous_21\JJ\1740 gall_22\NN\14253124 stone_23\NN\19128 disease_24\NN\14061805 ,_25\,\1740 at_26\IN\14622893 presentation_27\NN\1027379 some_28\DT\1740 patients_29\NNS\9898892 will_30\MD\5650329 have_31\VB\2108377 a_32\DT\13649268 blocked_33\VBN\1476483 cystic_34\JJ\1740 duct_35\NN\5248181 and_36\CC\1740 some_37\DT\1740 gall_38\NN\14253124 stones_39\NNS\19128 containing_40\VBG\2632940 calcium_41\NN\14625458 ._42\.\1740
D002784_D042882 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 octreotide_3\NN\1740 induced_4\VBD\1627355 gall_5\NN\14253124 stones_6\NNS\19128 are_7\VBP\836236 generally_8\RB\1740 small_9\JJ\1740 ,_10\,\1740 multiple_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 <e1>cholesterol</e1>_14\NN\15058310 rich_15\JJ\1740 although_16\IN\1740 ,_17\,\1740 in_18\IN\13603305 common_19\JJ\1740 with_20\IN\1740 spontaneous_21\JJ\1740 <e2>gall_22\NN\14253124 stone_23\NN\19128 disease</e2>_24\NN\14061805 ,_25\,\1740 at_26\IN\14622893 presentation_27\NN\1027379 some_28\DT\1740 patients_29\NNS\9898892 will_30\MD\5650329 have_31\VB\2108377 a_32\DT\13649268 blocked_33\VBN\1476483 cystic_34\JJ\1740 duct_35\NN\5248181 and_36\CC\1740 some_37\DT\1740 gall_38\NN\14253124 stones_39\NNS\19128 containing_40\VBG\2632940 calcium_41\NN\14625458 ._42\.\1740
D002784_D042882 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 octreotide_3\NN\1740 induced_4\VBD\1627355 gall_5\NN\14253124 stones_6\NNS\19128 are_7\VBP\836236 generally_8\RB\1740 small_9\JJ\1740 ,_10\,\1740 multiple_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 <e1>cholesterol</e1>_14\NN\15058310 rich_15\JJ\1740 although_16\IN\1740 ,_17\,\1740 in_18\IN\13603305 common_19\JJ\1740 with_20\IN\1740 spontaneous_21\JJ\1740 gall_22\NN\14253124 stone_23\NN\19128 disease_24\NN\14061805 ,_25\,\1740 at_26\IN\14622893 presentation_27\NN\1027379 some_28\DT\1740 patients_29\NNS\9898892 will_30\MD\5650329 have_31\VB\2108377 a_32\DT\13649268 blocked_33\VBN\1476483 cystic_34\JJ\1740 duct_35\NN\5248181 and_36\CC\1740 some_37\DT\1740 <e2>gall_38\NN\14253124 stones</e2>_39\NNS\19128 containing_40\VBG\2632940 calcium_41\NN\14625458 ._42\.\1740
D002118_D042882 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 octreotide_3\NN\1740 induced_4\VBD\1627355 <e2>gall_5\NN\14253124 stones</e2>_6\NNS\19128 are_7\VBP\836236 generally_8\RB\1740 small_9\JJ\1740 ,_10\,\1740 multiple_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 cholesterol_14\NN\15058310 rich_15\JJ\1740 although_16\IN\1740 ,_17\,\1740 in_18\IN\13603305 common_19\JJ\1740 with_20\IN\1740 spontaneous_21\JJ\1740 gall_22\NN\14253124 stone_23\NN\19128 disease_24\NN\14061805 ,_25\,\1740 at_26\IN\14622893 presentation_27\NN\1027379 some_28\DT\1740 patients_29\NNS\9898892 will_30\MD\5650329 have_31\VB\2108377 a_32\DT\13649268 blocked_33\VBN\1476483 cystic_34\JJ\1740 duct_35\NN\5248181 and_36\CC\1740 some_37\DT\1740 gall_38\NN\14253124 stones_39\NNS\19128 containing_40\VBG\2632940 <e1>calcium</e1>_41\NN\14625458 ._42\.\1740
D002118_D042882 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 octreotide_3\NN\1740 induced_4\VBD\1627355 gall_5\NN\14253124 stones_6\NNS\19128 are_7\VBP\836236 generally_8\RB\1740 small_9\JJ\1740 ,_10\,\1740 multiple_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 cholesterol_14\NN\15058310 rich_15\JJ\1740 although_16\IN\1740 ,_17\,\1740 in_18\IN\13603305 common_19\JJ\1740 with_20\IN\1740 spontaneous_21\JJ\1740 <e2>gall_22\NN\14253124 stone_23\NN\19128 disease</e2>_24\NN\14061805 ,_25\,\1740 at_26\IN\14622893 presentation_27\NN\1027379 some_28\DT\1740 patients_29\NNS\9898892 will_30\MD\5650329 have_31\VB\2108377 a_32\DT\13649268 blocked_33\VBN\1476483 cystic_34\JJ\1740 duct_35\NN\5248181 and_36\CC\1740 some_37\DT\1740 gall_38\NN\14253124 stones_39\NNS\19128 containing_40\VBG\2632940 <e1>calcium</e1>_41\NN\14625458 ._42\.\1740
D002118_D042882 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 octreotide_3\NN\1740 induced_4\VBD\1627355 gall_5\NN\14253124 stones_6\NNS\19128 are_7\VBP\836236 generally_8\RB\1740 small_9\JJ\1740 ,_10\,\1740 multiple_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 cholesterol_14\NN\15058310 rich_15\JJ\1740 although_16\IN\1740 ,_17\,\1740 in_18\IN\13603305 common_19\JJ\1740 with_20\IN\1740 spontaneous_21\JJ\1740 gall_22\NN\14253124 stone_23\NN\19128 disease_24\NN\14061805 ,_25\,\1740 at_26\IN\14622893 presentation_27\NN\1027379 some_28\DT\1740 patients_29\NNS\9898892 will_30\MD\5650329 have_31\VB\2108377 a_32\DT\13649268 blocked_33\VBN\1476483 cystic_34\JJ\1740 duct_35\NN\5248181 and_36\CC\1740 some_37\DT\1740 <e2>gall_38\NN\14253124 stones</e2>_39\NNS\19128 containing_40\VBG\2632940 <e1>calcium</e1>_41\NN\14625458 ._42\.\1740
9390208
D008942_D001943 NONE treatment_0\NN\654885 of_1\IN\1740 previously_2\RB\1740 treated_3\VBN\2376958 metastatic_4\JJ\1740 <e2>breast_5\NN\5225090 cancer</e2>_6\NN\14239425 by_7\IN\1740 <e1>mitoxantrone</e1>_8\NN\1740 and_9\CC\1740 48-hour_10\JJ\1740 continuous_11\JJ\1740 infusion_12\NN\14589223 of_13\IN\1740 high-dose_14\JJ\1740 5-fu_15\NN\1740 and_16\CC\1740 leucovorin_17\NN\1740 (_18\-LRB-\1740 mfl_19\NN\1740 ):_20\-RRB-\1740 low_21\JJ\1740 palliative_22\JJ\1740 benefit_23\NN\13278375 and_24\CC\1740 high_25\JJ\1740 treatment-related_26\JJ\1740 toxicity_27\NN\13576101 ._28\.\1740
D008942_D001943 NONE from_0\IN\1740 october_1\NNP\15209706 1993_2\CD\1740 to_3\IN\1740 november_4\NNP\15209706 1995_5\CD\1740 ,_6\,\1740 we_7\PRP\1740 treated_8\VBD\2376958 13_9\CD\13745420 patients_10\NNS\9898892 with_11\IN\1740 previously_12\RB\1740 chemotherapy-treated_13\JJ\1740 metastatic_14\JJ\1740 <e2>breast_15\NN\5225090 cancer</e2>_16\NN\14239425 by_17\IN\1740 <e1>mitoxantrone</e1>_18\NN\1740 ,_19\,\1740 12_20\CD\13745420 mg/m2_21\NN\1740 ,_22\,\1740 on_23\IN\1740 day_24\NN\15154774 1_25\CD\13741022 and_26\CC\1740 continuous_27\JJ\1740 infusion_28\NN\14589223 of_29\IN\1740 5-fu_30\NN\1740 ,_31\,\1740 3000_32\CD\1740 mg/m2_33\NN\1740 ,_34\,\1740 together_35\RB\1740 with_36\IN\1740 leucovorin_37\NN\1740 ,_38\,\1740 300_39\CD\1740 mg/m2_40\NN\1740 ,_41\,\1740 for_42\IN\1740 48_43\CD\1740 h_44\NN\14622893 from_45\IN\1740 day_46\NN\15154774 1_47\CD\13741022 to_48\TO\1740 2_49\CD\13741022 ._50\.\1740
D008942_D064420 NONE treatment_0\NN\654885 of_1\IN\1740 previously_2\RB\1740 treated_3\VBN\2376958 metastatic_4\JJ\1740 breast_5\NN\5225090 cancer_6\NN\14239425 by_7\IN\1740 <e1>mitoxantrone</e1>_8\NN\1740 and_9\CC\1740 48-hour_10\JJ\1740 continuous_11\JJ\1740 infusion_12\NN\14589223 of_13\IN\1740 high-dose_14\JJ\1740 5-fu_15\NN\1740 and_16\CC\1740 leucovorin_17\NN\1740 (_18\-LRB-\1740 mfl_19\NN\1740 ):_20\-RRB-\1740 low_21\JJ\1740 palliative_22\JJ\1740 benefit_23\NN\13278375 and_24\CC\1740 high_25\JJ\1740 treatment-related_26\JJ\1740 <e2>toxicity</e2>_27\NN\13576101 ._28\.\1740
D005472_D001943 NONE treatment_0\NN\654885 of_1\IN\1740 previously_2\RB\1740 treated_3\VBN\2376958 metastatic_4\JJ\1740 <e2>breast_5\NN\5225090 cancer</e2>_6\NN\14239425 by_7\IN\1740 mitoxantrone_8\NN\1740 and_9\CC\1740 48-hour_10\JJ\1740 continuous_11\JJ\1740 infusion_12\NN\14589223 of_13\IN\1740 high-dose_14\JJ\1740 <e1>5-fu</e1>_15\NN\1740 and_16\CC\1740 leucovorin_17\NN\1740 (_18\-LRB-\1740 mfl_19\NN\1740 ):_20\-RRB-\1740 low_21\JJ\1740 palliative_22\JJ\1740 benefit_23\NN\13278375 and_24\CC\1740 high_25\JJ\1740 treatment-related_26\JJ\1740 toxicity_27\NN\13576101 ._28\.\1740
D005472_D001943 NONE from_0\IN\1740 october_1\NNP\15209706 1993_2\CD\1740 to_3\IN\1740 november_4\NNP\15209706 1995_5\CD\1740 ,_6\,\1740 we_7\PRP\1740 treated_8\VBD\2376958 13_9\CD\13745420 patients_10\NNS\9898892 with_11\IN\1740 previously_12\RB\1740 chemotherapy-treated_13\JJ\1740 metastatic_14\JJ\1740 <e2>breast_15\NN\5225090 cancer</e2>_16\NN\14239425 by_17\IN\1740 mitoxantrone_18\NN\1740 ,_19\,\1740 12_20\CD\13745420 mg/m2_21\NN\1740 ,_22\,\1740 on_23\IN\1740 day_24\NN\15154774 1_25\CD\13741022 and_26\CC\1740 continuous_27\JJ\1740 infusion_28\NN\14589223 of_29\IN\1740 <e1>5-fu</e1>_30\NN\1740 ,_31\,\1740 3000_32\CD\1740 mg/m2_33\NN\1740 ,_34\,\1740 together_35\RB\1740 with_36\IN\1740 leucovorin_37\NN\1740 ,_38\,\1740 300_39\CD\1740 mg/m2_40\NN\1740 ,_41\,\1740 for_42\IN\1740 48_43\CD\1740 h_44\NN\14622893 from_45\IN\1740 day_46\NN\15154774 1_47\CD\13741022 to_48\TO\1740 2_49\CD\13741022 ._50\.\1740
D005472_D064420 NONE treatment_0\NN\654885 of_1\IN\1740 previously_2\RB\1740 treated_3\VBN\2376958 metastatic_4\JJ\1740 breast_5\NN\5225090 cancer_6\NN\14239425 by_7\IN\1740 mitoxantrone_8\NN\1740 and_9\CC\1740 48-hour_10\JJ\1740 continuous_11\JJ\1740 infusion_12\NN\14589223 of_13\IN\1740 high-dose_14\JJ\1740 <e1>5-fu</e1>_15\NN\1740 and_16\CC\1740 leucovorin_17\NN\1740 (_18\-LRB-\1740 mfl_19\NN\1740 ):_20\-RRB-\1740 low_21\JJ\1740 palliative_22\JJ\1740 benefit_23\NN\13278375 and_24\CC\1740 high_25\JJ\1740 treatment-related_26\JJ\1740 <e2>toxicity</e2>_27\NN\13576101 ._28\.\1740
D002955_D001943 NONE treatment_0\NN\654885 of_1\IN\1740 previously_2\RB\1740 treated_3\VBN\2376958 metastatic_4\JJ\1740 <e2>breast_5\NN\5225090 cancer</e2>_6\NN\14239425 by_7\IN\1740 mitoxantrone_8\NN\1740 and_9\CC\1740 48-hour_10\JJ\1740 continuous_11\JJ\1740 infusion_12\NN\14589223 of_13\IN\1740 high-dose_14\JJ\1740 5-fu_15\NN\1740 and_16\CC\1740 <e1>leucovorin</e1>_17\NN\1740 (_18\-LRB-\1740 mfl_19\NN\1740 ):_20\-RRB-\1740 low_21\JJ\1740 palliative_22\JJ\1740 benefit_23\NN\13278375 and_24\CC\1740 high_25\JJ\1740 treatment-related_26\JJ\1740 toxicity_27\NN\13576101 ._28\.\1740
D002955_D001943 NONE from_0\IN\1740 october_1\NNP\15209706 1993_2\CD\1740 to_3\IN\1740 november_4\NNP\15209706 1995_5\CD\1740 ,_6\,\1740 we_7\PRP\1740 treated_8\VBD\2376958 13_9\CD\13745420 patients_10\NNS\9898892 with_11\IN\1740 previously_12\RB\1740 chemotherapy-treated_13\JJ\1740 metastatic_14\JJ\1740 <e2>breast_15\NN\5225090 cancer</e2>_16\NN\14239425 by_17\IN\1740 mitoxantrone_18\NN\1740 ,_19\,\1740 12_20\CD\13745420 mg/m2_21\NN\1740 ,_22\,\1740 on_23\IN\1740 day_24\NN\15154774 1_25\CD\13741022 and_26\CC\1740 continuous_27\JJ\1740 infusion_28\NN\14589223 of_29\IN\1740 5-fu_30\NN\1740 ,_31\,\1740 3000_32\CD\1740 mg/m2_33\NN\1740 ,_34\,\1740 together_35\RB\1740 with_36\IN\1740 <e1>leucovorin</e1>_37\NN\1740 ,_38\,\1740 300_39\CD\1740 mg/m2_40\NN\1740 ,_41\,\1740 for_42\IN\1740 48_43\CD\1740 h_44\NN\14622893 from_45\IN\1740 day_46\NN\15154774 1_47\CD\13741022 to_48\TO\1740 2_49\CD\13741022 ._50\.\1740
D002955_D064420 NONE treatment_0\NN\654885 of_1\IN\1740 previously_2\RB\1740 treated_3\VBN\2376958 metastatic_4\JJ\1740 breast_5\NN\5225090 cancer_6\NN\14239425 by_7\IN\1740 mitoxantrone_8\NN\1740 and_9\CC\1740 48-hour_10\JJ\1740 continuous_11\JJ\1740 infusion_12\NN\14589223 of_13\IN\1740 high-dose_14\JJ\1740 5-fu_15\NN\1740 and_16\CC\1740 <e1>leucovorin</e1>_17\NN\1740 (_18\-LRB-\1740 mfl_19\NN\1740 ):_20\-RRB-\1740 low_21\JJ\1740 palliative_22\JJ\1740 benefit_23\NN\13278375 and_24\CC\1740 high_25\JJ\1740 treatment-related_26\JJ\1740 <e2>toxicity</e2>_27\NN\13576101 ._28\.\1740
C085788_D001943 NONE treatment_0\NN\654885 of_1\IN\1740 previously_2\RB\1740 treated_3\VBN\2376958 metastatic_4\JJ\1740 <e2>breast_5\NN\5225090 cancer</e2>_6\NN\14239425 by_7\IN\1740 mitoxantrone_8\NN\1740 and_9\CC\1740 48-hour_10\JJ\1740 continuous_11\JJ\1740 infusion_12\NN\14589223 of_13\IN\1740 high-dose_14\JJ\1740 5-fu_15\NN\1740 and_16\CC\1740 leucovorin_17\NN\1740 (_18\-LRB-\1740 <e1>mfl</e1>_19\NN\1740 ):_20\-RRB-\1740 low_21\JJ\1740 palliative_22\JJ\1740 benefit_23\NN\13278375 and_24\CC\1740 high_25\JJ\1740 treatment-related_26\JJ\1740 toxicity_27\NN\13576101 ._28\.\1740
C085788_D064420 NONE treatment_0\NN\654885 of_1\IN\1740 previously_2\RB\1740 treated_3\VBN\2376958 metastatic_4\JJ\1740 breast_5\NN\5225090 cancer_6\NN\14239425 by_7\IN\1740 mitoxantrone_8\NN\1740 and_9\CC\1740 48-hour_10\JJ\1740 continuous_11\JJ\1740 infusion_12\NN\14589223 of_13\IN\1740 high-dose_14\JJ\1740 5-fu_15\NN\1740 and_16\CC\1740 leucovorin_17\NN\1740 (_18\-LRB-\1740 <e1>mfl</e1>_19\NN\1740 ):_20\-RRB-\1740 low_21\JJ\1740 palliative_22\JJ\1740 benefit_23\NN\13278375 and_24\CC\1740 high_25\JJ\1740 treatment-related_26\JJ\1740 <e2>toxicity</e2>_27\NN\13576101 ._28\.\1740
C085788_D064420 NONE the_0\DT\1740 <e1>mfl_1\NNP\1740 regimen</e1>_2\NN\5898568 achieves_3\VBZ\2524171 little_4\JJ\1740 palliative_5\JJ\1740 benefit_6\NN\13278375 and_7\CC\1740 induces_8\VBZ\1627355 severe_9\JJ\1740 <e2>toxicity</e2>_10\NN\13576101 at_11\IN\14622893 a_12\DT\13649268 fairly_13\RB\1740 high_14\JJ\1740 rate_15\NN\13815152 ._16\.\1740
7088431
D004054_D018262 CID development_0\NN\248977 of_1\IN\1740 <e2>clear_2\JJ\1740 cell_3\NN\3080309 adenocarcinoma</e2>_4\NN\14242337 in_5\IN\13603305 <e1>des-exposed</e1>_6\JJ\1740 offspring_7\NN\10235549 under_8\IN\1740 observation_9\NN\996969 ._10\.\1740
D004054_D018262 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e2>clear_3\JJ\1740 cell_4\NN\3080309 adenocarcinoma_5\NN\14242337 of_6\IN\1740 the_7\DT\1740 vagina</e2>_8\NN\5250659 detected_9\VBN\2163746 at_10\IN\14622893 follow-up_11\NN\4599396 in_12\IN\13603305 young_13\JJ\1740 women_14\NNS\9605289 exposed_15\VBN\2110927 in_16\IN\13603305 utero_17\NN\1740 to_18\TO\1740 <e1>diethylstilbestrol</e1>_19\NN\14749794 are_20\VBP\836236 reported_21\VBN\831651 ._22\.\1740
D004054_D014625 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e2>clear_3\JJ\1740 cell_4\NN\3080309 adenocarcinoma_5\NN\14242337 of_6\IN\1740 the_7\DT\1740 vagina</e2>_8\NN\5250659 detected_9\VBN\2163746 at_10\IN\14622893 follow-up_11\NN\4599396 in_12\IN\13603305 young_13\JJ\1740 women_14\NNS\9605289 exposed_15\VBN\2110927 in_16\IN\13603305 utero_17\NN\1740 to_18\TO\1740 <e1>diethylstilbestrol</e1>_19\NN\14749794 are_20\VBP\836236 reported_21\VBN\831651 ._22\.\1740
18417364
D009538_D009759 CID <e1>nicotine-induced</e1>_0\JJ\1740 <e2>nystagmus</e2>_1\NN\337486 correlates_2\VBZ\2657219 with_3\IN\1740 midpontine_4\NN\1740 activation_5\NN\13561719 ._6\.\1740
D009538_D009759 CID the_0\DT\1740 pathomechanism_1\NN\1740 of_2\IN\1740 <e1>nicotine-induced</e1>_3\JJ\1740 <e2>nystagmus</e2>_4\NN\337486 (_5\-LRB-\1740 nin_6\NN\1740 )_7\-RRB-\1740 is_8\VBZ\836236 unknown_9\JJ\1740 ._10\.\1740
D009538_D009759 CID the_0\DT\1740 pathomechanism_1\NN\1740 of_2\IN\1740 <e1>nicotine-induced</e1>_3\JJ\1740 nystagmus_4\NN\337486 (_5\-LRB-\1740 <e2>nin</e2>_6\NN\1740 )_7\-RRB-\1740 is_8\VBZ\836236 unknown_9\JJ\1740 ._10\.\1740
D010100_D009759 NONE <e2>nin</e2>_0\NN\1740 correlated_1\VBD\2657219 with_2\IN\1740 blood_3\NN\5397468 <e1>oxygen</e1>_4\NN\14622893 level-dependent_5\JJ\1740 (_6\-LRB-\1740 bold_7\NN\6825399 )_8\-RRB-\1740 activity_9\NN\30358 levels_10\NNS\4916342 in_11\IN\13603305 a_12\DT\13649268 midpontine_13\NN\1740 site_14\NN\8673395 in_15\IN\13603305 the_16\DT\1740 posterior_17\JJ\1740 basis_18\NN\13790712 pontis_19\NN\1740 ._20\.\1740
9869257
C087567_D000647 NONE in_0\IN\13603305 the_1\DT\1740 mouse_2\NN\2329401 passive-avoidance_3\NN\1740 test_4\NN\5798043 ,_5\,\1740 <e1>pg-9</e1>_6\NN\1740 (_7\-LRB-\1740 10_8\CD\13745420 -_9\SYM\1740 30_10\CD\13745420 mg/kg_11\NN\1740 ,_12\,\1740 i.p._13\RB\1740 )_14\-RRB-\1740 ,_15\,\1740 administered_16\VBN\2436349 20_17\CD\13745420 min_18\NN\15154774 before_19\IN\1740 the_20\DT\1740 training_21\NN\407535 session_22\NN\7142566 ,_23\,\1740 prevented_24\VBD\1740 <e2>amnesia</e2>_25\NN\5669934 induced_26\VBN\1627355 by_27\IN\1740 both_28\CC\1740 the_29\DT\1740 non_30\RB\1740 selective_31\JJ\1740 antimuscarinic_32\JJ\1740 drug_33\NN\14778436 scopolamine_34\NN\14712692 and_35\CC\1740 the_36\DT\1740 m1-selective_37\JJ\1740 antagonist_38\NN\7846 s-(-)-et-126_39\NNS\1740 ._40\.\1740
C087567_D000647 NONE in_0\IN\13603305 the_1\DT\1740 same_2\JJ\1740 experimental_3\JJ\1740 conditions_4\NNS\14512817 ,_5\,\1740 <e1>pg-9</e1>_6\NN\1740 (_7\-LRB-\1740 5_8\CD\13741022 -_9\SYM\1740 20_10\CD\13745420 microg_11\NN\1740 per_12\IN\1740 mouse_13\NN\2329401 ,_14\,\1740 i.c.v._15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 also_18\RB\1740 able_19\JJ\1740 to_20\TO\1740 prevent_21\VB\1740 antimuscarine-induced_22\JJ\1740 <e2>amnesia</e2>_23\NN\5669934 ,_24\,\1740 demonstrating_25\VBG\2137132 a_26\DT\13649268 central_27\JJ\1740 localization_28\NN\151497 of_29\IN\1740 the_30\DT\1740 activity_31\NN\30358 ._32\.\1740
D012601_D000647 CID in_0\IN\13603305 the_1\DT\1740 mouse_2\NN\2329401 passive-avoidance_3\NN\1740 test_4\NN\5798043 ,_5\,\1740 pg-9_6\NN\1740 (_7\-LRB-\1740 10_8\CD\13745420 -_9\SYM\1740 30_10\CD\13745420 mg/kg_11\NN\1740 ,_12\,\1740 i.p._13\RB\1740 )_14\-RRB-\1740 ,_15\,\1740 administered_16\VBN\2436349 20_17\CD\13745420 min_18\NN\15154774 before_19\IN\1740 the_20\DT\1740 training_21\NN\407535 session_22\NN\7142566 ,_23\,\1740 prevented_24\VBD\1740 <e2>amnesia</e2>_25\NN\5669934 induced_26\VBN\1627355 by_27\IN\1740 both_28\CC\1740 the_29\DT\1740 non_30\RB\1740 selective_31\JJ\1740 antimuscarinic_32\JJ\1740 drug_33\NN\14778436 <e1>scopolamine</e1>_34\NN\14712692 and_35\CC\1740 the_36\DT\1740 m1-selective_37\JJ\1740 antagonist_38\NN\7846 s-(-)-et-126_39\NNS\1740 ._40\.\1740
C098725_D000647 CID in_0\IN\13603305 the_1\DT\1740 mouse_2\NN\2329401 passive-avoidance_3\NN\1740 test_4\NN\5798043 ,_5\,\1740 pg-9_6\NN\1740 (_7\-LRB-\1740 10_8\CD\13745420 -_9\SYM\1740 30_10\CD\13745420 mg/kg_11\NN\1740 ,_12\,\1740 i.p._13\RB\1740 )_14\-RRB-\1740 ,_15\,\1740 administered_16\VBN\2436349 20_17\CD\13745420 min_18\NN\15154774 before_19\IN\1740 the_20\DT\1740 training_21\NN\407535 session_22\NN\7142566 ,_23\,\1740 prevented_24\VBD\1740 <e2>amnesia</e2>_25\NN\5669934 induced_26\VBN\1627355 by_27\IN\1740 both_28\CC\1740 the_29\DT\1740 non_30\RB\1740 selective_31\JJ\1740 antimuscarinic_32\JJ\1740 drug_33\NN\14778436 scopolamine_34\NN\14712692 and_35\CC\1740 the_36\DT\1740 m1-selective_37\JJ\1740 antagonist_38\NN\7846 <e1>s-(-)-et-126</e1>_39\NNS\1740 ._40\.\1740
3015567
D009599_D007022 CID <e1>nitroprusside-induced</e1>_0\JJ\1740 <e2>hypotension</e2>_1\NN\14057371 evokes_2\VBZ\1617192 acth_3\NN\5407119 secretion_4\NN\13526110 which_5\WDT\1740 is_6\VBZ\836236 primarily_7\RB\1740 mediated_8\VBN\761713 by_9\IN\1740 enhanced_10\VBN\227165 secretion_11\NN\13526110 of_12\IN\1740 immunoreactive_13\JJ\1740 corticotropin-releasing_14\JJ\1740 factor_15\NN\7326557 (_16\-LRB-\1740 ircrf_17\NN\1740 )_18\-RRB-\1740 into_19\IN\1740 the_20\DT\1740 hypophysial-portal_21\JJ\1740 circulation_22\NN\6253140 ._23\.\1740
D009599_D007022 CID suppression_0\NN\13489037 of_1\IN\1740 ircrf_2\NN\1740 secretion_3\NN\13526110 in_4\IN\13603305 response_5\NN\11410625 to_6\TO\1740 <e1>nitroprusside-induced</e1>_7\JJ\1740 <e2>hypotension</e2>_8\NN\14057371 is_9\VBZ\836236 observed_10\VBN\2163746 and_11\CC\1740 occurs_12\VBZ\2623529 at_13\IN\14622893 a_14\DT\13649268 plasma_15\NN\5398023 corticosterone_16\NN\14752057 level_17\NN\4916342 between_18\IN\1740 8_19\CD\13741022 -_20\SYM\1740 12_21\CD\13745420 micrograms/dl_22\NN\1740 ._23\.\1740
D003345_D007022 NONE suppression_0\NN\13489037 of_1\IN\1740 ircrf_2\NN\1740 secretion_3\NN\13526110 in_4\IN\13603305 response_5\NN\11410625 to_6\TO\1740 nitroprusside-induced_7\JJ\1740 <e2>hypotension</e2>_8\NN\14057371 is_9\VBZ\836236 observed_10\VBN\2163746 and_11\CC\1740 occurs_12\VBZ\2623529 at_13\IN\14622893 a_14\DT\13649268 plasma_15\NN\5398023 <e1>corticosterone</e1>_16\NN\14752057 level_17\NN\4916342 between_18\IN\1740 8_19\CD\13741022 -_20\SYM\1740 12_21\CD\13745420 micrograms/dl_22\NN\1740 ._23\.\1740
8739323
D008466_D007674 NONE the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 action_2\NN\30358 of_3\IN\1740 anticancer_4\NN\1740 drugs_5\NNS\14778436 such_6\JJ\1740 as_7\IN\14622893 <e1>nitrogranulogen</e1>_8\NN\1740 (_9\-LRB-\1740 ng_10\NN\13717155 )_11\-RRB-\1740 ,_12\,\1740 methotrexate_13\VBP\1740 (_14\-LRB-\1740 mtx_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 cyclophosphamide_23\NN\1740 (_24\-LRB-\1740 cy_25\NN\1740 )_26\-RRB-\1740 administered_27\VBN\2436349 alone_28\RB\1740 or_29\CC\3541091 in_30\IN\13603305 combination_31\NN\7951464 [_32\-LRB-\1740 mtx_33\NN\1740 +_34\CC\1740 5-fu_35\NN\1740 +_36\CC\1740 cy_37\NN\1740 (_38\-LRB-\1740 cmf_39\NN\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 was_42\VBD\836236 evaluated_43\VBN\670261 in_44\IN\13603305 experiments_45\NNS\641820 on_46\IN\1740 wistar_47\NNP\1740 rats_48\NNS\2329401 ._49\.\1740
D008466_D007674 NONE the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 action_2\NN\30358 of_3\IN\1740 anticancer_4\NN\1740 drugs_5\NNS\14778436 such_6\JJ\1740 as_7\IN\14622893 nitrogranulogen_8\NN\1740 (_9\-LRB-\1740 <e1>ng</e1>_10\NN\13717155 )_11\-RRB-\1740 ,_12\,\1740 methotrexate_13\VBP\1740 (_14\-LRB-\1740 mtx_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 cyclophosphamide_23\NN\1740 (_24\-LRB-\1740 cy_25\NN\1740 )_26\-RRB-\1740 administered_27\VBN\2436349 alone_28\RB\1740 or_29\CC\3541091 in_30\IN\13603305 combination_31\NN\7951464 [_32\-LRB-\1740 mtx_33\NN\1740 +_34\CC\1740 5-fu_35\NN\1740 +_36\CC\1740 cy_37\NN\1740 (_38\-LRB-\1740 cmf_39\NN\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 was_42\VBD\836236 evaluated_43\VBN\670261 in_44\IN\13603305 experiments_45\NNS\641820 on_46\IN\1740 wistar_47\NNP\1740 rats_48\NNS\2329401 ._49\.\1740
D008727_D007674 NONE the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 action_2\NN\30358 of_3\IN\1740 anticancer_4\NN\1740 drugs_5\NNS\14778436 such_6\JJ\1740 as_7\IN\14622893 nitrogranulogen_8\NN\1740 (_9\-LRB-\1740 ng_10\NN\13717155 )_11\-RRB-\1740 ,_12\,\1740 <e1>methotrexate</e1>_13\VBP\1740 (_14\-LRB-\1740 mtx_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 cyclophosphamide_23\NN\1740 (_24\-LRB-\1740 cy_25\NN\1740 )_26\-RRB-\1740 administered_27\VBN\2436349 alone_28\RB\1740 or_29\CC\3541091 in_30\IN\13603305 combination_31\NN\7951464 [_32\-LRB-\1740 mtx_33\NN\1740 +_34\CC\1740 5-fu_35\NN\1740 +_36\CC\1740 cy_37\NN\1740 (_38\-LRB-\1740 cmf_39\NN\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 was_42\VBD\836236 evaluated_43\VBN\670261 in_44\IN\13603305 experiments_45\NNS\641820 on_46\IN\1740 wistar_47\NNP\1740 rats_48\NNS\2329401 ._49\.\1740
D008727_D007674 NONE the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 action_2\NN\30358 of_3\IN\1740 anticancer_4\NN\1740 drugs_5\NNS\14778436 such_6\JJ\1740 as_7\IN\14622893 nitrogranulogen_8\NN\1740 (_9\-LRB-\1740 ng_10\NN\13717155 )_11\-RRB-\1740 ,_12\,\1740 methotrexate_13\VBP\1740 (_14\-LRB-\1740 <e1>mtx</e1>_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 cyclophosphamide_23\NN\1740 (_24\-LRB-\1740 cy_25\NN\1740 )_26\-RRB-\1740 administered_27\VBN\2436349 alone_28\RB\1740 or_29\CC\3541091 in_30\IN\13603305 combination_31\NN\7951464 [_32\-LRB-\1740 mtx_33\NN\1740 +_34\CC\1740 5-fu_35\NN\1740 +_36\CC\1740 cy_37\NN\1740 (_38\-LRB-\1740 cmf_39\NN\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 was_42\VBD\836236 evaluated_43\VBN\670261 in_44\IN\13603305 experiments_45\NNS\641820 on_46\IN\1740 wistar_47\NNP\1740 rats_48\NNS\2329401 ._49\.\1740
D008727_D007674 NONE the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 action_2\NN\30358 of_3\IN\1740 anticancer_4\NN\1740 drugs_5\NNS\14778436 such_6\JJ\1740 as_7\IN\14622893 nitrogranulogen_8\NN\1740 (_9\-LRB-\1740 ng_10\NN\13717155 )_11\-RRB-\1740 ,_12\,\1740 methotrexate_13\VBP\1740 (_14\-LRB-\1740 mtx_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 cyclophosphamide_23\NN\1740 (_24\-LRB-\1740 cy_25\NN\1740 )_26\-RRB-\1740 administered_27\VBN\2436349 alone_28\RB\1740 or_29\CC\3541091 in_30\IN\13603305 combination_31\NN\7951464 [_32\-LRB-\1740 <e1>mtx</e1>_33\NN\1740 +_34\CC\1740 5-fu_35\NN\1740 +_36\CC\1740 cy_37\NN\1740 (_38\-LRB-\1740 cmf_39\NN\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 was_42\VBD\836236 evaluated_43\VBN\670261 in_44\IN\13603305 experiments_45\NNS\641820 on_46\IN\1740 wistar_47\NNP\1740 rats_48\NNS\2329401 ._49\.\1740
D008727_D007674 NONE our_0\PRP$\1740 studies_1\NNS\635850 indicate_2\VBP\952524 that_3\IN\1740 <e2>nephrotoxicity</e2>_4\NN\1740 of_5\IN\1740 <e1>mtx</e1>_6\NN\1740 +_7\CC\1740 5-fu_8\NN\1740 +_9\CC\1740 cy_10\NN\1740 administered_11\VBN\2436349 jointly_12\RB\1740 is_13\VBZ\836236 lower_14\JJR\1740 than_15\IN\1740 in_16\IN\13603305 monotherapy_17\NN\1740 ._18\.\1740
D005472_D007674 NONE the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 action_2\NN\30358 of_3\IN\1740 anticancer_4\NN\1740 drugs_5\NNS\14778436 such_6\JJ\1740 as_7\IN\14622893 nitrogranulogen_8\NN\1740 (_9\-LRB-\1740 ng_10\NN\13717155 )_11\-RRB-\1740 ,_12\,\1740 methotrexate_13\VBP\1740 (_14\-LRB-\1740 mtx_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 <e1>5-fluorouracil</e1>_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 cyclophosphamide_23\NN\1740 (_24\-LRB-\1740 cy_25\NN\1740 )_26\-RRB-\1740 administered_27\VBN\2436349 alone_28\RB\1740 or_29\CC\3541091 in_30\IN\13603305 combination_31\NN\7951464 [_32\-LRB-\1740 mtx_33\NN\1740 +_34\CC\1740 5-fu_35\NN\1740 +_36\CC\1740 cy_37\NN\1740 (_38\-LRB-\1740 cmf_39\NN\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 was_42\VBD\836236 evaluated_43\VBN\670261 in_44\IN\13603305 experiments_45\NNS\641820 on_46\IN\1740 wistar_47\NNP\1740 rats_48\NNS\2329401 ._49\.\1740
D005472_D007674 NONE the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 action_2\NN\30358 of_3\IN\1740 anticancer_4\NN\1740 drugs_5\NNS\14778436 such_6\JJ\1740 as_7\IN\14622893 nitrogranulogen_8\NN\1740 (_9\-LRB-\1740 ng_10\NN\13717155 )_11\-RRB-\1740 ,_12\,\1740 methotrexate_13\VBP\1740 (_14\-LRB-\1740 mtx_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 <e1>5-fu</e1>_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 cyclophosphamide_23\NN\1740 (_24\-LRB-\1740 cy_25\NN\1740 )_26\-RRB-\1740 administered_27\VBN\2436349 alone_28\RB\1740 or_29\CC\3541091 in_30\IN\13603305 combination_31\NN\7951464 [_32\-LRB-\1740 mtx_33\NN\1740 +_34\CC\1740 5-fu_35\NN\1740 +_36\CC\1740 cy_37\NN\1740 (_38\-LRB-\1740 cmf_39\NN\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 was_42\VBD\836236 evaluated_43\VBN\670261 in_44\IN\13603305 experiments_45\NNS\641820 on_46\IN\1740 wistar_47\NNP\1740 rats_48\NNS\2329401 ._49\.\1740
D005472_D007674 NONE the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 action_2\NN\30358 of_3\IN\1740 anticancer_4\NN\1740 drugs_5\NNS\14778436 such_6\JJ\1740 as_7\IN\14622893 nitrogranulogen_8\NN\1740 (_9\-LRB-\1740 ng_10\NN\13717155 )_11\-RRB-\1740 ,_12\,\1740 methotrexate_13\VBP\1740 (_14\-LRB-\1740 mtx_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 cyclophosphamide_23\NN\1740 (_24\-LRB-\1740 cy_25\NN\1740 )_26\-RRB-\1740 administered_27\VBN\2436349 alone_28\RB\1740 or_29\CC\3541091 in_30\IN\13603305 combination_31\NN\7951464 [_32\-LRB-\1740 mtx_33\NN\1740 +_34\CC\1740 <e1>5-fu</e1>_35\NN\1740 +_36\CC\1740 cy_37\NN\1740 (_38\-LRB-\1740 cmf_39\NN\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 was_42\VBD\836236 evaluated_43\VBN\670261 in_44\IN\13603305 experiments_45\NNS\641820 on_46\IN\1740 wistar_47\NNP\1740 rats_48\NNS\2329401 ._49\.\1740
D005472_D007674 NONE our_0\PRP$\1740 studies_1\NNS\635850 indicate_2\VBP\952524 that_3\IN\1740 <e2>nephrotoxicity</e2>_4\NN\1740 of_5\IN\1740 mtx_6\NN\1740 +_7\CC\1740 <e1>5-fu</e1>_8\NN\1740 +_9\CC\1740 cy_10\NN\1740 administered_11\VBN\2436349 jointly_12\RB\1740 is_13\VBZ\836236 lower_14\JJR\1740 than_15\IN\1740 in_16\IN\13603305 monotherapy_17\NN\1740 ._18\.\1740
D003520_D007674 NONE the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 action_2\NN\30358 of_3\IN\1740 anticancer_4\NN\1740 drugs_5\NNS\14778436 such_6\JJ\1740 as_7\IN\14622893 nitrogranulogen_8\NN\1740 (_9\-LRB-\1740 ng_10\NN\13717155 )_11\-RRB-\1740 ,_12\,\1740 methotrexate_13\VBP\1740 (_14\-LRB-\1740 mtx_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 <e1>cyclophosphamide</e1>_23\NN\1740 (_24\-LRB-\1740 cy_25\NN\1740 )_26\-RRB-\1740 administered_27\VBN\2436349 alone_28\RB\1740 or_29\CC\3541091 in_30\IN\13603305 combination_31\NN\7951464 [_32\-LRB-\1740 mtx_33\NN\1740 +_34\CC\1740 5-fu_35\NN\1740 +_36\CC\1740 cy_37\NN\1740 (_38\-LRB-\1740 cmf_39\NN\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 was_42\VBD\836236 evaluated_43\VBN\670261 in_44\IN\13603305 experiments_45\NNS\641820 on_46\IN\1740 wistar_47\NNP\1740 rats_48\NNS\2329401 ._49\.\1740
D003520_D007674 NONE the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 action_2\NN\30358 of_3\IN\1740 anticancer_4\NN\1740 drugs_5\NNS\14778436 such_6\JJ\1740 as_7\IN\14622893 nitrogranulogen_8\NN\1740 (_9\-LRB-\1740 ng_10\NN\13717155 )_11\-RRB-\1740 ,_12\,\1740 methotrexate_13\VBP\1740 (_14\-LRB-\1740 mtx_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 cyclophosphamide_23\NN\1740 (_24\-LRB-\1740 <e1>cy</e1>_25\NN\1740 )_26\-RRB-\1740 administered_27\VBN\2436349 alone_28\RB\1740 or_29\CC\3541091 in_30\IN\13603305 combination_31\NN\7951464 [_32\-LRB-\1740 mtx_33\NN\1740 +_34\CC\1740 5-fu_35\NN\1740 +_36\CC\1740 cy_37\NN\1740 (_38\-LRB-\1740 cmf_39\NN\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 was_42\VBD\836236 evaluated_43\VBN\670261 in_44\IN\13603305 experiments_45\NNS\641820 on_46\IN\1740 wistar_47\NNP\1740 rats_48\NNS\2329401 ._49\.\1740
D003520_D007674 NONE the_0\DT\1740 <e2>nephrotoxic</e2>_1\JJ\1740 action_2\NN\30358 of_3\IN\1740 anticancer_4\NN\1740 drugs_5\NNS\14778436 such_6\JJ\1740 as_7\IN\14622893 nitrogranulogen_8\NN\1740 (_9\-LRB-\1740 ng_10\NN\13717155 )_11\-RRB-\1740 ,_12\,\1740 methotrexate_13\VBP\1740 (_14\-LRB-\1740 mtx_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 cyclophosphamide_23\NN\1740 (_24\-LRB-\1740 cy_25\NN\1740 )_26\-RRB-\1740 administered_27\VBN\2436349 alone_28\RB\1740 or_29\CC\3541091 in_30\IN\13603305 combination_31\NN\7951464 [_32\-LRB-\1740 mtx_33\NN\1740 +_34\CC\1740 5-fu_35\NN\1740 +_36\CC\1740 <e1>cy</e1>_37\NN\1740 (_38\-LRB-\1740 cmf_39\NN\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 was_42\VBD\836236 evaluated_43\VBN\670261 in_44\IN\13603305 experiments_45\NNS\641820 on_46\IN\1740 wistar_47\NNP\1740 rats_48\NNS\2329401 ._49\.\1740
D003520_D007674 NONE our_0\PRP$\1740 studies_1\NNS\635850 indicate_2\VBP\952524 that_3\IN\1740 <e2>nephrotoxicity</e2>_4\NN\1740 of_5\IN\1740 mtx_6\NN\1740 +_7\CC\1740 5-fu_8\NN\1740 +_9\CC\1740 <e1>cy</e1>_10\NN\1740 administered_11\VBN\2436349 jointly_12\RB\1740 is_13\VBZ\836236 lower_14\JJR\1740 than_15\IN\1740 in_16\IN\13603305 monotherapy_17\NN\1740 ._18\.\1740
D003520_D006470 CID <e1>cy</e1>_0\NNP\1740 caused_1\VBD\1617192 <e2>hemorrhagic_2\JJ\1740 cystitis</e2>_3\NN\14566129 in_4\IN\13603305 40_5\CD\13745420 %_6\NN\1740 of_7\IN\1740 rats_8\NNS\2329401 ,_9\,\1740 but_10\CC\1740 it_11\PRP\6125041 did_12\VBD\1640855 not_13\RB\1740 cause_14\VB\1617192 this_15\DT\1740 complication_16\NN\1073995 when_17\WRB\1740 combined_18\VBN\2630189 with_19\IN\1740 5-fu_20\NN\1740 and_21\CC\1740 mtx_22\NN\1740 ._23\.\1740
D003520_D003556 CID <e1>cy</e1>_0\NNP\1740 caused_1\VBD\1617192 <e2>hemorrhagic_2\JJ\1740 cystitis</e2>_3\NN\14566129 in_4\IN\13603305 40_5\CD\13745420 %_6\NN\1740 of_7\IN\1740 rats_8\NNS\2329401 ,_9\,\1740 but_10\CC\1740 it_11\PRP\6125041 did_12\VBD\1640855 not_13\RB\1740 cause_14\VB\1617192 this_15\DT\1740 complication_16\NN\1073995 when_17\WRB\1740 combined_18\VBN\2630189 with_19\IN\1740 5-fu_20\NN\1740 and_21\CC\1740 mtx_22\NN\1740 ._23\.\1740
D005472_D006470 NONE cy_0\NNP\1740 caused_1\VBD\1617192 <e2>hemorrhagic_2\JJ\1740 cystitis</e2>_3\NN\14566129 in_4\IN\13603305 40_5\CD\13745420 %_6\NN\1740 of_7\IN\1740 rats_8\NNS\2329401 ,_9\,\1740 but_10\CC\1740 it_11\PRP\6125041 did_12\VBD\1640855 not_13\RB\1740 cause_14\VB\1617192 this_15\DT\1740 complication_16\NN\1073995 when_17\WRB\1740 combined_18\VBN\2630189 with_19\IN\1740 <e1>5-fu</e1>_20\NN\1740 and_21\CC\1740 mtx_22\NN\1740 ._23\.\1740
D005472_D003556 NONE cy_0\NNP\1740 caused_1\VBD\1617192 <e2>hemorrhagic_2\JJ\1740 cystitis</e2>_3\NN\14566129 in_4\IN\13603305 40_5\CD\13745420 %_6\NN\1740 of_7\IN\1740 rats_8\NNS\2329401 ,_9\,\1740 but_10\CC\1740 it_11\PRP\6125041 did_12\VBD\1640855 not_13\RB\1740 cause_14\VB\1617192 this_15\DT\1740 complication_16\NN\1073995 when_17\WRB\1740 combined_18\VBN\2630189 with_19\IN\1740 <e1>5-fu</e1>_20\NN\1740 and_21\CC\1740 mtx_22\NN\1740 ._23\.\1740
D008727_D006470 NONE cy_0\NNP\1740 caused_1\VBD\1617192 <e2>hemorrhagic_2\JJ\1740 cystitis</e2>_3\NN\14566129 in_4\IN\13603305 40_5\CD\13745420 %_6\NN\1740 of_7\IN\1740 rats_8\NNS\2329401 ,_9\,\1740 but_10\CC\1740 it_11\PRP\6125041 did_12\VBD\1640855 not_13\RB\1740 cause_14\VB\1617192 this_15\DT\1740 complication_16\NN\1073995 when_17\WRB\1740 combined_18\VBN\2630189 with_19\IN\1740 5-fu_20\NN\1740 and_21\CC\1740 <e1>mtx</e1>_22\NN\1740 ._23\.\1740
D008727_D003556 NONE cy_0\NNP\1740 caused_1\VBD\1617192 <e2>hemorrhagic_2\JJ\1740 cystitis</e2>_3\NN\14566129 in_4\IN\13603305 40_5\CD\13745420 %_6\NN\1740 of_7\IN\1740 rats_8\NNS\2329401 ,_9\,\1740 but_10\CC\1740 it_11\PRP\6125041 did_12\VBD\1640855 not_13\RB\1740 cause_14\VB\1617192 this_15\DT\1740 complication_16\NN\1073995 when_17\WRB\1740 combined_18\VBN\2630189 with_19\IN\1740 5-fu_20\NN\1740 and_21\CC\1740 <e1>mtx</e1>_22\NN\1740 ._23\.\1740
20880751
D007980_D004409 CID <e1>levodopa-induced</e1>_0\JJ\1740 <e2>dyskinesias</e2>_1\NNS\14084880 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 parkinson_5\NN\1740 's_6\POS\1740 disease_7\NN\14061805 :_8\:\1740 filling_9\VBG\126264 the_10\DT\1740 bench-to-bedside_11\JJ\1740 gap_12\NN\4752530 ._13\.\1740
D007980_D004409 CID although_0\IN\1740 preclinical_1\JJ\1740 and_2\CC\1740 clinical_3\JJ\1740 findings_4\NNS\7951464 suggest_5\VBP\1010118 pulsatile_6\JJ\1740 stimulation_7\NN\242808 of_8\IN\1740 striatal_9\JJ\1740 postsynaptic_10\JJ\1740 receptors_11\NNS\5225602 as_12\IN\14622893 a_13\DT\13649268 key_14\JJ\1740 mechanism_15\NN\13446390 underlying_16\VBG\2604760 <e1>levodopa-induced</e1>_17\JJ\1740 <e2>dyskinesias</e2>_18\NNS\14084880 ,_19\,\1740 their_20\PRP$\1740 pathogenesis_21\NN\13533470 is_22\VBZ\836236 still_23\RB\1740 unclear_24\JJ\1740 ._25\.\1740
D007980_D004409 CID recent_0\JJ\1740 preclinical_1\JJ\1740 and_2\CC\1740 clinical_3\JJ\1740 data_4\NNS\7951464 from_5\IN\1740 promising_6\JJ\1740 lines_7\NNS\8426461 of_8\IN\1740 research_9\NN\633864 focus_10\NN\5704266 on_11\IN\1740 the_12\DT\1740 differential_13\JJ\1740 role_14\NN\719494 of_15\IN\1740 presynaptic_16\JJ\1740 versus_17\CC\1740 postsynaptic_18\JJ\1740 mechanisms_19\NNS\13446390 ,_20\,\1740 dopamine_21\NN\14807737 receptor_22\NN\5225602 subtypes_23\NNS\1740 ,_24\,\1740 ionotropic_25\JJ\1740 and_26\CC\1740 metabotropic_27\NN\1740 glutamate_28\NN\15010703 receptors_29\NNS\5225602 ,_30\,\1740 and_31\CC\1740 non-dopaminergic_32\JJ\1740 neurotransmitter_33\NN\14807410 systems_34\NNS\3575240 in_35\IN\13603305 the_36\DT\1740 pathophysiology_37\NN\1740 of_38\IN\1740 <e1>levodopa-induced</e1>_39\JJ\1740 <e2>dyskinesias</e2>_40\NNS\14084880 ._41\.\1740
D007980_D010300 NONE <e1>levodopa-induced</e1>_0\JJ\1740 dyskinesias_1\NNS\14084880 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 <e2>parkinson_5\NN\1740 's_6\POS\1740 disease</e2>_7\NN\14061805 :_8\:\1740 filling_9\VBG\126264 the_10\DT\1740 bench-to-bedside_11\JJ\1740 gap_12\NN\4752530 ._13\.\1740
D007980_D010300 NONE <e1>levodopa</e1>_0\NN\14604959 is_1\VBZ\836236 the_2\DT\1740 most_3\RBS\1740 effective_4\JJ\1740 drug_5\NN\14778436 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 <e2>parkinson_10\NN\1740 's_11\POS\1740 disease</e2>_12\NN\14061805 ._13\.\1740
D004298_D004409 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 long-term_3\JJ\1740 use_4\NN\407535 of_5\IN\1740 this_6\DT\1740 <e1>dopamine</e1>_7\NN\14807737 precursor_8\NN\14580897 is_9\VBZ\836236 complicated_10\VBN\126264 by_11\IN\1740 highly_12\RB\1740 disabling_13\VBG\126264 fluctuations_14\NNS\7345593 and_15\CC\1740 <e2>dyskinesias</e2>_16\NNS\14084880 ._17\.\1740
D004298_D004409 NONE recent_0\JJ\1740 preclinical_1\JJ\1740 and_2\CC\1740 clinical_3\JJ\1740 data_4\NNS\7951464 from_5\IN\1740 promising_6\JJ\1740 lines_7\NNS\8426461 of_8\IN\1740 research_9\NN\633864 focus_10\NN\5704266 on_11\IN\1740 the_12\DT\1740 differential_13\JJ\1740 role_14\NN\719494 of_15\IN\1740 presynaptic_16\JJ\1740 versus_17\CC\1740 postsynaptic_18\JJ\1740 mechanisms_19\NNS\13446390 ,_20\,\1740 <e1>dopamine</e1>_21\NN\14807737 receptor_22\NN\5225602 subtypes_23\NNS\1740 ,_24\,\1740 ionotropic_25\JJ\1740 and_26\CC\1740 metabotropic_27\NN\1740 glutamate_28\NN\15010703 receptors_29\NNS\5225602 ,_30\,\1740 and_31\CC\1740 non-dopaminergic_32\JJ\1740 neurotransmitter_33\NN\14807410 systems_34\NNS\3575240 in_35\IN\13603305 the_36\DT\1740 pathophysiology_37\NN\1740 of_38\IN\1740 levodopa-induced_39\JJ\1740 <e2>dyskinesias</e2>_40\NNS\14084880 ._41\.\1740
D018698_D004409 NONE recent_0\JJ\1740 preclinical_1\JJ\1740 and_2\CC\1740 clinical_3\JJ\1740 data_4\NNS\7951464 from_5\IN\1740 promising_6\JJ\1740 lines_7\NNS\8426461 of_8\IN\1740 research_9\NN\633864 focus_10\NN\5704266 on_11\IN\1740 the_12\DT\1740 differential_13\JJ\1740 role_14\NN\719494 of_15\IN\1740 presynaptic_16\JJ\1740 versus_17\CC\1740 postsynaptic_18\JJ\1740 mechanisms_19\NNS\13446390 ,_20\,\1740 dopamine_21\NN\14807737 receptor_22\NN\5225602 subtypes_23\NNS\1740 ,_24\,\1740 ionotropic_25\JJ\1740 and_26\CC\1740 metabotropic_27\NN\1740 <e1>glutamate</e1>_28\NN\15010703 receptors_29\NNS\5225602 ,_30\,\1740 and_31\CC\1740 non-dopaminergic_32\JJ\1740 neurotransmitter_33\NN\14807410 systems_34\NNS\3575240 in_35\IN\13603305 the_36\DT\1740 pathophysiology_37\NN\1740 of_38\IN\1740 levodopa-induced_39\JJ\1740 <e2>dyskinesias</e2>_40\NNS\14084880 ._41\.\1740
20098969
D008694_D001145 NONE background_0\NN\4921011 :_1\:\1740 <e1>methamphetamine</e1>_2\NNP\2704153 is_3\VBZ\836236 a_4\DT\13649268 very_5\RB\1740 addictive_6\JJ\1740 ,_7\,\1740 powerful_8\JJ\1740 stimulant_9\NN\5816287 that_10\WDT\1740 increases_11\VBZ\169651 wakefulness_12\NN\14034177 and_13\CC\1740 physical_14\JJ\1740 activity_15\NN\30358 and_16\CC\1740 can_17\MD\3094503 produce_18\VB\1617192 other_19\JJ\1740 effects_20\NNS\13245626 such_21\JJ\1740 as_22\IN\14622893 <e2>cardiac_23\JJ\1740 dysrhythmias</e2>_24\NNS\1740 ,_25\,\1740 hypertension_26\NN\14057371 ,_27\,\1740 hallucinations_28\NNS\14376855 ,_29\,\1740 and_30\CC\1740 violent_31\JJ\1740 behavior_32\NN\407535 ._33\.\1740
D008694_D006973 NONE background_0\NN\4921011 :_1\:\1740 <e1>methamphetamine</e1>_2\NNP\2704153 is_3\VBZ\836236 a_4\DT\13649268 very_5\RB\1740 addictive_6\JJ\1740 ,_7\,\1740 powerful_8\JJ\1740 stimulant_9\NN\5816287 that_10\WDT\1740 increases_11\VBZ\169651 wakefulness_12\NN\14034177 and_13\CC\1740 physical_14\JJ\1740 activity_15\NN\30358 and_16\CC\1740 can_17\MD\3094503 produce_18\VB\1617192 other_19\JJ\1740 effects_20\NNS\13245626 such_21\JJ\1740 as_22\IN\14622893 cardiac_23\JJ\1740 dysrhythmias_24\NNS\1740 ,_25\,\1740 <e2>hypertension</e2>_26\NN\14057371 ,_27\,\1740 hallucinations_28\NNS\14376855 ,_29\,\1740 and_30\CC\1740 violent_31\JJ\1740 behavior_32\NN\407535 ._33\.\1740
D008694_D006212 NONE background_0\NN\4921011 :_1\:\1740 <e1>methamphetamine</e1>_2\NNP\2704153 is_3\VBZ\836236 a_4\DT\13649268 very_5\RB\1740 addictive_6\JJ\1740 ,_7\,\1740 powerful_8\JJ\1740 stimulant_9\NN\5816287 that_10\WDT\1740 increases_11\VBZ\169651 wakefulness_12\NN\14034177 and_13\CC\1740 physical_14\JJ\1740 activity_15\NN\30358 and_16\CC\1740 can_17\MD\3094503 produce_18\VB\1617192 other_19\JJ\1740 effects_20\NNS\13245626 such_21\JJ\1740 as_22\IN\14622893 cardiac_23\JJ\1740 dysrhythmias_24\NNS\1740 ,_25\,\1740 hypertension_26\NN\14057371 ,_27\,\1740 <e2>hallucinations</e2>_28\NNS\14376855 ,_29\,\1740 and_30\CC\1740 violent_31\JJ\1740 behavior_32\NN\407535 ._33\.\1740
D008694_D001523 NONE background_0\NN\4921011 :_1\:\1740 <e1>methamphetamine</e1>_2\NNP\2704153 is_3\VBZ\836236 a_4\DT\13649268 very_5\RB\1740 addictive_6\JJ\1740 ,_7\,\1740 powerful_8\JJ\1740 stimulant_9\NN\5816287 that_10\WDT\1740 increases_11\VBZ\169651 wakefulness_12\NN\14034177 and_13\CC\1740 physical_14\JJ\1740 activity_15\NN\30358 and_16\CC\1740 can_17\MD\3094503 produce_18\VB\1617192 other_19\JJ\1740 effects_20\NNS\13245626 such_21\JJ\1740 as_22\IN\14622893 cardiac_23\JJ\1740 dysrhythmias_24\NNS\1740 ,_25\,\1740 hypertension_26\NN\14057371 ,_27\,\1740 hallucinations_28\NNS\14376855 ,_29\,\1740 and_30\CC\1740 <e2>violent_31\JJ\1740 behavior</e2>_32\NN\407535 ._33\.\1740
D008694_D014987 NONE dental_0\JJ\1740 patients_1\NNS\9898892 abusing_2\VBG\2514187 <e1>methamphetamine</e1>_3\NN\2704153 can_4\MD\3094503 present_5\VB\2137132 with_6\IN\1740 poor_7\JJ\1740 oral_8\JJ\1740 hygiene_9\NN\14494893 ,_10\,\1740 <e2>xerostomia</e2>_11\NN\14536438 ,_12\,\1740 rampant_13\JJ\1740 caries_14\NNS\13456715 (_15\-LRB-\1740 "_16\``\1740 meth_17\NN\2704153 mouth_18\NN\5610008 "_19\''\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 excessive_23\JJ\1740 tooth_24\NN\5269901 wear_25\NN\14561618 ._26\.\1740
D008694_D003731 CID dental_0\JJ\1740 patients_1\NNS\9898892 abusing_2\VBG\2514187 <e1>methamphetamine</e1>_3\NN\2704153 can_4\MD\3094503 present_5\VB\2137132 with_6\IN\1740 poor_7\JJ\1740 oral_8\JJ\1740 hygiene_9\NN\14494893 ,_10\,\1740 xerostomia_11\NN\14536438 ,_12\,\1740 rampant_13\JJ\1740 <e2>caries</e2>_14\NNS\13456715 (_15\-LRB-\1740 "_16\``\1740 meth_17\NN\2704153 mouth_18\NN\5610008 "_19\''\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 excessive_23\JJ\1740 tooth_24\NN\5269901 wear_25\NN\14561618 ._26\.\1740
D008694_D003731 CID she_0\PRP\1740 reported_1\VBD\831651 her_2\PRP$\1740 use_3\NN\407535 of_4\IN\1740 <e1>methamphetamine</e1>_5\NN\2704153 for_6\IN\1740 five_7\CD\13741022 years_8\NNS\15144371 and_9\CC\1740 had_10\VBD\2108377 not_11\RB\1740 experienced_12\VBN\2108377 any_13\DT\1740 major_14\JJ\1740 <e2>carious_15\JJ\1740 episodes</e2>_16\NNS\7283608 before_17\IN\1740 she_18\PRP\1740 started_19\VBD\2009433 using_20\VBG\1156834 the_21\DT\1740 drug_22\NN\14778436 ._23\.\1740
D008694_-1 NONE dental_0\JJ\1740 patients_1\NNS\9898892 abusing_2\VBG\2514187 <e1>methamphetamine</e1>_3\NN\2704153 can_4\MD\3094503 present_5\VB\2137132 with_6\IN\1740 poor_7\JJ\1740 oral_8\JJ\1740 hygiene_9\NN\14494893 ,_10\,\1740 xerostomia_11\NN\14536438 ,_12\,\1740 rampant_13\JJ\1740 caries_14\NNS\13456715 (_15\-LRB-\1740 "_16\``\1740 <e2>meth_17\NN\2704153 mouth</e2>_18\NN\5610008 "_19\''\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 excessive_23\JJ\1740 tooth_24\NN\5269901 wear_25\NN\14561618 ._26\.\1740
D008694_-1 NONE clinical_0\NN\1740 significance_1\NN\5168261 :_2\:\1740 this_3\DT\1740 clinical_4\JJ\1740 case_5\NN\7283608 showing_6\VBG\2137132 oral_7\JJ\1740 manifestations_8\NNS\7321772 of_9\IN\1740 <e2>meth_10\NN\2704153 mouth</e2>_11\NN\5610008 was_12\VBD\836236 presented_13\VBN\2137132 to_14\TO\1740 help_15\VB\2556126 dental_16\JJ\1740 practitioners_17\NNS\10480253 recognize_18\VBP\686447 and_19\CC\1740 manage_20\VBP\2524171 patients_21\NNS\9898892 who_22\WP\8299493 may_23\MD\15209706 be_24\VB\836236 abusing_25\VBG\2514187 <e1>methamphetamines</e1>_26\NNS\2704153 ._27\.\1740
D008694_D057085 NONE dental_0\JJ\1740 patients_1\NNS\9898892 abusing_2\VBG\2514187 <e1>methamphetamine</e1>_3\NN\2704153 can_4\MD\3094503 present_5\VB\2137132 with_6\IN\1740 poor_7\JJ\1740 oral_8\JJ\1740 hygiene_9\NN\14494893 ,_10\,\1740 xerostomia_11\NN\14536438 ,_12\,\1740 rampant_13\JJ\1740 caries_14\NNS\13456715 (_15\-LRB-\1740 "_16\``\1740 meth_17\NN\2704153 mouth_18\NN\5610008 "_19\''\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 excessive_23\JJ\1740 <e2>tooth_24\NN\5269901 wear</e2>_25\NN\14561618 ._26\.\1740
16428221
D008774_D020293 CID <e2>cerebral_0\JJ\1740 vasculitis</e2>_1\NN\14336539 following_2\VBG\1835496 oral_3\JJ\1740 <e1>methylphenidate</e1>_4\NN\4320126 intake_5\NN\13440063 in_6\IN\13603305 an_7\DT\6697703 adult_8\NN\7846 :_9\:\1740 a_10\DT\13649268 case_11\NN\7283608 report_12\NN\6470073 ._13\.\1740
D008774_D020293 CID <e2>cerebral_0\JJ\1740 vasculitis</e2>_1\NN\14336539 associated_2\VBN\628491 with_3\IN\1740 amphetamine_4\NN\3248958 abuse_5\NN\418025 is_6\VBZ\836236 well_7\RB\1740 documented_8\VBN\1000214 ,_9\,\1740 and_10\CC\1740 in_11\IN\13603305 rare_12\JJ\1740 cases_13\NNS\7283608 ischaemic_14\JJ\1740 stroke_15\NN\556313 has_16\VBZ\2108377 been_17\VBN\836236 reported_18\VBN\831651 after_19\IN\1740 <e1>methylphenidate</e1>_20\JJ\1740 intake_21\NN\13440063 in_22\IN\13603305 children_23\NNS\9622049 ._24\.\1740
D008774_D019969 NONE cerebral_0\JJ\1740 vasculitis_1\NN\14336539 associated_2\VBN\628491 with_3\IN\1740 <e2>amphetamine_4\NN\3248958 abuse</e2>_5\NN\418025 is_6\VBZ\836236 well_7\RB\1740 documented_8\VBN\1000214 ,_9\,\1740 and_10\CC\1740 in_11\IN\13603305 rare_12\JJ\1740 cases_13\NNS\7283608 ischaemic_14\JJ\1740 stroke_15\NN\556313 has_16\VBZ\2108377 been_17\VBN\836236 reported_18\VBN\831651 after_19\IN\1740 <e1>methylphenidate</e1>_20\JJ\1740 intake_21\NN\13440063 in_22\IN\13603305 children_23\NNS\9622049 ._24\.\1740
D008774_D002544 NONE cerebral_0\JJ\1740 vasculitis_1\NN\14336539 associated_2\VBN\628491 with_3\IN\1740 amphetamine_4\NN\3248958 abuse_5\NN\418025 is_6\VBZ\836236 well_7\RB\1740 documented_8\VBN\1000214 ,_9\,\1740 and_10\CC\1740 in_11\IN\13603305 rare_12\JJ\1740 cases_13\NNS\7283608 <e2>ischaemic_14\JJ\1740 stroke</e2>_15\NN\556313 has_16\VBZ\2108377 been_17\VBN\836236 reported_18\VBN\831651 after_19\IN\1740 <e1>methylphenidate</e1>_20\JJ\1740 intake_21\NN\13440063 in_22\IN\13603305 children_23\NNS\9622049 ._24\.\1740
D008774_D002544 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 63-year-old_6\JJ\1740 female_7\NN\15388 who_8\WP\8299493 was_9\VBD\836236 treated_10\VBN\2376958 with_11\IN\1740 <e1>methylphenidate</e1>_12\NN\4320126 due_13\IN\5174653 to_14\TO\1740 hyperactivity_15\NN\14052403 and_16\CC\1740 suffered_17\VBN\2110220 from_18\IN\1740 multiple_19\JJ\1740 <e2>ischaemic_20\JJ\1740 strokes</e2>_21\NNS\556313 ._22\.\1740
D008774_D006948 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 63-year-old_6\JJ\1740 female_7\NN\15388 who_8\WP\8299493 was_9\VBD\836236 treated_10\VBN\2376958 with_11\IN\1740 <e1>methylphenidate</e1>_12\NN\4320126 due_13\IN\5174653 to_14\TO\1740 <e2>hyperactivity</e2>_15\NN\14052403 and_16\CC\1740 suffered_17\VBN\2110220 from_18\IN\1740 multiple_19\JJ\1740 ischaemic_20\JJ\1740 strokes_21\NNS\556313 ._22\.\1740
D008774_D014657 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>methylphenidate</e1>_3\VB\1740 mediated_4\JJ\1740 <e2>vasculitis</e2>_5\NN\14336539 should_6\MD\1740 be_7\VB\836236 considered_8\VBN\689344 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 neurological_12\JJ\1740 symptoms_13\NNS\5823932 and_14\CC\1740 a_15\DT\13649268 history_16\NN\15120823 of_17\IN\1740 methylphenidate_18\NN\4320126 therapy_19\NN\657604 ._20\.\1740
D008774_D014657 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 methylphenidate_3\VB\1740 mediated_4\JJ\1740 <e2>vasculitis</e2>_5\NN\14336539 should_6\MD\1740 be_7\VB\836236 considered_8\VBN\689344 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 neurological_12\JJ\1740 symptoms_13\NNS\5823932 and_14\CC\1740 a_15\DT\13649268 history_16\NN\15120823 of_17\IN\1740 <e1>methylphenidate</e1>_18\NN\4320126 therapy_19\NN\657604 ._20\.\1740
220563
C023470_D010523 CID <e1>perhexiline_0\NN\1740 maleate</e1>_1\NN\2718811 and_2\CC\1740 <e2>peripheral_3\JJ\1740 neuropathy</e2>_4\NN\14204950 ._5\.\1740
C023470_D010523 CID <e2>peripheral_0\JJ\1740 neuropathy</e2>_1\NN\14204950 has_2\VBZ\2108377 been_3\VBN\836236 noted_4\VBN\1009240 as_5\IN\14622893 a_6\DT\13649268 complication_7\NN\1073995 of_8\IN\1740 therapy_9\NN\657604 with_10\IN\1740 <e1>perhexiline_11\NN\1740 maleate</e1>_12\NN\2718811 ,_13\,\1740 a_14\DT\13649268 drug_15\NN\14778436 widely_16\RB\1740 used_17\VBN\1156834 in_18\IN\13603305 france_19\NNP\1740 (_20\-LRB-\1740 and_21\CC\1740 in_22\IN\13603305 clinical_23\JJ\1740 trials_24\NNS\786195 in_25\IN\13603305 the_26\DT\1740 united_27\NNP\1740 states_28\NNP\8491826 )_29\-RRB-\1740 for_30\IN\1740 the_31\DT\1740 prophylactic_32\JJ\1740 treatment_33\NN\654885 of_34\IN\1740 angina_35\JJ\1740 pectoris_36\NN\1740 ._37\.\1740
C023470_D000787 NONE peripheral_0\JJ\1740 neuropathy_1\NN\14204950 has_2\VBZ\2108377 been_3\VBN\836236 noted_4\VBN\1009240 as_5\IN\14622893 a_6\DT\13649268 complication_7\NN\1073995 of_8\IN\1740 therapy_9\NN\657604 with_10\IN\1740 <e1>perhexiline_11\NN\1740 maleate</e1>_12\NN\2718811 ,_13\,\1740 a_14\DT\13649268 drug_15\NN\14778436 widely_16\RB\1740 used_17\VBN\1156834 in_18\IN\13603305 france_19\NNP\1740 (_20\-LRB-\1740 and_21\CC\1740 in_22\IN\13603305 clinical_23\JJ\1740 trials_24\NNS\786195 in_25\IN\13603305 the_26\DT\1740 united_27\NNP\1740 states_28\NNP\8491826 )_29\-RRB-\1740 for_30\IN\1740 the_31\DT\1740 prophylactic_32\JJ\1740 treatment_33\NN\654885 of_34\IN\1740 <e2>angina_35\JJ\1740 pectoris</e2>_36\NN\1740 ._37\.\1740
9721172
D007052_D001649 NONE a_0\DT\13649268 previously_1\RB\1740 healthy_2\JJ\1740 child_3\NN\9622049 who_4\WP\8299493 developed_5\VBD\1753788 acute_6\JJ\1740 ,_7\,\1740 severe_8\JJ\1740 ,_9\,\1740 rapidly_10\RB\1740 progressive_11\JJ\1740 <e2>vanishing_12\NN\7335716 bile_13\NN\5405946 duct_14\NN\5248181 syndrome</e2>_15\NN\5870365 shortly_16\RB\1740 after_17\IN\1740 stevens-johnson_18\NN\1740 syndrome_19\NN\5870365 is_20\VBZ\836236 described_21\VBN\1001294 ;_22\:\1740 this_23\DT\1740 was_24\VBD\836236 temporally_25\RB\1740 associated_26\VBN\628491 with_27\IN\1740 <e1>ibuprofen</e1>_28\NN\3828465 use_29\NN\407535 ._30\.\1740
D007052_D013262 CID a_0\DT\13649268 previously_1\RB\1740 healthy_2\JJ\1740 child_3\NN\9622049 who_4\WP\8299493 developed_5\VBD\1753788 acute_6\JJ\1740 ,_7\,\1740 severe_8\JJ\1740 ,_9\,\1740 rapidly_10\RB\1740 progressive_11\JJ\1740 vanishing_12\NN\7335716 bile_13\NN\5405946 duct_14\NN\5248181 syndrome_15\NN\5870365 shortly_16\RB\1740 after_17\IN\1740 <e2>stevens-johnson_18\NN\1740 syndrome</e2>_19\NN\5870365 is_20\VBZ\836236 described_21\VBN\1001294 ;_22\:\1740 this_23\DT\1740 was_24\VBD\836236 temporally_25\RB\1740 associated_26\VBN\628491 with_27\IN\1740 <e1>ibuprofen</e1>_28\NN\3828465 use_29\NN\407535 ._30\.\1740
D014580_D002779 NONE despite_0\IN\7501545 therapy_1\NN\657604 with_2\IN\1740 <e1>ursodeoxycholic_3\JJ\1740 acid</e1>_4\NN\14818238 ,_5\,\1740 prednisone_6\NN\2721538 ,_7\,\1740 and_8\CC\1740 then_9\RB\1740 tacrolimus_10\NN\1740 ,_11\,\1740 her_12\PRP$\1740 <e2>cholestatic_13\JJ\1740 disease</e2>_14\NN\14061805 was_15\VBD\836236 unrelenting_16\VBG\1740 ,_17\,\1740 with_18\IN\1740 cirrhosis_19\NN\14116321 shown_20\VBN\2137132 by_21\IN\1740 biopsy_22\NN\5739043 6_23\CD\13741022 months_24\NNS\15113229 after_25\IN\1740 presentation_26\NN\1027379 ._27\.\1740
D014580_D005355 NONE despite_0\IN\7501545 therapy_1\NN\657604 with_2\IN\1740 <e1>ursodeoxycholic_3\JJ\1740 acid</e1>_4\NN\14818238 ,_5\,\1740 prednisone_6\NN\2721538 ,_7\,\1740 and_8\CC\1740 then_9\RB\1740 tacrolimus_10\NN\1740 ,_11\,\1740 her_12\PRP$\1740 cholestatic_13\JJ\1740 disease_14\NN\14061805 was_15\VBD\836236 unrelenting_16\VBG\1740 ,_17\,\1740 with_18\IN\1740 <e2>cirrhosis</e2>_19\NN\14116321 shown_20\VBN\2137132 by_21\IN\1740 biopsy_22\NN\5739043 6_23\CD\13741022 months_24\NNS\15113229 after_25\IN\1740 presentation_26\NN\1027379 ._27\.\1740
D011241_D002779 NONE despite_0\IN\7501545 therapy_1\NN\657604 with_2\IN\1740 ursodeoxycholic_3\JJ\1740 acid_4\NN\14818238 ,_5\,\1740 <e1>prednisone</e1>_6\NN\2721538 ,_7\,\1740 and_8\CC\1740 then_9\RB\1740 tacrolimus_10\NN\1740 ,_11\,\1740 her_12\PRP$\1740 <e2>cholestatic_13\JJ\1740 disease</e2>_14\NN\14061805 was_15\VBD\836236 unrelenting_16\VBG\1740 ,_17\,\1740 with_18\IN\1740 cirrhosis_19\NN\14116321 shown_20\VBN\2137132 by_21\IN\1740 biopsy_22\NN\5739043 6_23\CD\13741022 months_24\NNS\15113229 after_25\IN\1740 presentation_26\NN\1027379 ._27\.\1740
D011241_D005355 NONE despite_0\IN\7501545 therapy_1\NN\657604 with_2\IN\1740 ursodeoxycholic_3\JJ\1740 acid_4\NN\14818238 ,_5\,\1740 <e1>prednisone</e1>_6\NN\2721538 ,_7\,\1740 and_8\CC\1740 then_9\RB\1740 tacrolimus_10\NN\1740 ,_11\,\1740 her_12\PRP$\1740 cholestatic_13\JJ\1740 disease_14\NN\14061805 was_15\VBD\836236 unrelenting_16\VBG\1740 ,_17\,\1740 with_18\IN\1740 <e2>cirrhosis</e2>_19\NN\14116321 shown_20\VBN\2137132 by_21\IN\1740 biopsy_22\NN\5739043 6_23\CD\13741022 months_24\NNS\15113229 after_25\IN\1740 presentation_26\NN\1027379 ._27\.\1740
D016559_D002779 NONE despite_0\IN\7501545 therapy_1\NN\657604 with_2\IN\1740 ursodeoxycholic_3\JJ\1740 acid_4\NN\14818238 ,_5\,\1740 prednisone_6\NN\2721538 ,_7\,\1740 and_8\CC\1740 then_9\RB\1740 <e1>tacrolimus</e1>_10\NN\1740 ,_11\,\1740 her_12\PRP$\1740 <e2>cholestatic_13\JJ\1740 disease</e2>_14\NN\14061805 was_15\VBD\836236 unrelenting_16\VBG\1740 ,_17\,\1740 with_18\IN\1740 cirrhosis_19\NN\14116321 shown_20\VBN\2137132 by_21\IN\1740 biopsy_22\NN\5739043 6_23\CD\13741022 months_24\NNS\15113229 after_25\IN\1740 presentation_26\NN\1027379 ._27\.\1740
D016559_D005355 NONE despite_0\IN\7501545 therapy_1\NN\657604 with_2\IN\1740 ursodeoxycholic_3\JJ\1740 acid_4\NN\14818238 ,_5\,\1740 prednisone_6\NN\2721538 ,_7\,\1740 and_8\CC\1740 then_9\RB\1740 <e1>tacrolimus</e1>_10\NN\1740 ,_11\,\1740 her_12\PRP$\1740 cholestatic_13\JJ\1740 disease_14\NN\14061805 was_15\VBD\836236 unrelenting_16\VBG\1740 ,_17\,\1740 with_18\IN\1740 <e2>cirrhosis</e2>_19\NN\14116321 shown_20\VBN\2137132 by_21\IN\1740 biopsy_22\NN\5739043 6_23\CD\13741022 months_24\NNS\15113229 after_25\IN\1740 presentation_26\NN\1027379 ._27\.\1740
7919560
D000667_D004892 CID <e2>erythema_0\NNP\14227218 multiforme</e2>_1\VBD\1740 and_2\CC\1740 hypersensitivity_3\NN\14531772 myocarditis_4\NN\14338942 caused_5\VBN\1617192 by_6\IN\1740 <e1>ampicillin</e1>_7\NN\3910033 ._8\.\1740
D000667_D004892 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e2>erythema_7\NN\14227218 multiforme</e2>_8\JJ\1740 and_9\CC\1740 hypersensitivity_10\NN\14531772 myocarditis_11\NN\14338942 caused_12\VBN\1617192 by_13\IN\1740 <e1>ampicillin</e1>_14\NN\3910033 ._15\.\1740
D000667_D009205 CID erythema_0\NNP\14227218 multiforme_1\VBD\1740 and_2\CC\1740 <e2>hypersensitivity_3\NN\14531772 myocarditis</e2>_4\NN\14338942 caused_5\VBN\1617192 by_6\IN\1740 <e1>ampicillin</e1>_7\NN\3910033 ._8\.\1740
D000667_D009205 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 erythema_7\NN\14227218 multiforme_8\JJ\1740 and_9\CC\1740 <e2>hypersensitivity_10\NN\14531772 myocarditis</e2>_11\NN\14338942 caused_12\VBN\1617192 by_13\IN\1740 <e1>ampicillin</e1>_14\NN\3910033 ._15\.\1740
D000667_D018805 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 13-year-old_4\JJ\1740 boy_5\NN\9624168 was_6\VBD\836236 treated_7\VBN\2376958 with_8\IN\1740 <e1>ampicillin</e1>_9\NN\3910033 and_10\CC\1740 gentamicin_11\NN\2716866 because_12\IN\1740 of_13\IN\1740 suspected_14\VBN\916909 <e2>septicemia</e2>_15\NN\14189204 ._16\.\1740
D005839_D018805 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 13-year-old_4\JJ\1740 boy_5\NN\9624168 was_6\VBD\836236 treated_7\VBN\2376958 with_8\IN\1740 ampicillin_9\NN\3910033 and_10\CC\1740 <e1>gentamicin</e1>_11\NN\2716866 because_12\IN\1740 of_13\IN\1740 suspected_14\VBN\916909 <e2>septicemia</e2>_15\NN\14189204 ._16\.\1740
D010406_D009205 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e2>hypersensitivity_2\NN\14531772 myocarditis</e2>_3\NN\14338942 is_4\VBZ\836236 a_5\DT\13649268 rare_6\JJ\1740 and_7\CC\1740 dangerous_8\JJ\1740 manifestation_9\NN\7321772 of_10\IN\1740 allergy_11\NN\14533203 to_12\TO\1740 <e1>penicillins</e1>_13\NNS\2716866 ._14\.\1740
D010406_D004342 NONE conclusions_0\NNS\5837957 :_1\:\1740 hypersensitivity_2\NN\14531772 myocarditis_3\NN\14338942 is_4\VBZ\836236 a_5\DT\13649268 rare_6\JJ\1740 and_7\CC\1740 dangerous_8\JJ\1740 manifestation_9\NN\7321772 of_10\IN\1740 <e2>allergy</e2>_11\NN\14533203 to_12\TO\1740 <e1>penicillins</e1>_13\NNS\2716866 ._14\.\1740
2425813
D011239_D006529 CID <e2>liver_0\NN\5298729 enlargement</e2>_1\NN\363260 and_2\CC\1740 muscle_3\NN\5289601 wastage_4\NN\13458571 occurred_5\VBD\2623529 in_6\IN\13603305 wistar_7\NNP\1740 rats_8\NNS\2329401 following_9\VBG\1835496 the_10\DT\1740 subcutaneous_11\JJ\1740 administration_12\NN\1133281 of_13\IN\1740 <e1>prednisolone</e1>_14\NN\2721538 ._15\.\1740
D011239_D009133 CID liver_0\NN\5298729 enlargement_1\NN\363260 and_2\CC\1740 <e2>muscle_3\NN\5289601 wastage</e2>_4\NN\13458571 occurred_5\VBD\2623529 in_6\IN\13603305 wistar_7\NNP\1740 rats_8\NNS\2329401 following_9\VBG\1835496 the_10\DT\1740 subcutaneous_11\JJ\1740 administration_12\NN\1133281 of_13\IN\1740 <e1>prednisolone</e1>_14\NN\2721538 ._15\.\1740
12695819
D016559_D020258 NONE mr_0\NN\6339416 imaging_1\NN\5765159 with_2\IN\1740 quantitative_3\JJ\1740 diffusion_4\NN\13518963 mapping_5\NN\13783581 of_6\IN\1740 <e1>tacrolimus-induced</e1>_7\JJ\1740 <e2>neurotoxicity</e2>_8\NN\1740 in_9\IN\13603305 organ_10\JJ\1740 transplant_11\NN\5267548 patients_12\NNS\9898892 ._13\.\1740
D016559_D020258 NONE diffusion-weighted_0\JJ\1740 imaging_1\NN\5765159 may_2\MD\15209706 be_3\VB\836236 useful_4\JJ\1740 in_5\IN\13603305 predicting_6\VBG\916909 the_7\DT\1740 outcomes_8\NNS\7291312 of_9\IN\1740 the_10\DT\1740 lesions_11\NNS\14204950 of_12\IN\1740 <e1>tacrolimus-induced</e1>_13\JJ\1740 <e2>neurotoxicity</e2>_14\NN\1740 ._15\.\1740
D016559_D009422 NONE brain_0\NN\5462674 mr_1\NN\6339416 studies_2\NNS\635850 ,_3\,\1740 including_4\VBG\690614 dw_5\NN\1740 imaging_6\NN\5765159 ,_7\,\1740 were_8\VBD\836236 prospectively_9\RB\1740 performed_10\VBN\2367363 in_11\IN\13603305 14_12\CD\13745420 organ_13\NN\5220461 transplant_14\NN\5267548 patients_15\NNS\9898892 receiving_16\VBG\2210855 <e1>tacrolimus</e1>_17\NN\1740 who_18\WP\8299493 developed_19\VBD\1753788 <e2>neurologic_20\JJ\1740 complications</e2>_21\NNS\1073995 ._22\.\1740
6133211
D012460_D015212 NONE three_0\CD\13741022 infants_1\NNS\9918248 ,_2\,\1740 born_3\VBN\2630189 of_4\IN\1740 two_5\CD\13741022 mothers_6\NNS\10399491 with_7\IN\1740 <e2>inflammatory_8\JJ\1740 bowel_9\NN\5298729 disease</e2>_10\NN\14061805 who_11\WP\8299493 received_12\VBD\2210855 treatment_13\NN\654885 with_14\IN\1740 <e1>sulphasalazine</e1>_15\NN\1740 throughout_16\IN\1740 pregnancy_17\NN\14034177 ,_18\,\1740 were_19\VBD\836236 found_20\VBN\2426171 to_21\TO\1740 have_22\VB\2108377 major_23\JJ\1740 congenital_24\JJ\1740 anomalies_25\NNS\14501726 ._26\.\1740
D012460_D000013 NONE three_0\CD\13741022 infants_1\NNS\9918248 ,_2\,\1740 born_3\VBN\2630189 of_4\IN\1740 two_5\CD\13741022 mothers_6\NNS\10399491 with_7\IN\1740 inflammatory_8\JJ\1740 bowel_9\NN\5298729 disease_10\NN\14061805 who_11\WP\8299493 received_12\VBD\2210855 treatment_13\NN\654885 with_14\IN\1740 <e1>sulphasalazine</e1>_15\NN\1740 throughout_16\IN\1740 pregnancy_17\NN\14034177 ,_18\,\1740 were_19\VBD\836236 found_20\VBN\2426171 to_21\TO\1740 have_22\VB\2108377 major_23\JJ\1740 <e2>congenital_24\JJ\1740 anomalies</e2>_25\NNS\14501726 ._26\.\1740
2355241
D007980_D002543 NONE the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 <e2>cerebral_4\JJ\1740 haemorrhage</e2>_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 death_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 hypotensive_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 <e1>levodopa</e1>_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 hypotensive_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 noradrenaline_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 parkinsonian_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
D007980_D003643 NONE the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 cerebral_4\JJ\1740 haemorrhage_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 <e2>death</e2>_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 hypotensive_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 <e1>levodopa</e1>_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 hypotensive_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 noradrenaline_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 parkinsonian_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
D007980_D010300 NONE the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 cerebral_4\JJ\1740 haemorrhage_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 death_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e2>parkinson_14\NN\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 hypotensive_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 <e1>levodopa</e1>_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 hypotensive_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 noradrenaline_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 parkinsonian_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
D007980_D010300 NONE the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 cerebral_4\JJ\1740 haemorrhage_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 death_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 hypotensive_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 <e1>levodopa</e1>_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 hypotensive_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 noradrenaline_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 <e2>parkinsonian</e2>_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
D007980_D007022 CID the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 cerebral_4\JJ\1740 haemorrhage_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 death_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 <e2>hypotensive</e2>_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 <e1>levodopa</e1>_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 hypotensive_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 noradrenaline_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 parkinsonian_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
D007980_D007022 CID the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 cerebral_4\JJ\1740 haemorrhage_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 death_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 hypotensive_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 <e1>levodopa</e1>_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 <e2>hypotensive</e2>_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 noradrenaline_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 parkinsonian_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
D009638_D002543 NONE the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 <e2>cerebral_4\JJ\1740 haemorrhage</e2>_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 death_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 hypotensive_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 levodopa_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 hypotensive_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 <e1>noradrenaline</e1>_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 parkinsonian_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
D009638_D003643 NONE the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 cerebral_4\JJ\1740 haemorrhage_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 <e2>death</e2>_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 hypotensive_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 levodopa_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 hypotensive_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 <e1>noradrenaline</e1>_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 parkinsonian_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
D009638_D010300 NONE the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 cerebral_4\JJ\1740 haemorrhage_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 death_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e2>parkinson_14\NN\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 hypotensive_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 levodopa_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 hypotensive_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 <e1>noradrenaline</e1>_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 parkinsonian_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
D009638_D010300 NONE the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 cerebral_4\JJ\1740 haemorrhage_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 death_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 hypotensive_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 levodopa_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 hypotensive_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 <e1>noradrenaline</e1>_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 <e2>parkinsonian</e2>_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
D009638_D007022 NONE the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 cerebral_4\JJ\1740 haemorrhage_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 death_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 <e2>hypotensive</e2>_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 levodopa_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 hypotensive_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 <e1>noradrenaline</e1>_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 parkinsonian_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
D009638_D007022 NONE the_0\DT\1740 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 cerebral_4\JJ\1740 haemorrhage_5\NN\14285662 as_6\IN\14622893 a_7\DT\13649268 cause_8\NN\7323922 of_9\IN\1740 death_10\NN\7296428 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 may_17\MD\15209706 reflect_18\VB\923793 the_19\DT\1740 hypotensive_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 levodopa_23\NN\14604959 and_24\CC\1740 a_25\DT\13649268 <e2>hypotensive</e2>_26\JJ\1740 mechanism_27\NN\13446390 due_28\IN\5174653 to_29\TO\1740 reduced_30\VBN\441445 <e1>noradrenaline</e1>_31\JJ\1740 levels_32\NNS\4916342 in_33\IN\13603305 the_34\DT\1740 parkinsonian_35\JJ\1740 brain_36\NN\5462674 ._37\.\1740
17608141
D008694_D020258 NONE attenuation_0\NN\7427337 of_1\IN\1740 <e1>methamphetamine-induced</e1>_2\JJ\1740 nigrostriatal_3\JJ\1740 dopaminergic_4\JJ\1740 <e2>neurotoxicity</e2>_5\NN\1740 in_6\IN\13603305 mice_7\NNS\2329401 by_8\IN\1740 lipopolysaccharide_9\NN\1740 pretreatment_10\NN\1740 ._11\.\1740
D008694_D020258 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 examined_5\VBD\789138 the_6\DT\1740 roles_7\NNS\719494 of_8\IN\1740 lipopolysaccharide_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 pro-inflammatory_12\JJ\1740 and_13\CC\1740 inflammatory_14\JJ\1740 factor_15\NN\7326557 ,_16\,\1740 treatment_17\NN\654885 in_18\IN\13603305 modulating_19\VBG\1724459 the_20\DT\1740 <e1>methamphetamine-induced</e1>_21\JJ\1740 nigrostriatal_22\JJ\1740 dopamine_23\NN\14807737 <e2>neurotoxicity</e2>_24\NN\1740 ._25\.\1740
D008694_D020258 NONE we_0\PRP\1740 concluded_1\VBD\628491 a_2\DT\13649268 critical_3\JJ\1740 time_4\NN\7308889 window_5\NN\3391770 for_6\IN\1740 systemic_7\JJ\1740 lipopolysaccharide_8\NN\1740 pretreatment_9\NN\1740 in_10\IN\13603305 exerting_11\VBG\1158872 effective_12\JJ\1740 protection_13\NN\407535 against_14\IN\1740 <e1>methamphetamine-induced</e1>_15\JJ\1740 nigrostriatal_16\JJ\1740 dopamine_17\NN\14807737 <e2>neurotoxicity</e2>_18\NN\1740 ._19\.\1740
D008070_D020258 NONE attenuation_0\NN\7427337 of_1\IN\1740 methamphetamine-induced_2\JJ\1740 nigrostriatal_3\JJ\1740 dopaminergic_4\JJ\1740 <e2>neurotoxicity</e2>_5\NN\1740 in_6\IN\13603305 mice_7\NNS\2329401 by_8\IN\1740 <e1>lipopolysaccharide</e1>_9\NN\1740 pretreatment_10\NN\1740 ._11\.\1740
D008070_D020258 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 examined_5\VBD\789138 the_6\DT\1740 roles_7\NNS\719494 of_8\IN\1740 <e1>lipopolysaccharide</e1>_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 pro-inflammatory_12\JJ\1740 and_13\CC\1740 inflammatory_14\JJ\1740 factor_15\NN\7326557 ,_16\,\1740 treatment_17\NN\654885 in_18\IN\13603305 modulating_19\VBG\1724459 the_20\DT\1740 methamphetamine-induced_21\JJ\1740 nigrostriatal_22\JJ\1740 dopamine_23\NN\14807737 <e2>neurotoxicity</e2>_24\NN\1740 ._25\.\1740
D008070_D020258 NONE we_0\PRP\1740 concluded_1\VBD\628491 a_2\DT\13649268 critical_3\JJ\1740 time_4\NN\7308889 window_5\NN\3391770 for_6\IN\1740 systemic_7\JJ\1740 <e1>lipopolysaccharide</e1>_8\NN\1740 pretreatment_9\NN\1740 in_10\IN\13603305 exerting_11\VBG\1158872 effective_12\JJ\1740 protection_13\NN\407535 against_14\IN\1740 methamphetamine-induced_15\JJ\1740 nigrostriatal_16\JJ\1740 dopamine_17\NN\14807737 <e2>neurotoxicity</e2>_18\NN\1740 ._19\.\1740
D008694_D009422 NONE immunological_0\JJ\1740 activation_1\NN\13561719 has_2\VBZ\2108377 been_3\VBN\836236 proposed_4\VBN\1010118 to_5\TO\1740 play_6\VB\1072262 a_7\DT\13649268 role_8\NN\719494 in_9\IN\13603305 <e1>methamphetamine-induced</e1>_10\JJ\1740 <e2>dopaminergic_11\JJ\1740 terminal_12\JJ\1740 damage</e2>_13\NN\7296428 ._14\.\1740
D004298_D020258 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 examined_5\VBD\789138 the_6\DT\1740 roles_7\NNS\719494 of_8\IN\1740 lipopolysaccharide_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 pro-inflammatory_12\JJ\1740 and_13\CC\1740 inflammatory_14\JJ\1740 factor_15\NN\7326557 ,_16\,\1740 treatment_17\NN\654885 in_18\IN\13603305 modulating_19\VBG\1724459 the_20\DT\1740 methamphetamine-induced_21\JJ\1740 nigrostriatal_22\JJ\1740 <e1>dopamine</e1>_23\NN\14807737 <e2>neurotoxicity</e2>_24\NN\1740 ._25\.\1740
D004298_D020258 NONE we_0\PRP\1740 concluded_1\VBD\628491 a_2\DT\13649268 critical_3\JJ\1740 time_4\NN\7308889 window_5\NN\3391770 for_6\IN\1740 systemic_7\JJ\1740 lipopolysaccharide_8\NN\1740 pretreatment_9\NN\1740 in_10\IN\13603305 exerting_11\VBG\1158872 effective_12\JJ\1740 protection_13\NN\407535 against_14\IN\1740 methamphetamine-induced_15\JJ\1740 nigrostriatal_16\JJ\1740 <e1>dopamine</e1>_17\NN\14807737 <e2>neurotoxicity</e2>_18\NN\1740 ._19\.\1740
D008070_D005334 NONE <e1>lipopolysaccharide</e1>_0\NN\1740 pretreatment_1\NN\1740 did_2\VBD\1640855 not_3\RB\1740 affect_4\VB\126264 the_5\DT\1740 basal_6\JJ\1740 body_7\NN\19128 temperature_8\NN\13575869 or_9\CC\3541091 methamphetamine-elicited_10\JJ\1740 <e2>hyperthermia</e2>_11\NN\14034177 three_12\CD\13741022 days_13\NNS\15140892 later_14\RB\1740 ._15\.\1740
D008694_D005334 CID lipopolysaccharide_0\NN\1740 pretreatment_1\NN\1740 did_2\VBD\1640855 not_3\RB\1740 affect_4\VB\126264 the_5\DT\1740 basal_6\JJ\1740 body_7\NN\19128 temperature_8\NN\13575869 or_9\CC\3541091 <e1>methamphetamine-elicited</e1>_10\JJ\1740 <e2>hyperthermia</e2>_11\NN\14034177 three_12\CD\13741022 days_13\NNS\15140892 later_14\RB\1740 ._15\.\1740
1130930
D002512_D007674 NONE <e2>nephrotoxicity</e2>_0\NN\1740 of_1\IN\1740 combined_2\JJ\1740 <e1>cephalothin-gentamicin</e1>_3\JJ\1740 regimen_4\NN\5898568 ._5\.\1740
D005839_D007674 NONE <e2>nephrotoxicity</e2>_0\NN\1740 of_1\IN\1740 combined_2\JJ\1740 <e1>cephalothin-gentamicin</e1>_3\JJ\1740 regimen_4\NN\5898568 ._5\.\1740
D002512_D007683 CID two_0\CD\13741022 patients_1\NNS\9898892 developed_2\VBD\1753788 <e2>acute_3\JJ\1740 tubular_4\JJ\1740 necrosis</e2>_5\NN\11444117 ,_6\,\1740 characterized_7\VBN\609683 clinically_8\RB\1740 by_9\IN\1740 acute_10\JJ\1740 oliguric_11\JJ\1740 renal_12\JJ\1740 failure_13\NN\66216 ,_14\,\1740 while_15\IN\15122231 they_16\PRP\1740 were_17\VBD\836236 receiving_18\VBG\2210855 a_19\DT\13649268 combination_20\NN\7951464 of_21\IN\1740 <e1>cephalothin_22\JJ\1740 sodium</e1>_23\NN\14625458 and_24\CC\1740 gentamicin_25\NN\2716866 sulfate_26\NN\15010703 therapy_27\NN\657604 ._28\.\1740
D002512_D009846 NONE two_0\CD\13741022 patients_1\NNS\9898892 developed_2\VBD\1753788 acute_3\JJ\1740 tubular_4\JJ\1740 necrosis_5\NN\11444117 ,_6\,\1740 characterized_7\VBN\609683 clinically_8\RB\1740 by_9\IN\1740 acute_10\JJ\1740 <e2>oliguric_11\JJ\1740 renal_12\JJ\1740 failure</e2>_13\NN\66216 ,_14\,\1740 while_15\IN\15122231 they_16\PRP\1740 were_17\VBD\836236 receiving_18\VBG\2210855 a_19\DT\13649268 combination_20\NN\7951464 of_21\IN\1740 <e1>cephalothin_22\JJ\1740 sodium</e1>_23\NN\14625458 and_24\CC\1740 gentamicin_25\NN\2716866 sulfate_26\NN\15010703 therapy_27\NN\657604 ._28\.\1740
D002512_D051437 NONE two_0\CD\13741022 patients_1\NNS\9898892 developed_2\VBD\1753788 acute_3\JJ\1740 tubular_4\JJ\1740 necrosis_5\NN\11444117 ,_6\,\1740 characterized_7\VBN\609683 clinically_8\RB\1740 by_9\IN\1740 acute_10\JJ\1740 <e2>oliguric_11\JJ\1740 renal_12\JJ\1740 failure</e2>_13\NN\66216 ,_14\,\1740 while_15\IN\15122231 they_16\PRP\1740 were_17\VBD\836236 receiving_18\VBG\2210855 a_19\DT\13649268 combination_20\NN\7951464 of_21\IN\1740 <e1>cephalothin_22\JJ\1740 sodium</e1>_23\NN\14625458 and_24\CC\1740 gentamicin_25\NN\2716866 sulfate_26\NN\15010703 therapy_27\NN\657604 ._28\.\1740
D005839_D007683 CID two_0\CD\13741022 patients_1\NNS\9898892 developed_2\VBD\1753788 <e2>acute_3\JJ\1740 tubular_4\JJ\1740 necrosis</e2>_5\NN\11444117 ,_6\,\1740 characterized_7\VBN\609683 clinically_8\RB\1740 by_9\IN\1740 acute_10\JJ\1740 oliguric_11\JJ\1740 renal_12\JJ\1740 failure_13\NN\66216 ,_14\,\1740 while_15\IN\15122231 they_16\PRP\1740 were_17\VBD\836236 receiving_18\VBG\2210855 a_19\DT\13649268 combination_20\NN\7951464 of_21\IN\1740 cephalothin_22\JJ\1740 sodium_23\NN\14625458 and_24\CC\1740 <e1>gentamicin_25\NN\2716866 sulfate</e1>_26\NN\15010703 therapy_27\NN\657604 ._28\.\1740
D005839_D009846 NONE two_0\CD\13741022 patients_1\NNS\9898892 developed_2\VBD\1753788 acute_3\JJ\1740 tubular_4\JJ\1740 necrosis_5\NN\11444117 ,_6\,\1740 characterized_7\VBN\609683 clinically_8\RB\1740 by_9\IN\1740 acute_10\JJ\1740 <e2>oliguric_11\JJ\1740 renal_12\JJ\1740 failure</e2>_13\NN\66216 ,_14\,\1740 while_15\IN\15122231 they_16\PRP\1740 were_17\VBD\836236 receiving_18\VBG\2210855 a_19\DT\13649268 combination_20\NN\7951464 of_21\IN\1740 cephalothin_22\JJ\1740 sodium_23\NN\14625458 and_24\CC\1740 <e1>gentamicin_25\NN\2716866 sulfate</e1>_26\NN\15010703 therapy_27\NN\657604 ._28\.\1740
D005839_D051437 NONE two_0\CD\13741022 patients_1\NNS\9898892 developed_2\VBD\1753788 acute_3\JJ\1740 tubular_4\JJ\1740 necrosis_5\NN\11444117 ,_6\,\1740 characterized_7\VBN\609683 clinically_8\RB\1740 by_9\IN\1740 acute_10\JJ\1740 <e2>oliguric_11\JJ\1740 renal_12\JJ\1740 failure</e2>_13\NN\66216 ,_14\,\1740 while_15\IN\15122231 they_16\PRP\1740 were_17\VBD\836236 receiving_18\VBG\2210855 a_19\DT\13649268 combination_20\NN\7951464 of_21\IN\1740 cephalothin_22\JJ\1740 sodium_23\NN\14625458 and_24\CC\1740 <e1>gentamicin_25\NN\2716866 sulfate</e1>_26\NN\15010703 therapy_27\NN\657604 ._28\.\1740
8649546
D007980_D004409 CID improvement_0\NN\7359599 of_1\IN\1740 <e1>levodopa-induced</e1>_2\JJ\1740 <e2>dyskinesia</e2>_3\NN\14084880 by_4\IN\1740 propranolol_5\NN\1740 in_6\IN\13603305 parkinson_7\NN\1740 's_8\POS\1740 disease_9\NN\14061805 ._10\.\1740
D007980_D004409 CID this_0\DT\1740 study_1\NN\635850 suggests_2\VBZ\1010118 that_3\IN\1740 administration_4\NN\1133281 of_5\IN\1740 low_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 beta-blockers_9\NNS\1740 may_10\MD\15209706 improve_11\VB\126264 <e1>levodopa-induced</e1>_12\JJ\1740 ballistic_13\JJ\1740 and_14\CC\1740 choreic_15\JJ\1740 <e2>dyskinesia</e2>_16\NN\14084880 in_17\IN\13603305 pd_18\NN\14625458 ._19\.\1740
D007980_D010300 NONE improvement_0\NN\7359599 of_1\IN\1740 <e1>levodopa-induced</e1>_2\JJ\1740 dyskinesia_3\NN\14084880 by_4\IN\1740 propranolol_5\NN\1740 in_6\IN\13603305 <e2>parkinson_7\NN\1740 's_8\POS\1740 disease</e2>_9\NN\14061805 ._10\.\1740
D007980_D010300 NONE this_0\DT\1740 study_1\NN\635850 suggests_2\VBZ\1010118 that_3\IN\1740 administration_4\NN\1133281 of_5\IN\1740 low_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 beta-blockers_9\NNS\1740 may_10\MD\15209706 improve_11\VB\126264 <e1>levodopa-induced</e1>_12\JJ\1740 ballistic_13\JJ\1740 and_14\CC\1740 choreic_15\JJ\1740 dyskinesia_16\NN\14084880 in_17\IN\13603305 <e2>pd</e2>_18\NN\14625458 ._19\.\1740
D011433_D004409 NONE improvement_0\NN\7359599 of_1\IN\1740 levodopa-induced_2\JJ\1740 <e2>dyskinesia</e2>_3\NN\14084880 by_4\IN\1740 <e1>propranolol</e1>_5\NN\1740 in_6\IN\13603305 parkinson_7\NN\1740 's_8\POS\1740 disease_9\NN\14061805 ._10\.\1740
D011433_D004409 NONE seven_0\CD\13741022 patients_1\NNS\9898892 suffering_2\VBG\2110220 from_3\IN\1740 parkinson_4\NNP\1740 's_5\POS\1740 disease_6\NN\14061805 (_7\-LRB-\1740 pd_8\NN\14625458 )_9\-RRB-\1740 with_10\IN\1740 severely_11\RB\1740 disabling_12\VBG\126264 <e2>dyskinesia</e2>_13\NN\14084880 received_14\VBD\2210855 low-dose_15\JJ\1740 <e1>propranolol</e1>_16\NN\1740 as_17\IN\14622893 an_18\DT\6697703 adjunct_19\NN\9312645 to_20\TO\1740 the_21\DT\1740 currently_22\RB\1740 used_23\VBN\1156834 medical_24\JJ\1740 treatment_25\NN\654885 ._26\.\1740
D011433_D010300 NONE improvement_0\NN\7359599 of_1\IN\1740 levodopa-induced_2\JJ\1740 dyskinesia_3\NN\14084880 by_4\IN\1740 <e1>propranolol</e1>_5\NN\1740 in_6\IN\13603305 <e2>parkinson_7\NN\1740 's_8\POS\1740 disease</e2>_9\NN\14061805 ._10\.\1740
D011433_D010300 NONE seven_0\CD\13741022 patients_1\NNS\9898892 suffering_2\VBG\2110220 from_3\IN\1740 <e2>parkinson_4\NNP\1740 's_5\POS\1740 disease</e2>_6\NN\14061805 (_7\-LRB-\1740 pd_8\NN\14625458 )_9\-RRB-\1740 with_10\IN\1740 severely_11\RB\1740 disabling_12\VBG\126264 dyskinesia_13\NN\14084880 received_14\VBD\2210855 low-dose_15\JJ\1740 <e1>propranolol</e1>_16\NN\1740 as_17\IN\14622893 an_18\DT\6697703 adjunct_19\NN\9312645 to_20\TO\1740 the_21\DT\1740 currently_22\RB\1740 used_23\VBN\1156834 medical_24\JJ\1740 treatment_25\NN\654885 ._26\.\1740
D011433_D010300 NONE seven_0\CD\13741022 patients_1\NNS\9898892 suffering_2\VBG\2110220 from_3\IN\1740 parkinson_4\NNP\1740 's_5\POS\1740 disease_6\NN\14061805 (_7\-LRB-\1740 <e2>pd</e2>_8\NN\14625458 )_9\-RRB-\1740 with_10\IN\1740 severely_11\RB\1740 disabling_12\VBG\126264 dyskinesia_13\NN\14084880 received_14\VBD\2210855 low-dose_15\JJ\1740 <e1>propranolol</e1>_16\NN\1740 as_17\IN\14622893 an_18\DT\6697703 adjunct_19\NN\9312645 to_20\TO\1740 the_21\DT\1740 currently_22\RB\1740 used_23\VBN\1156834 medical_24\JJ\1740 treatment_25\NN\654885 ._26\.\1740
9406968
D014667_D003919 NONE upregulation_0\NN\1740 of_1\IN\1740 the_2\DT\1740 expression_3\NN\4679549 of_4\IN\1740 <e1>vasopressin</e1>_5\NN\5407119 gene_6\NN\8459252 in_7\IN\13603305 the_8\DT\1740 paraventricular_9\JJ\1740 and_10\CC\1740 supraoptic_11\JJ\1740 nuclei_12\NNS\5445668 of_13\IN\1740 the_14\DT\1740 lithium-induced_15\JJ\1740 <e2>diabetes_16\NN\14075199 insipidus</e2>_17\NN\1740 rat_18\NN\2329401 ._19\.\1740
D008094_D003919 NONE upregulation_0\NN\1740 of_1\IN\1740 the_2\DT\1740 expression_3\NN\4679549 of_4\IN\1740 vasopressin_5\NN\5407119 gene_6\NN\8459252 in_7\IN\13603305 the_8\DT\1740 paraventricular_9\JJ\1740 and_10\CC\1740 supraoptic_11\JJ\1740 nuclei_12\NNS\5445668 of_13\IN\1740 the_14\DT\1740 <e1>lithium-induced</e1>_15\JJ\1740 <e2>diabetes_16\NN\14075199 insipidus</e2>_17\NN\1740 rat_18\NN\2329401 ._19\.\1740
D008094_D003919 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 dehydration_4\NN\14536438 and/or_5\CC\1740 the_6\DT\1740 activation_7\NN\13561719 of_8\IN\1740 visceral_9\JJ\1740 afferent_10\JJ\1740 inputs_11\NNS\6791372 may_12\MD\15209706 contribute_13\VB\126264 to_14\TO\1740 the_15\DT\1740 elevation_16\NN\7445480 of_17\IN\1740 plasma_18\NN\5398023 avp_19\NN\1740 and_20\CC\1740 the_21\DT\1740 upregulation_22\NN\1740 of_23\IN\1740 avp_24\NN\1740 gene_25\NN\8459252 expression_26\NN\4679549 in_27\IN\13603305 the_28\DT\1740 pvn_29\NN\1740 and_30\CC\1740 the_31\DT\1740 son_32\NN\10285938 of_33\IN\1740 the_34\DT\1740 <e1>li-induced</e1>_35\JJ\1740 <e2>diabetes_36\NNS\14075199 insipidus</e2>_37\NN\1740 rat_38\NN\2329401 ._39\.\1740
D001127_D011141 NONE the_0\DT\1740 expression_1\NN\4679549 of_2\IN\1740 <e1>arginine_3\NN\14605787 vasopressin</e1>_4\NN\5407119 (_5\-LRB-\1740 avp_6\NN\1740 )_7\-RRB-\1740 gene_8\NN\8459252 in_9\IN\13603305 the_10\DT\1740 paraventricular_11\NN\1740 (_12\-LRB-\1740 pvn_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 supraoptic_16\JJ\1740 nuclei_17\NNS\5445668 (_18\-LRB-\1740 son_19\NN\10285938 )_20\-RRB-\1740 was_21\VBD\836236 investigated_22\VBN\644583 in_23\IN\13603305 rats_24\NNS\2329401 with_25\IN\1740 lithium_26\NN\14625458 (li)-induced_27\JJ\1740 <e2>polyuria</e2>_28\NN\14113228 ,_29\,\1740 using_30\VBG\1156834 in_31\FW\13603305 situ_32\FW\1740 hybridization_33\NN\847340 histochemistry_34\NN\1740 and_35\CC\1740 radioimmunoassay_36\JJ\1740 ._37\.\1740
D001127_D011141 NONE the_0\DT\1740 expression_1\NN\4679549 of_2\IN\1740 arginine_3\NN\14605787 vasopressin_4\NN\5407119 (_5\-LRB-\1740 <e1>avp</e1>_6\NN\1740 )_7\-RRB-\1740 gene_8\NN\8459252 in_9\IN\13603305 the_10\DT\1740 paraventricular_11\NN\1740 (_12\-LRB-\1740 pvn_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 supraoptic_16\JJ\1740 nuclei_17\NNS\5445668 (_18\-LRB-\1740 son_19\NN\10285938 )_20\-RRB-\1740 was_21\VBD\836236 investigated_22\VBN\644583 in_23\IN\13603305 rats_24\NNS\2329401 with_25\IN\1740 lithium_26\NN\14625458 (li)-induced_27\JJ\1740 <e2>polyuria</e2>_28\NN\14113228 ,_29\,\1740 using_30\VBG\1156834 in_31\FW\13603305 situ_32\FW\1740 hybridization_33\NN\847340 histochemistry_34\NN\1740 and_35\CC\1740 radioimmunoassay_36\JJ\1740 ._37\.\1740
D008094_D011141 NONE the_0\DT\1740 expression_1\NN\4679549 of_2\IN\1740 arginine_3\NN\14605787 vasopressin_4\NN\5407119 (_5\-LRB-\1740 avp_6\NN\1740 )_7\-RRB-\1740 gene_8\NN\8459252 in_9\IN\13603305 the_10\DT\1740 paraventricular_11\NN\1740 (_12\-LRB-\1740 pvn_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 supraoptic_16\JJ\1740 nuclei_17\NNS\5445668 (_18\-LRB-\1740 son_19\NN\10285938 )_20\-RRB-\1740 was_21\VBD\836236 investigated_22\VBN\644583 in_23\IN\13603305 rats_24\NNS\2329401 with_25\IN\1740 <e1>lithium</e1>_26\NN\14625458 (li)-induced_27\JJ\1740 <e2>polyuria</e2>_28\NN\14113228 ,_29\,\1740 using_30\VBG\1156834 in_31\FW\13603305 situ_32\FW\1740 hybridization_33\NN\847340 histochemistry_34\NN\1740 and_35\CC\1740 radioimmunoassay_36\JJ\1740 ._37\.\1740
D008094_D011141 NONE the_0\DT\1740 expression_1\NN\4679549 of_2\IN\1740 arginine_3\NN\14605787 vasopressin_4\NN\5407119 (_5\-LRB-\1740 avp_6\NN\1740 )_7\-RRB-\1740 gene_8\NN\8459252 in_9\IN\13603305 the_10\DT\1740 paraventricular_11\NN\1740 (_12\-LRB-\1740 pvn_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 supraoptic_16\JJ\1740 nuclei_17\NNS\5445668 (_18\-LRB-\1740 son_19\NN\10285938 )_20\-RRB-\1740 was_21\VBD\836236 investigated_22\VBN\644583 in_23\IN\13603305 rats_24\NNS\2329401 with_25\IN\1740 lithium_26\NN\14625458 <e1>(li)-induced</e1>_27\JJ\1740 <e2>polyuria</e2>_28\NN\14113228 ,_29\,\1740 using_30\VBG\1156834 in_31\FW\13603305 situ_32\FW\1740 hybridization_33\NN\847340 histochemistry_34\NN\1740 and_35\CC\1740 radioimmunoassay_36\JJ\1740 ._37\.\1740
D018021_D011141 CID the_0\DT\1740 male_1\JJ\1740 wistar_2\NNP\1740 rats_3\NNS\2329401 consuming_4\VBG\1168468 a_5\DT\13649268 diet_6\NN\7560652 that_7\WDT\1740 contained_8\VBD\2632940 <e1>licl</e1>_9\NN\1740 (_10\-LRB-\1740 60_11\CD\13745420 mmol/kg_12\NNS\1740 )_13\-RRB-\1740 for_14\IN\1740 4_15\CD\13741022 weeks_16\NNS\15113229 developed_17\VBD\1753788 marked_18\JJ\1740 <e2>polyuria</e2>_19\NN\14113228 ._20\.\1740
D001127_D003681 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e2>dehydration</e2>_4\NN\14536438 and/or_5\CC\1740 the_6\DT\1740 activation_7\NN\13561719 of_8\IN\1740 visceral_9\JJ\1740 afferent_10\JJ\1740 inputs_11\NNS\6791372 may_12\MD\15209706 contribute_13\VB\126264 to_14\TO\1740 the_15\DT\1740 elevation_16\NN\7445480 of_17\IN\1740 plasma_18\NN\5398023 <e1>avp</e1>_19\NN\1740 and_20\CC\1740 the_21\DT\1740 upregulation_22\NN\1740 of_23\IN\1740 avp_24\NN\1740 gene_25\NN\8459252 expression_26\NN\4679549 in_27\IN\13603305 the_28\DT\1740 pvn_29\NN\1740 and_30\CC\1740 the_31\DT\1740 son_32\NN\10285938 of_33\IN\1740 the_34\DT\1740 li-induced_35\JJ\1740 diabetes_36\NNS\14075199 insipidus_37\NN\1740 rat_38\NN\2329401 ._39\.\1740
D001127_D003681 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e2>dehydration</e2>_4\NN\14536438 and/or_5\CC\1740 the_6\DT\1740 activation_7\NN\13561719 of_8\IN\1740 visceral_9\JJ\1740 afferent_10\JJ\1740 inputs_11\NNS\6791372 may_12\MD\15209706 contribute_13\VB\126264 to_14\TO\1740 the_15\DT\1740 elevation_16\NN\7445480 of_17\IN\1740 plasma_18\NN\5398023 avp_19\NN\1740 and_20\CC\1740 the_21\DT\1740 upregulation_22\NN\1740 of_23\IN\1740 <e1>avp</e1>_24\NN\1740 gene_25\NN\8459252 expression_26\NN\4679549 in_27\IN\13603305 the_28\DT\1740 pvn_29\NN\1740 and_30\CC\1740 the_31\DT\1740 son_32\NN\10285938 of_33\IN\1740 the_34\DT\1740 li-induced_35\JJ\1740 diabetes_36\NNS\14075199 insipidus_37\NN\1740 rat_38\NN\2329401 ._39\.\1740
D001127_D003919 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 dehydration_4\NN\14536438 and/or_5\CC\1740 the_6\DT\1740 activation_7\NN\13561719 of_8\IN\1740 visceral_9\JJ\1740 afferent_10\JJ\1740 inputs_11\NNS\6791372 may_12\MD\15209706 contribute_13\VB\126264 to_14\TO\1740 the_15\DT\1740 elevation_16\NN\7445480 of_17\IN\1740 plasma_18\NN\5398023 <e1>avp</e1>_19\NN\1740 and_20\CC\1740 the_21\DT\1740 upregulation_22\NN\1740 of_23\IN\1740 avp_24\NN\1740 gene_25\NN\8459252 expression_26\NN\4679549 in_27\IN\13603305 the_28\DT\1740 pvn_29\NN\1740 and_30\CC\1740 the_31\DT\1740 son_32\NN\10285938 of_33\IN\1740 the_34\DT\1740 li-induced_35\JJ\1740 <e2>diabetes_36\NNS\14075199 insipidus</e2>_37\NN\1740 rat_38\NN\2329401 ._39\.\1740
D001127_D003919 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 dehydration_4\NN\14536438 and/or_5\CC\1740 the_6\DT\1740 activation_7\NN\13561719 of_8\IN\1740 visceral_9\JJ\1740 afferent_10\JJ\1740 inputs_11\NNS\6791372 may_12\MD\15209706 contribute_13\VB\126264 to_14\TO\1740 the_15\DT\1740 elevation_16\NN\7445480 of_17\IN\1740 plasma_18\NN\5398023 avp_19\NN\1740 and_20\CC\1740 the_21\DT\1740 upregulation_22\NN\1740 of_23\IN\1740 <e1>avp</e1>_24\NN\1740 gene_25\NN\8459252 expression_26\NN\4679549 in_27\IN\13603305 the_28\DT\1740 pvn_29\NN\1740 and_30\CC\1740 the_31\DT\1740 son_32\NN\10285938 of_33\IN\1740 the_34\DT\1740 li-induced_35\JJ\1740 <e2>diabetes_36\NNS\14075199 insipidus</e2>_37\NN\1740 rat_38\NN\2329401 ._39\.\1740
D008094_D003681 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e2>dehydration</e2>_4\NN\14536438 and/or_5\CC\1740 the_6\DT\1740 activation_7\NN\13561719 of_8\IN\1740 visceral_9\JJ\1740 afferent_10\JJ\1740 inputs_11\NNS\6791372 may_12\MD\15209706 contribute_13\VB\126264 to_14\TO\1740 the_15\DT\1740 elevation_16\NN\7445480 of_17\IN\1740 plasma_18\NN\5398023 avp_19\NN\1740 and_20\CC\1740 the_21\DT\1740 upregulation_22\NN\1740 of_23\IN\1740 avp_24\NN\1740 gene_25\NN\8459252 expression_26\NN\4679549 in_27\IN\13603305 the_28\DT\1740 pvn_29\NN\1740 and_30\CC\1740 the_31\DT\1740 son_32\NN\10285938 of_33\IN\1740 the_34\DT\1740 <e1>li-induced</e1>_35\JJ\1740 diabetes_36\NNS\14075199 insipidus_37\NN\1740 rat_38\NN\2329401 ._39\.\1740
3187073
D005472_D002637 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 patients_4\NNS\9898892 on_5\IN\1740 <e1>5-fu</e1>_6\NN\1740 treatment_7\NN\654885 should_8\MD\1740 be_9\VB\836236 under_10\IN\1740 close_11\JJ\1740 supervision_12\NN\1133281 and_13\CC\1740 that_14\IN\1740 the_15\DT\1740 treatment_16\NN\654885 should_17\MD\1740 be_18\VB\836236 discontinued_19\VBN\2609764 if_20\IN\1740 <e2>chest_21\JJ\1740 pain</e2>_22\NN\14299637 or_23\CC\3541091 tachyarrhythmia_24\NN\1740 is_25\VBZ\836236 observed_26\VBN\2163746 ._27\.\1740
D005472_D013610 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 patients_4\NNS\9898892 on_5\IN\1740 <e1>5-fu</e1>_6\NN\1740 treatment_7\NN\654885 should_8\MD\1740 be_9\VB\836236 under_10\IN\1740 close_11\JJ\1740 supervision_12\NN\1133281 and_13\CC\1740 that_14\IN\1740 the_15\DT\1740 treatment_16\NN\654885 should_17\MD\1740 be_18\VB\836236 discontinued_19\VBN\2609764 if_20\IN\1740 chest_21\JJ\1740 pain_22\NN\14299637 or_23\CC\3541091 <e2>tachyarrhythmia</e2>_24\NN\1740 is_25\VBZ\836236 observed_26\VBN\2163746 ._27\.\1740
17400887
D013726_D020078 NONE <e2>neuroinflammation</e2>_0\NN\1740 and_1\CC\1740 behavioral_2\JJ\1740 abnormalities_3\NNS\14034177 after_4\IN\1740 neonatal_5\JJ\1740 <e1>terbutaline</e1>_6\NN\1740 treatment_7\NN\654885 in_8\IN\13603305 rats_9\NNS\2329401 :_10\:\1740 implications_11\NNS\5774614 for_12\IN\1740 autism_13\NN\14304060 ._14\.\1740
D013726_D001523 NONE neuroinflammation_0\NN\1740 and_1\CC\1740 <e2>behavioral_2\JJ\1740 abnormalities</e2>_3\NNS\14034177 after_4\IN\1740 neonatal_5\JJ\1740 <e1>terbutaline</e1>_6\NN\1740 treatment_7\NN\654885 in_8\IN\13603305 rats_9\NNS\2329401 :_10\:\1740 implications_11\NNS\5774614 for_12\IN\1740 autism_13\NN\14304060 ._14\.\1740
D013726_D001321 CID neuroinflammation_0\NN\1740 and_1\CC\1740 behavioral_2\JJ\1740 abnormalities_3\NNS\14034177 after_4\IN\1740 neonatal_5\JJ\1740 <e1>terbutaline</e1>_6\NN\1740 treatment_7\NN\654885 in_8\IN\13603305 rats_9\NNS\2329401 :_10\:\1740 implications_11\NNS\5774614 for_12\IN\1740 <e2>autism</e2>_13\NN\14304060 ._14\.\1740
D013726_D001321 CID <e1>terbutaline</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 beta2-adrenoceptor_3\NN\1740 agonist_4\NN\9613191 used_5\VBN\1156834 to_6\TO\1740 arrest_7\VB\1212572 preterm_8\NN\1740 labor_9\NN\7974025 ,_10\,\1740 has_11\VBZ\2108377 been_12\VBN\836236 associated_13\VBN\628491 with_14\IN\1740 increased_15\VBN\169651 concordance_16\NN\13968547 for_17\IN\1740 <e2>autism</e2>_18\NN\14304060 in_19\IN\13603305 dizygotic_20\JJ\1740 twins_21\NNS\14883206 ._22\.\1740
D013726_D007752 NONE <e1>terbutaline</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 beta2-adrenoceptor_3\NN\1740 agonist_4\NN\9613191 used_5\VBN\1156834 to_6\TO\1740 arrest_7\VB\1212572 <e2>preterm_8\NN\1740 labor</e2>_9\NN\7974025 ,_10\,\1740 has_11\VBZ\2108377 been_12\VBN\836236 associated_13\VBN\628491 with_14\IN\1740 increased_15\VBN\169651 concordance_16\NN\13968547 for_17\IN\1740 autism_18\NN\14304060 in_19\IN\13603305 dizygotic_20\JJ\1740 twins_21\NNS\14883206 ._22\.\1740
9522152
D002045_D009461 NONE a_0\DT\13649268 transient_1\JJ\1740 <e2>neurological_2\JJ\1740 deficit</e2>_3\NN\5113133 following_4\VBG\1835496 intrathecal_5\JJ\1740 injection_6\NN\320852 of_7\IN\1740 1_8\CD\13741022 %_9\NN\1740 hyperbaric_10\JJ\1740 <e1>bupivacaine</e1>_11\NN\1740 for_12\IN\1740 unilateral_13\JJ\1740 spinal_14\JJ\1740 anaesthesia_15\NN\14034177 ._16\.\1740
D002045_D009461 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 transient_5\JJ\1740 <e2>neurological_6\JJ\1740 deficit</e2>_7\NN\5113133 that_8\WDT\1740 occurred_9\VBD\2623529 after_10\IN\1740 unilateral_11\JJ\1740 spinal_12\JJ\1740 anaesthesia_13\NN\14034177 with_14\IN\1740 8_15\CD\13741022 mg_16\NN\13717155 of_17\IN\1740 1_18\CD\13741022 %_19\NN\1740 hyperbaric_20\NN\1740 <e1>bupivacaine</e1>_21\NN\1740 slowly_22\RB\1740 injected_23\VBN\81072 through_24\IN\1740 a_25\DT\13649268 25-gauge_26\JJ\1740 pencil-point_27\JJ\1740 spinal_28\JJ\1740 needle_29\NN\13156083 ._30\.\1740
17562951
D007479_D051436 NONE methods_0\NNS\5616786 and_1\CC\1740 results_2\NNS\34213 :_3\:\1740 the_4\DT\1740 present_5\JJ\1740 study_6\NN\635850 is_7\VBZ\836236 a_8\DT\13649268 multicenter_9\NN\1740 ,_10\,\1740 randomized_11\VBN\278117 ,_12\,\1740 double-blind_13\JJ\1740 comparison_14\NN\635850 of_15\IN\1740 <e1>iopamidol</e1>_16\NN\1740 and_17\CC\1740 iodixanol_18\NN\1740 in_19\IN\13603305 patients_20\NNS\9898892 with_21\IN\1740 <e2>chronic_22\JJ\1740 kidney_23\NN\5333259 disease</e2>_24\NN\14061805 (_25\-LRB-\1740 estimated_26\VBN\637259 glomerular_27\JJ\1740 filtration_28\NN\13518963 rate_29\NN\13815152 ,_30\,\1740 20_31\CD\13745420 to_32\TO\1740 59_33\CD\1740 ml/min_34\NN\1740 )_35\-RRB-\1740 who_36\WP\8299493 underwent_37\VBD\109660 cardiac_38\JJ\1740 angiography_39\NN\904623 or_40\CC\3541091 percutaneous_41\JJ\1740 coronary_42\JJ\1740 interventions_43\NNS\1239064 ._44\.\1740
C044834_D051436 NONE methods_0\NNS\5616786 and_1\CC\1740 results_2\NNS\34213 :_3\:\1740 the_4\DT\1740 present_5\JJ\1740 study_6\NN\635850 is_7\VBZ\836236 a_8\DT\13649268 multicenter_9\NN\1740 ,_10\,\1740 randomized_11\VBN\278117 ,_12\,\1740 double-blind_13\JJ\1740 comparison_14\NN\635850 of_15\IN\1740 iopamidol_16\NN\1740 and_17\CC\1740 <e1>iodixanol</e1>_18\NN\1740 in_19\IN\13603305 patients_20\NNS\9898892 with_21\IN\1740 <e2>chronic_22\JJ\1740 kidney_23\NN\5333259 disease</e2>_24\NN\14061805 (_25\-LRB-\1740 estimated_26\VBN\637259 glomerular_27\JJ\1740 filtration_28\NN\13518963 rate_29\NN\13815152 ,_30\,\1740 20_31\CD\13745420 to_32\TO\1740 59_33\CD\1740 ml/min_34\NN\1740 )_35\-RRB-\1740 who_36\WP\8299493 underwent_37\VBD\109660 cardiac_38\JJ\1740 angiography_39\NN\904623 or_40\CC\3541091 percutaneous_41\JJ\1740 coronary_42\JJ\1740 interventions_43\NNS\1239064 ._44\.\1740
D000111_D003920 NONE in_0\IN\13603305 414_1\CD\1740 patients_2\NNS\9898892 ,_3\,\1740 contrast_4\VBP\650353 volume_5\NN\33615 ,_6\,\1740 presence_7\NN\13954253 of_8\IN\1740 <e2>diabetes_9\NN\14075199 mellitus</e2>_10\NN\1740 ,_11\,\1740 use_12\NN\407535 of_13\IN\1740 <e1>n-acetylcysteine</e1>_14\NN\1740 ,_15\,\1740 mean_16\VBP\928630 baseline_17\NN\7260623 scr_18\NNS\1740 ,_19\,\1740 and_20\CC\1740 estimated_21\VBD\637259 glomerular_22\JJ\1740 filtration_23\NN\13518963 rate_24\NN\13815152 were_25\VBD\836236 comparable_26\JJ\1740 in_27\IN\13603305 the_28\DT\1740 2_29\CD\13741022 groups_30\NNS\2137 ._31\.\1740
D007479_D003920 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 <e2>diabetes</e2>_3\NNS\14075199 ,_4\,\1740 scr_5\NNS\1740 increases_6\VBZ\169651 >_7\NN\1740 or_8\CC\3541091 =_9\JJ\1740 0.5_10\CD\1740 mg/dl_11\NN\1740 were_12\VBD\836236 5.1_13\CD\1740 %_14\NN\1740 (_15\-LRB-\1740 4_16\CD\13741022 of_17\IN\1740 78_18\CD\13745420 patients_19\NNS\9898892 )_20\-RRB-\1740 with_21\IN\1740 <e1>iopamidol</e1>_22\NN\1740 and_23\CC\1740 13.0_24\CD\1740 %_25\NN\1740 (_26\-LRB-\1740 12_27\CD\13745420 of_28\IN\1740 92_29\CD\1740 patients_30\NNS\9898892 )_31\-RRB-\1740 with_32\IN\1740 iodixanol_33\NN\1740 (_34\-LRB-\1740 p=0.11_35\NNS\1740 )_36\-RRB-\1740 ,_37\,\1740 whereas_38\IN\1740 scr_39\NN\1740 increases_40\VBZ\169651 >_41\NN\1740 or_42\CC\3541091 =_43\JJ\1740 25_44\CD\13745420 %_45\NN\1740 were_46\VBD\836236 10.3_47\CD\1740 %_48\NN\1740 and_49\CC\1740 15.2_50\CD\1740 %_51\NN\1740 ,_52\,\1740 respectively_53\RB\1740 (_54\-LRB-\1740 p=0.37_55\NN\1740 )_56\-RRB-\1740 ._57\.\1740
D007479_D003920 NONE mean_0\NN\6021761 post-scr_1\NN\1740 increases_2\NNS\13576355 were_3\VBD\836236 significantly_4\RB\1740 less_5\JJR\1740 with_6\IN\1740 <e1>iopamidol</e1>_7\NN\1740 (_8\-LRB-\1740 all_9\DT\1740 patients_10\NNS\9898892 :_11\:\1740 0.07_12\CD\1740 versus_13\CC\1740 0.12_14\CD\1740 mg/dl_15\NN\1740 ,_16\,\1740 6.2_17\CD\1740 versus_18\CC\1740 10.6_19\CD\1740 micromol/l_20\NN\1740 ,_21\,\1740 p=0.03_22\JJ\1740 ;_23\:\1740 patients_24\NNS\9898892 with_25\IN\1740 <e2>diabetes</e2>_26\NNS\14075199 :_27\:\1740 0.07_28\CD\1740 versus_29\CC\1740 0.16_30\CD\1740 mg/dl_31\NN\1740 ,_32\,\1740 6.2_33\CD\1740 versus_34\CC\1740 14.1_35\CD\1740 micromol/l_36\NN\1740 ,_37\,\1740 p=0.01_38\NN\1740 )_39\-RRB-\1740 ._40\.\1740
D007479_D003920 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 rate_3\NN\13815152 of_4\IN\1740 contrast-induced_5\JJ\1740 nephropathy_6\NN\14573196 ,_7\,\1740 defined_8\VBN\2604760 by_9\IN\1740 multiple_10\JJ\1740 end_11\NN\8568978 points_12\NNS\5868954 ,_13\,\1740 is_14\VBZ\836236 not_15\RB\1740 statistically_16\RB\1740 different_17\JJ\1740 after_18\IN\1740 the_19\DT\1740 intraarterial_20\JJ\1740 administration_21\NN\1133281 of_22\IN\1740 <e1>iopamidol</e1>_23\NN\1740 or_24\CC\3541091 iodixanol_25\NN\1740 to_26\TO\1740 high-risk_27\JJ\1740 patients_28\NNS\9898892 ,_29\,\1740 with_30\IN\1740 or_31\CC\3541091 without_32\IN\1740 <e2>diabetes_33\NN\14075199 mellitus</e2>_34\NN\1740 ._35\.\1740
C044834_D003920 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 <e2>diabetes</e2>_3\NNS\14075199 ,_4\,\1740 scr_5\NNS\1740 increases_6\VBZ\169651 >_7\NN\1740 or_8\CC\3541091 =_9\JJ\1740 0.5_10\CD\1740 mg/dl_11\NN\1740 were_12\VBD\836236 5.1_13\CD\1740 %_14\NN\1740 (_15\-LRB-\1740 4_16\CD\13741022 of_17\IN\1740 78_18\CD\13745420 patients_19\NNS\9898892 )_20\-RRB-\1740 with_21\IN\1740 iopamidol_22\NN\1740 and_23\CC\1740 13.0_24\CD\1740 %_25\NN\1740 (_26\-LRB-\1740 12_27\CD\13745420 of_28\IN\1740 92_29\CD\1740 patients_30\NNS\9898892 )_31\-RRB-\1740 with_32\IN\1740 <e1>iodixanol</e1>_33\NN\1740 (_34\-LRB-\1740 p=0.11_35\NNS\1740 )_36\-RRB-\1740 ,_37\,\1740 whereas_38\IN\1740 scr_39\NN\1740 increases_40\VBZ\169651 >_41\NN\1740 or_42\CC\3541091 =_43\JJ\1740 25_44\CD\13745420 %_45\NN\1740 were_46\VBD\836236 10.3_47\CD\1740 %_48\NN\1740 and_49\CC\1740 15.2_50\CD\1740 %_51\NN\1740 ,_52\,\1740 respectively_53\RB\1740 (_54\-LRB-\1740 p=0.37_55\NN\1740 )_56\-RRB-\1740 ._57\.\1740
C044834_D003920 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 rate_3\NN\13815152 of_4\IN\1740 contrast-induced_5\JJ\1740 nephropathy_6\NN\14573196 ,_7\,\1740 defined_8\VBN\2604760 by_9\IN\1740 multiple_10\JJ\1740 end_11\NN\8568978 points_12\NNS\5868954 ,_13\,\1740 is_14\VBZ\836236 not_15\RB\1740 statistically_16\RB\1740 different_17\JJ\1740 after_18\IN\1740 the_19\DT\1740 intraarterial_20\JJ\1740 administration_21\NN\1133281 of_22\IN\1740 iopamidol_23\NN\1740 or_24\CC\3541091 <e1>iodixanol</e1>_25\NN\1740 to_26\TO\1740 high-risk_27\JJ\1740 patients_28\NNS\9898892 ,_29\,\1740 with_30\IN\1740 or_31\CC\3541091 without_32\IN\1740 <e2>diabetes_33\NN\14075199 mellitus</e2>_34\NN\1740 ._35\.\1740
D007479_D007674 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 rate_3\NN\13815152 of_4\IN\1740 contrast-induced_5\JJ\1740 <e2>nephropathy</e2>_6\NN\14573196 ,_7\,\1740 defined_8\VBN\2604760 by_9\IN\1740 multiple_10\JJ\1740 end_11\NN\8568978 points_12\NNS\5868954 ,_13\,\1740 is_14\VBZ\836236 not_15\RB\1740 statistically_16\RB\1740 different_17\JJ\1740 after_18\IN\1740 the_19\DT\1740 intraarterial_20\JJ\1740 administration_21\NN\1133281 of_22\IN\1740 <e1>iopamidol</e1>_23\NN\1740 or_24\CC\3541091 iodixanol_25\NN\1740 to_26\TO\1740 high-risk_27\JJ\1740 patients_28\NNS\9898892 ,_29\,\1740 with_30\IN\1740 or_31\CC\3541091 without_32\IN\1740 diabetes_33\NN\14075199 mellitus_34\NN\1740 ._35\.\1740
C044834_D007674 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 rate_3\NN\13815152 of_4\IN\1740 contrast-induced_5\JJ\1740 <e2>nephropathy</e2>_6\NN\14573196 ,_7\,\1740 defined_8\VBN\2604760 by_9\IN\1740 multiple_10\JJ\1740 end_11\NN\8568978 points_12\NNS\5868954 ,_13\,\1740 is_14\VBZ\836236 not_15\RB\1740 statistically_16\RB\1740 different_17\JJ\1740 after_18\IN\1740 the_19\DT\1740 intraarterial_20\JJ\1740 administration_21\NN\1133281 of_22\IN\1740 iopamidol_23\NN\1740 or_24\CC\3541091 <e1>iodixanol</e1>_25\NN\1740 to_26\TO\1740 high-risk_27\JJ\1740 patients_28\NNS\9898892 ,_29\,\1740 with_30\IN\1740 or_31\CC\3541091 without_32\IN\1740 diabetes_33\NN\14075199 mellitus_34\NN\1740 ._35\.\1740
12574103
D003907_D006973 CID prenatal_0\JJ\1740 <e1>dexamethasone</e1>_1\NN\2721538 programs_2\NNS\5833840 <e2>hypertension</e2>_3\NN\14057371 and_4\CC\1740 renal_5\JJ\1740 injury_6\NN\14052046 in_7\IN\13603305 the_8\DT\1740 rat_9\NN\2329401 ._10\.\1740
D003907_D006973 CID the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 if_9\IN\1740 prenatal_10\JJ\1740 <e1>dexamethasone</e1>_11\NN\2721538 programmed_12\VBD\794981 a_13\DT\13649268 progressive_14\JJ\1740 <e2>increase_15\NN\13576355 in_16\IN\13603305 blood_17\NN\5397468 pressure</e2>_18\NN\11419404 and_19\CC\1740 renal_20\JJ\1740 injury_21\NN\14052046 in_22\IN\13603305 rats_23\NNS\2329401 ._24\.\1740
D003907_D006973 CID male_0\JJ\1740 rats_1\NNS\2329401 that_2\WDT\1740 received_3\VBD\2210855 prenatal_4\JJ\1740 <e1>dexamethasone</e1>_5\NN\2721538 on_6\IN\1740 days_7\NNS\15140892 15_8\CD\13745420 and_9\CC\1740 16_10\CD\13745420 ,_11\,\1740 17_12\CD\13745420 and_13\CC\1740 18_14\CD\13745420 ,_15\,\1740 and_16\CC\1740 13_17\CD\13745420 and_18\CC\1740 14_19\CD\13745420 of_20\IN\1740 gestation_21\NN\15116532 had_22\VBD\2108377 <e2>elevated_23\JJ\1740 blood_24\NN\5397468 pressures</e2>_25\NNS\11419404 at_26\IN\14622893 6_27\CD\13741022 months_28\NNS\15113229 of_29\IN\1740 age_30\NN\4916342 ;_31\:\1740 the_32\DT\1740 latter_33\JJ\1740 group_34\NN\2137 did_35\VBD\1640855 not_36\RB\1740 have_37\VB\2108377 a_38\DT\13649268 reduction_39\NN\351485 in_40\IN\13603305 glomerular_41\JJ\1740 number_42\NN\5107765 ._43\.\1740
D003907_D006973 CID this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 prenatal_4\JJ\1740 <e1>dexamethasone</e1>_5\NN\2721538 in_6\IN\13603305 rats_7\NNS\2329401 results_8\VBZ\2633881 in_9\IN\13603305 a_10\DT\13649268 reduction_11\NN\351485 in_12\IN\13603305 glomerular_13\JJ\1740 number_14\NN\5107765 ,_15\,\1740 glomerulosclerosis_16\NN\1740 ,_17\,\1740 and_18\CC\1740 <e2>hypertension</e2>_19\NN\14057371 when_20\WRB\1740 administered_21\VBN\2436349 at_22\IN\14622893 specific_23\JJ\1740 points_24\NNS\5868954 during_25\IN\1740 gestation_26\NN\15116532 ._27\.\1740
D003907_D007674 CID prenatal_0\JJ\1740 <e1>dexamethasone</e1>_1\NN\2721538 programs_2\NNS\5833840 hypertension_3\NN\14057371 and_4\CC\1740 <e2>renal_5\JJ\1740 injury</e2>_6\NN\14052046 in_7\IN\13603305 the_8\DT\1740 rat_9\NN\2329401 ._10\.\1740
D003907_D007674 CID the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 if_9\IN\1740 prenatal_10\JJ\1740 <e1>dexamethasone</e1>_11\NN\2721538 programmed_12\VBD\794981 a_13\DT\13649268 progressive_14\JJ\1740 increase_15\NN\13576355 in_16\IN\13603305 blood_17\NN\5397468 pressure_18\NN\11419404 and_19\CC\1740 <e2>renal_20\JJ\1740 injury</e2>_21\NN\14052046 in_22\IN\13603305 rats_23\NNS\2329401 ._24\.\1740
D003907_D007674 CID offspring_0\NN\10235549 of_1\IN\1740 rats_2\NNS\2329401 administered_3\VBN\2436349 <e1>dexamethasone</e1>_4\NN\2721538 on_5\IN\1740 days_6\NNS\15140892 15_7\CD\13745420 and_8\CC\1740 16_9\CD\13745420 gestation_10\NN\15116532 had_11\VBD\2108377 a_12\DT\13649268 20_13\CD\13745420 %_14\NN\1740 <e2>reduction_15\NN\351485 in_16\IN\13603305 glomerular_17\JJ\1740 number</e2>_18\NN\5107765 compared_19\VBN\644583 with_20\IN\1740 control_21\NN\5190804 at_22\IN\14622893 6_23\CD\13741022 to_24\TO\1740 9_25\CD\13741022 months_26\NNS\15113229 of_27\IN\1740 age_28\NN\4916342 (_29\-LRB-\1740 22_30\CD\13745420 527+/-509_31\CD\1740 versus_32\CC\1740 28_33\CD\13745420 050+/-561_34\CD\1740 ,_35\,\1740 p<0.05_36\CD\1740 )_37\-RRB-\1740 ,_38\,\1740 which_39\WDT\1740 was_40\VBD\836236 comparable_41\JJ\1740 to_42\TO\1740 the_43\DT\1740 percent_44\NN\13815742 reduction_45\NN\351485 in_46\IN\13603305 glomeruli_47\NNS\5425910 measured_48\VBN\697589 at_49\IN\14622893 3_50\CD\13741022 weeks_51\NNS\15113229 of_52\IN\1740 age_53\NN\4916342 ._54\.\1740
D003907_D007674 CID male_0\JJ\1740 rats_1\NNS\2329401 that_2\WDT\1740 received_3\VBD\2210855 prenatal_4\JJ\1740 <e1>dexamethasone</e1>_5\NN\2721538 on_6\IN\1740 days_7\NNS\15140892 15_8\CD\13745420 and_9\CC\1740 16_10\CD\13745420 ,_11\,\1740 17_12\CD\13745420 and_13\CC\1740 18_14\CD\13745420 ,_15\,\1740 and_16\CC\1740 13_17\CD\13745420 and_18\CC\1740 14_19\CD\13745420 of_20\IN\1740 gestation_21\NN\15116532 had_22\VBD\2108377 elevated_23\JJ\1740 blood_24\NN\5397468 pressures_25\NNS\11419404 at_26\IN\14622893 6_27\CD\13741022 months_28\NNS\15113229 of_29\IN\1740 age_30\NN\4916342 ;_31\:\1740 the_32\DT\1740 latter_33\JJ\1740 group_34\NN\2137 did_35\VBD\1640855 not_36\RB\1740 have_37\VB\2108377 a_38\DT\13649268 <e2>reduction_39\NN\351485 in_40\IN\13603305 glomerular_41\JJ\1740 number</e2>_42\NN\5107765 ._43\.\1740
D003907_D007674 CID this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 prenatal_4\JJ\1740 <e1>dexamethasone</e1>_5\NN\2721538 in_6\IN\13603305 rats_7\NNS\2329401 results_8\VBZ\2633881 in_9\IN\13603305 a_10\DT\13649268 <e2>reduction_11\NN\351485 in_12\IN\13603305 glomerular_13\JJ\1740 number</e2>_14\NN\5107765 ,_15\,\1740 glomerulosclerosis_16\NN\1740 ,_17\,\1740 and_18\CC\1740 hypertension_19\NN\14057371 when_20\WRB\1740 administered_21\VBN\2436349 at_22\IN\14622893 specific_23\JJ\1740 points_24\NNS\5868954 during_25\IN\1740 gestation_26\NN\15116532 ._27\.\1740
D003907_D005921 NONE adult_0\JJ\1740 rats_1\NNS\2329401 given_2\VBD\2327200 <e1>dexamethasone</e1>_3\NN\2721538 on_4\IN\1740 days_5\NNS\15140892 15_6\CD\13745420 and_7\CC\1740 16_8\CD\13745420 of_9\IN\1740 gestation_10\NN\15116532 had_11\VBD\2108377 more_12\JJR\1740 glomeruli_13\NNS\5425910 with_14\IN\1740 <e2>glomerulosclerosis</e2>_15\NN\1740 than_16\IN\1740 control_17\NN\5190804 rats_18\NNS\2329401 ._19\.\1740
D003907_D005921 NONE this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 prenatal_4\JJ\1740 <e1>dexamethasone</e1>_5\NN\2721538 in_6\IN\13603305 rats_7\NNS\2329401 results_8\VBZ\2633881 in_9\IN\13603305 a_10\DT\13649268 reduction_11\NN\351485 in_12\IN\13603305 glomerular_13\JJ\1740 number_14\NN\5107765 ,_15\,\1740 <e2>glomerulosclerosis</e2>_16\NN\1740 ,_17\,\1740 and_18\CC\1740 hypertension_19\NN\14057371 when_20\WRB\1740 administered_21\VBN\2436349 at_22\IN\14622893 specific_23\JJ\1740 points_24\NNS\5868954 during_25\IN\1740 gestation_26\NN\15116532 ._27\.\1740
18023325
D004221_D014826 CID acute_0\JJ\1740 <e2>vocal_1\JJ\1740 fold_2\JJ\1740 palsy</e2>_3\NN\14557898 after_4\IN\1740 acute_5\JJ\1740 <e1>disulfiram</e1>_6\NN\3740161 intoxication_7\NN\14034177 ._8\.\1740
D004221_D014826 CID acute_0\JJ\1740 peripheral_1\JJ\1740 neuropathy_2\NN\14204950 caused_3\VBN\1617192 by_4\IN\1740 a_5\DT\13649268 <e1>disulfiram</e1>_6\NN\3740161 overdose_7\NN\1740 is_8\VBZ\836236 very_9\RB\1740 rare_10\JJ\1740 and_11\CC\1740 there_12\EX\27167 is_13\VBZ\836236 no_14\DT\7204911 report_15\NN\6470073 of_16\IN\1740 it_17\PRP\6125041 leading_18\VBG\1752884 to_19\TO\1740 <e2>vocal_20\JJ\1740 fold_21\JJ\1740 palsy</e2>_22\NN\14557898 ._23\.\1740
D004221_D010523 CID acute_0\JJ\1740 <e2>peripheral_1\JJ\1740 neuropathy</e2>_2\NN\14204950 caused_3\VBN\1617192 by_4\IN\1740 a_5\DT\13649268 <e1>disulfiram</e1>_6\NN\3740161 overdose_7\NN\1740 is_8\VBZ\836236 very_9\RB\1740 rare_10\JJ\1740 and_11\CC\1740 there_12\EX\27167 is_13\VBZ\836236 no_14\DT\7204911 report_15\NN\6470073 of_16\IN\1740 it_17\PRP\6125041 leading_18\VBG\1752884 to_19\TO\1740 vocal_20\JJ\1740 fold_21\JJ\1740 palsy_22\NN\14557898 ._23\.\1740
D004221_D062787 NONE acute_0\JJ\1740 peripheral_1\JJ\1740 neuropathy_2\NN\14204950 caused_3\VBN\1617192 by_4\IN\1740 a_5\DT\13649268 <e1>disulfiram</e1>_6\NN\3740161 <e2>overdose</e2>_7\NN\1740 is_8\VBZ\836236 very_9\RB\1740 rare_10\JJ\1740 and_11\CC\1740 there_12\EX\27167 is_13\VBZ\836236 no_14\DT\7204911 report_15\NN\6470073 of_16\IN\1740 it_17\PRP\6125041 leading_18\VBG\1752884 to_19\TO\1740 vocal_20\JJ\1740 fold_21\JJ\1740 palsy_22\NN\14557898 ._23\.\1740
D004221_D010243 NONE this_0\DT\1740 was_1\VBD\836236 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 acute_5\JJ\1740 <e2>palsy</e2>_6\NN\14557898 of_7\IN\1740 the_8\DT\1740 recurrent_9\JJ\1740 laryngeal_10\JJ\1740 nerve_11\NN\5475681 and_12\CC\1740 superimposed_13\VBD\1494310 severe_14\JJ\1740 acute_15\JJ\1740 sensorimotor_16\NN\1740 axonal_17\JJ\1740 polyneuropathy_18\NN\1740 caused_19\VBN\1617192 by_20\IN\1740 high-dose_21\JJ\1740 <e1>disulfiram</e1>_22\NN\3740161 intoxication_23\NN\14034177 ._24\.\1740
D004221_D011115 NONE this_0\DT\1740 was_1\VBD\836236 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 acute_5\JJ\1740 palsy_6\NN\14557898 of_7\IN\1740 the_8\DT\1740 recurrent_9\JJ\1740 laryngeal_10\JJ\1740 nerve_11\NN\5475681 and_12\CC\1740 superimposed_13\VBD\1494310 severe_14\JJ\1740 acute_15\JJ\1740 sensorimotor_16\NN\1740 axonal_17\JJ\1740 <e2>polyneuropathy</e2>_18\NN\1740 caused_19\VBN\1617192 by_20\IN\1740 high-dose_21\JJ\1740 <e1>disulfiram</e1>_22\NN\3740161 intoxication_23\NN\14034177 ._24\.\1740
12369736
D003042_D009069 CID effects_0\NNS\13245626 of_1\IN\1740 5-ht1b_2\NN\1740 receptor_3\NN\5225602 ligands_4\NNS\20090 microinjected_5\VBN\1740 into_6\IN\1740 the_7\DT\1740 accumbal_8\JJ\1740 shell_9\NN\2703275 or_10\CC\3541091 core_11\NN\7996689 on_12\IN\1740 the_13\DT\1740 <e1>cocaine-induced</e1>_14\JJ\1740 <e2>locomotor_15\NN\1740 hyperactivity</e2>_16\NN\14052403 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
D003042_D009069 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 examine_6\VB\789138 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 5-ht1b_10\NN\1740 receptor_11\NN\5225602 ligands_12\NNS\20090 microinjected_13\VBN\1740 into_14\IN\1740 the_15\DT\1740 subregions_16\NNS\1740 of_17\IN\1740 the_18\DT\1740 nucleus_19\NN\5445668 accumbens_20\NNS\1740 (_21\-LRB-\1740 the_22\DT\1740 shell_23\NN\2703275 and_24\CC\1740 the_25\DT\1740 core_26\NN\7996689 )_27\-RRB-\1740 on_28\IN\1740 the_29\DT\1740 <e2>locomotor_30\NN\1740 hyperactivity</e2>_31\NN\14052403 induced_32\VBN\1627355 by_33\IN\1740 <e1>cocaine</e1>_34\NN\3492717 in_35\IN\13603305 rats_36\NNS\2329401 ._37\.\1740
D003042_D009069 CID gr_0\NN\1740 55562_1\CD\1740 (_2\-LRB-\1740 0.1_3\CD\1740 -_4\SYM\1740 10_5\CD\13745420 microg/side_6\NN\1740 )_7\-RRB-\1740 ,_8\,\1740 administered_9\VBN\2436349 intra-accumbens_10\NNS\1740 shell_11\NN\2703275 prior_12\JJ\1740 to_13\TO\1740 <e1>cocaine</e1>_14\NN\3492717 ,_15\,\1740 dose-dependently_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 psychostimulant-induced_19\JJ\1740 <e2>locomotor_20\NN\1740 hyperactivity</e2>_21\NN\14052403 ._22\.\1740
D003042_D009069 CID our_0\PRP$\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>cocaine</e1>_4\NN\3492717 induced_5\VBD\1627355 <e2>hyperlocomotion</e2>_6\NN\1740 is_7\VBZ\836236 modified_8\VBN\109660 by_9\IN\1740 5-ht1b_10\NN\1740 receptor_11\NN\5225602 ligands_12\NNS\20090 microinjected_13\VBN\1740 into_14\IN\1740 the_15\DT\1740 accumbens_16\NNS\1740 shell_17\NN\2703275 ,_18\,\1740 but_19\CC\1740 not_20\RB\1740 core_21\NN\7996689 ,_22\,\1740 this_23\DT\1740 modification_24\NN\191142 consisting_25\VBG\2603699 in_26\IN\13603305 inhibitory_27\JJ\1740 and_28\CC\1740 facilitatory_29\JJ\1740 effects_30\NNS\13245626 of_31\IN\1740 the_32\DT\1740 5-ht1b_33\NN\1740 receptor_34\NN\5225602 antagonist_35\NN\7846 (_36\-LRB-\1740 gr_37\NN\1740 55562_38\CD\1740 )_39\-RRB-\1740 and_40\CC\1740 agonist_41\NN\9613191 (_42\-LRB-\1740 cp_43\NN\1740 93129_44\CD\1740 )_45\-RRB-\1740 ,_46\,\1740 respectively_47\RB\1740 ._48\.\1740
C103477_D009069 NONE <e1>gr_0\NN\1740 55562</e1>_1\CD\1740 (_2\-LRB-\1740 0.1_3\CD\1740 -_4\SYM\1740 10_5\CD\13745420 microg/side_6\NN\1740 )_7\-RRB-\1740 ,_8\,\1740 administered_9\VBN\2436349 intra-accumbens_10\NNS\1740 shell_11\NN\2703275 prior_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 ,_15\,\1740 dose-dependently_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 psychostimulant-induced_19\JJ\1740 <e2>locomotor_20\NN\1740 hyperactivity</e2>_21\NN\14052403 ._22\.\1740
C103477_D009069 NONE our_0\PRP$\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 cocaine_4\NN\3492717 induced_5\VBD\1627355 <e2>hyperlocomotion</e2>_6\NN\1740 is_7\VBZ\836236 modified_8\VBN\109660 by_9\IN\1740 5-ht1b_10\NN\1740 receptor_11\NN\5225602 ligands_12\NNS\20090 microinjected_13\VBN\1740 into_14\IN\1740 the_15\DT\1740 accumbens_16\NNS\1740 shell_17\NN\2703275 ,_18\,\1740 but_19\CC\1740 not_20\RB\1740 core_21\NN\7996689 ,_22\,\1740 this_23\DT\1740 modification_24\NN\191142 consisting_25\VBG\2603699 in_26\IN\13603305 inhibitory_27\JJ\1740 and_28\CC\1740 facilitatory_29\JJ\1740 effects_30\NNS\13245626 of_31\IN\1740 the_32\DT\1740 5-ht1b_33\NN\1740 receptor_34\NN\5225602 antagonist_35\NN\7846 (_36\-LRB-\1740 <e1>gr_37\NN\1740 55562</e1>_38\CD\1740 )_39\-RRB-\1740 and_40\CC\1740 agonist_41\NN\9613191 (_42\-LRB-\1740 cp_43\NN\1740 93129_44\CD\1740 )_45\-RRB-\1740 ,_46\,\1740 respectively_47\RB\1740 ._48\.\1740
C065046_D009069 CID our_0\PRP$\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 cocaine_4\NN\3492717 induced_5\VBD\1627355 <e2>hyperlocomotion</e2>_6\NN\1740 is_7\VBZ\836236 modified_8\VBN\109660 by_9\IN\1740 5-ht1b_10\NN\1740 receptor_11\NN\5225602 ligands_12\NNS\20090 microinjected_13\VBN\1740 into_14\IN\1740 the_15\DT\1740 accumbens_16\NNS\1740 shell_17\NN\2703275 ,_18\,\1740 but_19\CC\1740 not_20\RB\1740 core_21\NN\7996689 ,_22\,\1740 this_23\DT\1740 modification_24\NN\191142 consisting_25\VBG\2603699 in_26\IN\13603305 inhibitory_27\JJ\1740 and_28\CC\1740 facilitatory_29\JJ\1740 effects_30\NNS\13245626 of_31\IN\1740 the_32\DT\1740 5-ht1b_33\NN\1740 receptor_34\NN\5225602 antagonist_35\NN\7846 (_36\-LRB-\1740 gr_37\NN\1740 55562_38\CD\1740 )_39\-RRB-\1740 and_40\CC\1740 agonist_41\NN\9613191 (_42\-LRB-\1740 <e1>cp_43\NN\1740 93129</e1>_44\CD\1740 )_45\-RRB-\1740 ,_46\,\1740 respectively_47\RB\1740 ._48\.\1740
8953972
D004837_D013345 CID fatal_0\JJ\1740 <e2>intracranial_1\JJ\1740 bleeding</e2>_2\NN\14285662 associated_3\VBN\628491 with_4\IN\1740 prehospital_5\JJ\1740 use_6\NN\407535 of_7\IN\1740 <e1>epinephrine</e1>_8\NN\14807929 ._9\.\1740
D004837_D012128 NONE the_0\DT\1740 sudden_1\JJ\1740 onset_2\NN\7325190 of_3\IN\1740 <e2>respiratory_4\JJ\1740 distress</e2>_5\NN\7494363 ,_6\,\1740 rash_7\NN\14321469 ,_8\,\1740 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 a_13\DT\13649268 new_14\JJ\1740 medicine_15\NN\6045562 led_16\VBD\1752884 the_17\DT\1740 two_18\CD\13741022 paramedics_19\NNS\10398624 on_20\IN\1740 the_21\DT\1740 scene_22\NN\8497294 to_23\TO\1740 administer_24\VB\2436349 subcutaneous_25\JJ\1740 <e1>epinephrine</e1>_26\NN\14807929 ._27\.\1740
D004837_D005076 NONE the_0\DT\1740 sudden_1\JJ\1740 onset_2\NN\7325190 of_3\IN\1740 respiratory_4\JJ\1740 distress_5\NN\7494363 ,_6\,\1740 <e2>rash</e2>_7\NN\14321469 ,_8\,\1740 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 a_13\DT\13649268 new_14\JJ\1740 medicine_15\NN\6045562 led_16\VBD\1752884 the_17\DT\1740 two_18\CD\13741022 paramedics_19\NNS\10398624 on_20\IN\1740 the_21\DT\1740 scene_22\NN\8497294 to_23\TO\1740 administer_24\VB\2436349 subcutaneous_25\JJ\1740 <e1>epinephrine</e1>_26\NN\14807929 ._27\.\1740
D004837_D006323 CID <e1>epinephrine</e1>_0\NN\14807929 has_1\VBZ\2108377 a_2\DT\13649268 proven_3\VBN\2604760 role_4\NN\719494 in_5\IN\13603305 <e2>cardiac_6\JJ\1740 arrest</e2>_7\NN\88481 in_8\IN\13603305 prehospital_9\JJ\1740 care_10\NN\575741 ;_11\:\1740 however_12\RB\1740 ,_13\,\1740 use_14\NN\407535 by_15\IN\1740 paramedics_16\NNS\10398624 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 suspected_20\VBN\916909 allergic_21\JJ\1740 reaction_22\NN\13446390 and_23\CC\1740 severe_24\JJ\1740 hypertension_25\NN\14057371 should_26\MD\1740 be_27\VB\836236 viewed_28\VBN\689344 with_29\IN\1740 caution_30\NN\4662951 ._31\.\1740
D004837_D004342 NONE <e1>epinephrine</e1>_0\NN\14807929 has_1\VBZ\2108377 a_2\DT\13649268 proven_3\VBN\2604760 role_4\NN\719494 in_5\IN\13603305 cardiac_6\JJ\1740 arrest_7\NN\88481 in_8\IN\13603305 prehospital_9\JJ\1740 care_10\NN\575741 ;_11\:\1740 however_12\RB\1740 ,_13\,\1740 use_14\NN\407535 by_15\IN\1740 paramedics_16\NNS\10398624 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 suspected_20\VBN\916909 <e2>allergic_21\JJ\1740 reaction</e2>_22\NN\13446390 and_23\CC\1740 severe_24\JJ\1740 hypertension_25\NN\14057371 should_26\MD\1740 be_27\VB\836236 viewed_28\VBN\689344 with_29\IN\1740 caution_30\NN\4662951 ._31\.\1740
D004837_D006973 NONE <e1>epinephrine</e1>_0\NN\14807929 has_1\VBZ\2108377 a_2\DT\13649268 proven_3\VBN\2604760 role_4\NN\719494 in_5\IN\13603305 cardiac_6\JJ\1740 arrest_7\NN\88481 in_8\IN\13603305 prehospital_9\JJ\1740 care_10\NN\575741 ;_11\:\1740 however_12\RB\1740 ,_13\,\1740 use_14\NN\407535 by_15\IN\1740 paramedics_16\NNS\10398624 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 suspected_20\VBN\916909 allergic_21\JJ\1740 reaction_22\NN\13446390 and_23\CC\1740 severe_24\JJ\1740 <e2>hypertension</e2>_25\NN\14057371 should_26\MD\1740 be_27\VB\836236 viewed_28\VBN\689344 with_29\IN\1740 caution_30\NN\4662951 ._31\.\1740
20588063
D011692_D009401 CID permeability_0\NN\4940146 ,_1\,\1740 ultrastructural_2\JJ\1740 changes_3\NNS\7283608 ,_4\,\1740 and_5\CC\1740 distribution_6\NN\5726596 of_7\IN\1740 novel_8\JJ\1740 proteins_9\NNS\14944888 in_10\IN\13603305 the_11\DT\1740 glomerular_12\JJ\1740 barrier_13\NN\3839993 in_14\IN\13603305 early_15\JJ\1740 <e1>puromycin_16\NN\1740 aminonucleoside</e1>_17\NN\1740 <e2>nephrosis</e2>_18\NN\14304060 ._19\.\1740
D011692_D009401 CID using_0\VBG\1156834 <e1>puromycin_1\NN\1740 aminonucleoside</e1>_2\NN\1740 <e2>nephrosis</e2>_3\NN\14304060 (_4\-LRB-\1740 pan_5\NN\3101986 )_6\-RRB-\1740 rats_7\NNS\2329401 ,_8\,\1740 we_9\PRP\1740 studied_10\VBD\630380 early_11\JJ\1740 ultrastructural_12\JJ\1740 and_13\CC\1740 permeability_14\NN\4940146 changes_15\NNS\7283608 in_16\IN\13603305 relation_17\NN\2137 to_18\TO\1740 the_19\DT\1740 expression_20\NN\4679549 of_21\IN\1740 the_22\DT\1740 podocyte-associated_23\JJ\1740 molecules_24\NNS\9465459 nephrin_25\NN\1740 ,_26\,\1740 a-actinin_27\NN\1740 ,_28\,\1740 dendrin_29\NN\1740 ,_30\,\1740 and_31\CC\1740 plekhh2_32\NN\1740 ,_33\,\1740 the_34\DT\1740 last_35\JJ\1740 two_36\CD\13741022 of_37\IN\1740 which_38\WDT\1740 were_39\VBD\836236 only_40\RB\1740 recently_41\RB\1740 discovered_42\VBN\2163746 in_43\IN\13603305 podocytes_44\NNS\1740 ._45\.\1740
9293063
D003613_D001650 CID <e2>bile_0\NN\5405946 duct_1\NN\5248181 hamartoma</e2>_2\NN\14234074 occurring_3\VBG\2623529 in_4\IN\13603305 association_5\NN\8008335 with_6\IN\1740 long-term_7\JJ\1740 treatment_8\NN\654885 with_9\IN\1740 <e1>danazol</e1>_10\NN\1740 ._11\.\1740
D003613_D001650 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e2>bile_5\NN\5405946 duct_6\NN\5248181 hamartoma</e2>_7\NN\14234074 which_8\WDT\1740 developed_9\VBD\1753788 in_10\IN\13603305 a_11\DT\13649268 patient_12\NN\9898892 who_13\WP\8299493 had_14\VBD\2108377 been_15\VBN\836236 on_16\IN\1740 long-term_17\JJ\1740 <e1>danazol</e1>_18\NN\1740 treatment_19\NN\654885 ._20\.\1740
D003613_D006222 CID <e2>bile_0\NN\5405946 duct_1\NN\5248181 hamartoma</e2>_2\NN\14234074 occurring_3\VBG\2623529 in_4\IN\13603305 association_5\NN\8008335 with_6\IN\1740 long-term_7\JJ\1740 treatment_8\NN\654885 with_9\IN\1740 <e1>danazol</e1>_10\NN\1740 ._11\.\1740
D003613_D006222 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e2>bile_5\NN\5405946 duct_6\NN\5248181 hamartoma</e2>_7\NN\14234074 which_8\WDT\1740 developed_9\VBD\1753788 in_10\IN\13603305 a_11\DT\13649268 patient_12\NN\9898892 who_13\WP\8299493 had_14\VBD\2108377 been_15\VBN\836236 on_16\IN\1740 long-term_17\JJ\1740 <e1>danazol</e1>_18\NN\1740 treatment_19\NN\654885 ._20\.\1740
6634932
C002616_D017180 NONE <e1>um-272</e1>_0\NN\1740 (_1\-LRB-\1740 n_2\NN\14622893 ,_3\,\1740 n-dimethylpropranolol_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 a_7\DT\13649268 quaternary_8\JJ\1740 antiarrhythmic_9\JJ\1740 agent_10\NN\7347 ,_11\,\1740 was_12\VBD\836236 administered_13\VBN\2436349 sublingually_14\RB\1740 to_15\IN\1740 dogs_16\NNS\2083346 with_17\IN\1740 ouabain-induced_18\JJ\1740 <e2>ventricular_19\JJ\1740 tachycardias</e2>_20\NNS\14110674 ._21\.\1740
C002616_D017180 NONE um-272_0\NN\1740 (_1\-LRB-\1740 <e1>n_2\NN\14622893 ,_3\,\1740 n-dimethylpropranolol</e1>_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 a_7\DT\13649268 quaternary_8\JJ\1740 antiarrhythmic_9\JJ\1740 agent_10\NN\7347 ,_11\,\1740 was_12\VBD\836236 administered_13\VBN\2436349 sublingually_14\RB\1740 to_15\IN\1740 dogs_16\NNS\2083346 with_17\IN\1740 ouabain-induced_18\JJ\1740 <e2>ventricular_19\JJ\1740 tachycardias</e2>_20\NNS\14110674 ._21\.\1740
C002616_D017180 NONE sublingual_0\JJ\1740 <e1>um-272</e1>_1\NN\1740 converted_2\VBD\126264 <e2>ventricular_3\JJ\1740 tachycardia</e2>_4\NN\14110674 to_5\TO\1740 sinus_6\NN\5248181 rhythm_7\NN\15122011 in_8\IN\13603305 all_9\DT\1740 5_10\CD\13741022 dogs_11\NNS\2083346 ._12\.\1740
D010042_D017180 CID um-272_0\NN\1740 (_1\-LRB-\1740 n_2\NN\14622893 ,_3\,\1740 n-dimethylpropranolol_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 a_7\DT\13649268 quaternary_8\JJ\1740 antiarrhythmic_9\JJ\1740 agent_10\NN\7347 ,_11\,\1740 was_12\VBD\836236 administered_13\VBN\2436349 sublingually_14\RB\1740 to_15\IN\1740 dogs_16\NNS\2083346 with_17\IN\1740 <e1>ouabain-induced</e1>_18\JJ\1740 <e2>ventricular_19\JJ\1740 tachycardias</e2>_20\NNS\14110674 ._21\.\1740
15602202
D017963_D009395 CID recurrent_0\JJ\1740 acute_1\JJ\1740 <e2>interstitial_2\JJ\1740 nephritis</e2>_3\NN\14113228 induced_4\VBN\1627355 by_5\IN\1740 <e1>azithromycin</e1>_6\NN\2716205 ._7\.\1740
D017963_D009395 CID a_0\DT\13649268 14-year-old_1\JJ\1740 girl_2\NN\10787470 is_3\VBZ\836236 reported_4\VBN\831651 with_5\IN\1740 recurrent_6\JJ\1740 ,_7\,\1740 <e1>azithromycin-induced</e1>_8\JJ\1740 ,_9\,\1740 acute_10\JJ\1740 <e2>interstitial_11\JJ\1740 nephritis</e2>_12\NN\14113228 ._13\.\1740
8638206
D001279_D010243 CID persistent_0\JJ\1740 <e2>paralysis</e2>_1\NN\14557898 after_2\IN\1740 prolonged_3\JJ\1740 use_4\NN\407535 of_5\IN\1740 <e1>atracurium</e1>_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 absence_9\NN\14449405 of_10\IN\1740 corticosteroids_11\NNS\14745635 ._12\.\1740
D001279_D010243 CID <e1>atracurium_0\NN\1740 besylate</e1>_1\VBP\1740 ,_2\,\1740 a_3\DT\13649268 short-acting_4\JJ\1740 benzylisoquinolinium_5\NN\1740 nmba_6\NN\1740 that_7\WDT\1740 is_8\VBZ\836236 eliminated_9\VBN\1619929 independently_10\RB\1740 of_11\IN\1740 renal_12\JJ\1740 or_13\CC\3541091 hepatic_14\JJ\1740 function_15\NN\13783581 ,_16\,\1740 has_17\VBZ\2108377 also_18\RB\1740 been_19\VBN\836236 associated_20\VBN\628491 with_21\IN\1740 persistent_22\JJ\1740 <e2>paralysis</e2>_23\NN\14557898 ,_24\,\1740 but_25\CC\1740 only_26\RB\1740 when_27\WRB\1740 used_28\VBN\1156834 with_29\IN\1740 corticosteroids_30\NNS\14745635 ._31\.\1740
D001279_D010243 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e1>atracurium-related</e1>_5\JJ\1740 <e2>paralysis</e2>_6\NN\14557898 persisting_7\VBG\118523 for_8\IN\1740 approximately_9\RB\1740 50_10\CD\13745420 hours_11\NNS\15118228 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 who_15\WP\8299493 was_16\VBD\836236 not_17\RB\1740 treated_18\VBN\2376958 with_19\IN\1740 corticosteroids_20\NNS\14745635 ._21\.\1740
D014673_D010243 CID reports_0\NNS\6470073 of_1\IN\1740 persistent_2\JJ\1740 <e2>paralysis</e2>_3\NN\14557898 after_4\IN\1740 the_5\DT\1740 discontinuance_6\NN\209943 of_7\IN\1740 these_8\DT\1740 drugs_9\NNS\14778436 have_10\VBP\2108377 most_11\RBS\1740 often_12\RB\1740 involved_13\VBN\2676054 aminosteroid-based_14\JJ\1740 nmbas_15\NN\1740 such_16\JJ\1740 as_17\IN\14622893 <e1>vecuronium_18\NN\1740 bromide</e1>_19\NN\14904359 ,_20\,\1740 especially_21\RB\1740 when_22\WRB\1740 used_23\VBN\1156834 in_24\IN\13603305 conjunction_25\NN\5048123 with_26\IN\1740 corticosteroids_27\NNS\14745635 ._28\.\1740
-1_D010243 NONE atracurium_0\NN\1740 besylate_1\VBP\1740 ,_2\,\1740 a_3\DT\13649268 short-acting_4\JJ\1740 <e1>benzylisoquinolinium</e1>_5\NN\1740 nmba_6\NN\1740 that_7\WDT\1740 is_8\VBZ\836236 eliminated_9\VBN\1619929 independently_10\RB\1740 of_11\IN\1740 renal_12\JJ\1740 or_13\CC\3541091 hepatic_14\JJ\1740 function_15\NN\13783581 ,_16\,\1740 has_17\VBZ\2108377 also_18\RB\1740 been_19\VBN\836236 associated_20\VBN\628491 with_21\IN\1740 persistent_22\JJ\1740 <e2>paralysis</e2>_23\NN\14557898 ,_24\,\1740 but_25\CC\1740 only_26\RB\1740 when_27\WRB\1740 used_28\VBN\1156834 with_29\IN\1740 corticosteroids_30\NNS\14745635 ._31\.\1740
15632880
D013148_D051437 CID <e1>spironolactone-induced</e1>_0\JJ\1740 <e2>renal_1\JJ\1740 insufficiency</e2>_2\NN\14462946 and_3\CC\1740 hyperkalemia_4\NN\14299637 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 heart_8\NN\5919034 failure_9\NN\66216 ._10\.\1740
D013148_D051437 CID background_0\NN\4921011 :_1\:\1740 a_2\DT\13649268 previous_3\JJ\1740 randomized_4\NN\1740 controlled_5\JJ\1740 trial_6\NN\786195 evaluating_7\VBG\670261 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>spironolactone</e1>_11\NN\2721160 in_12\IN\13603305 heart_13\NN\5919034 failure_14\NN\66216 patients_15\NNS\9898892 reported_16\VBD\831651 a_17\DT\13649268 low_18\JJ\1740 risk_19\NN\14541044 of_20\IN\1740 hyperkalemia_21\NN\14299637 (_22\-LRB-\1740 2_23\CD\13741022 %_24\NN\1740 )_25\-RRB-\1740 and_26\CC\1740 <e2>renal_27\JJ\1740 insufficiency</e2>_28\NN\14462946 (_29\-LRB-\1740 0_30\CD\13741022 %_31\NN\1740 )_32\-RRB-\1740 ._33\.\1740
D013148_D051437 CID we_0\PRP\1740 therefore_1\RB\1740 sought_2\VBD\1825237 to_3\TO\1740 determine_4\VB\1645601 the_5\DT\1740 prevalence_6\NN\4764412 and_7\CC\1740 clinical_8\JJ\1740 associations_9\NNS\8008335 of_10\IN\1740 hyperkalemia_11\NN\14299637 and_12\CC\1740 <e2>renal_13\JJ\1740 insufficiency</e2>_14\NN\14462946 in_15\IN\13603305 heart_16\NN\5919034 failure_17\NN\66216 patients_18\NNS\9898892 treated_19\VBN\2376958 with_20\IN\1740 <e1>spironolactone</e1>_21\NN\2721160 ._22\.\1740
D013148_D051437 CID results_0\NNS\34213 :_1\:\1740 sixty-seven_2\CD\1740 of_3\IN\1740 926_4\CD\1740 patients_5\NNS\9898892 (_6\-LRB-\1740 7.2_7\CD\1740 %_8\NN\1740 )_9\-RRB-\1740 required_10\VBD\754942 discontinuation_11\NN\209943 of_12\IN\1740 <e1>spironolactone</e1>_13\NN\2721160 due_14\JJ\1740 to_15\TO\1740 hyperkalemia_16\NN\14299637 (_17\-LRB-\1740 n_18\NN\14622893 =_19\JJ\1740 33_20\CD\1740 )_21\-RRB-\1740 or_22\CC\3541091 <e2>renal_23\JJ\1740 failure</e2>_24\NN\66216 (_25\-LRB-\1740 n_26\NN\14622893 =_27\JJ\1740 34_28\CD\1740 )_29\-RRB-\1740 ._30\.\1740
D013148_D051437 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>spironolactone-induced</e1>_2\JJ\1740 hyperkalemia_3\NN\14299637 and_4\CC\1740 <e2>renal_5\JJ\1740 insufficiency</e2>_6\NN\14462946 are_7\VBP\836236 more_8\RBR\1740 common_9\JJ\1740 in_10\IN\13603305 our_11\PRP$\1740 clinical_12\JJ\1740 experience_13\NN\5984287 than_14\IN\1740 reported_15\VBN\831651 previously_16\RB\1740 ._17\.\1740
D013148_D006947 CID <e1>spironolactone-induced</e1>_0\JJ\1740 renal_1\JJ\1740 insufficiency_2\NN\14462946 and_3\CC\1740 <e2>hyperkalemia</e2>_4\NN\14299637 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 heart_8\NN\5919034 failure_9\NN\66216 ._10\.\1740
D013148_D006947 CID background_0\NN\4921011 :_1\:\1740 a_2\DT\13649268 previous_3\JJ\1740 randomized_4\NN\1740 controlled_5\JJ\1740 trial_6\NN\786195 evaluating_7\VBG\670261 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>spironolactone</e1>_11\NN\2721160 in_12\IN\13603305 heart_13\NN\5919034 failure_14\NN\66216 patients_15\NNS\9898892 reported_16\VBD\831651 a_17\DT\13649268 low_18\JJ\1740 risk_19\NN\14541044 of_20\IN\1740 <e2>hyperkalemia</e2>_21\NN\14299637 (_22\-LRB-\1740 2_23\CD\13741022 %_24\NN\1740 )_25\-RRB-\1740 and_26\CC\1740 renal_27\JJ\1740 insufficiency_28\NN\14462946 (_29\-LRB-\1740 0_30\CD\13741022 %_31\NN\1740 )_32\-RRB-\1740 ._33\.\1740
D013148_D006947 CID we_0\PRP\1740 therefore_1\RB\1740 sought_2\VBD\1825237 to_3\TO\1740 determine_4\VB\1645601 the_5\DT\1740 prevalence_6\NN\4764412 and_7\CC\1740 clinical_8\JJ\1740 associations_9\NNS\8008335 of_10\IN\1740 <e2>hyperkalemia</e2>_11\NN\14299637 and_12\CC\1740 renal_13\JJ\1740 insufficiency_14\NN\14462946 in_15\IN\13603305 heart_16\NN\5919034 failure_17\NN\66216 patients_18\NNS\9898892 treated_19\VBN\2376958 with_20\IN\1740 <e1>spironolactone</e1>_21\NN\2721160 ._22\.\1740
D013148_D006947 CID results_0\NNS\34213 :_1\:\1740 sixty-seven_2\CD\1740 of_3\IN\1740 926_4\CD\1740 patients_5\NNS\9898892 (_6\-LRB-\1740 7.2_7\CD\1740 %_8\NN\1740 )_9\-RRB-\1740 required_10\VBD\754942 discontinuation_11\NN\209943 of_12\IN\1740 <e1>spironolactone</e1>_13\NN\2721160 due_14\JJ\1740 to_15\TO\1740 <e2>hyperkalemia</e2>_16\NN\14299637 (_17\-LRB-\1740 n_18\NN\14622893 =_19\JJ\1740 33_20\CD\1740 )_21\-RRB-\1740 or_22\CC\3541091 renal_23\JJ\1740 failure_24\NN\66216 (_25\-LRB-\1740 n_26\NN\14622893 =_27\JJ\1740 34_28\CD\1740 )_29\-RRB-\1740 ._30\.\1740
D013148_D006947 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>spironolactone-induced</e1>_2\JJ\1740 <e2>hyperkalemia</e2>_3\NN\14299637 and_4\CC\1740 renal_5\JJ\1740 insufficiency_6\NN\14462946 are_7\VBP\836236 more_8\RBR\1740 common_9\JJ\1740 in_10\IN\13603305 our_11\PRP$\1740 clinical_12\JJ\1740 experience_13\NN\5984287 than_14\IN\1740 reported_15\VBN\831651 previously_16\RB\1740 ._17\.\1740
D013148_D006333 NONE <e1>spironolactone-induced</e1>_0\JJ\1740 renal_1\JJ\1740 insufficiency_2\NN\14462946 and_3\CC\1740 hyperkalemia_4\NN\14299637 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 <e2>heart_8\NN\5919034 failure</e2>_9\NN\66216 ._10\.\1740
D013148_D006333 NONE background_0\NN\4921011 :_1\:\1740 a_2\DT\13649268 previous_3\JJ\1740 randomized_4\NN\1740 controlled_5\JJ\1740 trial_6\NN\786195 evaluating_7\VBG\670261 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>spironolactone</e1>_11\NN\2721160 in_12\IN\13603305 <e2>heart_13\NN\5919034 failure</e2>_14\NN\66216 patients_15\NNS\9898892 reported_16\VBD\831651 a_17\DT\13649268 low_18\JJ\1740 risk_19\NN\14541044 of_20\IN\1740 hyperkalemia_21\NN\14299637 (_22\-LRB-\1740 2_23\CD\13741022 %_24\NN\1740 )_25\-RRB-\1740 and_26\CC\1740 renal_27\JJ\1740 insufficiency_28\NN\14462946 (_29\-LRB-\1740 0_30\CD\13741022 %_31\NN\1740 )_32\-RRB-\1740 ._33\.\1740
D013148_D006333 NONE because_0\IN\1740 treatments_1\NNS\654885 for_2\IN\1740 <e2>heart_3\NN\5919034 failure</e2>_4\NN\66216 have_5\VBP\2108377 changed_6\VBN\46534 since_7\IN\1740 the_8\DT\1740 benefits_9\NNS\13278375 of_10\IN\1740 <e1>spironolactone</e1>_11\NN\2721160 were_12\VBD\836236 reported_13\VBN\831651 ,_14\,\1740 the_15\DT\1740 prevalence_16\NN\4764412 of_17\IN\1740 these_18\DT\1740 complications_19\NNS\1073995 may_20\MD\15209706 differ_21\VB\1740 in_22\IN\13603305 current_23\JJ\1740 clinical_24\JJ\1740 practice_25\NN\407535 ._26\.\1740
D013148_D006333 NONE we_0\PRP\1740 therefore_1\RB\1740 sought_2\VBD\1825237 to_3\TO\1740 determine_4\VB\1645601 the_5\DT\1740 prevalence_6\NN\4764412 and_7\CC\1740 clinical_8\JJ\1740 associations_9\NNS\8008335 of_10\IN\1740 hyperkalemia_11\NN\14299637 and_12\CC\1740 renal_13\JJ\1740 insufficiency_14\NN\14462946 in_15\IN\13603305 <e2>heart_16\NN\5919034 failure</e2>_17\NN\66216 patients_18\NNS\9898892 treated_19\VBN\2376958 with_20\IN\1740 <e1>spironolactone</e1>_21\NN\2721160 ._22\.\1740
D013148_D006333 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 performed_3\VBD\2367363 a_4\DT\13649268 case_5\NN\7283608 control_6\NN\5190804 study_7\NN\635850 of_8\IN\1740 <e2>heart_9\NN\5919034 failure</e2>_10\NN\66216 patients_11\NNS\9898892 treated_12\VBN\2376958 with_13\IN\1740 <e1>spironolactone</e1>_14\NN\2721160 in_15\IN\13603305 our_16\PRP$\1740 clinical_17\JJ\1740 practice_18\NN\407535 ._19\.\1740
D011188_D006947 NONE cases_0\NNS\7283608 were_1\VBD\836236 patients_2\NNS\9898892 who_3\WP\8299493 developed_4\VBD\1753788 <e2>hyperkalemia</e2>_5\NN\14299637 (_6\-LRB-\1740 <e1>k(+</e1>_7\NNS\1740 )_8\-RRB-\1740 >_9\NN\1740 5.0_10\CD\1740 meq/l_11\NN\1740 )_12\-RRB-\1740 or_13\CC\3541091 renal_14\JJ\1740 insufficiency_15\NN\14462946 (_16\-LRB-\1740 cr_17\NN\14625458 >_18\NN\1740 or=2.5_19\NN\1740 mg/dl_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 they_24\PRP\1740 were_25\VBD\836236 compared_26\VBN\644583 to_27\TO\1740 2_28\CD\13741022 randomly_29\RB\1740 selected_30\VBD\697589 controls_31\NNS\5190804 per_32\IN\1740 case_33\NN\7283608 ._34\.\1740
D011188_D006947 NONE patients_0\NNS\9898892 who_1\WP\8299493 developed_2\VBD\1753788 <e2>hyperkalemia</e2>_3\NN\14299637 were_4\VBD\836236 older_5\JJR\1740 and_6\CC\1740 more_7\RBR\1740 likely_8\JJ\1740 to_9\TO\1740 have_10\VB\2108377 diabetes_11\NNS\14075199 ,_12\,\1740 had_13\VBD\2108377 higher_14\JJR\1740 baseline_15\NN\7260623 serum_16\NN\5397468 <e1>potassium</e1>_17\NN\14625458 levels_18\NNS\4916342 and_19\CC\1740 lower_20\JJR\1740 baseline_21\NN\7260623 potassium_22\NN\14625458 supplement_23\NN\6365467 doses_24\NNS\3740161 ,_25\,\1740 and_26\CC\1740 were_27\VBD\836236 more_28\RBR\1740 likely_29\JJ\1740 to_30\TO\1740 be_31\VB\836236 treated_32\VBN\2376958 with_33\IN\1740 beta-blockers_34\NNS\1740 than_35\IN\1740 controls_36\NNS\5190804 (_37\-LRB-\1740 n_38\NN\14622893 =_39\JJ\1740 134_40\CD\1740 )_41\-RRB-\1740 ._42\.\1740
D011188_D006947 NONE patients_0\NNS\9898892 who_1\WP\8299493 developed_2\VBD\1753788 <e2>hyperkalemia</e2>_3\NN\14299637 were_4\VBD\836236 older_5\JJR\1740 and_6\CC\1740 more_7\RBR\1740 likely_8\JJ\1740 to_9\TO\1740 have_10\VB\2108377 diabetes_11\NNS\14075199 ,_12\,\1740 had_13\VBD\2108377 higher_14\JJR\1740 baseline_15\NN\7260623 serum_16\NN\5397468 potassium_17\NN\14625458 levels_18\NNS\4916342 and_19\CC\1740 lower_20\JJR\1740 baseline_21\NN\7260623 <e1>potassium</e1>_22\NN\14625458 supplement_23\NN\6365467 doses_24\NNS\3740161 ,_25\,\1740 and_26\CC\1740 were_27\VBD\836236 more_28\RBR\1740 likely_29\JJ\1740 to_30\TO\1740 be_31\VB\836236 treated_32\VBN\2376958 with_33\IN\1740 beta-blockers_34\NNS\1740 than_35\IN\1740 controls_36\NNS\5190804 (_37\-LRB-\1740 n_38\NN\14622893 =_39\JJ\1740 134_40\CD\1740 )_41\-RRB-\1740 ._42\.\1740
D011188_D051437 NONE cases_0\NNS\7283608 were_1\VBD\836236 patients_2\NNS\9898892 who_3\WP\8299493 developed_4\VBD\1753788 hyperkalemia_5\NN\14299637 (_6\-LRB-\1740 <e1>k(+</e1>_7\NNS\1740 )_8\-RRB-\1740 >_9\NN\1740 5.0_10\CD\1740 meq/l_11\NN\1740 )_12\-RRB-\1740 or_13\CC\3541091 <e2>renal_14\JJ\1740 insufficiency</e2>_15\NN\14462946 (_16\-LRB-\1740 cr_17\NN\14625458 >_18\NN\1740 or=2.5_19\NN\1740 mg/dl_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 they_24\PRP\1740 were_25\VBD\836236 compared_26\VBN\644583 to_27\TO\1740 2_28\CD\13741022 randomly_29\RB\1740 selected_30\VBD\697589 controls_31\NNS\5190804 per_32\IN\1740 case_33\NN\7283608 ._34\.\1740
D002857_D006947 NONE cases_0\NNS\7283608 were_1\VBD\836236 patients_2\NNS\9898892 who_3\WP\8299493 developed_4\VBD\1753788 <e2>hyperkalemia</e2>_5\NN\14299637 (_6\-LRB-\1740 k(+_7\NNS\1740 )_8\-RRB-\1740 >_9\NN\1740 5.0_10\CD\1740 meq/l_11\NN\1740 )_12\-RRB-\1740 or_13\CC\3541091 renal_14\JJ\1740 insufficiency_15\NN\14462946 (_16\-LRB-\1740 <e1>cr</e1>_17\NN\14625458 >_18\NN\1740 or=2.5_19\NN\1740 mg/dl_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 they_24\PRP\1740 were_25\VBD\836236 compared_26\VBN\644583 to_27\TO\1740 2_28\CD\13741022 randomly_29\RB\1740 selected_30\VBD\697589 controls_31\NNS\5190804 per_32\IN\1740 case_33\NN\7283608 ._34\.\1740
D002857_D051437 NONE cases_0\NNS\7283608 were_1\VBD\836236 patients_2\NNS\9898892 who_3\WP\8299493 developed_4\VBD\1753788 hyperkalemia_5\NN\14299637 (_6\-LRB-\1740 k(+_7\NNS\1740 )_8\-RRB-\1740 >_9\NN\1740 5.0_10\CD\1740 meq/l_11\NN\1740 )_12\-RRB-\1740 or_13\CC\3541091 <e2>renal_14\JJ\1740 insufficiency</e2>_15\NN\14462946 (_16\-LRB-\1740 <e1>cr</e1>_17\NN\14625458 >_18\NN\1740 or=2.5_19\NN\1740 mg/dl_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 they_24\PRP\1740 were_25\VBD\836236 compared_26\VBN\644583 to_27\TO\1740 2_28\CD\13741022 randomly_29\RB\1740 selected_30\VBD\697589 controls_31\NNS\5190804 per_32\IN\1740 case_33\NN\7283608 ._34\.\1740
D011188_D003920 NONE patients_0\NNS\9898892 who_1\WP\8299493 developed_2\VBD\1753788 hyperkalemia_3\NN\14299637 were_4\VBD\836236 older_5\JJR\1740 and_6\CC\1740 more_7\RBR\1740 likely_8\JJ\1740 to_9\TO\1740 have_10\VB\2108377 <e2>diabetes</e2>_11\NNS\14075199 ,_12\,\1740 had_13\VBD\2108377 higher_14\JJR\1740 baseline_15\NN\7260623 serum_16\NN\5397468 <e1>potassium</e1>_17\NN\14625458 levels_18\NNS\4916342 and_19\CC\1740 lower_20\JJR\1740 baseline_21\NN\7260623 potassium_22\NN\14625458 supplement_23\NN\6365467 doses_24\NNS\3740161 ,_25\,\1740 and_26\CC\1740 were_27\VBD\836236 more_28\RBR\1740 likely_29\JJ\1740 to_30\TO\1740 be_31\VB\836236 treated_32\VBN\2376958 with_33\IN\1740 beta-blockers_34\NNS\1740 than_35\IN\1740 controls_36\NNS\5190804 (_37\-LRB-\1740 n_38\NN\14622893 =_39\JJ\1740 134_40\CD\1740 )_41\-RRB-\1740 ._42\.\1740
D011188_D003920 NONE patients_0\NNS\9898892 who_1\WP\8299493 developed_2\VBD\1753788 hyperkalemia_3\NN\14299637 were_4\VBD\836236 older_5\JJR\1740 and_6\CC\1740 more_7\RBR\1740 likely_8\JJ\1740 to_9\TO\1740 have_10\VB\2108377 <e2>diabetes</e2>_11\NNS\14075199 ,_12\,\1740 had_13\VBD\2108377 higher_14\JJR\1740 baseline_15\NN\7260623 serum_16\NN\5397468 potassium_17\NN\14625458 levels_18\NNS\4916342 and_19\CC\1740 lower_20\JJR\1740 baseline_21\NN\7260623 <e1>potassium</e1>_22\NN\14625458 supplement_23\NN\6365467 doses_24\NNS\3740161 ,_25\,\1740 and_26\CC\1740 were_27\VBD\836236 more_28\RBR\1740 likely_29\JJ\1740 to_30\TO\1740 be_31\VB\836236 treated_32\VBN\2376958 with_33\IN\1740 beta-blockers_34\NNS\1740 than_35\IN\1740 controls_36\NNS\5190804 (_37\-LRB-\1740 n_38\NN\14622893 =_39\JJ\1740 134_40\CD\1740 )_41\-RRB-\1740 ._42\.\1740
D003404_D051437 NONE patients_0\NNS\9898892 who_1\WP\8299493 developed_2\VBD\1753788 <e2>renal_3\JJ\1740 insufficiency</e2>_4\NN\14462946 had_5\VBD\2108377 lower_6\JJR\1740 baseline_7\NN\7260623 body_8\NN\19128 weight_9\NN\5009170 and_10\CC\1740 higher_11\JJR\1740 baseline_12\NN\7260623 serum_13\NN\5397468 <e1>creatinine</e1>_14\NN\1740 ,_15\,\1740 required_16\VBD\754942 higher_17\JJR\1740 doses_18\NNS\3740161 of_19\IN\1740 loop_20\NN\3323703 diuretics_21\NNS\3247620 ,_22\,\1740 and_23\CC\1740 were_24\VBD\836236 more_25\RBR\1740 likely_26\JJ\1740 to_27\TO\1740 be_28\VB\836236 treated_29\VBN\2376958 with_30\IN\1740 thiazide_31\NN\3214670 diuretics_32\NNS\3247620 than_33\IN\1740 controls_34\NNS\5190804 ._35\.\1740
D049971_D051437 NONE patients_0\NNS\9898892 who_1\WP\8299493 developed_2\VBD\1753788 <e2>renal_3\JJ\1740 insufficiency</e2>_4\NN\14462946 had_5\VBD\2108377 lower_6\JJR\1740 baseline_7\NN\7260623 body_8\NN\19128 weight_9\NN\5009170 and_10\CC\1740 higher_11\JJR\1740 baseline_12\NN\7260623 serum_13\NN\5397468 creatinine_14\NN\1740 ,_15\,\1740 required_16\VBD\754942 higher_17\JJR\1740 doses_18\NNS\3740161 of_19\IN\1740 loop_20\NN\3323703 diuretics_21\NNS\3247620 ,_22\,\1740 and_23\CC\1740 were_24\VBD\836236 more_25\RBR\1740 likely_26\JJ\1740 to_27\TO\1740 be_28\VB\836236 treated_29\VBN\2376958 with_30\IN\1740 <e1>thiazide</e1>_31\NN\3214670 diuretics_32\NNS\3247620 than_33\IN\1740 controls_34\NNS\5190804 ._35\.\1740
6386793
D004308_D003866 NONE a_0\DT\13649268 double-blind_1\JJ\1740 study_2\NN\635850 of_3\IN\1740 the_4\DT\1740 efficacy_5\NN\5199286 and_6\CC\1740 safety_7\NN\13920835 of_8\IN\1740 <e1>dothiepin_9\NN\1740 hydrochloride</e1>_10\NN\14817592 in_11\IN\13603305 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 major_15\JJ\1740 <e2>depressive_16\JJ\1740 disorder</e2>_17\NN\14034177 ._18\.\1740
D004308_D003866 NONE in_0\IN\13603305 a_1\DT\13649268 6-week_2\JJ\1740 double-blind_3\JJ\1740 parallel_4\NN\4743605 treatment_5\NN\654885 study_6\NN\635850 ,_7\,\1740 <e1>dothiepin</e1>_8\NN\1740 and_9\CC\1740 amitriptyline_10\NN\4482543 were_11\VBD\836236 compared_12\VBN\644583 to_13\TO\1740 placebo_14\VB\1740 in_15\IN\13603305 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 33_19\CD\1740 <e2>depressed</e2>_20\JJ\1740 outpatients_21\NNS\10405694 ._22\.\1740
D004308_D003866 NONE <e1>dothiepin</e1>_0\NN\1740 and_1\CC\1740 amitriptyline_2\NN\4482543 were_3\VBD\836236 equally_4\RB\1740 effective_5\JJ\1740 in_6\IN\13603305 alleviating_7\VBG\205885 the_8\DT\1740 symptoms_9\NNS\5823932 of_10\IN\1740 <e2>depressive_11\JJ\1740 illness</e2>_12\NN\14052046 ,_13\,\1740 and_14\CC\1740 both_15\DT\1740 were_16\VBD\836236 significantly_17\RB\1740 superior_18\JJ\1740 to_19\TO\1740 placebo_20\NN\3740161 ._21\.\1740
D004308_D003866 NONE <e1>dothiepin</e1>_0\NNP\1740 thus_1\RB\1740 was_2\VBD\836236 found_3\VBN\2426171 to_4\TO\1740 be_5\VB\836236 an_6\DT\6697703 effective_7\JJ\1740 antidepressant_8\JJ\1740 drug_9\NN\14778436 associated_10\VBN\628491 with_11\IN\1740 fewer_12\JJR\1740 side_13\JJ\1740 effects_14\NNS\13245626 than_15\IN\1740 amitriptyline_16\NN\4482543 in_17\IN\13603305 the_18\DT\1740 treatment_19\NN\654885 of_20\IN\1740 <e2>depressed</e2>_21\JJ\1740 outpatients_22\NNS\10405694 ._23\.\1740
D000639_D003866 NONE in_0\IN\13603305 a_1\DT\13649268 6-week_2\JJ\1740 double-blind_3\JJ\1740 parallel_4\NN\4743605 treatment_5\NN\654885 study_6\NN\635850 ,_7\,\1740 dothiepin_8\NN\1740 and_9\CC\1740 <e1>amitriptyline</e1>_10\NN\4482543 were_11\VBD\836236 compared_12\VBN\644583 to_13\TO\1740 placebo_14\VB\1740 in_15\IN\13603305 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 33_19\CD\1740 <e2>depressed</e2>_20\JJ\1740 outpatients_21\NNS\10405694 ._22\.\1740
D000639_D003866 NONE dothiepin_0\NN\1740 and_1\CC\1740 <e1>amitriptyline</e1>_2\NN\4482543 were_3\VBD\836236 equally_4\RB\1740 effective_5\JJ\1740 in_6\IN\13603305 alleviating_7\VBG\205885 the_8\DT\1740 symptoms_9\NNS\5823932 of_10\IN\1740 <e2>depressive_11\JJ\1740 illness</e2>_12\NN\14052046 ,_13\,\1740 and_14\CC\1740 both_15\DT\1740 were_16\VBD\836236 significantly_17\RB\1740 superior_18\JJ\1740 to_19\TO\1740 placebo_20\NN\3740161 ._21\.\1740
D000639_D003866 NONE dothiepin_0\NNP\1740 thus_1\RB\1740 was_2\VBD\836236 found_3\VBN\2426171 to_4\TO\1740 be_5\VB\836236 an_6\DT\6697703 effective_7\JJ\1740 antidepressant_8\JJ\1740 drug_9\NN\14778436 associated_10\VBN\628491 with_11\IN\1740 fewer_12\JJR\1740 side_13\JJ\1740 effects_14\NNS\13245626 than_15\IN\1740 <e1>amitriptyline</e1>_16\NN\4482543 in_17\IN\13603305 the_18\DT\1740 treatment_19\NN\654885 of_20\IN\1740 <e2>depressed</e2>_21\JJ\1740 outpatients_22\NNS\10405694 ._23\.\1740
D004308_D014786 NONE the_0\DT\1740 overall_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 side_4\NN\8630039 effects_5\NNS\13245626 and_6\CC\1740 the_7\DT\1740 frequency_8\NN\15286249 and_9\CC\1740 severity_10\NN\5036394 of_11\IN\1740 <e2>blurred_12\JJ\1740 vision</e2>_13\NN\5767733 ,_14\,\1740 dry_15\JJ\1740 mouth_16\NN\5610008 ,_17\,\1740 and_18\CC\1740 drowsiness_19\VBD\1740 were_20\VBD\836236 significantly_21\RB\1740 less_22\JJR\1740 with_23\IN\1740 <e1>dothiepin</e1>_24\NN\1740 than_25\IN\1740 with_26\IN\1740 amitriptyline_27\NN\4482543 ._28\.\1740
D004308_D014987 NONE the_0\DT\1740 overall_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 side_4\NN\8630039 effects_5\NNS\13245626 and_6\CC\1740 the_7\DT\1740 frequency_8\NN\15286249 and_9\CC\1740 severity_10\NN\5036394 of_11\IN\1740 blurred_12\JJ\1740 vision_13\NN\5767733 ,_14\,\1740 <e2>dry_15\JJ\1740 mouth</e2>_16\NN\5610008 ,_17\,\1740 and_18\CC\1740 drowsiness_19\VBD\1740 were_20\VBD\836236 significantly_21\RB\1740 less_22\JJR\1740 with_23\IN\1740 <e1>dothiepin</e1>_24\NN\1740 than_25\IN\1740 with_26\IN\1740 amitriptyline_27\NN\4482543 ._28\.\1740
D000639_D014786 CID the_0\DT\1740 overall_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 side_4\NN\8630039 effects_5\NNS\13245626 and_6\CC\1740 the_7\DT\1740 frequency_8\NN\15286249 and_9\CC\1740 severity_10\NN\5036394 of_11\IN\1740 <e2>blurred_12\JJ\1740 vision</e2>_13\NN\5767733 ,_14\,\1740 dry_15\JJ\1740 mouth_16\NN\5610008 ,_17\,\1740 and_18\CC\1740 drowsiness_19\VBD\1740 were_20\VBD\836236 significantly_21\RB\1740 less_22\JJR\1740 with_23\IN\1740 dothiepin_24\NN\1740 than_25\IN\1740 with_26\IN\1740 <e1>amitriptyline</e1>_27\NN\4482543 ._28\.\1740
D000639_D014987 CID the_0\DT\1740 overall_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 side_4\NN\8630039 effects_5\NNS\13245626 and_6\CC\1740 the_7\DT\1740 frequency_8\NN\15286249 and_9\CC\1740 severity_10\NN\5036394 of_11\IN\1740 blurred_12\JJ\1740 vision_13\NN\5767733 ,_14\,\1740 <e2>dry_15\JJ\1740 mouth</e2>_16\NN\5610008 ,_17\,\1740 and_18\CC\1740 drowsiness_19\VBD\1740 were_20\VBD\836236 significantly_21\RB\1740 less_22\JJR\1740 with_23\IN\1740 dothiepin_24\NN\1740 than_25\IN\1740 with_26\IN\1740 <e1>amitriptyline</e1>_27\NN\4482543 ._28\.\1740
D000928_D003866 NONE dothiepin_0\NNP\1740 thus_1\RB\1740 was_2\VBD\836236 found_3\VBN\2426171 to_4\TO\1740 be_5\VB\836236 an_6\DT\6697703 effective_7\JJ\1740 <e1>antidepressant</e1>_8\JJ\1740 drug_9\NN\14778436 associated_10\VBN\628491 with_11\IN\1740 fewer_12\JJR\1740 side_13\JJ\1740 effects_14\NNS\13245626 than_15\IN\1740 amitriptyline_16\NN\4482543 in_17\IN\13603305 the_18\DT\1740 treatment_19\NN\654885 of_20\IN\1740 <e2>depressed</e2>_21\JJ\1740 outpatients_22\NNS\10405694 ._23\.\1740
2673163
D003042_D020521 NONE <e2>stroke</e2>_0\NNP\556313 associated_1\VBN\628491 with_2\IN\1740 <e1>cocaine</e1>_3\NN\3492717 use_4\NN\407535 ._5\.\1740
D003042_D020521 NONE we_0\PRP\1740 describe_1\VBP\1001294 eight_2\CD\13741022 patients_3\NNS\9898892 in_4\IN\13603305 whom_5\WP\1740 <e1>cocaine</e1>_6\NN\3492717 use_7\NN\407535 was_8\VBD\836236 related_9\JJ\1740 to_10\TO\1740 <e2>stroke</e2>_11\VB\1206218 and_12\CC\1740 review_13\VB\644583 39_14\CD\1740 cases_15\NNS\7283608 from_16\IN\1740 the_17\DT\1740 literature_18\NN\6362953 ._19\.\1740
D003042_D020521 NONE <e2>stroke</e2>_0\NN\556313 followed_1\VBD\1835496 <e1>cocaine</e1>_2\NN\3492717 use_3\NN\407535 by_4\IN\1740 inhalation_5\NN\835032 ,_6\,\1740 intranasal_7\JJ\1740 ,_8\,\1740 intravenous_9\JJ\1740 ,_10\,\1740 and_11\CC\1740 intramuscular_12\JJ\1740 routes_13\NNS\8593262 ._14\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 <e2>stroke</e2>_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 <e1>cocaine</e1>_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 <e1>cocaine</e1>_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 <e2>stroke</e2>_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 <e1>cocaine</e1>_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 <e2>stroke</e2>_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 <e1>cocaine</e1>_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 <e2>stroke</e2>_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 <e1>cocaine</e1>_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 <e2>stroke</e2>_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 <e2>stroke</e2>_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 <e1>cocaine-associated</e1>_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 <e1>cocaine-associated</e1>_22\JJ\1740 <e2>stroke</e2>_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 <e1>cocaine-associated</e1>_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 <e2>stroke</e2>_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 <e1>cocaine-associated</e1>_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 <e2>stroke</e2>_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 <e1>cocaine-associated</e1>_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 <e2>stroke</e2>_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 <e2>stroke</e2>_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 <e1>cocaine</e1>_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 <e2>stroke</e2>_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 <e1>cocaine</e1>_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 <e2>stroke</e2>_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 <e1>cocaine</e1>_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 <e1>cocaine</e1>_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 <e2>stroke</e2>_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 <e1>cocaine</e1>_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 <e2>stroke</e2>_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 <e2>stroke</e2>_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 <e1>cocaine</e1>_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 <e2>stroke</e2>_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 <e1>cocaine</e1>_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 <e2>stroke</e2>_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 <e1>cocaine</e1>_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 <e2>stroke</e2>_45\NN\556313 after_46\IN\1740 <e1>cocaine</e1>_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 <e1>cocaine</e1>_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 <e2>stroke</e2>_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 <e2>stroke</e2>_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 <e1>cocaine-associated</e1>_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 <e2>stroke</e2>_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 <e1>cocaine-associated</e1>_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 <e2>stroke</e2>_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 <e1>cocaine-associated</e1>_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 <e2>stroke</e2>_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 <e1>cocaine-associated</e1>_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020521 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 <e1>cocaine-associated</e1>_64\JJ\1740 <e2>stroke</e2>_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D002532 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 <e1>cocaine</e1>_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 <e2>intracranial_53\JJ\1740 aneurysms</e2>_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D002532 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 <e1>cocaine-associated</e1>_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 <e2>intracranial_53\JJ\1740 aneurysms</e2>_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D002532 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 <e1>cocaine</e1>_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 <e2>intracranial_53\JJ\1740 aneurysms</e2>_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D002532 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 <e1>cocaine</e1>_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 <e2>intracranial_53\JJ\1740 aneurysms</e2>_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D002532 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 <e2>intracranial_53\JJ\1740 aneurysms</e2>_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 <e1>cocaine-associated</e1>_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D001165 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 <e1>cocaine</e1>_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 <e2>arteriovenous_56\JJ\1740 malformations</e2>_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D001165 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 <e1>cocaine-associated</e1>_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 <e2>arteriovenous_56\JJ\1740 malformations</e2>_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D001165 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 <e1>cocaine</e1>_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 <e2>arteriovenous_56\JJ\1740 malformations</e2>_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D001165 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 <e1>cocaine</e1>_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 <e2>arteriovenous_56\JJ\1740 malformations</e2>_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D001165 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 <e2>arteriovenous_56\JJ\1740 malformations</e2>_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 <e1>cocaine-associated</e1>_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020300 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 <e1>cocaine</e1>_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 <e2>intracranial_70\JJ\1740 hemorrhage</e2>_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020300 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 <e1>cocaine-associated</e1>_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 <e2>intracranial_70\JJ\1740 hemorrhage</e2>_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020300 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 <e1>cocaine</e1>_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 <e2>intracranial_70\JJ\1740 hemorrhage</e2>_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020300 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 <e1>cocaine</e1>_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 <e2>intracranial_70\JJ\1740 hemorrhage</e2>_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D020300 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 <e1>cocaine-associated</e1>_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 <e2>intracranial_70\JJ\1740 hemorrhage</e2>_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 cerebral_75\JJ\1740 infarction_76\NN\14204950 ._77\.\1740
D003042_D002544 CID these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 <e1>cocaine</e1>_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 <e2>cerebral_75\JJ\1740 infarction</e2>_76\NN\14204950 ._77\.\1740
D003042_D002544 CID these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 <e1>cocaine-associated</e1>_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 <e2>cerebral_75\JJ\1740 infarction</e2>_76\NN\14204950 ._77\.\1740
D003042_D002544 CID these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 <e1>cocaine</e1>_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 <e2>cerebral_75\JJ\1740 infarction</e2>_76\NN\14204950 ._77\.\1740
D003042_D002544 CID these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 <e1>cocaine</e1>_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 cocaine-associated_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 <e2>cerebral_75\JJ\1740 infarction</e2>_76\NN\14204950 ._77\.\1740
D003042_D002544 CID these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 (_4\-LRB-\1740 1_5\LS\13741022 )_6\-RRB-\1740 the_7\DT\1740 apparent_8\JJ\1740 incidence_9\NN\13821570 of_10\IN\1740 stroke_11\NN\556313 related_12\JJ\1740 to_13\TO\1740 cocaine_14\NN\3492717 use_15\NN\407535 is_16\VBZ\836236 increasing_17\VBG\169651 ;_18\:\1740 (_19\-LRB-\1740 2_20\LS\13741022 )_21\-RRB-\1740 cocaine-associated_22\JJ\1740 stroke_23\NN\556313 occurs_24\VBZ\2623529 primarily_25\RB\1740 in_26\IN\13603305 young_27\JJ\1740 adults_28\NNS\7846 ;_29\:\1740 (_30\-LRB-\1740 3_31\LS\13741022 )_32\-RRB-\1740 stroke_33\NN\556313 may_34\MD\15209706 follow_35\VB\1835496 any_36\DT\1740 route_37\NN\8593262 of_38\IN\1740 cocaine_39\NN\3492717 administration_40\NN\1133281 ;_41\:\1740 (_42\-LRB-\1740 4_43\LS\13741022 )_44\-RRB-\1740 stroke_45\NN\556313 after_46\IN\1740 cocaine_47\NN\3492717 use_48\NN\407535 is_49\VBZ\836236 frequently_50\RB\1740 associated_51\VBN\628491 with_52\IN\1740 intracranial_53\JJ\1740 aneurysms_54\NNS\14057371 and_55\CC\1740 arteriovenous_56\JJ\1740 malformations_57\NNS\14213199 ;_58\:\1740 and_59\CC\1740 (_60\-LRB-\1740 5_61\LS\13741022 )_62\-RRB-\1740 in_63\IN\13603305 <e1>cocaine-associated</e1>_64\JJ\1740 stroke_65\NN\556313 ,_66\,\1740 the_67\DT\1740 frequency_68\NN\15286249 of_69\IN\1740 intracranial_70\JJ\1740 hemorrhage_71\NN\14285662 exceeds_72\NNS\1740 that_73\DT\1740 of_74\IN\1740 <e2>cerebral_75\JJ\1740 infarction</e2>_76\NN\14204950 ._77\.\1740
19803309
D013390_D009224 NONE we_0\PRP\1740 report_1\VBP\831651 an_2\DT\6697703 undiagnosed_3\JJ\1740 case_4\NN\7283608 of_5\IN\1740 <e2>myotonia_6\NN\14544672 congenita</e2>_7\NN\1740 in_8\IN\13603305 a_9\DT\13649268 24-year-old_10\JJ\1740 previously_11\RB\1740 healthy_12\JJ\1740 primigravida_13\NN\10144838 ,_14\,\1740 who_15\WP\8299493 developed_16\VBD\1753788 life_17\NN\13954253 threatening_18\VBG\2603699 masseter_19\NN\5602132 spasm_20\NN\14299637 following_21\VBG\1835496 a_22\DT\13649268 standard_23\JJ\1740 dose_24\NN\3740161 of_25\IN\1740 intravenous_26\JJ\1740 <e1>suxamethonium</e1>_27\NN\1740 for_28\IN\1740 induction_29\NN\7450842 of_30\IN\1740 anaesthesia_31\NN\14034177 ._32\.\1740
D013390_D014313 CID we_0\PRP\1740 report_1\VBP\831651 an_2\DT\6697703 undiagnosed_3\JJ\1740 case_4\NN\7283608 of_5\IN\1740 myotonia_6\NN\14544672 congenita_7\NN\1740 in_8\IN\13603305 a_9\DT\13649268 24-year-old_10\JJ\1740 previously_11\RB\1740 healthy_12\JJ\1740 primigravida_13\NN\10144838 ,_14\,\1740 who_15\WP\8299493 developed_16\VBD\1753788 life_17\NN\13954253 threatening_18\VBG\2603699 <e2>masseter_19\NN\5602132 spasm</e2>_20\NN\14299637 following_21\VBG\1835496 a_22\DT\13649268 standard_23\JJ\1740 dose_24\NN\3740161 of_25\IN\1740 intravenous_26\JJ\1740 <e1>suxamethonium</e1>_27\NN\1740 for_28\IN\1740 induction_29\NN\7450842 of_30\IN\1740 anaesthesia_31\NN\14034177 ._32\.\1740
234669
D000628_D014693 CID effects_0\NNS\13245626 of_1\IN\1740 <e1>aminophylline</e1>_2\NN\2905612 on_3\IN\1740 the_4\DT\1740 threshold_5\NN\15265518 for_6\IN\1740 initiating_7\VBG\1617192 <e2>ventricular_8\JJ\1740 fibrillation</e2>_9\NN\14361664 during_10\IN\1740 respiratory_11\JJ\1740 failure_12\NN\66216 ._13\.\1740
D000628_D014693 CID the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>aminophylline</e1>_3\NN\2905612 on_4\IN\1740 the_5\DT\1740 <e2>ventricular_6\JJ\1740 fibrillation</e2>_7\NN\14361664 threshold_8\NN\15265518 during_9\IN\1740 normal_10\JJ\1740 acid-base_11\JJ\1740 conditions_12\NNS\14512817 and_13\CC\1740 during_14\IN\1740 respiratory_15\JJ\1740 failure_16\NN\66216 were_17\VBD\836236 studied_18\VBN\630380 in_19\IN\13603305 anesthetized_20\JJ\1740 open_21\JJ\1740 chest_22\JJS\1740 dogs_23\NNS\2083346 ._24\.\1740
D000628_D014693 CID during_0\IN\1740 the_1\DT\1740 infusion_2\NN\14589223 of_3\IN\1740 <e1>aminophylline</e1>_4\NN\2905612 ,_5\,\1740 the_6\DT\1740 <e2>ventricular_7\JJ\1740 fibrillation</e2>_8\NN\14361664 threshold_9\NN\15265518 was_10\VBD\836236 reduced_11\VBN\441445 by_12\IN\1740 30_13\CD\13745420 to_14\TO\1740 40_15\CD\13745420 percent_16\NN\13815742 of_17\IN\1740 the_18\DT\1740 control_19\NN\5190804 when_20\WRB\1740 ph_21\NN\5038959 and_22\CC\1740 partial_23\JJ\1740 pressures_24\NNS\11419404 of_25\IN\1740 oxygen_26\NN\14622893 (_27\-LRB-\1740 po2_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 carbon_31\NN\14622893 dioxide_32\NN\14971519 (_33\-LRB-\1740 co2_34\NN\14836127 )_35\-RRB-\1740 were_36\VBD\836236 kept_37\VBN\2367363 within_38\IN\1740 normal_39\JJ\1740 limits_40\NNS\5123416 ._41\.\1740
D000628_D014693 CID when_0\WRB\1740 respiratory_1\JJ\1740 failure_2\NN\66216 was_3\VBD\836236 produced_4\VBN\1617192 by_5\IN\1740 hypoventilation_6\NN\1740 (_7\-LRB-\1740 ph_8\NN\5038959 7.05_9\CD\1740 to_10\TO\1740 7.25_11\CD\1740 ;_12\:\1740 pc02_13\NN\1740 70_14\CD\13745420 to_15\TO\1740 100_16\CD\13745420 mm_17\NN\13649268 hg_18\NNP\14625458 :_19\:\1740 p02_20\NN\1740 20_21\CD\13745420 to_22\TO\1740 40_23\CD\13745420 mm_24\NN\13649268 hg_25\NN\14625458 )_26\-RRB-\1740 ,_27\,\1740 infusion_28\NN\14589223 of_29\IN\1740 <e1>aminophylline</e1>_30\NN\2905612 resulted_31\VBD\2633881 in_32\IN\13603305 an_33\DT\6697703 even_34\RB\1740 greater_35\JJR\1740 decrease_36\NN\7296428 in_37\IN\13603305 <e2>ventricular_38\JJ\1740 fibrillation</e2>_39\NN\14361664 threshold_40\NN\15265518 to_41\IN\1740 60_42\CD\13745420 percent_43\NN\13815742 of_44\IN\1740 the_45\DT\1740 control_46\NN\5190804 level_47\NN\4916342 ._48\.\1740
D000628_D012131 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>aminophylline</e1>_2\NN\2905612 on_3\IN\1740 the_4\DT\1740 threshold_5\NN\15265518 for_6\IN\1740 initiating_7\VBG\1617192 ventricular_8\JJ\1740 fibrillation_9\NN\14361664 during_10\IN\1740 <e2>respiratory_11\JJ\1740 failure</e2>_12\NN\66216 ._13\.\1740
D000628_D012131 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>aminophylline</e1>_3\NN\2905612 on_4\IN\1740 the_5\DT\1740 ventricular_6\JJ\1740 fibrillation_7\NN\14361664 threshold_8\NN\15265518 during_9\IN\1740 normal_10\JJ\1740 acid-base_11\JJ\1740 conditions_12\NNS\14512817 and_13\CC\1740 during_14\IN\1740 <e2>respiratory_15\JJ\1740 failure</e2>_16\NN\66216 were_17\VBD\836236 studied_18\VBN\630380 in_19\IN\13603305 anesthetized_20\JJ\1740 open_21\JJ\1740 chest_22\JJS\1740 dogs_23\NNS\2083346 ._24\.\1740
D000628_D012131 NONE when_0\WRB\1740 <e2>respiratory_1\JJ\1740 failure</e2>_2\NN\66216 was_3\VBD\836236 produced_4\VBN\1617192 by_5\IN\1740 hypoventilation_6\NN\1740 (_7\-LRB-\1740 ph_8\NN\5038959 7.05_9\CD\1740 to_10\TO\1740 7.25_11\CD\1740 ;_12\:\1740 pc02_13\NN\1740 70_14\CD\13745420 to_15\TO\1740 100_16\CD\13745420 mm_17\NN\13649268 hg_18\NNP\14625458 :_19\:\1740 p02_20\NN\1740 20_21\CD\13745420 to_22\TO\1740 40_23\CD\13745420 mm_24\NN\13649268 hg_25\NN\14625458 )_26\-RRB-\1740 ,_27\,\1740 infusion_28\NN\14589223 of_29\IN\1740 <e1>aminophylline</e1>_30\NN\2905612 resulted_31\VBD\2633881 in_32\IN\13603305 an_33\DT\6697703 even_34\RB\1740 greater_35\JJR\1740 decrease_36\NN\7296428 in_37\IN\13603305 ventricular_38\JJ\1740 fibrillation_39\NN\14361664 threshold_40\NN\15265518 to_41\IN\1740 60_42\CD\13745420 percent_43\NN\13815742 of_44\IN\1740 the_45\DT\1740 control_46\NN\5190804 level_47\NN\4916342 ._48\.\1740
D000628_D012131 NONE these_0\DT\1740 experiments_1\NNS\641820 suggest_2\VBP\1010118 that_3\IN\1740 although_4\IN\1740 many_5\JJ\1740 factors_6\NNS\7326557 may_7\MD\15209706 contribute_8\VB\126264 to_9\TO\1740 the_10\DT\1740 increased_11\VBN\169651 incidence_12\NN\13821570 of_13\IN\1740 ventricular_14\JJ\1740 arrhythmias_15\NNS\14103288 in_16\IN\13603305 <e2>respiratory_17\JJ\1740 failure</e2>_18\NN\66216 ,_19\,\1740 pharmacologic_20\JJ\1740 agents_21\NNS\7347 ,_22\,\1740 particularly_23\RB\1740 <e1>aminophylline</e1>_24\NN\2905612 ,_25\,\1740 may_26\MD\15209706 play_27\VB\1072262 a_28\DT\13649268 significant_29\JJ\1740 role_30\NN\719494 ._31\.\1740
D010100_D014693 NONE during_0\IN\1740 the_1\DT\1740 infusion_2\NN\14589223 of_3\IN\1740 aminophylline_4\NN\2905612 ,_5\,\1740 the_6\DT\1740 <e2>ventricular_7\JJ\1740 fibrillation</e2>_8\NN\14361664 threshold_9\NN\15265518 was_10\VBD\836236 reduced_11\VBN\441445 by_12\IN\1740 30_13\CD\13745420 to_14\TO\1740 40_15\CD\13745420 percent_16\NN\13815742 of_17\IN\1740 the_18\DT\1740 control_19\NN\5190804 when_20\WRB\1740 ph_21\NN\5038959 and_22\CC\1740 partial_23\JJ\1740 pressures_24\NNS\11419404 of_25\IN\1740 <e1>oxygen</e1>_26\NN\14622893 (_27\-LRB-\1740 po2_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 carbon_31\NN\14622893 dioxide_32\NN\14971519 (_33\-LRB-\1740 co2_34\NN\14836127 )_35\-RRB-\1740 were_36\VBD\836236 kept_37\VBN\2367363 within_38\IN\1740 normal_39\JJ\1740 limits_40\NNS\5123416 ._41\.\1740
C093415_D014693 NONE during_0\IN\1740 the_1\DT\1740 infusion_2\NN\14589223 of_3\IN\1740 aminophylline_4\NN\2905612 ,_5\,\1740 the_6\DT\1740 <e2>ventricular_7\JJ\1740 fibrillation</e2>_8\NN\14361664 threshold_9\NN\15265518 was_10\VBD\836236 reduced_11\VBN\441445 by_12\IN\1740 30_13\CD\13745420 to_14\TO\1740 40_15\CD\13745420 percent_16\NN\13815742 of_17\IN\1740 the_18\DT\1740 control_19\NN\5190804 when_20\WRB\1740 ph_21\NN\5038959 and_22\CC\1740 partial_23\JJ\1740 pressures_24\NNS\11419404 of_25\IN\1740 oxygen_26\NN\14622893 (_27\-LRB-\1740 <e1>po2</e1>_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 carbon_31\NN\14622893 dioxide_32\NN\14971519 (_33\-LRB-\1740 co2_34\NN\14836127 )_35\-RRB-\1740 were_36\VBD\836236 kept_37\VBN\2367363 within_38\IN\1740 normal_39\JJ\1740 limits_40\NNS\5123416 ._41\.\1740
D002245_D014693 NONE during_0\IN\1740 the_1\DT\1740 infusion_2\NN\14589223 of_3\IN\1740 aminophylline_4\NN\2905612 ,_5\,\1740 the_6\DT\1740 <e2>ventricular_7\JJ\1740 fibrillation</e2>_8\NN\14361664 threshold_9\NN\15265518 was_10\VBD\836236 reduced_11\VBN\441445 by_12\IN\1740 30_13\CD\13745420 to_14\TO\1740 40_15\CD\13745420 percent_16\NN\13815742 of_17\IN\1740 the_18\DT\1740 control_19\NN\5190804 when_20\WRB\1740 ph_21\NN\5038959 and_22\CC\1740 partial_23\JJ\1740 pressures_24\NNS\11419404 of_25\IN\1740 oxygen_26\NN\14622893 (_27\-LRB-\1740 po2_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 <e1>carbon_31\NN\14622893 dioxide</e1>_32\NN\14971519 (_33\-LRB-\1740 co2_34\NN\14836127 )_35\-RRB-\1740 were_36\VBD\836236 kept_37\VBN\2367363 within_38\IN\1740 normal_39\JJ\1740 limits_40\NNS\5123416 ._41\.\1740
D002245_D014693 NONE during_0\IN\1740 the_1\DT\1740 infusion_2\NN\14589223 of_3\IN\1740 aminophylline_4\NN\2905612 ,_5\,\1740 the_6\DT\1740 <e2>ventricular_7\JJ\1740 fibrillation</e2>_8\NN\14361664 threshold_9\NN\15265518 was_10\VBD\836236 reduced_11\VBN\441445 by_12\IN\1740 30_13\CD\13745420 to_14\TO\1740 40_15\CD\13745420 percent_16\NN\13815742 of_17\IN\1740 the_18\DT\1740 control_19\NN\5190804 when_20\WRB\1740 ph_21\NN\5038959 and_22\CC\1740 partial_23\JJ\1740 pressures_24\NNS\11419404 of_25\IN\1740 oxygen_26\NN\14622893 (_27\-LRB-\1740 po2_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 carbon_31\NN\14622893 dioxide_32\NN\14971519 (_33\-LRB-\1740 <e1>co2</e1>_34\NN\14836127 )_35\-RRB-\1740 were_36\VBD\836236 kept_37\VBN\2367363 within_38\IN\1740 normal_39\JJ\1740 limits_40\NNS\5123416 ._41\.\1740
D000628_D007040 NONE when_0\WRB\1740 respiratory_1\JJ\1740 failure_2\NN\66216 was_3\VBD\836236 produced_4\VBN\1617192 by_5\IN\1740 <e2>hypoventilation</e2>_6\NN\1740 (_7\-LRB-\1740 ph_8\NN\5038959 7.05_9\CD\1740 to_10\TO\1740 7.25_11\CD\1740 ;_12\:\1740 pc02_13\NN\1740 70_14\CD\13745420 to_15\TO\1740 100_16\CD\13745420 mm_17\NN\13649268 hg_18\NNP\14625458 :_19\:\1740 p02_20\NN\1740 20_21\CD\13745420 to_22\TO\1740 40_23\CD\13745420 mm_24\NN\13649268 hg_25\NN\14625458 )_26\-RRB-\1740 ,_27\,\1740 infusion_28\NN\14589223 of_29\IN\1740 <e1>aminophylline</e1>_30\NN\2905612 resulted_31\VBD\2633881 in_32\IN\13603305 an_33\DT\6697703 even_34\RB\1740 greater_35\JJR\1740 decrease_36\NN\7296428 in_37\IN\13603305 ventricular_38\JJ\1740 fibrillation_39\NN\14361664 threshold_40\NN\15265518 to_41\IN\1740 60_42\CD\13745420 percent_43\NN\13815742 of_44\IN\1740 the_45\DT\1740 control_46\NN\5190804 level_47\NN\4916342 ._48\.\1740
D000628_D001145 NONE these_0\DT\1740 experiments_1\NNS\641820 suggest_2\VBP\1010118 that_3\IN\1740 although_4\IN\1740 many_5\JJ\1740 factors_6\NNS\7326557 may_7\MD\15209706 contribute_8\VB\126264 to_9\TO\1740 the_10\DT\1740 increased_11\VBN\169651 incidence_12\NN\13821570 of_13\IN\1740 <e2>ventricular_14\JJ\1740 arrhythmias</e2>_15\NNS\14103288 in_16\IN\13603305 respiratory_17\JJ\1740 failure_18\NN\66216 ,_19\,\1740 pharmacologic_20\JJ\1740 agents_21\NNS\7347 ,_22\,\1740 particularly_23\RB\1740 <e1>aminophylline</e1>_24\NN\2905612 ,_25\,\1740 may_26\MD\15209706 play_27\VB\1072262 a_28\DT\13649268 significant_29\JJ\1740 role_30\NN\719494 ._31\.\1740
3985451
D014859_D006470 NONE <e1>warfarin-induced</e1>_0\JJ\1740 iliopsoas_1\NN\1740 <e2>hemorrhage</e2>_2\NN\14285662 with_3\IN\1740 subsequent_4\JJ\1740 femoral_5\JJ\1740 nerve_6\NN\5475681 palsy_7\NN\14557898 ._8\.\1740
D014859_D020428 CID <e1>warfarin-induced</e1>_0\JJ\1740 iliopsoas_1\NN\1740 hemorrhage_2\NN\14285662 with_3\IN\1740 subsequent_4\JJ\1740 <e2>femoral_5\JJ\1740 nerve_6\NN\5475681 palsy</e2>_7\NN\14557898 ._8\.\1740
D014859_D020428 CID anticoagulant-induced_0\JJ\1740 <e2>femoral_1\JJ\1740 nerve_2\NN\5475681 palsy</e2>_3\NN\14557898 represents_4\VBZ\2664769 the_5\DT\1740 most_6\RBS\1740 common_7\JJ\1740 form_8\NN\6286395 of_9\IN\1740 <e1>warfarin-induced</e1>_10\JJ\1740 peripheral_11\JJ\1740 neuropathy_12\NN\14204950 ;_13\:\1740 it_14\PRP\6125041 is_15\VBZ\836236 characterized_16\VBN\609683 by_17\IN\1740 severe_18\JJ\1740 pain_19\NN\14299637 in_20\IN\13603305 the_21\DT\1740 inguinal_22\JJ\1740 region_23\NN\27167 ,_24\,\1740 varying_25\VBG\2666239 degrees_26\NNS\4916342 of_27\IN\1740 motor_28\NN\3699975 and_29\CC\1740 sensory_30\JJ\1740 impairment_31\NN\7296428 ,_32\,\1740 and_33\CC\1740 flexure_34\JJ\1740 contracture_35\NN\369802 of_36\IN\1740 the_37\DT\1740 involved_38\JJ\1740 extremity_39\NN\5225090 ._40\.\1740
D014859_D009135 CID we_0\PRP\1740 present_1\VBP\2137132 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 28-year-old_6\JJ\1740 man_7\NN\9605289 on_8\IN\1740 chronic_9\JJ\1740 <e1>warfarin</e1>_10\NN\2718259 therapy_11\NN\657604 who_12\WP\8299493 sustained_13\VBD\2679899 a_14\DT\13649268 minor_15\JJ\1740 <e2>muscle_16\NN\5289601 tear</e2>_17\NN\13771404 and_18\CC\1740 developed_19\VBD\1753788 increasing_20\VBG\169651 pain_21\NN\14299637 and_22\CC\1740 a_23\DT\13649268 flexure_24\JJ\1740 contracture_25\NN\369802 of_26\IN\1740 the_27\DT\1740 right_28\JJ\1740 hip_29\NN\5220461 ._30\.\1740
D014859_D010146 NONE we_0\PRP\1740 present_1\VBP\2137132 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 28-year-old_6\JJ\1740 man_7\NN\9605289 on_8\IN\1740 chronic_9\JJ\1740 <e1>warfarin</e1>_10\NN\2718259 therapy_11\NN\657604 who_12\WP\8299493 sustained_13\VBD\2679899 a_14\DT\13649268 minor_15\JJ\1740 muscle_16\NN\5289601 tear_17\NN\13771404 and_18\CC\1740 developed_19\VBD\1753788 increasing_20\VBG\169651 <e2>pain</e2>_21\NN\14299637 and_22\CC\1740 a_23\DT\13649268 flexure_24\JJ\1740 contracture_25\NN\369802 of_26\IN\1740 the_27\DT\1740 right_28\JJ\1740 hip_29\NN\5220461 ._30\.\1740
D014859_D010146 NONE anticoagulant-induced_0\JJ\1740 femoral_1\JJ\1740 nerve_2\NN\5475681 palsy_3\NN\14557898 represents_4\VBZ\2664769 the_5\DT\1740 most_6\RBS\1740 common_7\JJ\1740 form_8\NN\6286395 of_9\IN\1740 <e1>warfarin-induced</e1>_10\JJ\1740 peripheral_11\JJ\1740 neuropathy_12\NN\14204950 ;_13\:\1740 it_14\PRP\6125041 is_15\VBZ\836236 characterized_16\VBN\609683 by_17\IN\1740 severe_18\JJ\1740 <e2>pain</e2>_19\NN\14299637 in_20\IN\13603305 the_21\DT\1740 inguinal_22\JJ\1740 region_23\NN\27167 ,_24\,\1740 varying_25\VBG\2666239 degrees_26\NNS\4916342 of_27\IN\1740 motor_28\NN\3699975 and_29\CC\1740 sensory_30\JJ\1740 impairment_31\NN\7296428 ,_32\,\1740 and_33\CC\1740 flexure_34\JJ\1740 contracture_35\NN\369802 of_36\IN\1740 the_37\DT\1740 involved_38\JJ\1740 extremity_39\NN\5225090 ._40\.\1740
D014859_D003286 NONE we_0\PRP\1740 present_1\VBP\2137132 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 28-year-old_6\JJ\1740 man_7\NN\9605289 on_8\IN\1740 chronic_9\JJ\1740 <e1>warfarin</e1>_10\NN\2718259 therapy_11\NN\657604 who_12\WP\8299493 sustained_13\VBD\2679899 a_14\DT\13649268 minor_15\JJ\1740 muscle_16\NN\5289601 tear_17\NN\13771404 and_18\CC\1740 developed_19\VBD\1753788 increasing_20\VBG\169651 pain_21\NN\14299637 and_22\CC\1740 a_23\DT\13649268 flexure_24\JJ\1740 <e2>contracture</e2>_25\NN\369802 of_26\IN\1740 the_27\DT\1740 right_28\JJ\1740 hip_29\NN\5220461 ._30\.\1740
D014859_D003286 NONE anticoagulant-induced_0\JJ\1740 femoral_1\JJ\1740 nerve_2\NN\5475681 palsy_3\NN\14557898 represents_4\VBZ\2664769 the_5\DT\1740 most_6\RBS\1740 common_7\JJ\1740 form_8\NN\6286395 of_9\IN\1740 <e1>warfarin-induced</e1>_10\JJ\1740 peripheral_11\JJ\1740 neuropathy_12\NN\14204950 ;_13\:\1740 it_14\PRP\6125041 is_15\VBZ\836236 characterized_16\VBN\609683 by_17\IN\1740 severe_18\JJ\1740 pain_19\NN\14299637 in_20\IN\13603305 the_21\DT\1740 inguinal_22\JJ\1740 region_23\NN\27167 ,_24\,\1740 varying_25\VBG\2666239 degrees_26\NNS\4916342 of_27\IN\1740 motor_28\NN\3699975 and_29\CC\1740 sensory_30\JJ\1740 impairment_31\NN\7296428 ,_32\,\1740 and_33\CC\1740 flexure_34\JJ\1740 <e2>contracture</e2>_35\NN\369802 of_36\IN\1740 the_37\DT\1740 involved_38\JJ\1740 extremity_39\NN\5225090 ._40\.\1740
D014859_D010523 NONE anticoagulant-induced_0\JJ\1740 femoral_1\JJ\1740 nerve_2\NN\5475681 palsy_3\NN\14557898 represents_4\VBZ\2664769 the_5\DT\1740 most_6\RBS\1740 common_7\JJ\1740 form_8\NN\6286395 of_9\IN\1740 <e1>warfarin-induced</e1>_10\JJ\1740 <e2>peripheral_11\JJ\1740 neuropathy</e2>_12\NN\14204950 ;_13\:\1740 it_14\PRP\6125041 is_15\VBZ\836236 characterized_16\VBN\609683 by_17\IN\1740 severe_18\JJ\1740 pain_19\NN\14299637 in_20\IN\13603305 the_21\DT\1740 inguinal_22\JJ\1740 region_23\NN\27167 ,_24\,\1740 varying_25\VBG\2666239 degrees_26\NNS\4916342 of_27\IN\1740 motor_28\NN\3699975 and_29\CC\1740 sensory_30\JJ\1740 impairment_31\NN\7296428 ,_32\,\1740 and_33\CC\1740 flexure_34\JJ\1740 contracture_35\NN\369802 of_36\IN\1740 the_37\DT\1740 involved_38\JJ\1740 extremity_39\NN\5225090 ._40\.\1740
D014859_D015417 NONE anticoagulant-induced_0\JJ\1740 femoral_1\JJ\1740 nerve_2\NN\5475681 palsy_3\NN\14557898 represents_4\VBZ\2664769 the_5\DT\1740 most_6\RBS\1740 common_7\JJ\1740 form_8\NN\6286395 of_9\IN\1740 <e1>warfarin-induced</e1>_10\JJ\1740 peripheral_11\JJ\1740 neuropathy_12\NN\14204950 ;_13\:\1740 it_14\PRP\6125041 is_15\VBZ\836236 characterized_16\VBN\609683 by_17\IN\1740 severe_18\JJ\1740 pain_19\NN\14299637 in_20\IN\13603305 the_21\DT\1740 inguinal_22\JJ\1740 region_23\NN\27167 ,_24\,\1740 varying_25\VBG\2666239 degrees_26\NNS\4916342 of_27\IN\1740 <e2>motor_28\NN\3699975 and_29\CC\1740 sensory_30\JJ\1740 impairment</e2>_31\NN\7296428 ,_32\,\1740 and_33\CC\1740 flexure_34\JJ\1740 contracture_35\NN\369802 of_36\IN\1740 the_37\DT\1740 involved_38\JJ\1740 extremity_39\NN\5225090 ._40\.\1740
19356053
D020123_D011507 CID clinically_0\RB\1740 significant_1\JJ\1740 <e2>proteinuria</e2>_2\NN\14299637 following_3\VBG\1835496 the_4\DT\1740 administration_5\NN\1133281 of_6\IN\1740 <e1>sirolimus</e1>_7\NN\1740 to_8\TO\1740 renal_9\JJ\1740 transplant_10\NN\5267548 recipients_11\NNS\9764201 ._12\.\1740
D020123_D011507 CID to_0\IN\1740 date_1\NN\15155220 there_2\EX\27167 has_3\VBZ\2108377 been_4\VBN\836236 little_5\JJ\1740 documentation_6\NN\6650070 of_7\IN\1740 clinically_8\RB\1740 significant_9\JJ\1740 <e2>proteinuria</e2>_10\NN\14299637 linked_11\VBN\628491 with_12\IN\1740 the_13\DT\1740 use_14\NN\407535 of_15\IN\1740 <e1>sirolimus</e1>_16\NN\1740 ._17\.\1740
D020123_D011507 CID we_0\PRP\1740 have_1\VBP\2108377 encountered_2\VBN\2604760 several_3\JJ\1740 patients_4\NNS\9898892 who_5\WP\8299493 developed_6\VBD\1753788 substantial_7\JJ\1740 <e2>proteinuria</e2>_8\NN\14299637 associated_9\VBN\628491 with_10\IN\1740 <e1>sirolimus</e1>_11\NN\1740 use_12\NN\407535 ._13\.\1740
D020123_D011507 CID in_0\IN\13603305 each_1\DT\1740 patient_2\NN\9898892 ,_3\,\1740 the_4\DT\1740 close_5\JJ\1740 temporal_6\JJ\1740 association_7\NN\8008335 between_8\IN\1740 the_9\DT\1740 commencement_10\NN\15180528 of_11\IN\1740 <e1>sirolimus</e1>_12\NN\1740 therapy_13\NN\657604 and_14\CC\1740 <e2>proteinuria</e2>_15\NN\14299637 implicated_16\VBD\2677097 sirolimus_17\NN\1740 as_18\IN\14622893 the_19\DT\1740 most_20\RBS\1740 likely_21\JJ\1740 etiology_22\NN\7326557 of_23\IN\1740 the_24\DT\1740 proteinuria_25\NN\14299637 ._26\.\1740
D020123_D011507 CID in_0\IN\13603305 each_1\DT\1740 patient_2\NN\9898892 ,_3\,\1740 the_4\DT\1740 close_5\JJ\1740 temporal_6\JJ\1740 association_7\NN\8008335 between_8\IN\1740 the_9\DT\1740 commencement_10\NN\15180528 of_11\IN\1740 <e1>sirolimus</e1>_12\NN\1740 therapy_13\NN\657604 and_14\CC\1740 proteinuria_15\NN\14299637 implicated_16\VBD\2677097 sirolimus_17\NN\1740 as_18\IN\14622893 the_19\DT\1740 most_20\RBS\1740 likely_21\JJ\1740 etiology_22\NN\7326557 of_23\IN\1740 the_24\DT\1740 <e2>proteinuria</e2>_25\NN\14299637 ._26\.\1740
D020123_D011507 CID in_0\IN\13603305 each_1\DT\1740 patient_2\NN\9898892 ,_3\,\1740 the_4\DT\1740 close_5\JJ\1740 temporal_6\JJ\1740 association_7\NN\8008335 between_8\IN\1740 the_9\DT\1740 commencement_10\NN\15180528 of_11\IN\1740 sirolimus_12\NN\1740 therapy_13\NN\657604 and_14\CC\1740 <e2>proteinuria</e2>_15\NN\14299637 implicated_16\VBD\2677097 <e1>sirolimus</e1>_17\NN\1740 as_18\IN\14622893 the_19\DT\1740 most_20\RBS\1740 likely_21\JJ\1740 etiology_22\NN\7326557 of_23\IN\1740 the_24\DT\1740 proteinuria_25\NN\14299637 ._26\.\1740
D020123_D011507 CID in_0\IN\13603305 each_1\DT\1740 patient_2\NN\9898892 ,_3\,\1740 the_4\DT\1740 close_5\JJ\1740 temporal_6\JJ\1740 association_7\NN\8008335 between_8\IN\1740 the_9\DT\1740 commencement_10\NN\15180528 of_11\IN\1740 sirolimus_12\NN\1740 therapy_13\NN\657604 and_14\CC\1740 proteinuria_15\NN\14299637 implicated_16\VBD\2677097 <e1>sirolimus</e1>_17\NN\1740 as_18\IN\14622893 the_19\DT\1740 most_20\RBS\1740 likely_21\JJ\1740 etiology_22\NN\7326557 of_23\IN\1740 the_24\DT\1740 <e2>proteinuria</e2>_25\NN\14299637 ._26\.\1740
D020123_D011507 CID in_0\IN\13603305 7_1\CD\13741022 of_2\IN\1740 the_3\DT\1740 28_4\CD\13745420 patients_5\NNS\9898892 there_6\EX\27167 was_7\VBD\836236 a_8\DT\13649268 striking_9\JJ\1740 temporal_10\JJ\1740 association_11\NN\8008335 between_12\IN\1740 the_13\DT\1740 initiation_14\NN\7450842 of_15\IN\1740 <e1>sirolimus</e1>_16\NN\1740 and_17\CC\1740 the_18\DT\1740 development_19\NN\248977 of_20\IN\1740 nephrotic-range_21\JJ\1740 <e2>proteinuria</e2>_22\NN\14299637 ._23\.\1740
D020123_D011507 CID <e2>proteinuria</e2>_0\NNP\14299637 correlated_1\VBD\2657219 most_2\RBS\1740 strongly_3\RB\1740 with_4\IN\1740 <e1>sirolimus</e1>_5\NN\1740 therapy_6\NN\657604 when_7\WRB\1740 compared_8\VBN\644583 to_9\TO\1740 other_10\JJ\1740 demographic_11\NN\6021499 and_12\CC\1740 clinical_13\JJ\1740 variables_14\NNS\2452 ._15\.\1740
D020123_D011507 CID in_0\IN\13603305 most_1\JJS\1740 patients_2\NNS\9898892 ,_3\,\1740 discontinuation_4\NN\209943 of_5\IN\1740 <e1>sirolimus</e1>_6\NN\1740 resulted_7\VBD\2633881 in_8\IN\13603305 a_9\DT\13649268 decrease_10\NN\7296428 ,_11\,\1740 but_12\CC\1740 not_13\RB\1740 resolution_14\NN\6470073 ,_15\,\1740 of_16\IN\1740 <e2>proteinuria</e2>_17\NN\14299637 ._18\.\1740
D020123_D011507 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>sirolimus</e1>_2\NN\1740 induces_3\VBZ\1627355 or_4\CC\3541091 aggravates_5\VBZ\126264 pre-existing_6\JJ\1740 <e2>proteinuria</e2>_7\NN\14299637 in_8\IN\13603305 an_9\DT\6697703 unpredictable_10\JJ\1740 subset_11\NN\7999699 of_12\IN\1740 renal_13\JJ\1740 allograft_14\NN\5582859 recipients_15\NNS\9764201 ._16\.\1740
D020123_D011507 CID <e2>proteinuria</e2>_0\NNP\14299637 may_1\MD\15209706 improve_2\VB\126264 ,_3\,\1740 but_4\CC\1740 does_5\VBZ\1640855 not_6\RB\1740 resolve_7\VB\352826 ,_8\,\1740 when_9\WRB\1740 <e1>sirolimus</e1>_10\NN\1740 is_11\VBZ\836236 withdrawn_12\VBN\1835496 ._13\.\1740
D020123_D007674 NONE background_0\NN\4921011 :_1\:\1740 <e1>sirolimus</e1>_2\NN\1740 is_3\VBZ\836236 the_4\DT\1740 latest_5\JJS\1740 immunosuppressive_6\JJ\1740 agent_7\NN\7347 used_8\VBN\1156834 to_9\TO\1740 prevent_10\VB\1740 rejection_11\NN\30358 ,_12\,\1740 and_13\CC\1740 may_14\MD\15209706 have_15\VB\2108377 less_16\JJR\1740 <e2>nephrotoxicity</e2>_17\NN\1740 than_18\IN\1740 calcineurin_19\NN\1740 inhibitor_20\NN\20090 (cni)-based_21\VBN\1740 regimens_22\NNS\5898568 ._23\.\1740
D003404_D011507 NONE in_0\IN\13603305 these_1\DT\1740 patients_2\NNS\9898892 ,_3\,\1740 the_4\DT\1740 magnitude_5\NN\4916342 of_6\IN\1740 <e2>proteinuria</e2>_7\NN\14299637 was_8\VBD\836236 assessed_9\VBN\670261 on_10\IN\1740 morning_11\NN\15113229 urine_12\NN\14853947 samples_13\NNS\5820620 by_14\IN\1740 turbidometric_15\JJ\1740 measurement_16\NN\407535 or_17\CC\3541091 random_18\JJ\1740 urine_19\NN\14853947 protein_20\NN\14944888 :_21\:\1740 <e1>creatinine</e1>_22\NN\1740 ratios_23\NNS\13815152 ,_24\,\1740 an_25\DT\6697703 estimate_26\NN\5802185 of_27\IN\1740 grams_28\NNS\13717155 of_29\IN\1740 proteinuria/day_30\NN\1740 ._31\.\1740
D003404_D011507 NONE in_0\IN\13603305 these_1\DT\1740 patients_2\NNS\9898892 ,_3\,\1740 the_4\DT\1740 magnitude_5\NN\4916342 of_6\IN\1740 proteinuria_7\NN\14299637 was_8\VBD\836236 assessed_9\VBN\670261 on_10\IN\1740 morning_11\NN\15113229 urine_12\NN\14853947 samples_13\NNS\5820620 by_14\IN\1740 turbidometric_15\JJ\1740 measurement_16\NN\407535 or_17\CC\3541091 random_18\JJ\1740 urine_19\NN\14853947 protein_20\NN\14944888 :_21\:\1740 <e1>creatinine</e1>_22\NN\1740 ratios_23\NNS\13815152 ,_24\,\1740 an_25\DT\6697703 estimate_26\NN\5802185 of_27\IN\1740 grams_28\NNS\13717155 of_29\IN\1740 <e2>proteinuria/day</e2>_30\NN\1740 ._31\.\1740
D020123_D009404 NONE in_0\IN\13603305 7_1\CD\13741022 of_2\IN\1740 the_3\DT\1740 28_4\CD\13745420 patients_5\NNS\9898892 there_6\EX\27167 was_7\VBD\836236 a_8\DT\13649268 striking_9\JJ\1740 temporal_10\JJ\1740 association_11\NN\8008335 between_12\IN\1740 the_13\DT\1740 initiation_14\NN\7450842 of_15\IN\1740 <e1>sirolimus</e1>_16\NN\1740 and_17\CC\1740 the_18\DT\1740 development_19\NN\248977 of_20\IN\1740 <e2>nephrotic-range</e2>_21\JJ\1740 proteinuria_22\NN\14299637 ._23\.\1740
7802851
D000525_D016584 NONE the_0\DT\1740 efficacy_1\NN\5199286 of_2\IN\1740 <e1>alprazolam</e1>_3\NNS\2830852 and_4\CC\1740 placebo_5\NN\3740161 in_6\IN\13603305 <e2>panic_7\JJ\1740 disorder</e2>_8\NN\14034177 with_9\IN\1740 agoraphobia_10\NN\14381416 ,_11\,\1740 and_12\CC\1740 the_13\DT\1740 side-effect_14\JJ\1740 and_15\CC\1740 adverse_16\JJ\1740 effect_17\NN\34213 profiles_18\NNS\6999802 of_19\IN\1740 both_20\DT\1740 drug_21\NN\14778436 groups_22\NNS\2137 were_23\VBD\836236 measured_24\VBN\697589 ._25\.\1740
D000525_D016584 NONE method_0\NNP\5616786 :_1\:\1740 in_2\IN\13603305 london_3\NNP\1740 and_4\CC\1740 toronto_5\NNP\1740 154_6\CD\1740 patients_7\NNS\9898892 who_8\WP\8299493 met_9\VBD\1182709 dsm-iii_10\NN\1740 criteria_11\NNS\13577171 for_12\IN\1740 <e2>panic_13\JJ\1740 disorder</e2>_14\NN\14034177 with_15\IN\1740 agoraphobia_16\NN\14381416 were_17\VBD\836236 randomised_18\VBN\278117 to_19\TO\1740 <e1>alprazolam</e1>_20\NNS\2830852 or_21\CC\3541091 placebo_22\NN\3740161 ._23\.\1740
D000525_D000379 NONE the_0\DT\1740 efficacy_1\NN\5199286 of_2\IN\1740 <e1>alprazolam</e1>_3\NNS\2830852 and_4\CC\1740 placebo_5\NN\3740161 in_6\IN\13603305 panic_7\JJ\1740 disorder_8\NN\14034177 with_9\IN\1740 <e2>agoraphobia</e2>_10\NN\14381416 ,_11\,\1740 and_12\CC\1740 the_13\DT\1740 side-effect_14\JJ\1740 and_15\CC\1740 adverse_16\JJ\1740 effect_17\NN\34213 profiles_18\NNS\6999802 of_19\IN\1740 both_20\DT\1740 drug_21\NN\14778436 groups_22\NNS\2137 were_23\VBD\836236 measured_24\VBN\697589 ._25\.\1740
D000525_D000379 NONE method_0\NNP\5616786 :_1\:\1740 in_2\IN\13603305 london_3\NNP\1740 and_4\CC\1740 toronto_5\NNP\1740 154_6\CD\1740 patients_7\NNS\9898892 who_8\WP\8299493 met_9\VBD\1182709 dsm-iii_10\NN\1740 criteria_11\NNS\13577171 for_12\IN\1740 panic_13\JJ\1740 disorder_14\NN\14034177 with_15\IN\1740 <e2>agoraphobia</e2>_16\NN\14381416 were_17\VBD\836236 randomised_18\VBN\278117 to_19\TO\1740 <e1>alprazolam</e1>_20\NNS\2830852 or_21\CC\3541091 placebo_22\NN\3740161 ._23\.\1740
D000525_D003866 CID compared_0\VBN\644583 with_1\IN\1740 placebo_2\JJ\1740 subjects_3\NNS\6598915 ,_4\,\1740 <e1>alprazolam</e1>_5\NN\2830852 patients_6\NNS\9898892 developed_7\VBD\1753788 more_8\JJR\1740 adverse_9\JJ\1740 reactions_10\NNS\13446390 (_11\-LRB-\1740 21_12\CD\13745420 %_13\NN\1740 v._14\NN\1740 0_15\CD\13741022 %_16\NN\1740 )_17\-RRB-\1740 of_18\IN\1740 <e2>depression</e2>_19\NN\14373582 ,_20\,\1740 enuresis_21\NN\13496972 ,_22\,\1740 disinhibition_23\NN\1740 and_24\CC\1740 aggression_25\NN\4657876 ;_26\:\1740 and_27\CC\1740 more_28\JJR\1740 side-effects_29\NNS\1740 ,_30\,\1740 particularly_31\RB\1740 sedation_32\NN\14034177 ,_33\,\1740 irritability_34\NN\7552087 ,_35\,\1740 impaired_36\JJ\1740 memory_37\NN\5926676 ,_38\,\1740 weight_39\NN\5009170 loss_40\NN\13252973 and_41\CC\1740 ataxia_42\NN\14084880 ._43\.\1740
D000525_D004775 CID compared_0\VBN\644583 with_1\IN\1740 placebo_2\JJ\1740 subjects_3\NNS\6598915 ,_4\,\1740 <e1>alprazolam</e1>_5\NN\2830852 patients_6\NNS\9898892 developed_7\VBD\1753788 more_8\JJR\1740 adverse_9\JJ\1740 reactions_10\NNS\13446390 (_11\-LRB-\1740 21_12\CD\13745420 %_13\NN\1740 v._14\NN\1740 0_15\CD\13741022 %_16\NN\1740 )_17\-RRB-\1740 of_18\IN\1740 depression_19\NN\14373582 ,_20\,\1740 <e2>enuresis</e2>_21\NN\13496972 ,_22\,\1740 disinhibition_23\NN\1740 and_24\CC\1740 aggression_25\NN\4657876 ;_26\:\1740 and_27\CC\1740 more_28\JJR\1740 side-effects_29\NNS\1740 ,_30\,\1740 particularly_31\RB\1740 sedation_32\NN\14034177 ,_33\,\1740 irritability_34\NN\7552087 ,_35\,\1740 impaired_36\JJ\1740 memory_37\NN\5926676 ,_38\,\1740 weight_39\NN\5009170 loss_40\NN\13252973 and_41\CC\1740 ataxia_42\NN\14084880 ._43\.\1740
D000525_D001523 NONE compared_0\VBN\644583 with_1\IN\1740 placebo_2\JJ\1740 subjects_3\NNS\6598915 ,_4\,\1740 <e1>alprazolam</e1>_5\NN\2830852 patients_6\NNS\9898892 developed_7\VBD\1753788 more_8\JJR\1740 adverse_9\JJ\1740 reactions_10\NNS\13446390 (_11\-LRB-\1740 21_12\CD\13745420 %_13\NN\1740 v._14\NN\1740 0_15\CD\13741022 %_16\NN\1740 )_17\-RRB-\1740 of_18\IN\1740 depression_19\NN\14373582 ,_20\,\1740 enuresis_21\NN\13496972 ,_22\,\1740 disinhibition_23\NN\1740 and_24\CC\1740 <e2>aggression</e2>_25\NN\4657876 ;_26\:\1740 and_27\CC\1740 more_28\JJR\1740 side-effects_29\NNS\1740 ,_30\,\1740 particularly_31\RB\1740 sedation_32\NN\14034177 ,_33\,\1740 irritability_34\NN\7552087 ,_35\,\1740 impaired_36\JJ\1740 memory_37\NN\5926676 ,_38\,\1740 weight_39\NN\5009170 loss_40\NN\13252973 and_41\CC\1740 ataxia_42\NN\14084880 ._43\.\1740
D000525_D001523 NONE compared_0\VBN\644583 with_1\IN\1740 placebo_2\JJ\1740 subjects_3\NNS\6598915 ,_4\,\1740 <e1>alprazolam</e1>_5\NN\2830852 patients_6\NNS\9898892 developed_7\VBD\1753788 more_8\JJR\1740 adverse_9\JJ\1740 reactions_10\NNS\13446390 (_11\-LRB-\1740 21_12\CD\13745420 %_13\NN\1740 v._14\NN\1740 0_15\CD\13741022 %_16\NN\1740 )_17\-RRB-\1740 of_18\IN\1740 depression_19\NN\14373582 ,_20\,\1740 enuresis_21\NN\13496972 ,_22\,\1740 disinhibition_23\NN\1740 and_24\CC\1740 aggression_25\NN\4657876 ;_26\:\1740 and_27\CC\1740 more_28\JJR\1740 side-effects_29\NNS\1740 ,_30\,\1740 particularly_31\RB\1740 sedation_32\NN\14034177 ,_33\,\1740 <e2>irritability</e2>_34\NN\7552087 ,_35\,\1740 impaired_36\JJ\1740 memory_37\NN\5926676 ,_38\,\1740 weight_39\NN\5009170 loss_40\NN\13252973 and_41\CC\1740 ataxia_42\NN\14084880 ._43\.\1740
D000525_D008569 CID compared_0\VBN\644583 with_1\IN\1740 placebo_2\JJ\1740 subjects_3\NNS\6598915 ,_4\,\1740 <e1>alprazolam</e1>_5\NN\2830852 patients_6\NNS\9898892 developed_7\VBD\1753788 more_8\JJR\1740 adverse_9\JJ\1740 reactions_10\NNS\13446390 (_11\-LRB-\1740 21_12\CD\13745420 %_13\NN\1740 v._14\NN\1740 0_15\CD\13741022 %_16\NN\1740 )_17\-RRB-\1740 of_18\IN\1740 depression_19\NN\14373582 ,_20\,\1740 enuresis_21\NN\13496972 ,_22\,\1740 disinhibition_23\NN\1740 and_24\CC\1740 aggression_25\NN\4657876 ;_26\:\1740 and_27\CC\1740 more_28\JJR\1740 side-effects_29\NNS\1740 ,_30\,\1740 particularly_31\RB\1740 sedation_32\NN\14034177 ,_33\,\1740 irritability_34\NN\7552087 ,_35\,\1740 <e2>impaired_36\JJ\1740 memory</e2>_37\NN\5926676 ,_38\,\1740 weight_39\NN\5009170 loss_40\NN\13252973 and_41\CC\1740 ataxia_42\NN\14084880 ._43\.\1740
D000525_D015431 CID compared_0\VBN\644583 with_1\IN\1740 placebo_2\JJ\1740 subjects_3\NNS\6598915 ,_4\,\1740 <e1>alprazolam</e1>_5\NN\2830852 patients_6\NNS\9898892 developed_7\VBD\1753788 more_8\JJR\1740 adverse_9\JJ\1740 reactions_10\NNS\13446390 (_11\-LRB-\1740 21_12\CD\13745420 %_13\NN\1740 v._14\NN\1740 0_15\CD\13741022 %_16\NN\1740 )_17\-RRB-\1740 of_18\IN\1740 depression_19\NN\14373582 ,_20\,\1740 enuresis_21\NN\13496972 ,_22\,\1740 disinhibition_23\NN\1740 and_24\CC\1740 aggression_25\NN\4657876 ;_26\:\1740 and_27\CC\1740 more_28\JJR\1740 side-effects_29\NNS\1740 ,_30\,\1740 particularly_31\RB\1740 sedation_32\NN\14034177 ,_33\,\1740 irritability_34\NN\7552087 ,_35\,\1740 impaired_36\JJ\1740 memory_37\NN\5926676 ,_38\,\1740 <e2>weight_39\NN\5009170 loss</e2>_40\NN\13252973 and_41\CC\1740 ataxia_42\NN\14084880 ._43\.\1740
D000525_D001259 CID compared_0\VBN\644583 with_1\IN\1740 placebo_2\JJ\1740 subjects_3\NNS\6598915 ,_4\,\1740 <e1>alprazolam</e1>_5\NN\2830852 patients_6\NNS\9898892 developed_7\VBD\1753788 more_8\JJR\1740 adverse_9\JJ\1740 reactions_10\NNS\13446390 (_11\-LRB-\1740 21_12\CD\13745420 %_13\NN\1740 v._14\NN\1740 0_15\CD\13741022 %_16\NN\1740 )_17\-RRB-\1740 of_18\IN\1740 depression_19\NN\14373582 ,_20\,\1740 enuresis_21\NN\13496972 ,_22\,\1740 disinhibition_23\NN\1740 and_24\CC\1740 aggression_25\NN\4657876 ;_26\:\1740 and_27\CC\1740 more_28\JJR\1740 side-effects_29\NNS\1740 ,_30\,\1740 particularly_31\RB\1740 sedation_32\NN\14034177 ,_33\,\1740 irritability_34\NN\7552087 ,_35\,\1740 impaired_36\JJ\1740 memory_37\NN\5926676 ,_38\,\1740 weight_39\NN\5009170 loss_40\NN\13252973 and_41\CC\1740 <e2>ataxia</e2>_42\NN\14084880 ._43\.\1740
6503301
D003606_D006504 CID <e2>veno-occlusive_0\JJ\1740 liver_1\NN\5298729 disease</e2>_2\NN\14061805 after_3\IN\1740 <e1>dacarbazine</e1>_4\NN\1740 therapy_5\NN\657604 (_6\-LRB-\1740 dtic_7\NN\8337324 )_8\-RRB-\1740 for_9\IN\1740 melanoma_10\NN\14252320 ._11\.\1740
D003606_D006504 CID <e2>veno-occlusive_0\JJ\1740 liver_1\NN\5298729 disease</e2>_2\NN\14061805 after_3\IN\1740 dacarbazine_4\NN\1740 therapy_5\NN\657604 (_6\-LRB-\1740 <e1>dtic</e1>_7\NN\8337324 )_8\-RRB-\1740 for_9\IN\1740 melanoma_10\NN\14252320 ._11\.\1740
D003606_D006504 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>veno-occlusive_3\JJ\1740 disease_4\NN\14061805 of_5\IN\1740 the_6\DT\1740 liver</e2>_7\NN\5298729 with_8\IN\1740 fatal_9\JJ\1740 outcome_10\NN\7291312 after_11\IN\1740 <e1>dacarbazine</e1>_12\NN\1740 (_13\-LRB-\1740 dtic_14\NN\8337324 )_15\-RRB-\1740 therapy_16\NN\657604 for_17\IN\1740 melanoma_18\NN\14252320 is_19\VBZ\836236 reported_20\VBN\831651 ._21\.\1740
D003606_D006504 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>veno-occlusive_3\JJ\1740 disease_4\NN\14061805 of_5\IN\1740 the_6\DT\1740 liver</e2>_7\NN\5298729 with_8\IN\1740 fatal_9\JJ\1740 outcome_10\NN\7291312 after_11\IN\1740 dacarbazine_12\NN\1740 (_13\-LRB-\1740 <e1>dtic</e1>_14\NN\8337324 )_15\-RRB-\1740 therapy_16\NN\657604 for_17\IN\1740 melanoma_18\NN\14252320 is_19\VBZ\836236 reported_20\VBN\831651 ._21\.\1740
D003606_D008545 NONE veno-occlusive_0\JJ\1740 liver_1\NN\5298729 disease_2\NN\14061805 after_3\IN\1740 <e1>dacarbazine</e1>_4\NN\1740 therapy_5\NN\657604 (_6\-LRB-\1740 dtic_7\NN\8337324 )_8\-RRB-\1740 for_9\IN\1740 <e2>melanoma</e2>_10\NN\14252320 ._11\.\1740
D003606_D008545 NONE veno-occlusive_0\JJ\1740 liver_1\NN\5298729 disease_2\NN\14061805 after_3\IN\1740 dacarbazine_4\NN\1740 therapy_5\NN\657604 (_6\-LRB-\1740 <e1>dtic</e1>_7\NN\8337324 )_8\-RRB-\1740 for_9\IN\1740 <e2>melanoma</e2>_10\NN\14252320 ._11\.\1740
D003606_D008545 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 veno-occlusive_3\JJ\1740 disease_4\NN\14061805 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 with_8\IN\1740 fatal_9\JJ\1740 outcome_10\NN\7291312 after_11\IN\1740 <e1>dacarbazine</e1>_12\NN\1740 (_13\-LRB-\1740 dtic_14\NN\8337324 )_15\-RRB-\1740 therapy_16\NN\657604 for_17\IN\1740 <e2>melanoma</e2>_18\NN\14252320 is_19\VBZ\836236 reported_20\VBN\831651 ._21\.\1740
D003606_D008545 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 veno-occlusive_3\JJ\1740 disease_4\NN\14061805 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 with_8\IN\1740 fatal_9\JJ\1740 outcome_10\NN\7291312 after_11\IN\1740 dacarbazine_12\NN\1740 (_13\-LRB-\1740 <e1>dtic</e1>_14\NN\8337324 )_15\-RRB-\1740 therapy_16\NN\657604 for_17\IN\1740 <e2>melanoma</e2>_18\NN\14252320 is_19\VBZ\836236 reported_20\VBN\831651 ._21\.\1740
3714122
C005238_D020258 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 <e2>neurotoxic</e2>_3\JJ\1740 esterase_4\NN\1740 inhibition_5\NN\1068773 and_6\CC\1740 <e1>mipafox-induced</e1>_7\JJ\1740 neuropathic_8\JJ\1740 damage_9\NN\7296428 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
C005238_D020258 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 neuropathic_3\JJ\1740 damage_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 <e2>neurotoxic</e2>_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 neuropathy_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 <e1>mipafox</e1>_24\NNP\1740 (_25\-LRB-\1740 n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 neurotoxic_32\JJ\1740 organophosphate_33\NN\14919948 ._34\.\1740
C005238_D020258 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 neuropathic_3\JJ\1740 damage_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 neurotoxic_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 neuropathy_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 <e1>mipafox</e1>_24\NNP\1740 (_25\-LRB-\1740 n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 <e2>neurotoxic</e2>_32\JJ\1740 organophosphate_33\NN\14919948 ._34\.\1740
C005238_D020258 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 neuropathic_3\JJ\1740 damage_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 <e2>neurotoxic</e2>_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 neuropathy_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 mipafox_24\NNP\1740 (_25\-LRB-\1740 <e1>n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate</e1>_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 neurotoxic_32\JJ\1740 organophosphate_33\NN\14919948 ._34\.\1740
C005238_D020258 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 neuropathic_3\JJ\1740 damage_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 neurotoxic_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 neuropathy_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 mipafox_24\NNP\1740 (_25\-LRB-\1740 <e1>n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate</e1>_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 <e2>neurotoxic</e2>_32\JJ\1740 organophosphate_33\NN\14919948 ._34\.\1740
C005238_D009422 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 neurotoxic_3\JJ\1740 esterase_4\NN\1740 inhibition_5\NN\1068773 and_6\CC\1740 <e1>mipafox-induced</e1>_7\JJ\1740 <e2>neuropathic_8\JJ\1740 damage</e2>_9\NN\7296428 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
C005238_D009422 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 <e2>neuropathic_3\JJ\1740 damage</e2>_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 neurotoxic_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 neuropathy_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 <e1>mipafox</e1>_24\NNP\1740 (_25\-LRB-\1740 n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 neurotoxic_32\JJ\1740 organophosphate_33\NN\14919948 ._34\.\1740
C005238_D009422 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 neuropathic_3\JJ\1740 damage_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 neurotoxic_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 <e2>neuropathy</e2>_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 <e1>mipafox</e1>_24\NNP\1740 (_25\-LRB-\1740 n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 neurotoxic_32\JJ\1740 organophosphate_33\NN\14919948 ._34\.\1740
C005238_D009422 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 <e2>neuropathic_3\JJ\1740 damage</e2>_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 neurotoxic_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 neuropathy_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 mipafox_24\NNP\1740 (_25\-LRB-\1740 <e1>n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate</e1>_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 neurotoxic_32\JJ\1740 organophosphate_33\NN\14919948 ._34\.\1740
C005238_D009422 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 neuropathic_3\JJ\1740 damage_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 neurotoxic_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 <e2>neuropathy</e2>_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 mipafox_24\NNP\1740 (_25\-LRB-\1740 <e1>n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate</e1>_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 neurotoxic_32\JJ\1740 organophosphate_33\NN\14919948 ._34\.\1740
C005238_D009422 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 a_4\DT\13649268 critical_5\JJ\1740 percentage_6\NN\13815742 of_7\IN\1740 nte_8\NN\1740 inhibition_9\NN\1068773 in_10\IN\13603305 brain_11\NN\5462674 and_12\CC\1740 spinal_13\JJ\1740 cord_14\NN\3670849 sampled_15\VBN\1156834 shortly_16\RB\1740 after_17\IN\1740 <e1>mipafox</e1>_18\NNP\1740 exposure_19\NN\5042871 can_20\MD\3094503 predict_21\VB\916909 <e2>neuropathic_22\JJ\1740 damage</e2>_23\NN\7296428 in_24\IN\13603305 rats_25\NNS\2329401 several_26\JJ\1740 weeks_27\NNS\15113229 later_28\RB\1740 ._29\.\1740
D010755_D009422 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 <e2>neuropathic_3\JJ\1740 damage</e2>_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 neurotoxic_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 neuropathy_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 mipafox_24\NNP\1740 (_25\-LRB-\1740 n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 neurotoxic_32\JJ\1740 <e1>organophosphate</e1>_33\NN\14919948 ._34\.\1740
D010755_D009422 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 neuropathic_3\JJ\1740 damage_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 neurotoxic_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 <e2>neuropathy</e2>_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 mipafox_24\NNP\1740 (_25\-LRB-\1740 n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 neurotoxic_32\JJ\1740 <e1>organophosphate</e1>_33\NN\14919948 ._34\.\1740
D010755_D020258 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 neuropathic_3\JJ\1740 damage_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 <e2>neurotoxic</e2>_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 neuropathy_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 mipafox_24\NNP\1740 (_25\-LRB-\1740 n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 neurotoxic_32\JJ\1740 <e1>organophosphate</e1>_33\NN\14919948 ._34\.\1740
D010755_D020258 NONE the_0\DT\1740 correlation_1\NN\13841213 between_2\IN\1740 neuropathic_3\JJ\1740 damage_4\NN\7296428 and_5\CC\1740 inhibition_6\NN\1068773 of_7\IN\1740 neurotoxic_8\JJ\1740 esterase_9\NN\1740 or_10\CC\3541091 neuropathy_11\JJ\1740 target_12\NN\7258332 enzyme_13\NN\14723628 (_14\-LRB-\1740 nte_15\NN\1740 )_16\-RRB-\1740 was_17\VBD\836236 examined_18\VBN\789138 in_19\IN\13603305 rats_20\NNS\2329401 acutely_21\RB\1740 exposed_22\VBN\2110927 to_23\IN\1740 mipafox_24\NNP\1740 (_25\-LRB-\1740 n_26\NN\14622893 ,_27\,\1740 n'-diisopropylphosphorodiamidofluoridate_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 a_31\DT\13649268 <e2>neurotoxic</e2>_32\JJ\1740 <e1>organophosphate</e1>_33\NN\14919948 ._34\.\1740
C005238_D013118 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 dosages_3\NNS\13576355 of_4\IN\1740 <e1>mipafox</e1>_5\NNP\1740 (_6\-LRB-\1740 less_7\JJR\1740 than_8\IN\1740 or_9\CC\3541091 equal_10\JJ\1740 to_11\TO\1740 5_12\CD\13741022 mg/kg_13\NN\1740 )_14\-RRB-\1740 which_15\WDT\1740 inhibited_16\VBD\2510337 mean_17\NN\6021761 nte_18\NN\1740 activity_19\NN\30358 in_20\IN\13603305 spinal_21\JJ\1740 cord_22\NN\3670849 less_23\JJR\1740 than_24\IN\1740 or_25\CC\3541091 equal_26\JJ\1740 to_27\TO\1740 61_28\CD\1740 %_29\NN\1740 and_30\CC\1740 brain_31\NN\5462674 less_32\JJR\1740 than_33\IN\1740 or_34\CC\3541091 equal_35\JJ\1740 to_36\TO\1740 60_37\CD\13745420 %_38\NN\1740 produced_39\VBD\1617192 this_40\DT\1740 degree_41\NN\4916342 of_42\IN\1740 <e2>cord_43\NN\3670849 damage</e2>_44\NN\7296428 in_45\IN\13603305 only_46\RB\1740 9_47\CD\13741022 %_48\NN\1740 of_49\IN\1740 the_50\DT\1740 animals_51\NNS\4475 ._52\.\1740
2559236
D004317_D007674 NONE effect_0\NN\34213 of_1\IN\1740 converting_2\VBG\126264 enzyme_3\NN\14723628 inhibition_4\NN\1068773 on_5\IN\1740 the_6\DT\1740 course_7\NN\883297 of_8\IN\1740 <e1>adriamycin-induced</e1>_9\JJ\1740 <e2>nephropathy</e2>_10\NN\14573196 ._11\.\1740
D004317_D007674 NONE groups_0\NNS\2137 3_1\CD\13741022 and_2\CC\1740 4_3\CD\13741022 were_4\VBD\836236 studied_5\VBN\630380 at_6\IN\14622893 four_7\CD\13741022 and_8\CC\1740 at_9\IN\14622893 six_10\CD\13741022 months_11\NNS\15113229 to_12\TO\1740 assess_13\VB\670261 the_14\DT\1740 effect_15\NN\34213 of_16\IN\1740 enalapril_17\NN\2673637 on_18\IN\1740 progression_19\NN\8457976 of_20\IN\1740 <e2>renal_21\JJ\1740 injury</e2>_22\NN\14052046 in_23\IN\13603305 <e1>adriamycin</e1>_24\NN\1740 nephrosis_25\NN\14304060 ._26\.\1740
D004656_D009401 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 the_3\DT\1740 converting_4\NN\1740 enzyme_5\NN\14723628 inhibitor_6\NN\20090 (_7\-LRB-\1740 cei_8\NN\1740 )_9\-RRB-\1740 <e1>enalapril</e1>_10\NN\2673637 was_11\VBD\836236 assessed_12\VBN\670261 in_13\IN\13603305 munich-wistar_14\JJ\1740 rats_15\NNS\2329401 with_16\IN\1740 established_17\JJ\1740 adriamycin_18\NN\1740 <e2>nephrosis</e2>_19\NN\14304060 ._20\.\1740
D004656_D009401 NONE groups_0\NNS\2137 3_1\CD\13741022 and_2\CC\1740 4_3\CD\13741022 were_4\VBD\836236 studied_5\VBN\630380 at_6\IN\14622893 four_7\CD\13741022 and_8\CC\1740 at_9\IN\14622893 six_10\CD\13741022 months_11\NNS\15113229 to_12\TO\1740 assess_13\VB\670261 the_14\DT\1740 effect_15\NN\34213 of_16\IN\1740 <e1>enalapril</e1>_17\NN\2673637 on_18\IN\1740 progression_19\NN\8457976 of_20\IN\1740 renal_21\JJ\1740 injury_22\NN\14052046 in_23\IN\13603305 adriamycin_24\NN\1740 <e2>nephrosis</e2>_25\NN\14304060 ._26\.\1740
D004317_D009401 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 the_3\DT\1740 converting_4\NN\1740 enzyme_5\NN\14723628 inhibitor_6\NN\20090 (_7\-LRB-\1740 cei_8\NN\1740 )_9\-RRB-\1740 enalapril_10\NN\2673637 was_11\VBD\836236 assessed_12\VBN\670261 in_13\IN\13603305 munich-wistar_14\JJ\1740 rats_15\NNS\2329401 with_16\IN\1740 established_17\JJ\1740 <e1>adriamycin</e1>_18\NN\1740 <e2>nephrosis</e2>_19\NN\14304060 ._20\.\1740
D004317_D009401 CID groups_0\NNS\2137 3_1\CD\13741022 and_2\CC\1740 4_3\CD\13741022 were_4\VBD\836236 studied_5\VBN\630380 at_6\IN\14622893 four_7\CD\13741022 and_8\CC\1740 at_9\IN\14622893 six_10\CD\13741022 months_11\NNS\15113229 to_12\TO\1740 assess_13\VB\670261 the_14\DT\1740 effect_15\NN\34213 of_16\IN\1740 enalapril_17\NN\2673637 on_18\IN\1740 progression_19\NN\8457976 of_20\IN\1740 renal_21\JJ\1740 injury_22\NN\14052046 in_23\IN\13603305 <e1>adriamycin</e1>_24\NN\1740 <e2>nephrosis</e2>_25\NN\14304060 ._26\.\1740
D004317_D000419 CID rats_0\NNS\2329401 were_1\VBD\836236 given_2\VBN\2327200 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 <e1>adriamycin</e1>_7\NN\1740 and_8\CC\1740 one_9\CD\13741022 month_10\NN\15113229 later_11\RB\1740 divided_12\VBD\140123 into_13\IN\1740 four_14\CD\13741022 groups_15\NNS\2137 matched_16\VBN\2664769 for_17\IN\1740 <e2>albuminuria</e2>_18\NN\14299637 ,_19\,\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 and_23\CC\1740 plasma_24\NN\5398023 albumin_25\NN\14736972 concentration_26\NN\4916342 ._27\.\1740
D004656_D000419 NONE these_0\DT\1740 short-term_1\JJ\1740 studies_2\NNS\635850 showed_3\VBD\2137132 that_4\IN\1740 <e1>enalapril</e1>_5\NN\2673637 reduced_6\VBD\441445 arterial_7\JJ\1740 blood_8\NN\5397468 pressure_9\NN\11419404 (_10\-LRB-\1740 101_11\CD\1740 +/-_12\CC\1740 2_13\CD\13741022 vs._14\CC\1740 124_15\CD\1740 +/-_16\CC\1740 3_17\CD\13741022 mm_18\NN\13649268 hg_19\NNP\14625458 ,_20\,\1740 group_21\NN\2137 2_22\CD\13741022 vs._23\CC\1740 1_24\CD\13741022 ,_25\,\1740 p_26\NN\14622893 less_27\JJR\1740 than_28\IN\1740 0.05_29\CD\1740 )_30\-RRB-\1740 and_31\CC\1740 glomerular_32\JJ\1740 capillary_33\JJ\1740 pressure_34\NN\11419404 (_35\-LRB-\1740 54_36\CD\1740 +/-_37\CC\1740 1_38\CD\13741022 vs._39\CC\1740 61_40\CD\1740 +/-_41\CC\1740 2_42\CD\13741022 mm_43\NN\13649268 hg_44\NNP\14625458 ,_45\,\1740 p_46\NN\14622893 less_47\JJR\1740 than_48\IN\1740 0.05_49\CD\1740 )_50\-RRB-\1740 without_51\IN\1740 reducing_52\VBG\441445 <e2>albuminuria</e2>_53\NN\14299637 (_54\-LRB-\1740 617_55\CD\1740 +/-_56\CC\1740 50_57\CD\13745420 vs._58\CC\1740 570_59\CD\1740 +/-_60\CC\1740 47_61\CD\1740 mg/day_62\NN\1740 )_63\-RRB-\1740 or_64\CC\3541091 gfr_65\NN\1740 (_66\-LRB-\1740 1.03_67\CD\1740 +/-_68\CC\1740 0.04_69\CD\1740 vs._70\CC\1740 1.04_71\CD\1740 +/-_72\CC\1740 0.11_73\CD\1740 ml/min_74\NN\1740 )_75\-RRB-\1740 ._76\.\1740
D004656_D000419 NONE chronic_0\JJ\1740 <e1>enalapril</e1>_1\NN\2673637 treatment_2\NN\654885 reduced_3\VBD\441445 blood_4\NN\5397468 pressure_5\NN\11419404 without_6\IN\1740 reducing_7\VBG\441445 <e2>albuminuria</e2>_8\NN\14299637 in_9\IN\13603305 group_10\NN\2137 4_11\CD\13741022 ._12\.\1740
D004656_D007674 NONE groups_0\NNS\2137 3_1\CD\13741022 and_2\CC\1740 4_3\CD\13741022 were_4\VBD\836236 studied_5\VBN\630380 at_6\IN\14622893 four_7\CD\13741022 and_8\CC\1740 at_9\IN\14622893 six_10\CD\13741022 months_11\NNS\15113229 to_12\TO\1740 assess_13\VB\670261 the_14\DT\1740 effect_15\NN\34213 of_16\IN\1740 <e1>enalapril</e1>_17\NN\2673637 on_18\IN\1740 progression_19\NN\8457976 of_20\IN\1740 <e2>renal_21\JJ\1740 injury</e2>_22\NN\14052046 in_23\IN\13603305 adriamycin_24\NN\1740 nephrosis_25\NN\14304060 ._26\.\1740
10739826
D003276_D054556 CID recurrent_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 newer_3\JJR\1740 <e1>oral_4\JJ\1740 contraceptives</e1>_5\NNS\3183080 and_6\CC\1740 the_7\DT\1740 risk_8\NN\14541044 of_9\IN\1740 <e2>venous_10\JJ\1740 thromboembolism</e2>_11\NN\14100769 ._12\.\1740
D003276_D054556 CID the_0\DT\1740 epidemiological_1\JJ\1740 studies_2\NNS\635850 that_3\WDT\1740 assessed_4\VBD\670261 the_5\DT\1740 risk_6\NN\14541044 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 newer_15\JJR\1740 <e1>oral_16\JJ\1740 contraceptives</e1>_17\NNS\3183080 (_18\-LRB-\1740 oc_19\NNP\1740 )_20\-RRB-\1740 did_21\VBD\1640855 not_22\RB\1740 distinguish_23\VB\618878 between_24\IN\1740 patterns_25\NNS\5726345 of_26\IN\1740 oc_27\NN\1740 use_28\NN\407535 ,_29\,\1740 namely_30\RB\1740 first-time_31\JJ\1740 users_32\NNS\7846 ,_33\,\1740 repeaters_34\NNS\7846 and_35\CC\1740 switchers_36\NNS\10379758 ._37\.\1740
D003276_D054556 CID the_0\DT\1740 epidemiological_1\JJ\1740 studies_2\NNS\635850 that_3\WDT\1740 assessed_4\VBD\670261 the_5\DT\1740 risk_6\NN\14541044 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 newer_15\JJR\1740 <e1>oral_16\JJ\1740 contraceptives</e1>_17\NNS\3183080 (_18\-LRB-\1740 oc_19\NNP\1740 )_20\-RRB-\1740 did_21\VBD\1640855 not_22\RB\1740 distinguish_23\VB\618878 between_24\IN\1740 patterns_25\NNS\5726345 of_26\IN\1740 oc_27\NN\1740 use_28\NN\407535 ,_29\,\1740 namely_30\RB\1740 first-time_31\JJ\1740 users_32\NNS\7846 ,_33\,\1740 repeaters_34\NNS\7846 and_35\CC\1740 switchers_36\NNS\10379758 ._37\.\1740
D003276_D054556 CID the_0\DT\1740 epidemiological_1\JJ\1740 studies_2\NNS\635850 that_3\WDT\1740 assessed_4\VBD\670261 the_5\DT\1740 risk_6\NN\14541044 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 newer_15\JJR\1740 oral_16\JJ\1740 contraceptives_17\NNS\3183080 (_18\-LRB-\1740 <e1>oc</e1>_19\NNP\1740 )_20\-RRB-\1740 did_21\VBD\1640855 not_22\RB\1740 distinguish_23\VB\618878 between_24\IN\1740 patterns_25\NNS\5726345 of_26\IN\1740 oc_27\NN\1740 use_28\NN\407535 ,_29\,\1740 namely_30\RB\1740 first-time_31\JJ\1740 users_32\NNS\7846 ,_33\,\1740 repeaters_34\NNS\7846 and_35\CC\1740 switchers_36\NNS\10379758 ._37\.\1740
D003276_D054556 CID the_0\DT\1740 epidemiological_1\JJ\1740 studies_2\NNS\635850 that_3\WDT\1740 assessed_4\VBD\670261 the_5\DT\1740 risk_6\NN\14541044 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 newer_15\JJR\1740 oral_16\JJ\1740 contraceptives_17\NNS\3183080 (_18\-LRB-\1740 <e1>oc</e1>_19\NNP\1740 )_20\-RRB-\1740 did_21\VBD\1640855 not_22\RB\1740 distinguish_23\VB\618878 between_24\IN\1740 patterns_25\NNS\5726345 of_26\IN\1740 oc_27\NN\1740 use_28\NN\407535 ,_29\,\1740 namely_30\RB\1740 first-time_31\JJ\1740 users_32\NNS\7846 ,_33\,\1740 repeaters_34\NNS\7846 and_35\CC\1740 switchers_36\NNS\10379758 ._37\.\1740
D003276_D054556 CID the_0\DT\1740 epidemiological_1\JJ\1740 studies_2\NNS\635850 that_3\WDT\1740 assessed_4\VBD\670261 the_5\DT\1740 risk_6\NN\14541044 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 newer_15\JJR\1740 oral_16\JJ\1740 contraceptives_17\NNS\3183080 (_18\-LRB-\1740 oc_19\NNP\1740 )_20\-RRB-\1740 did_21\VBD\1640855 not_22\RB\1740 distinguish_23\VB\618878 between_24\IN\1740 patterns_25\NNS\5726345 of_26\IN\1740 <e1>oc</e1>_27\NN\1740 use_28\NN\407535 ,_29\,\1740 namely_30\RB\1740 first-time_31\JJ\1740 users_32\NNS\7846 ,_33\,\1740 repeaters_34\NNS\7846 and_35\CC\1740 switchers_36\NNS\10379758 ._37\.\1740
D003276_D054556 CID the_0\DT\1740 epidemiological_1\JJ\1740 studies_2\NNS\635850 that_3\WDT\1740 assessed_4\VBD\670261 the_5\DT\1740 risk_6\NN\14541044 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 newer_15\JJR\1740 oral_16\JJ\1740 contraceptives_17\NNS\3183080 (_18\-LRB-\1740 oc_19\NNP\1740 )_20\-RRB-\1740 did_21\VBD\1640855 not_22\RB\1740 distinguish_23\VB\618878 between_24\IN\1740 patterns_25\NNS\5726345 of_26\IN\1740 <e1>oc</e1>_27\NN\1740 use_28\NN\407535 ,_29\,\1740 namely_30\RB\1740 first-time_31\JJ\1740 users_32\NNS\7846 ,_33\,\1740 repeaters_34\NNS\7846 and_35\CC\1740 switchers_36\NNS\10379758 ._37\.\1740
D003276_D054556 CID the_0\DT\1740 adjusted_1\VBN\126264 rate_2\NN\13815152 ratio_3\NN\13815152 of_4\IN\1740 <e2>vte</e2>_5\NN\1740 for_6\IN\1740 repeat_7\NN\7296190 users_8\NNS\7846 of_9\IN\1740 third_10\JJ\1740 generation_11\NN\7942152 <e1>oc</e1>_12\NNP\1740 was_13\VBD\836236 0.6_14\CD\1740 (_15\-LRB-\1740 95_16\CD\1740 %_17\NN\1740 ci:0.3_18\JJ\1740 -_19\HYPH\1740 1.2_20\CD\1740 )_21\-RRB-\1740 relative_22\JJ\1740 to_23\TO\1740 repeat_24\NN\7296190 users_25\NNS\7846 of_26\IN\1740 second_27\JJ\1740 generation_28\NN\7942152 pills_29\NNS\4424218 ,_30\,\1740 whereas_31\IN\1740 it_32\PRP\6125041 was_33\VBD\836236 1.3_34\CD\1740 (_35\-LRB-\1740 95_36\CD\1740 %_37\NN\1740 ci:0.7_38\NN\1740 -_39\HYPH\1740 2.4_40\CD\1740 )_41\-RRB-\1740 for_42\IN\1740 switchers_43\NNS\10379758 from_44\IN\1740 second_45\JJ\1740 to_46\TO\1740 third_47\JJ\1740 generation_48\NN\7942152 pills_49\NNS\4424218 relative_50\JJ\1740 to_51\TO\1740 switchers_52\NNS\10379758 from_53\IN\1740 third_54\JJ\1740 to_55\TO\1740 second_56\JJ\1740 generation_57\NN\7942152 pills_58\NNS\4424218 ._59\.\1740
12627929
C067311_D054556 CID increased_0\VBN\169651 frequency_1\NN\15286249 of_2\IN\1740 <e2>venous_3\JJ\1740 thromboembolism</e2>_4\NN\14100769 with_5\IN\1740 the_6\DT\1740 combination_7\NN\7951464 of_8\IN\1740 <e1>docetaxel</e1>_9\NN\1740 and_10\CC\1740 thalidomide_11\VBP\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 metastatic_15\JJ\1740 androgen-independent_16\JJ\1740 prostate_17\NN\5329735 cancer_18\NN\14239425 ._19\.\1740
C067311_D054556 CID study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 frequency_6\NN\15286249 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 advanced_16\JJ\1740 androgen-independent_17\JJ\1740 prostate_18\NN\5329735 cancer_19\NN\14239425 who_20\WP\8299493 were_21\VBD\836236 treated_22\VBN\2376958 with_23\IN\1740 <e1>docetaxel</e1>_24\NN\1740 alone_25\RB\1740 or_26\CC\3541091 in_27\IN\13603305 combination_28\NN\7951464 with_29\IN\1740 thalidomide_30\NN\4166841 ._31\.\1740
C067311_D054556 CID study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 frequency_6\NN\15286249 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 advanced_16\JJ\1740 androgen-independent_17\JJ\1740 prostate_18\NN\5329735 cancer_19\NN\14239425 who_20\WP\8299493 were_21\VBD\836236 treated_22\VBN\2376958 with_23\IN\1740 <e1>docetaxel</e1>_24\NN\1740 alone_25\RB\1740 or_26\CC\3541091 in_27\IN\13603305 combination_28\NN\7951464 with_29\IN\1740 thalidomide_30\NN\4166841 ._31\.\1740
C067311_D054556 CID measurements_0\NNS\407535 and_1\CC\1740 main_2\JJ\1740 results_3\NNS\34213 :_4\:\1740 none_5\NN\15228378 of_6\IN\1740 23_7\CD\13745420 patients_8\NNS\9898892 who_9\WP\8299493 received_10\VBD\2210855 <e1>docetaxel</e1>_11\NN\1740 alone_12\RB\1740 developed_13\VBD\1753788 <e2>vte</e2>_14\NN\1740 ,_15\,\1740 whereas_16\IN\1740 9_17\CD\13741022 of_18\IN\1740 47_19\CD\1740 patients_20\NNS\9898892 (_21\-LRB-\1740 19_22\CD\13745420 %_23\NN\1740 )_24\-RRB-\1740 who_25\WP\8299493 received_26\VBD\2210855 docetaxel_27\NN\1740 plus_28\CC\4723816 thalidomide_29\NN\4166841 developed_30\VBD\1753788 vte_31\NN\1740 (_32\-LRB-\1740 p=0.025_33\NNP\1740 )_34\-RRB-\1740 ._35\.\1740
C067311_D054556 CID measurements_0\NNS\407535 and_1\CC\1740 main_2\JJ\1740 results_3\NNS\34213 :_4\:\1740 none_5\NN\15228378 of_6\IN\1740 23_7\CD\13745420 patients_8\NNS\9898892 who_9\WP\8299493 received_10\VBD\2210855 <e1>docetaxel</e1>_11\NN\1740 alone_12\RB\1740 developed_13\VBD\1753788 vte_14\NN\1740 ,_15\,\1740 whereas_16\IN\1740 9_17\CD\13741022 of_18\IN\1740 47_19\CD\1740 patients_20\NNS\9898892 (_21\-LRB-\1740 19_22\CD\13745420 %_23\NN\1740 )_24\-RRB-\1740 who_25\WP\8299493 received_26\VBD\2210855 docetaxel_27\NN\1740 plus_28\CC\4723816 thalidomide_29\NN\4166841 developed_30\VBD\1753788 <e2>vte</e2>_31\NN\1740 (_32\-LRB-\1740 p=0.025_33\NNP\1740 )_34\-RRB-\1740 ._35\.\1740
C067311_D054556 CID measurements_0\NNS\407535 and_1\CC\1740 main_2\JJ\1740 results_3\NNS\34213 :_4\:\1740 none_5\NN\15228378 of_6\IN\1740 23_7\CD\13745420 patients_8\NNS\9898892 who_9\WP\8299493 received_10\VBD\2210855 docetaxel_11\NN\1740 alone_12\RB\1740 developed_13\VBD\1753788 <e2>vte</e2>_14\NN\1740 ,_15\,\1740 whereas_16\IN\1740 9_17\CD\13741022 of_18\IN\1740 47_19\CD\1740 patients_20\NNS\9898892 (_21\-LRB-\1740 19_22\CD\13745420 %_23\NN\1740 )_24\-RRB-\1740 who_25\WP\8299493 received_26\VBD\2210855 <e1>docetaxel</e1>_27\NN\1740 plus_28\CC\4723816 thalidomide_29\NN\4166841 developed_30\VBD\1753788 vte_31\NN\1740 (_32\-LRB-\1740 p=0.025_33\NNP\1740 )_34\-RRB-\1740 ._35\.\1740
C067311_D054556 CID measurements_0\NNS\407535 and_1\CC\1740 main_2\JJ\1740 results_3\NNS\34213 :_4\:\1740 none_5\NN\15228378 of_6\IN\1740 23_7\CD\13745420 patients_8\NNS\9898892 who_9\WP\8299493 received_10\VBD\2210855 docetaxel_11\NN\1740 alone_12\RB\1740 developed_13\VBD\1753788 vte_14\NN\1740 ,_15\,\1740 whereas_16\IN\1740 9_17\CD\13741022 of_18\IN\1740 47_19\CD\1740 patients_20\NNS\9898892 (_21\-LRB-\1740 19_22\CD\13745420 %_23\NN\1740 )_24\-RRB-\1740 who_25\WP\8299493 received_26\VBD\2210855 <e1>docetaxel</e1>_27\NN\1740 plus_28\CC\4723816 thalidomide_29\NN\4166841 developed_30\VBD\1753788 <e2>vte</e2>_31\NN\1740 (_32\-LRB-\1740 p=0.025_33\NNP\1740 )_34\-RRB-\1740 ._35\.\1740
C067311_D054556 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 addition_3\NN\3081021 of_4\IN\1740 thalidomide_5\NN\4166841 to_6\TO\1740 <e1>docetaxel</e1>_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 prostate_12\NN\5329735 cancer_13\NN\14239425 significantly_14\RB\1740 increases_15\VBZ\169651 the_16\DT\1740 frequency_17\NN\15286249 of_18\IN\1740 <e2>vte</e2>_19\NN\1740 ._20\.\1740
C067311_D011471 NONE increased_0\VBN\169651 frequency_1\NN\15286249 of_2\IN\1740 venous_3\JJ\1740 thromboembolism_4\NN\14100769 with_5\IN\1740 the_6\DT\1740 combination_7\NN\7951464 of_8\IN\1740 <e1>docetaxel</e1>_9\NN\1740 and_10\CC\1740 thalidomide_11\VBP\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 metastatic_15\JJ\1740 androgen-independent_16\JJ\1740 <e2>prostate_17\NN\5329735 cancer</e2>_18\NN\14239425 ._19\.\1740
C067311_D011471 NONE study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 frequency_6\NN\15286249 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 advanced_16\JJ\1740 androgen-independent_17\JJ\1740 <e2>prostate_18\NN\5329735 cancer</e2>_19\NN\14239425 who_20\WP\8299493 were_21\VBD\836236 treated_22\VBN\2376958 with_23\IN\1740 <e1>docetaxel</e1>_24\NN\1740 alone_25\RB\1740 or_26\CC\3541091 in_27\IN\13603305 combination_28\NN\7951464 with_29\IN\1740 thalidomide_30\NN\4166841 ._31\.\1740
C067311_D011471 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 addition_3\NN\3081021 of_4\IN\1740 thalidomide_5\NN\4166841 to_6\TO\1740 <e1>docetaxel</e1>_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 <e2>prostate_12\NN\5329735 cancer</e2>_13\NN\14239425 significantly_14\RB\1740 increases_15\VBZ\169651 the_16\DT\1740 frequency_17\NN\15286249 of_18\IN\1740 vte_19\NN\1740 ._20\.\1740
D013792_D054556 CID increased_0\VBN\169651 frequency_1\NN\15286249 of_2\IN\1740 <e2>venous_3\JJ\1740 thromboembolism</e2>_4\NN\14100769 with_5\IN\1740 the_6\DT\1740 combination_7\NN\7951464 of_8\IN\1740 docetaxel_9\NN\1740 and_10\CC\1740 <e1>thalidomide</e1>_11\VBP\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 metastatic_15\JJ\1740 androgen-independent_16\JJ\1740 prostate_17\NN\5329735 cancer_18\NN\14239425 ._19\.\1740
D013792_D054556 CID study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 frequency_6\NN\15286249 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 advanced_16\JJ\1740 androgen-independent_17\JJ\1740 prostate_18\NN\5329735 cancer_19\NN\14239425 who_20\WP\8299493 were_21\VBD\836236 treated_22\VBN\2376958 with_23\IN\1740 docetaxel_24\NN\1740 alone_25\RB\1740 or_26\CC\3541091 in_27\IN\13603305 combination_28\NN\7951464 with_29\IN\1740 <e1>thalidomide</e1>_30\NN\4166841 ._31\.\1740
D013792_D054556 CID study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 frequency_6\NN\15286249 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 advanced_16\JJ\1740 androgen-independent_17\JJ\1740 prostate_18\NN\5329735 cancer_19\NN\14239425 who_20\WP\8299493 were_21\VBD\836236 treated_22\VBN\2376958 with_23\IN\1740 docetaxel_24\NN\1740 alone_25\RB\1740 or_26\CC\3541091 in_27\IN\13603305 combination_28\NN\7951464 with_29\IN\1740 <e1>thalidomide</e1>_30\NN\4166841 ._31\.\1740
D013792_D054556 CID measurements_0\NNS\407535 and_1\CC\1740 main_2\JJ\1740 results_3\NNS\34213 :_4\:\1740 none_5\NN\15228378 of_6\IN\1740 23_7\CD\13745420 patients_8\NNS\9898892 who_9\WP\8299493 received_10\VBD\2210855 docetaxel_11\NN\1740 alone_12\RB\1740 developed_13\VBD\1753788 <e2>vte</e2>_14\NN\1740 ,_15\,\1740 whereas_16\IN\1740 9_17\CD\13741022 of_18\IN\1740 47_19\CD\1740 patients_20\NNS\9898892 (_21\-LRB-\1740 19_22\CD\13745420 %_23\NN\1740 )_24\-RRB-\1740 who_25\WP\8299493 received_26\VBD\2210855 docetaxel_27\NN\1740 plus_28\CC\4723816 <e1>thalidomide</e1>_29\NN\4166841 developed_30\VBD\1753788 vte_31\NN\1740 (_32\-LRB-\1740 p=0.025_33\NNP\1740 )_34\-RRB-\1740 ._35\.\1740
D013792_D054556 CID measurements_0\NNS\407535 and_1\CC\1740 main_2\JJ\1740 results_3\NNS\34213 :_4\:\1740 none_5\NN\15228378 of_6\IN\1740 23_7\CD\13745420 patients_8\NNS\9898892 who_9\WP\8299493 received_10\VBD\2210855 docetaxel_11\NN\1740 alone_12\RB\1740 developed_13\VBD\1753788 vte_14\NN\1740 ,_15\,\1740 whereas_16\IN\1740 9_17\CD\13741022 of_18\IN\1740 47_19\CD\1740 patients_20\NNS\9898892 (_21\-LRB-\1740 19_22\CD\13745420 %_23\NN\1740 )_24\-RRB-\1740 who_25\WP\8299493 received_26\VBD\2210855 docetaxel_27\NN\1740 plus_28\CC\4723816 <e1>thalidomide</e1>_29\NN\4166841 developed_30\VBD\1753788 <e2>vte</e2>_31\NN\1740 (_32\-LRB-\1740 p=0.025_33\NNP\1740 )_34\-RRB-\1740 ._35\.\1740
D013792_D054556 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 addition_3\NN\3081021 of_4\IN\1740 <e1>thalidomide</e1>_5\NN\4166841 to_6\TO\1740 docetaxel_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 prostate_12\NN\5329735 cancer_13\NN\14239425 significantly_14\RB\1740 increases_15\VBZ\169651 the_16\DT\1740 frequency_17\NN\15286249 of_18\IN\1740 <e2>vte</e2>_19\NN\1740 ._20\.\1740
D013792_D011471 NONE increased_0\VBN\169651 frequency_1\NN\15286249 of_2\IN\1740 venous_3\JJ\1740 thromboembolism_4\NN\14100769 with_5\IN\1740 the_6\DT\1740 combination_7\NN\7951464 of_8\IN\1740 docetaxel_9\NN\1740 and_10\CC\1740 <e1>thalidomide</e1>_11\VBP\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 metastatic_15\JJ\1740 androgen-independent_16\JJ\1740 <e2>prostate_17\NN\5329735 cancer</e2>_18\NN\14239425 ._19\.\1740
D013792_D011471 NONE study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 frequency_6\NN\15286249 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 advanced_16\JJ\1740 androgen-independent_17\JJ\1740 <e2>prostate_18\NN\5329735 cancer</e2>_19\NN\14239425 who_20\WP\8299493 were_21\VBD\836236 treated_22\VBN\2376958 with_23\IN\1740 docetaxel_24\NN\1740 alone_25\RB\1740 or_26\CC\3541091 in_27\IN\13603305 combination_28\NN\7951464 with_29\IN\1740 <e1>thalidomide</e1>_30\NN\4166841 ._31\.\1740
D013792_D011471 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 addition_3\NN\3081021 of_4\IN\1740 <e1>thalidomide</e1>_5\NN\4166841 to_6\TO\1740 docetaxel_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 <e2>prostate_12\NN\5329735 cancer</e2>_13\NN\14239425 significantly_14\RB\1740 increases_15\VBZ\169651 the_16\DT\1740 frequency_17\NN\15286249 of_18\IN\1740 vte_19\NN\1740 ._20\.\1740
8919272
D014635_D001927 CID morphological_0\JJ\1740 features_1\NNS\5849040 of_2\IN\1740 <e2>encephalopathy</e2>_3\JJ\1740 after_4\IN\1740 chronic_5\JJ\1740 administration_6\NN\1133281 of_7\IN\1740 the_8\DT\1740 antiepileptic_9\JJ\1740 drug_10\NN\14778436 <e1>valproate</e1>_11\VBP\1740 to_12\IN\1740 rats_13\NNS\2329401 ._14\.\1740
D014635_D001927 CID long-term_0\JJ\1740 intragastric_1\JJ\1740 application_2\NN\947128 of_3\IN\1740 the_4\DT\1740 antiepileptic_5\JJ\1740 drug_6\NN\14778436 <e1>sodium_7\NN\14625458 valproate</e1>_8\NN\1740 (_9\-LRB-\1740 vupral_10\NNP\1740 "_11\``\1740 polfa_12\NNP\1740 "_13\''\1740 )_14\-RRB-\1740 at_15\IN\14622893 the_16\DT\1740 effective_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 200_20\CD\1740 mg/kg_21\NN\1740 b._22\NN\1740 w._23\NN\1740 once_24\RB\1740 daily_25\RB\1740 to_26\TO\1740 rats_27\NNS\2329401 for_28\IN\1740 1_29\CD\13741022 ,_30\,\1740 3_31\CD\13741022 ,_32\,\1740 6_33\CD\13741022 ,_34\,\1740 9_35\CD\13741022 and_36\CC\1740 12_37\CD\13745420 months_38\NNS\15113229 revealed_39\VBD\2137132 neurological_40\JJ\1740 disorders_41\NNS\14034177 indicating_42\VBG\952524 cerebellum_43\NN\5462674 damage_44\NN\7296428 (_45\-LRB-\1740 "_46\``\1740 valproate_47\VB\1740 <e2>encephalopathy</e2>_48\RB\1740 "_49\''\1740 )_50\-RRB-\1740 ._51\.\1740
D014635_D001927 CID long-term_0\JJ\1740 intragastric_1\JJ\1740 application_2\NN\947128 of_3\IN\1740 the_4\DT\1740 antiepileptic_5\JJ\1740 drug_6\NN\14778436 sodium_7\NN\14625458 valproate_8\NN\1740 (_9\-LRB-\1740 vupral_10\NNP\1740 "_11\``\1740 polfa_12\NNP\1740 "_13\''\1740 )_14\-RRB-\1740 at_15\IN\14622893 the_16\DT\1740 effective_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 200_20\CD\1740 mg/kg_21\NN\1740 b._22\NN\1740 w._23\NN\1740 once_24\RB\1740 daily_25\RB\1740 to_26\TO\1740 rats_27\NNS\2329401 for_28\IN\1740 1_29\CD\13741022 ,_30\,\1740 3_31\CD\13741022 ,_32\,\1740 6_33\CD\13741022 ,_34\,\1740 9_35\CD\13741022 and_36\CC\1740 12_37\CD\13745420 months_38\NNS\15113229 revealed_39\VBD\2137132 neurological_40\JJ\1740 disorders_41\NNS\14034177 indicating_42\VBG\952524 cerebellum_43\NN\5462674 damage_44\NN\7296428 (_45\-LRB-\1740 "_46\``\1740 <e1>valproate</e1>_47\VB\1740 <e2>encephalopathy</e2>_48\RB\1740 "_49\''\1740 )_50\-RRB-\1740 ._51\.\1740
D014635_D001927 CID the_0\DT\1740 possible_1\JJ\1740 influence_2\NN\5190804 of_3\IN\1740 the_4\DT\1740 hepatic_5\JJ\1740 damage_6\NN\7296428 ,_7\,\1740 mainly_8\RB\1740 hyperammonemia_9\NN\1740 ,_10\,\1740 upon_11\IN\1740 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 <e1>valproate</e1>_15\NN\1740 <e2>encephalopathy</e2>_16\NN\14084880 is_17\VBZ\836236 discussed_18\VBN\1033527 ._19\.\1740
D014635_D009422 NONE long-term_0\JJ\1740 intragastric_1\JJ\1740 application_2\NN\947128 of_3\IN\1740 the_4\DT\1740 antiepileptic_5\JJ\1740 drug_6\NN\14778436 <e1>sodium_7\NN\14625458 valproate</e1>_8\NN\1740 (_9\-LRB-\1740 vupral_10\NNP\1740 "_11\``\1740 polfa_12\NNP\1740 "_13\''\1740 )_14\-RRB-\1740 at_15\IN\14622893 the_16\DT\1740 effective_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 200_20\CD\1740 mg/kg_21\NN\1740 b._22\NN\1740 w._23\NN\1740 once_24\RB\1740 daily_25\RB\1740 to_26\TO\1740 rats_27\NNS\2329401 for_28\IN\1740 1_29\CD\13741022 ,_30\,\1740 3_31\CD\13741022 ,_32\,\1740 6_33\CD\13741022 ,_34\,\1740 9_35\CD\13741022 and_36\CC\1740 12_37\CD\13745420 months_38\NNS\15113229 revealed_39\VBD\2137132 <e2>neurological_40\JJ\1740 disorders</e2>_41\NNS\14034177 indicating_42\VBG\952524 cerebellum_43\NN\5462674 damage_44\NN\7296428 (_45\-LRB-\1740 "_46\``\1740 valproate_47\VB\1740 encephalopathy_48\RB\1740 "_49\''\1740 )_50\-RRB-\1740 ._51\.\1740
D014635_D009422 NONE long-term_0\JJ\1740 intragastric_1\JJ\1740 application_2\NN\947128 of_3\IN\1740 the_4\DT\1740 antiepileptic_5\JJ\1740 drug_6\NN\14778436 sodium_7\NN\14625458 valproate_8\NN\1740 (_9\-LRB-\1740 vupral_10\NNP\1740 "_11\``\1740 polfa_12\NNP\1740 "_13\''\1740 )_14\-RRB-\1740 at_15\IN\14622893 the_16\DT\1740 effective_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 200_20\CD\1740 mg/kg_21\NN\1740 b._22\NN\1740 w._23\NN\1740 once_24\RB\1740 daily_25\RB\1740 to_26\TO\1740 rats_27\NNS\2329401 for_28\IN\1740 1_29\CD\13741022 ,_30\,\1740 3_31\CD\13741022 ,_32\,\1740 6_33\CD\13741022 ,_34\,\1740 9_35\CD\13741022 and_36\CC\1740 12_37\CD\13745420 months_38\NNS\15113229 revealed_39\VBD\2137132 <e2>neurological_40\JJ\1740 disorders</e2>_41\NNS\14034177 indicating_42\VBG\952524 cerebellum_43\NN\5462674 damage_44\NN\7296428 (_45\-LRB-\1740 "_46\``\1740 <e1>valproate</e1>_47\VB\1740 encephalopathy_48\RB\1740 "_49\''\1740 )_50\-RRB-\1740 ._51\.\1740
D014635_D002526 NONE long-term_0\JJ\1740 intragastric_1\JJ\1740 application_2\NN\947128 of_3\IN\1740 the_4\DT\1740 antiepileptic_5\JJ\1740 drug_6\NN\14778436 <e1>sodium_7\NN\14625458 valproate</e1>_8\NN\1740 (_9\-LRB-\1740 vupral_10\NNP\1740 "_11\``\1740 polfa_12\NNP\1740 "_13\''\1740 )_14\-RRB-\1740 at_15\IN\14622893 the_16\DT\1740 effective_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 200_20\CD\1740 mg/kg_21\NN\1740 b._22\NN\1740 w._23\NN\1740 once_24\RB\1740 daily_25\RB\1740 to_26\TO\1740 rats_27\NNS\2329401 for_28\IN\1740 1_29\CD\13741022 ,_30\,\1740 3_31\CD\13741022 ,_32\,\1740 6_33\CD\13741022 ,_34\,\1740 9_35\CD\13741022 and_36\CC\1740 12_37\CD\13745420 months_38\NNS\15113229 revealed_39\VBD\2137132 neurological_40\JJ\1740 disorders_41\NNS\14034177 indicating_42\VBG\952524 <e2>cerebellum_43\NN\5462674 damage</e2>_44\NN\7296428 (_45\-LRB-\1740 "_46\``\1740 valproate_47\VB\1740 encephalopathy_48\RB\1740 "_49\''\1740 )_50\-RRB-\1740 ._51\.\1740
D014635_D002526 NONE long-term_0\JJ\1740 intragastric_1\JJ\1740 application_2\NN\947128 of_3\IN\1740 the_4\DT\1740 antiepileptic_5\JJ\1740 drug_6\NN\14778436 sodium_7\NN\14625458 valproate_8\NN\1740 (_9\-LRB-\1740 vupral_10\NNP\1740 "_11\``\1740 polfa_12\NNP\1740 "_13\''\1740 )_14\-RRB-\1740 at_15\IN\14622893 the_16\DT\1740 effective_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 200_20\CD\1740 mg/kg_21\NN\1740 b._22\NN\1740 w._23\NN\1740 once_24\RB\1740 daily_25\RB\1740 to_26\TO\1740 rats_27\NNS\2329401 for_28\IN\1740 1_29\CD\13741022 ,_30\,\1740 3_31\CD\13741022 ,_32\,\1740 6_33\CD\13741022 ,_34\,\1740 9_35\CD\13741022 and_36\CC\1740 12_37\CD\13745420 months_38\NNS\15113229 revealed_39\VBD\2137132 neurological_40\JJ\1740 disorders_41\NNS\14034177 indicating_42\VBG\952524 <e2>cerebellum_43\NN\5462674 damage</e2>_44\NN\7296428 (_45\-LRB-\1740 "_46\``\1740 <e1>valproate</e1>_47\VB\1740 encephalopathy_48\RB\1740 "_49\''\1740 )_50\-RRB-\1740 ._51\.\1740
D014635_D056486 NONE the_0\DT\1740 possible_1\JJ\1740 influence_2\NN\5190804 of_3\IN\1740 the_4\DT\1740 <e2>hepatic_5\JJ\1740 damage</e2>_6\NN\7296428 ,_7\,\1740 mainly_8\RB\1740 hyperammonemia_9\NN\1740 ,_10\,\1740 upon_11\IN\1740 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 <e1>valproate</e1>_15\NN\1740 encephalopathy_16\NN\14084880 is_17\VBZ\836236 discussed_18\VBN\1033527 ._19\.\1740
D014635_D022124 NONE the_0\DT\1740 possible_1\JJ\1740 influence_2\NN\5190804 of_3\IN\1740 the_4\DT\1740 hepatic_5\JJ\1740 damage_6\NN\7296428 ,_7\,\1740 mainly_8\RB\1740 <e2>hyperammonemia</e2>_9\NN\1740 ,_10\,\1740 upon_11\IN\1740 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 <e1>valproate</e1>_15\NN\1740 encephalopathy_16\NN\14084880 is_17\VBZ\836236 discussed_18\VBN\1033527 ._19\.\1740
18439803
C108761_D012640 NONE acute_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>n-(2-propylpentanoyl)urea</e1>_3\NN\1740 on_4\IN\1740 hippocampal_5\NN\1740 amino_6\NN\14621446 acid_7\NN\14818238 neurotransmitters_8\NNS\14807410 in_9\IN\13603305 pilocarpine-induced_10\JJ\1740 <e2>seizure</e2>_11\NN\14081375 in_12\IN\13603305 rats_13\NNS\2329401 ._14\.\1740
C108761_D012640 NONE <e1>vpu</e1>_0\NNP\1740 was_1\VBD\836236 more_2\RBR\1740 potent_3\JJ\1740 than_4\IN\1740 vpa_5\NN\1740 ,_6\,\1740 exhibiting_7\VBG\2632167 the_8\DT\1740 median_9\JJ\1740 effective_10\JJ\1740 dose_11\NN\3740161 (_12\-LRB-\1740 ed(50_13\NN\1740 )_14\-RRB-\1740 )_15\-RRB-\1740 of_16\IN\1740 49_17\CD\1740 mg/kg_18\NN\1740 in_19\IN\13603305 protecting_20\VBG\1127795 rats_21\NNS\2329401 against_22\IN\1740 pilocarpine-induced_23\JJ\1740 <e2>seizure</e2>_24\NN\14081375 whereas_25\IN\1740 the_26\DT\1740 corresponding_27\JJ\1740 value_28\NN\5856066 for_29\IN\1740 vpa_30\NN\1740 was_31\VBD\836236 322_32\CD\1740 mg/kg_33\NN\1740 ._34\.\1740
C108761_D012640 NONE based_0\VBN\2694933 on_1\IN\1740 the_2\DT\1740 finding_3\NN\43195 that_4\IN\1740 <e1>vpu</e1>_5\NNP\1740 and_6\CC\1740 vpa_7\NN\1740 could_8\MD\1740 protect_9\VB\1127795 the_10\DT\1740 animals_11\NNS\4475 against_12\IN\1740 pilocarpine-induced_13\JJ\1740 <e2>seizure</e2>_14\JJ\1740 it_15\PRP\6125041 is_16\VBZ\836236 suggested_17\VBN\1010118 that_18\IN\1740 the_19\DT\1740 reduction_20\NN\351485 of_21\IN\1740 inhibitory_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 neurotransmitters_25\NNS\14807410 was_26\VBD\836236 comparatively_27\RB\1740 minor_28\JJ\1740 and_29\CC\1740 offset_30\VB\2673134 by_31\IN\1740 a_32\DT\13649268 pronounced_33\JJ\1740 reduction_34\NN\351485 of_35\IN\1740 glutamate_36\NN\15010703 and_37\CC\1740 aspartate_38\VBP\1740 ._39\.\1740
C108761_D012640 NONE therefore_0\RB\1740 ,_1\,\1740 like_2\IN\5839024 vpa_3\NN\1740 ,_4\,\1740 the_5\DT\1740 finding_6\NN\43195 that_7\IN\1740 <e1>vpu</e1>_8\NNP\1740 could_9\MD\1740 drastically_10\RB\1740 reduce_11\VB\441445 pilocarpine-induced_12\JJ\1740 increases_13\NNS\13576355 in_14\IN\13603305 glutamate_15\NN\15010703 and_16\CC\1740 aspartate_17\NN\1740 should_18\MD\1740 account_19\VB\2604760 ,_20\,\1740 at_21\IN\14622893 least_22\JJS\1740 partly_23\RB\1740 ,_24\,\1740 for_25\IN\1740 its_26\PRP$\6125041 anticonvulsant_27\JJ\1740 activity_28\NN\30358 observed_29\VBN\2163746 in_30\IN\13603305 pilocarpine-induced_31\JJ\1740 <e2>seizure</e2>_32\NN\14081375 in_33\IN\13603305 experimental_34\JJ\1740 animals_35\NNS\4475 ._36\.\1740
D000596_D012640 NONE acute_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 n-(2-propylpentanoyl)urea_3\NN\1740 on_4\IN\1740 hippocampal_5\NN\1740 <e1>amino_6\NN\14621446 acid</e1>_7\NN\14818238 neurotransmitters_8\NNS\14807410 in_9\IN\13603305 pilocarpine-induced_10\JJ\1740 <e2>seizure</e2>_11\NN\14081375 in_12\IN\13603305 rats_13\NNS\2329401 ._14\.\1740
D000596_D012640 NONE based_0\VBN\2694933 on_1\IN\1740 the_2\DT\1740 finding_3\NN\43195 that_4\IN\1740 vpu_5\NNP\1740 and_6\CC\1740 vpa_7\NN\1740 could_8\MD\1740 protect_9\VB\1127795 the_10\DT\1740 animals_11\NNS\4475 against_12\IN\1740 pilocarpine-induced_13\JJ\1740 <e2>seizure</e2>_14\JJ\1740 it_15\PRP\6125041 is_16\VBZ\836236 suggested_17\VBN\1010118 that_18\IN\1740 the_19\DT\1740 reduction_20\NN\351485 of_21\IN\1740 inhibitory_22\JJ\1740 <e1>amino_23\NN\14621446 acid</e1>_24\NN\14818238 neurotransmitters_25\NNS\14807410 was_26\VBD\836236 comparatively_27\RB\1740 minor_28\JJ\1740 and_29\CC\1740 offset_30\VB\2673134 by_31\IN\1740 a_32\DT\13649268 pronounced_33\JJ\1740 reduction_34\NN\351485 of_35\IN\1740 glutamate_36\NN\15010703 and_37\CC\1740 aspartate_38\VBP\1740 ._39\.\1740
D010862_D012640 CID acute_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 n-(2-propylpentanoyl)urea_3\NN\1740 on_4\IN\1740 hippocampal_5\NN\1740 amino_6\NN\14621446 acid_7\NN\14818238 neurotransmitters_8\NNS\14807410 in_9\IN\13603305 <e1>pilocarpine-induced</e1>_10\JJ\1740 <e2>seizure</e2>_11\NN\14081375 in_12\IN\13603305 rats_13\NNS\2329401 ._14\.\1740
D010862_D012640 CID vpu_0\NNP\1740 was_1\VBD\836236 more_2\RBR\1740 potent_3\JJ\1740 than_4\IN\1740 vpa_5\NN\1740 ,_6\,\1740 exhibiting_7\VBG\2632167 the_8\DT\1740 median_9\JJ\1740 effective_10\JJ\1740 dose_11\NN\3740161 (_12\-LRB-\1740 ed(50_13\NN\1740 )_14\-RRB-\1740 )_15\-RRB-\1740 of_16\IN\1740 49_17\CD\1740 mg/kg_18\NN\1740 in_19\IN\13603305 protecting_20\VBG\1127795 rats_21\NNS\2329401 against_22\IN\1740 <e1>pilocarpine-induced</e1>_23\JJ\1740 <e2>seizure</e2>_24\NN\14081375 whereas_25\IN\1740 the_26\DT\1740 corresponding_27\JJ\1740 value_28\NN\5856066 for_29\IN\1740 vpa_30\NN\1740 was_31\VBD\836236 322_32\CD\1740 mg/kg_33\NN\1740 ._34\.\1740
D010862_D012640 CID based_0\VBN\2694933 on_1\IN\1740 the_2\DT\1740 finding_3\NN\43195 that_4\IN\1740 vpu_5\NNP\1740 and_6\CC\1740 vpa_7\NN\1740 could_8\MD\1740 protect_9\VB\1127795 the_10\DT\1740 animals_11\NNS\4475 against_12\IN\1740 <e1>pilocarpine-induced</e1>_13\JJ\1740 <e2>seizure</e2>_14\JJ\1740 it_15\PRP\6125041 is_16\VBZ\836236 suggested_17\VBN\1010118 that_18\IN\1740 the_19\DT\1740 reduction_20\NN\351485 of_21\IN\1740 inhibitory_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 neurotransmitters_25\NNS\14807410 was_26\VBD\836236 comparatively_27\RB\1740 minor_28\JJ\1740 and_29\CC\1740 offset_30\VB\2673134 by_31\IN\1740 a_32\DT\13649268 pronounced_33\JJ\1740 reduction_34\NN\351485 of_35\IN\1740 glutamate_36\NN\15010703 and_37\CC\1740 aspartate_38\VBP\1740 ._39\.\1740
D010862_D012640 CID therefore_0\RB\1740 ,_1\,\1740 like_2\IN\5839024 vpa_3\NN\1740 ,_4\,\1740 the_5\DT\1740 finding_6\NN\43195 that_7\IN\1740 vpu_8\NNP\1740 could_9\MD\1740 drastically_10\RB\1740 reduce_11\VB\441445 <e1>pilocarpine-induced</e1>_12\JJ\1740 increases_13\NNS\13576355 in_14\IN\13603305 glutamate_15\NN\15010703 and_16\CC\1740 aspartate_17\NN\1740 should_18\MD\1740 account_19\VB\2604760 ,_20\,\1740 at_21\IN\14622893 least_22\JJS\1740 partly_23\RB\1740 ,_24\,\1740 for_25\IN\1740 its_26\PRP$\6125041 anticonvulsant_27\JJ\1740 activity_28\NN\30358 observed_29\VBN\2163746 in_30\IN\13603305 pilocarpine-induced_31\JJ\1740 <e2>seizure</e2>_32\NN\14081375 in_33\IN\13603305 experimental_34\JJ\1740 animals_35\NNS\4475 ._36\.\1740
D010862_D012640 CID therefore_0\RB\1740 ,_1\,\1740 like_2\IN\5839024 vpa_3\NN\1740 ,_4\,\1740 the_5\DT\1740 finding_6\NN\43195 that_7\IN\1740 vpu_8\NNP\1740 could_9\MD\1740 drastically_10\RB\1740 reduce_11\VB\441445 pilocarpine-induced_12\JJ\1740 increases_13\NNS\13576355 in_14\IN\13603305 glutamate_15\NN\15010703 and_16\CC\1740 aspartate_17\NN\1740 should_18\MD\1740 account_19\VB\2604760 ,_20\,\1740 at_21\IN\14622893 least_22\JJS\1740 partly_23\RB\1740 ,_24\,\1740 for_25\IN\1740 its_26\PRP$\6125041 anticonvulsant_27\JJ\1740 activity_28\NN\30358 observed_29\VBN\2163746 in_30\IN\13603305 <e1>pilocarpine-induced</e1>_31\JJ\1740 <e2>seizure</e2>_32\NN\14081375 in_33\IN\13603305 experimental_34\JJ\1740 animals_35\NNS\4475 ._36\.\1740
D014635_D012640 NONE vpu_0\NNP\1740 was_1\VBD\836236 more_2\RBR\1740 potent_3\JJ\1740 than_4\IN\1740 <e1>vpa</e1>_5\NN\1740 ,_6\,\1740 exhibiting_7\VBG\2632167 the_8\DT\1740 median_9\JJ\1740 effective_10\JJ\1740 dose_11\NN\3740161 (_12\-LRB-\1740 ed(50_13\NN\1740 )_14\-RRB-\1740 )_15\-RRB-\1740 of_16\IN\1740 49_17\CD\1740 mg/kg_18\NN\1740 in_19\IN\13603305 protecting_20\VBG\1127795 rats_21\NNS\2329401 against_22\IN\1740 pilocarpine-induced_23\JJ\1740 <e2>seizure</e2>_24\NN\14081375 whereas_25\IN\1740 the_26\DT\1740 corresponding_27\JJ\1740 value_28\NN\5856066 for_29\IN\1740 vpa_30\NN\1740 was_31\VBD\836236 322_32\CD\1740 mg/kg_33\NN\1740 ._34\.\1740
D014635_D012640 NONE vpu_0\NNP\1740 was_1\VBD\836236 more_2\RBR\1740 potent_3\JJ\1740 than_4\IN\1740 vpa_5\NN\1740 ,_6\,\1740 exhibiting_7\VBG\2632167 the_8\DT\1740 median_9\JJ\1740 effective_10\JJ\1740 dose_11\NN\3740161 (_12\-LRB-\1740 ed(50_13\NN\1740 )_14\-RRB-\1740 )_15\-RRB-\1740 of_16\IN\1740 49_17\CD\1740 mg/kg_18\NN\1740 in_19\IN\13603305 protecting_20\VBG\1127795 rats_21\NNS\2329401 against_22\IN\1740 pilocarpine-induced_23\JJ\1740 <e2>seizure</e2>_24\NN\14081375 whereas_25\IN\1740 the_26\DT\1740 corresponding_27\JJ\1740 value_28\NN\5856066 for_29\IN\1740 <e1>vpa</e1>_30\NN\1740 was_31\VBD\836236 322_32\CD\1740 mg/kg_33\NN\1740 ._34\.\1740
D014635_D012640 NONE based_0\VBN\2694933 on_1\IN\1740 the_2\DT\1740 finding_3\NN\43195 that_4\IN\1740 vpu_5\NNP\1740 and_6\CC\1740 <e1>vpa</e1>_7\NN\1740 could_8\MD\1740 protect_9\VB\1127795 the_10\DT\1740 animals_11\NNS\4475 against_12\IN\1740 pilocarpine-induced_13\JJ\1740 <e2>seizure</e2>_14\JJ\1740 it_15\PRP\6125041 is_16\VBZ\836236 suggested_17\VBN\1010118 that_18\IN\1740 the_19\DT\1740 reduction_20\NN\351485 of_21\IN\1740 inhibitory_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 neurotransmitters_25\NNS\14807410 was_26\VBD\836236 comparatively_27\RB\1740 minor_28\JJ\1740 and_29\CC\1740 offset_30\VB\2673134 by_31\IN\1740 a_32\DT\13649268 pronounced_33\JJ\1740 reduction_34\NN\351485 of_35\IN\1740 glutamate_36\NN\15010703 and_37\CC\1740 aspartate_38\VBP\1740 ._39\.\1740
D014635_D012640 NONE therefore_0\RB\1740 ,_1\,\1740 like_2\IN\5839024 <e1>vpa</e1>_3\NN\1740 ,_4\,\1740 the_5\DT\1740 finding_6\NN\43195 that_7\IN\1740 vpu_8\NNP\1740 could_9\MD\1740 drastically_10\RB\1740 reduce_11\VB\441445 pilocarpine-induced_12\JJ\1740 increases_13\NNS\13576355 in_14\IN\13603305 glutamate_15\NN\15010703 and_16\CC\1740 aspartate_17\NN\1740 should_18\MD\1740 account_19\VB\2604760 ,_20\,\1740 at_21\IN\14622893 least_22\JJS\1740 partly_23\RB\1740 ,_24\,\1740 for_25\IN\1740 its_26\PRP$\6125041 anticonvulsant_27\JJ\1740 activity_28\NN\30358 observed_29\VBN\2163746 in_30\IN\13603305 pilocarpine-induced_31\JJ\1740 <e2>seizure</e2>_32\NN\14081375 in_33\IN\13603305 experimental_34\JJ\1740 animals_35\NNS\4475 ._36\.\1740
D018698_D012640 NONE based_0\VBN\2694933 on_1\IN\1740 the_2\DT\1740 finding_3\NN\43195 that_4\IN\1740 vpu_5\NNP\1740 and_6\CC\1740 vpa_7\NN\1740 could_8\MD\1740 protect_9\VB\1127795 the_10\DT\1740 animals_11\NNS\4475 against_12\IN\1740 pilocarpine-induced_13\JJ\1740 <e2>seizure</e2>_14\JJ\1740 it_15\PRP\6125041 is_16\VBZ\836236 suggested_17\VBN\1010118 that_18\IN\1740 the_19\DT\1740 reduction_20\NN\351485 of_21\IN\1740 inhibitory_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 neurotransmitters_25\NNS\14807410 was_26\VBD\836236 comparatively_27\RB\1740 minor_28\JJ\1740 and_29\CC\1740 offset_30\VB\2673134 by_31\IN\1740 a_32\DT\13649268 pronounced_33\JJ\1740 reduction_34\NN\351485 of_35\IN\1740 <e1>glutamate</e1>_36\NN\15010703 and_37\CC\1740 aspartate_38\VBP\1740 ._39\.\1740
D018698_D012640 NONE therefore_0\RB\1740 ,_1\,\1740 like_2\IN\5839024 vpa_3\NN\1740 ,_4\,\1740 the_5\DT\1740 finding_6\NN\43195 that_7\IN\1740 vpu_8\NNP\1740 could_9\MD\1740 drastically_10\RB\1740 reduce_11\VB\441445 pilocarpine-induced_12\JJ\1740 increases_13\NNS\13576355 in_14\IN\13603305 <e1>glutamate</e1>_15\NN\15010703 and_16\CC\1740 aspartate_17\NN\1740 should_18\MD\1740 account_19\VB\2604760 ,_20\,\1740 at_21\IN\14622893 least_22\JJS\1740 partly_23\RB\1740 ,_24\,\1740 for_25\IN\1740 its_26\PRP$\6125041 anticonvulsant_27\JJ\1740 activity_28\NN\30358 observed_29\VBN\2163746 in_30\IN\13603305 pilocarpine-induced_31\JJ\1740 <e2>seizure</e2>_32\NN\14081375 in_33\IN\13603305 experimental_34\JJ\1740 animals_35\NNS\4475 ._36\.\1740
D001224_D012640 NONE based_0\VBN\2694933 on_1\IN\1740 the_2\DT\1740 finding_3\NN\43195 that_4\IN\1740 vpu_5\NNP\1740 and_6\CC\1740 vpa_7\NN\1740 could_8\MD\1740 protect_9\VB\1127795 the_10\DT\1740 animals_11\NNS\4475 against_12\IN\1740 pilocarpine-induced_13\JJ\1740 <e2>seizure</e2>_14\JJ\1740 it_15\PRP\6125041 is_16\VBZ\836236 suggested_17\VBN\1010118 that_18\IN\1740 the_19\DT\1740 reduction_20\NN\351485 of_21\IN\1740 inhibitory_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 neurotransmitters_25\NNS\14807410 was_26\VBD\836236 comparatively_27\RB\1740 minor_28\JJ\1740 and_29\CC\1740 offset_30\VB\2673134 by_31\IN\1740 a_32\DT\13649268 pronounced_33\JJ\1740 reduction_34\NN\351485 of_35\IN\1740 glutamate_36\NN\15010703 and_37\CC\1740 <e1>aspartate</e1>_38\VBP\1740 ._39\.\1740
D001224_D012640 NONE therefore_0\RB\1740 ,_1\,\1740 like_2\IN\5839024 vpa_3\NN\1740 ,_4\,\1740 the_5\DT\1740 finding_6\NN\43195 that_7\IN\1740 vpu_8\NNP\1740 could_9\MD\1740 drastically_10\RB\1740 reduce_11\VB\441445 pilocarpine-induced_12\JJ\1740 increases_13\NNS\13576355 in_14\IN\13603305 glutamate_15\NN\15010703 and_16\CC\1740 <e1>aspartate</e1>_17\NN\1740 should_18\MD\1740 account_19\VB\2604760 ,_20\,\1740 at_21\IN\14622893 least_22\JJS\1740 partly_23\RB\1740 ,_24\,\1740 for_25\IN\1740 its_26\PRP$\6125041 anticonvulsant_27\JJ\1740 activity_28\NN\30358 observed_29\VBN\2163746 in_30\IN\13603305 pilocarpine-induced_31\JJ\1740 <e2>seizure</e2>_32\NN\14081375 in_33\IN\13603305 experimental_34\JJ\1740 animals_35\NNS\4475 ._36\.\1740
1720453
D007069_D007674 CID long-term_0\JJ\1740 follow-up_1\NN\4599396 of_2\IN\1740 <e1>ifosfamide</e1>_3\NN\1740 <e2>renal_4\JJ\1740 toxicity</e2>_5\NN\13576101 in_6\IN\13603305 children_7\NNS\9622049 treated_8\VBN\2376958 for_9\IN\1740 malignant_10\JJ\1740 mesenchymal_11\JJ\1740 tumors_12\NNS\14234074 :_13\:\1740 an_14\DT\6697703 international_15\NNP\8366202 society_16\NNP\7950920 of_17\IN\1740 pediatric_18\NNP\1740 oncology_19\NNP\6043075 report_20\NN\6470073 ._21\.\1740
D007069_C535700 NONE long-term_0\JJ\1740 follow-up_1\NN\4599396 of_2\IN\1740 <e1>ifosfamide</e1>_3\NN\1740 renal_4\JJ\1740 toxicity_5\NN\13576101 in_6\IN\13603305 children_7\NNS\9622049 treated_8\VBN\2376958 for_9\IN\1740 <e2>malignant_10\JJ\1740 mesenchymal_11\JJ\1740 tumors</e2>_12\NNS\14234074 :_13\:\1740 an_14\DT\6697703 international_15\NNP\8366202 society_16\NNP\7950920 of_17\IN\1740 pediatric_18\NNP\1740 oncology_19\NNP\6043075 report_20\NN\6470073 ._21\.\1740
D007069_C535700 NONE the_0\DT\1740 renal_1\JJ\1740 function_2\NN\13783581 of_3\IN\1740 74_4\CD\1740 children_5\NNS\9622049 with_6\IN\1740 <e2>malignant_7\JJ\1740 mesenchymal_8\JJ\1740 tumors</e2>_9\NNS\14234074 in_10\IN\13603305 complete_11\JJ\1740 remission_12\NN\7368256 and_13\CC\1740 who_14\WP\8299493 have_15\VBP\2108377 received_16\VBN\2210855 the_17\DT\1740 same_18\JJ\1740 <e1>ifosfamide</e1>_19\NN\1740 chemotherapy_20\NN\661091 protocol_21\NN\6652242 (_22\-LRB-\1740 international_23\NNP\8366202 society_24\NNP\7950920 of_25\IN\1740 pediatric_26\NNP\1740 oncology_27\NNP\6043075 malignant_28\NNP\1740 mesenchymal_29\NNP\1740 tumor_30\NNP\14234074 study_31\NN\635850 84_32\CD\1740 [_33\-LRB-\1740 siop_34\NN\1740 mmt_35\NN\1740 84_36\CD\1740 ]_37\-RRB-\1740 )_38\-RRB-\1740 were_39\VBD\836236 studied_40\VBN\630380 1_41\CD\13741022 year_42\NN\15113229 after_43\IN\1740 the_44\DT\1740 completion_45\NN\556313 of_46\IN\1740 treatment_47\NN\654885 ._48\.\1740
D007069_C535700 NONE the_0\DT\1740 renal_1\JJ\1740 function_2\NN\13783581 of_3\IN\1740 74_4\CD\1740 children_5\NNS\9622049 with_6\IN\1740 malignant_7\JJ\1740 mesenchymal_8\JJ\1740 tumors_9\NNS\14234074 in_10\IN\13603305 complete_11\JJ\1740 remission_12\NN\7368256 and_13\CC\1740 who_14\WP\8299493 have_15\VBP\2108377 received_16\VBN\2210855 the_17\DT\1740 same_18\JJ\1740 <e1>ifosfamide</e1>_19\NN\1740 chemotherapy_20\NN\661091 protocol_21\NN\6652242 (_22\-LRB-\1740 international_23\NNP\8366202 society_24\NNP\7950920 of_25\IN\1740 pediatric_26\NNP\1740 oncology_27\NNP\6043075 <e2>malignant_28\NNP\1740 mesenchymal_29\NNP\1740 tumor</e2>_30\NNP\14234074 study_31\NN\635850 84_32\CD\1740 [_33\-LRB-\1740 siop_34\NN\1740 mmt_35\NN\1740 84_36\CD\1740 ]_37\-RRB-\1740 )_38\-RRB-\1740 were_39\VBD\836236 studied_40\VBN\630380 1_41\CD\13741022 year_42\NN\15113229 after_43\IN\1740 the_44\DT\1740 completion_45\NN\556313 of_46\IN\1740 treatment_47\NN\654885 ._48\.\1740
D007069_C535700 NONE this_0\DT\1740 low_1\JJ\1740 percentage_2\NN\13815742 (_3\-LRB-\1740 5_4\CD\13741022 %_5\NN\1740 )_6\-RRB-\1740 of_7\IN\1740 tdfs_8\NN\1740 must_9\MD\9367203 be_10\VB\836236 evaluated_11\VBN\670261 with_12\IN\1740 respect_13\NN\5817845 to_14\TO\1740 the_15\DT\1740 efficacy_16\NN\5199286 of_17\IN\1740 <e1>ifosfamide</e1>_18\NN\1740 in_19\IN\13603305 the_20\DT\1740 treatment_21\NN\654885 of_22\IN\1740 <e2>mesenchymal_23\JJ\1740 tumors</e2>_24\NNS\14234074 in_25\IN\13603305 children_26\NNS\9622049 ._27\.\1740
D003404_D006030 NONE renal_0\JJ\1740 function_1\NN\13783581 was_2\VBD\836236 investigated_3\VBN\644583 by_4\IN\1740 measuring_5\VBG\697589 plasma_6\NN\5398023 and_7\CC\1740 urinary_8\JJ\1740 electrolytes_9\NNS\14589223 ,_10\,\1740 <e2>glucosuria</e2>_11\NNS\14267841 ,_12\,\1740 proteinuria_13\NN\14299637 ,_14\,\1740 aminoaciduria_15\NN\14299637 ,_16\,\1740 urinary_17\JJ\1740 ph_18\NN\5038959 ,_19\,\1740 osmolarity_20\NN\1740 ,_21\,\1740 <e1>creatinine</e1>_22\NN\1740 clearance_23\NN\5089947 ,_24\,\1740 phosphate_25\NN\15010703 tubular_26\JJ\1740 reabsorption_27\NN\13526110 ,_28\,\1740 beta_29\NN\6828818 2_30\CD\13741022 microglobulinuria_31\NN\1740 ,_32\,\1740 and_33\CC\1740 lysozymuria_34\NNS\1740 ._35\.\1740
D003404_D011507 NONE renal_0\JJ\1740 function_1\NN\13783581 was_2\VBD\836236 investigated_3\VBN\644583 by_4\IN\1740 measuring_5\VBG\697589 plasma_6\NN\5398023 and_7\CC\1740 urinary_8\JJ\1740 electrolytes_9\NNS\14589223 ,_10\,\1740 glucosuria_11\NNS\14267841 ,_12\,\1740 <e2>proteinuria</e2>_13\NN\14299637 ,_14\,\1740 aminoaciduria_15\NN\14299637 ,_16\,\1740 urinary_17\JJ\1740 ph_18\NN\5038959 ,_19\,\1740 osmolarity_20\NN\1740 ,_21\,\1740 <e1>creatinine</e1>_22\NN\1740 clearance_23\NN\5089947 ,_24\,\1740 phosphate_25\NN\15010703 tubular_26\JJ\1740 reabsorption_27\NN\13526110 ,_28\,\1740 beta_29\NN\6828818 2_30\CD\13741022 microglobulinuria_31\NN\1740 ,_32\,\1740 and_33\CC\1740 lysozymuria_34\NNS\1740 ._35\.\1740
D003404_D000608 NONE renal_0\JJ\1740 function_1\NN\13783581 was_2\VBD\836236 investigated_3\VBN\644583 by_4\IN\1740 measuring_5\VBG\697589 plasma_6\NN\5398023 and_7\CC\1740 urinary_8\JJ\1740 electrolytes_9\NNS\14589223 ,_10\,\1740 glucosuria_11\NNS\14267841 ,_12\,\1740 proteinuria_13\NN\14299637 ,_14\,\1740 <e2>aminoaciduria</e2>_15\NN\14299637 ,_16\,\1740 urinary_17\JJ\1740 ph_18\NN\5038959 ,_19\,\1740 osmolarity_20\NN\1740 ,_21\,\1740 <e1>creatinine</e1>_22\NN\1740 clearance_23\NN\5089947 ,_24\,\1740 phosphate_25\NN\15010703 tubular_26\JJ\1740 reabsorption_27\NN\13526110 ,_28\,\1740 beta_29\NN\6828818 2_30\CD\13741022 microglobulinuria_31\NN\1740 ,_32\,\1740 and_33\CC\1740 lysozymuria_34\NNS\1740 ._35\.\1740
D010710_D006030 NONE renal_0\JJ\1740 function_1\NN\13783581 was_2\VBD\836236 investigated_3\VBN\644583 by_4\IN\1740 measuring_5\VBG\697589 plasma_6\NN\5398023 and_7\CC\1740 urinary_8\JJ\1740 electrolytes_9\NNS\14589223 ,_10\,\1740 <e2>glucosuria</e2>_11\NNS\14267841 ,_12\,\1740 proteinuria_13\NN\14299637 ,_14\,\1740 aminoaciduria_15\NN\14299637 ,_16\,\1740 urinary_17\JJ\1740 ph_18\NN\5038959 ,_19\,\1740 osmolarity_20\NN\1740 ,_21\,\1740 creatinine_22\NN\1740 clearance_23\NN\5089947 ,_24\,\1740 <e1>phosphate</e1>_25\NN\15010703 tubular_26\JJ\1740 reabsorption_27\NN\13526110 ,_28\,\1740 beta_29\NN\6828818 2_30\CD\13741022 microglobulinuria_31\NN\1740 ,_32\,\1740 and_33\CC\1740 lysozymuria_34\NNS\1740 ._35\.\1740
D010710_D011507 NONE renal_0\JJ\1740 function_1\NN\13783581 was_2\VBD\836236 investigated_3\VBN\644583 by_4\IN\1740 measuring_5\VBG\697589 plasma_6\NN\5398023 and_7\CC\1740 urinary_8\JJ\1740 electrolytes_9\NNS\14589223 ,_10\,\1740 glucosuria_11\NNS\14267841 ,_12\,\1740 <e2>proteinuria</e2>_13\NN\14299637 ,_14\,\1740 aminoaciduria_15\NN\14299637 ,_16\,\1740 urinary_17\JJ\1740 ph_18\NN\5038959 ,_19\,\1740 osmolarity_20\NN\1740 ,_21\,\1740 creatinine_22\NN\1740 clearance_23\NN\5089947 ,_24\,\1740 <e1>phosphate</e1>_25\NN\15010703 tubular_26\JJ\1740 reabsorption_27\NN\13526110 ,_28\,\1740 beta_29\NN\6828818 2_30\CD\13741022 microglobulinuria_31\NN\1740 ,_32\,\1740 and_33\CC\1740 lysozymuria_34\NNS\1740 ._35\.\1740
D010710_D000608 NONE renal_0\JJ\1740 function_1\NN\13783581 was_2\VBD\836236 investigated_3\VBN\644583 by_4\IN\1740 measuring_5\VBG\697589 plasma_6\NN\5398023 and_7\CC\1740 urinary_8\JJ\1740 electrolytes_9\NNS\14589223 ,_10\,\1740 glucosuria_11\NNS\14267841 ,_12\,\1740 proteinuria_13\NN\14299637 ,_14\,\1740 <e2>aminoaciduria</e2>_15\NN\14299637 ,_16\,\1740 urinary_17\JJ\1740 ph_18\NN\5038959 ,_19\,\1740 osmolarity_20\NN\1740 ,_21\,\1740 creatinine_22\NN\1740 clearance_23\NN\5089947 ,_24\,\1740 <e1>phosphate</e1>_25\NN\15010703 tubular_26\JJ\1740 reabsorption_27\NN\13526110 ,_28\,\1740 beta_29\NN\6828818 2_30\CD\13741022 microglobulinuria_31\NN\1740 ,_32\,\1740 and_33\CC\1740 lysozymuria_34\NNS\1740 ._35\.\1740
D010710_D064420 NONE two_0\CD\13741022 subsets_1\NNS\7999699 of_2\IN\1740 patients_3\NNS\9898892 were_4\VBD\836236 identified_5\VBN\699815 from_6\IN\1740 this_7\DT\1740 latter_8\JJ\1740 group_9\NN\2137 :_10\:\1740 the_11\DT\1740 first_12\RB\1740 included_13\VBN\690614 four_14\CD\13741022 patients_15\NNS\9898892 (_16\-LRB-\1740 5_17\CD\13741022 %_18\NN\1740 of_19\IN\1740 the_20\DT\1740 total_21\JJ\1740 population_22\NN\7942152 )_23\-RRB-\1740 who_24\WP\8299493 developed_25\VBD\1753788 major_26\JJ\1740 <e2>toxicity</e2>_27\NN\13576101 resulting_28\VBG\2633881 in_29\IN\13603305 fanconi_30\NNP\1740 's_31\POS\1740 syndrome_32\NN\5870365 (_33\-LRB-\1740 tdfs_34\NN\1740 )_35\-RRB-\1740 ;_36\:\1740 and_37\CC\1740 the_38\DT\1740 second_39\JJ\1740 group_40\NN\2137 included_41\VBD\690614 five_42\CD\13741022 patients_43\NNS\9898892 with_44\IN\1740 elevated_45\JJ\1740 beta_46\NN\6828818 2_47\CD\13741022 microglobulinuria_48\NN\1740 and_49\CC\1740 low_50\JJ\1740 <e1>phosphate</e1>_51\NN\15010703 reabsorption_52\NN\13526110 ._53\.\1740
D010710_D005198 NONE two_0\CD\13741022 subsets_1\NNS\7999699 of_2\IN\1740 patients_3\NNS\9898892 were_4\VBD\836236 identified_5\VBN\699815 from_6\IN\1740 this_7\DT\1740 latter_8\JJ\1740 group_9\NN\2137 :_10\:\1740 the_11\DT\1740 first_12\RB\1740 included_13\VBN\690614 four_14\CD\13741022 patients_15\NNS\9898892 (_16\-LRB-\1740 5_17\CD\13741022 %_18\NN\1740 of_19\IN\1740 the_20\DT\1740 total_21\JJ\1740 population_22\NN\7942152 )_23\-RRB-\1740 who_24\WP\8299493 developed_25\VBD\1753788 major_26\JJ\1740 toxicity_27\NN\13576101 resulting_28\VBG\2633881 in_29\IN\13603305 <e2>fanconi_30\NNP\1740 's_31\POS\1740 syndrome</e2>_32\NN\5870365 (_33\-LRB-\1740 tdfs_34\NN\1740 )_35\-RRB-\1740 ;_36\:\1740 and_37\CC\1740 the_38\DT\1740 second_39\JJ\1740 group_40\NN\2137 included_41\VBD\690614 five_42\CD\13741022 patients_43\NNS\9898892 with_44\IN\1740 elevated_45\JJ\1740 beta_46\NN\6828818 2_47\CD\13741022 microglobulinuria_48\NN\1740 and_49\CC\1740 low_50\JJ\1740 <e1>phosphate</e1>_51\NN\15010703 reabsorption_52\NN\13526110 ._53\.\1740
D010710_D005198 NONE two_0\CD\13741022 subsets_1\NNS\7999699 of_2\IN\1740 patients_3\NNS\9898892 were_4\VBD\836236 identified_5\VBN\699815 from_6\IN\1740 this_7\DT\1740 latter_8\JJ\1740 group_9\NN\2137 :_10\:\1740 the_11\DT\1740 first_12\RB\1740 included_13\VBN\690614 four_14\CD\13741022 patients_15\NNS\9898892 (_16\-LRB-\1740 5_17\CD\13741022 %_18\NN\1740 of_19\IN\1740 the_20\DT\1740 total_21\JJ\1740 population_22\NN\7942152 )_23\-RRB-\1740 who_24\WP\8299493 developed_25\VBD\1753788 major_26\JJ\1740 toxicity_27\NN\13576101 resulting_28\VBG\2633881 in_29\IN\13603305 fanconi_30\NNP\1740 's_31\POS\1740 syndrome_32\NN\5870365 (_33\-LRB-\1740 <e2>tdfs</e2>_34\NN\1740 )_35\-RRB-\1740 ;_36\:\1740 and_37\CC\1740 the_38\DT\1740 second_39\JJ\1740 group_40\NN\2137 included_41\VBD\690614 five_42\CD\13741022 patients_43\NNS\9898892 with_44\IN\1740 elevated_45\JJ\1740 beta_46\NN\6828818 2_47\CD\13741022 microglobulinuria_48\NN\1740 and_49\CC\1740 low_50\JJ\1740 <e1>phosphate</e1>_51\NN\15010703 reabsorption_52\NN\13526110 ._53\.\1740
D007069_D064420 NONE severe_0\JJ\1740 <e2>toxicity</e2>_1\NN\13576101 was_2\VBD\836236 correlated_3\VBN\2657219 with_4\IN\1740 the_5\DT\1740 higher_6\JJR\1740 cumulative_7\JJ\1740 dose_8\NN\3740161 of_9\IN\1740 60_10\CD\13745420 g/m2_11\NN\1740 of_12\IN\1740 <e1>ifosfamide</e1>_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 younger_16\JJR\1740 age_17\NN\4916342 (_18\-LRB-\1740 less_19\JJR\1740 than_20\IN\1740 2_21\CD\13741022 1/2_22\CD\1740 years_23\NNS\15144371 old_24\JJ\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 a_28\DT\13649268 predominance_29\NN\14441825 of_30\IN\1740 vesicoprostatic_31\JJ\1740 tumor_32\NN\14234074 involvement_33\NN\1080366 ._34\.\1740
D007069_D009369 NONE severe_0\JJ\1740 toxicity_1\NN\13576101 was_2\VBD\836236 correlated_3\VBN\2657219 with_4\IN\1740 the_5\DT\1740 higher_6\JJR\1740 cumulative_7\JJ\1740 dose_8\NN\3740161 of_9\IN\1740 60_10\CD\13745420 g/m2_11\NN\1740 of_12\IN\1740 <e1>ifosfamide</e1>_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 younger_16\JJR\1740 age_17\NN\4916342 (_18\-LRB-\1740 less_19\JJR\1740 than_20\IN\1740 2_21\CD\13741022 1/2_22\CD\1740 years_23\NNS\15144371 old_24\JJ\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 a_28\DT\13649268 predominance_29\NN\14441825 of_30\IN\1740 vesicoprostatic_31\JJ\1740 <e2>tumor</e2>_32\NN\14234074 involvement_33\NN\1080366 ._34\.\1740
9245658
D009538_D002318 CID the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 <e1>nicotine</e1>_3\NN\14712692 in_4\IN\13603305 smoking-related_5\JJ\1740 <e2>cardiovascular_6\JJ\1740 disease</e2>_7\NN\14061805 ._8\.\1740
D009538_D002318 CID <e1>nicotine</e1>_0\NN\14712692 activates_1\VBZ\1641914 the_2\DT\1740 sympathetic_3\JJ\1740 nervous_4\JJ\1740 system_5\NN\3575240 and_6\CC\1740 in_7\IN\13603305 this_8\DT\1740 way_9\NN\4916342 could_10\MD\1740 contribute_11\VB\126264 to_12\TO\1740 <e2>cardiovascular_13\JJ\1740 disease</e2>_14\NN\14061805 ._15\.\1740
D009538_D050197 CID animal_0\JJ\1740 studies_1\NNS\635850 and_2\CC\1740 mechanistic_3\JJ\1740 studies_4\NNS\635850 indicate_5\VBP\952524 that_6\IN\1740 <e1>nicotine</e1>_7\NN\14712692 could_8\MD\1740 play_9\VB\1072262 a_10\DT\13649268 role_11\NN\719494 in_12\IN\13603305 accelerating_13\VBG\226566 <e2>atherosclerosis</e2>_14\NN\14108324 ,_15\,\1740 but_16\CC\1740 evidence_17\NN\5816287 among_18\IN\1740 humans_19\NNS\31264 is_20\VBZ\836236 too_21\RB\1740 inadequate_22\JJ\1740 to_23\TO\1740 be_24\VB\836236 definitive_25\JJ\1740 about_26\IN\1740 such_27\PDT\1740 an_28\DT\6697703 effect_29\NN\34213 ._30\.\1740
D009538_D013927 NONE <e1>nicotine</e1>_0\NN\14712692 does_1\VBZ\1640855 not_2\RB\1740 appear_3\VB\2604760 to_4\TO\1740 enhance_5\VB\227165 <e2>thrombosis</e2>_6\NN\14100769 among_7\IN\1740 humans_8\NNS\31264 ._9\.\1740
9746003
D002220_D004832 CID inappropriate_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 <e1>carbamazepine</e1>_3\NN\1740 and_4\CC\1740 vigabatrin_5\NN\1740 in_6\IN\13603305 typical_7\JJ\1740 <e2>absence_8\NN\14449405 seizures</e2>_9\NNS\14081375 ._10\.\1740
D002220_D004832 CID <e1>carbamazepine</e1>_0\NNP\1740 and_1\CC\1740 vigabatrin_2\NN\1740 are_3\VBP\836236 contraindicated_4\VBN\872886 in_5\IN\13603305 typical_6\JJ\1740 <e2>absence_7\NN\14449405 seizures</e2>_8\NNS\14081375 ._9\.\1740
D020888_D004832 CID inappropriate_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 carbamazepine_3\NN\1740 and_4\CC\1740 <e1>vigabatrin</e1>_5\NN\1740 in_6\IN\13603305 typical_7\JJ\1740 <e2>absence_8\NN\14449405 seizures</e2>_9\NNS\14081375 ._10\.\1740
D020888_D004832 CID carbamazepine_0\NNP\1740 and_1\CC\1740 <e1>vigabatrin</e1>_2\NN\1740 are_3\VBP\836236 contraindicated_4\VBN\872886 in_5\IN\13603305 typical_6\JJ\1740 <e2>absence_7\NN\14449405 seizures</e2>_8\NNS\14081375 ._9\.\1740
D002220_D009207 CID frequency_0\NN\15286249 of_1\IN\1740 absences_2\NNS\14449405 increased_3\VBD\169651 in_4\IN\13603305 four_5\CD\13741022 children_6\NNS\9622049 treated_7\VBN\2376958 with_8\IN\1740 <e1>carbamazepine</e1>_9\NN\1740 and_10\CC\1740 two_11\CD\13741022 of_12\IN\1740 these_13\DT\1740 developed_14\VBN\1753788 <e2>myoclonic_15\JJ\1740 jerks</e2>_16\NNS\10322238 ,_17\,\1740 which_18\WDT\1740 resolved_19\VBD\352826 on_20\IN\1740 withdrawal_21\NN\7206096 of_22\IN\1740 carbamazepine_23\NN\1740 ._24\.\1740
D002220_D009207 CID frequency_0\NN\15286249 of_1\IN\1740 absences_2\NNS\14449405 increased_3\VBD\169651 in_4\IN\13603305 four_5\CD\13741022 children_6\NNS\9622049 treated_7\VBN\2376958 with_8\IN\1740 carbamazepine_9\NN\1740 and_10\CC\1740 two_11\CD\13741022 of_12\IN\1740 these_13\DT\1740 developed_14\VBN\1753788 <e2>myoclonic_15\JJ\1740 jerks</e2>_16\NNS\10322238 ,_17\,\1740 which_18\WDT\1740 resolved_19\VBD\352826 on_20\IN\1740 withdrawal_21\NN\7206096 of_22\IN\1740 <e1>carbamazepine</e1>_23\NN\1740 ._24\.\1740
18081909
C026098_D001927 CID <e2>encephalopathy</e2>_0\NNP\14084880 induced_1\VBN\1627355 by_2\IN\1740 <e1>levetiracetam</e1>_3\NN\1740 added_4\VBN\156601 to_5\TO\1740 valproate_6\VB\1740 ._7\.\1740
C026098_D001927 CID background_0\NN\4921011 :_1\:\1740 we_2\PRP\1740 report_3\VBP\831651 on_4\IN\1740 the_5\DT\1740 manifestation_6\NN\7321772 of_7\IN\1740 a_8\DT\13649268 <e1>levetiracetam</e1>_9\NN\1740 (lev)-induced_10\NN\1740 <e2>encephalopathy</e2>_11\JJ\1740 ._12\.\1740
C026098_D001927 CID background_0\NN\4921011 :_1\:\1740 we_2\PRP\1740 report_3\VBP\831651 on_4\IN\1740 the_5\DT\1740 manifestation_6\NN\7321772 of_7\IN\1740 a_8\DT\13649268 levetiracetam_9\NN\1740 <e1>(lev)-induced</e1>_10\NN\1740 <e2>encephalopathy</e2>_11\JJ\1740 ._12\.\1740
D014635_D001927 CID <e2>encephalopathy</e2>_0\NNP\14084880 induced_1\VBN\1627355 by_2\IN\1740 levetiracetam_3\NN\1740 added_4\VBN\156601 to_5\TO\1740 <e1>valproate</e1>_6\VB\1740 ._7\.\1740
C026098_C562694 NONE findings_0\NNS\7951464 :_1\:\1740 a_2\DT\13649268 28-year-old_3\JJ\1740 man_4\NN\9605289 suffering_5\VBG\2110220 from_6\IN\1740 <e2>idiopathic_7\JJ\1740 epilepsy</e2>_8\NN\14085708 with_9\IN\1740 generalized_10\JJ\1740 seizures_11\NNS\14081375 was_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 <e1>lev</e1>_15\NN\13685678 (_16\-LRB-\1740 3000_17\CD\1740 mg_18\NN\13717155 )_19\-RRB-\1740 added_20\VBN\156601 to_21\TO\1740 valproate_22\VB\1740 (_23\-LRB-\1740 vpa_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 2000_27\CD\1740 mg_28\NN\13717155 )_29\-RRB-\1740 ._30\.\1740
C026098_D012640 NONE findings_0\NNS\7951464 :_1\:\1740 a_2\DT\13649268 28-year-old_3\JJ\1740 man_4\NN\9605289 suffering_5\VBG\2110220 from_6\IN\1740 idiopathic_7\JJ\1740 epilepsy_8\NN\14085708 with_9\IN\1740 generalized_10\JJ\1740 <e2>seizures</e2>_11\NNS\14081375 was_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 <e1>lev</e1>_15\NN\13685678 (_16\-LRB-\1740 3000_17\CD\1740 mg_18\NN\13717155 )_19\-RRB-\1740 added_20\VBN\156601 to_21\TO\1740 valproate_22\VB\1740 (_23\-LRB-\1740 vpa_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 2000_27\CD\1740 mg_28\NN\13717155 )_29\-RRB-\1740 ._30\.\1740
C026098_D012640 NONE outcome_0\NN\7291312 :_1\:\1740 following_2\VBG\1835496 discontinuation_3\NN\209943 of_4\IN\1740 <e1>lev</e1>_5\NN\13685678 ,_6\,\1740 eeg_7\NN\7000195 and_8\CC\1740 neuropsychological_9\JJ\1740 findings_10\NNS\7951464 improved_11\VBD\126264 and_12\CC\1740 <e2>seizure</e2>_13\JJ\1740 frequency_14\NN\15286249 decreased_15\VBD\169651 ._16\.\1740
D014635_C562694 NONE findings_0\NNS\7951464 :_1\:\1740 a_2\DT\13649268 28-year-old_3\JJ\1740 man_4\NN\9605289 suffering_5\VBG\2110220 from_6\IN\1740 <e2>idiopathic_7\JJ\1740 epilepsy</e2>_8\NN\14085708 with_9\IN\1740 generalized_10\JJ\1740 seizures_11\NNS\14081375 was_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 lev_15\NN\13685678 (_16\-LRB-\1740 3000_17\CD\1740 mg_18\NN\13717155 )_19\-RRB-\1740 added_20\VBN\156601 to_21\TO\1740 <e1>valproate</e1>_22\VB\1740 (_23\-LRB-\1740 vpa_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 2000_27\CD\1740 mg_28\NN\13717155 )_29\-RRB-\1740 ._30\.\1740
D014635_C562694 NONE findings_0\NNS\7951464 :_1\:\1740 a_2\DT\13649268 28-year-old_3\JJ\1740 man_4\NN\9605289 suffering_5\VBG\2110220 from_6\IN\1740 <e2>idiopathic_7\JJ\1740 epilepsy</e2>_8\NN\14085708 with_9\IN\1740 generalized_10\JJ\1740 seizures_11\NNS\14081375 was_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 lev_15\NN\13685678 (_16\-LRB-\1740 3000_17\CD\1740 mg_18\NN\13717155 )_19\-RRB-\1740 added_20\VBN\156601 to_21\TO\1740 valproate_22\VB\1740 (_23\-LRB-\1740 <e1>vpa</e1>_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 2000_27\CD\1740 mg_28\NN\13717155 )_29\-RRB-\1740 ._30\.\1740
D014635_D012640 NONE findings_0\NNS\7951464 :_1\:\1740 a_2\DT\13649268 28-year-old_3\JJ\1740 man_4\NN\9605289 suffering_5\VBG\2110220 from_6\IN\1740 idiopathic_7\JJ\1740 epilepsy_8\NN\14085708 with_9\IN\1740 generalized_10\JJ\1740 <e2>seizures</e2>_11\NNS\14081375 was_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 lev_15\NN\13685678 (_16\-LRB-\1740 3000_17\CD\1740 mg_18\NN\13717155 )_19\-RRB-\1740 added_20\VBN\156601 to_21\TO\1740 <e1>valproate</e1>_22\VB\1740 (_23\-LRB-\1740 vpa_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 2000_27\CD\1740 mg_28\NN\13717155 )_29\-RRB-\1740 ._30\.\1740
D014635_D012640 NONE findings_0\NNS\7951464 :_1\:\1740 a_2\DT\13649268 28-year-old_3\JJ\1740 man_4\NN\9605289 suffering_5\VBG\2110220 from_6\IN\1740 idiopathic_7\JJ\1740 epilepsy_8\NN\14085708 with_9\IN\1740 generalized_10\JJ\1740 <e2>seizures</e2>_11\NNS\14081375 was_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 lev_15\NN\13685678 (_16\-LRB-\1740 3000_17\CD\1740 mg_18\NN\13717155 )_19\-RRB-\1740 added_20\VBN\156601 to_21\TO\1740 valproate_22\VB\1740 (_23\-LRB-\1740 <e1>vpa</e1>_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 2000_27\CD\1740 mg_28\NN\13717155 )_29\-RRB-\1740 ._30\.\1740
20520283
C522667_D012559 NONE efficacy_0\NNP\5199286 and_1\CC\1740 safety_2\NN\13920835 of_3\IN\1740 <e1>asenapine</e1>_4\NN\1740 in_5\IN\13603305 a_6\DT\13649268 placebo-_7\NN\1740 and_8\CC\1740 haloperidol-controlled_9\JJ\1740 trial_10\NN\786195 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 acute_14\JJ\1740 exacerbation_15\NN\374224 of_16\IN\1740 <e2>schizophrenia</e2>_17\NN\14398067 ._18\.\1740
C522667_D012559 NONE <e1>asenapine</e1>_0\NNP\1740 is_1\VBZ\836236 approved_2\VBN\803325 by_3\IN\1740 the_4\DT\1740 food_5\NNP\20090 and_6\CC\1740 drugs_7\NNP\14778436 administration_8\NNP\1133281 in_9\IN\13603305 adults_10\NNS\7846 for_11\IN\1740 acute_12\JJ\1740 treatment_13\NN\654885 of_14\IN\1740 <e2>schizophrenia</e2>_15\NN\14398067 or_16\CC\3541091 of_17\IN\1740 manic_18\JJ\1740 or_19\CC\3541091 mixed_20\JJ\1740 episodes_21\NNS\7283608 associated_22\VBN\628491 with_23\IN\1740 bipolar_24\JJ\1740 i_25\CD\14622893 disorder_26\NN\14034177 with_27\IN\1740 or_28\CC\3541091 without_29\IN\1740 psychotic_30\JJ\1740 features_31\NNS\5849040 ._32\.\1740
C522667_D012559 NONE in_0\IN\13603305 a_1\DT\13649268 double-blind_2\JJ\1740 6-week_3\JJ\1740 trial_4\NN\786195 ,_5\,\1740 458_6\CD\1740 patients_7\NNS\9898892 with_8\IN\1740 acute_9\JJ\1740 <e2>schizophrenia</e2>_10\NN\14398067 were_11\VBD\836236 randomly_12\RB\1740 assigned_13\VBN\2475922 to_14\TO\1740 fixed-dose_15\JJ\1740 treatment_16\NN\654885 with_17\IN\1740 <e1>asenapine</e1>_18\NN\1740 at_19\IN\14622893 5_20\CD\13741022 mg_21\NN\13717155 twice_22\RB\1740 daily_23\RB\1740 (_24\-LRB-\1740 bid_25\NN\7160883 )_26\-RRB-\1740 ,_27\,\1740 asenapine_28\NN\1740 at_29\IN\14622893 10_30\CD\13745420 mg_31\NN\13717155 bid_32\NN\7160883 ,_33\,\1740 placebo_34\NN\3740161 ,_35\,\1740 or_36\CC\3541091 haloperidol_37\VB\1740 at_38\IN\14622893 4_39\CD\13741022 mg_40\NN\13717155 bid_41\NN\7160883 (_42\-LRB-\1740 to_43\TO\1740 verify_44\VB\665886 assay_45\NN\5733583 sensitivity_46\NN\5651971 )_47\-RRB-\1740 ._48\.\1740
C522667_D012559 NONE in_0\IN\13603305 a_1\DT\13649268 double-blind_2\JJ\1740 6-week_3\JJ\1740 trial_4\NN\786195 ,_5\,\1740 458_6\CD\1740 patients_7\NNS\9898892 with_8\IN\1740 acute_9\JJ\1740 <e2>schizophrenia</e2>_10\NN\14398067 were_11\VBD\836236 randomly_12\RB\1740 assigned_13\VBN\2475922 to_14\TO\1740 fixed-dose_15\JJ\1740 treatment_16\NN\654885 with_17\IN\1740 asenapine_18\NN\1740 at_19\IN\14622893 5_20\CD\13741022 mg_21\NN\13717155 twice_22\RB\1740 daily_23\RB\1740 (_24\-LRB-\1740 bid_25\NN\7160883 )_26\-RRB-\1740 ,_27\,\1740 <e1>asenapine</e1>_28\NN\1740 at_29\IN\14622893 10_30\CD\13745420 mg_31\NN\13717155 bid_32\NN\7160883 ,_33\,\1740 placebo_34\NN\3740161 ,_35\,\1740 or_36\CC\3541091 haloperidol_37\VB\1740 at_38\IN\14622893 4_39\CD\13741022 mg_40\NN\13717155 bid_41\NN\7160883 (_42\-LRB-\1740 to_43\TO\1740 verify_44\VB\665886 assay_45\NN\5733583 sensitivity_46\NN\5651971 )_47\-RRB-\1740 ._48\.\1740
D006220_D012559 NONE efficacy_0\NNP\5199286 and_1\CC\1740 safety_2\NN\13920835 of_3\IN\1740 asenapine_4\NN\1740 in_5\IN\13603305 a_6\DT\13649268 placebo-_7\NN\1740 and_8\CC\1740 <e1>haloperidol-controlled</e1>_9\JJ\1740 trial_10\NN\786195 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 acute_14\JJ\1740 exacerbation_15\NN\374224 of_16\IN\1740 <e2>schizophrenia</e2>_17\NN\14398067 ._18\.\1740
D006220_D012559 NONE in_0\IN\13603305 a_1\DT\13649268 double-blind_2\JJ\1740 6-week_3\JJ\1740 trial_4\NN\786195 ,_5\,\1740 458_6\CD\1740 patients_7\NNS\9898892 with_8\IN\1740 acute_9\JJ\1740 <e2>schizophrenia</e2>_10\NN\14398067 were_11\VBD\836236 randomly_12\RB\1740 assigned_13\VBN\2475922 to_14\TO\1740 fixed-dose_15\JJ\1740 treatment_16\NN\654885 with_17\IN\1740 asenapine_18\NN\1740 at_19\IN\14622893 5_20\CD\13741022 mg_21\NN\13717155 twice_22\RB\1740 daily_23\RB\1740 (_24\-LRB-\1740 bid_25\NN\7160883 )_26\-RRB-\1740 ,_27\,\1740 asenapine_28\NN\1740 at_29\IN\14622893 10_30\CD\13745420 mg_31\NN\13717155 bid_32\NN\7160883 ,_33\,\1740 placebo_34\NN\3740161 ,_35\,\1740 or_36\CC\3541091 <e1>haloperidol</e1>_37\VB\1740 at_38\IN\14622893 4_39\CD\13741022 mg_40\NN\13717155 bid_41\NN\7160883 (_42\-LRB-\1740 to_43\TO\1740 verify_44\VB\665886 assay_45\NN\5733583 sensitivity_46\NN\5651971 )_47\-RRB-\1740 ._48\.\1740
C522667_D001714 NONE <e1>asenapine</e1>_0\NNP\1740 is_1\VBZ\836236 approved_2\VBN\803325 by_3\IN\1740 the_4\DT\1740 food_5\NNP\20090 and_6\CC\1740 drugs_7\NNP\14778436 administration_8\NNP\1133281 in_9\IN\13603305 adults_10\NNS\7846 for_11\IN\1740 acute_12\JJ\1740 treatment_13\NN\654885 of_14\IN\1740 schizophrenia_15\NN\14398067 or_16\CC\3541091 of_17\IN\1740 <e2>manic</e2>_18\JJ\1740 or_19\CC\3541091 mixed_20\JJ\1740 episodes_21\NNS\7283608 associated_22\VBN\628491 with_23\IN\1740 bipolar_24\JJ\1740 i_25\CD\14622893 disorder_26\NN\14034177 with_27\IN\1740 or_28\CC\3541091 without_29\IN\1740 psychotic_30\JJ\1740 features_31\NNS\5849040 ._32\.\1740
C522667_D001714 NONE <e1>asenapine</e1>_0\NNP\1740 is_1\VBZ\836236 approved_2\VBN\803325 by_3\IN\1740 the_4\DT\1740 food_5\NNP\20090 and_6\CC\1740 drugs_7\NNP\14778436 administration_8\NNP\1133281 in_9\IN\13603305 adults_10\NNS\7846 for_11\IN\1740 acute_12\JJ\1740 treatment_13\NN\654885 of_14\IN\1740 schizophrenia_15\NN\14398067 or_16\CC\3541091 of_17\IN\1740 manic_18\JJ\1740 or_19\CC\3541091 mixed_20\JJ\1740 episodes_21\NNS\7283608 associated_22\VBN\628491 with_23\IN\1740 <e2>bipolar_24\JJ\1740 i_25\CD\14622893 disorder</e2>_26\NN\14034177 with_27\IN\1740 or_28\CC\3541091 without_29\IN\1740 psychotic_30\JJ\1740 features_31\NNS\5849040 ._32\.\1740
C522667_D011618 NONE <e1>asenapine</e1>_0\NNP\1740 is_1\VBZ\836236 approved_2\VBN\803325 by_3\IN\1740 the_4\DT\1740 food_5\NNP\20090 and_6\CC\1740 drugs_7\NNP\14778436 administration_8\NNP\1133281 in_9\IN\13603305 adults_10\NNS\7846 for_11\IN\1740 acute_12\JJ\1740 treatment_13\NN\654885 of_14\IN\1740 schizophrenia_15\NN\14398067 or_16\CC\3541091 of_17\IN\1740 manic_18\JJ\1740 or_19\CC\3541091 mixed_20\JJ\1740 episodes_21\NNS\7283608 associated_22\VBN\628491 with_23\IN\1740 bipolar_24\JJ\1740 i_25\CD\14622893 disorder_26\NN\14034177 with_27\IN\1740 or_28\CC\3541091 without_29\IN\1740 <e2>psychotic</e2>_30\JJ\1740 features_31\NNS\5849040 ._32\.\1740
C522667_D001480 CID <e2>extrapyramidal_0\JJ\1740 symptoms</e2>_1\NNS\5823932 reported_2\VBN\831651 as_3\IN\14622893 aes_4\NN\1740 occurred_5\VBD\2623529 in_6\IN\13603305 15_7\CD\13745420 %_8\NN\1740 and_9\CC\1740 18_10\CD\13745420 %_11\NN\1740 ,_12\,\1740 34_13\CD\1740 %_14\NN\1740 ,_15\,\1740 and_16\CC\1740 10_17\CD\13745420 %_18\NN\1740 of_19\IN\1740 the_20\DT\1740 <e1>asenapine</e1>_21\NN\1740 at_22\IN\14622893 5_23\CD\13741022 and_24\CC\1740 10_25\CD\13745420 mg_26\NN\13717155 bid_27\NN\7160883 ,_28\,\1740 haloperidol_29\VB\1740 ,_30\,\1740 and_31\CC\1740 placebo_32\JJ\1740 groups_33\NNS\2137 ,_34\,\1740 respectively_35\RB\1740 ._36\.\1740
C522667_D001480 CID post_0\NN\8621598 hoc_1\NN\1740 analyses_2\NNS\633864 indicated_3\VBD\952524 that_4\IN\1740 efficacy_5\NN\5199286 was_6\VBD\836236 similar_7\JJ\1740 with_8\IN\1740 <e1>asenapine</e1>_9\NN\1740 and_10\CC\1740 haloperidol_11\VB\1740 ;_12\:\1740 greater_13\JJR\1740 contrasts_14\NNS\13854649 were_15\VBD\836236 seen_16\VBN\2106506 in_17\IN\13603305 aes_18\NNS\1740 ,_19\,\1740 especially_20\RB\1740 <e2>extrapyramidal_21\JJ\1740 symptoms</e2>_22\NNS\5823932 ._23\.\1740
D006220_D001480 CID <e2>extrapyramidal_0\JJ\1740 symptoms</e2>_1\NNS\5823932 reported_2\VBN\831651 as_3\IN\14622893 aes_4\NN\1740 occurred_5\VBD\2623529 in_6\IN\13603305 15_7\CD\13745420 %_8\NN\1740 and_9\CC\1740 18_10\CD\13745420 %_11\NN\1740 ,_12\,\1740 34_13\CD\1740 %_14\NN\1740 ,_15\,\1740 and_16\CC\1740 10_17\CD\13745420 %_18\NN\1740 of_19\IN\1740 the_20\DT\1740 asenapine_21\NN\1740 at_22\IN\14622893 5_23\CD\13741022 and_24\CC\1740 10_25\CD\13745420 mg_26\NN\13717155 bid_27\NN\7160883 ,_28\,\1740 <e1>haloperidol</e1>_29\VB\1740 ,_30\,\1740 and_31\CC\1740 placebo_32\JJ\1740 groups_33\NNS\2137 ,_34\,\1740 respectively_35\RB\1740 ._36\.\1740
D006220_D001480 CID post_0\NN\8621598 hoc_1\NN\1740 analyses_2\NNS\633864 indicated_3\VBD\952524 that_4\IN\1740 efficacy_5\NN\5199286 was_6\VBD\836236 similar_7\JJ\1740 with_8\IN\1740 asenapine_9\NN\1740 and_10\CC\1740 <e1>haloperidol</e1>_11\VB\1740 ;_12\:\1740 greater_13\JJR\1740 contrasts_14\NNS\13854649 were_15\VBD\836236 seen_16\VBN\2106506 in_17\IN\13603305 aes_18\NNS\1740 ,_19\,\1740 especially_20\RB\1740 <e2>extrapyramidal_21\JJ\1740 symptoms</e2>_22\NNS\5823932 ._23\.\1740
7504976
D002231_D056486 CID <e2>toxic_0\JJ\1740 hepatitis</e2>_1\NN\14127211 induced_2\VBN\1627355 by_3\IN\1740 antithyroid_4\NN\1740 drugs_5\NNS\14778436 :_6\:\1740 four_7\CD\13741022 cases_8\NNS\7283608 including_9\VBG\690614 one_10\CD\13741022 with_11\IN\1740 cross-reactivity_12\NN\1740 between_13\IN\1740 <e1>carbimazole</e1>_14\NN\1740 and_15\CC\1740 benzylthiouracil_16\NN\1740 ._17\.\1740
D002231_D056486 CID two_0\CD\13741022 patients_1\NNS\9898892 had_2\VBD\2108377 a_3\DT\13649268 <e2>cholestatic_4\JJ\1740 hepatitis</e2>_5\NN\14127211 induced_6\VBN\1627355 by_7\IN\1740 <e1>carbimazole</e1>_8\NN\1740 (_9\-LRB-\1740 n_10\NN\14622893 omercazole_11\NN\1740 )_12\-RRB-\1740 ._13\.\1740
D002231_D056486 CID two_0\CD\13741022 patients_1\NNS\9898892 had_2\VBD\2108377 a_3\DT\13649268 <e2>cholestatic_4\JJ\1740 hepatitis</e2>_5\NN\14127211 induced_6\VBN\1627355 by_7\IN\1740 carbimazole_8\NN\1740 (_9\-LRB-\1740 <e1>n_10\NN\14622893 omercazole</e1>_11\NN\1740 )_12\-RRB-\1740 ._13\.\1740
D002231_D056486 CID two_0\CD\13741022 others_1\NNS\1740 had_2\VBD\2108377 a_3\DT\13649268 mixed_4\JJ\1740 (_5\-LRB-\1740 cholestatic_6\JJ\1740 and_7\CC\1740 cytolytic_8\JJ\1740 )_9\-RRB-\1740 <e2>hepatitis</e2>_10\NN\14127211 following_11\VBG\1835496 <e1>carbimazole</e1>_12\NN\1740 ._13\.\1740
D002231_D056486 CID one_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 latter_3\JJ\1740 two_4\CD\13741022 patients_5\NNS\9898892 further_6\RB\1740 experienced_7\VBD\2108377 a_8\DT\13649268 cytolytic_9\JJ\1740 <e2>hepatitis</e2>_10\NN\14127211 which_11\WDT\1740 appeared_12\VBD\2604760 after_13\IN\1740 benzylthiouracil_14\NNP\1740 (_15\-LRB-\1740 basd_16\NNP\1740 ne_17\NN\14622893 )_18\-RRB-\1740 had_19\VBD\2108377 replaced_20\VBN\1631072 <e1>carbimazole</e1>_21\NN\1740 ._22\.\1740
C019269_D056486 NONE <e2>toxic_0\JJ\1740 hepatitis</e2>_1\NN\14127211 induced_2\VBN\1627355 by_3\IN\1740 antithyroid_4\NN\1740 drugs_5\NNS\14778436 :_6\:\1740 four_7\CD\13741022 cases_8\NNS\7283608 including_9\VBG\690614 one_10\CD\13741022 with_11\IN\1740 cross-reactivity_12\NN\1740 between_13\IN\1740 carbimazole_14\NN\1740 and_15\CC\1740 <e1>benzylthiouracil</e1>_16\NN\1740 ._17\.\1740
C019269_D056486 NONE one_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 latter_3\JJ\1740 two_4\CD\13741022 patients_5\NNS\9898892 further_6\RB\1740 experienced_7\VBD\2108377 a_8\DT\13649268 cytolytic_9\JJ\1740 <e2>hepatitis</e2>_10\NN\14127211 which_11\WDT\1740 appeared_12\VBD\2604760 after_13\IN\1740 <e1>benzylthiouracil</e1>_14\NNP\1740 (_15\-LRB-\1740 basd_16\NNP\1740 ne_17\NN\14622893 )_18\-RRB-\1740 had_19\VBD\2108377 replaced_20\VBN\1631072 carbimazole_21\NN\1740 ._22\.\1740
C019269_D056486 NONE one_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 latter_3\JJ\1740 two_4\CD\13741022 patients_5\NNS\9898892 further_6\RB\1740 experienced_7\VBD\2108377 a_8\DT\13649268 cytolytic_9\JJ\1740 <e2>hepatitis</e2>_10\NN\14127211 which_11\WDT\1740 appeared_12\VBD\2604760 after_13\IN\1740 benzylthiouracil_14\NNP\1740 (_15\-LRB-\1740 <e1>basd_16\NNP\1740 ne</e1>_17\NN\14622893 )_18\-RRB-\1740 had_19\VBD\2108377 replaced_20\VBN\1631072 carbimazole_21\NN\1740 ._22\.\1740
D002231_D002779 CID two_0\CD\13741022 patients_1\NNS\9898892 had_2\VBD\2108377 a_3\DT\13649268 <e2>cholestatic_4\JJ\1740 hepatitis</e2>_5\NN\14127211 induced_6\VBN\1627355 by_7\IN\1740 <e1>carbimazole</e1>_8\NN\1740 (_9\-LRB-\1740 n_10\NN\14622893 omercazole_11\NN\1740 )_12\-RRB-\1740 ._13\.\1740
D002231_D002779 CID two_0\CD\13741022 patients_1\NNS\9898892 had_2\VBD\2108377 a_3\DT\13649268 <e2>cholestatic_4\JJ\1740 hepatitis</e2>_5\NN\14127211 induced_6\VBN\1627355 by_7\IN\1740 carbimazole_8\NN\1740 (_9\-LRB-\1740 <e1>n_10\NN\14622893 omercazole</e1>_11\NN\1740 )_12\-RRB-\1740 ._13\.\1740
D002231_D002779 CID two_0\CD\13741022 others_1\NNS\1740 had_2\VBD\2108377 a_3\DT\13649268 mixed_4\JJ\1740 (_5\-LRB-\1740 <e2>cholestatic</e2>_6\JJ\1740 and_7\CC\1740 cytolytic_8\JJ\1740 )_9\-RRB-\1740 hepatitis_10\NN\14127211 following_11\VBG\1835496 <e1>carbimazole</e1>_12\NN\1740 ._13\.\1740
11007689
D016572_D057049 CID <e1>cyclosporine</e1>_0\NN\1740 and_1\CC\1740 tacrolimus-associated_2\JJ\1740 <e2>thrombotic_3\JJ\1740 microangiopathy</e2>_4\NN\1740 ._5\.\1740
D016572_D057049 CID the_0\DT\1740 development_1\NN\248977 of_2\IN\1740 <e2>thrombotic_3\JJ\1740 microangiopathy</e2>_4\NN\1740 (_5\-LRB-\1740 tma_6\NN\1740 )_7\-RRB-\1740 associated_8\VBN\628491 with_9\IN\1740 the_10\DT\1740 use_11\NN\407535 of_12\IN\1740 <e1>cyclosporine</e1>_13\NN\1740 has_14\VBZ\2108377 been_15\VBN\836236 well_16\RB\1740 documented_17\VBN\1000214 ._18\.\1740
D016572_D057049 CID the_0\DT\1740 development_1\NN\248977 of_2\IN\1740 thrombotic_3\JJ\1740 microangiopathy_4\NN\1740 (_5\-LRB-\1740 <e2>tma</e2>_6\NN\1740 )_7\-RRB-\1740 associated_8\VBN\628491 with_9\IN\1740 the_10\DT\1740 use_11\NN\407535 of_12\IN\1740 <e1>cyclosporine</e1>_13\NN\1740 has_14\VBZ\2108377 been_15\VBN\836236 well_16\RB\1740 documented_17\VBN\1000214 ._18\.\1740
D016572_D057049 CID as_0\IN\14622893 a_1\DT\13649268 result_2\NN\34213 ,_3\,\1740 switching_4\NN\191142 to_5\TO\1740 tacrolimus_6\NN\1740 has_7\VBZ\2108377 been_8\VBN\836236 reported_9\VBN\831651 to_10\TO\1740 be_11\VB\836236 a_12\DT\13649268 viable_13\JJ\1740 therapeutic_14\JJ\1740 option_15\NN\6480506 in_16\IN\13603305 the_17\DT\1740 setting_18\NN\8567235 of_19\IN\1740 <e1>cyclosporine-induced</e1>_20\JJ\1740 <e2>tma</e2>_21\NN\1740 ._22\.\1740
D016572_D057049 CID however_0\RB\1740 ,_1\,\1740 literature_2\NN\6362953 regarding_3\VBG\689344 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 the_7\DT\1740 recurrence_8\NN\7342049 of_9\IN\1740 <e2>tma</e2>_10\NN\1740 in_11\IN\13603305 patients_12\NNS\9898892 exposed_13\VBN\2110927 sequentially_14\RB\1740 to_15\TO\1740 <e1>cyclosporine</e1>_16\NN\1740 and_17\CC\1740 tacrolimus_18\NN\1740 is_19\VBZ\836236 limited_20\JJ\1740 ._21\.\1740
D016572_D057049 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 living_6\VBG\2655135 donor_7\NN\9608709 renal_8\JJ\1740 transplant_9\NN\5267548 recipient_10\NN\9764201 who_11\WP\8299493 developed_12\VBD\1753788 <e1>cyclosporine-induced</e1>_13\JJ\1740 <e2>tma</e2>_14\NN\1740 that_15\WDT\1740 responded_16\VBD\2367363 to_17\IN\1740 the_18\DT\1740 withdrawal_19\NN\7206096 of_20\IN\1740 cyclosporine_21\NN\1740 in_22\IN\13603305 conjunction_23\NN\5048123 with_24\IN\1740 plasmapheresis_25\NN\649992 and_26\CC\1740 fresh_27\JJ\1740 frozen_28\JJ\1740 plasma_29\NN\5398023 replacement_30\NN\196485 therapy_31\NN\657604 ._32\.\1740
D016572_D057049 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 living_6\VBG\2655135 donor_7\NN\9608709 renal_8\JJ\1740 transplant_9\NN\5267548 recipient_10\NN\9764201 who_11\WP\8299493 developed_12\VBD\1753788 cyclosporine-induced_13\JJ\1740 <e2>tma</e2>_14\NN\1740 that_15\WDT\1740 responded_16\VBD\2367363 to_17\IN\1740 the_18\DT\1740 withdrawal_19\NN\7206096 of_20\IN\1740 <e1>cyclosporine</e1>_21\NN\1740 in_22\IN\13603305 conjunction_23\NN\5048123 with_24\IN\1740 plasmapheresis_25\NN\649992 and_26\CC\1740 fresh_27\JJ\1740 frozen_28\JJ\1740 plasma_29\NN\5398023 replacement_30\NN\196485 therapy_31\NN\657604 ._32\.\1740
D016572_D057049 CID patients_0\NNS\9898892 who_1\WP\8299493 are_2\VBP\836236 switched_3\VBN\138508 from_4\IN\1740 <e1>cyclosporine</e1>_5\NN\1740 to_6\TO\1740 tacrolimus_7\NN\1740 or_8\CC\3541091 vice_9\RB\1740 versa_10\RB\1740 should_11\MD\1740 be_12\VB\836236 closely_13\RB\1740 monitored_14\VBN\2169352 for_15\IN\1740 the_16\DT\1740 signs_17\NNS\6643763 and_18\CC\1740 symptoms_19\NNS\5823932 of_20\IN\1740 recurrent_21\JJ\1740 <e2>tma</e2>_22\NN\1740 ._23\.\1740
D016559_D057049 CID cyclosporine_0\NN\1740 and_1\CC\1740 <e1>tacrolimus-associated</e1>_2\JJ\1740 <e2>thrombotic_3\JJ\1740 microangiopathy</e2>_4\NN\1740 ._5\.\1740
D016559_D057049 CID as_0\IN\14622893 a_1\DT\13649268 result_2\NN\34213 ,_3\,\1740 switching_4\NN\191142 to_5\TO\1740 <e1>tacrolimus</e1>_6\NN\1740 has_7\VBZ\2108377 been_8\VBN\836236 reported_9\VBN\831651 to_10\TO\1740 be_11\VB\836236 a_12\DT\13649268 viable_13\JJ\1740 therapeutic_14\JJ\1740 option_15\NN\6480506 in_16\IN\13603305 the_17\DT\1740 setting_18\NN\8567235 of_19\IN\1740 cyclosporine-induced_20\JJ\1740 <e2>tma</e2>_21\NN\1740 ._22\.\1740
D016559_D057049 CID with_0\IN\1740 the_1\DT\1740 more_2\RBR\1740 widespread_3\JJ\1740 application_4\NN\947128 of_5\IN\1740 <e1>tacrolimus</e1>_6\NN\1740 in_7\IN\13603305 organ_8\NN\5220461 transplantation_9\NN\671351 ,_10\,\1740 tacrolimus-associated_11\JJ\1740 <e2>tma</e2>_12\NN\1740 has_13\VBZ\2108377 also_14\RB\1740 been_15\VBN\836236 recognized_16\VBN\686447 ._17\.\1740
D016559_D057049 CID with_0\IN\1740 the_1\DT\1740 more_2\RBR\1740 widespread_3\JJ\1740 application_4\NN\947128 of_5\IN\1740 tacrolimus_6\NN\1740 in_7\IN\13603305 organ_8\NN\5220461 transplantation_9\NN\671351 ,_10\,\1740 <e1>tacrolimus-associated</e1>_11\JJ\1740 <e2>tma</e2>_12\NN\1740 has_13\VBZ\2108377 also_14\RB\1740 been_15\VBN\836236 recognized_16\VBN\686447 ._17\.\1740
D016559_D057049 CID however_0\RB\1740 ,_1\,\1740 literature_2\NN\6362953 regarding_3\VBG\689344 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 the_7\DT\1740 recurrence_8\NN\7342049 of_9\IN\1740 <e2>tma</e2>_10\NN\1740 in_11\IN\13603305 patients_12\NNS\9898892 exposed_13\VBN\2110927 sequentially_14\RB\1740 to_15\TO\1740 cyclosporine_16\NN\1740 and_17\CC\1740 <e1>tacrolimus</e1>_18\NN\1740 is_19\VBZ\836236 limited_20\JJ\1740 ._21\.\1740
D016559_D057049 CID introduction_0\NN\235435 of_1\IN\1740 <e1>tacrolimus</e1>_2\NN\1740 as_3\IN\14622893 an_4\DT\6697703 alternative_5\JJ\1740 immunosuppressive_6\JJ\1740 agent_7\NN\7347 resulted_8\VBD\2633881 in_9\IN\13603305 the_10\DT\1740 recurrence_11\NN\7342049 of_12\IN\1740 <e2>tma</e2>_13\NN\1740 and_14\CC\1740 the_15\DT\1740 subsequent_16\JJ\1740 loss_17\NN\13252973 of_18\IN\1740 the_19\DT\1740 renal_20\JJ\1740 allograft_21\NN\5582859 ._22\.\1740
D016559_D057049 CID patients_0\NNS\9898892 who_1\WP\8299493 are_2\VBP\836236 switched_3\VBN\138508 from_4\IN\1740 cyclosporine_5\NN\1740 to_6\TO\1740 <e1>tacrolimus</e1>_7\NN\1740 or_8\CC\3541091 vice_9\RB\1740 versa_10\RB\1740 should_11\MD\1740 be_12\VB\836236 closely_13\RB\1740 monitored_14\VBN\2169352 for_15\IN\1740 the_16\DT\1740 signs_17\NNS\6643763 and_18\CC\1740 symptoms_19\NNS\5823932 of_20\IN\1740 recurrent_21\JJ\1740 <e2>tma</e2>_22\NN\1740 ._23\.\1740
8682684
D000082_D007022 CID <e1>acetaminophen-induced</e1>_0\JJ\1740 <e2>hypotension</e2>_1\NN\14057371 ._2\.\1740
D000082_D007022 CID however_0\RB\1740 ,_1\,\1740 <e1>acetaminophen</e1>_2\RB\1740 has_3\VBZ\2108377 been_4\VBN\836236 demonstrated_5\VBN\2137132 to_6\TO\1740 produce_7\VB\1617192 symptoms_8\NNS\5823932 of_9\IN\1740 anaphylaxis_10\NN\14533203 ,_11\,\1740 including_12\VBG\690614 <e2>hypotension</e2>_13\NN\14057371 ,_14\,\1740 in_15\IN\13603305 sensitive_16\JJ\1740 individuals_17\NNS\7347 ._18\.\1740
D000082_D007022 CID this_0\DT\1740 article_1\NN\6367571 describes_2\VBZ\1001294 two_3\CD\13741022 critically_4\RB\1740 ill_5\JJ\1740 patients_6\NNS\9898892 in_7\IN\13603305 whom_8\WP\1740 transient_9\JJ\1740 episodes_10\NNS\7283608 of_11\IN\1740 <e2>hypotension</e2>_12\NN\14057371 reproducibly_13\RB\1740 developed_14\VBD\1753788 after_15\IN\1740 administration_16\NN\1133281 of_17\IN\1740 <e1>acetaminophen</e1>_18\NN\2707683 ._19\.\1740
D000082_D007022 CID the_0\DT\1740 reports_1\NNS\6470073 illustrate_2\VBP\955601 the_3\DT\1740 need_4\NN\13920835 for_5\IN\1740 clinicians_6\NNS\10462860 to_7\TO\1740 consider_8\VB\689344 <e1>acetaminophen</e1>_9\NN\2707683 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 <e2>hypotension</e2>_13\NN\14057371 of_14\IN\1740 unknown_15\JJ\1740 origin_16\NN\8620061 ._17\.\1740
D000082_D002318 NONE the_0\DT\1740 potential_1\NN\14481929 for_2\IN\1740 <e1>acetaminophen</e1>_3\NN\2707683 to_4\TO\1740 produce_5\VB\1617192 <e2>cardiovascular_6\JJ\1740 toxicities</e2>_7\NNS\13576101 is_8\VBZ\836236 very_9\RB\1740 low_10\JJ\1740 ._11\.\1740
D000082_D000707 NONE however_0\RB\1740 ,_1\,\1740 <e1>acetaminophen</e1>_2\RB\1740 has_3\VBZ\2108377 been_4\VBN\836236 demonstrated_5\VBN\2137132 to_6\TO\1740 produce_7\VB\1617192 symptoms_8\NNS\5823932 of_9\IN\1740 <e2>anaphylaxis</e2>_10\NN\14533203 ,_11\,\1740 including_12\VBG\690614 hypotension_13\NN\14057371 ,_14\,\1740 in_15\IN\13603305 sensitive_16\JJ\1740 individuals_17\NNS\7347 ._18\.\1740
D000082_D016638 NONE this_0\DT\1740 article_1\NN\6367571 describes_2\VBZ\1001294 two_3\CD\13741022 <e2>critically_4\RB\1740 ill</e2>_5\JJ\1740 patients_6\NNS\9898892 in_7\IN\13603305 whom_8\WP\1740 transient_9\JJ\1740 episodes_10\NNS\7283608 of_11\IN\1740 hypotension_12\NN\14057371 reproducibly_13\RB\1740 developed_14\VBD\1753788 after_15\IN\1740 administration_16\NN\1133281 of_17\IN\1740 <e1>acetaminophen</e1>_18\NN\2707683 ._19\.\1740
15737522
D002443_D001660 CID <e1>ceftriaxone-associated</e1>_0\JJ\1740 <e2>biliary_1\JJ\1740 pseudolithiasis</e2>_2\NN\1740 in_3\IN\13603305 paediatric_4\JJ\1740 surgical_5\JJ\1740 patients_6\NNS\9898892 ._7\.\1740
D002443_D001660 CID it_0\PRP\6125041 is_1\VBZ\836236 well_2\RB\1740 known_3\VBN\2110220 that_4\IN\1740 <e1>ceftriaxone</e1>_5\NN\2996840 leads_6\VBZ\1752884 to_7\TO\1740 <e2>pseudolithiasis</e2>_8\NN\1740 in_9\IN\13603305 some_10\DT\1740 patients_11\NNS\9898892 ._12\.\1740
D002443_D001660 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 prospectively_5\RB\1740 evaluated_6\VBD\670261 the_7\DT\1740 incidence_8\NN\13821570 and_9\CC\1740 clinical_10\JJ\1740 importance_11\NN\5138488 of_12\IN\1740 <e2>pseudolithiasis</e2>_13\NN\1740 in_14\IN\13603305 paediatric_15\JJ\1740 surgical_16\JJ\1740 patients_17\NNS\9898892 receiving_18\VBG\2210855 <e1>ceftriaxone</e1>_19\NN\2996840 treatment_20\NN\654885 ,_21\,\1740 who_22\WP\8299493 often_23\RB\1740 had_24\VBD\2108377 to_25\TO\1740 fast_26\VB\1196037 in_27\IN\13603305 the_28\DT\1740 post-operative_29\JJ\1740 period_30\NN\13575869 ._31\.\1740
19767176
C020972_D013226 NONE <e1>pyrrolidine_0\NNP\1740 dithiocarbamate</e1>_1\NN\1740 protects_2\VBZ\1127795 the_3\DT\1740 piriform_4\NN\1740 cortex_5\NN\5462674 in_6\IN\13603305 the_7\DT\1740 pilocarpine_8\NN\14712692 <e2>status_9\NN\24720 epilepticus</e2>_10\NN\1740 model_11\NN\5888929 ._12\.\1740
C020972_D013226 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>pdtc</e1>_3\NN\1740 on_4\IN\1740 <e2>status_5\NN\24720 epilepticus-associated</e2>_6\JJ\1740 cell_7\NN\3080309 loss_8\NN\13252973 in_9\IN\13603305 the_10\DT\1740 hippocampus_11\NN\5462674 and_12\CC\1740 piriform_13\NN\1740 cortex_14\NN\5462674 was_15\VBD\836236 evaluated_16\VBN\670261 in_17\IN\13603305 the_18\DT\1740 rat_19\NN\2329401 fractionated_20\VBD\1458973 pilocarpine_21\NN\14712692 model_22\NN\5888929 ._23\.\1740
C020972_D013226 NONE treatment_0\NN\654885 with_1\IN\1740 150_2\CD\1740 mg/kg_3\NN\1740 <e1>pdtc</e1>_4\NN\1740 before_5\IN\1740 and_6\CC\1740 following_7\VBG\1835496 <e2>status_8\NN\24720 epilepticus</e2>_9\NN\1740 significantly_10\RB\1740 increased_11\VBD\169651 the_12\DT\1740 mortality_13\NN\5054863 rate_14\NN\13815152 to_15\IN\1740 100_16\CD\13745420 %_17\NN\1740 ._18\.\1740
C020972_D013226 NONE administration_0\NN\1133281 of_1\IN\1740 50_2\CD\13745420 mg/kg_3\NN\1740 <e1>pdtc</e1>_4\NN\1740 (_5\-LRB-\1740 low-dose_6\JJ\1740 )_7\-RRB-\1740 did_8\VBD\1640855 not_9\RB\1740 exert_10\VB\1158872 major_11\JJ\1740 effects_12\NNS\13245626 on_13\IN\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 a_17\DT\13649268 <e2>status_18\NN\24720 epilepticus</e2>_19\NN\1740 or_20\CC\3541091 the_21\DT\1740 mortality_22\NN\5054863 rate_23\NN\13815152 ._24\.\1740
C020972_D013226 NONE a_0\DT\13649268 significant_1\JJ\1740 decrease_2\NN\7296428 in_3\IN\13603305 neuronal_4\JJ\1740 density_5\NN\4941325 of_6\IN\1740 the_7\DT\1740 hippocampal_8\NN\1740 hilar_9\JJ\1740 formation_10\NN\7938773 was_11\VBD\836236 identified_12\VBN\699815 in_13\IN\13603305 vehicle-_14\NN\1740 and_15\CC\1740 <e1>pdtc-treated</e1>_16\JJ\1740 rats_17\NNS\2329401 following_18\VBG\1835496 <e2>status_19\NN\24720 epilepticus</e2>_20\NN\1740 ._21\.\1740
D010862_D013226 CID pyrrolidine_0\NNP\1740 dithiocarbamate_1\NN\1740 protects_2\VBZ\1127795 the_3\DT\1740 piriform_4\NN\1740 cortex_5\NN\5462674 in_6\IN\13603305 the_7\DT\1740 <e1>pilocarpine</e1>_8\NN\14712692 <e2>status_9\NN\24720 epilepticus</e2>_10\NN\1740 model_11\NN\5888929 ._12\.\1740
D010862_D013226 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 pdtc_3\NN\1740 on_4\IN\1740 <e2>status_5\NN\24720 epilepticus-associated</e2>_6\JJ\1740 cell_7\NN\3080309 loss_8\NN\13252973 in_9\IN\13603305 the_10\DT\1740 hippocampus_11\NN\5462674 and_12\CC\1740 piriform_13\NN\1740 cortex_14\NN\5462674 was_15\VBD\836236 evaluated_16\VBN\670261 in_17\IN\13603305 the_18\DT\1740 rat_19\NN\2329401 fractionated_20\VBD\1458973 <e1>pilocarpine</e1>_21\NN\14712692 model_22\NN\5888929 ._23\.\1740
D010100_D009410 NONE both_0\DT\1740 ,_1\,\1740 production_2\NN\30358 of_3\IN\1740 reactive_4\JJ\1740 <e1>oxygen</e1>_5\NN\14622893 species_6\NNS\7992450 as_7\RB\1740 well_8\RB\1740 as_9\IN\14622893 activation_10\NN\13561719 of_11\IN\1740 nf-kappab_12\NN\1740 have_13\VBP\2108377 been_14\VBN\836236 implicated_15\VBN\2677097 in_16\IN\13603305 severe_17\JJ\1740 <e2>neuronal_18\JJ\1740 damage</e2>_19\NN\7296428 in_20\IN\13603305 different_21\JJ\1740 sub-regions_22\NNS\1740 of_23\IN\1740 the_24\DT\1740 hippocampus_25\NN\5462674 as_26\RB\1740 well_27\RB\1740 as_28\IN\14622893 in_29\IN\13603305 the_30\DT\1740 surrounding_31\VBG\1205696 cortices_32\NNS\5462674 ._33\.\1740
D010100_D009410 NONE these_0\DT\1740 data_1\NNS\7951464 might_2\MD\5029706 indicate_3\VB\952524 that_4\IN\1740 the_5\DT\1740 generation_6\NN\7942152 of_7\IN\1740 reactive_8\JJ\1740 <e1>oxygen</e1>_9\NN\14622893 species_10\NNS\7992450 and_11\CC\1740 activation_12\NN\13561719 of_13\IN\1740 nf-kappab_14\NN\1740 plays_15\VBZ\1072262 a_16\DT\13649268 more_17\RBR\1740 central_18\JJ\1740 role_19\NN\719494 in_20\IN\13603305 seizure-associated_21\JJ\1740 <e2>neuronal_22\JJ\1740 damage</e2>_23\NN\7296428 in_24\IN\13603305 the_25\DT\1740 temporal_26\JJ\1740 cortex_27\NN\5462674 as_28\IN\14622893 compared_29\VBN\644583 to_30\IN\1740 the_31\DT\1740 hippocampal_32\NN\1740 hilus_33\NN\5223370 ._34\.\1740
C020972_D009410 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 nf-kappab_4\NN\1740 inhibitor_5\NN\20090 and_6\CC\1740 antioxidant_7\JJ\1740 <e1>pdtc</e1>_8\NN\1740 protected_9\VBD\1127795 the_10\DT\1740 piriform_11\NN\1740 cortex_12\NN\5462674 ,_13\,\1740 whereas_14\IN\1740 it_15\PRP\6125041 did_16\VBD\1640855 not_17\RB\1740 affect_18\VB\126264 hilar_19\JJ\1740 <e2>neuronal_20\JJ\1740 loss</e2>_21\NN\13252973 ._22\.\1740
D010100_D012640 NONE these_0\DT\1740 data_1\NNS\7951464 might_2\MD\5029706 indicate_3\VB\952524 that_4\IN\1740 the_5\DT\1740 generation_6\NN\7942152 of_7\IN\1740 reactive_8\JJ\1740 <e1>oxygen</e1>_9\NN\14622893 species_10\NNS\7992450 and_11\CC\1740 activation_12\NN\13561719 of_13\IN\1740 nf-kappab_14\NN\1740 plays_15\VBZ\1072262 a_16\DT\13649268 more_17\RBR\1740 central_18\JJ\1740 role_19\NN\719494 in_20\IN\13603305 <e2>seizure-associated</e2>_21\JJ\1740 neuronal_22\JJ\1740 damage_23\NN\7296428 in_24\IN\13603305 the_25\DT\1740 temporal_26\JJ\1740 cortex_27\NN\5462674 as_28\IN\14622893 compared_29\VBN\644583 to_30\IN\1740 the_31\DT\1740 hippocampal_32\NN\1740 hilus_33\NN\5223370 ._34\.\1740
10193204
C009438_D013927 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>tetrandrine</e1>_2\NN\1740 and_3\CC\1740 fangchinoline_4\NN\1740 on_5\IN\1740 experimental_6\JJ\1740 <e2>thrombosis</e2>_7\NN\14100769 in_8\IN\13603305 mice_9\NNS\2329401 and_10\CC\1740 human_11\JJ\1740 platelet_12\NN\5432736 aggregation_13\NN\31264 ._14\.\1740
C009438_D013927 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 <e1>tet</e1>_10\NN\15157225 and_11\CC\1740 fan_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 <e2>thrombosis</e2>_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 epinephrine_21\NN\14807929 (_22\-LRB-\1740 ep_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 platelet_29\NN\5432736 aggregation_30\NN\31264 and_31\CC\1740 blood_32\NN\5397468 coagulation_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
C009438_D013927 NONE in_0\IN\13603305 the_1\DT\1740 in_2\FW\13603305 vivo_3\FW\1740 study_4\NN\635850 ,_5\,\1740 the_6\DT\1740 administration_7\NN\1133281 (_8\-LRB-\1740 50_9\CD\13745420 mg/kg_10\NN\1740 ,_11\,\1740 i.p._12\RB\1740 )_13\-RRB-\1740 of_14\IN\1740 <e1>tet</e1>_15\NN\15157225 and_16\CC\1740 fan_17\NN\3183080 in_18\IN\13603305 mice_19\NNS\2329401 showed_20\VBD\2137132 the_21\DT\1740 inhibition_22\NN\1068773 of_23\IN\1740 <e2>thrombosis</e2>_24\NN\14100769 by_25\IN\1740 55_26\CD\1740 %_27\NN\1740 and_28\CC\1740 35_29\CD\1740 %_30\NN\1740 ,_31\,\1740 respectively_32\RB\1740 ,_33\,\1740 while_34\IN\15122231 acetylsalicylic_35\JJ\1740 acid_36\NN\14818238 (_37\-LRB-\1740 asa_38\NN\1740 ,_39\,\1740 50_40\CD\13745420 mg/kg_41\NN\1740 ,_42\,\1740 i.p._43\RB\1740 )_44\-RRB-\1740 ,_45\,\1740 a_46\DT\13649268 positive_47\JJ\1740 control_48\NN\5190804 ,_49\,\1740 showed_50\VBD\2137132 only_51\RB\1740 30_52\CD\13745420 %_53\NN\1740 inhibition_54\NN\1068773 ._55\.\1740
C009438_D001791 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>tetrandrine</e1>_2\NN\1740 and_3\CC\1740 fangchinoline_4\NN\1740 on_5\IN\1740 experimental_6\JJ\1740 thrombosis_7\NN\14100769 in_8\IN\13603305 mice_9\NNS\2329401 and_10\CC\1740 human_11\JJ\1740 <e2>platelet_12\NN\5432736 aggregation</e2>_13\NN\31264 ._14\.\1740
C009438_D001791 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 <e1>tet</e1>_10\NN\15157225 and_11\CC\1740 fan_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 thrombosis_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 epinephrine_21\NN\14807929 (_22\-LRB-\1740 ep_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 <e2>platelet_29\NN\5432736 aggregation</e2>_30\NN\31264 and_31\CC\1740 blood_32\NN\5397468 coagulation_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
C009438_D001791 NONE in_0\IN\13603305 the_1\DT\1740 vitro_2\FW\1740 human_3\JJ\1740 <e2>platelet_4\NN\5432736 aggregations</e2>_5\NNS\31264 induced_6\VBN\1627355 by_7\IN\1740 the_8\DT\1740 agonists_9\NNS\9613191 used_10\VBN\1156834 in_11\IN\13603305 tests_12\NNS\5798043 ,_13\,\1740 <e1>tet</e1>_14\NN\15157225 and_15\CC\1740 fan_16\NN\3183080 showed_17\VBD\2137132 the_18\DT\1740 inhibitions_19\NN\1068773 dose_20\NN\3740161 dependently_21\RB\1740 ._22\.\1740
C060802_D013927 NONE effects_0\NNS\13245626 of_1\IN\1740 tetrandrine_2\NN\1740 and_3\CC\1740 <e1>fangchinoline</e1>_4\NN\1740 on_5\IN\1740 experimental_6\JJ\1740 <e2>thrombosis</e2>_7\NN\14100769 in_8\IN\13603305 mice_9\NNS\2329401 and_10\CC\1740 human_11\JJ\1740 platelet_12\NN\5432736 aggregation_13\NN\31264 ._14\.\1740
C060802_D013927 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 tet_10\NN\15157225 and_11\CC\1740 <e1>fan</e1>_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 <e2>thrombosis</e2>_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 epinephrine_21\NN\14807929 (_22\-LRB-\1740 ep_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 platelet_29\NN\5432736 aggregation_30\NN\31264 and_31\CC\1740 blood_32\NN\5397468 coagulation_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
C060802_D013927 NONE in_0\IN\13603305 the_1\DT\1740 in_2\FW\13603305 vivo_3\FW\1740 study_4\NN\635850 ,_5\,\1740 the_6\DT\1740 administration_7\NN\1133281 (_8\-LRB-\1740 50_9\CD\13745420 mg/kg_10\NN\1740 ,_11\,\1740 i.p._12\RB\1740 )_13\-RRB-\1740 of_14\IN\1740 tet_15\NN\15157225 and_16\CC\1740 <e1>fan</e1>_17\NN\3183080 in_18\IN\13603305 mice_19\NNS\2329401 showed_20\VBD\2137132 the_21\DT\1740 inhibition_22\NN\1068773 of_23\IN\1740 <e2>thrombosis</e2>_24\NN\14100769 by_25\IN\1740 55_26\CD\1740 %_27\NN\1740 and_28\CC\1740 35_29\CD\1740 %_30\NN\1740 ,_31\,\1740 respectively_32\RB\1740 ,_33\,\1740 while_34\IN\15122231 acetylsalicylic_35\JJ\1740 acid_36\NN\14818238 (_37\-LRB-\1740 asa_38\NN\1740 ,_39\,\1740 50_40\CD\13745420 mg/kg_41\NN\1740 ,_42\,\1740 i.p._43\RB\1740 )_44\-RRB-\1740 ,_45\,\1740 a_46\DT\13649268 positive_47\JJ\1740 control_48\NN\5190804 ,_49\,\1740 showed_50\VBD\2137132 only_51\RB\1740 30_52\CD\13745420 %_53\NN\1740 inhibition_54\NN\1068773 ._55\.\1740
C060802_D001791 NONE effects_0\NNS\13245626 of_1\IN\1740 tetrandrine_2\NN\1740 and_3\CC\1740 <e1>fangchinoline</e1>_4\NN\1740 on_5\IN\1740 experimental_6\JJ\1740 thrombosis_7\NN\14100769 in_8\IN\13603305 mice_9\NNS\2329401 and_10\CC\1740 human_11\JJ\1740 <e2>platelet_12\NN\5432736 aggregation</e2>_13\NN\31264 ._14\.\1740
C060802_D001791 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 tet_10\NN\15157225 and_11\CC\1740 <e1>fan</e1>_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 thrombosis_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 epinephrine_21\NN\14807929 (_22\-LRB-\1740 ep_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 <e2>platelet_29\NN\5432736 aggregation</e2>_30\NN\31264 and_31\CC\1740 blood_32\NN\5397468 coagulation_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
C060802_D001791 NONE in_0\IN\13603305 the_1\DT\1740 vitro_2\FW\1740 human_3\JJ\1740 <e2>platelet_4\NN\5432736 aggregations</e2>_5\NNS\31264 induced_6\VBN\1627355 by_7\IN\1740 the_8\DT\1740 agonists_9\NNS\9613191 used_10\VBN\1156834 in_11\IN\13603305 tests_12\NNS\5798043 ,_13\,\1740 tet_14\NN\15157225 and_15\CC\1740 <e1>fan</e1>_16\NN\3183080 showed_17\VBD\2137132 the_18\DT\1740 inhibitions_19\NN\1068773 dose_20\NN\3740161 dependently_21\RB\1740 ._22\.\1740
C009438_D001778 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 <e1>tet</e1>_10\NN\15157225 and_11\CC\1740 fan_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 thrombosis_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 epinephrine_21\NN\14807929 (_22\-LRB-\1740 ep_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 platelet_29\NN\5432736 aggregation_30\NN\31264 and_31\CC\1740 <e2>blood_32\NN\5397468 coagulation</e2>_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
C060802_D001778 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 tet_10\NN\15157225 and_11\CC\1740 <e1>fan</e1>_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 thrombosis_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 epinephrine_21\NN\14807929 (_22\-LRB-\1740 ep_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 platelet_29\NN\5432736 aggregation_30\NN\31264 and_31\CC\1740 <e2>blood_32\NN\5397468 coagulation</e2>_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
D004837_D013927 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 tet_10\NN\15157225 and_11\CC\1740 fan_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 <e2>thrombosis</e2>_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 <e1>epinephrine</e1>_21\NN\14807929 (_22\-LRB-\1740 ep_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 platelet_29\NN\5432736 aggregation_30\NN\31264 and_31\CC\1740 blood_32\NN\5397468 coagulation_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
D004837_D013927 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 tet_10\NN\15157225 and_11\CC\1740 fan_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 <e2>thrombosis</e2>_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 epinephrine_21\NN\14807929 (_22\-LRB-\1740 <e1>ep</e1>_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 platelet_29\NN\5432736 aggregation_30\NN\31264 and_31\CC\1740 blood_32\NN\5397468 coagulation_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
D004837_D001791 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 tet_10\NN\15157225 and_11\CC\1740 fan_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 thrombosis_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 <e1>epinephrine</e1>_21\NN\14807929 (_22\-LRB-\1740 ep_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 <e2>platelet_29\NN\5432736 aggregation</e2>_30\NN\31264 and_31\CC\1740 blood_32\NN\5397468 coagulation_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
D004837_D001791 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 tet_10\NN\15157225 and_11\CC\1740 fan_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 thrombosis_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 epinephrine_21\NN\14807929 (_22\-LRB-\1740 <e1>ep</e1>_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 <e2>platelet_29\NN\5432736 aggregation</e2>_30\NN\31264 and_31\CC\1740 blood_32\NN\5397468 coagulation_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
D004837_D001778 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 tet_10\NN\15157225 and_11\CC\1740 fan_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 thrombosis_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 <e1>epinephrine</e1>_21\NN\14807929 (_22\-LRB-\1740 ep_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 platelet_29\NN\5432736 aggregation_30\NN\31264 and_31\CC\1740 <e2>blood_32\NN\5397468 coagulation</e2>_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
D004837_D001778 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effects_8\NNS\13245626 of_9\IN\1740 tet_10\NN\15157225 and_11\CC\1740 fan_12\NN\3183080 on_13\IN\1740 the_14\DT\1740 experimental_15\JJ\1740 thrombosis_16\NN\14100769 induced_17\VBN\1627355 by_18\IN\1740 collagen_19\NN\15026716 plus_20\CC\4723816 epinephrine_21\NN\14807929 (_22\-LRB-\1740 <e1>ep</e1>_23\NN\1740 )_24\-RRB-\1740 in_25\IN\13603305 mice_26\NNS\2329401 ,_27\,\1740 and_28\CC\1740 platelet_29\NN\5432736 aggregation_30\NN\31264 and_31\CC\1740 <e2>blood_32\NN\5397468 coagulation</e2>_33\NN\13518963 in_34\FW\13603305 vitro_35\FW\1740 ._36\.\1740
D001241_D013927 NONE in_0\IN\13603305 the_1\DT\1740 in_2\FW\13603305 vivo_3\FW\1740 study_4\NN\635850 ,_5\,\1740 the_6\DT\1740 administration_7\NN\1133281 (_8\-LRB-\1740 50_9\CD\13745420 mg/kg_10\NN\1740 ,_11\,\1740 i.p._12\RB\1740 )_13\-RRB-\1740 of_14\IN\1740 tet_15\NN\15157225 and_16\CC\1740 fan_17\NN\3183080 in_18\IN\13603305 mice_19\NNS\2329401 showed_20\VBD\2137132 the_21\DT\1740 inhibition_22\NN\1068773 of_23\IN\1740 <e2>thrombosis</e2>_24\NN\14100769 by_25\IN\1740 55_26\CD\1740 %_27\NN\1740 and_28\CC\1740 35_29\CD\1740 %_30\NN\1740 ,_31\,\1740 respectively_32\RB\1740 ,_33\,\1740 while_34\IN\15122231 <e1>acetylsalicylic_35\JJ\1740 acid</e1>_36\NN\14818238 (_37\-LRB-\1740 asa_38\NN\1740 ,_39\,\1740 50_40\CD\13745420 mg/kg_41\NN\1740 ,_42\,\1740 i.p._43\RB\1740 )_44\-RRB-\1740 ,_45\,\1740 a_46\DT\13649268 positive_47\JJ\1740 control_48\NN\5190804 ,_49\,\1740 showed_50\VBD\2137132 only_51\RB\1740 30_52\CD\13745420 %_53\NN\1740 inhibition_54\NN\1068773 ._55\.\1740
D001241_D013927 NONE in_0\IN\13603305 the_1\DT\1740 in_2\FW\13603305 vivo_3\FW\1740 study_4\NN\635850 ,_5\,\1740 the_6\DT\1740 administration_7\NN\1133281 (_8\-LRB-\1740 50_9\CD\13745420 mg/kg_10\NN\1740 ,_11\,\1740 i.p._12\RB\1740 )_13\-RRB-\1740 of_14\IN\1740 tet_15\NN\15157225 and_16\CC\1740 fan_17\NN\3183080 in_18\IN\13603305 mice_19\NNS\2329401 showed_20\VBD\2137132 the_21\DT\1740 inhibition_22\NN\1068773 of_23\IN\1740 <e2>thrombosis</e2>_24\NN\14100769 by_25\IN\1740 55_26\CD\1740 %_27\NN\1740 and_28\CC\1740 35_29\CD\1740 %_30\NN\1740 ,_31\,\1740 respectively_32\RB\1740 ,_33\,\1740 while_34\IN\15122231 acetylsalicylic_35\JJ\1740 acid_36\NN\14818238 (_37\-LRB-\1740 <e1>asa</e1>_38\NN\1740 ,_39\,\1740 50_40\CD\13745420 mg/kg_41\NN\1740 ,_42\,\1740 i.p._43\RB\1740 )_44\-RRB-\1740 ,_45\,\1740 a_46\DT\13649268 positive_47\JJ\1740 control_48\NN\5190804 ,_49\,\1740 showed_50\VBD\2137132 only_51\RB\1740 30_52\CD\13745420 %_53\NN\1740 inhibition_54\NN\1068773 ._55\.\1740
7083920
D000638_D006327 CID a_0\DT\13649268 case_1\NN\7283608 is_2\VBZ\836236 presented_3\VBN\2137132 of_4\IN\1740 a_5\DT\13649268 reversible_6\JJ\1740 <e2>intra-hisian_7\JJ\1740 block</e2>_8\NN\21939 occurring_9\VBG\2623529 under_10\IN\1740 <e1>amiodarone</e1>_11\JJ\1740 treatment_12\NN\654885 for_13\IN\1740 atrial_14\JJ\1740 tachycardia_15\NN\14110674 in_16\IN\13603305 a_17\DT\13649268 patient_18\NN\9898892 without_19\IN\1740 clear_20\JJ\1740 intraventricular_21\JJ\1740 conduction_22\NN\11419404 abnormalities_23\NNS\14034177 ._24\.\1740
D000638_D013617 NONE a_0\DT\13649268 case_1\NN\7283608 is_2\VBZ\836236 presented_3\VBN\2137132 of_4\IN\1740 a_5\DT\13649268 reversible_6\JJ\1740 intra-hisian_7\JJ\1740 block_8\NN\21939 occurring_9\VBG\2623529 under_10\IN\1740 <e1>amiodarone</e1>_11\JJ\1740 treatment_12\NN\654885 for_13\IN\1740 <e2>atrial_14\JJ\1740 tachycardia</e2>_15\NN\14110674 in_16\IN\13603305 a_17\DT\13649268 patient_18\NN\9898892 without_19\IN\1740 clear_20\JJ\1740 intraventricular_21\JJ\1740 conduction_22\NN\11419404 abnormalities_23\NNS\14034177 ._24\.\1740
D000638_D006345 NONE a_0\DT\13649268 case_1\NN\7283608 is_2\VBZ\836236 presented_3\VBN\2137132 of_4\IN\1740 a_5\DT\13649268 reversible_6\JJ\1740 intra-hisian_7\JJ\1740 block_8\NN\21939 occurring_9\VBG\2623529 under_10\IN\1740 <e1>amiodarone</e1>_11\JJ\1740 treatment_12\NN\654885 for_13\IN\1740 atrial_14\JJ\1740 tachycardia_15\NN\14110674 in_16\IN\13603305 a_17\DT\13649268 patient_18\NN\9898892 without_19\IN\1740 clear_20\JJ\1740 <e2>intraventricular_21\JJ\1740 conduction_22\NN\11419404 abnormalities</e2>_23\NNS\14034177 ._24\.\1740
D000638_D001282 NONE thirty_0\CD\13745420 days_1\NNS\15140892 after_2\IN\1740 <e1>amiodarone</e1>_3\JJ\1740 discontinuation_4\NN\209943 ,_5\,\1740 his_6\PRP$\1740 bundle_7\NN\7951464 electrograms_8\NNS\1740 showed_9\VBD\2137132 <e2>atrial_10\JJ\1740 flutter</e2>_11\NN\331950 without_12\IN\1740 intra-hisian_13\JJ\1740 or_14\CC\3541091 infra-hisian_15\JJ\1740 delay_16\NN\15271008 ._17\.\1740
8558192
C030852_C562729 NONE phase_0\NN\15113229 ii_1\CD\13741022 trial_2\NN\786195 of_3\IN\1740 <e1>vinorelbine</e1>_4\NN\1740 in_5\IN\13603305 metastatic_6\JJ\1740 <e2>squamous_7\JJ\1740 cell_8\NN\3080309 esophageal_9\NN\1740 carcinoma</e2>_10\NN\14239918 ._11\.\1740
C030852_C562729 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 response_5\NN\11410625 rate_6\NN\13815152 and_7\CC\1740 toxic_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 <e1>vinorelbine</e1>_11\NN\1740 (_12\-LRB-\1740 vnb_13\NN\1740 )_14\-RRB-\1740 administered_15\VBN\2436349 as_16\IN\14622893 a_17\DT\13649268 single_18\JJ\1740 agent_19\NN\7347 in_20\IN\13603305 metastatic_21\JJ\1740 <e2>squamous_22\JJ\1740 cell_23\NN\3080309 esophageal_24\NN\1740 carcinoma</e2>_25\NN\14239918 ._26\.\1740
C030852_C562729 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 response_5\NN\11410625 rate_6\NN\13815152 and_7\CC\1740 toxic_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 vinorelbine_11\NN\1740 (_12\-LRB-\1740 <e1>vnb</e1>_13\NN\1740 )_14\-RRB-\1740 administered_15\VBN\2436349 as_16\IN\14622893 a_17\DT\13649268 single_18\JJ\1740 agent_19\NN\7347 in_20\IN\13603305 metastatic_21\JJ\1740 <e2>squamous_22\JJ\1740 cell_23\NN\3080309 esophageal_24\NN\1740 carcinoma</e2>_25\NN\14239918 ._26\.\1740
C030852_C562729 NONE conclusion_0\NN\5837957 :_1\:\1740 these_2\DT\1740 data_3\NNS\7951464 indicate_4\VBP\952524 that_5\IN\1740 <e1>vnb</e1>_6\NNP\1740 is_7\VBZ\836236 an_8\DT\6697703 active_9\JJ\1740 agent_10\NN\7347 in_11\IN\13603305 metastatic_12\JJ\1740 <e2>esophageal_13\NN\1740 squamous_14\JJ\1740 cell_15\NN\3080309 carcinoma</e2>_16\NN\14239918 ._17\.\1740
D002945_D064420 NONE thirty_0\CD\13745420 patients_1\NNS\9898892 without_2\IN\1740 prior_3\JJ\1740 chemotherapy_4\NN\661091 and_5\CC\1740 16_6\CD\13745420 pretreated_7\JJ\1740 with_8\IN\1740 <e1>cisplatin-based</e1>_9\JJ\1740 chemotherapy_10\NN\661091 were_11\VBD\836236 assessable_12\JJ\1740 for_13\IN\1740 <e2>toxicity</e2>_14\NN\13576101 and_15\CC\1740 response_16\NN\11410625 ._17\.\1740
C030852_D064420 NONE <e1>vnb</e1>_0\NNP\1740 was_1\VBD\836236 well_2\RB\1740 tolerated_3\VBN\802318 and_4\CC\1740 zero_5\CD\13576982 instances_6\NNS\7283608 of_7\IN\1740 who_8\WP\8299493 grade_9\NN\7975026 4_10\CD\13741022 nonhematologic_11\JJ\1740 <e2>toxicity</e2>_12\NN\13576101 occurred_13\VBD\2623529 ._14\.\1740
C030852_D064420 NONE given_0\VBN\2327200 its_1\PRP$\6125041 excellent_2\JJ\1740 tolerance_3\NN\5032565 profile_4\NN\6999802 and_5\CC\1740 low_6\JJ\1740 <e2>toxicity</e2>_7\NN\13576101 ,_8\,\1740 further_9\JJ\1740 evaluation_10\NN\874067 of_11\IN\1740 <e1>vnb</e1>_12\NN\1740 in_13\IN\13603305 combination_14\NN\7951464 therapy_15\NN\657604 is_16\VBZ\836236 warranted_17\VBN\1012073 ._18\.\1740
19299179
D015662_D002779 NONE severe_0\JJ\1740 and_1\CC\1740 long_2\JJ\1740 lasting_3\VBG\2704349 <e2>cholestasis</e2>_4\NN\14052403 after_5\IN\1740 high-dose_6\JJ\1740 <e1>co-trimoxazole</e1>_7\NN\1740 treatment_8\NN\654885 for_9\IN\1740 pneumocystis_10\NN\1740 pneumonia_11\NN\14145095 in_12\IN\13603305 hiv-infected_13\JJ\1740 patients_14\NNS\9898892 --_15\:\1740 a_16\DT\13649268 report_17\NN\6470073 of_18\IN\1740 two_19\CD\13741022 cases_20\NNS\7283608 ._21\.\1740
D015662_D011020 NONE severe_0\JJ\1740 and_1\CC\1740 long_2\JJ\1740 lasting_3\VBG\2704349 cholestasis_4\NN\14052403 after_5\IN\1740 high-dose_6\JJ\1740 <e1>co-trimoxazole</e1>_7\NN\1740 treatment_8\NN\654885 for_9\IN\1740 <e2>pneumocystis_10\NN\1740 pneumonia</e2>_11\NN\14145095 in_12\IN\13603305 hiv-infected_13\JJ\1740 patients_14\NNS\9898892 --_15\:\1740 a_16\DT\13649268 report_17\NN\6470073 of_18\IN\1740 two_19\CD\13741022 cases_20\NNS\7283608 ._21\.\1740
D015662_D011020 NONE <e2>pneumocystis_0\NN\1740 pneumonia</e2>_1\NN\14145095 (_2\-LRB-\1740 pcp_3\NN\10480253 )_4\-RRB-\1740 ,_5\,\1740 a_6\DT\13649268 common_7\JJ\1740 opportunistic_8\JJ\1740 infection_9\NN\14052046 in_10\IN\13603305 hiv-infected_11\JJ\1740 individuals_12\NNS\7347 ,_13\,\1740 is_14\VBZ\836236 generally_15\RB\1740 treated_16\VBN\2376958 with_17\IN\1740 high_18\JJ\1740 doses_19\NNS\3740161 of_20\IN\1740 <e1>co-trimoxazole</e1>_21\NN\1740 ._22\.\1740
D015662_D011020 NONE pneumocystis_0\NN\1740 pneumonia_1\NN\14145095 (_2\-LRB-\1740 <e2>pcp</e2>_3\NN\10480253 )_4\-RRB-\1740 ,_5\,\1740 a_6\DT\13649268 common_7\JJ\1740 opportunistic_8\JJ\1740 infection_9\NN\14052046 in_10\IN\13603305 hiv-infected_11\JJ\1740 individuals_12\NNS\7347 ,_13\,\1740 is_14\VBZ\836236 generally_15\RB\1740 treated_16\VBN\2376958 with_17\IN\1740 high_18\JJ\1740 doses_19\NNS\3740161 of_20\IN\1740 <e1>co-trimoxazole</e1>_21\NN\1740 ._22\.\1740
D015662_D011020 NONE here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 report_3\VBP\831651 two_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 severely_7\RB\1740 immunocompromised_8\VBN\1740 hiv-infected_9\JJ\1740 patients_10\NNS\9898892 who_11\WP\8299493 developed_12\VBD\1753788 severe_13\JJ\1740 intrahepatic_14\JJ\1740 cholestasis_15\NN\14052403 ,_16\,\1740 and_17\CC\1740 in_18\IN\13603305 one_19\CD\13741022 patient_20\NN\9898892 lesions_21\NNS\14204950 mimicking_22\VBG\1742886 liver_23\NN\5298729 abscess_24\NN\14299637 formation_25\NN\7938773 on_26\IN\1740 radiologic_27\JJ\1740 exams_28\NNS\6252138 ,_29\,\1740 during_30\IN\1740 <e1>co-trimoxazole</e1>_31\NN\1740 treatment_32\NN\654885 for_33\IN\1740 <e2>pcp</e2>_34\NN\10480253 ._35\.\1740
D015662_D015658 NONE severe_0\JJ\1740 and_1\CC\1740 long_2\JJ\1740 lasting_3\VBG\2704349 cholestasis_4\NN\14052403 after_5\IN\1740 high-dose_6\JJ\1740 <e1>co-trimoxazole</e1>_7\NN\1740 treatment_8\NN\654885 for_9\IN\1740 pneumocystis_10\NN\1740 pneumonia_11\NN\14145095 in_12\IN\13603305 <e2>hiv-infected</e2>_13\JJ\1740 patients_14\NNS\9898892 --_15\:\1740 a_16\DT\13649268 report_17\NN\6470073 of_18\IN\1740 two_19\CD\13741022 cases_20\NNS\7283608 ._21\.\1740
D015662_D015658 NONE pneumocystis_0\NN\1740 pneumonia_1\NN\14145095 (_2\-LRB-\1740 pcp_3\NN\10480253 )_4\-RRB-\1740 ,_5\,\1740 a_6\DT\13649268 common_7\JJ\1740 opportunistic_8\JJ\1740 infection_9\NN\14052046 in_10\IN\13603305 <e2>hiv-infected</e2>_11\JJ\1740 individuals_12\NNS\7347 ,_13\,\1740 is_14\VBZ\836236 generally_15\RB\1740 treated_16\VBN\2376958 with_17\IN\1740 high_18\JJ\1740 doses_19\NNS\3740161 of_20\IN\1740 <e1>co-trimoxazole</e1>_21\NN\1740 ._22\.\1740
D015662_D015658 NONE here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 report_3\VBP\831651 two_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 severely_7\RB\1740 immunocompromised_8\VBN\1740 <e2>hiv-infected</e2>_9\JJ\1740 patients_10\NNS\9898892 who_11\WP\8299493 developed_12\VBD\1753788 severe_13\JJ\1740 intrahepatic_14\JJ\1740 cholestasis_15\NN\14052403 ,_16\,\1740 and_17\CC\1740 in_18\IN\13603305 one_19\CD\13741022 patient_20\NN\9898892 lesions_21\NNS\14204950 mimicking_22\VBG\1742886 liver_23\NN\5298729 abscess_24\NN\14299637 formation_25\NN\7938773 on_26\IN\1740 radiologic_27\JJ\1740 exams_28\NNS\6252138 ,_29\,\1740 during_30\IN\1740 <e1>co-trimoxazole</e1>_31\NN\1740 treatment_32\NN\654885 for_33\IN\1740 pcp_34\NN\10480253 ._35\.\1740
D015662_D009894 NONE pneumocystis_0\NN\1740 pneumonia_1\NN\14145095 (_2\-LRB-\1740 pcp_3\NN\10480253 )_4\-RRB-\1740 ,_5\,\1740 a_6\DT\13649268 common_7\JJ\1740 <e2>opportunistic_8\JJ\1740 infection</e2>_9\NN\14052046 in_10\IN\13603305 hiv-infected_11\JJ\1740 individuals_12\NNS\7347 ,_13\,\1740 is_14\VBZ\836236 generally_15\RB\1740 treated_16\VBN\2376958 with_17\IN\1740 high_18\JJ\1740 doses_19\NNS\3740161 of_20\IN\1740 <e1>co-trimoxazole</e1>_21\NN\1740 ._22\.\1740
D015662_D002780 CID here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 report_3\VBP\831651 two_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 severely_7\RB\1740 immunocompromised_8\VBN\1740 hiv-infected_9\JJ\1740 patients_10\NNS\9898892 who_11\WP\8299493 developed_12\VBD\1753788 severe_13\JJ\1740 <e2>intrahepatic_14\JJ\1740 cholestasis</e2>_15\NN\14052403 ,_16\,\1740 and_17\CC\1740 in_18\IN\13603305 one_19\CD\13741022 patient_20\NN\9898892 lesions_21\NNS\14204950 mimicking_22\VBG\1742886 liver_23\NN\5298729 abscess_24\NN\14299637 formation_25\NN\7938773 on_26\IN\1740 radiologic_27\JJ\1740 exams_28\NNS\6252138 ,_29\,\1740 during_30\IN\1740 <e1>co-trimoxazole</e1>_31\NN\1740 treatment_32\NN\654885 for_33\IN\1740 pcp_34\NN\10480253 ._35\.\1740
D015662_D008100 NONE here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 report_3\VBP\831651 two_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 severely_7\RB\1740 immunocompromised_8\VBN\1740 hiv-infected_9\JJ\1740 patients_10\NNS\9898892 who_11\WP\8299493 developed_12\VBD\1753788 severe_13\JJ\1740 intrahepatic_14\JJ\1740 cholestasis_15\NN\14052403 ,_16\,\1740 and_17\CC\1740 in_18\IN\13603305 one_19\CD\13741022 patient_20\NN\9898892 lesions_21\NNS\14204950 mimicking_22\VBG\1742886 <e2>liver_23\NN\5298729 abscess</e2>_24\NN\14299637 formation_25\NN\7938773 on_26\IN\1740 radiologic_27\JJ\1740 exams_28\NNS\6252138 ,_29\,\1740 during_30\IN\1740 <e1>co-trimoxazole</e1>_31\NN\1740 treatment_32\NN\654885 for_33\IN\1740 pcp_34\NN\10480253 ._35\.\1740
19889778
12639165
D013988_D002779 CID <e1>ticlopidine-induced</e1>_0\JJ\1740 <e2>cholestatic_1\JJ\1740 hepatitis</e2>_2\NN\14127211 ._3\.\1740
D013988_D002779 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 2_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 <e1>ticlopidine-induced</e1>_7\JJ\1740 <e2>cholestatic_8\JJ\1740 hepatitis</e2>_9\NN\14127211 ,_10\,\1740 investigate_11\VBP\644583 its_12\PRP$\6125041 mechanism_13\NN\13446390 ,_14\,\1740 and_15\CC\1740 compare_16\VB\644583 the_17\DT\1740 observed_18\VBN\2163746 main_19\JJ\1740 characteristics_20\NNS\5849040 with_21\IN\1740 those_22\DT\1740 of_23\IN\1740 the_24\DT\1740 published_25\VBN\1621555 cases_26\NNS\7283608 ._27\.\1740
D013988_D002779 CID case_0\NN\7283608 summaries_1\NN\6722453 :_2\:\1740 two_3\CD\13741022 patients_4\NNS\9898892 developed_5\VBD\1753788 prolonged_6\JJ\1740 <e2>cholestatic_7\JJ\1740 hepatitis</e2>_8\NN\14127211 after_9\IN\1740 receiving_10\VBG\2210855 <e1>ticlopidine</e1>_11\NN\1740 following_12\VBG\1835496 percutaneous_13\JJ\1740 coronary_14\JJ\1740 angioplasty_15\NN\671351 ,_16\,\1740 with_17\IN\1740 complete_18\JJ\1740 remission_19\NN\7368256 during_20\IN\1740 the_21\DT\1740 follow-up_22\JJ\1740 period_23\NN\13575869 ._24\.\1740
D013988_D002779 CID discussion_0\NN\6252138 :_1\:\1740 <e2>cholestatic_2\JJ\1740 hepatitis</e2>_3\NN\14127211 is_4\VBZ\836236 a_5\DT\13649268 rare_6\JJ\1740 complication_7\NN\1073995 of_8\IN\1740 the_9\DT\1740 antiplatelet_10\NN\1740 agent_11\NN\7347 <e1>ticlopidine</e1>_12\NN\1740 ;_13\:\1740 several_14\JJ\1740 cases_15\NNS\7283608 have_16\VBP\2108377 been_17\VBN\836236 reported_18\VBN\831651 but_19\CC\1740 few_20\JJ\1740 in_21\IN\13603305 the_22\DT\1740 english_23\NNP\6946823 literature_24\NN\6362953 ._25\.\1740
D013988_D002779 CID our_0\PRP$\1740 patients_1\NNS\9898892 developed_2\VBD\1753788 jaundice_3\NN\14299637 following_4\VBG\1835496 treatment_5\NN\654885 with_6\IN\1740 <e1>ticlopidine</e1>_7\NN\1740 and_8\CC\1740 showed_9\VBD\2137132 the_10\DT\1740 clinical_11\JJ\1740 and_12\CC\1740 laboratory_13\JJ\1740 characteristics_14\NNS\5849040 of_15\IN\1740 <e2>cholestatic_16\JJ\1740 hepatitis</e2>_17\NN\14127211 ,_18\,\1740 which_19\WDT\1740 resolved_20\VBD\352826 after_21\IN\1740 discontinuation_22\NN\209943 of_23\IN\1740 the_24\DT\1740 drug_25\NN\14778436 ._26\.\1740
D013988_D002779 CID the_0\DT\1740 mechanisms_1\NNS\13446390 of_2\IN\1740 this_3\DT\1740 <e1>ticlopidine-induced</e1>_4\JJ\1740 <e2>cholestasis</e2>_5\NN\14052403 are_6\VBP\836236 unclear_7\JJ\1740 ._8\.\1740
D013988_D002779 CID conclusions_0\NNS\5837957 :_1\:\1740 <e2>cholestatic_2\JJ\1740 hepatitis</e2>_3\NN\14127211 is_4\VBZ\836236 a_5\DT\13649268 rare_6\JJ\1740 adverse_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 <e1>ticlopidine</e1>_10\NN\1740 that_11\WDT\1740 may_12\MD\15209706 be_13\VB\836236 immune_14\JJ\1740 mediated_15\JJ\1740 ._16\.\1740
D013988_D056486 CID <e1>ticlopidine-induced</e1>_0\JJ\1740 <e2>cholestatic_1\JJ\1740 hepatitis</e2>_2\NN\14127211 ._3\.\1740
D013988_D056486 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 2_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 <e1>ticlopidine-induced</e1>_7\JJ\1740 <e2>cholestatic_8\JJ\1740 hepatitis</e2>_9\NN\14127211 ,_10\,\1740 investigate_11\VBP\644583 its_12\PRP$\6125041 mechanism_13\NN\13446390 ,_14\,\1740 and_15\CC\1740 compare_16\VB\644583 the_17\DT\1740 observed_18\VBN\2163746 main_19\JJ\1740 characteristics_20\NNS\5849040 with_21\IN\1740 those_22\DT\1740 of_23\IN\1740 the_24\DT\1740 published_25\VBN\1621555 cases_26\NNS\7283608 ._27\.\1740
D013988_D056486 CID case_0\NN\7283608 summaries_1\NN\6722453 :_2\:\1740 two_3\CD\13741022 patients_4\NNS\9898892 developed_5\VBD\1753788 prolonged_6\JJ\1740 <e2>cholestatic_7\JJ\1740 hepatitis</e2>_8\NN\14127211 after_9\IN\1740 receiving_10\VBG\2210855 <e1>ticlopidine</e1>_11\NN\1740 following_12\VBG\1835496 percutaneous_13\JJ\1740 coronary_14\JJ\1740 angioplasty_15\NN\671351 ,_16\,\1740 with_17\IN\1740 complete_18\JJ\1740 remission_19\NN\7368256 during_20\IN\1740 the_21\DT\1740 follow-up_22\JJ\1740 period_23\NN\13575869 ._24\.\1740
D013988_D056486 CID discussion_0\NN\6252138 :_1\:\1740 <e2>cholestatic_2\JJ\1740 hepatitis</e2>_3\NN\14127211 is_4\VBZ\836236 a_5\DT\13649268 rare_6\JJ\1740 complication_7\NN\1073995 of_8\IN\1740 the_9\DT\1740 antiplatelet_10\NN\1740 agent_11\NN\7347 <e1>ticlopidine</e1>_12\NN\1740 ;_13\:\1740 several_14\JJ\1740 cases_15\NNS\7283608 have_16\VBP\2108377 been_17\VBN\836236 reported_18\VBN\831651 but_19\CC\1740 few_20\JJ\1740 in_21\IN\13603305 the_22\DT\1740 english_23\NNP\6946823 literature_24\NN\6362953 ._25\.\1740
D013988_D056486 CID our_0\PRP$\1740 patients_1\NNS\9898892 developed_2\VBD\1753788 jaundice_3\NN\14299637 following_4\VBG\1835496 treatment_5\NN\654885 with_6\IN\1740 <e1>ticlopidine</e1>_7\NN\1740 and_8\CC\1740 showed_9\VBD\2137132 the_10\DT\1740 clinical_11\JJ\1740 and_12\CC\1740 laboratory_13\JJ\1740 characteristics_14\NNS\5849040 of_15\IN\1740 <e2>cholestatic_16\JJ\1740 hepatitis</e2>_17\NN\14127211 ,_18\,\1740 which_19\WDT\1740 resolved_20\VBD\352826 after_21\IN\1740 discontinuation_22\NN\209943 of_23\IN\1740 the_24\DT\1740 drug_25\NN\14778436 ._26\.\1740
D013988_D056486 CID conclusions_0\NNS\5837957 :_1\:\1740 <e2>cholestatic_2\JJ\1740 hepatitis</e2>_3\NN\14127211 is_4\VBZ\836236 a_5\DT\13649268 rare_6\JJ\1740 adverse_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 <e1>ticlopidine</e1>_10\NN\1740 that_11\WDT\1740 may_12\MD\15209706 be_13\VB\836236 immune_14\JJ\1740 mediated_15\JJ\1740 ._16\.\1740
D013988_D007565 CID our_0\PRP$\1740 patients_1\NNS\9898892 developed_2\VBD\1753788 <e2>jaundice</e2>_3\NN\14299637 following_4\VBG\1835496 treatment_5\NN\654885 with_6\IN\1740 <e1>ticlopidine</e1>_7\NN\1740 and_8\CC\1740 showed_9\VBD\2137132 the_10\DT\1740 clinical_11\JJ\1740 and_12\CC\1740 laboratory_13\JJ\1740 characteristics_14\NNS\5849040 of_15\IN\1740 cholestatic_16\JJ\1740 hepatitis_17\NN\14127211 ,_18\,\1740 which_19\WDT\1740 resolved_20\VBD\352826 after_21\IN\1740 discontinuation_22\NN\209943 of_23\IN\1740 the_24\DT\1740 drug_25\NN\14778436 ._26\.\1740
12063090
D004177_D003248 NONE <e1>metamizol</e1>_0\JJ\1740 potentiates_1\VBZ\229605 morphine_2\JJ\1740 antinociception_3\NN\1740 but_4\CC\1740 not_5\RB\1740 <e2>constipation</e2>_6\NN\14299637 after_7\IN\1740 chronic_8\JJ\1740 treatment_9\NN\654885 ._10\.\1740
D004177_D003248 NONE this_0\DT\1740 work_1\NN\407535 evaluates_2\VBZ\670261 the_3\DT\1740 antinociceptive_4\JJ\1740 and_5\CC\1740 <e2>constipating</e2>_6\VBG\440786 effects_7\NNS\13245626 of_8\IN\1740 the_9\DT\1740 combination_10\NN\7951464 of_11\IN\1740 3.2_12\CD\1740 mg/kg_13\NN\1740 s.c._14\NN\1740 morphine_15\NN\2707683 with_16\IN\1740 177.8_17\CD\1740 mg/kg_18\NN\1740 s.c._19\NN\1740 <e1>metamizol</e1>_20\NN\1740 in_21\IN\13603305 acutely_22\RB\1740 and_23\CC\1740 chronically_24\RB\1740 treated_25\VBN\2376958 (_26\-LRB-\1740 once_27\RB\1740 a_28\DT\13649268 day_29\NN\15154774 for_30\IN\1740 12_31\CD\13745420 days_32\NNS\15140892 )_33\-RRB-\1740 rats_34\NNS\2329401 ._35\.\1740
D004177_D003248 NONE the_0\DT\1740 combination_1\NN\7951464 inhibited_2\VBD\2510337 intestinal_3\JJ\1740 transit_4\NN\4365484 similar_5\JJ\1740 to_6\TO\1740 that_7\DT\1740 produced_8\VBN\1617192 by_9\IN\1740 morphine_10\NN\2707683 regardless_11\RB\1740 of_12\IN\1740 the_13\DT\1740 time_14\NN\7308889 of_15\IN\1740 treatment_16\NN\654885 ,_17\,\1740 suggesting_18\VBG\1010118 that_19\IN\1740 <e1>metamizol</e1>_20\NN\1740 did_21\VBD\1640855 not_22\RB\1740 potentiate_23\VB\229605 morphine-induced_24\JJ\1740 <e2>constipation</e2>_25\NN\14299637 ._26\.\1740
D009020_D003248 CID metamizol_0\JJ\1740 potentiates_1\VBZ\229605 <e1>morphine</e1>_2\JJ\1740 antinociception_3\NN\1740 but_4\CC\1740 not_5\RB\1740 <e2>constipation</e2>_6\NN\14299637 after_7\IN\1740 chronic_8\JJ\1740 treatment_9\NN\654885 ._10\.\1740
D009020_D003248 CID this_0\DT\1740 work_1\NN\407535 evaluates_2\VBZ\670261 the_3\DT\1740 antinociceptive_4\JJ\1740 and_5\CC\1740 <e2>constipating</e2>_6\VBG\440786 effects_7\NNS\13245626 of_8\IN\1740 the_9\DT\1740 combination_10\NN\7951464 of_11\IN\1740 3.2_12\CD\1740 mg/kg_13\NN\1740 s.c._14\NN\1740 <e1>morphine</e1>_15\NN\2707683 with_16\IN\1740 177.8_17\CD\1740 mg/kg_18\NN\1740 s.c._19\NN\1740 metamizol_20\NN\1740 in_21\IN\13603305 acutely_22\RB\1740 and_23\CC\1740 chronically_24\RB\1740 treated_25\VBN\2376958 (_26\-LRB-\1740 once_27\RB\1740 a_28\DT\13649268 day_29\NN\15154774 for_30\IN\1740 12_31\CD\13745420 days_32\NNS\15140892 )_33\-RRB-\1740 rats_34\NNS\2329401 ._35\.\1740
D009020_D003248 CID in_0\IN\13603305 independent_1\JJ\1740 groups_2\NNS\2137 ,_3\,\1740 <e1>morphine</e1>_4\NN\2707683 inhibited_5\VBD\2510337 the_6\DT\1740 intestinal_7\JJ\1740 transit_8\NN\4365484 in_9\IN\13603305 48+/-4_10\CD\1740 %_11\NN\1740 and_12\CC\1740 38+/-4_13\CD\1740 %_14\NN\1740 after_15\IN\1740 acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 treatment_19\NN\654885 ,_20\,\1740 respectively_21\RB\1740 ,_22\,\1740 suggesting_23\VBG\1010118 that_24\IN\1740 tolerance_25\NN\5032565 did_26\VBD\1640855 not_27\RB\1740 develop_28\VB\1753788 to_29\IN\1740 the_30\DT\1740 <e2>constipating</e2>_31\VBG\440786 effects_32\NNS\13245626 ._33\.\1740
D009020_D003248 CID the_0\DT\1740 combination_1\NN\7951464 inhibited_2\VBD\2510337 intestinal_3\JJ\1740 transit_4\NN\4365484 similar_5\JJ\1740 to_6\TO\1740 that_7\DT\1740 produced_8\VBN\1617192 by_9\IN\1740 <e1>morphine</e1>_10\NN\2707683 regardless_11\RB\1740 of_12\IN\1740 the_13\DT\1740 time_14\NN\7308889 of_15\IN\1740 treatment_16\NN\654885 ,_17\,\1740 suggesting_18\VBG\1010118 that_19\IN\1740 metamizol_20\NN\1740 did_21\VBD\1640855 not_22\RB\1740 potentiate_23\VB\229605 morphine-induced_24\JJ\1740 <e2>constipation</e2>_25\NN\14299637 ._26\.\1740
D009020_D003248 CID the_0\DT\1740 combination_1\NN\7951464 inhibited_2\VBD\2510337 intestinal_3\JJ\1740 transit_4\NN\4365484 similar_5\JJ\1740 to_6\TO\1740 that_7\DT\1740 produced_8\VBN\1617192 by_9\IN\1740 morphine_10\NN\2707683 regardless_11\RB\1740 of_12\IN\1740 the_13\DT\1740 time_14\NN\7308889 of_15\IN\1740 treatment_16\NN\654885 ,_17\,\1740 suggesting_18\VBG\1010118 that_19\IN\1740 metamizol_20\NN\1740 did_21\VBD\1640855 not_22\RB\1740 potentiate_23\VB\229605 <e1>morphine-induced</e1>_24\JJ\1740 <e2>constipation</e2>_25\NN\14299637 ._26\.\1740
D002606_D010146 NONE on_0\IN\1740 the_1\DT\1740 13th_2\NN\1740 day_3\NN\15154774 ,_4\,\1740 antinociceptive_5\JJ\1740 effects_6\NNS\13245626 were_7\VBD\836236 assessed_8\VBN\670261 using_9\VBG\1156834 a_10\DT\13649268 model_11\NN\5888929 of_12\IN\1740 inflammatory_13\JJ\1740 nociception_14\NN\1740 ,_15\,\1740 <e2>pain-induced</e2>_16\JJ\1740 functional_17\JJ\1740 impairment_18\NN\7296428 model_19\NN\5888929 ,_20\,\1740 and_21\CC\1740 the_22\DT\1740 <e1>charcoal</e1>_23\NN\14633206 meal_24\NN\7570720 test_25\NN\5798043 was_26\VBD\836236 used_27\VBN\1156834 to_28\TO\1740 evaluate_29\VB\670261 the_30\DT\1740 intestinal_31\JJ\1740 transit_32\NN\4365484 ._33\.\1740
D009020_D059350 NONE these_0\DT\1740 findings_1\NNS\7951464 show_2\VBP\2137132 a_3\DT\13649268 significant_4\JJ\1740 interaction_5\NN\37396 between_6\IN\1740 <e1>morphine</e1>_7\NN\2707683 and_8\CC\1740 metamizol_9\JJ\1740 in_10\IN\13603305 chronically_11\RB\1740 treated_12\VBN\2376958 rats_13\NNS\2329401 ,_14\,\1740 suggesting_15\VBG\1010118 that_16\IN\1740 this_17\DT\1740 combination_18\NN\7951464 could_19\MD\1740 be_20\VB\836236 useful_21\JJ\1740 for_22\IN\1740 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 <e2>chronic_26\JJ\1740 pain</e2>_27\NN\14299637 ._28\.\1740
D004177_D059350 NONE these_0\DT\1740 findings_1\NNS\7951464 show_2\VBP\2137132 a_3\DT\13649268 significant_4\JJ\1740 interaction_5\NN\37396 between_6\IN\1740 morphine_7\NN\2707683 and_8\CC\1740 <e1>metamizol</e1>_9\JJ\1740 in_10\IN\13603305 chronically_11\RB\1740 treated_12\VBN\2376958 rats_13\NNS\2329401 ,_14\,\1740 suggesting_15\VBG\1010118 that_16\IN\1740 this_17\DT\1740 combination_18\NN\7951464 could_19\MD\1740 be_20\VB\836236 useful_21\JJ\1740 for_22\IN\1740 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 <e2>chronic_26\JJ\1740 pain</e2>_27\NN\14299637 ._28\.\1740
9672936
D008614_D012640 CID <e1>pethidine-associated</e1>_0\JJ\1740 <e2>seizure</e2>_1\NN\14081375 in_2\IN\13603305 a_3\DT\13649268 healthy_4\JJ\1740 adolescent_5\JJ\1740 receiving_6\NN\1740 pethidine_7\NN\1740 for_8\IN\1740 postoperative_9\JJ\1740 pain_10\NN\14299637 control_11\NN\5190804 ._12\.\1740
D008614_D012640 CID pethidine-associated_0\JJ\1740 <e2>seizure</e2>_1\NN\14081375 in_2\IN\13603305 a_3\DT\13649268 healthy_4\JJ\1740 adolescent_5\JJ\1740 receiving_6\NN\1740 <e1>pethidine</e1>_7\NN\1740 for_8\IN\1740 postoperative_9\JJ\1740 pain_10\NN\14299637 control_11\NN\5190804 ._12\.\1740
D008614_D010149 NONE <e1>pethidine-associated</e1>_0\JJ\1740 seizure_1\NN\14081375 in_2\IN\13603305 a_3\DT\13649268 healthy_4\JJ\1740 adolescent_5\JJ\1740 receiving_6\NN\1740 pethidine_7\NN\1740 for_8\IN\1740 <e2>postoperative_9\JJ\1740 pain</e2>_10\NN\14299637 control_11\NN\5190804 ._12\.\1740
D008614_D010149 NONE pethidine-associated_0\JJ\1740 seizure_1\NN\14081375 in_2\IN\13603305 a_3\DT\13649268 healthy_4\JJ\1740 adolescent_5\JJ\1740 receiving_6\NN\1740 <e1>pethidine</e1>_7\NN\1740 for_8\IN\1740 <e2>postoperative_9\JJ\1740 pain</e2>_10\NN\14299637 control_11\NN\5190804 ._12\.\1740
D008614_D010149 NONE a_0\DT\13649268 healthy_1\JJ\1740 17-year-old_2\JJ\1740 male_3\JJ\1740 received_4\VBD\2210855 standard_5\JJ\1740 intermittent_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 <e1>pethidine</e1>_9\NN\1740 via_10\IN\1740 a_11\DT\13649268 patient-controlled_12\JJ\1740 analgesia_13\NN\14034177 (_14\-LRB-\1740 pca_15\NN\1740 )_16\-RRB-\1740 pump_17\VBP\1224415 for_18\IN\1740 management_19\NN\1123598 of_20\IN\1740 <e2>postoperative_21\JJ\1740 pain</e2>_22\NN\14299637 control_23\NN\5190804 ._24\.\1740
1749407
D003042_D009203 CID <e1>cocaine-induced</e1>_0\JJ\1740 <e2>myocardial_1\JJ\1740 infarction</e2>_2\NN\14204950 :_3\:\1740 clinical_4\JJ\1740 observations_5\NNS\996969 and_6\CC\1740 pathogenetic_7\JJ\1740 considerations_8\NNS\5770926 ._9\.\1740
D003042_D009203 CID clinical_0\JJ\1740 and_1\CC\1740 experimental_2\JJ\1740 data_3\NNS\7951464 published_4\VBN\1621555 to_5\TO\1740 date_6\NN\15155220 suggest_7\VBP\1010118 several_8\JJ\1740 possible_9\JJ\1740 mechanisms_10\NNS\13446390 by_11\IN\1740 which_12\WDT\1740 <e1>cocaine</e1>_13\NN\3492717 may_14\MD\15209706 result_15\VB\2633881 in_16\IN\13603305 <e2>acute_17\JJ\1740 myocardial_18\JJ\1740 infarction</e2>_19\NN\14204950 ._20\.\1740
D003042_D009203 CID in_0\IN\13603305 individuals_1\NNS\7347 with_2\IN\1740 preexisting_3\JJ\1740 ,_4\,\1740 high-grade_5\JJ\1740 coronary_6\JJ\1740 arterial_7\JJ\1740 narrowing_8\NN\5064037 ,_9\,\1740 <e2>acute_10\JJ\1740 myocardial_11\JJ\1740 infarction</e2>_12\NN\14204950 may_13\MD\15209706 result_14\VB\2633881 from_15\IN\1740 an_16\DT\6697703 increase_17\NN\13576355 in_18\IN\13603305 myocardial_19\JJ\1740 oxygen_20\NN\14622893 demand_21\NN\6513366 associated_22\VBN\628491 with_23\IN\1740 <e1>cocaine-induced</e1>_24\JJ\1740 increase_25\NN\13576355 in_26\IN\13603305 rate-pressure_27\JJ\1740 product_28\NN\3076708 ._29\.\1740
D010100_D009203 NONE in_0\IN\13603305 individuals_1\NNS\7347 with_2\IN\1740 preexisting_3\JJ\1740 ,_4\,\1740 high-grade_5\JJ\1740 coronary_6\JJ\1740 arterial_7\JJ\1740 narrowing_8\NN\5064037 ,_9\,\1740 <e2>acute_10\JJ\1740 myocardial_11\JJ\1740 infarction</e2>_12\NN\14204950 may_13\MD\15209706 result_14\VB\2633881 from_15\IN\1740 an_16\DT\6697703 increase_17\NN\13576355 in_18\IN\13603305 myocardial_19\JJ\1740 <e1>oxygen</e1>_20\NN\14622893 demand_21\NN\6513366 associated_22\VBN\628491 with_23\IN\1740 cocaine-induced_24\JJ\1740 increase_25\NN\13576355 in_26\IN\13603305 rate-pressure_27\JJ\1740 product_28\NN\3076708 ._29\.\1740
D003042_D013035 NONE with_0\IN\1740 regard_1\NN\5817845 to_2\TO\1740 <e2>spasm</e2>_3\NN\14299637 ,_4\,\1740 the_5\DT\1740 clinical_6\JJ\1740 findings_7\NNS\7951464 are_8\VBP\836236 largely_9\RB\1740 circumstantial_10\JJ\1740 ,_11\,\1740 and_12\CC\1740 the_13\DT\1740 locus_14\NN\8645963 of_15\IN\1740 <e1>cocaine-induced</e1>_16\JJ\1740 vasoconstriction_17\NN\1149911 remains_18\VBZ\2604760 speculative_19\JJ\1740 ._20\.\1740
D003042_D013927 NONE finally_0\RB\1740 ,_1\,\1740 the_2\DT\1740 contribution_3\NN\786195 of_4\IN\1740 a_5\DT\13649268 primary_6\JJ\1740 ,_7\,\1740 <e2>thrombotic</e2>_8\JJ\1740 effect_9\NN\34213 of_10\IN\1740 <e1>cocaine</e1>_11\NN\3492717 has_12\VBZ\2108377 not_13\RB\1740 been_14\VBN\836236 excluded_15\VBN\471711 ._16\.\1740
4812392
D001379_D011565 NONE treatment_0\NN\654885 of_1\IN\1740 <e2>psoriasis</e2>_2\NN\14219661 with_3\IN\1740 <e1>azathioprine</e1>_4\NN\3740161 ._5\.\1740
D001379_D011565 NONE <e1>azathioprine</e1>_0\NN\3740161 treatment_1\NN\654885 benefited_2\VBD\2210855 19_3\CD\13745420 (_4\-LRB-\1740 66_5\CD\1740 %_6\NN\1740 )_7\-RRB-\1740 out_8\IN\66636 of_9\IN\1740 29_10\CD\13745420 patients_11\NNS\9898892 suffering_12\VBG\2110220 from_13\IN\1740 severe_14\JJ\1740 <e2>psoriasis</e2>_15\NN\14219661 ._16\.\1740
D001379_D056486 NONE liver_0\NN\5298729 biopsies_1\NNS\5739043 should_2\MD\1740 be_3\VB\836236 undertaken_4\VBN\1641914 at_5\IN\14622893 regular_6\JJ\1740 intervals_7\NNS\33615 if_8\IN\1740 <e1>azathioprine</e1>_9\NN\3740161 therapy_10\NN\657604 is_11\VBZ\836236 continued_12\VBN\2367363 so_13\RB\1740 that_14\IN\1740 structural_15\JJ\1740 <e2>liver_16\NN\5298729 damage</e2>_17\NN\7296428 may_18\MD\15209706 be_19\VB\836236 detected_20\VBN\2163746 at_21\IN\14622893 an_22\DT\6697703 early_23\JJ\1740 and_24\CC\1740 reversible_25\JJ\1740 stage_26\NN\15113229 ._27\.\1740
18343374
D002996_D012170 CID central_0\JJ\1740 <e2>retinal_1\JJ\1740 vein_2\NN\5417975 occlusion</e2>_3\NN\14081375 associated_4\VBN\628491 with_5\IN\1740 <e1>clomiphene-induced</e1>_6\JJ\1740 ovulation_7\NN\13526110 ._8\.\1740
D002996_D012170 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 central_7\JJ\1740 <e2>retinal_8\JJ\1740 vein_9\NN\5417975 occlusion</e2>_10\NN\14081375 associated_11\VBN\628491 with_12\IN\1740 <e1>clomiphene_13\NN\3329880 citrate</e1>_14\NN\14850483 (_15\-LRB-\1740 cc_16\NN\13616054 )_17\-RRB-\1740 ._18\.\1740
D002996_D012170 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 central_7\JJ\1740 <e2>retinal_8\JJ\1740 vein_9\NN\5417975 occlusion</e2>_10\NN\14081375 associated_11\VBN\628491 with_12\IN\1740 clomiphene_13\NN\3329880 citrate_14\NN\14850483 (_15\-LRB-\1740 <e1>cc</e1>_16\NN\13616054 )_17\-RRB-\1740 ._18\.\1740
D002996_D012170 CID main_0\NNP\9225146 outcome_1\NN\7291312 measure(s_2\NNP\1740 ):_3\-RRB-\1740 central_4\JJ\1740 <e2>retinal_5\JJ\1740 vein_6\NN\5417975 occlusion</e2>_7\NN\14081375 after_8\IN\1740 ovulation_9\NN\13526110 induction_10\NN\7450842 with_11\IN\1740 <e1>cc</e1>_12\NN\13616054 ._13\.\1740
D002996_D012170 CID result(s_0\NN\1740 ):_1\NN\1740 a_2\NN\13649268 36-year-old_3\JJ\1740 chinese_4\JJ\1740 woman_5\NN\9605289 developed_6\VBD\1753788 central_7\JJ\1740 <e2>retinal_8\JJ\1740 vein_9\NN\5417975 occlusion</e2>_10\NN\14081375 after_11\IN\1740 eight_12\CD\13741022 courses_13\NNS\883297 of_14\IN\1740 <e1>cc</e1>_15\NNP\13616054 ._16\.\1740
D002996_D012170 CID conclusion(s_0\NN\1740 ):_1\NFP\1740 this_2\DT\1740 is_3\VBZ\836236 the_4\DT\1740 first_5\JJ\1740 reported_6\VBN\831651 case_7\NN\7283608 of_8\IN\1740 central_9\JJ\1740 <e2>retinal_10\JJ\1740 vein_11\NN\5417975 occlusion</e2>_12\NN\14081375 after_13\IN\1740 treatment_14\NN\654885 with_15\IN\1740 <e1>cc</e1>_16\NN\13616054 ._17\.\1740
D002996_D013923 NONE a_0\DT\13649268 search_1\NN\407535 of_2\IN\1740 the_3\DT\1740 literature_4\NN\6362953 on_5\IN\1740 the_6\DT\1740 <e2>thromboembolic</e2>_7\JJ\1740 complications_8\NNS\1073995 of_9\IN\1740 <e1>cc</e1>_10\NN\13616054 does_11\VBZ\1640855 not_12\RB\1740 include_13\VB\690614 this_14\DT\1740 severe_15\JJ\1740 ophthalmic_16\JJ\1740 complication_17\NN\1073995 ,_18\,\1740 although_19\IN\1740 mild_20\JJ\1740 visual_21\JJ\1740 disturbance_22\NN\407535 after_23\IN\1740 cc_24\NNP\13616054 intake_25\NN\13440063 is_26\VBZ\836236 not_27\RB\1740 uncommon_28\JJ\1740 ._29\.\1740
D002996_D013923 NONE a_0\DT\13649268 search_1\NN\407535 of_2\IN\1740 the_3\DT\1740 literature_4\NN\6362953 on_5\IN\1740 the_6\DT\1740 <e2>thromboembolic</e2>_7\JJ\1740 complications_8\NNS\1073995 of_9\IN\1740 cc_10\NN\13616054 does_11\VBZ\1640855 not_12\RB\1740 include_13\VB\690614 this_14\DT\1740 severe_15\JJ\1740 ophthalmic_16\JJ\1740 complication_17\NN\1073995 ,_18\,\1740 although_19\IN\1740 mild_20\JJ\1740 visual_21\JJ\1740 disturbance_22\NN\407535 after_23\IN\1740 <e1>cc</e1>_24\NNP\13616054 intake_25\NN\13440063 is_26\VBZ\836236 not_27\RB\1740 uncommon_28\JJ\1740 ._29\.\1740
D002996_D014786 CID a_0\DT\13649268 search_1\NN\407535 of_2\IN\1740 the_3\DT\1740 literature_4\NN\6362953 on_5\IN\1740 the_6\DT\1740 thromboembolic_7\JJ\1740 complications_8\NNS\1073995 of_9\IN\1740 <e1>cc</e1>_10\NN\13616054 does_11\VBZ\1640855 not_12\RB\1740 include_13\VB\690614 this_14\DT\1740 severe_15\JJ\1740 ophthalmic_16\JJ\1740 complication_17\NN\1073995 ,_18\,\1740 although_19\IN\1740 mild_20\JJ\1740 <e2>visual_21\JJ\1740 disturbance</e2>_22\NN\407535 after_23\IN\1740 cc_24\NNP\13616054 intake_25\NN\13440063 is_26\VBZ\836236 not_27\RB\1740 uncommon_28\JJ\1740 ._29\.\1740
D002996_D014786 CID a_0\DT\13649268 search_1\NN\407535 of_2\IN\1740 the_3\DT\1740 literature_4\NN\6362953 on_5\IN\1740 the_6\DT\1740 thromboembolic_7\JJ\1740 complications_8\NNS\1073995 of_9\IN\1740 cc_10\NN\13616054 does_11\VBZ\1640855 not_12\RB\1740 include_13\VB\690614 this_14\DT\1740 severe_15\JJ\1740 ophthalmic_16\JJ\1740 complication_17\NN\1073995 ,_18\,\1740 although_19\IN\1740 mild_20\JJ\1740 <e2>visual_21\JJ\1740 disturbance</e2>_22\NN\407535 after_23\IN\1740 <e1>cc</e1>_24\NNP\13616054 intake_25\NN\13440063 is_26\VBZ\836236 not_27\RB\1740 uncommon_28\JJ\1740 ._29\.\1740
D002996_D007247 NONE extra_0\JJ\1740 caution_1\NN\4662951 is_2\VBZ\836236 warranted_3\VBN\1012073 in_4\IN\13603305 treating_5\VBG\2376958 <e2>infertility</e2>_6\NN\14034177 patients_7\NNS\9898892 with_8\IN\1740 <e1>cc</e1>_9\NN\13616054 ,_10\,\1740 and_11\CC\1740 patients_12\NNS\9898892 should_13\MD\1740 be_14\VB\836236 well_15\RB\1740 informed_16\JJ\1740 of_17\IN\1740 this_18\DT\1740 side_19\NN\8630039 effect_20\NN\34213 before_21\IN\1740 commencement_22\NN\15180528 of_23\IN\1740 therapy_24\NN\657604 ._25\.\1740
6203452
D002945_D002277 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>carcinoma</e2>_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>cisplatin</e1>_24\NN\1740 ,_25\,\1740 bleomycin_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 vinca_30\JJ\1740 alkaloid_31\NN\14727670 ._32\.\1740
D002945_D057049 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 <e2>thrombotic_5\JJ\1740 microangiopathy</e2>_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>cisplatin</e1>_24\NN\1740 ,_25\,\1740 bleomycin_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 vinca_30\JJ\1740 alkaloid_31\NN\14727670 ._32\.\1740
D002945_D051437 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 <e2>renal_10\JJ\1740 insufficiency</e2>_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>cisplatin</e1>_24\NN\1740 ,_25\,\1740 bleomycin_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 vinca_30\JJ\1740 alkaloid_31\NN\14727670 ._32\.\1740
D002945_D051437 NONE diagnosis_0\NN\152018 of_1\IN\1740 this_2\DT\1740 potentially_3\RB\1740 fatal_4\JJ\1740 complication_5\NN\1073995 may_6\MD\15209706 be_7\VB\836236 delayed_8\VBN\439958 or_9\CC\3541091 missed_10\VBN\1825237 if_11\IN\1740 renal_12\JJ\1740 tissue_13\NN\5220461 or_14\CC\3541091 the_15\DT\1740 peripheral_16\JJ\1740 blood_17\NN\5397468 smear_18\NN\6719579 is_19\VBZ\836236 not_20\RB\1740 examined_21\VBN\789138 ,_22\,\1740 because_23\IN\1740 <e2>renal_24\JJ\1740 failure</e2>_25\NN\66216 may_26\MD\15209706 be_27\VB\836236 ascribed_28\VBN\670261 to_29\TO\1740 <e1>cisplatin</e1>_30\NN\1740 nephrotoxicity_31\NN\1740 and_32\CC\1740 the_33\DT\1740 anemia_34\NN\14189204 and_35\CC\1740 thrombocytopenia_36\NN\14189204 to_37\TO\1740 drug-induced_38\JJ\1740 bone_39\NN\5286536 marrow_40\NN\5286536 suppression_41\NN\13489037 ._42\.\1740
D002945_D000743 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 <e2>microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia</e2>_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>cisplatin</e1>_24\NN\1740 ,_25\,\1740 bleomycin_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 vinca_30\JJ\1740 alkaloid_31\NN\14727670 ._32\.\1740
D002945_D013921 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 <e2>thrombocytopenia</e2>_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>cisplatin</e1>_24\NN\1740 ,_25\,\1740 bleomycin_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 vinca_30\JJ\1740 alkaloid_31\NN\14727670 ._32\.\1740
D002945_D013921 NONE diagnosis_0\NN\152018 of_1\IN\1740 this_2\DT\1740 potentially_3\RB\1740 fatal_4\JJ\1740 complication_5\NN\1073995 may_6\MD\15209706 be_7\VB\836236 delayed_8\VBN\439958 or_9\CC\3541091 missed_10\VBN\1825237 if_11\IN\1740 renal_12\JJ\1740 tissue_13\NN\5220461 or_14\CC\3541091 the_15\DT\1740 peripheral_16\JJ\1740 blood_17\NN\5397468 smear_18\NN\6719579 is_19\VBZ\836236 not_20\RB\1740 examined_21\VBN\789138 ,_22\,\1740 because_23\IN\1740 renal_24\JJ\1740 failure_25\NN\66216 may_26\MD\15209706 be_27\VB\836236 ascribed_28\VBN\670261 to_29\TO\1740 <e1>cisplatin</e1>_30\NN\1740 nephrotoxicity_31\NN\1740 and_32\CC\1740 the_33\DT\1740 anemia_34\NN\14189204 and_35\CC\1740 <e2>thrombocytopenia</e2>_36\NN\14189204 to_37\TO\1740 drug-induced_38\JJ\1740 bone_39\NN\5286536 marrow_40\NN\5286536 suppression_41\NN\13489037 ._42\.\1740
D001761_D002277 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>carcinoma</e2>_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 cisplatin_24\NN\1740 ,_25\,\1740 <e1>bleomycin</e1>_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 vinca_30\JJ\1740 alkaloid_31\NN\14727670 ._32\.\1740
D001761_D057049 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 <e2>thrombotic_5\JJ\1740 microangiopathy</e2>_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 cisplatin_24\NN\1740 ,_25\,\1740 <e1>bleomycin</e1>_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 vinca_30\JJ\1740 alkaloid_31\NN\14727670 ._32\.\1740
D001761_D051437 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 <e2>renal_10\JJ\1740 insufficiency</e2>_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 cisplatin_24\NN\1740 ,_25\,\1740 <e1>bleomycin</e1>_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 vinca_30\JJ\1740 alkaloid_31\NN\14727670 ._32\.\1740
D001761_D000743 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 <e2>microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia</e2>_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 cisplatin_24\NN\1740 ,_25\,\1740 <e1>bleomycin</e1>_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 vinca_30\JJ\1740 alkaloid_31\NN\14727670 ._32\.\1740
D001761_D013921 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 <e2>thrombocytopenia</e2>_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 cisplatin_24\NN\1740 ,_25\,\1740 <e1>bleomycin</e1>_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 vinca_30\JJ\1740 alkaloid_31\NN\14727670 ._32\.\1740
D014748_D002277 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>carcinoma</e2>_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 cisplatin_24\NN\1740 ,_25\,\1740 bleomycin_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 <e1>vinca_30\JJ\1740 alkaloid</e1>_31\NN\14727670 ._32\.\1740
D014748_D057049 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 <e2>thrombotic_5\JJ\1740 microangiopathy</e2>_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 cisplatin_24\NN\1740 ,_25\,\1740 bleomycin_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 <e1>vinca_30\JJ\1740 alkaloid</e1>_31\NN\14727670 ._32\.\1740
D014748_D051437 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 <e2>renal_10\JJ\1740 insufficiency</e2>_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 cisplatin_24\NN\1740 ,_25\,\1740 bleomycin_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 <e1>vinca_30\JJ\1740 alkaloid</e1>_31\NN\14727670 ._32\.\1740
D014748_D000743 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 <e2>microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia</e2>_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 thrombocytopenia_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 cisplatin_24\NN\1740 ,_25\,\1740 bleomycin_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 <e1>vinca_30\JJ\1740 alkaloid</e1>_31\NN\14727670 ._32\.\1740
D014748_D013921 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 carcinoma_3\NN\14239918 developed_4\VBD\1753788 thrombotic_5\JJ\1740 microangiopathy_6\NN\1740 (_7\-LRB-\1740 characterized_8\VBN\609683 by_9\IN\1740 renal_10\JJ\1740 insufficiency_11\NN\14462946 ,_12\,\1740 microangiopathic_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ,_16\,\1740 and_17\CC\1740 usually_18\RB\1740 <e2>thrombocytopenia</e2>_19\NN\14189204 )_20\-RRB-\1740 after_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 cisplatin_24\NN\1740 ,_25\,\1740 bleomycin_26\NN\1740 ,_27\,\1740 and_28\CC\1740 a_29\DT\13649268 <e1>vinca_30\JJ\1740 alkaloid</e1>_31\NN\14727670 ._32\.\1740
D002945_D007674 CID diagnosis_0\NN\152018 of_1\IN\1740 this_2\DT\1740 potentially_3\RB\1740 fatal_4\JJ\1740 complication_5\NN\1073995 may_6\MD\15209706 be_7\VB\836236 delayed_8\VBN\439958 or_9\CC\3541091 missed_10\VBN\1825237 if_11\IN\1740 renal_12\JJ\1740 tissue_13\NN\5220461 or_14\CC\3541091 the_15\DT\1740 peripheral_16\JJ\1740 blood_17\NN\5397468 smear_18\NN\6719579 is_19\VBZ\836236 not_20\RB\1740 examined_21\VBN\789138 ,_22\,\1740 because_23\IN\1740 renal_24\JJ\1740 failure_25\NN\66216 may_26\MD\15209706 be_27\VB\836236 ascribed_28\VBN\670261 to_29\TO\1740 <e1>cisplatin</e1>_30\NN\1740 <e2>nephrotoxicity</e2>_31\NN\1740 and_32\CC\1740 the_33\DT\1740 anemia_34\NN\14189204 and_35\CC\1740 thrombocytopenia_36\NN\14189204 to_37\TO\1740 drug-induced_38\JJ\1740 bone_39\NN\5286536 marrow_40\NN\5286536 suppression_41\NN\13489037 ._42\.\1740
D002945_D000740 NONE diagnosis_0\NN\152018 of_1\IN\1740 this_2\DT\1740 potentially_3\RB\1740 fatal_4\JJ\1740 complication_5\NN\1073995 may_6\MD\15209706 be_7\VB\836236 delayed_8\VBN\439958 or_9\CC\3541091 missed_10\VBN\1825237 if_11\IN\1740 renal_12\JJ\1740 tissue_13\NN\5220461 or_14\CC\3541091 the_15\DT\1740 peripheral_16\JJ\1740 blood_17\NN\5397468 smear_18\NN\6719579 is_19\VBZ\836236 not_20\RB\1740 examined_21\VBN\789138 ,_22\,\1740 because_23\IN\1740 renal_24\JJ\1740 failure_25\NN\66216 may_26\MD\15209706 be_27\VB\836236 ascribed_28\VBN\670261 to_29\TO\1740 <e1>cisplatin</e1>_30\NN\1740 nephrotoxicity_31\NN\1740 and_32\CC\1740 the_33\DT\1740 <e2>anemia</e2>_34\NN\14189204 and_35\CC\1740 thrombocytopenia_36\NN\14189204 to_37\TO\1740 drug-induced_38\JJ\1740 bone_39\NN\5286536 marrow_40\NN\5286536 suppression_41\NN\13489037 ._42\.\1740
D002945_D001855 NONE diagnosis_0\NN\152018 of_1\IN\1740 this_2\DT\1740 potentially_3\RB\1740 fatal_4\JJ\1740 complication_5\NN\1073995 may_6\MD\15209706 be_7\VB\836236 delayed_8\VBN\439958 or_9\CC\3541091 missed_10\VBN\1825237 if_11\IN\1740 renal_12\JJ\1740 tissue_13\NN\5220461 or_14\CC\3541091 the_15\DT\1740 peripheral_16\JJ\1740 blood_17\NN\5397468 smear_18\NN\6719579 is_19\VBZ\836236 not_20\RB\1740 examined_21\VBN\789138 ,_22\,\1740 because_23\IN\1740 renal_24\JJ\1740 failure_25\NN\66216 may_26\MD\15209706 be_27\VB\836236 ascribed_28\VBN\670261 to_29\TO\1740 <e1>cisplatin</e1>_30\NN\1740 nephrotoxicity_31\NN\1740 and_32\CC\1740 the_33\DT\1740 anemia_34\NN\14189204 and_35\CC\1740 thrombocytopenia_36\NN\14189204 to_37\TO\1740 drug-induced_38\JJ\1740 <e2>bone_39\NN\5286536 marrow_40\NN\5286536 suppression</e2>_41\NN\13489037 ._42\.\1740
11279304
D018943_D066126 NONE brain_0\NN\5462674 natriuretic_1\JJ\1740 peptide_2\NN\14724264 is_3\VBZ\836236 a_4\DT\13649268 predictor_5\NN\10756433 of_6\IN\1740 <e1>anthracycline-induced</e1>_7\JJ\1740 <e2>cardiotoxicity</e2>_8\NN\1740 ._9\.\1740
D018943_D066126 NONE <e1>anthracyclines</e1>_0\NNS\1740 are_1\VBP\836236 effective_2\JJ\1740 antineoplastic_3\JJ\1740 drugs_4\NNS\14778436 ,_5\,\1740 but_6\CC\1740 they_7\PRP\1740 frequently_8\RB\1740 cause_9\VBP\1617192 dose-related_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 ._12\.\1740
D018943_D066126 NONE the_0\DT\1740 <e2>cardiotoxicity</e2>_1\NN\1740 of_2\IN\1740 conventional_3\JJ\1740 <e1>anthracycline</e1>_4\NN\1740 therapy_5\NN\657604 highlights_6\VBZ\514463 a_7\DT\13649268 need_8\NN\13920835 to_9\TO\1740 search_10\VB\2131279 for_11\IN\1740 methods_12\NNS\5616786 that_13\WDT\1740 are_14\VBP\836236 highly_15\RB\1740 sensitive_16\JJ\1740 and_17\CC\1740 capable_18\JJ\1740 of_19\IN\1740 predicting_20\VBG\916909 cardiac_21\JJ\1740 dysfunction_22\NN\14204950 ._23\.\1740
D018943_D066126 NONE we_0\PRP\1740 measured_1\VBD\697589 the_2\DT\1740 plasma_3\NN\5398023 level_4\NN\4916342 of_5\IN\1740 brain_6\NN\5462674 natriuretic_7\JJ\1740 peptide_8\NN\14724264 (_9\-LRB-\1740 bnp_10\NN\1740 )_11\-RRB-\1740 to_12\TO\1740 determine_13\VB\1645601 whether_14\IN\1740 bnp_15\NN\1740 might_16\MD\5029706 serve_17\VB\2669789 as_18\IN\14622893 a_19\DT\13649268 simple_20\JJ\1740 diagnostic_21\JJ\1740 indicator_22\NN\6636259 of_23\IN\1740 <e1>anthracycline-induced</e1>_24\JJ\1740 <e2>cardiotoxicity</e2>_25\NN\1740 in_26\IN\13603305 patients_27\NNS\9898892 with_28\IN\1740 acute_29\JJ\1740 leukemia_30\NN\14239918 treated_31\VBN\2376958 with_32\IN\1740 a_33\DT\13649268 daunorubicin_34\NN\1740 (dnr)-containing_35\NN\1740 regimen_36\NN\5898568 ._37\.\1740
D018943_D066126 NONE these_0\DT\1740 preliminary_1\JJ\1740 results_2\NNS\34213 suggest_3\VBP\1010118 that_4\IN\1740 bnp_5\NN\1740 may_6\MD\15209706 be_7\VB\836236 useful_8\JJ\1740 as_9\IN\14622893 an_10\DT\6697703 early_11\JJ\1740 and_12\CC\1740 sensitive_13\JJ\1740 indicator_14\NN\6636259 of_15\IN\1740 <e1>anthracycline-induced</e1>_16\JJ\1740 <e2>cardiotoxicity</e2>_17\NN\1740 ._18\.\1740
D018943_D006331 NONE the_0\DT\1740 cardiotoxicity_1\NN\1740 of_2\IN\1740 conventional_3\JJ\1740 <e1>anthracycline</e1>_4\NN\1740 therapy_5\NN\657604 highlights_6\VBZ\514463 a_7\DT\13649268 need_8\NN\13920835 to_9\TO\1740 search_10\VB\2131279 for_11\IN\1740 methods_12\NNS\5616786 that_13\WDT\1740 are_14\VBP\836236 highly_15\RB\1740 sensitive_16\JJ\1740 and_17\CC\1740 capable_18\JJ\1740 of_19\IN\1740 predicting_20\VBG\916909 <e2>cardiac_21\JJ\1740 dysfunction</e2>_22\NN\14204950 ._23\.\1740
D018943_D015470 NONE we_0\PRP\1740 measured_1\VBD\697589 the_2\DT\1740 plasma_3\NN\5398023 level_4\NN\4916342 of_5\IN\1740 brain_6\NN\5462674 natriuretic_7\JJ\1740 peptide_8\NN\14724264 (_9\-LRB-\1740 bnp_10\NN\1740 )_11\-RRB-\1740 to_12\TO\1740 determine_13\VB\1645601 whether_14\IN\1740 bnp_15\NN\1740 might_16\MD\5029706 serve_17\VB\2669789 as_18\IN\14622893 a_19\DT\13649268 simple_20\JJ\1740 diagnostic_21\JJ\1740 indicator_22\NN\6636259 of_23\IN\1740 <e1>anthracycline-induced</e1>_24\JJ\1740 cardiotoxicity_25\NN\1740 in_26\IN\13603305 patients_27\NNS\9898892 with_28\IN\1740 <e2>acute_29\JJ\1740 leukemia</e2>_30\NN\14239918 treated_31\VBN\2376958 with_32\IN\1740 a_33\DT\13649268 daunorubicin_34\NN\1740 (dnr)-containing_35\NN\1740 regimen_36\NN\5898568 ._37\.\1740
D003630_D066126 NONE we_0\PRP\1740 measured_1\VBD\697589 the_2\DT\1740 plasma_3\NN\5398023 level_4\NN\4916342 of_5\IN\1740 brain_6\NN\5462674 natriuretic_7\JJ\1740 peptide_8\NN\14724264 (_9\-LRB-\1740 bnp_10\NN\1740 )_11\-RRB-\1740 to_12\TO\1740 determine_13\VB\1645601 whether_14\IN\1740 bnp_15\NN\1740 might_16\MD\5029706 serve_17\VB\2669789 as_18\IN\14622893 a_19\DT\13649268 simple_20\JJ\1740 diagnostic_21\JJ\1740 indicator_22\NN\6636259 of_23\IN\1740 anthracycline-induced_24\JJ\1740 <e2>cardiotoxicity</e2>_25\NN\1740 in_26\IN\13603305 patients_27\NNS\9898892 with_28\IN\1740 acute_29\JJ\1740 leukemia_30\NN\14239918 treated_31\VBN\2376958 with_32\IN\1740 a_33\DT\13649268 <e1>daunorubicin</e1>_34\NN\1740 (dnr)-containing_35\NN\1740 regimen_36\NN\5898568 ._37\.\1740
D003630_D066126 NONE we_0\PRP\1740 measured_1\VBD\697589 the_2\DT\1740 plasma_3\NN\5398023 level_4\NN\4916342 of_5\IN\1740 brain_6\NN\5462674 natriuretic_7\JJ\1740 peptide_8\NN\14724264 (_9\-LRB-\1740 bnp_10\NN\1740 )_11\-RRB-\1740 to_12\TO\1740 determine_13\VB\1645601 whether_14\IN\1740 bnp_15\NN\1740 might_16\MD\5029706 serve_17\VB\2669789 as_18\IN\14622893 a_19\DT\13649268 simple_20\JJ\1740 diagnostic_21\JJ\1740 indicator_22\NN\6636259 of_23\IN\1740 anthracycline-induced_24\JJ\1740 <e2>cardiotoxicity</e2>_25\NN\1740 in_26\IN\13603305 patients_27\NNS\9898892 with_28\IN\1740 acute_29\JJ\1740 leukemia_30\NN\14239918 treated_31\VBN\2376958 with_32\IN\1740 a_33\DT\13649268 daunorubicin_34\NN\1740 <e1>(dnr)-containing</e1>_35\NN\1740 regimen_36\NN\5898568 ._37\.\1740
D003630_D015470 NONE we_0\PRP\1740 measured_1\VBD\697589 the_2\DT\1740 plasma_3\NN\5398023 level_4\NN\4916342 of_5\IN\1740 brain_6\NN\5462674 natriuretic_7\JJ\1740 peptide_8\NN\14724264 (_9\-LRB-\1740 bnp_10\NN\1740 )_11\-RRB-\1740 to_12\TO\1740 determine_13\VB\1645601 whether_14\IN\1740 bnp_15\NN\1740 might_16\MD\5029706 serve_17\VB\2669789 as_18\IN\14622893 a_19\DT\13649268 simple_20\JJ\1740 diagnostic_21\JJ\1740 indicator_22\NN\6636259 of_23\IN\1740 anthracycline-induced_24\JJ\1740 cardiotoxicity_25\NN\1740 in_26\IN\13603305 patients_27\NNS\9898892 with_28\IN\1740 <e2>acute_29\JJ\1740 leukemia</e2>_30\NN\14239918 treated_31\VBN\2376958 with_32\IN\1740 a_33\DT\13649268 <e1>daunorubicin</e1>_34\NN\1740 (dnr)-containing_35\NN\1740 regimen_36\NN\5898568 ._37\.\1740
D003630_D015470 NONE we_0\PRP\1740 measured_1\VBD\697589 the_2\DT\1740 plasma_3\NN\5398023 level_4\NN\4916342 of_5\IN\1740 brain_6\NN\5462674 natriuretic_7\JJ\1740 peptide_8\NN\14724264 (_9\-LRB-\1740 bnp_10\NN\1740 )_11\-RRB-\1740 to_12\TO\1740 determine_13\VB\1645601 whether_14\IN\1740 bnp_15\NN\1740 might_16\MD\5029706 serve_17\VB\2669789 as_18\IN\14622893 a_19\DT\13649268 simple_20\JJ\1740 diagnostic_21\JJ\1740 indicator_22\NN\6636259 of_23\IN\1740 anthracycline-induced_24\JJ\1740 cardiotoxicity_25\NN\1740 in_26\IN\13603305 patients_27\NNS\9898892 with_28\IN\1740 <e2>acute_29\JJ\1740 leukemia</e2>_30\NN\14239918 treated_31\VBN\2376958 with_32\IN\1740 a_33\DT\13649268 daunorubicin_34\NN\1740 <e1>(dnr)-containing</e1>_35\NN\1740 regimen_36\NN\5898568 ._37\.\1740
D003630_D015470 NONE thirteen_0\CD\13745420 patients_1\NNS\9898892 with_2\IN\1740 <e2>acute_3\JJ\1740 leukemia</e2>_4\NN\14239918 were_5\VBD\836236 treated_6\VBN\2376958 with_7\IN\1740 a_8\DT\13649268 <e1>dnr-containing</e1>_9\JJ\1740 regimen_10\NN\5898568 ._11\.\1740
D003630_D006333 CID on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 bnp_5\NN\1740 did_6\VBD\1640855 not_7\RB\1740 increase_8\VB\169651 in_9\IN\13603305 the_10\DT\1740 patients_11\NNS\9898892 without_12\IN\1740 <e2>heart_13\NN\5919034 failure</e2>_14\NN\66216 given_15\VBN\2327200 <e1>dnr</e1>_16\NN\1740 ,_17\,\1740 even_18\RB\1740 at_19\IN\14622893 more_20\JJR\1740 than_21\IN\1740 700_22\CD\1740 mg/m(2_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
20067456
D016642_D012735 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 the_3\DT\1740 adjunctive_4\JJ\1740 <e1>bupropion</e1>_5\NN\1740 on_6\IN\1740 male_7\JJ\1740 <e2>sexual_8\JJ\1740 dysfunction</e2>_9\NN\14204950 induced_10\VBN\1627355 by_11\IN\1740 a_12\DT\13649268 selective_13\JJ\1740 serotonin_14\NN\14807737 reuptake_15\NN\13571580 inhibitor_16\NN\20090 :_17\:\1740 a_18\DT\13649268 double-blind_19\JJ\1740 placebo-controlled_20\JJ\1740 and_21\CC\1740 randomized_22\JJ\1740 study_23\NN\635850 ._24\.\1740
D016642_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 <e1>bupropion</e1>_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 <e2>sexual_17\JJ\1740 dysfunction</e2>_18\NN\14204950 (_19\-LRB-\1740 sd_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor_28\NN\20090 (_29\-LRB-\1740 ssri_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 sd_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 ssris_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D016642_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 <e1>bupropion</e1>_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 sexual_17\JJ\1740 dysfunction_18\NN\14204950 (_19\-LRB-\1740 <e2>sd</e2>_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor_28\NN\20090 (_29\-LRB-\1740 ssri_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 sd_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 ssris_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D016642_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 <e1>bupropion</e1>_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 sexual_17\JJ\1740 dysfunction_18\NN\14204950 (_19\-LRB-\1740 sd_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor_28\NN\20090 (_29\-LRB-\1740 ssri_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 <e2>sd</e2>_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 ssris_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D016642_D012735 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>bupropion</e1>_2\NN\1740 is_3\VBZ\836236 an_4\DT\6697703 effective_5\JJ\1740 treatment_6\NN\654885 for_7\IN\1740 male_8\JJ\1740 <e2>sd</e2>_9\NN\1740 induced_10\VBN\1627355 by_11\IN\1740 ssris_12\NNP\2718811 ._13\.\1740
D017367_D012735 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 the_3\DT\1740 adjunctive_4\JJ\1740 bupropion_5\NN\1740 on_6\IN\1740 male_7\JJ\1740 <e2>sexual_8\JJ\1740 dysfunction</e2>_9\NN\14204950 induced_10\VBN\1627355 by_11\IN\1740 a_12\DT\13649268 <e1>selective_13\JJ\1740 serotonin_14\NN\14807737 reuptake_15\NN\13571580 inhibitor</e1>_16\NN\20090 :_17\:\1740 a_18\DT\13649268 double-blind_19\JJ\1740 placebo-controlled_20\JJ\1740 and_21\CC\1740 randomized_22\JJ\1740 study_23\NN\635850 ._24\.\1740
D017367_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 bupropion_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 <e2>sexual_17\JJ\1740 dysfunction</e2>_18\NN\14204950 (_19\-LRB-\1740 sd_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 <e1>selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor</e1>_28\NN\20090 (_29\-LRB-\1740 ssri_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 sd_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 ssris_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D017367_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 bupropion_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 sexual_17\JJ\1740 dysfunction_18\NN\14204950 (_19\-LRB-\1740 <e2>sd</e2>_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 <e1>selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor</e1>_28\NN\20090 (_29\-LRB-\1740 ssri_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 sd_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 ssris_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D017367_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 bupropion_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 sexual_17\JJ\1740 dysfunction_18\NN\14204950 (_19\-LRB-\1740 sd_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 <e1>selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor</e1>_28\NN\20090 (_29\-LRB-\1740 ssri_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 <e2>sd</e2>_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 ssris_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D017367_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 bupropion_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 <e2>sexual_17\JJ\1740 dysfunction</e2>_18\NN\14204950 (_19\-LRB-\1740 sd_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor_28\NN\20090 (_29\-LRB-\1740 <e1>ssri</e1>_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 sd_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 ssris_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D017367_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 bupropion_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 sexual_17\JJ\1740 dysfunction_18\NN\14204950 (_19\-LRB-\1740 <e2>sd</e2>_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor_28\NN\20090 (_29\-LRB-\1740 <e1>ssri</e1>_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 sd_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 ssris_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D017367_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 bupropion_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 sexual_17\JJ\1740 dysfunction_18\NN\14204950 (_19\-LRB-\1740 sd_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor_28\NN\20090 (_29\-LRB-\1740 <e1>ssri</e1>_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 <e2>sd</e2>_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 ssris_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D017367_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 bupropion_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 <e2>sexual_17\JJ\1740 dysfunction</e2>_18\NN\14204950 (_19\-LRB-\1740 sd_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor_28\NN\20090 (_29\-LRB-\1740 ssri_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 sd_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 <e1>ssris</e1>_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D017367_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 bupropion_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 sexual_17\JJ\1740 dysfunction_18\NN\14204950 (_19\-LRB-\1740 <e2>sd</e2>_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor_28\NN\20090 (_29\-LRB-\1740 ssri_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 sd_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 <e1>ssris</e1>_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D017367_D012735 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 efficacy_7\NN\5199286 of_8\IN\1740 adjunctive_9\JJ\1740 bupropion_10\NN\1740 sustained-release_11\NN\1740 (_12\-LRB-\1740 sr_13\NN\14625458 )_14\-RRB-\1740 on_15\IN\1740 male_16\JJ\1740 sexual_17\JJ\1740 dysfunction_18\NN\14204950 (_19\-LRB-\1740 sd_20\NN\1740 )_21\-RRB-\1740 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 selective_25\JJ\1740 serotonin_26\NN\14807737 reuptake_27\NN\13571580 inhibitor_28\NN\20090 (_29\-LRB-\1740 ssri_30\NN\2718811 )_31\-RRB-\1740 ,_32\,\1740 as_33\IN\14622893 <e2>sd</e2>_34\NN\1740 is_35\VBZ\836236 a_36\DT\13649268 common_37\JJ\1740 side-effect_38\NN\1740 of_39\IN\1740 <e1>ssris</e1>_40\NNP\2718811 and_41\CC\1740 the_42\DT\1740 most_43\RBS\1740 effective_44\JJ\1740 treatments_45\NNS\654885 have_46\VBP\2108377 yet_47\RB\1740 to_48\TO\1740 be_49\VB\836236 determined_50\VBN\1645601 ._51\.\1740
D017367_D012735 NONE in_0\IN\13603305 linear_1\JJ\1740 regression_2\NN\14501726 analyses_3\VBZ\78760 the_4\DT\1740 cgi-sf_5\NN\1740 score_6\NN\5736149 was_7\VBD\836236 not_8\RB\1740 affected_9\VBN\126264 significantly_10\RB\1740 by_11\IN\1740 the_12\DT\1740 duration_13\NN\15113229 of_14\IN\1740 <e2>sd</e2>_15\NN\1740 ,_16\,\1740 type_17\NN\5839024 of_18\IN\1740 <e1>ssri</e1>_19\NN\2718811 used_20\VBN\1156834 and_21\CC\1740 age_22\NN\4916342 ._23\.\1740
D017367_D012735 NONE conclusions_0\NNS\5837957 :_1\:\1740 bupropion_2\NN\1740 is_3\VBZ\836236 an_4\DT\6697703 effective_5\JJ\1740 treatment_6\NN\654885 for_7\IN\1740 male_8\JJ\1740 <e2>sd</e2>_9\NN\1740 induced_10\VBN\1627355 by_11\IN\1740 <e1>ssris</e1>_12\NNP\2718811 ._13\.\1740
8231633
D002118_D064420 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>calcium</e1>_2\NN\14625458 channel_3\NN\6251781 blockers_4\NNS\10101634 on_5\IN\1740 bupivacaine-induced_6\JJ\1740 <e2>toxicity</e2>_7\NN\13576101 ._8\.\1740
D002118_D064420 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 investigate_7\VB\644583 the_8\DT\1740 influence_9\NN\5190804 of_10\IN\1740 <e1>calcium</e1>_11\NN\14625458 channel_12\NN\6251781 blockers_13\NNS\10101634 on_14\IN\1740 bupivacaine-induced_15\JJ\1740 acute_16\JJ\1740 <e2>toxicity</e2>_17\NN\13576101 ._18\.\1740
D002045_D064420 NONE effects_0\NNS\13245626 of_1\IN\1740 calcium_2\NN\14625458 channel_3\NN\6251781 blockers_4\NNS\10101634 on_5\IN\1740 <e1>bupivacaine-induced</e1>_6\JJ\1740 <e2>toxicity</e2>_7\NN\13576101 ._8\.\1740
D002045_D064420 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 investigate_7\VB\644583 the_8\DT\1740 influence_9\NN\5190804 of_10\IN\1740 calcium_11\NN\14625458 channel_12\NN\6251781 blockers_13\NNS\10101634 on_14\IN\1740 <e1>bupivacaine-induced</e1>_15\JJ\1740 acute_16\JJ\1740 <e2>toxicity</e2>_17\NN\13576101 ._18\.\1740
D002045_D012640 CID the_0\DT\1740 convulsant_1\JJ\1740 activity_2\NN\30358 of_3\IN\1740 <e1>bupivacaine</e1>_4\NN\1740 was_5\VBD\836236 not_6\RB\1740 significantly_7\RB\1740 modified_8\VBN\109660 but_9\CC\1740 calcium_10\NN\14625458 channel_11\NN\6251781 blockers_12\NNS\10101634 decreased_13\VBD\169651 the_14\DT\1740 time_15\NN\7308889 of_16\IN\1740 latency_17\NN\15269513 to_18\TO\1740 obtain_19\VB\2210855 bupivacaine-induced_20\JJ\1740 <e2>convulsions</e2>_21\NNS\14081375 ;_22\:\1740 this_23\DT\1740 effect_24\NN\34213 was_25\VBD\836236 less_26\RBR\1740 pronounced_27\JJ\1740 with_28\IN\1740 bepridil_29\NN\1740 ._30\.\1740
D002045_D012640 CID the_0\DT\1740 convulsant_1\JJ\1740 activity_2\NN\30358 of_3\IN\1740 bupivacaine_4\NN\1740 was_5\VBD\836236 not_6\RB\1740 significantly_7\RB\1740 modified_8\VBN\109660 but_9\CC\1740 calcium_10\NN\14625458 channel_11\NN\6251781 blockers_12\NNS\10101634 decreased_13\VBD\169651 the_14\DT\1740 time_15\NN\7308889 of_16\IN\1740 latency_17\NN\15269513 to_18\TO\1740 obtain_19\VB\2210855 <e1>bupivacaine-induced</e1>_20\JJ\1740 <e2>convulsions</e2>_21\NNS\14081375 ;_22\:\1740 this_23\DT\1740 effect_24\NN\34213 was_25\VBD\836236 less_26\RBR\1740 pronounced_27\JJ\1740 with_28\IN\1740 bepridil_29\NN\1740 ._30\.\1740
D002118_D012640 NONE the_0\DT\1740 convulsant_1\JJ\1740 activity_2\NN\30358 of_3\IN\1740 bupivacaine_4\NN\1740 was_5\VBD\836236 not_6\RB\1740 significantly_7\RB\1740 modified_8\VBN\109660 but_9\CC\1740 <e1>calcium</e1>_10\NN\14625458 channel_11\NN\6251781 blockers_12\NNS\10101634 decreased_13\VBD\169651 the_14\DT\1740 time_15\NN\7308889 of_16\IN\1740 latency_17\NN\15269513 to_18\TO\1740 obtain_19\VB\2210855 bupivacaine-induced_20\JJ\1740 <e2>convulsions</e2>_21\NNS\14081375 ;_22\:\1740 this_23\DT\1740 effect_24\NN\34213 was_25\VBD\836236 less_26\RBR\1740 pronounced_27\JJ\1740 with_28\IN\1740 bepridil_29\NN\1740 ._30\.\1740
D015764_D012640 NONE the_0\DT\1740 convulsant_1\JJ\1740 activity_2\NN\30358 of_3\IN\1740 bupivacaine_4\NN\1740 was_5\VBD\836236 not_6\RB\1740 significantly_7\RB\1740 modified_8\VBN\109660 but_9\CC\1740 calcium_10\NN\14625458 channel_11\NN\6251781 blockers_12\NNS\10101634 decreased_13\VBD\169651 the_14\DT\1740 time_15\NN\7308889 of_16\IN\1740 latency_17\NN\15269513 to_18\TO\1740 obtain_19\VB\2210855 bupivacaine-induced_20\JJ\1740 <e2>convulsions</e2>_21\NNS\14081375 ;_22\:\1740 this_23\DT\1740 effect_24\NN\34213 was_25\VBD\836236 less_26\RBR\1740 pronounced_27\JJ\1740 with_28\IN\1740 <e1>bepridil</e1>_29\NN\1740 ._30\.\1740
2549018
D005473_D017109 CID <e1>fluoxetine-induced</e1>_0\JJ\1740 <e2>akathisia</e2>_1\NN\1740 :_2\:\1740 clinical_3\JJ\1740 and_4\CC\1740 theoretical_5\JJ\1740 implications_6\NNS\5774614 ._7\.\1740
D005473_D017109 CID five_0\CD\13741022 patients_1\NNS\9898892 receiving_2\VBG\2210855 <e1>fluoxetine</e1>_3\NN\4169152 for_4\IN\1740 the_5\DT\1740 treatment_6\NN\654885 of_7\IN\1740 obsessive_8\JJ\1740 compulsive_9\JJ\1740 disorder_10\NN\14034177 or_11\CC\3541091 major_12\JJ\1740 depression_13\NN\14373582 developed_14\VBD\1753788 <e2>akathisia</e2>_15\NN\1740 ._16\.\1740
D005473_D017109 CID the_0\DT\1740 typical_1\JJ\1740 <e1>fluoxetine-induced</e1>_2\JJ\1740 symptoms_3\NNS\5823932 of_4\IN\1740 restlessness_5\NN\4773351 ,_6\,\1740 constant_7\JJ\1740 pacing_8\NN\15122011 ,_9\,\1740 purposeless_10\NN\1740 movements_11\NNS\191142 of_12\IN\1740 the_13\DT\1740 feet_14\NNS\5563034 and_15\CC\1740 legs_16\NNS\5032918 ,_17\,\1740 and_18\CC\1740 marked_19\JJ\1740 anxiety_20\NN\14373582 were_21\VBD\836236 indistinguishable_22\JJ\1740 from_23\IN\1740 those_24\DT\1740 of_25\IN\1740 neuroleptic-induced_26\JJ\1740 <e2>akathisia</e2>_27\NN\1740 ._28\.\1740
D005473_D017109 CID three_0\CD\13741022 patients_1\NNS\9898892 who_2\WP\8299493 had_3\VBD\2108377 experienced_4\VBN\2108377 neuroleptic-induced_5\JJ\1740 <e2>akathisia</e2>_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 past_9\NN\28270 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 symptoms_13\NNS\5823932 of_14\IN\1740 <e1>fluoxetine-induced</e1>_15\JJ\1740 akathisia_16\NN\1740 were_17\VBD\836236 identical_18\JJ\1740 ,_19\,\1740 although_20\IN\1740 somewhat_21\RB\1740 milder_22\NN\1740 ._23\.\1740
D005473_D017109 CID three_0\CD\13741022 patients_1\NNS\9898892 who_2\WP\8299493 had_3\VBD\2108377 experienced_4\VBN\2108377 neuroleptic-induced_5\JJ\1740 akathisia_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 past_9\NN\28270 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 symptoms_13\NNS\5823932 of_14\IN\1740 <e1>fluoxetine-induced</e1>_15\JJ\1740 <e2>akathisia</e2>_16\NN\1740 were_17\VBD\836236 identical_18\JJ\1740 ,_19\,\1740 although_20\IN\1740 somewhat_21\RB\1740 milder_22\NN\1740 ._23\.\1740
D005473_D017109 CID <e2>akathisia</e2>_0\NNP\1740 appeared_1\VBD\2604760 to_2\TO\1740 be_3\VB\836236 a_4\DT\13649268 common_5\JJ\1740 side_6\NN\8630039 effect_7\NN\34213 of_8\IN\1740 <e1>fluoxetine</e1>_9\NN\4169152 and_10\CC\1740 generally_11\RB\1740 responded_12\VBD\2367363 well_13\RB\1740 to_14\IN\1740 treatment_15\NN\654885 with_16\IN\1740 the_17\DT\1740 beta-adrenergic_18\JJ\1740 antagonist_19\NN\7846 propranolol_20\NN\1740 ,_21\,\1740 dose_22\NN\3740161 reduction_23\NN\351485 ,_24\,\1740 or_25\CC\3541091 both_26\DT\1740 ._27\.\1740
D005473_D017109 CID the_0\DT\1740 authors_1\NNS\9610660 suggest_2\VBP\1010118 that_3\IN\1740 <e1>fluoxetine-induced</e1>_4\JJ\1740 <e2>akathisia</e2>_5\NN\1740 may_6\MD\15209706 be_7\VB\836236 caused_8\VBN\1617192 by_9\IN\1740 serotonergically_10\RB\1740 mediated_11\VBN\761713 inhibition_12\NN\1068773 of_13\IN\1740 dopaminergic_14\JJ\1740 neurotransmission_15\NN\1740 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 pathophysiology_19\NN\1740 of_20\IN\1740 fluoxetine-induced_21\JJ\1740 akathisia_22\NN\1740 and_23\CC\1740 tricyclic_24\JJ\1740 antidepressant-induced_25\JJ\1740 "_26\``\1740 jitteriness_27\NN\7523905 "_28\''\1740 may_29\MD\15209706 be_30\VB\836236 identical_31\JJ\1740 ._32\.\1740
D005473_D017109 CID the_0\DT\1740 authors_1\NNS\9610660 suggest_2\VBP\1010118 that_3\IN\1740 <e1>fluoxetine-induced</e1>_4\JJ\1740 akathisia_5\NN\1740 may_6\MD\15209706 be_7\VB\836236 caused_8\VBN\1617192 by_9\IN\1740 serotonergically_10\RB\1740 mediated_11\VBN\761713 inhibition_12\NN\1068773 of_13\IN\1740 dopaminergic_14\JJ\1740 neurotransmission_15\NN\1740 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 pathophysiology_19\NN\1740 of_20\IN\1740 fluoxetine-induced_21\JJ\1740 <e2>akathisia</e2>_22\NN\1740 and_23\CC\1740 tricyclic_24\JJ\1740 antidepressant-induced_25\JJ\1740 "_26\``\1740 jitteriness_27\NN\7523905 "_28\''\1740 may_29\MD\15209706 be_30\VB\836236 identical_31\JJ\1740 ._32\.\1740
D005473_D017109 CID the_0\DT\1740 authors_1\NNS\9610660 suggest_2\VBP\1010118 that_3\IN\1740 fluoxetine-induced_4\JJ\1740 <e2>akathisia</e2>_5\NN\1740 may_6\MD\15209706 be_7\VB\836236 caused_8\VBN\1617192 by_9\IN\1740 serotonergically_10\RB\1740 mediated_11\VBN\761713 inhibition_12\NN\1068773 of_13\IN\1740 dopaminergic_14\JJ\1740 neurotransmission_15\NN\1740 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 pathophysiology_19\NN\1740 of_20\IN\1740 <e1>fluoxetine-induced</e1>_21\JJ\1740 akathisia_22\NN\1740 and_23\CC\1740 tricyclic_24\JJ\1740 antidepressant-induced_25\JJ\1740 "_26\``\1740 jitteriness_27\NN\7523905 "_28\''\1740 may_29\MD\15209706 be_30\VB\836236 identical_31\JJ\1740 ._32\.\1740
D005473_D017109 CID the_0\DT\1740 authors_1\NNS\9610660 suggest_2\VBP\1010118 that_3\IN\1740 fluoxetine-induced_4\JJ\1740 akathisia_5\NN\1740 may_6\MD\15209706 be_7\VB\836236 caused_8\VBN\1617192 by_9\IN\1740 serotonergically_10\RB\1740 mediated_11\VBN\761713 inhibition_12\NN\1068773 of_13\IN\1740 dopaminergic_14\JJ\1740 neurotransmission_15\NN\1740 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 pathophysiology_19\NN\1740 of_20\IN\1740 <e1>fluoxetine-induced</e1>_21\JJ\1740 <e2>akathisia</e2>_22\NN\1740 and_23\CC\1740 tricyclic_24\JJ\1740 antidepressant-induced_25\JJ\1740 "_26\``\1740 jitteriness_27\NN\7523905 "_28\''\1740 may_29\MD\15209706 be_30\VB\836236 identical_31\JJ\1740 ._32\.\1740
D005473_D009771 NONE five_0\CD\13741022 patients_1\NNS\9898892 receiving_2\VBG\2210855 <e1>fluoxetine</e1>_3\NN\4169152 for_4\IN\1740 the_5\DT\1740 treatment_6\NN\654885 of_7\IN\1740 <e2>obsessive_8\JJ\1740 compulsive_9\JJ\1740 disorder</e2>_10\NN\14034177 or_11\CC\3541091 major_12\JJ\1740 depression_13\NN\14373582 developed_14\VBD\1753788 akathisia_15\NN\1740 ._16\.\1740
D005473_D003865 NONE five_0\CD\13741022 patients_1\NNS\9898892 receiving_2\VBG\2210855 <e1>fluoxetine</e1>_3\NN\4169152 for_4\IN\1740 the_5\DT\1740 treatment_6\NN\654885 of_7\IN\1740 obsessive_8\JJ\1740 compulsive_9\JJ\1740 disorder_10\NN\14034177 or_11\CC\3541091 <e2>major_12\JJ\1740 depression</e2>_13\NN\14373582 developed_14\VBD\1753788 akathisia_15\NN\1740 ._16\.\1740
D005473_D001008 NONE the_0\DT\1740 typical_1\JJ\1740 <e1>fluoxetine-induced</e1>_2\JJ\1740 symptoms_3\NNS\5823932 of_4\IN\1740 restlessness_5\NN\4773351 ,_6\,\1740 constant_7\JJ\1740 pacing_8\NN\15122011 ,_9\,\1740 purposeless_10\NN\1740 movements_11\NNS\191142 of_12\IN\1740 the_13\DT\1740 feet_14\NNS\5563034 and_15\CC\1740 legs_16\NNS\5032918 ,_17\,\1740 and_18\CC\1740 marked_19\JJ\1740 <e2>anxiety</e2>_20\NN\14373582 were_21\VBD\836236 indistinguishable_22\JJ\1740 from_23\IN\1740 those_24\DT\1740 of_25\IN\1740 neuroleptic-induced_26\JJ\1740 akathisia_27\NN\1740 ._28\.\1740
D011433_D017109 NONE <e2>akathisia</e2>_0\NNP\1740 appeared_1\VBD\2604760 to_2\TO\1740 be_3\VB\836236 a_4\DT\13649268 common_5\JJ\1740 side_6\NN\8630039 effect_7\NN\34213 of_8\IN\1740 fluoxetine_9\NN\4169152 and_10\CC\1740 generally_11\RB\1740 responded_12\VBD\2367363 well_13\RB\1740 to_14\IN\1740 treatment_15\NN\654885 with_16\IN\1740 the_17\DT\1740 beta-adrenergic_18\JJ\1740 antagonist_19\NN\7846 <e1>propranolol</e1>_20\NN\1740 ,_21\,\1740 dose_22\NN\3740161 reduction_23\NN\351485 ,_24\,\1740 or_25\CC\3541091 both_26\DT\1740 ._27\.\1740
D000928_D017109 NONE the_0\DT\1740 authors_1\NNS\9610660 suggest_2\VBP\1010118 that_3\IN\1740 fluoxetine-induced_4\JJ\1740 <e2>akathisia</e2>_5\NN\1740 may_6\MD\15209706 be_7\VB\836236 caused_8\VBN\1617192 by_9\IN\1740 serotonergically_10\RB\1740 mediated_11\VBN\761713 inhibition_12\NN\1068773 of_13\IN\1740 dopaminergic_14\JJ\1740 neurotransmission_15\NN\1740 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 pathophysiology_19\NN\1740 of_20\IN\1740 fluoxetine-induced_21\JJ\1740 akathisia_22\NN\1740 and_23\CC\1740 tricyclic_24\JJ\1740 <e1>antidepressant-induced</e1>_25\JJ\1740 "_26\``\1740 jitteriness_27\NN\7523905 "_28\''\1740 may_29\MD\15209706 be_30\VB\836236 identical_31\JJ\1740 ._32\.\1740
D000928_D017109 NONE the_0\DT\1740 authors_1\NNS\9610660 suggest_2\VBP\1010118 that_3\IN\1740 fluoxetine-induced_4\JJ\1740 akathisia_5\NN\1740 may_6\MD\15209706 be_7\VB\836236 caused_8\VBN\1617192 by_9\IN\1740 serotonergically_10\RB\1740 mediated_11\VBN\761713 inhibition_12\NN\1068773 of_13\IN\1740 dopaminergic_14\JJ\1740 neurotransmission_15\NN\1740 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 pathophysiology_19\NN\1740 of_20\IN\1740 fluoxetine-induced_21\JJ\1740 <e2>akathisia</e2>_22\NN\1740 and_23\CC\1740 tricyclic_24\JJ\1740 <e1>antidepressant-induced</e1>_25\JJ\1740 "_26\``\1740 jitteriness_27\NN\7523905 "_28\''\1740 may_29\MD\15209706 be_30\VB\836236 identical_31\JJ\1740 ._32\.\1740
3997294
D000638_D010996 CID pneumonitis_0\NN\14336539 with_1\IN\1740 <e2>pleural_2\JJ\1740 and_3\CC\1740 pericardial_4\JJ\1740 effusion</e2>_5\NN\6880249 and_6\CC\1740 neuropathy_7\JJ\1740 during_8\IN\1740 <e1>amiodarone</e1>_9\NN\2715941 therapy_10\NN\657604 ._11\.\1740
D000638_D010490 CID pneumonitis_0\NN\14336539 with_1\IN\1740 <e2>pleural_2\JJ\1740 and_3\CC\1740 pericardial_4\JJ\1740 effusion</e2>_5\NN\6880249 and_6\CC\1740 neuropathy_7\JJ\1740 during_8\IN\1740 <e1>amiodarone</e1>_9\NN\2715941 therapy_10\NN\657604 ._11\.\1740
D000638_D009422 NONE pneumonitis_0\NN\14336539 with_1\IN\1740 pleural_2\JJ\1740 and_3\CC\1740 pericardial_4\JJ\1740 effusion_5\NN\6880249 and_6\CC\1740 <e2>neuropathy</e2>_7\JJ\1740 during_8\IN\1740 <e1>amiodarone</e1>_9\NN\2715941 therapy_10\NN\657604 ._11\.\1740
D000638_D002318 NONE a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 <e2>sinuatrial_3\JJ\1740 disease</e2>_4\NN\14061805 and_5\CC\1740 implanted_6\JJ\1740 pacemaker_7\NN\5925366 was_8\VBD\836236 treated_9\VBN\2376958 with_10\IN\1740 <e1>amiodarone</e1>_11\NN\2715941 (_12\-LRB-\1740 maximum_13\NN\13653902 dose_14\NN\3740161 1000_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 maintenance_18\NN\266806 dose_19\NN\3740161 800_20\CD\1740 mg_21\NN\13717155 daily_22\RB\1740 )_23\-RRB-\1740 for_24\IN\1740 10_25\CD\13745420 months_26\NNS\15113229 ,_27\,\1740 for_28\IN\1740 control_29\NN\5190804 of_30\IN\1740 supraventricular_31\JJ\1740 tachyarrhythmias_32\NNS\1740 ._33\.\1740
D000638_D013617 NONE a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 sinuatrial_3\JJ\1740 disease_4\NN\14061805 and_5\CC\1740 implanted_6\JJ\1740 pacemaker_7\NN\5925366 was_8\VBD\836236 treated_9\VBN\2376958 with_10\IN\1740 <e1>amiodarone</e1>_11\NN\2715941 (_12\-LRB-\1740 maximum_13\NN\13653902 dose_14\NN\3740161 1000_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 maintenance_18\NN\266806 dose_19\NN\3740161 800_20\CD\1740 mg_21\NN\13717155 daily_22\RB\1740 )_23\-RRB-\1740 for_24\IN\1740 10_25\CD\13745420 months_26\NNS\15113229 ,_27\,\1740 for_28\IN\1740 control_29\NN\5190804 of_30\IN\1740 <e2>supraventricular_31\JJ\1740 tachyarrhythmias</e2>_32\NNS\1740 ._33\.\1740
D000638_D011014 CID review_0\NN\5733583 of_1\IN\1740 this_2\DT\1740 and_3\CC\1740 previously_4\RB\1740 reported_5\VBN\831651 cases_6\NNS\7283608 indicates_7\VBZ\952524 the_8\DT\1740 need_9\NN\13920835 for_10\IN\1740 early_11\JJ\1740 diagnosis_12\NN\152018 of_13\IN\1740 <e1>amiodarone</e1>_14\JJ\1740 <e2>pneumonitis</e2>_15\NN\14336539 ,_16\,\1740 immediate_17\JJ\1740 withdrawal_18\NN\7206096 of_19\IN\1740 amiodarone_20\NN\2715941 ,_21\,\1740 and_22\CC\1740 prompt_23\NN\7011209 but_24\CC\1740 continued_25\JJ\1740 steroid_26\NN\14727670 therapy_27\NN\657604 to_28\TO\1740 ensure_29\VB\664483 full_30\JJ\1740 recovery_31\NN\7357388 ._32\.\1740
D000638_D011014 CID review_0\NN\5733583 of_1\IN\1740 this_2\DT\1740 and_3\CC\1740 previously_4\RB\1740 reported_5\VBN\831651 cases_6\NNS\7283608 indicates_7\VBZ\952524 the_8\DT\1740 need_9\NN\13920835 for_10\IN\1740 early_11\JJ\1740 diagnosis_12\NN\152018 of_13\IN\1740 amiodarone_14\JJ\1740 <e2>pneumonitis</e2>_15\NN\14336539 ,_16\,\1740 immediate_17\JJ\1740 withdrawal_18\NN\7206096 of_19\IN\1740 <e1>amiodarone</e1>_20\NN\2715941 ,_21\,\1740 and_22\CC\1740 prompt_23\NN\7011209 but_24\CC\1740 continued_25\JJ\1740 steroid_26\NN\14727670 therapy_27\NN\657604 to_28\TO\1740 ensure_29\VB\664483 full_30\JJ\1740 recovery_31\NN\7357388 ._32\.\1740
D013256_D011014 NONE review_0\NN\5733583 of_1\IN\1740 this_2\DT\1740 and_3\CC\1740 previously_4\RB\1740 reported_5\VBN\831651 cases_6\NNS\7283608 indicates_7\VBZ\952524 the_8\DT\1740 need_9\NN\13920835 for_10\IN\1740 early_11\JJ\1740 diagnosis_12\NN\152018 of_13\IN\1740 amiodarone_14\JJ\1740 <e2>pneumonitis</e2>_15\NN\14336539 ,_16\,\1740 immediate_17\JJ\1740 withdrawal_18\NN\7206096 of_19\IN\1740 amiodarone_20\NN\2715941 ,_21\,\1740 and_22\CC\1740 prompt_23\NN\7011209 but_24\CC\1740 continued_25\JJ\1740 <e1>steroid</e1>_26\NN\14727670 therapy_27\NN\657604 to_28\TO\1740 ensure_29\VB\664483 full_30\JJ\1740 recovery_31\NN\7357388 ._32\.\1740
2265898
C009265_D004827 CID serial_0\JJ\1740 <e2>epilepsy</e2>_1\NN\14085708 caused_2\VBN\1617192 by_3\IN\1740 <e1>levodopa/carbidopa</e1>_4\JJ\1740 administration_5\NN\1133281 in_6\IN\13603305 two_7\CD\13741022 patients_8\NNS\9898892 on_9\IN\1740 hemodialysis_10\NN\649760 ._11\.\1740
C009265_D007676 NONE two_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 similar_3\JJ\1740 clinical_4\JJ\1740 features_5\NNS\5849040 are_6\VBP\836236 presented_7\VBN\2137132 :_8\:\1740 both_9\DT\1740 patients_10\NNS\9898892 had_11\VBD\2108377 <e2>chronic_12\JJ\1740 renal_13\JJ\1740 failure</e2>_14\NN\66216 ,_15\,\1740 on_16\IN\1740 hemodialysis_17\NN\649760 for_18\IN\1740 many_19\JJ\1740 years_20\NNS\15144371 but_21\CC\1740 recently_22\RB\1740 begun_23\VBN\941990 on_24\IN\1740 a_25\DT\13649268 high-flux_26\JJ\1740 dialyzer_27\NN\3739693 ;_28\:\1740 both_29\DT\1740 had_30\VBD\2108377 been_31\VBN\836236 receiving_32\VBG\2210855 a_33\DT\13649268 <e1>carbidopa/levodopa</e1>_34\NN\1740 preparation_35\NN\407535 ;_36\:\1740 and_37\CC\1740 both_38\DT\1740 had_39\VBD\2108377 the_40\DT\1740 onset_41\NN\7325190 of_42\IN\1740 hallucinosis_43\NN\14373582 and_44\CC\1740 recurrent_45\JJ\1740 seizures_46\NNS\14081375 ,_47\,\1740 which_48\WDT\1740 were_49\VBD\836236 refractory_50\JJ\1740 to_51\TO\1740 anticonvulsants_52\NNS\3740161 ._53\.\1740
C009265_D001523 NONE two_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 similar_3\JJ\1740 clinical_4\JJ\1740 features_5\NNS\5849040 are_6\VBP\836236 presented_7\VBN\2137132 :_8\:\1740 both_9\DT\1740 patients_10\NNS\9898892 had_11\VBD\2108377 chronic_12\JJ\1740 renal_13\JJ\1740 failure_14\NN\66216 ,_15\,\1740 on_16\IN\1740 hemodialysis_17\NN\649760 for_18\IN\1740 many_19\JJ\1740 years_20\NNS\15144371 but_21\CC\1740 recently_22\RB\1740 begun_23\VBN\941990 on_24\IN\1740 a_25\DT\13649268 high-flux_26\JJ\1740 dialyzer_27\NN\3739693 ;_28\:\1740 both_29\DT\1740 had_30\VBD\2108377 been_31\VBN\836236 receiving_32\VBG\2210855 a_33\DT\13649268 <e1>carbidopa/levodopa</e1>_34\NN\1740 preparation_35\NN\407535 ;_36\:\1740 and_37\CC\1740 both_38\DT\1740 had_39\VBD\2108377 the_40\DT\1740 onset_41\NN\7325190 of_42\IN\1740 <e2>hallucinosis</e2>_43\NN\14373582 and_44\CC\1740 recurrent_45\JJ\1740 seizures_46\NNS\14081375 ,_47\,\1740 which_48\WDT\1740 were_49\VBD\836236 refractory_50\JJ\1740 to_51\TO\1740 anticonvulsants_52\NNS\3740161 ._53\.\1740
C009265_D012640 NONE two_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 similar_3\JJ\1740 clinical_4\JJ\1740 features_5\NNS\5849040 are_6\VBP\836236 presented_7\VBN\2137132 :_8\:\1740 both_9\DT\1740 patients_10\NNS\9898892 had_11\VBD\2108377 chronic_12\JJ\1740 renal_13\JJ\1740 failure_14\NN\66216 ,_15\,\1740 on_16\IN\1740 hemodialysis_17\NN\649760 for_18\IN\1740 many_19\JJ\1740 years_20\NNS\15144371 but_21\CC\1740 recently_22\RB\1740 begun_23\VBN\941990 on_24\IN\1740 a_25\DT\13649268 high-flux_26\JJ\1740 dialyzer_27\NN\3739693 ;_28\:\1740 both_29\DT\1740 had_30\VBD\2108377 been_31\VBN\836236 receiving_32\VBG\2210855 a_33\DT\13649268 <e1>carbidopa/levodopa</e1>_34\NN\1740 preparation_35\NN\407535 ;_36\:\1740 and_37\CC\1740 both_38\DT\1740 had_39\VBD\2108377 the_40\DT\1740 onset_41\NN\7325190 of_42\IN\1740 hallucinosis_43\NN\14373582 and_44\CC\1740 recurrent_45\JJ\1740 <e2>seizures</e2>_46\NNS\14081375 ,_47\,\1740 which_48\WDT\1740 were_49\VBD\836236 refractory_50\JJ\1740 to_51\TO\1740 anticonvulsants_52\NNS\3740161 ._53\.\1740
1147734
D011441_D008107 NONE <e2>liver_0\NN\5298729 disease</e2>_1\NN\14061805 caused_2\VBN\1617192 by_3\IN\1740 <e1>propylthiouracil</e1>_4\NN\14727670 ._5\.\1740
D011441_D006521 CID this_0\DT\1740 report_1\NN\6470073 presents_2\VBZ\2137132 the_3\DT\1740 clinical_4\JJ\1740 ,_5\,\1740 laboratory_6\NN\4602044 ,_7\,\1740 and_8\CC\1740 light_9\NN\11421401 and_10\CC\1740 electron_11\NN\9338013 microscopic_12\JJ\1740 observations_13\NNS\996969 on_14\IN\1740 a_15\DT\13649268 patient_16\NN\9898892 with_17\IN\1740 <e2>chronic_18\JJ\1740 active_19\JJ\1740 (_20\-LRB-\1740 aggressive_21\JJ\1740 )_22\-RRB-\1740 hepatitis</e2>_23\NN\14127211 caused_24\VBN\1617192 by_25\IN\1740 the_26\DT\1740 administration_27\NN\1133281 of_28\IN\1740 <e1>propylthiouracil</e1>_29\NN\14727670 ._30\.\1740
14659530
D009569_D008881 NONE <e1>no-induced</e1>_0\JJ\1740 <e2>migraine</e2>_1\NN\14326607 attack_2\NN\955060 :_3\:\1740 strong_4\JJ\1740 increase_5\NN\13576355 in_6\IN\13603305 plasma_7\NN\5398023 calcitonin_8\NN\5413241 gene-related_9\JJ\1740 peptide_10\NN\14724264 (_11\-LRB-\1740 cgrp_12\NN\1740 )_13\-RRB-\1740 concentration_14\NN\4916342 and_15\CC\1740 negative_16\JJ\1740 correlation_17\NN\13841213 with_18\IN\1740 platelet_19\NN\5432736 serotonin_20\NN\14807737 release_21\NN\3748886 ._22\.\1740
D015740_D008881 NONE no-induced_0\JJ\1740 <e2>migraine</e2>_1\NN\14326607 attack_2\NN\955060 :_3\:\1740 strong_4\JJ\1740 increase_5\NN\13576355 in_6\IN\13603305 plasma_7\NN\5398023 <e1>calcitonin_8\NN\5413241 gene-related_9\JJ\1740 peptide</e1>_10\NN\14724264 (_11\-LRB-\1740 cgrp_12\NN\1740 )_13\-RRB-\1740 concentration_14\NN\4916342 and_15\CC\1740 negative_16\JJ\1740 correlation_17\NN\13841213 with_18\IN\1740 platelet_19\NN\5432736 serotonin_20\NN\14807737 release_21\NN\3748886 ._22\.\1740
D015740_D008881 NONE no-induced_0\JJ\1740 <e2>migraine</e2>_1\NN\14326607 attack_2\NN\955060 :_3\:\1740 strong_4\JJ\1740 increase_5\NN\13576355 in_6\IN\13603305 plasma_7\NN\5398023 calcitonin_8\NN\5413241 gene-related_9\JJ\1740 peptide_10\NN\14724264 (_11\-LRB-\1740 <e1>cgrp</e1>_12\NN\1740 )_13\-RRB-\1740 concentration_14\NN\4916342 and_15\CC\1740 negative_16\JJ\1740 correlation_17\NN\13841213 with_18\IN\1740 platelet_19\NN\5432736 serotonin_20\NN\14807737 release_21\NN\3748886 ._22\.\1740
D015740_D008881 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 <e1>calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide</e1>_15\NN\14724264 (_16\-LRB-\1740 cgrp_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 serotonin_22\NN\14807737 (_23\-LRB-\1740 5-hydroxytriptamine_24\NN\1740 ,_25\,\1740 5-ht_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 headache_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 <e2>migraine</e2>_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 nitroglycerin_41\NN\15015501 ._42\.\1740
D015740_D008881 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide_15\NN\14724264 (_16\-LRB-\1740 <e1>cgrp</e1>_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 serotonin_22\NN\14807737 (_23\-LRB-\1740 5-hydroxytriptamine_24\NN\1740 ,_25\,\1740 5-ht_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 headache_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 <e2>migraine</e2>_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 nitroglycerin_41\NN\15015501 ._42\.\1740
D015740_D008881 NONE plasma_0\NN\5398023 <e1>cgrp</e1>_1\NN\1740 concentration_2\NN\4916342 increased_3\VBD\169651 significantly_4\RB\1740 (_5\-LRB-\1740 p<0.01_6\NN\1740 )_7\-RRB-\1740 during_8\IN\1740 the_9\DT\1740 <e2>migraine</e2>_10\NN\14326607 attack_11\NN\955060 and_12\CC\1740 returned_13\VBD\1835496 to_14\TO\1740 baseline_15\NN\7260623 after_16\IN\1740 the_17\DT\1740 cessation_18\NN\7365849 of_19\IN\1740 the_20\DT\1740 migraine_21\NN\14326607 ._22\.\1740
D015740_D008881 NONE plasma_0\NN\5398023 <e1>cgrp</e1>_1\NN\1740 concentration_2\NN\4916342 increased_3\VBD\169651 significantly_4\RB\1740 (_5\-LRB-\1740 p<0.01_6\NN\1740 )_7\-RRB-\1740 during_8\IN\1740 the_9\DT\1740 migraine_10\NN\14326607 attack_11\NN\955060 and_12\CC\1740 returned_13\VBD\1835496 to_14\TO\1740 baseline_15\NN\7260623 after_16\IN\1740 the_17\DT\1740 cessation_18\NN\7365849 of_19\IN\1740 the_20\DT\1740 <e2>migraine</e2>_21\NN\14326607 ._22\.\1740
D015740_D008881 NONE however_0\RB\1740 ,_1\,\1740 plasma_2\NN\5398023 <e1>cgrp</e1>_3\NN\1740 concentrations_4\NNS\4916342 failed_5\VBD\1798936 to_6\TO\1740 change_7\VB\46534 during_8\IN\1740 immediate_9\JJ\1740 headache_10\NN\5829480 and_11\CC\1740 in_12\IN\13603305 the_13\DT\1740 subjects_14\NNS\6598915 with_15\IN\1740 no_16\DT\7204911 <e2>migraine</e2>_17\NN\14326607 attack_18\NN\955060 ._19\.\1740
D015740_D008881 NONE basal_0\JJ\1740 <e1>cgrp</e1>_1\NN\1740 concentration_2\NN\4916342 was_3\VBD\836236 significantly_4\RB\1740 higher_5\JJR\1740 and_6\CC\1740 platelet_7\NN\5432736 5-ht_8\NN\1740 content_9\NN\7951464 tended_10\VBD\2604760 to_11\TO\1740 be_12\VB\836236 lower_13\JJR\1740 in_14\IN\13603305 subjects_15\NNS\6598915 who_16\WP\8299493 experienced_17\VBD\2108377 a_18\DT\13649268 <e2>migraine</e2>_19\NN\14326607 attack_20\NN\955060 ._21\.\1740
D015740_D008881 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 fact_4\NN\5816287 that_5\IN\1740 plasma_6\NN\5398023 <e1>cgrp</e1>_7\NN\1740 concentration_8\NN\4916342 correlates_9\VBZ\2657219 with_10\IN\1740 the_11\DT\1740 timing_12\NN\5044673 and_13\CC\1740 severity_14\NN\5036394 of_15\IN\1740 a_16\DT\13649268 <e2>migraine</e2>_17\NN\14326607 headache_18\NN\5829480 suggests_19\VBZ\1010118 a_20\DT\13649268 direct_21\JJ\1740 relationship_22\NN\31921 between_23\IN\1740 cgrp_24\NN\1740 and_25\CC\1740 migraine_26\NN\14326607 ._27\.\1740
D015740_D008881 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 fact_4\NN\5816287 that_5\IN\1740 plasma_6\NN\5398023 <e1>cgrp</e1>_7\NN\1740 concentration_8\NN\4916342 correlates_9\VBZ\2657219 with_10\IN\1740 the_11\DT\1740 timing_12\NN\5044673 and_13\CC\1740 severity_14\NN\5036394 of_15\IN\1740 a_16\DT\13649268 migraine_17\NN\14326607 headache_18\NN\5829480 suggests_19\VBZ\1010118 a_20\DT\13649268 direct_21\JJ\1740 relationship_22\NN\31921 between_23\IN\1740 cgrp_24\NN\1740 and_25\CC\1740 <e2>migraine</e2>_26\NN\14326607 ._27\.\1740
D015740_D008881 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 fact_4\NN\5816287 that_5\IN\1740 plasma_6\NN\5398023 cgrp_7\NN\1740 concentration_8\NN\4916342 correlates_9\VBZ\2657219 with_10\IN\1740 the_11\DT\1740 timing_12\NN\5044673 and_13\CC\1740 severity_14\NN\5036394 of_15\IN\1740 a_16\DT\13649268 <e2>migraine</e2>_17\NN\14326607 headache_18\NN\5829480 suggests_19\VBZ\1010118 a_20\DT\13649268 direct_21\JJ\1740 relationship_22\NN\31921 between_23\IN\1740 <e1>cgrp</e1>_24\NN\1740 and_25\CC\1740 migraine_26\NN\14326607 ._27\.\1740
D015740_D008881 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 fact_4\NN\5816287 that_5\IN\1740 plasma_6\NN\5398023 cgrp_7\NN\1740 concentration_8\NN\4916342 correlates_9\VBZ\2657219 with_10\IN\1740 the_11\DT\1740 timing_12\NN\5044673 and_13\CC\1740 severity_14\NN\5036394 of_15\IN\1740 a_16\DT\13649268 migraine_17\NN\14326607 headache_18\NN\5829480 suggests_19\VBZ\1010118 a_20\DT\13649268 direct_21\JJ\1740 relationship_22\NN\31921 between_23\IN\1740 <e1>cgrp</e1>_24\NN\1740 and_25\CC\1740 <e2>migraine</e2>_26\NN\14326607 ._27\.\1740
D015740_D008881 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 serotonin_3\NN\14807737 release_4\NN\3748886 from_5\IN\1740 platelets_6\NNS\5432736 does_7\VBZ\1640855 not_8\RB\1740 provoke_9\VB\1617192 <e2>migraine</e2>_10\NN\14326607 ,_11\,\1740 it_12\PRP\6125041 may_13\MD\15209706 even_14\RB\1740 counteract_15\VB\2367363 the_16\DT\1740 headache_17\NN\5829480 and_18\CC\1740 the_19\DT\1740 concomitant_20\JJ\1740 <e1>cgrp</e1>_21\NN\1740 release_22\NN\3748886 in_23\IN\13603305 this_24\DT\1740 model_25\NN\5888929 ._26\.\1740
D012701_D008881 NONE no-induced_0\JJ\1740 <e2>migraine</e2>_1\NN\14326607 attack_2\NN\955060 :_3\:\1740 strong_4\JJ\1740 increase_5\NN\13576355 in_6\IN\13603305 plasma_7\NN\5398023 calcitonin_8\NN\5413241 gene-related_9\JJ\1740 peptide_10\NN\14724264 (_11\-LRB-\1740 cgrp_12\NN\1740 )_13\-RRB-\1740 concentration_14\NN\4916342 and_15\CC\1740 negative_16\JJ\1740 correlation_17\NN\13841213 with_18\IN\1740 platelet_19\NN\5432736 <e1>serotonin</e1>_20\NN\14807737 release_21\NN\3748886 ._22\.\1740
D012701_D008881 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide_15\NN\14724264 (_16\-LRB-\1740 cgrp_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 <e1>serotonin</e1>_22\NN\14807737 (_23\-LRB-\1740 5-hydroxytriptamine_24\NN\1740 ,_25\,\1740 5-ht_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 headache_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 <e2>migraine</e2>_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 nitroglycerin_41\NN\15015501 ._42\.\1740
D012701_D008881 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide_15\NN\14724264 (_16\-LRB-\1740 cgrp_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 serotonin_22\NN\14807737 (_23\-LRB-\1740 <e1>5-hydroxytriptamine</e1>_24\NN\1740 ,_25\,\1740 5-ht_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 headache_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 <e2>migraine</e2>_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 nitroglycerin_41\NN\15015501 ._42\.\1740
D012701_D008881 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide_15\NN\14724264 (_16\-LRB-\1740 cgrp_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 serotonin_22\NN\14807737 (_23\-LRB-\1740 5-hydroxytriptamine_24\NN\1740 ,_25\,\1740 <e1>5-ht</e1>_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 headache_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 <e2>migraine</e2>_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 nitroglycerin_41\NN\15015501 ._42\.\1740
D012701_D008881 NONE basal_0\JJ\1740 cgrp_1\NN\1740 concentration_2\NN\4916342 was_3\VBD\836236 significantly_4\RB\1740 higher_5\JJR\1740 and_6\CC\1740 platelet_7\NN\5432736 <e1>5-ht</e1>_8\NN\1740 content_9\NN\7951464 tended_10\VBD\2604760 to_11\TO\1740 be_12\VB\836236 lower_13\JJR\1740 in_14\IN\13603305 subjects_15\NNS\6598915 who_16\WP\8299493 experienced_17\VBD\2108377 a_18\DT\13649268 <e2>migraine</e2>_19\NN\14326607 attack_20\NN\955060 ._21\.\1740
D012701_D008881 NONE platelet_0\NN\5432736 <e1>serotonin</e1>_1\NN\14807737 content_2\NN\7951464 decreased_3\VBD\169651 significantly_4\RB\1740 (_5\-LRB-\1740 p<0.01_6\NN\1740 )_7\-RRB-\1740 after_8\IN\1740 nitroglycerin_9\NN\15015501 in_10\IN\13603305 subjects_11\NNS\6598915 with_12\IN\1740 no_13\DT\7204911 <e2>migraine</e2>_14\NN\14326607 attack_15\NN\955060 but_16\CC\1740 no_17\DT\7204911 consistent_18\JJ\1740 change_19\NN\7283608 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 patients_23\NNS\9898892 with_24\IN\1740 migraine_25\NN\14326607 attack_26\NN\955060 ._27\.\1740
D012701_D008881 NONE platelet_0\NN\5432736 <e1>serotonin</e1>_1\NN\14807737 content_2\NN\7951464 decreased_3\VBD\169651 significantly_4\RB\1740 (_5\-LRB-\1740 p<0.01_6\NN\1740 )_7\-RRB-\1740 after_8\IN\1740 nitroglycerin_9\NN\15015501 in_10\IN\13603305 subjects_11\NNS\6598915 with_12\IN\1740 no_13\DT\7204911 migraine_14\NN\14326607 attack_15\NN\955060 but_16\CC\1740 no_17\DT\7204911 consistent_18\JJ\1740 change_19\NN\7283608 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 patients_23\NNS\9898892 with_24\IN\1740 <e2>migraine</e2>_25\NN\14326607 attack_26\NN\955060 ._27\.\1740
D012701_D008881 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 <e1>serotonin</e1>_3\NN\14807737 release_4\NN\3748886 from_5\IN\1740 platelets_6\NNS\5432736 does_7\VBZ\1640855 not_8\RB\1740 provoke_9\VB\1617192 <e2>migraine</e2>_10\NN\14326607 ,_11\,\1740 it_12\PRP\6125041 may_13\MD\15209706 even_14\RB\1740 counteract_15\VB\2367363 the_16\DT\1740 headache_17\NN\5829480 and_18\CC\1740 the_19\DT\1740 concomitant_20\JJ\1740 cgrp_21\NN\1740 release_22\NN\3748886 in_23\IN\13603305 this_24\DT\1740 model_25\NN\5888929 ._26\.\1740
D015740_D006261 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 <e1>calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide</e1>_15\NN\14724264 (_16\-LRB-\1740 cgrp_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 serotonin_22\NN\14807737 (_23\-LRB-\1740 5-hydroxytriptamine_24\NN\1740 ,_25\,\1740 5-ht_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 <e2>headache</e2>_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 migraine_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 nitroglycerin_41\NN\15015501 ._42\.\1740
D015740_D006261 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide_15\NN\14724264 (_16\-LRB-\1740 <e1>cgrp</e1>_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 serotonin_22\NN\14807737 (_23\-LRB-\1740 5-hydroxytriptamine_24\NN\1740 ,_25\,\1740 5-ht_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 <e2>headache</e2>_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 migraine_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 nitroglycerin_41\NN\15015501 ._42\.\1740
D015740_D006261 NONE however_0\RB\1740 ,_1\,\1740 plasma_2\NN\5398023 <e1>cgrp</e1>_3\NN\1740 concentrations_4\NNS\4916342 failed_5\VBD\1798936 to_6\TO\1740 change_7\VB\46534 during_8\IN\1740 immediate_9\JJ\1740 <e2>headache</e2>_10\NN\5829480 and_11\CC\1740 in_12\IN\13603305 the_13\DT\1740 subjects_14\NNS\6598915 with_15\IN\1740 no_16\DT\7204911 migraine_17\NN\14326607 attack_18\NN\955060 ._19\.\1740
D015740_D006261 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 fact_4\NN\5816287 that_5\IN\1740 plasma_6\NN\5398023 <e1>cgrp</e1>_7\NN\1740 concentration_8\NN\4916342 correlates_9\VBZ\2657219 with_10\IN\1740 the_11\DT\1740 timing_12\NN\5044673 and_13\CC\1740 severity_14\NN\5036394 of_15\IN\1740 a_16\DT\13649268 migraine_17\NN\14326607 <e2>headache</e2>_18\NN\5829480 suggests_19\VBZ\1010118 a_20\DT\13649268 direct_21\JJ\1740 relationship_22\NN\31921 between_23\IN\1740 cgrp_24\NN\1740 and_25\CC\1740 migraine_26\NN\14326607 ._27\.\1740
D015740_D006261 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 fact_4\NN\5816287 that_5\IN\1740 plasma_6\NN\5398023 cgrp_7\NN\1740 concentration_8\NN\4916342 correlates_9\VBZ\2657219 with_10\IN\1740 the_11\DT\1740 timing_12\NN\5044673 and_13\CC\1740 severity_14\NN\5036394 of_15\IN\1740 a_16\DT\13649268 migraine_17\NN\14326607 <e2>headache</e2>_18\NN\5829480 suggests_19\VBZ\1010118 a_20\DT\13649268 direct_21\JJ\1740 relationship_22\NN\31921 between_23\IN\1740 <e1>cgrp</e1>_24\NN\1740 and_25\CC\1740 migraine_26\NN\14326607 ._27\.\1740
D015740_D006261 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 serotonin_3\NN\14807737 release_4\NN\3748886 from_5\IN\1740 platelets_6\NNS\5432736 does_7\VBZ\1640855 not_8\RB\1740 provoke_9\VB\1617192 migraine_10\NN\14326607 ,_11\,\1740 it_12\PRP\6125041 may_13\MD\15209706 even_14\RB\1740 counteract_15\VB\2367363 the_16\DT\1740 <e2>headache</e2>_17\NN\5829480 and_18\CC\1740 the_19\DT\1740 concomitant_20\JJ\1740 <e1>cgrp</e1>_21\NN\1740 release_22\NN\3748886 in_23\IN\13603305 this_24\DT\1740 model_25\NN\5888929 ._26\.\1740
D012701_D006261 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide_15\NN\14724264 (_16\-LRB-\1740 cgrp_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 <e1>serotonin</e1>_22\NN\14807737 (_23\-LRB-\1740 5-hydroxytriptamine_24\NN\1740 ,_25\,\1740 5-ht_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 <e2>headache</e2>_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 migraine_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 nitroglycerin_41\NN\15015501 ._42\.\1740
D012701_D006261 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide_15\NN\14724264 (_16\-LRB-\1740 cgrp_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 serotonin_22\NN\14807737 (_23\-LRB-\1740 <e1>5-hydroxytriptamine</e1>_24\NN\1740 ,_25\,\1740 5-ht_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 <e2>headache</e2>_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 migraine_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 nitroglycerin_41\NN\15015501 ._42\.\1740
D012701_D006261 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide_15\NN\14724264 (_16\-LRB-\1740 cgrp_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 serotonin_22\NN\14807737 (_23\-LRB-\1740 5-hydroxytriptamine_24\NN\1740 ,_25\,\1740 <e1>5-ht</e1>_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 <e2>headache</e2>_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 migraine_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 nitroglycerin_41\NN\15015501 ._42\.\1740
D012701_D006261 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 <e1>serotonin</e1>_3\NN\14807737 release_4\NN\3748886 from_5\IN\1740 platelets_6\NNS\5432736 does_7\VBZ\1640855 not_8\RB\1740 provoke_9\VB\1617192 migraine_10\NN\14326607 ,_11\,\1740 it_12\PRP\6125041 may_13\MD\15209706 even_14\RB\1740 counteract_15\VB\2367363 the_16\DT\1740 <e2>headache</e2>_17\NN\5829480 and_18\CC\1740 the_19\DT\1740 concomitant_20\JJ\1740 cgrp_21\NN\1740 release_22\NN\3748886 in_23\IN\13603305 this_24\DT\1740 model_25\NN\5888929 ._26\.\1740
D005996_D006261 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide_15\NN\14724264 (_16\-LRB-\1740 cgrp_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 serotonin_22\NN\14807737 (_23\-LRB-\1740 5-hydroxytriptamine_24\NN\1740 ,_25\,\1740 5-ht_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 <e2>headache</e2>_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 migraine_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 <e1>nitroglycerin</e1>_41\NN\15015501 ._42\.\1740
D005996_D008881 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 changes_9\NNS\7283608 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 calcitonin_13\NN\5413241 gene-related_14\JJ\1740 peptide_15\NN\14724264 (_16\-LRB-\1740 cgrp_17\NN\1740 )_18\-RRB-\1740 concentration_19\NN\4916342 and_20\CC\1740 platelet_21\NN\5432736 serotonin_22\NN\14807737 (_23\-LRB-\1740 5-hydroxytriptamine_24\NN\1740 ,_25\,\1740 5-ht_26\NN\1740 )_27\-RRB-\1740 content_28\NN\7951464 during_29\IN\1740 the_30\DT\1740 immediate_31\JJ\1740 headache_32\NN\5829480 and_33\CC\1740 the_34\DT\1740 delayed_35\VBN\439958 genuine_36\NN\1740 <e2>migraine</e2>_37\NN\14326607 attack_38\NN\955060 provoked_39\VBN\1617192 by_40\IN\1740 <e1>nitroglycerin</e1>_41\NN\15015501 ._42\.\1740
D005996_D008881 NONE blood_0\NNP\5397468 was_1\VBD\836236 collected_2\VBN\2281093 from_3\IN\1740 the_4\DT\1740 antecubital_5\JJ\1740 vein_6\NN\5417975 four_7\CD\13741022 times_8\NNS\15113229 :_9\:\1740 60_10\CD\13745420 min_11\NN\15154774 before_12\RB\1740 and_13\CC\1740 after_14\IN\1740 the_15\DT\1740 <e1>nitroglycerin</e1>_16\NN\15015501 application_17\NN\947128 ,_18\,\1740 and_19\CC\1740 60_20\CD\13745420 and_21\CC\1740 120_22\CD\13745420 min_23\NN\15154774 after_24\IN\1740 the_25\DT\1740 beginning_26\NN\7283608 of_27\IN\1740 the_28\DT\1740 <e2>migraine</e2>_29\NN\14326607 attack_30\NN\955060 (_31\-LRB-\1740 mean_32\NN\6021761 344_33\CD\1740 and_34\CC\1740 404_35\CD\1740 min_36\NN\15154774 ;_37\:\1740 12_38\CD\13745420 subjects_39\NNS\6598915 )_40\-RRB-\1740 ._41\.\1740
D005996_D008881 NONE platelet_0\NN\5432736 serotonin_1\NN\14807737 content_2\NN\7951464 decreased_3\VBD\169651 significantly_4\RB\1740 (_5\-LRB-\1740 p<0.01_6\NN\1740 )_7\-RRB-\1740 after_8\IN\1740 <e1>nitroglycerin</e1>_9\NN\15015501 in_10\IN\13603305 subjects_11\NNS\6598915 with_12\IN\1740 no_13\DT\7204911 <e2>migraine</e2>_14\NN\14326607 attack_15\NN\955060 but_16\CC\1740 no_17\DT\7204911 consistent_18\JJ\1740 change_19\NN\7283608 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 patients_23\NNS\9898892 with_24\IN\1740 migraine_25\NN\14326607 attack_26\NN\955060 ._27\.\1740
D005996_D008881 NONE platelet_0\NN\5432736 serotonin_1\NN\14807737 content_2\NN\7951464 decreased_3\VBD\169651 significantly_4\RB\1740 (_5\-LRB-\1740 p<0.01_6\NN\1740 )_7\-RRB-\1740 after_8\IN\1740 <e1>nitroglycerin</e1>_9\NN\15015501 in_10\IN\13603305 subjects_11\NNS\6598915 with_12\IN\1740 no_13\DT\7204911 migraine_14\NN\14326607 attack_15\NN\955060 but_16\CC\1740 no_17\DT\7204911 consistent_18\JJ\1740 change_19\NN\7283608 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 patients_23\NNS\9898892 with_24\IN\1740 <e2>migraine</e2>_25\NN\14326607 attack_26\NN\955060 ._27\.\1740
9034419
C047426_D012640 CID <e2>seizure</e2>_0\NNP\14081375 resulting_1\VBG\2633881 from_2\IN\1740 a_3\DT\13649268 <e1>venlafaxine</e1>_4\NN\1740 overdose_5\NN\1740 ._6\.\1740
C047426_D012640 CID after_0\IN\1740 the_1\DT\1740 ingestion_2\NN\13440063 of_3\IN\1740 26_4\CD\13745420 <e1>venlafaxine</e1>_5\NN\1740 50-mg_6\JJ\1740 tablets_7\NNS\4233405 ,_8\,\1740 the_9\DT\1740 patient_10\NN\9898892 experienced_11\VBD\2108377 a_12\DT\13649268 witnessed_13\VBN\2150510 generalized_14\VBN\634472 <e2>seizure</e2>_15\JJ\1740 ._16\.\1740
C047426_D012640 CID discussion_0\NN\6252138 :_1\:\1740 to_2\IN\1740 our_3\PRP$\1740 knowledge_4\NN\23100 ,_5\,\1740 this_6\DT\1740 is_7\VBZ\836236 the_8\DT\1740 first_9\JJ\1740 reported_10\VBN\831651 case_11\NN\7283608 of_12\IN\1740 <e1>venlafaxine</e1>_13\NN\1740 overdose_14\NN\1740 that_15\WDT\1740 resulted_16\VBD\2633881 in_17\IN\13603305 a_18\DT\13649268 generalized_19\JJ\1740 <e2>seizure</e2>_20\NN\14081375 ._21\.\1740
C047426_D012640 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 <e1>venlafaxine</e1>_3\NN\1740 overdose_4\NN\1740 in_5\IN\13603305 our_6\PRP$\1740 patient_7\NN\9898892 resulted_8\VBD\2633881 in_9\IN\13603305 a_10\DT\13649268 single_11\JJ\1740 episode_12\NN\7283608 of_13\IN\1740 generalized_14\VBN\634472 <e2>seizure</e2>_15\NN\14081375 but_16\CC\1740 elicited_17\VBD\1617192 no_18\DT\7204911 further_19\RB\1740 sequelae_20\JJ\1740 ._21\.\1740
C047426_D062787 CID seizure_0\NNP\14081375 resulting_1\VBG\2633881 from_2\IN\1740 a_3\DT\13649268 <e1>venlafaxine</e1>_4\NN\1740 <e2>overdose</e2>_5\NN\1740 ._6\.\1740
C047426_D062787 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e1>venlafaxine</e1>_7\NN\1740 <e2>overdose</e2>_8\NN\1740 ._9\.\1740
C047426_D062787 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 40-year-old_4\JJ\1740 woman_5\NN\9605289 with_6\IN\1740 major_7\JJ\1740 depression_8\NN\14373582 took_9\VBD\2367363 an_10\DT\6697703 <e2>overdose</e2>_11\NN\1740 of_12\IN\1740 <e1>venlafaxine</e1>_13\NN\1740 in_14\IN\13603305 an_15\DT\6697703 apparent_16\JJ\1740 suicide_17\NN\219012 attempt_18\NN\407535 ._19\.\1740
C047426_D062787 CID discussion_0\NN\6252138 :_1\:\1740 to_2\IN\1740 our_3\PRP$\1740 knowledge_4\NN\23100 ,_5\,\1740 this_6\DT\1740 is_7\VBZ\836236 the_8\DT\1740 first_9\JJ\1740 reported_10\VBN\831651 case_11\NN\7283608 of_12\IN\1740 <e1>venlafaxine</e1>_13\NN\1740 <e2>overdose</e2>_14\NN\1740 that_15\WDT\1740 resulted_16\VBD\2633881 in_17\IN\13603305 a_18\DT\13649268 generalized_19\JJ\1740 seizure_20\NN\14081375 ._21\.\1740
C047426_D062787 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 <e1>venlafaxine</e1>_3\NN\1740 <e2>overdose</e2>_4\NN\1740 in_5\IN\13603305 our_6\PRP$\1740 patient_7\NN\9898892 resulted_8\VBD\2633881 in_9\IN\13603305 a_10\DT\13649268 single_11\JJ\1740 episode_12\NN\7283608 of_13\IN\1740 generalized_14\VBN\634472 seizure_15\NN\14081375 but_16\CC\1740 elicited_17\VBD\1617192 no_18\DT\7204911 further_19\RB\1740 sequelae_20\JJ\1740 ._21\.\1740
C047426_D003865 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 40-year-old_4\JJ\1740 woman_5\NN\9605289 with_6\IN\1740 <e2>major_7\JJ\1740 depression</e2>_8\NN\14373582 took_9\VBD\2367363 an_10\DT\6697703 overdose_11\NN\1740 of_12\IN\1740 <e1>venlafaxine</e1>_13\NN\1740 in_14\IN\13603305 an_15\DT\6697703 apparent_16\JJ\1740 suicide_17\NN\219012 attempt_18\NN\407535 ._19\.\1740
18560792
D010479_D006349 NONE <e2>valvular_0\JJ\1740 heart_1\NN\5919034 disease</e2>_2\NN\14061805 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 parkinson_6\NN\1740 's_7\POS\1740 disease_8\NN\14061805 treated_9\VBN\2376958 with_10\IN\1740 <e1>pergolide</e1>_11\NN\1740 ._12\.\1740
D010479_D006349 NONE <e2>valvular_0\JJ\1740 heart_1\NN\5919034 abnormalities</e2>_2\NNS\14034177 have_3\VBP\2108377 been_4\VBN\836236 reported_5\VBN\831651 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 parkinson_9\NN\1740 's_10\POS\1740 disease_11\NN\14061805 (_12\-LRB-\1740 pd_13\NN\14625458 )_14\-RRB-\1740 treated_15\VBN\2376958 with_16\IN\1740 <e1>pergolide</e1>_17\NN\1740 ._18\.\1740
D010479_D006349 NONE a_0\DT\13649268 restrictive_1\JJ\1740 pattern_2\NN\5726345 of_3\IN\1740 <e2>valvular_4\JJ\1740 regurgitation</e2>_5\NN\7406350 ,_6\,\1740 suggestive_7\JJ\1740 of_8\IN\1740 the_9\DT\1740 role_10\NN\719494 of_11\IN\1740 <e1>pergolide</e1>_12\NN\1740 ,_13\,\1740 was_14\VBD\836236 observed_15\VBN\2163746 in_16\IN\13603305 12/30_17\CD\1740 (_18\-LRB-\1740 40_19\CD\13745420 %_20\NN\1740 )_21\-RRB-\1740 patients_22\NNS\9898892 including_23\VBG\690614 two_24\CD\13741022 with_25\IN\1740 heart_26\NN\5919034 failure_27\NN\66216 ._28\.\1740
D010479_D006349 NONE <e1>pergolide</e1>_0\NN\1740 was_1\VBD\836236 discontinued_2\VBN\2609764 in_3\IN\13603305 10_4\CD\13745420 patients_5\NNS\9898892 with_6\IN\1740 <e2>valvular_7\JJ\1740 heart_8\NN\5919034 disease</e2>_9\NN\14061805 ,_10\,\1740 resulting_11\VBG\2633881 in_12\IN\13603305 a_13\DT\13649268 lower_14\JJR\1740 regurgitation_15\NN\7406350 grade_16\NN\7975026 (_17\-LRB-\1740 p=0.01_18\NN\1740 )_19\-RRB-\1740 at_20\IN\14622893 the_21\DT\1740 second_22\JJ\1740 transthoracic_23\NN\1740 echocardiography_24\NN\177127 and_25\CC\1740 the_26\DT\1740 two_27\CD\13741022 patients_28\NNS\9898892 with_29\IN\1740 heart_30\NN\5919034 failure_31\NN\66216 returned_32\VBD\1835496 to_33\TO\1740 nearly_34\RB\1740 normal_35\JJ\1740 clinical_36\JJ\1740 examination_37\NN\633864 ._38\.\1740
D010479_D006349 NONE this_0\DT\1740 study_1\NN\635850 supports_2\VBZ\2199590 the_3\DT\1740 high_4\JJ\1740 frequency_5\NN\15286249 of_6\IN\1740 restrictive_7\JJ\1740 <e2>valve_8\NN\5225602 regurgitation</e2>_9\NN\7406350 in_10\IN\13603305 pd_11\NN\14625458 patients_12\NNS\9898892 treated_13\VBN\2376958 with_14\IN\1740 <e1>pergolide</e1>_15\NN\1740 and_16\CC\1740 reveals_17\VBZ\2137132 that_18\IN\1740 a_19\DT\13649268 significant_20\JJ\1740 improvement_21\NN\7359599 is_22\VBZ\836236 usual_23\JJ\1740 when_24\WRB\1740 the_25\DT\1740 treatment_26\NN\654885 is_27\VBZ\836236 converted_28\VBN\126264 to_29\TO\1740 non-ergot_30\JJ\1740 dopamine_31\NN\14807737 agonists_32\NNS\9613191 ._33\.\1740
D010479_D010300 NONE valvular_0\JJ\1740 heart_1\NN\5919034 disease_2\NN\14061805 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 <e2>parkinson_6\NN\1740 's_7\POS\1740 disease</e2>_8\NN\14061805 treated_9\VBN\2376958 with_10\IN\1740 <e1>pergolide</e1>_11\NN\1740 ._12\.\1740
D010479_D010300 NONE valvular_0\JJ\1740 heart_1\NN\5919034 abnormalities_2\NNS\14034177 have_3\VBP\2108377 been_4\VBN\836236 reported_5\VBN\831651 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 <e2>parkinson_9\NN\1740 's_10\POS\1740 disease</e2>_11\NN\14061805 (_12\-LRB-\1740 pd_13\NN\14625458 )_14\-RRB-\1740 treated_15\VBN\2376958 with_16\IN\1740 <e1>pergolide</e1>_17\NN\1740 ._18\.\1740
D010479_D010300 NONE valvular_0\JJ\1740 heart_1\NN\5919034 abnormalities_2\NNS\14034177 have_3\VBP\2108377 been_4\VBN\836236 reported_5\VBN\831651 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 parkinson_9\NN\1740 's_10\POS\1740 disease_11\NN\14061805 (_12\-LRB-\1740 <e2>pd</e2>_13\NN\14625458 )_14\-RRB-\1740 treated_15\VBN\2376958 with_16\IN\1740 <e1>pergolide</e1>_17\NN\1740 ._18\.\1740
D010479_D010300 NONE methods_0\NNS\5616786 :_1\:\1740 all_2\DT\1740 <e2>pd</e2>_3\NN\14625458 patients_4\NNS\9898892 in_5\IN\13603305 the_6\DT\1740 amiens_7\NNPS\1740 area_8\NN\8630985 treated_9\VBN\2376958 with_10\IN\1740 <e1>pergolide</e1>_11\NN\1740 were_12\VBD\836236 invited_13\VBN\1759326 to_14\TO\1740 attend_15\VB\2655135 a_16\DT\13649268 cardiologic_17\JJ\1740 assessment_18\NN\5732756 including_19\VBG\690614 transthoracic_20\JJ\1740 echocardiography_21\NN\177127 ._22\.\1740
D010479_D010300 NONE this_0\DT\1740 study_1\NN\635850 supports_2\VBZ\2199590 the_3\DT\1740 high_4\JJ\1740 frequency_5\NN\15286249 of_6\IN\1740 restrictive_7\JJ\1740 valve_8\NN\5225602 regurgitation_9\NN\7406350 in_10\IN\13603305 <e2>pd</e2>_11\NN\14625458 patients_12\NNS\9898892 treated_13\VBN\2376958 with_14\IN\1740 <e1>pergolide</e1>_15\NN\1740 and_16\CC\1740 reveals_17\VBZ\2137132 that_18\IN\1740 a_19\DT\13649268 significant_20\JJ\1740 improvement_21\NN\7359599 is_22\VBZ\836236 usual_23\JJ\1740 when_24\WRB\1740 the_25\DT\1740 treatment_26\NN\654885 is_27\VBZ\836236 converted_28\VBN\126264 to_29\TO\1740 non-ergot_30\JJ\1740 dopamine_31\NN\14807737 agonists_32\NNS\9613191 ._33\.\1740
D010479_D006333 NONE a_0\DT\13649268 restrictive_1\JJ\1740 pattern_2\NN\5726345 of_3\IN\1740 valvular_4\JJ\1740 regurgitation_5\NN\7406350 ,_6\,\1740 suggestive_7\JJ\1740 of_8\IN\1740 the_9\DT\1740 role_10\NN\719494 of_11\IN\1740 <e1>pergolide</e1>_12\NN\1740 ,_13\,\1740 was_14\VBD\836236 observed_15\VBN\2163746 in_16\IN\13603305 12/30_17\CD\1740 (_18\-LRB-\1740 40_19\CD\13745420 %_20\NN\1740 )_21\-RRB-\1740 patients_22\NNS\9898892 including_23\VBG\690614 two_24\CD\13741022 with_25\IN\1740 <e2>heart_26\NN\5919034 failure</e2>_27\NN\66216 ._28\.\1740
D010479_D006333 NONE <e1>pergolide</e1>_0\NN\1740 was_1\VBD\836236 discontinued_2\VBN\2609764 in_3\IN\13603305 10_4\CD\13745420 patients_5\NNS\9898892 with_6\IN\1740 valvular_7\JJ\1740 heart_8\NN\5919034 disease_9\NN\14061805 ,_10\,\1740 resulting_11\VBG\2633881 in_12\IN\13603305 a_13\DT\13649268 lower_14\JJR\1740 regurgitation_15\NN\7406350 grade_16\NN\7975026 (_17\-LRB-\1740 p=0.01_18\NN\1740 )_19\-RRB-\1740 at_20\IN\14622893 the_21\DT\1740 second_22\JJ\1740 transthoracic_23\NN\1740 echocardiography_24\NN\177127 and_25\CC\1740 the_26\DT\1740 two_27\CD\13741022 patients_28\NNS\9898892 with_29\IN\1740 <e2>heart_30\NN\5919034 failure</e2>_31\NN\66216 returned_32\VBD\1835496 to_33\TO\1740 nearly_34\RB\1740 normal_35\JJ\1740 clinical_36\JJ\1740 examination_37\NN\633864 ._38\.\1740
D004298_D006349 NONE this_0\DT\1740 study_1\NN\635850 supports_2\VBZ\2199590 the_3\DT\1740 high_4\JJ\1740 frequency_5\NN\15286249 of_6\IN\1740 restrictive_7\JJ\1740 <e2>valve_8\NN\5225602 regurgitation</e2>_9\NN\7406350 in_10\IN\13603305 pd_11\NN\14625458 patients_12\NNS\9898892 treated_13\VBN\2376958 with_14\IN\1740 pergolide_15\NN\1740 and_16\CC\1740 reveals_17\VBZ\2137132 that_18\IN\1740 a_19\DT\13649268 significant_20\JJ\1740 improvement_21\NN\7359599 is_22\VBZ\836236 usual_23\JJ\1740 when_24\WRB\1740 the_25\DT\1740 treatment_26\NN\654885 is_27\VBZ\836236 converted_28\VBN\126264 to_29\TO\1740 non-ergot_30\JJ\1740 <e1>dopamine</e1>_31\NN\14807737 agonists_32\NNS\9613191 ._33\.\1740
D004298_D010300 NONE this_0\DT\1740 study_1\NN\635850 supports_2\VBZ\2199590 the_3\DT\1740 high_4\JJ\1740 frequency_5\NN\15286249 of_6\IN\1740 restrictive_7\JJ\1740 valve_8\NN\5225602 regurgitation_9\NN\7406350 in_10\IN\13603305 <e2>pd</e2>_11\NN\14625458 patients_12\NNS\9898892 treated_13\VBN\2376958 with_14\IN\1740 pergolide_15\NN\1740 and_16\CC\1740 reveals_17\VBZ\2137132 that_18\IN\1740 a_19\DT\13649268 significant_20\JJ\1740 improvement_21\NN\7359599 is_22\VBZ\836236 usual_23\JJ\1740 when_24\WRB\1740 the_25\DT\1740 treatment_26\NN\654885 is_27\VBZ\836236 converted_28\VBN\126264 to_29\TO\1740 non-ergot_30\JJ\1740 <e1>dopamine</e1>_31\NN\14807737 agonists_32\NNS\9613191 ._33\.\1740
16181582
D014635_D001927 CID <e1>valproate-induced</e1>_0\JJ\1740 <e2>encephalopathy</e2>_1\RB\1740 ._2\.\1740
D014635_D001927 CID <e1>valproate-induced</e1>_0\JJ\1740 <e2>encephalopathy</e2>_1\JJ\1740 is_2\VBZ\836236 a_3\DT\13649268 rare_4\JJ\1740 syndrome_5\NN\5870365 that_6\WDT\1740 may_7\MD\15209706 manifest_8\VB\1015244 in_9\IN\13603305 otherwise_10\JJ\1740 normal_11\JJ\1740 epileptic_12\JJ\1740 individuals_13\NNS\7347 ._14\.\1740
D014635_D001927 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e1>valproate-induced</e1>_3\JJ\1740 <e2>encephalopathy</e2>_4\JJ\1740 is_5\VBZ\836236 presented_6\VBN\2137132 ._7\.\1740
D014635_D004827 NONE <e1>valproate-induced</e1>_0\JJ\1740 encephalopathy_1\JJ\1740 is_2\VBZ\836236 a_3\DT\13649268 rare_4\JJ\1740 syndrome_5\NN\5870365 that_6\WDT\1740 may_7\MD\15209706 manifest_8\VB\1015244 in_9\IN\13603305 otherwise_10\JJ\1740 normal_11\JJ\1740 <e2>epileptic</e2>_12\JJ\1740 individuals_13\NNS\7347 ._14\.\1740
869641
D007980_D001919 NONE mediation_0\NN\7148192 of_1\IN\1740 enhanced_2\VBN\227165 reflex_3\JJ\1740 vagal_4\NN\1740 <e2>bradycardia</e2>_5\NN\14110674 by_6\IN\1740 <e1>l-dopa</e1>_7\NN\14604959 via_8\IN\1740 central_9\JJ\1740 dopamine_10\NN\14807737 formation_11\NN\7938773 in_12\IN\13603305 dogs_13\NNS\2083346 ._14\.\1740
D007980_D001919 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 reflex_3\JJ\1740 <e2>bradycardia</e2>_4\NN\14110674 caused_5\VBN\1617192 by_6\IN\1740 injected_7\VBN\81072 norepinephrine_8\NN\14807929 was_9\VBD\836236 significantly_10\RB\1740 enhanced_11\VBN\227165 by_12\IN\1740 <e1>l-dopa</e1>_13\JJ\1740 ,_14\,\1740 dl-threo-dihydroxyphenylserine_15\NN\1740 had_16\VBD\2108377 no_17\DT\7204911 effect_18\NN\34213 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 heart_23\NN\5919034 rate_24\NN\13815152 or_25\CC\3541091 reflex_26\JJ\1740 responses_27\NNS\11410625 to_28\TO\1740 norepinephrine_29\NN\14807929 ._30\.\1740
D007980_D001919 NONE fla-63_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 dopamine-beta-oxidase_3\NN\1740 inhibitor_4\NN\20090 ,_5\,\1740 did_6\VBD\1640855 not_7\RB\1740 have_8\VB\2108377 any_9\DT\1740 effect_10\NN\34213 on_11\IN\1740 the_12\DT\1740 hypotension_13\NN\14057371 ,_14\,\1740 <e2>bradycardia</e2>_15\NN\14110674 or_16\CC\3541091 reflex-enhancing_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 <e1>l-dopa</e1>_20\JJ\1740 ._21\.\1740
D007980_D001919 NONE however_0\RB\1740 ,_1\,\1740 <e1>l-dopa</e1>_2\NN\14604959 restored_3\VBD\1631072 the_4\DT\1740 <e2>bradycardia</e2>_5\NN\14110674 caused_6\VBN\1617192 by_7\IN\1740 norepinephrine_8\NN\14807929 in_9\IN\13603305 addition_10\NN\3081021 to_11\TO\1740 decreasing_12\VBG\169651 blood_13\NN\5397468 pressure_14\NN\11419404 and_15\CC\1740 heart_16\NN\5919034 rate_17\NN\13815152 ._18\.\1740
D007980_D001919 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 <e1>l-dopa</e1>_4\NN\14604959 enhances_5\VBZ\227165 reflex_6\JJ\1740 <e2>bradycardia</e2>_7\NN\14110674 through_8\IN\1740 central_9\JJ\1740 alpha-receptor_10\NN\1740 stimulation_11\NN\242808 ._12\.\1740
D004298_D001919 NONE mediation_0\NN\7148192 of_1\IN\1740 enhanced_2\VBN\227165 reflex_3\JJ\1740 vagal_4\NN\1740 <e2>bradycardia</e2>_5\NN\14110674 by_6\IN\1740 l-dopa_7\NN\14604959 via_8\IN\1740 central_9\JJ\1740 <e1>dopamine</e1>_10\NN\14807737 formation_11\NN\7938773 in_12\IN\13603305 dogs_13\NNS\2083346 ._14\.\1740
D004298_D001919 NONE fla-63_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 <e1>dopamine-beta-oxidase</e1>_3\NN\1740 inhibitor_4\NN\20090 ,_5\,\1740 did_6\VBD\1640855 not_7\RB\1740 have_8\VB\2108377 any_9\DT\1740 effect_10\NN\34213 on_11\IN\1740 the_12\DT\1740 hypotension_13\NN\14057371 ,_14\,\1740 <e2>bradycardia</e2>_15\NN\14110674 or_16\CC\3541091 reflex-enhancing_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 l-dopa_20\JJ\1740 ._21\.\1740
D009638_D001919 CID in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 reflex_3\JJ\1740 <e2>bradycardia</e2>_4\NN\14110674 caused_5\VBN\1617192 by_6\IN\1740 injected_7\VBN\81072 <e1>norepinephrine</e1>_8\NN\14807929 was_9\VBD\836236 significantly_10\RB\1740 enhanced_11\VBN\227165 by_12\IN\1740 l-dopa_13\JJ\1740 ,_14\,\1740 dl-threo-dihydroxyphenylserine_15\NN\1740 had_16\VBD\2108377 no_17\DT\7204911 effect_18\NN\34213 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 heart_23\NN\5919034 rate_24\NN\13815152 or_25\CC\3541091 reflex_26\JJ\1740 responses_27\NNS\11410625 to_28\TO\1740 norepinephrine_29\NN\14807929 ._30\.\1740
D009638_D001919 CID in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 reflex_3\JJ\1740 <e2>bradycardia</e2>_4\NN\14110674 caused_5\VBN\1617192 by_6\IN\1740 injected_7\VBN\81072 norepinephrine_8\NN\14807929 was_9\VBD\836236 significantly_10\RB\1740 enhanced_11\VBN\227165 by_12\IN\1740 l-dopa_13\JJ\1740 ,_14\,\1740 dl-threo-dihydroxyphenylserine_15\NN\1740 had_16\VBD\2108377 no_17\DT\7204911 effect_18\NN\34213 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 heart_23\NN\5919034 rate_24\NN\13815152 or_25\CC\3541091 reflex_26\JJ\1740 responses_27\NNS\11410625 to_28\TO\1740 <e1>norepinephrine</e1>_29\NN\14807929 ._30\.\1740
D009638_D001919 CID however_0\RB\1740 ,_1\,\1740 l-dopa_2\NN\14604959 restored_3\VBD\1631072 the_4\DT\1740 <e2>bradycardia</e2>_5\NN\14110674 caused_6\VBN\1617192 by_7\IN\1740 <e1>norepinephrine</e1>_8\NN\14807929 in_9\IN\13603305 addition_10\NN\3081021 to_11\TO\1740 decreasing_12\VBG\169651 blood_13\NN\5397468 pressure_14\NN\11419404 and_15\CC\1740 heart_16\NN\5919034 rate_17\NN\13815152 ._18\.\1740
D009638_D001919 CID 5-htp_0\NN\1740 (_1\-LRB-\1740 5_2\CD\13741022 mg/kg_3\NN\1740 i.v._4\NN\1740 )_5\-RRB-\1740 decreased_6\VBN\169651 blood_7\NN\5397468 pressure_8\NN\11419404 and_9\CC\1740 heart_10\NN\5919034 rate_11\NN\13815152 and_12\CC\1740 decreased_13\VBD\169651 the_14\DT\1740 reflex_15\JJ\1740 <e2>bradycardia</e2>_16\NN\14110674 to_17\TO\1740 <e1>norepinephrine</e1>_18\NN\14807929 ._19\.\1740
D015103_D001919 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 reflex_3\JJ\1740 <e2>bradycardia</e2>_4\NN\14110674 caused_5\VBN\1617192 by_6\IN\1740 injected_7\VBN\81072 norepinephrine_8\NN\14807929 was_9\VBD\836236 significantly_10\RB\1740 enhanced_11\VBN\227165 by_12\IN\1740 l-dopa_13\JJ\1740 ,_14\,\1740 <e1>dl-threo-dihydroxyphenylserine</e1>_15\NN\1740 had_16\VBD\2108377 no_17\DT\7204911 effect_18\NN\34213 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 heart_23\NN\5919034 rate_24\NN\13815152 or_25\CC\3541091 reflex_26\JJ\1740 responses_27\NNS\11410625 to_28\TO\1740 norepinephrine_29\NN\14807929 ._30\.\1740
D005406_D007022 NONE <e1>fla-63</e1>_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 dopamine-beta-oxidase_3\NN\1740 inhibitor_4\NN\20090 ,_5\,\1740 did_6\VBD\1640855 not_7\RB\1740 have_8\VB\2108377 any_9\DT\1740 effect_10\NN\34213 on_11\IN\1740 the_12\DT\1740 <e2>hypotension</e2>_13\NN\14057371 ,_14\,\1740 bradycardia_15\NN\14110674 or_16\CC\3541091 reflex-enhancing_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 l-dopa_20\JJ\1740 ._21\.\1740
D005406_D001919 NONE <e1>fla-63</e1>_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 dopamine-beta-oxidase_3\NN\1740 inhibitor_4\NN\20090 ,_5\,\1740 did_6\VBD\1640855 not_7\RB\1740 have_8\VB\2108377 any_9\DT\1740 effect_10\NN\34213 on_11\IN\1740 the_12\DT\1740 hypotension_13\NN\14057371 ,_14\,\1740 <e2>bradycardia</e2>_15\NN\14110674 or_16\CC\3541091 reflex-enhancing_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 l-dopa_20\JJ\1740 ._21\.\1740
D004298_D007022 NONE fla-63_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 <e1>dopamine-beta-oxidase</e1>_3\NN\1740 inhibitor_4\NN\20090 ,_5\,\1740 did_6\VBD\1640855 not_7\RB\1740 have_8\VB\2108377 any_9\DT\1740 effect_10\NN\34213 on_11\IN\1740 the_12\DT\1740 <e2>hypotension</e2>_13\NN\14057371 ,_14\,\1740 bradycardia_15\NN\14110674 or_16\CC\3541091 reflex-enhancing_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 l-dopa_20\JJ\1740 ._21\.\1740
D007980_D007022 NONE fla-63_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 dopamine-beta-oxidase_3\NN\1740 inhibitor_4\NN\20090 ,_5\,\1740 did_6\VBD\1640855 not_7\RB\1740 have_8\VB\2108377 any_9\DT\1740 effect_10\NN\34213 on_11\IN\1740 the_12\DT\1740 <e2>hypotension</e2>_13\NN\14057371 ,_14\,\1740 bradycardia_15\NN\14110674 or_16\CC\3541091 reflex-enhancing_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 <e1>l-dopa</e1>_20\JJ\1740 ._21\.\1740
D006916_D001919 NONE <e1>5-htp</e1>_0\NN\1740 (_1\-LRB-\1740 5_2\CD\13741022 mg/kg_3\NN\1740 i.v._4\NN\1740 )_5\-RRB-\1740 decreased_6\VBN\169651 blood_7\NN\5397468 pressure_8\NN\11419404 and_9\CC\1740 heart_10\NN\5919034 rate_11\NN\13815152 and_12\CC\1740 decreased_13\VBD\169651 the_14\DT\1740 reflex_15\JJ\1740 <e2>bradycardia</e2>_16\NN\14110674 to_17\TO\1740 norepinephrine_18\NN\14807929 ._19\.\1740
7423039
D004317_D066126 CID metabolic_0\JJ\1740 involvement_1\NN\1080366 in_2\IN\13603305 <e1>adriamycin</e1>_3\NN\1740 <e2>cardiotoxicity</e2>_4\NN\1740 ._5\.\1740
D004317_D066126 CID the_0\DT\1740 <e2>cardiotoxic</e2>_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>adriamycin</e1>_4\NN\1740 were_5\VBD\836236 studied_6\VBN\630380 in_7\IN\13603305 mammalian_8\JJ\1740 myocardial_9\JJ\1740 cells_10\NNS\3080309 in_11\IN\13603305 culture_12\NN\7966140 as_13\IN\14622893 a_14\DT\13649268 model_15\NN\5888929 system_16\NN\3575240 ._17\.\1740
8386779
D017693_D004414 NONE <e1>sodium_0\NN\14625458 bicarbonate</e1>_1\NN\14798450 alleviates_2\VBZ\205885 <e2>penile_3\JJ\1740 pain</e2>_4\NN\14299637 induced_5\VBN\1627355 by_6\IN\1740 intracavernous_7\JJ\1740 injections_8\NNS\320852 for_9\IN\1740 erectile_10\JJ\1740 dysfunction_11\NN\14204950 ._12\.\1740
D017693_D004414 NONE in_0\IN\13603305 an_1\DT\6697703 attempt_2\NN\407535 to_3\TO\1740 determine_4\VB\1645601 whether_5\IN\1740 <e2>penile_6\NN\1740 pain</e2>_7\NN\14299637 associated_8\VBN\628491 with_9\IN\1740 intracorporeal_10\JJ\1740 injections_11\NNS\320852 could_12\MD\1740 be_13\VB\836236 due_14\JJ\1740 to_15\TO\1740 the_16\DT\1740 acidity_17\NN\4992163 of_18\IN\1740 the_19\DT\1740 medication_20\NN\3247620 ,_21\,\1740 we_22\PRP\1740 performed_23\VBD\2367363 a_24\DT\13649268 randomized_25\JJ\1740 study_26\NN\635850 comparing_27\VBG\644583 the_28\DT\1740 incidence_29\NN\13821570 of_30\IN\1740 penile_31\NN\1740 pain_32\NN\14299637 following_33\VBG\1835496 intracorporeal_34\JJ\1740 injections_35\NNS\320852 with_36\IN\1740 or_37\CC\3541091 without_38\IN\1740 the_39\DT\1740 addition_40\NN\3081021 of_41\IN\1740 <e1>sodium_42\NN\14625458 bicarbonate</e1>_43\NN\14798450 to_44\IN\1740 the_45\DT\1740 intracorporeal_46\NN\1740 medications._47\NN\1740 a_48\NN\13649268 total_49\NN\3553 of_50\IN\1740 38_51\CD\1740 consecutive_52\JJ\1740 patients_53\NNS\9898892 who_54\WP\8299493 presented_55\VBD\2137132 to_56\TO\1740 our_57\PRP$\1740 clinic_58\NN\8053905 with_59\IN\1740 impotence_60\NN\4723816 received_61\VBD\2210855 0.2_62\CD\1740 ml._63\NN\1740 of_64\IN\1740 a_65\DT\13649268 combination_66\NN\7951464 of_67\IN\1740 3_68\CD\13741022 drugs_69\NNS\14778436 :_70\:\1740 6_71\CD\13741022 mg._72\NN\1740 papaverine_73\JJ\1740 ,_74\,\1740 100_75\CD\13745420 micrograms_76\NNS\13717155 ._77\.\1740
D017693_D004414 NONE in_0\IN\13603305 an_1\DT\6697703 attempt_2\NN\407535 to_3\TO\1740 determine_4\VB\1645601 whether_5\IN\1740 penile_6\NN\1740 pain_7\NN\14299637 associated_8\VBN\628491 with_9\IN\1740 intracorporeal_10\JJ\1740 injections_11\NNS\320852 could_12\MD\1740 be_13\VB\836236 due_14\JJ\1740 to_15\TO\1740 the_16\DT\1740 acidity_17\NN\4992163 of_18\IN\1740 the_19\DT\1740 medication_20\NN\3247620 ,_21\,\1740 we_22\PRP\1740 performed_23\VBD\2367363 a_24\DT\13649268 randomized_25\JJ\1740 study_26\NN\635850 comparing_27\VBG\644583 the_28\DT\1740 incidence_29\NN\13821570 of_30\IN\1740 <e2>penile_31\NN\1740 pain</e2>_32\NN\14299637 following_33\VBG\1835496 intracorporeal_34\JJ\1740 injections_35\NNS\320852 with_36\IN\1740 or_37\CC\3541091 without_38\IN\1740 the_39\DT\1740 addition_40\NN\3081021 of_41\IN\1740 <e1>sodium_42\NN\14625458 bicarbonate</e1>_43\NN\14798450 to_44\IN\1740 the_45\DT\1740 intracorporeal_46\NN\1740 medications._47\NN\1740 a_48\NN\13649268 total_49\NN\3553 of_50\IN\1740 38_51\CD\1740 consecutive_52\JJ\1740 patients_53\NNS\9898892 who_54\WP\8299493 presented_55\VBD\2137132 to_56\TO\1740 our_57\PRP$\1740 clinic_58\NN\8053905 with_59\IN\1740 impotence_60\NN\4723816 received_61\VBD\2210855 0.2_62\CD\1740 ml._63\NN\1740 of_64\IN\1740 a_65\DT\13649268 combination_66\NN\7951464 of_67\IN\1740 3_68\CD\13741022 drugs_69\NNS\14778436 :_70\:\1740 6_71\CD\13741022 mg._72\NN\1740 papaverine_73\JJ\1740 ,_74\,\1740 100_75\CD\13745420 micrograms_76\NNS\13717155 ._77\.\1740
D017693_D004414 NONE of_0\IN\1740 the_1\DT\1740 19_2\CD\13745420 patients_3\NNS\9898892 without_4\IN\1740 <e1>sodium_5\NN\14625458 bicarbonate</e1>_6\NN\14798450 added_7\VBN\156601 to_8\IN\1740 the_9\DT\1740 medication_10\NN\3247620 11_11\CD\13745420 (_12\-LRB-\1740 58_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 complained_16\VBD\843959 of_17\IN\1740 <e2>penile_18\NN\1740 pain</e2>_19\NN\14299637 due_20\JJ\1740 to_21\IN\1740 the_22\DT\1740 medication_23\NN\3247620 ,_24\,\1740 while_25\IN\15122231 only_26\RB\1740 1_27\CD\13741022 of_28\IN\1740 the_29\DT\1740 19_30\CD\13745420 men_31\NNS\8208016 (_32\-LRB-\1740 5_33\CD\13741022 %_34\NN\1740 )_35\-RRB-\1740 who_36\WP\8299493 received_37\VBD\2210855 sodium_38\NN\14625458 bicarbonate_39\NN\14798450 complained_40\VBD\843959 of_41\IN\1740 penile_42\NN\1740 pain_43\NN\14299637 ._44\.\1740
D017693_D004414 NONE of_0\IN\1740 the_1\DT\1740 19_2\CD\13745420 patients_3\NNS\9898892 without_4\IN\1740 <e1>sodium_5\NN\14625458 bicarbonate</e1>_6\NN\14798450 added_7\VBN\156601 to_8\IN\1740 the_9\DT\1740 medication_10\NN\3247620 11_11\CD\13745420 (_12\-LRB-\1740 58_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 complained_16\VBD\843959 of_17\IN\1740 penile_18\NN\1740 pain_19\NN\14299637 due_20\JJ\1740 to_21\IN\1740 the_22\DT\1740 medication_23\NN\3247620 ,_24\,\1740 while_25\IN\15122231 only_26\RB\1740 1_27\CD\13741022 of_28\IN\1740 the_29\DT\1740 19_30\CD\13745420 men_31\NNS\8208016 (_32\-LRB-\1740 5_33\CD\13741022 %_34\NN\1740 )_35\-RRB-\1740 who_36\WP\8299493 received_37\VBD\2210855 sodium_38\NN\14625458 bicarbonate_39\NN\14798450 complained_40\VBD\843959 of_41\IN\1740 <e2>penile_42\NN\1740 pain</e2>_43\NN\14299637 ._44\.\1740
D017693_D004414 NONE of_0\IN\1740 the_1\DT\1740 19_2\CD\13745420 patients_3\NNS\9898892 without_4\IN\1740 sodium_5\NN\14625458 bicarbonate_6\NN\14798450 added_7\VBN\156601 to_8\IN\1740 the_9\DT\1740 medication_10\NN\3247620 11_11\CD\13745420 (_12\-LRB-\1740 58_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 complained_16\VBD\843959 of_17\IN\1740 <e2>penile_18\NN\1740 pain</e2>_19\NN\14299637 due_20\JJ\1740 to_21\IN\1740 the_22\DT\1740 medication_23\NN\3247620 ,_24\,\1740 while_25\IN\15122231 only_26\RB\1740 1_27\CD\13741022 of_28\IN\1740 the_29\DT\1740 19_30\CD\13745420 men_31\NNS\8208016 (_32\-LRB-\1740 5_33\CD\13741022 %_34\NN\1740 )_35\-RRB-\1740 who_36\WP\8299493 received_37\VBD\2210855 <e1>sodium_38\NN\14625458 bicarbonate</e1>_39\NN\14798450 complained_40\VBD\843959 of_41\IN\1740 penile_42\NN\1740 pain_43\NN\14299637 ._44\.\1740
D017693_D004414 NONE of_0\IN\1740 the_1\DT\1740 19_2\CD\13745420 patients_3\NNS\9898892 without_4\IN\1740 sodium_5\NN\14625458 bicarbonate_6\NN\14798450 added_7\VBN\156601 to_8\IN\1740 the_9\DT\1740 medication_10\NN\3247620 11_11\CD\13745420 (_12\-LRB-\1740 58_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 complained_16\VBD\843959 of_17\IN\1740 penile_18\NN\1740 pain_19\NN\14299637 due_20\JJ\1740 to_21\IN\1740 the_22\DT\1740 medication_23\NN\3247620 ,_24\,\1740 while_25\IN\15122231 only_26\RB\1740 1_27\CD\13741022 of_28\IN\1740 the_29\DT\1740 19_30\CD\13745420 men_31\NNS\8208016 (_32\-LRB-\1740 5_33\CD\13741022 %_34\NN\1740 )_35\-RRB-\1740 who_36\WP\8299493 received_37\VBD\2210855 <e1>sodium_38\NN\14625458 bicarbonate</e1>_39\NN\14798450 complained_40\VBD\843959 of_41\IN\1740 <e2>penile_42\NN\1740 pain</e2>_43\NN\14299637 ._44\.\1740
D017693_D007172 NONE <e1>sodium_0\NN\14625458 bicarbonate</e1>_1\NN\14798450 alleviates_2\VBZ\205885 penile_3\JJ\1740 pain_4\NN\14299637 induced_5\VBN\1627355 by_6\IN\1740 intracavernous_7\JJ\1740 injections_8\NNS\320852 for_9\IN\1740 <e2>erectile_10\JJ\1740 dysfunction</e2>_11\NN\14204950 ._12\.\1740
D017693_D007172 NONE in_0\IN\13603305 an_1\DT\6697703 attempt_2\NN\407535 to_3\TO\1740 determine_4\VB\1645601 whether_5\IN\1740 penile_6\NN\1740 pain_7\NN\14299637 associated_8\VBN\628491 with_9\IN\1740 intracorporeal_10\JJ\1740 injections_11\NNS\320852 could_12\MD\1740 be_13\VB\836236 due_14\JJ\1740 to_15\TO\1740 the_16\DT\1740 acidity_17\NN\4992163 of_18\IN\1740 the_19\DT\1740 medication_20\NN\3247620 ,_21\,\1740 we_22\PRP\1740 performed_23\VBD\2367363 a_24\DT\13649268 randomized_25\JJ\1740 study_26\NN\635850 comparing_27\VBG\644583 the_28\DT\1740 incidence_29\NN\13821570 of_30\IN\1740 penile_31\NN\1740 pain_32\NN\14299637 following_33\VBG\1835496 intracorporeal_34\JJ\1740 injections_35\NNS\320852 with_36\IN\1740 or_37\CC\3541091 without_38\IN\1740 the_39\DT\1740 addition_40\NN\3081021 of_41\IN\1740 <e1>sodium_42\NN\14625458 bicarbonate</e1>_43\NN\14798450 to_44\IN\1740 the_45\DT\1740 intracorporeal_46\NN\1740 medications._47\NN\1740 a_48\NN\13649268 total_49\NN\3553 of_50\IN\1740 38_51\CD\1740 consecutive_52\JJ\1740 patients_53\NNS\9898892 who_54\WP\8299493 presented_55\VBD\2137132 to_56\TO\1740 our_57\PRP$\1740 clinic_58\NN\8053905 with_59\IN\1740 <e2>impotence</e2>_60\NN\4723816 received_61\VBD\2210855 0.2_62\CD\1740 ml._63\NN\1740 of_64\IN\1740 a_65\DT\13649268 combination_66\NN\7951464 of_67\IN\1740 3_68\CD\13741022 drugs_69\NNS\14778436 :_70\:\1740 6_71\CD\13741022 mg._72\NN\1740 papaverine_73\JJ\1740 ,_74\,\1740 100_75\CD\13745420 micrograms_76\NNS\13717155 ._77\.\1740
D010208_D004414 NONE in_0\IN\13603305 an_1\DT\6697703 attempt_2\NN\407535 to_3\TO\1740 determine_4\VB\1645601 whether_5\IN\1740 <e2>penile_6\NN\1740 pain</e2>_7\NN\14299637 associated_8\VBN\628491 with_9\IN\1740 intracorporeal_10\JJ\1740 injections_11\NNS\320852 could_12\MD\1740 be_13\VB\836236 due_14\JJ\1740 to_15\TO\1740 the_16\DT\1740 acidity_17\NN\4992163 of_18\IN\1740 the_19\DT\1740 medication_20\NN\3247620 ,_21\,\1740 we_22\PRP\1740 performed_23\VBD\2367363 a_24\DT\13649268 randomized_25\JJ\1740 study_26\NN\635850 comparing_27\VBG\644583 the_28\DT\1740 incidence_29\NN\13821570 of_30\IN\1740 penile_31\NN\1740 pain_32\NN\14299637 following_33\VBG\1835496 intracorporeal_34\JJ\1740 injections_35\NNS\320852 with_36\IN\1740 or_37\CC\3541091 without_38\IN\1740 the_39\DT\1740 addition_40\NN\3081021 of_41\IN\1740 sodium_42\NN\14625458 bicarbonate_43\NN\14798450 to_44\IN\1740 the_45\DT\1740 intracorporeal_46\NN\1740 medications._47\NN\1740 a_48\NN\13649268 total_49\NN\3553 of_50\IN\1740 38_51\CD\1740 consecutive_52\JJ\1740 patients_53\NNS\9898892 who_54\WP\8299493 presented_55\VBD\2137132 to_56\TO\1740 our_57\PRP$\1740 clinic_58\NN\8053905 with_59\IN\1740 impotence_60\NN\4723816 received_61\VBD\2210855 0.2_62\CD\1740 ml._63\NN\1740 of_64\IN\1740 a_65\DT\13649268 combination_66\NN\7951464 of_67\IN\1740 3_68\CD\13741022 drugs_69\NNS\14778436 :_70\:\1740 6_71\CD\13741022 mg._72\NN\1740 <e1>papaverine</e1>_73\JJ\1740 ,_74\,\1740 100_75\CD\13745420 micrograms_76\NNS\13717155 ._77\.\1740
D010208_D004414 NONE in_0\IN\13603305 an_1\DT\6697703 attempt_2\NN\407535 to_3\TO\1740 determine_4\VB\1645601 whether_5\IN\1740 penile_6\NN\1740 pain_7\NN\14299637 associated_8\VBN\628491 with_9\IN\1740 intracorporeal_10\JJ\1740 injections_11\NNS\320852 could_12\MD\1740 be_13\VB\836236 due_14\JJ\1740 to_15\TO\1740 the_16\DT\1740 acidity_17\NN\4992163 of_18\IN\1740 the_19\DT\1740 medication_20\NN\3247620 ,_21\,\1740 we_22\PRP\1740 performed_23\VBD\2367363 a_24\DT\13649268 randomized_25\JJ\1740 study_26\NN\635850 comparing_27\VBG\644583 the_28\DT\1740 incidence_29\NN\13821570 of_30\IN\1740 <e2>penile_31\NN\1740 pain</e2>_32\NN\14299637 following_33\VBG\1835496 intracorporeal_34\JJ\1740 injections_35\NNS\320852 with_36\IN\1740 or_37\CC\3541091 without_38\IN\1740 the_39\DT\1740 addition_40\NN\3081021 of_41\IN\1740 sodium_42\NN\14625458 bicarbonate_43\NN\14798450 to_44\IN\1740 the_45\DT\1740 intracorporeal_46\NN\1740 medications._47\NN\1740 a_48\NN\13649268 total_49\NN\3553 of_50\IN\1740 38_51\CD\1740 consecutive_52\JJ\1740 patients_53\NNS\9898892 who_54\WP\8299493 presented_55\VBD\2137132 to_56\TO\1740 our_57\PRP$\1740 clinic_58\NN\8053905 with_59\IN\1740 impotence_60\NN\4723816 received_61\VBD\2210855 0.2_62\CD\1740 ml._63\NN\1740 of_64\IN\1740 a_65\DT\13649268 combination_66\NN\7951464 of_67\IN\1740 3_68\CD\13741022 drugs_69\NNS\14778436 :_70\:\1740 6_71\CD\13741022 mg._72\NN\1740 <e1>papaverine</e1>_73\JJ\1740 ,_74\,\1740 100_75\CD\13745420 micrograms_76\NNS\13717155 ._77\.\1740
D010208_D007172 NONE in_0\IN\13603305 an_1\DT\6697703 attempt_2\NN\407535 to_3\TO\1740 determine_4\VB\1645601 whether_5\IN\1740 penile_6\NN\1740 pain_7\NN\14299637 associated_8\VBN\628491 with_9\IN\1740 intracorporeal_10\JJ\1740 injections_11\NNS\320852 could_12\MD\1740 be_13\VB\836236 due_14\JJ\1740 to_15\TO\1740 the_16\DT\1740 acidity_17\NN\4992163 of_18\IN\1740 the_19\DT\1740 medication_20\NN\3247620 ,_21\,\1740 we_22\PRP\1740 performed_23\VBD\2367363 a_24\DT\13649268 randomized_25\JJ\1740 study_26\NN\635850 comparing_27\VBG\644583 the_28\DT\1740 incidence_29\NN\13821570 of_30\IN\1740 penile_31\NN\1740 pain_32\NN\14299637 following_33\VBG\1835496 intracorporeal_34\JJ\1740 injections_35\NNS\320852 with_36\IN\1740 or_37\CC\3541091 without_38\IN\1740 the_39\DT\1740 addition_40\NN\3081021 of_41\IN\1740 sodium_42\NN\14625458 bicarbonate_43\NN\14798450 to_44\IN\1740 the_45\DT\1740 intracorporeal_46\NN\1740 medications._47\NN\1740 a_48\NN\13649268 total_49\NN\3553 of_50\IN\1740 38_51\CD\1740 consecutive_52\JJ\1740 patients_53\NNS\9898892 who_54\WP\8299493 presented_55\VBD\2137132 to_56\TO\1740 our_57\PRP$\1740 clinic_58\NN\8053905 with_59\IN\1740 <e2>impotence</e2>_60\NN\4723816 received_61\VBD\2210855 0.2_62\CD\1740 ml._63\NN\1740 of_64\IN\1740 a_65\DT\13649268 combination_66\NN\7951464 of_67\IN\1740 3_68\CD\13741022 drugs_69\NNS\14778436 :_70\:\1740 6_71\CD\13741022 mg._72\NN\1740 <e1>papaverine</e1>_73\JJ\1740 ,_74\,\1740 100_75\CD\13745420 micrograms_76\NNS\13717155 ._77\.\1740
11569530
D016593_D016171 CID <e2>tdp</e2>_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 side-effect_3\NN\1740 that_4\WDT\1740 has_5\VBZ\2108377 led_6\VBN\1752884 to_7\IN\1740 withdrawal_8\NN\7206096 of_9\IN\1740 several_10\JJ\1740 drugs_11\NNS\14778436 from_12\IN\1740 the_13\DT\1740 market_14\NN\407535 (_15\-LRB-\1740 e.g._16\FW\1740 <e1>terfenadine</e1>_17\NN\1740 and_18\CC\1740 terodiline_19\NN\1740 )_20\-RRB-\1740 ._21\.\1740
D016593_D016171 CID four_0\CD\13741022 compounds_1\NNS\5869584 known_2\VBN\2110220 to_3\TO\1740 increase_4\VB\169651 qt_5\NN\1740 interval_6\NN\33615 and_7\CC\1740 cause_8\VB\1617192 <e2>tdp</e2>_9\NN\1740 were_10\VBD\836236 investigated_11\VBN\644583 :_12\:\1740 <e1>terfenadine</e1>_13\NN\1740 ,_14\,\1740 terodiline_15\NN\1740 ,_16\,\1740 cisapride_17\NN\1740 and_18\CC\1740 e4031_19\NN\1740 ._20\.\1740
D016593_D016171 CID for_0\IN\1740 compounds_1\NNS\5869584 that_2\WDT\1740 have_3\VBP\2108377 shown_4\VBN\2137132 <e2>tdp</e2>_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 clinic_8\NN\8053905 (_9\-LRB-\1740 <e1>terfenadine</e1>_10\NN\1740 ,_11\,\1740 terodiline_12\NN\1740 ,_13\,\1740 cisapride_14\NN\1740 )_15\-RRB-\1740 there_16\EX\27167 is_17\VBZ\836236 little_18\JJ\1740 differentiation_19\NN\5748054 between_20\IN\1740 the_21\DT\1740 dog_22\NN\2083346 ed50_23\NN\1740 and_24\CC\1740 the_25\DT\1740 efficacious_26\JJ\1740 free_27\JJ\1740 plasma_28\NN\5398023 concentrations_29\NNS\4916342 in_30\IN\13603305 man_31\NN\9605289 (_32\-LRB-\1740 <_33\XX\1740 10-fold_34\RB\1740 )_35\-RRB-\1740 reflecting_36\VBG\923793 their_37\PRP$\1740 limited_38\JJ\1740 safety_39\NN\13920835 margins_40\NNS\13903079 ._41\.\1740
C010637_D016171 CID <e2>tdp</e2>_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 side-effect_3\NN\1740 that_4\WDT\1740 has_5\VBZ\2108377 led_6\VBN\1752884 to_7\IN\1740 withdrawal_8\NN\7206096 of_9\IN\1740 several_10\JJ\1740 drugs_11\NNS\14778436 from_12\IN\1740 the_13\DT\1740 market_14\NN\407535 (_15\-LRB-\1740 e.g._16\FW\1740 terfenadine_17\NN\1740 and_18\CC\1740 <e1>terodiline</e1>_19\NN\1740 )_20\-RRB-\1740 ._21\.\1740
C010637_D016171 CID four_0\CD\13741022 compounds_1\NNS\5869584 known_2\VBN\2110220 to_3\TO\1740 increase_4\VB\169651 qt_5\NN\1740 interval_6\NN\33615 and_7\CC\1740 cause_8\VB\1617192 <e2>tdp</e2>_9\NN\1740 were_10\VBD\836236 investigated_11\VBN\644583 :_12\:\1740 terfenadine_13\NN\1740 ,_14\,\1740 <e1>terodiline</e1>_15\NN\1740 ,_16\,\1740 cisapride_17\NN\1740 and_18\CC\1740 e4031_19\NN\1740 ._20\.\1740
C010637_D016171 CID for_0\IN\1740 compounds_1\NNS\5869584 that_2\WDT\1740 have_3\VBP\2108377 shown_4\VBN\2137132 <e2>tdp</e2>_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 clinic_8\NN\8053905 (_9\-LRB-\1740 terfenadine_10\NN\1740 ,_11\,\1740 <e1>terodiline</e1>_12\NN\1740 ,_13\,\1740 cisapride_14\NN\1740 )_15\-RRB-\1740 there_16\EX\27167 is_17\VBZ\836236 little_18\JJ\1740 differentiation_19\NN\5748054 between_20\IN\1740 the_21\DT\1740 dog_22\NN\2083346 ed50_23\NN\1740 and_24\CC\1740 the_25\DT\1740 efficacious_26\JJ\1740 free_27\JJ\1740 plasma_28\NN\5398023 concentrations_29\NNS\4916342 in_30\IN\13603305 man_31\NN\9605289 (_32\-LRB-\1740 <_33\XX\1740 10-fold_34\RB\1740 )_35\-RRB-\1740 reflecting_36\VBG\923793 their_37\PRP$\1740 limited_38\JJ\1740 safety_39\NN\13920835 margins_40\NNS\13903079 ._41\.\1740
D020117_D016171 CID four_0\CD\13741022 compounds_1\NNS\5869584 known_2\VBN\2110220 to_3\TO\1740 increase_4\VB\169651 qt_5\NN\1740 interval_6\NN\33615 and_7\CC\1740 cause_8\VB\1617192 <e2>tdp</e2>_9\NN\1740 were_10\VBD\836236 investigated_11\VBN\644583 :_12\:\1740 terfenadine_13\NN\1740 ,_14\,\1740 terodiline_15\NN\1740 ,_16\,\1740 <e1>cisapride</e1>_17\NN\1740 and_18\CC\1740 e4031_19\NN\1740 ._20\.\1740
D020117_D016171 CID for_0\IN\1740 compounds_1\NNS\5869584 that_2\WDT\1740 have_3\VBP\2108377 shown_4\VBN\2137132 <e2>tdp</e2>_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 clinic_8\NN\8053905 (_9\-LRB-\1740 terfenadine_10\NN\1740 ,_11\,\1740 terodiline_12\NN\1740 ,_13\,\1740 <e1>cisapride</e1>_14\NN\1740 )_15\-RRB-\1740 there_16\EX\27167 is_17\VBZ\836236 little_18\JJ\1740 differentiation_19\NN\5748054 between_20\IN\1740 the_21\DT\1740 dog_22\NN\2083346 ed50_23\NN\1740 and_24\CC\1740 the_25\DT\1740 efficacious_26\JJ\1740 free_27\JJ\1740 plasma_28\NN\5398023 concentrations_29\NNS\4916342 in_30\IN\13603305 man_31\NN\9605289 (_32\-LRB-\1740 <_33\XX\1740 10-fold_34\RB\1740 )_35\-RRB-\1740 reflecting_36\VBG\923793 their_37\PRP$\1740 limited_38\JJ\1740 safety_39\NN\13920835 margins_40\NNS\13903079 ._41\.\1740
C063968_D016171 NONE four_0\CD\13741022 compounds_1\NNS\5869584 known_2\VBN\2110220 to_3\TO\1740 increase_4\VB\169651 qt_5\NN\1740 interval_6\NN\33615 and_7\CC\1740 cause_8\VB\1617192 <e2>tdp</e2>_9\NN\1740 were_10\VBD\836236 investigated_11\VBN\644583 :_12\:\1740 terfenadine_13\NN\1740 ,_14\,\1740 terodiline_15\NN\1740 ,_16\,\1740 cisapride_17\NN\1740 and_18\CC\1740 <e1>e4031</e1>_19\NN\1740 ._20\.\1740
6308277
D002110_D064420 NONE reduction_0\NN\351485 in_1\IN\13603305 <e1>caffeine</e1>_2\NN\14712692 <e2>toxicity</e2>_3\NN\13576101 by_4\IN\1740 acetaminophen_5\RB\1740 ._6\.\1740
D002110_D064420 NONE because_0\IN\1740 salicylates_1\NNS\3828465 have_2\VBP\2108377 been_3\VBN\836236 reported_4\VBN\831651 to_5\TO\1740 augment_6\VB\153263 the_7\DT\1740 stimulatory_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 <e1>caffeine</e1>_11\NN\14712692 on_12\IN\1740 the_13\DT\1740 cns_14\NN\5237227 ,_15\,\1740 attention_16\NN\5701944 was_17\VBD\836236 focused_18\VBN\628491 on_19\IN\1740 the_20\DT\1740 possibility_21\NN\5944958 that_22\IN\1740 the_23\DT\1740 presence_24\NN\13954253 of_25\IN\1740 acetaminophen_26\NN\2707683 (_27\-LRB-\1740 52_28\CD\1740 micrograms/ml_29\NNS\1740 )_30\-RRB-\1740 reduced_31\VBD\441445 the_32\DT\1740 cns_33\NN\5237227 <e2>toxicity</e2>_34\NN\13576101 of_35\IN\1740 caffeine_36\NN\14712692 ._37\.\1740
D002110_D064420 NONE because_0\IN\1740 salicylates_1\NNS\3828465 have_2\VBP\2108377 been_3\VBN\836236 reported_4\VBN\831651 to_5\TO\1740 augment_6\VB\153263 the_7\DT\1740 stimulatory_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 caffeine_11\NN\14712692 on_12\IN\1740 the_13\DT\1740 cns_14\NN\5237227 ,_15\,\1740 attention_16\NN\5701944 was_17\VBD\836236 focused_18\VBN\628491 on_19\IN\1740 the_20\DT\1740 possibility_21\NN\5944958 that_22\IN\1740 the_23\DT\1740 presence_24\NN\13954253 of_25\IN\1740 acetaminophen_26\NN\2707683 (_27\-LRB-\1740 52_28\CD\1740 micrograms/ml_29\NNS\1740 )_30\-RRB-\1740 reduced_31\VBD\441445 the_32\DT\1740 cns_33\NN\5237227 <e2>toxicity</e2>_34\NN\13576101 of_35\IN\1740 <e1>caffeine</e1>_36\NN\14712692 ._37\.\1740
D000082_D064420 NONE reduction_0\NN\351485 in_1\IN\13603305 caffeine_2\NN\14712692 <e2>toxicity</e2>_3\NN\13576101 by_4\IN\1740 <e1>acetaminophen</e1>_5\RB\1740 ._6\.\1740
D000082_D064420 NONE because_0\IN\1740 salicylates_1\NNS\3828465 have_2\VBP\2108377 been_3\VBN\836236 reported_4\VBN\831651 to_5\TO\1740 augment_6\VB\153263 the_7\DT\1740 stimulatory_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 caffeine_11\NN\14712692 on_12\IN\1740 the_13\DT\1740 cns_14\NN\5237227 ,_15\,\1740 attention_16\NN\5701944 was_17\VBD\836236 focused_18\VBN\628491 on_19\IN\1740 the_20\DT\1740 possibility_21\NN\5944958 that_22\IN\1740 the_23\DT\1740 presence_24\NN\13954253 of_25\IN\1740 <e1>acetaminophen</e1>_26\NN\2707683 (_27\-LRB-\1740 52_28\CD\1740 micrograms/ml_29\NNS\1740 )_30\-RRB-\1740 reduced_31\VBD\441445 the_32\DT\1740 cns_33\NN\5237227 <e2>toxicity</e2>_34\NN\13576101 of_35\IN\1740 caffeine_36\NN\14712692 ._37\.\1740
D000082_D012640 NONE studies_0\NNS\635850 in_1\IN\13603305 dba/2j_2\NN\1740 mice_3\NNS\2329401 showed_4\VBD\2137132 that_5\IN\1740 :_6\:\1740 1_7\LS\13741022 )_8\-RRB-\1740 pretreatment_9\NN\1740 with_10\IN\1740 <e1>acetaminophen</e1>_11\NN\2707683 (_12\-LRB-\1740 100_13\CD\13745420 mg/kg_14\NN\1740 )_15\-RRB-\1740 increased_16\VBD\169651 the_17\DT\1740 interval_18\NN\33615 between_19\IN\1740 the_20\DT\1740 administration_21\NN\1133281 of_22\IN\1740 caffeine_23\NN\14712692 (_24\-LRB-\1740 300_25\CD\1740 to_26\TO\1740 450_27\CD\1740 mg/kg_28\NN\1740 ip_29\NN\5999797 )_30\-RRB-\1740 and_31\CC\1740 the_32\DT\1740 onset_33\NN\7325190 of_34\IN\1740 fatal_35\JJ\1740 <e2>convulsions</e2>_36\NNS\14081375 by_37\IN\1740 a_38\DT\13649268 factor_39\NN\7326557 of_40\IN\1740 about_41\RB\1740 two_42\CD\13741022 ;_43\:\1740 and_44\CC\1740 2_45\LS\13741022 )_46\-RRB-\1740 pretreatment_47\NN\1740 with_48\IN\1740 acetaminophen_49\NN\2707683 (_50\-LRB-\1740 75_51\CD\1740 mg/kg_52\NN\1740 )_53\-RRB-\1740 reduced_54\VBD\441445 the_55\DT\1740 incidence_56\NN\13821570 of_57\IN\1740 audiogenic_58\JJ\1740 seizures_59\NNS\14081375 produced_60\VBN\1617192 in_61\IN\13603305 the_62\DT\1740 presence_63\NN\13954253 of_64\IN\1740 caffeine_65\NN\14712692 (_66\-LRB-\1740 12.5_67\CD\1740 to_68\TO\1740 75_69\CD\1740 mg/kg_70\NN\1740 ip_71\NN\5999797 )_72\-RRB-\1740 ._73\.\1740
D000082_D012640 NONE studies_0\NNS\635850 in_1\IN\13603305 dba/2j_2\NN\1740 mice_3\NNS\2329401 showed_4\VBD\2137132 that_5\IN\1740 :_6\:\1740 1_7\LS\13741022 )_8\-RRB-\1740 pretreatment_9\NN\1740 with_10\IN\1740 <e1>acetaminophen</e1>_11\NN\2707683 (_12\-LRB-\1740 100_13\CD\13745420 mg/kg_14\NN\1740 )_15\-RRB-\1740 increased_16\VBD\169651 the_17\DT\1740 interval_18\NN\33615 between_19\IN\1740 the_20\DT\1740 administration_21\NN\1133281 of_22\IN\1740 caffeine_23\NN\14712692 (_24\-LRB-\1740 300_25\CD\1740 to_26\TO\1740 450_27\CD\1740 mg/kg_28\NN\1740 ip_29\NN\5999797 )_30\-RRB-\1740 and_31\CC\1740 the_32\DT\1740 onset_33\NN\7325190 of_34\IN\1740 fatal_35\JJ\1740 convulsions_36\NNS\14081375 by_37\IN\1740 a_38\DT\13649268 factor_39\NN\7326557 of_40\IN\1740 about_41\RB\1740 two_42\CD\13741022 ;_43\:\1740 and_44\CC\1740 2_45\LS\13741022 )_46\-RRB-\1740 pretreatment_47\NN\1740 with_48\IN\1740 acetaminophen_49\NN\2707683 (_50\-LRB-\1740 75_51\CD\1740 mg/kg_52\NN\1740 )_53\-RRB-\1740 reduced_54\VBD\441445 the_55\DT\1740 incidence_56\NN\13821570 of_57\IN\1740 audiogenic_58\JJ\1740 <e2>seizures</e2>_59\NNS\14081375 produced_60\VBN\1617192 in_61\IN\13603305 the_62\DT\1740 presence_63\NN\13954253 of_64\IN\1740 caffeine_65\NN\14712692 (_66\-LRB-\1740 12.5_67\CD\1740 to_68\TO\1740 75_69\CD\1740 mg/kg_70\NN\1740 ip_71\NN\5999797 )_72\-RRB-\1740 ._73\.\1740
D000082_D012640 NONE studies_0\NNS\635850 in_1\IN\13603305 dba/2j_2\NN\1740 mice_3\NNS\2329401 showed_4\VBD\2137132 that_5\IN\1740 :_6\:\1740 1_7\LS\13741022 )_8\-RRB-\1740 pretreatment_9\NN\1740 with_10\IN\1740 acetaminophen_11\NN\2707683 (_12\-LRB-\1740 100_13\CD\13745420 mg/kg_14\NN\1740 )_15\-RRB-\1740 increased_16\VBD\169651 the_17\DT\1740 interval_18\NN\33615 between_19\IN\1740 the_20\DT\1740 administration_21\NN\1133281 of_22\IN\1740 caffeine_23\NN\14712692 (_24\-LRB-\1740 300_25\CD\1740 to_26\TO\1740 450_27\CD\1740 mg/kg_28\NN\1740 ip_29\NN\5999797 )_30\-RRB-\1740 and_31\CC\1740 the_32\DT\1740 onset_33\NN\7325190 of_34\IN\1740 fatal_35\JJ\1740 <e2>convulsions</e2>_36\NNS\14081375 by_37\IN\1740 a_38\DT\13649268 factor_39\NN\7326557 of_40\IN\1740 about_41\RB\1740 two_42\CD\13741022 ;_43\:\1740 and_44\CC\1740 2_45\LS\13741022 )_46\-RRB-\1740 pretreatment_47\NN\1740 with_48\IN\1740 <e1>acetaminophen</e1>_49\NN\2707683 (_50\-LRB-\1740 75_51\CD\1740 mg/kg_52\NN\1740 )_53\-RRB-\1740 reduced_54\VBD\441445 the_55\DT\1740 incidence_56\NN\13821570 of_57\IN\1740 audiogenic_58\JJ\1740 seizures_59\NNS\14081375 produced_60\VBN\1617192 in_61\IN\13603305 the_62\DT\1740 presence_63\NN\13954253 of_64\IN\1740 caffeine_65\NN\14712692 (_66\-LRB-\1740 12.5_67\CD\1740 to_68\TO\1740 75_69\CD\1740 mg/kg_70\NN\1740 ip_71\NN\5999797 )_72\-RRB-\1740 ._73\.\1740
D000082_D012640 NONE studies_0\NNS\635850 in_1\IN\13603305 dba/2j_2\NN\1740 mice_3\NNS\2329401 showed_4\VBD\2137132 that_5\IN\1740 :_6\:\1740 1_7\LS\13741022 )_8\-RRB-\1740 pretreatment_9\NN\1740 with_10\IN\1740 acetaminophen_11\NN\2707683 (_12\-LRB-\1740 100_13\CD\13745420 mg/kg_14\NN\1740 )_15\-RRB-\1740 increased_16\VBD\169651 the_17\DT\1740 interval_18\NN\33615 between_19\IN\1740 the_20\DT\1740 administration_21\NN\1133281 of_22\IN\1740 caffeine_23\NN\14712692 (_24\-LRB-\1740 300_25\CD\1740 to_26\TO\1740 450_27\CD\1740 mg/kg_28\NN\1740 ip_29\NN\5999797 )_30\-RRB-\1740 and_31\CC\1740 the_32\DT\1740 onset_33\NN\7325190 of_34\IN\1740 fatal_35\JJ\1740 convulsions_36\NNS\14081375 by_37\IN\1740 a_38\DT\13649268 factor_39\NN\7326557 of_40\IN\1740 about_41\RB\1740 two_42\CD\13741022 ;_43\:\1740 and_44\CC\1740 2_45\LS\13741022 )_46\-RRB-\1740 pretreatment_47\NN\1740 with_48\IN\1740 <e1>acetaminophen</e1>_49\NN\2707683 (_50\-LRB-\1740 75_51\CD\1740 mg/kg_52\NN\1740 )_53\-RRB-\1740 reduced_54\VBD\441445 the_55\DT\1740 incidence_56\NN\13821570 of_57\IN\1740 audiogenic_58\JJ\1740 <e2>seizures</e2>_59\NNS\14081375 produced_60\VBN\1617192 in_61\IN\13603305 the_62\DT\1740 presence_63\NN\13954253 of_64\IN\1740 caffeine_65\NN\14712692 (_66\-LRB-\1740 12.5_67\CD\1740 to_68\TO\1740 75_69\CD\1740 mg/kg_70\NN\1740 ip_71\NN\5999797 )_72\-RRB-\1740 ._73\.\1740
D000082_D012640 NONE the_0\DT\1740 frequency_1\NN\15286249 of_2\IN\1740 sound-induced_3\JJ\1740 <e2>seizures</e2>_4\NNS\14081375 after_5\IN\1740 12.5_6\CD\1740 or_7\CC\3541091 25_8\CD\13745420 mg/kg_9\NN\1740 caffeine_10\NN\14712692 was_11\VBD\836236 reduced_12\VBN\441445 from_13\IN\1740 50_14\CD\13745420 to_15\TO\1740 5_16\CD\13741022 %_17\NN\1740 by_18\IN\1740 <e1>acetaminophen</e1>_19\RB\1740 ._20\.\1740
D000082_D012640 NONE in_0\IN\13603305 the_1\DT\1740 absence_2\NN\14449405 of_3\IN\1740 caffeine_4\NN\14712692 ,_5\,\1740 <e1>acetaminophen</e1>_6\RB\1740 (_7\-LRB-\1740 up_8\RB\1740 to_9\TO\1740 300_10\CD\1740 mg/kg_11\NN\1740 )_12\-RRB-\1740 did_13\VBD\1640855 not_14\RB\1740 modify_15\VB\109660 the_16\DT\1740 <e2>seizures</e2>_17\NNS\14081375 induced_18\VBN\1627355 by_19\IN\1740 maximal_20\JJ\1740 electroshock_21\NN\662681 and_22\CC\1740 did_23\VBD\1640855 not_24\RB\1740 alter_25\VB\126264 the_26\DT\1740 convulsant_27\JJ\1740 dose_28\NN\3740161 of_29\IN\1740 pentylenetetrezol_30\NN\1740 in_31\IN\13603305 mice_32\NNS\2329401 (_33\-LRB-\1740 tests_34\NNS\5798043 performed_35\VBN\2367363 by_36\IN\1740 the_37\DT\1740 anticonvulsant_38\NNP\3740161 screening_39\NNP\6887726 project_40\NNP\575741 of_41\IN\1740 nincds_42\NNP\1740 )_43\-RRB-\1740 ._44\.\1740
D002110_D012640 CID studies_0\NNS\635850 in_1\IN\13603305 dba/2j_2\NN\1740 mice_3\NNS\2329401 showed_4\VBD\2137132 that_5\IN\1740 :_6\:\1740 1_7\LS\13741022 )_8\-RRB-\1740 pretreatment_9\NN\1740 with_10\IN\1740 acetaminophen_11\NN\2707683 (_12\-LRB-\1740 100_13\CD\13745420 mg/kg_14\NN\1740 )_15\-RRB-\1740 increased_16\VBD\169651 the_17\DT\1740 interval_18\NN\33615 between_19\IN\1740 the_20\DT\1740 administration_21\NN\1133281 of_22\IN\1740 <e1>caffeine</e1>_23\NN\14712692 (_24\-LRB-\1740 300_25\CD\1740 to_26\TO\1740 450_27\CD\1740 mg/kg_28\NN\1740 ip_29\NN\5999797 )_30\-RRB-\1740 and_31\CC\1740 the_32\DT\1740 onset_33\NN\7325190 of_34\IN\1740 fatal_35\JJ\1740 <e2>convulsions</e2>_36\NNS\14081375 by_37\IN\1740 a_38\DT\13649268 factor_39\NN\7326557 of_40\IN\1740 about_41\RB\1740 two_42\CD\13741022 ;_43\:\1740 and_44\CC\1740 2_45\LS\13741022 )_46\-RRB-\1740 pretreatment_47\NN\1740 with_48\IN\1740 acetaminophen_49\NN\2707683 (_50\-LRB-\1740 75_51\CD\1740 mg/kg_52\NN\1740 )_53\-RRB-\1740 reduced_54\VBD\441445 the_55\DT\1740 incidence_56\NN\13821570 of_57\IN\1740 audiogenic_58\JJ\1740 seizures_59\NNS\14081375 produced_60\VBN\1617192 in_61\IN\13603305 the_62\DT\1740 presence_63\NN\13954253 of_64\IN\1740 caffeine_65\NN\14712692 (_66\-LRB-\1740 12.5_67\CD\1740 to_68\TO\1740 75_69\CD\1740 mg/kg_70\NN\1740 ip_71\NN\5999797 )_72\-RRB-\1740 ._73\.\1740
D002110_D012640 CID studies_0\NNS\635850 in_1\IN\13603305 dba/2j_2\NN\1740 mice_3\NNS\2329401 showed_4\VBD\2137132 that_5\IN\1740 :_6\:\1740 1_7\LS\13741022 )_8\-RRB-\1740 pretreatment_9\NN\1740 with_10\IN\1740 acetaminophen_11\NN\2707683 (_12\-LRB-\1740 100_13\CD\13745420 mg/kg_14\NN\1740 )_15\-RRB-\1740 increased_16\VBD\169651 the_17\DT\1740 interval_18\NN\33615 between_19\IN\1740 the_20\DT\1740 administration_21\NN\1133281 of_22\IN\1740 <e1>caffeine</e1>_23\NN\14712692 (_24\-LRB-\1740 300_25\CD\1740 to_26\TO\1740 450_27\CD\1740 mg/kg_28\NN\1740 ip_29\NN\5999797 )_30\-RRB-\1740 and_31\CC\1740 the_32\DT\1740 onset_33\NN\7325190 of_34\IN\1740 fatal_35\JJ\1740 convulsions_36\NNS\14081375 by_37\IN\1740 a_38\DT\13649268 factor_39\NN\7326557 of_40\IN\1740 about_41\RB\1740 two_42\CD\13741022 ;_43\:\1740 and_44\CC\1740 2_45\LS\13741022 )_46\-RRB-\1740 pretreatment_47\NN\1740 with_48\IN\1740 acetaminophen_49\NN\2707683 (_50\-LRB-\1740 75_51\CD\1740 mg/kg_52\NN\1740 )_53\-RRB-\1740 reduced_54\VBD\441445 the_55\DT\1740 incidence_56\NN\13821570 of_57\IN\1740 audiogenic_58\JJ\1740 <e2>seizures</e2>_59\NNS\14081375 produced_60\VBN\1617192 in_61\IN\13603305 the_62\DT\1740 presence_63\NN\13954253 of_64\IN\1740 caffeine_65\NN\14712692 (_66\-LRB-\1740 12.5_67\CD\1740 to_68\TO\1740 75_69\CD\1740 mg/kg_70\NN\1740 ip_71\NN\5999797 )_72\-RRB-\1740 ._73\.\1740
D002110_D012640 CID studies_0\NNS\635850 in_1\IN\13603305 dba/2j_2\NN\1740 mice_3\NNS\2329401 showed_4\VBD\2137132 that_5\IN\1740 :_6\:\1740 1_7\LS\13741022 )_8\-RRB-\1740 pretreatment_9\NN\1740 with_10\IN\1740 acetaminophen_11\NN\2707683 (_12\-LRB-\1740 100_13\CD\13745420 mg/kg_14\NN\1740 )_15\-RRB-\1740 increased_16\VBD\169651 the_17\DT\1740 interval_18\NN\33615 between_19\IN\1740 the_20\DT\1740 administration_21\NN\1133281 of_22\IN\1740 caffeine_23\NN\14712692 (_24\-LRB-\1740 300_25\CD\1740 to_26\TO\1740 450_27\CD\1740 mg/kg_28\NN\1740 ip_29\NN\5999797 )_30\-RRB-\1740 and_31\CC\1740 the_32\DT\1740 onset_33\NN\7325190 of_34\IN\1740 fatal_35\JJ\1740 <e2>convulsions</e2>_36\NNS\14081375 by_37\IN\1740 a_38\DT\13649268 factor_39\NN\7326557 of_40\IN\1740 about_41\RB\1740 two_42\CD\13741022 ;_43\:\1740 and_44\CC\1740 2_45\LS\13741022 )_46\-RRB-\1740 pretreatment_47\NN\1740 with_48\IN\1740 acetaminophen_49\NN\2707683 (_50\-LRB-\1740 75_51\CD\1740 mg/kg_52\NN\1740 )_53\-RRB-\1740 reduced_54\VBD\441445 the_55\DT\1740 incidence_56\NN\13821570 of_57\IN\1740 audiogenic_58\JJ\1740 seizures_59\NNS\14081375 produced_60\VBN\1617192 in_61\IN\13603305 the_62\DT\1740 presence_63\NN\13954253 of_64\IN\1740 <e1>caffeine</e1>_65\NN\14712692 (_66\-LRB-\1740 12.5_67\CD\1740 to_68\TO\1740 75_69\CD\1740 mg/kg_70\NN\1740 ip_71\NN\5999797 )_72\-RRB-\1740 ._73\.\1740
D002110_D012640 CID studies_0\NNS\635850 in_1\IN\13603305 dba/2j_2\NN\1740 mice_3\NNS\2329401 showed_4\VBD\2137132 that_5\IN\1740 :_6\:\1740 1_7\LS\13741022 )_8\-RRB-\1740 pretreatment_9\NN\1740 with_10\IN\1740 acetaminophen_11\NN\2707683 (_12\-LRB-\1740 100_13\CD\13745420 mg/kg_14\NN\1740 )_15\-RRB-\1740 increased_16\VBD\169651 the_17\DT\1740 interval_18\NN\33615 between_19\IN\1740 the_20\DT\1740 administration_21\NN\1133281 of_22\IN\1740 caffeine_23\NN\14712692 (_24\-LRB-\1740 300_25\CD\1740 to_26\TO\1740 450_27\CD\1740 mg/kg_28\NN\1740 ip_29\NN\5999797 )_30\-RRB-\1740 and_31\CC\1740 the_32\DT\1740 onset_33\NN\7325190 of_34\IN\1740 fatal_35\JJ\1740 convulsions_36\NNS\14081375 by_37\IN\1740 a_38\DT\13649268 factor_39\NN\7326557 of_40\IN\1740 about_41\RB\1740 two_42\CD\13741022 ;_43\:\1740 and_44\CC\1740 2_45\LS\13741022 )_46\-RRB-\1740 pretreatment_47\NN\1740 with_48\IN\1740 acetaminophen_49\NN\2707683 (_50\-LRB-\1740 75_51\CD\1740 mg/kg_52\NN\1740 )_53\-RRB-\1740 reduced_54\VBD\441445 the_55\DT\1740 incidence_56\NN\13821570 of_57\IN\1740 audiogenic_58\JJ\1740 <e2>seizures</e2>_59\NNS\14081375 produced_60\VBN\1617192 in_61\IN\13603305 the_62\DT\1740 presence_63\NN\13954253 of_64\IN\1740 <e1>caffeine</e1>_65\NN\14712692 (_66\-LRB-\1740 12.5_67\CD\1740 to_68\TO\1740 75_69\CD\1740 mg/kg_70\NN\1740 ip_71\NN\5999797 )_72\-RRB-\1740 ._73\.\1740
D002110_D012640 CID the_0\DT\1740 frequency_1\NN\15286249 of_2\IN\1740 sound-induced_3\JJ\1740 <e2>seizures</e2>_4\NNS\14081375 after_5\IN\1740 12.5_6\CD\1740 or_7\CC\3541091 25_8\CD\13745420 mg/kg_9\NN\1740 <e1>caffeine</e1>_10\NN\14712692 was_11\VBD\836236 reduced_12\VBN\441445 from_13\IN\1740 50_14\CD\13745420 to_15\TO\1740 5_16\CD\13741022 %_17\NN\1740 by_18\IN\1740 acetaminophen_19\RB\1740 ._20\.\1740
D002110_D012640 CID in_0\IN\13603305 the_1\DT\1740 absence_2\NN\14449405 of_3\IN\1740 <e1>caffeine</e1>_4\NN\14712692 ,_5\,\1740 acetaminophen_6\RB\1740 (_7\-LRB-\1740 up_8\RB\1740 to_9\TO\1740 300_10\CD\1740 mg/kg_11\NN\1740 )_12\-RRB-\1740 did_13\VBD\1640855 not_14\RB\1740 modify_15\VB\109660 the_16\DT\1740 <e2>seizures</e2>_17\NNS\14081375 induced_18\VBN\1627355 by_19\IN\1740 maximal_20\JJ\1740 electroshock_21\NN\662681 and_22\CC\1740 did_23\VBD\1640855 not_24\RB\1740 alter_25\VB\126264 the_26\DT\1740 convulsant_27\JJ\1740 dose_28\NN\3740161 of_29\IN\1740 pentylenetetrezol_30\NN\1740 in_31\IN\13603305 mice_32\NNS\2329401 (_33\-LRB-\1740 tests_34\NNS\5798043 performed_35\VBN\2367363 by_36\IN\1740 the_37\DT\1740 anticonvulsant_38\NNP\3740161 screening_39\NNP\6887726 project_40\NNP\575741 of_41\IN\1740 nincds_42\NNP\1740 )_43\-RRB-\1740 ._44\.\1740
D010433_D012640 CID in_0\IN\13603305 the_1\DT\1740 absence_2\NN\14449405 of_3\IN\1740 caffeine_4\NN\14712692 ,_5\,\1740 acetaminophen_6\RB\1740 (_7\-LRB-\1740 up_8\RB\1740 to_9\TO\1740 300_10\CD\1740 mg/kg_11\NN\1740 )_12\-RRB-\1740 did_13\VBD\1640855 not_14\RB\1740 modify_15\VB\109660 the_16\DT\1740 <e2>seizures</e2>_17\NNS\14081375 induced_18\VBN\1627355 by_19\IN\1740 maximal_20\JJ\1740 electroshock_21\NN\662681 and_22\CC\1740 did_23\VBD\1640855 not_24\RB\1740 alter_25\VB\126264 the_26\DT\1740 convulsant_27\JJ\1740 dose_28\NN\3740161 of_29\IN\1740 <e1>pentylenetetrezol</e1>_30\NN\1740 in_31\IN\13603305 mice_32\NNS\2329401 (_33\-LRB-\1740 tests_34\NNS\5798043 performed_35\VBN\2367363 by_36\IN\1740 the_37\DT\1740 anticonvulsant_38\NNP\3740161 screening_39\NNP\6887726 project_40\NNP\575741 of_41\IN\1740 nincds_42\NNP\1740 )_43\-RRB-\1740 ._44\.\1740
16574712
D018817_D003072 CID <e1>mdma</e1>_0\NN\3054098 polydrug_1\NN\1740 users_2\NNS\7846 show_3\VBP\2137132 process-specific_4\JJ\1740 central_5\JJ\1740 executive_6\JJ\1740 impairments_7\NNS\7296428 coupled_8\VBN\1295275 with_9\IN\1740 <e2>impaired_10\JJ\1740 social_11\JJ\1740 and_12\CC\1740 emotional_13\JJ\1740 judgement_14\NN\6479665 processes</e2>_15\NNS\407535 ._16\.\1740
D018817_D008569 NONE in_0\IN\13603305 recent_1\JJ\1740 years_2\NNS\15144371 working_3\VBG\2524171 <e2>memory_4\NN\5926676 deficits</e2>_5\NNS\5113133 have_6\VBP\2108377 been_7\VBN\836236 reported_8\VBN\831651 in_9\IN\13603305 users_10\NNS\7846 of_11\IN\1740 <e1>mdma</e1>_12\NN\3054098 (_13\-LRB-\1740 3,4-methylenedioxymethamphetamine_14\NN\1740 ,_15\,\1740 ecstasy_16\NN\13985818 )_17\-RRB-\1740 ._18\.\1740
D018817_D008569 NONE in_0\IN\13603305 recent_1\JJ\1740 years_2\NNS\15144371 working_3\VBG\2524171 <e2>memory_4\NN\5926676 deficits</e2>_5\NNS\5113133 have_6\VBP\2108377 been_7\VBN\836236 reported_8\VBN\831651 in_9\IN\13603305 users_10\NNS\7846 of_11\IN\1740 mdma_12\NN\3054098 (_13\-LRB-\1740 <e1>3,4-methylenedioxymethamphetamine</e1>_14\NN\1740 ,_15\,\1740 ecstasy_16\NN\13985818 )_17\-RRB-\1740 ._18\.\1740
D018817_D008569 NONE in_0\IN\13603305 recent_1\JJ\1740 years_2\NNS\15144371 working_3\VBG\2524171 <e2>memory_4\NN\5926676 deficits</e2>_5\NNS\5113133 have_6\VBP\2108377 been_7\VBN\836236 reported_8\VBN\831651 in_9\IN\13603305 users_10\NNS\7846 of_11\IN\1740 mdma_12\NN\3054098 (_13\-LRB-\1740 3,4-methylenedioxymethamphetamine_14\NN\1740 ,_15\,\1740 <e1>ecstasy</e1>_16\NN\13985818 )_17\-RRB-\1740 ._18\.\1740
6773726
D005996_D007022 CID provocation_0\NN\1221611 of_1\IN\1740 postural_2\JJ\1740 <e2>hypotension</e2>_3\NN\14057371 by_4\IN\1740 <e1>nitroglycerin</e1>_5\NN\15015501 in_6\IN\13603305 diabetic_7\JJ\1740 autonomic_8\JJ\1740 neuropathy_9\JJ\1740 ?_10\.\1740
D005996_D003929 NONE provocation_0\NN\1221611 of_1\IN\1740 postural_2\JJ\1740 hypotension_3\NN\14057371 by_4\IN\1740 <e1>nitroglycerin</e1>_5\NN\15015501 in_6\IN\13603305 <e2>diabetic_7\JJ\1740 autonomic_8\JJ\1740 neuropathy</e2>_9\JJ\1740 ?_10\.\1740
D005996_D003920 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>nitroglycerin</e1>_3\NN\15015501 on_4\IN\1740 heart_5\NN\5919034 rate_6\NN\13815152 and_7\CC\1740 systolic_8\JJ\1740 blood_9\NN\5397468 pressure_10\NN\11419404 was_11\VBD\836236 compared_12\VBN\644583 in_13\IN\13603305 5_14\CD\13741022 normal_15\JJ\1740 subjects_16\NNS\6598915 ,_17\,\1740 12_18\CD\13745420 <e2>diabetic</e2>_19\JJ\1740 subjects_20\NNS\6598915 without_21\IN\1740 autonomic_22\JJ\1740 neuropathy_23\RB\1740 ,_24\,\1740 and_25\CC\1740 5_26\CD\13741022 diabetic_27\JJ\1740 subjects_28\NNS\6598915 with_29\IN\1740 autonomic_30\JJ\1740 neuropathy_31\NN\14204950 ._32\.\1740
D005996_D003920 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>nitroglycerin</e1>_3\NN\15015501 on_4\IN\1740 heart_5\NN\5919034 rate_6\NN\13815152 and_7\CC\1740 systolic_8\JJ\1740 blood_9\NN\5397468 pressure_10\NN\11419404 was_11\VBD\836236 compared_12\VBN\644583 in_13\IN\13603305 5_14\CD\13741022 normal_15\JJ\1740 subjects_16\NNS\6598915 ,_17\,\1740 12_18\CD\13745420 diabetic_19\JJ\1740 subjects_20\NNS\6598915 without_21\IN\1740 autonomic_22\JJ\1740 neuropathy_23\RB\1740 ,_24\,\1740 and_25\CC\1740 5_26\CD\13741022 <e2>diabetic</e2>_27\JJ\1740 subjects_28\NNS\6598915 with_29\IN\1740 autonomic_30\JJ\1740 neuropathy_31\NN\14204950 ._32\.\1740
D005996_D003920 NONE the_0\DT\1740 magnitude_1\NN\4916342 and_2\CC\1740 time_3\NN\7308889 course_4\NN\883297 of_5\IN\1740 the_6\DT\1740 increase_7\NN\13576355 in_8\IN\13603305 heart_9\NN\5919034 rate_10\NN\13815152 and_11\CC\1740 the_12\DT\1740 decrease_13\NN\7296428 in_14\IN\13603305 systolic_15\JJ\1740 blood_16\NN\5397468 pressure_17\NN\11419404 after_18\IN\1740 <e1>nitroglycerin</e1>_19\NN\15015501 were_20\VBD\836236 similar_21\JJ\1740 in_22\IN\13603305 the_23\DT\1740 normal_24\JJ\1740 and_25\CC\1740 <e2>diabetic</e2>_26\JJ\1740 subjects_27\NNS\6598915 without_28\IN\1740 autonomic_29\JJ\1740 neuropathy_30\JJ\1740 ,_31\,\1740 whereas_32\IN\1740 a_33\DT\13649268 lesser_34\JJR\1740 increase_35\NN\13576355 in_36\IN\13603305 heart_37\NN\5919034 rate_38\NN\13815152 and_39\CC\1740 a_40\DT\13649268 greater_41\JJR\1740 decrease_42\NN\7296428 in_43\IN\13603305 systolic_44\JJ\1740 blood_45\NN\5397468 pressure_46\NN\11419404 occurred_47\VBD\2623529 in_48\IN\13603305 the_49\DT\1740 diabetic_50\JJ\1740 subjects_51\NNS\6598915 with_52\IN\1740 autonomic_53\JJ\1740 neuropathy_54\NN\14204950 ._55\.\1740
D005996_D003920 NONE the_0\DT\1740 magnitude_1\NN\4916342 and_2\CC\1740 time_3\NN\7308889 course_4\NN\883297 of_5\IN\1740 the_6\DT\1740 increase_7\NN\13576355 in_8\IN\13603305 heart_9\NN\5919034 rate_10\NN\13815152 and_11\CC\1740 the_12\DT\1740 decrease_13\NN\7296428 in_14\IN\13603305 systolic_15\JJ\1740 blood_16\NN\5397468 pressure_17\NN\11419404 after_18\IN\1740 <e1>nitroglycerin</e1>_19\NN\15015501 were_20\VBD\836236 similar_21\JJ\1740 in_22\IN\13603305 the_23\DT\1740 normal_24\JJ\1740 and_25\CC\1740 diabetic_26\JJ\1740 subjects_27\NNS\6598915 without_28\IN\1740 autonomic_29\JJ\1740 neuropathy_30\JJ\1740 ,_31\,\1740 whereas_32\IN\1740 a_33\DT\13649268 lesser_34\JJR\1740 increase_35\NN\13576355 in_36\IN\13603305 heart_37\NN\5919034 rate_38\NN\13815152 and_39\CC\1740 a_40\DT\13649268 greater_41\JJR\1740 decrease_42\NN\7296428 in_43\IN\13603305 systolic_44\JJ\1740 blood_45\NN\5397468 pressure_46\NN\11419404 occurred_47\VBD\2623529 in_48\IN\13603305 the_49\DT\1740 <e2>diabetic</e2>_50\JJ\1740 subjects_51\NNS\6598915 with_52\IN\1740 autonomic_53\JJ\1740 neuropathy_54\NN\14204950 ._55\.\1740
D005996_D009422 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>nitroglycerin</e1>_3\NN\15015501 on_4\IN\1740 heart_5\NN\5919034 rate_6\NN\13815152 and_7\CC\1740 systolic_8\JJ\1740 blood_9\NN\5397468 pressure_10\NN\11419404 was_11\VBD\836236 compared_12\VBN\644583 in_13\IN\13603305 5_14\CD\13741022 normal_15\JJ\1740 subjects_16\NNS\6598915 ,_17\,\1740 12_18\CD\13745420 diabetic_19\JJ\1740 subjects_20\NNS\6598915 without_21\IN\1740 <e2>autonomic_22\JJ\1740 neuropathy</e2>_23\RB\1740 ,_24\,\1740 and_25\CC\1740 5_26\CD\13741022 diabetic_27\JJ\1740 subjects_28\NNS\6598915 with_29\IN\1740 autonomic_30\JJ\1740 neuropathy_31\NN\14204950 ._32\.\1740
D005996_D009422 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>nitroglycerin</e1>_3\NN\15015501 on_4\IN\1740 heart_5\NN\5919034 rate_6\NN\13815152 and_7\CC\1740 systolic_8\JJ\1740 blood_9\NN\5397468 pressure_10\NN\11419404 was_11\VBD\836236 compared_12\VBN\644583 in_13\IN\13603305 5_14\CD\13741022 normal_15\JJ\1740 subjects_16\NNS\6598915 ,_17\,\1740 12_18\CD\13745420 diabetic_19\JJ\1740 subjects_20\NNS\6598915 without_21\IN\1740 autonomic_22\JJ\1740 neuropathy_23\RB\1740 ,_24\,\1740 and_25\CC\1740 5_26\CD\13741022 diabetic_27\JJ\1740 subjects_28\NNS\6598915 with_29\IN\1740 <e2>autonomic_30\JJ\1740 neuropathy</e2>_31\NN\14204950 ._32\.\1740
D005996_D009422 NONE the_0\DT\1740 magnitude_1\NN\4916342 and_2\CC\1740 time_3\NN\7308889 course_4\NN\883297 of_5\IN\1740 the_6\DT\1740 increase_7\NN\13576355 in_8\IN\13603305 heart_9\NN\5919034 rate_10\NN\13815152 and_11\CC\1740 the_12\DT\1740 decrease_13\NN\7296428 in_14\IN\13603305 systolic_15\JJ\1740 blood_16\NN\5397468 pressure_17\NN\11419404 after_18\IN\1740 <e1>nitroglycerin</e1>_19\NN\15015501 were_20\VBD\836236 similar_21\JJ\1740 in_22\IN\13603305 the_23\DT\1740 normal_24\JJ\1740 and_25\CC\1740 diabetic_26\JJ\1740 subjects_27\NNS\6598915 without_28\IN\1740 <e2>autonomic_29\JJ\1740 neuropathy</e2>_30\JJ\1740 ,_31\,\1740 whereas_32\IN\1740 a_33\DT\13649268 lesser_34\JJR\1740 increase_35\NN\13576355 in_36\IN\13603305 heart_37\NN\5919034 rate_38\NN\13815152 and_39\CC\1740 a_40\DT\13649268 greater_41\JJR\1740 decrease_42\NN\7296428 in_43\IN\13603305 systolic_44\JJ\1740 blood_45\NN\5397468 pressure_46\NN\11419404 occurred_47\VBD\2623529 in_48\IN\13603305 the_49\DT\1740 diabetic_50\JJ\1740 subjects_51\NNS\6598915 with_52\IN\1740 autonomic_53\JJ\1740 neuropathy_54\NN\14204950 ._55\.\1740
D005996_D009422 NONE the_0\DT\1740 magnitude_1\NN\4916342 and_2\CC\1740 time_3\NN\7308889 course_4\NN\883297 of_5\IN\1740 the_6\DT\1740 increase_7\NN\13576355 in_8\IN\13603305 heart_9\NN\5919034 rate_10\NN\13815152 and_11\CC\1740 the_12\DT\1740 decrease_13\NN\7296428 in_14\IN\13603305 systolic_15\JJ\1740 blood_16\NN\5397468 pressure_17\NN\11419404 after_18\IN\1740 <e1>nitroglycerin</e1>_19\NN\15015501 were_20\VBD\836236 similar_21\JJ\1740 in_22\IN\13603305 the_23\DT\1740 normal_24\JJ\1740 and_25\CC\1740 diabetic_26\JJ\1740 subjects_27\NNS\6598915 without_28\IN\1740 autonomic_29\JJ\1740 neuropathy_30\JJ\1740 ,_31\,\1740 whereas_32\IN\1740 a_33\DT\13649268 lesser_34\JJR\1740 increase_35\NN\13576355 in_36\IN\13603305 heart_37\NN\5919034 rate_38\NN\13815152 and_39\CC\1740 a_40\DT\13649268 greater_41\JJR\1740 decrease_42\NN\7296428 in_43\IN\13603305 systolic_44\JJ\1740 blood_45\NN\5397468 pressure_46\NN\11419404 occurred_47\VBD\2623529 in_48\IN\13603305 the_49\DT\1740 diabetic_50\JJ\1740 subjects_51\NNS\6598915 with_52\IN\1740 <e2>autonomic_53\JJ\1740 neuropathy</e2>_54\NN\14204950 ._55\.\1740
15130900
D003520_D001749 CID <e2>urinary_0\JJ\1740 bladder_1\NN\5515670 cancer</e2>_2\NN\14239425 in_3\IN\13603305 wegener_4\NNP\1740 's_5\POS\1740 granulomatosis_6\NN\1740 :_7\:\1740 risks_8\NNS\14541044 and_9\CC\1740 relation_10\NN\2137 to_11\TO\1740 <e1>cyclophosphamide</e1>_12\NN\1740 ._13\.\1740
D003520_D001749 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 and_4\CC\1740 characterise_5\VB\651991 the_6\DT\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>bladder_9\NN\5515670 cancer</e2>_10\NN\14239425 ,_11\,\1740 and_12\CC\1740 its_13\PRP$\6125041 relation_14\NN\2137 to_15\TO\1740 <e1>cyclophosphamide</e1>_16\NN\1740 ,_17\,\1740 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 wegener_21\NNP\1740 's_22\POS\1740 granulomatosis_23\NN\1740 ._24\.\1740
D003520_D001749 CID nested_0\VBN\2649830 within_1\IN\1740 the_2\DT\1740 cohort_3\NN\8184861 ,_4\,\1740 a_5\DT\13649268 matched_6\VBN\2664769 case-control_7\JJ\1740 study_8\NN\635850 was_9\VBD\836236 performed_10\VBN\2367363 to_11\TO\1740 estimate_12\VB\637259 the_13\DT\1740 association_14\NN\8008335 between_15\IN\1740 <e1>cyclophosphamide</e1>_16\NN\1740 and_17\CC\1740 <e2>bladder_18\NN\5515670 cancer</e2>_19\NN\14239425 using_20\VBG\1156834 odds_21\NNS\4756635 ratios_22\NNS\13815152 (_23\-LRB-\1740 ors_24\NNS\3541091 )_25\-RRB-\1740 as_26\IN\14622893 relative_27\JJ\1740 risk_28\NN\14541044 ._29\.\1740
D003520_D001749 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 <e2>bladder_3\NN\5515670 cancer</e2>_4\NN\14239425 doubled_5\VBN\247390 for_6\IN\1740 every_7\DT\1740 10_8\CD\13745420 g_9\NN\13717155 increment_10\NN\29677 in_11\IN\13603305 <e1>cyclophosphamide</e1>_12\NN\1740 (_13\-LRB-\1740 or_14\NN\3541091 =_15\JJ\1740 2.0_16\CD\1740 ,_17\,\1740 95_18\CD\1740 %_19\NN\1740 confidence_20\NN\5697135 interval_21\NN\33615 (_22\-LRB-\1740 ci_23\NN\13635336 )_24\-RRB-\1740 0.8_25\CD\1740 to_26\TO\1740 4.9_27\CD\1740 )_28\-RRB-\1740 ._29\.\1740
D003520_D001749 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 indicate_4\VBP\952524 a_5\DT\13649268 dose-response_6\JJ\1740 relationship_7\NN\31921 between_8\IN\1740 <e1>cyclophosphamide</e1>_9\NN\1740 and_10\CC\1740 the_11\DT\1740 risk_12\NN\14541044 of_13\IN\1740 <e2>bladder_14\NN\5515670 cancer</e2>_15\NN\14239425 ,_16\,\1740 high_17\JJ\1740 cumulative_18\JJ\1740 risks_19\NNS\14541044 in_20\IN\13603305 the_21\DT\1740 entire_22\JJ\1740 cohort_23\NN\8184861 ,_24\,\1740 and_25\CC\1740 also_26\RB\1740 the_27\DT\1740 possibility_28\NN\5944958 of_29\IN\1740 risk_30\NN\14541044 factors_31\NNS\7326557 operating_32\VBG\2439501 even_33\RB\1740 before_34\IN\1740 wegener_35\NNP\1740 's_36\POS\1740 granulomatosis_37\NN\1740 ._38\.\1740
D003520_D014890 NONE urinary_0\JJ\1740 bladder_1\NN\5515670 cancer_2\NN\14239425 in_3\IN\13603305 <e2>wegener_4\NNP\1740 's_5\POS\1740 granulomatosis</e2>_6\NN\1740 :_7\:\1740 risks_8\NNS\14541044 and_9\CC\1740 relation_10\NN\2137 to_11\TO\1740 <e1>cyclophosphamide</e1>_12\NN\1740 ._13\.\1740
D003520_D014890 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 and_4\CC\1740 characterise_5\VB\651991 the_6\DT\1740 risk_7\NN\14541044 of_8\IN\1740 bladder_9\NN\5515670 cancer_10\NN\14239425 ,_11\,\1740 and_12\CC\1740 its_13\PRP$\6125041 relation_14\NN\2137 to_15\TO\1740 <e1>cyclophosphamide</e1>_16\NN\1740 ,_17\,\1740 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 <e2>wegener_21\NNP\1740 's_22\POS\1740 granulomatosis</e2>_23\NN\1740 ._24\.\1740
D003520_D014890 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 indicate_4\VBP\952524 a_5\DT\13649268 dose-response_6\JJ\1740 relationship_7\NN\31921 between_8\IN\1740 <e1>cyclophosphamide</e1>_9\NN\1740 and_10\CC\1740 the_11\DT\1740 risk_12\NN\14541044 of_13\IN\1740 bladder_14\NN\5515670 cancer_15\NN\14239425 ,_16\,\1740 high_17\JJ\1740 cumulative_18\JJ\1740 risks_19\NNS\14541044 in_20\IN\13603305 the_21\DT\1740 entire_22\JJ\1740 cohort_23\NN\8184861 ,_24\,\1740 and_25\CC\1740 also_26\RB\1740 the_27\DT\1740 possibility_28\NN\5944958 of_29\IN\1740 risk_30\NN\14541044 factors_31\NNS\7326557 operating_32\VBG\2439501 even_33\RB\1740 before_34\IN\1740 <e2>wegener_35\NNP\1740 's_36\POS\1740 granulomatosis</e2>_37\NN\1740 ._38\.\1740
150790
D011736_D002653 NONE a_0\DT\13649268 <e1>pyridoxine-dependent</e1>_1\JJ\1740 <e2>behavioral_2\JJ\1740 disorder</e2>_3\NN\14034177 unmasked_4\VBN\853195 by_5\IN\1740 isoniazid_6\NNS\2716205 ._7\.\1740
D007538_D002653 CID a_0\DT\13649268 pyridoxine-dependent_1\JJ\1740 <e2>behavioral_2\JJ\1740 disorder</e2>_3\NN\14034177 unmasked_4\VBN\853195 by_5\IN\1740 <e1>isoniazid</e1>_6\NNS\2716205 ._7\.\1740
D007538_D002653 CID a_0\DT\13649268 3-year-old_1\JJ\1740 girl_2\NN\10787470 had_3\VBD\2108377 <e2>behavioral_4\JJ\1740 deterioration</e2>_5\NN\14560612 ,_6\,\1740 with_7\IN\1740 hyperkinesis_8\NN\1740 ,_9\,\1740 irritability_10\NN\7552087 ,_11\,\1740 and_12\CC\1740 sleeping_13\VBG\14405 difficulties_14\NNS\621627 after_15\IN\1740 the_16\DT\1740 therapeutic_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 <e1>isoniazid</e1>_20\NN\2716205 ._21\.\1740
D007538_D006948 CID a_0\DT\13649268 3-year-old_1\JJ\1740 girl_2\NN\10787470 had_3\VBD\2108377 behavioral_4\JJ\1740 deterioration_5\NN\14560612 ,_6\,\1740 with_7\IN\1740 <e2>hyperkinesis</e2>_8\NN\1740 ,_9\,\1740 irritability_10\NN\7552087 ,_11\,\1740 and_12\CC\1740 sleeping_13\VBG\14405 difficulties_14\NNS\621627 after_15\IN\1740 the_16\DT\1740 therapeutic_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 <e1>isoniazid</e1>_20\NN\2716205 ._21\.\1740
D007538_D001523 NONE a_0\DT\13649268 3-year-old_1\JJ\1740 girl_2\NN\10787470 had_3\VBD\2108377 behavioral_4\JJ\1740 deterioration_5\NN\14560612 ,_6\,\1740 with_7\IN\1740 hyperkinesis_8\NN\1740 ,_9\,\1740 <e2>irritability</e2>_10\NN\7552087 ,_11\,\1740 and_12\CC\1740 sleeping_13\VBG\14405 difficulties_14\NNS\621627 after_15\IN\1740 the_16\DT\1740 therapeutic_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 <e1>isoniazid</e1>_20\NN\2716205 ._21\.\1740
D007538_D012893 NONE a_0\DT\13649268 3-year-old_1\JJ\1740 girl_2\NN\10787470 had_3\VBD\2108377 behavioral_4\JJ\1740 deterioration_5\NN\14560612 ,_6\,\1740 with_7\IN\1740 hyperkinesis_8\NN\1740 ,_9\,\1740 irritability_10\NN\7552087 ,_11\,\1740 and_12\CC\1740 <e2>sleeping_13\VBG\14405 difficulties</e2>_14\NNS\621627 after_15\IN\1740 the_16\DT\1740 therapeutic_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 <e1>isoniazid</e1>_20\NN\2716205 ._21\.\1740
D011736_D006948 NONE periodic_0\JJ\1740 withdrawal_1\NN\7206096 of_2\IN\1740 <e1>pyridoxine</e1>_3\NN\15090742 was_4\VBD\836236 associated_5\VBN\628491 with_6\IN\1740 return_7\NN\6479665 of_8\IN\1740 the_9\DT\1740 <e2>hyperkinesis</e2>_10\NN\1740 ._11\.\1740
3719553
D005472_D004342 NONE <e2>allergic_0\JJ\1740 reaction</e2>_1\NN\13446390 to_2\TO\1740 <e1>5-fluorouracil</e1>_3\NN\1740 infusion_4\NN\14589223 ._5\.\1740
D005472_D004342 NONE an_0\DT\6697703 <e2>allergic_1\JJ\1740 reaction</e2>_2\NN\13446390 consisting_3\VBG\2603699 of_4\IN\1740 angioneurotic_5\JJ\1740 edema_6\NN\14315192 secondary_7\JJ\1740 to_8\TO\1740 continuous_9\JJ\1740 infusion_10\NN\14589223 <e1>5-fluorouracil</e1>_11\NN\1740 occurred_12\VBD\2623529 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 recurrent_17\JJ\1740 carcinoma_18\NN\14239918 of_19\IN\1740 the_20\DT\1740 oral_21\JJ\1740 cavity_22\NN\9304750 ,_23\,\1740 cirrhosis_24\NN\14116321 ,_25\,\1740 and_26\CC\1740 cisplatin-induced_27\JJ\1740 impaired_28\JJ\1740 renal_29\JJ\1740 function_30\NN\13783581 ._31\.\1740
D005472_D000799 CID an_0\DT\6697703 allergic_1\JJ\1740 reaction_2\NN\13446390 consisting_3\VBG\2603699 of_4\IN\1740 <e2>angioneurotic_5\JJ\1740 edema</e2>_6\NN\14315192 secondary_7\JJ\1740 to_8\TO\1740 continuous_9\JJ\1740 infusion_10\NN\14589223 <e1>5-fluorouracil</e1>_11\NN\1740 occurred_12\VBD\2623529 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 recurrent_17\JJ\1740 carcinoma_18\NN\14239918 of_19\IN\1740 the_20\DT\1740 oral_21\JJ\1740 cavity_22\NN\9304750 ,_23\,\1740 cirrhosis_24\NN\14116321 ,_25\,\1740 and_26\CC\1740 cisplatin-induced_27\JJ\1740 impaired_28\JJ\1740 renal_29\JJ\1740 function_30\NN\13783581 ._31\.\1740
D005472_D009062 NONE an_0\DT\6697703 allergic_1\JJ\1740 reaction_2\NN\13446390 consisting_3\VBG\2603699 of_4\IN\1740 angioneurotic_5\JJ\1740 edema_6\NN\14315192 secondary_7\JJ\1740 to_8\TO\1740 continuous_9\JJ\1740 infusion_10\NN\14589223 <e1>5-fluorouracil</e1>_11\NN\1740 occurred_12\VBD\2623529 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 recurrent_17\JJ\1740 <e2>carcinoma_18\NN\14239918 of_19\IN\1740 the_20\DT\1740 oral_21\JJ\1740 cavity</e2>_22\NN\9304750 ,_23\,\1740 cirrhosis_24\NN\14116321 ,_25\,\1740 and_26\CC\1740 cisplatin-induced_27\JJ\1740 impaired_28\JJ\1740 renal_29\JJ\1740 function_30\NN\13783581 ._31\.\1740
D005472_D005355 NONE an_0\DT\6697703 allergic_1\JJ\1740 reaction_2\NN\13446390 consisting_3\VBG\2603699 of_4\IN\1740 angioneurotic_5\JJ\1740 edema_6\NN\14315192 secondary_7\JJ\1740 to_8\TO\1740 continuous_9\JJ\1740 infusion_10\NN\14589223 <e1>5-fluorouracil</e1>_11\NN\1740 occurred_12\VBD\2623529 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 recurrent_17\JJ\1740 carcinoma_18\NN\14239918 of_19\IN\1740 the_20\DT\1740 oral_21\JJ\1740 cavity_22\NN\9304750 ,_23\,\1740 <e2>cirrhosis</e2>_24\NN\14116321 ,_25\,\1740 and_26\CC\1740 cisplatin-induced_27\JJ\1740 impaired_28\JJ\1740 renal_29\JJ\1740 function_30\NN\13783581 ._31\.\1740
D005472_D007674 NONE an_0\DT\6697703 allergic_1\JJ\1740 reaction_2\NN\13446390 consisting_3\VBG\2603699 of_4\IN\1740 angioneurotic_5\JJ\1740 edema_6\NN\14315192 secondary_7\JJ\1740 to_8\TO\1740 continuous_9\JJ\1740 infusion_10\NN\14589223 <e1>5-fluorouracil</e1>_11\NN\1740 occurred_12\VBD\2623529 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 recurrent_17\JJ\1740 carcinoma_18\NN\14239918 of_19\IN\1740 the_20\DT\1740 oral_21\JJ\1740 cavity_22\NN\9304750 ,_23\,\1740 cirrhosis_24\NN\14116321 ,_25\,\1740 and_26\CC\1740 cisplatin-induced_27\JJ\1740 <e2>impaired_28\JJ\1740 renal_29\JJ\1740 function</e2>_30\NN\13783581 ._31\.\1740
D002945_D004342 NONE an_0\DT\6697703 <e2>allergic_1\JJ\1740 reaction</e2>_2\NN\13446390 consisting_3\VBG\2603699 of_4\IN\1740 angioneurotic_5\JJ\1740 edema_6\NN\14315192 secondary_7\JJ\1740 to_8\TO\1740 continuous_9\JJ\1740 infusion_10\NN\14589223 5-fluorouracil_11\NN\1740 occurred_12\VBD\2623529 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 recurrent_17\JJ\1740 carcinoma_18\NN\14239918 of_19\IN\1740 the_20\DT\1740 oral_21\JJ\1740 cavity_22\NN\9304750 ,_23\,\1740 cirrhosis_24\NN\14116321 ,_25\,\1740 and_26\CC\1740 <e1>cisplatin-induced</e1>_27\JJ\1740 impaired_28\JJ\1740 renal_29\JJ\1740 function_30\NN\13783581 ._31\.\1740
D002945_D000799 NONE an_0\DT\6697703 allergic_1\JJ\1740 reaction_2\NN\13446390 consisting_3\VBG\2603699 of_4\IN\1740 <e2>angioneurotic_5\JJ\1740 edema</e2>_6\NN\14315192 secondary_7\JJ\1740 to_8\TO\1740 continuous_9\JJ\1740 infusion_10\NN\14589223 5-fluorouracil_11\NN\1740 occurred_12\VBD\2623529 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 recurrent_17\JJ\1740 carcinoma_18\NN\14239918 of_19\IN\1740 the_20\DT\1740 oral_21\JJ\1740 cavity_22\NN\9304750 ,_23\,\1740 cirrhosis_24\NN\14116321 ,_25\,\1740 and_26\CC\1740 <e1>cisplatin-induced</e1>_27\JJ\1740 impaired_28\JJ\1740 renal_29\JJ\1740 function_30\NN\13783581 ._31\.\1740
D002945_D009062 NONE an_0\DT\6697703 allergic_1\JJ\1740 reaction_2\NN\13446390 consisting_3\VBG\2603699 of_4\IN\1740 angioneurotic_5\JJ\1740 edema_6\NN\14315192 secondary_7\JJ\1740 to_8\TO\1740 continuous_9\JJ\1740 infusion_10\NN\14589223 5-fluorouracil_11\NN\1740 occurred_12\VBD\2623529 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 recurrent_17\JJ\1740 <e2>carcinoma_18\NN\14239918 of_19\IN\1740 the_20\DT\1740 oral_21\JJ\1740 cavity</e2>_22\NN\9304750 ,_23\,\1740 cirrhosis_24\NN\14116321 ,_25\,\1740 and_26\CC\1740 <e1>cisplatin-induced</e1>_27\JJ\1740 impaired_28\JJ\1740 renal_29\JJ\1740 function_30\NN\13783581 ._31\.\1740
D002945_D005355 NONE an_0\DT\6697703 allergic_1\JJ\1740 reaction_2\NN\13446390 consisting_3\VBG\2603699 of_4\IN\1740 angioneurotic_5\JJ\1740 edema_6\NN\14315192 secondary_7\JJ\1740 to_8\TO\1740 continuous_9\JJ\1740 infusion_10\NN\14589223 5-fluorouracil_11\NN\1740 occurred_12\VBD\2623529 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 recurrent_17\JJ\1740 carcinoma_18\NN\14239918 of_19\IN\1740 the_20\DT\1740 oral_21\JJ\1740 cavity_22\NN\9304750 ,_23\,\1740 <e2>cirrhosis</e2>_24\NN\14116321 ,_25\,\1740 and_26\CC\1740 <e1>cisplatin-induced</e1>_27\JJ\1740 impaired_28\JJ\1740 renal_29\JJ\1740 function_30\NN\13783581 ._31\.\1740
D002945_D007674 NONE an_0\DT\6697703 allergic_1\JJ\1740 reaction_2\NN\13446390 consisting_3\VBG\2603699 of_4\IN\1740 angioneurotic_5\JJ\1740 edema_6\NN\14315192 secondary_7\JJ\1740 to_8\TO\1740 continuous_9\JJ\1740 infusion_10\NN\14589223 5-fluorouracil_11\NN\1740 occurred_12\VBD\2623529 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 recurrent_17\JJ\1740 carcinoma_18\NN\14239918 of_19\IN\1740 the_20\DT\1740 oral_21\JJ\1740 cavity_22\NN\9304750 ,_23\,\1740 cirrhosis_24\NN\14116321 ,_25\,\1740 and_26\CC\1740 <e1>cisplatin-induced</e1>_27\JJ\1740 <e2>impaired_28\JJ\1740 renal_29\JJ\1740 function</e2>_30\NN\13783581 ._31\.\1740
D004155_D004342 NONE oral_0\JJ\1740 <e1>diphenhydramine</e1>_1\NN\2720725 and_2\CC\1740 prednisone_3\NN\2721538 were_4\VBD\836236 ineffective_5\JJ\1740 in_6\IN\13603305 preventing_7\VBG\1740 the_8\DT\1740 recurrence_9\NN\7342049 of_10\IN\1740 the_11\DT\1740 <e2>allergic_12\JJ\1740 reaction</e2>_13\NN\13446390 ._14\.\1740
D011241_D004342 NONE oral_0\JJ\1740 diphenhydramine_1\NN\2720725 and_2\CC\1740 <e1>prednisone</e1>_3\NN\2721538 were_4\VBD\836236 ineffective_5\JJ\1740 in_6\IN\13603305 preventing_7\VBG\1740 the_8\DT\1740 recurrence_9\NN\7342049 of_10\IN\1740 the_11\DT\1740 <e2>allergic_12\JJ\1740 reaction</e2>_13\NN\13446390 ._14\.\1740
12090760
D015215_D000740 CID antagonism_0\NN\24720 between_1\IN\1740 interleukin_2\NN\14943950 3_3\CD\13741022 and_4\CC\1740 erythropoietin_5\NN\14888310 in_6\IN\13603305 mice_7\NNS\2329401 with_8\IN\1740 <e1>azidothymidine-induced</e1>_9\JJ\1740 <e2>anemia</e2>_10\NN\14189204 and_11\CC\1740 in_12\IN\13603305 bone_13\NN\5286536 marrow_14\NN\5286536 endothelial_15\JJ\1740 cells_16\NNS\3080309 ._17\.\1740
D015215_D000740 CID <e1>azidothymidine</e1>_0\NN\1740 (azt)-induced_1\JJ\1740 <e2>anemia</e2>_2\NN\14189204 in_3\IN\13603305 mice_4\NNS\2329401 can_5\MD\3094503 be_6\VB\836236 reversed_7\VBN\109660 by_8\IN\1740 the_9\DT\1740 administration_10\NN\1133281 of_11\IN\1740 igf-il-3_12\NN\1740 (_13\-LRB-\1740 fusion_14\NN\7373277 protein_15\NN\14944888 of_16\IN\1740 insulin-like_17\JJ\1740 growth_18\NN\13526110 factor_19\NN\7326557 ii_20\CD\13741022 (_21\-LRB-\1740 igf_22\NN\1740 ii_23\CD\13741022 )_24\-RRB-\1740 and_25\CC\1740 interleukin_26\NN\14943950 3_27\CD\13741022 )_28\-RRB-\1740 ._29\.\1740
D015215_D000740 CID azidothymidine_0\NN\1740 <e1>(azt)-induced</e1>_1\JJ\1740 <e2>anemia</e2>_2\NN\14189204 in_3\IN\13603305 mice_4\NNS\2329401 can_5\MD\3094503 be_6\VB\836236 reversed_7\VBN\109660 by_8\IN\1740 the_9\DT\1740 administration_10\NN\1133281 of_11\IN\1740 igf-il-3_12\NN\1740 (_13\-LRB-\1740 fusion_14\NN\7373277 protein_15\NN\14944888 of_16\IN\1740 insulin-like_17\JJ\1740 growth_18\NN\13526110 factor_19\NN\7326557 ii_20\CD\13741022 (_21\-LRB-\1740 igf_22\NN\1740 ii_23\CD\13741022 )_24\-RRB-\1740 and_25\CC\1740 interleukin_26\NN\14943950 3_27\CD\13741022 )_28\-RRB-\1740 ._29\.\1740
15120741
D010862_D013226 CID similar_0\JJ\1740 to_1\TO\1740 rats_2\NNS\2329401 ,_3\,\1740 systemic_4\JJ\1740 <e1>pilocarpine</e1>_5\NN\14712692 injection_6\NN\320852 causes_7\VBZ\1617192 <e2>status_8\NN\24720 epilepticus</e2>_9\NN\1740 (_10\-LRB-\1740 se_11\NN\14724645 )_12\-RRB-\1740 and_13\CC\1740 the_14\DT\1740 eventual_15\JJ\1740 development_16\NN\248977 of_17\IN\1740 spontaneous_18\JJ\1740 seizures_19\NNS\14081375 and_20\CC\1740 mossy_21\NN\1740 fiber_22\NN\14580897 sprouting_23\VBG\231557 in_24\IN\13603305 c57bl/6_25\NN\1740 and_26\CC\1740 cd1_27\NN\1740 mice_28\NNS\2329401 ,_29\,\1740 but_30\CC\1740 the_31\DT\1740 physiological_32\JJ\1740 correlates_33\NNS\5857459 of_34\IN\1740 these_35\DT\1740 events_36\NNS\23100 have_37\VBP\2108377 not_38\RB\1740 been_39\VBN\836236 identified_40\VBN\699815 in_41\IN\13603305 mice_42\NNS\2329401 ._43\.\1740
D010862_D013226 CID similar_0\JJ\1740 to_1\TO\1740 rats_2\NNS\2329401 ,_3\,\1740 systemic_4\JJ\1740 <e1>pilocarpine</e1>_5\NN\14712692 injection_6\NN\320852 causes_7\VBZ\1617192 status_8\NN\24720 epilepticus_9\NN\1740 (_10\-LRB-\1740 <e2>se</e2>_11\NN\14724645 )_12\-RRB-\1740 and_13\CC\1740 the_14\DT\1740 eventual_15\JJ\1740 development_16\NN\248977 of_17\IN\1740 spontaneous_18\JJ\1740 seizures_19\NNS\14081375 and_20\CC\1740 mossy_21\NN\1740 fiber_22\NN\14580897 sprouting_23\VBG\231557 in_24\IN\13603305 c57bl/6_25\NN\1740 and_26\CC\1740 cd1_27\NN\1740 mice_28\NNS\2329401 ,_29\,\1740 but_30\CC\1740 the_31\DT\1740 physiological_32\JJ\1740 correlates_33\NNS\5857459 of_34\IN\1740 these_35\DT\1740 events_36\NNS\23100 have_37\VBP\2108377 not_38\RB\1740 been_39\VBN\836236 identified_40\VBN\699815 in_41\IN\13603305 mice_42\NNS\2329401 ._43\.\1740
D010862_D013226 CID in_0\IN\13603305 mg(2+)-free_1\NN\1740 bathing_2\NN\426928 medium_3\NN\3575240 containing_4\VBG\2632940 bicuculline_5\NN\1740 ,_6\,\1740 conditions_7\NNS\14512817 designed_8\VBN\1631534 to_9\TO\1740 increase_10\VB\169651 excitability_11\NN\5653575 in_12\IN\13603305 the_13\DT\1740 slices_14\NNS\13285176 ,_15\,\1740 electrical_16\JJ\1740 stimulation_17\NN\242808 of_18\IN\1740 the_19\DT\1740 hilus_20\NN\5223370 resulted_21\VBD\2633881 in_22\IN\13603305 a_23\DT\13649268 single_24\JJ\1740 population_25\NN\7942152 spike_26\JJ\1740 in_27\IN\13603305 granule_28\NN\9290777 cells_29\NNS\3080309 from_30\IN\1740 control_31\NN\5190804 mice_32\NNS\2329401 and_33\CC\1740 <e1>pilocarpine-treated</e1>_34\JJ\1740 mice_35\NNS\2329401 that_36\WDT\1740 did_37\VBD\1640855 not_38\RB\1740 experience_39\VB\2108377 <e2>se</e2>_40\NN\14724645 ._41\.\1740
D010862_D012640 CID similar_0\JJ\1740 to_1\TO\1740 rats_2\NNS\2329401 ,_3\,\1740 systemic_4\JJ\1740 <e1>pilocarpine</e1>_5\NN\14712692 injection_6\NN\320852 causes_7\VBZ\1617192 status_8\NN\24720 epilepticus_9\NN\1740 (_10\-LRB-\1740 se_11\NN\14724645 )_12\-RRB-\1740 and_13\CC\1740 the_14\DT\1740 eventual_15\JJ\1740 development_16\NN\248977 of_17\IN\1740 spontaneous_18\JJ\1740 <e2>seizures</e2>_19\NNS\14081375 and_20\CC\1740 mossy_21\NN\1740 fiber_22\NN\14580897 sprouting_23\VBG\231557 in_24\IN\13603305 c57bl/6_25\NN\1740 and_26\CC\1740 cd1_27\NN\1740 mice_28\NNS\2329401 ,_29\,\1740 but_30\CC\1740 the_31\DT\1740 physiological_32\JJ\1740 correlates_33\NNS\5857459 of_34\IN\1740 these_35\DT\1740 events_36\NNS\23100 have_37\VBP\2108377 not_38\RB\1740 been_39\VBN\836236 identified_40\VBN\699815 in_41\IN\13603305 mice_42\NNS\2329401 ._43\.\1740
D008274_D013226 NONE in_0\IN\13603305 <e1>mg(2+)-free</e1>_1\NN\1740 bathing_2\NN\426928 medium_3\NN\3575240 containing_4\VBG\2632940 bicuculline_5\NN\1740 ,_6\,\1740 conditions_7\NNS\14512817 designed_8\VBN\1631534 to_9\TO\1740 increase_10\VB\169651 excitability_11\NN\5653575 in_12\IN\13603305 the_13\DT\1740 slices_14\NNS\13285176 ,_15\,\1740 electrical_16\JJ\1740 stimulation_17\NN\242808 of_18\IN\1740 the_19\DT\1740 hilus_20\NN\5223370 resulted_21\VBD\2633881 in_22\IN\13603305 a_23\DT\13649268 single_24\JJ\1740 population_25\NN\7942152 spike_26\JJ\1740 in_27\IN\13603305 granule_28\NN\9290777 cells_29\NNS\3080309 from_30\IN\1740 control_31\NN\5190804 mice_32\NNS\2329401 and_33\CC\1740 pilocarpine-treated_34\JJ\1740 mice_35\NNS\2329401 that_36\WDT\1740 did_37\VBD\1640855 not_38\RB\1740 experience_39\VB\2108377 <e2>se</e2>_40\NN\14724645 ._41\.\1740
D001640_D013226 NONE in_0\IN\13603305 mg(2+)-free_1\NN\1740 bathing_2\NN\426928 medium_3\NN\3575240 containing_4\VBG\2632940 <e1>bicuculline</e1>_5\NN\1740 ,_6\,\1740 conditions_7\NNS\14512817 designed_8\VBN\1631534 to_9\TO\1740 increase_10\VB\169651 excitability_11\NN\5653575 in_12\IN\13603305 the_13\DT\1740 slices_14\NNS\13285176 ,_15\,\1740 electrical_16\JJ\1740 stimulation_17\NN\242808 of_18\IN\1740 the_19\DT\1740 hilus_20\NN\5223370 resulted_21\VBD\2633881 in_22\IN\13603305 a_23\DT\13649268 single_24\JJ\1740 population_25\NN\7942152 spike_26\JJ\1740 in_27\IN\13603305 granule_28\NN\9290777 cells_29\NNS\3080309 from_30\IN\1740 control_31\NN\5190804 mice_32\NNS\2329401 and_33\CC\1740 pilocarpine-treated_34\JJ\1740 mice_35\NNS\2329401 that_36\WDT\1740 did_37\VBD\1640855 not_38\RB\1740 experience_39\VB\2108377 <e2>se</e2>_40\NN\14724645 ._41\.\1740
D018698_D013226 NONE in_0\IN\13603305 <e2>se</e2>_1\NN\14724645 survivors_2\NNS\9630641 ,_3\,\1740 similar_4\JJ\1740 stimulation_5\NN\242808 resulted_6\VBD\2633881 in_7\IN\13603305 a_8\DT\13649268 population_9\NN\7942152 spike_10\NN\7307895 followed_11\VBD\1835496 ,_12\,\1740 at_13\IN\14622893 a_14\DT\13649268 variable_15\JJ\1740 latency_16\NN\15269513 ,_17\,\1740 by_18\IN\1740 negative_19\JJ\1740 dc_20\NN\11450566 shifts_21\NNS\7446404 and_22\CC\1740 repetitive_23\JJ\1740 afterdischarges_24\NNS\1740 of_25\IN\1740 3_26\CD\13741022 -_27\SYM\1740 60_28\CD\13745420 s_29\NN\15154774 duration_30\NN\15113229 ,_31\,\1740 which_32\WDT\1740 were_33\VBD\836236 blocked_34\VBN\1476483 by_35\IN\1740 ionotropic_36\JJ\1740 <e1>glutamate</e1>_37\JJ\1740 receptor_38\NN\5225602 antagonists_39\NNS\7846 ._40\.\1740
D018698_D013226 NONE focal_0\JJ\1740 <e1>glutamate</e1>_1\JJ\1740 photostimulation_2\NN\1740 of_3\IN\1740 the_4\DT\1740 granule_5\NN\9290777 cell_6\NN\3080309 layer_7\NN\21939 at_8\IN\14622893 sites_9\NNS\8673395 distant_10\JJ\1740 from_11\IN\1740 the_12\DT\1740 recording_13\NN\6791372 pipette_14\NN\3733925 resulted_15\VBD\2633881 in_16\IN\13603305 population_17\NN\7942152 responses_18\NNS\11410625 of_19\IN\1740 1_20\CD\13741022 -_21\SYM\1740 30_22\CD\13745420 s_23\NN\15154774 duration_24\NN\15113229 in_25\IN\13603305 slices_26\NNS\13285176 from_27\IN\1740 <e2>se</e2>_28\NN\14724645 survivors_29\NNS\9630641 but_30\CC\1740 not_31\RB\1740 other_32\JJ\1740 groups_33\NNS\2137 ._34\.\1740
14765563
D011803_D020922 NONE although_0\IN\1740 the_1\DT\1740 united_2\NNP\1740 states_3\NNP\8491826 food_4\NNP\20090 and_5\CC\1740 drug_6\NNP\14778436 administration_7\NNP\1133281 banned_8\VBD\2480923 its_9\PRP$\6125041 use_10\NN\407535 for_11\IN\1740 <e2>nocturnal_12\JJ\1740 leg_13\NN\5560244 cramps</e2>_14\NNS\14299637 due_15\JJ\1740 to_16\TO\1740 lack_17\NN\14449126 of_18\IN\1740 safety_19\NN\13920835 and_20\CC\1740 efficacy_21\NN\5199286 ,_22\,\1740 <e1>quinine</e1>_23\NN\2721948 is_24\VBZ\836236 widely_25\RB\1740 available_26\JJ\1740 in_27\IN\13603305 beverages_28\NNS\21265 including_29\VBG\690614 tonic_30\JJ\1740 water_31\NN\14618834 and_32\CC\1740 bitter_33\JJ\1740 lemon_34\RB\1740 ._35\.\1740
D011803_D002493 NONE numerous_0\JJ\1740 anecdotal_1\JJ\1740 reports_2\NNS\6470073 suggest_3\VBP\1010118 that_4\IN\1740 products_5\NNS\3076708 containing_6\VBG\2632940 <e1>quinine</e1>_7\NN\2721948 may_8\MD\15209706 produce_9\VB\1617192 <e2>neurological_10\JJ\1740 complications</e2>_11\NNS\1073995 ,_12\,\1740 including_13\VBG\690614 confusion_14\NN\13972797 ,_15\,\1740 altered_16\JJ\1740 mental_17\JJ\1740 status_18\NN\24720 ,_19\,\1740 seizures_20\NNS\14081375 ,_21\,\1740 and_22\CC\1740 coma_23\NN\5678932 ,_24\,\1740 particularly_25\RB\1740 in_26\IN\13603305 older_27\JJR\1740 women_28\NNS\9605289 ._29\.\1740
D011803_D003221 CID numerous_0\JJ\1740 anecdotal_1\JJ\1740 reports_2\NNS\6470073 suggest_3\VBP\1010118 that_4\IN\1740 products_5\NNS\3076708 containing_6\VBG\2632940 <e1>quinine</e1>_7\NN\2721948 may_8\MD\15209706 produce_9\VB\1617192 neurological_10\JJ\1740 complications_11\NNS\1073995 ,_12\,\1740 including_13\VBG\690614 <e2>confusion</e2>_14\NN\13972797 ,_15\,\1740 altered_16\JJ\1740 mental_17\JJ\1740 status_18\NN\24720 ,_19\,\1740 seizures_20\NNS\14081375 ,_21\,\1740 and_22\CC\1740 coma_23\NN\5678932 ,_24\,\1740 particularly_25\RB\1740 in_26\IN\13603305 older_27\JJR\1740 women_28\NNS\9605289 ._29\.\1740
D011803_D012640 CID numerous_0\JJ\1740 anecdotal_1\JJ\1740 reports_2\NNS\6470073 suggest_3\VBP\1010118 that_4\IN\1740 products_5\NNS\3076708 containing_6\VBG\2632940 <e1>quinine</e1>_7\NN\2721948 may_8\MD\15209706 produce_9\VB\1617192 neurological_10\JJ\1740 complications_11\NNS\1073995 ,_12\,\1740 including_13\VBG\690614 confusion_14\NN\13972797 ,_15\,\1740 altered_16\JJ\1740 mental_17\JJ\1740 status_18\NN\24720 ,_19\,\1740 <e2>seizures</e2>_20\NNS\14081375 ,_21\,\1740 and_22\CC\1740 coma_23\NN\5678932 ,_24\,\1740 particularly_25\RB\1740 in_26\IN\13603305 older_27\JJR\1740 women_28\NNS\9605289 ._29\.\1740
D011803_D003128 CID numerous_0\JJ\1740 anecdotal_1\JJ\1740 reports_2\NNS\6470073 suggest_3\VBP\1010118 that_4\IN\1740 products_5\NNS\3076708 containing_6\VBG\2632940 <e1>quinine</e1>_7\NN\2721948 may_8\MD\15209706 produce_9\VB\1617192 neurological_10\JJ\1740 complications_11\NNS\1073995 ,_12\,\1740 including_13\VBG\690614 confusion_14\NN\13972797 ,_15\,\1740 altered_16\JJ\1740 mental_17\JJ\1740 status_18\NN\24720 ,_19\,\1740 seizures_20\NNS\14081375 ,_21\,\1740 and_22\CC\1740 <e2>coma</e2>_23\NN\5678932 ,_24\,\1740 particularly_25\RB\1740 in_26\IN\13603305 older_27\JJR\1740 women_28\NNS\9605289 ._29\.\1740
10835440
D009553_D020521 NONE effect_0\NN\34213 of_1\IN\1740 intravenous_2\JJ\1740 <e1>nimodipine</e1>_3\NN\1740 on_4\IN\1740 blood_5\NN\5397468 pressure_6\NN\11419404 and_7\CC\1740 outcome_8\VB\1740 after_9\IN\1740 <e2>acute_10\JJ\1740 stroke</e2>_11\NN\556313 ._12\.\1740
D009553_D020521 NONE background_0\NN\4921011 and_1\CC\1740 purpose_2\NNP\5980875 :_3\:\1740 the_4\DT\1740 intravenous_5\NNP\1740 <e1>nimodipine</e1>_6\NNP\1740 west_7\NNP\13831000 european_8\NNP\9620078 <e2>stroke</e2>_9\NNP\556313 trial_10\NNP\786195 (_11\-LRB-\1740 inwest_12\NN\1740 )_13\-RRB-\1740 found_14\VBD\2426171 a_15\DT\13649268 correlation_16\NN\13841213 between_17\IN\1740 nimodipine-induced_18\JJ\1740 reduction_19\NN\351485 in_20\IN\13603305 blood_21\NN\5397468 pressure_22\NN\11419404 (_23\-LRB-\1740 bp_24\NN\1740 )_25\-RRB-\1740 and_26\CC\1740 an_27\DT\6697703 unfavorable_28\JJ\1740 outcome_29\NN\7291312 in_30\IN\13603305 acute_31\JJ\1740 stroke_32\NN\556313 ._33\.\1740
D009553_D020521 NONE background_0\NN\4921011 and_1\CC\1740 purpose_2\NNP\5980875 :_3\:\1740 the_4\DT\1740 intravenous_5\NNP\1740 <e1>nimodipine</e1>_6\NNP\1740 west_7\NNP\13831000 european_8\NNP\9620078 stroke_9\NNP\556313 trial_10\NNP\786195 (_11\-LRB-\1740 inwest_12\NN\1740 )_13\-RRB-\1740 found_14\VBD\2426171 a_15\DT\13649268 correlation_16\NN\13841213 between_17\IN\1740 nimodipine-induced_18\JJ\1740 reduction_19\NN\351485 in_20\IN\13603305 blood_21\NN\5397468 pressure_22\NN\11419404 (_23\-LRB-\1740 bp_24\NN\1740 )_25\-RRB-\1740 and_26\CC\1740 an_27\DT\6697703 unfavorable_28\JJ\1740 outcome_29\NN\7291312 in_30\IN\13603305 <e2>acute_31\JJ\1740 stroke</e2>_32\NN\556313 ._33\.\1740
D009553_D020521 NONE background_0\NN\4921011 and_1\CC\1740 purpose_2\NNP\5980875 :_3\:\1740 the_4\DT\1740 intravenous_5\NNP\1740 nimodipine_6\NNP\1740 west_7\NNP\13831000 european_8\NNP\9620078 <e2>stroke</e2>_9\NNP\556313 trial_10\NNP\786195 (_11\-LRB-\1740 inwest_12\NN\1740 )_13\-RRB-\1740 found_14\VBD\2426171 a_15\DT\13649268 correlation_16\NN\13841213 between_17\IN\1740 <e1>nimodipine-induced</e1>_18\JJ\1740 reduction_19\NN\351485 in_20\IN\13603305 blood_21\NN\5397468 pressure_22\NN\11419404 (_23\-LRB-\1740 bp_24\NN\1740 )_25\-RRB-\1740 and_26\CC\1740 an_27\DT\6697703 unfavorable_28\JJ\1740 outcome_29\NN\7291312 in_30\IN\13603305 acute_31\JJ\1740 stroke_32\NN\556313 ._33\.\1740
D009553_D020521 NONE background_0\NN\4921011 and_1\CC\1740 purpose_2\NNP\5980875 :_3\:\1740 the_4\DT\1740 intravenous_5\NNP\1740 nimodipine_6\NNP\1740 west_7\NNP\13831000 european_8\NNP\9620078 stroke_9\NNP\556313 trial_10\NNP\786195 (_11\-LRB-\1740 inwest_12\NN\1740 )_13\-RRB-\1740 found_14\VBD\2426171 a_15\DT\13649268 correlation_16\NN\13841213 between_17\IN\1740 <e1>nimodipine-induced</e1>_18\JJ\1740 reduction_19\NN\351485 in_20\IN\13603305 blood_21\NN\5397468 pressure_22\NN\11419404 (_23\-LRB-\1740 bp_24\NN\1740 )_25\-RRB-\1740 and_26\CC\1740 an_27\DT\6697703 unfavorable_28\JJ\1740 outcome_29\NN\7291312 in_30\IN\13603305 <e2>acute_31\JJ\1740 stroke</e2>_32\NN\556313 ._33\.\1740
D009553_D020521 NONE conclusions_0\NNS\5837957 :_1\:\1740 dbp_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 sbp_6\NN\1740 ,_7\,\1740 reduction_8\NN\351485 was_9\VBD\836236 associated_10\VBN\628491 with_11\IN\1740 neurological_12\JJ\1740 worsening_13\NN\13457378 after_14\IN\1740 the_15\DT\1740 intravenous_16\JJ\1740 administration_17\NN\1133281 of_18\IN\1740 high-dose_19\JJ\1740 <e1>nimodipine</e1>_20\NN\1740 after_21\IN\1740 <e2>acute_22\JJ\1740 stroke</e2>_23\NN\556313 ._24\.\1740
D009553_D007022 CID background_0\NN\4921011 and_1\CC\1740 purpose_2\NNP\5980875 :_3\:\1740 the_4\DT\1740 intravenous_5\NNP\1740 <e1>nimodipine</e1>_6\NNP\1740 west_7\NNP\13831000 european_8\NNP\9620078 stroke_9\NNP\556313 trial_10\NNP\786195 (_11\-LRB-\1740 inwest_12\NN\1740 )_13\-RRB-\1740 found_14\VBD\2426171 a_15\DT\13649268 correlation_16\NN\13841213 between_17\IN\1740 nimodipine-induced_18\JJ\1740 <e2>reduction_19\NN\351485 in_20\IN\13603305 blood_21\NN\5397468 pressure</e2>_22\NN\11419404 (_23\-LRB-\1740 bp_24\NN\1740 )_25\-RRB-\1740 and_26\CC\1740 an_27\DT\6697703 unfavorable_28\JJ\1740 outcome_29\NN\7291312 in_30\IN\13603305 acute_31\JJ\1740 stroke_32\NN\556313 ._33\.\1740
D009553_D007022 CID background_0\NN\4921011 and_1\CC\1740 purpose_2\NNP\5980875 :_3\:\1740 the_4\DT\1740 intravenous_5\NNP\1740 nimodipine_6\NNP\1740 west_7\NNP\13831000 european_8\NNP\9620078 stroke_9\NNP\556313 trial_10\NNP\786195 (_11\-LRB-\1740 inwest_12\NN\1740 )_13\-RRB-\1740 found_14\VBD\2426171 a_15\DT\13649268 correlation_16\NN\13841213 between_17\IN\1740 <e1>nimodipine-induced</e1>_18\JJ\1740 <e2>reduction_19\NN\351485 in_20\IN\13603305 blood_21\NN\5397468 pressure</e2>_22\NN\11419404 (_23\-LRB-\1740 bp_24\NN\1740 )_25\-RRB-\1740 and_26\CC\1740 an_27\DT\6697703 unfavorable_28\JJ\1740 outcome_29\NN\7291312 in_30\IN\13603305 acute_31\JJ\1740 stroke_32\NN\556313 ._33\.\1740
D009553_D007022 CID <e1>nimodipine</e1>_0\NN\1740 treatment_1\NN\654885 resulted_2\VBD\2633881 in_3\IN\13603305 a_4\DT\13649268 statistically_5\RB\1740 significant_6\JJ\1740 <e2>reduction_7\NN\351485 in_8\IN\13603305 systolic_9\JJ\1740 bp</e2>_10\NN\1740 (_11\-LRB-\1740 sbp_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 diastolic_15\JJ\1740 bp_16\NN\1740 (_17\-LRB-\1740 dbp_18\NN\1740 )_19\-RRB-\1740 from_20\IN\1740 baseline_21\NN\7260623 compared_22\VBN\644583 with_23\IN\1740 placebo_24\NN\3740161 during_25\IN\1740 the_26\DT\1740 first_27\JJ\1740 few_28\JJ\1740 days_29\NNS\15140892 ._30\.\1740
D009553_D002544 NONE methods_0\NNS\5616786 :_1\:\1740 patients_2\NNS\9898892 with_3\IN\1740 a_4\DT\13649268 clinical_5\JJ\1740 diagnosis_6\NN\152018 of_7\IN\1740 <e2>ischemic_8\JJ\1740 stroke</e2>_9\NN\556313 (_10\-LRB-\1740 within_11\IN\1740 24_12\CD\13745420 hours_13\NNS\15118228 )_14\-RRB-\1740 were_15\VBD\836236 consecutively_16\RB\1740 allocated_17\VBN\2228698 to_18\TO\1740 receive_19\VB\2210855 placebo_20\NN\3740161 (_21\-LRB-\1740 n=100_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 1_25\CD\13741022 mg/h_26\NN\1740 (_27\-LRB-\1740 low-dose_28\JJ\1740 )_29\-RRB-\1740 <e1>nimodipine</e1>_30\NN\1740 (_31\-LRB-\1740 n=101_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 or_35\CC\3541091 2_36\CD\13741022 mg/h_37\NNS\1740 (_38\-LRB-\1740 high-dose_39\JJ\1740 )_40\-RRB-\1740 nimodipine_41\NN\1740 (_42\-LRB-\1740 n=94_43\NN\1740 )_44\-RRB-\1740 ._45\.\1740
D009553_D002544 NONE methods_0\NNS\5616786 :_1\:\1740 patients_2\NNS\9898892 with_3\IN\1740 a_4\DT\13649268 clinical_5\JJ\1740 diagnosis_6\NN\152018 of_7\IN\1740 <e2>ischemic_8\JJ\1740 stroke</e2>_9\NN\556313 (_10\-LRB-\1740 within_11\IN\1740 24_12\CD\13745420 hours_13\NNS\15118228 )_14\-RRB-\1740 were_15\VBD\836236 consecutively_16\RB\1740 allocated_17\VBN\2228698 to_18\TO\1740 receive_19\VB\2210855 placebo_20\NN\3740161 (_21\-LRB-\1740 n=100_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 1_25\CD\13741022 mg/h_26\NN\1740 (_27\-LRB-\1740 low-dose_28\JJ\1740 )_29\-RRB-\1740 nimodipine_30\NN\1740 (_31\-LRB-\1740 n=101_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 or_35\CC\3541091 2_36\CD\13741022 mg/h_37\NNS\1740 (_38\-LRB-\1740 high-dose_39\JJ\1740 )_40\-RRB-\1740 <e1>nimodipine</e1>_41\NN\1740 (_42\-LRB-\1740 n=94_43\NN\1740 )_44\-RRB-\1740 ._45\.\1740
18464113
D019259_D006509 NONE <e1>lamivudine</e1>_0\NN\3834836 for_1\IN\1740 the_2\DT\1740 prevention_3\NN\1073995 of_4\IN\1740 <e2>hepatitis_5\NN\14127211 b</e2>_6\NN\1355326 virus_7\NN\9312843 reactivation_8\NN\1740 in_9\IN\13603305 hepatitis-b_10\NN\1740 surface_11\NN\21939 antigen_12\NN\20090 (_13\-LRB-\1740 hbsag_14\NN\1740 )_15\-RRB-\1740 seropositive_16\JJ\1740 cancer_17\NN\14239425 patients_18\NNS\9898892 undergoing_19\VBG\109660 cytotoxic_20\JJ\1740 chemotherapy_21\NN\661091 ._22\.\1740
D019259_D006509 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 cancer_4\NN\14239425 patients_5\NNS\9898892 who_6\WP\8299493 have_7\VBP\2108377 solid_8\JJ\1740 and_9\CC\1740 hematological_10\JJ\1740 malignancies_11\NNS\14070360 with_12\IN\1740 chronic_13\JJ\1740 <e2>hbv_14\NN\1740 infection</e2>_15\NN\14052046 received_16\VBD\2210855 the_17\DT\1740 antiviral_18\JJ\1740 agent_19\NN\7347 <e1>lamivudine</e1>_20\NN\3834836 prior_21\RB\1740 and_22\CC\1740 during_23\IN\1740 ct_24\NN\901316 compared_25\VBN\644583 with_26\IN\1740 historical_27\JJ\1740 control_28\NN\5190804 group_29\NN\2137 who_30\WP\8299493 did_31\VBD\1640855 not_32\RB\1740 receive_33\VB\2210855 lamivudine_34\NN\3834836 ._35\.\1740
D019259_D006509 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 cancer_4\NN\14239425 patients_5\NNS\9898892 who_6\WP\8299493 have_7\VBP\2108377 solid_8\JJ\1740 and_9\CC\1740 hematological_10\JJ\1740 malignancies_11\NNS\14070360 with_12\IN\1740 chronic_13\JJ\1740 <e2>hbv_14\NN\1740 infection</e2>_15\NN\14052046 received_16\VBD\2210855 the_17\DT\1740 antiviral_18\JJ\1740 agent_19\NN\7347 lamivudine_20\NN\3834836 prior_21\RB\1740 and_22\CC\1740 during_23\IN\1740 ct_24\NN\901316 compared_25\VBN\644583 with_26\IN\1740 historical_27\JJ\1740 control_28\NN\5190804 group_29\NN\2137 who_30\WP\8299493 did_31\VBD\1640855 not_32\RB\1740 receive_33\VB\2210855 <e1>lamivudine</e1>_34\NN\3834836 ._35\.\1740
D019259_D009369 NONE <e1>lamivudine</e1>_0\NN\3834836 for_1\IN\1740 the_2\DT\1740 prevention_3\NN\1073995 of_4\IN\1740 hepatitis_5\NN\14127211 b_6\NN\1355326 virus_7\NN\9312843 reactivation_8\NN\1740 in_9\IN\13603305 hepatitis-b_10\NN\1740 surface_11\NN\21939 antigen_12\NN\20090 (_13\-LRB-\1740 hbsag_14\NN\1740 )_15\-RRB-\1740 seropositive_16\JJ\1740 <e2>cancer</e2>_17\NN\14239425 patients_18\NNS\9898892 undergoing_19\VBG\109660 cytotoxic_20\JJ\1740 chemotherapy_21\NN\661091 ._22\.\1740
D019259_D009369 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 <e2>cancer</e2>_4\NN\14239425 patients_5\NNS\9898892 who_6\WP\8299493 have_7\VBP\2108377 solid_8\JJ\1740 and_9\CC\1740 hematological_10\JJ\1740 malignancies_11\NNS\14070360 with_12\IN\1740 chronic_13\JJ\1740 hbv_14\NN\1740 infection_15\NN\14052046 received_16\VBD\2210855 the_17\DT\1740 antiviral_18\JJ\1740 agent_19\NN\7347 <e1>lamivudine</e1>_20\NN\3834836 prior_21\RB\1740 and_22\CC\1740 during_23\IN\1740 ct_24\NN\901316 compared_25\VBN\644583 with_26\IN\1740 historical_27\JJ\1740 control_28\NN\5190804 group_29\NN\2137 who_30\WP\8299493 did_31\VBD\1640855 not_32\RB\1740 receive_33\VB\2210855 lamivudine_34\NN\3834836 ._35\.\1740
D019259_D009369 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 <e2>cancer</e2>_4\NN\14239425 patients_5\NNS\9898892 who_6\WP\8299493 have_7\VBP\2108377 solid_8\JJ\1740 and_9\CC\1740 hematological_10\JJ\1740 malignancies_11\NNS\14070360 with_12\IN\1740 chronic_13\JJ\1740 hbv_14\NN\1740 infection_15\NN\14052046 received_16\VBD\2210855 the_17\DT\1740 antiviral_18\JJ\1740 agent_19\NN\7347 lamivudine_20\NN\3834836 prior_21\RB\1740 and_22\CC\1740 during_23\IN\1740 ct_24\NN\901316 compared_25\VBN\644583 with_26\IN\1740 historical_27\JJ\1740 control_28\NN\5190804 group_29\NN\2137 who_30\WP\8299493 did_31\VBD\1640855 not_32\RB\1740 receive_33\VB\2210855 <e1>lamivudine</e1>_34\NN\3834836 ._35\.\1740
D019259_D009369 NONE our_0\PRP$\1740 study_1\NN\635850 suggests_2\VBZ\1010118 that_3\IN\1740 prophylactic_4\JJ\1740 <e1>lamivudine</e1>_5\NN\3834836 significantly_6\RB\1740 decreases_7\VBZ\169651 the_8\DT\1740 incidence_9\NN\13821570 of_10\IN\1740 hbv_11\NN\1740 reactivation_12\NN\1740 and_13\CC\1740 overall_14\JJ\1740 morbidity_15\NN\13826959 in_16\IN\13603305 <e2>cancer</e2>_17\NN\14239425 patients_18\NNS\9898892 during_19\IN\1740 and_20\CC\1740 after_21\IN\1740 immunosuppressive_22\JJ\1740 therapy_23\NN\657604 ._24\.\1740
D006514_D006509 CID lamivudine_0\NN\3834836 for_1\IN\1740 the_2\DT\1740 prevention_3\NN\1073995 of_4\IN\1740 <e2>hepatitis_5\NN\14127211 b</e2>_6\NN\1355326 virus_7\NN\9312843 reactivation_8\NN\1740 in_9\IN\13603305 <e1>hepatitis-b_10\NN\1740 surface_11\NN\21939 antigen</e1>_12\NN\20090 (_13\-LRB-\1740 hbsag_14\NN\1740 )_15\-RRB-\1740 seropositive_16\JJ\1740 cancer_17\NN\14239425 patients_18\NNS\9898892 undergoing_19\VBG\109660 cytotoxic_20\JJ\1740 chemotherapy_21\NN\661091 ._22\.\1740
D006514_D006509 CID lamivudine_0\NN\3834836 for_1\IN\1740 the_2\DT\1740 prevention_3\NN\1073995 of_4\IN\1740 <e2>hepatitis_5\NN\14127211 b</e2>_6\NN\1355326 virus_7\NN\9312843 reactivation_8\NN\1740 in_9\IN\13603305 hepatitis-b_10\NN\1740 surface_11\NN\21939 antigen_12\NN\20090 (_13\-LRB-\1740 <e1>hbsag</e1>_14\NN\1740 )_15\-RRB-\1740 seropositive_16\JJ\1740 cancer_17\NN\14239425 patients_18\NNS\9898892 undergoing_19\VBG\109660 cytotoxic_20\JJ\1740 chemotherapy_21\NN\661091 ._22\.\1740
D006514_D009369 NONE lamivudine_0\NN\3834836 for_1\IN\1740 the_2\DT\1740 prevention_3\NN\1073995 of_4\IN\1740 hepatitis_5\NN\14127211 b_6\NN\1355326 virus_7\NN\9312843 reactivation_8\NN\1740 in_9\IN\13603305 <e1>hepatitis-b_10\NN\1740 surface_11\NN\21939 antigen</e1>_12\NN\20090 (_13\-LRB-\1740 hbsag_14\NN\1740 )_15\-RRB-\1740 seropositive_16\JJ\1740 <e2>cancer</e2>_17\NN\14239425 patients_18\NNS\9898892 undergoing_19\VBG\109660 cytotoxic_20\JJ\1740 chemotherapy_21\NN\661091 ._22\.\1740
D006514_D009369 NONE lamivudine_0\NN\3834836 for_1\IN\1740 the_2\DT\1740 prevention_3\NN\1073995 of_4\IN\1740 hepatitis_5\NN\14127211 b_6\NN\1355326 virus_7\NN\9312843 reactivation_8\NN\1740 in_9\IN\13603305 hepatitis-b_10\NN\1740 surface_11\NN\21939 antigen_12\NN\20090 (_13\-LRB-\1740 <e1>hbsag</e1>_14\NN\1740 )_15\-RRB-\1740 seropositive_16\JJ\1740 <e2>cancer</e2>_17\NN\14239425 patients_18\NNS\9898892 undergoing_19\VBG\109660 cytotoxic_20\JJ\1740 chemotherapy_21\NN\661091 ._22\.\1740
D019259_D019337 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 cancer_4\NN\14239425 patients_5\NNS\9898892 who_6\WP\8299493 have_7\VBP\2108377 solid_8\JJ\1740 and_9\CC\1740 <e2>hematological_10\JJ\1740 malignancies</e2>_11\NNS\14070360 with_12\IN\1740 chronic_13\JJ\1740 hbv_14\NN\1740 infection_15\NN\14052046 received_16\VBD\2210855 the_17\DT\1740 antiviral_18\JJ\1740 agent_19\NN\7347 <e1>lamivudine</e1>_20\NN\3834836 prior_21\RB\1740 and_22\CC\1740 during_23\IN\1740 ct_24\NN\901316 compared_25\VBN\644583 with_26\IN\1740 historical_27\JJ\1740 control_28\NN\5190804 group_29\NN\2137 who_30\WP\8299493 did_31\VBD\1640855 not_32\RB\1740 receive_33\VB\2210855 lamivudine_34\NN\3834836 ._35\.\1740
D019259_D019337 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 cancer_4\NN\14239425 patients_5\NNS\9898892 who_6\WP\8299493 have_7\VBP\2108377 solid_8\JJ\1740 and_9\CC\1740 <e2>hematological_10\JJ\1740 malignancies</e2>_11\NNS\14070360 with_12\IN\1740 chronic_13\JJ\1740 hbv_14\NN\1740 infection_15\NN\14052046 received_16\VBD\2210855 the_17\DT\1740 antiviral_18\JJ\1740 agent_19\NN\7347 lamivudine_20\NN\3834836 prior_21\RB\1740 and_22\CC\1740 during_23\IN\1740 ct_24\NN\901316 compared_25\VBN\644583 with_26\IN\1740 historical_27\JJ\1740 control_28\NN\5190804 group_29\NN\2137 who_30\WP\8299493 did_31\VBD\1640855 not_32\RB\1740 receive_33\VB\2210855 <e1>lamivudine</e1>_34\NN\3834836 ._35\.\1740
D019259_D056486 NONE in_0\IN\13603305 the_1\DT\1740 prophylactic_2\JJ\1740 <e1>lamivudine</e1>_3\NN\3834836 group_4\NN\2137 severe_5\JJ\1740 <e2>hepatitis</e2>_6\NN\14127211 were_7\VBD\836236 observed_8\VBN\2163746 only_9\RB\1740 in_10\IN\13603305 1_11\CD\13741022 patient_12\NN\9898892 (_13\-LRB-\1740 2.7_14\CD\1740 %_15\NN\1740 )_16\-RRB-\1740 of_17\IN\1740 37_18\CD\1740 patients_19\NNS\9898892 (_20\-LRB-\1740 p_21\NN\14622893 <_22\XX\1740 0.006_23\CD\1740 )_24\-RRB-\1740 ._25\.\1740
2924746
D002220_D064420 NONE chronic_0\JJ\1740 <e1>carbamazepine</e1>_1\NN\1740 treatment_2\NN\654885 in_3\IN\13603305 the_4\DT\1740 rat_5\NN\2329401 :_6\:\1740 efficacy_7\NN\5199286 ,_8\,\1740 <e2>toxicity</e2>_9\NN\13576101 ,_10\,\1740 and_11\CC\1740 effect_12\NN\34213 on_13\IN\1740 plasma_14\NN\5398023 and_15\CC\1740 tissue_16\NN\5220461 folate_17\NN\15090742 concentrations_18\NNS\4916342 ._19\.\1740
D005492_D064420 NONE chronic_0\JJ\1740 carbamazepine_1\NN\1740 treatment_2\NN\654885 in_3\IN\13603305 the_4\DT\1740 rat_5\NN\2329401 :_6\:\1740 efficacy_7\NN\5199286 ,_8\,\1740 <e2>toxicity</e2>_9\NN\13576101 ,_10\,\1740 and_11\CC\1740 effect_12\NN\34213 on_13\IN\1740 plasma_14\NN\5398023 and_15\CC\1740 tissue_16\NN\5220461 <e1>folate</e1>_17\NN\15090742 concentrations_18\NNS\4916342 ._19\.\1740
D019946_D012640 NONE in_0\IN\13603305 the_1\DT\1740 course_2\NN\883297 of_3\IN\1740 developing_4\VBG\1753788 this_5\DT\1740 model_6\NN\5888929 ,_7\,\1740 a_8\DT\13649268 common_9\JJ\1740 vehicle_10\NN\3100490 ,_11\,\1740 <e1>propylene_12\NN\14877585 glycol</e1>_13\NN\14766364 ,_14\,\1740 by_15\IN\1740 itself_16\PRP\1740 in_17\IN\13603305 high_18\JJ\1740 doses_19\NNS\3740161 ,_20\,\1740 was_21\VBD\836236 found_22\VBN\2426171 to_23\TO\1740 exhibit_24\VB\2632167 protective_25\JJ\1740 properties_26\NNS\32613 against_27\IN\1740 induced_28\VBN\1627355 <e2>seizures</e2>_29\NNS\14081375 and_30\CC\1740 inhibited_31\VBD\2510337 weight_32\NN\5009170 gain_33\NN\13576355 ._34\.\1740
D019946_D015430 NONE in_0\IN\13603305 the_1\DT\1740 course_2\NN\883297 of_3\IN\1740 developing_4\VBG\1753788 this_5\DT\1740 model_6\NN\5888929 ,_7\,\1740 a_8\DT\13649268 common_9\JJ\1740 vehicle_10\NN\3100490 ,_11\,\1740 <e1>propylene_12\NN\14877585 glycol</e1>_13\NN\14766364 ,_14\,\1740 by_15\IN\1740 itself_16\PRP\1740 in_17\IN\13603305 high_18\JJ\1740 doses_19\NNS\3740161 ,_20\,\1740 was_21\VBD\836236 found_22\VBN\2426171 to_23\TO\1740 exhibit_24\VB\2632167 protective_25\JJ\1740 properties_26\NNS\32613 against_27\IN\1740 induced_28\VBN\1627355 seizures_29\NNS\14081375 and_30\CC\1740 inhibited_31\VBD\2510337 <e2>weight_32\NN\5009170 gain</e2>_33\NN\13576355 ._34\.\1740
D005481_D012640 CID <e2>seizures</e2>_0\NNP\14081375 induced_1\VBN\1627355 by_2\IN\1740 <e1>hexafluorodiethyl_3\JJ\1740 ether</e1>_4\NN\14840755 (_5\-LRB-\1740 hfde_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 also_9\RB\1740 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 a_13\DT\13649268 more_14\RBR\1740 sensitive_15\JJ\1740 measure_16\NN\168237 of_17\IN\1740 protection_18\NN\407535 by_19\IN\1740 cbz_20\NN\1740 than_21\IN\1740 seizures_22\NNS\14081375 induced_23\VBN\1627355 by_24\IN\1740 maximal_25\JJ\1740 electroshock_26\NN\662681 (_27\-LRB-\1740 mes_28\NN\1740 )_29\-RRB-\1740 ._30\.\1740
D005481_D012640 CID seizures_0\NNP\14081375 induced_1\VBN\1627355 by_2\IN\1740 <e1>hexafluorodiethyl_3\JJ\1740 ether</e1>_4\NN\14840755 (_5\-LRB-\1740 hfde_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 also_9\RB\1740 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 a_13\DT\13649268 more_14\RBR\1740 sensitive_15\JJ\1740 measure_16\NN\168237 of_17\IN\1740 protection_18\NN\407535 by_19\IN\1740 cbz_20\NN\1740 than_21\IN\1740 <e2>seizures</e2>_22\NNS\14081375 induced_23\VBN\1627355 by_24\IN\1740 maximal_25\JJ\1740 electroshock_26\NN\662681 (_27\-LRB-\1740 mes_28\NN\1740 )_29\-RRB-\1740 ._30\.\1740
D005481_D012640 CID <e2>seizures</e2>_0\NNP\14081375 induced_1\VBN\1627355 by_2\IN\1740 hexafluorodiethyl_3\JJ\1740 ether_4\NN\14840755 (_5\-LRB-\1740 <e1>hfde</e1>_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 also_9\RB\1740 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 a_13\DT\13649268 more_14\RBR\1740 sensitive_15\JJ\1740 measure_16\NN\168237 of_17\IN\1740 protection_18\NN\407535 by_19\IN\1740 cbz_20\NN\1740 than_21\IN\1740 seizures_22\NNS\14081375 induced_23\VBN\1627355 by_24\IN\1740 maximal_25\JJ\1740 electroshock_26\NN\662681 (_27\-LRB-\1740 mes_28\NN\1740 )_29\-RRB-\1740 ._30\.\1740
D005481_D012640 CID seizures_0\NNP\14081375 induced_1\VBN\1627355 by_2\IN\1740 hexafluorodiethyl_3\JJ\1740 ether_4\NN\14840755 (_5\-LRB-\1740 <e1>hfde</e1>_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 also_9\RB\1740 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 a_13\DT\13649268 more_14\RBR\1740 sensitive_15\JJ\1740 measure_16\NN\168237 of_17\IN\1740 protection_18\NN\407535 by_19\IN\1740 cbz_20\NN\1740 than_21\IN\1740 <e2>seizures</e2>_22\NNS\14081375 induced_23\VBN\1627355 by_24\IN\1740 maximal_25\JJ\1740 electroshock_26\NN\662681 (_27\-LRB-\1740 mes_28\NN\1740 )_29\-RRB-\1740 ._30\.\1740
D005481_D012640 CID oral_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 cbz_3\NN\1740 as_4\IN\14622893 an_5\DT\6697703 aqueous_6\JJ\1740 suspension_7\NN\14586258 every_8\DT\1740 8_9\CD\13741022 h_10\NN\14622893 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 of_14\IN\1740 250_15\CD\1740 mg/kg_16\NN\1740 was_17\VBD\836236 continuously_18\RB\1740 protective_19\JJ\1740 against_20\IN\1740 <e1>hfde-induced</e1>_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 and_23\CC\1740 was_24\VBD\836236 minimally_25\RB\1740 toxic_26\JJ\1740 as_27\IN\14622893 measured_28\VBN\697589 by_29\IN\1740 weight_30\NN\5009170 gain_31\NN\13576355 over_32\IN\5867413 8_33\CD\13741022 weeks_34\NNS\15113229 of_35\IN\1740 treatment_36\NN\654885 ._37\.\1740
D002220_D012640 NONE <e2>seizures</e2>_0\NNP\14081375 induced_1\VBN\1627355 by_2\IN\1740 hexafluorodiethyl_3\JJ\1740 ether_4\NN\14840755 (_5\-LRB-\1740 hfde_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 also_9\RB\1740 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 a_13\DT\13649268 more_14\RBR\1740 sensitive_15\JJ\1740 measure_16\NN\168237 of_17\IN\1740 protection_18\NN\407535 by_19\IN\1740 <e1>cbz</e1>_20\NN\1740 than_21\IN\1740 seizures_22\NNS\14081375 induced_23\VBN\1627355 by_24\IN\1740 maximal_25\JJ\1740 electroshock_26\NN\662681 (_27\-LRB-\1740 mes_28\NN\1740 )_29\-RRB-\1740 ._30\.\1740
D002220_D012640 NONE seizures_0\NNP\14081375 induced_1\VBN\1627355 by_2\IN\1740 hexafluorodiethyl_3\JJ\1740 ether_4\NN\14840755 (_5\-LRB-\1740 hfde_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 also_9\RB\1740 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 a_13\DT\13649268 more_14\RBR\1740 sensitive_15\JJ\1740 measure_16\NN\168237 of_17\IN\1740 protection_18\NN\407535 by_19\IN\1740 <e1>cbz</e1>_20\NN\1740 than_21\IN\1740 <e2>seizures</e2>_22\NNS\14081375 induced_23\VBN\1627355 by_24\IN\1740 maximal_25\JJ\1740 electroshock_26\NN\662681 (_27\-LRB-\1740 mes_28\NN\1740 )_29\-RRB-\1740 ._30\.\1740
D002220_D012640 NONE oral_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>cbz</e1>_3\NN\1740 as_4\IN\14622893 an_5\DT\6697703 aqueous_6\JJ\1740 suspension_7\NN\14586258 every_8\DT\1740 8_9\CD\13741022 h_10\NN\14622893 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 of_14\IN\1740 250_15\CD\1740 mg/kg_16\NN\1740 was_17\VBD\836236 continuously_18\RB\1740 protective_19\JJ\1740 against_20\IN\1740 hfde-induced_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 and_23\CC\1740 was_24\VBD\836236 minimally_25\RB\1740 toxic_26\JJ\1740 as_27\IN\14622893 measured_28\VBN\697589 by_29\IN\1740 weight_30\NN\5009170 gain_31\NN\13576355 over_32\IN\5867413 8_33\CD\13741022 weeks_34\NNS\15113229 of_35\IN\1740 treatment_36\NN\654885 ._37\.\1740
D002220_D015430 NONE oral_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>cbz</e1>_3\NN\1740 as_4\IN\14622893 an_5\DT\6697703 aqueous_6\JJ\1740 suspension_7\NN\14586258 every_8\DT\1740 8_9\CD\13741022 h_10\NN\14622893 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 of_14\IN\1740 250_15\CD\1740 mg/kg_16\NN\1740 was_17\VBD\836236 continuously_18\RB\1740 protective_19\JJ\1740 against_20\IN\1740 hfde-induced_21\JJ\1740 seizures_22\NNS\14081375 and_23\CC\1740 was_24\VBD\836236 minimally_25\RB\1740 toxic_26\JJ\1740 as_27\IN\14622893 measured_28\VBN\697589 by_29\IN\1740 <e2>weight_30\NN\5009170 gain</e2>_31\NN\13576355 over_32\IN\5867413 8_33\CD\13741022 weeks_34\NNS\15113229 of_35\IN\1740 treatment_36\NN\654885 ._37\.\1740
D005481_D015430 NONE oral_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 cbz_3\NN\1740 as_4\IN\14622893 an_5\DT\6697703 aqueous_6\JJ\1740 suspension_7\NN\14586258 every_8\DT\1740 8_9\CD\13741022 h_10\NN\14622893 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 of_14\IN\1740 250_15\CD\1740 mg/kg_16\NN\1740 was_17\VBD\836236 continuously_18\RB\1740 protective_19\JJ\1740 against_20\IN\1740 <e1>hfde-induced</e1>_21\JJ\1740 seizures_22\NNS\14081375 and_23\CC\1740 was_24\VBD\836236 minimally_25\RB\1740 toxic_26\JJ\1740 as_27\IN\14622893 measured_28\VBN\697589 by_29\IN\1740 <e2>weight_30\NN\5009170 gain</e2>_31\NN\13576355 over_32\IN\5867413 8_33\CD\13741022 weeks_34\NNS\15113229 of_35\IN\1740 treatment_36\NN\654885 ._37\.\1740
2224762
C027260_D009369 NONE a_0\DT\13649268 phase_1\NN\15113229 i_2\CD\14622893 study_3\NN\635850 of_4\IN\1740 intravenous_5\JJ\1740 (_6\-LRB-\1740 iv_7\CD\13741022 )_8\-RRB-\1740 bolus_9\NN\13899404 <e1>4'-0-tetrahydropyranyladriamycin</e1>_10\CD\1740 (_11\-LRB-\1740 pirarubicin_12\NN\1740 )_13\-RRB-\1740 was_14\VBD\836236 done_15\VBN\1640855 in_16\IN\13603305 55_17\CD\1740 patients_18\NNS\9898892 in_19\IN\13603305 good_20\JJ\1740 performance_21\NN\6619065 status_22\NN\24720 with_23\IN\1740 refractory_24\JJ\1740 <e2>tumors</e2>_25\NNS\14234074 ._26\.\1740
C027260_D009369 NONE a_0\DT\13649268 phase_1\NN\15113229 i_2\CD\14622893 study_3\NN\635850 of_4\IN\1740 intravenous_5\JJ\1740 (_6\-LRB-\1740 iv_7\CD\13741022 )_8\-RRB-\1740 bolus_9\NN\13899404 4'-0-tetrahydropyranyladriamycin_10\CD\1740 (_11\-LRB-\1740 <e1>pirarubicin</e1>_12\NN\1740 )_13\-RRB-\1740 was_14\VBD\836236 done_15\VBN\1640855 in_16\IN\13603305 55_17\CD\1740 patients_18\NNS\9898892 in_19\IN\13603305 good_20\JJ\1740 performance_21\NN\6619065 status_22\NN\24720 with_23\IN\1740 refractory_24\JJ\1740 <e2>tumors</e2>_25\NNS\14234074 ._26\.\1740
10721819
D007545_D013610 NONE effects_0\NNS\13245626 of_1\IN\1740 long-term_2\JJ\1740 pretreatment_3\NN\1740 with_4\IN\1740 <e1>isoproterenol</e1>_5\NN\3740161 on_6\IN\1740 bromocriptine-induced_7\JJ\1740 <e2>tachycardia</e2>_8\NN\14110674 in_9\IN\13603305 conscious_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
D007545_D013610 NONE it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 shown_3\VBN\2137132 that_4\IN\1740 bromocriptine-induced_5\JJ\1740 <e2>tachycardia</e2>_6\NN\14110674 ,_7\,\1740 which_8\WDT\1740 persisted_9\VBD\118523 after_10\IN\1740 adrenalectomy_11\NN\393369 ,_12\,\1740 is_13\VBZ\836236 (_14\-LRB-\1740 i_15\LS\14622893 )_16\-RRB-\1740 mediated_17\VBN\761713 by_18\IN\1740 central_19\JJ\1740 dopamine_20\NN\14807737 d2_21\NN\1740 receptor_22\NN\5225602 activation_23\NN\13561719 and_24\CC\1740 (_25\-LRB-\1740 ii_26\LS\13741022 )_27\-RRB-\1740 reduced_28\VBN\441445 by_29\IN\1740 5-day_30\JJ\1740 <e1>isoproterenol</e1>_31\NN\3740161 pretreatment_32\NN\1740 ,_33\,\1740 supporting_34\VBG\2199590 therefore_35\RB\1740 the_36\DT\1740 hypothesis_37\NN\7162194 that_38\IN\1740 this_39\DT\1740 effect_40\NN\34213 is_41\VBZ\836236 dependent_42\JJ\1740 on_43\IN\1740 sympathetic_44\JJ\1740 outflow_45\NN\7407777 to_46\IN\1740 the_47\DT\1740 heart_48\NN\5919034 ._49\.\1740
D007545_D013610 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 conducted_3\VBN\2436349 to_4\TO\1740 examine_5\VB\789138 whether_6\IN\1740 prolonged_7\JJ\1740 pretreatment_8\NN\1740 with_9\IN\1740 <e1>isoproterenol</e1>_10\NN\3740161 could_11\MD\1740 abolish_12\VB\1740 bromocriptine-induced_13\JJ\1740 <e2>tachycardia</e2>_14\NN\14110674 in_15\IN\13603305 conscious_16\JJ\1740 rats_17\NNS\2329401 ._18\.\1740
D007545_D013610 NONE bromocriptine-induced_0\JJ\1740 hypotension_1\NN\14057371 was_2\VBD\836236 unaffected_3\JJ\1740 by_4\IN\1740 <e1>isoproterenol</e1>_5\NN\3740161 pretreatment_6\NN\1740 ,_7\,\1740 while_8\IN\15122231 <e2>tachycardia</e2>_9\NN\14110674 was_10\VBD\836236 reversed_11\VBN\109660 to_12\TO\1740 significant_13\JJ\1740 bradycardia_14\NN\14110674 ,_15\,\1740 an_16\DT\6697703 effect_17\NN\34213 that_18\WDT\1740 was_19\VBD\836236 partly_20\RB\1740 reduced_21\VBN\441445 by_22\IN\1740 i.v._23\NN\1740 domperidone_24\NN\1740 (_25\-LRB-\1740 0.5_26\CD\1740 mg/kg_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D007545_D013610 NONE these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 15-day_4\JJ\1740 <e1>isoproterenol</e1>_5\NN\3740161 pretreatment_6\NN\1740 not_7\RB\1740 only_8\RB\1740 abolished_9\VBD\1740 but_10\CC\1740 reversed_11\VBN\109660 bromocriptine-induced_12\JJ\1740 <e2>tachycardia</e2>_13\NN\14110674 to_14\TO\1740 bradycardia_15\NN\14110674 ,_16\,\1740 an_17\DT\6697703 effect_18\NN\34213 that_19\WDT\1740 is_20\VBZ\836236 mainly_21\RB\1740 related_22\JJ\1740 to_23\TO\1740 further_24\RB\1740 cardiac_25\JJ\1740 beta-adrenoceptor_26\NN\5608868 desensitization_27\NN\13458571 rather_28\RB\1740 than_29\IN\1740 to_30\TO\1740 impairment_31\NN\7296428 of_32\IN\1740 autonomic_33\JJ\1740 regulation_34\NN\6652242 of_35\IN\1740 the_36\DT\1740 heart_37\NN\5919034 ._38\.\1740
D001971_D013610 CID effects_0\NNS\13245626 of_1\IN\1740 long-term_2\JJ\1740 pretreatment_3\NN\1740 with_4\IN\1740 isoproterenol_5\NN\3740161 on_6\IN\1740 <e1>bromocriptine-induced</e1>_7\JJ\1740 <e2>tachycardia</e2>_8\NN\14110674 in_9\IN\13603305 conscious_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
D001971_D013610 CID it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 shown_3\VBN\2137132 that_4\IN\1740 <e1>bromocriptine-induced</e1>_5\JJ\1740 <e2>tachycardia</e2>_6\NN\14110674 ,_7\,\1740 which_8\WDT\1740 persisted_9\VBD\118523 after_10\IN\1740 adrenalectomy_11\NN\393369 ,_12\,\1740 is_13\VBZ\836236 (_14\-LRB-\1740 i_15\LS\14622893 )_16\-RRB-\1740 mediated_17\VBN\761713 by_18\IN\1740 central_19\JJ\1740 dopamine_20\NN\14807737 d2_21\NN\1740 receptor_22\NN\5225602 activation_23\NN\13561719 and_24\CC\1740 (_25\-LRB-\1740 ii_26\LS\13741022 )_27\-RRB-\1740 reduced_28\VBN\441445 by_29\IN\1740 5-day_30\JJ\1740 isoproterenol_31\NN\3740161 pretreatment_32\NN\1740 ,_33\,\1740 supporting_34\VBG\2199590 therefore_35\RB\1740 the_36\DT\1740 hypothesis_37\NN\7162194 that_38\IN\1740 this_39\DT\1740 effect_40\NN\34213 is_41\VBZ\836236 dependent_42\JJ\1740 on_43\IN\1740 sympathetic_44\JJ\1740 outflow_45\NN\7407777 to_46\IN\1740 the_47\DT\1740 heart_48\NN\5919034 ._49\.\1740
D001971_D013610 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 conducted_3\VBN\2436349 to_4\TO\1740 examine_5\VB\789138 whether_6\IN\1740 prolonged_7\JJ\1740 pretreatment_8\NN\1740 with_9\IN\1740 isoproterenol_10\NN\3740161 could_11\MD\1740 abolish_12\VB\1740 <e1>bromocriptine-induced</e1>_13\JJ\1740 <e2>tachycardia</e2>_14\NN\14110674 in_15\IN\13603305 conscious_16\JJ\1740 rats_17\NNS\2329401 ._18\.\1740
D001971_D013610 CID in_0\IN\13603305 control_1\JJ\1740 rats_2\NNS\2329401 ,_3\,\1740 intravenous_4\JJ\1740 <e1>bromocriptine</e1>_5\NN\1740 (_6\-LRB-\1740 150_7\CD\1740 microg/kg_8\NNS\1740 )_9\-RRB-\1740 induced_10\VBD\1627355 significant_11\JJ\1740 hypotension_12\NN\14057371 and_13\CC\1740 <e2>tachycardia</e2>_14\NN\14110674 ._15\.\1740
D001971_D013610 CID <e1>bromocriptine-induced</e1>_0\JJ\1740 hypotension_1\NN\14057371 was_2\VBD\836236 unaffected_3\JJ\1740 by_4\IN\1740 isoproterenol_5\NN\3740161 pretreatment_6\NN\1740 ,_7\,\1740 while_8\IN\15122231 <e2>tachycardia</e2>_9\NN\14110674 was_10\VBD\836236 reversed_11\VBN\109660 to_12\TO\1740 significant_13\JJ\1740 bradycardia_14\NN\14110674 ,_15\,\1740 an_16\DT\6697703 effect_17\NN\34213 that_18\WDT\1740 was_19\VBD\836236 partly_20\RB\1740 reduced_21\VBN\441445 by_22\IN\1740 i.v._23\NN\1740 domperidone_24\NN\1740 (_25\-LRB-\1740 0.5_26\CD\1740 mg/kg_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D001971_D013610 CID these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 15-day_4\JJ\1740 isoproterenol_5\NN\3740161 pretreatment_6\NN\1740 not_7\RB\1740 only_8\RB\1740 abolished_9\VBD\1740 but_10\CC\1740 reversed_11\VBN\109660 <e1>bromocriptine-induced</e1>_12\JJ\1740 <e2>tachycardia</e2>_13\NN\14110674 to_14\TO\1740 bradycardia_15\NN\14110674 ,_16\,\1740 an_17\DT\6697703 effect_18\NN\34213 that_19\WDT\1740 is_20\VBZ\836236 mainly_21\RB\1740 related_22\JJ\1740 to_23\TO\1740 further_24\RB\1740 cardiac_25\JJ\1740 beta-adrenoceptor_26\NN\5608868 desensitization_27\NN\13458571 rather_28\RB\1740 than_29\IN\1740 to_30\TO\1740 impairment_31\NN\7296428 of_32\IN\1740 autonomic_33\JJ\1740 regulation_34\NN\6652242 of_35\IN\1740 the_36\DT\1740 heart_37\NN\5919034 ._38\.\1740
D001971_D013610 CID they_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 ,_3\,\1740 in_4\IN\13603305 normal_5\JJ\1740 conscious_6\JJ\1740 rats_7\NNS\2329401 ,_8\,\1740 the_9\DT\1740 central_10\JJ\1740 <e2>tachycardia</e2>_11\NN\14110674 of_12\IN\1740 <e1>bromocriptine</e1>_13\NN\1740 appears_14\VBZ\2604760 to_15\TO\1740 predominate_16\VB\2696801 and_17\CC\1740 to_18\TO\1740 mask_19\VB\2158587 the_20\DT\1740 bradycardia_21\NN\14110674 of_22\IN\1740 this_23\DT\1740 agonist_24\NN\9613191 at_25\IN\14622893 peripheral_26\JJ\1740 dopamine_27\NN\14807737 d2_28\NN\1740 receptors_29\NNS\5225602 ._30\.\1740
D004298_D013610 NONE it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 shown_3\VBN\2137132 that_4\IN\1740 bromocriptine-induced_5\JJ\1740 <e2>tachycardia</e2>_6\NN\14110674 ,_7\,\1740 which_8\WDT\1740 persisted_9\VBD\118523 after_10\IN\1740 adrenalectomy_11\NN\393369 ,_12\,\1740 is_13\VBZ\836236 (_14\-LRB-\1740 i_15\LS\14622893 )_16\-RRB-\1740 mediated_17\VBN\761713 by_18\IN\1740 central_19\JJ\1740 <e1>dopamine</e1>_20\NN\14807737 d2_21\NN\1740 receptor_22\NN\5225602 activation_23\NN\13561719 and_24\CC\1740 (_25\-LRB-\1740 ii_26\LS\13741022 )_27\-RRB-\1740 reduced_28\VBN\441445 by_29\IN\1740 5-day_30\JJ\1740 isoproterenol_31\NN\3740161 pretreatment_32\NN\1740 ,_33\,\1740 supporting_34\VBG\2199590 therefore_35\RB\1740 the_36\DT\1740 hypothesis_37\NN\7162194 that_38\IN\1740 this_39\DT\1740 effect_40\NN\34213 is_41\VBZ\836236 dependent_42\JJ\1740 on_43\IN\1740 sympathetic_44\JJ\1740 outflow_45\NN\7407777 to_46\IN\1740 the_47\DT\1740 heart_48\NN\5919034 ._49\.\1740
D004298_D013610 NONE they_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 ,_3\,\1740 in_4\IN\13603305 normal_5\JJ\1740 conscious_6\JJ\1740 rats_7\NNS\2329401 ,_8\,\1740 the_9\DT\1740 central_10\JJ\1740 <e2>tachycardia</e2>_11\NN\14110674 of_12\IN\1740 bromocriptine_13\NN\1740 appears_14\VBZ\2604760 to_15\TO\1740 predominate_16\VB\2696801 and_17\CC\1740 to_18\TO\1740 mask_19\VB\2158587 the_20\DT\1740 bradycardia_21\NN\14110674 of_22\IN\1740 this_23\DT\1740 agonist_24\NN\9613191 at_25\IN\14622893 peripheral_26\JJ\1740 <e1>dopamine</e1>_27\NN\14807737 d2_28\NN\1740 receptors_29\NNS\5225602 ._30\.\1740
D007545_D006332 CID <e1>isoproterenol</e1>_0\NN\3740161 pretreatment_1\NN\1740 for_2\IN\1740 15_3\CD\13745420 days_4\NNS\15140892 caused_5\VBD\1617192 <e2>cardiac_6\JJ\1740 hypertrophy</e2>_7\NN\14365950 without_8\IN\1740 affecting_9\VBG\126264 baseline_10\NN\7260623 blood_11\NN\5397468 pressure_12\NN\11419404 and_13\CC\1740 heart_14\NN\5919034 rate_15\NN\13815152 ._16\.\1740
D001971_D007022 CID in_0\IN\13603305 control_1\JJ\1740 rats_2\NNS\2329401 ,_3\,\1740 intravenous_4\JJ\1740 <e1>bromocriptine</e1>_5\NN\1740 (_6\-LRB-\1740 150_7\CD\1740 microg/kg_8\NNS\1740 )_9\-RRB-\1740 induced_10\VBD\1627355 significant_11\JJ\1740 <e2>hypotension</e2>_12\NN\14057371 and_13\CC\1740 tachycardia_14\NN\14110674 ._15\.\1740
D001971_D007022 CID <e1>bromocriptine-induced</e1>_0\JJ\1740 <e2>hypotension</e2>_1\NN\14057371 was_2\VBD\836236 unaffected_3\JJ\1740 by_4\IN\1740 isoproterenol_5\NN\3740161 pretreatment_6\NN\1740 ,_7\,\1740 while_8\IN\15122231 tachycardia_9\NN\14110674 was_10\VBD\836236 reversed_11\VBN\109660 to_12\TO\1740 significant_13\JJ\1740 bradycardia_14\NN\14110674 ,_15\,\1740 an_16\DT\6697703 effect_17\NN\34213 that_18\WDT\1740 was_19\VBD\836236 partly_20\RB\1740 reduced_21\VBN\441445 by_22\IN\1740 i.v._23\NN\1740 domperidone_24\NN\1740 (_25\-LRB-\1740 0.5_26\CD\1740 mg/kg_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D001971_D001919 NONE <e1>bromocriptine-induced</e1>_0\JJ\1740 hypotension_1\NN\14057371 was_2\VBD\836236 unaffected_3\JJ\1740 by_4\IN\1740 isoproterenol_5\NN\3740161 pretreatment_6\NN\1740 ,_7\,\1740 while_8\IN\15122231 tachycardia_9\NN\14110674 was_10\VBD\836236 reversed_11\VBN\109660 to_12\TO\1740 significant_13\JJ\1740 <e2>bradycardia</e2>_14\NN\14110674 ,_15\,\1740 an_16\DT\6697703 effect_17\NN\34213 that_18\WDT\1740 was_19\VBD\836236 partly_20\RB\1740 reduced_21\VBN\441445 by_22\IN\1740 i.v._23\NN\1740 domperidone_24\NN\1740 (_25\-LRB-\1740 0.5_26\CD\1740 mg/kg_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D001971_D001919 NONE these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 15-day_4\JJ\1740 isoproterenol_5\NN\3740161 pretreatment_6\NN\1740 not_7\RB\1740 only_8\RB\1740 abolished_9\VBD\1740 but_10\CC\1740 reversed_11\VBN\109660 <e1>bromocriptine-induced</e1>_12\JJ\1740 tachycardia_13\NN\14110674 to_14\TO\1740 <e2>bradycardia</e2>_15\NN\14110674 ,_16\,\1740 an_17\DT\6697703 effect_18\NN\34213 that_19\WDT\1740 is_20\VBZ\836236 mainly_21\RB\1740 related_22\JJ\1740 to_23\TO\1740 further_24\RB\1740 cardiac_25\JJ\1740 beta-adrenoceptor_26\NN\5608868 desensitization_27\NN\13458571 rather_28\RB\1740 than_29\IN\1740 to_30\TO\1740 impairment_31\NN\7296428 of_32\IN\1740 autonomic_33\JJ\1740 regulation_34\NN\6652242 of_35\IN\1740 the_36\DT\1740 heart_37\NN\5919034 ._38\.\1740
D001971_D001919 NONE they_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 ,_3\,\1740 in_4\IN\13603305 normal_5\JJ\1740 conscious_6\JJ\1740 rats_7\NNS\2329401 ,_8\,\1740 the_9\DT\1740 central_10\JJ\1740 tachycardia_11\NN\14110674 of_12\IN\1740 <e1>bromocriptine</e1>_13\NN\1740 appears_14\VBZ\2604760 to_15\TO\1740 predominate_16\VB\2696801 and_17\CC\1740 to_18\TO\1740 mask_19\VB\2158587 the_20\DT\1740 <e2>bradycardia</e2>_21\NN\14110674 of_22\IN\1740 this_23\DT\1740 agonist_24\NN\9613191 at_25\IN\14622893 peripheral_26\JJ\1740 dopamine_27\NN\14807737 d2_28\NN\1740 receptors_29\NNS\5225602 ._30\.\1740
D007545_D007022 NONE bromocriptine-induced_0\JJ\1740 <e2>hypotension</e2>_1\NN\14057371 was_2\VBD\836236 unaffected_3\JJ\1740 by_4\IN\1740 <e1>isoproterenol</e1>_5\NN\3740161 pretreatment_6\NN\1740 ,_7\,\1740 while_8\IN\15122231 tachycardia_9\NN\14110674 was_10\VBD\836236 reversed_11\VBN\109660 to_12\TO\1740 significant_13\JJ\1740 bradycardia_14\NN\14110674 ,_15\,\1740 an_16\DT\6697703 effect_17\NN\34213 that_18\WDT\1740 was_19\VBD\836236 partly_20\RB\1740 reduced_21\VBN\441445 by_22\IN\1740 i.v._23\NN\1740 domperidone_24\NN\1740 (_25\-LRB-\1740 0.5_26\CD\1740 mg/kg_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D007545_D001919 CID bromocriptine-induced_0\JJ\1740 hypotension_1\NN\14057371 was_2\VBD\836236 unaffected_3\JJ\1740 by_4\IN\1740 <e1>isoproterenol</e1>_5\NN\3740161 pretreatment_6\NN\1740 ,_7\,\1740 while_8\IN\15122231 tachycardia_9\NN\14110674 was_10\VBD\836236 reversed_11\VBN\109660 to_12\TO\1740 significant_13\JJ\1740 <e2>bradycardia</e2>_14\NN\14110674 ,_15\,\1740 an_16\DT\6697703 effect_17\NN\34213 that_18\WDT\1740 was_19\VBD\836236 partly_20\RB\1740 reduced_21\VBN\441445 by_22\IN\1740 i.v._23\NN\1740 domperidone_24\NN\1740 (_25\-LRB-\1740 0.5_26\CD\1740 mg/kg_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D007545_D001919 CID these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 15-day_4\JJ\1740 <e1>isoproterenol</e1>_5\NN\3740161 pretreatment_6\NN\1740 not_7\RB\1740 only_8\RB\1740 abolished_9\VBD\1740 but_10\CC\1740 reversed_11\VBN\109660 bromocriptine-induced_12\JJ\1740 tachycardia_13\NN\14110674 to_14\TO\1740 <e2>bradycardia</e2>_15\NN\14110674 ,_16\,\1740 an_17\DT\6697703 effect_18\NN\34213 that_19\WDT\1740 is_20\VBZ\836236 mainly_21\RB\1740 related_22\JJ\1740 to_23\TO\1740 further_24\RB\1740 cardiac_25\JJ\1740 beta-adrenoceptor_26\NN\5608868 desensitization_27\NN\13458571 rather_28\RB\1740 than_29\IN\1740 to_30\TO\1740 impairment_31\NN\7296428 of_32\IN\1740 autonomic_33\JJ\1740 regulation_34\NN\6652242 of_35\IN\1740 the_36\DT\1740 heart_37\NN\5919034 ._38\.\1740
D004294_D007022 NONE bromocriptine-induced_0\JJ\1740 <e2>hypotension</e2>_1\NN\14057371 was_2\VBD\836236 unaffected_3\JJ\1740 by_4\IN\1740 isoproterenol_5\NN\3740161 pretreatment_6\NN\1740 ,_7\,\1740 while_8\IN\15122231 tachycardia_9\NN\14110674 was_10\VBD\836236 reversed_11\VBN\109660 to_12\TO\1740 significant_13\JJ\1740 bradycardia_14\NN\14110674 ,_15\,\1740 an_16\DT\6697703 effect_17\NN\34213 that_18\WDT\1740 was_19\VBD\836236 partly_20\RB\1740 reduced_21\VBN\441445 by_22\IN\1740 i.v._23\NN\1740 <e1>domperidone</e1>_24\NN\1740 (_25\-LRB-\1740 0.5_26\CD\1740 mg/kg_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D004294_D013610 NONE bromocriptine-induced_0\JJ\1740 hypotension_1\NN\14057371 was_2\VBD\836236 unaffected_3\JJ\1740 by_4\IN\1740 isoproterenol_5\NN\3740161 pretreatment_6\NN\1740 ,_7\,\1740 while_8\IN\15122231 <e2>tachycardia</e2>_9\NN\14110674 was_10\VBD\836236 reversed_11\VBN\109660 to_12\TO\1740 significant_13\JJ\1740 bradycardia_14\NN\14110674 ,_15\,\1740 an_16\DT\6697703 effect_17\NN\34213 that_18\WDT\1740 was_19\VBD\836236 partly_20\RB\1740 reduced_21\VBN\441445 by_22\IN\1740 i.v._23\NN\1740 <e1>domperidone</e1>_24\NN\1740 (_25\-LRB-\1740 0.5_26\CD\1740 mg/kg_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D004294_D001919 CID bromocriptine-induced_0\JJ\1740 hypotension_1\NN\14057371 was_2\VBD\836236 unaffected_3\JJ\1740 by_4\IN\1740 isoproterenol_5\NN\3740161 pretreatment_6\NN\1740 ,_7\,\1740 while_8\IN\15122231 tachycardia_9\NN\14110674 was_10\VBD\836236 reversed_11\VBN\109660 to_12\TO\1740 significant_13\JJ\1740 <e2>bradycardia</e2>_14\NN\14110674 ,_15\,\1740 an_16\DT\6697703 effect_17\NN\34213 that_18\WDT\1740 was_19\VBD\836236 partly_20\RB\1740 reduced_21\VBN\441445 by_22\IN\1740 i.v._23\NN\1740 <e1>domperidone</e1>_24\NN\1740 (_25\-LRB-\1740 0.5_26\CD\1740 mg/kg_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D004298_D001919 NONE they_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 ,_3\,\1740 in_4\IN\13603305 normal_5\JJ\1740 conscious_6\JJ\1740 rats_7\NNS\2329401 ,_8\,\1740 the_9\DT\1740 central_10\JJ\1740 tachycardia_11\NN\14110674 of_12\IN\1740 bromocriptine_13\NN\1740 appears_14\VBZ\2604760 to_15\TO\1740 predominate_16\VB\2696801 and_17\CC\1740 to_18\TO\1740 mask_19\VB\2158587 the_20\DT\1740 <e2>bradycardia</e2>_21\NN\14110674 of_22\IN\1740 this_23\DT\1740 agonist_24\NN\9613191 at_25\IN\14622893 peripheral_26\JJ\1740 <e1>dopamine</e1>_27\NN\14807737 d2_28\NN\1740 receptors_29\NNS\5225602 ._30\.\1740
18754075
D004164_D011507 NONE massive_0\JJ\1740 <e2>proteinuria</e2>_1\NN\14299637 and_2\CC\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 after_6\IN\1740 oral_7\JJ\1740 <e1>bisphosphonate</e1>_8\NN\1740 (_9\-LRB-\1740 alendronate_10\NN\3740161 )_11\-RRB-\1740 administration_12\NN\1133281 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 focal_17\JJ\1740 segmental_18\JJ\1740 glomerulosclerosis_19\NN\1740 ._20\.\1740
D004164_D011507 NONE this_0\DT\1740 report_1\NN\6470073 demonstrates_2\VBZ\2137132 that_3\IN\1740 not_4\RB\1740 only_5\RB\1740 intravenous_6\JJ\1740 ,_7\,\1740 but_8\CC\1740 also_9\RB\1740 oral_10\JJ\1740 <e1>bisphosphonates</e1>_11\NNS\1740 can_12\MD\3094503 aggravate_13\VB\126264 <e2>proteinuria</e2>_14\NN\14299637 and_15\CC\1740 acute_16\JJ\1740 renal_17\JJ\1740 failure_18\NN\66216 ._19\.\1740
D004164_D058186 NONE massive_0\JJ\1740 proteinuria_1\NN\14299637 and_2\CC\1740 <e2>acute_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 after_6\IN\1740 oral_7\JJ\1740 <e1>bisphosphonate</e1>_8\NN\1740 (_9\-LRB-\1740 alendronate_10\NN\3740161 )_11\-RRB-\1740 administration_12\NN\1133281 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 focal_17\JJ\1740 segmental_18\JJ\1740 glomerulosclerosis_19\NN\1740 ._20\.\1740
D004164_D058186 NONE the_0\DT\1740 amount_1\NN\13329641 of_2\IN\1740 daily_3\JJ\1740 urinary_4\JJ\1740 protein_5\NN\14944888 decreased_6\VBD\169651 from_7\IN\1740 15.6_8\CD\1740 to_9\TO\1740 2.8_10\CD\1740 g._11\NN\1740 within_12\IN\1740 14_13\CD\13745420 days_14\NNS\15140892 of_15\IN\1740 the_16\DT\1740 oral_17\JJ\1740 <e1>bisphosphonate</e1>_18\NN\1740 (_19\-LRB-\1740 alendronate_20\NN\3740161 sodium_21\NN\14625458 )_22\-RRB-\1740 administration_23\NN\1133281 ,_24\,\1740 the_25\DT\1740 amount_26\NN\13329641 of_27\IN\1740 daily_28\JJ\1740 urinary_29\JJ\1740 protein_30\NN\14944888 increased_31\VBD\169651 rapidly_32\RB\1740 up_33\RB\1740 to_34\TO\1740 12.8_35\CD\1740 g_36\NN\13717155 with_37\IN\1740 <e2>acute_38\JJ\1740 renal_39\JJ\1740 failure</e2>_40\NN\66216 ._41\.\1740
D004164_D058186 NONE this_0\DT\1740 report_1\NN\6470073 demonstrates_2\VBZ\2137132 that_3\IN\1740 not_4\RB\1740 only_5\RB\1740 intravenous_6\JJ\1740 ,_7\,\1740 but_8\CC\1740 also_9\RB\1740 oral_10\JJ\1740 <e1>bisphosphonates</e1>_11\NNS\1740 can_12\MD\3094503 aggravate_13\VB\126264 proteinuria_14\NN\14299637 and_15\CC\1740 <e2>acute_16\JJ\1740 renal_17\JJ\1740 failure</e2>_18\NN\66216 ._19\.\1740
D004164_D005923 NONE massive_0\JJ\1740 proteinuria_1\NN\14299637 and_2\CC\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 after_6\IN\1740 oral_7\JJ\1740 <e1>bisphosphonate</e1>_8\NN\1740 (_9\-LRB-\1740 alendronate_10\NN\3740161 )_11\-RRB-\1740 administration_12\NN\1133281 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 <e2>focal_17\JJ\1740 segmental_18\JJ\1740 glomerulosclerosis</e2>_19\NN\1740 ._20\.\1740
D019386_D011507 CID massive_0\JJ\1740 <e2>proteinuria</e2>_1\NN\14299637 and_2\CC\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 after_6\IN\1740 oral_7\JJ\1740 bisphosphonate_8\NN\1740 (_9\-LRB-\1740 <e1>alendronate</e1>_10\NN\3740161 )_11\-RRB-\1740 administration_12\NN\1133281 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 focal_17\JJ\1740 segmental_18\JJ\1740 glomerulosclerosis_19\NN\1740 ._20\.\1740
D019386_D058186 CID massive_0\JJ\1740 proteinuria_1\NN\14299637 and_2\CC\1740 <e2>acute_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 after_6\IN\1740 oral_7\JJ\1740 bisphosphonate_8\NN\1740 (_9\-LRB-\1740 <e1>alendronate</e1>_10\NN\3740161 )_11\-RRB-\1740 administration_12\NN\1133281 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 focal_17\JJ\1740 segmental_18\JJ\1740 glomerulosclerosis_19\NN\1740 ._20\.\1740
D019386_D058186 CID the_0\DT\1740 amount_1\NN\13329641 of_2\IN\1740 daily_3\JJ\1740 urinary_4\JJ\1740 protein_5\NN\14944888 decreased_6\VBD\169651 from_7\IN\1740 15.6_8\CD\1740 to_9\TO\1740 2.8_10\CD\1740 g._11\NN\1740 within_12\IN\1740 14_13\CD\13745420 days_14\NNS\15140892 of_15\IN\1740 the_16\DT\1740 oral_17\JJ\1740 bisphosphonate_18\NN\1740 (_19\-LRB-\1740 <e1>alendronate_20\NN\3740161 sodium</e1>_21\NN\14625458 )_22\-RRB-\1740 administration_23\NN\1133281 ,_24\,\1740 the_25\DT\1740 amount_26\NN\13329641 of_27\IN\1740 daily_28\JJ\1740 urinary_29\JJ\1740 protein_30\NN\14944888 increased_31\VBD\169651 rapidly_32\RB\1740 up_33\RB\1740 to_34\TO\1740 12.8_35\CD\1740 g_36\NN\13717155 with_37\IN\1740 <e2>acute_38\JJ\1740 renal_39\JJ\1740 failure</e2>_40\NN\66216 ._41\.\1740
D019386_D005923 NONE massive_0\JJ\1740 proteinuria_1\NN\14299637 and_2\CC\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 after_6\IN\1740 oral_7\JJ\1740 bisphosphonate_8\NN\1740 (_9\-LRB-\1740 <e1>alendronate</e1>_10\NN\3740161 )_11\-RRB-\1740 administration_12\NN\1133281 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 <e2>focal_17\JJ\1740 segmental_18\JJ\1740 glomerulosclerosis</e2>_19\NN\1740 ._20\.\1740
D013256_D009404 NONE a_0\DT\13649268 61-year-old_1\JJ\1740 japanese_2\JJ\1740 man_3\NN\9605289 with_4\IN\1740 <e2>nephrotic_5\JJ\1740 syndrome</e2>_6\NN\5870365 due_7\JJ\1740 to_8\TO\1740 focal_9\JJ\1740 segmental_10\JJ\1740 glomerulosclerosis_11\NN\1740 was_12\VBD\836236 initially_13\RB\1740 responding_14\VBG\2367363 well_15\RB\1740 to_16\TO\1740 <e1>steroid</e1>_17\NN\14727670 therapy_18\NN\657604 ._19\.\1740
D013256_D005923 NONE a_0\DT\13649268 61-year-old_1\JJ\1740 japanese_2\JJ\1740 man_3\NN\9605289 with_4\IN\1740 nephrotic_5\JJ\1740 syndrome_6\NN\5870365 due_7\JJ\1740 to_8\TO\1740 <e2>focal_9\JJ\1740 segmental_10\JJ\1740 glomerulosclerosis</e2>_11\NN\1740 was_12\VBD\836236 initially_13\RB\1740 responding_14\VBG\2367363 well_15\RB\1740 to_16\TO\1740 <e1>steroid</e1>_17\NN\14727670 therapy_18\NN\657604 ._19\.\1740
6747681
D002330_D005910 NONE intra-arterial_0\JJ\1740 <e1>bcnu</e1>_1\NNS\1740 chemotherapy_2\NN\661091 for_3\IN\1740 treatment_4\NN\654885 of_5\IN\1740 <e2>malignant_6\JJ\1740 gliomas</e2>_7\NNS\14236743 of_8\IN\1740 the_9\DT\1740 central_10\JJ\1740 nervous_11\JJ\1740 system_12\NN\3575240 ._13\.\1740
D002330_D005910 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 rapid_3\JJ\1740 systemic_4\JJ\1740 clearance_5\NN\5089947 of_6\IN\1740 <e1>bcnu</e1>_7\NN\1740 (_8\-LRB-\1740 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 intra-arterial_12\JJ\1740 administration_13\NN\1133281 should_14\MD\1740 provide_15\VB\2199590 a_16\DT\13649268 substantial_17\JJ\1740 advantage_18\NN\5154517 over_19\IN\5867413 intravenous_20\JJ\1740 administration_21\NN\1133281 for_22\IN\1740 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 <e2>malignant_26\JJ\1740 gliomas</e2>_27\NNS\14236743 ._28\.\1740
D002330_D005910 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 rapid_3\JJ\1740 systemic_4\JJ\1740 clearance_5\NN\5089947 of_6\IN\1740 bcnu_7\NN\1740 (_8\-LRB-\1740 <e1>1,3-bis-(2-chloroethyl)-1-nitrosourea</e1>_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 intra-arterial_12\JJ\1740 administration_13\NN\1133281 should_14\MD\1740 provide_15\VB\2199590 a_16\DT\13649268 substantial_17\JJ\1740 advantage_18\NN\5154517 over_19\IN\5867413 intravenous_20\JJ\1740 administration_21\NN\1133281 for_22\IN\1740 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 <e2>malignant_26\JJ\1740 gliomas</e2>_27\NNS\14236743 ._28\.\1740
D002330_D001254 NONE twenty-four_0\CD\13745420 patients_1\NNS\9898892 with_2\IN\1740 recurrent_3\JJ\1740 grade_4\NNP\7975026 i_5\CD\14622893 to_6\TO\1740 iv_7\CD\13741022 <e2>astrocytomas</e2>_8\NNS\1740 ,_9\,\1740 whose_10\WP$\1740 resection_11\NN\671351 and_12\CC\1740 irradiation_13\NN\13920835 therapy_14\NN\657604 had_15\VBD\2108377 failed_16\VBN\1798936 ,_17\,\1740 received_18\VBD\2210855 two_19\CD\13741022 to_20\TO\1740 eight_21\CD\13741022 courses_22\NNS\883297 of_23\IN\1740 intra-arterial_24\JJ\1740 <e1>bcnu</e1>_25\NN\1740 therapy_26\NN\657604 ._27\.\1740
D000431_D014786 NONE the_0\DT\1740 frequency_1\NN\15286249 of_2\IN\1740 <e2>visual_3\JJ\1740 loss</e2>_4\NN\13252973 decreased_5\VBD\169651 after_6\IN\1740 the_7\DT\1740 concentration_8\NN\4916342 of_9\IN\1740 the_10\DT\1740 <e1>ethanol</e1>_11\NN\14708720 diluent_12\NN\14778436 was_13\VBD\836236 lowered_14\VBN\1850315 ._15\.\1740
2522601
D002220_D004342 CID <e2>hypersensitivity</e2>_0\NN\14531772 to_1\TO\1740 <e1>carbamazepine</e1>_2\VB\1740 presenting_3\NN\1740 with_4\IN\1740 a_5\DT\13649268 leukemoid_6\JJ\1740 reaction_7\NN\13446390 ,_8\,\1740 eosinophilia_9\NN\14299637 ,_10\,\1740 erythroderma_11\NN\14219661 ,_12\,\1740 and_13\CC\1740 renal_14\JJ\1740 failure_15\NN\66216 ._16\.\1740
D002220_D004342 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 patient_3\NN\9898892 in_4\IN\13603305 whom_5\WP\1740 <e2>hypersensitivity</e2>_6\NN\14531772 to_7\TO\1740 <e1>carbamazepine</e1>_8\NN\1740 presented_9\VBN\2137132 with_10\IN\1740 generalized_11\JJ\1740 erythroderma_12\NN\14219661 ,_13\,\1740 a_14\DT\13649268 severe_15\JJ\1740 leukemoid_16\JJ\1740 reaction_17\NN\13446390 ,_18\,\1740 eosinophilia_19\NN\14299637 ,_20\,\1740 hyponatremia_21\NN\14299637 ,_22\,\1740 and_23\CC\1740 renal_24\JJ\1740 failure_25\NN\66216 ._26\.\1740
D002220_D007955 CID hypersensitivity_0\NN\14531772 to_1\TO\1740 <e1>carbamazepine</e1>_2\VB\1740 presenting_3\NN\1740 with_4\IN\1740 a_5\DT\13649268 <e2>leukemoid_6\JJ\1740 reaction</e2>_7\NN\13446390 ,_8\,\1740 eosinophilia_9\NN\14299637 ,_10\,\1740 erythroderma_11\NN\14219661 ,_12\,\1740 and_13\CC\1740 renal_14\JJ\1740 failure_15\NN\66216 ._16\.\1740
D002220_D007955 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 patient_3\NN\9898892 in_4\IN\13603305 whom_5\WP\1740 hypersensitivity_6\NN\14531772 to_7\TO\1740 <e1>carbamazepine</e1>_8\NN\1740 presented_9\VBN\2137132 with_10\IN\1740 generalized_11\JJ\1740 erythroderma_12\NN\14219661 ,_13\,\1740 a_14\DT\13649268 severe_15\JJ\1740 <e2>leukemoid_16\JJ\1740 reaction</e2>_17\NN\13446390 ,_18\,\1740 eosinophilia_19\NN\14299637 ,_20\,\1740 hyponatremia_21\NN\14299637 ,_22\,\1740 and_23\CC\1740 renal_24\JJ\1740 failure_25\NN\66216 ._26\.\1740
D002220_D004802 NONE hypersensitivity_0\NN\14531772 to_1\TO\1740 <e1>carbamazepine</e1>_2\VB\1740 presenting_3\NN\1740 with_4\IN\1740 a_5\DT\13649268 leukemoid_6\JJ\1740 reaction_7\NN\13446390 ,_8\,\1740 <e2>eosinophilia</e2>_9\NN\14299637 ,_10\,\1740 erythroderma_11\NN\14219661 ,_12\,\1740 and_13\CC\1740 renal_14\JJ\1740 failure_15\NN\66216 ._16\.\1740
D002220_D004802 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 patient_3\NN\9898892 in_4\IN\13603305 whom_5\WP\1740 hypersensitivity_6\NN\14531772 to_7\TO\1740 <e1>carbamazepine</e1>_8\NN\1740 presented_9\VBN\2137132 with_10\IN\1740 generalized_11\JJ\1740 erythroderma_12\NN\14219661 ,_13\,\1740 a_14\DT\13649268 severe_15\JJ\1740 leukemoid_16\JJ\1740 reaction_17\NN\13446390 ,_18\,\1740 <e2>eosinophilia</e2>_19\NN\14299637 ,_20\,\1740 hyponatremia_21\NN\14299637 ,_22\,\1740 and_23\CC\1740 renal_24\JJ\1740 failure_25\NN\66216 ._26\.\1740
D002220_D003873 CID hypersensitivity_0\NN\14531772 to_1\TO\1740 <e1>carbamazepine</e1>_2\VB\1740 presenting_3\NN\1740 with_4\IN\1740 a_5\DT\13649268 leukemoid_6\JJ\1740 reaction_7\NN\13446390 ,_8\,\1740 eosinophilia_9\NN\14299637 ,_10\,\1740 <e2>erythroderma</e2>_11\NN\14219661 ,_12\,\1740 and_13\CC\1740 renal_14\JJ\1740 failure_15\NN\66216 ._16\.\1740
D002220_D003873 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 patient_3\NN\9898892 in_4\IN\13603305 whom_5\WP\1740 hypersensitivity_6\NN\14531772 to_7\TO\1740 <e1>carbamazepine</e1>_8\NN\1740 presented_9\VBN\2137132 with_10\IN\1740 generalized_11\JJ\1740 <e2>erythroderma</e2>_12\NN\14219661 ,_13\,\1740 a_14\DT\13649268 severe_15\JJ\1740 leukemoid_16\JJ\1740 reaction_17\NN\13446390 ,_18\,\1740 eosinophilia_19\NN\14299637 ,_20\,\1740 hyponatremia_21\NN\14299637 ,_22\,\1740 and_23\CC\1740 renal_24\JJ\1740 failure_25\NN\66216 ._26\.\1740
D002220_D051437 CID hypersensitivity_0\NN\14531772 to_1\TO\1740 <e1>carbamazepine</e1>_2\VB\1740 presenting_3\NN\1740 with_4\IN\1740 a_5\DT\13649268 leukemoid_6\JJ\1740 reaction_7\NN\13446390 ,_8\,\1740 eosinophilia_9\NN\14299637 ,_10\,\1740 erythroderma_11\NN\14219661 ,_12\,\1740 and_13\CC\1740 <e2>renal_14\JJ\1740 failure</e2>_15\NN\66216 ._16\.\1740
D002220_D051437 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 patient_3\NN\9898892 in_4\IN\13603305 whom_5\WP\1740 hypersensitivity_6\NN\14531772 to_7\TO\1740 <e1>carbamazepine</e1>_8\NN\1740 presented_9\VBN\2137132 with_10\IN\1740 generalized_11\JJ\1740 erythroderma_12\NN\14219661 ,_13\,\1740 a_14\DT\13649268 severe_15\JJ\1740 leukemoid_16\JJ\1740 reaction_17\NN\13446390 ,_18\,\1740 eosinophilia_19\NN\14299637 ,_20\,\1740 hyponatremia_21\NN\14299637 ,_22\,\1740 and_23\CC\1740 <e2>renal_24\JJ\1740 failure</e2>_25\NN\66216 ._26\.\1740
D002220_D007010 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 patient_3\NN\9898892 in_4\IN\13603305 whom_5\WP\1740 hypersensitivity_6\NN\14531772 to_7\TO\1740 <e1>carbamazepine</e1>_8\NN\1740 presented_9\VBN\2137132 with_10\IN\1740 generalized_11\JJ\1740 erythroderma_12\NN\14219661 ,_13\,\1740 a_14\DT\13649268 severe_15\JJ\1740 leukemoid_16\JJ\1740 reaction_17\NN\13446390 ,_18\,\1740 eosinophilia_19\NN\14299637 ,_20\,\1740 <e2>hyponatremia</e2>_21\NN\14299637 ,_22\,\1740 and_23\CC\1740 renal_24\JJ\1740 failure_25\NN\66216 ._26\.\1740
11426838
-1_D012640 NONE in_0\IN\13603305 behavioral_1\JJ\1740 studies_2\NNS\635850 ,_3\,\1740 pre-treatment_4\NN\1740 of_5\IN\1740 mice_6\NNS\2329401 with_7\IN\1740 <e1>bd1018</e1>_8\NN\1740 ,_9\,\1740 bd1063_10\NN\1740 ,_11\,\1740 or_12\CC\3541091 lr132_13\NN\1740 significantly_14\RB\1740 attenuated_15\VBD\224901 cocaine-induced_16\JJ\1740 <e2>convulsions</e2>_17\NNS\14081375 and_18\CC\1740 lethality_19\NN\4790449 ._20\.\1740
-1_D012640 NONE in_0\IN\13603305 behavioral_1\JJ\1740 studies_2\NNS\635850 ,_3\,\1740 pre-treatment_4\NN\1740 of_5\IN\1740 mice_6\NNS\2329401 with_7\IN\1740 bd1018_8\NN\1740 ,_9\,\1740 bd1063_10\NN\1740 ,_11\,\1740 or_12\CC\3541091 <e1>lr132</e1>_13\NN\1740 significantly_14\RB\1740 attenuated_15\VBD\224901 cocaine-induced_16\JJ\1740 <e2>convulsions</e2>_17\NNS\14081375 and_18\CC\1740 lethality_19\NN\4790449 ._20\.\1740
C093337_D012640 NONE in_0\IN\13603305 behavioral_1\JJ\1740 studies_2\NNS\635850 ,_3\,\1740 pre-treatment_4\NN\1740 of_5\IN\1740 mice_6\NNS\2329401 with_7\IN\1740 bd1018_8\NN\1740 ,_9\,\1740 <e1>bd1063</e1>_10\NN\1740 ,_11\,\1740 or_12\CC\3541091 lr132_13\NN\1740 significantly_14\RB\1740 attenuated_15\VBD\224901 cocaine-induced_16\JJ\1740 <e2>convulsions</e2>_17\NNS\14081375 and_18\CC\1740 lethality_19\NN\4790449 ._20\.\1740
D003042_D012640 CID in_0\IN\13603305 behavioral_1\JJ\1740 studies_2\NNS\635850 ,_3\,\1740 pre-treatment_4\NN\1740 of_5\IN\1740 mice_6\NNS\2329401 with_7\IN\1740 bd1018_8\NN\1740 ,_9\,\1740 bd1063_10\NN\1740 ,_11\,\1740 or_12\CC\3541091 lr132_13\NN\1740 significantly_14\RB\1740 attenuated_15\VBD\224901 <e1>cocaine-induced</e1>_16\JJ\1740 <e2>convulsions</e2>_17\NNS\14081375 and_18\CC\1740 lethality_19\NN\4790449 ._20\.\1740
D003042_D012640 CID to_0\TO\1740 further_1\RB\1740 validate_2\VB\803325 the_3\DT\1740 hypothesis_4\NN\7162194 that_5\IN\1740 the_6\DT\1740 <e1>anti-cocaine</e1>_7\JJ\1740 effects_8\NNS\13245626 of_9\IN\1740 the_10\DT\1740 novel_11\JJ\1740 ligands_12\NNS\20090 involved_13\VBD\2676054 antagonism_14\NN\24720 of_15\IN\1740 sigma_16\NN\6828818 receptors_17\NNS\5225602 ,_18\,\1740 an_19\DT\6697703 antisense_20\JJ\1740 oligodeoxynucleotide_21\NN\1740 against_22\IN\1740 sigma1_23\CD\1740 receptors_24\NNS\5225602 was_25\VBD\836236 also_26\RB\1740 shown_27\VBN\2137132 to_28\TO\1740 significantly_29\RB\1740 attenuate_30\VB\224901 the_31\DT\1740 <e2>convulsive</e2>_32\JJ\1740 and_33\CC\1740 locomotor_34\NN\1740 stimulatory_35\JJ\1740 effects_36\NNS\13245626 of_37\IN\1740 cocaine_38\NN\3492717 ._39\.\1740
D003042_D012640 CID to_0\TO\1740 further_1\RB\1740 validate_2\VB\803325 the_3\DT\1740 hypothesis_4\NN\7162194 that_5\IN\1740 the_6\DT\1740 anti-cocaine_7\JJ\1740 effects_8\NNS\13245626 of_9\IN\1740 the_10\DT\1740 novel_11\JJ\1740 ligands_12\NNS\20090 involved_13\VBD\2676054 antagonism_14\NN\24720 of_15\IN\1740 sigma_16\NN\6828818 receptors_17\NNS\5225602 ,_18\,\1740 an_19\DT\6697703 antisense_20\JJ\1740 oligodeoxynucleotide_21\NN\1740 against_22\IN\1740 sigma1_23\CD\1740 receptors_24\NNS\5225602 was_25\VBD\836236 also_26\RB\1740 shown_27\VBN\2137132 to_28\TO\1740 significantly_29\RB\1740 attenuate_30\VB\224901 the_31\DT\1740 <e2>convulsive</e2>_32\JJ\1740 and_33\CC\1740 locomotor_34\NN\1740 stimulatory_35\JJ\1740 effects_36\NNS\13245626 of_37\IN\1740 <e1>cocaine</e1>_38\NN\3492717 ._39\.\1740
C050232_D064420 NONE in_0\IN\13603305 contrast_1\NN\13854649 to_2\TO\1740 the_3\DT\1740 protection_4\NN\407535 provided_5\VBN\2199590 by_6\IN\1740 the_7\DT\1740 putative_8\JJ\1740 antagonists_9\NNS\7846 ,_10\,\1740 the_11\DT\1740 well-characterized_12\JJ\1740 sigma_13\NN\6828818 receptor_14\NN\5225602 agonist_15\NN\9613191 <e1>di-o-tolylguanidine</e1>_16\NN\1740 (_17\-LRB-\1740 dtg_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 the_21\DT\1740 novel_22\JJ\1740 sigma_23\NN\6828818 receptor_24\NN\5225602 agonist_25\NN\9613191 bd1031_26\NN\1740 (_27\-LRB-\1740 3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_28\NN\1740 )_29\-RRB-\1740 each_30\DT\1740 worsened_31\VBD\146138 the_32\DT\1740 behavioral_33\JJ\1740 <e2>toxicity</e2>_34\NN\13576101 of_35\IN\1740 cocaine_36\NN\3492717 ._37\.\1740
C050232_D064420 NONE in_0\IN\13603305 contrast_1\NN\13854649 to_2\TO\1740 the_3\DT\1740 protection_4\NN\407535 provided_5\VBN\2199590 by_6\IN\1740 the_7\DT\1740 putative_8\JJ\1740 antagonists_9\NNS\7846 ,_10\,\1740 the_11\DT\1740 well-characterized_12\JJ\1740 sigma_13\NN\6828818 receptor_14\NN\5225602 agonist_15\NN\9613191 di-o-tolylguanidine_16\NN\1740 (_17\-LRB-\1740 <e1>dtg</e1>_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 the_21\DT\1740 novel_22\JJ\1740 sigma_23\NN\6828818 receptor_24\NN\5225602 agonist_25\NN\9613191 bd1031_26\NN\1740 (_27\-LRB-\1740 3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_28\NN\1740 )_29\-RRB-\1740 each_30\DT\1740 worsened_31\VBD\146138 the_32\DT\1740 behavioral_33\JJ\1740 <e2>toxicity</e2>_34\NN\13576101 of_35\IN\1740 cocaine_36\NN\3492717 ._37\.\1740
-1_D064420 NONE in_0\IN\13603305 contrast_1\NN\13854649 to_2\TO\1740 the_3\DT\1740 protection_4\NN\407535 provided_5\VBN\2199590 by_6\IN\1740 the_7\DT\1740 putative_8\JJ\1740 antagonists_9\NNS\7846 ,_10\,\1740 the_11\DT\1740 well-characterized_12\JJ\1740 sigma_13\NN\6828818 receptor_14\NN\5225602 agonist_15\NN\9613191 di-o-tolylguanidine_16\NN\1740 (_17\-LRB-\1740 dtg_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 the_21\DT\1740 novel_22\JJ\1740 sigma_23\NN\6828818 receptor_24\NN\5225602 agonist_25\NN\9613191 <e1>bd1031</e1>_26\NN\1740 (_27\-LRB-\1740 3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_28\NN\1740 )_29\-RRB-\1740 each_30\DT\1740 worsened_31\VBD\146138 the_32\DT\1740 behavioral_33\JJ\1740 <e2>toxicity</e2>_34\NN\13576101 of_35\IN\1740 cocaine_36\NN\3492717 ._37\.\1740
-1_D064420 NONE in_0\IN\13603305 contrast_1\NN\13854649 to_2\TO\1740 the_3\DT\1740 protection_4\NN\407535 provided_5\VBN\2199590 by_6\IN\1740 the_7\DT\1740 putative_8\JJ\1740 antagonists_9\NNS\7846 ,_10\,\1740 the_11\DT\1740 well-characterized_12\JJ\1740 sigma_13\NN\6828818 receptor_14\NN\5225602 agonist_15\NN\9613191 di-o-tolylguanidine_16\NN\1740 (_17\-LRB-\1740 dtg_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 the_21\DT\1740 novel_22\JJ\1740 sigma_23\NN\6828818 receptor_24\NN\5225602 agonist_25\NN\9613191 bd1031_26\NN\1740 (_27\-LRB-\1740 <e1>3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane</e1>_28\NN\1740 )_29\-RRB-\1740 each_30\DT\1740 worsened_31\VBD\146138 the_32\DT\1740 behavioral_33\JJ\1740 <e2>toxicity</e2>_34\NN\13576101 of_35\IN\1740 cocaine_36\NN\3492717 ._37\.\1740
D003042_D064420 NONE in_0\IN\13603305 contrast_1\NN\13854649 to_2\TO\1740 the_3\DT\1740 protection_4\NN\407535 provided_5\VBN\2199590 by_6\IN\1740 the_7\DT\1740 putative_8\JJ\1740 antagonists_9\NNS\7846 ,_10\,\1740 the_11\DT\1740 well-characterized_12\JJ\1740 sigma_13\NN\6828818 receptor_14\NN\5225602 agonist_15\NN\9613191 di-o-tolylguanidine_16\NN\1740 (_17\-LRB-\1740 dtg_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 the_21\DT\1740 novel_22\JJ\1740 sigma_23\NN\6828818 receptor_24\NN\5225602 agonist_25\NN\9613191 bd1031_26\NN\1740 (_27\-LRB-\1740 3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_28\NN\1740 )_29\-RRB-\1740 each_30\DT\1740 worsened_31\VBD\146138 the_32\DT\1740 behavioral_33\JJ\1740 <e2>toxicity</e2>_34\NN\13576101 of_35\IN\1740 <e1>cocaine</e1>_36\NN\3492717 ._37\.\1740
D009838_D012640 NONE to_0\TO\1740 further_1\RB\1740 validate_2\VB\803325 the_3\DT\1740 hypothesis_4\NN\7162194 that_5\IN\1740 the_6\DT\1740 anti-cocaine_7\JJ\1740 effects_8\NNS\13245626 of_9\IN\1740 the_10\DT\1740 novel_11\JJ\1740 ligands_12\NNS\20090 involved_13\VBD\2676054 antagonism_14\NN\24720 of_15\IN\1740 sigma_16\NN\6828818 receptors_17\NNS\5225602 ,_18\,\1740 an_19\DT\6697703 antisense_20\JJ\1740 <e1>oligodeoxynucleotide</e1>_21\NN\1740 against_22\IN\1740 sigma1_23\CD\1740 receptors_24\NNS\5225602 was_25\VBD\836236 also_26\RB\1740 shown_27\VBN\2137132 to_28\TO\1740 significantly_29\RB\1740 attenuate_30\VB\224901 the_31\DT\1740 <e2>convulsive</e2>_32\JJ\1740 and_33\CC\1740 locomotor_34\NN\1740 stimulatory_35\JJ\1740 effects_36\NNS\13245626 of_37\IN\1740 cocaine_38\NN\3492717 ._39\.\1740
19957053
D010656_D002534 CID <e1>phenylephrine</e1>_0\NNP\2682038 but_1\CC\1740 not_2\RB\1740 ephedrine_3\NN\14712692 <e2>reduces_4\VBZ\441445 frontal_5\JJ\1740 lobe_6\JJ\1740 oxygenation</e2>_7\NN\13518963 following_8\VBG\1835496 anesthesia-induced_9\JJ\1740 hypotension_10\NN\14057371 ._11\.\1740
D010656_D007022 NONE <e1>phenylephrine</e1>_0\NNP\2682038 but_1\CC\1740 not_2\RB\1740 ephedrine_3\NN\14712692 reduces_4\VBZ\441445 frontal_5\JJ\1740 lobe_6\JJ\1740 oxygenation_7\NN\13518963 following_8\VBG\1835496 anesthesia-induced_9\JJ\1740 <e2>hypotension</e2>_10\NN\14057371 ._11\.\1740
D010656_D007022 NONE we_0\PRP\1740 describe_1\VBP\1001294 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 <e1>phenylephrine</e1>_5\NN\2682038 and_6\CC\1740 ephedrine_7\NN\14712692 on_8\IN\1740 frontal_9\JJ\1740 lobe_10\JJ\1740 oxygenation_11\NN\13518963 (_12\-LRB-\1740 s(c)o(2_13\NN\1740 )_14\-RRB-\1740 )_15\-RRB-\1740 following_16\VBG\1835496 anesthesia-induced_17\JJ\1740 <e2>hypotension</e2>_18\NN\14057371 ._19\.\1740
D010656_D007022 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 utilization_3\NN\407535 of_4\IN\1740 <e1>phenylephrine</e1>_5\NN\2682038 to_6\TO\1740 correct_7\VB\138508 <e2>hypotension</e2>_8\NN\14057371 induced_9\VBN\1627355 by_10\IN\1740 anesthesia_11\NN\14034177 has_12\VBZ\2108377 a_13\DT\13649268 negative_14\JJ\1740 impact_15\NN\7339329 on_16\IN\1740 s(c)o(2_17\NN\1740 )_18\-RRB-\1740 while_19\IN\15122231 ephedrine_20\NN\14712692 maintains_21\VBZ\2202928 frontal_22\JJ\1740 lobe_23\VBD\1740 oxygenation_24\NN\13518963 potentially_25\RB\1740 related_26\JJ\1740 to_27\TO\1740 an_28\DT\6697703 increase_29\NN\13576355 in_30\IN\13603305 co_31\NN\14954601 ._32\.\1740
D004809_D002534 NONE phenylephrine_0\NNP\2682038 but_1\CC\1740 not_2\RB\1740 <e1>ephedrine</e1>_3\NN\14712692 <e2>reduces_4\VBZ\441445 frontal_5\JJ\1740 lobe_6\JJ\1740 oxygenation</e2>_7\NN\13518963 following_8\VBG\1835496 anesthesia-induced_9\JJ\1740 hypotension_10\NN\14057371 ._11\.\1740
D004809_D007022 NONE phenylephrine_0\NNP\2682038 but_1\CC\1740 not_2\RB\1740 <e1>ephedrine</e1>_3\NN\14712692 reduces_4\VBZ\441445 frontal_5\JJ\1740 lobe_6\JJ\1740 oxygenation_7\NN\13518963 following_8\VBG\1835496 anesthesia-induced_9\JJ\1740 <e2>hypotension</e2>_10\NN\14057371 ._11\.\1740
D004809_D007022 NONE we_0\PRP\1740 describe_1\VBP\1001294 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 phenylephrine_5\NN\2682038 and_6\CC\1740 <e1>ephedrine</e1>_7\NN\14712692 on_8\IN\1740 frontal_9\JJ\1740 lobe_10\JJ\1740 oxygenation_11\NN\13518963 (_12\-LRB-\1740 s(c)o(2_13\NN\1740 )_14\-RRB-\1740 )_15\-RRB-\1740 following_16\VBG\1835496 anesthesia-induced_17\JJ\1740 <e2>hypotension</e2>_18\NN\14057371 ._19\.\1740
D004809_D007022 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 utilization_3\NN\407535 of_4\IN\1740 phenylephrine_5\NN\2682038 to_6\TO\1740 correct_7\VB\138508 <e2>hypotension</e2>_8\NN\14057371 induced_9\VBN\1627355 by_10\IN\1740 anesthesia_11\NN\14034177 has_12\VBZ\2108377 a_13\DT\13649268 negative_14\JJ\1740 impact_15\NN\7339329 on_16\IN\1740 s(c)o(2_17\NN\1740 )_18\-RRB-\1740 while_19\IN\15122231 <e1>ephedrine</e1>_20\NN\14712692 maintains_21\VBZ\2202928 frontal_22\JJ\1740 lobe_23\VBD\1740 oxygenation_24\NN\13518963 potentially_25\RB\1740 related_26\JJ\1740 to_27\TO\1740 an_28\DT\6697703 increase_29\NN\13576355 in_30\IN\13603305 co_31\NN\14954601 ._32\.\1740
12684739
D020888_D019966 NONE objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 <e2>substance_8\NN\20827 abuse</e2>_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 visual_15\JJ\1740 field_16\NN\8673395 defects_17\NNS\14462666 (_18\-LRB-\1740 vfd_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 <e1>gvg</e1>_35\NN\1740 on_36\IN\1740 cocaine-induced_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 dopamine_45\NN\14807737 (_46\-LRB-\1740 da_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
D020888_D005128 CID objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 substance_8\NN\20827 abuse_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 <e2>visual_15\JJ\1740 field_16\NN\8673395 defects</e2>_17\NNS\14462666 (_18\-LRB-\1740 vfd_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 <e1>gvg</e1>_35\NN\1740 on_36\IN\1740 cocaine-induced_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 dopamine_45\NN\14807737 (_46\-LRB-\1740 da_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
D020888_D005128 CID objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 substance_8\NN\20827 abuse_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 visual_15\JJ\1740 field_16\NN\8673395 defects_17\NNS\14462666 (_18\-LRB-\1740 <e2>vfd</e2>_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 <e1>gvg</e1>_35\NN\1740 on_36\IN\1740 cocaine-induced_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 dopamine_45\NN\14807737 (_46\-LRB-\1740 da_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
D003042_D019966 NONE objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 <e2>substance_8\NN\20827 abuse</e2>_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 visual_15\JJ\1740 field_16\NN\8673395 defects_17\NNS\14462666 (_18\-LRB-\1740 vfd_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 gvg_35\NN\1740 on_36\IN\1740 <e1>cocaine-induced</e1>_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 dopamine_45\NN\14807737 (_46\-LRB-\1740 da_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
D003042_D005128 NONE objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 substance_8\NN\20827 abuse_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 <e2>visual_15\JJ\1740 field_16\NN\8673395 defects</e2>_17\NNS\14462666 (_18\-LRB-\1740 vfd_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 gvg_35\NN\1740 on_36\IN\1740 <e1>cocaine-induced</e1>_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 dopamine_45\NN\14807737 (_46\-LRB-\1740 da_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
D003042_D005128 NONE objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 substance_8\NN\20827 abuse_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 visual_15\JJ\1740 field_16\NN\8673395 defects_17\NNS\14462666 (_18\-LRB-\1740 <e2>vfd</e2>_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 gvg_35\NN\1740 on_36\IN\1740 <e1>cocaine-induced</e1>_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 dopamine_45\NN\14807737 (_46\-LRB-\1740 da_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
D004298_D019966 NONE objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 <e2>substance_8\NN\20827 abuse</e2>_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 visual_15\JJ\1740 field_16\NN\8673395 defects_17\NNS\14462666 (_18\-LRB-\1740 vfd_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 gvg_35\NN\1740 on_36\IN\1740 cocaine-induced_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 <e1>dopamine</e1>_45\NN\14807737 (_46\-LRB-\1740 da_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
D004298_D019966 NONE objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 <e2>substance_8\NN\20827 abuse</e2>_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 visual_15\JJ\1740 field_16\NN\8673395 defects_17\NNS\14462666 (_18\-LRB-\1740 vfd_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 gvg_35\NN\1740 on_36\IN\1740 cocaine-induced_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 dopamine_45\NN\14807737 (_46\-LRB-\1740 <e1>da</e1>_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
D004298_D005128 NONE objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 substance_8\NN\20827 abuse_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 <e2>visual_15\JJ\1740 field_16\NN\8673395 defects</e2>_17\NNS\14462666 (_18\-LRB-\1740 vfd_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 gvg_35\NN\1740 on_36\IN\1740 cocaine-induced_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 <e1>dopamine</e1>_45\NN\14807737 (_46\-LRB-\1740 da_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
D004298_D005128 NONE objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 substance_8\NN\20827 abuse_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 visual_15\JJ\1740 field_16\NN\8673395 defects_17\NNS\14462666 (_18\-LRB-\1740 <e2>vfd</e2>_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 gvg_35\NN\1740 on_36\IN\1740 cocaine-induced_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 <e1>dopamine</e1>_45\NN\14807737 (_46\-LRB-\1740 da_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
D004298_D005128 NONE objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 substance_8\NN\20827 abuse_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 <e2>visual_15\JJ\1740 field_16\NN\8673395 defects</e2>_17\NNS\14462666 (_18\-LRB-\1740 vfd_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 gvg_35\NN\1740 on_36\IN\1740 cocaine-induced_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 dopamine_45\NN\14807737 (_46\-LRB-\1740 <e1>da</e1>_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
D004298_D005128 NONE objectives_0\NNS\5980875 :_1\:\1740 given_2\VBN\2327200 its_3\PRP$\6125041 preclinical_4\JJ\1740 success_5\NN\7283608 for_6\IN\1740 treating_7\VBG\2376958 substance_8\NN\20827 abuse_9\NN\418025 and_10\CC\1740 the_11\DT\1740 increased_12\VBN\169651 risk_13\NN\14541044 of_14\IN\1740 visual_15\JJ\1740 field_16\NN\8673395 defects_17\NNS\14462666 (_18\-LRB-\1740 <e2>vfd</e2>_19\NN\1740 )_20\-RRB-\1740 associated_21\VBN\628491 with_22\IN\1740 cumulative_23\JJ\1740 lifetime_24\NN\15113229 exposure_25\NN\5042871 ,_26\,\1740 we_27\PRP\1740 explored_28\VBD\789138 the_29\DT\1740 effects_30\NNS\13245626 of_31\IN\1740 sub-chronic_32\JJ\1740 low_33\JJ\1740 dose_34\NN\3740161 gvg_35\NN\1740 on_36\IN\1740 cocaine-induced_37\JJ\1740 increases_38\NNS\13576355 in_39\IN\13603305 nucleus_40\NN\5445668 accumbens_41\NNS\1740 (_42\-LRB-\1740 nacc_43\NN\1740 )_44\-RRB-\1740 dopamine_45\NN\14807737 (_46\-LRB-\1740 <e1>da</e1>_47\NN\10484858 )_48\-RRB-\1740 ._49\.\1740
17919553
C106791_D056486 CID acute_0\JJ\1740 <e2>hepatitis</e2>_1\NN\14127211 attack_2\NN\955060 after_3\IN\1740 exposure_4\NN\5042871 to_5\TO\1740 <e1>telithromycin</e1>_6\NN\1740 ._7\.\1740
C106791_D056486 CID the_0\DT\1740 patient_1\NN\9898892 had_2\VBD\2108377 suffered_3\VBN\2110220 a_4\DT\13649268 previous_5\JJ\1740 episode_6\NN\7283608 of_7\IN\1740 "_8\``\1740 acute_9\JJ\1740 <e2>hepatitis</e2>_10\NN\14127211 of_11\IN\1740 unknown_12\JJ\1740 origin_13\NN\8620061 ,_14\,\1740 "_15\''\1740 that_16\WDT\1740 occurred_17\VBD\2623529 after_18\IN\1740 <e1>telithromycin</e1>_19\NN\1740 usage_20\NN\407535 ._21\.\1740
C106791_D056486 CID based_0\VBN\2694933 on_1\IN\1740 a_2\DT\13649268 score_3\NN\5736149 of_4\IN\1740 8_5\CD\13741022 on_6\IN\1740 the_7\DT\1740 naranjo_8\NNP\1740 adverse_9\JJ\1740 drug_10\NN\14778436 reaction_11\NN\13446390 probability_12\NN\33615 scale_13\NN\7260623 ,_14\,\1740 <e1>telithromycin</e1>_15\NN\1740 was_16\VBD\836236 the_17\DT\1740 probable_18\JJ\1740 cause_19\NN\7323922 of_20\IN\1740 acute_21\JJ\1740 <e2>hepatitis</e2>_22\NN\14127211 in_23\IN\13603305 this_24\DT\1740 patient_25\NN\9898892 ,_26\,\1740 and_27\CC\1740 pathological_28\JJ\1740 findings_29\NNS\7951464 suggested_30\VBD\1010118 drug-induced_31\JJ\1740 toxic_32\JJ\1740 hepatitis_33\NN\14127211 ._34\.\1740
C106791_D056486 CID based_0\VBN\2694933 on_1\IN\1740 a_2\DT\13649268 score_3\NN\5736149 of_4\IN\1740 8_5\CD\13741022 on_6\IN\1740 the_7\DT\1740 naranjo_8\NNP\1740 adverse_9\JJ\1740 drug_10\NN\14778436 reaction_11\NN\13446390 probability_12\NN\33615 scale_13\NN\7260623 ,_14\,\1740 <e1>telithromycin</e1>_15\NN\1740 was_16\VBD\836236 the_17\DT\1740 probable_18\JJ\1740 cause_19\NN\7323922 of_20\IN\1740 acute_21\JJ\1740 hepatitis_22\NN\14127211 in_23\IN\13603305 this_24\DT\1740 patient_25\NN\9898892 ,_26\,\1740 and_27\CC\1740 pathological_28\JJ\1740 findings_29\NNS\7951464 suggested_30\VBD\1010118 drug-induced_31\JJ\1740 <e2>toxic_32\JJ\1740 hepatitis</e2>_33\NN\14127211 ._34\.\1740
C106791_D056486 CID recurrence_0\NN\7342049 of_1\IN\1740 <e2>hepatitis</e2>_2\NN\14127211 attack_3\NN\955060 might_4\MD\5029706 have_5\VB\2108377 been_6\VBN\836236 avoided_7\VBN\2452885 if_8\IN\1740 the_9\DT\1740 initial_10\JJ\1740 incident_11\NN\7283608 had_12\VBD\2108377 been_13\VBN\836236 communicated_14\VBN\2231661 to_15\IN\1740 the_16\DT\1740 attending_17\VBG\2655135 physician_18\NN\10305802 who_19\WP\8299493 prescribed_20\VBD\748282 <e1>telithromycin</e1>_21\NN\1740 the_22\DT\1740 second_23\JJ\1740 time_24\NN\7308889 ._25\.\1740
C106791_D056486 CID conclusion_0\NN\5837957 :_1\:\1740 here_2\RB\1740 we_3\PRP\1740 report_4\VBP\831651 a_5\DT\13649268 case_6\NN\7283608 of_7\IN\1740 acute_8\JJ\1740 <e2>hepatitis</e2>_9\NN\14127211 probably_10\RB\1740 associated_11\VBN\628491 with_12\IN\1740 the_13\DT\1740 administration_14\NN\1133281 of_15\IN\1740 <e1>telithromycin</e1>_16\NN\1740 ._17\.\1740
C106791_D012141 NONE he_0\PRP\14622893 had_1\VBD\2108377 been_2\VBN\836236 prescribed_3\VBN\748282 <e1>telithromycin</e1>_4\NN\1740 400_5\CD\1740 mg/d_6\NN\1740 po_7\NN\14625458 to_8\TO\1740 treat_9\VB\2376958 an_10\DT\6697703 <e2>upper_11\JJ\1740 respiratory_12\JJ\1740 tract_13\NN\8574314 infection</e2>_14\NN\14052046 7_15\CD\13741022 days_16\NNS\15140892 prior_17\RB\1740 ._18\.\1740
C106791_D064420 NONE based_0\VBN\2694933 on_1\IN\1740 a_2\DT\13649268 score_3\NN\5736149 of_4\IN\1740 8_5\CD\13741022 on_6\IN\1740 the_7\DT\1740 naranjo_8\NNP\1740 <e2>adverse_9\JJ\1740 drug_10\NN\14778436 reaction</e2>_11\NN\13446390 probability_12\NN\33615 scale_13\NN\7260623 ,_14\,\1740 <e1>telithromycin</e1>_15\NN\1740 was_16\VBD\836236 the_17\DT\1740 probable_18\JJ\1740 cause_19\NN\7323922 of_20\IN\1740 acute_21\JJ\1740 hepatitis_22\NN\14127211 in_23\IN\13603305 this_24\DT\1740 patient_25\NN\9898892 ,_26\,\1740 and_27\CC\1740 pathological_28\JJ\1740 findings_29\NNS\7951464 suggested_30\VBD\1010118 drug-induced_31\JJ\1740 toxic_32\JJ\1740 hepatitis_33\NN\14127211 ._34\.\1740
7248170
D010634_D006529 CID <e1>phenobarbitone-induced</e1>_0\JJ\1740 <e2>enlargement_1\NN\363260 of_2\IN\1740 the_3\DT\1740 liver</e2>_4\NN\5298729 in_5\IN\13603305 the_6\DT\1740 rat_7\NN\2329401 :_8\:\1740 its_9\PRP$\6125041 relationship_10\NN\31921 to_11\TO\1740 carbon_12\NN\14622893 tetrachloride-induced_13\JJ\1740 cirrhosis_14\NN\14116321 ._15\.\1740
D010634_D006529 CID the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 <e1>phenobarbitone-primed</e1>_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 <e2>enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver</e2>_88\NN\5298729 ._89\.\1740
D010634_D006529 CID the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 <e1>phenobarbitone-induced</e1>_84\JJ\1740 <e2>enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver</e2>_88\NN\5298729 ._89\.\1740
D010634_D005355 NONE <e1>phenobarbitone-induced</e1>_0\JJ\1740 enlargement_1\NN\363260 of_2\IN\1740 the_3\DT\1740 liver_4\NN\5298729 in_5\IN\13603305 the_6\DT\1740 rat_7\NN\2329401 :_8\:\1740 its_9\PRP$\6125041 relationship_10\NN\31921 to_11\TO\1740 carbon_12\NN\14622893 tetrachloride-induced_13\JJ\1740 <e2>cirrhosis</e2>_14\NN\14116321 ._15\.\1740
D002251_D006529 NONE phenobarbitone-induced_0\JJ\1740 <e2>enlargement_1\NN\363260 of_2\IN\1740 the_3\DT\1740 liver</e2>_4\NN\5298729 in_5\IN\13603305 the_6\DT\1740 rat_7\NN\2329401 :_8\:\1740 its_9\PRP$\6125041 relationship_10\NN\31921 to_11\TO\1740 <e1>carbon_12\NN\14622893 tetrachloride-induced</e1>_13\JJ\1740 cirrhosis_14\NN\14116321 ._15\.\1740
D002251_D006529 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 <e1>carbon_52\NN\14622893 tetrachloride</e1>_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 <e2>enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver</e2>_88\NN\5298729 ._89\.\1740
D002251_D006529 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 <e1>carbon_77\NN\14622893 tetrachloride</e1>_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 <e2>enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver</e2>_88\NN\5298729 ._89\.\1740
D002251_D005355 NONE phenobarbitone-induced_0\JJ\1740 enlargement_1\NN\363260 of_2\IN\1740 the_3\DT\1740 liver_4\NN\5298729 in_5\IN\13603305 the_6\DT\1740 rat_7\NN\2329401 :_8\:\1740 its_9\PRP$\6125041 relationship_10\NN\31921 to_11\TO\1740 <e1>carbon_12\NN\14622893 tetrachloride-induced</e1>_13\JJ\1740 <e2>cirrhosis</e2>_14\NN\14116321 ._15\.\1740
D002251_D008103 CID the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 <e2>cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver</e2>_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 <e1>carbon_52\NN\14622893 tetrachloride</e1>_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D002251_D008103 CID the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 <e2>cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver</e2>_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 <e1>carbon_77\NN\14622893 tetrachloride</e1>_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D002251_D001201 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 <e2>ascites</e2>_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 <e1>carbon_52\NN\14622893 tetrachloride</e1>_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D002251_D001201 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 <e2>ascites</e2>_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 <e1>carbon_77\NN\14622893 tetrachloride</e1>_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D002251_D013163 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 <e2>splenomegaly</e2>_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 <e1>carbon_52\NN\14622893 tetrachloride</e1>_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D002251_D013163 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 <e2>splenomegaly</e2>_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 <e1>carbon_77\NN\14622893 tetrachloride</e1>_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D002251_D001284 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 <e2>atrophy</e2>_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 <e1>carbon_52\NN\14622893 tetrachloride</e1>_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D002251_D001284 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 <e2>atrophy</e2>_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 <e1>carbon_77\NN\14622893 tetrachloride</e1>_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D010634_D008103 CID the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 <e2>cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver</e2>_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 <e1>phenobarbitone-primed</e1>_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D010634_D008103 CID the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 <e2>cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver</e2>_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 <e1>phenobarbitone-induced</e1>_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D010634_D001201 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 <e2>ascites</e2>_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 <e1>phenobarbitone-primed</e1>_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D010634_D001201 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 <e2>ascites</e2>_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 <e1>phenobarbitone-induced</e1>_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D010634_D013163 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 <e2>splenomegaly</e2>_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 <e1>phenobarbitone-primed</e1>_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D010634_D013163 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 <e2>splenomegaly</e2>_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 atrophy_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 <e1>phenobarbitone-induced</e1>_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D010634_D001284 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 <e2>atrophy</e2>_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 <e1>phenobarbitone-primed</e1>_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 phenobarbitone-induced_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
D010634_D001284 NONE the_0\DT\1740 yield_1\NN\913705 of_2\IN\1740 severe_3\JJ\1740 cirrhosis_4\NN\14116321 of_5\IN\1740 the_6\DT\1740 liver_7\NN\5298729 (_8\-LRB-\1740 defined_9\VBN\2604760 as_10\IN\14622893 a_11\DT\13649268 shrunken_12\JJ\1740 finely_13\RB\1740 nodular_14\JJ\1740 liver_15\NN\5298729 with_16\IN\1740 micronodular_17\JJ\1740 histology_18\NN\6060049 ,_19\,\1740 ascites_20\NNS\14204950 greater_21\JJR\1740 than_22\IN\1740 30_23\CD\13745420 ml_24\NN\13616054 ,_25\,\1740 plasma_26\NN\5398023 albumin_27\NN\14736972 less_28\JJR\1740 than_29\IN\1740 2.2_30\CD\1740 g/dl_31\NN\1740 ,_32\,\1740 splenomegaly_33\NN\14366759 2_34\CD\13741022 -_35\SYM\1740 3_36\CD\13741022 times_37\NNS\15113229 normal_38\JJ\1740 ,_39\,\1740 and_40\CC\1740 testicular_41\JJ\1740 <e2>atrophy</e2>_42\NN\14299637 approximately_43\RB\1740 half_44\NN\13732295 normal_45\JJ\1740 weight_46\NN\5009170 )_47\-RRB-\1740 after_48\IN\1740 12_49\CD\13745420 doses_50\NNS\3740161 of_51\IN\1740 carbon_52\NN\14622893 tetrachloride_53\NN\14818238 given_54\VBN\2327200 intragastrically_55\RB\1740 in_56\IN\13603305 the_57\DT\1740 phenobarbitone-primed_58\JJ\1740 rat_59\NN\2329401 was_60\VBD\836236 increased_61\VBN\169651 from_62\IN\1740 25_63\CD\13745420 %_64\NN\1740 to_65\TO\1740 56_66\CD\1740 %_67\NN\1740 by_68\IN\1740 giving_69\VBG\2327200 the_70\DT\1740 initial_71\JJ\1740 "_72\``\1740 calibrating_73\VBG\296178 "_74\``\1740 dose_75\NN\3740161 of_76\IN\1740 carbon_77\NN\14622893 tetrachloride_78\NN\14818238 at_79\IN\14622893 the_80\DT\1740 peak_81\NN\13758296 of_82\IN\1740 the_83\DT\1740 <e1>phenobarbitone-induced</e1>_84\JJ\1740 enlargement_85\NN\363260 of_86\IN\1740 the_87\DT\1740 liver_88\NN\5298729 ._89\.\1740
17242861
D010862_D012640 NONE qtls_0\NNS\1740 for_1\IN\1740 susceptibility_2\NN\13920835 to_3\TO\1740 <e1>pilocarpine-induced</e1>_4\JJ\1740 <e2>seizures</e2>_5\NNS\14081375 ,_6\,\1740 a_7\DT\13649268 model_8\NN\5888929 of_9\IN\1740 temporal_10\JJ\1740 lobe_11\JJ\1740 epilepsy_12\NN\14085708 ,_13\,\1740 have_14\VBP\2108377 not_15\RB\1740 been_16\VBN\836236 reported_17\VBN\831651 ,_18\,\1740 and_19\CC\1740 css_20\NN\14625458 have_21\VBP\2108377 not_22\RB\1740 previously_23\RB\1740 been_24\VBN\836236 used_25\VBN\1156834 to_26\TO\1740 localize_27\VB\2694933 seizure_28\JJ\1740 susceptibility_29\NN\13920835 genes_30\NNS\8459252 ._31\.\1740
D010862_D012640 NONE qtls_0\NNS\1740 for_1\IN\1740 susceptibility_2\NN\13920835 to_3\TO\1740 <e1>pilocarpine-induced</e1>_4\JJ\1740 seizures_5\NNS\14081375 ,_6\,\1740 a_7\DT\13649268 model_8\NN\5888929 of_9\IN\1740 temporal_10\JJ\1740 lobe_11\JJ\1740 epilepsy_12\NN\14085708 ,_13\,\1740 have_14\VBP\2108377 not_15\RB\1740 been_16\VBN\836236 reported_17\VBN\831651 ,_18\,\1740 and_19\CC\1740 css_20\NN\14625458 have_21\VBP\2108377 not_22\RB\1740 previously_23\RB\1740 been_24\VBN\836236 used_25\VBN\1156834 to_26\TO\1740 localize_27\VB\2694933 <e2>seizure</e2>_28\JJ\1740 susceptibility_29\NN\13920835 genes_30\NNS\8459252 ._31\.\1740
D010862_D012640 NONE we_0\PRP\1740 report_1\VBP\831651 qtls_2\NNS\1740 identified_3\VBN\699815 using_4\VBG\1156834 a_5\DT\13649268 b6_6\NN\1740 (_7\-LRB-\1740 host_8\NN\9605289 )_9\-RRB-\1740 x_10\CC\13745420 a/j_11\NN\1740 (_12\-LRB-\1740 donor_13\NN\9608709 )_14\-RRB-\1740 css_15\NN\14625458 panel_16\NN\4188643 to_17\TO\1740 localize_18\VB\2694933 genes_19\NNS\8459252 involved_20\VBN\2676054 in_21\IN\13603305 susceptibility_22\NN\13920835 to_23\TO\1740 <e1>pilocarpine-induced</e1>_24\JJ\1740 <e2>seizures</e2>_25\NNS\14081375 ._26\.\1740
D010862_D012640 NONE three_0\CD\13741022 hundred_1\CD\13745420 fifty-five_2\JJ\1740 adult_3\JJ\1740 male_4\JJ\1740 css_5\NN\14625458 mice_6\NNS\2329401 ,_7\,\1740 58_8\CD\1740 b6_9\NN\1740 ,_10\,\1740 and_11\CC\1740 39_12\CD\1740 a/j_13\NN\1740 were_14\VBD\836236 tested_15\VBN\670261 for_16\IN\1740 susceptibility_17\NN\13920835 to_18\TO\1740 <e1>pilocarpine-induced</e1>_19\JJ\1740 <e2>seizures</e2>_20\NNS\14081375 ._21\.\1740
D010862_D004833 CID qtls_0\NNS\1740 for_1\IN\1740 susceptibility_2\NN\13920835 to_3\TO\1740 <e1>pilocarpine-induced</e1>_4\JJ\1740 seizures_5\NNS\14081375 ,_6\,\1740 a_7\DT\13649268 model_8\NN\5888929 of_9\IN\1740 <e2>temporal_10\JJ\1740 lobe_11\JJ\1740 epilepsy</e2>_12\NN\14085708 ,_13\,\1740 have_14\VBP\2108377 not_15\RB\1740 been_16\VBN\836236 reported_17\VBN\831651 ,_18\,\1740 and_19\CC\1740 css_20\NN\14625458 have_21\VBP\2108377 not_22\RB\1740 previously_23\RB\1740 been_24\VBN\836236 used_25\VBN\1156834 to_26\TO\1740 localize_27\VB\2694933 seizure_28\JJ\1740 susceptibility_29\NN\13920835 genes_30\NNS\8459252 ._31\.\1740
15278670
C009250_D012640 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>sevoflurane</e1>_3\NN\1740 on_4\IN\1740 lidocaine-induced_5\JJ\1740 <e2>convulsions</e2>_6\NNS\14081375 ._7\.\1740
C009250_D012640 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 <e1>sevoflurane</e1>_3\NN\1740 on_4\IN\1740 lidocaine-induced_5\JJ\1740 <e2>convulsions</e2>_6\NNS\14081375 was_7\VBD\836236 studied_8\VBN\630380 in_9\IN\13603305 cats_10\NNS\2120997 ._11\.\1740
C009250_D012640 NONE the_0\DT\1740 <e2>convulsive</e2>_1\JJ\1740 threshold_2\NN\15265518 (_3\-LRB-\1740 mean_4\NN\6021761 +/-_5\CC\1740 sd_6\NN\1740 )_7\-RRB-\1740 was_8\VBD\836236 41.4_9\CD\1740 +/-_10\CC\1740 6.5_11\CD\1740 mg._12\NN\1740 l(-1_13\NN\1740 )_14\-RRB-\1740 with_15\IN\1740 lidocaine_16\NN\3681148 infusion_17\NN\14589223 (_18\-LRB-\1740 6_19\CD\13741022 mg.kg(-1).min(-1_20\NN\1740 )_21\-RRB-\1740 )_22\-RRB-\1740 ,_23\,\1740 increasing_24\VBG\169651 significantly_25\RB\1740 to_26\TO\1740 66.6_27\CD\1740 +/-_28\CC\1740 10.9_29\CD\1740 mg._30\NN\1740 l(-1_31\NN\1740 )_32\-RRB-\1740 when_33\WRB\1740 the_34\DT\1740 end-tidal_35\JJ\1740 concentration_36\NN\4916342 of_37\IN\1740 <e1>sevoflurane</e1>_38\NN\1740 was_39\VBD\836236 0.8_40\CD\1740 %_41\NN\1740 ._42\.\1740
C009250_D012640 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 the_6\DT\1740 <e2>convulsive</e2>_7\JJ\1740 threshold_8\NN\15265518 between_9\IN\1740 <e1>sevoflurane</e1>_10\NN\1740 and_11\CC\1740 enflurane_12\NN\3299929 ._13\.\1740
C009250_D012640 NONE the_0\DT\1740 rise_1\NN\7324673 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 became_5\VBD\146138 less_6\RBR\1740 marked_7\JJ\1740 when_8\WRB\1740 higher_9\JJR\1740 concentrations_10\NNS\4916342 of_11\IN\1740 <e1>sevoflurane</e1>_12\NN\1740 or_13\CC\3541091 enflurane_14\NN\3299929 were_15\VBD\836236 administered_16\VBN\2436349 and_17\CC\1740 the_18\DT\1740 blood_19\NN\5397468 pressure_20\NN\11419404 at_21\IN\14622893 <e2>convulsions</e2>_22\NNS\14081375 decreased_23\VBD\169651 significantly_24\RB\1740 in_25\IN\13603305 1.6_26\CD\1740 %_27\NN\1740 sevoflurane_28\NN\1740 ,_29\,\1740 and_30\CC\1740 in_31\IN\13603305 0.8_32\CD\1740 %_33\NN\1740 and_34\CC\1740 1.6_35\CD\1740 %_36\NN\1740 enflurane_37\NN\3299929 ._38\.\1740
C009250_D012640 NONE the_0\DT\1740 rise_1\NN\7324673 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 became_5\VBD\146138 less_6\RBR\1740 marked_7\JJ\1740 when_8\WRB\1740 higher_9\JJR\1740 concentrations_10\NNS\4916342 of_11\IN\1740 sevoflurane_12\NN\1740 or_13\CC\3541091 enflurane_14\NN\3299929 were_15\VBD\836236 administered_16\VBN\2436349 and_17\CC\1740 the_18\DT\1740 blood_19\NN\5397468 pressure_20\NN\11419404 at_21\IN\14622893 <e2>convulsions</e2>_22\NNS\14081375 decreased_23\VBD\169651 significantly_24\RB\1740 in_25\IN\13603305 1.6_26\CD\1740 %_27\NN\1740 <e1>sevoflurane</e1>_28\NN\1740 ,_29\,\1740 and_30\CC\1740 in_31\IN\13603305 0.8_32\CD\1740 %_33\NN\1740 and_34\CC\1740 1.6_35\CD\1740 %_36\NN\1740 enflurane_37\NN\3299929 ._38\.\1740
C009250_D012640 NONE it_0\PRP\6125041 is_1\VBZ\836236 suggested_2\VBN\1010118 that_3\IN\1740 <e1>sevoflurane</e1>_4\NN\1740 reduces_5\VBZ\441445 the_6\DT\1740 <e2>convulsive</e2>_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 lidocaine_10\NN\3681148 toxicity_11\NN\13576101 but_12\CC\1740 carries_13\VBZ\1850315 some_14\DT\1740 risk_15\NN\14541044 due_16\IN\5174653 to_17\IN\1740 circulatory_18\JJ\1740 depression_19\NN\14373582 ._20\.\1740
D008012_D012640 CID the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 sevoflurane_3\NN\1740 on_4\IN\1740 <e1>lidocaine-induced</e1>_5\JJ\1740 <e2>convulsions</e2>_6\NNS\14081375 ._7\.\1740
D008012_D012640 CID the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 sevoflurane_3\NN\1740 on_4\IN\1740 <e1>lidocaine-induced</e1>_5\JJ\1740 <e2>convulsions</e2>_6\NNS\14081375 was_7\VBD\836236 studied_8\VBN\630380 in_9\IN\13603305 cats_10\NNS\2120997 ._11\.\1740
D008012_D012640 CID the_0\DT\1740 <e2>convulsive</e2>_1\JJ\1740 threshold_2\NN\15265518 (_3\-LRB-\1740 mean_4\NN\6021761 +/-_5\CC\1740 sd_6\NN\1740 )_7\-RRB-\1740 was_8\VBD\836236 41.4_9\CD\1740 +/-_10\CC\1740 6.5_11\CD\1740 mg._12\NN\1740 l(-1_13\NN\1740 )_14\-RRB-\1740 with_15\IN\1740 <e1>lidocaine</e1>_16\NN\3681148 infusion_17\NN\14589223 (_18\-LRB-\1740 6_19\CD\13741022 mg.kg(-1).min(-1_20\NN\1740 )_21\-RRB-\1740 )_22\-RRB-\1740 ,_23\,\1740 increasing_24\VBG\169651 significantly_25\RB\1740 to_26\TO\1740 66.6_27\CD\1740 +/-_28\CC\1740 10.9_29\CD\1740 mg._30\NN\1740 l(-1_31\NN\1740 )_32\-RRB-\1740 when_33\WRB\1740 the_34\DT\1740 end-tidal_35\JJ\1740 concentration_36\NN\4916342 of_37\IN\1740 sevoflurane_38\NN\1740 was_39\VBD\836236 0.8_40\CD\1740 %_41\NN\1740 ._42\.\1740
D008012_D012640 CID it_0\PRP\6125041 is_1\VBZ\836236 suggested_2\VBN\1010118 that_3\IN\1740 sevoflurane_4\NN\1740 reduces_5\VBZ\441445 the_6\DT\1740 <e2>convulsive</e2>_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 <e1>lidocaine</e1>_10\NN\3681148 toxicity_11\NN\13576101 but_12\CC\1740 carries_13\VBZ\1850315 some_14\DT\1740 risk_15\NN\14541044 due_16\IN\5174653 to_17\IN\1740 circulatory_18\JJ\1740 depression_19\NN\14373582 ._20\.\1740
D004737_D012640 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 the_6\DT\1740 <e2>convulsive</e2>_7\JJ\1740 threshold_8\NN\15265518 between_9\IN\1740 sevoflurane_10\NN\1740 and_11\CC\1740 <e1>enflurane</e1>_12\NN\3299929 ._13\.\1740
D004737_D012640 NONE the_0\DT\1740 rise_1\NN\7324673 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 became_5\VBD\146138 less_6\RBR\1740 marked_7\JJ\1740 when_8\WRB\1740 higher_9\JJR\1740 concentrations_10\NNS\4916342 of_11\IN\1740 sevoflurane_12\NN\1740 or_13\CC\3541091 <e1>enflurane</e1>_14\NN\3299929 were_15\VBD\836236 administered_16\VBN\2436349 and_17\CC\1740 the_18\DT\1740 blood_19\NN\5397468 pressure_20\NN\11419404 at_21\IN\14622893 <e2>convulsions</e2>_22\NNS\14081375 decreased_23\VBD\169651 significantly_24\RB\1740 in_25\IN\13603305 1.6_26\CD\1740 %_27\NN\1740 sevoflurane_28\NN\1740 ,_29\,\1740 and_30\CC\1740 in_31\IN\13603305 0.8_32\CD\1740 %_33\NN\1740 and_34\CC\1740 1.6_35\CD\1740 %_36\NN\1740 enflurane_37\NN\3299929 ._38\.\1740
D004737_D012640 NONE the_0\DT\1740 rise_1\NN\7324673 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 became_5\VBD\146138 less_6\RBR\1740 marked_7\JJ\1740 when_8\WRB\1740 higher_9\JJR\1740 concentrations_10\NNS\4916342 of_11\IN\1740 sevoflurane_12\NN\1740 or_13\CC\3541091 enflurane_14\NN\3299929 were_15\VBD\836236 administered_16\VBN\2436349 and_17\CC\1740 the_18\DT\1740 blood_19\NN\5397468 pressure_20\NN\11419404 at_21\IN\14622893 <e2>convulsions</e2>_22\NNS\14081375 decreased_23\VBD\169651 significantly_24\RB\1740 in_25\IN\13603305 1.6_26\CD\1740 %_27\NN\1740 sevoflurane_28\NN\1740 ,_29\,\1740 and_30\CC\1740 in_31\IN\13603305 0.8_32\CD\1740 %_33\NN\1740 and_34\CC\1740 1.6_35\CD\1740 %_36\NN\1740 <e1>enflurane</e1>_37\NN\3299929 ._38\.\1740
D001030_D012640 NONE <e1>apamin</e1>_0\NN\1740 (_1\-LRB-\1740 10_2\CD\13745420 ng_3\NN\13717155 )_4\-RRB-\1740 had_5\VBD\2108377 a_6\DT\13649268 tendency_7\NN\6193203 to_8\TO\1740 decrease_9\VB\169651 the_10\DT\1740 <e2>convulsive</e2>_11\JJ\1740 threshold_12\NN\15265518 (_13\-LRB-\1740 21.6_14\CD\1740 +/-_15\CC\1740 2.2_16\CD\1740 to_17\IN\1740 19.9_18\CD\1740 +/-_19\CC\1740 2.5_20\CD\1740 mg._21\NN\1740 l(-1_22\NN\1740 )_23\-RRB-\1740 )_24\-RRB-\1740 but_25\CC\1740 this_26\DT\1740 was_27\VBD\836236 not_28\RB\1740 statistically_29\RB\1740 significant_30\JJ\1740 ._31\.\1740
C009250_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 suggested_2\VBN\1010118 that_3\IN\1740 <e1>sevoflurane</e1>_4\NN\1740 reduces_5\VBZ\441445 the_6\DT\1740 convulsive_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 lidocaine_10\NN\3681148 <e2>toxicity</e2>_11\NN\13576101 but_12\CC\1740 carries_13\VBZ\1850315 some_14\DT\1740 risk_15\NN\14541044 due_16\IN\5174653 to_17\IN\1740 circulatory_18\JJ\1740 depression_19\NN\14373582 ._20\.\1740
C009250_D003866 NONE it_0\PRP\6125041 is_1\VBZ\836236 suggested_2\VBN\1010118 that_3\IN\1740 <e1>sevoflurane</e1>_4\NN\1740 reduces_5\VBZ\441445 the_6\DT\1740 convulsive_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 lidocaine_10\NN\3681148 toxicity_11\NN\13576101 but_12\CC\1740 carries_13\VBZ\1850315 some_14\DT\1740 risk_15\NN\14541044 due_16\IN\5174653 to_17\IN\1740 circulatory_18\JJ\1740 <e2>depression</e2>_19\NN\14373582 ._20\.\1740
D008012_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 suggested_2\VBN\1010118 that_3\IN\1740 sevoflurane_4\NN\1740 reduces_5\VBZ\441445 the_6\DT\1740 convulsive_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 <e1>lidocaine</e1>_10\NN\3681148 <e2>toxicity</e2>_11\NN\13576101 but_12\CC\1740 carries_13\VBZ\1850315 some_14\DT\1740 risk_15\NN\14541044 due_16\IN\5174653 to_17\IN\1740 circulatory_18\JJ\1740 depression_19\NN\14373582 ._20\.\1740
D008012_D003866 NONE it_0\PRP\6125041 is_1\VBZ\836236 suggested_2\VBN\1010118 that_3\IN\1740 sevoflurane_4\NN\1740 reduces_5\VBZ\441445 the_6\DT\1740 convulsive_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 <e1>lidocaine</e1>_10\NN\3681148 toxicity_11\NN\13576101 but_12\CC\1740 carries_13\VBZ\1850315 some_14\DT\1740 risk_15\NN\14541044 due_16\IN\5174653 to_17\IN\1740 circulatory_18\JJ\1740 <e2>depression</e2>_19\NN\14373582 ._20\.\1740
3856631
D008727_D008577 NONE remission_0\NN\7368256 induction_1\NN\7450842 of_2\IN\1740 <e2>meningeal_3\NN\1740 leukemia</e2>_4\NN\14239918 with_5\IN\1740 high-dose_6\JJ\1740 intravenous_7\JJ\1740 <e1>methotrexate</e1>_8\NN\2722166 ._9\.\1740
D008727_D054198 NONE twenty_0\CD\13745420 children_1\NNS\9622049 with_2\IN\1740 <e2>acute_3\JJ\1740 lymphoblastic_4\JJ\1740 leukemia</e2>_5\NN\14239918 who_6\WP\8299493 developed_7\VBD\1753788 meningeal_8\NN\1740 disease_9\NN\14061805 were_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 a_13\DT\13649268 high-dose_14\JJ\1740 intravenous_15\JJ\1740 <e1>methotrexate</e1>_16\VBP\1740 regimen_17\NN\5898568 that_18\WDT\1740 was_19\VBD\836236 designed_20\VBN\1631534 to_21\TO\1740 achieve_22\VB\2524171 and_23\CC\1740 maintain_24\VB\2202928 csf_25\NN\1740 methotrexate_26\VBP\1740 concentrations_27\NNS\4916342 of_28\IN\1740 10(-5_29\NN\1740 )_30\-RRB-\1740 mol/l_31\NN\1740 without_32\IN\1740 the_33\DT\1740 need_34\NN\13920835 for_35\IN\1740 concomitant_36\JJ\1740 intrathecal_37\JJ\1740 dosing_38\NN\1740 ._39\.\1740
D008727_D054198 NONE twenty_0\CD\13745420 children_1\NNS\9622049 with_2\IN\1740 <e2>acute_3\JJ\1740 lymphoblastic_4\JJ\1740 leukemia</e2>_5\NN\14239918 who_6\WP\8299493 developed_7\VBD\1753788 meningeal_8\NN\1740 disease_9\NN\14061805 were_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 a_13\DT\13649268 high-dose_14\JJ\1740 intravenous_15\JJ\1740 methotrexate_16\VBP\1740 regimen_17\NN\5898568 that_18\WDT\1740 was_19\VBD\836236 designed_20\VBN\1631534 to_21\TO\1740 achieve_22\VB\2524171 and_23\CC\1740 maintain_24\VB\2202928 csf_25\NN\1740 <e1>methotrexate</e1>_26\VBP\1740 concentrations_27\NNS\4916342 of_28\IN\1740 10(-5_29\NN\1740 )_30\-RRB-\1740 mol/l_31\NN\1740 without_32\IN\1740 the_33\DT\1740 need_34\NN\13920835 for_35\IN\1740 concomitant_36\JJ\1740 intrathecal_37\JJ\1740 dosing_38\NN\1740 ._39\.\1740
D008727_D054198 NONE high-dose_0\JJ\1740 intravenous_1\JJ\1740 <e1>methotrexate</e1>_2\NN\2722166 is_3\VBZ\836236 an_4\DT\6697703 effective_5\JJ\1740 treatment_6\NN\654885 for_7\IN\1740 the_8\DT\1740 induction_9\NN\7450842 of_10\IN\1740 remission_11\NN\7368256 after_12\IN\1740 meningeal_13\NN\1740 relapse_14\NN\66636 in_15\IN\13603305 <e2>acute_16\JJ\1740 lymphoblastic_17\JJ\1740 leukemia</e2>_18\NN\14239918 ._19\.\1740
D008727_D002493 NONE twenty_0\CD\13745420 children_1\NNS\9622049 with_2\IN\1740 acute_3\JJ\1740 lymphoblastic_4\JJ\1740 leukemia_5\NN\14239918 who_6\WP\8299493 developed_7\VBD\1753788 <e2>meningeal_8\NN\1740 disease</e2>_9\NN\14061805 were_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 a_13\DT\13649268 high-dose_14\JJ\1740 intravenous_15\JJ\1740 <e1>methotrexate</e1>_16\VBP\1740 regimen_17\NN\5898568 that_18\WDT\1740 was_19\VBD\836236 designed_20\VBN\1631534 to_21\TO\1740 achieve_22\VB\2524171 and_23\CC\1740 maintain_24\VB\2202928 csf_25\NN\1740 methotrexate_26\VBP\1740 concentrations_27\NNS\4916342 of_28\IN\1740 10(-5_29\NN\1740 )_30\-RRB-\1740 mol/l_31\NN\1740 without_32\IN\1740 the_33\DT\1740 need_34\NN\13920835 for_35\IN\1740 concomitant_36\JJ\1740 intrathecal_37\JJ\1740 dosing_38\NN\1740 ._39\.\1740
D008727_D002493 NONE twenty_0\CD\13745420 children_1\NNS\9622049 with_2\IN\1740 acute_3\JJ\1740 lymphoblastic_4\JJ\1740 leukemia_5\NN\14239918 who_6\WP\8299493 developed_7\VBD\1753788 <e2>meningeal_8\NN\1740 disease</e2>_9\NN\14061805 were_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 a_13\DT\13649268 high-dose_14\JJ\1740 intravenous_15\JJ\1740 methotrexate_16\VBP\1740 regimen_17\NN\5898568 that_18\WDT\1740 was_19\VBD\836236 designed_20\VBN\1631534 to_21\TO\1740 achieve_22\VB\2524171 and_23\CC\1740 maintain_24\VB\2202928 csf_25\NN\1740 <e1>methotrexate</e1>_26\VBP\1740 concentrations_27\NNS\4916342 of_28\IN\1740 10(-5_29\NN\1740 )_30\-RRB-\1740 mol/l_31\NN\1740 without_32\IN\1740 the_33\DT\1740 need_34\NN\13920835 for_35\IN\1740 concomitant_36\JJ\1740 intrathecal_37\JJ\1740 dosing_38\NN\1740 ._39\.\1740
D001663_D064420 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 <e2>toxicities</e2>_3\NNS\13576101 encountered_4\VBN\2604760 were_5\VBD\836236 transient_6\JJ\1740 serum_7\NN\5397468 transaminase_8\NN\15077571 and_9\CC\1740 <e1>bilirubin</e1>_10\NN\14756039 elevations_11\NNS\7445480 ,_12\,\1740 neutropenia_13\NN\14196405 ,_14\,\1740 and_15\CC\1740 mucositis_16\NN\1740 ._17\.\1740
D001663_D009503 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 toxicities_3\NNS\13576101 encountered_4\VBN\2604760 were_5\VBD\836236 transient_6\JJ\1740 serum_7\NN\5397468 transaminase_8\NN\15077571 and_9\CC\1740 <e1>bilirubin</e1>_10\NN\14756039 elevations_11\NNS\7445480 ,_12\,\1740 <e2>neutropenia</e2>_13\NN\14196405 ,_14\,\1740 and_15\CC\1740 mucositis_16\NN\1740 ._17\.\1740
D001663_D052016 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 toxicities_3\NNS\13576101 encountered_4\VBN\2604760 were_5\VBD\836236 transient_6\JJ\1740 serum_7\NN\5397468 transaminase_8\NN\15077571 and_9\CC\1740 <e1>bilirubin</e1>_10\NN\14756039 elevations_11\NNS\7445480 ,_12\,\1740 neutropenia_13\NN\14196405 ,_14\,\1740 and_15\CC\1740 <e2>mucositis</e2>_16\NN\1740 ._17\.\1740
15957009
C507242_D008569 NONE the_0\DT\1740 selective_1\JJ\1740 5-ht6_2\NN\1740 receptor_3\NN\5225602 antagonist_4\NN\7846 <e1>ro4368554</e1>_5\NNS\1740 restores_6\VBZ\1631072 memory_7\NN\5926676 performance_8\NN\6619065 in_9\IN\13603305 cholinergic_10\JJ\1740 and_11\CC\1740 serotonergic_12\JJ\1740 models_13\NNS\5888929 of_14\IN\1740 <e2>memory_15\NN\5926676 deficiency</e2>_16\NN\14449126 in_17\IN\13603305 the_18\DT\1740 rat_19\NN\2329401 ._20\.\1740
C507242_D008569 NONE both_0\DT\1740 ,_1\,\1740 <e1>ro4368554</e1>_2\NNP\1740 (_3\-LRB-\1740 3_4\CD\13741022 and_5\CC\1740 10_6\CD\13745420 mg/kg_7\NN\1740 ,_8\,\1740 intraperitoneally_9\RB\1740 (_10\-LRB-\1740 i.p._11\RB\1740 )_12\-RRB-\1740 )_13\-RRB-\1740 and_14\CC\1740 metrifonate_15\NN\1740 (_16\-LRB-\1740 10_17\CD\13745420 mg/kg_18\NN\1740 ,_19\,\1740 p.o._20\NN\10360747 ,_21\,\1740 respectively_22\RB\1740 )_23\-RRB-\1740 reversed_24\VBN\109660 <e2>memory_25\NN\5926676 deficits</e2>_26\NNS\5113133 induced_27\VBN\1627355 by_28\IN\1740 scopolamine_29\NN\14712692 and_30\CC\1740 trp_31\NN\1740 depletion_32\NN\351638 (_33\-LRB-\1740 10_34\CD\13745420 mg/kg_35\NN\1740 ,_36\,\1740 i.p._37\RB\1740 ,_38\,\1740 and_39\CC\1740 3_40\CD\13741022 mg/kg_41\NN\1740 ,_42\,\1740 p.o._43\NN\10360747 ,_44\,\1740 respectively_45\RB\1740 )_46\-RRB-\1740 ._47\.\1740
C507242_D008569 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 although_3\IN\1740 <e1>ro4368554</e1>_4\NNS\1740 did_5\VBD\1640855 not_6\RB\1740 improve_7\VB\126264 a_8\DT\13649268 time-related_9\JJ\1740 retention_10\NN\809465 deficit_11\NN\5113133 ,_12\,\1740 it_13\PRP\6125041 reversed_14\VBD\109660 a_15\DT\13649268 cholinergic_16\NN\1740 and_17\CC\1740 a_18\DT\13649268 serotonergic_19\JJ\1740 <e2>memory_20\NN\5926676 deficit</e2>_21\NN\5113133 ,_22\,\1740 suggesting_23\VBG\1010118 that_24\IN\1740 both_25\DT\1740 mechanisms_26\NNS\13446390 may_27\MD\15209706 be_28\VB\836236 involved_29\VBN\2676054 in_30\IN\13603305 the_31\DT\1740 facilitation_32\NN\13920835 of_33\IN\1740 object_34\NN\1930 memory_35\NN\5926676 by_36\IN\1740 ro4368554_37\NNS\1740 and_38\CC\1740 ,_39\,\1740 possibly_40\RB\1740 ,_41\,\1740 other_42\JJ\1740 5-ht(6_43\NN\1740 )_44\-RRB-\1740 receptor_45\NN\5225602 antagonists_46\NNS\7846 ._47\.\1740
C507242_D008569 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 although_3\IN\1740 ro4368554_4\NNS\1740 did_5\VBD\1640855 not_6\RB\1740 improve_7\VB\126264 a_8\DT\13649268 time-related_9\JJ\1740 retention_10\NN\809465 deficit_11\NN\5113133 ,_12\,\1740 it_13\PRP\6125041 reversed_14\VBD\109660 a_15\DT\13649268 cholinergic_16\NN\1740 and_17\CC\1740 a_18\DT\13649268 serotonergic_19\JJ\1740 <e2>memory_20\NN\5926676 deficit</e2>_21\NN\5113133 ,_22\,\1740 suggesting_23\VBG\1010118 that_24\IN\1740 both_25\DT\1740 mechanisms_26\NNS\13446390 may_27\MD\15209706 be_28\VB\836236 involved_29\VBN\2676054 in_30\IN\13603305 the_31\DT\1740 facilitation_32\NN\13920835 of_33\IN\1740 object_34\NN\1930 memory_35\NN\5926676 by_36\IN\1740 <e1>ro4368554</e1>_37\NNS\1740 and_38\CC\1740 ,_39\,\1740 possibly_40\RB\1740 ,_41\,\1740 other_42\JJ\1740 5-ht(6_43\NN\1740 )_44\-RRB-\1740 receptor_45\NN\5225602 antagonists_46\NNS\7846 ._47\.\1740
D014236_D008569 NONE both_0\DT\1740 ,_1\,\1740 ro4368554_2\NNP\1740 (_3\-LRB-\1740 3_4\CD\13741022 and_5\CC\1740 10_6\CD\13745420 mg/kg_7\NN\1740 ,_8\,\1740 intraperitoneally_9\RB\1740 (_10\-LRB-\1740 i.p._11\RB\1740 )_12\-RRB-\1740 )_13\-RRB-\1740 and_14\CC\1740 <e1>metrifonate</e1>_15\NN\1740 (_16\-LRB-\1740 10_17\CD\13745420 mg/kg_18\NN\1740 ,_19\,\1740 p.o._20\NN\10360747 ,_21\,\1740 respectively_22\RB\1740 )_23\-RRB-\1740 reversed_24\VBN\109660 <e2>memory_25\NN\5926676 deficits</e2>_26\NNS\5113133 induced_27\VBN\1627355 by_28\IN\1740 scopolamine_29\NN\14712692 and_30\CC\1740 trp_31\NN\1740 depletion_32\NN\351638 (_33\-LRB-\1740 10_34\CD\13745420 mg/kg_35\NN\1740 ,_36\,\1740 i.p._37\RB\1740 ,_38\,\1740 and_39\CC\1740 3_40\CD\13741022 mg/kg_41\NN\1740 ,_42\,\1740 p.o._43\NN\10360747 ,_44\,\1740 respectively_45\RB\1740 )_46\-RRB-\1740 ._47\.\1740
D012601_D008569 CID both_0\DT\1740 ,_1\,\1740 ro4368554_2\NNP\1740 (_3\-LRB-\1740 3_4\CD\13741022 and_5\CC\1740 10_6\CD\13745420 mg/kg_7\NN\1740 ,_8\,\1740 intraperitoneally_9\RB\1740 (_10\-LRB-\1740 i.p._11\RB\1740 )_12\-RRB-\1740 )_13\-RRB-\1740 and_14\CC\1740 metrifonate_15\NN\1740 (_16\-LRB-\1740 10_17\CD\13745420 mg/kg_18\NN\1740 ,_19\,\1740 p.o._20\NN\10360747 ,_21\,\1740 respectively_22\RB\1740 )_23\-RRB-\1740 reversed_24\VBN\109660 <e2>memory_25\NN\5926676 deficits</e2>_26\NNS\5113133 induced_27\VBN\1627355 by_28\IN\1740 <e1>scopolamine</e1>_29\NN\14712692 and_30\CC\1740 trp_31\NN\1740 depletion_32\NN\351638 (_33\-LRB-\1740 10_34\CD\13745420 mg/kg_35\NN\1740 ,_36\,\1740 i.p._37\RB\1740 ,_38\,\1740 and_39\CC\1740 3_40\CD\13741022 mg/kg_41\NN\1740 ,_42\,\1740 p.o._43\NN\10360747 ,_44\,\1740 respectively_45\RB\1740 )_46\-RRB-\1740 ._47\.\1740
D014364_D008569 NONE both_0\DT\1740 ,_1\,\1740 ro4368554_2\NNP\1740 (_3\-LRB-\1740 3_4\CD\13741022 and_5\CC\1740 10_6\CD\13745420 mg/kg_7\NN\1740 ,_8\,\1740 intraperitoneally_9\RB\1740 (_10\-LRB-\1740 i.p._11\RB\1740 )_12\-RRB-\1740 )_13\-RRB-\1740 and_14\CC\1740 metrifonate_15\NN\1740 (_16\-LRB-\1740 10_17\CD\13745420 mg/kg_18\NN\1740 ,_19\,\1740 p.o._20\NN\10360747 ,_21\,\1740 respectively_22\RB\1740 )_23\-RRB-\1740 reversed_24\VBN\109660 <e2>memory_25\NN\5926676 deficits</e2>_26\NNS\5113133 induced_27\VBN\1627355 by_28\IN\1740 scopolamine_29\NN\14712692 and_30\CC\1740 <e1>trp</e1>_31\NN\1740 depletion_32\NN\351638 (_33\-LRB-\1740 10_34\CD\13745420 mg/kg_35\NN\1740 ,_36\,\1740 i.p._37\RB\1740 ,_38\,\1740 and_39\CC\1740 3_40\CD\13741022 mg/kg_41\NN\1740 ,_42\,\1740 p.o._43\NN\10360747 ,_44\,\1740 respectively_45\RB\1740 )_46\-RRB-\1740 ._47\.\1740
D012701_D008569 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 although_3\IN\1740 ro4368554_4\NNS\1740 did_5\VBD\1640855 not_6\RB\1740 improve_7\VB\126264 a_8\DT\13649268 time-related_9\JJ\1740 retention_10\NN\809465 deficit_11\NN\5113133 ,_12\,\1740 it_13\PRP\6125041 reversed_14\VBD\109660 a_15\DT\13649268 cholinergic_16\NN\1740 and_17\CC\1740 a_18\DT\13649268 serotonergic_19\JJ\1740 <e2>memory_20\NN\5926676 deficit</e2>_21\NN\5113133 ,_22\,\1740 suggesting_23\VBG\1010118 that_24\IN\1740 both_25\DT\1740 mechanisms_26\NNS\13446390 may_27\MD\15209706 be_28\VB\836236 involved_29\VBN\2676054 in_30\IN\13603305 the_31\DT\1740 facilitation_32\NN\13920835 of_33\IN\1740 object_34\NN\1930 memory_35\NN\5926676 by_36\IN\1740 ro4368554_37\NNS\1740 and_38\CC\1740 ,_39\,\1740 possibly_40\RB\1740 ,_41\,\1740 other_42\JJ\1740 <e1>5-ht(6</e1>_43\NN\1740 )_44\-RRB-\1740 receptor_45\NN\5225602 antagonists_46\NNS\7846 ._47\.\1740
15188772
D004837_D018487 NONE severe_0\JJ\1740 reversible_1\JJ\1740 <e2>left_2\VBD\120316 ventricular_3\JJ\1740 systolic_4\NN\1740 and_5\CC\1740 diastolic_6\JJ\1740 dysfunction</e2>_7\NN\14204950 due_8\IN\5174653 to_9\TO\1740 accidental_10\JJ\1740 iatrogenic_11\JJ\1740 <e1>epinephrine</e1>_12\NN\14807929 overdose_13\NN\1740 ._14\.\1740
D004837_D018487 NONE a_0\DT\13649268 35-year-old_1\JJ\1740 woman_2\NN\9605289 whose_3\WP$\1740 cervix_4\NN\5225090 uteri_5\NN\5514717 was_6\VBD\836236 inadvertently_7\RB\1740 injected_8\VBN\81072 with_9\IN\1740 8_10\CD\13741022 mg_11\NN\13717155 of_12\IN\1740 <e1>epinephrine</e1>_13\NN\14807929 developed_14\VBD\1753788 myocardial_15\JJ\1740 stunning_16\NN\1740 that_17\WDT\1740 was_18\VBD\836236 characterized_19\VBN\609683 by_20\IN\1740 severe_21\JJ\1740 hemodynamic_22\JJ\1740 compromise_23\NN\1202904 ,_24\,\1740 profound_25\JJ\1740 ,_26\,\1740 albeit_27\IN\1740 transient_28\JJ\1740 ,_29\,\1740 <e2>left_30\VBD\120316 ventricular_31\JJ\1740 systolic_32\NN\1740 and_33\CC\1740 diastolic_34\JJ\1740 dysfunction</e2>_35\NN\14204950 ,_36\,\1740 and_37\CC\1740 only_38\RB\1740 modestly_39\RB\1740 elevated_40\JJ\1740 biochemical_41\JJ\1740 markers_42\NNS\21939 of_43\IN\1740 myocardial_44\JJ\1740 necrosis_45\NN\11444117 ._46\.\1740
D004837_D062787 NONE severe_0\JJ\1740 reversible_1\JJ\1740 left_2\VBD\120316 ventricular_3\JJ\1740 systolic_4\NN\1740 and_5\CC\1740 diastolic_6\JJ\1740 dysfunction_7\NN\14204950 due_8\IN\5174653 to_9\TO\1740 accidental_10\JJ\1740 iatrogenic_11\JJ\1740 <e1>epinephrine</e1>_12\NN\14807929 <e2>overdose</e2>_13\NN\1740 ._14\.\1740
D002395_D009202 NONE <e1>catecholamine-induced</e1>_0\JJ\1740 <e2>cardiomyopathy</e2>_1\NN\14103288 due_2\JJ\1740 to_3\TO\1740 chronic_4\JJ\1740 excess_5\NN\5119367 of_6\IN\1740 endogenous_7\JJ\1740 catecholamines_8\NNS\5407119 has_9\VBZ\2108377 been_10\VBN\836236 recognized_11\VBN\686447 for_12\IN\1740 decades_13\NNS\15113229 as_14\IN\14622893 a_15\DT\13649268 clinical_16\JJ\1740 phenomenon_17\NN\29677 ._18\.\1740
D002395_D009202 NONE catecholamine-induced_0\JJ\1740 <e2>cardiomyopathy</e2>_1\NN\14103288 due_2\JJ\1740 to_3\TO\1740 chronic_4\JJ\1740 excess_5\NN\5119367 of_6\IN\1740 endogenous_7\JJ\1740 <e1>catecholamines</e1>_8\NNS\5407119 has_9\VBZ\2108377 been_10\VBN\836236 recognized_11\VBN\686447 for_12\IN\1740 decades_13\NNS\15113229 as_14\IN\14622893 a_15\DT\13649268 clinical_16\JJ\1740 phenomenon_17\NN\29677 ._18\.\1740
D004837_D017682 CID a_0\DT\13649268 35-year-old_1\JJ\1740 woman_2\NN\9605289 whose_3\WP$\1740 cervix_4\NN\5225090 uteri_5\NN\5514717 was_6\VBD\836236 inadvertently_7\RB\1740 injected_8\VBN\81072 with_9\IN\1740 8_10\CD\13741022 mg_11\NN\13717155 of_12\IN\1740 <e1>epinephrine</e1>_13\NN\14807929 developed_14\VBD\1753788 <e2>myocardial_15\JJ\1740 stunning</e2>_16\NN\1740 that_17\WDT\1740 was_18\VBD\836236 characterized_19\VBN\609683 by_20\IN\1740 severe_21\JJ\1740 hemodynamic_22\JJ\1740 compromise_23\NN\1202904 ,_24\,\1740 profound_25\JJ\1740 ,_26\,\1740 albeit_27\IN\1740 transient_28\JJ\1740 ,_29\,\1740 left_30\VBD\120316 ventricular_31\JJ\1740 systolic_32\NN\1740 and_33\CC\1740 diastolic_34\JJ\1740 dysfunction_35\NN\14204950 ,_36\,\1740 and_37\CC\1740 only_38\RB\1740 modestly_39\RB\1740 elevated_40\JJ\1740 biochemical_41\JJ\1740 markers_42\NNS\21939 of_43\IN\1740 myocardial_44\JJ\1740 necrosis_45\NN\11444117 ._46\.\1740
D004837_D009202 NONE a_0\DT\13649268 35-year-old_1\JJ\1740 woman_2\NN\9605289 whose_3\WP$\1740 cervix_4\NN\5225090 uteri_5\NN\5514717 was_6\VBD\836236 inadvertently_7\RB\1740 injected_8\VBN\81072 with_9\IN\1740 8_10\CD\13741022 mg_11\NN\13717155 of_12\IN\1740 <e1>epinephrine</e1>_13\NN\14807929 developed_14\VBD\1753788 myocardial_15\JJ\1740 stunning_16\NN\1740 that_17\WDT\1740 was_18\VBD\836236 characterized_19\VBN\609683 by_20\IN\1740 severe_21\JJ\1740 hemodynamic_22\JJ\1740 compromise_23\NN\1202904 ,_24\,\1740 profound_25\JJ\1740 ,_26\,\1740 albeit_27\IN\1740 transient_28\JJ\1740 ,_29\,\1740 left_30\VBD\120316 ventricular_31\JJ\1740 systolic_32\NN\1740 and_33\CC\1740 diastolic_34\JJ\1740 dysfunction_35\NN\14204950 ,_36\,\1740 and_37\CC\1740 only_38\RB\1740 modestly_39\RB\1740 elevated_40\JJ\1740 biochemical_41\JJ\1740 markers_42\NNS\21939 of_43\IN\1740 <e2>myocardial_44\JJ\1740 necrosis</e2>_45\NN\11444117 ._46\.\1740
17615423
D019821_D012206 CID severe_0\JJ\1740 <e2>rhabdomyolysis</e2>_1\NN\1740 and_2\CC\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 secondary_6\JJ\1740 to_7\TO\1740 concomitant_8\JJ\1740 use_9\NN\407535 of_10\IN\1740 <e1>simvastatin</e1>_11\NN\3676175 ,_12\,\1740 amiodarone_13\RB\1740 ,_14\,\1740 and_15\CC\1740 atazanavir_16\NN\1740 ._17\.\1740
D019821_D012206 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 severe_8\JJ\1740 interaction_9\NN\37396 between_10\IN\1740 <e1>simvastatin</e1>_11\NN\3676175 ,_12\,\1740 amiodarone_13\RB\1740 ,_14\,\1740 and_15\CC\1740 atazanavir_16\NN\1740 resulting_17\VBG\2633881 in_18\IN\13603305 <e2>rhabdomyolysis</e2>_19\NN\1740 and_20\CC\1740 acute_21\JJ\1740 renal_22\JJ\1740 failure_23\NN\66216 ._24\.\1740
D019821_D012206 CID discussion_0\NN\6252138 :_1\:\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>rhabdomyolysis</e2>_5\NN\1740 is_6\VBZ\836236 increased_7\VBN\169651 in_8\IN\13603305 the_9\DT\1740 presence_10\NN\13954253 of_11\IN\1740 concomitant_12\JJ\1740 drugs_13\NNS\14778436 that_14\WDT\1740 inhibit_15\VBP\2510337 <e1>simvastatin</e1>_16\NN\3676175 metabolism_17\NN\13526110 ._18\.\1740
D019821_D058186 CID severe_0\JJ\1740 rhabdomyolysis_1\NN\1740 and_2\CC\1740 <e2>acute_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 secondary_6\JJ\1740 to_7\TO\1740 concomitant_8\JJ\1740 use_9\NN\407535 of_10\IN\1740 <e1>simvastatin</e1>_11\NN\3676175 ,_12\,\1740 amiodarone_13\RB\1740 ,_14\,\1740 and_15\CC\1740 atazanavir_16\NN\1740 ._17\.\1740
D019821_D058186 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 severe_8\JJ\1740 interaction_9\NN\37396 between_10\IN\1740 <e1>simvastatin</e1>_11\NN\3676175 ,_12\,\1740 amiodarone_13\RB\1740 ,_14\,\1740 and_15\CC\1740 atazanavir_16\NN\1740 resulting_17\VBG\2633881 in_18\IN\13603305 rhabdomyolysis_19\NN\1740 and_20\CC\1740 <e2>acute_21\JJ\1740 renal_22\JJ\1740 failure</e2>_23\NN\66216 ._24\.\1740
D000638_D012206 CID severe_0\JJ\1740 <e2>rhabdomyolysis</e2>_1\NN\1740 and_2\CC\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 secondary_6\JJ\1740 to_7\TO\1740 concomitant_8\JJ\1740 use_9\NN\407535 of_10\IN\1740 simvastatin_11\NN\3676175 ,_12\,\1740 <e1>amiodarone</e1>_13\RB\1740 ,_14\,\1740 and_15\CC\1740 atazanavir_16\NN\1740 ._17\.\1740
D000638_D012206 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 severe_8\JJ\1740 interaction_9\NN\37396 between_10\IN\1740 simvastatin_11\NN\3676175 ,_12\,\1740 <e1>amiodarone</e1>_13\RB\1740 ,_14\,\1740 and_15\CC\1740 atazanavir_16\NN\1740 resulting_17\VBG\2633881 in_18\IN\13603305 <e2>rhabdomyolysis</e2>_19\NN\1740 and_20\CC\1740 acute_21\JJ\1740 renal_22\JJ\1740 failure_23\NN\66216 ._24\.\1740
D000638_D058186 CID severe_0\JJ\1740 rhabdomyolysis_1\NN\1740 and_2\CC\1740 <e2>acute_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 secondary_6\JJ\1740 to_7\TO\1740 concomitant_8\JJ\1740 use_9\NN\407535 of_10\IN\1740 simvastatin_11\NN\3676175 ,_12\,\1740 <e1>amiodarone</e1>_13\RB\1740 ,_14\,\1740 and_15\CC\1740 atazanavir_16\NN\1740 ._17\.\1740
D000638_D058186 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 severe_8\JJ\1740 interaction_9\NN\37396 between_10\IN\1740 simvastatin_11\NN\3676175 ,_12\,\1740 <e1>amiodarone</e1>_13\RB\1740 ,_14\,\1740 and_15\CC\1740 atazanavir_16\NN\1740 resulting_17\VBG\2633881 in_18\IN\13603305 rhabdomyolysis_19\NN\1740 and_20\CC\1740 <e2>acute_21\JJ\1740 renal_22\JJ\1740 failure</e2>_23\NN\66216 ._24\.\1740
C413408_D012206 CID severe_0\JJ\1740 <e2>rhabdomyolysis</e2>_1\NN\1740 and_2\CC\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 secondary_6\JJ\1740 to_7\TO\1740 concomitant_8\JJ\1740 use_9\NN\407535 of_10\IN\1740 simvastatin_11\NN\3676175 ,_12\,\1740 amiodarone_13\RB\1740 ,_14\,\1740 and_15\CC\1740 <e1>atazanavir</e1>_16\NN\1740 ._17\.\1740
C413408_D012206 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 severe_8\JJ\1740 interaction_9\NN\37396 between_10\IN\1740 simvastatin_11\NN\3676175 ,_12\,\1740 amiodarone_13\RB\1740 ,_14\,\1740 and_15\CC\1740 <e1>atazanavir</e1>_16\NN\1740 resulting_17\VBG\2633881 in_18\IN\13603305 <e2>rhabdomyolysis</e2>_19\NN\1740 and_20\CC\1740 acute_21\JJ\1740 renal_22\JJ\1740 failure_23\NN\66216 ._24\.\1740
C413408_D058186 CID severe_0\JJ\1740 rhabdomyolysis_1\NN\1740 and_2\CC\1740 <e2>acute_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 secondary_6\JJ\1740 to_7\TO\1740 concomitant_8\JJ\1740 use_9\NN\407535 of_10\IN\1740 simvastatin_11\NN\3676175 ,_12\,\1740 amiodarone_13\RB\1740 ,_14\,\1740 and_15\CC\1740 <e1>atazanavir</e1>_16\NN\1740 ._17\.\1740
C413408_D058186 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 severe_8\JJ\1740 interaction_9\NN\37396 between_10\IN\1740 simvastatin_11\NN\3676175 ,_12\,\1740 amiodarone_13\RB\1740 ,_14\,\1740 and_15\CC\1740 <e1>atazanavir</e1>_16\NN\1740 resulting_17\VBG\2633881 in_18\IN\13603305 rhabdomyolysis_19\NN\1740 and_20\CC\1740 <e2>acute_21\JJ\1740 renal_22\JJ\1740 failure</e2>_23\NN\66216 ._24\.\1740
D019821_D015658 NONE <e1>simvastatin</e1>_0\NN\3676175 ,_1\,\1740 amiodarone_2\RB\1740 ,_3\,\1740 and_4\CC\1740 the_5\DT\1740 patient_6\NN\9898892 's_7\POS\1740 <e2>human_8\JJ\1740 immunodeficiency_9\NN\13973990 virus</e2>_10\NN\9312843 medications_11\NNS\3247620 were_12\VBD\836236 all_13\DT\1740 temporarily_14\RB\1740 discontinued_15\VBN\2609764 and_16\CC\1740 the_17\DT\1740 patient_18\NN\9898892 was_19\VBD\836236 given_20\VBN\2327200 forced_21\VBN\2506546 alkaline_22\NN\1740 diuresis_23\NN\14299637 and_24\CC\1740 started_25\VBD\2009433 on_26\IN\1740 dialysis_27\NN\646833 ._28\.\1740
D000638_D015658 NONE simvastatin_0\NN\3676175 ,_1\,\1740 <e1>amiodarone</e1>_2\RB\1740 ,_3\,\1740 and_4\CC\1740 the_5\DT\1740 patient_6\NN\9898892 's_7\POS\1740 <e2>human_8\JJ\1740 immunodeficiency_9\NN\13973990 virus</e2>_10\NN\9312843 medications_11\NNS\3247620 were_12\VBD\836236 all_13\DT\1740 temporarily_14\RB\1740 discontinued_15\VBN\2609764 and_16\CC\1740 the_17\DT\1740 patient_18\NN\9898892 was_19\VBD\836236 given_20\VBN\2327200 forced_21\VBN\2506546 alkaline_22\NN\1740 diuresis_23\NN\14299637 and_24\CC\1740 started_25\VBD\2009433 on_26\IN\1740 dialysis_27\NN\646833 ._28\.\1740
12584269
D020123_D007674 CID these_0\DT\1740 are_1\VBP\836236 <e2>nephrotoxic</e2>_2\JJ\1740 ,_3\,\1740 but_4\CC\1740 <e1>srl</e1>_5\NN\1740 seems_6\VBZ\2604760 to_7\TO\1740 act_8\VB\1619354 differently_9\RB\1740 displaying_10\VBG\2137132 only_11\RB\1740 minor_12\JJ\1740 nephrotoxic_13\JJ\1740 effects_14\NNS\13245626 ,_15\,\1740 although_16\IN\1740 this_17\DT\1740 question_18\NN\7193184 is_19\VBZ\836236 still_20\RB\1740 open_21\JJ\1740 ._22\.\1740
D020123_D007674 CID these_0\DT\1740 are_1\VBP\836236 nephrotoxic_2\JJ\1740 ,_3\,\1740 but_4\CC\1740 <e1>srl</e1>_5\NN\1740 seems_6\VBZ\2604760 to_7\TO\1740 act_8\VB\1619354 differently_9\RB\1740 displaying_10\VBG\2137132 only_11\RB\1740 minor_12\JJ\1740 <e2>nephrotoxic</e2>_13\JJ\1740 effects_14\NNS\13245626 ,_15\,\1740 although_16\IN\1740 this_17\DT\1740 question_18\NN\7193184 is_19\VBZ\836236 still_20\RB\1740 open_21\JJ\1740 ._22\.\1740
D020123_D007674 CID in_0\IN\13603305 a_1\DT\13649268 number_2\NN\5107765 of_3\IN\1740 treatment_4\NN\654885 protocols_5\NNS\6652242 where_6\WRB\1740 <e1>srl</e1>_7\NN\1740 was_8\VBD\836236 combined_9\VBN\2630189 with_10\IN\1740 a_11\DT\13649268 calcineurin_12\NN\1740 inhibitor_13\NN\20090 indications_14\NNS\33020 of_15\IN\1740 a_16\DT\13649268 synergistic_17\JJ\1740 <e2>nephrotoxic</e2>_18\JJ\1740 effect_19\NN\34213 were_20\VBD\836236 described_21\VBN\1001294 ._22\.\1740
D020123_D007674 CID conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 rat_3\NN\2329401 study_4\NN\635850 demonstrated_5\VBD\2137132 a_6\DT\13649268 synergistic_7\JJ\1740 <e2>nephrotoxic</e2>_8\JJ\1740 effect_9\NN\34213 of_10\IN\1740 csa_11\NN\1740 plus_12\CC\4723816 <e1>srl</e1>_13\NN\1740 ,_14\,\1740 whereas_15\IN\1740 fk506_16\NN\1740 plus_17\CC\4723816 srl_18\NN\1740 was_19\VBD\836236 better_20\RBR\1740 tolerated_21\VBN\802318 ._22\.\1740
D020123_D007674 CID conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 rat_3\NN\2329401 study_4\NN\635850 demonstrated_5\VBD\2137132 a_6\DT\13649268 synergistic_7\JJ\1740 <e2>nephrotoxic</e2>_8\JJ\1740 effect_9\NN\34213 of_10\IN\1740 csa_11\NN\1740 plus_12\CC\4723816 srl_13\NN\1740 ,_14\,\1740 whereas_15\IN\1740 fk506_16\NN\1740 plus_17\CC\4723816 <e1>srl</e1>_18\NN\1740 was_19\VBD\836236 better_20\RBR\1740 tolerated_21\VBN\802318 ._22\.\1740
D016572_D005355 NONE the_0\DT\1740 semi-quantitative_1\JJ\1740 scoring_2\NN\874806 was_3\VBD\836236 significantly_4\RB\1740 worst_5\VBN\1101913 in_6\IN\13603305 the_7\DT\1740 group_8\NN\2137 treated_9\VBN\2376958 with_10\IN\1740 <e1>csa</e1>_11\NN\1740 plus_12\CC\4723816 srl_13\NN\1740 (_14\-LRB-\1740 p<0.001_15\NN\1740 compared_16\VBN\644583 with_17\IN\1740 controls_18\NNS\5190804 )_19\-RRB-\1740 and_20\CC\1740 the_21\DT\1740 analysis_22\NN\633864 of_23\IN\1740 the_24\DT\1740 total_25\JJ\1740 grade_26\NN\7975026 of_27\IN\1740 <e2>fibrosis</e2>_28\NN\14204950 also_29\RB\1740 showed_30\VBD\2137132 the_31\DT\1740 highest_32\JJS\1740 proportion_33\NN\13824815 in_34\IN\13603305 the_35\DT\1740 same_36\JJ\1740 group_37\NN\2137 and_38\CC\1740 was_39\VBD\836236 significantly_40\RB\1740 different_41\JJ\1740 from_42\IN\1740 controls_43\NNS\5190804 (_44\-LRB-\1740 p<0.02_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
D020123_D005355 NONE the_0\DT\1740 semi-quantitative_1\JJ\1740 scoring_2\NN\874806 was_3\VBD\836236 significantly_4\RB\1740 worst_5\VBN\1101913 in_6\IN\13603305 the_7\DT\1740 group_8\NN\2137 treated_9\VBN\2376958 with_10\IN\1740 csa_11\NN\1740 plus_12\CC\4723816 <e1>srl</e1>_13\NN\1740 (_14\-LRB-\1740 p<0.001_15\NN\1740 compared_16\VBN\644583 with_17\IN\1740 controls_18\NNS\5190804 )_19\-RRB-\1740 and_20\CC\1740 the_21\DT\1740 analysis_22\NN\633864 of_23\IN\1740 the_24\DT\1740 total_25\JJ\1740 grade_26\NN\7975026 of_27\IN\1740 <e2>fibrosis</e2>_28\NN\14204950 also_29\RB\1740 showed_30\VBD\2137132 the_31\DT\1740 highest_32\JJS\1740 proportion_33\NN\13824815 in_34\IN\13603305 the_35\DT\1740 same_36\JJ\1740 group_37\NN\2137 and_38\CC\1740 was_39\VBD\836236 significantly_40\RB\1740 different_41\JJ\1740 from_42\IN\1740 controls_43\NNS\5190804 (_44\-LRB-\1740 p<0.02_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
D020123_D005355 NONE the_0\DT\1740 fk506_1\NN\1740 plus_2\CC\4723816 <e1>srl</e1>_3\NN\1740 combination_4\NN\7951464 showed_5\VBD\2137132 only_6\RB\1740 a_7\DT\13649268 marginally_8\RB\1740 higher_9\JJR\1740 degree_10\NN\4916342 of_11\IN\1740 <e2>fibrosis</e2>_12\NN\14204950 as_13\IN\14622893 compared_14\VBN\644583 with_15\IN\1740 controls_16\NNS\5190804 (_17\-LRB-\1740 p=0.05_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D016559_D005355 NONE the_0\DT\1740 <e1>fk506</e1>_1\NN\1740 plus_2\CC\4723816 srl_3\NN\1740 combination_4\NN\7951464 showed_5\VBD\2137132 only_6\RB\1740 a_7\DT\13649268 marginally_8\RB\1740 higher_9\JJR\1740 degree_10\NN\4916342 of_11\IN\1740 <e2>fibrosis</e2>_12\NN\14204950 as_13\IN\14622893 compared_14\VBN\644583 with_15\IN\1740 controls_16\NNS\5190804 (_17\-LRB-\1740 p=0.05_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D016572_D007674 CID conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 rat_3\NN\2329401 study_4\NN\635850 demonstrated_5\VBD\2137132 a_6\DT\13649268 synergistic_7\JJ\1740 <e2>nephrotoxic</e2>_8\JJ\1740 effect_9\NN\34213 of_10\IN\1740 <e1>csa</e1>_11\NN\1740 plus_12\CC\4723816 srl_13\NN\1740 ,_14\,\1740 whereas_15\IN\1740 fk506_16\NN\1740 plus_17\CC\4723816 srl_18\NN\1740 was_19\VBD\836236 better_20\RBR\1740 tolerated_21\VBN\802318 ._22\.\1740
D016559_D007674 CID conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 rat_3\NN\2329401 study_4\NN\635850 demonstrated_5\VBD\2137132 a_6\DT\13649268 synergistic_7\JJ\1740 <e2>nephrotoxic</e2>_8\JJ\1740 effect_9\NN\34213 of_10\IN\1740 csa_11\NN\1740 plus_12\CC\4723816 srl_13\NN\1740 ,_14\,\1740 whereas_15\IN\1740 <e1>fk506</e1>_16\NN\1740 plus_17\CC\4723816 srl_18\NN\1740 was_19\VBD\836236 better_20\RBR\1740 tolerated_21\VBN\802318 ._22\.\1740
14976857
D011405_-1 NONE transient_0\JJ\1740 <e2>platypnea-orthodeoxia-like_1\JJ\1740 syndrome</e2>_2\NN\5870365 induced_3\VBN\1627355 by_4\IN\1740 <e1>propafenone</e1>_5\NN\1740 overdose_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 young_9\JJ\1740 woman_10\NN\9605289 with_11\IN\1740 ebstein_12\NNP\1740 's_13\POS\1740 anomaly_14\NN\14501726 ._15\.\1740
D011405_D062787 NONE transient_0\JJ\1740 platypnea-orthodeoxia-like_1\JJ\1740 syndrome_2\NN\5870365 induced_3\VBN\1627355 by_4\IN\1740 <e1>propafenone</e1>_5\NN\1740 <e2>overdose</e2>_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 young_9\JJ\1740 woman_10\NN\9605289 with_11\IN\1740 ebstein_12\NNP\1740 's_13\POS\1740 anomaly_14\NN\14501726 ._15\.\1740
D011405_D062787 NONE this_0\DT\1740 shunt_1\NN\5248181 of_2\IN\1740 blood_3\NN\5397468 via_4\IN\1740 a_5\DT\13649268 patent_6\NN\6470073 foramen_7\NN\9379111 ovale_8\NN\1740 occurred_9\VBD\2623529 in_10\IN\13603305 the_11\DT\1740 presence_12\NN\13954253 of_13\IN\1740 a_14\DT\13649268 normal_15\JJ\1740 pulmonary_16\JJ\1740 artery_17\NN\5417975 pressure_18\NN\11419404 ,_19\,\1740 and_20\CC\1740 was_21\VBD\836236 probably_22\RB\1740 precipitated_23\VBN\1642924 by_24\IN\1740 a_25\DT\13649268 <e1>propafenone</e1>_26\NN\1740 <e2>overdose</e2>_27\NN\1740 ._28\.\1740
D011405_D004437 NONE transient_0\JJ\1740 platypnea-orthodeoxia-like_1\JJ\1740 syndrome_2\NN\5870365 induced_3\VBN\1627355 by_4\IN\1740 <e1>propafenone</e1>_5\NN\1740 overdose_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 young_9\JJ\1740 woman_10\NN\9605289 with_11\IN\1740 <e2>ebstein_12\NNP\1740 's_13\POS\1740 anomaly</e2>_14\NN\14501726 ._15\.\1740
D011405_D054092 NONE this_0\DT\1740 shunt_1\NN\5248181 of_2\IN\1740 blood_3\NN\5397468 via_4\IN\1740 a_5\DT\13649268 <e2>patent_6\NN\6470073 foramen_7\NN\9379111 ovale</e2>_8\NN\1740 occurred_9\VBD\2623529 in_10\IN\13603305 the_11\DT\1740 presence_12\NN\13954253 of_13\IN\1740 a_14\DT\13649268 normal_15\JJ\1740 pulmonary_16\JJ\1740 artery_17\NN\5417975 pressure_18\NN\11419404 ,_19\,\1740 and_20\CC\1740 was_21\VBD\836236 probably_22\RB\1740 precipitated_23\VBN\1642924 by_24\IN\1740 a_25\DT\13649268 <e1>propafenone</e1>_26\NN\1740 overdose_27\NN\1740 ._28\.\1740
11166519
D003042_D012640 CID acute_0\JJ\1740 <e1>cocaine-induced</e1>_1\JJ\1740 <e2>seizures</e2>_2\NNS\14081375 :_3\:\1740 differential_4\JJ\1740 sensitivity_5\NN\5651971 of_6\IN\1740 six_7\CD\13741022 inbred_8\JJ\1740 mouse_9\NN\2329401 strains_10\NNS\7358060 ._11\.\1740
D003042_D012640 CID mature_0\JJ\1740 male_1\JJ\1740 and_2\CC\1740 female_3\JJ\1740 mice_4\NNS\2329401 from_5\IN\1740 six_6\CD\13741022 inbred_7\VBN\1740 stains_8\NNS\4673965 were_9\VBD\836236 tested_10\VBN\670261 for_11\IN\1740 susceptibility_12\NN\13920835 to_13\TO\1740 behavioral_14\JJ\1740 <e2>seizures</e2>_15\NNS\14081375 induced_16\VBN\1627355 by_17\IN\1740 a_18\DT\13649268 single_19\JJ\1740 injection_20\NN\320852 of_21\IN\1740 <e1>cocaine</e1>_22\NN\3492717 ._23\.\1740
D003042_D012640 CID additional_0\JJ\1740 studies_1\NNS\635850 of_2\IN\1740 these_3\DT\1740 murine_4\JJ\1740 strains_5\NNS\7358060 may_6\MD\15209706 be_7\VB\836236 useful_8\JJ\1740 for_9\IN\1740 investigating_10\VBG\644583 genetic_11\JJ\1740 influences_12\NNS\5190804 on_13\IN\1740 <e1>cocaine-induced</e1>_14\JJ\1740 <e2>seizures</e2>_15\NNS\14081375 ._16\.\1740
6209318
D008801_D001145 NONE international_0\JJ\1740 <e1>mexiletine</e1>_1\NN\2715941 and_2\CC\1740 placebo_3\JJ\1740 antiarrhythmic_4\JJ\1740 coronary_5\JJ\1740 trial_6\NN\786195 :_7\:\1740 i._8\NNP\1740 report_9\NNP\6470073 on_10\IN\1740 <e2>arrhythmia</e2>_11\NN\14103288 and_12\CC\1740 other_13\JJ\1740 findings_14\NNS\7951464 ._15\.\1740
D008801_D009203 NONE the_0\DT\1740 antiarrhythmic_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 the_4\DT\1740 sustained_5\JJ\1740 release_6\NN\3748886 form_7\NN\6286395 of_8\IN\1740 <e1>mexiletine</e1>_9\NN\2715941 (_10\-LRB-\1740 mexitil-perlongets_11\NNS\1740 )_12\-RRB-\1740 were_13\VBD\836236 evaluated_14\VBN\670261 in_15\IN\13603305 a_16\DT\13649268 double-blind_17\JJ\1740 placebo_18\NN\3740161 trial_19\NN\786195 in_20\IN\13603305 630_21\CD\1740 patients_22\NNS\9898892 with_23\IN\1740 recent_24\JJ\1740 documented_25\VBN\1000214 <e2>myocardial_26\JJ\1740 infarction</e2>_27\NN\14204950 ._28\.\1740
D008801_D009203 NONE the_0\DT\1740 antiarrhythmic_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 the_4\DT\1740 sustained_5\JJ\1740 release_6\NN\3748886 form_7\NN\6286395 of_8\IN\1740 mexiletine_9\NN\2715941 (_10\-LRB-\1740 <e1>mexitil-perlongets</e1>_11\NNS\1740 )_12\-RRB-\1740 were_13\VBD\836236 evaluated_14\VBN\670261 in_15\IN\13603305 a_16\DT\13649268 double-blind_17\JJ\1740 placebo_18\NN\3740161 trial_19\NN\786195 in_20\IN\13603305 630_21\CD\1740 patients_22\NNS\9898892 with_23\IN\1740 recent_24\JJ\1740 documented_25\VBN\1000214 <e2>myocardial_26\JJ\1740 infarction</e2>_27\NN\14204950 ._28\.\1740
D008801_D003643 NONE there_0\EX\27167 were_1\VBD\836236 more_2\JJR\1740 <e2>deaths</e2>_3\NNS\7296428 in_4\IN\13603305 the_5\DT\1740 <e1>mexiletine</e1>_6\NN\2715941 group_7\NN\2137 (_8\-LRB-\1740 7.6_9\CD\1740 %_10\NN\1740 )_11\-RRB-\1740 than_12\IN\1740 in_13\IN\13603305 the_14\DT\1740 placebo_15\NN\3740161 group_16\NN\2137 (_17\-LRB-\1740 4.8_18\CD\1740 %_19\NN\1740 )_20\-RRB-\1740 ;_21\:\1740 the_22\DT\1740 difference_23\NN\4723816 was_24\VBD\836236 not_25\RB\1740 statistically_26\RB\1740 significant_27\JJ\1740 ._28\.\1740
D008801_D014202 CID previously_0\RB\1740 recognized_1\VBN\686447 side_2\NN\8630039 effects_3\NNS\13245626 ,_4\,\1740 particularly_5\RB\1740 <e2>tremor</e2>_6\NN\345926 and_7\CC\1740 gastrointestinal_8\JJ\1740 problems_9\NNS\14408086 ,_10\,\1740 were_11\VBD\836236 more_12\RBR\1740 frequent_13\JJ\1740 in_14\IN\13603305 the_15\DT\1740 <e1>mexiletine</e1>_16\NN\2715941 group_17\NN\2137 than_18\IN\1740 in_19\IN\13603305 the_20\DT\1740 placebo_21\NN\3740161 group_22\NN\2137 ._23\.\1740
D008801_D012817 CID previously_0\RB\1740 recognized_1\VBN\686447 side_2\NN\8630039 effects_3\NNS\13245626 ,_4\,\1740 particularly_5\RB\1740 tremor_6\NN\345926 and_7\CC\1740 <e2>gastrointestinal_8\JJ\1740 problems</e2>_9\NNS\14408086 ,_10\,\1740 were_11\VBD\836236 more_12\RBR\1740 frequent_13\JJ\1740 in_14\IN\13603305 the_15\DT\1740 <e1>mexiletine</e1>_16\NN\2715941 group_17\NN\2137 than_18\IN\1740 in_19\IN\13603305 the_20\DT\1740 placebo_21\NN\3740161 group_22\NN\2137 ._23\.\1740
20196116
D000995_D017114 CID <e1>antituberculosis</e1>_0\NN\1740 therapy-induced_1\JJ\1740 <e2>acute_2\JJ\1740 liver_3\NN\5298729 failure</e2>_4\NN\66216 :_5\:\1740 magnitude_6\NN\4916342 ,_7\,\1740 profile_8\NN\6999802 ,_9\,\1740 prognosis_10\NN\6748969 ,_11\,\1740 and_12\CC\1740 predictors_13\NNS\10756433 of_14\IN\1740 outcome_15\NN\7291312 ._16\.\1740
D000995_D017114 CID <e1>antituberculosis</e1>_0\NN\1740 therapy_1\NN\657604 (att)-associated_2\VBD\1740 <e2>acute_3\JJ\1740 liver_4\NN\5298729 failure</e2>_5\NN\66216 (_6\-LRB-\1740 att-alf_7\NN\1740 )_8\-RRB-\1740 is_9\VBZ\836236 the_10\DT\1740 commonest_11\NN\1740 drug-induced_12\JJ\1740 alf_13\NN\1740 in_14\IN\13603305 south_15\NNP\13831000 asia_16\NNP\7951464 ._17\.\1740
D000995_D017114 CID <e1>antituberculosis</e1>_0\NN\1740 therapy_1\NN\657604 (att)-associated_2\VBD\1740 acute_3\JJ\1740 liver_4\NN\5298729 failure_5\NN\66216 (_6\-LRB-\1740 <e2>att-alf</e2>_7\NN\1740 )_8\-RRB-\1740 is_9\VBZ\836236 the_10\DT\1740 commonest_11\NN\1740 drug-induced_12\JJ\1740 alf_13\NN\1740 in_14\IN\13603305 south_15\NNP\13831000 asia_16\NNP\7951464 ._17\.\1740
D000995_D017114 CID <e1>antituberculosis</e1>_0\NN\1740 therapy_1\NN\657604 (att)-associated_2\VBD\1740 acute_3\JJ\1740 liver_4\NN\5298729 failure_5\NN\66216 (_6\-LRB-\1740 att-alf_7\NN\1740 )_8\-RRB-\1740 is_9\VBZ\836236 the_10\DT\1740 commonest_11\NN\1740 drug-induced_12\JJ\1740 <e2>alf</e2>_13\NN\1740 in_14\IN\13603305 south_15\NNP\13831000 asia_16\NNP\7951464 ._17\.\1740
D001663_D001927 NONE in_0\IN\13603305 multivariate_1\JJ\1740 analysis_2\NN\633864 ,_3\,\1740 three_4\CD\13741022 factors_5\NNS\7326557 independently_6\RB\1740 predicted_7\VBD\916909 mortality_8\NN\5054863 :_9\:\1740 serum_10\NN\5397468 <e1>bilirubin</e1>_11\NN\14756039 (_12\-LRB-\1740 >_13\NN\1740 or=10.8_14\NN\1740 mg/dl_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 prothrombin_18\NN\15022776 time_19\NN\7308889 (_20\-LRB-\1740 pt_21\NN\14627081 )_22\-RRB-\1740 prolongation_23\NN\1017987 (_24\-LRB-\1740 >_25\NNS\1740 or=26_26\NN\1740 seconds_27\NNS\15154774 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 grade_31\NN\7975026 iii/iv_32\NN\1740 <e2>encephalopathy</e2>_33\JJ\1740 at_34\IN\14622893 presentation_35\NN\1027379 ._36\.\1740
20477932
D003042_D008569 CID <e1>cocaine</e1>_0\NN\3492717 causes_1\VBZ\1617192 <e2>memory_2\NN\5926676 and_3\CC\1740 learning_4\NN\5701944 impairments</e2>_5\NNS\7296428 in_6\IN\13603305 rats_7\NNS\2329401 :_8\:\1740 involvement_9\NN\1080366 of_10\IN\1740 nuclear_11\JJ\1740 factor_12\NN\7326557 kappa_13\NN\6828818 b_14\NN\1355326 and_15\CC\1740 oxidative_16\JJ\1740 stress_17\NN\7083732 ,_18\,\1740 and_19\CC\1740 prevention_20\NN\1073995 by_21\IN\1740 topiramate_22\NN\1740 ._23\.\1740
D003042_D007859 CID <e1>cocaine</e1>_0\NN\3492717 causes_1\VBZ\1617192 <e2>memory_2\NN\5926676 and_3\CC\1740 learning_4\NN\5701944 impairments</e2>_5\NNS\7296428 in_6\IN\13603305 rats_7\NNS\2329401 :_8\:\1740 involvement_9\NN\1080366 of_10\IN\1740 nuclear_11\JJ\1740 factor_12\NN\7326557 kappa_13\NN\6828818 b_14\NN\1355326 and_15\CC\1740 oxidative_16\JJ\1740 stress_17\NN\7083732 ,_18\,\1740 and_19\CC\1740 prevention_20\NN\1073995 by_21\IN\1740 topiramate_22\NN\1740 ._23\.\1740
C052342_D008569 NONE cocaine_0\NN\3492717 causes_1\VBZ\1617192 <e2>memory_2\NN\5926676 and_3\CC\1740 learning_4\NN\5701944 impairments</e2>_5\NNS\7296428 in_6\IN\13603305 rats_7\NNS\2329401 :_8\:\1740 involvement_9\NN\1080366 of_10\IN\1740 nuclear_11\JJ\1740 factor_12\NN\7326557 kappa_13\NN\6828818 b_14\NN\1355326 and_15\CC\1740 oxidative_16\JJ\1740 stress_17\NN\7083732 ,_18\,\1740 and_19\CC\1740 prevention_20\NN\1073995 by_21\IN\1740 <e1>topiramate</e1>_22\NN\1740 ._23\.\1740
C052342_D007859 NONE cocaine_0\NN\3492717 causes_1\VBZ\1617192 <e2>memory_2\NN\5926676 and_3\CC\1740 learning_4\NN\5701944 impairments</e2>_5\NNS\7296428 in_6\IN\13603305 rats_7\NNS\2329401 :_8\:\1740 involvement_9\NN\1080366 of_10\IN\1740 nuclear_11\JJ\1740 factor_12\NN\7326557 kappa_13\NN\6828818 b_14\NN\1355326 and_15\CC\1740 oxidative_16\JJ\1740 stress_17\NN\7083732 ,_18\,\1740 and_19\CC\1740 prevention_20\NN\1073995 by_21\IN\1740 <e1>topiramate</e1>_22\NN\1740 ._23\.\1740
D003042_D064420 NONE different_0\JJ\1740 mechanisms_1\NNS\13446390 have_2\VBP\2108377 been_3\VBN\836236 suggested_4\VBN\1010118 for_5\IN\1740 <e1>cocaine</e1>_6\NN\3492717 <e2>toxicity</e2>_7\NN\13576101 including_8\VBG\690614 an_9\DT\6697703 increase_10\NN\13576355 in_11\IN\13603305 oxidative_12\JJ\1740 stress_13\NN\7083732 but_14\CC\1740 the_15\DT\1740 association_16\NN\8008335 between_17\IN\1740 oxidative_18\JJ\1740 status_19\NN\24720 in_20\IN\13603305 the_21\DT\1740 brain_22\NN\5462674 and_23\CC\1740 cocaine_24\NN\3492717 induced-behaviour_25\NN\1740 is_26\VBZ\836236 poorly_27\RB\1740 understood_28\VBN\588888 ._29\.\1740
D003042_D064420 NONE different_0\JJ\1740 mechanisms_1\NNS\13446390 have_2\VBP\2108377 been_3\VBN\836236 suggested_4\VBN\1010118 for_5\IN\1740 cocaine_6\NN\3492717 <e2>toxicity</e2>_7\NN\13576101 including_8\VBG\690614 an_9\DT\6697703 increase_10\NN\13576355 in_11\IN\13603305 oxidative_12\JJ\1740 stress_13\NN\7083732 but_14\CC\1740 the_15\DT\1740 association_16\NN\8008335 between_17\IN\1740 oxidative_18\JJ\1740 status_19\NN\24720 in_20\IN\13603305 the_21\DT\1740 brain_22\NN\5462674 and_23\CC\1740 <e1>cocaine</e1>_24\NN\3492717 induced-behaviour_25\NN\1740 is_26\VBZ\836236 poorly_27\RB\1740 understood_28\VBN\588888 ._29\.\1740
D009569_D019970 NONE therefore_0\RB\1740 nfkappab_1\NN\1740 activity_2\NN\30358 ,_3\,\1740 oxidative_4\JJ\1740 stress_5\NN\7083732 ,_6\,\1740 neuronal_7\JJ\1740 <e1>nitric_8\JJ\1740 oxide</e1>_9\NN\14818238 synthase_10\NN\1740 (_11\-LRB-\1740 nnos_12\NN\1740 )_13\-RRB-\1740 activity_14\NN\30358 ,_15\,\1740 spatial_16\JJ\1740 learning_17\NN\5701944 and_18\CC\1740 memory_19\NN\5926676 as_20\RB\1740 well_21\RB\1740 as_22\IN\14622893 the_23\DT\1740 effect_24\NN\34213 of_25\IN\1740 topiramate_26\NN\1740 ,_27\,\1740 a_28\DT\13649268 previously_29\RB\1740 proposed_30\VBN\1010118 therapy_31\NN\657604 for_32\IN\1740 <e2>cocaine_33\NN\3492717 addiction</e2>_34\NN\14034177 ,_35\,\1740 were_36\VBD\836236 evaluated_37\VBN\670261 in_38\IN\13603305 an_39\DT\6697703 experimental_40\JJ\1740 model_41\NN\5888929 of_42\IN\1740 cocaine_43\NN\3492717 administration_44\NN\1133281 in_45\IN\13603305 rats_46\NNS\2329401 ._47\.\1740
C052342_D019970 NONE therefore_0\RB\1740 nfkappab_1\NN\1740 activity_2\NN\30358 ,_3\,\1740 oxidative_4\JJ\1740 stress_5\NN\7083732 ,_6\,\1740 neuronal_7\JJ\1740 nitric_8\JJ\1740 oxide_9\NN\14818238 synthase_10\NN\1740 (_11\-LRB-\1740 nnos_12\NN\1740 )_13\-RRB-\1740 activity_14\NN\30358 ,_15\,\1740 spatial_16\JJ\1740 learning_17\NN\5701944 and_18\CC\1740 memory_19\NN\5926676 as_20\RB\1740 well_21\RB\1740 as_22\IN\14622893 the_23\DT\1740 effect_24\NN\34213 of_25\IN\1740 <e1>topiramate</e1>_26\NN\1740 ,_27\,\1740 a_28\DT\13649268 previously_29\RB\1740 proposed_30\VBN\1010118 therapy_31\NN\657604 for_32\IN\1740 <e2>cocaine_33\NN\3492717 addiction</e2>_34\NN\14034177 ,_35\,\1740 were_36\VBD\836236 evaluated_37\VBN\670261 in_38\IN\13603305 an_39\DT\6697703 experimental_40\JJ\1740 model_41\NN\5888929 of_42\IN\1740 cocaine_43\NN\3492717 administration_44\NN\1133281 in_45\IN\13603305 rats_46\NNS\2329401 ._47\.\1740
D003042_D019970 NONE therefore_0\RB\1740 nfkappab_1\NN\1740 activity_2\NN\30358 ,_3\,\1740 oxidative_4\JJ\1740 stress_5\NN\7083732 ,_6\,\1740 neuronal_7\JJ\1740 nitric_8\JJ\1740 oxide_9\NN\14818238 synthase_10\NN\1740 (_11\-LRB-\1740 nnos_12\NN\1740 )_13\-RRB-\1740 activity_14\NN\30358 ,_15\,\1740 spatial_16\JJ\1740 learning_17\NN\5701944 and_18\CC\1740 memory_19\NN\5926676 as_20\RB\1740 well_21\RB\1740 as_22\IN\14622893 the_23\DT\1740 effect_24\NN\34213 of_25\IN\1740 topiramate_26\NN\1740 ,_27\,\1740 a_28\DT\13649268 previously_29\RB\1740 proposed_30\VBN\1010118 therapy_31\NN\657604 for_32\IN\1740 <e2>cocaine_33\NN\3492717 addiction</e2>_34\NN\14034177 ,_35\,\1740 were_36\VBD\836236 evaluated_37\VBN\670261 in_38\IN\13603305 an_39\DT\6697703 experimental_40\JJ\1740 model_41\NN\5888929 of_42\IN\1740 <e1>cocaine</e1>_43\NN\3492717 administration_44\NN\1133281 in_45\IN\13603305 rats_46\NNS\2329401 ._47\.\1740
7265370
D014223_D053040 CID <e1>triamterene</e1>_0\NN\1740 <e2>nephrolithiasis</e2>_1\NN\14115914 complicating_2\VBG\126264 dyazide_3\NN\1740 therapy_4\NN\657604 ._5\.\1740
D014223_D053040 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e1>triamterene</e1>_3\JJ\1740 <e2>nephrolithiasis</e2>_4\NN\14115914 is_5\VBZ\836236 reported_6\VBN\831651 in_7\IN\13603305 a_8\DT\13649268 man_9\NN\9605289 after_10\IN\1740 4_11\CD\13741022 years_12\NNS\15144371 of_13\IN\1740 hydrochlorothiazide-triamterene_14\NN\1740 therapy_15\NN\657604 for_16\IN\1740 hypertension_17\NN\14057371 ._18\.\1740
D014223_D053040 CID factors_0\NNS\7326557 affecting_1\VBG\126264 <e1>triamterene</e1>_2\JJ\1740 <e2>nephrolithiasis</e2>_3\NN\14115914 are_4\VBP\836236 discussed_5\VBN\1033527 and_6\CC\1740 2_7\CD\13741022 previously_8\RB\1740 reported_9\VBN\831651 cases_10\NNS\7283608 are_11\VBP\836236 reviewed_12\VBN\644583 ._13\.\1740
C020743_D053040 NONE triamterene_0\NN\1740 <e2>nephrolithiasis</e2>_1\NN\14115914 complicating_2\VBG\126264 <e1>dyazide</e1>_3\NN\1740 therapy_4\NN\657604 ._5\.\1740
C020743_D053040 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 triamterene_3\JJ\1740 <e2>nephrolithiasis</e2>_4\NN\14115914 is_5\VBZ\836236 reported_6\VBN\831651 in_7\IN\13603305 a_8\DT\13649268 man_9\NN\9605289 after_10\IN\1740 4_11\CD\13741022 years_12\NNS\15144371 of_13\IN\1740 <e1>hydrochlorothiazide-triamterene</e1>_14\NN\1740 therapy_15\NN\657604 for_16\IN\1740 hypertension_17\NN\14057371 ._18\.\1740
D014223_D006973 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e1>triamterene</e1>_3\JJ\1740 nephrolithiasis_4\NN\14115914 is_5\VBZ\836236 reported_6\VBN\831651 in_7\IN\13603305 a_8\DT\13649268 man_9\NN\9605289 after_10\IN\1740 4_11\CD\13741022 years_12\NNS\15144371 of_13\IN\1740 hydrochlorothiazide-triamterene_14\NN\1740 therapy_15\NN\657604 for_16\IN\1740 <e2>hypertension</e2>_17\NN\14057371 ._18\.\1740
C020743_D006973 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 triamterene_3\JJ\1740 nephrolithiasis_4\NN\14115914 is_5\VBZ\836236 reported_6\VBN\831651 in_7\IN\13603305 a_8\DT\13649268 man_9\NN\9605289 after_10\IN\1740 4_11\CD\13741022 years_12\NNS\15144371 of_13\IN\1740 <e1>hydrochlorothiazide-triamterene</e1>_14\NN\1740 therapy_15\NN\657604 for_16\IN\1740 <e2>hypertension</e2>_17\NN\14057371 ._18\.\1740
424937
D008750_D056486 CID patterns_0\NNS\5726345 of_1\IN\1740 <e2>hepatic_2\JJ\1740 injury</e2>_3\NN\14052046 induced_4\VBN\1627355 by_5\IN\1740 <e1>methyldopa</e1>_6\NN\2721160 ._7\.\1740
D008750_D056486 CID the_0\DT\1740 remaining_1\VBG\2604760 patient_2\NN\9898892 in_3\IN\13603305 the_4\DT\1740 series_5\NN\8456993 developed_6\VBD\1753788 fulminant_7\JJ\1740 hepatitis_8\NN\14127211 when_9\WRB\1740 the_10\DT\1740 drug_11\NN\14778436 was_12\VBD\836236 accidentally_13\RB\1740 recommenced_14\VBN\348746 1_15\CD\13741022 year_16\NN\15113229 after_17\IN\1740 a_18\DT\13649268 prior_19\JJ\1740 episode_20\NN\7283608 of_21\IN\1740 <e1>methyldopa-induced</e1>_22\JJ\1740 <e2>hepatitis</e2>_23\NN\14127211 ._24\.\1740
D008750_D056486 CID in_0\IN\13603305 this_1\DT\1740 latter_2\JJ\1740 patient_3\NN\9898892 ,_4\,\1740 and_5\CC\1740 in_6\IN\13603305 2_7\CD\13741022 others_8\NNS\1740 ,_9\,\1740 the_10\DT\1740 causal_11\JJ\1740 relationship_12\NN\31921 between_13\IN\1740 <e1>methyldopa</e1>_14\JJ\1740 and_15\CC\1740 hepatic_16\JJ\1740 dysfunction_17\NN\14204950 was_18\VBD\836236 proved_19\VBN\2604760 with_20\IN\1740 the_21\DT\1740 recurrence_22\NN\7342049 of_23\IN\1740 <e2>hepatitis</e2>_24\NN\14127211 within_25\IN\1740 2_26\CD\13741022 weeks_27\NNS\15113229 of_28\IN\1740 re-exposure_29\NN\1740 to_30\IN\1740 the_31\DT\1740 drug_32\NN\14778436 ._33\.\1740
D008750_D008107 NONE twelve_0\CD\13745420 patients_1\NNS\9898892 with_2\IN\1740 <e2>liver_3\NN\5298729 disease</e2>_4\NN\14061805 related_5\JJ\1740 to_6\TO\1740 <e1>methyldopa</e1>_7\NN\2721160 were_8\VBD\836236 seen_9\VBN\2106506 between_10\IN\1740 1967_11\CD\1740 and_12\CC\1740 1977_13\CD\1740 ._14\.\1740
D008750_D008107 NONE in_0\IN\13603305 this_1\DT\1740 latter_2\JJ\1740 patient_3\NN\9898892 ,_4\,\1740 and_5\CC\1740 in_6\IN\13603305 2_7\CD\13741022 others_8\NNS\1740 ,_9\,\1740 the_10\DT\1740 causal_11\JJ\1740 relationship_12\NN\31921 between_13\IN\1740 <e1>methyldopa</e1>_14\JJ\1740 and_15\CC\1740 <e2>hepatic_16\JJ\1740 dysfunction</e2>_17\NN\14204950 was_18\VBD\836236 proved_19\VBN\2604760 with_20\IN\1740 the_21\DT\1740 recurrence_22\NN\7342049 of_23\IN\1740 hepatitis_24\NN\14127211 within_25\IN\1740 2_26\CD\13741022 weeks_27\NNS\15113229 of_28\IN\1740 re-exposure_29\NN\1740 to_30\IN\1740 the_31\DT\1740 drug_32\NN\14778436 ._33\.\1740
D008750_D017093 NONE one_0\CD\13741022 patient_1\NN\9898892 died_2\VBD\146138 ,_3\,\1740 having_4\VBG\2108377 presented_5\VBN\2137132 in_6\IN\13603305 <e2>hepatic_7\JJ\1740 failure</e2>_8\NN\66216 ,_9\,\1740 and_10\CC\1740 another_11\DT\1740 ,_12\,\1740 who_13\WP\8299493 had_14\VBD\2108377 been_15\VBN\836236 taking_16\VBG\2367363 <e1>methyldopa</e1>_17\JJ\1740 for_18\IN\1740 7_19\CD\13741022 years_20\NNS\15144371 ,_21\,\1740 showed_22\VBD\2137132 slower_23\JJR\1740 clinical_24\JJ\1740 and_25\CC\1740 biochemical_26\JJ\1740 resolution_27\NN\6470073 over_28\IN\5867413 a_29\DT\13649268 period_30\NN\13575869 of_31\IN\1740 several_32\JJ\1740 months_33\NNS\15113229 ._34\.\1740
D008750_D017114 NONE the_0\DT\1740 remaining_1\VBG\2604760 patient_2\NN\9898892 in_3\IN\13603305 the_4\DT\1740 series_5\NN\8456993 developed_6\VBD\1753788 <e2>fulminant_7\JJ\1740 hepatitis</e2>_8\NN\14127211 when_9\WRB\1740 the_10\DT\1740 drug_11\NN\14778436 was_12\VBD\836236 accidentally_13\RB\1740 recommenced_14\VBN\348746 1_15\CD\13741022 year_16\NN\15113229 after_17\IN\1740 a_18\DT\13649268 prior_19\JJ\1740 episode_20\NN\7283608 of_21\IN\1740 <e1>methyldopa-induced</e1>_22\JJ\1740 hepatitis_23\NN\14127211 ._24\.\1740
20470218
D008727_D056784 NONE cns_0\NN\5237227 complications_1\NNS\1073995 included_2\VBD\690614 posterior_3\JJ\1740 reversible_4\JJ\1740 <e2>leukoencephalopathy</e2>_5\NN\1740 syndrome_6\NN\5870365 (_7\-LRB-\1740 n_8\NN\14622893 =_9\JJ\1740 10_10\CD\13745420 )_11\-RRB-\1740 ,_12\,\1740 stroke_13\NN\556313 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 5_17\CD\13741022 )_18\-RRB-\1740 ,_19\,\1740 temporal_20\JJ\1740 lobe_21\VBD\1740 epilepsy_22\NN\14085708 (_23\-LRB-\1740 n_24\NN\14622893 =_25\JJ\1740 2_26\CD\13741022 )_27\-RRB-\1740 ,_28\,\1740 high-dose_29\NN\1740 <e1>methotrexate</e1>_30\VBP\1740 toxicity_31\NN\13576101 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 2_35\CD\13741022 )_36\-RRB-\1740 ,_37\,\1740 syndrome_38\NN\5870365 of_39\IN\1740 inappropriate_40\JJ\1740 antidiuretic_41\JJ\1740 hormone_42\NN\5404728 secretion_43\NN\13526110 (_44\-LRB-\1740 n_45\NN\14622893 =_46\JJ\1740 1_47\CD\13741022 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 other_51\JJ\1740 unclassified_52\JJ\1740 events_53\NNS\23100 (_54\-LRB-\1740 n_55\NN\14622893 =_56\JJ\1740 7_57\CD\13741022 )_58\-RRB-\1740 ._59\.\1740
D008727_D020521 NONE cns_0\NN\5237227 complications_1\NNS\1073995 included_2\VBD\690614 posterior_3\JJ\1740 reversible_4\JJ\1740 leukoencephalopathy_5\NN\1740 syndrome_6\NN\5870365 (_7\-LRB-\1740 n_8\NN\14622893 =_9\JJ\1740 10_10\CD\13745420 )_11\-RRB-\1740 ,_12\,\1740 <e2>stroke</e2>_13\NN\556313 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 5_17\CD\13741022 )_18\-RRB-\1740 ,_19\,\1740 temporal_20\JJ\1740 lobe_21\VBD\1740 epilepsy_22\NN\14085708 (_23\-LRB-\1740 n_24\NN\14622893 =_25\JJ\1740 2_26\CD\13741022 )_27\-RRB-\1740 ,_28\,\1740 high-dose_29\NN\1740 <e1>methotrexate</e1>_30\VBP\1740 toxicity_31\NN\13576101 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 2_35\CD\13741022 )_36\-RRB-\1740 ,_37\,\1740 syndrome_38\NN\5870365 of_39\IN\1740 inappropriate_40\JJ\1740 antidiuretic_41\JJ\1740 hormone_42\NN\5404728 secretion_43\NN\13526110 (_44\-LRB-\1740 n_45\NN\14622893 =_46\JJ\1740 1_47\CD\13741022 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 other_51\JJ\1740 unclassified_52\JJ\1740 events_53\NNS\23100 (_54\-LRB-\1740 n_55\NN\14622893 =_56\JJ\1740 7_57\CD\13741022 )_58\-RRB-\1740 ._59\.\1740
D008727_D004833 NONE cns_0\NN\5237227 complications_1\NNS\1073995 included_2\VBD\690614 posterior_3\JJ\1740 reversible_4\JJ\1740 leukoencephalopathy_5\NN\1740 syndrome_6\NN\5870365 (_7\-LRB-\1740 n_8\NN\14622893 =_9\JJ\1740 10_10\CD\13745420 )_11\-RRB-\1740 ,_12\,\1740 stroke_13\NN\556313 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 5_17\CD\13741022 )_18\-RRB-\1740 ,_19\,\1740 <e2>temporal_20\JJ\1740 lobe_21\VBD\1740 epilepsy</e2>_22\NN\14085708 (_23\-LRB-\1740 n_24\NN\14622893 =_25\JJ\1740 2_26\CD\13741022 )_27\-RRB-\1740 ,_28\,\1740 high-dose_29\NN\1740 <e1>methotrexate</e1>_30\VBP\1740 toxicity_31\NN\13576101 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 2_35\CD\13741022 )_36\-RRB-\1740 ,_37\,\1740 syndrome_38\NN\5870365 of_39\IN\1740 inappropriate_40\JJ\1740 antidiuretic_41\JJ\1740 hormone_42\NN\5404728 secretion_43\NN\13526110 (_44\-LRB-\1740 n_45\NN\14622893 =_46\JJ\1740 1_47\CD\13741022 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 other_51\JJ\1740 unclassified_52\JJ\1740 events_53\NNS\23100 (_54\-LRB-\1740 n_55\NN\14622893 =_56\JJ\1740 7_57\CD\13741022 )_58\-RRB-\1740 ._59\.\1740
D008727_D064420 NONE cns_0\NN\5237227 complications_1\NNS\1073995 included_2\VBD\690614 posterior_3\JJ\1740 reversible_4\JJ\1740 leukoencephalopathy_5\NN\1740 syndrome_6\NN\5870365 (_7\-LRB-\1740 n_8\NN\14622893 =_9\JJ\1740 10_10\CD\13745420 )_11\-RRB-\1740 ,_12\,\1740 stroke_13\NN\556313 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 5_17\CD\13741022 )_18\-RRB-\1740 ,_19\,\1740 temporal_20\JJ\1740 lobe_21\VBD\1740 epilepsy_22\NN\14085708 (_23\-LRB-\1740 n_24\NN\14622893 =_25\JJ\1740 2_26\CD\13741022 )_27\-RRB-\1740 ,_28\,\1740 high-dose_29\NN\1740 <e1>methotrexate</e1>_30\VBP\1740 <e2>toxicity</e2>_31\NN\13576101 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 2_35\CD\13741022 )_36\-RRB-\1740 ,_37\,\1740 syndrome_38\NN\5870365 of_39\IN\1740 inappropriate_40\JJ\1740 antidiuretic_41\JJ\1740 hormone_42\NN\5404728 secretion_43\NN\13526110 (_44\-LRB-\1740 n_45\NN\14622893 =_46\JJ\1740 1_47\CD\13741022 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 other_51\JJ\1740 unclassified_52\JJ\1740 events_53\NNS\23100 (_54\-LRB-\1740 n_55\NN\14622893 =_56\JJ\1740 7_57\CD\13741022 )_58\-RRB-\1740 ._59\.\1740
D008727_D007177 NONE cns_0\NN\5237227 complications_1\NNS\1073995 included_2\VBD\690614 posterior_3\JJ\1740 reversible_4\JJ\1740 leukoencephalopathy_5\NN\1740 syndrome_6\NN\5870365 (_7\-LRB-\1740 n_8\NN\14622893 =_9\JJ\1740 10_10\CD\13745420 )_11\-RRB-\1740 ,_12\,\1740 stroke_13\NN\556313 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 5_17\CD\13741022 )_18\-RRB-\1740 ,_19\,\1740 temporal_20\JJ\1740 lobe_21\VBD\1740 epilepsy_22\NN\14085708 (_23\-LRB-\1740 n_24\NN\14622893 =_25\JJ\1740 2_26\CD\13741022 )_27\-RRB-\1740 ,_28\,\1740 high-dose_29\NN\1740 <e1>methotrexate</e1>_30\VBP\1740 toxicity_31\NN\13576101 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 2_35\CD\13741022 )_36\-RRB-\1740 ,_37\,\1740 syndrome_38\NN\5870365 of_39\IN\1740 <e2>inappropriate_40\JJ\1740 antidiuretic_41\JJ\1740 hormone_42\NN\5404728 secretion</e2>_43\NN\13526110 (_44\-LRB-\1740 n_45\NN\14622893 =_46\JJ\1740 1_47\CD\13741022 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 other_51\JJ\1740 unclassified_52\JJ\1740 events_53\NNS\23100 (_54\-LRB-\1740 n_55\NN\14622893 =_56\JJ\1740 7_57\CD\13741022 )_58\-RRB-\1740 ._59\.\1740
15572383
D004317_D007674 NONE individual_0\JJ\1740 differences_1\NNS\4723816 in_2\IN\13603305 renal_3\JJ\1740 ace_4\NN\13741022 activity_5\NN\30358 in_6\IN\13603305 healthy_7\JJ\1740 rats_8\NNS\2329401 predict_9\VBP\916909 susceptibility_10\NN\13920835 to_11\TO\1740 <e1>adriamycin-induced</e1>_12\JJ\1740 <e2>renal_13\JJ\1740 damage</e2>_14\NN\7296428 ._15\.\1740
D004317_D007674 NONE therefore_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 studied_3\VBD\630380 the_4\DT\1740 predictive_5\JJ\1740 effect_6\NN\34213 of_7\IN\1740 renal_8\JJ\1740 ace_9\NN\13741022 activity_10\NN\30358 for_11\IN\1740 the_12\DT\1740 severity_13\NN\5036394 of_14\IN\1740 <e2>renal_15\JJ\1740 damage</e2>_16\NN\7296428 induced_17\VBN\1627355 by_18\IN\1740 a_19\DT\13649268 single_20\JJ\1740 injection_21\NN\320852 of_22\IN\1740 <e1>adriamycin</e1>_23\NN\1740 in_24\IN\13603305 rats_25\NNS\2329401 ._26\.\1740
D004317_D007674 NONE results_0\NNS\34213 :_1\:\1740 as_2\IN\14622893 anticipated_3\VBN\670261 ,_4\,\1740 <e1>adriamycin</e1>_5\NN\1740 elicited_6\VBD\1617192 nephrotic_7\JJ\1740 range_8\NN\5123416 proteinuria_9\NN\14299637 ,_10\,\1740 <e2>renal_11\JJ\1740 interstitial_12\JJ\1740 damage</e2>_13\NN\7296428 and_14\CC\1740 mild_15\JJ\1740 focal_16\JJ\1740 glomerulosclerosis_17\NN\1740 ._18\.\1740
D004317_D007674 NONE conclusion_0\NN\5837957 :_1\:\1740 individual_2\JJ\1740 differences_3\NNS\4723816 in_4\IN\13603305 renal_5\JJ\1740 ace_6\NN\13741022 activity_7\NN\30358 predict_8\VBP\916909 the_9\DT\1740 severity_10\NN\5036394 of_11\IN\1740 <e1>adriamycin-induced</e1>_12\JJ\1740 <e2>renal_13\JJ\1740 damage</e2>_14\NN\7296428 in_15\IN\13603305 this_16\DT\1740 outbred_17\JJ\1740 rat_18\NN\2329401 strain_19\NN\7358060 ._20\.\1740
D004317_D011507 CID after_0\IN\1740 1_1\CD\13741022 week_2\NN\15113229 of_3\IN\1740 recovery_4\NN\7357388 ,_5\,\1740 <e2>proteinuria</e2>_6\NN\14299637 was_7\VBD\836236 induced_8\VBN\1627355 by_9\IN\1740 <e1>adriamycin</e1>_10\NN\1740 [_11\-LRB-\1740 1.5_12\CD\1740 mg/kg_13\NN\1740 intravenously_14\RB\1740 (_15\-LRB-\1740 i.v._16\NN\1740 )_17\-RRB-\1740 n_18\NN\14622893 =_19\JJ\1740 18_20\CD\13745420 ;_21\:\1740 controls_22\NNS\5190804 ,_23\,\1740 saline_24\NN\14849367 i.v._25\NN\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 ]_29\-RRB-\1740 ._30\.\1740
D004317_D011507 CID results_0\NNS\34213 :_1\:\1740 as_2\IN\14622893 anticipated_3\VBN\670261 ,_4\,\1740 <e1>adriamycin</e1>_5\NN\1740 elicited_6\VBD\1617192 nephrotic_7\JJ\1740 range_8\NN\5123416 <e2>proteinuria</e2>_9\NN\14299637 ,_10\,\1740 renal_11\JJ\1740 interstitial_12\JJ\1740 damage_13\NN\7296428 and_14\CC\1740 mild_15\JJ\1740 focal_16\JJ\1740 glomerulosclerosis_17\NN\1740 ._18\.\1740
D004317_D011507 CID baseline_0\NN\7260623 renal_1\JJ\1740 ace_2\NN\13741022 positively_3\RB\1740 correlated_4\VBD\2657219 with_5\IN\1740 the_6\DT\1740 relative_7\JJ\1740 rise_8\NN\7324673 in_9\IN\13603305 <e2>proteinuria</e2>_10\NN\14299637 after_11\IN\1740 <e1>adriamycin</e1>_12\NN\1740 (_13\-LRB-\1740 r_14\NN\13635336 =_15\JJ\1740 0.62_16\CD\1740 ,_17\,\1740 p<0.01_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 renal_21\JJ\1740 interstitial_22\JJ\1740 alpha-smooth_23\NN\1740 muscle_24\NN\5289601 actin_25\NN\14736972 (_26\-LRB-\1740 r_27\NN\13635336 =_28\JJ\1740 0.49_29\CD\1740 ,_30\,\1740 p<0.05_31\CD\1740 )_32\-RRB-\1740 ,_33\,\1740 interstitial_34\JJ\1740 macrophage_35\NN\5450888 influx_36\NN\13482330 (_37\-LRB-\1740 r_38\NN\13635336 =_39\JJ\1740 0.56_40\CD\1740 ,_41\,\1740 p<0.05_42\CD\1740 )_43\-RRB-\1740 ,_44\,\1740 interstitial_45\JJ\1740 collagen_46\NN\15026716 iii_47\CD\13741022 (_48\-LRB-\1740 r_49\NN\13635336 =_50\JJ\1740 0.53_51\CD\1740 ,_52\,\1740 p<0.05_53\CD\1740 )_54\-RRB-\1740 ,_55\,\1740 glomerular_56\JJ\1740 alpha-smooth_57\JJ\1740 muscle_58\NN\5289601 actin_59\NN\14736972 (_60\-LRB-\1740 r_61\NN\13635336 =_62\JJ\1740 0.74_63\CD\1740 ,_64\,\1740 p<0.01_65\NN\1740 )_66\-RRB-\1740 and_67\CC\1740 glomerular_68\JJ\1740 desmin_69\NN\1740 (_70\-LRB-\1740 r_71\NN\13635336 =_72\JJ\1740 0.48_73\CD\1740 ,_74\,\1740 p<0.05_75\CD\1740 )_76\-RRB-\1740 ._77\.\1740
D004317_D009404 NONE results_0\NNS\34213 :_1\:\1740 as_2\IN\14622893 anticipated_3\VBN\670261 ,_4\,\1740 <e1>adriamycin</e1>_5\NN\1740 elicited_6\VBD\1617192 <e2>nephrotic</e2>_7\JJ\1740 range_8\NN\5123416 proteinuria_9\NN\14299637 ,_10\,\1740 renal_11\JJ\1740 interstitial_12\JJ\1740 damage_13\NN\7296428 and_14\CC\1740 mild_15\JJ\1740 focal_16\JJ\1740 glomerulosclerosis_17\NN\1740 ._18\.\1740
D004317_D005923 NONE results_0\NNS\34213 :_1\:\1740 as_2\IN\14622893 anticipated_3\VBN\670261 ,_4\,\1740 <e1>adriamycin</e1>_5\NN\1740 elicited_6\VBD\1617192 nephrotic_7\JJ\1740 range_8\NN\5123416 proteinuria_9\NN\14299637 ,_10\,\1740 renal_11\JJ\1740 interstitial_12\JJ\1740 damage_13\NN\7296428 and_14\CC\1740 mild_15\JJ\1740 <e2>focal_16\JJ\1740 glomerulosclerosis</e2>_17\NN\1740 ._18\.\1740
7582165
D000305_D004342 NONE <e2>pseudo-allergic_0\JJ\1740 reactions</e2>_1\NNS\13446390 to_2\TO\1740 <e1>corticosteroids</e1>_3\NNS\14745635 :_4\:\1740 diagnosis_5\NN\152018 and_6\CC\1740 alternatives_7\NNS\5788149 ._8\.\1740
D010248_D004342 NONE corticosteroids_0\NNS\14745635 different_1\JJ\1740 from_2\IN\1740 <e1>paramethasone</e1>_3\NN\1740 also_4\RB\1740 produced_5\VBD\1617192 <e2>hypersensitivity</e2>_6\NN\14531772 reactions_7\NNS\13446390 in_8\IN\13603305 these_9\DT\1740 patients_10\NNS\9898892 ;_11\:\1740 however_12\RB\1740 ,_13\,\1740 a_14\DT\13649268 few_15\JJ\1740 of_16\IN\1740 them_17\PRP\1740 were_18\VBD\836236 tolerated_19\VBN\802318 ._20\.\1740
D010248_D004342 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 first_7\JJ\1740 report_8\NN\6470073 of_9\IN\1740 a_10\DT\13649268 <e2>pseudo-allergy</e2>_11\NN\1740 caused_12\VBN\1617192 by_13\IN\1740 <e1>paramethasone</e1>_14\NN\1740 ._15\.\1740
18208574
D006493_D013927 CID higher_0\JJR\1740 optical_1\JJ\1740 density_2\NN\4941325 of_3\IN\1740 an_4\DT\6697703 antigen_5\NN\20090 assay_6\NN\5733583 predicts_7\VBZ\916909 <e2>thrombosis</e2>_8\NN\14100769 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 <e1>heparin-induced</e1>_12\JJ\1740 thrombocytopenia_13\NN\14189204 ._14\.\1740
D006493_D013927 CID objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 correlate_3\VB\2657219 optical_4\JJ\1740 density_5\NN\4941325 and_6\CC\1740 percent_7\NN\13815742 inhibition_8\NN\1068773 of_9\IN\1740 a_10\DT\13649268 two-step_11\JJ\1740 <e1>heparin-induced</e1>_12\JJ\1740 thrombocytopenia_13\NN\14189204 (_14\-LRB-\1740 hit_15\NN\36762 )_16\-RRB-\1740 antigen_17\NN\20090 assay_18\NN\5733583 with_19\IN\1740 <e2>thrombosis</e2>_20\NN\14100769 ;_21\:\1740 the_22\DT\1740 assay_23\NN\5733583 utilizes_24\VBZ\161225 reaction_25\NN\13446390 inhibition_26\NN\1068773 characteristics_27\NNS\5849040 of_28\IN\1740 a_29\DT\13649268 high_30\JJ\1740 heparin_31\NN\2718259 concentration_32\NN\4916342 ._33\.\1740
D006493_D013927 CID objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 correlate_3\VB\2657219 optical_4\JJ\1740 density_5\NN\4941325 and_6\CC\1740 percent_7\NN\13815742 inhibition_8\NN\1068773 of_9\IN\1740 a_10\DT\13649268 two-step_11\JJ\1740 heparin-induced_12\JJ\1740 thrombocytopenia_13\NN\14189204 (_14\-LRB-\1740 hit_15\NN\36762 )_16\-RRB-\1740 antigen_17\NN\20090 assay_18\NN\5733583 with_19\IN\1740 <e2>thrombosis</e2>_20\NN\14100769 ;_21\:\1740 the_22\DT\1740 assay_23\NN\5733583 utilizes_24\VBZ\161225 reaction_25\NN\13446390 inhibition_26\NN\1068773 characteristics_27\NNS\5849040 of_28\IN\1740 a_29\DT\13649268 high_30\JJ\1740 <e1>heparin</e1>_31\NN\2718259 concentration_32\NN\4916342 ._33\.\1740
D006493_D013921 CID higher_0\JJR\1740 optical_1\JJ\1740 density_2\NN\4941325 of_3\IN\1740 an_4\DT\6697703 antigen_5\NN\20090 assay_6\NN\5733583 predicts_7\VBZ\916909 thrombosis_8\NN\14100769 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 <e1>heparin-induced</e1>_12\JJ\1740 <e2>thrombocytopenia</e2>_13\NN\14189204 ._14\.\1740
D006493_D013921 CID objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 correlate_3\VB\2657219 optical_4\JJ\1740 density_5\NN\4941325 and_6\CC\1740 percent_7\NN\13815742 inhibition_8\NN\1068773 of_9\IN\1740 a_10\DT\13649268 two-step_11\JJ\1740 <e1>heparin-induced</e1>_12\JJ\1740 <e2>thrombocytopenia</e2>_13\NN\14189204 (_14\-LRB-\1740 hit_15\NN\36762 )_16\-RRB-\1740 antigen_17\NN\20090 assay_18\NN\5733583 with_19\IN\1740 thrombosis_20\NN\14100769 ;_21\:\1740 the_22\DT\1740 assay_23\NN\5733583 utilizes_24\VBZ\161225 reaction_25\NN\13446390 inhibition_26\NN\1068773 characteristics_27\NNS\5849040 of_28\IN\1740 a_29\DT\13649268 high_30\JJ\1740 heparin_31\NN\2718259 concentration_32\NN\4916342 ._33\.\1740
D006493_D013921 CID objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 correlate_3\VB\2657219 optical_4\JJ\1740 density_5\NN\4941325 and_6\CC\1740 percent_7\NN\13815742 inhibition_8\NN\1068773 of_9\IN\1740 a_10\DT\13649268 two-step_11\JJ\1740 <e1>heparin-induced</e1>_12\JJ\1740 thrombocytopenia_13\NN\14189204 (_14\-LRB-\1740 <e2>hit</e2>_15\NN\36762 )_16\-RRB-\1740 antigen_17\NN\20090 assay_18\NN\5733583 with_19\IN\1740 thrombosis_20\NN\14100769 ;_21\:\1740 the_22\DT\1740 assay_23\NN\5733583 utilizes_24\VBZ\161225 reaction_25\NN\13446390 inhibition_26\NN\1068773 characteristics_27\NNS\5849040 of_28\IN\1740 a_29\DT\13649268 high_30\JJ\1740 heparin_31\NN\2718259 concentration_32\NN\4916342 ._33\.\1740
D006493_D013921 CID objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 correlate_3\VB\2657219 optical_4\JJ\1740 density_5\NN\4941325 and_6\CC\1740 percent_7\NN\13815742 inhibition_8\NN\1068773 of_9\IN\1740 a_10\DT\13649268 two-step_11\JJ\1740 heparin-induced_12\JJ\1740 <e2>thrombocytopenia</e2>_13\NN\14189204 (_14\-LRB-\1740 hit_15\NN\36762 )_16\-RRB-\1740 antigen_17\NN\20090 assay_18\NN\5733583 with_19\IN\1740 thrombosis_20\NN\14100769 ;_21\:\1740 the_22\DT\1740 assay_23\NN\5733583 utilizes_24\VBZ\161225 reaction_25\NN\13446390 inhibition_26\NN\1068773 characteristics_27\NNS\5849040 of_28\IN\1740 a_29\DT\13649268 high_30\JJ\1740 <e1>heparin</e1>_31\NN\2718259 concentration_32\NN\4916342 ._33\.\1740
D006493_D013921 CID objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 correlate_3\VB\2657219 optical_4\JJ\1740 density_5\NN\4941325 and_6\CC\1740 percent_7\NN\13815742 inhibition_8\NN\1068773 of_9\IN\1740 a_10\DT\13649268 two-step_11\JJ\1740 heparin-induced_12\JJ\1740 thrombocytopenia_13\NN\14189204 (_14\-LRB-\1740 <e2>hit</e2>_15\NN\36762 )_16\-RRB-\1740 antigen_17\NN\20090 assay_18\NN\5733583 with_19\IN\1740 thrombosis_20\NN\14100769 ;_21\:\1740 the_22\DT\1740 assay_23\NN\5733583 utilizes_24\VBZ\161225 reaction_25\NN\13446390 inhibition_26\NN\1068773 characteristics_27\NNS\5849040 of_28\IN\1740 a_29\DT\13649268 high_30\JJ\1740 <e1>heparin</e1>_31\NN\2718259 concentration_32\NN\4916342 ._33\.\1740
D006493_D013921 CID patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 patients_4\NNS\9898892 with_5\IN\1740 more_6\JJR\1740 than_7\IN\1740 50_8\CD\13745420 %_9\NN\1740 decrease_10\NN\7296428 in_11\IN\13603305 platelet_12\NN\5432736 count_13\NN\13582013 or_14\CC\3541091 <e2>thrombocytopenia</e2>_15\NN\14189204 (_16\-LRB-\1740 <_17\XX\1740 150_18\CD\1740 x_19\CC\13745420 10(9)/l_20\CD\1740 )_21\-RRB-\1740 after_22\IN\1740 exposure_23\NN\5042871 to_24\TO\1740 <e1>heparin</e1>_25\NN\2718259 ,_26\,\1740 who_27\WP\8299493 had_28\VBD\2108377 a_29\DT\13649268 positive_30\JJ\1740 two-step_31\JJ\1740 antigen_32\NN\20090 assay_33\NN\5733583 [_34\-LRB-\1740 optical_35\JJ\1740 density_36\NN\4941325 (_37\-LRB-\1740 od_38\NN\6702458 )_39\-RRB-\1740 >_40\NN\1740 0.4_41\CD\1740 and_42\CC\1740 >_43\NN\1740 50_44\CD\13745420 inhibition_45\NN\1068773 with_46\IN\1740 high_47\JJ\1740 concentration_48\NN\4916342 of_49\IN\1740 heparin_50\NN\2718259 ]_51\-RRB-\1740 were_52\VBD\836236 included_53\VBN\690614 in_54\IN\13603305 the_55\DT\1740 study_56\NN\635850 ._57\.\1740
D006493_D013921 CID patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 patients_4\NNS\9898892 with_5\IN\1740 more_6\JJR\1740 than_7\IN\1740 50_8\CD\13745420 %_9\NN\1740 decrease_10\NN\7296428 in_11\IN\13603305 platelet_12\NN\5432736 count_13\NN\13582013 or_14\CC\3541091 <e2>thrombocytopenia</e2>_15\NN\14189204 (_16\-LRB-\1740 <_17\XX\1740 150_18\CD\1740 x_19\CC\13745420 10(9)/l_20\CD\1740 )_21\-RRB-\1740 after_22\IN\1740 exposure_23\NN\5042871 to_24\TO\1740 heparin_25\NN\2718259 ,_26\,\1740 who_27\WP\8299493 had_28\VBD\2108377 a_29\DT\13649268 positive_30\JJ\1740 two-step_31\JJ\1740 antigen_32\NN\20090 assay_33\NN\5733583 [_34\-LRB-\1740 optical_35\JJ\1740 density_36\NN\4941325 (_37\-LRB-\1740 od_38\NN\6702458 )_39\-RRB-\1740 >_40\NN\1740 0.4_41\CD\1740 and_42\CC\1740 >_43\NN\1740 50_44\CD\13745420 inhibition_45\NN\1068773 with_46\IN\1740 high_47\JJ\1740 concentration_48\NN\4916342 of_49\IN\1740 <e1>heparin</e1>_50\NN\2718259 ]_51\-RRB-\1740 were_52\VBD\836236 included_53\VBN\690614 in_54\IN\13603305 the_55\DT\1740 study_56\NN\635850 ._57\.\1740
19884587
D013449_D000757 CID <e1>sulfonamides</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 <e2>anencephaly</e2>_4\NN\14465048 (_5\-LRB-\1740 adjusted_6\VBN\126264 or_7\NN\3541091 [_8\-LRB-\1740 aor_9\NN\1740 ]_10\-RRB-\1740 =_11\JJ\1740 3.4_12\CD\1740 ;_13\:\1740 95_14\CD\1740 %_15\NN\1740 confidence_16\NN\5697135 interval_17\NN\33615 [_18\-LRB-\1740 ci_19\NNP\13635336 ]_20\-RRB-\1740 ,_21\,\1740 1.3_22\CD\1740 -_23\SYM\1740 8.8_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 hypoplastic_27\JJ\1740 left_28\VBD\120316 heart_29\NN\5919034 syndrome_30\NN\5870365 (_31\-LRB-\1740 aor_32\NN\1740 =_33\JJ\1740 3.2_34\CD\1740 ;_35\:\1740 95_36\CD\1740 %_37\NN\1740 ci_38\NN\13635336 ,_39\,\1740 1.3_40\CD\1740 -_41\SYM\1740 7.6_42\CD\1740 )_43\-RRB-\1740 ,_44\,\1740 coarctation_45\NN\7313241 of_46\IN\1740 the_47\DT\1740 aorta_48\NN\5333777 (_49\-LRB-\1740 aor_50\NN\1740 =_51\JJ\1740 2.7_52\CD\1740 ;_53\:\1740 95_54\CD\1740 %_55\NN\1740 ci_56\NN\13635336 ,_57\,\1740 1.3_58\CD\1740 -_59\SYM\1740 5.6_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 choanal_63\JJ\1740 atresia_64\NN\14501726 (_65\-LRB-\1740 aor_66\NN\1740 =_67\JJ\1740 8.0_68\CD\1740 ;_69\:\1740 95_70\CD\1740 %_71\NN\1740 ci_72\NN\13635336 ,_73\,\1740 2.7_74\CD\1740 -_75\SYM\1740 23.5_76\CD\1740 )_77\-RRB-\1740 ,_78\,\1740 transverse_79\JJ\1740 limb_80\JJ\1740 deficiency_81\NN\14449126 (_82\-LRB-\1740 aor_83\NN\1740 =_84\JJ\1740 2.5_85\CD\1740 ;_86\:\1740 95_87\CD\1740 %_88\NN\1740 ci_89\NN\13635336 ,_90\,\1740 1.0_91\CD\1740 -_92\SYM\1740 5.9_93\CD\1740 )_94\-RRB-\1740 ,_95\,\1740 and_96\CC\1740 diaphragmatic_97\JJ\1740 hernia_98\NN\14295248 (_99\-LRB-\1740 aor_100\NN\1740 =_101\JJ\1740 2.4_102\CD\1740 ;_103\:\1740 95_104\CD\1740 %_105\NN\1740 ci_106\NN\13635336 ,_107\,\1740 1.1_108\CD\1740 -_109\SYM\1740 5.4_110\CD\1740 )_111\-RRB-\1740 ._112\.\1740
D013449_D018636 CID <e1>sulfonamides</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 anencephaly_4\NN\14465048 (_5\-LRB-\1740 adjusted_6\VBN\126264 or_7\NN\3541091 [_8\-LRB-\1740 aor_9\NN\1740 ]_10\-RRB-\1740 =_11\JJ\1740 3.4_12\CD\1740 ;_13\:\1740 95_14\CD\1740 %_15\NN\1740 confidence_16\NN\5697135 interval_17\NN\33615 [_18\-LRB-\1740 ci_19\NNP\13635336 ]_20\-RRB-\1740 ,_21\,\1740 1.3_22\CD\1740 -_23\SYM\1740 8.8_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 <e2>hypoplastic_27\JJ\1740 left_28\VBD\120316 heart_29\NN\5919034 syndrome</e2>_30\NN\5870365 (_31\-LRB-\1740 aor_32\NN\1740 =_33\JJ\1740 3.2_34\CD\1740 ;_35\:\1740 95_36\CD\1740 %_37\NN\1740 ci_38\NN\13635336 ,_39\,\1740 1.3_40\CD\1740 -_41\SYM\1740 7.6_42\CD\1740 )_43\-RRB-\1740 ,_44\,\1740 coarctation_45\NN\7313241 of_46\IN\1740 the_47\DT\1740 aorta_48\NN\5333777 (_49\-LRB-\1740 aor_50\NN\1740 =_51\JJ\1740 2.7_52\CD\1740 ;_53\:\1740 95_54\CD\1740 %_55\NN\1740 ci_56\NN\13635336 ,_57\,\1740 1.3_58\CD\1740 -_59\SYM\1740 5.6_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 choanal_63\JJ\1740 atresia_64\NN\14501726 (_65\-LRB-\1740 aor_66\NN\1740 =_67\JJ\1740 8.0_68\CD\1740 ;_69\:\1740 95_70\CD\1740 %_71\NN\1740 ci_72\NN\13635336 ,_73\,\1740 2.7_74\CD\1740 -_75\SYM\1740 23.5_76\CD\1740 )_77\-RRB-\1740 ,_78\,\1740 transverse_79\JJ\1740 limb_80\JJ\1740 deficiency_81\NN\14449126 (_82\-LRB-\1740 aor_83\NN\1740 =_84\JJ\1740 2.5_85\CD\1740 ;_86\:\1740 95_87\CD\1740 %_88\NN\1740 ci_89\NN\13635336 ,_90\,\1740 1.0_91\CD\1740 -_92\SYM\1740 5.9_93\CD\1740 )_94\-RRB-\1740 ,_95\,\1740 and_96\CC\1740 diaphragmatic_97\JJ\1740 hernia_98\NN\14295248 (_99\-LRB-\1740 aor_100\NN\1740 =_101\JJ\1740 2.4_102\CD\1740 ;_103\:\1740 95_104\CD\1740 %_105\NN\1740 ci_106\NN\13635336 ,_107\,\1740 1.1_108\CD\1740 -_109\SYM\1740 5.4_110\CD\1740 )_111\-RRB-\1740 ._112\.\1740
D013449_D001017 CID <e1>sulfonamides</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 anencephaly_4\NN\14465048 (_5\-LRB-\1740 adjusted_6\VBN\126264 or_7\NN\3541091 [_8\-LRB-\1740 aor_9\NN\1740 ]_10\-RRB-\1740 =_11\JJ\1740 3.4_12\CD\1740 ;_13\:\1740 95_14\CD\1740 %_15\NN\1740 confidence_16\NN\5697135 interval_17\NN\33615 [_18\-LRB-\1740 ci_19\NNP\13635336 ]_20\-RRB-\1740 ,_21\,\1740 1.3_22\CD\1740 -_23\SYM\1740 8.8_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 hypoplastic_27\JJ\1740 left_28\VBD\120316 heart_29\NN\5919034 syndrome_30\NN\5870365 (_31\-LRB-\1740 aor_32\NN\1740 =_33\JJ\1740 3.2_34\CD\1740 ;_35\:\1740 95_36\CD\1740 %_37\NN\1740 ci_38\NN\13635336 ,_39\,\1740 1.3_40\CD\1740 -_41\SYM\1740 7.6_42\CD\1740 )_43\-RRB-\1740 ,_44\,\1740 <e2>coarctation_45\NN\7313241 of_46\IN\1740 the_47\DT\1740 aorta</e2>_48\NN\5333777 (_49\-LRB-\1740 aor_50\NN\1740 =_51\JJ\1740 2.7_52\CD\1740 ;_53\:\1740 95_54\CD\1740 %_55\NN\1740 ci_56\NN\13635336 ,_57\,\1740 1.3_58\CD\1740 -_59\SYM\1740 5.6_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 choanal_63\JJ\1740 atresia_64\NN\14501726 (_65\-LRB-\1740 aor_66\NN\1740 =_67\JJ\1740 8.0_68\CD\1740 ;_69\:\1740 95_70\CD\1740 %_71\NN\1740 ci_72\NN\13635336 ,_73\,\1740 2.7_74\CD\1740 -_75\SYM\1740 23.5_76\CD\1740 )_77\-RRB-\1740 ,_78\,\1740 transverse_79\JJ\1740 limb_80\JJ\1740 deficiency_81\NN\14449126 (_82\-LRB-\1740 aor_83\NN\1740 =_84\JJ\1740 2.5_85\CD\1740 ;_86\:\1740 95_87\CD\1740 %_88\NN\1740 ci_89\NN\13635336 ,_90\,\1740 1.0_91\CD\1740 -_92\SYM\1740 5.9_93\CD\1740 )_94\-RRB-\1740 ,_95\,\1740 and_96\CC\1740 diaphragmatic_97\JJ\1740 hernia_98\NN\14295248 (_99\-LRB-\1740 aor_100\NN\1740 =_101\JJ\1740 2.4_102\CD\1740 ;_103\:\1740 95_104\CD\1740 %_105\NN\1740 ci_106\NN\13635336 ,_107\,\1740 1.1_108\CD\1740 -_109\SYM\1740 5.4_110\CD\1740 )_111\-RRB-\1740 ._112\.\1740
D013449_D002754 CID <e1>sulfonamides</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 anencephaly_4\NN\14465048 (_5\-LRB-\1740 adjusted_6\VBN\126264 or_7\NN\3541091 [_8\-LRB-\1740 aor_9\NN\1740 ]_10\-RRB-\1740 =_11\JJ\1740 3.4_12\CD\1740 ;_13\:\1740 95_14\CD\1740 %_15\NN\1740 confidence_16\NN\5697135 interval_17\NN\33615 [_18\-LRB-\1740 ci_19\NNP\13635336 ]_20\-RRB-\1740 ,_21\,\1740 1.3_22\CD\1740 -_23\SYM\1740 8.8_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 hypoplastic_27\JJ\1740 left_28\VBD\120316 heart_29\NN\5919034 syndrome_30\NN\5870365 (_31\-LRB-\1740 aor_32\NN\1740 =_33\JJ\1740 3.2_34\CD\1740 ;_35\:\1740 95_36\CD\1740 %_37\NN\1740 ci_38\NN\13635336 ,_39\,\1740 1.3_40\CD\1740 -_41\SYM\1740 7.6_42\CD\1740 )_43\-RRB-\1740 ,_44\,\1740 coarctation_45\NN\7313241 of_46\IN\1740 the_47\DT\1740 aorta_48\NN\5333777 (_49\-LRB-\1740 aor_50\NN\1740 =_51\JJ\1740 2.7_52\CD\1740 ;_53\:\1740 95_54\CD\1740 %_55\NN\1740 ci_56\NN\13635336 ,_57\,\1740 1.3_58\CD\1740 -_59\SYM\1740 5.6_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 <e2>choanal_63\JJ\1740 atresia</e2>_64\NN\14501726 (_65\-LRB-\1740 aor_66\NN\1740 =_67\JJ\1740 8.0_68\CD\1740 ;_69\:\1740 95_70\CD\1740 %_71\NN\1740 ci_72\NN\13635336 ,_73\,\1740 2.7_74\CD\1740 -_75\SYM\1740 23.5_76\CD\1740 )_77\-RRB-\1740 ,_78\,\1740 transverse_79\JJ\1740 limb_80\JJ\1740 deficiency_81\NN\14449126 (_82\-LRB-\1740 aor_83\NN\1740 =_84\JJ\1740 2.5_85\CD\1740 ;_86\:\1740 95_87\CD\1740 %_88\NN\1740 ci_89\NN\13635336 ,_90\,\1740 1.0_91\CD\1740 -_92\SYM\1740 5.9_93\CD\1740 )_94\-RRB-\1740 ,_95\,\1740 and_96\CC\1740 diaphragmatic_97\JJ\1740 hernia_98\NN\14295248 (_99\-LRB-\1740 aor_100\NN\1740 =_101\JJ\1740 2.4_102\CD\1740 ;_103\:\1740 95_104\CD\1740 %_105\NN\1740 ci_106\NN\13635336 ,_107\,\1740 1.1_108\CD\1740 -_109\SYM\1740 5.4_110\CD\1740 )_111\-RRB-\1740 ._112\.\1740
D013449_D017880 CID <e1>sulfonamides</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 anencephaly_4\NN\14465048 (_5\-LRB-\1740 adjusted_6\VBN\126264 or_7\NN\3541091 [_8\-LRB-\1740 aor_9\NN\1740 ]_10\-RRB-\1740 =_11\JJ\1740 3.4_12\CD\1740 ;_13\:\1740 95_14\CD\1740 %_15\NN\1740 confidence_16\NN\5697135 interval_17\NN\33615 [_18\-LRB-\1740 ci_19\NNP\13635336 ]_20\-RRB-\1740 ,_21\,\1740 1.3_22\CD\1740 -_23\SYM\1740 8.8_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 hypoplastic_27\JJ\1740 left_28\VBD\120316 heart_29\NN\5919034 syndrome_30\NN\5870365 (_31\-LRB-\1740 aor_32\NN\1740 =_33\JJ\1740 3.2_34\CD\1740 ;_35\:\1740 95_36\CD\1740 %_37\NN\1740 ci_38\NN\13635336 ,_39\,\1740 1.3_40\CD\1740 -_41\SYM\1740 7.6_42\CD\1740 )_43\-RRB-\1740 ,_44\,\1740 coarctation_45\NN\7313241 of_46\IN\1740 the_47\DT\1740 aorta_48\NN\5333777 (_49\-LRB-\1740 aor_50\NN\1740 =_51\JJ\1740 2.7_52\CD\1740 ;_53\:\1740 95_54\CD\1740 %_55\NN\1740 ci_56\NN\13635336 ,_57\,\1740 1.3_58\CD\1740 -_59\SYM\1740 5.6_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 choanal_63\JJ\1740 atresia_64\NN\14501726 (_65\-LRB-\1740 aor_66\NN\1740 =_67\JJ\1740 8.0_68\CD\1740 ;_69\:\1740 95_70\CD\1740 %_71\NN\1740 ci_72\NN\13635336 ,_73\,\1740 2.7_74\CD\1740 -_75\SYM\1740 23.5_76\CD\1740 )_77\-RRB-\1740 ,_78\,\1740 <e2>transverse_79\JJ\1740 limb_80\JJ\1740 deficiency</e2>_81\NN\14449126 (_82\-LRB-\1740 aor_83\NN\1740 =_84\JJ\1740 2.5_85\CD\1740 ;_86\:\1740 95_87\CD\1740 %_88\NN\1740 ci_89\NN\13635336 ,_90\,\1740 1.0_91\CD\1740 -_92\SYM\1740 5.9_93\CD\1740 )_94\-RRB-\1740 ,_95\,\1740 and_96\CC\1740 diaphragmatic_97\JJ\1740 hernia_98\NN\14295248 (_99\-LRB-\1740 aor_100\NN\1740 =_101\JJ\1740 2.4_102\CD\1740 ;_103\:\1740 95_104\CD\1740 %_105\NN\1740 ci_106\NN\13635336 ,_107\,\1740 1.1_108\CD\1740 -_109\SYM\1740 5.4_110\CD\1740 )_111\-RRB-\1740 ._112\.\1740
D013449_D006548 CID <e1>sulfonamides</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 anencephaly_4\NN\14465048 (_5\-LRB-\1740 adjusted_6\VBN\126264 or_7\NN\3541091 [_8\-LRB-\1740 aor_9\NN\1740 ]_10\-RRB-\1740 =_11\JJ\1740 3.4_12\CD\1740 ;_13\:\1740 95_14\CD\1740 %_15\NN\1740 confidence_16\NN\5697135 interval_17\NN\33615 [_18\-LRB-\1740 ci_19\NNP\13635336 ]_20\-RRB-\1740 ,_21\,\1740 1.3_22\CD\1740 -_23\SYM\1740 8.8_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 hypoplastic_27\JJ\1740 left_28\VBD\120316 heart_29\NN\5919034 syndrome_30\NN\5870365 (_31\-LRB-\1740 aor_32\NN\1740 =_33\JJ\1740 3.2_34\CD\1740 ;_35\:\1740 95_36\CD\1740 %_37\NN\1740 ci_38\NN\13635336 ,_39\,\1740 1.3_40\CD\1740 -_41\SYM\1740 7.6_42\CD\1740 )_43\-RRB-\1740 ,_44\,\1740 coarctation_45\NN\7313241 of_46\IN\1740 the_47\DT\1740 aorta_48\NN\5333777 (_49\-LRB-\1740 aor_50\NN\1740 =_51\JJ\1740 2.7_52\CD\1740 ;_53\:\1740 95_54\CD\1740 %_55\NN\1740 ci_56\NN\13635336 ,_57\,\1740 1.3_58\CD\1740 -_59\SYM\1740 5.6_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 choanal_63\JJ\1740 atresia_64\NN\14501726 (_65\-LRB-\1740 aor_66\NN\1740 =_67\JJ\1740 8.0_68\CD\1740 ;_69\:\1740 95_70\CD\1740 %_71\NN\1740 ci_72\NN\13635336 ,_73\,\1740 2.7_74\CD\1740 -_75\SYM\1740 23.5_76\CD\1740 )_77\-RRB-\1740 ,_78\,\1740 transverse_79\JJ\1740 limb_80\JJ\1740 deficiency_81\NN\14449126 (_82\-LRB-\1740 aor_83\NN\1740 =_84\JJ\1740 2.5_85\CD\1740 ;_86\:\1740 95_87\CD\1740 %_88\NN\1740 ci_89\NN\13635336 ,_90\,\1740 1.0_91\CD\1740 -_92\SYM\1740 5.9_93\CD\1740 )_94\-RRB-\1740 ,_95\,\1740 and_96\CC\1740 <e2>diaphragmatic_97\JJ\1740 hernia</e2>_98\NN\14295248 (_99\-LRB-\1740 aor_100\NN\1740 =_101\JJ\1740 2.4_102\CD\1740 ;_103\:\1740 95_104\CD\1740 %_105\NN\1740 ci_106\NN\13635336 ,_107\,\1740 1.1_108\CD\1740 -_109\SYM\1740 5.4_110\CD\1740 )_111\-RRB-\1740 ._112\.\1740
D009582_D000853 CID <e1>nitrofurantoins</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 <e2>anophthalmia</e2>_4\NN\1740 or_5\CC\3541091 microphthalmos_6\NN\1740 (_7\-LRB-\1740 aor_8\NN\1740 =_9\JJ\1740 3.7_10\CD\1740 ;_11\:\1740 95_12\CD\1740 %_13\NN\1740 ci_14\NN\13635336 ,_15\,\1740 1.1_16\CD\1740 -_17\SYM\1740 12.2_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 hypoplastic_21\JJ\1740 left_22\VBD\120316 heart_23\NN\5919034 syndrome_24\NN\5870365 (_25\-LRB-\1740 aor_26\NN\1740 =_27\JJ\1740 4.2_28\CD\1740 ;_29\:\1740 95_30\CD\1740 %_31\NN\1740 ci_32\NN\13635336 ,_33\,\1740 1.9_34\CD\1740 -_35\SYM\1740 9.1_36\CD\1740 )_37\-RRB-\1740 ,_38\,\1740 atrial_39\JJ\1740 septal_40\JJ\1740 defects_41\NNS\14462666 (_42\-LRB-\1740 aor_43\NN\1740 =_44\JJ\1740 1.9_45\CD\1740 ;_46\:\1740 95_47\CD\1740 %_48\NN\1740 ci_49\NN\13635336 ,_50\,\1740 1.1_51\CD\1740 -_52\SYM\1740 3.4_53\CD\1740 )_54\-RRB-\1740 ,_55\,\1740 and_56\CC\1740 cleft_57\VBD\1556346 lip_58\NN\5301392 with_59\IN\1740 cleft_60\NN\13908021 palate_61\NN\8660339 (_62\-LRB-\1740 aor_63\NN\1740 =_64\JJ\1740 2.1_65\CD\1740 ;_66\:\1740 95_67\CD\1740 %_68\NN\1740 ci_69\NN\13635336 ,_70\,\1740 1.2_71\CD\1740 -_72\SYM\1740 3.9_73\CD\1740 )_74\-RRB-\1740 ._75\.\1740
D009582_D008850 CID <e1>nitrofurantoins</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 anophthalmia_4\NN\1740 or_5\CC\3541091 <e2>microphthalmos</e2>_6\NN\1740 (_7\-LRB-\1740 aor_8\NN\1740 =_9\JJ\1740 3.7_10\CD\1740 ;_11\:\1740 95_12\CD\1740 %_13\NN\1740 ci_14\NN\13635336 ,_15\,\1740 1.1_16\CD\1740 -_17\SYM\1740 12.2_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 hypoplastic_21\JJ\1740 left_22\VBD\120316 heart_23\NN\5919034 syndrome_24\NN\5870365 (_25\-LRB-\1740 aor_26\NN\1740 =_27\JJ\1740 4.2_28\CD\1740 ;_29\:\1740 95_30\CD\1740 %_31\NN\1740 ci_32\NN\13635336 ,_33\,\1740 1.9_34\CD\1740 -_35\SYM\1740 9.1_36\CD\1740 )_37\-RRB-\1740 ,_38\,\1740 atrial_39\JJ\1740 septal_40\JJ\1740 defects_41\NNS\14462666 (_42\-LRB-\1740 aor_43\NN\1740 =_44\JJ\1740 1.9_45\CD\1740 ;_46\:\1740 95_47\CD\1740 %_48\NN\1740 ci_49\NN\13635336 ,_50\,\1740 1.1_51\CD\1740 -_52\SYM\1740 3.4_53\CD\1740 )_54\-RRB-\1740 ,_55\,\1740 and_56\CC\1740 cleft_57\VBD\1556346 lip_58\NN\5301392 with_59\IN\1740 cleft_60\NN\13908021 palate_61\NN\8660339 (_62\-LRB-\1740 aor_63\NN\1740 =_64\JJ\1740 2.1_65\CD\1740 ;_66\:\1740 95_67\CD\1740 %_68\NN\1740 ci_69\NN\13635336 ,_70\,\1740 1.2_71\CD\1740 -_72\SYM\1740 3.9_73\CD\1740 )_74\-RRB-\1740 ._75\.\1740
D009582_D018636 CID <e1>nitrofurantoins</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 anophthalmia_4\NN\1740 or_5\CC\3541091 microphthalmos_6\NN\1740 (_7\-LRB-\1740 aor_8\NN\1740 =_9\JJ\1740 3.7_10\CD\1740 ;_11\:\1740 95_12\CD\1740 %_13\NN\1740 ci_14\NN\13635336 ,_15\,\1740 1.1_16\CD\1740 -_17\SYM\1740 12.2_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 <e2>hypoplastic_21\JJ\1740 left_22\VBD\120316 heart_23\NN\5919034 syndrome</e2>_24\NN\5870365 (_25\-LRB-\1740 aor_26\NN\1740 =_27\JJ\1740 4.2_28\CD\1740 ;_29\:\1740 95_30\CD\1740 %_31\NN\1740 ci_32\NN\13635336 ,_33\,\1740 1.9_34\CD\1740 -_35\SYM\1740 9.1_36\CD\1740 )_37\-RRB-\1740 ,_38\,\1740 atrial_39\JJ\1740 septal_40\JJ\1740 defects_41\NNS\14462666 (_42\-LRB-\1740 aor_43\NN\1740 =_44\JJ\1740 1.9_45\CD\1740 ;_46\:\1740 95_47\CD\1740 %_48\NN\1740 ci_49\NN\13635336 ,_50\,\1740 1.1_51\CD\1740 -_52\SYM\1740 3.4_53\CD\1740 )_54\-RRB-\1740 ,_55\,\1740 and_56\CC\1740 cleft_57\VBD\1556346 lip_58\NN\5301392 with_59\IN\1740 cleft_60\NN\13908021 palate_61\NN\8660339 (_62\-LRB-\1740 aor_63\NN\1740 =_64\JJ\1740 2.1_65\CD\1740 ;_66\:\1740 95_67\CD\1740 %_68\NN\1740 ci_69\NN\13635336 ,_70\,\1740 1.2_71\CD\1740 -_72\SYM\1740 3.9_73\CD\1740 )_74\-RRB-\1740 ._75\.\1740
D009582_D006344 CID <e1>nitrofurantoins</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 anophthalmia_4\NN\1740 or_5\CC\3541091 microphthalmos_6\NN\1740 (_7\-LRB-\1740 aor_8\NN\1740 =_9\JJ\1740 3.7_10\CD\1740 ;_11\:\1740 95_12\CD\1740 %_13\NN\1740 ci_14\NN\13635336 ,_15\,\1740 1.1_16\CD\1740 -_17\SYM\1740 12.2_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 hypoplastic_21\JJ\1740 left_22\VBD\120316 heart_23\NN\5919034 syndrome_24\NN\5870365 (_25\-LRB-\1740 aor_26\NN\1740 =_27\JJ\1740 4.2_28\CD\1740 ;_29\:\1740 95_30\CD\1740 %_31\NN\1740 ci_32\NN\13635336 ,_33\,\1740 1.9_34\CD\1740 -_35\SYM\1740 9.1_36\CD\1740 )_37\-RRB-\1740 ,_38\,\1740 <e2>atrial_39\JJ\1740 septal_40\JJ\1740 defects</e2>_41\NNS\14462666 (_42\-LRB-\1740 aor_43\NN\1740 =_44\JJ\1740 1.9_45\CD\1740 ;_46\:\1740 95_47\CD\1740 %_48\NN\1740 ci_49\NN\13635336 ,_50\,\1740 1.1_51\CD\1740 -_52\SYM\1740 3.4_53\CD\1740 )_54\-RRB-\1740 ,_55\,\1740 and_56\CC\1740 cleft_57\VBD\1556346 lip_58\NN\5301392 with_59\IN\1740 cleft_60\NN\13908021 palate_61\NN\8660339 (_62\-LRB-\1740 aor_63\NN\1740 =_64\JJ\1740 2.1_65\CD\1740 ;_66\:\1740 95_67\CD\1740 %_68\NN\1740 ci_69\NN\13635336 ,_70\,\1740 1.2_71\CD\1740 -_72\SYM\1740 3.9_73\CD\1740 )_74\-RRB-\1740 ._75\.\1740
D009582_D002971 CID <e1>nitrofurantoins</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 anophthalmia_4\NN\1740 or_5\CC\3541091 microphthalmos_6\NN\1740 (_7\-LRB-\1740 aor_8\NN\1740 =_9\JJ\1740 3.7_10\CD\1740 ;_11\:\1740 95_12\CD\1740 %_13\NN\1740 ci_14\NN\13635336 ,_15\,\1740 1.1_16\CD\1740 -_17\SYM\1740 12.2_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 hypoplastic_21\JJ\1740 left_22\VBD\120316 heart_23\NN\5919034 syndrome_24\NN\5870365 (_25\-LRB-\1740 aor_26\NN\1740 =_27\JJ\1740 4.2_28\CD\1740 ;_29\:\1740 95_30\CD\1740 %_31\NN\1740 ci_32\NN\13635336 ,_33\,\1740 1.9_34\CD\1740 -_35\SYM\1740 9.1_36\CD\1740 )_37\-RRB-\1740 ,_38\,\1740 atrial_39\JJ\1740 septal_40\JJ\1740 defects_41\NNS\14462666 (_42\-LRB-\1740 aor_43\NN\1740 =_44\JJ\1740 1.9_45\CD\1740 ;_46\:\1740 95_47\CD\1740 %_48\NN\1740 ci_49\NN\13635336 ,_50\,\1740 1.1_51\CD\1740 -_52\SYM\1740 3.4_53\CD\1740 )_54\-RRB-\1740 ,_55\,\1740 and_56\CC\1740 <e2>cleft_57\VBD\1556346 lip</e2>_58\NN\5301392 with_59\IN\1740 cleft_60\NN\13908021 palate_61\NN\8660339 (_62\-LRB-\1740 aor_63\NN\1740 =_64\JJ\1740 2.1_65\CD\1740 ;_66\:\1740 95_67\CD\1740 %_68\NN\1740 ci_69\NN\13635336 ,_70\,\1740 1.2_71\CD\1740 -_72\SYM\1740 3.9_73\CD\1740 )_74\-RRB-\1740 ._75\.\1740
D009582_D002972 CID <e1>nitrofurantoins</e1>_0\NNS\2716205 were_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 anophthalmia_4\NN\1740 or_5\CC\3541091 microphthalmos_6\NN\1740 (_7\-LRB-\1740 aor_8\NN\1740 =_9\JJ\1740 3.7_10\CD\1740 ;_11\:\1740 95_12\CD\1740 %_13\NN\1740 ci_14\NN\13635336 ,_15\,\1740 1.1_16\CD\1740 -_17\SYM\1740 12.2_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 hypoplastic_21\JJ\1740 left_22\VBD\120316 heart_23\NN\5919034 syndrome_24\NN\5870365 (_25\-LRB-\1740 aor_26\NN\1740 =_27\JJ\1740 4.2_28\CD\1740 ;_29\:\1740 95_30\CD\1740 %_31\NN\1740 ci_32\NN\13635336 ,_33\,\1740 1.9_34\CD\1740 -_35\SYM\1740 9.1_36\CD\1740 )_37\-RRB-\1740 ,_38\,\1740 atrial_39\JJ\1740 septal_40\JJ\1740 defects_41\NNS\14462666 (_42\-LRB-\1740 aor_43\NN\1740 =_44\JJ\1740 1.9_45\CD\1740 ;_46\:\1740 95_47\CD\1740 %_48\NN\1740 ci_49\NN\13635336 ,_50\,\1740 1.1_51\CD\1740 -_52\SYM\1740 3.4_53\CD\1740 )_54\-RRB-\1740 ,_55\,\1740 and_56\CC\1740 cleft_57\VBD\1556346 lip_58\NN\5301392 with_59\IN\1740 <e2>cleft_60\NN\13908021 palate</e2>_61\NN\8660339 (_62\-LRB-\1740 aor_63\NN\1740 =_64\JJ\1740 2.1_65\CD\1740 ;_66\:\1740 95_67\CD\1740 %_68\NN\1740 ci_69\NN\13635336 ,_70\,\1740 1.2_71\CD\1740 -_72\SYM\1740 3.9_73\CD\1740 )_74\-RRB-\1740 ._75\.\1740
D010406_D000014 NONE conclusions_0\NNS\5837957 :_1\:\1740 reassuringly_2\RB\1740 ,_3\,\1740 <e1>penicillins</e1>_4\NNS\2716866 ,_5\,\1740 erythromycins_6\NNS\2716866 ,_7\,\1740 and_8\CC\1740 cephalosporins_9\NNS\2716866 ,_10\,\1740 although_11\IN\1740 used_12\VBN\1156834 commonly_13\RB\1740 by_14\IN\1740 pregnant_15\JJ\1740 women_16\NNS\9605289 ,_17\,\1740 were_18\VBD\836236 not_19\RB\1740 associated_20\VBN\628491 with_21\IN\1740 many_22\JJ\1740 <e2>birth_23\NN\15265518 defects</e2>_24\NNS\14462666 ._25\.\1740
D004917_D000014 NONE conclusions_0\NNS\5837957 :_1\:\1740 reassuringly_2\RB\1740 ,_3\,\1740 penicillins_4\NNS\2716866 ,_5\,\1740 <e1>erythromycins</e1>_6\NNS\2716866 ,_7\,\1740 and_8\CC\1740 cephalosporins_9\NNS\2716866 ,_10\,\1740 although_11\IN\1740 used_12\VBN\1156834 commonly_13\RB\1740 by_14\IN\1740 pregnant_15\JJ\1740 women_16\NNS\9605289 ,_17\,\1740 were_18\VBD\836236 not_19\RB\1740 associated_20\VBN\628491 with_21\IN\1740 many_22\JJ\1740 <e2>birth_23\NN\15265518 defects</e2>_24\NNS\14462666 ._25\.\1740
D002511_D000014 NONE conclusions_0\NNS\5837957 :_1\:\1740 reassuringly_2\RB\1740 ,_3\,\1740 penicillins_4\NNS\2716866 ,_5\,\1740 erythromycins_6\NNS\2716866 ,_7\,\1740 and_8\CC\1740 <e1>cephalosporins</e1>_9\NNS\2716866 ,_10\,\1740 although_11\IN\1740 used_12\VBN\1156834 commonly_13\RB\1740 by_14\IN\1740 pregnant_15\JJ\1740 women_16\NNS\9605289 ,_17\,\1740 were_18\VBD\836236 not_19\RB\1740 associated_20\VBN\628491 with_21\IN\1740 many_22\JJ\1740 <e2>birth_23\NN\15265518 defects</e2>_24\NNS\14462666 ._25\.\1740
D013449_D000014 CID <e1>sulfonamides</e1>_0\NNS\2716205 and_1\CC\1740 nitrofurantoins_2\NNS\2716205 were_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 several_6\JJ\1740 <e2>birth_7\NN\15265518 defects</e2>_8\NNS\14462666 ,_9\,\1740 indicating_10\VBG\952524 a_11\DT\13649268 need_12\NN\13920835 for_13\IN\1740 additional_14\JJ\1740 scrutiny_15\NN\633864 ._16\.\1740
D009582_D000014 CID sulfonamides_0\NNS\2716205 and_1\CC\1740 <e1>nitrofurantoins</e1>_2\NNS\2716205 were_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 several_6\JJ\1740 <e2>birth_7\NN\15265518 defects</e2>_8\NNS\14462666 ,_9\,\1740 indicating_10\VBG\952524 a_11\DT\13649268 need_12\NN\13920835 for_13\IN\1740 additional_14\JJ\1740 scrutiny_15\NN\633864 ._16\.\1740
17343925
D012906_D034381 CID the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 <e1>smoking</e1>_3\VBG\1156834 during_4\IN\1740 pregnancy_5\NN\14034177 on_6\IN\1740 the_7\DT\1740 developing_8\VBG\1753788 cochlea_9\NN\5246511 has_10\VBZ\2108377 not_11\RB\1740 been_12\VBN\836236 estimated_13\VBN\637259 ,_14\,\1740 although_15\IN\1740 smoking_16\NN\831191 has_17\VBZ\2108377 been_18\VBN\836236 positively_19\RB\1740 associated_20\VBN\628491 with_21\IN\1740 <e2>hearing_22\VBG\2106506 loss</e2>_23\NN\13252973 in_24\IN\13603305 adults_25\NNS\7846 ._26\.\1740
D012906_D034381 CID the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 smoking_3\VBG\1156834 during_4\IN\1740 pregnancy_5\NN\14034177 on_6\IN\1740 the_7\DT\1740 developing_8\VBG\1753788 cochlea_9\NN\5246511 has_10\VBZ\2108377 not_11\RB\1740 been_12\VBN\836236 estimated_13\VBN\637259 ,_14\,\1740 although_15\IN\1740 <e1>smoking</e1>_16\NN\831191 has_17\VBZ\2108377 been_18\VBN\836236 positively_19\RB\1740 associated_20\VBN\628491 with_21\IN\1740 <e2>hearing_22\VBG\2106506 loss</e2>_23\NN\13252973 in_24\IN\13603305 adults_25\NNS\7846 ._26\.\1740
8387218
D016049_D064420 NONE the_0\DT\1740 use_1\NN\407535 and_2\CC\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 <e1>didanosine</e1>_5\NN\2725367 (_6\-LRB-\1740 ddi_7\NN\2725367 )_8\-RRB-\1740 in_9\IN\13603305 hiv_10\NN\14186340 antibody-positive_11\JJ\1740 individuals_12\NNS\7347 intolerant_13\JJ\1740 to_14\TO\1740 zidovudine_15\NN\3834836 (_16\-LRB-\1740 azt_17\NN\3834836 )_18\-RRB-\1740
D016049_D064420 NONE the_0\DT\1740 use_1\NN\407535 and_2\CC\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 didanosine_5\NN\2725367 (_6\-LRB-\1740 <e1>ddi</e1>_7\NN\2725367 )_8\-RRB-\1740 in_9\IN\13603305 hiv_10\NN\14186340 antibody-positive_11\JJ\1740 individuals_12\NNS\7347 intolerant_13\JJ\1740 to_14\TO\1740 zidovudine_15\NN\3834836 (_16\-LRB-\1740 azt_17\NN\3834836 )_18\-RRB-\1740
D016049_D015658 NONE the_0\DT\1740 use_1\NN\407535 and_2\CC\1740 toxicity_3\NN\13576101 of_4\IN\1740 <e1>didanosine</e1>_5\NN\2725367 (_6\-LRB-\1740 ddi_7\NN\2725367 )_8\-RRB-\1740 in_9\IN\13603305 <e2>hiv_10\NN\14186340 antibody-positive</e2>_11\JJ\1740 individuals_12\NNS\7347 intolerant_13\JJ\1740 to_14\TO\1740 zidovudine_15\NN\3834836 (_16\-LRB-\1740 azt_17\NN\3834836 )_18\-RRB-\1740
D016049_D015658 NONE the_0\DT\1740 use_1\NN\407535 and_2\CC\1740 toxicity_3\NN\13576101 of_4\IN\1740 didanosine_5\NN\2725367 (_6\-LRB-\1740 <e1>ddi</e1>_7\NN\2725367 )_8\-RRB-\1740 in_9\IN\13603305 <e2>hiv_10\NN\14186340 antibody-positive</e2>_11\JJ\1740 individuals_12\NNS\7347 intolerant_13\JJ\1740 to_14\TO\1740 zidovudine_15\NN\3834836 (_16\-LRB-\1740 azt_17\NN\3834836 )_18\-RRB-\1740
D015215_D064420 NONE the_0\DT\1740 use_1\NN\407535 and_2\CC\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 didanosine_5\NN\2725367 (_6\-LRB-\1740 ddi_7\NN\2725367 )_8\-RRB-\1740 in_9\IN\13603305 hiv_10\NN\14186340 antibody-positive_11\JJ\1740 individuals_12\NNS\7347 intolerant_13\JJ\1740 to_14\TO\1740 <e1>zidovudine</e1>_15\NN\3834836 (_16\-LRB-\1740 azt_17\NN\3834836 )_18\-RRB-\1740
D015215_D064420 NONE the_0\DT\1740 use_1\NN\407535 and_2\CC\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 didanosine_5\NN\2725367 (_6\-LRB-\1740 ddi_7\NN\2725367 )_8\-RRB-\1740 in_9\IN\13603305 hiv_10\NN\14186340 antibody-positive_11\JJ\1740 individuals_12\NNS\7347 intolerant_13\JJ\1740 to_14\TO\1740 zidovudine_15\NN\3834836 (_16\-LRB-\1740 <e1>azt</e1>_17\NN\3834836 )_18\-RRB-\1740
D015215_D015658 NONE the_0\DT\1740 use_1\NN\407535 and_2\CC\1740 toxicity_3\NN\13576101 of_4\IN\1740 didanosine_5\NN\2725367 (_6\-LRB-\1740 ddi_7\NN\2725367 )_8\-RRB-\1740 in_9\IN\13603305 <e2>hiv_10\NN\14186340 antibody-positive</e2>_11\JJ\1740 individuals_12\NNS\7347 intolerant_13\JJ\1740 to_14\TO\1740 <e1>zidovudine</e1>_15\NN\3834836 (_16\-LRB-\1740 azt_17\NN\3834836 )_18\-RRB-\1740
D015215_D015658 NONE the_0\DT\1740 use_1\NN\407535 and_2\CC\1740 toxicity_3\NN\13576101 of_4\IN\1740 didanosine_5\NN\2725367 (_6\-LRB-\1740 ddi_7\NN\2725367 )_8\-RRB-\1740 in_9\IN\13603305 <e2>hiv_10\NN\14186340 antibody-positive</e2>_11\JJ\1740 individuals_12\NNS\7347 intolerant_13\JJ\1740 to_14\TO\1740 zidovudine_15\NN\3834836 (_16\-LRB-\1740 <e1>azt</e1>_17\NN\3834836 )_18\-RRB-\1740
D016049_D018149 CID seven_0\CD\13741022 patients_1\NNS\9898892 developed_2\VBD\1753788 <e2>glucose_3\NN\14710501 tolerance_4\NN\5032565 curves</e2>_5\NNS\13863771 characteristic_6\JJ\1740 of_7\IN\1740 diabetes_8\NNS\14075199 but_9\CC\1740 these_10\DT\1740 were_11\VBD\836236 mild_12\JJ\1740 ,_13\,\1740 did_14\VBD\1640855 not_15\RB\1740 require_16\VB\754942 treatment_17\NN\654885 and_18\CC\1740 returned_19\VBD\1835496 to_20\IN\1740 normal_21\JJ\1740 on_22\IN\1740 ceasing_23\VBG\1740 <e1>didanosine</e1>_24\NN\2725367 ._25\.\1740
D016049_D003920 NONE seven_0\CD\13741022 patients_1\NNS\9898892 developed_2\VBD\1753788 glucose_3\NN\14710501 tolerance_4\NN\5032565 curves_5\NNS\13863771 characteristic_6\JJ\1740 of_7\IN\1740 <e2>diabetes</e2>_8\NNS\14075199 but_9\CC\1740 these_10\DT\1740 were_11\VBD\836236 mild_12\JJ\1740 ,_13\,\1740 did_14\VBD\1640855 not_15\RB\1740 require_16\VB\754942 treatment_17\NN\654885 and_18\CC\1740 returned_19\VBD\1835496 to_20\IN\1740 normal_21\JJ\1740 on_22\IN\1740 ceasing_23\VBG\1740 <e1>didanosine</e1>_24\NN\2725367 ._25\.\1740
1639466
D002118_D009400 NONE adverse_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 the_3\DT\1740 <e1>calcium</e1>_4\NN\14625458 channel_5\NN\6251781 blocker_6\NN\10101634 nitrendipine_7\NN\1740 on_8\IN\1740 <e2>nephrosclerosis</e2>_9\NN\14113228 in_10\IN\13603305 rats_11\NNS\2329401 with_12\IN\1740 renovascular_13\JJ\1740 hypertension_14\NN\14057371 ._15\.\1740
D002118_D006978 NONE adverse_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 the_3\DT\1740 <e1>calcium</e1>_4\NN\14625458 channel_5\NN\6251781 blocker_6\NN\10101634 nitrendipine_7\NN\1740 on_8\IN\1740 nephrosclerosis_9\NN\14113228 in_10\IN\13603305 rats_11\NNS\2329401 with_12\IN\1740 <e2>renovascular_13\JJ\1740 hypertension</e2>_14\NN\14057371 ._15\.\1740
D002118_D006978 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 a_3\DT\13649268 6-week_4\JJ\1740 treatment_5\NN\654885 with_6\IN\1740 the_7\DT\1740 <e1>calcium</e1>_8\NN\14625458 channel_9\NN\6251781 blocker_10\NN\10101634 nitrendipine_11\NN\1740 or_12\CC\3541091 the_13\DT\1740 angiotensin_14\NN\4522421 converting_15\NN\1740 enzyme_16\NN\14723628 inhibitor_17\NN\20090 enalapril_18\NN\2673637 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 albuminuria_23\NN\14299637 ,_24\,\1740 renal_25\JJ\1740 hemodynamics_26\NNS\6080522 ,_27\,\1740 and_28\CC\1740 morphology_29\NN\6037666 of_30\IN\1740 the_31\DT\1740 nonclipped_32\JJ\1740 kidney_33\NN\5333259 was_34\VBD\836236 studied_35\VBN\630380 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 two-kidney_39\NN\1740 ,_40\,\1740 one_41\CD\13741022 clip_42\NN\4359335 <e2>renovascular_43\JJ\1740 hypertension</e2>_44\NN\14057371 ._45\.\1740
D009568_D009400 CID adverse_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 the_3\DT\1740 calcium_4\NN\14625458 channel_5\NN\6251781 blocker_6\NN\10101634 <e1>nitrendipine</e1>_7\NN\1740 on_8\IN\1740 <e2>nephrosclerosis</e2>_9\NN\14113228 in_10\IN\13603305 rats_11\NNS\2329401 with_12\IN\1740 renovascular_13\JJ\1740 hypertension_14\NN\14057371 ._15\.\1740
D009568_D006978 NONE adverse_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 the_3\DT\1740 calcium_4\NN\14625458 channel_5\NN\6251781 blocker_6\NN\10101634 <e1>nitrendipine</e1>_7\NN\1740 on_8\IN\1740 nephrosclerosis_9\NN\14113228 in_10\IN\13603305 rats_11\NNS\2329401 with_12\IN\1740 <e2>renovascular_13\JJ\1740 hypertension</e2>_14\NN\14057371 ._15\.\1740
D009568_D006978 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 a_3\DT\13649268 6-week_4\JJ\1740 treatment_5\NN\654885 with_6\IN\1740 the_7\DT\1740 calcium_8\NN\14625458 channel_9\NN\6251781 blocker_10\NN\10101634 <e1>nitrendipine</e1>_11\NN\1740 or_12\CC\3541091 the_13\DT\1740 angiotensin_14\NN\4522421 converting_15\NN\1740 enzyme_16\NN\14723628 inhibitor_17\NN\20090 enalapril_18\NN\2673637 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 albuminuria_23\NN\14299637 ,_24\,\1740 renal_25\JJ\1740 hemodynamics_26\NNS\6080522 ,_27\,\1740 and_28\CC\1740 morphology_29\NN\6037666 of_30\IN\1740 the_31\DT\1740 nonclipped_32\JJ\1740 kidney_33\NN\5333259 was_34\VBD\836236 studied_35\VBN\630380 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 two-kidney_39\NN\1740 ,_40\,\1740 one_41\CD\13741022 clip_42\NN\4359335 <e2>renovascular_43\JJ\1740 hypertension</e2>_44\NN\14057371 ._45\.\1740
D002118_D000419 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 a_3\DT\13649268 6-week_4\JJ\1740 treatment_5\NN\654885 with_6\IN\1740 the_7\DT\1740 <e1>calcium</e1>_8\NN\14625458 channel_9\NN\6251781 blocker_10\NN\10101634 nitrendipine_11\NN\1740 or_12\CC\3541091 the_13\DT\1740 angiotensin_14\NN\4522421 converting_15\NN\1740 enzyme_16\NN\14723628 inhibitor_17\NN\20090 enalapril_18\NN\2673637 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 <e2>albuminuria</e2>_23\NN\14299637 ,_24\,\1740 renal_25\JJ\1740 hemodynamics_26\NNS\6080522 ,_27\,\1740 and_28\CC\1740 morphology_29\NN\6037666 of_30\IN\1740 the_31\DT\1740 nonclipped_32\JJ\1740 kidney_33\NN\5333259 was_34\VBD\836236 studied_35\VBN\630380 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 two-kidney_39\NN\1740 ,_40\,\1740 one_41\CD\13741022 clip_42\NN\4359335 renovascular_43\JJ\1740 hypertension_44\NN\14057371 ._45\.\1740
D009568_D000419 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 a_3\DT\13649268 6-week_4\JJ\1740 treatment_5\NN\654885 with_6\IN\1740 the_7\DT\1740 calcium_8\NN\14625458 channel_9\NN\6251781 blocker_10\NN\10101634 <e1>nitrendipine</e1>_11\NN\1740 or_12\CC\3541091 the_13\DT\1740 angiotensin_14\NN\4522421 converting_15\NN\1740 enzyme_16\NN\14723628 inhibitor_17\NN\20090 enalapril_18\NN\2673637 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 <e2>albuminuria</e2>_23\NN\14299637 ,_24\,\1740 renal_25\JJ\1740 hemodynamics_26\NNS\6080522 ,_27\,\1740 and_28\CC\1740 morphology_29\NN\6037666 of_30\IN\1740 the_31\DT\1740 nonclipped_32\JJ\1740 kidney_33\NN\5333259 was_34\VBD\836236 studied_35\VBN\630380 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 two-kidney_39\NN\1740 ,_40\,\1740 one_41\CD\13741022 clip_42\NN\4359335 renovascular_43\JJ\1740 hypertension_44\NN\14057371 ._45\.\1740
D009568_D000419 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 in_3\IN\13603305 the_4\DT\1740 <e1>nitrendipine-treated</e1>_5\JJ\1740 group_6\NN\2137 <e2>albuminuria</e2>_7\NN\14299637 increased_8\VBD\169651 from_9\IN\1740 12.8_10\CD\1740 +/-_11\CC\1740 2_12\CD\13741022 progressively_13\RB\1740 to_14\TO\1740 163_15\CD\1740 +/-_16\CC\1740 55_17\CD\1740 compared_18\VBN\644583 with_19\IN\1740 19.2_20\CD\1740 +/-_21\CC\1740 9_22\CD\13741022 mg/24_23\NNS\1740 hr_24\NN\15154774 in_25\IN\13603305 the_26\DT\1740 hypertensive_27\JJ\1740 controls_28\NNS\5190804 ._29\.\1740
D000809_D000419 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 a_3\DT\13649268 6-week_4\JJ\1740 treatment_5\NN\654885 with_6\IN\1740 the_7\DT\1740 calcium_8\NN\14625458 channel_9\NN\6251781 blocker_10\NN\10101634 nitrendipine_11\NN\1740 or_12\CC\3541091 the_13\DT\1740 <e1>angiotensin</e1>_14\NN\4522421 converting_15\NN\1740 enzyme_16\NN\14723628 inhibitor_17\NN\20090 enalapril_18\NN\2673637 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 <e2>albuminuria</e2>_23\NN\14299637 ,_24\,\1740 renal_25\JJ\1740 hemodynamics_26\NNS\6080522 ,_27\,\1740 and_28\CC\1740 morphology_29\NN\6037666 of_30\IN\1740 the_31\DT\1740 nonclipped_32\JJ\1740 kidney_33\NN\5333259 was_34\VBD\836236 studied_35\VBN\630380 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 two-kidney_39\NN\1740 ,_40\,\1740 one_41\CD\13741022 clip_42\NN\4359335 renovascular_43\JJ\1740 hypertension_44\NN\14057371 ._45\.\1740
D000809_D006978 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 a_3\DT\13649268 6-week_4\JJ\1740 treatment_5\NN\654885 with_6\IN\1740 the_7\DT\1740 calcium_8\NN\14625458 channel_9\NN\6251781 blocker_10\NN\10101634 nitrendipine_11\NN\1740 or_12\CC\3541091 the_13\DT\1740 <e1>angiotensin</e1>_14\NN\4522421 converting_15\NN\1740 enzyme_16\NN\14723628 inhibitor_17\NN\20090 enalapril_18\NN\2673637 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 albuminuria_23\NN\14299637 ,_24\,\1740 renal_25\JJ\1740 hemodynamics_26\NNS\6080522 ,_27\,\1740 and_28\CC\1740 morphology_29\NN\6037666 of_30\IN\1740 the_31\DT\1740 nonclipped_32\JJ\1740 kidney_33\NN\5333259 was_34\VBD\836236 studied_35\VBN\630380 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 two-kidney_39\NN\1740 ,_40\,\1740 one_41\CD\13741022 clip_42\NN\4359335 <e2>renovascular_43\JJ\1740 hypertension</e2>_44\NN\14057371 ._45\.\1740
D004656_D000419 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 a_3\DT\13649268 6-week_4\JJ\1740 treatment_5\NN\654885 with_6\IN\1740 the_7\DT\1740 calcium_8\NN\14625458 channel_9\NN\6251781 blocker_10\NN\10101634 nitrendipine_11\NN\1740 or_12\CC\3541091 the_13\DT\1740 angiotensin_14\NN\4522421 converting_15\NN\1740 enzyme_16\NN\14723628 inhibitor_17\NN\20090 <e1>enalapril</e1>_18\NN\2673637 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 <e2>albuminuria</e2>_23\NN\14299637 ,_24\,\1740 renal_25\JJ\1740 hemodynamics_26\NNS\6080522 ,_27\,\1740 and_28\CC\1740 morphology_29\NN\6037666 of_30\IN\1740 the_31\DT\1740 nonclipped_32\JJ\1740 kidney_33\NN\5333259 was_34\VBD\836236 studied_35\VBN\630380 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 two-kidney_39\NN\1740 ,_40\,\1740 one_41\CD\13741022 clip_42\NN\4359335 renovascular_43\JJ\1740 hypertension_44\NN\14057371 ._45\.\1740
D004656_D006978 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 a_3\DT\13649268 6-week_4\JJ\1740 treatment_5\NN\654885 with_6\IN\1740 the_7\DT\1740 calcium_8\NN\14625458 channel_9\NN\6251781 blocker_10\NN\10101634 nitrendipine_11\NN\1740 or_12\CC\3541091 the_13\DT\1740 angiotensin_14\NN\4522421 converting_15\NN\1740 enzyme_16\NN\14723628 inhibitor_17\NN\20090 <e1>enalapril</e1>_18\NN\2673637 on_19\IN\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 albuminuria_23\NN\14299637 ,_24\,\1740 renal_25\JJ\1740 hemodynamics_26\NNS\6080522 ,_27\,\1740 and_28\CC\1740 morphology_29\NN\6037666 of_30\IN\1740 the_31\DT\1740 nonclipped_32\JJ\1740 kidney_33\NN\5333259 was_34\VBD\836236 studied_35\VBN\630380 in_36\IN\13603305 rats_37\NNS\2329401 with_38\IN\1740 two-kidney_39\NN\1740 ,_40\,\1740 one_41\CD\13741022 clip_42\NN\4359335 <e2>renovascular_43\JJ\1740 hypertension</e2>_44\NN\14057371 ._45\.\1740
D004656_D006973 NONE six_0\CD\13741022 weeks_1\NNS\15113229 after_2\IN\1740 clipping_3\VBG\1552519 of_4\IN\1740 one_5\CD\13741022 renal_6\JJ\1740 artery_7\NN\5417975 ,_8\,\1740 <e2>hypertensive</e2>_9\JJ\1740 rats_10\NNS\2329401 (_11\-LRB-\1740 178_12\CD\1740 +/-_13\CC\1740 4_14\CD\13741022 mm_15\NN\13649268 hg_16\NN\14625458 )_17\-RRB-\1740 were_18\VBD\836236 randomly_19\RB\1740 assigned_20\VBN\2475922 to_21\TO\1740 three_22\CD\13741022 groups_23\NNS\2137 :_24\:\1740 untreated_25\JJ\1740 hypertensive_26\JJ\1740 controls_27\NNS\5190804 (_28\-LRB-\1740 n_29\NN\14622893 =_30\JJ\1740 8)_31\CD\1740 ,_32\,\1740 <e1>enalapril-treated</e1>_33\JJ\1740 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 8)_37\CD\1740 ,_38\,\1740 or_39\CC\3541091 nitrendipine-treated_40\JJ\1740 (_41\-LRB-\1740 n_42\NN\14622893 =_43\JJ\1740 10_44\CD\13745420 )_45\-RRB-\1740 ._46\.\1740
D004656_D006973 NONE six_0\CD\13741022 weeks_1\NNS\15113229 after_2\IN\1740 clipping_3\VBG\1552519 of_4\IN\1740 one_5\CD\13741022 renal_6\JJ\1740 artery_7\NN\5417975 ,_8\,\1740 hypertensive_9\JJ\1740 rats_10\NNS\2329401 (_11\-LRB-\1740 178_12\CD\1740 +/-_13\CC\1740 4_14\CD\13741022 mm_15\NN\13649268 hg_16\NN\14625458 )_17\-RRB-\1740 were_18\VBD\836236 randomly_19\RB\1740 assigned_20\VBN\2475922 to_21\TO\1740 three_22\CD\13741022 groups_23\NNS\2137 :_24\:\1740 untreated_25\JJ\1740 <e2>hypertensive</e2>_26\JJ\1740 controls_27\NNS\5190804 (_28\-LRB-\1740 n_29\NN\14622893 =_30\JJ\1740 8)_31\CD\1740 ,_32\,\1740 <e1>enalapril-treated</e1>_33\JJ\1740 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 8)_37\CD\1740 ,_38\,\1740 or_39\CC\3541091 nitrendipine-treated_40\JJ\1740 (_41\-LRB-\1740 n_42\NN\14622893 =_43\JJ\1740 10_44\CD\13745420 )_45\-RRB-\1740 ._46\.\1740
D004656_D006973 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 glomerular_3\JJ\1740 size_4\NN\5090441 was_5\VBD\836236 higher_6\JJR\1740 in_7\IN\13603305 the_8\DT\1740 nitrendipine-treated_9\JJ\1740 group_10\NN\2137 (_11\-LRB-\1740 14.9_12\CD\1740 +/-_13\CC\1740 0.17_14\CD\1740 10(-3_15\NN\1740 )_16\-RRB-\1740 mm2_17\CD\1740 )_18\-RRB-\1740 but_19\CC\1740 lower_20\JJR\1740 in_21\IN\13603305 the_22\DT\1740 <e1>enalapril-treated</e1>_23\JJ\1740 group_24\NN\2137 (_25\-LRB-\1740 11.5_26\CD\1740 +/-_27\CC\1740 0.15_28\CD\1740 10(-3_29\NN\1740 )_30\-RRB-\1740 mm2_31\CD\1740 )_32\-RRB-\1740 compared_33\VBN\644583 with_34\IN\1740 the_35\DT\1740 <e2>hypertensive</e2>_36\JJ\1740 controls_37\NNS\5190804 (_38\-LRB-\1740 12.1_39\CD\1740 +/-_40\CC\1740 0.17_41\CD\1740 10(-3_42\NN\1740 )_43\-RRB-\1740 mm2_44\CD\1740 )_45\-RRB-\1740 ._46\.\1740
D009568_D006973 NONE six_0\CD\13741022 weeks_1\NNS\15113229 after_2\IN\1740 clipping_3\VBG\1552519 of_4\IN\1740 one_5\CD\13741022 renal_6\JJ\1740 artery_7\NN\5417975 ,_8\,\1740 <e2>hypertensive</e2>_9\JJ\1740 rats_10\NNS\2329401 (_11\-LRB-\1740 178_12\CD\1740 +/-_13\CC\1740 4_14\CD\13741022 mm_15\NN\13649268 hg_16\NN\14625458 )_17\-RRB-\1740 were_18\VBD\836236 randomly_19\RB\1740 assigned_20\VBN\2475922 to_21\TO\1740 three_22\CD\13741022 groups_23\NNS\2137 :_24\:\1740 untreated_25\JJ\1740 hypertensive_26\JJ\1740 controls_27\NNS\5190804 (_28\-LRB-\1740 n_29\NN\14622893 =_30\JJ\1740 8)_31\CD\1740 ,_32\,\1740 enalapril-treated_33\JJ\1740 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 8)_37\CD\1740 ,_38\,\1740 or_39\CC\3541091 <e1>nitrendipine-treated</e1>_40\JJ\1740 (_41\-LRB-\1740 n_42\NN\14622893 =_43\JJ\1740 10_44\CD\13745420 )_45\-RRB-\1740 ._46\.\1740
D009568_D006973 NONE six_0\CD\13741022 weeks_1\NNS\15113229 after_2\IN\1740 clipping_3\VBG\1552519 of_4\IN\1740 one_5\CD\13741022 renal_6\JJ\1740 artery_7\NN\5417975 ,_8\,\1740 hypertensive_9\JJ\1740 rats_10\NNS\2329401 (_11\-LRB-\1740 178_12\CD\1740 +/-_13\CC\1740 4_14\CD\13741022 mm_15\NN\13649268 hg_16\NN\14625458 )_17\-RRB-\1740 were_18\VBD\836236 randomly_19\RB\1740 assigned_20\VBN\2475922 to_21\TO\1740 three_22\CD\13741022 groups_23\NNS\2137 :_24\:\1740 untreated_25\JJ\1740 <e2>hypertensive</e2>_26\JJ\1740 controls_27\NNS\5190804 (_28\-LRB-\1740 n_29\NN\14622893 =_30\JJ\1740 8)_31\CD\1740 ,_32\,\1740 enalapril-treated_33\JJ\1740 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 8)_37\CD\1740 ,_38\,\1740 or_39\CC\3541091 <e1>nitrendipine-treated</e1>_40\JJ\1740 (_41\-LRB-\1740 n_42\NN\14622893 =_43\JJ\1740 10_44\CD\13745420 )_45\-RRB-\1740 ._46\.\1740
D009568_D006973 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 in_3\IN\13603305 the_4\DT\1740 <e1>nitrendipine-treated</e1>_5\JJ\1740 group_6\NN\2137 albuminuria_7\NN\14299637 increased_8\VBD\169651 from_9\IN\1740 12.8_10\CD\1740 +/-_11\CC\1740 2_12\CD\13741022 progressively_13\RB\1740 to_14\TO\1740 163_15\CD\1740 +/-_16\CC\1740 55_17\CD\1740 compared_18\VBN\644583 with_19\IN\1740 19.2_20\CD\1740 +/-_21\CC\1740 9_22\CD\13741022 mg/24_23\NNS\1740 hr_24\NN\15154774 in_25\IN\13603305 the_26\DT\1740 <e2>hypertensive</e2>_27\JJ\1740 controls_28\NNS\5190804 ._29\.\1740
D009568_D006973 NONE furthermore_0\RB\1740 ,_1\,\1740 glomerulosclerosis_2\NN\1740 index_3\NN\13850304 was_4\VBD\836236 significantly_5\RB\1740 increased_6\VBN\169651 in_7\IN\13603305 the_8\DT\1740 <e1>nitrendipine-treated</e1>_9\JJ\1740 group_10\NN\2137 compared_11\VBN\644583 with_12\IN\1740 the_13\DT\1740 <e2>hypertensive</e2>_14\JJ\1740 controls_15\NNS\5190804 (_16\-LRB-\1740 0.38_17\CD\1740 +/-_18\CC\1740 0.1_19\CD\1740 versus_20\CC\1740 0.13_21\CD\1740 +/-_22\CC\1740 0.04_23\CD\1740 )_24\-RRB-\1740 ._25\.\1740
D009568_D006973 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 glomerular_3\JJ\1740 size_4\NN\5090441 was_5\VBD\836236 higher_6\JJR\1740 in_7\IN\13603305 the_8\DT\1740 <e1>nitrendipine-treated</e1>_9\JJ\1740 group_10\NN\2137 (_11\-LRB-\1740 14.9_12\CD\1740 +/-_13\CC\1740 0.17_14\CD\1740 10(-3_15\NN\1740 )_16\-RRB-\1740 mm2_17\CD\1740 )_18\-RRB-\1740 but_19\CC\1740 lower_20\JJR\1740 in_21\IN\13603305 the_22\DT\1740 enalapril-treated_23\JJ\1740 group_24\NN\2137 (_25\-LRB-\1740 11.5_26\CD\1740 +/-_27\CC\1740 0.15_28\CD\1740 10(-3_29\NN\1740 )_30\-RRB-\1740 mm2_31\CD\1740 )_32\-RRB-\1740 compared_33\VBN\644583 with_34\IN\1740 the_35\DT\1740 <e2>hypertensive</e2>_36\JJ\1740 controls_37\NNS\5190804 (_38\-LRB-\1740 12.1_39\CD\1740 +/-_40\CC\1740 0.17_41\CD\1740 10(-3_42\NN\1740 )_43\-RRB-\1740 mm2_44\CD\1740 )_45\-RRB-\1740 ._46\.\1740
D004656_D005921 NONE renal_0\JJ\1740 plasma_1\NN\5398023 flow_2\NN\7311115 increased_3\VBD\169651 ,_4\,\1740 but_5\CC\1740 albumin_6\NN\14736972 excretion_7\NN\13466586 and_8\CC\1740 <e2>glomerulosclerosis</e2>_9\NN\1740 did_10\VBD\1640855 not_11\RB\1740 change_12\VB\46534 after_13\IN\1740 <e1>enalapril</e1>_14\JJ\1740 treatment_15\NN\654885 ._16\.\1740
D009568_D005921 NONE furthermore_0\RB\1740 ,_1\,\1740 <e2>glomerulosclerosis</e2>_2\NN\1740 index_3\NN\13850304 was_4\VBD\836236 significantly_5\RB\1740 increased_6\VBN\169651 in_7\IN\13603305 the_8\DT\1740 <e1>nitrendipine-treated</e1>_9\JJ\1740 group_10\NN\2137 compared_11\VBN\644583 with_12\IN\1740 the_13\DT\1740 hypertensive_14\JJ\1740 controls_15\NNS\5190804 (_16\-LRB-\1740 0.38_17\CD\1740 +/-_18\CC\1740 0.1_19\CD\1740 versus_20\CC\1740 0.13_21\CD\1740 +/-_22\CC\1740 0.04_23\CD\1740 )_24\-RRB-\1740 ._25\.\1740
16858720
D014859_D002543 CID <e2>cerebral_0\JJ\1740 haemorrhage</e2>_1\NN\14285662 induced_2\VBN\1627355 by_3\IN\1740 <e1>warfarin</e1>_4\NN\2718259 -_5\:\1740 the_6\DT\1740 influence_7\NN\5190804 of_8\IN\1740 drug-drug_9\JJ\1740 interactions_10\NNS\37396 ._11\.\1740
D014859_D002543 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 frequency_5\NN\15286249 ,_6\,\1740 severity_7\NN\5036394 and_8\CC\1740 preventability_9\NN\1740 of_10\IN\1740 <e1>warfarin-induced</e1>_11\JJ\1740 <e2>cerebral_12\JJ\1740 haemorrhages</e2>_13\NNS\14285662 due_14\JJ\1740 to_15\TO\1740 warfarin_16\NN\2718259 and_17\CC\1740 warfarin-drug_18\JJ\1740 interactions_19\NNS\37396 in_20\IN\13603305 patients_21\NNS\9898892 living_22\VBG\2655135 in_23\IN\13603305 the_24\DT\1740 county_25\NN\8630039 of_26\IN\1740 osterg_27\NNP\1740 tland_28\NN\1740 ,_29\,\1740 sweden_30\NNP\1740 ._31\.\1740
D014859_D002543 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 frequency_5\NN\15286249 ,_6\,\1740 severity_7\NN\5036394 and_8\CC\1740 preventability_9\NN\1740 of_10\IN\1740 warfarin-induced_11\JJ\1740 <e2>cerebral_12\JJ\1740 haemorrhages</e2>_13\NNS\14285662 due_14\JJ\1740 to_15\TO\1740 <e1>warfarin</e1>_16\NN\2718259 and_17\CC\1740 warfarin-drug_18\JJ\1740 interactions_19\NNS\37396 in_20\IN\13603305 patients_21\NNS\9898892 living_22\VBG\2655135 in_23\IN\13603305 the_24\DT\1740 county_25\NN\8630039 of_26\IN\1740 osterg_27\NNP\1740 tland_28\NN\1740 ,_29\,\1740 sweden_30\NNP\1740 ._31\.\1740
D014859_D002543 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 frequency_5\NN\15286249 ,_6\,\1740 severity_7\NN\5036394 and_8\CC\1740 preventability_9\NN\1740 of_10\IN\1740 warfarin-induced_11\JJ\1740 <e2>cerebral_12\JJ\1740 haemorrhages</e2>_13\NNS\14285662 due_14\JJ\1740 to_15\TO\1740 warfarin_16\NN\2718259 and_17\CC\1740 <e1>warfarin-drug</e1>_18\JJ\1740 interactions_19\NNS\37396 in_20\IN\13603305 patients_21\NNS\9898892 living_22\VBG\2655135 in_23\IN\13603305 the_24\DT\1740 county_25\NN\8630039 of_26\IN\1740 osterg_27\NNP\1740 tland_28\NN\1740 ,_29\,\1740 sweden_30\NNP\1740 ._31\.\1740
D014859_D002543 CID medical_0\JJ\1740 records_1\NNS\6643408 were_2\VBD\836236 studied_3\VBN\630380 retrospectively_4\RB\1740 to_5\TO\1740 evaluate_6\VB\670261 whether_7\IN\1740 <e1>warfarin</e1>_8\NN\2718259 and_9\CC\1740 warfarin-drug_10\JJ\1740 interactions_11\NNS\37396 could_12\MD\1740 have_13\VB\2108377 caused_14\VBN\1617192 the_15\DT\1740 <e2>cerebral_16\JJ\1740 haemorrhage</e2>_17\NN\14285662 ._18\.\1740
D014859_D002543 CID medical_0\JJ\1740 records_1\NNS\6643408 were_2\VBD\836236 studied_3\VBN\630380 retrospectively_4\RB\1740 to_5\TO\1740 evaluate_6\VB\670261 whether_7\IN\1740 warfarin_8\NN\2718259 and_9\CC\1740 <e1>warfarin-drug</e1>_10\JJ\1740 interactions_11\NNS\37396 could_12\MD\1740 have_13\VB\2108377 caused_14\VBN\1617192 the_15\DT\1740 <e2>cerebral_16\JJ\1740 haemorrhage</e2>_17\NN\14285662 ._18\.\1740
D014859_D002543 CID results_0\NNS\34213 :_1\:\1740 among_2\IN\1740 593_3\CD\1740 patients_4\NNS\9898892 with_5\IN\1740 <e2>cerebral_6\JJ\1740 haemorrhage</e2>_7\NN\14285662 ,_8\,\1740 59_9\CD\1740 (_10\-LRB-\1740 10_11\CD\13745420 %_12\NN\1740 )_13\-RRB-\1740 were_14\VBD\836236 assessed_15\VBN\670261 as_16\IN\14622893 related_17\JJ\1740 to_18\TO\1740 <e1>warfarin</e1>_19\NN\2718259 treatment_20\NN\654885 ._21\.\1740
D014859_D002543 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>warfarin-induced</e1>_2\JJ\1740 <e2>cerebral_3\JJ\1740 haemorrhages</e2>_4\NNS\14285662 are_5\VBP\836236 a_6\DT\13649268 major_7\JJ\1740 clinical_8\JJ\1740 problem_9\NN\14408086 with_10\IN\1740 a_11\DT\13649268 high_12\JJ\1740 fatality_13\NN\7355491 rate_14\NN\13815152 ._15\.\1740
D014859_D002543 CID a_0\DT\13649268 significant_1\JJ\1740 proportion_2\NN\13824815 of_3\IN\1740 <e1>warfarin-related</e1>_4\JJ\1740 <e2>cerebral_5\JJ\1740 haemorrhages</e2>_6\NNS\14285662 might_7\MD\5029706 have_8\VB\2108377 been_9\VBN\836236 prevented_10\VBN\1740 if_11\IN\1740 greater_12\JJR\1740 caution_13\NN\4662951 had_14\VBD\2108377 been_15\VBN\836236 taken_16\VBN\2367363 when_17\WRB\1740 prescribing_18\VBG\748282 drugs_19\NNS\14778436 known_20\VBN\2110220 to_21\TO\1740 interact_22\VB\2367363 with_23\IN\1740 warfarin_24\NN\2718259 ._25\.\1740
D014859_D002543 CID a_0\DT\13649268 significant_1\JJ\1740 proportion_2\NN\13824815 of_3\IN\1740 warfarin-related_4\JJ\1740 <e2>cerebral_5\JJ\1740 haemorrhages</e2>_6\NNS\14285662 might_7\MD\5029706 have_8\VB\2108377 been_9\VBN\836236 prevented_10\VBN\1740 if_11\IN\1740 greater_12\JJR\1740 caution_13\NN\4662951 had_14\VBD\2108377 been_15\VBN\836236 taken_16\VBN\2367363 when_17\WRB\1740 prescribing_18\VBG\748282 drugs_19\NNS\14778436 known_20\VBN\2110220 to_21\TO\1740 interact_22\VB\2367363 with_23\IN\1740 <e1>warfarin</e1>_24\NN\2718259 ._25\.\1740
D014859_D006470 NONE a_0\DT\13649268 <e1>warfarin-drug</e1>_1\JJ\1740 interaction_2\NN\37396 could_3\MD\1740 have_4\VB\2108377 contributed_5\VBN\126264 to_6\IN\1740 the_7\DT\1740 <e2>haemorrhage</e2>_8\NN\14285662 in_9\IN\13603305 24_10\CD\13745420 (_11\-LRB-\1740 41_12\CD\1740 %_13\NN\1740 )_14\-RRB-\1740 of_15\IN\1740 the_16\DT\1740 warfarin_17\NN\2718259 patients_18\NNS\9898892 and_19\CC\1740 in_20\IN\13603305 7_21\CD\13741022 of_22\IN\1740 these_23\DT\1740 (_24\-LRB-\1740 12_25\CD\13745420 %_26\NN\1740 )_27\-RRB-\1740 the_28\DT\1740 bleeding_29\VBG\104868 complication_30\NN\1073995 was_31\VBD\836236 considered_32\VBN\689344 being_33\VBG\836236 possible_34\JJ\1740 to_35\TO\1740 avoid_36\VB\2452885 ._37\.\1740
D014859_D006470 NONE a_0\DT\13649268 <e1>warfarin-drug</e1>_1\JJ\1740 interaction_2\NN\37396 could_3\MD\1740 have_4\VB\2108377 contributed_5\VBN\126264 to_6\IN\1740 the_7\DT\1740 haemorrhage_8\NN\14285662 in_9\IN\13603305 24_10\CD\13745420 (_11\-LRB-\1740 41_12\CD\1740 %_13\NN\1740 )_14\-RRB-\1740 of_15\IN\1740 the_16\DT\1740 warfarin_17\NN\2718259 patients_18\NNS\9898892 and_19\CC\1740 in_20\IN\13603305 7_21\CD\13741022 of_22\IN\1740 these_23\DT\1740 (_24\-LRB-\1740 12_25\CD\13745420 %_26\NN\1740 )_27\-RRB-\1740 the_28\DT\1740 <e2>bleeding</e2>_29\VBG\104868 complication_30\NN\1073995 was_31\VBD\836236 considered_32\VBN\689344 being_33\VBG\836236 possible_34\JJ\1740 to_35\TO\1740 avoid_36\VB\2452885 ._37\.\1740
D014859_D006470 NONE a_0\DT\13649268 warfarin-drug_1\JJ\1740 interaction_2\NN\37396 could_3\MD\1740 have_4\VB\2108377 contributed_5\VBN\126264 to_6\IN\1740 the_7\DT\1740 <e2>haemorrhage</e2>_8\NN\14285662 in_9\IN\13603305 24_10\CD\13745420 (_11\-LRB-\1740 41_12\CD\1740 %_13\NN\1740 )_14\-RRB-\1740 of_15\IN\1740 the_16\DT\1740 <e1>warfarin</e1>_17\NN\2718259 patients_18\NNS\9898892 and_19\CC\1740 in_20\IN\13603305 7_21\CD\13741022 of_22\IN\1740 these_23\DT\1740 (_24\-LRB-\1740 12_25\CD\13745420 %_26\NN\1740 )_27\-RRB-\1740 the_28\DT\1740 bleeding_29\VBG\104868 complication_30\NN\1073995 was_31\VBD\836236 considered_32\VBN\689344 being_33\VBG\836236 possible_34\JJ\1740 to_35\TO\1740 avoid_36\VB\2452885 ._37\.\1740
D014859_D006470 NONE a_0\DT\13649268 warfarin-drug_1\JJ\1740 interaction_2\NN\37396 could_3\MD\1740 have_4\VB\2108377 contributed_5\VBN\126264 to_6\IN\1740 the_7\DT\1740 haemorrhage_8\NN\14285662 in_9\IN\13603305 24_10\CD\13745420 (_11\-LRB-\1740 41_12\CD\1740 %_13\NN\1740 )_14\-RRB-\1740 of_15\IN\1740 the_16\DT\1740 <e1>warfarin</e1>_17\NN\2718259 patients_18\NNS\9898892 and_19\CC\1740 in_20\IN\13603305 7_21\CD\13741022 of_22\IN\1740 these_23\DT\1740 (_24\-LRB-\1740 12_25\CD\13745420 %_26\NN\1740 )_27\-RRB-\1740 the_28\DT\1740 <e2>bleeding</e2>_29\VBG\104868 complication_30\NN\1073995 was_31\VBD\836236 considered_32\VBN\689344 being_33\VBG\836236 possible_34\JJ\1740 to_35\TO\1740 avoid_36\VB\2452885 ._37\.\1740
3173179
D014700_D009203 CID <e1>verapamil</e1>_0\NN\2938514 withdrawal_1\NN\7206096 as_2\IN\14622893 a_3\DT\13649268 possible_4\JJ\1740 cause_5\NN\7323922 of_6\IN\1740 <e2>myocardial_7\JJ\1740 infarction</e2>_8\NN\14204950 in_9\IN\13603305 a_10\DT\13649268 hypertensive_11\JJ\1740 woman_12\NN\9605289 with_13\IN\1740 a_14\DT\13649268 normal_15\JJ\1740 coronary_16\JJ\1740 angiogram_17\NN\4100620 ._18\.\1740
D014700_D009203 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 in_4\IN\13603305 which_5\WDT\1740 <e2>myocardial_6\JJ\1740 infarction</e2>_7\NN\14204950 coincided_8\VBD\2604477 with_9\IN\1740 the_10\DT\1740 introduction_11\NN\235435 of_12\IN\1740 captopril_13\NN\2673637 and_14\CC\1740 the_15\DT\1740 withdrawal_16\NN\7206096 of_17\IN\1740 <e1>verapamil</e1>_18\NN\2938514 in_19\IN\13603305 a_20\DT\13649268 previously_21\RB\1740 asymptomatic_22\JJ\1740 woman_23\NN\9605289 with_24\IN\1740 severe_25\JJ\1740 hypertension_26\NN\14057371 ._27\.\1740
D014700_D006973 NONE <e1>verapamil</e1>_0\NN\2938514 withdrawal_1\NN\7206096 as_2\IN\14622893 a_3\DT\13649268 possible_4\JJ\1740 cause_5\NN\7323922 of_6\IN\1740 myocardial_7\JJ\1740 infarction_8\NN\14204950 in_9\IN\13603305 a_10\DT\13649268 <e2>hypertensive</e2>_11\JJ\1740 woman_12\NN\9605289 with_13\IN\1740 a_14\DT\13649268 normal_15\JJ\1740 coronary_16\JJ\1740 angiogram_17\NN\4100620 ._18\.\1740
D014700_D006973 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 in_4\IN\13603305 which_5\WDT\1740 myocardial_6\JJ\1740 infarction_7\NN\14204950 coincided_8\VBD\2604477 with_9\IN\1740 the_10\DT\1740 introduction_11\NN\235435 of_12\IN\1740 captopril_13\NN\2673637 and_14\CC\1740 the_15\DT\1740 withdrawal_16\NN\7206096 of_17\IN\1740 <e1>verapamil</e1>_18\NN\2938514 in_19\IN\13603305 a_20\DT\13649268 previously_21\RB\1740 asymptomatic_22\JJ\1740 woman_23\NN\9605289 with_24\IN\1740 severe_25\JJ\1740 <e2>hypertension</e2>_26\NN\14057371 ._27\.\1740
D002216_D009203 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 in_4\IN\13603305 which_5\WDT\1740 <e2>myocardial_6\JJ\1740 infarction</e2>_7\NN\14204950 coincided_8\VBD\2604477 with_9\IN\1740 the_10\DT\1740 introduction_11\NN\235435 of_12\IN\1740 <e1>captopril</e1>_13\NN\2673637 and_14\CC\1740 the_15\DT\1740 withdrawal_16\NN\7206096 of_17\IN\1740 verapamil_18\NN\2938514 in_19\IN\13603305 a_20\DT\13649268 previously_21\RB\1740 asymptomatic_22\JJ\1740 woman_23\NN\9605289 with_24\IN\1740 severe_25\JJ\1740 hypertension_26\NN\14057371 ._27\.\1740
D002216_D006973 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 in_4\IN\13603305 which_5\WDT\1740 myocardial_6\JJ\1740 infarction_7\NN\14204950 coincided_8\VBD\2604477 with_9\IN\1740 the_10\DT\1740 introduction_11\NN\235435 of_12\IN\1740 <e1>captopril</e1>_13\NN\2673637 and_14\CC\1740 the_15\DT\1740 withdrawal_16\NN\7206096 of_17\IN\1740 verapamil_18\NN\2938514 in_19\IN\13603305 a_20\DT\13649268 previously_21\RB\1740 asymptomatic_22\JJ\1740 woman_23\NN\9605289 with_24\IN\1740 severe_25\JJ\1740 <e2>hypertension</e2>_26\NN\14057371 ._27\.\1740
12202650
D002211_D063806 NONE <e1>capsaicin-induced</e1>_0\JJ\1740 <e2>muscle_1\NN\5289601 pain</e2>_2\NN\14299637 alters_3\VBZ\126264 the_4\DT\1740 excitability_5\NN\5653575 of_6\IN\1740 the_7\DT\1740 human_8\JJ\1740 jaw-stretch_9\JJ\1740 reflex_10\NN\859001 ._11\.\1740
D002211_D010146 CID <e1>capsaicin</e1>_0\NN\15032661 (_1\-LRB-\1740 10_2\CD\13745420 micro_3\JJ\1740 g_4\NN\13717155 )_5\-RRB-\1740 was_6\VBD\836236 injected_7\VBN\81072 into_8\IN\1740 the_9\DT\1740 masseter_10\NN\5602132 muscle_11\NN\5289601 to_12\TO\1740 induce_13\VB\1627355 <e2>pain</e2>_14\NN\14299637 in_15\IN\13603305 11_16\CD\13745420 healthy_17\JJ\1740 volunteers_18\NNS\10582746 ._19\.\1740
1833784
D004298_D006948 NONE evidence_0\NN\5816287 for_1\IN\1740 an_2\DT\6697703 involvement_3\NN\1080366 of_4\IN\1740 d1_5\NN\1740 and_6\CC\1740 d2_7\NN\1740 <e1>dopamine</e1>_8\NN\14807737 receptors_9\NNS\5225602 in_10\IN\13603305 mediating_11\VBG\761713 nicotine-induced_12\JJ\1740 <e2>hyperactivity</e2>_13\NN\14052403 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D009538_D006948 CID evidence_0\NN\5816287 for_1\IN\1740 an_2\DT\6697703 involvement_3\NN\1080366 of_4\IN\1740 d1_5\NN\1740 and_6\CC\1740 d2_7\NN\1740 dopamine_8\NN\14807737 receptors_9\NNS\5225602 in_10\IN\13603305 mediating_11\VBG\761713 <e1>nicotine-induced</e1>_12\JJ\1740 <e2>hyperactivity</e2>_13\NN\14052403 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D009538_D006948 CID <e1>nicotine</e1>_0\NN\14712692 (_1\-LRB-\1740 1.0_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 caused_5\VBD\1617192 a_6\DT\13649268 significant_7\JJ\1740 <e2>increase_8\NN\13576355 in_9\IN\13603305 locomotor_10\NN\1740 activity</e2>_11\NN\30358 in_12\IN\13603305 rats_13\NNS\2329401 that_14\WDT\1740 were_15\VBD\836236 habituated_16\VBN\1156834 to_17\IN\1740 the_18\DT\1740 test_19\NN\5798043 environment_20\NN\13927383 ,_21\,\1740 but_22\CC\1740 had_23\VBD\2108377 only_24\RB\1740 a_25\DT\13649268 weak_26\JJ\1740 and_27\CC\1740 delayed_28\VBN\439958 stimulant_29\JJ\1740 action_30\NN\30358 in_31\IN\13603305 rats_32\NNS\2329401 that_33\WDT\1740 were_34\VBD\836236 unfamiliar_35\JJ\1740 with_36\IN\1740 the_37\DT\1740 test_38\NN\5798043 environment_39\NN\13927383 ._40\.\1740
D009538_D006948 CID <e1>nicotine-induced</e1>_0\JJ\1740 <e2>hyperactivity</e2>_1\NN\14052403 was_2\VBD\836236 blocked_3\VBN\1476483 by_4\IN\1740 the_5\DT\1740 selective_6\JJ\1740 d1_7\NN\1740 antagonist_8\NN\7846 sch_9\NN\1740 23390_10\CD\1740 ,_11\,\1740 the_12\DT\1740 selective_13\JJ\1740 d2_14\NN\1740 antagonist_15\NN\7846 raclopride_16\NN\1740 and_17\CC\1740 the_18\DT\1740 d1/d2_19\NN\1740 antagonist_20\NN\7846 fluphenazine_21\NN\3713736 ._22\.\1740
D009538_D006948 CID pretreatment_0\NN\1740 with_1\IN\1740 the_2\DT\1740 d2_3\NN\1740 agonist_4\NN\9613191 phno_5\NN\1740 enhanced_6\VBD\227165 <e1>nicotine-induced</e1>_7\JJ\1740 <e2>hyperactivity</e2>_8\NN\14052403 ,_9\,\1740 whereas_10\IN\1740 the_11\DT\1740 d1_12\NN\1740 agonist_13\NN\9613191 skf_14\NN\1740 38393_15\CD\1740 had_16\VBD\2108377 no_17\DT\7204911 effect_18\NN\34213 ._19\.\1740
D009538_D006948 CID the_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 acute_4\JJ\1740 <e1>nicotine</e1>_5\NN\14712692 injection_6\NN\320852 induces_7\VBZ\1627355 a_8\DT\13649268 pronounced_9\JJ\1740 <e2>hyperactivity</e2>_10\NN\14052403 in_11\IN\13603305 rats_12\NNS\2329401 habituated_13\VBN\1156834 to_14\IN\1740 the_15\DT\1740 test_16\NN\5798043 environment_17\NN\13927383 ._18\.\1740
C534628_D006948 NONE nicotine-induced_0\JJ\1740 <e2>hyperactivity</e2>_1\NN\14052403 was_2\VBD\836236 blocked_3\VBN\1476483 by_4\IN\1740 the_5\DT\1740 selective_6\JJ\1740 d1_7\NN\1740 antagonist_8\NN\7846 <e1>sch_9\NN\1740 23390</e1>_10\CD\1740 ,_11\,\1740 the_12\DT\1740 selective_13\JJ\1740 d2_14\NN\1740 antagonist_15\NN\7846 raclopride_16\NN\1740 and_17\CC\1740 the_18\DT\1740 d1/d2_19\NN\1740 antagonist_20\NN\7846 fluphenazine_21\NN\3713736 ._22\.\1740
D020891_D006948 NONE nicotine-induced_0\JJ\1740 <e2>hyperactivity</e2>_1\NN\14052403 was_2\VBD\836236 blocked_3\VBN\1476483 by_4\IN\1740 the_5\DT\1740 selective_6\JJ\1740 d1_7\NN\1740 antagonist_8\NN\7846 sch_9\NN\1740 23390_10\CD\1740 ,_11\,\1740 the_12\DT\1740 selective_13\JJ\1740 d2_14\NN\1740 antagonist_15\NN\7846 <e1>raclopride</e1>_16\NN\1740 and_17\CC\1740 the_18\DT\1740 d1/d2_19\NN\1740 antagonist_20\NN\7846 fluphenazine_21\NN\3713736 ._22\.\1740
D005476_D006948 NONE nicotine-induced_0\JJ\1740 <e2>hyperactivity</e2>_1\NN\14052403 was_2\VBD\836236 blocked_3\VBN\1476483 by_4\IN\1740 the_5\DT\1740 selective_6\JJ\1740 d1_7\NN\1740 antagonist_8\NN\7846 sch_9\NN\1740 23390_10\CD\1740 ,_11\,\1740 the_12\DT\1740 selective_13\JJ\1740 d2_14\NN\1740 antagonist_15\NN\7846 raclopride_16\NN\1740 and_17\CC\1740 the_18\DT\1740 d1/d2_19\NN\1740 antagonist_20\NN\7846 <e1>fluphenazine</e1>_21\NN\3713736 ._22\.\1740
-1_D006948 NONE pretreatment_0\NN\1740 with_1\IN\1740 the_2\DT\1740 d2_3\NN\1740 agonist_4\NN\9613191 <e1>phno</e1>_5\NN\1740 enhanced_6\VBD\227165 nicotine-induced_7\JJ\1740 <e2>hyperactivity</e2>_8\NN\14052403 ,_9\,\1740 whereas_10\IN\1740 the_11\DT\1740 d1_12\NN\1740 agonist_13\NN\9613191 skf_14\NN\1740 38393_15\CD\1740 had_16\VBD\2108377 no_17\DT\7204911 effect_18\NN\34213 ._19\.\1740
D015647_D006948 NONE pretreatment_0\NN\1740 with_1\IN\1740 the_2\DT\1740 d2_3\NN\1740 agonist_4\NN\9613191 phno_5\NN\1740 enhanced_6\VBD\227165 nicotine-induced_7\JJ\1740 <e2>hyperactivity</e2>_8\NN\14052403 ,_9\,\1740 whereas_10\IN\1740 the_11\DT\1740 d1_12\NN\1740 agonist_13\NN\9613191 <e1>skf_14\NN\1740 38393</e1>_15\CD\1740 had_16\VBD\2108377 no_17\DT\7204911 effect_18\NN\34213 ._19\.\1740
3371379
D014700_D020258 CID <e1>verapamil-induced</e1>_0\JJ\1740 carbamazepine_1\NN\1740 <e2>neurotoxicity</e2>_2\NN\1740 ._3\.\1740
D014700_D020258 CID two_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 signs_3\NNS\6643763 of_4\IN\1740 carbamazepine_5\NN\1740 <e2>neurotoxicity</e2>_6\NN\1740 after_7\IN\1740 combined_8\JJ\1740 treatment_9\NN\654885 with_10\IN\1740 <e1>verapamil</e1>_11\NNS\2938514 showed_12\VBD\2137132 complete_13\JJ\1740 recovery_14\NN\7357388 after_15\IN\1740 discontinuation_16\NN\209943 of_17\IN\1740 the_18\DT\1740 calcium_19\NN\14625458 entry_20\NN\6502378 blocker_21\NN\10101634 ._22\.\1740
D002220_D020258 CID verapamil-induced_0\JJ\1740 <e1>carbamazepine</e1>_1\NN\1740 <e2>neurotoxicity</e2>_2\NN\1740 ._3\.\1740
D002220_D020258 CID two_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 signs_3\NNS\6643763 of_4\IN\1740 <e1>carbamazepine</e1>_5\NN\1740 <e2>neurotoxicity</e2>_6\NN\1740 after_7\IN\1740 combined_8\JJ\1740 treatment_9\NN\654885 with_10\IN\1740 verapamil_11\NNS\2938514 showed_12\VBD\2137132 complete_13\JJ\1740 recovery_14\NN\7357388 after_15\IN\1740 discontinuation_16\NN\209943 of_17\IN\1740 the_18\DT\1740 calcium_19\NN\14625458 entry_20\NN\6502378 blocker_21\NN\10101634 ._22\.\1740
D002118_D020258 NONE two_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 signs_3\NNS\6643763 of_4\IN\1740 carbamazepine_5\NN\1740 <e2>neurotoxicity</e2>_6\NN\1740 after_7\IN\1740 combined_8\JJ\1740 treatment_9\NN\654885 with_10\IN\1740 verapamil_11\NNS\2938514 showed_12\VBD\2137132 complete_13\JJ\1740 recovery_14\NN\7357388 after_15\IN\1740 discontinuation_16\NN\209943 of_17\IN\1740 the_18\DT\1740 <e1>calcium</e1>_19\NN\14625458 entry_20\NN\6502378 blocker_21\NN\10101634 ._22\.\1740
20080419
D010862_D004827 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 investigated_5\VBD\644583 the_6\DT\1740 therapeutic_7\JJ\1740 potential_8\NN\14481929 of_9\IN\1740 bone_10\NN\5286536 marrow_11\NN\5286536 mononuclear_12\JJ\1740 cells_13\NNS\3080309 (_14\-LRB-\1740 bmcs_15\NNS\1740 )_16\-RRB-\1740 in_17\IN\13603305 a_18\DT\13649268 model_19\NN\5888929 of_20\IN\1740 <e2>epilepsy</e2>_21\NN\14085708 induced_22\VBN\1627355 by_23\IN\1740 <e1>pilocarpine</e1>_24\NN\14712692 in_25\IN\13603305 rats_26\NNS\2329401 ._27\.\1740
10457883
16938416
D013739_D050197 CID high-dose_0\JJ\1740 <e1>testosterone</e1>_1\NN\14747587 is_2\VBZ\836236 associated_3\VBN\628491 with_4\IN\1740 <e2>atherosclerosis</e2>_5\NN\14108324 in_6\IN\13603305 postmenopausal_7\JJ\1740 women_8\NNS\9605289 ._9\.\1740
D013739_D050197 CID methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 population-based_4\JJ\1740 study_5\NN\635850 in_6\IN\13603305 513_7\CD\1740 naturally_8\RB\1740 postmenopausal_9\JJ\1740 women_10\NNS\9605289 aged_11\JJ\1740 54_12\CD\1740 -_13\SYM\1740 67_14\CD\1740 years_15\NNS\15144371 ,_16\,\1740 we_17\PRP\1740 studied_18\VBD\630380 the_19\DT\1740 association_20\NN\8008335 between_21\IN\1740 self-reported_22\JJ\1740 intramuscularly_23\RB\1740 administered_24\VBN\2436349 high-dose_25\JJ\1740 <e1>estrogen-testosterone</e1>_26\JJ\1740 therapy_27\NN\657604 (_28\-LRB-\1740 estradiol-_29\NN\1740 and_30\CC\1740 testosterone_31\NN\14747587 esters_32\NNS\14727670 )_33\-RRB-\1740 and_34\CC\1740 aortic_35\JJ\1740 <e2>atherosclerosis</e2>_36\NN\14108324 ._37\.\1740
D013739_D050197 CID conclusion_0\NN\5837957 :_1\:\1740 our_2\PRP$\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 high-dose_6\JJ\1740 <e1>testosterone</e1>_7\NN\14747587 therapy_8\NN\657604 may_9\MD\15209706 adversely_10\RB\1740 affect_11\VB\126264 <e2>atherosclerosis</e2>_12\NN\14108324 in_13\IN\13603305 postmenopausal_14\JJ\1740 women_15\NNS\9605289 and_16\CC\1740 indicate_17\VBP\952524 that_18\IN\1740 androgen_19\NN\14745635 replacement_20\NN\196485 in_21\IN\13603305 these_22\DT\1740 women_23\NNS\9605289 may_24\MD\15209706 not_25\RB\1740 be_26\VB\836236 harmless_27\NN\1740 ._28\.\1740
D004967_D050197 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 population-based_4\JJ\1740 study_5\NN\635850 in_6\IN\13603305 513_7\CD\1740 naturally_8\RB\1740 postmenopausal_9\JJ\1740 women_10\NNS\9605289 aged_11\JJ\1740 54_12\CD\1740 -_13\SYM\1740 67_14\CD\1740 years_15\NNS\15144371 ,_16\,\1740 we_17\PRP\1740 studied_18\VBD\630380 the_19\DT\1740 association_20\NN\8008335 between_21\IN\1740 self-reported_22\JJ\1740 intramuscularly_23\RB\1740 administered_24\VBN\2436349 high-dose_25\JJ\1740 <e1>estrogen-testosterone</e1>_26\JJ\1740 therapy_27\NN\657604 (_28\-LRB-\1740 estradiol-_29\NN\1740 and_30\CC\1740 testosterone_31\NN\14747587 esters_32\NNS\14727670 )_33\-RRB-\1740 and_34\CC\1740 aortic_35\JJ\1740 <e2>atherosclerosis</e2>_36\NN\14108324 ._37\.\1740
C032109_D050197 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 population-based_4\JJ\1740 study_5\NN\635850 in_6\IN\13603305 513_7\CD\1740 naturally_8\RB\1740 postmenopausal_9\JJ\1740 women_10\NNS\9605289 aged_11\JJ\1740 54_12\CD\1740 -_13\SYM\1740 67_14\CD\1740 years_15\NNS\15144371 ,_16\,\1740 we_17\PRP\1740 studied_18\VBD\630380 the_19\DT\1740 association_20\NN\8008335 between_21\IN\1740 self-reported_22\JJ\1740 intramuscularly_23\RB\1740 administered_24\VBN\2436349 high-dose_25\JJ\1740 estrogen-testosterone_26\JJ\1740 therapy_27\NN\657604 (_28\-LRB-\1740 <e1>estradiol-_29\NN\1740 and_30\CC\1740 testosterone_31\NN\14747587 esters</e1>_32\NNS\14727670 )_33\-RRB-\1740 and_34\CC\1740 aortic_35\JJ\1740 <e2>atherosclerosis</e2>_36\NN\14108324 ._37\.\1740
D002784_D003920 NONE the_0\DT\1740 association_1\NN\8008335 remained_2\VBD\2604760 after_3\IN\1740 additional_4\JJ\1740 adjustment_5\NN\7357388 for_6\IN\1740 <e2>diabetes</e2>_7\NNS\14075199 ,_8\,\1740 <e1>cholesterol</e1>_9\NN\15058310 level_10\NN\4916342 ,_11\,\1740 systolic_12\JJ\1740 blood_13\NN\5397468 pressure_14\NN\11419404 ,_15\,\1740 or_16\CC\3541091 alcohol_17\NN\7881800 use_18\NN\407535 ._19\.\1740
D000431_D003920 NONE the_0\DT\1740 association_1\NN\8008335 remained_2\VBD\2604760 after_3\IN\1740 additional_4\JJ\1740 adjustment_5\NN\7357388 for_6\IN\1740 <e2>diabetes</e2>_7\NNS\14075199 ,_8\,\1740 cholesterol_9\NN\15058310 level_10\NN\4916342 ,_11\,\1740 systolic_12\JJ\1740 blood_13\NN\5397468 pressure_14\NN\11419404 ,_15\,\1740 or_16\CC\3541091 <e1>alcohol</e1>_17\NN\7881800 use_18\NN\407535 ._19\.\1740
17612891
D003024_D009205 CID acute_0\JJ\1740 <e2>myocarditis</e2>_1\NN\14338942 associated_2\VBN\628491 with_3\IN\1740 <e1>clozapine</e1>_4\NN\3713736 ._5\.\1740
D003024_D009205 CID objective_0\NN\5980875 :_1\:\1740 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 acute_5\JJ\1740 <e2>myocarditis</e2>_6\NN\14338942 associated_7\VBN\628491 with_8\IN\1740 the_9\DT\1740 commencement_10\NN\15180528 of_11\IN\1740 <e1>clozapine</e1>_12\NN\3713736 is_13\VBZ\836236 described_14\VBN\1001294 ,_15\,\1740 highlighting_16\VBG\514463 the_17\DT\1740 onset_18\NN\7325190 ,_19\,\1740 course_20\NN\883297 and_21\CC\1740 possible_22\JJ\1740 contributing_23\VBG\126264 factors_24\NNS\7326557 ._25\.\1740
D003024_D009205 CID results_0\NNS\34213 :_1\:\1740 a_2\DT\13649268 20-year-old_3\NN\1740 male_4\JJ\1740 with_5\IN\1740 schizophrenia_6\NN\14398067 developed_7\VBD\1753788 a_8\DT\13649268 sudden_9\JJ\1740 onset_10\NN\7325190 of_11\IN\1740 <e2>myocarditis</e2>_12\NN\14338942 after_13\IN\1740 commencement_14\NN\15180528 of_15\IN\1740 <e1>clozapine</e1>_16\NN\3713736 ._17\.\1740
D003024_D009205 CID conclusions_0\NNS\5837957 :_1\:\1740 <e2>myocarditis</e2>_2\NNP\14338942 is_3\VBZ\836236 an_4\DT\6697703 increasingly_5\RB\1740 recognized_6\VBN\686447 complication_7\NN\1073995 associated_8\VBN\628491 with_9\IN\1740 the_10\DT\1740 use_11\NN\407535 of_12\IN\1740 <e1>clozapine</e1>_13\NN\3713736 ._14\.\1740
D003024_D012559 NONE results_0\NNS\34213 :_1\:\1740 a_2\DT\13649268 20-year-old_3\NN\1740 male_4\JJ\1740 with_5\IN\1740 <e2>schizophrenia</e2>_6\NN\14398067 developed_7\VBD\1753788 a_8\DT\13649268 sudden_9\JJ\1740 onset_10\NN\7325190 of_11\IN\1740 myocarditis_12\NN\14338942 after_13\IN\1740 commencement_14\NN\15180528 of_15\IN\1740 <e1>clozapine</e1>_16\NN\3713736 ._17\.\1740
D003024_D011618 NONE considering_0\VBG\689344 that_1\DT\1740 <e1>clozapine</e1>_2\NN\3713736 remains_3\VBZ\2604760 the_4\DT\1740 gold_5\NN\13371489 standard_6\JJ\1740 in_7\IN\13603305 treatment_8\NN\654885 of_9\IN\1740 resistant_10\JJ\1740 <e2>psychosis</e2>_11\NN\14380140 ,_12\,\1740 there_13\EX\27167 is_14\VBZ\836236 an_15\DT\6697703 urgent_16\JJ\1740 need_17\NN\13920835 to_18\TO\1740 raise_19\VB\153263 awareness_20\NN\5804793 among_21\IN\1740 medical_22\JJ\1740 and_23\CC\1740 paramedical_24\JJ\1740 staff_25\NN\8208016 involved_26\VBN\2676054 in_27\IN\13603305 the_28\DT\1740 care_29\NN\575741 of_30\IN\1740 these_31\DT\1740 patients_32\NNS\9898892 ._33\.\1740
12716030
D006493_D002543 NONE in_0\IN\13603305 <e2>ich</e2>_1\NN\1740 induction_2\NN\7450842 using_3\VBG\1156834 0.014-unit_4\NN\1740 collagenase_5\NN\14732946 ,_6\,\1740 <e1>heparin</e1>_7\NN\2718259 enhanced_8\VBD\227165 the_9\DT\1740 hematoma_10\NN\14317720 volume_11\NN\33615 3.4-fold_12\RB\1740 over_13\IN\5867413 that_14\DT\1740 seen_15\VBN\2106506 in_16\IN\13603305 control_17\NN\5190804 ich_18\NN\1740 animals_19\NNS\4475 and_20\CC\1740 the_21\DT\1740 bleeding_22\NN\14285662 7.6-fold_23\RB\1740 ._24\.\1740
D006493_D002543 NONE in_0\IN\13603305 ich_1\NN\1740 induction_2\NN\7450842 using_3\VBG\1156834 0.014-unit_4\NN\1740 collagenase_5\NN\14732946 ,_6\,\1740 <e1>heparin</e1>_7\NN\2718259 enhanced_8\VBD\227165 the_9\DT\1740 hematoma_10\NN\14317720 volume_11\NN\33615 3.4-fold_12\RB\1740 over_13\IN\5867413 that_14\DT\1740 seen_15\VBN\2106506 in_16\IN\13603305 control_17\NN\5190804 <e2>ich</e2>_18\NN\1740 animals_19\NNS\4475 and_20\CC\1740 the_21\DT\1740 bleeding_22\NN\14285662 7.6-fold_23\RB\1740 ._24\.\1740
D006493_D006406 CID in_0\IN\13603305 ich_1\NN\1740 induction_2\NN\7450842 using_3\VBG\1156834 0.014-unit_4\NN\1740 collagenase_5\NN\14732946 ,_6\,\1740 <e1>heparin</e1>_7\NN\2718259 enhanced_8\VBD\227165 the_9\DT\1740 <e2>hematoma</e2>_10\NN\14317720 volume_11\NN\33615 3.4-fold_12\RB\1740 over_13\IN\5867413 that_14\DT\1740 seen_15\VBN\2106506 in_16\IN\13603305 control_17\NN\5190804 ich_18\NN\1740 animals_19\NNS\4475 and_20\CC\1740 the_21\DT\1740 bleeding_22\NN\14285662 7.6-fold_23\RB\1740 ._24\.\1740
D006493_D006470 NONE in_0\IN\13603305 ich_1\NN\1740 induction_2\NN\7450842 using_3\VBG\1156834 0.014-unit_4\NN\1740 collagenase_5\NN\14732946 ,_6\,\1740 <e1>heparin</e1>_7\NN\2718259 enhanced_8\VBD\227165 the_9\DT\1740 hematoma_10\NN\14317720 volume_11\NN\33615 3.4-fold_12\RB\1740 over_13\IN\5867413 that_14\DT\1740 seen_15\VBN\2106506 in_16\IN\13603305 control_17\NN\5190804 ich_18\NN\1740 animals_19\NNS\4475 and_20\CC\1740 the_21\DT\1740 <e2>bleeding</e2>_22\NN\14285662 7.6-fold_23\RB\1740 ._24\.\1740
16274958
D017255_D055154 CID recurrent_0\JJ\1740 <e2>dysphonia</e2>_1\NN\14400677 and_2\CC\1740 <e1>acitretin</e1>_3\NN\1740 ._4\.\1740
D017255_D055154 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 woman_6\NN\9605289 complaining_7\NN\1740 of_8\IN\1740 <e2>dysphonia</e2>_9\NN\14400677 while_10\IN\15122231 she_11\PRP\1740 was_12\VBD\836236 treated_13\VBN\2376958 by_14\IN\1740 <e1>acitretin</e1>_15\NN\1740 ._16\.\1740
D017255_D055154 CID to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 first_7\JJ\1740 case_8\NN\7283608 of_9\IN\1740 <e1>acitretin-induced</e1>_10\JJ\1740 <e2>dysphonia</e2>_11\NN\14400677 ._12\.\1740
19631624
D018817_D007859 CID <e2>learning_0\NN\5701944 and_1\CC\1740 memory_2\NN\5926676 deficits</e2>_3\NNS\5113133 in_4\IN\13603305 <e1>ecstasy</e1>_5\NN\13985818 users_6\NNS\7846 and_7\CC\1740 their_8\PRP$\1740 neural_9\JJ\1740 correlates_10\VBZ\2657219 during_11\IN\1740 a_12\DT\13649268 face-learning_13\JJ\1740 task_14\NN\575741 ._15\.\1740
D018817_D007859 CID it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 consistently_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 <e1>ecstasy</e1>_6\NN\13985818 users_7\NNS\7846 display_8\VBP\2137132 <e2>impairments_9\NNS\7296428 in_10\IN\13603305 learning_11\NN\5701944 and_12\CC\1740 memory</e2>_13\NN\5926676 performance_14\NN\6619065 ._15\.\1740
D018817_D008569 CID <e2>learning_0\NN\5701944 and_1\CC\1740 memory_2\NN\5926676 deficits</e2>_3\NNS\5113133 in_4\IN\13603305 <e1>ecstasy</e1>_5\NN\13985818 users_6\NNS\7846 and_7\CC\1740 their_8\PRP$\1740 neural_9\JJ\1740 correlates_10\VBZ\2657219 during_11\IN\1740 a_12\DT\13649268 face-learning_13\JJ\1740 task_14\NN\575741 ._15\.\1740
D018817_D008569 CID it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 consistently_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 <e1>ecstasy</e1>_6\NN\13985818 users_7\NNS\7846 display_8\VBP\2137132 <e2>impairments_9\NNS\7296428 in_10\IN\13603305 learning_11\NN\5701944 and_12\CC\1740 memory</e2>_13\NN\5926676 performance_14\NN\6619065 ._15\.\1740
D002188_D007859 NONE <e2>deficits_0\NNS\5113133 in_1\IN\13603305 learning_2\NN\5701944 and_3\CC\1740 memory</e2>_4\NN\5926676 :_5\:\1740 parahippocampal_6\JJ\1740 hyperactivity_7\NN\14052403 and_8\CC\1740 frontocortical_9\JJ\1740 hypoactivity_10\NN\1740 in_11\IN\13603305 <e1>cannabis</e1>_12\NN\13112664 users_13\NNS\7846 ._14\.\1740
D002188_D008569 NONE <e2>deficits_0\NNS\5113133 in_1\IN\13603305 learning_2\NN\5701944 and_3\CC\1740 memory</e2>_4\NN\5926676 :_5\:\1740 parahippocampal_6\JJ\1740 hyperactivity_7\NN\14052403 and_8\CC\1740 frontocortical_9\JJ\1740 hypoactivity_10\NN\1740 in_11\IN\13603305 <e1>cannabis</e1>_12\NN\13112664 users_13\NNS\7846 ._14\.\1740
D002188_D006948 NONE deficits_0\NNS\5113133 in_1\IN\13603305 learning_2\NN\5701944 and_3\CC\1740 memory_4\NN\5926676 :_5\:\1740 parahippocampal_6\JJ\1740 <e2>hyperactivity</e2>_7\NN\14052403 and_8\CC\1740 frontocortical_9\JJ\1740 hypoactivity_10\NN\1740 in_11\IN\13603305 <e1>cannabis</e1>_12\NN\13112664 users_13\NNS\7846 ._14\.\1740
D018817_D006948 NONE a_0\DT\13649268 conjunction_1\NN\5048123 analysis_2\NN\633864 of_3\IN\1740 the_4\DT\1740 encode_5\NN\1740 and_6\CC\1740 recall_7\VB\931467 phases_8\NNS\15113229 of_9\IN\1740 the_10\DT\1740 task_11\NN\575741 revealed_12\VBD\2137132 <e1>ecstasy-specific</e1>_13\JJ\1740 <e2>hyperactivity</e2>_14\NN\14052403 in_15\IN\13603305 bilateral_16\JJ\1740 frontal_17\JJ\1740 regions_18\NNS\27167 ,_19\,\1740 left_20\VBD\120316 temporal_21\JJ\1740 ,_22\,\1740 right_23\JJ\1740 parietal_24\JJ\1740 ,_25\,\1740 bilateral_26\JJ\1740 temporal_27\JJ\1740 ,_28\,\1740 and_29\CC\1740 bilateral_30\JJ\1740 occipital_31\NN\1740 brain_32\NN\5462674 regions_33\NNS\27167 ._34\.\1740
D018817_D020258 NONE these_0\DT\1740 <e1>ecstasy-specific</e1>_1\JJ\1740 effects_2\NNS\13245626 may_3\MD\15209706 be_4\VB\836236 related_5\JJ\1740 to_6\TO\1740 the_7\DT\1740 vulnerability_8\NN\14540765 of_9\IN\1740 isocortical_10\JJ\1740 and_11\CC\1740 allocortical_12\JJ\1740 regions_13\NNS\27167 to_14\TO\1740 the_15\DT\1740 <e2>neurotoxic</e2>_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 ecstasy_19\NN\13985818 ._20\.\1740
D018817_D020258 NONE these_0\DT\1740 ecstasy-specific_1\JJ\1740 effects_2\NNS\13245626 may_3\MD\15209706 be_4\VB\836236 related_5\JJ\1740 to_6\TO\1740 the_7\DT\1740 vulnerability_8\NN\14540765 of_9\IN\1740 isocortical_10\JJ\1740 and_11\CC\1740 allocortical_12\JJ\1740 regions_13\NNS\27167 to_14\TO\1740 the_15\DT\1740 <e2>neurotoxic</e2>_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 <e1>ecstasy</e1>_19\NN\13985818 ._20\.\1740
1732369
D004280_D009369 NONE <e1>dobutamine</e1>_0\JJ\1740 stress_1\NN\7083732 echocardiography_2\NN\177127 :_3\:\1740 a_4\DT\13649268 sensitive_5\JJ\1740 indicator_6\NN\6636259 of_7\IN\1740 diminished_8\VBN\169651 myocardial_9\JJ\1740 function_10\NN\13783581 in_11\IN\13603305 asymptomatic_12\JJ\1740 doxorubicin-treated_13\JJ\1740 long-term_14\JJ\1740 survivors_15\NNS\9630641 of_16\IN\1740 childhood_17\NN\15144371 <e2>cancer</e2>_18\NN\14239425 ._19\.\1740
D004280_D009369 NONE to_0\TO\1740 develop_1\VB\1753788 a_2\DT\13649268 more_3\RBR\1740 sensitive_4\JJ\1740 echocardiographic_5\JJ\1740 screening_6\NN\6887726 test_7\NN\5798043 for_8\IN\1740 cardiac_9\JJ\1740 damage_10\NN\7296428 due_11\IN\5174653 to_12\IN\1740 doxorubicin_13\NN\2716866 ,_14\,\1740 a_15\DT\13649268 cohort_16\NN\8184861 study_17\NN\635850 was_18\VBD\836236 performed_19\VBN\2367363 using_20\VBG\1156834 <e1>dobutamine</e1>_21\NN\1740 infusion_22\NN\14589223 to_23\TO\1740 differentiate_24\VB\618878 asymptomatic_25\JJ\1740 long-term_26\JJ\1740 survivors_27\NNS\9630641 of_28\IN\1740 childhood_29\NN\15144371 <e2>cancer</e2>_30\NN\14239425 treated_31\VBN\2376958 with_32\IN\1740 doxorubicin_33\NN\2716866 from_34\IN\1740 healthy_35\JJ\1740 control_36\NN\5190804 subjects_37\NNS\6598915 ._38\.\1740
D004317_D009369 NONE dobutamine_0\JJ\1740 stress_1\NN\7083732 echocardiography_2\NN\177127 :_3\:\1740 a_4\DT\13649268 sensitive_5\JJ\1740 indicator_6\NN\6636259 of_7\IN\1740 diminished_8\VBN\169651 myocardial_9\JJ\1740 function_10\NN\13783581 in_11\IN\13603305 asymptomatic_12\JJ\1740 <e1>doxorubicin-treated</e1>_13\JJ\1740 long-term_14\JJ\1740 survivors_15\NNS\9630641 of_16\IN\1740 childhood_17\NN\15144371 <e2>cancer</e2>_18\NN\14239425 ._19\.\1740
D004317_D009369 NONE to_0\TO\1740 develop_1\VB\1753788 a_2\DT\13649268 more_3\RBR\1740 sensitive_4\JJ\1740 echocardiographic_5\JJ\1740 screening_6\NN\6887726 test_7\NN\5798043 for_8\IN\1740 cardiac_9\JJ\1740 damage_10\NN\7296428 due_11\IN\5174653 to_12\IN\1740 <e1>doxorubicin</e1>_13\NN\2716866 ,_14\,\1740 a_15\DT\13649268 cohort_16\NN\8184861 study_17\NN\635850 was_18\VBD\836236 performed_19\VBN\2367363 using_20\VBG\1156834 dobutamine_21\NN\1740 infusion_22\NN\14589223 to_23\TO\1740 differentiate_24\VB\618878 asymptomatic_25\JJ\1740 long-term_26\JJ\1740 survivors_27\NNS\9630641 of_28\IN\1740 childhood_29\NN\15144371 <e2>cancer</e2>_30\NN\14239425 treated_31\VBN\2376958 with_32\IN\1740 doxorubicin_33\NN\2716866 from_34\IN\1740 healthy_35\JJ\1740 control_36\NN\5190804 subjects_37\NNS\6598915 ._38\.\1740
D004317_D009369 NONE to_0\TO\1740 develop_1\VB\1753788 a_2\DT\13649268 more_3\RBR\1740 sensitive_4\JJ\1740 echocardiographic_5\JJ\1740 screening_6\NN\6887726 test_7\NN\5798043 for_8\IN\1740 cardiac_9\JJ\1740 damage_10\NN\7296428 due_11\IN\5174653 to_12\IN\1740 doxorubicin_13\NN\2716866 ,_14\,\1740 a_15\DT\13649268 cohort_16\NN\8184861 study_17\NN\635850 was_18\VBD\836236 performed_19\VBN\2367363 using_20\VBG\1156834 dobutamine_21\NN\1740 infusion_22\NN\14589223 to_23\TO\1740 differentiate_24\VB\618878 asymptomatic_25\JJ\1740 long-term_26\JJ\1740 survivors_27\NNS\9630641 of_28\IN\1740 childhood_29\NN\15144371 <e2>cancer</e2>_30\NN\14239425 treated_31\VBN\2376958 with_32\IN\1740 <e1>doxorubicin</e1>_33\NN\2716866 from_34\IN\1740 healthy_35\JJ\1740 control_36\NN\5190804 subjects_37\NNS\6598915 ._38\.\1740
D004317_D009202 CID <e1>doxorubicin</e1>_0\NNP\2716866 is_1\VBZ\836236 an_2\DT\6697703 effective_3\JJ\1740 anticancer_4\NN\1740 chemotherapeutic_5\NN\1740 agent_6\NN\7347 known_7\VBN\2110220 to_8\TO\1740 cause_9\VB\1617192 acute_10\JJ\1740 and_11\CC\1740 chronic_12\JJ\1740 <e2>cardiomyopathy</e2>_13\JJ\1740 ._14\.\1740
D004317_D006331 NONE to_0\TO\1740 develop_1\VB\1753788 a_2\DT\13649268 more_3\RBR\1740 sensitive_4\JJ\1740 echocardiographic_5\JJ\1740 screening_6\NN\6887726 test_7\NN\5798043 for_8\IN\1740 <e2>cardiac_9\JJ\1740 damage</e2>_10\NN\7296428 due_11\IN\5174653 to_12\IN\1740 <e1>doxorubicin</e1>_13\NN\2716866 ,_14\,\1740 a_15\DT\13649268 cohort_16\NN\8184861 study_17\NN\635850 was_18\VBD\836236 performed_19\VBN\2367363 using_20\VBG\1156834 dobutamine_21\NN\1740 infusion_22\NN\14589223 to_23\TO\1740 differentiate_24\VB\618878 asymptomatic_25\JJ\1740 long-term_26\JJ\1740 survivors_27\NNS\9630641 of_28\IN\1740 childhood_29\NN\15144371 cancer_30\NN\14239425 treated_31\VBN\2376958 with_32\IN\1740 doxorubicin_33\NN\2716866 from_34\IN\1740 healthy_35\JJ\1740 control_36\NN\5190804 subjects_37\NNS\6598915 ._38\.\1740
D004317_D006331 NONE to_0\TO\1740 develop_1\VB\1753788 a_2\DT\13649268 more_3\RBR\1740 sensitive_4\JJ\1740 echocardiographic_5\JJ\1740 screening_6\NN\6887726 test_7\NN\5798043 for_8\IN\1740 <e2>cardiac_9\JJ\1740 damage</e2>_10\NN\7296428 due_11\IN\5174653 to_12\IN\1740 doxorubicin_13\NN\2716866 ,_14\,\1740 a_15\DT\13649268 cohort_16\NN\8184861 study_17\NN\635850 was_18\VBD\836236 performed_19\VBN\2367363 using_20\VBG\1156834 dobutamine_21\NN\1740 infusion_22\NN\14589223 to_23\TO\1740 differentiate_24\VB\618878 asymptomatic_25\JJ\1740 long-term_26\JJ\1740 survivors_27\NNS\9630641 of_28\IN\1740 childhood_29\NN\15144371 cancer_30\NN\14239425 treated_31\VBN\2376958 with_32\IN\1740 <e1>doxorubicin</e1>_33\NN\2716866 from_34\IN\1740 healthy_35\JJ\1740 control_36\NN\5190804 subjects_37\NNS\6598915 ._38\.\1740
D004280_D006331 NONE to_0\TO\1740 develop_1\VB\1753788 a_2\DT\13649268 more_3\RBR\1740 sensitive_4\JJ\1740 echocardiographic_5\JJ\1740 screening_6\NN\6887726 test_7\NN\5798043 for_8\IN\1740 <e2>cardiac_9\JJ\1740 damage</e2>_10\NN\7296428 due_11\IN\5174653 to_12\IN\1740 doxorubicin_13\NN\2716866 ,_14\,\1740 a_15\DT\13649268 cohort_16\NN\8184861 study_17\NN\635850 was_18\VBD\836236 performed_19\VBN\2367363 using_20\VBG\1156834 <e1>dobutamine</e1>_21\NN\1740 infusion_22\NN\14589223 to_23\TO\1740 differentiate_24\VB\618878 asymptomatic_25\JJ\1740 long-term_26\JJ\1740 survivors_27\NNS\9630641 of_28\IN\1740 childhood_29\NN\15144371 cancer_30\NN\14239425 treated_31\VBN\2376958 with_32\IN\1740 doxorubicin_33\NN\2716866 from_34\IN\1740 healthy_35\JJ\1740 control_36\NN\5190804 subjects_37\NNS\6598915 ._38\.\1740
3629586
D015790_D006402 NONE the_0\DT\1740 hematologic_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>cefonicid</e1>_4\NN\1740 and_5\CC\1740 cefazedone_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 dog_9\NN\2083346 :_10\:\1740 a_11\DT\13649268 potential_12\JJ\1740 model_13\NN\5888929 of_14\IN\1740 cephalosporin_15\NN\2716866 <e2>hematotoxicity</e2>_16\NN\1740 in_17\IN\13603305 man_18\NN\9605289 ._19\.\1740
D015790_D006402 NONE a_0\DT\13649268 nonregenerative_1\JJ\1740 anemia_2\NN\14189204 was_3\VBD\836236 the_4\DT\1740 most_5\RBS\1740 compromising_6\VBG\1035530 of_7\IN\1740 the_8\DT\1740 <e2>cytopenias</e2>_9\NNS\14189204 and_10\CC\1740 occurred_11\VBD\2623529 in_12\IN\13603305 approximately_13\RB\1740 50_14\CD\13745420 %_15\NN\1740 of_16\IN\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 400_19\CD\1740 -_20\SYM\1740 500_21\CD\13745420 mg/kg_22\NN\1740 <e1>cefonicid</e1>_23\NN\1740 or_24\CC\3541091 540_25\CD\1740 -_26\SYM\1740 840_27\CD\1740 mg/kg_28\NN\1740 cefazedone_29\NN\1740 ._30\.\1740
D015790_D006402 NONE upon_0\IN\1740 rechallenge_1\NN\1740 with_2\IN\1740 either_3\CC\1740 cephalosporin_4\NN\2716866 ,_5\,\1740 the_6\DT\1740 <e2>hematologic_7\JJ\1740 syndrome</e2>_8\NN\5870365 was_9\VBD\836236 reproduced_10\VBN\1621555 in_11\IN\13603305 most_12\JJS\1740 dogs_13\NNS\2083346 tested_14\VBN\670261 ;_15\:\1740 <e1>cefonicid</e1>_16\NN\1740 (_17\-LRB-\1740 but_18\CC\1740 not_19\RB\1740 cefazedone)-treated_20\VBN\1740 dogs_21\NNS\2083346 showed_22\VBD\2137132 a_23\DT\13649268 substantially_24\RB\1740 reduced_25\VBN\441445 induction_26\NN\7450842 period_27\NN\13575869 (_28\-LRB-\1740 15_29\CD\13745420 +/-_30\CC\1740 5_31\CD\13741022 days_32\NNS\15140892 )_33\-RRB-\1740 compared_34\VBN\644583 to_35\TO\1740 that_36\DT\1740 of_37\IN\1740 the_38\DT\1740 first_39\JJ\1740 exposure_40\NN\5042871 to_41\TO\1740 the_42\DT\1740 drug_43\NN\14778436 (_44\-LRB-\1740 61_45\CD\1740 +/-_46\CC\1740 24_47\CD\13745420 days_48\NNS\15140892 )_49\-RRB-\1740 ._50\.\1740
D015790_D006402 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 administration_4\NN\1133281 of_5\IN\1740 high_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 <e1>cefonicid</e1>_9\NN\1740 or_10\CC\3541091 cefazedone_11\NN\1740 to_12\IN\1740 dogs_13\NNS\2083346 can_14\MD\3094503 induce_15\VB\1627355 <e2>hematotoxicity</e2>_16\NN\1740 similar_17\JJ\1740 to_18\TO\1740 the_19\DT\1740 cephalosporin-induced_20\JJ\1740 blood_21\NN\5397468 dyscrasias_22\NN\14052046 described_23\VBN\1001294 in_24\IN\13603305 man_25\NN\9605289 and_26\CC\1740 thus_27\RB\1740 provides_28\VBZ\2199590 a_29\DT\13649268 useful_30\JJ\1740 model_31\NN\5888929 for_32\IN\1740 studying_33\VBG\630380 the_34\DT\1740 mechanisms_35\NNS\13446390 of_36\IN\1740 these_37\DT\1740 disorders_38\NNS\14034177 ._39\.\1740
D015790_D006402 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 administration_4\NN\1133281 of_5\IN\1740 high_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 <e1>cefonicid</e1>_9\NN\1740 or_10\CC\3541091 cefazedone_11\NN\1740 to_12\IN\1740 dogs_13\NNS\2083346 can_14\MD\3094503 induce_15\VB\1627355 hematotoxicity_16\NN\1740 similar_17\JJ\1740 to_18\TO\1740 the_19\DT\1740 cephalosporin-induced_20\JJ\1740 <e2>blood_21\NN\5397468 dyscrasias</e2>_22\NN\14052046 described_23\VBN\1001294 in_24\IN\13603305 man_25\NN\9605289 and_26\CC\1740 thus_27\RB\1740 provides_28\VBZ\2199590 a_29\DT\13649268 useful_30\JJ\1740 model_31\NN\5888929 for_32\IN\1740 studying_33\VBG\630380 the_34\DT\1740 mechanisms_35\NNS\13446390 of_36\IN\1740 these_37\DT\1740 disorders_38\NNS\14034177 ._39\.\1740
C021341_D006402 NONE the_0\DT\1740 hematologic_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 cefonicid_4\NN\1740 and_5\CC\1740 <e1>cefazedone</e1>_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 dog_9\NN\2083346 :_10\:\1740 a_11\DT\13649268 potential_12\JJ\1740 model_13\NN\5888929 of_14\IN\1740 cephalosporin_15\NN\2716866 <e2>hematotoxicity</e2>_16\NN\1740 in_17\IN\13603305 man_18\NN\9605289 ._19\.\1740
C021341_D006402 NONE a_0\DT\13649268 nonregenerative_1\JJ\1740 anemia_2\NN\14189204 was_3\VBD\836236 the_4\DT\1740 most_5\RBS\1740 compromising_6\VBG\1035530 of_7\IN\1740 the_8\DT\1740 <e2>cytopenias</e2>_9\NNS\14189204 and_10\CC\1740 occurred_11\VBD\2623529 in_12\IN\13603305 approximately_13\RB\1740 50_14\CD\13745420 %_15\NN\1740 of_16\IN\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 400_19\CD\1740 -_20\SYM\1740 500_21\CD\13745420 mg/kg_22\NN\1740 cefonicid_23\NN\1740 or_24\CC\3541091 540_25\CD\1740 -_26\SYM\1740 840_27\CD\1740 mg/kg_28\NN\1740 <e1>cefazedone</e1>_29\NN\1740 ._30\.\1740
C021341_D006402 NONE upon_0\IN\1740 rechallenge_1\NN\1740 with_2\IN\1740 either_3\CC\1740 cephalosporin_4\NN\2716866 ,_5\,\1740 the_6\DT\1740 <e2>hematologic_7\JJ\1740 syndrome</e2>_8\NN\5870365 was_9\VBD\836236 reproduced_10\VBN\1621555 in_11\IN\13603305 most_12\JJS\1740 dogs_13\NNS\2083346 tested_14\VBN\670261 ;_15\:\1740 cefonicid_16\NN\1740 (_17\-LRB-\1740 but_18\CC\1740 not_19\RB\1740 <e1>cefazedone)-treated</e1>_20\VBN\1740 dogs_21\NNS\2083346 showed_22\VBD\2137132 a_23\DT\13649268 substantially_24\RB\1740 reduced_25\VBN\441445 induction_26\NN\7450842 period_27\NN\13575869 (_28\-LRB-\1740 15_29\CD\13745420 +/-_30\CC\1740 5_31\CD\13741022 days_32\NNS\15140892 )_33\-RRB-\1740 compared_34\VBN\644583 to_35\TO\1740 that_36\DT\1740 of_37\IN\1740 the_38\DT\1740 first_39\JJ\1740 exposure_40\NN\5042871 to_41\TO\1740 the_42\DT\1740 drug_43\NN\14778436 (_44\-LRB-\1740 61_45\CD\1740 +/-_46\CC\1740 24_47\CD\13745420 days_48\NNS\15140892 )_49\-RRB-\1740 ._50\.\1740
C021341_D006402 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 administration_4\NN\1133281 of_5\IN\1740 high_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 cefonicid_9\NN\1740 or_10\CC\3541091 <e1>cefazedone</e1>_11\NN\1740 to_12\IN\1740 dogs_13\NNS\2083346 can_14\MD\3094503 induce_15\VB\1627355 <e2>hematotoxicity</e2>_16\NN\1740 similar_17\JJ\1740 to_18\TO\1740 the_19\DT\1740 cephalosporin-induced_20\JJ\1740 blood_21\NN\5397468 dyscrasias_22\NN\14052046 described_23\VBN\1001294 in_24\IN\13603305 man_25\NN\9605289 and_26\CC\1740 thus_27\RB\1740 provides_28\VBZ\2199590 a_29\DT\13649268 useful_30\JJ\1740 model_31\NN\5888929 for_32\IN\1740 studying_33\VBG\630380 the_34\DT\1740 mechanisms_35\NNS\13446390 of_36\IN\1740 these_37\DT\1740 disorders_38\NNS\14034177 ._39\.\1740
C021341_D006402 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 administration_4\NN\1133281 of_5\IN\1740 high_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 cefonicid_9\NN\1740 or_10\CC\3541091 <e1>cefazedone</e1>_11\NN\1740 to_12\IN\1740 dogs_13\NNS\2083346 can_14\MD\3094503 induce_15\VB\1627355 hematotoxicity_16\NN\1740 similar_17\JJ\1740 to_18\TO\1740 the_19\DT\1740 cephalosporin-induced_20\JJ\1740 <e2>blood_21\NN\5397468 dyscrasias</e2>_22\NN\14052046 described_23\VBN\1001294 in_24\IN\13603305 man_25\NN\9605289 and_26\CC\1740 thus_27\RB\1740 provides_28\VBZ\2199590 a_29\DT\13649268 useful_30\JJ\1740 model_31\NN\5888929 for_32\IN\1740 studying_33\VBG\630380 the_34\DT\1740 mechanisms_35\NNS\13446390 of_36\IN\1740 these_37\DT\1740 disorders_38\NNS\14034177 ._39\.\1740
D002511_D006402 NONE the_0\DT\1740 hematologic_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 cefonicid_4\NN\1740 and_5\CC\1740 cefazedone_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 dog_9\NN\2083346 :_10\:\1740 a_11\DT\13649268 potential_12\JJ\1740 model_13\NN\5888929 of_14\IN\1740 <e1>cephalosporin</e1>_15\NN\2716866 <e2>hematotoxicity</e2>_16\NN\1740 in_17\IN\13603305 man_18\NN\9605289 ._19\.\1740
D002511_D006402 NONE <e1>cephalosporin</e1>_0\NN\2716866 antibiotics_1\NNS\2716205 cause_2\VBP\1617192 a_3\DT\13649268 variety_4\NN\7951464 of_5\IN\1740 <e2>hematologic_6\JJ\1740 disturbances</e2>_7\NNS\407535 in_8\IN\13603305 man_9\NN\9605289 ,_10\,\1740 the_11\DT\1740 pathogeneses_12\NNS\1740 and_13\CC\1740 hematopathology_14\NN\1740 of_15\IN\1740 which_16\WDT\1740 remain_17\VBP\2604760 poorly_18\RB\1740 characterized_19\VBN\609683 ._20\.\1740
D002511_D006402 NONE upon_0\IN\1740 rechallenge_1\NN\1740 with_2\IN\1740 either_3\CC\1740 <e1>cephalosporin</e1>_4\NN\2716866 ,_5\,\1740 the_6\DT\1740 <e2>hematologic_7\JJ\1740 syndrome</e2>_8\NN\5870365 was_9\VBD\836236 reproduced_10\VBN\1621555 in_11\IN\13603305 most_12\JJS\1740 dogs_13\NNS\2083346 tested_14\VBN\670261 ;_15\:\1740 cefonicid_16\NN\1740 (_17\-LRB-\1740 but_18\CC\1740 not_19\RB\1740 cefazedone)-treated_20\VBN\1740 dogs_21\NNS\2083346 showed_22\VBD\2137132 a_23\DT\13649268 substantially_24\RB\1740 reduced_25\VBN\441445 induction_26\NN\7450842 period_27\NN\13575869 (_28\-LRB-\1740 15_29\CD\13745420 +/-_30\CC\1740 5_31\CD\13741022 days_32\NNS\15140892 )_33\-RRB-\1740 compared_34\VBN\644583 to_35\TO\1740 that_36\DT\1740 of_37\IN\1740 the_38\DT\1740 first_39\JJ\1740 exposure_40\NN\5042871 to_41\TO\1740 the_42\DT\1740 drug_43\NN\14778436 (_44\-LRB-\1740 61_45\CD\1740 +/-_46\CC\1740 24_47\CD\13745420 days_48\NNS\15140892 )_49\-RRB-\1740 ._50\.\1740
D002511_D006402 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 administration_4\NN\1133281 of_5\IN\1740 high_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 cefonicid_9\NN\1740 or_10\CC\3541091 cefazedone_11\NN\1740 to_12\IN\1740 dogs_13\NNS\2083346 can_14\MD\3094503 induce_15\VB\1627355 <e2>hematotoxicity</e2>_16\NN\1740 similar_17\JJ\1740 to_18\TO\1740 the_19\DT\1740 <e1>cephalosporin-induced</e1>_20\JJ\1740 blood_21\NN\5397468 dyscrasias_22\NN\14052046 described_23\VBN\1001294 in_24\IN\13603305 man_25\NN\9605289 and_26\CC\1740 thus_27\RB\1740 provides_28\VBZ\2199590 a_29\DT\13649268 useful_30\JJ\1740 model_31\NN\5888929 for_32\IN\1740 studying_33\VBG\630380 the_34\DT\1740 mechanisms_35\NNS\13446390 of_36\IN\1740 these_37\DT\1740 disorders_38\NNS\14034177 ._39\.\1740
D002511_D006402 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 administration_4\NN\1133281 of_5\IN\1740 high_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 cefonicid_9\NN\1740 or_10\CC\3541091 cefazedone_11\NN\1740 to_12\IN\1740 dogs_13\NNS\2083346 can_14\MD\3094503 induce_15\VB\1627355 hematotoxicity_16\NN\1740 similar_17\JJ\1740 to_18\TO\1740 the_19\DT\1740 <e1>cephalosporin-induced</e1>_20\JJ\1740 <e2>blood_21\NN\5397468 dyscrasias</e2>_22\NN\14052046 described_23\VBN\1001294 in_24\IN\13603305 man_25\NN\9605289 and_26\CC\1740 thus_27\RB\1740 provides_28\VBZ\2199590 a_29\DT\13649268 useful_30\JJ\1740 model_31\NN\5888929 for_32\IN\1740 studying_33\VBG\630380 the_34\DT\1740 mechanisms_35\NNS\13446390 of_36\IN\1740 these_37\DT\1740 disorders_38\NNS\14034177 ._39\.\1740
D015790_D064420 NONE in_0\IN\13603305 four_1\CD\13741022 subacute_2\NN\1740 <e2>toxicity</e2>_3\NN\13576101 studies_4\NNS\635850 ,_5\,\1740 the_6\DT\1740 intravenous_7\JJ\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>cefonicid</e1>_10\NN\1740 or_11\CC\3541091 cefazedone_12\NN\1740 to_13\TO\1740 beagle_14\VB\1740 dogs_15\NNS\2083346 caused_16\VBD\1617192 a_17\DT\13649268 dose-dependent_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 anemia_21\NN\14189204 ,_22\,\1740 neutropenia_23\NN\14196405 ,_24\,\1740 and_25\CC\1740 thrombocytopenia_26\NN\14189204 after_27\IN\1740 1_28\CD\13741022 -_29\SYM\1740 3_30\CD\13741022 months_31\NNS\15113229 of_32\IN\1740 treatment_33\NN\654885 ._34\.\1740
D015790_D000740 CID in_0\IN\13603305 four_1\CD\13741022 subacute_2\NN\1740 toxicity_3\NN\13576101 studies_4\NNS\635850 ,_5\,\1740 the_6\DT\1740 intravenous_7\JJ\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>cefonicid</e1>_10\NN\1740 or_11\CC\3541091 cefazedone_12\NN\1740 to_13\TO\1740 beagle_14\VB\1740 dogs_15\NNS\2083346 caused_16\VBD\1617192 a_17\DT\13649268 dose-dependent_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 <e2>anemia</e2>_21\NN\14189204 ,_22\,\1740 neutropenia_23\NN\14196405 ,_24\,\1740 and_25\CC\1740 thrombocytopenia_26\NN\14189204 after_27\IN\1740 1_28\CD\13741022 -_29\SYM\1740 3_30\CD\13741022 months_31\NNS\15113229 of_32\IN\1740 treatment_33\NN\654885 ._34\.\1740
D015790_D000740 CID a_0\DT\13649268 nonregenerative_1\JJ\1740 <e2>anemia</e2>_2\NN\14189204 was_3\VBD\836236 the_4\DT\1740 most_5\RBS\1740 compromising_6\VBG\1035530 of_7\IN\1740 the_8\DT\1740 cytopenias_9\NNS\14189204 and_10\CC\1740 occurred_11\VBD\2623529 in_12\IN\13603305 approximately_13\RB\1740 50_14\CD\13745420 %_15\NN\1740 of_16\IN\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 400_19\CD\1740 -_20\SYM\1740 500_21\CD\13745420 mg/kg_22\NN\1740 <e1>cefonicid</e1>_23\NN\1740 or_24\CC\3541091 540_25\CD\1740 -_26\SYM\1740 840_27\CD\1740 mg/kg_28\NN\1740 cefazedone_29\NN\1740 ._30\.\1740
D015790_D009503 CID in_0\IN\13603305 four_1\CD\13741022 subacute_2\NN\1740 toxicity_3\NN\13576101 studies_4\NNS\635850 ,_5\,\1740 the_6\DT\1740 intravenous_7\JJ\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>cefonicid</e1>_10\NN\1740 or_11\CC\3541091 cefazedone_12\NN\1740 to_13\TO\1740 beagle_14\VB\1740 dogs_15\NNS\2083346 caused_16\VBD\1617192 a_17\DT\13649268 dose-dependent_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 anemia_21\NN\14189204 ,_22\,\1740 <e2>neutropenia</e2>_23\NN\14196405 ,_24\,\1740 and_25\CC\1740 thrombocytopenia_26\NN\14189204 after_27\IN\1740 1_28\CD\13741022 -_29\SYM\1740 3_30\CD\13741022 months_31\NNS\15113229 of_32\IN\1740 treatment_33\NN\654885 ._34\.\1740
D015790_D013921 CID in_0\IN\13603305 four_1\CD\13741022 subacute_2\NN\1740 toxicity_3\NN\13576101 studies_4\NNS\635850 ,_5\,\1740 the_6\DT\1740 intravenous_7\JJ\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>cefonicid</e1>_10\NN\1740 or_11\CC\3541091 cefazedone_12\NN\1740 to_13\TO\1740 beagle_14\VB\1740 dogs_15\NNS\2083346 caused_16\VBD\1617192 a_17\DT\13649268 dose-dependent_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 anemia_21\NN\14189204 ,_22\,\1740 neutropenia_23\NN\14196405 ,_24\,\1740 and_25\CC\1740 <e2>thrombocytopenia</e2>_26\NN\14189204 after_27\IN\1740 1_28\CD\13741022 -_29\SYM\1740 3_30\CD\13741022 months_31\NNS\15113229 of_32\IN\1740 treatment_33\NN\654885 ._34\.\1740
C021341_D064420 NONE in_0\IN\13603305 four_1\CD\13741022 subacute_2\NN\1740 <e2>toxicity</e2>_3\NN\13576101 studies_4\NNS\635850 ,_5\,\1740 the_6\DT\1740 intravenous_7\JJ\1740 administration_8\NN\1133281 of_9\IN\1740 cefonicid_10\NN\1740 or_11\CC\3541091 <e1>cefazedone</e1>_12\NN\1740 to_13\TO\1740 beagle_14\VB\1740 dogs_15\NNS\2083346 caused_16\VBD\1617192 a_17\DT\13649268 dose-dependent_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 anemia_21\NN\14189204 ,_22\,\1740 neutropenia_23\NN\14196405 ,_24\,\1740 and_25\CC\1740 thrombocytopenia_26\NN\14189204 after_27\IN\1740 1_28\CD\13741022 -_29\SYM\1740 3_30\CD\13741022 months_31\NNS\15113229 of_32\IN\1740 treatment_33\NN\654885 ._34\.\1740
C021341_D000740 CID in_0\IN\13603305 four_1\CD\13741022 subacute_2\NN\1740 toxicity_3\NN\13576101 studies_4\NNS\635850 ,_5\,\1740 the_6\DT\1740 intravenous_7\JJ\1740 administration_8\NN\1133281 of_9\IN\1740 cefonicid_10\NN\1740 or_11\CC\3541091 <e1>cefazedone</e1>_12\NN\1740 to_13\TO\1740 beagle_14\VB\1740 dogs_15\NNS\2083346 caused_16\VBD\1617192 a_17\DT\13649268 dose-dependent_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 <e2>anemia</e2>_21\NN\14189204 ,_22\,\1740 neutropenia_23\NN\14196405 ,_24\,\1740 and_25\CC\1740 thrombocytopenia_26\NN\14189204 after_27\IN\1740 1_28\CD\13741022 -_29\SYM\1740 3_30\CD\13741022 months_31\NNS\15113229 of_32\IN\1740 treatment_33\NN\654885 ._34\.\1740
C021341_D000740 CID a_0\DT\13649268 nonregenerative_1\JJ\1740 <e2>anemia</e2>_2\NN\14189204 was_3\VBD\836236 the_4\DT\1740 most_5\RBS\1740 compromising_6\VBG\1035530 of_7\IN\1740 the_8\DT\1740 cytopenias_9\NNS\14189204 and_10\CC\1740 occurred_11\VBD\2623529 in_12\IN\13603305 approximately_13\RB\1740 50_14\CD\13745420 %_15\NN\1740 of_16\IN\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 400_19\CD\1740 -_20\SYM\1740 500_21\CD\13745420 mg/kg_22\NN\1740 cefonicid_23\NN\1740 or_24\CC\3541091 540_25\CD\1740 -_26\SYM\1740 840_27\CD\1740 mg/kg_28\NN\1740 <e1>cefazedone</e1>_29\NN\1740 ._30\.\1740
C021341_D009503 CID in_0\IN\13603305 four_1\CD\13741022 subacute_2\NN\1740 toxicity_3\NN\13576101 studies_4\NNS\635850 ,_5\,\1740 the_6\DT\1740 intravenous_7\JJ\1740 administration_8\NN\1133281 of_9\IN\1740 cefonicid_10\NN\1740 or_11\CC\3541091 <e1>cefazedone</e1>_12\NN\1740 to_13\TO\1740 beagle_14\VB\1740 dogs_15\NNS\2083346 caused_16\VBD\1617192 a_17\DT\13649268 dose-dependent_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 anemia_21\NN\14189204 ,_22\,\1740 <e2>neutropenia</e2>_23\NN\14196405 ,_24\,\1740 and_25\CC\1740 thrombocytopenia_26\NN\14189204 after_27\IN\1740 1_28\CD\13741022 -_29\SYM\1740 3_30\CD\13741022 months_31\NNS\15113229 of_32\IN\1740 treatment_33\NN\654885 ._34\.\1740
C021341_D013921 CID in_0\IN\13603305 four_1\CD\13741022 subacute_2\NN\1740 toxicity_3\NN\13576101 studies_4\NNS\635850 ,_5\,\1740 the_6\DT\1740 intravenous_7\JJ\1740 administration_8\NN\1133281 of_9\IN\1740 cefonicid_10\NN\1740 or_11\CC\3541091 <e1>cefazedone</e1>_12\NN\1740 to_13\TO\1740 beagle_14\VB\1740 dogs_15\NNS\2083346 caused_16\VBD\1617192 a_17\DT\13649268 dose-dependent_18\JJ\1740 incidence_19\NN\13821570 of_20\IN\1740 anemia_21\NN\14189204 ,_22\,\1740 neutropenia_23\NN\14196405 ,_24\,\1740 and_25\CC\1740 <e2>thrombocytopenia</e2>_26\NN\14189204 after_27\IN\1740 1_28\CD\13741022 -_29\SYM\1740 3_30\CD\13741022 months_31\NNS\15113229 of_32\IN\1740 treatment_33\NN\654885 ._34\.\1740
14698717
D010672_D011605 NONE <e2>acute_0\JJ\1740 psychosis</e2>_1\NN\14380140 due_2\IN\5174653 to_3\TO\1740 treatment_4\NN\654885 with_5\IN\1740 <e1>phenytoin</e1>_6\NN\3550533 in_7\IN\13603305 a_8\DT\13649268 nonepileptic_9\JJ\1740 patient_10\NN\9898892 ._11\.\1740
D010672_D011605 NONE the_0\DT\1740 case_1\NN\7283608 of_2\IN\1740 a_3\DT\13649268 nonepileptic_4\JJ\1740 patient_5\NN\9898892 who_6\WP\8299493 developed_7\VBD\1753788 <e2>psychosis</e2>_8\NN\14380140 following_9\VBG\1835496 <e1>phenytoin</e1>_10\NN\3550533 treatment_11\NN\654885 for_12\IN\1740 trigeminal_13\JJ\1740 neuralgia_14\NN\14322699 is_15\VBZ\836236 described_16\VBN\1001294 ._17\.\1740
D010672_D011605 NONE this_0\DT\1740 case_1\NN\7283608 suggests_2\VBZ\1010118 that_3\IN\1740 the_4\DT\1740 <e2>psychotic_5\JJ\1740 symptoms</e2>_6\NNS\5823932 that_7\WDT\1740 occur_8\VBP\2623529 following_9\VBG\1835496 <e1>phenytoin</e1>_10\NN\3550533 treatment_11\NN\654885 in_12\IN\13603305 some_13\DT\1740 epileptic_14\JJ\1740 patients_15\NNS\9898892 may_16\MD\15209706 be_17\VB\836236 the_18\DT\1740 direct_19\JJ\1740 result_20\NN\34213 of_21\IN\1740 medication_22\NN\3247620 ,_23\,\1740 unrelated_24\JJ\1740 to_25\IN\1740 seizures_26\NNS\14081375 ._27\.\1740
D010672_D014277 NONE the_0\DT\1740 case_1\NN\7283608 of_2\IN\1740 a_3\DT\13649268 nonepileptic_4\JJ\1740 patient_5\NN\9898892 who_6\WP\8299493 developed_7\VBD\1753788 psychosis_8\NN\14380140 following_9\VBG\1835496 <e1>phenytoin</e1>_10\NN\3550533 treatment_11\NN\654885 for_12\IN\1740 <e2>trigeminal_13\JJ\1740 neuralgia</e2>_14\NN\14322699 is_15\VBZ\836236 described_16\VBN\1001294 ._17\.\1740
D010672_D004827 NONE this_0\DT\1740 case_1\NN\7283608 suggests_2\VBZ\1010118 that_3\IN\1740 the_4\DT\1740 psychotic_5\JJ\1740 symptoms_6\NNS\5823932 that_7\WDT\1740 occur_8\VBP\2623529 following_9\VBG\1835496 <e1>phenytoin</e1>_10\NN\3550533 treatment_11\NN\654885 in_12\IN\13603305 some_13\DT\1740 <e2>epileptic</e2>_14\JJ\1740 patients_15\NNS\9898892 may_16\MD\15209706 be_17\VB\836236 the_18\DT\1740 direct_19\JJ\1740 result_20\NN\34213 of_21\IN\1740 medication_22\NN\3247620 ,_23\,\1740 unrelated_24\JJ\1740 to_25\IN\1740 seizures_26\NNS\14081375 ._27\.\1740
D010672_D012640 NONE this_0\DT\1740 case_1\NN\7283608 suggests_2\VBZ\1010118 that_3\IN\1740 the_4\DT\1740 psychotic_5\JJ\1740 symptoms_6\NNS\5823932 that_7\WDT\1740 occur_8\VBP\2623529 following_9\VBG\1835496 <e1>phenytoin</e1>_10\NN\3550533 treatment_11\NN\654885 in_12\IN\13603305 some_13\DT\1740 epileptic_14\JJ\1740 patients_15\NNS\9898892 may_16\MD\15209706 be_17\VB\836236 the_18\DT\1740 direct_19\JJ\1740 result_20\NN\34213 of_21\IN\1740 medication_22\NN\3247620 ,_23\,\1740 unrelated_24\JJ\1740 to_25\IN\1740 <e2>seizures</e2>_26\NNS\14081375 ._27\.\1740
17931375
D006493_D003288 CID a_0\DT\13649268 study_1\NN\635850 on_2\IN\1740 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 the_6\DT\1740 duration_7\NN\15113229 of_8\IN\1740 subcutaneous_9\JJ\1740 <e1>heparin</e1>_10\NN\2718259 injection_11\NN\320852 on_12\IN\1740 <e2>bruising</e2>_13\NN\1740 and_14\CC\1740 pain_15\NN\14299637 ._16\.\1740
D006493_D003288 CID aim_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 was_4\VBD\836236 carried_5\VBN\1850315 out_6\RP\1740 to_7\TO\1740 determine_8\VB\1645601 the_9\DT\1740 effect_10\NN\34213 of_11\IN\1740 injection_12\NN\320852 duration_13\NN\15113229 on_14\IN\1740 <e2>bruising</e2>_15\NN\1740 and_16\CC\1740 pain_17\NN\14299637 following_18\VBG\1835496 the_19\DT\1740 administration_20\NN\1133281 of_21\IN\1740 the_22\DT\1740 subcutaneous_23\JJ\1740 injection_24\NN\320852 of_25\IN\1740 <e1>heparin</e1>_26\NN\2718259 ._27\.\1740
D006493_D003288 CID background_0\NN\4921011 :_1\:\1740 although_2\IN\1740 different_3\JJ\1740 methods_4\NNS\5616786 to_5\TO\1740 prevent_6\VB\1740 <e2>bruising</e2>_7\NN\1740 and_8\CC\1740 pain_9\NN\14299637 following_10\VBG\1835496 the_11\DT\1740 subcutaneous_12\JJ\1740 injection_13\NN\320852 of_14\IN\1740 <e1>heparin</e1>_15\NN\2718259 have_16\VBP\2108377 been_17\VBN\836236 widely_18\RB\1740 studied_19\VBN\630380 and_20\CC\1740 described_21\VBN\1001294 ,_22\,\1740 the_23\DT\1740 effect_24\NN\34213 of_25\IN\1740 injection_26\NN\320852 duration_27\NN\15113229 on_28\IN\1740 the_29\DT\1740 occurrence_30\NN\29378 of_31\IN\1740 bruising_32\NN\1740 and_33\CC\1740 pain_34\NN\14299637 is_35\VBZ\836236 little_36\RB\1740 documented_37\VBN\1000214 ._38\.\1740
D006493_D003288 CID background_0\NN\4921011 :_1\:\1740 although_2\IN\1740 different_3\JJ\1740 methods_4\NNS\5616786 to_5\TO\1740 prevent_6\VB\1740 bruising_7\NN\1740 and_8\CC\1740 pain_9\NN\14299637 following_10\VBG\1835496 the_11\DT\1740 subcutaneous_12\JJ\1740 injection_13\NN\320852 of_14\IN\1740 <e1>heparin</e1>_15\NN\2718259 have_16\VBP\2108377 been_17\VBN\836236 widely_18\RB\1740 studied_19\VBN\630380 and_20\CC\1740 described_21\VBN\1001294 ,_22\,\1740 the_23\DT\1740 effect_24\NN\34213 of_25\IN\1740 injection_26\NN\320852 duration_27\NN\15113229 on_28\IN\1740 the_29\DT\1740 occurrence_30\NN\29378 of_31\IN\1740 <e2>bruising</e2>_32\NN\1740 and_33\CC\1740 pain_34\NN\14299637 is_35\VBZ\836236 little_36\RB\1740 documented_37\VBN\1000214 ._38\.\1740
D006493_D003288 CID dimensions_0\NNS\5090441 of_1\IN\1740 the_2\DT\1740 <e2>bruising</e2>_3\NN\1740 on_4\IN\1740 the_5\DT\1740 <e1>heparin</e1>_6\NN\2718259 applied_7\JJ\1740 areas_8\NNS\8630985 were_9\VBD\836236 measured_10\VBN\697589 using_11\VBG\1156834 transparent_12\JJ\1740 millimetric_13\JJ\1740 measuring_14\NN\407535 paper_15\NN\14580897 ._16\.\1740
D006493_D003288 CID conclusions_0\NNS\5837957 :_1\:\1740 it_2\PRP\6125041 was_3\VBD\836236 determined_4\VBN\1645601 that_5\IN\1740 injection_6\NN\320852 duration_7\NN\15113229 had_8\VBD\2108377 an_9\DT\6697703 effect_10\NN\34213 on_11\IN\1740 <e2>bruising</e2>_12\NN\1740 and_13\CC\1740 pain_14\NN\14299637 following_15\VBG\1835496 the_16\DT\1740 subcutaneous_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 <e1>heparin</e1>_20\NN\2718259 ._21\.\1740
D006493_D010146 CID a_0\DT\13649268 study_1\NN\635850 on_2\IN\1740 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 the_6\DT\1740 duration_7\NN\15113229 of_8\IN\1740 subcutaneous_9\JJ\1740 <e1>heparin</e1>_10\NN\2718259 injection_11\NN\320852 on_12\IN\1740 bruising_13\NN\1740 and_14\CC\1740 <e2>pain</e2>_15\NN\14299637 ._16\.\1740
D006493_D010146 CID aim_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 was_4\VBD\836236 carried_5\VBN\1850315 out_6\RP\1740 to_7\TO\1740 determine_8\VB\1645601 the_9\DT\1740 effect_10\NN\34213 of_11\IN\1740 injection_12\NN\320852 duration_13\NN\15113229 on_14\IN\1740 bruising_15\NN\1740 and_16\CC\1740 <e2>pain</e2>_17\NN\14299637 following_18\VBG\1835496 the_19\DT\1740 administration_20\NN\1133281 of_21\IN\1740 the_22\DT\1740 subcutaneous_23\JJ\1740 injection_24\NN\320852 of_25\IN\1740 <e1>heparin</e1>_26\NN\2718259 ._27\.\1740
D006493_D010146 CID background_0\NN\4921011 :_1\:\1740 although_2\IN\1740 different_3\JJ\1740 methods_4\NNS\5616786 to_5\TO\1740 prevent_6\VB\1740 bruising_7\NN\1740 and_8\CC\1740 <e2>pain</e2>_9\NN\14299637 following_10\VBG\1835496 the_11\DT\1740 subcutaneous_12\JJ\1740 injection_13\NN\320852 of_14\IN\1740 <e1>heparin</e1>_15\NN\2718259 have_16\VBP\2108377 been_17\VBN\836236 widely_18\RB\1740 studied_19\VBN\630380 and_20\CC\1740 described_21\VBN\1001294 ,_22\,\1740 the_23\DT\1740 effect_24\NN\34213 of_25\IN\1740 injection_26\NN\320852 duration_27\NN\15113229 on_28\IN\1740 the_29\DT\1740 occurrence_30\NN\29378 of_31\IN\1740 bruising_32\NN\1740 and_33\CC\1740 pain_34\NN\14299637 is_35\VBZ\836236 little_36\RB\1740 documented_37\VBN\1000214 ._38\.\1740
D006493_D010146 CID background_0\NN\4921011 :_1\:\1740 although_2\IN\1740 different_3\JJ\1740 methods_4\NNS\5616786 to_5\TO\1740 prevent_6\VB\1740 bruising_7\NN\1740 and_8\CC\1740 pain_9\NN\14299637 following_10\VBG\1835496 the_11\DT\1740 subcutaneous_12\JJ\1740 injection_13\NN\320852 of_14\IN\1740 <e1>heparin</e1>_15\NN\2718259 have_16\VBP\2108377 been_17\VBN\836236 widely_18\RB\1740 studied_19\VBN\630380 and_20\CC\1740 described_21\VBN\1001294 ,_22\,\1740 the_23\DT\1740 effect_24\NN\34213 of_25\IN\1740 injection_26\NN\320852 duration_27\NN\15113229 on_28\IN\1740 the_29\DT\1740 occurrence_30\NN\29378 of_31\IN\1740 bruising_32\NN\1740 and_33\CC\1740 <e2>pain</e2>_34\NN\14299637 is_35\VBZ\836236 little_36\RB\1740 documented_37\VBN\1000214 ._38\.\1740
D006493_D010146 CID conclusions_0\NNS\5837957 :_1\:\1740 it_2\PRP\6125041 was_3\VBD\836236 determined_4\VBN\1645601 that_5\IN\1740 injection_6\NN\320852 duration_7\NN\15113229 had_8\VBD\2108377 an_9\DT\6697703 effect_10\NN\34213 on_11\IN\1740 bruising_12\NN\1740 and_13\CC\1740 <e2>pain</e2>_14\NN\14299637 following_15\VBG\1835496 the_16\DT\1740 subcutaneous_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 <e1>heparin</e1>_20\NN\2718259 ._21\.\1740
2696505
D007741_D007022 CID a_0\DT\13649268 randomized_1\JJ\1740 comparison_2\NN\635850 of_3\IN\1740 <e1>labetalol</e1>_4\NN\2721160 and_5\CC\1740 nitroprusside_6\NN\1740 for_7\IN\1740 induced_8\VBN\1627355 <e2>hypotension</e2>_9\NN\14057371 ._10\.\1740
D007741_D007022 CID in_0\IN\13603305 a_1\DT\13649268 randomized_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 <e1>labetalol-induced</e1>_5\JJ\1740 <e2>hypotension</e2>_6\NN\14057371 and_7\CC\1740 nitroprusside-induced_8\JJ\1740 hypotension_9\NN\14057371 were_10\VBD\836236 compared_11\VBN\644583 in_12\IN\13603305 20_13\CD\13745420 patients_14\NNS\9898892 (_15\-LRB-\1740 10_16\CD\13745420 in_17\IN\13603305 each_18\DT\1740 group_19\NN\2137 )_20\-RRB-\1740 scheduled_21\VBN\704690 for_22\IN\1740 major_23\JJ\1740 orthopedic_24\JJ\1740 procedures_25\NNS\407535 ._26\.\1740
D007741_D007022 CID in_0\IN\13603305 a_1\DT\13649268 randomized_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 <e1>labetalol-induced</e1>_5\JJ\1740 hypotension_6\NN\14057371 and_7\CC\1740 nitroprusside-induced_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 were_10\VBD\836236 compared_11\VBN\644583 in_12\IN\13603305 20_13\CD\13745420 patients_14\NNS\9898892 (_15\-LRB-\1740 10_16\CD\13745420 in_17\IN\13603305 each_18\DT\1740 group_19\NN\2137 )_20\-RRB-\1740 scheduled_21\VBN\704690 for_22\IN\1740 major_23\JJ\1740 orthopedic_24\JJ\1740 procedures_25\NNS\407535 ._26\.\1740
D009599_D007022 CID a_0\DT\13649268 randomized_1\JJ\1740 comparison_2\NN\635850 of_3\IN\1740 labetalol_4\NN\2721160 and_5\CC\1740 <e1>nitroprusside</e1>_6\NN\1740 for_7\IN\1740 induced_8\VBN\1627355 <e2>hypotension</e2>_9\NN\14057371 ._10\.\1740
D009599_D007022 CID in_0\IN\13603305 a_1\DT\13649268 randomized_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 labetalol-induced_5\JJ\1740 <e2>hypotension</e2>_6\NN\14057371 and_7\CC\1740 <e1>nitroprusside-induced</e1>_8\JJ\1740 hypotension_9\NN\14057371 were_10\VBD\836236 compared_11\VBN\644583 in_12\IN\13603305 20_13\CD\13745420 patients_14\NNS\9898892 (_15\-LRB-\1740 10_16\CD\13745420 in_17\IN\13603305 each_18\DT\1740 group_19\NN\2137 )_20\-RRB-\1740 scheduled_21\VBN\704690 for_22\IN\1740 major_23\JJ\1740 orthopedic_24\JJ\1740 procedures_25\NNS\407535 ._26\.\1740
D009599_D007022 CID in_0\IN\13603305 a_1\DT\13649268 randomized_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 labetalol-induced_5\JJ\1740 hypotension_6\NN\14057371 and_7\CC\1740 <e1>nitroprusside-induced</e1>_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 were_10\VBD\836236 compared_11\VBN\644583 in_12\IN\13603305 20_13\CD\13745420 patients_14\NNS\9898892 (_15\-LRB-\1740 10_16\CD\13745420 in_17\IN\13603305 each_18\DT\1740 group_19\NN\2137 )_20\-RRB-\1740 scheduled_21\VBN\704690 for_22\IN\1740 major_23\JJ\1740 orthopedic_24\JJ\1740 procedures_25\NNS\407535 ._26\.\1740
D009599_D016534 CID nitroprusside_0\NN\1740 infusion_1\NN\14589223 was_2\VBD\836236 associated_3\VBN\628491 with_4\IN\1740 a_5\DT\13649268 significant_6\JJ\1740 (_7\-LRB-\1740 p_8\NN\14622893 less_9\JJR\1740 than_10\IN\1740 0.05_11\CD\1740 )_12\-RRB-\1740 <e2>increase_13\NN\13576355 in_14\IN\13603305 heart_15\NN\5919034 rate_16\NN\13815152 and_17\CC\1740 cardiac_18\JJ\1740 output</e2>_19\NN\4007894 ;_20\:\1740 rebound_21\NN\7309781 hypertension_22\NN\14057371 was_23\VBD\836236 observed_24\VBN\2163746 in_25\IN\13603305 three_26\CD\13741022 patients_27\NNS\9898892 after_28\IN\1740 discontinuation_29\NN\209943 of_30\IN\1740 <e1>nitroprusside</e1>_31\NN\1740 ._32\.\1740
D009599_D006973 NONE nitroprusside_0\NN\1740 infusion_1\NN\14589223 was_2\VBD\836236 associated_3\VBN\628491 with_4\IN\1740 a_5\DT\13649268 significant_6\JJ\1740 (_7\-LRB-\1740 p_8\NN\14622893 less_9\JJR\1740 than_10\IN\1740 0.05_11\CD\1740 )_12\-RRB-\1740 increase_13\NN\13576355 in_14\IN\13603305 heart_15\NN\5919034 rate_16\NN\13815152 and_17\CC\1740 cardiac_18\JJ\1740 output_19\NN\4007894 ;_20\:\1740 rebound_21\NN\7309781 <e2>hypertension</e2>_22\NN\14057371 was_23\VBD\836236 observed_24\VBN\2163746 in_25\IN\13603305 three_26\CD\13741022 patients_27\NNS\9898892 after_28\IN\1740 discontinuation_29\NN\209943 of_30\IN\1740 <e1>nitroprusside</e1>_31\NN\1740 ._32\.\1740
10579464
C121249_D006948 NONE <e1>nra0160</e1>_0\NN\1740 and_1\CC\1740 clozapine_2\NN\3713736 antagonized_3\JJ\1740 locomotor_4\NN\1740 <e2>hyperactivity</e2>_5\NN\14052403 induced_6\VBN\1627355 by_7\IN\1740 methamphetamine_8\NN\2704153 (_9\-LRB-\1740 map_10\NN\4076846 )_11\-RRB-\1740 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
D003024_D006948 NONE nra0160_0\NN\1740 and_1\CC\1740 <e1>clozapine</e1>_2\NN\3713736 antagonized_3\JJ\1740 locomotor_4\NN\1740 <e2>hyperactivity</e2>_5\NN\14052403 induced_6\VBN\1627355 by_7\IN\1740 methamphetamine_8\NN\2704153 (_9\-LRB-\1740 map_10\NN\4076846 )_11\-RRB-\1740 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
D008694_D006948 CID nra0160_0\NN\1740 and_1\CC\1740 clozapine_2\NN\3713736 antagonized_3\JJ\1740 locomotor_4\NN\1740 <e2>hyperactivity</e2>_5\NN\14052403 induced_6\VBN\1627355 by_7\IN\1740 <e1>methamphetamine</e1>_8\NN\2704153 (_9\-LRB-\1740 map_10\NN\4076846 )_11\-RRB-\1740 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
D008694_D006948 CID nra0160_0\NN\1740 and_1\CC\1740 clozapine_2\NN\3713736 antagonized_3\JJ\1740 locomotor_4\NN\1740 <e2>hyperactivity</e2>_5\NN\14052403 induced_6\VBN\1627355 by_7\IN\1740 methamphetamine_8\NN\2704153 (_9\-LRB-\1740 <e1>map</e1>_10\NN\4076846 )_11\-RRB-\1740 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
C121249_D002375 CID <e1>nra0160</e1>_0\NN\1740 and_1\CC\1740 clozapine_2\NN\3713736 significantly_3\RB\1740 induced_4\VBD\1627355 <e2>catalepsy</e2>_5\NN\14023236 in_6\IN\13603305 rats_7\NNS\2329401 ,_8\,\1740 although_9\IN\1740 their_10\PRP$\1740 effects_11\NNS\13245626 did_12\VBD\1640855 not_13\RB\1740 exceed_14\VB\2673965 50_15\CD\13745420 %_16\NN\1740 induction_17\NN\7450842 even_18\RB\1740 at_19\IN\14622893 the_20\DT\1740 highest_21\JJS\1740 dose_22\NN\3740161 given_23\VBN\2327200 ._24\.\1740
D003024_D002375 CID nra0160_0\NN\1740 and_1\CC\1740 <e1>clozapine</e1>_2\NN\3713736 significantly_3\RB\1740 induced_4\VBD\1627355 <e2>catalepsy</e2>_5\NN\14023236 in_6\IN\13603305 rats_7\NNS\2329401 ,_8\,\1740 although_9\IN\1740 their_10\PRP$\1740 effects_11\NNS\13245626 did_12\VBD\1640855 not_13\RB\1740 exceed_14\VB\2673965 50_15\CD\13745420 %_16\NN\1740 induction_17\NN\7450842 even_18\RB\1740 at_19\IN\14622893 the_20\DT\1740 highest_21\JJS\1740 dose_22\NN\3740161 given_23\VBN\2327200 ._24\.\1740
19356307
D012601_D003704 NONE components_0\NNS\5867413 of_1\IN\1740 lemon_2\JJ\1740 essential_3\JJ\1740 oil_4\NN\14938907 attenuate_5\NN\1740 <e2>dementia</e2>_6\NN\14395018 induced_7\VBN\1627355 by_8\IN\1740 <e1>scopolamine</e1>_9\NN\14712692 ._10\.\1740
C008281_D003704 NONE the_0\DT\1740 <e2>anti-dementia</e2>_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>s-limonene</e1>_4\NN\1740 and_5\CC\1740 s-perillyl_6\JJ\1740 alcohol_7\NN\7881800 were_8\VBD\836236 observed_9\VBN\2163746 using_10\VBG\1156834 the_11\DT\1740 passive_12\JJ\1740 avoidance_13\NN\203342 test_14\NN\5798043 (_15\-LRB-\1740 pa_16\NN\10080869 )_17\-RRB-\1740 and_18\CC\1740 the_19\DT\1740 open_20\JJ\1740 field_21\NN\8673395 habituation_22\NN\14034177 test_23\NN\5798043 (_24\-LRB-\1740 ofh_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
C032208_D003704 NONE the_0\DT\1740 <e2>anti-dementia</e2>_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 s-limonene_4\NN\1740 and_5\CC\1740 <e1>s-perillyl_6\JJ\1740 alcohol</e1>_7\NN\7881800 were_8\VBD\836236 observed_9\VBN\2163746 using_10\VBG\1156834 the_11\DT\1740 passive_12\JJ\1740 avoidance_13\NN\203342 test_14\NN\5798043 (_15\-LRB-\1740 pa_16\NN\10080869 )_17\-RRB-\1740 and_18\CC\1740 the_19\DT\1740 open_20\JJ\1740 field_21\NN\8673395 habituation_22\NN\14034177 test_23\NN\5798043 (_24\-LRB-\1740 ofh_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D012601_D008569 CID these_0\DT\1740 lemon_1\JJ\1740 essential_2\JJ\1740 oils_3\NNS\14938907 showed_4\VBD\2137132 strong_5\JJ\1740 ability_6\NN\4723816 to_7\TO\1740 improve_8\VB\126264 <e2>memory_9\NN\5926676 impaired</e2>_10\VBN\258857 by_11\IN\1740 <e1>scopolamine</e1>_12\NN\14712692 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 s-perillyl_16\NN\1740 alcohol_17\NN\7881800 relieved_18\VBD\205885 the_19\DT\1740 deficit_20\NN\5113133 of_21\IN\1740 associative_22\JJ\1740 memory_23\NN\5926676 in_24\IN\13603305 pa_25\NN\10080869 only_26\RB\1740 ,_27\,\1740 and_28\CC\1740 did_29\VBD\1640855 not_30\RB\1740 improve_31\VB\126264 non-associative_32\JJ\1740 memory_33\NN\5926676 significantly_34\RB\1740 in_35\IN\13603305 ofh_36\NN\1740 ._37\.\1740
D012601_D008569 CID these_0\DT\1740 lemon_1\JJ\1740 essential_2\JJ\1740 oils_3\NNS\14938907 showed_4\VBD\2137132 strong_5\JJ\1740 ability_6\NN\4723816 to_7\TO\1740 improve_8\VB\126264 memory_9\NN\5926676 impaired_10\VBN\258857 by_11\IN\1740 <e1>scopolamine</e1>_12\NN\14712692 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 s-perillyl_16\NN\1740 alcohol_17\NN\7881800 relieved_18\VBD\205885 the_19\DT\1740 <e2>deficit_20\NN\5113133 of_21\IN\1740 associative_22\JJ\1740 memory</e2>_23\NN\5926676 in_24\IN\13603305 pa_25\NN\10080869 only_26\RB\1740 ,_27\,\1740 and_28\CC\1740 did_29\VBD\1640855 not_30\RB\1740 improve_31\VB\126264 non-associative_32\JJ\1740 memory_33\NN\5926676 significantly_34\RB\1740 in_35\IN\13603305 ofh_36\NN\1740 ._37\.\1740
C032208_D008569 NONE these_0\DT\1740 lemon_1\JJ\1740 essential_2\JJ\1740 oils_3\NNS\14938907 showed_4\VBD\2137132 strong_5\JJ\1740 ability_6\NN\4723816 to_7\TO\1740 improve_8\VB\126264 <e2>memory_9\NN\5926676 impaired</e2>_10\VBN\258857 by_11\IN\1740 scopolamine_12\NN\14712692 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e1>s-perillyl_16\NN\1740 alcohol</e1>_17\NN\7881800 relieved_18\VBD\205885 the_19\DT\1740 deficit_20\NN\5113133 of_21\IN\1740 associative_22\JJ\1740 memory_23\NN\5926676 in_24\IN\13603305 pa_25\NN\10080869 only_26\RB\1740 ,_27\,\1740 and_28\CC\1740 did_29\VBD\1640855 not_30\RB\1740 improve_31\VB\126264 non-associative_32\JJ\1740 memory_33\NN\5926676 significantly_34\RB\1740 in_35\IN\13603305 ofh_36\NN\1740 ._37\.\1740
C032208_D008569 NONE these_0\DT\1740 lemon_1\JJ\1740 essential_2\JJ\1740 oils_3\NNS\14938907 showed_4\VBD\2137132 strong_5\JJ\1740 ability_6\NN\4723816 to_7\TO\1740 improve_8\VB\126264 memory_9\NN\5926676 impaired_10\VBN\258857 by_11\IN\1740 scopolamine_12\NN\14712692 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e1>s-perillyl_16\NN\1740 alcohol</e1>_17\NN\7881800 relieved_18\VBD\205885 the_19\DT\1740 <e2>deficit_20\NN\5113133 of_21\IN\1740 associative_22\JJ\1740 memory</e2>_23\NN\5926676 in_24\IN\13603305 pa_25\NN\10080869 only_26\RB\1740 ,_27\,\1740 and_28\CC\1740 did_29\VBD\1640855 not_30\RB\1740 improve_31\VB\126264 non-associative_32\JJ\1740 memory_33\NN\5926676 significantly_34\RB\1740 in_35\IN\13603305 ofh_36\NN\1740 ._37\.\1740
2273650
D012601_D000647 CID <e2>amnesia</e2>_0\NNP\5669934 produced_1\VBN\1617192 by_2\IN\1740 <e1>scopolamine</e1>_3\NN\14712692 and_4\CC\1740 cycloheximide_5\NN\1740 were_6\VBD\836236 reversed_7\VBN\109660 by_8\IN\1740 morphine_9\NN\2707683 given_10\VBN\2327200 30_11\CD\13745420 min_12\NN\15154774 before_13\IN\1740 the_14\DT\1740 test_15\NN\5798043 trial_16\NN\786195 (_17\-LRB-\1740 pre-test_18\JJ\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 pre-test_22\JJ\1740 morphine_23\NN\2707683 also_24\RB\1740 facilitated_25\VBD\2547586 the_26\DT\1740 memory_27\NN\5926676 retrieval_28\NN\13450862 in_29\IN\13603305 the_30\DT\1740 animals_31\NNS\4475 administered_32\VBN\2436349 naloxone_33\NN\3808977 during_34\IN\1740 the_35\DT\1740 training_36\NN\407535 trial_37\NN\786195 ._38\.\1740
D012601_D000647 CID similarly_0\RB\1740 ,_1\,\1740 pre-test_2\JJ\1740 <e1>scopolamine</e1>_3\NN\14712692 partially_4\RB\1740 reversed_5\VBD\109660 the_6\DT\1740 scopolamine-induced_7\JJ\1740 <e2>amnesia</e2>_8\NN\5669934 ,_9\,\1740 but_10\CC\1740 not_11\RB\1740 significantly_12\RB\1740 ;_13\:\1740 and_14\CC\1740 pre-test_15\JJ\1740 cycloheximide_16\NN\1740 failed_17\VBD\1798936 to_18\TO\1740 reverse_19\VB\109660 the_20\DT\1740 cycloheximide-induced_21\JJ\1740 amnesia_22\NN\5669934 ._23\.\1740
D012601_D000647 CID similarly_0\RB\1740 ,_1\,\1740 pre-test_2\JJ\1740 <e1>scopolamine</e1>_3\NN\14712692 partially_4\RB\1740 reversed_5\VBD\109660 the_6\DT\1740 scopolamine-induced_7\JJ\1740 amnesia_8\NN\5669934 ,_9\,\1740 but_10\CC\1740 not_11\RB\1740 significantly_12\RB\1740 ;_13\:\1740 and_14\CC\1740 pre-test_15\JJ\1740 cycloheximide_16\NN\1740 failed_17\VBD\1798936 to_18\TO\1740 reverse_19\VB\109660 the_20\DT\1740 cycloheximide-induced_21\JJ\1740 <e2>amnesia</e2>_22\NN\5669934 ._23\.\1740
D012601_D000647 CID similarly_0\RB\1740 ,_1\,\1740 pre-test_2\JJ\1740 scopolamine_3\NN\14712692 partially_4\RB\1740 reversed_5\VBD\109660 the_6\DT\1740 <e1>scopolamine-induced</e1>_7\JJ\1740 <e2>amnesia</e2>_8\NN\5669934 ,_9\,\1740 but_10\CC\1740 not_11\RB\1740 significantly_12\RB\1740 ;_13\:\1740 and_14\CC\1740 pre-test_15\JJ\1740 cycloheximide_16\NN\1740 failed_17\VBD\1798936 to_18\TO\1740 reverse_19\VB\109660 the_20\DT\1740 cycloheximide-induced_21\JJ\1740 amnesia_22\NN\5669934 ._23\.\1740
D012601_D000647 CID similarly_0\RB\1740 ,_1\,\1740 pre-test_2\JJ\1740 scopolamine_3\NN\14712692 partially_4\RB\1740 reversed_5\VBD\109660 the_6\DT\1740 <e1>scopolamine-induced</e1>_7\JJ\1740 amnesia_8\NN\5669934 ,_9\,\1740 but_10\CC\1740 not_11\RB\1740 significantly_12\RB\1740 ;_13\:\1740 and_14\CC\1740 pre-test_15\JJ\1740 cycloheximide_16\NN\1740 failed_17\VBD\1798936 to_18\TO\1740 reverse_19\VB\109660 the_20\DT\1740 cycloheximide-induced_21\JJ\1740 <e2>amnesia</e2>_22\NN\5669934 ._23\.\1740
D003513_D000647 CID <e2>amnesia</e2>_0\NNP\5669934 produced_1\VBN\1617192 by_2\IN\1740 scopolamine_3\NN\14712692 and_4\CC\1740 <e1>cycloheximide</e1>_5\NN\1740 were_6\VBD\836236 reversed_7\VBN\109660 by_8\IN\1740 morphine_9\NN\2707683 given_10\VBN\2327200 30_11\CD\13745420 min_12\NN\15154774 before_13\IN\1740 the_14\DT\1740 test_15\NN\5798043 trial_16\NN\786195 (_17\-LRB-\1740 pre-test_18\JJ\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 pre-test_22\JJ\1740 morphine_23\NN\2707683 also_24\RB\1740 facilitated_25\VBD\2547586 the_26\DT\1740 memory_27\NN\5926676 retrieval_28\NN\13450862 in_29\IN\13603305 the_30\DT\1740 animals_31\NNS\4475 administered_32\VBN\2436349 naloxone_33\NN\3808977 during_34\IN\1740 the_35\DT\1740 training_36\NN\407535 trial_37\NN\786195 ._38\.\1740
D003513_D000647 CID similarly_0\RB\1740 ,_1\,\1740 pre-test_2\JJ\1740 scopolamine_3\NN\14712692 partially_4\RB\1740 reversed_5\VBD\109660 the_6\DT\1740 scopolamine-induced_7\JJ\1740 <e2>amnesia</e2>_8\NN\5669934 ,_9\,\1740 but_10\CC\1740 not_11\RB\1740 significantly_12\RB\1740 ;_13\:\1740 and_14\CC\1740 pre-test_15\JJ\1740 <e1>cycloheximide</e1>_16\NN\1740 failed_17\VBD\1798936 to_18\TO\1740 reverse_19\VB\109660 the_20\DT\1740 cycloheximide-induced_21\JJ\1740 amnesia_22\NN\5669934 ._23\.\1740
D003513_D000647 CID similarly_0\RB\1740 ,_1\,\1740 pre-test_2\JJ\1740 scopolamine_3\NN\14712692 partially_4\RB\1740 reversed_5\VBD\109660 the_6\DT\1740 scopolamine-induced_7\JJ\1740 amnesia_8\NN\5669934 ,_9\,\1740 but_10\CC\1740 not_11\RB\1740 significantly_12\RB\1740 ;_13\:\1740 and_14\CC\1740 pre-test_15\JJ\1740 <e1>cycloheximide</e1>_16\NN\1740 failed_17\VBD\1798936 to_18\TO\1740 reverse_19\VB\109660 the_20\DT\1740 cycloheximide-induced_21\JJ\1740 <e2>amnesia</e2>_22\NN\5669934 ._23\.\1740
D003513_D000647 CID similarly_0\RB\1740 ,_1\,\1740 pre-test_2\JJ\1740 scopolamine_3\NN\14712692 partially_4\RB\1740 reversed_5\VBD\109660 the_6\DT\1740 scopolamine-induced_7\JJ\1740 <e2>amnesia</e2>_8\NN\5669934 ,_9\,\1740 but_10\CC\1740 not_11\RB\1740 significantly_12\RB\1740 ;_13\:\1740 and_14\CC\1740 pre-test_15\JJ\1740 cycloheximide_16\NN\1740 failed_17\VBD\1798936 to_18\TO\1740 reverse_19\VB\109660 the_20\DT\1740 <e1>cycloheximide-induced</e1>_21\JJ\1740 amnesia_22\NN\5669934 ._23\.\1740
D003513_D000647 CID similarly_0\RB\1740 ,_1\,\1740 pre-test_2\JJ\1740 scopolamine_3\NN\14712692 partially_4\RB\1740 reversed_5\VBD\109660 the_6\DT\1740 scopolamine-induced_7\JJ\1740 amnesia_8\NN\5669934 ,_9\,\1740 but_10\CC\1740 not_11\RB\1740 significantly_12\RB\1740 ;_13\:\1740 and_14\CC\1740 pre-test_15\JJ\1740 cycloheximide_16\NN\1740 failed_17\VBD\1798936 to_18\TO\1740 reverse_19\VB\109660 the_20\DT\1740 <e1>cycloheximide-induced</e1>_21\JJ\1740 <e2>amnesia</e2>_22\NN\5669934 ._23\.\1740
D009020_D000647 NONE <e2>amnesia</e2>_0\NNP\5669934 produced_1\VBN\1617192 by_2\IN\1740 scopolamine_3\NN\14712692 and_4\CC\1740 cycloheximide_5\NN\1740 were_6\VBD\836236 reversed_7\VBN\109660 by_8\IN\1740 <e1>morphine</e1>_9\NN\2707683 given_10\VBN\2327200 30_11\CD\13745420 min_12\NN\15154774 before_13\IN\1740 the_14\DT\1740 test_15\NN\5798043 trial_16\NN\786195 (_17\-LRB-\1740 pre-test_18\JJ\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 pre-test_22\JJ\1740 morphine_23\NN\2707683 also_24\RB\1740 facilitated_25\VBD\2547586 the_26\DT\1740 memory_27\NN\5926676 retrieval_28\NN\13450862 in_29\IN\13603305 the_30\DT\1740 animals_31\NNS\4475 administered_32\VBN\2436349 naloxone_33\NN\3808977 during_34\IN\1740 the_35\DT\1740 training_36\NN\407535 trial_37\NN\786195 ._38\.\1740
D009020_D000647 NONE <e2>amnesia</e2>_0\NNP\5669934 produced_1\VBN\1617192 by_2\IN\1740 scopolamine_3\NN\14712692 and_4\CC\1740 cycloheximide_5\NN\1740 were_6\VBD\836236 reversed_7\VBN\109660 by_8\IN\1740 morphine_9\NN\2707683 given_10\VBN\2327200 30_11\CD\13745420 min_12\NN\15154774 before_13\IN\1740 the_14\DT\1740 test_15\NN\5798043 trial_16\NN\786195 (_17\-LRB-\1740 pre-test_18\JJ\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 pre-test_22\JJ\1740 <e1>morphine</e1>_23\NN\2707683 also_24\RB\1740 facilitated_25\VBD\2547586 the_26\DT\1740 memory_27\NN\5926676 retrieval_28\NN\13450862 in_29\IN\13603305 the_30\DT\1740 animals_31\NNS\4475 administered_32\VBN\2436349 naloxone_33\NN\3808977 during_34\IN\1740 the_35\DT\1740 training_36\NN\407535 trial_37\NN\786195 ._38\.\1740
D009270_D000647 NONE <e2>amnesia</e2>_0\NNP\5669934 produced_1\VBN\1617192 by_2\IN\1740 scopolamine_3\NN\14712692 and_4\CC\1740 cycloheximide_5\NN\1740 were_6\VBD\836236 reversed_7\VBN\109660 by_8\IN\1740 morphine_9\NN\2707683 given_10\VBN\2327200 30_11\CD\13745420 min_12\NN\15154774 before_13\IN\1740 the_14\DT\1740 test_15\NN\5798043 trial_16\NN\786195 (_17\-LRB-\1740 pre-test_18\JJ\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 pre-test_22\JJ\1740 morphine_23\NN\2707683 also_24\RB\1740 facilitated_25\VBD\2547586 the_26\DT\1740 memory_27\NN\5926676 retrieval_28\NN\13450862 in_29\IN\13603305 the_30\DT\1740 animals_31\NNS\4475 administered_32\VBN\2436349 <e1>naloxone</e1>_33\NN\3808977 during_34\IN\1740 the_35\DT\1740 training_36\NN\407535 trial_37\NN\786195 ._38\.\1740
18217897
D013792_D008228 NONE <e1>thalidomide</e1>_0\NN\4166841 has_1\VBZ\2108377 limited_2\VBN\2510337 single-agent_3\JJ\1740 activity_4\NN\30358 in_5\IN\13603305 relapsed_6\JJ\1740 or_7\CC\3541091 refractory_8\JJ\1740 indolent_9\JJ\1740 <e2>non-hodgkin_10\JJ\1740 lymphomas</e2>_11\NNS\14239918 :_12\:\1740 a_13\DT\13649268 phase_14\NN\15113229 ii_15\CD\13741022 trial_16\NN\786195 of_17\IN\1740 the_18\DT\1740 cancer_19\NN\14239425 and_20\CC\1740 leukemia_21\NNP\14239918 group_22\NNP\2137 b._23\NNP\1740
D013792_D009369 NONE <e1>thalidomide</e1>_0\NN\4166841 has_1\VBZ\2108377 limited_2\VBN\2510337 single-agent_3\JJ\1740 activity_4\NN\30358 in_5\IN\13603305 relapsed_6\JJ\1740 or_7\CC\3541091 refractory_8\JJ\1740 indolent_9\JJ\1740 non-hodgkin_10\JJ\1740 lymphomas_11\NNS\14239918 :_12\:\1740 a_13\DT\13649268 phase_14\NN\15113229 ii_15\CD\13741022 trial_16\NN\786195 of_17\IN\1740 the_18\DT\1740 <e2>cancer</e2>_19\NN\14239425 and_20\CC\1740 leukemia_21\NNP\14239918 group_22\NNP\2137 b._23\NNP\1740
D013792_D007938 NONE <e1>thalidomide</e1>_0\NN\4166841 has_1\VBZ\2108377 limited_2\VBN\2510337 single-agent_3\JJ\1740 activity_4\NN\30358 in_5\IN\13603305 relapsed_6\JJ\1740 or_7\CC\3541091 refractory_8\JJ\1740 indolent_9\JJ\1740 non-hodgkin_10\JJ\1740 lymphomas_11\NNS\14239918 :_12\:\1740 a_13\DT\13649268 phase_14\NN\15113229 ii_15\CD\13741022 trial_16\NN\786195 of_17\IN\1740 the_18\DT\1740 cancer_19\NN\14239425 and_20\CC\1740 <e2>leukemia</e2>_21\NNP\14239918 group_22\NNP\2137 b._23\NNP\1740
D013792_D009101 NONE <e1>thalidomide</e1>_0\NN\4166841 is_1\VBZ\836236 an_2\DT\6697703 immunomodulatory_3\JJ\1740 agent_4\NN\7347 with_5\IN\1740 demonstrated_6\VBN\2137132 activity_7\NN\30358 in_8\IN\13603305 <e2>multiple_9\JJ\1740 myeloma</e2>_10\NN\14239425 ,_11\,\1740 mantle_12\NN\6806469 cell_13\NN\3080309 lymphoma_14\NN\14239918 and_15\CC\1740 lymphoplasmacytic_16\JJ\1740 lymphoma_17\NN\14239918 ._18\.\1740
D013792_D020522 NONE <e1>thalidomide</e1>_0\NN\4166841 is_1\VBZ\836236 an_2\DT\6697703 immunomodulatory_3\JJ\1740 agent_4\NN\7347 with_5\IN\1740 demonstrated_6\VBN\2137132 activity_7\NN\30358 in_8\IN\13603305 multiple_9\JJ\1740 myeloma_10\NN\14239425 ,_11\,\1740 <e2>mantle_12\NN\6806469 cell_13\NN\3080309 lymphoma</e2>_14\NN\14239918 and_15\CC\1740 lymphoplasmacytic_16\JJ\1740 lymphoma_17\NN\14239918 ._18\.\1740
D013792_D008223 NONE <e1>thalidomide</e1>_0\NN\4166841 is_1\VBZ\836236 an_2\DT\6697703 immunomodulatory_3\JJ\1740 agent_4\NN\7347 with_5\IN\1740 demonstrated_6\VBN\2137132 activity_7\NN\30358 in_8\IN\13603305 multiple_9\JJ\1740 myeloma_10\NN\14239425 ,_11\,\1740 mantle_12\NN\6806469 cell_13\NN\3080309 lymphoma_14\NN\14239918 and_15\CC\1740 <e2>lymphoplasmacytic_16\JJ\1740 lymphoma</e2>_17\NN\14239918 ._18\.\1740
D013792_D008223 NONE between_0\IN\1740 july_1\NNP\15209706 2001_2\CD\1740 and_3\CC\1740 april_4\NNP\15209706 2004_5\CD\1740 ,_6\,\1740 24_7\CD\13745420 patients_8\NNS\9898892 with_9\IN\1740 relapsed/refractory_10\JJ\1740 indolent_11\JJ\1740 <e2>lymphomas</e2>_12\NNS\14239918 received_13\VBD\2210855 <e1>thalidomide</e1>_14\NN\4166841 200_15\CD\1740 mg_16\NN\13717155 daily_17\RB\1740 with_18\IN\1740 escalation_19\NN\363260 by_20\IN\1740 100_21\CD\13745420 mg_22\NN\13717155 daily_23\RB\1740 every_24\DT\1740 1_25\CD\13741022 -_26\SYM\1740 2_27\CD\13741022 weeks_28\NNS\15113229 as_29\IN\14622893 tolerated_30\VBN\802318 ,_31\,\1740 up_32\RB\1740 to_33\TO\1740 a_34\DT\13649268 maximum_35\NN\13653902 of_36\IN\1740 800_37\CD\1740 mg_38\NN\13717155 daily_39\RB\1740 ._40\.\1740
D013792_D008223 NONE our_0\PRP$\1740 results_1\NNS\34213 failed_2\VBD\1798936 to_3\TO\1740 demonstrate_4\VB\2137132 an_5\DT\6697703 important_6\JJ\1740 response_7\NN\11410625 rate_8\NN\13815152 to_9\IN\1740 single_10\JJ\1740 agent_11\NN\7347 <e1>thalidomide</e1>_12\NN\4166841 in_13\IN\13603305 indolent_14\JJ\1740 <e2>lymphomas</e2>_15\NNS\14239918 and_16\CC\1740 contrast_17\VB\650353 with_18\IN\1740 the_19\DT\1740 higher_20\JJR\1740 activity_21\NN\30358 level_22\NN\4916342 reported_23\VBN\831651 with_24\IN\1740 the_25\DT\1740 second_26\JJ\1740 generation_27\NN\7942152 immunomodulatory_28\JJ\1740 agent_29\NN\7347 ,_30\,\1740 lenalidomide_31\NN\1740 ._32\.\1740
C467567_D008223 NONE our_0\PRP$\1740 results_1\NNS\34213 failed_2\VBD\1798936 to_3\TO\1740 demonstrate_4\VB\2137132 an_5\DT\6697703 important_6\JJ\1740 response_7\NN\11410625 rate_8\NN\13815152 to_9\IN\1740 single_10\JJ\1740 agent_11\NN\7347 thalidomide_12\NN\4166841 in_13\IN\13603305 indolent_14\JJ\1740 <e2>lymphomas</e2>_15\NNS\14239918 and_16\CC\1740 contrast_17\VB\650353 with_18\IN\1740 the_19\DT\1740 higher_20\JJR\1740 activity_21\NN\30358 level_22\NN\4916342 reported_23\VBN\831651 with_24\IN\1740 the_25\DT\1740 second_26\JJ\1740 generation_27\NN\7942152 immunomodulatory_28\JJ\1740 agent_29\NN\7347 ,_30\,\1740 <e1>lenalidomide</e1>_31\NN\1740 ._32\.\1740
3070035
D002216_D051437 NONE reversibility_0\NN\4733640 of_1\IN\1740 <e1>captopril-induced</e1>_2\JJ\1740 <e2>renal_3\JJ\1740 insufficiency</e2>_4\NN\14462946 after_5\IN\1740 prolonged_6\JJ\1740 use_7\NN\407535 in_8\IN\13603305 an_9\DT\6697703 unusual_10\JJ\1740 case_11\NN\7283608 of_12\IN\1740 renovascular_13\JJ\1740 hypertension_14\NN\14057371 ._15\.\1740
D002216_D051437 NONE this_0\DT\1740 indicates_1\VBZ\952524 reversibility_2\NN\4733640 in_3\IN\13603305 <e1>captopril-induced</e1>_4\JJ\1740 <e2>renal_5\JJ\1740 failure</e2>_6\NN\66216 even_7\RB\1740 after_8\IN\1740 its_9\PRP$\6125041 prolonged_10\JJ\1740 use_11\NN\407535 and_12\CC\1740 suggests_13\VBZ\1010118 that_14\IN\1740 no_15\DT\7204911 organic_16\JJ\1740 damage_17\NN\7296428 occurs_18\VBZ\2623529 to_19\TO\1740 glomerular_20\JJ\1740 arterioles_21\NNS\5333777 following_22\VBG\1835496 chronic_23\JJ\1740 ace_24\NN\13741022 inhibition_25\NN\1068773 ._26\.\1740
D002216_D006978 NONE reversibility_0\NN\4733640 of_1\IN\1740 <e1>captopril-induced</e1>_2\JJ\1740 renal_3\JJ\1740 insufficiency_4\NN\14462946 after_5\IN\1740 prolonged_6\JJ\1740 use_7\NN\407535 in_8\IN\13603305 an_9\DT\6697703 unusual_10\JJ\1740 case_11\NN\7283608 of_12\IN\1740 <e2>renovascular_13\JJ\1740 hypertension</e2>_14\NN\14057371 ._15\.\1740
D002216_D006973 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 severe_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 with_7\IN\1740 an_8\DT\6697703 occluded_9\VBN\2451370 renal_10\JJ\1740 artery_11\NN\5417975 to_12\TO\1740 a_13\DT\13649268 solitary_14\JJ\1740 kidney_15\NN\5333259 ,_16\,\1740 who_17\WP\8299493 developed_18\VBD\1753788 sudden_19\JJ\1740 deterioration_20\NN\14560612 of_21\IN\1740 renal_22\JJ\1740 function_23\NN\13783581 following_24\VBG\1835496 treatment_25\NN\654885 with_26\IN\1740 <e1>captopril</e1>_27\NN\2673637 ._28\.\1740
D002216_D058186 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 severe_5\JJ\1740 hypertension_6\NN\14057371 with_7\IN\1740 an_8\DT\6697703 occluded_9\VBN\2451370 renal_10\JJ\1740 artery_11\NN\5417975 to_12\TO\1740 a_13\DT\13649268 solitary_14\JJ\1740 kidney_15\NN\5333259 ,_16\,\1740 who_17\WP\8299493 developed_18\VBD\1753788 <e2>sudden_19\JJ\1740 deterioration_20\NN\14560612 of_21\IN\1740 renal_22\JJ\1740 function</e2>_23\NN\13783581 following_24\VBG\1835496 treatment_25\NN\654885 with_26\IN\1740 <e1>captopril</e1>_27\NN\2673637 ._28\.\1740
1987816
D008094_D011141 CID <e1>lithium-induced</e1>_0\JJ\1740 <e2>polyuria</e2>_1\NN\14113228 seems_2\VBZ\2604760 to_3\TO\1740 be_4\VB\836236 related_5\JJ\1740 to_6\TO\1740 extrarenal_7\JJ\1740 as_8\RB\1740 well_9\RB\1740 as_10\IN\14622893 to_11\TO\1740 renal_12\JJ\1740 effects_13\NNS\13245626 ._14\.\1740
4008111
D000638_D012848 CID <e1>amiodarone-induced</e1>_0\JJ\1740 <e2>sinoatrial_1\NN\1740 block</e2>_2\NN\21939 ._3\.\1740
D000638_D012848 CID we_0\PRP\1740 observed_1\VBD\2163746 <e2>sinoatrial_2\JJ\1740 block</e2>_3\NN\21939 due_4\JJ\1740 to_5\TO\1740 chronic_6\JJ\1740 <e1>amiodarone</e1>_7\NN\2715941 administration_8\NN\1133281 in_9\IN\13603305 a_10\DT\13649268 5-year-old_11\JJ\1740 boy_12\NN\9624168 with_13\IN\1740 primary_14\JJ\1740 cardiomyopathy_15\JJ\1740 ,_16\,\1740 wolff-parkinson-white_17\JJ\1740 syndrome_18\NN\5870365 and_19\CC\1740 supraventricular_20\JJ\1740 tachycardia_21\NN\14110674 ._22\.\1740
D000638_D012848 CID reduction_0\NN\351485 in_1\IN\13603305 the_2\DT\1740 dosage_3\NN\13576355 of_4\IN\1740 <e1>amiodarone</e1>_5\NN\2715941 resulted_6\VBD\2633881 in_7\IN\13603305 the_8\DT\1740 disappearance_9\NN\42757 of_10\IN\1740 the_11\DT\1740 <e2>sinoatrial_12\JJ\1740 block</e2>_13\NN\21939 and_14\CC\1740 the_15\DT\1740 persistence_16\NN\5053688 of_17\IN\1740 asymptomatic_18\JJ\1740 sinus_19\NN\5248181 bradycardia_20\NN\14110674 ._21\.\1740
D000638_D009202 NONE we_0\PRP\1740 observed_1\VBD\2163746 sinoatrial_2\JJ\1740 block_3\NN\21939 due_4\JJ\1740 to_5\TO\1740 chronic_6\JJ\1740 <e1>amiodarone</e1>_7\NN\2715941 administration_8\NN\1133281 in_9\IN\13603305 a_10\DT\13649268 5-year-old_11\JJ\1740 boy_12\NN\9624168 with_13\IN\1740 <e2>primary_14\JJ\1740 cardiomyopathy</e2>_15\JJ\1740 ,_16\,\1740 wolff-parkinson-white_17\JJ\1740 syndrome_18\NN\5870365 and_19\CC\1740 supraventricular_20\JJ\1740 tachycardia_21\NN\14110674 ._22\.\1740
D000638_D014927 NONE we_0\PRP\1740 observed_1\VBD\2163746 sinoatrial_2\JJ\1740 block_3\NN\21939 due_4\JJ\1740 to_5\TO\1740 chronic_6\JJ\1740 <e1>amiodarone</e1>_7\NN\2715941 administration_8\NN\1133281 in_9\IN\13603305 a_10\DT\13649268 5-year-old_11\JJ\1740 boy_12\NN\9624168 with_13\IN\1740 primary_14\JJ\1740 cardiomyopathy_15\JJ\1740 ,_16\,\1740 <e2>wolff-parkinson-white_17\JJ\1740 syndrome</e2>_18\NN\5870365 and_19\CC\1740 supraventricular_20\JJ\1740 tachycardia_21\NN\14110674 ._22\.\1740
D000638_D013617 NONE we_0\PRP\1740 observed_1\VBD\2163746 sinoatrial_2\JJ\1740 block_3\NN\21939 due_4\JJ\1740 to_5\TO\1740 chronic_6\JJ\1740 <e1>amiodarone</e1>_7\NN\2715941 administration_8\NN\1133281 in_9\IN\13603305 a_10\DT\13649268 5-year-old_11\JJ\1740 boy_12\NN\9624168 with_13\IN\1740 primary_14\JJ\1740 cardiomyopathy_15\JJ\1740 ,_16\,\1740 wolff-parkinson-white_17\JJ\1740 syndrome_18\NN\5870365 and_19\CC\1740 <e2>supraventricular_20\JJ\1740 tachycardia</e2>_21\NN\14110674 ._22\.\1740
D000638_D012804 NONE reduction_0\NN\351485 in_1\IN\13603305 the_2\DT\1740 dosage_3\NN\13576355 of_4\IN\1740 <e1>amiodarone</e1>_5\NN\2715941 resulted_6\VBD\2633881 in_7\IN\13603305 the_8\DT\1740 disappearance_9\NN\42757 of_10\IN\1740 the_11\DT\1740 sinoatrial_12\JJ\1740 block_13\NN\21939 and_14\CC\1740 the_15\DT\1740 persistence_16\NN\5053688 of_17\IN\1740 asymptomatic_18\JJ\1740 <e2>sinus_19\NN\5248181 bradycardia</e2>_20\NN\14110674 ._21\.\1740
3425586
D003622_D000743 CID <e1>dapsone-associated</e1>_0\JJ\1740 heinz_1\NNP\1740 body_2\NN\19128 <e2>hemolytic_3\JJ\1740 anemia</e2>_4\NN\14189204 in_5\IN\13603305 a_6\DT\13649268 cambodian_7\JJ\1740 woman_8\NN\9605289 with_9\IN\1740 hemoglobin_10\NN\14888884 e_11\NN\14724645 trait_12\NN\24264 ._13\.\1740
D003622_D000743 CID a_0\DT\13649268 cambodian_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 hemoglobin_4\NN\14888884 e_5\NN\14724645 trait_6\NN\24264 (_7\-LRB-\1740 ae_8\NN\1740 )_9\-RRB-\1740 and_10\CC\1740 leprosy_11\NN\14127211 developed_12\VBD\1753788 a_13\DT\13649268 heinz_14\NNP\1740 body_15\NN\19128 <e2>hemolytic_16\JJ\1740 anemia</e2>_17\NN\14189204 while_18\IN\15122231 taking_19\VBG\2367363 a_20\DT\13649268 dose_21\NN\3740161 of_22\IN\1740 <e1>dapsone</e1>_23\NN\2716205 (_24\-LRB-\1740 50_25\CD\13745420 mg/day_26\NN\1740 )_27\-RRB-\1740 not_28\RB\1740 usually_29\RB\1740 associated_30\VBN\628491 with_31\IN\1740 clinical_32\JJ\1740 hemolysis_33\NN\13509528 ._34\.\1740
D003622_D000743 CID thus_0\RB\1740 ,_1\,\1740 ae_2\NN\1740 rbcs_3\NNS\5449268 appear_4\VBP\2604760 to_5\TO\1740 have_6\VB\2108377 an_7\DT\6697703 increased_8\VBN\169651 sensitivity_9\NN\5651971 to_10\TO\1740 oxidant_11\JJ\1740 stress_12\NN\7083732 both_13\CC\1740 in_14\FW\13603305 vitro_15\FW\1740 and_16\CC\1740 in_17\FW\13603305 vivo_18\FW\1740 ,_19\,\1740 since_20\IN\1740 <e1>dapsone</e1>_21\NN\2716205 does_22\VBZ\1640855 not_23\RB\1740 cause_24\VB\1617192 <e2>hemolytic_25\JJ\1740 anemia</e2>_26\NN\14189204 at_27\IN\14622893 this_28\DT\1740 dose_29\NN\3740161 in_30\IN\13603305 hematologically_31\RB\1740 normal_32\JJ\1740 individuals_33\NNS\7347 ._34\.\1740
D003622_D007918 NONE a_0\DT\13649268 cambodian_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 hemoglobin_4\NN\14888884 e_5\NN\14724645 trait_6\NN\24264 (_7\-LRB-\1740 ae_8\NN\1740 )_9\-RRB-\1740 and_10\CC\1740 <e2>leprosy</e2>_11\NN\14127211 developed_12\VBD\1753788 a_13\DT\13649268 heinz_14\NNP\1740 body_15\NN\19128 hemolytic_16\JJ\1740 anemia_17\NN\14189204 while_18\IN\15122231 taking_19\VBG\2367363 a_20\DT\13649268 dose_21\NN\3740161 of_22\IN\1740 <e1>dapsone</e1>_23\NN\2716205 (_24\-LRB-\1740 50_25\CD\13745420 mg/day_26\NN\1740 )_27\-RRB-\1740 not_28\RB\1740 usually_29\RB\1740 associated_30\VBN\628491 with_31\IN\1740 clinical_32\JJ\1740 hemolysis_33\NN\13509528 ._34\.\1740
D003622_D006461 NONE a_0\DT\13649268 cambodian_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 hemoglobin_4\NN\14888884 e_5\NN\14724645 trait_6\NN\24264 (_7\-LRB-\1740 ae_8\NN\1740 )_9\-RRB-\1740 and_10\CC\1740 leprosy_11\NN\14127211 developed_12\VBD\1753788 a_13\DT\13649268 heinz_14\NNP\1740 body_15\NN\19128 hemolytic_16\JJ\1740 anemia_17\NN\14189204 while_18\IN\15122231 taking_19\VBG\2367363 a_20\DT\13649268 dose_21\NN\3740161 of_22\IN\1740 <e1>dapsone</e1>_23\NN\2716205 (_24\-LRB-\1740 50_25\CD\13745420 mg/day_26\NN\1740 )_27\-RRB-\1740 not_28\RB\1740 usually_29\RB\1740 associated_30\VBN\628491 with_31\IN\1740 clinical_32\JJ\1740 <e2>hemolysis</e2>_33\NN\13509528 ._34\.\1740
15338796
D000420_D014202 CID <e2>tremor</e2>_0\NN\345926 side_1\NN\8630039 effects_2\NNS\13245626 of_3\IN\1740 <e1>salbutamol</e1>_4\NN\1740 ,_5\,\1740 quantified_6\VBN\947077 by_7\IN\1740 a_8\DT\13649268 laser_9\NN\3851341 pointer_10\NN\6817782 technique_11\NN\5660268 ._12\.\1740
D000420_D014202 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 study_3\VB\630380 <e2>tremor</e2>_4\NN\345926 side_5\NN\8630039 effects_6\NNS\13245626 of_7\IN\1740 <e1>salbutamol</e1>_8\JJ\1740 an_9\DT\6697703 easily_10\RB\1740 applicable_11\JJ\1740 ,_12\,\1740 quick_13\JJ\1740 and_14\CC\1740 low-priced_15\JJ\1740 method_16\NN\5616786 is_17\VBZ\836236 needed_18\VBN\2604760 ._19\.\1740
D000420_D014202 CID to_0\TO\1740 determine_1\VB\1645601 sensitivity_2\NN\5651971 we_3\PRP\1740 assessed_4\VBD\670261 <e2>tremor</e2>_5\NN\345926 in_6\IN\13603305 44_7\CD\1740 patients_8\NNS\9898892 with_9\IN\1740 obstructive_10\JJ\1740 lung_11\NN\5528060 disease_12\NN\14061805 after_13\IN\1740 administration_14\NN\1133281 of_15\IN\1740 cumulative_16\JJ\1740 doses_17\NNS\3740161 of_18\IN\1740 <e1>salbutamol</e1>_19\NN\1740 ._20\.\1740
D000420_D014202 CID results_0\NNS\34213 :_1\:\1740 <e1>salbutamol</e1>_2\NN\1740 significantly_3\RB\1740 increased_4\VBD\169651 <e2>tremor</e2>_5\NN\345926 severity_6\NN\5036394 in_7\IN\13603305 patients_8\NNS\9898892 in_9\IN\13603305 a_10\DT\13649268 dose-dependent_11\JJ\1740 way_12\NN\4916342 ._13\.\1740
D000420_D008173 NONE to_0\TO\1740 determine_1\VB\1645601 sensitivity_2\NN\5651971 we_3\PRP\1740 assessed_4\VBD\670261 tremor_5\NN\345926 in_6\IN\13603305 44_7\CD\1740 patients_8\NNS\9898892 with_9\IN\1740 <e2>obstructive_10\JJ\1740 lung_11\NN\5528060 disease</e2>_12\NN\14061805 after_13\IN\1740 administration_14\NN\1133281 of_15\IN\1740 cumulative_16\JJ\1740 doses_17\NNS\3740161 of_18\IN\1740 <e1>salbutamol</e1>_19\NN\1740 ._20\.\1740
3358181
D012312_D014693 CID <e2>ventricular_0\JJ\1740 tachyarrhythmias</e2>_1\NNS\1740 during_2\IN\1740 cesarean_3\JJ\1740 section_4\NN\7020895 after_5\IN\1740 <e1>ritodrine</e1>_6\NN\1740 therapy_7\NN\657604 :_8\:\1740 interaction_9\NN\37396 with_10\IN\1740 anesthetics_11\NNS\3247620 ._12\.\1740
D012312_D007752 NONE this_0\DT\1740 case_1\NN\7283608 illustrates_2\VBZ\955601 that_3\IN\1740 patients_4\NNS\9898892 receiving_5\VBG\2210855 <e1>ritodrine</e1>_6\NN\1740 for_7\IN\1740 <e2>preterm_8\NN\1740 labor</e2>_9\NN\7974025 may_10\MD\15209706 risk_11\VB\2530167 interactions_12\NNS\37396 between_13\IN\1740 the_14\DT\1740 residual_15\JJ\1740 betamimetic_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 ritodrine_19\NN\1740 and_20\CC\1740 the_21\DT\1740 effects_22\NNS\13245626 of_23\IN\1740 anesthetics_24\NNS\3247620 during_25\IN\1740 cesarean_26\JJ\1740 section_27\NN\7020895 ._28\.\1740
D012312_D007752 NONE this_0\DT\1740 case_1\NN\7283608 illustrates_2\VBZ\955601 that_3\IN\1740 patients_4\NNS\9898892 receiving_5\VBG\2210855 ritodrine_6\NN\1740 for_7\IN\1740 <e2>preterm_8\NN\1740 labor</e2>_9\NN\7974025 may_10\MD\15209706 risk_11\VB\2530167 interactions_12\NNS\37396 between_13\IN\1740 the_14\DT\1740 residual_15\JJ\1740 betamimetic_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 <e1>ritodrine</e1>_19\NN\1740 and_20\CC\1740 the_21\DT\1740 effects_22\NNS\13245626 of_23\IN\1740 anesthetics_24\NNS\3247620 during_25\IN\1740 cesarean_26\JJ\1740 section_27\NN\7020895 ._28\.\1740
D012312_D002318 NONE such_0\JJ\1740 interactions_1\NNS\37396 may_2\MD\15209706 result_3\VB\2633881 in_4\IN\13603305 serious_5\JJ\1740 <e2>cardiovascular_6\JJ\1740 complications</e2>_7\NNS\1073995 even_8\RB\1740 after_9\IN\1740 cessation_10\NN\7365849 of_11\IN\1740 an_12\DT\6697703 infusion_13\NN\14589223 of_14\IN\1740 <e1>ritodrine</e1>_15\NN\1740 ._16\.\1740
D010656_D007022 NONE after_0\IN\1740 delivery_1\NN\315986 of_2\IN\1740 the_3\DT\1740 infant_4\NN\9918248 ,_5\,\1740 there_6\EX\27167 should_7\MD\1740 be_8\VB\836236 no_9\DT\7204911 contraindication_10\NN\5819149 to_11\IN\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 an_15\DT\6697703 alpha-adrenergic_16\JJ\1740 vasopressor_17\NN\4522421 such_18\JJ\1740 as_19\IN\14622893 <e1>phenylephrine</e1>_20\NN\2682038 to_21\TO\1740 treat_22\VB\2376958 <e2>hypotensive</e2>_23\JJ\1740 patients_24\NNS\9898892 with_25\IN\1740 tachycardia_26\NN\14110674 ._27\.\1740
D010656_D013610 NONE after_0\IN\1740 delivery_1\NN\315986 of_2\IN\1740 the_3\DT\1740 infant_4\NN\9918248 ,_5\,\1740 there_6\EX\27167 should_7\MD\1740 be_8\VB\836236 no_9\DT\7204911 contraindication_10\NN\5819149 to_11\IN\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 an_15\DT\6697703 alpha-adrenergic_16\JJ\1740 vasopressor_17\NN\4522421 such_18\JJ\1740 as_19\IN\14622893 <e1>phenylephrine</e1>_20\NN\2682038 to_21\TO\1740 treat_22\VB\2376958 hypotensive_23\JJ\1740 patients_24\NNS\9898892 with_25\IN\1740 <e2>tachycardia</e2>_26\NN\14110674 ._27\.\1740
19581773
C417083_D009157 CID development_0\NN\248977 of_1\IN\1740 <e2>ocular_2\JJ\1740 myasthenia</e2>_3\NN\14187378 during_4\IN\1740 <e1>pegylated_5\JJ\1740 interferon</e1>_6\NN\2725367 and_7\CC\1740 ribavirin_8\NN\2725367 treatment_9\NN\654885 for_10\IN\1740 chronic_11\JJ\1740 hepatitis_12\NN\14127211 c._13\NN\1740
C417083_D009157 CID the_0\DT\1740 <e2>ocular_1\JJ\1740 myasthenia</e2>_2\NN\14187378 associated_3\VBN\628491 with_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 of_7\IN\1740 <e1>pegylated_8\JJ\1740 ifn_9\NN\1740 alpha-2b</e1>_10\NN\1740 and_11\CC\1740 ribavirin_12\NN\2725367 for_13\IN\1740 chc_14\NN\1740 is_15\VBZ\836236 very_16\RB\1740 rarely_17\RB\1740 reported_18\VBN\831651 ;_19\:\1740 therefore_20\RB\1740 ,_21\,\1740 we_22\PRP\1740 present_23\VBP\2137132 this_24\DT\1740 case_25\NN\7283608 with_26\IN\1740 a_27\DT\13649268 review_28\NN\5733583 of_29\IN\1740 the_30\DT\1740 various_31\JJ\1740 eye_32\NN\5299178 complications_33\NNS\1073995 of_34\IN\1740 ifn_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
C417083_D009157 CID the_0\DT\1740 <e2>ocular_1\JJ\1740 myasthenia</e2>_2\NN\14187378 associated_3\VBN\628491 with_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 of_7\IN\1740 pegylated_8\JJ\1740 ifn_9\NN\1740 alpha-2b_10\NN\1740 and_11\CC\1740 ribavirin_12\NN\2725367 for_13\IN\1740 chc_14\NN\1740 is_15\VBZ\836236 very_16\RB\1740 rarely_17\RB\1740 reported_18\VBN\831651 ;_19\:\1740 therefore_20\RB\1740 ,_21\,\1740 we_22\PRP\1740 present_23\VBP\2137132 this_24\DT\1740 case_25\NN\7283608 with_26\IN\1740 a_27\DT\13649268 review_28\NN\5733583 of_29\IN\1740 the_30\DT\1740 various_31\JJ\1740 eye_32\NN\5299178 complications_33\NNS\1073995 of_34\IN\1740 <e1>ifn</e1>_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
C417083_D019698 NONE development_0\NN\248977 of_1\IN\1740 ocular_2\JJ\1740 myasthenia_3\NN\14187378 during_4\IN\1740 <e1>pegylated_5\JJ\1740 interferon</e1>_6\NN\2725367 and_7\CC\1740 ribavirin_8\NN\2725367 treatment_9\NN\654885 for_10\IN\1740 <e2>chronic_11\JJ\1740 hepatitis_12\NN\14127211 c.</e2>_13\NN\1740
C417083_D019698 NONE a_0\DT\13649268 63-year-old_1\JJ\1740 male_2\JJ\1740 experienced_3\VBD\2108377 sudden_4\JJ\1740 diplopia_5\NN\14552802 after_6\IN\1740 9_7\CD\13741022 weeks_8\NNS\15113229 of_9\IN\1740 administration_10\NN\1133281 of_11\IN\1740 <e1>pegylated_12\JJ\1740 interferon_13\NN\2725367 (_14\-LRB-\1740 ifn_15\NN\1740 )_16\-RRB-\1740 alpha-2b</e1>_17\NN\1740 and_18\CC\1740 ribavirin_19\NN\2725367 for_20\IN\1740 <e2>chronic_21\JJ\1740 hepatitis_22\NN\14127211 c</e2>_23\NN\13714184 (_24\-LRB-\1740 chc_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
C417083_D019698 NONE a_0\DT\13649268 63-year-old_1\JJ\1740 male_2\JJ\1740 experienced_3\VBD\2108377 sudden_4\JJ\1740 diplopia_5\NN\14552802 after_6\IN\1740 9_7\CD\13741022 weeks_8\NNS\15113229 of_9\IN\1740 administration_10\NN\1133281 of_11\IN\1740 <e1>pegylated_12\JJ\1740 interferon_13\NN\2725367 (_14\-LRB-\1740 ifn_15\NN\1740 )_16\-RRB-\1740 alpha-2b</e1>_17\NN\1740 and_18\CC\1740 ribavirin_19\NN\2725367 for_20\IN\1740 chronic_21\JJ\1740 hepatitis_22\NN\14127211 c_23\NN\13714184 (_24\-LRB-\1740 <e2>chc</e2>_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
C417083_D019698 NONE the_0\DT\1740 ocular_1\JJ\1740 myasthenia_2\NN\14187378 associated_3\VBN\628491 with_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 of_7\IN\1740 <e1>pegylated_8\JJ\1740 ifn_9\NN\1740 alpha-2b</e1>_10\NN\1740 and_11\CC\1740 ribavirin_12\NN\2725367 for_13\IN\1740 <e2>chc</e2>_14\NN\1740 is_15\VBZ\836236 very_16\RB\1740 rarely_17\RB\1740 reported_18\VBN\831651 ;_19\:\1740 therefore_20\RB\1740 ,_21\,\1740 we_22\PRP\1740 present_23\VBP\2137132 this_24\DT\1740 case_25\NN\7283608 with_26\IN\1740 a_27\DT\13649268 review_28\NN\5733583 of_29\IN\1740 the_30\DT\1740 various_31\JJ\1740 eye_32\NN\5299178 complications_33\NNS\1073995 of_34\IN\1740 ifn_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
C417083_D019698 NONE the_0\DT\1740 ocular_1\JJ\1740 myasthenia_2\NN\14187378 associated_3\VBN\628491 with_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 of_7\IN\1740 pegylated_8\JJ\1740 ifn_9\NN\1740 alpha-2b_10\NN\1740 and_11\CC\1740 ribavirin_12\NN\2725367 for_13\IN\1740 <e2>chc</e2>_14\NN\1740 is_15\VBZ\836236 very_16\RB\1740 rarely_17\RB\1740 reported_18\VBN\831651 ;_19\:\1740 therefore_20\RB\1740 ,_21\,\1740 we_22\PRP\1740 present_23\VBP\2137132 this_24\DT\1740 case_25\NN\7283608 with_26\IN\1740 a_27\DT\13649268 review_28\NN\5733583 of_29\IN\1740 the_30\DT\1740 various_31\JJ\1740 eye_32\NN\5299178 complications_33\NNS\1073995 of_34\IN\1740 <e1>ifn</e1>_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
D012254_D009157 CID development_0\NN\248977 of_1\IN\1740 <e2>ocular_2\JJ\1740 myasthenia</e2>_3\NN\14187378 during_4\IN\1740 pegylated_5\JJ\1740 interferon_6\NN\2725367 and_7\CC\1740 <e1>ribavirin</e1>_8\NN\2725367 treatment_9\NN\654885 for_10\IN\1740 chronic_11\JJ\1740 hepatitis_12\NN\14127211 c._13\NN\1740
D012254_D009157 CID the_0\DT\1740 <e2>ocular_1\JJ\1740 myasthenia</e2>_2\NN\14187378 associated_3\VBN\628491 with_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 of_7\IN\1740 pegylated_8\JJ\1740 ifn_9\NN\1740 alpha-2b_10\NN\1740 and_11\CC\1740 <e1>ribavirin</e1>_12\NN\2725367 for_13\IN\1740 chc_14\NN\1740 is_15\VBZ\836236 very_16\RB\1740 rarely_17\RB\1740 reported_18\VBN\831651 ;_19\:\1740 therefore_20\RB\1740 ,_21\,\1740 we_22\PRP\1740 present_23\VBP\2137132 this_24\DT\1740 case_25\NN\7283608 with_26\IN\1740 a_27\DT\13649268 review_28\NN\5733583 of_29\IN\1740 the_30\DT\1740 various_31\JJ\1740 eye_32\NN\5299178 complications_33\NNS\1073995 of_34\IN\1740 ifn_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
D012254_D019698 NONE development_0\NN\248977 of_1\IN\1740 ocular_2\JJ\1740 myasthenia_3\NN\14187378 during_4\IN\1740 pegylated_5\JJ\1740 interferon_6\NN\2725367 and_7\CC\1740 <e1>ribavirin</e1>_8\NN\2725367 treatment_9\NN\654885 for_10\IN\1740 <e2>chronic_11\JJ\1740 hepatitis_12\NN\14127211 c.</e2>_13\NN\1740
D012254_D019698 NONE a_0\DT\13649268 63-year-old_1\JJ\1740 male_2\JJ\1740 experienced_3\VBD\2108377 sudden_4\JJ\1740 diplopia_5\NN\14552802 after_6\IN\1740 9_7\CD\13741022 weeks_8\NNS\15113229 of_9\IN\1740 administration_10\NN\1133281 of_11\IN\1740 pegylated_12\JJ\1740 interferon_13\NN\2725367 (_14\-LRB-\1740 ifn_15\NN\1740 )_16\-RRB-\1740 alpha-2b_17\NN\1740 and_18\CC\1740 <e1>ribavirin</e1>_19\NN\2725367 for_20\IN\1740 <e2>chronic_21\JJ\1740 hepatitis_22\NN\14127211 c</e2>_23\NN\13714184 (_24\-LRB-\1740 chc_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D012254_D019698 NONE a_0\DT\13649268 63-year-old_1\JJ\1740 male_2\JJ\1740 experienced_3\VBD\2108377 sudden_4\JJ\1740 diplopia_5\NN\14552802 after_6\IN\1740 9_7\CD\13741022 weeks_8\NNS\15113229 of_9\IN\1740 administration_10\NN\1133281 of_11\IN\1740 pegylated_12\JJ\1740 interferon_13\NN\2725367 (_14\-LRB-\1740 ifn_15\NN\1740 )_16\-RRB-\1740 alpha-2b_17\NN\1740 and_18\CC\1740 <e1>ribavirin</e1>_19\NN\2725367 for_20\IN\1740 chronic_21\JJ\1740 hepatitis_22\NN\14127211 c_23\NN\13714184 (_24\-LRB-\1740 <e2>chc</e2>_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D012254_D019698 NONE the_0\DT\1740 ocular_1\JJ\1740 myasthenia_2\NN\14187378 associated_3\VBN\628491 with_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 of_7\IN\1740 pegylated_8\JJ\1740 ifn_9\NN\1740 alpha-2b_10\NN\1740 and_11\CC\1740 <e1>ribavirin</e1>_12\NN\2725367 for_13\IN\1740 <e2>chc</e2>_14\NN\1740 is_15\VBZ\836236 very_16\RB\1740 rarely_17\RB\1740 reported_18\VBN\831651 ;_19\:\1740 therefore_20\RB\1740 ,_21\,\1740 we_22\PRP\1740 present_23\VBP\2137132 this_24\DT\1740 case_25\NN\7283608 with_26\IN\1740 a_27\DT\13649268 review_28\NN\5733583 of_29\IN\1740 the_30\DT\1740 various_31\JJ\1740 eye_32\NN\5299178 complications_33\NNS\1073995 of_34\IN\1740 ifn_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
C417083_D004172 NONE a_0\DT\13649268 63-year-old_1\JJ\1740 male_2\JJ\1740 experienced_3\VBD\2108377 sudden_4\JJ\1740 <e2>diplopia</e2>_5\NN\14552802 after_6\IN\1740 9_7\CD\13741022 weeks_8\NNS\15113229 of_9\IN\1740 administration_10\NN\1133281 of_11\IN\1740 <e1>pegylated_12\JJ\1740 interferon_13\NN\2725367 (_14\-LRB-\1740 ifn_15\NN\1740 )_16\-RRB-\1740 alpha-2b</e1>_17\NN\1740 and_18\CC\1740 ribavirin_19\NN\2725367 for_20\IN\1740 chronic_21\JJ\1740 hepatitis_22\NN\14127211 c_23\NN\13714184 (_24\-LRB-\1740 chc_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D012254_D004172 NONE a_0\DT\13649268 63-year-old_1\JJ\1740 male_2\JJ\1740 experienced_3\VBD\2108377 sudden_4\JJ\1740 <e2>diplopia</e2>_5\NN\14552802 after_6\IN\1740 9_7\CD\13741022 weeks_8\NNS\15113229 of_9\IN\1740 administration_10\NN\1133281 of_11\IN\1740 pegylated_12\JJ\1740 interferon_13\NN\2725367 (_14\-LRB-\1740 ifn_15\NN\1740 )_16\-RRB-\1740 alpha-2b_17\NN\1740 and_18\CC\1740 <e1>ribavirin</e1>_19\NN\2725367 for_20\IN\1740 chronic_21\JJ\1740 hepatitis_22\NN\14127211 c_23\NN\13714184 (_24\-LRB-\1740 chc_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
9088814
D000527_D007022 CID combined_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 prolonged_3\JJ\1740 <e1>prostaglandin_4\NN\5414534 e1-induced</e1>_5\JJ\1740 <e2>hypotension</e2>_6\NN\14057371 and_7\CC\1740 haemodilution_8\NN\1740 on_9\IN\1740 human_10\JJ\1740 hepatic_11\JJ\1740 function_12\NN\13783581 ._13\.\1740
D000527_D007022 CID combined_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 prolonged_3\JJ\1740 <e1>prostaglandin_4\NN\5414534 e1</e1>_5\NN\1740 (pge1)-induced_6\VBD\1740 <e2>hypotension</e2>_7\NN\14057371 and_8\CC\1740 haemodilution_9\NN\1740 on_10\IN\1740 hepatic_11\JJ\1740 function_12\NN\13783581 were_13\VBD\836236 studied_14\VBN\630380 in_15\IN\13603305 30_16\CD\13745420 patients_17\NNS\9898892 undergoing_18\VBG\109660 hip_19\NN\5220461 surgery_20\NN\6045562 ._21\.\1740
D000527_D007022 CID combined_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 prolonged_3\JJ\1740 prostaglandin_4\NN\5414534 e1_5\NN\1740 <e1>(pge1)-induced</e1>_6\VBD\1740 <e2>hypotension</e2>_7\NN\14057371 and_8\CC\1740 haemodilution_9\NN\1740 on_10\IN\1740 hepatic_11\JJ\1740 function_12\NN\13783581 were_13\VBD\836236 studied_14\VBN\630380 in_15\IN\13603305 30_16\CD\13745420 patients_17\NNS\9898892 undergoing_18\VBG\109660 hip_19\NN\5220461 surgery_20\NN\6045562 ._21\.\1740
D000527_D007022 CID controlled_0\VBN\2422663 <e2>hypotension</e2>_1\NN\14057371 in_2\IN\13603305 groups_3\NNS\2137 a_4\NN\13649268 and_5\CC\1740 c_6\NN\13714184 was_7\VBD\836236 induced_8\VBN\1627355 with_9\IN\1740 <e1>pge1</e1>_10\NN\1740 to_11\TO\1740 maintain_12\VB\2202928 mean_13\VB\928630 arterial_14\JJ\1740 blood_15\NN\5397468 pressure_16\NN\11419404 at_17\IN\14622893 55_18\CD\1740 mmhg_19\NN\1740 for_20\IN\1740 180_21\CD\1740 min_22\NN\15154774 ._23\.\1740
D000527_D007022 CID the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 a_4\DT\13649268 prolonged_5\JJ\1740 combination_6\NN\7951464 of_7\IN\1740 more_8\JJR\1740 than_9\IN\1740 120_10\CD\13745420 min_11\NN\15154774 of_12\IN\1740 <e1>pge1-induced</e1>_13\JJ\1740 <e2>hypotension</e2>_14\NN\14057371 and_15\CC\1740 moderate_16\JJ\1740 haemodilution_17\NN\1740 would_18\MD\1740 cause_19\VB\1617192 impairment_20\NN\7296428 of_21\IN\1740 hepatic_22\JJ\1740 function_23\NN\13783581 ._24\.\1740
D000527_D020141 NONE combined_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 prolonged_3\JJ\1740 <e1>prostaglandin_4\NN\5414534 e1-induced</e1>_5\JJ\1740 hypotension_6\NN\14057371 and_7\CC\1740 <e2>haemodilution</e2>_8\NN\1740 on_9\IN\1740 human_10\JJ\1740 hepatic_11\JJ\1740 function_12\NN\13783581 ._13\.\1740
D000527_D020141 NONE combined_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 prolonged_3\JJ\1740 <e1>prostaglandin_4\NN\5414534 e1</e1>_5\NN\1740 (pge1)-induced_6\VBD\1740 hypotension_7\NN\14057371 and_8\CC\1740 <e2>haemodilution</e2>_9\NN\1740 on_10\IN\1740 hepatic_11\JJ\1740 function_12\NN\13783581 were_13\VBD\836236 studied_14\VBN\630380 in_15\IN\13603305 30_16\CD\13745420 patients_17\NNS\9898892 undergoing_18\VBG\109660 hip_19\NN\5220461 surgery_20\NN\6045562 ._21\.\1740
D000527_D020141 NONE combined_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 prolonged_3\JJ\1740 prostaglandin_4\NN\5414534 e1_5\NN\1740 <e1>(pge1)-induced</e1>_6\VBD\1740 hypotension_7\NN\14057371 and_8\CC\1740 <e2>haemodilution</e2>_9\NN\1740 on_10\IN\1740 hepatic_11\JJ\1740 function_12\NN\13783581 were_13\VBD\836236 studied_14\VBN\630380 in_15\IN\13603305 30_16\CD\13745420 patients_17\NNS\9898892 undergoing_18\VBG\109660 hip_19\NN\5220461 surgery_20\NN\6045562 ._21\.\1740
D000527_D020141 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 a_4\DT\13649268 prolonged_5\JJ\1740 combination_6\NN\7951464 of_7\IN\1740 more_8\JJR\1740 than_9\IN\1740 120_10\CD\13745420 min_11\NN\15154774 of_12\IN\1740 <e1>pge1-induced</e1>_13\JJ\1740 hypotension_14\NN\14057371 and_15\CC\1740 moderate_16\JJ\1740 <e2>haemodilution</e2>_17\NN\1740 would_18\MD\1740 cause_19\VB\1617192 impairment_20\NN\7296428 of_21\IN\1740 hepatic_22\JJ\1740 function_23\NN\13783581 ._24\.\1740
D003911_D020141 NONE <e2>haemodilution</e2>_0\NN\1740 in_1\IN\13603305 groups_2\NNS\2137 b_3\NN\1355326 and_4\CC\1740 c_5\NN\13714184 was_6\VBD\836236 produced_7\VBN\1617192 by_8\IN\1740 withdrawing_9\VBG\1835496 approximately_10\RB\1740 1000_11\CD\13745420 ml_12\NN\13616054 of_13\IN\1740 blood_14\NN\5397468 and_15\CC\1740 replacing_16\VBG\1631072 it_17\PRP\6125041 with_18\IN\1740 the_19\DT\1740 same_20\JJ\1740 amount_21\NN\13329641 of_22\IN\1740 <e1>dextran</e1>_23\NN\1740 solution_24\NN\14586258 ,_25\,\1740 and_26\CC\1740 final_27\JJ\1740 haematocrit_28\NN\13819207 values_29\NNS\5941423 were_30\VBD\836236 21_31\CD\13745420 or_32\CC\3541091 22_33\CD\13745420 %_34\NN\1740 ._35\.\1740
D001663_D007022 NONE akbr_0\NN\1740 and_1\CC\1740 biological_2\JJ\1740 hepatic_3\JJ\1740 function_4\NN\13783581 tests_5\NNS\5798043 showed_6\VBD\2137132 no_7\DT\7204911 change_8\NN\7283608 throughout_9\IN\1740 the_10\DT\1740 time_11\NN\7308889 course_12\NN\883297 in_13\IN\13603305 groups_14\NNS\2137 a_15\NN\13649268 and_16\CC\1740 b._17\NN\1740 in_18\IN\13603305 group_19\NN\2137 c_20\NN\13714184 ,_21\,\1740 akbr_22\NN\1740 showed_23\VBD\2137132 a_24\DT\13649268 significant_25\JJ\1740 decrease_26\NN\7296428 at_27\IN\14622893 120_28\CD\13745420 min_29\NN\15154774 (_30\-LRB-\1740 -40_31\CD\1740 %_32\NN\1740 )_33\-RRB-\1740 and_34\CC\1740 at_35\IN\14622893 180_36\CD\1740 min_37\NN\15154774 (_38\-LRB-\1740 -49_39\CD\1740 %_40\NN\1740 )_41\-RRB-\1740 after_42\IN\1740 the_43\DT\1740 start_44\NN\7290905 of_45\IN\1740 <e2>hypotension</e2>_46\NN\14057371 and_47\CC\1740 at_48\IN\14622893 60_49\CD\13745420 min_50\NN\15154774 (_51\-LRB-\1740 -32_52\CD\1740 %_53\NN\1740 )_54\-RRB-\1740 after_55\IN\1740 recovery_56\NN\7357388 of_57\IN\1740 normotension_58\NN\1740 ,_59\,\1740 and_60\CC\1740 sgot_61\NNS\1740 ,_62\,\1740 sgpt_63\NN\1740 ,_64\,\1740 ldh_65\NN\1740 and_66\CC\1740 total_67\JJ\1740 <e1>bilirubin</e1>_68\NN\14756039 showed_69\VBD\2137132 significant_70\JJ\1740 increases_71\NNS\13576355 after_72\IN\1740 operation_73\NN\14006945 ._74\.\1740
D000527_D008107 CID the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 a_4\DT\13649268 prolonged_5\JJ\1740 combination_6\NN\7951464 of_7\IN\1740 more_8\JJR\1740 than_9\IN\1740 120_10\CD\13745420 min_11\NN\15154774 of_12\IN\1740 <e1>pge1-induced</e1>_13\JJ\1740 hypotension_14\NN\14057371 and_15\CC\1740 moderate_16\JJ\1740 haemodilution_17\NN\1740 would_18\MD\1740 cause_19\VB\1617192 <e2>impairment_20\NN\7296428 of_21\IN\1740 hepatic_22\JJ\1740 function</e2>_23\NN\13783581 ._24\.\1740
18726058
D010208_D020301 NONE background_0\NN\4921011 :_1\:\1740 <e1>papaverine_2\NNP\3800001 hydrochloride</e1>_3\NN\14817592 is_4\VBZ\836236 a_5\DT\13649268 direct-acting_6\JJ\1740 vasodilator_7\NN\3198383 used_8\VBN\1156834 to_9\TO\1740 manage_10\VB\2524171 <e2>vasospasm</e2>_11\NN\1740 during_12\IN\1740 various_13\JJ\1740 neurosurgical_14\JJ\1740 operations_15\NNS\1106808 ._16\.\1740
D010208_D020301 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 conducted_3\VBD\2436349 a_4\DT\13649268 retrospective_5\JJ\1740 review_6\NN\5733583 of_7\IN\1740 70_8\CD\13745420 consecutive_9\JJ\1740 microvascular_10\JJ\1740 decompression_11\NN\617059 operations_12\NNS\1106808 and_13\CC\1740 studied_14\VBD\630380 those_15\DT\1740 patients_16\NNS\9898892 who_17\WP\8299493 received_18\VBD\2210855 topical_19\JJ\1740 <e1>papaverine</e1>_20\NN\3800001 for_21\IN\1740 <e2>vasospasm</e2>_22\NN\1740 ._23\.\1740
D010208_D020301 NONE topical_0\JJ\1740 <e1>papaverine</e1>_1\NN\3800001 was_2\VBD\836236 used_3\VBN\1156834 as_4\IN\14622893 a_5\DT\13649268 direct_6\JJ\1740 therapeutic_7\JJ\1740 action_8\NN\30358 to_9\TO\1740 manage_10\VB\2524171 <e2>vasospasm</e2>_11\NN\1740 in_12\IN\13603305 a_13\DT\13649268 total_14\NN\3553 of_15\IN\1740 11_16\CD\13745420 patients_17\NNS\9898892 ._18\.\1740
D010208_D020301 NONE conclusions_0\NNS\5837957 :_1\:\1740 topical_2\JJ\1740 <e1>papaverine</e1>_3\NN\3800001 for_4\IN\1740 the_5\DT\1740 treatment_6\NN\654885 of_7\IN\1740 <e2>vasospasm</e2>_8\NN\1740 was_9\VBD\836236 associated_10\VBN\628491 with_11\IN\1740 the_12\DT\1740 onset_13\NN\7325190 of_14\IN\1740 a_15\DT\13649268 transient_16\JJ\1740 disturbance_17\NN\407535 in_18\IN\13603305 neurophysiological_19\JJ\1740 function_20\NN\13783581 of_21\IN\1740 the_22\DT\1740 ascending_23\VBG\1835496 auditory_24\JJ\1740 brainstem_25\NN\5462674 pathway_26\NN\5483677 ._27\.\1740
D010208_D003389 NONE transient_0\JJ\1740 <e2>cranial_1\JJ\1740 nerve_2\NN\5475681 dysfunction</e2>_3\NN\14204950 has_4\VBZ\2108377 been_5\VBN\836236 described_6\VBN\1001294 in_7\IN\13603305 a_8\DT\13649268 few_9\JJ\1740 cases_10\NNS\7283608 with_11\IN\1740 topical_12\JJ\1740 <e1>papaverine</e1>_13\NN\3800001 ._14\.\1740
D010208_D003389 NONE recommendations_0\NNS\6671484 to_1\TO\1740 avoid_2\VB\2452885 potential_3\JJ\1740 <e2>cranial_4\JJ\1740 nerve_5\NN\5475681 deficits</e2>_6\NNS\5113133 from_7\IN\1740 <e1>papaverine</e1>_8\NN\3800001 are_9\VBP\836236 provided_10\VBN\2199590 ._11\.\1740
17639754
D014859_D006470 CID we_0\PRP\1740 report_1\VBP\831651 3_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 serious_5\JJ\1740 <e2>bleeding</e2>_6\VBG\104868 complications_7\NNS\1073995 that_8\WDT\1740 appear_9\VBP\2604760 to_10\TO\1740 be_11\VB\836236 the_12\DT\1740 result_13\NN\34213 of_14\IN\1740 the_15\DT\1740 interaction_16\NN\37396 between_17\IN\1740 <e1>warfarin</e1>_18\NN\2718259 and_19\CC\1740 levofloxacin_20\NN\1740 ._21\.\1740
D064704_D006470 CID we_0\PRP\1740 report_1\VBP\831651 3_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 serious_5\JJ\1740 <e2>bleeding</e2>_6\VBG\104868 complications_7\NNS\1073995 that_8\WDT\1740 appear_9\VBP\2604760 to_10\TO\1740 be_11\VB\836236 the_12\DT\1740 result_13\NN\34213 of_14\IN\1740 the_15\DT\1740 interaction_16\NN\37396 between_17\IN\1740 warfarin_18\NN\2718259 and_19\CC\1740 <e1>levofloxacin</e1>_20\NN\1740 ._21\.\1740
19473225
D018698_D010523 NONE long-term_0\JJ\1740 <e1>glutamate</e1>_1\JJ\1740 supplementation_2\NN\5108947 failed_3\VBD\1798936 to_4\TO\1740 protect_5\VB\1127795 against_6\IN\1740 <e2>peripheral_7\JJ\1740 neurotoxicity</e2>_8\NN\1740 of_9\IN\1740 paclitaxel_10\NN\1740 ._11\.\1740
D018698_D010523 NONE toxic_0\JJ\1740 <e2>peripheral_1\JJ\1740 neuropathy</e2>_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 pac_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 <e1>glutamate</e1>_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 glutamine_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 pac_30\NN\8324514 neurotoxicity_31\NN\1740 ._32\.\1740
D018698_D010523 NONE toxic_0\JJ\1740 <e2>peripheral_1\JJ\1740 neuropathy</e2>_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 pac_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 glutamate_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 <e1>glutamine</e1>_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 pac_30\NN\8324514 neurotoxicity_31\NN\1740 ._32\.\1740
D018698_D010523 NONE this_0\DT\1740 pilot_1\NN\9826204 trial_2\NN\786195 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 role_7\NN\719494 of_8\IN\1740 <e1>glutamate</e1>_9\JJ\1740 supplementation_10\NN\5108947 for_11\IN\1740 preventing_12\VBG\1740 pac-induced_13\JJ\1740 <e2>peripheral_14\JJ\1740 neuropathy</e2>_15\NN\14204950 in_16\IN\13603305 a_17\DT\13649268 randomized_18\JJ\1740 ,_19\,\1740 placebo-controlled_20\JJ\1740 ,_21\,\1740 double-blinded_22\JJ\1740 clinical_23\JJ\1740 and_24\CC\1740 electro-diagnostic_25\JJ\1740 study_26\NN\635850 ._27\.\1740
D018698_D010523 NONE this_0\DT\1740 pilot_1\NN\9826204 study_2\NN\635850 leads_3\VBZ\1752884 to_4\TO\1740 the_5\DT\1740 conclusion_6\NN\5837957 that_7\WDT\1740 <e1>glutamate</e1>_8\VBP\1740 supplementation_9\NN\5108947 at_10\IN\14622893 the_11\DT\1740 chosen_12\VBN\697589 regimen_13\NN\5898568 fails_14\VBZ\1798936 to_15\TO\1740 protect_16\VB\1127795 against_17\IN\1740 <e2>peripheral_18\JJ\1740 neurotoxicity</e2>_19\NN\1740 of_20\IN\1740 pac_21\NN\8324514 ._22\.\1740
D017239_D010523 CID long-term_0\JJ\1740 glutamate_1\JJ\1740 supplementation_2\NN\5108947 failed_3\VBD\1798936 to_4\TO\1740 protect_5\VB\1127795 against_6\IN\1740 <e2>peripheral_7\JJ\1740 neurotoxicity</e2>_8\NN\1740 of_9\IN\1740 <e1>paclitaxel</e1>_10\NN\1740 ._11\.\1740
D017239_D010523 CID toxic_0\JJ\1740 <e2>peripheral_1\JJ\1740 neuropathy</e2>_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 <e1>paclitaxel</e1>_12\NN\1740 (_13\-LRB-\1740 pac_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 glutamate_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 glutamine_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 pac_30\NN\8324514 neurotoxicity_31\NN\1740 ._32\.\1740
D017239_D010523 CID toxic_0\JJ\1740 <e2>peripheral_1\JJ\1740 neuropathy</e2>_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 <e1>pac</e1>_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 glutamate_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 glutamine_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 pac_30\NN\8324514 neurotoxicity_31\NN\1740 ._32\.\1740
D017239_D010523 CID toxic_0\JJ\1740 <e2>peripheral_1\JJ\1740 neuropathy</e2>_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 pac_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 glutamate_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 glutamine_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 <e1>pac</e1>_30\NN\8324514 neurotoxicity_31\NN\1740 ._32\.\1740
D017239_D010523 CID this_0\DT\1740 pilot_1\NN\9826204 trial_2\NN\786195 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 role_7\NN\719494 of_8\IN\1740 glutamate_9\JJ\1740 supplementation_10\NN\5108947 for_11\IN\1740 preventing_12\VBG\1740 <e1>pac-induced</e1>_13\JJ\1740 <e2>peripheral_14\JJ\1740 neuropathy</e2>_15\NN\14204950 in_16\IN\13603305 a_17\DT\13649268 randomized_18\JJ\1740 ,_19\,\1740 placebo-controlled_20\JJ\1740 ,_21\,\1740 double-blinded_22\JJ\1740 clinical_23\JJ\1740 and_24\CC\1740 electro-diagnostic_25\JJ\1740 study_26\NN\635850 ._27\.\1740
D017239_D010523 CID this_0\DT\1740 pilot_1\NN\9826204 study_2\NN\635850 leads_3\VBZ\1752884 to_4\TO\1740 the_5\DT\1740 conclusion_6\NN\5837957 that_7\WDT\1740 glutamate_8\VBP\1740 supplementation_9\NN\5108947 at_10\IN\14622893 the_11\DT\1740 chosen_12\VBN\697589 regimen_13\NN\5898568 fails_14\VBZ\1798936 to_15\TO\1740 protect_16\VB\1127795 against_17\IN\1740 <e2>peripheral_18\JJ\1740 neurotoxicity</e2>_19\NN\1740 of_20\IN\1740 <e1>pac</e1>_21\NN\8324514 ._22\.\1740
D017239_D020258 NONE toxic_0\JJ\1740 peripheral_1\JJ\1740 neuropathy_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 <e1>paclitaxel</e1>_12\NN\1740 (_13\-LRB-\1740 pac_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 glutamate_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 glutamine_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 pac_30\NN\8324514 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D017239_D020258 NONE toxic_0\JJ\1740 peripheral_1\JJ\1740 neuropathy_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 <e1>pac</e1>_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 glutamate_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 glutamine_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 pac_30\NN\8324514 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D017239_D020258 NONE toxic_0\JJ\1740 peripheral_1\JJ\1740 neuropathy_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 pac_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 glutamate_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 glutamine_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 <e1>pac</e1>_30\NN\8324514 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D018698_D020258 NONE toxic_0\JJ\1740 peripheral_1\JJ\1740 neuropathy_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 pac_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 <e1>glutamate</e1>_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 glutamine_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 pac_30\NN\8324514 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D018698_D020258 NONE toxic_0\JJ\1740 peripheral_1\JJ\1740 neuropathy_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 pac_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 glutamate_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 amino_23\NN\14621446 acid_24\NN\14818238 <e1>glutamine</e1>_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 pac_30\NN\8324514 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D000596_D010523 NONE toxic_0\JJ\1740 <e2>peripheral_1\JJ\1740 neuropathy</e2>_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 pac_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 glutamate_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 <e1>amino_23\NN\14621446 acid</e1>_24\NN\14818238 glutamine_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 pac_30\NN\8324514 neurotoxicity_31\NN\1740 ._32\.\1740
D000596_D020258 NONE toxic_0\JJ\1740 peripheral_1\JJ\1740 neuropathy_2\NN\14204950 is_3\VBZ\836236 still_4\RB\1740 a_5\DT\13649268 significant_6\JJ\1740 limiting_7\NN\13796779 factor_8\NN\7326557 for_9\IN\1740 chemotherapy_10\NN\661091 with_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 pac_14\NN\8324514 )_15\-RRB-\1740 ,_16\,\1740 although_17\IN\1740 glutamate_18\NN\15010703 and_19\CC\1740 its_20\PRP$\6125041 closely_21\RB\1740 related_22\JJ\1740 <e1>amino_23\NN\14621446 acid</e1>_24\NN\14818238 glutamine_25\NN\14601829 were_26\VBD\836236 claimed_27\VBN\1011725 to_28\TO\1740 ameliorate_29\VB\126264 pac_30\NN\8324514 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D017239_D010051 NONE forty-three_0\JJ\1740 <e2>ovarian_1\NN\1740 cancer</e2>_2\NN\14239425 patients_3\NNS\9898892 were_4\VBD\836236 available_5\JJ\1740 for_6\IN\1740 analysis_7\NN\633864 following_8\VBG\1835496 six_9\CD\13741022 cycles_10\NNS\15269513 of_11\IN\1740 the_12\DT\1740 same_13\JJ\1740 <e1>pac-containing</e1>_14\JJ\1740 regimen_15\NNS\5898568 :_16\:\1740 23_17\CD\13745420 had_18\VBD\2108377 been_19\VBN\836236 supplemented_20\VBN\182406 by_21\IN\1740 glutamate_22\NN\15010703 all_23\RB\1740 along_24\IN\1740 the_25\DT\1740 treatment_26\NN\654885 period_27\NN\13575869 ,_28\,\1740 at_29\IN\14622893 a_30\DT\13649268 daily_31\JJ\1740 dose_32\NN\3740161 of_33\IN\1740 three_34\CD\13741022 times_35\NNS\15113229 500_36\CD\13745420 mg_37\NN\13717155 (_38\-LRB-\1740 group_39\NN\2137 g_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 20_44\CD\13745420 had_45\VBD\2108377 received_46\VBN\2210855 a_47\DT\13649268 placebo_48\NN\3740161 (_49\-LRB-\1740 group_50\NN\2137 p_51\NN\14622893 )_52\-RRB-\1740 ._53\.\1740
D018698_D010051 NONE forty-three_0\JJ\1740 <e2>ovarian_1\NN\1740 cancer</e2>_2\NN\14239425 patients_3\NNS\9898892 were_4\VBD\836236 available_5\JJ\1740 for_6\IN\1740 analysis_7\NN\633864 following_8\VBG\1835496 six_9\CD\13741022 cycles_10\NNS\15269513 of_11\IN\1740 the_12\DT\1740 same_13\JJ\1740 pac-containing_14\JJ\1740 regimen_15\NNS\5898568 :_16\:\1740 23_17\CD\13745420 had_18\VBD\2108377 been_19\VBN\836236 supplemented_20\VBN\182406 by_21\IN\1740 <e1>glutamate</e1>_22\NN\15010703 all_23\RB\1740 along_24\IN\1740 the_25\DT\1740 treatment_26\NN\654885 period_27\NN\13575869 ,_28\,\1740 at_29\IN\14622893 a_30\DT\13649268 daily_31\JJ\1740 dose_32\NN\3740161 of_33\IN\1740 three_34\CD\13741022 times_35\NNS\15113229 500_36\CD\13745420 mg_37\NN\13717155 (_38\-LRB-\1740 group_39\NN\2137 g_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 and_43\CC\1740 20_44\CD\13745420 had_45\VBD\2108377 received_46\VBN\2210855 a_47\DT\13649268 placebo_48\NN\3740161 (_49\-LRB-\1740 group_50\NN\2137 p_51\NN\14622893 )_52\-RRB-\1740 ._53\.\1740
435349
D013390_D005207 CID <e1>suxamethonium</e1>_0\NN\1740 infusion_1\NN\14589223 rate_2\NN\13815152 and_3\CC\1740 observed_4\VBN\2163746 <e2>fasciculations</e2>_5\NNS\14361664 ._6\.\1740
D013390_D013746 NONE the_0\DT\1740 infusion_1\NN\14589223 was_2\VBD\836236 discontinued_3\VBN\2609764 either_4\CC\1740 when_5\WRB\1740 there_6\EX\27167 was_7\VBD\836236 no_8\DT\7204911 muscular_9\JJ\1740 response_10\NN\11410625 to_11\TO\1740 <e2>tetanic</e2>_12\JJ\1740 stimulation_13\NN\242808 of_14\IN\1740 the_15\DT\1740 ulnar_16\JJ\1740 nerve_17\NN\5475681 or_18\CC\3541091 when_19\WRB\1740 <e1>sch</e1>_20\NN\1740 120_21\CD\13745420 mg_22\NN\13717155 was_23\VBD\836236 exceeded_24\VBN\2673965 ._25\.\1740
3827439
D000666_D058186 CID recurrent_0\JJ\1740 reversible_1\JJ\1740 <e2>acute_2\JJ\1740 renal_3\JJ\1740 failure</e2>_4\NN\66216 from_5\IN\1740 <e1>amphotericin</e1>_6\NN\2716866 ._7\.\1740
D000666_D058186 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 cryptogenic_3\JJ\1740 cirrhosis_4\NN\14116321 and_5\CC\1740 disseminated_6\JJ\1740 sporotrichosis_7\NN\14176895 developed_8\VBD\1753788 <e2>acute_9\JJ\1740 renal_10\JJ\1740 failure</e2>_11\NN\66216 immediately_12\RB\1740 following_13\VBG\1835496 the_14\DT\1740 administration_15\NN\1133281 of_16\IN\1740 <e1>amphotericin_17\NN\2716866 b</e1>_18\NN\1355326 on_19\IN\1740 four_20\CD\13741022 separate_21\JJ\1740 occasions_22\NNS\5983801 ._23\.\1740
D000666_D058186 CID we_0\PRP\1740 propose_1\VBP\1010118 that_2\IN\1740 <e1>amphotericin</e1>_3\NN\2716866 ,_4\,\1740 in_5\IN\13603305 the_6\DT\1740 setting_7\NN\8567235 of_8\IN\1740 reduced_9\VBN\441445 effective_10\JJ\1740 arterial_11\JJ\1740 volume_12\NN\33615 ,_13\,\1740 may_14\MD\15209706 activate_15\VB\1641914 tubuloglomerular_16\JJ\1740 feedback_17\NN\13518963 ,_18\,\1740 thereby_19\RB\1740 contributing_20\VBG\126264 to_21\TO\1740 <e2>acute_22\JJ\1740 renal_23\JJ\1740 failure</e2>_24\NN\66216 ._25\.\1740
D000666_D005355 NONE a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 cryptogenic_3\JJ\1740 <e2>cirrhosis</e2>_4\NN\14116321 and_5\CC\1740 disseminated_6\JJ\1740 sporotrichosis_7\NN\14176895 developed_8\VBD\1753788 acute_9\JJ\1740 renal_10\JJ\1740 failure_11\NN\66216 immediately_12\RB\1740 following_13\VBG\1835496 the_14\DT\1740 administration_15\NN\1133281 of_16\IN\1740 <e1>amphotericin_17\NN\2716866 b</e1>_18\NN\1355326 on_19\IN\1740 four_20\CD\13741022 separate_21\JJ\1740 occasions_22\NNS\5983801 ._23\.\1740
D000666_D013174 NONE a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 cryptogenic_3\JJ\1740 cirrhosis_4\NN\14116321 and_5\CC\1740 disseminated_6\JJ\1740 <e2>sporotrichosis</e2>_7\NN\14176895 developed_8\VBD\1753788 acute_9\JJ\1740 renal_10\JJ\1740 failure_11\NN\66216 immediately_12\RB\1740 following_13\VBG\1835496 the_14\DT\1740 administration_15\NN\1133281 of_16\IN\1740 <e1>amphotericin_17\NN\2716866 b</e1>_18\NN\1355326 on_19\IN\1740 four_20\CD\13741022 separate_21\JJ\1740 occasions_22\NNS\5983801 ._23\.\1740
20667451
D003474_D003072 NONE <e1>curcumin</e1>_0\NN\1740 ameliorates_1\VBZ\126264 <e2>cognitive_2\JJ\1740 dysfunction</e2>_3\NN\14204950 and_4\CC\1740 oxidative_5\JJ\1740 damage_6\NN\7296428 in_7\IN\13603305 phenobarbitone_8\NN\2792049 and_9\CC\1740 carbamazepine_10\NN\1740 administered_11\JJ\1740 rats_12\NNS\2329401 ._13\.\1740
D003474_D003072 NONE therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 present_3\JJ\1740 study_4\NN\635850 was_5\VBD\836236 carried_6\VBN\1850315 out_7\RP\1740 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 effect_11\NN\34213 of_12\IN\1740 chronic_13\JJ\1740 <e1>curcumin</e1>_14\NN\1740 administration_15\NN\1133281 on_16\IN\1740 phenobarbitone-_17\NN\1740 and_18\CC\1740 carbamazepine-induced_19\JJ\1740 <e2>cognitive_20\JJ\1740 impairment</e2>_21\NN\7296428 and_22\CC\1740 oxidative_23\JJ\1740 stress_24\NN\7083732 in_25\IN\13603305 rats_26\NNS\2329401 ._27\.\1740
D003474_D003072 NONE concomitant_0\JJ\1740 <e1>curcumin</e1>_1\NN\1740 administration_2\NN\1133281 prevented_3\VBD\1740 the_4\DT\1740 <e2>cognitive_5\JJ\1740 impairment</e2>_6\NN\7296428 and_7\CC\1740 decreased_8\VBD\169651 the_9\DT\1740 increased_10\VBN\169651 oxidative_11\JJ\1740 stress_12\NN\7083732 induced_13\VBN\1627355 by_14\IN\1740 these_15\DT\1740 antiepileptic_16\JJ\1740 drugs_17\NNS\14778436 ._18\.\1740
D003474_D003072 NONE these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 <e1>curcumin</e1>_4\NN\1740 has_5\VBZ\2108377 beneficial_6\JJ\1740 effect_7\NN\34213 in_8\IN\13603305 mitigating_9\VBG\894738 the_10\DT\1740 <e2>deterioration_11\NN\14560612 of_12\IN\1740 cognitive_13\JJ\1740 functions</e2>_14\NNS\13783581 and_15\CC\1740 oxidative_16\JJ\1740 damage_17\NN\7296428 in_18\IN\13603305 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 phenobarbitone_22\NN\2792049 and_23\CC\1740 carbamazepine_24\NN\1740 without_25\IN\1740 significantly_26\RB\1740 altering_27\VBG\126264 their_28\PRP$\1740 serum_29\NN\5397468 concentrations_30\NNS\4916342 ._31\.\1740
D003474_D003072 NONE the_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>curcumin</e1>_4\NN\1740 can_5\MD\3094503 be_6\VB\836236 considered_7\VBN\689344 as_8\IN\14622893 a_9\DT\13649268 potential_10\JJ\1740 safe_11\JJ\1740 and_12\CC\1740 effective_13\JJ\1740 adjuvant_14\JJ\1740 to_15\TO\1740 phenobarbitone_16\NN\2792049 and_17\CC\1740 carbamazepine_18\NN\1740 therapy_19\NN\657604 in_20\IN\13603305 preventing_21\VBG\1740 <e2>cognitive_22\JJ\1740 impairment</e2>_23\NN\7296428 associated_24\VBN\628491 with_25\IN\1740 these_26\DT\1740 drugs_27\NNS\14778436 ._28\.\1740
D010634_D003072 CID curcumin_0\NN\1740 ameliorates_1\VBZ\126264 <e2>cognitive_2\JJ\1740 dysfunction</e2>_3\NN\14204950 and_4\CC\1740 oxidative_5\JJ\1740 damage_6\NN\7296428 in_7\IN\13603305 <e1>phenobarbitone</e1>_8\NN\2792049 and_9\CC\1740 carbamazepine_10\NN\1740 administered_11\JJ\1740 rats_12\NNS\2329401 ._13\.\1740
D010634_D003072 CID the_0\DT\1740 antiepileptic_1\JJ\1740 drugs_2\NNS\14778436 ,_3\,\1740 <e1>phenobarbitone</e1>_4\NN\2792049 and_5\CC\1740 carbamazepine_6\NN\1740 are_7\VBP\836236 well_8\RB\1740 known_9\VBN\2110220 to_10\TO\1740 cause_11\VB\1617192 <e2>cognitive_12\JJ\1740 impairment</e2>_13\NN\7296428 on_14\IN\1740 chronic_15\JJ\1740 use_16\NN\407535 ._17\.\1740
D010634_D003072 CID therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 present_3\JJ\1740 study_4\NN\635850 was_5\VBD\836236 carried_6\VBN\1850315 out_7\RP\1740 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 effect_11\NN\34213 of_12\IN\1740 chronic_13\JJ\1740 curcumin_14\NN\1740 administration_15\NN\1133281 on_16\IN\1740 <e1>phenobarbitone-</e1>_17\NN\1740 and_18\CC\1740 carbamazepine-induced_19\JJ\1740 <e2>cognitive_20\JJ\1740 impairment</e2>_21\NN\7296428 and_22\CC\1740 oxidative_23\JJ\1740 stress_24\NN\7083732 in_25\IN\13603305 rats_26\NNS\2329401 ._27\.\1740
D010634_D003072 CID the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>phenobarbitone</e1>_3\NN\2792049 and_4\CC\1740 carbamazepine_5\NN\1740 for_6\IN\1740 21days_7\NNS\1740 caused_8\VBD\1617192 a_9\DT\13649268 significant_10\JJ\1740 <e2>impairment_11\NN\7296428 of_12\IN\1740 learning_13\NN\5701944 and_14\CC\1740 memory</e2>_15\NN\5926676 as_16\RB\1740 well_17\RB\1740 as_18\IN\14622893 an_19\DT\6697703 increased_20\VBN\169651 oxidative_21\JJ\1740 stress_22\NN\7083732 ._23\.\1740
D010634_D003072 CID these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 curcumin_4\NN\1740 has_5\VBZ\2108377 beneficial_6\JJ\1740 effect_7\NN\34213 in_8\IN\13603305 mitigating_9\VBG\894738 the_10\DT\1740 <e2>deterioration_11\NN\14560612 of_12\IN\1740 cognitive_13\JJ\1740 functions</e2>_14\NNS\13783581 and_15\CC\1740 oxidative_16\JJ\1740 damage_17\NN\7296428 in_18\IN\13603305 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 <e1>phenobarbitone</e1>_22\NN\2792049 and_23\CC\1740 carbamazepine_24\NN\1740 without_25\IN\1740 significantly_26\RB\1740 altering_27\VBG\126264 their_28\PRP$\1740 serum_29\NN\5397468 concentrations_30\NNS\4916342 ._31\.\1740
D010634_D003072 CID the_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 curcumin_4\NN\1740 can_5\MD\3094503 be_6\VB\836236 considered_7\VBN\689344 as_8\IN\14622893 a_9\DT\13649268 potential_10\JJ\1740 safe_11\JJ\1740 and_12\CC\1740 effective_13\JJ\1740 adjuvant_14\JJ\1740 to_15\TO\1740 <e1>phenobarbitone</e1>_16\NN\2792049 and_17\CC\1740 carbamazepine_18\NN\1740 therapy_19\NN\657604 in_20\IN\13603305 preventing_21\VBG\1740 <e2>cognitive_22\JJ\1740 impairment</e2>_23\NN\7296428 associated_24\VBN\628491 with_25\IN\1740 these_26\DT\1740 drugs_27\NNS\14778436 ._28\.\1740
D002220_D003072 CID curcumin_0\NN\1740 ameliorates_1\VBZ\126264 <e2>cognitive_2\JJ\1740 dysfunction</e2>_3\NN\14204950 and_4\CC\1740 oxidative_5\JJ\1740 damage_6\NN\7296428 in_7\IN\13603305 phenobarbitone_8\NN\2792049 and_9\CC\1740 <e1>carbamazepine</e1>_10\NN\1740 administered_11\JJ\1740 rats_12\NNS\2329401 ._13\.\1740
D002220_D003072 CID the_0\DT\1740 antiepileptic_1\JJ\1740 drugs_2\NNS\14778436 ,_3\,\1740 phenobarbitone_4\NN\2792049 and_5\CC\1740 <e1>carbamazepine</e1>_6\NN\1740 are_7\VBP\836236 well_8\RB\1740 known_9\VBN\2110220 to_10\TO\1740 cause_11\VB\1617192 <e2>cognitive_12\JJ\1740 impairment</e2>_13\NN\7296428 on_14\IN\1740 chronic_15\JJ\1740 use_16\NN\407535 ._17\.\1740
D002220_D003072 CID therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 present_3\JJ\1740 study_4\NN\635850 was_5\VBD\836236 carried_6\VBN\1850315 out_7\RP\1740 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 effect_11\NN\34213 of_12\IN\1740 chronic_13\JJ\1740 curcumin_14\NN\1740 administration_15\NN\1133281 on_16\IN\1740 phenobarbitone-_17\NN\1740 and_18\CC\1740 <e1>carbamazepine-induced</e1>_19\JJ\1740 <e2>cognitive_20\JJ\1740 impairment</e2>_21\NN\7296428 and_22\CC\1740 oxidative_23\JJ\1740 stress_24\NN\7083732 in_25\IN\13603305 rats_26\NNS\2329401 ._27\.\1740
D002220_D003072 CID the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 phenobarbitone_3\NN\2792049 and_4\CC\1740 <e1>carbamazepine</e1>_5\NN\1740 for_6\IN\1740 21days_7\NNS\1740 caused_8\VBD\1617192 a_9\DT\13649268 significant_10\JJ\1740 <e2>impairment_11\NN\7296428 of_12\IN\1740 learning_13\NN\5701944 and_14\CC\1740 memory</e2>_15\NN\5926676 as_16\RB\1740 well_17\RB\1740 as_18\IN\14622893 an_19\DT\6697703 increased_20\VBN\169651 oxidative_21\JJ\1740 stress_22\NN\7083732 ._23\.\1740
D002220_D003072 CID these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 curcumin_4\NN\1740 has_5\VBZ\2108377 beneficial_6\JJ\1740 effect_7\NN\34213 in_8\IN\13603305 mitigating_9\VBG\894738 the_10\DT\1740 <e2>deterioration_11\NN\14560612 of_12\IN\1740 cognitive_13\JJ\1740 functions</e2>_14\NNS\13783581 and_15\CC\1740 oxidative_16\JJ\1740 damage_17\NN\7296428 in_18\IN\13603305 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 phenobarbitone_22\NN\2792049 and_23\CC\1740 <e1>carbamazepine</e1>_24\NN\1740 without_25\IN\1740 significantly_26\RB\1740 altering_27\VBG\126264 their_28\PRP$\1740 serum_29\NN\5397468 concentrations_30\NNS\4916342 ._31\.\1740
D002220_D003072 CID the_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 curcumin_4\NN\1740 can_5\MD\3094503 be_6\VB\836236 considered_7\VBN\689344 as_8\IN\14622893 a_9\DT\13649268 potential_10\JJ\1740 safe_11\JJ\1740 and_12\CC\1740 effective_13\JJ\1740 adjuvant_14\JJ\1740 to_15\TO\1740 phenobarbitone_16\NN\2792049 and_17\CC\1740 <e1>carbamazepine</e1>_18\NN\1740 therapy_19\NN\657604 in_20\IN\13603305 preventing_21\VBG\1740 <e2>cognitive_22\JJ\1740 impairment</e2>_23\NN\7296428 associated_24\VBN\628491 with_25\IN\1740 these_26\DT\1740 drugs_27\NNS\14778436 ._28\.\1740
12907309
C121465_D020258 NONE neuroprotective_0\JJ\1740 action_1\NN\30358 of_2\IN\1740 <e1>mpep</e1>_3\NN\1740 ,_4\,\1740 a_5\DT\13649268 selective_6\JJ\1740 mglur5_7\NN\1740 antagonist_8\NN\7846 ,_9\,\1740 in_10\IN\13603305 methamphetamine-induced_11\JJ\1740 dopaminergic_12\JJ\1740 <e2>neurotoxicity</e2>_13\NN\1740 is_14\VBZ\836236 associated_15\VBN\628491 with_16\IN\1740 a_17\DT\13649268 decrease_18\NN\7296428 in_19\IN\13603305 dopamine_20\NN\14807737 outflow_21\NN\7407777 and_22\CC\1740 inhibition_23\NN\1068773 of_24\IN\1740 hyperthermia_25\NN\14034177 in_26\IN\13603305 rats_27\NNS\2329401 ._28\.\1740
C121465_D005334 NONE neuroprotective_0\JJ\1740 action_1\NN\30358 of_2\IN\1740 <e1>mpep</e1>_3\NN\1740 ,_4\,\1740 a_5\DT\13649268 selective_6\JJ\1740 mglur5_7\NN\1740 antagonist_8\NN\7846 ,_9\,\1740 in_10\IN\13603305 methamphetamine-induced_11\JJ\1740 dopaminergic_12\JJ\1740 neurotoxicity_13\NN\1740 is_14\VBZ\836236 associated_15\VBN\628491 with_16\IN\1740 a_17\DT\13649268 decrease_18\NN\7296428 in_19\IN\13603305 dopamine_20\NN\14807737 outflow_21\NN\7407777 and_22\CC\1740 inhibition_23\NN\1068773 of_24\IN\1740 <e2>hyperthermia</e2>_25\NN\14034177 in_26\IN\13603305 rats_27\NNS\2329401 ._28\.\1740
C121465_D005334 NONE neuroprotection_0\NN\1740 rendered_1\VBN\120316 by_2\IN\1740 <e1>mpep</e1>_3\NN\1740 may_4\MD\15209706 be_5\VB\836236 associated_6\VBN\628491 with_7\IN\1740 the_8\DT\1740 reduction_9\NN\351485 of_10\IN\1740 the_11\DT\1740 methamphetamine-induced_12\JJ\1740 dopamine_13\NN\14807737 efflux_14\NN\13482330 in_15\IN\13603305 the_16\DT\1740 striatum_17\NN\5497363 due_18\JJ\1740 to_19\TO\1740 the_20\DT\1740 blockade_21\NN\952963 of_22\IN\1740 extrastriatal_23\JJ\1740 mglur5_24\NN\1740 ,_25\,\1740 and_26\CC\1740 with_27\IN\1740 a_28\DT\13649268 decrease_29\NN\7296428 in_30\IN\13603305 <e2>hyperthermia</e2>_31\NN\14034177 ._32\.\1740
D008694_D020258 NONE neuroprotective_0\JJ\1740 action_1\NN\30358 of_2\IN\1740 mpep_3\NN\1740 ,_4\,\1740 a_5\DT\13649268 selective_6\JJ\1740 mglur5_7\NN\1740 antagonist_8\NN\7846 ,_9\,\1740 in_10\IN\13603305 <e1>methamphetamine-induced</e1>_11\JJ\1740 dopaminergic_12\JJ\1740 <e2>neurotoxicity</e2>_13\NN\1740 is_14\VBZ\836236 associated_15\VBN\628491 with_16\IN\1740 a_17\DT\13649268 decrease_18\NN\7296428 in_19\IN\13603305 dopamine_20\NN\14807737 outflow_21\NN\7407777 and_22\CC\1740 inhibition_23\NN\1068773 of_24\IN\1740 hyperthermia_25\NN\14034177 in_26\IN\13603305 rats_27\NNS\2329401 ._28\.\1740
D008694_D005334 CID neuroprotective_0\JJ\1740 action_1\NN\30358 of_2\IN\1740 mpep_3\NN\1740 ,_4\,\1740 a_5\DT\13649268 selective_6\JJ\1740 mglur5_7\NN\1740 antagonist_8\NN\7846 ,_9\,\1740 in_10\IN\13603305 <e1>methamphetamine-induced</e1>_11\JJ\1740 dopaminergic_12\JJ\1740 neurotoxicity_13\NN\1740 is_14\VBZ\836236 associated_15\VBN\628491 with_16\IN\1740 a_17\DT\13649268 decrease_18\NN\7296428 in_19\IN\13603305 dopamine_20\NN\14807737 outflow_21\NN\7407777 and_22\CC\1740 inhibition_23\NN\1068773 of_24\IN\1740 <e2>hyperthermia</e2>_25\NN\14034177 in_26\IN\13603305 rats_27\NNS\2329401 ._28\.\1740
D008694_D005334 CID moreover_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 transiently_3\RB\1740 diminished_4\VBD\169651 the_5\DT\1740 <e1>methamphetamine</e1>_6\NN\2704153 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 sc)-induced_10\JJ\1740 <e2>hyperthermia</e2>_11\NN\14034177 and_12\CC\1740 reduced_13\VBN\441445 basal_14\JJ\1740 body_15\NN\19128 temperature_16\NN\13575869 ._17\.\1740
D008694_D005334 CID neuroprotection_0\NN\1740 rendered_1\VBN\120316 by_2\IN\1740 mpep_3\NN\1740 may_4\MD\15209706 be_5\VB\836236 associated_6\VBN\628491 with_7\IN\1740 the_8\DT\1740 reduction_9\NN\351485 of_10\IN\1740 the_11\DT\1740 <e1>methamphetamine-induced</e1>_12\JJ\1740 dopamine_13\NN\14807737 efflux_14\NN\13482330 in_15\IN\13603305 the_16\DT\1740 striatum_17\NN\5497363 due_18\JJ\1740 to_19\TO\1740 the_20\DT\1740 blockade_21\NN\952963 of_22\IN\1740 extrastriatal_23\JJ\1740 mglur5_24\NN\1740 ,_25\,\1740 and_26\CC\1740 with_27\IN\1740 a_28\DT\13649268 decrease_29\NN\7296428 in_30\IN\13603305 <e2>hyperthermia</e2>_31\NN\14034177 ._32\.\1740
D004298_D020258 NONE neuroprotective_0\JJ\1740 action_1\NN\30358 of_2\IN\1740 mpep_3\NN\1740 ,_4\,\1740 a_5\DT\13649268 selective_6\JJ\1740 mglur5_7\NN\1740 antagonist_8\NN\7846 ,_9\,\1740 in_10\IN\13603305 methamphetamine-induced_11\JJ\1740 dopaminergic_12\JJ\1740 <e2>neurotoxicity</e2>_13\NN\1740 is_14\VBZ\836236 associated_15\VBN\628491 with_16\IN\1740 a_17\DT\13649268 decrease_18\NN\7296428 in_19\IN\13603305 <e1>dopamine</e1>_20\NN\14807737 outflow_21\NN\7407777 and_22\CC\1740 inhibition_23\NN\1068773 of_24\IN\1740 hyperthermia_25\NN\14034177 in_26\IN\13603305 rats_27\NNS\2329401 ._28\.\1740
D004298_D005334 NONE neuroprotective_0\JJ\1740 action_1\NN\30358 of_2\IN\1740 mpep_3\NN\1740 ,_4\,\1740 a_5\DT\13649268 selective_6\JJ\1740 mglur5_7\NN\1740 antagonist_8\NN\7846 ,_9\,\1740 in_10\IN\13603305 methamphetamine-induced_11\JJ\1740 dopaminergic_12\JJ\1740 neurotoxicity_13\NN\1740 is_14\VBZ\836236 associated_15\VBN\628491 with_16\IN\1740 a_17\DT\13649268 decrease_18\NN\7296428 in_19\IN\13603305 <e1>dopamine</e1>_20\NN\14807737 outflow_21\NN\7407777 and_22\CC\1740 inhibition_23\NN\1068773 of_24\IN\1740 <e2>hyperthermia</e2>_25\NN\14034177 in_26\IN\13603305 rats_27\NNS\2329401 ._28\.\1740
D004298_D005334 NONE neuroprotection_0\NN\1740 rendered_1\VBN\120316 by_2\IN\1740 mpep_3\NN\1740 may_4\MD\15209706 be_5\VB\836236 associated_6\VBN\628491 with_7\IN\1740 the_8\DT\1740 reduction_9\NN\351485 of_10\IN\1740 the_11\DT\1740 methamphetamine-induced_12\JJ\1740 <e1>dopamine</e1>_13\NN\14807737 efflux_14\NN\13482330 in_15\IN\13603305 the_16\DT\1740 striatum_17\NN\5497363 due_18\JJ\1740 to_19\TO\1740 the_20\DT\1740 blockade_21\NN\952963 of_22\IN\1740 extrastriatal_23\JJ\1740 mglur5_24\NN\1740 ,_25\,\1740 and_26\CC\1740 with_27\IN\1740 a_28\DT\13649268 decrease_29\NN\7296428 in_30\IN\13603305 <e2>hyperthermia</e2>_31\NN\14034177 ._32\.\1740
C121465_D064420 NONE the_0\DT\1740 results_1\NNS\34213 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 suggest_5\VBP\1010118 that_6\IN\1740 the_7\DT\1740 blockade_8\NN\952963 of_9\IN\1740 mglur5_10\NN\1740 by_11\IN\1740 <e1>mpep</e1>_12\NN\1740 may_13\MD\15209706 protect_14\VB\1127795 dopaminergic_15\JJ\1740 neurones_16\NNS\1740 against_17\IN\1740 methamphetamine-induced_18\JJ\1740 <e2>toxicity</e2>_19\NN\13576101 ._20\.\1740
D008694_D064420 NONE the_0\DT\1740 results_1\NNS\34213 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 suggest_5\VBP\1010118 that_6\IN\1740 the_7\DT\1740 blockade_8\NN\952963 of_9\IN\1740 mglur5_10\NN\1740 by_11\IN\1740 mpep_12\NN\1740 may_13\MD\15209706 protect_14\VB\1127795 dopaminergic_15\JJ\1740 neurones_16\NNS\1740 against_17\IN\1740 <e1>methamphetamine-induced</e1>_18\JJ\1740 <e2>toxicity</e2>_19\NN\13576101 ._20\.\1740
11391224
D003042_D006974 NONE these_0\DT\1740 13_1\CD\13745420 included_2\VBD\690614 cases_3\NNS\7283608 of_4\IN\1740 <e2>malignant_5\JJ\1740 hypertension</e2>_6\NN\14057371 ,_7\,\1740 thrombotic_8\JJ\1740 microangiopathy_9\NN\1740 ,_10\,\1740 lupus_11\NN\14219661 nephritis_12\NN\14113228 ,_13\,\1740 henoch-schonlein_14\NN\1740 nephritis_15\NN\14113228 ,_16\,\1740 crescentic_17\JJ\1740 glomerulonephritis_18\NN\14113798 ,_19\,\1740 and_20\CC\1740 <e1>cocaine-related</e1>_21\JJ\1740 acute_22\JJ\1740 renal_23\JJ\1740 failure_24\NN\66216 ._25\.\1740
D003042_D057049 NONE these_0\DT\1740 13_1\CD\13745420 included_2\VBD\690614 cases_3\NNS\7283608 of_4\IN\1740 malignant_5\JJ\1740 hypertension_6\NN\14057371 ,_7\,\1740 <e2>thrombotic_8\JJ\1740 microangiopathy</e2>_9\NN\1740 ,_10\,\1740 lupus_11\NN\14219661 nephritis_12\NN\14113228 ,_13\,\1740 henoch-schonlein_14\NN\1740 nephritis_15\NN\14113228 ,_16\,\1740 crescentic_17\JJ\1740 glomerulonephritis_18\NN\14113798 ,_19\,\1740 and_20\CC\1740 <e1>cocaine-related</e1>_21\JJ\1740 acute_22\JJ\1740 renal_23\JJ\1740 failure_24\NN\66216 ._25\.\1740
D003042_D008181 NONE these_0\DT\1740 13_1\CD\13745420 included_2\VBD\690614 cases_3\NNS\7283608 of_4\IN\1740 malignant_5\JJ\1740 hypertension_6\NN\14057371 ,_7\,\1740 thrombotic_8\JJ\1740 microangiopathy_9\NN\1740 ,_10\,\1740 <e2>lupus_11\NN\14219661 nephritis</e2>_12\NN\14113228 ,_13\,\1740 henoch-schonlein_14\NN\1740 nephritis_15\NN\14113228 ,_16\,\1740 crescentic_17\JJ\1740 glomerulonephritis_18\NN\14113798 ,_19\,\1740 and_20\CC\1740 <e1>cocaine-related</e1>_21\JJ\1740 acute_22\JJ\1740 renal_23\JJ\1740 failure_24\NN\66216 ._25\.\1740
D003042_D011695 NONE these_0\DT\1740 13_1\CD\13745420 included_2\VBD\690614 cases_3\NNS\7283608 of_4\IN\1740 malignant_5\JJ\1740 hypertension_6\NN\14057371 ,_7\,\1740 thrombotic_8\JJ\1740 microangiopathy_9\NN\1740 ,_10\,\1740 lupus_11\NN\14219661 nephritis_12\NN\14113228 ,_13\,\1740 <e2>henoch-schonlein_14\NN\1740 nephritis</e2>_15\NN\14113228 ,_16\,\1740 crescentic_17\JJ\1740 glomerulonephritis_18\NN\14113798 ,_19\,\1740 and_20\CC\1740 <e1>cocaine-related</e1>_21\JJ\1740 acute_22\JJ\1740 renal_23\JJ\1740 failure_24\NN\66216 ._25\.\1740
D003042_D005921 NONE these_0\DT\1740 13_1\CD\13745420 included_2\VBD\690614 cases_3\NNS\7283608 of_4\IN\1740 malignant_5\JJ\1740 hypertension_6\NN\14057371 ,_7\,\1740 thrombotic_8\JJ\1740 microangiopathy_9\NN\1740 ,_10\,\1740 lupus_11\NN\14219661 nephritis_12\NN\14113228 ,_13\,\1740 henoch-schonlein_14\NN\1740 nephritis_15\NN\14113228 ,_16\,\1740 crescentic_17\JJ\1740 <e2>glomerulonephritis</e2>_18\NN\14113798 ,_19\,\1740 and_20\CC\1740 <e1>cocaine-related</e1>_21\JJ\1740 acute_22\JJ\1740 renal_23\JJ\1740 failure_24\NN\66216 ._25\.\1740
D003042_D058186 CID these_0\DT\1740 13_1\CD\13745420 included_2\VBD\690614 cases_3\NNS\7283608 of_4\IN\1740 malignant_5\JJ\1740 hypertension_6\NN\14057371 ,_7\,\1740 thrombotic_8\JJ\1740 microangiopathy_9\NN\1740 ,_10\,\1740 lupus_11\NN\14219661 nephritis_12\NN\14113228 ,_13\,\1740 henoch-schonlein_14\NN\1740 nephritis_15\NN\14113228 ,_16\,\1740 crescentic_17\JJ\1740 glomerulonephritis_18\NN\14113798 ,_19\,\1740 and_20\CC\1740 <e1>cocaine-related</e1>_21\JJ\1740 <e2>acute_22\JJ\1740 renal_23\JJ\1740 failure</e2>_24\NN\66216 ._25\.\1740
14596845
D000661_D019966 NONE a_0\DT\13649268 diet_1\NN\7560652 promoting_2\VBG\2556126 <e2>sugar_3\NN\7858595 dependency</e2>_4\NN\24720 causes_5\VBZ\1617192 behavioral_6\JJ\1740 cross-sensitization_7\NN\1740 to_8\TO\1740 a_9\DT\13649268 low_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 <e1>amphetamine</e1>_13\NN\3248958 ._14\.\1740
D000661_D006948 CID a_0\DT\13649268 diet_1\NN\7560652 promoting_2\VBG\2556126 sugar_3\NN\7858595 dependency_4\NN\24720 causes_5\VBZ\1617192 <e2>behavioral_6\JJ\1740 cross-sensitization</e2>_7\NN\1740 to_8\TO\1740 a_9\DT\13649268 low_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 <e1>amphetamine</e1>_13\NN\3248958 ._14\.\1740
D000661_D006948 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 examined_3\VBD\789138 whether_4\IN\1740 female_5\JJ\1740 rats_6\NNS\2329401 on_7\IN\1740 various_8\JJ\1740 regimens_9\NNS\5898568 of_10\IN\1740 sugar_11\NN\7858595 access_12\NN\5174653 would_13\MD\1740 show_14\VB\2137132 <e2>behavioral_15\JJ\1740 cross-sensitization</e2>_16\NN\1740 to_17\TO\1740 a_18\DT\13649268 low_19\JJ\1740 dose_20\NN\3740161 of_21\IN\1740 <e1>amphetamine</e1>_22\NN\3248958 ._23\.\1740
D000661_D006948 CID the_0\DT\1740 animals_1\NNS\4475 that_2\WDT\1740 had_3\VBD\2108377 experienced_4\VBN\2108377 cyclic_5\JJ\1740 sucrose_6\NN\14836642 and_7\CC\1740 chow_8\VB\1740 were_9\VBD\836236 <e2>hyperactive</e2>_10\JJ\1740 in_11\IN\13603305 response_12\NN\11410625 to_13\TO\1740 <e1>amphetamine</e1>_14\NN\3248958 compared_15\VBN\644583 with_16\IN\1740 four_17\CD\13741022 control_18\NN\5190804 groups_19\NNS\2137 (_20\-LRB-\1740 ad_21\NN\7247071 libitum_22\NN\1740 10_23\CD\13745420 %_24\NN\1740 sucrose_25\NN\14836642 and_26\CC\1740 chow_27\VB\1740 followed_28\VBN\1835496 by_29\IN\1740 amphetamine_30\NN\3248958 injection_31\NN\320852 ,_32\,\1740 cyclic_33\JJ\1740 chow_34\NN\7971582 followed_35\VBN\1835496 by_36\IN\1740 amphetamine_37\NN\3248958 injection_38\NN\320852 ,_39\,\1740 ad_40\NN\7247071 libitum_41\NN\1740 chow_42\VBP\1740 with_43\IN\1740 amphetamine_44\NN\3248958 ,_45\,\1740 or_46\CC\3541091 cyclic_47\JJ\1740 10_48\CD\13745420 %_49\NN\1740 sucrose_50\NN\14836642 and_51\CC\1740 chow_52\VB\1740 with_53\IN\1740 a_54\DT\13649268 saline_55\NN\14849367 injection_56\NN\320852 )_57\-RRB-\1740 ._58\.\1740
D000661_D006948 CID the_0\DT\1740 animals_1\NNS\4475 that_2\WDT\1740 had_3\VBD\2108377 experienced_4\VBN\2108377 cyclic_5\JJ\1740 sucrose_6\NN\14836642 and_7\CC\1740 chow_8\VB\1740 were_9\VBD\836236 <e2>hyperactive</e2>_10\JJ\1740 in_11\IN\13603305 response_12\NN\11410625 to_13\TO\1740 amphetamine_14\NN\3248958 compared_15\VBN\644583 with_16\IN\1740 four_17\CD\13741022 control_18\NN\5190804 groups_19\NNS\2137 (_20\-LRB-\1740 ad_21\NN\7247071 libitum_22\NN\1740 10_23\CD\13745420 %_24\NN\1740 sucrose_25\NN\14836642 and_26\CC\1740 chow_27\VB\1740 followed_28\VBN\1835496 by_29\IN\1740 <e1>amphetamine</e1>_30\NN\3248958 injection_31\NN\320852 ,_32\,\1740 cyclic_33\JJ\1740 chow_34\NN\7971582 followed_35\VBN\1835496 by_36\IN\1740 amphetamine_37\NN\3248958 injection_38\NN\320852 ,_39\,\1740 ad_40\NN\7247071 libitum_41\NN\1740 chow_42\VBP\1740 with_43\IN\1740 amphetamine_44\NN\3248958 ,_45\,\1740 or_46\CC\3541091 cyclic_47\JJ\1740 10_48\CD\13745420 %_49\NN\1740 sucrose_50\NN\14836642 and_51\CC\1740 chow_52\VB\1740 with_53\IN\1740 a_54\DT\13649268 saline_55\NN\14849367 injection_56\NN\320852 )_57\-RRB-\1740 ._58\.\1740
D000661_D006948 CID the_0\DT\1740 animals_1\NNS\4475 that_2\WDT\1740 had_3\VBD\2108377 experienced_4\VBN\2108377 cyclic_5\JJ\1740 sucrose_6\NN\14836642 and_7\CC\1740 chow_8\VB\1740 were_9\VBD\836236 <e2>hyperactive</e2>_10\JJ\1740 in_11\IN\13603305 response_12\NN\11410625 to_13\TO\1740 amphetamine_14\NN\3248958 compared_15\VBN\644583 with_16\IN\1740 four_17\CD\13741022 control_18\NN\5190804 groups_19\NNS\2137 (_20\-LRB-\1740 ad_21\NN\7247071 libitum_22\NN\1740 10_23\CD\13745420 %_24\NN\1740 sucrose_25\NN\14836642 and_26\CC\1740 chow_27\VB\1740 followed_28\VBN\1835496 by_29\IN\1740 amphetamine_30\NN\3248958 injection_31\NN\320852 ,_32\,\1740 cyclic_33\JJ\1740 chow_34\NN\7971582 followed_35\VBN\1835496 by_36\IN\1740 <e1>amphetamine</e1>_37\NN\3248958 injection_38\NN\320852 ,_39\,\1740 ad_40\NN\7247071 libitum_41\NN\1740 chow_42\VBP\1740 with_43\IN\1740 amphetamine_44\NN\3248958 ,_45\,\1740 or_46\CC\3541091 cyclic_47\JJ\1740 10_48\CD\13745420 %_49\NN\1740 sucrose_50\NN\14836642 and_51\CC\1740 chow_52\VB\1740 with_53\IN\1740 a_54\DT\13649268 saline_55\NN\14849367 injection_56\NN\320852 )_57\-RRB-\1740 ._58\.\1740
D000661_D006948 CID the_0\DT\1740 animals_1\NNS\4475 that_2\WDT\1740 had_3\VBD\2108377 experienced_4\VBN\2108377 cyclic_5\JJ\1740 sucrose_6\NN\14836642 and_7\CC\1740 chow_8\VB\1740 were_9\VBD\836236 <e2>hyperactive</e2>_10\JJ\1740 in_11\IN\13603305 response_12\NN\11410625 to_13\TO\1740 amphetamine_14\NN\3248958 compared_15\VBN\644583 with_16\IN\1740 four_17\CD\13741022 control_18\NN\5190804 groups_19\NNS\2137 (_20\-LRB-\1740 ad_21\NN\7247071 libitum_22\NN\1740 10_23\CD\13745420 %_24\NN\1740 sucrose_25\NN\14836642 and_26\CC\1740 chow_27\VB\1740 followed_28\VBN\1835496 by_29\IN\1740 amphetamine_30\NN\3248958 injection_31\NN\320852 ,_32\,\1740 cyclic_33\JJ\1740 chow_34\NN\7971582 followed_35\VBN\1835496 by_36\IN\1740 amphetamine_37\NN\3248958 injection_38\NN\320852 ,_39\,\1740 ad_40\NN\7247071 libitum_41\NN\1740 chow_42\VBP\1740 with_43\IN\1740 <e1>amphetamine</e1>_44\NN\3248958 ,_45\,\1740 or_46\CC\3541091 cyclic_47\JJ\1740 10_48\CD\13745420 %_49\NN\1740 sucrose_50\NN\14836642 and_51\CC\1740 chow_52\VB\1740 with_53\IN\1740 a_54\DT\13649268 saline_55\NN\14849367 injection_56\NN\320852 )_57\-RRB-\1740 ._58\.\1740
D013395_D006948 CID the_0\DT\1740 animals_1\NNS\4475 that_2\WDT\1740 had_3\VBD\2108377 experienced_4\VBN\2108377 cyclic_5\JJ\1740 <e1>sucrose</e1>_6\NN\14836642 and_7\CC\1740 chow_8\VB\1740 were_9\VBD\836236 <e2>hyperactive</e2>_10\JJ\1740 in_11\IN\13603305 response_12\NN\11410625 to_13\TO\1740 amphetamine_14\NN\3248958 compared_15\VBN\644583 with_16\IN\1740 four_17\CD\13741022 control_18\NN\5190804 groups_19\NNS\2137 (_20\-LRB-\1740 ad_21\NN\7247071 libitum_22\NN\1740 10_23\CD\13745420 %_24\NN\1740 sucrose_25\NN\14836642 and_26\CC\1740 chow_27\VB\1740 followed_28\VBN\1835496 by_29\IN\1740 amphetamine_30\NN\3248958 injection_31\NN\320852 ,_32\,\1740 cyclic_33\JJ\1740 chow_34\NN\7971582 followed_35\VBN\1835496 by_36\IN\1740 amphetamine_37\NN\3248958 injection_38\NN\320852 ,_39\,\1740 ad_40\NN\7247071 libitum_41\NN\1740 chow_42\VBP\1740 with_43\IN\1740 amphetamine_44\NN\3248958 ,_45\,\1740 or_46\CC\3541091 cyclic_47\JJ\1740 10_48\CD\13745420 %_49\NN\1740 sucrose_50\NN\14836642 and_51\CC\1740 chow_52\VB\1740 with_53\IN\1740 a_54\DT\13649268 saline_55\NN\14849367 injection_56\NN\320852 )_57\-RRB-\1740 ._58\.\1740
D013395_D006948 CID the_0\DT\1740 animals_1\NNS\4475 that_2\WDT\1740 had_3\VBD\2108377 experienced_4\VBN\2108377 cyclic_5\JJ\1740 sucrose_6\NN\14836642 and_7\CC\1740 chow_8\VB\1740 were_9\VBD\836236 <e2>hyperactive</e2>_10\JJ\1740 in_11\IN\13603305 response_12\NN\11410625 to_13\TO\1740 amphetamine_14\NN\3248958 compared_15\VBN\644583 with_16\IN\1740 four_17\CD\13741022 control_18\NN\5190804 groups_19\NNS\2137 (_20\-LRB-\1740 ad_21\NN\7247071 libitum_22\NN\1740 10_23\CD\13745420 %_24\NN\1740 <e1>sucrose</e1>_25\NN\14836642 and_26\CC\1740 chow_27\VB\1740 followed_28\VBN\1835496 by_29\IN\1740 amphetamine_30\NN\3248958 injection_31\NN\320852 ,_32\,\1740 cyclic_33\JJ\1740 chow_34\NN\7971582 followed_35\VBN\1835496 by_36\IN\1740 amphetamine_37\NN\3248958 injection_38\NN\320852 ,_39\,\1740 ad_40\NN\7247071 libitum_41\NN\1740 chow_42\VBP\1740 with_43\IN\1740 amphetamine_44\NN\3248958 ,_45\,\1740 or_46\CC\3541091 cyclic_47\JJ\1740 10_48\CD\13745420 %_49\NN\1740 sucrose_50\NN\14836642 and_51\CC\1740 chow_52\VB\1740 with_53\IN\1740 a_54\DT\13649268 saline_55\NN\14849367 injection_56\NN\320852 )_57\-RRB-\1740 ._58\.\1740
D013395_D006948 CID the_0\DT\1740 animals_1\NNS\4475 that_2\WDT\1740 had_3\VBD\2108377 experienced_4\VBN\2108377 cyclic_5\JJ\1740 sucrose_6\NN\14836642 and_7\CC\1740 chow_8\VB\1740 were_9\VBD\836236 <e2>hyperactive</e2>_10\JJ\1740 in_11\IN\13603305 response_12\NN\11410625 to_13\TO\1740 amphetamine_14\NN\3248958 compared_15\VBN\644583 with_16\IN\1740 four_17\CD\13741022 control_18\NN\5190804 groups_19\NNS\2137 (_20\-LRB-\1740 ad_21\NN\7247071 libitum_22\NN\1740 10_23\CD\13745420 %_24\NN\1740 sucrose_25\NN\14836642 and_26\CC\1740 chow_27\VB\1740 followed_28\VBN\1835496 by_29\IN\1740 amphetamine_30\NN\3248958 injection_31\NN\320852 ,_32\,\1740 cyclic_33\JJ\1740 chow_34\NN\7971582 followed_35\VBN\1835496 by_36\IN\1740 amphetamine_37\NN\3248958 injection_38\NN\320852 ,_39\,\1740 ad_40\NN\7247071 libitum_41\NN\1740 chow_42\VBP\1740 with_43\IN\1740 amphetamine_44\NN\3248958 ,_45\,\1740 or_46\CC\3541091 cyclic_47\JJ\1740 10_48\CD\13745420 %_49\NN\1740 <e1>sucrose</e1>_50\NN\14836642 and_51\CC\1740 chow_52\VB\1740 with_53\IN\1740 a_54\DT\13649268 saline_55\NN\14849367 injection_56\NN\320852 )_57\-RRB-\1740 ._58\.\1740
19445921
C066201_D009203 NONE cardioprotective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>salvianolic_3\JJ\1740 acid_4\NN\14818238 a</e1>_5\NN\13649268 on_6\IN\1740 isoproterenol-induced_7\JJ\1740 <e2>myocardial_8\JJ\1740 infarction</e2>_9\NN\14204950 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
C066201_D009203 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 cardioprotective_8\JJ\1740 potential_9\NN\14481929 of_10\IN\1740 <e1>salvianolic_11\JJ\1740 acid_12\NN\14818238 a</e1>_13\NN\13649268 on_14\IN\1740 isoproterenol-induced_15\JJ\1740 <e2>myocardial_16\JJ\1740 infarction</e2>_17\NN\14204950 in_18\IN\13603305 rats_19\NNS\2329401 ._20\.\1740
C066201_D009203 NONE the_0\DT\1740 results_1\NNS\34213 of_2\IN\1740 our_3\PRP$\1740 study_4\NN\635850 suggest_5\VBP\1010118 that_6\IN\1740 <e1>salvianolic_7\JJ\1740 acid_8\NN\14818238 a</e1>_9\NN\13649268 possessing_10\VBG\2630189 antioxidant_11\JJ\1740 activity_12\NN\30358 has_13\VBZ\2108377 a_14\DT\13649268 significant_15\JJ\1740 protective_16\JJ\1740 effect_17\NN\34213 against_18\IN\1740 isoproterenol-induced_19\JJ\1740 <e2>myocardial_20\JJ\1740 infarction</e2>_21\NN\14204950 ._22\.\1740
D007545_D009203 CID cardioprotective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 salvianolic_3\JJ\1740 acid_4\NN\14818238 a_5\NN\13649268 on_6\IN\1740 <e1>isoproterenol-induced</e1>_7\JJ\1740 <e2>myocardial_8\JJ\1740 infarction</e2>_9\NN\14204950 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D007545_D009203 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 cardioprotective_8\JJ\1740 potential_9\NN\14481929 of_10\IN\1740 salvianolic_11\JJ\1740 acid_12\NN\14818238 a_13\NN\13649268 on_14\IN\1740 <e1>isoproterenol-induced</e1>_15\JJ\1740 <e2>myocardial_16\JJ\1740 infarction</e2>_17\NN\14204950 in_18\IN\13603305 rats_19\NNS\2329401 ._20\.\1740
D007545_D009203 CID the_0\DT\1740 results_1\NNS\34213 of_2\IN\1740 our_3\PRP$\1740 study_4\NN\635850 suggest_5\VBP\1010118 that_6\IN\1740 salvianolic_7\JJ\1740 acid_8\NN\14818238 a_9\NN\13649268 possessing_10\VBG\2630189 antioxidant_11\JJ\1740 activity_12\NN\30358 has_13\VBZ\2108377 a_14\DT\13649268 significant_15\JJ\1740 protective_16\JJ\1740 effect_17\NN\34213 against_18\IN\1740 <e1>isoproterenol-induced</e1>_19\JJ\1740 <e2>myocardial_20\JJ\1740 infarction</e2>_21\NN\14204950 ._22\.\1740
D000244_D012131 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 mitochondrial_3\JJ\1740 <e2>respiratory_4\JJ\1740 dysfunction</e2>_5\NN\14204950 characterized_6\VBN\609683 by_7\IN\1740 decreased_8\VBN\169651 respiratory_9\JJ\1740 control_10\NN\5190804 ratio_11\NN\13815152 and_12\CC\1740 <e1>adp/o</e1>_13\NN\1740 was_14\VBD\836236 observed_15\VBN\2163746 in_16\IN\13603305 isoproterenol-treated_17\JJ\1740 rats_18\NNS\2329401 ._19\.\1740
D007545_D012131 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 mitochondrial_3\JJ\1740 <e2>respiratory_4\JJ\1740 dysfunction</e2>_5\NN\14204950 characterized_6\VBN\609683 by_7\IN\1740 decreased_8\VBN\169651 respiratory_9\JJ\1740 control_10\NN\5190804 ratio_11\NN\13815152 and_12\CC\1740 adp/o_13\NN\1740 was_14\VBD\836236 observed_15\VBN\2163746 in_16\IN\13603305 <e1>isoproterenol-treated</e1>_17\JJ\1740 rats_18\NNS\2329401 ._19\.\1740
C066201_D006331 NONE administration_0\NN\1133281 of_1\IN\1740 <e1>salvianolic_2\JJ\1740 acid_3\NN\14818238 a</e1>_4\NN\13649268 for_5\IN\1740 a_6\DT\13649268 period_7\NN\13575869 of_8\IN\1740 8_9\CD\13741022 days_10\NNS\15140892 significantly_11\RB\1740 attenuated_12\VBD\224901 isoproterenol-induced_13\JJ\1740 <e2>cardiac_14\JJ\1740 dysfunction</e2>_15\NN\14204950 and_16\CC\1740 myocardial_17\JJ\1740 injury_18\NN\14052046 and_19\CC\1740 improved_20\VBD\126264 mitochondrial_21\JJ\1740 respiratory_22\JJ\1740 function_23\NN\13783581 ._24\.\1740
C066201_D009202 NONE administration_0\NN\1133281 of_1\IN\1740 <e1>salvianolic_2\JJ\1740 acid_3\NN\14818238 a</e1>_4\NN\13649268 for_5\IN\1740 a_6\DT\13649268 period_7\NN\13575869 of_8\IN\1740 8_9\CD\13741022 days_10\NNS\15140892 significantly_11\RB\1740 attenuated_12\VBD\224901 isoproterenol-induced_13\JJ\1740 cardiac_14\JJ\1740 dysfunction_15\NN\14204950 and_16\CC\1740 <e2>myocardial_17\JJ\1740 injury</e2>_18\NN\14052046 and_19\CC\1740 improved_20\VBD\126264 mitochondrial_21\JJ\1740 respiratory_22\JJ\1740 function_23\NN\13783581 ._24\.\1740
C066201_D009202 NONE the_0\DT\1740 protective_1\JJ\1740 role_2\NN\719494 of_3\IN\1740 <e1>salvianolic_4\JJ\1740 acid_5\NN\14818238 a</e1>_6\NN\13649268 against_7\IN\1740 isoproterenol-induced_8\JJ\1740 <e2>myocardial_9\JJ\1740 damage</e2>_10\NN\7296428 was_11\VBD\836236 further_12\RB\1740 confirmed_13\VBN\1011725 by_14\IN\1740 histopathological_15\JJ\1740 examination_16\NN\633864 ._17\.\1740
D007545_D006331 NONE administration_0\NN\1133281 of_1\IN\1740 salvianolic_2\JJ\1740 acid_3\NN\14818238 a_4\NN\13649268 for_5\IN\1740 a_6\DT\13649268 period_7\NN\13575869 of_8\IN\1740 8_9\CD\13741022 days_10\NNS\15140892 significantly_11\RB\1740 attenuated_12\VBD\224901 <e1>isoproterenol-induced</e1>_13\JJ\1740 <e2>cardiac_14\JJ\1740 dysfunction</e2>_15\NN\14204950 and_16\CC\1740 myocardial_17\JJ\1740 injury_18\NN\14052046 and_19\CC\1740 improved_20\VBD\126264 mitochondrial_21\JJ\1740 respiratory_22\JJ\1740 function_23\NN\13783581 ._24\.\1740
D007545_D009202 NONE administration_0\NN\1133281 of_1\IN\1740 salvianolic_2\JJ\1740 acid_3\NN\14818238 a_4\NN\13649268 for_5\IN\1740 a_6\DT\13649268 period_7\NN\13575869 of_8\IN\1740 8_9\CD\13741022 days_10\NNS\15140892 significantly_11\RB\1740 attenuated_12\VBD\224901 <e1>isoproterenol-induced</e1>_13\JJ\1740 cardiac_14\JJ\1740 dysfunction_15\NN\14204950 and_16\CC\1740 <e2>myocardial_17\JJ\1740 injury</e2>_18\NN\14052046 and_19\CC\1740 improved_20\VBD\126264 mitochondrial_21\JJ\1740 respiratory_22\JJ\1740 function_23\NN\13783581 ._24\.\1740
D007545_D009202 NONE the_0\DT\1740 protective_1\JJ\1740 role_2\NN\719494 of_3\IN\1740 salvianolic_4\JJ\1740 acid_5\NN\14818238 a_6\NN\13649268 against_7\IN\1740 <e1>isoproterenol-induced</e1>_8\JJ\1740 <e2>myocardial_9\JJ\1740 damage</e2>_10\NN\7296428 was_11\VBD\836236 further_12\RB\1740 confirmed_13\VBN\1011725 by_14\IN\1740 histopathological_15\JJ\1740 examination_16\NN\633864 ._17\.\1740
7930386
D002997_D012893 CID <e1>clomipramine-induced</e1>_0\JJ\1740 <e2>sleep_1\NN\14034177 disturbance</e2>_2\NN\407535 does_3\VBZ\1640855 not_4\RB\1740 impair_5\VB\258857 its_6\PRP$\6125041 prolactin-releasing_7\JJ\1740 action_8\NN\30358 ._9\.\1740
D002997_D012893 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 examine_6\VB\789138 the_7\DT\1740 role_8\NN\719494 of_9\IN\1740 <e2>sleep_10\NN\14034177 disturbance</e2>_11\NN\407535 ,_12\,\1740 induced_13\VBN\1627355 by_14\IN\1740 <e1>clomipramine</e1>_15\NN\4482543 administration_16\NN\1133281 ,_17\,\1740 on_18\IN\1740 the_19\DT\1740 secretory_20\JJ\1740 rate_21\NN\13815152 of_22\IN\1740 prolactin_23\NN\5410315 (_24\-LRB-\1740 prl_25\NN\1740 )_26\-RRB-\1740 in_27\IN\13603305 addition_28\NN\3081021 to_29\TO\1740 the_30\DT\1740 direct_31\JJ\1740 drug_32\NN\14778436 effect_33\NN\34213 ._34\.\1740
9587734
D013390_D006323 CID <e1>suxamethonium-induced</e1>_0\JJ\1740 <e2>cardiac_1\JJ\1740 arrest</e2>_2\NN\88481 and_3\CC\1740 death_4\NN\7296428 following_5\VBG\1835496 5_6\CD\13741022 days_7\NNS\15140892 of_8\IN\1740 immobilization_9\NN\819024 ._10\.\1740
D013390_D006323 CID the_0\DT\1740 present_1\JJ\1740 report_2\NN\6470073 describes_3\VBZ\1001294 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e2>cardiac_7\JJ\1740 arrest</e2>_8\NN\88481 and_9\CC\1740 subsequent_10\JJ\1740 death_11\NN\7296428 as_12\IN\14622893 a_13\DT\13649268 result_14\NN\34213 of_15\IN\1740 hyperkalaemia_16\NN\1740 following_17\VBG\1835496 the_18\DT\1740 use_19\NN\407535 of_20\IN\1740 <e1>suxamethonium</e1>_21\NN\1740 in_22\IN\13603305 a_23\DT\13649268 23-year-old_24\JJ\1740 malawian_25\JJ\1740 woman_26\NN\9605289 ._27\.\1740
D013390_D006323 CID forty_0\CD\13745420 seconds_1\NNS\15154774 after_2\IN\1740 injection_3\NN\320852 of_4\IN\1740 <e1>suxamethonium</e1>_5\NN\1740 ,_6\,\1740 bradycardia_7\NN\14110674 and_8\CC\1740 <e2>cardiac_9\JJ\1740 arrest</e2>_10\NN\88481 occurred_11\VBD\2623529 ._12\.\1740
D013390_D003643 NONE <e1>suxamethonium-induced</e1>_0\JJ\1740 cardiac_1\JJ\1740 arrest_2\NN\88481 and_3\CC\1740 <e2>death</e2>_4\NN\7296428 following_5\VBG\1835496 5_6\CD\13741022 days_7\NNS\15140892 of_8\IN\1740 immobilization_9\NN\819024 ._10\.\1740
D013390_D003643 NONE the_0\DT\1740 present_1\JJ\1740 report_2\NN\6470073 describes_3\VBZ\1001294 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 cardiac_7\JJ\1740 arrest_8\NN\88481 and_9\CC\1740 subsequent_10\JJ\1740 <e2>death</e2>_11\NN\7296428 as_12\IN\14622893 a_13\DT\13649268 result_14\NN\34213 of_15\IN\1740 hyperkalaemia_16\NN\1740 following_17\VBG\1835496 the_18\DT\1740 use_19\NN\407535 of_20\IN\1740 <e1>suxamethonium</e1>_21\NN\1740 in_22\IN\13603305 a_23\DT\13649268 23-year-old_24\JJ\1740 malawian_25\JJ\1740 woman_26\NN\9605289 ._27\.\1740
D013390_D003643 NONE it_0\PRP\6125041 is_1\VBZ\836236 postulated_2\VBN\756338 that_3\IN\1740 her_4\PRP$\1740 <e2>death</e2>_5\NN\7296428 was_6\VBD\836236 caused_7\VBN\1617192 by_8\IN\1740 hypersensitivity_9\NN\14531772 to_10\TO\1740 <e1>suxamethonium</e1>_11\NN\1740 ,_12\,\1740 associated_13\VBN\628491 with_14\IN\1740 her_15\PRP$\1740 5-day_16\JJ\1740 immobilization_17\NN\819024 ._18\.\1740
D013390_D006947 CID the_0\DT\1740 present_1\JJ\1740 report_2\NN\6470073 describes_3\VBZ\1001294 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 cardiac_7\JJ\1740 arrest_8\NN\88481 and_9\CC\1740 subsequent_10\JJ\1740 death_11\NN\7296428 as_12\IN\14622893 a_13\DT\13649268 result_14\NN\34213 of_15\IN\1740 <e2>hyperkalaemia</e2>_16\NN\1740 following_17\VBG\1835496 the_18\DT\1740 use_19\NN\407535 of_20\IN\1740 <e1>suxamethonium</e1>_21\NN\1740 in_22\IN\13603305 a_23\DT\13649268 23-year-old_24\JJ\1740 malawian_25\JJ\1740 woman_26\NN\9605289 ._27\.\1740
D013390_D006947 CID apart_0\RB\1740 from_1\IN\1740 the_2\DT\1740 reduction_3\NN\351485 in_4\IN\13603305 the_5\DT\1740 patient_6\NN\9898892 's_7\POS\1740 level_8\NN\4916342 of_9\IN\1740 consciousness_10\NN\5669934 ,_11\,\1740 there_12\EX\27167 were_13\VBD\836236 no_14\DT\7204911 signs_15\NNS\6643763 of_16\IN\1740 motor_17\NN\3699975 neurone_18\NN\1740 damage_19\NN\7296428 or_20\CC\3541091 of_21\IN\1740 any_22\DT\1740 of_23\IN\1740 the_24\DT\1740 other_25\JJ\1740 known_26\JJ\1740 predisposing_27\VBG\680841 conditions_28\NNS\14512817 for_29\IN\1740 <e2>hyperkalaemia</e2>_30\NN\1740 following_31\VBG\1835496 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 <e1>suxamethonium</e1>_35\NN\1740 ._36\.\1740
D013390_D001919 CID forty_0\CD\13745420 seconds_1\NNS\15154774 after_2\IN\1740 injection_3\NN\320852 of_4\IN\1740 <e1>suxamethonium</e1>_5\NN\1740 ,_6\,\1740 <e2>bradycardia</e2>_7\NN\14110674 and_8\CC\1740 cardiac_9\JJ\1740 arrest_10\NN\88481 occurred_11\VBD\2623529 ._12\.\1740
D013390_D004342 CID it_0\PRP\6125041 is_1\VBZ\836236 postulated_2\VBN\756338 that_3\IN\1740 her_4\PRP$\1740 death_5\NN\7296428 was_6\VBD\836236 caused_7\VBN\1617192 by_8\IN\1740 <e2>hypersensitivity</e2>_9\NN\14531772 to_10\TO\1740 <e1>suxamethonium</e1>_11\NN\1740 ,_12\,\1740 associated_13\VBN\628491 with_14\IN\1740 her_15\PRP$\1740 5-day_16\JJ\1740 immobilization_17\NN\819024 ._18\.\1740
11752354
D003276_D009203 CID <e1>oral_0\JJ\1740 contraceptives</e1>_1\NNS\3183080 and_2\CC\1740 the_3\DT\1740 risk_4\NN\14541044 of_5\IN\1740 <e2>myocardial_6\JJ\1740 infarction</e2>_7\NN\14204950 ._8\.\1740
D003276_D009203 CID background_0\NN\4921011 :_1\:\1740 an_2\DT\6697703 association_3\NN\8008335 between_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 <e1>oral_8\JJ\1740 contraceptives</e1>_9\NNS\3183080 and_10\CC\1740 the_11\DT\1740 risk_12\NN\14541044 of_13\IN\1740 <e2>myocardial_14\JJ\1740 infarction</e2>_15\NN\14204950 has_16\VBZ\2108377 been_17\VBN\836236 found_18\VBN\2426171 in_19\IN\13603305 some_20\DT\1740 ,_21\,\1740 but_22\CC\1740 not_23\RB\1740 all_24\DT\1740 ,_25\,\1740 studies_26\NNS\635850 ._27\.\1740
D003276_D009203 CID we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 progestagen_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 desogestrel_17\NN\1740 or_18\CC\3541091 gestodene_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 levonorgestrel_26\NN\1740 )_27\-RRB-\1740 <e1>oral_28\JJ\1740 contraceptives</e1>_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 estrogen_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 <e2>myocardial_72\JJ\1740 infarction</e2>_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 myocardial_87\JJ\1740 infarction_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
D003276_D009203 CID we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 progestagen_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 desogestrel_17\NN\1740 or_18\CC\3541091 gestodene_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 levonorgestrel_26\NN\1740 )_27\-RRB-\1740 <e1>oral_28\JJ\1740 contraceptives</e1>_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 estrogen_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 myocardial_72\JJ\1740 infarction_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 <e2>myocardial_87\JJ\1740 infarction</e2>_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
D003276_D009203 CID an_0\DT\6697703 analysis_1\NN\633864 for_2\IN\1740 factor_3\NN\7326557 v_4\NN\13634784 leiden_5\NNP\1740 and_6\CC\1740 the_7\DT\1740 g20210a_8\NN\1740 mutation_9\NN\4475 in_10\IN\13603305 the_11\DT\1740 prothrombin_12\NN\15022776 gene_13\NN\8459252 was_14\VBD\836236 conducted_15\VBN\2436349 in_16\IN\13603305 217_17\CD\1740 patients_18\NNS\9898892 and_19\CC\1740 763_20\CD\1740 controls_21\NNS\5190804 results_22\NNS\34213 :_23\:\1740 the_24\DT\1740 odds_25\NNS\4756635 ratio_26\NN\13815152 for_27\IN\1740 <e2>myocardial_28\JJ\1740 infarction</e2>_29\NN\14204950 among_30\IN\1740 women_31\NNS\9605289 who_32\WP\8299493 used_33\VBD\1156834 any_34\DT\1740 type_35\NN\5839024 of_36\IN\1740 combined_37\JJ\1740 <e1>oral_38\JJ\1740 contraceptive</e1>_39\NN\3183080 ,_40\,\1740 as_41\IN\14622893 compared_42\VBN\644583 with_43\IN\1740 nonusers_44\NNS\1740 ,_45\,\1740 was_46\VBD\836236 2.0_47\CD\1740 (_48\-LRB-\1740 95_49\CD\1740 percent_50\NN\13815742 confidence_51\NN\5697135 interval_52\NN\33615 ,_53\,\1740 1.5_54\CD\1740 to_55\TO\1740 2.8_56\CD\1740 )_57\-RRB-\1740 ._58\.\1740
D003276_D009203 CID among_0\IN\1740 women_1\NNS\9605289 who_2\WP\8299493 used_3\VBD\1156834 <e1>oral_4\JJ\1740 contraceptives</e1>_5\NNS\3183080 ,_6\,\1740 the_7\DT\1740 odds_8\NNS\4756635 ratio_9\NN\13815152 was_10\VBD\836236 2.1_11\CD\1740 (_12\-LRB-\1740 95_13\CD\1740 percent_14\NN\13815742 confidence_15\NN\5697135 interval_16\NN\33615 ,_17\,\1740 1.5_18\CD\1740 to_19\TO\1740 3.0_20\CD\1740 )_21\-RRB-\1740 for_22\IN\1740 those_23\DT\1740 without_24\IN\1740 a_25\DT\13649268 prothrombotic_26\JJ\1740 mutation_27\NN\4475 and_28\CC\1740 1.9_29\CD\1740 (_30\-LRB-\1740 95_31\CD\1740 percent_32\NN\13815742 confidence_33\NN\5697135 interval_34\NN\33615 ,_35\,\1740 0.6_36\CD\1740 to_37\TO\1740 5.5_38\CD\1740 )_39\-RRB-\1740 for_40\IN\1740 those_41\DT\1740 with_42\IN\1740 a_43\DT\13649268 mutation_44\NN\4475 conclusions_45\NNS\5837957 :_46\:\1740 the_47\DT\1740 risk_48\NN\14541044 of_49\IN\1740 <e2>myocardial_50\JJ\1740 infarction</e2>_51\NN\14204950 was_52\VBD\836236 increased_53\VBN\169651 among_54\IN\1740 women_55\NNS\9605289 who_56\WP\8299493 used_57\VBD\1156834 second-generation_58\JJ\1740 oral_59\JJ\1740 contraceptives_60\NNS\3183080 ._61\.\1740
D003276_D009203 CID among_0\IN\1740 women_1\NNS\9605289 who_2\WP\8299493 used_3\VBD\1156834 oral_4\JJ\1740 contraceptives_5\NNS\3183080 ,_6\,\1740 the_7\DT\1740 odds_8\NNS\4756635 ratio_9\NN\13815152 was_10\VBD\836236 2.1_11\CD\1740 (_12\-LRB-\1740 95_13\CD\1740 percent_14\NN\13815742 confidence_15\NN\5697135 interval_16\NN\33615 ,_17\,\1740 1.5_18\CD\1740 to_19\TO\1740 3.0_20\CD\1740 )_21\-RRB-\1740 for_22\IN\1740 those_23\DT\1740 without_24\IN\1740 a_25\DT\13649268 prothrombotic_26\JJ\1740 mutation_27\NN\4475 and_28\CC\1740 1.9_29\CD\1740 (_30\-LRB-\1740 95_31\CD\1740 percent_32\NN\13815742 confidence_33\NN\5697135 interval_34\NN\33615 ,_35\,\1740 0.6_36\CD\1740 to_37\TO\1740 5.5_38\CD\1740 )_39\-RRB-\1740 for_40\IN\1740 those_41\DT\1740 with_42\IN\1740 a_43\DT\13649268 mutation_44\NN\4475 conclusions_45\NNS\5837957 :_46\:\1740 the_47\DT\1740 risk_48\NN\14541044 of_49\IN\1740 <e2>myocardial_50\JJ\1740 infarction</e2>_51\NN\14204950 was_52\VBD\836236 increased_53\VBN\169651 among_54\IN\1740 women_55\NNS\9605289 who_56\WP\8299493 used_57\VBD\1156834 second-generation_58\JJ\1740 <e1>oral_59\JJ\1740 contraceptives</e1>_60\NNS\3183080 ._61\.\1740
D003276_D009203 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 <e2>myocardial_3\JJ\1740 infarction</e2>_4\NN\14204950 was_5\VBD\836236 similar_6\JJ\1740 among_7\IN\1740 women_8\NNS\9605289 who_9\WP\8299493 used_10\VBD\1156834 <e1>oral_11\JJ\1740 contraceptives</e1>_12\NNS\3183080 whether_13\IN\1740 or_14\CC\3541091 not_15\RB\1740 they_16\PRP\1740 had_17\VBD\2108377 a_18\DT\13649268 prothrombotic_19\JJ\1740 mutation_20\NN\4475 ._21\.\1740
D011372_D009203 NONE we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 <e1>progestagen</e1>_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 desogestrel_17\NN\1740 or_18\CC\3541091 gestodene_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 levonorgestrel_26\NN\1740 )_27\-RRB-\1740 oral_28\JJ\1740 contraceptives_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 estrogen_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 <e2>myocardial_72\JJ\1740 infarction</e2>_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 myocardial_87\JJ\1740 infarction_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
D011372_D009203 NONE we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 <e1>progestagen</e1>_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 desogestrel_17\NN\1740 or_18\CC\3541091 gestodene_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 levonorgestrel_26\NN\1740 )_27\-RRB-\1740 oral_28\JJ\1740 contraceptives_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 estrogen_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 myocardial_72\JJ\1740 infarction_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 <e2>myocardial_87\JJ\1740 infarction</e2>_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
D017135_D009203 NONE we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 progestagen_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 <e1>desogestrel</e1>_17\NN\1740 or_18\CC\3541091 gestodene_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 levonorgestrel_26\NN\1740 )_27\-RRB-\1740 oral_28\JJ\1740 contraceptives_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 estrogen_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 <e2>myocardial_72\JJ\1740 infarction</e2>_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 myocardial_87\JJ\1740 infarction_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
D017135_D009203 NONE we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 progestagen_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 <e1>desogestrel</e1>_17\NN\1740 or_18\CC\3541091 gestodene_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 levonorgestrel_26\NN\1740 )_27\-RRB-\1740 oral_28\JJ\1740 contraceptives_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 estrogen_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 myocardial_72\JJ\1740 infarction_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 <e2>myocardial_87\JJ\1740 infarction</e2>_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
C033273_D009203 NONE we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 progestagen_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 desogestrel_17\NN\1740 or_18\CC\3541091 <e1>gestodene</e1>_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 levonorgestrel_26\NN\1740 )_27\-RRB-\1740 oral_28\JJ\1740 contraceptives_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 estrogen_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 <e2>myocardial_72\JJ\1740 infarction</e2>_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 myocardial_87\JJ\1740 infarction_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
C033273_D009203 NONE we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 progestagen_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 desogestrel_17\NN\1740 or_18\CC\3541091 <e1>gestodene</e1>_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 levonorgestrel_26\NN\1740 )_27\-RRB-\1740 oral_28\JJ\1740 contraceptives_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 estrogen_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 myocardial_72\JJ\1740 infarction_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 <e2>myocardial_87\JJ\1740 infarction</e2>_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
D016912_D009203 NONE we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 progestagen_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 desogestrel_17\NN\1740 or_18\CC\3541091 gestodene_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 <e1>levonorgestrel</e1>_26\NN\1740 )_27\-RRB-\1740 oral_28\JJ\1740 contraceptives_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 estrogen_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 <e2>myocardial_72\JJ\1740 infarction</e2>_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 myocardial_87\JJ\1740 infarction_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
D016912_D009203 NONE we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 progestagen_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 desogestrel_17\NN\1740 or_18\CC\3541091 gestodene_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 <e1>levonorgestrel</e1>_26\NN\1740 )_27\-RRB-\1740 oral_28\JJ\1740 contraceptives_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 estrogen_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 myocardial_72\JJ\1740 infarction_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 <e2>myocardial_87\JJ\1740 infarction</e2>_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
D004967_D009203 NONE we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 progestagen_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 desogestrel_17\NN\1740 or_18\CC\3541091 gestodene_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 levonorgestrel_26\NN\1740 )_27\-RRB-\1740 oral_28\JJ\1740 contraceptives_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 <e1>estrogen</e1>_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 <e2>myocardial_72\JJ\1740 infarction</e2>_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 myocardial_87\JJ\1740 infarction_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
D004967_D009203 NONE we_0\PRP\1740 investigated_1\VBD\644583 this_2\DT\1740 association_3\NN\8008335 ,_4\,\1740 according_5\VBG\2657219 to_6\IN\1740 the_7\DT\1740 type_8\NN\5839024 of_9\IN\1740 progestagen_10\NN\1740 included_11\VBN\690614 in_12\IN\13603305 third-generation_13\NN\1740 (_14\-LRB-\1740 i.e._15\FW\1740 ,_16\,\1740 desogestrel_17\NN\1740 or_18\CC\3541091 gestodene_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 second-generation_22\NN\1740 (_23\-LRB-\1740 i.e._24\FW\1740 ,_25\,\1740 levonorgestrel_26\NN\1740 )_27\-RRB-\1740 oral_28\JJ\1740 contraceptives_29\NNS\3183080 ,_30\,\1740 the_31\DT\1740 dose_32\NN\3740161 of_33\IN\1740 <e1>estrogen</e1>_34\NN\14745635 ,_35\,\1740 and_36\CC\1740 the_37\DT\1740 presence_38\NN\13954253 or_39\CC\3541091 absence_40\NN\14449405 of_41\IN\1740 prothrombotic_42\JJ\1740 mutations_43\NNS\4475 methods_44\NNS\5616786 :_45\:\1740 in_46\IN\13603305 a_47\DT\13649268 nationwide_48\JJ\1740 ,_49\,\1740 population-based_50\JJ\1740 ,_51\,\1740 case-control_52\JJ\1740 study_53\NN\635850 ,_54\,\1740 we_55\PRP\1740 identified_56\VBD\699815 and_57\CC\1740 enrolled_58\VBD\2471690 248_59\CD\1740 women_60\NNS\9605289 18_61\CD\13745420 through_62\IN\1740 49_63\CD\1740 years_64\NNS\15144371 of_65\IN\1740 age_66\NN\4916342 who_67\WP\8299493 had_68\VBD\2108377 had_69\VBN\2108377 a_70\DT\13649268 first_71\JJ\1740 myocardial_72\JJ\1740 infarction_73\NN\14204950 between_74\IN\1740 1990_75\CD\1740 and_76\CC\1740 1995_77\CD\1740 and_78\CC\1740 925_79\CD\1740 control_80\NN\5190804 women_81\NNS\9605289 who_82\WP\8299493 had_83\VBD\2108377 not_84\RB\1740 had_85\VBN\2108377 a_86\DT\13649268 <e2>myocardial_87\JJ\1740 infarction</e2>_88\NN\14204950 and_89\CC\1740 who_90\WP\8299493 were_91\VBD\836236 matched_92\VBN\2664769 for_93\IN\1740 age_94\NN\4916342 ,_95\,\1740 calendar_96\NN\5726596 year_97\NN\15113229 of_98\IN\1740 the_99\DT\1740 index_100\NN\13850304 event_101\NN\23100 ,_102\,\1740 and_103\CC\1740 area_104\NN\8630985 of_105\IN\1740 residence_106\NN\8491027 ._107\.\1740
7444978
D013307_D020258 NONE age-dependent_0\JJ\1740 sensitivity_1\NN\5651971 of_2\IN\1740 the_3\DT\1740 rat_4\NN\2329401 to_5\TO\1740 <e2>neurotoxic</e2>_6\JJ\1740 effects_7\NNS\13245626 of_8\IN\1740 <e1>streptomycin</e1>_9\NN\2716866 ._10\.\1740
D013307_D004409 CID <e2>abnormal_0\JJ\1740 movements</e2>_1\NNS\191142 and_2\CC\1740 deafness_3\VBP\1740 occurred_4\VBD\2623529 only_5\RB\1740 in_6\IN\13603305 rats_7\NNS\2329401 treated_8\VBN\2376958 during_9\IN\1740 the_10\DT\1740 preweaning_11\VBG\1740 period_12\NN\13575869 ;_13\:\1740 within_14\IN\1740 this_15\DT\1740 period_16\NN\13575869 the_17\DT\1740 greatest_18\JJS\1740 sensitivities_19\NNS\5651971 for_20\IN\1740 these_21\DT\1740 abnormalities_22\NNS\14034177 occurred_23\VBD\2623529 from_24\IN\1740 2_25\CD\13741022 to_26\TO\1740 11_27\CD\13745420 -_28\SYM\1740 17_29\CD\13745420 and_30\CC\1740 5_31\CD\13741022 to_32\TO\1740 11_33\CD\13745420 days_34\NNS\15140892 of_35\IN\1740 age_36\NN\4916342 ,_37\,\1740 respectively_38\RB\1740 ,_39\,\1740 indicating_40\VBG\952524 that_41\IN\1740 the_42\DT\1740 cochlea_43\NN\5246511 is_44\VBZ\836236 more_45\RBR\1740 sensitive_46\JJ\1740 to_47\TO\1740 <e1>streptomycin</e1>_48\NN\2716866 than_49\IN\1740 the_50\DT\1740 site_51\NN\8673395 (_52\-LRB-\1740 vestibular_53\JJ\1740 or_54\CC\3541091 central_55\JJ\1740 )_56\-RRB-\1740 responsible_57\JJ\1740 for_58\IN\1740 the_59\DT\1740 dyskinesias_60\NNS\14084880 ._61\.\1740
D013307_D004409 CID abnormal_0\JJ\1740 movements_1\NNS\191142 and_2\CC\1740 deafness_3\VBP\1740 occurred_4\VBD\2623529 only_5\RB\1740 in_6\IN\13603305 rats_7\NNS\2329401 treated_8\VBN\2376958 during_9\IN\1740 the_10\DT\1740 preweaning_11\VBG\1740 period_12\NN\13575869 ;_13\:\1740 within_14\IN\1740 this_15\DT\1740 period_16\NN\13575869 the_17\DT\1740 greatest_18\JJS\1740 sensitivities_19\NNS\5651971 for_20\IN\1740 these_21\DT\1740 abnormalities_22\NNS\14034177 occurred_23\VBD\2623529 from_24\IN\1740 2_25\CD\13741022 to_26\TO\1740 11_27\CD\13745420 -_28\SYM\1740 17_29\CD\13745420 and_30\CC\1740 5_31\CD\13741022 to_32\TO\1740 11_33\CD\13745420 days_34\NNS\15140892 of_35\IN\1740 age_36\NN\4916342 ,_37\,\1740 respectively_38\RB\1740 ,_39\,\1740 indicating_40\VBG\952524 that_41\IN\1740 the_42\DT\1740 cochlea_43\NN\5246511 is_44\VBZ\836236 more_45\RBR\1740 sensitive_46\JJ\1740 to_47\TO\1740 <e1>streptomycin</e1>_48\NN\2716866 than_49\IN\1740 the_50\DT\1740 site_51\NN\8673395 (_52\-LRB-\1740 vestibular_53\JJ\1740 or_54\CC\3541091 central_55\JJ\1740 )_56\-RRB-\1740 responsible_57\JJ\1740 for_58\IN\1740 the_59\DT\1740 <e2>dyskinesias</e2>_60\NNS\14084880 ._61\.\1740
D013307_D003638 CID abnormal_0\JJ\1740 movements_1\NNS\191142 and_2\CC\1740 <e2>deafness</e2>_3\VBP\1740 occurred_4\VBD\2623529 only_5\RB\1740 in_6\IN\13603305 rats_7\NNS\2329401 treated_8\VBN\2376958 during_9\IN\1740 the_10\DT\1740 preweaning_11\VBG\1740 period_12\NN\13575869 ;_13\:\1740 within_14\IN\1740 this_15\DT\1740 period_16\NN\13575869 the_17\DT\1740 greatest_18\JJS\1740 sensitivities_19\NNS\5651971 for_20\IN\1740 these_21\DT\1740 abnormalities_22\NNS\14034177 occurred_23\VBD\2623529 from_24\IN\1740 2_25\CD\13741022 to_26\TO\1740 11_27\CD\13745420 -_28\SYM\1740 17_29\CD\13745420 and_30\CC\1740 5_31\CD\13741022 to_32\TO\1740 11_33\CD\13745420 days_34\NNS\15140892 of_35\IN\1740 age_36\NN\4916342 ,_37\,\1740 respectively_38\RB\1740 ,_39\,\1740 indicating_40\VBG\952524 that_41\IN\1740 the_42\DT\1740 cochlea_43\NN\5246511 is_44\VBZ\836236 more_45\RBR\1740 sensitive_46\JJ\1740 to_47\TO\1740 <e1>streptomycin</e1>_48\NN\2716866 than_49\IN\1740 the_50\DT\1740 site_51\NN\8673395 (_52\-LRB-\1740 vestibular_53\JJ\1740 or_54\CC\3541091 central_55\JJ\1740 )_56\-RRB-\1740 responsible_57\JJ\1740 for_58\IN\1740 the_59\DT\1740 dyskinesias_60\NNS\14084880 ._61\.\1740
18544179
D005283_D009325 NONE omitting_0\VBG\471711 <e1>fentanyl</e1>_1\NN\2707683 reduces_2\VBZ\441445 <e2>nausea</e2>_3\NN\14299637 and_4\CC\1740 vomiting_5\NN\116687 ,_6\,\1740 without_7\IN\1740 increasing_8\VBG\169651 pain_9\NN\14299637 ,_10\,\1740 after_11\IN\1740 sevoflurane_12\NN\1740 for_13\IN\1740 day_14\NN\15154774 surgery_15\NN\6045562 ._16\.\1740
D005283_D009325 NONE results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 <e1>fentanyl</e1>_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 vomiting_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 <e2>nausea</e2>_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 fentanyl_39\NN\2707683 and_40\CC\1740 fentanyl-dexamethasone_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D005283_D009325 NONE results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 fentanyl_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 vomiting_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 <e2>nausea</e2>_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 <e1>fentanyl</e1>_39\NN\2707683 and_40\CC\1740 fentanyl-dexamethasone_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D005283_D009325 NONE results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 fentanyl_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 vomiting_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 <e2>nausea</e2>_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 fentanyl_39\NN\2707683 and_40\CC\1740 <e1>fentanyl-dexamethasone</e1>_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D005283_D009325 NONE combining_0\VBG\2630189 the_1\DT\1740 two_2\CD\13741022 <e1>fentanyl</e1>_3\JJ\1740 groups_4\NNS\2137 revealed_5\VBD\2137132 further_6\RB\1740 significant_7\JJ\1740 benefits_8\NNS\13278375 from_9\IN\1740 the_10\DT\1740 avoidance_11\NN\203342 of_12\IN\1740 opioids_13\NNS\1740 ,_14\,\1740 reducing_15\VBG\441445 postoperative_16\JJ\1740 nausea_17\NN\14299637 and_18\CC\1740 vomiting_19\NN\116687 and_20\CC\1740 <e2>nausea</e2>_21\NN\14299637 prior_22\RB\1740 to_23\TO\1740 discharge_24\VB\1640855 from_25\IN\1740 35_26\CD\1740 %_27\NN\1740 and_28\CC\1740 33_29\CD\1740 %_30\NN\1740 to_31\TO\1740 22_32\CD\13745420 %_33\NN\1740 and_34\CC\1740 19_35\CD\13745420 %_36\NN\1740 (_37\-LRB-\1740 p_38\NN\14622893 =_39\JJ\1740 0.049_40\CD\1740 and_41\CC\1740 p_42\NN\14622893 =_43\JJ\1740 0.035_44\CD\1740 )_45\-RRB-\1740 ,_46\,\1740 respectively_47\RB\1740 ,_48\,\1740 while_49\IN\15122231 nausea_50\NN\14299637 in_51\IN\13603305 the_52\DT\1740 first_53\JJ\1740 24_54\CD\13745420 h_55\NN\14622893 was_56\VBD\836236 decreased_57\VBN\169651 from_58\IN\1740 42_59\CD\1740 %_60\NN\1740 to_61\TO\1740 27_62\CD\13745420 %_63\NN\1740 (_64\-LRB-\1740 p_65\NN\14622893 =_66\JJ\1740 0.034_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D005283_D009325 NONE combining_0\VBG\2630189 the_1\DT\1740 two_2\CD\13741022 <e1>fentanyl</e1>_3\JJ\1740 groups_4\NNS\2137 revealed_5\VBD\2137132 further_6\RB\1740 significant_7\JJ\1740 benefits_8\NNS\13278375 from_9\IN\1740 the_10\DT\1740 avoidance_11\NN\203342 of_12\IN\1740 opioids_13\NNS\1740 ,_14\,\1740 reducing_15\VBG\441445 postoperative_16\JJ\1740 nausea_17\NN\14299637 and_18\CC\1740 vomiting_19\NN\116687 and_20\CC\1740 nausea_21\NN\14299637 prior_22\RB\1740 to_23\TO\1740 discharge_24\VB\1640855 from_25\IN\1740 35_26\CD\1740 %_27\NN\1740 and_28\CC\1740 33_29\CD\1740 %_30\NN\1740 to_31\TO\1740 22_32\CD\13745420 %_33\NN\1740 and_34\CC\1740 19_35\CD\13745420 %_36\NN\1740 (_37\-LRB-\1740 p_38\NN\14622893 =_39\JJ\1740 0.049_40\CD\1740 and_41\CC\1740 p_42\NN\14622893 =_43\JJ\1740 0.035_44\CD\1740 )_45\-RRB-\1740 ,_46\,\1740 respectively_47\RB\1740 ,_48\,\1740 while_49\IN\15122231 <e2>nausea</e2>_50\NN\14299637 in_51\IN\13603305 the_52\DT\1740 first_53\JJ\1740 24_54\CD\13745420 h_55\NN\14622893 was_56\VBD\836236 decreased_57\VBN\169651 from_58\IN\1740 42_59\CD\1740 %_60\NN\1740 to_61\TO\1740 27_62\CD\13745420 %_63\NN\1740 (_64\-LRB-\1740 p_65\NN\14622893 =_66\JJ\1740 0.034_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D005283_D014839 NONE omitting_0\VBG\471711 <e1>fentanyl</e1>_1\NN\2707683 reduces_2\VBZ\441445 nausea_3\NN\14299637 and_4\CC\1740 <e2>vomiting</e2>_5\NN\116687 ,_6\,\1740 without_7\IN\1740 increasing_8\VBG\169651 pain_9\NN\14299637 ,_10\,\1740 after_11\IN\1740 sevoflurane_12\NN\1740 for_13\IN\1740 day_14\NN\15154774 surgery_15\NN\6045562 ._16\.\1740
D005283_D014839 NONE results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 <e1>fentanyl</e1>_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 <e2>vomiting</e2>_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 nausea_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 fentanyl_39\NN\2707683 and_40\CC\1740 fentanyl-dexamethasone_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D005283_D014839 NONE results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 fentanyl_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 <e2>vomiting</e2>_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 nausea_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 <e1>fentanyl</e1>_39\NN\2707683 and_40\CC\1740 fentanyl-dexamethasone_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D005283_D014839 NONE results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 fentanyl_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 <e2>vomiting</e2>_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 nausea_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 fentanyl_39\NN\2707683 and_40\CC\1740 <e1>fentanyl-dexamethasone</e1>_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D005283_D010146 NONE omitting_0\VBG\471711 <e1>fentanyl</e1>_1\NN\2707683 reduces_2\VBZ\441445 nausea_3\NN\14299637 and_4\CC\1740 vomiting_5\NN\116687 ,_6\,\1740 without_7\IN\1740 increasing_8\VBG\169651 <e2>pain</e2>_9\NN\14299637 ,_10\,\1740 after_11\IN\1740 sevoflurane_12\NN\1740 for_13\IN\1740 day_14\NN\15154774 surgery_15\NN\6045562 ._16\.\1740
D005283_D010146 NONE <e2>pain</e2>_0\NN\14299637 severity_1\NN\5036394 and_2\CC\1740 analgesic_3\NN\3740161 requirements_4\NNS\1129920 were_5\VBD\836236 unaffected_6\JJ\1740 by_7\IN\1740 the_8\DT\1740 omission_9\NN\70965 of_10\IN\1740 <e1>fentanyl</e1>_11\NN\2707683 ._12\.\1740
C009250_D009325 NONE omitting_0\VBG\471711 fentanyl_1\NN\2707683 reduces_2\VBZ\441445 <e2>nausea</e2>_3\NN\14299637 and_4\CC\1740 vomiting_5\NN\116687 ,_6\,\1740 without_7\IN\1740 increasing_8\VBG\169651 pain_9\NN\14299637 ,_10\,\1740 after_11\IN\1740 <e1>sevoflurane</e1>_12\NN\1740 for_13\IN\1740 day_14\NN\15154774 surgery_15\NN\6045562 ._16\.\1740
C009250_D014839 NONE omitting_0\VBG\471711 fentanyl_1\NN\2707683 reduces_2\VBZ\441445 nausea_3\NN\14299637 and_4\CC\1740 <e2>vomiting</e2>_5\NN\116687 ,_6\,\1740 without_7\IN\1740 increasing_8\VBG\169651 pain_9\NN\14299637 ,_10\,\1740 after_11\IN\1740 <e1>sevoflurane</e1>_12\NN\1740 for_13\IN\1740 day_14\NN\15154774 surgery_15\NN\6045562 ._16\.\1740
C009250_D010146 NONE omitting_0\VBG\471711 fentanyl_1\NN\2707683 reduces_2\VBZ\441445 nausea_3\NN\14299637 and_4\CC\1740 vomiting_5\NN\116687 ,_6\,\1740 without_7\IN\1740 increasing_8\VBG\169651 <e2>pain</e2>_9\NN\14299637 ,_10\,\1740 after_11\IN\1740 <e1>sevoflurane</e1>_12\NN\1740 for_13\IN\1740 day_14\NN\15154774 surgery_15\NN\6045562 ._16\.\1740
C009250_D010146 NONE methods_0\NNS\5616786 :_1\:\1740 this_2\DT\1740 double-blind_3\JJ\1740 study_4\NN\635850 examined_5\VBD\789138 the_6\DT\1740 incidence_7\NN\13821570 and_8\CC\1740 severity_9\NN\5036394 of_10\IN\1740 postoperative_11\JJ\1740 nausea_12\NN\14299637 and_13\CC\1740 vomiting_14\NN\116687 and_15\CC\1740 <e2>pain</e2>_16\NN\14299637 in_17\IN\13603305 the_18\DT\1740 first_19\JJ\1740 24_20\CD\13745420 h_21\NN\14622893 after_22\IN\1740 <e1>sevoflurane</e1>_23\NN\1740 anaesthesia_24\NN\14034177 in_25\IN\13603305 216_26\CD\1740 adult_27\JJ\1740 day_28\NN\15154774 surgery_29\NN\6045562 patients_30\NNS\9898892 ._31\.\1740
C009250_D020250 NONE background_0\NN\4921011 and_1\CC\1740 objective_2\NN\5980875 :_3\:\1740 despite_4\IN\7501545 advantages_5\NNS\5154517 of_6\IN\1740 induction_7\NN\7450842 and_8\CC\1740 maintenance_9\NN\266806 of_10\IN\1740 anaesthesia_11\NN\14034177 with_12\IN\1740 <e1>sevoflurane</e1>_13\NN\1740 ,_14\,\1740 <e2>postoperative_15\JJ\1740 nausea_16\NN\14299637 and_17\CC\1740 vomiting</e2>_18\NN\116687 occurs_19\VBZ\2623529 frequently_20\RB\1740 ._21\.\1740
C009250_D020250 NONE methods_0\NNS\5616786 :_1\:\1740 this_2\DT\1740 double-blind_3\JJ\1740 study_4\NN\635850 examined_5\VBD\789138 the_6\DT\1740 incidence_7\NN\13821570 and_8\CC\1740 severity_9\NN\5036394 of_10\IN\1740 <e2>postoperative_11\JJ\1740 nausea_12\NN\14299637 and_13\CC\1740 vomiting</e2>_14\NN\116687 and_15\CC\1740 pain_16\NN\14299637 in_17\IN\13603305 the_18\DT\1740 first_19\JJ\1740 24_20\CD\13745420 h_21\NN\14622893 after_22\IN\1740 <e1>sevoflurane</e1>_23\NN\1740 anaesthesia_24\NN\14034177 in_25\IN\13603305 216_26\CD\1740 adult_27\JJ\1740 day_28\NN\15154774 surgery_29\NN\6045562 patients_30\NNS\9898892 ._31\.\1740
C009250_D020250 NONE conclusion_0\NN\5837957 :_1\:\1740 as_2\IN\14622893 fentanyl_3\JJ\1740 exacerbated_4\JJ\1740 <e2>postoperative_5\JJ\1740 nausea_6\NN\14299637 and_7\CC\1740 vomiting</e2>_8\NN\116687 without_9\IN\1740 an_10\DT\6697703 improvement_11\NN\7359599 in_12\IN\13603305 postoperative_13\JJ\1740 pain_14\NN\14299637 and_15\CC\1740 also_16\RB\1740 had_17\VBD\2108377 adverse_18\JJ\1740 cardiorespiratory_19\JJ\1740 effects_20\NNS\13245626 ,_21\,\1740 it_22\PRP\6125041 appears_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 an_26\DT\6697703 unnecessary_27\JJ\1740 and_28\CC\1740 possibly_29\RB\1740 detrimental_30\VB\1740 supplement_31\NN\6365467 to_32\TO\1740 <e1>sevoflurane</e1>_33\NN\1740 in_34\IN\13603305 day_35\NN\15154774 surgery_36\NN\6045562 ._37\.\1740
D005283_D020250 CID results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 <e1>fentanyl</e1>_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 <e2>postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting</e2>_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 vomiting_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 nausea_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 fentanyl_39\NN\2707683 and_40\CC\1740 fentanyl-dexamethasone_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D005283_D020250 CID results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 fentanyl_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 <e2>postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting</e2>_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 vomiting_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 nausea_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 <e1>fentanyl</e1>_39\NN\2707683 and_40\CC\1740 fentanyl-dexamethasone_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D005283_D020250 CID results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 fentanyl_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 <e2>postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting</e2>_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 vomiting_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 nausea_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 fentanyl_39\NN\2707683 and_40\CC\1740 <e1>fentanyl-dexamethasone</e1>_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D005283_D020250 CID combining_0\VBG\2630189 the_1\DT\1740 two_2\CD\13741022 <e1>fentanyl</e1>_3\JJ\1740 groups_4\NNS\2137 revealed_5\VBD\2137132 further_6\RB\1740 significant_7\JJ\1740 benefits_8\NNS\13278375 from_9\IN\1740 the_10\DT\1740 avoidance_11\NN\203342 of_12\IN\1740 opioids_13\NNS\1740 ,_14\,\1740 reducing_15\VBG\441445 <e2>postoperative_16\JJ\1740 nausea_17\NN\14299637 and_18\CC\1740 vomiting</e2>_19\NN\116687 and_20\CC\1740 nausea_21\NN\14299637 prior_22\RB\1740 to_23\TO\1740 discharge_24\VB\1640855 from_25\IN\1740 35_26\CD\1740 %_27\NN\1740 and_28\CC\1740 33_29\CD\1740 %_30\NN\1740 to_31\TO\1740 22_32\CD\13745420 %_33\NN\1740 and_34\CC\1740 19_35\CD\13745420 %_36\NN\1740 (_37\-LRB-\1740 p_38\NN\14622893 =_39\JJ\1740 0.049_40\CD\1740 and_41\CC\1740 p_42\NN\14622893 =_43\JJ\1740 0.035_44\CD\1740 )_45\-RRB-\1740 ,_46\,\1740 respectively_47\RB\1740 ,_48\,\1740 while_49\IN\15122231 nausea_50\NN\14299637 in_51\IN\13603305 the_52\DT\1740 first_53\JJ\1740 24_54\CD\13745420 h_55\NN\14622893 was_56\VBD\836236 decreased_57\VBN\169651 from_58\IN\1740 42_59\CD\1740 %_60\NN\1740 to_61\TO\1740 27_62\CD\13745420 %_63\NN\1740 (_64\-LRB-\1740 p_65\NN\14622893 =_66\JJ\1740 0.034_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D005283_D020250 CID conclusion_0\NN\5837957 :_1\:\1740 as_2\IN\14622893 <e1>fentanyl</e1>_3\JJ\1740 exacerbated_4\JJ\1740 <e2>postoperative_5\JJ\1740 nausea_6\NN\14299637 and_7\CC\1740 vomiting</e2>_8\NN\116687 without_9\IN\1740 an_10\DT\6697703 improvement_11\NN\7359599 in_12\IN\13603305 postoperative_13\JJ\1740 pain_14\NN\14299637 and_15\CC\1740 also_16\RB\1740 had_17\VBD\2108377 adverse_18\JJ\1740 cardiorespiratory_19\JJ\1740 effects_20\NNS\13245626 ,_21\,\1740 it_22\PRP\6125041 appears_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 an_26\DT\6697703 unnecessary_27\JJ\1740 and_28\CC\1740 possibly_29\RB\1740 detrimental_30\VB\1740 supplement_31\NN\6365467 to_32\TO\1740 sevoflurane_33\NN\1740 in_34\IN\13603305 day_35\NN\15154774 surgery_36\NN\6045562 ._37\.\1740
D003907_D020250 NONE results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 fentanyl_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 <e2>postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting</e2>_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 vomiting_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 nausea_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 fentanyl_39\NN\2707683 and_40\CC\1740 <e1>fentanyl-dexamethasone</e1>_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D003907_D020250 NONE <e1>dexamethasone</e1>_0\NN\2721538 had_1\VBD\2108377 no_2\DT\7204911 significant_3\JJ\1740 effect_4\NN\34213 on_5\IN\1740 the_6\DT\1740 incidence_7\NN\13821570 or_8\CC\3541091 severity_9\NN\5036394 of_10\IN\1740 <e2>postoperative_11\JJ\1740 nausea_12\NN\14299637 and_13\CC\1740 vomiting</e2>_14\NN\116687 ._15\.\1740
D003907_D014839 NONE results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 fentanyl_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 <e2>vomiting</e2>_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 nausea_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 fentanyl_39\NN\2707683 and_40\CC\1740 <e1>fentanyl-dexamethasone</e1>_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D003907_D009325 NONE results_0\NNS\34213 :_1\:\1740 omission_2\NN\70965 of_3\IN\1740 fentanyl_4\NN\2707683 did_5\VBD\1640855 not_6\RB\1740 reduce_7\VB\441445 the_8\DT\1740 overall_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 postoperative_12\JJ\1740 nausea_13\NN\14299637 and_14\CC\1740 vomiting_15\NN\116687 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 reduce_19\VB\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 vomiting_23\NN\116687 and/or_24\CC\1740 moderate_25\JJ\1740 to_26\IN\1740 severe_27\JJ\1740 <e2>nausea</e2>_28\NN\14299637 prior_29\RB\1740 to_30\TO\1740 discharge_31\VB\1640855 from_32\IN\1740 20_33\CD\13745420 %_34\NN\1740 and_35\CC\1740 17_36\CD\13745420 %_37\NN\1740 with_38\IN\1740 fentanyl_39\NN\2707683 and_40\CC\1740 <e1>fentanyl-dexamethasone</e1>_41\NN\1740 ,_42\,\1740 respectively_43\RB\1740 ,_44\,\1740 to_45\TO\1740 5_46\CD\13741022 %_47\NN\1740 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.013_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D005283_D012131 CID <e1>fentanyl</e1>_0\NNP\2707683 did_1\VBD\1640855 reduce_2\VB\441445 minor_3\JJ\1740 intraoperative_4\JJ\1740 movement_5\NN\191142 but_6\CC\1740 had_7\VBD\2108377 no_8\DT\7204911 sevoflurane-sparing_9\JJ\1740 effect_10\NN\34213 and_11\CC\1740 increased_12\VBN\169651 <e2>respiratory_13\JJ\1740 depression</e2>_14\NN\14373582 ,_15\,\1740 hypotension_16\NN\14057371 and_17\CC\1740 bradycardia_18\NN\14110674 ._19\.\1740
D005283_D007022 CID <e1>fentanyl</e1>_0\NNP\2707683 did_1\VBD\1640855 reduce_2\VB\441445 minor_3\JJ\1740 intraoperative_4\JJ\1740 movement_5\NN\191142 but_6\CC\1740 had_7\VBD\2108377 no_8\DT\7204911 sevoflurane-sparing_9\JJ\1740 effect_10\NN\34213 and_11\CC\1740 increased_12\VBN\169651 respiratory_13\JJ\1740 depression_14\NN\14373582 ,_15\,\1740 <e2>hypotension</e2>_16\NN\14057371 and_17\CC\1740 bradycardia_18\NN\14110674 ._19\.\1740
D005283_D001919 CID <e1>fentanyl</e1>_0\NNP\2707683 did_1\VBD\1640855 reduce_2\VB\441445 minor_3\JJ\1740 intraoperative_4\JJ\1740 movement_5\NN\191142 but_6\CC\1740 had_7\VBD\2108377 no_8\DT\7204911 sevoflurane-sparing_9\JJ\1740 effect_10\NN\34213 and_11\CC\1740 increased_12\VBN\169651 respiratory_13\JJ\1740 depression_14\NN\14373582 ,_15\,\1740 hypotension_16\NN\14057371 and_17\CC\1740 <e2>bradycardia</e2>_18\NN\14110674 ._19\.\1740
C009250_D012131 NONE fentanyl_0\NNP\2707683 did_1\VBD\1640855 reduce_2\VB\441445 minor_3\JJ\1740 intraoperative_4\JJ\1740 movement_5\NN\191142 but_6\CC\1740 had_7\VBD\2108377 no_8\DT\7204911 <e1>sevoflurane-sparing</e1>_9\JJ\1740 effect_10\NN\34213 and_11\CC\1740 increased_12\VBN\169651 <e2>respiratory_13\JJ\1740 depression</e2>_14\NN\14373582 ,_15\,\1740 hypotension_16\NN\14057371 and_17\CC\1740 bradycardia_18\NN\14110674 ._19\.\1740
C009250_D007022 NONE fentanyl_0\NNP\2707683 did_1\VBD\1640855 reduce_2\VB\441445 minor_3\JJ\1740 intraoperative_4\JJ\1740 movement_5\NN\191142 but_6\CC\1740 had_7\VBD\2108377 no_8\DT\7204911 <e1>sevoflurane-sparing</e1>_9\JJ\1740 effect_10\NN\34213 and_11\CC\1740 increased_12\VBN\169651 respiratory_13\JJ\1740 depression_14\NN\14373582 ,_15\,\1740 <e2>hypotension</e2>_16\NN\14057371 and_17\CC\1740 bradycardia_18\NN\14110674 ._19\.\1740
C009250_D001919 NONE fentanyl_0\NNP\2707683 did_1\VBD\1640855 reduce_2\VB\441445 minor_3\JJ\1740 intraoperative_4\JJ\1740 movement_5\NN\191142 but_6\CC\1740 had_7\VBD\2108377 no_8\DT\7204911 <e1>sevoflurane-sparing</e1>_9\JJ\1740 effect_10\NN\34213 and_11\CC\1740 increased_12\VBN\169651 respiratory_13\JJ\1740 depression_14\NN\14373582 ,_15\,\1740 hypotension_16\NN\14057371 and_17\CC\1740 <e2>bradycardia</e2>_18\NN\14110674 ._19\.\1740
D005283_D010149 NONE conclusion_0\NN\5837957 :_1\:\1740 as_2\IN\14622893 <e1>fentanyl</e1>_3\JJ\1740 exacerbated_4\JJ\1740 postoperative_5\JJ\1740 nausea_6\NN\14299637 and_7\CC\1740 vomiting_8\NN\116687 without_9\IN\1740 an_10\DT\6697703 improvement_11\NN\7359599 in_12\IN\13603305 <e2>postoperative_13\JJ\1740 pain</e2>_14\NN\14299637 and_15\CC\1740 also_16\RB\1740 had_17\VBD\2108377 adverse_18\JJ\1740 cardiorespiratory_19\JJ\1740 effects_20\NNS\13245626 ,_21\,\1740 it_22\PRP\6125041 appears_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 an_26\DT\6697703 unnecessary_27\JJ\1740 and_28\CC\1740 possibly_29\RB\1740 detrimental_30\VB\1740 supplement_31\NN\6365467 to_32\TO\1740 sevoflurane_33\NN\1740 in_34\IN\13603305 day_35\NN\15154774 surgery_36\NN\6045562 ._37\.\1740
C009250_D010149 NONE conclusion_0\NN\5837957 :_1\:\1740 as_2\IN\14622893 fentanyl_3\JJ\1740 exacerbated_4\JJ\1740 postoperative_5\JJ\1740 nausea_6\NN\14299637 and_7\CC\1740 vomiting_8\NN\116687 without_9\IN\1740 an_10\DT\6697703 improvement_11\NN\7359599 in_12\IN\13603305 <e2>postoperative_13\JJ\1740 pain</e2>_14\NN\14299637 and_15\CC\1740 also_16\RB\1740 had_17\VBD\2108377 adverse_18\JJ\1740 cardiorespiratory_19\JJ\1740 effects_20\NNS\13245626 ,_21\,\1740 it_22\PRP\6125041 appears_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 an_26\DT\6697703 unnecessary_27\JJ\1740 and_28\CC\1740 possibly_29\RB\1740 detrimental_30\VB\1740 supplement_31\NN\6365467 to_32\TO\1740 <e1>sevoflurane</e1>_33\NN\1740 in_34\IN\13603305 day_35\NN\15154774 surgery_36\NN\6045562 ._37\.\1740
17241784
D019821_D009135 CID progressive_0\JJ\1740 <e2>myopathy</e2>_1\NN\14204950 with_2\IN\1740 up-regulation_3\NN\1740 of_4\IN\1740 mhc-i_5\NN\1740 associated_6\VBN\628491 with_7\IN\1740 <e1>statin</e1>_8\NN\3740161 therapy_9\NN\657604 ._10\.\1740
D019821_D009135 CID <e1>statins</e1>_0\NNS\3740161 can_1\MD\3094503 cause_2\VB\1617192 a_3\DT\13649268 necrotizing_4\NN\1740 <e2>myopathy</e2>_5\NN\14204950 and_6\CC\1740 hyperckaemia_7\NN\1740 which_8\WDT\1740 is_9\VBZ\836236 reversible_10\JJ\1740 on_11\IN\1740 cessation_12\NN\7365849 of_13\IN\1740 the_14\DT\1740 drug_15\NN\14778436 ._16\.\1740
D019821_D009135 CID what_0\WP\1740 is_1\VBZ\836236 less_2\RBR\1740 well_3\RB\1740 known_4\JJ\1740 is_5\VBZ\836236 a_6\DT\13649268 phenomenon_7\NN\29677 whereby_8\WRB\1740 <e1>statins</e1>_9\NNS\3740161 may_10\MD\15209706 induce_11\VB\1627355 a_12\DT\13649268 <e2>myopathy</e2>_13\JJ\1740 ,_14\,\1740 which_15\WDT\1740 persists_16\VBZ\118523 or_17\CC\3541091 may_18\MD\15209706 progress_19\VB\252019 after_20\IN\1740 stopping_21\VBG\2452885 the_22\DT\1740 drug_23\NN\14778436 ._24\.\1740
D019821_D009135 CID these_0\DT\1740 observations_1\NNS\996969 suggest_2\VBP\1010118 that_3\IN\1740 <e1>statins</e1>_4\NNS\3740161 may_5\MD\15209706 initiate_6\VB\1617192 an_7\DT\6697703 immune-mediated_8\JJ\1740 <e2>myopathy</e2>_9\NN\14204950 that_10\WDT\1740 persists_11\VBZ\118523 after_12\IN\1740 withdrawal_13\NN\7206096 of_14\IN\1740 the_15\DT\1740 drug_16\NN\14778436 and_17\CC\1740 responds_18\VBZ\2367363 to_19\TO\1740 immunosuppressive_20\JJ\1740 therapy_21\NN\657604 ._22\.\1740
D019821_D009135 CID the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 this_3\DT\1740 <e2>myopathy</e2>_4\NN\14204950 is_5\VBZ\836236 uncertain_6\JJ\1740 but_7\CC\1740 may_8\MD\15209706 involve_9\VB\2676054 the_10\DT\1740 induction_11\NN\7450842 by_12\IN\1740 <e1>statins</e1>_13\NNS\3740161 of_14\IN\1740 an_15\DT\6697703 endoplasmic_16\JJ\1740 reticulum_17\NN\8434259 stress_18\NN\7083732 response_19\NN\11410625 with_20\IN\1740 associated_21\VBN\628491 up-regulation_22\NN\1740 of_23\IN\1740 mhc-i_24\NN\1740 expression_25\NN\4679549 and_26\CC\1740 antigen_27\NN\20090 presentation_28\NN\1027379 by_29\IN\1740 muscle_30\NN\5289601 fibres_31\NNS\14580897 ._32\.\1740
D019821_-1 NONE <e1>statins</e1>_0\NNS\3740161 can_1\MD\3094503 cause_2\VB\1617192 a_3\DT\13649268 necrotizing_4\NN\1740 myopathy_5\NN\14204950 and_6\CC\1740 <e2>hyperckaemia</e2>_7\NN\1740 which_8\WDT\1740 is_9\VBZ\836236 reversible_10\JJ\1740 on_11\IN\1740 cessation_12\NN\7365849 of_13\IN\1740 the_14\DT\1740 drug_15\NN\14778436 ._16\.\1740
19308880
D014635_D003221 CID <e2>confusion</e2>_0\NN\13972797 ,_1\,\1740 a_2\DT\13649268 rather_3\RB\1740 serious_4\JJ\1740 adverse_5\JJ\1740 drug_6\NN\14778436 reaction_7\NN\13446390 with_8\IN\1740 <e1>valproic_9\JJ\1740 acid</e1>_10\NN\14818238 :_11\:\1740 a_12\DT\13649268 review_13\NN\5733583 of_14\IN\1740 the_15\DT\1740 french_16\JJ\1740 pharmacovigilance_17\NN\1740 database_18\NN\6634376 ._19\.\1740
D014635_D003221 CID introduction_0\NNP\235435 :_1\:\1740 <e2>confusion</e2>_2\NN\13972797 is_3\VBZ\836236 an_4\DT\6697703 adverse_5\JJ\1740 drug_6\NN\14778436 reaction_7\NN\13446390 frequently_8\RB\1740 observed_9\VBN\2163746 with_10\IN\1740 <e1>valproic_11\JJ\1740 acid</e1>_12\NN\14818238 ._13\.\1740
D014635_D003221 CID methods_0\NNS\5616786 :_1\:\1740 using_2\VBG\1156834 the_3\DT\1740 french_4\JJ\1740 pharmacovigilance_5\NN\1740 database_6\NN\6634376 ,_7\,\1740 we_8\PRP\1740 selected_9\VBD\697589 the_10\DT\1740 cases_11\NNS\7283608 of_12\IN\1740 <e2>confusion</e2>_13\NN\13972797 reported_14\VBN\831651 since_15\IN\1740 1985_16\CD\1740 with_17\IN\1740 <e1>valproic_18\JJ\1740 acid</e1>_19\NN\14818238 ._20\.\1740
D014635_D003221 CID results_0\NNS\34213 :_1\:\1740 272_2\CD\1740 cases_3\NNS\7283608 of_4\IN\1740 <e2>confusion</e2>_5\NN\13972797 were_6\VBD\836236 reported_7\VBN\831651 with_8\IN\1740 <e1>valproic_9\JJ\1740 acid</e1>_10\NN\14818238 :_11\:\1740 153_12\CD\1740 women_13\NNS\9605289 and_14\CC\1740 119_15\CD\1740 men_16\NNS\8208016 ._17\.\1740
D014635_D003221 CID <e2>confusion</e2>_0\NN\13972797 mostly_1\RB\1740 occurred_2\VBD\2623529 during_3\IN\1740 the_4\DT\1740 two_5\CD\13741022 first_6\JJ\1740 weeks_7\NNS\15113229 following_8\VBG\1835496 <e1>valproic_9\JJ\1740 acid</e1>_10\NN\14818238 exposure_11\NN\5042871 (_12\-LRB-\1740 39.7_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 ._16\.\1740
D014635_D003221 CID conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 work_3\NN\407535 shows_4\VBZ\2137132 that_5\IN\1740 <e2>confusion</e2>_6\NN\13972797 with_7\IN\1740 <e1>valproic_8\JJ\1740 acid</e1>_9\NN\14818238 is_10\VBZ\836236 a_11\DT\13649268 serious_12\JJ\1740 ,_13\,\1740 rather_14\RB\1740 frequent_15\JJ\1740 but_16\CC\1740 reversible_17\JJ\1740 adverse_18\JJ\1740 drug_19\NN\14778436 reaction_20\NN\13446390 ._21\.\1740
18182964
D003000_D001289 NONE <e1>clonidine</e1>_0\NN\2721160 for_1\IN\1740 <e2>attention-deficit/hyperactivity_2\JJ\1740 disorder</e2>_3\NN\14034177 :_4\:\1740 ii_5\CD\13741022 ._6\.\1740
D003000_D001289 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 examine_3\VB\789138 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 tolerability_7\NN\1740 of_8\IN\1740 <e1>clonidine</e1>_9\NN\2721160 used_10\VBN\1156834 alone_11\RB\1740 or_12\CC\3541091 with_13\IN\1740 methylphenidate_14\NN\4320126 in_15\IN\13603305 children_16\NNS\9622049 with_17\IN\1740 <e2>attention-deficit/hyperactivity_18\NN\1740 disorder</e2>_19\NN\14034177 (_20\-LRB-\1740 adhd_21\NN\14304060 )_22\-RRB-\1740 ._23\.\1740
D003000_D001289 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 examine_3\VB\789138 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 tolerability_7\NN\1740 of_8\IN\1740 <e1>clonidine</e1>_9\NN\2721160 used_10\VBN\1156834 alone_11\RB\1740 or_12\CC\3541091 with_13\IN\1740 methylphenidate_14\NN\4320126 in_15\IN\13603305 children_16\NNS\9622049 with_17\IN\1740 attention-deficit/hyperactivity_18\NN\1740 disorder_19\NN\14034177 (_20\-LRB-\1740 <e2>adhd</e2>_21\NN\14304060 )_22\-RRB-\1740 ._23\.\1740
D003000_D001289 NONE method_0\NNP\5616786 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 16-week_4\NN\1740 multicenter_5\NN\1740 ,_6\,\1740 double-blind_7\JJ\1740 trial_8\NN\786195 ,_9\,\1740 122_10\CD\1740 children_11\NNS\9622049 with_12\IN\1740 <e2>adhd</e2>_13\NN\14304060 were_14\VBD\836236 randomly_15\RB\1740 assigned_16\VBN\2475922 to_17\TO\1740 <e1>clonidine</e1>_18\NN\2721160 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 31_22\CD\1740 )_23\-RRB-\1740 ,_24\,\1740 methylphenidate_25\NN\4320126 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 29_29\CD\13745420 )_30\-RRB-\1740 ,_31\,\1740 clonidine_32\NN\2721160 and_33\CC\1740 methylphenidate_34\NN\4320126 (_35\-LRB-\1740 n_36\NN\14622893 =_37\JJ\1740 32_38\CD\1740 )_39\-RRB-\1740 ,_40\,\1740 or_41\CC\3541091 placebo_42\NN\3740161 (_43\-LRB-\1740 n_44\NN\14622893 =_45\JJ\1740 30_46\CD\13745420 )_47\-RRB-\1740 ._48\.\1740
D003000_D001289 NONE method_0\NNP\5616786 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 16-week_4\NN\1740 multicenter_5\NN\1740 ,_6\,\1740 double-blind_7\JJ\1740 trial_8\NN\786195 ,_9\,\1740 122_10\CD\1740 children_11\NNS\9622049 with_12\IN\1740 <e2>adhd</e2>_13\NN\14304060 were_14\VBD\836236 randomly_15\RB\1740 assigned_16\VBN\2475922 to_17\TO\1740 clonidine_18\NN\2721160 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 31_22\CD\1740 )_23\-RRB-\1740 ,_24\,\1740 methylphenidate_25\NN\4320126 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 29_29\CD\13745420 )_30\-RRB-\1740 ,_31\,\1740 <e1>clonidine</e1>_32\NN\2721160 and_33\CC\1740 methylphenidate_34\NN\4320126 (_35\-LRB-\1740 n_36\NN\14622893 =_37\JJ\1740 32_38\CD\1740 )_39\-RRB-\1740 ,_40\,\1740 or_41\CC\3541091 placebo_42\NN\3740161 (_43\-LRB-\1740 n_44\NN\14622893 =_45\JJ\1740 30_46\CD\13745420 )_47\-RRB-\1740 ._48\.\1740
D003000_D001289 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>clonidine</e1>_2\NNP\2721160 ,_3\,\1740 used_4\VBN\1156834 alone_5\RB\1740 or_6\CC\3541091 with_7\IN\1740 methylphenidate_8\NN\4320126 ,_9\,\1740 appears_10\VBZ\2604760 safe_11\JJ\1740 and_12\CC\1740 well_13\RB\1740 tolerated_14\VBN\802318 in_15\IN\13603305 childhood_16\NN\15144371 <e2>adhd</e2>_17\NN\14304060 ._18\.\1740
D008774_D001289 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 examine_3\VB\789138 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 tolerability_7\NN\1740 of_8\IN\1740 clonidine_9\NN\2721160 used_10\VBN\1156834 alone_11\RB\1740 or_12\CC\3541091 with_13\IN\1740 <e1>methylphenidate</e1>_14\NN\4320126 in_15\IN\13603305 children_16\NNS\9622049 with_17\IN\1740 <e2>attention-deficit/hyperactivity_18\NN\1740 disorder</e2>_19\NN\14034177 (_20\-LRB-\1740 adhd_21\NN\14304060 )_22\-RRB-\1740 ._23\.\1740
D008774_D001289 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 examine_3\VB\789138 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 tolerability_7\NN\1740 of_8\IN\1740 clonidine_9\NN\2721160 used_10\VBN\1156834 alone_11\RB\1740 or_12\CC\3541091 with_13\IN\1740 <e1>methylphenidate</e1>_14\NN\4320126 in_15\IN\13603305 children_16\NNS\9622049 with_17\IN\1740 attention-deficit/hyperactivity_18\NN\1740 disorder_19\NN\14034177 (_20\-LRB-\1740 <e2>adhd</e2>_21\NN\14304060 )_22\-RRB-\1740 ._23\.\1740
D008774_D001289 NONE method_0\NNP\5616786 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 16-week_4\NN\1740 multicenter_5\NN\1740 ,_6\,\1740 double-blind_7\JJ\1740 trial_8\NN\786195 ,_9\,\1740 122_10\CD\1740 children_11\NNS\9622049 with_12\IN\1740 <e2>adhd</e2>_13\NN\14304060 were_14\VBD\836236 randomly_15\RB\1740 assigned_16\VBN\2475922 to_17\TO\1740 clonidine_18\NN\2721160 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 31_22\CD\1740 )_23\-RRB-\1740 ,_24\,\1740 <e1>methylphenidate</e1>_25\NN\4320126 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 29_29\CD\13745420 )_30\-RRB-\1740 ,_31\,\1740 clonidine_32\NN\2721160 and_33\CC\1740 methylphenidate_34\NN\4320126 (_35\-LRB-\1740 n_36\NN\14622893 =_37\JJ\1740 32_38\CD\1740 )_39\-RRB-\1740 ,_40\,\1740 or_41\CC\3541091 placebo_42\NN\3740161 (_43\-LRB-\1740 n_44\NN\14622893 =_45\JJ\1740 30_46\CD\13745420 )_47\-RRB-\1740 ._48\.\1740
D008774_D001289 NONE method_0\NNP\5616786 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 16-week_4\NN\1740 multicenter_5\NN\1740 ,_6\,\1740 double-blind_7\JJ\1740 trial_8\NN\786195 ,_9\,\1740 122_10\CD\1740 children_11\NNS\9622049 with_12\IN\1740 <e2>adhd</e2>_13\NN\14304060 were_14\VBD\836236 randomly_15\RB\1740 assigned_16\VBN\2475922 to_17\TO\1740 clonidine_18\NN\2721160 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 31_22\CD\1740 )_23\-RRB-\1740 ,_24\,\1740 methylphenidate_25\NN\4320126 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 29_29\CD\13745420 )_30\-RRB-\1740 ,_31\,\1740 clonidine_32\NN\2721160 and_33\CC\1740 <e1>methylphenidate</e1>_34\NN\4320126 (_35\-LRB-\1740 n_36\NN\14622893 =_37\JJ\1740 32_38\CD\1740 )_39\-RRB-\1740 ,_40\,\1740 or_41\CC\3541091 placebo_42\NN\3740161 (_43\-LRB-\1740 n_44\NN\14622893 =_45\JJ\1740 30_46\CD\13745420 )_47\-RRB-\1740 ._48\.\1740
D008774_D001289 NONE conclusions_0\NNS\5837957 :_1\:\1740 clonidine_2\NNP\2721160 ,_3\,\1740 used_4\VBN\1156834 alone_5\RB\1740 or_6\CC\3541091 with_7\IN\1740 <e1>methylphenidate</e1>_8\NN\4320126 ,_9\,\1740 appears_10\VBZ\2604760 safe_11\JJ\1740 and_12\CC\1740 well_13\RB\1740 tolerated_14\VBN\802318 in_15\IN\13603305 childhood_16\NN\15144371 <e2>adhd</e2>_17\NN\14304060 ._18\.\1740
D003000_D001919 CID results_0\NNS\34213 :_1\:\1740 there_2\EX\27167 were_3\VBD\836236 more_4\JJR\1740 incidents_5\NNS\7283608 of_6\IN\1740 <e2>bradycardia</e2>_7\NN\14110674 in_8\IN\13603305 subjects_9\NNS\6598915 treated_10\VBN\2376958 with_11\IN\1740 <e1>clonidine</e1>_12\NN\2721160 compared_13\VBN\644583 with_14\IN\1740 those_15\DT\1740 not_16\RB\1740 treated_17\VBN\2376958 with_18\IN\1740 clonidine_19\NN\2721160 (_20\-LRB-\1740 17.5_21\CD\1740 %_22\NN\1740 versus_23\CC\1740 3.4_24\CD\1740 %_25\NN\1740 ;_26\:\1740 p_27\NN\14622893 =_28\JJ\1740 .02_29\CD\1740 )_30\-RRB-\1740 ,_31\,\1740 but_32\CC\1740 no_33\DT\7204911 other_34\JJ\1740 significant_35\JJ\1740 group_36\NN\2137 differences_37\NNS\4723816 regarding_38\VBG\689344 electrocardiogram_39\NN\7000195 and_40\CC\1740 other_41\JJ\1740 cardiovascular_42\JJ\1740 outcomes_43\NNS\7291312 ._44\.\1740
D003000_D001919 CID results_0\NNS\34213 :_1\:\1740 there_2\EX\27167 were_3\VBD\836236 more_4\JJR\1740 incidents_5\NNS\7283608 of_6\IN\1740 <e2>bradycardia</e2>_7\NN\14110674 in_8\IN\13603305 subjects_9\NNS\6598915 treated_10\VBN\2376958 with_11\IN\1740 clonidine_12\NN\2721160 compared_13\VBN\644583 with_14\IN\1740 those_15\DT\1740 not_16\RB\1740 treated_17\VBN\2376958 with_18\IN\1740 <e1>clonidine</e1>_19\NN\2721160 (_20\-LRB-\1740 17.5_21\CD\1740 %_22\NN\1740 versus_23\CC\1740 3.4_24\CD\1740 %_25\NN\1740 ;_26\:\1740 p_27\NN\14622893 =_28\JJ\1740 .02_29\CD\1740 )_30\-RRB-\1740 ,_31\,\1740 but_32\CC\1740 no_33\DT\7204911 other_34\JJ\1740 significant_35\JJ\1740 group_36\NN\2137 differences_37\NNS\4723816 regarding_38\VBG\689344 electrocardiogram_39\NN\7000195 and_40\CC\1740 other_41\JJ\1740 cardiovascular_42\JJ\1740 outcomes_43\NNS\7291312 ._44\.\1740
D003000_D001919 CID physicians_0\NNS\10305802 prescribing_1\NN\1740 <e1>clonidine</e1>_2\NN\2721160 should_3\MD\1740 monitor_4\VB\2169352 for_5\IN\1740 <e2>bradycardia</e2>_6\NN\14110674 and_7\CC\1740 advise_8\VB\813978 patients_9\NNS\9898892 about_10\IN\1740 the_11\DT\1740 high_12\JJ\1740 likelihood_13\NN\4756172 of_14\IN\1740 initial_15\JJ\1740 drowsiness_16\NN\14015731 ._17\.\1740
D003000_D006970 NONE <e2>drowsiness</e2>_0\NNP\14015731 was_1\VBD\836236 common_2\JJ\1740 on_3\IN\1740 <e1>clonidine</e1>_4\NN\2721160 ,_5\,\1740 but_6\CC\1740 generally_7\RB\1740 resolved_8\VBN\352826 by_9\IN\1740 6_10\CD\13741022 to_11\TO\1740 8_12\CD\13741022 weeks_13\NNS\15113229 ._14\.\1740
D003000_D006970 NONE physicians_0\NNS\10305802 prescribing_1\NN\1740 <e1>clonidine</e1>_2\NN\2721160 should_3\MD\1740 monitor_4\VB\2169352 for_5\IN\1740 bradycardia_6\NN\14110674 and_7\CC\1740 advise_8\VB\813978 patients_9\NNS\9898892 about_10\IN\1740 the_11\DT\1740 high_12\JJ\1740 likelihood_13\NN\4756172 of_14\IN\1740 initial_15\JJ\1740 <e2>drowsiness</e2>_16\NN\14015731 ._17\.\1740
20528871
C104457_D015458 NONE salvage_0\NN\3076708 therapy_1\NN\657604 with_2\IN\1740 <e1>nelarabine</e1>_3\NN\1740 ,_4\,\1740 etoposide_5\NN\1740 ,_6\,\1740 and_7\CC\1740 cyclophosphamide_8\NN\1740 in_9\IN\13603305 relapsed/refractory_10\JJ\1740 paediatric_11\JJ\1740 <e2>t-cell_12\NN\1740 lymphoblastic_13\JJ\1740 leukaemia_14\NN\14239918 and_15\CC\1740 lymphoma</e2>_16\NN\14239918 ._17\.\1740
C104457_D015458 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 <e1>nelarabine</e1>_6\NN\1740 (_7\-LRB-\1740 arag_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 etoposide_14\NN\1740 (_15\-LRB-\1740 vp_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 cyclophosphamide_19\NN\1740 (_20\-LRB-\1740 cpm_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
C104457_D015458 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 nelarabine_6\NN\1740 (_7\-LRB-\1740 <e1>arag</e1>_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 etoposide_14\NN\1740 (_15\-LRB-\1740 vp_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 cyclophosphamide_19\NN\1740 (_20\-LRB-\1740 cpm_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
C104457_D016399 NONE salvage_0\NN\3076708 therapy_1\NN\657604 with_2\IN\1740 <e1>nelarabine</e1>_3\NN\1740 ,_4\,\1740 etoposide_5\NN\1740 ,_6\,\1740 and_7\CC\1740 cyclophosphamide_8\NN\1740 in_9\IN\13603305 relapsed/refractory_10\JJ\1740 paediatric_11\JJ\1740 <e2>t-cell_12\NN\1740 lymphoblastic_13\JJ\1740 leukaemia_14\NN\14239918 and_15\CC\1740 lymphoma</e2>_16\NN\14239918 ._17\.\1740
C104457_D016399 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 <e1>nelarabine</e1>_6\NN\1740 (_7\-LRB-\1740 arag_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 etoposide_14\NN\1740 (_15\-LRB-\1740 vp_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 cyclophosphamide_19\NN\1740 (_20\-LRB-\1740 cpm_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
C104457_D016399 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 nelarabine_6\NN\1740 (_7\-LRB-\1740 <e1>arag</e1>_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 etoposide_14\NN\1740 (_15\-LRB-\1740 vp_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 cyclophosphamide_19\NN\1740 (_20\-LRB-\1740 cpm_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
D005047_D015458 NONE salvage_0\NN\3076708 therapy_1\NN\657604 with_2\IN\1740 nelarabine_3\NN\1740 ,_4\,\1740 <e1>etoposide</e1>_5\NN\1740 ,_6\,\1740 and_7\CC\1740 cyclophosphamide_8\NN\1740 in_9\IN\13603305 relapsed/refractory_10\JJ\1740 paediatric_11\JJ\1740 <e2>t-cell_12\NN\1740 lymphoblastic_13\JJ\1740 leukaemia_14\NN\14239918 and_15\CC\1740 lymphoma</e2>_16\NN\14239918 ._17\.\1740
D005047_D015458 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 nelarabine_6\NN\1740 (_7\-LRB-\1740 arag_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 <e1>etoposide</e1>_14\NN\1740 (_15\-LRB-\1740 vp_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 cyclophosphamide_19\NN\1740 (_20\-LRB-\1740 cpm_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
D005047_D015458 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 nelarabine_6\NN\1740 (_7\-LRB-\1740 arag_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 etoposide_14\NN\1740 (_15\-LRB-\1740 <e1>vp</e1>_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 cyclophosphamide_19\NN\1740 (_20\-LRB-\1740 cpm_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
D005047_D016399 NONE salvage_0\NN\3076708 therapy_1\NN\657604 with_2\IN\1740 nelarabine_3\NN\1740 ,_4\,\1740 <e1>etoposide</e1>_5\NN\1740 ,_6\,\1740 and_7\CC\1740 cyclophosphamide_8\NN\1740 in_9\IN\13603305 relapsed/refractory_10\JJ\1740 paediatric_11\JJ\1740 <e2>t-cell_12\NN\1740 lymphoblastic_13\JJ\1740 leukaemia_14\NN\14239918 and_15\CC\1740 lymphoma</e2>_16\NN\14239918 ._17\.\1740
D005047_D016399 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 nelarabine_6\NN\1740 (_7\-LRB-\1740 arag_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 <e1>etoposide</e1>_14\NN\1740 (_15\-LRB-\1740 vp_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 cyclophosphamide_19\NN\1740 (_20\-LRB-\1740 cpm_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
D005047_D016399 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 nelarabine_6\NN\1740 (_7\-LRB-\1740 arag_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 etoposide_14\NN\1740 (_15\-LRB-\1740 <e1>vp</e1>_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 cyclophosphamide_19\NN\1740 (_20\-LRB-\1740 cpm_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
D003520_D015458 NONE salvage_0\NN\3076708 therapy_1\NN\657604 with_2\IN\1740 nelarabine_3\NN\1740 ,_4\,\1740 etoposide_5\NN\1740 ,_6\,\1740 and_7\CC\1740 <e1>cyclophosphamide</e1>_8\NN\1740 in_9\IN\13603305 relapsed/refractory_10\JJ\1740 paediatric_11\JJ\1740 <e2>t-cell_12\NN\1740 lymphoblastic_13\JJ\1740 leukaemia_14\NN\14239918 and_15\CC\1740 lymphoma</e2>_16\NN\14239918 ._17\.\1740
D003520_D015458 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 nelarabine_6\NN\1740 (_7\-LRB-\1740 arag_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 etoposide_14\NN\1740 (_15\-LRB-\1740 vp_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 <e1>cyclophosphamide</e1>_19\NN\1740 (_20\-LRB-\1740 cpm_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
D003520_D015458 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 nelarabine_6\NN\1740 (_7\-LRB-\1740 arag_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 etoposide_14\NN\1740 (_15\-LRB-\1740 vp_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 cyclophosphamide_19\NN\1740 (_20\-LRB-\1740 <e1>cpm</e1>_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
D003520_D016399 NONE salvage_0\NN\3076708 therapy_1\NN\657604 with_2\IN\1740 nelarabine_3\NN\1740 ,_4\,\1740 etoposide_5\NN\1740 ,_6\,\1740 and_7\CC\1740 <e1>cyclophosphamide</e1>_8\NN\1740 in_9\IN\13603305 relapsed/refractory_10\JJ\1740 paediatric_11\JJ\1740 <e2>t-cell_12\NN\1740 lymphoblastic_13\JJ\1740 leukaemia_14\NN\14239918 and_15\CC\1740 lymphoma</e2>_16\NN\14239918 ._17\.\1740
D003520_D016399 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 nelarabine_6\NN\1740 (_7\-LRB-\1740 arag_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 etoposide_14\NN\1740 (_15\-LRB-\1740 vp_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 <e1>cyclophosphamide</e1>_19\NN\1740 (_20\-LRB-\1740 cpm_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
D003520_D016399 NONE a_0\DT\13649268 combination_1\NN\7951464 of_2\IN\1740 5_3\CD\13741022 d_4\NN\15089472 of_5\IN\1740 nelarabine_6\NN\1740 (_7\-LRB-\1740 arag_8\NN\1740 )_9\-RRB-\1740 with_10\IN\1740 5_11\CD\13741022 d_12\NN\15089472 of_13\IN\1740 etoposide_14\NN\1740 (_15\-LRB-\1740 vp_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 cyclophosphamide_19\NN\1740 (_20\-LRB-\1740 <e1>cpm</e1>_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 prophylactic_24\JJ\1740 intrathecal_25\JJ\1740 chemotherapy_26\NN\661091 was_27\VBD\836236 used_28\VBN\1156834 as_29\IN\14622893 salvage_30\NN\3076708 therapy_31\NN\657604 in_32\IN\13603305 seven_33\CD\13741022 children_34\NNS\9622049 with_35\IN\1740 refractory_36\JJ\1740 or_37\CC\3541091 relapsed_38\JJ\1740 <e2>t-cell_39\NN\1740 leukaemia_40\NN\14239918 or_41\CC\3541091 lymphoma</e2>_42\NN\14239918 ._43\.\1740
C104457_D009422 CID the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 side_3\NN\8630039 effects_4\NNS\13245626 attributable_5\JJ\1740 to_6\TO\1740 the_7\DT\1740 <e1>arag</e1>_8\NN\1740 included_9\VBD\690614 grade_10\NNP\7975026 2_11\CD\13741022 and_12\CC\1740 3_13\CD\13741022 sensory_14\JJ\1740 and_15\CC\1740 motor_16\NN\3699975 <e2>neuropathy</e2>_17\JJ\1740 and_18\CC\1740 musculoskeletal_19\JJ\1740 pain_20\NN\14299637 ._21\.\1740
C104457_D009422 CID our_0\PRP$\1740 experience_1\NN\5984287 supports_2\VBZ\2199590 the_3\DT\1740 safety_4\NN\13920835 of_5\IN\1740 giving_6\VBG\2327200 <e1>arag</e1>_7\NN\1740 as_8\IN\14622893 salvage_9\NN\3076708 therapy_10\NN\657604 in_11\IN\13603305 synchrony_12\NN\13844690 with_13\IN\1740 etoposide_14\NN\1740 and_15\CC\1740 cyclophosphamide_16\NN\1740 ,_17\,\1740 although_18\IN\1740 <e2>neurological_19\JJ\1740 toxicity</e2>_20\NN\13576101 must_21\MD\9367203 be_22\VB\836236 closely_23\RB\1740 monitored_24\VBN\2169352 ._25\.\1740
C104457_D059352 CID the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 side_3\NN\8630039 effects_4\NNS\13245626 attributable_5\JJ\1740 to_6\TO\1740 the_7\DT\1740 <e1>arag</e1>_8\NN\1740 included_9\VBD\690614 grade_10\NNP\7975026 2_11\CD\13741022 and_12\CC\1740 3_13\CD\13741022 sensory_14\JJ\1740 and_15\CC\1740 motor_16\NN\3699975 neuropathy_17\JJ\1740 and_18\CC\1740 <e2>musculoskeletal_19\JJ\1740 pain</e2>_20\NN\14299637 ._21\.\1740
C104457_D006402 CID <e2>haematological_0\JJ\1740 toxicity</e2>_1\NN\13576101 was_2\VBD\836236 greater_3\JJR\1740 for_4\IN\1740 the_5\DT\1740 combination_6\NN\7951464 than_7\IN\1740 <e1>arag</e1>_8\NN\1740 alone_9\RB\1740 ,_10\,\1740 although_11\IN\1740 median_12\JJ\1740 time_13\NN\7308889 to_14\IN\1740 neutrophil_15\NN\5449959 and_16\CC\1740 platelet_17\NN\5432736 recovery_18\NN\7357388 was_19\VBD\836236 consistent_20\JJ\1740 with_21\IN\1740 other_22\JJ\1740 salvage_23\NN\3076708 therapies_24\NNS\657604 ._25\.\1740
D005047_D009422 NONE our_0\PRP$\1740 experience_1\NN\5984287 supports_2\VBZ\2199590 the_3\DT\1740 safety_4\NN\13920835 of_5\IN\1740 giving_6\VBG\2327200 arag_7\NN\1740 as_8\IN\14622893 salvage_9\NN\3076708 therapy_10\NN\657604 in_11\IN\13603305 synchrony_12\NN\13844690 with_13\IN\1740 <e1>etoposide</e1>_14\NN\1740 and_15\CC\1740 cyclophosphamide_16\NN\1740 ,_17\,\1740 although_18\IN\1740 <e2>neurological_19\JJ\1740 toxicity</e2>_20\NN\13576101 must_21\MD\9367203 be_22\VB\836236 closely_23\RB\1740 monitored_24\VBN\2169352 ._25\.\1740
D003520_D009422 NONE our_0\PRP$\1740 experience_1\NN\5984287 supports_2\VBZ\2199590 the_3\DT\1740 safety_4\NN\13920835 of_5\IN\1740 giving_6\VBG\2327200 arag_7\NN\1740 as_8\IN\14622893 salvage_9\NN\3076708 therapy_10\NN\657604 in_11\IN\13603305 synchrony_12\NN\13844690 with_13\IN\1740 etoposide_14\NN\1740 and_15\CC\1740 <e1>cyclophosphamide</e1>_16\NN\1740 ,_17\,\1740 although_18\IN\1740 <e2>neurological_19\JJ\1740 toxicity</e2>_20\NN\13576101 must_21\MD\9367203 be_22\VB\836236 closely_23\RB\1740 monitored_24\VBN\2169352 ._25\.\1740
10704919
D013629_D006461 CID <e2>hemolysis</e2>_0\NN\13509528 of_1\IN\1740 human_2\JJ\1740 erythrocytes_3\NNS\5449268 induced_4\VBN\1627355 by_5\IN\1740 <e1>tamoxifen</e1>_6\NN\2714883 is_7\VBZ\836236 related_8\JJ\1740 to_9\TO\1740 disruption_10\NN\1066163 of_11\IN\1740 membrane_12\NN\4188643 structure_13\NN\21939 ._14\.\1740
D013629_D006461 CID <e1>tam</e1>_0\NN\2954340 induces_1\VBZ\1627355 <e2>hemolysis</e2>_2\NN\13509528 of_3\IN\1740 erythrocytes_4\NNS\5449268 as_5\IN\14622893 a_6\DT\13649268 function_7\NN\13783581 of_8\IN\1740 concentration_9\NN\4916342 ._10\.\1740
D013629_D006461 CID the_0\DT\1740 extension_1\NN\15272029 of_2\IN\1740 <e2>hemolysis</e2>_3\NN\13509528 is_4\VBZ\836236 variable_5\JJ\1740 with_6\IN\1740 erythrocyte_7\NN\5449268 samples_8\NNS\5820620 ,_9\,\1740 but_10\CC\1740 12.5_11\CD\1740 microm_12\NN\1740 <e1>tam</e1>_13\NN\2954340 induces_14\VBZ\1627355 total_15\JJ\1740 hemolysis_16\NN\13509528 of_17\IN\1740 all_18\DT\1740 tested_19\VBN\670261 suspensions_20\NNS\14586258 ._21\.\1740
D013629_D006461 CID the_0\DT\1740 extension_1\NN\15272029 of_2\IN\1740 hemolysis_3\NN\13509528 is_4\VBZ\836236 variable_5\JJ\1740 with_6\IN\1740 erythrocyte_7\NN\5449268 samples_8\NNS\5820620 ,_9\,\1740 but_10\CC\1740 12.5_11\CD\1740 microm_12\NN\1740 <e1>tam</e1>_13\NN\2954340 induces_14\VBZ\1627355 total_15\JJ\1740 <e2>hemolysis</e2>_16\NN\13509528 of_17\IN\1740 all_18\DT\1740 tested_19\VBN\670261 suspensions_20\NNS\14586258 ._21\.\1740
D013629_D006461 CID the_0\DT\1740 <e2>hemolytic</e2>_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 <e1>tam</e1>_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 hemolysis_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D013629_D006461 CID the_0\DT\1740 hemolytic_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 <e1>tam</e1>_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 <e2>hemolysis</e2>_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D013629_D006461 CID the_0\DT\1740 <e2>hemolytic</e2>_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 <e1>tam-induced</e1>_28\JJ\1740 hemolysis_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D013629_D006461 CID the_0\DT\1740 hemolytic_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 <e1>tam-induced</e1>_28\JJ\1740 <e2>hemolysis</e2>_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D013629_D006461 CID this_0\DT\1740 was_1\VBD\836236 further_2\RB\1740 evidenced_3\VBN\1015244 by_4\IN\1740 absence_5\NN\14449405 of_6\IN\1740 oxygen_7\NN\14622893 consumption_8\NN\13440063 and_9\CC\1740 hemoglobin_10\NN\14888884 oxidation_11\NN\13447361 both_12\CC\1740 determined_13\VBN\1645601 in_14\IN\13603305 parallel_15\NN\4743605 with_16\IN\1740 <e1>tam-induced</e1>_17\JJ\1740 <e2>hemolysis</e2>_18\NN\13509528 ._19\.\1740
D013629_D006461 CID <e2>hemolysis</e2>_0\NN\13509528 caused_1\VBN\1617192 by_2\IN\1740 <e1>tam</e1>_3\NN\2954340 was_4\VBD\836236 not_5\RB\1740 preceded_6\VBN\2690708 by_7\IN\1740 the_8\DT\1740 leakage_9\NN\7407777 of_10\IN\1740 k(+_11\NN\1740 )_12\-RRB-\1740 from_13\IN\1740 the_14\DT\1740 cells_15\NNS\3080309 ,_16\,\1740 also_17\RB\1740 excluding_18\VBG\471711 a_19\DT\13649268 colloid-osmotic_20\JJ\1740 type_21\NN\5839024 mechanism_22\NN\13446390 of_23\IN\1740 hemolysis_24\NN\13509528 ,_25\,\1740 according_26\VBG\2657219 to_27\IN\1740 the_28\DT\1740 effects_29\NNS\13245626 on_30\IN\1740 osmotic_31\JJ\1740 fragility_32\NN\5042871 curves_33\NNS\13863771 ._34\.\1740
D013629_D006461 CID hemolysis_0\NN\13509528 caused_1\VBN\1617192 by_2\IN\1740 <e1>tam</e1>_3\NN\2954340 was_4\VBD\836236 not_5\RB\1740 preceded_6\VBN\2690708 by_7\IN\1740 the_8\DT\1740 leakage_9\NN\7407777 of_10\IN\1740 k(+_11\NN\1740 )_12\-RRB-\1740 from_13\IN\1740 the_14\DT\1740 cells_15\NNS\3080309 ,_16\,\1740 also_17\RB\1740 excluding_18\VBG\471711 a_19\DT\13649268 colloid-osmotic_20\JJ\1740 type_21\NN\5839024 mechanism_22\NN\13446390 of_23\IN\1740 <e2>hemolysis</e2>_24\NN\13509528 ,_25\,\1740 according_26\VBG\2657219 to_27\IN\1740 the_28\DT\1740 effects_29\NNS\13245626 on_30\IN\1740 osmotic_31\JJ\1740 fragility_32\NN\5042871 curves_33\NNS\13863771 ._34\.\1740
D013629_D006461 CID these_0\DT\1740 effects_1\NNS\13245626 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 protection_5\NN\407535 from_6\IN\1740 <e2>hemolysis</e2>_7\NN\13509528 by_8\IN\1740 tocopherols_9\NNS\14724645 is_10\VBZ\836236 related_11\JJ\1740 to_12\TO\1740 a_13\DT\13649268 decreased_14\VBN\169651 <e1>tam</e1>_15\NN\2954340 incorporation_16\NN\1237415 in_17\IN\13603305 condensed_18\VBN\443984 membranes_19\NNS\4188643 and_20\CC\1740 the_21\DT\1740 structural_22\JJ\1740 damage_23\NN\7296428 of_24\IN\1740 the_25\DT\1740 erythrocyte_26\NN\5449268 membrane_27\NN\4188643 is_28\VBZ\836236 consequently_29\RB\1740 avoided_30\VBN\2452885 ._31\.\1740
D013629_D006461 CID therefore_0\RB\1740 ,_1\,\1740 <e1>tam-induced</e1>_2\JJ\1740 <e2>hemolysis</e2>_3\NN\13509528 results_4\VBZ\2633881 from_5\IN\1740 a_6\DT\13649268 structural_7\JJ\1740 perturbation_8\NN\14403107 of_9\IN\1740 red_10\JJ\1740 cell_11\NN\3080309 membrane_12\NN\4188643 ,_13\,\1740 leading_14\VBG\1752884 to_15\TO\1740 changes_16\NNS\7283608 in_17\IN\13603305 the_18\DT\1740 framework_19\NN\5888929 of_20\IN\1740 the_21\DT\1740 erythrocyte_22\NN\5449268 membrane_23\NN\4188643 and_24\CC\1740 its_25\PRP$\6125041 cytoskeleton_26\NN\5225602 caused_27\VBN\1617192 by_28\IN\1740 its_29\PRP$\6125041 high_30\JJ\1740 partition_31\NN\4341686 in_32\IN\13603305 the_33\DT\1740 membrane_34\NN\4188643 ._35\.\1740
D013629_D001943 NONE <e1>tamoxifen</e1>_0\NN\2714883 (_1\-LRB-\1740 tam_2\NNP\2954340 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 antiestrogenic_6\JJ\1740 drug_7\NN\14778436 most_8\RBS\1740 widely_9\RB\1740 prescribed_10\VBN\748282 in_11\IN\13603305 the_12\DT\1740 chemotherapy_13\NN\661091 of_14\IN\1740 <e2>breast_15\NN\5225090 cancer</e2>_16\NN\14239425 ,_17\,\1740 induces_18\VBZ\1627355 changes_19\NNS\7283608 in_20\IN\13603305 normal_21\JJ\1740 discoid_22\JJ\1740 shape_23\NN\5062748 of_24\IN\1740 erythrocytes_25\NNS\5449268 and_26\CC\1740 hemolytic_27\JJ\1740 anemia_28\NN\14189204 ._29\.\1740
D013629_D001943 NONE tamoxifen_0\NN\2714883 (_1\-LRB-\1740 <e1>tam</e1>_2\NNP\2954340 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 antiestrogenic_6\JJ\1740 drug_7\NN\14778436 most_8\RBS\1740 widely_9\RB\1740 prescribed_10\VBN\748282 in_11\IN\13603305 the_12\DT\1740 chemotherapy_13\NN\661091 of_14\IN\1740 <e2>breast_15\NN\5225090 cancer</e2>_16\NN\14239425 ,_17\,\1740 induces_18\VBZ\1627355 changes_19\NNS\7283608 in_20\IN\13603305 normal_21\JJ\1740 discoid_22\JJ\1740 shape_23\NN\5062748 of_24\IN\1740 erythrocytes_25\NNS\5449268 and_26\CC\1740 hemolytic_27\JJ\1740 anemia_28\NN\14189204 ._29\.\1740
D013629_D000743 CID <e1>tamoxifen</e1>_0\NN\2714883 (_1\-LRB-\1740 tam_2\NNP\2954340 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 antiestrogenic_6\JJ\1740 drug_7\NN\14778436 most_8\RBS\1740 widely_9\RB\1740 prescribed_10\VBN\748282 in_11\IN\13603305 the_12\DT\1740 chemotherapy_13\NN\661091 of_14\IN\1740 breast_15\NN\5225090 cancer_16\NN\14239425 ,_17\,\1740 induces_18\VBZ\1627355 changes_19\NNS\7283608 in_20\IN\13603305 normal_21\JJ\1740 discoid_22\JJ\1740 shape_23\NN\5062748 of_24\IN\1740 erythrocytes_25\NNS\5449268 and_26\CC\1740 <e2>hemolytic_27\JJ\1740 anemia</e2>_28\NN\14189204 ._29\.\1740
D013629_D000743 CID tamoxifen_0\NN\2714883 (_1\-LRB-\1740 <e1>tam</e1>_2\NNP\2954340 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 antiestrogenic_6\JJ\1740 drug_7\NN\14778436 most_8\RBS\1740 widely_9\RB\1740 prescribed_10\VBN\748282 in_11\IN\13603305 the_12\DT\1740 chemotherapy_13\NN\661091 of_14\IN\1740 breast_15\NN\5225090 cancer_16\NN\14239425 ,_17\,\1740 induces_18\VBZ\1627355 changes_19\NNS\7283608 in_20\IN\13603305 normal_21\JJ\1740 discoid_22\JJ\1740 shape_23\NN\5062748 of_24\IN\1740 erythrocytes_25\NNS\5449268 and_26\CC\1740 <e2>hemolytic_27\JJ\1740 anemia</e2>_28\NN\14189204 ._29\.\1740
D013629_D000743 CID this_0\DT\1740 work_1\NN\407535 evaluates_2\VBZ\670261 the_3\DT\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>tam</e1>_6\NN\2954340 on_7\IN\1740 isolated_8\VBN\2512305 human_9\JJ\1740 erythrocytes_10\NNS\5449268 ,_11\,\1740 attempting_12\VBG\2367363 to_13\TO\1740 identify_14\VB\699815 the_15\DT\1740 underlying_16\VBG\2604760 mechanisms_17\NNS\13446390 on_18\IN\1740 tam-induced_19\JJ\1740 <e2>hemolytic_20\JJ\1740 anemia</e2>_21\NN\14189204 and_22\CC\1740 the_23\DT\1740 involvement_24\NN\1080366 of_25\IN\1740 biomembranes_26\NNS\1740 in_27\IN\13603305 its_28\PRP$\6125041 cytostatic_29\JJ\1740 action_30\NN\30358 mechanisms_31\NNS\13446390 ._32\.\1740
D013629_D000743 CID this_0\DT\1740 work_1\NN\407535 evaluates_2\VBZ\670261 the_3\DT\1740 effects_4\NNS\13245626 of_5\IN\1740 tam_6\NN\2954340 on_7\IN\1740 isolated_8\VBN\2512305 human_9\JJ\1740 erythrocytes_10\NNS\5449268 ,_11\,\1740 attempting_12\VBG\2367363 to_13\TO\1740 identify_14\VB\699815 the_15\DT\1740 underlying_16\VBG\2604760 mechanisms_17\NNS\13446390 on_18\IN\1740 <e1>tam-induced</e1>_19\JJ\1740 <e2>hemolytic_20\JJ\1740 anemia</e2>_21\NN\14189204 and_22\CC\1740 the_23\DT\1740 involvement_24\NN\1080366 of_25\IN\1740 biomembranes_26\NNS\1740 in_27\IN\13603305 its_28\PRP$\6125041 cytostatic_29\JJ\1740 action_30\NN\30358 mechanisms_31\NNS\13446390 ._32\.\1740
D013629_D000743 CID these_0\DT\1740 defects_1\NNS\14462666 explain_2\VBP\831651 the_3\DT\1740 abnormal_4\JJ\1740 erythrocyte_5\NN\5449268 shape_6\NN\5062748 and_7\CC\1740 decreased_8\VBD\169651 mechanical_9\JJ\1740 stability_10\NN\4777852 promoted_11\VBN\2556126 by_12\IN\1740 <e1>tam</e1>_13\NN\2954340 ,_14\,\1740 resulting_15\VBG\2633881 in_16\IN\13603305 <e2>hemolytic_17\JJ\1740 anemia</e2>_18\NN\14189204 ._19\.\1740
D024502_D006461 NONE the_0\DT\1740 <e2>hemolytic</e2>_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 <e1>alpha-tocopherol</e1>_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 hemolysis_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D024502_D006461 NONE the_0\DT\1740 hemolytic_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 <e1>alpha-tocopherol</e1>_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 <e2>hemolysis</e2>_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D024502_D006461 NONE the_0\DT\1740 <e2>hemolytic</e2>_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 <e1>alpha-t</e1>_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 hemolysis_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D024502_D006461 NONE the_0\DT\1740 hemolytic_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 <e1>alpha-t</e1>_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 <e2>hemolysis</e2>_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D024502_D006461 NONE the_0\DT\1740 <e2>hemolytic</e2>_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 <e1>alpha-tocopherol_16\NN\1740 acetate</e1>_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 hemolysis_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D024502_D006461 NONE the_0\DT\1740 hemolytic_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 <e1>alpha-tocopherol_16\NN\1740 acetate</e1>_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 <e2>hemolysis</e2>_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D024502_D006461 NONE the_0\DT\1740 <e2>hemolytic</e2>_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 <e1>alpha-tac</e1>_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 hemolysis_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D024502_D006461 NONE the_0\DT\1740 hemolytic_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 <e1>alpha-tac</e1>_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 hydroxyl_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 <e2>hemolysis</e2>_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D017665_D006461 NONE the_0\DT\1740 <e2>hemolytic</e2>_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 <e1>hydroxyl</e1>_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 hemolysis_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D017665_D006461 NONE the_0\DT\1740 hemolytic_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 tam_4\NN\2954340 is_5\VBZ\836236 prevented_6\VBN\1740 by_7\IN\1740 low_8\JJ\1740 concentrations_9\NNS\4916342 of_10\IN\1740 alpha-tocopherol_11\NN\1740 (_12\-LRB-\1740 alpha-t_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 alpha-tocopherol_16\NN\1740 acetate_17\NN\15010703 (_18\-LRB-\1740 alpha-tac_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 inactivated_22\VBD\1097743 functional_23\JJ\1740 <e1>hydroxyl</e1>_24\NN\14621446 )_25\-RRB-\1740 indicating_26\VBG\952524 that_27\IN\1740 tam-induced_28\JJ\1740 <e2>hemolysis</e2>_29\NN\13509528 is_30\VBZ\836236 not_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 oxidative_34\JJ\1740 membrane_35\NN\4188643 damage_36\NN\7296428 ._37\.\1740
D010100_D006461 NONE this_0\DT\1740 was_1\VBD\836236 further_2\RB\1740 evidenced_3\VBN\1015244 by_4\IN\1740 absence_5\NN\14449405 of_6\IN\1740 <e1>oxygen</e1>_7\NN\14622893 consumption_8\NN\13440063 and_9\CC\1740 hemoglobin_10\NN\14888884 oxidation_11\NN\13447361 both_12\CC\1740 determined_13\VBN\1645601 in_14\IN\13603305 parallel_15\NN\4743605 with_16\IN\1740 tam-induced_17\JJ\1740 <e2>hemolysis</e2>_18\NN\13509528 ._19\.\1740
D011188_D006461 NONE <e2>hemolysis</e2>_0\NN\13509528 caused_1\VBN\1617192 by_2\IN\1740 tam_3\NN\2954340 was_4\VBD\836236 not_5\RB\1740 preceded_6\VBN\2690708 by_7\IN\1740 the_8\DT\1740 leakage_9\NN\7407777 of_10\IN\1740 <e1>k(+</e1>_11\NN\1740 )_12\-RRB-\1740 from_13\IN\1740 the_14\DT\1740 cells_15\NNS\3080309 ,_16\,\1740 also_17\RB\1740 excluding_18\VBG\471711 a_19\DT\13649268 colloid-osmotic_20\JJ\1740 type_21\NN\5839024 mechanism_22\NN\13446390 of_23\IN\1740 hemolysis_24\NN\13509528 ,_25\,\1740 according_26\VBG\2657219 to_27\IN\1740 the_28\DT\1740 effects_29\NNS\13245626 on_30\IN\1740 osmotic_31\JJ\1740 fragility_32\NN\5042871 curves_33\NNS\13863771 ._34\.\1740
D011188_D006461 NONE hemolysis_0\NN\13509528 caused_1\VBN\1617192 by_2\IN\1740 tam_3\NN\2954340 was_4\VBD\836236 not_5\RB\1740 preceded_6\VBN\2690708 by_7\IN\1740 the_8\DT\1740 leakage_9\NN\7407777 of_10\IN\1740 <e1>k(+</e1>_11\NN\1740 )_12\-RRB-\1740 from_13\IN\1740 the_14\DT\1740 cells_15\NNS\3080309 ,_16\,\1740 also_17\RB\1740 excluding_18\VBG\471711 a_19\DT\13649268 colloid-osmotic_20\JJ\1740 type_21\NN\5839024 mechanism_22\NN\13446390 of_23\IN\1740 <e2>hemolysis</e2>_24\NN\13509528 ,_25\,\1740 according_26\VBG\2657219 to_27\IN\1740 the_28\DT\1740 effects_29\NNS\13245626 on_30\IN\1740 osmotic_31\JJ\1740 fragility_32\NN\5042871 curves_33\NNS\13863771 ._34\.\1740
D024505_D006461 NONE these_0\DT\1740 effects_1\NNS\13245626 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 protection_5\NN\407535 from_6\IN\1740 <e2>hemolysis</e2>_7\NN\13509528 by_8\IN\1740 <e1>tocopherols</e1>_9\NNS\14724645 is_10\VBZ\836236 related_11\JJ\1740 to_12\TO\1740 a_13\DT\13649268 decreased_14\VBN\169651 tam_15\NN\2954340 incorporation_16\NN\1237415 in_17\IN\13603305 condensed_18\VBN\443984 membranes_19\NNS\4188643 and_20\CC\1740 the_21\DT\1740 structural_22\JJ\1740 damage_23\NN\7296428 of_24\IN\1740 the_25\DT\1740 erythrocyte_26\NN\5449268 membrane_27\NN\4188643 is_28\VBZ\836236 consequently_29\RB\1740 avoided_30\VBN\2452885 ._31\.\1740
10683478
D001058_D007035 CID <e1>apomorphine</e1>_0\NNP\3786417 ,_1\,\1740 a_2\DT\13649268 nonselective_3\JJ\1740 dopamine_4\NN\14807737 agonist_5\NN\9613191 ,_6\,\1740 was_7\VBD\836236 selected_8\VBN\697589 due_9\IN\5174653 to_10\TO\1740 its_11\PRP$\6125041 biphasic_12\JJ\1740 behavioral_13\JJ\1740 effects_14\NNS\13245626 ,_15\,\1740 its_16\PRP$\6125041 ability_17\NN\4723816 to_18\TO\1740 induce_19\VB\1627355 <e2>hypothermia</e2>_20\NN\14034177 ,_21\,\1740 and_22\CC\1740 to_23\TO\1740 produce_24\VB\1617192 distinct_25\JJ\1740 changes_26\NNS\7283608 to_27\TO\1740 dopamine_28\NN\14807737 turnover_29\NN\13819207 in_30\IN\13603305 the_31\DT\1740 rodent_32\JJ\1740 brain_33\NN\5462674 ._34\.\1740
D001058_D007035 CID moreover_0\RB\1740 ,_1\,\1740 test_2\NN\5798043 conditions_3\NNS\14512817 can_4\MD\3094503 impact_5\VB\1527271 upon_6\IN\1740 other_7\JJ\1740 physiological_8\JJ\1740 responses_9\NNS\11410625 to_10\TO\1740 <e1>apomorphine</e1>_11\VB\1740 such_12\JJ\1740 as_13\IN\14622893 drug-induced_14\JJ\1740 <e2>hypothermia</e2>_15\NN\14034177 ._16\.\1740
D018491_D007035 NONE apomorphine_0\NNP\3786417 ,_1\,\1740 a_2\DT\13649268 nonselective_3\JJ\1740 <e1>dopamine_4\NN\14807737 agonist</e1>_5\NN\9613191 ,_6\,\1740 was_7\VBD\836236 selected_8\VBN\697589 due_9\IN\5174653 to_10\TO\1740 its_11\PRP$\6125041 biphasic_12\JJ\1740 behavioral_13\JJ\1740 effects_14\NNS\13245626 ,_15\,\1740 its_16\PRP$\6125041 ability_17\NN\4723816 to_18\TO\1740 induce_19\VB\1627355 <e2>hypothermia</e2>_20\NN\14034177 ,_21\,\1740 and_22\CC\1740 to_23\TO\1740 produce_24\VB\1617192 distinct_25\JJ\1740 changes_26\NNS\7283608 to_27\TO\1740 dopamine_28\NN\14807737 turnover_29\NN\13819207 in_30\IN\13603305 the_31\DT\1740 rodent_32\JJ\1740 brain_33\NN\5462674 ._34\.\1740
D004298_D007035 NONE apomorphine_0\NNP\3786417 ,_1\,\1740 a_2\DT\13649268 nonselective_3\JJ\1740 dopamine_4\NN\14807737 agonist_5\NN\9613191 ,_6\,\1740 was_7\VBD\836236 selected_8\VBN\697589 due_9\IN\5174653 to_10\TO\1740 its_11\PRP$\6125041 biphasic_12\JJ\1740 behavioral_13\JJ\1740 effects_14\NNS\13245626 ,_15\,\1740 its_16\PRP$\6125041 ability_17\NN\4723816 to_18\TO\1740 induce_19\VB\1627355 <e2>hypothermia</e2>_20\NN\14034177 ,_21\,\1740 and_22\CC\1740 to_23\TO\1740 produce_24\VB\1617192 distinct_25\JJ\1740 changes_26\NNS\7283608 to_27\TO\1740 <e1>dopamine</e1>_28\NN\14807737 turnover_29\NN\13819207 in_30\IN\13603305 the_31\DT\1740 rodent_32\JJ\1740 brain_33\NN\5462674 ._34\.\1740
D001058_D006948 CID in_0\IN\13603305 rats_1\NNS\2329401 ,_2\,\1740 detection_3\NN\5708432 of_4\IN\1740 <e1>apomorphine-induced</e1>_5\JJ\1740 <e2>hyperactivity</e2>_6\NN\14052403 was_7\VBD\836236 facilitated_8\VBN\2547586 by_9\IN\1740 a_10\DT\13649268 period_11\NN\13575869 of_12\IN\1740 acclimatization_13\NN\13427078 to_14\IN\1740 the_15\DT\1740 test_16\NN\5798043 conditions_17\NNS\14512817 ._18\.\1740
12041669
D000961_D000741 NONE <e1>antithymocyte_0\NNP\1740 globulin</e1>_1\NN\14736972 in_2\IN\13603305 the_3\DT\1740 treatment_4\NN\654885 of_5\IN\1740 d-penicillamine-induced_6\JJ\1740 <e2>aplastic_7\JJ\1740 anemia</e2>_8\NN\14189204 ._9\.\1740
D000961_D000741 NONE a_0\DT\13649268 patient_1\NN\9898892 who_2\WP\8299493 received_3\VBD\2210855 <e1>antithymocyte_4\NN\1740 globulin</e1>_5\NN\14736972 therapy_6\NN\657604 for_7\IN\1740 <e2>aplastic_8\JJ\1740 anemia</e2>_9\NN\14189204 due_10\IN\5174653 to_11\TO\1740 d-penicillamine_12\NN\1740 therapy_13\NN\657604 is_14\VBZ\836236 described_15\VBN\1001294 ._16\.\1740
D000961_D000741 NONE use_0\NN\407535 of_1\IN\1740 <e1>antithymocyte_2\NN\1740 globulin</e1>_3\NN\14736972 may_4\MD\15209706 be_5\VB\836236 the_6\DT\1740 optimal_7\JJ\1740 treatment_8\NN\654885 of_9\IN\1740 d-penicillamine-induced_10\JJ\1740 <e2>aplastic_11\JJ\1740 anemia</e2>_12\NN\14189204 ._13\.\1740
D010396_D000741 CID antithymocyte_0\NNP\1740 globulin_1\NN\14736972 in_2\IN\13603305 the_3\DT\1740 treatment_4\NN\654885 of_5\IN\1740 <e1>d-penicillamine-induced</e1>_6\JJ\1740 <e2>aplastic_7\JJ\1740 anemia</e2>_8\NN\14189204 ._9\.\1740
D010396_D000741 CID a_0\DT\13649268 patient_1\NN\9898892 who_2\WP\8299493 received_3\VBD\2210855 antithymocyte_4\NN\1740 globulin_5\NN\14736972 therapy_6\NN\657604 for_7\IN\1740 <e2>aplastic_8\JJ\1740 anemia</e2>_9\NN\14189204 due_10\IN\5174653 to_11\TO\1740 <e1>d-penicillamine</e1>_12\NN\1740 therapy_13\NN\657604 is_14\VBZ\836236 described_15\VBN\1001294 ._16\.\1740
D010396_D000741 CID use_0\NN\407535 of_1\IN\1740 antithymocyte_2\NN\1740 globulin_3\NN\14736972 may_4\MD\15209706 be_5\VB\836236 the_6\DT\1740 optimal_7\JJ\1740 treatment_8\NN\654885 of_9\IN\1740 <e1>d-penicillamine-induced</e1>_10\JJ\1740 <e2>aplastic_11\JJ\1740 anemia</e2>_12\NN\14189204 ._13\.\1740
12536034
D002220_D004832 CID the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 three_3\CD\13741022 patients_4\NNS\9898892 with_5\IN\1740 de_6\FW\1740 novo_7\FW\1740 <e2>absence_8\NN\14449405 epilepsy</e2>_9\NN\14085708 after_10\IN\1740 administration_11\NN\1133281 of_12\IN\1740 <e1>carbamazepine</e1>_13\NN\1740 and_14\CC\1740 vigabatrin_15\NN\1740 ._16\.\1740
D020888_D004832 CID the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 three_3\CD\13741022 patients_4\NNS\9898892 with_5\IN\1740 de_6\FW\1740 novo_7\FW\1740 <e2>absence_8\NN\14449405 epilepsy</e2>_9\NN\14085708 after_10\IN\1740 administration_11\NN\1133281 of_12\IN\1740 carbamazepine_13\NN\1740 and_14\CC\1740 <e1>vigabatrin</e1>_15\NN\1740 ._16\.\1740
D005680_D004832 NONE the_0\DT\1740 <e1>gamma-aminobutyric_1\JJ\1740 acid-transmitted</e1>_2\JJ\1740 thalamocortical_3\JJ\1740 circuitry_4\NN\3278248 accounts_5\NNS\6647206 for_6\IN\1740 a_7\DT\13649268 major_8\JJ\1740 part_9\NN\31921 of_10\IN\1740 the_11\DT\1740 underlying_12\VBG\2604760 neurophysiology_13\NN\6081833 of_14\IN\1740 the_15\DT\1740 <e2>absence_16\NN\14449405 epilepsy</e2>_17\NN\14085708 ._18\.\1740
10365197
D003042_D019964 CID <e1>cocaine-induced</e1>_0\JJ\1740 <e2>mood_1\NN\26192 disorder</e2>_2\NN\14034177 :_3\:\1740 prevalence_4\NN\4764412 rates_5\NNS\13308999 and_6\CC\1740 psychiatric_7\JJ\1740 symptoms_8\NNS\5823932 in_9\IN\13603305 an_10\DT\6697703 outpatient_11\JJ\1740 cocaine-dependent_12\JJ\1740 sample_13\NN\5820620 ._14\.\1740
D003042_D019964 CID cocaine-induced_0\JJ\1740 <e2>mood_1\NN\26192 disorder</e2>_2\NN\14034177 :_3\:\1740 prevalence_4\NN\4764412 rates_5\NNS\13308999 and_6\CC\1740 psychiatric_7\JJ\1740 symptoms_8\NNS\5823932 in_9\IN\13603305 an_10\DT\6697703 outpatient_11\JJ\1740 <e1>cocaine-dependent</e1>_12\JJ\1740 sample_13\NN\5820620 ._14\.\1740
D003042_D019964 CID 243_0\CD\1740 <e1>cocaine-dependent</e1>_1\JJ\1740 outpatients_2\NNS\10405694 with_3\IN\1740 cocaine-induced_4\JJ\1740 <e2>mood_5\NN\26192 disorder</e2>_6\NN\14034177 (_7\-LRB-\1740 cimd_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 other_11\JJ\1740 mood_12\NN\26192 disorders_13\NNS\14034177 ,_14\,\1740 or_15\CC\3541091 no_16\DT\7204911 mood_17\NN\26192 disorder_18\NN\14034177 were_19\VBD\836236 compared_20\VBN\644583 on_21\IN\1740 measures_22\NNS\168237 of_23\IN\1740 psychiatric_24\JJ\1740 symptoms_25\NNS\5823932 ._26\.\1740
D003042_D019964 CID 243_0\CD\1740 <e1>cocaine-dependent</e1>_1\JJ\1740 outpatients_2\NNS\10405694 with_3\IN\1740 cocaine-induced_4\JJ\1740 mood_5\NN\26192 disorder_6\NN\14034177 (_7\-LRB-\1740 cimd_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 other_11\JJ\1740 <e2>mood_12\NN\26192 disorders</e2>_13\NNS\14034177 ,_14\,\1740 or_15\CC\3541091 no_16\DT\7204911 mood_17\NN\26192 disorder_18\NN\14034177 were_19\VBD\836236 compared_20\VBN\644583 on_21\IN\1740 measures_22\NNS\168237 of_23\IN\1740 psychiatric_24\JJ\1740 symptoms_25\NNS\5823932 ._26\.\1740
D003042_D019964 CID 243_0\CD\1740 <e1>cocaine-dependent</e1>_1\JJ\1740 outpatients_2\NNS\10405694 with_3\IN\1740 cocaine-induced_4\JJ\1740 mood_5\NN\26192 disorder_6\NN\14034177 (_7\-LRB-\1740 cimd_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 other_11\JJ\1740 mood_12\NN\26192 disorders_13\NNS\14034177 ,_14\,\1740 or_15\CC\3541091 no_16\DT\7204911 <e2>mood_17\NN\26192 disorder</e2>_18\NN\14034177 were_19\VBD\836236 compared_20\VBN\644583 on_21\IN\1740 measures_22\NNS\168237 of_23\IN\1740 psychiatric_24\JJ\1740 symptoms_25\NNS\5823932 ._26\.\1740
D003042_D019964 CID 243_0\CD\1740 cocaine-dependent_1\JJ\1740 outpatients_2\NNS\10405694 with_3\IN\1740 <e1>cocaine-induced</e1>_4\JJ\1740 <e2>mood_5\NN\26192 disorder</e2>_6\NN\14034177 (_7\-LRB-\1740 cimd_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 other_11\JJ\1740 mood_12\NN\26192 disorders_13\NNS\14034177 ,_14\,\1740 or_15\CC\3541091 no_16\DT\7204911 mood_17\NN\26192 disorder_18\NN\14034177 were_19\VBD\836236 compared_20\VBN\644583 on_21\IN\1740 measures_22\NNS\168237 of_23\IN\1740 psychiatric_24\JJ\1740 symptoms_25\NNS\5823932 ._26\.\1740
D003042_D019964 CID 243_0\CD\1740 cocaine-dependent_1\JJ\1740 outpatients_2\NNS\10405694 with_3\IN\1740 <e1>cocaine-induced</e1>_4\JJ\1740 mood_5\NN\26192 disorder_6\NN\14034177 (_7\-LRB-\1740 cimd_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 other_11\JJ\1740 <e2>mood_12\NN\26192 disorders</e2>_13\NNS\14034177 ,_14\,\1740 or_15\CC\3541091 no_16\DT\7204911 mood_17\NN\26192 disorder_18\NN\14034177 were_19\VBD\836236 compared_20\VBN\644583 on_21\IN\1740 measures_22\NNS\168237 of_23\IN\1740 psychiatric_24\JJ\1740 symptoms_25\NNS\5823932 ._26\.\1740
D003042_D019964 CID 243_0\CD\1740 cocaine-dependent_1\JJ\1740 outpatients_2\NNS\10405694 with_3\IN\1740 <e1>cocaine-induced</e1>_4\JJ\1740 mood_5\NN\26192 disorder_6\NN\14034177 (_7\-LRB-\1740 cimd_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 other_11\JJ\1740 mood_12\NN\26192 disorders_13\NNS\14034177 ,_14\,\1740 or_15\CC\3541091 no_16\DT\7204911 <e2>mood_17\NN\26192 disorder</e2>_18\NN\14034177 were_19\VBD\836236 compared_20\VBN\644583 on_21\IN\1740 measures_22\NNS\168237 of_23\IN\1740 psychiatric_24\JJ\1740 symptoms_25\NNS\5823932 ._26\.\1740
D003042_D001523 NONE <e1>cocaine-induced</e1>_0\JJ\1740 mood_1\NN\26192 disorder_2\NN\14034177 :_3\:\1740 prevalence_4\NN\4764412 rates_5\NNS\13308999 and_6\CC\1740 <e2>psychiatric</e2>_7\JJ\1740 symptoms_8\NNS\5823932 in_9\IN\13603305 an_10\DT\6697703 outpatient_11\JJ\1740 cocaine-dependent_12\JJ\1740 sample_13\NN\5820620 ._14\.\1740
D003042_D001523 NONE cocaine-induced_0\JJ\1740 mood_1\NN\26192 disorder_2\NN\14034177 :_3\:\1740 prevalence_4\NN\4764412 rates_5\NNS\13308999 and_6\CC\1740 <e2>psychiatric</e2>_7\JJ\1740 symptoms_8\NNS\5823932 in_9\IN\13603305 an_10\DT\6697703 outpatient_11\JJ\1740 <e1>cocaine-dependent</e1>_12\JJ\1740 sample_13\NN\5820620 ._14\.\1740
D003042_D001523 NONE 243_0\CD\1740 <e1>cocaine-dependent</e1>_1\JJ\1740 outpatients_2\NNS\10405694 with_3\IN\1740 cocaine-induced_4\JJ\1740 mood_5\NN\26192 disorder_6\NN\14034177 (_7\-LRB-\1740 cimd_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 other_11\JJ\1740 mood_12\NN\26192 disorders_13\NNS\14034177 ,_14\,\1740 or_15\CC\3541091 no_16\DT\7204911 mood_17\NN\26192 disorder_18\NN\14034177 were_19\VBD\836236 compared_20\VBN\644583 on_21\IN\1740 measures_22\NNS\168237 of_23\IN\1740 <e2>psychiatric</e2>_24\JJ\1740 symptoms_25\NNS\5823932 ._26\.\1740
D003042_D001523 NONE 243_0\CD\1740 cocaine-dependent_1\JJ\1740 outpatients_2\NNS\10405694 with_3\IN\1740 <e1>cocaine-induced</e1>_4\JJ\1740 mood_5\NN\26192 disorder_6\NN\14034177 (_7\-LRB-\1740 cimd_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 other_11\JJ\1740 mood_12\NN\26192 disorders_13\NNS\14034177 ,_14\,\1740 or_15\CC\3541091 no_16\DT\7204911 mood_17\NN\26192 disorder_18\NN\14034177 were_19\VBD\836236 compared_20\VBN\644583 on_21\IN\1740 measures_22\NNS\168237 of_23\IN\1740 <e2>psychiatric</e2>_24\JJ\1740 symptoms_25\NNS\5823932 ._26\.\1740
D003042_D019970 NONE 243_0\CD\1740 <e1>cocaine-dependent</e1>_1\JJ\1740 outpatients_2\NNS\10405694 with_3\IN\1740 cocaine-induced_4\JJ\1740 mood_5\NN\26192 disorder_6\NN\14034177 (_7\-LRB-\1740 <e2>cimd</e2>_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 other_11\JJ\1740 mood_12\NN\26192 disorders_13\NNS\14034177 ,_14\,\1740 or_15\CC\3541091 no_16\DT\7204911 mood_17\NN\26192 disorder_18\NN\14034177 were_19\VBD\836236 compared_20\VBN\644583 on_21\IN\1740 measures_22\NNS\168237 of_23\IN\1740 psychiatric_24\JJ\1740 symptoms_25\NNS\5823932 ._26\.\1740
D003042_D019970 NONE 243_0\CD\1740 cocaine-dependent_1\JJ\1740 outpatients_2\NNS\10405694 with_3\IN\1740 <e1>cocaine-induced</e1>_4\JJ\1740 mood_5\NN\26192 disorder_6\NN\14034177 (_7\-LRB-\1740 <e2>cimd</e2>_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 other_11\JJ\1740 mood_12\NN\26192 disorders_13\NNS\14034177 ,_14\,\1740 or_15\CC\3541091 no_16\DT\7204911 mood_17\NN\26192 disorder_18\NN\14034177 were_19\VBD\836236 compared_20\VBN\644583 on_21\IN\1740 measures_22\NNS\168237 of_23\IN\1740 psychiatric_24\JJ\1740 symptoms_25\NNS\5823932 ._26\.\1740
16160878
D014579_D006973 NONE intracerebroventricular_0\JJ\1740 (_1\-LRB-\1740 i.c.v._2\NN\1740 )_3\-RRB-\1740 injection_4\NN\320852 of_5\IN\1740 <e1>u-ii</e1>_6\NN\1740 causes_7\VBZ\1617192 <e2>hypertension</e2>_8\NN\14057371 and_9\CC\1740 bradycardia_10\NN\14110674 and_11\CC\1740 stimulates_12\VBZ\137313 prolactin_13\NN\5410315 and_14\CC\1740 thyrotropin_15\NN\5407119 secretion_16\NN\13526110 ._17\.\1740
D014579_D001919 NONE intracerebroventricular_0\JJ\1740 (_1\-LRB-\1740 i.c.v._2\NN\1740 )_3\-RRB-\1740 injection_4\NN\320852 of_5\IN\1740 <e1>u-ii</e1>_6\NN\1740 causes_7\VBZ\1617192 hypertension_8\NN\14057371 and_9\CC\1740 <e2>bradycardia</e2>_10\NN\14110674 and_11\CC\1740 stimulates_12\VBZ\137313 prolactin_13\NN\5410315 and_14\CC\1740 thyrotropin_15\NN\5407119 secretion_16\NN\13526110 ._17\.\1740
D014579_D010409 NONE whatever_0\WP\1740 was_1\VBD\836236 the_2\DT\1740 dose_3\NN\3740161 ,_4\,\1740 the_5\DT\1740 central_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 <e1>u-ii</e1>_9\NN\1740 had_10\VBD\2108377 no_11\DT\7204911 effect_12\NN\34213 on_13\IN\1740 body_14\NN\19128 temperature_15\NN\13575869 ,_16\,\1740 nociception_17\NN\1740 ,_18\,\1740 apomorphine-induced_19\JJ\1740 <e2>penile_20\NN\1740 erection</e2>_21\NN\14037619 and_22\CC\1740 climbing_23\NN\7445480 behavior_24\NN\407535 ,_25\,\1740 and_26\CC\1740 stress-induced_27\JJ\1740 plasma_28\NN\5398023 corticosterone_29\NN\14752057 level_30\NN\4916342 ._31\.\1740
D001058_D010409 CID whatever_0\WP\1740 was_1\VBD\836236 the_2\DT\1740 dose_3\NN\3740161 ,_4\,\1740 the_5\DT\1740 central_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 u-ii_9\NN\1740 had_10\VBD\2108377 no_11\DT\7204911 effect_12\NN\34213 on_13\IN\1740 body_14\NN\19128 temperature_15\NN\13575869 ,_16\,\1740 nociception_17\NN\1740 ,_18\,\1740 <e1>apomorphine-induced</e1>_19\JJ\1740 <e2>penile_20\NN\1740 erection</e2>_21\NN\14037619 and_22\CC\1740 climbing_23\NN\7445480 behavior_24\NN\407535 ,_25\,\1740 and_26\CC\1740 stress-induced_27\JJ\1740 plasma_28\NN\5398023 corticosterone_29\NN\14752057 level_30\NN\4916342 ._31\.\1740
D003345_D010409 NONE whatever_0\WP\1740 was_1\VBD\836236 the_2\DT\1740 dose_3\NN\3740161 ,_4\,\1740 the_5\DT\1740 central_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 u-ii_9\NN\1740 had_10\VBD\2108377 no_11\DT\7204911 effect_12\NN\34213 on_13\IN\1740 body_14\NN\19128 temperature_15\NN\13575869 ,_16\,\1740 nociception_17\NN\1740 ,_18\,\1740 apomorphine-induced_19\JJ\1740 <e2>penile_20\NN\1740 erection</e2>_21\NN\14037619 and_22\CC\1740 climbing_23\NN\7445480 behavior_24\NN\407535 ,_25\,\1740 and_26\CC\1740 stress-induced_27\JJ\1740 plasma_28\NN\5398023 <e1>corticosterone</e1>_29\NN\14752057 level_30\NN\4916342 ._31\.\1740
D014579_D001523 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>u-ii</e1>_4\NN\1740 may_5\MD\15209706 be_6\VB\836236 involved_7\VBN\2676054 in_8\IN\13603305 some_9\DT\1740 aspects_10\NNS\5849789 of_11\IN\1740 <e2>psychiatric_12\JJ\1740 disorders</e2>_13\NNS\14034177 ._14\.\1740
2385256
D008274_D009157 CID <e2>myasthenia_0\NNP\14187378 gravis</e2>_1\NN\1740 presenting_2\VBG\2137132 as_3\IN\14622893 weakness_4\NN\14462666 after_5\IN\1740 <e1>magnesium</e1>_6\NN\14625458 administration_7\NN\1133281 ._8\.\1740
D008274_D009157 CID although_0\IN\1740 paralysis_1\NN\14557898 after_2\IN\1740 <e1>magnesium</e1>_3\NN\14625458 administration_4\NN\1133281 has_5\VBZ\2108377 been_6\VBN\836236 described_7\VBN\1001294 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 known_11\JJ\1740 <e2>myasthenia_12\NN\14187378 gravis</e2>_13\NN\1740 ,_14\,\1740 it_15\PRP\6125041 has_16\VBZ\2108377 not_17\RB\1740 previously_18\RB\1740 been_19\VBN\836236 reported_20\VBN\831651 to_21\TO\1740 be_22\VB\836236 the_23\DT\1740 initial_24\JJ\1740 or_25\CC\3541091 only_26\JJ\1740 manifestation_27\NN\7321772 of_28\IN\1740 the_29\DT\1740 disease_30\NN\14061805 ._31\.\1740
D008274_D009468 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 no_5\DT\7204911 prior_6\JJ\1740 history_7\NN\15120823 of_8\IN\1740 <e2>neuromuscular_9\JJ\1740 disease</e2>_10\NN\14061805 who_11\WP\8299493 became_12\VBD\146138 virtually_13\RB\1740 quadriplegic_14\JJ\1740 after_15\IN\1740 parenteral_16\JJ\1740 <e1>magnesium</e1>_17\NN\14625458 administration_18\NN\1133281 for_19\IN\1740 preeclampsia_20\NN\14191037 ._21\.\1740
D008274_D011782 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 no_5\DT\7204911 prior_6\JJ\1740 history_7\NN\15120823 of_8\IN\1740 neuromuscular_9\JJ\1740 disease_10\NN\14061805 who_11\WP\8299493 became_12\VBD\146138 virtually_13\RB\1740 <e2>quadriplegic</e2>_14\JJ\1740 after_15\IN\1740 parenteral_16\JJ\1740 <e1>magnesium</e1>_17\NN\14625458 administration_18\NN\1133281 for_19\IN\1740 preeclampsia_20\NN\14191037 ._21\.\1740
D008274_D011225 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 no_5\DT\7204911 prior_6\JJ\1740 history_7\NN\15120823 of_8\IN\1740 neuromuscular_9\JJ\1740 disease_10\NN\14061805 who_11\WP\8299493 became_12\VBD\146138 virtually_13\RB\1740 quadriplegic_14\JJ\1740 after_15\IN\1740 parenteral_16\JJ\1740 <e1>magnesium</e1>_17\NN\14625458 administration_18\NN\1133281 for_19\IN\1740 <e2>preeclampsia</e2>_20\NN\14191037 ._21\.\1740
D008274_D010243 NONE although_0\IN\1740 <e2>paralysis</e2>_1\NN\14557898 after_2\IN\1740 <e1>magnesium</e1>_3\NN\14625458 administration_4\NN\1133281 has_5\VBZ\2108377 been_6\VBN\836236 described_7\VBN\1001294 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 known_11\JJ\1740 myasthenia_12\NN\14187378 gravis_13\NN\1740 ,_14\,\1740 it_15\PRP\6125041 has_16\VBZ\2108377 not_17\RB\1740 previously_18\RB\1740 been_19\VBN\836236 reported_20\VBN\831651 to_21\TO\1740 be_22\VB\836236 the_23\DT\1740 initial_24\JJ\1740 or_25\CC\3541091 only_26\JJ\1740 manifestation_27\NN\7321772 of_28\IN\1740 the_29\DT\1740 disease_30\NN\14061805 ._31\.\1740
D008274_D020511 NONE patients_0\NNS\9898892 who_1\WP\8299493 are_2\VBP\836236 unusually_3\RB\1740 sensitive_4\JJ\1740 to_5\TO\1740 the_6\DT\1740 neuromuscular_7\JJ\1740 effects_8\NNS\13245626 of_9\IN\1740 <e1>magnesium</e1>_10\NN\14625458 should_11\MD\1740 be_12\VB\836236 suspected_13\VBN\916909 of_14\IN\1740 having_15\VBG\2108377 an_16\DT\6697703 underlying_17\VBG\2604760 <e2>disorder_18\NN\14034177 of_19\IN\1740 neuromuscular_20\JJ\1740 transmission</e2>_21\NN\121166 ._22\.\1740
3076126
D008148_D009135 NONE <e2>myopathy</e2>_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 myoglobinuria_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 renal_15\JJ\1740 failure_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 <e1>lovastatin</e1>_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 cyclosporin_31\NN\1740 ,_32\,\1740 gemfibrozil_33\NN\3740161 or_34\CC\3541091 niacin_35\NN\15090742 ._36\.\1740
D008148_D009212 CID myopathy_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 <e2>myoglobinuria</e2>_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 renal_15\JJ\1740 failure_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 <e1>lovastatin</e1>_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 cyclosporin_31\NN\1740 ,_32\,\1740 gemfibrozil_33\NN\3740161 or_34\CC\3541091 niacin_35\NN\15090742 ._36\.\1740
D008148_D051437 CID myopathy_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 myoglobinuria_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 <e2>renal_15\JJ\1740 failure</e2>_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 <e1>lovastatin</e1>_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 cyclosporin_31\NN\1740 ,_32\,\1740 gemfibrozil_33\NN\3740161 or_34\CC\3541091 niacin_35\NN\15090742 ._36\.\1740
D016572_D009135 CID <e2>myopathy</e2>_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 myoglobinuria_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 renal_15\JJ\1740 failure_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 lovastatin_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 <e1>cyclosporin</e1>_31\NN\1740 ,_32\,\1740 gemfibrozil_33\NN\3740161 or_34\CC\3541091 niacin_35\NN\15090742 ._36\.\1740
D016572_D009212 NONE myopathy_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 <e2>myoglobinuria</e2>_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 renal_15\JJ\1740 failure_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 lovastatin_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 <e1>cyclosporin</e1>_31\NN\1740 ,_32\,\1740 gemfibrozil_33\NN\3740161 or_34\CC\3541091 niacin_35\NN\15090742 ._36\.\1740
D016572_D051437 NONE myopathy_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 myoglobinuria_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 <e2>renal_15\JJ\1740 failure</e2>_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 lovastatin_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 <e1>cyclosporin</e1>_31\NN\1740 ,_32\,\1740 gemfibrozil_33\NN\3740161 or_34\CC\3541091 niacin_35\NN\15090742 ._36\.\1740
D015248_D009135 CID <e2>myopathy</e2>_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 myoglobinuria_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 renal_15\JJ\1740 failure_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 lovastatin_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 cyclosporin_31\NN\1740 ,_32\,\1740 <e1>gemfibrozil</e1>_33\NN\3740161 or_34\CC\3541091 niacin_35\NN\15090742 ._36\.\1740
D015248_D009212 NONE myopathy_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 <e2>myoglobinuria</e2>_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 renal_15\JJ\1740 failure_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 lovastatin_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 cyclosporin_31\NN\1740 ,_32\,\1740 <e1>gemfibrozil</e1>_33\NN\3740161 or_34\CC\3541091 niacin_35\NN\15090742 ._36\.\1740
D015248_D051437 NONE myopathy_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 myoglobinuria_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 <e2>renal_15\JJ\1740 failure</e2>_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 lovastatin_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 cyclosporin_31\NN\1740 ,_32\,\1740 <e1>gemfibrozil</e1>_33\NN\3740161 or_34\CC\3541091 niacin_35\NN\15090742 ._36\.\1740
D009525_D009135 CID <e2>myopathy</e2>_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 myoglobinuria_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 renal_15\JJ\1740 failure_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 lovastatin_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 cyclosporin_31\NN\1740 ,_32\,\1740 gemfibrozil_33\NN\3740161 or_34\CC\3541091 <e1>niacin</e1>_35\NN\15090742 ._36\.\1740
D009525_D009212 NONE myopathy_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 <e2>myoglobinuria</e2>_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 renal_15\JJ\1740 failure_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 lovastatin_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 cyclosporin_31\NN\1740 ,_32\,\1740 gemfibrozil_33\NN\3740161 or_34\CC\3541091 <e1>niacin</e1>_35\NN\15090742 ._36\.\1740
D009525_D051437 NONE myopathy_0\NNP\14204950 ,_1\,\1740 associated_2\VBN\628491 in_3\IN\13603305 some_4\DT\1740 cases_5\NNS\7283608 with_6\IN\1740 myoglobinuria_7\NNS\14299637 ,_8\,\1740 and_9\CC\1740 in_10\IN\13603305 2_11\CD\13741022 cases_12\NNS\7283608 with_13\IN\1740 transient_14\JJ\1740 <e2>renal_15\JJ\1740 failure</e2>_16\NN\66216 ,_17\,\1740 has_18\VBZ\2108377 been_19\VBN\836236 rarely_20\RB\1740 reported_21\VBN\831651 with_22\IN\1740 lovastatin_23\NN\3676175 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 patients_27\NNS\9898892 concomitantly_28\RB\1740 treated_29\VBN\2376958 with_30\IN\1740 cyclosporin_31\NN\1740 ,_32\,\1740 gemfibrozil_33\NN\3740161 or_34\CC\3541091 <e1>niacin</e1>_35\NN\15090742 ._36\.\1740
1592014
D003042_D012640 CID <e2>seizures</e2>_0\NNP\14081375 induced_1\VBN\1627355 by_2\IN\1740 the_3\DT\1740 <e1>cocaine</e1>_4\NN\3492717 metabolite_5\NN\20090 benzoylecgonine_6\NN\1740 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D003042_D012640 CID the_0\DT\1740 half-life_1\NN\15113229 (_2\-LRB-\1740 t1/2_3\NN\1740 )_4\-RRB-\1740 of_5\IN\1740 <e1>cocaine</e1>_6\NN\3492717 is_7\VBZ\836236 relatively_8\RB\1740 short_9\JJ\1740 ,_10\,\1740 but_11\CC\1740 some_12\DT\1740 of_13\IN\1740 the_14\DT\1740 consequences_15\NNS\34213 of_16\IN\1740 its_17\PRP$\6125041 use_18\NN\407535 ,_19\,\1740 such_20\JJ\1740 as_21\IN\14622893 <e2>seizures</e2>_22\NNS\14081375 and_23\CC\1740 strokes_24\NNS\556313 ,_25\,\1740 can_26\MD\3094503 occur_27\VB\2623529 hours_28\NNS\15118228 after_29\IN\1740 exposure_30\NN\5042871 ._31\.\1740
D003042_D012640 CID we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 potential_3\NN\14481929 of_4\IN\1740 the_5\DT\1740 major_6\JJ\1740 metabolite_7\NN\20090 of_8\IN\1740 <e1>cocaine</e1>_9\NN\3492717 ,_10\,\1740 benzoylecgonine_11\NN\1740 (_12\-LRB-\1740 be_13\NN\14625458 )_14\-RRB-\1740 ,_15\,\1740 to_16\TO\1740 cause_17\VB\1617192 <e2>seizures</e2>_18\NNS\14081375 ._19\.\1740
D003042_D012640 CID be-induced_0\JJ\1740 <e2>seizures</e2>_1\NNS\14081375 occurred_2\VBD\2623529 more_3\RBR\1740 frequently_4\RB\1740 and_5\CC\1740 had_6\VBD\2108377 significantly_7\RB\1740 longer_8\JJR\1740 latencies_9\NNS\15269513 than_10\IN\1740 those_11\DT\1740 induced_12\VBN\1627355 by_13\IN\1740 equimolar_14\JJ\1740 amounts_15\NNS\13329641 of_16\IN\1740 <e1>cocaine</e1>_17\NN\3492717 ._18\.\1740
D003042_D012640 CID whereas_0\IN\1740 <e1>cocaine-induced</e1>_1\JJ\1740 <e2>seizures</e2>_2\NNS\14081375 were_3\VBD\836236 best_4\RBS\1740 characterized_5\VBN\609683 as_6\IN\14622893 brief_7\JJ\1740 ,_8\,\1740 generalized_9\VBN\634472 ,_10\,\1740 and_11\CC\1740 tonic_12\JJ\1740 and_13\CC\1740 resulted_14\VBD\2633881 in_15\IN\13603305 death_16\NN\7296428 ,_17\,\1740 those_18\DT\1740 induced_19\VBN\1627355 by_20\IN\1740 be_21\NN\14625458 were_22\VBD\836236 prolonged_23\JJ\1740 ,_24\,\1740 often_25\RB\1740 multiple_26\JJ\1740 and_27\CC\1740 mixed_28\JJ\1740 in_29\IN\13603305 type_30\NN\5839024 ,_31\,\1740 and_32\CC\1740 rarely_33\RB\1740 resulted_34\VBD\2633881 in_35\IN\13603305 death_36\NN\7296428 ._37\.\1740
D003042_D012640 CID be-injected_0\JJ\1740 rats_1\NNS\2329401 that_2\WDT\1740 did_3\VBD\1640855 not_4\RB\1740 have_5\VB\2108377 <e2>seizures</e2>_6\NNS\14081375 had_7\VBD\2108377 significantly_8\RB\1740 more_9\JJR\1740 locomotor_10\NN\1740 activity_11\NN\30358 than_12\IN\1740 <e1>cocaine-injected</e1>_13\JJ\1740 animals_14\NNS\4475 without_15\IN\1740 seizures_16\NNS\14081375 ._17\.\1740
D003042_D012640 CID be-injected_0\JJ\1740 rats_1\NNS\2329401 that_2\WDT\1740 did_3\VBD\1640855 not_4\RB\1740 have_5\VB\2108377 seizures_6\NNS\14081375 had_7\VBD\2108377 significantly_8\RB\1740 more_9\JJR\1740 locomotor_10\NN\1740 activity_11\NN\30358 than_12\IN\1740 <e1>cocaine-injected</e1>_13\JJ\1740 animals_14\NNS\4475 without_15\IN\1740 <e2>seizures</e2>_16\NNS\14081375 ._17\.\1740
D003042_D012640 CID the_0\DT\1740 finding_1\NN\43195 that_2\IN\1740 <e1>cocaine-</e1>_3\NN\1740 and_4\CC\1740 be-induced_5\JJ\1740 <e2>seizures</e2>_6\NNS\14081375 differ_7\VBP\1740 in_8\IN\13603305 several_9\JJ\1740 respects_10\NNS\6598915 suggests_11\VBZ\1010118 more_12\JJR\1740 than_13\IN\1740 one_14\CD\13741022 mechanism_15\NN\13446390 for_16\IN\1740 cocaine-induced_17\JJ\1740 seizures_18\NNS\14081375 and_19\CC\1740 emphasizes_20\VBZ\943837 the_21\DT\1740 importance_22\NN\5138488 of_23\IN\1740 a_24\DT\13649268 cocaine_25\NN\3492717 metabolite_26\NN\20090 ,_27\,\1740 be_28\NN\14625458 ._29\.\1740
D003042_D012640 CID the_0\DT\1740 finding_1\NN\43195 that_2\IN\1740 <e1>cocaine-</e1>_3\NN\1740 and_4\CC\1740 be-induced_5\JJ\1740 seizures_6\NNS\14081375 differ_7\VBP\1740 in_8\IN\13603305 several_9\JJ\1740 respects_10\NNS\6598915 suggests_11\VBZ\1010118 more_12\JJR\1740 than_13\IN\1740 one_14\CD\13741022 mechanism_15\NN\13446390 for_16\IN\1740 cocaine-induced_17\JJ\1740 <e2>seizures</e2>_18\NNS\14081375 and_19\CC\1740 emphasizes_20\VBZ\943837 the_21\DT\1740 importance_22\NN\5138488 of_23\IN\1740 a_24\DT\13649268 cocaine_25\NN\3492717 metabolite_26\NN\20090 ,_27\,\1740 be_28\NN\14625458 ._29\.\1740
D003042_D012640 CID the_0\DT\1740 finding_1\NN\43195 that_2\IN\1740 cocaine-_3\NN\1740 and_4\CC\1740 be-induced_5\JJ\1740 <e2>seizures</e2>_6\NNS\14081375 differ_7\VBP\1740 in_8\IN\13603305 several_9\JJ\1740 respects_10\NNS\6598915 suggests_11\VBZ\1010118 more_12\JJR\1740 than_13\IN\1740 one_14\CD\13741022 mechanism_15\NN\13446390 for_16\IN\1740 <e1>cocaine-induced</e1>_17\JJ\1740 seizures_18\NNS\14081375 and_19\CC\1740 emphasizes_20\VBZ\943837 the_21\DT\1740 importance_22\NN\5138488 of_23\IN\1740 a_24\DT\13649268 cocaine_25\NN\3492717 metabolite_26\NN\20090 ,_27\,\1740 be_28\NN\14625458 ._29\.\1740
D003042_D012640 CID the_0\DT\1740 finding_1\NN\43195 that_2\IN\1740 cocaine-_3\NN\1740 and_4\CC\1740 be-induced_5\JJ\1740 seizures_6\NNS\14081375 differ_7\VBP\1740 in_8\IN\13603305 several_9\JJ\1740 respects_10\NNS\6598915 suggests_11\VBZ\1010118 more_12\JJR\1740 than_13\IN\1740 one_14\CD\13741022 mechanism_15\NN\13446390 for_16\IN\1740 <e1>cocaine-induced</e1>_17\JJ\1740 <e2>seizures</e2>_18\NNS\14081375 and_19\CC\1740 emphasizes_20\VBZ\943837 the_21\DT\1740 importance_22\NN\5138488 of_23\IN\1740 a_24\DT\13649268 cocaine_25\NN\3492717 metabolite_26\NN\20090 ,_27\,\1740 be_28\NN\14625458 ._29\.\1740
D003042_D012640 CID the_0\DT\1740 finding_1\NN\43195 that_2\IN\1740 cocaine-_3\NN\1740 and_4\CC\1740 be-induced_5\JJ\1740 <e2>seizures</e2>_6\NNS\14081375 differ_7\VBP\1740 in_8\IN\13603305 several_9\JJ\1740 respects_10\NNS\6598915 suggests_11\VBZ\1010118 more_12\JJR\1740 than_13\IN\1740 one_14\CD\13741022 mechanism_15\NN\13446390 for_16\IN\1740 cocaine-induced_17\JJ\1740 seizures_18\NNS\14081375 and_19\CC\1740 emphasizes_20\VBZ\943837 the_21\DT\1740 importance_22\NN\5138488 of_23\IN\1740 a_24\DT\13649268 <e1>cocaine</e1>_25\NN\3492717 metabolite_26\NN\20090 ,_27\,\1740 be_28\NN\14625458 ._29\.\1740
D003042_D012640 CID the_0\DT\1740 finding_1\NN\43195 that_2\IN\1740 cocaine-_3\NN\1740 and_4\CC\1740 be-induced_5\JJ\1740 seizures_6\NNS\14081375 differ_7\VBP\1740 in_8\IN\13603305 several_9\JJ\1740 respects_10\NNS\6598915 suggests_11\VBZ\1010118 more_12\JJR\1740 than_13\IN\1740 one_14\CD\13741022 mechanism_15\NN\13446390 for_16\IN\1740 cocaine-induced_17\JJ\1740 <e2>seizures</e2>_18\NNS\14081375 and_19\CC\1740 emphasizes_20\VBZ\943837 the_21\DT\1740 importance_22\NN\5138488 of_23\IN\1740 a_24\DT\13649268 <e1>cocaine</e1>_25\NN\3492717 metabolite_26\NN\20090 ,_27\,\1740 be_28\NN\14625458 ._29\.\1740
C005618_D012640 CID <e2>seizures</e2>_0\NNP\14081375 induced_1\VBN\1627355 by_2\IN\1740 the_3\DT\1740 cocaine_4\NN\3492717 metabolite_5\NN\20090 <e1>benzoylecgonine</e1>_6\NN\1740 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
C005618_D012640 CID we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 potential_3\NN\14481929 of_4\IN\1740 the_5\DT\1740 major_6\JJ\1740 metabolite_7\NN\20090 of_8\IN\1740 cocaine_9\NN\3492717 ,_10\,\1740 <e1>benzoylecgonine</e1>_11\NN\1740 (_12\-LRB-\1740 be_13\NN\14625458 )_14\-RRB-\1740 ,_15\,\1740 to_16\TO\1740 cause_17\VB\1617192 <e2>seizures</e2>_18\NNS\14081375 ._19\.\1740
C005618_D012640 CID we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 potential_3\NN\14481929 of_4\IN\1740 the_5\DT\1740 major_6\JJ\1740 metabolite_7\NN\20090 of_8\IN\1740 cocaine_9\NN\3492717 ,_10\,\1740 benzoylecgonine_11\NN\1740 (_12\-LRB-\1740 <e1>be</e1>_13\NN\14625458 )_14\-RRB-\1740 ,_15\,\1740 to_16\TO\1740 cause_17\VB\1617192 <e2>seizures</e2>_18\NNS\14081375 ._19\.\1740
C005618_D012640 CID <e1>be-induced</e1>_0\JJ\1740 <e2>seizures</e2>_1\NNS\14081375 occurred_2\VBD\2623529 more_3\RBR\1740 frequently_4\RB\1740 and_5\CC\1740 had_6\VBD\2108377 significantly_7\RB\1740 longer_8\JJR\1740 latencies_9\NNS\15269513 than_10\IN\1740 those_11\DT\1740 induced_12\VBN\1627355 by_13\IN\1740 equimolar_14\JJ\1740 amounts_15\NNS\13329641 of_16\IN\1740 cocaine_17\NN\3492717 ._18\.\1740
C005618_D012640 CID whereas_0\IN\1740 cocaine-induced_1\JJ\1740 <e2>seizures</e2>_2\NNS\14081375 were_3\VBD\836236 best_4\RBS\1740 characterized_5\VBN\609683 as_6\IN\14622893 brief_7\JJ\1740 ,_8\,\1740 generalized_9\VBN\634472 ,_10\,\1740 and_11\CC\1740 tonic_12\JJ\1740 and_13\CC\1740 resulted_14\VBD\2633881 in_15\IN\13603305 death_16\NN\7296428 ,_17\,\1740 those_18\DT\1740 induced_19\VBN\1627355 by_20\IN\1740 <e1>be</e1>_21\NN\14625458 were_22\VBD\836236 prolonged_23\JJ\1740 ,_24\,\1740 often_25\RB\1740 multiple_26\JJ\1740 and_27\CC\1740 mixed_28\JJ\1740 in_29\IN\13603305 type_30\NN\5839024 ,_31\,\1740 and_32\CC\1740 rarely_33\RB\1740 resulted_34\VBD\2633881 in_35\IN\13603305 death_36\NN\7296428 ._37\.\1740
C005618_D012640 CID <e1>be-injected</e1>_0\JJ\1740 rats_1\NNS\2329401 that_2\WDT\1740 did_3\VBD\1640855 not_4\RB\1740 have_5\VB\2108377 <e2>seizures</e2>_6\NNS\14081375 had_7\VBD\2108377 significantly_8\RB\1740 more_9\JJR\1740 locomotor_10\NN\1740 activity_11\NN\30358 than_12\IN\1740 cocaine-injected_13\JJ\1740 animals_14\NNS\4475 without_15\IN\1740 seizures_16\NNS\14081375 ._17\.\1740
C005618_D012640 CID <e1>be-injected</e1>_0\JJ\1740 rats_1\NNS\2329401 that_2\WDT\1740 did_3\VBD\1640855 not_4\RB\1740 have_5\VB\2108377 seizures_6\NNS\14081375 had_7\VBD\2108377 significantly_8\RB\1740 more_9\JJR\1740 locomotor_10\NN\1740 activity_11\NN\30358 than_12\IN\1740 cocaine-injected_13\JJ\1740 animals_14\NNS\4475 without_15\IN\1740 <e2>seizures</e2>_16\NNS\14081375 ._17\.\1740
C005618_D012640 CID the_0\DT\1740 finding_1\NN\43195 that_2\IN\1740 cocaine-_3\NN\1740 and_4\CC\1740 <e1>be-induced</e1>_5\JJ\1740 <e2>seizures</e2>_6\NNS\14081375 differ_7\VBP\1740 in_8\IN\13603305 several_9\JJ\1740 respects_10\NNS\6598915 suggests_11\VBZ\1010118 more_12\JJR\1740 than_13\IN\1740 one_14\CD\13741022 mechanism_15\NN\13446390 for_16\IN\1740 cocaine-induced_17\JJ\1740 seizures_18\NNS\14081375 and_19\CC\1740 emphasizes_20\VBZ\943837 the_21\DT\1740 importance_22\NN\5138488 of_23\IN\1740 a_24\DT\13649268 cocaine_25\NN\3492717 metabolite_26\NN\20090 ,_27\,\1740 be_28\NN\14625458 ._29\.\1740
C005618_D012640 CID the_0\DT\1740 finding_1\NN\43195 that_2\IN\1740 cocaine-_3\NN\1740 and_4\CC\1740 <e1>be-induced</e1>_5\JJ\1740 seizures_6\NNS\14081375 differ_7\VBP\1740 in_8\IN\13603305 several_9\JJ\1740 respects_10\NNS\6598915 suggests_11\VBZ\1010118 more_12\JJR\1740 than_13\IN\1740 one_14\CD\13741022 mechanism_15\NN\13446390 for_16\IN\1740 cocaine-induced_17\JJ\1740 <e2>seizures</e2>_18\NNS\14081375 and_19\CC\1740 emphasizes_20\VBZ\943837 the_21\DT\1740 importance_22\NN\5138488 of_23\IN\1740 a_24\DT\13649268 cocaine_25\NN\3492717 metabolite_26\NN\20090 ,_27\,\1740 be_28\NN\14625458 ._29\.\1740
C005618_D012640 CID the_0\DT\1740 finding_1\NN\43195 that_2\IN\1740 cocaine-_3\NN\1740 and_4\CC\1740 be-induced_5\JJ\1740 <e2>seizures</e2>_6\NNS\14081375 differ_7\VBP\1740 in_8\IN\13603305 several_9\JJ\1740 respects_10\NNS\6598915 suggests_11\VBZ\1010118 more_12\JJR\1740 than_13\IN\1740 one_14\CD\13741022 mechanism_15\NN\13446390 for_16\IN\1740 cocaine-induced_17\JJ\1740 seizures_18\NNS\14081375 and_19\CC\1740 emphasizes_20\VBZ\943837 the_21\DT\1740 importance_22\NN\5138488 of_23\IN\1740 a_24\DT\13649268 cocaine_25\NN\3492717 metabolite_26\NN\20090 ,_27\,\1740 <e1>be</e1>_28\NN\14625458 ._29\.\1740
C005618_D012640 CID the_0\DT\1740 finding_1\NN\43195 that_2\IN\1740 cocaine-_3\NN\1740 and_4\CC\1740 be-induced_5\JJ\1740 seizures_6\NNS\14081375 differ_7\VBP\1740 in_8\IN\13603305 several_9\JJ\1740 respects_10\NNS\6598915 suggests_11\VBZ\1010118 more_12\JJR\1740 than_13\IN\1740 one_14\CD\13741022 mechanism_15\NN\13446390 for_16\IN\1740 cocaine-induced_17\JJ\1740 <e2>seizures</e2>_18\NNS\14081375 and_19\CC\1740 emphasizes_20\VBZ\943837 the_21\DT\1740 importance_22\NN\5138488 of_23\IN\1740 a_24\DT\13649268 cocaine_25\NN\3492717 metabolite_26\NN\20090 ,_27\,\1740 <e1>be</e1>_28\NN\14625458 ._29\.\1740
D003042_D020521 NONE the_0\DT\1740 half-life_1\NN\15113229 (_2\-LRB-\1740 t1/2_3\NN\1740 )_4\-RRB-\1740 of_5\IN\1740 <e1>cocaine</e1>_6\NN\3492717 is_7\VBZ\836236 relatively_8\RB\1740 short_9\JJ\1740 ,_10\,\1740 but_11\CC\1740 some_12\DT\1740 of_13\IN\1740 the_14\DT\1740 consequences_15\NNS\34213 of_16\IN\1740 its_17\PRP$\6125041 use_18\NN\407535 ,_19\,\1740 such_20\JJ\1740 as_21\IN\14622893 seizures_22\NNS\14081375 and_23\CC\1740 <e2>strokes</e2>_24\NNS\556313 ,_25\,\1740 can_26\MD\3094503 occur_27\VB\2623529 hours_28\NNS\15118228 after_29\IN\1740 exposure_30\NN\5042871 ._31\.\1740
D003042_D003643 NONE whereas_0\IN\1740 <e1>cocaine-induced</e1>_1\JJ\1740 seizures_2\NNS\14081375 were_3\VBD\836236 best_4\RBS\1740 characterized_5\VBN\609683 as_6\IN\14622893 brief_7\JJ\1740 ,_8\,\1740 generalized_9\VBN\634472 ,_10\,\1740 and_11\CC\1740 tonic_12\JJ\1740 and_13\CC\1740 resulted_14\VBD\2633881 in_15\IN\13603305 <e2>death</e2>_16\NN\7296428 ,_17\,\1740 those_18\DT\1740 induced_19\VBN\1627355 by_20\IN\1740 be_21\NN\14625458 were_22\VBD\836236 prolonged_23\JJ\1740 ,_24\,\1740 often_25\RB\1740 multiple_26\JJ\1740 and_27\CC\1740 mixed_28\JJ\1740 in_29\IN\13603305 type_30\NN\5839024 ,_31\,\1740 and_32\CC\1740 rarely_33\RB\1740 resulted_34\VBD\2633881 in_35\IN\13603305 death_36\NN\7296428 ._37\.\1740
D003042_D003643 NONE whereas_0\IN\1740 <e1>cocaine-induced</e1>_1\JJ\1740 seizures_2\NNS\14081375 were_3\VBD\836236 best_4\RBS\1740 characterized_5\VBN\609683 as_6\IN\14622893 brief_7\JJ\1740 ,_8\,\1740 generalized_9\VBN\634472 ,_10\,\1740 and_11\CC\1740 tonic_12\JJ\1740 and_13\CC\1740 resulted_14\VBD\2633881 in_15\IN\13603305 death_16\NN\7296428 ,_17\,\1740 those_18\DT\1740 induced_19\VBN\1627355 by_20\IN\1740 be_21\NN\14625458 were_22\VBD\836236 prolonged_23\JJ\1740 ,_24\,\1740 often_25\RB\1740 multiple_26\JJ\1740 and_27\CC\1740 mixed_28\JJ\1740 in_29\IN\13603305 type_30\NN\5839024 ,_31\,\1740 and_32\CC\1740 rarely_33\RB\1740 resulted_34\VBD\2633881 in_35\IN\13603305 <e2>death</e2>_36\NN\7296428 ._37\.\1740
C005618_D003643 NONE whereas_0\IN\1740 cocaine-induced_1\JJ\1740 seizures_2\NNS\14081375 were_3\VBD\836236 best_4\RBS\1740 characterized_5\VBN\609683 as_6\IN\14622893 brief_7\JJ\1740 ,_8\,\1740 generalized_9\VBN\634472 ,_10\,\1740 and_11\CC\1740 tonic_12\JJ\1740 and_13\CC\1740 resulted_14\VBD\2633881 in_15\IN\13603305 <e2>death</e2>_16\NN\7296428 ,_17\,\1740 those_18\DT\1740 induced_19\VBN\1627355 by_20\IN\1740 <e1>be</e1>_21\NN\14625458 were_22\VBD\836236 prolonged_23\JJ\1740 ,_24\,\1740 often_25\RB\1740 multiple_26\JJ\1740 and_27\CC\1740 mixed_28\JJ\1740 in_29\IN\13603305 type_30\NN\5839024 ,_31\,\1740 and_32\CC\1740 rarely_33\RB\1740 resulted_34\VBD\2633881 in_35\IN\13603305 death_36\NN\7296428 ._37\.\1740
C005618_D003643 NONE whereas_0\IN\1740 cocaine-induced_1\JJ\1740 seizures_2\NNS\14081375 were_3\VBD\836236 best_4\RBS\1740 characterized_5\VBN\609683 as_6\IN\14622893 brief_7\JJ\1740 ,_8\,\1740 generalized_9\VBN\634472 ,_10\,\1740 and_11\CC\1740 tonic_12\JJ\1740 and_13\CC\1740 resulted_14\VBD\2633881 in_15\IN\13603305 death_16\NN\7296428 ,_17\,\1740 those_18\DT\1740 induced_19\VBN\1627355 by_20\IN\1740 <e1>be</e1>_21\NN\14625458 were_22\VBD\836236 prolonged_23\JJ\1740 ,_24\,\1740 often_25\RB\1740 multiple_26\JJ\1740 and_27\CC\1740 mixed_28\JJ\1740 in_29\IN\13603305 type_30\NN\5839024 ,_31\,\1740 and_32\CC\1740 rarely_33\RB\1740 resulted_34\VBD\2633881 in_35\IN\13603305 <e2>death</e2>_36\NN\7296428 ._37\.\1740
1867351
D015767_D008288 NONE therefore_0\RB\1740 ,_1\,\1740 certain_2\JJ\1740 limitations_3\NNS\5846054 for_4\IN\1740 <e2>malaria</e2>_5\NN\14178913 prophylaxis_6\NN\1077350 and_7\CC\1740 treatment_8\NN\654885 with_9\IN\1740 <e1>mefloquine</e1>_10\NN\2721948 are_11\VBP\836236 recommended_12\VBN\875394 ._13\.\1740
21029050
D013390_D001049 CID butyrylcholinesterase_0\NN\1740 gene_1\NN\8459252 mutations_2\NNS\4475 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 prolonged_6\JJ\1740 <e2>apnea</e2>_7\NN\14299637 after_8\IN\1740 <e1>succinylcholine</e1>_9\NN\3800001 for_10\IN\1740 electroconvulsive_11\JJ\1740 therapy_12\NN\657604 ._13\.\1740
D013390_D001049 CID conclusion_0\NN\5837957 :_1\:\1740 eleven_2\CD\13745420 of_3\IN\1740 13_4\CD\13745420 patients_5\NNS\9898892 with_6\IN\1740 a_7\DT\13649268 prolonged_8\JJ\1740 duration_9\NN\15113229 of_10\IN\1740 action_11\NN\30358 of_12\IN\1740 <e1>succinylcholine</e1>_13\NN\3800001 had_14\VBD\2108377 mutations_15\NNS\4475 in_16\IN\13603305 bche_17\NN\1740 ,_18\,\1740 indicating_19\VBG\952524 that_20\IN\1740 this_21\DT\1740 is_22\VBZ\836236 the_23\DT\1740 possible_24\JJ\1740 reason_25\NN\9178821 for_26\IN\1740 a_27\DT\13649268 prolonged_28\JJ\1740 period_29\NN\13575869 of_30\IN\1740 <e2>apnea</e2>_31\NN\14299637 ._32\.\1740
322550
D009599_D007022 CID pulmonary_0\JJ\1740 shunt_1\NN\5248181 and_2\CC\1740 cardiovascular_3\JJ\1740 responses_4\NNS\11410625 to_5\TO\1740 cpap_6\NN\1740 during_7\IN\1740 <e1>nitroprusside-induced</e1>_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 ._10\.\1740
D009599_D007022 CID ten_0\CD\13745420 cm_1\NNS\13649268 h2o_2\NN\14618834 cpap_3\NN\1740 before_4\IN\1740 <e1>nitroprusside</e1>_5\NN\1740 infusion_6\NN\14589223 produced_7\VBD\1617192 a_8\DT\13649268 further_9\JJ\1740 <e2>decrease_10\NN\7296428 in_11\IN\13603305 arterial_12\JJ\1740 blood_13\NN\5397468 pressure</e2>_14\NN\11419404 and_15\CC\1740 significantly_16\RB\1740 increased_17\VBD\169651 heart_18\NN\5919034 rate_19\NN\13815152 and_20\CC\1740 decreased_21\VBD\169651 cardiac_22\JJ\1740 output_23\NN\4007894 and_24\CC\1740 qs/qt_25\NN\1740 ._26\.\1740
D009599_D007022 CID <e1>nitroprusside</e1>_0\NNP\1740 caused_1\VBD\1617192 significant_2\JJ\1740 <e2>decreases_3\NNS\7296428 in_4\IN\13603305 arterial_5\JJ\1740 blood_6\NN\5397468 pressure</e2>_7\NN\11419404 and_8\CC\1740 systemic_9\JJ\1740 vascular_10\JJ\1740 resistance_11\NN\37396 and_12\CC\1740 increases_13\VBZ\169651 in_14\IN\13603305 heart_15\NN\5919034 rate_16\NN\13815152 ,_17\,\1740 but_18\CC\1740 did_19\VBD\1640855 not_20\RB\1740 change_21\VB\46534 cardiac_22\JJ\1740 output_23\NN\4007894 or_24\CC\3541091 qs/qt_25\NN\1740 ._26\.\1740
D009599_D007022 NONE during_0\IN\1740 <e1>nitroprusside</e1>_1\NN\1740 infusion_2\NN\14589223 low_3\JJ\1740 levels_4\NNS\4916342 of_5\IN\1740 cpap_6\NN\1740 do_7\VBP\1640855 not_8\RB\1740 markedly_9\RB\1740 alter_10\VB\126264 cardiovascular_11\JJ\1740 dynamics_12\NNS\6100236 ,_13\,\1740 but_14\CC\1740 high_15\JJ\1740 levels_16\NNS\4916342 of_17\IN\1740 cpap_18\NN\1740 (_19\-LRB-\1740 10_20\CD\13745420 cm_21\NNS\13649268 h2o_22\NN\14618834 )_23\-RRB-\1740 ,_24\,\1740 while_25\IN\15122231 decreasing_26\VBG\169651 qs/qt_27\NN\1740 ,_28\,\1740 produce_29\VB\1617192 marked_30\JJ\1740 <e2>decreases_31\NNS\7296428 in_32\IN\13603305 arterial_33\JJ\1740 blood_34\NN\5397468 pressure_35\NN\11419404 and_36\CC\1740 cardiac_37\JJ\1740 output</e2>_38\NN\4007894 ._39\.\1740
D014867_D007022 NONE ten_0\CD\13745420 cm_1\NNS\13649268 <e1>h2o</e1>_2\NN\14618834 cpap_3\NN\1740 before_4\IN\1740 nitroprusside_5\NN\1740 infusion_6\NN\14589223 produced_7\VBD\1617192 a_8\DT\13649268 further_9\JJ\1740 <e2>decrease_10\NN\7296428 in_11\IN\13603305 arterial_12\JJ\1740 blood_13\NN\5397468 pressure</e2>_14\NN\11419404 and_15\CC\1740 significantly_16\RB\1740 increased_17\VBD\169651 heart_18\NN\5919034 rate_19\NN\13815152 and_20\CC\1740 decreased_21\VBD\169651 cardiac_22\JJ\1740 output_23\NN\4007894 and_24\CC\1740 qs/qt_25\NN\1740 ._26\.\1740
D014867_D007022 NONE during_0\IN\1740 nitroprusside_1\NN\1740 infusion_2\NN\14589223 low_3\JJ\1740 levels_4\NNS\4916342 of_5\IN\1740 cpap_6\NN\1740 do_7\VBP\1640855 not_8\RB\1740 markedly_9\RB\1740 alter_10\VB\126264 cardiovascular_11\JJ\1740 dynamics_12\NNS\6100236 ,_13\,\1740 but_14\CC\1740 high_15\JJ\1740 levels_16\NNS\4916342 of_17\IN\1740 cpap_18\NN\1740 (_19\-LRB-\1740 10_20\CD\13745420 cm_21\NNS\13649268 <e1>h2o</e1>_22\NN\14618834 )_23\-RRB-\1740 ,_24\,\1740 while_25\IN\15122231 decreasing_26\VBG\169651 qs/qt_27\NN\1740 ,_28\,\1740 produce_29\VB\1617192 marked_30\JJ\1740 <e2>decreases_31\NNS\7296428 in_32\IN\13603305 arterial_33\JJ\1740 blood_34\NN\5397468 pressure_35\NN\11419404 and_36\CC\1740 cardiac_37\JJ\1740 output</e2>_38\NN\4007894 ._39\.\1740
D014867_D002303 NONE ten_0\CD\13745420 cm_1\NNS\13649268 <e1>h2o</e1>_2\NN\14618834 cpap_3\NN\1740 before_4\IN\1740 nitroprusside_5\NN\1740 infusion_6\NN\14589223 produced_7\VBD\1617192 a_8\DT\13649268 further_9\JJ\1740 decrease_10\NN\7296428 in_11\IN\13603305 arterial_12\JJ\1740 blood_13\NN\5397468 pressure_14\NN\11419404 and_15\CC\1740 significantly_16\RB\1740 increased_17\VBD\169651 heart_18\NN\5919034 rate_19\NN\13815152 and_20\CC\1740 <e2>decreased_21\VBD\169651 cardiac_22\JJ\1740 output</e2>_23\NN\4007894 and_24\CC\1740 qs/qt_25\NN\1740 ._26\.\1740
D014867_D002303 NONE during_0\IN\1740 nitroprusside_1\NN\1740 infusion_2\NN\14589223 low_3\JJ\1740 levels_4\NNS\4916342 of_5\IN\1740 cpap_6\NN\1740 do_7\VBP\1640855 not_8\RB\1740 markedly_9\RB\1740 alter_10\VB\126264 cardiovascular_11\JJ\1740 dynamics_12\NNS\6100236 ,_13\,\1740 but_14\CC\1740 high_15\JJ\1740 levels_16\NNS\4916342 of_17\IN\1740 cpap_18\NN\1740 (_19\-LRB-\1740 10_20\CD\13745420 cm_21\NNS\13649268 <e1>h2o</e1>_22\NN\14618834 )_23\-RRB-\1740 ,_24\,\1740 while_25\IN\15122231 decreasing_26\VBG\169651 qs/qt_27\NN\1740 ,_28\,\1740 produce_29\VB\1617192 marked_30\JJ\1740 <e2>decreases_31\NNS\7296428 in_32\IN\13603305 arterial_33\JJ\1740 blood_34\NN\5397468 pressure_35\NN\11419404 and_36\CC\1740 cardiac_37\JJ\1740 output</e2>_38\NN\4007894 ._39\.\1740
D009599_D002303 NONE ten_0\CD\13745420 cm_1\NNS\13649268 h2o_2\NN\14618834 cpap_3\NN\1740 before_4\IN\1740 <e1>nitroprusside</e1>_5\NN\1740 infusion_6\NN\14589223 produced_7\VBD\1617192 a_8\DT\13649268 further_9\JJ\1740 decrease_10\NN\7296428 in_11\IN\13603305 arterial_12\JJ\1740 blood_13\NN\5397468 pressure_14\NN\11419404 and_15\CC\1740 significantly_16\RB\1740 increased_17\VBD\169651 heart_18\NN\5919034 rate_19\NN\13815152 and_20\CC\1740 <e2>decreased_21\VBD\169651 cardiac_22\JJ\1740 output</e2>_23\NN\4007894 and_24\CC\1740 qs/qt_25\NN\1740 ._26\.\1740
D009599_D002303 NONE during_0\IN\1740 <e1>nitroprusside</e1>_1\NN\1740 infusion_2\NN\14589223 low_3\JJ\1740 levels_4\NNS\4916342 of_5\IN\1740 cpap_6\NN\1740 do_7\VBP\1640855 not_8\RB\1740 markedly_9\RB\1740 alter_10\VB\126264 cardiovascular_11\JJ\1740 dynamics_12\NNS\6100236 ,_13\,\1740 but_14\CC\1740 high_15\JJ\1740 levels_16\NNS\4916342 of_17\IN\1740 cpap_18\NN\1740 (_19\-LRB-\1740 10_20\CD\13745420 cm_21\NNS\13649268 h2o_22\NN\14618834 )_23\-RRB-\1740 ,_24\,\1740 while_25\IN\15122231 decreasing_26\VBG\169651 qs/qt_27\NN\1740 ,_28\,\1740 produce_29\VB\1617192 marked_30\JJ\1740 <e2>decreases_31\NNS\7296428 in_32\IN\13603305 arterial_33\JJ\1740 blood_34\NN\5397468 pressure_35\NN\11419404 and_36\CC\1740 cardiac_37\JJ\1740 output</e2>_38\NN\4007894 ._39\.\1740
3031535
D013759_D002375 CID noradrenergic_0\JJ\1740 involvement_1\NN\1080366 in_2\IN\13603305 <e2>catalepsy</e2>_3\NN\14023236 induced_4\VBN\1627355 by_5\IN\1740 <e1>delta_6\NN\9193282 9-tetrahydrocannabinol</e1>_7\NN\1740 ._8\.\1740
D013759_D002375 CID these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 noradrenergic_4\JJ\1740 neurons_5\NNS\5430628 have_6\VBP\2108377 an_7\DT\6697703 important_8\JJ\1740 role_9\NN\719494 in_10\IN\13603305 the_11\DT\1740 manifestation_12\NN\7321772 of_13\IN\1740 <e2>catalepsy</e2>_14\NN\14023236 induced_15\VBN\1627355 by_16\IN\1740 <e1>thc</e1>_17\NN\4017137 ,_18\,\1740 whereas_19\IN\1740 dopaminergic_20\JJ\1740 neurons_21\NNS\5430628 are_22\VBP\836236 important_23\JJ\1740 in_24\IN\13603305 catalepsy_25\NN\14023236 induced_26\VBN\1627355 by_27\IN\1740 haloperidol_28\NN\3713736 ._29\.\1740
D013759_D002375 CID these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 noradrenergic_4\JJ\1740 neurons_5\NNS\5430628 have_6\VBP\2108377 an_7\DT\6697703 important_8\JJ\1740 role_9\NN\719494 in_10\IN\13603305 the_11\DT\1740 manifestation_12\NN\7321772 of_13\IN\1740 catalepsy_14\NN\14023236 induced_15\VBN\1627355 by_16\IN\1740 <e1>thc</e1>_17\NN\4017137 ,_18\,\1740 whereas_19\IN\1740 dopaminergic_20\JJ\1740 neurons_21\NNS\5430628 are_22\VBP\836236 important_23\JJ\1740 in_24\IN\13603305 <e2>catalepsy</e2>_25\NN\14023236 induced_26\VBN\1627355 by_27\IN\1740 haloperidol_28\NN\3713736 ._29\.\1740
D006220_D002375 CID these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 noradrenergic_4\JJ\1740 neurons_5\NNS\5430628 have_6\VBP\2108377 an_7\DT\6697703 important_8\JJ\1740 role_9\NN\719494 in_10\IN\13603305 the_11\DT\1740 manifestation_12\NN\7321772 of_13\IN\1740 <e2>catalepsy</e2>_14\NN\14023236 induced_15\VBN\1627355 by_16\IN\1740 thc_17\NN\4017137 ,_18\,\1740 whereas_19\IN\1740 dopaminergic_20\JJ\1740 neurons_21\NNS\5430628 are_22\VBP\836236 important_23\JJ\1740 in_24\IN\13603305 catalepsy_25\NN\14023236 induced_26\VBN\1627355 by_27\IN\1740 <e1>haloperidol</e1>_28\NN\3713736 ._29\.\1740
D006220_D002375 CID these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 noradrenergic_4\JJ\1740 neurons_5\NNS\5430628 have_6\VBP\2108377 an_7\DT\6697703 important_8\JJ\1740 role_9\NN\719494 in_10\IN\13603305 the_11\DT\1740 manifestation_12\NN\7321772 of_13\IN\1740 catalepsy_14\NN\14023236 induced_15\VBN\1627355 by_16\IN\1740 thc_17\NN\4017137 ,_18\,\1740 whereas_19\IN\1740 dopaminergic_20\JJ\1740 neurons_21\NNS\5430628 are_22\VBP\836236 important_23\JJ\1740 in_24\IN\13603305 <e2>catalepsy</e2>_25\NN\14023236 induced_26\VBN\1627355 by_27\IN\1740 <e1>haloperidol</e1>_28\NN\3713736 ._29\.\1740
9284778
-1_D008107 NONE epidemic_0\NN\7435273 of_1\IN\1740 <e2>liver_2\NN\5298729 disease</e2>_3\NN\14061805 caused_4\VBN\1617192 by_5\IN\1740 <e1>hydrochlorofluorocarbons</e1>_6\NNS\14603497 used_7\VBN\1156834 as_8\IN\14622893 ozone-sparing_9\JJ\1740 substitutes_10\NNS\5695554 of_11\IN\1740 chlorofluorocarbons_12\NNS\14871968 ._13\.\1740
D010126_D008107 NONE epidemic_0\NN\7435273 of_1\IN\1740 <e2>liver_2\NN\5298729 disease</e2>_3\NN\14061805 caused_4\VBN\1617192 by_5\IN\1740 hydrochlorofluorocarbons_6\NNS\14603497 used_7\VBN\1156834 as_8\IN\14622893 <e1>ozone-sparing</e1>_9\JJ\1740 substitutes_10\NNS\5695554 of_11\IN\1740 chlorofluorocarbons_12\NNS\14871968 ._13\.\1740
D017402_D008107 NONE epidemic_0\NN\7435273 of_1\IN\1740 <e2>liver_2\NN\5298729 disease</e2>_3\NN\14061805 caused_4\VBN\1617192 by_5\IN\1740 hydrochlorofluorocarbons_6\NNS\14603497 used_7\VBN\1156834 as_8\IN\14622893 ozone-sparing_9\JJ\1740 substitutes_10\NNS\5695554 of_11\IN\1740 <e1>chlorofluorocarbons</e1>_12\NNS\14871968 ._13\.\1740
C067411_D008107 CID we_0\PRP\1740 investigated_1\VBD\644583 an_2\DT\6697703 epidemic_3\NN\7435273 of_4\IN\1740 <e2>liver_5\NN\5298729 disease</e2>_6\NN\14061805 in_7\IN\13603305 nine_8\CD\13741022 industrial_9\JJ\1740 workers_10\NNS\7846 who_11\WP\8299493 had_12\VBD\2108377 had_13\VBN\2108377 repeated_14\VBN\952524 accidental_15\JJ\1740 exposure_16\NN\5042871 to_17\TO\1740 a_18\DT\13649268 mixture_19\NN\19613 of_20\IN\1740 <e1>1,1-dichloro-2,2,2-trifluoroethane</e1>_21\NN\1740 (_22\-LRB-\1740 hcfc_23\NN\14603497 123_24\CD\1740 )_25\-RRB-\1740 and_26\CC\1740 1-chloro-1,2,2,2-tetrafluoroethane_27\NN\1740 (_28\-LRB-\1740 hcfc_29\NN\14603497 124_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
C067411_D008107 CID we_0\PRP\1740 investigated_1\VBD\644583 an_2\DT\6697703 epidemic_3\NN\7435273 of_4\IN\1740 <e2>liver_5\NN\5298729 disease</e2>_6\NN\14061805 in_7\IN\13603305 nine_8\CD\13741022 industrial_9\JJ\1740 workers_10\NNS\7846 who_11\WP\8299493 had_12\VBD\2108377 had_13\VBN\2108377 repeated_14\VBN\952524 accidental_15\JJ\1740 exposure_16\NN\5042871 to_17\TO\1740 a_18\DT\13649268 mixture_19\NN\19613 of_20\IN\1740 1,1-dichloro-2,2,2-trifluoroethane_21\NN\1740 (_22\-LRB-\1740 <e1>hcfc_23\NN\14603497 123</e1>_24\CD\1740 )_25\-RRB-\1740 and_26\CC\1740 1-chloro-1,2,2,2-tetrafluoroethane_27\NN\1740 (_28\-LRB-\1740 hcfc_29\NN\14603497 124_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
C067411_D008107 CID we_0\PRP\1740 aimed_1\VBD\1987160 to_2\TO\1740 test_3\VB\670261 whether_4\IN\1740 <e1>hcfcs_5\NNS\14603497 123_6\CD\1740 and_7\CC\1740 124</e1>_8\CD\1740 can_9\MD\3094503 result_10\VB\2633881 in_11\IN\13603305 serious_12\JJ\1740 <e2>liver_13\NN\5298729 disease</e2>_14\NN\14061805 ._15\.\1740
C072959_D008107 CID we_0\PRP\1740 investigated_1\VBD\644583 an_2\DT\6697703 epidemic_3\NN\7435273 of_4\IN\1740 <e2>liver_5\NN\5298729 disease</e2>_6\NN\14061805 in_7\IN\13603305 nine_8\CD\13741022 industrial_9\JJ\1740 workers_10\NNS\7846 who_11\WP\8299493 had_12\VBD\2108377 had_13\VBN\2108377 repeated_14\VBN\952524 accidental_15\JJ\1740 exposure_16\NN\5042871 to_17\TO\1740 a_18\DT\13649268 mixture_19\NN\19613 of_20\IN\1740 1,1-dichloro-2,2,2-trifluoroethane_21\NN\1740 (_22\-LRB-\1740 hcfc_23\NN\14603497 123_24\CD\1740 )_25\-RRB-\1740 and_26\CC\1740 <e1>1-chloro-1,2,2,2-tetrafluoroethane</e1>_27\NN\1740 (_28\-LRB-\1740 hcfc_29\NN\14603497 124_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
C072959_D008107 CID we_0\PRP\1740 investigated_1\VBD\644583 an_2\DT\6697703 epidemic_3\NN\7435273 of_4\IN\1740 <e2>liver_5\NN\5298729 disease</e2>_6\NN\14061805 in_7\IN\13603305 nine_8\CD\13741022 industrial_9\JJ\1740 workers_10\NNS\7846 who_11\WP\8299493 had_12\VBD\2108377 had_13\VBN\2108377 repeated_14\VBN\952524 accidental_15\JJ\1740 exposure_16\NN\5042871 to_17\TO\1740 a_18\DT\13649268 mixture_19\NN\19613 of_20\IN\1740 1,1-dichloro-2,2,2-trifluoroethane_21\NN\1740 (_22\-LRB-\1740 hcfc_23\NN\14603497 123_24\CD\1740 )_25\-RRB-\1740 and_26\CC\1740 1-chloro-1,2,2,2-tetrafluoroethane_27\NN\1740 (_28\-LRB-\1740 <e1>hcfc_29\NN\14603497 124</e1>_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
C072959_D008107 CID we_0\PRP\1740 aimed_1\VBD\1987160 to_2\TO\1740 test_3\VB\670261 whether_4\IN\1740 <e1>hcfcs_5\NNS\14603497 123_6\CD\1740 and_7\CC\1740 124</e1>_8\CD\1740 can_9\MD\3094503 result_10\VB\2633881 in_11\IN\13603305 serious_12\JJ\1740 <e2>liver_13\NN\5298729 disease</e2>_14\NN\14061805 ._15\.\1740
D006221_D056486 NONE both_0\DT\1740 compounds_1\NNS\5869584 are_2\VBP\836236 metabolised_3\VBN\1740 in_4\IN\13603305 the_5\DT\1740 same_6\JJ\1740 way_7\NN\4916342 as_8\IN\14622893 <e1>1-bromo-1-chloro-2,2,2-trifluoroethane</e1>_9\NN\1740 (_10\-LRB-\1740 halothane_11\NN\3570838 )_12\-RRB-\1740 to_13\TO\1740 form_14\VB\1617192 reactive_15\JJ\1740 trifluoroacetyl_16\NN\1740 halide_17\NN\15010703 intermediates_18\NNS\14806838 ,_19\,\1740 which_20\WDT\1740 have_21\VBP\2108377 been_22\VBN\836236 implicated_23\VBN\2677097 in_24\IN\13603305 the_25\DT\1740 <e2>hepatotoxicity</e2>_26\NN\1740 of_27\IN\1740 halothane_28\NN\3570838 ._29\.\1740
D006221_D056486 NONE both_0\DT\1740 compounds_1\NNS\5869584 are_2\VBP\836236 metabolised_3\VBN\1740 in_4\IN\13603305 the_5\DT\1740 same_6\JJ\1740 way_7\NN\4916342 as_8\IN\14622893 1-bromo-1-chloro-2,2,2-trifluoroethane_9\NN\1740 (_10\-LRB-\1740 <e1>halothane</e1>_11\NN\3570838 )_12\-RRB-\1740 to_13\TO\1740 form_14\VB\1617192 reactive_15\JJ\1740 trifluoroacetyl_16\NN\1740 halide_17\NN\15010703 intermediates_18\NNS\14806838 ,_19\,\1740 which_20\WDT\1740 have_21\VBP\2108377 been_22\VBN\836236 implicated_23\VBN\2677097 in_24\IN\13603305 the_25\DT\1740 <e2>hepatotoxicity</e2>_26\NN\1740 of_27\IN\1740 halothane_28\NN\3570838 ._29\.\1740
D006221_D056486 NONE both_0\DT\1740 compounds_1\NNS\5869584 are_2\VBP\836236 metabolised_3\VBN\1740 in_4\IN\13603305 the_5\DT\1740 same_6\JJ\1740 way_7\NN\4916342 as_8\IN\14622893 1-bromo-1-chloro-2,2,2-trifluoroethane_9\NN\1740 (_10\-LRB-\1740 halothane_11\NN\3570838 )_12\-RRB-\1740 to_13\TO\1740 form_14\VB\1617192 reactive_15\JJ\1740 trifluoroacetyl_16\NN\1740 halide_17\NN\15010703 intermediates_18\NNS\14806838 ,_19\,\1740 which_20\WDT\1740 have_21\VBP\2108377 been_22\VBN\836236 implicated_23\VBN\2677097 in_24\IN\13603305 the_25\DT\1740 <e2>hepatotoxicity</e2>_26\NN\1740 of_27\IN\1740 <e1>halothane</e1>_28\NN\3570838 ._29\.\1740
D014269_D056486 NONE both_0\DT\1740 compounds_1\NNS\5869584 are_2\VBP\836236 metabolised_3\VBN\1740 in_4\IN\13603305 the_5\DT\1740 same_6\JJ\1740 way_7\NN\4916342 as_8\IN\14622893 1-bromo-1-chloro-2,2,2-trifluoroethane_9\NN\1740 (_10\-LRB-\1740 halothane_11\NN\3570838 )_12\-RRB-\1740 to_13\TO\1740 form_14\VB\1617192 reactive_15\JJ\1740 <e1>trifluoroacetyl</e1>_16\NN\1740 halide_17\NN\15010703 intermediates_18\NNS\14806838 ,_19\,\1740 which_20\WDT\1740 have_21\VBP\2108377 been_22\VBN\836236 implicated_23\VBN\2677097 in_24\IN\13603305 the_25\DT\1740 <e2>hepatotoxicity</e2>_26\NN\1740 of_27\IN\1740 halothane_28\NN\3570838 ._29\.\1740
D014269_D056486 NONE although_0\IN\1740 the_1\DT\1740 exact_2\JJ\1740 mechanism_3\NN\13446390 of_4\IN\1740 <e2>hepatotoxicity</e2>_5\NN\1740 of_6\IN\1740 these_7\DT\1740 agents_8\NNS\7347 is_9\VBZ\836236 not_10\RB\1740 known_11\VBN\2110220 ,_12\,\1740 the_13\DT\1740 results_14\NNS\34213 suggest_15\VBP\1010118 that_16\IN\1740 <e1>trifluoroacetyl-altered</e1>_17\JJ\1740 liver_18\NN\5298729 proteins_19\NNS\14944888 are_20\VBP\836236 involved_21\VBN\2676054 ._22\.\1740
C067411_D056486 NONE interpretation_0\NN\5926676 :_1\:\1740 repeated_2\VBN\952524 exposure_3\NN\5042871 of_4\IN\1740 human_5\JJ\1740 beings_6\NNS\24720 to_7\IN\1740 <e1>hcfcs_8\NNS\14603497 123_9\CD\1740 and_10\CC\1740 124</e1>_11\CD\1740 can_12\MD\3094503 result_13\VB\2633881 in_14\IN\13603305 serious_15\JJ\1740 <e2>liver_16\NN\5298729 injury</e2>_17\NN\14052046 in_18\IN\13603305 a_19\DT\13649268 large_20\JJ\1740 proportion_21\NN\13824815 of_22\IN\1740 the_23\DT\1740 exposed_24\VBN\2110927 population_25\NN\7942152 ._26\.\1740
C072959_D056486 NONE interpretation_0\NN\5926676 :_1\:\1740 repeated_2\VBN\952524 exposure_3\NN\5042871 of_4\IN\1740 human_5\JJ\1740 beings_6\NNS\24720 to_7\IN\1740 <e1>hcfcs_8\NNS\14603497 123_9\CD\1740 and_10\CC\1740 124</e1>_11\CD\1740 can_12\MD\3094503 result_13\VB\2633881 in_14\IN\13603305 serious_15\JJ\1740 <e2>liver_16\NN\5298729 injury</e2>_17\NN\14052046 in_18\IN\13603305 a_19\DT\13649268 large_20\JJ\1740 proportion_21\NN\13824815 of_22\IN\1740 the_23\DT\1740 exposed_24\VBN\2110927 population_25\NN\7942152 ._26\.\1740
8752018
D008094_D003072 CID <e1>lithium-associated</e1>_0\JJ\1740 <e2>cognitive_1\JJ\1740 and_2\CC\1740 functional_3\JJ\1740 deficits</e2>_4\NNS\5113133 reduced_5\VBN\441445 by_6\IN\1740 a_7\DT\13649268 switch_8\NN\3096960 to_9\TO\1740 divalproex_10\NN\1740 sodium_11\NN\14625458 :_12\:\1740 a_13\DT\13649268 case_14\NN\7283608 series_15\NN\8456993 ._16\.\1740
D008094_D003072 CID although_0\IN\1740 much_1\JJ\1740 has_2\VBZ\2108377 been_3\VBN\836236 written_4\VBN\1697816 about_5\IN\1740 the_6\DT\1740 management_7\NN\1123598 of_8\IN\1740 the_9\DT\1740 more_10\RBR\1740 common_11\JJ\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 <e1>lithium</e1>_15\NN\14625458 ,_16\,\1740 such_17\JJ\1740 as_18\IN\14622893 polyuria_19\NN\14113228 and_20\CC\1740 tremor_21\NN\345926 ,_22\,\1740 more_23\RBR\1740 subtle_24\JJ\1740 lithium_25\NN\14625458 side_26\NN\8630039 effects_27\NNS\13245626 such_28\JJ\1740 as_29\IN\14622893 <e2>cognitive_30\JJ\1740 deficits</e2>_31\NNS\5113133 ,_32\,\1740 loss_33\NN\13252973 of_34\IN\1740 creativity_35\NN\5616246 ,_36\,\1740 and_37\CC\1740 functional_38\JJ\1740 impairments_39\NNS\7296428 remain_40\VBP\2604760 understudied_41\JJ\1740 ._42\.\1740
D008094_D003072 CID although_0\IN\1740 much_1\JJ\1740 has_2\VBZ\2108377 been_3\VBN\836236 written_4\VBN\1697816 about_5\IN\1740 the_6\DT\1740 management_7\NN\1123598 of_8\IN\1740 the_9\DT\1740 more_10\RBR\1740 common_11\JJ\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 <e1>lithium</e1>_15\NN\14625458 ,_16\,\1740 such_17\JJ\1740 as_18\IN\14622893 polyuria_19\NN\14113228 and_20\CC\1740 tremor_21\NN\345926 ,_22\,\1740 more_23\RBR\1740 subtle_24\JJ\1740 lithium_25\NN\14625458 side_26\NN\8630039 effects_27\NNS\13245626 such_28\JJ\1740 as_29\IN\14622893 cognitive_30\JJ\1740 deficits_31\NNS\5113133 ,_32\,\1740 <e2>loss_33\NN\13252973 of_34\IN\1740 creativity</e2>_35\NN\5616246 ,_36\,\1740 and_37\CC\1740 functional_38\JJ\1740 impairments_39\NNS\7296428 remain_40\VBP\2604760 understudied_41\JJ\1740 ._42\.\1740
D008094_D003072 CID although_0\IN\1740 much_1\JJ\1740 has_2\VBZ\2108377 been_3\VBN\836236 written_4\VBN\1697816 about_5\IN\1740 the_6\DT\1740 management_7\NN\1123598 of_8\IN\1740 the_9\DT\1740 more_10\RBR\1740 common_11\JJ\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 <e1>lithium</e1>_15\NN\14625458 ,_16\,\1740 such_17\JJ\1740 as_18\IN\14622893 polyuria_19\NN\14113228 and_20\CC\1740 tremor_21\NN\345926 ,_22\,\1740 more_23\RBR\1740 subtle_24\JJ\1740 lithium_25\NN\14625458 side_26\NN\8630039 effects_27\NNS\13245626 such_28\JJ\1740 as_29\IN\14622893 cognitive_30\JJ\1740 deficits_31\NNS\5113133 ,_32\,\1740 loss_33\NN\13252973 of_34\IN\1740 creativity_35\NN\5616246 ,_36\,\1740 and_37\CC\1740 <e2>functional_38\JJ\1740 impairments</e2>_39\NNS\7296428 remain_40\VBP\2604760 understudied_41\JJ\1740 ._42\.\1740
D008094_D003072 CID although_0\IN\1740 much_1\JJ\1740 has_2\VBZ\2108377 been_3\VBN\836236 written_4\VBN\1697816 about_5\IN\1740 the_6\DT\1740 management_7\NN\1123598 of_8\IN\1740 the_9\DT\1740 more_10\RBR\1740 common_11\JJ\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 lithium_15\NN\14625458 ,_16\,\1740 such_17\JJ\1740 as_18\IN\14622893 polyuria_19\NN\14113228 and_20\CC\1740 tremor_21\NN\345926 ,_22\,\1740 more_23\RBR\1740 subtle_24\JJ\1740 <e1>lithium</e1>_25\NN\14625458 side_26\NN\8630039 effects_27\NNS\13245626 such_28\JJ\1740 as_29\IN\14622893 <e2>cognitive_30\JJ\1740 deficits</e2>_31\NNS\5113133 ,_32\,\1740 loss_33\NN\13252973 of_34\IN\1740 creativity_35\NN\5616246 ,_36\,\1740 and_37\CC\1740 functional_38\JJ\1740 impairments_39\NNS\7296428 remain_40\VBP\2604760 understudied_41\JJ\1740 ._42\.\1740
D008094_D003072 CID although_0\IN\1740 much_1\JJ\1740 has_2\VBZ\2108377 been_3\VBN\836236 written_4\VBN\1697816 about_5\IN\1740 the_6\DT\1740 management_7\NN\1123598 of_8\IN\1740 the_9\DT\1740 more_10\RBR\1740 common_11\JJ\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 lithium_15\NN\14625458 ,_16\,\1740 such_17\JJ\1740 as_18\IN\14622893 polyuria_19\NN\14113228 and_20\CC\1740 tremor_21\NN\345926 ,_22\,\1740 more_23\RBR\1740 subtle_24\JJ\1740 <e1>lithium</e1>_25\NN\14625458 side_26\NN\8630039 effects_27\NNS\13245626 such_28\JJ\1740 as_29\IN\14622893 cognitive_30\JJ\1740 deficits_31\NNS\5113133 ,_32\,\1740 <e2>loss_33\NN\13252973 of_34\IN\1740 creativity</e2>_35\NN\5616246 ,_36\,\1740 and_37\CC\1740 functional_38\JJ\1740 impairments_39\NNS\7296428 remain_40\VBP\2604760 understudied_41\JJ\1740 ._42\.\1740
D008094_D003072 CID although_0\IN\1740 much_1\JJ\1740 has_2\VBZ\2108377 been_3\VBN\836236 written_4\VBN\1697816 about_5\IN\1740 the_6\DT\1740 management_7\NN\1123598 of_8\IN\1740 the_9\DT\1740 more_10\RBR\1740 common_11\JJ\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 lithium_15\NN\14625458 ,_16\,\1740 such_17\JJ\1740 as_18\IN\14622893 polyuria_19\NN\14113228 and_20\CC\1740 tremor_21\NN\345926 ,_22\,\1740 more_23\RBR\1740 subtle_24\JJ\1740 <e1>lithium</e1>_25\NN\14625458 side_26\NN\8630039 effects_27\NNS\13245626 such_28\JJ\1740 as_29\IN\14622893 cognitive_30\JJ\1740 deficits_31\NNS\5113133 ,_32\,\1740 loss_33\NN\13252973 of_34\IN\1740 creativity_35\NN\5616246 ,_36\,\1740 and_37\CC\1740 <e2>functional_38\JJ\1740 impairments</e2>_39\NNS\7296428 remain_40\VBP\2604760 understudied_41\JJ\1740 ._42\.\1740
D008094_D003072 CID this_0\DT\1740 report_1\NN\6470073 summarizes_2\VBZ\958334 our_3\PRP$\1740 experience_4\NN\5984287 in_5\IN\13603305 switching_6\VBG\138508 bipolar_7\JJ\1740 patients_8\NNS\9898892 from_9\IN\1740 <e1>lithium</e1>_10\NN\14625458 to_11\TO\1740 divalproex_12\JJ\1740 sodium_13\NN\14625458 to_14\TO\1740 alleviate_15\VB\205885 such_16\JJ\1740 <e2>cognitive_17\JJ\1740 and_18\CC\1740 functional_19\JJ\1740 impairments</e2>_20\NNS\7296428 ._21\.\1740
D008094_D003072 CID results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 report_3\VBP\831651 seven_4\CD\13741022 cases_5\NNS\7283608 where_6\WRB\1740 substitution_7\NN\7337390 of_8\IN\1740 <e1>lithium</e1>_9\NN\14625458 ,_10\,\1740 either_11\CC\1740 fully_12\RB\1740 or_13\CC\3541091 partially_14\RB\1740 ,_15\,\1740 with_16\IN\1740 divalproex_17\NN\1740 sodium_18\NN\14625458 was_19\VBD\836236 extremely_20\RB\1740 helpful_21\JJ\1740 in_22\IN\13603305 reducing_23\VBG\441445 the_24\DT\1740 <e2>cognitive_25\JJ\1740 ,_26\,\1740 motivational_27\JJ\1740 ,_28\,\1740 or_29\CC\3541091 creative_30\JJ\1740 deficits</e2>_31\NNS\5113133 attributed_32\VBN\670261 to_33\TO\1740 lithium_34\NN\14625458 in_35\IN\13603305 our_36\PRP$\1740 bipolar_37\JJ\1740 patients_38\NNS\9898892 ._39\.\1740
D008094_D003072 CID results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 report_3\VBP\831651 seven_4\CD\13741022 cases_5\NNS\7283608 where_6\WRB\1740 substitution_7\NN\7337390 of_8\IN\1740 lithium_9\NN\14625458 ,_10\,\1740 either_11\CC\1740 fully_12\RB\1740 or_13\CC\3541091 partially_14\RB\1740 ,_15\,\1740 with_16\IN\1740 divalproex_17\NN\1740 sodium_18\NN\14625458 was_19\VBD\836236 extremely_20\RB\1740 helpful_21\JJ\1740 in_22\IN\13603305 reducing_23\VBG\441445 the_24\DT\1740 <e2>cognitive_25\JJ\1740 ,_26\,\1740 motivational_27\JJ\1740 ,_28\,\1740 or_29\CC\3541091 creative_30\JJ\1740 deficits</e2>_31\NNS\5113133 attributed_32\VBN\670261 to_33\TO\1740 <e1>lithium</e1>_34\NN\14625458 in_35\IN\13603305 our_36\PRP$\1740 bipolar_37\JJ\1740 patients_38\NNS\9898892 ._39\.\1740
D008094_D003072 CID conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 preliminary_4\JJ\1740 report_5\NN\6470073 ,_6\,\1740 divalproex_7\NN\1740 sodium_8\NN\14625458 was_9\VBD\836236 a_10\DT\13649268 superior_11\JJ\1740 alternative_12\NN\5788149 to_13\TO\1740 <e1>lithium</e1>_14\NN\14625458 in_15\IN\13603305 bipolar_16\JJ\1740 patients_17\NNS\9898892 experiencing_18\VBG\2108377 <e2>cognitive_19\JJ\1740 deficits</e2>_20\NNS\5113133 ,_21\,\1740 loss_22\NN\13252973 of_23\IN\1740 creativity_24\NN\5616246 ,_25\,\1740 and_26\CC\1740 functional_27\JJ\1740 impairments_28\NNS\7296428 ._29\.\1740
D008094_D003072 CID conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 preliminary_4\JJ\1740 report_5\NN\6470073 ,_6\,\1740 divalproex_7\NN\1740 sodium_8\NN\14625458 was_9\VBD\836236 a_10\DT\13649268 superior_11\JJ\1740 alternative_12\NN\5788149 to_13\TO\1740 <e1>lithium</e1>_14\NN\14625458 in_15\IN\13603305 bipolar_16\JJ\1740 patients_17\NNS\9898892 experiencing_18\VBG\2108377 cognitive_19\JJ\1740 deficits_20\NNS\5113133 ,_21\,\1740 <e2>loss_22\NN\13252973 of_23\IN\1740 creativity</e2>_24\NN\5616246 ,_25\,\1740 and_26\CC\1740 functional_27\JJ\1740 impairments_28\NNS\7296428 ._29\.\1740
D008094_D003072 CID conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 preliminary_4\JJ\1740 report_5\NN\6470073 ,_6\,\1740 divalproex_7\NN\1740 sodium_8\NN\14625458 was_9\VBD\836236 a_10\DT\13649268 superior_11\JJ\1740 alternative_12\NN\5788149 to_13\TO\1740 <e1>lithium</e1>_14\NN\14625458 in_15\IN\13603305 bipolar_16\JJ\1740 patients_17\NNS\9898892 experiencing_18\VBG\2108377 cognitive_19\JJ\1740 deficits_20\NNS\5113133 ,_21\,\1740 loss_22\NN\13252973 of_23\IN\1740 creativity_24\NN\5616246 ,_25\,\1740 and_26\CC\1740 <e2>functional_27\JJ\1740 impairments</e2>_28\NNS\7296428 ._29\.\1740
D014635_D003072 NONE lithium-associated_0\JJ\1740 <e2>cognitive_1\JJ\1740 and_2\CC\1740 functional_3\JJ\1740 deficits</e2>_4\NNS\5113133 reduced_5\VBN\441445 by_6\IN\1740 a_7\DT\13649268 switch_8\NN\3096960 to_9\TO\1740 <e1>divalproex_10\NN\1740 sodium</e1>_11\NN\14625458 :_12\:\1740 a_13\DT\13649268 case_14\NN\7283608 series_15\NN\8456993 ._16\.\1740
D014635_D003072 NONE this_0\DT\1740 report_1\NN\6470073 summarizes_2\VBZ\958334 our_3\PRP$\1740 experience_4\NN\5984287 in_5\IN\13603305 switching_6\VBG\138508 bipolar_7\JJ\1740 patients_8\NNS\9898892 from_9\IN\1740 lithium_10\NN\14625458 to_11\TO\1740 <e1>divalproex_12\JJ\1740 sodium</e1>_13\NN\14625458 to_14\TO\1740 alleviate_15\VB\205885 such_16\JJ\1740 <e2>cognitive_17\JJ\1740 and_18\CC\1740 functional_19\JJ\1740 impairments</e2>_20\NNS\7296428 ._21\.\1740
D014635_D003072 NONE results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 report_3\VBP\831651 seven_4\CD\13741022 cases_5\NNS\7283608 where_6\WRB\1740 substitution_7\NN\7337390 of_8\IN\1740 lithium_9\NN\14625458 ,_10\,\1740 either_11\CC\1740 fully_12\RB\1740 or_13\CC\3541091 partially_14\RB\1740 ,_15\,\1740 with_16\IN\1740 <e1>divalproex_17\NN\1740 sodium</e1>_18\NN\14625458 was_19\VBD\836236 extremely_20\RB\1740 helpful_21\JJ\1740 in_22\IN\13603305 reducing_23\VBG\441445 the_24\DT\1740 <e2>cognitive_25\JJ\1740 ,_26\,\1740 motivational_27\JJ\1740 ,_28\,\1740 or_29\CC\3541091 creative_30\JJ\1740 deficits</e2>_31\NNS\5113133 attributed_32\VBN\670261 to_33\TO\1740 lithium_34\NN\14625458 in_35\IN\13603305 our_36\PRP$\1740 bipolar_37\JJ\1740 patients_38\NNS\9898892 ._39\.\1740
D014635_D003072 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 preliminary_4\JJ\1740 report_5\NN\6470073 ,_6\,\1740 <e1>divalproex_7\NN\1740 sodium</e1>_8\NN\14625458 was_9\VBD\836236 a_10\DT\13649268 superior_11\JJ\1740 alternative_12\NN\5788149 to_13\TO\1740 lithium_14\NN\14625458 in_15\IN\13603305 bipolar_16\JJ\1740 patients_17\NNS\9898892 experiencing_18\VBG\2108377 <e2>cognitive_19\JJ\1740 deficits</e2>_20\NNS\5113133 ,_21\,\1740 loss_22\NN\13252973 of_23\IN\1740 creativity_24\NN\5616246 ,_25\,\1740 and_26\CC\1740 functional_27\JJ\1740 impairments_28\NNS\7296428 ._29\.\1740
D014635_D003072 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 preliminary_4\JJ\1740 report_5\NN\6470073 ,_6\,\1740 <e1>divalproex_7\NN\1740 sodium</e1>_8\NN\14625458 was_9\VBD\836236 a_10\DT\13649268 superior_11\JJ\1740 alternative_12\NN\5788149 to_13\TO\1740 lithium_14\NN\14625458 in_15\IN\13603305 bipolar_16\JJ\1740 patients_17\NNS\9898892 experiencing_18\VBG\2108377 cognitive_19\JJ\1740 deficits_20\NNS\5113133 ,_21\,\1740 <e2>loss_22\NN\13252973 of_23\IN\1740 creativity</e2>_24\NN\5616246 ,_25\,\1740 and_26\CC\1740 functional_27\JJ\1740 impairments_28\NNS\7296428 ._29\.\1740
D014635_D003072 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 preliminary_4\JJ\1740 report_5\NN\6470073 ,_6\,\1740 <e1>divalproex_7\NN\1740 sodium</e1>_8\NN\14625458 was_9\VBD\836236 a_10\DT\13649268 superior_11\JJ\1740 alternative_12\NN\5788149 to_13\TO\1740 lithium_14\NN\14625458 in_15\IN\13603305 bipolar_16\JJ\1740 patients_17\NNS\9898892 experiencing_18\VBG\2108377 cognitive_19\JJ\1740 deficits_20\NNS\5113133 ,_21\,\1740 loss_22\NN\13252973 of_23\IN\1740 creativity_24\NN\5616246 ,_25\,\1740 and_26\CC\1740 <e2>functional_27\JJ\1740 impairments</e2>_28\NNS\7296428 ._29\.\1740
D008094_D001714 NONE background_0\NN\4921011 :_1\:\1740 <e1>lithium</e1>_2\NNP\14625458 remains_3\VBZ\2604760 a_4\DT\13649268 first-line_5\JJ\1740 treatment_6\NN\654885 for_7\IN\1740 the_8\DT\1740 acute_9\JJ\1740 and_10\CC\1740 maintenance_11\NN\266806 treatment_12\NN\654885 of_13\IN\1740 <e2>bipolar_14\JJ\1740 disorder</e2>_15\NN\14034177 ._16\.\1740
D008094_D001714 NONE this_0\DT\1740 report_1\NN\6470073 summarizes_2\VBZ\958334 our_3\PRP$\1740 experience_4\NN\5984287 in_5\IN\13603305 switching_6\VBG\138508 <e2>bipolar</e2>_7\JJ\1740 patients_8\NNS\9898892 from_9\IN\1740 <e1>lithium</e1>_10\NN\14625458 to_11\TO\1740 divalproex_12\JJ\1740 sodium_13\NN\14625458 to_14\TO\1740 alleviate_15\VB\205885 such_16\JJ\1740 cognitive_17\JJ\1740 and_18\CC\1740 functional_19\JJ\1740 impairments_20\NNS\7296428 ._21\.\1740
D008094_D001714 NONE results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 report_3\VBP\831651 seven_4\CD\13741022 cases_5\NNS\7283608 where_6\WRB\1740 substitution_7\NN\7337390 of_8\IN\1740 <e1>lithium</e1>_9\NN\14625458 ,_10\,\1740 either_11\CC\1740 fully_12\RB\1740 or_13\CC\3541091 partially_14\RB\1740 ,_15\,\1740 with_16\IN\1740 divalproex_17\NN\1740 sodium_18\NN\14625458 was_19\VBD\836236 extremely_20\RB\1740 helpful_21\JJ\1740 in_22\IN\13603305 reducing_23\VBG\441445 the_24\DT\1740 cognitive_25\JJ\1740 ,_26\,\1740 motivational_27\JJ\1740 ,_28\,\1740 or_29\CC\3541091 creative_30\JJ\1740 deficits_31\NNS\5113133 attributed_32\VBN\670261 to_33\TO\1740 lithium_34\NN\14625458 in_35\IN\13603305 our_36\PRP$\1740 <e2>bipolar</e2>_37\JJ\1740 patients_38\NNS\9898892 ._39\.\1740
D008094_D001714 NONE results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 report_3\VBP\831651 seven_4\CD\13741022 cases_5\NNS\7283608 where_6\WRB\1740 substitution_7\NN\7337390 of_8\IN\1740 lithium_9\NN\14625458 ,_10\,\1740 either_11\CC\1740 fully_12\RB\1740 or_13\CC\3541091 partially_14\RB\1740 ,_15\,\1740 with_16\IN\1740 divalproex_17\NN\1740 sodium_18\NN\14625458 was_19\VBD\836236 extremely_20\RB\1740 helpful_21\JJ\1740 in_22\IN\13603305 reducing_23\VBG\441445 the_24\DT\1740 cognitive_25\JJ\1740 ,_26\,\1740 motivational_27\JJ\1740 ,_28\,\1740 or_29\CC\3541091 creative_30\JJ\1740 deficits_31\NNS\5113133 attributed_32\VBN\670261 to_33\TO\1740 <e1>lithium</e1>_34\NN\14625458 in_35\IN\13603305 our_36\PRP$\1740 <e2>bipolar</e2>_37\JJ\1740 patients_38\NNS\9898892 ._39\.\1740
D008094_D001714 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 preliminary_4\JJ\1740 report_5\NN\6470073 ,_6\,\1740 divalproex_7\NN\1740 sodium_8\NN\14625458 was_9\VBD\836236 a_10\DT\13649268 superior_11\JJ\1740 alternative_12\NN\5788149 to_13\TO\1740 <e1>lithium</e1>_14\NN\14625458 in_15\IN\13603305 <e2>bipolar</e2>_16\JJ\1740 patients_17\NNS\9898892 experiencing_18\VBG\2108377 cognitive_19\JJ\1740 deficits_20\NNS\5113133 ,_21\,\1740 loss_22\NN\13252973 of_23\IN\1740 creativity_24\NN\5616246 ,_25\,\1740 and_26\CC\1740 functional_27\JJ\1740 impairments_28\NNS\7296428 ._29\.\1740
D008094_D011141 NONE although_0\IN\1740 much_1\JJ\1740 has_2\VBZ\2108377 been_3\VBN\836236 written_4\VBN\1697816 about_5\IN\1740 the_6\DT\1740 management_7\NN\1123598 of_8\IN\1740 the_9\DT\1740 more_10\RBR\1740 common_11\JJ\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 <e1>lithium</e1>_15\NN\14625458 ,_16\,\1740 such_17\JJ\1740 as_18\IN\14622893 <e2>polyuria</e2>_19\NN\14113228 and_20\CC\1740 tremor_21\NN\345926 ,_22\,\1740 more_23\RBR\1740 subtle_24\JJ\1740 lithium_25\NN\14625458 side_26\NN\8630039 effects_27\NNS\13245626 such_28\JJ\1740 as_29\IN\14622893 cognitive_30\JJ\1740 deficits_31\NNS\5113133 ,_32\,\1740 loss_33\NN\13252973 of_34\IN\1740 creativity_35\NN\5616246 ,_36\,\1740 and_37\CC\1740 functional_38\JJ\1740 impairments_39\NNS\7296428 remain_40\VBP\2604760 understudied_41\JJ\1740 ._42\.\1740
D008094_D011141 NONE although_0\IN\1740 much_1\JJ\1740 has_2\VBZ\2108377 been_3\VBN\836236 written_4\VBN\1697816 about_5\IN\1740 the_6\DT\1740 management_7\NN\1123598 of_8\IN\1740 the_9\DT\1740 more_10\RBR\1740 common_11\JJ\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 lithium_15\NN\14625458 ,_16\,\1740 such_17\JJ\1740 as_18\IN\14622893 <e2>polyuria</e2>_19\NN\14113228 and_20\CC\1740 tremor_21\NN\345926 ,_22\,\1740 more_23\RBR\1740 subtle_24\JJ\1740 <e1>lithium</e1>_25\NN\14625458 side_26\NN\8630039 effects_27\NNS\13245626 such_28\JJ\1740 as_29\IN\14622893 cognitive_30\JJ\1740 deficits_31\NNS\5113133 ,_32\,\1740 loss_33\NN\13252973 of_34\IN\1740 creativity_35\NN\5616246 ,_36\,\1740 and_37\CC\1740 functional_38\JJ\1740 impairments_39\NNS\7296428 remain_40\VBP\2604760 understudied_41\JJ\1740 ._42\.\1740
D008094_D014202 NONE although_0\IN\1740 much_1\JJ\1740 has_2\VBZ\2108377 been_3\VBN\836236 written_4\VBN\1697816 about_5\IN\1740 the_6\DT\1740 management_7\NN\1123598 of_8\IN\1740 the_9\DT\1740 more_10\RBR\1740 common_11\JJ\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 <e1>lithium</e1>_15\NN\14625458 ,_16\,\1740 such_17\JJ\1740 as_18\IN\14622893 polyuria_19\NN\14113228 and_20\CC\1740 <e2>tremor</e2>_21\NN\345926 ,_22\,\1740 more_23\RBR\1740 subtle_24\JJ\1740 lithium_25\NN\14625458 side_26\NN\8630039 effects_27\NNS\13245626 such_28\JJ\1740 as_29\IN\14622893 cognitive_30\JJ\1740 deficits_31\NNS\5113133 ,_32\,\1740 loss_33\NN\13252973 of_34\IN\1740 creativity_35\NN\5616246 ,_36\,\1740 and_37\CC\1740 functional_38\JJ\1740 impairments_39\NNS\7296428 remain_40\VBP\2604760 understudied_41\JJ\1740 ._42\.\1740
D008094_D014202 NONE although_0\IN\1740 much_1\JJ\1740 has_2\VBZ\2108377 been_3\VBN\836236 written_4\VBN\1697816 about_5\IN\1740 the_6\DT\1740 management_7\NN\1123598 of_8\IN\1740 the_9\DT\1740 more_10\RBR\1740 common_11\JJ\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 lithium_15\NN\14625458 ,_16\,\1740 such_17\JJ\1740 as_18\IN\14622893 polyuria_19\NN\14113228 and_20\CC\1740 <e2>tremor</e2>_21\NN\345926 ,_22\,\1740 more_23\RBR\1740 subtle_24\JJ\1740 <e1>lithium</e1>_25\NN\14625458 side_26\NN\8630039 effects_27\NNS\13245626 such_28\JJ\1740 as_29\IN\14622893 cognitive_30\JJ\1740 deficits_31\NNS\5113133 ,_32\,\1740 loss_33\NN\13252973 of_34\IN\1740 creativity_35\NN\5616246 ,_36\,\1740 and_37\CC\1740 functional_38\JJ\1740 impairments_39\NNS\7296428 remain_40\VBP\2604760 understudied_41\JJ\1740 ._42\.\1740
D014635_D001714 NONE this_0\DT\1740 report_1\NN\6470073 summarizes_2\VBZ\958334 our_3\PRP$\1740 experience_4\NN\5984287 in_5\IN\13603305 switching_6\VBG\138508 <e2>bipolar</e2>_7\JJ\1740 patients_8\NNS\9898892 from_9\IN\1740 lithium_10\NN\14625458 to_11\TO\1740 <e1>divalproex_12\JJ\1740 sodium</e1>_13\NN\14625458 to_14\TO\1740 alleviate_15\VB\205885 such_16\JJ\1740 cognitive_17\JJ\1740 and_18\CC\1740 functional_19\JJ\1740 impairments_20\NNS\7296428 ._21\.\1740
D014635_D001714 NONE results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 report_3\VBP\831651 seven_4\CD\13741022 cases_5\NNS\7283608 where_6\WRB\1740 substitution_7\NN\7337390 of_8\IN\1740 lithium_9\NN\14625458 ,_10\,\1740 either_11\CC\1740 fully_12\RB\1740 or_13\CC\3541091 partially_14\RB\1740 ,_15\,\1740 with_16\IN\1740 <e1>divalproex_17\NN\1740 sodium</e1>_18\NN\14625458 was_19\VBD\836236 extremely_20\RB\1740 helpful_21\JJ\1740 in_22\IN\13603305 reducing_23\VBG\441445 the_24\DT\1740 cognitive_25\JJ\1740 ,_26\,\1740 motivational_27\JJ\1740 ,_28\,\1740 or_29\CC\3541091 creative_30\JJ\1740 deficits_31\NNS\5113133 attributed_32\VBN\670261 to_33\TO\1740 lithium_34\NN\14625458 in_35\IN\13603305 our_36\PRP$\1740 <e2>bipolar</e2>_37\JJ\1740 patients_38\NNS\9898892 ._39\.\1740
D014635_D001714 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 preliminary_4\JJ\1740 report_5\NN\6470073 ,_6\,\1740 <e1>divalproex_7\NN\1740 sodium</e1>_8\NN\14625458 was_9\VBD\836236 a_10\DT\13649268 superior_11\JJ\1740 alternative_12\NN\5788149 to_13\TO\1740 lithium_14\NN\14625458 in_15\IN\13603305 <e2>bipolar</e2>_16\JJ\1740 patients_17\NNS\9898892 experiencing_18\VBG\2108377 cognitive_19\JJ\1740 deficits_20\NNS\5113133 ,_21\,\1740 loss_22\NN\13252973 of_23\IN\1740 creativity_24\NN\5616246 ,_25\,\1740 and_26\CC\1740 functional_27\JJ\1740 impairments_28\NNS\7296428 ._29\.\1740
7516729
D014700_D001919 CID dose-dependent_0\JJ\1740 <e2>bradycardia</e2>_1\NN\14110674 induced_2\VBN\1627355 by_3\IN\1740 <e1>verapamil</e1>_4\NN\2938514 was_5\VBD\836236 potentiated_6\VBN\229605 by_7\IN\1740 lna_8\NNS\1740 ,_9\,\1740 lca_10\NNS\1740 ,_11\,\1740 and_12\CC\1740 hca_13\NN\1740 ._14\.\1740
6727060
D008787_D004409 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>tardive_3\JJ\1740 dyskinesia</e2>_4\NN\14084880 caused_5\VBN\1617192 by_6\IN\1740 <e1>metoclopramide</e1>_7\NN\1740 ._8\.\1740
D008787_D004409 CID <e2>abnormal_0\JJ\1740 involuntary_1\JJ\1740 movements</e2>_2\NNS\191142 appeared_3\VBD\2604760 in_4\IN\13603305 the_5\DT\1740 mouth_6\NN\5610008 ,_7\,\1740 tongue_8\NN\5301392 ,_9\,\1740 neck_10\NN\5225090 and_11\CC\1740 abdomen_12\NNS\5220461 of_13\IN\1740 a_14\DT\13649268 64-year-old_15\JJ\1740 male_16\JJ\1740 patient_17\NN\9898892 after_18\IN\1740 he_19\PRP\14622893 took_20\VBD\2367363 <e1>metoclopramide</e1>_21\NN\1740 for_22\IN\1740 gastrointestinal_23\JJ\1740 disorder_24\NN\14034177 in_25\IN\13603305 a_26\DT\13649268 regimen_27\NN\5898568 of_28\IN\1740 30_29\CD\13745420 mg_30\NN\13717155 per_31\IN\1740 day_32\NN\15154774 for_33\IN\1740 a_34\DT\13649268 total_35\NN\3553 of_36\IN\1740 about_37\RB\1740 260_38\CD\1740 days_39\NNS\15140892 ._40\.\1740
D008787_D004409 CID when_0\WRB\1740 the_1\DT\1740 <e1>metoclopramide</e1>_2\NN\1740 administration_3\NN\1133281 was_4\VBD\836236 discontinued_5\VBN\2609764 ,_6\,\1740 the_7\DT\1740 <e2>abnormal_8\JJ\1740 movements</e2>_9\NNS\191142 gradually_10\RB\1740 improved_11\VBD\126264 to_12\TO\1740 a_13\DT\13649268 considerable_14\JJ\1740 extent_15\NN\13939892 ._16\.\1740
D008787_D005767 NONE abnormal_0\JJ\1740 involuntary_1\JJ\1740 movements_2\NNS\191142 appeared_3\VBD\2604760 in_4\IN\13603305 the_5\DT\1740 mouth_6\NN\5610008 ,_7\,\1740 tongue_8\NN\5301392 ,_9\,\1740 neck_10\NN\5225090 and_11\CC\1740 abdomen_12\NNS\5220461 of_13\IN\1740 a_14\DT\13649268 64-year-old_15\JJ\1740 male_16\JJ\1740 patient_17\NN\9898892 after_18\IN\1740 he_19\PRP\14622893 took_20\VBD\2367363 <e1>metoclopramide</e1>_21\NN\1740 for_22\IN\1740 <e2>gastrointestinal_23\JJ\1740 disorder</e2>_24\NN\14034177 in_25\IN\13603305 a_26\DT\13649268 regimen_27\NN\5898568 of_28\IN\1740 30_29\CD\13745420 mg_30\NN\13717155 per_31\IN\1740 day_32\NN\15154774 for_33\IN\1740 a_34\DT\13649268 total_35\NN\3553 of_36\IN\1740 about_37\RB\1740 260_38\CD\1740 days_39\NNS\15140892 ._40\.\1740
983936
D001241_D009202 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>acetylsalicylic_2\JJ\1740 acid</e1>_3\NN\14818238 ,_4\,\1740 dipyridamole_5\NN\1740 ,_6\,\1740 and_7\CC\1740 hydrocortisone_8\NN\14751417 on_9\IN\1740 epinephrine-induced_10\JJ\1740 <e2>myocardial_11\JJ\1740 injury</e2>_12\NN\14052046 in_13\IN\13603305 dogs_14\NNS\2083346 ._15\.\1740
D004176_D009202 NONE effects_0\NNS\13245626 of_1\IN\1740 acetylsalicylic_2\JJ\1740 acid_3\NN\14818238 ,_4\,\1740 <e1>dipyridamole</e1>_5\NN\1740 ,_6\,\1740 and_7\CC\1740 hydrocortisone_8\NN\14751417 on_9\IN\1740 epinephrine-induced_10\JJ\1740 <e2>myocardial_11\JJ\1740 injury</e2>_12\NN\14052046 in_13\IN\13603305 dogs_14\NNS\2083346 ._15\.\1740
D006854_D009202 NONE effects_0\NNS\13245626 of_1\IN\1740 acetylsalicylic_2\JJ\1740 acid_3\NN\14818238 ,_4\,\1740 dipyridamole_5\NN\1740 ,_6\,\1740 and_7\CC\1740 <e1>hydrocortisone</e1>_8\NN\14751417 on_9\IN\1740 epinephrine-induced_10\JJ\1740 <e2>myocardial_11\JJ\1740 injury</e2>_12\NN\14052046 in_13\IN\13603305 dogs_14\NNS\2083346 ._15\.\1740
D004837_D009202 CID effects_0\NNS\13245626 of_1\IN\1740 acetylsalicylic_2\JJ\1740 acid_3\NN\14818238 ,_4\,\1740 dipyridamole_5\NN\1740 ,_6\,\1740 and_7\CC\1740 hydrocortisone_8\NN\14751417 on_9\IN\1740 <e1>epinephrine-induced</e1>_10\JJ\1740 <e2>myocardial_11\JJ\1740 injury</e2>_12\NN\14052046 in_13\IN\13603305 dogs_14\NNS\2083346 ._15\.\1740
D004837_D009202 CID a_0\DT\13649268 reproducible_1\JJ\1740 model_2\NN\5888929 for_3\IN\1740 producing_4\VBG\1617192 diffuse_5\JJ\1740 <e2>myocardial_6\JJ\1740 injury</e2>_7\NN\14052046 (_8\-LRB-\1740 <e1>epinephrine</e1>_9\NN\14807929 infusion_10\NN\14589223 )_11\-RRB-\1740 has_12\VBZ\2108377 been_13\VBN\836236 developed_14\VBN\1753788 to_15\TO\1740 study_16\VB\630380 the_17\DT\1740 cardioprotective_18\JJ\1740 effects_19\NNS\13245626 of_20\IN\1740 agents_21\NNS\7347 or_22\CC\3541091 maneuvers_23\NNS\955060 which_24\WDT\1740 might_25\MD\5029706 alter_26\VB\126264 the_27\DT\1740 evolution_28\NN\29677 of_29\IN\1740 acute_30\JJ\1740 myocardial_31\JJ\1740 infarction_32\NN\14204950 ._33\.\1740
D004837_D009203 NONE a_0\DT\13649268 reproducible_1\JJ\1740 model_2\NN\5888929 for_3\IN\1740 producing_4\VBG\1617192 diffuse_5\JJ\1740 myocardial_6\JJ\1740 injury_7\NN\14052046 (_8\-LRB-\1740 <e1>epinephrine</e1>_9\NN\14807929 infusion_10\NN\14589223 )_11\-RRB-\1740 has_12\VBZ\2108377 been_13\VBN\836236 developed_14\VBN\1753788 to_15\TO\1740 study_16\VB\630380 the_17\DT\1740 cardioprotective_18\JJ\1740 effects_19\NNS\13245626 of_20\IN\1740 agents_21\NNS\7347 or_22\CC\3541091 maneuvers_23\NNS\955060 which_24\WDT\1740 might_25\MD\5029706 alter_26\VB\126264 the_27\DT\1740 evolution_28\NN\29677 of_29\IN\1740 acute_30\JJ\1740 <e2>myocardial_31\JJ\1740 infarction</e2>_32\NN\14204950 ._33\.\1740
11431197
D011899_D009395 CID <e1>ranitidine-induced</e1>_0\JJ\1740 acute_1\JJ\1740 <e2>interstitial_2\JJ\1740 nephritis</e2>_3\NN\14113228 in_4\IN\13603305 a_5\DT\13649268 cadaveric_6\JJ\1740 renal_7\JJ\1740 allograft_8\NN\5582859 ._9\.\1740
D011899_D009395 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e1>ranitidine-induced</e1>_5\JJ\1740 acute_6\JJ\1740 <e2>interstitial_7\JJ\1740 nephritis</e2>_8\NN\14113228 in_9\IN\13603305 a_10\DT\13649268 recipient_11\NN\9764201 of_12\IN\1740 a_13\DT\13649268 cadaveric_14\JJ\1740 renal_15\JJ\1740 allograft_16\NN\5582859 presenting_17\VBG\2137132 with_18\IN\1740 acute_19\JJ\1740 allograft_20\NN\5582859 dysfunction_21\NN\14204950 within_22\IN\1740 48_23\CD\1740 hours_24\NNS\15118228 of_25\IN\1740 exposure_26\NN\5042871 to_27\TO\1740 the_28\DT\1740 drug_29\NN\14778436 ._30\.\1740
12757899
D004958_D012640 NONE <e1>estradiol</e1>_0\NN\14749794 reduces_1\VBZ\441445 <e2>seizure-induced</e2>_2\JJ\1740 hippocampal_3\NN\1740 injury_4\NN\14052046 in_5\IN\13603305 ovariectomized_6\JJ\1740 female_7\NN\15388 but_8\CC\1740 not_9\RB\1740 in_10\IN\13603305 male_11\JJ\1740 rats_12\NNS\2329401 ._13\.\1740
D004958_D012640 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>estradiol</e1>_7\NN\14749794 on_8\IN\1740 <e2>seizure</e2>_9\JJ\1740 threshold_10\NN\15265518 and_11\CC\1740 damage_12\NN\7296428 may_13\MD\15209706 be_14\VB\836236 altered_15\VBN\126264 by_16\IN\1740 sex-related_17\JJ\1740 differences_18\NNS\4723816 in_19\IN\13603305 the_20\DT\1740 hormonal_21\JJ\1740 environment_22\NN\13927383 ._23\.\1740
D004958_D001930 NONE <e1>estradiol</e1>_0\NN\14749794 reduces_1\VBZ\441445 seizure-induced_2\JJ\1740 <e2>hippocampal_3\NN\1740 injury</e2>_4\NN\14052046 in_5\IN\13603305 ovariectomized_6\JJ\1740 female_7\NN\15388 but_8\CC\1740 not_9\RB\1740 in_10\IN\13603305 male_11\JJ\1740 rats_12\NNS\2329401 ._13\.\1740
D007608_D001930 NONE estrogens_0\NNS\14745635 protect_1\VBP\1127795 ovariectomized_2\JJ\1740 rats_3\NNS\2329401 from_4\IN\1740 <e2>hippocampal_5\NN\1740 injury</e2>_6\NN\14052046 induced_7\VBN\1627355 by_8\IN\1740 <e1>kainic_9\JJ\1740 acid-induced</e1>_10\JJ\1740 status_11\NN\24720 epilepticus_12\NN\1740 (_13\-LRB-\1740 se_14\NN\14724645 )_15\-RRB-\1740 ._16\.\1740
D007608_D013226 NONE estrogens_0\NNS\14745635 protect_1\VBP\1127795 ovariectomized_2\JJ\1740 rats_3\NNS\2329401 from_4\IN\1740 hippocampal_5\NN\1740 injury_6\NN\14052046 induced_7\VBN\1627355 by_8\IN\1740 <e1>kainic_9\JJ\1740 acid-induced</e1>_10\JJ\1740 <e2>status_11\NN\24720 epilepticus</e2>_12\NN\1740 (_13\-LRB-\1740 se_14\NN\14724645 )_15\-RRB-\1740 ._16\.\1740
D007608_D013226 NONE estrogens_0\NNS\14745635 protect_1\VBP\1127795 ovariectomized_2\JJ\1740 rats_3\NNS\2329401 from_4\IN\1740 hippocampal_5\NN\1740 injury_6\NN\14052046 induced_7\VBN\1627355 by_8\IN\1740 <e1>kainic_9\JJ\1740 acid-induced</e1>_10\JJ\1740 status_11\NN\24720 epilepticus_12\NN\1740 (_13\-LRB-\1740 <e2>se</e2>_14\NN\14724645 )_15\-RRB-\1740 ._16\.\1740
D004958_D013226 NONE we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>17beta-estradiol</e1>_5\NN\1740 in_6\IN\13603305 adult_7\JJ\1740 male_8\JJ\1740 and_9\CC\1740 ovariectomized_10\JJ\1740 female_11\JJ\1740 rats_12\NNS\2329401 subjected_13\VBN\137313 to_14\TO\1740 lithium-pilocarpine-induced_15\JJ\1740 <e2>se</e2>_16\NN\14724645 ._17\.\1740
D008094_D013226 CID we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 17beta-estradiol_5\NN\1740 in_6\IN\13603305 adult_7\JJ\1740 male_8\JJ\1740 and_9\CC\1740 ovariectomized_10\JJ\1740 female_11\JJ\1740 rats_12\NNS\2329401 subjected_13\VBN\137313 to_14\TO\1740 <e1>lithium-pilocarpine-induced</e1>_15\JJ\1740 <e2>se</e2>_16\NN\14724645 ._17\.\1740
D010862_D013226 CID we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 17beta-estradiol_5\NN\1740 in_6\IN\13603305 adult_7\JJ\1740 male_8\JJ\1740 and_9\CC\1740 ovariectomized_10\JJ\1740 female_11\JJ\1740 rats_12\NNS\2329401 subjected_13\VBN\137313 to_14\TO\1740 <e1>lithium-pilocarpine-induced</e1>_15\JJ\1740 <e2>se</e2>_16\NN\14724645 ._17\.\1740
D012834_D013226 NONE the_0\DT\1740 extent_1\NN\13939892 of_2\IN\1740 <e1>silver-stained</e1>_3\JJ\1740 ca3_4\NN\1740 and_5\CC\1740 ca1_6\NN\1740 hippocampal_7\NN\1740 neurons_8\NNS\5430628 was_9\VBD\836236 evaluated_10\VBN\670261 2_11\CD\13741022 days_12\NNS\15140892 after_13\IN\1740 <e2>se</e2>_14\NNP\14724645 ._15\.\1740
8073369
C007112_D001176 CID however_0\RB\1740 ,_1\,\1740 <e1>coniine</e1>_2\NN\1740 has_3\VBZ\2108377 failed_4\VBN\1798936 to_5\TO\1740 produce_6\VB\1617192 <e2>arthrogryposis</e2>_7\NN\1740 in_8\IN\13603305 rats_9\NNS\2329401 or_10\CC\3541091 mice_11\NNS\2329401 and_12\CC\1740 is_13\VBZ\836236 only_14\RB\1740 weakly_15\RB\1740 teratogenic_16\JJ\1740 in_17\IN\13603305 rabbits_18\NNS\2323902 ._19\.\1740
C007112_D001176 CID in_0\IN\13603305 summary_1\NN\6722453 ,_2\,\1740 the_3\DT\1740 chick_4\JJ\1740 embryo_5\NN\17222 provides_6\VBZ\2199590 a_7\DT\13649268 reliable_8\JJ\1740 and_9\CC\1740 simple_10\JJ\1740 experimental_11\JJ\1740 animal_12\JJ\1740 model_13\NN\5888929 of_14\IN\1740 <e1>coniine-induced</e1>_15\JJ\1740 <e2>arthrogryposis</e2>_16\NN\1740 ._17\.\1740
C007112_D009140 NONE the_0\DT\1740 <e2>deformations</e2>_1\NNS\7420770 caused_2\VBN\1617192 by_3\IN\1740 both_4\CC\1740 <e1>coniine</e1>_5\NN\1740 and_6\CC\1740 nicotine_7\NN\14712692 sulfate_8\NN\15010703 were_9\VBD\836236 excessive_10\JJ\1740 flexion_11\NN\14034177 or_12\CC\3541091 extension_13\NN\15272029 of_14\IN\1740 one_15\CD\13741022 or_16\CC\3541091 more_17\JJR\1740 toes_18\NNS\5566097 ._19\.\1740
C007112_D009140 NONE the_0\DT\1740 deformations_1\NNS\7420770 caused_2\VBN\1617192 by_3\IN\1740 both_4\CC\1740 <e1>coniine</e1>_5\NN\1740 and_6\CC\1740 nicotine_7\NN\14712692 sulfate_8\NN\15010703 were_9\VBD\836236 <e2>excessive_10\JJ\1740 flexion_11\NN\14034177 or_12\CC\3541091 extension_13\NN\15272029 of_14\IN\1740 one_15\CD\13741022 or_16\CC\3541091 more_17\JJR\1740 toes</e2>_18\NNS\5566097 ._19\.\1740
D009538_D009140 NONE the_0\DT\1740 <e2>deformations</e2>_1\NNS\7420770 caused_2\VBN\1617192 by_3\IN\1740 both_4\CC\1740 coniine_5\NN\1740 and_6\CC\1740 <e1>nicotine</e1>_7\NN\14712692 sulfate_8\NN\15010703 were_9\VBD\836236 excessive_10\JJ\1740 flexion_11\NN\14034177 or_12\CC\3541091 extension_13\NN\15272029 of_14\IN\1740 one_15\CD\13741022 or_16\CC\3541091 more_17\JJR\1740 toes_18\NNS\5566097 ._19\.\1740
D009538_D009140 NONE the_0\DT\1740 deformations_1\NNS\7420770 caused_2\VBN\1617192 by_3\IN\1740 both_4\CC\1740 coniine_5\NN\1740 and_6\CC\1740 <e1>nicotine</e1>_7\NN\14712692 sulfate_8\NN\15010703 were_9\VBD\836236 <e2>excessive_10\JJ\1740 flexion_11\NN\14034177 or_12\CC\3541091 extension_13\NN\15272029 of_14\IN\1740 one_15\CD\13741022 or_16\CC\3541091 more_17\JJR\1740 toes</e2>_18\NNS\5566097 ._19\.\1740
D009538_D002543 CID no_0\DT\7204911 histopathological_1\JJ\1740 alterations_2\NNS\7283608 or_3\CC\3541091 differences_4\NNS\4723816 in_5\IN\13603305 bone_6\NN\5286536 formation_7\NN\7938773 were_8\VBD\836236 seen_9\VBN\2106506 in_10\IN\13603305 the_11\DT\1740 limbs_12\NNS\5559908 or_13\CC\3541091 toes_14\NNS\5566097 of_15\IN\1740 any_16\DT\1740 chicks_17\NNS\1791625 from_18\IN\1740 any_19\DT\1740 group_20\NN\2137 ;_21\:\1740 however_22\RB\1740 ,_23\,\1740 extensive_24\JJ\1740 <e2>cranial_25\JJ\1740 hemorrhage</e2>_26\NN\14285662 occurred_27\VBD\2623529 in_28\IN\13603305 all_29\DT\1740 <e1>nicotine</e1>_30\NN\14712692 sulfate-treated_31\JJ\1740 chicks_32\NNS\1791625 ._33\.\1740
15863244
C106876_D064420 NONE comparison_0\NN\635850 of_1\IN\1740 developmental_2\JJ\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 selective_5\JJ\1740 and_6\CC\1740 non-selective_7\JJ\1740 cyclooxygenase-2_8\NN\14737847 inhibitors_9\NNS\20090 in_10\IN\13603305 crl:(wi)wubr_11\NN\1740 wistar_12\NNP\1740 rats_13\NNS\2329401 --_14\:\1740 <e1>dfu</e1>_15\NN\1740 and_16\CC\1740 piroxicam_17\NN\3828465 study_18\NN\635850 ._19\.\1740
C106876_D064420 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 experiment_4\NN\641820 was_5\VBD\836236 to_6\TO\1740 evaluate_7\VB\670261 the_8\DT\1740 developmental_9\JJ\1740 <e2>toxicity</e2>_10\NN\13576101 of_11\IN\1740 the_12\DT\1740 non-selective_13\JJ\1740 (_14\-LRB-\1740 piroxicam_15\NNS\3828465 )_16\-RRB-\1740 and_17\CC\1740 selective_18\JJ\1740 (_19\-LRB-\1740 <e1>dfu</e1>_20\NN\1740 ;_21\:\1740 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl_22\NN\1740 )_23\-RRB-\1740 phenyl-2(5h)-furanon_24\NN\1740 )_25\-RRB-\1740 cox-2_26\NN\14737847 inhibitors_27\NNS\20090 ._28\.\1740
C106876_D064420 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 experiment_4\NN\641820 was_5\VBD\836236 to_6\TO\1740 evaluate_7\VB\670261 the_8\DT\1740 developmental_9\JJ\1740 <e2>toxicity</e2>_10\NN\13576101 of_11\IN\1740 the_12\DT\1740 non-selective_13\JJ\1740 (_14\-LRB-\1740 piroxicam_15\NNS\3828465 )_16\-RRB-\1740 and_17\CC\1740 selective_18\JJ\1740 (_19\-LRB-\1740 dfu_20\NN\1740 ;_21\:\1740 <e1>5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl_22\NN\1740 )_23\-RRB-\1740 phenyl-2(5h)-furanon</e1>_24\NN\1740 )_25\-RRB-\1740 cox-2_26\NN\14737847 inhibitors_27\NNS\20090 ._28\.\1740
C106876_D064420 NONE decrease_0\NN\7296428 of_1\IN\1740 fetal_2\JJ\1740 length_3\NN\5093581 was_4\VBD\836236 the_5\DT\1740 only_6\JJ\1740 signs_7\NNS\6643763 of_8\IN\1740 the_9\DT\1740 <e1>dfu</e1>_10\NN\1740 developmental_11\JJ\1740 <e2>toxicity</e2>_12\NN\13576101 observed_13\VBN\2163746 in_14\IN\13603305 pups_15\NNS\1321854 exposed_16\VBN\2110927 to_17\TO\1740 the_18\DT\1740 highest_19\JJS\1740 compound_20\NN\5869584 dose_21\NN\3740161 ._22\.\1740
D010894_D064420 NONE comparison_0\NN\635850 of_1\IN\1740 developmental_2\JJ\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 selective_5\JJ\1740 and_6\CC\1740 non-selective_7\JJ\1740 cyclooxygenase-2_8\NN\14737847 inhibitors_9\NNS\20090 in_10\IN\13603305 crl:(wi)wubr_11\NN\1740 wistar_12\NNP\1740 rats_13\NNS\2329401 --_14\:\1740 dfu_15\NN\1740 and_16\CC\1740 <e1>piroxicam</e1>_17\NN\3828465 study_18\NN\635850 ._19\.\1740
D010894_D064420 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 experiment_4\NN\641820 was_5\VBD\836236 to_6\TO\1740 evaluate_7\VB\670261 the_8\DT\1740 developmental_9\JJ\1740 <e2>toxicity</e2>_10\NN\13576101 of_11\IN\1740 the_12\DT\1740 non-selective_13\JJ\1740 (_14\-LRB-\1740 <e1>piroxicam</e1>_15\NNS\3828465 )_16\-RRB-\1740 and_17\CC\1740 selective_18\JJ\1740 (_19\-LRB-\1740 dfu_20\NN\1740 ;_21\:\1740 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl_22\NN\1740 )_23\-RRB-\1740 phenyl-2(5h)-furanon_24\NN\1740 )_25\-RRB-\1740 cox-2_26\NN\14737847 inhibitors_27\NNS\20090 ._28\.\1740
D010894_D064420 NONE results_0\NNS\34213 :_1\:\1740 maternal_2\JJ\1740 <e2>toxicity</e2>_3\NN\13576101 ,_4\,\1740 intrauterine_5\NN\1740 growth_6\NN\13526110 retardation_7\NN\7296428 ,_8\,\1740 and_9\CC\1740 increase_10\NN\13576355 of_11\IN\1740 external_12\JJ\1740 and_13\CC\1740 skeletal_14\JJ\1740 variations_15\NNS\7296428 were_16\VBD\836236 found_17\VBN\2426171 in_18\IN\13603305 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 the_22\DT\1740 highest_23\JJS\1740 dose_24\NN\3740161 of_25\IN\1740 <e1>piroxicam</e1>_26\NN\3828465 ._27\.\1740
D010894_D006345 NONE the_0\DT\1740 pooled_1\VBN\2295550 statistical_2\JJ\1740 analysis_3\NN\633864 for_4\IN\1740 <e2>ventricular_5\JJ\1740 septal_6\NN\1740 (_7\-LRB-\1740 vsd_8\NN\1740 )_9\-RRB-\1740 and_10\CC\1740 midline_11\NN\13861050 (_12\-LRB-\1740 md_13\NN\14622893 )_14\-RRB-\1740 defects</e2>_15\NNS\14462666 was_16\VBD\836236 performed_17\VBN\2367363 for_18\IN\1740 rat_19\NN\2329401 fetuses_20\NNS\1471682 exposed_21\VBN\2110927 to_22\TO\1740 <e1>piroxicam</e1>_23\VB\1740 ,_24\,\1740 selective_25\JJ\1740 and_26\CC\1740 non-selective_27\JJ\1740 cox-2_28\NN\14737847 inhibitor_29\NN\20090 based_30\VBN\2694933 on_31\IN\1740 present_32\JJ\1740 and_33\CC\1740 historic_34\JJ\1740 data_35\NNS\7951464 ._36\.\1740
D010894_D009436 NONE the_0\DT\1740 pooled_1\VBN\2295550 statistical_2\JJ\1740 analysis_3\NN\633864 for_4\IN\1740 <e2>ventricular_5\JJ\1740 septal_6\NN\1740 (_7\-LRB-\1740 vsd_8\NN\1740 )_9\-RRB-\1740 and_10\CC\1740 midline_11\NN\13861050 (_12\-LRB-\1740 md_13\NN\14622893 )_14\-RRB-\1740 defects</e2>_15\NNS\14462666 was_16\VBD\836236 performed_17\VBN\2367363 for_18\IN\1740 rat_19\NN\2329401 fetuses_20\NNS\1471682 exposed_21\VBN\2110927 to_22\TO\1740 <e1>piroxicam</e1>_23\VB\1740 ,_24\,\1740 selective_25\JJ\1740 and_26\CC\1740 non-selective_27\JJ\1740 cox-2_28\NN\14737847 inhibitor_29\NN\20090 based_30\VBN\2694933 on_31\IN\1740 present_32\JJ\1740 and_33\CC\1740 historic_34\JJ\1740 data_35\NNS\7951464 ._36\.\1740
D010894_D005317 CID results_0\NNS\34213 :_1\:\1740 maternal_2\JJ\1740 toxicity_3\NN\13576101 ,_4\,\1740 <e2>intrauterine_5\NN\1740 growth_6\NN\13526110 retardation</e2>_7\NN\7296428 ,_8\,\1740 and_9\CC\1740 increase_10\NN\13576355 of_11\IN\1740 external_12\JJ\1740 and_13\CC\1740 skeletal_14\JJ\1740 variations_15\NNS\7296428 were_16\VBD\836236 found_17\VBN\2426171 in_18\IN\13603305 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 the_22\DT\1740 highest_23\JJS\1740 dose_24\NN\3740161 of_25\IN\1740 <e1>piroxicam</e1>_26\NN\3828465 ._27\.\1740
D010894_D009139 CID results_0\NNS\34213 :_1\:\1740 maternal_2\JJ\1740 toxicity_3\NN\13576101 ,_4\,\1740 intrauterine_5\NN\1740 growth_6\NN\13526110 retardation_7\NN\7296428 ,_8\,\1740 and_9\CC\1740 <e2>increase_10\NN\13576355 of_11\IN\1740 external_12\JJ\1740 and_13\CC\1740 skeletal_14\JJ\1740 variations</e2>_15\NNS\7296428 were_16\VBD\836236 found_17\VBN\2426171 in_18\IN\13603305 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 the_22\DT\1740 highest_23\JJS\1740 dose_24\NN\3740161 of_25\IN\1740 <e1>piroxicam</e1>_26\NN\3828465 ._27\.\1740
9495837
C087567_D000647 NONE <e1>(+/-)-pg-9</e1>_0\NN\1740 (_1\-LRB-\1740 10_2\CD\13745420 -_3\SYM\1740 40_4\CD\13745420 mg_5\NN\13717155 kg-1_6\NN\1740 i.p._7\RB\1740 )_8\-RRB-\1740 was_9\VBD\836236 able_10\JJ\1740 to_11\TO\1740 prevent_12\VB\1740 <e2>amnesia</e2>_13\NN\5669934 induced_14\VBN\1627355 by_15\IN\1740 scopolamine_16\NN\14712692 (_17\-LRB-\1740 1_18\CD\13741022 mg_19\NN\13717155 kg-1_20\NN\1740 i.p._21\RB\1740 )_22\-RRB-\1740 and_23\CC\1740 dicyclomine_24\NN\1740 (_25\-LRB-\1740 2_26\CD\13741022 mg_27\NN\13717155 kg-1_28\NN\1740 i.p._29\RB\1740 )_30\-RRB-\1740 in_31\IN\13603305 the_32\DT\1740 mouse_33\NN\2329401 passive-avoidance_34\NN\1740 test_35\NN\5798043 ._36\.\1740
C087567_D000647 NONE affinity_0\NN\11426530 profiles_1\NNS\6999802 of_2\IN\1740 <e1>(+/-)-pg-9</e1>_3\NN\1740 for_4\IN\1740 muscarinic_5\JJ\1740 receptor_6\NN\5225602 subtypes_7\NNS\1740 ,_8\,\1740 determined_9\VBN\1645601 by_10\IN\1740 functional_11\JJ\1740 studies_12\NNS\635850 (_13\-LRB-\1740 rabbit_14\NN\2323902 vas_15\NN\5246511 deferens_16\NNS\1740 for_17\IN\1740 m1_18\NN\13357178 ,_19\,\1740 guinea_20\NN\13388245 pig_21\NN\2395003 atrium_22\NN\5392744 for_23\IN\1740 m2_24\NN\13357178 ,_25\,\1740 guinea_26\NN\13388245 pig_27\NN\2395003 ileum_28\NN\5534712 for_29\IN\1740 m3_30\NN\13357178 and_31\CC\1740 immature_32\JJ\1740 guinea_33\NN\13388245 pig_34\NN\2395003 uterus_35\NN\5514717 for_36\IN\1740 putative_37\JJ\1740 m4_38\NN\1740 )_39\-RRB-\1740 ,_40\,\1740 have_41\VBP\2108377 shown_42\VBN\2137132 an_43\DT\6697703 m4/m1_44\NN\1740 selectivity_45\NN\4916342 ratio_46\NN\13815152 of_47\IN\1740 10.2_48\CD\1740 that_49\WDT\1740 might_50\MD\5029706 be_51\VB\836236 responsible_52\JJ\1740 for_53\IN\1740 the_54\DT\1740 antinociception_55\NN\1740 and_56\CC\1740 the_57\DT\1740 <e2>anti-amnesic</e2>_58\JJ\1740 effect_59\NN\34213 induced_60\VBN\1627355 by_61\IN\1740 (+/-)-pg-9_62\NN\1740 through_63\IN\1740 an_64\DT\6697703 increase_65\NN\13576355 in_66\IN\13603305 acetylcholine_67\NN\14807558 extracellular_68\JJ\1740 levels_69\NNS\4916342 ._70\.\1740
C087567_D000647 NONE affinity_0\NN\11426530 profiles_1\NNS\6999802 of_2\IN\1740 (+/-)-pg-9_3\NN\1740 for_4\IN\1740 muscarinic_5\JJ\1740 receptor_6\NN\5225602 subtypes_7\NNS\1740 ,_8\,\1740 determined_9\VBN\1645601 by_10\IN\1740 functional_11\JJ\1740 studies_12\NNS\635850 (_13\-LRB-\1740 rabbit_14\NN\2323902 vas_15\NN\5246511 deferens_16\NNS\1740 for_17\IN\1740 m1_18\NN\13357178 ,_19\,\1740 guinea_20\NN\13388245 pig_21\NN\2395003 atrium_22\NN\5392744 for_23\IN\1740 m2_24\NN\13357178 ,_25\,\1740 guinea_26\NN\13388245 pig_27\NN\2395003 ileum_28\NN\5534712 for_29\IN\1740 m3_30\NN\13357178 and_31\CC\1740 immature_32\JJ\1740 guinea_33\NN\13388245 pig_34\NN\2395003 uterus_35\NN\5514717 for_36\IN\1740 putative_37\JJ\1740 m4_38\NN\1740 )_39\-RRB-\1740 ,_40\,\1740 have_41\VBP\2108377 shown_42\VBN\2137132 an_43\DT\6697703 m4/m1_44\NN\1740 selectivity_45\NN\4916342 ratio_46\NN\13815152 of_47\IN\1740 10.2_48\CD\1740 that_49\WDT\1740 might_50\MD\5029706 be_51\VB\836236 responsible_52\JJ\1740 for_53\IN\1740 the_54\DT\1740 antinociception_55\NN\1740 and_56\CC\1740 the_57\DT\1740 <e2>anti-amnesic</e2>_58\JJ\1740 effect_59\NN\34213 induced_60\VBN\1627355 by_61\IN\1740 <e1>(+/-)-pg-9</e1>_62\NN\1740 through_63\IN\1740 an_64\DT\6697703 increase_65\NN\13576355 in_66\IN\13603305 acetylcholine_67\NN\14807558 extracellular_68\JJ\1740 levels_69\NNS\4916342 ._70\.\1740
D012601_D000647 CID (+/-)-pg-9_0\NN\1740 (_1\-LRB-\1740 10_2\CD\13745420 -_3\SYM\1740 40_4\CD\13745420 mg_5\NN\13717155 kg-1_6\NN\1740 i.p._7\RB\1740 )_8\-RRB-\1740 was_9\VBD\836236 able_10\JJ\1740 to_11\TO\1740 prevent_12\VB\1740 <e2>amnesia</e2>_13\NN\5669934 induced_14\VBN\1627355 by_15\IN\1740 <e1>scopolamine</e1>_16\NN\14712692 (_17\-LRB-\1740 1_18\CD\13741022 mg_19\NN\13717155 kg-1_20\NN\1740 i.p._21\RB\1740 )_22\-RRB-\1740 and_23\CC\1740 dicyclomine_24\NN\1740 (_25\-LRB-\1740 2_26\CD\13741022 mg_27\NN\13717155 kg-1_28\NN\1740 i.p._29\RB\1740 )_30\-RRB-\1740 in_31\IN\13603305 the_32\DT\1740 mouse_33\NN\2329401 passive-avoidance_34\NN\1740 test_35\NN\5798043 ._36\.\1740
D004025_D000647 CID (+/-)-pg-9_0\NN\1740 (_1\-LRB-\1740 10_2\CD\13745420 -_3\SYM\1740 40_4\CD\13745420 mg_5\NN\13717155 kg-1_6\NN\1740 i.p._7\RB\1740 )_8\-RRB-\1740 was_9\VBD\836236 able_10\JJ\1740 to_11\TO\1740 prevent_12\VB\1740 <e2>amnesia</e2>_13\NN\5669934 induced_14\VBN\1627355 by_15\IN\1740 scopolamine_16\NN\14712692 (_17\-LRB-\1740 1_18\CD\13741022 mg_19\NN\13717155 kg-1_20\NN\1740 i.p._21\RB\1740 )_22\-RRB-\1740 and_23\CC\1740 <e1>dicyclomine</e1>_24\NN\1740 (_25\-LRB-\1740 2_26\CD\13741022 mg_27\NN\13717155 kg-1_28\NN\1740 i.p._29\RB\1740 )_30\-RRB-\1740 in_31\IN\13603305 the_32\DT\1740 mouse_33\NN\2329401 passive-avoidance_34\NN\1740 test_35\NN\5798043 ._36\.\1740
D000109_D000647 NONE affinity_0\NN\11426530 profiles_1\NNS\6999802 of_2\IN\1740 (+/-)-pg-9_3\NN\1740 for_4\IN\1740 muscarinic_5\JJ\1740 receptor_6\NN\5225602 subtypes_7\NNS\1740 ,_8\,\1740 determined_9\VBN\1645601 by_10\IN\1740 functional_11\JJ\1740 studies_12\NNS\635850 (_13\-LRB-\1740 rabbit_14\NN\2323902 vas_15\NN\5246511 deferens_16\NNS\1740 for_17\IN\1740 m1_18\NN\13357178 ,_19\,\1740 guinea_20\NN\13388245 pig_21\NN\2395003 atrium_22\NN\5392744 for_23\IN\1740 m2_24\NN\13357178 ,_25\,\1740 guinea_26\NN\13388245 pig_27\NN\2395003 ileum_28\NN\5534712 for_29\IN\1740 m3_30\NN\13357178 and_31\CC\1740 immature_32\JJ\1740 guinea_33\NN\13388245 pig_34\NN\2395003 uterus_35\NN\5514717 for_36\IN\1740 putative_37\JJ\1740 m4_38\NN\1740 )_39\-RRB-\1740 ,_40\,\1740 have_41\VBP\2108377 shown_42\VBN\2137132 an_43\DT\6697703 m4/m1_44\NN\1740 selectivity_45\NN\4916342 ratio_46\NN\13815152 of_47\IN\1740 10.2_48\CD\1740 that_49\WDT\1740 might_50\MD\5029706 be_51\VB\836236 responsible_52\JJ\1740 for_53\IN\1740 the_54\DT\1740 antinociception_55\NN\1740 and_56\CC\1740 the_57\DT\1740 <e2>anti-amnesic</e2>_58\JJ\1740 effect_59\NN\34213 induced_60\VBN\1627355 by_61\IN\1740 (+/-)-pg-9_62\NN\1740 through_63\IN\1740 an_64\DT\6697703 increase_65\NN\13576355 in_66\IN\13603305 <e1>acetylcholine</e1>_67\NN\14807558 extracellular_68\JJ\1740 levels_69\NNS\4916342 ._70\.\1740
11875660
D001374_D009436 NONE we_0\PRP\1740 observed_1\VBD\2163746 the_2\DT\1740 <e2>exencephaly</e2>_3\NN\1740 induced_4\VBN\1627355 by_5\IN\1740 <e1>5-azacytidine</e1>_6\NN\1740 at_7\IN\14622893 embryonic_8\JJ\1740 day_9\NN\15154774 13.5_10\CD\1740 (_11\-LRB-\1740 e13.5_12\NN\1740 )_13\-RRB-\1740 ,_14\,\1740 let_15\VB\770437 the_16\DT\1740 embryos_17\NNS\17222 develop_18\VBP\1753788 exo_19\NN\1740 utero_20\NN\1740 until_21\IN\1740 e18.5_22\NNP\1740 ,_23\,\1740 and_24\CC\1740 re-observed_25\VBD\1740 the_26\DT\1740 same_27\JJ\1740 embryos_28\NNS\17222 at_29\IN\14622893 e18.5_30\NN\1740 ._31\.\1740
17532790
D007980_D004409 CID proteomic_0\JJ\1740 analysis_1\NN\633864 of_2\IN\1740 striatal_3\JJ\1740 proteins_4\NNS\14944888 in_5\IN\13603305 the_6\DT\1740 rat_7\NN\2329401 model_8\NN\5888929 of_9\IN\1740 <e1>l-dopa-induced</e1>_10\JJ\1740 <e2>dyskinesia</e2>_11\NN\14084880 ._12\.\1740
D007980_D004409 CID <e1>l-dopa-induced</e1>_0\VBN\1740 <e2>dyskinesia</e2>_1\NN\14084880 (_2\-LRB-\1740 lid_3\NN\5313679 )_4\-RRB-\1740 is_5\VBZ\836236 among_6\IN\1740 the_7\DT\1740 motor_8\NN\3699975 complications_9\NNS\1073995 that_10\WDT\1740 arise_11\VBP\2623529 in_12\IN\13603305 parkinson_13\NNP\1740 's_14\POS\1740 disease_15\NN\14061805 (_16\-LRB-\1740 pd_17\NN\14625458 )_18\-RRB-\1740 patients_19\NNS\9898892 after_20\IN\1740 a_21\DT\13649268 prolonged_22\JJ\1740 treatment_23\NN\654885 with_24\IN\1740 l-dopa_25\NN\14604959 ._26\.\1740
D007980_D004409 CID <e1>l-dopa-induced</e1>_0\VBN\1740 dyskinesia_1\NN\14084880 (_2\-LRB-\1740 <e2>lid</e2>_3\NN\5313679 )_4\-RRB-\1740 is_5\VBZ\836236 among_6\IN\1740 the_7\DT\1740 motor_8\NN\3699975 complications_9\NNS\1073995 that_10\WDT\1740 arise_11\VBP\2623529 in_12\IN\13603305 parkinson_13\NNP\1740 's_14\POS\1740 disease_15\NN\14061805 (_16\-LRB-\1740 pd_17\NN\14625458 )_18\-RRB-\1740 patients_19\NNS\9898892 after_20\IN\1740 a_21\DT\13649268 prolonged_22\JJ\1740 treatment_23\NN\654885 with_24\IN\1740 l-dopa_25\NN\14604959 ._26\.\1740
D007980_D004409 CID l-dopa-induced_0\VBN\1740 <e2>dyskinesia</e2>_1\NN\14084880 (_2\-LRB-\1740 lid_3\NN\5313679 )_4\-RRB-\1740 is_5\VBZ\836236 among_6\IN\1740 the_7\DT\1740 motor_8\NN\3699975 complications_9\NNS\1073995 that_10\WDT\1740 arise_11\VBP\2623529 in_12\IN\13603305 parkinson_13\NNP\1740 's_14\POS\1740 disease_15\NN\14061805 (_16\-LRB-\1740 pd_17\NN\14625458 )_18\-RRB-\1740 patients_19\NNS\9898892 after_20\IN\1740 a_21\DT\13649268 prolonged_22\JJ\1740 treatment_23\NN\654885 with_24\IN\1740 <e1>l-dopa</e1>_25\NN\14604959 ._26\.\1740
D007980_D004409 CID l-dopa-induced_0\VBN\1740 dyskinesia_1\NN\14084880 (_2\-LRB-\1740 <e2>lid</e2>_3\NN\5313679 )_4\-RRB-\1740 is_5\VBZ\836236 among_6\IN\1740 the_7\DT\1740 motor_8\NN\3699975 complications_9\NNS\1073995 that_10\WDT\1740 arise_11\VBP\2623529 in_12\IN\13603305 parkinson_13\NNP\1740 's_14\POS\1740 disease_15\NN\14061805 (_16\-LRB-\1740 pd_17\NN\14625458 )_18\-RRB-\1740 patients_19\NNS\9898892 after_20\IN\1740 a_21\DT\13649268 prolonged_22\JJ\1740 treatment_23\NN\654885 with_24\IN\1740 <e1>l-dopa</e1>_25\NN\14604959 ._26\.\1740
D007980_D004409 CID rats_0\NNS\2329401 treated_1\VBN\2376958 with_2\IN\1740 <e1>l-dopa</e1>_3\NN\14604959 were_4\VBD\836236 allocated_5\VBN\2228698 to_6\TO\1740 two_7\CD\13741022 groups_8\NNS\2137 based_9\VBN\2694933 on_10\IN\1740 the_11\DT\1740 presence_12\NN\13954253 or_13\CC\3541091 absence_14\NN\14449405 of_15\IN\1740 <e2>lid</e2>_16\NN\5313679 ._17\.\1740
D007980_D010300 NONE <e1>l-dopa-induced</e1>_0\VBN\1740 dyskinesia_1\NN\14084880 (_2\-LRB-\1740 lid_3\NN\5313679 )_4\-RRB-\1740 is_5\VBZ\836236 among_6\IN\1740 the_7\DT\1740 motor_8\NN\3699975 complications_9\NNS\1073995 that_10\WDT\1740 arise_11\VBP\2623529 in_12\IN\13603305 <e2>parkinson_13\NNP\1740 's_14\POS\1740 disease</e2>_15\NN\14061805 (_16\-LRB-\1740 pd_17\NN\14625458 )_18\-RRB-\1740 patients_19\NNS\9898892 after_20\IN\1740 a_21\DT\13649268 prolonged_22\JJ\1740 treatment_23\NN\654885 with_24\IN\1740 l-dopa_25\NN\14604959 ._26\.\1740
D007980_D010300 NONE <e1>l-dopa-induced</e1>_0\VBN\1740 dyskinesia_1\NN\14084880 (_2\-LRB-\1740 lid_3\NN\5313679 )_4\-RRB-\1740 is_5\VBZ\836236 among_6\IN\1740 the_7\DT\1740 motor_8\NN\3699975 complications_9\NNS\1073995 that_10\WDT\1740 arise_11\VBP\2623529 in_12\IN\13603305 parkinson_13\NNP\1740 's_14\POS\1740 disease_15\NN\14061805 (_16\-LRB-\1740 <e2>pd</e2>_17\NN\14625458 )_18\-RRB-\1740 patients_19\NNS\9898892 after_20\IN\1740 a_21\DT\13649268 prolonged_22\JJ\1740 treatment_23\NN\654885 with_24\IN\1740 l-dopa_25\NN\14604959 ._26\.\1740
D007980_D010300 NONE l-dopa-induced_0\VBN\1740 dyskinesia_1\NN\14084880 (_2\-LRB-\1740 lid_3\NN\5313679 )_4\-RRB-\1740 is_5\VBZ\836236 among_6\IN\1740 the_7\DT\1740 motor_8\NN\3699975 complications_9\NNS\1073995 that_10\WDT\1740 arise_11\VBP\2623529 in_12\IN\13603305 <e2>parkinson_13\NNP\1740 's_14\POS\1740 disease</e2>_15\NN\14061805 (_16\-LRB-\1740 pd_17\NN\14625458 )_18\-RRB-\1740 patients_19\NNS\9898892 after_20\IN\1740 a_21\DT\13649268 prolonged_22\JJ\1740 treatment_23\NN\654885 with_24\IN\1740 <e1>l-dopa</e1>_25\NN\14604959 ._26\.\1740
D007980_D010300 NONE l-dopa-induced_0\VBN\1740 dyskinesia_1\NN\14084880 (_2\-LRB-\1740 lid_3\NN\5313679 )_4\-RRB-\1740 is_5\VBZ\836236 among_6\IN\1740 the_7\DT\1740 motor_8\NN\3699975 complications_9\NNS\1073995 that_10\WDT\1740 arise_11\VBP\2623529 in_12\IN\13603305 parkinson_13\NNP\1740 's_14\POS\1740 disease_15\NN\14061805 (_16\-LRB-\1740 <e2>pd</e2>_17\NN\14625458 )_18\-RRB-\1740 patients_19\NNS\9898892 after_20\IN\1740 a_21\DT\13649268 prolonged_22\JJ\1740 treatment_23\NN\654885 with_24\IN\1740 <e1>l-dopa</e1>_25\NN\14604959 ._26\.\1740
D007980_D010300 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 the_7\DT\1740 changes_8\NNS\7283608 occurring_9\VBG\2623529 at_10\IN\14622893 the_11\DT\1740 protein_12\NN\14944888 level_13\NN\4916342 in_14\IN\13603305 striatal_15\JJ\1740 samples_16\NNS\5820620 obtained_17\VBN\2210855 from_18\IN\1740 the_19\DT\1740 unilaterally_20\RB\1740 6-hydroxydopamine-lesion_21\NN\1740 rat_22\NN\2329401 model_23\NN\5888929 of_24\IN\1740 <e2>pd</e2>_25\NN\14625458 treated_26\VBN\2376958 with_27\IN\1740 saline_28\NN\14849367 ,_29\,\1740 <e1>l-dopa</e1>_30\NN\14604959 or_31\CC\3541091 bromocriptine_32\NN\1740 using_33\VBG\1156834 two-dimensional_34\JJ\1740 difference_35\NN\4723816 gel_36\NN\14588219 electrophoresis_37\NN\13518963 and_38\CC\1740 mass_39\JJ\1740 spectrometry_40\NN\646833 (_41\-LRB-\1740 ms_42\NN\14187378 )_43\-RRB-\1740 ._44\.\1740
D016627_D010300 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 the_7\DT\1740 changes_8\NNS\7283608 occurring_9\VBG\2623529 at_10\IN\14622893 the_11\DT\1740 protein_12\NN\14944888 level_13\NN\4916342 in_14\IN\13603305 striatal_15\JJ\1740 samples_16\NNS\5820620 obtained_17\VBN\2210855 from_18\IN\1740 the_19\DT\1740 unilaterally_20\RB\1740 <e1>6-hydroxydopamine-lesion</e1>_21\NN\1740 rat_22\NN\2329401 model_23\NN\5888929 of_24\IN\1740 <e2>pd</e2>_25\NN\14625458 treated_26\VBN\2376958 with_27\IN\1740 saline_28\NN\14849367 ,_29\,\1740 l-dopa_30\NN\14604959 or_31\CC\3541091 bromocriptine_32\NN\1740 using_33\VBG\1156834 two-dimensional_34\JJ\1740 difference_35\NN\4723816 gel_36\NN\14588219 electrophoresis_37\NN\13518963 and_38\CC\1740 mass_39\JJ\1740 spectrometry_40\NN\646833 (_41\-LRB-\1740 ms_42\NN\14187378 )_43\-RRB-\1740 ._44\.\1740
D001971_D010300 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 the_7\DT\1740 changes_8\NNS\7283608 occurring_9\VBG\2623529 at_10\IN\14622893 the_11\DT\1740 protein_12\NN\14944888 level_13\NN\4916342 in_14\IN\13603305 striatal_15\JJ\1740 samples_16\NNS\5820620 obtained_17\VBN\2210855 from_18\IN\1740 the_19\DT\1740 unilaterally_20\RB\1740 6-hydroxydopamine-lesion_21\NN\1740 rat_22\NN\2329401 model_23\NN\5888929 of_24\IN\1740 <e2>pd</e2>_25\NN\14625458 treated_26\VBN\2376958 with_27\IN\1740 saline_28\NN\14849367 ,_29\,\1740 l-dopa_30\NN\14604959 or_31\CC\3541091 <e1>bromocriptine</e1>_32\NN\1740 using_33\VBG\1156834 two-dimensional_34\JJ\1740 difference_35\NN\4723816 gel_36\NN\14588219 electrophoresis_37\NN\13518963 and_38\CC\1740 mass_39\JJ\1740 spectrometry_40\NN\646833 (_41\-LRB-\1740 ms_42\NN\14187378 )_43\-RRB-\1740 ._44\.\1740
11198499
C023754_D007022 CID <e2>hypotension</e2>_0\NN\14057371 following_1\VBG\1835496 the_2\DT\1740 initiation_3\NN\7450842 of_4\IN\1740 <e1>tizanidine</e1>_5\NN\1740 in_6\IN\13603305 a_7\DT\13649268 patient_8\NN\9898892 treated_9\VBN\2376958 with_10\IN\1740 an_11\DT\6697703 angiotensin_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 for_16\IN\1740 chronic_17\JJ\1740 hypertension_18\NN\14057371 ._19\.\1740
C023754_D007022 CID the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 10-year-old_4\JJ\1740 boy_5\NN\9624168 chronically_6\RB\1740 treated_7\VBN\2376958 with_8\IN\1740 lisinopril_9\NN\2673637 ,_10\,\1740 an_11\DT\6697703 angiotensin_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 ,_16\,\1740 to_17\TO\1740 control_18\VB\2422663 hypertension_19\NN\14057371 who_20\WP\8299493 developed_21\VBD\1753788 <e2>hypotension</e2>_22\NN\14057371 following_23\VBG\1835496 the_24\DT\1740 addition_25\NN\3081021 of_26\IN\1740 <e1>tizanidine</e1>_27\NN\1740 ,_28\,\1740 an_29\DT\6697703 alpha-2_30\NN\1740 agonist_31\NN\9613191 ,_32\,\1740 for_33\IN\1740 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 spasticity_37\NN\4770535 ._38\.\1740
C023754_D006973 NONE hypotension_0\NN\14057371 following_1\VBG\1835496 the_2\DT\1740 initiation_3\NN\7450842 of_4\IN\1740 <e1>tizanidine</e1>_5\NN\1740 in_6\IN\13603305 a_7\DT\13649268 patient_8\NN\9898892 treated_9\VBN\2376958 with_10\IN\1740 an_11\DT\6697703 angiotensin_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 for_16\IN\1740 chronic_17\JJ\1740 <e2>hypertension</e2>_18\NN\14057371 ._19\.\1740
C023754_D006973 NONE the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 10-year-old_4\JJ\1740 boy_5\NN\9624168 chronically_6\RB\1740 treated_7\VBN\2376958 with_8\IN\1740 lisinopril_9\NN\2673637 ,_10\,\1740 an_11\DT\6697703 angiotensin_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 ,_16\,\1740 to_17\TO\1740 control_18\VB\2422663 <e2>hypertension</e2>_19\NN\14057371 who_20\WP\8299493 developed_21\VBD\1753788 hypotension_22\NN\14057371 following_23\VBG\1835496 the_24\DT\1740 addition_25\NN\3081021 of_26\IN\1740 <e1>tizanidine</e1>_27\NN\1740 ,_28\,\1740 an_29\DT\6697703 alpha-2_30\NN\1740 agonist_31\NN\9613191 ,_32\,\1740 for_33\IN\1740 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 spasticity_37\NN\4770535 ._38\.\1740
C023754_D006973 NONE the_0\DT\1740 possible_1\JJ\1740 interaction_2\NN\37396 of_3\IN\1740 <e1>tizanidine</e1>_4\NN\1740 and_5\CC\1740 other_6\JJ\1740 antihypertensive_7\JJ\1740 agents_8\NNS\7347 should_9\MD\1740 be_10\VB\836236 kept_11\VBN\2367363 in_12\IN\13603305 mind_13\NN\23271 when_14\WRB\1740 prescribing_15\NN\1740 therapy_16\NN\657604 to_17\TO\1740 treat_18\VB\2376958 either_19\CC\1740 <e2>hypertension</e2>_20\NN\14057371 or_21\CC\3541091 spasticity_22\NN\4770535 in_23\IN\13603305 such_24\JJ\1740 patients_25\NNS\9898892 ._26\.\1740
D000809_D007022 NONE <e2>hypotension</e2>_0\NN\14057371 following_1\VBG\1835496 the_2\DT\1740 initiation_3\NN\7450842 of_4\IN\1740 tizanidine_5\NN\1740 in_6\IN\13603305 a_7\DT\13649268 patient_8\NN\9898892 treated_9\VBN\2376958 with_10\IN\1740 an_11\DT\6697703 <e1>angiotensin</e1>_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 for_16\IN\1740 chronic_17\JJ\1740 hypertension_18\NN\14057371 ._19\.\1740
D000809_D007022 NONE adults_0\NNS\7846 chronically_1\RB\1740 treated_2\VBN\2376958 with_3\IN\1740 <e1>angiotensin</e1>_4\NN\4522421 converting_5\NN\1740 enzyme_6\NN\14723628 inhibitors_7\NNS\20090 may_8\MD\15209706 have_9\VB\2108377 a_10\DT\13649268 limited_11\JJ\1740 ability_12\NN\4723816 to_13\TO\1740 respond_14\VB\2367363 to_15\TO\1740 <e2>hypotension</e2>_16\NN\14057371 when_17\WRB\1740 the_18\DT\1740 sympathetic_19\JJ\1740 response_20\NN\11410625 is_21\VBZ\836236 simultaneously_22\RB\1740 blocked_23\VBN\1476483 ._24\.\1740
D000809_D007022 NONE the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 10-year-old_4\JJ\1740 boy_5\NN\9624168 chronically_6\RB\1740 treated_7\VBN\2376958 with_8\IN\1740 lisinopril_9\NN\2673637 ,_10\,\1740 an_11\DT\6697703 <e1>angiotensin</e1>_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 ,_16\,\1740 to_17\TO\1740 control_18\VB\2422663 hypertension_19\NN\14057371 who_20\WP\8299493 developed_21\VBD\1753788 <e2>hypotension</e2>_22\NN\14057371 following_23\VBG\1835496 the_24\DT\1740 addition_25\NN\3081021 of_26\IN\1740 tizanidine_27\NN\1740 ,_28\,\1740 an_29\DT\6697703 alpha-2_30\NN\1740 agonist_31\NN\9613191 ,_32\,\1740 for_33\IN\1740 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 spasticity_37\NN\4770535 ._38\.\1740
D000809_D006973 NONE hypotension_0\NN\14057371 following_1\VBG\1835496 the_2\DT\1740 initiation_3\NN\7450842 of_4\IN\1740 tizanidine_5\NN\1740 in_6\IN\13603305 a_7\DT\13649268 patient_8\NN\9898892 treated_9\VBN\2376958 with_10\IN\1740 an_11\DT\6697703 <e1>angiotensin</e1>_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 for_16\IN\1740 chronic_17\JJ\1740 <e2>hypertension</e2>_18\NN\14057371 ._19\.\1740
D000809_D006973 NONE the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 10-year-old_4\JJ\1740 boy_5\NN\9624168 chronically_6\RB\1740 treated_7\VBN\2376958 with_8\IN\1740 lisinopril_9\NN\2673637 ,_10\,\1740 an_11\DT\6697703 <e1>angiotensin</e1>_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 ,_16\,\1740 to_17\TO\1740 control_18\VB\2422663 <e2>hypertension</e2>_19\NN\14057371 who_20\WP\8299493 developed_21\VBD\1753788 hypotension_22\NN\14057371 following_23\VBG\1835496 the_24\DT\1740 addition_25\NN\3081021 of_26\IN\1740 tizanidine_27\NN\1740 ,_28\,\1740 an_29\DT\6697703 alpha-2_30\NN\1740 agonist_31\NN\9613191 ,_32\,\1740 for_33\IN\1740 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 spasticity_37\NN\4770535 ._38\.\1740
D017706_D006973 NONE the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 10-year-old_4\JJ\1740 boy_5\NN\9624168 chronically_6\RB\1740 treated_7\VBN\2376958 with_8\IN\1740 <e1>lisinopril</e1>_9\NN\2673637 ,_10\,\1740 an_11\DT\6697703 angiotensin_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 ,_16\,\1740 to_17\TO\1740 control_18\VB\2422663 <e2>hypertension</e2>_19\NN\14057371 who_20\WP\8299493 developed_21\VBD\1753788 hypotension_22\NN\14057371 following_23\VBG\1835496 the_24\DT\1740 addition_25\NN\3081021 of_26\IN\1740 tizanidine_27\NN\1740 ,_28\,\1740 an_29\DT\6697703 alpha-2_30\NN\1740 agonist_31\NN\9613191 ,_32\,\1740 for_33\IN\1740 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 spasticity_37\NN\4770535 ._38\.\1740
D017706_D007022 CID the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 10-year-old_4\JJ\1740 boy_5\NN\9624168 chronically_6\RB\1740 treated_7\VBN\2376958 with_8\IN\1740 <e1>lisinopril</e1>_9\NN\2673637 ,_10\,\1740 an_11\DT\6697703 angiotensin_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 ,_16\,\1740 to_17\TO\1740 control_18\VB\2422663 hypertension_19\NN\14057371 who_20\WP\8299493 developed_21\VBD\1753788 <e2>hypotension</e2>_22\NN\14057371 following_23\VBG\1835496 the_24\DT\1740 addition_25\NN\3081021 of_26\IN\1740 tizanidine_27\NN\1740 ,_28\,\1740 an_29\DT\6697703 alpha-2_30\NN\1740 agonist_31\NN\9613191 ,_32\,\1740 for_33\IN\1740 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 spasticity_37\NN\4770535 ._38\.\1740
D017706_D009128 NONE the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 10-year-old_4\JJ\1740 boy_5\NN\9624168 chronically_6\RB\1740 treated_7\VBN\2376958 with_8\IN\1740 <e1>lisinopril</e1>_9\NN\2673637 ,_10\,\1740 an_11\DT\6697703 angiotensin_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 ,_16\,\1740 to_17\TO\1740 control_18\VB\2422663 hypertension_19\NN\14057371 who_20\WP\8299493 developed_21\VBD\1753788 hypotension_22\NN\14057371 following_23\VBG\1835496 the_24\DT\1740 addition_25\NN\3081021 of_26\IN\1740 tizanidine_27\NN\1740 ,_28\,\1740 an_29\DT\6697703 alpha-2_30\NN\1740 agonist_31\NN\9613191 ,_32\,\1740 for_33\IN\1740 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 <e2>spasticity</e2>_37\NN\4770535 ._38\.\1740
D000809_D009128 NONE the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 10-year-old_4\JJ\1740 boy_5\NN\9624168 chronically_6\RB\1740 treated_7\VBN\2376958 with_8\IN\1740 lisinopril_9\NN\2673637 ,_10\,\1740 an_11\DT\6697703 <e1>angiotensin</e1>_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 ,_16\,\1740 to_17\TO\1740 control_18\VB\2422663 hypertension_19\NN\14057371 who_20\WP\8299493 developed_21\VBD\1753788 hypotension_22\NN\14057371 following_23\VBG\1835496 the_24\DT\1740 addition_25\NN\3081021 of_26\IN\1740 tizanidine_27\NN\1740 ,_28\,\1740 an_29\DT\6697703 alpha-2_30\NN\1740 agonist_31\NN\9613191 ,_32\,\1740 for_33\IN\1740 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 <e2>spasticity</e2>_37\NN\4770535 ._38\.\1740
C023754_D009128 NONE the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 10-year-old_4\JJ\1740 boy_5\NN\9624168 chronically_6\RB\1740 treated_7\VBN\2376958 with_8\IN\1740 lisinopril_9\NN\2673637 ,_10\,\1740 an_11\DT\6697703 angiotensin_12\NN\4522421 converting_13\NN\1740 enzyme_14\NN\14723628 inhibitor_15\NN\20090 ,_16\,\1740 to_17\TO\1740 control_18\VB\2422663 hypertension_19\NN\14057371 who_20\WP\8299493 developed_21\VBD\1753788 hypotension_22\NN\14057371 following_23\VBG\1835496 the_24\DT\1740 addition_25\NN\3081021 of_26\IN\1740 <e1>tizanidine</e1>_27\NN\1740 ,_28\,\1740 an_29\DT\6697703 alpha-2_30\NN\1740 agonist_31\NN\9613191 ,_32\,\1740 for_33\IN\1740 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 <e2>spasticity</e2>_37\NN\4770535 ._38\.\1740
C023754_D009128 NONE the_0\DT\1740 possible_1\JJ\1740 interaction_2\NN\37396 of_3\IN\1740 <e1>tizanidine</e1>_4\NN\1740 and_5\CC\1740 other_6\JJ\1740 antihypertensive_7\JJ\1740 agents_8\NNS\7347 should_9\MD\1740 be_10\VB\836236 kept_11\VBN\2367363 in_12\IN\13603305 mind_13\NN\23271 when_14\WRB\1740 prescribing_15\NN\1740 therapy_16\NN\657604 to_17\TO\1740 treat_18\VB\2376958 either_19\CC\1740 hypertension_20\NN\14057371 or_21\CC\3541091 <e2>spasticity</e2>_22\NN\4770535 in_23\IN\13603305 such_24\JJ\1740 patients_25\NNS\9898892 ._26\.\1740
8423889
D005473_D009069 CID increase_0\NN\13576355 of_1\IN\1740 <e2>parkinson_2\NN\1740 disability</e2>_3\NN\14547369 after_4\IN\1740 <e1>fluoxetine</e1>_5\NN\4169152 medication_6\NN\3247620 ._7\.\1740
D005473_D009069 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 increased_3\VBN\169651 amount_4\NN\13329641 of_5\IN\1740 <e2>motor_6\NN\3699975 disability</e2>_7\NN\14547369 in_8\IN\13603305 four_9\CD\13741022 patients_10\NNS\9898892 with_11\IN\1740 idiopathic_12\JJ\1740 parkinson_13\NNP\1740 's_14\POS\1740 disease_15\NN\14061805 after_16\IN\1740 exposure_17\NN\5042871 to_18\TO\1740 the_19\DT\1740 antidepressant_20\JJ\1740 <e1>fluoxetine</e1>_21\NN\4169152 ._22\.\1740
D000928_D009069 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 increased_3\VBN\169651 amount_4\NN\13329641 of_5\IN\1740 <e2>motor_6\NN\3699975 disability</e2>_7\NN\14547369 in_8\IN\13603305 four_9\CD\13741022 patients_10\NNS\9898892 with_11\IN\1740 idiopathic_12\JJ\1740 parkinson_13\NNP\1740 's_14\POS\1740 disease_15\NN\14061805 after_16\IN\1740 exposure_17\NN\5042871 to_18\TO\1740 the_19\DT\1740 <e1>antidepressant</e1>_20\JJ\1740 fluoxetine_21\NN\4169152 ._22\.\1740
D000928_D010300 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 increased_3\VBN\169651 amount_4\NN\13329641 of_5\IN\1740 motor_6\NN\3699975 disability_7\NN\14547369 in_8\IN\13603305 four_9\CD\13741022 patients_10\NNS\9898892 with_11\IN\1740 <e2>idiopathic_12\JJ\1740 parkinson_13\NNP\1740 's_14\POS\1740 disease</e2>_15\NN\14061805 after_16\IN\1740 exposure_17\NN\5042871 to_18\TO\1740 the_19\DT\1740 <e1>antidepressant</e1>_20\JJ\1740 fluoxetine_21\NN\4169152 ._22\.\1740
D005473_D010300 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 increased_3\VBN\169651 amount_4\NN\13329641 of_5\IN\1740 motor_6\NN\3699975 disability_7\NN\14547369 in_8\IN\13603305 four_9\CD\13741022 patients_10\NNS\9898892 with_11\IN\1740 <e2>idiopathic_12\JJ\1740 parkinson_13\NNP\1740 's_14\POS\1740 disease</e2>_15\NN\14061805 after_16\IN\1740 exposure_17\NN\5042871 to_18\TO\1740 the_19\DT\1740 antidepressant_20\JJ\1740 <e1>fluoxetine</e1>_21\NN\4169152 ._22\.\1740
D005473_D010300 NONE the_0\DT\1740 possibility_1\NN\5944958 of_2\IN\1740 a_3\DT\13649268 clinically_4\RB\1740 relevant_5\JJ\1740 dopamine-antagonistic_6\JJ\1740 capacity_7\NN\5202497 of_8\IN\1740 <e1>fluoxetine</e1>_9\NN\4169152 in_10\IN\13603305 <e2>parkinson_11\NN\1740 's_12\POS\1740 disease</e2>_13\NN\14061805 patients_14\NNS\9898892 must_15\MD\9367203 be_16\VB\836236 considered_17\VBN\689344 ._18\.\1740
D004298_D010300 NONE the_0\DT\1740 possibility_1\NN\5944958 of_2\IN\1740 a_3\DT\13649268 clinically_4\RB\1740 relevant_5\JJ\1740 <e1>dopamine-antagonistic</e1>_6\JJ\1740 capacity_7\NN\5202497 of_8\IN\1740 fluoxetine_9\NN\4169152 in_10\IN\13603305 <e2>parkinson_11\NN\1740 's_12\POS\1740 disease</e2>_13\NN\14061805 patients_14\NNS\9898892 must_15\MD\9367203 be_16\VB\836236 considered_17\VBN\689344 ._18\.\1740
1420741
D005672_D003424 NONE treatment_0\NN\654885 of_1\IN\1740 <e2>crohn_2\NN\1740 's_3\POS\1740 disease</e2>_4\NN\14061805 with_5\IN\1740 <e1>fusidic_6\JJ\1740 acid</e1>_7\NN\14818238 :_8\:\1740 an_9\DT\6697703 antibiotic_10\NN\2716205 with_11\IN\1740 immunosuppressive_12\JJ\1740 properties_13\NNS\32613 similar_14\JJ\1740 to_15\TO\1740 cyclosporin_16\NN\1740 ._17\.\1740
D005672_D003424 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 need_3\NN\13920835 for_4\IN\1740 the_5\DT\1740 development_6\NN\248977 of_7\IN\1740 new_8\JJ\1740 treatments_9\NNS\654885 for_10\IN\1740 <e2>crohn_11\NN\1740 's_12\POS\1740 disease</e2>_13\NN\14061805 ,_14\,\1740 a_15\DT\13649268 pilot_16\NN\9826204 study_17\NN\635850 was_18\VBD\836236 undertaken_19\VBN\1641914 to_20\TO\1740 estimate_21\VB\637259 the_22\DT\1740 pharmacodynamics_23\NNS\1740 and_24\CC\1740 tolerability_25\NN\1740 of_26\IN\1740 <e1>fusidic_27\JJ\1740 acid</e1>_28\NN\14818238 treatment_29\NN\654885 in_30\IN\13603305 chronic_31\JJ\1740 active_32\JJ\1740 ,_33\,\1740 therapy-resistant_34\JJ\1740 patients_35\NNS\9898892 ._36\.\1740
D005672_D003424 NONE the_0\DT\1740 results_1\NNS\34213 of_2\IN\1740 this_3\DT\1740 pilot_4\NN\9826204 study_5\NN\635850 suggest_6\VBP\1010118 that_7\IN\1740 <e1>fusidic_8\JJ\1740 acid</e1>_9\NN\14818238 may_10\MD\15209706 be_11\VB\836236 of_12\IN\1740 benefit_13\NN\13278375 in_14\IN\13603305 selected_15\VBN\697589 chronic_16\JJ\1740 active_17\JJ\1740 <e2>crohn_18\NN\1740 's_19\POS\1740 disease</e2>_20\NN\14061805 patients_21\NNS\9898892 in_22\IN\13603305 whom_23\WP\1740 conventional_24\JJ\1740 treatment_25\NN\654885 is_26\VBZ\836236 ineffective_27\JJ\1740 ._28\.\1740
D016572_D003424 NONE treatment_0\NN\654885 of_1\IN\1740 <e2>crohn_2\NN\1740 's_3\POS\1740 disease</e2>_4\NN\14061805 with_5\IN\1740 fusidic_6\JJ\1740 acid_7\NN\14818238 :_8\:\1740 an_9\DT\6697703 antibiotic_10\NN\2716205 with_11\IN\1740 immunosuppressive_12\JJ\1740 properties_13\NNS\32613 similar_14\JJ\1740 to_15\TO\1740 <e1>cyclosporin</e1>_16\NN\1740 ._17\.\1740
D005672_D015212 NONE because_0\IN\1740 there_1\EX\27167 seems_2\VBZ\2604760 to_3\TO\1740 exist_4\VB\1740 a_5\DT\13649268 scientific_6\JJ\1740 rationale_7\NN\5793000 for_8\IN\1740 the_9\DT\1740 use_10\NN\407535 of_11\IN\1740 <e1>fusidic_12\JJ\1740 acid</e1>_13\NN\14818238 at_14\IN\14622893 the_15\DT\1740 cytokine_16\NN\14728724 level_17\NN\4916342 in_18\IN\13603305 <e2>inflammatory_19\JJ\1740 bowel_20\NN\5298729 disease</e2>_21\NN\14061805 ,_22\,\1740 we_23\PRP\1740 suggest_24\VBP\1010118 that_25\IN\1740 the_26\DT\1740 role_27\NN\719494 of_28\IN\1740 this_29\DT\1740 treatment_30\NN\654885 should_31\MD\1740 be_32\VB\836236 further_33\RB\1740 investigated_34\VBN\644583 ._35\.\1740
18703024
D006220_D002375 CID no_0\DT\7204911 changes_1\NNS\7283608 in_2\IN\13603305 <e1>haloperidol-induced</e1>_3\JJ\1740 <e2>catalepsy</e2>_4\NN\14023236 or_5\CC\3541091 mk-801-induced_6\JJ\1740 locomotion_7\NN\4773351 were_8\VBD\836236 seen_9\VBN\2106506 following_10\VBG\1835496 pd_11\NN\14625458 ._12\.\1740
D016291_D002375 NONE no_0\DT\7204911 changes_1\NNS\7283608 in_2\IN\13603305 haloperidol-induced_3\JJ\1740 <e2>catalepsy</e2>_4\NN\14023236 or_5\CC\3541091 <e1>mk-801-induced</e1>_6\JJ\1740 locomotion_7\NN\4773351 were_8\VBD\836236 seen_9\VBN\2106506 following_10\VBG\1835496 pd_11\NN\14625458 ._12\.\1740
11679859
D011346_D017109 CID intravenous_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>prochlorperazine</e1>_3\NN\2719750 by_4\IN\1740 15-minute_5\JJ\1740 infusion_6\NN\14589223 versus_7\CC\1740 2-minute_8\JJ\1740 bolus_9\NN\13899404 does_10\VBZ\1640855 not_11\RB\1740 affect_12\VB\126264 the_13\DT\1740 incidence_14\NN\13821570 of_15\IN\1740 <e2>akathisia</e2>_16\NN\1740 :_17\:\1740 a_18\DT\13649268 prospective_19\JJ\1740 ,_20\,\1740 randomized_21\JJ\1740 ,_22\,\1740 controlled_23\VBN\2422663 trial_24\NN\786195 ._25\.\1740
D011346_D017109 CID study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 we_3\PRP\1740 sought_4\VBD\1825237 to_5\TO\1740 compare_6\VB\644583 the_7\DT\1740 rate_8\NN\13815152 of_9\IN\1740 <e2>akathisia</e2>_10\NN\1740 after_11\IN\1740 administration_12\NN\1133281 of_13\IN\1740 intravenous_14\JJ\1740 <e1>prochlorperazine</e1>_15\NN\2719750 as_16\IN\14622893 a_17\DT\13649268 2-minute_18\JJ\1740 bolus_19\NN\13899404 or_20\CC\3541091 15-minute_21\JJ\1740 infusion_22\NN\14589223 ._23\.\1740
D011346_D017109 CID conclusion_0\NN\5837957 :_1\:\1740 a_2\DT\13649268 50_3\CD\13745420 %_4\NN\1740 reduction_5\NN\351485 in_6\IN\13603305 the_7\DT\1740 incidence_8\NN\13821570 of_9\IN\1740 <e2>akathisia</e2>_10\NN\1740 when_11\WRB\1740 <e1>prochlorperazine</e1>_12\NN\2719750 was_13\VBD\836236 administered_14\VBN\2436349 by_15\IN\1740 means_16\NNS\44150 of_17\IN\1740 15-minute_18\JJ\1740 intravenous_19\JJ\1740 infusion_20\NN\14589223 versus_21\CC\1740 a_22\DT\13649268 2-minute_23\JJ\1740 intravenous_24\JJ\1740 push_25\NN\45250 was_26\VBD\836236 not_27\RB\1740 detected_28\VBN\2163746 ._29\.\1740
D011346_D006261 NONE patients_0\NNS\9898892 aged_1\JJ\1740 18_2\CD\13745420 years_3\NNS\15144371 or_4\CC\3541091 older_5\JJR\1740 treated_6\VBN\2376958 with_7\IN\1740 <e1>prochlorperazine</e1>_8\NN\2719750 for_9\IN\1740 <e2>headache</e2>_10\NN\5829480 ,_11\,\1740 nausea_12\NN\14299637 ,_13\,\1740 or_14\CC\3541091 vomiting_15\NN\116687 were_16\VBD\836236 eligible_17\JJ\1740 for_18\IN\1740 inclusion_19\NN\13927383 ._20\.\1740
D011346_D006261 NONE the_0\DT\1740 efficacy_1\NN\5199286 of_2\IN\1740 <e1>prochlorperazine</e1>_3\NN\2719750 in_4\IN\13603305 the_5\DT\1740 treatment_6\NN\654885 of_7\IN\1740 <e2>headache</e2>_8\NN\5829480 and_9\CC\1740 nausea_10\NN\14299637 likewise_11\RB\1740 did_12\VBD\1640855 not_13\RB\1740 appear_14\VB\2604760 to_15\TO\1740 be_16\VB\836236 affected_17\VBN\126264 by_18\IN\1740 the_19\DT\1740 rate_20\NN\13815152 of_21\IN\1740 administration_22\NN\1133281 ,_23\,\1740 although_24\IN\1740 no_25\DT\7204911 formal_26\JJ\1740 statistical_27\JJ\1740 comparisons_28\NNS\635850 were_29\VBD\836236 made_30\VBN\126264 ._31\.\1740
D011346_D009325 NONE patients_0\NNS\9898892 aged_1\JJ\1740 18_2\CD\13745420 years_3\NNS\15144371 or_4\CC\3541091 older_5\JJR\1740 treated_6\VBN\2376958 with_7\IN\1740 <e1>prochlorperazine</e1>_8\NN\2719750 for_9\IN\1740 headache_10\NN\5829480 ,_11\,\1740 <e2>nausea</e2>_12\NN\14299637 ,_13\,\1740 or_14\CC\3541091 vomiting_15\NN\116687 were_16\VBD\836236 eligible_17\JJ\1740 for_18\IN\1740 inclusion_19\NN\13927383 ._20\.\1740
D011346_D009325 NONE the_0\DT\1740 efficacy_1\NN\5199286 of_2\IN\1740 <e1>prochlorperazine</e1>_3\NN\2719750 in_4\IN\13603305 the_5\DT\1740 treatment_6\NN\654885 of_7\IN\1740 headache_8\NN\5829480 and_9\CC\1740 <e2>nausea</e2>_10\NN\14299637 likewise_11\RB\1740 did_12\VBD\1640855 not_13\RB\1740 appear_14\VB\2604760 to_15\TO\1740 be_16\VB\836236 affected_17\VBN\126264 by_18\IN\1740 the_19\DT\1740 rate_20\NN\13815152 of_21\IN\1740 administration_22\NN\1133281 ,_23\,\1740 although_24\IN\1740 no_25\DT\7204911 formal_26\JJ\1740 statistical_27\JJ\1740 comparisons_28\NNS\635850 were_29\VBD\836236 made_30\VBN\126264 ._31\.\1740
D011346_D014839 NONE patients_0\NNS\9898892 aged_1\JJ\1740 18_2\CD\13745420 years_3\NNS\15144371 or_4\CC\3541091 older_5\JJR\1740 treated_6\VBN\2376958 with_7\IN\1740 <e1>prochlorperazine</e1>_8\NN\2719750 for_9\IN\1740 headache_10\NN\5829480 ,_11\,\1740 nausea_12\NN\14299637 ,_13\,\1740 or_14\CC\3541091 <e2>vomiting</e2>_15\NN\116687 were_16\VBD\836236 eligible_17\JJ\1740 for_18\IN\1740 inclusion_19\NN\13927383 ._20\.\1740
3828020
D010665_D002544 CID <e2>cerebral_0\JJ\1740 infarction</e2>_1\NN\14204950 with_2\IN\1740 a_3\DT\13649268 single_4\JJ\1740 oral_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 <e1>phenylpropanolamine</e1>_8\NN\2682038 ._9\.\1740
D010665_D002544 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 young_6\JJ\1740 woman_7\NN\9605289 who_8\WP\8299493 suffered_9\VBD\2110220 a_10\DT\13649268 <e2>cerebral_11\JJ\1740 infarction</e2>_12\NN\14204950 after_13\IN\1740 taking_14\VBG\2367363 a_15\DT\13649268 single_16\JJ\1740 oral_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 <e1>ppa</e1>_20\NN\1740 ._21\.\1740
2396046
D002794_D006528 CID no_0\DT\7204911 hepatic_1\JJ\1740 preneoplastic_2\JJ\1740 nodules_3\NNS\5264913 or_4\CC\3541091 <e2>hepatocellular_5\JJ\1740 carcinomas</e2>_6\NNS\14239918 developed_7\VBN\1753788 in_8\IN\13603305 rats_9\NNS\2329401 fed_10\VBD\1182709 the_11\DT\1740 plain_12\JJ\1740 <e1>choline-supplemented</e1>_13\JJ\1740 diet_14\NN\7560652 ,_15\,\1740 while_16\IN\15122231 one_17\CD\13741022 preneoplastic_18\JJ\1740 nodule_19\NN\5264913 and_20\CC\1740 one_21\CD\13741022 hepatocellular_22\JJ\1740 carcinoma_23\NN\14239918 developed_24\VBD\1753788 in_25\IN\13603305 two_26\CD\13741022 rats_27\NNS\2329401 fed_28\VBD\1182709 the_29\DT\1740 same_30\JJ\1740 diet_31\NN\7560652 containing_32\VBG\2632940 phenobarbital_33\JJ\1740 ._34\.\1740
D002794_D006528 CID no_0\DT\7204911 hepatic_1\JJ\1740 preneoplastic_2\JJ\1740 nodules_3\NNS\5264913 or_4\CC\3541091 hepatocellular_5\JJ\1740 carcinomas_6\NNS\14239918 developed_7\VBN\1753788 in_8\IN\13603305 rats_9\NNS\2329401 fed_10\VBD\1182709 the_11\DT\1740 plain_12\JJ\1740 <e1>choline-supplemented</e1>_13\JJ\1740 diet_14\NN\7560652 ,_15\,\1740 while_16\IN\15122231 one_17\CD\13741022 preneoplastic_18\JJ\1740 nodule_19\NN\5264913 and_20\CC\1740 one_21\CD\13741022 <e2>hepatocellular_22\JJ\1740 carcinoma</e2>_23\NN\14239918 developed_24\VBD\1753788 in_25\IN\13603305 two_26\CD\13741022 rats_27\NNS\2329401 fed_28\VBD\1182709 the_29\DT\1740 same_30\JJ\1740 diet_31\NN\7560652 containing_32\VBG\2632940 phenobarbital_33\JJ\1740 ._34\.\1740
D002794_D006528 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 preneoplastic_3\JJ\1740 nodules_4\NNS\5264913 and_5\CC\1740 of_6\IN\1740 <e2>hepatocellular_7\JJ\1740 carcinomas</e2>_8\NNS\14239918 was_9\VBD\836236 10_10\CD\13745420 %_11\NN\1740 and_12\CC\1740 37_13\CD\1740 %_14\NN\1740 ,_15\,\1740 respectively_16\RB\1740 ,_17\,\1740 in_18\IN\13603305 rats_19\NNS\2329401 fed_20\VBD\1182709 the_21\DT\1740 plain_22\JJ\1740 <e1>choline-devoid</e1>_23\JJ\1740 diet_24\NN\7560652 ,_25\,\1740 and_26\CC\1740 17_27\CD\13745420 %_28\NN\1740 and_29\CC\1740 30_30\CD\13745420 %_31\NN\1740 ,_32\,\1740 in_33\IN\13603305 rats_34\NNS\2329401 fed_35\VBD\1182709 the_36\DT\1740 phenobarbital-containing_37\JJ\1740 choline-devoid_38\JJ\1740 diet_39\NN\7560652 ._40\.\1740
D002794_D006528 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 preneoplastic_3\JJ\1740 nodules_4\NNS\5264913 and_5\CC\1740 of_6\IN\1740 <e2>hepatocellular_7\JJ\1740 carcinomas</e2>_8\NNS\14239918 was_9\VBD\836236 10_10\CD\13745420 %_11\NN\1740 and_12\CC\1740 37_13\CD\1740 %_14\NN\1740 ,_15\,\1740 respectively_16\RB\1740 ,_17\,\1740 in_18\IN\13603305 rats_19\NNS\2329401 fed_20\VBD\1182709 the_21\DT\1740 plain_22\JJ\1740 choline-devoid_23\JJ\1740 diet_24\NN\7560652 ,_25\,\1740 and_26\CC\1740 17_27\CD\13745420 %_28\NN\1740 and_29\CC\1740 30_30\CD\13745420 %_31\NN\1740 ,_32\,\1740 in_33\IN\13603305 rats_34\NNS\2329401 fed_35\VBD\1182709 the_36\DT\1740 phenobarbital-containing_37\JJ\1740 <e1>choline-devoid</e1>_38\JJ\1740 diet_39\NN\7560652 ._40\.\1740
D010634_D006528 NONE no_0\DT\7204911 hepatic_1\JJ\1740 preneoplastic_2\JJ\1740 nodules_3\NNS\5264913 or_4\CC\3541091 <e2>hepatocellular_5\JJ\1740 carcinomas</e2>_6\NNS\14239918 developed_7\VBN\1753788 in_8\IN\13603305 rats_9\NNS\2329401 fed_10\VBD\1182709 the_11\DT\1740 plain_12\JJ\1740 choline-supplemented_13\JJ\1740 diet_14\NN\7560652 ,_15\,\1740 while_16\IN\15122231 one_17\CD\13741022 preneoplastic_18\JJ\1740 nodule_19\NN\5264913 and_20\CC\1740 one_21\CD\13741022 hepatocellular_22\JJ\1740 carcinoma_23\NN\14239918 developed_24\VBD\1753788 in_25\IN\13603305 two_26\CD\13741022 rats_27\NNS\2329401 fed_28\VBD\1182709 the_29\DT\1740 same_30\JJ\1740 diet_31\NN\7560652 containing_32\VBG\2632940 <e1>phenobarbital</e1>_33\JJ\1740 ._34\.\1740
D010634_D006528 NONE no_0\DT\7204911 hepatic_1\JJ\1740 preneoplastic_2\JJ\1740 nodules_3\NNS\5264913 or_4\CC\3541091 hepatocellular_5\JJ\1740 carcinomas_6\NNS\14239918 developed_7\VBN\1753788 in_8\IN\13603305 rats_9\NNS\2329401 fed_10\VBD\1182709 the_11\DT\1740 plain_12\JJ\1740 choline-supplemented_13\JJ\1740 diet_14\NN\7560652 ,_15\,\1740 while_16\IN\15122231 one_17\CD\13741022 preneoplastic_18\JJ\1740 nodule_19\NN\5264913 and_20\CC\1740 one_21\CD\13741022 <e2>hepatocellular_22\JJ\1740 carcinoma</e2>_23\NN\14239918 developed_24\VBD\1753788 in_25\IN\13603305 two_26\CD\13741022 rats_27\NNS\2329401 fed_28\VBD\1182709 the_29\DT\1740 same_30\JJ\1740 diet_31\NN\7560652 containing_32\VBG\2632940 <e1>phenobarbital</e1>_33\JJ\1740 ._34\.\1740
D010634_D006528 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 preneoplastic_3\JJ\1740 nodules_4\NNS\5264913 and_5\CC\1740 of_6\IN\1740 <e2>hepatocellular_7\JJ\1740 carcinomas</e2>_8\NNS\14239918 was_9\VBD\836236 10_10\CD\13745420 %_11\NN\1740 and_12\CC\1740 37_13\CD\1740 %_14\NN\1740 ,_15\,\1740 respectively_16\RB\1740 ,_17\,\1740 in_18\IN\13603305 rats_19\NNS\2329401 fed_20\VBD\1182709 the_21\DT\1740 plain_22\JJ\1740 choline-devoid_23\JJ\1740 diet_24\NN\7560652 ,_25\,\1740 and_26\CC\1740 17_27\CD\13745420 %_28\NN\1740 and_29\CC\1740 30_30\CD\13745420 %_31\NN\1740 ,_32\,\1740 in_33\IN\13603305 rats_34\NNS\2329401 fed_35\VBD\1182709 the_36\DT\1740 <e1>phenobarbital-containing</e1>_37\JJ\1740 choline-devoid_38\JJ\1740 diet_39\NN\7560652 ._40\.\1740
9698967
D008619_D006973 CID an_0\DT\6697703 <e2>increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure</e2>_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 atrial_8\JJ\1740 fibrillation_9\NN\14361664 ,_10\,\1740 agitation_11\NN\14373582 ,_12\,\1740 incomprehensible_13\JJ\1740 shouts_14\NNS\7109847 and_15\CC\1740 loss_16\NN\13252973 of_17\IN\1740 consciousness_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 <e1>mepivacaine</e1>_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 adrenaline_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 dupuytren_54\NN\1740 's_55\POS\1740 contracture_56\NN\369802 ._57\.\1740
D008619_D001281 CID an_0\DT\6697703 increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 <e2>atrial_8\JJ\1740 fibrillation</e2>_9\NN\14361664 ,_10\,\1740 agitation_11\NN\14373582 ,_12\,\1740 incomprehensible_13\JJ\1740 shouts_14\NNS\7109847 and_15\CC\1740 loss_16\NN\13252973 of_17\IN\1740 consciousness_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 <e1>mepivacaine</e1>_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 adrenaline_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 dupuytren_54\NN\1740 's_55\POS\1740 contracture_56\NN\369802 ._57\.\1740
D008619_D011595 NONE an_0\DT\6697703 increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 atrial_8\JJ\1740 fibrillation_9\NN\14361664 ,_10\,\1740 <e2>agitation</e2>_11\NN\14373582 ,_12\,\1740 incomprehensible_13\JJ\1740 shouts_14\NNS\7109847 and_15\CC\1740 loss_16\NN\13252973 of_17\IN\1740 consciousness_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 <e1>mepivacaine</e1>_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 adrenaline_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 dupuytren_54\NN\1740 's_55\POS\1740 contracture_56\NN\369802 ._57\.\1740
D008619_D019954 NONE an_0\DT\6697703 increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 atrial_8\JJ\1740 fibrillation_9\NN\14361664 ,_10\,\1740 agitation_11\NN\14373582 ,_12\,\1740 <e2>incomprehensible_13\JJ\1740 shouts</e2>_14\NNS\7109847 and_15\CC\1740 loss_16\NN\13252973 of_17\IN\1740 consciousness_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 <e1>mepivacaine</e1>_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 adrenaline_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 dupuytren_54\NN\1740 's_55\POS\1740 contracture_56\NN\369802 ._57\.\1740
D008619_D014474 NONE an_0\DT\6697703 increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 atrial_8\JJ\1740 fibrillation_9\NN\14361664 ,_10\,\1740 agitation_11\NN\14373582 ,_12\,\1740 incomprehensible_13\JJ\1740 shouts_14\NNS\7109847 and_15\CC\1740 <e2>loss_16\NN\13252973 of_17\IN\1740 consciousness</e2>_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 <e1>mepivacaine</e1>_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 adrenaline_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 dupuytren_54\NN\1740 's_55\POS\1740 contracture_56\NN\369802 ._57\.\1740
D008619_D004387 NONE an_0\DT\6697703 increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 atrial_8\JJ\1740 fibrillation_9\NN\14361664 ,_10\,\1740 agitation_11\NN\14373582 ,_12\,\1740 incomprehensible_13\JJ\1740 shouts_14\NNS\7109847 and_15\CC\1740 loss_16\NN\13252973 of_17\IN\1740 consciousness_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 <e1>mepivacaine</e1>_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 adrenaline_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 <e2>dupuytren_54\NN\1740 's_55\POS\1740 contracture</e2>_56\NN\369802 ._57\.\1740
D004837_D006973 CID an_0\DT\6697703 <e2>increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure</e2>_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 atrial_8\JJ\1740 fibrillation_9\NN\14361664 ,_10\,\1740 agitation_11\NN\14373582 ,_12\,\1740 incomprehensible_13\JJ\1740 shouts_14\NNS\7109847 and_15\CC\1740 loss_16\NN\13252973 of_17\IN\1740 consciousness_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 mepivacaine_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 <e1>adrenaline</e1>_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 dupuytren_54\NN\1740 's_55\POS\1740 contracture_56\NN\369802 ._57\.\1740
D004837_D001281 CID an_0\DT\6697703 increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 <e2>atrial_8\JJ\1740 fibrillation</e2>_9\NN\14361664 ,_10\,\1740 agitation_11\NN\14373582 ,_12\,\1740 incomprehensible_13\JJ\1740 shouts_14\NNS\7109847 and_15\CC\1740 loss_16\NN\13252973 of_17\IN\1740 consciousness_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 mepivacaine_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 <e1>adrenaline</e1>_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 dupuytren_54\NN\1740 's_55\POS\1740 contracture_56\NN\369802 ._57\.\1740
D004837_D011595 NONE an_0\DT\6697703 increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 atrial_8\JJ\1740 fibrillation_9\NN\14361664 ,_10\,\1740 <e2>agitation</e2>_11\NN\14373582 ,_12\,\1740 incomprehensible_13\JJ\1740 shouts_14\NNS\7109847 and_15\CC\1740 loss_16\NN\13252973 of_17\IN\1740 consciousness_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 mepivacaine_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 <e1>adrenaline</e1>_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 dupuytren_54\NN\1740 's_55\POS\1740 contracture_56\NN\369802 ._57\.\1740
D004837_D019954 NONE an_0\DT\6697703 increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 atrial_8\JJ\1740 fibrillation_9\NN\14361664 ,_10\,\1740 agitation_11\NN\14373582 ,_12\,\1740 <e2>incomprehensible_13\JJ\1740 shouts</e2>_14\NNS\7109847 and_15\CC\1740 loss_16\NN\13252973 of_17\IN\1740 consciousness_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 mepivacaine_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 <e1>adrenaline</e1>_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 dupuytren_54\NN\1740 's_55\POS\1740 contracture_56\NN\369802 ._57\.\1740
D004837_D014474 NONE an_0\DT\6697703 increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 atrial_8\JJ\1740 fibrillation_9\NN\14361664 ,_10\,\1740 agitation_11\NN\14373582 ,_12\,\1740 incomprehensible_13\JJ\1740 shouts_14\NNS\7109847 and_15\CC\1740 <e2>loss_16\NN\13252973 of_17\IN\1740 consciousness</e2>_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 mepivacaine_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 <e1>adrenaline</e1>_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 dupuytren_54\NN\1740 's_55\POS\1740 contracture_56\NN\369802 ._57\.\1740
D004837_D004387 NONE an_0\DT\6697703 increase_1\NN\13576355 in_2\IN\13603305 blood_3\NN\5397468 pressure_4\NN\11419404 ,_5\,\1740 accompanied_6\VBN\1835496 by_7\IN\1740 atrial_8\JJ\1740 fibrillation_9\NN\14361664 ,_10\,\1740 agitation_11\NN\14373582 ,_12\,\1740 incomprehensible_13\JJ\1740 shouts_14\NNS\7109847 and_15\CC\1740 loss_16\NN\13252973 of_17\IN\1740 consciousness_18\NN\5669934 ,_19\,\1740 was_20\VBD\836236 observed_21\VBN\2163746 in_22\IN\13603305 an_23\DT\6697703 elderly_24\JJ\1740 ,_25\,\1740 asa_26\NN\1740 classification_27\NN\1012360 group_28\NN\2137 ii_29\CD\13741022 ,_30\,\1740 cardiovascularly_31\RB\1740 medicated_32\VBD\497705 male_33\JJ\1740 ,_34\,\1740 12_35\CD\13745420 min_36\NN\15154774 after_37\IN\1740 performance_38\NN\6619065 of_39\IN\1740 axillary_40\JJ\1740 block_41\NN\21939 with_42\IN\1740 mepivacaine_43\NN\1740 850_44\CD\1740 mg_45\NN\13717155 containing_46\VBG\2632940 <e1>adrenaline</e1>_47\NN\14807929 0.225_48\CD\1740 mg_49\NN\13717155 ,_50\,\1740 for_51\IN\1740 correction_52\NN\248977 of_53\IN\1740 <e2>dupuytren_54\NN\1740 's_55\POS\1740 contracture</e2>_56\NN\369802 ._57\.\1740
1616457
D010424_D000647 CID learning_0\NN\5701944 of_1\IN\1740 rats_2\NNS\2329401 under_3\IN\1740 <e2>amnesia</e2>_4\NN\5669934 caused_5\VBN\1617192 by_6\IN\1740 <e1>pentobarbital</e1>_7\JJ\1740 ._8\.\1740
D010424_D000647 CID dissociated_0\VBN\2431320 learning_1\NN\5701944 of_2\IN\1740 rats_3\NNS\2329401 in_4\IN\13603305 the_5\DT\1740 normal_6\JJ\1740 state_7\NN\8491826 and_8\CC\1740 the_9\DT\1740 state_10\NN\8491826 of_11\IN\1740 <e2>amnesia</e2>_12\NN\5669934 produced_13\VBN\1617192 by_14\IN\1740 <e1>pentobarbital</e1>_15\JJ\1740 (_16\-LRB-\1740 15_17\CD\13745420 mg/kg_18\NN\1740 ,_19\,\1740 ip_20\FW\5999797 )_21\-RRB-\1740 was_22\VBD\836236 carried_23\VBN\1850315 out_24\RP\1740 ._25\.\1740
12589964
D004317_D009202 CID evaluation_0\NN\874067 of_1\IN\1740 cardiac_2\JJ\1740 troponin_3\NN\1740 i_4\CD\14622893 and_5\CC\1740 t_6\NN\14999913 levels_7\NNS\4916342 as_8\IN\14622893 markers_9\NNS\21939 of_10\IN\1740 <e2>myocardial_11\JJ\1740 damage</e2>_12\NN\7296428 in_13\IN\13603305 <e1>doxorubicin-induced</e1>_14\JJ\1740 cardiomyopathy_15\JJ\1740 rats_16\NNS\2329401 ,_17\,\1740 and_18\CC\1740 their_19\PRP$\1740 relationship_20\NN\31921 with_21\IN\1740 echocardiographic_22\JJ\1740 and_23\CC\1740 histological_24\JJ\1740 findings_25\NNS\7951464 ._26\.\1740
D004317_D009202 CID evaluation_0\NN\874067 of_1\IN\1740 cardiac_2\JJ\1740 troponin_3\NN\1740 i_4\CD\14622893 and_5\CC\1740 t_6\NN\14999913 levels_7\NNS\4916342 as_8\IN\14622893 markers_9\NNS\21939 of_10\IN\1740 myocardial_11\JJ\1740 damage_12\NN\7296428 in_13\IN\13603305 <e1>doxorubicin-induced</e1>_14\JJ\1740 <e2>cardiomyopathy</e2>_15\JJ\1740 rats_16\NNS\2329401 ,_17\,\1740 and_18\CC\1740 their_19\PRP$\1740 relationship_20\NN\31921 with_21\IN\1740 echocardiographic_22\JJ\1740 and_23\CC\1740 histological_24\JJ\1740 findings_25\NNS\7951464 ._26\.\1740
D004317_D009202 CID we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 diagnostic_3\JJ\1740 value_4\NN\5856066 of_5\IN\1740 ctni_6\NN\1740 and_7\CC\1740 ctnt_8\NN\1740 for_9\IN\1740 the_10\DT\1740 diagnosis_11\NN\152018 of_12\IN\1740 <e2>myocardial_13\JJ\1740 damage</e2>_14\NN\7296428 in_15\IN\13603305 a_16\DT\13649268 rat_17\NN\2329401 model_18\NN\5888929 of_19\IN\1740 <e1>doxorubicin</e1>_20\NN\2716866 (dox)-induced_21\NN\1740 cardiomyopathy_22\JJ\1740 ,_23\,\1740 and_24\CC\1740 we_25\PRP\1740 examined_26\VBD\789138 the_27\DT\1740 relationship_28\NN\31921 between_29\IN\1740 serial_30\JJ\1740 ctni_31\NN\1740 and_32\CC\1740 ctnt_33\NN\1740 with_34\IN\1740 the_35\DT\1740 development_36\NN\248977 of_37\IN\1740 cardiac_38\JJ\1740 disorders_39\NNS\14034177 monitored_40\VBN\2169352 by_41\IN\1740 echocardiography_42\NN\177127 and_43\CC\1740 histological_44\JJ\1740 examinations_45\NNS\633864 in_46\IN\13603305 this_47\DT\1740 model_48\NN\5888929 ._49\.\1740
D004317_D009202 CID we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 diagnostic_3\JJ\1740 value_4\NN\5856066 of_5\IN\1740 ctni_6\NN\1740 and_7\CC\1740 ctnt_8\NN\1740 for_9\IN\1740 the_10\DT\1740 diagnosis_11\NN\152018 of_12\IN\1740 myocardial_13\JJ\1740 damage_14\NN\7296428 in_15\IN\13603305 a_16\DT\13649268 rat_17\NN\2329401 model_18\NN\5888929 of_19\IN\1740 <e1>doxorubicin</e1>_20\NN\2716866 (dox)-induced_21\NN\1740 <e2>cardiomyopathy</e2>_22\JJ\1740 ,_23\,\1740 and_24\CC\1740 we_25\PRP\1740 examined_26\VBD\789138 the_27\DT\1740 relationship_28\NN\31921 between_29\IN\1740 serial_30\JJ\1740 ctni_31\NN\1740 and_32\CC\1740 ctnt_33\NN\1740 with_34\IN\1740 the_35\DT\1740 development_36\NN\248977 of_37\IN\1740 cardiac_38\JJ\1740 disorders_39\NNS\14034177 monitored_40\VBN\2169352 by_41\IN\1740 echocardiography_42\NN\177127 and_43\CC\1740 histological_44\JJ\1740 examinations_45\NNS\633864 in_46\IN\13603305 this_47\DT\1740 model_48\NN\5888929 ._49\.\1740
D004317_D009202 CID we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 diagnostic_3\JJ\1740 value_4\NN\5856066 of_5\IN\1740 ctni_6\NN\1740 and_7\CC\1740 ctnt_8\NN\1740 for_9\IN\1740 the_10\DT\1740 diagnosis_11\NN\152018 of_12\IN\1740 <e2>myocardial_13\JJ\1740 damage</e2>_14\NN\7296428 in_15\IN\13603305 a_16\DT\13649268 rat_17\NN\2329401 model_18\NN\5888929 of_19\IN\1740 doxorubicin_20\NN\2716866 <e1>(dox)-induced</e1>_21\NN\1740 cardiomyopathy_22\JJ\1740 ,_23\,\1740 and_24\CC\1740 we_25\PRP\1740 examined_26\VBD\789138 the_27\DT\1740 relationship_28\NN\31921 between_29\IN\1740 serial_30\JJ\1740 ctni_31\NN\1740 and_32\CC\1740 ctnt_33\NN\1740 with_34\IN\1740 the_35\DT\1740 development_36\NN\248977 of_37\IN\1740 cardiac_38\JJ\1740 disorders_39\NNS\14034177 monitored_40\VBN\2169352 by_41\IN\1740 echocardiography_42\NN\177127 and_43\CC\1740 histological_44\JJ\1740 examinations_45\NNS\633864 in_46\IN\13603305 this_47\DT\1740 model_48\NN\5888929 ._49\.\1740
D004317_D009202 CID we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 diagnostic_3\JJ\1740 value_4\NN\5856066 of_5\IN\1740 ctni_6\NN\1740 and_7\CC\1740 ctnt_8\NN\1740 for_9\IN\1740 the_10\DT\1740 diagnosis_11\NN\152018 of_12\IN\1740 myocardial_13\JJ\1740 damage_14\NN\7296428 in_15\IN\13603305 a_16\DT\13649268 rat_17\NN\2329401 model_18\NN\5888929 of_19\IN\1740 doxorubicin_20\NN\2716866 <e1>(dox)-induced</e1>_21\NN\1740 <e2>cardiomyopathy</e2>_22\JJ\1740 ,_23\,\1740 and_24\CC\1740 we_25\PRP\1740 examined_26\VBD\789138 the_27\DT\1740 relationship_28\NN\31921 between_29\IN\1740 serial_30\JJ\1740 ctni_31\NN\1740 and_32\CC\1740 ctnt_33\NN\1740 with_34\IN\1740 the_35\DT\1740 development_36\NN\248977 of_37\IN\1740 cardiac_38\JJ\1740 disorders_39\NNS\14034177 monitored_40\VBN\2169352 by_41\IN\1740 echocardiography_42\NN\177127 and_43\CC\1740 histological_44\JJ\1740 examinations_45\NNS\633864 in_46\IN\13603305 this_47\DT\1740 model_48\NN\5888929 ._49\.\1740
D004317_D009202 CID conclusions_0\NNS\5837957 :_1\:\1740 among_2\IN\1740 markers_3\NNS\21939 of_4\IN\1740 ischemic_5\JJ\1740 injury_6\NN\14052046 after_7\IN\1740 <e1>dox</e1>_8\NN\1740 in_9\IN\13603305 rats_10\NNS\2329401 ,_11\,\1740 ctnt_12\NN\1740 showed_13\VBD\2137132 the_14\DT\1740 greatest_15\JJS\1740 ability_16\NN\4723816 to_17\TO\1740 detect_18\VB\2163746 <e2>myocardial_19\JJ\1740 damage</e2>_20\NN\7296428 assessed_21\VBN\670261 by_22\IN\1740 echocardiographic_23\JJ\1740 detection_24\NN\5708432 and_25\CC\1740 histological_26\JJ\1740 changes_27\NNS\7283608 ._28\.\1740
D004317_D006331 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 diagnostic_3\JJ\1740 value_4\NN\5856066 of_5\IN\1740 ctni_6\NN\1740 and_7\CC\1740 ctnt_8\NN\1740 for_9\IN\1740 the_10\DT\1740 diagnosis_11\NN\152018 of_12\IN\1740 myocardial_13\JJ\1740 damage_14\NN\7296428 in_15\IN\13603305 a_16\DT\13649268 rat_17\NN\2329401 model_18\NN\5888929 of_19\IN\1740 <e1>doxorubicin</e1>_20\NN\2716866 (dox)-induced_21\NN\1740 cardiomyopathy_22\JJ\1740 ,_23\,\1740 and_24\CC\1740 we_25\PRP\1740 examined_26\VBD\789138 the_27\DT\1740 relationship_28\NN\31921 between_29\IN\1740 serial_30\JJ\1740 ctni_31\NN\1740 and_32\CC\1740 ctnt_33\NN\1740 with_34\IN\1740 the_35\DT\1740 development_36\NN\248977 of_37\IN\1740 <e2>cardiac_38\JJ\1740 disorders</e2>_39\NNS\14034177 monitored_40\VBN\2169352 by_41\IN\1740 echocardiography_42\NN\177127 and_43\CC\1740 histological_44\JJ\1740 examinations_45\NNS\633864 in_46\IN\13603305 this_47\DT\1740 model_48\NN\5888929 ._49\.\1740
D004317_D006331 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 diagnostic_3\JJ\1740 value_4\NN\5856066 of_5\IN\1740 ctni_6\NN\1740 and_7\CC\1740 ctnt_8\NN\1740 for_9\IN\1740 the_10\DT\1740 diagnosis_11\NN\152018 of_12\IN\1740 myocardial_13\JJ\1740 damage_14\NN\7296428 in_15\IN\13603305 a_16\DT\13649268 rat_17\NN\2329401 model_18\NN\5888929 of_19\IN\1740 doxorubicin_20\NN\2716866 <e1>(dox)-induced</e1>_21\NN\1740 cardiomyopathy_22\JJ\1740 ,_23\,\1740 and_24\CC\1740 we_25\PRP\1740 examined_26\VBD\789138 the_27\DT\1740 relationship_28\NN\31921 between_29\IN\1740 serial_30\JJ\1740 ctni_31\NN\1740 and_32\CC\1740 ctnt_33\NN\1740 with_34\IN\1740 the_35\DT\1740 development_36\NN\248977 of_37\IN\1740 <e2>cardiac_38\JJ\1740 disorders</e2>_39\NNS\14034177 monitored_40\VBN\2169352 by_41\IN\1740 echocardiography_42\NN\177127 and_43\CC\1740 histological_44\JJ\1740 examinations_45\NNS\633864 in_46\IN\13603305 this_47\DT\1740 model_48\NN\5888929 ._49\.\1740
D004317_D064420 NONE results_0\NNS\34213 :_1\:\1740 eighteen_2\CD\13745420 of_3\IN\1740 the_4\DT\1740 <e1>dox</e1>_5\NN\1740 rats_6\NNS\2329401 died_7\VBD\146138 prematurely_8\RB\1740 of_9\IN\1740 general_10\JJ\1740 <e2>toxicity</e2>_11\NN\13576101 during_12\IN\1740 the_13\DT\1740 9-week_14\JJ\1740 period_15\NN\13575869 ._16\.\1740
D004317_D005355 NONE histological_0\JJ\1740 evaluation_1\NN\874067 of_2\IN\1740 hearts_3\NNS\496167 from_4\IN\1740 all_5\DT\1740 rats_6\NNS\2329401 given_7\VBN\2327200 <e1>dox</e1>_8\NN\1740 revealed_9\VBD\2137132 significant_10\JJ\1740 slight_11\JJ\1740 degrees_12\NNS\4916342 of_13\IN\1740 perivascular_14\JJ\1740 and_15\CC\1740 interstitial_16\JJ\1740 <e2>fibrosis</e2>_17\NN\14204950 ._18\.\1740
D004317_D017202 NONE conclusions_0\NNS\5837957 :_1\:\1740 among_2\IN\1740 markers_3\NNS\21939 of_4\IN\1740 <e2>ischemic_5\JJ\1740 injury</e2>_6\NN\14052046 after_7\IN\1740 <e1>dox</e1>_8\NN\1740 in_9\IN\13603305 rats_10\NNS\2329401 ,_11\,\1740 ctnt_12\NN\1740 showed_13\VBD\2137132 the_14\DT\1740 greatest_15\JJS\1740 ability_16\NN\4723816 to_17\TO\1740 detect_18\VB\2163746 myocardial_19\JJ\1740 damage_20\NN\7296428 assessed_21\VBN\670261 by_22\IN\1740 echocardiographic_23\JJ\1740 detection_24\NN\5708432 and_25\CC\1740 histological_26\JJ\1740 changes_27\NNS\7283608 ._28\.\1740
D004317_D066126 NONE although_0\IN\1740 there_1\EX\27167 was_2\VBD\836236 a_3\DT\13649268 discrepancy_4\NN\4748836 between_5\IN\1740 the_6\DT\1740 amount_7\NN\13329641 of_8\IN\1740 ctni_9\NN\1740 and_10\CC\1740 ctnt_11\NN\1740 after_12\IN\1740 <e1>dox</e1>_13\NN\1740 ,_14\,\1740 probably_15\RB\1740 due_16\JJ\1740 to_17\TO\1740 heterogeneity_18\NN\4750940 in_19\IN\13603305 cross-reactivities_20\NNS\1740 of_21\IN\1740 mabs_22\NNS\1740 to_23\TO\1740 various_24\JJ\1740 ctni_25\NN\1740 and_26\CC\1740 ctnt_27\NN\1740 forms_28\NNS\6286395 ,_29\,\1740 it_30\PRP\6125041 is_31\VBZ\836236 likely_32\JJ\1740 that_33\IN\1740 ctnt_34\NN\1740 in_35\IN\13603305 rats_36\NNS\2329401 after_37\IN\1740 dox_38\NN\1740 indicates_39\VBZ\952524 cell_40\NN\3080309 damage_41\NN\7296428 determined_42\VBN\1645601 by_43\IN\1740 the_44\DT\1740 magnitude_45\NN\4916342 of_46\IN\1740 injury_47\NN\14052046 induced_48\VBN\1627355 and_49\CC\1740 that_50\IN\1740 ctnt_51\NN\1740 should_52\MD\1740 be_53\VB\836236 a_54\DT\13649268 useful_55\JJ\1740 marker_56\NN\21939 for_57\IN\1740 the_58\DT\1740 prediction_59\NN\5772356 of_60\IN\1740 experimentally_61\RB\1740 induced_62\VBN\1627355 <e2>cardiotoxicity</e2>_63\NN\1740 and_64\CC\1740 possibly_65\RB\1740 for_66\IN\1740 cardioprotective_67\JJ\1740 experiments_68\NNS\641820 ._69\.\1740
D004317_D066126 NONE although_0\IN\1740 there_1\EX\27167 was_2\VBD\836236 a_3\DT\13649268 discrepancy_4\NN\4748836 between_5\IN\1740 the_6\DT\1740 amount_7\NN\13329641 of_8\IN\1740 ctni_9\NN\1740 and_10\CC\1740 ctnt_11\NN\1740 after_12\IN\1740 dox_13\NN\1740 ,_14\,\1740 probably_15\RB\1740 due_16\JJ\1740 to_17\TO\1740 heterogeneity_18\NN\4750940 in_19\IN\13603305 cross-reactivities_20\NNS\1740 of_21\IN\1740 mabs_22\NNS\1740 to_23\TO\1740 various_24\JJ\1740 ctni_25\NN\1740 and_26\CC\1740 ctnt_27\NN\1740 forms_28\NNS\6286395 ,_29\,\1740 it_30\PRP\6125041 is_31\VBZ\836236 likely_32\JJ\1740 that_33\IN\1740 ctnt_34\NN\1740 in_35\IN\13603305 rats_36\NNS\2329401 after_37\IN\1740 <e1>dox</e1>_38\NN\1740 indicates_39\VBZ\952524 cell_40\NN\3080309 damage_41\NN\7296428 determined_42\VBN\1645601 by_43\IN\1740 the_44\DT\1740 magnitude_45\NN\4916342 of_46\IN\1740 injury_47\NN\14052046 induced_48\VBN\1627355 and_49\CC\1740 that_50\IN\1740 ctnt_51\NN\1740 should_52\MD\1740 be_53\VB\836236 a_54\DT\13649268 useful_55\JJ\1740 marker_56\NN\21939 for_57\IN\1740 the_58\DT\1740 prediction_59\NN\5772356 of_60\IN\1740 experimentally_61\RB\1740 induced_62\VBN\1627355 <e2>cardiotoxicity</e2>_63\NN\1740 and_64\CC\1740 possibly_65\RB\1740 for_66\IN\1740 cardioprotective_67\JJ\1740 experiments_68\NNS\641820 ._69\.\1740
11379838
D000928_D001714 CID <e1>antidepressant-induced</e1>_0\JJ\1740 <e2>mania</e2>_1\NN\9180259 in_2\IN\13603305 bipolar_3\JJ\1740 patients_4\NNS\9898892 :_5\:\1740 identification_6\NN\151497 of_7\IN\1740 risk_8\NN\14541044 factors_9\NNS\7326557 ._10\.\1740
D000928_D001714 CID <e1>antidepressant-induced</e1>_0\JJ\1740 mania_1\NN\9180259 in_2\IN\13603305 <e2>bipolar</e2>_3\JJ\1740 patients_4\NNS\9898892 :_5\:\1740 identification_6\NN\151497 of_7\IN\1740 risk_8\NN\14541044 factors_9\NNS\7326557 ._10\.\1740
D000928_D001714 CID background_0\NN\4921011 :_1\:\1740 concerns_2\NNS\5682950 about_3\IN\1740 possible_4\JJ\1740 risks_5\NNS\14541044 of_6\IN\1740 switching_7\NN\191142 to_8\TO\1740 <e2>mania</e2>_9\NN\9180259 associated_10\VBN\628491 with_11\IN\1740 <e1>antidepressants</e1>_12\NNS\3740161 continue_13\VBP\2367363 to_14\TO\1740 interfere_15\VB\2451370 with_16\IN\1740 the_17\DT\1740 establishment_18\NN\235435 of_19\IN\1740 an_20\DT\6697703 optimal_21\JJ\1740 treatment_22\NN\654885 paradigm_23\NN\13803782 for_24\IN\1740 bipolar_25\JJ\1740 depression_26\NN\14373582 ._27\.\1740
D000928_D001714 CID background_0\NN\4921011 :_1\:\1740 concerns_2\NNS\5682950 about_3\IN\1740 possible_4\JJ\1740 risks_5\NNS\14541044 of_6\IN\1740 switching_7\NN\191142 to_8\TO\1740 mania_9\NN\9180259 associated_10\VBN\628491 with_11\IN\1740 <e1>antidepressants</e1>_12\NNS\3740161 continue_13\VBP\2367363 to_14\TO\1740 interfere_15\VB\2451370 with_16\IN\1740 the_17\DT\1740 establishment_18\NN\235435 of_19\IN\1740 an_20\DT\6697703 optimal_21\JJ\1740 treatment_22\NN\654885 paradigm_23\NN\13803782 for_24\IN\1740 <e2>bipolar_25\JJ\1740 depression</e2>_26\NN\14373582 ._27\.\1740
D000928_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 <e2>manic</e2>_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 <e1>antidepressant</e1>_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D000928_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 <e2>hypomanic</e2>_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 <e1>antidepressant</e1>_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D000928_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 <e2>dsm-iv_25\NN\1740 bipolar_26\NN\1740 i</e2>_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 <e1>antidepressant</e1>_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D000928_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 <e2>bipolar_29\NN\1740 ii</e2>_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 <e1>antidepressant</e1>_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D000928_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 <e2>manic</e2>_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 <e1>antidepressant</e1>_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D000928_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 <e2>manic</e2>_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 <e1>antidepressant</e1>_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D000928_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 <e2>hypomanic</e2>_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 <e1>antidepressant</e1>_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D000928_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 <e2>dsm-iv_25\NN\1740 bipolar_26\NN\1740 i</e2>_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 <e1>antidepressant</e1>_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D000928_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 <e2>bipolar_29\NN\1740 ii</e2>_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 <e1>antidepressant</e1>_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D000928_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 <e2>manic</e2>_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 <e1>antidepressant</e1>_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D017367_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 <e2>manic</e2>_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 <e1>serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors</e1>_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D017367_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 <e2>hypomanic</e2>_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 <e1>serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors</e1>_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D017367_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 <e2>dsm-iv_25\NN\1740 bipolar_26\NN\1740 i</e2>_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 <e1>serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors</e1>_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D017367_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 <e2>bipolar_29\NN\1740 ii</e2>_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 <e1>serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors</e1>_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D017367_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 <e2>manic</e2>_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 <e1>serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors</e1>_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D017367_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 <e2>manic</e2>_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 <e1>ssris</e1>_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D017367_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 <e2>hypomanic</e2>_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 <e1>ssris</e1>_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D017367_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 <e2>dsm-iv_25\NN\1740 bipolar_26\NN\1740 i</e2>_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 <e1>ssris</e1>_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D017367_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 <e2>bipolar_29\NN\1740 ii</e2>_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 <e1>ssris</e1>_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D017367_D001714 CID patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 <e2>manic</e2>_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 <e1>ssris</e1>_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 lithium_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D017367_D001714 CID results_0\NNS\34213 :_1\:\1740 switches_2\NNS\3096960 to_3\TO\1740 <e2>hypomania</e2>_4\NN\1740 or_5\CC\3541091 mania_6\NN\9180259 occurred_7\VBD\2623529 in_8\IN\13603305 27_9\CD\13745420 %_10\NN\1740 of_11\IN\1740 all_12\DT\1740 patients_13\NNS\9898892 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 12_17\CD\13745420 )_18\-RRB-\1740 (_19\-LRB-\1740 and_20\CC\1740 in_21\IN\13603305 24_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 the_25\DT\1740 subgroup_26\NN\31264 of_27\IN\1740 patients_28\NNS\9898892 treated_29\VBN\2376958 with_30\IN\1740 <e1>ssris</e1>_31\NN\2718811 [_32\-LRB-\1740 8/33_33\CD\1740 ]_34\-RRB-\1740 )_35\-RRB-\1740 ;_36\:\1740 16_37\CD\13745420 %_38\NN\1740 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 7_42\CD\13741022 )_43\-RRB-\1740 experienced_44\JJ\1740 manic_45\JJ\1740 episodes_46\NNS\7283608 ,_47\,\1740 and_48\CC\1740 11_49\CD\13745420 %_50\NN\1740 (_51\-LRB-\1740 n_52\NN\14622893 =_53\JJ\1740 5_54\CD\13741022 )_55\-RRB-\1740 experienced_56\JJ\1740 hypomanic_57\JJ\1740 episodes_58\NNS\7283608 ._59\.\1740
D017367_D001714 CID results_0\NNS\34213 :_1\:\1740 switches_2\NNS\3096960 to_3\TO\1740 hypomania_4\NN\1740 or_5\CC\3541091 <e2>mania</e2>_6\NN\9180259 occurred_7\VBD\2623529 in_8\IN\13603305 27_9\CD\13745420 %_10\NN\1740 of_11\IN\1740 all_12\DT\1740 patients_13\NNS\9898892 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 12_17\CD\13745420 )_18\-RRB-\1740 (_19\-LRB-\1740 and_20\CC\1740 in_21\IN\13603305 24_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 the_25\DT\1740 subgroup_26\NN\31264 of_27\IN\1740 patients_28\NNS\9898892 treated_29\VBN\2376958 with_30\IN\1740 <e1>ssris</e1>_31\NN\2718811 [_32\-LRB-\1740 8/33_33\CD\1740 ]_34\-RRB-\1740 )_35\-RRB-\1740 ;_36\:\1740 16_37\CD\13745420 %_38\NN\1740 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 7_42\CD\13741022 )_43\-RRB-\1740 experienced_44\JJ\1740 manic_45\JJ\1740 episodes_46\NNS\7283608 ,_47\,\1740 and_48\CC\1740 11_49\CD\13745420 %_50\NN\1740 (_51\-LRB-\1740 n_52\NN\14622893 =_53\JJ\1740 5_54\CD\13741022 )_55\-RRB-\1740 experienced_56\JJ\1740 hypomanic_57\JJ\1740 episodes_58\NNS\7283608 ._59\.\1740
D017367_D001714 CID results_0\NNS\34213 :_1\:\1740 switches_2\NNS\3096960 to_3\TO\1740 hypomania_4\NN\1740 or_5\CC\3541091 mania_6\NN\9180259 occurred_7\VBD\2623529 in_8\IN\13603305 27_9\CD\13745420 %_10\NN\1740 of_11\IN\1740 all_12\DT\1740 patients_13\NNS\9898892 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 12_17\CD\13745420 )_18\-RRB-\1740 (_19\-LRB-\1740 and_20\CC\1740 in_21\IN\13603305 24_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 the_25\DT\1740 subgroup_26\NN\31264 of_27\IN\1740 patients_28\NNS\9898892 treated_29\VBN\2376958 with_30\IN\1740 <e1>ssris</e1>_31\NN\2718811 [_32\-LRB-\1740 8/33_33\CD\1740 ]_34\-RRB-\1740 )_35\-RRB-\1740 ;_36\:\1740 16_37\CD\13745420 %_38\NN\1740 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 7_42\CD\13741022 )_43\-RRB-\1740 experienced_44\JJ\1740 <e2>manic</e2>_45\JJ\1740 episodes_46\NNS\7283608 ,_47\,\1740 and_48\CC\1740 11_49\CD\13745420 %_50\NN\1740 (_51\-LRB-\1740 n_52\NN\14622893 =_53\JJ\1740 5_54\CD\13741022 )_55\-RRB-\1740 experienced_56\JJ\1740 hypomanic_57\JJ\1740 episodes_58\NNS\7283608 ._59\.\1740
D017367_D001714 CID results_0\NNS\34213 :_1\:\1740 switches_2\NNS\3096960 to_3\TO\1740 hypomania_4\NN\1740 or_5\CC\3541091 mania_6\NN\9180259 occurred_7\VBD\2623529 in_8\IN\13603305 27_9\CD\13745420 %_10\NN\1740 of_11\IN\1740 all_12\DT\1740 patients_13\NNS\9898892 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 12_17\CD\13745420 )_18\-RRB-\1740 (_19\-LRB-\1740 and_20\CC\1740 in_21\IN\13603305 24_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 the_25\DT\1740 subgroup_26\NN\31264 of_27\IN\1740 patients_28\NNS\9898892 treated_29\VBN\2376958 with_30\IN\1740 <e1>ssris</e1>_31\NN\2718811 [_32\-LRB-\1740 8/33_33\CD\1740 ]_34\-RRB-\1740 )_35\-RRB-\1740 ;_36\:\1740 16_37\CD\13745420 %_38\NN\1740 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 7_42\CD\13741022 )_43\-RRB-\1740 experienced_44\JJ\1740 manic_45\JJ\1740 episodes_46\NNS\7283608 ,_47\,\1740 and_48\CC\1740 11_49\CD\13745420 %_50\NN\1740 (_51\-LRB-\1740 n_52\NN\14622893 =_53\JJ\1740 5_54\CD\13741022 )_55\-RRB-\1740 experienced_56\JJ\1740 <e2>hypomanic</e2>_57\JJ\1740 episodes_58\NNS\7283608 ._59\.\1740
D008094_D001714 NONE patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 <e2>manic</e2>_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 <e1>lithium</e1>_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D008094_D001714 NONE patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 <e2>hypomanic</e2>_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 <e1>lithium</e1>_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D008094_D001714 NONE patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 <e2>dsm-iv_25\NN\1740 bipolar_26\NN\1740 i</e2>_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 <e1>lithium</e1>_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D008094_D001714 NONE patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 <e2>bipolar_29\NN\1740 ii</e2>_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 manic_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 <e1>lithium</e1>_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
D008094_D001714 NONE patients_0\NNS\9898892 who_1\WP\8299493 experienced_2\VBD\2108377 a_3\DT\13649268 manic_4\JJ\1740 or_5\CC\3541091 hypomanic_6\JJ\1740 switch_7\NN\3096960 were_8\VBD\836236 compared_9\VBN\644583 with_10\IN\1740 those_11\DT\1740 who_12\WP\8299493 did_13\VBD\1640855 not_14\RB\1740 on_15\IN\1740 several_16\JJ\1740 variables_17\NNS\2452 including_18\VBG\690614 age_19\NN\4916342 ,_20\,\1740 sex_21\NN\13440063 ,_22\,\1740 diagnosis_23\NN\152018 (_24\-LRB-\1740 dsm-iv_25\NN\1740 bipolar_26\NN\1740 i_27\CD\14622893 vs._28\CC\1740 bipolar_29\NN\1740 ii_30\CD\13741022 )_31\-RRB-\1740 ,_32\,\1740 number_33\NN\5107765 of_34\IN\1740 previous_35\JJ\1740 <e2>manic</e2>_36\JJ\1740 episodes_37\NNS\7283608 ,_38\,\1740 type_39\NN\5839024 of_40\IN\1740 antidepressant_41\JJ\1740 therapy_42\NN\657604 used_43\VBN\1156834 (_44\-LRB-\1740 electroconvulsive_45\JJ\1740 therapy_46\NN\657604 vs._47\CC\1740 antidepressant_48\JJ\1740 drugs_49\NNS\14778436 and_50\CC\1740 ,_51\,\1740 more_52\RBR\1740 particularly_53\RB\1740 ,_54\,\1740 selective_55\JJ\1740 serotonin_56\NN\14807737 reuptake_57\NN\13571580 inhibitors_58\NNS\20090 [_59\-LRB-\1740 ssris_60\NNP\2718811 ]_61\-RRB-\1740 )_62\-RRB-\1740 ,_63\,\1740 use_64\NN\407535 and_65\CC\1740 type_66\NN\5839024 of_67\IN\1740 mood_68\NN\26192 stabilizers_69\NNS\14806838 (_70\-LRB-\1740 <e1>lithium</e1>_71\NN\14625458 vs._72\FW\1740 anticonvulsants_73\NNS\3740161 )_74\-RRB-\1740 ,_75\,\1740 and_76\CC\1740 temperament_77\NN\4623113 of_78\IN\1740 the_79\DT\1740 patient_80\NN\9898892 ,_81\,\1740 assessed_82\VBN\670261 during_83\IN\1740 a_84\DT\13649268 normothymic_85\JJ\1740 period_86\NN\13575869 using_87\VBG\1156834 the_88\DT\1740 hyperthymia_89\JJ\1740 component_90\NN\5867413 of_91\IN\1740 the_92\DT\1740 semi-structured_93\JJ\1740 affective_94\JJ\1740 temperament_95\NNP\4623113 interview_96\NNP\7193958 ._97\.\1740
7977601
11206082
C036150_D012640 CID two_0\CD\13741022 mouse_1\NN\2329401 lines_2\NNS\8426461 selected_3\VBN\697589 for_4\IN\1740 differential_5\JJ\1740 sensitivities_6\NNS\5651971 to_7\TO\1740 <e1>beta-carboline-induced</e1>_8\JJ\1740 <e2>seizures</e2>_9\NNS\14081375 are_10\VBP\836236 also_11\RB\1740 differentially_12\RB\1740 sensitive_13\JJ\1740 to_14\TO\1740 various_15\JJ\1740 pharmacological_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 other_19\JJ\1740 gaba(a_20\NN\1740 )_21\-RRB-\1740 receptor_22\NN\5225602 ligands_23\NNS\20090 ._24\.\1740
C036150_D012640 CID two_0\CD\13741022 mouse_1\NN\2329401 lines_2\NNS\8426461 were_3\VBD\836236 selectively_4\RB\1740 bred_5\VBN\1645601 according_6\VBG\2657219 to_7\IN\1740 their_8\PRP$\1740 sensitivity_9\NN\5651971 (_10\-LRB-\1740 bs_11\NN\6698252 line_12\NN\8426461 )_13\-RRB-\1740 or_14\CC\3541091 resistance_15\NN\37396 (_16\-LRB-\1740 br_17\NN\14622893 line_18\NN\8426461 )_19\-RRB-\1740 to_20\TO\1740 <e2>seizures</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 single_25\JJ\1740 i.p._26\RB\1740 injection_27\NN\320852 of_28\IN\1740 <e1>methyl_29\JJ\1740 beta-carboline-3-carboxylate</e1>_30\NN\1740 (_31\-LRB-\1740 beta-ccm_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 an_35\DT\6697703 inverse_36\JJ\1740 agonist_37\NN\9613191 of_38\IN\1740 the_39\DT\1740 gaba(a_40\NN\1740 )_41\-RRB-\1740 receptor_42\NN\5225602 benzodiazepine_43\NN\3771443 site_44\NN\8673395 ._45\.\1740
C036150_D012640 CID two_0\CD\13741022 mouse_1\NN\2329401 lines_2\NNS\8426461 were_3\VBD\836236 selectively_4\RB\1740 bred_5\VBN\1645601 according_6\VBG\2657219 to_7\IN\1740 their_8\PRP$\1740 sensitivity_9\NN\5651971 (_10\-LRB-\1740 bs_11\NN\6698252 line_12\NN\8426461 )_13\-RRB-\1740 or_14\CC\3541091 resistance_15\NN\37396 (_16\-LRB-\1740 br_17\NN\14622893 line_18\NN\8426461 )_19\-RRB-\1740 to_20\TO\1740 <e2>seizures</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 single_25\JJ\1740 i.p._26\RB\1740 injection_27\NN\320852 of_28\IN\1740 methyl_29\JJ\1740 beta-carboline-3-carboxylate_30\NN\1740 (_31\-LRB-\1740 <e1>beta-ccm</e1>_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 an_35\DT\6697703 inverse_36\JJ\1740 agonist_37\NN\9613191 of_38\IN\1740 the_39\DT\1740 gaba(a_40\NN\1740 )_41\-RRB-\1740 receptor_42\NN\5225602 benzodiazepine_43\NN\3771443 site_44\NN\8673395 ._45\.\1740
D005680_D012640 NONE two_0\CD\13741022 mouse_1\NN\2329401 lines_2\NNS\8426461 selected_3\VBN\697589 for_4\IN\1740 differential_5\JJ\1740 sensitivities_6\NNS\5651971 to_7\TO\1740 beta-carboline-induced_8\JJ\1740 <e2>seizures</e2>_9\NNS\14081375 are_10\VBP\836236 also_11\RB\1740 differentially_12\RB\1740 sensitive_13\JJ\1740 to_14\TO\1740 various_15\JJ\1740 pharmacological_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 other_19\JJ\1740 <e1>gaba(a</e1>_20\NN\1740 )_21\-RRB-\1740 receptor_22\NN\5225602 ligands_23\NNS\20090 ._24\.\1740
D005680_D012640 NONE two_0\CD\13741022 mouse_1\NN\2329401 lines_2\NNS\8426461 were_3\VBD\836236 selectively_4\RB\1740 bred_5\VBN\1645601 according_6\VBG\2657219 to_7\IN\1740 their_8\PRP$\1740 sensitivity_9\NN\5651971 (_10\-LRB-\1740 bs_11\NN\6698252 line_12\NN\8426461 )_13\-RRB-\1740 or_14\CC\3541091 resistance_15\NN\37396 (_16\-LRB-\1740 br_17\NN\14622893 line_18\NN\8426461 )_19\-RRB-\1740 to_20\TO\1740 <e2>seizures</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 single_25\JJ\1740 i.p._26\RB\1740 injection_27\NN\320852 of_28\IN\1740 methyl_29\JJ\1740 beta-carboline-3-carboxylate_30\NN\1740 (_31\-LRB-\1740 beta-ccm_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 an_35\DT\6697703 inverse_36\JJ\1740 agonist_37\NN\9613191 of_38\IN\1740 the_39\DT\1740 <e1>gaba(a</e1>_40\NN\1740 )_41\-RRB-\1740 receptor_42\NN\5225602 benzodiazepine_43\NN\3771443 site_44\NN\8673395 ._45\.\1740
D001569_D012640 NONE two_0\CD\13741022 mouse_1\NN\2329401 lines_2\NNS\8426461 were_3\VBD\836236 selectively_4\RB\1740 bred_5\VBN\1645601 according_6\VBG\2657219 to_7\IN\1740 their_8\PRP$\1740 sensitivity_9\NN\5651971 (_10\-LRB-\1740 bs_11\NN\6698252 line_12\NN\8426461 )_13\-RRB-\1740 or_14\CC\3541091 resistance_15\NN\37396 (_16\-LRB-\1740 br_17\NN\14622893 line_18\NN\8426461 )_19\-RRB-\1740 to_20\TO\1740 <e2>seizures</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 a_24\DT\13649268 single_25\JJ\1740 i.p._26\RB\1740 injection_27\NN\320852 of_28\IN\1740 methyl_29\JJ\1740 beta-carboline-3-carboxylate_30\NN\1740 (_31\-LRB-\1740 beta-ccm_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 an_35\DT\6697703 inverse_36\JJ\1740 agonist_37\NN\9613191 of_38\IN\1740 the_39\DT\1740 gaba(a_40\NN\1740 )_41\-RRB-\1740 receptor_42\NN\5225602 <e1>benzodiazepine</e1>_43\NN\3771443 site_44\NN\8673395 ._45\.\1740
D003975_D012640 NONE we_0\PRP\1740 measured_1\VBD\697589 <e1>diazepam-induced</e1>_2\JJ\1740 anxiolysis_3\NN\1740 with_4\IN\1740 the_5\DT\1740 elevated_6\JJ\1740 plus-maze_7\JJ\1740 test_8\NN\5798043 ,_9\,\1740 diazepam-induced_10\JJ\1740 sedation_11\NN\14034177 by_12\IN\1740 recording_13\VBG\2225492 the_14\DT\1740 vigilance_15\NN\5650579 states_16\NNS\8491826 ,_17\,\1740 and_18\CC\1740 picrotoxin-_19\NN\1740 and_20\CC\1740 pentylenetetrazol-induced_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 after_23\IN\1740 i.p._24\RB\1740 injections_25\NNS\320852 ._26\.\1740
D003975_D012640 NONE we_0\PRP\1740 measured_1\VBD\697589 diazepam-induced_2\JJ\1740 anxiolysis_3\NN\1740 with_4\IN\1740 the_5\DT\1740 elevated_6\JJ\1740 plus-maze_7\JJ\1740 test_8\NN\5798043 ,_9\,\1740 <e1>diazepam-induced</e1>_10\JJ\1740 sedation_11\NN\14034177 by_12\IN\1740 recording_13\VBG\2225492 the_14\DT\1740 vigilance_15\NN\5650579 states_16\NNS\8491826 ,_17\,\1740 and_18\CC\1740 picrotoxin-_19\NN\1740 and_20\CC\1740 pentylenetetrazol-induced_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 after_23\IN\1740 i.p._24\RB\1740 injections_25\NNS\320852 ._26\.\1740
D010852_D012640 CID we_0\PRP\1740 measured_1\VBD\697589 diazepam-induced_2\JJ\1740 anxiolysis_3\NN\1740 with_4\IN\1740 the_5\DT\1740 elevated_6\JJ\1740 plus-maze_7\JJ\1740 test_8\NN\5798043 ,_9\,\1740 diazepam-induced_10\JJ\1740 sedation_11\NN\14034177 by_12\IN\1740 recording_13\VBG\2225492 the_14\DT\1740 vigilance_15\NN\5650579 states_16\NNS\8491826 ,_17\,\1740 and_18\CC\1740 <e1>picrotoxin-</e1>_19\NN\1740 and_20\CC\1740 pentylenetetrazol-induced_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 after_23\IN\1740 i.p._24\RB\1740 injections_25\NNS\320852 ._26\.\1740
D010433_D012640 CID we_0\PRP\1740 measured_1\VBD\697589 diazepam-induced_2\JJ\1740 anxiolysis_3\NN\1740 with_4\IN\1740 the_5\DT\1740 elevated_6\JJ\1740 plus-maze_7\JJ\1740 test_8\NN\5798043 ,_9\,\1740 diazepam-induced_10\JJ\1740 sedation_11\NN\14034177 by_12\IN\1740 recording_13\VBG\2225492 the_14\DT\1740 vigilance_15\NN\5650579 states_16\NNS\8491826 ,_17\,\1740 and_18\CC\1740 picrotoxin-_19\NN\1740 and_20\CC\1740 <e1>pentylenetetrazol-induced</e1>_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 after_23\IN\1740 i.p._24\RB\1740 injections_25\NNS\320852 ._26\.\1740
18951540
D007980_D004409 CID repetitive_0\JJ\1740 transcranial_1\JJ\1740 magnetic_2\JJ\1740 stimulation_3\NN\242808 for_4\IN\1740 <e1>levodopa-induced</e1>_5\JJ\1740 <e2>dyskinesias</e2>_6\NNS\14084880 in_7\IN\13603305 parkinson_8\NN\1740 's_9\POS\1740 disease_10\NN\14061805 ._11\.\1740
D007980_D010300 NONE repetitive_0\JJ\1740 transcranial_1\JJ\1740 magnetic_2\JJ\1740 stimulation_3\NN\242808 for_4\IN\1740 <e1>levodopa-induced</e1>_5\JJ\1740 dyskinesias_6\NNS\14084880 in_7\IN\13603305 <e2>parkinson_8\NN\1740 's_9\POS\1740 disease</e2>_10\NN\14061805 ._11\.\1740
17879945
D019438_D050197 CID we_0\PRP\1740 have_1\VBP\2108377 previously_2\RB\1740 demonstrated_3\VBN\2137132 that_4\IN\1740 <e1>ritonavir</e1>_5\NN\4013993 treatment_6\NN\654885 increases_7\VBZ\169651 <e2>atherosclerotic_8\JJ\1740 lesion</e2>_9\NN\14204950 formation_10\NN\7938773 in_11\IN\13603305 male_12\JJ\1740 mice_13\NNS\2329401 to_14\TO\1740 a_15\DT\13649268 greater_16\JJR\1740 extent_17\NN\13939892 than_18\IN\1740 in_19\IN\13603305 female_20\JJ\1740 mice_21\NNS\2329401 ._22\.\1740
4027862
D003891_D003693 CID <e1>desipramine-induced</e1>_0\JJ\1740 <e2>delirium</e2>_1\NN\14391660 at_2\IN\14622893 "_3\``\1740 subtherapeutic_4\JJ\1740 "_5\''\1740 concentrations_6\NNS\4916342 :_7\:\1740 a_8\DT\13649268 case_9\NN\7283608 report_10\NN\6470073 ._11\.\1740
D003891_D003693 CID an_0\DT\6697703 elderly_1\JJ\1740 patient_2\NN\9898892 treated_3\VBN\2376958 with_4\IN\1740 low_5\JJ\1740 dose_6\NN\3740161 <e1>desipramine</e1>_7\NN\4482543 developed_8\VBD\1753788 a_9\DT\13649268 <e2>delirium</e2>_10\NN\14391660 while_11\IN\15122231 her_12\PRP$\1740 plasma_13\NN\5398023 level_14\NN\4916342 was_15\VBD\836236 in_16\IN\13603305 the_17\DT\1740 "_18\``\1740 subtherapeutic_19\JJ\1740 "_20\''\1740 range_21\NN\5123416 ._22\.\1740
7862923
D002220_D012559 NONE <e1>carbamazepine</e1>_0\NNP\1740 was_1\VBD\836236 switched_2\VBN\138508 to_3\TO\1740 its_4\PRP$\6125041 10-keto_5\NN\1740 analogue_6\NN\4743605 oxcarbazepine_7\NN\1740 among_8\IN\1740 six_9\CD\13741022 difficult-to-treat_10\JJ\1740 <e2>schizophrenic</e2>_11\NN\10490141 or_12\CC\3541091 organic_13\JJ\1740 psychotic_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 concomitantly_17\RB\1740 haloperidol_18\JJ\1740 ,_19\,\1740 chlorpromazine_20\NN\3713736 or_21\CC\3541091 clozapine_22\NN\3713736 ._23\.\1740
D002220_D019965 NONE <e1>carbamazepine</e1>_0\NNP\1740 was_1\VBD\836236 switched_2\VBN\138508 to_3\TO\1740 its_4\PRP$\6125041 10-keto_5\NN\1740 analogue_6\NN\4743605 oxcarbazepine_7\NN\1740 among_8\IN\1740 six_9\CD\13741022 difficult-to-treat_10\JJ\1740 schizophrenic_11\NN\10490141 or_12\CC\3541091 <e2>organic_13\JJ\1740 psychotic</e2>_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 concomitantly_17\RB\1740 haloperidol_18\JJ\1740 ,_19\,\1740 chlorpromazine_20\NN\3713736 or_21\CC\3541091 clozapine_22\NN\3713736 ._23\.\1740
C036006_D012559 NONE carbamazepine_0\NNP\1740 was_1\VBD\836236 switched_2\VBN\138508 to_3\TO\1740 its_4\PRP$\6125041 10-keto_5\NN\1740 analogue_6\NN\4743605 <e1>oxcarbazepine</e1>_7\NN\1740 among_8\IN\1740 six_9\CD\13741022 difficult-to-treat_10\JJ\1740 <e2>schizophrenic</e2>_11\NN\10490141 or_12\CC\3541091 organic_13\JJ\1740 psychotic_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 concomitantly_17\RB\1740 haloperidol_18\JJ\1740 ,_19\,\1740 chlorpromazine_20\NN\3713736 or_21\CC\3541091 clozapine_22\NN\3713736 ._23\.\1740
C036006_D019965 NONE carbamazepine_0\NNP\1740 was_1\VBD\836236 switched_2\VBN\138508 to_3\TO\1740 its_4\PRP$\6125041 10-keto_5\NN\1740 analogue_6\NN\4743605 <e1>oxcarbazepine</e1>_7\NN\1740 among_8\IN\1740 six_9\CD\13741022 difficult-to-treat_10\JJ\1740 schizophrenic_11\NN\10490141 or_12\CC\3541091 <e2>organic_13\JJ\1740 psychotic</e2>_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 concomitantly_17\RB\1740 haloperidol_18\JJ\1740 ,_19\,\1740 chlorpromazine_20\NN\3713736 or_21\CC\3541091 clozapine_22\NN\3713736 ._23\.\1740
D006220_D012559 NONE carbamazepine_0\NNP\1740 was_1\VBD\836236 switched_2\VBN\138508 to_3\TO\1740 its_4\PRP$\6125041 10-keto_5\NN\1740 analogue_6\NN\4743605 oxcarbazepine_7\NN\1740 among_8\IN\1740 six_9\CD\13741022 difficult-to-treat_10\JJ\1740 <e2>schizophrenic</e2>_11\NN\10490141 or_12\CC\3541091 organic_13\JJ\1740 psychotic_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 concomitantly_17\RB\1740 <e1>haloperidol</e1>_18\JJ\1740 ,_19\,\1740 chlorpromazine_20\NN\3713736 or_21\CC\3541091 clozapine_22\NN\3713736 ._23\.\1740
D006220_D019965 NONE carbamazepine_0\NNP\1740 was_1\VBD\836236 switched_2\VBN\138508 to_3\TO\1740 its_4\PRP$\6125041 10-keto_5\NN\1740 analogue_6\NN\4743605 oxcarbazepine_7\NN\1740 among_8\IN\1740 six_9\CD\13741022 difficult-to-treat_10\JJ\1740 schizophrenic_11\NN\10490141 or_12\CC\3541091 <e2>organic_13\JJ\1740 psychotic</e2>_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 concomitantly_17\RB\1740 <e1>haloperidol</e1>_18\JJ\1740 ,_19\,\1740 chlorpromazine_20\NN\3713736 or_21\CC\3541091 clozapine_22\NN\3713736 ._23\.\1740
D002746_D012559 NONE carbamazepine_0\NNP\1740 was_1\VBD\836236 switched_2\VBN\138508 to_3\TO\1740 its_4\PRP$\6125041 10-keto_5\NN\1740 analogue_6\NN\4743605 oxcarbazepine_7\NN\1740 among_8\IN\1740 six_9\CD\13741022 difficult-to-treat_10\JJ\1740 <e2>schizophrenic</e2>_11\NN\10490141 or_12\CC\3541091 organic_13\JJ\1740 psychotic_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 concomitantly_17\RB\1740 haloperidol_18\JJ\1740 ,_19\,\1740 <e1>chlorpromazine</e1>_20\NN\3713736 or_21\CC\3541091 clozapine_22\NN\3713736 ._23\.\1740
D002746_D019965 NONE carbamazepine_0\NNP\1740 was_1\VBD\836236 switched_2\VBN\138508 to_3\TO\1740 its_4\PRP$\6125041 10-keto_5\NN\1740 analogue_6\NN\4743605 oxcarbazepine_7\NN\1740 among_8\IN\1740 six_9\CD\13741022 difficult-to-treat_10\JJ\1740 schizophrenic_11\NN\10490141 or_12\CC\3541091 <e2>organic_13\JJ\1740 psychotic</e2>_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 concomitantly_17\RB\1740 haloperidol_18\JJ\1740 ,_19\,\1740 <e1>chlorpromazine</e1>_20\NN\3713736 or_21\CC\3541091 clozapine_22\NN\3713736 ._23\.\1740
D003024_D012559 NONE carbamazepine_0\NNP\1740 was_1\VBD\836236 switched_2\VBN\138508 to_3\TO\1740 its_4\PRP$\6125041 10-keto_5\NN\1740 analogue_6\NN\4743605 oxcarbazepine_7\NN\1740 among_8\IN\1740 six_9\CD\13741022 difficult-to-treat_10\JJ\1740 <e2>schizophrenic</e2>_11\NN\10490141 or_12\CC\3541091 organic_13\JJ\1740 psychotic_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 concomitantly_17\RB\1740 haloperidol_18\JJ\1740 ,_19\,\1740 chlorpromazine_20\NN\3713736 or_21\CC\3541091 <e1>clozapine</e1>_22\NN\3713736 ._23\.\1740
D003024_D019965 NONE carbamazepine_0\NNP\1740 was_1\VBD\836236 switched_2\VBN\138508 to_3\TO\1740 its_4\PRP$\6125041 10-keto_5\NN\1740 analogue_6\NN\4743605 oxcarbazepine_7\NN\1740 among_8\IN\1740 six_9\CD\13741022 difficult-to-treat_10\JJ\1740 schizophrenic_11\NN\10490141 or_12\CC\3541091 <e2>organic_13\JJ\1740 psychotic</e2>_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 concomitantly_17\RB\1740 haloperidol_18\JJ\1740 ,_19\,\1740 chlorpromazine_20\NN\3713736 or_21\CC\3541091 <e1>clozapine</e1>_22\NN\3713736 ._23\.\1740
18221780
D016202_D010146 NONE sex_0\NN\13440063 differences_1\NNS\4723816 in_2\IN\13603305 <e1>nmda</e1>_3\NN\1740 antagonist_4\NN\7846 enhancement_5\NN\248977 of_6\IN\1740 morphine_7\NN\2707683 antihyperalgesia_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 capsaicin_11\NN\15032661 model_12\NN\5888929 of_13\IN\1740 persistent_14\JJ\1740 <e2>pain</e2>_15\NN\14299637 :_16\:\1740 comparisons_17\NNS\635850 to_18\TO\1740 two_19\CD\13741022 models_20\NNS\5888929 of_21\IN\1740 acute_22\JJ\1740 pain_23\NN\14299637 ._24\.\1740
D016202_D010146 NONE these_0\DT\1740 findings_1\NNS\7951464 demonstrate_2\VBP\2137132 a_3\DT\13649268 sexually-dimorphic_4\JJ\1740 interaction_5\NN\37396 between_6\IN\1740 <e1>nmda</e1>_7\NN\1740 antagonists_8\NNS\7846 and_9\CC\1740 morphine_10\NN\2707683 in_11\IN\13603305 a_12\DT\13649268 persistent_13\JJ\1740 <e2>pain</e2>_14\NN\14299637 model_15\NN\5888929 that_16\WDT\1740 can_17\MD\3094503 be_18\VB\836236 distinguished_19\VBN\618878 from_20\IN\1740 those_21\DT\1740 observed_22\VBN\2163746 in_23\IN\13603305 acute_24\JJ\1740 pain_25\NN\14299637 models_26\NNS\5888929 ._27\.\1740
D016202_D059787 NONE sex_0\NN\13440063 differences_1\NNS\4723816 in_2\IN\13603305 <e1>nmda</e1>_3\NN\1740 antagonist_4\NN\7846 enhancement_5\NN\248977 of_6\IN\1740 morphine_7\NN\2707683 antihyperalgesia_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 capsaicin_11\NN\15032661 model_12\NN\5888929 of_13\IN\1740 persistent_14\JJ\1740 pain_15\NN\14299637 :_16\:\1740 comparisons_17\NNS\635850 to_18\TO\1740 two_19\CD\13741022 models_20\NNS\5888929 of_21\IN\1740 <e2>acute_22\JJ\1740 pain</e2>_23\NN\14299637 ._24\.\1740
D016202_D059787 NONE in_0\IN\13603305 <e2>acute_1\JJ\1740 pain</e2>_2\NN\14299637 models_3\NNS\5888929 ,_4\,\1740 <e1>n-methyl-d-aspartate</e1>_5\NN\1740 (_6\-LRB-\1740 nmda_7\NN\1740 )_8\-RRB-\1740 antagonists_9\NNS\7846 enhance_10\VBP\227165 the_11\DT\1740 antinociceptive_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 morphine_15\NN\2707683 to_16\TO\1740 a_17\DT\13649268 greater_18\JJR\1740 extent_19\NN\13939892 in_20\IN\13603305 males_21\NNS\15388 than_22\IN\1740 females_23\NNS\15388 ._24\.\1740
D016202_D059787 NONE in_0\IN\13603305 <e2>acute_1\JJ\1740 pain</e2>_2\NN\14299637 models_3\NNS\5888929 ,_4\,\1740 n-methyl-d-aspartate_5\NN\1740 (_6\-LRB-\1740 <e1>nmda</e1>_7\NN\1740 )_8\-RRB-\1740 antagonists_9\NNS\7846 enhance_10\VBP\227165 the_11\DT\1740 antinociceptive_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 morphine_15\NN\2707683 to_16\TO\1740 a_17\DT\13649268 greater_18\JJR\1740 extent_19\NN\13939892 in_20\IN\13603305 males_21\NNS\15388 than_22\IN\1740 females_23\NNS\15388 ._24\.\1740
D016202_D059787 NONE these_0\DT\1740 findings_1\NNS\7951464 demonstrate_2\VBP\2137132 a_3\DT\13649268 sexually-dimorphic_4\JJ\1740 interaction_5\NN\37396 between_6\IN\1740 <e1>nmda</e1>_7\NN\1740 antagonists_8\NNS\7846 and_9\CC\1740 morphine_10\NN\2707683 in_11\IN\13603305 a_12\DT\13649268 persistent_13\JJ\1740 pain_14\NN\14299637 model_15\NN\5888929 that_16\WDT\1740 can_17\MD\3094503 be_18\VB\836236 distinguished_19\VBN\618878 from_20\IN\1740 those_21\DT\1740 observed_22\VBN\2163746 in_23\IN\13603305 <e2>acute_24\JJ\1740 pain</e2>_25\NN\14299637 models_26\NNS\5888929 ._27\.\1740
D009020_D010146 NONE sex_0\NN\13440063 differences_1\NNS\4723816 in_2\IN\13603305 nmda_3\NN\1740 antagonist_4\NN\7846 enhancement_5\NN\248977 of_6\IN\1740 <e1>morphine</e1>_7\NN\2707683 antihyperalgesia_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 capsaicin_11\NN\15032661 model_12\NN\5888929 of_13\IN\1740 persistent_14\JJ\1740 <e2>pain</e2>_15\NN\14299637 :_16\:\1740 comparisons_17\NNS\635850 to_18\TO\1740 two_19\CD\13741022 models_20\NNS\5888929 of_21\IN\1740 acute_22\JJ\1740 pain_23\NN\14299637 ._24\.\1740
D009020_D010146 NONE these_0\DT\1740 findings_1\NNS\7951464 demonstrate_2\VBP\2137132 a_3\DT\13649268 sexually-dimorphic_4\JJ\1740 interaction_5\NN\37396 between_6\IN\1740 nmda_7\NN\1740 antagonists_8\NNS\7846 and_9\CC\1740 <e1>morphine</e1>_10\NN\2707683 in_11\IN\13603305 a_12\DT\13649268 persistent_13\JJ\1740 <e2>pain</e2>_14\NN\14299637 model_15\NN\5888929 that_16\WDT\1740 can_17\MD\3094503 be_18\VB\836236 distinguished_19\VBN\618878 from_20\IN\1740 those_21\DT\1740 observed_22\VBN\2163746 in_23\IN\13603305 acute_24\JJ\1740 pain_25\NN\14299637 models_26\NNS\5888929 ._27\.\1740
D009020_D059787 NONE sex_0\NN\13440063 differences_1\NNS\4723816 in_2\IN\13603305 nmda_3\NN\1740 antagonist_4\NN\7846 enhancement_5\NN\248977 of_6\IN\1740 <e1>morphine</e1>_7\NN\2707683 antihyperalgesia_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 capsaicin_11\NN\15032661 model_12\NN\5888929 of_13\IN\1740 persistent_14\JJ\1740 pain_15\NN\14299637 :_16\:\1740 comparisons_17\NNS\635850 to_18\TO\1740 two_19\CD\13741022 models_20\NNS\5888929 of_21\IN\1740 <e2>acute_22\JJ\1740 pain</e2>_23\NN\14299637 ._24\.\1740
D009020_D059787 NONE in_0\IN\13603305 <e2>acute_1\JJ\1740 pain</e2>_2\NN\14299637 models_3\NNS\5888929 ,_4\,\1740 n-methyl-d-aspartate_5\NN\1740 (_6\-LRB-\1740 nmda_7\NN\1740 )_8\-RRB-\1740 antagonists_9\NNS\7846 enhance_10\VBP\227165 the_11\DT\1740 antinociceptive_12\JJ\1740 effects_13\NNS\13245626 of_14\IN\1740 <e1>morphine</e1>_15\NN\2707683 to_16\TO\1740 a_17\DT\13649268 greater_18\JJR\1740 extent_19\NN\13939892 in_20\IN\13603305 males_21\NNS\15388 than_22\IN\1740 females_23\NNS\15388 ._24\.\1740
D009020_D059787 NONE enhancement_0\NN\248977 of_1\IN\1740 <e1>morphine</e1>_2\NN\2707683 antinociception_3\NN\1740 by_4\IN\1740 dextromethorphan_5\NN\1740 was_6\VBD\836236 seen_7\VBN\2106506 in_8\IN\13603305 both_9\DT\1740 males_10\NNS\15388 and_11\CC\1740 females_12\NNS\15388 in_13\IN\13603305 the_14\DT\1740 <e2>acute_15\JJ\1740 pain</e2>_16\NN\14299637 models_17\NNS\5888929 ,_18\,\1740 with_19\IN\1740 the_20\DT\1740 magnitude_21\NN\4916342 of_22\IN\1740 this_23\DT\1740 effect_24\NN\34213 being_25\VBG\836236 greater_26\JJR\1740 in_27\IN\13603305 males_28\NNS\15388 ._29\.\1740
D009020_D059787 NONE these_0\DT\1740 findings_1\NNS\7951464 demonstrate_2\VBP\2137132 a_3\DT\13649268 sexually-dimorphic_4\JJ\1740 interaction_5\NN\37396 between_6\IN\1740 nmda_7\NN\1740 antagonists_8\NNS\7846 and_9\CC\1740 <e1>morphine</e1>_10\NN\2707683 in_11\IN\13603305 a_12\DT\13649268 persistent_13\JJ\1740 pain_14\NN\14299637 model_15\NN\5888929 that_16\WDT\1740 can_17\MD\3094503 be_18\VB\836236 distinguished_19\VBN\618878 from_20\IN\1740 those_21\DT\1740 observed_22\VBN\2163746 in_23\IN\13603305 <e2>acute_24\JJ\1740 pain</e2>_25\NN\14299637 models_26\NNS\5888929 ._27\.\1740
D002211_D010146 NONE sex_0\NN\13440063 differences_1\NNS\4723816 in_2\IN\13603305 nmda_3\NN\1740 antagonist_4\NN\7846 enhancement_5\NN\248977 of_6\IN\1740 morphine_7\NN\2707683 antihyperalgesia_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 <e1>capsaicin</e1>_11\NN\15032661 model_12\NN\5888929 of_13\IN\1740 persistent_14\JJ\1740 <e2>pain</e2>_15\NN\14299637 :_16\:\1740 comparisons_17\NNS\635850 to_18\TO\1740 two_19\CD\13741022 models_20\NNS\5888929 of_21\IN\1740 acute_22\JJ\1740 pain_23\NN\14299637 ._24\.\1740
D002211_D059787 NONE sex_0\NN\13440063 differences_1\NNS\4723816 in_2\IN\13603305 nmda_3\NN\1740 antagonist_4\NN\7846 enhancement_5\NN\248977 of_6\IN\1740 morphine_7\NN\2707683 antihyperalgesia_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 <e1>capsaicin</e1>_11\NN\15032661 model_12\NN\5888929 of_13\IN\1740 persistent_14\JJ\1740 pain_15\NN\14299637 :_16\:\1740 comparisons_17\NNS\635850 to_18\TO\1740 two_19\CD\13741022 models_20\NNS\5888929 of_21\IN\1740 <e2>acute_22\JJ\1740 pain</e2>_23\NN\14299637 ._24\.\1740
D002211_D006930 CID to_0\IN\1740 this_1\DT\1740 end_2\NN\8568978 ,_3\,\1740 persistent_4\JJ\1740 <e2>hyperalgesia</e2>_5\NN\1740 was_6\VBD\836236 induced_7\VBN\1627355 by_8\IN\1740 administration_9\NN\1133281 of_10\IN\1740 <e1>capsaicin</e1>_11\NN\15032661 in_12\IN\13603305 the_13\DT\1740 tail_14\NN\5470189 of_15\IN\1740 gonadally_16\RB\1740 intact_17\JJ\1740 f344_18\NN\1740 rats_19\NNS\2329401 ,_20\,\1740 following_21\VBG\1835496 which_22\WDT\1740 the_23\DT\1740 tail_24\NN\5470189 was_25\VBD\836236 immersed_26\VBN\1227675 in_27\IN\13603305 a_28\DT\13649268 mildly_29\RB\1740 noxious_30\JJ\1740 thermal_31\JJ\1740 stimulus_32\NN\5816287 ,_33\,\1740 and_34\CC\1740 tail-withdrawal_35\JJ\1740 latencies_36\NNS\15269513 measured_37\VBN\697589 ._38\.\1740
D003915_D059787 NONE enhancement_0\NN\248977 of_1\IN\1740 morphine_2\NN\2707683 antinociception_3\NN\1740 by_4\IN\1740 <e1>dextromethorphan</e1>_5\NN\1740 was_6\VBD\836236 seen_7\VBN\2106506 in_8\IN\13603305 both_9\DT\1740 males_10\NNS\15388 and_11\CC\1740 females_12\NNS\15388 in_13\IN\13603305 the_14\DT\1740 <e2>acute_15\JJ\1740 pain</e2>_16\NN\14299637 models_17\NNS\5888929 ,_18\,\1740 with_19\IN\1740 the_20\DT\1740 magnitude_21\NN\4916342 of_22\IN\1740 this_23\DT\1740 effect_24\NN\34213 being_25\VBG\836236 greater_26\JJR\1740 in_27\IN\13603305 males_28\NNS\15388 ._29\.\1740
17261653
D003000_D001919 CID <e1>clonidine-induced</e1>_0\JJ\1740 <e2>bradycardia</e2>_1\NN\14110674 in_2\IN\13603305 conscious_3\JJ\1740 alpha2abc-/-_4\JJ\1740 mice_5\NNS\2329401 was_6\VBD\836236 32.3_7\CD\1740 %_8\NN\1740 (_9\-LRB-\1740 10_10\CD\13745420 microg/kg_11\NNS\1740 )_12\-RRB-\1740 and_13\CC\1740 26.6_14\CD\1740 %_15\NN\1740 (_16\-LRB-\1740 100_17\CD\13745420 microg/kg_18\NNS\1740 )_19\-RRB-\1740 of_20\IN\1740 the_21\DT\1740 effect_22\NN\34213 in_23\IN\13603305 wild-type_24\JJ\1740 mice_25\NNS\2329401 ._26\.\1740
7858459
D005472_D003221 CID acute_0\JJ\1740 <e2>confusion</e2>_1\NN\13972797 induced_2\VBN\1627355 by_3\IN\1740 a_4\DT\13649268 high-dose_5\JJ\1740 infusion_6\NN\14589223 of_7\IN\1740 <e1>5-fluorouracil</e1>_8\NN\1740 and_9\CC\1740 folinic_10\JJ\1740 acid_11\NN\14818238 ._12\.\1740
D005472_D003221 CID he_0\PRP\14622893 developed_1\VBD\1753788 acute_2\JJ\1740 neurologic_3\JJ\1740 symptoms_4\NNS\5823932 of_5\IN\1740 mental_6\JJ\1740 <e2>confusion</e2>_7\NN\13972797 ,_8\,\1740 disorientation_9\NN\5896733 and_10\CC\1740 irritability_11\NN\7552087 ,_12\,\1740 and_13\CC\1740 then_14\RB\1740 lapsed_15\VBN\124442 into_16\IN\1740 a_17\DT\13649268 deep_18\JJ\1740 coma_19\NN\5678932 ,_20\,\1740 lasting_21\VBG\2704349 for_22\IN\1740 approximately_23\RB\1740 40_24\CD\13745420 hours_25\NNS\15118228 during_26\IN\1740 the_27\DT\1740 first_28\JJ\1740 dose_29\NN\3740161 (_30\-LRB-\1740 day_31\NN\15154774 2_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 <e1>5-fluorouracil</e1>_35\NN\1740 and_36\CC\1740 folinic_37\JJ\1740 acid_38\NN\14818238 infusion_39\NN\14589223 ._40\.\1740
D005472_D003221 CID he_0\PRP\14622893 developed_1\VBD\1753788 acute_2\JJ\1740 neurologic_3\JJ\1740 symptoms_4\NNS\5823932 of_5\IN\1740 mental_6\JJ\1740 confusion_7\NN\13972797 ,_8\,\1740 <e2>disorientation</e2>_9\NN\5896733 and_10\CC\1740 irritability_11\NN\7552087 ,_12\,\1740 and_13\CC\1740 then_14\RB\1740 lapsed_15\VBN\124442 into_16\IN\1740 a_17\DT\13649268 deep_18\JJ\1740 coma_19\NN\5678932 ,_20\,\1740 lasting_21\VBG\2704349 for_22\IN\1740 approximately_23\RB\1740 40_24\CD\13745420 hours_25\NNS\15118228 during_26\IN\1740 the_27\DT\1740 first_28\JJ\1740 dose_29\NN\3740161 (_30\-LRB-\1740 day_31\NN\15154774 2_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 <e1>5-fluorouracil</e1>_35\NN\1740 and_36\CC\1740 folinic_37\JJ\1740 acid_38\NN\14818238 infusion_39\NN\14589223 ._40\.\1740
D002955_D003221 CID acute_0\JJ\1740 <e2>confusion</e2>_1\NN\13972797 induced_2\VBN\1627355 by_3\IN\1740 a_4\DT\13649268 high-dose_5\JJ\1740 infusion_6\NN\14589223 of_7\IN\1740 5-fluorouracil_8\NN\1740 and_9\CC\1740 <e1>folinic_10\JJ\1740 acid</e1>_11\NN\14818238 ._12\.\1740
D002955_D003221 CID he_0\PRP\14622893 developed_1\VBD\1753788 acute_2\JJ\1740 neurologic_3\JJ\1740 symptoms_4\NNS\5823932 of_5\IN\1740 mental_6\JJ\1740 <e2>confusion</e2>_7\NN\13972797 ,_8\,\1740 disorientation_9\NN\5896733 and_10\CC\1740 irritability_11\NN\7552087 ,_12\,\1740 and_13\CC\1740 then_14\RB\1740 lapsed_15\VBN\124442 into_16\IN\1740 a_17\DT\13649268 deep_18\JJ\1740 coma_19\NN\5678932 ,_20\,\1740 lasting_21\VBG\2704349 for_22\IN\1740 approximately_23\RB\1740 40_24\CD\13745420 hours_25\NNS\15118228 during_26\IN\1740 the_27\DT\1740 first_28\JJ\1740 dose_29\NN\3740161 (_30\-LRB-\1740 day_31\NN\15154774 2_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 5-fluorouracil_35\NN\1740 and_36\CC\1740 <e1>folinic_37\JJ\1740 acid</e1>_38\NN\14818238 infusion_39\NN\14589223 ._40\.\1740
D002955_D003221 CID he_0\PRP\14622893 developed_1\VBD\1753788 acute_2\JJ\1740 neurologic_3\JJ\1740 symptoms_4\NNS\5823932 of_5\IN\1740 mental_6\JJ\1740 confusion_7\NN\13972797 ,_8\,\1740 <e2>disorientation</e2>_9\NN\5896733 and_10\CC\1740 irritability_11\NN\7552087 ,_12\,\1740 and_13\CC\1740 then_14\RB\1740 lapsed_15\VBN\124442 into_16\IN\1740 a_17\DT\13649268 deep_18\JJ\1740 coma_19\NN\5678932 ,_20\,\1740 lasting_21\VBG\2704349 for_22\IN\1740 approximately_23\RB\1740 40_24\CD\13745420 hours_25\NNS\15118228 during_26\IN\1740 the_27\DT\1740 first_28\JJ\1740 dose_29\NN\3740161 (_30\-LRB-\1740 day_31\NN\15154774 2_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 5-fluorouracil_35\NN\1740 and_36\CC\1740 <e1>folinic_37\JJ\1740 acid</e1>_38\NN\14818238 infusion_39\NN\14589223 ._40\.\1740
D002945_D013274 NONE a_0\DT\13649268 61-year-old_1\JJ\1740 man_2\NN\9605289 was_3\VBD\836236 treated_4\VBN\2376958 with_5\IN\1740 combination_6\NN\7951464 chemotherapy_7\NN\661091 incorporating_8\VBG\1461328 <e1>cisplatinum</e1>_9\NN\1740 ,_10\,\1740 etoposide_11\NN\1740 ,_12\,\1740 high-dose_13\NN\1740 5-fluorouracil_14\NN\1740 (_15\-LRB-\1740 2,250_16\CD\1740 mg/m2/24_17\NNS\1740 hours_18\NNS\15118228 )_19\-RRB-\1740 and_20\CC\1740 folinic_21\JJ\1740 acid_22\NN\14818238 for_23\IN\1740 an_24\DT\6697703 inoperable_25\JJ\1740 <e2>gastric_26\JJ\1740 adenocarcinoma</e2>_27\NN\14242337 ._28\.\1740
D005047_D013274 NONE a_0\DT\13649268 61-year-old_1\JJ\1740 man_2\NN\9605289 was_3\VBD\836236 treated_4\VBN\2376958 with_5\IN\1740 combination_6\NN\7951464 chemotherapy_7\NN\661091 incorporating_8\VBG\1461328 cisplatinum_9\NN\1740 ,_10\,\1740 <e1>etoposide</e1>_11\NN\1740 ,_12\,\1740 high-dose_13\NN\1740 5-fluorouracil_14\NN\1740 (_15\-LRB-\1740 2,250_16\CD\1740 mg/m2/24_17\NNS\1740 hours_18\NNS\15118228 )_19\-RRB-\1740 and_20\CC\1740 folinic_21\JJ\1740 acid_22\NN\14818238 for_23\IN\1740 an_24\DT\6697703 inoperable_25\JJ\1740 <e2>gastric_26\JJ\1740 adenocarcinoma</e2>_27\NN\14242337 ._28\.\1740
D005472_D013274 NONE a_0\DT\13649268 61-year-old_1\JJ\1740 man_2\NN\9605289 was_3\VBD\836236 treated_4\VBN\2376958 with_5\IN\1740 combination_6\NN\7951464 chemotherapy_7\NN\661091 incorporating_8\VBG\1461328 cisplatinum_9\NN\1740 ,_10\,\1740 etoposide_11\NN\1740 ,_12\,\1740 high-dose_13\NN\1740 <e1>5-fluorouracil</e1>_14\NN\1740 (_15\-LRB-\1740 2,250_16\CD\1740 mg/m2/24_17\NNS\1740 hours_18\NNS\15118228 )_19\-RRB-\1740 and_20\CC\1740 folinic_21\JJ\1740 acid_22\NN\14818238 for_23\IN\1740 an_24\DT\6697703 inoperable_25\JJ\1740 <e2>gastric_26\JJ\1740 adenocarcinoma</e2>_27\NN\14242337 ._28\.\1740
D002955_D013274 NONE a_0\DT\13649268 61-year-old_1\JJ\1740 man_2\NN\9605289 was_3\VBD\836236 treated_4\VBN\2376958 with_5\IN\1740 combination_6\NN\7951464 chemotherapy_7\NN\661091 incorporating_8\VBG\1461328 cisplatinum_9\NN\1740 ,_10\,\1740 etoposide_11\NN\1740 ,_12\,\1740 high-dose_13\NN\1740 5-fluorouracil_14\NN\1740 (_15\-LRB-\1740 2,250_16\CD\1740 mg/m2/24_17\NNS\1740 hours_18\NNS\15118228 )_19\-RRB-\1740 and_20\CC\1740 <e1>folinic_21\JJ\1740 acid</e1>_22\NN\14818238 for_23\IN\1740 an_24\DT\6697703 inoperable_25\JJ\1740 <e2>gastric_26\JJ\1740 adenocarcinoma</e2>_27\NN\14242337 ._28\.\1740
D005472_D001523 NONE he_0\PRP\14622893 developed_1\VBD\1753788 acute_2\JJ\1740 neurologic_3\JJ\1740 symptoms_4\NNS\5823932 of_5\IN\1740 mental_6\JJ\1740 confusion_7\NN\13972797 ,_8\,\1740 disorientation_9\NN\5896733 and_10\CC\1740 <e2>irritability</e2>_11\NN\7552087 ,_12\,\1740 and_13\CC\1740 then_14\RB\1740 lapsed_15\VBN\124442 into_16\IN\1740 a_17\DT\13649268 deep_18\JJ\1740 coma_19\NN\5678932 ,_20\,\1740 lasting_21\VBG\2704349 for_22\IN\1740 approximately_23\RB\1740 40_24\CD\13745420 hours_25\NNS\15118228 during_26\IN\1740 the_27\DT\1740 first_28\JJ\1740 dose_29\NN\3740161 (_30\-LRB-\1740 day_31\NN\15154774 2_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 <e1>5-fluorouracil</e1>_35\NN\1740 and_36\CC\1740 folinic_37\JJ\1740 acid_38\NN\14818238 infusion_39\NN\14589223 ._40\.\1740
D005472_D003128 CID he_0\PRP\14622893 developed_1\VBD\1753788 acute_2\JJ\1740 neurologic_3\JJ\1740 symptoms_4\NNS\5823932 of_5\IN\1740 mental_6\JJ\1740 confusion_7\NN\13972797 ,_8\,\1740 disorientation_9\NN\5896733 and_10\CC\1740 irritability_11\NN\7552087 ,_12\,\1740 and_13\CC\1740 then_14\RB\1740 lapsed_15\VBN\124442 into_16\IN\1740 a_17\DT\13649268 deep_18\JJ\1740 <e2>coma</e2>_19\NN\5678932 ,_20\,\1740 lasting_21\VBG\2704349 for_22\IN\1740 approximately_23\RB\1740 40_24\CD\13745420 hours_25\NNS\15118228 during_26\IN\1740 the_27\DT\1740 first_28\JJ\1740 dose_29\NN\3740161 (_30\-LRB-\1740 day_31\NN\15154774 2_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 <e1>5-fluorouracil</e1>_35\NN\1740 and_36\CC\1740 folinic_37\JJ\1740 acid_38\NN\14818238 infusion_39\NN\14589223 ._40\.\1740
D002955_D001523 NONE he_0\PRP\14622893 developed_1\VBD\1753788 acute_2\JJ\1740 neurologic_3\JJ\1740 symptoms_4\NNS\5823932 of_5\IN\1740 mental_6\JJ\1740 confusion_7\NN\13972797 ,_8\,\1740 disorientation_9\NN\5896733 and_10\CC\1740 <e2>irritability</e2>_11\NN\7552087 ,_12\,\1740 and_13\CC\1740 then_14\RB\1740 lapsed_15\VBN\124442 into_16\IN\1740 a_17\DT\13649268 deep_18\JJ\1740 coma_19\NN\5678932 ,_20\,\1740 lasting_21\VBG\2704349 for_22\IN\1740 approximately_23\RB\1740 40_24\CD\13745420 hours_25\NNS\15118228 during_26\IN\1740 the_27\DT\1740 first_28\JJ\1740 dose_29\NN\3740161 (_30\-LRB-\1740 day_31\NN\15154774 2_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 5-fluorouracil_35\NN\1740 and_36\CC\1740 <e1>folinic_37\JJ\1740 acid</e1>_38\NN\14818238 infusion_39\NN\14589223 ._40\.\1740
D002955_D003128 CID he_0\PRP\14622893 developed_1\VBD\1753788 acute_2\JJ\1740 neurologic_3\JJ\1740 symptoms_4\NNS\5823932 of_5\IN\1740 mental_6\JJ\1740 confusion_7\NN\13972797 ,_8\,\1740 disorientation_9\NN\5896733 and_10\CC\1740 irritability_11\NN\7552087 ,_12\,\1740 and_13\CC\1740 then_14\RB\1740 lapsed_15\VBN\124442 into_16\IN\1740 a_17\DT\13649268 deep_18\JJ\1740 <e2>coma</e2>_19\NN\5678932 ,_20\,\1740 lasting_21\VBG\2704349 for_22\IN\1740 approximately_23\RB\1740 40_24\CD\13745420 hours_25\NNS\15118228 during_26\IN\1740 the_27\DT\1740 first_28\JJ\1740 dose_29\NN\3740161 (_30\-LRB-\1740 day_31\NN\15154774 2_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 5-fluorouracil_35\NN\1740 and_36\CC\1740 <e1>folinic_37\JJ\1740 acid</e1>_38\NN\14818238 infusion_39\NN\14589223 ._40\.\1740
D002955_D020258 NONE because_0\IN\1740 <e1>folinic_1\JJ\1740 acid</e1>_2\NN\14818238 was_3\VBD\836236 unlikely_4\JJ\1740 to_5\TO\1740 be_6\VB\836236 associated_7\VBN\628491 with_8\IN\1740 this_9\DT\1740 condition_10\NN\24720 ,_11\,\1740 <e2>neurotoxicity</e2>_12\NN\1740 due_13\JJ\1740 to_14\TO\1740 high-dose_15\JJ\1740 5-fluorouracil_16\NN\1740 was_17\VBD\836236 highly_18\RB\1740 suspected_19\VBN\916909 ._20\.\1740
D005472_D020258 NONE because_0\IN\1740 folinic_1\JJ\1740 acid_2\NN\14818238 was_3\VBD\836236 unlikely_4\JJ\1740 to_5\TO\1740 be_6\VB\836236 associated_7\VBN\628491 with_8\IN\1740 this_9\DT\1740 condition_10\NN\24720 ,_11\,\1740 <e2>neurotoxicity</e2>_12\NN\1740 due_13\JJ\1740 to_14\TO\1740 high-dose_15\JJ\1740 <e1>5-fluorouracil</e1>_16\NN\1740 was_17\VBD\836236 highly_18\RB\1740 suspected_19\VBN\916909 ._20\.\1740
D005472_D020258 NONE the_0\DT\1740 pathogenesis_1\NN\13533470 of_2\IN\1740 <e1>5-fluorouracil</e1>_3\NN\1740 <e2>neurotoxicity</e2>_4\NN\1740 may_5\MD\15209706 be_6\VB\836236 due_7\JJ\1740 to_8\TO\1740 a_9\DT\13649268 krebs_10\NN\1740 cycle_11\NN\15269513 blockade_12\NN\952963 by_13\IN\1740 fluoroacetate_14\NN\1740 and_15\CC\1740 fluorocitrate_16\VB\1740 ,_17\,\1740 thiamine_18\NN\15090742 deficiency_19\NN\14449126 ,_20\,\1740 or_21\CC\3541091 dihydrouracil_22\NN\1740 dehydrogenase_23\NN\1740 deficiency_24\NN\14449126 ._25\.\1740
D005463_D020258 NONE the_0\DT\1740 pathogenesis_1\NN\13533470 of_2\IN\1740 5-fluorouracil_3\NN\1740 <e2>neurotoxicity</e2>_4\NN\1740 may_5\MD\15209706 be_6\VB\836236 due_7\JJ\1740 to_8\TO\1740 a_9\DT\13649268 krebs_10\NN\1740 cycle_11\NN\15269513 blockade_12\NN\952963 by_13\IN\1740 <e1>fluoroacetate</e1>_14\NN\1740 and_15\CC\1740 fluorocitrate_16\VB\1740 ,_17\,\1740 thiamine_18\NN\15090742 deficiency_19\NN\14449126 ,_20\,\1740 or_21\CC\3541091 dihydrouracil_22\NN\1740 dehydrogenase_23\NN\1740 deficiency_24\NN\14449126 ._25\.\1740
C007744_D020258 NONE the_0\DT\1740 pathogenesis_1\NN\13533470 of_2\IN\1740 5-fluorouracil_3\NN\1740 <e2>neurotoxicity</e2>_4\NN\1740 may_5\MD\15209706 be_6\VB\836236 due_7\JJ\1740 to_8\TO\1740 a_9\DT\13649268 krebs_10\NN\1740 cycle_11\NN\15269513 blockade_12\NN\952963 by_13\IN\1740 fluoroacetate_14\NN\1740 and_15\CC\1740 <e1>fluorocitrate</e1>_16\VB\1740 ,_17\,\1740 thiamine_18\NN\15090742 deficiency_19\NN\14449126 ,_20\,\1740 or_21\CC\3541091 dihydrouracil_22\NN\1740 dehydrogenase_23\NN\1740 deficiency_24\NN\14449126 ._25\.\1740
D013831_D020258 NONE the_0\DT\1740 pathogenesis_1\NN\13533470 of_2\IN\1740 5-fluorouracil_3\NN\1740 <e2>neurotoxicity</e2>_4\NN\1740 may_5\MD\15209706 be_6\VB\836236 due_7\JJ\1740 to_8\TO\1740 a_9\DT\13649268 krebs_10\NN\1740 cycle_11\NN\15269513 blockade_12\NN\952963 by_13\IN\1740 fluoroacetate_14\NN\1740 and_15\CC\1740 fluorocitrate_16\VB\1740 ,_17\,\1740 <e1>thiamine</e1>_18\NN\15090742 deficiency_19\NN\14449126 ,_20\,\1740 or_21\CC\3541091 dihydrouracil_22\NN\1740 dehydrogenase_23\NN\1740 deficiency_24\NN\14449126 ._25\.\1740
C007419_D020258 NONE the_0\DT\1740 pathogenesis_1\NN\13533470 of_2\IN\1740 5-fluorouracil_3\NN\1740 <e2>neurotoxicity</e2>_4\NN\1740 may_5\MD\15209706 be_6\VB\836236 due_7\JJ\1740 to_8\TO\1740 a_9\DT\13649268 krebs_10\NN\1740 cycle_11\NN\15269513 blockade_12\NN\952963 by_13\IN\1740 fluoroacetate_14\NN\1740 and_15\CC\1740 fluorocitrate_16\VB\1740 ,_17\,\1740 thiamine_18\NN\15090742 deficiency_19\NN\14449126 ,_20\,\1740 or_21\CC\3541091 <e1>dihydrouracil</e1>_22\NN\1740 dehydrogenase_23\NN\1740 deficiency_24\NN\14449126 ._25\.\1740
D005472_D009369 NONE high-dose_0\JJ\1740 <e1>5-fluorouracil/folinic</e1>_1\NN\1740 acid_2\NN\14818238 infusion_3\NN\14589223 therapy_4\NN\657604 has_5\VBZ\2108377 recently_6\RB\1740 become_7\VBN\146138 a_8\DT\13649268 popular_9\JJ\1740 regimen_10\NN\5898568 for_11\IN\1740 various_12\JJ\1740 <e2>cancers</e2>_13\NNS\14239425 ._14\.\1740
D002955_D009369 NONE high-dose_0\JJ\1740 <e1>5-fluorouracil/folinic_1\NN\1740 acid</e1>_2\NN\14818238 infusion_3\NN\14589223 therapy_4\NN\657604 has_5\VBZ\2108377 recently_6\RB\1740 become_7\VBN\146138 a_8\DT\13649268 popular_9\JJ\1740 regimen_10\NN\5898568 for_11\IN\1740 various_12\JJ\1740 <e2>cancers</e2>_13\NNS\14239425 ._14\.\1740
2234245
D003676_D014786 NONE <e2>ocular_0\JJ\1740 and_1\CC\1740 auditory_2\JJ\1740 toxicity</e2>_3\NN\13576101 in_4\IN\13603305 hemodialyzed_5\VBN\1740 patients_6\NNS\9898892 receiving_7\VBG\2210855 <e1>desferrioxamine</e1>_8\NN\1740 ._9\.\1740
D003676_D014786 NONE during_0\IN\1740 an_1\DT\6697703 18-month_2\JJ\1740 period_3\NN\13575869 of_4\IN\1740 study_5\NN\635850 41_6\CD\1740 hemodialyzed_7\VBD\1740 patients_8\NNS\9898892 receiving_9\VBG\2210855 <e1>desferrioxamine</e1>_10\NN\1740 (_11\-LRB-\1740 10_12\CD\13745420 -_13\SYM\1740 40_14\CD\13745420 mg/kg_15\NN\1740 bw/3_16\NN\1740 times_17\NNS\15113229 weekly_18\RB\1740 )_19\-RRB-\1740 for_20\IN\1740 the_21\DT\1740 first_22\JJ\1740 time_23\NN\7308889 were_24\VBD\836236 monitored_25\VBN\2169352 for_26\IN\1740 detection_27\NN\5708432 of_28\IN\1740 <e2>audiovisual_29\JJ\1740 toxicity</e2>_30\NN\13576101 ._31\.\1740
D003676_D014786 NONE the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e2>audiovisual_4\JJ\1740 toxicity</e2>_5\NN\13576101 is_6\VBZ\836236 not_7\RB\1740 an_8\DT\6697703 infrequent_9\JJ\1740 complication_10\NN\1073995 in_11\IN\13603305 hemodialyzed_12\VBN\1740 patients_13\NNS\9898892 receiving_14\VBG\2210855 <e1>desferrioxamine</e1>_15\NN\1740 ._16\.\1740
D003676_D006311 NONE <e2>ocular_0\JJ\1740 and_1\CC\1740 auditory_2\JJ\1740 toxicity</e2>_3\NN\13576101 in_4\IN\13603305 hemodialyzed_5\VBN\1740 patients_6\NNS\9898892 receiving_7\VBG\2210855 <e1>desferrioxamine</e1>_8\NN\1740 ._9\.\1740
D003676_D006311 NONE during_0\IN\1740 an_1\DT\6697703 18-month_2\JJ\1740 period_3\NN\13575869 of_4\IN\1740 study_5\NN\635850 41_6\CD\1740 hemodialyzed_7\VBD\1740 patients_8\NNS\9898892 receiving_9\VBG\2210855 <e1>desferrioxamine</e1>_10\NN\1740 (_11\-LRB-\1740 10_12\CD\13745420 -_13\SYM\1740 40_14\CD\13745420 mg/kg_15\NN\1740 bw/3_16\NN\1740 times_17\NNS\15113229 weekly_18\RB\1740 )_19\-RRB-\1740 for_20\IN\1740 the_21\DT\1740 first_22\JJ\1740 time_23\NN\7308889 were_24\VBD\836236 monitored_25\VBN\2169352 for_26\IN\1740 detection_27\NN\5708432 of_28\IN\1740 <e2>audiovisual_29\JJ\1740 toxicity</e2>_30\NN\13576101 ._31\.\1740
D003676_D006311 NONE the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e2>audiovisual_4\JJ\1740 toxicity</e2>_5\NN\13576101 is_6\VBZ\836236 not_7\RB\1740 an_8\DT\6697703 infrequent_9\JJ\1740 complication_10\NN\1073995 in_11\IN\13603305 hemodialyzed_12\VBN\1740 patients_13\NNS\9898892 receiving_14\VBG\2210855 <e1>desferrioxamine</e1>_15\NN\1740 ._16\.\1740
D003676_D034381 NONE <e1>desferrioxamine</e1>_0\NN\1740 withdrawal_1\NN\7206096 resulted_2\VBD\2633881 in_3\IN\13603305 a_4\DT\13649268 complete_5\JJ\1740 recovery_6\NN\7357388 of_7\IN\1740 visual_8\JJ\1740 function_9\NN\13783581 in_10\IN\13603305 1_11\CD\13741022 patient_12\NN\9898892 and_13\CC\1740 partial_14\JJ\1740 recovery_15\NN\7357388 in_16\IN\13603305 3_17\CD\13741022 ,_18\,\1740 and_19\CC\1740 a_20\DT\13649268 complete_21\JJ\1740 reversal_22\NN\199130 of_23\IN\1740 <e2>hearing_24\VBG\2106506 loss</e2>_25\NN\13252973 in_26\IN\13603305 3_27\CD\13741022 patients_28\NNS\9898892 and_29\CC\1740 partial_30\JJ\1740 recovery_31\NN\7357388 in_32\IN\13603305 3_33\CD\13741022 ._34\.\1740
D003676_D064420 NONE this_0\DT\1740 <e2>toxicity</e2>_1\NN\13576101 appeared_2\VBD\2604760 in_3\IN\13603305 patients_4\NNS\9898892 receiving_5\VBG\2210855 the_6\DT\1740 higher_7\JJR\1740 doses_8\NNS\3740161 of_9\IN\1740 <e1>desferrioxamine</e1>_10\NN\1740 or_11\CC\3541091 coincided_12\VBD\2604477 with_13\IN\1740 the_14\DT\1740 normalization_15\NN\1123598 of_16\IN\1740 ferritin_17\NN\14728724 or_18\CC\3541091 aluminium_19\NN\14625458 serum_20\NN\5397468 levels_21\NNS\4916342 ._22\.\1740
-1_D064420 NONE this_0\DT\1740 <e2>toxicity</e2>_1\NN\13576101 appeared_2\VBD\2604760 in_3\IN\13603305 patients_4\NNS\9898892 receiving_5\VBG\2210855 the_6\DT\1740 higher_7\JJR\1740 doses_8\NNS\3740161 of_9\IN\1740 desferrioxamine_10\NN\1740 or_11\CC\3541091 coincided_12\VBD\2604477 with_13\IN\1740 the_14\DT\1740 normalization_15\NN\1123598 of_16\IN\1740 ferritin_17\NN\14728724 or_18\CC\3541091 <e1>aluminium</e1>_19\NN\14625458 serum_20\NN\5397468 levels_21\NNS\4916342 ._22\.\1740
17437408
D010862_D012640 CID a_0\DT\13649268 comparable_1\JJ\1740 overexpression_2\NN\1740 of_3\IN\1740 pgp_4\NN\1740 in_5\IN\13603305 the_6\DT\1740 bbb_7\NN\1740 was_8\VBD\836236 obtained_9\VBN\2210855 after_10\IN\1740 <e1>pilocarpine-induced</e1>_11\JJ\1740 <e2>seizures</e2>_12\NNS\14081375 in_13\IN\13603305 wild-type_14\JJ\1740 wistar_15\NNP\1740 rats_16\NNS\2329401 ._17\.\1740
18020536
D001569_D004244 CID however_0\RB\1740 ,_1\,\1740 use_2\NN\407535 of_3\IN\1740 <e1>bzds/rds</e1>_4\NN\1740 was_5\VBD\836236 associated_6\VBN\628491 with_7\IN\1740 <e2>dizziness</e2>_8\NN\14299637 ,_9\,\1740 inability_10\NN\23271 to_11\TO\1740 sleep_12\VB\14405 after_13\IN\1740 awaking_14\VBG\146138 at_15\IN\14622893 night_16\NN\15113229 and_17\CC\1740 tiredness_18\VB\1740 in_19\IN\13603305 the_20\DT\1740 mornings_21\NNS\15113229 during_22\IN\1740 the_23\DT\1740 week_24\NN\15113229 prior_25\RB\1740 to_26\IN\1740 admission_27\NN\49003 and_28\CC\1740 with_29\IN\1740 stronger_30\JJR\1740 depressive_31\JJ\1740 symptoms_32\NNS\5823932 measured_33\VBN\697589 at_34\IN\14622893 the_35\DT\1740 beginning_36\NN\7283608 of_37\IN\1740 the_38\DT\1740 hospital_39\NN\3739518 stay_40\VBP\2604760 ._41\.\1740
D001569_D007319 CID however_0\RB\1740 ,_1\,\1740 use_2\NN\407535 of_3\IN\1740 <e1>bzds/rds</e1>_4\NN\1740 was_5\VBD\836236 associated_6\VBN\628491 with_7\IN\1740 dizziness_8\NN\14299637 ,_9\,\1740 <e2>inability_10\NN\23271 to_11\TO\1740 sleep</e2>_12\VB\14405 after_13\IN\1740 awaking_14\VBG\146138 at_15\IN\14622893 night_16\NN\15113229 and_17\CC\1740 tiredness_18\VB\1740 in_19\IN\13603305 the_20\DT\1740 mornings_21\NNS\15113229 during_22\IN\1740 the_23\DT\1740 week_24\NN\15113229 prior_25\RB\1740 to_26\IN\1740 admission_27\NN\49003 and_28\CC\1740 with_29\IN\1740 stronger_30\JJR\1740 depressive_31\JJ\1740 symptoms_32\NNS\5823932 measured_33\VBN\697589 at_34\IN\14622893 the_35\DT\1740 beginning_36\NN\7283608 of_37\IN\1740 the_38\DT\1740 hospital_39\NN\3739518 stay_40\VBP\2604760 ._41\.\1740
D001569_D005221 CID however_0\RB\1740 ,_1\,\1740 use_2\NN\407535 of_3\IN\1740 <e1>bzds/rds</e1>_4\NN\1740 was_5\VBD\836236 associated_6\VBN\628491 with_7\IN\1740 dizziness_8\NN\14299637 ,_9\,\1740 inability_10\NN\23271 to_11\TO\1740 sleep_12\VB\14405 after_13\IN\1740 awaking_14\VBG\146138 at_15\IN\14622893 night_16\NN\15113229 and_17\CC\1740 <e2>tiredness</e2>_18\VB\1740 in_19\IN\13603305 the_20\DT\1740 mornings_21\NNS\15113229 during_22\IN\1740 the_23\DT\1740 week_24\NN\15113229 prior_25\RB\1740 to_26\IN\1740 admission_27\NN\49003 and_28\CC\1740 with_29\IN\1740 stronger_30\JJR\1740 depressive_31\JJ\1740 symptoms_32\NNS\5823932 measured_33\VBN\697589 at_34\IN\14622893 the_35\DT\1740 beginning_36\NN\7283608 of_37\IN\1740 the_38\DT\1740 hospital_39\NN\3739518 stay_40\VBP\2604760 ._41\.\1740
D001569_D003866 CID however_0\RB\1740 ,_1\,\1740 use_2\NN\407535 of_3\IN\1740 <e1>bzds/rds</e1>_4\NN\1740 was_5\VBD\836236 associated_6\VBN\628491 with_7\IN\1740 dizziness_8\NN\14299637 ,_9\,\1740 inability_10\NN\23271 to_11\TO\1740 sleep_12\VB\14405 after_13\IN\1740 awaking_14\VBG\146138 at_15\IN\14622893 night_16\NN\15113229 and_17\CC\1740 tiredness_18\VB\1740 in_19\IN\13603305 the_20\DT\1740 mornings_21\NNS\15113229 during_22\IN\1740 the_23\DT\1740 week_24\NN\15113229 prior_25\RB\1740 to_26\IN\1740 admission_27\NN\49003 and_28\CC\1740 with_29\IN\1740 stronger_30\JJR\1740 <e2>depressive_31\JJ\1740 symptoms</e2>_32\NNS\5823932 measured_33\VBN\697589 at_34\IN\14622893 the_35\DT\1740 beginning_36\NN\7283608 of_37\IN\1740 the_38\DT\1740 hospital_39\NN\3739518 stay_40\VBP\2604760 ._41\.\1740
9625142
D002443_D056486 CID acute_0\JJ\1740 <e2>hepatitis</e2>_1\NN\14127211 ,_2\,\1740 autoimmune_3\JJ\1740 hemolytic_4\JJ\1740 anemia_5\NN\14189204 ,_6\,\1740 and_7\CC\1740 erythroblastocytopenia_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 <e1>ceftriaxone</e1>_11\NN\2996840 ._12\.\1740
D002443_D056486 CID an_0\DT\6697703 80-yr-old_1\NN\1740 man_2\NN\9605289 developed_3\VBD\1753788 acute_4\JJ\1740 <e2>hepatitis</e2>_5\NN\14127211 shortly_6\RB\1740 after_7\IN\1740 ingesting_8\VBG\597915 oral_9\JJ\1740 <e1>ceftriaxone</e1>_10\NN\2996840 ._11\.\1740
D002443_D000744 CID acute_0\JJ\1740 hepatitis_1\NN\14127211 ,_2\,\1740 <e2>autoimmune_3\JJ\1740 hemolytic_4\JJ\1740 anemia</e2>_5\NN\14189204 ,_6\,\1740 and_7\CC\1740 erythroblastocytopenia_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 <e1>ceftriaxone</e1>_11\NN\2996840 ._12\.\1740
D002443_-1 NONE acute_0\JJ\1740 hepatitis_1\NN\14127211 ,_2\,\1740 autoimmune_3\JJ\1740 hemolytic_4\JJ\1740 anemia_5\NN\14189204 ,_6\,\1740 and_7\CC\1740 <e2>erythroblastocytopenia</e2>_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 <e1>ceftriaxone</e1>_11\NN\2996840 ._12\.\1740
D047090_D000744 NONE although_0\IN\1740 the_1\DT\1740 transaminases_2\NNS\15077571 gradually_3\RB\1740 returned_4\VBD\1835496 to_5\TO\1740 baseline_6\NN\7260623 after_7\IN\1740 withholding_8\VBG\2212825 the_9\DT\1740 <e1>beta_10\NN\6828818 lactam</e1>_11\NN\1740 antibiotic_12\NN\2716205 ,_13\,\1740 there_14\EX\27167 was_15\VBD\836236 a_16\DT\13649268 gradual_17\JJ\1740 increase_18\NN\13576355 in_19\IN\13603305 serum_20\NN\5397468 bilirubin_21\NN\14756039 and_22\CC\1740 a_23\DT\13649268 decrease_24\NN\7296428 in_25\IN\13603305 hemoglobin_26\NN\14888884 concentration_27\NN\4916342 caused_28\VBN\1617192 by_29\IN\1740 an_30\DT\6697703 <e2>autoimmune_31\JJ\1740 hemolytic_32\JJ\1740 anemia</e2>_33\NN\14189204 and_34\CC\1740 erythroblastocytopenia_35\NN\1740 ._36\.\1740
D047090_-1 NONE although_0\IN\1740 the_1\DT\1740 transaminases_2\NNS\15077571 gradually_3\RB\1740 returned_4\VBD\1835496 to_5\TO\1740 baseline_6\NN\7260623 after_7\IN\1740 withholding_8\VBG\2212825 the_9\DT\1740 <e1>beta_10\NN\6828818 lactam</e1>_11\NN\1740 antibiotic_12\NN\2716205 ,_13\,\1740 there_14\EX\27167 was_15\VBD\836236 a_16\DT\13649268 gradual_17\JJ\1740 increase_18\NN\13576355 in_19\IN\13603305 serum_20\NN\5397468 bilirubin_21\NN\14756039 and_22\CC\1740 a_23\DT\13649268 decrease_24\NN\7296428 in_25\IN\13603305 hemoglobin_26\NN\14888884 concentration_27\NN\4916342 caused_28\VBN\1617192 by_29\IN\1740 an_30\DT\6697703 autoimmune_31\JJ\1740 hemolytic_32\JJ\1740 anemia_33\NN\14189204 and_34\CC\1740 <e2>erythroblastocytopenia</e2>_35\NN\1740 ._36\.\1740
D001663_D000744 NONE although_0\IN\1740 the_1\DT\1740 transaminases_2\NNS\15077571 gradually_3\RB\1740 returned_4\VBD\1835496 to_5\TO\1740 baseline_6\NN\7260623 after_7\IN\1740 withholding_8\VBG\2212825 the_9\DT\1740 beta_10\NN\6828818 lactam_11\NN\1740 antibiotic_12\NN\2716205 ,_13\,\1740 there_14\EX\27167 was_15\VBD\836236 a_16\DT\13649268 gradual_17\JJ\1740 increase_18\NN\13576355 in_19\IN\13603305 serum_20\NN\5397468 <e1>bilirubin</e1>_21\NN\14756039 and_22\CC\1740 a_23\DT\13649268 decrease_24\NN\7296428 in_25\IN\13603305 hemoglobin_26\NN\14888884 concentration_27\NN\4916342 caused_28\VBN\1617192 by_29\IN\1740 an_30\DT\6697703 <e2>autoimmune_31\JJ\1740 hemolytic_32\JJ\1740 anemia</e2>_33\NN\14189204 and_34\CC\1740 erythroblastocytopenia_35\NN\1740 ._36\.\1740
D001663_-1 NONE although_0\IN\1740 the_1\DT\1740 transaminases_2\NNS\15077571 gradually_3\RB\1740 returned_4\VBD\1835496 to_5\TO\1740 baseline_6\NN\7260623 after_7\IN\1740 withholding_8\VBG\2212825 the_9\DT\1740 beta_10\NN\6828818 lactam_11\NN\1740 antibiotic_12\NN\2716205 ,_13\,\1740 there_14\EX\27167 was_15\VBD\836236 a_16\DT\13649268 gradual_17\JJ\1740 increase_18\NN\13576355 in_19\IN\13603305 serum_20\NN\5397468 <e1>bilirubin</e1>_21\NN\14756039 and_22\CC\1740 a_23\DT\13649268 decrease_24\NN\7296428 in_25\IN\13603305 hemoglobin_26\NN\14888884 concentration_27\NN\4916342 caused_28\VBN\1617192 by_29\IN\1740 an_30\DT\6697703 autoimmune_31\JJ\1740 hemolytic_32\JJ\1740 anemia_33\NN\14189204 and_34\CC\1740 <e2>erythroblastocytopenia</e2>_35\NN\1740 ._36\.\1740
16403073
D007654_D016171 CID <e1>ketoconazole</e1>_0\NNP\1740 induced_1\VBD\1627355 <e2>torsades_2\NNS\1740 de_3\IN\1740 pointes</e2>_4\NNS\1740 without_5\IN\1740 concomitant_6\JJ\1740 use_7\NN\407535 of_8\IN\1740 qt_9\NN\1740 interval-prolonging_10\JJ\1740 drug_11\NN\14778436 ._12\.\1740
D007654_D016171 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 woman_3\NN\9605289 with_4\IN\1740 coronary_5\JJ\1740 artery_6\NN\5417975 disease_7\NN\14061805 who_8\WP\8299493 developed_9\VBD\1753788 a_10\DT\13649268 markedly_11\RB\1740 prolonged_12\JJ\1740 qt_13\NN\1740 interval_14\NN\33615 and_15\CC\1740 <e2>torsades_16\NNS\1740 de_17\IN\1740 pointes</e2>_18\NNS\1740 (_19\-LRB-\1740 tdp_20\NN\1740 )_21\-RRB-\1740 after_22\IN\1740 taking_23\VBG\2367363 <e1>ketoconazole</e1>_24\NN\1740 for_25\IN\1740 treatment_26\NN\654885 of_27\IN\1740 fungal_28\JJ\1740 infection_29\NN\14052046 ._30\.\1740
D007654_D016171 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 woman_3\NN\9605289 with_4\IN\1740 coronary_5\JJ\1740 artery_6\NN\5417975 disease_7\NN\14061805 who_8\WP\8299493 developed_9\VBD\1753788 a_10\DT\13649268 markedly_11\RB\1740 prolonged_12\JJ\1740 qt_13\NN\1740 interval_14\NN\33615 and_15\CC\1740 torsades_16\NNS\1740 de_17\IN\1740 pointes_18\NNS\1740 (_19\-LRB-\1740 <e2>tdp</e2>_20\NN\1740 )_21\-RRB-\1740 after_22\IN\1740 taking_23\VBG\2367363 <e1>ketoconazole</e1>_24\NN\1740 for_25\IN\1740 treatment_26\NN\654885 of_27\IN\1740 fungal_28\JJ\1740 infection_29\NN\14052046 ._30\.\1740
D007654_D016171 CID we_0\PRP\1740 postulate_1\VBP\756338 that_2\IN\1740 by_3\IN\1740 virtue_4\NN\4849241 of_5\IN\1740 its_6\PRP$\6125041 direct_7\JJ\1740 blocking_8\NN\562280 action_9\NN\30358 on_10\IN\1740 ikr_11\NN\1740 ,_12\,\1740 <e1>ketoconazole</e1>_13\NN\1740 alone_14\RB\1740 may_15\MD\15209706 prolong_16\VB\317700 qt_17\NN\1740 interval_18\NN\33615 and_19\CC\1740 induce_20\VBP\1627355 <e2>tdp.</e2>_21\NN\1740 this_22\DT\1740 calls_23\VBZ\1029852 for_24\IN\1740 attention_25\NN\5701944 when_26\WRB\1740 ketoconazole_27\NN\1740 is_28\VBZ\836236 administered_29\VBN\2436349 to_30\TO\1740 patients_31\NNS\9898892 with_32\IN\1740 risk_33\NN\14541044 factors_34\NNS\7326557 for_35\IN\1740 acquired_36\VBN\109660 long_37\JJ\1740 qt_38\NN\1740 syndrome_39\NN\5870365 ._40\.\1740
D007654_D016171 CID we_0\PRP\1740 postulate_1\VBP\756338 that_2\IN\1740 by_3\IN\1740 virtue_4\NN\4849241 of_5\IN\1740 its_6\PRP$\6125041 direct_7\JJ\1740 blocking_8\NN\562280 action_9\NN\30358 on_10\IN\1740 ikr_11\NN\1740 ,_12\,\1740 ketoconazole_13\NN\1740 alone_14\RB\1740 may_15\MD\15209706 prolong_16\VB\317700 qt_17\NN\1740 interval_18\NN\33615 and_19\CC\1740 induce_20\VBP\1627355 <e2>tdp.</e2>_21\NN\1740 this_22\DT\1740 calls_23\VBZ\1029852 for_24\IN\1740 attention_25\NN\5701944 when_26\WRB\1740 <e1>ketoconazole</e1>_27\NN\1740 is_28\VBZ\836236 administered_29\VBN\2436349 to_30\TO\1740 patients_31\NNS\9898892 with_32\IN\1740 risk_33\NN\14541044 factors_34\NNS\7326557 for_35\IN\1740 acquired_36\VBN\109660 long_37\JJ\1740 qt_38\NN\1740 syndrome_39\NN\5870365 ._40\.\1740
D007654_D003324 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 woman_3\NN\9605289 with_4\IN\1740 <e2>coronary_5\JJ\1740 artery_6\NN\5417975 disease</e2>_7\NN\14061805 who_8\WP\8299493 developed_9\VBD\1753788 a_10\DT\13649268 markedly_11\RB\1740 prolonged_12\JJ\1740 qt_13\NN\1740 interval_14\NN\33615 and_15\CC\1740 torsades_16\NNS\1740 de_17\IN\1740 pointes_18\NNS\1740 (_19\-LRB-\1740 tdp_20\NN\1740 )_21\-RRB-\1740 after_22\IN\1740 taking_23\VBG\2367363 <e1>ketoconazole</e1>_24\NN\1740 for_25\IN\1740 treatment_26\NN\654885 of_27\IN\1740 fungal_28\JJ\1740 infection_29\NN\14052046 ._30\.\1740
D007654_D008133 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 woman_3\NN\9605289 with_4\IN\1740 coronary_5\JJ\1740 artery_6\NN\5417975 disease_7\NN\14061805 who_8\WP\8299493 developed_9\VBD\1753788 a_10\DT\13649268 markedly_11\RB\1740 <e2>prolonged_12\JJ\1740 qt_13\NN\1740 interval</e2>_14\NN\33615 and_15\CC\1740 torsades_16\NNS\1740 de_17\IN\1740 pointes_18\NNS\1740 (_19\-LRB-\1740 tdp_20\NN\1740 )_21\-RRB-\1740 after_22\IN\1740 taking_23\VBG\2367363 <e1>ketoconazole</e1>_24\NN\1740 for_25\IN\1740 treatment_26\NN\654885 of_27\IN\1740 fungal_28\JJ\1740 infection_29\NN\14052046 ._30\.\1740
D007654_D008133 CID we_0\PRP\1740 postulate_1\VBP\756338 that_2\IN\1740 by_3\IN\1740 virtue_4\NN\4849241 of_5\IN\1740 its_6\PRP$\6125041 direct_7\JJ\1740 blocking_8\NN\562280 action_9\NN\30358 on_10\IN\1740 ikr_11\NN\1740 ,_12\,\1740 <e1>ketoconazole</e1>_13\NN\1740 alone_14\RB\1740 may_15\MD\15209706 prolong_16\VB\317700 qt_17\NN\1740 interval_18\NN\33615 and_19\CC\1740 induce_20\VBP\1627355 tdp._21\NN\1740 this_22\DT\1740 calls_23\VBZ\1029852 for_24\IN\1740 attention_25\NN\5701944 when_26\WRB\1740 ketoconazole_27\NN\1740 is_28\VBZ\836236 administered_29\VBN\2436349 to_30\TO\1740 patients_31\NNS\9898892 with_32\IN\1740 risk_33\NN\14541044 factors_34\NNS\7326557 for_35\IN\1740 acquired_36\VBN\109660 <e2>long_37\JJ\1740 qt_38\NN\1740 syndrome</e2>_39\NN\5870365 ._40\.\1740
D007654_D008133 CID we_0\PRP\1740 postulate_1\VBP\756338 that_2\IN\1740 by_3\IN\1740 virtue_4\NN\4849241 of_5\IN\1740 its_6\PRP$\6125041 direct_7\JJ\1740 blocking_8\NN\562280 action_9\NN\30358 on_10\IN\1740 ikr_11\NN\1740 ,_12\,\1740 ketoconazole_13\NN\1740 alone_14\RB\1740 may_15\MD\15209706 prolong_16\VB\317700 qt_17\NN\1740 interval_18\NN\33615 and_19\CC\1740 induce_20\VBP\1627355 tdp._21\NN\1740 this_22\DT\1740 calls_23\VBZ\1029852 for_24\IN\1740 attention_25\NN\5701944 when_26\WRB\1740 <e1>ketoconazole</e1>_27\NN\1740 is_28\VBZ\836236 administered_29\VBN\2436349 to_30\TO\1740 patients_31\NNS\9898892 with_32\IN\1740 risk_33\NN\14541044 factors_34\NNS\7326557 for_35\IN\1740 acquired_36\VBN\109660 <e2>long_37\JJ\1740 qt_38\NN\1740 syndrome</e2>_39\NN\5870365 ._40\.\1740
D007654_D009181 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 woman_3\NN\9605289 with_4\IN\1740 coronary_5\JJ\1740 artery_6\NN\5417975 disease_7\NN\14061805 who_8\WP\8299493 developed_9\VBD\1753788 a_10\DT\13649268 markedly_11\RB\1740 prolonged_12\JJ\1740 qt_13\NN\1740 interval_14\NN\33615 and_15\CC\1740 torsades_16\NNS\1740 de_17\IN\1740 pointes_18\NNS\1740 (_19\-LRB-\1740 tdp_20\NN\1740 )_21\-RRB-\1740 after_22\IN\1740 taking_23\VBG\2367363 <e1>ketoconazole</e1>_24\NN\1740 for_25\IN\1740 treatment_26\NN\654885 of_27\IN\1740 <e2>fungal_28\JJ\1740 infection</e2>_29\NN\14052046 ._30\.\1740
3341566
D009599_D006470 NONE systolic_0\JJ\1740 pressure_1\NN\11419404 variation_2\NN\7296428 is_3\VBZ\836236 greater_4\JJR\1740 during_5\IN\1740 <e2>hemorrhage</e2>_6\NN\14285662 than_7\IN\1740 during_8\IN\1740 <e1>sodium_9\NN\14625458 nitroprusside-induced</e1>_10\JJ\1740 hypotension_11\NN\14057371 in_12\IN\13603305 ventilated_13\VBN\164444 dogs_14\NNS\2083346 ._15\.\1740
D009599_D006470 NONE mean_0\VB\928630 arterial_1\JJ\1740 pressure_2\NN\11419404 was_3\VBD\836236 decreased_4\VBN\169651 to_5\TO\1740 50_6\CD\13745420 mm_7\NN\13649268 hg_8\NNP\14625458 for_9\IN\1740 30_10\CD\13745420 minutes_11\NNS\6502378 either_12\CC\1740 by_13\IN\1740 <e2>hemorrhage</e2>_14\NN\14285662 (_15\-LRB-\1740 hem_16\NN\3264542 ,_17\,\1740 n_18\NN\14622893 =_19\JJ\1740 7_20\CD\13741022 )_21\-RRB-\1740 or_22\CC\3541091 by_23\IN\1740 continuous_24\JJ\1740 infusion_25\NN\14589223 of_26\IN\1740 <e1>sodium_27\NN\14625458 nitroprusside</e1>_28\NN\1740 (_29\-LRB-\1740 snp_30\NN\11493266 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 7_34\CD\13741022 )_35\-RRB-\1740 ._36\.\1740
D009599_D006470 NONE mean_0\VB\928630 arterial_1\JJ\1740 pressure_2\NN\11419404 was_3\VBD\836236 decreased_4\VBN\169651 to_5\TO\1740 50_6\CD\13745420 mm_7\NN\13649268 hg_8\NNP\14625458 for_9\IN\1740 30_10\CD\13745420 minutes_11\NNS\6502378 either_12\CC\1740 by_13\IN\1740 hemorrhage_14\NN\14285662 (_15\-LRB-\1740 <e2>hem</e2>_16\NN\3264542 ,_17\,\1740 n_18\NN\14622893 =_19\JJ\1740 7_20\CD\13741022 )_21\-RRB-\1740 or_22\CC\3541091 by_23\IN\1740 continuous_24\JJ\1740 infusion_25\NN\14589223 of_26\IN\1740 <e1>sodium_27\NN\14625458 nitroprusside</e1>_28\NN\1740 (_29\-LRB-\1740 snp_30\NN\11493266 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 7_34\CD\13741022 )_35\-RRB-\1740 ._36\.\1740
D009599_D006470 NONE mean_0\VB\928630 arterial_1\JJ\1740 pressure_2\NN\11419404 was_3\VBD\836236 decreased_4\VBN\169651 to_5\TO\1740 50_6\CD\13745420 mm_7\NN\13649268 hg_8\NNP\14625458 for_9\IN\1740 30_10\CD\13745420 minutes_11\NNS\6502378 either_12\CC\1740 by_13\IN\1740 <e2>hemorrhage</e2>_14\NN\14285662 (_15\-LRB-\1740 hem_16\NN\3264542 ,_17\,\1740 n_18\NN\14622893 =_19\JJ\1740 7_20\CD\13741022 )_21\-RRB-\1740 or_22\CC\3541091 by_23\IN\1740 continuous_24\JJ\1740 infusion_25\NN\14589223 of_26\IN\1740 sodium_27\NN\14625458 nitroprusside_28\NN\1740 (_29\-LRB-\1740 <e1>snp</e1>_30\NN\11493266 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 7_34\CD\13741022 )_35\-RRB-\1740 ._36\.\1740
D009599_D006470 NONE mean_0\VB\928630 arterial_1\JJ\1740 pressure_2\NN\11419404 was_3\VBD\836236 decreased_4\VBN\169651 to_5\TO\1740 50_6\CD\13745420 mm_7\NN\13649268 hg_8\NNP\14625458 for_9\IN\1740 30_10\CD\13745420 minutes_11\NNS\6502378 either_12\CC\1740 by_13\IN\1740 hemorrhage_14\NN\14285662 (_15\-LRB-\1740 <e2>hem</e2>_16\NN\3264542 ,_17\,\1740 n_18\NN\14622893 =_19\JJ\1740 7_20\CD\13741022 )_21\-RRB-\1740 or_22\CC\3541091 by_23\IN\1740 continuous_24\JJ\1740 infusion_25\NN\14589223 of_26\IN\1740 sodium_27\NN\14625458 nitroprusside_28\NN\1740 (_29\-LRB-\1740 <e1>snp</e1>_30\NN\11493266 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 7_34\CD\13741022 )_35\-RRB-\1740 ._36\.\1740
D009599_D006470 NONE during_0\IN\1740 <e2>hem-induced</e2>_1\JJ\1740 hypotension_2\NN\14057371 the_3\DT\1740 cardiac_4\JJ\1740 output_5\NN\4007894 was_6\VBD\836236 significantly_7\RB\1740 lower_8\JJR\1740 and_9\CC\1740 systemic_10\JJ\1740 vascular_11\JJ\1740 resistance_12\NN\37396 higher_13\JJR\1740 compared_14\VBN\644583 with_15\IN\1740 that_16\DT\1740 in_17\IN\13603305 the_18\DT\1740 <e1>snp</e1>_19\NN\11493266 group_20\NN\2137 ._21\.\1740
D009599_D006470 NONE the_0\DT\1740 spv_1\NN\1740 during_2\IN\1740 hypotension_3\NN\14057371 was_4\VBD\836236 15.7_5\CD\1740 +/-_6\CC\1740 6.7_7\CD\1740 mm_8\NN\13649268 hg_9\NNP\14625458 in_10\IN\13603305 the_11\DT\1740 <e2>hem</e2>_12\NN\3264542 group_13\NN\2137 ,_14\,\1740 compared_15\VBN\644583 with_16\IN\1740 9.1_17\CD\1740 +/-_18\CC\1740 2.0_19\CD\1740 mm_20\NN\13649268 hg_21\NNP\14625458 in_22\IN\13603305 the_23\DT\1740 <e1>snp</e1>_24\NN\11493266 group_25\NN\2137 (_26\-LRB-\1740 p_27\NN\14622893 less_28\JJR\1740 than_29\IN\1740 0.02_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D009599_D006470 NONE the_0\DT\1740 delta_1\NN\9193282 down_2\RP\1740 ,_3\,\1740 which_4\WDT\1740 is_5\VBZ\836236 the_6\DT\1740 measure_7\NN\168237 of_8\IN\1740 decrease_9\NN\7296428 of_10\IN\1740 sbp_11\NN\1740 after_12\IN\1740 a_13\DT\13649268 mechanical_14\JJ\1740 breath_15\NN\13440063 ,_16\,\1740 was_17\VBD\836236 20.3_18\CD\1740 +/-_19\CC\1740 8.4_20\CD\1740 and_21\CC\1740 10.1_22\CD\1740 +/-_23\CC\1740 3.8_24\CD\1740 mm_25\NN\13649268 hg_26\NNP\14625458 in_27\IN\13603305 the_28\DT\1740 <e2>hem</e2>_29\NN\3264542 and_30\CC\1740 <e1>snp</e1>_31\NN\11493266 groups_32\NNS\2137 ,_33\,\1740 respectively_34\RB\1740 ,_35\,\1740 during_36\IN\1740 hypotension_37\NN\14057371 (_38\-LRB-\1740 p_39\NN\14622893 less_40\JJR\1740 than_41\IN\1740 0.02_42\CD\1740 )_43\-RRB-\1740 ._44\.\1740
D009599_D007022 CID systolic_0\JJ\1740 pressure_1\NN\11419404 variation_2\NN\7296428 is_3\VBZ\836236 greater_4\JJR\1740 during_5\IN\1740 hemorrhage_6\NN\14285662 than_7\IN\1740 during_8\IN\1740 <e1>sodium_9\NN\14625458 nitroprusside-induced</e1>_10\JJ\1740 <e2>hypotension</e2>_11\NN\14057371 in_12\IN\13603305 ventilated_13\VBN\164444 dogs_14\NNS\2083346 ._15\.\1740
D009599_D007022 CID during_0\IN\1740 hem-induced_1\JJ\1740 <e2>hypotension</e2>_2\NN\14057371 the_3\DT\1740 cardiac_4\JJ\1740 output_5\NN\4007894 was_6\VBD\836236 significantly_7\RB\1740 lower_8\JJR\1740 and_9\CC\1740 systemic_10\JJ\1740 vascular_11\JJ\1740 resistance_12\NN\37396 higher_13\JJR\1740 compared_14\VBN\644583 with_15\IN\1740 that_16\DT\1740 in_17\IN\13603305 the_18\DT\1740 <e1>snp</e1>_19\NN\11493266 group_20\NN\2137 ._21\.\1740
D009599_D007022 CID the_0\DT\1740 spv_1\NN\1740 during_2\IN\1740 <e2>hypotension</e2>_3\NN\14057371 was_4\VBD\836236 15.7_5\CD\1740 +/-_6\CC\1740 6.7_7\CD\1740 mm_8\NN\13649268 hg_9\NNP\14625458 in_10\IN\13603305 the_11\DT\1740 hem_12\NN\3264542 group_13\NN\2137 ,_14\,\1740 compared_15\VBN\644583 with_16\IN\1740 9.1_17\CD\1740 +/-_18\CC\1740 2.0_19\CD\1740 mm_20\NN\13649268 hg_21\NNP\14625458 in_22\IN\13603305 the_23\DT\1740 <e1>snp</e1>_24\NN\11493266 group_25\NN\2137 (_26\-LRB-\1740 p_27\NN\14622893 less_28\JJR\1740 than_29\IN\1740 0.02_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D009599_D007022 CID the_0\DT\1740 delta_1\NN\9193282 down_2\RP\1740 ,_3\,\1740 which_4\WDT\1740 is_5\VBZ\836236 the_6\DT\1740 measure_7\NN\168237 of_8\IN\1740 decrease_9\NN\7296428 of_10\IN\1740 sbp_11\NN\1740 after_12\IN\1740 a_13\DT\13649268 mechanical_14\JJ\1740 breath_15\NN\13440063 ,_16\,\1740 was_17\VBD\836236 20.3_18\CD\1740 +/-_19\CC\1740 8.4_20\CD\1740 and_21\CC\1740 10.1_22\CD\1740 +/-_23\CC\1740 3.8_24\CD\1740 mm_25\NN\13649268 hg_26\NNP\14625458 in_27\IN\13603305 the_28\DT\1740 hem_29\NN\3264542 and_30\CC\1740 <e1>snp</e1>_31\NN\11493266 groups_32\NNS\2137 ,_33\,\1740 respectively_34\RB\1740 ,_35\,\1740 during_36\IN\1740 <e2>hypotension</e2>_37\NN\14057371 (_38\-LRB-\1740 p_39\NN\14622893 less_40\JJR\1740 than_41\IN\1740 0.02_42\CD\1740 )_43\-RRB-\1740 ._44\.\1740
15009014
D002211_D006940 CID <e1>capsaicin</e1>_0\NN\15032661 (_1\-LRB-\1740 0.01_2\CD\1740 -_3\SYM\1740 1_4\CD\13741022 mm_5\NN\13649268 )_6\-RRB-\1740 applied_7\VBD\2676054 to_8\TO\1740 oral_9\JJ\1740 or_10\CC\3541091 nasal_11\JJ\1740 mucosa_12\NN\5426243 induced_13\VBN\1627355 <e2>increases_14\NNS\13576355 in_15\IN\13603305 dural_16\JJ\1740 and_17\CC\1740 cortical_18\JJ\1740 blood_19\NN\5397468 flow</e2>_20\NN\7311115 and_21\CC\1740 provoked_22\VBD\1617192 lacrimation_23\NN\13440063 ._24\.\1740
D001285_D006940 NONE the_0\DT\1740 evoked_1\VBN\1617192 <e2>increases_2\NNS\13576355 in_3\IN\13603305 dural_4\JJ\1740 blood_5\NN\5397468 flow</e2>_6\NN\7311115 were_7\VBD\836236 also_8\RB\1740 abolished_9\VBN\1740 by_10\IN\1740 topical_11\JJ\1740 pre-administration_12\NN\1740 of_13\IN\1740 <e1>atropine</e1>_14\NN\14712692 (_15\-LRB-\1740 1_16\CD\13741022 mm_17\NN\13649268 )_18\-RRB-\1740 and_19\CC\1740 [_20\-LRB-\1740 lys1_21\NN\1740 ,_22\,\1740 pro2,5_23\NN\1740 ,_24\,\1740 arg3,4_25\NN\1740 ,_26\,\1740 tyr6]-vip_27\NN\1740 (_28\-LRB-\1740 0.1_29\CD\1740 mm_30\NN\13649268 )_31\-RRB-\1740 ,_32\,\1740 a_33\DT\13649268 vasoactive_34\JJ\1740 intestinal_35\JJ\1740 polypeptide_36\NN\14743046 (_37\-LRB-\1740 vip_38\NN\10200781 )_39\-RRB-\1740 antagonist_40\NN\7846 ,_41\,\1740 onto_42\IN\1740 the_43\DT\1740 exposed_44\VBN\2110927 dura_45\JJ\1740 mater_46\NN\10332385 ._47\.\1740
19058010
D010936_D009203 NONE effect_0\NN\34213 of_1\IN\1740 <e1>green_2\JJ\1740 tea</e1>_3\NN\7881800 and_4\CC\1740 vitamin_5\NN\7570720 e_6\NN\14724645 combination_7\NN\7951464 in_8\IN\13603305 isoproterenol_9\NN\3740161 induced_10\JJ\1740 <e2>myocardial_11\JJ\1740 infarction</e2>_12\NN\14204950 in_13\IN\13603305 rats_14\NNS\2329401 ._15\.\1740
D010936_D009203 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 aimed_4\VBN\1987160 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 combined_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 <e1>green_11\JJ\1740 tea</e1>_12\NN\7881800 and_13\CC\1740 vitamin_14\NN\7570720 e_15\NN\14724645 on_16\IN\1740 heart_17\NN\5919034 weight_18\NN\5009170 ,_19\,\1740 body_20\NN\19128 weight_21\NN\5009170 ,_22\,\1740 serum_23\NN\5397468 marker_24\NN\21939 enzymes_25\NNS\14723628 ,_26\,\1740 lipid_27\NN\14944888 peroxidation_28\NN\1740 ,_29\,\1740 endogenous_30\JJ\1740 antioxidants_31\NNS\14724436 and_32\CC\1740 membrane_33\NN\4188643 bound_34\VBD\1831531 atpases_35\NNS\1740 in_36\IN\13603305 isoproterenol_37\NN\3740161 (iso)-induced_38\VBN\1740 <e2>myocardial_39\JJ\1740 infarction</e2>_40\NN\14204950 in_41\IN\13603305 rats_42\NNS\2329401 ._43\.\1740
D010936_D009203 NONE these_0\DT\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 the_3\DT\1740 synergistic_4\JJ\1740 protective_5\JJ\1740 effect_6\NN\34213 of_7\IN\1740 <e1>green_8\JJ\1740 tea</e1>_9\NN\7881800 and_10\CC\1740 vitamin_11\NN\7570720 e_12\NN\14724645 during_13\IN\1740 iso_14\NN\1740 induced_15\JJ\1740 <e2>myocardial_16\JJ\1740 infarction</e2>_17\NN\14204950 in_18\IN\13603305 rats_19\NNS\2329401 ._20\.\1740
D014810_D009203 NONE effect_0\NN\34213 of_1\IN\1740 green_2\JJ\1740 tea_3\NN\7881800 and_4\CC\1740 <e1>vitamin_5\NN\7570720 e</e1>_6\NN\14724645 combination_7\NN\7951464 in_8\IN\13603305 isoproterenol_9\NN\3740161 induced_10\JJ\1740 <e2>myocardial_11\JJ\1740 infarction</e2>_12\NN\14204950 in_13\IN\13603305 rats_14\NNS\2329401 ._15\.\1740
D014810_D009203 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 aimed_4\VBN\1987160 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 combined_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 green_11\JJ\1740 tea_12\NN\7881800 and_13\CC\1740 <e1>vitamin_14\NN\7570720 e</e1>_15\NN\14724645 on_16\IN\1740 heart_17\NN\5919034 weight_18\NN\5009170 ,_19\,\1740 body_20\NN\19128 weight_21\NN\5009170 ,_22\,\1740 serum_23\NN\5397468 marker_24\NN\21939 enzymes_25\NNS\14723628 ,_26\,\1740 lipid_27\NN\14944888 peroxidation_28\NN\1740 ,_29\,\1740 endogenous_30\JJ\1740 antioxidants_31\NNS\14724436 and_32\CC\1740 membrane_33\NN\4188643 bound_34\VBD\1831531 atpases_35\NNS\1740 in_36\IN\13603305 isoproterenol_37\NN\3740161 (iso)-induced_38\VBN\1740 <e2>myocardial_39\JJ\1740 infarction</e2>_40\NN\14204950 in_41\IN\13603305 rats_42\NNS\2329401 ._43\.\1740
D014810_D009203 NONE these_0\DT\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 the_3\DT\1740 synergistic_4\JJ\1740 protective_5\JJ\1740 effect_6\NN\34213 of_7\IN\1740 green_8\JJ\1740 tea_9\NN\7881800 and_10\CC\1740 <e1>vitamin_11\NN\7570720 e</e1>_12\NN\14724645 during_13\IN\1740 iso_14\NN\1740 induced_15\JJ\1740 <e2>myocardial_16\JJ\1740 infarction</e2>_17\NN\14204950 in_18\IN\13603305 rats_19\NNS\2329401 ._20\.\1740
D007545_D009203 CID effect_0\NN\34213 of_1\IN\1740 green_2\JJ\1740 tea_3\NN\7881800 and_4\CC\1740 vitamin_5\NN\7570720 e_6\NN\14724645 combination_7\NN\7951464 in_8\IN\13603305 <e1>isoproterenol</e1>_9\NN\3740161 induced_10\JJ\1740 <e2>myocardial_11\JJ\1740 infarction</e2>_12\NN\14204950 in_13\IN\13603305 rats_14\NNS\2329401 ._15\.\1740
D007545_D009203 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 aimed_4\VBN\1987160 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 combined_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 green_11\JJ\1740 tea_12\NN\7881800 and_13\CC\1740 vitamin_14\NN\7570720 e_15\NN\14724645 on_16\IN\1740 heart_17\NN\5919034 weight_18\NN\5009170 ,_19\,\1740 body_20\NN\19128 weight_21\NN\5009170 ,_22\,\1740 serum_23\NN\5397468 marker_24\NN\21939 enzymes_25\NNS\14723628 ,_26\,\1740 lipid_27\NN\14944888 peroxidation_28\NN\1740 ,_29\,\1740 endogenous_30\JJ\1740 antioxidants_31\NNS\14724436 and_32\CC\1740 membrane_33\NN\4188643 bound_34\VBD\1831531 atpases_35\NNS\1740 in_36\IN\13603305 <e1>isoproterenol</e1>_37\NN\3740161 (iso)-induced_38\VBN\1740 <e2>myocardial_39\JJ\1740 infarction</e2>_40\NN\14204950 in_41\IN\13603305 rats_42\NNS\2329401 ._43\.\1740
D007545_D009203 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 aimed_4\VBN\1987160 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 combined_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 green_11\JJ\1740 tea_12\NN\7881800 and_13\CC\1740 vitamin_14\NN\7570720 e_15\NN\14724645 on_16\IN\1740 heart_17\NN\5919034 weight_18\NN\5009170 ,_19\,\1740 body_20\NN\19128 weight_21\NN\5009170 ,_22\,\1740 serum_23\NN\5397468 marker_24\NN\21939 enzymes_25\NNS\14723628 ,_26\,\1740 lipid_27\NN\14944888 peroxidation_28\NN\1740 ,_29\,\1740 endogenous_30\JJ\1740 antioxidants_31\NNS\14724436 and_32\CC\1740 membrane_33\NN\4188643 bound_34\VBD\1831531 atpases_35\NNS\1740 in_36\IN\13603305 isoproterenol_37\NN\3740161 <e1>(iso)-induced</e1>_38\VBN\1740 <e2>myocardial_39\JJ\1740 infarction</e2>_40\NN\14204950 in_41\IN\13603305 rats_42\NNS\2329401 ._43\.\1740
D007545_D009203 CID these_0\DT\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 the_3\DT\1740 synergistic_4\JJ\1740 protective_5\JJ\1740 effect_6\NN\34213 of_7\IN\1740 green_8\JJ\1740 tea_9\NN\7881800 and_10\CC\1740 vitamin_11\NN\7570720 e_12\NN\14724645 during_13\IN\1740 <e1>iso</e1>_14\NN\1740 induced_15\JJ\1740 <e2>myocardial_16\JJ\1740 infarction</e2>_17\NN\14204950 in_18\IN\13603305 rats_19\NNS\2329401 ._20\.\1740
2096243
C017367_D019965 CID <e1>carmofur-induced</e1>_0\JJ\1740 <e2>organic_1\JJ\1740 mental_2\JJ\1740 disorders</e2>_3\NNS\14034177 ._4\.\1740
C017367_D019965 CID <e2>organic_0\JJ\1740 mental_1\JJ\1740 disorder</e2>_2\NN\14034177 was_3\VBD\836236 observed_4\VBN\2163746 in_5\IN\13603305 a_6\DT\13649268 29-year-old_7\JJ\1740 female_8\NN\15388 in_9\IN\13603305 the_10\DT\1740 prognostic_11\JJ\1740 period_12\NN\13575869 after_13\IN\1740 the_14\DT\1740 onset_15\NN\7325190 of_16\IN\1740 <e1>carmofur-induced</e1>_17\JJ\1740 leukoencephalopathy_18\NN\1740 ._19\.\1740
C017367_D056784 CID organic_0\JJ\1740 mental_1\JJ\1740 disorder_2\NN\14034177 was_3\VBD\836236 observed_4\VBN\2163746 in_5\IN\13603305 a_6\DT\13649268 29-year-old_7\JJ\1740 female_8\NN\15388 in_9\IN\13603305 the_10\DT\1740 prognostic_11\JJ\1740 period_12\NN\13575869 after_13\IN\1740 the_14\DT\1740 onset_15\NN\7325190 of_16\IN\1740 <e1>carmofur-induced</e1>_17\JJ\1740 <e2>leukoencephalopathy</e2>_18\NN\1740 ._19\.\1740
C017367_D056784 CID consequently_0\RB\1740 ,_1\,\1740 <e1>carmofur-induced</e1>_2\JJ\1740 <e2>leukoencephalopathy</e2>_3\NN\1740 may_4\MD\15209706 uncommonly_5\RB\1740 result_6\VB\2633881 in_7\IN\13603305 organic_8\JJ\1740 personality_9\NN\24264 syndrome_10\NN\5870365 in_11\IN\13603305 the_12\DT\1740 residual_13\JJ\1740 state_14\NN\8491826 ._15\.\1740
C017367_D010554 NONE consequently_0\RB\1740 ,_1\,\1740 <e1>carmofur-induced</e1>_2\JJ\1740 leukoencephalopathy_3\NN\1740 may_4\MD\15209706 uncommonly_5\RB\1740 result_6\VB\2633881 in_7\IN\13603305 <e2>organic_8\JJ\1740 personality_9\NN\24264 syndrome</e2>_10\NN\5870365 in_11\IN\13603305 the_12\DT\1740 residual_13\JJ\1740 state_14\NN\8491826 ._15\.\1740
3676049
D007530_D007022 CID cerebral_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 and_3\CC\1740 metabolism_4\NN\13526110 during_5\IN\1740 <e1>isoflurane-induced</e1>_6\JJ\1740 <e2>hypotension</e2>_7\NN\14057371 in_8\IN\13603305 patients_9\NNS\9898892 subjected_10\VBN\137313 to_11\TO\1740 surgery_12\NN\6045562 for_13\IN\1740 cerebral_14\JJ\1740 aneurysms_15\NNS\14057371 ._16\.\1740
D007530_D007022 CID cerebral_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 and_3\CC\1740 cerebral_4\JJ\1740 metabolic_5\JJ\1740 rate_6\NN\13815152 for_7\IN\1740 oxygen_8\NN\14622893 were_9\VBD\836236 measured_10\VBN\697589 during_11\IN\1740 <e1>isoflurane-induced</e1>_12\JJ\1740 <e2>hypotension</e2>_13\NN\14057371 in_14\IN\13603305 10_15\CD\13745420 patients_16\NNS\9898892 subjected_17\VBN\137313 to_18\TO\1740 craniotomy_19\VB\1740 for_20\IN\1740 clipping_21\VBG\1552519 of_22\IN\1740 a_23\DT\13649268 cerebral_24\JJ\1740 aneurysm_25\NN\14057371 ._26\.\1740
D007530_D007022 CID controlled_0\VBN\2422663 <e2>hypotension</e2>_1\NN\14057371 to_2\TO\1740 an_3\DT\6697703 average_4\JJ\1740 map_5\NN\4076846 of_6\IN\1740 50_7\CD\13745420 -_8\SYM\1740 55_9\CD\1740 mm_10\NNS\13649268 hg_11\NNP\14625458 was_12\VBD\836236 induced_13\VBN\1627355 by_14\IN\1740 increasing_15\VBG\169651 the_16\DT\1740 dose_17\NN\3740161 of_18\IN\1740 <e1>isoflurane</e1>_19\NN\3570838 ,_20\,\1740 and_21\CC\1740 maintained_22\VBN\2202928 at_23\IN\14622893 an_24\DT\6697703 inspired_25\JJ\1740 concentration_26\NN\4916342 of_27\IN\1740 2.2_28\CD\1740 +/-_29\CC\1740 0.2_30\CD\1740 %_31\NN\1740 ._32\.\1740
D007530_D002532 NONE cerebral_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 and_3\CC\1740 metabolism_4\NN\13526110 during_5\IN\1740 <e1>isoflurane-induced</e1>_6\JJ\1740 hypotension_7\NN\14057371 in_8\IN\13603305 patients_9\NNS\9898892 subjected_10\VBN\137313 to_11\TO\1740 surgery_12\NN\6045562 for_13\IN\1740 <e2>cerebral_14\JJ\1740 aneurysms</e2>_15\NNS\14057371 ._16\.\1740
D007530_D002532 NONE cerebral_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 and_3\CC\1740 cerebral_4\JJ\1740 metabolic_5\JJ\1740 rate_6\NN\13815152 for_7\IN\1740 oxygen_8\NN\14622893 were_9\VBD\836236 measured_10\VBN\697589 during_11\IN\1740 <e1>isoflurane-induced</e1>_12\JJ\1740 hypotension_13\NN\14057371 in_14\IN\13603305 10_15\CD\13745420 patients_16\NNS\9898892 subjected_17\VBN\137313 to_18\TO\1740 craniotomy_19\VB\1740 for_20\IN\1740 clipping_21\VBG\1552519 of_22\IN\1740 a_23\DT\13649268 <e2>cerebral_24\JJ\1740 aneurysm</e2>_25\NN\14057371 ._26\.\1740
D010100_D007022 NONE cerebral_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 and_3\CC\1740 cerebral_4\JJ\1740 metabolic_5\JJ\1740 rate_6\NN\13815152 for_7\IN\1740 <e1>oxygen</e1>_8\NN\14622893 were_9\VBD\836236 measured_10\VBN\697589 during_11\IN\1740 isoflurane-induced_12\JJ\1740 <e2>hypotension</e2>_13\NN\14057371 in_14\IN\13603305 10_15\CD\13745420 patients_16\NNS\9898892 subjected_17\VBN\137313 to_18\TO\1740 craniotomy_19\VB\1740 for_20\IN\1740 clipping_21\VBG\1552519 of_22\IN\1740 a_23\DT\13649268 cerebral_24\JJ\1740 aneurysm_25\NN\14057371 ._26\.\1740
D010100_D002532 NONE cerebral_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 and_3\CC\1740 cerebral_4\JJ\1740 metabolic_5\JJ\1740 rate_6\NN\13815152 for_7\IN\1740 <e1>oxygen</e1>_8\NN\14622893 were_9\VBD\836236 measured_10\VBN\697589 during_11\IN\1740 isoflurane-induced_12\JJ\1740 hypotension_13\NN\14057371 in_14\IN\13603305 10_15\CD\13745420 patients_16\NNS\9898892 subjected_17\VBN\137313 to_18\TO\1740 craniotomy_19\VB\1740 for_20\IN\1740 clipping_21\VBG\1552519 of_22\IN\1740 a_23\DT\13649268 <e2>cerebral_24\JJ\1740 aneurysm</e2>_25\NN\14057371 ._26\.\1740
D014978_D013345 NONE flow_0\NN\7311115 and_1\CC\1740 metabolism_2\NN\13526110 were_3\VBD\836236 measured_4\VBN\697589 5_5\CD\13741022 -_6\SYM\1740 13_7\CD\13745420 days_8\NNS\15140892 after_9\IN\1740 the_10\DT\1740 <e2>subarachnoid_11\JJ\1740 haemorrhage</e2>_12\NN\14285662 by_13\IN\1740 a_14\DT\13649268 modification_15\NN\191142 of_16\IN\1740 the_17\DT\1740 classical_18\JJ\1740 kety-schmidt_19\JJ\1740 technique_20\NN\5660268 using_21\VBG\1156834 <e1>xenon-133</e1>_22\NN\1740 i.v._23\NN\1740 anaesthesia_24\NNP\14034177 was_25\VBD\836236 maintained_26\VBN\2202928 with_27\IN\1740 an_28\DT\6697703 inspired_29\JJ\1740 isoflurane_30\NN\3570838 concentration_31\NN\4916342 of_32\IN\1740 0.75_33\CD\1740 %_34\NN\1740 (_35\-LRB-\1740 plus_36\CC\4723816 67_37\CD\1740 %_38\NN\1740 nitrous_39\JJ\1740 oxide_40\NN\14818238 in_41\IN\13603305 oxygen_42\NN\14622893 )_43\-RRB-\1740 ,_44\,\1740 during_45\IN\1740 which_46\WDT\1740 cbf_47\NN\1740 and_48\CC\1740 cmro2_49\NN\1740 were_50\VBD\836236 34.3_51\CD\1740 +/-_52\CC\1740 2.1_53\CD\1740 ml/100_54\CD\1740 g_55\NN\13717155 min-1_56\NN\1740 and_57\CC\1740 2.32_58\CD\1740 +/-_59\CC\1740 0.16_60\CD\1740 ml/100_61\CD\1740 g_62\NN\13717155 min-1_63\NN\1740 at_64\IN\14622893 paco2_65\NN\1740 4.1_66\CD\1740 +/-_67\CC\1740 0.1_68\CD\1740 kpa_69\NN\1740 (_70\-LRB-\1740 mean_71\NN\6021761 +/-_72\CC\1740 sem_73\NN\1740 )_74\-RRB-\1740 ._75\.\1740
D007530_D013345 NONE flow_0\NN\7311115 and_1\CC\1740 metabolism_2\NN\13526110 were_3\VBD\836236 measured_4\VBN\697589 5_5\CD\13741022 -_6\SYM\1740 13_7\CD\13745420 days_8\NNS\15140892 after_9\IN\1740 the_10\DT\1740 <e2>subarachnoid_11\JJ\1740 haemorrhage</e2>_12\NN\14285662 by_13\IN\1740 a_14\DT\13649268 modification_15\NN\191142 of_16\IN\1740 the_17\DT\1740 classical_18\JJ\1740 kety-schmidt_19\JJ\1740 technique_20\NN\5660268 using_21\VBG\1156834 xenon-133_22\NN\1740 i.v._23\NN\1740 anaesthesia_24\NNP\14034177 was_25\VBD\836236 maintained_26\VBN\2202928 with_27\IN\1740 an_28\DT\6697703 inspired_29\JJ\1740 <e1>isoflurane</e1>_30\NN\3570838 concentration_31\NN\4916342 of_32\IN\1740 0.75_33\CD\1740 %_34\NN\1740 (_35\-LRB-\1740 plus_36\CC\4723816 67_37\CD\1740 %_38\NN\1740 nitrous_39\JJ\1740 oxide_40\NN\14818238 in_41\IN\13603305 oxygen_42\NN\14622893 )_43\-RRB-\1740 ,_44\,\1740 during_45\IN\1740 which_46\WDT\1740 cbf_47\NN\1740 and_48\CC\1740 cmro2_49\NN\1740 were_50\VBD\836236 34.3_51\CD\1740 +/-_52\CC\1740 2.1_53\CD\1740 ml/100_54\CD\1740 g_55\NN\13717155 min-1_56\NN\1740 and_57\CC\1740 2.32_58\CD\1740 +/-_59\CC\1740 0.16_60\CD\1740 ml/100_61\CD\1740 g_62\NN\13717155 min-1_63\NN\1740 at_64\IN\14622893 paco2_65\NN\1740 4.1_66\CD\1740 +/-_67\CC\1740 0.1_68\CD\1740 kpa_69\NN\1740 (_70\-LRB-\1740 mean_71\NN\6021761 +/-_72\CC\1740 sem_73\NN\1740 )_74\-RRB-\1740 ._75\.\1740
D009609_D013345 NONE flow_0\NN\7311115 and_1\CC\1740 metabolism_2\NN\13526110 were_3\VBD\836236 measured_4\VBN\697589 5_5\CD\13741022 -_6\SYM\1740 13_7\CD\13745420 days_8\NNS\15140892 after_9\IN\1740 the_10\DT\1740 <e2>subarachnoid_11\JJ\1740 haemorrhage</e2>_12\NN\14285662 by_13\IN\1740 a_14\DT\13649268 modification_15\NN\191142 of_16\IN\1740 the_17\DT\1740 classical_18\JJ\1740 kety-schmidt_19\JJ\1740 technique_20\NN\5660268 using_21\VBG\1156834 xenon-133_22\NN\1740 i.v._23\NN\1740 anaesthesia_24\NNP\14034177 was_25\VBD\836236 maintained_26\VBN\2202928 with_27\IN\1740 an_28\DT\6697703 inspired_29\JJ\1740 isoflurane_30\NN\3570838 concentration_31\NN\4916342 of_32\IN\1740 0.75_33\CD\1740 %_34\NN\1740 (_35\-LRB-\1740 plus_36\CC\4723816 67_37\CD\1740 %_38\NN\1740 <e1>nitrous_39\JJ\1740 oxide</e1>_40\NN\14818238 in_41\IN\13603305 oxygen_42\NN\14622893 )_43\-RRB-\1740 ,_44\,\1740 during_45\IN\1740 which_46\WDT\1740 cbf_47\NN\1740 and_48\CC\1740 cmro2_49\NN\1740 were_50\VBD\836236 34.3_51\CD\1740 +/-_52\CC\1740 2.1_53\CD\1740 ml/100_54\CD\1740 g_55\NN\13717155 min-1_56\NN\1740 and_57\CC\1740 2.32_58\CD\1740 +/-_59\CC\1740 0.16_60\CD\1740 ml/100_61\CD\1740 g_62\NN\13717155 min-1_63\NN\1740 at_64\IN\14622893 paco2_65\NN\1740 4.1_66\CD\1740 +/-_67\CC\1740 0.1_68\CD\1740 kpa_69\NN\1740 (_70\-LRB-\1740 mean_71\NN\6021761 +/-_72\CC\1740 sem_73\NN\1740 )_74\-RRB-\1740 ._75\.\1740
D010100_D013345 NONE flow_0\NN\7311115 and_1\CC\1740 metabolism_2\NN\13526110 were_3\VBD\836236 measured_4\VBN\697589 5_5\CD\13741022 -_6\SYM\1740 13_7\CD\13745420 days_8\NNS\15140892 after_9\IN\1740 the_10\DT\1740 <e2>subarachnoid_11\JJ\1740 haemorrhage</e2>_12\NN\14285662 by_13\IN\1740 a_14\DT\13649268 modification_15\NN\191142 of_16\IN\1740 the_17\DT\1740 classical_18\JJ\1740 kety-schmidt_19\JJ\1740 technique_20\NN\5660268 using_21\VBG\1156834 xenon-133_22\NN\1740 i.v._23\NN\1740 anaesthesia_24\NNP\14034177 was_25\VBD\836236 maintained_26\VBN\2202928 with_27\IN\1740 an_28\DT\6697703 inspired_29\JJ\1740 isoflurane_30\NN\3570838 concentration_31\NN\4916342 of_32\IN\1740 0.75_33\CD\1740 %_34\NN\1740 (_35\-LRB-\1740 plus_36\CC\4723816 67_37\CD\1740 %_38\NN\1740 nitrous_39\JJ\1740 oxide_40\NN\14818238 in_41\IN\13603305 <e1>oxygen</e1>_42\NN\14622893 )_43\-RRB-\1740 ,_44\,\1740 during_45\IN\1740 which_46\WDT\1740 cbf_47\NN\1740 and_48\CC\1740 cmro2_49\NN\1740 were_50\VBD\836236 34.3_51\CD\1740 +/-_52\CC\1740 2.1_53\CD\1740 ml/100_54\CD\1740 g_55\NN\13717155 min-1_56\NN\1740 and_57\CC\1740 2.32_58\CD\1740 +/-_59\CC\1740 0.16_60\CD\1740 ml/100_61\CD\1740 g_62\NN\13717155 min-1_63\NN\1740 at_64\IN\14622893 paco2_65\NN\1740 4.1_66\CD\1740 +/-_67\CC\1740 0.1_68\CD\1740 kpa_69\NN\1740 (_70\-LRB-\1740 mean_71\NN\6021761 +/-_72\CC\1740 sem_73\NN\1740 )_74\-RRB-\1740 ._75\.\1740
D008628_D007022 NONE controlled_0\VBN\2422663 <e2>hypotension</e2>_1\NN\14057371 to_2\TO\1740 an_3\DT\6697703 average_4\JJ\1740 map_5\NN\4076846 of_6\IN\1740 50_7\CD\13745420 -_8\SYM\1740 55_9\CD\1740 mm_10\NNS\13649268 <e1>hg</e1>_11\NNP\14625458 was_12\VBD\836236 induced_13\VBN\1627355 by_14\IN\1740 increasing_15\VBG\169651 the_16\DT\1740 dose_17\NN\3740161 of_18\IN\1740 isoflurane_19\NN\3570838 ,_20\,\1740 and_21\CC\1740 maintained_22\VBN\2202928 at_23\IN\14622893 an_24\DT\6697703 inspired_25\JJ\1740 concentration_26\NN\4916342 of_27\IN\1740 2.2_28\CD\1740 +/-_29\CC\1740 0.2_30\CD\1740 %_31\NN\1740 ._32\.\1740
D007530_D000783 NONE after_0\IN\1740 the_1\DT\1740 clipping_2\NN\6400510 of_3\IN\1740 the_4\DT\1740 <e2>aneurysm</e2>_5\NN\14057371 the_6\DT\1740 <e1>isoflurane</e1>_7\NN\3570838 concentration_8\NN\4916342 was_9\VBD\836236 reduced_10\VBN\441445 to_11\TO\1740 0.75_12\CD\1740 %_13\NN\1740 ._14\.\1740
10706004
D012964_D006973 NONE changes_0\NNS\7283608 of_1\IN\1740 <e1>sodium</e1>_2\NN\14625458 and_3\CC\1740 atp_4\NN\14964590 affinities_5\NNS\11426530 of_6\IN\1740 the_7\DT\1740 cardiac_8\JJ\1740 (na_9\NN\1740 ,_10\,\1740 k)-atpase_11\NN\1740 during_12\IN\1740 and_13\CC\1740 after_14\IN\1740 nitric_15\JJ\1740 oxide_16\NN\14818238 deficient_17\JJ\1740 <e2>hypertension</e2>_18\NN\14057371 ._19\.\1740
D012964_D006973 NONE changes_0\NNS\7283608 of_1\IN\1740 sodium_2\NN\14625458 and_3\CC\1740 atp_4\NN\14964590 affinities_5\NNS\11426530 of_6\IN\1740 the_7\DT\1740 cardiac_8\JJ\1740 <e1>(na</e1>_9\NN\1740 ,_10\,\1740 k)-atpase_11\NN\1740 during_12\IN\1740 and_13\CC\1740 after_14\IN\1740 nitric_15\JJ\1740 oxide_16\NN\14818238 deficient_17\JJ\1740 <e2>hypertension</e2>_18\NN\14057371 ._19\.\1740
D012964_D006973 NONE in_0\IN\13603305 several_1\JJ\1740 models_2\NNS\5888929 of_3\IN\1740 <e2>hypertension</e2>_4\NN\14057371 ,_5\,\1740 elevation_6\NN\7445480 of_7\IN\1740 intracellular_8\JJ\1740 <e1>sodium</e1>_9\NN\14625458 level_10\NN\4916342 was_11\VBD\836236 documented_12\VBN\1000214 in_13\IN\13603305 cardiac_14\JJ\1740 tissue_15\NN\5220461 ._16\.\1740
D012964_D006973 NONE to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 molecular_3\JJ\1740 basis_4\NN\13790712 of_5\IN\1740 disturbances_6\NNS\407535 in_7\IN\13603305 transmembraneous_8\JJ\1740 transport_9\NN\3575240 of_10\IN\1740 <e1>na+</e1>_11\NN\1740 ,_12\,\1740 we_13\PRP\1740 studied_14\VBD\630380 the_15\DT\1740 response_16\NN\11410625 of_17\IN\1740 cardiac_18\JJ\1740 (na_19\NN\1740 ,_20\,\1740 k)-atpase_21\NN\1740 to_22\TO\1740 no-deficient_23\JJ\1740 <e2>hypertension</e2>_24\NN\14057371 induced_25\VBN\1627355 in_26\IN\13603305 rats_27\NNS\2329401 by_28\IN\1740 no-synthase_29\NN\1740 inhibition_30\NN\1068773 with_31\IN\1740 40_32\CD\13745420 mg/kg/day_33\NN\1740 n(g)-nitro-l-arginine_34\NN\1740 methyl_35\NN\14617189 ester_36\NN\14727670 (_37\-LRB-\1740 l-name_38\NN\1740 )_39\-RRB-\1740 for_40\IN\1740 4_41\CD\13741022 four_42\CD\13741022 weeks_43\NNS\15113229 ._44\.\1740
D012964_D006973 NONE to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 molecular_3\JJ\1740 basis_4\NN\13790712 of_5\IN\1740 disturbances_6\NNS\407535 in_7\IN\13603305 transmembraneous_8\JJ\1740 transport_9\NN\3575240 of_10\IN\1740 na+_11\NN\1740 ,_12\,\1740 we_13\PRP\1740 studied_14\VBD\630380 the_15\DT\1740 response_16\NN\11410625 of_17\IN\1740 cardiac_18\JJ\1740 <e1>(na</e1>_19\NN\1740 ,_20\,\1740 k)-atpase_21\NN\1740 to_22\TO\1740 no-deficient_23\JJ\1740 <e2>hypertension</e2>_24\NN\14057371 induced_25\VBN\1627355 in_26\IN\13603305 rats_27\NNS\2329401 by_28\IN\1740 no-synthase_29\NN\1740 inhibition_30\NN\1068773 with_31\IN\1740 40_32\CD\13745420 mg/kg/day_33\NN\1740 n(g)-nitro-l-arginine_34\NN\1740 methyl_35\NN\14617189 ester_36\NN\14727670 (_37\-LRB-\1740 l-name_38\NN\1740 )_39\-RRB-\1740 for_40\IN\1740 4_41\CD\13741022 four_42\CD\13741022 weeks_43\NNS\15113229 ._44\.\1740
D012964_D006973 NONE after_0\IN\1740 recovery_1\NN\7357388 from_2\IN\1740 <e2>hypertension</e2>_3\NN\14057371 ,_4\,\1740 the_5\DT\1740 activity_6\NN\30358 of_7\IN\1740 <e1>(na</e1>_8\NN\1740 ,_9\,\1740 k)-atpase_10\NN\1740 increased_11\VBD\169651 ,_12\,\1740 due_13\JJ\1740 to_14\TO\1740 higher_15\JJR\1740 affinity_16\NN\11426530 of_17\IN\1740 the_18\DT\1740 atp-binding_19\JJ\1740 site_20\NN\8673395 ,_21\,\1740 as_22\IN\14622893 revealed_23\VBN\2137132 from_24\IN\1740 the_25\DT\1740 lowered_26\JJ\1740 km_27\NN\13649268 value_28\NN\5856066 for_29\IN\1740 atp_30\NN\14964590 ._31\.\1740
D012964_D006973 NONE inhibition_0\NN\1068773 of_1\IN\1740 no-synthase_2\NN\1740 induced_3\VBD\1627355 a_4\DT\13649268 reversible_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 accompanied_7\VBN\1835496 by_8\IN\1740 depressed_9\JJ\1740 <e1>na+-extrusion</e1>_10\NN\1740 from_11\IN\1740 cardiac_12\JJ\1740 cells_13\NNS\3080309 as_14\IN\14622893 a_15\DT\13649268 consequence_16\NN\34213 of_17\IN\1740 deteriorated_18\VBN\208836 na+-binding_19\NN\1740 properties_20\NNS\32613 of_21\IN\1740 the_22\DT\1740 (na_23\NN\1740 ,_24\,\1740 k)-atpase_25\NN\1740 ._26\.\1740
D012964_D006973 NONE inhibition_0\NN\1068773 of_1\IN\1740 no-synthase_2\NN\1740 induced_3\VBD\1627355 a_4\DT\13649268 reversible_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 accompanied_7\VBN\1835496 by_8\IN\1740 depressed_9\JJ\1740 na+-extrusion_10\NN\1740 from_11\IN\1740 cardiac_12\JJ\1740 cells_13\NNS\3080309 as_14\IN\14622893 a_15\DT\13649268 consequence_16\NN\34213 of_17\IN\1740 deteriorated_18\VBN\208836 <e1>na+-binding</e1>_19\NN\1740 properties_20\NNS\32613 of_21\IN\1740 the_22\DT\1740 (na_23\NN\1740 ,_24\,\1740 k)-atpase_25\NN\1740 ._26\.\1740
D012964_D006973 NONE inhibition_0\NN\1068773 of_1\IN\1740 no-synthase_2\NN\1740 induced_3\VBD\1627355 a_4\DT\13649268 reversible_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 accompanied_7\VBN\1835496 by_8\IN\1740 depressed_9\JJ\1740 na+-extrusion_10\NN\1740 from_11\IN\1740 cardiac_12\JJ\1740 cells_13\NNS\3080309 as_14\IN\14622893 a_15\DT\13649268 consequence_16\NN\34213 of_17\IN\1740 deteriorated_18\VBN\208836 na+-binding_19\NN\1740 properties_20\NNS\32613 of_21\IN\1740 the_22\DT\1740 <e1>(na</e1>_23\NN\1740 ,_24\,\1740 k)-atpase_25\NN\1740 ._26\.\1740
D000255_D006973 NONE changes_0\NNS\7283608 of_1\IN\1740 sodium_2\NN\14625458 and_3\CC\1740 <e1>atp</e1>_4\NN\14964590 affinities_5\NNS\11426530 of_6\IN\1740 the_7\DT\1740 cardiac_8\JJ\1740 (na_9\NN\1740 ,_10\,\1740 k)-atpase_11\NN\1740 during_12\IN\1740 and_13\CC\1740 after_14\IN\1740 nitric_15\JJ\1740 oxide_16\NN\14818238 deficient_17\JJ\1740 <e2>hypertension</e2>_18\NN\14057371 ._19\.\1740
D000255_D006973 NONE after_0\IN\1740 recovery_1\NN\7357388 from_2\IN\1740 <e2>hypertension</e2>_3\NN\14057371 ,_4\,\1740 the_5\DT\1740 activity_6\NN\30358 of_7\IN\1740 (na_8\NN\1740 ,_9\,\1740 k)-atpase_10\NN\1740 increased_11\VBD\169651 ,_12\,\1740 due_13\JJ\1740 to_14\TO\1740 higher_15\JJR\1740 affinity_16\NN\11426530 of_17\IN\1740 the_18\DT\1740 <e1>atp-binding</e1>_19\JJ\1740 site_20\NN\8673395 ,_21\,\1740 as_22\IN\14622893 revealed_23\VBN\2137132 from_24\IN\1740 the_25\DT\1740 lowered_26\JJ\1740 km_27\NN\13649268 value_28\NN\5856066 for_29\IN\1740 atp_30\NN\14964590 ._31\.\1740
D000255_D006973 NONE after_0\IN\1740 recovery_1\NN\7357388 from_2\IN\1740 <e2>hypertension</e2>_3\NN\14057371 ,_4\,\1740 the_5\DT\1740 activity_6\NN\30358 of_7\IN\1740 (na_8\NN\1740 ,_9\,\1740 k)-atpase_10\NN\1740 increased_11\VBD\169651 ,_12\,\1740 due_13\JJ\1740 to_14\TO\1740 higher_15\JJR\1740 affinity_16\NN\11426530 of_17\IN\1740 the_18\DT\1740 atp-binding_19\JJ\1740 site_20\NN\8673395 ,_21\,\1740 as_22\IN\14622893 revealed_23\VBN\2137132 from_24\IN\1740 the_25\DT\1740 lowered_26\JJ\1740 km_27\NN\13649268 value_28\NN\5856066 for_29\IN\1740 <e1>atp</e1>_30\NN\14964590 ._31\.\1740
D011188_D006973 NONE changes_0\NNS\7283608 of_1\IN\1740 sodium_2\NN\14625458 and_3\CC\1740 atp_4\NN\14964590 affinities_5\NNS\11426530 of_6\IN\1740 the_7\DT\1740 cardiac_8\JJ\1740 (na_9\NN\1740 ,_10\,\1740 <e1>k)-atpase</e1>_11\NN\1740 during_12\IN\1740 and_13\CC\1740 after_14\IN\1740 nitric_15\JJ\1740 oxide_16\NN\14818238 deficient_17\JJ\1740 <e2>hypertension</e2>_18\NN\14057371 ._19\.\1740
D011188_D006973 NONE to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 molecular_3\JJ\1740 basis_4\NN\13790712 of_5\IN\1740 disturbances_6\NNS\407535 in_7\IN\13603305 transmembraneous_8\JJ\1740 transport_9\NN\3575240 of_10\IN\1740 na+_11\NN\1740 ,_12\,\1740 we_13\PRP\1740 studied_14\VBD\630380 the_15\DT\1740 response_16\NN\11410625 of_17\IN\1740 cardiac_18\JJ\1740 (na_19\NN\1740 ,_20\,\1740 <e1>k)-atpase</e1>_21\NN\1740 to_22\TO\1740 no-deficient_23\JJ\1740 <e2>hypertension</e2>_24\NN\14057371 induced_25\VBN\1627355 in_26\IN\13603305 rats_27\NNS\2329401 by_28\IN\1740 no-synthase_29\NN\1740 inhibition_30\NN\1068773 with_31\IN\1740 40_32\CD\13745420 mg/kg/day_33\NN\1740 n(g)-nitro-l-arginine_34\NN\1740 methyl_35\NN\14617189 ester_36\NN\14727670 (_37\-LRB-\1740 l-name_38\NN\1740 )_39\-RRB-\1740 for_40\IN\1740 4_41\CD\13741022 four_42\CD\13741022 weeks_43\NNS\15113229 ._44\.\1740
D011188_D006973 NONE after_0\IN\1740 recovery_1\NN\7357388 from_2\IN\1740 <e2>hypertension</e2>_3\NN\14057371 ,_4\,\1740 the_5\DT\1740 activity_6\NN\30358 of_7\IN\1740 (na_8\NN\1740 ,_9\,\1740 <e1>k)-atpase</e1>_10\NN\1740 increased_11\VBD\169651 ,_12\,\1740 due_13\JJ\1740 to_14\TO\1740 higher_15\JJR\1740 affinity_16\NN\11426530 of_17\IN\1740 the_18\DT\1740 atp-binding_19\JJ\1740 site_20\NN\8673395 ,_21\,\1740 as_22\IN\14622893 revealed_23\VBN\2137132 from_24\IN\1740 the_25\DT\1740 lowered_26\JJ\1740 km_27\NN\13649268 value_28\NN\5856066 for_29\IN\1740 atp_30\NN\14964590 ._31\.\1740
D011188_D006973 NONE inhibition_0\NN\1068773 of_1\IN\1740 no-synthase_2\NN\1740 induced_3\VBD\1627355 a_4\DT\13649268 reversible_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 accompanied_7\VBN\1835496 by_8\IN\1740 depressed_9\JJ\1740 na+-extrusion_10\NN\1740 from_11\IN\1740 cardiac_12\JJ\1740 cells_13\NNS\3080309 as_14\IN\14622893 a_15\DT\13649268 consequence_16\NN\34213 of_17\IN\1740 deteriorated_18\VBN\208836 na+-binding_19\NN\1740 properties_20\NNS\32613 of_21\IN\1740 the_22\DT\1740 (na_23\NN\1740 ,_24\,\1740 <e1>k)-atpase</e1>_25\NN\1740 ._26\.\1740
D009569_D006973 CID changes_0\NNS\7283608 of_1\IN\1740 sodium_2\NN\14625458 and_3\CC\1740 atp_4\NN\14964590 affinities_5\NNS\11426530 of_6\IN\1740 the_7\DT\1740 cardiac_8\JJ\1740 (na_9\NN\1740 ,_10\,\1740 k)-atpase_11\NN\1740 during_12\IN\1740 and_13\CC\1740 after_14\IN\1740 <e1>nitric_15\JJ\1740 oxide</e1>_16\NN\14818238 deficient_17\JJ\1740 <e2>hypertension</e2>_18\NN\14057371 ._19\.\1740
D009569_D006973 CID inhibition_0\NN\1068773 of_1\IN\1740 <e1>no</e1>_2\NN\7204911 synthesis_3\NN\13446390 induces_4\VBZ\1627355 sustained_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 ._7\.\1740
D009569_D006973 CID to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 molecular_3\JJ\1740 basis_4\NN\13790712 of_5\IN\1740 disturbances_6\NNS\407535 in_7\IN\13603305 transmembraneous_8\JJ\1740 transport_9\NN\3575240 of_10\IN\1740 na+_11\NN\1740 ,_12\,\1740 we_13\PRP\1740 studied_14\VBD\630380 the_15\DT\1740 response_16\NN\11410625 of_17\IN\1740 cardiac_18\JJ\1740 (na_19\NN\1740 ,_20\,\1740 k)-atpase_21\NN\1740 to_22\TO\1740 <e1>no-deficient</e1>_23\JJ\1740 <e2>hypertension</e2>_24\NN\14057371 induced_25\VBN\1627355 in_26\IN\13603305 rats_27\NNS\2329401 by_28\IN\1740 no-synthase_29\NN\1740 inhibition_30\NN\1068773 with_31\IN\1740 40_32\CD\13745420 mg/kg/day_33\NN\1740 n(g)-nitro-l-arginine_34\NN\1740 methyl_35\NN\14617189 ester_36\NN\14727670 (_37\-LRB-\1740 l-name_38\NN\1740 )_39\-RRB-\1740 for_40\IN\1740 4_41\CD\13741022 four_42\CD\13741022 weeks_43\NNS\15113229 ._44\.\1740
D009569_D006973 CID to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 molecular_3\JJ\1740 basis_4\NN\13790712 of_5\IN\1740 disturbances_6\NNS\407535 in_7\IN\13603305 transmembraneous_8\JJ\1740 transport_9\NN\3575240 of_10\IN\1740 na+_11\NN\1740 ,_12\,\1740 we_13\PRP\1740 studied_14\VBD\630380 the_15\DT\1740 response_16\NN\11410625 of_17\IN\1740 cardiac_18\JJ\1740 (na_19\NN\1740 ,_20\,\1740 k)-atpase_21\NN\1740 to_22\TO\1740 no-deficient_23\JJ\1740 <e2>hypertension</e2>_24\NN\14057371 induced_25\VBN\1627355 in_26\IN\13603305 rats_27\NNS\2329401 by_28\IN\1740 <e1>no-synthase</e1>_29\NN\1740 inhibition_30\NN\1068773 with_31\IN\1740 40_32\CD\13745420 mg/kg/day_33\NN\1740 n(g)-nitro-l-arginine_34\NN\1740 methyl_35\NN\14617189 ester_36\NN\14727670 (_37\-LRB-\1740 l-name_38\NN\1740 )_39\-RRB-\1740 for_40\IN\1740 4_41\CD\13741022 four_42\CD\13741022 weeks_43\NNS\15113229 ._44\.\1740
D009569_D006973 CID inhibition_0\NN\1068773 of_1\IN\1740 <e1>no-synthase</e1>_2\NN\1740 induced_3\VBD\1627355 a_4\DT\13649268 reversible_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 accompanied_7\VBN\1835496 by_8\IN\1740 depressed_9\JJ\1740 na+-extrusion_10\NN\1740 from_11\IN\1740 cardiac_12\JJ\1740 cells_13\NNS\3080309 as_14\IN\14622893 a_15\DT\13649268 consequence_16\NN\34213 of_17\IN\1740 deteriorated_18\VBN\208836 na+-binding_19\NN\1740 properties_20\NNS\32613 of_21\IN\1740 the_22\DT\1740 (na_23\NN\1740 ,_24\,\1740 k)-atpase_25\NN\1740 ._26\.\1740
D019331_D006973 NONE to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 molecular_3\JJ\1740 basis_4\NN\13790712 of_5\IN\1740 disturbances_6\NNS\407535 in_7\IN\13603305 transmembraneous_8\JJ\1740 transport_9\NN\3575240 of_10\IN\1740 na+_11\NN\1740 ,_12\,\1740 we_13\PRP\1740 studied_14\VBD\630380 the_15\DT\1740 response_16\NN\11410625 of_17\IN\1740 cardiac_18\JJ\1740 (na_19\NN\1740 ,_20\,\1740 k)-atpase_21\NN\1740 to_22\TO\1740 no-deficient_23\JJ\1740 <e2>hypertension</e2>_24\NN\14057371 induced_25\VBN\1627355 in_26\IN\13603305 rats_27\NNS\2329401 by_28\IN\1740 no-synthase_29\NN\1740 inhibition_30\NN\1068773 with_31\IN\1740 40_32\CD\13745420 mg/kg/day_33\NN\1740 <e1>n(g)-nitro-l-arginine_34\NN\1740 methyl_35\NN\14617189 ester</e1>_36\NN\14727670 (_37\-LRB-\1740 l-name_38\NN\1740 )_39\-RRB-\1740 for_40\IN\1740 4_41\CD\13741022 four_42\CD\13741022 weeks_43\NNS\15113229 ._44\.\1740
D019331_D006973 NONE to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 molecular_3\JJ\1740 basis_4\NN\13790712 of_5\IN\1740 disturbances_6\NNS\407535 in_7\IN\13603305 transmembraneous_8\JJ\1740 transport_9\NN\3575240 of_10\IN\1740 na+_11\NN\1740 ,_12\,\1740 we_13\PRP\1740 studied_14\VBD\630380 the_15\DT\1740 response_16\NN\11410625 of_17\IN\1740 cardiac_18\JJ\1740 (na_19\NN\1740 ,_20\,\1740 k)-atpase_21\NN\1740 to_22\TO\1740 no-deficient_23\JJ\1740 <e2>hypertension</e2>_24\NN\14057371 induced_25\VBN\1627355 in_26\IN\13603305 rats_27\NNS\2329401 by_28\IN\1740 no-synthase_29\NN\1740 inhibition_30\NN\1068773 with_31\IN\1740 40_32\CD\13745420 mg/kg/day_33\NN\1740 n(g)-nitro-l-arginine_34\NN\1740 methyl_35\NN\14617189 ester_36\NN\14727670 (_37\-LRB-\1740 <e1>l-name</e1>_38\NN\1740 )_39\-RRB-\1740 for_40\IN\1740 4_41\CD\13741022 four_42\CD\13741022 weeks_43\NNS\15113229 ._44\.\1740
D009569_D003866 NONE inhibition_0\NN\1068773 of_1\IN\1740 <e1>no-synthase</e1>_2\NN\1740 induced_3\VBD\1627355 a_4\DT\13649268 reversible_5\JJ\1740 hypertension_6\NN\14057371 accompanied_7\VBN\1835496 by_8\IN\1740 <e2>depressed</e2>_9\JJ\1740 na+-extrusion_10\NN\1740 from_11\IN\1740 cardiac_12\JJ\1740 cells_13\NNS\3080309 as_14\IN\14622893 a_15\DT\13649268 consequence_16\NN\34213 of_17\IN\1740 deteriorated_18\VBN\208836 na+-binding_19\NN\1740 properties_20\NNS\32613 of_21\IN\1740 the_22\DT\1740 (na_23\NN\1740 ,_24\,\1740 k)-atpase_25\NN\1740 ._26\.\1740
D012964_D003866 NONE inhibition_0\NN\1068773 of_1\IN\1740 no-synthase_2\NN\1740 induced_3\VBD\1627355 a_4\DT\13649268 reversible_5\JJ\1740 hypertension_6\NN\14057371 accompanied_7\VBN\1835496 by_8\IN\1740 <e2>depressed</e2>_9\JJ\1740 <e1>na+-extrusion</e1>_10\NN\1740 from_11\IN\1740 cardiac_12\JJ\1740 cells_13\NNS\3080309 as_14\IN\14622893 a_15\DT\13649268 consequence_16\NN\34213 of_17\IN\1740 deteriorated_18\VBN\208836 na+-binding_19\NN\1740 properties_20\NNS\32613 of_21\IN\1740 the_22\DT\1740 (na_23\NN\1740 ,_24\,\1740 k)-atpase_25\NN\1740 ._26\.\1740
D012964_D003866 NONE inhibition_0\NN\1068773 of_1\IN\1740 no-synthase_2\NN\1740 induced_3\VBD\1627355 a_4\DT\13649268 reversible_5\JJ\1740 hypertension_6\NN\14057371 accompanied_7\VBN\1835496 by_8\IN\1740 <e2>depressed</e2>_9\JJ\1740 na+-extrusion_10\NN\1740 from_11\IN\1740 cardiac_12\JJ\1740 cells_13\NNS\3080309 as_14\IN\14622893 a_15\DT\13649268 consequence_16\NN\34213 of_17\IN\1740 deteriorated_18\VBN\208836 <e1>na+-binding</e1>_19\NN\1740 properties_20\NNS\32613 of_21\IN\1740 the_22\DT\1740 (na_23\NN\1740 ,_24\,\1740 k)-atpase_25\NN\1740 ._26\.\1740
D012964_D003866 NONE inhibition_0\NN\1068773 of_1\IN\1740 no-synthase_2\NN\1740 induced_3\VBD\1627355 a_4\DT\13649268 reversible_5\JJ\1740 hypertension_6\NN\14057371 accompanied_7\VBN\1835496 by_8\IN\1740 <e2>depressed</e2>_9\JJ\1740 na+-extrusion_10\NN\1740 from_11\IN\1740 cardiac_12\JJ\1740 cells_13\NNS\3080309 as_14\IN\14622893 a_15\DT\13649268 consequence_16\NN\34213 of_17\IN\1740 deteriorated_18\VBN\208836 na+-binding_19\NN\1740 properties_20\NNS\32613 of_21\IN\1740 the_22\DT\1740 <e1>(na</e1>_23\NN\1740 ,_24\,\1740 k)-atpase_25\NN\1740 ._26\.\1740
D011188_D003866 NONE inhibition_0\NN\1068773 of_1\IN\1740 no-synthase_2\NN\1740 induced_3\VBD\1627355 a_4\DT\13649268 reversible_5\JJ\1740 hypertension_6\NN\14057371 accompanied_7\VBN\1835496 by_8\IN\1740 <e2>depressed</e2>_9\JJ\1740 na+-extrusion_10\NN\1740 from_11\IN\1740 cardiac_12\JJ\1740 cells_13\NNS\3080309 as_14\IN\14622893 a_15\DT\13649268 consequence_16\NN\34213 of_17\IN\1740 deteriorated_18\VBN\208836 na+-binding_19\NN\1740 properties_20\NNS\32613 of_21\IN\1740 the_22\DT\1740 (na_23\NN\1740 ,_24\,\1740 <e1>k)-atpase</e1>_25\NN\1740 ._26\.\1740
10737864
D003000_D001919 CID given_0\VBN\2327200 that_1\DT\1740 sympathetic_2\JJ\1740 neural_3\JJ\1740 dominance_4\NN\4997988 exhibits_5\VBZ\2632167 a_6\DT\13649268 similar_7\JJ\1740 developmental_8\JJ\1740 pattern_9\NN\5726345 ,_10\,\1740 and_11\CC\1740 given_12\VBN\2327200 that_13\DT\1740 <e1>clonidine</e1>_14\NN\2721160 induces_15\VBZ\1627355 sympathetic_16\JJ\1740 withdrawal_17\NN\7206096 and_18\CC\1740 <e2>bradycardia</e2>_19\NN\14110674 ,_20\,\1740 we_21\PRP\1740 hypothesized_22\VBD\719734 that_23\IN\1740 clonidine_24\NN\2721160 's_25\POS\1740 developmental_26\JJ\1740 effects_27\NNS\13245626 on_28\IN\1740 cardiac_29\JJ\1740 rate_30\NN\13815152 and_31\CC\1740 ultrasound_32\NN\11480930 production_33\NN\30358 would_34\MD\1740 mirror_35\VB\2136271 each_36\DT\1740 other_37\JJ\1740 ._38\.\1740
D003000_D001919 CID given_0\VBN\2327200 that_1\DT\1740 sympathetic_2\JJ\1740 neural_3\JJ\1740 dominance_4\NN\4997988 exhibits_5\VBZ\2632167 a_6\DT\13649268 similar_7\JJ\1740 developmental_8\JJ\1740 pattern_9\NN\5726345 ,_10\,\1740 and_11\CC\1740 given_12\VBN\2327200 that_13\DT\1740 clonidine_14\NN\2721160 induces_15\VBZ\1627355 sympathetic_16\JJ\1740 withdrawal_17\NN\7206096 and_18\CC\1740 <e2>bradycardia</e2>_19\NN\14110674 ,_20\,\1740 we_21\PRP\1740 hypothesized_22\VBD\719734 that_23\IN\1740 <e1>clonidine</e1>_24\NN\2721160 's_25\POS\1740 developmental_26\JJ\1740 effects_27\NNS\13245626 on_28\IN\1740 cardiac_29\JJ\1740 rate_30\NN\13815152 and_31\CC\1740 ultrasound_32\NN\11480930 production_33\NN\30358 would_34\MD\1740 mirror_35\VB\2136271 each_36\DT\1740 other_37\JJ\1740 ._38\.\1740
D003000_D001919 CID age-related_0\JJ\1740 changes_1\NNS\7283608 in_2\IN\13603305 ultrasound_3\JJ\1740 production_4\NN\30358 corresponded_5\VBD\2664769 with_6\IN\1740 changes_7\NNS\7283608 in_8\IN\13603305 cardiovascular_9\JJ\1740 variables_10\NNS\2452 ,_11\,\1740 including_12\VBG\690614 baseline_13\NN\7260623 cardiac_14\JJ\1740 rate_15\NN\13815152 and_16\CC\1740 <e1>clonidine-induced</e1>_17\JJ\1740 <e2>bradycardia</e2>_18\NN\14110674 ._19\.\1740
12617329
D006170_D007674 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 treatment_3\NN\654885 with_4\IN\1740 <e1>gum_5\JJ\1740 arabic</e1>_6\NNP\6986894 on_7\IN\1740 gentamicin_8\NN\2716866 <e2>nephrotoxicity</e2>_9\NN\1740 in_10\IN\13603305 rats_11\NNS\2329401 :_12\:\1740 a_13\DT\13649268 preliminary_14\JJ\1740 study_15\NN\635850 ._16\.\1740
D006170_D007674 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 work_3\NN\407535 we_4\PRP\1740 assessed_5\VBD\670261 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 treatment_9\NN\654885 of_10\IN\1740 rats_11\NNS\2329401 with_12\IN\1740 <e1>gum_13\JJ\1740 arabic</e1>_14\NNP\6986894 on_15\IN\1740 acute_16\JJ\1740 renal_17\JJ\1740 failure_18\NN\66216 induced_19\VBN\1627355 by_20\IN\1740 gentamicin_21\NN\2716866 (_22\-LRB-\1740 gm_23\NN\13717155 )_24\-RRB-\1740 <e2>nephrotoxicity</e2>_25\NN\1740 ._26\.\1740
D006170_D007674 NONE it_0\PRP\6125041 could_1\MD\1740 be_2\VB\836236 inferred_3\VBN\634472 that_4\IN\1740 <e1>gum_5\NN\7596684 arabic</e1>_6\NNP\6986894 treatment_7\NN\654885 has_8\VBZ\2108377 induced_9\VBN\1627355 a_10\DT\13649268 modest_11\JJ\1740 amelioration_12\NN\248977 of_13\IN\1740 some_14\DT\1740 of_15\IN\1740 the_16\DT\1740 histological_17\JJ\1740 and_18\CC\1740 biochemical_19\JJ\1740 indices_20\NNS\13850304 of_21\IN\1740 gm_22\NNP\13717155 <e2>nephrotoxicity</e2>_23\NN\1740 ._24\.\1740
D005839_D007674 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 treatment_3\NN\654885 with_4\IN\1740 gum_5\JJ\1740 arabic_6\NNP\6986894 on_7\IN\1740 <e1>gentamicin</e1>_8\NN\2716866 <e2>nephrotoxicity</e2>_9\NN\1740 in_10\IN\13603305 rats_11\NNS\2329401 :_12\:\1740 a_13\DT\13649268 preliminary_14\JJ\1740 study_15\NN\635850 ._16\.\1740
D005839_D007674 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 work_3\NN\407535 we_4\PRP\1740 assessed_5\VBD\670261 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 treatment_9\NN\654885 of_10\IN\1740 rats_11\NNS\2329401 with_12\IN\1740 gum_13\JJ\1740 arabic_14\NNP\6986894 on_15\IN\1740 acute_16\JJ\1740 renal_17\JJ\1740 failure_18\NN\66216 induced_19\VBN\1627355 by_20\IN\1740 <e1>gentamicin</e1>_21\NN\2716866 (_22\-LRB-\1740 gm_23\NN\13717155 )_24\-RRB-\1740 <e2>nephrotoxicity</e2>_25\NN\1740 ._26\.\1740
D005839_D007674 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 work_3\NN\407535 we_4\PRP\1740 assessed_5\VBD\670261 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 treatment_9\NN\654885 of_10\IN\1740 rats_11\NNS\2329401 with_12\IN\1740 gum_13\JJ\1740 arabic_14\NNP\6986894 on_15\IN\1740 acute_16\JJ\1740 renal_17\JJ\1740 failure_18\NN\66216 induced_19\VBN\1627355 by_20\IN\1740 gentamicin_21\NN\2716866 (_22\-LRB-\1740 <e1>gm</e1>_23\NN\13717155 )_24\-RRB-\1740 <e2>nephrotoxicity</e2>_25\NN\1740 ._26\.\1740
D005839_D007674 NONE it_0\PRP\6125041 could_1\MD\1740 be_2\VB\836236 inferred_3\VBN\634472 that_4\IN\1740 gum_5\NN\7596684 arabic_6\NNP\6986894 treatment_7\NN\654885 has_8\VBZ\2108377 induced_9\VBN\1627355 a_10\DT\13649268 modest_11\JJ\1740 amelioration_12\NN\248977 of_13\IN\1740 some_14\DT\1740 of_15\IN\1740 the_16\DT\1740 histological_17\JJ\1740 and_18\CC\1740 biochemical_19\JJ\1740 indices_20\NNS\13850304 of_21\IN\1740 <e1>gm</e1>_22\NNP\13717155 <e2>nephrotoxicity</e2>_23\NN\1740 ._24\.\1740
D006170_D058186 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 work_3\NN\407535 we_4\PRP\1740 assessed_5\VBD\670261 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 treatment_9\NN\654885 of_10\IN\1740 rats_11\NNS\2329401 with_12\IN\1740 <e1>gum_13\JJ\1740 arabic</e1>_14\NNP\6986894 on_15\IN\1740 <e2>acute_16\JJ\1740 renal_17\JJ\1740 failure</e2>_18\NN\66216 induced_19\VBN\1627355 by_20\IN\1740 gentamicin_21\NN\2716866 (_22\-LRB-\1740 gm_23\NN\13717155 )_24\-RRB-\1740 nephrotoxicity_25\NN\1740 ._26\.\1740
D005839_D058186 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 work_3\NN\407535 we_4\PRP\1740 assessed_5\VBD\670261 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 treatment_9\NN\654885 of_10\IN\1740 rats_11\NNS\2329401 with_12\IN\1740 gum_13\JJ\1740 arabic_14\NNP\6986894 on_15\IN\1740 <e2>acute_16\JJ\1740 renal_17\JJ\1740 failure</e2>_18\NN\66216 induced_19\VBN\1627355 by_20\IN\1740 <e1>gentamicin</e1>_21\NN\2716866 (_22\-LRB-\1740 gm_23\NN\13717155 )_24\-RRB-\1740 nephrotoxicity_25\NN\1740 ._26\.\1740
D005839_D058186 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 work_3\NN\407535 we_4\PRP\1740 assessed_5\VBD\670261 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 treatment_9\NN\654885 of_10\IN\1740 rats_11\NNS\2329401 with_12\IN\1740 gum_13\JJ\1740 arabic_14\NNP\6986894 on_15\IN\1740 <e2>acute_16\JJ\1740 renal_17\JJ\1740 failure</e2>_18\NN\66216 induced_19\VBN\1627355 by_20\IN\1740 gentamicin_21\NN\2716866 (_22\-LRB-\1740 <e1>gm</e1>_23\NN\13717155 )_24\-RRB-\1740 nephrotoxicity_25\NN\1740 ._26\.\1740
D003404_D007674 NONE <e2>nephrotoxicity</e2>_0\NN\1740 was_1\VBD\836236 assessed_2\VBN\670261 by_3\IN\1740 measuring_4\VBG\697589 the_5\DT\1740 concentrations_6\NNS\4916342 of_7\IN\1740 <e1>creatinine</e1>_8\NN\1740 and_9\CC\1740 urea_10\NN\14727670 in_11\IN\13603305 the_12\DT\1740 plasma_13\NN\5398023 and_14\CC\1740 reduced_15\VBN\441445 glutathione_16\NN\1740 (_17\-LRB-\1740 gsh_18\NN\1740 )_19\-RRB-\1740 in_20\IN\13603305 the_21\DT\1740 kidney_22\NN\5333259 cortex_23\NN\5462674 ,_24\,\1740 and_25\CC\1740 by_26\IN\1740 light_27\JJ\1740 microscopic_28\JJ\1740 examination_29\NN\633864 of_30\IN\1740 kidney_31\NN\5333259 sections_32\NNS\7020895 ._33\.\1740
D014508_D007674 NONE <e2>nephrotoxicity</e2>_0\NN\1740 was_1\VBD\836236 assessed_2\VBN\670261 by_3\IN\1740 measuring_4\VBG\697589 the_5\DT\1740 concentrations_6\NNS\4916342 of_7\IN\1740 creatinine_8\NN\1740 and_9\CC\1740 <e1>urea</e1>_10\NN\14727670 in_11\IN\13603305 the_12\DT\1740 plasma_13\NN\5398023 and_14\CC\1740 reduced_15\VBN\441445 glutathione_16\NN\1740 (_17\-LRB-\1740 gsh_18\NN\1740 )_19\-RRB-\1740 in_20\IN\13603305 the_21\DT\1740 kidney_22\NN\5333259 cortex_23\NN\5462674 ,_24\,\1740 and_25\CC\1740 by_26\IN\1740 light_27\JJ\1740 microscopic_28\JJ\1740 examination_29\NN\633864 of_30\IN\1740 kidney_31\NN\5333259 sections_32\NNS\7020895 ._33\.\1740
D005978_D007674 NONE <e2>nephrotoxicity</e2>_0\NN\1740 was_1\VBD\836236 assessed_2\VBN\670261 by_3\IN\1740 measuring_4\VBG\697589 the_5\DT\1740 concentrations_6\NNS\4916342 of_7\IN\1740 creatinine_8\NN\1740 and_9\CC\1740 urea_10\NN\14727670 in_11\IN\13603305 the_12\DT\1740 plasma_13\NN\5398023 and_14\CC\1740 reduced_15\VBN\441445 <e1>glutathione</e1>_16\NN\1740 (_17\-LRB-\1740 gsh_18\NN\1740 )_19\-RRB-\1740 in_20\IN\13603305 the_21\DT\1740 kidney_22\NN\5333259 cortex_23\NN\5462674 ,_24\,\1740 and_25\CC\1740 by_26\IN\1740 light_27\JJ\1740 microscopic_28\JJ\1740 examination_29\NN\633864 of_30\IN\1740 kidney_31\NN\5333259 sections_32\NNS\7020895 ._33\.\1740
D005978_D007674 NONE <e2>nephrotoxicity</e2>_0\NN\1740 was_1\VBD\836236 assessed_2\VBN\670261 by_3\IN\1740 measuring_4\VBG\697589 the_5\DT\1740 concentrations_6\NNS\4916342 of_7\IN\1740 creatinine_8\NN\1740 and_9\CC\1740 urea_10\NN\14727670 in_11\IN\13603305 the_12\DT\1740 plasma_13\NN\5398023 and_14\CC\1740 reduced_15\VBN\441445 glutathione_16\NN\1740 (_17\-LRB-\1740 <e1>gsh</e1>_18\NN\1740 )_19\-RRB-\1740 in_20\IN\13603305 the_21\DT\1740 kidney_22\NN\5333259 cortex_23\NN\5462674 ,_24\,\1740 and_25\CC\1740 by_26\IN\1740 light_27\JJ\1740 microscopic_28\JJ\1740 examination_29\NN\633864 of_30\IN\1740 kidney_31\NN\5333259 sections_32\NNS\7020895 ._33\.\1740
D005839_D007683 NONE the_0\DT\1740 <e1>gm-induced</e1>_1\JJ\1740 proximal_2\JJ\1740 <e2>tubular_3\JJ\1740 necrosis</e2>_4\NN\11444117 appeared_5\VBD\2604760 to_6\TO\1740 be_7\VB\836236 slightly_8\RB\1740 less_9\RBR\1740 severe_10\JJ\1740 in_11\IN\13603305 rats_12\NNS\2329401 given_13\VBN\2327200 gm_14\NNP\13717155 together_15\RB\1740 with_16\IN\1740 gum_17\NN\7596684 arabic_18\NNP\6986894 than_19\IN\1740 in_20\IN\13603305 those_21\DT\1740 given_22\VBN\2327200 gm_23\NNP\13717155 and_24\CC\1740 cellulose_25\VB\1740 ._26\.\1740
D005839_D007683 NONE the_0\DT\1740 gm-induced_1\JJ\1740 proximal_2\JJ\1740 <e2>tubular_3\JJ\1740 necrosis</e2>_4\NN\11444117 appeared_5\VBD\2604760 to_6\TO\1740 be_7\VB\836236 slightly_8\RB\1740 less_9\RBR\1740 severe_10\JJ\1740 in_11\IN\13603305 rats_12\NNS\2329401 given_13\VBN\2327200 <e1>gm</e1>_14\NNP\13717155 together_15\RB\1740 with_16\IN\1740 gum_17\NN\7596684 arabic_18\NNP\6986894 than_19\IN\1740 in_20\IN\13603305 those_21\DT\1740 given_22\VBN\2327200 gm_23\NNP\13717155 and_24\CC\1740 cellulose_25\VB\1740 ._26\.\1740
D005839_D007683 NONE the_0\DT\1740 gm-induced_1\JJ\1740 proximal_2\JJ\1740 <e2>tubular_3\JJ\1740 necrosis</e2>_4\NN\11444117 appeared_5\VBD\2604760 to_6\TO\1740 be_7\VB\836236 slightly_8\RB\1740 less_9\RBR\1740 severe_10\JJ\1740 in_11\IN\13603305 rats_12\NNS\2329401 given_13\VBN\2327200 gm_14\NNP\13717155 together_15\RB\1740 with_16\IN\1740 gum_17\NN\7596684 arabic_18\NNP\6986894 than_19\IN\1740 in_20\IN\13603305 those_21\DT\1740 given_22\VBN\2327200 <e1>gm</e1>_23\NNP\13717155 and_24\CC\1740 cellulose_25\VB\1740 ._26\.\1740
D006170_D007683 NONE the_0\DT\1740 gm-induced_1\JJ\1740 proximal_2\JJ\1740 <e2>tubular_3\JJ\1740 necrosis</e2>_4\NN\11444117 appeared_5\VBD\2604760 to_6\TO\1740 be_7\VB\836236 slightly_8\RB\1740 less_9\RBR\1740 severe_10\JJ\1740 in_11\IN\13603305 rats_12\NNS\2329401 given_13\VBN\2327200 gm_14\NNP\13717155 together_15\RB\1740 with_16\IN\1740 <e1>gum_17\NN\7596684 arabic</e1>_18\NNP\6986894 than_19\IN\1740 in_20\IN\13603305 those_21\DT\1740 given_22\VBN\2327200 gm_23\NNP\13717155 and_24\CC\1740 cellulose_25\VB\1740 ._26\.\1740
6466532
D006024_D001919 NONE comparison_0\NN\635850 of_1\IN\1740 i.v._2\NN\1740 <e1>glycopyrrolate</e1>_3\NN\1740 and_4\CC\1740 atropine_5\NN\14712692 in_6\IN\13603305 the_7\DT\1740 prevention_8\NN\1073995 of_9\IN\1740 <e2>bradycardia</e2>_10\NN\14110674 and_11\CC\1740 arrhythmias_12\VBZ\1740 following_13\VBG\1835496 repeated_14\VBN\952524 doses_15\NNS\3740161 of_16\IN\1740 suxamethonium_17\NN\1740 in_18\IN\13603305 children_19\NNS\9622049 ._20\.\1740
D006024_D001919 NONE the_0\DT\1740 effectiveness_1\NN\5190804 of_2\IN\1740 administration_3\NN\1133281 of_4\IN\1740 <e1>glycopyrrolate</e1>_5\NN\1740 5_6\CD\13741022 and_7\CC\1740 10_8\CD\13745420 micrograms_9\NNS\13717155 kg-1_10\NN\1740 and_11\CC\1740 atropine_12\NN\14712692 10_13\CD\13745420 and_14\CC\1740 20_15\CD\13745420 micrograms_16\NNS\13717155 kg-1_17\NN\1740 i.v._18\RBR\1740 immediately_19\RB\1740 before_20\IN\1740 the_21\DT\1740 induction_22\NN\7450842 of_23\IN\1740 anaesthesia_24\NN\14034177 ,_25\,\1740 to_26\TO\1740 prevent_27\VB\1740 arrhythmia_28\NN\14103288 and_29\CC\1740 <e2>bradycardia</e2>_30\NN\14110674 following_31\VBG\1835496 repeated_32\VBN\952524 doses_33\NNS\3740161 of_34\IN\1740 suxamethonium_35\NN\1740 in_36\IN\13603305 children_37\NNS\9622049 ,_38\,\1740 was_39\VBD\836236 studied_40\VBN\630380 ._41\.\1740
D006024_D001145 NONE comparison_0\NN\635850 of_1\IN\1740 i.v._2\NN\1740 <e1>glycopyrrolate</e1>_3\NN\1740 and_4\CC\1740 atropine_5\NN\14712692 in_6\IN\13603305 the_7\DT\1740 prevention_8\NN\1073995 of_9\IN\1740 bradycardia_10\NN\14110674 and_11\CC\1740 <e2>arrhythmias</e2>_12\VBZ\1740 following_13\VBG\1835496 repeated_14\VBN\952524 doses_15\NNS\3740161 of_16\IN\1740 suxamethonium_17\NN\1740 in_18\IN\13603305 children_19\NNS\9622049 ._20\.\1740
D006024_D001145 NONE the_0\DT\1740 effectiveness_1\NN\5190804 of_2\IN\1740 administration_3\NN\1133281 of_4\IN\1740 <e1>glycopyrrolate</e1>_5\NN\1740 5_6\CD\13741022 and_7\CC\1740 10_8\CD\13745420 micrograms_9\NNS\13717155 kg-1_10\NN\1740 and_11\CC\1740 atropine_12\NN\14712692 10_13\CD\13745420 and_14\CC\1740 20_15\CD\13745420 micrograms_16\NNS\13717155 kg-1_17\NN\1740 i.v._18\RBR\1740 immediately_19\RB\1740 before_20\IN\1740 the_21\DT\1740 induction_22\NN\7450842 of_23\IN\1740 anaesthesia_24\NN\14034177 ,_25\,\1740 to_26\TO\1740 prevent_27\VB\1740 <e2>arrhythmia</e2>_28\NN\14103288 and_29\CC\1740 bradycardia_30\NN\14110674 following_31\VBG\1835496 repeated_32\VBN\952524 doses_33\NNS\3740161 of_34\IN\1740 suxamethonium_35\NN\1740 in_36\IN\13603305 children_37\NNS\9622049 ,_38\,\1740 was_39\VBD\836236 studied_40\VBN\630380 ._41\.\1740
D001285_D001919 NONE comparison_0\NN\635850 of_1\IN\1740 i.v._2\NN\1740 glycopyrrolate_3\NN\1740 and_4\CC\1740 <e1>atropine</e1>_5\NN\14712692 in_6\IN\13603305 the_7\DT\1740 prevention_8\NN\1073995 of_9\IN\1740 <e2>bradycardia</e2>_10\NN\14110674 and_11\CC\1740 arrhythmias_12\VBZ\1740 following_13\VBG\1835496 repeated_14\VBN\952524 doses_15\NNS\3740161 of_16\IN\1740 suxamethonium_17\NN\1740 in_18\IN\13603305 children_19\NNS\9622049 ._20\.\1740
D001285_D001919 NONE the_0\DT\1740 effectiveness_1\NN\5190804 of_2\IN\1740 administration_3\NN\1133281 of_4\IN\1740 glycopyrrolate_5\NN\1740 5_6\CD\13741022 and_7\CC\1740 10_8\CD\13745420 micrograms_9\NNS\13717155 kg-1_10\NN\1740 and_11\CC\1740 <e1>atropine</e1>_12\NN\14712692 10_13\CD\13745420 and_14\CC\1740 20_15\CD\13745420 micrograms_16\NNS\13717155 kg-1_17\NN\1740 i.v._18\RBR\1740 immediately_19\RB\1740 before_20\IN\1740 the_21\DT\1740 induction_22\NN\7450842 of_23\IN\1740 anaesthesia_24\NN\14034177 ,_25\,\1740 to_26\TO\1740 prevent_27\VB\1740 arrhythmia_28\NN\14103288 and_29\CC\1740 <e2>bradycardia</e2>_30\NN\14110674 following_31\VBG\1835496 repeated_32\VBN\952524 doses_33\NNS\3740161 of_34\IN\1740 suxamethonium_35\NN\1740 in_36\IN\13603305 children_37\NNS\9622049 ,_38\,\1740 was_39\VBD\836236 studied_40\VBN\630380 ._41\.\1740
D001285_D001145 NONE comparison_0\NN\635850 of_1\IN\1740 i.v._2\NN\1740 glycopyrrolate_3\NN\1740 and_4\CC\1740 <e1>atropine</e1>_5\NN\14712692 in_6\IN\13603305 the_7\DT\1740 prevention_8\NN\1073995 of_9\IN\1740 bradycardia_10\NN\14110674 and_11\CC\1740 <e2>arrhythmias</e2>_12\VBZ\1740 following_13\VBG\1835496 repeated_14\VBN\952524 doses_15\NNS\3740161 of_16\IN\1740 suxamethonium_17\NN\1740 in_18\IN\13603305 children_19\NNS\9622049 ._20\.\1740
D001285_D001145 NONE the_0\DT\1740 effectiveness_1\NN\5190804 of_2\IN\1740 administration_3\NN\1133281 of_4\IN\1740 glycopyrrolate_5\NN\1740 5_6\CD\13741022 and_7\CC\1740 10_8\CD\13745420 micrograms_9\NNS\13717155 kg-1_10\NN\1740 and_11\CC\1740 <e1>atropine</e1>_12\NN\14712692 10_13\CD\13745420 and_14\CC\1740 20_15\CD\13745420 micrograms_16\NNS\13717155 kg-1_17\NN\1740 i.v._18\RBR\1740 immediately_19\RB\1740 before_20\IN\1740 the_21\DT\1740 induction_22\NN\7450842 of_23\IN\1740 anaesthesia_24\NN\14034177 ,_25\,\1740 to_26\TO\1740 prevent_27\VB\1740 <e2>arrhythmia</e2>_28\NN\14103288 and_29\CC\1740 bradycardia_30\NN\14110674 following_31\VBG\1835496 repeated_32\VBN\952524 doses_33\NNS\3740161 of_34\IN\1740 suxamethonium_35\NN\1740 in_36\IN\13603305 children_37\NNS\9622049 ,_38\,\1740 was_39\VBD\836236 studied_40\VBN\630380 ._41\.\1740
D013390_D001919 CID comparison_0\NN\635850 of_1\IN\1740 i.v._2\NN\1740 glycopyrrolate_3\NN\1740 and_4\CC\1740 atropine_5\NN\14712692 in_6\IN\13603305 the_7\DT\1740 prevention_8\NN\1073995 of_9\IN\1740 <e2>bradycardia</e2>_10\NN\14110674 and_11\CC\1740 arrhythmias_12\VBZ\1740 following_13\VBG\1835496 repeated_14\VBN\952524 doses_15\NNS\3740161 of_16\IN\1740 <e1>suxamethonium</e1>_17\NN\1740 in_18\IN\13603305 children_19\NNS\9622049 ._20\.\1740
D013390_D001919 CID the_0\DT\1740 effectiveness_1\NN\5190804 of_2\IN\1740 administration_3\NN\1133281 of_4\IN\1740 glycopyrrolate_5\NN\1740 5_6\CD\13741022 and_7\CC\1740 10_8\CD\13745420 micrograms_9\NNS\13717155 kg-1_10\NN\1740 and_11\CC\1740 atropine_12\NN\14712692 10_13\CD\13745420 and_14\CC\1740 20_15\CD\13745420 micrograms_16\NNS\13717155 kg-1_17\NN\1740 i.v._18\RBR\1740 immediately_19\RB\1740 before_20\IN\1740 the_21\DT\1740 induction_22\NN\7450842 of_23\IN\1740 anaesthesia_24\NN\14034177 ,_25\,\1740 to_26\TO\1740 prevent_27\VB\1740 arrhythmia_28\NN\14103288 and_29\CC\1740 <e2>bradycardia</e2>_30\NN\14110674 following_31\VBG\1835496 repeated_32\VBN\952524 doses_33\NNS\3740161 of_34\IN\1740 <e1>suxamethonium</e1>_35\NN\1740 in_36\IN\13603305 children_37\NNS\9622049 ,_38\,\1740 was_39\VBD\836236 studied_40\VBN\630380 ._41\.\1740
D013390_D001145 NONE comparison_0\NN\635850 of_1\IN\1740 i.v._2\NN\1740 glycopyrrolate_3\NN\1740 and_4\CC\1740 atropine_5\NN\14712692 in_6\IN\13603305 the_7\DT\1740 prevention_8\NN\1073995 of_9\IN\1740 bradycardia_10\NN\14110674 and_11\CC\1740 <e2>arrhythmias</e2>_12\VBZ\1740 following_13\VBG\1835496 repeated_14\VBN\952524 doses_15\NNS\3740161 of_16\IN\1740 <e1>suxamethonium</e1>_17\NN\1740 in_18\IN\13603305 children_19\NNS\9622049 ._20\.\1740
D013390_D001145 NONE the_0\DT\1740 effectiveness_1\NN\5190804 of_2\IN\1740 administration_3\NN\1133281 of_4\IN\1740 glycopyrrolate_5\NN\1740 5_6\CD\13741022 and_7\CC\1740 10_8\CD\13745420 micrograms_9\NNS\13717155 kg-1_10\NN\1740 and_11\CC\1740 atropine_12\NN\14712692 10_13\CD\13745420 and_14\CC\1740 20_15\CD\13745420 micrograms_16\NNS\13717155 kg-1_17\NN\1740 i.v._18\RBR\1740 immediately_19\RB\1740 before_20\IN\1740 the_21\DT\1740 induction_22\NN\7450842 of_23\IN\1740 anaesthesia_24\NN\14034177 ,_25\,\1740 to_26\TO\1740 prevent_27\VB\1740 <e2>arrhythmia</e2>_28\NN\14103288 and_29\CC\1740 bradycardia_30\NN\14110674 following_31\VBG\1835496 repeated_32\VBN\952524 doses_33\NNS\3740161 of_34\IN\1740 <e1>suxamethonium</e1>_35\NN\1740 in_36\IN\13603305 children_37\NNS\9622049 ,_38\,\1740 was_39\VBD\836236 studied_40\VBN\630380 ._41\.\1740
9199746
D000583_D064420 NONE macula_0\CD\4682462 <e2>toxicity</e2>_1\NN\13576101 after_2\IN\1740 intravitreal_3\JJ\1740 <e1>amikacin</e1>_4\NN\1740 ._5\.\1740
D000617_D009877 NONE background_0\NN\4921011 :_1\:\1740 although_2\IN\1740 intravitreal_3\NN\1740 <e1>aminoglycosides</e1>_4\NNS\1740 have_5\VBP\2108377 substantially_6\RB\1740 improved_7\VBN\126264 visual_8\JJ\1740 prognosis_9\NN\6748969 in_10\IN\13603305 <e2>endophthalmitis</e2>_11\NN\1740 ,_12\,\1740 macular_13\JJ\1740 infarction_14\NN\14204950 may_15\MD\15209706 impair_16\VB\258857 full_17\JJ\1740 visual_18\JJ\1740 recovery_19\NN\7357388 ._20\.\1740
D000617_D007238 NONE background_0\NN\4921011 :_1\:\1740 although_2\IN\1740 intravitreal_3\NN\1740 <e1>aminoglycosides</e1>_4\NNS\1740 have_5\VBP\2108377 substantially_6\RB\1740 improved_7\VBN\126264 visual_8\JJ\1740 prognosis_9\NN\6748969 in_10\IN\13603305 endophthalmitis_11\NN\1740 ,_12\,\1740 macular_13\JJ\1740 <e2>infarction</e2>_14\NN\14204950 may_15\MD\15209706 impair_16\VB\258857 full_17\JJ\1740 visual_18\JJ\1740 recovery_19\NN\7357388 ._20\.\1740
D000583_D012164 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 presumed_7\VBN\719734 <e1>amikacin</e1>_8\NN\1740 <e2>retinal_9\JJ\1740 toxicity</e2>_10\NN\13576101 following_11\VBG\1835496 treatment_12\NN\654885 with_13\IN\1740 amikacin_14\NN\1740 and_15\CC\1740 vancomycin_16\NN\2716866 for_17\IN\1740 alpha-haemolytic_18\JJ\1740 streptococcal_19\JJ\1740 endophthalmitis_20\NN\1740 ._21\.\1740
D000583_D012164 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 presumed_7\VBN\719734 amikacin_8\NN\1740 <e2>retinal_9\JJ\1740 toxicity</e2>_10\NN\13576101 following_11\VBG\1835496 treatment_12\NN\654885 with_13\IN\1740 <e1>amikacin</e1>_14\NN\1740 and_15\CC\1740 vancomycin_16\NN\2716866 for_17\IN\1740 alpha-haemolytic_18\JJ\1740 streptococcal_19\JJ\1740 endophthalmitis_20\NN\1740 ._21\.\1740
D000583_D013290 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 presumed_7\VBN\719734 <e1>amikacin</e1>_8\NN\1740 retinal_9\JJ\1740 toxicity_10\NN\13576101 following_11\VBG\1835496 treatment_12\NN\654885 with_13\IN\1740 amikacin_14\NN\1740 and_15\CC\1740 vancomycin_16\NN\2716866 for_17\IN\1740 alpha-haemolytic_18\JJ\1740 <e2>streptococcal_19\JJ\1740 endophthalmitis</e2>_20\NN\1740 ._21\.\1740
D000583_D013290 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 presumed_7\VBN\719734 amikacin_8\NN\1740 retinal_9\JJ\1740 toxicity_10\NN\13576101 following_11\VBG\1835496 treatment_12\NN\654885 with_13\IN\1740 <e1>amikacin</e1>_14\NN\1740 and_15\CC\1740 vancomycin_16\NN\2716866 for_17\IN\1740 alpha-haemolytic_18\JJ\1740 <e2>streptococcal_19\JJ\1740 endophthalmitis</e2>_20\NN\1740 ._21\.\1740
D014640_D012164 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 presumed_7\VBN\719734 amikacin_8\NN\1740 <e2>retinal_9\JJ\1740 toxicity</e2>_10\NN\13576101 following_11\VBG\1835496 treatment_12\NN\654885 with_13\IN\1740 amikacin_14\NN\1740 and_15\CC\1740 <e1>vancomycin</e1>_16\NN\2716866 for_17\IN\1740 alpha-haemolytic_18\JJ\1740 streptococcal_19\JJ\1740 endophthalmitis_20\NN\1740 ._21\.\1740
D014640_D013290 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 presumed_7\VBN\719734 amikacin_8\NN\1740 retinal_9\JJ\1740 toxicity_10\NN\13576101 following_11\VBG\1835496 treatment_12\NN\654885 with_13\IN\1740 amikacin_14\NN\1740 and_15\CC\1740 <e1>vancomycin</e1>_16\NN\2716866 for_17\IN\1740 alpha-haemolytic_18\JJ\1740 <e2>streptococcal_19\JJ\1740 endophthalmitis</e2>_20\NN\1740 ._21\.\1740
D019793_D013684 NONE fundus_0\NN\5225602 <e1>fluorescein</e1>_1\NN\14598383 angiography_2\NN\904623 confirmed_3\VBD\1011725 macular_4\JJ\1740 capillary_5\JJ\1740 closure_6\NN\280853 and_7\CC\1740 <e2>telangiectasis</e2>_8\NN\1740 ._9\.\1740
17175308
D020123_D011507 CID <e2>proteinuria</e2>_0\NNP\14299637 after_1\IN\1740 conversion_2\NN\7359599 to_3\TO\1740 <e1>sirolimus</e1>_4\NN\1740 in_5\IN\13603305 renal_6\JJ\1740 transplant_7\NN\5267548 recipients_8\NNS\9764201 ._9\.\1740
D020123_D011507 CID more_0\RBR\1740 recently_1\RB\1740 ,_2\,\1740 <e2>proteinuria</e2>_3\NN\14299637 has_4\VBZ\2108377 been_5\VBN\836236 reported_6\VBN\831651 as_7\IN\14622893 a_8\DT\13649268 consequence_9\NN\34213 of_10\IN\1740 <e1>sirolimus</e1>_11\NN\1740 therapy_12\NN\657604 ,_13\,\1740 although_14\IN\1740 the_15\DT\1740 mechanism_16\NN\13446390 has_17\VBZ\2108377 remained_18\VBN\2604760 unclear_19\JJ\1740 ._20\.\1740
D020123_D011507 CID we_0\PRP\1740 retrospectively_1\RB\1740 examined_2\VBD\789138 the_3\DT\1740 records_4\NNS\6643408 of_5\IN\1740 25_6\CD\13745420 renal_7\JJ\1740 transplant_8\NN\5267548 patients_9\NNS\9898892 ,_10\,\1740 who_11\WP\8299493 developed_12\VBD\1753788 or_13\CC\3541091 displayed_14\VBD\2137132 increased_15\VBN\169651 <e2>proteinuria</e2>_16\NN\14299637 after_17\IN\1740 <e1>srl</e1>_18\NN\1740 conversion_19\NN\7359599 ._20\.\1740
D020123_D011507 CID heavy_0\JJ\1740 <e2>proteinuria</e2>_1\NN\14299637 was_2\VBD\836236 common_3\JJ\1740 after_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 <e1>srl</e1>_8\NN\1740 as_9\IN\14622893 rescue_10\NN\45907 therapy_11\NN\657604 for_12\IN\1740 renal_13\JJ\1740 transplantation_14\NN\671351 ._15\.\1740
D020123_D051436 NONE the_0\DT\1740 patient_1\NN\9898892 cohort_2\NN\8184861 (_3\-LRB-\1740 14_4\CD\13745420 men_5\NNS\8208016 ,_6\,\1740 11_7\CD\13745420 women_8\NNS\9605289 )_9\-RRB-\1740 was_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 <e1>srl</e1>_13\NN\1740 as_14\IN\14622893 conversion_15\NN\7359599 therapy_16\NN\657604 ,_17\,\1740 due_18\JJ\1740 to_19\TO\1740 <e2>chronic_20\JJ\1740 allograft_21\NN\5582859 nephropathy</e2>_22\NN\14573196 (_23\-LRB-\1740 can_24\NN\3094503 )_25\-RRB-\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 15_29\CD\13745420 )_30\-RRB-\1740 neoplasia_31\NN\13533470 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 8)_35\CD\1740 ;_36\:\1740 kaposi_37\NN\1740 's_38\POS\1740 sarcoma_39\NN\14239918 ,_40\,\1740 four_41\CD\13741022 skin_42\NN\5237755 cancers_43\NNS\14239425 ,_44\,\1740 one_45\CD\13741022 intestinal_46\JJ\1740 tumors_47\NNS\14234074 ,_48\,\1740 one_49\CD\13741022 renal_50\JJ\1740 cell_51\NN\3080309 carsinom_52\NN\1740 )_53\-RRB-\1740 or_54\CC\3541091 bk_55\NN\14625458 virus_56\NN\9312843 nephropathy_57\NN\14573196 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 2_61\CD\13741022 )_62\-RRB-\1740 ._63\.\1740
D020123_D007674 NONE the_0\DT\1740 patient_1\NN\9898892 cohort_2\NN\8184861 (_3\-LRB-\1740 14_4\CD\13745420 men_5\NNS\8208016 ,_6\,\1740 11_7\CD\13745420 women_8\NNS\9605289 )_9\-RRB-\1740 was_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 <e1>srl</e1>_13\NN\1740 as_14\IN\14622893 conversion_15\NN\7359599 therapy_16\NN\657604 ,_17\,\1740 due_18\JJ\1740 to_19\TO\1740 chronic_20\JJ\1740 allograft_21\NN\5582859 nephropathy_22\NN\14573196 (_23\-LRB-\1740 <e2>can</e2>_24\NN\3094503 )_25\-RRB-\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 15_29\CD\13745420 )_30\-RRB-\1740 neoplasia_31\NN\13533470 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 8)_35\CD\1740 ;_36\:\1740 kaposi_37\NN\1740 's_38\POS\1740 sarcoma_39\NN\14239918 ,_40\,\1740 four_41\CD\13741022 skin_42\NN\5237755 cancers_43\NNS\14239425 ,_44\,\1740 one_45\CD\13741022 intestinal_46\JJ\1740 tumors_47\NNS\14234074 ,_48\,\1740 one_49\CD\13741022 renal_50\JJ\1740 cell_51\NN\3080309 carsinom_52\NN\1740 )_53\-RRB-\1740 or_54\CC\3541091 bk_55\NN\14625458 virus_56\NN\9312843 nephropathy_57\NN\14573196 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 2_61\CD\13741022 )_62\-RRB-\1740 ._63\.\1740
D020123_D007674 NONE the_0\DT\1740 patient_1\NN\9898892 cohort_2\NN\8184861 (_3\-LRB-\1740 14_4\CD\13745420 men_5\NNS\8208016 ,_6\,\1740 11_7\CD\13745420 women_8\NNS\9605289 )_9\-RRB-\1740 was_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 <e1>srl</e1>_13\NN\1740 as_14\IN\14622893 conversion_15\NN\7359599 therapy_16\NN\657604 ,_17\,\1740 due_18\JJ\1740 to_19\TO\1740 chronic_20\JJ\1740 allograft_21\NN\5582859 nephropathy_22\NN\14573196 (_23\-LRB-\1740 can_24\NN\3094503 )_25\-RRB-\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 15_29\CD\13745420 )_30\-RRB-\1740 neoplasia_31\NN\13533470 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 8)_35\CD\1740 ;_36\:\1740 kaposi_37\NN\1740 's_38\POS\1740 sarcoma_39\NN\14239918 ,_40\,\1740 four_41\CD\13741022 skin_42\NN\5237755 cancers_43\NNS\14239425 ,_44\,\1740 one_45\CD\13741022 intestinal_46\JJ\1740 tumors_47\NNS\14234074 ,_48\,\1740 one_49\CD\13741022 renal_50\JJ\1740 cell_51\NN\3080309 carsinom_52\NN\1740 )_53\-RRB-\1740 or_54\CC\3541091 bk_55\NN\14625458 virus_56\NN\9312843 <e2>nephropathy</e2>_57\NN\14573196 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 2_61\CD\13741022 )_62\-RRB-\1740 ._63\.\1740
D020123_D009369 NONE the_0\DT\1740 patient_1\NN\9898892 cohort_2\NN\8184861 (_3\-LRB-\1740 14_4\CD\13745420 men_5\NNS\8208016 ,_6\,\1740 11_7\CD\13745420 women_8\NNS\9605289 )_9\-RRB-\1740 was_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 <e1>srl</e1>_13\NN\1740 as_14\IN\14622893 conversion_15\NN\7359599 therapy_16\NN\657604 ,_17\,\1740 due_18\JJ\1740 to_19\TO\1740 chronic_20\JJ\1740 allograft_21\NN\5582859 nephropathy_22\NN\14573196 (_23\-LRB-\1740 can_24\NN\3094503 )_25\-RRB-\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 15_29\CD\13745420 )_30\-RRB-\1740 <e2>neoplasia</e2>_31\NN\13533470 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 8)_35\CD\1740 ;_36\:\1740 kaposi_37\NN\1740 's_38\POS\1740 sarcoma_39\NN\14239918 ,_40\,\1740 four_41\CD\13741022 skin_42\NN\5237755 cancers_43\NNS\14239425 ,_44\,\1740 one_45\CD\13741022 intestinal_46\JJ\1740 tumors_47\NNS\14234074 ,_48\,\1740 one_49\CD\13741022 renal_50\JJ\1740 cell_51\NN\3080309 carsinom_52\NN\1740 )_53\-RRB-\1740 or_54\CC\3541091 bk_55\NN\14625458 virus_56\NN\9312843 nephropathy_57\NN\14573196 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 2_61\CD\13741022 )_62\-RRB-\1740 ._63\.\1740
D020123_D012514 NONE the_0\DT\1740 patient_1\NN\9898892 cohort_2\NN\8184861 (_3\-LRB-\1740 14_4\CD\13745420 men_5\NNS\8208016 ,_6\,\1740 11_7\CD\13745420 women_8\NNS\9605289 )_9\-RRB-\1740 was_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 <e1>srl</e1>_13\NN\1740 as_14\IN\14622893 conversion_15\NN\7359599 therapy_16\NN\657604 ,_17\,\1740 due_18\JJ\1740 to_19\TO\1740 chronic_20\JJ\1740 allograft_21\NN\5582859 nephropathy_22\NN\14573196 (_23\-LRB-\1740 can_24\NN\3094503 )_25\-RRB-\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 15_29\CD\13745420 )_30\-RRB-\1740 neoplasia_31\NN\13533470 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 8)_35\CD\1740 ;_36\:\1740 <e2>kaposi_37\NN\1740 's_38\POS\1740 sarcoma</e2>_39\NN\14239918 ,_40\,\1740 four_41\CD\13741022 skin_42\NN\5237755 cancers_43\NNS\14239425 ,_44\,\1740 one_45\CD\13741022 intestinal_46\JJ\1740 tumors_47\NNS\14234074 ,_48\,\1740 one_49\CD\13741022 renal_50\JJ\1740 cell_51\NN\3080309 carsinom_52\NN\1740 )_53\-RRB-\1740 or_54\CC\3541091 bk_55\NN\14625458 virus_56\NN\9312843 nephropathy_57\NN\14573196 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 2_61\CD\13741022 )_62\-RRB-\1740 ._63\.\1740
D020123_D012878 NONE the_0\DT\1740 patient_1\NN\9898892 cohort_2\NN\8184861 (_3\-LRB-\1740 14_4\CD\13745420 men_5\NNS\8208016 ,_6\,\1740 11_7\CD\13745420 women_8\NNS\9605289 )_9\-RRB-\1740 was_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 <e1>srl</e1>_13\NN\1740 as_14\IN\14622893 conversion_15\NN\7359599 therapy_16\NN\657604 ,_17\,\1740 due_18\JJ\1740 to_19\TO\1740 chronic_20\JJ\1740 allograft_21\NN\5582859 nephropathy_22\NN\14573196 (_23\-LRB-\1740 can_24\NN\3094503 )_25\-RRB-\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 15_29\CD\13745420 )_30\-RRB-\1740 neoplasia_31\NN\13533470 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 8)_35\CD\1740 ;_36\:\1740 kaposi_37\NN\1740 's_38\POS\1740 sarcoma_39\NN\14239918 ,_40\,\1740 four_41\CD\13741022 <e2>skin_42\NN\5237755 cancers</e2>_43\NNS\14239425 ,_44\,\1740 one_45\CD\13741022 intestinal_46\JJ\1740 tumors_47\NNS\14234074 ,_48\,\1740 one_49\CD\13741022 renal_50\JJ\1740 cell_51\NN\3080309 carsinom_52\NN\1740 )_53\-RRB-\1740 or_54\CC\3541091 bk_55\NN\14625458 virus_56\NN\9312843 nephropathy_57\NN\14573196 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 2_61\CD\13741022 )_62\-RRB-\1740 ._63\.\1740
D020123_D007414 NONE the_0\DT\1740 patient_1\NN\9898892 cohort_2\NN\8184861 (_3\-LRB-\1740 14_4\CD\13745420 men_5\NNS\8208016 ,_6\,\1740 11_7\CD\13745420 women_8\NNS\9605289 )_9\-RRB-\1740 was_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 <e1>srl</e1>_13\NN\1740 as_14\IN\14622893 conversion_15\NN\7359599 therapy_16\NN\657604 ,_17\,\1740 due_18\JJ\1740 to_19\TO\1740 chronic_20\JJ\1740 allograft_21\NN\5582859 nephropathy_22\NN\14573196 (_23\-LRB-\1740 can_24\NN\3094503 )_25\-RRB-\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 15_29\CD\13745420 )_30\-RRB-\1740 neoplasia_31\NN\13533470 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 8)_35\CD\1740 ;_36\:\1740 kaposi_37\NN\1740 's_38\POS\1740 sarcoma_39\NN\14239918 ,_40\,\1740 four_41\CD\13741022 skin_42\NN\5237755 cancers_43\NNS\14239425 ,_44\,\1740 one_45\CD\13741022 <e2>intestinal_46\JJ\1740 tumors</e2>_47\NNS\14234074 ,_48\,\1740 one_49\CD\13741022 renal_50\JJ\1740 cell_51\NN\3080309 carsinom_52\NN\1740 )_53\-RRB-\1740 or_54\CC\3541091 bk_55\NN\14625458 virus_56\NN\9312843 nephropathy_57\NN\14573196 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 2_61\CD\13741022 )_62\-RRB-\1740 ._63\.\1740
D020123_D002292 NONE the_0\DT\1740 patient_1\NN\9898892 cohort_2\NN\8184861 (_3\-LRB-\1740 14_4\CD\13745420 men_5\NNS\8208016 ,_6\,\1740 11_7\CD\13745420 women_8\NNS\9605289 )_9\-RRB-\1740 was_10\VBD\836236 treated_11\VBN\2376958 with_12\IN\1740 <e1>srl</e1>_13\NN\1740 as_14\IN\14622893 conversion_15\NN\7359599 therapy_16\NN\657604 ,_17\,\1740 due_18\JJ\1740 to_19\TO\1740 chronic_20\JJ\1740 allograft_21\NN\5582859 nephropathy_22\NN\14573196 (_23\-LRB-\1740 can_24\NN\3094503 )_25\-RRB-\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 15_29\CD\13745420 )_30\-RRB-\1740 neoplasia_31\NN\13533470 (_32\-LRB-\1740 n_33\NN\14622893 =_34\JJ\1740 8)_35\CD\1740 ;_36\:\1740 kaposi_37\NN\1740 's_38\POS\1740 sarcoma_39\NN\14239918 ,_40\,\1740 four_41\CD\13741022 skin_42\NN\5237755 cancers_43\NNS\14239425 ,_44\,\1740 one_45\CD\13741022 intestinal_46\JJ\1740 tumors_47\NNS\14234074 ,_48\,\1740 one_49\CD\13741022 <e2>renal_50\JJ\1740 cell_51\NN\3080309 carsinom</e2>_52\NN\1740 )_53\-RRB-\1740 or_54\CC\3541091 bk_55\NN\14625458 virus_56\NN\9312843 nephropathy_57\NN\14573196 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 2_61\CD\13741022 )_62\-RRB-\1740 ._63\.\1740
3750012
D010396_D009157 CID <e2>myasthenia_0\NNP\14187378 gravis</e2>_1\NN\1740 caused_2\VBN\1617192 by_3\IN\1740 <e1>penicillamine</e1>_4\NN\3740161 and_5\CC\1740 chloroquine_6\NN\2721948 therapy_7\NN\657604 for_8\IN\1740 rheumatoid_9\JJ\1740 arthritis_10\NN\14171682 ._11\.\1740
D010396_D009157 CID we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 unique_4\JJ\1740 patient_5\NN\9898892 who_6\WP\8299493 had_7\VBD\2108377 reversible_8\JJ\1740 and_9\CC\1740 dose-related_10\JJ\1740 <e2>myasthenia_11\NN\14187378 gravis</e2>_12\NN\1740 after_13\IN\1740 <e1>penicillamine</e1>_14\NN\3740161 and_15\CC\1740 chloroquine_16\NN\2721948 therapy_17\NN\657604 for_18\IN\1740 rheumatoid_19\JJ\1740 arthritis_20\NN\14171682 ._21\.\1740
D010396_D001172 NONE myasthenia_0\NNP\14187378 gravis_1\NN\1740 caused_2\VBN\1617192 by_3\IN\1740 <e1>penicillamine</e1>_4\NN\3740161 and_5\CC\1740 chloroquine_6\NN\2721948 therapy_7\NN\657604 for_8\IN\1740 <e2>rheumatoid_9\JJ\1740 arthritis</e2>_10\NN\14171682 ._11\.\1740
D010396_D001172 NONE we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 unique_4\JJ\1740 patient_5\NN\9898892 who_6\WP\8299493 had_7\VBD\2108377 reversible_8\JJ\1740 and_9\CC\1740 dose-related_10\JJ\1740 myasthenia_11\NN\14187378 gravis_12\NN\1740 after_13\IN\1740 <e1>penicillamine</e1>_14\NN\3740161 and_15\CC\1740 chloroquine_16\NN\2721948 therapy_17\NN\657604 for_18\IN\1740 <e2>rheumatoid_19\JJ\1740 arthritis</e2>_20\NN\14171682 ._21\.\1740
D002738_D009157 CID <e2>myasthenia_0\NNP\14187378 gravis</e2>_1\NN\1740 caused_2\VBN\1617192 by_3\IN\1740 penicillamine_4\NN\3740161 and_5\CC\1740 <e1>chloroquine</e1>_6\NN\2721948 therapy_7\NN\657604 for_8\IN\1740 rheumatoid_9\JJ\1740 arthritis_10\NN\14171682 ._11\.\1740
D002738_D009157 CID we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 unique_4\JJ\1740 patient_5\NN\9898892 who_6\WP\8299493 had_7\VBD\2108377 reversible_8\JJ\1740 and_9\CC\1740 dose-related_10\JJ\1740 <e2>myasthenia_11\NN\14187378 gravis</e2>_12\NN\1740 after_13\IN\1740 penicillamine_14\NN\3740161 and_15\CC\1740 <e1>chloroquine</e1>_16\NN\2721948 therapy_17\NN\657604 for_18\IN\1740 rheumatoid_19\JJ\1740 arthritis_20\NN\14171682 ._21\.\1740
D002738_D001172 NONE myasthenia_0\NNP\14187378 gravis_1\NN\1740 caused_2\VBN\1617192 by_3\IN\1740 penicillamine_4\NN\3740161 and_5\CC\1740 <e1>chloroquine</e1>_6\NN\2721948 therapy_7\NN\657604 for_8\IN\1740 <e2>rheumatoid_9\JJ\1740 arthritis</e2>_10\NN\14171682 ._11\.\1740
D002738_D001172 NONE we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 unique_4\JJ\1740 patient_5\NN\9898892 who_6\WP\8299493 had_7\VBD\2108377 reversible_8\JJ\1740 and_9\CC\1740 dose-related_10\JJ\1740 myasthenia_11\NN\14187378 gravis_12\NN\1740 after_13\IN\1740 penicillamine_14\NN\3740161 and_15\CC\1740 <e1>chloroquine</e1>_16\NN\2721948 therapy_17\NN\657604 for_18\IN\1740 <e2>rheumatoid_19\JJ\1740 arthritis</e2>_20\NN\14171682 ._21\.\1740
18186898
D019259_D006509 NONE <e1>lamivudine</e1>_0\NNP\3834836 was_1\VBD\836236 added_2\VBN\156601 because_3\IN\1740 of_4\IN\1740 de_5\FW\1740 nova_6\JJ\1740 <e2>hepatitis_7\NN\14127211 b_8\NN\1355326 infection</e2>_9\NN\14052046 during_10\IN\1740 her_11\PRP$\1740 follow-up_12\NN\4599396 ._13\.\1740
D016559_D000138 NONE although_0\IN\1740 <e1>tacrolimus</e1>_1\NN\1740 was_2\VBD\836236 suspected_3\VBN\916909 to_4\TO\1740 be_5\VB\836236 the_6\DT\1740 cause_7\NN\7323922 of_8\IN\1740 late_9\JJ\1740 post-transplant_10\JJ\1740 renal_11\JJ\1740 <e2>acidosis</e2>_12\NN\14204950 and_13\CC\1740 was_14\VBD\836236 replaced_15\VBN\1631072 by_16\IN\1740 sirolimus_17\NN\1740 ,_18\,\1740 acidosis_19\NN\14204950 ,_20\,\1740 and_21\CC\1740 electrolyte_22\NN\14589223 imbalance_23\NN\13934274 got_24\VBD\146138 worse_25\JJR\1740 ._26\.\1740
D016559_D000138 NONE although_0\IN\1740 <e1>tacrolimus</e1>_1\NN\1740 was_2\VBD\836236 suspected_3\VBN\916909 to_4\TO\1740 be_5\VB\836236 the_6\DT\1740 cause_7\NN\7323922 of_8\IN\1740 late_9\JJ\1740 post-transplant_10\JJ\1740 renal_11\JJ\1740 acidosis_12\NN\14204950 and_13\CC\1740 was_14\VBD\836236 replaced_15\VBN\1631072 by_16\IN\1740 sirolimus_17\NN\1740 ,_18\,\1740 <e2>acidosis</e2>_19\NN\14204950 ,_20\,\1740 and_21\CC\1740 electrolyte_22\NN\14589223 imbalance_23\NN\13934274 got_24\VBD\146138 worse_25\JJR\1740 ._26\.\1740
D020123_D000138 NONE although_0\IN\1740 tacrolimus_1\NN\1740 was_2\VBD\836236 suspected_3\VBN\916909 to_4\TO\1740 be_5\VB\836236 the_6\DT\1740 cause_7\NN\7323922 of_8\IN\1740 late_9\JJ\1740 post-transplant_10\JJ\1740 renal_11\JJ\1740 <e2>acidosis</e2>_12\NN\14204950 and_13\CC\1740 was_14\VBD\836236 replaced_15\VBN\1631072 by_16\IN\1740 <e1>sirolimus</e1>_17\NN\1740 ,_18\,\1740 acidosis_19\NN\14204950 ,_20\,\1740 and_21\CC\1740 electrolyte_22\NN\14589223 imbalance_23\NN\13934274 got_24\VBD\146138 worse_25\JJR\1740 ._26\.\1740
D020123_D000138 NONE although_0\IN\1740 tacrolimus_1\NN\1740 was_2\VBD\836236 suspected_3\VBN\916909 to_4\TO\1740 be_5\VB\836236 the_6\DT\1740 cause_7\NN\7323922 of_8\IN\1740 late_9\JJ\1740 post-transplant_10\JJ\1740 renal_11\JJ\1740 acidosis_12\NN\14204950 and_13\CC\1740 was_14\VBD\836236 replaced_15\VBN\1631072 by_16\IN\1740 <e1>sirolimus</e1>_17\NN\1740 ,_18\,\1740 <e2>acidosis</e2>_19\NN\14204950 ,_20\,\1740 and_21\CC\1740 electrolyte_22\NN\14589223 imbalance_23\NN\13934274 got_24\VBD\146138 worse_25\JJR\1740 ._26\.\1740
D016559_D005198 CID we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 our_3\PRP$\1740 patient_4\NN\9898892 's_5\POS\1740 <e2>tubular_6\JJ\1740 dysfunction</e2>_7\NN\14204950 and_8\CC\1740 myopathy_9\NN\14204950 may_10\MD\15209706 have_11\VB\2108377 resulted_12\VBN\2633881 from_13\IN\1740 mitochondrial_14\JJ\1740 dysfunction_15\NN\14204950 which_16\WDT\1740 is_17\VBZ\836236 triggered_18\VBN\1641914 by_19\IN\1740 <e1>tacrolimus</e1>_20\NN\1740 and_21\CC\1740 augmented_22\VBN\153263 by_23\IN\1740 lamivudine_24\NN\3834836 ._25\.\1740
D016559_D009135 CID we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 our_3\PRP$\1740 patient_4\NN\9898892 's_5\POS\1740 tubular_6\JJ\1740 dysfunction_7\NN\14204950 and_8\CC\1740 <e2>myopathy</e2>_9\NN\14204950 may_10\MD\15209706 have_11\VB\2108377 resulted_12\VBN\2633881 from_13\IN\1740 mitochondrial_14\JJ\1740 dysfunction_15\NN\14204950 which_16\WDT\1740 is_17\VBZ\836236 triggered_18\VBN\1641914 by_19\IN\1740 <e1>tacrolimus</e1>_20\NN\1740 and_21\CC\1740 augmented_22\VBN\153263 by_23\IN\1740 lamivudine_24\NN\3834836 ._25\.\1740
D016559_D028361 NONE we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 our_3\PRP$\1740 patient_4\NN\9898892 's_5\POS\1740 tubular_6\JJ\1740 dysfunction_7\NN\14204950 and_8\CC\1740 myopathy_9\NN\14204950 may_10\MD\15209706 have_11\VB\2108377 resulted_12\VBN\2633881 from_13\IN\1740 <e2>mitochondrial_14\JJ\1740 dysfunction</e2>_15\NN\14204950 which_16\WDT\1740 is_17\VBZ\836236 triggered_18\VBN\1641914 by_19\IN\1740 <e1>tacrolimus</e1>_20\NN\1740 and_21\CC\1740 augmented_22\VBN\153263 by_23\IN\1740 lamivudine_24\NN\3834836 ._25\.\1740
D019259_D005198 CID we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 our_3\PRP$\1740 patient_4\NN\9898892 's_5\POS\1740 <e2>tubular_6\JJ\1740 dysfunction</e2>_7\NN\14204950 and_8\CC\1740 myopathy_9\NN\14204950 may_10\MD\15209706 have_11\VB\2108377 resulted_12\VBN\2633881 from_13\IN\1740 mitochondrial_14\JJ\1740 dysfunction_15\NN\14204950 which_16\WDT\1740 is_17\VBZ\836236 triggered_18\VBN\1641914 by_19\IN\1740 tacrolimus_20\NN\1740 and_21\CC\1740 augmented_22\VBN\153263 by_23\IN\1740 <e1>lamivudine</e1>_24\NN\3834836 ._25\.\1740
D019259_D009135 CID we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 our_3\PRP$\1740 patient_4\NN\9898892 's_5\POS\1740 tubular_6\JJ\1740 dysfunction_7\NN\14204950 and_8\CC\1740 <e2>myopathy</e2>_9\NN\14204950 may_10\MD\15209706 have_11\VB\2108377 resulted_12\VBN\2633881 from_13\IN\1740 mitochondrial_14\JJ\1740 dysfunction_15\NN\14204950 which_16\WDT\1740 is_17\VBZ\836236 triggered_18\VBN\1641914 by_19\IN\1740 tacrolimus_20\NN\1740 and_21\CC\1740 augmented_22\VBN\153263 by_23\IN\1740 <e1>lamivudine</e1>_24\NN\3834836 ._25\.\1740
D019259_D028361 NONE we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 our_3\PRP$\1740 patient_4\NN\9898892 's_5\POS\1740 tubular_6\JJ\1740 dysfunction_7\NN\14204950 and_8\CC\1740 myopathy_9\NN\14204950 may_10\MD\15209706 have_11\VB\2108377 resulted_12\VBN\2633881 from_13\IN\1740 <e2>mitochondrial_14\JJ\1740 dysfunction</e2>_15\NN\14204950 which_16\WDT\1740 is_17\VBZ\836236 triggered_18\VBN\1641914 by_19\IN\1740 tacrolimus_20\NN\1740 and_21\CC\1740 augmented_22\VBN\153263 by_23\IN\1740 <e1>lamivudine</e1>_24\NN\3834836 ._25\.\1740
16330293
12084448
D007069_D001927 CID <e1>ifosfamide</e1>_0\NN\1740 <e2>encephalopathy</e2>_1\JJ\1740 presenting_2\VBG\2137132 with_3\IN\1740 asterixis_4\NN\1740 ._5\.\1740
D007069_D020820 NONE <e1>ifosfamide</e1>_0\NN\1740 encephalopathy_1\JJ\1740 presenting_2\VBG\2137132 with_3\IN\1740 <e2>asterixis</e2>_4\NN\1740 ._5\.\1740
D007069_D020820 NONE the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>ifosfamide</e1>_3\NN\1740 was_4\VBD\836236 discontinued_5\VBN\2609764 and_6\CC\1740 within_7\IN\1740 12_8\CD\13745420 h_9\NN\14622893 the_10\DT\1740 <e2>asterixis</e2>_11\NN\1740 resolved_12\VBN\352826 completely_13\RB\1740 ._14\.\1740
D007069_D020820 NONE in_0\IN\13603305 the_1\DT\1740 patient_2\NN\9898892 described_3\VBN\1001294 ,_4\,\1740 the_5\DT\1740 presence_6\NN\13954253 of_7\IN\1740 <e2>asterixis</e2>_8\NN\1740 during_9\IN\1740 infusion_10\NN\14589223 of_11\IN\1740 <e1>ifosfamide</e1>_12\NN\1740 ,_13\,\1740 normal_14\JJ\1740 laboratory_15\NN\4602044 findings_16\NNS\7951464 and_17\CC\1740 imaging_18\NN\5765159 studies_19\NNS\635850 and_20\CC\1740 the_21\DT\1740 resolution_22\NN\6470073 of_23\IN\1740 symptoms_24\NNS\5823932 following_25\VBG\1835496 the_26\DT\1740 discontinuation_27\NN\209943 of_28\IN\1740 the_29\DT\1740 drug_30\NN\14778436 suggest_31\VBP\1010118 that_32\IN\1740 negative_33\JJ\1740 myoclonus_34\NN\14360459 is_35\VBZ\836236 associated_36\VBN\628491 with_37\IN\1740 the_38\DT\1740 use_39\NN\407535 of_40\IN\1740 ifx_41\NN\1740 ._42\.\1740
D007069_D020820 NONE in_0\IN\13603305 the_1\DT\1740 patient_2\NN\9898892 described_3\VBN\1001294 ,_4\,\1740 the_5\DT\1740 presence_6\NN\13954253 of_7\IN\1740 <e2>asterixis</e2>_8\NN\1740 during_9\IN\1740 infusion_10\NN\14589223 of_11\IN\1740 ifosfamide_12\NN\1740 ,_13\,\1740 normal_14\JJ\1740 laboratory_15\NN\4602044 findings_16\NNS\7951464 and_17\CC\1740 imaging_18\NN\5765159 studies_19\NNS\635850 and_20\CC\1740 the_21\DT\1740 resolution_22\NN\6470073 of_23\IN\1740 symptoms_24\NNS\5823932 following_25\VBG\1835496 the_26\DT\1740 discontinuation_27\NN\209943 of_28\IN\1740 the_29\DT\1740 drug_30\NN\14778436 suggest_31\VBP\1010118 that_32\IN\1740 negative_33\JJ\1740 myoclonus_34\NN\14360459 is_35\VBZ\836236 associated_36\VBN\628491 with_37\IN\1740 the_38\DT\1740 use_39\NN\407535 of_40\IN\1740 <e1>ifx</e1>_41\NN\1740 ._42\.\1740
D007069_D009207 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 51-year-old_6\JJ\1740 man_7\NN\9605289 who_8\WP\8299493 developed_9\VBD\1753788 severe_10\JJ\1740 ,_11\,\1740 disabling_12\VBG\126264 negative_13\JJ\1740 <e2>myoclonus</e2>_14\NN\14360459 of_15\IN\1740 the_16\DT\1740 upper_17\JJ\1740 and_18\CC\1740 lower_19\JJR\1740 extremities_20\NNS\5225090 after_21\IN\1740 the_22\DT\1740 infusion_23\NN\14589223 of_24\IN\1740 <e1>ifosfamide</e1>_25\NN\1740 for_26\IN\1740 plasmacytoma_27\NN\14235200 ._28\.\1740
D007069_D009207 CID in_0\IN\13603305 the_1\DT\1740 patient_2\NN\9898892 described_3\VBN\1001294 ,_4\,\1740 the_5\DT\1740 presence_6\NN\13954253 of_7\IN\1740 asterixis_8\NN\1740 during_9\IN\1740 infusion_10\NN\14589223 of_11\IN\1740 <e1>ifosfamide</e1>_12\NN\1740 ,_13\,\1740 normal_14\JJ\1740 laboratory_15\NN\4602044 findings_16\NNS\7951464 and_17\CC\1740 imaging_18\NN\5765159 studies_19\NNS\635850 and_20\CC\1740 the_21\DT\1740 resolution_22\NN\6470073 of_23\IN\1740 symptoms_24\NNS\5823932 following_25\VBG\1835496 the_26\DT\1740 discontinuation_27\NN\209943 of_28\IN\1740 the_29\DT\1740 drug_30\NN\14778436 suggest_31\VBP\1010118 that_32\IN\1740 negative_33\JJ\1740 <e2>myoclonus</e2>_34\NN\14360459 is_35\VBZ\836236 associated_36\VBN\628491 with_37\IN\1740 the_38\DT\1740 use_39\NN\407535 of_40\IN\1740 ifx_41\NN\1740 ._42\.\1740
D007069_D009207 CID in_0\IN\13603305 the_1\DT\1740 patient_2\NN\9898892 described_3\VBN\1001294 ,_4\,\1740 the_5\DT\1740 presence_6\NN\13954253 of_7\IN\1740 asterixis_8\NN\1740 during_9\IN\1740 infusion_10\NN\14589223 of_11\IN\1740 ifosfamide_12\NN\1740 ,_13\,\1740 normal_14\JJ\1740 laboratory_15\NN\4602044 findings_16\NNS\7951464 and_17\CC\1740 imaging_18\NN\5765159 studies_19\NNS\635850 and_20\CC\1740 the_21\DT\1740 resolution_22\NN\6470073 of_23\IN\1740 symptoms_24\NNS\5823932 following_25\VBG\1835496 the_26\DT\1740 discontinuation_27\NN\209943 of_28\IN\1740 the_29\DT\1740 drug_30\NN\14778436 suggest_31\VBP\1010118 that_32\IN\1740 negative_33\JJ\1740 <e2>myoclonus</e2>_34\NN\14360459 is_35\VBZ\836236 associated_36\VBN\628491 with_37\IN\1740 the_38\DT\1740 use_39\NN\407535 of_40\IN\1740 <e1>ifx</e1>_41\NN\1740 ._42\.\1740
D007069_D010954 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 51-year-old_6\JJ\1740 man_7\NN\9605289 who_8\WP\8299493 developed_9\VBD\1753788 severe_10\JJ\1740 ,_11\,\1740 disabling_12\VBG\126264 negative_13\JJ\1740 myoclonus_14\NN\14360459 of_15\IN\1740 the_16\DT\1740 upper_17\JJ\1740 and_18\CC\1740 lower_19\JJR\1740 extremities_20\NNS\5225090 after_21\IN\1740 the_22\DT\1740 infusion_23\NN\14589223 of_24\IN\1740 <e1>ifosfamide</e1>_25\NN\1740 for_26\IN\1740 <e2>plasmacytoma</e2>_27\NN\14235200 ._28\.\1740
15458908
D020849_D010024 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 multiple_3\JJ\1740 outcomes_4\NNPS\7291312 of_5\IN\1740 <e1>raloxifene</e1>_6\NNP\1740 evaluation_7\NNP\874067 ,_8\,\1740 a_9\DT\13649268 multicenter_10\NN\1740 ,_11\,\1740 randomized_12\VBN\278117 ,_13\,\1740 double-blind_14\JJ\1740 trial_15\NN\786195 ,_16\,\1740 enrolled_17\VBD\2471690 7,705_18\CD\1740 postmenopausal_19\JJ\1740 women_20\NNS\9605289 with_21\IN\1740 <e2>osteoporosis</e2>_22\NN\14204950 ._23\.\1740
D020849_D054556 CID results_0\NNS\34213 :_1\:\1740 during_2\IN\1740 a_3\DT\13649268 mean_4\NN\6021761 follow-up_5\NN\4599396 of_6\IN\1740 3.3_7\CD\1740 years_8\NNS\15144371 ,_9\,\1740 <e1>raloxifene</e1>_10\NN\1740 was_11\VBD\836236 associated_12\VBN\628491 with_13\IN\1740 an_14\DT\6697703 increased_15\VBN\169651 risk_16\NN\14541044 for_17\IN\1740 <e2>venous_18\JJ\1740 thromboembolism</e2>_19\NN\14100769 (_20\-LRB-\1740 relative_21\JJ\1740 risk_22\NN\14541044 [_23\-LRB-\1740 rr_24\NN\1740 ]_25\-RRB-\1740 2.1_26\CD\1740 ;_27\:\1740 95_28\CD\1740 %_29\NN\1740 confidence_30\NN\5697135 interval_31\NN\33615 [_32\-LRB-\1740 ci_33\NNP\13635336 ]_34\-RRB-\1740 1.2_35\CD\1740 -_36\SYM\1740 3.8_37\CD\1740 )_38\-RRB-\1740 ._39\.\1740
D020849_D054556 CID conclusion_0\NN\5837957 :_1\:\1740 <e1>raloxifene</e1>_2\NNP\1740 was_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 an_6\DT\6697703 increased_7\VBN\169651 risk_8\NN\14541044 for_9\IN\1740 <e2>venous_10\JJ\1740 thromboembolism</e2>_11\NN\14100769 ,_12\,\1740 but_13\CC\1740 there_14\EX\27167 was_15\VBD\836236 no_16\DT\7204911 increased_17\VBN\169651 risk_18\NN\14541044 for_19\IN\1740 cataracts_20\NNS\14252864 ,_21\,\1740 gallbladder_22\NN\5512139 disease_23\NN\14061805 ,_24\,\1740 endometrial_25\JJ\1740 hyperplasia_26\NN\14365950 ,_27\,\1740 or_28\CC\3541091 endometrial_29\JJ\1740 cancer_30\NN\14239425 ._31\.\1740
D020849_D002386 NONE <e1>raloxifene</e1>_0\NN\1740 did_1\VBD\1640855 not_2\RB\1740 increase_3\VB\169651 risk_4\NN\14541044 for_5\IN\1740 <e2>cataracts</e2>_6\NNS\14252864 (_7\-LRB-\1740 rr_8\NN\1740 0.9_9\CD\1740 ;_10\:\1740 95_11\CD\1740 %_12\NN\1740 ci_13\NN\13635336 0.8_14\CD\1740 -_15\SYM\1740 1.1_16\CD\1740 )_17\-RRB-\1740 ,_18\,\1740 gallbladder_19\NN\5512139 disease_20\NN\14061805 (_21\-LRB-\1740 rr_22\NN\1740 1.0_23\CD\1740 ;_24\:\1740 95_25\CD\1740 %_26\NN\1740 ci_27\NN\13635336 0.7_28\CD\1740 -_29\SYM\1740 1.3_30\CD\1740 )_31\-RRB-\1740 ,_32\,\1740 endometrial_33\JJ\1740 hyperplasia_34\NN\14365950 (_35\-LRB-\1740 rr_36\NN\1740 1.3_37\CD\1740 ;_38\:\1740 95_39\CD\1740 %_40\NN\1740 ci_41\NN\13635336 0.4_42\CD\1740 -_43\SYM\1740 5.1_44\CD\1740 )_45\-RRB-\1740 ,_46\,\1740 or_47\CC\3541091 endometrial_48\JJ\1740 cancer_49\NN\14239425 (_50\-LRB-\1740 rr_51\NN\1740 0.9_52\CD\1740 ;_53\:\1740 95_54\CD\1740 %_55\NN\1740 ci_56\NN\13635336 0.3_57\CD\1740 -_58\SYM\1740 2.7_59\CD\1740 )_60\-RRB-\1740 ._61\.\1740
D020849_D002386 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>raloxifene</e1>_2\NNP\1740 was_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 an_6\DT\6697703 increased_7\VBN\169651 risk_8\NN\14541044 for_9\IN\1740 venous_10\JJ\1740 thromboembolism_11\NN\14100769 ,_12\,\1740 but_13\CC\1740 there_14\EX\27167 was_15\VBD\836236 no_16\DT\7204911 increased_17\VBN\169651 risk_18\NN\14541044 for_19\IN\1740 <e2>cataracts</e2>_20\NNS\14252864 ,_21\,\1740 gallbladder_22\NN\5512139 disease_23\NN\14061805 ,_24\,\1740 endometrial_25\JJ\1740 hyperplasia_26\NN\14365950 ,_27\,\1740 or_28\CC\3541091 endometrial_29\JJ\1740 cancer_30\NN\14239425 ._31\.\1740
D020849_D005705 NONE <e1>raloxifene</e1>_0\NN\1740 did_1\VBD\1640855 not_2\RB\1740 increase_3\VB\169651 risk_4\NN\14541044 for_5\IN\1740 cataracts_6\NNS\14252864 (_7\-LRB-\1740 rr_8\NN\1740 0.9_9\CD\1740 ;_10\:\1740 95_11\CD\1740 %_12\NN\1740 ci_13\NN\13635336 0.8_14\CD\1740 -_15\SYM\1740 1.1_16\CD\1740 )_17\-RRB-\1740 ,_18\,\1740 <e2>gallbladder_19\NN\5512139 disease</e2>_20\NN\14061805 (_21\-LRB-\1740 rr_22\NN\1740 1.0_23\CD\1740 ;_24\:\1740 95_25\CD\1740 %_26\NN\1740 ci_27\NN\13635336 0.7_28\CD\1740 -_29\SYM\1740 1.3_30\CD\1740 )_31\-RRB-\1740 ,_32\,\1740 endometrial_33\JJ\1740 hyperplasia_34\NN\14365950 (_35\-LRB-\1740 rr_36\NN\1740 1.3_37\CD\1740 ;_38\:\1740 95_39\CD\1740 %_40\NN\1740 ci_41\NN\13635336 0.4_42\CD\1740 -_43\SYM\1740 5.1_44\CD\1740 )_45\-RRB-\1740 ,_46\,\1740 or_47\CC\3541091 endometrial_48\JJ\1740 cancer_49\NN\14239425 (_50\-LRB-\1740 rr_51\NN\1740 0.9_52\CD\1740 ;_53\:\1740 95_54\CD\1740 %_55\NN\1740 ci_56\NN\13635336 0.3_57\CD\1740 -_58\SYM\1740 2.7_59\CD\1740 )_60\-RRB-\1740 ._61\.\1740
D020849_D005705 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>raloxifene</e1>_2\NNP\1740 was_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 an_6\DT\6697703 increased_7\VBN\169651 risk_8\NN\14541044 for_9\IN\1740 venous_10\JJ\1740 thromboembolism_11\NN\14100769 ,_12\,\1740 but_13\CC\1740 there_14\EX\27167 was_15\VBD\836236 no_16\DT\7204911 increased_17\VBN\169651 risk_18\NN\14541044 for_19\IN\1740 cataracts_20\NNS\14252864 ,_21\,\1740 <e2>gallbladder_22\NN\5512139 disease</e2>_23\NN\14061805 ,_24\,\1740 endometrial_25\JJ\1740 hyperplasia_26\NN\14365950 ,_27\,\1740 or_28\CC\3541091 endometrial_29\JJ\1740 cancer_30\NN\14239425 ._31\.\1740
D020849_D004714 NONE <e1>raloxifene</e1>_0\NN\1740 did_1\VBD\1640855 not_2\RB\1740 increase_3\VB\169651 risk_4\NN\14541044 for_5\IN\1740 cataracts_6\NNS\14252864 (_7\-LRB-\1740 rr_8\NN\1740 0.9_9\CD\1740 ;_10\:\1740 95_11\CD\1740 %_12\NN\1740 ci_13\NN\13635336 0.8_14\CD\1740 -_15\SYM\1740 1.1_16\CD\1740 )_17\-RRB-\1740 ,_18\,\1740 gallbladder_19\NN\5512139 disease_20\NN\14061805 (_21\-LRB-\1740 rr_22\NN\1740 1.0_23\CD\1740 ;_24\:\1740 95_25\CD\1740 %_26\NN\1740 ci_27\NN\13635336 0.7_28\CD\1740 -_29\SYM\1740 1.3_30\CD\1740 )_31\-RRB-\1740 ,_32\,\1740 <e2>endometrial_33\JJ\1740 hyperplasia</e2>_34\NN\14365950 (_35\-LRB-\1740 rr_36\NN\1740 1.3_37\CD\1740 ;_38\:\1740 95_39\CD\1740 %_40\NN\1740 ci_41\NN\13635336 0.4_42\CD\1740 -_43\SYM\1740 5.1_44\CD\1740 )_45\-RRB-\1740 ,_46\,\1740 or_47\CC\3541091 endometrial_48\JJ\1740 cancer_49\NN\14239425 (_50\-LRB-\1740 rr_51\NN\1740 0.9_52\CD\1740 ;_53\:\1740 95_54\CD\1740 %_55\NN\1740 ci_56\NN\13635336 0.3_57\CD\1740 -_58\SYM\1740 2.7_59\CD\1740 )_60\-RRB-\1740 ._61\.\1740
D020849_D004714 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>raloxifene</e1>_2\NNP\1740 was_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 an_6\DT\6697703 increased_7\VBN\169651 risk_8\NN\14541044 for_9\IN\1740 venous_10\JJ\1740 thromboembolism_11\NN\14100769 ,_12\,\1740 but_13\CC\1740 there_14\EX\27167 was_15\VBD\836236 no_16\DT\7204911 increased_17\VBN\169651 risk_18\NN\14541044 for_19\IN\1740 cataracts_20\NNS\14252864 ,_21\,\1740 gallbladder_22\NN\5512139 disease_23\NN\14061805 ,_24\,\1740 <e2>endometrial_25\JJ\1740 hyperplasia</e2>_26\NN\14365950 ,_27\,\1740 or_28\CC\3541091 endometrial_29\JJ\1740 cancer_30\NN\14239425 ._31\.\1740
D020849_D016889 NONE <e1>raloxifene</e1>_0\NN\1740 did_1\VBD\1640855 not_2\RB\1740 increase_3\VB\169651 risk_4\NN\14541044 for_5\IN\1740 cataracts_6\NNS\14252864 (_7\-LRB-\1740 rr_8\NN\1740 0.9_9\CD\1740 ;_10\:\1740 95_11\CD\1740 %_12\NN\1740 ci_13\NN\13635336 0.8_14\CD\1740 -_15\SYM\1740 1.1_16\CD\1740 )_17\-RRB-\1740 ,_18\,\1740 gallbladder_19\NN\5512139 disease_20\NN\14061805 (_21\-LRB-\1740 rr_22\NN\1740 1.0_23\CD\1740 ;_24\:\1740 95_25\CD\1740 %_26\NN\1740 ci_27\NN\13635336 0.7_28\CD\1740 -_29\SYM\1740 1.3_30\CD\1740 )_31\-RRB-\1740 ,_32\,\1740 endometrial_33\JJ\1740 hyperplasia_34\NN\14365950 (_35\-LRB-\1740 rr_36\NN\1740 1.3_37\CD\1740 ;_38\:\1740 95_39\CD\1740 %_40\NN\1740 ci_41\NN\13635336 0.4_42\CD\1740 -_43\SYM\1740 5.1_44\CD\1740 )_45\-RRB-\1740 ,_46\,\1740 or_47\CC\3541091 <e2>endometrial_48\JJ\1740 cancer</e2>_49\NN\14239425 (_50\-LRB-\1740 rr_51\NN\1740 0.9_52\CD\1740 ;_53\:\1740 95_54\CD\1740 %_55\NN\1740 ci_56\NN\13635336 0.3_57\CD\1740 -_58\SYM\1740 2.7_59\CD\1740 )_60\-RRB-\1740 ._61\.\1740
D020849_D016889 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>raloxifene</e1>_2\NNP\1740 was_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 an_6\DT\6697703 increased_7\VBN\169651 risk_8\NN\14541044 for_9\IN\1740 venous_10\JJ\1740 thromboembolism_11\NN\14100769 ,_12\,\1740 but_13\CC\1740 there_14\EX\27167 was_15\VBD\836236 no_16\DT\7204911 increased_17\VBN\169651 risk_18\NN\14541044 for_19\IN\1740 cataracts_20\NNS\14252864 ,_21\,\1740 gallbladder_22\NN\5512139 disease_23\NN\14061805 ,_24\,\1740 endometrial_25\JJ\1740 hyperplasia_26\NN\14365950 ,_27\,\1740 or_28\CC\3541091 <e2>endometrial_29\JJ\1740 cancer</e2>_30\NN\14239425 ._31\.\1740
17491223
D004280_D017202 CID assessment_0\NN\5732756 of_1\IN\1740 a_2\DT\13649268 new_3\JJ\1740 non-invasive_4\JJ\1740 index_5\NN\13850304 of_6\IN\1740 cardiac_7\JJ\1740 performance_8\NN\6619065 for_9\IN\1740 detection_10\NN\5708432 of_11\IN\1740 <e1>dobutamine-induced</e1>_12\JJ\1740 <e2>myocardial_13\JJ\1740 ischemia</e2>_14\NN\14195315 ._15\.\1740
D004280_D017202 CID background_0\NN\4921011 :_1\:\1740 electrocardiography_2\NN\177127 has_3\VBZ\2108377 a_4\DT\13649268 very_5\RB\1740 low_6\JJ\1740 sensitivity_7\NN\5651971 in_8\IN\13603305 detecting_9\VBG\2163746 <e1>dobutamine-induced</e1>_10\JJ\1740 <e2>myocardial_11\JJ\1740 ischemia</e2>_12\NN\14195315 ._13\.\1740
D004280_D017202 CID objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 added_5\VBN\156601 diagnostic_6\JJ\1740 value_7\NN\5856066 of_8\IN\1740 a_9\DT\13649268 new_10\JJ\1740 cardiac_11\JJ\1740 performance_12\NN\6619065 index_13\NN\13850304 (_14\-LRB-\1740 dp/dtejc_15\NN\1740 )_16\-RRB-\1740 measurement_17\NN\407535 ,_18\,\1740 based_19\VBN\2694933 on_20\IN\1740 brachial_21\JJ\1740 artery_22\NN\5417975 flow_23\NN\7311115 changes_24\NNS\7283608 ,_25\,\1740 as_26\IN\14622893 compared_27\VBN\644583 to_28\TO\1740 standard_29\JJ\1740 12-lead_30\JJ\1740 ecg_31\NNP\7000195 ,_32\,\1740 for_33\IN\1740 detecting_34\VBG\2163746 <e1>dobutamine-induced</e1>_35\JJ\1740 <e2>myocardial_36\JJ\1740 ischemia</e2>_37\NN\14195315 ,_38\,\1740 using_39\VBG\1156834 tc99m-sestamibi_40\NN\1740 single-photon_41\NN\1740 emission_42\NN\44455 computed_43\VBD\632627 tomography_44\NN\900375 as_45\IN\14622893 the_46\DT\1740 gold_47\NN\13371489 standard_48\NN\13577171 of_49\IN\1740 comparison_50\NN\635850 to_51\TO\1740 assess_52\VB\670261 the_53\DT\1740 presence_54\NN\13954253 or_55\CC\3541091 absence_56\NN\14449405 of_57\IN\1740 ischemia_58\NN\14195315 ._59\.\1740
D004280_D007511 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 added_5\VBN\156601 diagnostic_6\JJ\1740 value_7\NN\5856066 of_8\IN\1740 a_9\DT\13649268 new_10\JJ\1740 cardiac_11\JJ\1740 performance_12\NN\6619065 index_13\NN\13850304 (_14\-LRB-\1740 dp/dtejc_15\NN\1740 )_16\-RRB-\1740 measurement_17\NN\407535 ,_18\,\1740 based_19\VBN\2694933 on_20\IN\1740 brachial_21\JJ\1740 artery_22\NN\5417975 flow_23\NN\7311115 changes_24\NNS\7283608 ,_25\,\1740 as_26\IN\14622893 compared_27\VBN\644583 to_28\TO\1740 standard_29\JJ\1740 12-lead_30\JJ\1740 ecg_31\NNP\7000195 ,_32\,\1740 for_33\IN\1740 detecting_34\VBG\2163746 <e1>dobutamine-induced</e1>_35\JJ\1740 myocardial_36\JJ\1740 ischemia_37\NN\14195315 ,_38\,\1740 using_39\VBG\1156834 tc99m-sestamibi_40\NN\1740 single-photon_41\NN\1740 emission_42\NN\44455 computed_43\VBD\632627 tomography_44\NN\900375 as_45\IN\14622893 the_46\DT\1740 gold_47\NN\13371489 standard_48\NN\13577171 of_49\IN\1740 comparison_50\NN\635850 to_51\TO\1740 assess_52\VB\670261 the_53\DT\1740 presence_54\NN\13954253 or_55\CC\3541091 absence_56\NN\14449405 of_57\IN\1740 <e2>ischemia</e2>_58\NN\14195315 ._59\.\1740
D017256_D017202 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 added_5\VBN\156601 diagnostic_6\JJ\1740 value_7\NN\5856066 of_8\IN\1740 a_9\DT\13649268 new_10\JJ\1740 cardiac_11\JJ\1740 performance_12\NN\6619065 index_13\NN\13850304 (_14\-LRB-\1740 dp/dtejc_15\NN\1740 )_16\-RRB-\1740 measurement_17\NN\407535 ,_18\,\1740 based_19\VBN\2694933 on_20\IN\1740 brachial_21\JJ\1740 artery_22\NN\5417975 flow_23\NN\7311115 changes_24\NNS\7283608 ,_25\,\1740 as_26\IN\14622893 compared_27\VBN\644583 to_28\TO\1740 standard_29\JJ\1740 12-lead_30\JJ\1740 ecg_31\NNP\7000195 ,_32\,\1740 for_33\IN\1740 detecting_34\VBG\2163746 dobutamine-induced_35\JJ\1740 <e2>myocardial_36\JJ\1740 ischemia</e2>_37\NN\14195315 ,_38\,\1740 using_39\VBG\1156834 <e1>tc99m-sestamibi</e1>_40\NN\1740 single-photon_41\NN\1740 emission_42\NN\44455 computed_43\VBD\632627 tomography_44\NN\900375 as_45\IN\14622893 the_46\DT\1740 gold_47\NN\13371489 standard_48\NN\13577171 of_49\IN\1740 comparison_50\NN\635850 to_51\TO\1740 assess_52\VB\670261 the_53\DT\1740 presence_54\NN\13954253 or_55\CC\3541091 absence_56\NN\14449405 of_57\IN\1740 ischemia_58\NN\14195315 ._59\.\1740
D017256_D007511 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 added_5\VBN\156601 diagnostic_6\JJ\1740 value_7\NN\5856066 of_8\IN\1740 a_9\DT\13649268 new_10\JJ\1740 cardiac_11\JJ\1740 performance_12\NN\6619065 index_13\NN\13850304 (_14\-LRB-\1740 dp/dtejc_15\NN\1740 )_16\-RRB-\1740 measurement_17\NN\407535 ,_18\,\1740 based_19\VBN\2694933 on_20\IN\1740 brachial_21\JJ\1740 artery_22\NN\5417975 flow_23\NN\7311115 changes_24\NNS\7283608 ,_25\,\1740 as_26\IN\14622893 compared_27\VBN\644583 to_28\TO\1740 standard_29\JJ\1740 12-lead_30\JJ\1740 ecg_31\NNP\7000195 ,_32\,\1740 for_33\IN\1740 detecting_34\VBG\2163746 dobutamine-induced_35\JJ\1740 myocardial_36\JJ\1740 ischemia_37\NN\14195315 ,_38\,\1740 using_39\VBG\1156834 <e1>tc99m-sestamibi</e1>_40\NN\1740 single-photon_41\NN\1740 emission_42\NN\44455 computed_43\VBD\632627 tomography_44\NN\900375 as_45\IN\14622893 the_46\DT\1740 gold_47\NN\13371489 standard_48\NN\13577171 of_49\IN\1740 comparison_50\NN\635850 to_51\TO\1740 assess_52\VB\670261 the_53\DT\1740 presence_54\NN\13954253 or_55\CC\3541091 absence_56\NN\14449405 of_57\IN\1740 <e2>ischemia</e2>_58\NN\14195315 ._59\.\1740
10091617
D012642_D007024 CID <e1>selegiline-induced</e1>_0\JJ\1740 <e2>postural_1\JJ\1740 hypotension</e2>_2\NN\14057371 in_3\IN\13603305 parkinson_4\NN\1740 's_5\POS\1740 disease_6\NN\14061805 :_7\:\1740 a_8\DT\13649268 longitudinal_9\JJ\1740 study_10\NN\635850 on_11\IN\1740 the_12\DT\1740 effects_13\NNS\13245626 of_14\IN\1740 drug_15\NN\14778436 withdrawal_16\NN\7206096 ._17\.\1740
D012642_D007024 CID recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 found_3\VBD\2426171 that_4\IN\1740 therapy_5\NN\657604 with_6\IN\1740 <e1>selegiline</e1>_7\NN\1740 and_8\CC\1740 l-dopa_9\NN\14604959 was_10\VBD\836236 associated_11\VBN\628491 with_12\IN\1740 selective_13\JJ\1740 <e2>systolic_14\NN\1740 orthostatic_15\JJ\1740 hypotension</e2>_16\NN\14057371 which_17\WDT\1740 was_18\VBD\836236 abolished_19\VBN\1740 by_20\IN\1740 withdrawal_21\NN\7206096 of_22\IN\1740 selegiline_23\NN\1740 ._24\.\1740
D012642_D007024 CID recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 found_3\VBD\2426171 that_4\IN\1740 therapy_5\NN\657604 with_6\IN\1740 selegiline_7\NN\1740 and_8\CC\1740 l-dopa_9\NN\14604959 was_10\VBD\836236 associated_11\VBN\628491 with_12\IN\1740 selective_13\JJ\1740 <e2>systolic_14\NN\1740 orthostatic_15\JJ\1740 hypotension</e2>_16\NN\14057371 which_17\WDT\1740 was_18\VBD\836236 abolished_19\VBN\1740 by_20\IN\1740 withdrawal_21\NN\7206096 of_22\IN\1740 <e1>selegiline</e1>_23\NN\1740 ._24\.\1740
D012642_D007024 CID the_0\DT\1740 aims_1\NNS\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 were_5\VBD\836236 to_6\TO\1740 confirm_7\VB\1011725 our_8\PRP$\1740 previous_9\JJ\1740 findings_10\NNS\7951464 in_11\IN\13603305 a_12\DT\13649268 separate_13\JJ\1740 cohort_14\NN\8184861 of_15\IN\1740 patients_16\NNS\9898892 and_17\CC\1740 to_18\TO\1740 determine_19\VB\1645601 the_20\DT\1740 time_21\NN\7308889 course_22\NN\883297 of_23\IN\1740 the_24\DT\1740 cardiovascular_25\JJ\1740 consequences_26\NNS\34213 of_27\IN\1740 stopping_28\VBG\2452885 <e1>selegiline</e1>_29\NN\1740 in_30\IN\13603305 the_31\DT\1740 expectation_32\NN\5941423 that_33\IN\1740 this_34\DT\1740 might_35\MD\5029706 shed_36\VB\173338 light_37\NN\11421401 on_38\IN\1740 the_39\DT\1740 mechanisms_40\NNS\13446390 by_41\IN\1740 which_42\WDT\1740 the_43\DT\1740 drug_44\NN\14778436 causes_45\VBZ\1617192 <e2>orthostatic_46\JJ\1740 hypotension</e2>_47\NN\14057371 ._48\.\1740
D012642_D007024 CID results_0\NNS\34213 :_1\:\1740 head-up_2\NN\1740 tilt_3\NN\788973 caused_4\VBD\1617192 <e2>systolic_5\JJ\1740 orthostatic_6\JJ\1740 hypotension</e2>_7\NN\14057371 which_8\WDT\1740 was_9\VBD\836236 marked_10\VBN\1296462 in_11\IN\13603305 six_12\CD\13741022 of_13\IN\1740 20_14\CD\13745420 pd_15\NN\14625458 patients_16\NNS\9898892 on_17\IN\1740 <e1>selegiline</e1>_18\NN\1740 ,_19\,\1740 one_20\CD\13741022 of_21\IN\1740 whom_22\WP\1740 lost_23\VBD\1794668 consciousness_24\NN\5669934 with_25\IN\1740 unrecordable_26\JJ\1740 blood_27\NN\5397468 pressures_28\NNS\11419404 ._29\.\1740
D012642_D007024 CID <e2>orthostatic_0\JJ\1740 hypotension</e2>_1\NN\14057371 was_2\VBD\836236 ameliorated_3\VBN\126264 4_4\CD\13741022 days_5\NNS\15140892 after_6\IN\1740 withdrawal_7\NN\7206096 of_8\IN\1740 <e1>selegiline</e1>_9\NN\1740 and_10\CC\1740 totally_11\RB\1740 abolished_12\VBD\1740 7_13\CD\13741022 days_14\NNS\15140892 after_15\IN\1740 discontinuation_16\NN\209943 of_17\IN\1740 the_18\DT\1740 drug_19\NN\14778436 ._20\.\1740
D012642_D007024 CID stopping_0\VBG\2452885 <e1>selegiline</e1>_1\NN\1740 also_2\RB\1740 significantly_3\RB\1740 <e2>reduced_4\VBD\441445 the_5\DT\1740 supine_6\JJ\1740 systolic_7\NN\1740 and_8\CC\1740 diastolic_9\JJ\1740 blood_10\NN\5397468 pressures</e2>_11\NNS\11419404 consistent_12\JJ\1740 with_13\IN\1740 a_14\DT\13649268 previously_15\RB\1740 undescribed_16\JJ\1740 supine_17\NN\1740 pressor_18\NN\9190918 action_19\NN\30358 ._20\.\1740
D012642_D007024 CID conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 confirms_4\VBZ\1011725 our_5\PRP$\1740 previous_6\JJ\1740 finding_7\NN\43195 that_8\IN\1740 <e1>selegiline</e1>_9\NN\1740 in_10\IN\13603305 combination_11\NN\7951464 with_12\IN\1740 l-dopa_13\NN\14604959 is_14\VBZ\836236 associated_15\VBN\628491 with_16\IN\1740 selective_17\JJ\1740 <e2>orthostatic_18\JJ\1740 hypotension</e2>_19\NN\14057371 ._20\.\1740
D012642_D010300 NONE <e1>selegiline-induced</e1>_0\JJ\1740 postural_1\JJ\1740 hypotension_2\NN\14057371 in_3\IN\13603305 <e2>parkinson_4\NN\1740 's_5\POS\1740 disease</e2>_6\NN\14061805 :_7\:\1740 a_8\DT\13649268 longitudinal_9\JJ\1740 study_10\NN\635850 on_11\IN\1740 the_12\DT\1740 effects_13\NNS\13245626 of_14\IN\1740 drug_15\NN\14778436 withdrawal_16\NN\7206096 ._17\.\1740
D012642_D010300 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 united_3\NNP\1740 kingdom_4\NNP\14514039 <e2>parkinson_5\NNP\1740 's_6\POS\1740 disease</e2>_7\NNP\14061805 research_8\NNP\633864 group_9\NNP\2137 (_10\-LRB-\1740 ukpdrg_11\NN\1740 )_12\-RRB-\1740 trial_13\NN\786195 found_14\VBD\2426171 an_15\DT\6697703 increased_16\VBN\169651 mortality_17\NN\5054863 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 parkinson_21\NN\1740 's_22\POS\1740 disease_23\NN\14061805 (_24\-LRB-\1740 pd_25\NN\14625458 )_26\-RRB-\1740 randomized_27\VBD\278117 to_28\TO\1740 receive_29\VB\2210855 10_30\CD\13745420 mg_31\NN\13717155 <e1>selegiline</e1>_32\NN\1740 per_33\IN\1740 day_34\NN\15154774 and_35\CC\1740 l-dopa_36\JJ\1740 compared_37\VBN\644583 with_38\IN\1740 those_39\DT\1740 taking_40\VBG\2367363 l-dopa_41\NN\14604959 alone_42\RB\1740 ._43\.\1740
D012642_D010300 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 united_3\NNP\1740 kingdom_4\NNP\14514039 parkinson_5\NNP\1740 's_6\POS\1740 disease_7\NNP\14061805 research_8\NNP\633864 group_9\NNP\2137 (_10\-LRB-\1740 ukpdrg_11\NN\1740 )_12\-RRB-\1740 trial_13\NN\786195 found_14\VBD\2426171 an_15\DT\6697703 increased_16\VBN\169651 mortality_17\NN\5054863 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 <e2>parkinson_21\NN\1740 's_22\POS\1740 disease</e2>_23\NN\14061805 (_24\-LRB-\1740 pd_25\NN\14625458 )_26\-RRB-\1740 randomized_27\VBD\278117 to_28\TO\1740 receive_29\VB\2210855 10_30\CD\13745420 mg_31\NN\13717155 <e1>selegiline</e1>_32\NN\1740 per_33\IN\1740 day_34\NN\15154774 and_35\CC\1740 l-dopa_36\JJ\1740 compared_37\VBN\644583 with_38\IN\1740 those_39\DT\1740 taking_40\VBG\2367363 l-dopa_41\NN\14604959 alone_42\RB\1740 ._43\.\1740
D012642_D010300 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 united_3\NNP\1740 kingdom_4\NNP\14514039 parkinson_5\NNP\1740 's_6\POS\1740 disease_7\NNP\14061805 research_8\NNP\633864 group_9\NNP\2137 (_10\-LRB-\1740 ukpdrg_11\NN\1740 )_12\-RRB-\1740 trial_13\NN\786195 found_14\VBD\2426171 an_15\DT\6697703 increased_16\VBN\169651 mortality_17\NN\5054863 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 parkinson_21\NN\1740 's_22\POS\1740 disease_23\NN\14061805 (_24\-LRB-\1740 <e2>pd</e2>_25\NN\14625458 )_26\-RRB-\1740 randomized_27\VBD\278117 to_28\TO\1740 receive_29\VB\2210855 10_30\CD\13745420 mg_31\NN\13717155 <e1>selegiline</e1>_32\NN\1740 per_33\IN\1740 day_34\NN\15154774 and_35\CC\1740 l-dopa_36\JJ\1740 compared_37\VBN\644583 with_38\IN\1740 those_39\DT\1740 taking_40\VBG\2367363 l-dopa_41\NN\14604959 alone_42\RB\1740 ._43\.\1740
D012642_D010300 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 cardiovascular_3\JJ\1740 responses_4\NNS\11410625 to_5\TO\1740 standing_6\NN\13945919 and_7\CC\1740 head-up_8\JJ\1740 tilt_9\NN\788973 were_10\VBD\836236 studied_11\VBN\630380 repeatedly_12\RB\1740 in_13\IN\13603305 <e2>pd</e2>_14\NN\14625458 patients_15\NNS\9898892 receiving_16\VBG\2210855 <e1>selegiline</e1>_17\NN\1740 and_18\CC\1740 as_19\IN\14622893 the_20\DT\1740 drug_21\NN\14778436 was_22\VBD\836236 withdrawn_23\VBN\1835496 ._24\.\1740
D012642_D010300 NONE results_0\NNS\34213 :_1\:\1740 head-up_2\NN\1740 tilt_3\NN\788973 caused_4\VBD\1617192 systolic_5\JJ\1740 orthostatic_6\JJ\1740 hypotension_7\NN\14057371 which_8\WDT\1740 was_9\VBD\836236 marked_10\VBN\1296462 in_11\IN\13603305 six_12\CD\13741022 of_13\IN\1740 20_14\CD\13745420 <e2>pd</e2>_15\NN\14625458 patients_16\NNS\9898892 on_17\IN\1740 <e1>selegiline</e1>_18\NN\1740 ,_19\,\1740 one_20\CD\13741022 of_21\IN\1740 whom_22\WP\1740 lost_23\VBD\1794668 consciousness_24\NN\5669934 with_25\IN\1740 unrecordable_26\JJ\1740 blood_27\NN\5397468 pressures_28\NNS\11419404 ._29\.\1740
D007980_D010300 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 united_3\NNP\1740 kingdom_4\NNP\14514039 <e2>parkinson_5\NNP\1740 's_6\POS\1740 disease</e2>_7\NNP\14061805 research_8\NNP\633864 group_9\NNP\2137 (_10\-LRB-\1740 ukpdrg_11\NN\1740 )_12\-RRB-\1740 trial_13\NN\786195 found_14\VBD\2426171 an_15\DT\6697703 increased_16\VBN\169651 mortality_17\NN\5054863 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 parkinson_21\NN\1740 's_22\POS\1740 disease_23\NN\14061805 (_24\-LRB-\1740 pd_25\NN\14625458 )_26\-RRB-\1740 randomized_27\VBD\278117 to_28\TO\1740 receive_29\VB\2210855 10_30\CD\13745420 mg_31\NN\13717155 selegiline_32\NN\1740 per_33\IN\1740 day_34\NN\15154774 and_35\CC\1740 <e1>l-dopa</e1>_36\JJ\1740 compared_37\VBN\644583 with_38\IN\1740 those_39\DT\1740 taking_40\VBG\2367363 l-dopa_41\NN\14604959 alone_42\RB\1740 ._43\.\1740
D007980_D010300 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 united_3\NNP\1740 kingdom_4\NNP\14514039 parkinson_5\NNP\1740 's_6\POS\1740 disease_7\NNP\14061805 research_8\NNP\633864 group_9\NNP\2137 (_10\-LRB-\1740 ukpdrg_11\NN\1740 )_12\-RRB-\1740 trial_13\NN\786195 found_14\VBD\2426171 an_15\DT\6697703 increased_16\VBN\169651 mortality_17\NN\5054863 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 <e2>parkinson_21\NN\1740 's_22\POS\1740 disease</e2>_23\NN\14061805 (_24\-LRB-\1740 pd_25\NN\14625458 )_26\-RRB-\1740 randomized_27\VBD\278117 to_28\TO\1740 receive_29\VB\2210855 10_30\CD\13745420 mg_31\NN\13717155 selegiline_32\NN\1740 per_33\IN\1740 day_34\NN\15154774 and_35\CC\1740 <e1>l-dopa</e1>_36\JJ\1740 compared_37\VBN\644583 with_38\IN\1740 those_39\DT\1740 taking_40\VBG\2367363 l-dopa_41\NN\14604959 alone_42\RB\1740 ._43\.\1740
D007980_D010300 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 united_3\NNP\1740 kingdom_4\NNP\14514039 parkinson_5\NNP\1740 's_6\POS\1740 disease_7\NNP\14061805 research_8\NNP\633864 group_9\NNP\2137 (_10\-LRB-\1740 ukpdrg_11\NN\1740 )_12\-RRB-\1740 trial_13\NN\786195 found_14\VBD\2426171 an_15\DT\6697703 increased_16\VBN\169651 mortality_17\NN\5054863 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 parkinson_21\NN\1740 's_22\POS\1740 disease_23\NN\14061805 (_24\-LRB-\1740 <e2>pd</e2>_25\NN\14625458 )_26\-RRB-\1740 randomized_27\VBD\278117 to_28\TO\1740 receive_29\VB\2210855 10_30\CD\13745420 mg_31\NN\13717155 selegiline_32\NN\1740 per_33\IN\1740 day_34\NN\15154774 and_35\CC\1740 <e1>l-dopa</e1>_36\JJ\1740 compared_37\VBN\644583 with_38\IN\1740 those_39\DT\1740 taking_40\VBG\2367363 l-dopa_41\NN\14604959 alone_42\RB\1740 ._43\.\1740
D007980_D010300 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 united_3\NNP\1740 kingdom_4\NNP\14514039 <e2>parkinson_5\NNP\1740 's_6\POS\1740 disease</e2>_7\NNP\14061805 research_8\NNP\633864 group_9\NNP\2137 (_10\-LRB-\1740 ukpdrg_11\NN\1740 )_12\-RRB-\1740 trial_13\NN\786195 found_14\VBD\2426171 an_15\DT\6697703 increased_16\VBN\169651 mortality_17\NN\5054863 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 parkinson_21\NN\1740 's_22\POS\1740 disease_23\NN\14061805 (_24\-LRB-\1740 pd_25\NN\14625458 )_26\-RRB-\1740 randomized_27\VBD\278117 to_28\TO\1740 receive_29\VB\2210855 10_30\CD\13745420 mg_31\NN\13717155 selegiline_32\NN\1740 per_33\IN\1740 day_34\NN\15154774 and_35\CC\1740 l-dopa_36\JJ\1740 compared_37\VBN\644583 with_38\IN\1740 those_39\DT\1740 taking_40\VBG\2367363 <e1>l-dopa</e1>_41\NN\14604959 alone_42\RB\1740 ._43\.\1740
D007980_D010300 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 united_3\NNP\1740 kingdom_4\NNP\14514039 parkinson_5\NNP\1740 's_6\POS\1740 disease_7\NNP\14061805 research_8\NNP\633864 group_9\NNP\2137 (_10\-LRB-\1740 ukpdrg_11\NN\1740 )_12\-RRB-\1740 trial_13\NN\786195 found_14\VBD\2426171 an_15\DT\6697703 increased_16\VBN\169651 mortality_17\NN\5054863 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 <e2>parkinson_21\NN\1740 's_22\POS\1740 disease</e2>_23\NN\14061805 (_24\-LRB-\1740 pd_25\NN\14625458 )_26\-RRB-\1740 randomized_27\VBD\278117 to_28\TO\1740 receive_29\VB\2210855 10_30\CD\13745420 mg_31\NN\13717155 selegiline_32\NN\1740 per_33\IN\1740 day_34\NN\15154774 and_35\CC\1740 l-dopa_36\JJ\1740 compared_37\VBN\644583 with_38\IN\1740 those_39\DT\1740 taking_40\VBG\2367363 <e1>l-dopa</e1>_41\NN\14604959 alone_42\RB\1740 ._43\.\1740
D007980_D010300 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 united_3\NNP\1740 kingdom_4\NNP\14514039 parkinson_5\NNP\1740 's_6\POS\1740 disease_7\NNP\14061805 research_8\NNP\633864 group_9\NNP\2137 (_10\-LRB-\1740 ukpdrg_11\NN\1740 )_12\-RRB-\1740 trial_13\NN\786195 found_14\VBD\2426171 an_15\DT\6697703 increased_16\VBN\169651 mortality_17\NN\5054863 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 parkinson_21\NN\1740 's_22\POS\1740 disease_23\NN\14061805 (_24\-LRB-\1740 <e2>pd</e2>_25\NN\14625458 )_26\-RRB-\1740 randomized_27\VBD\278117 to_28\TO\1740 receive_29\VB\2210855 10_30\CD\13745420 mg_31\NN\13717155 selegiline_32\NN\1740 per_33\IN\1740 day_34\NN\15154774 and_35\CC\1740 l-dopa_36\JJ\1740 compared_37\VBN\644583 with_38\IN\1740 those_39\DT\1740 taking_40\VBG\2367363 <e1>l-dopa</e1>_41\NN\14604959 alone_42\RB\1740 ._43\.\1740
D007980_D007024 NONE recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 found_3\VBD\2426171 that_4\IN\1740 therapy_5\NN\657604 with_6\IN\1740 selegiline_7\NN\1740 and_8\CC\1740 <e1>l-dopa</e1>_9\NN\14604959 was_10\VBD\836236 associated_11\VBN\628491 with_12\IN\1740 selective_13\JJ\1740 <e2>systolic_14\NN\1740 orthostatic_15\JJ\1740 hypotension</e2>_16\NN\14057371 which_17\WDT\1740 was_18\VBD\836236 abolished_19\VBN\1740 by_20\IN\1740 withdrawal_21\NN\7206096 of_22\IN\1740 selegiline_23\NN\1740 ._24\.\1740
D007980_D007024 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 confirms_4\VBZ\1011725 our_5\PRP$\1740 previous_6\JJ\1740 finding_7\NN\43195 that_8\IN\1740 selegiline_9\NN\1740 in_10\IN\13603305 combination_11\NN\7951464 with_12\IN\1740 <e1>l-dopa</e1>_13\NN\14604959 is_14\VBZ\836236 associated_15\VBN\628491 with_16\IN\1740 selective_17\JJ\1740 <e2>orthostatic_18\JJ\1740 hypotension</e2>_19\NN\14057371 ._20\.\1740
2951327
D009638_D013610 NONE mean_0\VB\928630 arterial_1\JJ\1740 pressure_2\NN\11419404 (_3\-LRB-\1740 as_4\IN\14622893 a_5\DT\13649268 percentage_6\NN\13815742 of_7\IN\1740 control_8\NN\5190804 +/-_9\CC\1740 sem_10\NN\1740 )_11\-RRB-\1740 during_12\IN\1740 randomized_13\JJ\1740 infusions_14\NNS\14589223 of_15\IN\1740 0.03_16\CD\1740 ,_17\,\1740 0.1_18\CD\1740 ,_19\,\1740 0.3_20\CD\1740 ,_21\,\1740 or_22\CC\3541091 1.0_23\CD\1740 microgram/kg/min_24\NN\1740 was_25\VBD\836236 99_26\CD\1740 +/-_27\CC\1740 1_28\CD\13741022 ,_29\,\1740 95_30\CD\1740 +/-_31\CC\1740 1_32\CD\13741022 (_33\-LRB-\1740 p_34\NN\14622893 less_35\JJR\1740 than_36\IN\1740 0.05_37\CD\1740 )_38\-RRB-\1740 ,_39\,\1740 93_40\CD\1740 +/-_41\CC\1740 1_42\CD\13741022 (_43\-LRB-\1740 p_44\NN\14622893 less_45\JJR\1740 than_46\IN\1740 0.01_47\CD\1740 )_48\-RRB-\1740 ,_49\,\1740 or_50\CC\3541091 79_51\CD\1740 +/-_52\CC\1740 6_53\CD\13741022 %_54\NN\1740 (_55\-LRB-\1740 p_56\NN\14622893 less_57\JJR\1740 than_58\IN\1740 0.001_59\CD\1740 )_60\-RRB-\1740 ,_61\,\1740 respectively_62\RB\1740 ,_63\,\1740 but_64\CC\1740 no_65\DT\7204911 <e2>tachycardia</e2>_66\NN\14110674 and_67\CC\1740 no_68\DT\7204911 augmentation_69\NN\7356676 of_70\IN\1740 the_71\DT\1740 <e1>norepinephrine</e1>_72\NN\14807929 release_73\NN\3748886 rate_74\NN\13815152 (_75\-LRB-\1740 up_76\RB\1740 to_77\TO\1740 0.3_78\CD\1740 microgram/kg/min_79\NN\1740 )_80\-RRB-\1740 were_81\VBD\836236 observed_82\VBN\2163746 ,_83\,\1740 which_84\WDT\1740 is_85\VBZ\836236 in_86\IN\13603305 contrast_87\NN\13854649 to_88\TO\1740 comparable_89\JJ\1740 hypotension_90\NN\14057371 induced_91\VBN\1627355 by_92\IN\1740 hydralazine_93\NN\2721160 or_94\CC\3541091 nitroglycerin_95\NN\15015501 ._96\.\1740
D009638_D007022 NONE mean_0\VB\928630 arterial_1\JJ\1740 pressure_2\NN\11419404 (_3\-LRB-\1740 as_4\IN\14622893 a_5\DT\13649268 percentage_6\NN\13815742 of_7\IN\1740 control_8\NN\5190804 +/-_9\CC\1740 sem_10\NN\1740 )_11\-RRB-\1740 during_12\IN\1740 randomized_13\JJ\1740 infusions_14\NNS\14589223 of_15\IN\1740 0.03_16\CD\1740 ,_17\,\1740 0.1_18\CD\1740 ,_19\,\1740 0.3_20\CD\1740 ,_21\,\1740 or_22\CC\3541091 1.0_23\CD\1740 microgram/kg/min_24\NN\1740 was_25\VBD\836236 99_26\CD\1740 +/-_27\CC\1740 1_28\CD\13741022 ,_29\,\1740 95_30\CD\1740 +/-_31\CC\1740 1_32\CD\13741022 (_33\-LRB-\1740 p_34\NN\14622893 less_35\JJR\1740 than_36\IN\1740 0.05_37\CD\1740 )_38\-RRB-\1740 ,_39\,\1740 93_40\CD\1740 +/-_41\CC\1740 1_42\CD\13741022 (_43\-LRB-\1740 p_44\NN\14622893 less_45\JJR\1740 than_46\IN\1740 0.01_47\CD\1740 )_48\-RRB-\1740 ,_49\,\1740 or_50\CC\3541091 79_51\CD\1740 +/-_52\CC\1740 6_53\CD\13741022 %_54\NN\1740 (_55\-LRB-\1740 p_56\NN\14622893 less_57\JJR\1740 than_58\IN\1740 0.001_59\CD\1740 )_60\-RRB-\1740 ,_61\,\1740 respectively_62\RB\1740 ,_63\,\1740 but_64\CC\1740 no_65\DT\7204911 tachycardia_66\NN\14110674 and_67\CC\1740 no_68\DT\7204911 augmentation_69\NN\7356676 of_70\IN\1740 the_71\DT\1740 <e1>norepinephrine</e1>_72\NN\14807929 release_73\NN\3748886 rate_74\NN\13815152 (_75\-LRB-\1740 up_76\RB\1740 to_77\TO\1740 0.3_78\CD\1740 microgram/kg/min_79\NN\1740 )_80\-RRB-\1740 were_81\VBD\836236 observed_82\VBN\2163746 ,_83\,\1740 which_84\WDT\1740 is_85\VBZ\836236 in_86\IN\13603305 contrast_87\NN\13854649 to_88\TO\1740 comparable_89\JJ\1740 <e2>hypotension</e2>_90\NN\14057371 induced_91\VBN\1627355 by_92\IN\1740 hydralazine_93\NN\2721160 or_94\CC\3541091 nitroglycerin_95\NN\15015501 ._96\.\1740
D006830_D013610 NONE mean_0\VB\928630 arterial_1\JJ\1740 pressure_2\NN\11419404 (_3\-LRB-\1740 as_4\IN\14622893 a_5\DT\13649268 percentage_6\NN\13815742 of_7\IN\1740 control_8\NN\5190804 +/-_9\CC\1740 sem_10\NN\1740 )_11\-RRB-\1740 during_12\IN\1740 randomized_13\JJ\1740 infusions_14\NNS\14589223 of_15\IN\1740 0.03_16\CD\1740 ,_17\,\1740 0.1_18\CD\1740 ,_19\,\1740 0.3_20\CD\1740 ,_21\,\1740 or_22\CC\3541091 1.0_23\CD\1740 microgram/kg/min_24\NN\1740 was_25\VBD\836236 99_26\CD\1740 +/-_27\CC\1740 1_28\CD\13741022 ,_29\,\1740 95_30\CD\1740 +/-_31\CC\1740 1_32\CD\13741022 (_33\-LRB-\1740 p_34\NN\14622893 less_35\JJR\1740 than_36\IN\1740 0.05_37\CD\1740 )_38\-RRB-\1740 ,_39\,\1740 93_40\CD\1740 +/-_41\CC\1740 1_42\CD\13741022 (_43\-LRB-\1740 p_44\NN\14622893 less_45\JJR\1740 than_46\IN\1740 0.01_47\CD\1740 )_48\-RRB-\1740 ,_49\,\1740 or_50\CC\3541091 79_51\CD\1740 +/-_52\CC\1740 6_53\CD\13741022 %_54\NN\1740 (_55\-LRB-\1740 p_56\NN\14622893 less_57\JJR\1740 than_58\IN\1740 0.001_59\CD\1740 )_60\-RRB-\1740 ,_61\,\1740 respectively_62\RB\1740 ,_63\,\1740 but_64\CC\1740 no_65\DT\7204911 <e2>tachycardia</e2>_66\NN\14110674 and_67\CC\1740 no_68\DT\7204911 augmentation_69\NN\7356676 of_70\IN\1740 the_71\DT\1740 norepinephrine_72\NN\14807929 release_73\NN\3748886 rate_74\NN\13815152 (_75\-LRB-\1740 up_76\RB\1740 to_77\TO\1740 0.3_78\CD\1740 microgram/kg/min_79\NN\1740 )_80\-RRB-\1740 were_81\VBD\836236 observed_82\VBN\2163746 ,_83\,\1740 which_84\WDT\1740 is_85\VBZ\836236 in_86\IN\13603305 contrast_87\NN\13854649 to_88\TO\1740 comparable_89\JJ\1740 hypotension_90\NN\14057371 induced_91\VBN\1627355 by_92\IN\1740 <e1>hydralazine</e1>_93\NN\2721160 or_94\CC\3541091 nitroglycerin_95\NN\15015501 ._96\.\1740
D006830_D007022 CID mean_0\VB\928630 arterial_1\JJ\1740 pressure_2\NN\11419404 (_3\-LRB-\1740 as_4\IN\14622893 a_5\DT\13649268 percentage_6\NN\13815742 of_7\IN\1740 control_8\NN\5190804 +/-_9\CC\1740 sem_10\NN\1740 )_11\-RRB-\1740 during_12\IN\1740 randomized_13\JJ\1740 infusions_14\NNS\14589223 of_15\IN\1740 0.03_16\CD\1740 ,_17\,\1740 0.1_18\CD\1740 ,_19\,\1740 0.3_20\CD\1740 ,_21\,\1740 or_22\CC\3541091 1.0_23\CD\1740 microgram/kg/min_24\NN\1740 was_25\VBD\836236 99_26\CD\1740 +/-_27\CC\1740 1_28\CD\13741022 ,_29\,\1740 95_30\CD\1740 +/-_31\CC\1740 1_32\CD\13741022 (_33\-LRB-\1740 p_34\NN\14622893 less_35\JJR\1740 than_36\IN\1740 0.05_37\CD\1740 )_38\-RRB-\1740 ,_39\,\1740 93_40\CD\1740 +/-_41\CC\1740 1_42\CD\13741022 (_43\-LRB-\1740 p_44\NN\14622893 less_45\JJR\1740 than_46\IN\1740 0.01_47\CD\1740 )_48\-RRB-\1740 ,_49\,\1740 or_50\CC\3541091 79_51\CD\1740 +/-_52\CC\1740 6_53\CD\13741022 %_54\NN\1740 (_55\-LRB-\1740 p_56\NN\14622893 less_57\JJR\1740 than_58\IN\1740 0.001_59\CD\1740 )_60\-RRB-\1740 ,_61\,\1740 respectively_62\RB\1740 ,_63\,\1740 but_64\CC\1740 no_65\DT\7204911 tachycardia_66\NN\14110674 and_67\CC\1740 no_68\DT\7204911 augmentation_69\NN\7356676 of_70\IN\1740 the_71\DT\1740 norepinephrine_72\NN\14807929 release_73\NN\3748886 rate_74\NN\13815152 (_75\-LRB-\1740 up_76\RB\1740 to_77\TO\1740 0.3_78\CD\1740 microgram/kg/min_79\NN\1740 )_80\-RRB-\1740 were_81\VBD\836236 observed_82\VBN\2163746 ,_83\,\1740 which_84\WDT\1740 is_85\VBZ\836236 in_86\IN\13603305 contrast_87\NN\13854649 to_88\TO\1740 comparable_89\JJ\1740 <e2>hypotension</e2>_90\NN\14057371 induced_91\VBN\1627355 by_92\IN\1740 <e1>hydralazine</e1>_93\NN\2721160 or_94\CC\3541091 nitroglycerin_95\NN\15015501 ._96\.\1740
D005996_D013610 NONE mean_0\VB\928630 arterial_1\JJ\1740 pressure_2\NN\11419404 (_3\-LRB-\1740 as_4\IN\14622893 a_5\DT\13649268 percentage_6\NN\13815742 of_7\IN\1740 control_8\NN\5190804 +/-_9\CC\1740 sem_10\NN\1740 )_11\-RRB-\1740 during_12\IN\1740 randomized_13\JJ\1740 infusions_14\NNS\14589223 of_15\IN\1740 0.03_16\CD\1740 ,_17\,\1740 0.1_18\CD\1740 ,_19\,\1740 0.3_20\CD\1740 ,_21\,\1740 or_22\CC\3541091 1.0_23\CD\1740 microgram/kg/min_24\NN\1740 was_25\VBD\836236 99_26\CD\1740 +/-_27\CC\1740 1_28\CD\13741022 ,_29\,\1740 95_30\CD\1740 +/-_31\CC\1740 1_32\CD\13741022 (_33\-LRB-\1740 p_34\NN\14622893 less_35\JJR\1740 than_36\IN\1740 0.05_37\CD\1740 )_38\-RRB-\1740 ,_39\,\1740 93_40\CD\1740 +/-_41\CC\1740 1_42\CD\13741022 (_43\-LRB-\1740 p_44\NN\14622893 less_45\JJR\1740 than_46\IN\1740 0.01_47\CD\1740 )_48\-RRB-\1740 ,_49\,\1740 or_50\CC\3541091 79_51\CD\1740 +/-_52\CC\1740 6_53\CD\13741022 %_54\NN\1740 (_55\-LRB-\1740 p_56\NN\14622893 less_57\JJR\1740 than_58\IN\1740 0.001_59\CD\1740 )_60\-RRB-\1740 ,_61\,\1740 respectively_62\RB\1740 ,_63\,\1740 but_64\CC\1740 no_65\DT\7204911 <e2>tachycardia</e2>_66\NN\14110674 and_67\CC\1740 no_68\DT\7204911 augmentation_69\NN\7356676 of_70\IN\1740 the_71\DT\1740 norepinephrine_72\NN\14807929 release_73\NN\3748886 rate_74\NN\13815152 (_75\-LRB-\1740 up_76\RB\1740 to_77\TO\1740 0.3_78\CD\1740 microgram/kg/min_79\NN\1740 )_80\-RRB-\1740 were_81\VBD\836236 observed_82\VBN\2163746 ,_83\,\1740 which_84\WDT\1740 is_85\VBZ\836236 in_86\IN\13603305 contrast_87\NN\13854649 to_88\TO\1740 comparable_89\JJ\1740 hypotension_90\NN\14057371 induced_91\VBN\1627355 by_92\IN\1740 hydralazine_93\NN\2721160 or_94\CC\3541091 <e1>nitroglycerin</e1>_95\NN\15015501 ._96\.\1740
D005996_D007022 CID mean_0\VB\928630 arterial_1\JJ\1740 pressure_2\NN\11419404 (_3\-LRB-\1740 as_4\IN\14622893 a_5\DT\13649268 percentage_6\NN\13815742 of_7\IN\1740 control_8\NN\5190804 +/-_9\CC\1740 sem_10\NN\1740 )_11\-RRB-\1740 during_12\IN\1740 randomized_13\JJ\1740 infusions_14\NNS\14589223 of_15\IN\1740 0.03_16\CD\1740 ,_17\,\1740 0.1_18\CD\1740 ,_19\,\1740 0.3_20\CD\1740 ,_21\,\1740 or_22\CC\3541091 1.0_23\CD\1740 microgram/kg/min_24\NN\1740 was_25\VBD\836236 99_26\CD\1740 +/-_27\CC\1740 1_28\CD\13741022 ,_29\,\1740 95_30\CD\1740 +/-_31\CC\1740 1_32\CD\13741022 (_33\-LRB-\1740 p_34\NN\14622893 less_35\JJR\1740 than_36\IN\1740 0.05_37\CD\1740 )_38\-RRB-\1740 ,_39\,\1740 93_40\CD\1740 +/-_41\CC\1740 1_42\CD\13741022 (_43\-LRB-\1740 p_44\NN\14622893 less_45\JJR\1740 than_46\IN\1740 0.01_47\CD\1740 )_48\-RRB-\1740 ,_49\,\1740 or_50\CC\3541091 79_51\CD\1740 +/-_52\CC\1740 6_53\CD\13741022 %_54\NN\1740 (_55\-LRB-\1740 p_56\NN\14622893 less_57\JJR\1740 than_58\IN\1740 0.001_59\CD\1740 )_60\-RRB-\1740 ,_61\,\1740 respectively_62\RB\1740 ,_63\,\1740 but_64\CC\1740 no_65\DT\7204911 tachycardia_66\NN\14110674 and_67\CC\1740 no_68\DT\7204911 augmentation_69\NN\7356676 of_70\IN\1740 the_71\DT\1740 norepinephrine_72\NN\14807929 release_73\NN\3748886 rate_74\NN\13815152 (_75\-LRB-\1740 up_76\RB\1740 to_77\TO\1740 0.3_78\CD\1740 microgram/kg/min_79\NN\1740 )_80\-RRB-\1740 were_81\VBD\836236 observed_82\VBN\2163746 ,_83\,\1740 which_84\WDT\1740 is_85\VBZ\836236 in_86\IN\13603305 contrast_87\NN\13854649 to_88\TO\1740 comparable_89\JJ\1740 <e2>hypotension</e2>_90\NN\14057371 induced_91\VBN\1627355 by_92\IN\1740 hydralazine_93\NN\2721160 or_94\CC\3541091 <e1>nitroglycerin</e1>_95\NN\15015501 ._96\.\1740
19657887
D000431_D005483 CID in_0\IN\13603305 less_1\JJR\1740 than_2\IN\1740 1_3\CD\13741022 hour_4\NN\15154774 after_5\IN\1740 the_6\DT\1740 ingestion_7\NN\13440063 of_8\IN\1740 <e1>alcohol</e1>_9\NN\7881800 ,_10\,\1740 he_11\PRP\14622893 developed_12\VBD\1753788 malaise_13\NN\14446652 with_14\IN\1740 <e2>flushing_15\NN\1740 of_16\IN\1740 the_17\DT\1740 face</e2>_18\NN\5225090 ,_19\,\1740 tachycardia_20\NN\14110674 ,_21\,\1740 and_22\CC\1740 dyspnea_23\VB\1740 ._24\.\1740
D000431_D013610 CID in_0\IN\13603305 less_1\JJR\1740 than_2\IN\1740 1_3\CD\13741022 hour_4\NN\15154774 after_5\IN\1740 the_6\DT\1740 ingestion_7\NN\13440063 of_8\IN\1740 <e1>alcohol</e1>_9\NN\7881800 ,_10\,\1740 he_11\PRP\14622893 developed_12\VBD\1753788 malaise_13\NN\14446652 with_14\IN\1740 flushing_15\NN\1740 of_16\IN\1740 the_17\DT\1740 face_18\NN\5225090 ,_19\,\1740 <e2>tachycardia</e2>_20\NN\14110674 ,_21\,\1740 and_22\CC\1740 dyspnea_23\VB\1740 ._24\.\1740
D000431_D004417 CID in_0\IN\13603305 less_1\JJR\1740 than_2\IN\1740 1_3\CD\13741022 hour_4\NN\15154774 after_5\IN\1740 the_6\DT\1740 ingestion_7\NN\13440063 of_8\IN\1740 <e1>alcohol</e1>_9\NN\7881800 ,_10\,\1740 he_11\PRP\14622893 developed_12\VBD\1753788 malaise_13\NN\14446652 with_14\IN\1740 flushing_15\NN\1740 of_16\IN\1740 the_17\DT\1740 face_18\NN\5225090 ,_19\,\1740 tachycardia_20\NN\14110674 ,_21\,\1740 and_22\CC\1740 <e2>dyspnea</e2>_23\VB\1740 ._24\.\1740
D004221_D005483 NONE five_0\CD\13741022 hours_1\NNS\15118228 after_2\IN\1740 exposure_3\NN\5042871 ,_4\,\1740 he_5\PRP\14622893 developed_6\VBD\1753788 <e1>disulfiram-like</e1>_7\JJ\1740 syndrome_8\NN\5870365 with_9\IN\1740 <e2>flushing</e2>_10\NN\1740 ,_11\,\1740 tachycardia_12\NN\14110674 ,_13\,\1740 and_14\CC\1740 arterial_15\JJ\1740 hypotension_16\NN\14057371 after_17\IN\1740 consuming_18\VBG\1168468 three_19\CD\13741022 glasses_20\NNS\3852280 of_21\IN\1740 wine_22\NN\7884567 ._23\.\1740
D004221_D013610 NONE five_0\CD\13741022 hours_1\NNS\15118228 after_2\IN\1740 exposure_3\NN\5042871 ,_4\,\1740 he_5\PRP\14622893 developed_6\VBD\1753788 <e1>disulfiram-like</e1>_7\JJ\1740 syndrome_8\NN\5870365 with_9\IN\1740 flushing_10\NN\1740 ,_11\,\1740 <e2>tachycardia</e2>_12\NN\14110674 ,_13\,\1740 and_14\CC\1740 arterial_15\JJ\1740 hypotension_16\NN\14057371 after_17\IN\1740 consuming_18\VBG\1168468 three_19\CD\13741022 glasses_20\NNS\3852280 of_21\IN\1740 wine_22\NN\7884567 ._23\.\1740
D004221_D007022 NONE five_0\CD\13741022 hours_1\NNS\15118228 after_2\IN\1740 exposure_3\NN\5042871 ,_4\,\1740 he_5\PRP\14622893 developed_6\VBD\1753788 <e1>disulfiram-like</e1>_7\JJ\1740 syndrome_8\NN\5870365 with_9\IN\1740 flushing_10\NN\1740 ,_11\,\1740 tachycardia_12\NN\14110674 ,_13\,\1740 and_14\CC\1740 <e2>arterial_15\JJ\1740 hypotension</e2>_16\NN\14057371 after_17\IN\1740 consuming_18\VBG\1168468 three_19\CD\13741022 glasses_20\NNS\3852280 of_21\IN\1740 wine_22\NN\7884567 ._23\.\1740
2071257
D005997_D000647 NONE effect_0\NN\34213 of_1\IN\1740 <e1>l-alpha-glyceryl-phosphorylcholine</e1>_2\NN\1740 on_3\IN\1740 <e2>amnesia</e2>_4\NN\5669934 caused_5\VBN\1617192 by_6\IN\1740 scopolamine_7\NN\14712692 ._8\.\1740
D012601_D000647 NONE effect_0\NN\34213 of_1\IN\1740 l-alpha-glyceryl-phosphorylcholine_2\NN\1740 on_3\IN\1740 <e2>amnesia</e2>_4\NN\5669934 caused_5\VBN\1617192 by_6\IN\1740 <e1>scopolamine</e1>_7\NN\14712692 ._8\.\1740
D005997_D008569 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 carried_4\VBN\1850315 out_5\RP\1740 to_6\TO\1740 test_7\VB\670261 the_8\DT\1740 effects_9\NNS\13245626 of_10\IN\1740 <e1>l-alpha-glycerylphosphorylcholine</e1>_11\NN\1740 (_12\-LRB-\1740 l-alpha-gfc_13\NN\1740 )_14\-RRB-\1740 on_15\IN\1740 <e2>memory_16\NN\5926676 impairment</e2>_17\NN\7296428 induced_18\VBN\1627355 by_19\IN\1740 scopolamine_20\NN\14712692 in_21\IN\13603305 man_22\NN\9605289 ._23\.\1740
D005997_D008569 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 carried_4\VBN\1850315 out_5\RP\1740 to_6\TO\1740 test_7\VB\670261 the_8\DT\1740 effects_9\NNS\13245626 of_10\IN\1740 l-alpha-glycerylphosphorylcholine_11\NN\1740 (_12\-LRB-\1740 <e1>l-alpha-gfc</e1>_13\NN\1740 )_14\-RRB-\1740 on_15\IN\1740 <e2>memory_16\NN\5926676 impairment</e2>_17\NN\7296428 induced_18\VBN\1627355 by_19\IN\1740 scopolamine_20\NN\14712692 in_21\IN\13603305 man_22\NN\9605289 ._23\.\1740
D012601_D008569 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 carried_4\VBN\1850315 out_5\RP\1740 to_6\TO\1740 test_7\VB\670261 the_8\DT\1740 effects_9\NNS\13245626 of_10\IN\1740 l-alpha-glycerylphosphorylcholine_11\NN\1740 (_12\-LRB-\1740 l-alpha-gfc_13\NN\1740 )_14\-RRB-\1740 on_15\IN\1740 <e2>memory_16\NN\5926676 impairment</e2>_17\NN\7296428 induced_18\VBN\1627355 by_19\IN\1740 <e1>scopolamine</e1>_20\NN\14712692 in_21\IN\13603305 man_22\NN\9605289 ._23\.\1740
D012601_D008569 CID the_0\DT\1740 findings_1\NNS\7951464 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 indicate_5\VBP\952524 that_6\IN\1740 the_7\DT\1740 drug_8\NN\14778436 is_9\VBZ\836236 able_10\JJ\1740 to_11\TO\1740 antagonize_12\VB\1787955 <e2>impairment_13\NN\7296428 of_14\IN\1740 attention_15\NN\5701944 and_16\CC\1740 memory</e2>_17\NN\5926676 induced_18\VBN\1627355 by_19\IN\1740 <e1>scopolamine</e1>_20\NN\14712692 ._21\.\1740
2375138
D008874_D006323 CID possible_0\JJ\1740 intramuscular_1\JJ\1740 <e1>midazolam-associated</e1>_2\JJ\1740 <e2>cardiorespiratory_3\JJ\1740 arrest</e2>_4\NN\88481 and_5\CC\1740 death_6\NN\7296428 ._7\.\1740
D008874_D006323 CID this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 the_3\DT\1740 first_4\JJ\1740 published_5\VBN\1621555 case_6\NN\7283608 of_7\IN\1740 <e2>cardiorespiratory_8\JJ\1740 arrest</e2>_9\NN\88481 and_10\CC\1740 death_11\NN\7296428 associated_12\VBN\628491 with_13\IN\1740 intramuscular_14\JJ\1740 administration_15\NN\1133281 of_16\IN\1740 <e1>midazolam</e1>_17\NN\2830852 ._18\.\1740
D008874_D003643 NONE possible_0\JJ\1740 intramuscular_1\JJ\1740 <e1>midazolam-associated</e1>_2\JJ\1740 cardiorespiratory_3\JJ\1740 arrest_4\NN\88481 and_5\CC\1740 <e2>death</e2>_6\NN\7296428 ._7\.\1740
D008874_D003643 NONE this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 the_3\DT\1740 first_4\JJ\1740 published_5\VBN\1621555 case_6\NN\7283608 of_7\IN\1740 cardiorespiratory_8\JJ\1740 arrest_9\NN\88481 and_10\CC\1740 <e2>death</e2>_11\NN\7296428 associated_12\VBN\628491 with_13\IN\1740 intramuscular_14\JJ\1740 administration_15\NN\1133281 of_16\IN\1740 <e1>midazolam</e1>_17\NN\2830852 ._18\.\1740
1436384
D000661_D020258 CID protection_0\NN\407535 against_1\IN\1740 <e1>amphetamine-induced</e1>_2\JJ\1740 <e2>neurotoxicity</e2>_3\NN\1740 toward_4\IN\1740 striatal_5\JJ\1740 dopamine_6\NN\14807737 neurons_7\NNS\5430628 in_8\IN\13603305 rodents_9\NNS\1886756 by_10\IN\1740 ly274614_11\NN\1740 ,_12\,\1740 an_13\DT\6697703 excitatory_14\JJ\1740 amino_15\NN\14621446 acid_16\NN\14818238 antagonist_17\NN\7846 ._18\.\1740
D000661_D020258 CID the_0\DT\1740 data_1\NNS\7951464 strengthen_2\VBP\126264 the_3\DT\1740 evidence_4\NN\5816287 that_5\IN\1740 the_6\DT\1740 <e2>neurotoxic</e2>_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 <e1>amphetamine</e1>_10\NN\3248958 and_11\CC\1740 related_12\JJ\1740 compounds_13\NNS\5869584 toward_14\IN\1740 nigrostriatal_15\JJ\1740 dopamine_16\NN\14807737 neurons_17\NNS\5430628 involves_18\VBZ\2676054 nmda_19\NN\1740 receptors_20\NNS\5225602 and_21\CC\1740 that_22\IN\1740 ly274614_23\NN\1740 is_24\VBZ\836236 an_25\DT\6697703 nmda_26\NN\1740 receptor_27\NN\5225602 antagonist_28\NN\7846 with_29\IN\1740 long-lasting_30\JJ\1740 in_31\FW\13603305 vivo_32\FW\1740 effects_33\NNS\13245626 in_34\IN\13603305 rats_35\NNS\2329401 ._36\.\1740
D004298_D020258 NONE protection_0\NN\407535 against_1\IN\1740 amphetamine-induced_2\JJ\1740 <e2>neurotoxicity</e2>_3\NN\1740 toward_4\IN\1740 striatal_5\JJ\1740 <e1>dopamine</e1>_6\NN\14807737 neurons_7\NNS\5430628 in_8\IN\13603305 rodents_9\NNS\1886756 by_10\IN\1740 ly274614_11\NN\1740 ,_12\,\1740 an_13\DT\6697703 excitatory_14\JJ\1740 amino_15\NN\14621446 acid_16\NN\14818238 antagonist_17\NN\7846 ._18\.\1740
D004298_D020258 NONE the_0\DT\1740 data_1\NNS\7951464 strengthen_2\VBP\126264 the_3\DT\1740 evidence_4\NN\5816287 that_5\IN\1740 the_6\DT\1740 <e2>neurotoxic</e2>_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 amphetamine_10\NN\3248958 and_11\CC\1740 related_12\JJ\1740 compounds_13\NNS\5869584 toward_14\IN\1740 nigrostriatal_15\JJ\1740 <e1>dopamine</e1>_16\NN\14807737 neurons_17\NNS\5430628 involves_18\VBZ\2676054 nmda_19\NN\1740 receptors_20\NNS\5225602 and_21\CC\1740 that_22\IN\1740 ly274614_23\NN\1740 is_24\VBZ\836236 an_25\DT\6697703 nmda_26\NN\1740 receptor_27\NN\5225602 antagonist_28\NN\7846 with_29\IN\1740 long-lasting_30\JJ\1740 in_31\FW\13603305 vivo_32\FW\1740 effects_33\NNS\13245626 in_34\IN\13603305 rats_35\NNS\2329401 ._36\.\1740
C070935_D020258 NONE protection_0\NN\407535 against_1\IN\1740 amphetamine-induced_2\JJ\1740 <e2>neurotoxicity</e2>_3\NN\1740 toward_4\IN\1740 striatal_5\JJ\1740 dopamine_6\NN\14807737 neurons_7\NNS\5430628 in_8\IN\13603305 rodents_9\NNS\1886756 by_10\IN\1740 <e1>ly274614</e1>_11\NN\1740 ,_12\,\1740 an_13\DT\6697703 excitatory_14\JJ\1740 amino_15\NN\14621446 acid_16\NN\14818238 antagonist_17\NN\7846 ._18\.\1740
C070935_D020258 NONE the_0\DT\1740 data_1\NNS\7951464 strengthen_2\VBP\126264 the_3\DT\1740 evidence_4\NN\5816287 that_5\IN\1740 the_6\DT\1740 <e2>neurotoxic</e2>_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 amphetamine_10\NN\3248958 and_11\CC\1740 related_12\JJ\1740 compounds_13\NNS\5869584 toward_14\IN\1740 nigrostriatal_15\JJ\1740 dopamine_16\NN\14807737 neurons_17\NNS\5430628 involves_18\VBZ\2676054 nmda_19\NN\1740 receptors_20\NNS\5225602 and_21\CC\1740 that_22\IN\1740 <e1>ly274614</e1>_23\NN\1740 is_24\VBZ\836236 an_25\DT\6697703 nmda_26\NN\1740 receptor_27\NN\5225602 antagonist_28\NN\7846 with_29\IN\1740 long-lasting_30\JJ\1740 in_31\FW\13603305 vivo_32\FW\1740 effects_33\NNS\13245626 in_34\IN\13603305 rats_35\NNS\2329401 ._36\.\1740
D000596_D020258 NONE protection_0\NN\407535 against_1\IN\1740 amphetamine-induced_2\JJ\1740 <e2>neurotoxicity</e2>_3\NN\1740 toward_4\IN\1740 striatal_5\JJ\1740 dopamine_6\NN\14807737 neurons_7\NNS\5430628 in_8\IN\13603305 rodents_9\NNS\1886756 by_10\IN\1740 ly274614_11\NN\1740 ,_12\,\1740 an_13\DT\6697703 excitatory_14\JJ\1740 <e1>amino_15\NN\14621446 acid</e1>_16\NN\14818238 antagonist_17\NN\7846 ._18\.\1740
D016202_D020258 NONE the_0\DT\1740 data_1\NNS\7951464 strengthen_2\VBP\126264 the_3\DT\1740 evidence_4\NN\5816287 that_5\IN\1740 the_6\DT\1740 <e2>neurotoxic</e2>_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 amphetamine_10\NN\3248958 and_11\CC\1740 related_12\JJ\1740 compounds_13\NNS\5869584 toward_14\IN\1740 nigrostriatal_15\JJ\1740 dopamine_16\NN\14807737 neurons_17\NNS\5430628 involves_18\VBZ\2676054 <e1>nmda</e1>_19\NN\1740 receptors_20\NNS\5225602 and_21\CC\1740 that_22\IN\1740 ly274614_23\NN\1740 is_24\VBZ\836236 an_25\DT\6697703 nmda_26\NN\1740 receptor_27\NN\5225602 antagonist_28\NN\7846 with_29\IN\1740 long-lasting_30\JJ\1740 in_31\FW\13603305 vivo_32\FW\1740 effects_33\NNS\13245626 in_34\IN\13603305 rats_35\NNS\2329401 ._36\.\1740
D016202_D020258 NONE the_0\DT\1740 data_1\NNS\7951464 strengthen_2\VBP\126264 the_3\DT\1740 evidence_4\NN\5816287 that_5\IN\1740 the_6\DT\1740 <e2>neurotoxic</e2>_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 amphetamine_10\NN\3248958 and_11\CC\1740 related_12\JJ\1740 compounds_13\NNS\5869584 toward_14\IN\1740 nigrostriatal_15\JJ\1740 dopamine_16\NN\14807737 neurons_17\NNS\5430628 involves_18\VBZ\2676054 nmda_19\NN\1740 receptors_20\NNS\5225602 and_21\CC\1740 that_22\IN\1740 ly274614_23\NN\1740 is_24\VBZ\836236 an_25\DT\6697703 <e1>nmda</e1>_26\NN\1740 receptor_27\NN\5225602 antagonist_28\NN\7846 with_29\IN\1740 long-lasting_30\JJ\1740 in_31\FW\13603305 vivo_32\FW\1740 effects_33\NNS\13245626 in_34\IN\13603305 rats_35\NNS\2329401 ._36\.\1740
12443032
D003042_D002637 CID <e1>cocaine</e1>_0\NN\3492717 related_1\JJ\1740 <e2>chest_2\JJS\1740 pain</e2>_3\NN\14299637 :_4\:\1740 are_5\VBP\836236 we_6\PRP\1740 seeing_7\VBG\2106506 the_8\DT\1740 tip_9\NN\8566028 of_10\IN\1740 an_11\DT\6697703 iceberg_12\NN\9281777 ?_13\.\1740
D003042_D002637 CID in_0\IN\13603305 particular_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 tendency_4\NN\6193203 of_5\IN\1740 <e1>cocaine</e1>_6\NN\3492717 to_7\TO\1740 produce_8\VB\1617192 <e2>chest_9\JJ\1740 pain</e2>_10\NN\14299637 ought_11\MD\1740 to_12\TO\1740 be_13\VB\836236 in_14\IN\13603305 the_15\DT\1740 mind_16\NN\23271 of_17\IN\1740 the_18\DT\1740 emergency_19\NN\7417644 nurse_20\NN\10165109 when_21\WRB\1740 faced_22\VBN\2439281 with_23\IN\1740 a_24\DT\13649268 young_25\JJ\1740 victim_26\NN\9630641 of_27\IN\1740 chest_28\JJ\1740 pain_29\NN\14299637 who_30\WP\8299493 is_31\VBZ\836236 otherwise_32\RB\1740 at_33\IN\14622893 low_34\JJ\1740 risk_35\NN\14541044 ._36\.\1740
D003042_D002637 CID in_0\IN\13603305 particular_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 tendency_4\NN\6193203 of_5\IN\1740 <e1>cocaine</e1>_6\NN\3492717 to_7\TO\1740 produce_8\VB\1617192 chest_9\JJ\1740 pain_10\NN\14299637 ought_11\MD\1740 to_12\TO\1740 be_13\VB\836236 in_14\IN\13603305 the_15\DT\1740 mind_16\NN\23271 of_17\IN\1740 the_18\DT\1740 emergency_19\NN\7417644 nurse_20\NN\10165109 when_21\WRB\1740 faced_22\VBN\2439281 with_23\IN\1740 a_24\DT\13649268 young_25\JJ\1740 victim_26\NN\9630641 of_27\IN\1740 <e2>chest_28\JJ\1740 pain</e2>_29\NN\14299637 who_30\WP\8299493 is_31\VBZ\836236 otherwise_32\RB\1740 at_33\IN\14622893 low_34\JJ\1740 risk_35\NN\14541044 ._36\.\1740
D003042_D002637 CID the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 <e2>chest_3\JJ\1740 pain</e2>_4\NN\14299637 related_5\JJ\1740 to_6\TO\1740 <e1>cocaine</e1>_7\NN\3492717 use_8\NN\407535 is_9\VBZ\836236 discussed_10\VBN\1033527 and_11\CC\1740 treatment_12\NN\654885 dilemmas_13\NNS\5685363 are_14\VBP\836236 discussed_15\VBN\1033527 ._16\.\1740
11135224
D017239_D002289 NONE <e1>paclitaxel</e1>_0\NNP\1740 ,_1\,\1740 cisplatin_2\NN\1740 ,_3\,\1740 and_4\CC\1740 gemcitabine_5\NN\1740 combination_6\NN\7951464 chemotherapy_7\NN\661091 within_8\IN\1740 a_9\DT\13649268 multidisciplinary_10\JJ\1740 therapeutic_11\JJ\1740 approach_12\NN\940842 in_13\IN\13603305 metastatic_14\JJ\1740 <e2>nonsmall_15\NN\1740 cell_16\NN\3080309 lung_17\NN\5528060 carcinoma</e2>_18\NN\14239918 ._19\.\1740
D017239_D002289 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 objective_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 the_10\DT\1740 feasibility_11\NN\5152150 ,_12\,\1740 response_13\NN\11410625 rate_14\NN\13815152 ,_15\,\1740 and_16\CC\1740 toxicity_17\NN\13576101 of_18\IN\1740 a_19\DT\13649268 <e1>paclitaxel</e1>_20\NN\1740 ,_21\,\1740 cisplatin_22\NN\1740 ,_23\,\1740 and_24\CC\1740 gemcitabine_25\NN\1740 combination_26\NN\7951464 to_27\TO\1740 treat_28\VB\2376958 metastatic_29\JJ\1740 <e2>nsclc</e2>_30\NN\1740 ._31\.\1740
D017239_D002289 NONE thirty-five_0\JJ\1740 consecutive_1\JJ\1740 chemotherapy-naive_2\JJ\1740 patients_3\NNS\9898892 with_4\IN\1740 stage_5\NN\15113229 iv_6\CD\13741022 <e2>nsclc</e2>_7\NN\1740 and_8\CC\1740 an_9\DT\6697703 eastern_10\JJ\1740 cooperative_11\NNP\8065093 oncology_12\NNP\6043075 group_13\NNP\2137 performance_14\NN\6619065 status_15\NN\24720 of_16\IN\1740 0_17\CD\13741022 -_18\SYM\1740 2_19\CD\13741022 were_20\VBD\836236 treated_21\VBN\2376958 with_22\IN\1740 a_23\DT\13649268 combination_24\NN\7951464 of_25\IN\1740 <e1>paclitaxel</e1>_26\NN\1740 (_27\-LRB-\1740 135_28\CD\1740 mg/m(2_29\NN\1740 )_30\-RRB-\1740 given_31\VBN\2327200 intravenously_32\RB\1740 in_33\IN\13603305 3_34\CD\13741022 hours_35\NNS\15118228 )_36\-RRB-\1740 on_37\IN\1740 day_38\NN\15154774 1_39\CD\13741022 ,_40\,\1740 cisplatin_41\NN\1740 (_42\-LRB-\1740 120_43\CD\13745420 mg/m(2_44\NN\1740 )_45\-RRB-\1740 given_46\VBN\2327200 intravenously_47\RB\1740 in_48\IN\13603305 6_49\CD\13741022 hours_50\NNS\15118228 )_51\-RRB-\1740 on_52\IN\1740 day_53\NN\15154774 1_54\CD\13741022 ,_55\,\1740 and_56\CC\1740 gemcitabine_57\NN\1740 (_58\-LRB-\1740 800_59\CD\1740 mg/m(2_60\NN\1740 )_61\-RRB-\1740 given_62\VBN\2327200 intravenously_63\RB\1740 in_64\IN\13603305 30_65\CD\13745420 minutes_66\NNS\6502378 )_67\-RRB-\1740 on_68\IN\1740 days_69\NNS\15140892 1_70\CD\13741022 and_71\CC\1740 8_72\CD\13741022 ,_73\,\1740 every_74\DT\1740 4_75\CD\13741022 weeks_76\NNS\15113229 ._77\.\1740
D017239_D002289 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 <e1>paclitaxel</e1>_5\NN\1740 ,_6\,\1740 cisplatin_7\NN\1740 ,_8\,\1740 and_9\CC\1740 gemcitabine_10\NN\1740 is_11\VBZ\836236 well_12\RB\1740 tolerated_13\VBN\802318 and_14\CC\1740 shows_15\VBZ\2137132 high_16\JJ\1740 activity_17\NN\30358 in_18\IN\13603305 metastatic_19\JJ\1740 <e2>nsclc</e2>_20\NN\1740 ._21\.\1740
D002945_D002289 NONE paclitaxel_0\NNP\1740 ,_1\,\1740 <e1>cisplatin</e1>_2\NN\1740 ,_3\,\1740 and_4\CC\1740 gemcitabine_5\NN\1740 combination_6\NN\7951464 chemotherapy_7\NN\661091 within_8\IN\1740 a_9\DT\13649268 multidisciplinary_10\JJ\1740 therapeutic_11\JJ\1740 approach_12\NN\940842 in_13\IN\13603305 metastatic_14\JJ\1740 <e2>nonsmall_15\NN\1740 cell_16\NN\3080309 lung_17\NN\5528060 carcinoma</e2>_18\NN\14239918 ._19\.\1740
D002945_D002289 NONE background_0\NN\4921011 :_1\:\1740 <e1>cisplatin-based</e1>_2\JJ\1740 chemotherapy_3\NN\661091 combinations_4\NNS\7951464 improve_5\VBP\126264 quality_6\NN\24264 of_7\IN\1740 life_8\NN\13954253 and_9\CC\1740 survival_10\NN\13961642 in_11\IN\13603305 advanced_12\JJ\1740 <e2>nonsmall_13\NN\1740 cell_14\NN\3080309 lung_15\NN\5528060 carcinoma</e2>_16\NN\14239918 (_17\-LRB-\1740 nsclc_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D002945_D002289 NONE background_0\NN\4921011 :_1\:\1740 <e1>cisplatin-based</e1>_2\JJ\1740 chemotherapy_3\NN\661091 combinations_4\NNS\7951464 improve_5\VBP\126264 quality_6\NN\24264 of_7\IN\1740 life_8\NN\13954253 and_9\CC\1740 survival_10\NN\13961642 in_11\IN\13603305 advanced_12\JJ\1740 nonsmall_13\NN\1740 cell_14\NN\3080309 lung_15\NN\5528060 carcinoma_16\NN\14239918 (_17\-LRB-\1740 <e2>nsclc</e2>_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D002945_D002289 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 objective_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 the_10\DT\1740 feasibility_11\NN\5152150 ,_12\,\1740 response_13\NN\11410625 rate_14\NN\13815152 ,_15\,\1740 and_16\CC\1740 toxicity_17\NN\13576101 of_18\IN\1740 a_19\DT\13649268 paclitaxel_20\NN\1740 ,_21\,\1740 <e1>cisplatin</e1>_22\NN\1740 ,_23\,\1740 and_24\CC\1740 gemcitabine_25\NN\1740 combination_26\NN\7951464 to_27\TO\1740 treat_28\VB\2376958 metastatic_29\JJ\1740 <e2>nsclc</e2>_30\NN\1740 ._31\.\1740
D002945_D002289 NONE thirty-five_0\JJ\1740 consecutive_1\JJ\1740 chemotherapy-naive_2\JJ\1740 patients_3\NNS\9898892 with_4\IN\1740 stage_5\NN\15113229 iv_6\CD\13741022 <e2>nsclc</e2>_7\NN\1740 and_8\CC\1740 an_9\DT\6697703 eastern_10\JJ\1740 cooperative_11\NNP\8065093 oncology_12\NNP\6043075 group_13\NNP\2137 performance_14\NN\6619065 status_15\NN\24720 of_16\IN\1740 0_17\CD\13741022 -_18\SYM\1740 2_19\CD\13741022 were_20\VBD\836236 treated_21\VBN\2376958 with_22\IN\1740 a_23\DT\13649268 combination_24\NN\7951464 of_25\IN\1740 paclitaxel_26\NN\1740 (_27\-LRB-\1740 135_28\CD\1740 mg/m(2_29\NN\1740 )_30\-RRB-\1740 given_31\VBN\2327200 intravenously_32\RB\1740 in_33\IN\13603305 3_34\CD\13741022 hours_35\NNS\15118228 )_36\-RRB-\1740 on_37\IN\1740 day_38\NN\15154774 1_39\CD\13741022 ,_40\,\1740 <e1>cisplatin</e1>_41\NN\1740 (_42\-LRB-\1740 120_43\CD\13745420 mg/m(2_44\NN\1740 )_45\-RRB-\1740 given_46\VBN\2327200 intravenously_47\RB\1740 in_48\IN\13603305 6_49\CD\13741022 hours_50\NNS\15118228 )_51\-RRB-\1740 on_52\IN\1740 day_53\NN\15154774 1_54\CD\13741022 ,_55\,\1740 and_56\CC\1740 gemcitabine_57\NN\1740 (_58\-LRB-\1740 800_59\CD\1740 mg/m(2_60\NN\1740 )_61\-RRB-\1740 given_62\VBN\2327200 intravenously_63\RB\1740 in_64\IN\13603305 30_65\CD\13745420 minutes_66\NNS\6502378 )_67\-RRB-\1740 on_68\IN\1740 days_69\NNS\15140892 1_70\CD\13741022 and_71\CC\1740 8_72\CD\13741022 ,_73\,\1740 every_74\DT\1740 4_75\CD\13741022 weeks_76\NNS\15113229 ._77\.\1740
D002945_D002289 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 paclitaxel_5\NN\1740 ,_6\,\1740 <e1>cisplatin</e1>_7\NN\1740 ,_8\,\1740 and_9\CC\1740 gemcitabine_10\NN\1740 is_11\VBZ\836236 well_12\RB\1740 tolerated_13\VBN\802318 and_14\CC\1740 shows_15\VBZ\2137132 high_16\JJ\1740 activity_17\NN\30358 in_18\IN\13603305 metastatic_19\JJ\1740 <e2>nsclc</e2>_20\NN\1740 ._21\.\1740
C056507_D002289 NONE paclitaxel_0\NNP\1740 ,_1\,\1740 cisplatin_2\NN\1740 ,_3\,\1740 and_4\CC\1740 <e1>gemcitabine</e1>_5\NN\1740 combination_6\NN\7951464 chemotherapy_7\NN\661091 within_8\IN\1740 a_9\DT\13649268 multidisciplinary_10\JJ\1740 therapeutic_11\JJ\1740 approach_12\NN\940842 in_13\IN\13603305 metastatic_14\JJ\1740 <e2>nonsmall_15\NN\1740 cell_16\NN\3080309 lung_17\NN\5528060 carcinoma</e2>_18\NN\14239918 ._19\.\1740
C056507_D002289 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 objective_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 the_10\DT\1740 feasibility_11\NN\5152150 ,_12\,\1740 response_13\NN\11410625 rate_14\NN\13815152 ,_15\,\1740 and_16\CC\1740 toxicity_17\NN\13576101 of_18\IN\1740 a_19\DT\13649268 paclitaxel_20\NN\1740 ,_21\,\1740 cisplatin_22\NN\1740 ,_23\,\1740 and_24\CC\1740 <e1>gemcitabine</e1>_25\NN\1740 combination_26\NN\7951464 to_27\TO\1740 treat_28\VB\2376958 metastatic_29\JJ\1740 <e2>nsclc</e2>_30\NN\1740 ._31\.\1740
C056507_D002289 NONE thirty-five_0\JJ\1740 consecutive_1\JJ\1740 chemotherapy-naive_2\JJ\1740 patients_3\NNS\9898892 with_4\IN\1740 stage_5\NN\15113229 iv_6\CD\13741022 <e2>nsclc</e2>_7\NN\1740 and_8\CC\1740 an_9\DT\6697703 eastern_10\JJ\1740 cooperative_11\NNP\8065093 oncology_12\NNP\6043075 group_13\NNP\2137 performance_14\NN\6619065 status_15\NN\24720 of_16\IN\1740 0_17\CD\13741022 -_18\SYM\1740 2_19\CD\13741022 were_20\VBD\836236 treated_21\VBN\2376958 with_22\IN\1740 a_23\DT\13649268 combination_24\NN\7951464 of_25\IN\1740 paclitaxel_26\NN\1740 (_27\-LRB-\1740 135_28\CD\1740 mg/m(2_29\NN\1740 )_30\-RRB-\1740 given_31\VBN\2327200 intravenously_32\RB\1740 in_33\IN\13603305 3_34\CD\13741022 hours_35\NNS\15118228 )_36\-RRB-\1740 on_37\IN\1740 day_38\NN\15154774 1_39\CD\13741022 ,_40\,\1740 cisplatin_41\NN\1740 (_42\-LRB-\1740 120_43\CD\13745420 mg/m(2_44\NN\1740 )_45\-RRB-\1740 given_46\VBN\2327200 intravenously_47\RB\1740 in_48\IN\13603305 6_49\CD\13741022 hours_50\NNS\15118228 )_51\-RRB-\1740 on_52\IN\1740 day_53\NN\15154774 1_54\CD\13741022 ,_55\,\1740 and_56\CC\1740 <e1>gemcitabine</e1>_57\NN\1740 (_58\-LRB-\1740 800_59\CD\1740 mg/m(2_60\NN\1740 )_61\-RRB-\1740 given_62\VBN\2327200 intravenously_63\RB\1740 in_64\IN\13603305 30_65\CD\13745420 minutes_66\NNS\6502378 )_67\-RRB-\1740 on_68\IN\1740 days_69\NNS\15140892 1_70\CD\13741022 and_71\CC\1740 8_72\CD\13741022 ,_73\,\1740 every_74\DT\1740 4_75\CD\13741022 weeks_76\NNS\15113229 ._77\.\1740
C056507_D002289 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 paclitaxel_5\NN\1740 ,_6\,\1740 cisplatin_7\NN\1740 ,_8\,\1740 and_9\CC\1740 <e1>gemcitabine</e1>_10\NN\1740 is_11\VBZ\836236 well_12\RB\1740 tolerated_13\VBN\802318 and_14\CC\1740 shows_15\VBZ\2137132 high_16\JJ\1740 activity_17\NN\30358 in_18\IN\13603305 metastatic_19\JJ\1740 <e2>nsclc</e2>_20\NN\1740 ._21\.\1740
D017239_D064420 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 objective_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 the_10\DT\1740 feasibility_11\NN\5152150 ,_12\,\1740 response_13\NN\11410625 rate_14\NN\13815152 ,_15\,\1740 and_16\CC\1740 <e2>toxicity</e2>_17\NN\13576101 of_18\IN\1740 a_19\DT\13649268 <e1>paclitaxel</e1>_20\NN\1740 ,_21\,\1740 cisplatin_22\NN\1740 ,_23\,\1740 and_24\CC\1740 gemcitabine_25\NN\1740 combination_26\NN\7951464 to_27\TO\1740 treat_28\VB\2376958 metastatic_29\JJ\1740 nsclc_30\NN\1740 ._31\.\1740
D002945_D064420 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 objective_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 the_10\DT\1740 feasibility_11\NN\5152150 ,_12\,\1740 response_13\NN\11410625 rate_14\NN\13815152 ,_15\,\1740 and_16\CC\1740 <e2>toxicity</e2>_17\NN\13576101 of_18\IN\1740 a_19\DT\13649268 paclitaxel_20\NN\1740 ,_21\,\1740 <e1>cisplatin</e1>_22\NN\1740 ,_23\,\1740 and_24\CC\1740 gemcitabine_25\NN\1740 combination_26\NN\7951464 to_27\TO\1740 treat_28\VB\2376958 metastatic_29\JJ\1740 nsclc_30\NN\1740 ._31\.\1740
C056507_D064420 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 objective_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 the_10\DT\1740 feasibility_11\NN\5152150 ,_12\,\1740 response_13\NN\11410625 rate_14\NN\13815152 ,_15\,\1740 and_16\CC\1740 <e2>toxicity</e2>_17\NN\13576101 of_18\IN\1740 a_19\DT\13649268 paclitaxel_20\NN\1740 ,_21\,\1740 cisplatin_22\NN\1740 ,_23\,\1740 and_24\CC\1740 <e1>gemcitabine</e1>_25\NN\1740 combination_26\NN\7951464 to_27\TO\1740 treat_28\VB\2376958 metastatic_29\JJ\1740 nsclc_30\NN\1740 ._31\.\1740
3403780
D000082_D003128 NONE <e1>paracetamol-associated</e1>_0\JJ\1740 <e2>coma</e2>_1\NN\5678932 ,_2\,\1740 metabolic_3\JJ\1740 acidosis_4\NN\14204950 ,_5\,\1740 renal_6\JJ\1740 and_7\CC\1740 hepatic_8\JJ\1740 failure_9\NN\66216 ._10\.\1740
D000082_D000138 CID <e1>paracetamol-associated</e1>_0\JJ\1740 coma_1\NN\5678932 ,_2\,\1740 <e2>metabolic_3\JJ\1740 acidosis</e2>_4\NN\14204950 ,_5\,\1740 renal_6\JJ\1740 and_7\CC\1740 hepatic_8\JJ\1740 failure_9\NN\66216 ._10\.\1740
D000082_D000138 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>metabolic_3\JJ\1740 acidosis</e2>_4\NN\14204950 ,_5\,\1740 acute_6\JJ\1740 renal_7\JJ\1740 failure_8\NN\66216 and_9\CC\1740 hepatic_10\JJ\1740 failure_11\NN\66216 following_12\VBG\1835496 <e1>paracetamol</e1>_13\NN\1740 ingestion_14\NN\13440063 is_15\VBZ\836236 presented_16\VBN\2137132 ._17\.\1740
D000082_D058186 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 metabolic_3\JJ\1740 acidosis_4\NN\14204950 ,_5\,\1740 <e2>acute_6\JJ\1740 renal_7\JJ\1740 failure_8\NN\66216 and_9\CC\1740 hepatic_10\JJ\1740 failure</e2>_11\NN\66216 following_12\VBG\1835496 <e1>paracetamol</e1>_13\NN\1740 ingestion_14\NN\13440063 is_15\VBZ\836236 presented_16\VBN\2137132 ._17\.\1740
D000082_D058186 NONE <e1>paracetamol-associated</e1>_0\JJ\1740 coma_1\NN\5678932 ,_2\,\1740 metabolic_3\JJ\1740 acidosis_4\NN\14204950 ,_5\,\1740 <e2>renal_6\JJ\1740 and_7\CC\1740 hepatic_8\JJ\1740 failure</e2>_9\NN\66216 ._10\.\1740
D000082_D017093 NONE <e1>paracetamol-associated</e1>_0\JJ\1740 coma_1\NN\5678932 ,_2\,\1740 metabolic_3\JJ\1740 acidosis_4\NN\14204950 ,_5\,\1740 <e2>renal_6\JJ\1740 and_7\CC\1740 hepatic_8\JJ\1740 failure</e2>_9\NN\66216 ._10\.\1740
D000082_D017114 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 metabolic_3\JJ\1740 acidosis_4\NN\14204950 ,_5\,\1740 <e2>acute_6\JJ\1740 renal_7\JJ\1740 failure_8\NN\66216 and_9\CC\1740 hepatic_10\JJ\1740 failure</e2>_11\NN\66216 following_12\VBG\1835496 <e1>paracetamol</e1>_13\NN\1740 ingestion_14\NN\13440063 is_15\VBZ\836236 presented_16\VBN\2137132 ._17\.\1740
2632720
D007654_D006973 CID arterial_0\JJ\1740 <e2>hypertension</e2>_1\NN\14057371 as_2\IN\14622893 a_3\DT\13649268 complication_4\NN\1073995 of_5\IN\1740 prolonged_6\JJ\1740 <e1>ketoconazole</e1>_7\NN\1740 treatment_8\NN\654885 ._9\.\1740
D007654_D006973 CID two_0\CD\13741022 of_1\IN\1740 14_2\CD\13745420 patients_3\NNS\9898892 with_4\IN\1740 cushing_5\NN\1740 's_6\POS\1740 syndrome_7\NN\5870365 treated_8\VBN\2376958 on_9\IN\1740 a_10\DT\13649268 long-term_11\JJ\1740 basis_12\NN\13790712 with_13\IN\1740 <e1>ketoconazole</e1>_14\NN\1740 developed_15\VBD\1753788 sustained_16\JJ\1740 <e2>hypertension</e2>_17\NN\14057371 ._18\.\1740
D007654_D006973 CID in_0\IN\13603305 both_1\DT\1740 cases_2\NNS\7283608 normal_3\JJ\1740 plasma_4\NN\5398023 and_5\CC\1740 urinary_6\JJ\1740 free_7\JJ\1740 cortisol_8\NN\14751417 levels_9\NNS\4916342 had_10\VBD\2108377 been_11\VBN\836236 achieved_12\VBN\2524171 following_13\VBG\1835496 <e1>ketoconazole</e1>_14\NN\1740 therapy_15\NN\657604 ,_16\,\1740 yet_17\RB\1740 continuous_18\JJ\1740 blood_19\NN\5397468 pressure_20\NN\11419404 monitoring_21\NN\879759 demonstrated_22\VBD\2137132 <e2>hypertension</e2>_23\NN\14057371 31_24\CD\1740 (_25\-LRB-\1740 patient_26\NN\9898892 1_27\CD\13741022 )_28\-RRB-\1740 and_29\CC\1740 52_30\CD\1740 weeks_31\NNS\15113229 (_32\-LRB-\1740 patient_33\NN\9898892 2_34\CD\13741022 )_35\-RRB-\1740 after_36\IN\1740 treatment_37\NN\654885 ._38\.\1740
D007654_D006973 CID our_0\PRP$\1740 findings_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 long-term_4\JJ\1740 treatment_5\NN\654885 with_6\IN\1740 high_7\JJ\1740 doses_8\NNS\3740161 of_9\IN\1740 <e1>ketoconazole</e1>_10\NN\1740 may_11\MD\15209706 induce_12\VB\1627355 enzyme_13\NN\14723628 blockade_14\NN\952963 leading_15\VBG\1752884 to_16\TO\1740 mineralocorticoid-related_17\JJ\1740 <e2>hypertension</e2>_18\NN\14057371 ._19\.\1740
D007654_D003480 NONE two_0\CD\13741022 of_1\IN\1740 14_2\CD\13745420 patients_3\NNS\9898892 with_4\IN\1740 <e2>cushing_5\NN\1740 's_6\POS\1740 syndrome</e2>_7\NN\5870365 treated_8\VBN\2376958 on_9\IN\1740 a_10\DT\13649268 long-term_11\JJ\1740 basis_12\NN\13790712 with_13\IN\1740 <e1>ketoconazole</e1>_14\NN\1740 developed_15\VBD\1753788 sustained_16\JJ\1740 hypertension_17\NN\14057371 ._18\.\1740
D006854_D006973 NONE in_0\IN\13603305 both_1\DT\1740 cases_2\NNS\7283608 normal_3\JJ\1740 plasma_4\NN\5398023 and_5\CC\1740 urinary_6\JJ\1740 free_7\JJ\1740 <e1>cortisol</e1>_8\NN\14751417 levels_9\NNS\4916342 had_10\VBD\2108377 been_11\VBN\836236 achieved_12\VBN\2524171 following_13\VBG\1835496 ketoconazole_14\NN\1740 therapy_15\NN\657604 ,_16\,\1740 yet_17\RB\1740 continuous_18\JJ\1740 blood_19\NN\5397468 pressure_20\NN\11419404 monitoring_21\NN\879759 demonstrated_22\VBD\2137132 <e2>hypertension</e2>_23\NN\14057371 31_24\CD\1740 (_25\-LRB-\1740 patient_26\NN\9898892 1_27\CD\13741022 )_28\-RRB-\1740 and_29\CC\1740 52_30\CD\1740 weeks_31\NNS\15113229 (_32\-LRB-\1740 patient_33\NN\9898892 2_34\CD\13741022 )_35\-RRB-\1740 after_36\IN\1740 treatment_37\NN\654885 ._38\.\1740
17042910
C065179_D006973 NONE anti-oxidant_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>atorvastatin</e1>_3\NN\3676175 in_4\IN\13603305 dexamethasone-induced_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 in_7\IN\13603305 the_8\DT\1740 rat_9\NN\2329401 ._10\.\1740
C065179_D006973 NONE <e1>atorvastatin</e1>_0\NN\3676175 (_1\-LRB-\1740 ato_2\NN\1740 )_3\-RRB-\1740 possesses_4\VBZ\2630189 pleiotropic_5\JJ\1740 properties_6\NNS\32613 that_7\WDT\1740 have_8\VBP\2108377 been_9\VBN\836236 reported_10\VBN\831651 to_11\TO\1740 improve_12\VB\126264 endothelial_13\JJ\1740 function_14\NN\13783581 through_15\IN\1740 increased_16\VBN\169651 availability_17\NN\4718563 of_18\IN\1740 no_19\NN\7204911 and_20\CC\1740 reduced_21\VBD\441445 o2-_22\NN\1740 production_23\NN\30358 in_24\IN\13603305 various_25\JJ\1740 forms_26\NNS\6286395 of_27\IN\1740 <e2>hypertension</e2>_28\NN\14057371 ._29\.\1740
C065179_D006973 NONE atorvastatin_0\NN\3676175 (_1\-LRB-\1740 <e1>ato</e1>_2\NN\1740 )_3\-RRB-\1740 possesses_4\VBZ\2630189 pleiotropic_5\JJ\1740 properties_6\NNS\32613 that_7\WDT\1740 have_8\VBP\2108377 been_9\VBN\836236 reported_10\VBN\831651 to_11\TO\1740 improve_12\VB\126264 endothelial_13\JJ\1740 function_14\NN\13783581 through_15\IN\1740 increased_16\VBN\169651 availability_17\NN\4718563 of_18\IN\1740 no_19\NN\7204911 and_20\CC\1740 reduced_21\VBD\441445 o2-_22\NN\1740 production_23\NN\30358 in_24\IN\13603305 various_25\JJ\1740 forms_26\NNS\6286395 of_27\IN\1740 <e2>hypertension</e2>_28\NN\14057371 ._29\.\1740
D003907_D006973 CID anti-oxidant_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 atorvastatin_3\NN\3676175 in_4\IN\13603305 <e1>dexamethasone-induced</e1>_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 in_7\IN\13603305 the_8\DT\1740 rat_9\NN\2329401 ._10\.\1740
D003907_D006973 CID 1_0\LS\13741022 ._1\.\1740 <e1>dexamethasone</e1>_2\NN\2721538 (dex)-induced_3\VBD\1740 <e2>hypertension</e2>_4\NN\14057371 is_5\VBZ\836236 characterized_6\VBN\609683 by_7\IN\1740 endothelial_8\JJ\1740 dysfunction_9\NN\14204950 associated_10\VBN\628491 with_11\IN\1740 nitric_12\JJ\1740 oxide_13\NN\14818238 (_14\-LRB-\1740 no_15\NN\7204911 )_16\-RRB-\1740 deficiency_17\NN\14449126 and_18\CC\1740 increased_19\VBN\169651 superoxide_20\NN\14971519 (_21\-LRB-\1740 o2-_22\NN\1740 )_23\-RRB-\1740 production_24\NN\30358 ._25\.\1740
D003907_D006973 CID 1_0\LS\13741022 ._1\.\1740 dexamethasone_2\NN\2721538 <e1>(dex)-induced</e1>_3\VBD\1740 <e2>hypertension</e2>_4\NN\14057371 is_5\VBZ\836236 characterized_6\VBN\609683 by_7\IN\1740 endothelial_8\JJ\1740 dysfunction_9\NN\14204950 associated_10\VBN\628491 with_11\IN\1740 nitric_12\JJ\1740 oxide_13\NN\14818238 (_14\-LRB-\1740 no_15\NN\7204911 )_16\-RRB-\1740 deficiency_17\NN\14449126 and_18\CC\1740 increased_19\VBN\169651 superoxide_20\NN\14971519 (_21\-LRB-\1740 o2-_22\NN\1740 )_23\-RRB-\1740 production_24\NN\30358 ._25\.\1740
D009569_D006973 NONE 1_0\LS\13741022 ._1\.\1740 dexamethasone_2\NN\2721538 (dex)-induced_3\VBD\1740 <e2>hypertension</e2>_4\NN\14057371 is_5\VBZ\836236 characterized_6\VBN\609683 by_7\IN\1740 endothelial_8\JJ\1740 dysfunction_9\NN\14204950 associated_10\VBN\628491 with_11\IN\1740 <e1>nitric_12\JJ\1740 oxide</e1>_13\NN\14818238 (_14\-LRB-\1740 no_15\NN\7204911 )_16\-RRB-\1740 deficiency_17\NN\14449126 and_18\CC\1740 increased_19\VBN\169651 superoxide_20\NN\14971519 (_21\-LRB-\1740 o2-_22\NN\1740 )_23\-RRB-\1740 production_24\NN\30358 ._25\.\1740
D009569_D006973 NONE 1_0\LS\13741022 ._1\.\1740 dexamethasone_2\NN\2721538 (dex)-induced_3\VBD\1740 <e2>hypertension</e2>_4\NN\14057371 is_5\VBZ\836236 characterized_6\VBN\609683 by_7\IN\1740 endothelial_8\JJ\1740 dysfunction_9\NN\14204950 associated_10\VBN\628491 with_11\IN\1740 nitric_12\JJ\1740 oxide_13\NN\14818238 (_14\-LRB-\1740 <e1>no</e1>_15\NN\7204911 )_16\-RRB-\1740 deficiency_17\NN\14449126 and_18\CC\1740 increased_19\VBN\169651 superoxide_20\NN\14971519 (_21\-LRB-\1740 o2-_22\NN\1740 )_23\-RRB-\1740 production_24\NN\30358 ._25\.\1740
D009569_D006973 NONE atorvastatin_0\NN\3676175 (_1\-LRB-\1740 ato_2\NN\1740 )_3\-RRB-\1740 possesses_4\VBZ\2630189 pleiotropic_5\JJ\1740 properties_6\NNS\32613 that_7\WDT\1740 have_8\VBP\2108377 been_9\VBN\836236 reported_10\VBN\831651 to_11\TO\1740 improve_12\VB\126264 endothelial_13\JJ\1740 function_14\NN\13783581 through_15\IN\1740 increased_16\VBN\169651 availability_17\NN\4718563 of_18\IN\1740 <e1>no</e1>_19\NN\7204911 and_20\CC\1740 reduced_21\VBD\441445 o2-_22\NN\1740 production_23\NN\30358 in_24\IN\13603305 various_25\JJ\1740 forms_26\NNS\6286395 of_27\IN\1740 <e2>hypertension</e2>_28\NN\14057371 ._29\.\1740
D013481_D006973 NONE 1_0\LS\13741022 ._1\.\1740 dexamethasone_2\NN\2721538 (dex)-induced_3\VBD\1740 <e2>hypertension</e2>_4\NN\14057371 is_5\VBZ\836236 characterized_6\VBN\609683 by_7\IN\1740 endothelial_8\JJ\1740 dysfunction_9\NN\14204950 associated_10\VBN\628491 with_11\IN\1740 nitric_12\JJ\1740 oxide_13\NN\14818238 (_14\-LRB-\1740 no_15\NN\7204911 )_16\-RRB-\1740 deficiency_17\NN\14449126 and_18\CC\1740 increased_19\VBN\169651 <e1>superoxide</e1>_20\NN\14971519 (_21\-LRB-\1740 o2-_22\NN\1740 )_23\-RRB-\1740 production_24\NN\30358 ._25\.\1740
D013481_D006973 NONE 1_0\LS\13741022 ._1\.\1740 dexamethasone_2\NN\2721538 (dex)-induced_3\VBD\1740 <e2>hypertension</e2>_4\NN\14057371 is_5\VBZ\836236 characterized_6\VBN\609683 by_7\IN\1740 endothelial_8\JJ\1740 dysfunction_9\NN\14204950 associated_10\VBN\628491 with_11\IN\1740 nitric_12\JJ\1740 oxide_13\NN\14818238 (_14\-LRB-\1740 no_15\NN\7204911 )_16\-RRB-\1740 deficiency_17\NN\14449126 and_18\CC\1740 increased_19\VBN\169651 superoxide_20\NN\14971519 (_21\-LRB-\1740 <e1>o2-</e1>_22\NN\1740 )_23\-RRB-\1740 production_24\NN\30358 ._25\.\1740
D013481_D006973 NONE atorvastatin_0\NN\3676175 (_1\-LRB-\1740 ato_2\NN\1740 )_3\-RRB-\1740 possesses_4\VBZ\2630189 pleiotropic_5\JJ\1740 properties_6\NNS\32613 that_7\WDT\1740 have_8\VBP\2108377 been_9\VBN\836236 reported_10\VBN\831651 to_11\TO\1740 improve_12\VB\126264 endothelial_13\JJ\1740 function_14\NN\13783581 through_15\IN\1740 increased_16\VBN\169651 availability_17\NN\4718563 of_18\IN\1740 no_19\NN\7204911 and_20\CC\1740 reduced_21\VBD\441445 <e1>o2-</e1>_22\NN\1740 production_23\NN\30358 in_24\IN\13603305 various_25\JJ\1740 forms_26\NNS\6286395 of_27\IN\1740 <e2>hypertension</e2>_28\NN\14057371 ._29\.\1740
3780846
D009020_D009127 CID on_0\IN\1740 the_1\DT\1740 mechanisms_2\NNS\13446390 of_3\IN\1740 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 tolerance_7\NN\5032565 to_8\TO\1740 the_9\DT\1740 <e2>muscular_10\JJ\1740 rigidity</e2>_11\NN\5023233 produced_12\VBN\1617192 by_13\IN\1740 <e1>morphine</e1>_14\NN\2707683 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
D009020_D009127 CID the_0\DT\1740 development_1\NN\248977 of_2\IN\1740 tolerance_3\NN\5032565 to_4\TO\1740 the_5\DT\1740 <e2>muscular_6\JJ\1740 rigidity</e2>_7\NN\5023233 produced_8\VBN\1617192 by_9\IN\1740 <e1>morphine</e1>_10\NN\2707683 was_11\VBD\836236 studied_12\VBN\630380 in_13\IN\13603305 rats_14\NNS\2329401 ._15\.\1740
D009020_D009127 CID saline-pretreated_0\JJ\1740 controls_1\NNS\5190804 given_2\VBN\2327200 a_3\DT\13649268 test_4\NN\5798043 dose_5\NN\3740161 of_6\IN\1740 <e1>morphine</e1>_7\NN\2707683 (_8\-LRB-\1740 20_9\CD\13745420 mg/kg_10\NN\1740 i.p._11\RB\1740 )_12\-RRB-\1740 showed_13\VBD\2137132 a_14\DT\13649268 pronounced_15\JJ\1740 <e2>rigidity</e2>_16\NN\5023233 recorded_17\VBN\2225492 as_18\IN\14622893 tonic_19\JJ\1740 activity_20\NN\30358 in_21\IN\13603305 the_22\DT\1740 electromyogram_23\NN\7005158 ._24\.\1740
D009020_D009127 CID rats_0\NNS\2329401 treated_1\VBN\2376958 for_2\IN\1740 11_3\CD\13745420 days_4\NNS\15140892 with_5\IN\1740 <e1>morphine</e1>_6\NN\2707683 and_7\CC\1740 withdrawn_8\VBN\1835496 for_9\IN\1740 36_10\CD\1740 -_11\SYM\1740 40_12\CD\13745420 h_13\NN\14622893 showed_14\VBD\2137132 differences_15\NNS\4723816 in_16\IN\13603305 the_17\DT\1740 development_18\NN\248977 of_19\IN\1740 tolerance_20\NN\5032565 :_21\:\1740 about_22\RB\1740 half_23\NN\13732295 of_24\IN\1740 the_25\DT\1740 animals_26\NNS\4475 showed_27\VBD\2137132 a_28\DT\13649268 <e2>rigidity</e2>_29\NN\5023233 after_30\IN\1740 the_31\DT\1740 test_32\NN\5798043 dose_33\NN\3740161 of_34\IN\1740 morphine_35\NN\2707683 that_36\WDT\1740 was_37\VBD\836236 not_38\RB\1740 significantly_39\RB\1740 less_40\JJR\1740 than_41\IN\1740 in_42\IN\13603305 the_43\DT\1740 controls_44\NNS\5190804 and_45\CC\1740 were_46\VBD\836236 akinetic_47\JJ\1740 (_48\-LRB-\1740 a_49\NN\13649268 group_50\NN\2137 )_51\-RRB-\1740 ._52\.\1740
D009020_D009127 CID rats_0\NNS\2329401 treated_1\VBN\2376958 for_2\IN\1740 11_3\CD\13745420 days_4\NNS\15140892 with_5\IN\1740 morphine_6\NN\2707683 and_7\CC\1740 withdrawn_8\VBN\1835496 for_9\IN\1740 36_10\CD\1740 -_11\SYM\1740 40_12\CD\13745420 h_13\NN\14622893 showed_14\VBD\2137132 differences_15\NNS\4723816 in_16\IN\13603305 the_17\DT\1740 development_18\NN\248977 of_19\IN\1740 tolerance_20\NN\5032565 :_21\:\1740 about_22\RB\1740 half_23\NN\13732295 of_24\IN\1740 the_25\DT\1740 animals_26\NNS\4475 showed_27\VBD\2137132 a_28\DT\13649268 <e2>rigidity</e2>_29\NN\5023233 after_30\IN\1740 the_31\DT\1740 test_32\NN\5798043 dose_33\NN\3740161 of_34\IN\1740 <e1>morphine</e1>_35\NN\2707683 that_36\WDT\1740 was_37\VBD\836236 not_38\RB\1740 significantly_39\RB\1740 less_40\JJR\1740 than_41\IN\1740 in_42\IN\13603305 the_43\DT\1740 controls_44\NNS\5190804 and_45\CC\1740 were_46\VBD\836236 akinetic_47\JJ\1740 (_48\-LRB-\1740 a_49\NN\13649268 group_50\NN\2137 )_51\-RRB-\1740 ._52\.\1740
D009020_D009127 CID the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e2>rigidity</e2>_4\NN\5023233 ,_5\,\1740 which_6\WDT\1740 is_7\VBZ\836236 assumed_8\VBN\719734 to_9\TO\1740 be_10\VB\836236 due_11\JJ\1740 to_12\TO\1740 an_13\DT\6697703 action_14\NN\30358 of_15\IN\1740 <e1>morphine</e1>_16\NN\2707683 in_17\IN\13603305 the_18\DT\1740 striatum_19\NN\5497363 ,_20\,\1740 can_21\MD\3094503 be_22\VB\836236 antagonized_23\VBN\1787955 by_24\IN\1740 another_25\DT\1740 process_26\NN\407535 leading_27\VBG\1752884 to_28\TO\1740 dopaminergic_29\JJ\1740 activation_30\NN\13561719 in_31\IN\13603305 the_32\DT\1740 striatum_33\NN\5497363 ._34\.\1740
D009020_D018476 CID rats_0\NNS\2329401 treated_1\VBN\2376958 for_2\IN\1740 11_3\CD\13745420 days_4\NNS\15140892 with_5\IN\1740 <e1>morphine</e1>_6\NN\2707683 and_7\CC\1740 withdrawn_8\VBN\1835496 for_9\IN\1740 36_10\CD\1740 -_11\SYM\1740 40_12\CD\13745420 h_13\NN\14622893 showed_14\VBD\2137132 differences_15\NNS\4723816 in_16\IN\13603305 the_17\DT\1740 development_18\NN\248977 of_19\IN\1740 tolerance_20\NN\5032565 :_21\:\1740 about_22\RB\1740 half_23\NN\13732295 of_24\IN\1740 the_25\DT\1740 animals_26\NNS\4475 showed_27\VBD\2137132 a_28\DT\13649268 rigidity_29\NN\5023233 after_30\IN\1740 the_31\DT\1740 test_32\NN\5798043 dose_33\NN\3740161 of_34\IN\1740 morphine_35\NN\2707683 that_36\WDT\1740 was_37\VBD\836236 not_38\RB\1740 significantly_39\RB\1740 less_40\JJR\1740 than_41\IN\1740 in_42\IN\13603305 the_43\DT\1740 controls_44\NNS\5190804 and_45\CC\1740 were_46\VBD\836236 <e2>akinetic</e2>_47\JJ\1740 (_48\-LRB-\1740 a_49\NN\13649268 group_50\NN\2137 )_51\-RRB-\1740 ._52\.\1740
D009020_D018476 CID rats_0\NNS\2329401 treated_1\VBN\2376958 for_2\IN\1740 11_3\CD\13745420 days_4\NNS\15140892 with_5\IN\1740 morphine_6\NN\2707683 and_7\CC\1740 withdrawn_8\VBN\1835496 for_9\IN\1740 36_10\CD\1740 -_11\SYM\1740 40_12\CD\13745420 h_13\NN\14622893 showed_14\VBD\2137132 differences_15\NNS\4723816 in_16\IN\13603305 the_17\DT\1740 development_18\NN\248977 of_19\IN\1740 tolerance_20\NN\5032565 :_21\:\1740 about_22\RB\1740 half_23\NN\13732295 of_24\IN\1740 the_25\DT\1740 animals_26\NNS\4475 showed_27\VBD\2137132 a_28\DT\13649268 rigidity_29\NN\5023233 after_30\IN\1740 the_31\DT\1740 test_32\NN\5798043 dose_33\NN\3740161 of_34\IN\1740 <e1>morphine</e1>_35\NN\2707683 that_36\WDT\1740 was_37\VBD\836236 not_38\RB\1740 significantly_39\RB\1740 less_40\JJR\1740 than_41\IN\1740 in_42\IN\13603305 the_43\DT\1740 controls_44\NNS\5190804 and_45\CC\1740 were_46\VBD\836236 <e2>akinetic</e2>_47\JJ\1740 (_48\-LRB-\1740 a_49\NN\13649268 group_50\NN\2137 )_51\-RRB-\1740 ._52\.\1740
D006220_D009127 CID in_0\IN\13603305 a_1\DT\13649268 further_2\JJ\1740 series_3\NN\8456993 of_4\IN\1740 experiments_5\NNS\641820 ,_6\,\1740 <e1>haloperidol</e1>_7\NN\3713736 (_8\-LRB-\1740 0.2_9\CD\1740 mg/kg_10\NN\1740 i.p._11\RB\1740 )_12\-RRB-\1740 was_13\VBD\836236 used_14\VBN\1156834 in_15\IN\13603305 order_16\NN\7168131 to_17\TO\1740 block_18\VB\1476483 the_19\DT\1740 dopaminergic_20\JJ\1740 activation_21\NN\13561719 and_22\CC\1740 to_23\TO\1740 estimate_24\VB\637259 the_25\DT\1740 real_26\JJ\1740 degree_27\NN\4916342 of_28\IN\1740 the_29\DT\1740 tolerance_30\NN\5032565 to_31\TO\1740 the_32\DT\1740 <e2>rigidity</e2>_33\NN\5023233 without_34\IN\1740 any_35\DT\1740 dopaminergic_36\JJ\1740 interference_37\NN\6660942 ._38\.\1740
D006220_D009127 CID <e1>haloperidol</e1>_0\NNP\3713736 enhanced_1\VBD\227165 the_2\DT\1740 <e2>rigidity</e2>_3\NN\5023233 in_4\IN\13603305 the_5\DT\1740 a_6\NN\13649268 group_7\NN\2137 ._8\.\1740
3693336
D014229_D001714 CID <e1>triazolam-induced</e1>_0\JJ\1740 brief_1\JJ\1740 episodes_2\NNS\7283608 of_3\IN\1740 secondary_4\JJ\1740 <e2>mania</e2>_5\NN\9180259 in_6\IN\13603305 a_7\DT\13649268 depressed_8\JJ\1740 patient_9\NN\9898892 ._10\.\1740
D014229_D001714 CID large_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 <e1>triazolam</e1>_3\NNS\2830852 repeatedly_4\RB\1740 induced_5\VBD\1627355 brief_6\JJ\1740 episodes_7\NNS\7283608 of_8\IN\1740 <e2>mania</e2>_9\NN\9180259 in_10\IN\13603305 a_11\DT\13649268 depressed_12\JJ\1740 elderly_13\JJ\1740 woman_14\NN\9605289 ._15\.\1740
D014229_D001714 CID <e2>manic</e2>_0\JJ\1740 excitement_1\NN\7527352 was_2\VBD\836236 coincident_3\JJ\1740 with_4\IN\1740 the_5\DT\1740 duration_6\NN\15113229 of_7\IN\1740 action_8\NN\30358 of_9\IN\1740 <e1>triazolam</e1>_10\NNS\2830852 ._11\.\1740
D014229_D003866 NONE <e1>triazolam-induced</e1>_0\JJ\1740 brief_1\JJ\1740 episodes_2\NNS\7283608 of_3\IN\1740 secondary_4\JJ\1740 mania_5\NN\9180259 in_6\IN\13603305 a_7\DT\13649268 <e2>depressed</e2>_8\JJ\1740 patient_9\NN\9898892 ._10\.\1740
D014229_D003866 NONE large_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 <e1>triazolam</e1>_3\NNS\2830852 repeatedly_4\RB\1740 induced_5\VBD\1627355 brief_6\JJ\1740 episodes_7\NNS\7283608 of_8\IN\1740 mania_9\NN\9180259 in_10\IN\13603305 a_11\DT\13649268 <e2>depressed</e2>_12\JJ\1740 elderly_13\JJ\1740 woman_14\NN\9605289 ._15\.\1740
12523465
C022189_D006212 CID <e2>visual_0\JJ\1740 hallucinations</e2>_1\NNS\14376855 associated_2\VBN\628491 with_3\IN\1740 <e1>zonisamide</e1>_4\NN\1740 ._5\.\1740
C022189_D006212 CID although_0\IN\1740 <e2>visual_1\JJ\1740 hallucinations</e2>_2\NNS\14376855 have_3\VBP\2108377 not_4\RB\1740 been_5\VBN\836236 reported_6\VBN\831651 as_7\IN\14622893 an_8\DT\6697703 adverse_9\JJ\1740 effect_10\NN\34213 of_11\IN\1740 this_12\DT\1740 agent_13\NN\7347 ,_14\,\1740 we_15\PRP\1740 describe_16\VBP\1001294 three_17\CD\13741022 patients_18\NNS\9898892 who_19\WP\8299493 experienced_20\VBD\2108377 complex_21\JJ\1740 visual_22\JJ\1740 hallucinations_23\NNS\14376855 and_24\CC\1740 altered_25\JJ\1740 mental_26\JJ\1740 status_27\NN\24720 after_28\IN\1740 <e1>zonisamide</e1>_29\NN\1740 treatment_30\NN\654885 was_31\VBD\836236 begun_32\VBN\941990 or_33\CC\3541091 its_34\PRP$\6125041 dosage_35\NN\13576355 increased_36\VBD\169651 ._37\.\1740
C022189_D006212 CID although_0\IN\1740 visual_1\JJ\1740 hallucinations_2\NNS\14376855 have_3\VBP\2108377 not_4\RB\1740 been_5\VBN\836236 reported_6\VBN\831651 as_7\IN\14622893 an_8\DT\6697703 adverse_9\JJ\1740 effect_10\NN\34213 of_11\IN\1740 this_12\DT\1740 agent_13\NN\7347 ,_14\,\1740 we_15\PRP\1740 describe_16\VBP\1001294 three_17\CD\13741022 patients_18\NNS\9898892 who_19\WP\8299493 experienced_20\VBD\2108377 complex_21\JJ\1740 <e2>visual_22\JJ\1740 hallucinations</e2>_23\NNS\14376855 and_24\CC\1740 altered_25\JJ\1740 mental_26\JJ\1740 status_27\NN\24720 after_28\IN\1740 <e1>zonisamide</e1>_29\NN\1740 treatment_30\NN\654885 was_31\VBD\836236 begun_32\VBN\941990 or_33\CC\3541091 its_34\PRP$\6125041 dosage_35\NN\13576355 increased_36\VBD\169651 ._37\.\1740
C022189_D012640 NONE <e1>zonisamide</e1>_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 broad-spectrum_3\NN\1740 antiepileptic_4\JJ\1740 drug_5\NN\14778436 used_6\VBN\1156834 to_7\TO\1740 treat_8\VB\2376958 various_9\JJ\1740 types_10\NNS\5839024 of_11\IN\1740 <e2>seizures</e2>_12\NNS\14081375 ._13\.\1740
15649445
D012110_D004409 CID acute_0\JJ\1740 <e1>reserpine</e1>_1\NN\2721160 and_2\CC\1740 subchronic_3\JJ\1740 haloperidol_4\NN\3713736 treatments_5\NNS\654885 change_6\VBP\46534 synaptosomal_7\JJ\1740 brain_8\NN\5462674 glutamate_9\NN\15010703 uptake_10\NN\13440063 and_11\CC\1740 elicit_12\VB\1617192 <e2>orofacial_13\JJ\1740 dyskinesia</e2>_14\NN\14084880 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
D012110_D004409 CID <e1>reserpine-</e1>_0\NN\1740 and_1\CC\1740 haloperidol-induced_2\JJ\1740 <e2>orofacial_3\JJ\1740 dyskinesia</e2>_4\NN\14084880 are_5\VBP\836236 putative_6\JJ\1740 animal_7\NN\4475 models_8\NNS\5888929 of_9\IN\1740 tardive_10\JJ\1740 dyskinesia_11\NN\14084880 (_12\-LRB-\1740 td_13\NN\1740 )_14\-RRB-\1740 whose_15\WP$\1740 pathophysiology_16\NN\1740 has_17\VBZ\2108377 been_18\VBN\836236 related_19\JJ\1740 to_20\TO\1740 free_21\JJ\1740 radical_22\JJ\1740 generation_23\NN\7942152 and_24\CC\1740 oxidative_25\JJ\1740 stress_26\NN\7083732 ._27\.\1740
D012110_D004409 CID <e1>reserpine-</e1>_0\NN\1740 and_1\CC\1740 haloperidol-induced_2\JJ\1740 orofacial_3\JJ\1740 dyskinesia_4\NN\14084880 are_5\VBP\836236 putative_6\JJ\1740 animal_7\NN\4475 models_8\NNS\5888929 of_9\IN\1740 <e2>tardive_10\JJ\1740 dyskinesia</e2>_11\NN\14084880 (_12\-LRB-\1740 td_13\NN\1740 )_14\-RRB-\1740 whose_15\WP$\1740 pathophysiology_16\NN\1740 has_17\VBZ\2108377 been_18\VBN\836236 related_19\JJ\1740 to_20\TO\1740 free_21\JJ\1740 radical_22\JJ\1740 generation_23\NN\7942152 and_24\CC\1740 oxidative_25\JJ\1740 stress_26\NN\7083732 ._27\.\1740
D012110_D004409 CID <e1>reserpine-</e1>_0\NN\1740 and_1\CC\1740 haloperidol-induced_2\JJ\1740 orofacial_3\JJ\1740 dyskinesia_4\NN\14084880 are_5\VBP\836236 putative_6\JJ\1740 animal_7\NN\4475 models_8\NNS\5888929 of_9\IN\1740 tardive_10\JJ\1740 dyskinesia_11\NN\14084880 (_12\-LRB-\1740 <e2>td</e2>_13\NN\1740 )_14\-RRB-\1740 whose_15\WP$\1740 pathophysiology_16\NN\1740 has_17\VBZ\2108377 been_18\VBN\836236 related_19\JJ\1740 to_20\TO\1740 free_21\JJ\1740 radical_22\JJ\1740 generation_23\NN\7942152 and_24\CC\1740 oxidative_25\JJ\1740 stress_26\NN\7083732 ._27\.\1740
D012110_D004409 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 authors_6\NNS\9610660 induced_7\VBD\1627355 <e2>orofacial_8\JJ\1740 dyskinesia</e2>_9\NN\14084880 by_10\IN\1740 acute_11\JJ\1740 <e1>reserpine</e1>_12\NN\2721160 and_13\CC\1740 subchronic_14\JJ\1740 haloperidol_15\NN\3713736 administration_16\NN\1133281 to_17\TO\1740 rats_18\NNS\2329401 ._19\.\1740
D006220_D004409 CID acute_0\JJ\1740 reserpine_1\NN\2721160 and_2\CC\1740 subchronic_3\JJ\1740 <e1>haloperidol</e1>_4\NN\3713736 treatments_5\NNS\654885 change_6\VBP\46534 synaptosomal_7\JJ\1740 brain_8\NN\5462674 glutamate_9\NN\15010703 uptake_10\NN\13440063 and_11\CC\1740 elicit_12\VB\1617192 <e2>orofacial_13\JJ\1740 dyskinesia</e2>_14\NN\14084880 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
D006220_D004409 CID reserpine-_0\NN\1740 and_1\CC\1740 <e1>haloperidol-induced</e1>_2\JJ\1740 <e2>orofacial_3\JJ\1740 dyskinesia</e2>_4\NN\14084880 are_5\VBP\836236 putative_6\JJ\1740 animal_7\NN\4475 models_8\NNS\5888929 of_9\IN\1740 tardive_10\JJ\1740 dyskinesia_11\NN\14084880 (_12\-LRB-\1740 td_13\NN\1740 )_14\-RRB-\1740 whose_15\WP$\1740 pathophysiology_16\NN\1740 has_17\VBZ\2108377 been_18\VBN\836236 related_19\JJ\1740 to_20\TO\1740 free_21\JJ\1740 radical_22\JJ\1740 generation_23\NN\7942152 and_24\CC\1740 oxidative_25\JJ\1740 stress_26\NN\7083732 ._27\.\1740
D006220_D004409 CID reserpine-_0\NN\1740 and_1\CC\1740 <e1>haloperidol-induced</e1>_2\JJ\1740 orofacial_3\JJ\1740 dyskinesia_4\NN\14084880 are_5\VBP\836236 putative_6\JJ\1740 animal_7\NN\4475 models_8\NNS\5888929 of_9\IN\1740 <e2>tardive_10\JJ\1740 dyskinesia</e2>_11\NN\14084880 (_12\-LRB-\1740 td_13\NN\1740 )_14\-RRB-\1740 whose_15\WP$\1740 pathophysiology_16\NN\1740 has_17\VBZ\2108377 been_18\VBN\836236 related_19\JJ\1740 to_20\TO\1740 free_21\JJ\1740 radical_22\JJ\1740 generation_23\NN\7942152 and_24\CC\1740 oxidative_25\JJ\1740 stress_26\NN\7083732 ._27\.\1740
D006220_D004409 CID reserpine-_0\NN\1740 and_1\CC\1740 <e1>haloperidol-induced</e1>_2\JJ\1740 orofacial_3\JJ\1740 dyskinesia_4\NN\14084880 are_5\VBP\836236 putative_6\JJ\1740 animal_7\NN\4475 models_8\NNS\5888929 of_9\IN\1740 tardive_10\JJ\1740 dyskinesia_11\NN\14084880 (_12\-LRB-\1740 <e2>td</e2>_13\NN\1740 )_14\-RRB-\1740 whose_15\WP$\1740 pathophysiology_16\NN\1740 has_17\VBZ\2108377 been_18\VBN\836236 related_19\JJ\1740 to_20\TO\1740 free_21\JJ\1740 radical_22\JJ\1740 generation_23\NN\7942152 and_24\CC\1740 oxidative_25\JJ\1740 stress_26\NN\7083732 ._27\.\1740
D006220_D004409 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 authors_6\NNS\9610660 induced_7\VBD\1627355 <e2>orofacial_8\JJ\1740 dyskinesia</e2>_9\NN\14084880 by_10\IN\1740 acute_11\JJ\1740 reserpine_12\NN\2721160 and_13\CC\1740 subchronic_14\JJ\1740 <e1>haloperidol</e1>_15\NN\3713736 administration_16\NN\1133281 to_17\TO\1740 rats_18\NNS\2329401 ._19\.\1740
D018698_D004409 NONE acute_0\JJ\1740 reserpine_1\NN\2721160 and_2\CC\1740 subchronic_3\JJ\1740 haloperidol_4\NN\3713736 treatments_5\NNS\654885 change_6\VBP\46534 synaptosomal_7\JJ\1740 brain_8\NN\5462674 <e1>glutamate</e1>_9\NN\15010703 uptake_10\NN\13440063 and_11\CC\1740 elicit_12\VB\1617192 <e2>orofacial_13\JJ\1740 dyskinesia</e2>_14\NN\14084880 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
D018698_D004409 NONE importantly_0\RB\1740 ,_1\,\1740 a_2\DT\13649268 decrease_3\NN\7296428 in_4\IN\13603305 <e1>glutamate</e1>_5\JJ\1740 uptake_6\NN\13440063 correlates_7\VBZ\2657219 negatively_8\RB\1740 with_9\IN\1740 an_10\DT\6697703 increase_11\NN\13576355 in_12\IN\13603305 the_13\DT\1740 incidence_14\NN\13821570 of_15\IN\1740 <e2>orofacial_16\JJ\1740 diskinesia</e2>_17\NN\1740 ._18\.\1740
18631865
D020123_D051436 NONE massive_0\JJ\1740 urinary_1\JJ\1740 protein_2\NN\14944888 excretion_3\NN\13466586 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 after_7\IN\1740 conversion_8\NN\7359599 from_9\IN\1740 calcineurin_10\NN\1740 inhibitors_11\NNS\20090 to_12\TO\1740 mammalian_13\JJ\1740 target_14\NN\7258332 of_15\IN\1740 <e1>rapamycin</e1>_16\NN\1740 (_17\-LRB-\1740 mtor_18\NN\1740 )_19\-RRB-\1740 inhibitors_20\NNS\20090 ,_21\,\1740 especially_22\RB\1740 sirolimus_23\NN\1740 ,_24\,\1740 in_25\IN\13603305 renal_26\JJ\1740 transplant_27\NN\5267548 recipients_28\NNS\9764201 with_29\IN\1740 <e2>chronic_30\JJ\1740 allograft_31\NN\5582859 nephropathy</e2>_32\NN\14573196 ._33\.\1740
D020123_D051436 NONE massive_0\JJ\1740 urinary_1\JJ\1740 protein_2\NN\14944888 excretion_3\NN\13466586 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 after_7\IN\1740 conversion_8\NN\7359599 from_9\IN\1740 calcineurin_10\NN\1740 inhibitors_11\NNS\20090 to_12\TO\1740 mammalian_13\JJ\1740 target_14\NN\7258332 of_15\IN\1740 rapamycin_16\NN\1740 (_17\-LRB-\1740 mtor_18\NN\1740 )_19\-RRB-\1740 inhibitors_20\NNS\20090 ,_21\,\1740 especially_22\RB\1740 <e1>sirolimus</e1>_23\NN\1740 ,_24\,\1740 in_25\IN\13603305 renal_26\JJ\1740 transplant_27\NN\5267548 recipients_28\NNS\9764201 with_29\IN\1740 <e2>chronic_30\JJ\1740 allograft_31\NN\5582859 nephropathy</e2>_32\NN\14573196 ._33\.\1740
D020123_D011507 CID whether_0\IN\1740 <e2>proteinuria</e2>_1\NN\14299637 was_2\VBD\836236 due_3\JJ\1740 to_4\TO\1740 <e1>sirolimus</e1>_5\NN\1740 or_6\CC\3541091 only_7\RB\1740 a_8\DT\13649268 consequence_9\NN\34213 of_10\IN\1740 calcineurin_11\NN\1740 inhibitors_12\NNS\20090 withdrawal_13\NN\7206096 remained_14\VBD\2604760 unsolved_15\JJ\1740 until_16\IN\1740 high_17\JJ\1740 range_18\NN\5123416 proteinuria_19\NN\14299637 has_20\VBZ\2108377 been_21\VBN\836236 observed_22\VBN\2163746 during_23\IN\1740 sirolimus_24\NN\1740 therapy_25\NN\657604 in_26\IN\13603305 islet_27\NN\1740 transplantation_28\NN\671351 and_29\CC\1740 in_30\IN\13603305 patients_31\NNS\9898892 who_32\WP\8299493 received_33\VBD\2210855 sirolimus_34\NN\1740 de_35\FW\1740 novo_36\FW\1740 ._37\.\1740
D020123_D011507 CID whether_0\IN\1740 proteinuria_1\NN\14299637 was_2\VBD\836236 due_3\JJ\1740 to_4\TO\1740 <e1>sirolimus</e1>_5\NN\1740 or_6\CC\3541091 only_7\RB\1740 a_8\DT\13649268 consequence_9\NN\34213 of_10\IN\1740 calcineurin_11\NN\1740 inhibitors_12\NNS\20090 withdrawal_13\NN\7206096 remained_14\VBD\2604760 unsolved_15\JJ\1740 until_16\IN\1740 high_17\JJ\1740 range_18\NN\5123416 <e2>proteinuria</e2>_19\NN\14299637 has_20\VBZ\2108377 been_21\VBN\836236 observed_22\VBN\2163746 during_23\IN\1740 sirolimus_24\NN\1740 therapy_25\NN\657604 in_26\IN\13603305 islet_27\NN\1740 transplantation_28\NN\671351 and_29\CC\1740 in_30\IN\13603305 patients_31\NNS\9898892 who_32\WP\8299493 received_33\VBD\2210855 sirolimus_34\NN\1740 de_35\FW\1740 novo_36\FW\1740 ._37\.\1740
D020123_D011507 CID whether_0\IN\1740 <e2>proteinuria</e2>_1\NN\14299637 was_2\VBD\836236 due_3\JJ\1740 to_4\TO\1740 sirolimus_5\NN\1740 or_6\CC\3541091 only_7\RB\1740 a_8\DT\13649268 consequence_9\NN\34213 of_10\IN\1740 calcineurin_11\NN\1740 inhibitors_12\NNS\20090 withdrawal_13\NN\7206096 remained_14\VBD\2604760 unsolved_15\JJ\1740 until_16\IN\1740 high_17\JJ\1740 range_18\NN\5123416 proteinuria_19\NN\14299637 has_20\VBZ\2108377 been_21\VBN\836236 observed_22\VBN\2163746 during_23\IN\1740 <e1>sirolimus</e1>_24\NN\1740 therapy_25\NN\657604 in_26\IN\13603305 islet_27\NN\1740 transplantation_28\NN\671351 and_29\CC\1740 in_30\IN\13603305 patients_31\NNS\9898892 who_32\WP\8299493 received_33\VBD\2210855 sirolimus_34\NN\1740 de_35\FW\1740 novo_36\FW\1740 ._37\.\1740
D020123_D011507 CID whether_0\IN\1740 proteinuria_1\NN\14299637 was_2\VBD\836236 due_3\JJ\1740 to_4\TO\1740 sirolimus_5\NN\1740 or_6\CC\3541091 only_7\RB\1740 a_8\DT\13649268 consequence_9\NN\34213 of_10\IN\1740 calcineurin_11\NN\1740 inhibitors_12\NNS\20090 withdrawal_13\NN\7206096 remained_14\VBD\2604760 unsolved_15\JJ\1740 until_16\IN\1740 high_17\JJ\1740 range_18\NN\5123416 <e2>proteinuria</e2>_19\NN\14299637 has_20\VBZ\2108377 been_21\VBN\836236 observed_22\VBN\2163746 during_23\IN\1740 <e1>sirolimus</e1>_24\NN\1740 therapy_25\NN\657604 in_26\IN\13603305 islet_27\NN\1740 transplantation_28\NN\671351 and_29\CC\1740 in_30\IN\13603305 patients_31\NNS\9898892 who_32\WP\8299493 received_33\VBD\2210855 sirolimus_34\NN\1740 de_35\FW\1740 novo_36\FW\1740 ._37\.\1740
D020123_D011507 CID whether_0\IN\1740 <e2>proteinuria</e2>_1\NN\14299637 was_2\VBD\836236 due_3\JJ\1740 to_4\TO\1740 sirolimus_5\NN\1740 or_6\CC\3541091 only_7\RB\1740 a_8\DT\13649268 consequence_9\NN\34213 of_10\IN\1740 calcineurin_11\NN\1740 inhibitors_12\NNS\20090 withdrawal_13\NN\7206096 remained_14\VBD\2604760 unsolved_15\JJ\1740 until_16\IN\1740 high_17\JJ\1740 range_18\NN\5123416 proteinuria_19\NN\14299637 has_20\VBZ\2108377 been_21\VBN\836236 observed_22\VBN\2163746 during_23\IN\1740 sirolimus_24\NN\1740 therapy_25\NN\657604 in_26\IN\13603305 islet_27\NN\1740 transplantation_28\NN\671351 and_29\CC\1740 in_30\IN\13603305 patients_31\NNS\9898892 who_32\WP\8299493 received_33\VBD\2210855 <e1>sirolimus</e1>_34\NN\1740 de_35\FW\1740 novo_36\FW\1740 ._37\.\1740
D020123_D011507 CID whether_0\IN\1740 proteinuria_1\NN\14299637 was_2\VBD\836236 due_3\JJ\1740 to_4\TO\1740 sirolimus_5\NN\1740 or_6\CC\3541091 only_7\RB\1740 a_8\DT\13649268 consequence_9\NN\34213 of_10\IN\1740 calcineurin_11\NN\1740 inhibitors_12\NNS\20090 withdrawal_13\NN\7206096 remained_14\VBD\2604760 unsolved_15\JJ\1740 until_16\IN\1740 high_17\JJ\1740 range_18\NN\5123416 <e2>proteinuria</e2>_19\NN\14299637 has_20\VBZ\2108377 been_21\VBN\836236 observed_22\VBN\2163746 during_23\IN\1740 sirolimus_24\NN\1740 therapy_25\NN\657604 in_26\IN\13603305 islet_27\NN\1740 transplantation_28\NN\671351 and_29\CC\1740 in_30\IN\13603305 patients_31\NNS\9898892 who_32\WP\8299493 received_33\VBD\2210855 <e1>sirolimus</e1>_34\NN\1740 de_35\FW\1740 novo_36\FW\1740 ._37\.\1740
1085609
D011736_D012640 NONE neonatal_0\JJ\1740 <e1>pyridoxine</e1>_1\NN\15090742 responsive_2\JJ\1740 <e2>convulsions</e2>_3\NNS\14081375 due_4\JJ\1740 to_5\IN\1740 isoniazid_6\NN\2716205 therapy_7\NN\657604 ._8\.\1740
D011736_D012640 NONE the_0\DT\1740 <e2>fits</e2>_1\NNS\7518132 ceased_2\VBD\1740 within_3\IN\1740 4_4\CD\13741022 hours_5\NNS\15118228 of_6\IN\1740 administering_7\VBG\2436349 intramuscular_8\JJ\1740 <e1>pyridoxine</e1>_9\NN\15090742 ,_10\,\1740 suggesting_11\VBG\1010118 an_12\DT\6697703 aetiology_13\NN\7326557 of_14\IN\1740 pyridoxine_15\NN\15090742 deficiency_16\NN\14449126 secondary_17\JJ\1740 to_18\IN\1740 isoniazid_19\NN\2716205 medication_20\NN\3247620 ._21\.\1740
D011736_D012640 NONE the_0\DT\1740 <e2>fits</e2>_1\NNS\7518132 ceased_2\VBD\1740 within_3\IN\1740 4_4\CD\13741022 hours_5\NNS\15118228 of_6\IN\1740 administering_7\VBG\2436349 intramuscular_8\JJ\1740 pyridoxine_9\NN\15090742 ,_10\,\1740 suggesting_11\VBG\1010118 an_12\DT\6697703 aetiology_13\NN\7326557 of_14\IN\1740 <e1>pyridoxine</e1>_15\NN\15090742 deficiency_16\NN\14449126 secondary_17\JJ\1740 to_18\IN\1740 isoniazid_19\NN\2716205 medication_20\NN\3247620 ._21\.\1740
D007538_D012640 CID neonatal_0\JJ\1740 pyridoxine_1\NN\15090742 responsive_2\JJ\1740 <e2>convulsions</e2>_3\NNS\14081375 due_4\JJ\1740 to_5\IN\1740 <e1>isoniazid</e1>_6\NN\2716205 therapy_7\NN\657604 ._8\.\1740
D007538_D012640 CID a_0\DT\13649268 17-day-old_1\JJ\1740 infant_2\NN\9918248 on_3\IN\1740 <e1>isoniazid</e1>_4\NN\2716205 therapy_5\NN\657604 13_6\CD\13745420 mg/kg_7\NN\1740 daily_8\RB\1740 from_9\IN\1740 birth_10\NN\15265518 because_11\IN\1740 of_12\IN\1740 maternal_13\JJ\1740 tuberculosis_14\NN\14127211 was_15\VBD\836236 admitted_16\VBN\822367 after_17\IN\1740 4_18\CD\13741022 days_19\NNS\15140892 of_20\IN\1740 <e2>clonic_21\JJ\1740 fits</e2>_22\NNS\7518132 ._23\.\1740
D007538_D012640 CID the_0\DT\1740 <e2>fits</e2>_1\NNS\7518132 ceased_2\VBD\1740 within_3\IN\1740 4_4\CD\13741022 hours_5\NNS\15118228 of_6\IN\1740 administering_7\VBG\2436349 intramuscular_8\JJ\1740 pyridoxine_9\NN\15090742 ,_10\,\1740 suggesting_11\VBG\1010118 an_12\DT\6697703 aetiology_13\NN\7326557 of_14\IN\1740 pyridoxine_15\NN\15090742 deficiency_16\NN\14449126 secondary_17\JJ\1740 to_18\IN\1740 <e1>isoniazid</e1>_19\NN\2716205 medication_20\NN\3247620 ._21\.\1740
D007538_D014376 NONE a_0\DT\13649268 17-day-old_1\JJ\1740 infant_2\NN\9918248 on_3\IN\1740 <e1>isoniazid</e1>_4\NN\2716205 therapy_5\NN\657604 13_6\CD\13745420 mg/kg_7\NN\1740 daily_8\RB\1740 from_9\IN\1740 birth_10\NN\15265518 because_11\IN\1740 of_12\IN\1740 maternal_13\JJ\1740 <e2>tuberculosis</e2>_14\NN\14127211 was_15\VBD\836236 admitted_16\VBN\822367 after_17\IN\1740 4_18\CD\13741022 days_19\NNS\15140892 of_20\IN\1740 clonic_21\JJ\1740 fits_22\NNS\7518132 ._23\.\1740
891050
D003276_D006463 CID a_0\DT\13649268 case_1\NN\7283608 is_2\VBZ\836236 reported_3\VBN\831651 of_4\IN\1740 the_5\DT\1740 <e2>hemolytic_6\JJ\1740 uremic_7\JJ\1740 syndrome</e2>_8\NN\5870365 (_9\-LRB-\1740 hus_10\NN\1740 )_11\-RRB-\1740 in_12\IN\13603305 a_13\DT\13649268 woman_14\NN\9605289 taking_15\VBG\2367363 <e1>oral_16\JJ\1740 contraceptives</e1>_17\NNS\3183080 ._18\.\1740
D003276_D006463 CID a_0\DT\13649268 case_1\NN\7283608 is_2\VBZ\836236 reported_3\VBN\831651 of_4\IN\1740 the_5\DT\1740 hemolytic_6\JJ\1740 uremic_7\JJ\1740 syndrome_8\NN\5870365 (_9\-LRB-\1740 <e2>hus</e2>_10\NN\1740 )_11\-RRB-\1740 in_12\IN\13603305 a_13\DT\13649268 woman_14\NN\9605289 taking_15\VBG\2367363 <e1>oral_16\JJ\1740 contraceptives</e1>_17\NNS\3183080 ._18\.\1740
D006493_D001002 NONE she_0\PRP\1740 was_1\VBD\836236 treated_2\VBN\2376958 with_3\IN\1740 <e1>heparin</e1>_4\NN\2718259 ,_5\,\1740 dipyridamole_6\NN\1740 and_7\CC\1740 hemodialysis_8\NN\649760 ;_9\:\1740 and_10\CC\1740 after_11\IN\1740 more_12\JJR\1740 than_13\IN\1740 three_14\CD\13741022 months_15\NNS\15113229 ,_16\,\1740 her_17\PRP$\1740 urinary_18\JJ\1740 output_19\NN\4007894 rose_20\VBD\1835496 above_21\IN\6392001 500_22\CD\13745420 ml_23\NN\13616054 ;_24\:\1740 and_25\CC\1740 six_26\CD\13741022 months_27\NNS\15113229 after_28\IN\1740 the_29\DT\1740 onset_30\NN\7325190 of_31\IN\1740 <e2>anuria</e2>_32\NN\14061805 ,_33\,\1740 dialysis_34\NN\646833 treatment_35\NN\654885 was_36\VBD\836236 stopped_37\VBN\2452885 ._38\.\1740
D004176_D001002 NONE she_0\PRP\1740 was_1\VBD\836236 treated_2\VBN\2376958 with_3\IN\1740 heparin_4\NN\2718259 ,_5\,\1740 <e1>dipyridamole</e1>_6\NN\1740 and_7\CC\1740 hemodialysis_8\NN\649760 ;_9\:\1740 and_10\CC\1740 after_11\IN\1740 more_12\JJR\1740 than_13\IN\1740 three_14\CD\13741022 months_15\NNS\15113229 ,_16\,\1740 her_17\PRP$\1740 urinary_18\JJ\1740 output_19\NN\4007894 rose_20\VBD\1835496 above_21\IN\6392001 500_22\CD\13745420 ml_23\NN\13616054 ;_24\:\1740 and_25\CC\1740 six_26\CD\13741022 months_27\NNS\15113229 after_28\IN\1740 the_29\DT\1740 onset_30\NN\7325190 of_31\IN\1740 <e2>anuria</e2>_32\NN\14061805 ,_33\,\1740 dialysis_34\NN\646833 treatment_35\NN\654885 was_36\VBD\836236 stopped_37\VBN\2452885 ._38\.\1740
7199841
C004616_D010243 CID of_0\IN\1740 the_1\DT\1740 20_2\CD\13745420 animals_3\NNS\4475 that_4\WDT\1740 received_5\VBD\2210855 subarachnoid_6\JJ\1740 injection_7\NN\320852 of_8\IN\1740 <e1>2-chloroprocaine-ce</e1>_9\CD\1740 seven_10\CD\13741022 (_11\-LRB-\1740 35_12\CD\1740 %_13\NN\1740 )_14\-RRB-\1740 developed_15\VBD\1753788 hind-limb_16\JJ\1740 <e2>paralysis</e2>_17\NN\14557898 ._18\.\1740
D002045_D010243 NONE none_0\NN\15228378 of_1\IN\1740 the_2\DT\1740 animals_3\NNS\4475 that_4\WDT\1740 received_5\VBD\2210855 <e1>bupivacaine</e1>_6\NN\1740 ,_7\,\1740 normal_8\JJ\1740 saline_9\NN\14849367 ,_10\,\1740 or_11\CC\3541091 normal_12\JJ\1740 saline_13\NN\14849367 titrated_14\VBN\489837 to_15\TO\1740 a_16\DT\13649268 ph_17\NN\5038959 3.0_18\CD\1740 developed_19\VBD\1753788 hind-limb_20\JJ\1740 <e2>paralysis</e2>_21\NN\14557898 ._22\.\1740
C004616_D013118 CID of_0\IN\1740 the_1\DT\1740 15_2\CD\13745420 spinal_3\JJ\1740 cords_4\NNS\4489008 of_5\IN\1740 the_6\DT\1740 animals_7\NNS\4475 that_8\WDT\1740 received_9\VBD\2210855 <e1>2-chloroprocaine-ce</e1>_10\CD\1740 ,_11\,\1740 13_12\CD\13745420 showed_13\VBD\2137132 <e2>subpial_14\JJ\1740 necrosis</e2>_15\NN\11444117 ;_16\:\1740 the_17\DT\1740 nerve_18\NN\5475681 roots_19\NNS\13920429 and_20\CC\1740 subarachnoid_21\JJ\1740 vessels_22\NNS\5246511 were_23\VBD\836236 normal_24\JJ\1740 ._25\.\1740
11256525
D019808_D001002 CID repeated_0\VBN\952524 transient_1\JJ\1740 <e2>anuria</e2>_2\NN\14061805 following_3\VBG\1835496 <e1>losartan</e1>_4\JJ\1740 administration_5\NN\1133281 in_6\IN\13603305 a_7\DT\13649268 patient_8\NN\9898892 with_9\IN\1740 a_10\DT\13649268 solitary_11\JJ\1740 kidney_12\NN\5333259 ._13\.\1740
D019808_D001002 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 70-year-old_6\JJ\1740 hypertensive_7\JJ\1740 man_8\NN\9605289 with_9\IN\1740 a_10\DT\13649268 solitary_11\JJ\1740 kidney_12\NN\5333259 and_13\CC\1740 chronic_14\JJ\1740 renal_15\JJ\1740 insufficiency_16\NN\14462946 who_17\WP\8299493 developed_18\VBD\1753788 two_19\CD\13741022 episodes_20\NNS\7283608 of_21\IN\1740 transient_22\JJ\1740 <e2>anuria</e2>_23\NN\14061805 after_24\IN\1740 <e1>losartan</e1>_25\JJ\1740 administration_26\NN\1133281 ._27\.\1740
D019808_D001002 CID surprisingly_0\RB\1740 ,_1\,\1740 the_2\DT\1740 first_3\JJ\1740 dose_4\NN\3740161 of_5\IN\1740 50_6\CD\13745420 mg_7\NN\13717155 of_8\IN\1740 <e1>losartan</e1>_9\NN\1740 resulted_10\VBD\2633881 in_11\IN\13603305 a_12\DT\13649268 sudden_13\JJ\1740 <e2>anuria</e2>_14\NN\14061805 ,_15\,\1740 which_16\WDT\1740 lasted_17\VBD\2704349 eight_18\CD\13741022 hours_19\NNS\15118228 despite_20\IN\7501545 high-dose_21\JJ\1740 furosemide_22\NN\3214670 and_23\CC\1740 amine_24\NN\14951377 infusion_25\NN\14589223 ._26\.\1740
D019808_D001002 CID one_0\CD\13741022 week_1\NN\15113229 later_2\RB\1740 ,_3\,\1740 by_4\IN\1740 mistake_5\NN\66216 ,_6\,\1740 <e1>losartan</e1>_7\NN\1740 was_8\VBD\836236 prescribed_9\VBN\748282 again_10\RB\1740 and_11\CC\1740 after_12\IN\1740 the_13\DT\1740 second_14\JJ\1740 dose_15\NN\3740161 of_16\IN\1740 50_17\CD\13745420 mg_18\NN\13717155 ,_19\,\1740 the_20\DT\1740 patient_21\NN\9898892 developed_22\VBD\1753788 a_23\DT\13649268 second_24\JJ\1740 episode_25\NN\7283608 of_26\IN\1740 transient_27\JJ\1740 <e2>anuria</e2>_28\NN\14061805 lasting_29\VBG\2704349 10_30\CD\13745420 hours_31\NNS\15118228 ._32\.\1740
D019808_D006973 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 70-year-old_6\JJ\1740 <e2>hypertensive</e2>_7\JJ\1740 man_8\NN\9605289 with_9\IN\1740 a_10\DT\13649268 solitary_11\JJ\1740 kidney_12\NN\5333259 and_13\CC\1740 chronic_14\JJ\1740 renal_15\JJ\1740 insufficiency_16\NN\14462946 who_17\WP\8299493 developed_18\VBD\1753788 two_19\CD\13741022 episodes_20\NNS\7283608 of_21\IN\1740 transient_22\JJ\1740 anuria_23\NN\14061805 after_24\IN\1740 <e1>losartan</e1>_25\JJ\1740 administration_26\NN\1133281 ._27\.\1740
D019808_D051436 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 70-year-old_6\JJ\1740 hypertensive_7\JJ\1740 man_8\NN\9605289 with_9\IN\1740 a_10\DT\13649268 solitary_11\JJ\1740 kidney_12\NN\5333259 and_13\CC\1740 <e2>chronic_14\JJ\1740 renal_15\JJ\1740 insufficiency</e2>_16\NN\14462946 who_17\WP\8299493 developed_18\VBD\1753788 two_19\CD\13741022 episodes_20\NNS\7283608 of_21\IN\1740 transient_22\JJ\1740 anuria_23\NN\14061805 after_24\IN\1740 <e1>losartan</e1>_25\JJ\1740 administration_26\NN\1133281 ._27\.\1740
D019808_D006331 NONE due_0\IN\5174653 to_1\TO\1740 severe_2\JJ\1740 <e2>systolic_3\JJ\1740 dysfunction</e2>_4\NN\14204950 <e1>losartan</e1>_5\NN\1740 was_6\VBD\836236 prescribed_7\VBN\748282 ._8\.\1740
D005665_D001002 NONE surprisingly_0\RB\1740 ,_1\,\1740 the_2\DT\1740 first_3\JJ\1740 dose_4\NN\3740161 of_5\IN\1740 50_6\CD\13745420 mg_7\NN\13717155 of_8\IN\1740 losartan_9\NN\1740 resulted_10\VBD\2633881 in_11\IN\13603305 a_12\DT\13649268 sudden_13\JJ\1740 <e2>anuria</e2>_14\NN\14061805 ,_15\,\1740 which_16\WDT\1740 lasted_17\VBD\2704349 eight_18\CD\13741022 hours_19\NNS\15118228 despite_20\IN\7501545 high-dose_21\JJ\1740 <e1>furosemide</e1>_22\NN\3214670 and_23\CC\1740 amine_24\NN\14951377 infusion_25\NN\14589223 ._26\.\1740
D000588_D001002 NONE surprisingly_0\RB\1740 ,_1\,\1740 the_2\DT\1740 first_3\JJ\1740 dose_4\NN\3740161 of_5\IN\1740 50_6\CD\13745420 mg_7\NN\13717155 of_8\IN\1740 losartan_9\NN\1740 resulted_10\VBD\2633881 in_11\IN\13603305 a_12\DT\13649268 sudden_13\JJ\1740 <e2>anuria</e2>_14\NN\14061805 ,_15\,\1740 which_16\WDT\1740 lasted_17\VBD\2704349 eight_18\CD\13741022 hours_19\NNS\15118228 despite_20\IN\7501545 high-dose_21\JJ\1740 furosemide_22\NN\3214670 and_23\CC\1740 <e1>amine</e1>_24\NN\14951377 infusion_25\NN\14589223 ._26\.\1740
D000809_D012078 NONE in_0\IN\13603305 this_1\DT\1740 patient_2\NN\9898892 ,_3\,\1740 <e2>renal_4\JJ\1740 artery_5\NN\5417975 stenosis</e2>_6\NN\14204950 combined_7\VBN\2630189 with_8\IN\1740 heart_9\NN\5919034 failure_10\NN\66216 and_11\CC\1740 diuretic_12\NN\3247620 therapy_13\NN\657604 certainly_14\RB\1740 resulted_15\VBD\2633881 in_16\IN\13603305 a_17\DT\13649268 strong_18\JJ\1740 activation_19\NN\13561719 of_20\IN\1740 the_21\DT\1740 <e1>renin-angiotensin</e1>_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 ras_25\NN\5501711 )_26\-RRB-\1740 ._27\.\1740
D000809_D006333 NONE in_0\IN\13603305 this_1\DT\1740 patient_2\NN\9898892 ,_3\,\1740 renal_4\JJ\1740 artery_5\NN\5417975 stenosis_6\NN\14204950 combined_7\VBN\2630189 with_8\IN\1740 <e2>heart_9\NN\5919034 failure</e2>_10\NN\66216 and_11\CC\1740 diuretic_12\NN\3247620 therapy_13\NN\657604 certainly_14\RB\1740 resulted_15\VBD\2633881 in_16\IN\13603305 a_17\DT\13649268 strong_18\JJ\1740 activation_19\NN\13561719 of_20\IN\1740 the_21\DT\1740 <e1>renin-angiotensin</e1>_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 ras_25\NN\5501711 )_26\-RRB-\1740 ._27\.\1740
D000804_D014652 NONE this_0\DT\1740 case_1\NN\7283608 report_2\NN\6470073 highlights_3\VBZ\514463 the_4\DT\1740 fact_5\NN\5816287 that_6\IN\1740 the_7\DT\1740 <e1>angiotensin_8\NN\4522421 ii</e1>_9\CD\13741022 receptor_10\NN\5225602 antagonist_11\NN\7846 losartan_12\NN\1740 can_13\MD\3094503 cause_14\VB\1617192 serious_15\JJ\1740 unexpected_16\JJ\1740 complications_17\NNS\1073995 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 <e2>renovascular_21\JJ\1740 disease</e2>_22\NN\14061805 and_23\CC\1740 should_24\MD\1740 be_25\VB\836236 used_26\VBN\1156834 with_27\IN\1740 extreme_28\JJ\1740 caution_29\NN\4662951 in_30\IN\13603305 this_31\DT\1740 setting_32\NN\8567235 ._33\.\1740
D019808_D014652 NONE this_0\DT\1740 case_1\NN\7283608 report_2\NN\6470073 highlights_3\VBZ\514463 the_4\DT\1740 fact_5\NN\5816287 that_6\IN\1740 the_7\DT\1740 angiotensin_8\NN\4522421 ii_9\CD\13741022 receptor_10\NN\5225602 antagonist_11\NN\7846 <e1>losartan</e1>_12\NN\1740 can_13\MD\3094503 cause_14\VB\1617192 serious_15\JJ\1740 unexpected_16\JJ\1740 complications_17\NNS\1073995 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 <e2>renovascular_21\JJ\1740 disease</e2>_22\NN\14061805 and_23\CC\1740 should_24\MD\1740 be_25\VB\836236 used_26\VBN\1156834 with_27\IN\1740 extreme_28\JJ\1740 caution_29\NN\4662951 in_30\IN\13603305 this_31\DT\1740 setting_32\NN\8567235 ._33\.\1740
3412544
D000082_D014523 NONE does_0\VBZ\1640855 <e1>paracetamol</e1>_1\NN\1740 cause_2\VB\1617192 <e2>urothelial_3\JJ\1740 cancer</e2>_4\NN\14239425 or_5\CC\3541091 renal_6\JJ\1740 papillary_7\NN\1740 necrosis_8\NN\11444117 ?_9\.\1740
D000082_D007681 NONE does_0\VBZ\1640855 <e1>paracetamol</e1>_1\NN\1740 cause_2\VB\1617192 urothelial_3\JJ\1740 cancer_4\NN\14239425 or_5\CC\3541091 <e2>renal_6\JJ\1740 papillary_7\NN\1740 necrosis</e2>_8\NN\11444117 ?_9\.\1740
D000082_D007681 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 developing_3\VBG\1753788 <e2>renal_4\JJ\1740 papillary_5\NN\1740 necrosis</e2>_6\NN\11444117 or_7\CC\3541091 cancer_8\NN\14239425 of_9\IN\1740 the_10\DT\1740 renal_11\JJ\1740 pelvis_12\NNS\5578911 ,_13\,\1740 ureter_14\NN\5250659 or_15\CC\3541091 bladder_16\NN\5515670 associated_17\VBN\628491 with_18\IN\1740 consumption_19\NN\13440063 of_20\IN\1740 either_21\CC\1740 phenacetin_22\NN\2707683 or_23\CC\3541091 <e1>paracetamol</e1>_24\NN\1740 was_25\VBD\836236 calculated_26\VBN\632627 from_27\IN\1740 data_28\NNS\7951464 acquired_29\VBN\109660 by_30\IN\1740 questionnaire_31\NN\6473563 from_32\IN\1740 381_33\CD\1740 cases_34\NNS\7283608 and_35\CC\1740 808_36\CD\1740 controls_37\NNS\5190804 ._38\.\1740
D000082_D007681 NONE by_0\IN\1740 contrast_1\NN\13854649 ,_2\,\1740 we_3\PRP\1740 were_4\VBD\836236 unable_5\JJ\1740 to_6\TO\1740 substantiate_7\VB\2604760 an_8\DT\6697703 increased_9\VBN\169651 risk_10\NN\14541044 from_11\IN\1740 <e1>paracetamol</e1>_12\NN\1740 consumption_13\NN\13440063 for_14\IN\1740 <e2>renal_15\JJ\1740 papillary_16\NN\1740 necrosis</e2>_17\NN\11444117 or_18\CC\3541091 any_19\DT\1740 of_20\IN\1740 these_21\DT\1740 cancers_22\NNS\14239425 although_23\IN\1740 there_24\EX\27167 was_25\VBD\836236 a_26\DT\13649268 suggestion_27\NN\5833840 of_28\IN\1740 an_29\DT\6697703 association_30\NN\8008335 with_31\IN\1740 cancer_32\NN\14239425 of_33\IN\1740 the_34\DT\1740 ureter_35\NN\5250659 ._36\.\1740
D010615_D007681 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 developing_3\VBG\1753788 <e2>renal_4\JJ\1740 papillary_5\NN\1740 necrosis</e2>_6\NN\11444117 or_7\CC\3541091 cancer_8\NN\14239425 of_9\IN\1740 the_10\DT\1740 renal_11\JJ\1740 pelvis_12\NNS\5578911 ,_13\,\1740 ureter_14\NN\5250659 or_15\CC\3541091 bladder_16\NN\5515670 associated_17\VBN\628491 with_18\IN\1740 consumption_19\NN\13440063 of_20\IN\1740 either_21\CC\1740 <e1>phenacetin</e1>_22\NN\2707683 or_23\CC\3541091 paracetamol_24\NN\1740 was_25\VBD\836236 calculated_26\VBN\632627 from_27\IN\1740 data_28\NNS\7951464 acquired_29\VBN\109660 by_30\IN\1740 questionnaire_31\NN\6473563 from_32\IN\1740 381_33\CD\1740 cases_34\NNS\7283608 and_35\CC\1740 808_36\CD\1740 controls_37\NNS\5190804 ._38\.\1740
D010615_D007681 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 <e2>renal_3\JJ\1740 papillary_4\NN\1740 necrosis</e2>_5\NN\11444117 was_6\VBD\836236 increased_7\VBN\169651 nearly_8\RB\1740 20-fold_9\RB\1740 by_10\IN\1740 consumption_11\NN\13440063 of_12\IN\1740 <e1>phenacetin</e1>_13\NN\2707683 ,_14\,\1740 which_15\WDT\1740 also_16\RB\1740 increased_17\VBD\169651 the_18\DT\1740 risk_19\NN\14541044 for_20\IN\1740 cancer_21\NN\14239425 of_22\IN\1740 the_23\DT\1740 renal_24\JJ\1740 pelvis_25\NN\5578911 and_26\CC\1740 bladder_27\NN\5515670 but_28\CC\1740 not_29\RB\1740 for_30\IN\1740 ureteric_31\JJ\1740 cancer_32\NN\14239425 ._33\.\1740
D010615_D007680 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 renal_3\JJ\1740 papillary_4\NN\1740 necrosis_5\NN\11444117 was_6\VBD\836236 increased_7\VBN\169651 nearly_8\RB\1740 20-fold_9\RB\1740 by_10\IN\1740 consumption_11\NN\13440063 of_12\IN\1740 <e1>phenacetin</e1>_13\NN\2707683 ,_14\,\1740 which_15\WDT\1740 also_16\RB\1740 increased_17\VBD\169651 the_18\DT\1740 risk_19\NN\14541044 for_20\IN\1740 <e2>cancer_21\NN\14239425 of_22\IN\1740 the_23\DT\1740 renal_24\JJ\1740 pelvis_25\NN\5578911 and_26\CC\1740 bladder</e2>_27\NN\5515670 but_28\CC\1740 not_29\RB\1740 for_30\IN\1740 ureteric_31\JJ\1740 cancer_32\NN\14239425 ._33\.\1740
D010615_D007680 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 developing_3\VBG\1753788 renal_4\JJ\1740 papillary_5\NN\1740 necrosis_6\NN\11444117 or_7\CC\3541091 <e2>cancer_8\NN\14239425 of_9\IN\1740 the_10\DT\1740 renal_11\JJ\1740 pelvis_12\NNS\5578911 ,_13\,\1740 ureter_14\NN\5250659 or_15\CC\3541091 bladder</e2>_16\NN\5515670 associated_17\VBN\628491 with_18\IN\1740 consumption_19\NN\13440063 of_20\IN\1740 either_21\CC\1740 <e1>phenacetin</e1>_22\NN\2707683 or_23\CC\3541091 paracetamol_24\NN\1740 was_25\VBD\836236 calculated_26\VBN\632627 from_27\IN\1740 data_28\NNS\7951464 acquired_29\VBN\109660 by_30\IN\1740 questionnaire_31\NN\6473563 from_32\IN\1740 381_33\CD\1740 cases_34\NNS\7283608 and_35\CC\1740 808_36\CD\1740 controls_37\NNS\5190804 ._38\.\1740
D010615_D014516 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 developing_3\VBG\1753788 renal_4\JJ\1740 papillary_5\NN\1740 necrosis_6\NN\11444117 or_7\CC\3541091 <e2>cancer_8\NN\14239425 of_9\IN\1740 the_10\DT\1740 renal_11\JJ\1740 pelvis_12\NNS\5578911 ,_13\,\1740 ureter_14\NN\5250659 or_15\CC\3541091 bladder</e2>_16\NN\5515670 associated_17\VBN\628491 with_18\IN\1740 consumption_19\NN\13440063 of_20\IN\1740 either_21\CC\1740 <e1>phenacetin</e1>_22\NN\2707683 or_23\CC\3541091 paracetamol_24\NN\1740 was_25\VBD\836236 calculated_26\VBN\632627 from_27\IN\1740 data_28\NNS\7951464 acquired_29\VBN\109660 by_30\IN\1740 questionnaire_31\NN\6473563 from_32\IN\1740 381_33\CD\1740 cases_34\NNS\7283608 and_35\CC\1740 808_36\CD\1740 controls_37\NNS\5190804 ._38\.\1740
D010615_D014516 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 renal_3\JJ\1740 papillary_4\NN\1740 necrosis_5\NN\11444117 was_6\VBD\836236 increased_7\VBN\169651 nearly_8\RB\1740 20-fold_9\RB\1740 by_10\IN\1740 consumption_11\NN\13440063 of_12\IN\1740 <e1>phenacetin</e1>_13\NN\2707683 ,_14\,\1740 which_15\WDT\1740 also_16\RB\1740 increased_17\VBD\169651 the_18\DT\1740 risk_19\NN\14541044 for_20\IN\1740 cancer_21\NN\14239425 of_22\IN\1740 the_23\DT\1740 renal_24\JJ\1740 pelvis_25\NN\5578911 and_26\CC\1740 bladder_27\NN\5515670 but_28\CC\1740 not_29\RB\1740 for_30\IN\1740 <e2>ureteric_31\JJ\1740 cancer</e2>_32\NN\14239425 ._33\.\1740
D010615_D001749 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 renal_3\JJ\1740 papillary_4\NN\1740 necrosis_5\NN\11444117 was_6\VBD\836236 increased_7\VBN\169651 nearly_8\RB\1740 20-fold_9\RB\1740 by_10\IN\1740 consumption_11\NN\13440063 of_12\IN\1740 <e1>phenacetin</e1>_13\NN\2707683 ,_14\,\1740 which_15\WDT\1740 also_16\RB\1740 increased_17\VBD\169651 the_18\DT\1740 risk_19\NN\14541044 for_20\IN\1740 <e2>cancer_21\NN\14239425 of_22\IN\1740 the_23\DT\1740 renal_24\JJ\1740 pelvis_25\NN\5578911 and_26\CC\1740 bladder</e2>_27\NN\5515670 but_28\CC\1740 not_29\RB\1740 for_30\IN\1740 ureteric_31\JJ\1740 cancer_32\NN\14239425 ._33\.\1740
D010615_D001749 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 developing_3\VBG\1753788 renal_4\JJ\1740 papillary_5\NN\1740 necrosis_6\NN\11444117 or_7\CC\3541091 <e2>cancer_8\NN\14239425 of_9\IN\1740 the_10\DT\1740 renal_11\JJ\1740 pelvis_12\NNS\5578911 ,_13\,\1740 ureter_14\NN\5250659 or_15\CC\3541091 bladder</e2>_16\NN\5515670 associated_17\VBN\628491 with_18\IN\1740 consumption_19\NN\13440063 of_20\IN\1740 either_21\CC\1740 <e1>phenacetin</e1>_22\NN\2707683 or_23\CC\3541091 paracetamol_24\NN\1740 was_25\VBD\836236 calculated_26\VBN\632627 from_27\IN\1740 data_28\NNS\7951464 acquired_29\VBN\109660 by_30\IN\1740 questionnaire_31\NN\6473563 from_32\IN\1740 381_33\CD\1740 cases_34\NNS\7283608 and_35\CC\1740 808_36\CD\1740 controls_37\NNS\5190804 ._38\.\1740
D000082_D007680 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 developing_3\VBG\1753788 renal_4\JJ\1740 papillary_5\NN\1740 necrosis_6\NN\11444117 or_7\CC\3541091 <e2>cancer_8\NN\14239425 of_9\IN\1740 the_10\DT\1740 renal_11\JJ\1740 pelvis_12\NNS\5578911 ,_13\,\1740 ureter_14\NN\5250659 or_15\CC\3541091 bladder</e2>_16\NN\5515670 associated_17\VBN\628491 with_18\IN\1740 consumption_19\NN\13440063 of_20\IN\1740 either_21\CC\1740 phenacetin_22\NN\2707683 or_23\CC\3541091 <e1>paracetamol</e1>_24\NN\1740 was_25\VBD\836236 calculated_26\VBN\632627 from_27\IN\1740 data_28\NNS\7951464 acquired_29\VBN\109660 by_30\IN\1740 questionnaire_31\NN\6473563 from_32\IN\1740 381_33\CD\1740 cases_34\NNS\7283608 and_35\CC\1740 808_36\CD\1740 controls_37\NNS\5190804 ._38\.\1740
D000082_D014516 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 developing_3\VBG\1753788 renal_4\JJ\1740 papillary_5\NN\1740 necrosis_6\NN\11444117 or_7\CC\3541091 <e2>cancer_8\NN\14239425 of_9\IN\1740 the_10\DT\1740 renal_11\JJ\1740 pelvis_12\NNS\5578911 ,_13\,\1740 ureter_14\NN\5250659 or_15\CC\3541091 bladder</e2>_16\NN\5515670 associated_17\VBN\628491 with_18\IN\1740 consumption_19\NN\13440063 of_20\IN\1740 either_21\CC\1740 phenacetin_22\NN\2707683 or_23\CC\3541091 <e1>paracetamol</e1>_24\NN\1740 was_25\VBD\836236 calculated_26\VBN\632627 from_27\IN\1740 data_28\NNS\7951464 acquired_29\VBN\109660 by_30\IN\1740 questionnaire_31\NN\6473563 from_32\IN\1740 381_33\CD\1740 cases_34\NNS\7283608 and_35\CC\1740 808_36\CD\1740 controls_37\NNS\5190804 ._38\.\1740
D000082_D014516 NONE by_0\IN\1740 contrast_1\NN\13854649 ,_2\,\1740 we_3\PRP\1740 were_4\VBD\836236 unable_5\JJ\1740 to_6\TO\1740 substantiate_7\VB\2604760 an_8\DT\6697703 increased_9\VBN\169651 risk_10\NN\14541044 from_11\IN\1740 <e1>paracetamol</e1>_12\NN\1740 consumption_13\NN\13440063 for_14\IN\1740 renal_15\JJ\1740 papillary_16\NN\1740 necrosis_17\NN\11444117 or_18\CC\3541091 any_19\DT\1740 of_20\IN\1740 these_21\DT\1740 cancers_22\NNS\14239425 although_23\IN\1740 there_24\EX\27167 was_25\VBD\836236 a_26\DT\13649268 suggestion_27\NN\5833840 of_28\IN\1740 an_29\DT\6697703 association_30\NN\8008335 with_31\IN\1740 <e2>cancer_32\NN\14239425 of_33\IN\1740 the_34\DT\1740 ureter</e2>_35\NN\5250659 ._36\.\1740
D000082_D001749 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 developing_3\VBG\1753788 renal_4\JJ\1740 papillary_5\NN\1740 necrosis_6\NN\11444117 or_7\CC\3541091 <e2>cancer_8\NN\14239425 of_9\IN\1740 the_10\DT\1740 renal_11\JJ\1740 pelvis_12\NNS\5578911 ,_13\,\1740 ureter_14\NN\5250659 or_15\CC\3541091 bladder</e2>_16\NN\5515670 associated_17\VBN\628491 with_18\IN\1740 consumption_19\NN\13440063 of_20\IN\1740 either_21\CC\1740 phenacetin_22\NN\2707683 or_23\CC\3541091 <e1>paracetamol</e1>_24\NN\1740 was_25\VBD\836236 calculated_26\VBN\632627 from_27\IN\1740 data_28\NNS\7951464 acquired_29\VBN\109660 by_30\IN\1740 questionnaire_31\NN\6473563 from_32\IN\1740 381_33\CD\1740 cases_34\NNS\7283608 and_35\CC\1740 808_36\CD\1740 controls_37\NNS\5190804 ._38\.\1740
D000082_D009369 NONE by_0\IN\1740 contrast_1\NN\13854649 ,_2\,\1740 we_3\PRP\1740 were_4\VBD\836236 unable_5\JJ\1740 to_6\TO\1740 substantiate_7\VB\2604760 an_8\DT\6697703 increased_9\VBN\169651 risk_10\NN\14541044 from_11\IN\1740 <e1>paracetamol</e1>_12\NN\1740 consumption_13\NN\13440063 for_14\IN\1740 renal_15\JJ\1740 papillary_16\NN\1740 necrosis_17\NN\11444117 or_18\CC\3541091 any_19\DT\1740 of_20\IN\1740 these_21\DT\1740 <e2>cancers</e2>_22\NNS\14239425 although_23\IN\1740 there_24\EX\27167 was_25\VBD\836236 a_26\DT\13649268 suggestion_27\NN\5833840 of_28\IN\1740 an_29\DT\6697703 association_30\NN\8008335 with_31\IN\1740 cancer_32\NN\14239425 of_33\IN\1740 the_34\DT\1740 ureter_35\NN\5250659 ._36\.\1740
9862868
D004997_D002780 CID we_0\PRP\1740 used_1\VBD\1156834 rat_2\NN\2329401 models_3\NNS\5888929 of_4\IN\1740 <e2>intrahepatic_5\JJ\1740 cholestasis</e2>_6\NN\14052403 by_7\IN\1740 <e1>ethinyl_8\JJ\1740 estradiol</e1>_9\NN\14749794 (_10\-LRB-\1740 ee_11\NN\6125041 )_12\-RRB-\1740 treatment_13\NN\654885 and_14\CC\1740 extrahepatic_15\JJ\1740 cholestasis_16\NN\14052403 by_17\IN\1740 bile_18\NN\5405946 duct_19\NN\5248181 ligation_20\NN\149084 (_21\-LRB-\1740 bdl_22\NN\1740 )_23\-RRB-\1740 to_24\TO\1740 precisely_25\RB\1740 determine_26\VB\1645601 the_27\DT\1740 site_28\NN\8673395 of_29\IN\1740 tj_30\NN\1740 damage_31\NN\7296428 ._32\.\1740
D004997_D002780 CID we_0\PRP\1740 used_1\VBD\1156834 rat_2\NN\2329401 models_3\NNS\5888929 of_4\IN\1740 <e2>intrahepatic_5\JJ\1740 cholestasis</e2>_6\NN\14052403 by_7\IN\1740 ethinyl_8\JJ\1740 estradiol_9\NN\14749794 (_10\-LRB-\1740 <e1>ee</e1>_11\NN\6125041 )_12\-RRB-\1740 treatment_13\NN\654885 and_14\CC\1740 extrahepatic_15\JJ\1740 cholestasis_16\NN\14052403 by_17\IN\1740 bile_18\NN\5405946 duct_19\NN\5248181 ligation_20\NN\149084 (_21\-LRB-\1740 bdl_22\NN\1740 )_23\-RRB-\1740 to_24\TO\1740 precisely_25\RB\1740 determine_26\VB\1645601 the_27\DT\1740 site_28\NN\8673395 of_29\IN\1740 tj_30\NN\1740 damage_31\NN\7296428 ._32\.\1740
D004997_D001651 NONE we_0\PRP\1740 used_1\VBD\1156834 rat_2\NN\2329401 models_3\NNS\5888929 of_4\IN\1740 intrahepatic_5\JJ\1740 cholestasis_6\NN\14052403 by_7\IN\1740 <e1>ethinyl_8\JJ\1740 estradiol</e1>_9\NN\14749794 (_10\-LRB-\1740 ee_11\NN\6125041 )_12\-RRB-\1740 treatment_13\NN\654885 and_14\CC\1740 <e2>extrahepatic_15\JJ\1740 cholestasis</e2>_16\NN\14052403 by_17\IN\1740 bile_18\NN\5405946 duct_19\NN\5248181 ligation_20\NN\149084 (_21\-LRB-\1740 bdl_22\NN\1740 )_23\-RRB-\1740 to_24\TO\1740 precisely_25\RB\1740 determine_26\VB\1645601 the_27\DT\1740 site_28\NN\8673395 of_29\IN\1740 tj_30\NN\1740 damage_31\NN\7296428 ._32\.\1740
D004997_D001651 NONE we_0\PRP\1740 used_1\VBD\1156834 rat_2\NN\2329401 models_3\NNS\5888929 of_4\IN\1740 intrahepatic_5\JJ\1740 cholestasis_6\NN\14052403 by_7\IN\1740 ethinyl_8\JJ\1740 estradiol_9\NN\14749794 (_10\-LRB-\1740 <e1>ee</e1>_11\NN\6125041 )_12\-RRB-\1740 treatment_13\NN\654885 and_14\CC\1740 <e2>extrahepatic_15\JJ\1740 cholestasis</e2>_16\NN\14052403 by_17\IN\1740 bile_18\NN\5405946 duct_19\NN\5248181 ligation_20\NN\149084 (_21\-LRB-\1740 bdl_22\NN\1740 )_23\-RRB-\1740 to_24\TO\1740 precisely_25\RB\1740 determine_26\VB\1645601 the_27\DT\1740 site_28\NN\8673395 of_29\IN\1740 tj_30\NN\1740 damage_31\NN\7296428 ._32\.\1740
2008831
D008755_D000788 NONE effect_0\NN\34213 of_1\IN\1740 direct_2\JJ\1740 intracoronary_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>methylergonovine</e1>_6\NN\1740 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 and_10\CC\1740 without_11\IN\1740 <e2>variant_12\JJ\1740 angina</e2>_13\NN\14171682 ._14\.\1740
D008755_D000788 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 intracoronary_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>methylergonovine</e1>_6\NN\1740 were_7\VBD\836236 studied_8\VBN\630380 in_9\IN\13603305 21_10\CD\13745420 patients_11\NNS\9898892 with_12\IN\1740 <e2>variant_13\JJ\1740 angina</e2>_14\NN\14171682 and_15\CC\1740 22_16\CD\13745420 patients_17\NNS\9898892 with_18\IN\1740 atypical_19\JJ\1740 chest_20\NN\5220461 pain_21\NN\14299637 and_22\CC\1740 in_23\IN\13603305 others_24\NNS\1740 without_25\IN\1740 angina_26\JJ\1740 pectoris_27\NN\1740 (_28\-LRB-\1740 control_29\NN\5190804 group_30\NN\2137 )_31\-RRB-\1740 ._32\.\1740
D008755_D000788 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 spasm_4\NN\14299637 provocation_5\NN\1221611 tests_6\NNS\5798043 ,_7\,\1740 which_8\WDT\1740 use_9\VBP\1156834 an_10\DT\6697703 intracoronary_11\JJ\1740 injection_12\NN\320852 of_13\IN\1740 a_14\DT\13649268 relatively_15\RB\1740 low_16\JJ\1740 dose_17\NN\3740161 of_18\IN\1740 <e1>methylergonovine</e1>_19\NN\1740 ,_20\,\1740 have_21\VBP\2108377 a_22\DT\13649268 high_23\JJ\1740 sensitivity_24\NN\5651971 in_25\IN\13603305 <e2>variant_26\JJ\1740 angina</e2>_27\NN\14171682 and_28\CC\1740 the_29\DT\1740 vasoreactivity_30\NN\1740 of_31\IN\1740 the_32\DT\1740 right_33\JJ\1740 coronary_34\JJ\1740 artery_35\NN\5417975 may_36\MD\15209706 be_37\VB\836236 greater_38\JJR\1740 than_39\IN\1740 that_40\DT\1740 of_41\IN\1740 the_42\DT\1740 other_43\JJ\1740 coronary_44\JJ\1740 arteries_45\NNS\5417975 ._46\.\1740
D008755_D002637 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 intracoronary_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>methylergonovine</e1>_6\NN\1740 were_7\VBD\836236 studied_8\VBN\630380 in_9\IN\13603305 21_10\CD\13745420 patients_11\NNS\9898892 with_12\IN\1740 variant_13\JJ\1740 angina_14\NN\14171682 and_15\CC\1740 22_16\CD\13745420 patients_17\NNS\9898892 with_18\IN\1740 atypical_19\JJ\1740 <e2>chest_20\NN\5220461 pain</e2>_21\NN\14299637 and_22\CC\1740 in_23\IN\13603305 others_24\NNS\1740 without_25\IN\1740 angina_26\JJ\1740 pectoris_27\NN\1740 (_28\-LRB-\1740 control_29\NN\5190804 group_30\NN\2137 )_31\-RRB-\1740 ._32\.\1740
D008755_D000787 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 intracoronary_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>methylergonovine</e1>_6\NN\1740 were_7\VBD\836236 studied_8\VBN\630380 in_9\IN\13603305 21_10\CD\13745420 patients_11\NNS\9898892 with_12\IN\1740 variant_13\JJ\1740 angina_14\NN\14171682 and_15\CC\1740 22_16\CD\13745420 patients_17\NNS\9898892 with_18\IN\1740 atypical_19\JJ\1740 chest_20\NN\5220461 pain_21\NN\14299637 and_22\CC\1740 in_23\IN\13603305 others_24\NNS\1740 without_25\IN\1740 <e2>angina_26\JJ\1740 pectoris</e2>_27\NN\1740 (_28\-LRB-\1740 control_29\NN\5190804 group_30\NN\2137 )_31\-RRB-\1740 ._32\.\1740
D008755_D013035 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e2>spasm</e2>_4\NN\14299637 provocation_5\NN\1221611 tests_6\NNS\5798043 ,_7\,\1740 which_8\WDT\1740 use_9\VBP\1156834 an_10\DT\6697703 intracoronary_11\JJ\1740 injection_12\NN\320852 of_13\IN\1740 a_14\DT\13649268 relatively_15\RB\1740 low_16\JJ\1740 dose_17\NN\3740161 of_18\IN\1740 <e1>methylergonovine</e1>_19\NN\1740 ,_20\,\1740 have_21\VBP\2108377 a_22\DT\13649268 high_23\JJ\1740 sensitivity_24\NN\5651971 in_25\IN\13603305 variant_26\JJ\1740 angina_27\NN\14171682 and_28\CC\1740 the_29\DT\1740 vasoreactivity_30\NN\1740 of_31\IN\1740 the_32\DT\1740 right_33\JJ\1740 coronary_34\JJ\1740 artery_35\NN\5417975 may_36\MD\15209706 be_37\VB\836236 greater_38\JJR\1740 than_39\IN\1740 that_40\DT\1740 of_41\IN\1740 the_42\DT\1740 other_43\JJ\1740 coronary_44\JJ\1740 arteries_45\NNS\5417975 ._46\.\1740
17020434
D014859_D020521 NONE pooled_0\JJ\1740 data_1\NNS\7951464 from_2\IN\1740 trials_3\NNS\786195 comparing_4\VBG\644583 antithrombotic_5\JJ\1740 treatment_6\NN\654885 with_7\IN\1740 placebo_8\NN\3740161 have_9\VBP\2108377 shown_10\VBN\2137132 that_11\IN\1740 <e1>warfarin</e1>_12\NN\2718259 reduces_13\VBZ\441445 the_14\DT\1740 risk_15\NN\14541044 of_16\IN\1740 <e2>stroke</e2>_17\NN\556313 by_18\IN\1740 62_19\CD\1740 %_20\NN\1740 ,_21\,\1740 and_22\CC\1740 that_23\IN\1740 aspirin_24\NN\2707683 alone_25\RB\1740 reduces_26\VBZ\441445 the_27\DT\1740 risk_28\NN\14541044 by_29\IN\1740 22_30\CD\13745420 %_31\NN\1740 ._32\.\1740
D014859_D020521 NONE overall_0\RB\1740 ,_1\,\1740 in_2\IN\13603305 high-risk_3\JJ\1740 patients_4\NNS\9898892 ,_5\,\1740 <e1>warfarin</e1>_6\NN\2718259 is_7\VBZ\836236 superior_8\JJ\1740 to_9\TO\1740 aspirin_10\NN\2707683 in_11\IN\13603305 preventing_12\VBG\1740 <e2>strokes</e2>_13\NNS\556313 ,_14\,\1740 with_15\IN\1740 a_16\DT\13649268 relative_17\JJ\1740 risk_18\NN\14541044 reduction_19\NN\351485 of_20\IN\1740 36_21\CD\1740 %_22\NN\1740 ._23\.\1740
D001241_D020521 NONE pooled_0\JJ\1740 data_1\NNS\7951464 from_2\IN\1740 trials_3\NNS\786195 comparing_4\VBG\644583 antithrombotic_5\JJ\1740 treatment_6\NN\654885 with_7\IN\1740 placebo_8\NN\3740161 have_9\VBP\2108377 shown_10\VBN\2137132 that_11\IN\1740 warfarin_12\NN\2718259 reduces_13\VBZ\441445 the_14\DT\1740 risk_15\NN\14541044 of_16\IN\1740 <e2>stroke</e2>_17\NN\556313 by_18\IN\1740 62_19\CD\1740 %_20\NN\1740 ,_21\,\1740 and_22\CC\1740 that_23\IN\1740 <e1>aspirin</e1>_24\NN\2707683 alone_25\RB\1740 reduces_26\VBZ\441445 the_27\DT\1740 risk_28\NN\14541044 by_29\IN\1740 22_30\CD\13745420 %_31\NN\1740 ._32\.\1740
D001241_D020521 NONE overall_0\RB\1740 ,_1\,\1740 in_2\IN\13603305 high-risk_3\JJ\1740 patients_4\NNS\9898892 ,_5\,\1740 warfarin_6\NN\2718259 is_7\VBZ\836236 superior_8\JJ\1740 to_9\TO\1740 <e1>aspirin</e1>_10\NN\2707683 in_11\IN\13603305 preventing_12\VBG\1740 <e2>strokes</e2>_13\NNS\556313 ,_14\,\1740 with_15\IN\1740 a_16\DT\13649268 relative_17\JJ\1740 risk_18\NN\14541044 reduction_19\NN\351485 of_20\IN\1740 36_21\CD\1740 %_22\NN\1740 ._23\.\1740
C426686_D004617 NONE <e1>ximelagatran</e1>_0\NNP\1740 ,_1\,\1740 an_2\DT\6697703 oral_3\JJ\1740 direct_4\JJ\1740 thrombin_5\NN\14735953 inhibitor_6\NN\20090 ,_7\,\1740 was_8\VBD\836236 found_9\VBN\2426171 to_10\TO\1740 be_11\VB\836236 as_12\RB\1740 efficient_13\JJ\1740 as_14\IN\14622893 vitamin_15\NN\7570720 k_16\NN\13608598 antagonist_17\NN\7846 drugs_18\NNS\14778436 in_19\IN\13603305 the_20\DT\1740 prevention_21\NN\1073995 of_22\IN\1740 <e2>embolic_23\JJ\1740 events</e2>_24\NNS\23100 ,_25\,\1740 but_26\CC\1740 has_27\VBZ\2108377 been_28\VBN\836236 recently_29\RB\1740 withdrawn_30\VBN\1835496 because_31\IN\1740 of_32\IN\1740 abnormal_33\JJ\1740 liver_34\NN\5298729 function_35\NN\13783581 tests_36\NNS\5798043 ._37\.\1740
C426686_D056486 CID <e1>ximelagatran</e1>_0\NNP\1740 ,_1\,\1740 an_2\DT\6697703 oral_3\JJ\1740 direct_4\JJ\1740 thrombin_5\NN\14735953 inhibitor_6\NN\20090 ,_7\,\1740 was_8\VBD\836236 found_9\VBN\2426171 to_10\TO\1740 be_11\VB\836236 as_12\RB\1740 efficient_13\JJ\1740 as_14\IN\14622893 vitamin_15\NN\7570720 k_16\NN\13608598 antagonist_17\NN\7846 drugs_18\NNS\14778436 in_19\IN\13603305 the_20\DT\1740 prevention_21\NN\1073995 of_22\IN\1740 embolic_23\JJ\1740 events_24\NNS\23100 ,_25\,\1740 but_26\CC\1740 has_27\VBZ\2108377 been_28\VBN\836236 recently_29\RB\1740 withdrawn_30\VBN\1835496 because_31\IN\1740 of_32\IN\1740 <e2>abnormal_33\JJ\1740 liver_34\NN\5298729 function</e2>_35\NN\13783581 tests_36\NNS\5798043 ._37\.\1740
D014812_D004617 NONE ximelagatran_0\NNP\1740 ,_1\,\1740 an_2\DT\6697703 oral_3\JJ\1740 direct_4\JJ\1740 thrombin_5\NN\14735953 inhibitor_6\NN\20090 ,_7\,\1740 was_8\VBD\836236 found_9\VBN\2426171 to_10\TO\1740 be_11\VB\836236 as_12\RB\1740 efficient_13\JJ\1740 as_14\IN\14622893 <e1>vitamin_15\NN\7570720 k</e1>_16\NN\13608598 antagonist_17\NN\7846 drugs_18\NNS\14778436 in_19\IN\13603305 the_20\DT\1740 prevention_21\NN\1073995 of_22\IN\1740 <e2>embolic_23\JJ\1740 events</e2>_24\NNS\23100 ,_25\,\1740 but_26\CC\1740 has_27\VBZ\2108377 been_28\VBN\836236 recently_29\RB\1740 withdrawn_30\VBN\1835496 because_31\IN\1740 of_32\IN\1740 abnormal_33\JJ\1740 liver_34\NN\5298729 function_35\NN\13783581 tests_36\NNS\5798043 ._37\.\1740
D014812_D056486 NONE ximelagatran_0\NNP\1740 ,_1\,\1740 an_2\DT\6697703 oral_3\JJ\1740 direct_4\JJ\1740 thrombin_5\NN\14735953 inhibitor_6\NN\20090 ,_7\,\1740 was_8\VBD\836236 found_9\VBN\2426171 to_10\TO\1740 be_11\VB\836236 as_12\RB\1740 efficient_13\JJ\1740 as_14\IN\14622893 <e1>vitamin_15\NN\7570720 k</e1>_16\NN\13608598 antagonist_17\NN\7846 drugs_18\NNS\14778436 in_19\IN\13603305 the_20\DT\1740 prevention_21\NN\1073995 of_22\IN\1740 embolic_23\JJ\1740 events_24\NNS\23100 ,_25\,\1740 but_26\CC\1740 has_27\VBZ\2108377 been_28\VBN\836236 recently_29\RB\1740 withdrawn_30\VBN\1835496 because_31\IN\1740 of_32\IN\1740 <e2>abnormal_33\JJ\1740 liver_34\NN\5298729 function</e2>_35\NN\13783581 tests_36\NNS\5798043 ._37\.\1740
C055162_D001281 NONE the_0\DT\1740 active-w_1\NN\1740 (_2\-LRB-\1740 <e2>atrial_3\NNP\1740 fibrillation</e2>_4\NNP\14361664 <e1>clopidogrel</e1>_5\NNP\1740 trial_6\NNP\786195 with_7\IN\1740 irbesartan_8\NNP\1740 for_9\IN\1740 prevention_10\NN\1073995 of_11\IN\1740 vascular_12\NNP\1740 events_13\NNPS\23100 )_14\-RRB-\1740 study_15\NN\635850 has_16\VBZ\2108377 demonstrated_17\VBN\2137132 that_18\IN\1740 warfarin_19\NN\2718259 is_20\VBZ\836236 superior_21\JJ\1740 to_22\TO\1740 platelet_23\NN\5432736 therapy_24\NN\657604 (_25\-LRB-\1740 clopidogrel_26\NN\1740 plus_27\CC\4723816 aspirin_28\NN\2707683 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 prevention_32\NN\1073995 af_33\IN\1740 embolic_34\JJ\1740 events_35\NNS\23100 ._36\.\1740
C055162_D001281 NONE the_0\DT\1740 active-w_1\NN\1740 (_2\-LRB-\1740 <e2>atrial_3\NNP\1740 fibrillation</e2>_4\NNP\14361664 clopidogrel_5\NNP\1740 trial_6\NNP\786195 with_7\IN\1740 irbesartan_8\NNP\1740 for_9\IN\1740 prevention_10\NN\1073995 of_11\IN\1740 vascular_12\NNP\1740 events_13\NNPS\23100 )_14\-RRB-\1740 study_15\NN\635850 has_16\VBZ\2108377 demonstrated_17\VBN\2137132 that_18\IN\1740 warfarin_19\NN\2718259 is_20\VBZ\836236 superior_21\JJ\1740 to_22\TO\1740 platelet_23\NN\5432736 therapy_24\NN\657604 (_25\-LRB-\1740 <e1>clopidogrel</e1>_26\NN\1740 plus_27\CC\4723816 aspirin_28\NN\2707683 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 prevention_32\NN\1073995 af_33\IN\1740 embolic_34\JJ\1740 events_35\NNS\23100 ._36\.\1740
C055162_D004617 NONE the_0\DT\1740 active-w_1\NN\1740 (_2\-LRB-\1740 atrial_3\NNP\1740 fibrillation_4\NNP\14361664 <e1>clopidogrel</e1>_5\NNP\1740 trial_6\NNP\786195 with_7\IN\1740 irbesartan_8\NNP\1740 for_9\IN\1740 prevention_10\NN\1073995 of_11\IN\1740 vascular_12\NNP\1740 events_13\NNPS\23100 )_14\-RRB-\1740 study_15\NN\635850 has_16\VBZ\2108377 demonstrated_17\VBN\2137132 that_18\IN\1740 warfarin_19\NN\2718259 is_20\VBZ\836236 superior_21\JJ\1740 to_22\TO\1740 platelet_23\NN\5432736 therapy_24\NN\657604 (_25\-LRB-\1740 clopidogrel_26\NN\1740 plus_27\CC\4723816 aspirin_28\NN\2707683 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 prevention_32\NN\1073995 af_33\IN\1740 <e2>embolic_34\JJ\1740 events</e2>_35\NNS\23100 ._36\.\1740
C055162_D004617 NONE the_0\DT\1740 active-w_1\NN\1740 (_2\-LRB-\1740 atrial_3\NNP\1740 fibrillation_4\NNP\14361664 clopidogrel_5\NNP\1740 trial_6\NNP\786195 with_7\IN\1740 irbesartan_8\NNP\1740 for_9\IN\1740 prevention_10\NN\1073995 of_11\IN\1740 vascular_12\NNP\1740 events_13\NNPS\23100 )_14\-RRB-\1740 study_15\NN\635850 has_16\VBZ\2108377 demonstrated_17\VBN\2137132 that_18\IN\1740 warfarin_19\NN\2718259 is_20\VBZ\836236 superior_21\JJ\1740 to_22\TO\1740 platelet_23\NN\5432736 therapy_24\NN\657604 (_25\-LRB-\1740 <e1>clopidogrel</e1>_26\NN\1740 plus_27\CC\4723816 aspirin_28\NN\2707683 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 prevention_32\NN\1073995 af_33\IN\1740 <e2>embolic_34\JJ\1740 events</e2>_35\NNS\23100 ._36\.\1740
C081309_D001281 NONE the_0\DT\1740 active-w_1\NN\1740 (_2\-LRB-\1740 <e2>atrial_3\NNP\1740 fibrillation</e2>_4\NNP\14361664 clopidogrel_5\NNP\1740 trial_6\NNP\786195 with_7\IN\1740 <e1>irbesartan</e1>_8\NNP\1740 for_9\IN\1740 prevention_10\NN\1073995 of_11\IN\1740 vascular_12\NNP\1740 events_13\NNPS\23100 )_14\-RRB-\1740 study_15\NN\635850 has_16\VBZ\2108377 demonstrated_17\VBN\2137132 that_18\IN\1740 warfarin_19\NN\2718259 is_20\VBZ\836236 superior_21\JJ\1740 to_22\TO\1740 platelet_23\NN\5432736 therapy_24\NN\657604 (_25\-LRB-\1740 clopidogrel_26\NN\1740 plus_27\CC\4723816 aspirin_28\NN\2707683 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 prevention_32\NN\1073995 af_33\IN\1740 embolic_34\JJ\1740 events_35\NNS\23100 ._36\.\1740
C081309_D004617 NONE the_0\DT\1740 active-w_1\NN\1740 (_2\-LRB-\1740 atrial_3\NNP\1740 fibrillation_4\NNP\14361664 clopidogrel_5\NNP\1740 trial_6\NNP\786195 with_7\IN\1740 <e1>irbesartan</e1>_8\NNP\1740 for_9\IN\1740 prevention_10\NN\1073995 of_11\IN\1740 vascular_12\NNP\1740 events_13\NNPS\23100 )_14\-RRB-\1740 study_15\NN\635850 has_16\VBZ\2108377 demonstrated_17\VBN\2137132 that_18\IN\1740 warfarin_19\NN\2718259 is_20\VBZ\836236 superior_21\JJ\1740 to_22\TO\1740 platelet_23\NN\5432736 therapy_24\NN\657604 (_25\-LRB-\1740 clopidogrel_26\NN\1740 plus_27\CC\4723816 aspirin_28\NN\2707683 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 prevention_32\NN\1073995 af_33\IN\1740 <e2>embolic_34\JJ\1740 events</e2>_35\NNS\23100 ._36\.\1740
D014859_D001281 NONE the_0\DT\1740 active-w_1\NN\1740 (_2\-LRB-\1740 <e2>atrial_3\NNP\1740 fibrillation</e2>_4\NNP\14361664 clopidogrel_5\NNP\1740 trial_6\NNP\786195 with_7\IN\1740 irbesartan_8\NNP\1740 for_9\IN\1740 prevention_10\NN\1073995 of_11\IN\1740 vascular_12\NNP\1740 events_13\NNPS\23100 )_14\-RRB-\1740 study_15\NN\635850 has_16\VBZ\2108377 demonstrated_17\VBN\2137132 that_18\IN\1740 <e1>warfarin</e1>_19\NN\2718259 is_20\VBZ\836236 superior_21\JJ\1740 to_22\TO\1740 platelet_23\NN\5432736 therapy_24\NN\657604 (_25\-LRB-\1740 clopidogrel_26\NN\1740 plus_27\CC\4723816 aspirin_28\NN\2707683 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 prevention_32\NN\1073995 af_33\IN\1740 embolic_34\JJ\1740 events_35\NNS\23100 ._36\.\1740
D014859_D004617 NONE the_0\DT\1740 active-w_1\NN\1740 (_2\-LRB-\1740 atrial_3\NNP\1740 fibrillation_4\NNP\14361664 clopidogrel_5\NNP\1740 trial_6\NNP\786195 with_7\IN\1740 irbesartan_8\NNP\1740 for_9\IN\1740 prevention_10\NN\1073995 of_11\IN\1740 vascular_12\NNP\1740 events_13\NNPS\23100 )_14\-RRB-\1740 study_15\NN\635850 has_16\VBZ\2108377 demonstrated_17\VBN\2137132 that_18\IN\1740 <e1>warfarin</e1>_19\NN\2718259 is_20\VBZ\836236 superior_21\JJ\1740 to_22\TO\1740 platelet_23\NN\5432736 therapy_24\NN\657604 (_25\-LRB-\1740 clopidogrel_26\NN\1740 plus_27\CC\4723816 aspirin_28\NN\2707683 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 prevention_32\NN\1073995 af_33\IN\1740 <e2>embolic_34\JJ\1740 events</e2>_35\NNS\23100 ._36\.\1740
D001241_D001281 NONE the_0\DT\1740 active-w_1\NN\1740 (_2\-LRB-\1740 <e2>atrial_3\NNP\1740 fibrillation</e2>_4\NNP\14361664 clopidogrel_5\NNP\1740 trial_6\NNP\786195 with_7\IN\1740 irbesartan_8\NNP\1740 for_9\IN\1740 prevention_10\NN\1073995 of_11\IN\1740 vascular_12\NNP\1740 events_13\NNPS\23100 )_14\-RRB-\1740 study_15\NN\635850 has_16\VBZ\2108377 demonstrated_17\VBN\2137132 that_18\IN\1740 warfarin_19\NN\2718259 is_20\VBZ\836236 superior_21\JJ\1740 to_22\TO\1740 platelet_23\NN\5432736 therapy_24\NN\657604 (_25\-LRB-\1740 clopidogrel_26\NN\1740 plus_27\CC\4723816 <e1>aspirin</e1>_28\NN\2707683 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 prevention_32\NN\1073995 af_33\IN\1740 embolic_34\JJ\1740 events_35\NNS\23100 ._36\.\1740
D001241_D004617 NONE the_0\DT\1740 active-w_1\NN\1740 (_2\-LRB-\1740 atrial_3\NNP\1740 fibrillation_4\NNP\14361664 clopidogrel_5\NNP\1740 trial_6\NNP\786195 with_7\IN\1740 irbesartan_8\NNP\1740 for_9\IN\1740 prevention_10\NN\1073995 of_11\IN\1740 vascular_12\NNP\1740 events_13\NNPS\23100 )_14\-RRB-\1740 study_15\NN\635850 has_16\VBZ\2108377 demonstrated_17\VBN\2137132 that_18\IN\1740 warfarin_19\NN\2718259 is_20\VBZ\836236 superior_21\JJ\1740 to_22\TO\1740 platelet_23\NN\5432736 therapy_24\NN\657604 (_25\-LRB-\1740 clopidogrel_26\NN\1740 plus_27\CC\4723816 <e1>aspirin</e1>_28\NN\2707683 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 prevention_32\NN\1073995 af_33\IN\1740 <e2>embolic_34\JJ\1740 events</e2>_35\NNS\23100 ._36\.\1740
C479958_D001281 NONE <e1>idraparinux</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 factor_3\NN\7326557 xa_4\NN\1740 inhibitor_5\NN\20090 ,_6\,\1740 is_7\VBZ\836236 being_8\VBG\836236 evaluated_9\VBN\670261 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 <e2>atrial_13\JJ\1740 fibrillation</e2>_14\NN\14361664 ._15\.\1740
D000809_D001281 NONE <e1>angiotensin-converting</e1>_0\JJ\1740 enzyme_1\NN\14723628 inhibitors_2\NNS\20090 and_3\CC\1740 angiotensin_4\NN\4522421 ii_5\CD\13741022 receptor-blocking_6\JJ\1740 drugs_7\NNS\14778436 hold_8\VBP\2439501 promise_9\NN\6684383 in_10\IN\13603305 <e2>atrial_11\JJ\1740 fibrillation</e2>_12\NN\14361664 through_13\IN\1740 cardiac_14\JJ\1740 remodelling_15\NN\1740 ._16\.\1740
D000809_D020257 NONE <e1>angiotensin-converting</e1>_0\JJ\1740 enzyme_1\NN\14723628 inhibitors_2\NNS\20090 and_3\CC\1740 angiotensin_4\NN\4522421 ii_5\CD\13741022 receptor-blocking_6\JJ\1740 drugs_7\NNS\14778436 hold_8\VBP\2439501 promise_9\NN\6684383 in_10\IN\13603305 atrial_11\JJ\1740 fibrillation_12\NN\14361664 through_13\IN\1740 <e2>cardiac_14\JJ\1740 remodelling</e2>_15\NN\1740 ._16\.\1740
D000804_D001281 NONE angiotensin-converting_0\JJ\1740 enzyme_1\NN\14723628 inhibitors_2\NNS\20090 and_3\CC\1740 <e1>angiotensin_4\NN\4522421 ii</e1>_5\CD\13741022 receptor-blocking_6\JJ\1740 drugs_7\NNS\14778436 hold_8\VBP\2439501 promise_9\NN\6684383 in_10\IN\13603305 <e2>atrial_11\JJ\1740 fibrillation</e2>_12\NN\14361664 through_13\IN\1740 cardiac_14\JJ\1740 remodelling_15\NN\1740 ._16\.\1740
D000804_D020257 NONE angiotensin-converting_0\JJ\1740 enzyme_1\NN\14723628 inhibitors_2\NNS\20090 and_3\CC\1740 <e1>angiotensin_4\NN\4522421 ii</e1>_5\CD\13741022 receptor-blocking_6\JJ\1740 drugs_7\NNS\14778436 hold_8\VBP\2439501 promise_9\NN\6684383 in_10\IN\13603305 atrial_11\JJ\1740 fibrillation_12\NN\14361664 through_13\IN\1740 <e2>cardiac_14\JJ\1740 remodelling</e2>_15\NN\1740 ._16\.\1740
11745184
D002945_D001943 NONE a_0\DT\13649268 phase_1\NN\15113229 ii_2\CD\13741022 trial_3\NN\786195 of_4\IN\1740 <e1>cisplatin</e1>_5\NN\1740 plus_6\CC\4723816 wr-2721_7\JJ\1740 (_8\-LRB-\1740 amifostine_9\NN\1740 )_10\-RRB-\1740 for_11\IN\1740 metastatic_12\JJ\1740 <e2>breast_13\NN\5225090 carcinoma</e2>_14\NN\14239918 :_15\:\1740 an_16\DT\6697703 eastern_17\JJ\1740 cooperative_18\JJ\1740 oncology_19\NN\6043075 group_20\NNP\2137 study_21\NN\635850 (_22\-LRB-\1740 e8188_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D002945_D001943 NONE background_0\NN\4921011 :_1\:\1740 <e1>cisplatin</e1>_2\NNP\1740 has_3\VBZ\2108377 minimal_4\JJ\1740 antitumor_5\NN\1740 activity_6\NN\30358 when_7\WRB\1740 used_8\VBN\1156834 as_9\IN\14622893 second-_10\NN\1740 or_11\CC\3541091 third-line_12\JJ\1740 treatment_13\NN\654885 of_14\IN\1740 metastatic_15\JJ\1740 <e2>breast_16\NN\5225090 carcinoma</e2>_17\NN\14239918 ._18\.\1740
D002945_D001943 NONE although_0\IN\1740 a_1\DT\13649268 dose-response_2\JJ\1740 effect_3\NN\34213 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 with_7\IN\1740 <e1>cisplatin</e1>_8\NN\1740 ,_9\,\1740 the_10\DT\1740 dose-limiting_11\JJ\1740 toxicities_12\NNS\13576101 associated_13\VBN\628491 with_14\IN\1740 cisplatin_15\NN\1740 (_16\-LRB-\1740 e.g._17\FW\1740 ,_18\,\1740 nephrotoxicity_19\NN\1740 ,_20\,\1740 ototoxicity_21\NN\1740 ,_22\,\1740 and_23\CC\1740 neurotoxicity_24\NN\1740 )_25\-RRB-\1740 have_26\VBP\2108377 limited_27\VBN\2510337 its_28\PRP$\6125041 use_29\NN\407535 as_30\IN\14622893 a_31\DT\13649268 treatment_32\NN\654885 for_33\IN\1740 <e2>breast_34\NN\5225090 carcinoma</e2>_35\NN\14239918 ._36\.\1740
D002945_D001943 NONE although_0\IN\1740 a_1\DT\13649268 dose-response_2\JJ\1740 effect_3\NN\34213 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 with_7\IN\1740 cisplatin_8\NN\1740 ,_9\,\1740 the_10\DT\1740 dose-limiting_11\JJ\1740 toxicities_12\NNS\13576101 associated_13\VBN\628491 with_14\IN\1740 <e1>cisplatin</e1>_15\NN\1740 (_16\-LRB-\1740 e.g._17\FW\1740 ,_18\,\1740 nephrotoxicity_19\NN\1740 ,_20\,\1740 ototoxicity_21\NN\1740 ,_22\,\1740 and_23\CC\1740 neurotoxicity_24\NN\1740 )_25\-RRB-\1740 have_26\VBP\2108377 limited_27\VBN\2510337 its_28\PRP$\6125041 use_29\NN\407535 as_30\IN\14622893 a_31\DT\13649268 treatment_32\NN\654885 for_33\IN\1740 <e2>breast_34\NN\5225090 carcinoma</e2>_35\NN\14239918 ._36\.\1740
D002945_D001943 NONE methods_0\NNS\5616786 :_1\:\1740 a_2\DT\13649268 phase_3\NN\15113229 ii_4\CD\13741022 study_5\NN\635850 of_6\IN\1740 the_7\DT\1740 combination_8\NN\7951464 of_9\IN\1740 <e1>cisplatin</e1>_10\NN\1740 plus_11\CC\4723816 amifostine_12\NN\1740 was_13\VBD\836236 conducted_14\VBN\2436349 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 progressive_18\JJ\1740 metastatic_19\JJ\1740 <e2>breast_20\NN\5225090 carcinoma</e2>_21\NN\14239918 who_22\WP\8299493 had_23\VBD\2108377 received_24\VBN\2210855 one_25\CD\13741022 ,_26\,\1740 but_27\CC\1740 not_28\RB\1740 more_29\JJR\1740 than_30\IN\1740 one_31\CD\13741022 ,_32\,\1740 chemotherapy_33\NN\661091 regimen_34\NNS\5898568 for_35\IN\1740 metastatic_36\JJ\1740 disease_37\NN\14061805 ._38\.\1740
D004999_D001943 NONE a_0\DT\13649268 phase_1\NN\15113229 ii_2\CD\13741022 trial_3\NN\786195 of_4\IN\1740 cisplatin_5\NN\1740 plus_6\CC\4723816 <e1>wr-2721</e1>_7\JJ\1740 (_8\-LRB-\1740 amifostine_9\NN\1740 )_10\-RRB-\1740 for_11\IN\1740 metastatic_12\JJ\1740 <e2>breast_13\NN\5225090 carcinoma</e2>_14\NN\14239918 :_15\:\1740 an_16\DT\6697703 eastern_17\JJ\1740 cooperative_18\JJ\1740 oncology_19\NN\6043075 group_20\NNP\2137 study_21\NN\635850 (_22\-LRB-\1740 e8188_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D004999_D001943 NONE a_0\DT\13649268 phase_1\NN\15113229 ii_2\CD\13741022 trial_3\NN\786195 of_4\IN\1740 cisplatin_5\NN\1740 plus_6\CC\4723816 wr-2721_7\JJ\1740 (_8\-LRB-\1740 <e1>amifostine</e1>_9\NN\1740 )_10\-RRB-\1740 for_11\IN\1740 metastatic_12\JJ\1740 <e2>breast_13\NN\5225090 carcinoma</e2>_14\NN\14239918 :_15\:\1740 an_16\DT\6697703 eastern_17\JJ\1740 cooperative_18\JJ\1740 oncology_19\NN\6043075 group_20\NNP\2137 study_21\NN\635850 (_22\-LRB-\1740 e8188_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D004999_D001943 NONE methods_0\NNS\5616786 :_1\:\1740 a_2\DT\13649268 phase_3\NN\15113229 ii_4\CD\13741022 study_5\NN\635850 of_6\IN\1740 the_7\DT\1740 combination_8\NN\7951464 of_9\IN\1740 cisplatin_10\NN\1740 plus_11\CC\4723816 <e1>amifostine</e1>_12\NN\1740 was_13\VBD\836236 conducted_14\VBN\2436349 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 progressive_18\JJ\1740 metastatic_19\JJ\1740 <e2>breast_20\NN\5225090 carcinoma</e2>_21\NN\14239918 who_22\WP\8299493 had_23\VBD\2108377 received_24\VBN\2210855 one_25\CD\13741022 ,_26\,\1740 but_27\CC\1740 not_28\RB\1740 more_29\JJR\1740 than_30\IN\1740 one_31\CD\13741022 ,_32\,\1740 chemotherapy_33\NN\661091 regimen_34\NNS\5898568 for_35\IN\1740 metastatic_36\JJ\1740 disease_37\NN\14061805 ._38\.\1740
D002945_D064420 NONE although_0\IN\1740 a_1\DT\13649268 dose-response_2\JJ\1740 effect_3\NN\34213 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 with_7\IN\1740 <e1>cisplatin</e1>_8\NN\1740 ,_9\,\1740 the_10\DT\1740 dose-limiting_11\JJ\1740 <e2>toxicities</e2>_12\NNS\13576101 associated_13\VBN\628491 with_14\IN\1740 cisplatin_15\NN\1740 (_16\-LRB-\1740 e.g._17\FW\1740 ,_18\,\1740 nephrotoxicity_19\NN\1740 ,_20\,\1740 ototoxicity_21\NN\1740 ,_22\,\1740 and_23\CC\1740 neurotoxicity_24\NN\1740 )_25\-RRB-\1740 have_26\VBP\2108377 limited_27\VBN\2510337 its_28\PRP$\6125041 use_29\NN\407535 as_30\IN\14622893 a_31\DT\13649268 treatment_32\NN\654885 for_33\IN\1740 breast_34\NN\5225090 carcinoma_35\NN\14239918 ._36\.\1740
D002945_D064420 NONE although_0\IN\1740 a_1\DT\13649268 dose-response_2\JJ\1740 effect_3\NN\34213 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 with_7\IN\1740 cisplatin_8\NN\1740 ,_9\,\1740 the_10\DT\1740 dose-limiting_11\JJ\1740 <e2>toxicities</e2>_12\NNS\13576101 associated_13\VBN\628491 with_14\IN\1740 <e1>cisplatin</e1>_15\NN\1740 (_16\-LRB-\1740 e.g._17\FW\1740 ,_18\,\1740 nephrotoxicity_19\NN\1740 ,_20\,\1740 ototoxicity_21\NN\1740 ,_22\,\1740 and_23\CC\1740 neurotoxicity_24\NN\1740 )_25\-RRB-\1740 have_26\VBP\2108377 limited_27\VBN\2510337 its_28\PRP$\6125041 use_29\NN\407535 as_30\IN\14622893 a_31\DT\13649268 treatment_32\NN\654885 for_33\IN\1740 breast_34\NN\5225090 carcinoma_35\NN\14239918 ._36\.\1740
D002945_D064420 NONE neither_0\CC\1740 a_1\DT\13649268 tumor-protective_2\JJ\1740 effect_3\NN\34213 nor_4\CC\1740 reduced_5\VBN\441445 <e2>toxicity</e2>_6\NN\13576101 to_7\TO\1740 normal_8\JJ\1740 tissues_9\NNS\5220461 was_10\VBD\836236 observed_11\VBN\2163746 with_12\IN\1740 the_13\DT\1740 addition_14\NN\3081021 of_15\IN\1740 amifostine_16\NN\1740 to_17\TO\1740 <e1>cisplatin</e1>_18\NN\1740 in_19\IN\13603305 this_20\DT\1740 trial_21\NN\786195 ._22\.\1740
D002945_D007674 CID although_0\IN\1740 a_1\DT\13649268 dose-response_2\JJ\1740 effect_3\NN\34213 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 with_7\IN\1740 <e1>cisplatin</e1>_8\NN\1740 ,_9\,\1740 the_10\DT\1740 dose-limiting_11\JJ\1740 toxicities_12\NNS\13576101 associated_13\VBN\628491 with_14\IN\1740 cisplatin_15\NN\1740 (_16\-LRB-\1740 e.g._17\FW\1740 ,_18\,\1740 <e2>nephrotoxicity</e2>_19\NN\1740 ,_20\,\1740 ototoxicity_21\NN\1740 ,_22\,\1740 and_23\CC\1740 neurotoxicity_24\NN\1740 )_25\-RRB-\1740 have_26\VBP\2108377 limited_27\VBN\2510337 its_28\PRP$\6125041 use_29\NN\407535 as_30\IN\14622893 a_31\DT\13649268 treatment_32\NN\654885 for_33\IN\1740 breast_34\NN\5225090 carcinoma_35\NN\14239918 ._36\.\1740
D002945_D007674 CID although_0\IN\1740 a_1\DT\13649268 dose-response_2\JJ\1740 effect_3\NN\34213 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 with_7\IN\1740 cisplatin_8\NN\1740 ,_9\,\1740 the_10\DT\1740 dose-limiting_11\JJ\1740 toxicities_12\NNS\13576101 associated_13\VBN\628491 with_14\IN\1740 <e1>cisplatin</e1>_15\NN\1740 (_16\-LRB-\1740 e.g._17\FW\1740 ,_18\,\1740 <e2>nephrotoxicity</e2>_19\NN\1740 ,_20\,\1740 ototoxicity_21\NN\1740 ,_22\,\1740 and_23\CC\1740 neurotoxicity_24\NN\1740 )_25\-RRB-\1740 have_26\VBP\2108377 limited_27\VBN\2510337 its_28\PRP$\6125041 use_29\NN\407535 as_30\IN\14622893 a_31\DT\13649268 treatment_32\NN\654885 for_33\IN\1740 breast_34\NN\5225090 carcinoma_35\NN\14239918 ._36\.\1740
D002945_D007674 CID early_0\JJ\1740 trials_1\NNS\786195 of_2\IN\1740 <e1>cisplatin</e1>_3\NN\1740 and_4\CC\1740 amifostine_5\NN\1740 also_6\RB\1740 suggested_7\VBD\1010118 that_8\IN\1740 the_9\DT\1740 incidence_10\NN\13821570 and_11\CC\1740 severity_12\NN\5036394 of_13\IN\1740 cisplatin-induced_14\JJ\1740 <e2>nephrotoxicity</e2>_15\NN\1740 ,_16\,\1740 ototoxicity_17\NN\1740 ,_18\,\1740 and_19\CC\1740 neuropathy_20\RB\1740 were_21\VBD\836236 reduced_22\VBN\441445 ._23\.\1740
D002945_D007674 CID early_0\JJ\1740 trials_1\NNS\786195 of_2\IN\1740 cisplatin_3\NN\1740 and_4\CC\1740 amifostine_5\NN\1740 also_6\RB\1740 suggested_7\VBD\1010118 that_8\IN\1740 the_9\DT\1740 incidence_10\NN\13821570 and_11\CC\1740 severity_12\NN\5036394 of_13\IN\1740 <e1>cisplatin-induced</e1>_14\JJ\1740 <e2>nephrotoxicity</e2>_15\NN\1740 ,_16\,\1740 ototoxicity_17\NN\1740 ,_18\,\1740 and_19\CC\1740 neuropathy_20\RB\1740 were_21\VBD\836236 reduced_22\VBN\441445 ._23\.\1740
D002945_D006311 CID although_0\IN\1740 a_1\DT\13649268 dose-response_2\JJ\1740 effect_3\NN\34213 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 with_7\IN\1740 <e1>cisplatin</e1>_8\NN\1740 ,_9\,\1740 the_10\DT\1740 dose-limiting_11\JJ\1740 toxicities_12\NNS\13576101 associated_13\VBN\628491 with_14\IN\1740 cisplatin_15\NN\1740 (_16\-LRB-\1740 e.g._17\FW\1740 ,_18\,\1740 nephrotoxicity_19\NN\1740 ,_20\,\1740 <e2>ototoxicity</e2>_21\NN\1740 ,_22\,\1740 and_23\CC\1740 neurotoxicity_24\NN\1740 )_25\-RRB-\1740 have_26\VBP\2108377 limited_27\VBN\2510337 its_28\PRP$\6125041 use_29\NN\407535 as_30\IN\14622893 a_31\DT\13649268 treatment_32\NN\654885 for_33\IN\1740 breast_34\NN\5225090 carcinoma_35\NN\14239918 ._36\.\1740
D002945_D006311 CID although_0\IN\1740 a_1\DT\13649268 dose-response_2\JJ\1740 effect_3\NN\34213 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 with_7\IN\1740 cisplatin_8\NN\1740 ,_9\,\1740 the_10\DT\1740 dose-limiting_11\JJ\1740 toxicities_12\NNS\13576101 associated_13\VBN\628491 with_14\IN\1740 <e1>cisplatin</e1>_15\NN\1740 (_16\-LRB-\1740 e.g._17\FW\1740 ,_18\,\1740 nephrotoxicity_19\NN\1740 ,_20\,\1740 <e2>ototoxicity</e2>_21\NN\1740 ,_22\,\1740 and_23\CC\1740 neurotoxicity_24\NN\1740 )_25\-RRB-\1740 have_26\VBP\2108377 limited_27\VBN\2510337 its_28\PRP$\6125041 use_29\NN\407535 as_30\IN\14622893 a_31\DT\13649268 treatment_32\NN\654885 for_33\IN\1740 breast_34\NN\5225090 carcinoma_35\NN\14239918 ._36\.\1740
D002945_D006311 CID early_0\JJ\1740 trials_1\NNS\786195 of_2\IN\1740 <e1>cisplatin</e1>_3\NN\1740 and_4\CC\1740 amifostine_5\NN\1740 also_6\RB\1740 suggested_7\VBD\1010118 that_8\IN\1740 the_9\DT\1740 incidence_10\NN\13821570 and_11\CC\1740 severity_12\NN\5036394 of_13\IN\1740 cisplatin-induced_14\JJ\1740 nephrotoxicity_15\NN\1740 ,_16\,\1740 <e2>ototoxicity</e2>_17\NN\1740 ,_18\,\1740 and_19\CC\1740 neuropathy_20\RB\1740 were_21\VBD\836236 reduced_22\VBN\441445 ._23\.\1740
D002945_D006311 CID early_0\JJ\1740 trials_1\NNS\786195 of_2\IN\1740 cisplatin_3\NN\1740 and_4\CC\1740 amifostine_5\NN\1740 also_6\RB\1740 suggested_7\VBD\1010118 that_8\IN\1740 the_9\DT\1740 incidence_10\NN\13821570 and_11\CC\1740 severity_12\NN\5036394 of_13\IN\1740 <e1>cisplatin-induced</e1>_14\JJ\1740 nephrotoxicity_15\NN\1740 ,_16\,\1740 <e2>ototoxicity</e2>_17\NN\1740 ,_18\,\1740 and_19\CC\1740 neuropathy_20\RB\1740 were_21\VBD\836236 reduced_22\VBN\441445 ._23\.\1740
D002945_D020258 NONE although_0\IN\1740 a_1\DT\13649268 dose-response_2\JJ\1740 effect_3\NN\34213 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 with_7\IN\1740 <e1>cisplatin</e1>_8\NN\1740 ,_9\,\1740 the_10\DT\1740 dose-limiting_11\JJ\1740 toxicities_12\NNS\13576101 associated_13\VBN\628491 with_14\IN\1740 cisplatin_15\NN\1740 (_16\-LRB-\1740 e.g._17\FW\1740 ,_18\,\1740 nephrotoxicity_19\NN\1740 ,_20\,\1740 ototoxicity_21\NN\1740 ,_22\,\1740 and_23\CC\1740 <e2>neurotoxicity</e2>_24\NN\1740 )_25\-RRB-\1740 have_26\VBP\2108377 limited_27\VBN\2510337 its_28\PRP$\6125041 use_29\NN\407535 as_30\IN\14622893 a_31\DT\13649268 treatment_32\NN\654885 for_33\IN\1740 breast_34\NN\5225090 carcinoma_35\NN\14239918 ._36\.\1740
D002945_D020258 NONE although_0\IN\1740 a_1\DT\13649268 dose-response_2\JJ\1740 effect_3\NN\34213 has_4\VBZ\2108377 been_5\VBN\836236 observed_6\VBN\2163746 with_7\IN\1740 cisplatin_8\NN\1740 ,_9\,\1740 the_10\DT\1740 dose-limiting_11\JJ\1740 toxicities_12\NNS\13576101 associated_13\VBN\628491 with_14\IN\1740 <e1>cisplatin</e1>_15\NN\1740 (_16\-LRB-\1740 e.g._17\FW\1740 ,_18\,\1740 nephrotoxicity_19\NN\1740 ,_20\,\1740 ototoxicity_21\NN\1740 ,_22\,\1740 and_23\CC\1740 <e2>neurotoxicity</e2>_24\NN\1740 )_25\-RRB-\1740 have_26\VBP\2108377 limited_27\VBN\2510337 its_28\PRP$\6125041 use_29\NN\407535 as_30\IN\14622893 a_31\DT\13649268 treatment_32\NN\654885 for_33\IN\1740 breast_34\NN\5225090 carcinoma_35\NN\14239918 ._36\.\1740
D002945_D009422 CID early_0\JJ\1740 trials_1\NNS\786195 of_2\IN\1740 <e1>cisplatin</e1>_3\NN\1740 and_4\CC\1740 amifostine_5\NN\1740 also_6\RB\1740 suggested_7\VBD\1010118 that_8\IN\1740 the_9\DT\1740 incidence_10\NN\13821570 and_11\CC\1740 severity_12\NN\5036394 of_13\IN\1740 cisplatin-induced_14\JJ\1740 nephrotoxicity_15\NN\1740 ,_16\,\1740 ototoxicity_17\NN\1740 ,_18\,\1740 and_19\CC\1740 <e2>neuropathy</e2>_20\RB\1740 were_21\VBD\836236 reduced_22\VBN\441445 ._23\.\1740
D002945_D009422 CID early_0\JJ\1740 trials_1\NNS\786195 of_2\IN\1740 cisplatin_3\NN\1740 and_4\CC\1740 amifostine_5\NN\1740 also_6\RB\1740 suggested_7\VBD\1010118 that_8\IN\1740 the_9\DT\1740 incidence_10\NN\13821570 and_11\CC\1740 severity_12\NN\5036394 of_13\IN\1740 <e1>cisplatin-induced</e1>_14\JJ\1740 nephrotoxicity_15\NN\1740 ,_16\,\1740 ototoxicity_17\NN\1740 ,_18\,\1740 and_19\CC\1740 <e2>neuropathy</e2>_20\RB\1740 were_21\VBD\836236 reduced_22\VBN\441445 ._23\.\1740
D004999_D007674 NONE early_0\JJ\1740 trials_1\NNS\786195 of_2\IN\1740 cisplatin_3\NN\1740 and_4\CC\1740 <e1>amifostine</e1>_5\NN\1740 also_6\RB\1740 suggested_7\VBD\1010118 that_8\IN\1740 the_9\DT\1740 incidence_10\NN\13821570 and_11\CC\1740 severity_12\NN\5036394 of_13\IN\1740 cisplatin-induced_14\JJ\1740 <e2>nephrotoxicity</e2>_15\NN\1740 ,_16\,\1740 ototoxicity_17\NN\1740 ,_18\,\1740 and_19\CC\1740 neuropathy_20\RB\1740 were_21\VBD\836236 reduced_22\VBN\441445 ._23\.\1740
D004999_D006311 NONE early_0\JJ\1740 trials_1\NNS\786195 of_2\IN\1740 cisplatin_3\NN\1740 and_4\CC\1740 <e1>amifostine</e1>_5\NN\1740 also_6\RB\1740 suggested_7\VBD\1010118 that_8\IN\1740 the_9\DT\1740 incidence_10\NN\13821570 and_11\CC\1740 severity_12\NN\5036394 of_13\IN\1740 cisplatin-induced_14\JJ\1740 nephrotoxicity_15\NN\1740 ,_16\,\1740 <e2>ototoxicity</e2>_17\NN\1740 ,_18\,\1740 and_19\CC\1740 neuropathy_20\RB\1740 were_21\VBD\836236 reduced_22\VBN\441445 ._23\.\1740
D004999_D009422 NONE early_0\JJ\1740 trials_1\NNS\786195 of_2\IN\1740 cisplatin_3\NN\1740 and_4\CC\1740 <e1>amifostine</e1>_5\NN\1740 also_6\RB\1740 suggested_7\VBD\1010118 that_8\IN\1740 the_9\DT\1740 incidence_10\NN\13821570 and_11\CC\1740 severity_12\NN\5036394 of_13\IN\1740 cisplatin-induced_14\JJ\1740 nephrotoxicity_15\NN\1740 ,_16\,\1740 ototoxicity_17\NN\1740 ,_18\,\1740 and_19\CC\1740 <e2>neuropathy</e2>_20\RB\1740 were_21\VBD\836236 reduced_22\VBN\441445 ._23\.\1740
D004999_D009369 NONE neither_0\CC\1740 a_1\DT\13649268 <e2>tumor-protective</e2>_2\JJ\1740 effect_3\NN\34213 nor_4\CC\1740 reduced_5\VBN\441445 toxicity_6\NN\13576101 to_7\TO\1740 normal_8\JJ\1740 tissues_9\NNS\5220461 was_10\VBD\836236 observed_11\VBN\2163746 with_12\IN\1740 the_13\DT\1740 addition_14\NN\3081021 of_15\IN\1740 <e1>amifostine</e1>_16\NN\1740 to_17\TO\1740 cisplatin_18\NN\1740 in_19\IN\13603305 this_20\DT\1740 trial_21\NN\786195 ._22\.\1740
D004999_D064420 NONE neither_0\CC\1740 a_1\DT\13649268 tumor-protective_2\JJ\1740 effect_3\NN\34213 nor_4\CC\1740 reduced_5\VBN\441445 <e2>toxicity</e2>_6\NN\13576101 to_7\TO\1740 normal_8\JJ\1740 tissues_9\NNS\5220461 was_10\VBD\836236 observed_11\VBN\2163746 with_12\IN\1740 the_13\DT\1740 addition_14\NN\3081021 of_15\IN\1740 <e1>amifostine</e1>_16\NN\1740 to_17\TO\1740 cisplatin_18\NN\1740 in_19\IN\13603305 this_20\DT\1740 trial_21\NN\786195 ._22\.\1740
D002945_D009369 NONE neither_0\CC\1740 a_1\DT\13649268 <e2>tumor-protective</e2>_2\JJ\1740 effect_3\NN\34213 nor_4\CC\1740 reduced_5\VBN\441445 toxicity_6\NN\13576101 to_7\TO\1740 normal_8\JJ\1740 tissues_9\NNS\5220461 was_10\VBD\836236 observed_11\VBN\2163746 with_12\IN\1740 the_13\DT\1740 addition_14\NN\3081021 of_15\IN\1740 amifostine_16\NN\1740 to_17\TO\1740 <e1>cisplatin</e1>_18\NN\1740 in_19\IN\13603305 this_20\DT\1740 trial_21\NN\786195 ._22\.\1740
8410052
D019344_D001480 NONE focal_0\JJ\1740 <e2>injury_1\NN\14052046 in_2\IN\13603305 the_3\DT\1740 cortex</e2>_4\NN\5462674 was_5\VBD\836236 produced_6\VBN\1617192 by_7\IN\1740 infusion_8\NN\14589223 of_9\IN\1740 <e1>lactate</e1>_10\NN\14850483 at_11\IN\14622893 acid_12\NN\14818238 ph_13\NN\5038959 or_14\CC\3541091 by_15\IN\1740 stab_16\JJ\1740 caused_17\VBN\1617192 by_18\IN\1740 needle_19\NN\13156083 insertion_20\NN\6598915 ._21\.\1740
D010862_D002544 CID <e2>infarcts_0\NNS\14204950 in_1\IN\13603305 substantia_2\RB\1740 nigra_3\JJ\1740 pars_4\NNS\13594585 reticulata</e2>_5\NNS\1740 were_6\VBD\836236 evoked_7\VBN\1617192 by_8\IN\1740 prolonged_9\JJ\1740 <e1>pilocarpine-induced</e1>_10\JJ\1740 status_11\NN\24720 epilepticus_12\NN\1740 ._13\.\1740
D010862_D013226 CID infarcts_0\NNS\14204950 in_1\IN\13603305 substantia_2\RB\1740 nigra_3\JJ\1740 pars_4\NNS\13594585 reticulata_5\NNS\1740 were_6\VBD\836236 evoked_7\VBN\1617192 by_8\IN\1740 prolonged_9\JJ\1740 <e1>pilocarpine-induced</e1>_10\JJ\1740 <e2>status_11\NN\24720 epilepticus</e2>_12\NN\1740 ._13\.\1740
14657095
D000666_D002311 CID reversible_0\JJ\1740 <e2>dilated_1\VBD\303465 cardiomyopathy</e2>_2\DT\14103288 related_3\JJ\1740 to_4\TO\1740 <e1>amphotericin_5\NN\2716866 b</e1>_6\NN\1355326 therapy_7\NN\657604 ._8\.\1740
D000666_D002311 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 who_4\WP\8299493 developed_5\VBD\1753788 <e2>dilated_6\VBN\303465 cardiomyopathy</e2>_7\JJ\1740 and_8\CC\1740 clinical_9\JJ\1740 congestive_10\JJ\1740 heart_11\NN\5919034 failure_12\NN\66216 after_13\IN\1740 2_14\CD\13741022 months_15\NNS\15113229 of_16\IN\1740 therapy_17\NN\657604 with_18\IN\1740 <e1>amphotericin_19\NN\2716866 b</e1>_20\NN\1355326 (_21\-LRB-\1740 amb_22\NN\1740 )_23\-RRB-\1740 for_24\IN\1740 disseminated_25\VBN\954608 coccidioidomycosis_26\NN\14176895 ._27\.\1740
D000666_D002311 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 who_4\WP\8299493 developed_5\VBD\1753788 <e2>dilated_6\VBN\303465 cardiomyopathy</e2>_7\JJ\1740 and_8\CC\1740 clinical_9\JJ\1740 congestive_10\JJ\1740 heart_11\NN\5919034 failure_12\NN\66216 after_13\IN\1740 2_14\CD\13741022 months_15\NNS\15113229 of_16\IN\1740 therapy_17\NN\657604 with_18\IN\1740 amphotericin_19\NN\2716866 b_20\NN\1355326 (_21\-LRB-\1740 <e1>amb</e1>_22\NN\1740 )_23\-RRB-\1740 for_24\IN\1740 disseminated_25\VBN\954608 coccidioidomycosis_26\NN\14176895 ._27\.\1740
D000666_D006333 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 who_4\WP\8299493 developed_5\VBD\1753788 dilated_6\VBN\303465 cardiomyopathy_7\JJ\1740 and_8\CC\1740 clinical_9\JJ\1740 congestive_10\JJ\1740 <e2>heart_11\NN\5919034 failure</e2>_12\NN\66216 after_13\IN\1740 2_14\CD\13741022 months_15\NNS\15113229 of_16\IN\1740 therapy_17\NN\657604 with_18\IN\1740 <e1>amphotericin_19\NN\2716866 b</e1>_20\NN\1355326 (_21\-LRB-\1740 amb_22\NN\1740 )_23\-RRB-\1740 for_24\IN\1740 disseminated_25\VBN\954608 coccidioidomycosis_26\NN\14176895 ._27\.\1740
D000666_D006333 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 who_4\WP\8299493 developed_5\VBD\1753788 dilated_6\VBN\303465 cardiomyopathy_7\JJ\1740 and_8\CC\1740 clinical_9\JJ\1740 congestive_10\JJ\1740 <e2>heart_11\NN\5919034 failure</e2>_12\NN\66216 after_13\IN\1740 2_14\CD\13741022 months_15\NNS\15113229 of_16\IN\1740 therapy_17\NN\657604 with_18\IN\1740 amphotericin_19\NN\2716866 b_20\NN\1355326 (_21\-LRB-\1740 <e1>amb</e1>_22\NN\1740 )_23\-RRB-\1740 for_24\IN\1740 disseminated_25\VBN\954608 coccidioidomycosis_26\NN\14176895 ._27\.\1740
D000666_D006333 CID his_0\PRP$\1740 echocardiographic_1\JJ\1740 abnormalities_2\NNS\14034177 and_3\CC\1740 <e2>heart_4\NN\5919034 failure</e2>_5\NN\66216 resolved_6\VBN\352826 after_7\IN\1740 posaconazole_8\NN\1740 was_9\VBD\836236 substituted_10\VBN\126264 for_11\IN\1740 <e1>amb.</e1>_12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 important_15\JJ\1740 to_16\TO\1740 recognize_17\VB\686447 the_18\DT\1740 rare_19\JJ\1740 and_20\CC\1740 potentially_21\RB\1740 reversible_22\JJ\1740 toxicity_23\NN\13576101 of_24\IN\1740 amb._25\NN\1740
D000666_D006333 CID his_0\PRP$\1740 echocardiographic_1\JJ\1740 abnormalities_2\NNS\14034177 and_3\CC\1740 <e2>heart_4\NN\5919034 failure</e2>_5\NN\66216 resolved_6\VBN\352826 after_7\IN\1740 posaconazole_8\NN\1740 was_9\VBD\836236 substituted_10\VBN\126264 for_11\IN\1740 amb._12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 important_15\JJ\1740 to_16\TO\1740 recognize_17\VB\686447 the_18\DT\1740 rare_19\JJ\1740 and_20\CC\1740 potentially_21\RB\1740 reversible_22\JJ\1740 toxicity_23\NN\13576101 of_24\IN\1740 <e1>amb.</e1>_25\NN\1740
D000666_D003047 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 who_4\WP\8299493 developed_5\VBD\1753788 dilated_6\VBN\303465 cardiomyopathy_7\JJ\1740 and_8\CC\1740 clinical_9\JJ\1740 congestive_10\JJ\1740 heart_11\NN\5919034 failure_12\NN\66216 after_13\IN\1740 2_14\CD\13741022 months_15\NNS\15113229 of_16\IN\1740 therapy_17\NN\657604 with_18\IN\1740 <e1>amphotericin_19\NN\2716866 b</e1>_20\NN\1355326 (_21\-LRB-\1740 amb_22\NN\1740 )_23\-RRB-\1740 for_24\IN\1740 disseminated_25\VBN\954608 <e2>coccidioidomycosis</e2>_26\NN\14176895 ._27\.\1740
D000666_D003047 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 who_4\WP\8299493 developed_5\VBD\1753788 dilated_6\VBN\303465 cardiomyopathy_7\JJ\1740 and_8\CC\1740 clinical_9\JJ\1740 congestive_10\JJ\1740 heart_11\NN\5919034 failure_12\NN\66216 after_13\IN\1740 2_14\CD\13741022 months_15\NNS\15113229 of_16\IN\1740 therapy_17\NN\657604 with_18\IN\1740 amphotericin_19\NN\2716866 b_20\NN\1355326 (_21\-LRB-\1740 <e1>amb</e1>_22\NN\1740 )_23\-RRB-\1740 for_24\IN\1740 disseminated_25\VBN\954608 <e2>coccidioidomycosis</e2>_26\NN\14176895 ._27\.\1740
C101425_D006333 NONE his_0\PRP$\1740 echocardiographic_1\JJ\1740 abnormalities_2\NNS\14034177 and_3\CC\1740 <e2>heart_4\NN\5919034 failure</e2>_5\NN\66216 resolved_6\VBN\352826 after_7\IN\1740 <e1>posaconazole</e1>_8\NN\1740 was_9\VBD\836236 substituted_10\VBN\126264 for_11\IN\1740 amb._12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 important_15\JJ\1740 to_16\TO\1740 recognize_17\VB\686447 the_18\DT\1740 rare_19\JJ\1740 and_20\CC\1740 potentially_21\RB\1740 reversible_22\JJ\1740 toxicity_23\NN\13576101 of_24\IN\1740 amb._25\NN\1740
C101425_D064420 NONE his_0\PRP$\1740 echocardiographic_1\JJ\1740 abnormalities_2\NNS\14034177 and_3\CC\1740 heart_4\NN\5919034 failure_5\NN\66216 resolved_6\VBN\352826 after_7\IN\1740 <e1>posaconazole</e1>_8\NN\1740 was_9\VBD\836236 substituted_10\VBN\126264 for_11\IN\1740 amb._12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 important_15\JJ\1740 to_16\TO\1740 recognize_17\VB\686447 the_18\DT\1740 rare_19\JJ\1740 and_20\CC\1740 potentially_21\RB\1740 reversible_22\JJ\1740 <e2>toxicity</e2>_23\NN\13576101 of_24\IN\1740 amb._25\NN\1740
D000666_D064420 NONE his_0\PRP$\1740 echocardiographic_1\JJ\1740 abnormalities_2\NNS\14034177 and_3\CC\1740 heart_4\NN\5919034 failure_5\NN\66216 resolved_6\VBN\352826 after_7\IN\1740 posaconazole_8\NN\1740 was_9\VBD\836236 substituted_10\VBN\126264 for_11\IN\1740 <e1>amb.</e1>_12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 important_15\JJ\1740 to_16\TO\1740 recognize_17\VB\686447 the_18\DT\1740 rare_19\JJ\1740 and_20\CC\1740 potentially_21\RB\1740 reversible_22\JJ\1740 <e2>toxicity</e2>_23\NN\13576101 of_24\IN\1740 amb._25\NN\1740
D000666_D064420 NONE his_0\PRP$\1740 echocardiographic_1\JJ\1740 abnormalities_2\NNS\14034177 and_3\CC\1740 heart_4\NN\5919034 failure_5\NN\66216 resolved_6\VBN\352826 after_7\IN\1740 posaconazole_8\NN\1740 was_9\VBD\836236 substituted_10\VBN\126264 for_11\IN\1740 amb._12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 important_15\JJ\1740 to_16\TO\1740 recognize_17\VB\686447 the_18\DT\1740 rare_19\JJ\1740 and_20\CC\1740 potentially_21\RB\1740 reversible_22\JJ\1740 <e2>toxicity</e2>_23\NN\13576101 of_24\IN\1740 <e1>amb.</e1>_25\NN\1740
2334618
D009020_D001049 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 postoperative_3\JJ\1740 respiratory_4\JJ\1740 <e2>apnoea</e2>_5\NN\1740 was_6\VBD\836236 compared_7\VBN\644583 between_8\IN\1740 five_9\CD\13741022 patients_10\NNS\9898892 receiving_11\VBG\2210855 a_12\DT\13649268 continuous_13\JJ\1740 i.v._14\NN\1740 infusion_15\NN\14589223 of_16\IN\1740 <e1>morphine</e1>_17\NN\2707683 (_18\-LRB-\1740 mean_19\NN\6021761 73.6_20\CD\1740 mg_21\NN\13717155 )_22\-RRB-\1740 and_23\CC\1740 five_24\CD\13741022 patients_25\NNS\9898892 receiving_26\VBG\2210855 a_27\DT\13649268 continuous_28\JJ\1740 extradural_29\JJ\1740 infusion_30\NN\14589223 of_31\IN\1740 0.25_32\CD\1740 %_33\NN\1740 bupivacaine_34\NN\1740 (_35\-LRB-\1740 mean_36\NN\6021761 192_37\CD\1740 mg_38\NN\13717155 )_39\-RRB-\1740 in_40\IN\13603305 the_41\DT\1740 24-h_42\JJ\1740 period_43\NN\13575869 following_44\VBG\1835496 upper_45\JJ\1740 abdominal_46\JJ\1740 surgery_47\NN\6045562 ._48\.\1740
D002045_D001049 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 postoperative_3\JJ\1740 respiratory_4\JJ\1740 <e2>apnoea</e2>_5\NN\1740 was_6\VBD\836236 compared_7\VBN\644583 between_8\IN\1740 five_9\CD\13741022 patients_10\NNS\9898892 receiving_11\VBG\2210855 a_12\DT\13649268 continuous_13\JJ\1740 i.v._14\NN\1740 infusion_15\NN\14589223 of_16\IN\1740 morphine_17\NN\2707683 (_18\-LRB-\1740 mean_19\NN\6021761 73.6_20\CD\1740 mg_21\NN\13717155 )_22\-RRB-\1740 and_23\CC\1740 five_24\CD\13741022 patients_25\NNS\9898892 receiving_26\VBG\2210855 a_27\DT\13649268 continuous_28\JJ\1740 extradural_29\JJ\1740 infusion_30\NN\14589223 of_31\IN\1740 0.25_32\CD\1740 %_33\NN\1740 <e1>bupivacaine</e1>_34\NN\1740 (_35\-LRB-\1740 mean_36\NN\6021761 192_37\CD\1740 mg_38\NN\13717155 )_39\-RRB-\1740 in_40\IN\13603305 the_41\DT\1740 24-h_42\JJ\1740 period_43\NN\13575869 following_44\VBG\1835496 upper_45\JJ\1740 abdominal_46\JJ\1740 surgery_47\NN\6045562 ._48\.\1740
D009020_D020181 CID both_0\CC\1740 <e2>obstructive_1\JJ\1740 (_2\-LRB-\1740 p_3\NN\14622893 less_4\JJR\1740 than_5\IN\1740 0.05_6\CD\1740 )_7\-RRB-\1740 and_8\CC\1740 central_9\JJ\1740 apnoea</e2>_10\NN\1740 (_11\-LRB-\1740 p_12\NN\14622893 less_13\JJR\1740 than_14\IN\1740 0.05_15\CD\1740 )_16\-RRB-\1740 occurred_17\VBD\2623529 more_18\RBR\1740 frequently_19\RB\1740 in_20\IN\13603305 patients_21\NNS\9898892 who_22\WP\8299493 had_23\VBD\2108377 a_24\DT\13649268 <e1>morphine</e1>_25\NN\2707683 infusion_26\NN\14589223 ._27\.\1740
D009020_D020182 CID both_0\CC\1740 <e2>obstructive_1\JJ\1740 (_2\-LRB-\1740 p_3\NN\14622893 less_4\JJR\1740 than_5\IN\1740 0.05_6\CD\1740 )_7\-RRB-\1740 and_8\CC\1740 central_9\JJ\1740 apnoea</e2>_10\NN\1740 (_11\-LRB-\1740 p_12\NN\14622893 less_13\JJR\1740 than_14\IN\1740 0.05_15\CD\1740 )_16\-RRB-\1740 occurred_17\VBD\2623529 more_18\RBR\1740 frequently_19\RB\1740 in_20\IN\13603305 patients_21\NNS\9898892 who_22\WP\8299493 had_23\VBD\2108377 a_24\DT\13649268 <e1>morphine</e1>_25\NN\2707683 infusion_26\NN\14589223 ._27\.\1740
D009020_D013610 NONE there_0\EX\27167 was_1\VBD\836236 also_2\RB\1740 a_3\DT\13649268 higher_4\JJR\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>tachyarrhythmias</e2>_7\NNS\1740 (_8\-LRB-\1740 p_9\NN\14622893 less_10\JJR\1740 than_11\IN\1740 0.05_12\CD\1740 )_13\-RRB-\1740 and_14\CC\1740 ventricular_15\JJ\1740 ectopic_16\JJ\1740 beats_17\NNS\8289449 (_18\-LRB-\1740 p_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.05_22\CD\1740 )_23\-RRB-\1740 in_24\IN\13603305 the_25\DT\1740 <e1>morphine</e1>_26\NN\2707683 infusion_27\NN\14589223 group_28\NN\2137 ._29\.\1740
D009020_D018879 CID there_0\EX\27167 was_1\VBD\836236 also_2\RB\1740 a_3\DT\13649268 higher_4\JJR\1740 incidence_5\NN\13821570 of_6\IN\1740 tachyarrhythmias_7\NNS\1740 (_8\-LRB-\1740 p_9\NN\14622893 less_10\JJR\1740 than_11\IN\1740 0.05_12\CD\1740 )_13\-RRB-\1740 and_14\CC\1740 <e2>ventricular_15\JJ\1740 ectopic_16\JJ\1740 beats</e2>_17\NNS\8289449 (_18\-LRB-\1740 p_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.05_22\CD\1740 )_23\-RRB-\1740 in_24\IN\13603305 the_25\DT\1740 <e1>morphine</e1>_26\NN\2707683 infusion_27\NN\14589223 group_28\NN\2137 ._29\.\1740
8437969
D002927_D054138 CID <e2>sinus_0\NN\5248181 arrest</e2>_1\NN\88481 associated_2\VBN\628491 with_3\IN\1740 continuous-infusion_4\JJ\1740 <e1>cimetidine</e1>_5\NN\14778019 ._6\.\1740
D002927_D054138 CID a_0\DT\13649268 40-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 leukemia_4\NN\14239918 and_5\CC\1740 no_6\DT\7204911 history_7\NN\15120823 of_8\IN\1740 cardiac_9\JJ\1740 disease_10\NN\14061805 developed_11\VBD\1753788 recurrent_12\JJ\1740 ,_13\,\1740 brief_14\JJ\1740 episodes_15\NNS\7283608 of_16\IN\1740 apparent_17\JJ\1740 <e2>sinus_18\NN\5248181 arrest</e2>_19\NN\88481 while_20\IN\15122231 receiving_21\VBG\2210855 continuous-infusion_22\JJ\1740 <e1>cimetidine</e1>_23\NN\14778019 50_24\CD\13745420 mg/hour_25\NN\1740 ._26\.\1740
D002927_D054138 CID this_0\DT\1740 is_1\VBZ\836236 the_2\DT\1740 first_3\JJ\1740 reported_4\VBN\831651 case_5\NN\7283608 of_6\IN\1740 <e2>sinus_7\NN\5248181 arrest</e2>_8\NN\88481 associated_9\VBN\628491 with_10\IN\1740 continuous-infusion_11\JJ\1740 <e1>cimetidine</e1>_12\NN\14778019 ._13\.\1740
D002927_D001919 CID the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 intermittent_3\JJ\1740 intravenous_4\JJ\1740 infusions_5\NNS\14589223 of_6\IN\1740 <e1>cimetidine</e1>_7\NN\14778019 is_8\VBZ\836236 infrequently_9\RB\1740 associated_10\VBN\628491 with_11\IN\1740 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 <e2>bradyarrhythmias</e2>_15\NNS\1740 ._16\.\1740
D002927_D007938 NONE a_0\DT\13649268 40-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 <e2>leukemia</e2>_4\NN\14239918 and_5\CC\1740 no_6\DT\7204911 history_7\NN\15120823 of_8\IN\1740 cardiac_9\JJ\1740 disease_10\NN\14061805 developed_11\VBD\1753788 recurrent_12\JJ\1740 ,_13\,\1740 brief_14\JJ\1740 episodes_15\NNS\7283608 of_16\IN\1740 apparent_17\JJ\1740 sinus_18\NN\5248181 arrest_19\NN\88481 while_20\IN\15122231 receiving_21\VBG\2210855 continuous-infusion_22\JJ\1740 <e1>cimetidine</e1>_23\NN\14778019 50_24\CD\13745420 mg/hour_25\NN\1740 ._26\.\1740
D002927_D006331 NONE a_0\DT\13649268 40-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 leukemia_4\NN\14239918 and_5\CC\1740 no_6\DT\7204911 history_7\NN\15120823 of_8\IN\1740 <e2>cardiac_9\JJ\1740 disease</e2>_10\NN\14061805 developed_11\VBD\1753788 recurrent_12\JJ\1740 ,_13\,\1740 brief_14\JJ\1740 episodes_15\NNS\7283608 of_16\IN\1740 apparent_17\JJ\1740 sinus_18\NN\5248181 arrest_19\NN\88481 while_20\IN\15122231 receiving_21\VBG\2210855 continuous-infusion_22\JJ\1740 <e1>cimetidine</e1>_23\NN\14778019 50_24\CD\13745420 mg/hour_25\NN\1740 ._26\.\1740
D002927_D001145 NONE the_0\DT\1740 <e2>arrhythmias</e2>_1\NNS\14103288 were_2\VBD\836236 temporally_3\RB\1740 related_4\JJ\1740 to_5\TO\1740 <e1>cimetidine</e1>_6\NN\14778019 administration_7\NN\1133281 ,_8\,\1740 disappeared_9\VBD\2609764 after_10\IN\1740 dechallenge_11\NN\1740 ,_12\,\1740 and_13\CC\1740 did_14\VBD\1640855 not_15\RB\1740 recur_16\VB\339934 during_17\IN\1740 ranitidine_18\NN\14778019 treatment_19\NN\654885 ._20\.\1740
D011899_D001145 NONE the_0\DT\1740 <e2>arrhythmias</e2>_1\NNS\14103288 were_2\VBD\836236 temporally_3\RB\1740 related_4\JJ\1740 to_5\TO\1740 cimetidine_6\NN\14778019 administration_7\NN\1133281 ,_8\,\1740 disappeared_9\VBD\2609764 after_10\IN\1740 dechallenge_11\NN\1740 ,_12\,\1740 and_13\CC\1740 did_14\VBD\1640855 not_15\RB\1740 recur_16\VB\339934 during_17\IN\1740 <e1>ranitidine</e1>_18\NN\14778019 treatment_19\NN\654885 ._20\.\1740
2870085
C047847_D013610 NONE <e1>flestolol</e1>_0\NNP\1740 produced_1\VBD\1617192 a_2\DT\13649268 dose-dependent_3\JJ\1740 attenuation_4\NN\7427337 of_5\IN\1740 isoproterenol-induced_6\JJ\1740 <e2>tachycardia</e2>_7\NN\14110674 ._8\.\1740
D007545_D013610 CID flestolol_0\NNP\1740 produced_1\VBD\1617192 a_2\DT\13649268 dose-dependent_3\JJ\1740 attenuation_4\NN\7427337 of_5\IN\1740 <e1>isoproterenol-induced</e1>_6\JJ\1740 <e2>tachycardia</e2>_7\NN\14110674 ._8\.\1740
C047847_D013617 NONE <e1>flestolol</e1>_0\NNP\1740 effectively_1\RB\1740 reduced_2\VBD\441445 heart_3\NN\5919034 rate_4\NN\13815152 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 <e2>supraventricular_8\JJ\1740 tachyarrhythmia</e2>_9\NN\1740 ._10\.\1740
C047847_D000789 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 <e2>unstable_3\JJ\1740 angina</e2>_4\NN\14171682 ,_5\,\1740 <e1>flestolol</e1>_6\NN\1740 infusion_7\NN\14589223 was_8\VBD\836236 found_9\VBN\2426171 to_10\TO\1740 be_11\VB\836236 safe_12\JJ\1740 and_13\CC\1740 effective_14\JJ\1740 in_15\IN\13603305 controlling_16\VBG\2422663 chest_17\JJ\1740 pain_18\NN\14299637 ._19\.\1740
C047847_D002637 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 unstable_3\JJ\1740 angina_4\NN\14171682 ,_5\,\1740 <e1>flestolol</e1>_6\NN\1740 infusion_7\NN\14589223 was_8\VBD\836236 found_9\VBN\2426171 to_10\TO\1740 be_11\VB\836236 safe_12\JJ\1740 and_13\CC\1740 effective_14\JJ\1740 in_15\IN\13603305 controlling_16\VBG\2422663 <e2>chest_17\JJ\1740 pain</e2>_18\NN\14299637 ._19\.\1740
7053303
D002927_D003704 CID there_0\EX\27167 was_1\VBD\836236 only_2\RB\1740 one_3\CD\13741022 case_4\NN\7283608 of_5\IN\1740 <e2>dementia</e2>_6\NN\14395018 possibly_7\RB\1740 due_8\JJ\1740 to_9\TO\1740 <e1>cimetidine</e1>_10\NN\14778019 (_11\-LRB-\1740 with_12\IN\1740 a_13\DT\13649268 drug_14\NN\14778436 level_15\NN\4916342 of_16\IN\1740 1.9_17\CD\1740 microgram/ml_18\NN\1740 6_19\CD\13741022 hr_20\NN\15154774 after_21\IN\1740 a_22\DT\13649268 dose_23\NN\3740161 )_24\-RRB-\1740 in_25\IN\13603305 a_26\DT\13649268 group_27\NN\2137 of_28\IN\1740 13_29\CD\13745420 patients_30\NNS\9898892 without_31\IN\1740 liver_32\NN\5298729 or_33\CC\3541091 kidney_34\NN\5333259 disease_35\NN\14061805 who_36\WP\8299493 had_37\VBD\2108377 cimetidine_38\NN\14778019 levels_39\NNS\4916342 above_40\IN\6392001 1.25_41\CD\1740 microgram/ml_42\NN\1740 ._43\.\1740
D002927_D003704 CID there_0\EX\27167 was_1\VBD\836236 only_2\RB\1740 one_3\CD\13741022 case_4\NN\7283608 of_5\IN\1740 <e2>dementia</e2>_6\NN\14395018 possibly_7\RB\1740 due_8\JJ\1740 to_9\TO\1740 cimetidine_10\NN\14778019 (_11\-LRB-\1740 with_12\IN\1740 a_13\DT\13649268 drug_14\NN\14778436 level_15\NN\4916342 of_16\IN\1740 1.9_17\CD\1740 microgram/ml_18\NN\1740 6_19\CD\13741022 hr_20\NN\15154774 after_21\IN\1740 a_22\DT\13649268 dose_23\NN\3740161 )_24\-RRB-\1740 in_25\IN\13603305 a_26\DT\13649268 group_27\NN\2137 of_28\IN\1740 13_29\CD\13745420 patients_30\NNS\9898892 without_31\IN\1740 liver_32\NN\5298729 or_33\CC\3541091 kidney_34\NN\5333259 disease_35\NN\14061805 who_36\WP\8299493 had_37\VBD\2108377 <e1>cimetidine</e1>_38\NN\14778019 levels_39\NNS\4916342 above_40\IN\6392001 1.25_41\CD\1740 microgram/ml_42\NN\1740 ._43\.\1740
D002927_D003704 CID thus_0\RB\1740 ,_1\,\1740 high_2\JJ\1740 <e1>cimetidine</e1>_3\NN\14778019 levels_4\NNS\4916342 alone_5\RB\1740 do_6\VBP\1640855 not_7\RB\1740 always_8\RB\1740 induce_9\VB\1627355 <e2>dementia</e2>_10\NN\14395018 ._11\.\1740
D002927_D008107 NONE there_0\EX\27167 was_1\VBD\836236 only_2\RB\1740 one_3\CD\13741022 case_4\NN\7283608 of_5\IN\1740 dementia_6\NN\14395018 possibly_7\RB\1740 due_8\JJ\1740 to_9\TO\1740 <e1>cimetidine</e1>_10\NN\14778019 (_11\-LRB-\1740 with_12\IN\1740 a_13\DT\13649268 drug_14\NN\14778436 level_15\NN\4916342 of_16\IN\1740 1.9_17\CD\1740 microgram/ml_18\NN\1740 6_19\CD\13741022 hr_20\NN\15154774 after_21\IN\1740 a_22\DT\13649268 dose_23\NN\3740161 )_24\-RRB-\1740 in_25\IN\13603305 a_26\DT\13649268 group_27\NN\2137 of_28\IN\1740 13_29\CD\13745420 patients_30\NNS\9898892 without_31\IN\1740 <e2>liver_32\NN\5298729 or_33\CC\3541091 kidney_34\NN\5333259 disease</e2>_35\NN\14061805 who_36\WP\8299493 had_37\VBD\2108377 cimetidine_38\NN\14778019 levels_39\NNS\4916342 above_40\IN\6392001 1.25_41\CD\1740 microgram/ml_42\NN\1740 ._43\.\1740
D002927_D008107 NONE there_0\EX\27167 was_1\VBD\836236 only_2\RB\1740 one_3\CD\13741022 case_4\NN\7283608 of_5\IN\1740 dementia_6\NN\14395018 possibly_7\RB\1740 due_8\JJ\1740 to_9\TO\1740 cimetidine_10\NN\14778019 (_11\-LRB-\1740 with_12\IN\1740 a_13\DT\13649268 drug_14\NN\14778436 level_15\NN\4916342 of_16\IN\1740 1.9_17\CD\1740 microgram/ml_18\NN\1740 6_19\CD\13741022 hr_20\NN\15154774 after_21\IN\1740 a_22\DT\13649268 dose_23\NN\3740161 )_24\-RRB-\1740 in_25\IN\13603305 a_26\DT\13649268 group_27\NN\2137 of_28\IN\1740 13_29\CD\13745420 patients_30\NNS\9898892 without_31\IN\1740 <e2>liver_32\NN\5298729 or_33\CC\3541091 kidney_34\NN\5333259 disease</e2>_35\NN\14061805 who_36\WP\8299493 had_37\VBD\2108377 <e1>cimetidine</e1>_38\NN\14778019 levels_39\NNS\4916342 above_40\IN\6392001 1.25_41\CD\1740 microgram/ml_42\NN\1740 ._43\.\1740
D002927_D007674 NONE there_0\EX\27167 was_1\VBD\836236 only_2\RB\1740 one_3\CD\13741022 case_4\NN\7283608 of_5\IN\1740 dementia_6\NN\14395018 possibly_7\RB\1740 due_8\JJ\1740 to_9\TO\1740 <e1>cimetidine</e1>_10\NN\14778019 (_11\-LRB-\1740 with_12\IN\1740 a_13\DT\13649268 drug_14\NN\14778436 level_15\NN\4916342 of_16\IN\1740 1.9_17\CD\1740 microgram/ml_18\NN\1740 6_19\CD\13741022 hr_20\NN\15154774 after_21\IN\1740 a_22\DT\13649268 dose_23\NN\3740161 )_24\-RRB-\1740 in_25\IN\13603305 a_26\DT\13649268 group_27\NN\2137 of_28\IN\1740 13_29\CD\13745420 patients_30\NNS\9898892 without_31\IN\1740 <e2>liver_32\NN\5298729 or_33\CC\3541091 kidney_34\NN\5333259 disease</e2>_35\NN\14061805 who_36\WP\8299493 had_37\VBD\2108377 cimetidine_38\NN\14778019 levels_39\NNS\4916342 above_40\IN\6392001 1.25_41\CD\1740 microgram/ml_42\NN\1740 ._43\.\1740
D002927_D007674 NONE there_0\EX\27167 was_1\VBD\836236 only_2\RB\1740 one_3\CD\13741022 case_4\NN\7283608 of_5\IN\1740 dementia_6\NN\14395018 possibly_7\RB\1740 due_8\JJ\1740 to_9\TO\1740 cimetidine_10\NN\14778019 (_11\-LRB-\1740 with_12\IN\1740 a_13\DT\13649268 drug_14\NN\14778436 level_15\NN\4916342 of_16\IN\1740 1.9_17\CD\1740 microgram/ml_18\NN\1740 6_19\CD\13741022 hr_20\NN\15154774 after_21\IN\1740 a_22\DT\13649268 dose_23\NN\3740161 )_24\-RRB-\1740 in_25\IN\13603305 a_26\DT\13649268 group_27\NN\2137 of_28\IN\1740 13_29\CD\13745420 patients_30\NNS\9898892 without_31\IN\1740 <e2>liver_32\NN\5298729 or_33\CC\3541091 kidney_34\NN\5333259 disease</e2>_35\NN\14061805 who_36\WP\8299493 had_37\VBD\2108377 <e1>cimetidine</e1>_38\NN\14778019 levels_39\NNS\4916342 above_40\IN\6392001 1.25_41\CD\1740 microgram/ml_42\NN\1740 ._43\.\1740
12921865
D013256_D012640 NONE protective_0\JJ\1740 efficacy_1\NN\5199286 of_2\IN\1740 neuroactive_3\JJ\1740 <e1>steroids</e1>_4\NNS\14727670 against_5\IN\1740 cocaine_6\NN\3492717 <e2>kindled-seizures</e2>_7\NN\1740 in_8\IN\13603305 mice_9\NNS\2329401 ._10\.\1740
D013256_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 evaluate_6\VB\670261 two_7\CD\13741022 endogenous_8\JJ\1740 and_9\CC\1740 one_10\CD\13741022 synthetic_11\JJ\1740 neuroactive_12\JJ\1740 <e1>steroid</e1>_13\NN\14727670 that_14\WDT\1740 positively_15\RB\1740 modulate_16\VBP\1724459 the_17\DT\1740 gamma-aminobutyric_18\JJ\1740 acid_19\NN\14818238 (_20\-LRB-\1740 gaba(a_21\NN\1740 )_22\-RRB-\1740 )_23\-RRB-\1740 receptor_24\NN\5225602 against_25\IN\1740 the_26\DT\1740 increase_27\NN\13576355 in_28\IN\13603305 sensitivity_29\NN\5651971 to_30\TO\1740 the_31\DT\1740 convulsant_32\JJ\1740 effects_33\NNS\13245626 of_34\IN\1740 cocaine_35\NN\3492717 engendered_36\VBN\1645601 by_37\IN\1740 repeated_38\VBN\952524 cocaine_39\NN\3492717 administration_40\NN\1133281 (_41\-LRB-\1740 <e2>seizure</e2>_42\JJ\1740 kindling_43\NN\15101361 )_44\-RRB-\1740 ._45\.\1740
D003042_D012640 CID protective_0\JJ\1740 efficacy_1\NN\5199286 of_2\IN\1740 neuroactive_3\JJ\1740 steroids_4\NNS\14727670 against_5\IN\1740 <e1>cocaine</e1>_6\NN\3492717 <e2>kindled-seizures</e2>_7\NN\1740 in_8\IN\13603305 mice_9\NNS\2329401 ._10\.\1740
D003042_D012640 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 evaluate_6\VB\670261 two_7\CD\13741022 endogenous_8\JJ\1740 and_9\CC\1740 one_10\CD\13741022 synthetic_11\JJ\1740 neuroactive_12\JJ\1740 steroid_13\NN\14727670 that_14\WDT\1740 positively_15\RB\1740 modulate_16\VBP\1724459 the_17\DT\1740 gamma-aminobutyric_18\JJ\1740 acid_19\NN\14818238 (_20\-LRB-\1740 gaba(a_21\NN\1740 )_22\-RRB-\1740 )_23\-RRB-\1740 receptor_24\NN\5225602 against_25\IN\1740 the_26\DT\1740 increase_27\NN\13576355 in_28\IN\13603305 sensitivity_29\NN\5651971 to_30\TO\1740 the_31\DT\1740 convulsant_32\JJ\1740 effects_33\NNS\13245626 of_34\IN\1740 <e1>cocaine</e1>_35\NN\3492717 engendered_36\VBN\1645601 by_37\IN\1740 repeated_38\VBN\952524 cocaine_39\NN\3492717 administration_40\NN\1133281 (_41\-LRB-\1740 <e2>seizure</e2>_42\JJ\1740 kindling_43\NN\15101361 )_44\-RRB-\1740 ._45\.\1740
D003042_D012640 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 evaluate_6\VB\670261 two_7\CD\13741022 endogenous_8\JJ\1740 and_9\CC\1740 one_10\CD\13741022 synthetic_11\JJ\1740 neuroactive_12\JJ\1740 steroid_13\NN\14727670 that_14\WDT\1740 positively_15\RB\1740 modulate_16\VBP\1724459 the_17\DT\1740 gamma-aminobutyric_18\JJ\1740 acid_19\NN\14818238 (_20\-LRB-\1740 gaba(a_21\NN\1740 )_22\-RRB-\1740 )_23\-RRB-\1740 receptor_24\NN\5225602 against_25\IN\1740 the_26\DT\1740 increase_27\NN\13576355 in_28\IN\13603305 sensitivity_29\NN\5651971 to_30\TO\1740 the_31\DT\1740 convulsant_32\JJ\1740 effects_33\NNS\13245626 of_34\IN\1740 cocaine_35\NN\3492717 engendered_36\VBN\1645601 by_37\IN\1740 repeated_38\VBN\952524 <e1>cocaine</e1>_39\NN\3492717 administration_40\NN\1133281 (_41\-LRB-\1740 <e2>seizure</e2>_42\JJ\1740 kindling_43\NN\15101361 )_44\-RRB-\1740 ._45\.\1740
D003042_D012640 CID allopregnanolone_0\NN\1740 (_1\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 pregnanolone_5\NN\1740 (_6\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one_7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 ganaxolone_10\NN\1740 (_11\-LRB-\1740 a_12\DT\13649268 synthetic_13\JJ\1740 derivative_14\NN\5802185 of_15\IN\1740 allopregnanolone_16\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one_17\CD\1740 )_18\-RRB-\1740 were_19\VBD\836236 tested_20\VBN\670261 for_21\IN\1740 their_22\PRP$\1740 ability_23\NN\4723816 to_24\TO\1740 suppress_25\VB\2510337 the_26\DT\1740 expression_27\NN\4679549 (_28\-LRB-\1740 anticonvulsant_29\JJ\1740 effect_30\NN\34213 )_31\-RRB-\1740 and_32\CC\1740 development_33\NN\248977 (_34\-LRB-\1740 antiepileptogenic_35\JJ\1740 effect_36\NN\34213 )_37\-RRB-\1740 of_38\IN\1740 <e1>cocaine-kindled</e1>_39\JJ\1740 <e2>seizures</e2>_40\NNS\14081375 in_41\IN\13603305 male_42\JJ\1740 ,_43\,\1740 swiss-webster_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
D003042_D012640 CID kindled_0\JJ\1740 <e2>seizures</e2>_1\NNS\14081375 were_2\VBD\836236 induced_3\VBN\1627355 by_4\IN\1740 daily_5\JJ\1740 administration_6\NN\1133281 of_7\IN\1740 60_8\CD\13745420 mg/kg_9\NN\1740 <e1>cocaine</e1>_10\NN\3492717 for_11\IN\1740 5_12\CD\13741022 days_13\NNS\15140892 ._14\.\1740
D013256_D009422 NONE neuroactive_0\JJ\1740 <e1>steroids</e1>_1\NNS\14727670 demonstrate_2\VBP\2137132 pharmacological_3\JJ\1740 actions_4\NNS\30358 that_5\WDT\1740 have_6\VBP\2108377 relevance_7\NN\13791389 for_8\IN\1740 a_9\DT\13649268 host_10\NN\9605289 of_11\IN\1740 <e2>neurological_12\JJ\1740 and_13\CC\1740 psychiatric_14\JJ\1740 disorders</e2>_15\NNS\14034177 ._16\.\1740
D013256_D001523 NONE neuroactive_0\JJ\1740 <e1>steroids</e1>_1\NNS\14727670 demonstrate_2\VBP\2137132 pharmacological_3\JJ\1740 actions_4\NNS\30358 that_5\WDT\1740 have_6\VBP\2108377 relevance_7\NN\13791389 for_8\IN\1740 a_9\DT\13649268 host_10\NN\9605289 of_11\IN\1740 <e2>neurological_12\JJ\1740 and_13\CC\1740 psychiatric_14\JJ\1740 disorders</e2>_15\NNS\14034177 ._16\.\1740
D005680_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 evaluate_6\VB\670261 two_7\CD\13741022 endogenous_8\JJ\1740 and_9\CC\1740 one_10\CD\13741022 synthetic_11\JJ\1740 neuroactive_12\JJ\1740 steroid_13\NN\14727670 that_14\WDT\1740 positively_15\RB\1740 modulate_16\VBP\1724459 the_17\DT\1740 <e1>gamma-aminobutyric_18\JJ\1740 acid</e1>_19\NN\14818238 (_20\-LRB-\1740 gaba(a_21\NN\1740 )_22\-RRB-\1740 )_23\-RRB-\1740 receptor_24\NN\5225602 against_25\IN\1740 the_26\DT\1740 increase_27\NN\13576355 in_28\IN\13603305 sensitivity_29\NN\5651971 to_30\TO\1740 the_31\DT\1740 convulsant_32\JJ\1740 effects_33\NNS\13245626 of_34\IN\1740 cocaine_35\NN\3492717 engendered_36\VBN\1645601 by_37\IN\1740 repeated_38\VBN\952524 cocaine_39\NN\3492717 administration_40\NN\1133281 (_41\-LRB-\1740 <e2>seizure</e2>_42\JJ\1740 kindling_43\NN\15101361 )_44\-RRB-\1740 ._45\.\1740
D005680_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 evaluate_6\VB\670261 two_7\CD\13741022 endogenous_8\JJ\1740 and_9\CC\1740 one_10\CD\13741022 synthetic_11\JJ\1740 neuroactive_12\JJ\1740 steroid_13\NN\14727670 that_14\WDT\1740 positively_15\RB\1740 modulate_16\VBP\1724459 the_17\DT\1740 gamma-aminobutyric_18\JJ\1740 acid_19\NN\14818238 (_20\-LRB-\1740 <e1>gaba(a</e1>_21\NN\1740 )_22\-RRB-\1740 )_23\-RRB-\1740 receptor_24\NN\5225602 against_25\IN\1740 the_26\DT\1740 increase_27\NN\13576355 in_28\IN\13603305 sensitivity_29\NN\5651971 to_30\TO\1740 the_31\DT\1740 convulsant_32\JJ\1740 effects_33\NNS\13245626 of_34\IN\1740 cocaine_35\NN\3492717 engendered_36\VBN\1645601 by_37\IN\1740 repeated_38\VBN\952524 cocaine_39\NN\3492717 administration_40\NN\1133281 (_41\-LRB-\1740 <e2>seizure</e2>_42\JJ\1740 kindling_43\NN\15101361 )_44\-RRB-\1740 ._45\.\1740
D005680_D012640 NONE all_0\DT\1740 of_1\IN\1740 these_2\DT\1740 positive_3\JJ\1740 <e1>gaba(a</e1>_4\NN\1740 )_5\-RRB-\1740 modulators_6\NNS\1740 suppressed_7\VBD\2510337 the_8\DT\1740 expression_9\NN\4679549 of_10\IN\1740 kindled_11\VBN\2764245 <e2>seizures</e2>_12\NNS\14081375 ,_13\,\1740 whereas_14\IN\1740 only_15\RB\1740 allopregnanolone_16\NN\1740 and_17\CC\1740 ganaxolone_18\NN\1740 inhibited_19\VBD\2510337 the_20\DT\1740 development_21\NN\248977 of_22\IN\1740 kindling_23\NN\15101361 ._24\.\1740
D011280_D012640 NONE <e1>allopregnanolone</e1>_0\NN\1740 (_1\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 pregnanolone_5\NN\1740 (_6\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one_7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 ganaxolone_10\NN\1740 (_11\-LRB-\1740 a_12\DT\13649268 synthetic_13\JJ\1740 derivative_14\NN\5802185 of_15\IN\1740 allopregnanolone_16\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one_17\CD\1740 )_18\-RRB-\1740 were_19\VBD\836236 tested_20\VBN\670261 for_21\IN\1740 their_22\PRP$\1740 ability_23\NN\4723816 to_24\TO\1740 suppress_25\VB\2510337 the_26\DT\1740 expression_27\NN\4679549 (_28\-LRB-\1740 anticonvulsant_29\JJ\1740 effect_30\NN\34213 )_31\-RRB-\1740 and_32\CC\1740 development_33\NN\248977 (_34\-LRB-\1740 antiepileptogenic_35\JJ\1740 effect_36\NN\34213 )_37\-RRB-\1740 of_38\IN\1740 cocaine-kindled_39\JJ\1740 <e2>seizures</e2>_40\NNS\14081375 in_41\IN\13603305 male_42\JJ\1740 ,_43\,\1740 swiss-webster_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
D011280_D012640 NONE allopregnanolone_0\NN\1740 (_1\-LRB-\1740 <e1>3alpha-hydroxy-5alpha-pregnan-20-one</e1>_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 pregnanolone_5\NN\1740 (_6\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one_7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 ganaxolone_10\NN\1740 (_11\-LRB-\1740 a_12\DT\13649268 synthetic_13\JJ\1740 derivative_14\NN\5802185 of_15\IN\1740 allopregnanolone_16\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one_17\CD\1740 )_18\-RRB-\1740 were_19\VBD\836236 tested_20\VBN\670261 for_21\IN\1740 their_22\PRP$\1740 ability_23\NN\4723816 to_24\TO\1740 suppress_25\VB\2510337 the_26\DT\1740 expression_27\NN\4679549 (_28\-LRB-\1740 anticonvulsant_29\JJ\1740 effect_30\NN\34213 )_31\-RRB-\1740 and_32\CC\1740 development_33\NN\248977 (_34\-LRB-\1740 antiepileptogenic_35\JJ\1740 effect_36\NN\34213 )_37\-RRB-\1740 of_38\IN\1740 cocaine-kindled_39\JJ\1740 <e2>seizures</e2>_40\NNS\14081375 in_41\IN\13603305 male_42\JJ\1740 ,_43\,\1740 swiss-webster_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
D011280_D012640 NONE allopregnanolone_0\NN\1740 (_1\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 <e1>pregnanolone</e1>_5\NN\1740 (_6\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one_7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 ganaxolone_10\NN\1740 (_11\-LRB-\1740 a_12\DT\13649268 synthetic_13\JJ\1740 derivative_14\NN\5802185 of_15\IN\1740 allopregnanolone_16\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one_17\CD\1740 )_18\-RRB-\1740 were_19\VBD\836236 tested_20\VBN\670261 for_21\IN\1740 their_22\PRP$\1740 ability_23\NN\4723816 to_24\TO\1740 suppress_25\VB\2510337 the_26\DT\1740 expression_27\NN\4679549 (_28\-LRB-\1740 anticonvulsant_29\JJ\1740 effect_30\NN\34213 )_31\-RRB-\1740 and_32\CC\1740 development_33\NN\248977 (_34\-LRB-\1740 antiepileptogenic_35\JJ\1740 effect_36\NN\34213 )_37\-RRB-\1740 of_38\IN\1740 cocaine-kindled_39\JJ\1740 <e2>seizures</e2>_40\NNS\14081375 in_41\IN\13603305 male_42\JJ\1740 ,_43\,\1740 swiss-webster_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
D011280_D012640 NONE allopregnanolone_0\NN\1740 (_1\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 pregnanolone_5\NN\1740 (_6\-LRB-\1740 <e1>3alpha-hydroxy-5beta-pregnan-20-one</e1>_7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 ganaxolone_10\NN\1740 (_11\-LRB-\1740 a_12\DT\13649268 synthetic_13\JJ\1740 derivative_14\NN\5802185 of_15\IN\1740 allopregnanolone_16\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one_17\CD\1740 )_18\-RRB-\1740 were_19\VBD\836236 tested_20\VBN\670261 for_21\IN\1740 their_22\PRP$\1740 ability_23\NN\4723816 to_24\TO\1740 suppress_25\VB\2510337 the_26\DT\1740 expression_27\NN\4679549 (_28\-LRB-\1740 anticonvulsant_29\JJ\1740 effect_30\NN\34213 )_31\-RRB-\1740 and_32\CC\1740 development_33\NN\248977 (_34\-LRB-\1740 antiepileptogenic_35\JJ\1740 effect_36\NN\34213 )_37\-RRB-\1740 of_38\IN\1740 cocaine-kindled_39\JJ\1740 <e2>seizures</e2>_40\NNS\14081375 in_41\IN\13603305 male_42\JJ\1740 ,_43\,\1740 swiss-webster_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
D011280_D012640 NONE allopregnanolone_0\NN\1740 (_1\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 pregnanolone_5\NN\1740 (_6\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one_7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 ganaxolone_10\NN\1740 (_11\-LRB-\1740 a_12\DT\13649268 synthetic_13\JJ\1740 derivative_14\NN\5802185 of_15\IN\1740 <e1>allopregnanolone</e1>_16\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one_17\CD\1740 )_18\-RRB-\1740 were_19\VBD\836236 tested_20\VBN\670261 for_21\IN\1740 their_22\PRP$\1740 ability_23\NN\4723816 to_24\TO\1740 suppress_25\VB\2510337 the_26\DT\1740 expression_27\NN\4679549 (_28\-LRB-\1740 anticonvulsant_29\JJ\1740 effect_30\NN\34213 )_31\-RRB-\1740 and_32\CC\1740 development_33\NN\248977 (_34\-LRB-\1740 antiepileptogenic_35\JJ\1740 effect_36\NN\34213 )_37\-RRB-\1740 of_38\IN\1740 cocaine-kindled_39\JJ\1740 <e2>seizures</e2>_40\NNS\14081375 in_41\IN\13603305 male_42\JJ\1740 ,_43\,\1740 swiss-webster_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
D011280_D012640 NONE all_0\DT\1740 of_1\IN\1740 these_2\DT\1740 positive_3\JJ\1740 gaba(a_4\NN\1740 )_5\-RRB-\1740 modulators_6\NNS\1740 suppressed_7\VBD\2510337 the_8\DT\1740 expression_9\NN\4679549 of_10\IN\1740 kindled_11\VBN\2764245 <e2>seizures</e2>_12\NNS\14081375 ,_13\,\1740 whereas_14\IN\1740 only_15\RB\1740 <e1>allopregnanolone</e1>_16\NN\1740 and_17\CC\1740 ganaxolone_18\NN\1740 inhibited_19\VBD\2510337 the_20\DT\1740 development_21\NN\248977 of_22\IN\1740 kindling_23\NN\15101361 ._24\.\1740
C105051_D012640 NONE allopregnanolone_0\NN\1740 (_1\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 pregnanolone_5\NN\1740 (_6\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one_7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 <e1>ganaxolone</e1>_10\NN\1740 (_11\-LRB-\1740 a_12\DT\13649268 synthetic_13\JJ\1740 derivative_14\NN\5802185 of_15\IN\1740 allopregnanolone_16\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one_17\CD\1740 )_18\-RRB-\1740 were_19\VBD\836236 tested_20\VBN\670261 for_21\IN\1740 their_22\PRP$\1740 ability_23\NN\4723816 to_24\TO\1740 suppress_25\VB\2510337 the_26\DT\1740 expression_27\NN\4679549 (_28\-LRB-\1740 anticonvulsant_29\JJ\1740 effect_30\NN\34213 )_31\-RRB-\1740 and_32\CC\1740 development_33\NN\248977 (_34\-LRB-\1740 antiepileptogenic_35\JJ\1740 effect_36\NN\34213 )_37\-RRB-\1740 of_38\IN\1740 cocaine-kindled_39\JJ\1740 <e2>seizures</e2>_40\NNS\14081375 in_41\IN\13603305 male_42\JJ\1740 ,_43\,\1740 swiss-webster_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
C105051_D012640 NONE allopregnanolone_0\NN\1740 (_1\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 pregnanolone_5\NN\1740 (_6\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one_7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 ganaxolone_10\NN\1740 (_11\-LRB-\1740 a_12\DT\13649268 synthetic_13\JJ\1740 derivative_14\NN\5802185 of_15\IN\1740 allopregnanolone_16\NN\1740 <e1>3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one</e1>_17\CD\1740 )_18\-RRB-\1740 were_19\VBD\836236 tested_20\VBN\670261 for_21\IN\1740 their_22\PRP$\1740 ability_23\NN\4723816 to_24\TO\1740 suppress_25\VB\2510337 the_26\DT\1740 expression_27\NN\4679549 (_28\-LRB-\1740 anticonvulsant_29\JJ\1740 effect_30\NN\34213 )_31\-RRB-\1740 and_32\CC\1740 development_33\NN\248977 (_34\-LRB-\1740 antiepileptogenic_35\JJ\1740 effect_36\NN\34213 )_37\-RRB-\1740 of_38\IN\1740 cocaine-kindled_39\JJ\1740 <e2>seizures</e2>_40\NNS\14081375 in_41\IN\13603305 male_42\JJ\1740 ,_43\,\1740 swiss-webster_44\NN\1740 mice_45\NNS\2329401 ._46\.\1740
C105051_D012640 NONE all_0\DT\1740 of_1\IN\1740 these_2\DT\1740 positive_3\JJ\1740 gaba(a_4\NN\1740 )_5\-RRB-\1740 modulators_6\NNS\1740 suppressed_7\VBD\2510337 the_8\DT\1740 expression_9\NN\4679549 of_10\IN\1740 kindled_11\VBN\2764245 <e2>seizures</e2>_12\NNS\14081375 ,_13\,\1740 whereas_14\IN\1740 only_15\RB\1740 allopregnanolone_16\NN\1740 and_17\CC\1740 <e1>ganaxolone</e1>_18\NN\1740 inhibited_19\VBD\2510337 the_20\DT\1740 development_21\NN\248977 of_22\IN\1740 kindling_23\NN\15101361 ._24\.\1740
16904497
D013256_D011128 NONE <e2>cauda_0\JJ\1740 equina_1\NN\1740 syndrome</e2>_2\NN\5870365 after_3\IN\1740 epidural_4\JJ\1740 <e1>steroid</e1>_5\NN\14727670 injection_6\NN\320852 :_7\:\1740 a_8\DT\13649268 case_9\NN\7283608 report_10\NN\6470073 ._11\.\1740
D013256_D011843 NONE objective_0\NN\5980875 :_1\:\1740 conventional_2\JJ\1740 treatment_3\NN\654885 methods_4\NNS\5616786 of_5\IN\1740 lumbusacral_6\JJ\1740 <e2>radiculopathy</e2>_7\NN\1740 are_8\VBP\836236 physical_9\JJ\1740 therapy_10\NN\657604 ,_11\,\1740 epidural_12\JJ\1740 <e1>steroid</e1>_13\NN\14727670 injections_14\NNS\320852 ,_15\,\1740 oral_16\JJ\1740 medications_17\NNS\3247620 ,_18\,\1740 and_19\CC\1740 spinal_20\JJ\1740 manipulative_21\NN\1740 therapy_22\NN\657604 ._23\.\1740
D014221_D011128 NONE the_0\DT\1740 following_1\VBG\1835496 case_2\NN\7283608 is_3\VBZ\836236 a_4\DT\13649268 report_5\NN\6470073 of_6\IN\1740 <e2>cauda_7\JJ\1740 equina_8\NN\1740 syndrome</e2>_9\NN\5870365 possibly_10\RB\1740 caused_11\VBN\1617192 by_12\IN\1740 epidural_13\JJ\1740 injection_14\NN\320852 of_15\IN\1740 <e1>triamcinolone</e1>_16\NN\14751417 and_17\CC\1740 bupivacaine_18\NN\1740 ._19\.\1740
D002045_D011128 CID the_0\DT\1740 following_1\VBG\1835496 case_2\NN\7283608 is_3\VBZ\836236 a_4\DT\13649268 report_5\NN\6470073 of_6\IN\1740 <e2>cauda_7\JJ\1740 equina_8\NN\1740 syndrome</e2>_9\NN\5870365 possibly_10\RB\1740 caused_11\VBN\1617192 by_12\IN\1740 epidural_13\JJ\1740 injection_14\NN\320852 of_15\IN\1740 triamcinolone_16\NN\14751417 and_17\CC\1740 <e1>bupivacaine</e1>_18\NN\1740 ._19\.\1740
D013256_D017116 NONE clinical_0\NN\1740 features_1\NN\5849040 :_2\:\1740 a_3\DT\13649268 50-year-old_4\JJ\1740 woman_5\NN\9605289 with_6\IN\1740 <e2>low_7\JJ\1740 back_8\NN\5220461 and_9\CC\1740 right_10\JJ\1740 leg_11\NN\5560244 pain</e2>_12\NN\14299637 was_13\VBD\836236 scheduled_14\VBN\704690 for_15\IN\1740 epidural_16\JJ\1740 <e1>steroid</e1>_17\NN\14727670 injection_18\NN\320852 ._19\.\1740
D013256_D010146 NONE clinical_0\NN\1740 features_1\NN\5849040 :_2\:\1740 a_3\DT\13649268 50-year-old_4\JJ\1740 woman_5\NN\9605289 with_6\IN\1740 <e2>low_7\JJ\1740 back_8\NN\5220461 and_9\CC\1740 right_10\JJ\1740 leg_11\NN\5560244 pain</e2>_12\NN\14299637 was_13\VBD\836236 scheduled_14\VBN\704690 for_15\IN\1740 epidural_16\JJ\1740 <e1>steroid</e1>_17\NN\14727670 injection_18\NN\320852 ._19\.\1740
D013256_D009422 NONE clinical_0\JJ\1740 examination_1\NN\633864 and_2\CC\1740 continued_3\VBD\2367363 vigilance_4\NN\5650579 for_5\IN\1740 <e2>neurologic_6\JJ\1740 deterioration</e2>_7\NN\14560612 after_8\IN\1740 epidural_9\JJ\1740 <e1>steroid</e1>_10\NN\14727670 injections_11\NNS\320852 is_12\VBZ\836236 important_13\JJ\1740 ._14\.\1740
12596116
D015282_D000860 NONE <e1>octreotide-induced</e1>_0\JJ\1740 <e2>hypoxemia</e2>_1\NN\1740 and_2\CC\1740 pulmonary_3\JJ\1740 hypertension_4\NN\14057371 in_5\IN\13603305 premature_6\JJ\1740 neonates_7\NNS\9827683 ._8\.\1740
D015282_D006976 CID <e1>octreotide-induced</e1>_0\JJ\1740 hypoxemia_1\NN\1740 and_2\CC\1740 <e2>pulmonary_3\JJ\1740 hypertension</e2>_4\NN\14057371 in_5\IN\13603305 premature_6\JJ\1740 neonates_7\NNS\9827683 ._8\.\1740
D015282_D006976 CID <e2>pulmonary_0\JJ\1740 hypertension</e2>_1\NN\14057371 developed_2\VBD\1753788 after_3\IN\1740 administration_4\NN\1133281 of_5\IN\1740 a_6\DT\13649268 somatostatin_7\NN\1740 analogue_8\NN\4743605 ,_9\,\1740 <e1>octreotide</e1>_10\NN\1740 ,_11\,\1740 to_12\TO\1740 enhance_13\VB\227165 resolution_14\NN\6470073 of_15\IN\1740 the_16\DT\1740 fistula_17\NN\14253124 ._18\.\1740
D015282_D005402 NONE pulmonary_0\JJ\1740 hypertension_1\NN\14057371 developed_2\VBD\1753788 after_3\IN\1740 administration_4\NN\1133281 of_5\IN\1740 a_6\DT\13649268 somatostatin_7\NN\1740 analogue_8\NN\4743605 ,_9\,\1740 <e1>octreotide</e1>_10\NN\1740 ,_11\,\1740 to_12\TO\1740 enhance_13\VB\227165 resolution_14\NN\6470073 of_15\IN\1740 the_16\DT\1740 <e2>fistula</e2>_17\NN\14253124 ._18\.\1740
16337777
D010862_D004827 NONE investigation_0\NN\5797597 of_1\IN\1740 mitochondrial_2\JJ\1740 involvement_3\NN\1080366 in_4\IN\13603305 the_5\DT\1740 experimental_6\JJ\1740 model_7\NN\5888929 of_8\IN\1740 <e2>epilepsy</e2>_9\NN\14085708 induced_10\VBN\1627355 by_11\IN\1740 <e1>pilocarpine</e1>_12\NN\14712692 ._13\.\1740
D010862_D013226 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 investigated_5\VBD\644583 whether_6\IN\1740 increased_7\VBN\169651 generation_8\NN\7942152 of_9\IN\1740 fr_10\NN\14625458 during_11\IN\1740 <e2>status_12\NN\24720 epilepticus</e2>_13\NN\1740 would_14\MD\1740 be_15\VB\836236 sufficient_16\JJ\1740 to_17\TO\1740 provoke_18\VB\1617192 abnormalities_19\NNS\14034177 in_20\IN\13603305 mtdna_21\NN\1740 and_22\CC\1740 in_23\IN\13603305 the_24\DT\1740 expression_25\NN\4679549 and_26\CC\1740 activity_27\NN\30358 of_28\IN\1740 cytochrome_29\NN\14888884 c_30\NN\13714184 oxidase_31\NN\14732946 (_32\-LRB-\1740 cco_33\NN\1740 )_34\-RRB-\1740 ,_35\,\1740 complex_36\NN\5869584 iv_37\CD\13741022 of_38\IN\1740 the_39\DT\1740 respiratory_40\JJ\1740 chain_41\NN\8457976 ,_42\,\1740 in_43\IN\13603305 the_44\DT\1740 chronic_45\JJ\1740 phase_46\NN\15113229 of_47\IN\1740 the_48\DT\1740 <e1>pilocarpine</e1>_49\NN\14712692 model_50\NN\5888929 of_51\IN\1740 temporal_52\JJ\1740 lobe_53\JJ\1740 epilepsy_54\NN\14085708 ._55\.\1740
D010862_D004833 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 investigated_5\VBD\644583 whether_6\IN\1740 increased_7\VBN\169651 generation_8\NN\7942152 of_9\IN\1740 fr_10\NN\14625458 during_11\IN\1740 status_12\NN\24720 epilepticus_13\NN\1740 would_14\MD\1740 be_15\VB\836236 sufficient_16\JJ\1740 to_17\TO\1740 provoke_18\VB\1617192 abnormalities_19\NNS\14034177 in_20\IN\13603305 mtdna_21\NN\1740 and_22\CC\1740 in_23\IN\13603305 the_24\DT\1740 expression_25\NN\4679549 and_26\CC\1740 activity_27\NN\30358 of_28\IN\1740 cytochrome_29\NN\14888884 c_30\NN\13714184 oxidase_31\NN\14732946 (_32\-LRB-\1740 cco_33\NN\1740 )_34\-RRB-\1740 ,_35\,\1740 complex_36\NN\5869584 iv_37\CD\13741022 of_38\IN\1740 the_39\DT\1740 respiratory_40\JJ\1740 chain_41\NN\8457976 ,_42\,\1740 in_43\IN\13603305 the_44\DT\1740 chronic_45\JJ\1740 phase_46\NN\15113229 of_47\IN\1740 the_48\DT\1740 <e1>pilocarpine</e1>_49\NN\14712692 model_50\NN\5888929 of_51\IN\1740 <e2>temporal_52\JJ\1740 lobe_53\JJ\1740 epilepsy</e2>_54\NN\14085708 ._55\.\1740
18503483
D016559_D020968 CID recovery_0\NN\7357388 of_1\IN\1740 <e1>tacrolimus-associated</e1>_2\JJ\1740 <e2>brachial_3\JJ\1740 neuritis</e2>_4\NN\14336539 after_5\IN\1740 conversion_6\NN\7359599 to_7\TO\1740 everolimus_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 pediatric_11\JJ\1740 renal_12\JJ\1740 transplant_13\NN\5267548 recipient_14\NN\9764201 --_15\:\1740 case_16\NN\7283608 report_17\NN\6470073 and_18\CC\1740 review_19\NN\5733583 of_20\IN\1740 the_21\DT\1740 literature_22\NN\6362953 ._23\.\1740
C107135_D020968 NONE recovery_0\NN\7357388 of_1\IN\1740 tacrolimus-associated_2\JJ\1740 <e2>brachial_3\JJ\1740 neuritis</e2>_4\NN\14336539 after_5\IN\1740 conversion_6\NN\7359599 to_7\TO\1740 <e1>everolimus</e1>_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 pediatric_11\JJ\1740 renal_12\JJ\1740 transplant_13\NN\5267548 recipient_14\NN\9764201 --_15\:\1740 case_16\NN\7283608 report_17\NN\6470073 and_18\CC\1740 review_19\NN\5733583 of_20\IN\1740 the_21\DT\1740 literature_22\NN\6362953 ._23\.\1740
11334364
D000082_D009336 CID in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 <e2>necrotic</e2>_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 <e1>acetaminophen-induced</e1>_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D000082_D009336 CID interestingly_0\RB\1740 ,_1\,\1740 all_2\PDT\1740 the_3\DT\1740 drugs_4\NNS\14778436 ,_5\,\1740 such_6\JJ\1740 as_7\IN\14622893 ,_8\,\1740 <e1>aap</e1>_9\NNP\1740 ,_10\,\1740 ami_11\NN\1740 and_12\CC\1740 dox_13\NN\1740 induced_14\VBD\1627355 apoptotic_15\JJ\1740 death_16\NN\7296428 in_17\IN\13603305 addition_18\NN\3081021 to_19\TO\1740 <e2>necrosis</e2>_20\NN\11444117 in_21\IN\13603305 the_22\DT\1740 respective_23\JJ\1740 organs_24\NNS\7649854 which_25\WDT\1740 was_26\VBD\836236 very_27\RB\1740 effectively_28\RB\1740 blocked_29\VBN\1476483 by_30\IN\1740 gspe_31\NN\1740 ._32\.\1740
D000082_D007674 CID in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 <e1>acetaminophen-induced</e1>_13\JJ\1740 <e2>nephrotoxicity</e2>_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D000082_D007674 CID this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 <e1>acetaminophen</e1>_16\RB\1740 (aap)-induced_17\VBN\1740 <e2>nephrotoxicity</e2>_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D000082_D007674 CID this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 <e1>(aap)-induced</e1>_17\VBN\1740 <e2>nephrotoxicity</e2>_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D000082_D008171 NONE in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 <e1>acetaminophen-induced</e1>_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 <e2>lung_17\NN\5528060 toxicity</e2>_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D000082_D008171 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 <e1>acetaminophen</e1>_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 <e2>lung_22\NN\5528060 toxicity</e2>_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D000082_D008171 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 <e1>(aap)-induced</e1>_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 <e2>lung_22\NN\5528060 toxicity</e2>_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D000082_D066126 NONE in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 <e1>acetaminophen-induced</e1>_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 <e2>cardiotoxicity</e2>_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D000082_D066126 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 <e1>acetaminophen</e1>_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 <e2>cardiotoxicity</e2>_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D000082_D066126 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 <e1>(aap)-induced</e1>_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 <e2>cardiotoxicity</e2>_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D000638_D009336 CID in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 <e2>necrotic</e2>_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 <e1>amiodarone-induced</e1>_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D000638_D009336 CID interestingly_0\RB\1740 ,_1\,\1740 all_2\PDT\1740 the_3\DT\1740 drugs_4\NNS\14778436 ,_5\,\1740 such_6\JJ\1740 as_7\IN\14622893 ,_8\,\1740 aap_9\NNP\1740 ,_10\,\1740 <e1>ami</e1>_11\NN\1740 and_12\CC\1740 dox_13\NN\1740 induced_14\VBD\1627355 apoptotic_15\JJ\1740 death_16\NN\7296428 in_17\IN\13603305 addition_18\NN\3081021 to_19\TO\1740 <e2>necrosis</e2>_20\NN\11444117 in_21\IN\13603305 the_22\DT\1740 respective_23\JJ\1740 organs_24\NNS\7649854 which_25\WDT\1740 was_26\VBD\836236 very_27\RB\1740 effectively_28\RB\1740 blocked_29\VBN\1476483 by_30\IN\1740 gspe_31\NN\1740 ._32\.\1740
D000638_D007674 NONE in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 <e2>nephrotoxicity</e2>_14\NN\1740 ,_15\,\1740 <e1>amiodarone-induced</e1>_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D000638_D007674 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 <e2>nephrotoxicity</e2>_18\NN\1740 ,_19\,\1740 <e1>amiodarone</e1>_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D000638_D007674 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 <e2>nephrotoxicity</e2>_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 <e1>(ami)-induced</e1>_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D000638_D008171 CID in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 <e1>amiodarone-induced</e1>_16\JJ\1740 <e2>lung_17\NN\5528060 toxicity</e2>_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D000638_D008171 CID this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 <e1>amiodarone</e1>_20\JJ\1740 (ami)-induced_21\VBN\1740 <e2>lung_22\NN\5528060 toxicity</e2>_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D000638_D008171 CID this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 <e1>(ami)-induced</e1>_21\VBN\1740 <e2>lung_22\NN\5528060 toxicity</e2>_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D000638_D066126 NONE in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 <e1>amiodarone-induced</e1>_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 <e2>cardiotoxicity</e2>_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D000638_D066126 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 <e1>amiodarone</e1>_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 <e2>cardiotoxicity</e2>_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D000638_D066126 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 <e1>(ami)-induced</e1>_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 <e2>cardiotoxicity</e2>_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D004317_D009336 CID in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 <e2>necrotic</e2>_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 <e1>doxorubicin-induced</e1>_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D004317_D009336 CID interestingly_0\RB\1740 ,_1\,\1740 all_2\PDT\1740 the_3\DT\1740 drugs_4\NNS\14778436 ,_5\,\1740 such_6\JJ\1740 as_7\IN\14622893 ,_8\,\1740 aap_9\NNP\1740 ,_10\,\1740 ami_11\NN\1740 and_12\CC\1740 <e1>dox</e1>_13\NN\1740 induced_14\VBD\1627355 apoptotic_15\JJ\1740 death_16\NN\7296428 in_17\IN\13603305 addition_18\NN\3081021 to_19\TO\1740 <e2>necrosis</e2>_20\NN\11444117 in_21\IN\13603305 the_22\DT\1740 respective_23\JJ\1740 organs_24\NNS\7649854 which_25\WDT\1740 was_26\VBD\836236 very_27\RB\1740 effectively_28\RB\1740 blocked_29\VBN\1476483 by_30\IN\1740 gspe_31\NN\1740 ._32\.\1740
D004317_D007674 NONE in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 <e2>nephrotoxicity</e2>_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 <e1>doxorubicin-induced</e1>_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D004317_D007674 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 <e2>nephrotoxicity</e2>_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 <e1>doxorubicin</e1>_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D004317_D007674 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 <e2>nephrotoxicity</e2>_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 <e1>(dox)-induced</e1>_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D004317_D008171 NONE in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 <e2>lung_17\NN\5528060 toxicity</e2>_18\NN\13576101 and_19\CC\1740 <e1>doxorubicin-induced</e1>_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D004317_D008171 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 <e2>lung_22\NN\5528060 toxicity</e2>_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 <e1>doxorubicin</e1>_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D004317_D008171 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 <e2>lung_22\NN\5528060 toxicity</e2>_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 <e1>(dox)-induced</e1>_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D004317_D066126 CID in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 <e1>doxorubicin-induced</e1>_20\JJ\1740 <e2>cardiotoxicity</e2>_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract_29\NN\14589223 ._30\.\1740
D004317_D066126 CID this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 <e1>doxorubicin</e1>_26\NN\2716866 (dox)-induced_27\JJ\1740 <e2>cardiotoxicity</e2>_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
D004317_D066126 CID this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 <e1>(dox)-induced</e1>_27\JJ\1740 <e2>cardiotoxicity</e2>_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
C511402_D009336 NONE in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 <e2>necrotic</e2>_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 <e1>ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract</e1>_29\NN\14589223 ._30\.\1740
C511402_D009336 NONE interestingly_0\RB\1740 ,_1\,\1740 all_2\PDT\1740 the_3\DT\1740 drugs_4\NNS\14778436 ,_5\,\1740 such_6\JJ\1740 as_7\IN\14622893 ,_8\,\1740 aap_9\NNP\1740 ,_10\,\1740 ami_11\NN\1740 and_12\CC\1740 dox_13\NN\1740 induced_14\VBD\1627355 apoptotic_15\JJ\1740 death_16\NN\7296428 in_17\IN\13603305 addition_18\NN\3081021 to_19\TO\1740 <e2>necrosis</e2>_20\NN\11444117 in_21\IN\13603305 the_22\DT\1740 respective_23\JJ\1740 organs_24\NNS\7649854 which_25\WDT\1740 was_26\VBD\836236 very_27\RB\1740 effectively_28\RB\1740 blocked_29\VBN\1476483 by_30\IN\1740 <e1>gspe</e1>_31\NN\1740 ._32\.\1740
C511402_D007674 NONE in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 <e2>nephrotoxicity</e2>_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 <e1>ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract</e1>_29\NN\14589223 ._30\.\1740
C511402_D007674 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 <e1>ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract</e1>_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 <e2>nephrotoxicity</e2>_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
C511402_D007674 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 <e1>gspe</e1>_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 <e2>nephrotoxicity</e2>_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
C511402_D008171 NONE in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 <e2>lung_17\NN\5528060 toxicity</e2>_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 cardiotoxicity_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 <e1>ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract</e1>_29\NN\14589223 ._30\.\1740
C511402_D008171 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 <e1>ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract</e1>_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 <e2>lung_22\NN\5528060 toxicity</e2>_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
C511402_D008171 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 <e1>gspe</e1>_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 <e2>lung_22\NN\5528060 toxicity</e2>_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 cardiotoxicity_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
C511402_D066126 NONE in_0\FW\13603305 vivo_1\FW\1740 protection_2\NN\407535 of_3\IN\1740 dna_4\JJ\1740 damage_5\NN\7296428 associated_6\VBN\628491 apoptotic_7\JJ\1740 and_8\CC\1740 necrotic_9\JJ\1740 cell_10\NN\3080309 deaths_11\NNS\7296428 during_12\IN\1740 acetaminophen-induced_13\JJ\1740 nephrotoxicity_14\NN\1740 ,_15\,\1740 amiodarone-induced_16\JJ\1740 lung_17\NN\5528060 toxicity_18\NN\13576101 and_19\CC\1740 doxorubicin-induced_20\JJ\1740 <e2>cardiotoxicity</e2>_21\NN\1740 by_22\IN\1740 a_23\DT\13649268 novel_24\JJ\1740 <e1>ih636_25\NN\1740 grape_26\NN\7705931 seed_27\NN\13134947 proanthocyanidin_28\NN\1740 extract</e1>_29\NN\14589223 ._30\.\1740
C511402_D066126 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 <e1>ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract</e1>_10\NN\14589223 (_11\-LRB-\1740 gspe_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 <e2>cardiotoxicity</e2>_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
C511402_D066126 NONE this_0\DT\1740 study_1\NN\635850 assessed_2\VBD\670261 the_3\DT\1740 ability_4\NN\4723816 of_5\IN\1740 ih636_6\NN\1740 grape_7\NN\7705931 seed_8\NN\13134947 proanthocyanidin_9\NN\1740 extract_10\NN\14589223 (_11\-LRB-\1740 <e1>gspe</e1>_12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 prevent_15\VB\1740 acetaminophen_16\RB\1740 (aap)-induced_17\VBN\1740 nephrotoxicity_18\NN\1740 ,_19\,\1740 amiodarone_20\JJ\1740 (ami)-induced_21\VBN\1740 lung_22\NN\5528060 toxicity_23\NN\13576101 ,_24\,\1740 and_25\CC\1740 doxorubicin_26\NN\2716866 (dox)-induced_27\JJ\1740 <e2>cardiotoxicity</e2>_28\NN\1740 in_29\IN\13603305 mice_30\NNS\2329401 ._31\.\1740
C511402_D017695 NONE histopathological_0\JJ\1740 examination_1\NN\633864 of_2\IN\1740 kidney_3\NN\5333259 ,_4\,\1740 heart_5\NN\5919034 and_6\CC\1740 lung_7\NN\5528060 sections_8\NNS\7020895 revealed_9\VBD\2137132 moderate_10\JJ\1740 to_11\TO\1740 massive_12\JJ\1740 <e2>tissue_13\NN\5220461 damage</e2>_14\NN\7296428 with_15\IN\1740 a_16\DT\13649268 variety_17\NN\7951464 of_18\IN\1740 morphological_19\JJ\1740 aberrations_20\NNS\14501726 by_21\IN\1740 all_22\PDT\1740 the_23\DT\1740 three_24\CD\13741022 drugs_25\NNS\14778436 in_26\IN\13603305 the_27\DT\1740 absence_28\NN\14449405 of_29\IN\1740 <e1>gspe</e1>_30\NN\1740 preexposure_31\NN\1740 than_32\IN\1740 in_33\IN\13603305 its_34\PRP$\6125041 presence_35\NN\13954253 ._36\.\1740
19346865
D008795_D001927 CID reversible_0\JJ\1740 <e2>inferior_1\JJ\1740 colliculus_2\NN\1740 lesion</e2>_3\NN\14204950 in_4\IN\13603305 <e1>metronidazole-induced</e1>_5\JJ\1740 encephalopathy_6\JJ\1740 :_7\:\1740 magnetic_8\JJ\1740 resonance_9\NN\11419404 findings_10\NNS\7951464 on_11\IN\1740 diffusion-weighted_12\JJ\1740 and_13\CC\1740 fluid_14\NN\19613 attenuated_15\VBN\224901 inversion_16\NN\11425580 recovery_17\NN\7357388 imaging_18\NN\5765159 ._19\.\1740
D008795_D001927 CID reversible_0\JJ\1740 inferior_1\JJ\1740 colliculus_2\NN\1740 lesion_3\NN\14204950 in_4\IN\13603305 <e1>metronidazole-induced</e1>_5\JJ\1740 <e2>encephalopathy</e2>_6\JJ\1740 :_7\:\1740 magnetic_8\JJ\1740 resonance_9\NN\11419404 findings_10\NNS\7951464 on_11\IN\1740 diffusion-weighted_12\JJ\1740 and_13\CC\1740 fluid_14\NN\19613 attenuated_15\VBN\224901 inversion_16\NN\11425580 recovery_17\NN\7357388 imaging_18\NN\5765159 ._19\.\1740
D008795_D001927 CID objective_0\NN\5980875 :_1\:\1740 this_2\DT\1740 is_3\VBZ\836236 to_4\TO\1740 present_5\VB\2137132 reversible_6\JJ\1740 <e2>inferior_7\JJ\1740 colliculus_8\NN\1740 lesions</e2>_9\NNS\14204950 in_10\IN\13603305 <e1>metronidazole-induced</e1>_11\JJ\1740 encephalopathy_12\JJ\1740 ,_13\,\1740 to_14\TO\1740 focus_15\VB\628491 on_16\IN\1740 the_17\DT\1740 diffusion-weighted_18\JJ\1740 imaging_19\NN\5765159 (_20\-LRB-\1740 dwi_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 fluid_24\NN\19613 attenuated_25\VBN\224901 inversion_26\NN\11425580 recovery_27\NN\7357388 (_28\-LRB-\1740 flair_29\NN\5624042 )_30\-RRB-\1740 imaging_31\NN\5765159 ._32\.\1740
D008795_D001927 CID objective_0\NN\5980875 :_1\:\1740 this_2\DT\1740 is_3\VBZ\836236 to_4\TO\1740 present_5\VB\2137132 reversible_6\JJ\1740 inferior_7\JJ\1740 colliculus_8\NN\1740 lesions_9\NNS\14204950 in_10\IN\13603305 <e1>metronidazole-induced</e1>_11\JJ\1740 <e2>encephalopathy</e2>_12\JJ\1740 ,_13\,\1740 to_14\TO\1740 focus_15\VB\628491 on_16\IN\1740 the_17\DT\1740 diffusion-weighted_18\JJ\1740 imaging_19\NN\5765159 (_20\-LRB-\1740 dwi_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 fluid_24\NN\19613 attenuated_25\VBN\224901 inversion_26\NN\11425580 recovery_27\NN\7357388 (_28\-LRB-\1740 flair_29\NN\5624042 )_30\-RRB-\1740 imaging_31\NN\5765159 ._32\.\1740
D008795_D001927 CID materials_0\NNS\19613 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 from_4\IN\1740 november_5\NNP\15209706 2005_6\CD\1740 to_7\IN\1740 september_8\NNP\15209706 2007_9\CD\1740 ,_10\,\1740 8_11\CD\13741022 patients_12\NNS\9898892 (_13\-LRB-\1740 5_14\CD\13741022 men_15\NNS\8208016 and_16\CC\1740 3_17\CD\13741022 women_18\NNS\9605289 )_19\-RRB-\1740 were_20\VBD\836236 diagnosed_21\VBN\644583 as_22\IN\14622893 having_23\VBG\2108377 <e1>metronidazole-induced</e1>_24\JJ\1740 <e2>encephalopathy</e2>_25\JJ\1740 (_26\-LRB-\1740 age_27\NN\4916342 range_28\NN\5123416 ;_29\:\1740 43_30\CD\1740 -_31\SYM\1740 78_32\CD\13745420 years_33\NNS\15144371 )_34\-RRB-\1740 ._35\.\1740
D008795_D001927 CID conclusions_0\NNS\5837957 :_1\:\1740 reversible_2\JJ\1740 <e2>inferior_3\JJ\1740 colliculus_4\NN\1740 lesions</e2>_5\NNS\14204950 could_6\MD\1740 be_7\VB\836236 considered_8\VBN\689344 as_9\IN\14622893 the_10\DT\1740 characteristic_11\NN\5849040 for_12\IN\1740 <e1>metronidazole-induced</e1>_13\JJ\1740 encephalopathy_14\JJ\1740 ,_15\,\1740 next_16\RB\1740 to_17\IN\1740 the_18\DT\1740 dentate_19\NN\1740 nucleus_20\NN\5445668 involvement_21\NN\1080366 ._22\.\1740
D008795_D001927 CID conclusions_0\NNS\5837957 :_1\:\1740 reversible_2\JJ\1740 inferior_3\JJ\1740 colliculus_4\NN\1740 lesions_5\NNS\14204950 could_6\MD\1740 be_7\VB\836236 considered_8\VBN\689344 as_9\IN\14622893 the_10\DT\1740 characteristic_11\NN\5849040 for_12\IN\1740 <e1>metronidazole-induced</e1>_13\JJ\1740 <e2>encephalopathy</e2>_14\JJ\1740 ,_15\,\1740 next_16\RB\1740 to_17\IN\1740 the_18\DT\1740 dentate_19\NN\1740 nucleus_20\NN\5445668 involvement_21\NN\1080366 ._22\.\1740
D008795_D007239 NONE they_0\PRP\1740 had_1\VBD\2108377 been_2\VBN\836236 taking_3\VBG\2367363 <e1>metronidazole</e1>_4\NN\2723292 (_5\-LRB-\1740 total_6\JJ\1740 dosage_7\NN\13576355 ,_8\,\1740 45_9\CD\1740 -_10\SYM\1740 120_11\CD\13745420 g_12\NN\13717155 ;_13\:\1740 duration_14\NN\15113229 ,_15\,\1740 30_16\CD\13745420 days_17\NNS\15140892 to_18\IN\1740 2_19\CD\13741022 months_20\NNS\15113229 )_21\-RRB-\1740 to_22\TO\1740 treat_23\VB\2376958 the_24\DT\1740 <e2>infection</e2>_25\NN\14052046 in_26\IN\13603305 various_27\JJ\1740 organs_28\NNS\7649854 ._29\.\1740
3970039
D000477_D015470 CID patients_0\NNS\9898892 treated_1\VBN\2376958 with_2\IN\1740 <e1>alkylating_3\VBG\1740 agents</e1>_4\NNS\7347 have_5\VBP\2108377 an_6\DT\6697703 increased_7\VBN\169651 risk_8\NN\14541044 of_9\IN\1740 development_10\NN\248977 of_11\IN\1740 <e2>acute_12\JJ\1740 nonlymphocytic_13\JJ\1740 leukemia</e2>_14\NN\14239918 ,_15\,\1740 and_16\CC\1740 both_17\DT\1740 alkylating_18\VBG\1740 agents_19\NNS\7347 and_20\CC\1740 azathioprine_21\NN\3740161 are_22\VBP\836236 associated_23\VBN\628491 with_24\IN\1740 the_25\DT\1740 development_26\NN\248977 of_27\IN\1740 non-hodgkin_28\JJ\1740 's_29\POS\1740 lymphoma_30\NN\14239918 ._31\.\1740
D000477_D015470 CID patients_0\NNS\9898892 treated_1\VBN\2376958 with_2\IN\1740 alkylating_3\VBG\1740 agents_4\NNS\7347 have_5\VBP\2108377 an_6\DT\6697703 increased_7\VBN\169651 risk_8\NN\14541044 of_9\IN\1740 development_10\NN\248977 of_11\IN\1740 <e2>acute_12\JJ\1740 nonlymphocytic_13\JJ\1740 leukemia</e2>_14\NN\14239918 ,_15\,\1740 and_16\CC\1740 both_17\DT\1740 <e1>alkylating_18\VBG\1740 agents</e1>_19\NNS\7347 and_20\CC\1740 azathioprine_21\NN\3740161 are_22\VBP\836236 associated_23\VBN\628491 with_24\IN\1740 the_25\DT\1740 development_26\NN\248977 of_27\IN\1740 non-hodgkin_28\JJ\1740 's_29\POS\1740 lymphoma_30\NN\14239918 ._31\.\1740
D000477_D008228 CID patients_0\NNS\9898892 treated_1\VBN\2376958 with_2\IN\1740 <e1>alkylating_3\VBG\1740 agents</e1>_4\NNS\7347 have_5\VBP\2108377 an_6\DT\6697703 increased_7\VBN\169651 risk_8\NN\14541044 of_9\IN\1740 development_10\NN\248977 of_11\IN\1740 acute_12\JJ\1740 nonlymphocytic_13\JJ\1740 leukemia_14\NN\14239918 ,_15\,\1740 and_16\CC\1740 both_17\DT\1740 alkylating_18\VBG\1740 agents_19\NNS\7347 and_20\CC\1740 azathioprine_21\NN\3740161 are_22\VBP\836236 associated_23\VBN\628491 with_24\IN\1740 the_25\DT\1740 development_26\NN\248977 of_27\IN\1740 <e2>non-hodgkin_28\JJ\1740 's_29\POS\1740 lymphoma</e2>_30\NN\14239918 ._31\.\1740
D000477_D008228 CID patients_0\NNS\9898892 treated_1\VBN\2376958 with_2\IN\1740 alkylating_3\VBG\1740 agents_4\NNS\7347 have_5\VBP\2108377 an_6\DT\6697703 increased_7\VBN\169651 risk_8\NN\14541044 of_9\IN\1740 development_10\NN\248977 of_11\IN\1740 acute_12\JJ\1740 nonlymphocytic_13\JJ\1740 leukemia_14\NN\14239918 ,_15\,\1740 and_16\CC\1740 both_17\DT\1740 <e1>alkylating_18\VBG\1740 agents</e1>_19\NNS\7347 and_20\CC\1740 azathioprine_21\NN\3740161 are_22\VBP\836236 associated_23\VBN\628491 with_24\IN\1740 the_25\DT\1740 development_26\NN\248977 of_27\IN\1740 <e2>non-hodgkin_28\JJ\1740 's_29\POS\1740 lymphoma</e2>_30\NN\14239918 ._31\.\1740
D001379_D015470 NONE patients_0\NNS\9898892 treated_1\VBN\2376958 with_2\IN\1740 alkylating_3\VBG\1740 agents_4\NNS\7347 have_5\VBP\2108377 an_6\DT\6697703 increased_7\VBN\169651 risk_8\NN\14541044 of_9\IN\1740 development_10\NN\248977 of_11\IN\1740 <e2>acute_12\JJ\1740 nonlymphocytic_13\JJ\1740 leukemia</e2>_14\NN\14239918 ,_15\,\1740 and_16\CC\1740 both_17\DT\1740 alkylating_18\VBG\1740 agents_19\NNS\7347 and_20\CC\1740 <e1>azathioprine</e1>_21\NN\3740161 are_22\VBP\836236 associated_23\VBN\628491 with_24\IN\1740 the_25\DT\1740 development_26\NN\248977 of_27\IN\1740 non-hodgkin_28\JJ\1740 's_29\POS\1740 lymphoma_30\NN\14239918 ._31\.\1740
D001379_D008228 CID patients_0\NNS\9898892 treated_1\VBN\2376958 with_2\IN\1740 alkylating_3\VBG\1740 agents_4\NNS\7347 have_5\VBP\2108377 an_6\DT\6697703 increased_7\VBN\169651 risk_8\NN\14541044 of_9\IN\1740 development_10\NN\248977 of_11\IN\1740 acute_12\JJ\1740 nonlymphocytic_13\JJ\1740 leukemia_14\NN\14239918 ,_15\,\1740 and_16\CC\1740 both_17\DT\1740 alkylating_18\VBG\1740 agents_19\NNS\7347 and_20\CC\1740 <e1>azathioprine</e1>_21\NN\3740161 are_22\VBP\836236 associated_23\VBN\628491 with_24\IN\1740 the_25\DT\1740 development_26\NN\248977 of_27\IN\1740 <e2>non-hodgkin_28\JJ\1740 's_29\POS\1740 lymphoma</e2>_30\NN\14239918 ._31\.\1740
D003520_D001749 CID <e1>cyclophosphamide</e1>_0\NN\1740 therapy_1\NN\657604 increases_2\VBZ\169651 the_3\DT\1740 risk_4\NN\14541044 of_5\IN\1740 <e2>carcinoma_6\NN\14239918 of_7\IN\1740 the_8\DT\1740 bladder</e2>_9\NN\5515670 ._10\.\1740
D003520_D002277 CID <e1>cyclophosphamide</e1>_0\NN\1740 therapy_1\NN\657604 increases_2\VBZ\169651 the_3\DT\1740 risk_4\NN\14541044 of_5\IN\1740 <e2>carcinoma_6\NN\14239918 of_7\IN\1740 the_8\DT\1740 bladder</e2>_9\NN\5515670 ._10\.\1740
D001379_D001172 NONE there_0\EX\27167 have_1\VBP\2108377 been_2\VBN\836236 several_3\JJ\1740 long-term_4\JJ\1740 studies_5\NNS\635850 of_6\IN\1740 patients_7\NNS\9898892 with_8\IN\1740 <e2>rheumatoid_9\JJ\1740 arthritis</e2>_10\NN\14171682 treated_11\VBN\2376958 with_12\IN\1740 <e1>azathioprine</e1>_13\NN\3740161 and_14\CC\1740 cyclophosphamide_15\NN\1740 and_16\CC\1740 the_17\DT\1740 incidence_18\NN\13821570 of_19\IN\1740 most_20\JJS\1740 of_21\IN\1740 the_22\DT\1740 common_23\JJ\1740 cancers_24\NNS\14239425 is_25\VBZ\836236 not_26\RB\1740 increased_27\VBN\169651 ._28\.\1740
D001379_D009369 NONE there_0\EX\27167 have_1\VBP\2108377 been_2\VBN\836236 several_3\JJ\1740 long-term_4\JJ\1740 studies_5\NNS\635850 of_6\IN\1740 patients_7\NNS\9898892 with_8\IN\1740 rheumatoid_9\JJ\1740 arthritis_10\NN\14171682 treated_11\VBN\2376958 with_12\IN\1740 <e1>azathioprine</e1>_13\NN\3740161 and_14\CC\1740 cyclophosphamide_15\NN\1740 and_16\CC\1740 the_17\DT\1740 incidence_18\NN\13821570 of_19\IN\1740 most_20\JJS\1740 of_21\IN\1740 the_22\DT\1740 common_23\JJ\1740 <e2>cancers</e2>_24\NNS\14239425 is_25\VBZ\836236 not_26\RB\1740 increased_27\VBN\169651 ._28\.\1740
D003520_D001172 NONE there_0\EX\27167 have_1\VBP\2108377 been_2\VBN\836236 several_3\JJ\1740 long-term_4\JJ\1740 studies_5\NNS\635850 of_6\IN\1740 patients_7\NNS\9898892 with_8\IN\1740 <e2>rheumatoid_9\JJ\1740 arthritis</e2>_10\NN\14171682 treated_11\VBN\2376958 with_12\IN\1740 azathioprine_13\NN\3740161 and_14\CC\1740 <e1>cyclophosphamide</e1>_15\NN\1740 and_16\CC\1740 the_17\DT\1740 incidence_18\NN\13821570 of_19\IN\1740 most_20\JJS\1740 of_21\IN\1740 the_22\DT\1740 common_23\JJ\1740 cancers_24\NNS\14239425 is_25\VBZ\836236 not_26\RB\1740 increased_27\VBN\169651 ._28\.\1740
D003520_D009369 NONE there_0\EX\27167 have_1\VBP\2108377 been_2\VBN\836236 several_3\JJ\1740 long-term_4\JJ\1740 studies_5\NNS\635850 of_6\IN\1740 patients_7\NNS\9898892 with_8\IN\1740 rheumatoid_9\JJ\1740 arthritis_10\NN\14171682 treated_11\VBN\2376958 with_12\IN\1740 azathioprine_13\NN\3740161 and_14\CC\1740 <e1>cyclophosphamide</e1>_15\NN\1740 and_16\CC\1740 the_17\DT\1740 incidence_18\NN\13821570 of_19\IN\1740 most_20\JJS\1740 of_21\IN\1740 the_22\DT\1740 common_23\JJ\1740 <e2>cancers</e2>_24\NNS\14239425 is_25\VBZ\836236 not_26\RB\1740 increased_27\VBN\169651 ._28\.\1740
D000477_D009369 NONE data_0\NNS\7951464 on_1\IN\1740 the_2\DT\1740 possible_3\JJ\1740 increased_4\VBN\169651 risk_5\NN\14541044 of_6\IN\1740 <e2>malignancy</e2>_7\NN\14070360 in_8\IN\13603305 rheumatoid_9\JJ\1740 arthritis_10\NN\14171682 are_11\VBP\836236 still_12\RB\1740 being_13\VBG\836236 collected_14\VBN\2281093 ,_15\,\1740 and_16\CC\1740 until_17\IN\1740 further_18\JJ\1740 information_19\NN\6598915 is_20\VBZ\836236 available_21\JJ\1740 ,_22\,\1740 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 immunosuppressive_26\JJ\1740 drugs_27\NNS\14778436 ,_28\,\1740 particularly_29\RB\1740 <e1>alkylating_30\VBG\1740 agents</e1>_31\NNS\7347 ,_32\,\1740 in_33\IN\13603305 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 rheumatoid_37\JJ\1740 arthritis_38\NN\14171682 should_39\MD\1740 be_40\VB\836236 reserved_41\VBN\2213690 for_42\IN\1740 patients_43\NNS\9898892 with_44\IN\1740 severe_45\JJ\1740 progressive_46\JJ\1740 disease_47\NN\14061805 or_48\CC\3541091 life-threatening_49\JJ\1740 complications_50\NNS\1073995 ._51\.\1740
D000477_D001172 NONE data_0\NNS\7951464 on_1\IN\1740 the_2\DT\1740 possible_3\JJ\1740 increased_4\VBN\169651 risk_5\NN\14541044 of_6\IN\1740 malignancy_7\NN\14070360 in_8\IN\13603305 <e2>rheumatoid_9\JJ\1740 arthritis</e2>_10\NN\14171682 are_11\VBP\836236 still_12\RB\1740 being_13\VBG\836236 collected_14\VBN\2281093 ,_15\,\1740 and_16\CC\1740 until_17\IN\1740 further_18\JJ\1740 information_19\NN\6598915 is_20\VBZ\836236 available_21\JJ\1740 ,_22\,\1740 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 immunosuppressive_26\JJ\1740 drugs_27\NNS\14778436 ,_28\,\1740 particularly_29\RB\1740 <e1>alkylating_30\VBG\1740 agents</e1>_31\NNS\7347 ,_32\,\1740 in_33\IN\13603305 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 rheumatoid_37\JJ\1740 arthritis_38\NN\14171682 should_39\MD\1740 be_40\VB\836236 reserved_41\VBN\2213690 for_42\IN\1740 patients_43\NNS\9898892 with_44\IN\1740 severe_45\JJ\1740 progressive_46\JJ\1740 disease_47\NN\14061805 or_48\CC\3541091 life-threatening_49\JJ\1740 complications_50\NNS\1073995 ._51\.\1740
D000477_D001172 NONE data_0\NNS\7951464 on_1\IN\1740 the_2\DT\1740 possible_3\JJ\1740 increased_4\VBN\169651 risk_5\NN\14541044 of_6\IN\1740 malignancy_7\NN\14070360 in_8\IN\13603305 rheumatoid_9\JJ\1740 arthritis_10\NN\14171682 are_11\VBP\836236 still_12\RB\1740 being_13\VBG\836236 collected_14\VBN\2281093 ,_15\,\1740 and_16\CC\1740 until_17\IN\1740 further_18\JJ\1740 information_19\NN\6598915 is_20\VBZ\836236 available_21\JJ\1740 ,_22\,\1740 the_23\DT\1740 use_24\NN\407535 of_25\IN\1740 immunosuppressive_26\JJ\1740 drugs_27\NNS\14778436 ,_28\,\1740 particularly_29\RB\1740 <e1>alkylating_30\VBG\1740 agents</e1>_31\NNS\7347 ,_32\,\1740 in_33\IN\13603305 the_34\DT\1740 treatment_35\NN\654885 of_36\IN\1740 <e2>rheumatoid_37\JJ\1740 arthritis</e2>_38\NN\14171682 should_39\MD\1740 be_40\VB\836236 reserved_41\VBN\2213690 for_42\IN\1740 patients_43\NNS\9898892 with_44\IN\1740 severe_45\JJ\1740 progressive_46\JJ\1740 disease_47\NN\14061805 or_48\CC\3541091 life-threatening_49\JJ\1740 complications_50\NNS\1073995 ._51\.\1740
2266990
D008454_D020388 NONE randomized_0\JJ\1740 ,_1\,\1740 double-blind_2\JJ\1740 trial_3\NN\786195 of_4\IN\1740 <e1>mazindol</e1>_5\NN\1740 in_6\IN\13603305 <e2>duchenne_7\NNP\1740 dystrophy</e2>_8\NN\14151139 ._9\.\1740
D008454_D020388 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 12-month_3\NN\1740 controlled_4\VBN\2422663 trial_5\NN\786195 of_6\IN\1740 <e1>mazindol</e1>_7\NN\1740 ,_8\,\1740 a_9\DT\13649268 putative_10\JJ\1740 growth_11\NN\13526110 hormone_12\NN\5404728 secretion_13\NN\13526110 inhibitor_14\NN\20090 ,_15\,\1740 in_16\IN\13603305 83_17\CD\1740 boys_18\NNS\9624168 with_19\IN\1740 <e2>duchenne_20\NNP\1740 dystrophy</e2>_21\NN\14151139 ._22\.\1740
D008454_D020388 NONE <e1>mazindol</e1>_0\NN\1740 doses_1\NNS\3740161 not_2\RB\1740 slow_3\VB\151689 the_4\DT\1740 progression_5\NN\8457976 of_6\IN\1740 weakness_7\NN\14462666 in_8\IN\13603305 <e2>duchenne_9\NNP\1740 dystrophy</e2>_10\NN\14151139 ._11\.\1740
D008454_D001068 CID side_0\JJ\1740 effects_1\NNS\13245626 attributable_2\JJ\1740 to_3\TO\1740 <e1>mazindol</e1>_4\NN\1740 included_5\VBN\690614 <e2>decreased_6\VBN\169651 appetite</e2>_7\NN\7485475 (_8\-LRB-\1740 36_9\CD\1740 %_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 dry_13\JJ\1740 mouth_14\NN\5610008 (_15\-LRB-\1740 10_16\CD\13745420 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 behavioral_20\JJ\1740 change_21\NN\7283608 (_22\-LRB-\1740 22_23\CD\13745420 %_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 gastrointestinal_28\JJ\1740 symptoms_29\NNS\5823932 (_30\-LRB-\1740 18_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ;_34\:\1740 mazindol_35\NN\1740 dosage_36\NN\13576355 was_37\VBD\836236 reduced_38\VBN\441445 in_39\IN\13603305 43_40\CD\1740 %_41\NN\1740 of_42\IN\1740 patients_43\NNS\9898892 ._44\.\1740
D008454_D001068 CID side_0\JJ\1740 effects_1\NNS\13245626 attributable_2\JJ\1740 to_3\TO\1740 mazindol_4\NN\1740 included_5\VBN\690614 <e2>decreased_6\VBN\169651 appetite</e2>_7\NN\7485475 (_8\-LRB-\1740 36_9\CD\1740 %_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 dry_13\JJ\1740 mouth_14\NN\5610008 (_15\-LRB-\1740 10_16\CD\13745420 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 behavioral_20\JJ\1740 change_21\NN\7283608 (_22\-LRB-\1740 22_23\CD\13745420 %_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 gastrointestinal_28\JJ\1740 symptoms_29\NNS\5823932 (_30\-LRB-\1740 18_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ;_34\:\1740 <e1>mazindol</e1>_35\NN\1740 dosage_36\NN\13576355 was_37\VBD\836236 reduced_38\VBN\441445 in_39\IN\13603305 43_40\CD\1740 %_41\NN\1740 of_42\IN\1740 patients_43\NNS\9898892 ._44\.\1740
D008454_D014987 CID side_0\JJ\1740 effects_1\NNS\13245626 attributable_2\JJ\1740 to_3\TO\1740 <e1>mazindol</e1>_4\NN\1740 included_5\VBN\690614 decreased_6\VBN\169651 appetite_7\NN\7485475 (_8\-LRB-\1740 36_9\CD\1740 %_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 <e2>dry_13\JJ\1740 mouth</e2>_14\NN\5610008 (_15\-LRB-\1740 10_16\CD\13745420 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 behavioral_20\JJ\1740 change_21\NN\7283608 (_22\-LRB-\1740 22_23\CD\13745420 %_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 gastrointestinal_28\JJ\1740 symptoms_29\NNS\5823932 (_30\-LRB-\1740 18_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ;_34\:\1740 mazindol_35\NN\1740 dosage_36\NN\13576355 was_37\VBD\836236 reduced_38\VBN\441445 in_39\IN\13603305 43_40\CD\1740 %_41\NN\1740 of_42\IN\1740 patients_43\NNS\9898892 ._44\.\1740
D008454_D014987 CID side_0\JJ\1740 effects_1\NNS\13245626 attributable_2\JJ\1740 to_3\TO\1740 mazindol_4\NN\1740 included_5\VBN\690614 decreased_6\VBN\169651 appetite_7\NN\7485475 (_8\-LRB-\1740 36_9\CD\1740 %_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 <e2>dry_13\JJ\1740 mouth</e2>_14\NN\5610008 (_15\-LRB-\1740 10_16\CD\13745420 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 behavioral_20\JJ\1740 change_21\NN\7283608 (_22\-LRB-\1740 22_23\CD\13745420 %_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 gastrointestinal_28\JJ\1740 symptoms_29\NNS\5823932 (_30\-LRB-\1740 18_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ;_34\:\1740 <e1>mazindol</e1>_35\NN\1740 dosage_36\NN\13576355 was_37\VBD\836236 reduced_38\VBN\441445 in_39\IN\13603305 43_40\CD\1740 %_41\NN\1740 of_42\IN\1740 patients_43\NNS\9898892 ._44\.\1740
D008454_D012817 CID side_0\JJ\1740 effects_1\NNS\13245626 attributable_2\JJ\1740 to_3\TO\1740 <e1>mazindol</e1>_4\NN\1740 included_5\VBN\690614 decreased_6\VBN\169651 appetite_7\NN\7485475 (_8\-LRB-\1740 36_9\CD\1740 %_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 dry_13\JJ\1740 mouth_14\NN\5610008 (_15\-LRB-\1740 10_16\CD\13745420 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 behavioral_20\JJ\1740 change_21\NN\7283608 (_22\-LRB-\1740 22_23\CD\13745420 %_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 <e2>gastrointestinal_28\JJ\1740 symptoms</e2>_29\NNS\5823932 (_30\-LRB-\1740 18_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ;_34\:\1740 mazindol_35\NN\1740 dosage_36\NN\13576355 was_37\VBD\836236 reduced_38\VBN\441445 in_39\IN\13603305 43_40\CD\1740 %_41\NN\1740 of_42\IN\1740 patients_43\NNS\9898892 ._44\.\1740
D008454_D012817 CID side_0\JJ\1740 effects_1\NNS\13245626 attributable_2\JJ\1740 to_3\TO\1740 mazindol_4\NN\1740 included_5\VBN\690614 decreased_6\VBN\169651 appetite_7\NN\7485475 (_8\-LRB-\1740 36_9\CD\1740 %_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 dry_13\JJ\1740 mouth_14\NN\5610008 (_15\-LRB-\1740 10_16\CD\13745420 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 behavioral_20\JJ\1740 change_21\NN\7283608 (_22\-LRB-\1740 22_23\CD\13745420 %_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 <e2>gastrointestinal_28\JJ\1740 symptoms</e2>_29\NNS\5823932 (_30\-LRB-\1740 18_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ;_34\:\1740 <e1>mazindol</e1>_35\NN\1740 dosage_36\NN\13576355 was_37\VBD\836236 reduced_38\VBN\441445 in_39\IN\13603305 43_40\CD\1740 %_41\NN\1740 of_42\IN\1740 patients_43\NNS\9898892 ._44\.\1740
D008454_D018908 NONE <e1>mazindol</e1>_0\NN\1740 doses_1\NNS\3740161 not_2\RB\1740 slow_3\VB\151689 the_4\DT\1740 progression_5\NN\8457976 of_6\IN\1740 <e2>weakness</e2>_7\NN\14462666 in_8\IN\13603305 duchenne_9\NNP\1740 dystrophy_10\NN\14151139 ._11\.\1740
6861444
D009638_D006973 CID intrarenal_0\JJ\1740 infusion_1\NN\14589223 of_2\IN\1740 <e1>noradrenaline</e1>_3\NN\14807929 caused_4\VBD\1617192 <e2>hypertension</e2>_5\NN\14057371 at_6\IN\14622893 doses_7\NNS\3740161 which_8\WDT\1740 did_9\VBD\1640855 not_10\RB\1740 do_11\VB\1640855 so_12\RB\1740 when_13\WRB\1740 infused_14\VBN\606335 intravenously_15\RB\1740 ._16\.\1740
D009638_D006973 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e2>hypertension</e2>_4\NN\14057371 after_5\IN\1740 chronic_6\JJ\1740 intrarenal_7\JJ\1740 <e1>noradrenaline</e1>_8\NN\14807929 infusion_9\NN\14589223 is_10\VBZ\836236 produced_11\VBN\1617192 by_12\IN\1740 relatively_13\RB\1740 higher_14\JJR\1740 levels_15\NNS\4916342 of_16\IN\1740 circulating_17\VBG\1835496 noradrenaline_18\NN\14807929 and_19\CC\1740 by_20\IN\1740 triggering_21\NN\1740 of_22\IN\1740 an_23\DT\6697703 additional_24\JJ\1740 intrarenal_25\JJ\1740 pressor_26\NN\9190918 mechanism_27\NN\13446390 ._28\.\1740
D009638_D006973 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e2>hypertension</e2>_4\NN\14057371 after_5\IN\1740 chronic_6\JJ\1740 intrarenal_7\JJ\1740 noradrenaline_8\NN\14807929 infusion_9\NN\14589223 is_10\VBZ\836236 produced_11\VBN\1617192 by_12\IN\1740 relatively_13\RB\1740 higher_14\JJR\1740 levels_15\NNS\4916342 of_16\IN\1740 circulating_17\VBG\1835496 <e1>noradrenaline</e1>_18\NN\14807929 and_19\CC\1740 by_20\IN\1740 triggering_21\NN\1740 of_22\IN\1740 an_23\DT\6697703 additional_24\JJ\1740 intrarenal_25\JJ\1740 pressor_26\NN\9190918 mechanism_27\NN\13446390 ._28\.\1740
137340
D009020_D006948 CID effect_0\NN\34213 of_1\IN\1740 humoral_2\JJ\1740 modulators_3\NNS\1740 of_4\IN\1740 <e1>morphine-induced</e1>_5\JJ\1740 <e2>increase_6\NN\13576355 in_7\IN\13603305 locomotor_8\NN\1740 activity</e2>_9\NN\30358 of_10\IN\1740 mice_11\NNS\2329401 ._12\.\1740
D009020_D006948 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 humoral_3\JJ\1740 modulators_4\NNS\1740 on_5\IN\1740 the_6\DT\1740 <e1>morphine-induced</e1>_7\JJ\1740 <e2>increase_8\NN\13576355 in_9\IN\13603305 locomotor_10\NN\1740 activity</e2>_11\NN\30358 of_12\IN\1740 mice_13\NNS\2329401 was_14\VBD\836236 studied_15\VBN\630380 ._16\.\1740
D009020_D006948 CID the_0\DT\1740 subcutaneous_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 10_4\CD\13745420 mg/kg_5\NN\1740 of_6\IN\1740 <e1>morphine-hc1</e1>_7\NN\1740 produced_8\VBD\1617192 a_9\DT\13649268 marked_10\JJ\1740 <e2>increase_11\NN\13576355 in_12\IN\13603305 locomotor_13\NN\1740 activity</e2>_14\NN\30358 in_15\IN\13603305 mice_16\NNS\2329401 ._17\.\1740
D009020_D006948 CID the_0\DT\1740 <e1>morphine-induced</e1>_1\JJ\1740 <e2>hyperactivity</e2>_2\NN\14052403 was_3\VBD\836236 potentiated_4\VBN\229605 by_5\IN\1740 scopolamine_6\NN\14712692 and_7\CC\1740 attenuated_8\VBN\224901 by_9\IN\1740 physostigmine_10\NN\14712692 ._11\.\1740
D009020_D006948 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 both_3\CC\1740 methscopolamine_4\NN\1740 and_5\CC\1740 neostigmine_6\NN\2718084 ,_7\,\1740 which_8\WDT\1740 do_9\VBP\1640855 not_10\RB\1740 penetrate_11\VB\2016523 the_12\DT\1740 blood-brain_13\JJ\1740 barrier_14\NN\3839993 ,_15\,\1740 had_16\VBD\2108377 no_17\DT\7204911 effect_18\NN\34213 on_19\IN\1740 the_20\DT\1740 <e2>hyperactivity</e2>_21\NN\14052403 produced_22\VBN\1617192 by_23\IN\1740 <e1>morphine</e1>_24\NN\2707683 ._25\.\1740
D012601_D006948 CID the_0\DT\1740 morphine-induced_1\JJ\1740 <e2>hyperactivity</e2>_2\NN\14052403 was_3\VBD\836236 potentiated_4\VBN\229605 by_5\IN\1740 <e1>scopolamine</e1>_6\NN\14712692 and_7\CC\1740 attenuated_8\VBN\224901 by_9\IN\1740 physostigmine_10\NN\14712692 ._11\.\1740
D010830_D006948 NONE the_0\DT\1740 morphine-induced_1\JJ\1740 <e2>hyperactivity</e2>_2\NN\14052403 was_3\VBD\836236 potentiated_4\VBN\229605 by_5\IN\1740 scopolamine_6\NN\14712692 and_7\CC\1740 attenuated_8\VBN\224901 by_9\IN\1740 <e1>physostigmine</e1>_10\NN\14712692 ._11\.\1740
D019832_D006948 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 both_3\CC\1740 <e1>methscopolamine</e1>_4\NN\1740 and_5\CC\1740 neostigmine_6\NN\2718084 ,_7\,\1740 which_8\WDT\1740 do_9\VBP\1640855 not_10\RB\1740 penetrate_11\VB\2016523 the_12\DT\1740 blood-brain_13\JJ\1740 barrier_14\NN\3839993 ,_15\,\1740 had_16\VBD\2108377 no_17\DT\7204911 effect_18\NN\34213 on_19\IN\1740 the_20\DT\1740 <e2>hyperactivity</e2>_21\NN\14052403 produced_22\VBN\1617192 by_23\IN\1740 morphine_24\NN\2707683 ._25\.\1740
D009388_D006948 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 both_3\CC\1740 methscopolamine_4\NN\1740 and_5\CC\1740 <e1>neostigmine</e1>_6\NN\2718084 ,_7\,\1740 which_8\WDT\1740 do_9\VBP\1640855 not_10\RB\1740 penetrate_11\VB\2016523 the_12\DT\1740 blood-brain_13\JJ\1740 barrier_14\NN\3839993 ,_15\,\1740 had_16\VBD\2108377 no_17\DT\7204911 effect_18\NN\34213 on_19\IN\1740 the_20\DT\1740 <e2>hyperactivity</e2>_21\NN\14052403 produced_22\VBN\1617192 by_23\IN\1740 morphine_24\NN\2707683 ._25\.\1740
D010134_D006948 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 pretreatment_5\NN\1740 with_6\IN\1740 <e1>p-chlorophenylalamine</e1>_7\NN\1740 (_8\-LRB-\1740 3_9\CD\13741022 x_10\NN\13745420 320_11\CD\1740 mg/kg_12\NN\1740 i.p._13\RB\1740 ,_14\,\1740 24_15\CD\13745420 hr_16\NN\15154774 )_17\-RRB-\1740 ,_18\,\1740 a_19\DT\13649268 serotonin_20\NN\14807737 depletor_21\NN\1740 ,_22\,\1740 caused_23\VBD\1617192 no_24\DT\7204911 significant_25\JJ\1740 change_26\NN\7283608 in_27\IN\13603305 the_28\DT\1740 <e2>hyperactivity</e2>_29\NN\14052403 ._30\.\1740
D012701_D006948 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 pretreatment_5\NN\1740 with_6\IN\1740 p-chlorophenylalamine_7\NN\1740 (_8\-LRB-\1740 3_9\CD\13741022 x_10\NN\13745420 320_11\CD\1740 mg/kg_12\NN\1740 i.p._13\RB\1740 ,_14\,\1740 24_15\CD\13745420 hr_16\NN\15154774 )_17\-RRB-\1740 ,_18\,\1740 a_19\DT\13649268 <e1>serotonin</e1>_20\NN\14807737 depletor_21\NN\1740 ,_22\,\1740 caused_23\VBD\1617192 no_24\DT\7204911 significant_25\JJ\1740 change_26\NN\7283608 in_27\IN\13603305 the_28\DT\1740 <e2>hyperactivity</e2>_29\NN\14052403 ._30\.\1740
227508
D003000_D006973 NONE in_0\IN\13603305 unanesthetized_1\VBN\1740 ,_2\,\1740 spontaneously_3\JJ\1740 <e2>hypertensive</e2>_4\JJ\1740 rats_5\VBZ\2584097 the_6\DT\1740 decrease_7\NN\7296428 in_8\IN\13603305 blood_9\NN\5397468 pressure_10\NN\11419404 and_11\CC\1740 heart_12\NN\5919034 rate_13\NN\13815152 produced_14\VBN\1617192 by_15\IN\1740 intravenous_16\JJ\1740 <e1>clonidine</e1>_17\NN\2721160 ,_18\,\1740 5_19\CD\13741022 to_20\TO\1740 20_21\CD\13745420 micrograms/kg_22\NNS\1740 ,_23\,\1740 was_24\VBD\836236 inhibited_25\VBN\2510337 or_26\CC\3541091 reversed_27\VBN\109660 by_28\IN\1740 nalozone_29\NN\1740 ,_30\,\1740 0.2_31\CD\1740 to_32\TO\1740 2_33\CD\13741022 mg/kg_34\NN\1740 ._35\.\1740
D003000_D006973 NONE in_0\IN\13603305 brain_1\NN\5462674 membranes_2\NNS\4188643 from_3\IN\1740 spontaneously_4\JJ\1740 <e2>hypertensive</e2>_5\JJ\1740 rats_6\NNS\2329401 <e1>clonidine</e1>_7\NN\2721160 ,_8\,\1740 10(-8_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 10(-5_12\NN\1740 )_13\-RRB-\1740 m_14\NN\13649268 ,_15\,\1740 did_16\VBD\1640855 not_17\RB\1740 influence_18\VB\137313 stereoselective_19\JJ\1740 binding_20\NN\4688246 of_21\IN\1740 [3h]-naloxone_22\XX\1740 (_23\-LRB-\1740 8_24\CD\13741022 nm_25\NN\13649268 )_26\-RRB-\1740 ,_27\,\1740 and_28\CC\1740 naloxone_29\NN\3808977 ,_30\,\1740 10(-8_31\NN\1740 )_32\-RRB-\1740 to_33\TO\1740 10(-4_34\NN\1740 )_35\-RRB-\1740 m_36\NN\13649268 ,_37\,\1740 did_38\VBD\1640855 not_39\RB\1740 influence_40\VB\137313 clonidine-suppressible_41\JJ\1740 binding_42\NN\4688246 of_43\IN\1740 [3h]-dihydroergocryptine_44\XX\1740 (_45\-LRB-\1740 1_46\CD\13741022 nm_47\NN\13649268 )_48\-RRB-\1740 ._49\.\1740
D003000_D006973 NONE in_0\IN\13603305 brain_1\NN\5462674 membranes_2\NNS\4188643 from_3\IN\1740 spontaneously_4\JJ\1740 <e2>hypertensive</e2>_5\JJ\1740 rats_6\NNS\2329401 clonidine_7\NN\2721160 ,_8\,\1740 10(-8_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 10(-5_12\NN\1740 )_13\-RRB-\1740 m_14\NN\13649268 ,_15\,\1740 did_16\VBD\1640855 not_17\RB\1740 influence_18\VB\137313 stereoselective_19\JJ\1740 binding_20\NN\4688246 of_21\IN\1740 [3h]-naloxone_22\XX\1740 (_23\-LRB-\1740 8_24\CD\13741022 nm_25\NN\13649268 )_26\-RRB-\1740 ,_27\,\1740 and_28\CC\1740 naloxone_29\NN\3808977 ,_30\,\1740 10(-8_31\NN\1740 )_32\-RRB-\1740 to_33\TO\1740 10(-4_34\NN\1740 )_35\-RRB-\1740 m_36\NN\13649268 ,_37\,\1740 did_38\VBD\1640855 not_39\RB\1740 influence_40\VB\137313 <e1>clonidine-suppressible</e1>_41\JJ\1740 binding_42\NN\4688246 of_43\IN\1740 [3h]-dihydroergocryptine_44\XX\1740 (_45\-LRB-\1740 1_46\CD\13741022 nm_47\NN\13649268 )_48\-RRB-\1740 ._49\.\1740
-1_D006973 NONE in_0\IN\13603305 unanesthetized_1\VBN\1740 ,_2\,\1740 spontaneously_3\JJ\1740 <e2>hypertensive</e2>_4\JJ\1740 rats_5\VBZ\2584097 the_6\DT\1740 decrease_7\NN\7296428 in_8\IN\13603305 blood_9\NN\5397468 pressure_10\NN\11419404 and_11\CC\1740 heart_12\NN\5919034 rate_13\NN\13815152 produced_14\VBN\1617192 by_15\IN\1740 intravenous_16\JJ\1740 clonidine_17\NN\2721160 ,_18\,\1740 5_19\CD\13741022 to_20\TO\1740 20_21\CD\13745420 micrograms/kg_22\NNS\1740 ,_23\,\1740 was_24\VBD\836236 inhibited_25\VBN\2510337 or_26\CC\3541091 reversed_27\VBN\109660 by_28\IN\1740 <e1>nalozone</e1>_29\NN\1740 ,_30\,\1740 0.2_31\CD\1740 to_32\TO\1740 2_33\CD\13741022 mg/kg_34\NN\1740 ._35\.\1740
-1_D006973 NONE in_0\IN\13603305 brain_1\NN\5462674 membranes_2\NNS\4188643 from_3\IN\1740 spontaneously_4\JJ\1740 <e2>hypertensive</e2>_5\JJ\1740 rats_6\NNS\2329401 clonidine_7\NN\2721160 ,_8\,\1740 10(-8_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 10(-5_12\NN\1740 )_13\-RRB-\1740 m_14\NN\13649268 ,_15\,\1740 did_16\VBD\1640855 not_17\RB\1740 influence_18\VB\137313 stereoselective_19\JJ\1740 binding_20\NN\4688246 of_21\IN\1740 <e1>[3h]-naloxone</e1>_22\XX\1740 (_23\-LRB-\1740 8_24\CD\13741022 nm_25\NN\13649268 )_26\-RRB-\1740 ,_27\,\1740 and_28\CC\1740 naloxone_29\NN\3808977 ,_30\,\1740 10(-8_31\NN\1740 )_32\-RRB-\1740 to_33\TO\1740 10(-4_34\NN\1740 )_35\-RRB-\1740 m_36\NN\13649268 ,_37\,\1740 did_38\VBD\1640855 not_39\RB\1740 influence_40\VB\137313 clonidine-suppressible_41\JJ\1740 binding_42\NN\4688246 of_43\IN\1740 [3h]-dihydroergocryptine_44\XX\1740 (_45\-LRB-\1740 1_46\CD\13741022 nm_47\NN\13649268 )_48\-RRB-\1740 ._49\.\1740
-1_D006973 NONE in_0\IN\13603305 brain_1\NN\5462674 membranes_2\NNS\4188643 from_3\IN\1740 spontaneously_4\JJ\1740 <e2>hypertensive</e2>_5\JJ\1740 rats_6\NNS\2329401 clonidine_7\NN\2721160 ,_8\,\1740 10(-8_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 10(-5_12\NN\1740 )_13\-RRB-\1740 m_14\NN\13649268 ,_15\,\1740 did_16\VBD\1640855 not_17\RB\1740 influence_18\VB\137313 stereoselective_19\JJ\1740 binding_20\NN\4688246 of_21\IN\1740 [3h]-naloxone_22\XX\1740 (_23\-LRB-\1740 8_24\CD\13741022 nm_25\NN\13649268 )_26\-RRB-\1740 ,_27\,\1740 and_28\CC\1740 naloxone_29\NN\3808977 ,_30\,\1740 10(-8_31\NN\1740 )_32\-RRB-\1740 to_33\TO\1740 10(-4_34\NN\1740 )_35\-RRB-\1740 m_36\NN\13649268 ,_37\,\1740 did_38\VBD\1640855 not_39\RB\1740 influence_40\VB\137313 clonidine-suppressible_41\JJ\1740 binding_42\NN\4688246 of_43\IN\1740 <e1>[3h]-dihydroergocryptine</e1>_44\XX\1740 (_45\-LRB-\1740 1_46\CD\13741022 nm_47\NN\13649268 )_48\-RRB-\1740 ._49\.\1740
D008750_D007022 CID the_0\DT\1740 <e2>hypotensive</e2>_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 100_4\CD\13745420 mg/kg_5\NN\1740 <e1>alpha-methyldopa</e1>_6\NN\1740 was_7\VBD\836236 also_8\RB\1740 partially_9\RB\1740 reversed_10\VBN\109660 by_11\IN\1740 naloxone_12\NN\3808977 ._13\.\1740
D009270_D007022 NONE the_0\DT\1740 <e2>hypotensive</e2>_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 100_4\CD\13745420 mg/kg_5\NN\1740 alpha-methyldopa_6\NN\1740 was_7\VBD\836236 also_8\RB\1740 partially_9\RB\1740 reversed_10\VBN\109660 by_11\IN\1740 <e1>naloxone</e1>_12\NN\3808977 ._13\.\1740
D009270_D006973 NONE in_0\IN\13603305 brain_1\NN\5462674 membranes_2\NNS\4188643 from_3\IN\1740 spontaneously_4\JJ\1740 <e2>hypertensive</e2>_5\JJ\1740 rats_6\NNS\2329401 clonidine_7\NN\2721160 ,_8\,\1740 10(-8_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 10(-5_12\NN\1740 )_13\-RRB-\1740 m_14\NN\13649268 ,_15\,\1740 did_16\VBD\1640855 not_17\RB\1740 influence_18\VB\137313 stereoselective_19\JJ\1740 binding_20\NN\4688246 of_21\IN\1740 [3h]-naloxone_22\XX\1740 (_23\-LRB-\1740 8_24\CD\13741022 nm_25\NN\13649268 )_26\-RRB-\1740 ,_27\,\1740 and_28\CC\1740 <e1>naloxone</e1>_29\NN\3808977 ,_30\,\1740 10(-8_31\NN\1740 )_32\-RRB-\1740 to_33\TO\1740 10(-4_34\NN\1740 )_35\-RRB-\1740 m_36\NN\13649268 ,_37\,\1740 did_38\VBD\1640855 not_39\RB\1740 influence_40\VB\137313 clonidine-suppressible_41\JJ\1740 binding_42\NN\4688246 of_43\IN\1740 [3h]-dihydroergocryptine_44\XX\1740 (_45\-LRB-\1740 1_46\CD\13741022 nm_47\NN\13649268 )_48\-RRB-\1740 ._49\.\1740
16680561
D003891_D009325 CID fewer_0\JJR\1740 subjects_1\NNS\6598915 reported_2\VBD\831651 adverse_3\JJ\1740 events_4\NNS\23100 following_5\VBG\1835496 treatment_6\NN\654885 with_7\IN\1740 <e1>desipramine</e1>_8\NN\4482543 alone_9\RB\1740 than_10\IN\1740 when_11\WRB\1740 receiving_12\VBG\2210855 desipramine_13\NN\4482543 with_14\IN\1740 cinacalcet_15\NN\1740 (_16\-LRB-\1740 33_17\CD\1740 versus_18\CC\1740 86_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 the_23\DT\1740 most_24\RBS\1740 frequent_25\JJ\1740 of_26\IN\1740 which_27\WDT\1740 (_28\-LRB-\1740 <e2>nausea</e2>_29\NN\14299637 and_30\CC\1740 headache_31\NN\5829480 )_32\-RRB-\1740 have_33\VBP\2108377 been_34\VBN\836236 reported_35\VBN\831651 for_36\IN\1740 patients_37\NNS\9898892 treated_38\VBN\2376958 with_39\IN\1740 either_40\CC\1740 desipramine_41\NN\4482543 or_42\CC\3541091 cinacalcet_43\NN\1740 ._44\.\1740
D003891_D009325 CID fewer_0\JJR\1740 subjects_1\NNS\6598915 reported_2\VBD\831651 adverse_3\JJ\1740 events_4\NNS\23100 following_5\VBG\1835496 treatment_6\NN\654885 with_7\IN\1740 desipramine_8\NN\4482543 alone_9\RB\1740 than_10\IN\1740 when_11\WRB\1740 receiving_12\VBG\2210855 <e1>desipramine</e1>_13\NN\4482543 with_14\IN\1740 cinacalcet_15\NN\1740 (_16\-LRB-\1740 33_17\CD\1740 versus_18\CC\1740 86_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 the_23\DT\1740 most_24\RBS\1740 frequent_25\JJ\1740 of_26\IN\1740 which_27\WDT\1740 (_28\-LRB-\1740 <e2>nausea</e2>_29\NN\14299637 and_30\CC\1740 headache_31\NN\5829480 )_32\-RRB-\1740 have_33\VBP\2108377 been_34\VBN\836236 reported_35\VBN\831651 for_36\IN\1740 patients_37\NNS\9898892 treated_38\VBN\2376958 with_39\IN\1740 either_40\CC\1740 desipramine_41\NN\4482543 or_42\CC\3541091 cinacalcet_43\NN\1740 ._44\.\1740
D003891_D009325 CID fewer_0\JJR\1740 subjects_1\NNS\6598915 reported_2\VBD\831651 adverse_3\JJ\1740 events_4\NNS\23100 following_5\VBG\1835496 treatment_6\NN\654885 with_7\IN\1740 desipramine_8\NN\4482543 alone_9\RB\1740 than_10\IN\1740 when_11\WRB\1740 receiving_12\VBG\2210855 desipramine_13\NN\4482543 with_14\IN\1740 cinacalcet_15\NN\1740 (_16\-LRB-\1740 33_17\CD\1740 versus_18\CC\1740 86_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 the_23\DT\1740 most_24\RBS\1740 frequent_25\JJ\1740 of_26\IN\1740 which_27\WDT\1740 (_28\-LRB-\1740 <e2>nausea</e2>_29\NN\14299637 and_30\CC\1740 headache_31\NN\5829480 )_32\-RRB-\1740 have_33\VBP\2108377 been_34\VBN\836236 reported_35\VBN\831651 for_36\IN\1740 patients_37\NNS\9898892 treated_38\VBN\2376958 with_39\IN\1740 either_40\CC\1740 <e1>desipramine</e1>_41\NN\4482543 or_42\CC\3541091 cinacalcet_43\NN\1740 ._44\.\1740
D003891_D006261 CID fewer_0\JJR\1740 subjects_1\NNS\6598915 reported_2\VBD\831651 adverse_3\JJ\1740 events_4\NNS\23100 following_5\VBG\1835496 treatment_6\NN\654885 with_7\IN\1740 <e1>desipramine</e1>_8\NN\4482543 alone_9\RB\1740 than_10\IN\1740 when_11\WRB\1740 receiving_12\VBG\2210855 desipramine_13\NN\4482543 with_14\IN\1740 cinacalcet_15\NN\1740 (_16\-LRB-\1740 33_17\CD\1740 versus_18\CC\1740 86_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 the_23\DT\1740 most_24\RBS\1740 frequent_25\JJ\1740 of_26\IN\1740 which_27\WDT\1740 (_28\-LRB-\1740 nausea_29\NN\14299637 and_30\CC\1740 <e2>headache</e2>_31\NN\5829480 )_32\-RRB-\1740 have_33\VBP\2108377 been_34\VBN\836236 reported_35\VBN\831651 for_36\IN\1740 patients_37\NNS\9898892 treated_38\VBN\2376958 with_39\IN\1740 either_40\CC\1740 desipramine_41\NN\4482543 or_42\CC\3541091 cinacalcet_43\NN\1740 ._44\.\1740
D003891_D006261 CID fewer_0\JJR\1740 subjects_1\NNS\6598915 reported_2\VBD\831651 adverse_3\JJ\1740 events_4\NNS\23100 following_5\VBG\1835496 treatment_6\NN\654885 with_7\IN\1740 desipramine_8\NN\4482543 alone_9\RB\1740 than_10\IN\1740 when_11\WRB\1740 receiving_12\VBG\2210855 <e1>desipramine</e1>_13\NN\4482543 with_14\IN\1740 cinacalcet_15\NN\1740 (_16\-LRB-\1740 33_17\CD\1740 versus_18\CC\1740 86_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 the_23\DT\1740 most_24\RBS\1740 frequent_25\JJ\1740 of_26\IN\1740 which_27\WDT\1740 (_28\-LRB-\1740 nausea_29\NN\14299637 and_30\CC\1740 <e2>headache</e2>_31\NN\5829480 )_32\-RRB-\1740 have_33\VBP\2108377 been_34\VBN\836236 reported_35\VBN\831651 for_36\IN\1740 patients_37\NNS\9898892 treated_38\VBN\2376958 with_39\IN\1740 either_40\CC\1740 desipramine_41\NN\4482543 or_42\CC\3541091 cinacalcet_43\NN\1740 ._44\.\1740
D003891_D006261 CID fewer_0\JJR\1740 subjects_1\NNS\6598915 reported_2\VBD\831651 adverse_3\JJ\1740 events_4\NNS\23100 following_5\VBG\1835496 treatment_6\NN\654885 with_7\IN\1740 desipramine_8\NN\4482543 alone_9\RB\1740 than_10\IN\1740 when_11\WRB\1740 receiving_12\VBG\2210855 desipramine_13\NN\4482543 with_14\IN\1740 cinacalcet_15\NN\1740 (_16\-LRB-\1740 33_17\CD\1740 versus_18\CC\1740 86_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 the_23\DT\1740 most_24\RBS\1740 frequent_25\JJ\1740 of_26\IN\1740 which_27\WDT\1740 (_28\-LRB-\1740 nausea_29\NN\14299637 and_30\CC\1740 <e2>headache</e2>_31\NN\5829480 )_32\-RRB-\1740 have_33\VBP\2108377 been_34\VBN\836236 reported_35\VBN\831651 for_36\IN\1740 patients_37\NNS\9898892 treated_38\VBN\2376958 with_39\IN\1740 either_40\CC\1740 <e1>desipramine</e1>_41\NN\4482543 or_42\CC\3541091 cinacalcet_43\NN\1740 ._44\.\1740
C476217_D009325 CID fewer_0\JJR\1740 subjects_1\NNS\6598915 reported_2\VBD\831651 adverse_3\JJ\1740 events_4\NNS\23100 following_5\VBG\1835496 treatment_6\NN\654885 with_7\IN\1740 desipramine_8\NN\4482543 alone_9\RB\1740 than_10\IN\1740 when_11\WRB\1740 receiving_12\VBG\2210855 desipramine_13\NN\4482543 with_14\IN\1740 <e1>cinacalcet</e1>_15\NN\1740 (_16\-LRB-\1740 33_17\CD\1740 versus_18\CC\1740 86_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 the_23\DT\1740 most_24\RBS\1740 frequent_25\JJ\1740 of_26\IN\1740 which_27\WDT\1740 (_28\-LRB-\1740 <e2>nausea</e2>_29\NN\14299637 and_30\CC\1740 headache_31\NN\5829480 )_32\-RRB-\1740 have_33\VBP\2108377 been_34\VBN\836236 reported_35\VBN\831651 for_36\IN\1740 patients_37\NNS\9898892 treated_38\VBN\2376958 with_39\IN\1740 either_40\CC\1740 desipramine_41\NN\4482543 or_42\CC\3541091 cinacalcet_43\NN\1740 ._44\.\1740
C476217_D009325 CID fewer_0\JJR\1740 subjects_1\NNS\6598915 reported_2\VBD\831651 adverse_3\JJ\1740 events_4\NNS\23100 following_5\VBG\1835496 treatment_6\NN\654885 with_7\IN\1740 desipramine_8\NN\4482543 alone_9\RB\1740 than_10\IN\1740 when_11\WRB\1740 receiving_12\VBG\2210855 desipramine_13\NN\4482543 with_14\IN\1740 cinacalcet_15\NN\1740 (_16\-LRB-\1740 33_17\CD\1740 versus_18\CC\1740 86_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 the_23\DT\1740 most_24\RBS\1740 frequent_25\JJ\1740 of_26\IN\1740 which_27\WDT\1740 (_28\-LRB-\1740 <e2>nausea</e2>_29\NN\14299637 and_30\CC\1740 headache_31\NN\5829480 )_32\-RRB-\1740 have_33\VBP\2108377 been_34\VBN\836236 reported_35\VBN\831651 for_36\IN\1740 patients_37\NNS\9898892 treated_38\VBN\2376958 with_39\IN\1740 either_40\CC\1740 desipramine_41\NN\4482543 or_42\CC\3541091 <e1>cinacalcet</e1>_43\NN\1740 ._44\.\1740
C476217_D006261 CID fewer_0\JJR\1740 subjects_1\NNS\6598915 reported_2\VBD\831651 adverse_3\JJ\1740 events_4\NNS\23100 following_5\VBG\1835496 treatment_6\NN\654885 with_7\IN\1740 desipramine_8\NN\4482543 alone_9\RB\1740 than_10\IN\1740 when_11\WRB\1740 receiving_12\VBG\2210855 desipramine_13\NN\4482543 with_14\IN\1740 <e1>cinacalcet</e1>_15\NN\1740 (_16\-LRB-\1740 33_17\CD\1740 versus_18\CC\1740 86_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 the_23\DT\1740 most_24\RBS\1740 frequent_25\JJ\1740 of_26\IN\1740 which_27\WDT\1740 (_28\-LRB-\1740 nausea_29\NN\14299637 and_30\CC\1740 <e2>headache</e2>_31\NN\5829480 )_32\-RRB-\1740 have_33\VBP\2108377 been_34\VBN\836236 reported_35\VBN\831651 for_36\IN\1740 patients_37\NNS\9898892 treated_38\VBN\2376958 with_39\IN\1740 either_40\CC\1740 desipramine_41\NN\4482543 or_42\CC\3541091 cinacalcet_43\NN\1740 ._44\.\1740
C476217_D006261 CID fewer_0\JJR\1740 subjects_1\NNS\6598915 reported_2\VBD\831651 adverse_3\JJ\1740 events_4\NNS\23100 following_5\VBG\1835496 treatment_6\NN\654885 with_7\IN\1740 desipramine_8\NN\4482543 alone_9\RB\1740 than_10\IN\1740 when_11\WRB\1740 receiving_12\VBG\2210855 desipramine_13\NN\4482543 with_14\IN\1740 cinacalcet_15\NN\1740 (_16\-LRB-\1740 33_17\CD\1740 versus_18\CC\1740 86_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 the_23\DT\1740 most_24\RBS\1740 frequent_25\JJ\1740 of_26\IN\1740 which_27\WDT\1740 (_28\-LRB-\1740 nausea_29\NN\14299637 and_30\CC\1740 <e2>headache</e2>_31\NN\5829480 )_32\-RRB-\1740 have_33\VBP\2108377 been_34\VBN\836236 reported_35\VBN\831651 for_36\IN\1740 patients_37\NNS\9898892 treated_38\VBN\2376958 with_39\IN\1740 either_40\CC\1740 desipramine_41\NN\4482543 or_42\CC\3541091 <e1>cinacalcet</e1>_43\NN\1740 ._44\.\1740
7881871
D011692_D007674 CID time_0\NN\7308889 course_1\NN\883297 of_2\IN\1740 lipid_3\NN\14944888 peroxidation_4\NN\1740 in_5\IN\13603305 <e1>puromycin_6\NN\1740 aminonucleoside-induced</e1>_7\JJ\1740 <e2>nephropathy</e2>_8\NN\14573196 ._9\.\1740
D011692_D007674 CID reactive_0\JJ\1740 oxygen_1\NN\14622893 species_2\NNS\7992450 have_3\VBP\2108377 been_4\VBN\836236 implicated_5\VBN\2677097 in_6\IN\13603305 the_7\DT\1740 pathogenesis_8\NN\13533470 of_9\IN\1740 acute_10\JJ\1740 <e1>puromycin_11\NN\1740 aminonucleoside</e1>_12\NN\1740 (pan)-induced_13\VBN\1740 <e2>nephropathy</e2>_14\NN\14573196 ,_15\,\1740 with_16\IN\1740 antioxidants_17\NNS\14724436 significantly_18\RB\1740 reducing_19\VBG\441445 the_20\DT\1740 proteinuria_21\NN\14299637 ._22\.\1740
D011692_D007674 CID reactive_0\JJ\1740 oxygen_1\NN\14622893 species_2\NNS\7992450 have_3\VBP\2108377 been_4\VBN\836236 implicated_5\VBN\2677097 in_6\IN\13603305 the_7\DT\1740 pathogenesis_8\NN\13533470 of_9\IN\1740 acute_10\JJ\1740 puromycin_11\NN\1740 aminonucleoside_12\NN\1740 <e1>(pan)-induced</e1>_13\VBN\1740 <e2>nephropathy</e2>_14\NN\14573196 ,_15\,\1740 with_16\IN\1740 antioxidants_17\NNS\14724436 significantly_18\RB\1740 reducing_19\VBG\441445 the_20\DT\1740 proteinuria_21\NN\14299637 ._22\.\1740
D011692_D007674 CID this_0\DT\1740 study_1\NN\635850 supports_2\VBZ\2199590 the_3\DT\1740 role_4\NN\719494 of_5\IN\1740 lipid_6\NN\14944888 peroxidation_7\NN\1740 in_8\IN\13603305 mediating_9\VBG\761713 the_10\DT\1740 proteinuric_11\JJ\1740 injury_12\NN\14052046 in_13\IN\13603305 <e1>pan</e1>_14\NN\3101986 <e2>nephropathy</e2>_15\NN\14573196 ._16\.\1740
D010100_D007674 NONE reactive_0\JJ\1740 <e1>oxygen</e1>_1\NN\14622893 species_2\NNS\7992450 have_3\VBP\2108377 been_4\VBN\836236 implicated_5\VBN\2677097 in_6\IN\13603305 the_7\DT\1740 pathogenesis_8\NN\13533470 of_9\IN\1740 acute_10\JJ\1740 puromycin_11\NN\1740 aminonucleoside_12\NN\1740 (pan)-induced_13\VBN\1740 <e2>nephropathy</e2>_14\NN\14573196 ,_15\,\1740 with_16\IN\1740 antioxidants_17\NNS\14724436 significantly_18\RB\1740 reducing_19\VBG\441445 the_20\DT\1740 proteinuria_21\NN\14299637 ._22\.\1740
D010100_D011507 NONE reactive_0\JJ\1740 <e1>oxygen</e1>_1\NN\14622893 species_2\NNS\7992450 have_3\VBP\2108377 been_4\VBN\836236 implicated_5\VBN\2677097 in_6\IN\13603305 the_7\DT\1740 pathogenesis_8\NN\13533470 of_9\IN\1740 acute_10\JJ\1740 puromycin_11\NN\1740 aminonucleoside_12\NN\1740 (pan)-induced_13\VBN\1740 nephropathy_14\NN\14573196 ,_15\,\1740 with_16\IN\1740 antioxidants_17\NNS\14724436 significantly_18\RB\1740 reducing_19\VBG\441445 the_20\DT\1740 <e2>proteinuria</e2>_21\NN\14299637 ._22\.\1740
D011692_D011507 CID reactive_0\JJ\1740 oxygen_1\NN\14622893 species_2\NNS\7992450 have_3\VBP\2108377 been_4\VBN\836236 implicated_5\VBN\2677097 in_6\IN\13603305 the_7\DT\1740 pathogenesis_8\NN\13533470 of_9\IN\1740 acute_10\JJ\1740 <e1>puromycin_11\NN\1740 aminonucleoside</e1>_12\NN\1740 (pan)-induced_13\VBN\1740 nephropathy_14\NN\14573196 ,_15\,\1740 with_16\IN\1740 antioxidants_17\NNS\14724436 significantly_18\RB\1740 reducing_19\VBG\441445 the_20\DT\1740 <e2>proteinuria</e2>_21\NN\14299637 ._22\.\1740
D011692_D011507 CID reactive_0\JJ\1740 oxygen_1\NN\14622893 species_2\NNS\7992450 have_3\VBP\2108377 been_4\VBN\836236 implicated_5\VBN\2677097 in_6\IN\13603305 the_7\DT\1740 pathogenesis_8\NN\13533470 of_9\IN\1740 acute_10\JJ\1740 puromycin_11\NN\1740 aminonucleoside_12\NN\1740 <e1>(pan)-induced</e1>_13\VBN\1740 nephropathy_14\NN\14573196 ,_15\,\1740 with_16\IN\1740 antioxidants_17\NNS\14724436 significantly_18\RB\1740 reducing_19\VBG\441445 the_20\DT\1740 <e2>proteinuria</e2>_21\NN\14299637 ._22\.\1740
D011692_D011507 CID this_0\DT\1740 study_1\NN\635850 supports_2\VBZ\2199590 the_3\DT\1740 role_4\NN\719494 of_5\IN\1740 lipid_6\NN\14944888 peroxidation_7\NN\1740 in_8\IN\13603305 mediating_9\VBG\761713 the_10\DT\1740 <e2>proteinuric_11\JJ\1740 injury</e2>_12\NN\14052046 in_13\IN\13603305 <e1>pan</e1>_14\NN\3101986 nephropathy_15\NN\14573196 ._16\.\1740
16740173
6666578
D010396_D001018 CID <e1>d-penicillamine-induced</e1>_0\JJ\1740 <e2>angiopathy</e2>_1\NN\14204950 in_2\IN\13603305 rats_3\NNS\2329401 ._4\.\1740
9249847
D014700_D013611 CID iatrogenically_0\RB\1740 induced_1\VBN\1627355 intractable_2\JJ\1740 <e2>atrioventricular_3\JJ\1740 reentrant_4\JJ\1740 tachycardia</e2>_5\NN\14110674 after_6\IN\1740 <e1>verapamil</e1>_7\NN\2938514 and_8\CC\1740 catheter_9\NN\4493505 ablation_10\NN\671351 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 with_14\IN\1740 wolff-parkinson-white_15\JJ\1740 syndrome_16\NN\5870365 and_17\CC\1740 idiopathic_18\JJ\1740 dilated_19\VBN\303465 cardiomyopathy_20\JJ\1740 ._21\.\1740
D014700_D013611 CID qrs_0\NN\1740 without_1\IN\1740 preexcitation_2\NN\1740 ,_3\,\1740 caused_4\VBN\1617192 by_5\IN\1740 junctional_6\JJ\1740 escape_7\NN\46177 beats_8\VBZ\1108148 after_9\IN\1740 <e1>verapamil</e1>_10\NN\2938514 or_11\CC\3541091 unidirectional_12\JJ\1740 antegrade_13\NN\1740 block_14\NN\21939 of_15\IN\1740 accessory_16\NN\3051540 pathway_17\NN\5483677 after_18\IN\1740 catheter_19\NN\4493505 ablation_20\NN\671351 ,_21\,\1740 established_22\JJ\1740 frequent_23\JJ\1740 <e2>avrt</e2>_24\NN\1740 attack_25\NN\955060 ._26\.\1740
D014700_D014927 NONE iatrogenically_0\RB\1740 induced_1\VBN\1627355 intractable_2\JJ\1740 atrioventricular_3\JJ\1740 reentrant_4\JJ\1740 tachycardia_5\NN\14110674 after_6\IN\1740 <e1>verapamil</e1>_7\NN\2938514 and_8\CC\1740 catheter_9\NN\4493505 ablation_10\NN\671351 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 with_14\IN\1740 <e2>wolff-parkinson-white_15\JJ\1740 syndrome</e2>_16\NN\5870365 and_17\CC\1740 idiopathic_18\JJ\1740 dilated_19\VBN\303465 cardiomyopathy_20\JJ\1740 ._21\.\1740
D014700_D002311 NONE iatrogenically_0\RB\1740 induced_1\VBN\1627355 intractable_2\JJ\1740 atrioventricular_3\JJ\1740 reentrant_4\JJ\1740 tachycardia_5\NN\14110674 after_6\IN\1740 <e1>verapamil</e1>_7\NN\2938514 and_8\CC\1740 catheter_9\NN\4493505 ablation_10\NN\671351 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 with_14\IN\1740 wolff-parkinson-white_15\JJ\1740 syndrome_16\NN\5870365 and_17\CC\1740 <e2>idiopathic_18\JJ\1740 dilated_19\VBN\303465 cardiomyopathy</e2>_20\JJ\1740 ._21\.\1740
3107448
D005905_D056486 CID <e1>glyburide-induced</e1>_0\JJ\1740 <e2>hepatitis</e2>_1\NN\14127211 ._2\.\1740
D005905_D056486 CID for_0\IN\1740 <e1>glyburide</e1>_1\VB\1740 ,_2\,\1740 a_3\DT\13649268 second-generation_4\JJ\1740 sulfonylurea_5\NN\2719105 ,_6\,\1740 only_7\RB\1740 two_8\CD\13741022 brief_9\JJ\1740 reports_10\NNS\6470073 of_11\IN\1740 <e2>hepatotoxicity</e2>_12\NN\1740 exist_13\NN\1740 ._14\.\1740
D005905_D056486 CID two_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 type_3\NN\5839024 ii_4\CD\13741022 diabetes_5\NN\14075199 mellitus_6\NN\1740 developed_7\VBD\1753788 an_8\DT\6697703 <e2>acute_9\JJ\1740 hepatitis-like_10\JJ\1740 syndrome</e2>_11\NN\5870365 soon_12\RB\1740 after_13\IN\1740 initiation_14\NN\7450842 of_15\IN\1740 <e1>glyburide</e1>_16\NN\2719105 therapy_17\NN\657604 ._18\.\1740
D005905_D056486 CID <e1>glyburide</e1>_0\NNP\2719105 can_1\MD\3094503 produce_2\VB\1617192 an_3\DT\6697703 <e2>acute_4\JJ\1740 hepatitis-like_5\JJ\1740 illness</e2>_6\NN\14052046 in_7\IN\13603305 some_8\DT\1740 persons_9\NNS\7347 ._10\.\1740
D013453_D056486 NONE drug-induced_0\JJ\1740 <e2>hepatotoxicity</e2>_1\NN\1740 ,_2\,\1740 although_3\IN\1740 common_4\JJ\1740 ,_5\,\1740 has_6\VBZ\2108377 been_7\VBN\836236 reported_8\VBN\831651 only_9\RB\1740 infrequently_10\RB\1740 with_11\IN\1740 <e1>sulfonylureas</e1>_12\NNS\2719105 ._13\.\1740
D013453_D056486 NONE for_0\IN\1740 glyburide_1\VB\1740 ,_2\,\1740 a_3\DT\13649268 second-generation_4\JJ\1740 <e1>sulfonylurea</e1>_5\NN\2719105 ,_6\,\1740 only_7\RB\1740 two_8\CD\13741022 brief_9\JJ\1740 reports_10\NNS\6470073 of_11\IN\1740 <e2>hepatotoxicity</e2>_12\NN\1740 exist_13\NN\1740 ._14\.\1740
D005905_D003924 NONE two_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>type_3\NN\5839024 ii_4\CD\13741022 diabetes_5\NN\14075199 mellitus</e2>_6\NN\1740 developed_7\VBD\1753788 an_8\DT\6697703 acute_9\JJ\1740 hepatitis-like_10\JJ\1740 syndrome_11\NN\5870365 soon_12\RB\1740 after_13\IN\1740 initiation_14\NN\7450842 of_15\IN\1740 <e1>glyburide</e1>_16\NN\2719105 therapy_17\NN\657604 ._18\.\1740
6387529
D003975_D016584 NONE behavioral_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>diazepam</e1>_3\NN\2830852 and_4\CC\1740 propranolol_5\NN\1740 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 <e2>panic_9\JJ\1740 disorder</e2>_10\NN\14034177 and_11\CC\1740 agoraphobia_12\NN\14381416 ._13\.\1740
D003975_D016584 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 <e1>diazepam</e1>_6\NN\2830852 (_7\-LRB-\1740 single_8\JJ\1740 dose_9\NN\3740161 of_10\IN\1740 10_11\CD\13745420 mg_12\NN\13717155 and_13\CC\1740 a_14\DT\13649268 median_15\JJ\1740 dose_16\NN\3740161 of_17\IN\1740 30_18\CD\13745420 mg/day_19\NN\1740 for_20\IN\1740 2_21\CD\13741022 weeks_22\NNS\15113229 )_23\-RRB-\1740 and_24\CC\1740 propranolol_25\NN\1740 (_26\-LRB-\1740 single_27\JJ\1740 dose_28\NN\3740161 of_29\IN\1740 80_30\CD\13745420 mg_31\NN\13717155 and_32\CC\1740 a_33\DT\13649268 median_34\JJ\1740 dose_35\NN\3740161 of_36\IN\1740 240_37\CD\1740 mg/day_38\NN\1740 for_39\IN\1740 2_40\CD\13741022 weeks_41\NNS\15113229 )_42\-RRB-\1740 on_43\IN\1740 psychological_44\JJ\1740 performance_45\NN\6619065 of_46\IN\1740 patients_47\NNS\9898892 with_48\IN\1740 <e2>panic_49\NN\7519253 disorders</e2>_50\NNS\14034177 and_51\CC\1740 agoraphobia_52\NN\14381416 were_53\VBD\836236 investigated_54\VBN\644583 in_55\IN\13603305 a_56\DT\13649268 double-blind_57\JJ\1740 ,_58\,\1740 randomized_59\JJ\1740 and_60\CC\1740 crossover_61\NN\13526110 design_62\NN\927261 ._63\.\1740
D003975_D000379 NONE behavioral_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>diazepam</e1>_3\NN\2830852 and_4\CC\1740 propranolol_5\NN\1740 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 panic_9\JJ\1740 disorder_10\NN\14034177 and_11\CC\1740 <e2>agoraphobia</e2>_12\NN\14381416 ._13\.\1740
D003975_D000379 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 <e1>diazepam</e1>_6\NN\2830852 (_7\-LRB-\1740 single_8\JJ\1740 dose_9\NN\3740161 of_10\IN\1740 10_11\CD\13745420 mg_12\NN\13717155 and_13\CC\1740 a_14\DT\13649268 median_15\JJ\1740 dose_16\NN\3740161 of_17\IN\1740 30_18\CD\13745420 mg/day_19\NN\1740 for_20\IN\1740 2_21\CD\13741022 weeks_22\NNS\15113229 )_23\-RRB-\1740 and_24\CC\1740 propranolol_25\NN\1740 (_26\-LRB-\1740 single_27\JJ\1740 dose_28\NN\3740161 of_29\IN\1740 80_30\CD\13745420 mg_31\NN\13717155 and_32\CC\1740 a_33\DT\13649268 median_34\JJ\1740 dose_35\NN\3740161 of_36\IN\1740 240_37\CD\1740 mg/day_38\NN\1740 for_39\IN\1740 2_40\CD\13741022 weeks_41\NNS\15113229 )_42\-RRB-\1740 on_43\IN\1740 psychological_44\JJ\1740 performance_45\NN\6619065 of_46\IN\1740 patients_47\NNS\9898892 with_48\IN\1740 panic_49\NN\7519253 disorders_50\NNS\14034177 and_51\CC\1740 <e2>agoraphobia</e2>_52\NN\14381416 were_53\VBD\836236 investigated_54\VBN\644583 in_55\IN\13603305 a_56\DT\13649268 double-blind_57\JJ\1740 ,_58\,\1740 randomized_59\JJ\1740 and_60\CC\1740 crossover_61\NN\13526110 design_62\NN\927261 ._63\.\1740
D011433_D016584 NONE behavioral_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 diazepam_3\NN\2830852 and_4\CC\1740 <e1>propranolol</e1>_5\NN\1740 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 <e2>panic_9\JJ\1740 disorder</e2>_10\NN\14034177 and_11\CC\1740 agoraphobia_12\NN\14381416 ._13\.\1740
D011433_D016584 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 diazepam_6\NN\2830852 (_7\-LRB-\1740 single_8\JJ\1740 dose_9\NN\3740161 of_10\IN\1740 10_11\CD\13745420 mg_12\NN\13717155 and_13\CC\1740 a_14\DT\13649268 median_15\JJ\1740 dose_16\NN\3740161 of_17\IN\1740 30_18\CD\13745420 mg/day_19\NN\1740 for_20\IN\1740 2_21\CD\13741022 weeks_22\NNS\15113229 )_23\-RRB-\1740 and_24\CC\1740 <e1>propranolol</e1>_25\NN\1740 (_26\-LRB-\1740 single_27\JJ\1740 dose_28\NN\3740161 of_29\IN\1740 80_30\CD\13745420 mg_31\NN\13717155 and_32\CC\1740 a_33\DT\13649268 median_34\JJ\1740 dose_35\NN\3740161 of_36\IN\1740 240_37\CD\1740 mg/day_38\NN\1740 for_39\IN\1740 2_40\CD\13741022 weeks_41\NNS\15113229 )_42\-RRB-\1740 on_43\IN\1740 psychological_44\JJ\1740 performance_45\NN\6619065 of_46\IN\1740 patients_47\NNS\9898892 with_48\IN\1740 <e2>panic_49\NN\7519253 disorders</e2>_50\NNS\14034177 and_51\CC\1740 agoraphobia_52\NN\14381416 were_53\VBD\836236 investigated_54\VBN\644583 in_55\IN\13603305 a_56\DT\13649268 double-blind_57\JJ\1740 ,_58\,\1740 randomized_59\JJ\1740 and_60\CC\1740 crossover_61\NN\13526110 design_62\NN\927261 ._63\.\1740
D011433_D000379 NONE behavioral_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 diazepam_3\NN\2830852 and_4\CC\1740 <e1>propranolol</e1>_5\NN\1740 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 panic_9\JJ\1740 disorder_10\NN\14034177 and_11\CC\1740 <e2>agoraphobia</e2>_12\NN\14381416 ._13\.\1740
D011433_D000379 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 diazepam_6\NN\2830852 (_7\-LRB-\1740 single_8\JJ\1740 dose_9\NN\3740161 of_10\IN\1740 10_11\CD\13745420 mg_12\NN\13717155 and_13\CC\1740 a_14\DT\13649268 median_15\JJ\1740 dose_16\NN\3740161 of_17\IN\1740 30_18\CD\13745420 mg/day_19\NN\1740 for_20\IN\1740 2_21\CD\13741022 weeks_22\NNS\15113229 )_23\-RRB-\1740 and_24\CC\1740 <e1>propranolol</e1>_25\NN\1740 (_26\-LRB-\1740 single_27\JJ\1740 dose_28\NN\3740161 of_29\IN\1740 80_30\CD\13745420 mg_31\NN\13717155 and_32\CC\1740 a_33\DT\13649268 median_34\JJ\1740 dose_35\NN\3740161 of_36\IN\1740 240_37\CD\1740 mg/day_38\NN\1740 for_39\IN\1740 2_40\CD\13741022 weeks_41\NNS\15113229 )_42\-RRB-\1740 on_43\IN\1740 psychological_44\JJ\1740 performance_45\NN\6619065 of_46\IN\1740 patients_47\NNS\9898892 with_48\IN\1740 panic_49\NN\7519253 disorders_50\NNS\14034177 and_51\CC\1740 <e2>agoraphobia</e2>_52\NN\14381416 were_53\VBD\836236 investigated_54\VBN\644583 in_55\IN\13603305 a_56\DT\13649268 double-blind_57\JJ\1740 ,_58\,\1740 randomized_59\JJ\1740 and_60\CC\1740 crossover_61\NN\13526110 design_62\NN\927261 ._63\.\1740
D003975_D008569 CID both_0\DT\1740 drugs_1\NNS\14778436 <e2>impaired_2\VBD\258857 immediate_3\JJ\1740 free_4\JJ\1740 recall</e2>_5\NN\7185325 but_6\CC\1740 the_7\DT\1740 decrease_8\NN\7296428 was_9\VBD\836236 greater_10\JJR\1740 for_11\IN\1740 <e1>diazepam</e1>_12\NN\2830852 than_13\IN\1740 propranolol_14\NN\1740 ._15\.\1740
D011433_D008569 CID both_0\DT\1740 drugs_1\NNS\14778436 <e2>impaired_2\VBD\258857 immediate_3\JJ\1740 free_4\JJ\1740 recall</e2>_5\NN\7185325 but_6\CC\1740 the_7\DT\1740 decrease_8\NN\7296428 was_9\VBD\836236 greater_10\JJR\1740 for_11\IN\1740 diazepam_12\NN\2830852 than_13\IN\1740 <e1>propranolol</e1>_14\NN\1740 ._15\.\1740
18083142
D009638_D001008 NONE <e1>norepinephrine</e1>_0\NN\14807929 signaling_1\NN\33020 through_2\IN\1740 beta-adrenergic_3\JJ\1740 receptors_4\NNS\5225602 is_5\VBZ\836236 critical_6\JJ\1740 for_7\IN\1740 expression_8\NN\4679549 of_9\IN\1740 cocaine-induced_10\JJ\1740 <e2>anxiety</e2>_11\NN\14373582 ._12\.\1740
D009638_D001008 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 ,_5\,\1740 we_6\PRP\1740 evaluated_7\VBD\670261 the_8\DT\1740 performance_9\NN\6619065 of_10\IN\1740 dopamine_11\NN\14807737 beta-hydroxylase_12\NN\1740 knockout_13\NN\10787470 (_14\-LRB-\1740 dbh_15\NN\1740 -/-_16\JJ\1740 )_17\-RRB-\1740 mice_18\NNS\2329401 ,_19\,\1740 which_20\WDT\1740 lack_21\VBP\1740 <e1>norepinephrine</e1>_22\NN\14807929 (_23\-LRB-\1740 ne_24\NN\14622893 )_25\-RRB-\1740 ,_26\,\1740 in_27\IN\13603305 the_28\DT\1740 elevated_29\JJ\1740 plus_30\CC\4723816 maze_31\NN\4377057 (_32\-LRB-\1740 epm_33\NN\1740 )_34\-RRB-\1740 to_35\TO\1740 examine_36\VB\789138 the_37\DT\1740 contribution_38\NN\786195 of_39\IN\1740 noradrenergic_40\JJ\1740 signaling_41\NN\33020 to_42\TO\1740 cocaine-induced_43\JJ\1740 <e2>anxiety</e2>_44\NN\14373582 ._45\.\1740
D009638_D001008 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 ,_5\,\1740 we_6\PRP\1740 evaluated_7\VBD\670261 the_8\DT\1740 performance_9\NN\6619065 of_10\IN\1740 dopamine_11\NN\14807737 beta-hydroxylase_12\NN\1740 knockout_13\NN\10787470 (_14\-LRB-\1740 dbh_15\NN\1740 -/-_16\JJ\1740 )_17\-RRB-\1740 mice_18\NNS\2329401 ,_19\,\1740 which_20\WDT\1740 lack_21\VBP\1740 norepinephrine_22\NN\14807929 (_23\-LRB-\1740 <e1>ne</e1>_24\NN\14622893 )_25\-RRB-\1740 ,_26\,\1740 in_27\IN\13603305 the_28\DT\1740 elevated_29\JJ\1740 plus_30\CC\4723816 maze_31\NN\4377057 (_32\-LRB-\1740 epm_33\NN\1740 )_34\-RRB-\1740 to_35\TO\1740 examine_36\VB\789138 the_37\DT\1740 contribution_38\NN\786195 of_39\IN\1740 noradrenergic_40\JJ\1740 signaling_41\NN\33020 to_42\TO\1740 cocaine-induced_43\JJ\1740 <e2>anxiety</e2>_44\NN\14373582 ._45\.\1740
D003042_D001008 CID norepinephrine_0\NN\14807929 signaling_1\NN\33020 through_2\IN\1740 beta-adrenergic_3\JJ\1740 receptors_4\NNS\5225602 is_5\VBZ\836236 critical_6\JJ\1740 for_7\IN\1740 expression_8\NN\4679549 of_9\IN\1740 <e1>cocaine-induced</e1>_10\JJ\1740 <e2>anxiety</e2>_11\NN\14373582 ._12\.\1740
D003042_D001008 CID while_0\IN\15122231 the_1\DT\1740 mechanisms_2\NNS\13446390 underlying_3\VBG\2604760 <e1>cocaine</e1>_4\NN\3492717 's_5\POS\1740 rewarding_6\VBG\2546467 effects_7\NNS\13245626 have_8\VBP\2108377 been_9\VBN\836236 studied_10\VBN\630380 extensively_11\RB\1740 ,_12\,\1740 less_13\JJR\1740 attention_14\NN\5701944 has_15\VBZ\2108377 been_16\VBN\836236 paid_17\VBN\2199590 to_18\IN\1740 the_19\DT\1740 unpleasant_20\JJ\1740 behavioral_21\JJ\1740 states_22\NNS\8491826 induced_23\VBN\1627355 by_24\IN\1740 cocaine_25\NN\3492717 ,_26\,\1740 such_27\JJ\1740 as_28\IN\14622893 <e2>anxiety</e2>_29\NN\14373582 ._30\.\1740
D003042_D001008 CID while_0\IN\15122231 the_1\DT\1740 mechanisms_2\NNS\13446390 underlying_3\VBG\2604760 cocaine_4\NN\3492717 's_5\POS\1740 rewarding_6\VBG\2546467 effects_7\NNS\13245626 have_8\VBP\2108377 been_9\VBN\836236 studied_10\VBN\630380 extensively_11\RB\1740 ,_12\,\1740 less_13\JJR\1740 attention_14\NN\5701944 has_15\VBZ\2108377 been_16\VBN\836236 paid_17\VBN\2199590 to_18\IN\1740 the_19\DT\1740 unpleasant_20\JJ\1740 behavioral_21\JJ\1740 states_22\NNS\8491826 induced_23\VBN\1627355 by_24\IN\1740 <e1>cocaine</e1>_25\NN\3492717 ,_26\,\1740 such_27\JJ\1740 as_28\IN\14622893 <e2>anxiety</e2>_29\NN\14373582 ._30\.\1740
D003042_D001008 CID methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 ,_5\,\1740 we_6\PRP\1740 evaluated_7\VBD\670261 the_8\DT\1740 performance_9\NN\6619065 of_10\IN\1740 dopamine_11\NN\14807737 beta-hydroxylase_12\NN\1740 knockout_13\NN\10787470 (_14\-LRB-\1740 dbh_15\NN\1740 -/-_16\JJ\1740 )_17\-RRB-\1740 mice_18\NNS\2329401 ,_19\,\1740 which_20\WDT\1740 lack_21\VBP\1740 norepinephrine_22\NN\14807929 (_23\-LRB-\1740 ne_24\NN\14622893 )_25\-RRB-\1740 ,_26\,\1740 in_27\IN\13603305 the_28\DT\1740 elevated_29\JJ\1740 plus_30\CC\4723816 maze_31\NN\4377057 (_32\-LRB-\1740 epm_33\NN\1740 )_34\-RRB-\1740 to_35\TO\1740 examine_36\VB\789138 the_37\DT\1740 contribution_38\NN\786195 of_39\IN\1740 noradrenergic_40\JJ\1740 signaling_41\NN\33020 to_42\TO\1740 <e1>cocaine-induced</e1>_43\JJ\1740 <e2>anxiety</e2>_44\NN\14373582 ._45\.\1740
D003042_D001008 CID results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 found_3\VBD\2426171 that_4\IN\1740 <e1>cocaine</e1>_5\NN\3492717 dose-dependently_6\RB\1740 increased_7\VBD\169651 <e2>anxiety-like</e2>_8\JJ\1740 behavior_9\NN\407535 in_10\IN\13603305 control_11\NN\5190804 (_12\-LRB-\1740 dbh_13\NN\1740 +/-_14\CC\1740 )_15\-RRB-\1740 mice_16\NNS\2329401 ,_17\,\1740 as_18\IN\14622893 measured_19\VBN\697589 by_20\IN\1740 a_21\DT\13649268 decrease_22\NN\7296428 in_23\IN\13603305 open_24\JJ\1740 arm_25\NN\5560244 exploration_26\NN\309647 ._27\.\1740
D003042_D001008 CID <e1>cocaine-induced</e1>_0\JJ\1740 <e2>anxiety</e2>_1\NN\14373582 was_2\VBD\836236 also_3\RB\1740 attenuated_4\VBN\224901 in_5\IN\13603305 dbh_6\NNP\1740 +/-_7\CC\1740 mice_8\NNS\2329401 following_9\VBG\1835496 administration_10\NN\1133281 of_11\IN\1740 disulfiram_12\NN\3740161 ,_13\,\1740 a_14\DT\13649268 dopamine_15\NN\14807737 beta-hydroxylase_16\NN\1740 (_17\-LRB-\1740 dbh_18\NN\1740 )_19\-RRB-\1740 inhibitor_20\NN\20090 ._21\.\1740
D003042_D001008 CID in_0\IN\13603305 experiments_1\NNS\641820 using_2\VBG\1156834 specific_3\JJ\1740 adrenergic_4\JJ\1740 antagonists_5\NNS\7846 ,_6\,\1740 we_7\PRP\1740 found_8\VBD\2426171 that_9\IN\1740 pretreatment_10\NN\1740 with_11\IN\1740 the_12\DT\1740 beta-adrenergic_13\JJ\1740 receptor_14\NN\5225602 antagonist_15\NN\7846 propranolol_16\NN\1740 blocked_17\VBD\1476483 <e1>cocaine-induced</e1>_18\JJ\1740 <e2>anxiety-like</e2>_19\JJ\1740 behavior_20\NN\407535 in_21\IN\13603305 dbh_22\NNP\1740 +/-_23\CC\1740 and_24\CC\1740 wild-type_25\JJ\1740 c57bl6/j_26\NN\1740 mice_27\NNS\2329401 ,_28\,\1740 while_29\IN\15122231 the_30\DT\1740 alpha(1_31\NN\1740 )_32\-RRB-\1740 antagonist_33\NN\7846 prazosin_34\NN\2698769 and_35\CC\1740 the_36\DT\1740 alpha(2_37\NN\1740 )_38\-RRB-\1740 antagonist_39\NN\7846 yohimbine_40\NN\1740 had_41\VBD\2108377 no_42\DT\7204911 effect_43\NN\34213 ._44\.\1740
D003042_D001008 CID conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 indicate_4\VBP\952524 that_5\IN\1740 noradrenergic_6\JJ\1740 signaling_7\NN\33020 via_8\IN\1740 beta-adrenergic_9\JJ\1740 receptors_10\NNS\5225602 is_11\VBZ\836236 required_12\VBN\754942 for_13\IN\1740 <e1>cocaine-induced</e1>_14\JJ\1740 <e2>anxiety</e2>_15\NN\14373582 in_16\IN\13603305 mice_17\NNS\2329401 ._18\.\1740
D004298_D001008 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 ,_5\,\1740 we_6\PRP\1740 evaluated_7\VBD\670261 the_8\DT\1740 performance_9\NN\6619065 of_10\IN\1740 <e1>dopamine</e1>_11\NN\14807737 beta-hydroxylase_12\NN\1740 knockout_13\NN\10787470 (_14\-LRB-\1740 dbh_15\NN\1740 -/-_16\JJ\1740 )_17\-RRB-\1740 mice_18\NNS\2329401 ,_19\,\1740 which_20\WDT\1740 lack_21\VBP\1740 norepinephrine_22\NN\14807929 (_23\-LRB-\1740 ne_24\NN\14622893 )_25\-RRB-\1740 ,_26\,\1740 in_27\IN\13603305 the_28\DT\1740 elevated_29\JJ\1740 plus_30\CC\4723816 maze_31\NN\4377057 (_32\-LRB-\1740 epm_33\NN\1740 )_34\-RRB-\1740 to_35\TO\1740 examine_36\VB\789138 the_37\DT\1740 contribution_38\NN\786195 of_39\IN\1740 noradrenergic_40\JJ\1740 signaling_41\NN\33020 to_42\TO\1740 cocaine-induced_43\JJ\1740 <e2>anxiety</e2>_44\NN\14373582 ._45\.\1740
D004298_D001008 NONE cocaine-induced_0\JJ\1740 <e2>anxiety</e2>_1\NN\14373582 was_2\VBD\836236 also_3\RB\1740 attenuated_4\VBN\224901 in_5\IN\13603305 dbh_6\NNP\1740 +/-_7\CC\1740 mice_8\NNS\2329401 following_9\VBG\1835496 administration_10\NN\1133281 of_11\IN\1740 disulfiram_12\NN\3740161 ,_13\,\1740 a_14\DT\13649268 <e1>dopamine</e1>_15\NN\14807737 beta-hydroxylase_16\NN\1740 (_17\-LRB-\1740 dbh_18\NN\1740 )_19\-RRB-\1740 inhibitor_20\NN\20090 ._21\.\1740
D004221_D001008 NONE cocaine-induced_0\JJ\1740 <e2>anxiety</e2>_1\NN\14373582 was_2\VBD\836236 also_3\RB\1740 attenuated_4\VBN\224901 in_5\IN\13603305 dbh_6\NNP\1740 +/-_7\CC\1740 mice_8\NNS\2329401 following_9\VBG\1835496 administration_10\NN\1133281 of_11\IN\1740 <e1>disulfiram</e1>_12\NN\3740161 ,_13\,\1740 a_14\DT\13649268 dopamine_15\NN\14807737 beta-hydroxylase_16\NN\1740 (_17\-LRB-\1740 dbh_18\NN\1740 )_19\-RRB-\1740 inhibitor_20\NN\20090 ._21\.\1740
D011433_D001008 NONE in_0\IN\13603305 experiments_1\NNS\641820 using_2\VBG\1156834 specific_3\JJ\1740 adrenergic_4\JJ\1740 antagonists_5\NNS\7846 ,_6\,\1740 we_7\PRP\1740 found_8\VBD\2426171 that_9\IN\1740 pretreatment_10\NN\1740 with_11\IN\1740 the_12\DT\1740 beta-adrenergic_13\JJ\1740 receptor_14\NN\5225602 antagonist_15\NN\7846 <e1>propranolol</e1>_16\NN\1740 blocked_17\VBD\1476483 cocaine-induced_18\JJ\1740 <e2>anxiety-like</e2>_19\JJ\1740 behavior_20\NN\407535 in_21\IN\13603305 dbh_22\NNP\1740 +/-_23\CC\1740 and_24\CC\1740 wild-type_25\JJ\1740 c57bl6/j_26\NN\1740 mice_27\NNS\2329401 ,_28\,\1740 while_29\IN\15122231 the_30\DT\1740 alpha(1_31\NN\1740 )_32\-RRB-\1740 antagonist_33\NN\7846 prazosin_34\NN\2698769 and_35\CC\1740 the_36\DT\1740 alpha(2_37\NN\1740 )_38\-RRB-\1740 antagonist_39\NN\7846 yohimbine_40\NN\1740 had_41\VBD\2108377 no_42\DT\7204911 effect_43\NN\34213 ._44\.\1740
D011224_D001008 NONE in_0\IN\13603305 experiments_1\NNS\641820 using_2\VBG\1156834 specific_3\JJ\1740 adrenergic_4\JJ\1740 antagonists_5\NNS\7846 ,_6\,\1740 we_7\PRP\1740 found_8\VBD\2426171 that_9\IN\1740 pretreatment_10\NN\1740 with_11\IN\1740 the_12\DT\1740 beta-adrenergic_13\JJ\1740 receptor_14\NN\5225602 antagonist_15\NN\7846 propranolol_16\NN\1740 blocked_17\VBD\1476483 cocaine-induced_18\JJ\1740 <e2>anxiety-like</e2>_19\JJ\1740 behavior_20\NN\407535 in_21\IN\13603305 dbh_22\NNP\1740 +/-_23\CC\1740 and_24\CC\1740 wild-type_25\JJ\1740 c57bl6/j_26\NN\1740 mice_27\NNS\2329401 ,_28\,\1740 while_29\IN\15122231 the_30\DT\1740 alpha(1_31\NN\1740 )_32\-RRB-\1740 antagonist_33\NN\7846 <e1>prazosin</e1>_34\NN\2698769 and_35\CC\1740 the_36\DT\1740 alpha(2_37\NN\1740 )_38\-RRB-\1740 antagonist_39\NN\7846 yohimbine_40\NN\1740 had_41\VBD\2108377 no_42\DT\7204911 effect_43\NN\34213 ._44\.\1740
D015016_D001008 NONE in_0\IN\13603305 experiments_1\NNS\641820 using_2\VBG\1156834 specific_3\JJ\1740 adrenergic_4\JJ\1740 antagonists_5\NNS\7846 ,_6\,\1740 we_7\PRP\1740 found_8\VBD\2426171 that_9\IN\1740 pretreatment_10\NN\1740 with_11\IN\1740 the_12\DT\1740 beta-adrenergic_13\JJ\1740 receptor_14\NN\5225602 antagonist_15\NN\7846 propranolol_16\NN\1740 blocked_17\VBD\1476483 cocaine-induced_18\JJ\1740 <e2>anxiety-like</e2>_19\JJ\1740 behavior_20\NN\407535 in_21\IN\13603305 dbh_22\NNP\1740 +/-_23\CC\1740 and_24\CC\1740 wild-type_25\JJ\1740 c57bl6/j_26\NN\1740 mice_27\NNS\2329401 ,_28\,\1740 while_29\IN\15122231 the_30\DT\1740 alpha(1_31\NN\1740 )_32\-RRB-\1740 antagonist_33\NN\7846 prazosin_34\NN\2698769 and_35\CC\1740 the_36\DT\1740 alpha(2_37\NN\1740 )_38\-RRB-\1740 antagonist_39\NN\7846 <e1>yohimbine</e1>_40\NN\1740 had_41\VBD\2108377 no_42\DT\7204911 effect_43\NN\34213 ._44\.\1740
3173180
D008795_D006463 CID <e2>haemolytic-uraemic_0\JJ\1740 syndrome</e2>_1\NN\5870365 after_2\IN\1740 treatment_3\NN\654885 with_4\IN\1740 <e1>metronidazole</e1>_5\NN\2723292 ._6\.\1740
D008795_D006463 CID this_0\DT\1740 paper_1\NN\14580897 describes_2\VBZ\1001294 the_3\DT\1740 clinical_4\JJ\1740 features_5\NNS\5849040 of_6\IN\1740 six_7\CD\13741022 children_8\NNS\9622049 who_9\WP\8299493 developed_10\VBD\1753788 the_11\DT\1740 <e2>haemolytic-uraemic_12\JJ\1740 syndrome</e2>_13\NN\5870365 after_14\IN\1740 treatment_15\NN\654885 with_16\IN\1740 <e1>metronidazole</e1>_17\NN\2723292 ._18\.\1740
D008795_D006463 CID while_0\IN\15122231 the_1\DT\1740 involvement_2\NN\1080366 of_3\IN\1740 <e1>metronidazole</e1>_4\NN\2723292 in_5\IN\13603305 the_6\DT\1740 aetiology_7\NN\7326557 of_8\IN\1740 the_9\DT\1740 <e2>haemolytic-uraemic_10\JJ\1740 syndrome</e2>_11\NN\5870365 is_12\VBZ\836236 not_13\RB\1740 established_14\VBN\2426171 firmly_15\RB\1740 ,_16\,\1740 the_17\DT\1740 action_18\NN\30358 of_19\IN\1740 this_20\DT\1740 drug_21\NN\14778436 in_22\IN\13603305 sensitizing_23\VBG\126264 tissues_24\NNS\5220461 to_25\IN\1740 oxidation_26\NN\13447361 injury_27\NN\14052046 and_28\CC\1740 the_29\DT\1740 reported_30\VBN\831651 evidence_31\NN\5816287 of_32\IN\1740 oxidation_33\NN\13447361 changes_34\NNS\7283608 in_35\IN\13603305 the_36\DT\1740 haemolytic-uraemic_37\JJ\1740 syndrome_38\NN\5870365 suggest_39\VBP\1010118 a_40\DT\13649268 possible_41\JJ\1740 link_42\NN\13792579 between_43\IN\1740 metronidazole_44\NN\2723292 treatment_45\NN\654885 and_46\CC\1740 some_47\DT\1740 cases_48\NNS\7283608 of_49\IN\1740 the_50\DT\1740 haemolytic-uraemic_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D008795_D006463 CID while_0\IN\15122231 the_1\DT\1740 involvement_2\NN\1080366 of_3\IN\1740 <e1>metronidazole</e1>_4\NN\2723292 in_5\IN\13603305 the_6\DT\1740 aetiology_7\NN\7326557 of_8\IN\1740 the_9\DT\1740 haemolytic-uraemic_10\JJ\1740 syndrome_11\NN\5870365 is_12\VBZ\836236 not_13\RB\1740 established_14\VBN\2426171 firmly_15\RB\1740 ,_16\,\1740 the_17\DT\1740 action_18\NN\30358 of_19\IN\1740 this_20\DT\1740 drug_21\NN\14778436 in_22\IN\13603305 sensitizing_23\VBG\126264 tissues_24\NNS\5220461 to_25\IN\1740 oxidation_26\NN\13447361 injury_27\NN\14052046 and_28\CC\1740 the_29\DT\1740 reported_30\VBN\831651 evidence_31\NN\5816287 of_32\IN\1740 oxidation_33\NN\13447361 changes_34\NNS\7283608 in_35\IN\13603305 the_36\DT\1740 <e2>haemolytic-uraemic_37\JJ\1740 syndrome</e2>_38\NN\5870365 suggest_39\VBP\1010118 a_40\DT\13649268 possible_41\JJ\1740 link_42\NN\13792579 between_43\IN\1740 metronidazole_44\NN\2723292 treatment_45\NN\654885 and_46\CC\1740 some_47\DT\1740 cases_48\NNS\7283608 of_49\IN\1740 the_50\DT\1740 haemolytic-uraemic_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D008795_D006463 CID while_0\IN\15122231 the_1\DT\1740 involvement_2\NN\1080366 of_3\IN\1740 <e1>metronidazole</e1>_4\NN\2723292 in_5\IN\13603305 the_6\DT\1740 aetiology_7\NN\7326557 of_8\IN\1740 the_9\DT\1740 haemolytic-uraemic_10\JJ\1740 syndrome_11\NN\5870365 is_12\VBZ\836236 not_13\RB\1740 established_14\VBN\2426171 firmly_15\RB\1740 ,_16\,\1740 the_17\DT\1740 action_18\NN\30358 of_19\IN\1740 this_20\DT\1740 drug_21\NN\14778436 in_22\IN\13603305 sensitizing_23\VBG\126264 tissues_24\NNS\5220461 to_25\IN\1740 oxidation_26\NN\13447361 injury_27\NN\14052046 and_28\CC\1740 the_29\DT\1740 reported_30\VBN\831651 evidence_31\NN\5816287 of_32\IN\1740 oxidation_33\NN\13447361 changes_34\NNS\7283608 in_35\IN\13603305 the_36\DT\1740 haemolytic-uraemic_37\JJ\1740 syndrome_38\NN\5870365 suggest_39\VBP\1010118 a_40\DT\13649268 possible_41\JJ\1740 link_42\NN\13792579 between_43\IN\1740 metronidazole_44\NN\2723292 treatment_45\NN\654885 and_46\CC\1740 some_47\DT\1740 cases_48\NNS\7283608 of_49\IN\1740 the_50\DT\1740 <e2>haemolytic-uraemic_51\JJ\1740 syndrome</e2>_52\NN\5870365 ._53\.\1740
D008795_D006463 CID while_0\IN\15122231 the_1\DT\1740 involvement_2\NN\1080366 of_3\IN\1740 metronidazole_4\NN\2723292 in_5\IN\13603305 the_6\DT\1740 aetiology_7\NN\7326557 of_8\IN\1740 the_9\DT\1740 <e2>haemolytic-uraemic_10\JJ\1740 syndrome</e2>_11\NN\5870365 is_12\VBZ\836236 not_13\RB\1740 established_14\VBN\2426171 firmly_15\RB\1740 ,_16\,\1740 the_17\DT\1740 action_18\NN\30358 of_19\IN\1740 this_20\DT\1740 drug_21\NN\14778436 in_22\IN\13603305 sensitizing_23\VBG\126264 tissues_24\NNS\5220461 to_25\IN\1740 oxidation_26\NN\13447361 injury_27\NN\14052046 and_28\CC\1740 the_29\DT\1740 reported_30\VBN\831651 evidence_31\NN\5816287 of_32\IN\1740 oxidation_33\NN\13447361 changes_34\NNS\7283608 in_35\IN\13603305 the_36\DT\1740 haemolytic-uraemic_37\JJ\1740 syndrome_38\NN\5870365 suggest_39\VBP\1010118 a_40\DT\13649268 possible_41\JJ\1740 link_42\NN\13792579 between_43\IN\1740 <e1>metronidazole</e1>_44\NN\2723292 treatment_45\NN\654885 and_46\CC\1740 some_47\DT\1740 cases_48\NNS\7283608 of_49\IN\1740 the_50\DT\1740 haemolytic-uraemic_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D008795_D006463 CID while_0\IN\15122231 the_1\DT\1740 involvement_2\NN\1080366 of_3\IN\1740 metronidazole_4\NN\2723292 in_5\IN\13603305 the_6\DT\1740 aetiology_7\NN\7326557 of_8\IN\1740 the_9\DT\1740 haemolytic-uraemic_10\JJ\1740 syndrome_11\NN\5870365 is_12\VBZ\836236 not_13\RB\1740 established_14\VBN\2426171 firmly_15\RB\1740 ,_16\,\1740 the_17\DT\1740 action_18\NN\30358 of_19\IN\1740 this_20\DT\1740 drug_21\NN\14778436 in_22\IN\13603305 sensitizing_23\VBG\126264 tissues_24\NNS\5220461 to_25\IN\1740 oxidation_26\NN\13447361 injury_27\NN\14052046 and_28\CC\1740 the_29\DT\1740 reported_30\VBN\831651 evidence_31\NN\5816287 of_32\IN\1740 oxidation_33\NN\13447361 changes_34\NNS\7283608 in_35\IN\13603305 the_36\DT\1740 <e2>haemolytic-uraemic_37\JJ\1740 syndrome</e2>_38\NN\5870365 suggest_39\VBP\1010118 a_40\DT\13649268 possible_41\JJ\1740 link_42\NN\13792579 between_43\IN\1740 <e1>metronidazole</e1>_44\NN\2723292 treatment_45\NN\654885 and_46\CC\1740 some_47\DT\1740 cases_48\NNS\7283608 of_49\IN\1740 the_50\DT\1740 haemolytic-uraemic_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D008795_D006463 CID while_0\IN\15122231 the_1\DT\1740 involvement_2\NN\1080366 of_3\IN\1740 metronidazole_4\NN\2723292 in_5\IN\13603305 the_6\DT\1740 aetiology_7\NN\7326557 of_8\IN\1740 the_9\DT\1740 haemolytic-uraemic_10\JJ\1740 syndrome_11\NN\5870365 is_12\VBZ\836236 not_13\RB\1740 established_14\VBN\2426171 firmly_15\RB\1740 ,_16\,\1740 the_17\DT\1740 action_18\NN\30358 of_19\IN\1740 this_20\DT\1740 drug_21\NN\14778436 in_22\IN\13603305 sensitizing_23\VBG\126264 tissues_24\NNS\5220461 to_25\IN\1740 oxidation_26\NN\13447361 injury_27\NN\14052046 and_28\CC\1740 the_29\DT\1740 reported_30\VBN\831651 evidence_31\NN\5816287 of_32\IN\1740 oxidation_33\NN\13447361 changes_34\NNS\7283608 in_35\IN\13603305 the_36\DT\1740 haemolytic-uraemic_37\JJ\1740 syndrome_38\NN\5870365 suggest_39\VBP\1010118 a_40\DT\13649268 possible_41\JJ\1740 link_42\NN\13792579 between_43\IN\1740 <e1>metronidazole</e1>_44\NN\2723292 treatment_45\NN\654885 and_46\CC\1740 some_47\DT\1740 cases_48\NNS\7283608 of_49\IN\1740 the_50\DT\1740 <e2>haemolytic-uraemic_51\JJ\1740 syndrome</e2>_52\NN\5870365 ._53\.\1740
2578334
D001374_D011230 CID <e1>5-azacytidine</e1>_0\NN\1740 potentiates_1\VBZ\229605 <e2>initiation_2\NN\7450842 induced_3\VBN\1627355 by_4\IN\1740 carcinogens</e2>_5\NNS\20090 in_6\IN\13603305 rat_7\NN\2329401 liver_8\NN\5298729 ._9\.\1740
D001374_D011230 CID to_0\TO\1740 test_1\VB\670261 the_2\DT\1740 validity_3\NN\4782878 of_4\IN\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 hypomethylation_8\NN\1740 of_9\IN\1740 dna_10\NN\14994328 plays_11\VBZ\1072262 an_12\DT\6697703 important_13\JJ\1740 role_14\NN\719494 in_15\IN\13603305 the_16\DT\1740 <e2>initiation_17\NN\7450842 of_18\IN\1740 carcinogenic_19\JJ\1740 process</e2>_20\NN\407535 ,_21\,\1740 <e1>5-azacytidine</e1>_22\NN\1740 (_23\-LRB-\1740 5-azc_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 10_27\CD\13745420 mg/kg_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 an_31\DT\6697703 inhibitor_32\NN\20090 of_33\IN\1740 dna_34\NN\14994328 methylation_35\NN\1740 ,_36\,\1740 was_37\VBD\836236 given_38\VBN\2327200 to_39\TO\1740 rats_40\NNS\2329401 during_41\IN\1740 the_42\DT\1740 phase_43\NN\15113229 of_44\IN\1740 repair_45\NN\248977 synthesis_46\NN\13446390 induced_47\VBN\1627355 by_48\IN\1740 the_49\DT\1740 three_50\CD\13741022 carcinogens_51\NNS\20090 ,_52\,\1740 benzo[a]-pyrene_53\NN\1740 (_54\-LRB-\1740 200_55\CD\1740 mg/kg_56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 n-methyl-n-nitrosourea_59\NN\1740 (_60\-LRB-\1740 60_61\CD\13745420 mg/kg_62\NN\1740 )_63\-RRB-\1740 and_64\CC\1740 1,2-dimethylhydrazine_65\NN\1740 (_66\-LRB-\1740 1,2-dmh_67\CD\1740 )_68\-RRB-\1740 (_69\-LRB-\1740 100_70\CD\13745420 mg/kg_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D001374_D011230 CID to_0\TO\1740 test_1\VB\670261 the_2\DT\1740 validity_3\NN\4782878 of_4\IN\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 hypomethylation_8\NN\1740 of_9\IN\1740 dna_10\NN\14994328 plays_11\VBZ\1072262 an_12\DT\6697703 important_13\JJ\1740 role_14\NN\719494 in_15\IN\13603305 the_16\DT\1740 <e2>initiation_17\NN\7450842 of_18\IN\1740 carcinogenic_19\JJ\1740 process</e2>_20\NN\407535 ,_21\,\1740 5-azacytidine_22\NN\1740 (_23\-LRB-\1740 <e1>5-azc</e1>_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 10_27\CD\13745420 mg/kg_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 an_31\DT\6697703 inhibitor_32\NN\20090 of_33\IN\1740 dna_34\NN\14994328 methylation_35\NN\1740 ,_36\,\1740 was_37\VBD\836236 given_38\VBN\2327200 to_39\TO\1740 rats_40\NNS\2329401 during_41\IN\1740 the_42\DT\1740 phase_43\NN\15113229 of_44\IN\1740 repair_45\NN\248977 synthesis_46\NN\13446390 induced_47\VBN\1627355 by_48\IN\1740 the_49\DT\1740 three_50\CD\13741022 carcinogens_51\NNS\20090 ,_52\,\1740 benzo[a]-pyrene_53\NN\1740 (_54\-LRB-\1740 200_55\CD\1740 mg/kg_56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 n-methyl-n-nitrosourea_59\NN\1740 (_60\-LRB-\1740 60_61\CD\13745420 mg/kg_62\NN\1740 )_63\-RRB-\1740 and_64\CC\1740 1,2-dimethylhydrazine_65\NN\1740 (_66\-LRB-\1740 1,2-dmh_67\CD\1740 )_68\-RRB-\1740 (_69\-LRB-\1740 100_70\CD\13745420 mg/kg_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D001564_D011230 CID to_0\TO\1740 test_1\VB\670261 the_2\DT\1740 validity_3\NN\4782878 of_4\IN\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 hypomethylation_8\NN\1740 of_9\IN\1740 dna_10\NN\14994328 plays_11\VBZ\1072262 an_12\DT\6697703 important_13\JJ\1740 role_14\NN\719494 in_15\IN\13603305 the_16\DT\1740 <e2>initiation_17\NN\7450842 of_18\IN\1740 carcinogenic_19\JJ\1740 process</e2>_20\NN\407535 ,_21\,\1740 5-azacytidine_22\NN\1740 (_23\-LRB-\1740 5-azc_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 10_27\CD\13745420 mg/kg_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 an_31\DT\6697703 inhibitor_32\NN\20090 of_33\IN\1740 dna_34\NN\14994328 methylation_35\NN\1740 ,_36\,\1740 was_37\VBD\836236 given_38\VBN\2327200 to_39\TO\1740 rats_40\NNS\2329401 during_41\IN\1740 the_42\DT\1740 phase_43\NN\15113229 of_44\IN\1740 repair_45\NN\248977 synthesis_46\NN\13446390 induced_47\VBN\1627355 by_48\IN\1740 the_49\DT\1740 three_50\CD\13741022 carcinogens_51\NNS\20090 ,_52\,\1740 <e1>benzo[a]-pyrene</e1>_53\NN\1740 (_54\-LRB-\1740 200_55\CD\1740 mg/kg_56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 n-methyl-n-nitrosourea_59\NN\1740 (_60\-LRB-\1740 60_61\CD\13745420 mg/kg_62\NN\1740 )_63\-RRB-\1740 and_64\CC\1740 1,2-dimethylhydrazine_65\NN\1740 (_66\-LRB-\1740 1,2-dmh_67\CD\1740 )_68\-RRB-\1740 (_69\-LRB-\1740 100_70\CD\13745420 mg/kg_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D008770_D011230 CID to_0\TO\1740 test_1\VB\670261 the_2\DT\1740 validity_3\NN\4782878 of_4\IN\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 hypomethylation_8\NN\1740 of_9\IN\1740 dna_10\NN\14994328 plays_11\VBZ\1072262 an_12\DT\6697703 important_13\JJ\1740 role_14\NN\719494 in_15\IN\13603305 the_16\DT\1740 <e2>initiation_17\NN\7450842 of_18\IN\1740 carcinogenic_19\JJ\1740 process</e2>_20\NN\407535 ,_21\,\1740 5-azacytidine_22\NN\1740 (_23\-LRB-\1740 5-azc_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 10_27\CD\13745420 mg/kg_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 an_31\DT\6697703 inhibitor_32\NN\20090 of_33\IN\1740 dna_34\NN\14994328 methylation_35\NN\1740 ,_36\,\1740 was_37\VBD\836236 given_38\VBN\2327200 to_39\TO\1740 rats_40\NNS\2329401 during_41\IN\1740 the_42\DT\1740 phase_43\NN\15113229 of_44\IN\1740 repair_45\NN\248977 synthesis_46\NN\13446390 induced_47\VBN\1627355 by_48\IN\1740 the_49\DT\1740 three_50\CD\13741022 carcinogens_51\NNS\20090 ,_52\,\1740 benzo[a]-pyrene_53\NN\1740 (_54\-LRB-\1740 200_55\CD\1740 mg/kg_56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 <e1>n-methyl-n-nitrosourea</e1>_59\NN\1740 (_60\-LRB-\1740 60_61\CD\13745420 mg/kg_62\NN\1740 )_63\-RRB-\1740 and_64\CC\1740 1,2-dimethylhydrazine_65\NN\1740 (_66\-LRB-\1740 1,2-dmh_67\CD\1740 )_68\-RRB-\1740 (_69\-LRB-\1740 100_70\CD\13745420 mg/kg_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D019813_D011230 CID to_0\TO\1740 test_1\VB\670261 the_2\DT\1740 validity_3\NN\4782878 of_4\IN\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 hypomethylation_8\NN\1740 of_9\IN\1740 dna_10\NN\14994328 plays_11\VBZ\1072262 an_12\DT\6697703 important_13\JJ\1740 role_14\NN\719494 in_15\IN\13603305 the_16\DT\1740 <e2>initiation_17\NN\7450842 of_18\IN\1740 carcinogenic_19\JJ\1740 process</e2>_20\NN\407535 ,_21\,\1740 5-azacytidine_22\NN\1740 (_23\-LRB-\1740 5-azc_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 10_27\CD\13745420 mg/kg_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 an_31\DT\6697703 inhibitor_32\NN\20090 of_33\IN\1740 dna_34\NN\14994328 methylation_35\NN\1740 ,_36\,\1740 was_37\VBD\836236 given_38\VBN\2327200 to_39\TO\1740 rats_40\NNS\2329401 during_41\IN\1740 the_42\DT\1740 phase_43\NN\15113229 of_44\IN\1740 repair_45\NN\248977 synthesis_46\NN\13446390 induced_47\VBN\1627355 by_48\IN\1740 the_49\DT\1740 three_50\CD\13741022 carcinogens_51\NNS\20090 ,_52\,\1740 benzo[a]-pyrene_53\NN\1740 (_54\-LRB-\1740 200_55\CD\1740 mg/kg_56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 n-methyl-n-nitrosourea_59\NN\1740 (_60\-LRB-\1740 60_61\CD\13745420 mg/kg_62\NN\1740 )_63\-RRB-\1740 and_64\CC\1740 <e1>1,2-dimethylhydrazine</e1>_65\NN\1740 (_66\-LRB-\1740 1,2-dmh_67\CD\1740 )_68\-RRB-\1740 (_69\-LRB-\1740 100_70\CD\13745420 mg/kg_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D019813_D011230 CID to_0\TO\1740 test_1\VB\670261 the_2\DT\1740 validity_3\NN\4782878 of_4\IN\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 hypomethylation_8\NN\1740 of_9\IN\1740 dna_10\NN\14994328 plays_11\VBZ\1072262 an_12\DT\6697703 important_13\JJ\1740 role_14\NN\719494 in_15\IN\13603305 the_16\DT\1740 <e2>initiation_17\NN\7450842 of_18\IN\1740 carcinogenic_19\JJ\1740 process</e2>_20\NN\407535 ,_21\,\1740 5-azacytidine_22\NN\1740 (_23\-LRB-\1740 5-azc_24\NN\1740 )_25\-RRB-\1740 (_26\-LRB-\1740 10_27\CD\13745420 mg/kg_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 an_31\DT\6697703 inhibitor_32\NN\20090 of_33\IN\1740 dna_34\NN\14994328 methylation_35\NN\1740 ,_36\,\1740 was_37\VBD\836236 given_38\VBN\2327200 to_39\TO\1740 rats_40\NNS\2329401 during_41\IN\1740 the_42\DT\1740 phase_43\NN\15113229 of_44\IN\1740 repair_45\NN\248977 synthesis_46\NN\13446390 induced_47\VBN\1627355 by_48\IN\1740 the_49\DT\1740 three_50\CD\13741022 carcinogens_51\NNS\20090 ,_52\,\1740 benzo[a]-pyrene_53\NN\1740 (_54\-LRB-\1740 200_55\CD\1740 mg/kg_56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 n-methyl-n-nitrosourea_59\NN\1740 (_60\-LRB-\1740 60_61\CD\13745420 mg/kg_62\NN\1740 )_63\-RRB-\1740 and_64\CC\1740 1,2-dimethylhydrazine_65\NN\1740 (_66\-LRB-\1740 <e1>1,2-dmh</e1>_67\CD\1740 )_68\-RRB-\1740 (_69\-LRB-\1740 100_70\CD\13745420 mg/kg_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
8669433
D000082_D007676 NONE habitual_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 <e1>acetaminophen</e1>_3\NN\2707683 as_4\IN\14622893 a_5\DT\13649268 risk_6\NN\14541044 factor_7\NN\7326557 for_8\IN\1740 <e2>chronic_9\JJ\1740 renal_10\JJ\1740 failure</e2>_11\NN\66216 :_12\:\1740 a_13\DT\13649268 comparison_14\NN\635850 with_15\IN\1740 phenacetin_16\NN\2707683 ._17\.\1740
D000082_D007676 NONE however_0\RB\1740 ,_1\,\1740 three_2\CD\13741022 case_3\NN\7283608 control_4\NN\5190804 studies_5\NNS\635850 ,_6\,\1740 one_7\CD\13741022 each_8\DT\1740 in_9\IN\13603305 north_10\NNP\13831000 carolina_11\NNP\1740 ,_12\,\1740 northern_13\JJ\1740 maryland_14\NNP\1740 ,_15\,\1740 and_16\CC\1740 west_17\NNP\13831000 berlin_18\NNP\3670208 ,_19\,\1740 germany_20\NNP\1740 ,_21\,\1740 showed_22\VBD\2137132 that_23\IN\1740 habitual_24\JJ\1740 use_25\NN\407535 of_26\IN\1740 <e1>acetaminophen</e1>_27\NN\2707683 is_28\VBZ\836236 also_29\RB\1740 associated_30\VBN\628491 with_31\IN\1740 <e2>chronic_32\JJ\1740 renal_33\JJ\1740 failure</e2>_34\NN\66216 and_35\CC\1740 esrd_36\NN\1740 ,_37\,\1740 with_38\IN\1740 a_39\DT\13649268 relative_40\JJ\1740 risk_41\NN\14541044 in_42\IN\13603305 the_43\DT\1740 range_44\NN\5123416 of_45\IN\1740 2_46\CD\13741022 to_47\TO\1740 4_48\CD\13741022 ._49\.\1740
D000082_D007676 NONE however_0\RB\1740 ,_1\,\1740 three_2\CD\13741022 case_3\NN\7283608 control_4\NN\5190804 studies_5\NNS\635850 ,_6\,\1740 one_7\CD\13741022 each_8\DT\1740 in_9\IN\13603305 north_10\NNP\13831000 carolina_11\NNP\1740 ,_12\,\1740 northern_13\JJ\1740 maryland_14\NNP\1740 ,_15\,\1740 and_16\CC\1740 west_17\NNP\13831000 berlin_18\NNP\3670208 ,_19\,\1740 germany_20\NNP\1740 ,_21\,\1740 showed_22\VBD\2137132 that_23\IN\1740 habitual_24\JJ\1740 use_25\NN\407535 of_26\IN\1740 <e1>acetaminophen</e1>_27\NN\2707683 is_28\VBZ\836236 also_29\RB\1740 associated_30\VBN\628491 with_31\IN\1740 chronic_32\JJ\1740 renal_33\JJ\1740 failure_34\NN\66216 and_35\CC\1740 <e2>esrd</e2>_36\NN\1740 ,_37\,\1740 with_38\IN\1740 a_39\DT\13649268 relative_40\JJ\1740 risk_41\NN\14541044 in_42\IN\13603305 the_43\DT\1740 range_44\NN\5123416 of_45\IN\1740 2_46\CD\13741022 to_47\TO\1740 4_48\CD\13741022 ._49\.\1740
D000082_D007676 NONE these_0\DT\1740 studies_1\NNS\635850 suggest_2\VBP\1010118 that_3\IN\1740 both_4\CC\1740 phenacetin_5\NN\2707683 and_6\CC\1740 <e1>acetaminophen</e1>_7\NN\2707683 may_8\MD\15209706 contribute_9\VB\126264 to_10\TO\1740 the_11\DT\1740 burden_12\NN\5832264 of_13\IN\1740 <e2>esrd</e2>_14\NN\1740 ,_15\,\1740 with_16\IN\1740 the_17\DT\1740 risk_18\NN\14541044 of_19\IN\1740 the_20\DT\1740 latter_21\NN\13846546 being_22\VBG\836236 somewhat_23\RB\1740 less_24\JJR\1740 than_25\IN\1740 that_26\DT\1740 of_27\IN\1740 the_28\DT\1740 former_29\JJ\1740 ._30\.\1740
D000082_D007676 NONE the_0\DT\1740 possibility_1\NN\5944958 that_2\IN\1740 habitual_3\JJ\1740 use_4\NN\407535 of_5\IN\1740 <e1>acetaminophen</e1>_6\NN\2707683 alone_7\RB\1740 increases_8\VBZ\169651 the_9\DT\1740 risk_10\NN\14541044 of_11\IN\1740 <e2>esrd</e2>_12\NN\1740 has_13\VBZ\2108377 not_14\RB\1740 been_15\VBN\836236 clearly_16\RB\1740 demonstrated_17\VBN\2137132 ,_18\,\1740 but_19\CC\1740 can_20\MD\3094503 not_21\RB\1740 be_22\VB\836236 dismissed_23\VBN\685683 ._24\.\1740
D010615_D007676 CID habitual_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 acetaminophen_3\NN\2707683 as_4\IN\14622893 a_5\DT\13649268 risk_6\NN\14541044 factor_7\NN\7326557 for_8\IN\1740 <e2>chronic_9\JJ\1740 renal_10\JJ\1740 failure</e2>_11\NN\66216 :_12\:\1740 a_13\DT\13649268 comparison_14\NN\635850 with_15\IN\1740 <e1>phenacetin</e1>_16\NN\2707683 ._17\.\1740
D010615_D007676 CID six_0\CD\13741022 epidemiologic_1\JJ\1740 studies_2\NNS\635850 in_3\IN\13603305 the_4\DT\1740 united_5\NNP\1740 states_6\NNP\8491826 and_7\CC\1740 europe_8\NNP\8294696 indicate_9\VBP\952524 that_10\IN\1740 habitual_11\JJ\1740 use_12\NN\407535 of_13\IN\1740 <e1>phenacetin</e1>_14\NN\2707683 is_15\VBZ\836236 associated_16\VBN\628491 with_17\IN\1740 the_18\DT\1740 development_19\NN\248977 of_20\IN\1740 <e2>chronic_21\JJ\1740 renal_22\JJ\1740 failure</e2>_23\NN\66216 and_24\CC\1740 end-stage_25\JJ\1740 renal_26\JJ\1740 disease_27\NN\14061805 (_28\-LRB-\1740 esrd_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 with_32\IN\1740 a_33\DT\13649268 relative_34\JJ\1740 risk_35\NN\14541044 in_36\IN\13603305 the_37\DT\1740 range_38\NN\5123416 of_39\IN\1740 4_40\CD\13741022 to_41\TO\1740 19_42\CD\13745420 ._43\.\1740
D010615_D007676 CID six_0\CD\13741022 epidemiologic_1\JJ\1740 studies_2\NNS\635850 in_3\IN\13603305 the_4\DT\1740 united_5\NNP\1740 states_6\NNP\8491826 and_7\CC\1740 europe_8\NNP\8294696 indicate_9\VBP\952524 that_10\IN\1740 habitual_11\JJ\1740 use_12\NN\407535 of_13\IN\1740 <e1>phenacetin</e1>_14\NN\2707683 is_15\VBZ\836236 associated_16\VBN\628491 with_17\IN\1740 the_18\DT\1740 development_19\NN\248977 of_20\IN\1740 chronic_21\JJ\1740 renal_22\JJ\1740 failure_23\NN\66216 and_24\CC\1740 <e2>end-stage_25\JJ\1740 renal_26\JJ\1740 disease</e2>_27\NN\14061805 (_28\-LRB-\1740 esrd_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 with_32\IN\1740 a_33\DT\13649268 relative_34\JJ\1740 risk_35\NN\14541044 in_36\IN\13603305 the_37\DT\1740 range_38\NN\5123416 of_39\IN\1740 4_40\CD\13741022 to_41\TO\1740 19_42\CD\13745420 ._43\.\1740
D010615_D007676 CID six_0\CD\13741022 epidemiologic_1\JJ\1740 studies_2\NNS\635850 in_3\IN\13603305 the_4\DT\1740 united_5\NNP\1740 states_6\NNP\8491826 and_7\CC\1740 europe_8\NNP\8294696 indicate_9\VBP\952524 that_10\IN\1740 habitual_11\JJ\1740 use_12\NN\407535 of_13\IN\1740 <e1>phenacetin</e1>_14\NN\2707683 is_15\VBZ\836236 associated_16\VBN\628491 with_17\IN\1740 the_18\DT\1740 development_19\NN\248977 of_20\IN\1740 chronic_21\JJ\1740 renal_22\JJ\1740 failure_23\NN\66216 and_24\CC\1740 end-stage_25\JJ\1740 renal_26\JJ\1740 disease_27\NN\14061805 (_28\-LRB-\1740 <e2>esrd</e2>_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 with_32\IN\1740 a_33\DT\13649268 relative_34\JJ\1740 risk_35\NN\14541044 in_36\IN\13603305 the_37\DT\1740 range_38\NN\5123416 of_39\IN\1740 4_40\CD\13741022 to_41\TO\1740 19_42\CD\13745420 ._43\.\1740
D010615_D007676 CID these_0\DT\1740 studies_1\NNS\635850 suggest_2\VBP\1010118 that_3\IN\1740 both_4\CC\1740 <e1>phenacetin</e1>_5\NN\2707683 and_6\CC\1740 acetaminophen_7\NN\2707683 may_8\MD\15209706 contribute_9\VB\126264 to_10\TO\1740 the_11\DT\1740 burden_12\NN\5832264 of_13\IN\1740 <e2>esrd</e2>_14\NN\1740 ,_15\,\1740 with_16\IN\1740 the_17\DT\1740 risk_18\NN\14541044 of_19\IN\1740 the_20\DT\1740 latter_21\NN\13846546 being_22\VBG\836236 somewhat_23\RB\1740 less_24\JJR\1740 than_25\IN\1740 that_26\DT\1740 of_27\IN\1740 the_28\DT\1740 former_29\JJ\1740 ._30\.\1740
8741744
D009538_D009069 NONE compared_0\VBN\644583 with_1\IN\1740 sham-operated_2\JJ\1740 controls_3\NNS\5190804 ,_4\,\1740 lesions_5\NNS\14204950 significantly_6\RB\1740 (_7\-LRB-\1740 p_8\NN\14622893 <_9\XX\1740 0.25_10\CD\1740 )_11\-RRB-\1740 blunted_12\VBD\224901 the_13\DT\1740 early_14\JJ\1740 (_15\-LRB-\1740 <_16\XX\1740 60_17\CD\13745420 min_18\NN\15154774 )_19\-RRB-\1740 free-field_20\JJ\1740 <e2>locomotor_21\NN\1740 hypoactivity</e2>_22\NN\1740 caused_23\VBN\1617192 by_24\IN\1740 <e1>nicotine</e1>_25\NN\14712692 (_26\-LRB-\1740 0.5_27\CD\1740 mg_28\NN\13717155 kg(-1_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 i.m._32\RB\1740 )_33\-RRB-\1740 ,_34\,\1740 enhanced_35\VBD\227165 the_36\DT\1740 later_37\JJR\1740 (_38\-LRB-\1740 60_39\CD\13745420 -_40\SYM\1740 120_41\CD\13745420 min_42\NN\15154774 )_43\-RRB-\1740 nicotine-induced_44\JJ\1740 hyperactivity_45\NN\14052403 ,_46\,\1740 and_47\CC\1740 raised_48\VBD\153263 spontaneous_49\JJ\1740 nocturnal_50\JJ\1740 activity_51\NN\30358 ._52\.\1740
D009538_D009069 NONE compared_0\VBN\644583 with_1\IN\1740 sham-operated_2\JJ\1740 controls_3\NNS\5190804 ,_4\,\1740 lesions_5\NNS\14204950 significantly_6\RB\1740 (_7\-LRB-\1740 p_8\NN\14622893 <_9\XX\1740 0.25_10\CD\1740 )_11\-RRB-\1740 blunted_12\VBD\224901 the_13\DT\1740 early_14\JJ\1740 (_15\-LRB-\1740 <_16\XX\1740 60_17\CD\13745420 min_18\NN\15154774 )_19\-RRB-\1740 free-field_20\JJ\1740 <e2>locomotor_21\NN\1740 hypoactivity</e2>_22\NN\1740 caused_23\VBN\1617192 by_24\IN\1740 nicotine_25\NN\14712692 (_26\-LRB-\1740 0.5_27\CD\1740 mg_28\NN\13717155 kg(-1_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 i.m._32\RB\1740 )_33\-RRB-\1740 ,_34\,\1740 enhanced_35\VBD\227165 the_36\DT\1740 later_37\JJR\1740 (_38\-LRB-\1740 60_39\CD\13745420 -_40\SYM\1740 120_41\CD\13745420 min_42\NN\15154774 )_43\-RRB-\1740 <e1>nicotine-induced</e1>_44\JJ\1740 hyperactivity_45\NN\14052403 ,_46\,\1740 and_47\CC\1740 raised_48\VBD\153263 spontaneous_49\JJ\1740 nocturnal_50\JJ\1740 activity_51\NN\30358 ._52\.\1740
D009538_D006948 CID compared_0\VBN\644583 with_1\IN\1740 sham-operated_2\JJ\1740 controls_3\NNS\5190804 ,_4\,\1740 lesions_5\NNS\14204950 significantly_6\RB\1740 (_7\-LRB-\1740 p_8\NN\14622893 <_9\XX\1740 0.25_10\CD\1740 )_11\-RRB-\1740 blunted_12\VBD\224901 the_13\DT\1740 early_14\JJ\1740 (_15\-LRB-\1740 <_16\XX\1740 60_17\CD\13745420 min_18\NN\15154774 )_19\-RRB-\1740 free-field_20\JJ\1740 locomotor_21\NN\1740 hypoactivity_22\NN\1740 caused_23\VBN\1617192 by_24\IN\1740 <e1>nicotine</e1>_25\NN\14712692 (_26\-LRB-\1740 0.5_27\CD\1740 mg_28\NN\13717155 kg(-1_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 i.m._32\RB\1740 )_33\-RRB-\1740 ,_34\,\1740 enhanced_35\VBD\227165 the_36\DT\1740 later_37\JJR\1740 (_38\-LRB-\1740 60_39\CD\13745420 -_40\SYM\1740 120_41\CD\13745420 min_42\NN\15154774 )_43\-RRB-\1740 nicotine-induced_44\JJ\1740 <e2>hyperactivity</e2>_45\NN\14052403 ,_46\,\1740 and_47\CC\1740 raised_48\VBD\153263 spontaneous_49\JJ\1740 nocturnal_50\JJ\1740 activity_51\NN\30358 ._52\.\1740
D009538_D006948 CID compared_0\VBN\644583 with_1\IN\1740 sham-operated_2\JJ\1740 controls_3\NNS\5190804 ,_4\,\1740 lesions_5\NNS\14204950 significantly_6\RB\1740 (_7\-LRB-\1740 p_8\NN\14622893 <_9\XX\1740 0.25_10\CD\1740 )_11\-RRB-\1740 blunted_12\VBD\224901 the_13\DT\1740 early_14\JJ\1740 (_15\-LRB-\1740 <_16\XX\1740 60_17\CD\13745420 min_18\NN\15154774 )_19\-RRB-\1740 free-field_20\JJ\1740 locomotor_21\NN\1740 hypoactivity_22\NN\1740 caused_23\VBN\1617192 by_24\IN\1740 nicotine_25\NN\14712692 (_26\-LRB-\1740 0.5_27\CD\1740 mg_28\NN\13717155 kg(-1_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 i.m._32\RB\1740 )_33\-RRB-\1740 ,_34\,\1740 enhanced_35\VBD\227165 the_36\DT\1740 later_37\JJR\1740 (_38\-LRB-\1740 60_39\CD\13745420 -_40\SYM\1740 120_41\CD\13745420 min_42\NN\15154774 )_43\-RRB-\1740 <e1>nicotine-induced</e1>_44\JJ\1740 <e2>hyperactivity</e2>_45\NN\14052403 ,_46\,\1740 and_47\CC\1740 raised_48\VBD\153263 spontaneous_49\JJ\1740 nocturnal_50\JJ\1740 activity_51\NN\30358 ._52\.\1740
2894766
D012460_D008180 CID <e1>sulfasalazine-induced</e1>_0\JJ\1740 <e2>lupus_1\NN\14219661 erythematosus</e2>_2\NN\1740 ._3\.\1740
D012460_D008180 CID it_0\PRP\6125041 is_1\VBZ\836236 suggested_2\VBN\1010118 that_3\IN\1740 the_4\DT\1740 patient_5\NN\9898892 had_6\VBD\2108377 <e1>sulfasalazine-induced</e1>_7\JJ\1740 <e2>lupus</e2>_8\NN\14219661 ,_9\,\1740 which_10\WDT\1740 manifested_11\VBD\1015244 with_12\IN\1740 serositis_13\NN\1740 and_14\CC\1740 pulmonary_15\JJ\1740 parenchymal_16\JJ\1740 involvement_17\NN\1080366 in_18\IN\13603305 the_19\DT\1740 absence_20\NN\14449405 of_21\IN\1740 joint_22\JJ\1740 symptoms_23\NNS\5823932 ._24\.\1740
D012460_D008180 CID physicians_0\NNS\10305802 who_1\WP\8299493 use_2\VBP\1156834 <e1>sulfasalazine</e1>_3\NN\1740 to_4\TO\1740 treat_5\VB\2376958 patients_6\NNS\9898892 with_7\IN\1740 inflammatory_8\JJ\1740 bowel_9\NN\5298729 disease_10\NN\14061805 should_11\MD\1740 be_12\VB\836236 aware_13\JJ\1740 of_14\IN\1740 the_15\DT\1740 signs_16\NNS\6643763 of_17\IN\1740 sulfasalazine-induced_18\JJ\1740 <e2>lupus_19\NN\14219661 syndrome</e2>_20\NN\5870365 ._21\.\1740
D012460_D008180 CID physicians_0\NNS\10305802 who_1\WP\8299493 use_2\VBP\1156834 sulfasalazine_3\NN\1740 to_4\TO\1740 treat_5\VB\2376958 patients_6\NNS\9898892 with_7\IN\1740 inflammatory_8\JJ\1740 bowel_9\NN\5298729 disease_10\NN\14061805 should_11\MD\1740 be_12\VB\836236 aware_13\JJ\1740 of_14\IN\1740 the_15\DT\1740 signs_16\NNS\6643763 of_17\IN\1740 <e1>sulfasalazine-induced</e1>_18\JJ\1740 <e2>lupus_19\NN\14219661 syndrome</e2>_20\NN\5870365 ._21\.\1740
D012460_D011014 CID <e2>pneumonitis</e2>_0\NN\14336539 ,_1\,\1740 bilateral_2\JJ\1740 pleural_3\JJ\1740 effusions_4\NNS\6880249 ,_5\,\1740 echocardiographic_6\JJ\1740 evidence_7\NN\5816287 of_8\IN\1740 cardiac_9\JJ\1740 tamponade_10\NN\14507951 ,_11\,\1740 and_12\CC\1740 positive_13\JJ\1740 autoantibodies_14\NNS\15027189 developed_15\VBD\1753788 in_16\IN\13603305 a_17\DT\13649268 43-year-old_18\JJ\1740 man_19\NN\9605289 ,_20\,\1740 who_21\WP\8299493 was_22\VBD\836236 receiving_23\VBG\2210855 long-term_24\JJ\1740 <e1>sulfasalazine</e1>_25\NN\1740 therapy_26\NN\657604 for_27\IN\1740 chronic_28\JJ\1740 ulcerative_29\JJ\1740 colitis_30\NN\14336539 ._31\.\1740
D012460_D010996 CID pneumonitis_0\NN\14336539 ,_1\,\1740 bilateral_2\JJ\1740 <e2>pleural_3\JJ\1740 effusions</e2>_4\NNS\6880249 ,_5\,\1740 echocardiographic_6\JJ\1740 evidence_7\NN\5816287 of_8\IN\1740 cardiac_9\JJ\1740 tamponade_10\NN\14507951 ,_11\,\1740 and_12\CC\1740 positive_13\JJ\1740 autoantibodies_14\NNS\15027189 developed_15\VBD\1753788 in_16\IN\13603305 a_17\DT\13649268 43-year-old_18\JJ\1740 man_19\NN\9605289 ,_20\,\1740 who_21\WP\8299493 was_22\VBD\836236 receiving_23\VBG\2210855 long-term_24\JJ\1740 <e1>sulfasalazine</e1>_25\NN\1740 therapy_26\NN\657604 for_27\IN\1740 chronic_28\JJ\1740 ulcerative_29\JJ\1740 colitis_30\NN\14336539 ._31\.\1740
D012460_D002305 CID pneumonitis_0\NN\14336539 ,_1\,\1740 bilateral_2\JJ\1740 pleural_3\JJ\1740 effusions_4\NNS\6880249 ,_5\,\1740 echocardiographic_6\JJ\1740 evidence_7\NN\5816287 of_8\IN\1740 <e2>cardiac_9\JJ\1740 tamponade</e2>_10\NN\14507951 ,_11\,\1740 and_12\CC\1740 positive_13\JJ\1740 autoantibodies_14\NNS\15027189 developed_15\VBD\1753788 in_16\IN\13603305 a_17\DT\13649268 43-year-old_18\JJ\1740 man_19\NN\9605289 ,_20\,\1740 who_21\WP\8299493 was_22\VBD\836236 receiving_23\VBG\2210855 long-term_24\JJ\1740 <e1>sulfasalazine</e1>_25\NN\1740 therapy_26\NN\657604 for_27\IN\1740 chronic_28\JJ\1740 ulcerative_29\JJ\1740 colitis_30\NN\14336539 ._31\.\1740
D012460_D003093 NONE pneumonitis_0\NN\14336539 ,_1\,\1740 bilateral_2\JJ\1740 pleural_3\JJ\1740 effusions_4\NNS\6880249 ,_5\,\1740 echocardiographic_6\JJ\1740 evidence_7\NN\5816287 of_8\IN\1740 cardiac_9\JJ\1740 tamponade_10\NN\14507951 ,_11\,\1740 and_12\CC\1740 positive_13\JJ\1740 autoantibodies_14\NNS\15027189 developed_15\VBD\1753788 in_16\IN\13603305 a_17\DT\13649268 43-year-old_18\JJ\1740 man_19\NN\9605289 ,_20\,\1740 who_21\WP\8299493 was_22\VBD\836236 receiving_23\VBG\2210855 long-term_24\JJ\1740 <e1>sulfasalazine</e1>_25\NN\1740 therapy_26\NN\657604 for_27\IN\1740 chronic_28\JJ\1740 <e2>ulcerative_29\JJ\1740 colitis</e2>_30\NN\14336539 ._31\.\1740
D012460_D012700 NONE it_0\PRP\6125041 is_1\VBZ\836236 suggested_2\VBN\1010118 that_3\IN\1740 the_4\DT\1740 patient_5\NN\9898892 had_6\VBD\2108377 <e1>sulfasalazine-induced</e1>_7\JJ\1740 lupus_8\NN\14219661 ,_9\,\1740 which_10\WDT\1740 manifested_11\VBD\1015244 with_12\IN\1740 <e2>serositis</e2>_13\NN\1740 and_14\CC\1740 pulmonary_15\JJ\1740 parenchymal_16\JJ\1740 involvement_17\NN\1080366 in_18\IN\13603305 the_19\DT\1740 absence_20\NN\14449405 of_21\IN\1740 joint_22\JJ\1740 symptoms_23\NNS\5823932 ._24\.\1740
D012460_D015212 NONE physicians_0\NNS\10305802 who_1\WP\8299493 use_2\VBP\1156834 <e1>sulfasalazine</e1>_3\NN\1740 to_4\TO\1740 treat_5\VB\2376958 patients_6\NNS\9898892 with_7\IN\1740 <e2>inflammatory_8\JJ\1740 bowel_9\NN\5298729 disease</e2>_10\NN\14061805 should_11\MD\1740 be_12\VB\836236 aware_13\JJ\1740 of_14\IN\1740 the_15\DT\1740 signs_16\NNS\6643763 of_17\IN\1740 sulfasalazine-induced_18\JJ\1740 lupus_19\NN\14219661 syndrome_20\NN\5870365 ._21\.\1740
D012460_D015212 NONE physicians_0\NNS\10305802 who_1\WP\8299493 use_2\VBP\1156834 sulfasalazine_3\NN\1740 to_4\TO\1740 treat_5\VB\2376958 patients_6\NNS\9898892 with_7\IN\1740 <e2>inflammatory_8\JJ\1740 bowel_9\NN\5298729 disease</e2>_10\NN\14061805 should_11\MD\1740 be_12\VB\836236 aware_13\JJ\1740 of_14\IN\1740 the_15\DT\1740 signs_16\NNS\6643763 of_17\IN\1740 <e1>sulfasalazine-induced</e1>_18\JJ\1740 lupus_19\NN\14219661 syndrome_20\NN\5870365 ._21\.\1740
19729346
D010098_D010146 NONE this_0\DT\1740 study_1\NN\635850 measured_2\VBD\697589 the_3\DT\1740 objective_4\JJ\1740 and_5\CC\1740 subjective_6\JJ\1740 neurocognitive_7\JJ\1740 effects_8\NNS\13245626 of_9\IN\1740 a_10\DT\13649268 single_11\JJ\1740 10-mg_12\JJ\1740 dose_13\NN\3740161 of_14\IN\1740 immediate-release_15\NN\1740 <e1>oxycodone</e1>_16\NN\1740 in_17\IN\13603305 healthy_18\JJ\1740 ,_19\,\1740 older_20\JJR\1740 (_21\-LRB-\1740 >_22\NNS\1740 65_23\CD\1740 years_24\NNS\15144371 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 middle-aged_28\JJ\1740 (_29\-LRB-\1740 35_30\CD\1740 to_31\TO\1740 55_32\CD\1740 years_33\NNS\15144371 )_34\-RRB-\1740 adults_35\NNS\7846 who_36\WP\8299493 were_37\VBD\836236 not_38\RB\1740 suffering_39\VBG\2110220 from_40\IN\1740 chronic_41\JJ\1740 or_42\CC\3541091 significant_43\JJ\1740 daily_44\NN\6267145 <e2>pain</e2>_45\NN\14299637 ._46\.\1740
D010098_D059350 NONE this_0\DT\1740 study_1\NN\635850 suggests_2\VBZ\1010118 that_3\IN\1740 for_4\IN\1740 healthy_5\JJ\1740 older_6\JJR\1740 adults_7\NNS\7846 who_8\WP\8299493 are_9\VBP\836236 not_10\RB\1740 suffering_11\VBG\2110220 from_12\IN\1740 <e2>chronic_13\JJ\1740 pain</e2>_14\NN\14299637 ,_15\,\1740 neurocognitive_16\JJ\1740 and_17\CC\1740 pharmacodynamic_18\JJ\1740 changes_19\NNS\7283608 in_20\IN\13603305 response_21\NN\11410625 to_22\TO\1740 a_23\DT\13649268 10-mg_24\JJ\1740 dose_25\NN\3740161 of_26\IN\1740 immediate-release_27\NN\1740 <e1>oxycodone</e1>_28\NN\1740 are_29\VBP\836236 similar_30\JJ\1740 to_31\TO\1740 those_32\DT\1740 observed_33\VBN\2163746 for_34\IN\1740 middle-aged_35\JJ\1740 adults_36\NNS\7846 ._37\.\1740
14513889
D007654_D009422 NONE <e1>ketoconazole-induced</e1>_0\JJ\1740 <e2>neurologic_1\JJ\1740 sequelae</e2>_2\NN\14501726 ._3\.\1740
D007654_D018908 CID a_0\DT\13649268 77-y-old_1\JJ\1740 patient_2\NN\9898892 developed_3\VBD\1753788 <e2>weakness_4\NN\14462666 of_5\IN\1740 extremities</e2>_6\NNS\5225090 ,_7\,\1740 legs_8\NNS\5032918 paralysis_9\NN\14557898 ,_10\,\1740 dysarthria_11\NN\14400677 and_12\CC\1740 tremor_13\NN\345926 1_14\CD\13741022 h_15\NN\14622893 after_16\IN\1740 ingestion_17\NN\13440063 of_18\IN\1740 200_19\CD\1740 mg_20\NN\13717155 <e1>ketoconazole</e1>_21\NN\1740 for_22\IN\1740 the_23\DT\1740 first_24\JJ\1740 time_25\NN\7308889 in_26\IN\13603305 his_27\PRP$\1740 life_28\NN\13954253 ._29\.\1740
D007654_D010243 CID a_0\DT\13649268 77-y-old_1\JJ\1740 patient_2\NN\9898892 developed_3\VBD\1753788 weakness_4\NN\14462666 of_5\IN\1740 extremities_6\NNS\5225090 ,_7\,\1740 <e2>legs_8\NNS\5032918 paralysis</e2>_9\NN\14557898 ,_10\,\1740 dysarthria_11\NN\14400677 and_12\CC\1740 tremor_13\NN\345926 1_14\CD\13741022 h_15\NN\14622893 after_16\IN\1740 ingestion_17\NN\13440063 of_18\IN\1740 200_19\CD\1740 mg_20\NN\13717155 <e1>ketoconazole</e1>_21\NN\1740 for_22\IN\1740 the_23\DT\1740 first_24\JJ\1740 time_25\NN\7308889 in_26\IN\13603305 his_27\PRP$\1740 life_28\NN\13954253 ._29\.\1740
D007654_D004401 CID a_0\DT\13649268 77-y-old_1\JJ\1740 patient_2\NN\9898892 developed_3\VBD\1753788 weakness_4\NN\14462666 of_5\IN\1740 extremities_6\NNS\5225090 ,_7\,\1740 legs_8\NNS\5032918 paralysis_9\NN\14557898 ,_10\,\1740 <e2>dysarthria</e2>_11\NN\14400677 and_12\CC\1740 tremor_13\NN\345926 1_14\CD\13741022 h_15\NN\14622893 after_16\IN\1740 ingestion_17\NN\13440063 of_18\IN\1740 200_19\CD\1740 mg_20\NN\13717155 <e1>ketoconazole</e1>_21\NN\1740 for_22\IN\1740 the_23\DT\1740 first_24\JJ\1740 time_25\NN\7308889 in_26\IN\13603305 his_27\PRP$\1740 life_28\NN\13954253 ._29\.\1740
D007654_D014202 CID a_0\DT\13649268 77-y-old_1\JJ\1740 patient_2\NN\9898892 developed_3\VBD\1753788 weakness_4\NN\14462666 of_5\IN\1740 extremities_6\NNS\5225090 ,_7\,\1740 legs_8\NNS\5032918 paralysis_9\NN\14557898 ,_10\,\1740 dysarthria_11\NN\14400677 and_12\CC\1740 <e2>tremor</e2>_13\NN\345926 1_14\CD\13741022 h_15\NN\14622893 after_16\IN\1740 ingestion_17\NN\13440063 of_18\IN\1740 200_19\CD\1740 mg_20\NN\13717155 <e1>ketoconazole</e1>_21\NN\1740 for_22\IN\1740 the_23\DT\1740 first_24\JJ\1740 time_25\NN\7308889 in_26\IN\13603305 his_27\PRP$\1740 life_28\NN\13954253 ._29\.\1740
20633755
D013390_D001049 CID <e1>suxamethonium</e1>_0\NNP\1740 induced_1\VBD\1627355 prolonged_2\JJ\1740 <e2>apnea</e2>_3\NN\14299637 in_4\IN\13603305 a_5\DT\13649268 patient_6\NN\9898892 receiving_7\VBG\2210855 electroconvulsive_8\JJ\1740 therapy_9\NN\657604 ._10\.\1740
D013390_D001049 CID <e1>suxamethonium</e1>_0\NNP\1740 causes_1\VBZ\1617192 prolonged_2\JJ\1740 <e2>apnea</e2>_3\NN\14299637 in_4\IN\13603305 patients_5\NNS\9898892 in_6\IN\13603305 whom_7\WP\1740 pseudocholinesterase_8\NN\1740 enzyme_9\NN\14723628 gets_10\VBZ\146138 deactivated_11\VBN\1097743 by_12\IN\1740 organophosphorus_13\NN\1740 (_14\-LRB-\1740 op_15\NN\1740 )_16\-RRB-\1740 poisons_17\NNS\20090 ._18\.\1740
D009943_D001049 CID suxamethonium_0\NNP\1740 causes_1\VBZ\1617192 prolonged_2\JJ\1740 <e2>apnea</e2>_3\NN\14299637 in_4\IN\13603305 patients_5\NNS\9898892 in_6\IN\13603305 whom_7\WP\1740 pseudocholinesterase_8\NN\1740 enzyme_9\NN\14723628 gets_10\VBZ\146138 deactivated_11\VBN\1097743 by_12\IN\1740 <e1>organophosphorus_13\NN\1740 (_14\-LRB-\1740 op_15\NN\1740 )_16\-RRB-\1740 poisons</e1>_17\NNS\20090 ._18\.\1740
D009943_D001049 CID prolonged_0\JJ\1740 <e2>apnea</e2>_1\NN\14299637 in_2\IN\13603305 our_3\PRP$\1740 case_4\NN\7283608 ensued_5\VBN\2633881 because_6\IN\1740 the_7\DT\1740 information_8\NN\6598915 about_9\IN\1740 suicidal_10\JJ\1740 attempt_11\NN\407535 by_12\IN\1740 <e1>op_13\NN\1740 compound</e1>_14\NN\5869584 was_15\VBD\836236 concealed_16\VBN\1740 from_17\IN\1740 the_18\DT\1740 treating_19\NN\1740 team_20\NN\8189659 ._21\.\1740
8319760
D019808_D009401 NONE <e1>dup_0\NN\1740 753</e1>_1\CD\1740 prevents_2\VBZ\1740 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 puromycin_6\NN\1740 aminonucleoside-induced_7\JJ\1740 <e2>nephrosis</e2>_8\NN\14304060 ._9\.\1740
D011692_D009401 NONE dup_0\NN\1740 753_1\CD\1740 prevents_2\VBZ\1740 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 <e1>puromycin_6\NN\1740 aminonucleoside-induced</e1>_7\JJ\1740 <e2>nephrosis</e2>_8\NN\14304060 ._9\.\1740
D011692_D009401 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 a_3\DT\13649268 possible_4\JJ\1740 involvement_5\NN\1080366 of_6\IN\1740 the_7\DT\1740 renin-angiotensin_8\JJ\1740 system_9\NN\3575240 in_10\IN\13603305 the_11\DT\1740 development_12\NN\248977 of_13\IN\1740 <e1>puromycin_14\NN\1740 aminonucleoside-induced</e1>_15\JJ\1740 <e2>nephrosis</e2>_16\NN\14304060 ._17\.\1740
D001806_D009404 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 <e2>nephrotic_3\JJ\1740 syndromes</e2>_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 <e1>blood_15\NN\5397468 nitrogen_16\NN\14622893 urea</e1>_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D001806_D011507 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 <e2>proteinuria</e2>_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 <e1>blood_15\NN\5397468 nitrogen_16\NN\14622893 urea</e1>_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D001806_D034141 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 <e2>hypoalbuminemia</e2>_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 <e1>blood_15\NN\5397468 nitrogen_16\NN\14622893 urea</e1>_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D001806_D006937 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 <e2>hypercholesterolemia</e2>_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 <e1>blood_15\NN\5397468 nitrogen_16\NN\14622893 urea</e1>_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D011692_D009404 CID the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 <e2>nephrotic_3\JJ\1740 syndromes</e2>_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 <e1>puromycin_25\NN\1740 aminonucleoside</e1>_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D011692_D011507 CID the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 <e2>proteinuria</e2>_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 <e1>puromycin_25\NN\1740 aminonucleoside</e1>_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D011692_D034141 CID the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 <e2>hypoalbuminemia</e2>_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 <e1>puromycin_25\NN\1740 aminonucleoside</e1>_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D011692_D006937 CID the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 <e2>hypercholesterolemia</e2>_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 <e1>puromycin_25\NN\1740 aminonucleoside</e1>_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D019808_D009404 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 <e2>nephrotic_3\JJ\1740 syndromes</e2>_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 <e1>dup_34\NN\1740 753</e1>_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D019808_D009404 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 <e2>nephrotic_3\JJ\1740 syndromes</e2>_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 <e1>losartan</e1>_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D019808_D011507 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 <e2>proteinuria</e2>_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 <e1>dup_34\NN\1740 753</e1>_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D019808_D011507 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 <e2>proteinuria</e2>_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 <e1>losartan</e1>_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D019808_D034141 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 <e2>hypoalbuminemia</e2>_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 <e1>dup_34\NN\1740 753</e1>_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D019808_D034141 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 <e2>hypoalbuminemia</e2>_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 <e1>losartan</e1>_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D019808_D006937 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 <e2>hypercholesterolemia</e2>_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 <e1>dup_34\NN\1740 753</e1>_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D019808_D006937 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 <e2>hypercholesterolemia</e2>_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 <e1>losartan</e1>_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 angiotensin_42\NN\4522421 ii_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D000804_D009404 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 <e2>nephrotic_3\JJ\1740 syndromes</e2>_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 <e1>angiotensin_42\NN\4522421 ii</e1>_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D000804_D011507 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 <e2>proteinuria</e2>_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 <e1>angiotensin_42\NN\4522421 ii</e1>_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D000804_D034141 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 <e2>hypoalbuminemia</e2>_9\NN\1740 ,_10\,\1740 hypercholesterolemia_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 <e1>angiotensin_42\NN\4522421 ii</e1>_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D000804_D006937 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 nephrotic_3\JJ\1740 syndromes_4\NNS\5870365 such_5\JJ\1740 as_6\IN\14622893 proteinuria_7\NN\14299637 ,_8\,\1740 hypoalbuminemia_9\NN\1740 ,_10\,\1740 <e2>hypercholesterolemia</e2>_11\NN\14299637 and_12\CC\1740 increase_13\VB\169651 in_14\IN\13603305 blood_15\NN\5397468 nitrogen_16\NN\14622893 urea_17\NN\14727670 ,_18\,\1740 induced_19\VBN\1627355 in_20\IN\13603305 rats_21\NNS\2329401 by_22\IN\1740 injection_23\NN\320852 of_24\IN\1740 puromycin_25\NN\1740 aminonucleoside_26\NN\1740 was_27\VBD\836236 markedly_28\RB\1740 inhibited_29\VBN\2510337 by_30\IN\1740 oral_31\JJ\1740 administration_32\NN\1133281 of_33\IN\1740 dup_34\NN\1740 753_35\CD\1740 (_36\-LRB-\1740 losartan_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 a_40\DT\13649268 novel_41\JJ\1740 <e1>angiotensin_42\NN\4522421 ii</e1>_43\CD\13741022 receptor_44\NN\5225602 antagonist_45\NN\7846 ,_46\,\1740 at_47\IN\14622893 a_48\DT\13649268 dose_49\NN\3740161 of_50\IN\1740 1_51\CD\13741022 or_52\CC\3541091 2_53\CD\13741022 mg/kg_54\NN\1740 per_55\IN\1740 day_56\NN\15154774 ._57\.\1740
D000809_D009401 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 a_3\DT\13649268 possible_4\JJ\1740 involvement_5\NN\1080366 of_6\IN\1740 the_7\DT\1740 <e1>renin-angiotensin</e1>_8\JJ\1740 system_9\NN\3575240 in_10\IN\13603305 the_11\DT\1740 development_12\NN\248977 of_13\IN\1740 puromycin_14\NN\1740 aminonucleoside-induced_15\JJ\1740 <e2>nephrosis</e2>_16\NN\14304060 ._17\.\1740
11147747
D018490_D014549 CID <e1>serotonergic_0\JJ\1740 antidepressants</e1>_1\NNS\3740161 and_2\CC\1740 <e2>urinary_3\JJ\1740 incontinence</e2>_4\NN\13473097 ._5\.\1740
D018490_D014549 CID animal_0\JJ\1740 studies_1\NNS\635850 suggest_2\VBP\1010118 that_3\IN\1740 <e2>incontinence</e2>_4\NN\13473097 secondary_5\JJ\1740 to_6\TO\1740 <e1>serotonergic_7\JJ\1740 antidepressants</e1>_8\NNS\3740161 could_9\MD\1740 be_10\VB\836236 mediated_11\VBN\761713 by_12\IN\1740 the_13\DT\1740 5ht4_14\NN\1740 receptors_15\NNS\5225602 found_16\VBN\2426171 on_17\IN\1740 the_18\DT\1740 bladder_19\NN\5515670 ._20\.\1740
C047426_D014549 CID this_0\DT\1740 concerns_1\NNS\5682950 2_2\CD\13741022 male_3\JJ\1740 patients_4\NNS\9898892 who_5\WP\8299493 experienced_6\VBD\2108377 <e2>incontinence</e2>_7\NN\13473097 while_8\IN\15122231 taking_9\VBG\2367363 <e1>venlafaxine</e1>_10\NN\1740 ._11\.\1740
C047426_D014549 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 paper_3\NN\14580897 the_4\DT\1740 authors_5\NNS\9610660 describe_6\VBP\1001294 2_7\CD\13741022 female_8\JJ\1740 patients_9\NNS\9898892 who_10\WP\8299493 developed_11\VBD\1753788 <e2>incontinence</e2>_12\NN\13473097 secondary_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 selective_16\JJ\1740 serotonin_17\NN\14807737 reuptake_18\NN\13571580 inhibitors_19\NNS\20090 paroxetine_20\NN\1740 and_21\CC\1740 sertraline_22\NN\4169152 ,_23\,\1740 as_24\RB\1740 well_25\RB\1740 as_26\IN\14622893 a_27\DT\13649268 third_28\NN\13732295 who_29\WP\8299493 developed_30\VBD\1753788 this_31\DT\1740 side_32\NN\8630039 effect_33\NN\34213 on_34\IN\1740 <e1>venlafaxine</e1>_35\NN\1740 ._36\.\1740
D012701_D014549 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 paper_3\NN\14580897 the_4\DT\1740 authors_5\NNS\9610660 describe_6\VBP\1001294 2_7\CD\13741022 female_8\JJ\1740 patients_9\NNS\9898892 who_10\WP\8299493 developed_11\VBD\1753788 <e2>incontinence</e2>_12\NN\13473097 secondary_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 selective_16\JJ\1740 <e1>serotonin</e1>_17\NN\14807737 reuptake_18\NN\13571580 inhibitors_19\NNS\20090 paroxetine_20\NN\1740 and_21\CC\1740 sertraline_22\NN\4169152 ,_23\,\1740 as_24\RB\1740 well_25\RB\1740 as_26\IN\14622893 a_27\DT\13649268 third_28\NN\13732295 who_29\WP\8299493 developed_30\VBD\1753788 this_31\DT\1740 side_32\NN\8630039 effect_33\NN\34213 on_34\IN\1740 venlafaxine_35\NN\1740 ._36\.\1740
D017374_D014549 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 paper_3\NN\14580897 the_4\DT\1740 authors_5\NNS\9610660 describe_6\VBP\1001294 2_7\CD\13741022 female_8\JJ\1740 patients_9\NNS\9898892 who_10\WP\8299493 developed_11\VBD\1753788 <e2>incontinence</e2>_12\NN\13473097 secondary_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 selective_16\JJ\1740 serotonin_17\NN\14807737 reuptake_18\NN\13571580 inhibitors_19\NNS\20090 <e1>paroxetine</e1>_20\NN\1740 and_21\CC\1740 sertraline_22\NN\4169152 ,_23\,\1740 as_24\RB\1740 well_25\RB\1740 as_26\IN\14622893 a_27\DT\13649268 third_28\NN\13732295 who_29\WP\8299493 developed_30\VBD\1753788 this_31\DT\1740 side_32\NN\8630039 effect_33\NN\34213 on_34\IN\1740 venlafaxine_35\NN\1740 ._36\.\1740
D020280_D014549 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 paper_3\NN\14580897 the_4\DT\1740 authors_5\NNS\9610660 describe_6\VBP\1001294 2_7\CD\13741022 female_8\JJ\1740 patients_9\NNS\9898892 who_10\WP\8299493 developed_11\VBD\1753788 <e2>incontinence</e2>_12\NN\13473097 secondary_13\JJ\1740 to_14\TO\1740 the_15\DT\1740 selective_16\JJ\1740 serotonin_17\NN\14807737 reuptake_18\NN\13571580 inhibitors_19\NNS\20090 paroxetine_20\NN\1740 and_21\CC\1740 <e1>sertraline</e1>_22\NN\4169152 ,_23\,\1740 as_24\RB\1740 well_25\RB\1740 as_26\IN\14622893 a_27\DT\13649268 third_28\NN\13732295 who_29\WP\8299493 developed_30\VBD\1753788 this_31\DT\1740 side_32\NN\8630039 effect_33\NN\34213 on_34\IN\1740 venlafaxine_35\NN\1740 ._36\.\1740
D016651_D014549 CID in_0\IN\13603305 2_1\CD\13741022 of_2\IN\1740 the_3\DT\1740 3_4\CD\13741022 cases_5\NNS\7283608 the_6\DT\1740 patients_7\NNS\9898892 were_8\VBD\836236 also_9\RB\1740 taking_10\VBG\2367363 <e1>lithium_11\NN\14625458 carbonate</e1>_12\NN\15010703 and_13\CC\1740 beta-blockers_14\NNS\1740 ,_15\,\1740 both_16\DT\1740 of_17\IN\1740 which_18\WDT\1740 could_19\MD\1740 have_20\VB\2108377 contributed_21\VBN\126264 to_22\IN\1740 the_23\DT\1740 <e2>incontinence</e2>_24\NN\13473097 ._25\.\1740
20882060
D009496_D002375 NONE effects_0\NNS\13245626 of_1\IN\1740 pallidal_2\JJ\1740 <e1>neurotensin</e1>_3\NN\1740 on_4\IN\1740 haloperidol-induced_5\JJ\1740 <e2>parkinsonian_6\JJ\1740 catalepsy</e2>_7\NN\14023236 :_8\:\1740 behavioral_9\JJ\1740 and_10\CC\1740 electrophysiological_11\JJ\1740 studies_12\NNS\635850 ._13\.\1740
D009496_D002375 NONE results_0\NNS\34213 :_1\:\1740 bilateral_2\JJ\1740 infusions_3\NNS\14589223 of_4\IN\1740 <e1>neurotensin</e1>_5\NN\1740 into_6\IN\1740 the_7\DT\1740 globus_8\NN\1740 pallidus_9\NN\1740 reversed_10\VBN\109660 haloperidol-induced_11\JJ\1740 <e2>parkinsonian_12\JJ\1740 catalepsy</e2>_13\NN\14023236 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D006220_D002375 CID effects_0\NNS\13245626 of_1\IN\1740 pallidal_2\JJ\1740 neurotensin_3\NN\1740 on_4\IN\1740 <e1>haloperidol-induced</e1>_5\JJ\1740 <e2>parkinsonian_6\JJ\1740 catalepsy</e2>_7\NN\14023236 :_8\:\1740 behavioral_9\JJ\1740 and_10\CC\1740 electrophysiological_11\JJ\1740 studies_12\NNS\635850 ._13\.\1740
D006220_D002375 CID results_0\NNS\34213 :_1\:\1740 bilateral_2\JJ\1740 infusions_3\NNS\14589223 of_4\IN\1740 neurotensin_5\NN\1740 into_6\IN\1740 the_7\DT\1740 globus_8\NN\1740 pallidus_9\NN\1740 reversed_10\VBN\109660 <e1>haloperidol-induced</e1>_11\JJ\1740 <e2>parkinsonian_12\JJ\1740 catalepsy</e2>_13\NN\14023236 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D009496_D010302 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 investigate_5\VB\644583 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 pallidal_9\JJ\1740 <e1>neurotensin</e1>_10\NN\1740 on_11\IN\1740 haloperidol-induced_12\JJ\1740 <e2>parkinsonian_13\JJ\1740 symptoms</e2>_14\NNS\5823932 ._15\.\1740
D006220_D010302 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 investigate_5\VB\644583 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 pallidal_9\JJ\1740 neurotensin_10\NN\1740 on_11\IN\1740 <e1>haloperidol-induced</e1>_12\JJ\1740 <e2>parkinsonian_13\JJ\1740 symptoms</e2>_14\NNS\5823932 ._15\.\1740
3496378
D014217_D002779 CID prolonged_0\JJ\1740 <e2>cholestasis</e2>_1\NN\14052403 after_2\IN\1740 <e1>troleandomycin-induced</e1>_3\JJ\1740 acute_4\JJ\1740 hepatitis_5\NN\14127211 ._6\.\1740
D014217_D002779 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 in_7\IN\13603305 whom_8\WP\1740 <e1>troleandomycin-induced</e1>_9\JJ\1740 hepatitis_10\NN\14127211 was_11\VBD\836236 followed_12\VBN\1835496 by_13\IN\1740 prolonged_14\JJ\1740 anicteric_15\JJ\1740 <e2>cholestasis</e2>_16\NN\14052403 ._17\.\1740
D014217_D002779 CID this_0\DT\1740 observation_1\NN\996969 demonstrates_2\VBZ\2137132 that_3\IN\1740 prolonged_4\JJ\1740 <e2>cholestasis</e2>_5\NN\14052403 can_6\MD\3094503 follow_7\VB\1835496 <e1>troleandomycin-induced</e1>_8\JJ\1740 acute_9\JJ\1740 hepatitis_10\NN\14127211 ._11\.\1740
D014217_D056486 CID prolonged_0\JJ\1740 cholestasis_1\NN\14052403 after_2\IN\1740 <e1>troleandomycin-induced</e1>_3\JJ\1740 acute_4\JJ\1740 <e2>hepatitis</e2>_5\NN\14127211 ._6\.\1740
D014217_D056486 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 in_7\IN\13603305 whom_8\WP\1740 <e1>troleandomycin-induced</e1>_9\JJ\1740 <e2>hepatitis</e2>_10\NN\14127211 was_11\VBD\836236 followed_12\VBN\1835496 by_13\IN\1740 prolonged_14\JJ\1740 anicteric_15\JJ\1740 cholestasis_16\NN\14052403 ._17\.\1740
D014217_D056486 CID this_0\DT\1740 observation_1\NN\996969 demonstrates_2\VBZ\2137132 that_3\IN\1740 prolonged_4\JJ\1740 cholestasis_5\NN\14052403 can_6\MD\3094503 follow_7\VB\1835496 <e1>troleandomycin-induced</e1>_8\JJ\1740 acute_9\JJ\1740 <e2>hepatitis</e2>_10\NN\14127211 ._11\.\1740
D014217_D007565 CID <e2>jaundice</e2>_0\NNP\14299637 occurred_1\VBD\2623529 after_2\IN\1740 administration_3\NN\1133281 of_4\IN\1740 <e1>troleandomycin</e1>_5\NN\1740 for_6\IN\1740 7_7\CD\13741022 days_8\NNS\15140892 and_9\CC\1740 was_10\VBD\836236 associated_11\VBN\628491 with_12\IN\1740 hypereosinophilia_13\NN\1740 ._14\.\1740
D014217_D004802 CID jaundice_0\NNP\14299637 occurred_1\VBD\2623529 after_2\IN\1740 administration_3\NN\1133281 of_4\IN\1740 <e1>troleandomycin</e1>_5\NN\1740 for_6\IN\1740 7_7\CD\13741022 days_8\NNS\15140892 and_9\CC\1740 was_10\VBD\836236 associated_11\VBN\628491 with_12\IN\1740 <e2>hypereosinophilia</e2>_13\NN\1740 ._14\.\1740
16005948
-1_D062787 NONE evaluation_0\NN\874067 of_1\IN\1740 the_2\DT\1740 anticocaine_3\JJ\1740 monoclonal_4\JJ\1740 antibody_5\NN\14728724 <e1>gnc92h2</e1>_6\NN\1740 as_7\IN\14622893 an_8\DT\6697703 immunotherapy_9\NN\661091 for_10\IN\1740 <e2>cocaine_11\NN\3492717 overdose</e2>_12\NN\1740 ._13\.\1740
-1_D062787 NONE the_0\DT\1740 therapeutic_1\JJ\1740 potential_2\NN\14481929 of_3\IN\1740 the_4\DT\1740 anticocaine_5\JJ\1740 antibody_6\NN\14728724 <e1>gnc92h2</e1>_7\NN\1740 was_8\VBD\836236 examined_9\VBN\789138 using_10\VBG\1156834 a_11\DT\13649268 model_12\NN\5888929 of_13\IN\1740 <e2>cocaine_14\NN\3492717 overdose</e2>_15\NN\1740 ._16\.\1740
-1_D062787 NONE the_0\DT\1740 results_1\NNS\34213 support_2\VBP\2199590 the_3\DT\1740 important_4\JJ\1740 potential_5\NN\14481929 of_6\IN\1740 <e1>gnc92h2</e1>_7\NN\1740 as_8\IN\14622893 a_9\DT\13649268 therapeutic_10\JJ\1740 tool_11\NN\3563967 against_12\IN\1740 <e2>cocaine_13\NN\3492717 overdose</e2>_14\NN\1740 ._15\.\1740
D003042_D062787 NONE the_0\DT\1740 illicit_1\NN\1740 use_2\NN\407535 of_3\IN\1740 <e1>cocaine</e1>_4\NN\3492717 continues_5\VBZ\2367363 in_6\IN\13603305 epidemic_7\JJ\1740 proportions_8\NNS\13824815 and_9\CC\1740 treatment_10\NN\654885 for_11\IN\1740 <e2>cocaine_12\NN\3492717 overdose</e2>_13\NN\1740 remains_14\VBZ\2604760 elusive_15\JJ\1740 ._16\.\1740
D003042_D064420 NONE significant_0\JJ\1740 blockade_1\NN\952963 of_2\IN\1740 <e1>cocaine</e1>_3\NN\3492717 <e2>toxicity</e2>_4\NN\13576101 was_5\VBD\836236 observed_6\VBN\2163746 with_7\IN\1740 the_8\DT\1740 higher_9\JJR\1740 dose_10\NN\3740161 of_11\IN\1740 gnc92h2_12\NN\1740 (_13\-LRB-\1740 190_14\CD\1740 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 where_18\WRB\1740 premorbid_19\JJ\1740 behaviors_20\NNS\407535 were_21\VBD\836236 reduced_22\VBN\441445 up_23\RB\1740 to_24\TO\1740 40_25\CD\13745420 %_26\NN\1740 ,_27\,\1740 seizures_28\VBZ\1740 up_29\RP\1740 to_30\TO\1740 77_31\CD\1740 %_32\NN\1740 and_33\CC\1740 death_34\NN\7296428 by_35\IN\1740 72_36\CD\1740 %_37\NN\1740 ._38\.\1740
D003042_D012640 CID significant_0\JJ\1740 blockade_1\NN\952963 of_2\IN\1740 <e1>cocaine</e1>_3\NN\3492717 toxicity_4\NN\13576101 was_5\VBD\836236 observed_6\VBN\2163746 with_7\IN\1740 the_8\DT\1740 higher_9\JJR\1740 dose_10\NN\3740161 of_11\IN\1740 gnc92h2_12\NN\1740 (_13\-LRB-\1740 190_14\CD\1740 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 where_18\WRB\1740 premorbid_19\JJ\1740 behaviors_20\NNS\407535 were_21\VBD\836236 reduced_22\VBN\441445 up_23\RB\1740 to_24\TO\1740 40_25\CD\13745420 %_26\NN\1740 ,_27\,\1740 <e2>seizures</e2>_28\VBZ\1740 up_29\RP\1740 to_30\TO\1740 77_31\CD\1740 %_32\NN\1740 and_33\CC\1740 death_34\NN\7296428 by_35\IN\1740 72_36\CD\1740 %_37\NN\1740 ._38\.\1740
D003042_D003643 NONE significant_0\JJ\1740 blockade_1\NN\952963 of_2\IN\1740 <e1>cocaine</e1>_3\NN\3492717 toxicity_4\NN\13576101 was_5\VBD\836236 observed_6\VBN\2163746 with_7\IN\1740 the_8\DT\1740 higher_9\JJR\1740 dose_10\NN\3740161 of_11\IN\1740 gnc92h2_12\NN\1740 (_13\-LRB-\1740 190_14\CD\1740 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 where_18\WRB\1740 premorbid_19\JJ\1740 behaviors_20\NNS\407535 were_21\VBD\836236 reduced_22\VBN\441445 up_23\RB\1740 to_24\TO\1740 40_25\CD\13745420 %_26\NN\1740 ,_27\,\1740 seizures_28\VBZ\1740 up_29\RP\1740 to_30\TO\1740 77_31\CD\1740 %_32\NN\1740 and_33\CC\1740 <e2>death</e2>_34\NN\7296428 by_35\IN\1740 72_36\CD\1740 %_37\NN\1740 ._38\.\1740
D003042_D003643 NONE importantly_0\RB\1740 ,_1\,\1740 gnc92h2_2\NNP\1740 prevented_3\VBD\1740 <e2>death</e2>_4\NN\7296428 even_5\RB\1740 <e1>post-cocaine</e1>_6\JJ\1740 injection_7\NN\320852 ._8\.\1740
-1_D064420 NONE significant_0\JJ\1740 blockade_1\NN\952963 of_2\IN\1740 cocaine_3\NN\3492717 <e2>toxicity</e2>_4\NN\13576101 was_5\VBD\836236 observed_6\VBN\2163746 with_7\IN\1740 the_8\DT\1740 higher_9\JJR\1740 dose_10\NN\3740161 of_11\IN\1740 <e1>gnc92h2</e1>_12\NN\1740 (_13\-LRB-\1740 190_14\CD\1740 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 where_18\WRB\1740 premorbid_19\JJ\1740 behaviors_20\NNS\407535 were_21\VBD\836236 reduced_22\VBN\441445 up_23\RB\1740 to_24\TO\1740 40_25\CD\13745420 %_26\NN\1740 ,_27\,\1740 seizures_28\VBZ\1740 up_29\RP\1740 to_30\TO\1740 77_31\CD\1740 %_32\NN\1740 and_33\CC\1740 death_34\NN\7296428 by_35\IN\1740 72_36\CD\1740 %_37\NN\1740 ._38\.\1740
-1_D012640 NONE significant_0\JJ\1740 blockade_1\NN\952963 of_2\IN\1740 cocaine_3\NN\3492717 toxicity_4\NN\13576101 was_5\VBD\836236 observed_6\VBN\2163746 with_7\IN\1740 the_8\DT\1740 higher_9\JJR\1740 dose_10\NN\3740161 of_11\IN\1740 <e1>gnc92h2</e1>_12\NN\1740 (_13\-LRB-\1740 190_14\CD\1740 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 where_18\WRB\1740 premorbid_19\JJ\1740 behaviors_20\NNS\407535 were_21\VBD\836236 reduced_22\VBN\441445 up_23\RB\1740 to_24\TO\1740 40_25\CD\13745420 %_26\NN\1740 ,_27\,\1740 <e2>seizures</e2>_28\VBZ\1740 up_29\RP\1740 to_30\TO\1740 77_31\CD\1740 %_32\NN\1740 and_33\CC\1740 death_34\NN\7296428 by_35\IN\1740 72_36\CD\1740 %_37\NN\1740 ._38\.\1740
-1_D003643 NONE significant_0\JJ\1740 blockade_1\NN\952963 of_2\IN\1740 cocaine_3\NN\3492717 toxicity_4\NN\13576101 was_5\VBD\836236 observed_6\VBN\2163746 with_7\IN\1740 the_8\DT\1740 higher_9\JJR\1740 dose_10\NN\3740161 of_11\IN\1740 <e1>gnc92h2</e1>_12\NN\1740 (_13\-LRB-\1740 190_14\CD\1740 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 where_18\WRB\1740 premorbid_19\JJ\1740 behaviors_20\NNS\407535 were_21\VBD\836236 reduced_22\VBN\441445 up_23\RB\1740 to_24\TO\1740 40_25\CD\13745420 %_26\NN\1740 ,_27\,\1740 seizures_28\VBZ\1740 up_29\RP\1740 to_30\TO\1740 77_31\CD\1740 %_32\NN\1740 and_33\CC\1740 <e2>death</e2>_34\NN\7296428 by_35\IN\1740 72_36\CD\1740 %_37\NN\1740 ._38\.\1740
-1_D003643 NONE importantly_0\RB\1740 ,_1\,\1740 <e1>gnc92h2</e1>_2\NNP\1740 prevented_3\VBD\1740 <e2>death</e2>_4\NN\7296428 even_5\RB\1740 post-cocaine_6\JJ\1740 injection_7\NN\320852 ._8\.\1740
11897407
C067171_D009203 NONE <e1>99mtc-glucarate</e1>_0\NN\1740 for_1\IN\1740 detection_2\NN\5708432 of_3\IN\1740 isoproterenol-induced_4\JJ\1740 <e2>myocardial_5\JJ\1740 infarction</e2>_6\NN\14204950 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
C067171_D009203 NONE <e1>99mtc-glucarate</e1>_0\NN\1740 was_1\VBD\836236 easy_2\JJ\1740 to_3\TO\1740 prepare_4\VB\126264 ,_5\,\1740 stable_6\JJ\1740 for_7\IN\1740 96_8\CD\1740 h_9\NN\14622893 and_10\CC\1740 was_11\VBD\836236 used_12\VBN\1156834 to_13\TO\1740 study_14\VB\630380 its_15\PRP$\6125041 biodistribution_16\NN\1740 in_17\IN\13603305 rats_18\NNS\2329401 with_19\IN\1740 isoproterenol-induced_20\JJ\1740 acute_21\JJ\1740 <e2>myocardial_22\JJ\1740 infarction</e2>_23\NN\14204950 ._24\.\1740
D007545_D009203 CID 99mtc-glucarate_0\NN\1740 for_1\IN\1740 detection_2\NN\5708432 of_3\IN\1740 <e1>isoproterenol-induced</e1>_4\JJ\1740 <e2>myocardial_5\JJ\1740 infarction</e2>_6\NN\14204950 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D007545_D009203 CID 99mtc-glucarate_0\NN\1740 was_1\VBD\836236 easy_2\JJ\1740 to_3\TO\1740 prepare_4\VB\126264 ,_5\,\1740 stable_6\JJ\1740 for_7\IN\1740 96_8\CD\1740 h_9\NN\14622893 and_10\CC\1740 was_11\VBD\836236 used_12\VBN\1156834 to_13\TO\1740 study_14\VB\630380 its_15\PRP$\6125041 biodistribution_16\NN\1740 in_17\IN\13603305 rats_18\NNS\2329401 with_19\IN\1740 <e1>isoproterenol-induced</e1>_20\JJ\1740 acute_21\JJ\1740 <e2>myocardial_22\JJ\1740 infarction</e2>_23\NN\14204950 ._24\.\1740
D007545_D007238 NONE the_0\DT\1740 animal_1\NN\4475 model_2\NN\5888929 used_3\VBN\1156834 to_4\TO\1740 produce_5\VB\1617192 <e2>infarction</e2>_6\NN\14204950 implies_7\VBZ\943837 artery_8\NN\5417975 ligation_9\NN\149084 but_10\CC\1740 chemical_11\NN\14580897 induction_12\NN\7450842 can_13\MD\3094503 be_14\VB\836236 easily_15\RB\1740 obtained_16\VBN\2210855 with_17\IN\1740 <e1>isoproterenol</e1>_18\NN\3740161 ._19\.\1740
D007545_D007238 NONE histological_0\JJ\1740 studies_1\NNS\635850 demonstrated_2\VBD\2137132 that_3\IN\1740 the_4\DT\1740 rats_5\NNS\2329401 developed_6\VBD\1753788 an_7\DT\6697703 <e2>infarct</e2>_8\NN\14204950 18_9\CD\13745420 h_10\NN\14622893 after_11\IN\1740 <e1>isoproterenol</e1>_12\JJ\1740 administration_13\NN\1133281 ._14\.\1740
D005937_D007238 NONE a_0\DT\13649268 new_1\JJ\1740 <e2>infarct-avid</e2>_2\JJ\1740 radiopharmaceutical_3\JJ\1740 based_4\VBN\2694933 on_5\IN\1740 <e1>glucaric_6\JJ\1740 acid</e1>_7\NN\14818238 was_8\VBD\836236 prepared_9\VBN\126264 in_10\IN\13603305 the_11\DT\1740 hospital_12\NN\3739518 radiopharmacy_13\NN\1740 of_14\IN\1740 the_15\DT\1740 incmnsz_16\NN\1740 ._17\.\1740
567256
D004054_D006394 CID <e2>angiosarcoma_0\NN\14239425 of_1\IN\1740 the_2\DT\1740 liver</e2>_3\NN\5298729 associated_4\VBN\628491 with_5\IN\1740 <e1>diethylstilbestrol</e1>_6\NN\14749794 ._7\.\1740
D004054_D006394 CID <e2>angiosarcoma_0\NN\14239425 of_1\IN\1740 the_2\DT\1740 liver</e2>_3\NN\5298729 occurred_4\VBD\2623529 in_5\IN\13603305 a_6\DT\13649268 76-year-old_7\JJ\1740 man_8\NN\9605289 who_9\WP\8299493 had_10\VBD\2108377 been_11\VBN\836236 treated_12\VBN\2376958 for_13\IN\1740 a_14\DT\13649268 well-differentiated_15\JJ\1740 adenocarcinoma_16\NN\14242337 of_17\IN\1740 the_18\DT\1740 liver_19\NN\5298729 with_20\IN\1740 <e1>diethylstilbestrol</e1>_21\NN\14749794 for_22\IN\1740 13_23\CD\13745420 years_24\NNS\15144371 ._25\.\1740
D004054_D008113 CID <e2>angiosarcoma_0\NN\14239425 of_1\IN\1740 the_2\DT\1740 liver</e2>_3\NN\5298729 associated_4\VBN\628491 with_5\IN\1740 <e1>diethylstilbestrol</e1>_6\NN\14749794 ._7\.\1740
D004054_D008113 CID <e2>angiosarcoma_0\NN\14239425 of_1\IN\1740 the_2\DT\1740 liver</e2>_3\NN\5298729 occurred_4\VBD\2623529 in_5\IN\13603305 a_6\DT\13649268 76-year-old_7\JJ\1740 man_8\NN\9605289 who_9\WP\8299493 had_10\VBD\2108377 been_11\VBN\836236 treated_12\VBN\2376958 for_13\IN\1740 a_14\DT\13649268 well-differentiated_15\JJ\1740 adenocarcinoma_16\NN\14242337 of_17\IN\1740 the_18\DT\1740 liver_19\NN\5298729 with_20\IN\1740 <e1>diethylstilbestrol</e1>_21\NN\14749794 for_22\IN\1740 13_23\CD\13745420 years_24\NNS\15144371 ._25\.\1740
D004054_D008113 NONE angiosarcoma_0\NN\14239425 of_1\IN\1740 the_2\DT\1740 liver_3\NN\5298729 occurred_4\VBD\2623529 in_5\IN\13603305 a_6\DT\13649268 76-year-old_7\JJ\1740 man_8\NN\9605289 who_9\WP\8299493 had_10\VBD\2108377 been_11\VBN\836236 treated_12\VBN\2376958 for_13\IN\1740 a_14\DT\13649268 well-differentiated_15\JJ\1740 <e2>adenocarcinoma_16\NN\14242337 of_17\IN\1740 the_18\DT\1740 liver</e2>_19\NN\5298729 with_20\IN\1740 <e1>diethylstilbestrol</e1>_21\NN\14749794 for_22\IN\1740 13_23\CD\13745420 years_24\NNS\15144371 ._25\.\1740
D004054_D000230 NONE angiosarcoma_0\NN\14239425 of_1\IN\1740 the_2\DT\1740 liver_3\NN\5298729 occurred_4\VBD\2623529 in_5\IN\13603305 a_6\DT\13649268 76-year-old_7\JJ\1740 man_8\NN\9605289 who_9\WP\8299493 had_10\VBD\2108377 been_11\VBN\836236 treated_12\VBN\2376958 for_13\IN\1740 a_14\DT\13649268 well-differentiated_15\JJ\1740 <e2>adenocarcinoma_16\NN\14242337 of_17\IN\1740 the_18\DT\1740 liver</e2>_19\NN\5298729 with_20\IN\1740 <e1>diethylstilbestrol</e1>_21\NN\14749794 for_22\IN\1740 13_23\CD\13745420 years_24\NNS\15144371 ._25\.\1740
15515654
D003676_D006311 NONE no_0\DT\7204911 <e2>ototoxic</e2>_1\JJ\1740 factor_2\NN\7326557 ,_3\,\1740 other_4\JJ\1740 than_5\IN\1740 <e1>dfo</e1>_6\NNP\1740 ,_7\,\1740 was_8\VBD\836236 present_9\JJ\1740 in_10\IN\13603305 any_11\DT\1740 of_12\IN\1740 the_13\DT\1740 patients_14\NNS\9898892 ._15\.\1740
D003676_D006319 CID subjects_0\NNS\6598915 with_1\IN\1740 <e2>snhl</e2>_2\NN\1740 were_3\VBD\836236 submitted_4\VBN\1952898 to_5\TO\1740 <e1>dfo</e1>_6\NN\1740 reduction_7\NN\351485 or_8\CC\3541091 temporary_9\JJ\1740 withdrawal_10\NN\7206096 ._11\.\1740
D003676_D034381 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 findings_3\NNS\7951464 are_4\VBP\836236 indicative_5\JJ\1740 of_6\IN\1740 <e1>dfo</e1>_7\NN\1740 's_8\POS\1740 contributing_9\VBG\126264 role_10\NN\719494 in_11\IN\13603305 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 <e2>hearing_15\NN\1184814 impairment</e2>_16\NN\7296428 ._17\.\1740
18162529
D012313_D006966 NONE hypothalamic_0\JJ\1740 prolactin_1\NN\5410315 receptor_2\NN\5225602 messenger_3\NN\9629752 <e1>ribonucleic_4\JJ\1740 acid</e1>_5\NN\14818238 levels_6\NNS\4916342 ,_7\,\1740 prolactin_8\NN\5410315 signaling_9\NN\33020 ,_10\,\1740 and_11\CC\1740 <e2>hyperprolactinemic</e2>_12\JJ\1740 inhibition_13\NN\1068773 of_14\IN\1740 pulsatile_15\JJ\1740 luteinizing_16\NN\1740 hormone_17\NN\5404728 secretion_18\NN\13526110 are_19\VBP\836236 dependent_20\JJ\1740 on_21\IN\1740 estradiol_22\NN\14749794 ._23\.\1740
D004958_D006966 NONE hypothalamic_0\JJ\1740 prolactin_1\NN\5410315 receptor_2\NN\5225602 messenger_3\NN\9629752 ribonucleic_4\JJ\1740 acid_5\NN\14818238 levels_6\NNS\4916342 ,_7\,\1740 prolactin_8\NN\5410315 signaling_9\NN\33020 ,_10\,\1740 and_11\CC\1740 <e2>hyperprolactinemic</e2>_12\JJ\1740 inhibition_13\NN\1068773 of_14\IN\1740 pulsatile_15\JJ\1740 luteinizing_16\NN\1740 hormone_17\NN\5404728 secretion_18\NN\13526110 are_19\VBP\836236 dependent_20\JJ\1740 on_21\IN\1740 <e1>estradiol</e1>_22\NN\14749794 ._23\.\1740
D004958_D006966 NONE chronic_0\JJ\1740 <e2>hyperprolactinemia</e2>_1\NN\1740 induced_2\VBN\1627355 by_3\IN\1740 the_4\DT\1740 dopamine_5\NN\14807737 antagonist_6\NN\7846 sulpiride_7\NN\1740 caused_8\VBD\1617192 a_9\DT\13649268 40_10\CD\13745420 %_11\NN\1740 reduction_12\NN\351485 lh_13\NN\5410315 pulse_14\NN\7345593 frequency_15\NN\15286249 in_16\IN\13603305 ovariectomized_17\JJ\1740 rats_18\NNS\2329401 ,_19\,\1740 but_20\CC\1740 only_21\RB\1740 in_22\IN\13603305 the_23\DT\1740 presence_24\NN\13954253 of_25\IN\1740 chronic_26\JJ\1740 low_27\JJ\1740 levels_28\NNS\4916342 of_29\IN\1740 <e1>estradiol</e1>_30\NN\14749794 ._31\.\1740
D004967_D006966 NONE we_0\PRP\1740 first_1\RB\1740 tested_2\VBD\670261 whether_3\IN\1740 chronic_4\JJ\1740 <e2>hyperprolactinemia</e2>_5\NN\1740 inhibited_6\VBD\2510337 two_7\CD\13741022 neuroendocrine_8\JJ\1740 parameters_9\NNS\5858936 necessary_10\JJ\1740 for_11\IN\1740 female_12\JJ\1740 fertility_13\NN\15286249 :_14\:\1740 pulsatile_15\VB\1740 lh_16\NN\5410315 secretion_17\NN\13526110 and_18\CC\1740 the_19\DT\1740 <e1>estrogen-induced</e1>_20\JJ\1740 lh_21\NN\5410315 surge_22\VBP\264034 ._23\.\1740
D004298_D006966 NONE chronic_0\JJ\1740 <e2>hyperprolactinemia</e2>_1\NN\1740 induced_2\VBN\1627355 by_3\IN\1740 the_4\DT\1740 <e1>dopamine</e1>_5\NN\14807737 antagonist_6\NN\7846 sulpiride_7\NN\1740 caused_8\VBD\1617192 a_9\DT\13649268 40_10\CD\13745420 %_11\NN\1740 reduction_12\NN\351485 lh_13\NN\5410315 pulse_14\NN\7345593 frequency_15\NN\15286249 in_16\IN\13603305 ovariectomized_17\JJ\1740 rats_18\NNS\2329401 ,_19\,\1740 but_20\CC\1740 only_21\RB\1740 in_22\IN\13603305 the_23\DT\1740 presence_24\NN\13954253 of_25\IN\1740 chronic_26\JJ\1740 low_27\JJ\1740 levels_28\NNS\4916342 of_29\IN\1740 estradiol_30\NN\14749794 ._31\.\1740
D013469_D006966 CID chronic_0\JJ\1740 <e2>hyperprolactinemia</e2>_1\NN\1740 induced_2\VBN\1627355 by_3\IN\1740 the_4\DT\1740 dopamine_5\NN\14807737 antagonist_6\NN\7846 <e1>sulpiride</e1>_7\NN\1740 caused_8\VBD\1617192 a_9\DT\13649268 40_10\CD\13745420 %_11\NN\1740 reduction_12\NN\351485 lh_13\NN\5410315 pulse_14\NN\7345593 frequency_15\NN\15286249 in_16\IN\13603305 ovariectomized_17\JJ\1740 rats_18\NNS\2329401 ,_19\,\1740 but_20\CC\1740 only_21\RB\1740 in_22\IN\13603305 the_23\DT\1740 presence_24\NN\13954253 of_25\IN\1740 chronic_26\JJ\1740 low_27\JJ\1740 levels_28\NNS\4916342 of_29\IN\1740 estradiol_30\NN\14749794 ._31\.\1740
D013256_D006966 NONE these_0\DT\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 gnrh_4\NN\1740 pulse_5\NN\7345593 frequency_6\NN\15286249 is_7\VBZ\836236 inhibited_8\VBN\2510337 by_9\IN\1740 chronic_10\JJ\1740 <e2>hyperprolactinemia</e2>_11\NN\1740 in_12\IN\13603305 a_13\DT\13649268 <e1>steroid-dependent</e1>_14\JJ\1740 manner_15\NN\4916342 ._16\.\1740
11587867
D014750_D001927 NONE fatal_0\JJ\1740 <e2>myeloencephalopathy</e2>_1\NN\1740 due_2\JJ\1740 to_3\TO\1740 accidental_4\JJ\1740 intrathecal_5\JJ\1740 <e1>vincristin</e1>_6\NN\1740 administration_7\NN\1133281 :_8\:\1740 a_9\DT\13649268 report_10\NN\6470073 of_11\IN\1740 two_12\CD\13741022 cases_13\NNS\7283608 ._14\.\1740
D014750_D054198 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 two_3\CD\13741022 fatal_4\JJ\1740 cases_5\NNS\7283608 of_6\IN\1740 accidental_7\JJ\1740 intrathecal_8\JJ\1740 <e1>vincristine</e1>_9\NN\3917455 instillation_10\NN\320852 in_11\IN\13603305 a_12\DT\13649268 5-year_13\JJ\1740 old_14\JJ\1740 girl_15\NN\10787470 with_16\IN\1740 recurrent_17\JJ\1740 <e2>acute_18\JJ\1740 lymphoblastic_19\JJ\1740 leucemia</e2>_20\NN\1740 and_21\CC\1740 a_22\DT\13649268 57-year_23\JJ\1740 old_24\JJ\1740 man_25\NN\9605289 with_26\IN\1740 lymphoblastic_27\JJ\1740 lymphoma_28\NN\14239918 ._29\.\1740
D014750_D054198 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 two_3\CD\13741022 fatal_4\JJ\1740 cases_5\NNS\7283608 of_6\IN\1740 accidental_7\JJ\1740 intrathecal_8\JJ\1740 <e1>vincristine</e1>_9\NN\3917455 instillation_10\NN\320852 in_11\IN\13603305 a_12\DT\13649268 5-year_13\JJ\1740 old_14\JJ\1740 girl_15\NN\10787470 with_16\IN\1740 recurrent_17\JJ\1740 acute_18\JJ\1740 lymphoblastic_19\JJ\1740 leucemia_20\NN\1740 and_21\CC\1740 a_22\DT\13649268 57-year_23\JJ\1740 old_24\JJ\1740 man_25\NN\9605289 with_26\IN\1740 <e2>lymphoblastic_27\JJ\1740 lymphoma</e2>_28\NN\14239918 ._29\.\1740
D014750_D003711 CID histological_0\JJ\1740 and_1\CC\1740 immunohistochemical_2\JJ\1740 investigations_3\NNS\5797597 (_4\-LRB-\1740 he-lfb_5\NN\1740 ,_6\,\1740 cd-68_7\NN\1740 ,_8\,\1740 neurofilament_9\NN\1740 )_10\-RRB-\1740 revealed_11\VBD\2137132 <e2>degeneration_12\NN\29677 of_13\IN\1740 myelin_14\NN\14864360 and_15\CC\1740 axons</e2>_16\NNS\5464104 as_17\RB\1740 well_18\RB\1740 as_19\IN\14622893 pseudocystic_20\JJ\1740 transformation_21\NN\7296428 in_22\IN\13603305 areas_23\NNS\8630985 exposed_24\VBN\2110927 to_25\TO\1740 <e1>vincristine</e1>_26\NN\3917455 ,_27\,\1740 accompanied_28\VBN\1835496 by_29\IN\1740 secondary_30\JJ\1740 changes_31\NNS\7283608 with_32\IN\1740 numerous_33\JJ\1740 prominent_34\JJ\1740 macrophages_35\NNS\5450888 ._36\.\1740
D014750_D009410 CID histological_0\JJ\1740 and_1\CC\1740 immunohistochemical_2\JJ\1740 investigations_3\NNS\5797597 (_4\-LRB-\1740 he-lfb_5\NN\1740 ,_6\,\1740 cd-68_7\NN\1740 ,_8\,\1740 neurofilament_9\NN\1740 )_10\-RRB-\1740 revealed_11\VBD\2137132 <e2>degeneration_12\NN\29677 of_13\IN\1740 myelin_14\NN\14864360 and_15\CC\1740 axons</e2>_16\NNS\5464104 as_17\RB\1740 well_18\RB\1740 as_19\IN\14622893 pseudocystic_20\JJ\1740 transformation_21\NN\7296428 in_22\IN\13603305 areas_23\NNS\8630985 exposed_24\VBN\2110927 to_25\TO\1740 <e1>vincristine</e1>_26\NN\3917455 ,_27\,\1740 accompanied_28\VBN\1835496 by_29\IN\1740 secondary_30\JJ\1740 changes_31\NNS\7283608 with_32\IN\1740 numerous_33\JJ\1740 prominent_34\JJ\1740 macrophages_35\NNS\5450888 ._36\.\1740
D014750_-1 NONE histological_0\JJ\1740 and_1\CC\1740 immunohistochemical_2\JJ\1740 investigations_3\NNS\5797597 (_4\-LRB-\1740 he-lfb_5\NN\1740 ,_6\,\1740 cd-68_7\NN\1740 ,_8\,\1740 neurofilament_9\NN\1740 )_10\-RRB-\1740 revealed_11\VBD\2137132 degeneration_12\NN\29677 of_13\IN\1740 myelin_14\NN\14864360 and_15\CC\1740 axons_16\NNS\5464104 as_17\RB\1740 well_18\RB\1740 as_19\IN\14622893 <e2>pseudocystic_20\JJ\1740 transformation</e2>_21\NN\7296428 in_22\IN\13603305 areas_23\NNS\8630985 exposed_24\VBN\2110927 to_25\TO\1740 <e1>vincristine</e1>_26\NN\3917455 ,_27\,\1740 accompanied_28\VBN\1835496 by_29\IN\1740 secondary_30\JJ\1740 changes_31\NNS\7283608 with_32\IN\1740 numerous_33\JJ\1740 prominent_34\JJ\1740 macrophages_35\NNS\5450888 ._36\.\1740
2312209
D007548_D009203 CID <e2>myocardial_0\JJ\1740 infarction</e2>_1\NN\14204950 following_2\VBG\1835496 sublingual_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>isosorbide_6\JJ\1740 dinitrate</e1>_7\NN\1740 ._8\.\1740
D007548_D009203 CID a_0\DT\13649268 78-year-old_1\RB\1740 with_2\IN\1740 healed_3\VBN\205046 septal_4\JJ\1740 necrosis_5\NN\11444117 suffered_6\VBD\2110220 a_7\DT\13649268 recurrent_8\JJ\1740 <e2>myocardial_9\JJ\1740 infarction</e2>_10\NN\14204950 of_11\IN\1740 the_12\DT\1740 anterior_13\JJ\1740 wall_14\NN\3894379 following_15\VBG\1835496 the_16\DT\1740 administration_17\NN\1133281 of_18\IN\1740 <e1>isosorbide_19\JJ\1740 dinitrate</e1>_20\NN\1740 5_21\CD\13741022 mg_22\NN\13717155 sublingually_23\RB\1740 ._24\.\1740
D007548_D009336 NONE a_0\DT\13649268 78-year-old_1\RB\1740 with_2\IN\1740 healed_3\VBN\205046 septal_4\JJ\1740 <e2>necrosis</e2>_5\NN\11444117 suffered_6\VBD\2110220 a_7\DT\13649268 recurrent_8\JJ\1740 myocardial_9\JJ\1740 infarction_10\NN\14204950 of_11\IN\1740 the_12\DT\1740 anterior_13\JJ\1740 wall_14\NN\3894379 following_15\VBG\1835496 the_16\DT\1740 administration_17\NN\1133281 of_18\IN\1740 <e1>isosorbide_19\JJ\1740 dinitrate</e1>_20\NN\1740 5_21\CD\13741022 mg_22\NN\13717155 sublingually_23\RB\1740 ._24\.\1740
6229975
D013999_D009203 NONE changes_0\NNS\7283608 in_1\IN\13603305 heart_2\NN\5919034 size_3\NN\5090441 during_4\IN\1740 long-term_5\JJ\1740 <e1>timolol</e1>_6\NN\2832168 treatment_7\NN\654885 after_8\IN\1740 <e2>myocardial_9\JJ\1740 infarction</e2>_10\NN\14204950 ._11\.\1740
D013999_D009203 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 long-term_3\JJ\1740 <e1>timolol</e1>_4\CD\2832168 treatment_5\NN\654885 on_6\IN\1740 heart_7\NN\5919034 size_8\NN\5090441 after_9\IN\1740 <e2>myocardial_10\JJ\1740 infarction</e2>_11\NN\14204950 was_12\VBD\836236 evaluated_13\VBN\670261 by_14\IN\1740 x-ray_15\NN\11450869 in_16\IN\13603305 a_17\DT\13649268 double-blind_18\JJ\1740 study_19\NN\635850 including_20\VBG\690614 241_21\CD\1740 patients_22\NNS\9898892 (_23\-LRB-\1740 placebo_24\NN\3740161 126_25\CD\1740 ,_26\,\1740 timolol_27\NN\2832168 115_28\CD\1740 )_29\-RRB-\1740 ._30\.\1740
D013999_D009203 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 long-term_3\JJ\1740 timolol_4\CD\2832168 treatment_5\NN\654885 on_6\IN\1740 heart_7\NN\5919034 size_8\NN\5090441 after_9\IN\1740 <e2>myocardial_10\JJ\1740 infarction</e2>_11\NN\14204950 was_12\VBD\836236 evaluated_13\VBN\670261 by_14\IN\1740 x-ray_15\NN\11450869 in_16\IN\13603305 a_17\DT\13649268 double-blind_18\JJ\1740 study_19\NN\635850 including_20\VBG\690614 241_21\CD\1740 patients_22\NNS\9898892 (_23\-LRB-\1740 placebo_24\NN\3740161 126_25\CD\1740 ,_26\,\1740 <e1>timolol</e1>_27\NN\2832168 115_28\CD\1740 )_29\-RRB-\1740 ._30\.\1740
D013999_D001919 NONE these_0\DT\1740 differences_1\NNS\4723816 may_2\MD\15209706 be_3\VB\836236 caused_4\VBN\1617192 by_5\IN\1740 <e1>timolol-induced</e1>_6\JJ\1740 <e2>bradycardia</e2>_7\NN\14110674 and_8\CC\1740 a_9\DT\13649268 compensatory_10\JJ\1740 increase_11\NN\13576355 in_12\IN\13603305 end-diastolic_13\JJ\1740 volume_14\NN\33615 ._15\.\1740
D013999_D007238 NONE after_0\IN\1740 <e2>re-infarction</e2>_1\NN\1740 ,_2\,\1740 heart_3\NN\5919034 size_4\NN\5090441 increased_5\VBD\169651 in_6\IN\13603305 the_7\DT\1740 placebo_8\NN\3740161 group_9\NN\2137 and_10\CC\1740 remained_11\VBD\2604760 unchanged_12\JJ\1740 in_13\IN\13603305 the_14\DT\1740 <e1>timolol</e1>_15\CD\2832168 group_16\NN\2137 ._17\.\1740
10901305
D007649_D050723 NONE <e1>ketamine</e1>_0\NNP\3054098 sedation_1\NN\14034177 for_2\IN\1740 the_3\DT\1740 reduction_4\NN\351485 of_5\IN\1740 children_6\NNS\9622049 's_7\POS\1740 <e2>fractures</e2>_8\NNS\14285662 in_9\IN\13603305 the_10\DT\1740 emergency_11\NN\7417644 department_12\NN\8220714 ._13\.\1740
D007649_D050723 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 examine_8\VB\789138 the_9\DT\1740 safety_10\NN\13920835 and_11\CC\1740 efficacy_12\NN\5199286 of_13\IN\1740 <e1>ketamine</e1>_14\NN\3054098 for_15\IN\1740 sedation_16\NN\14034177 in_17\IN\13603305 the_18\DT\1740 treatment_19\NN\654885 of_20\IN\1740 children_21\NNS\9622049 's_22\POS\1740 <e2>fractures</e2>_23\NNS\14285662 in_24\IN\13603305 the_25\DT\1740 emergency_26\NN\7417644 department_27\NN\8220714 ._28\.\1740
D007649_D050723 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 average_3\JJ\1740 time_4\NN\7308889 from_5\IN\1740 intravenous_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 <e1>ketamine</e1>_9\NN\3054098 to_10\TO\1740 manipulation_11\NN\157081 of_12\IN\1740 the_13\DT\1740 <e2>fracture</e2>_14\NN\14285662 or_15\CC\3541091 dislocation_16\NN\7367812 was_17\VBD\836236 one_18\CD\13741022 minute_19\NN\15154774 and_20\CC\1740 thirty-six_21\CD\1740 seconds_22\NNS\15154774 (_23\-LRB-\1740 range_24\NN\5123416 ,_25\,\1740 twenty_26\CD\13745420 seconds_27\NNS\15154774 to_28\IN\1740 five_29\CD\13741022 minutes_30\NNS\6502378 )_31\-RRB-\1740 ,_32\,\1740 and_33\CC\1740 the_34\DT\1740 average_35\JJ\1740 time_36\NN\7308889 from_37\IN\1740 intramuscular_38\JJ\1740 administration_39\NN\1133281 to_40\TO\1740 manipulation_41\NN\157081 was_42\VBD\836236 four_43\CD\13741022 minutes_44\NNS\6502378 and_45\CC\1740 forty-two_46\JJ\1740 seconds_47\NNS\15154774 (_48\-LRB-\1740 range_49\NN\5123416 ,_50\,\1740 sixty_51\CD\13745420 seconds_52\NNS\15154774 to_53\IN\1740 fifteen_54\CD\13745420 minutes_55\NNS\6502378 )_56\-RRB-\1740 ._57\.\1740
D007649_D050723 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>ketamine</e1>_2\NNP\3054098 reliably_3\RB\1740 ,_4\,\1740 safely_5\RB\1740 ,_6\,\1740 and_7\CC\1740 quickly_8\RB\1740 provided_9\VBD\2199590 adequate_10\JJ\1740 sedation_11\NN\14034177 to_12\TO\1740 effectively_13\RB\1740 facilitate_14\VB\2547586 the_15\DT\1740 reduction_16\NN\351485 of_17\IN\1740 children_18\NNS\9622049 's_19\POS\1740 <e2>fractures</e2>_20\NNS\14285662 in_21\IN\13603305 the_22\DT\1740 emergency_23\NN\7417644 department_24\NN\8220714 at_25\IN\14622893 our_26\PRP$\1740 institution_27\NN\8008335 ._28\.\1740
D007649_D004204 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 average_3\JJ\1740 time_4\NN\7308889 from_5\IN\1740 intravenous_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 <e1>ketamine</e1>_9\NN\3054098 to_10\TO\1740 manipulation_11\NN\157081 of_12\IN\1740 the_13\DT\1740 fracture_14\NN\14285662 or_15\CC\3541091 <e2>dislocation</e2>_16\NN\7367812 was_17\VBD\836236 one_18\CD\13741022 minute_19\NN\15154774 and_20\CC\1740 thirty-six_21\CD\1740 seconds_22\NNS\15154774 (_23\-LRB-\1740 range_24\NN\5123416 ,_25\,\1740 twenty_26\CD\13745420 seconds_27\NNS\15154774 to_28\IN\1740 five_29\CD\13741022 minutes_30\NNS\6502378 )_31\-RRB-\1740 ,_32\,\1740 and_33\CC\1740 the_34\DT\1740 average_35\JJ\1740 time_36\NN\7308889 from_37\IN\1740 intramuscular_38\JJ\1740 administration_39\NN\1133281 to_40\TO\1740 manipulation_41\NN\157081 was_42\VBD\836236 four_43\CD\13741022 minutes_44\NNS\6502378 and_45\CC\1740 forty-two_46\JJ\1740 seconds_47\NNS\15154774 (_48\-LRB-\1740 range_49\NN\5123416 ,_50\,\1740 sixty_51\CD\13745420 seconds_52\NNS\15154774 to_53\IN\1740 fifteen_54\CD\13745420 minutes_55\NNS\6502378 )_56\-RRB-\1740 ._57\.\1740
7988234
D008790_D000799 CID <e2>angioedema</e2>_0\NNP\14316714 following_1\VBG\1835496 the_2\DT\1740 intravenous_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>metoprolol</e1>_6\NN\2832168 ._7\.\1740
D008790_D000799 CID during_0\IN\1740 the_1\DT\1740 first_2\JJ\1740 day_3\NN\15154774 of_4\IN\1740 hospitalization_5\NN\15113229 (_6\-LRB-\1740 while_7\IN\15122231 intubated_8\JJ\1740 )_9\-RRB-\1740 ,_10\,\1740 intravenous_11\JJ\1740 <e1>metoprolol</e1>_12\NN\2832168 was_13\VBD\836236 given_14\VBN\2327200 ,_15\,\1740 resulting_16\VBG\2633881 in_17\IN\13603305 severe_18\JJ\1740 <e2>angioedema</e2>_19\NN\14316714 ._20\.\1740
D017706_D000799 CID a_0\DT\13649268 history_1\NN\15120823 of_2\IN\1740 <e2>angioedema</e2>_3\NN\14316714 secondary_4\JJ\1740 to_5\TO\1740 <e1>lisinopril</e1>_6\NN\2673637 therapy_7\NN\657604 was_8\VBD\836236 elicited_9\VBN\1617192 ._10\.\1740
D013256_D000799 NONE the_0\DT\1740 <e2>angioedema</e2>_1\NN\14316714 resolved_2\VBN\352826 after_3\IN\1740 therapy_4\NN\657604 with_5\IN\1740 intravenous_6\JJ\1740 <e1>steroids</e1>_7\NNS\14727670 and_8\CC\1740 diphenhydramine_9\NN\2720725 hydrochloride_10\NN\14817592 ._11\.\1740
D004155_D000799 NONE the_0\DT\1740 <e2>angioedema</e2>_1\NN\14316714 resolved_2\VBN\352826 after_3\IN\1740 therapy_4\NN\657604 with_5\IN\1740 intravenous_6\JJ\1740 steroids_7\NNS\14727670 and_8\CC\1740 <e1>diphenhydramine</e1>_9\NN\2720725 hydrochloride_10\NN\14817592 ._11\.\1740
2054792
D004317_D005334 NONE effect_0\NN\34213 of_1\IN\1740 <e1>adriamycin</e1>_2\NN\1740 combined_3\VBN\2630189 with_4\IN\1740 whole_5\JJ\1740 body_6\NN\19128 <e2>hyperthermia</e2>_7\NN\14034177 on_8\IN\1740 tumor_9\NN\14234074 and_10\CC\1740 normal_11\JJ\1740 tissues_12\NNS\5220461 ._13\.\1740
D004317_D005334 NONE thermal_0\JJ\1740 enhancement_1\NN\248977 of_2\IN\1740 <e1>adriamycin-mediated</e1>_3\JJ\1740 antitumor_4\NN\1740 activity_5\NN\30358 and_6\CC\1740 normal_7\JJ\1740 tissue_8\NN\5220461 toxicities_9\NNS\13576101 by_10\IN\1740 whole_11\JJ\1740 body_12\NN\19128 <e2>hyperthermia</e2>_13\NN\14034177 were_14\VBD\836236 compared_15\VBN\644583 using_16\VBG\1156834 a_17\DT\13649268 f344_18\NN\1740 rat_19\NN\2329401 model_20\NN\5888929 ._21\.\1740
D004317_D005334 NONE whole_0\NN\5835747 body_1\NN\19128 <e2>hyperthermia</e2>_2\NN\14034177 (_3\-LRB-\1740 120_4\CD\13745420 min_5\NN\15154774 at_6\IN\14622893 41.5_7\CD\1740 degrees_8\NNS\4916342 c_9\NN\13714184 )_10\-RRB-\1740 enhanced_11\VBD\227165 both_12\CC\1740 <e1>adriamycin-mediated</e1>_13\JJ\1740 antitumor_14\NN\1740 activity_15\NN\30358 and_16\CC\1740 toxic_17\JJ\1740 side_18\NN\8630039 effects_19\NNS\13245626 ._20\.\1740
D004317_D005334 NONE thus_0\RB\1740 ,_1\,\1740 while_2\IN\15122231 whole_3\JJ\1740 body_4\NN\19128 <e2>hyperthermia</e2>_5\NN\14034177 enhances_6\VBZ\227165 <e1>adriamycin-mediated</e1>_7\JJ\1740 antitumor_8\NN\1740 effect_9\NN\34213 ,_10\,\1740 normal_11\JJ\1740 tissue_12\NN\5220461 toxicity_13\NN\13576101 is_14\VBZ\836236 also_15\RB\1740 increased_16\VBN\169651 ,_17\,\1740 and_18\CC\1740 the_19\DT\1740 potential_20\JJ\1740 therapeutic_21\JJ\1740 gain_22\NN\13576355 of_23\IN\1740 the_24\DT\1740 combined_25\JJ\1740 modality_26\NN\13783038 treatment_27\NN\654885 is_28\VBZ\836236 eroded_29\VBN\208836 ._30\.\1740
D004317_D009369 NONE effect_0\NN\34213 of_1\IN\1740 <e1>adriamycin</e1>_2\NN\1740 combined_3\VBN\2630189 with_4\IN\1740 whole_5\JJ\1740 body_6\NN\19128 hyperthermia_7\NN\14034177 on_8\IN\1740 <e2>tumor</e2>_9\NN\14234074 and_10\CC\1740 normal_11\JJ\1740 tissues_12\NNS\5220461 ._13\.\1740
D004317_D064420 NONE thermal_0\JJ\1740 enhancement_1\NN\248977 of_2\IN\1740 <e1>adriamycin-mediated</e1>_3\JJ\1740 antitumor_4\NN\1740 activity_5\NN\30358 and_6\CC\1740 normal_7\JJ\1740 tissue_8\NN\5220461 <e2>toxicities</e2>_9\NNS\13576101 by_10\IN\1740 whole_11\JJ\1740 body_12\NN\19128 hyperthermia_13\NN\14034177 were_14\VBD\836236 compared_15\VBN\644583 using_16\VBG\1156834 a_17\DT\13649268 f344_18\NN\1740 rat_19\NN\2329401 model_20\NN\5888929 ._21\.\1740
D004317_D064420 NONE thus_0\RB\1740 ,_1\,\1740 while_2\IN\15122231 whole_3\JJ\1740 body_4\NN\19128 hyperthermia_5\NN\14034177 enhances_6\VBZ\227165 <e1>adriamycin-mediated</e1>_7\JJ\1740 antitumor_8\NN\1740 effect_9\NN\34213 ,_10\,\1740 normal_11\JJ\1740 tissue_12\NN\5220461 <e2>toxicity</e2>_13\NN\13576101 is_14\VBZ\836236 also_15\RB\1740 increased_16\VBN\169651 ,_17\,\1740 and_18\CC\1740 the_19\DT\1740 potential_20\JJ\1740 therapeutic_21\JJ\1740 gain_22\NN\13576355 of_23\IN\1740 the_24\DT\1740 combined_25\JJ\1740 modality_26\NN\13783038 treatment_27\NN\654885 is_28\VBZ\836236 eroded_29\VBN\208836 ._30\.\1740
20621845
D002122_D017545 CID elevation_0\NN\7445480 of_1\IN\1740 adam10_2\NN\1740 ,_3\,\1740 adam17_4\NN\1740 ,_5\,\1740 mmp-2_6\NN\1740 and_7\CC\1740 mmp-9_8\NN\1740 expression_9\NN\4679549 with_10\IN\1740 media_11\NN\3575240 degeneration_12\NN\29677 features_13\NNS\5849040 <e1>cacl2-induced</e1>_14\JJ\1740 <e2>thoracic_15\NN\1740 aortic_16\JJ\1740 aneurysm</e2>_17\NN\14057371 in_18\IN\13603305 a_19\DT\13649268 rat_20\NN\2329401 model_21\NN\5888929 ._22\.\1740
D002122_D017545 CID purpose_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 was_4\VBD\836236 designed_5\VBN\1631534 to_6\TO\1740 establish_7\VB\2426171 a_8\DT\13649268 rat_9\NN\2329401 model_10\NN\5888929 of_11\IN\1740 <e2>thoracic_12\NN\1740 aortic_13\JJ\1740 aneurysm</e2>_14\NN\14057371 (_15\-LRB-\1740 taa_16\NN\1740 )_17\-RRB-\1740 by_18\IN\1740 <e1>calcium_19\NN\14625458 chloride</e1>_20\NN\14818238 (_21\-LRB-\1740 cacl(2))-induced_22\JJ\1740 arterial_23\JJ\1740 injury_24\NN\14052046 and_25\CC\1740 to_26\TO\1740 explore_27\VB\789138 the_28\DT\1740 potential_29\JJ\1740 role_30\NN\719494 of_31\IN\1740 a_32\DT\13649268 disintegrin_33\NN\1740 and_34\CC\1740 metalloproteinase_35\NN\1740 (_36\-LRB-\1740 adam_37\NN\3756184 )_38\-RRB-\1740 ,_39\,\1740 matrix_40\NN\7939382 metalloproteinases_41\NNS\1740 (_42\-LRB-\1740 mmps_43\NNS\1740 )_44\-RRB-\1740 and_45\CC\1740 their_46\PRP$\1740 endogenous_47\JJ\1740 inhibitors_48\NNS\20090 (_49\-LRB-\1740 timps_50\NNS\1740 )_51\-RRB-\1740 in_52\IN\13603305 taa_53\NN\1740 formation_54\NN\7938773 ._55\.\1740
D002122_D017545 CID purpose_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 was_4\VBD\836236 designed_5\VBN\1631534 to_6\TO\1740 establish_7\VB\2426171 a_8\DT\13649268 rat_9\NN\2329401 model_10\NN\5888929 of_11\IN\1740 thoracic_12\NN\1740 aortic_13\JJ\1740 aneurysm_14\NN\14057371 (_15\-LRB-\1740 <e2>taa</e2>_16\NN\1740 )_17\-RRB-\1740 by_18\IN\1740 <e1>calcium_19\NN\14625458 chloride</e1>_20\NN\14818238 (_21\-LRB-\1740 cacl(2))-induced_22\JJ\1740 arterial_23\JJ\1740 injury_24\NN\14052046 and_25\CC\1740 to_26\TO\1740 explore_27\VB\789138 the_28\DT\1740 potential_29\JJ\1740 role_30\NN\719494 of_31\IN\1740 a_32\DT\13649268 disintegrin_33\NN\1740 and_34\CC\1740 metalloproteinase_35\NN\1740 (_36\-LRB-\1740 adam_37\NN\3756184 )_38\-RRB-\1740 ,_39\,\1740 matrix_40\NN\7939382 metalloproteinases_41\NNS\1740 (_42\-LRB-\1740 mmps_43\NNS\1740 )_44\-RRB-\1740 and_45\CC\1740 their_46\PRP$\1740 endogenous_47\JJ\1740 inhibitors_48\NNS\20090 (_49\-LRB-\1740 timps_50\NNS\1740 )_51\-RRB-\1740 in_52\IN\13603305 taa_53\NN\1740 formation_54\NN\7938773 ._55\.\1740
D002122_D017545 CID purpose_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 was_4\VBD\836236 designed_5\VBN\1631534 to_6\TO\1740 establish_7\VB\2426171 a_8\DT\13649268 rat_9\NN\2329401 model_10\NN\5888929 of_11\IN\1740 thoracic_12\NN\1740 aortic_13\JJ\1740 aneurysm_14\NN\14057371 (_15\-LRB-\1740 taa_16\NN\1740 )_17\-RRB-\1740 by_18\IN\1740 <e1>calcium_19\NN\14625458 chloride</e1>_20\NN\14818238 (_21\-LRB-\1740 cacl(2))-induced_22\JJ\1740 arterial_23\JJ\1740 injury_24\NN\14052046 and_25\CC\1740 to_26\TO\1740 explore_27\VB\789138 the_28\DT\1740 potential_29\JJ\1740 role_30\NN\719494 of_31\IN\1740 a_32\DT\13649268 disintegrin_33\NN\1740 and_34\CC\1740 metalloproteinase_35\NN\1740 (_36\-LRB-\1740 adam_37\NN\3756184 )_38\-RRB-\1740 ,_39\,\1740 matrix_40\NN\7939382 metalloproteinases_41\NNS\1740 (_42\-LRB-\1740 mmps_43\NNS\1740 )_44\-RRB-\1740 and_45\CC\1740 their_46\PRP$\1740 endogenous_47\JJ\1740 inhibitors_48\NNS\20090 (_49\-LRB-\1740 timps_50\NNS\1740 )_51\-RRB-\1740 in_52\IN\13603305 <e2>taa</e2>_53\NN\1740 formation_54\NN\7938773 ._55\.\1740
D002122_D017545 CID purpose_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 was_4\VBD\836236 designed_5\VBN\1631534 to_6\TO\1740 establish_7\VB\2426171 a_8\DT\13649268 rat_9\NN\2329401 model_10\NN\5888929 of_11\IN\1740 <e2>thoracic_12\NN\1740 aortic_13\JJ\1740 aneurysm</e2>_14\NN\14057371 (_15\-LRB-\1740 taa_16\NN\1740 )_17\-RRB-\1740 by_18\IN\1740 calcium_19\NN\14625458 chloride_20\NN\14818238 (_21\-LRB-\1740 <e1>cacl(2))-induced</e1>_22\JJ\1740 arterial_23\JJ\1740 injury_24\NN\14052046 and_25\CC\1740 to_26\TO\1740 explore_27\VB\789138 the_28\DT\1740 potential_29\JJ\1740 role_30\NN\719494 of_31\IN\1740 a_32\DT\13649268 disintegrin_33\NN\1740 and_34\CC\1740 metalloproteinase_35\NN\1740 (_36\-LRB-\1740 adam_37\NN\3756184 )_38\-RRB-\1740 ,_39\,\1740 matrix_40\NN\7939382 metalloproteinases_41\NNS\1740 (_42\-LRB-\1740 mmps_43\NNS\1740 )_44\-RRB-\1740 and_45\CC\1740 their_46\PRP$\1740 endogenous_47\JJ\1740 inhibitors_48\NNS\20090 (_49\-LRB-\1740 timps_50\NNS\1740 )_51\-RRB-\1740 in_52\IN\13603305 taa_53\NN\1740 formation_54\NN\7938773 ._55\.\1740
D002122_D017545 CID purpose_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 was_4\VBD\836236 designed_5\VBN\1631534 to_6\TO\1740 establish_7\VB\2426171 a_8\DT\13649268 rat_9\NN\2329401 model_10\NN\5888929 of_11\IN\1740 thoracic_12\NN\1740 aortic_13\JJ\1740 aneurysm_14\NN\14057371 (_15\-LRB-\1740 <e2>taa</e2>_16\NN\1740 )_17\-RRB-\1740 by_18\IN\1740 calcium_19\NN\14625458 chloride_20\NN\14818238 (_21\-LRB-\1740 <e1>cacl(2))-induced</e1>_22\JJ\1740 arterial_23\JJ\1740 injury_24\NN\14052046 and_25\CC\1740 to_26\TO\1740 explore_27\VB\789138 the_28\DT\1740 potential_29\JJ\1740 role_30\NN\719494 of_31\IN\1740 a_32\DT\13649268 disintegrin_33\NN\1740 and_34\CC\1740 metalloproteinase_35\NN\1740 (_36\-LRB-\1740 adam_37\NN\3756184 )_38\-RRB-\1740 ,_39\,\1740 matrix_40\NN\7939382 metalloproteinases_41\NNS\1740 (_42\-LRB-\1740 mmps_43\NNS\1740 )_44\-RRB-\1740 and_45\CC\1740 their_46\PRP$\1740 endogenous_47\JJ\1740 inhibitors_48\NNS\20090 (_49\-LRB-\1740 timps_50\NNS\1740 )_51\-RRB-\1740 in_52\IN\13603305 taa_53\NN\1740 formation_54\NN\7938773 ._55\.\1740
D002122_D017545 CID purpose_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 was_4\VBD\836236 designed_5\VBN\1631534 to_6\TO\1740 establish_7\VB\2426171 a_8\DT\13649268 rat_9\NN\2329401 model_10\NN\5888929 of_11\IN\1740 thoracic_12\NN\1740 aortic_13\JJ\1740 aneurysm_14\NN\14057371 (_15\-LRB-\1740 taa_16\NN\1740 )_17\-RRB-\1740 by_18\IN\1740 calcium_19\NN\14625458 chloride_20\NN\14818238 (_21\-LRB-\1740 <e1>cacl(2))-induced</e1>_22\JJ\1740 arterial_23\JJ\1740 injury_24\NN\14052046 and_25\CC\1740 to_26\TO\1740 explore_27\VB\789138 the_28\DT\1740 potential_29\JJ\1740 role_30\NN\719494 of_31\IN\1740 a_32\DT\13649268 disintegrin_33\NN\1740 and_34\CC\1740 metalloproteinase_35\NN\1740 (_36\-LRB-\1740 adam_37\NN\3756184 )_38\-RRB-\1740 ,_39\,\1740 matrix_40\NN\7939382 metalloproteinases_41\NNS\1740 (_42\-LRB-\1740 mmps_43\NNS\1740 )_44\-RRB-\1740 and_45\CC\1740 their_46\PRP$\1740 endogenous_47\JJ\1740 inhibitors_48\NNS\20090 (_49\-LRB-\1740 timps_50\NNS\1740 )_51\-RRB-\1740 in_52\IN\13603305 <e2>taa</e2>_53\NN\1740 formation_54\NN\7938773 ._55\.\1740
D002122_D017545 CID conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 establishes_4\VBZ\2426171 a_5\DT\13649268 <e2>taa</e2>_6\NN\1740 model_7\NN\5888929 by_8\IN\1740 periarterial_9\JJ\1740 <e1>cacl(2_10\NNS\1740 )</e1>_11\-RRB-\1740 exposure_12\NN\5042871 in_13\IN\13603305 rats_14\NNS\2329401 ,_15\,\1740 and_16\CC\1740 demonstrates_17\VBZ\2137132 a_18\DT\13649268 significant_19\JJ\1740 elevation_20\NN\7445480 of_21\IN\1740 expression_22\NN\4679549 of_23\IN\1740 mmp-2_24\NN\1740 ,_25\,\1740 mmp-9_26\NN\1740 ,_27\,\1740 adam10_28\NN\1740 and_29\CC\1740 adam17_30\NN\1740 in_31\IN\13603305 the_32\DT\1740 pathogenesis_33\NN\13533470 of_34\IN\1740 vascular_35\JJ\1740 remodeling_36\NN\1740 ._37\.\1740
D002122_D014652 NONE purpose_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 was_4\VBD\836236 designed_5\VBN\1631534 to_6\TO\1740 establish_7\VB\2426171 a_8\DT\13649268 rat_9\NN\2329401 model_10\NN\5888929 of_11\IN\1740 thoracic_12\NN\1740 aortic_13\JJ\1740 aneurysm_14\NN\14057371 (_15\-LRB-\1740 taa_16\NN\1740 )_17\-RRB-\1740 by_18\IN\1740 <e1>calcium_19\NN\14625458 chloride</e1>_20\NN\14818238 (_21\-LRB-\1740 cacl(2))-induced_22\JJ\1740 <e2>arterial_23\JJ\1740 injury</e2>_24\NN\14052046 and_25\CC\1740 to_26\TO\1740 explore_27\VB\789138 the_28\DT\1740 potential_29\JJ\1740 role_30\NN\719494 of_31\IN\1740 a_32\DT\13649268 disintegrin_33\NN\1740 and_34\CC\1740 metalloproteinase_35\NN\1740 (_36\-LRB-\1740 adam_37\NN\3756184 )_38\-RRB-\1740 ,_39\,\1740 matrix_40\NN\7939382 metalloproteinases_41\NNS\1740 (_42\-LRB-\1740 mmps_43\NNS\1740 )_44\-RRB-\1740 and_45\CC\1740 their_46\PRP$\1740 endogenous_47\JJ\1740 inhibitors_48\NNS\20090 (_49\-LRB-\1740 timps_50\NNS\1740 )_51\-RRB-\1740 in_52\IN\13603305 taa_53\NN\1740 formation_54\NN\7938773 ._55\.\1740
D002122_D014652 NONE purpose_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 was_4\VBD\836236 designed_5\VBN\1631534 to_6\TO\1740 establish_7\VB\2426171 a_8\DT\13649268 rat_9\NN\2329401 model_10\NN\5888929 of_11\IN\1740 thoracic_12\NN\1740 aortic_13\JJ\1740 aneurysm_14\NN\14057371 (_15\-LRB-\1740 taa_16\NN\1740 )_17\-RRB-\1740 by_18\IN\1740 calcium_19\NN\14625458 chloride_20\NN\14818238 (_21\-LRB-\1740 <e1>cacl(2))-induced</e1>_22\JJ\1740 <e2>arterial_23\JJ\1740 injury</e2>_24\NN\14052046 and_25\CC\1740 to_26\TO\1740 explore_27\VB\789138 the_28\DT\1740 potential_29\JJ\1740 role_30\NN\719494 of_31\IN\1740 a_32\DT\13649268 disintegrin_33\NN\1740 and_34\CC\1740 metalloproteinase_35\NN\1740 (_36\-LRB-\1740 adam_37\NN\3756184 )_38\-RRB-\1740 ,_39\,\1740 matrix_40\NN\7939382 metalloproteinases_41\NNS\1740 (_42\-LRB-\1740 mmps_43\NNS\1740 )_44\-RRB-\1740 and_45\CC\1740 their_46\PRP$\1740 endogenous_47\JJ\1740 inhibitors_48\NNS\20090 (_49\-LRB-\1740 timps_50\NNS\1740 )_51\-RRB-\1740 in_52\IN\13603305 taa_53\NN\1740 formation_54\NN\7938773 ._55\.\1740
1835291
D009241_D029424 NONE acute_0\JJ\1740 bronchodilating_1\NN\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>ipratropium_4\NN\1740 bromide</e1>_5\NN\14904359 and_6\CC\1740 theophylline_7\NN\2905612 in_8\IN\13603305 <e2>chronic_9\JJ\1740 obstructive_10\JJ\1740 pulmonary_11\JJ\1740 disease</e2>_12\NN\14061805 ._13\.\1740
D009241_D029424 NONE the_0\DT\1740 bronchodilator_1\NN\3740161 effects_2\NNS\13245626 of_3\IN\1740 a_4\DT\13649268 single_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 <e1>ipratropium_8\NN\1740 bromide</e1>_9\NN\14904359 aerosol_10\NN\11439690 (_11\-LRB-\1740 36_12\CD\1740 micrograms_13\NNS\13717155 )_14\-RRB-\1740 and_15\CC\1740 short-acting_16\JJ\1740 theophylline_17\NN\2905612 tablets_18\NNS\4233405 (_19\-LRB-\1740 dose_20\NN\3740161 titrated_21\VBN\489837 to_22\TO\1740 produce_23\VB\1617192 serum_24\NN\5397468 levels_25\NNS\4916342 of_26\IN\1740 10_27\CD\13745420 -_28\SYM\1740 20_29\CD\13745420 micrograms/ml_30\NNS\1740 )_31\-RRB-\1740 were_32\VBD\836236 compared_33\VBN\644583 in_34\IN\13603305 a_35\DT\13649268 double-blind_36\JJ\1740 ,_37\,\1740 placebo-controlled_38\JJ\1740 crossover_39\NN\13526110 study_40\VBP\630380 in_41\IN\13603305 21_42\CD\13745420 patients_43\NNS\9898892 with_44\IN\1740 stable_45\JJ\1740 ,_46\,\1740 <e2>chronic_47\JJ\1740 obstructive_48\JJ\1740 pulmonary_49\JJ\1740 disease</e2>_50\NN\14061805 ._51\.\1740
D009241_D029424 NONE these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 <e1>ipratropium</e1>_4\NN\1740 is_5\VBZ\836236 a_6\DT\13649268 more_7\RBR\1740 potent_8\JJ\1740 bronchodilator_9\NN\3740161 than_10\IN\1740 oral_11\JJ\1740 theophylline_12\NN\2905612 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 <e2>chronic_16\JJ\1740 airflow_17\NN\7405893 obstruction</e2>_18\NN\4341686 ._19\.\1740
D013806_D029424 NONE acute_0\JJ\1740 bronchodilating_1\NN\1740 effects_2\NNS\13245626 of_3\IN\1740 ipratropium_4\NN\1740 bromide_5\NN\14904359 and_6\CC\1740 <e1>theophylline</e1>_7\NN\2905612 in_8\IN\13603305 <e2>chronic_9\JJ\1740 obstructive_10\JJ\1740 pulmonary_11\JJ\1740 disease</e2>_12\NN\14061805 ._13\.\1740
D013806_D029424 NONE the_0\DT\1740 bronchodilator_1\NN\3740161 effects_2\NNS\13245626 of_3\IN\1740 a_4\DT\13649268 single_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 ipratropium_8\NN\1740 bromide_9\NN\14904359 aerosol_10\NN\11439690 (_11\-LRB-\1740 36_12\CD\1740 micrograms_13\NNS\13717155 )_14\-RRB-\1740 and_15\CC\1740 short-acting_16\JJ\1740 <e1>theophylline</e1>_17\NN\2905612 tablets_18\NNS\4233405 (_19\-LRB-\1740 dose_20\NN\3740161 titrated_21\VBN\489837 to_22\TO\1740 produce_23\VB\1617192 serum_24\NN\5397468 levels_25\NNS\4916342 of_26\IN\1740 10_27\CD\13745420 -_28\SYM\1740 20_29\CD\13745420 micrograms/ml_30\NNS\1740 )_31\-RRB-\1740 were_32\VBD\836236 compared_33\VBN\644583 in_34\IN\13603305 a_35\DT\13649268 double-blind_36\JJ\1740 ,_37\,\1740 placebo-controlled_38\JJ\1740 crossover_39\NN\13526110 study_40\VBP\630380 in_41\IN\13603305 21_42\CD\13745420 patients_43\NNS\9898892 with_44\IN\1740 stable_45\JJ\1740 ,_46\,\1740 <e2>chronic_47\JJ\1740 obstructive_48\JJ\1740 pulmonary_49\JJ\1740 disease</e2>_50\NN\14061805 ._51\.\1740
D013806_D029424 NONE these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 ipratropium_4\NN\1740 is_5\VBZ\836236 a_6\DT\13649268 more_7\RBR\1740 potent_8\JJ\1740 bronchodilator_9\NN\3740161 than_10\IN\1740 oral_11\JJ\1740 <e1>theophylline</e1>_12\NN\2905612 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 <e2>chronic_16\JJ\1740 airflow_17\NN\7405893 obstruction</e2>_18\NN\4341686 ._19\.\1740
D013806_D002318 CID while_0\IN\15122231 side_1\NN\8630039 effects_2\NNS\13245626 were_3\VBD\836236 rare_4\JJ\1740 ,_5\,\1740 those_6\DT\1740 experienced_7\VBN\2108377 after_8\IN\1740 <e1>theophylline</e1>_9\NN\2905612 use_10\NN\407535 did_11\VBD\1640855 involve_12\VB\2676054 the_13\DT\1740 <e2>cardiovascular_14\JJ\1740 and_15\CC\1740 gastrointestinal_16\JJ\1740 systems</e2>_17\NNS\3575240 ._18\.\1740
D013806_D005767 CID while_0\IN\15122231 side_1\NN\8630039 effects_2\NNS\13245626 were_3\VBD\836236 rare_4\JJ\1740 ,_5\,\1740 those_6\DT\1740 experienced_7\VBN\2108377 after_8\IN\1740 <e1>theophylline</e1>_9\NN\2905612 use_10\NN\407535 did_11\VBD\1640855 involve_12\VB\2676054 the_13\DT\1740 <e2>cardiovascular_14\JJ\1740 and_15\CC\1740 gastrointestinal_16\JJ\1740 systems</e2>_17\NNS\3575240 ._18\.\1740
347884
D006220_D019967 NONE in_0\IN\13603305 the_1\DT\1740 double_2\JJ\1740 blind_3\NN\7942152 study_4\NN\635850 with_5\IN\1740 <e1>haloperidol</e1>_6\NN\3713736 ,_7\,\1740 both_8\DT\1740 substances_9\NNS\20827 were_10\VBD\836236 found_11\VBN\2426171 to_12\TO\1740 be_13\VB\836236 highly_14\RB\1740 effective_15\JJ\1740 in_16\IN\13603305 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 <e2>psychotic_20\JJ\1740 syndromes_21\NNS\5870365 belonging_22\VBG\2604760 predominantly_23\RB\1740 to_24\IN\1740 the_25\DT\1740 schizophrenia_26\NN\14398067 group</e2>_27\NN\2137 ._28\.\1740
2445283
D012254_D006478 NONE tolerance_0\NN\5032565 and_1\CC\1740 antiviral_2\JJ\1740 effect_3\NN\34213 of_4\IN\1740 <e1>ribavirin</e1>_5\NN\2725367 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 <e2>argentine_9\JJ\1740 hemorrhagic_10\JJ\1740 fever</e2>_11\NN\14299637 ._12\.\1740
D012254_D006478 NONE tolerance_0\NN\5032565 and_1\CC\1740 antiviral_2\JJ\1740 effect_3\NN\34213 of_4\IN\1740 <e1>ribavirin</e1>_5\NN\2725367 was_6\VBD\836236 studied_7\VBN\630380 in_8\IN\13603305 6_9\CD\13741022 patients_10\NNS\9898892 with_11\IN\1740 <e2>argentine_12\JJ\1740 hemorrhagic_13\JJ\1740 fever</e2>_14\NN\14299637 (_15\-LRB-\1740 ahf_16\NN\1740 )_17\-RRB-\1740 of_18\IN\1740 more_19\JJR\1740 than_20\IN\1740 8_21\CD\13741022 days_22\NNS\15140892 of_23\IN\1740 evolution_24\NN\29677 ._25\.\1740
D012254_D006478 NONE tolerance_0\NN\5032565 and_1\CC\1740 antiviral_2\JJ\1740 effect_3\NN\34213 of_4\IN\1740 <e1>ribavirin</e1>_5\NN\2725367 was_6\VBD\836236 studied_7\VBN\630380 in_8\IN\13603305 6_9\CD\13741022 patients_10\NNS\9898892 with_11\IN\1740 argentine_12\JJ\1740 hemorrhagic_13\JJ\1740 fever_14\NN\14299637 (_15\-LRB-\1740 <e2>ahf</e2>_16\NN\1740 )_17\-RRB-\1740 of_18\IN\1740 more_19\JJR\1740 than_20\IN\1740 8_21\CD\13741022 days_22\NNS\15140892 of_23\IN\1740 evolution_24\NN\29677 ._25\.\1740
D012254_D006478 NONE from_0\IN\1740 these_1\DT\1740 results_2\NNS\34213 ,_3\,\1740 we_4\PRP\1740 conclude_5\VBP\628491 that_6\IN\1740 <e1>ribavirin</e1>_7\NN\2725367 has_8\VBZ\2108377 an_9\DT\6697703 antiviral_10\JJ\1740 effect_11\NN\34213 in_12\IN\13603305 advanced_13\JJ\1740 cases_14\NNS\7283608 of_15\IN\1740 <e2>ahf</e2>_16\NN\1740 ,_17\,\1740 and_18\CC\1740 that_19\DT\1740 anemia_20\NN\14189204 ,_21\,\1740 the_22\DT\1740 only_23\JJ\1740 secondary_24\JJ\1740 reaction_25\NN\13446390 observed_26\VBN\2163746 ,_27\,\1740 can_28\MD\3094503 be_29\VB\836236 easily_30\RB\1740 managed_31\VBN\2524171 ._32\.\1740
D012254_D006478 NONE the_0\DT\1740 possible_1\JJ\1740 beneficial_2\JJ\1740 effect_3\NN\34213 of_4\IN\1740 <e1>ribavirin</e1>_5\NN\2725367 during_6\IN\1740 the_7\DT\1740 initial_8\JJ\1740 days_9\NNS\15140892 of_10\IN\1740 <e2>ahf</e2>_11\NN\1740 is_12\VBZ\836236 discussed_13\VBN\1033527 ._14\.\1740
D012254_D014766 NONE administration_0\NN\1133281 of_1\IN\1740 <e1>ribavirin</e1>_2\NN\2725367 resulted_3\VBD\2633881 in_4\IN\13603305 a_5\DT\13649268 neutralization_6\NN\231567 of_7\IN\1740 <e2>viremia</e2>_8\NN\14204950 and_9\CC\1740 a_10\DT\13649268 drop_11\NN\13899200 of_12\IN\1740 endogenous_13\JJ\1740 interferon_14\NN\2725367 titers_15\NNS\5038593 ._16\.\1740
D012254_D000740 CID from_0\IN\1740 these_1\DT\1740 results_2\NNS\34213 ,_3\,\1740 we_4\PRP\1740 conclude_5\VBP\628491 that_6\IN\1740 <e1>ribavirin</e1>_7\NN\2725367 has_8\VBZ\2108377 an_9\DT\6697703 antiviral_10\JJ\1740 effect_11\NN\34213 in_12\IN\13603305 advanced_13\JJ\1740 cases_14\NNS\7283608 of_15\IN\1740 ahf_16\NN\1740 ,_17\,\1740 and_18\CC\1740 that_19\DT\1740 <e2>anemia</e2>_20\NN\14189204 ,_21\,\1740 the_22\DT\1740 only_23\JJ\1740 secondary_24\JJ\1740 reaction_25\NN\13446390 observed_26\VBN\2163746 ,_27\,\1740 can_28\MD\3094503 be_29\VB\836236 easily_30\RB\1740 managed_31\VBN\2524171 ._32\.\1740
17854040
D019259_D006509 NONE mutations_0\NNS\4475 associated_1\VBN\628491 with_2\IN\1740 <e1>lamivudine-resistance</e1>_3\NN\1740 in_4\IN\13603305 therapy-na_5\JJ\1740 ve_6\NN\1740 <e2>hepatitis_7\NN\14127211 b_8\NN\1355326 virus_9\NN\9312843 (_10\-LRB-\1740 hbv_11\NN\1740 )_12\-RRB-\1740 infected</e2>_13\JJ\1740 patients_14\NNS\9898892 with_15\IN\1740 and_16\CC\1740 without_17\IN\1740 hiv_18\NN\14186340 co-infection_19\NN\1740 :_20\:\1740 implications_21\NNS\5774614 for_22\IN\1740 antiretroviral_23\JJ\1740 therapy_24\NN\657604 in_25\IN\13603305 hbv_26\NN\1740 and_27\CC\1740 hiv_28\NN\14186340 co-infected_29\VBD\1740 south_30\JJ\1740 african_31\JJ\1740 patients_32\NNS\9898892 ._33\.\1740
D019259_D006509 NONE mutations_0\NNS\4475 associated_1\VBN\628491 with_2\IN\1740 <e1>lamivudine-resistance</e1>_3\NN\1740 in_4\IN\13603305 therapy-na_5\JJ\1740 ve_6\NN\1740 hepatitis_7\NN\14127211 b_8\NN\1355326 virus_9\NN\9312843 (_10\-LRB-\1740 hbv_11\NN\1740 )_12\-RRB-\1740 infected_13\JJ\1740 patients_14\NNS\9898892 with_15\IN\1740 and_16\CC\1740 without_17\IN\1740 hiv_18\NN\14186340 co-infection_19\NN\1740 :_20\:\1740 implications_21\NNS\5774614 for_22\IN\1740 antiretroviral_23\JJ\1740 therapy_24\NN\657604 in_25\IN\13603305 <e2>hbv_26\NN\1740 and_27\CC\1740 hiv_28\NN\14186340 co-infected</e2>_29\VBD\1740 south_30\JJ\1740 african_31\JJ\1740 patients_32\NNS\9898892 ._33\.\1740
D019259_D006509 NONE this_0\DT\1740 was_1\VBD\836236 an_2\DT\6697703 exploratory_3\JJ\1740 study_4\NN\635850 to_5\TO\1740 investigate_6\VB\644583 <e1>lamivudine-resistant</e1>_7\JJ\1740 <e2>hepatitis_8\NN\14127211 b</e2>_9\NN\1355326 virus_10\NN\9312843 (_11\-LRB-\1740 hbv_12\NN\1740 )_13\-RRB-\1740 strains_14\NNS\7358060 in_15\IN\13603305 selected_16\VBN\697589 lamivudine-na_17\JJ\1740 ve_18\NN\1740 hbv_19\NN\1740 carriers_20\NNS\9629752 with_21\IN\1740 and_22\CC\1740 without_23\IN\1740 human_24\JJ\1740 immunodeficiency_25\NN\13973990 virus_26\NN\9312843 (_27\-LRB-\1740 hiv_28\NN\14186340 )_29\-RRB-\1740 co-infection_30\NN\1740 in_31\IN\13603305 south_32\JJ\1740 african_33\JJ\1740 patients_34\NNS\9898892 ._35\.\1740
D019259_D006509 NONE this_0\DT\1740 was_1\VBD\836236 an_2\DT\6697703 exploratory_3\JJ\1740 study_4\NN\635850 to_5\TO\1740 investigate_6\VB\644583 lamivudine-resistant_7\JJ\1740 <e2>hepatitis_8\NN\14127211 b</e2>_9\NN\1355326 virus_10\NN\9312843 (_11\-LRB-\1740 hbv_12\NN\1740 )_13\-RRB-\1740 strains_14\NNS\7358060 in_15\IN\13603305 selected_16\VBN\697589 <e1>lamivudine-na</e1>_17\JJ\1740 ve_18\NN\1740 hbv_19\NN\1740 carriers_20\NNS\9629752 with_21\IN\1740 and_22\CC\1740 without_23\IN\1740 human_24\JJ\1740 immunodeficiency_25\NN\13973990 virus_26\NN\9312843 (_27\-LRB-\1740 hiv_28\NN\14186340 )_29\-RRB-\1740 co-infection_30\NN\1740 in_31\IN\13603305 south_32\JJ\1740 african_33\JJ\1740 patients_34\NNS\9898892 ._35\.\1740
D019259_D006509 NONE thirty-five_0\JJ\1740 <e1>lamivudine-na</e1>_1\NN\1740 ve_2\NN\1740 <e2>hbv_3\NN\1740 infected</e2>_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 or_7\CC\3541091 without_8\IN\1740 hiv_9\NN\14186340 co-infection_10\NN\1740 were_11\VBD\836236 studied_12\VBN\630380 :_13\:\1740 15_14\CD\13745420 chronic_15\JJ\1740 hbv_16\NN\1740 mono-infected_17\JJ\1740 patients_18\NNS\9898892 and_19\CC\1740 20_20\CD\13745420 hbv-hiv_21\NN\1740 co-infected_22\VBD\1740 patients_23\NNS\9898892 ._24\.\1740
D019259_D006509 NONE thirty-five_0\JJ\1740 <e1>lamivudine-na</e1>_1\NN\1740 ve_2\NN\1740 hbv_3\NN\1740 infected_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 or_7\CC\3541091 without_8\IN\1740 hiv_9\NN\14186340 co-infection_10\NN\1740 were_11\VBD\836236 studied_12\VBN\630380 :_13\:\1740 15_14\CD\13745420 chronic_15\JJ\1740 <e2>hbv_16\NN\1740 mono-infected</e2>_17\JJ\1740 patients_18\NNS\9898892 and_19\CC\1740 20_20\CD\13745420 hbv-hiv_21\NN\1740 co-infected_22\VBD\1740 patients_23\NNS\9898892 ._24\.\1740
D019259_D006509 NONE thirty-five_0\JJ\1740 <e1>lamivudine-na</e1>_1\NN\1740 ve_2\NN\1740 hbv_3\NN\1740 infected_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 or_7\CC\3541091 without_8\IN\1740 hiv_9\NN\14186340 co-infection_10\NN\1740 were_11\VBD\836236 studied_12\VBN\630380 :_13\:\1740 15_14\CD\13745420 chronic_15\JJ\1740 hbv_16\NN\1740 mono-infected_17\JJ\1740 patients_18\NNS\9898892 and_19\CC\1740 20_20\CD\13745420 <e2>hbv-hiv_21\NN\1740 co-infected</e2>_22\VBD\1740 patients_23\NNS\9898892 ._24\.\1740
D019259_D006509 NONE hbv_0\NN\1740 <e1>lamivudine-resistant</e1>_1\JJ\1740 strains_2\NNS\7358060 were_3\VBD\836236 detected_4\VBN\2163746 in_5\IN\13603305 3_6\CD\13741022 of_7\IN\1740 15_8\CD\13745420 mono-infected_9\JJ\1740 chronic_10\JJ\1740 <e2>hepatitis_11\NN\14127211 b</e2>_12\NN\1355326 patients_13\NNS\9898892 and_14\CC\1740 10_15\CD\13745420 of_16\IN\1740 20_17\CD\13745420 hbv-hiv_18\NN\1740 co-infected_19\VBD\1740 patients_20\NNS\9898892 ._21\.\1740
D019259_D006509 NONE hbv_0\NN\1740 <e1>lamivudine-resistant</e1>_1\JJ\1740 strains_2\NNS\7358060 were_3\VBD\836236 detected_4\VBN\2163746 in_5\IN\13603305 3_6\CD\13741022 of_7\IN\1740 15_8\CD\13745420 mono-infected_9\JJ\1740 chronic_10\JJ\1740 hepatitis_11\NN\14127211 b_12\NN\1355326 patients_13\NNS\9898892 and_14\CC\1740 10_15\CD\13745420 of_16\IN\1740 20_17\CD\13745420 <e2>hbv-hiv_18\NN\1740 co-infected</e2>_19\VBD\1740 patients_20\NNS\9898892 ._21\.\1740
D019259_D006509 NONE to_0\IN\1740 the_1\DT\1740 best_2\JJS\1740 of_3\IN\1740 our_4\PRP$\1740 knowledge_5\NN\23100 ,_6\,\1740 this_7\DT\1740 constitutes_8\VBZ\1647229 the_9\DT\1740 first_10\JJ\1740 report_11\NN\6470073 of_12\IN\1740 hbv_13\NN\1740 <e1>lamivudine-resistant</e1>_14\JJ\1740 strains_15\NNS\7358060 in_16\IN\13603305 therapy-na_17\NN\1740 ve_18\NN\1740 <e2>hbv-hiv_19\NN\1740 co-infected</e2>_20\VBD\1740 patients_21\NNS\9898892 ._22\.\1740
D019259_D006509 NONE it_0\PRP\6125041 remains_1\VBZ\2604760 to_2\TO\1740 be_3\VB\836236 seen_4\VBN\2106506 whether_5\IN\1740 such_6\JJ\1740 pre-existing_7\JJ\1740 antiviral_8\JJ\1740 mutations_9\NNS\4475 could_10\MD\1740 result_11\VB\2633881 in_12\IN\13603305 widespread_13\JJ\1740 emergence_14\NN\7290905 of_15\IN\1740 hbv_16\NN\1740 resistant_17\JJ\1740 strains_18\NNS\7358060 when_19\WRB\1740 <e1>lamivudine-containing</e1>_20\JJ\1740 highly_21\RB\1740 active_22\JJ\1740 antiretroviral_23\JJ\1740 (_24\-LRB-\1740 arv_25\NN\1740 )_26\-RRB-\1740 treatment_27\NN\654885 (_28\-LRB-\1740 haart_29\NN\3740161 )_30\-RRB-\1740 regimens_31\NNS\5898568 become_32\VBP\146138 widely_33\RB\1740 applied_34\VBN\2676054 in_35\IN\13603305 south_36\NNP\13831000 africa_37\NNP\1740 ,_38\,\1740 as_39\IN\14622893 this_40\DT\1740 is_41\VBZ\836236 likely_42\JJ\1740 to_43\TO\1740 have_44\VB\2108377 potential_45\JJ\1740 implications_46\NNS\5774614 in_47\IN\13603305 the_48\DT\1740 management_49\NN\1123598 of_50\IN\1740 <e2>hbv-hiv_51\NN\1740 co-infected</e2>_52\VBD\1740 patients_53\NNS\9898892 ._54\.\1740
D019259_D015658 NONE mutations_0\NNS\4475 associated_1\VBN\628491 with_2\IN\1740 <e1>lamivudine-resistance</e1>_3\NN\1740 in_4\IN\13603305 therapy-na_5\JJ\1740 ve_6\NN\1740 hepatitis_7\NN\14127211 b_8\NN\1355326 virus_9\NN\9312843 (_10\-LRB-\1740 hbv_11\NN\1740 )_12\-RRB-\1740 infected_13\JJ\1740 patients_14\NNS\9898892 with_15\IN\1740 and_16\CC\1740 without_17\IN\1740 <e2>hiv_18\NN\14186340 co-infection</e2>_19\NN\1740 :_20\:\1740 implications_21\NNS\5774614 for_22\IN\1740 antiretroviral_23\JJ\1740 therapy_24\NN\657604 in_25\IN\13603305 hbv_26\NN\1740 and_27\CC\1740 hiv_28\NN\14186340 co-infected_29\VBD\1740 south_30\JJ\1740 african_31\JJ\1740 patients_32\NNS\9898892 ._33\.\1740
D019259_D015658 NONE mutations_0\NNS\4475 associated_1\VBN\628491 with_2\IN\1740 <e1>lamivudine-resistance</e1>_3\NN\1740 in_4\IN\13603305 therapy-na_5\JJ\1740 ve_6\NN\1740 hepatitis_7\NN\14127211 b_8\NN\1355326 virus_9\NN\9312843 (_10\-LRB-\1740 hbv_11\NN\1740 )_12\-RRB-\1740 infected_13\JJ\1740 patients_14\NNS\9898892 with_15\IN\1740 and_16\CC\1740 without_17\IN\1740 hiv_18\NN\14186340 co-infection_19\NN\1740 :_20\:\1740 implications_21\NNS\5774614 for_22\IN\1740 antiretroviral_23\JJ\1740 therapy_24\NN\657604 in_25\IN\13603305 <e2>hbv_26\NN\1740 and_27\CC\1740 hiv_28\NN\14186340 co-infected</e2>_29\VBD\1740 south_30\JJ\1740 african_31\JJ\1740 patients_32\NNS\9898892 ._33\.\1740
D019259_D015658 NONE this_0\DT\1740 was_1\VBD\836236 an_2\DT\6697703 exploratory_3\JJ\1740 study_4\NN\635850 to_5\TO\1740 investigate_6\VB\644583 <e1>lamivudine-resistant</e1>_7\JJ\1740 hepatitis_8\NN\14127211 b_9\NN\1355326 virus_10\NN\9312843 (_11\-LRB-\1740 hbv_12\NN\1740 )_13\-RRB-\1740 strains_14\NNS\7358060 in_15\IN\13603305 selected_16\VBN\697589 lamivudine-na_17\JJ\1740 ve_18\NN\1740 hbv_19\NN\1740 carriers_20\NNS\9629752 with_21\IN\1740 and_22\CC\1740 without_23\IN\1740 <e2>human_24\JJ\1740 immunodeficiency_25\NN\13973990 virus_26\NN\9312843 (_27\-LRB-\1740 hiv_28\NN\14186340 )_29\-RRB-\1740 co-infection</e2>_30\NN\1740 in_31\IN\13603305 south_32\JJ\1740 african_33\JJ\1740 patients_34\NNS\9898892 ._35\.\1740
D019259_D015658 NONE this_0\DT\1740 was_1\VBD\836236 an_2\DT\6697703 exploratory_3\JJ\1740 study_4\NN\635850 to_5\TO\1740 investigate_6\VB\644583 lamivudine-resistant_7\JJ\1740 hepatitis_8\NN\14127211 b_9\NN\1355326 virus_10\NN\9312843 (_11\-LRB-\1740 hbv_12\NN\1740 )_13\-RRB-\1740 strains_14\NNS\7358060 in_15\IN\13603305 selected_16\VBN\697589 <e1>lamivudine-na</e1>_17\JJ\1740 ve_18\NN\1740 hbv_19\NN\1740 carriers_20\NNS\9629752 with_21\IN\1740 and_22\CC\1740 without_23\IN\1740 <e2>human_24\JJ\1740 immunodeficiency_25\NN\13973990 virus_26\NN\9312843 (_27\-LRB-\1740 hiv_28\NN\14186340 )_29\-RRB-\1740 co-infection</e2>_30\NN\1740 in_31\IN\13603305 south_32\JJ\1740 african_33\JJ\1740 patients_34\NNS\9898892 ._35\.\1740
D019259_D015658 NONE thirty-five_0\JJ\1740 <e1>lamivudine-na</e1>_1\NN\1740 ve_2\NN\1740 hbv_3\NN\1740 infected_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 or_7\CC\3541091 without_8\IN\1740 <e2>hiv_9\NN\14186340 co-infection</e2>_10\NN\1740 were_11\VBD\836236 studied_12\VBN\630380 :_13\:\1740 15_14\CD\13745420 chronic_15\JJ\1740 hbv_16\NN\1740 mono-infected_17\JJ\1740 patients_18\NNS\9898892 and_19\CC\1740 20_20\CD\13745420 hbv-hiv_21\NN\1740 co-infected_22\VBD\1740 patients_23\NNS\9898892 ._24\.\1740
D019259_D015658 NONE thirty-five_0\JJ\1740 <e1>lamivudine-na</e1>_1\NN\1740 ve_2\NN\1740 hbv_3\NN\1740 infected_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 or_7\CC\3541091 without_8\IN\1740 hiv_9\NN\14186340 co-infection_10\NN\1740 were_11\VBD\836236 studied_12\VBN\630380 :_13\:\1740 15_14\CD\13745420 chronic_15\JJ\1740 hbv_16\NN\1740 mono-infected_17\JJ\1740 patients_18\NNS\9898892 and_19\CC\1740 20_20\CD\13745420 <e2>hbv-hiv_21\NN\1740 co-infected</e2>_22\VBD\1740 patients_23\NNS\9898892 ._24\.\1740
D019259_D015658 NONE hbv_0\NN\1740 <e1>lamivudine-resistant</e1>_1\JJ\1740 strains_2\NNS\7358060 were_3\VBD\836236 detected_4\VBN\2163746 in_5\IN\13603305 3_6\CD\13741022 of_7\IN\1740 15_8\CD\13745420 mono-infected_9\JJ\1740 chronic_10\JJ\1740 hepatitis_11\NN\14127211 b_12\NN\1355326 patients_13\NNS\9898892 and_14\CC\1740 10_15\CD\13745420 of_16\IN\1740 20_17\CD\13745420 <e2>hbv-hiv_18\NN\1740 co-infected</e2>_19\VBD\1740 patients_20\NNS\9898892 ._21\.\1740
D019259_D015658 NONE to_0\IN\1740 the_1\DT\1740 best_2\JJS\1740 of_3\IN\1740 our_4\PRP$\1740 knowledge_5\NN\23100 ,_6\,\1740 this_7\DT\1740 constitutes_8\VBZ\1647229 the_9\DT\1740 first_10\JJ\1740 report_11\NN\6470073 of_12\IN\1740 hbv_13\NN\1740 <e1>lamivudine-resistant</e1>_14\JJ\1740 strains_15\NNS\7358060 in_16\IN\13603305 therapy-na_17\NN\1740 ve_18\NN\1740 <e2>hbv-hiv_19\NN\1740 co-infected</e2>_20\VBD\1740 patients_21\NNS\9898892 ._22\.\1740
D019259_D015658 NONE it_0\PRP\6125041 remains_1\VBZ\2604760 to_2\TO\1740 be_3\VB\836236 seen_4\VBN\2106506 whether_5\IN\1740 such_6\JJ\1740 pre-existing_7\JJ\1740 antiviral_8\JJ\1740 mutations_9\NNS\4475 could_10\MD\1740 result_11\VB\2633881 in_12\IN\13603305 widespread_13\JJ\1740 emergence_14\NN\7290905 of_15\IN\1740 hbv_16\NN\1740 resistant_17\JJ\1740 strains_18\NNS\7358060 when_19\WRB\1740 <e1>lamivudine-containing</e1>_20\JJ\1740 highly_21\RB\1740 active_22\JJ\1740 antiretroviral_23\JJ\1740 (_24\-LRB-\1740 arv_25\NN\1740 )_26\-RRB-\1740 treatment_27\NN\654885 (_28\-LRB-\1740 haart_29\NN\3740161 )_30\-RRB-\1740 regimens_31\NNS\5898568 become_32\VBP\146138 widely_33\RB\1740 applied_34\VBN\2676054 in_35\IN\13603305 south_36\NNP\13831000 africa_37\NNP\1740 ,_38\,\1740 as_39\IN\14622893 this_40\DT\1740 is_41\VBZ\836236 likely_42\JJ\1740 to_43\TO\1740 have_44\VB\2108377 potential_45\JJ\1740 implications_46\NNS\5774614 in_47\IN\13603305 the_48\DT\1740 management_49\NN\1123598 of_50\IN\1740 <e2>hbv-hiv_51\NN\1740 co-infected</e2>_52\VBD\1740 patients_53\NNS\9898892 ._54\.\1740
D012964_D006509 NONE mutations_0\NNS\4475 associated_1\VBN\628491 with_2\IN\1740 lamivudine-resistance_3\NN\1740 in_4\IN\13603305 <e1>therapy-na</e1>_5\JJ\1740 ve_6\NN\1740 <e2>hepatitis_7\NN\14127211 b_8\NN\1355326 virus_9\NN\9312843 (_10\-LRB-\1740 hbv_11\NN\1740 )_12\-RRB-\1740 infected</e2>_13\JJ\1740 patients_14\NNS\9898892 with_15\IN\1740 and_16\CC\1740 without_17\IN\1740 hiv_18\NN\14186340 co-infection_19\NN\1740 :_20\:\1740 implications_21\NNS\5774614 for_22\IN\1740 antiretroviral_23\JJ\1740 therapy_24\NN\657604 in_25\IN\13603305 hbv_26\NN\1740 and_27\CC\1740 hiv_28\NN\14186340 co-infected_29\VBD\1740 south_30\JJ\1740 african_31\JJ\1740 patients_32\NNS\9898892 ._33\.\1740
D012964_D006509 NONE mutations_0\NNS\4475 associated_1\VBN\628491 with_2\IN\1740 lamivudine-resistance_3\NN\1740 in_4\IN\13603305 <e1>therapy-na</e1>_5\JJ\1740 ve_6\NN\1740 hepatitis_7\NN\14127211 b_8\NN\1355326 virus_9\NN\9312843 (_10\-LRB-\1740 hbv_11\NN\1740 )_12\-RRB-\1740 infected_13\JJ\1740 patients_14\NNS\9898892 with_15\IN\1740 and_16\CC\1740 without_17\IN\1740 hiv_18\NN\14186340 co-infection_19\NN\1740 :_20\:\1740 implications_21\NNS\5774614 for_22\IN\1740 antiretroviral_23\JJ\1740 therapy_24\NN\657604 in_25\IN\13603305 <e2>hbv_26\NN\1740 and_27\CC\1740 hiv_28\NN\14186340 co-infected</e2>_29\VBD\1740 south_30\JJ\1740 african_31\JJ\1740 patients_32\NNS\9898892 ._33\.\1740
D012964_D006509 NONE this_0\DT\1740 was_1\VBD\836236 an_2\DT\6697703 exploratory_3\JJ\1740 study_4\NN\635850 to_5\TO\1740 investigate_6\VB\644583 lamivudine-resistant_7\JJ\1740 <e2>hepatitis_8\NN\14127211 b</e2>_9\NN\1355326 virus_10\NN\9312843 (_11\-LRB-\1740 hbv_12\NN\1740 )_13\-RRB-\1740 strains_14\NNS\7358060 in_15\IN\13603305 selected_16\VBN\697589 <e1>lamivudine-na</e1>_17\JJ\1740 ve_18\NN\1740 hbv_19\NN\1740 carriers_20\NNS\9629752 with_21\IN\1740 and_22\CC\1740 without_23\IN\1740 human_24\JJ\1740 immunodeficiency_25\NN\13973990 virus_26\NN\9312843 (_27\-LRB-\1740 hiv_28\NN\14186340 )_29\-RRB-\1740 co-infection_30\NN\1740 in_31\IN\13603305 south_32\JJ\1740 african_33\JJ\1740 patients_34\NNS\9898892 ._35\.\1740
D012964_D006509 NONE thirty-five_0\JJ\1740 <e1>lamivudine-na</e1>_1\NN\1740 ve_2\NN\1740 <e2>hbv_3\NN\1740 infected</e2>_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 or_7\CC\3541091 without_8\IN\1740 hiv_9\NN\14186340 co-infection_10\NN\1740 were_11\VBD\836236 studied_12\VBN\630380 :_13\:\1740 15_14\CD\13745420 chronic_15\JJ\1740 hbv_16\NN\1740 mono-infected_17\JJ\1740 patients_18\NNS\9898892 and_19\CC\1740 20_20\CD\13745420 hbv-hiv_21\NN\1740 co-infected_22\VBD\1740 patients_23\NNS\9898892 ._24\.\1740
D012964_D006509 NONE thirty-five_0\JJ\1740 <e1>lamivudine-na</e1>_1\NN\1740 ve_2\NN\1740 hbv_3\NN\1740 infected_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 or_7\CC\3541091 without_8\IN\1740 hiv_9\NN\14186340 co-infection_10\NN\1740 were_11\VBD\836236 studied_12\VBN\630380 :_13\:\1740 15_14\CD\13745420 chronic_15\JJ\1740 <e2>hbv_16\NN\1740 mono-infected</e2>_17\JJ\1740 patients_18\NNS\9898892 and_19\CC\1740 20_20\CD\13745420 hbv-hiv_21\NN\1740 co-infected_22\VBD\1740 patients_23\NNS\9898892 ._24\.\1740
D012964_D006509 NONE thirty-five_0\JJ\1740 <e1>lamivudine-na</e1>_1\NN\1740 ve_2\NN\1740 hbv_3\NN\1740 infected_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 or_7\CC\3541091 without_8\IN\1740 hiv_9\NN\14186340 co-infection_10\NN\1740 were_11\VBD\836236 studied_12\VBN\630380 :_13\:\1740 15_14\CD\13745420 chronic_15\JJ\1740 hbv_16\NN\1740 mono-infected_17\JJ\1740 patients_18\NNS\9898892 and_19\CC\1740 20_20\CD\13745420 <e2>hbv-hiv_21\NN\1740 co-infected</e2>_22\VBD\1740 patients_23\NNS\9898892 ._24\.\1740
D012964_D006509 NONE to_0\IN\1740 the_1\DT\1740 best_2\JJS\1740 of_3\IN\1740 our_4\PRP$\1740 knowledge_5\NN\23100 ,_6\,\1740 this_7\DT\1740 constitutes_8\VBZ\1647229 the_9\DT\1740 first_10\JJ\1740 report_11\NN\6470073 of_12\IN\1740 hbv_13\NN\1740 lamivudine-resistant_14\JJ\1740 strains_15\NNS\7358060 in_16\IN\13603305 <e1>therapy-na</e1>_17\NN\1740 ve_18\NN\1740 <e2>hbv-hiv_19\NN\1740 co-infected</e2>_20\VBD\1740 patients_21\NNS\9898892 ._22\.\1740
D012964_D015658 NONE mutations_0\NNS\4475 associated_1\VBN\628491 with_2\IN\1740 lamivudine-resistance_3\NN\1740 in_4\IN\13603305 <e1>therapy-na</e1>_5\JJ\1740 ve_6\NN\1740 hepatitis_7\NN\14127211 b_8\NN\1355326 virus_9\NN\9312843 (_10\-LRB-\1740 hbv_11\NN\1740 )_12\-RRB-\1740 infected_13\JJ\1740 patients_14\NNS\9898892 with_15\IN\1740 and_16\CC\1740 without_17\IN\1740 <e2>hiv_18\NN\14186340 co-infection</e2>_19\NN\1740 :_20\:\1740 implications_21\NNS\5774614 for_22\IN\1740 antiretroviral_23\JJ\1740 therapy_24\NN\657604 in_25\IN\13603305 hbv_26\NN\1740 and_27\CC\1740 hiv_28\NN\14186340 co-infected_29\VBD\1740 south_30\JJ\1740 african_31\JJ\1740 patients_32\NNS\9898892 ._33\.\1740
D012964_D015658 NONE mutations_0\NNS\4475 associated_1\VBN\628491 with_2\IN\1740 lamivudine-resistance_3\NN\1740 in_4\IN\13603305 <e1>therapy-na</e1>_5\JJ\1740 ve_6\NN\1740 hepatitis_7\NN\14127211 b_8\NN\1355326 virus_9\NN\9312843 (_10\-LRB-\1740 hbv_11\NN\1740 )_12\-RRB-\1740 infected_13\JJ\1740 patients_14\NNS\9898892 with_15\IN\1740 and_16\CC\1740 without_17\IN\1740 hiv_18\NN\14186340 co-infection_19\NN\1740 :_20\:\1740 implications_21\NNS\5774614 for_22\IN\1740 antiretroviral_23\JJ\1740 therapy_24\NN\657604 in_25\IN\13603305 <e2>hbv_26\NN\1740 and_27\CC\1740 hiv_28\NN\14186340 co-infected</e2>_29\VBD\1740 south_30\JJ\1740 african_31\JJ\1740 patients_32\NNS\9898892 ._33\.\1740
D012964_D015658 NONE this_0\DT\1740 was_1\VBD\836236 an_2\DT\6697703 exploratory_3\JJ\1740 study_4\NN\635850 to_5\TO\1740 investigate_6\VB\644583 lamivudine-resistant_7\JJ\1740 hepatitis_8\NN\14127211 b_9\NN\1355326 virus_10\NN\9312843 (_11\-LRB-\1740 hbv_12\NN\1740 )_13\-RRB-\1740 strains_14\NNS\7358060 in_15\IN\13603305 selected_16\VBN\697589 <e1>lamivudine-na</e1>_17\JJ\1740 ve_18\NN\1740 hbv_19\NN\1740 carriers_20\NNS\9629752 with_21\IN\1740 and_22\CC\1740 without_23\IN\1740 <e2>human_24\JJ\1740 immunodeficiency_25\NN\13973990 virus_26\NN\9312843 (_27\-LRB-\1740 hiv_28\NN\14186340 )_29\-RRB-\1740 co-infection</e2>_30\NN\1740 in_31\IN\13603305 south_32\JJ\1740 african_33\JJ\1740 patients_34\NNS\9898892 ._35\.\1740
D012964_D015658 NONE thirty-five_0\JJ\1740 <e1>lamivudine-na</e1>_1\NN\1740 ve_2\NN\1740 hbv_3\NN\1740 infected_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 or_7\CC\3541091 without_8\IN\1740 <e2>hiv_9\NN\14186340 co-infection</e2>_10\NN\1740 were_11\VBD\836236 studied_12\VBN\630380 :_13\:\1740 15_14\CD\13745420 chronic_15\JJ\1740 hbv_16\NN\1740 mono-infected_17\JJ\1740 patients_18\NNS\9898892 and_19\CC\1740 20_20\CD\13745420 hbv-hiv_21\NN\1740 co-infected_22\VBD\1740 patients_23\NNS\9898892 ._24\.\1740
D012964_D015658 NONE thirty-five_0\JJ\1740 <e1>lamivudine-na</e1>_1\NN\1740 ve_2\NN\1740 hbv_3\NN\1740 infected_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 or_7\CC\3541091 without_8\IN\1740 hiv_9\NN\14186340 co-infection_10\NN\1740 were_11\VBD\836236 studied_12\VBN\630380 :_13\:\1740 15_14\CD\13745420 chronic_15\JJ\1740 hbv_16\NN\1740 mono-infected_17\JJ\1740 patients_18\NNS\9898892 and_19\CC\1740 20_20\CD\13745420 <e2>hbv-hiv_21\NN\1740 co-infected</e2>_22\VBD\1740 patients_23\NNS\9898892 ._24\.\1740
D012964_D015658 NONE to_0\IN\1740 the_1\DT\1740 best_2\JJS\1740 of_3\IN\1740 our_4\PRP$\1740 knowledge_5\NN\23100 ,_6\,\1740 this_7\DT\1740 constitutes_8\VBZ\1647229 the_9\DT\1740 first_10\JJ\1740 report_11\NN\6470073 of_12\IN\1740 hbv_13\NN\1740 lamivudine-resistant_14\JJ\1740 strains_15\NNS\7358060 in_16\IN\13603305 <e1>therapy-na</e1>_17\NN\1740 ve_18\NN\1740 <e2>hbv-hiv_19\NN\1740 co-infected</e2>_20\VBD\1740 patients_21\NNS\9898892 ._22\.\1740
7468724
D013726_D002318 CID <e2>cardiovascular_0\JJ\1740 complications</e2>_1\NNS\1073995 associated_2\VBN\628491 with_3\IN\1740 <e1>terbutaline</e1>_4\NN\1740 treatment_5\NN\654885 for_6\IN\1740 preterm_7\NN\1740 labor_8\NN\7974025 ._9\.\1740
D013726_D002318 CID severe_0\JJ\1740 <e2>cardiovascular_1\JJ\1740 complications</e2>_2\NNS\1073995 occurred_3\VBD\2623529 in_4\IN\13603305 eight_5\CD\13741022 of_6\IN\1740 160_7\CD\1740 patients_8\NNS\9898892 treated_9\VBN\2376958 with_10\IN\1740 <e1>terbutaline</e1>_11\NN\1740 for_12\IN\1740 preterm_13\NN\1740 labor_14\NN\7974025 ._15\.\1740
D013726_D007752 NONE cardiovascular_0\JJ\1740 complications_1\NNS\1073995 associated_2\VBN\628491 with_3\IN\1740 <e1>terbutaline</e1>_4\NN\1740 treatment_5\NN\654885 for_6\IN\1740 <e2>preterm_7\NN\1740 labor</e2>_8\NN\7974025 ._9\.\1740
D013726_D007752 NONE severe_0\JJ\1740 cardiovascular_1\JJ\1740 complications_2\NNS\1073995 occurred_3\VBD\2623529 in_4\IN\13603305 eight_5\CD\13741022 of_6\IN\1740 160_7\CD\1740 patients_8\NNS\9898892 treated_9\VBN\2376958 with_10\IN\1740 <e1>terbutaline</e1>_11\NN\1740 for_12\IN\1740 <e2>preterm_13\NN\1740 labor</e2>_14\NN\7974025 ._15\.\1740
7269015
D002066_D006470 CID <e1>busulfan-induced</e1>_0\JJ\1740 <e2>hemorrhagic_1\JJ\1740 cystitis</e2>_2\NN\14566129 ._3\.\1740
D002066_D006470 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 a_3\DT\13649268 <e1>busulfan-induced</e1>_4\JJ\1740 <e2>hemorrhage_5\NN\14285662 cystitis</e2>_6\NN\14566129 is_7\VBZ\836236 reported_8\VBN\831651 ._9\.\1740
D002066_D003556 CID <e1>busulfan-induced</e1>_0\JJ\1740 <e2>hemorrhagic_1\JJ\1740 cystitis</e2>_2\NN\14566129 ._3\.\1740
D002066_D003556 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 a_3\DT\13649268 <e1>busulfan-induced</e1>_4\JJ\1740 <e2>hemorrhage_5\NN\14285662 cystitis</e2>_6\NN\14566129 is_7\VBZ\836236 reported_8\VBN\831651 ._9\.\1740
D002066_D003556 CID the_0\DT\1740 similarity_1\NN\4742535 between_2\IN\1740 the_3\DT\1740 histologic_4\JJ\1740 appearances_5\NNS\4723816 of_6\IN\1740 <e1>busulfan</e1>_7\NNS\1740 <e2>cystitis</e2>_8\NN\14566129 and_9\CC\1740 both_10\DT\1740 radiation_11\NN\11452218 and_12\CC\1740 cyclophosphamide-induced_13\JJ\1740 cystitis_14\NN\14566129 is_15\VBZ\836236 discussed_16\VBN\1033527 and_17\CC\1740 the_18\DT\1740 world_19\NN\19128 literature_20\NN\6362953 reviewed_21\VBN\644583 ._22\.\1740
D002066_D003556 CID the_0\DT\1740 similarity_1\NN\4742535 between_2\IN\1740 the_3\DT\1740 histologic_4\JJ\1740 appearances_5\NNS\4723816 of_6\IN\1740 <e1>busulfan</e1>_7\NNS\1740 cystitis_8\NN\14566129 and_9\CC\1740 both_10\DT\1740 radiation_11\NN\11452218 and_12\CC\1740 cyclophosphamide-induced_13\JJ\1740 <e2>cystitis</e2>_14\NN\14566129 is_15\VBZ\836236 discussed_16\VBN\1033527 and_17\CC\1740 the_18\DT\1740 world_19\NN\19128 literature_20\NN\6362953 reviewed_21\VBN\644583 ._22\.\1740
D003520_D003556 NONE the_0\DT\1740 similarity_1\NN\4742535 between_2\IN\1740 the_3\DT\1740 histologic_4\JJ\1740 appearances_5\NNS\4723816 of_6\IN\1740 busulfan_7\NNS\1740 <e2>cystitis</e2>_8\NN\14566129 and_9\CC\1740 both_10\DT\1740 radiation_11\NN\11452218 and_12\CC\1740 <e1>cyclophosphamide-induced</e1>_13\JJ\1740 cystitis_14\NN\14566129 is_15\VBZ\836236 discussed_16\VBN\1033527 and_17\CC\1740 the_18\DT\1740 world_19\NN\19128 literature_20\NN\6362953 reviewed_21\VBN\644583 ._22\.\1740
D003520_D003556 NONE the_0\DT\1740 similarity_1\NN\4742535 between_2\IN\1740 the_3\DT\1740 histologic_4\JJ\1740 appearances_5\NNS\4723816 of_6\IN\1740 busulfan_7\NNS\1740 cystitis_8\NN\14566129 and_9\CC\1740 both_10\DT\1740 radiation_11\NN\11452218 and_12\CC\1740 <e1>cyclophosphamide-induced</e1>_13\JJ\1740 <e2>cystitis</e2>_14\NN\14566129 is_15\VBZ\836236 discussed_16\VBN\1033527 and_17\CC\1740 the_18\DT\1740 world_19\NN\19128 literature_20\NN\6362953 reviewed_21\VBN\644583 ._22\.\1740
D002066_D002277 NONE in_0\IN\13603305 view_1\NN\6208021 of_2\IN\1740 the_3\DT\1740 known_4\JJ\1740 tendency_5\NN\6193203 of_6\IN\1740 <e1>busulfan</e1>_7\NNS\1740 to_8\TO\1740 induce_9\VB\1627355 cellular_10\JJ\1740 atypia_11\NN\1740 and_12\CC\1740 <e2>carcinoma</e2>_13\NN\14239918 in_14\IN\13603305 other_15\JJ\1740 sites_16\NNS\8673395 ,_17\,\1740 periodic_18\JJ\1740 urinary_19\JJ\1740 cytology_20\NN\6037666 is_21\VBZ\836236 suggested_22\VBN\1010118 in_23\IN\13603305 patients_24\NNS\9898892 on_25\IN\1740 long-term_26\JJ\1740 therapy_27\NN\657604 ._28\.\1740
15899738
D003401_D001281 CID lone_0\JJ\1740 <e2>atrial_1\JJ\1740 fibrillation</e2>_2\NN\14361664 associated_3\VBN\628491 with_4\IN\1740 <e1>creatine</e1>_5\NN\14601829 monohydrate_6\NN\14910440 supplementation_7\NN\5108947 ._8\.\1740
D003401_D001145 NONE previous_0\JJ\1740 anecdotal_1\JJ\1740 reports_2\NNS\6470073 have_3\VBP\2108377 linked_4\VBN\628491 <e1>creatine</e1>_5\NN\14601829 to_6\TO\1740 the_7\DT\1740 development_8\NN\248977 of_9\IN\1740 <e2>arrhythmia</e2>_10\NN\14103288 ._11\.\1740
12615818
D017373_D054556 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 <e2>venous_3\JJ\1740 thromboembolism</e2>_4\NN\14100769 in_5\IN\13603305 women_6\NNS\9605289 prescribed_7\VBD\748282 <e1>cyproterone_8\NN\1740 acetate</e1>_9\NN\15010703 in_10\IN\13603305 combination_11\NN\7951464 with_12\IN\1740 ethinyl_13\JJ\1740 estradiol_14\NN\14749794 :_15\:\1740 a_16\DT\13649268 nested_17\JJ\1740 cohort_18\NN\8184861 analysis_19\NN\633864 and_20\CC\1740 case-control_21\JJ\1740 study_22\NN\635850 ._23\.\1740
D017373_D054556 CID previous_0\JJ\1740 studies_1\NNS\635850 have_2\VBP\2108377 demonstrated_3\VBN\2137132 an_4\DT\6697703 increased_5\VBN\169651 risk_6\NN\14541044 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 compared_16\VBN\644583 with_17\IN\1740 conventional_18\JJ\1740 combined_19\JJ\1740 oral_20\JJ\1740 contraceptives_21\NNS\3183080 (_22\-LRB-\1740 cocs_23\NNS\1740 )_24\-RRB-\1740 ._25\.\1740
D017373_D054556 CID previous_0\JJ\1740 studies_1\NNS\635850 have_2\VBP\2108377 demonstrated_3\VBN\2137132 an_4\DT\6697703 increased_5\VBN\169651 risk_6\NN\14541044 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 compared_16\VBN\644583 with_17\IN\1740 conventional_18\JJ\1740 combined_19\JJ\1740 oral_20\JJ\1740 contraceptives_21\NNS\3183080 (_22\-LRB-\1740 cocs_23\NNS\1740 )_24\-RRB-\1740 ._25\.\1740
D017373_D054556 CID methods_0\NNS\5616786 :_1\:\1740 using_2\VBG\1156834 the_3\DT\1740 general_4\NNP\10125786 practice_5\NNP\407535 research_6\NNP\633864 database_7\NNP\6634376 we_8\PRP\1740 conducted_9\VBD\2436349 a_10\DT\13649268 cohort_11\NN\8184861 analysis_12\NN\633864 and_13\CC\1740 case-control_14\JJ\1740 study_15\NN\635850 nested_16\VBN\2649830 within_17\IN\1740 a_18\DT\13649268 population_19\NN\7942152 of_20\IN\1740 women_21\NNS\9605289 aged_22\JJ\1740 between_23\IN\1740 15_24\CD\13745420 and_25\CC\1740 39_26\CD\1740 years_27\NNS\15144371 with_28\IN\1740 acne_29\NN\14171682 ,_30\,\1740 hirsutism_31\NN\4683453 or_32\CC\3541091 pcos_33\NN\1740 to_34\TO\1740 estimate_35\VB\637259 the_36\DT\1740 risk_37\NN\14541044 of_38\IN\1740 <e2>vte</e2>_39\NN\1740 associated_40\VBN\628491 with_41\IN\1740 <e1>cpa/ee</e1>_42\NN\1740 ._43\.\1740
D017373_D054556 CID conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 have_3\VBP\2108377 demonstrated_4\VBN\2137132 an_5\DT\6697703 increased_6\VBN\169651 risk_7\NN\14541044 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 in_16\IN\13603305 women_17\NNS\9605289 with_18\IN\1740 acne_19\NN\14171682 ,_20\,\1740 hirsutism_21\NN\4683453 or_22\CC\3541091 pcos_23\NN\1740 although_24\IN\1740 residual_25\JJ\1740 confounding_26\NN\1740 by_27\IN\1740 indication_28\NN\33020 can_29\MD\3094503 not_30\RB\1740 be_31\VB\836236 excluded_32\VBN\471711 ._33\.\1740
D004997_D054556 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 <e2>venous_3\JJ\1740 thromboembolism</e2>_4\NN\14100769 in_5\IN\13603305 women_6\NNS\9605289 prescribed_7\VBD\748282 cyproterone_8\NN\1740 acetate_9\NN\15010703 in_10\IN\13603305 combination_11\NN\7951464 with_12\IN\1740 <e1>ethinyl_13\JJ\1740 estradiol</e1>_14\NN\14749794 :_15\:\1740 a_16\DT\13649268 nested_17\JJ\1740 cohort_18\NN\8184861 analysis_19\NN\633864 and_20\CC\1740 case-control_21\JJ\1740 study_22\NN\635850 ._23\.\1740
D004997_D054556 CID previous_0\JJ\1740 studies_1\NNS\635850 have_2\VBP\2108377 demonstrated_3\VBN\2137132 an_4\DT\6697703 increased_5\VBN\169651 risk_6\NN\14541044 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 compared_16\VBN\644583 with_17\IN\1740 conventional_18\JJ\1740 combined_19\JJ\1740 oral_20\JJ\1740 contraceptives_21\NNS\3183080 (_22\-LRB-\1740 cocs_23\NNS\1740 )_24\-RRB-\1740 ._25\.\1740
D004997_D054556 CID previous_0\JJ\1740 studies_1\NNS\635850 have_2\VBP\2108377 demonstrated_3\VBN\2137132 an_4\DT\6697703 increased_5\VBN\169651 risk_6\NN\14541044 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 compared_16\VBN\644583 with_17\IN\1740 conventional_18\JJ\1740 combined_19\JJ\1740 oral_20\JJ\1740 contraceptives_21\NNS\3183080 (_22\-LRB-\1740 cocs_23\NNS\1740 )_24\-RRB-\1740 ._25\.\1740
D004997_D054556 CID methods_0\NNS\5616786 :_1\:\1740 using_2\VBG\1156834 the_3\DT\1740 general_4\NNP\10125786 practice_5\NNP\407535 research_6\NNP\633864 database_7\NNP\6634376 we_8\PRP\1740 conducted_9\VBD\2436349 a_10\DT\13649268 cohort_11\NN\8184861 analysis_12\NN\633864 and_13\CC\1740 case-control_14\JJ\1740 study_15\NN\635850 nested_16\VBN\2649830 within_17\IN\1740 a_18\DT\13649268 population_19\NN\7942152 of_20\IN\1740 women_21\NNS\9605289 aged_22\JJ\1740 between_23\IN\1740 15_24\CD\13745420 and_25\CC\1740 39_26\CD\1740 years_27\NNS\15144371 with_28\IN\1740 acne_29\NN\14171682 ,_30\,\1740 hirsutism_31\NN\4683453 or_32\CC\3541091 pcos_33\NN\1740 to_34\TO\1740 estimate_35\VB\637259 the_36\DT\1740 risk_37\NN\14541044 of_38\IN\1740 <e2>vte</e2>_39\NN\1740 associated_40\VBN\628491 with_41\IN\1740 <e1>cpa/ee</e1>_42\NN\1740 ._43\.\1740
D004997_D054556 CID conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 have_3\VBP\2108377 demonstrated_4\VBN\2137132 an_5\DT\6697703 increased_6\VBN\169651 risk_7\NN\14541044 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 in_16\IN\13603305 women_17\NNS\9605289 with_18\IN\1740 acne_19\NN\14171682 ,_20\,\1740 hirsutism_21\NN\4683453 or_22\CC\3541091 pcos_23\NN\1740 although_24\IN\1740 residual_25\JJ\1740 confounding_26\NN\1740 by_27\IN\1740 indication_28\NN\33020 can_29\MD\3094503 not_30\RB\1740 be_31\VB\836236 excluded_32\VBN\471711 ._33\.\1740
D017373_D000152 NONE background_0\NN\4921011 :_1\:\1740 <e1>cyproterone_2\NN\1740 acetate</e1>_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 cpa/ee_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 <e2>acne</e2>_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D017373_D000152 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 <e1>cpa/ee</e1>_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 <e2>acne</e2>_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D017373_D000152 NONE methods_0\NNS\5616786 :_1\:\1740 using_2\VBG\1156834 the_3\DT\1740 general_4\NNP\10125786 practice_5\NNP\407535 research_6\NNP\633864 database_7\NNP\6634376 we_8\PRP\1740 conducted_9\VBD\2436349 a_10\DT\13649268 cohort_11\NN\8184861 analysis_12\NN\633864 and_13\CC\1740 case-control_14\JJ\1740 study_15\NN\635850 nested_16\VBN\2649830 within_17\IN\1740 a_18\DT\13649268 population_19\NN\7942152 of_20\IN\1740 women_21\NNS\9605289 aged_22\JJ\1740 between_23\IN\1740 15_24\CD\13745420 and_25\CC\1740 39_26\CD\1740 years_27\NNS\15144371 with_28\IN\1740 <e2>acne</e2>_29\NN\14171682 ,_30\,\1740 hirsutism_31\NN\4683453 or_32\CC\3541091 pcos_33\NN\1740 to_34\TO\1740 estimate_35\VB\637259 the_36\DT\1740 risk_37\NN\14541044 of_38\IN\1740 vte_39\NN\1740 associated_40\VBN\628491 with_41\IN\1740 <e1>cpa/ee</e1>_42\NN\1740 ._43\.\1740
D017373_D000152 NONE conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 have_3\VBP\2108377 demonstrated_4\VBN\2137132 an_5\DT\6697703 increased_6\VBN\169651 risk_7\NN\14541044 of_8\IN\1740 vte_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 in_16\IN\13603305 women_17\NNS\9605289 with_18\IN\1740 <e2>acne</e2>_19\NN\14171682 ,_20\,\1740 hirsutism_21\NN\4683453 or_22\CC\3541091 pcos_23\NN\1740 although_24\IN\1740 residual_25\JJ\1740 confounding_26\NN\1740 by_27\IN\1740 indication_28\NN\33020 can_29\MD\3094503 not_30\RB\1740 be_31\VB\836236 excluded_32\VBN\471711 ._33\.\1740
D017373_D006628 NONE background_0\NN\4921011 :_1\:\1740 <e1>cyproterone_2\NN\1740 acetate</e1>_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 cpa/ee_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 <e2>hirsutism</e2>_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D017373_D006628 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 <e1>cpa/ee</e1>_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 <e2>hirsutism</e2>_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D017373_D006628 NONE methods_0\NNS\5616786 :_1\:\1740 using_2\VBG\1156834 the_3\DT\1740 general_4\NNP\10125786 practice_5\NNP\407535 research_6\NNP\633864 database_7\NNP\6634376 we_8\PRP\1740 conducted_9\VBD\2436349 a_10\DT\13649268 cohort_11\NN\8184861 analysis_12\NN\633864 and_13\CC\1740 case-control_14\JJ\1740 study_15\NN\635850 nested_16\VBN\2649830 within_17\IN\1740 a_18\DT\13649268 population_19\NN\7942152 of_20\IN\1740 women_21\NNS\9605289 aged_22\JJ\1740 between_23\IN\1740 15_24\CD\13745420 and_25\CC\1740 39_26\CD\1740 years_27\NNS\15144371 with_28\IN\1740 acne_29\NN\14171682 ,_30\,\1740 <e2>hirsutism</e2>_31\NN\4683453 or_32\CC\3541091 pcos_33\NN\1740 to_34\TO\1740 estimate_35\VB\637259 the_36\DT\1740 risk_37\NN\14541044 of_38\IN\1740 vte_39\NN\1740 associated_40\VBN\628491 with_41\IN\1740 <e1>cpa/ee</e1>_42\NN\1740 ._43\.\1740
D017373_D006628 NONE conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 have_3\VBP\2108377 demonstrated_4\VBN\2137132 an_5\DT\6697703 increased_6\VBN\169651 risk_7\NN\14541044 of_8\IN\1740 vte_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 in_16\IN\13603305 women_17\NNS\9605289 with_18\IN\1740 acne_19\NN\14171682 ,_20\,\1740 <e2>hirsutism</e2>_21\NN\4683453 or_22\CC\3541091 pcos_23\NN\1740 although_24\IN\1740 residual_25\JJ\1740 confounding_26\NN\1740 by_27\IN\1740 indication_28\NN\33020 can_29\MD\3094503 not_30\RB\1740 be_31\VB\836236 excluded_32\VBN\471711 ._33\.\1740
D017373_D011085 NONE background_0\NN\4921011 :_1\:\1740 <e1>cyproterone_2\NN\1740 acetate</e1>_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 cpa/ee_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 <e2>polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome</e2>_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D017373_D011085 NONE background_0\NN\4921011 :_1\:\1740 <e1>cyproterone_2\NN\1740 acetate</e1>_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 cpa/ee_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 <e2>pcos</e2>_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D017373_D011085 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 <e1>cpa/ee</e1>_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 <e2>polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome</e2>_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D017373_D011085 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 <e1>cpa/ee</e1>_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 <e2>pcos</e2>_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D017373_D011085 NONE methods_0\NNS\5616786 :_1\:\1740 using_2\VBG\1156834 the_3\DT\1740 general_4\NNP\10125786 practice_5\NNP\407535 research_6\NNP\633864 database_7\NNP\6634376 we_8\PRP\1740 conducted_9\VBD\2436349 a_10\DT\13649268 cohort_11\NN\8184861 analysis_12\NN\633864 and_13\CC\1740 case-control_14\JJ\1740 study_15\NN\635850 nested_16\VBN\2649830 within_17\IN\1740 a_18\DT\13649268 population_19\NN\7942152 of_20\IN\1740 women_21\NNS\9605289 aged_22\JJ\1740 between_23\IN\1740 15_24\CD\13745420 and_25\CC\1740 39_26\CD\1740 years_27\NNS\15144371 with_28\IN\1740 acne_29\NN\14171682 ,_30\,\1740 hirsutism_31\NN\4683453 or_32\CC\3541091 <e2>pcos</e2>_33\NN\1740 to_34\TO\1740 estimate_35\VB\637259 the_36\DT\1740 risk_37\NN\14541044 of_38\IN\1740 vte_39\NN\1740 associated_40\VBN\628491 with_41\IN\1740 <e1>cpa/ee</e1>_42\NN\1740 ._43\.\1740
D017373_D011085 NONE conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 have_3\VBP\2108377 demonstrated_4\VBN\2137132 an_5\DT\6697703 increased_6\VBN\169651 risk_7\NN\14541044 of_8\IN\1740 vte_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 in_16\IN\13603305 women_17\NNS\9605289 with_18\IN\1740 acne_19\NN\14171682 ,_20\,\1740 hirsutism_21\NN\4683453 or_22\CC\3541091 <e2>pcos</e2>_23\NN\1740 although_24\IN\1740 residual_25\JJ\1740 confounding_26\NN\1740 by_27\IN\1740 indication_28\NN\33020 can_29\MD\3094503 not_30\RB\1740 be_31\VB\836236 excluded_32\VBN\471711 ._33\.\1740
D004997_D000152 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 <e1>ethinyl_6\JJ\1740 estradiol</e1>_7\NN\14749794 (_8\-LRB-\1740 cpa/ee_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 <e2>acne</e2>_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D004997_D000152 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 <e1>cpa/ee</e1>_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 <e2>acne</e2>_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D004997_D000152 NONE methods_0\NNS\5616786 :_1\:\1740 using_2\VBG\1156834 the_3\DT\1740 general_4\NNP\10125786 practice_5\NNP\407535 research_6\NNP\633864 database_7\NNP\6634376 we_8\PRP\1740 conducted_9\VBD\2436349 a_10\DT\13649268 cohort_11\NN\8184861 analysis_12\NN\633864 and_13\CC\1740 case-control_14\JJ\1740 study_15\NN\635850 nested_16\VBN\2649830 within_17\IN\1740 a_18\DT\13649268 population_19\NN\7942152 of_20\IN\1740 women_21\NNS\9605289 aged_22\JJ\1740 between_23\IN\1740 15_24\CD\13745420 and_25\CC\1740 39_26\CD\1740 years_27\NNS\15144371 with_28\IN\1740 <e2>acne</e2>_29\NN\14171682 ,_30\,\1740 hirsutism_31\NN\4683453 or_32\CC\3541091 pcos_33\NN\1740 to_34\TO\1740 estimate_35\VB\637259 the_36\DT\1740 risk_37\NN\14541044 of_38\IN\1740 vte_39\NN\1740 associated_40\VBN\628491 with_41\IN\1740 <e1>cpa/ee</e1>_42\NN\1740 ._43\.\1740
D004997_D000152 NONE conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 have_3\VBP\2108377 demonstrated_4\VBN\2137132 an_5\DT\6697703 increased_6\VBN\169651 risk_7\NN\14541044 of_8\IN\1740 vte_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 in_16\IN\13603305 women_17\NNS\9605289 with_18\IN\1740 <e2>acne</e2>_19\NN\14171682 ,_20\,\1740 hirsutism_21\NN\4683453 or_22\CC\3541091 pcos_23\NN\1740 although_24\IN\1740 residual_25\JJ\1740 confounding_26\NN\1740 by_27\IN\1740 indication_28\NN\33020 can_29\MD\3094503 not_30\RB\1740 be_31\VB\836236 excluded_32\VBN\471711 ._33\.\1740
D004997_D006628 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 <e1>ethinyl_6\JJ\1740 estradiol</e1>_7\NN\14749794 (_8\-LRB-\1740 cpa/ee_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 <e2>hirsutism</e2>_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D004997_D006628 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 <e1>cpa/ee</e1>_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 <e2>hirsutism</e2>_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D004997_D006628 NONE methods_0\NNS\5616786 :_1\:\1740 using_2\VBG\1156834 the_3\DT\1740 general_4\NNP\10125786 practice_5\NNP\407535 research_6\NNP\633864 database_7\NNP\6634376 we_8\PRP\1740 conducted_9\VBD\2436349 a_10\DT\13649268 cohort_11\NN\8184861 analysis_12\NN\633864 and_13\CC\1740 case-control_14\JJ\1740 study_15\NN\635850 nested_16\VBN\2649830 within_17\IN\1740 a_18\DT\13649268 population_19\NN\7942152 of_20\IN\1740 women_21\NNS\9605289 aged_22\JJ\1740 between_23\IN\1740 15_24\CD\13745420 and_25\CC\1740 39_26\CD\1740 years_27\NNS\15144371 with_28\IN\1740 acne_29\NN\14171682 ,_30\,\1740 <e2>hirsutism</e2>_31\NN\4683453 or_32\CC\3541091 pcos_33\NN\1740 to_34\TO\1740 estimate_35\VB\637259 the_36\DT\1740 risk_37\NN\14541044 of_38\IN\1740 vte_39\NN\1740 associated_40\VBN\628491 with_41\IN\1740 <e1>cpa/ee</e1>_42\NN\1740 ._43\.\1740
D004997_D006628 NONE conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 have_3\VBP\2108377 demonstrated_4\VBN\2137132 an_5\DT\6697703 increased_6\VBN\169651 risk_7\NN\14541044 of_8\IN\1740 vte_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 in_16\IN\13603305 women_17\NNS\9605289 with_18\IN\1740 acne_19\NN\14171682 ,_20\,\1740 <e2>hirsutism</e2>_21\NN\4683453 or_22\CC\3541091 pcos_23\NN\1740 although_24\IN\1740 residual_25\JJ\1740 confounding_26\NN\1740 by_27\IN\1740 indication_28\NN\33020 can_29\MD\3094503 not_30\RB\1740 be_31\VB\836236 excluded_32\VBN\471711 ._33\.\1740
D004997_D011085 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 <e1>ethinyl_6\JJ\1740 estradiol</e1>_7\NN\14749794 (_8\-LRB-\1740 cpa/ee_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 <e2>polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome</e2>_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D004997_D011085 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 <e1>ethinyl_6\JJ\1740 estradiol</e1>_7\NN\14749794 (_8\-LRB-\1740 cpa/ee_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 <e2>pcos</e2>_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D004997_D011085 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 <e1>cpa/ee</e1>_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 <e2>polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome</e2>_34\NN\5870365 (_35\-LRB-\1740 pcos_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D004997_D011085 NONE background_0\NN\4921011 :_1\:\1740 cyproterone_2\NN\1740 acetate_3\NN\15010703 combined_4\VBN\2630189 with_5\IN\1740 ethinyl_6\JJ\1740 estradiol_7\NN\14749794 (_8\-LRB-\1740 <e1>cpa/ee</e1>_9\NN\1740 )_10\-RRB-\1740 is_11\VBZ\836236 licensed_12\VBN\803325 in_13\IN\13603305 the_14\DT\1740 uk_15\NNP\1740 for_16\IN\1740 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 women_20\NNS\9605289 with_21\IN\1740 acne_22\NN\14171682 and_23\CC\1740 hirsutism_24\NN\4683453 and_25\CC\1740 is_26\VBZ\836236 also_27\RB\1740 a_28\DT\13649268 treatment_29\NN\654885 option_30\NN\6480506 for_31\IN\1740 polycystic_32\JJ\1740 ovary_33\JJ\1740 syndrome_34\NN\5870365 (_35\-LRB-\1740 <e2>pcos</e2>_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D004997_D011085 NONE methods_0\NNS\5616786 :_1\:\1740 using_2\VBG\1156834 the_3\DT\1740 general_4\NNP\10125786 practice_5\NNP\407535 research_6\NNP\633864 database_7\NNP\6634376 we_8\PRP\1740 conducted_9\VBD\2436349 a_10\DT\13649268 cohort_11\NN\8184861 analysis_12\NN\633864 and_13\CC\1740 case-control_14\JJ\1740 study_15\NN\635850 nested_16\VBN\2649830 within_17\IN\1740 a_18\DT\13649268 population_19\NN\7942152 of_20\IN\1740 women_21\NNS\9605289 aged_22\JJ\1740 between_23\IN\1740 15_24\CD\13745420 and_25\CC\1740 39_26\CD\1740 years_27\NNS\15144371 with_28\IN\1740 acne_29\NN\14171682 ,_30\,\1740 hirsutism_31\NN\4683453 or_32\CC\3541091 <e2>pcos</e2>_33\NN\1740 to_34\TO\1740 estimate_35\VB\637259 the_36\DT\1740 risk_37\NN\14541044 of_38\IN\1740 vte_39\NN\1740 associated_40\VBN\628491 with_41\IN\1740 <e1>cpa/ee</e1>_42\NN\1740 ._43\.\1740
D004997_D011085 NONE conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 have_3\VBP\2108377 demonstrated_4\VBN\2137132 an_5\DT\6697703 increased_6\VBN\169651 risk_7\NN\14541044 of_8\IN\1740 vte_9\NN\1740 associated_10\VBN\628491 with_11\IN\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>cpa/ee</e1>_15\NN\1740 in_16\IN\13603305 women_17\NNS\9605289 with_18\IN\1740 acne_19\NN\14171682 ,_20\,\1740 hirsutism_21\NN\4683453 or_22\CC\3541091 <e2>pcos</e2>_23\NN\1740 although_24\IN\1740 residual_25\JJ\1740 confounding_26\NN\1740 by_27\IN\1740 indication_28\NN\33020 can_29\MD\3094503 not_30\RB\1740 be_31\VB\836236 excluded_32\VBN\471711 ._33\.\1740
D003276_D054556 NONE previous_0\JJ\1740 studies_1\NNS\635850 have_2\VBP\2108377 demonstrated_3\VBN\2137132 an_4\DT\6697703 increased_5\VBN\169651 risk_6\NN\14541044 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 cpa/ee_15\NN\1740 compared_16\VBN\644583 with_17\IN\1740 conventional_18\JJ\1740 combined_19\JJ\1740 <e1>oral_20\JJ\1740 contraceptives</e1>_21\NNS\3183080 (_22\-LRB-\1740 cocs_23\NNS\1740 )_24\-RRB-\1740 ._25\.\1740
D003276_D054556 NONE previous_0\JJ\1740 studies_1\NNS\635850 have_2\VBP\2108377 demonstrated_3\VBN\2137132 an_4\DT\6697703 increased_5\VBN\169651 risk_6\NN\14541044 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 associated_13\VBN\628491 with_14\IN\1740 cpa/ee_15\NN\1740 compared_16\VBN\644583 with_17\IN\1740 conventional_18\JJ\1740 combined_19\JJ\1740 <e1>oral_20\JJ\1740 contraceptives</e1>_21\NNS\3183080 (_22\-LRB-\1740 cocs_23\NNS\1740 )_24\-RRB-\1740 ._25\.\1740
12483326
D016190_D005128 NONE severe_0\JJ\1740 <e2>ocular_1\JJ\1740 and_2\CC\1740 orbital_3\JJ\1740 toxicity</e2>_4\NN\13576101 after_5\IN\1740 intracarotid_6\NN\1740 injection_7\NN\320852 of_8\IN\1740 <e1>carboplatin</e1>_9\NN\1740 for_10\IN\1740 recurrent_11\JJ\1740 glioblastomas_12\NNS\14236743 ._13\.\1740
D016190_D005128 NONE generally_0\RB\1740 ,_1\,\1740 <e1>carboplatin</e1>_2\NN\1740 is_3\VBZ\836236 said_4\VBN\940384 to_5\TO\1740 have_6\VB\2108377 milder_7\NN\1740 side_8\NN\8630039 effects_9\NNS\13245626 than_10\IN\1740 cisplatin_11\NN\1740 ,_12\,\1740 whose_13\WP$\1740 <e2>ocular_14\JJ\1740 and_15\CC\1740 orbital_16\JJ\1740 toxicity</e2>_17\NN\13576101 are_18\VBP\836236 well_19\RB\1740 known_20\JJ\1740 ._21\.\1740
D016190_D005128 NONE however_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 experienced_3\VBD\2108377 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 severe_7\JJ\1740 <e2>ocular_8\JJ\1740 and_9\CC\1740 orbital_10\JJ\1740 toxicity</e2>_11\NN\13576101 after_12\IN\1740 intracarotid_13\NN\1740 injection_14\NN\320852 of_15\IN\1740 <e1>carboplatin</e1>_16\NN\1740 ,_17\,\1740 which_18\WDT\1740 is_19\VBZ\836236 infrequently_20\RB\1740 reported_21\VBN\831651 ._22\.\1740
D016190_D005128 NONE conclusion_0\NN\5837957 :_1\:\1740 when_2\WRB\1740 performing_3\VBG\2367363 intracarotid_4\NN\1740 injection_5\NN\320852 of_6\IN\1740 <e1>carboplatin</e1>_7\NN\1740 ,_8\,\1740 we_9\PRP\1740 must_10\MD\9367203 be_11\VB\836236 aware_12\JJ\1740 of_13\IN\1740 its_14\PRP$\6125041 potentially_15\RB\1740 blinding_16\VBG\126264 <e2>ocular_17\JJ\1740 toxicity</e2>_18\NN\13576101 ._19\.\1740
D016190_D009916 NONE severe_0\JJ\1740 <e2>ocular_1\JJ\1740 and_2\CC\1740 orbital_3\JJ\1740 toxicity</e2>_4\NN\13576101 after_5\IN\1740 intracarotid_6\NN\1740 injection_7\NN\320852 of_8\IN\1740 <e1>carboplatin</e1>_9\NN\1740 for_10\IN\1740 recurrent_11\JJ\1740 glioblastomas_12\NNS\14236743 ._13\.\1740
D016190_D009916 NONE generally_0\RB\1740 ,_1\,\1740 <e1>carboplatin</e1>_2\NN\1740 is_3\VBZ\836236 said_4\VBN\940384 to_5\TO\1740 have_6\VB\2108377 milder_7\NN\1740 side_8\NN\8630039 effects_9\NNS\13245626 than_10\IN\1740 cisplatin_11\NN\1740 ,_12\,\1740 whose_13\WP$\1740 <e2>ocular_14\JJ\1740 and_15\CC\1740 orbital_16\JJ\1740 toxicity</e2>_17\NN\13576101 are_18\VBP\836236 well_19\RB\1740 known_20\JJ\1740 ._21\.\1740
D016190_D009916 NONE however_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 experienced_3\VBD\2108377 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 severe_7\JJ\1740 <e2>ocular_8\JJ\1740 and_9\CC\1740 orbital_10\JJ\1740 toxicity</e2>_11\NN\13576101 after_12\IN\1740 intracarotid_13\NN\1740 injection_14\NN\320852 of_15\IN\1740 <e1>carboplatin</e1>_16\NN\1740 ,_17\,\1740 which_18\WDT\1740 is_19\VBZ\836236 infrequently_20\RB\1740 reported_21\VBN\831651 ._22\.\1740
D016190_D005909 NONE severe_0\JJ\1740 ocular_1\JJ\1740 and_2\CC\1740 orbital_3\JJ\1740 toxicity_4\NN\13576101 after_5\IN\1740 intracarotid_6\NN\1740 injection_7\NN\320852 of_8\IN\1740 <e1>carboplatin</e1>_9\NN\1740 for_10\IN\1740 recurrent_11\JJ\1740 <e2>glioblastomas</e2>_12\NNS\14236743 ._13\.\1740
D016190_D005909 NONE case_0\NN\7283608 :_1\:\1740 a_2\DT\13649268 58-year-old_3\JJ\1740 man_4\NN\9605289 received_5\VBD\2210855 an_6\DT\6697703 intracarotid_7\NN\1740 injection_8\NN\320852 of_9\IN\1740 <e1>carboplatin</e1>_10\NN\1740 for_11\IN\1740 recurrent_12\JJ\1740 <e2>glioblastomas</e2>_13\NNS\14236743 in_14\IN\13603305 his_15\PRP$\1740 left_16\JJ\1740 temporal_17\JJ\1740 lobe_18\NN\5220461 ._19\.\1740
D002945_D005128 NONE generally_0\RB\1740 ,_1\,\1740 carboplatin_2\NN\1740 is_3\VBZ\836236 said_4\VBN\940384 to_5\TO\1740 have_6\VB\2108377 milder_7\NN\1740 side_8\NN\8630039 effects_9\NNS\13245626 than_10\IN\1740 <e1>cisplatin</e1>_11\NN\1740 ,_12\,\1740 whose_13\WP$\1740 <e2>ocular_14\JJ\1740 and_15\CC\1740 orbital_16\JJ\1740 toxicity</e2>_17\NN\13576101 are_18\VBP\836236 well_19\RB\1740 known_20\JJ\1740 ._21\.\1740
D002945_D009916 NONE generally_0\RB\1740 ,_1\,\1740 carboplatin_2\NN\1740 is_3\VBZ\836236 said_4\VBN\940384 to_5\TO\1740 have_6\VB\2108377 milder_7\NN\1740 side_8\NN\8630039 effects_9\NNS\13245626 than_10\IN\1740 <e1>cisplatin</e1>_11\NN\1740 ,_12\,\1740 whose_13\WP$\1740 <e2>ocular_14\JJ\1740 and_15\CC\1740 orbital_16\JJ\1740 toxicity</e2>_17\NN\13576101 are_18\VBP\836236 well_19\RB\1740 known_20\JJ\1740 ._21\.\1740
D016190_D064420 NONE various_0\JJ\1740 ocular_1\JJ\1740 symptoms_2\NNS\5823932 and_3\CC\1740 findings_4\NNS\7951464 caused_5\VBN\1617192 by_6\IN\1740 <e1>carboplatin</e1>_7\NN\1740 <e2>toxicity</e2>_8\NN\13576101 were_9\VBD\836236 seen_10\VBN\2106506 ._11\.\1740
7292072
D003891_D017180 CID variant_0\JJ\1740 <e2>ventricular_1\NN\1740 tachycardia</e2>_2\NN\14110674 in_3\IN\13603305 <e1>desipramine</e1>_4\NN\4482543 toxicity_5\NN\13576101 ._6\.\1740
D003891_D017180 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 variant_5\JJ\1740 <e2>ventricular_6\JJ\1740 tachycardia</e2>_7\NN\14110674 induced_8\VBN\1627355 by_9\IN\1740 <e1>desipramine</e1>_10\NN\4482543 toxicity_11\NN\13576101 ._12\.\1740
D003891_D064420 NONE variant_0\JJ\1740 ventricular_1\NN\1740 tachycardia_2\NN\14110674 in_3\IN\13603305 <e1>desipramine</e1>_4\NN\4482543 <e2>toxicity</e2>_5\NN\13576101 ._6\.\1740
D003891_D064420 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 variant_5\JJ\1740 ventricular_6\JJ\1740 tachycardia_7\NN\14110674 induced_8\VBN\1627355 by_9\IN\1740 <e1>desipramine</e1>_10\NN\4482543 <e2>toxicity</e2>_11\NN\13576101 ._12\.\1740
9401499
D013988_D000741 CID <e1>ticlopidine-induced</e1>_0\JJ\1740 <e2>aplastic_1\JJ\1740 anemia</e2>_2\NN\14189204 :_3\:\1740 report_4\NN\6470073 of_5\IN\1740 three_6\CD\13741022 chinese_7\JJ\1740 patients_8\NNS\9898892 and_9\CC\1740 review_10\NN\5733583 of_11\IN\1740 the_12\DT\1740 literature_13\NN\6362953 ._14\.\1740
D013988_D000741 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 three_4\CD\13741022 chinese_5\JJ\1740 patients_6\NNS\9898892 with_7\IN\1740 <e1>ticlopidine-induced</e1>_8\JJ\1740 <e2>aplastic_9\JJ\1740 anemia</e2>_10\NN\14189204 were_11\VBD\836236 reported_12\VBN\831651 and_13\CC\1740 another_14\DT\1740 13_15\CD\13745420 patients_16\NNS\9898892 in_17\IN\13603305 the_18\DT\1740 english_19\NNP\6946823 literature_20\NN\6362953 were_21\VBD\836236 reviewed_22\VBN\644583 ._23\.\1740
D013988_D000741 CID treatment_0\NN\654885 for_1\IN\1740 <e1>ticlopidine-induced</e1>_2\JJ\1740 <e2>aplastic_3\JJ\1740 anemia</e2>_4\NN\14189204 with_5\IN\1740 colony-stimulating_6\JJ\1740 factors_7\NNS\7326557 seemed_8\VBD\2604760 to_9\TO\1740 have_10\VB\2108377 little_11\JJ\1740 effect_12\NN\34213 ._13\.\1740
D013988_D000380 CID <e2>agranulocytosis</e2>_0\NN\14189204 occurred_1\VBD\2623529 3_2\CD\13741022 -_3\SYM\1740 20_4\CD\13745420 weeks_5\NNS\15113229 after_6\IN\1740 initiation_7\NN\7450842 of_8\IN\1740 <e1>ticlopidine</e1>_9\NN\1740 ,_10\,\1740 so_11\RB\1740 frequent_12\JJ\1740 examination_13\NN\633864 of_14\IN\1740 white_15\JJ\1740 cell_16\NN\3080309 count_17\NN\13582013 during_18\IN\1740 treatment_19\NN\654885 is_20\VBZ\836236 recommended_21\VBN\875394 ._22\.\1740
9195768
D018170_D010292 CID <e2>atypical_0\JJ\1740 sensations</e2>_1\NNS\5708432 following_2\VBG\1835496 the_3\DT\1740 use_4\NN\407535 of_5\IN\1740 subcutaneous_6\JJ\1740 <e1>sumatriptan</e1>_7\NN\1740 are_8\VBP\836236 common_9\JJ\1740 ,_10\,\1740 but_11\CC\1740 of_12\IN\1740 uncertain_13\JJ\1740 origin_14\NN\8620061 ._15\.\1740
17147461
D020123_D011507 CID <e1>sirolimus-associated</e1>_0\JJ\1740 <e2>proteinuria</e2>_1\NN\14299637 and_2\CC\1740 renal_3\JJ\1740 dysfunction_4\NN\14204950 ._5\.\1740
D020123_D011507 CID however_0\RB\1740 ,_1\,\1740 clinical_2\JJ\1740 reports_3\NNS\6470073 suggest_4\VBP\1010118 that_5\IN\1740 ,_6\,\1740 under_7\IN\1740 some_8\DT\1740 circumstances_9\NNS\13920429 ,_10\,\1740 <e1>sirolimus</e1>_11\NN\1740 is_12\VBZ\836236 associated_13\VBN\628491 with_14\IN\1740 <e2>proteinuria</e2>_15\NN\14299637 and_16\CC\1740 acute_17\JJ\1740 renal_18\JJ\1740 dysfunction_19\NN\14204950 ._20\.\1740
D020123_D011507 CID the_0\DT\1740 mechanisms_1\NNS\13446390 of_2\IN\1740 <e1>sirolimus-associated</e1>_3\JJ\1740 <e2>proteinuria</e2>_4\NN\14299637 are_5\VBP\836236 multifactorial_6\JJ\1740 and_7\CC\1740 may_8\MD\15209706 be_9\VB\836236 due_10\JJ\1740 to_11\TO\1740 an_12\DT\6697703 increase_13\NN\13576355 in_14\IN\13603305 glomerular_15\JJ\1740 capillary_16\JJ\1740 pressure_17\NN\11419404 following_18\VBG\1835496 calcineurin_19\NN\1740 inhibitor_20\NN\20090 withdrawal_21\NN\7206096 ._22\.\1740
D020123_D011507 CID although_0\IN\1740 these_1\DT\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 occur_4\VBP\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 their_9\PRP$\1740 occurrence_10\NN\29378 could_11\MD\1740 be_12\VB\836236 minimised_13\VBN\831651 by_14\IN\1740 knowledge_15\NN\23100 of_16\IN\1740 the_17\DT\1740 molecular_18\JJ\1740 effects_19\NNS\13245626 of_20\IN\1740 <e1>sirolimus</e1>_21\NN\1740 on_22\IN\1740 the_23\DT\1740 kidney_24\NN\5333259 ,_25\,\1740 the_26\DT\1740 use_27\NN\407535 of_28\IN\1740 sirolimus_29\NN\1740 in_30\IN\13603305 appropriate_31\JJ\1740 patient_32\NN\9898892 populations_33\NNS\7942152 ,_34\,\1740 close_35\JJ\1740 monitoring_36\NN\879759 of_37\IN\1740 <e2>proteinuria</e2>_38\NN\14299637 and_39\CC\1740 renal_40\JJ\1740 function_41\NN\13783581 ,_42\,\1740 use_43\NN\407535 of_44\IN\1740 angiotensin-converting_45\JJ\1740 enzyme_46\NN\14723628 inhibitors_47\NNS\20090 or_48\CC\3541091 angiotensin_49\NN\4522421 ii_50\CD\13741022 receptor_51\NN\5225602 blockers_52\NNS\10101634 if_53\IN\1740 proteinuria_54\NN\14299637 occurs_55\VBZ\2623529 and_56\CC\1740 withdrawal_57\NN\7206096 if_58\IN\1740 needed_59\VBN\2604760 ._60\.\1740
D020123_D011507 CID although_0\IN\1740 these_1\DT\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 occur_4\VBP\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 their_9\PRP$\1740 occurrence_10\NN\29378 could_11\MD\1740 be_12\VB\836236 minimised_13\VBN\831651 by_14\IN\1740 knowledge_15\NN\23100 of_16\IN\1740 the_17\DT\1740 molecular_18\JJ\1740 effects_19\NNS\13245626 of_20\IN\1740 <e1>sirolimus</e1>_21\NN\1740 on_22\IN\1740 the_23\DT\1740 kidney_24\NN\5333259 ,_25\,\1740 the_26\DT\1740 use_27\NN\407535 of_28\IN\1740 sirolimus_29\NN\1740 in_30\IN\13603305 appropriate_31\JJ\1740 patient_32\NN\9898892 populations_33\NNS\7942152 ,_34\,\1740 close_35\JJ\1740 monitoring_36\NN\879759 of_37\IN\1740 proteinuria_38\NN\14299637 and_39\CC\1740 renal_40\JJ\1740 function_41\NN\13783581 ,_42\,\1740 use_43\NN\407535 of_44\IN\1740 angiotensin-converting_45\JJ\1740 enzyme_46\NN\14723628 inhibitors_47\NNS\20090 or_48\CC\3541091 angiotensin_49\NN\4522421 ii_50\CD\13741022 receptor_51\NN\5225602 blockers_52\NNS\10101634 if_53\IN\1740 <e2>proteinuria</e2>_54\NN\14299637 occurs_55\VBZ\2623529 and_56\CC\1740 withdrawal_57\NN\7206096 if_58\IN\1740 needed_59\VBN\2604760 ._60\.\1740
D020123_D011507 CID although_0\IN\1740 these_1\DT\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 occur_4\VBP\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 their_9\PRP$\1740 occurrence_10\NN\29378 could_11\MD\1740 be_12\VB\836236 minimised_13\VBN\831651 by_14\IN\1740 knowledge_15\NN\23100 of_16\IN\1740 the_17\DT\1740 molecular_18\JJ\1740 effects_19\NNS\13245626 of_20\IN\1740 sirolimus_21\NN\1740 on_22\IN\1740 the_23\DT\1740 kidney_24\NN\5333259 ,_25\,\1740 the_26\DT\1740 use_27\NN\407535 of_28\IN\1740 <e1>sirolimus</e1>_29\NN\1740 in_30\IN\13603305 appropriate_31\JJ\1740 patient_32\NN\9898892 populations_33\NNS\7942152 ,_34\,\1740 close_35\JJ\1740 monitoring_36\NN\879759 of_37\IN\1740 <e2>proteinuria</e2>_38\NN\14299637 and_39\CC\1740 renal_40\JJ\1740 function_41\NN\13783581 ,_42\,\1740 use_43\NN\407535 of_44\IN\1740 angiotensin-converting_45\JJ\1740 enzyme_46\NN\14723628 inhibitors_47\NNS\20090 or_48\CC\3541091 angiotensin_49\NN\4522421 ii_50\CD\13741022 receptor_51\NN\5225602 blockers_52\NNS\10101634 if_53\IN\1740 proteinuria_54\NN\14299637 occurs_55\VBZ\2623529 and_56\CC\1740 withdrawal_57\NN\7206096 if_58\IN\1740 needed_59\VBN\2604760 ._60\.\1740
D020123_D011507 CID although_0\IN\1740 these_1\DT\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 occur_4\VBP\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 their_9\PRP$\1740 occurrence_10\NN\29378 could_11\MD\1740 be_12\VB\836236 minimised_13\VBN\831651 by_14\IN\1740 knowledge_15\NN\23100 of_16\IN\1740 the_17\DT\1740 molecular_18\JJ\1740 effects_19\NNS\13245626 of_20\IN\1740 sirolimus_21\NN\1740 on_22\IN\1740 the_23\DT\1740 kidney_24\NN\5333259 ,_25\,\1740 the_26\DT\1740 use_27\NN\407535 of_28\IN\1740 <e1>sirolimus</e1>_29\NN\1740 in_30\IN\13603305 appropriate_31\JJ\1740 patient_32\NN\9898892 populations_33\NNS\7942152 ,_34\,\1740 close_35\JJ\1740 monitoring_36\NN\879759 of_37\IN\1740 proteinuria_38\NN\14299637 and_39\CC\1740 renal_40\JJ\1740 function_41\NN\13783581 ,_42\,\1740 use_43\NN\407535 of_44\IN\1740 angiotensin-converting_45\JJ\1740 enzyme_46\NN\14723628 inhibitors_47\NNS\20090 or_48\CC\3541091 angiotensin_49\NN\4522421 ii_50\CD\13741022 receptor_51\NN\5225602 blockers_52\NNS\10101634 if_53\IN\1740 <e2>proteinuria</e2>_54\NN\14299637 occurs_55\VBZ\2623529 and_56\CC\1740 withdrawal_57\NN\7206096 if_58\IN\1740 needed_59\VBN\2604760 ._60\.\1740
D020123_D007674 CID <e1>sirolimus-associated</e1>_0\JJ\1740 proteinuria_1\NN\14299637 and_2\CC\1740 <e2>renal_3\JJ\1740 dysfunction</e2>_4\NN\14204950 ._5\.\1740
D020123_D007674 CID <e1>sirolimus</e1>_0\NN\1740 represents_1\VBZ\2664769 a_2\DT\13649268 major_3\JJ\1740 therapeutic_4\JJ\1740 advance_5\NN\7311115 in_6\IN\13603305 the_7\DT\1740 prevention_8\NN\1073995 of_9\IN\1740 acute_10\JJ\1740 renal_11\JJ\1740 allograft_12\NN\5582859 rejection_13\NN\30358 and_14\CC\1740 chronic_15\JJ\1740 allograft_16\NN\5582859 <e2>nephropathy</e2>_17\RB\1740 ._18\.\1740
D020123_D007674 CID because_0\IN\1740 <e1>sirolimus</e1>_1\NN\1740 does_2\VBZ\1640855 not_3\RB\1740 share_4\VB\2660631 the_5\DT\1740 vasomotor_6\NN\1740 renal_7\JJ\1740 adverse_8\JJ\1740 effects_9\NNS\13245626 exhibited_10\VBN\2632167 by_11\IN\1740 calcineurin_12\NN\1740 inhibitors_13\NNS\20090 ,_14\,\1740 it_15\PRP\6125041 has_16\VBZ\2108377 been_17\VBN\836236 designated_18\VBN\2475922 a_19\DT\13649268 '_20\``\1740 <e2>non-nephrotoxic</e2>_21\JJ\1740 drug_22\NN\14778436 '_23\''\1740 ._24\.\1740
D020123_D058186 NONE however_0\RB\1740 ,_1\,\1740 clinical_2\JJ\1740 reports_3\NNS\6470073 suggest_4\VBP\1010118 that_5\IN\1740 ,_6\,\1740 under_7\IN\1740 some_8\DT\1740 circumstances_9\NNS\13920429 ,_10\,\1740 <e1>sirolimus</e1>_11\NN\1740 is_12\VBZ\836236 associated_13\VBN\628491 with_14\IN\1740 proteinuria_15\NN\14299637 and_16\CC\1740 <e2>acute_17\JJ\1740 renal_18\JJ\1740 dysfunction</e2>_19\NN\14204950 ._20\.\1740
D020123_D058186 NONE the_0\DT\1740 <e2>acute_1\JJ\1740 renal_2\JJ\1740 dysfunction</e2>_3\NN\14204950 associated_4\VBN\628491 with_5\IN\1740 <e1>sirolimus</e1>_6\NN\1740 (_7\-LRB-\1740 such_8\JJ\1740 as_9\IN\14622893 in_10\IN\13603305 delayed_11\VBN\439958 graft_12\NN\5267548 function_13\NN\13783581 )_14\-RRB-\1740 may_15\MD\15209706 be_16\VB\836236 due_17\JJ\1740 to_18\TO\1740 suppression_19\NN\13489037 of_20\IN\1740 compensatory_21\JJ\1740 renal_22\JJ\1740 cell_23\NN\3080309 proliferation_24\NN\13489037 and_25\CC\1740 survival/repair_26\JJ\1740 processes_27\NNS\407535 ._28\.\1740
D000809_D011507 NONE although_0\IN\1740 these_1\DT\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 occur_4\VBP\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 their_9\PRP$\1740 occurrence_10\NN\29378 could_11\MD\1740 be_12\VB\836236 minimised_13\VBN\831651 by_14\IN\1740 knowledge_15\NN\23100 of_16\IN\1740 the_17\DT\1740 molecular_18\JJ\1740 effects_19\NNS\13245626 of_20\IN\1740 sirolimus_21\NN\1740 on_22\IN\1740 the_23\DT\1740 kidney_24\NN\5333259 ,_25\,\1740 the_26\DT\1740 use_27\NN\407535 of_28\IN\1740 sirolimus_29\NN\1740 in_30\IN\13603305 appropriate_31\JJ\1740 patient_32\NN\9898892 populations_33\NNS\7942152 ,_34\,\1740 close_35\JJ\1740 monitoring_36\NN\879759 of_37\IN\1740 <e2>proteinuria</e2>_38\NN\14299637 and_39\CC\1740 renal_40\JJ\1740 function_41\NN\13783581 ,_42\,\1740 use_43\NN\407535 of_44\IN\1740 <e1>angiotensin-converting</e1>_45\JJ\1740 enzyme_46\NN\14723628 inhibitors_47\NNS\20090 or_48\CC\3541091 angiotensin_49\NN\4522421 ii_50\CD\13741022 receptor_51\NN\5225602 blockers_52\NNS\10101634 if_53\IN\1740 proteinuria_54\NN\14299637 occurs_55\VBZ\2623529 and_56\CC\1740 withdrawal_57\NN\7206096 if_58\IN\1740 needed_59\VBN\2604760 ._60\.\1740
D000809_D011507 NONE although_0\IN\1740 these_1\DT\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 occur_4\VBP\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 their_9\PRP$\1740 occurrence_10\NN\29378 could_11\MD\1740 be_12\VB\836236 minimised_13\VBN\831651 by_14\IN\1740 knowledge_15\NN\23100 of_16\IN\1740 the_17\DT\1740 molecular_18\JJ\1740 effects_19\NNS\13245626 of_20\IN\1740 sirolimus_21\NN\1740 on_22\IN\1740 the_23\DT\1740 kidney_24\NN\5333259 ,_25\,\1740 the_26\DT\1740 use_27\NN\407535 of_28\IN\1740 sirolimus_29\NN\1740 in_30\IN\13603305 appropriate_31\JJ\1740 patient_32\NN\9898892 populations_33\NNS\7942152 ,_34\,\1740 close_35\JJ\1740 monitoring_36\NN\879759 of_37\IN\1740 proteinuria_38\NN\14299637 and_39\CC\1740 renal_40\JJ\1740 function_41\NN\13783581 ,_42\,\1740 use_43\NN\407535 of_44\IN\1740 <e1>angiotensin-converting</e1>_45\JJ\1740 enzyme_46\NN\14723628 inhibitors_47\NNS\20090 or_48\CC\3541091 angiotensin_49\NN\4522421 ii_50\CD\13741022 receptor_51\NN\5225602 blockers_52\NNS\10101634 if_53\IN\1740 <e2>proteinuria</e2>_54\NN\14299637 occurs_55\VBZ\2623529 and_56\CC\1740 withdrawal_57\NN\7206096 if_58\IN\1740 needed_59\VBN\2604760 ._60\.\1740
D000804_D011507 NONE although_0\IN\1740 these_1\DT\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 occur_4\VBP\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 their_9\PRP$\1740 occurrence_10\NN\29378 could_11\MD\1740 be_12\VB\836236 minimised_13\VBN\831651 by_14\IN\1740 knowledge_15\NN\23100 of_16\IN\1740 the_17\DT\1740 molecular_18\JJ\1740 effects_19\NNS\13245626 of_20\IN\1740 sirolimus_21\NN\1740 on_22\IN\1740 the_23\DT\1740 kidney_24\NN\5333259 ,_25\,\1740 the_26\DT\1740 use_27\NN\407535 of_28\IN\1740 sirolimus_29\NN\1740 in_30\IN\13603305 appropriate_31\JJ\1740 patient_32\NN\9898892 populations_33\NNS\7942152 ,_34\,\1740 close_35\JJ\1740 monitoring_36\NN\879759 of_37\IN\1740 <e2>proteinuria</e2>_38\NN\14299637 and_39\CC\1740 renal_40\JJ\1740 function_41\NN\13783581 ,_42\,\1740 use_43\NN\407535 of_44\IN\1740 angiotensin-converting_45\JJ\1740 enzyme_46\NN\14723628 inhibitors_47\NNS\20090 or_48\CC\3541091 <e1>angiotensin_49\NN\4522421 ii</e1>_50\CD\13741022 receptor_51\NN\5225602 blockers_52\NNS\10101634 if_53\IN\1740 proteinuria_54\NN\14299637 occurs_55\VBZ\2623529 and_56\CC\1740 withdrawal_57\NN\7206096 if_58\IN\1740 needed_59\VBN\2604760 ._60\.\1740
D000804_D011507 NONE although_0\IN\1740 these_1\DT\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 occur_4\VBP\2623529 in_5\IN\13603305 some_6\DT\1740 patients_7\NNS\9898892 ,_8\,\1740 their_9\PRP$\1740 occurrence_10\NN\29378 could_11\MD\1740 be_12\VB\836236 minimised_13\VBN\831651 by_14\IN\1740 knowledge_15\NN\23100 of_16\IN\1740 the_17\DT\1740 molecular_18\JJ\1740 effects_19\NNS\13245626 of_20\IN\1740 sirolimus_21\NN\1740 on_22\IN\1740 the_23\DT\1740 kidney_24\NN\5333259 ,_25\,\1740 the_26\DT\1740 use_27\NN\407535 of_28\IN\1740 sirolimus_29\NN\1740 in_30\IN\13603305 appropriate_31\JJ\1740 patient_32\NN\9898892 populations_33\NNS\7942152 ,_34\,\1740 close_35\JJ\1740 monitoring_36\NN\879759 of_37\IN\1740 proteinuria_38\NN\14299637 and_39\CC\1740 renal_40\JJ\1740 function_41\NN\13783581 ,_42\,\1740 use_43\NN\407535 of_44\IN\1740 angiotensin-converting_45\JJ\1740 enzyme_46\NN\14723628 inhibitors_47\NNS\20090 or_48\CC\3541091 <e1>angiotensin_49\NN\4522421 ii</e1>_50\CD\13741022 receptor_51\NN\5225602 blockers_52\NNS\10101634 if_53\IN\1740 <e2>proteinuria</e2>_54\NN\14299637 occurs_55\VBZ\2623529 and_56\CC\1740 withdrawal_57\NN\7206096 if_58\IN\1740 needed_59\VBN\2604760 ._60\.\1740
12464714
C093622_D008881 NONE crossover_0\NN\13526110 comparison_1\NN\635850 of_2\IN\1740 efficacy_3\NN\5199286 and_4\CC\1740 preference_5\NN\7497473 for_6\IN\1740 <e1>rizatriptan</e1>_7\JJ\1740 10_8\CD\13745420 mg_9\NN\13717155 versus_10\CC\1740 ergotamine/caffeine_11\NN\1740 in_12\IN\13603305 <e2>migraine</e2>_13\NN\14326607 ._14\.\1740
C093622_D008881 NONE <e1>rizatriptan</e1>_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 selective_3\JJ\1740 5-ht(1b/1d_4\NN\1740 )_5\-RRB-\1740 receptor_6\NN\5225602 agonist_7\NN\9613191 with_8\IN\1740 rapid_9\JJ\1740 oral_10\JJ\1740 absorption_11\NN\13558490 and_12\CC\1740 early_13\JJ\1740 onset_14\NN\7325190 of_15\IN\1740 action_16\NN\30358 in_17\IN\13603305 the_18\DT\1740 acute_19\JJ\1740 treatment_20\NN\654885 of_21\IN\1740 <e2>migraine</e2>_22\NN\14326607 ._23\.\1740
C093622_D008881 NONE this_0\DT\1740 randomized_1\JJ\1740 double-_2\NN\1740 blind_3\JJ\1740 crossover_4\NN\13526110 outpatient_5\JJ\1740 study_6\NN\635850 assessed_7\VBD\670261 the_8\DT\1740 preference_9\NN\7497473 for_10\IN\1740 1_11\CD\13741022 <e1>rizatriptan</e1>_12\JJ\1740 10_13\CD\13745420 mg_14\NN\13717155 tablet_15\NN\4233405 to_16\TO\1740 2_17\CD\13741022 ergotamine_18\NN\14712692 1_19\CD\13741022 mg/caffeine_20\NN\1740 100_21\CD\13745420 mg_22\NN\13717155 tablets_23\NNS\4233405 in_24\IN\13603305 439_25\CD\1740 patients_26\NNS\9898892 treating_27\VBG\2376958 a_28\DT\13649268 single_29\JJ\1740 <e2>migraine</e2>_30\NN\14326607 attack_31\NN\955060 with_32\IN\1740 each_33\DT\1740 therapy_34\NN\657604 ._35\.\1740
D004878_D008881 NONE crossover_0\NN\13526110 comparison_1\NN\635850 of_2\IN\1740 efficacy_3\NN\5199286 and_4\CC\1740 preference_5\NN\7497473 for_6\IN\1740 rizatriptan_7\JJ\1740 10_8\CD\13745420 mg_9\NN\13717155 versus_10\CC\1740 <e1>ergotamine/caffeine</e1>_11\NN\1740 in_12\IN\13603305 <e2>migraine</e2>_13\NN\14326607 ._14\.\1740
D004878_D008881 NONE this_0\DT\1740 randomized_1\JJ\1740 double-_2\NN\1740 blind_3\JJ\1740 crossover_4\NN\13526110 outpatient_5\JJ\1740 study_6\NN\635850 assessed_7\VBD\670261 the_8\DT\1740 preference_9\NN\7497473 for_10\IN\1740 1_11\CD\13741022 rizatriptan_12\JJ\1740 10_13\CD\13745420 mg_14\NN\13717155 tablet_15\NN\4233405 to_16\TO\1740 2_17\CD\13741022 <e1>ergotamine</e1>_18\NN\14712692 1_19\CD\13741022 mg/caffeine_20\NN\1740 100_21\CD\13745420 mg_22\NN\13717155 tablets_23\NNS\4233405 in_24\IN\13603305 439_25\CD\1740 patients_26\NNS\9898892 treating_27\VBG\2376958 a_28\DT\13649268 single_29\JJ\1740 <e2>migraine</e2>_30\NN\14326607 attack_31\NN\955060 with_32\IN\1740 each_33\DT\1740 therapy_34\NN\657604 ._35\.\1740
D002110_D008881 NONE crossover_0\NN\13526110 comparison_1\NN\635850 of_2\IN\1740 efficacy_3\NN\5199286 and_4\CC\1740 preference_5\NN\7497473 for_6\IN\1740 rizatriptan_7\JJ\1740 10_8\CD\13745420 mg_9\NN\13717155 versus_10\CC\1740 <e1>ergotamine/caffeine</e1>_11\NN\1740 in_12\IN\13603305 <e2>migraine</e2>_13\NN\14326607 ._14\.\1740
D002110_D008881 NONE this_0\DT\1740 randomized_1\JJ\1740 double-_2\NN\1740 blind_3\JJ\1740 crossover_4\NN\13526110 outpatient_5\JJ\1740 study_6\NN\635850 assessed_7\VBD\670261 the_8\DT\1740 preference_9\NN\7497473 for_10\IN\1740 1_11\CD\13741022 rizatriptan_12\JJ\1740 10_13\CD\13745420 mg_14\NN\13717155 tablet_15\NN\4233405 to_16\TO\1740 2_17\CD\13741022 ergotamine_18\NN\14712692 1_19\CD\13741022 <e1>mg/caffeine</e1>_20\NN\1740 100_21\CD\13745420 mg_22\NN\13717155 tablets_23\NNS\4233405 in_24\IN\13603305 439_25\CD\1740 patients_26\NNS\9898892 treating_27\VBG\2376958 a_28\DT\13649268 single_29\JJ\1740 <e2>migraine</e2>_30\NN\14326607 attack_31\NN\955060 with_32\IN\1740 each_33\DT\1740 therapy_34\NN\657604 ._35\.\1740
D012701_D008881 NONE rizatriptan_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 selective_3\JJ\1740 <e1>5-ht(1b/1d</e1>_4\NN\1740 )_5\-RRB-\1740 receptor_6\NN\5225602 agonist_7\NN\9613191 with_8\IN\1740 rapid_9\JJ\1740 oral_10\JJ\1740 absorption_11\NN\13558490 and_12\CC\1740 early_13\JJ\1740 onset_14\NN\7325190 of_15\IN\1740 action_16\NN\30358 in_17\IN\13603305 the_18\DT\1740 acute_19\JJ\1740 treatment_20\NN\654885 of_21\IN\1740 <e2>migraine</e2>_22\NN\14326607 ._23\.\1740
C093622_D006261 NONE faster_0\JJR\1740 relief_1\NN\7492516 of_2\IN\1740 <e2>headache</e2>_3\NN\5829480 was_4\VBD\836236 the_5\DT\1740 most_6\RBS\1740 important_7\JJ\1740 reason_8\NN\9178821 for_9\IN\1740 preference_10\NN\7497473 ,_11\,\1740 cited_12\VBN\730052 by_13\IN\1740 67.3_14\CD\1740 %_15\NN\1740 of_16\IN\1740 patients_17\NNS\9898892 preferring_18\VBG\1777210 <e1>rizatriptan</e1>_19\JJ\1740 and_20\CC\1740 54.2_21\CD\1740 %_22\NN\1740 of_23\IN\1740 patients_24\NNS\9898892 who_25\WP\8299493 preferred_26\VBD\1777210 ergotamine/caffeine_27\NN\1740 ._28\.\1740
C093622_D006261 NONE <e2>headache</e2>_0\NNP\5829480 relief_1\NN\7492516 at_2\IN\14622893 2_3\CD\13741022 h_4\NN\14622893 was_5\VBD\836236 75.9_6\CD\1740 %_7\NN\1740 for_8\IN\1740 <e1>rizatriptan</e1>_9\NN\1740 and_10\CC\1740 47.3_11\CD\1740 %_12\NN\1740 for_13\IN\1740 ergotamine/caffeine_14\NN\1740 (_15\-LRB-\1740 p_16\NN\14622893 <_17\XX\1740 or_18\CC\3541091 =_19\JJ\1740 0.001_20\CD\1740 )_21\-RRB-\1740 ,_22\,\1740 with_23\IN\1740 rizatriptan_24\NN\1740 being_25\VBG\836236 superior_26\JJ\1740 to_27\TO\1740 ergotamine/caffeine_28\NN\1740 within_29\IN\1740 30_30\CD\13745420 min_31\NN\15154774 of_32\IN\1740 dosing_33\NN\1740 ._34\.\1740
C093622_D006261 NONE <e2>headache</e2>_0\NNP\5829480 relief_1\NN\7492516 at_2\IN\14622893 2_3\CD\13741022 h_4\NN\14622893 was_5\VBD\836236 75.9_6\CD\1740 %_7\NN\1740 for_8\IN\1740 rizatriptan_9\NN\1740 and_10\CC\1740 47.3_11\CD\1740 %_12\NN\1740 for_13\IN\1740 ergotamine/caffeine_14\NN\1740 (_15\-LRB-\1740 p_16\NN\14622893 <_17\XX\1740 or_18\CC\3541091 =_19\JJ\1740 0.001_20\CD\1740 )_21\-RRB-\1740 ,_22\,\1740 with_23\IN\1740 <e1>rizatriptan</e1>_24\NN\1740 being_25\VBG\836236 superior_26\JJ\1740 to_27\TO\1740 ergotamine/caffeine_28\NN\1740 within_29\IN\1740 30_30\CD\13745420 min_31\NN\15154774 of_32\IN\1740 dosing_33\NN\1740 ._34\.\1740
D004878_D006261 NONE faster_0\JJR\1740 relief_1\NN\7492516 of_2\IN\1740 <e2>headache</e2>_3\NN\5829480 was_4\VBD\836236 the_5\DT\1740 most_6\RBS\1740 important_7\JJ\1740 reason_8\NN\9178821 for_9\IN\1740 preference_10\NN\7497473 ,_11\,\1740 cited_12\VBN\730052 by_13\IN\1740 67.3_14\CD\1740 %_15\NN\1740 of_16\IN\1740 patients_17\NNS\9898892 preferring_18\VBG\1777210 rizatriptan_19\JJ\1740 and_20\CC\1740 54.2_21\CD\1740 %_22\NN\1740 of_23\IN\1740 patients_24\NNS\9898892 who_25\WP\8299493 preferred_26\VBD\1777210 <e1>ergotamine/caffeine</e1>_27\NN\1740 ._28\.\1740
D004878_D006261 NONE <e2>headache</e2>_0\NNP\5829480 relief_1\NN\7492516 at_2\IN\14622893 2_3\CD\13741022 h_4\NN\14622893 was_5\VBD\836236 75.9_6\CD\1740 %_7\NN\1740 for_8\IN\1740 rizatriptan_9\NN\1740 and_10\CC\1740 47.3_11\CD\1740 %_12\NN\1740 for_13\IN\1740 <e1>ergotamine/caffeine</e1>_14\NN\1740 (_15\-LRB-\1740 p_16\NN\14622893 <_17\XX\1740 or_18\CC\3541091 =_19\JJ\1740 0.001_20\CD\1740 )_21\-RRB-\1740 ,_22\,\1740 with_23\IN\1740 rizatriptan_24\NN\1740 being_25\VBG\836236 superior_26\JJ\1740 to_27\TO\1740 ergotamine/caffeine_28\NN\1740 within_29\IN\1740 30_30\CD\13745420 min_31\NN\15154774 of_32\IN\1740 dosing_33\NN\1740 ._34\.\1740
D004878_D006261 NONE <e2>headache</e2>_0\NNP\5829480 relief_1\NN\7492516 at_2\IN\14622893 2_3\CD\13741022 h_4\NN\14622893 was_5\VBD\836236 75.9_6\CD\1740 %_7\NN\1740 for_8\IN\1740 rizatriptan_9\NN\1740 and_10\CC\1740 47.3_11\CD\1740 %_12\NN\1740 for_13\IN\1740 ergotamine/caffeine_14\NN\1740 (_15\-LRB-\1740 p_16\NN\14622893 <_17\XX\1740 or_18\CC\3541091 =_19\JJ\1740 0.001_20\CD\1740 )_21\-RRB-\1740 ,_22\,\1740 with_23\IN\1740 rizatriptan_24\NN\1740 being_25\VBG\836236 superior_26\JJ\1740 to_27\TO\1740 <e1>ergotamine/caffeine</e1>_28\NN\1740 within_29\IN\1740 30_30\CD\13745420 min_31\NN\15154774 of_32\IN\1740 dosing_33\NN\1740 ._34\.\1740
D002110_D006261 NONE faster_0\JJR\1740 relief_1\NN\7492516 of_2\IN\1740 <e2>headache</e2>_3\NN\5829480 was_4\VBD\836236 the_5\DT\1740 most_6\RBS\1740 important_7\JJ\1740 reason_8\NN\9178821 for_9\IN\1740 preference_10\NN\7497473 ,_11\,\1740 cited_12\VBN\730052 by_13\IN\1740 67.3_14\CD\1740 %_15\NN\1740 of_16\IN\1740 patients_17\NNS\9898892 preferring_18\VBG\1777210 rizatriptan_19\JJ\1740 and_20\CC\1740 54.2_21\CD\1740 %_22\NN\1740 of_23\IN\1740 patients_24\NNS\9898892 who_25\WP\8299493 preferred_26\VBD\1777210 <e1>ergotamine/caffeine</e1>_27\NN\1740 ._28\.\1740
D002110_D006261 NONE <e2>headache</e2>_0\NNP\5829480 relief_1\NN\7492516 at_2\IN\14622893 2_3\CD\13741022 h_4\NN\14622893 was_5\VBD\836236 75.9_6\CD\1740 %_7\NN\1740 for_8\IN\1740 rizatriptan_9\NN\1740 and_10\CC\1740 47.3_11\CD\1740 %_12\NN\1740 for_13\IN\1740 <e1>ergotamine/caffeine</e1>_14\NN\1740 (_15\-LRB-\1740 p_16\NN\14622893 <_17\XX\1740 or_18\CC\3541091 =_19\JJ\1740 0.001_20\CD\1740 )_21\-RRB-\1740 ,_22\,\1740 with_23\IN\1740 rizatriptan_24\NN\1740 being_25\VBG\836236 superior_26\JJ\1740 to_27\TO\1740 ergotamine/caffeine_28\NN\1740 within_29\IN\1740 30_30\CD\13745420 min_31\NN\15154774 of_32\IN\1740 dosing_33\NN\1740 ._34\.\1740
D002110_D006261 NONE <e2>headache</e2>_0\NNP\5829480 relief_1\NN\7492516 at_2\IN\14622893 2_3\CD\13741022 h_4\NN\14622893 was_5\VBD\836236 75.9_6\CD\1740 %_7\NN\1740 for_8\IN\1740 rizatriptan_9\NN\1740 and_10\CC\1740 47.3_11\CD\1740 %_12\NN\1740 for_13\IN\1740 ergotamine/caffeine_14\NN\1740 (_15\-LRB-\1740 p_16\NN\14622893 <_17\XX\1740 or_18\CC\3541091 =_19\JJ\1740 0.001_20\CD\1740 )_21\-RRB-\1740 ,_22\,\1740 with_23\IN\1740 rizatriptan_24\NN\1740 being_25\VBG\836236 superior_26\JJ\1740 to_27\TO\1740 <e1>ergotamine/caffeine</e1>_28\NN\1740 within_29\IN\1740 30_30\CD\13745420 min_31\NN\15154774 of_32\IN\1740 dosing_33\NN\1740 ._34\.\1740
C093622_D010146 NONE the_0\DT\1740 co-primary_1\JJ\1740 endpoint_2\NN\8566028 of_3\IN\1740 being_4\VBG\836236 <e2>pain</e2>_5\NN\14299637 free_6\JJ\1740 at_7\IN\14622893 2_8\CD\13741022 h_9\NN\14622893 was_10\VBD\836236 also_11\RB\1740 in_12\IN\13603305 favor_13\NN\34574 of_14\IN\1740 <e1>rizatriptan</e1>_15\NN\1740 ._16\.\1740
C093622_D010146 NONE forty-nine_0\JJ\1740 percent_1\NN\13815742 of_2\IN\1740 patients_3\NNS\9898892 were_4\VBD\836236 <e2>pain</e2>_5\NN\14299637 free_6\JJ\1740 2_7\CD\13741022 h_8\NN\14622893 after_9\IN\1740 <e1>rizatriptan</e1>_10\NN\1740 ,_11\,\1740 compared_12\VBN\644583 with_13\IN\1740 24.3_14\CD\1740 %_15\NN\1740 treated_16\VBN\2376958 with_17\IN\1740 ergotamine/caffeine_18\NN\1740 (_19\-LRB-\1740 p_20\NN\14622893 <_21\XX\1740 or_22\CC\3541091 =_23\JJ\1740 0.001_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 rizatriptan_27\NN\1740 being_28\VBG\836236 superior_29\JJ\1740 within_30\IN\1740 1_31\CD\13741022 h_32\NN\14622893 of_33\IN\1740 treatment_34\NN\654885 ._35\.\1740
C093622_D010146 NONE forty-nine_0\JJ\1740 percent_1\NN\13815742 of_2\IN\1740 patients_3\NNS\9898892 were_4\VBD\836236 <e2>pain</e2>_5\NN\14299637 free_6\JJ\1740 2_7\CD\13741022 h_8\NN\14622893 after_9\IN\1740 rizatriptan_10\NN\1740 ,_11\,\1740 compared_12\VBN\644583 with_13\IN\1740 24.3_14\CD\1740 %_15\NN\1740 treated_16\VBN\2376958 with_17\IN\1740 ergotamine/caffeine_18\NN\1740 (_19\-LRB-\1740 p_20\NN\14622893 <_21\XX\1740 or_22\CC\3541091 =_23\JJ\1740 0.001_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 <e1>rizatriptan</e1>_27\NN\1740 being_28\VBG\836236 superior_29\JJ\1740 within_30\IN\1740 1_31\CD\13741022 h_32\NN\14622893 of_33\IN\1740 treatment_34\NN\654885 ._35\.\1740
C093622_D010146 NONE almost_0\RB\1740 36_1\CD\1740 %_2\NN\1740 of_3\IN\1740 patients_4\NNS\9898892 taking_5\VBG\2367363 <e1>rizatriptan</e1>_6\NN\1740 were_7\VBD\836236 <e2>pain</e2>_8\NN\14299637 free_9\JJ\1740 at_10\IN\14622893 2_11\CD\13741022 h_12\NN\14622893 and_13\CC\1740 had_14\VBD\2108377 no_15\DT\7204911 recurrence_16\NN\7342049 or_17\CC\3541091 need_18\VBP\2604760 for_19\IN\1740 additional_20\JJ\1740 medication_21\NN\3247620 within_22\IN\1740 24_23\CD\13745420 h_24\NN\14622893 ,_25\,\1740 compared_26\VBN\644583 to_27\TO\1740 20_28\CD\13745420 %_29\NN\1740 of_30\IN\1740 patients_31\NNS\9898892 on_32\IN\1740 ergotamine/caffeine_33\NN\1740 (_34\-LRB-\1740 p_35\NN\14622893 <_36\XX\1740 or_37\CC\3541091 =_38\JJ\1740 0.001_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D004878_D010146 NONE forty-nine_0\JJ\1740 percent_1\NN\13815742 of_2\IN\1740 patients_3\NNS\9898892 were_4\VBD\836236 <e2>pain</e2>_5\NN\14299637 free_6\JJ\1740 2_7\CD\13741022 h_8\NN\14622893 after_9\IN\1740 rizatriptan_10\NN\1740 ,_11\,\1740 compared_12\VBN\644583 with_13\IN\1740 24.3_14\CD\1740 %_15\NN\1740 treated_16\VBN\2376958 with_17\IN\1740 <e1>ergotamine/caffeine</e1>_18\NN\1740 (_19\-LRB-\1740 p_20\NN\14622893 <_21\XX\1740 or_22\CC\3541091 =_23\JJ\1740 0.001_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 rizatriptan_27\NN\1740 being_28\VBG\836236 superior_29\JJ\1740 within_30\IN\1740 1_31\CD\13741022 h_32\NN\14622893 of_33\IN\1740 treatment_34\NN\654885 ._35\.\1740
D004878_D010146 NONE almost_0\RB\1740 36_1\CD\1740 %_2\NN\1740 of_3\IN\1740 patients_4\NNS\9898892 taking_5\VBG\2367363 rizatriptan_6\NN\1740 were_7\VBD\836236 <e2>pain</e2>_8\NN\14299637 free_9\JJ\1740 at_10\IN\14622893 2_11\CD\13741022 h_12\NN\14622893 and_13\CC\1740 had_14\VBD\2108377 no_15\DT\7204911 recurrence_16\NN\7342049 or_17\CC\3541091 need_18\VBP\2604760 for_19\IN\1740 additional_20\JJ\1740 medication_21\NN\3247620 within_22\IN\1740 24_23\CD\13745420 h_24\NN\14622893 ,_25\,\1740 compared_26\VBN\644583 to_27\TO\1740 20_28\CD\13745420 %_29\NN\1740 of_30\IN\1740 patients_31\NNS\9898892 on_32\IN\1740 <e1>ergotamine/caffeine</e1>_33\NN\1740 (_34\-LRB-\1740 p_35\NN\14622893 <_36\XX\1740 or_37\CC\3541091 =_38\JJ\1740 0.001_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D002110_D010146 NONE forty-nine_0\JJ\1740 percent_1\NN\13815742 of_2\IN\1740 patients_3\NNS\9898892 were_4\VBD\836236 <e2>pain</e2>_5\NN\14299637 free_6\JJ\1740 2_7\CD\13741022 h_8\NN\14622893 after_9\IN\1740 rizatriptan_10\NN\1740 ,_11\,\1740 compared_12\VBN\644583 with_13\IN\1740 24.3_14\CD\1740 %_15\NN\1740 treated_16\VBN\2376958 with_17\IN\1740 <e1>ergotamine/caffeine</e1>_18\NN\1740 (_19\-LRB-\1740 p_20\NN\14622893 <_21\XX\1740 or_22\CC\3541091 =_23\JJ\1740 0.001_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 rizatriptan_27\NN\1740 being_28\VBG\836236 superior_29\JJ\1740 within_30\IN\1740 1_31\CD\13741022 h_32\NN\14622893 of_33\IN\1740 treatment_34\NN\654885 ._35\.\1740
D002110_D010146 NONE almost_0\RB\1740 36_1\CD\1740 %_2\NN\1740 of_3\IN\1740 patients_4\NNS\9898892 taking_5\VBG\2367363 rizatriptan_6\NN\1740 were_7\VBD\836236 <e2>pain</e2>_8\NN\14299637 free_9\JJ\1740 at_10\IN\14622893 2_11\CD\13741022 h_12\NN\14622893 and_13\CC\1740 had_14\VBD\2108377 no_15\DT\7204911 recurrence_16\NN\7342049 or_17\CC\3541091 need_18\VBP\2604760 for_19\IN\1740 additional_20\JJ\1740 medication_21\NN\3247620 within_22\IN\1740 24_23\CD\13745420 h_24\NN\14622893 ,_25\,\1740 compared_26\VBN\644583 to_27\TO\1740 20_28\CD\13745420 %_29\NN\1740 of_30\IN\1740 patients_31\NNS\9898892 on_32\IN\1740 <e1>ergotamine/caffeine</e1>_33\NN\1740 (_34\-LRB-\1740 p_35\NN\14622893 <_36\XX\1740 or_37\CC\3541091 =_38\JJ\1740 0.001_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
C093622_D009325 CID <e1>rizatriptan</e1>_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 ergotamine/caffeine_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 <e2>nausea</e2>_13\NN\14299637 ,_14\,\1740 vomiting_15\NN\116687 ,_16\,\1740 phonophobia_17\NN\14382238 or_18\CC\3541091 photophobia_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
C093622_D009325 CID the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 (_5\-LRB-\1740 incidence_6\VBP\1740 >_7\NN\1740 or_8\CC\3541091 =_9\JJ\1740 5_10\CD\13741022 %_11\NN\1740 in_12\IN\13603305 one_13\CD\13741022 group_14\NN\2137 )_15\-RRB-\1740 after_16\IN\1740 <e1>rizatriptan</e1>_17\JJ\1740 and_18\CC\1740 ergotamine/caffeine_19\NN\1740 ,_20\,\1740 respectively_21\RB\1740 ,_22\,\1740 were_23\VBD\836236 dizziness_24\JJ\1740 (_25\-LRB-\1740 6.7_26\CD\1740 and_27\CC\1740 5.3_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 <e2>nausea</e2>_32\NN\14299637 (_33\-LRB-\1740 4.2_34\CD\1740 and_35\CC\1740 8.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 and_39\CC\1740 somnolence_40\NN\14015731 (_41\-LRB-\1740 5.5_42\CD\1740 and_43\CC\1740 2.3_44\CD\1740 %_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
C093622_D014839 NONE <e1>rizatriptan</e1>_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 ergotamine/caffeine_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 nausea_13\NN\14299637 ,_14\,\1740 <e2>vomiting</e2>_15\NN\116687 ,_16\,\1740 phonophobia_17\NN\14382238 or_18\CC\3541091 photophobia_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
C093622_D012001 NONE <e1>rizatriptan</e1>_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 ergotamine/caffeine_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 nausea_13\NN\14299637 ,_14\,\1740 vomiting_15\NN\116687 ,_16\,\1740 <e2>phonophobia</e2>_17\NN\14382238 or_18\CC\3541091 photophobia_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
C093622_D020795 NONE <e1>rizatriptan</e1>_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 ergotamine/caffeine_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 nausea_13\NN\14299637 ,_14\,\1740 vomiting_15\NN\116687 ,_16\,\1740 phonophobia_17\NN\14382238 or_18\CC\3541091 <e2>photophobia</e2>_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D004878_D009325 NONE rizatriptan_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 <e1>ergotamine/caffeine</e1>_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 <e2>nausea</e2>_13\NN\14299637 ,_14\,\1740 vomiting_15\NN\116687 ,_16\,\1740 phonophobia_17\NN\14382238 or_18\CC\3541091 photophobia_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D004878_D009325 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 (_5\-LRB-\1740 incidence_6\VBP\1740 >_7\NN\1740 or_8\CC\3541091 =_9\JJ\1740 5_10\CD\13741022 %_11\NN\1740 in_12\IN\13603305 one_13\CD\13741022 group_14\NN\2137 )_15\-RRB-\1740 after_16\IN\1740 rizatriptan_17\JJ\1740 and_18\CC\1740 <e1>ergotamine/caffeine</e1>_19\NN\1740 ,_20\,\1740 respectively_21\RB\1740 ,_22\,\1740 were_23\VBD\836236 dizziness_24\JJ\1740 (_25\-LRB-\1740 6.7_26\CD\1740 and_27\CC\1740 5.3_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 <e2>nausea</e2>_32\NN\14299637 (_33\-LRB-\1740 4.2_34\CD\1740 and_35\CC\1740 8.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 and_39\CC\1740 somnolence_40\NN\14015731 (_41\-LRB-\1740 5.5_42\CD\1740 and_43\CC\1740 2.3_44\CD\1740 %_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
D004878_D014839 NONE rizatriptan_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 <e1>ergotamine/caffeine</e1>_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 nausea_13\NN\14299637 ,_14\,\1740 <e2>vomiting</e2>_15\NN\116687 ,_16\,\1740 phonophobia_17\NN\14382238 or_18\CC\3541091 photophobia_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D004878_D012001 NONE rizatriptan_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 <e1>ergotamine/caffeine</e1>_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 nausea_13\NN\14299637 ,_14\,\1740 vomiting_15\NN\116687 ,_16\,\1740 <e2>phonophobia</e2>_17\NN\14382238 or_18\CC\3541091 photophobia_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D004878_D020795 NONE rizatriptan_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 <e1>ergotamine/caffeine</e1>_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 nausea_13\NN\14299637 ,_14\,\1740 vomiting_15\NN\116687 ,_16\,\1740 phonophobia_17\NN\14382238 or_18\CC\3541091 <e2>photophobia</e2>_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D002110_D009325 NONE rizatriptan_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 <e1>ergotamine/caffeine</e1>_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 <e2>nausea</e2>_13\NN\14299637 ,_14\,\1740 vomiting_15\NN\116687 ,_16\,\1740 phonophobia_17\NN\14382238 or_18\CC\3541091 photophobia_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D002110_D009325 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 (_5\-LRB-\1740 incidence_6\VBP\1740 >_7\NN\1740 or_8\CC\3541091 =_9\JJ\1740 5_10\CD\13741022 %_11\NN\1740 in_12\IN\13603305 one_13\CD\13741022 group_14\NN\2137 )_15\-RRB-\1740 after_16\IN\1740 rizatriptan_17\JJ\1740 and_18\CC\1740 <e1>ergotamine/caffeine</e1>_19\NN\1740 ,_20\,\1740 respectively_21\RB\1740 ,_22\,\1740 were_23\VBD\836236 dizziness_24\JJ\1740 (_25\-LRB-\1740 6.7_26\CD\1740 and_27\CC\1740 5.3_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 <e2>nausea</e2>_32\NN\14299637 (_33\-LRB-\1740 4.2_34\CD\1740 and_35\CC\1740 8.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 and_39\CC\1740 somnolence_40\NN\14015731 (_41\-LRB-\1740 5.5_42\CD\1740 and_43\CC\1740 2.3_44\CD\1740 %_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
D002110_D014839 NONE rizatriptan_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 <e1>ergotamine/caffeine</e1>_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 nausea_13\NN\14299637 ,_14\,\1740 <e2>vomiting</e2>_15\NN\116687 ,_16\,\1740 phonophobia_17\NN\14382238 or_18\CC\3541091 photophobia_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D002110_D012001 NONE rizatriptan_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 <e1>ergotamine/caffeine</e1>_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 nausea_13\NN\14299637 ,_14\,\1740 vomiting_15\NN\116687 ,_16\,\1740 <e2>phonophobia</e2>_17\NN\14382238 or_18\CC\3541091 photophobia_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D002110_D020795 NONE rizatriptan_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 superior_3\JJ\1740 to_4\TO\1740 <e1>ergotamine/caffeine</e1>_5\NN\1740 in_6\IN\13603305 the_7\DT\1740 proportions_8\NNS\13824815 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 no_12\DT\7204911 nausea_13\NN\14299637 ,_14\,\1740 vomiting_15\NN\116687 ,_16\,\1740 phonophobia_17\NN\14382238 or_18\CC\3541091 <e2>photophobia</e2>_19\NN\14382238 and_20\CC\1740 for_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 normal_24\JJ\1740 function_25\NN\13783581 2_26\CD\13741022 h_27\NN\14622893 after_28\IN\1740 drug_29\NN\14778436 intake_30\NN\13440063 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 or_34\CC\3541091 =_35\JJ\1740 0.001_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
C093622_D004244 CID the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 (_5\-LRB-\1740 incidence_6\VBP\1740 >_7\NN\1740 or_8\CC\3541091 =_9\JJ\1740 5_10\CD\13741022 %_11\NN\1740 in_12\IN\13603305 one_13\CD\13741022 group_14\NN\2137 )_15\-RRB-\1740 after_16\IN\1740 <e1>rizatriptan</e1>_17\JJ\1740 and_18\CC\1740 ergotamine/caffeine_19\NN\1740 ,_20\,\1740 respectively_21\RB\1740 ,_22\,\1740 were_23\VBD\836236 <e2>dizziness</e2>_24\JJ\1740 (_25\-LRB-\1740 6.7_26\CD\1740 and_27\CC\1740 5.3_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 nausea_32\NN\14299637 (_33\-LRB-\1740 4.2_34\CD\1740 and_35\CC\1740 8.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 and_39\CC\1740 somnolence_40\NN\14015731 (_41\-LRB-\1740 5.5_42\CD\1740 and_43\CC\1740 2.3_44\CD\1740 %_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
C093622_D006970 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 (_5\-LRB-\1740 incidence_6\VBP\1740 >_7\NN\1740 or_8\CC\3541091 =_9\JJ\1740 5_10\CD\13741022 %_11\NN\1740 in_12\IN\13603305 one_13\CD\13741022 group_14\NN\2137 )_15\-RRB-\1740 after_16\IN\1740 <e1>rizatriptan</e1>_17\JJ\1740 and_18\CC\1740 ergotamine/caffeine_19\NN\1740 ,_20\,\1740 respectively_21\RB\1740 ,_22\,\1740 were_23\VBD\836236 dizziness_24\JJ\1740 (_25\-LRB-\1740 6.7_26\CD\1740 and_27\CC\1740 5.3_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 nausea_32\NN\14299637 (_33\-LRB-\1740 4.2_34\CD\1740 and_35\CC\1740 8.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 and_39\CC\1740 <e2>somnolence</e2>_40\NN\14015731 (_41\-LRB-\1740 5.5_42\CD\1740 and_43\CC\1740 2.3_44\CD\1740 %_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
D004878_D004244 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 (_5\-LRB-\1740 incidence_6\VBP\1740 >_7\NN\1740 or_8\CC\3541091 =_9\JJ\1740 5_10\CD\13741022 %_11\NN\1740 in_12\IN\13603305 one_13\CD\13741022 group_14\NN\2137 )_15\-RRB-\1740 after_16\IN\1740 rizatriptan_17\JJ\1740 and_18\CC\1740 <e1>ergotamine/caffeine</e1>_19\NN\1740 ,_20\,\1740 respectively_21\RB\1740 ,_22\,\1740 were_23\VBD\836236 <e2>dizziness</e2>_24\JJ\1740 (_25\-LRB-\1740 6.7_26\CD\1740 and_27\CC\1740 5.3_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 nausea_32\NN\14299637 (_33\-LRB-\1740 4.2_34\CD\1740 and_35\CC\1740 8.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 and_39\CC\1740 somnolence_40\NN\14015731 (_41\-LRB-\1740 5.5_42\CD\1740 and_43\CC\1740 2.3_44\CD\1740 %_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
D004878_D006970 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 (_5\-LRB-\1740 incidence_6\VBP\1740 >_7\NN\1740 or_8\CC\3541091 =_9\JJ\1740 5_10\CD\13741022 %_11\NN\1740 in_12\IN\13603305 one_13\CD\13741022 group_14\NN\2137 )_15\-RRB-\1740 after_16\IN\1740 rizatriptan_17\JJ\1740 and_18\CC\1740 <e1>ergotamine/caffeine</e1>_19\NN\1740 ,_20\,\1740 respectively_21\RB\1740 ,_22\,\1740 were_23\VBD\836236 dizziness_24\JJ\1740 (_25\-LRB-\1740 6.7_26\CD\1740 and_27\CC\1740 5.3_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 nausea_32\NN\14299637 (_33\-LRB-\1740 4.2_34\CD\1740 and_35\CC\1740 8.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 and_39\CC\1740 <e2>somnolence</e2>_40\NN\14015731 (_41\-LRB-\1740 5.5_42\CD\1740 and_43\CC\1740 2.3_44\CD\1740 %_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
D002110_D004244 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 (_5\-LRB-\1740 incidence_6\VBP\1740 >_7\NN\1740 or_8\CC\3541091 =_9\JJ\1740 5_10\CD\13741022 %_11\NN\1740 in_12\IN\13603305 one_13\CD\13741022 group_14\NN\2137 )_15\-RRB-\1740 after_16\IN\1740 rizatriptan_17\JJ\1740 and_18\CC\1740 <e1>ergotamine/caffeine</e1>_19\NN\1740 ,_20\,\1740 respectively_21\RB\1740 ,_22\,\1740 were_23\VBD\836236 <e2>dizziness</e2>_24\JJ\1740 (_25\-LRB-\1740 6.7_26\CD\1740 and_27\CC\1740 5.3_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 nausea_32\NN\14299637 (_33\-LRB-\1740 4.2_34\CD\1740 and_35\CC\1740 8.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 and_39\CC\1740 somnolence_40\NN\14015731 (_41\-LRB-\1740 5.5_42\CD\1740 and_43\CC\1740 2.3_44\CD\1740 %_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
D002110_D006970 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 (_5\-LRB-\1740 incidence_6\VBP\1740 >_7\NN\1740 or_8\CC\3541091 =_9\JJ\1740 5_10\CD\13741022 %_11\NN\1740 in_12\IN\13603305 one_13\CD\13741022 group_14\NN\2137 )_15\-RRB-\1740 after_16\IN\1740 rizatriptan_17\JJ\1740 and_18\CC\1740 <e1>ergotamine/caffeine</e1>_19\NN\1740 ,_20\,\1740 respectively_21\RB\1740 ,_22\,\1740 were_23\VBD\836236 dizziness_24\JJ\1740 (_25\-LRB-\1740 6.7_26\CD\1740 and_27\CC\1740 5.3_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 nausea_32\NN\14299637 (_33\-LRB-\1740 4.2_34\CD\1740 and_35\CC\1740 8.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 and_39\CC\1740 <e2>somnolence</e2>_40\NN\14015731 (_41\-LRB-\1740 5.5_42\CD\1740 and_43\CC\1740 2.3_44\CD\1740 %_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
18619688
D004317_D003643 NONE <e1>adriamycin-induced</e1>_0\JJ\1740 autophagic_1\JJ\1740 cardiomyocyte_2\NN\1740 <e2>death</e2>_3\NN\7296428 plays_4\VBZ\1072262 a_5\DT\13649268 pathogenic_6\JJ\1740 role_7\NN\719494 in_8\IN\13603305 a_9\DT\13649268 rat_10\NN\2329401 model_11\NN\5888929 of_12\IN\1740 heart_13\NN\5919034 failure_14\NN\66216 ._15\.\1740
D004317_D003643 NONE conclusion_0\NN\5837957 :_1\:\1740 autophagic_2\JJ\1740 cardiomyocyte_3\NN\1740 <e2>death</e2>_4\NN\7296428 plays_5\VBZ\1072262 an_6\DT\6697703 important_7\JJ\1740 role_8\NN\719494 in_9\IN\13603305 the_10\DT\1740 pathogenesis_11\NN\13533470 of_12\IN\1740 heart_13\NN\5919034 failure_14\NN\66216 in_15\IN\13603305 rats_16\NNS\2329401 induced_17\VBN\1627355 by_18\IN\1740 <e1>adriamycin</e1>_19\NN\1740 ._20\.\1740
D004317_D006333 CID <e1>adriamycin-induced</e1>_0\JJ\1740 autophagic_1\JJ\1740 cardiomyocyte_2\NN\1740 death_3\NN\7296428 plays_4\VBZ\1072262 a_5\DT\13649268 pathogenic_6\JJ\1740 role_7\NN\719494 in_8\IN\13603305 a_9\DT\13649268 rat_10\NN\2329401 model_11\NN\5888929 of_12\IN\1740 <e2>heart_13\NN\5919034 failure</e2>_14\NN\66216 ._15\.\1740
D004317_D006333 CID background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 mechanisms_3\NNS\13446390 underlying_4\VBG\2604760 <e2>heart_5\NN\5919034 failure</e2>_6\NN\66216 induced_7\VBN\1627355 by_8\IN\1740 <e1>adriamycin</e1>_9\NN\1740 are_10\VBP\836236 very_11\RB\1740 complicated_12\JJ\1740 and_13\CC\1740 still_14\RB\1740 unclear_15\JJ\1740 ._16\.\1740
D004317_D006333 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 investigate_7\VB\644583 whether_8\IN\1740 autophagy_9\NN\1740 was_10\VBD\836236 involved_11\VBN\2676054 in_12\IN\13603305 the_13\DT\1740 progression_14\NN\8457976 of_15\IN\1740 <e2>heart_16\NN\5919034 failure</e2>_17\NN\66216 induced_18\VBN\1627355 by_19\IN\1740 <e1>adriamycin</e1>_20\NN\1740 ,_21\,\1740 so_22\IN\6868043 that_23\IN\1740 we_24\PRP\1740 can_25\MD\3094503 develop_26\VB\1753788 a_27\DT\13649268 novel_28\JJ\1740 treatment_29\NN\654885 strategy_30\NN\5902545 for_31\IN\1740 heart_32\NN\5919034 failure_33\NN\66216 ._34\.\1740
D004317_D006333 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 investigate_7\VB\644583 whether_8\IN\1740 autophagy_9\NN\1740 was_10\VBD\836236 involved_11\VBN\2676054 in_12\IN\13603305 the_13\DT\1740 progression_14\NN\8457976 of_15\IN\1740 heart_16\NN\5919034 failure_17\NN\66216 induced_18\VBN\1627355 by_19\IN\1740 <e1>adriamycin</e1>_20\NN\1740 ,_21\,\1740 so_22\IN\6868043 that_23\IN\1740 we_24\PRP\1740 can_25\MD\3094503 develop_26\VB\1753788 a_27\DT\13649268 novel_28\JJ\1740 treatment_29\NN\654885 strategy_30\NN\5902545 for_31\IN\1740 <e2>heart_32\NN\5919034 failure</e2>_33\NN\66216 ._34\.\1740
D004317_D006333 CID methods_0\NNS\5616786 :_1\:\1740 3-methyladenine_2\NN\1740 (_3\-LRB-\1740 3ma_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 a_7\DT\13649268 specific_8\JJ\1740 inhibitor_9\NN\20090 on_10\IN\1740 autophagy_11\NN\1740 was_12\VBD\836236 used_13\VBN\1156834 in_14\IN\13603305 a_15\DT\13649268 <e2>heart_16\NN\5919034 failure</e2>_17\NN\66216 model_18\NN\5888929 of_19\IN\1740 rats_20\NNS\2329401 induced_21\VBN\1627355 by_22\IN\1740 <e1>adriamycin</e1>_23\NN\1740 ._24\.\1740
D004317_D006333 CID conclusion_0\NN\5837957 :_1\:\1740 autophagic_2\JJ\1740 cardiomyocyte_3\NN\1740 death_4\NN\7296428 plays_5\VBZ\1072262 an_6\DT\6697703 important_7\JJ\1740 role_8\NN\719494 in_9\IN\13603305 the_10\DT\1740 pathogenesis_11\NN\13533470 of_12\IN\1740 <e2>heart_13\NN\5919034 failure</e2>_14\NN\66216 in_15\IN\13603305 rats_16\NNS\2329401 induced_17\VBN\1627355 by_18\IN\1740 <e1>adriamycin</e1>_19\NN\1740 ._20\.\1740
D004317_D006333 CID mitochondrial_0\JJ\1740 injury_1\NN\14052046 may_2\MD\15209706 be_3\VB\836236 involved_4\VBN\2676054 in_5\IN\13603305 the_6\DT\1740 progression_7\NN\8457976 of_8\IN\1740 <e2>heart_9\NN\5919034 failure</e2>_10\NN\66216 caused_11\VBN\1617192 by_12\IN\1740 <e1>adriamycin</e1>_13\NN\1740 via_14\IN\1740 the_15\DT\1740 autophagy_16\NN\1740 pathway_17\NN\5483677 ._18\.\1740
C025946_D006333 NONE methods_0\NNS\5616786 :_1\:\1740 <e1>3-methyladenine</e1>_2\NN\1740 (_3\-LRB-\1740 3ma_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 a_7\DT\13649268 specific_8\JJ\1740 inhibitor_9\NN\20090 on_10\IN\1740 autophagy_11\NN\1740 was_12\VBD\836236 used_13\VBN\1156834 in_14\IN\13603305 a_15\DT\13649268 <e2>heart_16\NN\5919034 failure</e2>_17\NN\66216 model_18\NN\5888929 of_19\IN\1740 rats_20\NNS\2329401 induced_21\VBN\1627355 by_22\IN\1740 adriamycin_23\NN\1740 ._24\.\1740
C025946_D006333 NONE methods_0\NNS\5616786 :_1\:\1740 3-methyladenine_2\NN\1740 (_3\-LRB-\1740 <e1>3ma</e1>_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 a_7\DT\13649268 specific_8\JJ\1740 inhibitor_9\NN\20090 on_10\IN\1740 autophagy_11\NN\1740 was_12\VBD\836236 used_13\VBN\1156834 in_14\IN\13603305 a_15\DT\13649268 <e2>heart_16\NN\5919034 failure</e2>_17\NN\66216 model_18\NN\5888929 of_19\IN\1740 rats_20\NNS\2329401 induced_21\VBN\1627355 by_22\IN\1740 adriamycin_23\NN\1740 ._24\.\1740
11250767
D011441_D014657 NONE <e1>propylthiouracil-induced</e1>_0\JJ\1740 perinuclear-staining_1\JJ\1740 antineutrophil_2\NN\1740 cytoplasmic_3\JJ\1740 autoantibody-positive_4\JJ\1740 <e2>vasculitis</e2>_5\NN\14336539 in_6\IN\13603305 conjunction_7\NN\5048123 with_8\IN\1740 pericarditis_9\NN\14338942 ._10\.\1740
D011441_D014657 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e1>propylthiouracil-induced</e1>_7\JJ\1740 <e2>vasculitis</e2>_8\NN\14336539 manifesting_9\NN\1740 with_10\IN\1740 pericarditis_11\NN\14338942 ._12\.\1740
D011441_D014657 NONE a_0\DT\13649268 literature_1\NN\6362953 review_2\NN\5733583 revealed_3\VBD\2137132 no_4\DT\7204911 prior_5\JJ\1740 reports_6\NNS\6470073 of_7\IN\1740 pericarditis_8\NN\14338942 in_9\IN\13603305 anti-mpo_10\NN\1740 panca-positive_11\NN\1740 <e2>vasculitis</e2>_12\NN\14336539 associated_13\VBN\628491 with_14\IN\1740 <e1>propylthio-_15\JJ\1740 uracil</e1>_16\NN\14964590 therapy_17\NN\657604 ._18\.\1740
D011441_D014657 NONE conclusion_0\NN\5837957 :_1\:\1740 pericarditis_2\NNP\14338942 may_3\MD\15209706 be_4\VB\836236 the_5\DT\1740 initial_6\JJ\1740 manifestation_7\NN\7321772 of_8\IN\1740 drug-induced_9\JJ\1740 <e2>vasculitis</e2>_10\NN\14336539 attributable_11\JJ\1740 to_12\TO\1740 <e1>propylthio-_13\JJ\1740 uracil</e1>_14\NN\14964590 therapy_15\NN\657604 ._16\.\1740
D011441_D010493 CID <e1>propylthiouracil-induced</e1>_0\JJ\1740 perinuclear-staining_1\JJ\1740 antineutrophil_2\NN\1740 cytoplasmic_3\JJ\1740 autoantibody-positive_4\JJ\1740 vasculitis_5\NN\14336539 in_6\IN\13603305 conjunction_7\NN\5048123 with_8\IN\1740 <e2>pericarditis</e2>_9\NN\14338942 ._10\.\1740
D011441_D010493 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e1>propylthiouracil-induced</e1>_7\JJ\1740 vasculitis_8\NN\14336539 manifesting_9\NN\1740 with_10\IN\1740 <e2>pericarditis</e2>_11\NN\14338942 ._12\.\1740
D011441_D010493 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 the_4\DT\1740 first_5\JJ\1740 case_6\NN\7283608 report_7\NN\6470073 of_8\IN\1740 a_9\DT\13649268 woman_10\NN\9605289 with_11\IN\1740 hyperthyroidism_12\NN\14059928 treated_13\VBN\2376958 with_14\IN\1740 <e1>propylthiouracil</e1>_15\NN\14727670 in_16\IN\13603305 whom_17\WP\1740 a_18\DT\13649268 syndrome_19\NN\5870365 of_20\IN\1740 <e2>pericarditis</e2>_21\NN\14338942 ,_22\,\1740 fever_23\NN\14299637 ,_24\,\1740 and_25\CC\1740 glomerulonephritis_26\NN\14113798 developed_27\VBD\1753788 ._28\.\1740
D011441_D010493 CID a_0\DT\13649268 literature_1\NN\6362953 review_2\NN\5733583 revealed_3\VBD\2137132 no_4\DT\7204911 prior_5\JJ\1740 reports_6\NNS\6470073 of_7\IN\1740 <e2>pericarditis</e2>_8\NN\14338942 in_9\IN\13603305 anti-mpo_10\NN\1740 panca-positive_11\NN\1740 vasculitis_12\NN\14336539 associated_13\VBN\628491 with_14\IN\1740 <e1>propylthio-_15\JJ\1740 uracil</e1>_16\NN\14964590 therapy_17\NN\657604 ._18\.\1740
D011441_D010493 CID conclusion_0\NN\5837957 :_1\:\1740 <e2>pericarditis</e2>_2\NNP\14338942 may_3\MD\15209706 be_4\VB\836236 the_5\DT\1740 initial_6\JJ\1740 manifestation_7\NN\7321772 of_8\IN\1740 drug-induced_9\JJ\1740 vasculitis_10\NN\14336539 attributable_11\JJ\1740 to_12\TO\1740 <e1>propylthio-_13\JJ\1740 uracil</e1>_14\NN\14964590 therapy_15\NN\657604 ._16\.\1740
D011441_D006980 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 the_4\DT\1740 first_5\JJ\1740 case_6\NN\7283608 report_7\NN\6470073 of_8\IN\1740 a_9\DT\13649268 woman_10\NN\9605289 with_11\IN\1740 <e2>hyperthyroidism</e2>_12\NN\14059928 treated_13\VBN\2376958 with_14\IN\1740 <e1>propylthiouracil</e1>_15\NN\14727670 in_16\IN\13603305 whom_17\WP\1740 a_18\DT\13649268 syndrome_19\NN\5870365 of_20\IN\1740 pericarditis_21\NN\14338942 ,_22\,\1740 fever_23\NN\14299637 ,_24\,\1740 and_25\CC\1740 glomerulonephritis_26\NN\14113798 developed_27\VBD\1753788 ._28\.\1740
D011441_D005334 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 the_4\DT\1740 first_5\JJ\1740 case_6\NN\7283608 report_7\NN\6470073 of_8\IN\1740 a_9\DT\13649268 woman_10\NN\9605289 with_11\IN\1740 hyperthyroidism_12\NN\14059928 treated_13\VBN\2376958 with_14\IN\1740 <e1>propylthiouracil</e1>_15\NN\14727670 in_16\IN\13603305 whom_17\WP\1740 a_18\DT\13649268 syndrome_19\NN\5870365 of_20\IN\1740 pericarditis_21\NN\14338942 ,_22\,\1740 <e2>fever</e2>_23\NN\14299637 ,_24\,\1740 and_25\CC\1740 glomerulonephritis_26\NN\14113798 developed_27\VBD\1753788 ._28\.\1740
D011441_D005921 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 the_4\DT\1740 first_5\JJ\1740 case_6\NN\7283608 report_7\NN\6470073 of_8\IN\1740 a_9\DT\13649268 woman_10\NN\9605289 with_11\IN\1740 hyperthyroidism_12\NN\14059928 treated_13\VBN\2376958 with_14\IN\1740 <e1>propylthiouracil</e1>_15\NN\14727670 in_16\IN\13603305 whom_17\WP\1740 a_18\DT\13649268 syndrome_19\NN\5870365 of_20\IN\1740 pericarditis_21\NN\14338942 ,_22\,\1740 fever_23\NN\14299637 ,_24\,\1740 and_25\CC\1740 <e2>glomerulonephritis</e2>_26\NN\14113798 developed_27\VBD\1753788 ._28\.\1740
11706060
D019344_D009202 NONE combined_0\JJ\1740 antiretroviral_1\JJ\1740 therapy_2\NN\657604 causes_3\VBZ\1617192 <e2>cardiomyopathy</e2>_4\JJ\1740 and_5\CC\1740 elevates_6\VBZ\2391803 plasma_7\NN\5398023 <e1>lactate</e1>_8\NN\14850483 in_9\IN\13603305 transgenic_10\JJ\1740 aids_11\NN\13974317 mice_12\NNS\2329401 ._13\.\1740
D019344_D009202 NONE highly_0\RB\1740 active_1\JJ\1740 antiretroviral_2\JJ\1740 therapy_3\NN\657604 (_4\-LRB-\1740 haart_5\NN\3740161 )_6\-RRB-\1740 is_7\VBZ\836236 implicated_8\VBN\2677097 in_9\IN\13603305 <e2>cardiomyopathy</e2>_10\JJ\1740 (_11\-LRB-\1740 cm_12\NN\13649268 )_13\-RRB-\1740 and_14\CC\1740 in_15\IN\13603305 elevated_16\JJ\1740 plasma_17\NN\5398023 <e1>lactate</e1>_18\NN\14850483 (_19\-LRB-\1740 la_20\NN\14625458 )_21\-RRB-\1740 in_22\IN\13603305 aids_23\NN\13974317 through_24\IN\1740 mechanisms_25\NNS\13446390 of_26\IN\1740 mitochondrial_27\JJ\1740 dysfunction_28\NN\14204950 ._29\.\1740
D019344_D009202 NONE highly_0\RB\1740 active_1\JJ\1740 antiretroviral_2\JJ\1740 therapy_3\NN\657604 (_4\-LRB-\1740 haart_5\NN\3740161 )_6\-RRB-\1740 is_7\VBZ\836236 implicated_8\VBN\2677097 in_9\IN\13603305 cardiomyopathy_10\JJ\1740 (_11\-LRB-\1740 <e2>cm</e2>_12\NN\13649268 )_13\-RRB-\1740 and_14\CC\1740 in_15\IN\13603305 elevated_16\JJ\1740 plasma_17\NN\5398023 <e1>lactate</e1>_18\NN\14850483 (_19\-LRB-\1740 la_20\NN\14625458 )_21\-RRB-\1740 in_22\IN\13603305 aids_23\NN\13974317 through_24\IN\1740 mechanisms_25\NNS\13446390 of_26\IN\1740 mitochondrial_27\JJ\1740 dysfunction_28\NN\14204950 ._29\.\1740
D019344_D009202 NONE highly_0\RB\1740 active_1\JJ\1740 antiretroviral_2\JJ\1740 therapy_3\NN\657604 (_4\-LRB-\1740 haart_5\NN\3740161 )_6\-RRB-\1740 is_7\VBZ\836236 implicated_8\VBN\2677097 in_9\IN\13603305 <e2>cardiomyopathy</e2>_10\JJ\1740 (_11\-LRB-\1740 cm_12\NN\13649268 )_13\-RRB-\1740 and_14\CC\1740 in_15\IN\13603305 elevated_16\JJ\1740 plasma_17\NN\5398023 lactate_18\NN\14850483 (_19\-LRB-\1740 <e1>la</e1>_20\NN\14625458 )_21\-RRB-\1740 in_22\IN\13603305 aids_23\NN\13974317 through_24\IN\1740 mechanisms_25\NNS\13446390 of_26\IN\1740 mitochondrial_27\JJ\1740 dysfunction_28\NN\14204950 ._29\.\1740
D019344_D009202 NONE highly_0\RB\1740 active_1\JJ\1740 antiretroviral_2\JJ\1740 therapy_3\NN\657604 (_4\-LRB-\1740 haart_5\NN\3740161 )_6\-RRB-\1740 is_7\VBZ\836236 implicated_8\VBN\2677097 in_9\IN\13603305 cardiomyopathy_10\JJ\1740 (_11\-LRB-\1740 <e2>cm</e2>_12\NN\13649268 )_13\-RRB-\1740 and_14\CC\1740 in_15\IN\13603305 elevated_16\JJ\1740 plasma_17\NN\5398023 lactate_18\NN\14850483 (_19\-LRB-\1740 <e1>la</e1>_20\NN\14625458 )_21\-RRB-\1740 in_22\IN\13603305 aids_23\NN\13974317 through_24\IN\1740 mechanisms_25\NNS\13446390 of_26\IN\1740 mitochondrial_27\JJ\1740 dysfunction_28\NN\14204950 ._29\.\1740
D019344_D009202 NONE at_0\IN\14622893 termination_1\NN\15266911 of_2\IN\1740 the_3\DT\1740 experiments_4\NNS\641820 ,_5\,\1740 mice_6\NNS\2329401 underwent_7\VBD\109660 echocardiography_8\NN\177127 ,_9\,\1740 quantitation_10\NN\1740 of_11\IN\1740 abundance_12\NN\5108740 of_13\IN\1740 molecular_14\JJ\1740 markers_15\NNS\21939 of_16\IN\1740 <e2>cm</e2>_17\NN\13649268 (_18\-LRB-\1740 ventricular_19\JJ\1740 mrna_20\NN\14832193 encoding_21\VBG\115157 atrial_22\JJ\1740 natriuretic_23\JJ\1740 factor_24\NN\7326557 [_25\-LRB-\1740 anf_26\NN\1740 ]_27\-RRB-\1740 and_28\CC\1740 sarcoplasmic_29\JJ\1740 calcium_30\NN\14625458 atpase_31\NN\1740 [_32\-LRB-\1740 serca2_33\NN\1740 ]_34\-RRB-\1740 )_35\-RRB-\1740 ,_36\,\1740 and_37\CC\1740 determination_38\NN\43195 of_39\IN\1740 plasma_40\NN\5398023 <e1>la</e1>_41\NNP\14625458 ._42\.\1740
D019344_D009202 NONE results_0\NNS\34213 show_1\VBP\2137132 that_2\IN\1740 cumulative_3\JJ\1740 haart_4\NN\3740161 caused_5\VBD\1617192 mitochondrial_6\JJ\1740 <e2>cm</e2>_7\NN\13649268 with_8\IN\1740 elevated_9\JJ\1740 <e1>la</e1>_10\NN\14625458 in_11\IN\13603305 aids_12\NN\13974317 transgenic_13\JJ\1740 mice_14\NNS\2329401 ._15\.\1740
D019344_D000163 NONE combined_0\JJ\1740 antiretroviral_1\JJ\1740 therapy_2\NN\657604 causes_3\VBZ\1617192 cardiomyopathy_4\JJ\1740 and_5\CC\1740 elevates_6\VBZ\2391803 plasma_7\NN\5398023 <e1>lactate</e1>_8\NN\14850483 in_9\IN\13603305 transgenic_10\JJ\1740 <e2>aids</e2>_11\NN\13974317 mice_12\NNS\2329401 ._13\.\1740
D019344_D000163 NONE highly_0\RB\1740 active_1\JJ\1740 antiretroviral_2\JJ\1740 therapy_3\NN\657604 (_4\-LRB-\1740 haart_5\NN\3740161 )_6\-RRB-\1740 is_7\VBZ\836236 implicated_8\VBN\2677097 in_9\IN\13603305 cardiomyopathy_10\JJ\1740 (_11\-LRB-\1740 cm_12\NN\13649268 )_13\-RRB-\1740 and_14\CC\1740 in_15\IN\13603305 elevated_16\JJ\1740 plasma_17\NN\5398023 <e1>lactate</e1>_18\NN\14850483 (_19\-LRB-\1740 la_20\NN\14625458 )_21\-RRB-\1740 in_22\IN\13603305 <e2>aids</e2>_23\NN\13974317 through_24\IN\1740 mechanisms_25\NNS\13446390 of_26\IN\1740 mitochondrial_27\JJ\1740 dysfunction_28\NN\14204950 ._29\.\1740
D019344_D000163 NONE highly_0\RB\1740 active_1\JJ\1740 antiretroviral_2\JJ\1740 therapy_3\NN\657604 (_4\-LRB-\1740 haart_5\NN\3740161 )_6\-RRB-\1740 is_7\VBZ\836236 implicated_8\VBN\2677097 in_9\IN\13603305 cardiomyopathy_10\JJ\1740 (_11\-LRB-\1740 cm_12\NN\13649268 )_13\-RRB-\1740 and_14\CC\1740 in_15\IN\13603305 elevated_16\JJ\1740 plasma_17\NN\5398023 lactate_18\NN\14850483 (_19\-LRB-\1740 <e1>la</e1>_20\NN\14625458 )_21\-RRB-\1740 in_22\IN\13603305 <e2>aids</e2>_23\NN\13974317 through_24\IN\1740 mechanisms_25\NNS\13446390 of_26\IN\1740 mitochondrial_27\JJ\1740 dysfunction_28\NN\14204950 ._29\.\1740
D019344_D000163 NONE results_0\NNS\34213 show_1\VBP\2137132 that_2\IN\1740 cumulative_3\JJ\1740 haart_4\NN\3740161 caused_5\VBD\1617192 mitochondrial_6\JJ\1740 cm_7\NN\13649268 with_8\IN\1740 elevated_9\JJ\1740 <e1>la</e1>_10\NN\14625458 in_11\IN\13603305 <e2>aids</e2>_12\NN\13974317 transgenic_13\JJ\1740 mice_14\NNS\2329401 ._15\.\1740
D019344_D028361 NONE highly_0\RB\1740 active_1\JJ\1740 antiretroviral_2\JJ\1740 therapy_3\NN\657604 (_4\-LRB-\1740 haart_5\NN\3740161 )_6\-RRB-\1740 is_7\VBZ\836236 implicated_8\VBN\2677097 in_9\IN\13603305 cardiomyopathy_10\JJ\1740 (_11\-LRB-\1740 cm_12\NN\13649268 )_13\-RRB-\1740 and_14\CC\1740 in_15\IN\13603305 elevated_16\JJ\1740 plasma_17\NN\5398023 <e1>lactate</e1>_18\NN\14850483 (_19\-LRB-\1740 la_20\NN\14625458 )_21\-RRB-\1740 in_22\IN\13603305 aids_23\NN\13974317 through_24\IN\1740 mechanisms_25\NNS\13446390 of_26\IN\1740 <e2>mitochondrial_27\JJ\1740 dysfunction</e2>_28\NN\14204950 ._29\.\1740
D019344_D028361 NONE highly_0\RB\1740 active_1\JJ\1740 antiretroviral_2\JJ\1740 therapy_3\NN\657604 (_4\-LRB-\1740 haart_5\NN\3740161 )_6\-RRB-\1740 is_7\VBZ\836236 implicated_8\VBN\2677097 in_9\IN\13603305 cardiomyopathy_10\JJ\1740 (_11\-LRB-\1740 cm_12\NN\13649268 )_13\-RRB-\1740 and_14\CC\1740 in_15\IN\13603305 elevated_16\JJ\1740 plasma_17\NN\5398023 lactate_18\NN\14850483 (_19\-LRB-\1740 <e1>la</e1>_20\NN\14625458 )_21\-RRB-\1740 in_22\IN\13603305 aids_23\NN\13974317 through_24\IN\1740 mechanisms_25\NNS\13446390 of_26\IN\1740 <e2>mitochondrial_27\JJ\1740 dysfunction</e2>_28\NN\14204950 ._29\.\1740
D015215_D000163 NONE to_0\TO\1740 determine_1\VB\1645601 mitochondrial_2\JJ\1740 events_3\NNS\23100 from_4\IN\1740 haart_5\NN\3740161 in_6\FW\13603305 vivo_7\FW\1740 ,_8\,\1740 8-week-old_9\JJ\1740 hemizygous_10\JJ\1740 transgenic_11\JJ\1740 <e2>aids</e2>_12\NN\13974317 mice_13\NNS\2329401 (_14\-LRB-\1740 nl4_15\NN\1740 -_16\HYPH\1740 3delta_17\NN\1740 gag/pol_18\NN\1740 ;_19\:\1740 tg_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 wild-type_23\JJ\1740 fvb/n_24\NN\1740 littermates_25\NNS\1740 were_26\VBD\836236 treated_27\VBN\2376958 with_28\IN\1740 the_29\DT\1740 haart_30\NN\3740161 combination_31\NN\7951464 of_32\IN\1740 <e1>zidovudine</e1>_33\NN\3834836 ,_34\,\1740 lamivudine_35\NN\3834836 ,_36\,\1740 and_37\CC\1740 indinavir_38\NN\4013993 or_39\CC\3541091 vehicle_40\NN\3100490 control_41\NN\5190804 for_42\IN\1740 10_43\CD\13745420 days_44\NNS\15140892 or_45\CC\3541091 35_46\CD\1740 days_47\NNS\15140892 ._48\.\1740
D019259_D000163 NONE to_0\TO\1740 determine_1\VB\1645601 mitochondrial_2\JJ\1740 events_3\NNS\23100 from_4\IN\1740 haart_5\NN\3740161 in_6\FW\13603305 vivo_7\FW\1740 ,_8\,\1740 8-week-old_9\JJ\1740 hemizygous_10\JJ\1740 transgenic_11\JJ\1740 <e2>aids</e2>_12\NN\13974317 mice_13\NNS\2329401 (_14\-LRB-\1740 nl4_15\NN\1740 -_16\HYPH\1740 3delta_17\NN\1740 gag/pol_18\NN\1740 ;_19\:\1740 tg_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 wild-type_23\JJ\1740 fvb/n_24\NN\1740 littermates_25\NNS\1740 were_26\VBD\836236 treated_27\VBN\2376958 with_28\IN\1740 the_29\DT\1740 haart_30\NN\3740161 combination_31\NN\7951464 of_32\IN\1740 zidovudine_33\NN\3834836 ,_34\,\1740 <e1>lamivudine</e1>_35\NN\3834836 ,_36\,\1740 and_37\CC\1740 indinavir_38\NN\4013993 or_39\CC\3541091 vehicle_40\NN\3100490 control_41\NN\5190804 for_42\IN\1740 10_43\CD\13745420 days_44\NNS\15140892 or_45\CC\3541091 35_46\CD\1740 days_47\NNS\15140892 ._48\.\1740
D019469_D000163 NONE to_0\TO\1740 determine_1\VB\1645601 mitochondrial_2\JJ\1740 events_3\NNS\23100 from_4\IN\1740 haart_5\NN\3740161 in_6\FW\13603305 vivo_7\FW\1740 ,_8\,\1740 8-week-old_9\JJ\1740 hemizygous_10\JJ\1740 transgenic_11\JJ\1740 <e2>aids</e2>_12\NN\13974317 mice_13\NNS\2329401 (_14\-LRB-\1740 nl4_15\NN\1740 -_16\HYPH\1740 3delta_17\NN\1740 gag/pol_18\NN\1740 ;_19\:\1740 tg_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 wild-type_23\JJ\1740 fvb/n_24\NN\1740 littermates_25\NNS\1740 were_26\VBD\836236 treated_27\VBN\2376958 with_28\IN\1740 the_29\DT\1740 haart_30\NN\3740161 combination_31\NN\7951464 of_32\IN\1740 zidovudine_33\NN\3834836 ,_34\,\1740 lamivudine_35\NN\3834836 ,_36\,\1740 and_37\CC\1740 <e1>indinavir</e1>_38\NN\4013993 or_39\CC\3541091 vehicle_40\NN\3100490 control_41\NN\5190804 for_42\IN\1740 10_43\CD\13745420 days_44\NNS\15140892 or_45\CC\3541091 35_46\CD\1740 days_47\NNS\15140892 ._48\.\1740
D002118_D009202 NONE at_0\IN\14622893 termination_1\NN\15266911 of_2\IN\1740 the_3\DT\1740 experiments_4\NNS\641820 ,_5\,\1740 mice_6\NNS\2329401 underwent_7\VBD\109660 echocardiography_8\NN\177127 ,_9\,\1740 quantitation_10\NN\1740 of_11\IN\1740 abundance_12\NN\5108740 of_13\IN\1740 molecular_14\JJ\1740 markers_15\NNS\21939 of_16\IN\1740 <e2>cm</e2>_17\NN\13649268 (_18\-LRB-\1740 ventricular_19\JJ\1740 mrna_20\NN\14832193 encoding_21\VBG\115157 atrial_22\JJ\1740 natriuretic_23\JJ\1740 factor_24\NN\7326557 [_25\-LRB-\1740 anf_26\NN\1740 ]_27\-RRB-\1740 and_28\CC\1740 sarcoplasmic_29\JJ\1740 <e1>calcium</e1>_30\NN\14625458 atpase_31\NN\1740 [_32\-LRB-\1740 serca2_33\NN\1740 ]_34\-RRB-\1740 )_35\-RRB-\1740 ,_36\,\1740 and_37\CC\1740 determination_38\NN\43195 of_39\IN\1740 plasma_40\NN\5398023 la_41\NNP\14625458 ._42\.\1740
9100294
D002118_D018376 NONE <e2>cardiovascular_0\JJ\1740 alterations</e2>_1\NNS\7283608 in_2\IN\13603305 rat_3\NN\2329401 fetuses_4\NNS\1471682 exposed_5\VBN\2110927 to_6\TO\1740 <e1>calcium</e1>_7\NN\14625458 channel_8\NN\6251781 blockers_9\NNS\10101634 ._10\.\1740
D002118_D018376 NONE preclinical_0\JJ\1740 toxicologic_1\JJ\1740 investigation_2\NN\5797597 suggested_3\VBD\1010118 that_4\IN\1740 a_5\DT\13649268 new_6\JJ\1740 <e1>calcium</e1>_7\NN\14625458 channel_8\NN\6251781 blocker_9\NN\10101634 ,_10\,\1740 ro_11\NN\6894544 40_12\CD\13745420 -_13\SYM\1740 5967_14\CD\1740 ,_15\,\1740 induced_16\VBN\1627355 <e2>cardiovascular_17\JJ\1740 alterations</e2>_18\NNS\7283608 in_19\IN\13603305 rat_20\NN\2329401 fetuses_21\NNS\1471682 exposed_22\VBN\2110927 to_23\TO\1740 this_24\DT\1740 agent_25\NN\7347 during_26\IN\1740 organogenesis_27\NN\1740 ._28\.\1740
D002118_D018376 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 hypothesis_8\NN\7162194 that_9\IN\1740 <e1>calcium</e1>_10\NN\14625458 channel_11\NN\6251781 blockers_12\NNS\10101634 in_13\IN\13603305 general_14\JJ\1740 induce_15\VBP\1627355 <e2>cardiovascular_16\JJ\1740 malformations</e2>_17\NNS\14213199 indicating_18\VBG\952524 a_19\DT\13649268 pharmacologic_20\JJ\1740 class_21\NN\7951464 effect_22\NN\34213 ._23\.\1740
D002118_D018376 NONE pregnant_0\JJ\1740 rats_1\NNS\2329401 were_2\VBD\836236 administered_3\VBN\2436349 one_4\CD\13741022 of_5\IN\1740 these_6\DT\1740 <e1>calcium</e1>_7\NN\14625458 channel_8\NN\6251781 blockers_9\NNS\10101634 during_10\IN\1740 the_11\DT\1740 period_12\NN\13575869 of_13\IN\1740 cardiac_14\JJ\1740 morphogenesis_15\NN\13489037 and_16\CC\1740 the_17\DT\1740 offspring_18\NN\10235549 examined_19\VBN\789138 on_20\IN\1740 day_21\NN\15154774 20_22\CD\13745420 of_23\IN\1740 gestation_24\NN\15116532 for_25\IN\1740 <e2>cardiovascular_26\JJ\1740 malformations</e2>_27\NNS\14213199 ._28\.\1740
D002118_D018376 NONE a_0\DT\13649268 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 <e2>cardiovascular_4\JJ\1740 malformations</e2>_5\NNS\14213199 was_6\VBD\836236 observed_7\VBN\2163746 after_8\IN\1740 exposure_9\NN\5042871 to_10\TO\1740 each_11\DT\1740 of_12\IN\1740 the_13\DT\1740 four_14\CD\13741022 <e1>calcium</e1>_15\NN\14625458 channel_16\NN\6251781 blockers_17\NNS\10101634 ,_18\,\1740 but_19\CC\1740 this_20\DT\1740 incidence_21\NN\13821570 was_22\VBD\836236 statistically_23\RB\1740 significant_24\JJ\1740 only_25\RB\1740 for_26\IN\1740 verapamil_27\NN\2938514 and_28\CC\1740 nifedipine_29\NN\2938514 ._30\.\1740
D020748_D018376 CID preclinical_0\JJ\1740 toxicologic_1\JJ\1740 investigation_2\NN\5797597 suggested_3\VBD\1010118 that_4\IN\1740 a_5\DT\13649268 new_6\JJ\1740 calcium_7\NN\14625458 channel_8\NN\6251781 blocker_9\NN\10101634 ,_10\,\1740 <e1>ro_11\NN\6894544 40_12\CD\13745420 -_13\SYM\1740 5967</e1>_14\CD\1740 ,_15\,\1740 induced_16\VBN\1627355 <e2>cardiovascular_17\JJ\1740 alterations</e2>_18\NNS\7283608 in_19\IN\13603305 rat_20\NN\2329401 fetuses_21\NNS\1471682 exposed_22\VBN\2110927 to_23\TO\1740 this_24\DT\1740 agent_25\NN\7347 during_26\IN\1740 organogenesis_27\NN\1740 ._28\.\1740
D014700_D018376 CID a_0\DT\13649268 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 <e2>cardiovascular_4\JJ\1740 malformations</e2>_5\NNS\14213199 was_6\VBD\836236 observed_7\VBN\2163746 after_8\IN\1740 exposure_9\NN\5042871 to_10\TO\1740 each_11\DT\1740 of_12\IN\1740 the_13\DT\1740 four_14\CD\13741022 calcium_15\NN\14625458 channel_16\NN\6251781 blockers_17\NNS\10101634 ,_18\,\1740 but_19\CC\1740 this_20\DT\1740 incidence_21\NN\13821570 was_22\VBD\836236 statistically_23\RB\1740 significant_24\JJ\1740 only_25\RB\1740 for_26\IN\1740 <e1>verapamil</e1>_27\NN\2938514 and_28\CC\1740 nifedipine_29\NN\2938514 ._30\.\1740
D009543_D018376 CID a_0\DT\13649268 low_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 <e2>cardiovascular_4\JJ\1740 malformations</e2>_5\NNS\14213199 was_6\VBD\836236 observed_7\VBN\2163746 after_8\IN\1740 exposure_9\NN\5042871 to_10\TO\1740 each_11\DT\1740 of_12\IN\1740 the_13\DT\1740 four_14\CD\13741022 calcium_15\NN\14625458 channel_16\NN\6251781 blockers_17\NNS\10101634 ,_18\,\1740 but_19\CC\1740 this_20\DT\1740 incidence_21\NN\13821570 was_22\VBD\836236 statistically_23\RB\1740 significant_24\JJ\1740 only_25\RB\1740 for_26\IN\1740 verapamil_27\NN\2938514 and_28\CC\1740 <e1>nifedipine</e1>_29\NN\2938514 ._30\.\1740
16867021
D006632_D002375 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 study_6\VB\630380 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 <e1>histamine</e1>_10\NN\14739004 h(3)-receptor_11\NN\1740 ligands_12\NNS\20090 on_13\IN\1740 neuroleptic-induced_14\JJ\1740 <e2>catalepsy</e2>_15\NN\14023236 ,_16\,\1740 apomorphine-induced_17\JJ\1740 climbing_18\NN\7445480 behavior_19\NN\407535 and_20\CC\1740 amphetamine-induced_21\JJ\1740 locomotor_22\NN\1740 activities_23\NNS\30358 in_24\IN\13603305 mice_25\NNS\2329401 ._26\.\1740
D001058_D002375 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 study_6\VB\630380 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 histamine_10\NN\14739004 h(3)-receptor_11\NN\1740 ligands_12\NNS\20090 on_13\IN\1740 neuroleptic-induced_14\JJ\1740 <e2>catalepsy</e2>_15\NN\14023236 ,_16\,\1740 <e1>apomorphine-induced</e1>_17\JJ\1740 climbing_18\NN\7445480 behavior_19\NN\407535 and_20\CC\1740 amphetamine-induced_21\JJ\1740 locomotor_22\NN\1740 activities_23\NNS\30358 in_24\IN\13603305 mice_25\NNS\2329401 ._26\.\1740
D001058_D002375 NONE <e2>catalepsy</e2>_0\NNP\14023236 was_1\VBD\836236 induced_2\VBN\1627355 by_3\IN\1740 haloperidol_4\NN\3713736 (_5\-LRB-\1740 2_6\CD\13741022 mg/kg_7\NN\1740 p.o._8\NN\10360747 )_9\-RRB-\1740 ,_10\,\1740 while_11\IN\15122231 <e1>apomorphine</e1>_12\NN\3786417 (_13\-LRB-\1740 1.5_14\CD\1740 mg/kg_15\NN\1740 s.c._16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 amphetamine_19\NN\3248958 (_20\-LRB-\1740 2_21\CD\13741022 mg/kg_22\NN\1740 s.c._23\NN\1740 )_24\-RRB-\1740 were_25\VBD\836236 used_26\VBN\1156834 for_27\IN\1740 studying_28\VBG\630380 climbing_29\NN\7445480 behavior_30\NN\407535 and_31\CC\1740 locomotor_32\NN\1740 activities_33\NNS\30358 ,_34\,\1740 respectively_35\RB\1740 ._36\.\1740
D001058_D002375 NONE thp_0\NN\1740 exhibited_1\VBD\2632167 an_2\DT\6697703 antipsychotic-like_3\JJ\1740 profile_4\NN\6999802 by_5\IN\1740 potentiating_6\VBG\229605 haloperidol-induced_7\JJ\1740 <e2>catalepsy</e2>_8\NN\14023236 ,_9\,\1740 reducing_10\VBG\441445 amphetamine-induced_11\JJ\1740 hyperactivity_12\NN\14052403 and_13\CC\1740 reducing_14\VBG\441445 <e1>apomorphine-induced</e1>_15\JJ\1740 climbing_16\NN\7445480 in_17\IN\13603305 mice_18\NNS\2329401 ._19\.\1740
D000661_D002375 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 study_6\VB\630380 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 histamine_10\NN\14739004 h(3)-receptor_11\NN\1740 ligands_12\NNS\20090 on_13\IN\1740 neuroleptic-induced_14\JJ\1740 <e2>catalepsy</e2>_15\NN\14023236 ,_16\,\1740 apomorphine-induced_17\JJ\1740 climbing_18\NN\7445480 behavior_19\NN\407535 and_20\CC\1740 <e1>amphetamine-induced</e1>_21\JJ\1740 locomotor_22\NN\1740 activities_23\NNS\30358 in_24\IN\13603305 mice_25\NNS\2329401 ._26\.\1740
D000661_D002375 NONE <e2>catalepsy</e2>_0\NNP\14023236 was_1\VBD\836236 induced_2\VBN\1627355 by_3\IN\1740 haloperidol_4\NN\3713736 (_5\-LRB-\1740 2_6\CD\13741022 mg/kg_7\NN\1740 p.o._8\NN\10360747 )_9\-RRB-\1740 ,_10\,\1740 while_11\IN\15122231 apomorphine_12\NN\3786417 (_13\-LRB-\1740 1.5_14\CD\1740 mg/kg_15\NN\1740 s.c._16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 <e1>amphetamine</e1>_19\NN\3248958 (_20\-LRB-\1740 2_21\CD\13741022 mg/kg_22\NN\1740 s.c._23\NN\1740 )_24\-RRB-\1740 were_25\VBD\836236 used_26\VBN\1156834 for_27\IN\1740 studying_28\VBG\630380 climbing_29\NN\7445480 behavior_30\NN\407535 and_31\CC\1740 locomotor_32\NN\1740 activities_33\NNS\30358 ,_34\,\1740 respectively_35\RB\1740 ._36\.\1740
D000661_D002375 NONE thp_0\NN\1740 exhibited_1\VBD\2632167 an_2\DT\6697703 antipsychotic-like_3\JJ\1740 profile_4\NN\6999802 by_5\IN\1740 potentiating_6\VBG\229605 haloperidol-induced_7\JJ\1740 <e2>catalepsy</e2>_8\NN\14023236 ,_9\,\1740 reducing_10\VBG\441445 <e1>amphetamine-induced</e1>_11\JJ\1740 hyperactivity_12\NN\14052403 and_13\CC\1740 reducing_14\VBG\441445 apomorphine-induced_15\JJ\1740 climbing_16\NN\7445480 in_17\IN\13603305 mice_18\NNS\2329401 ._19\.\1740
D006220_D002375 CID <e2>catalepsy</e2>_0\NNP\14023236 was_1\VBD\836236 induced_2\VBN\1627355 by_3\IN\1740 <e1>haloperidol</e1>_4\NN\3713736 (_5\-LRB-\1740 2_6\CD\13741022 mg/kg_7\NN\1740 p.o._8\NN\10360747 )_9\-RRB-\1740 ,_10\,\1740 while_11\IN\15122231 apomorphine_12\NN\3786417 (_13\-LRB-\1740 1.5_14\CD\1740 mg/kg_15\NN\1740 s.c._16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 amphetamine_19\NN\3248958 (_20\-LRB-\1740 2_21\CD\13741022 mg/kg_22\NN\1740 s.c._23\NN\1740 )_24\-RRB-\1740 were_25\VBD\836236 used_26\VBN\1156834 for_27\IN\1740 studying_28\VBG\630380 climbing_29\NN\7445480 behavior_30\NN\407535 and_31\CC\1740 locomotor_32\NN\1740 activities_33\NNS\30358 ,_34\,\1740 respectively_35\RB\1740 ._36\.\1740
D006220_D002375 CID administration_0\NN\1133281 of_1\IN\1740 thp_2\NN\1740 (_3\-LRB-\1740 3.75_4\CD\1740 ,_5\,\1740 7.5_6\CD\1740 and_7\CC\1740 15_8\CD\13745420 mg/kg_9\NN\1740 i.p._10\RB\1740 )_11\-RRB-\1740 1_12\CD\13741022 h_13\NN\14622893 prior_14\RB\1740 to_15\TO\1740 <e1>haloperidol</e1>_16\NN\3713736 resulted_17\VBD\2633881 in_18\IN\13603305 a_19\DT\13649268 dose-dependent_20\JJ\1740 increase_21\NN\13576355 in_22\IN\13603305 the_23\DT\1740 <e2>catalepsy</e2>_24\NN\14023236 times_25\NNS\15113229 (_26\-LRB-\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D006220_D002375 CID thp_0\NN\1740 exhibited_1\VBD\2632167 an_2\DT\6697703 antipsychotic-like_3\JJ\1740 profile_4\NN\6999802 by_5\IN\1740 potentiating_6\VBG\229605 <e1>haloperidol-induced</e1>_7\JJ\1740 <e2>catalepsy</e2>_8\NN\14023236 ,_9\,\1740 reducing_10\VBG\441445 amphetamine-induced_11\JJ\1740 hyperactivity_12\NN\14052403 and_13\CC\1740 reducing_14\VBG\441445 apomorphine-induced_15\JJ\1740 climbing_16\NN\7445480 in_17\IN\13603305 mice_18\NNS\2329401 ._19\.\1740
C069357_D002375 NONE <e1>(r)-alpha-methylhistamine</e1>_0\NN\1740 (_1\-LRB-\1740 ramh_2\NN\1740 )_3\-RRB-\1740 (_4\-LRB-\1740 5_5\CD\13741022 microg_6\NN\1740 i.c.v._7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 thioperamide_10\NN\1740 (_11\-LRB-\1740 thp_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 15_15\CD\13745420 mg/kg_16\NN\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 per_20\FW\1740 se_21\FW\14724645 did_22\VBD\1640855 not_23\RB\1740 cause_24\VB\1617192 <e2>catalepsy</e2>_25\NN\14023236 ._26\.\1740
C069357_D002375 NONE (r)-alpha-methylhistamine_0\NN\1740 (_1\-LRB-\1740 <e1>ramh</e1>_2\NN\1740 )_3\-RRB-\1740 (_4\-LRB-\1740 5_5\CD\13741022 microg_6\NN\1740 i.c.v._7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 thioperamide_10\NN\1740 (_11\-LRB-\1740 thp_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 15_15\CD\13745420 mg/kg_16\NN\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 per_20\FW\1740 se_21\FW\14724645 did_22\VBD\1640855 not_23\RB\1740 cause_24\VB\1617192 <e2>catalepsy</e2>_25\NN\14023236 ._26\.\1740
C052075_D002375 CID (r)-alpha-methylhistamine_0\NN\1740 (_1\-LRB-\1740 ramh_2\NN\1740 )_3\-RRB-\1740 (_4\-LRB-\1740 5_5\CD\13741022 microg_6\NN\1740 i.c.v._7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 <e1>thioperamide</e1>_10\NN\1740 (_11\-LRB-\1740 thp_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 15_15\CD\13745420 mg/kg_16\NN\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 per_20\FW\1740 se_21\FW\14724645 did_22\VBD\1640855 not_23\RB\1740 cause_24\VB\1617192 <e2>catalepsy</e2>_25\NN\14023236 ._26\.\1740
C052075_D002375 CID (r)-alpha-methylhistamine_0\NN\1740 (_1\-LRB-\1740 ramh_2\NN\1740 )_3\-RRB-\1740 (_4\-LRB-\1740 5_5\CD\13741022 microg_6\NN\1740 i.c.v._7\NN\1740 )_8\-RRB-\1740 and_9\CC\1740 thioperamide_10\NN\1740 (_11\-LRB-\1740 <e1>thp</e1>_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 15_15\CD\13745420 mg/kg_16\NN\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 per_20\FW\1740 se_21\FW\14724645 did_22\VBD\1640855 not_23\RB\1740 cause_24\VB\1617192 <e2>catalepsy</e2>_25\NN\14023236 ._26\.\1740
C052075_D002375 CID administration_0\NN\1133281 of_1\IN\1740 <e1>thp</e1>_2\NN\1740 (_3\-LRB-\1740 3.75_4\CD\1740 ,_5\,\1740 7.5_6\CD\1740 and_7\CC\1740 15_8\CD\13745420 mg/kg_9\NN\1740 i.p._10\RB\1740 )_11\-RRB-\1740 1_12\CD\13741022 h_13\NN\14622893 prior_14\RB\1740 to_15\TO\1740 haloperidol_16\NN\3713736 resulted_17\VBD\2633881 in_18\IN\13603305 a_19\DT\13649268 dose-dependent_20\JJ\1740 increase_21\NN\13576355 in_22\IN\13603305 the_23\DT\1740 <e2>catalepsy</e2>_24\NN\14023236 times_25\NNS\15113229 (_26\-LRB-\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
C052075_D002375 CID <e1>thp</e1>_0\NN\1740 exhibited_1\VBD\2632167 an_2\DT\6697703 antipsychotic-like_3\JJ\1740 profile_4\NN\6999802 by_5\IN\1740 potentiating_6\VBG\229605 haloperidol-induced_7\JJ\1740 <e2>catalepsy</e2>_8\NN\14023236 ,_9\,\1740 reducing_10\VBG\441445 amphetamine-induced_11\JJ\1740 hyperactivity_12\NN\14052403 and_13\CC\1740 reducing_14\VBG\441445 apomorphine-induced_15\JJ\1740 climbing_16\NN\7445480 in_17\IN\13603305 mice_18\NNS\2329401 ._19\.\1740
D000661_D006948 CID on_0\IN\1740 <e1>amphetamine-induced</e1>_1\JJ\1740 <e2>hyperactivity</e2>_2\NN\14052403 ,_3\,\1740 thp_4\NN\1740 (_5\-LRB-\1740 3.75_6\CD\1740 and_7\CC\1740 7.5_8\CD\1740 mg/kg_9\NN\1740 i.p._10\FW\1740 )_11\-RRB-\1740 reduced_12\VBN\441445 locomotor_13\NN\1740 time_14\NN\7308889 ,_15\,\1740 distance_16\NN\5083328 traveled_17\VBN\1843055 and_18\CC\1740 average_19\JJ\1740 speed_20\NN\15286249 (_21\-LRB-\1740 p_22\NN\14622893 <_23\XX\1740 0.05_24\CD\1740 )_25\-RRB-\1740 ._26\.\1740
D000661_D006948 CID thp_0\NN\1740 exhibited_1\VBD\2632167 an_2\DT\6697703 antipsychotic-like_3\JJ\1740 profile_4\NN\6999802 by_5\IN\1740 potentiating_6\VBG\229605 haloperidol-induced_7\JJ\1740 catalepsy_8\NN\14023236 ,_9\,\1740 reducing_10\VBG\441445 <e1>amphetamine-induced</e1>_11\JJ\1740 <e2>hyperactivity</e2>_12\NN\14052403 and_13\CC\1740 reducing_14\VBG\441445 apomorphine-induced_15\JJ\1740 climbing_16\NN\7445480 in_17\IN\13603305 mice_18\NNS\2329401 ._19\.\1740
C052075_D006948 NONE on_0\IN\1740 amphetamine-induced_1\JJ\1740 <e2>hyperactivity</e2>_2\NN\14052403 ,_3\,\1740 <e1>thp</e1>_4\NN\1740 (_5\-LRB-\1740 3.75_6\CD\1740 and_7\CC\1740 7.5_8\CD\1740 mg/kg_9\NN\1740 i.p._10\FW\1740 )_11\-RRB-\1740 reduced_12\VBN\441445 locomotor_13\NN\1740 time_14\NN\7308889 ,_15\,\1740 distance_16\NN\5083328 traveled_17\VBN\1843055 and_18\CC\1740 average_19\JJ\1740 speed_20\NN\15286249 (_21\-LRB-\1740 p_22\NN\14622893 <_23\XX\1740 0.05_24\CD\1740 )_25\-RRB-\1740 ._26\.\1740
C052075_D006948 NONE <e1>thp</e1>_0\NN\1740 exhibited_1\VBD\2632167 an_2\DT\6697703 antipsychotic-like_3\JJ\1740 profile_4\NN\6999802 by_5\IN\1740 potentiating_6\VBG\229605 haloperidol-induced_7\JJ\1740 catalepsy_8\NN\14023236 ,_9\,\1740 reducing_10\VBG\441445 amphetamine-induced_11\JJ\1740 <e2>hyperactivity</e2>_12\NN\14052403 and_13\CC\1740 reducing_14\VBG\441445 apomorphine-induced_15\JJ\1740 climbing_16\NN\7445480 in_17\IN\13603305 mice_18\NNS\2329401 ._19\.\1740
D006220_D006948 NONE thp_0\NN\1740 exhibited_1\VBD\2632167 an_2\DT\6697703 antipsychotic-like_3\JJ\1740 profile_4\NN\6999802 by_5\IN\1740 potentiating_6\VBG\229605 <e1>haloperidol-induced</e1>_7\JJ\1740 catalepsy_8\NN\14023236 ,_9\,\1740 reducing_10\VBG\441445 amphetamine-induced_11\JJ\1740 <e2>hyperactivity</e2>_12\NN\14052403 and_13\CC\1740 reducing_14\VBG\441445 apomorphine-induced_15\JJ\1740 climbing_16\NN\7445480 in_17\IN\13603305 mice_18\NNS\2329401 ._19\.\1740
D001058_D006948 NONE thp_0\NN\1740 exhibited_1\VBD\2632167 an_2\DT\6697703 antipsychotic-like_3\JJ\1740 profile_4\NN\6999802 by_5\IN\1740 potentiating_6\VBG\229605 haloperidol-induced_7\JJ\1740 catalepsy_8\NN\14023236 ,_9\,\1740 reducing_10\VBG\441445 amphetamine-induced_11\JJ\1740 <e2>hyperactivity</e2>_12\NN\14052403 and_13\CC\1740 reducing_14\VBG\441445 <e1>apomorphine-induced</e1>_15\JJ\1740 climbing_16\NN\7445480 in_17\IN\13603305 mice_18\NNS\2329401 ._19\.\1740
19269743
D002211_D010146 CID explicit_0\NN\1740 episodic_1\JJ\1740 memory_2\NN\5926676 for_3\IN\1740 sensory-discriminative_4\JJ\1740 components_5\NNS\5867413 of_6\IN\1740 <e1>capsaicin-induced</e1>_7\JJ\1740 <e2>pain</e2>_8\NN\14299637 :_9\:\1740 immediate_10\JJ\1740 and_11\CC\1740 delayed_12\VBN\439958 ratings_13\NNS\5733583 ._14\.\1740
D002211_D010146 CID in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 address_3\VB\740577 long-term_4\JJ\1740 <e2>pain</e2>_5\NN\14299637 memory_6\NN\5926676 ,_7\,\1740 nine_8\CD\13741022 healthy_9\JJ\1740 male_10\JJ\1740 volunteers_11\NNS\10582746 received_12\VBD\2210855 intradermal_13\JJ\1740 injections_14\NNS\320852 of_15\IN\1740 three_16\CD\13741022 doses_17\NNS\3740161 of_18\IN\1740 <e1>capsaicin</e1>_19\NN\15032661 (_20\-LRB-\1740 0.05_21\CD\1740 ,_22\,\1740 1_23\CD\13741022 and_24\CC\1740 20_25\CD\13745420 microg_26\NN\1740 ,_27\,\1740 separated_28\VBN\1850315 by_29\IN\1740 15_30\CD\13745420 min_31\NN\15154774 breaks_32\NNS\7283608 )_33\-RRB-\1740 ,_34\,\1740 each_35\DT\1740 given_36\VBN\2327200 three_37\CD\13741022 times_38\NNS\15113229 in_39\IN\13603305 a_40\DT\13649268 balanced_41\JJ\1740 design_42\NN\927261 across_43\IN\1740 three_44\CD\13741022 sessions_45\NNS\7142566 at_46\IN\14622893 one_47\CD\13741022 week_48\NN\15113229 intervals_49\NNS\33615 ._50\.\1740
D002211_D010146 CID subjects_0\NNS\6598915 were_1\VBD\836236 able_2\JJ\1740 to_3\TO\1740 reliably_4\RB\1740 discriminate_5\VB\650353 <e2>pain</e2>_6\NN\14299637 magnitude_7\NN\4916342 and_8\CC\1740 duration_9\NN\15113229 across_10\IN\1740 <e1>capsaicin</e1>_11\NN\15032661 doses_12\NNS\3740161 (_13\-LRB-\1740 both_14\CC\1740 p<0.001_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 regardless_18\RB\1740 of_19\IN\1740 whether_20\IN\1740 first-time_21\JJ\1740 ratings_22\NNS\5733583 were_23\VBD\836236 requested_24\VBN\742320 immediately_25\RB\1740 ,_26\,\1740 after_27\IN\1740 one_28\CD\13741022 hour_29\NN\15154774 or_30\CC\3541091 after_31\IN\1740 one_32\CD\13741022 day_33\NN\15154774 ._34\.\1740
84204
D002927_D003221 CID pharmacokinetic_0\JJ\1740 and_1\CC\1740 clinical_2\JJ\1740 studies_3\NNS\635850 in_4\IN\13603305 patients_5\NNS\9898892 with_6\IN\1740 <e1>cimetidine-associated</e1>_7\JJ\1740 mental_8\JJ\1740 <e2>confusion</e2>_9\NN\13972797 ._10\.\1740
D002927_D003221 CID 15_0\CD\13745420 cases_1\NNS\7283608 of_2\IN\1740 <e1>cimetidine-associated</e1>_3\JJ\1740 mental_4\JJ\1740 <e2>confusion</e2>_5\NN\13972797 have_6\VBP\2108377 been_7\VBN\836236 reported_8\VBN\831651 ._9\.\1740
D002927_D051437 NONE these_0\DT\1740 6_1\CD\13741022 patients_2\NNS\9898892 had_3\VBD\2108377 both_4\CC\1740 <e2>renal_5\JJ\1740 and_6\CC\1740 liver_7\NN\5298729 dysfunction</e2>_8\NN\14204950 (_9\-LRB-\1740 p_10\NN\14622893 less_11\JJR\1740 than_12\IN\1740 0.05_13\CD\1740 )_14\-RRB-\1740 ,_15\,\1740 as_16\RB\1740 well_17\RB\1740 as_18\IN\14622893 <e1>cimetidine</e1>_19\NN\14778019 trough-concentrations_20\NNS\1740 of_21\IN\1740 more_22\JJR\1740 than_23\IN\1740 1.25_24\CD\1740 microgram/ml_25\NN\1740 (_26\-LRB-\1740 p_27\NN\14622893 less_28\JJR\1740 than_29\IN\1740 0.05_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D002927_D008107 NONE these_0\DT\1740 6_1\CD\13741022 patients_2\NNS\9898892 had_3\VBD\2108377 both_4\CC\1740 <e2>renal_5\JJ\1740 and_6\CC\1740 liver_7\NN\5298729 dysfunction</e2>_8\NN\14204950 (_9\-LRB-\1740 p_10\NN\14622893 less_11\JJR\1740 than_12\IN\1740 0.05_13\CD\1740 )_14\-RRB-\1740 ,_15\,\1740 as_16\RB\1740 well_17\RB\1740 as_18\IN\14622893 <e1>cimetidine</e1>_19\NN\14778019 trough-concentrations_20\NNS\1740 of_21\IN\1740 more_22\JJR\1740 than_23\IN\1740 1.25_24\CD\1740 microgram/ml_25\NN\1740 (_26\-LRB-\1740 p_27\NN\14622893 less_28\JJR\1740 than_29\IN\1740 0.05_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
11027905
D007649_D009369 NONE analgesic_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 intravenous_3\JJ\1740 <e1>ketamine</e1>_4\NN\3054098 in_5\IN\13603305 <e2>cancer</e2>_6\NN\14239425 patients_7\NNS\9898892 on_8\IN\1740 morphine_9\NN\2707683 therapy_10\NN\657604 :_11\:\1740 a_12\DT\13649268 randomized_13\VBN\278117 ,_14\,\1740 controlled_15\VBN\2422663 ,_16\,\1740 double-blind_17\JJ\1740 ,_18\,\1740 crossover_19\NN\13526110 ,_20\,\1740 double-dose_21\JJ\1740 study_22\NN\635850 ._23\.\1740
D007649_D009369 NONE a_0\DT\13649268 slow_1\JJ\1740 bolus_2\NN\13899404 of_3\IN\1740 subhypnotic_4\JJ\1740 doses_5\NNS\3740161 of_6\IN\1740 <e1>ketamine</e1>_7\NN\3054098 (_8\-LRB-\1740 0.25_9\CD\1740 mg/kg_10\NN\1740 or_11\CC\3541091 0.50_12\CD\1740 mg/kg_13\NN\1740 )_14\-RRB-\1740 was_15\VBD\836236 given_16\VBN\2327200 to_17\TO\1740 10_18\CD\13745420 <e2>cancer</e2>_19\NN\14239425 patients_20\NNS\9898892 whose_21\WP$\1740 pain_22\NN\14299637 was_23\VBD\836236 unrelieved_24\VBN\1740 by_25\IN\1740 morphine_26\NN\2707683 in_27\IN\13603305 a_28\DT\13649268 randomized_29\JJ\1740 ,_30\,\1740 double-blind_31\JJ\1740 ,_32\,\1740 crossover_33\NN\13526110 ,_34\,\1740 double-dose_35\JJ\1740 study_36\NN\635850 ._37\.\1740
D009020_D009369 NONE analgesic_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 intravenous_3\JJ\1740 ketamine_4\NN\3054098 in_5\IN\13603305 <e2>cancer</e2>_6\NN\14239425 patients_7\NNS\9898892 on_8\IN\1740 <e1>morphine</e1>_9\NN\2707683 therapy_10\NN\657604 :_11\:\1740 a_12\DT\13649268 randomized_13\VBN\278117 ,_14\,\1740 controlled_15\VBN\2422663 ,_16\,\1740 double-blind_17\JJ\1740 ,_18\,\1740 crossover_19\NN\13526110 ,_20\,\1740 double-dose_21\JJ\1740 study_22\NN\635850 ._23\.\1740
D009020_D009369 NONE a_0\DT\13649268 slow_1\JJ\1740 bolus_2\NN\13899404 of_3\IN\1740 subhypnotic_4\JJ\1740 doses_5\NNS\3740161 of_6\IN\1740 ketamine_7\NN\3054098 (_8\-LRB-\1740 0.25_9\CD\1740 mg/kg_10\NN\1740 or_11\CC\3541091 0.50_12\CD\1740 mg/kg_13\NN\1740 )_14\-RRB-\1740 was_15\VBD\836236 given_16\VBN\2327200 to_17\TO\1740 10_18\CD\13745420 <e2>cancer</e2>_19\NN\14239425 patients_20\NNS\9898892 whose_21\WP$\1740 pain_22\NN\14299637 was_23\VBD\836236 unrelieved_24\VBN\1740 by_25\IN\1740 <e1>morphine</e1>_26\NN\2707683 in_27\IN\13603305 a_28\DT\13649268 randomized_29\JJ\1740 ,_30\,\1740 double-blind_31\JJ\1740 ,_32\,\1740 crossover_33\NN\13526110 ,_34\,\1740 double-dose_35\JJ\1740 study_36\NN\635850 ._37\.\1740
D009020_D010146 NONE <e2>pain</e2>_0\NN\14299637 not_1\RB\1740 responsive_2\JJ\1740 to_3\TO\1740 <e1>morphine</e1>_4\NN\2707683 is_5\VBZ\836236 often_6\RB\1740 problematic_7\JJ\1740 ._8\.\1740
D009020_D010146 NONE a_0\DT\13649268 slow_1\JJ\1740 bolus_2\NN\13899404 of_3\IN\1740 subhypnotic_4\JJ\1740 doses_5\NNS\3740161 of_6\IN\1740 ketamine_7\NN\3054098 (_8\-LRB-\1740 0.25_9\CD\1740 mg/kg_10\NN\1740 or_11\CC\3541091 0.50_12\CD\1740 mg/kg_13\NN\1740 )_14\-RRB-\1740 was_15\VBD\836236 given_16\VBN\2327200 to_17\TO\1740 10_18\CD\13745420 cancer_19\NN\14239425 patients_20\NNS\9898892 whose_21\WP$\1740 <e2>pain</e2>_22\NN\14299637 was_23\VBD\836236 unrelieved_24\VBN\1740 by_25\IN\1740 <e1>morphine</e1>_26\NN\2707683 in_27\IN\13603305 a_28\DT\13649268 randomized_29\JJ\1740 ,_30\,\1740 double-blind_31\JJ\1740 ,_32\,\1740 crossover_33\NN\13526110 ,_34\,\1740 double-dose_35\JJ\1740 study_36\NN\635850 ._37\.\1740
D009020_D010146 NONE ketamine_0\NNP\3054098 can_1\MD\3094503 improve_2\VB\126264 <e1>morphine</e1>_3\NN\2707683 analgesia_4\NN\14034177 in_5\IN\13603305 difficult_6\JJ\1740 <e2>pain</e2>_7\NN\14299637 syndromes_8\NNS\5870365 ,_9\,\1740 such_10\JJ\1740 as_11\IN\14622893 neuropathic_12\JJ\1740 pain_13\NN\14299637 ._14\.\1740
D016202_D010146 NONE animal_0\NN\4475 and_1\CC\1740 clinical_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 suggested_5\VBN\1010118 that_6\IN\1740 <e1>n-methyl-d-aspartate</e1>_7\NN\1740 (_8\-LRB-\1740 nmda_9\NN\1740 )_10\-RRB-\1740 antagonists_11\NNS\7846 ,_12\,\1740 such_13\JJ\1740 as_14\IN\14622893 ketamine_15\NN\3054098 ,_16\,\1740 may_17\MD\15209706 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 improving_21\VBG\126264 opioid_22\JJ\1740 analgesia_23\NN\14034177 in_24\IN\13603305 difficult_25\JJ\1740 <e2>pain</e2>_26\NN\14299637 syndromes_27\NNS\5870365 ,_28\,\1740 such_29\JJ\1740 as_30\IN\14622893 neuropathic_31\JJ\1740 pain_32\NN\14299637 ._33\.\1740
D016202_D010146 NONE animal_0\NN\4475 and_1\CC\1740 clinical_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 suggested_5\VBN\1010118 that_6\IN\1740 n-methyl-d-aspartate_7\NN\1740 (_8\-LRB-\1740 <e1>nmda</e1>_9\NN\1740 )_10\-RRB-\1740 antagonists_11\NNS\7846 ,_12\,\1740 such_13\JJ\1740 as_14\IN\14622893 ketamine_15\NN\3054098 ,_16\,\1740 may_17\MD\15209706 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 improving_21\VBG\126264 opioid_22\JJ\1740 analgesia_23\NN\14034177 in_24\IN\13603305 difficult_25\JJ\1740 <e2>pain</e2>_26\NN\14299637 syndromes_27\NNS\5870365 ,_28\,\1740 such_29\JJ\1740 as_30\IN\14622893 neuropathic_31\JJ\1740 pain_32\NN\14299637 ._33\.\1740
D016202_D009437 NONE animal_0\NN\4475 and_1\CC\1740 clinical_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 suggested_5\VBN\1010118 that_6\IN\1740 <e1>n-methyl-d-aspartate</e1>_7\NN\1740 (_8\-LRB-\1740 nmda_9\NN\1740 )_10\-RRB-\1740 antagonists_11\NNS\7846 ,_12\,\1740 such_13\JJ\1740 as_14\IN\14622893 ketamine_15\NN\3054098 ,_16\,\1740 may_17\MD\15209706 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 improving_21\VBG\126264 opioid_22\JJ\1740 analgesia_23\NN\14034177 in_24\IN\13603305 difficult_25\JJ\1740 pain_26\NN\14299637 syndromes_27\NNS\5870365 ,_28\,\1740 such_29\JJ\1740 as_30\IN\14622893 <e2>neuropathic_31\JJ\1740 pain</e2>_32\NN\14299637 ._33\.\1740
D016202_D009437 NONE animal_0\NN\4475 and_1\CC\1740 clinical_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 suggested_5\VBN\1010118 that_6\IN\1740 n-methyl-d-aspartate_7\NN\1740 (_8\-LRB-\1740 <e1>nmda</e1>_9\NN\1740 )_10\-RRB-\1740 antagonists_11\NNS\7846 ,_12\,\1740 such_13\JJ\1740 as_14\IN\14622893 ketamine_15\NN\3054098 ,_16\,\1740 may_17\MD\15209706 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 improving_21\VBG\126264 opioid_22\JJ\1740 analgesia_23\NN\14034177 in_24\IN\13603305 difficult_25\JJ\1740 pain_26\NN\14299637 syndromes_27\NNS\5870365 ,_28\,\1740 such_29\JJ\1740 as_30\IN\14622893 <e2>neuropathic_31\JJ\1740 pain</e2>_32\NN\14299637 ._33\.\1740
D007649_D010146 NONE animal_0\NN\4475 and_1\CC\1740 clinical_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 suggested_5\VBN\1010118 that_6\IN\1740 n-methyl-d-aspartate_7\NN\1740 (_8\-LRB-\1740 nmda_9\NN\1740 )_10\-RRB-\1740 antagonists_11\NNS\7846 ,_12\,\1740 such_13\JJ\1740 as_14\IN\14622893 <e1>ketamine</e1>_15\NN\3054098 ,_16\,\1740 may_17\MD\15209706 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 improving_21\VBG\126264 opioid_22\JJ\1740 analgesia_23\NN\14034177 in_24\IN\13603305 difficult_25\JJ\1740 <e2>pain</e2>_26\NN\14299637 syndromes_27\NNS\5870365 ,_28\,\1740 such_29\JJ\1740 as_30\IN\14622893 neuropathic_31\JJ\1740 pain_32\NN\14299637 ._33\.\1740
D007649_D010146 NONE a_0\DT\13649268 slow_1\JJ\1740 bolus_2\NN\13899404 of_3\IN\1740 subhypnotic_4\JJ\1740 doses_5\NNS\3740161 of_6\IN\1740 <e1>ketamine</e1>_7\NN\3054098 (_8\-LRB-\1740 0.25_9\CD\1740 mg/kg_10\NN\1740 or_11\CC\3541091 0.50_12\CD\1740 mg/kg_13\NN\1740 )_14\-RRB-\1740 was_15\VBD\836236 given_16\VBN\2327200 to_17\TO\1740 10_18\CD\13745420 cancer_19\NN\14239425 patients_20\NNS\9898892 whose_21\WP$\1740 <e2>pain</e2>_22\NN\14299637 was_23\VBD\836236 unrelieved_24\VBN\1740 by_25\IN\1740 morphine_26\NN\2707683 in_27\IN\13603305 a_28\DT\13649268 randomized_29\JJ\1740 ,_30\,\1740 double-blind_31\JJ\1740 ,_32\,\1740 crossover_33\NN\13526110 ,_34\,\1740 double-dose_35\JJ\1740 study_36\NN\635850 ._37\.\1740
D007649_D010146 NONE <e1>ketamine</e1>_0\NNP\3054098 ,_1\,\1740 but_2\CC\1740 not_3\RB\1740 saline_4\NN\14849367 solution_5\NN\14586258 ,_6\,\1740 significantly_7\RB\1740 reduced_8\VBD\441445 the_9\DT\1740 <e2>pain</e2>_10\NN\14299637 intensity_11\NN\5090441 in_12\IN\13603305 almost_13\RB\1740 all_14\PDT\1740 the_15\DT\1740 patients_16\NNS\9898892 at_17\IN\14622893 both_18\DT\1740 doses_19\NNS\3740161 ._20\.\1740
D007649_D010146 NONE <e1>ketamine</e1>_0\NNP\3054098 can_1\MD\3094503 improve_2\VB\126264 morphine_3\NN\2707683 analgesia_4\NN\14034177 in_5\IN\13603305 difficult_6\JJ\1740 <e2>pain</e2>_7\NN\14299637 syndromes_8\NNS\5870365 ,_9\,\1740 such_10\JJ\1740 as_11\IN\14622893 neuropathic_12\JJ\1740 pain_13\NN\14299637 ._14\.\1740
D007649_D009437 NONE animal_0\NN\4475 and_1\CC\1740 clinical_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 suggested_5\VBN\1010118 that_6\IN\1740 n-methyl-d-aspartate_7\NN\1740 (_8\-LRB-\1740 nmda_9\NN\1740 )_10\-RRB-\1740 antagonists_11\NNS\7846 ,_12\,\1740 such_13\JJ\1740 as_14\IN\14622893 <e1>ketamine</e1>_15\NN\3054098 ,_16\,\1740 may_17\MD\15209706 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 improving_21\VBG\126264 opioid_22\JJ\1740 analgesia_23\NN\14034177 in_24\IN\13603305 difficult_25\JJ\1740 pain_26\NN\14299637 syndromes_27\NNS\5870365 ,_28\,\1740 such_29\JJ\1740 as_30\IN\14622893 <e2>neuropathic_31\JJ\1740 pain</e2>_32\NN\14299637 ._33\.\1740
D007649_D009437 NONE <e1>ketamine</e1>_0\NNP\3054098 can_1\MD\3094503 improve_2\VB\126264 morphine_3\NN\2707683 analgesia_4\NN\14034177 in_5\IN\13603305 difficult_6\JJ\1740 pain_7\NN\14299637 syndromes_8\NNS\5870365 ,_9\,\1740 such_10\JJ\1740 as_11\IN\14622893 <e2>neuropathic_12\JJ\1740 pain</e2>_13\NN\14299637 ._14\.\1740
D009020_D009437 NONE ketamine_0\NNP\3054098 can_1\MD\3094503 improve_2\VB\126264 <e1>morphine</e1>_3\NN\2707683 analgesia_4\NN\14034177 in_5\IN\13603305 difficult_6\JJ\1740 pain_7\NN\14299637 syndromes_8\NNS\5870365 ,_9\,\1740 such_10\JJ\1740 as_11\IN\14622893 <e2>neuropathic_12\JJ\1740 pain</e2>_13\NN\14299637 ._14\.\1740
3409645
D008727_D007172 CID <e2>impotence</e2>_0\NN\4723816 was_1\VBD\836236 more_2\RBR\1740 common_3\JJ\1740 among_4\IN\1740 male_5\JJ\1740 patients_6\NNS\9898892 than_7\IN\1740 controls_8\NNS\5190804 and_9\CC\1740 was_10\VBD\836236 found_11\VBN\2426171 to_12\TO\1740 be_13\VB\836236 associated_14\VBN\628491 with_15\IN\1740 co-morbidity_16\NN\1740 and_17\CC\1740 the_18\DT\1740 taking_19\NN\37396 of_20\IN\1740 <e1>methotrexate</e1>_21\NN\2722166 ._22\.\1740
7234705
D011342_D017180 CID <e1>procainamide-induced</e1>_0\JJ\1740 polymorphous_1\JJ\1740 <e2>ventricular_2\NN\1740 tachycardia</e2>_3\NN\14110674 ._4\.\1740
D011342_D017180 CID seven_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e1>procainamide-induced</e1>_3\JJ\1740 polymorphous_4\JJ\1740 <e2>ventricular_5\NN\1740 tachycardia</e2>_6\NN\14110674 are_7\VBP\836236 presented_8\VBN\2137132 ._9\.\1740
D011342_D017180 CID in_0\IN\13603305 four_1\CD\13741022 patients_2\NNS\9898892 ,_3\,\1740 polymorphous_4\JJ\1740 <e2>ventricular_5\NN\1740 tachycardia</e2>_6\NN\14110674 appeared_7\VBD\2604760 after_8\IN\1740 intravenous_9\JJ\1740 administration_10\NN\1133281 of_11\IN\1740 200_12\CD\1740 to_13\TO\1740 400_14\CD\1740 mg_15\NN\13717155 of_16\IN\1740 <e1>procainamide</e1>_17\NN\1740 for_18\IN\1740 the_19\DT\1740 treatment_20\NN\654885 of_21\IN\1740 sustained_22\JJ\1740 ventricular_23\JJ\1740 tachycardia_24\NN\14110674 ._25\.\1740
D011342_D017180 CID in_0\IN\13603305 four_1\CD\13741022 patients_2\NNS\9898892 ,_3\,\1740 polymorphous_4\JJ\1740 ventricular_5\NN\1740 tachycardia_6\NN\14110674 appeared_7\VBD\2604760 after_8\IN\1740 intravenous_9\JJ\1740 administration_10\NN\1133281 of_11\IN\1740 200_12\CD\1740 to_13\TO\1740 400_14\CD\1740 mg_15\NN\13717155 of_16\IN\1740 <e1>procainamide</e1>_17\NN\1740 for_18\IN\1740 the_19\DT\1740 treatment_20\NN\654885 of_21\IN\1740 sustained_22\JJ\1740 <e2>ventricular_23\JJ\1740 tachycardia</e2>_24\NN\14110674 ._25\.\1740
D011342_D017180 CID in_0\IN\13603305 the_1\DT\1740 seventh_2\JJ\1740 patient_3\NN\9898892 ,_4\,\1740 a_5\DT\13649268 permanent_6\JJ\1740 ventricular_7\NN\1740 pacemaker_8\NN\5925366 was_9\VBD\836236 inserted_10\VBN\1296462 and_11\CC\1740 ,_12\,\1740 despite_13\IN\7501545 continuation_14\NN\407535 of_15\IN\1740 <e1>procainamide</e1>_16\NN\1740 therapy_17\NN\657604 ,_18\,\1740 polymorphous_19\JJ\1740 <e2>ventricular_20\NN\1740 tachycardia</e2>_21\NN\14110674 did_22\VBD\1640855 not_23\RB\1740 reoccur_24\VB\1740 ._25\.\1740
D011342_D017180 CID these_0\DT\1740 seven_1\CD\13741022 cases_2\NNS\7283608 demonstrate_3\VBP\2137132 that_4\IN\1740 <e1>procainamide</e1>_5\NN\1740 can_6\MD\3094503 produce_7\VB\1617192 an_8\DT\6697703 acquired_9\VBN\109660 prolonged_10\JJ\1740 q-t_11\NN\1740 syndrome_12\NN\5870365 with_13\IN\1740 polymorphous_14\JJ\1740 <e2>ventricular_15\NN\1740 tachycardia</e2>_16\NN\14110674 ._17\.\1740
D011342_D018879 NONE in_0\IN\13603305 the_1\DT\1740 remaining_2\VBG\2604760 three_3\CD\13741022 patients_4\NNS\9898892 ,_5\,\1740 <e1>procainamide</e1>_6\NN\1740 was_7\VBD\836236 administered_8\VBN\2436349 orally_9\RB\1740 for_10\IN\1740 treatment_11\NN\654885 of_12\IN\1740 chronic_13\JJ\1740 <e2>premature_14\JJ\1740 ventricular_15\JJ\1740 contractions</e2>_16\NNS\358931 or_17\CC\3541091 atrial_18\JJ\1740 flutter_19\NN\331950 ._20\.\1740
D011342_D001282 NONE in_0\IN\13603305 the_1\DT\1740 remaining_2\VBG\2604760 three_3\CD\13741022 patients_4\NNS\9898892 ,_5\,\1740 <e1>procainamide</e1>_6\NN\1740 was_7\VBD\836236 administered_8\VBN\2436349 orally_9\RB\1740 for_10\IN\1740 treatment_11\NN\654885 of_12\IN\1740 chronic_13\JJ\1740 premature_14\JJ\1740 ventricular_15\JJ\1740 contractions_16\NNS\358931 or_17\CC\3541091 <e2>atrial_18\JJ\1740 flutter</e2>_19\NN\331950 ._20\.\1740
D011342_D008133 NONE these_0\DT\1740 seven_1\CD\13741022 cases_2\NNS\7283608 demonstrate_3\VBP\2137132 that_4\IN\1740 <e1>procainamide</e1>_5\NN\1740 can_6\MD\3094503 produce_7\VB\1617192 an_8\DT\6697703 acquired_9\VBN\109660 <e2>prolonged_10\JJ\1740 q-t_11\NN\1740 syndrome</e2>_12\NN\5870365 with_13\IN\1740 polymorphous_14\JJ\1740 ventricular_15\NN\1740 tachycardia_16\NN\14110674 ._17\.\1740
1549199
D007980_D064420 NONE while_0\IN\15122231 there_1\EX\27167 is_2\VBZ\836236 no_3\DT\7204911 single_4\JJ\1740 correct_5\JJ\1740 starting_6\VBG\2009433 dose_7\NN\3740161 for_8\IN\1740 <e1>levodopa</e1>_9\NN\14604959 therapy_10\NN\657604 ,_11\,\1740 many_12\JJ\1740 individuals_13\NNS\7347 can_14\MD\3094503 be_15\VB\836236 started_16\VBN\2009433 on_17\IN\1740 either_18\CC\1740 the_19\DT\1740 25/100_20\CD\1740 or_21\CC\3541091 controlled-release_22\NN\1740 formula_23\NN\6732169 ,_24\,\1740 following_25\VBG\1835496 the_26\DT\1740 general_27\JJ\1740 rule_28\NN\5835747 not_29\RB\1740 to_30\TO\1740 attempt_31\VB\2367363 to_32\TO\1740 titrate_33\VB\489837 carbidopa-levodopa_34\JJ\1740 to_35\TO\1740 the_36\DT\1740 point_37\NN\5868954 of_38\IN\1740 "_39\``\1740 normality_40\NN\13920835 ,_41\,\1740 "_42\''\1740 which_43\WDT\1740 can_44\MD\3094503 lead_45\VB\1752884 to_46\IN\1740 <e2>toxicity</e2>_47\NN\13576101 ._48\.\1740
D007980_D064420 NONE while_0\IN\15122231 there_1\EX\27167 is_2\VBZ\836236 no_3\DT\7204911 single_4\JJ\1740 correct_5\JJ\1740 starting_6\VBG\2009433 dose_7\NN\3740161 for_8\IN\1740 levodopa_9\NN\14604959 therapy_10\NN\657604 ,_11\,\1740 many_12\JJ\1740 individuals_13\NNS\7347 can_14\MD\3094503 be_15\VB\836236 started_16\VBN\2009433 on_17\IN\1740 either_18\CC\1740 the_19\DT\1740 25/100_20\CD\1740 or_21\CC\3541091 controlled-release_22\NN\1740 formula_23\NN\6732169 ,_24\,\1740 following_25\VBG\1835496 the_26\DT\1740 general_27\JJ\1740 rule_28\NN\5835747 not_29\RB\1740 to_30\TO\1740 attempt_31\VB\2367363 to_32\TO\1740 titrate_33\VB\489837 <e1>carbidopa-levodopa</e1>_34\JJ\1740 to_35\TO\1740 the_36\DT\1740 point_37\NN\5868954 of_38\IN\1740 "_39\``\1740 normality_40\NN\13920835 ,_41\,\1740 "_42\''\1740 which_43\WDT\1740 can_44\MD\3094503 lead_45\VB\1752884 to_46\IN\1740 <e2>toxicity</e2>_47\NN\13576101 ._48\.\1740
D002230_D064420 NONE while_0\IN\15122231 there_1\EX\27167 is_2\VBZ\836236 no_3\DT\7204911 single_4\JJ\1740 correct_5\JJ\1740 starting_6\VBG\2009433 dose_7\NN\3740161 for_8\IN\1740 levodopa_9\NN\14604959 therapy_10\NN\657604 ,_11\,\1740 many_12\JJ\1740 individuals_13\NNS\7347 can_14\MD\3094503 be_15\VB\836236 started_16\VBN\2009433 on_17\IN\1740 either_18\CC\1740 the_19\DT\1740 25/100_20\CD\1740 or_21\CC\3541091 controlled-release_22\NN\1740 formula_23\NN\6732169 ,_24\,\1740 following_25\VBG\1835496 the_26\DT\1740 general_27\JJ\1740 rule_28\NN\5835747 not_29\RB\1740 to_30\TO\1740 attempt_31\VB\2367363 to_32\TO\1740 titrate_33\VB\489837 <e1>carbidopa-levodopa</e1>_34\JJ\1740 to_35\TO\1740 the_36\DT\1740 point_37\NN\5868954 of_38\IN\1740 "_39\``\1740 normality_40\NN\13920835 ,_41\,\1740 "_42\''\1740 which_43\WDT\1740 can_44\MD\3094503 lead_45\VB\1752884 to_46\IN\1740 <e2>toxicity</e2>_47\NN\13576101 ._48\.\1740
D007980_D005767 CID other_0\JJ\1740 possible_1\JJ\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 --_4\:\1740 such_5\JJ\1740 as_6\IN\14622893 <e2>gastrointestinal_7\JJ\1740 disorders</e2>_8\NNS\14034177 ,_9\,\1740 orthostatic_10\JJ\1740 hypotension_11\NN\14057371 ,_12\,\1740 <e1>levodopa-induced</e1>_13\JJ\1740 psychosis_14\NN\14380140 ,_15\,\1740 sleep_16\NN\14034177 disturbances_17\NNS\407535 or_18\CC\3541091 parasomnias_19\NNS\1740 ,_20\,\1740 or_21\CC\3541091 drug_22\NN\14778436 interactions_23\NNS\37396 --_24\:\1740 also_25\RB\1740 require_26\VBP\754942 carefully_27\RB\1740 monitored_28\VBN\2169352 individual_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
D007980_D007024 CID other_0\JJ\1740 possible_1\JJ\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 --_4\:\1740 such_5\JJ\1740 as_6\IN\14622893 gastrointestinal_7\JJ\1740 disorders_8\NNS\14034177 ,_9\,\1740 <e2>orthostatic_10\JJ\1740 hypotension</e2>_11\NN\14057371 ,_12\,\1740 <e1>levodopa-induced</e1>_13\JJ\1740 psychosis_14\NN\14380140 ,_15\,\1740 sleep_16\NN\14034177 disturbances_17\NNS\407535 or_18\CC\3541091 parasomnias_19\NNS\1740 ,_20\,\1740 or_21\CC\3541091 drug_22\NN\14778436 interactions_23\NNS\37396 --_24\:\1740 also_25\RB\1740 require_26\VBP\754942 carefully_27\RB\1740 monitored_28\VBN\2169352 individual_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
D007980_D011618 NONE other_0\JJ\1740 possible_1\JJ\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 --_4\:\1740 such_5\JJ\1740 as_6\IN\14622893 gastrointestinal_7\JJ\1740 disorders_8\NNS\14034177 ,_9\,\1740 orthostatic_10\JJ\1740 hypotension_11\NN\14057371 ,_12\,\1740 <e1>levodopa-induced</e1>_13\JJ\1740 <e2>psychosis</e2>_14\NN\14380140 ,_15\,\1740 sleep_16\NN\14034177 disturbances_17\NNS\407535 or_18\CC\3541091 parasomnias_19\NNS\1740 ,_20\,\1740 or_21\CC\3541091 drug_22\NN\14778436 interactions_23\NNS\37396 --_24\:\1740 also_25\RB\1740 require_26\VBP\754942 carefully_27\RB\1740 monitored_28\VBN\2169352 individual_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
D007980_D012893 NONE other_0\JJ\1740 possible_1\JJ\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 --_4\:\1740 such_5\JJ\1740 as_6\IN\14622893 gastrointestinal_7\JJ\1740 disorders_8\NNS\14034177 ,_9\,\1740 orthostatic_10\JJ\1740 hypotension_11\NN\14057371 ,_12\,\1740 <e1>levodopa-induced</e1>_13\JJ\1740 psychosis_14\NN\14380140 ,_15\,\1740 <e2>sleep_16\NN\14034177 disturbances</e2>_17\NNS\407535 or_18\CC\3541091 parasomnias_19\NNS\1740 ,_20\,\1740 or_21\CC\3541091 drug_22\NN\14778436 interactions_23\NNS\37396 --_24\:\1740 also_25\RB\1740 require_26\VBP\754942 carefully_27\RB\1740 monitored_28\VBN\2169352 individual_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
D007980_D020447 CID other_0\JJ\1740 possible_1\JJ\1740 adverse_2\JJ\1740 effects_3\NNS\13245626 --_4\:\1740 such_5\JJ\1740 as_6\IN\14622893 gastrointestinal_7\JJ\1740 disorders_8\NNS\14034177 ,_9\,\1740 orthostatic_10\JJ\1740 hypotension_11\NN\14057371 ,_12\,\1740 <e1>levodopa-induced</e1>_13\JJ\1740 psychosis_14\NN\14380140 ,_15\,\1740 sleep_16\NN\14034177 disturbances_17\NNS\407535 or_18\CC\3541091 <e2>parasomnias</e2>_19\NNS\1740 ,_20\,\1740 or_21\CC\3541091 drug_22\NN\14778436 interactions_23\NNS\37396 --_24\:\1740 also_25\RB\1740 require_26\VBP\754942 carefully_27\RB\1740 monitored_28\VBN\2169352 individual_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
18308784
C035054_D007859 NONE <e1>ginsenoside_0\NN\1740 rg1</e1>_1\NN\1740 restores_2\VBZ\1631072 the_3\DT\1740 <e2>impairment_4\NN\7296428 of_5\IN\1740 learning</e2>_6\NN\5701944 induced_7\VBN\1627355 by_8\IN\1740 chronic_9\JJ\1740 morphine_10\NN\2707683 administration_11\NN\1133281 in_12\IN\13603305 rats_13\NNS\2329401 ._14\.\1740
C035054_D007859 NONE <e1>rg1</e1>_0\NN\1740 ,_1\,\1740 as_2\IN\14622893 a_3\DT\13649268 ginsenoside_4\NN\1740 extracted_5\VBN\173338 from_6\IN\1740 panax_7\NNP\11585340 ginseng_8\NNP\13125117 ,_9\,\1740 could_10\MD\1740 ameliorate_11\VB\126264 spatial_12\JJ\1740 <e2>learning_13\NN\5701944 impairment</e2>_14\NN\7296428 ._15\.\1740
C035054_D007859 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 investigate_7\VB\644583 the_8\DT\1740 effect_9\NN\34213 of_10\IN\1740 <e1>rg1</e1>_11\NN\1740 on_12\IN\1740 <e2>learning_13\NN\5701944 impairment</e2>_14\NN\7296428 by_15\IN\1740 chronic_16\JJ\1740 morphine_17\NN\2707683 administration_18\NN\1133281 and_19\CC\1740 the_20\DT\1740 mechanism_21\NN\13446390 responsible_22\JJ\1740 for_23\IN\1740 this_24\DT\1740 effect_25\NN\34213 ._26\.\1740
D009020_D007859 CID ginsenoside_0\NN\1740 rg1_1\NN\1740 restores_2\VBZ\1631072 the_3\DT\1740 <e2>impairment_4\NN\7296428 of_5\IN\1740 learning</e2>_6\NN\5701944 induced_7\VBN\1627355 by_8\IN\1740 chronic_9\JJ\1740 <e1>morphine</e1>_10\NN\2707683 administration_11\NN\1133281 in_12\IN\13603305 rats_13\NNS\2329401 ._14\.\1740
D009020_D007859 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 investigate_7\VB\644583 the_8\DT\1740 effect_9\NN\34213 of_10\IN\1740 rg1_11\NN\1740 on_12\IN\1740 <e2>learning_13\NN\5701944 impairment</e2>_14\NN\7296428 by_15\IN\1740 chronic_16\JJ\1740 <e1>morphine</e1>_17\NN\2707683 administration_18\NN\1133281 and_19\CC\1740 the_20\DT\1740 mechanism_21\NN\13446390 responsible_22\JJ\1740 for_23\IN\1740 this_24\DT\1740 effect_25\NN\34213 ._26\.\1740
D036145_D007859 NONE rg1_0\NN\1740 ,_1\,\1740 as_2\IN\14622893 a_3\DT\13649268 <e1>ginsenoside</e1>_4\NN\1740 extracted_5\VBN\173338 from_6\IN\1740 panax_7\NNP\11585340 ginseng_8\NNP\13125117 ,_9\,\1740 could_10\MD\1740 ameliorate_11\VB\126264 spatial_12\JJ\1740 <e2>learning_13\NN\5701944 impairment</e2>_14\NN\7296428 ._15\.\1740
18768591
D004317_D009404 CID serum-_0\NN\1740 and_1\CC\1740 glucocorticoid-inducible_2\JJ\1740 kinase_3\NN\14732946 1_4\CD\13741022 in_5\IN\13603305 <e1>doxorubicin-induced</e1>_6\JJ\1740 <e2>nephrotic_7\JJ\1740 syndrome</e2>_8\NN\5870365 ._9\.\1740
D004317_D009404 CID <e1>doxorubicin</e1>_0\NN\2716866 treatment_1\NN\654885 resulted_2\VBD\2633881 in_3\IN\13603305 heavy_4\JJ\1740 proteinuria_5\NN\14299637 (_6\-LRB-\1740 >_7\NNS\1740 100_8\CD\13745420 mg_9\NN\13717155 protein/mg_10\NN\1740 crea_11\NNS\1740 )_12\-RRB-\1740 in_13\IN\13603305 15/44_14\CD\1740 of_15\IN\1740 sgk1(+/+_16\-LRB-\1740 )_17\-RRB-\1740 and_18\CC\1740 15/44_19\CD\1740 of_20\IN\1740 sgk1(-/-_21\NN\1740 )_22\-RRB-\1740 mice_23\NNS\2329401 leading_24\VBG\1752884 to_25\TO\1740 severe_26\JJ\1740 <e2>nephrotic_27\JJ\1740 syndrome</e2>_28\NN\5870365 with_29\IN\1740 ascites_30\NNS\14204950 ,_31\,\1740 lipidemia_32\NN\14299637 ,_33\,\1740 and_34\CC\1740 hypoalbuminemia_35\NN\1740 in_36\IN\13603305 both_37\DT\1740 genotypes_38\NNS\7941170 ._39\.\1740
D004317_D007674 NONE <e1>doxorubicin-induced</e1>_0\JJ\1740 <e2>nephropathy</e2>_1\NN\14573196 leads_2\VBZ\1752884 to_3\TO\1740 epithelial_4\JJ\1740 sodium_5\NN\14625458 channel_6\NN\6251781 (enac)-dependent_7\JJ\1740 volume_8\NN\33615 retention_9\NN\809465 and_10\CC\1740 renal_11\JJ\1740 fibrosis_12\NN\14204950 ._13\.\1740
D004317_D016055 NONE <e1>doxorubicin-induced</e1>_0\JJ\1740 nephropathy_1\NN\14573196 leads_2\VBZ\1752884 to_3\TO\1740 epithelial_4\JJ\1740 sodium_5\NN\14625458 channel_6\NN\6251781 (enac)-dependent_7\JJ\1740 <e2>volume_8\NN\33615 retention</e2>_9\NN\809465 and_10\CC\1740 renal_11\JJ\1740 fibrosis_12\NN\14204950 ._13\.\1740
D004317_D005355 NONE <e1>doxorubicin-induced</e1>_0\JJ\1740 nephropathy_1\NN\14573196 leads_2\VBZ\1752884 to_3\TO\1740 epithelial_4\JJ\1740 sodium_5\NN\14625458 channel_6\NN\6251781 (enac)-dependent_7\JJ\1740 volume_8\NN\33615 retention_9\NN\809465 and_10\CC\1740 renal_11\JJ\1740 <e2>fibrosis</e2>_12\NN\14204950 ._13\.\1740
D012964_D007674 NONE doxorubicin-induced_0\JJ\1740 <e2>nephropathy</e2>_1\NN\14573196 leads_2\VBZ\1752884 to_3\TO\1740 epithelial_4\JJ\1740 <e1>sodium</e1>_5\NN\14625458 channel_6\NN\6251781 (enac)-dependent_7\JJ\1740 volume_8\NN\33615 retention_9\NN\809465 and_10\CC\1740 renal_11\JJ\1740 fibrosis_12\NN\14204950 ._13\.\1740
D012964_D016055 NONE doxorubicin-induced_0\JJ\1740 nephropathy_1\NN\14573196 leads_2\VBZ\1752884 to_3\TO\1740 epithelial_4\JJ\1740 <e1>sodium</e1>_5\NN\14625458 channel_6\NN\6251781 (enac)-dependent_7\JJ\1740 <e2>volume_8\NN\33615 retention</e2>_9\NN\809465 and_10\CC\1740 renal_11\JJ\1740 fibrosis_12\NN\14204950 ._13\.\1740
D012964_D005355 NONE doxorubicin-induced_0\JJ\1740 nephropathy_1\NN\14573196 leads_2\VBZ\1752884 to_3\TO\1740 epithelial_4\JJ\1740 <e1>sodium</e1>_5\NN\14625458 channel_6\NN\6251781 (enac)-dependent_7\JJ\1740 volume_8\NN\33615 retention_9\NN\809465 and_10\CC\1740 renal_11\JJ\1740 <e2>fibrosis</e2>_12\NN\14204950 ._13\.\1740
D000450_D005355 NONE the_0\DT\1740 <e1>aldosterone-sensitive</e1>_1\JJ\1740 serum-_2\NN\1740 and_3\CC\1740 glucocorticoid-inducible_4\JJ\1740 kinase_5\NN\14732946 sgk1_6\NN\1740 has_7\VBZ\2108377 been_8\VBN\836236 shown_9\VBN\2137132 to_10\TO\1740 participate_11\VB\2367363 in_12\IN\13603305 the_13\DT\1740 stimulation_14\NN\242808 of_15\IN\1740 enac_16\NN\1740 and_17\CC\1740 to_18\TO\1740 mediate_19\VB\761713 renal_20\JJ\1740 <e2>fibrosis</e2>_21\NN\14204950 following_22\VBG\1835496 mineralocorticoid_23\NN\14751417 and_24\CC\1740 salt_25\NN\14818238 excess_26\NN\5119367 ._27\.\1740
D004317_D011507 CID <e1>doxorubicin</e1>_0\NN\2716866 treatment_1\NN\654885 resulted_2\VBD\2633881 in_3\IN\13603305 heavy_4\JJ\1740 <e2>proteinuria</e2>_5\NN\14299637 (_6\-LRB-\1740 >_7\NNS\1740 100_8\CD\13745420 mg_9\NN\13717155 protein/mg_10\NN\1740 crea_11\NNS\1740 )_12\-RRB-\1740 in_13\IN\13603305 15/44_14\CD\1740 of_15\IN\1740 sgk1(+/+_16\-LRB-\1740 )_17\-RRB-\1740 and_18\CC\1740 15/44_19\CD\1740 of_20\IN\1740 sgk1(-/-_21\NN\1740 )_22\-RRB-\1740 mice_23\NNS\2329401 leading_24\VBG\1752884 to_25\TO\1740 severe_26\JJ\1740 nephrotic_27\JJ\1740 syndrome_28\NN\5870365 with_29\IN\1740 ascites_30\NNS\14204950 ,_31\,\1740 lipidemia_32\NN\14299637 ,_33\,\1740 and_34\CC\1740 hypoalbuminemia_35\NN\1740 in_36\IN\13603305 both_37\DT\1740 genotypes_38\NNS\7941170 ._39\.\1740
D004317_D001201 CID <e1>doxorubicin</e1>_0\NN\2716866 treatment_1\NN\654885 resulted_2\VBD\2633881 in_3\IN\13603305 heavy_4\JJ\1740 proteinuria_5\NN\14299637 (_6\-LRB-\1740 >_7\NNS\1740 100_8\CD\13745420 mg_9\NN\13717155 protein/mg_10\NN\1740 crea_11\NNS\1740 )_12\-RRB-\1740 in_13\IN\13603305 15/44_14\CD\1740 of_15\IN\1740 sgk1(+/+_16\-LRB-\1740 )_17\-RRB-\1740 and_18\CC\1740 15/44_19\CD\1740 of_20\IN\1740 sgk1(-/-_21\NN\1740 )_22\-RRB-\1740 mice_23\NNS\2329401 leading_24\VBG\1752884 to_25\TO\1740 severe_26\JJ\1740 nephrotic_27\JJ\1740 syndrome_28\NN\5870365 with_29\IN\1740 <e2>ascites</e2>_30\NNS\14204950 ,_31\,\1740 lipidemia_32\NN\14299637 ,_33\,\1740 and_34\CC\1740 hypoalbuminemia_35\NN\1740 in_36\IN\13603305 both_37\DT\1740 genotypes_38\NNS\7941170 ._39\.\1740
D004317_D006949 CID <e1>doxorubicin</e1>_0\NN\2716866 treatment_1\NN\654885 resulted_2\VBD\2633881 in_3\IN\13603305 heavy_4\JJ\1740 proteinuria_5\NN\14299637 (_6\-LRB-\1740 >_7\NNS\1740 100_8\CD\13745420 mg_9\NN\13717155 protein/mg_10\NN\1740 crea_11\NNS\1740 )_12\-RRB-\1740 in_13\IN\13603305 15/44_14\CD\1740 of_15\IN\1740 sgk1(+/+_16\-LRB-\1740 )_17\-RRB-\1740 and_18\CC\1740 15/44_19\CD\1740 of_20\IN\1740 sgk1(-/-_21\NN\1740 )_22\-RRB-\1740 mice_23\NNS\2329401 leading_24\VBG\1752884 to_25\TO\1740 severe_26\JJ\1740 nephrotic_27\JJ\1740 syndrome_28\NN\5870365 with_29\IN\1740 ascites_30\NNS\14204950 ,_31\,\1740 <e2>lipidemia</e2>_32\NN\14299637 ,_33\,\1740 and_34\CC\1740 hypoalbuminemia_35\NN\1740 in_36\IN\13603305 both_37\DT\1740 genotypes_38\NNS\7941170 ._39\.\1740
D004317_D034141 CID <e1>doxorubicin</e1>_0\NN\2716866 treatment_1\NN\654885 resulted_2\VBD\2633881 in_3\IN\13603305 heavy_4\JJ\1740 proteinuria_5\NN\14299637 (_6\-LRB-\1740 >_7\NNS\1740 100_8\CD\13745420 mg_9\NN\13717155 protein/mg_10\NN\1740 crea_11\NNS\1740 )_12\-RRB-\1740 in_13\IN\13603305 15/44_14\CD\1740 of_15\IN\1740 sgk1(+/+_16\-LRB-\1740 )_17\-RRB-\1740 and_18\CC\1740 15/44_19\CD\1740 of_20\IN\1740 sgk1(-/-_21\NN\1740 )_22\-RRB-\1740 mice_23\NNS\2329401 leading_24\VBG\1752884 to_25\TO\1740 severe_26\JJ\1740 nephrotic_27\JJ\1740 syndrome_28\NN\5870365 with_29\IN\1740 ascites_30\NNS\14204950 ,_31\,\1740 lipidemia_32\NN\14299637 ,_33\,\1740 and_34\CC\1740 <e2>hypoalbuminemia</e2>_35\NN\1740 in_36\IN\13603305 both_37\DT\1740 genotypes_38\NNS\7941170 ._39\.\1740
D000450_D009404 NONE plasma_0\NN\5398023 <e1>aldosterone</e1>_1\NN\14751863 levels_2\NNS\4916342 increased_3\VBD\169651 in_4\IN\13603305 <e2>nephrotic</e2>_5\JJ\1740 mice_6\NNS\2329401 of_7\IN\1740 both_8\DT\1740 genotypes_9\NNS\7941170 and_10\CC\1740 was_11\VBD\836236 followed_12\VBN\1835496 by_13\IN\1740 increased_14\VBN\169651 sgk1_15\NN\1740 protein_16\NN\14944888 expression_17\NN\4679549 in_18\IN\13603305 sgk1(+/+_19\-RRB-\1740 )_20\-RRB-\1740 mice_21\NNS\2329401 ._22\.\1740
D012964_D015430 NONE urinary_0\JJ\1740 <e1>sodium</e1>_1\NN\14625458 excretion_2\NN\13466586 reached_3\VBD\2005948 signficantly_4\RB\1740 lower_5\JJR\1740 values_6\NNS\5941423 in_7\IN\13603305 sgk1(+/+_8\-RRB-\1740 )_9\-RRB-\1740 mice_10\NNS\2329401 (_11\-LRB-\1740 15_12\CD\13745420 +/-_13\CC\1740 5_14\CD\13741022 mumol/mg_15\NN\1740 crea_16\NNS\1740 )_17\-RRB-\1740 than_18\IN\1740 in_19\IN\13603305 sgk1(-/-_20\NN\1740 )_21\-RRB-\1740 mice_22\NNS\2329401 (_23\-LRB-\1740 35_24\CD\1740 +/-_25\CC\1740 5_26\CD\13741022 mumol/mg_27\NN\1740 crea_28\NNS\1740 )_29\-RRB-\1740 and_30\CC\1740 was_31\VBD\836236 associated_32\VBN\628491 with_33\IN\1740 a_34\DT\13649268 significantly_35\RB\1740 higher_36\JJR\1740 body_37\NN\19128 <e2>weight_38\NN\5009170 gain</e2>_39\NN\13576355 in_40\IN\13603305 sgk1(+/+_41\-RRB-\1740 )_42\-RRB-\1740 compared_43\VBN\644583 with_44\IN\1740 sgk1(-/-_45\NN\1740 )_46\-RRB-\1740 mice_47\NNS\2329401 (_48\-LRB-\1740 +_49\CC\1740 6.6_50\CD\1740 +/-_51\CC\1740 0.7_52\CD\1740 vs._53\CC\1740 +_54\CC\1740 4.1_55\CD\1740 +/-_56\CC\1740 0.8_57\CD\1740 g_58\NN\13717155 )_59\-RRB-\1740 ._60\.\1740
D014508_D009404 NONE during_0\IN\1740 the_1\DT\1740 course_2\NN\883297 of_3\IN\1740 <e2>nephrotic_4\JJ\1740 syndrome</e2>_5\NN\5870365 ,_6\,\1740 serum_7\NN\5397468 <e1>urea</e1>_8\NN\14727670 concentrations_9\NNS\4916342 increased_10\VBD\169651 significantly_11\RB\1740 faster_12\JJR\1740 in_13\IN\13603305 sgk1(-/-_14\NN\1740 )_15\-RRB-\1740 mice_16\NNS\2329401 than_17\IN\1740 in_18\IN\13603305 sgk1(+/+_19\-RRB-\1740 )_20\-RRB-\1740 mice_21\NNS\2329401 leading_22\VBG\1752884 to_23\TO\1740 uremia_24\NN\14204950 and_25\CC\1740 a_26\DT\13649268 reduced_27\VBN\441445 median_28\JJ\1740 survival_29\NN\13961642 in_30\IN\13603305 sgk1(-/-_31\NN\1740 )_32\-RRB-\1740 mice_33\NNS\2329401 (_34\-LRB-\1740 29_35\CD\13745420 vs._36\CC\1740 40_37\CD\13745420 days_38\NNS\15140892 in_39\IN\13603305 sgk1(+/+_40\-RRB-\1740 )_41\-RRB-\1740 mice_42\NNS\2329401 )_43\-RRB-\1740 ._44\.\1740
D014508_D014511 NONE during_0\IN\1740 the_1\DT\1740 course_2\NN\883297 of_3\IN\1740 nephrotic_4\JJ\1740 syndrome_5\NN\5870365 ,_6\,\1740 serum_7\NN\5397468 <e1>urea</e1>_8\NN\14727670 concentrations_9\NNS\4916342 increased_10\VBD\169651 significantly_11\RB\1740 faster_12\JJR\1740 in_13\IN\13603305 sgk1(-/-_14\NN\1740 )_15\-RRB-\1740 mice_16\NNS\2329401 than_17\IN\1740 in_18\IN\13603305 sgk1(+/+_19\-RRB-\1740 )_20\-RRB-\1740 mice_21\NNS\2329401 leading_22\VBG\1752884 to_23\TO\1740 <e2>uremia</e2>_24\NN\14204950 and_25\CC\1740 a_26\DT\13649268 reduced_27\VBN\441445 median_28\JJ\1740 survival_29\NN\13961642 in_30\IN\13603305 sgk1(-/-_31\NN\1740 )_32\-RRB-\1740 mice_33\NNS\2329401 (_34\-LRB-\1740 29_35\CD\13745420 vs._36\CC\1740 40_37\CD\13745420 days_38\NNS\15140892 in_39\IN\13603305 sgk1(+/+_40\-RRB-\1740 )_41\-RRB-\1740 mice_42\NNS\2329401 )_43\-RRB-\1740 ._44\.\1740
1967484
D013469_D004421 CID <e1>sulpiride-induced</e1>_0\JJ\1740 <e2>tardive_1\JJ\1740 dystonia</e2>_2\NN\1740 ._3\.\1740
D013469_D004421 CID we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 37-year-old_3\JJ\1740 man_4\NN\9605289 who_5\WP\8299493 developed_6\VBD\1753788 persistent_7\JJ\1740 segmental_8\JJ\1740 <e2>dystonia</e2>_9\NN\1740 within_10\IN\1740 2_11\CD\13741022 months_12\NNS\15113229 after_13\IN\1740 starting_14\VBG\2009433 <e1>sulpiride</e1>_15\NN\1740 therapy_16\NN\657604 ._17\.\1740
D013469_D004421 CID we_0\PRP\1740 could_1\MD\1740 not_2\RB\1740 find_3\VB\2163746 any_4\DT\1740 previous_5\JJ\1740 reports_6\NNS\6470073 of_7\IN\1740 <e1>sulpiride-induced</e1>_8\JJ\1740 <e2>tardive_9\JJ\1740 dystonia</e2>_10\NN\1740 ._11\.\1740
D013469_D004409 NONE although_0\IN\1740 initially_1\RB\1740 thought_2\VBN\670261 to_3\TO\1740 be_4\VB\836236 free_5\JJ\1740 of_6\IN\1740 extrapyramidal_7\JJ\1740 side_8\NN\8630039 effects_9\NNS\13245626 ,_10\,\1740 <e1>sulpiride-induced</e1>_11\JJ\1740 <e2>tardive_12\JJ\1740 dyskinesia</e2>_13\NN\14084880 and_14\CC\1740 parkinsonism_15\NN\14085708 have_16\VBP\2108377 been_17\VBN\836236 reported_18\VBN\831651 occasionally_19\RB\1740 ._20\.\1740
D013469_D010302 NONE although_0\IN\1740 initially_1\RB\1740 thought_2\VBN\670261 to_3\TO\1740 be_4\VB\836236 free_5\JJ\1740 of_6\IN\1740 extrapyramidal_7\JJ\1740 side_8\NN\8630039 effects_9\NNS\13245626 ,_10\,\1740 <e1>sulpiride-induced</e1>_11\JJ\1740 tardive_12\JJ\1740 dyskinesia_13\NN\14084880 and_14\CC\1740 <e2>parkinsonism</e2>_15\NN\14085708 have_16\VBP\2108377 been_17\VBN\836236 reported_18\VBN\831651 occasionally_19\RB\1740 ._20\.\1740
12707296
D001120_D006973 NONE <e1>l-arginine</e1>_0\NN\1740 transport_1\NN\3575240 in_2\IN\13603305 humans_3\NNS\31264 with_4\IN\1740 cortisol-induced_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 ._7\.\1740
D001120_D006973 NONE a_0\DT\13649268 deficient_1\JJ\1740 <e1>l-arginine-nitric</e1>_2\JJ\1740 oxide_3\NN\14818238 system_4\NN\3575240 is_5\VBZ\836236 implicated_6\VBN\2677097 in_7\IN\13603305 cortisol-induced_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 ._10\.\1740
D001120_D006973 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 cortisol-induced_3\JJ\1740 <e2>increases_4\NNS\13576355 in_5\IN\13603305 blood_6\NN\5397468 pressure</e2>_7\NN\11419404 are_8\VBP\836236 not_9\RB\1740 associated_10\VBN\628491 with_11\IN\1740 abnormalities_12\NNS\14034177 in_13\IN\13603305 the_14\DT\1740 <e1>l-arginine</e1>_15\NN\1740 transport_16\NN\3575240 system_17\NN\3575240 ._18\.\1740
D006854_D006973 NONE l-arginine_0\NN\1740 transport_1\NN\3575240 in_2\IN\13603305 humans_3\NNS\31264 with_4\IN\1740 <e1>cortisol-induced</e1>_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 ._7\.\1740
D006854_D006973 NONE a_0\DT\13649268 deficient_1\JJ\1740 l-arginine-nitric_2\JJ\1740 oxide_3\NN\14818238 system_4\NN\3575240 is_5\VBZ\836236 implicated_6\VBN\2677097 in_7\IN\13603305 <e1>cortisol-induced</e1>_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 ._10\.\1740
D006854_D006973 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>cortisol-induced</e1>_3\JJ\1740 <e2>increases_4\NNS\13576355 in_5\IN\13603305 blood_6\NN\5397468 pressure</e2>_7\NN\11419404 are_8\VBP\836236 not_9\RB\1740 associated_10\VBN\628491 with_11\IN\1740 abnormalities_12\NNS\14034177 in_13\IN\13603305 the_14\DT\1740 l-arginine_15\NN\1740 transport_16\NN\3575240 system_17\NN\3575240 ._18\.\1740
D009569_D006973 NONE a_0\DT\13649268 deficient_1\JJ\1740 <e1>l-arginine-nitric_2\JJ\1740 oxide</e1>_3\NN\14818238 system_4\NN\3575240 is_5\VBZ\836236 implicated_6\VBN\2677097 in_7\IN\13603305 cortisol-induced_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 ._10\.\1740
2440413
D001556_D012640 NONE differential_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>gamma-hexachlorocyclohexane</e1>_3\JJ\1740 (_4\-LRB-\1740 lindane_5\NN\14919948 )_6\-RRB-\1740 on_7\IN\1740 pharmacologically-induced_8\JJ\1740 <e2>seizures</e2>_9\NNS\14081375 ._10\.\1740
D001556_D012640 NONE differential_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 gamma-hexachlorocyclohexane_3\JJ\1740 (_4\-LRB-\1740 <e1>lindane</e1>_5\NN\14919948 )_6\-RRB-\1740 on_7\IN\1740 pharmacologically-induced_8\JJ\1740 <e2>seizures</e2>_9\NNS\14081375 ._10\.\1740
D001556_D012640 NONE <e1>gamma-hexachlorocyclohexane</e1>_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 <e2>seizure</e2>_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 seizures_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D001556_D012640 NONE <e1>gamma-hexachlorocyclohexane</e1>_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 seizure_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 <e2>seizures</e2>_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 <e1>gamma-hch</e1>_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 <e2>seizure</e2>_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 seizures_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 <e1>gamma-hch</e1>_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 seizure_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 <e2>seizures</e2>_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 <e1>lindane</e1>_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 <e2>seizure</e2>_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 seizures_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 <e1>lindane</e1>_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 seizure_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 <e2>seizures</e2>_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 <e2>seizure</e2>_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 <e1>gamma-hch</e1>_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 seizures_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 seizure_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 <e1>gamma-hch</e1>_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 <e2>seizures</e2>_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 <e2>seizure</e2>_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 seizures_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 <e1>gamma-hch</e1>_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 seizure_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 <e2>seizures</e2>_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 <e1>gamma-hch</e1>_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D001556_D012640 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 the_4\DT\1740 severity_5\NN\5036394 of_6\IN\1740 response_7\NN\11410625 to_8\TO\1740 other_9\JJ\1740 <e2>seizure-inducing</e2>_10\JJ\1740 agents_11\NNS\7347 was_12\VBD\836236 tested_13\VBN\670261 in_14\IN\13603305 mice_15\NNS\2329401 1_16\CD\13741022 and_17\CC\1740 24_18\CD\13745420 h_19\NN\14622893 after_20\IN\1740 intraperitoneal_21\JJ\1740 administration_22\NN\1133281 of_23\IN\1740 80_24\CD\13745420 mg/kg_25\NN\1740 <e1>gamma-hch</e1>_26\NN\1740 ._27\.\1740
D001556_D012640 NONE one_0\CD\13741022 hour_1\NN\15154774 after_2\IN\1740 the_3\DT\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>gamma-hch</e1>_6\NN\1740 ,_7\,\1740 the_8\DT\1740 activity_9\NN\30358 of_10\IN\1740 <e2>seizure-inducing</e2>_11\JJ\1740 agents_12\NNS\7347 was_13\VBD\836236 increased_14\VBN\169651 ,_15\,\1740 regardless_16\RB\1740 of_17\IN\1740 their_18\PRP$\1740 mechanism_19\NN\13446390 ,_20\,\1740 while_21\IN\15122231 24_22\CD\13745420 h_23\NN\14622893 after_24\IN\1740 gamma-hch_25\NN\1740 a_26\DT\13649268 differential_27\JJ\1740 response_28\NN\11410625 was_29\VBD\836236 observed_30\VBN\2163746 ._31\.\1740
D001556_D012640 NONE one_0\CD\13741022 hour_1\NN\15154774 after_2\IN\1740 the_3\DT\1740 administration_4\NN\1133281 of_5\IN\1740 gamma-hch_6\NN\1740 ,_7\,\1740 the_8\DT\1740 activity_9\NN\30358 of_10\IN\1740 <e2>seizure-inducing</e2>_11\JJ\1740 agents_12\NNS\7347 was_13\VBD\836236 increased_14\VBN\169651 ,_15\,\1740 regardless_16\RB\1740 of_17\IN\1740 their_18\PRP$\1740 mechanism_19\NN\13446390 ,_20\,\1740 while_21\IN\15122231 24_22\CD\13745420 h_23\NN\14622893 after_24\IN\1740 <e1>gamma-hch</e1>_25\NN\1740 a_26\DT\13649268 differential_27\JJ\1740 response_28\NN\11410625 was_29\VBD\836236 observed_30\VBN\2163746 ._31\.\1740
D001556_D012640 NONE the_0\DT\1740 pharmacological_1\JJ\1740 challenge_2\NN\13927383 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 tolerance_6\NN\5032565 may_7\MD\15209706 occur_8\VB\2623529 to_9\TO\1740 <e2>seizure</e2>_10\VB\1740 activity_11\NN\30358 induced_12\VBN\1627355 by_13\IN\1740 ptz_14\NN\1740 and_15\CC\1740 ptx_16\NN\1740 24_17\CD\13745420 h_18\NN\14622893 after_19\IN\1740 <e1>gamma-hch</e1>_20\NN\1740 ,_21\,\1740 since_22\IN\1740 the_23\DT\1740 response_24\NN\11410625 to_25\TO\1740 only_26\RB\1740 these_27\DT\1740 two_28\CD\13741022 seizure-inducing_29\JJ\1740 agents_30\NNS\7347 is_31\VBZ\836236 decreased_32\VBN\169651 ._33\.\1740
D001556_D012640 NONE the_0\DT\1740 pharmacological_1\JJ\1740 challenge_2\NN\13927383 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 tolerance_6\NN\5032565 may_7\MD\15209706 occur_8\VB\2623529 to_9\TO\1740 seizure_10\VB\1740 activity_11\NN\30358 induced_12\VBN\1627355 by_13\IN\1740 ptz_14\NN\1740 and_15\CC\1740 ptx_16\NN\1740 24_17\CD\13745420 h_18\NN\14622893 after_19\IN\1740 <e1>gamma-hch</e1>_20\NN\1740 ,_21\,\1740 since_22\IN\1740 the_23\DT\1740 response_24\NN\11410625 to_25\TO\1740 only_26\RB\1740 these_27\DT\1740 two_28\CD\13741022 <e2>seizure-inducing</e2>_29\JJ\1740 agents_30\NNS\7347 is_31\VBZ\836236 decreased_32\VBN\169651 ._33\.\1740
D001556_D012640 NONE the_0\DT\1740 in_1\FW\13603305 vitro_2\FW\1740 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 the_6\DT\1740 site_7\NN\8673395 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 decrease_11\NN\7296428 in_12\IN\13603305 <e2>seizure</e2>_13\JJ\1740 activity_14\NN\30358 24_15\CD\13745420 h_16\NN\14622893 after_17\IN\1740 <e1>gamma-hch</e1>_18\NN\1740 may_19\MD\15209706 be_20\VB\836236 the_21\DT\1740 gaba-a_22\NN\1740 receptor-linked_23\JJ\1740 chloride_24\NN\14818238 channel_25\NN\6251781 ._26\.\1740
D010433_D012640 CID gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 <e2>seizure</e2>_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 <e1>ptz</e1>_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 seizures_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D010433_D012640 CID gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 seizure_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 <e1>ptz</e1>_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 ptz-induced_36\JJ\1740 <e2>seizures</e2>_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D010433_D012640 CID gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 <e2>seizure</e2>_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 <e1>ptz-induced</e1>_36\JJ\1740 seizures_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D010433_D012640 CID gamma-hexachlorocyclohexane_0\JJ\1740 (_1\-LRB-\1740 gamma-hch_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 the_5\DT\1740 active_6\JJ\1740 ingredient_7\NN\3081021 of_8\IN\1740 the_9\DT\1740 insecticide_10\NN\14980215 lindane_11\NN\14919948 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 shown_15\VBN\2137132 to_16\TO\1740 decrease_17\VB\169651 seizure_18\JJ\1740 threshold_19\NN\15265518 to_20\TO\1740 pentylenetrazol_21\JJ\1740 (_22\-LRB-\1740 ptz_23\NN\1740 )_24\-RRB-\1740 3_25\CD\13741022 h_26\NN\14622893 after_27\IN\1740 exposure_28\NN\5042871 to_29\TO\1740 gamma-hch_30\NN\1740 and_31\CC\1740 conversely_32\RB\1740 increase_33\VB\169651 threshold_34\JJ\1740 to_35\TO\1740 <e1>ptz-induced</e1>_36\JJ\1740 <e2>seizures</e2>_37\NNS\14081375 24_38\CD\13745420 h_39\NN\14622893 after_40\IN\1740 exposure_41\NN\5042871 to_42\TO\1740 gamma-hch_43\NN\1740 (_44\-LRB-\1740 vohland_45\NNP\1740 et_46\FW\1740 al._47\FW\1740 1981_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D010433_D012640 CID <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 <e1>ptz</e1>_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 seizure_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D010433_D012640 CID seizure_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 <e1>ptz</e1>_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e2>seizure</e2>_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D010433_D012640 CID the_0\DT\1740 pharmacological_1\JJ\1740 challenge_2\NN\13927383 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 tolerance_6\NN\5032565 may_7\MD\15209706 occur_8\VB\2623529 to_9\TO\1740 <e2>seizure</e2>_10\VB\1740 activity_11\NN\30358 induced_12\VBN\1627355 by_13\IN\1740 <e1>ptz</e1>_14\NN\1740 and_15\CC\1740 ptx_16\NN\1740 24_17\CD\13745420 h_18\NN\14622893 after_19\IN\1740 gamma-hch_20\NN\1740 ,_21\,\1740 since_22\IN\1740 the_23\DT\1740 response_24\NN\11410625 to_25\TO\1740 only_26\RB\1740 these_27\DT\1740 two_28\CD\13741022 seizure-inducing_29\JJ\1740 agents_30\NNS\7347 is_31\VBZ\836236 decreased_32\VBN\169651 ._33\.\1740
D010433_D012640 CID the_0\DT\1740 pharmacological_1\JJ\1740 challenge_2\NN\13927383 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 tolerance_6\NN\5032565 may_7\MD\15209706 occur_8\VB\2623529 to_9\TO\1740 seizure_10\VB\1740 activity_11\NN\30358 induced_12\VBN\1627355 by_13\IN\1740 <e1>ptz</e1>_14\NN\1740 and_15\CC\1740 ptx_16\NN\1740 24_17\CD\13745420 h_18\NN\14622893 after_19\IN\1740 gamma-hch_20\NN\1740 ,_21\,\1740 since_22\IN\1740 the_23\DT\1740 response_24\NN\11410625 to_25\TO\1740 only_26\RB\1740 these_27\DT\1740 two_28\CD\13741022 <e2>seizure-inducing</e2>_29\JJ\1740 agents_30\NNS\7347 is_31\VBZ\836236 decreased_32\VBN\169651 ._33\.\1740
D010852_D012640 CID <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 <e1>picrotoxin</e1>_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 seizure_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D010852_D012640 CID seizure_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 <e1>picrotoxin</e1>_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e2>seizure</e2>_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D010852_D012640 CID <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 <e1>ptx</e1>_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 seizure_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D010852_D012640 CID seizure_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 <e1>ptx</e1>_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e2>seizure</e2>_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D010852_D012640 CID the_0\DT\1740 pharmacological_1\JJ\1740 challenge_2\NN\13927383 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 tolerance_6\NN\5032565 may_7\MD\15209706 occur_8\VB\2623529 to_9\TO\1740 <e2>seizure</e2>_10\VB\1740 activity_11\NN\30358 induced_12\VBN\1627355 by_13\IN\1740 ptz_14\NN\1740 and_15\CC\1740 <e1>ptx</e1>_16\NN\1740 24_17\CD\13745420 h_18\NN\14622893 after_19\IN\1740 gamma-hch_20\NN\1740 ,_21\,\1740 since_22\IN\1740 the_23\DT\1740 response_24\NN\11410625 to_25\TO\1740 only_26\RB\1740 these_27\DT\1740 two_28\CD\13741022 seizure-inducing_29\JJ\1740 agents_30\NNS\7347 is_31\VBZ\836236 decreased_32\VBN\169651 ._33\.\1740
D010852_D012640 CID the_0\DT\1740 pharmacological_1\JJ\1740 challenge_2\NN\13927383 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 tolerance_6\NN\5032565 may_7\MD\15209706 occur_8\VB\2623529 to_9\TO\1740 seizure_10\VB\1740 activity_11\NN\30358 induced_12\VBN\1627355 by_13\IN\1740 ptz_14\NN\1740 and_15\CC\1740 <e1>ptx</e1>_16\NN\1740 24_17\CD\13745420 h_18\NN\14622893 after_19\IN\1740 gamma-hch_20\NN\1740 ,_21\,\1740 since_22\IN\1740 the_23\DT\1740 response_24\NN\11410625 to_25\TO\1740 only_26\RB\1740 these_27\DT\1740 two_28\CD\13741022 <e2>seizure-inducing</e2>_29\JJ\1740 agents_30\NNS\7347 is_31\VBZ\836236 decreased_32\VBN\169651 ._33\.\1740
D015097_D012640 CID <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 seizure_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 <e1>3-mercaptopropionic_20\JJ\1740 acid</e1>_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D015097_D012640 CID seizure_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e2>seizure</e2>_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 <e1>3-mercaptopropionic_20\JJ\1740 acid</e1>_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D015097_D012640 CID <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 seizure_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 <e1>mpa</e1>_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D015097_D012640 CID seizure_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e2>seizure</e2>_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 <e1>mpa</e1>_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D001640_D012640 CID <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 seizure_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 <e1>bicuculline</e1>_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D001640_D012640 CID seizure_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e2>seizure</e2>_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 <e1>bicuculline</e1>_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D001640_D012640 CID <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 seizure_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 <e1>bcc</e1>_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D001640_D012640 CID seizure_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e2>seizure</e2>_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 <e1>bcc</e1>_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
C034818_D012640 CID <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 seizure_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 <e1>methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate</e1>_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
C034818_D012640 CID seizure_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e2>seizure</e2>_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 <e1>methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate</e1>_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
C034818_D012640 CID <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 seizure_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 <e1>dmcm</e1>_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
C034818_D012640 CID seizure_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e2>seizure</e2>_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 <e1>dmcm</e1>_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D013331_D012640 CID <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 seizure_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 <e1>strychnine</e1>_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D013331_D012640 CID seizure_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e2>seizure</e2>_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 <e1>strychnine</e1>_38\NN\14712692 (_39\-LRB-\1740 str_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D013331_D012640 CID <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 seizure_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 <e1>str</e1>_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D013331_D012640 CID seizure_0\NN\14081375 activity_1\NN\30358 due_2\IN\5174653 to_3\TO\1740 ptz_4\NN\1740 and_5\CC\1740 picrotoxin_6\NN\1740 (_7\-LRB-\1740 ptx_8\NN\1740 )_9\-RRB-\1740 was_10\VBD\836236 significantly_11\RB\1740 decreased_12\VBN\169651 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 <e2>seizure</e2>_16\JJ\1740 activity_17\NN\30358 due_18\JJ\1740 to_19\TO\1740 3-mercaptopropionic_20\JJ\1740 acid_21\NN\14818238 (_22\-LRB-\1740 mpa_23\NN\1740 )_24\-RRB-\1740 ,_25\,\1740 bicuculline_26\NN\1740 (_27\-LRB-\1740 bcc_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 methyl_31\NN\14617189 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740 (_33\-LRB-\1740 dmcm_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 or_37\CC\3541091 strychnine_38\NN\14712692 (_39\-LRB-\1740 <e1>str</e1>_40\NN\1740 )_41\-RRB-\1740 was_42\VBD\836236 not_43\RB\1740 different_44\JJ\1740 from_45\IN\1740 control_46\NN\5190804 ._47\.\1740
D005680_D012640 NONE the_0\DT\1740 in_1\FW\13603305 vitro_2\FW\1740 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 the_6\DT\1740 site_7\NN\8673395 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 decrease_11\NN\7296428 in_12\IN\13603305 <e2>seizure</e2>_13\JJ\1740 activity_14\NN\30358 24_15\CD\13745420 h_16\NN\14622893 after_17\IN\1740 gamma-hch_18\NN\1740 may_19\MD\15209706 be_20\VB\836236 the_21\DT\1740 <e1>gaba-a</e1>_22\NN\1740 receptor-linked_23\JJ\1740 chloride_24\NN\14818238 channel_25\NN\6251781 ._26\.\1740
1527456
D008012_D014012 NONE treatment_0\NN\654885 of_1\IN\1740 <e2>tinnitus</e2>_2\NN\14299637 by_3\IN\1740 intratympanic_4\JJ\1740 instillation_5\NN\320852 of_6\IN\1740 <e1>lignocaine</e1>_7\NN\1740 (_8\-LRB-\1740 lidocaine_9\NN\3681148 )_10\-RRB-\1740 2_11\CD\13741022 per_12\IN\1740 cent_13\NN\13662703 through_14\IN\1740 ventilation_15\NN\248977 tubes_16\NNS\3089014 ._17\.\1740
D008012_D014012 NONE treatment_0\NN\654885 of_1\IN\1740 <e2>tinnitus</e2>_2\NN\14299637 by_3\IN\1740 intratympanic_4\JJ\1740 instillation_5\NN\320852 of_6\IN\1740 lignocaine_7\NN\1740 (_8\-LRB-\1740 <e1>lidocaine</e1>_9\NN\3681148 )_10\-RRB-\1740 2_11\CD\13741022 per_12\IN\1740 cent_13\NN\13662703 through_14\IN\1740 ventilation_15\NN\248977 tubes_16\NNS\3089014 ._17\.\1740
D008012_D014012 NONE this_0\DT\1740 paper_1\NN\14580897 presents_2\VBZ\2137132 the_3\DT\1740 results_4\NNS\34213 of_5\IN\1740 treating_6\VBG\2376958 <e2>ist</e2>_7\NN\1740 by_8\IN\1740 intratympanic_9\JJ\1740 instillation_10\NN\320852 of_11\IN\1740 <e1>lignocaine</e1>_12\NN\1740 (_13\-LRB-\1740 lidocaine_14\NN\3681148 )_15\-RRB-\1740 2_16\CD\13741022 per_17\IN\1740 cent_18\NN\13662703 through_19\IN\1740 a_20\DT\13649268 grommet_21\NN\3323703 ,_22\,\1740 for_23\IN\1740 five_24\CD\13741022 weekly_25\JJ\1740 courses_26\NNS\883297 ._27\.\1740
D008012_D014012 NONE this_0\DT\1740 paper_1\NN\14580897 presents_2\VBZ\2137132 the_3\DT\1740 results_4\NNS\34213 of_5\IN\1740 treating_6\VBG\2376958 <e2>ist</e2>_7\NN\1740 by_8\IN\1740 intratympanic_9\JJ\1740 instillation_10\NN\320852 of_11\IN\1740 lignocaine_12\NN\1740 (_13\-LRB-\1740 <e1>lidocaine</e1>_14\NN\3681148 )_15\-RRB-\1740 2_16\CD\13741022 per_17\IN\1740 cent_18\NN\13662703 through_19\IN\1740 a_20\DT\13649268 grommet_21\NN\3323703 ,_22\,\1740 for_23\IN\1740 five_24\CD\13741022 weekly_25\JJ\1740 courses_26\NNS\883297 ._27\.\1740
2515254
D005996_D008881 CID twenty_0\CD\13745420 common_1\JJ\1740 <e2>migraine</e2>_2\NN\14326607 patients_3\NNS\9898892 received_4\VBD\2210855 a_5\DT\13649268 one_6\CD\13741022 sided_7\VBD\733632 frontotemporal_8\JJ\1740 application_9\NN\947128 of_10\IN\1740 <e1>nitroglycerin</e1>_11\NN\15015501 (_12\-LRB-\1740 10_13\CD\13745420 patients_14\NNS\9898892 )_15\-RRB-\1740 or_16\CC\3541091 placebo_17\NN\3740161 ointment_18\NN\4074482 (_19\-LRB-\1740 10_20\CD\13745420 patients_21\NNS\9898892 )_22\-RRB-\1740 in_23\IN\13603305 a_24\DT\13649268 double_25\JJ\1740 blind_26\NN\7942152 study_27\NN\635850 ._28\.\1740
D005996_D008881 CID early_0\JJ\1740 onset_1\NN\7325190 <e2>migraine</e2>_2\NN\14326607 attacks_3\NNS\955060 were_4\VBD\836236 induced_5\VBN\1627355 by_6\IN\1740 <e1>nitroglycerin</e1>_7\NN\15015501 in_8\IN\13603305 seven_9\CD\13741022 out_10\IN\66636 of_11\IN\1740 10_12\CD\13745420 patients_13\NNS\9898892 versus_14\CC\1740 no_15\DT\7204911 patient_16\NN\9898892 in_17\IN\13603305 the_18\DT\1740 placebo_19\NN\3740161 group_20\NN\2137 ._21\.\1740
D005996_D008881 CID subsequently_0\RB\1740 20_1\CD\13745420 <e2>migraine</e2>_2\NN\14326607 patients_3\NNS\9898892 ,_4\,\1740 who_5\WP\8299493 developed_6\VBD\1753788 an_7\DT\6697703 early_8\JJ\1740 onset_9\NN\7325190 attack_10\NN\955060 with_11\IN\1740 frontotemporal_12\JJ\1740 <e1>nitroglycerin</e1>_13\NN\15015501 ,_14\,\1740 received_15\VBD\2210855 the_16\DT\1740 drug_17\NN\14778436 in_18\IN\13603305 a_19\DT\13649268 second_20\JJ\1740 induction_21\NN\7450842 test_22\NN\5798043 at_23\IN\14622893 other_24\JJ\1740 body_25\NN\19128 areas_26\NNS\8630985 ._27\.\1740
D005996_D008881 CID thus_0\RB\1740 the_1\DT\1740 <e2>migraine-inducing</e2>_2\JJ\1740 effect_3\NN\34213 of_4\IN\1740 <e1>nitroglycerin</e1>_5\NN\15015501 seems_6\VBZ\2604760 to_7\TO\1740 depend_8\VB\2604760 on_9\IN\1740 direct_10\JJ\1740 stimulation_11\NN\242808 of_12\IN\1740 the_13\DT\1740 habitual_14\JJ\1740 site_15\NN\8673395 of_16\IN\1740 pain_17\NN\14299637 ,_18\,\1740 suggesting_19\VBG\1010118 that_20\IN\1740 the_21\DT\1740 frontotemporal_22\JJ\1740 region_23\NN\27167 is_24\VBZ\836236 of_25\IN\1740 crucial_26\JJ\1740 importance_27\NN\5138488 in_28\IN\13603305 the_29\DT\1740 development_30\NN\248977 of_31\IN\1740 a_32\DT\13649268 migraine_33\NN\14326607 crisis_34\NN\14411243 ._35\.\1740
D005996_D008881 CID thus_0\RB\1740 the_1\DT\1740 migraine-inducing_2\JJ\1740 effect_3\NN\34213 of_4\IN\1740 <e1>nitroglycerin</e1>_5\NN\15015501 seems_6\VBZ\2604760 to_7\TO\1740 depend_8\VB\2604760 on_9\IN\1740 direct_10\JJ\1740 stimulation_11\NN\242808 of_12\IN\1740 the_13\DT\1740 habitual_14\JJ\1740 site_15\NN\8673395 of_16\IN\1740 pain_17\NN\14299637 ,_18\,\1740 suggesting_19\VBG\1010118 that_20\IN\1740 the_21\DT\1740 frontotemporal_22\JJ\1740 region_23\NN\27167 is_24\VBZ\836236 of_25\IN\1740 crucial_26\JJ\1740 importance_27\NN\5138488 in_28\IN\13603305 the_29\DT\1740 development_30\NN\248977 of_31\IN\1740 a_32\DT\13649268 <e2>migraine</e2>_33\NN\14326607 crisis_34\NN\14411243 ._35\.\1740
D005996_D010146 NONE thus_0\RB\1740 the_1\DT\1740 migraine-inducing_2\JJ\1740 effect_3\NN\34213 of_4\IN\1740 <e1>nitroglycerin</e1>_5\NN\15015501 seems_6\VBZ\2604760 to_7\TO\1740 depend_8\VB\2604760 on_9\IN\1740 direct_10\JJ\1740 stimulation_11\NN\242808 of_12\IN\1740 the_13\DT\1740 habitual_14\JJ\1740 site_15\NN\8673395 of_16\IN\1740 <e2>pain</e2>_17\NN\14299637 ,_18\,\1740 suggesting_19\VBG\1010118 that_20\IN\1740 the_21\DT\1740 frontotemporal_22\JJ\1740 region_23\NN\27167 is_24\VBZ\836236 of_25\IN\1740 crucial_26\JJ\1740 importance_27\NN\5138488 in_28\IN\13603305 the_29\DT\1740 development_30\NN\248977 of_31\IN\1740 a_32\DT\13649268 migraine_33\NN\14326607 crisis_34\NN\14411243 ._35\.\1740
20080983
C048833_D012893 NONE objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 purpose_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 present_6\JJ\1740 study_7\NN\635850 was_8\VBD\836236 to_9\TO\1740 determine_10\VB\1645601 the_11\DT\1740 effect_12\NN\34213 of_13\IN\1740 morning-dosed_14\JJ\1740 <e1>modafinil</e1>_15\NN\1740 on_16\IN\1740 sleep_17\NN\14034177 and_18\CC\1740 <e2>daytime_19\NN\15113229 sleepiness</e2>_20\NN\14015731 in_21\IN\13603305 chronic_22\JJ\1740 cocaine_23\NN\3492717 users_24\NNS\7846 ._25\.\1740
C048833_D012893 NONE <e1>modafinil</e1>_0\NNP\1740 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 increased_4\VBN\169651 daytime_5\NN\15113229 sleep_6\NN\14034177 latency_7\NN\15269513 ,_8\,\1740 as_9\IN\14622893 measured_10\VBN\697589 by_11\IN\1740 the_12\DT\1740 multiple_13\JJ\1740 sleep_14\NNP\14034177 latency_15\NNP\15269513 test_16\NNP\5798043 ,_17\,\1740 and_18\CC\1740 a_19\DT\13649268 nearly_20\RB\1740 significant_21\JJ\1740 decrease_22\NN\7296428 in_23\IN\13603305 subjective_24\JJ\1740 <e2>daytime_25\NN\15113229 sleepiness</e2>_26\NN\14015731 ._27\.\1740
C048833_D012893 NONE conclusions_0\NNS\5837957 :_1\:\1740 morning-dosed_2\JJ\1740 <e1>modafinil</e1>_3\NN\1740 promotes_4\VBZ\2556126 nocturnal_5\JJ\1740 sleep_6\NN\14034177 ,_7\,\1740 normalizes_8\NNS\1740 sleep_9\NN\14034177 architecture_10\NN\2913152 ,_11\,\1740 and_12\CC\1740 decreases_13\VBZ\169651 <e2>daytime_14\NN\15113229 sleepiness</e2>_15\NN\14015731 in_16\IN\13603305 abstinent_17\JJ\1740 cocaine_18\NN\3492717 users_19\NNS\7846 ._20\.\1740
D003042_D012893 CID objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 purpose_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 present_6\JJ\1740 study_7\NN\635850 was_8\VBD\836236 to_9\TO\1740 determine_10\VB\1645601 the_11\DT\1740 effect_12\NN\34213 of_13\IN\1740 morning-dosed_14\JJ\1740 modafinil_15\NN\1740 on_16\IN\1740 sleep_17\NN\14034177 and_18\CC\1740 <e2>daytime_19\NN\15113229 sleepiness</e2>_20\NN\14015731 in_21\IN\13603305 chronic_22\JJ\1740 <e1>cocaine</e1>_23\NN\3492717 users_24\NNS\7846 ._25\.\1740
D003042_D012893 CID conclusions_0\NNS\5837957 :_1\:\1740 morning-dosed_2\JJ\1740 modafinil_3\NN\1740 promotes_4\VBZ\2556126 nocturnal_5\JJ\1740 sleep_6\NN\14034177 ,_7\,\1740 normalizes_8\NNS\1740 sleep_9\NN\14034177 architecture_10\NN\2913152 ,_11\,\1740 and_12\CC\1740 decreases_13\VBZ\169651 <e2>daytime_14\NN\15113229 sleepiness</e2>_15\NN\14015731 in_16\IN\13603305 abstinent_17\JJ\1740 <e1>cocaine</e1>_18\NN\3492717 users_19\NNS\7846 ._20\.\1740
3125768
D015760_D009127 CID intracranial_0\JJ\1740 pressure_1\NN\11419404 increases_2\VBZ\169651 during_3\IN\1740 <e1>alfentanil-induced</e1>_4\JJ\1740 <e2>rigidity</e2>_5\NN\5023233 ._6\.\1740
D015760_D009127 CID intracranial_0\JJ\1740 pressure_1\NN\11419404 (_2\-LRB-\1740 icp_3\NN\1740 )_4\-RRB-\1740 was_5\VBD\836236 measured_6\VBN\697589 during_7\IN\1740 <e1>alfentanil-induced</e1>_8\JJ\1740 <e2>rigidity</e2>_9\NN\5023233 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D015760_D009127 CID these_0\DT\1740 observations_1\NNS\996969 suggest_2\VBP\1010118 that_3\IN\1740 <e2>rigidity</e2>_4\NN\5023233 should_5\MD\1740 be_6\VB\836236 prevented_7\VBN\1740 when_8\WRB\1740 <e1>alfentanil</e1>_9\JJ\1740 ,_10\,\1740 and_11\CC\1740 ,_12\,\1740 presumably_13\RB\1740 ,_14\,\1740 other_15\JJ\1740 opiates_16\NNS\3808564 ,_17\,\1740 are_18\VBP\836236 used_19\VBN\1156834 in_20\IN\13603305 the_21\DT\1740 anesthetic_22\JJ\1740 management_23\NN\1123598 of_24\IN\1740 patients_25\NNS\9898892 with_26\IN\1740 icp_27\NN\1740 problems_28\NNS\14408086 ._29\.\1740
C032943_D009127 NONE these_0\DT\1740 variables_1\NNS\2452 returned_2\VBD\1835496 to_3\TO\1740 baseline_4\NN\7260623 when_5\WRB\1740 <e2>rigidity</e2>_6\NN\5023233 was_7\VBD\836236 abolished_8\VBN\1740 with_9\IN\1740 <e1>metocurine</e1>_10\NN\1740 ._11\.\1740
20698227
D012254_D000743 NONE can_0\MD\3094503 angiogenesis_1\NN\13489037 be_2\VB\836236 a_3\DT\13649268 target_4\NN\7258332 of_5\IN\1740 treatment_6\NN\654885 for_7\IN\1740 <e1>ribavirin</e1>_8\NN\2725367 associated_9\JJ\1740 <e2>hemolytic_10\JJ\1740 anemia</e2>_11\NN\14189204 ?_12\.\1740
D012254_D006461 NONE background/aims_0\JJ\1740 :_1\:\1740 recently_2\RB\1740 <e1>ribavirin</e1>_3\NN\2725367 has_4\VBZ\2108377 been_5\VBN\836236 found_6\VBN\2426171 to_7\TO\1740 inhibit_8\VB\2510337 angiogenesis_9\NN\13489037 and_10\CC\1740 a_11\DT\13649268 number_12\NN\5107765 of_13\IN\1740 angiogenesis_14\NN\13489037 inhibitors_15\NNS\20090 such_16\JJ\1740 as_17\IN\14622893 sunitinib_18\NN\1740 and_19\CC\1740 sorafenib_20\NN\1740 have_21\VBP\2108377 been_22\VBN\836236 found_23\VBN\2426171 to_24\TO\1740 cause_25\VB\1617192 acute_26\JJ\1740 <e2>hemolysis</e2>_27\NN\13509528 ._28\.\1740
C473478_D006461 CID background/aims_0\JJ\1740 :_1\:\1740 recently_2\RB\1740 ribavirin_3\NN\2725367 has_4\VBZ\2108377 been_5\VBN\836236 found_6\VBN\2426171 to_7\TO\1740 inhibit_8\VB\2510337 angiogenesis_9\NN\13489037 and_10\CC\1740 a_11\DT\13649268 number_12\NN\5107765 of_13\IN\1740 angiogenesis_14\NN\13489037 inhibitors_15\NNS\20090 such_16\JJ\1740 as_17\IN\14622893 <e1>sunitinib</e1>_18\NN\1740 and_19\CC\1740 sorafenib_20\NN\1740 have_21\VBP\2108377 been_22\VBN\836236 found_23\VBN\2426171 to_24\TO\1740 cause_25\VB\1617192 acute_26\JJ\1740 <e2>hemolysis</e2>_27\NN\13509528 ._28\.\1740
C471405_D006461 CID background/aims_0\JJ\1740 :_1\:\1740 recently_2\RB\1740 ribavirin_3\NN\2725367 has_4\VBZ\2108377 been_5\VBN\836236 found_6\VBN\2426171 to_7\TO\1740 inhibit_8\VB\2510337 angiogenesis_9\NN\13489037 and_10\CC\1740 a_11\DT\13649268 number_12\NN\5107765 of_13\IN\1740 angiogenesis_14\NN\13489037 inhibitors_15\NNS\20090 such_16\JJ\1740 as_17\IN\14622893 sunitinib_18\NN\1740 and_19\CC\1740 <e1>sorafenib</e1>_20\NN\1740 have_21\VBP\2108377 been_22\VBN\836236 found_23\VBN\2426171 to_24\TO\1740 cause_25\VB\1617192 acute_26\JJ\1740 <e2>hemolysis</e2>_27\NN\13509528 ._28\.\1740
C100416_D019698 NONE methods_0\NNS\5616786 :_1\:\1740 fourteen_2\CD\13745420 patients_3\NNS\9898892 <e2>chronically_4\RB\1740 infected_5\VBN\2316868 with_6\IN\1740 hepatitis_7\NN\14127211 c_8\NN\13714184 virus</e2>_9\NN\9312843 were_10\VBD\836236 treated_11\VBN\2376958 by_12\IN\1740 <e1>pegylated_13\JJ\1740 interferon_14\NN\2725367 alpha_15\NN\6828818 2a</e1>_16\NN\1740 and_17\CC\1740 ribavirin_18\NN\2725367 ._19\.\1740
D012254_D019698 NONE methods_0\NNS\5616786 :_1\:\1740 fourteen_2\CD\13745420 patients_3\NNS\9898892 <e2>chronically_4\RB\1740 infected_5\VBN\2316868 with_6\IN\1740 hepatitis_7\NN\14127211 c_8\NN\13714184 virus</e2>_9\NN\9312843 were_10\VBD\836236 treated_11\VBN\2376958 by_12\IN\1740 pegylated_13\JJ\1740 interferon_14\NN\2725367 alpha_15\NN\6828818 2a_16\NN\1740 and_17\CC\1740 <e1>ribavirin</e1>_18\NN\2725367 ._19\.\1740
D012254_D019698 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 is_3\VBZ\836236 the_4\DT\1740 first_5\JJ\1740 study_6\NN\635850 in_7\IN\13603305 the_8\DT\1740 literature_9\NN\6362953 investigating_10\VBG\644583 a_11\DT\13649268 link_12\NN\13792579 between_13\IN\1740 angiogenesis_14\NN\13489037 soluble_15\JJ\1740 markers_16\NNS\21939 and_17\CC\1740 <e1>ribavirin</e1>_18\NN\2725367 induced_19\VBD\1627355 anemia_20\NN\14189204 in_21\IN\13603305 patients_22\NNS\9898892 with_23\IN\1740 <e2>hepatitis_24\NN\14127211 c</e2>_25\NN\13714184 and_26\CC\1740 we_27\PRP\1740 could_28\MD\1740 not_29\RB\1740 find_30\VB\2163746 any_31\DT\1740 relation_32\NN\2137 ._33\.\1740
D012254_D000740 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 is_3\VBZ\836236 the_4\DT\1740 first_5\JJ\1740 study_6\NN\635850 in_7\IN\13603305 the_8\DT\1740 literature_9\NN\6362953 investigating_10\VBG\644583 a_11\DT\13649268 link_12\NN\13792579 between_13\IN\1740 angiogenesis_14\NN\13489037 soluble_15\JJ\1740 markers_16\NNS\21939 and_17\CC\1740 <e1>ribavirin</e1>_18\NN\2725367 induced_19\VBD\1627355 <e2>anemia</e2>_20\NN\14189204 in_21\IN\13603305 patients_22\NNS\9898892 with_23\IN\1740 hepatitis_24\NN\14127211 c_25\NN\13714184 and_26\CC\1740 we_27\PRP\1740 could_28\MD\1740 not_29\RB\1740 find_30\VB\2163746 any_31\DT\1740 relation_32\NN\2137 ._33\.\1740
18261172
D020123_D011507 CID development_0\NN\248977 of_1\IN\1740 <e2>proteinuria</e2>_2\NN\14299637 after_3\IN\1740 switch_4\NN\3096960 to_5\TO\1740 <e1>sirolimus-based</e1>_6\JJ\1740 immunosuppression_7\NN\13973990 in_8\IN\13603305 long-term_9\JJ\1740 cardiac_10\JJ\1740 transplant_11\NN\5267548 patients_12\NNS\9898892 ._13\.\1740
D020123_D011507 CID the_0\DT\1740 novel_1\JJ\1740 immunosuppressive_2\JJ\1740 (_3\-LRB-\1740 is_4\NN\1740 )_5\-RRB-\1740 drug_6\NN\14778436 <e1>sirolmus</e1>_7\NN\1740 (_8\-LRB-\1740 srl_9\NN\1740 )_10\-RRB-\1740 lacks_11\VBZ\1740 nephrotoxic_12\JJ\1740 effects_13\NNS\13245626 ;_14\:\1740 however_15\RB\1740 ,_16\,\1740 <e2>proteinuria</e2>_17\NN\14299637 associated_18\VBN\628491 with_19\IN\1740 srl_20\NNP\1740 has_21\VBZ\2108377 been_22\VBN\836236 reported_23\VBN\831651 following_24\VBG\1835496 renal_25\JJ\1740 transplantation_26\NN\671351 ._27\.\1740
D020123_D011507 CID the_0\DT\1740 novel_1\JJ\1740 immunosuppressive_2\JJ\1740 (_3\-LRB-\1740 is_4\NN\1740 )_5\-RRB-\1740 drug_6\NN\14778436 sirolmus_7\NN\1740 (_8\-LRB-\1740 <e1>srl</e1>_9\NN\1740 )_10\-RRB-\1740 lacks_11\VBZ\1740 nephrotoxic_12\JJ\1740 effects_13\NNS\13245626 ;_14\:\1740 however_15\RB\1740 ,_16\,\1740 <e2>proteinuria</e2>_17\NN\14299637 associated_18\VBN\628491 with_19\IN\1740 srl_20\NNP\1740 has_21\VBZ\2108377 been_22\VBN\836236 reported_23\VBN\831651 following_24\VBG\1835496 renal_25\JJ\1740 transplantation_26\NN\671351 ._27\.\1740
D020123_D011507 CID the_0\DT\1740 novel_1\JJ\1740 immunosuppressive_2\JJ\1740 (_3\-LRB-\1740 is_4\NN\1740 )_5\-RRB-\1740 drug_6\NN\14778436 sirolmus_7\NN\1740 (_8\-LRB-\1740 srl_9\NN\1740 )_10\-RRB-\1740 lacks_11\VBZ\1740 nephrotoxic_12\JJ\1740 effects_13\NNS\13245626 ;_14\:\1740 however_15\RB\1740 ,_16\,\1740 <e2>proteinuria</e2>_17\NN\14299637 associated_18\VBN\628491 with_19\IN\1740 <e1>srl</e1>_20\NNP\1740 has_21\VBZ\2108377 been_22\VBN\836236 reported_23\VBN\831651 following_24\VBG\1835496 renal_25\JJ\1740 transplantation_26\NN\671351 ._27\.\1740
D020123_D011507 CID in_0\IN\13603305 cardiac_1\JJ\1740 transplantation_2\NN\671351 ,_3\,\1740 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>proteinuria</e2>_7\NN\14299637 associated_8\VBN\628491 with_9\IN\1740 <e1>srl</e1>_10\NN\1740 is_11\VBZ\836236 unknown_12\JJ\1740 ._13\.\1740
D020123_D011507 CID thus_0\RB\1740 ,_1\,\1740 <e2>proteinuria</e2>_2\NN\14299637 may_3\MD\15209706 develop_4\VB\1753788 in_5\IN\13603305 cardiac_6\JJ\1740 transplant_7\NN\5267548 patients_8\NNS\9898892 after_9\IN\1740 switch_10\NN\3096960 to_11\IN\1740 <e1>srl</e1>_12\NNP\1740 ,_13\,\1740 which_14\WDT\1740 may_15\MD\15209706 have_16\VB\2108377 an_17\DT\6697703 adverse_18\JJ\1740 effect_19\NN\34213 on_20\IN\1740 renal_21\JJ\1740 function_22\NN\13783581 in_23\IN\13603305 these_24\DT\1740 patients_25\NNS\9898892 ._26\.\1740
D020123_D011507 CID <e1>srl</e1>_0\NN\1740 should_1\MD\1740 be_2\VB\836236 used_3\VBN\1156834 with_4\IN\1740 acei/arb_5\NN\1740 therapy_6\NN\657604 and_7\CC\1740 patients_8\NNS\9898892 monitored_9\VBN\2169352 for_10\IN\1740 <e2>proteinuria</e2>_11\NN\14299637 and_12\CC\1740 increased_13\VBD\169651 renal_14\JJ\1740 dysfunction_15\NN\14204950 ._16\.\1740
D020123_D007674 NONE the_0\DT\1740 novel_1\JJ\1740 immunosuppressive_2\JJ\1740 (_3\-LRB-\1740 is_4\NN\1740 )_5\-RRB-\1740 drug_6\NN\14778436 <e1>sirolmus</e1>_7\NN\1740 (_8\-LRB-\1740 srl_9\NN\1740 )_10\-RRB-\1740 lacks_11\VBZ\1740 <e2>nephrotoxic</e2>_12\JJ\1740 effects_13\NNS\13245626 ;_14\:\1740 however_15\RB\1740 ,_16\,\1740 proteinuria_17\NN\14299637 associated_18\VBN\628491 with_19\IN\1740 srl_20\NNP\1740 has_21\VBZ\2108377 been_22\VBN\836236 reported_23\VBN\831651 following_24\VBG\1835496 renal_25\JJ\1740 transplantation_26\NN\671351 ._27\.\1740
D020123_D007674 NONE the_0\DT\1740 novel_1\JJ\1740 immunosuppressive_2\JJ\1740 (_3\-LRB-\1740 is_4\NN\1740 )_5\-RRB-\1740 drug_6\NN\14778436 sirolmus_7\NN\1740 (_8\-LRB-\1740 <e1>srl</e1>_9\NN\1740 )_10\-RRB-\1740 lacks_11\VBZ\1740 <e2>nephrotoxic</e2>_12\JJ\1740 effects_13\NNS\13245626 ;_14\:\1740 however_15\RB\1740 ,_16\,\1740 proteinuria_17\NN\14299637 associated_18\VBN\628491 with_19\IN\1740 srl_20\NNP\1740 has_21\VBZ\2108377 been_22\VBN\836236 reported_23\VBN\831651 following_24\VBG\1835496 renal_25\JJ\1740 transplantation_26\NN\671351 ._27\.\1740
D020123_D007674 NONE the_0\DT\1740 novel_1\JJ\1740 immunosuppressive_2\JJ\1740 (_3\-LRB-\1740 is_4\NN\1740 )_5\-RRB-\1740 drug_6\NN\14778436 sirolmus_7\NN\1740 (_8\-LRB-\1740 srl_9\NN\1740 )_10\-RRB-\1740 lacks_11\VBZ\1740 <e2>nephrotoxic</e2>_12\JJ\1740 effects_13\NNS\13245626 ;_14\:\1740 however_15\RB\1740 ,_16\,\1740 proteinuria_17\NN\14299637 associated_18\VBN\628491 with_19\IN\1740 <e1>srl</e1>_20\NNP\1740 has_21\VBZ\2108377 been_22\VBN\836236 reported_23\VBN\831651 following_24\VBG\1835496 renal_25\JJ\1740 transplantation_26\NN\671351 ._27\.\1740
D020123_D007674 NONE <e1>srl</e1>_0\NN\1740 should_1\MD\1740 be_2\VB\836236 used_3\VBN\1156834 with_4\IN\1740 acei/arb_5\NN\1740 therapy_6\NN\657604 and_7\CC\1740 patients_8\NNS\9898892 monitored_9\VBN\2169352 for_10\IN\1740 proteinuria_11\NN\14299637 and_12\CC\1740 increased_13\VBD\169651 <e2>renal_14\JJ\1740 dysfunction</e2>_15\NN\14204950 ._16\.\1740
D000806_D011507 NONE <e1>ace_0\NN\13741022 inhibitor</e1>_1\NN\20090 and_2\CC\1740 angiotensin-releasing_3\JJ\1740 blocker_4\NN\10101634 (_5\-LRB-\1740 arb_6\NN\9882007 )_7\-RRB-\1740 therapy_8\NN\657604 reduced_9\VBD\441445 <e2>proteinuria</e2>_10\NN\14299637 development_11\NN\248977 ._12\.\1740
D000806_D011507 NONE srl_0\NN\1740 should_1\MD\1740 be_2\VB\836236 used_3\VBN\1156834 with_4\IN\1740 <e1>acei/arb</e1>_5\NN\1740 therapy_6\NN\657604 and_7\CC\1740 patients_8\NNS\9898892 monitored_9\VBN\2169352 for_10\IN\1740 <e2>proteinuria</e2>_11\NN\14299637 and_12\CC\1740 increased_13\VBD\169651 renal_14\JJ\1740 dysfunction_15\NN\14204950 ._16\.\1740
D057911_D011507 NONE ace_0\NN\13741022 inhibitor_1\NN\20090 and_2\CC\1740 <e1>angiotensin-releasing_3\JJ\1740 blocker</e1>_4\NN\10101634 (_5\-LRB-\1740 arb_6\NN\9882007 )_7\-RRB-\1740 therapy_8\NN\657604 reduced_9\VBD\441445 <e2>proteinuria</e2>_10\NN\14299637 development_11\NN\248977 ._12\.\1740
D057911_D011507 NONE ace_0\NN\13741022 inhibitor_1\NN\20090 and_2\CC\1740 angiotensin-releasing_3\JJ\1740 blocker_4\NN\10101634 (_5\-LRB-\1740 <e1>arb</e1>_6\NN\9882007 )_7\-RRB-\1740 therapy_8\NN\657604 reduced_9\VBD\441445 <e2>proteinuria</e2>_10\NN\14299637 development_11\NN\248977 ._12\.\1740
D057911_D011507 NONE srl_0\NN\1740 should_1\MD\1740 be_2\VB\836236 used_3\VBN\1156834 with_4\IN\1740 <e1>acei/arb</e1>_5\NN\1740 therapy_6\NN\657604 and_7\CC\1740 patients_8\NNS\9898892 monitored_9\VBN\2169352 for_10\IN\1740 <e2>proteinuria</e2>_11\NN\14299637 and_12\CC\1740 increased_13\VBD\169651 renal_14\JJ\1740 dysfunction_15\NN\14204950 ._16\.\1740
D000806_D007674 NONE srl_0\NN\1740 should_1\MD\1740 be_2\VB\836236 used_3\VBN\1156834 with_4\IN\1740 <e1>acei/arb</e1>_5\NN\1740 therapy_6\NN\657604 and_7\CC\1740 patients_8\NNS\9898892 monitored_9\VBN\2169352 for_10\IN\1740 proteinuria_11\NN\14299637 and_12\CC\1740 increased_13\VBD\169651 <e2>renal_14\JJ\1740 dysfunction</e2>_15\NN\14204950 ._16\.\1740
D057911_D007674 NONE srl_0\NN\1740 should_1\MD\1740 be_2\VB\836236 used_3\VBN\1156834 with_4\IN\1740 <e1>acei/arb</e1>_5\NN\1740 therapy_6\NN\657604 and_7\CC\1740 patients_8\NNS\9898892 monitored_9\VBN\2169352 for_10\IN\1740 proteinuria_11\NN\14299637 and_12\CC\1740 increased_13\VBD\169651 <e2>renal_14\JJ\1740 dysfunction</e2>_15\NN\14204950 ._16\.\1740
7834920
D012293_D005921 CID crescentic_0\JJ\1740 fibrillary_1\JJ\1740 <e2>glomerulonephritis</e2>_2\NN\14113798 associated_3\VBN\628491 with_4\IN\1740 intermittent_5\JJ\1740 <e1>rifampin</e1>_6\NN\2716205 therapy_7\NN\657604 for_8\IN\1740 pulmonary_9\JJ\1740 tuberculosis_10\NN\14127211 ._11\.\1740
D012293_D005921 CID this_0\DT\1740 case_1\NN\7283608 study_2\NN\635850 reveals_3\VBZ\2137132 an_4\DT\6697703 unusual_5\JJ\1740 finding_6\NN\43195 of_7\IN\1740 rapidly_8\RB\1740 proliferative_9\JJ\1740 crescentic_10\JJ\1740 <e2>glomerulonephritis</e2>_11\NN\14113798 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 treated_15\VBN\2376958 with_16\IN\1740 <e1>rifampin</e1>_17\NN\2716205 who_18\WP\8299493 had_19\VBD\2108377 no_20\DT\7204911 other_21\JJ\1740 identifiable_22\JJ\1740 causes_23\NNS\7323922 for_24\IN\1740 developing_25\VBG\1753788 this_26\DT\1740 disease_27\NN\14061805 ._28\.\1740
D012293_D005921 CID this_0\DT\1740 report_1\NN\6470073 documents_2\VBZ\1000214 the_3\DT\1740 unusual_4\JJ\1740 occurrence_5\NN\29378 of_6\IN\1740 rapidly_7\RB\1740 progressive_8\JJ\1740 <e2>glomerulonephritis</e2>_9\NN\14113798 with_10\IN\1740 crescents_11\NNS\13867641 and_12\CC\1740 fibrillar_13\JJ\1740 glomerulonephritis_14\NN\14113798 in_15\IN\13603305 a_16\DT\13649268 patient_17\NN\9898892 treated_18\VBN\2376958 with_19\IN\1740 <e1>rifampin</e1>_20\NN\2716205 ._21\.\1740
D012293_D005921 CID this_0\DT\1740 report_1\NN\6470073 documents_2\VBZ\1000214 the_3\DT\1740 unusual_4\JJ\1740 occurrence_5\NN\29378 of_6\IN\1740 rapidly_7\RB\1740 progressive_8\JJ\1740 glomerulonephritis_9\NN\14113798 with_10\IN\1740 crescents_11\NNS\13867641 and_12\CC\1740 fibrillar_13\JJ\1740 <e2>glomerulonephritis</e2>_14\NN\14113798 in_15\IN\13603305 a_16\DT\13649268 patient_17\NN\9898892 treated_18\VBN\2376958 with_19\IN\1740 <e1>rifampin</e1>_20\NN\2716205 ._21\.\1740
D012293_D014397 NONE crescentic_0\JJ\1740 fibrillary_1\JJ\1740 glomerulonephritis_2\NN\14113798 associated_3\VBN\628491 with_4\IN\1740 intermittent_5\JJ\1740 <e1>rifampin</e1>_6\NN\2716205 therapy_7\NN\657604 for_8\IN\1740 <e2>pulmonary_9\JJ\1740 tuberculosis</e2>_10\NN\14127211 ._11\.\1740
D012293_D014397 NONE this_0\DT\1740 patient_1\NN\9898892 underwent_2\VBD\109660 a_3\DT\13649268 10-month_4\JJ\1740 regimen_5\NN\5898568 of_6\IN\1740 <e1>rifampin</e1>_7\NN\2716205 and_8\CC\1740 isoniazid_9\NNS\2716205 for_10\IN\1740 <e2>pulmonary_11\JJ\1740 tuberculosis</e2>_12\NN\14127211 and_13\CC\1740 was_14\VBD\836236 discovered_15\VBN\2163746 to_16\TO\1740 have_17\VB\2108377 developed_18\VBN\1753788 signs_19\NNS\6643763 of_20\IN\1740 severe_21\JJ\1740 renal_22\JJ\1740 failure_23\NN\66216 five_24\CD\13741022 weeks_25\NNS\15113229 after_26\IN\1740 completion_27\NN\556313 of_28\IN\1740 therapy_29\NN\657604 ._30\.\1740
D012293_D051437 CID this_0\DT\1740 patient_1\NN\9898892 underwent_2\VBD\109660 a_3\DT\13649268 10-month_4\JJ\1740 regimen_5\NN\5898568 of_6\IN\1740 <e1>rifampin</e1>_7\NN\2716205 and_8\CC\1740 isoniazid_9\NNS\2716205 for_10\IN\1740 pulmonary_11\JJ\1740 tuberculosis_12\NN\14127211 and_13\CC\1740 was_14\VBD\836236 discovered_15\VBN\2163746 to_16\TO\1740 have_17\VB\2108377 developed_18\VBN\1753788 signs_19\NNS\6643763 of_20\IN\1740 severe_21\JJ\1740 <e2>renal_22\JJ\1740 failure</e2>_23\NN\66216 five_24\CD\13741022 weeks_25\NNS\15113229 after_26\IN\1740 completion_27\NN\556313 of_28\IN\1740 therapy_29\NN\657604 ._30\.\1740
D007538_D014397 NONE this_0\DT\1740 patient_1\NN\9898892 underwent_2\VBD\109660 a_3\DT\13649268 10-month_4\JJ\1740 regimen_5\NN\5898568 of_6\IN\1740 rifampin_7\NN\2716205 and_8\CC\1740 <e1>isoniazid</e1>_9\NNS\2716205 for_10\IN\1740 <e2>pulmonary_11\JJ\1740 tuberculosis</e2>_12\NN\14127211 and_13\CC\1740 was_14\VBD\836236 discovered_15\VBN\2163746 to_16\TO\1740 have_17\VB\2108377 developed_18\VBN\1753788 signs_19\NNS\6643763 of_20\IN\1740 severe_21\JJ\1740 renal_22\JJ\1740 failure_23\NN\66216 five_24\CD\13741022 weeks_25\NNS\15113229 after_26\IN\1740 completion_27\NN\556313 of_28\IN\1740 therapy_29\NN\657604 ._30\.\1740
D007538_D051437 NONE this_0\DT\1740 patient_1\NN\9898892 underwent_2\VBD\109660 a_3\DT\13649268 10-month_4\JJ\1740 regimen_5\NN\5898568 of_6\IN\1740 rifampin_7\NN\2716205 and_8\CC\1740 <e1>isoniazid</e1>_9\NNS\2716205 for_10\IN\1740 pulmonary_11\JJ\1740 tuberculosis_12\NN\14127211 and_13\CC\1740 was_14\VBD\836236 discovered_15\VBN\2163746 to_16\TO\1740 have_17\VB\2108377 developed_18\VBN\1753788 signs_19\NNS\6643763 of_20\IN\1740 severe_21\JJ\1740 <e2>renal_22\JJ\1740 failure</e2>_23\NN\66216 five_24\CD\13741022 weeks_25\NNS\15113229 after_26\IN\1740 completion_27\NN\556313 of_28\IN\1740 therapy_29\NN\657604 ._30\.\1740
11928786
D016642_D064420 NONE <e1>bupropion</e1>_0\NN\1740 (_1\-LRB-\1740 zyban_2\NN\1740 )_3\-RRB-\1740 <e2>toxicity</e2>_4\NN\13576101 ._5\.\1740
D016642_D064420 NONE bupropion_0\NN\1740 (_1\-LRB-\1740 <e1>zyban</e1>_2\NN\1740 )_3\-RRB-\1740 <e2>toxicity</e2>_4\NN\13576101 ._5\.\1740
D003975_D012640 NONE recurrent_0\JJ\1740 <e2>seizures</e2>_1\NNS\14081375 were_2\VBD\836236 treated_3\VBN\2376958 with_4\IN\1740 <e1>diazepam</e1>_5\NN\2830852 and_6\CC\1740 broad_7\JJ\1740 complex_8\JJ\1740 tachycardia_9\NN\14110674 was_10\VBD\836236 successfully_11\RB\1740 treated_12\VBN\2376958 with_13\IN\1740 adenosine_14\NN\14964367 ._15\.\1740
D003975_D013610 NONE recurrent_0\JJ\1740 seizures_1\NNS\14081375 were_2\VBD\836236 treated_3\VBN\2376958 with_4\IN\1740 <e1>diazepam</e1>_5\NN\2830852 and_6\CC\1740 broad_7\JJ\1740 complex_8\JJ\1740 <e2>tachycardia</e2>_9\NN\14110674 was_10\VBD\836236 successfully_11\RB\1740 treated_12\VBN\2376958 with_13\IN\1740 adenosine_14\NN\14964367 ._15\.\1740
D000241_D012640 NONE recurrent_0\JJ\1740 <e2>seizures</e2>_1\NNS\14081375 were_2\VBD\836236 treated_3\VBN\2376958 with_4\IN\1740 diazepam_5\NN\2830852 and_6\CC\1740 broad_7\JJ\1740 complex_8\JJ\1740 tachycardia_9\NN\14110674 was_10\VBD\836236 successfully_11\RB\1740 treated_12\VBN\2376958 with_13\IN\1740 <e1>adenosine</e1>_14\NN\14964367 ._15\.\1740
D000241_D013610 NONE recurrent_0\JJ\1740 seizures_1\NNS\14081375 were_2\VBD\836236 treated_3\VBN\2376958 with_4\IN\1740 diazepam_5\NN\2830852 and_6\CC\1740 broad_7\JJ\1740 complex_8\JJ\1740 <e2>tachycardia</e2>_9\NN\14110674 was_10\VBD\836236 successfully_11\RB\1740 treated_12\VBN\2376958 with_13\IN\1740 <e1>adenosine</e1>_14\NN\14964367 ._15\.\1740
D016642_D020258 NONE <e1>zyban</e1>_0\NNP\1740 caused_1\VBD\1617192 significant_2\JJ\1740 <e2>neurological_3\JJ\1740 and_4\CC\1740 cardiovascular_5\JJ\1740 toxicity</e2>_6\NN\13576101 in_7\IN\13603305 overdose_8\NN\1740 ._9\.\1740
D016642_D002318 NONE <e1>zyban</e1>_0\NNP\1740 caused_1\VBD\1617192 significant_2\JJ\1740 <e2>neurological_3\JJ\1740 and_4\CC\1740 cardiovascular_5\JJ\1740 toxicity</e2>_6\NN\13576101 in_7\IN\13603305 overdose_8\NN\1740 ._9\.\1740
D016642_D062787 NONE <e1>zyban</e1>_0\NNP\1740 caused_1\VBD\1617192 significant_2\JJ\1740 neurological_3\JJ\1740 and_4\CC\1740 cardiovascular_5\JJ\1740 toxicity_6\NN\13576101 in_7\IN\13603305 <e2>overdose</e2>_8\NN\1740 ._9\.\1740
3560095
D005480_D001171 NONE <e1>flurbiprofen</e1>_0\NN\3828465 in_1\IN\13603305 the_2\DT\1740 treatment_3\NN\654885 of_4\IN\1740 <e2>juvenile_5\NN\7846 rheumatoid_6\JJ\1740 arthritis</e2>_7\NN\14171682 ._8\.\1740
D005480_D001171 NONE thirty-four_0\NN\1740 patients_1\NNS\9898892 with_2\IN\1740 <e2>juvenile_3\NN\7846 rheumatoid_4\JJ\1740 arthritis</e2>_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 were_8\VBD\836236 treated_9\VBN\2376958 with_10\IN\1740 <e1>flurbiprofen</e1>_11\NN\3828465 at_12\IN\14622893 a_13\DT\13649268 maximum_14\NN\13653902 dose_15\NN\3740161 of_16\IN\1740 4_17\CD\13741022 mg/kg/day_18\NN\1740 ,_19\,\1740 had_20\VBD\2108377 statistically_21\RB\1740 significant_22\JJ\1740 decreases_23\NNS\7296428 from_24\IN\1740 baseline_25\NN\7260623 in_26\IN\13603305 6_27\CD\13741022 arthritis_28\NN\14171682 indices_29\NNS\13850304 after_30\IN\1740 12_31\CD\13745420 weeks_32\NNS\15113229 of_33\IN\1740 treatment_34\NN\654885 ._35\.\1740
D005480_D001168 NONE thirty-four_0\NN\1740 patients_1\NNS\9898892 with_2\IN\1740 juvenile_3\NN\7846 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 were_8\VBD\836236 treated_9\VBN\2376958 with_10\IN\1740 <e1>flurbiprofen</e1>_11\NN\3828465 at_12\IN\14622893 a_13\DT\13649268 maximum_14\NN\13653902 dose_15\NN\3740161 of_16\IN\1740 4_17\CD\13741022 mg/kg/day_18\NN\1740 ,_19\,\1740 had_20\VBD\2108377 statistically_21\RB\1740 significant_22\JJ\1740 decreases_23\NNS\7296428 from_24\IN\1740 baseline_25\NN\7260623 in_26\IN\13603305 6_27\CD\13741022 <e2>arthritis</e2>_28\NN\14171682 indices_29\NNS\13850304 after_30\IN\1740 12_31\CD\13745420 weeks_32\NNS\15113229 of_33\IN\1740 treatment_34\NN\654885 ._35\.\1740
8701950
D016559_D000743 CID <e2>microangiopathic_0\JJ\1740 hemolytic_1\JJ\1740 anemia</e2>_2\NN\14189204 complicating_3\VBG\126264 <e1>fk506</e1>_4\NN\1740 (_5\-LRB-\1740 tacrolimus_6\NN\1740 )_7\-RRB-\1740 therapy_8\NN\657604 ._9\.\1740
D016559_D000743 CID <e2>microangiopathic_0\JJ\1740 hemolytic_1\JJ\1740 anemia</e2>_2\NN\14189204 complicating_3\VBG\126264 fk506_4\NN\1740 (_5\-LRB-\1740 <e1>tacrolimus</e1>_6\NN\1740 )_7\-RRB-\1740 therapy_8\NN\657604 ._9\.\1740
D016559_D000743 CID we_0\PRP\1740 describe_1\VBP\1001294 3_2\CD\13741022 episodes_3\NNS\7283608 of_4\IN\1740 <e2>microangiopathic_5\JJ\1740 hemolytic_6\JJ\1740 anemia</e2>_7\NN\14189204 (_8\-LRB-\1740 maha_9\NN\9654687 )_10\-RRB-\1740 in_11\IN\13603305 2_12\CD\13741022 solid_13\JJ\1740 organ_14\NN\5220461 recipients_15\NNS\9764201 under_16\IN\1740 <e1>fk506</e1>_17\NN\1740 (_18\-LRB-\1740 tacrolimus_19\NN\1740 )_20\-RRB-\1740 therapy_21\NN\657604 ._22\.\1740
D016559_D000743 CID we_0\PRP\1740 describe_1\VBP\1001294 3_2\CD\13741022 episodes_3\NNS\7283608 of_4\IN\1740 microangiopathic_5\JJ\1740 hemolytic_6\JJ\1740 anemia_7\NN\14189204 (_8\-LRB-\1740 <e2>maha</e2>_9\NN\9654687 )_10\-RRB-\1740 in_11\IN\13603305 2_12\CD\13741022 solid_13\JJ\1740 organ_14\NN\5220461 recipients_15\NNS\9764201 under_16\IN\1740 <e1>fk506</e1>_17\NN\1740 (_18\-LRB-\1740 tacrolimus_19\NN\1740 )_20\-RRB-\1740 therapy_21\NN\657604 ._22\.\1740
D016559_D000743 CID we_0\PRP\1740 describe_1\VBP\1001294 3_2\CD\13741022 episodes_3\NNS\7283608 of_4\IN\1740 <e2>microangiopathic_5\JJ\1740 hemolytic_6\JJ\1740 anemia</e2>_7\NN\14189204 (_8\-LRB-\1740 maha_9\NN\9654687 )_10\-RRB-\1740 in_11\IN\13603305 2_12\CD\13741022 solid_13\JJ\1740 organ_14\NN\5220461 recipients_15\NNS\9764201 under_16\IN\1740 fk506_17\NN\1740 (_18\-LRB-\1740 <e1>tacrolimus</e1>_19\NN\1740 )_20\-RRB-\1740 therapy_21\NN\657604 ._22\.\1740
D016559_D000743 CID we_0\PRP\1740 describe_1\VBP\1001294 3_2\CD\13741022 episodes_3\NNS\7283608 of_4\IN\1740 microangiopathic_5\JJ\1740 hemolytic_6\JJ\1740 anemia_7\NN\14189204 (_8\-LRB-\1740 <e2>maha</e2>_9\NN\9654687 )_10\-RRB-\1740 in_11\IN\13603305 2_12\CD\13741022 solid_13\JJ\1740 organ_14\NN\5220461 recipients_15\NNS\9764201 under_16\IN\1740 fk506_17\NN\1740 (_18\-LRB-\1740 <e1>tacrolimus</e1>_19\NN\1740 )_20\-RRB-\1740 therapy_21\NN\657604 ._22\.\1740
D016559_D000743 CID in_0\IN\13603305 both_1\DT\1740 cases_2\NNS\7283608 ,_3\,\1740 discontinuation_4\NN\209943 of_5\IN\1740 <e1>fk506</e1>_6\NN\1740 and_7\CC\1740 treatment_8\NN\654885 with_9\IN\1740 plasma_10\NN\5398023 exchange_11\NN\11409059 ,_12\,\1740 fresh_13\JJ\1740 frozen_14\JJ\1740 plasma_15\NN\5398023 replacement_16\NN\196485 ,_17\,\1740 corticosteroids_18\NNS\14745635 ,_19\,\1740 aspirin_20\NN\2707683 ,_21\,\1740 and_22\CC\1740 dipyridamole_23\NN\1740 led_24\VBD\1752884 to_25\TO\1740 resolution_26\NN\6470073 of_27\IN\1740 <e2>maha</e2>_28\NN\9654687 ._29\.\1740
D016559_D000743 CID in_0\IN\13603305 one_1\CD\13741022 patient_2\NN\9898892 ,_3\,\1740 reintroduction_4\NN\7217349 of_5\IN\1740 <e1>fk506</e1>_6\NN\1740 led_7\VBD\1752884 to_8\TO\1740 rapid_9\JJ\1740 recurrence_10\NN\7342049 of_11\IN\1740 <e2>maha</e2>_12\NN\9654687 ._13\.\1740
D016559_D000743 CID <e1>fk506-associated</e1>_0\JJ\1740 <e2>maha</e2>_1\NN\9654687 is_2\VBZ\836236 probably_3\RB\1740 rare_4\JJ\1740 but_5\CC\1740 physicians_6\NNS\10305802 must_7\MD\9367203 be_8\VB\836236 aware_9\JJ\1740 of_10\IN\1740 this_11\DT\1740 severe_12\JJ\1740 complication_13\NN\1073995 ._14\.\1740
D016559_D000743 CID in_0\IN\13603305 our_1\PRP$\1740 experience_2\NN\5984287 and_3\CC\1740 according_4\VBG\2657219 to_5\IN\1740 the_6\DT\1740 literature_7\NN\6362953 ,_8\,\1740 <e1>fk506</e1>_9\NN\1740 does_10\VBZ\1640855 not_11\RB\1740 seem_12\VB\2604760 to_13\TO\1740 cross-react_14\VB\1740 with_15\IN\1740 cyclosporin_16\NN\1740 a_17\NN\13649268 (_18\-LRB-\1740 cya_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 an_22\DT\6697703 immuno-suppressive_23\JJ\1740 drug_24\NN\14778436 already_25\RB\1740 known_26\VBN\2110220 to_27\TO\1740 induce_28\VB\1627355 <e2>maha</e2>_29\NN\9654687 ._30\.\1740
D000305_D000743 NONE in_0\IN\13603305 both_1\DT\1740 cases_2\NNS\7283608 ,_3\,\1740 discontinuation_4\NN\209943 of_5\IN\1740 fk506_6\NN\1740 and_7\CC\1740 treatment_8\NN\654885 with_9\IN\1740 plasma_10\NN\5398023 exchange_11\NN\11409059 ,_12\,\1740 fresh_13\JJ\1740 frozen_14\JJ\1740 plasma_15\NN\5398023 replacement_16\NN\196485 ,_17\,\1740 <e1>corticosteroids</e1>_18\NNS\14745635 ,_19\,\1740 aspirin_20\NN\2707683 ,_21\,\1740 and_22\CC\1740 dipyridamole_23\NN\1740 led_24\VBD\1752884 to_25\TO\1740 resolution_26\NN\6470073 of_27\IN\1740 <e2>maha</e2>_28\NN\9654687 ._29\.\1740
D001241_D000743 NONE in_0\IN\13603305 both_1\DT\1740 cases_2\NNS\7283608 ,_3\,\1740 discontinuation_4\NN\209943 of_5\IN\1740 fk506_6\NN\1740 and_7\CC\1740 treatment_8\NN\654885 with_9\IN\1740 plasma_10\NN\5398023 exchange_11\NN\11409059 ,_12\,\1740 fresh_13\JJ\1740 frozen_14\JJ\1740 plasma_15\NN\5398023 replacement_16\NN\196485 ,_17\,\1740 corticosteroids_18\NNS\14745635 ,_19\,\1740 <e1>aspirin</e1>_20\NN\2707683 ,_21\,\1740 and_22\CC\1740 dipyridamole_23\NN\1740 led_24\VBD\1752884 to_25\TO\1740 resolution_26\NN\6470073 of_27\IN\1740 <e2>maha</e2>_28\NN\9654687 ._29\.\1740
D004176_D000743 NONE in_0\IN\13603305 both_1\DT\1740 cases_2\NNS\7283608 ,_3\,\1740 discontinuation_4\NN\209943 of_5\IN\1740 fk506_6\NN\1740 and_7\CC\1740 treatment_8\NN\654885 with_9\IN\1740 plasma_10\NN\5398023 exchange_11\NN\11409059 ,_12\,\1740 fresh_13\JJ\1740 frozen_14\JJ\1740 plasma_15\NN\5398023 replacement_16\NN\196485 ,_17\,\1740 corticosteroids_18\NNS\14745635 ,_19\,\1740 aspirin_20\NN\2707683 ,_21\,\1740 and_22\CC\1740 <e1>dipyridamole</e1>_23\NN\1740 led_24\VBD\1752884 to_25\TO\1740 resolution_26\NN\6470073 of_27\IN\1740 <e2>maha</e2>_28\NN\9654687 ._29\.\1740
D016572_D000743 NONE in_0\IN\13603305 our_1\PRP$\1740 experience_2\NN\5984287 and_3\CC\1740 according_4\VBG\2657219 to_5\IN\1740 the_6\DT\1740 literature_7\NN\6362953 ,_8\,\1740 fk506_9\NN\1740 does_10\VBZ\1640855 not_11\RB\1740 seem_12\VB\2604760 to_13\TO\1740 cross-react_14\VB\1740 with_15\IN\1740 <e1>cyclosporin_16\NN\1740 a</e1>_17\NN\13649268 (_18\-LRB-\1740 cya_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 an_22\DT\6697703 immuno-suppressive_23\JJ\1740 drug_24\NN\14778436 already_25\RB\1740 known_26\VBN\2110220 to_27\TO\1740 induce_28\VB\1627355 <e2>maha</e2>_29\NN\9654687 ._30\.\1740
D016572_D000743 NONE in_0\IN\13603305 our_1\PRP$\1740 experience_2\NN\5984287 and_3\CC\1740 according_4\VBG\2657219 to_5\IN\1740 the_6\DT\1740 literature_7\NN\6362953 ,_8\,\1740 fk506_9\NN\1740 does_10\VBZ\1640855 not_11\RB\1740 seem_12\VB\2604760 to_13\TO\1740 cross-react_14\VB\1740 with_15\IN\1740 cyclosporin_16\NN\1740 a_17\NN\13649268 (_18\-LRB-\1740 <e1>cya</e1>_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 an_22\DT\6697703 immuno-suppressive_23\JJ\1740 drug_24\NN\14778436 already_25\RB\1740 known_26\VBN\2110220 to_27\TO\1740 induce_28\VB\1627355 <e2>maha</e2>_29\NN\9654687 ._30\.\1740
18809400
D008063_D028361 NONE <e1>alpha-lipoic_0\JJ\1740 acid</e1>_1\NN\14818238 prevents_2\VBZ\1740 <e2>mitochondrial_3\JJ\1740 damage</e2>_4\NN\7296428 and_5\CC\1740 neurotoxicity_6\NN\1740 in_7\IN\13603305 experimental_8\JJ\1740 chemotherapy_9\NN\661091 neuropathy_10\JJ\1740 ._11\.\1740
D008063_D028361 NONE the_0\DT\1740 study_1\NN\635850 investigates_2\VBZ\644583 if_3\IN\1740 <e1>alpha-lipoic_4\JJ\1740 acid</e1>_5\NN\14818238 is_6\VBZ\836236 neuroprotective_7\JJ\1740 against_8\IN\1740 chemotherapy_9\NN\661091 induced_10\JJ\1740 neurotoxicity_11\NN\1740 ,_12\,\1740 if_13\IN\1740 <e2>mitochondrial_14\JJ\1740 damage</e2>_15\NN\7296428 plays_16\VBZ\1072262 a_17\DT\13649268 critical_18\JJ\1740 role_19\NN\719494 in_20\IN\13603305 toxic_21\JJ\1740 neurodegenerative_22\JJ\1740 cascade_23\NN\9475292 ,_24\,\1740 and_25\CC\1740 if_26\IN\1740 neuroprotective_27\JJ\1740 effects_28\NNS\13245626 of_29\IN\1740 alpha-lipoic_30\JJ\1740 acid_31\NN\14818238 depend_32\NN\1740 on_33\IN\1740 mitochondria_34\NN\5445668 protection_35\NN\407535 ._36\.\1740
D008063_D028361 NONE the_0\DT\1740 study_1\NN\635850 investigates_2\VBZ\644583 if_3\IN\1740 alpha-lipoic_4\JJ\1740 acid_5\NN\14818238 is_6\VBZ\836236 neuroprotective_7\JJ\1740 against_8\IN\1740 chemotherapy_9\NN\661091 induced_10\JJ\1740 neurotoxicity_11\NN\1740 ,_12\,\1740 if_13\IN\1740 <e2>mitochondrial_14\JJ\1740 damage</e2>_15\NN\7296428 plays_16\VBZ\1072262 a_17\DT\13649268 critical_18\JJ\1740 role_19\NN\719494 in_20\IN\13603305 toxic_21\JJ\1740 neurodegenerative_22\JJ\1740 cascade_23\NN\9475292 ,_24\,\1740 and_25\CC\1740 if_26\IN\1740 neuroprotective_27\JJ\1740 effects_28\NNS\13245626 of_29\IN\1740 <e1>alpha-lipoic_30\JJ\1740 acid</e1>_31\NN\14818238 depend_32\NN\1740 on_33\IN\1740 mitochondria_34\NN\5445668 protection_35\NN\407535 ._36\.\1740
D008063_D028361 NONE <e1>alpha-lipoic_0\JJ\1740 acid</e1>_1\NN\14818238 exerts_2\VBZ\1158872 neuroprotective_3\JJ\1740 effects_4\NNS\13245626 against_5\IN\1740 chemotherapy_6\NN\661091 induced_7\JJ\1740 neurotoxicity_8\NN\1740 in_9\IN\13603305 sensory_10\JJ\1740 neurons_11\NNS\5430628 :_12\:\1740 it_13\PRP\6125041 rescues_14\VBZ\2551832 the_15\DT\1740 <e2>mitochondrial_16\JJ\1740 toxicity</e2>_17\NN\13576101 and_18\CC\1740 induces_19\VBZ\1627355 the_20\DT\1740 expression_21\NN\4679549 of_22\IN\1740 frataxin_23\NN\1740 ,_24\,\1740 an_25\DT\6697703 essential_26\JJ\1740 mitochondrial_27\JJ\1740 protein_28\NN\14944888 with_29\IN\1740 anti-oxidant_30\JJ\1740 and_31\CC\1740 chaperone_32\NN\9614684 properties_33\NNS\32613 ._34\.\1740
D008063_D020258 NONE <e1>alpha-lipoic_0\JJ\1740 acid</e1>_1\NN\14818238 prevents_2\VBZ\1740 mitochondrial_3\JJ\1740 damage_4\NN\7296428 and_5\CC\1740 <e2>neurotoxicity</e2>_6\NN\1740 in_7\IN\13603305 experimental_8\JJ\1740 chemotherapy_9\NN\661091 neuropathy_10\JJ\1740 ._11\.\1740
D008063_D020258 NONE the_0\DT\1740 study_1\NN\635850 investigates_2\VBZ\644583 if_3\IN\1740 <e1>alpha-lipoic_4\JJ\1740 acid</e1>_5\NN\14818238 is_6\VBZ\836236 neuroprotective_7\JJ\1740 against_8\IN\1740 chemotherapy_9\NN\661091 induced_10\JJ\1740 <e2>neurotoxicity</e2>_11\NN\1740 ,_12\,\1740 if_13\IN\1740 mitochondrial_14\JJ\1740 damage_15\NN\7296428 plays_16\VBZ\1072262 a_17\DT\13649268 critical_18\JJ\1740 role_19\NN\719494 in_20\IN\13603305 toxic_21\JJ\1740 neurodegenerative_22\JJ\1740 cascade_23\NN\9475292 ,_24\,\1740 and_25\CC\1740 if_26\IN\1740 neuroprotective_27\JJ\1740 effects_28\NNS\13245626 of_29\IN\1740 alpha-lipoic_30\JJ\1740 acid_31\NN\14818238 depend_32\NN\1740 on_33\IN\1740 mitochondria_34\NN\5445668 protection_35\NN\407535 ._36\.\1740
D008063_D020258 NONE the_0\DT\1740 study_1\NN\635850 investigates_2\VBZ\644583 if_3\IN\1740 alpha-lipoic_4\JJ\1740 acid_5\NN\14818238 is_6\VBZ\836236 neuroprotective_7\JJ\1740 against_8\IN\1740 chemotherapy_9\NN\661091 induced_10\JJ\1740 <e2>neurotoxicity</e2>_11\NN\1740 ,_12\,\1740 if_13\IN\1740 mitochondrial_14\JJ\1740 damage_15\NN\7296428 plays_16\VBZ\1072262 a_17\DT\13649268 critical_18\JJ\1740 role_19\NN\719494 in_20\IN\13603305 toxic_21\JJ\1740 neurodegenerative_22\JJ\1740 cascade_23\NN\9475292 ,_24\,\1740 and_25\CC\1740 if_26\IN\1740 neuroprotective_27\JJ\1740 effects_28\NNS\13245626 of_29\IN\1740 <e1>alpha-lipoic_30\JJ\1740 acid</e1>_31\NN\14818238 depend_32\NN\1740 on_33\IN\1740 mitochondria_34\NN\5445668 protection_35\NN\407535 ._36\.\1740
D008063_D020258 NONE <e1>alpha-lipoic_0\JJ\1740 acid</e1>_1\NN\14818238 exerts_2\VBZ\1158872 neuroprotective_3\JJ\1740 effects_4\NNS\13245626 against_5\IN\1740 chemotherapy_6\NN\661091 induced_7\JJ\1740 <e2>neurotoxicity</e2>_8\NN\1740 in_9\IN\13603305 sensory_10\JJ\1740 neurons_11\NNS\5430628 :_12\:\1740 it_13\PRP\6125041 rescues_14\VBZ\2551832 the_15\DT\1740 mitochondrial_16\JJ\1740 toxicity_17\NN\13576101 and_18\CC\1740 induces_19\VBZ\1627355 the_20\DT\1740 expression_21\NN\4679549 of_22\IN\1740 frataxin_23\NN\1740 ,_24\,\1740 an_25\DT\6697703 essential_26\JJ\1740 mitochondrial_27\JJ\1740 protein_28\NN\14944888 with_29\IN\1740 anti-oxidant_30\JJ\1740 and_31\CC\1740 chaperone_32\NN\9614684 properties_33\NNS\32613 ._34\.\1740
D008063_D009422 NONE <e1>alpha-lipoic_0\JJ\1740 acid</e1>_1\NN\14818238 prevents_2\VBZ\1740 mitochondrial_3\JJ\1740 damage_4\NN\7296428 and_5\CC\1740 neurotoxicity_6\NN\1740 in_7\IN\13603305 experimental_8\JJ\1740 chemotherapy_9\NN\661091 <e2>neuropathy</e2>_10\JJ\1740 ._11\.\1740
D008063_D009410 NONE the_0\DT\1740 study_1\NN\635850 investigates_2\VBZ\644583 if_3\IN\1740 <e1>alpha-lipoic_4\JJ\1740 acid</e1>_5\NN\14818238 is_6\VBZ\836236 neuroprotective_7\JJ\1740 against_8\IN\1740 chemotherapy_9\NN\661091 induced_10\JJ\1740 neurotoxicity_11\NN\1740 ,_12\,\1740 if_13\IN\1740 mitochondrial_14\JJ\1740 damage_15\NN\7296428 plays_16\VBZ\1072262 a_17\DT\13649268 critical_18\JJ\1740 role_19\NN\719494 in_20\IN\13603305 <e2>toxic_21\JJ\1740 neurodegenerative_22\JJ\1740 cascade</e2>_23\NN\9475292 ,_24\,\1740 and_25\CC\1740 if_26\IN\1740 neuroprotective_27\JJ\1740 effects_28\NNS\13245626 of_29\IN\1740 alpha-lipoic_30\JJ\1740 acid_31\NN\14818238 depend_32\NN\1740 on_33\IN\1740 mitochondria_34\NN\5445668 protection_35\NN\407535 ._36\.\1740
D008063_D009410 NONE the_0\DT\1740 study_1\NN\635850 investigates_2\VBZ\644583 if_3\IN\1740 alpha-lipoic_4\JJ\1740 acid_5\NN\14818238 is_6\VBZ\836236 neuroprotective_7\JJ\1740 against_8\IN\1740 chemotherapy_9\NN\661091 induced_10\JJ\1740 neurotoxicity_11\NN\1740 ,_12\,\1740 if_13\IN\1740 mitochondrial_14\JJ\1740 damage_15\NN\7296428 plays_16\VBZ\1072262 a_17\DT\13649268 critical_18\JJ\1740 role_19\NN\719494 in_20\IN\13603305 <e2>toxic_21\JJ\1740 neurodegenerative_22\JJ\1740 cascade</e2>_23\NN\9475292 ,_24\,\1740 and_25\CC\1740 if_26\IN\1740 neuroprotective_27\JJ\1740 effects_28\NNS\13245626 of_29\IN\1740 <e1>alpha-lipoic_30\JJ\1740 acid</e1>_31\NN\14818238 depend_32\NN\1740 on_33\IN\1740 mitochondria_34\NN\5445668 protection_35\NN\407535 ._36\.\1740
D017239_D010523 CID we_0\PRP\1740 used_1\VBD\1156834 an_2\DT\6697703 in_3\FW\13603305 vitro_4\FW\1740 model_5\NN\5888929 of_6\IN\1740 chemotherapy_7\NN\661091 induced_8\JJ\1740 <e2>peripheral_9\JJ\1740 neuropathy</e2>_10\NN\14204950 that_11\WDT\1740 closely_12\RB\1740 mimic_13\VBP\1742886 the_14\DT\1740 in_15\FW\13603305 vivo_16\FW\1740 condition_17\NN\24720 by_18\IN\1740 exposing_19\VBG\2110927 primary_20\JJ\1740 cultures_21\NNS\7966140 of_22\IN\1740 dorsal_23\NN\1740 root_24\NN\13087625 ganglion_25\NN\5462674 (_26\-LRB-\1740 drg_27\NN\1740 )_28\-RRB-\1740 sensory_29\JJ\1740 neurons_30\NNS\5430628 to_31\TO\1740 <e1>paclitaxel</e1>_32\NN\1740 and_33\CC\1740 cisplatin_34\NN\1740 ,_35\,\1740 two_36\CD\13741022 widely_37\RB\1740 used_38\VBN\1156834 and_39\CC\1740 highly_40\RB\1740 effective_41\JJ\1740 chemotherapeutic_42\JJ\1740 drugs_43\NNS\14778436 ._44\.\1740
D002945_D010523 CID we_0\PRP\1740 used_1\VBD\1156834 an_2\DT\6697703 in_3\FW\13603305 vitro_4\FW\1740 model_5\NN\5888929 of_6\IN\1740 chemotherapy_7\NN\661091 induced_8\JJ\1740 <e2>peripheral_9\JJ\1740 neuropathy</e2>_10\NN\14204950 that_11\WDT\1740 closely_12\RB\1740 mimic_13\VBP\1742886 the_14\DT\1740 in_15\FW\13603305 vivo_16\FW\1740 condition_17\NN\24720 by_18\IN\1740 exposing_19\VBG\2110927 primary_20\JJ\1740 cultures_21\NNS\7966140 of_22\IN\1740 dorsal_23\NN\1740 root_24\NN\13087625 ganglion_25\NN\5462674 (_26\-LRB-\1740 drg_27\NN\1740 )_28\-RRB-\1740 sensory_29\JJ\1740 neurons_30\NNS\5430628 to_31\TO\1740 paclitaxel_32\NN\1740 and_33\CC\1740 <e1>cisplatin</e1>_34\NN\1740 ,_35\,\1740 two_36\CD\13741022 widely_37\RB\1740 used_38\VBN\1156834 and_39\CC\1740 highly_40\RB\1740 effective_41\JJ\1740 chemotherapeutic_42\JJ\1740 drugs_43\NNS\14778436 ._44\.\1740
D008063_D001480 NONE this_0\DT\1740 approach_1\NN\940842 allowed_2\VBD\797697 investigating_3\VBG\644583 the_4\DT\1740 efficacy_5\NN\5199286 of_6\IN\1740 <e1>alpha-lipoic_7\JJ\1740 acid</e1>_8\NN\14818238 in_9\IN\13603305 preventing_10\VBG\1740 <e2>axonal_11\JJ\1740 damage</e2>_12\NN\7296428 and_13\CC\1740 apoptosis_14\NN\11486178 and_15\CC\1740 the_16\DT\1740 function_17\NN\13783581 and_18\CC\1740 ultrastructural_19\JJ\1740 morphology_20\NN\6037666 of_21\IN\1740 mitochondria_22\NN\5445668 after_23\IN\1740 exposure_24\NN\5042871 to_25\TO\1740 toxic_26\JJ\1740 agents_27\NNS\7347 and_28\CC\1740 alpha-lipoic_29\JJ\1740 acid_30\NN\14818238 ._31\.\1740
D008063_D001480 NONE this_0\DT\1740 approach_1\NN\940842 allowed_2\VBD\797697 investigating_3\VBG\644583 the_4\DT\1740 efficacy_5\NN\5199286 of_6\IN\1740 alpha-lipoic_7\JJ\1740 acid_8\NN\14818238 in_9\IN\13603305 preventing_10\VBG\1740 <e2>axonal_11\JJ\1740 damage</e2>_12\NN\7296428 and_13\CC\1740 apoptosis_14\NN\11486178 and_15\CC\1740 the_16\DT\1740 function_17\NN\13783581 and_18\CC\1740 ultrastructural_19\JJ\1740 morphology_20\NN\6037666 of_21\IN\1740 mitochondria_22\NN\5445668 after_23\IN\1740 exposure_24\NN\5042871 to_25\TO\1740 toxic_26\JJ\1740 agents_27\NNS\7347 and_28\CC\1740 <e1>alpha-lipoic_29\JJ\1740 acid</e1>_30\NN\14818238 ._31\.\1740
D002945_D028361 NONE our_0\PRP$\1740 results_1\NNS\34213 demonstrate_2\VBP\2137132 that_3\IN\1740 both_4\CC\1740 <e1>cisplatin</e1>_5\NN\1740 and_6\CC\1740 paclitaxel_7\NN\1740 cause_8\VBP\1617192 early_9\JJ\1740 <e2>mitochondrial_10\JJ\1740 impairment</e2>_11\NN\7296428 with_12\IN\1740 loss_13\NN\13252973 of_14\IN\1740 membrane_15\NN\4188643 potential_16\NN\14481929 and_17\CC\1740 induction_18\NN\7450842 of_19\IN\1740 autophagic_20\JJ\1740 vacuoles_21\NNS\5303402 in_22\IN\13603305 neurons_23\NNS\5430628 ._24\.\1740
D002945_D028361 NONE in_0\IN\13603305 conclusion_1\NN\5837957 <e2>mitochondrial_2\JJ\1740 toxicity</e2>_3\NN\13576101 is_4\VBZ\836236 an_5\DT\6697703 early_6\JJ\1740 common_7\JJ\1740 event_8\NN\23100 both_9\CC\1740 in_10\IN\13603305 paclitaxel_11\NN\1740 and_12\CC\1740 <e1>cisplatin</e1>_13\NN\1740 induced_14\VBN\1627355 neurotoxicity_15\NN\1740 ._16\.\1740
D017239_D028361 NONE our_0\PRP$\1740 results_1\NNS\34213 demonstrate_2\VBP\2137132 that_3\IN\1740 both_4\CC\1740 cisplatin_5\NN\1740 and_6\CC\1740 <e1>paclitaxel</e1>_7\NN\1740 cause_8\VBP\1617192 early_9\JJ\1740 <e2>mitochondrial_10\JJ\1740 impairment</e2>_11\NN\7296428 with_12\IN\1740 loss_13\NN\13252973 of_14\IN\1740 membrane_15\NN\4188643 potential_16\NN\14481929 and_17\CC\1740 induction_18\NN\7450842 of_19\IN\1740 autophagic_20\JJ\1740 vacuoles_21\NNS\5303402 in_22\IN\13603305 neurons_23\NNS\5430628 ._24\.\1740
D017239_D028361 NONE in_0\IN\13603305 conclusion_1\NN\5837957 <e2>mitochondrial_2\JJ\1740 toxicity</e2>_3\NN\13576101 is_4\VBZ\836236 an_5\DT\6697703 early_6\JJ\1740 common_7\JJ\1740 event_8\NN\23100 both_9\CC\1740 in_10\IN\13603305 <e1>paclitaxel</e1>_11\NN\1740 and_12\CC\1740 cisplatin_13\NN\1740 induced_14\VBN\1627355 neurotoxicity_15\NN\1740 ._16\.\1740
D017239_D020258 NONE in_0\IN\13603305 conclusion_1\NN\5837957 mitochondrial_2\JJ\1740 toxicity_3\NN\13576101 is_4\VBZ\836236 an_5\DT\6697703 early_6\JJ\1740 common_7\JJ\1740 event_8\NN\23100 both_9\CC\1740 in_10\IN\13603305 <e1>paclitaxel</e1>_11\NN\1740 and_12\CC\1740 cisplatin_13\NN\1740 induced_14\VBN\1627355 <e2>neurotoxicity</e2>_15\NN\1740 ._16\.\1740
D002945_D020258 NONE in_0\IN\13603305 conclusion_1\NN\5837957 mitochondrial_2\JJ\1740 toxicity_3\NN\13576101 is_4\VBZ\836236 an_5\DT\6697703 early_6\JJ\1740 common_7\JJ\1740 event_8\NN\23100 both_9\CC\1740 in_10\IN\13603305 paclitaxel_11\NN\1740 and_12\CC\1740 <e1>cisplatin</e1>_13\NN\1740 induced_14\VBN\1627355 <e2>neurotoxicity</e2>_15\NN\1740 ._16\.\1740
D008063_D010523 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>alpha-lipoic_4\JJ\1740 acid</e1>_5\NN\14818238 might_6\MD\5029706 reduce_7\VB\441445 the_8\DT\1740 risk_9\NN\14541044 of_10\IN\1740 developing_11\VBG\1753788 <e2>peripheral_12\JJ\1740 nerve_13\NN\5475681 toxicity</e2>_14\NN\13576101 in_15\IN\13603305 patients_16\NNS\9898892 undergoing_17\VBG\109660 chemotherapy_18\NN\661091 and_19\CC\1740 encourage_20\VBP\2556126 further_21\JJ\1740 confirmatory_22\JJ\1740 clinical_23\JJ\1740 trials_24\NNS\786195 ._25\.\1740
11961407
D014443_D009401 NONE glepp1_0\NN\1740 receptor_1\NN\5225602 <e1>tyrosine</e1>_2\NN\14601829 phosphatase_3\NN\14732946 (_4\-LRB-\1740 ptpro_5\NN\1740 )_6\-RRB-\1740 in_7\IN\13603305 rat_8\NN\2329401 pan_9\NN\3101986 <e2>nephrosis</e2>_10\NN\14304060 ._11\.\1740
D011692_D009401 CID glepp1_0\NN\1740 receptor_1\NN\5225602 tyrosine_2\NN\14601829 phosphatase_3\NN\14732946 (_4\-LRB-\1740 ptpro_5\NN\1740 )_6\-RRB-\1740 in_7\IN\13603305 rat_8\NN\2329401 <e1>pan</e1>_9\NN\3101986 <e2>nephrosis</e2>_10\NN\14304060 ._11\.\1740
D011692_D009401 CID <e1>puromycin_0\NN\1740 aminonucleoside</e1>_1\NN\1740 <e2>nephrosis</e2>_2\NN\14304060 was_3\VBD\836236 induced_4\VBN\1627355 by_5\IN\1740 single_6\JJ\1740 intraperitoneal_7\JJ\1740 injection_8\NN\320852 of_9\IN\1740 puromycin_10\NN\1740 aminonucleoside_11\NN\1740 (_12\-LRB-\1740 pan_13\NN\3101986 ,_14\,\1740 20_15\CD\13745420 mg/100_16\CD\1740 g_17\NN\13717155 bw_18\NN\973077 )_19\-RRB-\1740 ._20\.\1740
D011692_D009401 CID puromycin_0\NN\1740 aminonucleoside_1\NN\1740 <e2>nephrosis</e2>_2\NN\14304060 was_3\VBD\836236 induced_4\VBN\1627355 by_5\IN\1740 single_6\JJ\1740 intraperitoneal_7\JJ\1740 injection_8\NN\320852 of_9\IN\1740 <e1>puromycin_10\NN\1740 aminonucleoside</e1>_11\NN\1740 (_12\-LRB-\1740 pan_13\NN\3101986 ,_14\,\1740 20_15\CD\13745420 mg/100_16\CD\1740 g_17\NN\13717155 bw_18\NN\973077 )_19\-RRB-\1740 ._20\.\1740
D011692_D009401 CID puromycin_0\NN\1740 aminonucleoside_1\NN\1740 <e2>nephrosis</e2>_2\NN\14304060 was_3\VBD\836236 induced_4\VBN\1627355 by_5\IN\1740 single_6\JJ\1740 intraperitoneal_7\JJ\1740 injection_8\NN\320852 of_9\IN\1740 puromycin_10\NN\1740 aminonucleoside_11\NN\1740 (_12\-LRB-\1740 <e1>pan</e1>_13\NN\3101986 ,_14\,\1740 20_15\CD\13745420 mg/100_16\CD\1740 g_17\NN\13717155 bw_18\NN\973077 )_19\-RRB-\1740 ._20\.\1740
D011692_D011507 CID tissues_0\NNS\5220461 were_1\VBD\836236 analyzed_2\VBN\78760 at_3\IN\14622893 0_4\CD\13741022 ,_5\,\1740 5_6\CD\13741022 ,_7\,\1740 7_8\CD\13741022 ,_9\,\1740 11_10\CD\13745420 ,_11\,\1740 21_12\CD\13745420 ,_13\,\1740 45_14\CD\1740 ,_15\,\1740 80_16\CD\13745420 and_17\CC\1740 126_18\CD\1740 days_19\NNS\15140892 after_20\IN\1740 <e1>pan</e1>_21\NN\3101986 injection_22\NN\320852 so_23\IN\6868043 as_24\IN\14622893 to_25\TO\1740 include_26\VB\690614 both_27\CC\1740 the_28\DT\1740 acute_29\JJ\1740 phase_30\NN\15113229 of_31\IN\1740 <e2>proteinuria</e2>_32\NN\14299637 associated_33\VBN\628491 with_34\IN\1740 foot_35\NN\5563034 process_36\NN\407535 effacement_37\NN\13526110 (_38\-LRB-\1740 days_39\NNS\15140892 5_40\CD\13741022 -_41\SYM\1740 11_42\CD\13745420 )_43\-RRB-\1740 and_44\CC\1740 the_45\DT\1740 chronic_46\JJ\1740 phase_47\NN\15113229 of_48\IN\1740 proteinuria_49\NN\14299637 associated_50\VBN\628491 with_51\IN\1740 glomerulosclerosis_52\NN\1740 (_53\-LRB-\1740 days_54\NNS\15140892 45_55\CD\1740 -_56\SYM\1740 126_57\CD\1740 )_58\-RRB-\1740 ._59\.\1740
D011692_D011507 CID tissues_0\NNS\5220461 were_1\VBD\836236 analyzed_2\VBN\78760 at_3\IN\14622893 0_4\CD\13741022 ,_5\,\1740 5_6\CD\13741022 ,_7\,\1740 7_8\CD\13741022 ,_9\,\1740 11_10\CD\13745420 ,_11\,\1740 21_12\CD\13745420 ,_13\,\1740 45_14\CD\1740 ,_15\,\1740 80_16\CD\13745420 and_17\CC\1740 126_18\CD\1740 days_19\NNS\15140892 after_20\IN\1740 <e1>pan</e1>_21\NN\3101986 injection_22\NN\320852 so_23\IN\6868043 as_24\IN\14622893 to_25\TO\1740 include_26\VB\690614 both_27\CC\1740 the_28\DT\1740 acute_29\JJ\1740 phase_30\NN\15113229 of_31\IN\1740 proteinuria_32\NN\14299637 associated_33\VBN\628491 with_34\IN\1740 foot_35\NN\5563034 process_36\NN\407535 effacement_37\NN\13526110 (_38\-LRB-\1740 days_39\NNS\15140892 5_40\CD\13741022 -_41\SYM\1740 11_42\CD\13745420 )_43\-RRB-\1740 and_44\CC\1740 the_45\DT\1740 chronic_46\JJ\1740 phase_47\NN\15113229 of_48\IN\1740 <e2>proteinuria</e2>_49\NN\14299637 associated_50\VBN\628491 with_51\IN\1740 glomerulosclerosis_52\NN\1740 (_53\-LRB-\1740 days_54\NNS\15140892 45_55\CD\1740 -_56\SYM\1740 126_57\CD\1740 )_58\-RRB-\1740 ._59\.\1740
D011692_D005921 NONE tissues_0\NNS\5220461 were_1\VBD\836236 analyzed_2\VBN\78760 at_3\IN\14622893 0_4\CD\13741022 ,_5\,\1740 5_6\CD\13741022 ,_7\,\1740 7_8\CD\13741022 ,_9\,\1740 11_10\CD\13745420 ,_11\,\1740 21_12\CD\13745420 ,_13\,\1740 45_14\CD\1740 ,_15\,\1740 80_16\CD\13745420 and_17\CC\1740 126_18\CD\1740 days_19\NNS\15140892 after_20\IN\1740 <e1>pan</e1>_21\NN\3101986 injection_22\NN\320852 so_23\IN\6868043 as_24\IN\14622893 to_25\TO\1740 include_26\VB\690614 both_27\CC\1740 the_28\DT\1740 acute_29\JJ\1740 phase_30\NN\15113229 of_31\IN\1740 proteinuria_32\NN\14299637 associated_33\VBN\628491 with_34\IN\1740 foot_35\NN\5563034 process_36\NN\407535 effacement_37\NN\13526110 (_38\-LRB-\1740 days_39\NNS\15140892 5_40\CD\13741022 -_41\SYM\1740 11_42\CD\13745420 )_43\-RRB-\1740 and_44\CC\1740 the_45\DT\1740 chronic_46\JJ\1740 phase_47\NN\15113229 of_48\IN\1740 proteinuria_49\NN\14299637 associated_50\VBN\628491 with_51\IN\1740 <e2>glomerulosclerosis</e2>_52\NN\1740 (_53\-LRB-\1740 days_54\NNS\15140892 45_55\CD\1740 -_56\SYM\1740 126_57\CD\1740 )_58\-RRB-\1740 ._59\.\1740
11581460
D005283_D016055 CID bladder_0\NN\5515670 <e2>retention_1\NN\809465 of_2\IN\1740 urine</e2>_3\NN\14853947 as_4\IN\14622893 a_5\DT\13649268 result_6\NN\34213 of_7\IN\1740 continuous_8\JJ\1740 intravenous_9\JJ\1740 infusion_10\NN\14589223 of_11\IN\1740 <e1>fentanyl</e1>_12\NN\2707683 :_13\:\1740 2_14\CD\13741022 case_15\NN\7283608 reports_16\NNS\6470073 ._17\.\1740
D005283_D009127 NONE various_0\NNP\1740 reported_1\VBD\831651 side_2\JJ\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>fentanyl</e1>_5\JJ\1740 administration_6\NN\1133281 include_7\VBP\690614 <e2>chest_8\JJ\1740 wall_9\NN\3894379 rigidity</e2>_10\NN\5023233 ,_11\,\1740 hypotension_12\NN\14057371 ,_13\,\1740 respiratory_14\JJ\1740 depression_15\NN\14373582 ,_16\,\1740 and_17\CC\1740 bradycardia_18\NN\14110674 ._19\.\1740
D005283_D007022 CID various_0\NNP\1740 reported_1\VBD\831651 side_2\JJ\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>fentanyl</e1>_5\JJ\1740 administration_6\NN\1133281 include_7\VBP\690614 chest_8\JJ\1740 wall_9\NN\3894379 rigidity_10\NN\5023233 ,_11\,\1740 <e2>hypotension</e2>_12\NN\14057371 ,_13\,\1740 respiratory_14\JJ\1740 depression_15\NN\14373582 ,_16\,\1740 and_17\CC\1740 bradycardia_18\NN\14110674 ._19\.\1740
D005283_D012131 CID various_0\NNP\1740 reported_1\VBD\831651 side_2\JJ\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>fentanyl</e1>_5\JJ\1740 administration_6\NN\1133281 include_7\VBP\690614 chest_8\JJ\1740 wall_9\NN\3894379 rigidity_10\NN\5023233 ,_11\,\1740 hypotension_12\NN\14057371 ,_13\,\1740 <e2>respiratory_14\JJ\1740 depression</e2>_15\NN\14373582 ,_16\,\1740 and_17\CC\1740 bradycardia_18\NN\14110674 ._19\.\1740
D005283_D001919 CID various_0\NNP\1740 reported_1\VBD\831651 side_2\JJ\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>fentanyl</e1>_5\JJ\1740 administration_6\NN\1133281 include_7\VBP\690614 chest_8\JJ\1740 wall_9\NN\3894379 rigidity_10\NN\5023233 ,_11\,\1740 hypotension_12\NN\14057371 ,_13\,\1740 respiratory_14\JJ\1740 depression_15\NN\14373582 ,_16\,\1740 and_17\CC\1740 <e2>bradycardia</e2>_18\NN\14110674 ._19\.\1740
D005283_D001745 CID here_0\RB\1740 ,_1\,\1740 2_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 <e2>urinary_5\JJ\1740 bladder_6\NN\5515670 retention</e2>_7\NN\809465 leading_8\VBG\1752884 to_9\TO\1740 renal_10\JJ\1740 pelvocalyceal_11\NN\1740 dilatation_12\NN\14034177 mimicking_13\VBG\1742886 hydronephrosis_14\NN\14204950 as_15\IN\14622893 a_16\DT\13649268 result_17\NN\34213 of_18\IN\1740 continuous_19\JJ\1740 infusion_20\NN\14589223 of_21\IN\1740 <e1>fentanyl</e1>_22\NN\2707683 are_23\VBP\836236 reported_24\VBN\831651 ._25\.\1740
D005283_D006869 NONE here_0\RB\1740 ,_1\,\1740 2_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 urinary_5\JJ\1740 bladder_6\NN\5515670 retention_7\NN\809465 leading_8\VBG\1752884 to_9\TO\1740 renal_10\JJ\1740 pelvocalyceal_11\NN\1740 dilatation_12\NN\14034177 mimicking_13\VBG\1742886 <e2>hydronephrosis</e2>_14\NN\14204950 as_15\IN\14622893 a_16\DT\13649268 result_17\NN\34213 of_18\IN\1740 continuous_19\JJ\1740 infusion_20\NN\14589223 of_21\IN\1740 <e1>fentanyl</e1>_22\NN\2707683 are_23\VBP\836236 reported_24\VBN\831651 ._25\.\1740
2024540
D004656_D006333 NONE design_0\NN\927261 and_1\CC\1740 analysis_2\NN\633864 of_3\IN\1740 the_4\DT\1740 hypren-trial_5\NN\1740 :_6\:\1740 safety_7\NN\13920835 of_8\IN\1740 <e1>enalapril</e1>_9\NN\2673637 and_10\CC\1740 prazosin_11\NN\2698769 in_12\IN\13603305 the_13\DT\1740 initial_14\JJ\1740 treatment_15\NN\654885 phase_16\NN\15113229 of_17\IN\1740 patients_18\NNS\9898892 with_19\IN\1740 <e2>congestive_20\JJ\1740 heart_21\NN\5919034 failure</e2>_22\NN\66216 ._23\.\1740
D011224_D006333 NONE design_0\NN\927261 and_1\CC\1740 analysis_2\NN\633864 of_3\IN\1740 the_4\DT\1740 hypren-trial_5\NN\1740 :_6\:\1740 safety_7\NN\13920835 of_8\IN\1740 enalapril_9\NN\2673637 and_10\CC\1740 <e1>prazosin</e1>_11\NN\2698769 in_12\IN\13603305 the_13\DT\1740 initial_14\JJ\1740 treatment_15\NN\654885 phase_16\NN\15113229 of_17\IN\1740 patients_18\NNS\9898892 with_19\IN\1740 <e2>congestive_20\JJ\1740 heart_21\NN\5919034 failure</e2>_22\NN\66216 ._23\.\1740
D000806_D006333 NONE since_0\IN\1740 the_1\DT\1740 introduction_2\NN\235435 of_3\IN\1740 <e1>angiotensin_4\NN\4522421 converting_5\NN\1740 enzyme_6\NN\14723628 (_7\-LRB-\1740 ace_8\NN\13741022 )_9\-RRB-\1740 inhibitors</e1>_10\NNS\20090 into_11\IN\1740 the_12\DT\1740 adjunctive_13\JJ\1740 treatment_14\NN\654885 of_15\IN\1740 patients_16\NNS\9898892 with_17\IN\1740 <e2>congestive_18\JJ\1740 heart_19\NN\5919034 failure</e2>_20\NN\66216 ,_21\,\1740 cases_22\NNS\7283608 of_23\IN\1740 severe_24\JJ\1740 hypotension_25\NN\14057371 ,_26\,\1740 especially_27\RB\1740 on_28\IN\1740 the_29\DT\1740 first_30\JJ\1740 day_31\NN\15154774 of_32\IN\1740 treatment_33\NN\654885 ,_34\,\1740 have_35\VBP\2108377 occasionally_36\RB\1740 been_37\VBN\836236 reported_38\VBN\831651 ._39\.\1740
D000806_D007022 CID since_0\IN\1740 the_1\DT\1740 introduction_2\NN\235435 of_3\IN\1740 <e1>angiotensin_4\NN\4522421 converting_5\NN\1740 enzyme_6\NN\14723628 (_7\-LRB-\1740 ace_8\NN\13741022 )_9\-RRB-\1740 inhibitors</e1>_10\NNS\20090 into_11\IN\1740 the_12\DT\1740 adjunctive_13\JJ\1740 treatment_14\NN\654885 of_15\IN\1740 patients_16\NNS\9898892 with_17\IN\1740 congestive_18\JJ\1740 heart_19\NN\5919034 failure_20\NN\66216 ,_21\,\1740 cases_22\NNS\7283608 of_23\IN\1740 severe_24\JJ\1740 <e2>hypotension</e2>_25\NN\14057371 ,_26\,\1740 especially_27\RB\1740 on_28\IN\1740 the_29\DT\1740 first_30\JJ\1740 day_31\NN\15154774 of_32\IN\1740 treatment_33\NN\654885 ,_34\,\1740 have_35\VBP\2108377 occasionally_36\RB\1740 been_37\VBN\836236 reported_38\VBN\831651 ._39\.\1740
D000806_D007022 CID to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 safety_3\NN\13920835 of_4\IN\1740 the_5\DT\1740 <e1>ace_6\NN\13741022 inhibitor</e1>_7\NN\20090 enalapril_8\NN\2673637 a_9\DT\13649268 multicenter_10\NN\1740 ,_11\,\1740 randomized_12\VBN\278117 ,_13\,\1740 prazosin-controlled_14\JJ\1740 trial_15\NN\786195 was_16\VBD\836236 designed_17\VBN\1631534 that_18\IN\1740 compared_19\VBD\644583 the_20\DT\1740 incidence_21\NN\13821570 and_22\CC\1740 severity_23\NN\5036394 of_24\IN\1740 symptomatic_25\JJ\1740 <e2>hypotension</e2>_26\NN\14057371 on_27\IN\1740 the_28\DT\1740 first_29\JJ\1740 day_30\NN\15154774 of_31\IN\1740 treatment_32\NN\654885 ._33\.\1740
D004656_D007022 NONE to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 safety_3\NN\13920835 of_4\IN\1740 the_5\DT\1740 ace_6\NN\13741022 inhibitor_7\NN\20090 <e1>enalapril</e1>_8\NN\2673637 a_9\DT\13649268 multicenter_10\NN\1740 ,_11\,\1740 randomized_12\VBN\278117 ,_13\,\1740 prazosin-controlled_14\JJ\1740 trial_15\NN\786195 was_16\VBD\836236 designed_17\VBN\1631534 that_18\IN\1740 compared_19\VBD\644583 the_20\DT\1740 incidence_21\NN\13821570 and_22\CC\1740 severity_23\NN\5036394 of_24\IN\1740 symptomatic_25\JJ\1740 <e2>hypotension</e2>_26\NN\14057371 on_27\IN\1740 the_28\DT\1740 first_29\JJ\1740 day_30\NN\15154774 of_31\IN\1740 treatment_32\NN\654885 ._33\.\1740
D004656_D007022 NONE patients_0\NNS\9898892 who_1\WP\8299493 received_2\VBD\2210855 <e1>enalapril</e1>_3\NN\2673637 experienced_4\VBN\2108377 clinically_5\RB\1740 and_6\CC\1740 statistically_7\RB\1740 significantly_8\RB\1740 less_9\RBR\1740 symptomatic_10\JJ\1740 <e2>hypotension</e2>_11\NN\14057371 (_12\-LRB-\1740 5.2_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 than_16\IN\1740 the_17\DT\1740 patients_18\NNS\9898892 who_19\WP\8299493 received_20\VBD\2210855 prazosin_21\NN\2698769 (_22\-LRB-\1740 12.9_23\CD\1740 %_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
D011224_D007022 CID to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 safety_3\NN\13920835 of_4\IN\1740 the_5\DT\1740 ace_6\NN\13741022 inhibitor_7\NN\20090 enalapril_8\NN\2673637 a_9\DT\13649268 multicenter_10\NN\1740 ,_11\,\1740 randomized_12\VBN\278117 ,_13\,\1740 <e1>prazosin-controlled</e1>_14\JJ\1740 trial_15\NN\786195 was_16\VBD\836236 designed_17\VBN\1631534 that_18\IN\1740 compared_19\VBD\644583 the_20\DT\1740 incidence_21\NN\13821570 and_22\CC\1740 severity_23\NN\5036394 of_24\IN\1740 symptomatic_25\JJ\1740 <e2>hypotension</e2>_26\NN\14057371 on_27\IN\1740 the_28\DT\1740 first_29\JJ\1740 day_30\NN\15154774 of_31\IN\1740 treatment_32\NN\654885 ._33\.\1740
D011224_D007022 CID patients_0\NNS\9898892 who_1\WP\8299493 received_2\VBD\2210855 enalapril_3\NN\2673637 experienced_4\VBN\2108377 clinically_5\RB\1740 and_6\CC\1740 statistically_7\RB\1740 significantly_8\RB\1740 less_9\RBR\1740 symptomatic_10\JJ\1740 <e2>hypotension</e2>_11\NN\14057371 (_12\-LRB-\1740 5.2_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 than_16\IN\1740 the_17\DT\1740 patients_18\NNS\9898892 who_19\WP\8299493 received_20\VBD\2210855 <e1>prazosin</e1>_21\NN\2698769 (_22\-LRB-\1740 12.9_23\CD\1740 %_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
19300402
D001920_D006930 NONE <e1>bradykinin</e1>_0\NNP\1740 receptors_1\NNS\5225602 antagonists_2\NNS\7846 and_3\CC\1740 nitric_4\JJ\1740 oxide_5\NN\14818238 synthase_6\NN\1740 inhibitors_7\NNS\20090 in_8\IN\13603305 vincristine_9\NN\3917455 and_10\CC\1740 streptozotocin_11\NN\1740 induced_12\VBD\1627355 <e2>hyperalgesia</e2>_13\NN\1740 in_14\IN\13603305 chemotherapy_15\NN\661091 and_16\CC\1740 diabetic_17\JJ\1740 neuropathy_18\JJ\1740 rat_19\NN\2329401 model_20\NN\5888929 ._21\.\1740
D001920_D006930 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 of_4\IN\1740 this_5\DT\1740 paper_6\NN\14580897 confirm_7\VBP\1011725 that_8\IN\1740 inhibition_9\NN\1068773 of_10\IN\1740 <e1>bradykinin</e1>_11\NN\1740 receptors_12\NNS\5225602 and_13\CC\1740 inducible_14\JJ\1740 no_15\NN\7204911 synthase_16\NN\1740 but_17\CC\1740 not_18\RB\1740 neuronal_19\JJ\1740 no_20\NN\7204911 synthase_21\NN\1740 activity_22\NN\30358 reduces_23\VBZ\441445 <e2>diabetic_24\JJ\1740 hyperalgesia</e2>_25\NN\1740 ._26\.\1740
D001920_D006930 NONE it_0\PRP\6125041 was_1\VBD\836236 also_2\RB\1740 shown_3\VBN\2137132 that_4\IN\1740 both_5\DT\1740 products_6\NNS\3076708 of_7\IN\1740 inducible_8\JJ\1740 no_9\NN\7204911 synthase_10\NN\1740 and_11\CC\1740 neuronal_12\JJ\1740 no_13\NN\7204911 synthase_14\NN\1740 activation_15\NN\13561719 as_16\RB\1740 well_17\RB\1740 as_18\IN\14622893 <e1>bradykinin</e1>_19\NN\1740 are_20\VBP\836236 involved_21\VBN\2676054 in_22\IN\13603305 <e2>hyperalgesia</e2>_23\NN\1740 produced_24\VBN\1617192 by_25\IN\1740 vincristine_26\NN\3917455 ._27\.\1740
D001920_D006930 NONE in_0\IN\13603305 streptozotocin-induced_1\JJ\1740 <e2>hyperalgesia</e2>_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 no_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 <e1>bradykinin</e1>_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 vincristine-induced_16\JJ\1740 hyperalgesia_17\NN\1740 bradykinin_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 no_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D001920_D006930 NONE in_0\IN\13603305 streptozotocin-induced_1\JJ\1740 hyperalgesia_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 no_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 <e1>bradykinin</e1>_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 vincristine-induced_16\JJ\1740 <e2>hyperalgesia</e2>_17\NN\1740 bradykinin_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 no_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D001920_D006930 NONE in_0\IN\13603305 streptozotocin-induced_1\JJ\1740 <e2>hyperalgesia</e2>_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 no_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 bradykinin_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 vincristine-induced_16\JJ\1740 hyperalgesia_17\NN\1740 <e1>bradykinin</e1>_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 no_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D001920_D006930 NONE in_0\IN\13603305 streptozotocin-induced_1\JJ\1740 hyperalgesia_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 no_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 bradykinin_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 vincristine-induced_16\JJ\1740 <e2>hyperalgesia</e2>_17\NN\1740 <e1>bradykinin</e1>_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 no_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D001920_D003929 NONE <e1>bradykinin</e1>_0\NNP\1740 receptors_1\NNS\5225602 antagonists_2\NNS\7846 and_3\CC\1740 nitric_4\JJ\1740 oxide_5\NN\14818238 synthase_6\NN\1740 inhibitors_7\NNS\20090 in_8\IN\13603305 vincristine_9\NN\3917455 and_10\CC\1740 streptozotocin_11\NN\1740 induced_12\VBD\1627355 hyperalgesia_13\NN\1740 in_14\IN\13603305 chemotherapy_15\NN\661091 and_16\CC\1740 <e2>diabetic_17\JJ\1740 neuropathy</e2>_18\JJ\1740 rat_19\NN\2329401 model_20\NN\5888929 ._21\.\1740
D001920_D003929 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 no_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 no_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 no_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 <e1>bradykinin</e1>_66\NN\1740 (_67\-LRB-\1740 hoe_68\NN\4451818 140_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
D009569_D006930 NONE bradykinin_0\NNP\1740 receptors_1\NNS\5225602 antagonists_2\NNS\7846 and_3\CC\1740 <e1>nitric_4\JJ\1740 oxide</e1>_5\NN\14818238 synthase_6\NN\1740 inhibitors_7\NNS\20090 in_8\IN\13603305 vincristine_9\NN\3917455 and_10\CC\1740 streptozotocin_11\NN\1740 induced_12\VBD\1627355 <e2>hyperalgesia</e2>_13\NN\1740 in_14\IN\13603305 chemotherapy_15\NN\661091 and_16\CC\1740 diabetic_17\JJ\1740 neuropathy_18\JJ\1740 rat_19\NN\2329401 model_20\NN\5888929 ._21\.\1740
D009569_D006930 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 of_4\IN\1740 this_5\DT\1740 paper_6\NN\14580897 confirm_7\VBP\1011725 that_8\IN\1740 inhibition_9\NN\1068773 of_10\IN\1740 bradykinin_11\NN\1740 receptors_12\NNS\5225602 and_13\CC\1740 inducible_14\JJ\1740 <e1>no</e1>_15\NN\7204911 synthase_16\NN\1740 but_17\CC\1740 not_18\RB\1740 neuronal_19\JJ\1740 no_20\NN\7204911 synthase_21\NN\1740 activity_22\NN\30358 reduces_23\VBZ\441445 <e2>diabetic_24\JJ\1740 hyperalgesia</e2>_25\NN\1740 ._26\.\1740
D009569_D006930 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 of_4\IN\1740 this_5\DT\1740 paper_6\NN\14580897 confirm_7\VBP\1011725 that_8\IN\1740 inhibition_9\NN\1068773 of_10\IN\1740 bradykinin_11\NN\1740 receptors_12\NNS\5225602 and_13\CC\1740 inducible_14\JJ\1740 no_15\NN\7204911 synthase_16\NN\1740 but_17\CC\1740 not_18\RB\1740 neuronal_19\JJ\1740 <e1>no</e1>_20\NN\7204911 synthase_21\NN\1740 activity_22\NN\30358 reduces_23\VBZ\441445 <e2>diabetic_24\JJ\1740 hyperalgesia</e2>_25\NN\1740 ._26\.\1740
D009569_D006930 NONE it_0\PRP\6125041 was_1\VBD\836236 also_2\RB\1740 shown_3\VBN\2137132 that_4\IN\1740 both_5\DT\1740 products_6\NNS\3076708 of_7\IN\1740 inducible_8\JJ\1740 <e1>no</e1>_9\NN\7204911 synthase_10\NN\1740 and_11\CC\1740 neuronal_12\JJ\1740 no_13\NN\7204911 synthase_14\NN\1740 activation_15\NN\13561719 as_16\RB\1740 well_17\RB\1740 as_18\IN\14622893 bradykinin_19\NN\1740 are_20\VBP\836236 involved_21\VBN\2676054 in_22\IN\13603305 <e2>hyperalgesia</e2>_23\NN\1740 produced_24\VBN\1617192 by_25\IN\1740 vincristine_26\NN\3917455 ._27\.\1740
D009569_D006930 NONE it_0\PRP\6125041 was_1\VBD\836236 also_2\RB\1740 shown_3\VBN\2137132 that_4\IN\1740 both_5\DT\1740 products_6\NNS\3076708 of_7\IN\1740 inducible_8\JJ\1740 no_9\NN\7204911 synthase_10\NN\1740 and_11\CC\1740 neuronal_12\JJ\1740 <e1>no</e1>_13\NN\7204911 synthase_14\NN\1740 activation_15\NN\13561719 as_16\RB\1740 well_17\RB\1740 as_18\IN\14622893 bradykinin_19\NN\1740 are_20\VBP\836236 involved_21\VBN\2676054 in_22\IN\13603305 <e2>hyperalgesia</e2>_23\NN\1740 produced_24\VBN\1617192 by_25\IN\1740 vincristine_26\NN\3917455 ._27\.\1740
D009569_D006930 NONE in_0\IN\13603305 streptozotocin-induced_1\JJ\1740 <e2>hyperalgesia</e2>_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 <e1>no</e1>_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 bradykinin_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 vincristine-induced_16\JJ\1740 hyperalgesia_17\NN\1740 bradykinin_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 no_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D009569_D006930 NONE in_0\IN\13603305 streptozotocin-induced_1\JJ\1740 hyperalgesia_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 <e1>no</e1>_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 bradykinin_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 vincristine-induced_16\JJ\1740 <e2>hyperalgesia</e2>_17\NN\1740 bradykinin_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 no_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D009569_D006930 NONE in_0\IN\13603305 streptozotocin-induced_1\JJ\1740 <e2>hyperalgesia</e2>_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 no_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 bradykinin_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 vincristine-induced_16\JJ\1740 hyperalgesia_17\NN\1740 bradykinin_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 <e1>no</e1>_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D009569_D006930 NONE in_0\IN\13603305 streptozotocin-induced_1\JJ\1740 hyperalgesia_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 no_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 bradykinin_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 vincristine-induced_16\JJ\1740 <e2>hyperalgesia</e2>_17\NN\1740 bradykinin_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 <e1>no</e1>_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D009569_D003929 NONE bradykinin_0\NNP\1740 receptors_1\NNS\5225602 antagonists_2\NNS\7846 and_3\CC\1740 <e1>nitric_4\JJ\1740 oxide</e1>_5\NN\14818238 synthase_6\NN\1740 inhibitors_7\NNS\20090 in_8\IN\13603305 vincristine_9\NN\3917455 and_10\CC\1740 streptozotocin_11\NN\1740 induced_12\VBD\1627355 hyperalgesia_13\NN\1740 in_14\IN\13603305 chemotherapy_15\NN\661091 and_16\CC\1740 <e2>diabetic_17\JJ\1740 neuropathy</e2>_18\JJ\1740 rat_19\NN\2329401 model_20\NN\5888929 ._21\.\1740
D009569_D003929 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 <e1>no</e1>_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 no_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 no_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 bradykinin_66\NN\1740 (_67\-LRB-\1740 hoe_68\NN\4451818 140_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
D009569_D003929 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 no_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 <e1>no</e1>_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 no_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 bradykinin_66\NN\1740 (_67\-LRB-\1740 hoe_68\NN\4451818 140_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
D009569_D003929 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 no_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 no_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 <e1>no</e1>_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 bradykinin_66\NN\1740 (_67\-LRB-\1740 hoe_68\NN\4451818 140_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
D014750_D006930 CID bradykinin_0\NNP\1740 receptors_1\NNS\5225602 antagonists_2\NNS\7846 and_3\CC\1740 nitric_4\JJ\1740 oxide_5\NN\14818238 synthase_6\NN\1740 inhibitors_7\NNS\20090 in_8\IN\13603305 <e1>vincristine</e1>_9\NN\3917455 and_10\CC\1740 streptozotocin_11\NN\1740 induced_12\VBD\1627355 <e2>hyperalgesia</e2>_13\NN\1740 in_14\IN\13603305 chemotherapy_15\NN\661091 and_16\CC\1740 diabetic_17\JJ\1740 neuropathy_18\JJ\1740 rat_19\NN\2329401 model_20\NN\5888929 ._21\.\1740
D014750_D006930 CID it_0\PRP\6125041 was_1\VBD\836236 also_2\RB\1740 shown_3\VBN\2137132 that_4\IN\1740 both_5\DT\1740 products_6\NNS\3076708 of_7\IN\1740 inducible_8\JJ\1740 no_9\NN\7204911 synthase_10\NN\1740 and_11\CC\1740 neuronal_12\JJ\1740 no_13\NN\7204911 synthase_14\NN\1740 activation_15\NN\13561719 as_16\RB\1740 well_17\RB\1740 as_18\IN\14622893 bradykinin_19\NN\1740 are_20\VBP\836236 involved_21\VBN\2676054 in_22\IN\13603305 <e2>hyperalgesia</e2>_23\NN\1740 produced_24\VBN\1617192 by_25\IN\1740 <e1>vincristine</e1>_26\NN\3917455 ._27\.\1740
D014750_D006930 CID in_0\IN\13603305 streptozotocin-induced_1\JJ\1740 <e2>hyperalgesia</e2>_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 no_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 bradykinin_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 <e1>vincristine-induced</e1>_16\JJ\1740 hyperalgesia_17\NN\1740 bradykinin_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 no_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D014750_D006930 CID in_0\IN\13603305 streptozotocin-induced_1\JJ\1740 hyperalgesia_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 no_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 bradykinin_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 <e1>vincristine-induced</e1>_16\JJ\1740 <e2>hyperalgesia</e2>_17\NN\1740 bradykinin_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 no_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D014750_D003929 NONE bradykinin_0\NNP\1740 receptors_1\NNS\5225602 antagonists_2\NNS\7846 and_3\CC\1740 nitric_4\JJ\1740 oxide_5\NN\14818238 synthase_6\NN\1740 inhibitors_7\NNS\20090 in_8\IN\13603305 <e1>vincristine</e1>_9\NN\3917455 and_10\CC\1740 streptozotocin_11\NN\1740 induced_12\VBD\1627355 hyperalgesia_13\NN\1740 in_14\IN\13603305 chemotherapy_15\NN\661091 and_16\CC\1740 <e2>diabetic_17\JJ\1740 neuropathy</e2>_18\JJ\1740 rat_19\NN\2329401 model_20\NN\5888929 ._21\.\1740
D013311_D006930 CID bradykinin_0\NNP\1740 receptors_1\NNS\5225602 antagonists_2\NNS\7846 and_3\CC\1740 nitric_4\JJ\1740 oxide_5\NN\14818238 synthase_6\NN\1740 inhibitors_7\NNS\20090 in_8\IN\13603305 vincristine_9\NN\3917455 and_10\CC\1740 <e1>streptozotocin</e1>_11\NN\1740 induced_12\VBD\1627355 <e2>hyperalgesia</e2>_13\NN\1740 in_14\IN\13603305 chemotherapy_15\NN\661091 and_16\CC\1740 diabetic_17\JJ\1740 neuropathy_18\JJ\1740 rat_19\NN\2329401 model_20\NN\5888929 ._21\.\1740
D013311_D006930 CID in_0\IN\13603305 <e1>streptozotocin-induced</e1>_1\JJ\1740 <e2>hyperalgesia</e2>_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 no_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 bradykinin_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 vincristine-induced_16\JJ\1740 hyperalgesia_17\NN\1740 bradykinin_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 no_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D013311_D006930 CID in_0\IN\13603305 <e1>streptozotocin-induced</e1>_1\JJ\1740 hyperalgesia_2\NN\1740 ,_3\,\1740 inducible_4\JJ\1740 no_5\NN\7204911 synthase_6\NN\1740 participates_7\VBZ\2367363 in_8\IN\13603305 pronociceptive_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 bradykinin_12\NN\1740 ,_13\,\1740 whereas_14\IN\1740 in_15\IN\13603305 vincristine-induced_16\JJ\1740 <e2>hyperalgesia</e2>_17\NN\1740 bradykinin_18\NN\1740 seemed_19\VBD\2604760 to_20\TO\1740 activate_21\VB\1641914 neuronal_22\JJ\1740 no_23\NN\7204911 synthase_24\NN\1740 pathway_25\NN\5483677 ._26\.\1740
D013311_D003929 CID bradykinin_0\NNP\1740 receptors_1\NNS\5225602 antagonists_2\NNS\7846 and_3\CC\1740 nitric_4\JJ\1740 oxide_5\NN\14818238 synthase_6\NN\1740 inhibitors_7\NNS\20090 in_8\IN\13603305 vincristine_9\NN\3917455 and_10\CC\1740 <e1>streptozotocin</e1>_11\NN\1740 induced_12\VBD\1627355 hyperalgesia_13\NN\1740 in_14\IN\13603305 chemotherapy_15\NN\661091 and_16\CC\1740 <e2>diabetic_17\JJ\1740 neuropathy</e2>_18\JJ\1740 rat_19\NN\2329401 model_20\NN\5888929 ._21\.\1740
D009569_D010523 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 <e1>no</e1>_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 no_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 no_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 bradykinin_66\NN\1740 (_67\-LRB-\1740 hoe_68\NN\4451818 140_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
D009569_D010523 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 no_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 <e1>no</e1>_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 no_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 bradykinin_66\NN\1740 (_67\-LRB-\1740 hoe_68\NN\4451818 140_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
D009569_D010523 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 no_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 no_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 <e1>no</e1>_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 bradykinin_66\NN\1740 (_67\-LRB-\1740 hoe_68\NN\4451818 140_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
D001920_D010523 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 no_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 no_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 no_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 <e1>bradykinin</e1>_66\NN\1740 (_67\-LRB-\1740 hoe_68\NN\4451818 140_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
C065679_D003929 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 no_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 no_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 no_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 bradykinin_66\NN\1740 (_67\-LRB-\1740 <e1>hoe_68\NN\4451818 140</e1>_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
C065679_D010523 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 no_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 no_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 no_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 bradykinin_66\NN\1740 (_67\-LRB-\1740 <e1>hoe_68\NN\4451818 140</e1>_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
C065679_D010523 NONE moreover_0\RB\1740 ,_1\,\1740 l-noarg_2\NN\1740 and_3\CC\1740 7-ni_4\CD\1740 but_5\CC\1740 not_6\RB\1740 l-nil_7\NN\1740 intensify_8\VBP\153263 antihyperalgesic_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 <e1>hoe_12\NN\4451818 140</e1>_13\CD\1740 or_14\CC\3541091 des-arg10hoe_15\NN\1740 140_16\CD\1740 in_17\IN\13603305 <e2>toxic_18\JJ\1740 neuropathy</e2>_19\NN\14204950 ._20\.\1740
C078665_D003929 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 no_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 no_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 no_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 bradykinin_66\NN\1740 (_67\-LRB-\1740 hoe_68\NN\4451818 140_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 <e1>des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140</e1>_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
C078665_D010523 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 influence_3\NN\5190804 of_4\IN\1740 an_5\DT\6697703 irreversible_6\JJ\1740 inhibitor_7\NN\20090 of_8\IN\1740 constitutive_9\JJ\1740 no_10\NN\7204911 synthase_11\NN\1740 (_12\-LRB-\1740 l-noarg_13\NN\1740 ;_14\:\1740 1.0_15\CD\1740 mg/kg_16\NN\1740 ip_17\NN\5999797 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 relatively_21\RB\1740 selective_22\JJ\1740 inhibitor_23\NN\20090 of_24\IN\1740 inducible_25\JJ\1740 no_26\NN\7204911 synthase_27\NN\1740 (_28\-LRB-\1740 l-nil_29\NN\1740 ;_30\:\1740 1.0_31\CD\1740 mg/kg_32\NN\1740 ip_33\NN\5999797 )_34\-RRB-\1740 and_35\CC\1740 a_36\DT\13649268 relatively_37\RB\1740 specific_38\JJ\1740 inhibitor_39\NN\20090 of_40\IN\1740 neuronal_41\JJ\1740 no_42\NN\7204911 synthase_43\NN\1740 (_44\-LRB-\1740 7-ni_45\CD\1740 ;_46\:\1740 0.1_47\CD\1740 mg/kg_48\NN\1740 ip_49\NN\5999797 )_50\-RRB-\1740 ,_51\,\1740 on_52\IN\1740 antihyperalgesic_53\JJ\1740 action_54\NN\30358 of_55\IN\1740 selective_56\JJ\1740 antagonists_57\NNS\7846 of_58\IN\1740 b2_59\NN\1740 and_60\CC\1740 b1_61\NN\1740 receptors_62\NNS\5225602 :_63\:\1740 d-arg-[hyp3,thi5,d-tic7,oic8_64\NN\1740 ]_65\-RRB-\1740 bradykinin_66\NN\1740 (_67\-LRB-\1740 hoe_68\NN\4451818 140_69\CD\1740 ;_70\:\1740 70_71\CD\13745420 nmol/kg_72\NN\1740 ip_73\NN\5999797 )_74\-RRB-\1740 or_75\CC\3541091 <e1>des_76\VBZ\1740 arg10_77\NN\1740 hoe_78\NN\4451818 140</e1>_79\CD\1740 (_80\-LRB-\1740 70_81\CD\13745420 nmol/kg_82\NN\1740 ip_83\NN\5999797 )_84\-RRB-\1740 respectively_85\RB\1740 ,_86\,\1740 in_87\IN\13603305 model_88\NN\5888929 of_89\IN\1740 <e2>diabetic_90\JJ\1740 (_91\-LRB-\1740 streptozotocin-induced_92\JJ\1740 )_93\-RRB-\1740 and_94\CC\1740 toxic_95\JJ\1740 (_96\-LRB-\1740 vincristine-induced_97\JJ\1740 )_98\-RRB-\1740 neuropathy</e2>_99\RB\1740 was_100\VBD\836236 investigated_101\VBN\644583 ._102\.\1740
C078665_D010523 NONE moreover_0\RB\1740 ,_1\,\1740 l-noarg_2\NN\1740 and_3\CC\1740 7-ni_4\CD\1740 but_5\CC\1740 not_6\RB\1740 l-nil_7\NN\1740 intensify_8\VBP\153263 antihyperalgesic_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 hoe_12\NN\4451818 140_13\CD\1740 or_14\CC\3541091 <e1>des-arg10hoe_15\NN\1740 140</e1>_16\CD\1740 in_17\IN\13603305 <e2>toxic_18\JJ\1740 neuropathy</e2>_19\NN\14204950 ._20\.\1740
D001920_D009437 NONE therefore_0\RB\1740 ,_1\,\1740 concomitant_2\JJ\1740 administration_3\NN\1133281 of_4\IN\1740 small_5\JJ\1740 doses_6\NNS\3740161 of_7\IN\1740 <e1>bradykinin</e1>_8\NN\1740 receptor_9\NN\5225602 antagonists_10\NNS\7846 and_11\CC\1740 no_12\NN\7204911 synthase_13\NN\1740 inhibitors_14\NNS\20090 can_15\MD\3094503 be_16\VB\836236 effective_17\JJ\1740 in_18\IN\13603305 alleviation_19\NN\7492516 of_20\IN\1740 <e2>neuropathic_21\JJ\1740 pain</e2>_22\NN\14299637 ,_23\,\1740 even_24\RB\1740 in_25\IN\13603305 hospital_26\NN\3739518 care_27\NN\575741 ._28\.\1740
D009569_D009437 NONE therefore_0\RB\1740 ,_1\,\1740 concomitant_2\JJ\1740 administration_3\NN\1133281 of_4\IN\1740 small_5\JJ\1740 doses_6\NNS\3740161 of_7\IN\1740 bradykinin_8\NN\1740 receptor_9\NN\5225602 antagonists_10\NNS\7846 and_11\CC\1740 <e1>no</e1>_12\NN\7204911 synthase_13\NN\1740 inhibitors_14\NNS\20090 can_15\MD\3094503 be_16\VB\836236 effective_17\JJ\1740 in_18\IN\13603305 alleviation_19\NN\7492516 of_20\IN\1740 <e2>neuropathic_21\JJ\1740 pain</e2>_22\NN\14299637 ,_23\,\1740 even_24\RB\1740 in_25\IN\13603305 hospital_26\NN\3739518 care_27\NN\575741 ._28\.\1740
11642480
D015283_D004409 CID <e2>palpebral_0\JJ\1740 twitching</e2>_1\VBG\10054 in_2\IN\13603305 a_3\DT\13649268 depressed_4\JJ\1740 adolescent_5\JJ\1740 on_6\IN\1740 <e1>citalopram</e1>_7\NN\1740 ._8\.\1740
D015283_D004409 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 favorable_3\JJ\1740 response_4\NN\11410625 to_5\TO\1740 treatment_6\NN\654885 with_7\IN\1740 <e1>citalopram</e1>_8\NN\1740 by_9\IN\1740 a_10\DT\13649268 15-year-old_11\JJ\1740 boy_12\NN\9624168 with_13\IN\1740 major_14\JJ\1740 depression_15\NN\14373582 who_16\WP\8299493 exhibited_17\VBD\2632167 <e2>palpebral_18\JJ\1740 twitching</e2>_19\NN\14360459 during_20\IN\1740 his_21\PRP$\1740 first_22\JJ\1740 2_23\CD\13741022 weeks_24\NNS\15113229 of_25\IN\1740 treatment_26\NN\654885 ._27\.\1740
D015283_D003866 NONE palpebral_0\JJ\1740 twitching_1\VBG\10054 in_2\IN\13603305 a_3\DT\13649268 <e2>depressed</e2>_4\JJ\1740 adolescent_5\JJ\1740 on_6\IN\1740 <e1>citalopram</e1>_7\NN\1740 ._8\.\1740
D015283_D003865 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 favorable_3\JJ\1740 response_4\NN\11410625 to_5\TO\1740 treatment_6\NN\654885 with_7\IN\1740 <e1>citalopram</e1>_8\NN\1740 by_9\IN\1740 a_10\DT\13649268 15-year-old_11\JJ\1740 boy_12\NN\9624168 with_13\IN\1740 <e2>major_14\JJ\1740 depression</e2>_15\NN\14373582 who_16\WP\8299493 exhibited_17\VBD\2632167 palpebral_18\JJ\1740 twitching_19\NN\14360459 during_20\IN\1740 his_21\PRP$\1740 first_22\JJ\1740 2_23\CD\13741022 weeks_24\NNS\15113229 of_25\IN\1740 treatment_26\NN\654885 ._27\.\1740
15859940
D016572_D064420 NONE other_0\JJ\1740 causes_1\NNS\7323922 include_2\VBP\690614 drug-related_3\JJ\1740 (_4\-LRB-\1740 <e1>cyclosporine</e1>_5\NN\1740 ,_6\,\1740 tacrolimus_7\NN\1740 )_8\-RRB-\1740 <e2>toxicity</e2>_9\NN\13576101 ,_10\,\1740 procoagulant_11\JJ\1740 status_12\NN\24720 ,_13\,\1740 and_14\CC\1740 antibody-mediated_15\JJ\1740 rejection_16\NN\30358 ._17\.\1740
D016559_D064420 NONE other_0\JJ\1740 causes_1\NNS\7323922 include_2\VBP\690614 drug-related_3\JJ\1740 (_4\-LRB-\1740 cyclosporine_5\NN\1740 ,_6\,\1740 <e1>tacrolimus</e1>_7\NN\1740 )_8\-RRB-\1740 <e2>toxicity</e2>_9\NN\13576101 ,_10\,\1740 procoagulant_11\JJ\1740 status_12\NN\24720 ,_13\,\1740 and_14\CC\1740 antibody-mediated_15\JJ\1740 rejection_16\NN\30358 ._17\.\1740
D016572_D057049 CID we_0\PRP\1740 found_1\VBD\2426171 that_2\IN\1740 the_3\DT\1740 most-frequent_4\JJ\1740 cause_5\NN\7323922 of_6\IN\1740 <e2>thrombotic_7\JJ\1740 microangiopathy</e2>_8\NN\1740 was_9\VBD\836236 drug_10\NN\14778436 related_11\JJ\1740 ,_12\,\1740 secondary_13\JJ\1740 mainly_14\RB\1740 to_15\TO\1740 <e1>cyclosporine</e1>_16\NN\1740 ._17\.\1740
8595686
D013874_D010146 NONE <e1>thiopentone</e1>_0\NN\1740 pretreatment_1\NN\1740 for_2\IN\1740 propofol_3\NN\1740 injection_4\NN\320852 <e2>pain</e2>_5\NN\14299637 in_6\IN\13603305 ambulatory_7\JJ\1740 patients_8\NNS\9898892 ._9\.\1740
D013874_D010146 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 lidocaine_3\NN\3681148 reduces_4\VBZ\441445 the_5\DT\1740 incidence_6\NN\13821570 and_7\CC\1740 severity_8\NN\5036394 of_9\IN\1740 propofol_10\NN\1740 injection_11\NN\320852 <e2>pain</e2>_12\NN\14299637 in_13\IN\13603305 ambulatory_14\JJ\1740 patients_15\NNS\9898892 whereas_16\IN\1740 <e1>thiopentone</e1>_17\NN\1740 only_18\RB\1740 reduces_19\VBZ\441445 its_20\PRP$\6125041 severity_21\NN\5036394 ._22\.\1740
D015742_D010146 CID thiopentone_0\NN\1740 pretreatment_1\NN\1740 for_2\IN\1740 <e1>propofol</e1>_3\NN\1740 injection_4\NN\320852 <e2>pain</e2>_5\NN\14299637 in_6\IN\13603305 ambulatory_7\JJ\1740 patients_8\NNS\9898892 ._9\.\1740
D015742_D010146 CID this_0\DT\1740 study_1\NN\635850 investigated_2\VBD\644583 <e1>propofol</e1>_3\NN\1740 injection_4\NN\320852 <e2>pain</e2>_5\NN\14299637 in_6\IN\13603305 patients_7\NNS\9898892 undergoing_8\VBG\109660 ambulatory_9\JJ\1740 anaesthesia_10\NN\14034177 ._11\.\1740
D015742_D010146 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 lidocaine_3\NN\3681148 reduces_4\VBZ\441445 the_5\DT\1740 incidence_6\NN\13821570 and_7\CC\1740 severity_8\NN\5036394 of_9\IN\1740 <e1>propofol</e1>_10\NN\1740 injection_11\NN\320852 <e2>pain</e2>_12\NN\14299637 in_13\IN\13603305 ambulatory_14\JJ\1740 patients_15\NNS\9898892 whereas_16\IN\1740 thiopentone_17\NN\1740 only_18\RB\1740 reduces_19\VBZ\441445 its_20\PRP$\6125041 severity_21\NN\5036394 ._22\.\1740
D008012_D010146 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>lidocaine</e1>_3\NN\3681148 reduces_4\VBZ\441445 the_5\DT\1740 incidence_6\NN\13821570 and_7\CC\1740 severity_8\NN\5036394 of_9\IN\1740 propofol_10\NN\1740 injection_11\NN\320852 <e2>pain</e2>_12\NN\14299637 in_13\IN\13603305 ambulatory_14\JJ\1740 patients_15\NNS\9898892 whereas_16\IN\1740 thiopentone_17\NN\1740 only_18\RB\1740 reduces_19\VBZ\441445 its_20\PRP$\6125041 severity_21\NN\5036394 ._22\.\1740
11263551
D016572_D010146 CID the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 <e1>cyclosporine-</e1>_3\NN\1740 or_4\CC\3541091 tacrolimus_5\NN\1740 trough_6\NN\9366017 levels_7\NNS\4916342 and_8\CC\1740 the_9\DT\1740 administration_10\NN\1133281 of_11\IN\1740 calcium_12\NN\14625458 channel_13\NN\6251781 blockers_14\NNS\10101634 led_15\VBD\1752884 to_16\TO\1740 relief_17\NN\7492516 of_18\IN\1740 <e2>pain</e2>_19\NN\14299637 ._20\.\1740
D016572_D010146 CID the_0\DT\1740 calcineurin-inhibitor_1\NN\1740 induced_2\VBD\1627355 <e2>pain</e2>_3\NN\14299637 syndrome_4\NN\5870365 (_5\-LRB-\1740 cips_6\NN\1740 )_7\-RRB-\1740 is_8\VBZ\836236 a_9\DT\13649268 rare_10\JJ\1740 but_11\CC\1740 severe_12\JJ\1740 side_13\NN\8630039 effect_14\NN\34213 of_15\IN\1740 <e1>cyclosporine</e1>_16\NN\1740 or_17\CC\3541091 tacrolimus_18\NN\1740 and_19\CC\1740 is_20\VBZ\836236 accurately_21\RB\1740 diagnosed_22\VBN\644583 by_23\IN\1740 its_24\PRP$\6125041 typical_25\JJ\1740 presentation_26\NN\1027379 ,_27\,\1740 magnetic_28\JJ\1740 resonance_29\NN\11419404 imaging_30\NN\5765159 and_31\CC\1740 bone_32\NN\5286536 scans_33\NNS\635850 ._34\.\1740
D016559_D010146 CID the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 cyclosporine-_3\NN\1740 or_4\CC\3541091 <e1>tacrolimus</e1>_5\NN\1740 trough_6\NN\9366017 levels_7\NNS\4916342 and_8\CC\1740 the_9\DT\1740 administration_10\NN\1133281 of_11\IN\1740 calcium_12\NN\14625458 channel_13\NN\6251781 blockers_14\NNS\10101634 led_15\VBD\1752884 to_16\TO\1740 relief_17\NN\7492516 of_18\IN\1740 <e2>pain</e2>_19\NN\14299637 ._20\.\1740
D016559_D010146 CID the_0\DT\1740 calcineurin-inhibitor_1\NN\1740 induced_2\VBD\1627355 <e2>pain</e2>_3\NN\14299637 syndrome_4\NN\5870365 (_5\-LRB-\1740 cips_6\NN\1740 )_7\-RRB-\1740 is_8\VBZ\836236 a_9\DT\13649268 rare_10\JJ\1740 but_11\CC\1740 severe_12\JJ\1740 side_13\NN\8630039 effect_14\NN\34213 of_15\IN\1740 cyclosporine_16\NN\1740 or_17\CC\3541091 <e1>tacrolimus</e1>_18\NN\1740 and_19\CC\1740 is_20\VBZ\836236 accurately_21\RB\1740 diagnosed_22\VBN\644583 by_23\IN\1740 its_24\PRP$\6125041 typical_25\JJ\1740 presentation_26\NN\1027379 ,_27\,\1740 magnetic_28\JJ\1740 resonance_29\NN\11419404 imaging_30\NN\5765159 and_31\CC\1740 bone_32\NN\5286536 scans_33\NNS\635850 ._34\.\1740
D002118_D010146 NONE the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 cyclosporine-_3\NN\1740 or_4\CC\3541091 tacrolimus_5\NN\1740 trough_6\NN\9366017 levels_7\NNS\4916342 and_8\CC\1740 the_9\DT\1740 administration_10\NN\1133281 of_11\IN\1740 <e1>calcium</e1>_12\NN\14625458 channel_13\NN\6251781 blockers_14\NNS\10101634 led_15\VBD\1752884 to_16\TO\1740 relief_17\NN\7492516 of_18\IN\1740 <e2>pain</e2>_19\NN\14299637 ._20\.\1740
D016572_-1 NONE the_0\DT\1740 calcineurin-inhibitor_1\NN\1740 induced_2\VBD\1627355 pain_3\NN\14299637 syndrome_4\NN\5870365 (_5\-LRB-\1740 <e2>cips</e2>_6\NN\1740 )_7\-RRB-\1740 is_8\VBZ\836236 a_9\DT\13649268 rare_10\JJ\1740 but_11\CC\1740 severe_12\JJ\1740 side_13\NN\8630039 effect_14\NN\34213 of_15\IN\1740 <e1>cyclosporine</e1>_16\NN\1740 or_17\CC\3541091 tacrolimus_18\NN\1740 and_19\CC\1740 is_20\VBZ\836236 accurately_21\RB\1740 diagnosed_22\VBN\644583 by_23\IN\1740 its_24\PRP$\6125041 typical_25\JJ\1740 presentation_26\NN\1027379 ,_27\,\1740 magnetic_28\JJ\1740 resonance_29\NN\11419404 imaging_30\NN\5765159 and_31\CC\1740 bone_32\NN\5286536 scans_33\NNS\635850 ._34\.\1740
D016559_-1 NONE the_0\DT\1740 calcineurin-inhibitor_1\NN\1740 induced_2\VBD\1627355 pain_3\NN\14299637 syndrome_4\NN\5870365 (_5\-LRB-\1740 <e2>cips</e2>_6\NN\1740 )_7\-RRB-\1740 is_8\VBZ\836236 a_9\DT\13649268 rare_10\JJ\1740 but_11\CC\1740 severe_12\JJ\1740 side_13\NN\8630039 effect_14\NN\34213 of_15\IN\1740 cyclosporine_16\NN\1740 or_17\CC\3541091 <e1>tacrolimus</e1>_18\NN\1740 and_19\CC\1740 is_20\VBZ\836236 accurately_21\RB\1740 diagnosed_22\VBN\644583 by_23\IN\1740 its_24\PRP$\6125041 typical_25\JJ\1740 presentation_26\NN\1027379 ,_27\,\1740 magnetic_28\JJ\1740 resonance_29\NN\11419404 imaging_30\NN\5765159 and_31\CC\1740 bone_32\NN\5286536 scans_33\NNS\635850 ._34\.\1740
2572625
C084599_D056486 CID <e1>clotiazepam-induced</e1>_0\JJ\1740 acute_1\JJ\1740 <e2>hepatitis</e2>_2\NN\14127211 ._3\.\1740
C084599_D056486 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 who_7\WP\8299493 developed_8\VBD\1753788 acute_9\JJ\1740 <e2>hepatitis</e2>_10\NN\14127211 with_11\IN\1740 extensive_12\JJ\1740 hepatocellular_13\JJ\1740 necrosis_14\NN\11444117 ,_15\,\1740 7_16\CD\13741022 months_17\NNS\15113229 after_18\IN\1740 the_19\DT\1740 onset_20\NN\7325190 of_21\IN\1740 administration_22\NN\1133281 of_23\IN\1740 <e1>clotiazepam</e1>_24\NN\1740 ,_25\,\1740 a_26\DT\13649268 thienodiazepine_27\NN\1740 derivative_28\NN\5802185 ._29\.\1740
C084599_D056486 CID the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 several_3\JJ\1740 benzodiazepines_4\NNS\3771443 ,_5\,\1740 chemically_6\RB\1740 related_7\JJ\1740 to_8\TO\1740 <e1>clotiazepam</e1>_9\VB\1740 ,_10\,\1740 did_11\VBD\1640855 not_12\RB\1740 interfere_13\VB\2451370 with_14\IN\1740 recovery_15\NN\7357388 and_16\CC\1740 did_17\VBD\1640855 not_18\RB\1740 induce_19\VB\1627355 any_20\DT\1740 relapse_21\NN\66636 of_22\IN\1740 <e2>hepatitis</e2>_23\NN\14127211 ._24\.\1740
C084599_D056486 CID this_0\DT\1740 observation_1\NN\996969 shows_2\VBZ\2137132 that_3\WDT\1740 <e1>clotiazepam</e1>_4\NN\1740 can_5\MD\3094503 induce_6\VB\1627355 acute_7\JJ\1740 <e2>hepatitis</e2>_8\NN\14127211 and_9\CC\1740 suggests_10\VBZ\1010118 that_11\IN\1740 there_12\EX\27167 is_13\VBZ\836236 no_14\DT\7204911 cross_15\NN\4341686 hepatotoxicity_16\NN\1740 between_17\IN\1740 clotiazepam_18\NN\1740 and_19\CC\1740 several_20\JJ\1740 benzodiazepines_21\NNS\3771443 ._22\.\1740
C084599_D056486 CID this_0\DT\1740 observation_1\NN\996969 shows_2\VBZ\2137132 that_3\WDT\1740 <e1>clotiazepam</e1>_4\NN\1740 can_5\MD\3094503 induce_6\VB\1627355 acute_7\JJ\1740 hepatitis_8\NN\14127211 and_9\CC\1740 suggests_10\VBZ\1010118 that_11\IN\1740 there_12\EX\27167 is_13\VBZ\836236 no_14\DT\7204911 cross_15\NN\4341686 <e2>hepatotoxicity</e2>_16\NN\1740 between_17\IN\1740 clotiazepam_18\NN\1740 and_19\CC\1740 several_20\JJ\1740 benzodiazepines_21\NNS\3771443 ._22\.\1740
C084599_D056486 CID this_0\DT\1740 observation_1\NN\996969 shows_2\VBZ\2137132 that_3\WDT\1740 clotiazepam_4\NN\1740 can_5\MD\3094503 induce_6\VB\1627355 acute_7\JJ\1740 <e2>hepatitis</e2>_8\NN\14127211 and_9\CC\1740 suggests_10\VBZ\1010118 that_11\IN\1740 there_12\EX\27167 is_13\VBZ\836236 no_14\DT\7204911 cross_15\NN\4341686 hepatotoxicity_16\NN\1740 between_17\IN\1740 <e1>clotiazepam</e1>_18\NN\1740 and_19\CC\1740 several_20\JJ\1740 benzodiazepines_21\NNS\3771443 ._22\.\1740
C084599_D056486 CID this_0\DT\1740 observation_1\NN\996969 shows_2\VBZ\2137132 that_3\WDT\1740 clotiazepam_4\NN\1740 can_5\MD\3094503 induce_6\VB\1627355 acute_7\JJ\1740 hepatitis_8\NN\14127211 and_9\CC\1740 suggests_10\VBZ\1010118 that_11\IN\1740 there_12\EX\27167 is_13\VBZ\836236 no_14\DT\7204911 cross_15\NN\4341686 <e2>hepatotoxicity</e2>_16\NN\1740 between_17\IN\1740 <e1>clotiazepam</e1>_18\NN\1740 and_19\CC\1740 several_20\JJ\1740 benzodiazepines_21\NNS\3771443 ._22\.\1740
C084599_D047508 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 who_7\WP\8299493 developed_8\VBD\1753788 acute_9\JJ\1740 hepatitis_10\NN\14127211 with_11\IN\1740 <e2>extensive_12\JJ\1740 hepatocellular_13\JJ\1740 necrosis</e2>_14\NN\11444117 ,_15\,\1740 7_16\CD\13741022 months_17\NNS\15113229 after_18\IN\1740 the_19\DT\1740 onset_20\NN\7325190 of_21\IN\1740 administration_22\NN\1133281 of_23\IN\1740 <e1>clotiazepam</e1>_24\NN\1740 ,_25\,\1740 a_26\DT\13649268 thienodiazepine_27\NN\1740 derivative_28\NN\5802185 ._29\.\1740
C013295_D056486 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 who_7\WP\8299493 developed_8\VBD\1753788 acute_9\JJ\1740 <e2>hepatitis</e2>_10\NN\14127211 with_11\IN\1740 extensive_12\JJ\1740 hepatocellular_13\JJ\1740 necrosis_14\NN\11444117 ,_15\,\1740 7_16\CD\13741022 months_17\NNS\15113229 after_18\IN\1740 the_19\DT\1740 onset_20\NN\7325190 of_21\IN\1740 administration_22\NN\1133281 of_23\IN\1740 clotiazepam_24\NN\1740 ,_25\,\1740 a_26\DT\13649268 <e1>thienodiazepine</e1>_27\NN\1740 derivative_28\NN\5802185 ._29\.\1740
C013295_D047508 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 who_7\WP\8299493 developed_8\VBD\1753788 acute_9\JJ\1740 hepatitis_10\NN\14127211 with_11\IN\1740 <e2>extensive_12\JJ\1740 hepatocellular_13\JJ\1740 necrosis</e2>_14\NN\11444117 ,_15\,\1740 7_16\CD\13741022 months_17\NNS\15113229 after_18\IN\1740 the_19\DT\1740 onset_20\NN\7325190 of_21\IN\1740 administration_22\NN\1133281 of_23\IN\1740 clotiazepam_24\NN\1740 ,_25\,\1740 a_26\DT\13649268 <e1>thienodiazepine</e1>_27\NN\1740 derivative_28\NN\5802185 ._29\.\1740
D001569_D056486 NONE the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 several_3\JJ\1740 <e1>benzodiazepines</e1>_4\NNS\3771443 ,_5\,\1740 chemically_6\RB\1740 related_7\JJ\1740 to_8\TO\1740 clotiazepam_9\VB\1740 ,_10\,\1740 did_11\VBD\1640855 not_12\RB\1740 interfere_13\VB\2451370 with_14\IN\1740 recovery_15\NN\7357388 and_16\CC\1740 did_17\VBD\1640855 not_18\RB\1740 induce_19\VB\1627355 any_20\DT\1740 relapse_21\NN\66636 of_22\IN\1740 <e2>hepatitis</e2>_23\NN\14127211 ._24\.\1740
D001569_D056486 NONE this_0\DT\1740 observation_1\NN\996969 shows_2\VBZ\2137132 that_3\WDT\1740 clotiazepam_4\NN\1740 can_5\MD\3094503 induce_6\VB\1627355 acute_7\JJ\1740 <e2>hepatitis</e2>_8\NN\14127211 and_9\CC\1740 suggests_10\VBZ\1010118 that_11\IN\1740 there_12\EX\27167 is_13\VBZ\836236 no_14\DT\7204911 cross_15\NN\4341686 hepatotoxicity_16\NN\1740 between_17\IN\1740 clotiazepam_18\NN\1740 and_19\CC\1740 several_20\JJ\1740 <e1>benzodiazepines</e1>_21\NNS\3771443 ._22\.\1740
D001569_D056486 NONE this_0\DT\1740 observation_1\NN\996969 shows_2\VBZ\2137132 that_3\WDT\1740 clotiazepam_4\NN\1740 can_5\MD\3094503 induce_6\VB\1627355 acute_7\JJ\1740 hepatitis_8\NN\14127211 and_9\CC\1740 suggests_10\VBZ\1010118 that_11\IN\1740 there_12\EX\27167 is_13\VBZ\836236 no_14\DT\7204911 cross_15\NN\4341686 <e2>hepatotoxicity</e2>_16\NN\1740 between_17\IN\1740 clotiazepam_18\NN\1740 and_19\CC\1740 several_20\JJ\1740 <e1>benzodiazepines</e1>_21\NNS\3771443 ._22\.\1740
10406016
C007789_D002543 NONE effect_0\NN\34213 of_1\IN\1740 <e1>fucoidan</e1>_2\JJ\1740 treatment_3\NN\654885 on_4\IN\1740 collagenase-induced_5\JJ\1740 <e2>intracerebral_6\JJ\1740 hemorrhage</e2>_7\NN\14285662 in_8\IN\13603305 rats_9\NNS\2329401 ._10\.\1740
C007789_D002543 NONE we_0\PRP\1740 tested_1\VBD\670261 the_2\DT\1740 sulfated_3\VBN\115157 polysaccharide_4\NN\14792703 <e1>fucoidan</e1>_5\JJ\1740 ,_6\,\1740 which_7\WDT\1740 has_8\VBZ\2108377 been_9\VBN\836236 reported_10\VBN\831651 to_11\TO\1740 reduce_12\VB\441445 inflammatory_13\JJ\1740 brain_14\NN\5462674 damage_15\NN\7296428 ,_16\,\1740 in_17\IN\13603305 a_18\DT\13649268 rat_19\NN\2329401 model_20\NN\5888929 of_21\IN\1740 <e2>intracerebral_22\JJ\1740 hemorrhage</e2>_23\NN\14285662 induced_24\VBN\1627355 by_25\IN\1740 injection_26\NN\320852 of_27\IN\1740 bacterial_28\JJ\1740 collagenase_29\NN\14732946 into_30\IN\1740 the_31\DT\1740 caudate_32\NN\5497363 nucleus_33\NN\5445668 ._34\.\1740
C007789_D001925 NONE we_0\PRP\1740 tested_1\VBD\670261 the_2\DT\1740 sulfated_3\VBN\115157 polysaccharide_4\NN\14792703 <e1>fucoidan</e1>_5\JJ\1740 ,_6\,\1740 which_7\WDT\1740 has_8\VBZ\2108377 been_9\VBN\836236 reported_10\VBN\831651 to_11\TO\1740 reduce_12\VB\441445 inflammatory_13\JJ\1740 <e2>brain_14\NN\5462674 damage</e2>_15\NN\7296428 ,_16\,\1740 in_17\IN\13603305 a_18\DT\13649268 rat_19\NN\2329401 model_20\NN\5888929 of_21\IN\1740 intracerebral_22\JJ\1740 hemorrhage_23\NN\14285662 induced_24\VBN\1627355 by_25\IN\1740 injection_26\NN\320852 of_27\IN\1740 bacterial_28\JJ\1740 collagenase_29\NN\14732946 into_30\IN\1740 the_31\DT\1740 caudate_32\NN\5497363 nucleus_33\NN\5445668 ._34\.\1740
C007789_D020141 CID <e1>fucoidan-treated</e1>_0\JJ\1740 rats_1\NNS\2329401 exhibited_2\VBD\2632167 evidence_3\NN\5816287 of_4\IN\1740 <e2>impaired_5\JJ\1740 blood_6\NN\5397468 clotting</e2>_7\NN\13518963 and_8\CC\1740 hemodilution_9\NN\1740 ,_10\,\1740 had_11\VBD\2108377 larger_12\JJR\1740 hematomas_13\NNS\14317720 ,_14\,\1740 and_15\CC\1740 tended_16\VBD\2604760 to_17\TO\1740 have_18\VB\2108377 less_19\JJR\1740 inflammation_20\NN\14299637 in_21\IN\13603305 the_22\DT\1740 vicinity_23\NN\8648322 of_24\IN\1740 the_25\DT\1740 hematoma_26\NN\14317720 after_27\IN\1740 three_28\CD\13741022 days_29\NNS\15140892 ._30\.\1740
C007789_D020141 CID <e1>fucoidan-treated</e1>_0\JJ\1740 rats_1\NNS\2329401 exhibited_2\VBD\2632167 evidence_3\NN\5816287 of_4\IN\1740 impaired_5\JJ\1740 blood_6\NN\5397468 clotting_7\NN\13518963 and_8\CC\1740 <e2>hemodilution</e2>_9\NN\1740 ,_10\,\1740 had_11\VBD\2108377 larger_12\JJR\1740 hematomas_13\NNS\14317720 ,_14\,\1740 and_15\CC\1740 tended_16\VBD\2604760 to_17\TO\1740 have_18\VB\2108377 less_19\JJR\1740 inflammation_20\NN\14299637 in_21\IN\13603305 the_22\DT\1740 vicinity_23\NN\8648322 of_24\IN\1740 the_25\DT\1740 hematoma_26\NN\14317720 after_27\IN\1740 three_28\CD\13741022 days_29\NNS\15140892 ._30\.\1740
C007789_D006406 NONE <e1>fucoidan-treated</e1>_0\JJ\1740 rats_1\NNS\2329401 exhibited_2\VBD\2632167 evidence_3\NN\5816287 of_4\IN\1740 impaired_5\JJ\1740 blood_6\NN\5397468 clotting_7\NN\13518963 and_8\CC\1740 hemodilution_9\NN\1740 ,_10\,\1740 had_11\VBD\2108377 larger_12\JJR\1740 <e2>hematomas</e2>_13\NNS\14317720 ,_14\,\1740 and_15\CC\1740 tended_16\VBD\2604760 to_17\TO\1740 have_18\VB\2108377 less_19\JJR\1740 inflammation_20\NN\14299637 in_21\IN\13603305 the_22\DT\1740 vicinity_23\NN\8648322 of_24\IN\1740 the_25\DT\1740 hematoma_26\NN\14317720 after_27\IN\1740 three_28\CD\13741022 days_29\NNS\15140892 ._30\.\1740
C007789_D006406 NONE <e1>fucoidan-treated</e1>_0\JJ\1740 rats_1\NNS\2329401 exhibited_2\VBD\2632167 evidence_3\NN\5816287 of_4\IN\1740 impaired_5\JJ\1740 blood_6\NN\5397468 clotting_7\NN\13518963 and_8\CC\1740 hemodilution_9\NN\1740 ,_10\,\1740 had_11\VBD\2108377 larger_12\JJR\1740 hematomas_13\NNS\14317720 ,_14\,\1740 and_15\CC\1740 tended_16\VBD\2604760 to_17\TO\1740 have_18\VB\2108377 less_19\JJR\1740 inflammation_20\NN\14299637 in_21\IN\13603305 the_22\DT\1740 vicinity_23\NN\8648322 of_24\IN\1740 the_25\DT\1740 <e2>hematoma</e2>_26\NN\14317720 after_27\IN\1740 three_28\CD\13741022 days_29\NNS\15140892 ._30\.\1740
C007789_D007249 NONE <e1>fucoidan-treated</e1>_0\JJ\1740 rats_1\NNS\2329401 exhibited_2\VBD\2632167 evidence_3\NN\5816287 of_4\IN\1740 impaired_5\JJ\1740 blood_6\NN\5397468 clotting_7\NN\13518963 and_8\CC\1740 hemodilution_9\NN\1740 ,_10\,\1740 had_11\VBD\2108377 larger_12\JJR\1740 hematomas_13\NNS\14317720 ,_14\,\1740 and_15\CC\1740 tended_16\VBD\2604760 to_17\TO\1740 have_18\VB\2108377 less_19\JJR\1740 <e2>inflammation</e2>_20\NN\14299637 in_21\IN\13603305 the_22\DT\1740 vicinity_23\NN\8648322 of_24\IN\1740 the_25\DT\1740 hematoma_26\NN\14317720 after_27\IN\1740 three_28\CD\13741022 days_29\NNS\15140892 ._30\.\1740
12820454
D016729_D000740 CID all_0\DT\1740 patients_1\NNS\9898892 received_2\VBD\2210855 cab_3\NN\3079741 [_4\-LRB-\1740 <e1>leuprolide_5\NN\1740 acetate</e1>_6\NN\15010703 (_7\-LRB-\1740 lhrh-a_8\NN\1740 )_9\-RRB-\1740 3.75_10\CD\1740 mg_11\NN\13717155 ,_12\,\1740 intramuscularly_13\RB\1740 ,_14\,\1740 every_15\DT\1740 28_16\CD\13745420 days_17\NNS\15140892 plus_18\CC\4723816 250_19\CD\1740 mg_20\NN\13717155 flutamide_21\NN\1740 ,_22\,\1740 tid_23\NN\1740 ,_24\,\1740 per_25\IN\1740 os_26\NNP\5249636 ]_27\-RRB-\1740 and_28\CC\1740 were_29\VBD\836236 evaluated_30\VBN\670261 for_31\IN\1740 <e2>anemia</e2>_32\NN\14189204 by_33\IN\1740 physical_34\JJ\1740 examination_35\NN\633864 and_36\CC\1740 laboratory_37\NN\4602044 tests_38\NNS\5798043 at_39\IN\14622893 baseline_40\NN\7260623 and_41\CC\1740 4_42\CD\13741022 subsequent_43\JJ\1740 intervals_44\NNS\33615 (_45\-LRB-\1740 1_46\CD\13741022 ,_47\,\1740 2_48\CD\13741022 ,_49\,\1740 3_50\CD\13741022 and_51\CC\1740 6_52\CD\13741022 months_53\NNS\15113229 post-cab_54\NN\1740 )_55\-RRB-\1740 ._56\.\1740
D016729_D000740 CID all_0\DT\1740 patients_1\NNS\9898892 received_2\VBD\2210855 cab_3\NN\3079741 [_4\-LRB-\1740 leuprolide_5\NN\1740 acetate_6\NN\15010703 (_7\-LRB-\1740 <e1>lhrh-a</e1>_8\NN\1740 )_9\-RRB-\1740 3.75_10\CD\1740 mg_11\NN\13717155 ,_12\,\1740 intramuscularly_13\RB\1740 ,_14\,\1740 every_15\DT\1740 28_16\CD\13745420 days_17\NNS\15140892 plus_18\CC\4723816 250_19\CD\1740 mg_20\NN\13717155 flutamide_21\NN\1740 ,_22\,\1740 tid_23\NN\1740 ,_24\,\1740 per_25\IN\1740 os_26\NNP\5249636 ]_27\-RRB-\1740 and_28\CC\1740 were_29\VBD\836236 evaluated_30\VBN\670261 for_31\IN\1740 <e2>anemia</e2>_32\NN\14189204 by_33\IN\1740 physical_34\JJ\1740 examination_35\NN\633864 and_36\CC\1740 laboratory_37\NN\4602044 tests_38\NNS\5798043 at_39\IN\14622893 baseline_40\NN\7260623 and_41\CC\1740 4_42\CD\13741022 subsequent_43\JJ\1740 intervals_44\NNS\33615 (_45\-LRB-\1740 1_46\CD\13741022 ,_47\,\1740 2_48\CD\13741022 ,_49\,\1740 3_50\CD\13741022 and_51\CC\1740 6_52\CD\13741022 months_53\NNS\15113229 post-cab_54\NN\1740 )_55\-RRB-\1740 ._56\.\1740
D005485_D000740 CID all_0\DT\1740 patients_1\NNS\9898892 received_2\VBD\2210855 cab_3\NN\3079741 [_4\-LRB-\1740 leuprolide_5\NN\1740 acetate_6\NN\15010703 (_7\-LRB-\1740 lhrh-a_8\NN\1740 )_9\-RRB-\1740 3.75_10\CD\1740 mg_11\NN\13717155 ,_12\,\1740 intramuscularly_13\RB\1740 ,_14\,\1740 every_15\DT\1740 28_16\CD\13745420 days_17\NNS\15140892 plus_18\CC\4723816 250_19\CD\1740 mg_20\NN\13717155 <e1>flutamide</e1>_21\NN\1740 ,_22\,\1740 tid_23\NN\1740 ,_24\,\1740 per_25\IN\1740 os_26\NNP\5249636 ]_27\-RRB-\1740 and_28\CC\1740 were_29\VBD\836236 evaluated_30\VBN\670261 for_31\IN\1740 <e2>anemia</e2>_32\NN\14189204 by_33\IN\1740 physical_34\JJ\1740 examination_35\NN\633864 and_36\CC\1740 laboratory_37\NN\4602044 tests_38\NNS\5798043 at_39\IN\14622893 baseline_40\NN\7260623 and_41\CC\1740 4_42\CD\13741022 subsequent_43\JJ\1740 intervals_44\NNS\33615 (_45\-LRB-\1740 1_46\CD\13741022 ,_47\,\1740 2_48\CD\13741022 ,_49\,\1740 3_50\CD\13741022 and_51\CC\1740 6_52\CD\13741022 months_53\NNS\15113229 post-cab_54\NN\1740 )_55\-RRB-\1740 ._56\.\1740
2476560
D001556_D012532 NONE treatment_0\NN\654885 for_1\IN\1740 <e2>scabies</e2>_2\NNS\14174549 is_3\VBZ\836236 usually_4\RB\1740 initiated_5\VBN\1617192 by_6\IN\1740 general_7\JJ\1740 practitioners_8\NNS\10480253 ;_9\:\1740 most_10\JJS\1740 consider_11\VB\689344 <e1>lindane</e1>_12\NN\14919948 (_13\-LRB-\1740 gamma_14\NN\6828818 benzene_15\NN\14767996 hexachloride_16\NN\1740 )_17\-RRB-\1740 the_18\DT\1740 treatment_19\NN\654885 of_20\IN\1740 choice_21\NN\5788149 ._22\.\1740
D001556_D012532 NONE treatment_0\NN\654885 for_1\IN\1740 <e2>scabies</e2>_2\NNS\14174549 is_3\VBZ\836236 usually_4\RB\1740 initiated_5\VBN\1617192 by_6\IN\1740 general_7\JJ\1740 practitioners_8\NNS\10480253 ;_9\:\1740 most_10\JJS\1740 consider_11\VB\689344 lindane_12\NN\14919948 (_13\-LRB-\1740 <e1>gamma_14\NN\6828818 benzene_15\NN\14767996 hexachloride</e1>_16\NN\1740 )_17\-RRB-\1740 the_18\DT\1740 treatment_19\NN\654885 of_20\IN\1740 choice_21\NN\5788149 ._22\.\1740
D001556_D002493 CID evidence_0\NN\5816287 is_1\VBZ\836236 accumulating_2\VBG\2281093 that_3\DT\1740 <e1>lindane</e1>_4\NN\14919948 can_5\MD\3094503 be_6\VB\836236 <e2>toxic_7\JJ\1740 to_8\TO\1740 the_9\DT\1740 central_10\JJ\1740 nervous_11\JJ\1740 system</e2>_12\NN\3575240 and_13\CC\1740 may_14\MD\15209706 be_15\VB\836236 associated_16\VBN\628491 with_17\IN\1740 aplastic_18\JJ\1740 anaemia_19\NN\14299637 ._20\.\1740
D001556_D000741 CID evidence_0\NN\5816287 is_1\VBZ\836236 accumulating_2\VBG\2281093 that_3\DT\1740 <e1>lindane</e1>_4\NN\14919948 can_5\MD\3094503 be_6\VB\836236 toxic_7\JJ\1740 to_8\TO\1740 the_9\DT\1740 central_10\JJ\1740 nervous_11\JJ\1740 system_12\NN\3575240 and_13\CC\1740 may_14\MD\15209706 be_15\VB\836236 associated_16\VBN\628491 with_17\IN\1740 <e2>aplastic_18\JJ\1740 anaemia</e2>_19\NN\14299637 ._20\.\1740
3560096
D013467_D006947 CID <e2>hyperkalemia</e2>_0\NN\14299637 associated_1\VBN\628491 with_2\IN\1740 <e1>sulindac</e1>_3\NN\3828465 therapy_4\NN\657604 ._5\.\1740
D013467_D006947 CID we_0\PRP\1740 describe_1\VBP\1001294 4_2\CD\13741022 patients_3\NNS\9898892 in_4\IN\13603305 whom_5\WP\1740 <e2>hyperkalemia</e2>_6\NN\14299637 ranging_7\VBG\2604760 from_8\IN\1740 6.1_9\CD\1740 to_10\TO\1740 6.9_11\CD\1740 meq/l_12\NN\1740 developed_13\VBD\1753788 within_14\IN\1740 3_15\CD\13741022 to_16\TO\1740 8_17\CD\13741022 days_18\NNS\15140892 of_19\IN\1740 <e1>sulindac</e1>_20\NN\3828465 administration_21\NN\1133281 ._22\.\1740
D013467_D006947 CID as_0\IN\14622893 no_1\DT\7204911 other_2\JJ\1740 medications_3\NNS\3247620 known_4\VBN\2110220 to_5\TO\1740 effect_6\NN\34213 serum_7\NN\5397468 potassium_8\NN\14625458 had_9\VBD\2108377 been_10\VBN\836236 given_11\VBN\2327200 concomitantly_12\RB\1740 ,_13\,\1740 this_14\DT\1740 course_15\NN\883297 of_16\IN\1740 events_17\NNS\23100 is_18\VBZ\836236 suggestive_19\JJ\1740 of_20\IN\1740 a_21\DT\13649268 cause-and-effect_22\JJ\1740 relationship_23\NN\31921 between_24\IN\1740 <e1>sulindac</e1>_25\NN\3828465 and_26\CC\1740 <e2>hyperkalemia</e2>_27\NN\14299637 ._28\.\1740
D007213_D006947 CID <e2>hyperkalemia</e2>_0\NN\14299637 has_1\VBZ\2108377 recently_2\RB\1740 been_3\VBN\836236 recognized_4\VBN\686447 as_5\IN\14622893 a_6\DT\13649268 complication_7\NN\1073995 of_8\IN\1740 nonsteroidal_9\JJ\1740 antiinflammatory_10\JJ\1740 agents_11\NNS\7347 (_12\-LRB-\1740 nsaid_13\NN\2721538 )_14\-RRB-\1740 such_15\JJ\1740 as_16\IN\14622893 <e1>indomethacin</e1>_17\NN\3828465 ._18\.\1740
D011188_D006947 NONE as_0\IN\14622893 no_1\DT\7204911 other_2\JJ\1740 medications_3\NNS\3247620 known_4\VBN\2110220 to_5\TO\1740 effect_6\NN\34213 serum_7\NN\5397468 <e1>potassium</e1>_8\NN\14625458 had_9\VBD\2108377 been_10\VBN\836236 given_11\VBN\2327200 concomitantly_12\RB\1740 ,_13\,\1740 this_14\DT\1740 course_15\NN\883297 of_16\IN\1740 events_17\NNS\23100 is_18\VBZ\836236 suggestive_19\JJ\1740 of_20\IN\1740 a_21\DT\13649268 cause-and-effect_22\JJ\1740 relationship_23\NN\31921 between_24\IN\1740 sulindac_25\NN\3828465 and_26\CC\1740 <e2>hyperkalemia</e2>_27\NN\14299637 ._28\.\1740
1009330
C004658_D003556 NONE the_0\DT\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 the_5\DT\1740 degradation_6\NN\199130 product_7\NN\3076708 <e1>p-choloroaniline</e1>_8\NN\1740 is_9\VBZ\836236 not_10\RB\1740 a_11\DT\13649268 significant_12\JJ\1740 factor_13\NN\7326557 in_14\IN\13603305 chlorhexidine-digluconate_15\JJ\1740 associated_16\JJ\1740 erosive_17\JJ\1740 <e2>cystitis</e2>_18\NN\14566129 ._19\.\1740
C010882_D003556 CID the_0\DT\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 the_5\DT\1740 degradation_6\NN\199130 product_7\NN\3076708 p-choloroaniline_8\NN\1740 is_9\VBZ\836236 not_10\RB\1740 a_11\DT\13649268 significant_12\JJ\1740 factor_13\NN\7326557 in_14\IN\13603305 <e1>chlorhexidine-digluconate</e1>_15\JJ\1740 associated_16\JJ\1740 erosive_17\JJ\1740 <e2>cystitis</e2>_18\NN\14566129 ._19\.\1740
D007612_D003556 CID a_0\DT\13649268 high_1\JJ\1740 percentage_2\NN\13815742 of_3\IN\1740 <e1>kanamycin-colistin</e1>_4\JJ\1740 and_5\CC\1740 povidone-iodine_6\JJ\1740 irrigations_7\NNS\1057200 were_8\VBD\836236 associated_9\VBN\628491 with_10\IN\1740 erosive_11\JJ\1740 <e2>cystitis</e2>_12\NN\14566129 and_13\CC\1740 suggested_14\VBD\1010118 a_15\DT\13649268 possible_16\JJ\1740 complication_17\NN\1073995 with_18\IN\1740 human_19\JJ\1740 usage_20\NN\407535 ._21\.\1740
D003091_D003556 CID a_0\DT\13649268 high_1\JJ\1740 percentage_2\NN\13815742 of_3\IN\1740 <e1>kanamycin-colistin</e1>_4\JJ\1740 and_5\CC\1740 povidone-iodine_6\JJ\1740 irrigations_7\NNS\1057200 were_8\VBD\836236 associated_9\VBN\628491 with_10\IN\1740 erosive_11\JJ\1740 <e2>cystitis</e2>_12\NN\14566129 and_13\CC\1740 suggested_14\VBD\1010118 a_15\DT\13649268 possible_16\JJ\1740 complication_17\NN\1073995 with_18\IN\1740 human_19\JJ\1740 usage_20\NN\407535 ._21\.\1740
D011206_D003556 CID a_0\DT\13649268 high_1\JJ\1740 percentage_2\NN\13815742 of_3\IN\1740 kanamycin-colistin_4\JJ\1740 and_5\CC\1740 <e1>povidone-iodine</e1>_6\JJ\1740 irrigations_7\NNS\1057200 were_8\VBD\836236 associated_9\VBN\628491 with_10\IN\1740 erosive_11\JJ\1740 <e2>cystitis</e2>_12\NN\14566129 and_13\CC\1740 suggested_14\VBD\1010118 a_15\DT\13649268 possible_16\JJ\1740 complication_17\NN\1073995 with_18\IN\1740 human_19\JJ\1740 usage_20\NN\407535 ._21\.\1740
C005253_D003556 NONE <e1>picloxydine</e1>_0\NN\1740 irrigations_1\NNS\1057200 appeared_2\VBD\2604760 to_3\TO\1740 have_4\VB\2108377 a_5\DT\13649268 lower_6\JJR\1740 incidence_7\NN\13821570 of_8\IN\1740 erosive_9\JJ\1740 <e2>cystitis</e2>_10\NN\14566129 but_11\CC\1740 further_12\JJ\1740 studies_13\NNS\635850 would_14\MD\1740 have_15\VB\2108377 to_16\TO\1740 be_17\VB\836236 performed_18\VBN\2367363 before_19\IN\1740 it_20\PRP\6125041 could_21\MD\1740 be_22\VB\836236 recommended_23\VBN\875394 for_24\IN\1740 use_25\NN\407535 in_26\IN\13603305 urological_27\JJ\1740 procedures_28\NNS\407535 ._29\.\1740
19387625
D002211_D010146 NONE attentional_0\JJ\1740 modulation_1\NN\7044917 of_2\IN\1740 perceived_3\VBN\591115 <e2>pain</e2>_4\NN\14299637 intensity_5\NN\5090441 in_6\IN\13603305 <e1>capsaicin-induced</e1>_7\JJ\1740 secondary_8\JJ\1740 hyperalgesia_9\NN\1740 ._10\.\1740
D002211_D010146 NONE however_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 is_3\VBZ\836236 not_4\RB\1740 known_5\VBN\2110220 that_6\IN\1740 how_7\WRB\1740 <e2>pain</e2>_8\NN\14299637 intensity_9\NN\5090441 ratings_10\NNS\5733583 are_11\VBP\836236 affected_12\VBN\126264 by_13\IN\1740 attention_14\NN\5701944 in_15\IN\13603305 <e1>capsaicin-induced</e1>_16\JJ\1740 secondary_17\JJ\1740 hyperalgesia_18\NN\1740 ._19\.\1740
D002211_D010146 NONE our_0\PRP$\1740 findings_1\NNS\7951464 ,_2\,\1740 showing_3\VBG\2137132 no_4\DT\7204911 interaction_5\NN\37396 between_6\IN\1740 <e1>capsaicin</e1>_7\NN\15032661 treatment_8\NN\654885 and_9\CC\1740 attentional_10\JJ\1740 modulation_11\NN\7044917 suggest_12\VBP\1010118 that_13\IN\1740 capsaicin-induced_14\JJ\1740 secondary_15\JJ\1740 hyperalgesia_16\NN\1740 and_17\CC\1740 attention_18\NN\5701944 might_19\MD\5029706 affect_20\VB\126264 mechanical_21\JJ\1740 <e2>pain</e2>_22\NN\14299637 through_23\IN\1740 independent_24\JJ\1740 mechanisms_25\NNS\13446390 ._26\.\1740
D002211_D010146 NONE our_0\PRP$\1740 findings_1\NNS\7951464 ,_2\,\1740 showing_3\VBG\2137132 no_4\DT\7204911 interaction_5\NN\37396 between_6\IN\1740 capsaicin_7\NN\15032661 treatment_8\NN\654885 and_9\CC\1740 attentional_10\JJ\1740 modulation_11\NN\7044917 suggest_12\VBP\1010118 that_13\IN\1740 <e1>capsaicin-induced</e1>_14\JJ\1740 secondary_15\JJ\1740 hyperalgesia_16\NN\1740 and_17\CC\1740 attention_18\NN\5701944 might_19\MD\5029706 affect_20\VB\126264 mechanical_21\JJ\1740 <e2>pain</e2>_22\NN\14299637 through_23\IN\1740 independent_24\JJ\1740 mechanisms_25\NNS\13446390 ._26\.\1740
D002211_D006930 CID attentional_0\JJ\1740 modulation_1\NN\7044917 of_2\IN\1740 perceived_3\VBN\591115 pain_4\NN\14299637 intensity_5\NN\5090441 in_6\IN\13603305 <e1>capsaicin-induced</e1>_7\JJ\1740 secondary_8\JJ\1740 <e2>hyperalgesia</e2>_9\NN\1740 ._10\.\1740
D002211_D006930 CID however_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 is_3\VBZ\836236 not_4\RB\1740 known_5\VBN\2110220 that_6\IN\1740 how_7\WRB\1740 pain_8\NN\14299637 intensity_9\NN\5090441 ratings_10\NNS\5733583 are_11\VBP\836236 affected_12\VBN\126264 by_13\IN\1740 attention_14\NN\5701944 in_15\IN\13603305 <e1>capsaicin-induced</e1>_16\JJ\1740 secondary_17\JJ\1740 <e2>hyperalgesia</e2>_18\NN\1740 ._19\.\1740
D002211_D006930 CID furthermore_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 was_3\VBD\836236 found_4\VBN\2426171 that_5\IN\1740 the_6\DT\1740 magnitude_7\NN\4916342 of_8\IN\1740 attentional_9\JJ\1740 modulation_10\NN\7044917 in_11\IN\13603305 secondary_12\JJ\1740 <e2>hyperalgesia</e2>_13\NN\1740 is_14\VBZ\836236 very_15\RB\1740 similar_16\JJ\1740 to_17\TO\1740 that_18\DT\1740 of_19\IN\1740 <e1>capsaicin-untreated</e1>_20\JJ\1740 ,_21\,\1740 control_22\NN\5190804 condition_23\NN\24720 ._24\.\1740
D002211_D006930 CID our_0\PRP$\1740 findings_1\NNS\7951464 ,_2\,\1740 showing_3\VBG\2137132 no_4\DT\7204911 interaction_5\NN\37396 between_6\IN\1740 <e1>capsaicin</e1>_7\NN\15032661 treatment_8\NN\654885 and_9\CC\1740 attentional_10\JJ\1740 modulation_11\NN\7044917 suggest_12\VBP\1010118 that_13\IN\1740 capsaicin-induced_14\JJ\1740 secondary_15\JJ\1740 <e2>hyperalgesia</e2>_16\NN\1740 and_17\CC\1740 attention_18\NN\5701944 might_19\MD\5029706 affect_20\VB\126264 mechanical_21\JJ\1740 pain_22\NN\14299637 through_23\IN\1740 independent_24\JJ\1740 mechanisms_25\NNS\13446390 ._26\.\1740
D002211_D006930 CID our_0\PRP$\1740 findings_1\NNS\7951464 ,_2\,\1740 showing_3\VBG\2137132 no_4\DT\7204911 interaction_5\NN\37396 between_6\IN\1740 capsaicin_7\NN\15032661 treatment_8\NN\654885 and_9\CC\1740 attentional_10\JJ\1740 modulation_11\NN\7044917 suggest_12\VBP\1010118 that_13\IN\1740 <e1>capsaicin-induced</e1>_14\JJ\1740 secondary_15\JJ\1740 <e2>hyperalgesia</e2>_16\NN\1740 and_17\CC\1740 attention_18\NN\5701944 might_19\MD\5029706 affect_20\VB\126264 mechanical_21\JJ\1740 pain_22\NN\14299637 through_23\IN\1740 independent_24\JJ\1740 mechanisms_25\NNS\13446390 ._26\.\1740
18821488
C080436_D064420 NONE <e2>toxicity</e2>_0\NN\13576101 in_1\IN\13603305 rhesus_2\NN\2487347 monkeys_3\NNS\2469914 following_4\VBG\1835496 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 <e1>8-aminoquinoline</e1>_8\NN\1740 8-[(4-amino-l-methylbutyl)amino]-_9\JJ\1740 5-(l-hexyloxy)-6-methoxy-4-methylquinoline_10\NN\1740 (_11\-LRB-\1740 wr242511_12\NN\1740 )_13\-RRB-\1740 ._14\.\1740
C068820_D064420 NONE <e2>toxicity</e2>_0\NN\13576101 in_1\IN\13603305 rhesus_2\NN\2487347 monkeys_3\NNS\2469914 following_4\VBG\1835496 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 8-aminoquinoline_8\NN\1740 <e1>8-[(4-amino-l-methylbutyl)amino]-_9\JJ\1740 5-(l-hexyloxy)-6-methoxy-4-methylquinoline</e1>_10\NN\1740 (_11\-LRB-\1740 wr242511_12\NN\1740 )_13\-RRB-\1740 ._14\.\1740
C068820_D064420 NONE <e2>toxicity</e2>_0\NN\13576101 in_1\IN\13603305 rhesus_2\NN\2487347 monkeys_3\NNS\2469914 following_4\VBG\1835496 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 8-aminoquinoline_8\NN\1740 8-[(4-amino-l-methylbutyl)amino]-_9\JJ\1740 5-(l-hexyloxy)-6-methoxy-4-methylquinoline_10\NN\1740 (_11\-LRB-\1740 <e1>wr242511</e1>_12\NN\1740 )_13\-RRB-\1740 ._14\.\1740
C068820_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 <e1>wr242511</e1>_4\NN\1740 should_5\MD\1740 not_6\RB\1740 be_7\VB\836236 pursued_8\VBN\2367363 as_9\IN\14622893 a_10\DT\13649268 pretreatment_11\NN\1740 for_12\IN\1740 cn_13\NN\1740 poisoning_14\NN\14034177 unless_15\IN\1740 the_16\DT\1740 anti-cn_17\JJ\1740 characteristics_18\NNS\5849040 of_19\IN\1740 this_20\DT\1740 compound_21\NN\5869584 can_22\MD\3094503 be_23\VB\836236 successfully_24\RB\1740 dissociated_25\VBN\2431320 from_26\IN\1740 those_27\DT\1740 producing_28\VBG\1617192 undesirable_29\JJ\1740 <e2>toxicity</e2>_30\NN\13576101 ._31\.\1740
C068820_D008708 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 selected_3\VBN\697589 doses_4\NNS\3740161 of_5\IN\1740 <e1>wr242511</e1>_6\NN\1740 ,_7\,\1740 which_8\WDT\1740 produced_9\VBD\1617192 significant_10\JJ\1740 <e2>methemoglobinemia</e2>_11\NN\1740 in_12\IN\13603305 beagle_13\JJ\1740 dogs_14\NNS\2083346 in_15\IN\13603305 earlier_16\JJR\1740 studies_17\NNS\635850 conducted_18\VBN\2436349 elsewhere_19\RB\1740 ,_20\,\1740 produced_21\VBD\1617192 very_22\RB\1740 little_23\JJ\1740 mhb_24\NN\1740 (_25\-LRB-\1740 mean_26\NN\6021761 <_27\XX\1740 2.0_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 in_31\IN\13603305 the_32\DT\1740 rhesus_33\NN\2487347 monkey_34\NN\2469914 ._35\.\1740
C068820_D006456 CID furthermore_0\RB\1740 ,_1\,\1740 transient_2\JJ\1740 <e2>hemoglobinuria</e2>_3\NN\14299637 was_4\VBD\836236 noted_5\VBN\1009240 approximately_6\RB\1740 60_7\CD\13745420 minutes_8\NNS\6502378 postinjection_9\NN\1740 of_10\IN\1740 <e1>wr242511</e1>_11\NN\1740 (_12\-LRB-\1740 3.5_13\CD\1740 or_14\CC\3541091 7.0_15\CD\1740 mg/kg_16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 and_19\CC\1740 2_20\CD\13741022 lethalities_21\NNS\4790449 occurred_22\VBD\2623529 (_23\-LRB-\1740 one_24\CD\13741022 iv_25\CD\13741022 and_26\CC\1740 one_27\CD\13741022 po_28\NN\14625458 )_29\-RRB-\1740 following_30\VBG\1835496 the_31\DT\1740 7.0_32\CD\1740 mg/kg_33\NN\1740 dose_34\NN\3740161 ._35\.\1740
C068820_D011041 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 <e1>wr242511</e1>_4\NN\1740 should_5\MD\1740 not_6\RB\1740 be_7\VB\836236 pursued_8\VBN\2367363 as_9\IN\14622893 a_10\DT\13649268 pretreatment_11\NN\1740 for_12\IN\1740 cn_13\NN\1740 <e2>poisoning</e2>_14\NN\14034177 unless_15\IN\1740 the_16\DT\1740 anti-cn_17\JJ\1740 characteristics_18\NNS\5849040 of_19\IN\1740 this_20\DT\1740 compound_21\NN\5869584 can_22\MD\3094503 be_23\VB\836236 successfully_24\RB\1740 dissociated_25\VBN\2431320 from_26\IN\1740 those_27\DT\1740 producing_28\VBG\1617192 undesirable_29\JJ\1740 toxicity_30\NN\13576101 ._31\.\1740
3782049
D008972_D012206 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 massive_3\JJ\1740 <e2>rhabdomyolysis</e2>_4\NN\1740 following_5\VBG\1835496 <e1>molindone</e1>_6\NN\3713736 administration_7\NN\1133281 ._8\.\1740
D008972_D012206 CID the_0\DT\1740 case_1\NN\7283608 of_2\IN\1740 a_3\DT\13649268 schizophrenic_4\JJ\1740 patient_5\NN\9898892 is_6\VBZ\836236 reported_7\VBN\831651 to_8\TO\1740 illustrate_9\VB\955601 massive_10\JJ\1740 <e2>rhabdomyolysis</e2>_11\NN\1740 and_12\CC\1740 subsequent_13\JJ\1740 acute_14\JJ\1740 renal_15\JJ\1740 failure_16\NN\66216 following_17\VBG\1835496 <e1>molindone</e1>_18\NN\3713736 administration_19\NN\1133281 ._20\.\1740
D008972_D012559 NONE the_0\DT\1740 case_1\NN\7283608 of_2\IN\1740 a_3\DT\13649268 <e2>schizophrenic</e2>_4\JJ\1740 patient_5\NN\9898892 is_6\VBZ\836236 reported_7\VBN\831651 to_8\TO\1740 illustrate_9\VB\955601 massive_10\JJ\1740 rhabdomyolysis_11\NN\1740 and_12\CC\1740 subsequent_13\JJ\1740 acute_14\JJ\1740 renal_15\JJ\1740 failure_16\NN\66216 following_17\VBG\1835496 <e1>molindone</e1>_18\NN\3713736 administration_19\NN\1133281 ._20\.\1740
D008972_D058186 CID the_0\DT\1740 case_1\NN\7283608 of_2\IN\1740 a_3\DT\13649268 schizophrenic_4\JJ\1740 patient_5\NN\9898892 is_6\VBZ\836236 reported_7\VBN\831651 to_8\TO\1740 illustrate_9\VB\955601 massive_10\JJ\1740 rhabdomyolysis_11\NN\1740 and_12\CC\1740 subsequent_13\JJ\1740 <e2>acute_14\JJ\1740 renal_15\JJ\1740 failure</e2>_16\NN\66216 following_17\VBG\1835496 <e1>molindone</e1>_18\NN\3713736 administration_19\NN\1133281 ._20\.\1740
8690168
D006497_D003928 NONE reduction_0\NN\351485 of_1\IN\1740 <e1>heparan_2\NN\1740 sulphate-associated</e1>_3\JJ\1740 anionic_4\JJ\1740 sites_5\NNS\8673395 in_6\IN\13603305 the_7\DT\1740 glomerular_8\JJ\1740 basement_9\NN\3365991 membrane_10\NN\4188643 of_11\IN\1740 rats_12\NNS\2329401 with_13\IN\1740 streptozotocin-induced_14\JJ\1740 <e2>diabetic_15\JJ\1740 nephropathy</e2>_16\NN\14573196 ._17\.\1740
D013311_D003928 CID reduction_0\NN\351485 of_1\IN\1740 heparan_2\NN\1740 sulphate-associated_3\JJ\1740 anionic_4\JJ\1740 sites_5\NNS\8673395 in_6\IN\13603305 the_7\DT\1740 glomerular_8\JJ\1740 basement_9\NN\3365991 membrane_10\NN\4188643 of_11\IN\1740 rats_12\NNS\2329401 with_13\IN\1740 <e1>streptozotocin-induced</e1>_14\JJ\1740 <e2>diabetic_15\JJ\1740 nephropathy</e2>_16\NN\14573196 ._17\.\1740
D006497_D003920 NONE <e1>heparan_0\NN\1740 sulphate-associated</e1>_1\JJ\1740 anionic_2\JJ\1740 sites_3\NNS\8673395 in_4\IN\13603305 the_5\DT\1740 glomerular_6\JJ\1740 basement_7\NN\3365991 membrane_8\NN\4188643 were_9\VBD\836236 studied_10\VBN\630380 in_11\IN\13603305 rats_12\NNS\2329401 8_13\CD\13741022 months_14\NNS\15113229 after_15\IN\1740 induction_16\NN\7450842 of_17\IN\1740 <e2>diabetes</e2>_18\NNS\14075199 by_19\IN\1740 streptozotocin_20\NN\1740 and_21\CC\1740 in_22\IN\13603305 age-_23\JJ\1740 adn_24\JJ\1740 sex-matched_25\JJ\1740 control_26\NN\5190804 rats_27\NNS\2329401 ,_28\,\1740 employing_29\VBG\1740 the_30\DT\1740 cationic_31\JJ\1740 dye_32\NN\14984973 cuprolinic_33\JJ\1740 blue_34\JJ\1740 ._35\.\1740
D006497_D003920 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 in_3\IN\13603305 <e2>streptozotocin-diabetic</e2>_4\JJ\1740 rats_5\NNS\2329401 with_6\IN\1740 an_7\DT\6697703 increased_8\VBN\169651 urinary_9\JJ\1740 albumin_10\NN\14736972 excretion_11\NN\13466586 ,_12\,\1740 a_13\DT\13649268 reduced_14\VBN\441445 <e1>heparan_15\NN\1740 sulphate</e1>_16\NN\15010703 charge_17\NN\972621 barrier/density_18\NN\1740 is_19\VBZ\836236 found_20\VBN\2426171 at_21\IN\14622893 the_22\DT\1740 lamina_23\NN\5581349 rara_24\NNS\1740 externa_25\NN\1740 of_26\IN\1740 the_27\DT\1740 glomerular_28\JJ\1740 basement_29\NN\3365991 membrane_30\NN\4188643 ._31\.\1740
D013311_D003920 NONE heparan_0\NN\1740 sulphate-associated_1\JJ\1740 anionic_2\JJ\1740 sites_3\NNS\8673395 in_4\IN\13603305 the_5\DT\1740 glomerular_6\JJ\1740 basement_7\NN\3365991 membrane_8\NN\4188643 were_9\VBD\836236 studied_10\VBN\630380 in_11\IN\13603305 rats_12\NNS\2329401 8_13\CD\13741022 months_14\NNS\15113229 after_15\IN\1740 induction_16\NN\7450842 of_17\IN\1740 <e2>diabetes</e2>_18\NNS\14075199 by_19\IN\1740 <e1>streptozotocin</e1>_20\NN\1740 and_21\CC\1740 in_22\IN\13603305 age-_23\JJ\1740 adn_24\JJ\1740 sex-matched_25\JJ\1740 control_26\NN\5190804 rats_27\NNS\2329401 ,_28\,\1740 employing_29\VBG\1740 the_30\DT\1740 cationic_31\JJ\1740 dye_32\NN\14984973 cuprolinic_33\JJ\1740 blue_34\JJ\1740 ._35\.\1740
D013311_D003920 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 in_3\IN\13603305 <e2><e1>streptozotocin-diabetic</e1></e2>_4\JJ\1740 rats_5\NNS\2329401 with_6\IN\1740 an_7\DT\6697703 increased_8\VBN\169651 urinary_9\JJ\1740 albumin_10\NN\14736972 excretion_11\NN\13466586 ,_12\,\1740 a_13\DT\13649268 reduced_14\VBN\441445 heparan_15\NN\1740 sulphate_16\NN\15010703 charge_17\NN\972621 barrier/density_18\NN\1740 is_19\VBZ\836236 found_20\VBN\2426171 at_21\IN\14622893 the_22\DT\1740 lamina_23\NN\5581349 rara_24\NNS\1740 externa_25\NN\1740 of_26\IN\1740 the_27\DT\1740 glomerular_28\JJ\1740 basement_29\NN\3365991 membrane_30\NN\4188643 ._31\.\1740
C015445_D003920 NONE heparan_0\NN\1740 sulphate-associated_1\JJ\1740 anionic_2\JJ\1740 sites_3\NNS\8673395 in_4\IN\13603305 the_5\DT\1740 glomerular_6\JJ\1740 basement_7\NN\3365991 membrane_8\NN\4188643 were_9\VBD\836236 studied_10\VBN\630380 in_11\IN\13603305 rats_12\NNS\2329401 8_13\CD\13741022 months_14\NNS\15113229 after_15\IN\1740 induction_16\NN\7450842 of_17\IN\1740 <e2>diabetes</e2>_18\NNS\14075199 by_19\IN\1740 streptozotocin_20\NN\1740 and_21\CC\1740 in_22\IN\13603305 age-_23\JJ\1740 adn_24\JJ\1740 sex-matched_25\JJ\1740 control_26\NN\5190804 rats_27\NNS\2329401 ,_28\,\1740 employing_29\VBG\1740 the_30\DT\1740 cationic_31\JJ\1740 dye_32\NN\14984973 <e1>cuprolinic_33\JJ\1740 blue</e1>_34\JJ\1740 ._35\.\1740
1468485
D010100_D006470 NONE hyperbaric_0\JJ\1740 <e1>oxygen</e1>_1\NN\14622893 therapy_2\NN\657604 for_3\IN\1740 control_4\NN\5190804 of_5\IN\1740 intractable_6\JJ\1740 cyclophosphamide-induced_7\JJ\1740 <e2>hemorrhagic_8\JJ\1740 cystitis</e2>_9\NN\14566129 ._10\.\1740
D010100_D003556 NONE hyperbaric_0\JJ\1740 <e1>oxygen</e1>_1\NN\14622893 therapy_2\NN\657604 for_3\IN\1740 control_4\NN\5190804 of_5\IN\1740 intractable_6\JJ\1740 cyclophosphamide-induced_7\JJ\1740 <e2>hemorrhagic_8\JJ\1740 cystitis</e2>_9\NN\14566129 ._10\.\1740
D003520_D006470 CID hyperbaric_0\JJ\1740 oxygen_1\NN\14622893 therapy_2\NN\657604 for_3\IN\1740 control_4\NN\5190804 of_5\IN\1740 intractable_6\JJ\1740 <e1>cyclophosphamide-induced</e1>_7\JJ\1740 <e2>hemorrhagic_8\JJ\1740 cystitis</e2>_9\NN\14566129 ._10\.\1740
D003520_D006470 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 intractable_5\JJ\1740 <e2>hemorrhagic_6\JJ\1740 cystitis</e2>_7\NN\14566129 due_8\JJ\1740 to_9\TO\1740 <e1>cyclophosphamide</e1>_10\NN\1740 therapy_11\NN\657604 for_12\IN\1740 wegener_13\NNP\1740 's_14\POS\1740 granulomatosis_15\NN\1740 ._16\.\1740
D003520_D006470 CID in_0\IN\13603305 future_1\NN\28270 ,_2\,\1740 this_3\DT\1740 form_4\NN\6286395 of_5\IN\1740 therapy_6\NN\657604 can_7\MD\3094503 offer_8\VB\2327200 a_9\DT\13649268 safe_10\JJ\1740 alternative_11\NN\5788149 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 <e1>cyclophosphamide-induced</e1>_16\JJ\1740 <e2>hemorrhagic_17\JJ\1740 cystitis</e2>_18\NN\14566129 ._19\.\1740
D003520_D003556 CID hyperbaric_0\JJ\1740 oxygen_1\NN\14622893 therapy_2\NN\657604 for_3\IN\1740 control_4\NN\5190804 of_5\IN\1740 intractable_6\JJ\1740 <e1>cyclophosphamide-induced</e1>_7\JJ\1740 <e2>hemorrhagic_8\JJ\1740 cystitis</e2>_9\NN\14566129 ._10\.\1740
D003520_D003556 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 intractable_5\JJ\1740 <e2>hemorrhagic_6\JJ\1740 cystitis</e2>_7\NN\14566129 due_8\JJ\1740 to_9\TO\1740 <e1>cyclophosphamide</e1>_10\NN\1740 therapy_11\NN\657604 for_12\IN\1740 wegener_13\NNP\1740 's_14\POS\1740 granulomatosis_15\NN\1740 ._16\.\1740
D003520_D003556 CID in_0\IN\13603305 future_1\NN\28270 ,_2\,\1740 this_3\DT\1740 form_4\NN\6286395 of_5\IN\1740 therapy_6\NN\657604 can_7\MD\3094503 offer_8\VB\2327200 a_9\DT\13649268 safe_10\JJ\1740 alternative_11\NN\5788149 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 <e1>cyclophosphamide-induced</e1>_16\JJ\1740 <e2>hemorrhagic_17\JJ\1740 cystitis</e2>_18\NN\14566129 ._19\.\1740
D003520_D014890 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 intractable_5\JJ\1740 hemorrhagic_6\JJ\1740 cystitis_7\NN\14566129 due_8\JJ\1740 to_9\TO\1740 <e1>cyclophosphamide</e1>_10\NN\1740 therapy_11\NN\657604 for_12\IN\1740 <e2>wegener_13\NNP\1740 's_14\POS\1740 granulomatosis</e2>_15\NN\1740 ._16\.\1740
D015237_D006470 NONE conservative_0\JJ\1740 treatment_1\NN\654885 ,_2\,\1740 including_3\VBG\690614 bladder_4\NN\5515670 irrigation_5\NN\1057200 with_6\IN\1740 physiological_7\JJ\1740 saline_8\NN\14849367 and_9\CC\1740 instillation_10\NN\320852 of_11\IN\1740 <e1>prostaglandin_12\NN\5414534 f2_13\NN\1740 alpha</e1>_14\NN\6828818 ,_15\,\1740 failed_16\VBD\1798936 to_17\TO\1740 totally_18\RB\1740 control_19\VB\2422663 <e2>hemorrhage</e2>_20\NN\14285662 ._21\.\1740
88336
D002719_D013375 NONE three_0\CD\13741022 patients_1\NNS\9898892 received_2\VBD\2210855 high_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 <e1>chlormethiazole</e1>_6\NN\1740 for_7\IN\1740 alcohol_8\NN\7881800 <e2>withdrawal_9\NN\7206096 symptoms</e2>_10\NNS\5823932 ,_11\,\1740 and_12\CC\1740 one_13\PRP\13741022 took_14\VBD\2367363 a_15\DT\13649268 suicidal_16\JJ\1740 overdose_17\NN\1740 of_18\IN\1740 nitrazepam_19\NN\2830852 ._20\.\1740
D002719_D062787 NONE three_0\CD\13741022 patients_1\NNS\9898892 received_2\VBD\2210855 high_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 <e1>chlormethiazole</e1>_6\NN\1740 for_7\IN\1740 alcohol_8\NN\7881800 withdrawal_9\NN\7206096 symptoms_10\NNS\5823932 ,_11\,\1740 and_12\CC\1740 one_13\PRP\13741022 took_14\VBD\2367363 a_15\DT\13649268 suicidal_16\JJ\1740 <e2>overdose</e2>_17\NN\1740 of_18\IN\1740 nitrazepam_19\NN\2830852 ._20\.\1740
D002719_D062787 NONE the_0\DT\1740 patient_1\NN\9898892 with_2\IN\1740 nitrazepam_3\NN\2830852 <e2>overdose</e2>_4\NN\1740 and_5\CC\1740 two_6\CD\13741022 of_7\IN\1740 those_8\DT\1740 with_9\IN\1740 <e1>chlormethiazole</e1>_10\NN\1740 intoxication_11\NN\14034177 conformed_12\VBN\109660 to_13\TO\1740 the_14\DT\1740 criteria_15\NNS\13577171 of_16\IN\1740 '_17\``\1740 alpha_18\NN\6828818 coma_19\NN\5678932 '_20\''\1740 ,_21\,\1740 showing_22\VBG\2137132 non-reactive_23\JJ\1740 generalized_24\JJ\1740 or_25\CC\3541091 frontally_26\RB\1740 predominant_27\JJ\1740 alpha_28\NN\6828818 activity_29\NN\30358 in_30\IN\13603305 the_31\DT\1740 eeg_32\NN\7000195 ._33\.\1740
D000431_D013375 NONE three_0\CD\13741022 patients_1\NNS\9898892 received_2\VBD\2210855 high_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 chlormethiazole_6\NN\1740 for_7\IN\1740 <e1>alcohol</e1>_8\NN\7881800 <e2>withdrawal_9\NN\7206096 symptoms</e2>_10\NNS\5823932 ,_11\,\1740 and_12\CC\1740 one_13\PRP\13741022 took_14\VBD\2367363 a_15\DT\13649268 suicidal_16\JJ\1740 overdose_17\NN\1740 of_18\IN\1740 nitrazepam_19\NN\2830852 ._20\.\1740
D000431_D062787 NONE three_0\CD\13741022 patients_1\NNS\9898892 received_2\VBD\2210855 high_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 chlormethiazole_6\NN\1740 for_7\IN\1740 <e1>alcohol</e1>_8\NN\7881800 withdrawal_9\NN\7206096 symptoms_10\NNS\5823932 ,_11\,\1740 and_12\CC\1740 one_13\PRP\13741022 took_14\VBD\2367363 a_15\DT\13649268 suicidal_16\JJ\1740 <e2>overdose</e2>_17\NN\1740 of_18\IN\1740 nitrazepam_19\NN\2830852 ._20\.\1740
D009567_D013375 NONE three_0\CD\13741022 patients_1\NNS\9898892 received_2\VBD\2210855 high_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 chlormethiazole_6\NN\1740 for_7\IN\1740 alcohol_8\NN\7881800 <e2>withdrawal_9\NN\7206096 symptoms</e2>_10\NNS\5823932 ,_11\,\1740 and_12\CC\1740 one_13\PRP\13741022 took_14\VBD\2367363 a_15\DT\13649268 suicidal_16\JJ\1740 overdose_17\NN\1740 of_18\IN\1740 <e1>nitrazepam</e1>_19\NN\2830852 ._20\.\1740
D009567_D062787 CID three_0\CD\13741022 patients_1\NNS\9898892 received_2\VBD\2210855 high_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 chlormethiazole_6\NN\1740 for_7\IN\1740 alcohol_8\NN\7881800 withdrawal_9\NN\7206096 symptoms_10\NNS\5823932 ,_11\,\1740 and_12\CC\1740 one_13\PRP\13741022 took_14\VBD\2367363 a_15\DT\13649268 suicidal_16\JJ\1740 <e2>overdose</e2>_17\NN\1740 of_18\IN\1740 <e1>nitrazepam</e1>_19\NN\2830852 ._20\.\1740
D009567_D062787 CID the_0\DT\1740 patient_1\NN\9898892 with_2\IN\1740 <e1>nitrazepam</e1>_3\NN\2830852 <e2>overdose</e2>_4\NN\1740 and_5\CC\1740 two_6\CD\13741022 of_7\IN\1740 those_8\DT\1740 with_9\IN\1740 chlormethiazole_10\NN\1740 intoxication_11\NN\14034177 conformed_12\VBN\109660 to_13\TO\1740 the_14\DT\1740 criteria_15\NNS\13577171 of_16\IN\1740 '_17\``\1740 alpha_18\NN\6828818 coma_19\NN\5678932 '_20\''\1740 ,_21\,\1740 showing_22\VBG\2137132 non-reactive_23\JJ\1740 generalized_24\JJ\1740 or_25\CC\3541091 frontally_26\RB\1740 predominant_27\JJ\1740 alpha_28\NN\6828818 activity_29\NN\30358 in_30\IN\13603305 the_31\DT\1740 eeg_32\NN\7000195 ._33\.\1740
D009567_D003128 CID the_0\DT\1740 patient_1\NN\9898892 with_2\IN\1740 <e1>nitrazepam</e1>_3\NN\2830852 overdose_4\NN\1740 and_5\CC\1740 two_6\CD\13741022 of_7\IN\1740 those_8\DT\1740 with_9\IN\1740 chlormethiazole_10\NN\1740 intoxication_11\NN\14034177 conformed_12\VBN\109660 to_13\TO\1740 the_14\DT\1740 criteria_15\NNS\13577171 of_16\IN\1740 '_17\``\1740 alpha_18\NN\6828818 <e2>coma</e2>_19\NN\5678932 '_20\''\1740 ,_21\,\1740 showing_22\VBG\2137132 non-reactive_23\JJ\1740 generalized_24\JJ\1740 or_25\CC\3541091 frontally_26\RB\1740 predominant_27\JJ\1740 alpha_28\NN\6828818 activity_29\NN\30358 in_30\IN\13603305 the_31\DT\1740 eeg_32\NN\7000195 ._33\.\1740
D002719_D003128 CID the_0\DT\1740 patient_1\NN\9898892 with_2\IN\1740 nitrazepam_3\NN\2830852 overdose_4\NN\1740 and_5\CC\1740 two_6\CD\13741022 of_7\IN\1740 those_8\DT\1740 with_9\IN\1740 <e1>chlormethiazole</e1>_10\NN\1740 intoxication_11\NN\14034177 conformed_12\VBN\109660 to_13\TO\1740 the_14\DT\1740 criteria_15\NNS\13577171 of_16\IN\1740 '_17\``\1740 alpha_18\NN\6828818 <e2>coma</e2>_19\NN\5678932 '_20\''\1740 ,_21\,\1740 showing_22\VBG\2137132 non-reactive_23\JJ\1740 generalized_24\JJ\1740 or_25\CC\3541091 frontally_26\RB\1740 predominant_27\JJ\1740 alpha_28\NN\6828818 activity_29\NN\30358 in_30\IN\13603305 the_31\DT\1740 eeg_32\NN\7000195 ._33\.\1740
9334596
D013739_D007172 NONE purpose_0\NNP\5980875 :_1\:\1740 we_2\PRP\1740 reviewed_3\VBD\644583 the_4\DT\1740 results_5\NNS\34213 of_6\IN\1740 serum_7\NN\5397468 <e1>testosterone</e1>_8\NN\14747587 and_9\CC\1740 prolactin_10\NN\5410315 determination_11\NN\43195 in_12\IN\13603305 1,022_13\CD\1740 patients_14\NNS\9898892 referred_15\VBN\730052 because_16\IN\1740 of_17\IN\1740 <e2>erectile_18\JJ\1740 dysfunction</e2>_19\NN\14204950 and_20\CC\1740 compared_21\VBD\644583 the_22\DT\1740 data_23\NNS\7951464 with_24\IN\1740 history_25\NN\15120823 ,_26\,\1740 results_27\NNS\34213 of_28\IN\1740 physical_29\JJ\1740 examination_30\NN\633864 ,_31\,\1740 other_32\JJ\1740 etiological_33\JJ\1740 investigations_34\NNS\5797597 and_35\CC\1740 effects_36\NNS\13245626 of_37\IN\1740 endocrine_38\NN\5404728 therapy_39\NN\657604 to_40\TO\1740 refine_41\VB\205885 the_42\DT\1740 rules_43\NNS\5835747 of_44\IN\1740 cost-effective_45\JJ\1740 endocrine_46\NN\5404728 screening_47\NN\6887726 and_48\CC\1740 to_49\TO\1740 pinpoint_50\VB\2286204 actual_51\JJ\1740 responsibility_52\NN\1123598 for_53\IN\1740 hormonal_54\JJ\1740 abnormalities_55\NNS\14034177 ._56\.\1740
D013739_D007172 NONE most_0\JJS\1740 of_1\IN\1740 the_2\DT\1740 other_3\JJ\1740 low_4\JJ\1740 <e1>testosterone</e1>_5\NN\14747587 levels_6\NNS\4916342 seemed_7\VBD\2604760 to_8\TO\1740 result_9\VB\2633881 from_10\IN\1740 nonorganic_11\JJ\1740 hypothalamic_12\JJ\1740 dysfunction_13\NN\14204950 because_14\IN\1740 of_15\IN\1740 normal_16\JJ\1740 serum_17\NN\5397468 luteinizing_18\NN\1740 hormone_19\NN\5404728 and_20\CC\1740 prolactin_21\NN\5410315 and_22\CC\1740 to_23\TO\1740 have_24\VB\2108377 only_25\RB\1740 a_26\DT\13649268 small_27\JJ\1740 role_28\NN\719494 in_29\IN\13603305 <e2>erectile_30\JJ\1740 dysfunction</e2>_31\NN\14204950 (_32\-LRB-\1740 definite_33\JJ\1740 improvement_34\NN\7359599 in_35\IN\13603305 only_36\RB\1740 16_37\CD\13745420 of_38\IN\1740 44_39\CD\1740 [_40\-LRB-\1740 36_41\CD\1740 %_42\NN\1740 ]_43\-RRB-\1740 after_44\IN\1740 androgen_45\NN\14745635 therapy_46\NN\657604 ,_47\,\1740 normal_48\JJ\1740 morning_49\NN\15113229 or_50\CC\3541091 nocturnal_51\JJ\1740 erections_52\NNS\14037619 in_53\IN\13603305 30_54\CD\13745420 %_55\NN\1740 and_56\CC\1740 definite_57\JJ\1740 vasculogenic_58\JJ\1740 contributions_59\NNS\786195 in_60\IN\13603305 42_61\CD\1740 %_62\NN\1740 )_63\-RRB-\1740 ._64\.\1740
D013739_D007172 NONE conclusions_0\NNS\5837957 :_1\:\1740 low_2\JJ\1740 prevalences_3\NNS\4764412 and_4\CC\1740 effects_5\NNS\13245626 of_6\IN\1740 low_7\JJ\1740 <e1>testosterone</e1>_8\NN\14747587 and_9\CC\1740 high_10\JJ\1740 prolactin_11\NN\5410315 in_12\IN\13603305 <e2>erectile_13\JJ\1740 dysfunction</e2>_14\NN\14204950 can_15\MD\3094503 not_16\RB\1740 justify_17\VB\1012073 their_18\PRP$\1740 routine_19\JJ\1740 determination_20\NN\43195 ._21\.\1740
D013739_D020018 CID every_0\DT\1740 patient_1\NN\9898892 was_2\VBD\836236 screened_3\VBN\2533282 for_4\IN\1740 <e1>testosterone</e1>_5\NN\14747587 and_6\CC\1740 451_7\CD\1740 were_8\VBD\836236 screened_9\VBN\2533282 for_10\IN\1740 prolactin_11\NN\5410315 on_12\IN\1740 the_13\DT\1740 basis_14\NN\13790712 of_15\IN\1740 <e2>low_16\JJ\1740 sexual_17\JJ\1740 desire</e2>_18\NN\26192 ,_19\,\1740 gynecomastia_20\NN\14501726 or_21\CC\3541091 testosterone_22\NN\14747587 less_23\JJR\1740 than_24\IN\1740 4_25\CD\13741022 ng./ml_26\NN\1740 ._27\.\1740
D013739_D020018 CID every_0\DT\1740 patient_1\NN\9898892 was_2\VBD\836236 screened_3\VBN\2533282 for_4\IN\1740 testosterone_5\NN\14747587 and_6\CC\1740 451_7\CD\1740 were_8\VBD\836236 screened_9\VBN\2533282 for_10\IN\1740 prolactin_11\NN\5410315 on_12\IN\1740 the_13\DT\1740 basis_14\NN\13790712 of_15\IN\1740 <e2>low_16\JJ\1740 sexual_17\JJ\1740 desire</e2>_18\NN\26192 ,_19\,\1740 gynecomastia_20\NN\14501726 or_21\CC\3541091 <e1>testosterone</e1>_22\NN\14747587 less_23\JJR\1740 than_24\IN\1740 4_25\CD\13741022 ng./ml_26\NN\1740 ._27\.\1740
D013739_D020018 CID determining_0\VBG\1645601 <e1>testosterone</e1>_1\NN\14747587 only_2\RB\1740 in_3\IN\13603305 cases_4\NNS\7283608 of_5\IN\1740 <e2>low_6\JJ\1740 sexual_7\JJ\1740 desire</e2>_8\NN\26192 or_9\CC\3541091 abnormal_10\JJ\1740 physical_11\JJ\1740 examination_12\NN\633864 would_13\MD\1740 have_14\VB\2108377 missed_15\VBN\1825237 40_16\CD\13745420 %_17\NN\1740 of_18\IN\1740 the_19\DT\1740 cases_20\NNS\7283608 with_21\IN\1740 low_22\JJ\1740 testosterone_23\NN\14747587 ,_24\,\1740 including_25\VBG\690614 37_26\CD\1740 %_27\NN\1740 of_28\IN\1740 those_29\DT\1740 subsequently_30\RB\1740 improved_31\VBN\126264 by_32\IN\1740 androgen_33\NN\14745635 therapy_34\NN\657604 ._35\.\1740
D013739_D020018 CID determining_0\VBG\1645601 testosterone_1\NN\14747587 only_2\RB\1740 in_3\IN\13603305 cases_4\NNS\7283608 of_5\IN\1740 <e2>low_6\JJ\1740 sexual_7\JJ\1740 desire</e2>_8\NN\26192 or_9\CC\3541091 abnormal_10\JJ\1740 physical_11\JJ\1740 examination_12\NN\633864 would_13\MD\1740 have_14\VB\2108377 missed_15\VBN\1825237 40_16\CD\13745420 %_17\NN\1740 of_18\IN\1740 the_19\DT\1740 cases_20\NNS\7283608 with_21\IN\1740 low_22\JJ\1740 <e1>testosterone</e1>_23\NN\14747587 ,_24\,\1740 including_25\VBG\690614 37_26\CD\1740 %_27\NN\1740 of_28\IN\1740 those_29\DT\1740 subsequently_30\RB\1740 improved_31\VBN\126264 by_32\IN\1740 androgen_33\NN\14745635 therapy_34\NN\657604 ._35\.\1740
D013739_D020018 CID we_0\PRP\1740 now_1\RB\1740 advocate_2\VBP\875394 that_3\IN\1740 before_4\IN\1740 age_5\NN\4916342 50_6\CD\13745420 years_7\NNS\15144371 <e1>testosterone</e1>_8\NN\14747587 be_9\VB\836236 determined_10\VBN\1645601 only_11\RB\1740 in_12\IN\13603305 cases_13\NNS\7283608 of_14\IN\1740 <e2>low_15\JJ\1740 sexual_16\JJ\1740 desire</e2>_17\NN\26192 and_18\CC\1740 abnormal_19\JJ\1740 physical_20\JJ\1740 examination_21\NN\633864 but_22\CC\1740 that_23\IN\1740 it_24\PRP\6125041 be_25\VB\836236 measured_26\VBN\697589 in_27\IN\13603305 all_28\DT\1740 men_29\NNS\8208016 older_30\JJR\1740 than_31\IN\1740 50_32\CD\13745420 years_33\NNS\15144371 ._34\.\1740
D013739_D020018 CID prolactin_0\NN\5410315 should_1\MD\1740 be_2\VB\836236 determined_3\VBN\1645601 only_4\RB\1740 in_5\IN\13603305 cases_6\NNS\7283608 of_7\IN\1740 <e2>low_8\JJ\1740 sexual_9\JJ\1740 desire</e2>_10\NN\26192 ,_11\,\1740 gynecomastia_12\NN\14501726 and/or_13\CC\1740 <e1>testosterone</e1>_14\NN\14747587 less_15\JJR\1740 than_16\IN\1740 4_17\CD\13741022 ng./ml_18\NN\1740 ._19\.\1740
D013739_D006177 NONE every_0\DT\1740 patient_1\NN\9898892 was_2\VBD\836236 screened_3\VBN\2533282 for_4\IN\1740 <e1>testosterone</e1>_5\NN\14747587 and_6\CC\1740 451_7\CD\1740 were_8\VBD\836236 screened_9\VBN\2533282 for_10\IN\1740 prolactin_11\NN\5410315 on_12\IN\1740 the_13\DT\1740 basis_14\NN\13790712 of_15\IN\1740 low_16\JJ\1740 sexual_17\JJ\1740 desire_18\NN\26192 ,_19\,\1740 <e2>gynecomastia</e2>_20\NN\14501726 or_21\CC\3541091 testosterone_22\NN\14747587 less_23\JJR\1740 than_24\IN\1740 4_25\CD\13741022 ng./ml_26\NN\1740 ._27\.\1740
D013739_D006177 NONE every_0\DT\1740 patient_1\NN\9898892 was_2\VBD\836236 screened_3\VBN\2533282 for_4\IN\1740 testosterone_5\NN\14747587 and_6\CC\1740 451_7\CD\1740 were_8\VBD\836236 screened_9\VBN\2533282 for_10\IN\1740 prolactin_11\NN\5410315 on_12\IN\1740 the_13\DT\1740 basis_14\NN\13790712 of_15\IN\1740 low_16\JJ\1740 sexual_17\JJ\1740 desire_18\NN\26192 ,_19\,\1740 <e2>gynecomastia</e2>_20\NN\14501726 or_21\CC\3541091 <e1>testosterone</e1>_22\NN\14747587 less_23\JJR\1740 than_24\IN\1740 4_25\CD\13741022 ng./ml_26\NN\1740 ._27\.\1740
D013739_D006177 NONE prolactin_0\NN\5410315 should_1\MD\1740 be_2\VB\836236 determined_3\VBN\1645601 only_4\RB\1740 in_5\IN\13603305 cases_6\NNS\7283608 of_7\IN\1740 low_8\JJ\1740 sexual_9\JJ\1740 desire_10\NN\26192 ,_11\,\1740 <e2>gynecomastia</e2>_12\NN\14501726 and/or_13\CC\1740 <e1>testosterone</e1>_14\NN\14747587 less_15\JJR\1740 than_16\IN\1740 4_17\CD\13741022 ng./ml_18\NN\1740 ._19\.\1740
C004648_D007006 NONE endocrine_0\NN\5404728 therapy_1\NN\657604 consisted_2\VBD\2603699 of_3\IN\1740 <e1>testosterone_4\NN\14747587 heptylate</e1>_5\NN\1740 or_6\CC\3541091 human_7\JJ\1740 chorionic_8\JJ\1740 gonadotropin_9\NN\5407119 for_10\IN\1740 <e2>hypogonadism</e2>_11\NN\14076126 and_12\CC\1740 bromocriptine_13\NN\1740 for_14\IN\1740 hyperprolactinemia_15\NN\1740 ._16\.\1740
C004648_D006966 NONE endocrine_0\NN\5404728 therapy_1\NN\657604 consisted_2\VBD\2603699 of_3\IN\1740 <e1>testosterone_4\NN\14747587 heptylate</e1>_5\NN\1740 or_6\CC\3541091 human_7\JJ\1740 chorionic_8\JJ\1740 gonadotropin_9\NN\5407119 for_10\IN\1740 hypogonadism_11\NN\14076126 and_12\CC\1740 bromocriptine_13\NN\1740 for_14\IN\1740 <e2>hyperprolactinemia</e2>_15\NN\1740 ._16\.\1740
D001971_D007006 NONE endocrine_0\NN\5404728 therapy_1\NN\657604 consisted_2\VBD\2603699 of_3\IN\1740 testosterone_4\NN\14747587 heptylate_5\NN\1740 or_6\CC\3541091 human_7\JJ\1740 chorionic_8\JJ\1740 gonadotropin_9\NN\5407119 for_10\IN\1740 <e2>hypogonadism</e2>_11\NN\14076126 and_12\CC\1740 <e1>bromocriptine</e1>_13\NN\1740 for_14\IN\1740 hyperprolactinemia_15\NN\1740 ._16\.\1740
D001971_D006966 NONE endocrine_0\NN\5404728 therapy_1\NN\657604 consisted_2\VBD\2603699 of_3\IN\1740 testosterone_4\NN\14747587 heptylate_5\NN\1740 or_6\CC\3541091 human_7\JJ\1740 chorionic_8\JJ\1740 gonadotropin_9\NN\5407119 for_10\IN\1740 hypogonadism_11\NN\14076126 and_12\CC\1740 <e1>bromocriptine</e1>_13\NN\1740 for_14\IN\1740 <e2>hyperprolactinemia</e2>_15\NN\1740 ._16\.\1740
D013739_D010911 NONE two_0\CD\13741022 <e2>pituitary_1\JJ\1740 tumors</e2>_2\NNS\14234074 were_3\VBD\836236 discovered_4\VBN\2163746 after_5\IN\1740 <e1>testosterone</e1>_6\NN\14747587 determination_7\NN\43195 ._8\.\1740
D013739_D007027 NONE most_0\JJS\1740 of_1\IN\1740 the_2\DT\1740 other_3\JJ\1740 low_4\JJ\1740 <e1>testosterone</e1>_5\NN\14747587 levels_6\NNS\4916342 seemed_7\VBD\2604760 to_8\TO\1740 result_9\VB\2633881 from_10\IN\1740 nonorganic_11\JJ\1740 <e2>hypothalamic_12\JJ\1740 dysfunction</e2>_13\NN\14204950 because_14\IN\1740 of_15\IN\1740 normal_16\JJ\1740 serum_17\NN\5397468 luteinizing_18\NN\1740 hormone_19\NN\5404728 and_20\CC\1740 prolactin_21\NN\5410315 and_22\CC\1740 to_23\TO\1740 have_24\VB\2108377 only_25\RB\1740 a_26\DT\13649268 small_27\JJ\1740 role_28\NN\719494 in_29\IN\13603305 erectile_30\JJ\1740 dysfunction_31\NN\14204950 (_32\-LRB-\1740 definite_33\JJ\1740 improvement_34\NN\7359599 in_35\IN\13603305 only_36\RB\1740 16_37\CD\13745420 of_38\IN\1740 44_39\CD\1740 [_40\-LRB-\1740 36_41\CD\1740 %_42\NN\1740 ]_43\-RRB-\1740 after_44\IN\1740 androgen_45\NN\14745635 therapy_46\NN\657604 ,_47\,\1740 normal_48\JJ\1740 morning_49\NN\15113229 or_50\CC\3541091 nocturnal_51\JJ\1740 erections_52\NNS\14037619 in_53\IN\13603305 30_54\CD\13745420 %_55\NN\1740 and_56\CC\1740 definite_57\JJ\1740 vasculogenic_58\JJ\1740 contributions_59\NNS\786195 in_60\IN\13603305 42_61\CD\1740 %_62\NN\1740 )_63\-RRB-\1740 ._64\.\1740
1919871
D001241_D007681 CID <e2>renal_0\JJ\1740 papillary_1\NN\1740 necrosis</e2>_2\NN\11444117 (_3\-LRB-\1740 rpn_4\NN\1740 )_5\-RRB-\1740 and_6\CC\1740 a_7\DT\13649268 decreased_8\VBN\169651 urinary_9\JJ\1740 concentrating_10\NN\1740 ability_11\NN\4723816 developed_12\VBN\1753788 during_13\IN\1740 continuous_14\JJ\1740 long-term_15\JJ\1740 treatment_16\NN\654885 with_17\IN\1740 <e1>aspirin</e1>_18\NN\2707683 and_19\CC\1740 paracetamol_20\NN\1740 in_21\IN\13603305 female_22\JJ\1740 fischer_23\NNP\1740 344_24\CD\1740 rats_25\NNS\2329401 ._26\.\1740
D001241_D007681 CID renal_0\JJ\1740 papillary_1\NN\1740 necrosis_2\NN\11444117 (_3\-LRB-\1740 <e2>rpn</e2>_4\NN\1740 )_5\-RRB-\1740 and_6\CC\1740 a_7\DT\13649268 decreased_8\VBN\169651 urinary_9\JJ\1740 concentrating_10\NN\1740 ability_11\NN\4723816 developed_12\VBN\1753788 during_13\IN\1740 continuous_14\JJ\1740 long-term_15\JJ\1740 treatment_16\NN\654885 with_17\IN\1740 <e1>aspirin</e1>_18\NN\2707683 and_19\CC\1740 paracetamol_20\NN\1740 in_21\IN\13603305 female_22\JJ\1740 fischer_23\NNP\1740 344_24\CD\1740 rats_25\NNS\2329401 ._26\.\1740
D000082_D007681 CID <e2>renal_0\JJ\1740 papillary_1\NN\1740 necrosis</e2>_2\NN\11444117 (_3\-LRB-\1740 rpn_4\NN\1740 )_5\-RRB-\1740 and_6\CC\1740 a_7\DT\13649268 decreased_8\VBN\169651 urinary_9\JJ\1740 concentrating_10\NN\1740 ability_11\NN\4723816 developed_12\VBN\1753788 during_13\IN\1740 continuous_14\JJ\1740 long-term_15\JJ\1740 treatment_16\NN\654885 with_17\IN\1740 aspirin_18\NN\2707683 and_19\CC\1740 <e1>paracetamol</e1>_20\NN\1740 in_21\IN\13603305 female_22\JJ\1740 fischer_23\NNP\1740 344_24\CD\1740 rats_25\NNS\2329401 ._26\.\1740
D000082_D007681 CID renal_0\JJ\1740 papillary_1\NN\1740 necrosis_2\NN\11444117 (_3\-LRB-\1740 <e2>rpn</e2>_4\NN\1740 )_5\-RRB-\1740 and_6\CC\1740 a_7\DT\13649268 decreased_8\VBN\169651 urinary_9\JJ\1740 concentrating_10\NN\1740 ability_11\NN\4723816 developed_12\VBN\1753788 during_13\IN\1740 continuous_14\JJ\1740 long-term_15\JJ\1740 treatment_16\NN\654885 with_17\IN\1740 aspirin_18\NN\2707683 and_19\CC\1740 <e1>paracetamol</e1>_20\NN\1740 in_21\IN\13603305 female_22\JJ\1740 fischer_23\NNP\1740 344_24\CD\1740 rats_25\NNS\2329401 ._26\.\1740
8955532
D001920_D006973 NONE role_0\NN\719494 of_1\IN\1740 activation_2\NN\13561719 of_3\IN\1740 <e1>bradykinin</e1>_4\NN\1740 b2_5\NN\1740 receptors_6\NNS\5225602 in_7\IN\13603305 disruption_8\NN\1066163 of_9\IN\1740 the_10\DT\1740 blood-brain_11\JJ\1740 barrier_12\NN\3839993 during_13\IN\1740 acute_14\JJ\1740 <e2>hypertension</e2>_15\NN\14057371 ._16\.\1740
D001920_D006973 NONE the_0\DT\1740 goal_1\NN\5809192 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 determine_7\VB\1645601 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 synthesis/release_11\NN\1740 of_12\IN\1740 <e1>bradykinin</e1>_13\NN\1740 to_14\TO\1740 activate_15\VB\1641914 b2_16\NN\1740 receptors_17\NNS\5225602 in_18\IN\13603305 disruption_19\NN\1066163 of_20\IN\1740 the_21\DT\1740 blood-brain_22\JJ\1740 barrier_23\NN\3839993 during_24\IN\1740 acute_25\JJ\1740 <e2>hypertension</e2>_26\NN\14057371 ._27\.\1740
D001920_D006973 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 disruption_4\NN\1066163 of_5\IN\1740 the_6\DT\1740 blood-brain_7\JJ\1740 barrier_8\NN\3839993 during_9\IN\1740 acute_10\JJ\1740 <e2>hypertension</e2>_11\NN\14057371 is_12\VBZ\836236 not_13\RB\1740 related_14\JJ\1740 to_15\TO\1740 the_16\DT\1740 synthesis/release_17\NN\1740 of_18\IN\1740 <e1>bradykinin</e1>_19\NN\1740 to_20\TO\1740 activate_21\VB\1641914 b2_22\NN\1740 receptors_23\NNS\5225602 ._24\.\1740
D003911_D006973 NONE permeability_0\NN\4940146 of_1\IN\1740 the_2\DT\1740 blood-brain_3\JJ\1740 barrier_4\NN\3839993 was_5\VBD\836236 quantitated_6\VBN\1740 by_7\IN\1740 clearance_8\NN\5089947 of_9\IN\1740 fluorescent-labeled_10\JJ\1740 <e1>dextran</e1>_11\NN\1740 before_12\IN\1740 and_13\CC\1740 during_14\IN\1740 phenylephrine-induced_15\JJ\1740 acute_16\JJ\1740 <e2>hypertension</e2>_17\NN\14057371 in_18\IN\13603305 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 vehicle_22\NN\3100490 and_23\CC\1740 hoe-140_24\NN\1740 (_25\-LRB-\1740 0.1_26\CD\1740 microm_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D010656_D006973 CID permeability_0\NN\4940146 of_1\IN\1740 the_2\DT\1740 blood-brain_3\JJ\1740 barrier_4\NN\3839993 was_5\VBD\836236 quantitated_6\VBN\1740 by_7\IN\1740 clearance_8\NN\5089947 of_9\IN\1740 fluorescent-labeled_10\JJ\1740 dextran_11\NN\1740 before_12\IN\1740 and_13\CC\1740 during_14\IN\1740 <e1>phenylephrine-induced</e1>_15\JJ\1740 acute_16\JJ\1740 <e2>hypertension</e2>_17\NN\14057371 in_18\IN\13603305 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 vehicle_22\NN\3100490 and_23\CC\1740 hoe-140_24\NN\1740 (_25\-LRB-\1740 0.1_26\CD\1740 microm_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
C065679_D006973 NONE permeability_0\NN\4940146 of_1\IN\1740 the_2\DT\1740 blood-brain_3\JJ\1740 barrier_4\NN\3839993 was_5\VBD\836236 quantitated_6\VBN\1740 by_7\IN\1740 clearance_8\NN\5089947 of_9\IN\1740 fluorescent-labeled_10\JJ\1740 dextran_11\NN\1740 before_12\IN\1740 and_13\CC\1740 during_14\IN\1740 phenylephrine-induced_15\JJ\1740 acute_16\JJ\1740 <e2>hypertension</e2>_17\NN\14057371 in_18\IN\13603305 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 vehicle_22\NN\3100490 and_23\CC\1740 <e1>hoe-140</e1>_24\NN\1740 (_25\-LRB-\1740 0.1_26\CD\1740 microm_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
19037603
D019259_D012216 NONE prophylactic_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 <e1>lamivudine</e1>_3\NN\3834836 with_4\IN\1740 chronic_5\JJ\1740 immunosuppressive_6\JJ\1740 therapy_7\NN\657604 for_8\IN\1740 <e2>rheumatologic_9\JJ\1740 disorders</e2>_10\NNS\14034177 ._11\.\1740
D019259_D012216 NONE the_0\DT\1740 objective_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 report_7\VB\831651 our_8\PRP$\1740 experience_9\NN\5984287 concerning_10\VBG\1740 the_11\DT\1740 effectiveness_12\NN\5190804 of_13\IN\1740 the_14\DT\1740 prophylactic_15\JJ\1740 administration_16\NN\1133281 of_17\IN\1740 <e1>lamivudine</e1>_18\NN\3834836 in_19\IN\13603305 hepatitis_20\NN\14127211 b_21\NN\1355326 virus_22\NN\9312843 surface_23\NN\21939 antigen_24\NN\20090 (_25\-LRB-\1740 hbs_26\NN\14888884 ag_27\NN\14821043 )_28\-RRB-\1740 positive_29\JJ\1740 patients_30\NNS\9898892 with_31\IN\1740 <e2>rheumatologic_32\JJ\1740 disease</e2>_33\NN\14061805 ._34\.\1740
D019259_D012216 NONE from_0\IN\1740 june_1\NNP\15209706 2004_2\CD\1740 to_3\IN\1740 october_4\NNP\15209706 2006_5\CD\1740 ,_6\,\1740 11_7\CD\13745420 hbs_8\NN\14888884 ag_9\NN\14821043 positive_10\JJ\1740 patients_11\NNS\9898892 with_12\IN\1740 <e2>rheumatologic_13\JJ\1740 diseases</e2>_14\NNS\14061805 ,_15\,\1740 who_16\WP\8299493 were_17\VBD\836236 on_18\IN\1740 both_19\CC\1740 immunosuppressive_20\JJ\1740 and_21\CC\1740 prophylactic_22\JJ\1740 <e1>lamivudine</e1>_23\NN\3834836 therapies_24\NNS\657604 ,_25\,\1740 were_26\VBD\836236 retrospectively_27\RB\1740 assessed_28\VBN\670261 ._29\.\1740
D006514_D012216 NONE the_0\DT\1740 objective_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 report_7\VB\831651 our_8\PRP$\1740 experience_9\NN\5984287 concerning_10\VBG\1740 the_11\DT\1740 effectiveness_12\NN\5190804 of_13\IN\1740 the_14\DT\1740 prophylactic_15\JJ\1740 administration_16\NN\1133281 of_17\IN\1740 lamivudine_18\NN\3834836 in_19\IN\13603305 <e1>hepatitis_20\NN\14127211 b_21\NN\1355326 virus_22\NN\9312843 surface_23\NN\21939 antigen</e1>_24\NN\20090 (_25\-LRB-\1740 hbs_26\NN\14888884 ag_27\NN\14821043 )_28\-RRB-\1740 positive_29\JJ\1740 patients_30\NNS\9898892 with_31\IN\1740 <e2>rheumatologic_32\JJ\1740 disease</e2>_33\NN\14061805 ._34\.\1740
D006514_D012216 NONE the_0\DT\1740 objective_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 report_7\VB\831651 our_8\PRP$\1740 experience_9\NN\5984287 concerning_10\VBG\1740 the_11\DT\1740 effectiveness_12\NN\5190804 of_13\IN\1740 the_14\DT\1740 prophylactic_15\JJ\1740 administration_16\NN\1133281 of_17\IN\1740 lamivudine_18\NN\3834836 in_19\IN\13603305 hepatitis_20\NN\14127211 b_21\NN\1355326 virus_22\NN\9312843 surface_23\NN\21939 antigen_24\NN\20090 (_25\-LRB-\1740 <e1>hbs_26\NN\14888884 ag</e1>_27\NN\14821043 )_28\-RRB-\1740 positive_29\JJ\1740 patients_30\NNS\9898892 with_31\IN\1740 <e2>rheumatologic_32\JJ\1740 disease</e2>_33\NN\14061805 ._34\.\1740
D006514_D012216 NONE from_0\IN\1740 june_1\NNP\15209706 2004_2\CD\1740 to_3\IN\1740 october_4\NNP\15209706 2006_5\CD\1740 ,_6\,\1740 11_7\CD\13745420 <e1>hbs_8\NN\14888884 ag</e1>_9\NN\14821043 positive_10\JJ\1740 patients_11\NNS\9898892 with_12\IN\1740 <e2>rheumatologic_13\JJ\1740 diseases</e2>_14\NNS\14061805 ,_15\,\1740 who_16\WP\8299493 were_17\VBD\836236 on_18\IN\1740 both_19\CC\1740 immunosuppressive_20\JJ\1740 and_21\CC\1740 prophylactic_22\JJ\1740 lamivudine_23\NN\3834836 therapies_24\NNS\657604 ,_25\,\1740 were_26\VBD\836236 retrospectively_27\RB\1740 assessed_28\VBN\670261 ._29\.\1740
809711
D010656_D009203 NONE reversal_0\NN\199130 by_1\IN\1740 <e1>phenylephrine</e1>_2\NN\2682038 of_3\IN\1740 the_4\DT\1740 beneficial_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 intravenous_8\JJ\1740 nitroglycerin_9\NN\15015501 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 <e2>acute_13\JJ\1740 myocardial_14\JJ\1740 infarction</e2>_15\NN\14204950 ._16\.\1740
D010656_D009203 NONE our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 addition_4\NN\3081021 of_5\IN\1740 <e1>phenylephrine</e1>_6\NN\2682038 to_7\TO\1740 nitroglycerin_8\NN\15015501 is_9\VBZ\836236 not_10\RB\1740 beneficial_11\JJ\1740 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 patients_16\NNS\9898892 with_17\IN\1740 <e2>acute_18\JJ\1740 myocardial_19\JJ\1740 infarction</e2>_20\NN\14204950 ._21\.\1740
D005996_D009203 NONE reversal_0\NN\199130 by_1\IN\1740 phenylephrine_2\NN\2682038 of_3\IN\1740 the_4\DT\1740 beneficial_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 intravenous_8\JJ\1740 <e1>nitroglycerin</e1>_9\NN\15015501 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 <e2>acute_13\JJ\1740 myocardial_14\JJ\1740 infarction</e2>_15\NN\14204950 ._16\.\1740
D005996_D009203 NONE <e1>nitroglycerin</e1>_0\NNP\15015501 has_1\VBZ\2108377 been_2\VBN\836236 shown_3\VBN\2137132 to_4\TO\1740 reduce_5\VB\441445 st-segment_6\JJ\1740 elevation_7\NN\7445480 during_8\IN\1740 <e2>acute_9\JJ\1740 myocardial_10\JJ\1740 infarction</e2>_11\NN\14204950 ,_12\,\1740 an_13\DT\6697703 effect_14\NN\34213 potentiated_15\VBD\229605 in_16\IN\13603305 the_17\DT\1740 dog_18\NN\2083346 by_19\IN\1740 agents_20\NNS\7347 that_21\WDT\1740 reverse_22\VBP\109660 nitroglycerin-induced_23\JJ\1740 hypotension_24\NN\14057371 ._25\.\1740
D005996_D009203 NONE nitroglycerin_0\NNP\15015501 has_1\VBZ\2108377 been_2\VBN\836236 shown_3\VBN\2137132 to_4\TO\1740 reduce_5\VB\441445 st-segment_6\JJ\1740 elevation_7\NN\7445480 during_8\IN\1740 <e2>acute_9\JJ\1740 myocardial_10\JJ\1740 infarction</e2>_11\NN\14204950 ,_12\,\1740 an_13\DT\6697703 effect_14\NN\34213 potentiated_15\VBD\229605 in_16\IN\13603305 the_17\DT\1740 dog_18\NN\2083346 by_19\IN\1740 agents_20\NNS\7347 that_21\WDT\1740 reverse_22\VBP\109660 <e1>nitroglycerin-induced</e1>_23\JJ\1740 hypotension_24\NN\14057371 ._25\.\1740
D005996_D009203 NONE ten_0\CD\13745420 patients_1\NNS\9898892 with_2\IN\1740 acute_3\JJ\1740 transmural_4\JJ\1740 <e2>myocardial_5\JJ\1740 infarctions</e2>_6\NNS\14204950 received_7\VBD\2210855 intravenous_8\JJ\1740 <e1>nitroglycerin</e1>_9\NN\15015501 ,_10\,\1740 sufficient_11\JJ\1740 to_12\TO\1740 reduce_13\VB\441445 mean_14\VB\928630 arterial_15\JJ\1740 pressure_16\NN\11419404 from_17\IN\1740 107_18\CD\1740 +/-_19\CC\1740 6_20\CD\13741022 to_21\TO\1740 85_22\CD\1740 +/-_23\CC\1740 6_24\CD\13741022 mm_25\NN\13649268 hg_26\NNP\14625458 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.001_31\CD\1740 )_32\-RRB-\1740 ,_33\,\1740 for_34\IN\1740 60_35\CD\13745420 minutes_36\NNS\6502378 ._37\.\1740
D005996_D009203 NONE our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 addition_4\NN\3081021 of_5\IN\1740 phenylephrine_6\NN\2682038 to_7\TO\1740 <e1>nitroglycerin</e1>_8\NN\15015501 is_9\VBZ\836236 not_10\RB\1740 beneficial_11\JJ\1740 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 patients_16\NNS\9898892 with_17\IN\1740 <e2>acute_18\JJ\1740 myocardial_19\JJ\1740 infarction</e2>_20\NN\14204950 ._21\.\1740
D005996_D007022 CID <e1>nitroglycerin</e1>_0\NNP\15015501 has_1\VBZ\2108377 been_2\VBN\836236 shown_3\VBN\2137132 to_4\TO\1740 reduce_5\VB\441445 st-segment_6\JJ\1740 elevation_7\NN\7445480 during_8\IN\1740 acute_9\JJ\1740 myocardial_10\JJ\1740 infarction_11\NN\14204950 ,_12\,\1740 an_13\DT\6697703 effect_14\NN\34213 potentiated_15\VBD\229605 in_16\IN\13603305 the_17\DT\1740 dog_18\NN\2083346 by_19\IN\1740 agents_20\NNS\7347 that_21\WDT\1740 reverse_22\VBP\109660 nitroglycerin-induced_23\JJ\1740 <e2>hypotension</e2>_24\NN\14057371 ._25\.\1740
D005996_D007022 CID nitroglycerin_0\NNP\15015501 has_1\VBZ\2108377 been_2\VBN\836236 shown_3\VBN\2137132 to_4\TO\1740 reduce_5\VB\441445 st-segment_6\JJ\1740 elevation_7\NN\7445480 during_8\IN\1740 acute_9\JJ\1740 myocardial_10\JJ\1740 infarction_11\NN\14204950 ,_12\,\1740 an_13\DT\6697703 effect_14\NN\34213 potentiated_15\VBD\229605 in_16\IN\13603305 the_17\DT\1740 dog_18\NN\2083346 by_19\IN\1740 agents_20\NNS\7347 that_21\WDT\1740 reverse_22\VBP\109660 <e1>nitroglycerin-induced</e1>_23\JJ\1740 <e2>hypotension</e2>_24\NN\14057371 ._25\.\1740
17600377
C524754_D003072 NONE a_0\DT\13649268 novel_1\JJ\1740 compound_2\NN\5869584 ,_3\,\1740 <e1>maltolyl_4\NN\1740 p-coumarate</e1>_5\NN\1740 ,_6\,\1740 attenuates_7\VBZ\224901 <e2>cognitive_8\JJ\1740 deficits</e2>_9\NNS\5113133 and_10\CC\1740 shows_11\VBZ\2137132 neuroprotective_12\JJ\1740 effects_13\NNS\13245626 in_14\FW\13603305 vitro_15\FW\1740 and_16\CC\1740 in_17\FW\13603305 vivo_18\FW\1740 dementia_19\NN\14395018 models_20\NNS\5888929 ._21\.\1740
C524754_D003072 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 whether_7\IN\1740 <e1>maltolyl_8\JJ\1740 p-coumarate</e1>_9\NN\1740 could_10\MD\1740 improve_11\VB\126264 <e2>cognitive_12\JJ\1740 decline</e2>_13\NN\13458571 in_14\IN\13603305 scopolamine-injected_15\JJ\1740 rats_16\NNS\2329401 and_17\CC\1740 in_18\IN\13603305 amyloid_19\NN\15053867 beta_20\NN\6828818 peptide(1_21\NN\1740 -_22\HYPH\1740 42)-infused_23\JJ\1740 rats_24\NNS\2329401 ._25\.\1740
C524754_D003072 NONE <e1>maltolyl_0\JJ\1740 p-coumarate</e1>_1\NN\1740 was_2\VBD\836236 found_3\VBN\2426171 to_4\TO\1740 attenuate_5\VB\224901 <e2>cognitive_6\JJ\1740 deficits</e2>_7\NNS\5113133 in_8\IN\13603305 both_9\DT\1740 rat_10\NN\2329401 models_11\NNS\5888929 using_12\VBG\1156834 passive_13\JJ\1740 avoidance_14\NN\203342 test_15\NN\5798043 and_16\CC\1740 to_17\TO\1740 reduce_18\VB\441445 apoptotic_19\JJ\1740 cell_20\NN\3080309 death_21\NN\7296428 observed_22\VBN\2163746 in_23\IN\13603305 the_24\DT\1740 hippocampus_25\NN\5462674 of_26\IN\1740 the_27\DT\1740 amyloid_28\NN\15053867 beta_29\NN\6828818 peptide(1_30\NN\1740 -_31\HYPH\1740 42)-infused_32\JJ\1740 rats_33\NNS\2329401 ._34\.\1740
C524754_D003072 NONE taking_0\VBG\2367363 these_1\DT\1740 in_2\FW\13603305 vitro_3\FW\1740 and_4\CC\1740 in_5\FW\13603305 vivo_6\FW\1740 results_7\NNS\34213 together_8\RB\1740 ,_9\,\1740 our_10\PRP$\1740 study_11\NN\635850 suggests_12\VBZ\1010118 that_13\IN\1740 <e1>maltolyl_14\JJ\1740 p-coumarate</e1>_15\NN\1740 is_16\VBZ\836236 a_17\DT\13649268 potentially_18\RB\1740 effective_19\JJ\1740 candidate_20\NN\10450303 against_21\IN\1740 alzheimer_22\NN\1740 's_23\POS\1740 disease_24\NN\14061805 that_25\WDT\1740 is_26\VBZ\836236 characterized_27\VBN\609683 by_28\IN\1740 wide_29\JJ\1740 spread_30\JJ\1740 neuronal_31\JJ\1740 death_32\NN\7296428 and_33\CC\1740 progressive_34\JJ\1740 <e2>decline_35\NN\13458571 of_36\IN\1740 cognitive_37\JJ\1740 function</e2>_38\NN\13783581 ._39\.\1740
C524754_D003704 NONE a_0\DT\13649268 novel_1\JJ\1740 compound_2\NN\5869584 ,_3\,\1740 <e1>maltolyl_4\NN\1740 p-coumarate</e1>_5\NN\1740 ,_6\,\1740 attenuates_7\VBZ\224901 cognitive_8\JJ\1740 deficits_9\NNS\5113133 and_10\CC\1740 shows_11\VBZ\2137132 neuroprotective_12\JJ\1740 effects_13\NNS\13245626 in_14\FW\13603305 vitro_15\FW\1740 and_16\CC\1740 in_17\FW\13603305 vivo_18\FW\1740 <e2>dementia</e2>_19\NN\14395018 models_20\NNS\5888929 ._21\.\1740
D012601_D003072 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 whether_7\IN\1740 maltolyl_8\JJ\1740 p-coumarate_9\NN\1740 could_10\MD\1740 improve_11\VB\126264 <e2>cognitive_12\JJ\1740 decline</e2>_13\NN\13458571 in_14\IN\13603305 <e1>scopolamine-injected</e1>_15\JJ\1740 rats_16\NNS\2329401 and_17\CC\1740 in_18\IN\13603305 amyloid_19\NN\15053867 beta_20\NN\6828818 peptide(1_21\NN\1740 -_22\HYPH\1740 42)-infused_23\JJ\1740 rats_24\NNS\2329401 ._25\.\1740
C544092_D003072 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 whether_7\IN\1740 maltolyl_8\JJ\1740 p-coumarate_9\NN\1740 could_10\MD\1740 improve_11\VB\126264 <e2>cognitive_12\JJ\1740 decline</e2>_13\NN\13458571 in_14\IN\13603305 scopolamine-injected_15\JJ\1740 rats_16\NNS\2329401 and_17\CC\1740 in_18\IN\13603305 <e1>amyloid_19\NN\15053867 beta_20\NN\6828818 peptide(1_21\NN\1740 -_22\HYPH\1740 42)-infused</e1>_23\JJ\1740 rats_24\NNS\2329401 ._25\.\1740
C544092_D003072 NONE maltolyl_0\JJ\1740 p-coumarate_1\NN\1740 was_2\VBD\836236 found_3\VBN\2426171 to_4\TO\1740 attenuate_5\VB\224901 <e2>cognitive_6\JJ\1740 deficits</e2>_7\NNS\5113133 in_8\IN\13603305 both_9\DT\1740 rat_10\NN\2329401 models_11\NNS\5888929 using_12\VBG\1156834 passive_13\JJ\1740 avoidance_14\NN\203342 test_15\NN\5798043 and_16\CC\1740 to_17\TO\1740 reduce_18\VB\441445 apoptotic_19\JJ\1740 cell_20\NN\3080309 death_21\NN\7296428 observed_22\VBN\2163746 in_23\IN\13603305 the_24\DT\1740 hippocampus_25\NN\5462674 of_26\IN\1740 the_27\DT\1740 <e1>amyloid_28\NN\15053867 beta_29\NN\6828818 peptide(1_30\NN\1740 -_31\HYPH\1740 42)-infused</e1>_32\JJ\1740 rats_33\NNS\2329401 ._34\.\1740
C524754_D000544 NONE taking_0\VBG\2367363 these_1\DT\1740 in_2\FW\13603305 vitro_3\FW\1740 and_4\CC\1740 in_5\FW\13603305 vivo_6\FW\1740 results_7\NNS\34213 together_8\RB\1740 ,_9\,\1740 our_10\PRP$\1740 study_11\NN\635850 suggests_12\VBZ\1010118 that_13\IN\1740 <e1>maltolyl_14\JJ\1740 p-coumarate</e1>_15\NN\1740 is_16\VBZ\836236 a_17\DT\13649268 potentially_18\RB\1740 effective_19\JJ\1740 candidate_20\NN\10450303 against_21\IN\1740 <e2>alzheimer_22\NN\1740 's_23\POS\1740 disease</e2>_24\NN\14061805 that_25\WDT\1740 is_26\VBZ\836236 characterized_27\VBN\609683 by_28\IN\1740 wide_29\JJ\1740 spread_30\JJ\1740 neuronal_31\JJ\1740 death_32\NN\7296428 and_33\CC\1740 progressive_34\JJ\1740 decline_35\NN\13458571 of_36\IN\1740 cognitive_37\JJ\1740 function_38\NN\13783581 ._39\.\1740
C524754_D009410 NONE taking_0\VBG\2367363 these_1\DT\1740 in_2\FW\13603305 vitro_3\FW\1740 and_4\CC\1740 in_5\FW\13603305 vivo_6\FW\1740 results_7\NNS\34213 together_8\RB\1740 ,_9\,\1740 our_10\PRP$\1740 study_11\NN\635850 suggests_12\VBZ\1010118 that_13\IN\1740 <e1>maltolyl_14\JJ\1740 p-coumarate</e1>_15\NN\1740 is_16\VBZ\836236 a_17\DT\13649268 potentially_18\RB\1740 effective_19\JJ\1740 candidate_20\NN\10450303 against_21\IN\1740 alzheimer_22\NN\1740 's_23\POS\1740 disease_24\NN\14061805 that_25\WDT\1740 is_26\VBZ\836236 characterized_27\VBN\609683 by_28\IN\1740 wide_29\JJ\1740 spread_30\JJ\1740 <e2>neuronal_31\JJ\1740 death</e2>_32\NN\7296428 and_33\CC\1740 progressive_34\JJ\1740 decline_35\NN\13458571 of_36\IN\1740 cognitive_37\JJ\1740 function_38\NN\13783581 ._39\.\1740
10526274
C056507_D002289 NONE <e1>gemcitabine</e1>_0\NN\1740 plus_1\CC\4723816 vinorelbine_2\NN\1740 in_3\IN\13603305 <e2>nonsmall_4\NN\1740 cell_5\NN\3080309 lung_6\NN\5528060 carcinoma</e2>_7\NN\14239918 patients_8\NNS\9898892 age_9\NN\4916342 70_10\CD\13745420 years_11\NNS\15144371 or_12\CC\3541091 older_13\JJR\1740 or_14\CC\3541091 patients_15\NNS\9898892 who_16\WP\8299493 can_17\MD\3094503 not_18\RB\1740 receive_19\VB\2210855 cisplatin_20\NN\1740 ._21\.\1740
C056507_D002289 NONE in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 the_4\DT\1740 efficacy_5\NN\5199286 and_6\CC\1740 toxicity_7\NN\13576101 of_8\IN\1740 the_9\DT\1740 combination_10\NN\7951464 of_11\IN\1740 <e1>gem</e1>_12\NN\2743547 and_13\CC\1740 vnb_14\NN\1740 in_15\IN\13603305 elderly_16\JJ\1740 patients_17\NNS\9898892 with_18\IN\1740 advanced_19\JJ\1740 <e2>nsclc</e2>_20\NN\1740 or_21\CC\3541091 those_22\DT\1740 with_23\IN\1740 some_24\DT\1740 contraindication_25\NN\5819149 to_26\IN\1740 receiving_27\VBG\2210855 cisplatin_28\NN\1740 were_29\VBD\836236 assessed_30\VBN\670261 ._31\.\1740
C030852_D002289 NONE gemcitabine_0\NN\1740 plus_1\CC\4723816 <e1>vinorelbine</e1>_2\NN\1740 in_3\IN\13603305 <e2>nonsmall_4\NN\1740 cell_5\NN\3080309 lung_6\NN\5528060 carcinoma</e2>_7\NN\14239918 patients_8\NNS\9898892 age_9\NN\4916342 70_10\CD\13745420 years_11\NNS\15144371 or_12\CC\3541091 older_13\JJR\1740 or_14\CC\3541091 patients_15\NNS\9898892 who_16\WP\8299493 can_17\MD\3094503 not_18\RB\1740 receive_19\VB\2210855 cisplatin_20\NN\1740 ._21\.\1740
C030852_D002289 NONE in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 the_4\DT\1740 efficacy_5\NN\5199286 and_6\CC\1740 toxicity_7\NN\13576101 of_8\IN\1740 the_9\DT\1740 combination_10\NN\7951464 of_11\IN\1740 gem_12\NN\2743547 and_13\CC\1740 <e1>vnb</e1>_14\NN\1740 in_15\IN\13603305 elderly_16\JJ\1740 patients_17\NNS\9898892 with_18\IN\1740 advanced_19\JJ\1740 <e2>nsclc</e2>_20\NN\1740 or_21\CC\3541091 those_22\DT\1740 with_23\IN\1740 some_24\DT\1740 contraindication_25\NN\5819149 to_26\IN\1740 receiving_27\VBG\2210855 cisplatin_28\NN\1740 were_29\VBD\836236 assessed_30\VBN\670261 ._31\.\1740
D002945_D002289 NONE gemcitabine_0\NN\1740 plus_1\CC\4723816 vinorelbine_2\NN\1740 in_3\IN\13603305 <e2>nonsmall_4\NN\1740 cell_5\NN\3080309 lung_6\NN\5528060 carcinoma</e2>_7\NN\14239918 patients_8\NNS\9898892 age_9\NN\4916342 70_10\CD\13745420 years_11\NNS\15144371 or_12\CC\3541091 older_13\JJR\1740 or_14\CC\3541091 patients_15\NNS\9898892 who_16\WP\8299493 can_17\MD\3094503 not_18\RB\1740 receive_19\VB\2210855 <e1>cisplatin</e1>_20\NN\1740 ._21\.\1740
D002945_D002289 NONE in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 the_4\DT\1740 efficacy_5\NN\5199286 and_6\CC\1740 toxicity_7\NN\13576101 of_8\IN\1740 the_9\DT\1740 combination_10\NN\7951464 of_11\IN\1740 gem_12\NN\2743547 and_13\CC\1740 vnb_14\NN\1740 in_15\IN\13603305 elderly_16\JJ\1740 patients_17\NNS\9898892 with_18\IN\1740 advanced_19\JJ\1740 <e2>nsclc</e2>_20\NN\1740 or_21\CC\3541091 those_22\DT\1740 with_23\IN\1740 some_24\DT\1740 contraindication_25\NN\5819149 to_26\IN\1740 receiving_27\VBG\2210855 <e1>cisplatin</e1>_28\NN\1740 were_29\VBD\836236 assessed_30\VBN\670261 ._31\.\1740
D002945_D002289 NONE methods_0\NNS\5616786 :_1\:\1740 forty-nine_2\JJ\1740 patients_3\NNS\9898892 with_4\IN\1740 advanced_5\JJ\1740 <e2>nsclc</e2>_6\NN\1740 were_7\VBD\836236 included_8\VBN\690614 ,_9\,\1740 38_10\CD\1740 of_11\IN\1740 whom_12\WP\1740 were_13\VBD\836236 age_14\NN\4916342 >_15\NNS\1740 /=_16\NN\1740 70_17\CD\13745420 years_18\NNS\15144371 and_19\CC\1740 11_20\CD\13745420 were_21\VBD\836236 age_22\NN\4916342 <_23\XX\1740 70_24\CD\13745420 years_25\NNS\15144371 but_26\CC\1740 who_27\WP\8299493 had_28\VBD\2108377 some_29\DT\1740 contraindication_30\NN\5819149 to_31\IN\1740 receiving_32\VBG\2210855 <e1>cisplatin</e1>_33\NN\1740 ._34\.\1740
C030852_D064420 NONE recent_0\JJ\1740 reports_1\NNS\6470073 indicate_2\VBP\952524 that_3\IN\1740 single_4\JJ\1740 agent_5\NN\7347 therapy_6\NN\657604 with_7\IN\1740 <e1>vinorelbine</e1>_8\NN\1740 (_9\-LRB-\1740 vnb_10\NN\1740 )_11\-RRB-\1740 or_12\CC\3541091 gemcitabine_13\NN\1740 (_14\-LRB-\1740 gem_15\NN\2743547 )_16\-RRB-\1740 may_17\MD\15209706 obtain_18\VB\2210855 a_19\DT\13649268 response_20\NN\11410625 rate_21\NN\13815152 of_22\IN\1740 20_23\CD\13745420 -_24\SYM\1740 30_25\CD\13745420 %_26\NN\1740 in_27\IN\13603305 elderly_28\JJ\1740 patients_29\NNS\9898892 ,_30\,\1740 with_31\IN\1740 acceptable_32\JJ\1740 <e2>toxicity</e2>_33\NN\13576101 and_34\CC\1740 improvement_35\NN\7359599 in_36\IN\13603305 symptoms_37\NNS\5823932 and_38\CC\1740 quality_39\NN\24264 of_40\IN\1740 life_41\NN\13954253 ._42\.\1740
C030852_D064420 NONE recent_0\JJ\1740 reports_1\NNS\6470073 indicate_2\VBP\952524 that_3\IN\1740 single_4\JJ\1740 agent_5\NN\7347 therapy_6\NN\657604 with_7\IN\1740 vinorelbine_8\NN\1740 (_9\-LRB-\1740 <e1>vnb</e1>_10\NN\1740 )_11\-RRB-\1740 or_12\CC\3541091 gemcitabine_13\NN\1740 (_14\-LRB-\1740 gem_15\NN\2743547 )_16\-RRB-\1740 may_17\MD\15209706 obtain_18\VB\2210855 a_19\DT\13649268 response_20\NN\11410625 rate_21\NN\13815152 of_22\IN\1740 20_23\CD\13745420 -_24\SYM\1740 30_25\CD\13745420 %_26\NN\1740 in_27\IN\13603305 elderly_28\JJ\1740 patients_29\NNS\9898892 ,_30\,\1740 with_31\IN\1740 acceptable_32\JJ\1740 <e2>toxicity</e2>_33\NN\13576101 and_34\CC\1740 improvement_35\NN\7359599 in_36\IN\13603305 symptoms_37\NNS\5823932 and_38\CC\1740 quality_39\NN\24264 of_40\IN\1740 life_41\NN\13954253 ._42\.\1740
C030852_D064420 NONE in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 the_4\DT\1740 efficacy_5\NN\5199286 and_6\CC\1740 <e2>toxicity</e2>_7\NN\13576101 of_8\IN\1740 the_9\DT\1740 combination_10\NN\7951464 of_11\IN\1740 gem_12\NN\2743547 and_13\CC\1740 <e1>vnb</e1>_14\NN\1740 in_15\IN\13603305 elderly_16\JJ\1740 patients_17\NNS\9898892 with_18\IN\1740 advanced_19\JJ\1740 nsclc_20\NN\1740 or_21\CC\3541091 those_22\DT\1740 with_23\IN\1740 some_24\DT\1740 contraindication_25\NN\5819149 to_26\IN\1740 receiving_27\VBG\2210855 cisplatin_28\NN\1740 were_29\VBD\836236 assessed_30\VBN\670261 ._31\.\1740
C056507_D064420 NONE recent_0\JJ\1740 reports_1\NNS\6470073 indicate_2\VBP\952524 that_3\IN\1740 single_4\JJ\1740 agent_5\NN\7347 therapy_6\NN\657604 with_7\IN\1740 vinorelbine_8\NN\1740 (_9\-LRB-\1740 vnb_10\NN\1740 )_11\-RRB-\1740 or_12\CC\3541091 <e1>gemcitabine</e1>_13\NN\1740 (_14\-LRB-\1740 gem_15\NN\2743547 )_16\-RRB-\1740 may_17\MD\15209706 obtain_18\VB\2210855 a_19\DT\13649268 response_20\NN\11410625 rate_21\NN\13815152 of_22\IN\1740 20_23\CD\13745420 -_24\SYM\1740 30_25\CD\13745420 %_26\NN\1740 in_27\IN\13603305 elderly_28\JJ\1740 patients_29\NNS\9898892 ,_30\,\1740 with_31\IN\1740 acceptable_32\JJ\1740 <e2>toxicity</e2>_33\NN\13576101 and_34\CC\1740 improvement_35\NN\7359599 in_36\IN\13603305 symptoms_37\NNS\5823932 and_38\CC\1740 quality_39\NN\24264 of_40\IN\1740 life_41\NN\13954253 ._42\.\1740
C056507_D064420 NONE recent_0\JJ\1740 reports_1\NNS\6470073 indicate_2\VBP\952524 that_3\IN\1740 single_4\JJ\1740 agent_5\NN\7347 therapy_6\NN\657604 with_7\IN\1740 vinorelbine_8\NN\1740 (_9\-LRB-\1740 vnb_10\NN\1740 )_11\-RRB-\1740 or_12\CC\3541091 gemcitabine_13\NN\1740 (_14\-LRB-\1740 <e1>gem</e1>_15\NN\2743547 )_16\-RRB-\1740 may_17\MD\15209706 obtain_18\VB\2210855 a_19\DT\13649268 response_20\NN\11410625 rate_21\NN\13815152 of_22\IN\1740 20_23\CD\13745420 -_24\SYM\1740 30_25\CD\13745420 %_26\NN\1740 in_27\IN\13603305 elderly_28\JJ\1740 patients_29\NNS\9898892 ,_30\,\1740 with_31\IN\1740 acceptable_32\JJ\1740 <e2>toxicity</e2>_33\NN\13576101 and_34\CC\1740 improvement_35\NN\7359599 in_36\IN\13603305 symptoms_37\NNS\5823932 and_38\CC\1740 quality_39\NN\24264 of_40\IN\1740 life_41\NN\13954253 ._42\.\1740
C056507_D064420 NONE in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 the_4\DT\1740 efficacy_5\NN\5199286 and_6\CC\1740 <e2>toxicity</e2>_7\NN\13576101 of_8\IN\1740 the_9\DT\1740 combination_10\NN\7951464 of_11\IN\1740 <e1>gem</e1>_12\NN\2743547 and_13\CC\1740 vnb_14\NN\1740 in_15\IN\13603305 elderly_16\JJ\1740 patients_17\NNS\9898892 with_18\IN\1740 advanced_19\JJ\1740 nsclc_20\NN\1740 or_21\CC\3541091 those_22\DT\1740 with_23\IN\1740 some_24\DT\1740 contraindication_25\NN\5819149 to_26\IN\1740 receiving_27\VBG\2210855 cisplatin_28\NN\1740 were_29\VBD\836236 assessed_30\VBN\670261 ._31\.\1740
D002945_D064420 NONE in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 the_4\DT\1740 efficacy_5\NN\5199286 and_6\CC\1740 <e2>toxicity</e2>_7\NN\13576101 of_8\IN\1740 the_9\DT\1740 combination_10\NN\7951464 of_11\IN\1740 gem_12\NN\2743547 and_13\CC\1740 vnb_14\NN\1740 in_15\IN\13603305 elderly_16\JJ\1740 patients_17\NNS\9898892 with_18\IN\1740 advanced_19\JJ\1740 nsclc_20\NN\1740 or_21\CC\3541091 those_22\DT\1740 with_23\IN\1740 some_24\DT\1740 contraindication_25\NN\5819149 to_26\IN\1740 receiving_27\VBG\2210855 <e1>cisplatin</e1>_28\NN\1740 were_29\VBD\836236 assessed_30\VBN\670261 ._31\.\1740
6692345
D001241_D001749 NONE the_0\DT\1740 co-administration_1\NN\1740 of_2\IN\1740 <e1>aspirin</e1>_3\NN\2707683 with_4\IN\1740 n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740 (_6\-LRB-\1740 fanft_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 rats_10\NNS\2329401 resulted_11\VBD\2633881 in_12\IN\13603305 a_13\DT\13649268 reduced_14\VBN\441445 incidence_15\NN\13821570 of_16\IN\1740 fanft-induced_17\JJ\1740 <e2>bladder_18\NN\5515670 carcinomas</e2>_19\NNS\14239918 but_20\CC\1740 a_21\DT\13649268 concomitant_22\JJ\1740 induction_23\NN\7450842 of_24\IN\1740 forestomach_25\NN\1740 tumors_26\NNS\14234074 ._27\.\1740
D001241_D013274 NONE the_0\DT\1740 co-administration_1\NN\1740 of_2\IN\1740 <e1>aspirin</e1>_3\NN\2707683 with_4\IN\1740 n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740 (_6\-LRB-\1740 fanft_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 rats_10\NNS\2329401 resulted_11\VBD\2633881 in_12\IN\13603305 a_13\DT\13649268 reduced_14\VBN\441445 incidence_15\NN\13821570 of_16\IN\1740 fanft-induced_17\JJ\1740 bladder_18\NN\5515670 carcinomas_19\NNS\14239918 but_20\CC\1740 a_21\DT\13649268 concomitant_22\JJ\1740 induction_23\NN\7450842 of_24\IN\1740 <e2>forestomach_25\NN\1740 tumors</e2>_26\NNS\14234074 ._27\.\1740
D005200_D001749 CID the_0\DT\1740 co-administration_1\NN\1740 of_2\IN\1740 aspirin_3\NN\2707683 with_4\IN\1740 <e1>n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide</e1>_5\NN\1740 (_6\-LRB-\1740 fanft_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 rats_10\NNS\2329401 resulted_11\VBD\2633881 in_12\IN\13603305 a_13\DT\13649268 reduced_14\VBN\441445 incidence_15\NN\13821570 of_16\IN\1740 fanft-induced_17\JJ\1740 <e2>bladder_18\NN\5515670 carcinomas</e2>_19\NNS\14239918 but_20\CC\1740 a_21\DT\13649268 concomitant_22\JJ\1740 induction_23\NN\7450842 of_24\IN\1740 forestomach_25\NN\1740 tumors_26\NNS\14234074 ._27\.\1740
D005200_D001749 CID the_0\DT\1740 co-administration_1\NN\1740 of_2\IN\1740 aspirin_3\NN\2707683 with_4\IN\1740 n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740 (_6\-LRB-\1740 <e1>fanft</e1>_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 rats_10\NNS\2329401 resulted_11\VBD\2633881 in_12\IN\13603305 a_13\DT\13649268 reduced_14\VBN\441445 incidence_15\NN\13821570 of_16\IN\1740 fanft-induced_17\JJ\1740 <e2>bladder_18\NN\5515670 carcinomas</e2>_19\NNS\14239918 but_20\CC\1740 a_21\DT\13649268 concomitant_22\JJ\1740 induction_23\NN\7450842 of_24\IN\1740 forestomach_25\NN\1740 tumors_26\NNS\14234074 ._27\.\1740
D005200_D001749 CID the_0\DT\1740 co-administration_1\NN\1740 of_2\IN\1740 aspirin_3\NN\2707683 with_4\IN\1740 n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740 (_6\-LRB-\1740 fanft_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 rats_10\NNS\2329401 resulted_11\VBD\2633881 in_12\IN\13603305 a_13\DT\13649268 reduced_14\VBN\441445 incidence_15\NN\13821570 of_16\IN\1740 <e1>fanft-induced</e1>_17\JJ\1740 <e2>bladder_18\NN\5515670 carcinomas</e2>_19\NNS\14239918 but_20\CC\1740 a_21\DT\13649268 concomitant_22\JJ\1740 induction_23\NN\7450842 of_24\IN\1740 forestomach_25\NN\1740 tumors_26\NNS\14234074 ._27\.\1740
D005200_D013274 CID the_0\DT\1740 co-administration_1\NN\1740 of_2\IN\1740 aspirin_3\NN\2707683 with_4\IN\1740 <e1>n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide</e1>_5\NN\1740 (_6\-LRB-\1740 fanft_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 rats_10\NNS\2329401 resulted_11\VBD\2633881 in_12\IN\13603305 a_13\DT\13649268 reduced_14\VBN\441445 incidence_15\NN\13821570 of_16\IN\1740 fanft-induced_17\JJ\1740 bladder_18\NN\5515670 carcinomas_19\NNS\14239918 but_20\CC\1740 a_21\DT\13649268 concomitant_22\JJ\1740 induction_23\NN\7450842 of_24\IN\1740 <e2>forestomach_25\NN\1740 tumors</e2>_26\NNS\14234074 ._27\.\1740
D005200_D013274 CID the_0\DT\1740 co-administration_1\NN\1740 of_2\IN\1740 aspirin_3\NN\2707683 with_4\IN\1740 n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740 (_6\-LRB-\1740 <e1>fanft</e1>_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 rats_10\NNS\2329401 resulted_11\VBD\2633881 in_12\IN\13603305 a_13\DT\13649268 reduced_14\VBN\441445 incidence_15\NN\13821570 of_16\IN\1740 fanft-induced_17\JJ\1740 bladder_18\NN\5515670 carcinomas_19\NNS\14239918 but_20\CC\1740 a_21\DT\13649268 concomitant_22\JJ\1740 induction_23\NN\7450842 of_24\IN\1740 <e2>forestomach_25\NN\1740 tumors</e2>_26\NNS\14234074 ._27\.\1740
D005200_D013274 CID the_0\DT\1740 co-administration_1\NN\1740 of_2\IN\1740 aspirin_3\NN\2707683 with_4\IN\1740 n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740 (_6\-LRB-\1740 fanft_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 rats_10\NNS\2329401 resulted_11\VBD\2633881 in_12\IN\13603305 a_13\DT\13649268 reduced_14\VBN\441445 incidence_15\NN\13821570 of_16\IN\1740 <e1>fanft-induced</e1>_17\JJ\1740 bladder_18\NN\5515670 carcinomas_19\NNS\14239918 but_20\CC\1740 a_21\DT\13649268 concomitant_22\JJ\1740 induction_23\NN\7450842 of_24\IN\1740 <e2>forestomach_25\NN\1740 tumors</e2>_26\NNS\14234074 ._27\.\1740
D005200_D063646 NONE the_0\DT\1740 present_1\JJ\1740 results_2\NNS\34213 are_3\VBP\836236 consistent_4\JJ\1740 with_5\IN\1740 the_6\DT\1740 carcinogenicity_7\NN\1740 experiment_8\NN\641820 suggesting_9\VBG\1010118 that_10\IN\1740 different_11\JJ\1740 mechanisms_12\NNS\13446390 are_13\VBP\836236 involved_14\VBN\2676054 in_15\IN\13603305 <e1>fanft</e1>_16\NN\1740 <e2>carcinogenesis</e2>_17\NN\1740 in_18\IN\13603305 the_19\DT\1740 bladder_20\NN\5515670 and_21\CC\1740 forestomach_22\NN\1740 ,_23\,\1740 and_24\CC\1740 that_25\IN\1740 aspirin_26\NN\2707683 's_27\POS\1740 effect_28\NN\34213 on_29\IN\1740 fanft_30\NN\1740 in_31\IN\13603305 the_32\DT\1740 forestomach_33\NN\1740 is_34\VBZ\836236 not_35\RB\1740 due_36\JJ\1740 to_37\TO\1740 an_38\DT\6697703 irritant_39\JJ\1740 effect_40\NN\34213 associated_41\VBN\628491 with_42\IN\1740 increased_43\VBN\169651 cell_44\NN\3080309 proliferation_45\NN\13489037 ._46\.\1740
D005200_D063646 NONE the_0\DT\1740 present_1\JJ\1740 results_2\NNS\34213 are_3\VBP\836236 consistent_4\JJ\1740 with_5\IN\1740 the_6\DT\1740 carcinogenicity_7\NN\1740 experiment_8\NN\641820 suggesting_9\VBG\1010118 that_10\IN\1740 different_11\JJ\1740 mechanisms_12\NNS\13446390 are_13\VBP\836236 involved_14\VBN\2676054 in_15\IN\13603305 fanft_16\NN\1740 <e2>carcinogenesis</e2>_17\NN\1740 in_18\IN\13603305 the_19\DT\1740 bladder_20\NN\5515670 and_21\CC\1740 forestomach_22\NN\1740 ,_23\,\1740 and_24\CC\1740 that_25\IN\1740 aspirin_26\NN\2707683 's_27\POS\1740 effect_28\NN\34213 on_29\IN\1740 <e1>fanft</e1>_30\NN\1740 in_31\IN\13603305 the_32\DT\1740 forestomach_33\NN\1740 is_34\VBZ\836236 not_35\RB\1740 due_36\JJ\1740 to_37\TO\1740 an_38\DT\6697703 irritant_39\JJ\1740 effect_40\NN\34213 associated_41\VBN\628491 with_42\IN\1740 increased_43\VBN\169651 cell_44\NN\3080309 proliferation_45\NN\13489037 ._46\.\1740
D001241_D063646 NONE the_0\DT\1740 present_1\JJ\1740 results_2\NNS\34213 are_3\VBP\836236 consistent_4\JJ\1740 with_5\IN\1740 the_6\DT\1740 carcinogenicity_7\NN\1740 experiment_8\NN\641820 suggesting_9\VBG\1010118 that_10\IN\1740 different_11\JJ\1740 mechanisms_12\NNS\13446390 are_13\VBP\836236 involved_14\VBN\2676054 in_15\IN\13603305 fanft_16\NN\1740 <e2>carcinogenesis</e2>_17\NN\1740 in_18\IN\13603305 the_19\DT\1740 bladder_20\NN\5515670 and_21\CC\1740 forestomach_22\NN\1740 ,_23\,\1740 and_24\CC\1740 that_25\IN\1740 <e1>aspirin</e1>_26\NN\2707683 's_27\POS\1740 effect_28\NN\34213 on_29\IN\1740 fanft_30\NN\1740 in_31\IN\13603305 the_32\DT\1740 forestomach_33\NN\1740 is_34\VBZ\836236 not_35\RB\1740 due_36\JJ\1740 to_37\TO\1740 an_38\DT\6697703 irritant_39\JJ\1740 effect_40\NN\34213 associated_41\VBN\628491 with_42\IN\1740 increased_43\VBN\169651 cell_44\NN\3080309 proliferation_45\NN\13489037 ._46\.\1740
2950248
D004176_D017202 NONE <e1>dipyridamole-induced</e1>_0\JJ\1740 <e2>myocardial_1\JJ\1740 ischemia</e2>_2\NN\14195315 ._3\.\1740
D004176_D017202 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 has_5\VBZ\2108377 not_6\RB\1740 previously_7\RB\1740 been_8\VBN\836236 reported_9\VBN\831651 as_10\IN\14622893 a_11\DT\13649268 side_12\JJ\1740 effect_13\NN\34213 of_14\IN\1740 preoperative_15\JJ\1740 <e1>dipyridamole</e1>_16\NN\1740 therapy_17\NN\657604 ,_18\,\1740 although_19\IN\1740 dipyridamole-induced_20\JJ\1740 <e2>myocardial_21\JJ\1740 ischemia</e2>_22\NN\14195315 has_23\VBZ\2108377 been_24\VBN\836236 demonstrated_25\VBN\2137132 to_26\TO\1740 occur_27\VB\2623529 in_28\IN\13603305 animals_29\NNS\4475 and_30\CC\1740 humans_31\NNS\31264 with_32\IN\1740 coronary_33\JJ\1740 artery_34\NN\5417975 disease_35\NN\14061805 ._36\.\1740
D004176_D017202 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 has_5\VBZ\2108377 not_6\RB\1740 previously_7\RB\1740 been_8\VBN\836236 reported_9\VBN\831651 as_10\IN\14622893 a_11\DT\13649268 side_12\JJ\1740 effect_13\NN\34213 of_14\IN\1740 preoperative_15\JJ\1740 dipyridamole_16\NN\1740 therapy_17\NN\657604 ,_18\,\1740 although_19\IN\1740 <e1>dipyridamole-induced</e1>_20\JJ\1740 <e2>myocardial_21\JJ\1740 ischemia</e2>_22\NN\14195315 has_23\VBZ\2108377 been_24\VBN\836236 demonstrated_25\VBN\2137132 to_26\TO\1740 occur_27\VB\2623529 in_28\IN\13603305 animals_29\NNS\4475 and_30\CC\1740 humans_31\NNS\31264 with_32\IN\1740 coronary_33\JJ\1740 artery_34\NN\5417975 disease_35\NN\14061805 ._36\.\1740
D004176_D000787 CID <e2>angina</e2>_0\JJ\1740 and_1\CC\1740 ischemic_2\JJ\1740 electrocardiographic_3\JJ\1740 changes_4\NNS\7283608 occurred_5\VBD\2623529 after_6\IN\1740 administration_7\NN\1133281 of_8\IN\1740 oral_9\JJ\1740 <e1>dipyridamole</e1>_10\NN\1740 in_11\IN\13603305 four_12\CD\13741022 patients_13\NNS\9898892 awaiting_14\VBG\1740 urgent_15\JJ\1740 myocardial_16\JJ\1740 revascularization_17\NN\1740 procedures_18\NNS\407535 ._19\.\1740
D004176_D003324 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 has_5\VBZ\2108377 not_6\RB\1740 previously_7\RB\1740 been_8\VBN\836236 reported_9\VBN\831651 as_10\IN\14622893 a_11\DT\13649268 side_12\JJ\1740 effect_13\NN\34213 of_14\IN\1740 preoperative_15\JJ\1740 <e1>dipyridamole</e1>_16\NN\1740 therapy_17\NN\657604 ,_18\,\1740 although_19\IN\1740 dipyridamole-induced_20\JJ\1740 myocardial_21\JJ\1740 ischemia_22\NN\14195315 has_23\VBZ\2108377 been_24\VBN\836236 demonstrated_25\VBN\2137132 to_26\TO\1740 occur_27\VB\2623529 in_28\IN\13603305 animals_29\NNS\4475 and_30\CC\1740 humans_31\NNS\31264 with_32\IN\1740 <e2>coronary_33\JJ\1740 artery_34\NN\5417975 disease</e2>_35\NN\14061805 ._36\.\1740
D004176_D003324 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 has_5\VBZ\2108377 not_6\RB\1740 previously_7\RB\1740 been_8\VBN\836236 reported_9\VBN\831651 as_10\IN\14622893 a_11\DT\13649268 side_12\JJ\1740 effect_13\NN\34213 of_14\IN\1740 preoperative_15\JJ\1740 dipyridamole_16\NN\1740 therapy_17\NN\657604 ,_18\,\1740 although_19\IN\1740 <e1>dipyridamole-induced</e1>_20\JJ\1740 myocardial_21\JJ\1740 ischemia_22\NN\14195315 has_23\VBZ\2108377 been_24\VBN\836236 demonstrated_25\VBN\2137132 to_26\TO\1740 occur_27\VB\2623529 in_28\IN\13603305 animals_29\NNS\4475 and_30\CC\1740 humans_31\NNS\31264 with_32\IN\1740 <e2>coronary_33\JJ\1740 artery_34\NN\5417975 disease</e2>_35\NN\14061805 ._36\.\1740
D004176_D007511 NONE epicardial_0\JJ\1740 coronary_1\JJ\1740 collateral_2\NN\13287984 vessels_3\NNS\5246511 were_4\VBD\836236 demonstrated_5\VBN\2137132 in_6\IN\13603305 all_7\DT\1740 four_8\CD\13741022 patients_9\NNS\9898892 ;_10\:\1740 a_11\DT\13649268 coronary_12\JJ\1740 "_13\``\1740 steal_14\JJ\1740 "_15\``\1740 phenomenon_16\NN\29677 may_17\MD\15209706 be_18\VB\836236 the_19\DT\1740 mechanism_20\NN\13446390 of_21\IN\1740 the_22\DT\1740 <e1>dipyridamole-induced</e1>_23\JJ\1740 <e2>ischemia</e2>_24\NN\14195315 observed_25\VBN\2163746 ._26\.\1740
18791946
D002939_D013921 CID severe_0\JJ\1740 <e2>thrombocytopenia</e2>_1\NN\14189204 and_2\CC\1740 haemolytic_3\JJ\1740 anaemia_4\NN\14299637 associated_5\VBN\628491 with_6\IN\1740 <e1>ciprofloxacin</e1>_7\NN\2716866 :_8\:\1740 a_9\DT\13649268 case_10\NN\7283608 report_11\NN\6470073 with_12\IN\1740 fatal_13\JJ\1740 outcome_14\NN\7291312 ._15\.\1740
D002939_D013921 CID this_0\DT\1740 case_1\NN\7283608 report_2\NN\6470073 shows_3\VBZ\2137132 that_4\IN\1740 <e1>ciprofloxacin</e1>_5\NN\2716866 may_6\MD\15209706 precipitate_7\VB\1642924 life-threatening_8\JJ\1740 <e2>thrombocytopenia</e2>_9\NN\14189204 and_10\CC\1740 haemolytic_11\JJ\1740 anaemia_12\NN\14299637 ,_13\,\1740 even_14\RB\1740 in_15\IN\13603305 the_16\DT\1740 early_17\JJ\1740 phases_18\NNS\15113229 of_19\IN\1740 treatment_20\NN\654885 and_21\CC\1740 without_22\IN\1740 apparent_23\JJ\1740 previous_24\JJ\1740 exposures_25\NNS\5042871 ._26\.\1740
D002939_D000743 CID severe_0\JJ\1740 thrombocytopenia_1\NN\14189204 and_2\CC\1740 <e2>haemolytic_3\JJ\1740 anaemia</e2>_4\NN\14299637 associated_5\VBN\628491 with_6\IN\1740 <e1>ciprofloxacin</e1>_7\NN\2716866 :_8\:\1740 a_9\DT\13649268 case_10\NN\7283608 report_11\NN\6470073 with_12\IN\1740 fatal_13\JJ\1740 outcome_14\NN\7291312 ._15\.\1740
D002939_D000743 CID this_0\DT\1740 case_1\NN\7283608 report_2\NN\6470073 shows_3\VBZ\2137132 that_4\IN\1740 <e1>ciprofloxacin</e1>_5\NN\2716866 may_6\MD\15209706 precipitate_7\VB\1642924 life-threatening_8\JJ\1740 thrombocytopenia_9\NN\14189204 and_10\CC\1740 <e2>haemolytic_11\JJ\1740 anaemia</e2>_12\NN\14299637 ,_13\,\1740 even_14\RB\1740 in_15\IN\13603305 the_16\DT\1740 early_17\JJ\1740 phases_18\NNS\15113229 of_19\IN\1740 treatment_20\NN\654885 and_21\CC\1740 without_22\IN\1740 apparent_23\JJ\1740 previous_24\JJ\1740 exposures_25\NNS\5042871 ._26\.\1740
D002939_D015746 CID a_0\DT\13649268 30-year_1\JJ\1740 old_2\JJ\1740 caucasian_3\JJ\1740 man_4\NN\9605289 reported_5\VBN\831651 with_6\IN\1740 <e2>abdominal_7\JJ\1740 pain</e2>_8\NN\14299637 and_9\CC\1740 jaundice_10\NN\14299637 after_11\IN\1740 3-day_12\JJ\1740 administration_13\NN\1133281 of_14\IN\1740 oral_15\JJ\1740 <e1>ciprofloxacin</e1>_16\NN\2716866 for_17\IN\1740 a_18\DT\13649268 suspect_19\NN\7846 of_20\IN\1740 urinary_21\JJ\1740 tract_22\NN\8574314 infection_23\NN\14052046 ._24\.\1740
D002939_D007565 CID a_0\DT\13649268 30-year_1\JJ\1740 old_2\JJ\1740 caucasian_3\JJ\1740 man_4\NN\9605289 reported_5\VBN\831651 with_6\IN\1740 abdominal_7\JJ\1740 pain_8\NN\14299637 and_9\CC\1740 <e2>jaundice</e2>_10\NN\14299637 after_11\IN\1740 3-day_12\JJ\1740 administration_13\NN\1133281 of_14\IN\1740 oral_15\JJ\1740 <e1>ciprofloxacin</e1>_16\NN\2716866 for_17\IN\1740 a_18\DT\13649268 suspect_19\NN\7846 of_20\IN\1740 urinary_21\JJ\1740 tract_22\NN\8574314 infection_23\NN\14052046 ._24\.\1740
D002939_D014552 NONE a_0\DT\13649268 30-year_1\JJ\1740 old_2\JJ\1740 caucasian_3\JJ\1740 man_4\NN\9605289 reported_5\VBN\831651 with_6\IN\1740 abdominal_7\JJ\1740 pain_8\NN\14299637 and_9\CC\1740 jaundice_10\NN\14299637 after_11\IN\1740 3-day_12\JJ\1740 administration_13\NN\1133281 of_14\IN\1740 oral_15\JJ\1740 <e1>ciprofloxacin</e1>_16\NN\2716866 for_17\IN\1740 a_18\DT\13649268 suspect_19\NN\7846 of_20\IN\1740 <e2>urinary_21\JJ\1740 tract_22\NN\8574314 infection</e2>_23\NN\14052046 ._24\.\1740
17344566
D019821_D003161 CID <e1>simvastatin-induced</e1>_0\JJ\1740 bilateral_1\JJ\1740 leg_2\NN\5560244 <e2>compartment_3\NN\13910384 syndrome</e2>_4\NN\5870365 and_5\CC\1740 myonecrosis_6\NN\11486708 associated_7\VBN\628491 with_8\IN\1740 hypothyroidism_9\NN\14059928 ._10\.\1740
D019821_D003161 CID a_0\DT\13649268 54-year-old_1\JJ\1740 hypothyroid_2\JJ\1740 male_3\JJ\1740 taking_4\VBG\2367363 thyroxine_5\NN\5413241 and_6\CC\1740 <e1>simvastatin</e1>_7\NN\3676175 presented_8\VBN\2137132 with_9\IN\1740 bilateral_10\JJ\1740 leg_11\NN\5560244 <e2>compartment_12\NN\13910384 syndrome</e2>_13\NN\5870365 and_14\CC\1740 myonecrosis_15\NN\11486708 ._16\.\1740
D019821_D009135 NONE <e1>simvastatin-induced</e1>_0\JJ\1740 bilateral_1\JJ\1740 leg_2\NN\5560244 compartment_3\NN\13910384 syndrome_4\NN\5870365 and_5\CC\1740 <e2>myonecrosis</e2>_6\NN\11486708 associated_7\VBN\628491 with_8\IN\1740 hypothyroidism_9\NN\14059928 ._10\.\1740
D019821_D009135 NONE a_0\DT\13649268 54-year-old_1\JJ\1740 hypothyroid_2\JJ\1740 male_3\JJ\1740 taking_4\VBG\2367363 thyroxine_5\NN\5413241 and_6\CC\1740 <e1>simvastatin</e1>_7\NN\3676175 presented_8\VBN\2137132 with_9\IN\1740 bilateral_10\JJ\1740 leg_11\NN\5560244 compartment_12\NN\13910384 syndrome_13\NN\5870365 and_14\CC\1740 <e2>myonecrosis</e2>_15\NN\11486708 ._16\.\1740
D019821_D007037 NONE <e1>simvastatin-induced</e1>_0\JJ\1740 bilateral_1\JJ\1740 leg_2\NN\5560244 compartment_3\NN\13910384 syndrome_4\NN\5870365 and_5\CC\1740 myonecrosis_6\NN\11486708 associated_7\VBN\628491 with_8\IN\1740 <e2>hypothyroidism</e2>_9\NN\14059928 ._10\.\1740
D019821_D007037 NONE a_0\DT\13649268 54-year-old_1\JJ\1740 <e2>hypothyroid</e2>_2\JJ\1740 male_3\JJ\1740 taking_4\VBG\2367363 thyroxine_5\NN\5413241 and_6\CC\1740 <e1>simvastatin</e1>_7\NN\3676175 presented_8\VBN\2137132 with_9\IN\1740 bilateral_10\JJ\1740 leg_11\NN\5560244 compartment_12\NN\13910384 syndrome_13\NN\5870365 and_14\CC\1740 myonecrosis_15\NN\11486708 ._16\.\1740
D013974_D007037 NONE a_0\DT\13649268 54-year-old_1\JJ\1740 <e2>hypothyroid</e2>_2\JJ\1740 male_3\JJ\1740 taking_4\VBG\2367363 <e1>thyroxine</e1>_5\NN\5413241 and_6\CC\1740 simvastatin_7\NN\3676175 presented_8\VBN\2137132 with_9\IN\1740 bilateral_10\JJ\1740 leg_11\NN\5560244 compartment_12\NN\13910384 syndrome_13\NN\5870365 and_14\CC\1740 myonecrosis_15\NN\11486708 ._16\.\1740
D013974_D003161 NONE a_0\DT\13649268 54-year-old_1\JJ\1740 hypothyroid_2\JJ\1740 male_3\JJ\1740 taking_4\VBG\2367363 <e1>thyroxine</e1>_5\NN\5413241 and_6\CC\1740 simvastatin_7\NN\3676175 presented_8\VBN\2137132 with_9\IN\1740 bilateral_10\JJ\1740 leg_11\NN\5560244 <e2>compartment_12\NN\13910384 syndrome</e2>_13\NN\5870365 and_14\CC\1740 myonecrosis_15\NN\11486708 ._16\.\1740
D013974_D009135 NONE a_0\DT\13649268 54-year-old_1\JJ\1740 hypothyroid_2\JJ\1740 male_3\JJ\1740 taking_4\VBG\2367363 <e1>thyroxine</e1>_5\NN\5413241 and_6\CC\1740 simvastatin_7\NN\3676175 presented_8\VBN\2137132 with_9\IN\1740 bilateral_10\JJ\1740 leg_11\NN\5560244 compartment_12\NN\13910384 syndrome_13\NN\5870365 and_14\CC\1740 <e2>myonecrosis</e2>_15\NN\11486708 ._16\.\1740
